Beneficial	O
effects	O
of	O
voglibose	O
administration	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	O
via	O
gastrointestinal	O
bile	O
acid	O
modification	O
.	O

This	O
study	O
was	O
designed	O
with	O
the	O
goal	O
of	O
examining	O
the	O
effects	O
of	O
voglibose	O
administration	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	O
and	O
underlying	O
mechanism	O
high	O
fat	O
diet	O
-induced	O
obese	O
mice	O
.	O

Male	O
C57BL/6	O
mice	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
groups	O
:	O
a	O
control	O
diet	O
(	O
CTL	O
)	O
,	O
high-fat	O
diet	O
(	O
HF	O
)	O
,	O
high-fat	O
diet	O
supplemented	O
with	O
voglibose	O
(	O
VO	O
)	O
,	O
and	O
high	O
fat	O
diet	O
pair-fed	O
group	O
(	O
PF	O
)	O
.	O

After	O
12	O
weeks	O
,	O
the	O
following	O
characteristics	O
were	O
investigated	O
:	O
serum	B-P
lipid	I-P
and	O
glucose	O
levels	O
,	O
serum	O
polar	O
metabolite	O
profiles	O
,	O
and	O
expression	O
levels	O
of	O
genes	O
involved	O
in	O
lipid	O
and	O
bile	O
acid	O
metabolism	O
.	O

In	O
addition	O
,	O
pyrosequencing	B-P
was	O
used	O
to	O
analyze	O
the	O
composition	O
of	O
gut	O
microbiota	O
found	O
in	O
feces	O
.	O

Total	O
body	O
weight	O
gain	O
was	O
significantly	O
lower	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
CTL	O
,	O
HF	O
,	O
and	O
PF	O
groups	O
.	O

The	O
VO	O
group	O
exhibited	O
improved	O
metabolic	O
profiles	O
including	O
those	O
of	O
blood	B-P
glucose	I-P
,	O
triglyceride	O
,	O
and	O
total	O
cholesterol	O
levels	O
.	O

The	O
12-	O
week	O
voglibose	O
administration	O
decreased	O
the	O
ratio	O
of	O
Firmicutes	O
to	O
Bacteroidetes	O
found	O
in	O
feces	O
.	O

Circulating	O
levels	O
of	O
taurocholic	O
and	O
cholic	O
acid	O
were	O
significantly	O
higher	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
HF	O
and	O
CTL	O
groups	O
.	O

Deoxycholic	O
acid	O
levels	O
tended	O
to	O
be	O
higher	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
HF	O
group	O
.	O

Voglibose	O
administration	O
downregulated	O
expression	O
levels	O
of	O
CYP8B1	O
and	O
HNF4α	O
genes	O
and	O
upregulated	O
those	O
of	O
PGC1α	O
,	O
whereas	O
FXRα	O
was	O
not	O
affected	O
.	O

Voglibose	O
administration	O
elicits	O
changes	O
in	O
the	O
composition	O
of	O
the	O
intestinal	O
microbiota	O
and	O
circulating	O
metabolites	O
,	O
which	O
ultimately	O
has	O
systemic	O
effects	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	O
in	O
mice	O
.	O

Clinical	O
application	O
and	O
outcomes	O
of	O
sentinel	O
node	O
navigation	O
surgery	O
in	O
patients	O
with	O
early	O
gastric	O
cancer	O
.	O

Sentinel	O
node	O
navigation	O
surgery	O
(	O
SNNS	O
)	O
has	O
been	O
recognized	O
as	O
a	O
minimally	O
invasive	O
tool	O
for	O
individualized	O
lymphadenectomy	O
in	O
patients	O
with	O
early	O
gastric	O
cancer	O
(	O
EGC	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
clinicopathological	O
factors	O
,	O
adverse	O
events	O
,	O
and	O
clinical	O
outcomes	O
between	O
sentinel	B-P
node	I-P
mapping	I-P
(	O
SNM	B-P
)	O
and	O
SN	O
dissection	O
(	O
SND	O
)	O
groups	O
and	O
assess	O
the	O
clinical	O
utility	O
of	O
SNNS	O
in	O
patients	O
with	O
EGC	O
.	O

The	O
clinical	O
data	O
of	O
157	O
patients	O
with	O
EGC	O
,	O
diagnosed	O
as	O
clinical	O
T1N0M0	O
with	O
tumors	O
≤	O
40	O
mm	O
,	O
undergoing	O
SNNS	O
between	O
March	O
2004	O
and	O
April	O
2016	O
were	O
retrospectively	O
reviewed	O
.	O

Twenty-seven	O
patients	O
were	O
excluded	O
from	O
the	O
analysis	O
.	O

In	O
the	O
remaining	O
130	O
patients	O
,	O
59	O
and	O
71	O
patients	O
underwent	O
standard	O
lymphadenectomy	O
for	O
SNM	B-P
and	O
SND	O
,	O
respectively	O
.	O

The	O
sentinel	O
node	O
detection	O
rate	O
in	O
the	O
SNM	B-P
and	O
SND	O
groups	O
was	O
98.3	O
%	O
(	O
58/59	O
)	O
and	O
100	O
%	O
(	O
71/71	O
)	O
,	O
respectively	O
.	O

Two	O
(	O
3.5	O
%	O
)	O
,	O
15	O
(	O
25.9	O
%	O
)	O
,	O
and	O
41	O
(	O
70.7	O
%	O
)	O
patients	O
having	O
sentinel	O
nodes	O
underwent	O
total	O
gastrectomy	O
,	O
proximal	O
gastrectomy	O
(	O
PG	O
)	O
,	O
and	O
distal	O
gastrectomy	O
(	O
DG	O
)	O
,	O
respectively	O
,	O
in	O
the	O
SNM	B-P
group	O
.	O

One	O
(	O
1.4	O
%	O
)	O
,	O
5	O
(	O
7.0	O
%	O
)	O
,	O
10	O
(	O
14.1	O
%	O
)	O
,	O
39	O
(	O
54.9	O
%	O
)	O
,	O
and	O
16	O
(	O
22.5	O
%	O
)	O
patients	O
underwent	O
PG	O
,	O
DG	O
,	O
segmental	O
gastrectomy	O
,	O
local	O
resection	O
,	O
and	O
endoscopic	O
submucosal	O
dissection	O
,	O
respectively	O
,	O
in	O
the	O
SND	O
group	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
postoperative	O
complications	O
between	O
the	O
SNM	B-P
and	O
SND	O
groups	O
(	O
P	O
=	O
0.781	O
)	O
.	O

Survival	O
did	O
not	O
differ	O
between	O
the	O
both	O
groups	O
(	O
P	O
=	O
0.856	O
)	O
.	O

The	O
present	O
results	O
suggest	O
that	O
personalized	O
surgery	O
with	O
SND	O
provides	O
technical	O
safety	O
and	O
curability	O
related	O
with	O
a	O
favorable	O
survival	O
outcome	O
in	O
patients	O
with	O
EGC	O
.	O

Airway	O
inflammation	O
phenotype	O
prediction	O
in	O
asthma	O
patients	O
using	O
lung	O
sound	B-P
analysis	I-P
with	O
fractional	O
exhaled	O
nitric	O
oxide	O
.	O

We	O
previously	O
reported	O
the	O
results	O
of	O
lung	O
sound	B-P
analysis	I-P
in	O
patients	O
with	O
bronchial	O
asthma	O
and	O
demonstrated	O
that	O
the	O
exhalation	O
-to-	O
inhalation	O
sound	O
pressure	O
ratio	O
in	O
the	O
low	O
frequency	O
range	O
between	O
100	O
and	O
200	O
Hz	O
(	O
E/I	O
LF	O
)	O
was	O
correlated	O
with	O
the	O
presence	O
of	O
airway	O
inflammation	O
and	O
airway	O
obstruction	O
.	O

We	O
classified	O
asthma	O
patients	O
by	O
airway	O
inflammation	O
phenotype	O
using	O
the	O
induced	O
sputum	O
eosinophil	O
and	O
neutrophil	O
ratio	O
and	O
determined	O
whether	O
this	O
phenotype	O
could	O
be	O
predicted	O
using	O
E/I	O
LF	O
and	O
fractional	O
exhaled	O
nitric	O
oxide	O
values	O
.	O

Steroid-naive	O
bronchial	O
asthma	O
patients	O
were	O
classified	O
into	O
four	O
phenotypes	O
,	O
including	O
``	O
Low	O
inflammation	O
``	O
(	O
35	O
patients	O
)	O
,	O
``	O
Eosinophilic	O
type	O
``	O
(	O
58	O
patients	O
)	O
,	O
``	O
Neutrophilic	O
type	O
``	O
(	O
15	O
patients	O
)	O
,	O
and	O
``	O
Mixed	O
type	O
``	O
(	O
15	O
patients	O
)	O
based	O
on	O
the	O
results	O
of	O
induced	O
sputum	O
examinations	O
.	O

The	O
E/I	O
LF	O
data	O
and	O
FeNO	O
levels	O
were	O
then	O
evaluated	O
for	O
the	O
four	O
phenotype	O
groups	O
;	O
the	O
prediction	O
powers	O
of	O
these	O
two	O
indices	O
were	O
then	O
analyzed	O
for	O
each	O
phenotype	O
.	O

The	O
median	O
E/I	O
LF	O
value	O
was	O
highest	O
in	O
the	O
``	O
Mixed	O
type	O
``	O
and	O
lowest	O
in	O
the	O
``	O
Low	O
inflammation	O
``	O
group	O
.	O

FeNO	O
differentiated	O
between	O
the	O
``	O
Low	O
inflammation	O
``	O
and	O
``	O
Eosinophilic	O
type	O
``	O
groups	O
,	O
``	O
Low	O
inflammation	O
``	O
and	O
``	O
Neutrophilic	O
type	O
``	O
groups	O
,	O
and	O
``	O
Neutrophilic	O
type	O
``	O
and	O
``	O
Mixed	O
type	O
``	O
(	O
p	O
<	O
0.0001	O
,	O
p	O
=	O
0.007	O
,	O
and	O
p	O
=	O
0.04	O
,	O
respectively	O
)	O
.	O

E/I	O
LF	O
differentiated	O
between	O
the	O
``	O
Low	O
inflammation	O
``	O
and	O
``	O
Eosinophilic	O
type	O
``	O
groups	O
(	O
p	O
=	O
0.006	O
)	O
.	O

E/I	O
LF	O
could	O
distinguish	O
the	O
``	O
Mixed	O
type	O
``	O
group	O
from	O
the	O
``	O
Low	O
inflammation	O
``	O
and	O
``	O
Eosinophilic	O
type	O
``	O
groups	O
(	O
p	O
=	O
0.002	O
)	O
.	O

A	O
combination	O
of	O
the	O
E/I	O
LF	O
value	O
and	O
FeNO	O
may	O
be	O
useful	O
for	O
the	O
classification	O
of	O
the	O
airway	O
inflammation	O
phenotype	O
in	O
patients	O
with	O
bronchial	O
asthma	O
.	O

Antidiabetic	O
potential	O
of	O
bioactive	O
molecules	O
coated	O
chitosan	O
nanoparticles	O
in	O
experimental	O
rats	O
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
to	O
examine	O
the	O
antidiabetic	O
effects	O
of	O
chitosan	O
nanoparticles	O
(	O
CNPs	O
)	O
loaded	O
with	O
(	O
Stevia	O
rebaudiana	O
leaf	O
extract	O
-	O
SRLE	O
)	O
bioactive	O
molecules	O
in	O
a	O
rat	O
model	O
of	O
streptozotocin	O
(	O
STZ	O
)	O
induced	O
diabetes	O
mellitus	O
.	O

Successful	O
crosslinking	O
of	O
the	O
bioactive	O
molecules	O
to	O
the	O
chitosan	O
nanoparticles	O
was	O
confirmed	O
by	O
Fourier	O
Transform	O
Infrared	O
Spectroscopy	O
(	O
FTIR	O
)	O
.	O

The	O
colloidal	O
characteristics	O
of	O
the	O
synthesized	O
nanoparticles	O
were	O
revealed	O
by	O
X-ray	B-P
Diffraction	I-P
(	I-P
XRD	I-P
)	I-P
analysis	I-P
.	O

Morphological	O
analysis	O
by	O
Transmission	B-P
Electron	I-P
Microscopy	I-P
(	O
TEM	B-P
)	O
revealed	O
that	O
the	O
bioactive	O
molecule	O
-loaded	O
CNPs	O
were	O
well-dispersed	O
and	O
spherical	O
or	O
polygonal	O
in	O
shape	O
with	O
an	O
average	O
size	O
of	O
<	O
73.27nm	O
than	O
the	O
z-average	O
value	O
(	O
327nm	O
)	O
as	O
measured	O
by	O
Dynamic	B-P
Light	I-P
Scattering	I-P
(	O
DLS	B-P
)	O
.	O

SRLE	O
CNP	O
-	O
treated	O
diabetic	O
rats	O
showed	O
a	O
significant	O
reduction	O
in	O
their	O
mean	O
fasting	O
blood	O
glucose	O
level	O
compared	O
with	O
the	O
diabetic	O
control	O
group	O
.	O

The	O
serum	O
levels	O
of	O
various	O
enzymes	O
viz.	O
,	O
serum	O
glutamic	O
oxaloacetic	O
transaminase	O
(	O
SGOT	O
)	O
,	O
serum	O
glutamic	O
pyruvic	O
transaminase	O
(	O
SGPT	O
)	O
,	O
alkaline	O
phosphatases	O
(	O
ALP	O
)	O
,	O
lipid	O
peroxidation	O
,	O
and	O
antioxidant	O
such	O
as	O
catalase	O
(	O
CAT	O
)	O
,	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
,	O
and	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
in	O
the	O
SRLE	O
CNP	O
-	O
treated	O
group	O
were	O
closer	O
to	O
normal	O
levels	O
than	O
those	O
in	O
the	O
diabetic	O
control	O
group	O
.	O

T2-Imaging	B-P
Changes	O
in	O
the	O
Nigrosome-1	O
Relate	O
to	O
Clinical	O
Measures	O
of	O
Parkinson	O
's	O
Disease	O
.	O

The	O
nigrosome-1	O
region	O
of	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
undergoes	O
the	O
greatest	O
and	O
earliest	O
dopaminergic	O
neuron	O
loss	O
in	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

As	O
T2-weighted	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	I-P
MRI	I-P
)	I-P
scans	I-P
are	O
often	O
collected	O
with	O
routine	O
clinical	O
MRI	B-P
protocols	O
,	O
this	O
investigation	O
aims	O
to	O
determine	O
whether	O
T2-imaging	B-P
changes	O
in	O
the	O
nigrosome-1	O
are	O
related	O
to	O
clinical	O
measures	O
of	O
PD	O
and	O
to	O
assess	O
their	O
potential	O
as	O
a	O
more	O
clinically	O
accessible	O
biomarker	O
for	O
PD	O
.	O

Voxel	O
intensity	O
ratios	O
were	O
calculated	O
for	O
T2-weighted	B-P
MRI	I-P
scans	I-P
from	O
47	O
subjects	O
from	O
the	O
Parkinson	O
's	O
Progression	O
Markers	O
Initiative	O
database	O
.	O

Three	O
approaches	O
were	O
used	O
to	O
delineate	O
the	O
SN	O
and	O
nigrosome-1	O
:	O
(	O
1	O
)	O
manual	O
segmentation	B-P
,	O
(	O
2	O
)	O
automated	O
segmentation	B-P
,	O
and	O
(	O
3	O
)	O
area	O
voxel	O
-based	O
morphometry	B-P
.	O

Voxel	O
intensity	O
ratios	O
were	O
calculated	O
from	O
voxel	O
intensity	O
values	O
taken	O
from	O
the	O
nigrosome-1	O
and	O
two	O
areas	O
of	O
the	O
remaining	O
SN	O
.	O

Linear	O
regression	O
analyses	O
were	O
conducted	O
relating	O
voxel	O
intensity	O
ratios	O
with	O
the	O
Movement	O
Disorder	O
Society-Unified	O
Parkinson	O
's	O
Disease	O
Rating	O
Scale	O
(	O
MDS-UPDRS	O
)	O
sub-scores	O
for	O
each	O
subject	O
.	O

For	O
manual	O
segmentation	B-P
,	O
linear	O
regression	O
tests	O
consistently	O
identified	O
the	O
voxel	O
intensity	O
ratio	O
derived	O
from	O
the	O
dorsolateral	O
SN	O
and	O
nigrosome-1	O
(	O
IR2	O
)	O
as	O
predictive	O
of	O
nBehav	O
(	O
p	O
=	O
0.0377	O
)	O
and	O
nExp	O
(	O
p	O
=	O
0.03856	O
)	O
.	O

For	O
automated	O
segmentation	B-P
,	O
linear	O
regression	O
tests	O
identified	O
IR2	O
as	O
predictive	O
of	O
Subscore	O
IA	O
(	O
nBehav	O
)	O
(	O
p	O
=	O
0.01134	O
)	O
,	O
Subscore	O
IB	O
(	O
nExp	O
)	O
(	O
p	O
=	O
0.00336	O
)	O
,	O
Score	O
II	O
(	O
mExp	O
)	O
(	O
p	O
=	O
0.02125	O
)	O
,	O
and	O
Score	O
III	O
(	O
mSign	O
)	O
(	O
p	O
=	O
0.008139	O
)	O
.	O

For	O
the	O
voxel	O
-based	O
morphometric	B-P
approach	I-P
,	O
univariate	O
simple	O
linear	O
regression	O
analysis	O
identified	O
IR2	O
as	O
yielding	O
significant	O
results	O
for	O
nBehav	O
(	O
p	O
=	O
0.003102	O
)	O
,	O
mExp	O
(	O
p	O
=	O
0.0172	O
)	O
,	O
and	O
mSign	O
(	O
p	O
=	O
0.00393	O
)	O
.	O

Neuroimaging	B-P
biomarkers	O
may	O
be	O
used	O
as	O
a	O
proxy	O
of	O
changes	O
in	O
the	O
nigrosome-1	O
,	O
measured	O
by	O
MDS-UPDRS	O
scores	O
as	O
an	O
indicator	O
of	O
the	O
severity	O
of	O
PD	O
.	O

The	O
voxel	O
intensity	O
ratio	O
derived	O
from	O
the	O
dorsolateral	O
SN	O
and	O
nigrosome-1	O
was	O
consistently	O
predictive	O
of	O
non-motor	O
complex	O
behaviors	O
in	O
all	O
three	O
analyses	O
and	O
predictive	O
of	O
non-motor	O
experiences	O
of	O
daily	O
living	O
,	O
motor	O
experiences	O
of	O
daily	O
living	O
,	O
and	O
motor	O
signs	O
of	O
PD	O
in	O
two	O
of	O
the	O
three	O
analyses	O
.	O

These	O
results	O
suggest	O
that	O
T2	O
changes	O
in	O
the	O
nigrosome-1	O
may	O
relate	O
to	O
certain	O
clinical	O
measures	O
of	O
PD	O
.	O

T2	O
changes	O
in	O
the	O
nigrosome-1	O
may	O
be	O
considered	O
when	O
developing	O
a	O
more	O
accessible	O
clinical	O
diagnostic	B-P
tool	I-P
for	O
patients	O
with	O
suspected	O
PD	O
.	O

Functional	O
states	O
of	O
rat	O
cortical	O
circuits	O
during	O
the	O
unpredictable	O
availability	O
of	O
a	O
reward	O
-	O
related	O
cue	O
.	O

Proper	O
performance	O
of	O
acquired	O
abilities	O
can	O
be	O
disturbed	O
by	O
the	O
unexpected	O
occurrence	O
of	O
external	O
changes	O
.	O

Rats	O
trained	O
with	O
an	O
operant	O
conditioning	O
task	O
(	O
to	O
press	O
a	O
lever	O
in	O
order	O
to	O
obtain	O
a	O
food	O
pellet	O
)	O
using	O
a	O
fixed-ratio	O
schedule	O
(	O
1:1	O
)	O
were	O
subsequently	O
placed	O
in	O
a	O
Skinner	O
box	O
in	O
which	O
the	O
lever	O
could	O
be	O
removed	O
randomly	O
.	O

Field	O
postsynaptic	O
potentials	O
(	O
fPSPs	O
)	O
were	O
chronically	O
evoked	O
in	O
perforant	O
pathway	O
-	O
hippocampal	O
CA1	O
(	O
PP-CA1	O
)	O
,	O
CA1	O
-	O
subiculum	O
(	O
CA1	O
-	O
SUB	O
)	O
,	O
CA1	O
-	O
medial	O
prefrontal	O
cortex	O
(	O
CA1	O
-	O
mPFC	O
)	O
,	O
mPFC	O
-	O
nucleus	O
accumbens	O
(	O
mPFC	O
-	O
NAc	O
)	O
,	O
and	O
mPFC	O
-	O
basolateral	O
amygdala	O
(	O
mPFC	O
-	O
BLA	O
)	O
synapses	O
during	O
lever	O
IN	O
and	O
lever	O
OUT	O
situations	O
.	O

While	O
lever	O
presses	O
were	O
accompanied	O
by	O
a	O
significant	O
increase	O
in	O
fPSP	O
slopes	O
at	O
the	O
five	O
synapses	O
,	O
the	O
unpredictable	O
absence	O
of	O
the	O
lever	O
were	O
accompanied	O
by	O
decreased	O
fPSP	O
slopes	O
in	O
all	O
,	O
except	O
PP-CA1	O
synapses	O
.	O

Spectral	B-P
analysis	I-P
of	O
local	O
field	O
potentials	O
(	O
LFPs	O
)	O
recorded	O
when	O
the	O
animal	O
approached	O
the	O
corresponding	O
area	O
in	O
the	O
lever	O
OUT	O
situation	O
presented	O
lower	O
spectral	O
powers	O
than	O
during	O
lever	O
IN	O
occasions	O
for	O
all	O
recording	O
sites	O
,	O
apart	O
from	O
CA1	O
.	O

Thus	O
,	O
the	O
unpredictable	O
availability	O
of	O
a	O
reward	O
-	O
related	O
cue	O
modified	O
the	O
activity	O
of	O
cortical	O
and	O
subcortical	O
areas	O
related	O
with	O
the	O
acquisition	O
of	O
operant	O
learning	O
tasks	O
,	O
suggesting	O
an	O
immediate	O
functional	O
reorganization	O
of	O
these	O
neural	O
circuits	O
to	O
address	O
the	O
changed	O
situation	O
and	O
to	O
modify	O
ongoing	O
behaviors	O
accordingly	O
.	O

Discovery	O
of	O
novel	O
antagonists	O
of	O
human	O
neurotensin	O
receptor	O
1	O
on	O
the	O
basis	O
of	O
ligand	O
and	O
protein	O
structure	O
.	O

Neurotensin	O
receptor	O
1	O
(	O
NTR1	O
)	O
is	O
a	O
cell	O
surface	O
receptor	O
belonging	O
to	O
the	O
G	O
protein-coupled	O
receptor	O
(	O
GPCR	O
)	O
A	O
superfamily	O
.	O

NTR1	O
plays	O
an	O
important	O
role	O
in	O
neuronal	O
and	O
non	O
-	O
neuronal	O
systems	O
.	O

Using	O
the	O
previously	O
identified	O
crystal	O
structure	O
of	O
rat	O
NTR1	O
(	O
rNTR1	O
)	O
,	O
we	O
screened	O
for	O
potential	O
candidates	O
of	O
human	O
NTR1	O
(	O
hNTR1	O
)	O
ligand	O
.	O

Approximately	O
10,000	O
compounds	O
were	O
selected	O
using	O
the	O
docking	O
score	O
,	O
followed	O
by	O
pharmacophore	O
-based	O
virtual	O
screening	O
and	O
a	O
two-dimensional	O
(	B-P
2D	I-P
)	I-P
-fingerprint	I-P
structural	I-P
similarity	I-P
search	I-P
.	O

The	O
identified	O
molecules	O
were	O
tested	O
by	O
in	O
vitro	O
calcium	B-P
flux	I-P
assay	I-P
.	O

Four	O
compounds	O
showed	O
micromolar	O
level	O
affinity	O
,	O
of	O
which	O
,	O
one	O
compound	O
can	O
inhibit	O
hNTR1	O
/	O
CHO	O
cells	O
'	O
proliferation	O
by	O
cell	O
viability	O
assays	O
.	O

To	O
improve	O
the	O
affinity	O
of	O
these	O
positive	O
hit	O
compounds	O
,	O
a	O
homology	O
model	O
of	O
hNTR1	O
was	O
built	O
on	O
the	O
basis	O
of	O
the	O
crystal	O
structure	O
of	O
rNTR1	O
.	O

The	O
hit	O
compounds	O
will	O
be	O
further	O
optimized	O
on	O
the	O
basis	O
of	O
the	O
structure	O
of	O
the	O
hNTR1	O
receptor	O
to	O
be	O
the	O
targets	O
for	O
drugs	O
directed	O
against	O
diseases	O
associated	O
with	O
hNTR1	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
method	O
we	O
used	O
is	O
valid	O
,	O
which	O
will	O
be	O
treated	O
as	O
a	O
useful	O
tool	O
to	O
search	O
for	O
the	O
agonists	O
or	O
antagonists	O
of	O
our	O
interested	O
target	O
protein	O
.	O

Moreover	O
,	O
the	O
compound	O
we	O
tested	O
may	O
provide	O
a	O
hopeful	O
clue	O
for	O
treating	O
the	O
diseases	O
related	O
with	O
hNTR1	O
.	O

A	O
comparative	O
study	O
of	O
glycerol	O
and	O
sorbitol	O
as	O
co-substrates	O
in	O
methanol	O
-	O
induced	O
cultures	B-P
of	O
Pichia	O
pastoris	O
:	O
temperature	O
effect	O
and	O
scale-up	O
simulation	O
.	O

The	O
production	O
of	O
recombinant	O
proteins	O
by	O
Pichia	O
pastoris	O
under	O
AOX1	O
promoter	O
is	O
usually	O
performed	O
using	O
methanol	O
together	O
with	O
either	O
glycerol	O
or	O
sorbitol	O
as	O
co-substrate	O
.	O

Although	O
both	O
co-substrates	O
have	O
been	O
widely	O
used	O
,	O
comparative	O
studies	O
are	O
scarce	O
.	O

In	O
addition	O
,	O
these	O
comparisons	O
have	O
been	O
performed	O
at	O
different	O
specific	O
growth	O
rate	O
(	O
µ	O
)	O
that	O
it	O
is	O
well	O
known	O
that	O
has	O
an	O
important	O
effect	O
on	O
productivity	O
.	O

Thus	O
,	O
the	O
effect	O
of	O
using	O
these	O
co-substrates	O
on	O
the	O
production	O
of	O
Rhyzopus	O
oryzae	O
lipase	O
(	O
ROL	O
)	O
by	O
P.	O
pastoris	O
was	O
compared	O
in	O
continuous	O
cultures	B-P
growing	O
at	O
the	O
same	O
µ	O
at	O
either	O
22	O
or	O
30	O
°C	O
.	O

Results	O
show	O
that	O
using	O
glycerol	O
as	O
co-substrate	O
led	O
to	O
higher	O
volumetric	O
productivities	O
,	O
and	O
lower	O
specific	O
and	O
volumetric	O
methanol	O
consumption	O
rates	O
.	O

Scale-up	O
simulation	O
with	O
10-10,000	O
L	O
bioreactor	O
sizes	O
indicated	O
that	O
glycerol	O
produced	O
the	O
highest	O
volumetric	O
productivity	O
of	O
ROL	O
with	O
lower	O
aeration	O
requirements	O
.	O

Therefore	O
,	O
glycerol	O
rises	O
as	O
a	O
better	O
option	O
than	O
sorbitol	O
in	O
ROL	O
production	O
.	O

Prediction	O
of	O
Estrogenic	O
Bioactivity	O
of	O
Environmental	O
Chemical	O
Metabolites	O
.	O

The	O
US	O
Environmental	O
Protection	O
Agency	O
's	O
(	O
EPA	O
)	O
Endocrine	O
Disruptor	O
Screening	O
Program	O
(	O
EDSP	O
)	O
is	O
using	O
in	O
vitro	O
data	O
generated	O
from	O
ToxCast	O
/	O
Tox21	O
high-throughput	B-P
screening	I-P
assays	I-P
to	O
assess	O
the	O
endocrine	O
activity	O
of	O
environmental	O
chemicals	O
.	O

Considering	O
that	O
in	O
vitro	O
assays	O
may	O
have	O
limited	O
metabolic	O
capacity	O
,	O
inactive	O
chemicals	O
that	O
are	O
biotransformed	O
into	O
metabolites	O
with	O
endocrine	O
bioactivity	O
may	O
be	O
missed	O
for	O
further	O
screening	O
and	O
testing	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
value	O
in	O
developing	O
novel	O
approaches	O
to	O
account	O
for	O
metabolism	O
and	O
endocrine	O
activity	O
of	O
both	O
parent	O
chemicals	O
and	O
their	O
associated	O
metabolites	O
.	O

We	O
used	O
commercially	O
available	O
software	O
to	O
predict	O
metabolites	O
of	O
50	O
parent	O
compounds	O
,	O
out	O
of	O
which	O
38	O
chemicals	O
are	O
known	O
to	O
have	O
estrogenic	O
metabolites	O
,	O
and	O
12	O
compounds	O
and	O
their	O
metabolites	O
are	O
negative	O
for	O
estrogenic	O
activity	O
.	O

Three	O
ER	O
QSAR	O
models	O
were	O
used	O
to	O
determine	O
potential	O
estrogen	O
bioactivity	O
of	O
the	O
parent	O
compounds	O
and	O
predicted	O
metabolites	O
,	O
the	O
outputs	O
of	O
the	O
models	O
were	O
averaged	O
,	O
and	O
the	O
chemicals	O
were	O
then	O
ranked	O
based	O
on	O
the	O
total	O
estrogenicity	O
of	O
the	O
parent	O
chemical	O
and	O
metabolites	O
.	O

The	O
metabolite	O
prediction	O
software	O
correctly	O
identified	O
known	O
estrogenic	O
metabolites	O
for	O
26	O
out	O
of	O
27	O
parent	O
chemicals	O
with	O
associated	O
metabolite	O
data	O
,	O
and	O
39	O
out	O
of	O
46	O
estrogenic	O
metabolites	O
were	O
predicted	O
as	O
potential	O
biotransformation	O
products	O
derived	O
from	O
the	O
parent	O
chemical	O
.	O

The	O
QSAR	O
models	O
estimated	O
stronger	O
estrogenic	O
activity	O
for	O
the	O
majority	O
of	O
the	O
known	O
estrogenic	O
metabolites	O
compared	O
to	O
their	O
parent	O
chemicals	O
.	O

Finally	O
,	O
the	O
three	O
models	O
identified	O
a	O
similar	O
set	O
of	O
parent	O
compounds	O
as	O
top	O
ranked	O
chemicals	O
based	O
on	O
the	O
estrogenicity	O
of	O
putative	O
metabolites	O
.	O

This	O
proposed	O
in	O
silico	O
approach	O
is	O
an	O
inexpensive	O
and	O
rapid	O
strategy	O
for	O
the	O
detection	O
of	O
chemicals	O
with	O
estrogenic	O
metabolites	O
and	O
may	O
reduce	O
potential	O
false	O
negative	O
results	O
from	O
in	O
vitro	O
assays	O
.	O

High	O
fidelity	B-P
visualization	I-P
of	O
cell	O
-to-	O
cell	O
variation	O
and	O
temporal	O
dynamics	O
in	O
nascent	O
extracellular	O
matrix	O
formation	O
.	O

Extracellular	O
matrix	O
dynamics	O
are	O
key	O
to	O
tissue	O
morphogenesis	O
,	O
homeostasis	O
,	O
injury	O
,	O
and	O
repair	O
.	O

The	O
spatiotemporal	O
organization	O
of	O
this	O
matrix	O
has	O
profound	O
biological	O
implications	O
,	O
but	O
is	O
challenging	O
to	O
monitor	O
using	O
standard	O
techniques	O
.	O

Here	O
,	O
we	O
address	O
these	O
challenges	O
by	O
using	O
noncanonical	O
amino	O
acid	O
tagging	B-P
to	O
fluorescently	O
label	O
extracellular	O
matrix	O
synthesized	O
in	O
the	O
presence	O
of	O
bio-orthogonal	O
methionine	O
analogs	O
.	O

This	O
strategy	O
labels	B-P
matrix	O
proteins	O
with	O
high	B-P
resolution	I-P
,	O
without	O
compromising	O
their	O
distribution	O
or	O
mechanical	O
function	O
.	O

We	O
demonstrate	O
that	O
the	O
organization	O
and	O
temporal	O
dynamics	O
of	O
the	O
proteinaceous	O
matrix	O
depend	O
on	O
the	O
biophysical	O
features	O
of	O
the	O
microenvironment	O
,	O
including	O
the	O
biomaterial	O
scaffold	O
and	O
the	O
niche	O
constructed	O
by	O
cells	O
themselves	O
.	O

Pulse	B-P
labeling	I-P
experiments	I-P
reveal	O
that	O
,	O
in	O
immature	O
constructs	O
,	O
nascent	O
matrix	O
is	O
highly	O
fibrous	O
and	O
interdigitates	O
with	O
pre-existing	O
matrix	O
,	O
while	O
in	O
more	O
developed	O
constructs	O
,	O
nascent	O
matrix	O
lacks	O
fibrous	O
organization	O
and	O
is	O
retained	O
in	O
the	O
immediate	O
pericellular	O
space	O
.	O

Inhibition	O
of	O
collagen	O
crosslinking	O
increases	O
matrix	O
synthesis	O
,	O
but	O
compromises	O
matrix	O
organization	O
.	O

Finally	O
,	O
these	O
data	O
demonstrate	O
marked	O
cell	O
-to-	O
cell	O
heterogeneity	O
amongst	O
both	O
chondrocytes	O
and	O
mesenchymal	O
stem	O
cells	O
undergoing	O
chondrogenesis	O
.	O

Collectively	O
,	O
these	O
results	O
introduce	O
fluorescent	O
noncanonical	O
amino	O
acid	O
tagging	B-P
as	O
a	O
strategy	O
to	O
investigate	O
spatiotemporal	O
matrix	O
organization	O
,	O
and	O
demonstrate	O
its	O
ability	O
to	O
identify	O
differences	O
in	O
phenotype	O
,	O
microenvironment	O
,	O
and	O
matrix	O
assembly	O
at	O
the	O
single	O
cell	O
level	O
.	O

Fatigue	O
in	O
multiple	O
sclerosis	O
:	O
Associations	O
with	O
clinical	O
,	O
MRI	B-P
and	O
CSF	O
parameters	O
.	O

Damage	O
of	O
different	O
brain	O
structures	O
has	O
been	O
related	O
to	O
fatigue	O
.	O

Alternatively	O
,	O
functional	O
alterations	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
cells	O
by	O
the	O
inflammatory	O
milieu	O
within	O
the	O
CNS	O
may	O
be	O
responsible	O
for	O
the	O
development	O
of	O
fatigue	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
structural	O
brain	O
damage	O
and	O
inflammatory	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
changes	O
on	O
fatigue	O
in	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

We	O
determined	O
the	O
association	O
of	O
different	O
clinical	O
,	O
CSF	O
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
parameters	O
with	O
prevalence	O
and	O
severity	O
of	O
fatigue	O
,	O
as	O
measured	O
by	O
the	O
Fatigue	O
Scale	O
for	O
Motor	O
and	O
Cognitive	O
Functions	O
in	O
68	O
early	O
MS	O
patients	O
(	O
discovery	O
cohort	O
)	O
.	O

We	O
validated	O
our	O
findings	O
in	O
two	O
MS	O
cohorts	O
:	O
the	O
MRI	B-P
validation	O
cohort	O
(	O
N	O
=	O
233	O
)	O
for	O
the	O
clinical	O
and	O
MRI	B-P
parameters	O
,	O
and	O
the	O
CSF	O
validation	O
cohort	O
(	O
N	O
=	O
81	O
)	O
for	O
the	O
clinical	O
and	O
CSF	O
parameters	O
.	O

Fatigue	O
was	O
associated	O
with	O
clinical	O
disability	O
.	O

Fatigue	O
did	O
not	O
correlate	O
with	O
any	O
CSF	O
parameter	O
but	O
correlated	O
negatively	O
with	O
total	O
and	O
cortical	O
grey	O
matter	O
volume	O
.	O

However	O
,	O
when	O
controlling	O
for	O
Expanded	O
Disability	O
Status	O
Scale	O
(	O
EDSS	O
)	O
in	O
a	O
multivariate	O
model	O
,	O
these	O
associations	O
lost	O
significance	O
.	O

Disability	O
and	O
disease	O
duration	O
best	O
explain	O
fatigue	O
severity	O
but	O
none	O
of	O
the	O
tested	O
MRI	B-P
or	O
CSF	O
parameter	O
was	O
reliably	O
associated	O
with	O
fatigue	O
.	O

Association	O
of	O
CKIP-1	O
P21A	O
polymorphism	O
with	O
risk	O
of	O
chronic	O
heart	O
failure	O
in	O
a	O
Chinese	O
population	O
.	O

Pathological	O
cardiac	O
hypertrophy	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
chronic	O
heart	O
failure	O
.	O

Casein	O
kinase-2	O
interacting	O
protein-1	O
(	O
CKIP-1	O
)	O
can	O
inhibit	O
pathological	O
cardiac	O
hypertrophy	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
CKIP-1	O
nonsynonymous	O
polymorphism	O
rs2306235	O
(	O
Pro21Ala	O
)	O
contributes	O
to	O
risk	O
and	O
prognosis	O
of	O
chronic	O
heart	O
failure	O
in	O
a	O
Chinese	O
population	O
.	O

A	O
total	O
of	O
923	O
adult	O
patients	O
with	O
chronic	O
heart	O
failure	O
and	O
1020	O
age	O
-	O
and	O
gender	O
-matched	O
healthy	O
controls	O
were	O
recruited	O
.	O

CKIP-1	O
rs2306235	O
polymorphism	O
was	O
genotyped	B-P
using	O
PCR	O
-	O
restriction	B-P
fragment	I-P
length	I-P
polymorphism	I-P
.	O

Additional	O
follow-up	O
data	O
for	O
140	O
chronic	O
heart	O
failure	O
patients	O
was	O
evaluated	O
.	O

The	O
rs2306235	O
G	O
allele	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
chronic	O
heart	O
failure	O
(	O
OR	O
=	O
1.38	O
,	O
95	O
%	O
CI	O
=	O
1.09-1.75	O
,	O
p	O
=	O
0.007	O
)	O
,	O
especially	O
in	O
patients	O
with	O
hypertension	O
(	O
OR	O
=	O
1.45	O
,	O
95	O
%	O
CI	O
=	O
1.09-1.75	O
,	O
p	O
=	O
0.006	O
)	O
and	O
coronary	O
heart	O
disease	O
(	O
OR	O
=	O
1.41	O
,	O
95	O
%	O
CI	O
=	O
1.09-1.83	O
,	O
p	O
=	O
0.010	O
)	O
after	O
adjustment	O
for	O
multiple	O
cardiovascular	O
risk	O
factors	O
.	O

However	O
,	O
rs2306235	O
polymorphism	O
was	O
not	O
associated	O
with	O
cardiovascular	O
mortality	O
in	O
chronic	O
heart	O
failure	O
(	O
p	O
=	O
0.875	O
)	O
.	O

CKIP-1	O
rs2306235	O
polymorphism	O
may	O
be	O
a	O
risk	O
factor	O
for	O
chronic	O
heart	O
failure	O
in	O
a	O
Chinese	O
Han	O
population	O
.	O

Haemophilus	O
influenzae	O
type	O
b	O
meningitis	O
in	O
a	O
vaccinated	O
and	O
immunocompetent	O
child	O
.	O

Invasive	O
Haemophilus	O
influenzae	O
type	O
b	O
(	O
Hib	O
)	O
disease	O
decreased	O
dramatically	O
after	O
the	O
introduction	O
of	O
conjugate	O
vaccine	O
in	O
routine	O
immunization	O
schedules	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
fifteen-months-old	O
girl	O
,	O
previously	O
healthy	O
and	O
vaccinated	O
,	O
admitted	O
in	O
the	O
emergency	O
room	O
with	O
fever	O
and	O
vomiting	O
.	O

She	O
was	O
irritable	O
and	O
the	O
Brudzinski	O
's	O
sign	O
was	O
positive	O
.	O

The	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
analysis	O
showed	O
pleocytosis	O
and	O
high	O
protein	O
level	O
.	O

Empiric	O
intravenous	O
antibiotics	O
(	O
ceftriaxone	O
and	O
vancomycin	O
)	O
were	O
administered	O
for	O
suspected	O
bacterial	O
meningitis	O
during	O
10	O
days	O
.	O

Serotyping	B-P
of	O
the	O
Haemophilus	O
influenzae	O
strain	O
found	O
in	O
CSF	O
revealed	O
a	O
serotype	O
b	O
.	O

After	O
one	O
year	O
of	O
follow-up	O
no	O
Hib	O
meningitis	O
sequelae	O
were	O
noted	O
.	O

Despite	O
vaccination	O
compliance	O
and	O
absence	O
of	O
risk	O
factors	O
,	O
invasive	O
Hib	O
disease	O
can	O
occur	O
due	O
to	O
vaccine	O
failure	O
.	O

Efforts	O
to	O
keep	O
the	O
low	O
incidence	O
of	O
invasive	O
Hib	O
disease	O
should	O
be	O
directed	O
to	O
the	O
maintenance	O
of	O
high	O
vaccination	O
coverage	O
rates	O
,	O
combined	O
with	O
the	O
notification	O
and	O
surveillance	O
strategies	O
already	O
implemented	O
in	O
each	O
country	O
.	O

Teleophthalmology	O
image-based	O
navigated	O
retinal	O
laser	O
therapy	O
for	O
diabetic	O
macular	O
edema	O
:	O
a	O
concept	O
of	O
retinal	O
telephotocoagulation	O
.	O

To	O
determine	B-P
the	O
feasibility	O
and	O
efficacy	O
of	O
a	O
retinal	O
telephotocoagulation	O
treatment	O
plan	O
for	O
diabetic	O
macular	O
edema	O
.	O

Prospective	O
,	O
interventional	O
cohort	O
study	O
at	O
two	O
clinical	O
sites	O
.	O

Sixteen	O
eyes	O
of	O
ten	O
subjects	O
with	O
diabetic	O
macular	O
edema	O
underwent	O
navigated	O
focal	O
laser	O
photocoagulation	O
using	O
a	O
novel	O
teleretinal	O
treatment	O
plan	O
.	O

Clinic	O
1	O
(	O
King	O
Khaled	O
Eye	O
Specialist	O
Hospital	O
,	O
Riyadh	O
,	O
Saudi	O
Arabia	O
)	O
collected	O
retinal	O
images	O
and	O
fundus	B-P
fluorescein	I-P
angiogram	I-P
.	O

Clinic	O
2	O
(	O
Palmetto	O
Retina	O
Center	O
,	O
West	O
Columbia	O
,	O
SC	O
,	O
USA	O
)	O
created	O
image	O
-based	O
treatment	O
plans	O
based	O
on	O
which	O
macular	O
laser	O
photocoagulation	O
was	O
performed	O
back	O
at	O
clinic	O
1	O
.	O

The	O
primary	O
outcome	O
of	O
the	O
study	O
was	O
feasibility	O
of	O
image	O
transfer	O
and	O
performing	O
navigated	O
laser	O
photocoagulation	O
for	O
subjects	O
with	O
diabetic	O
macular	O
edema	O
between	O
two	O
distant	O
clinics	O
.	O

Secondary	O
measures	O
were	O
change	O
in	O
best-corrected	O
visual	O
acuity	O
(	O
BCVA	O
)	O
and	O
central	O
retinal	O
thickness	O
(	O
CRT	O
)	O
by	O
spectral-domain	O
optical	O
coherence	O
tomography	O
at	O
3	O
months	O
after	O
treatment	O
.	O

The	O
teleretinal	O
treatment	O
plan	O
was	O
able	O
to	O
be	O
successfully	O
completed	O
in	O
all	O
16	O
eyes	O
.	O

The	O
mean	O
logMAR	O
BCVA	O
at	O
baseline	O
was	O
0.49	O
±	O
0.1	O
,	O
which	O
remained	O
stable	O
(	O
0.45	O
±	O
0.1	O
)	O
3	O
months	O
after	O
treatment	O
(	O
p	O
=	O
0.060	O
)	O
.	O

The	O
CRT	O
improved	O
from	O
290.1	O
±	O
37.6	O
μm	O
at	O
baseline	O
to	O
270.8	O
±	O
27.7	O
μm	O
3	O
months	O
after	O
treatment	O
(	O
p	O
=	O
0.005	O
)	O
.	O

All	O
eyes	O
demonstrated	O
improvement	O
in	O
the	O
area	O
of	O
retinal	O
edema	O
after	O
laser	O
photocoagulation	O
,	O
and	O
no	O
eyes	O
demonstrated	O
visual	O
acuity	O
loss	O
3	O
months	O
after	O
treatment	O
.	O

This	O
study	O
introduces	O
the	O
concept	O
of	O
retinal	O
telephotocoagulation	O
for	O
diabetic	O
macular	O
edema	O
,	O
and	O
demonstrates	O
the	O
feasibility	O
and	O
safety	O
of	O
using	O
telemedicine	O
to	O
perform	O
navigated	O
retinal	O
laser	O
treatments	O
regardless	O
of	O
geographical	O
distance	O
.	O

The	O
CD9	O
,	O
CD81	O
,	O
and	O
CD151	O
EC2	O
domains	O
bind	O
to	O
the	O
classical	O
RGD-binding	O
site	O
of	O
integrin	O
αvβ3	O
.	O

Tetraspanins	O
play	O
important	O
roles	O
in	O
normal	O
(	O
e.g.	O
,	O
cell	O
adhesion	O
,	O
motility	O
,	O
activation	O
,	O
and	O
proliferation	O
)	O
,	O
and	O
pathological	O
conditions	O
(	O
e.g.	O
,	O
metastasis	O
and	O
viral	O
infection	O
)	O
.	O

Tetraspanins	O
interact	O
with	O
integrins	O
and	O
regulate	O
integrin	O
functions	O
,	O
but	O
the	O
specifics	O
of	O
tetraspanin	O
-	O
integrin	O
interaction	O
are	O
unclear	O
.	O

Using	O
co-immunoprecipitation	B-P
with	O
integrins	O
as	O
a	O
sole	O
method	O
to	O
detect	O
interaction	O
between	O
integrins	O
and	O
full-length	O
tetraspanins	O
,	O
it	O
has	O
been	O
proposed	O
that	O
the	O
variable	O
region	O
(	O
helices	O
D	O
and	O
E	O
)	O
of	O
the	O
extracellular-2	O
(	O
EC2	O
)	O
of	O
tetraspanins	O
laterally	O
associate	O
with	O
non-ligand-binding	O
site	O
of	O
integrins	O
.	O

We	O
describe	O
that	O
,	O
using	O
adhesion	O
assays	B-P
,	O
the	O
EC2	O
domain	O
of	O
CD81	O
,	O
CD9	O
,	O
and	O
CD151	O
bound	O
to	O
integrin	O
αvβ3	O
and	O
this	O
binding	O
was	O
suppressed	O
by	O
cRGDfV	O
,	O
a	O
specific	O
inhibitor	O
of	O
αvβ3	O
,	O
and	O
antibody	O
7E3	O
that	O
is	O
mapped	O
to	O
the	O
ligand-binding	O
site	O
of	O
β3	O
.	O

We	O
also	O
present	O
evidence	O
that	O
the	O
specificity	O
loop	O
of	O
β3	O
directly	O
bound	O
to	O
the	O
EC2	O
domains	O
.	O

This	O
suggests	O
that	O
the	O
EC2	O
domains	O
specifically	O
binds	O
to	O
the	O
classical	O
ligand-binding	O
site	O
of	O
αvβ3	O
.	O

αvβ3	O
was	O
a	O
more	O
effective	O
receptor	O
for	O
the	O
EC2	O
domains	O
than	O
previously	O
known	O
tetraspanin	O
receptors	O
α3β1	O
,	O
α4β1	O
,	O
and	O
α6β1	O
.	O

Docking	O
simulation	O
predicted	O
that	O
the	O
helices	O
A	O
and	O
B	O
of	O
CD81	O
EC2	O
binds	O
to	O
the	O
RGD-binding	O
site	O
of	O
αvβ3	O
.	O

Substituting	O
Lys	O
residues	O
at	O
position	O
116	O
,	O
144/148	O
of	O
CD81	O
EC2	O
in	O
the	O
predicted	O
integrin	O
-	O
binding	O
interface	O
reduced	O
the	O
binding	O
of	O
CD81	O
EC2	O
to	O
αvβ3	O
,	O
consistent	O
with	O
the	O
docking	O
model	O
.	O

These	O
findings	O
suggest	O
that	O
,	O
in	O
contrast	O
to	O
previous	O
models	O
,	O
the	O
ligand-binding	O
site	O
of	O
integrin	O
αvβ3	O
,	O
a	O
new	O
tetraspanin	O
receptor	O
,	O
binds	O
to	O
the	O
constant	O
region	O
(	O
helices	O
A	O
and	O
B	O
)	O
of	O
the	O
EC2	O
domain	O
.	O

Content	O
of	O
cardiolipin	O
of	O
the	O
membrane	O
and	O
sensitivity	O
to	O
cationic	O
surfactants	O
in	O
Pseudomonas	O
putida	O
.	O

To	O
establish	O
the	O
role	O
of	O
cardiolipin	O
(	O
CL	O
)	O
of	O
the	O
membrane	O
in	O
response	O
to	O
the	O
presence	O
of	O
tetradecyltrimethylammonium	O
in	O
Pseudomonas	O
putida	O
A	O
(	O
ATCC	O
12633	O
)	O
.	O

Two	O
ORFs	O
of	O
Ps	O
.	O

putida	O
A	O
(	O
ATCC	O
12633	O
)	O
,	O
which	O
in	O
Ps	O
.	O

putida	O
KT2440	O
encode	O
the	O
putative	O
CL	O
synthase	O
genes	O
cls	O
and	O
cls2	O
,	O
were	O
cloned	O
,	O
sequenced	B-P
and	O
mutated	O
.	O

Only	O
the	O
double	O
mutant	O
lacking	O
cls	O
and	O
cls2	O
showed	O
a	O
reduction	O
of	O
the	O
CL	O
content	O
,	O
83	O
%	O
lower	O
than	O
the	O
amount	O
produced	O
by	O
the	O
wild-type	O
.	O

Accompanying	O
this	O
change	O
was	O
a	O
40	O
%	O
decrease	O
in	O
the	O
content	O
of	O
unsaturated	O
fatty	O
acid	O
.	O

Consequently	O
,	O
the	O
membrane	O
of	O
the	O
mutant	O
was	O
more	O
rigid	O
than	O
the	O
one	O
of	O
the	O
parental	O
strain	O
,	O
as	O
observed	O
using	O
fluorescence	B-P
polarization	I-P
techniques	I-P
.	O

The	O
mutant	O
strain	O
showed	O
reduced	O
viability	O
in	O
the	O
presence	O
of	O
tetradecyltrimethylammonium	O
.	O

The	O
incorporation	O
of	O
exogenous	O
CL	O
into	O
its	O
membrane	O
relieved	O
sensitivity	O
to	O
the	O
cationic	O
detergent	O
.	O

Pseudomonas	O
Putida	O
cells	O
with	O
low	O
levels	O
of	O
CL	O
die	O
in	O
the	O
presence	O
of	O
tetradecyltrimethylammonium	O
,	O
because	O
they	O
can	O
not	O
counter	O
the	O
fluidizing	O
effect	O
of	O
the	O
cationic	O
surfactant	O
.	O

The	O
modification	O
in	O
the	O
membrane	O
phospholipids	O
composition	O
allows	O
knowing	O
the	O
adaptation	O
strategy	O
of	O
Ps	O
.	O

putida	O
when	O
these	O
bacteria	O
are	O
exposed	O
to	O
cationic	O
surfactant	O
.	O

Iterative	O
Development	O
and	O
Evaluation	O
of	O
a	O
Pharmacogenomic	O
-Guided	O
Clinical	O
Decision	O
Support	O
System	O
for	O
Warfarin	O
Dosing	O
.	O

Pharmacogenomic	O
-guided	O
dosing	O
has	O
the	O
potential	O
to	O
improve	O
patient	O
outcomes	O
but	O
its	O
implementation	O
has	O
been	O
met	O
with	O
clinical	O
challenges	O
.	O

Our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	O
a	O
clinical	O
decision	O
support	O
system	O
(	O
CDSS	O
)	O
for	O
pharmacogenomic	O
-guided	O
warfarin	O
dosing	O
designed	O
for	O
physicians	O
and	O
pharmacists	O
.	O

Twelve	O
physicians	O
and	O
pharmacists	O
completed	O
6	O
prescribing	O
tasks	O
using	O
simulated	O
patient	O
scenarios	O
in	O
two	O
iterations	O
(	O
development	O
and	O
validation	O
phases	O
)	O
of	O
a	O
newly	O
developed	O
pharmacogenomic	O
-driven	O
CDSS	O
prototype	O
.	O

For	O
each	O
scenario	O
,	O
usability	O
was	O
measured	O
via	O
efficiency	O
,	O
recorded	O
as	O
time	O
to	O
task	O
completion	O
,	O
and	O
participants	O
'	O
perceived	O
satisfaction	O
which	O
were	O
compared	O
using	O
Kruskal-Wallis	O
and	O
Mann	O
Whitney	O
U	O
tests	O
,	O
respectively	O
.	O

Debrief	O
interviews	O
were	O
conducted	O
and	O
qualitatively	B-P
analyzed	I-P
.	O

Usability	O
findings	O
from	O
the	O
first	O
(	O
i.e	O
.	O

development	O
)	O
iteration	O
were	O
incorporated	O
into	O
the	O
CDSS	O
design	O
for	O
the	O
second	O
(	O
i.e	O
.	O

validation	O
)	O
iteration	O
.	O

During	O
the	O
CDSS	O
validation	O
iteration	O
,	O
participants	O
took	O
more	O
time	O
to	O
complete	O
tasks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
of	O
183	O
(	O
124-247	O
)	O
seconds	O
versus	O
101	O
(	O
73.5-197	O
)	O
seconds	O
in	O
the	O
development	O
iteration	O
(	O
p=0.01	O
)	O
.	O

This	O
increase	O
in	O
time	O
on	O
task	O
was	O
due	O
to	O
the	O
increase	O
in	O
time	O
spent	O
in	O
the	O
CDSS	O
corresponding	O
to	O
several	O
design	O
changes	O
.	O

Efficiency	O
differences	O
that	O
were	O
observed	O
between	O
pharmacists	O
and	O
physicians	O
in	O
the	O
development	O
iteration	O
were	O
eliminated	O
in	O
the	O
validation	O
iteration	O
.	O

The	O
increased	O
use	O
of	O
the	O
CDSS	O
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
CDSS	O
recommended	O
doses	O
in	O
the	O
validation	O
iteration	O
(	O
4	O
%	O
in	O
the	O
first	O
iteration	O
vs.	O
37.5	O
%	O
in	O
the	O
second	O
iteration	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Overall	O
satisfaction	O
did	O
not	O
change	O
statistically	O
between	O
the	O
iterations	O
but	O
the	O
qualitative	B-P
analysis	I-P
revealed	O
greater	O
trust	O
in	O
the	O
second	O
prototype	O
.	O

A	O
pharmacogenomic	O
-guided	O
CDSS	O
has	O
been	O
developed	O
using	O
warfarin	O
as	O
the	O
test	O
drug	O
.	O

The	O
final	O
CDSS	O
prototype	O
was	O
trusted	O
by	O
prescribers	O
and	O
significantly	O
increased	O
the	O
time	O
using	O
the	O
tool	O
and	O
acceptance	O
of	O
the	O
recommended	O
doses	O
.	O

This	O
study	O
is	O
an	O
important	O
step	O
toward	O
incorporating	O
pharmacogenomics	O
into	O
CDSS	O
design	O
for	O
clinical	O
testing	O
.	O

Recombinant	O
fibrinogen	O
reveals	O
the	O
differential	O
roles	O
of	O
α-	O
and	O
γ-chain	O
cross-linking	O
and	O
molecular	O
heterogeneity	O
in	O
fibrin	O
clot	O
strain-stiffening	O
.	O

Essentials	O
Fibrinogen	O
circulates	O
in	O
human	O
plasma	O
as	O
a	O
complex	O
mixture	O
of	O
heterogeneous	O
molecular	O
variants	O
.	O

We	O
measured	O
strain-stiffening	O
of	O
recombinantly	O
produced	O
fibrinogen	O
upon	O
clotting	O
.	O

Factor	O
XIII	O
and	O
molecular	O
heterogeneity	O
alter	O
clot	O
elasticity	O
at	O
the	O
protofibril	O
and	O
fiber	O
level	O
.	O

This	O
highlights	O
the	O
hitherto	O
unknown	O
role	O
of	O
molecular	O
composition	O
in	O
fibrin	O
clot	O
mechanics	O
.	O

Background	O
Fibrin	O
plays	O
a	O
crucial	O
role	O
in	O
haemostasis	O
and	O
wound	O
healing	O
by	O
forming	O
strain-stiffening	O
fibrous	O
networks	O
that	O
reinforce	O
blood	O
clots	O
.	O

The	O
molecular	O
origin	O
of	O
fibrin	O
's	O
strain-stiffening	O
behavior	O
remains	O
poorly	O
understood	O
,	O
primarily	O
because	O
plasma	O
fibrinogen	O
is	O
a	O
complex	O
mixture	O
of	O
heterogeneous	O
molecular	O
variants	O
and	O
is	O
often	O
contaminated	O
by	O
plasma	O
factors	O
that	O
affect	O
clot	O
properties	O
.	O

Objectives	O
and	O
methods	O
To	O
facilitate	O
mechanistic	O
dissection	O
of	O
fibrin	O
nonlinear	O
elasticity	O
,	O
we	O
produced	O
a	O
homogeneous	O
recombinant	O
fibrinogen	O
corresponding	O
to	O
the	O
main	O
variant	O
in	O
human	O
plasma	O
,	O
termed	O
rFib610	O
.	O

We	O
characterized	O
the	O
structure	O
of	O
rFib610	O
clots	O
using	O
turbidimetry	B-P
,	O
microscopy	B-P
and	O
X-ray	B-P
scattering	I-P
.	O

We	O
used	O
rheology	B-P
to	O
measure	O
the	O
strain-stiffening	O
behavior	O
of	O
the	O
clots	O
and	O
determined	O
the	O
fiber	O
properties	O
by	O
modeling	O
the	O
clots	O
as	O
semi-flexible	O
polymer	O
networks	O
.	O

Results	O
We	O
show	O
that	O
addition	O
of	O
FXIII	O
to	O
rFib610	O
clots	O
causes	O
a	O
dose-dependent	O
stiffness	O
increase	O
at	O
small	O
deformations	O
and	O
renders	O
the	O
strain-stiffening	O
response	O
reversible	O
.	O

We	O
find	O
that	O
γ-chain	O
cross-linking	O
contributes	O
to	O
clot	O
elasticity	O
by	O
changing	O
the	O
force-extension	O
behavior	O
of	O
the	O
protofibrils	O
,	O
whereas	O
α-chain	O
cross-linking	O
stiffens	O
the	O
fibers	O
,	O
as	O
a	O
consequence	O
of	O
tighter	O
coupling	O
between	O
the	O
constituent	O
protofibrils	O
.	O

Interestingly	O
,	O
rFib610	O
protofibrils	O
have	O
a	O
25	O
%	O
larger	O
bending	O
rigidity	O
than	O
plasma	O
-purified	O
fibrin	O
protofibrils	O
and	O
a	O
delayed	O
strain-stiffening	O
,	O
indicating	O
that	O
molecular	O
heterogeneity	O
influences	O
clot	O
mechanics	O
at	O
the	O
protofibril	O
scale	O
.	O

Conclusions	O
Fibrinogen	O
molecular	O
heterogeneity	O
and	O
FXIII	O
affect	O
the	O
mechanical	O
function	O
of	O
fibrin	O
clots	O
by	O
altering	O
the	O
nonlinear	O
viscoelastic	O
properties	O
at	O
the	O
protofibril	O
and	O
fiber	O
scale	O
.	O

This	O
work	O
provides	O
a	O
starting	O
point	O
to	O
investigate	O
the	O
role	O
of	O
molecular	O
heterogeneity	O
of	O
plasma	O
fibrinogen	O
in	O
fibrin	O
clot	O
mechanics	O
and	O
haemostasis	O
.	O

Variation	O
in	O
the	O
Obturator	O
Vasculature	O
During	O
Routine	O
Anatomy	O
Dissection	B-P
of	O
a	O
Cadaver	O
.	O

The	O
obturator	O
artery	O
normally	O
originates	O
from	O
the	O
internal	O
iliac	O
artery	O
while	O
the	O
obturator	O
vein	O
drains	O
into	O
the	O
internal	O
iliac	O
vein	O
.	O

During	O
a	O
routine	O
gross	O
anatomy	O
dissection	B-P
class	O
for	O
undergraduate	O
students	O
at	O
the	O
All	O
India	O
Institute	O
of	O
Medical	O
Sciences	O
,	O
New	O
Delhi	O
,	O
India	O
,	O
in	O
2016	O
,	O
a	O
rare	O
unilateral	O
variation	O
in	O
the	O
obturator	O
vasculature	O
was	O
found	O
in	O
a	O
female	O
cadaver	O
of	O
approximately	O
55	O
years	O
of	O
age	O
.	O

In	O
this	O
case	O
,	O
the	O
left	O
obturator	O
artery	O
originated	O
from	O
the	O
superior	O
gluteal	O
artery	O
and	O
the	O
left	O
obturator	O
vein	O
drained	O
into	O
the	O
external	O
iliac	O
vein	O
.	O

Knowledge	O
of	O
such	O
variations	O
is	O
necessary	O
during	O
hernia	O
procedures	O
,	O
ligation	O
of	O
the	O
internal	O
iliac	O
artery	O
and	O
muscle	O
graft	O
surgeries	O
.	O

Neutrophil	O
gelatinase-associated	O
lipocalin	O
in	O
a	O
triphasic	O
rat	O
model	O
of	O
adenine	O
-	O
induced	O
kidney	O
injury	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
whether	O
NGAL	O
,	O
given	O
its	O
advantages	O
over	O
traditional	O
biomarkers	O
,	O
can	O
be	O
used	O
to	O
describe	O
the	O
dynamic	O
characteristics	O
of	O
the	O
renal	O
tubulointerstitial	O
insult	O
caused	O
by	O
adenine	O
.	O

Subsequently	O
,	O
it	O
will	O
be	O
possible	O
to	O
assess	O
NGAL	O
as	O
a	O
biomarker	O
of	O
any	O
acute	O
kidney	O
injury	O
,	O
on	O
top	O
of	O
chronic	O
interstitial	O
disease	O
,	O
if	O
NGAL	O
levels	O
are	O
stable	O
through	O
the	O
chronic	O
phase	O
of	O
our	O
adenine	O
model	O
.	O

Study	O
group	O
rats	O
were	O
fed	O
an	O
adenine	O
diet	O
,	O
and	O
control	O
group	O
rats	O
were	O
fed	O
a	O
regular	O
diet	O
only	O
.	O

Blood	O
and	O
urine	O
samples	O
for	O
urea	O
,	O
creatinine	O
and	O
NGAL	O
were	O
drawn	O
from	O
each	O
rat	O
at	O
the	O
beginning	O
of	O
the	O
study	O
and	O
after	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
and	O
8	O
weeks	O
.	O

Kidney	O
slices	O
from	O
these	O
rats	O
were	O
stained	B-P
with	O
Hematoxylin-eosin	B-P
(	O
HE	B-P
)	O
and	O
β-actin	O
stainings	B-P
.	O

Serum	O
urea	O
,	O
creatinine	B-P
and	O
NGAL	O
levels	O
and	O
urinary	O
NGAL/creatinine	O
ratio	O
in	O
the	O
study	O
group	O
were	O
higher	O
than	O
baseline	O
and	O
than	O
in	O
the	O
control	O
group	O
;	O
these	O
differences	O
were	O
statistically	O
significant	O
in	O
some	O
of	O
the	O
intervals	O
.	O

Tubulointerstitial	O
changes	O
and	O
adenine	O
crystals	O
were	O
evident	O
in	O
the	O
study	O
group	O
rats	O
.	O

In	O
the	O
rats	O
fed	O
adenine	O
,	O
serum	O
urea	O
,	O
creatinine	B-P
and	O
NGAL	O
levels	O
and	O
urinary	O
NGAL/creatinine	O
ratio	O
followed	O
a	O
triphasic	O
pattern	O
of	O
kidney	O
injury	O
:	O
an	O
acute	O
phase	O
while	O
on	O
the	O
adenine	O
diet	O
,	O
a	O
partial	O
recovery	O
phase	O
after	O
switching	O
to	O
the	O
regular	O
diet	O
and	O
a	O
chronic	O
kidney	O
disease	O
phase	O
after	O
stabilization	O
of	O
renal	O
function	O
.	O

NGAL	O
can	O
serve	O
a	O
biomarker	O
for	O
acute	O
kidney	O
injury	O
and	O
possibly	O
for	O
chronic	O
kidney	O
disease	O
in	O
the	O
tubulointerstitial	O
rat	O
model	O
.	O

Fluorescence-	B-P
and	O
magnetic-activated	B-P
cell	I-P
sorting	I-P
strategies	O
to	O
separate	O
spermatozoa	O
involving	O
plural	O
contributors	O
from	O
biological	O
mixtures	O
for	O
human	B-P
identification	I-P
.	O

No	O
effective	O
method	O
has	O
been	O
developed	O
to	O
distinguish	O
sperm	O
cells	O
originating	O
from	O
different	O
men	O
in	O
multi-suspect	O
sexual	O
assault	O
cases	O
.	O

Here	O
we	O
combined	O
MACS	B-P
and	O
FACS	B-P
to	O
isolate	B-P
single	O
donor	O
sperm	O
cells	O
from	O
forensic	O
mixture	O
samples	O
including	O
female	O
vaginal	O
epithelial	O
cells	O
and	O
sperm	O
cells	O
from	O
multiple	O
contributors	O
.	O

Sperms	O
from	O
vaginal	O
swab	O
were	O
isolated	O
by	O
MACS	B-P
using	O
FITC	O
-conjugated	O
A	O
kinase	O
anchor	O
protein	O
3	O
(	O
AKAP3	O
)	O
antibody	O
;	O
target	O
individual	O
sperm	O
cells	O
involving	O
two	O
or	O
three	O
donors	O
were	O
separated	O
by	O
FACS	B-P
using	O
FITC	O
-labeled	O
blood	O
group	O
A/B	O
antigen	O
antibody	O
.	O

This	O
procedure	O
was	O
further	O
tested	O
in	O
two	O
mock	O
multi-suspect	O
sexual	O
assault	O
samples	O
and	O
one	O
practical	O
casework	O
sample	O
.	O

Our	O
results	O
showed	O
that	O
complete	O
single	O
donor	O
STR	O
profiles	O
could	O
be	O
successfully	O
obtained	O
from	O
sperm	O
/	O
epithelial	O
cell	O
and	O
sperm	O
mixtures	O
from	O
two	O
contributors	O
.	O

For	O
unbalanced	O
sperm	O
/	O
epithelial	O
cells	O
and	O
sperm	O
cells	O
mixtures	O
,	O
sensitivity	O
results	O
revealed	O
that	O
target	O
cells	O
could	O
be	O
detected	O
at	O
as	O
low	O
as	O
1:32	O
and	O
1:8	O
mixed	O
ratios	O
,	O
respectively	O
.	O

Although	O
highly	O
relies	O
on	O
cell	B-P
number	I-P
and	O
blood	O
types	O
or	O
secretor	O
status	O
of	O
the	O
individuals	O
,	O
this	O
procedure	O
would	O
still	O
be	O
useful	O
tools	O
for	O
forensic	B-P
DNA	I-P
analysis	I-P
of	O
multi-suspect	O
sexual	O
assault	O
cases	O
by	O
the	O
combined	O
use	O
of	O
FACS	B-P
and	O
MACS	B-P
based	O
on	O
sperm	O
-specific	O
AKAP3	O
antigen	O
and	O
human	O
blood	O
type	O
antigen	O
.	O

Liquid	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
quantification	O
of	O
acetamiprid	O
and	O
thiacloprid	O
residues	O
in	O
butterbur	O
grown	O
under	O
regulated	O
conditions	O
.	O

An	O
analytical	O
method	O
was	O
developed	O
to	O
quantify	O
the	O
residual	O
levels	O
of	O
the	O
neonicotinoid	O
insecticides	O
,	O
acetamiprid	O
and	O
thiacloprid	O
,	O
in	O
field-incurred	O
butterbur	O
samples	O
using	O
liquid	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
(	O
LC-MS/MS	B-P
)	O
.	O

Samples	O
were	O
extracted	B-P
with	O
acetonitrile	O
and	O
partitioned	O
with	O
dichloromethane	O
.	O

After	O
partitioning	O
,	O
purification	O
was	O
conducted	O
using	O
a	O
Florisil	O
(	O
®	O
)	O
cartridge	O
.	O

Linearity	O
of	O
a	O
matrix-matched	O
calibration	O
curve	O
of	O
the	O
two	O
compounds	O
over	O
a	O
concentration	O
range	O
of	O
0.004-0.4μg/g	O
was	O
excellent	O
,	O
with	O
determination	O
coefficients	O
(	O
R	O
(	O
2	O
)	O
)	O
≥0.9998	O
.	O

The	O
limits	O
of	O
detection	O
(	O
LOD	O
)	O
and	O
quantitation	O
(	O
LOQ	O
)	O
for	O
both	O
acetamiprid	O
and	O
thiacloprid	O
were	O
0.0006	O
and	O
0.002mg/kg	O
,	O
respectively	O
.	O

The	O
average	O
recoveries	O
for	O
acetamiprid	O
and	O
thiacloprid	O
at	O
two	O
spiking	O
levels	O
(	O
0.02	O
and	O
0.1mg/kg	O
,	O
i.e.	O
,	O
10×	O
LOQ	O
and	O
50×	O
LOQ	O
)	O
were	O
between	O
78.23	O
to	O
82.17	O
%	O
,	O
with	O
relative	O
standard	O
deviations	O
(	O
RSDs	O
)	O
≤7.22	O
%	O
.	O

The	O
method	O
was	O
successfully	O
applied	O
to	O
field-incurred	O
samples	O
treated	O
with	O
a	O
commercial	O
pesticide	O
product	O
,	O
either	O
once	O
(	O
zero	O
or	O
7	O
days	O
before	O
harvest	O
)	O
or	O
twice	O
(	O
0	O
and	O
7	O
,	O
7	O
and	O
14	O
,	O
or	O
14	O
and	O
21	O
days	O
before	O
harvest	O
)	O
.	O

The	O
highest	O
and	O
lowest	O
residues	O
were	O
obtained	O
for	O
the	O
7	O
and	O
0	O
days	O
'	O
treatment	O
and	O
the	O
21	O
and	O
14	O
days	O
'	O
treatment	O
,	O
respectively	O
.	O

The	O
developed	O
method	O
is	O
simple	O
and	O
accurate	O
and	O
can	O
be	O
extrapolated	O
to	O
other	O
leafy	O
vegetables	O
.	O

Simultaneous	O
Bilateral	O
Cataract	O
Surgery	O
in	O
Outreach	O
Surgical	O
Camps	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
safety	O
and	O
visual	O
outcomes	O
of	O
simultaneous	O
bilateral	O
cataract	O
surgery	O
(	O
SBCS	O
)	O
with	O
intraocular	O
lens	O
implantation	O
performed	O
in	O
outreach	O
surgical	O
eye	O
camps	O
.	O

The	O
medical	O
records	O
of	O
47	O
consecutive	O
patients	O
who	O
underwent	O
simultaneous	O
bilateral	O
small-incision	O
cataract	O
surgery	O
between	O
January	O
2010	O
and	O
December	O
2015	O
in	O
outreach	O
surgical	O
camps	O
in	O
rural	O
Cameroon	O
were	O
reviewed	O
.	O

The	O
measures	O
included	O
postoperative	O
visual	O
outcomes	O
and	O
intraoperative	O
and	O
postoperative	O
complications	O
.	O

Data	O
from	O
94	O
eyes	O
of	O
47	O
participants	O
(	O
30	O
men	O
,	O
17	O
women	O
;	O
mean	O
age	O
:	O
60.93	O
±	O
13.58	O
years	O
,	O
range	O
:	O
45-80	O
years	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
presented	O
best	O
visual	O
acuity	O
(	O
VA	O
)	O
was	O
less	O
than	O
3/60	O
in	O
100	O
%	O
of	O
the	O
eyes	O
.	O

At	O
the	O
4-	O
week	O
follow-up	O
,	O
84.04	O
%	O
of	O
the	O
eyes	O
showed	O
increased	O
VA	O
of	O
1	O
line	O
or	O
more	O
(	O
P	O
=	O
.001	O
)	O
.	O

Of	O
these	O
,	O
71	O
(	O
75.53	O
%	O
)	O
achieved	O
good	O
VA	O
(	O
greater	O
than	O
6/18	O
)	O
.	O

Intraoperative	O
or	O
postoperative	O
complications	O
occurred	O
in	O
19	O
(	O
20.21	O
%	O
)	O
eyes	O
.	O

The	O
most	O
serious	O
intraoperative	O
complication	O
was	O
a	O
posterior	O
capsule	O
rupture	O
and	O
vitreous	O
loss	O
(	O
2	O
patients	O
,	O
2	O
eyes	O
)	O
.	O

The	O
postoperative	O
complications	O
included	O
a	O
transient	O
elevation	O
in	O
the	O
intraocular	O
pressure	O
(	O
6	O
eyes	O
)	O
,	O
chronic	O
corneal	O
oedema	O
(	O
5	O
eyes	O
)	O
,	O
iris	O
capture	O
(	O
3	O
eyes	O
)	O
,	O
lens	B-P
decentration	I-P
(	O
2	O
eyes	O
)	O
,	O
and	O
hyphema	O
(	O
1	O
eye	O
)	O
.	O

No	O
cases	O
of	O
postoperative	O
endophthalmitis	O
were	O
recorded	O
.	O

Under	O
the	O
strict	O
observation	O
of	O
endophthalmitis	O
prophylaxis	O
,	O
SBCS	O
is	O
an	O
option	O
to	O
reduce	O
the	O
cataract	O
blindness	O
backlog	O
in	O
rural	O
areas	O
of	O
developing	O
countries	O
.	O

The	O
Aortic	O
Root	O
:	O
Natural	O
History	O
After	O
Root-Sparing	O
Ascending	O
Replacement	O
in	O
Nonsyndromic	O
Aneurysmal	O
Patients	O
.	O

Leaving	O
native	O
aortic	O
tissue	O
in	O
situ	O
in	O
root-sparing	O
ascending	O
aortic	O
replacement	O
raises	O
concern	O
regarding	O
potential	O
later	O
need	O
for	O
root	O
reoperation	O
or	O
for	O
the	O
potential	O
occurrence	O
of	O
localized	O
dissections	O
or	O
rupture	O
in	O
the	O
residual	O
root	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
natural	O
growth	O
of	O
the	O
aortic	O
root	O
after	O
root-sparing	O
aortic	O
replacement	O
.	O

In	O
all	O
,	O
102	O
consecutive	O
patients	O
(	O
mean	O
age	O
61.8	O
±	O
12.5	O
years	O
;	O
60	O
%	O
male	O
)	O
who	O
had	O
undergone	O
root-sparing	O
aortic	O
replacement	O
had	O
sufficient	O
retrievable	O
information	O
regarding	O
their	O
aortic	O
root	O
diameter	O
at	O
postoperative	O
baseline	O
and	O
follow-up	O
imaging	B-P
by	O
computed	B-P
tomography	I-P
or	O
echocardiography	B-P
.	O

The	O
annual	O
growth	O
rate	O
was	O
evaluated	O
and	O
also	O
compared	O
according	O
to	O
the	O
influence	O
of	O
valve	O
morphology	O
and	O
concomitant	O
aortic	O
valve	O
replacement	O
.	O

Furthermore	O
,	O
the	O
years	O
of	O
natural	O
history	O
that	O
would	O
require	O
for	O
root	O
enlargement	O
to	O
meet	O
a	O
50	O
mm	O
threshold	O
of	O
the	O
root	O
diameter	O
were	O
calculated	O
.	O

The	O
estimated	O
growth	O
rate	O
of	O
the	O
aortic	O
root	O
after	O
root-sparing	O
aortic	O
replacement	O
is	O
between	O
0.27	O
and	O
0.51	O
mm	O
per	O
year	O
(	O
mean	O
0.41	O
mm	O
,	O
varying	O
according	O
to	O
the	O
underlying	O
diameter	O
)	O
and	O
therefore	O
fivefold	O
less	O
than	O
other	O
aortic	O
regions	O
.	O

Accordingly	O
,	O
a	O
root	O
aneurysm	O
indicating	O
reoperation	O
would	O
not	O
be	O
expected	O
for	O
29.1	O
years	O
on	O
average	O
.	O

Only	O
patients	O
with	O
a	O
diameter	O
of	O
45	O
mm	O
or	O
more	O
are	O
at	O
risk	O
for	O
reoperation	O
,	O
and	O
not	O
until	O
at	O
least	O
after	O
10.4	O
years	O
have	O
passed	O
.	O

Neither	O
the	O
valve	O
morphology	O
(	O
p	O
=	O
0.62	O
)	O
nor	O
concomitant	O
aortic	O
valve	O
replacement	O
(	O
p	O
=	O
0.86	O
)	O
influenced	O
rate	O
of	O
root	O
dilation	O
.	O

In	O
nonsyndromic	O
patients	O
,	O
the	O
aortic	O
root	O
is	O
the	O
slowest	O
growing	O
portion	O
of	O
the	O
thoracic	O
aorta	O
.	O

Leaving	O
the	O
native	O
root	O
,	O
as	O
in	O
root-sparing	O
ascending	O
aortic	O
replacement	O
,	O
is	O
a	O
safe	O
approach	O
regarding	O
secondary	O
root	O
intervention	O
for	O
aortic	O
root	O
diameters	O
of	O
45	O
mm	O
or	O
less	O
.	O

Association	O
of	O
Albuminuria	O
With	O
Cardiac	O
Dysfunction	O
in	O
US	O
Hispanics	O
/	O
Latinos	O
.	O

Higher	O
urine	O
albumin-to-creatinine	O
ratio	O
(	O
UACR	O
)	O
has	O
been	O
associated	O
with	O
cardiac	O
dysfunction	O
in	O
the	O
general	O
population	O
.	O

We	O
assessed	O
the	O
association	O
of	O
UACR	O
with	O
cardiac	O
structure	O
and	O
function	O
in	O
the	O
Echocardiographic	O
Study	O
of	O
Latinos	O
(	O
Echo-SOL	O
)	O
,	O
an	O
ancillary	O
study	O
of	O
the	O
Hispanic	O
Community	O
Health	O
Study	O
/	O
Study	O
of	O
Latinos	O
across	O
4	O
US	O
sites	O
.	O

Echo-SOL	O
participants	O
underwent	O
standard	O
2-dimensional	B-P
echocardiography	I-P
,	O
including	O
speckle-tracking	B-P
strain	I-P
analysis	I-P
.	O

UACR	O
was	O
categorized	O
as	O
normal	O
and	O
high-normal	O
(	O
based	O
on	O
the	O
midpoint	O
of	O
values	O
below	O
microalbuminuria	O
)	O
,	O
microalbuminuria	O
(	O
≥17	O
mg/g	O
for	O
men	O
;	O
≥25	O
mg/g	O
for	O
women	O
)	O
,	O
and	O
macroalbuminuria	O
(	O
≥250	O
mg/g	O
;	O
≥355	O
mg/g	O
)	O
.	O

Simultaneous	O
assessments	O
were	O
made	O
of	O
left	O
ventricular	O
(	O
LV	O
)	O
mass	O
index	O
and	O
hypertrophy	O
and	O
measures	O
of	O
LV	O
systolic	O
and	O
diastolic	O
dysfunction	O
.	O

We	O
assessed	O
the	O
association	O
of	O
UACR	O
with	O
subclinical	B-P
cardiac	I-P
measures	I-P
,	O
adjusting	O
for	O
sociodemographic	O
and	O
cardiometabolic	O
factors	O
.	O

Among	O
1,815	O
participants	O
(	O
median	O
age	O
54	O
,	O
women	O
65	O
%	O
)	O
,	O
42	O
%	O
had	O
normal	O
UACR	O
,	O
43	O
%	O
high-normal	O
UACR	O
,	O
13	O
%	O
microalbuminuria	O
,	O
and	O
2	O
%	O
macroalbuminuria	O
.	O

Prevalence	O
of	O
LV	O
hypertrophy	O
was	O
13	O
%	O
,	O
LV	O
systolic	O
dysfunction	O
(	O
ejection	O
fraction	O
<	O
50	O
%	O
)	O
3	O
%	O
,	O
and	O
diastolic	O
dysfunction	O
53	O
%	O
.	O

After	O
covariate	O
adjustment	O
,	O
both	O
micro-	O
and	O
macroalbuminuria	O
were	O
significantly	O
associated	O
with	O
a	O
twofold	O
increase	O
in	O
LV	O
hypertrophy	O
.	O

Microalbuminuria	O
but	O
not	O
macroalbuminuria	O
was	O
associated	O
with	O
worse	O
global	O
longitudinal	O
strain	O
.	O

Elevated	O
UACR	O
,	O
even	O
at	O
high-normal	O
levels	O
,	O
was	O
significantly	O
associated	O
with	O
greater	O
diastolic	O
dysfunction	O
.	O

In	O
conclusion	O
,	O
elevated	O
UACR	O
was	O
associated	O
with	O
LV	O
hypertrophy	O
and	O
diastolic	O
dysfunction	O
in	O
the	O
largest	O
known	O
population	O
sample	O
of	O
US	O
Hispanic	O
/	O
Latinos	O
.	O

Screening	B-P
and	O
detection	O
of	O
even	O
high-normal	O
UACR	O
could	O
be	O
of	O
value	O
to	O
guide	O
cardiovascular	O
disease	O
prevention	O
efforts	O
among	O
Hispanic	O
/	O
Latino	O
Americans	O
.	O

Paraoxonases	O
and	O
psoriasis	O
:	O
negative	O
imbalance	O
of	O
anti	O
--	O
oxidant	O
endogenous	O
mechanisms	O
.	O

Numerous	O
reports	O
have	O
shown	O
that	O
psoriasis	O
patients	O
are	O
more	O
exposed	O
to	O
lipoprotein	O
peroxidation	O
and	O
to	O
a	O
decrease	O
in	O
the	O
activity	O
of	O
paraoxonase	O
(	O
PON	O
)	O
1	O
,	O
an	O
anti-oxidant	O
and	O
anti-inflammatory	O
enzyme	O
.	O

Thus	O
,	O
it	O
has	O
been	O
suggested	O
that	O
malfunction	O
of	O
the	O
anti-oxidant	O
system	O
and	O
an	O
increased	O
production	O
of	O
reactive	O
oxygen	O
species	O
drive	O
immune	O
inflammatory	O
events	O
,	O
that	O
result	O
in	O
progressive	O
skin	O
cell	O
damage	O
in	O
patients	O
with	O
psoriasis	O
.	O

The	O
PON	O
protein	O
family	O
,	O
including	O
PON1	O
,	O
PON2	O
and	O
PON3	O
,	O
is	O
one	O
of	O
the	O
most	O
important	O
endogenous	O
defense	O
mechanisms	O
against	O
oxidative	O
stress	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
PON	O
gene	O
expression	O
in	O
psoriasis	O
and	O
in	O
cutaneous	O
oxidative	O
stress	O
.	O

The	O
study	O
population	O
included	O
10	O
patients	O
affected	O
by	O
moderate	O
-to-	O
severe	O
plaque	O
psoriasis	O
and	O
15	O
healthy	O
donors	O
who	O
have	O
undergone	O
to	O
plastic	O
surgery	O
,	O
were	O
used	O
as	O
control	O
.	O

Skin	B-P
punch	I-P
biopsies	I-P
of	O
lesional	O
and	O
non	O
lesional	O
psoriatic	O
skin	O
were	O
performed	O
for	O
analysis	O
of	O
PON2	O
and	O
PON3	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
oxidation	O
assays	B-P
in	O
ex	O
vivo	O
full-thickness	O
healthy	O
skin	O
organ	B-P
cultures	I-P
were	O
performed	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
PON2	O
and	O
PON3	O
gene	O
expression	O
in	O
psoriatic	O
lesional	O
and	O
non	O
lesional	O
skin	O
compared	O
with	O
healthy	O
controls	O
.	O

H2O2	O
treatment	O
induced	O
a	O
significant	O
decrease	O
of	O
PON2	O
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full-thickness	O
healthy	O
skin	O
organ	B-P
cultures	I-P
;	O
conversely	O
the	O
pre-treatment	O
of	O
samples	O
with	O
the	O
anti-oxidant	O
reagent	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
induced	O
a	O
significant	O
increase	O
.	O

Interestingly	O
,	O
no	O
significant	O
alterations	O
were	O
reported	O
for	O
PON2	O
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full-thickness	O
healthy	O
skin	O
organ	B-P
cultures	I-P
stimulated	O
with	O
IL-17	O
.	O

Taken	O
together	O
our	O
findings	O
have	O
revealed	O
that	O
a	O
strong	O
pro-oxidative	O
activity	O
is	O
not	O
effectively	O
countered	O
by	O
anti-oxidant	O
endogenous	O
mechanisms	O
both	O
in	O
psoriatic	O
skin	O
and	O
in	O
ex	O
vivo	O
experimental	O
model	O
.	O

Consecutive	O
non-natural	O
PZ	O
nucleobase	O
pairs	O
in	O
DNA	O
impact	O
helical	O
structure	O
as	O
seen	O
in	O
50	O
μs	O
molecular	O
dynamics	O
simulations	O
.	O

Little	O
is	O
known	O
about	O
the	O
influence	O
of	O
multiple	O
consecutive	O
'	O
non-standard	O
'	O
(	O
,	O
6-amino-5-nitro-2	O
(	O
1H	O
)	O
-pyridone	O
,	O
and	O
,	O
2-amino-imidazo	O
[	O
1,2-a	O
]	O
-1,3,5-triazin-4	O
(	O
8H	O
)	O
-one	O
)	O
nucleobase	O
pairs	O
on	O
the	O
structural	O
parameters	O
of	O
duplex	O
DNA	O
.	O

nucleobase	O
pairs	O
follow	O
standard	O
rules	O
for	O
Watson-Crick	O
base	O
pairing	O
but	O
have	O
rearranged	O
hydrogen	O
bonding	O
donor	O
and	O
acceptor	O
groups	O
.	O

Using	O
the	O
X-ray	B-P
crystal	I-P
structure	I-P
as	O
a	O
starting	O
point	O
,	O
we	O
have	O
modeled	O
the	O
motions	O
of	O
a	O
DNA	O
duplex	O
built	O
from	O
a	O
self-complementary	O
oligonucleotide	O
(	O
5΄-CTTATPPPZZZATAAG-3΄	O
)	O
in	O
water	O
over	O
a	O
period	O
of	O
50	O
μs	O
and	O
calculated	B-P
DNA	O
local	O
parameters	O
,	O
step	O
parameters	O
,	O
helix	O
parameters	O
,	O
and	O
major	O
/	O
minor	O
groove	O
widths	O
to	O
examine	O
how	O
the	O
presence	O
of	O
multiple	O
,	O
consecutive	O
nucleobase	O
pairs	O
might	O
impact	O
helical	O
structure	O
.	O

In	O
these	O
simulations	O
,	O
the	O
-	O
containing	O
DNA	O
duplex	O
exhibits	O
a	O
significantly	O
wider	O
major	O
groove	O
and	O
greater	O
average	O
values	O
of	O
stagger	O
,	O
slide	O
,	O
rise	O
,	O
twist	O
and	O
h-rise	O
than	O
observed	O
for	O
a	O
'	O
control	O
'	O
oligonucleotide	O
in	O
which	O
nucleobase	O
pairs	O
are	O
replaced	O
by	O
.	O

The	O
molecular	O
origins	O
of	O
these	O
structural	O
changes	O
are	O
likely	O
associated	O
with	O
at	O
least	O
two	O
differences	O
between	O
and	O
.	O

First	O
,	O
the	O
electrostatic	O
properties	O
of	O
differ	O
from	O
in	O
terms	O
of	O
density	O
distribution	O
and	O
dipole	O
moment	O
.	O

Second	O
,	O
differences	O
are	O
seen	O
in	O
the	O
base	O
stacking	O
of	O
pairs	O
in	O
dinucleotide	O
steps	O
,	O
arising	O
from	O
energetically	O
favorable	O
stacking	O
of	O
the	O
nitro	O
group	O
in	O
with	O
π-electrons	O
of	O
the	O
adjacent	O
base	O
.	O

Data	O
on	O
the	O
uptake	O
and	O
metabolism	O
of	O
testosterone	O
by	O
the	O
common	O
mussel	O
,	O
Mytilus	O
spp	O
.	O

This	O
article	O
provides	O
data	O
in	O
support	O
of	O
the	O
research	O
article	O
entitled	O
``	O
Rapid	O
uptake	O
,	O
biotransformation	O
,	O
esterification	O
and	O
lack	O
of	O
depuration	O
of	O
testosterone	O
and	O
its	O
metabolites	O
by	O
the	O
common	O
mussel	O
,	O
Mytilus	O
spp	O
.	O
''	O

(	O
T.I	O
.	O

Schwarz	O
,	O
I.	O
Katsiadaki	O
,	O
B.H	O
.	O

Maskrey	O
,	O
A.P	O
.	O

Scott	O
,	O
2017	O
)	O
[	O
1	O
]	O
.	O

The	O
uptake	O
of	O
tritiated	O
testosterone	O
(	O
T	O
)	O
from	O
water	O
by	O
mussels	O
is	O
presented	O
.	O

The	O
two	O
main	O
radioactive	O
peaks	O
formed	O
from	O
T	O
and	O
present	O
in	O
the	O
fatty	O
acid	O
ester	O
fraction	O
of	O
mussel	O
tissues	O
were	O
shown	O
to	O
have	O
the	O
same	O
elution	B-P
positions	O
on	O
a	O
thin	B-P
layer	I-P
chromatography	I-P
plate	I-P
as	O
17β-hydroxy-5α-androstan-3-one	O
(	O
DHT	O
)	O
and	O
5α-androstan-3β,17β-diol	O
(	O
3β,17β-A5α	O
)	O
.	O

Reverse	B-P
phase	I-P
high	I-P
performance	I-P
liquid	I-P
chromatography	I-P
of	O
the	O
non-esterified	O
(	O
80	O
%	O
ethanol	O
)	O
fraction	O
of	O
the	O
mussel	O
tissue	O
extracts	O
also	O
presented	O
radioactive	O
peaks	O
at	O
the	O
elution	B-P
positions	O
of	O
DHT	O
and	O
3β,17β-A5α	O
.	O

There	O
was	O
no	O
evidence	O
for	O
sulfated	O
T	O
in	O
this	O
fraction	O
.	O

It	O
was	O
shown	O
that	O
aeration	O
led	O
to	O
significant	O
losses	O
of	O
radiolabeled	O
testosterone	O
from	O
the	O
water	O
column	O
.	O

MicroRNA-26a	O
protects	O
against	O
cardiac	O
hypertrophy	O
via	O
inhibiting	O
GATA4	O
in	O
rat	O
model	O
and	O
cultured	O
cardiomyocytes..	O
Pathological	O
cardiac	O
hypertrophy	O
is	O
characterized	O
by	O
deleterious	O
changes	O
developed	O
in	O
cardiovascular	O
diseases	O
,	O
whereas	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
involved	O
in	O
the	O
mediation	O
of	O
cardiac	O
hypertrophy	O
.	O

To	O
investigate	O
the	O
role	O
of	O
microRNA-26a	O
(	O
miR-26a	O
)	O
in	O
regulating	O
cardiac	O
hypertrophy	O
and	O
its	O
functioning	O
mechanisms	O
,	O
overexpression	O
and	O
suppression	O
of	O
miR-26a	O
via	O
its	O
mimic	O
and	O
inhibitor	O
in	O
a	O
transverse	O
abdominal	O
aortic	O
constriction	O
(	O
TAAC	O
)	O
-	O
induced	O
rat	O
model	O
and	O
in	O
angiotensin	O
II	O
(	O
Ang	O
II	O
)	O
-	O
induced	O
cardiomyocytes	O
(	O
CMs	O
)	O
was	O
performed	O
.	O

In	O
the	O
rat	O
model	O
,	O
the	O
heart	O
weight	O
(	O
HW	O
)	O
compared	O
with	O
the	O
body	O
weight	O
(	O
BW	O
)	O
,	O
the	O
CM	O
area	O
,	O
and	O
expression	O
of	O
the	O
hypertrophy	O
-	O
associated	O
factors	O
,	O
atrial	O
natriuretic	O
factor	O
(	O
ANF	O
)	O
and	O
ß-myosin	O
heavy	O
chain	O
(	O
ß-MHC	O
)	O
,	O
were	O
assessed	O
.	O

In	O
CMs	O
,	O
the	O
protein	O
synthesis	O
rate	O
was	O
determined	O
using	O
a	O
leucine	B-P
incorporation	I-P
assay	I-P
.	O

Mutation	O
of	O
the	O
GATA-binding	O
protein	O
4	O
(	O
GATA4	O
)	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
and	O
overexpression	O
of	O
GATA4	O
were	O
performed	O
to	O
confirm	O
whether	O
GATA4	O
is	O
the	O
target	O
of	O
miR-26a	O
.	O

The	O
results	O
indicated	O
that	O
miR-26a	O
was	O
significantly	O
downregulated	O
in	O
the	O
heart	O
tissue	O
of	O
the	O
rat	O
model	O
,	O
as	O
well	O
as	O
in	O
Ang	O
II	O
-	O
induced	O
CMs	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
TAAC	O
-	O
induced	O
rat	O
model	O
exhibited	O
a	O
higher	O
HW	O
/	O
BW	O
ratio	O
,	O
a	O
larger	O
CM	O
area	O
,	O
and	O
higher	O
expression	O
levels	O
of	O
ANF	O
and	O
ß-MHC	O
.	O

CMs	O
,	O
upon	O
Ang	O
II	O
treatment	O
,	O
also	O
demonstrated	O
a	O
larger	O
CM	O
area	O
,	O
higher	O
levels	O
of	O
ANF	O
and	O
ß-MHC	O
,	O
as	O
well	O
as	O
accelerated	O
protein	O
synthesis	O
.	O

miR-26a	O
was	O
not	O
able	O
to	O
regulate	O
GATA4	O
with	O
mutations	O
in	O
the	O
3'-UTR	O
,	O
indicating	O
that	O
GATA4	O
was	O
the	O
direct	O
target	O
of	O
miR-26a	O
.	O

Overexpression	O
of	O
GATA4	O
abrogated	O
the	O
inhibitory	O
functions	O
of	O
miR-26a	O
in	O
cardiac	O
hypertrophy	O
.	O

Taken	O
together	O
,	O
the	O
present	O
study	O
suggested	O
an	O
anti-hypertrophic	O
role	O
of	O
miR-26a	O
in	O
cardiac	O
hypertrophy	O
,	O
possibly	O
via	O
inhibition	O
of	O
GATA4	O
.	O

These	O
findings	O
may	O
be	O
useful	O
in	O
terms	O
of	O
facilitating	O
cardiac	O
treatment	O
,	O
with	O
potential	O
therapeutic	O
targets	O
and	O
strategies	O
.	O

Extrapulmonary	O
Small	O
Cell	O
Carcinoma	O
of	O
the	O
Seminal	O
Vesicles	O
and	O
Prostate	O
Demonstrated	O
on	O
18F-FDG	B-P
Positron	I-P
Emission	I-P
Tomography/Computed	I-P
Tomography	I-P
.	O

Extrapulmonary	O
primary	O
small	O
cell	O
carcinomas	O
arising	O
from	O
the	O
urogenital	O
tract	O
is	O
infrequent	O
.	O

It	O
can	O
rarely	O
arise	O
from	O
the	O
prostate	O
and	O
even	O
more	O
rarely	O
from	O
the	O
seminal	O
vesicles	O
.	O

We	O
present	O
a	O
79-	O
year	O
-old	O
male	O
who	O
was	O
admitted	O
due	O
to	O
acute	O
renal	O
failure	O
with	O
a	O
history	O
of	O
radical	O
radiotherapy	O
for	O
prostate	O
adenocarcinoma	O
13	O
years	O
ago	O
.	O

The	O
prostate	O
specific	O
antigen	O
level	O
was	O
not	O
elevated	O
.	O

An	O
abdominopelvic	B-P
computed	I-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
scan	I-P
showed	O
markedly	O
enlarged	O
seminal	O
vesicles	O
causing	O
bilateral	O
ureteral	O
obstruction	O
and	O
a	O
mildly	O
enlarged	O
prostate	O
.	O

Further	O
evaluation	O
with	O
fluorine-18-fluorodeoxyglucose	B-P
(	I-P
18F-FDG	I-P
)	I-P
positron	I-P
emission	I-P
tomography/CT	I-P
demonstrated	O
extensive	O
18F-FDG	O
uptake	O
in	O
the	O
pelvis	O
with	O
diffuse	O
involvement	O
of	O
both	O
seminal	O
vesicles	O
and	O
the	O
prostate	O
without	O
pathologic	O
uptake	O
in	O
the	O
lungs	O
or	O
elsewhere	O
in	O
the	O
body	O
.	O

Core	B-P
biopsies	I-P
of	O
the	O
prostate	O
and	O
both	O
seminal	O
vesicles	O
revealed	O
diffuse	O
involvement	O
by	O
small	O
cell	O
carcinoma	O
.	O

Therapy	O
could	O
not	O
be	O
instituted	O
due	O
to	O
a	O
rapid	O
deterioration	O
in	O
the	O
patient	O
's	O
clinical	O
condition	O
.	O

The	O
Role	O
of	O
Rehabilitation	O
in	O
the	O
Management	O
of	O
Patients	O
with	O
Charcot-Marie-Tooth	O
Disease	O
:	O
Report	O
of	O
Two	O
Cases	O
.	O

Charcot-Marie-Tooth	O
(	O
CMT	O
)	O
disease	O
is	O
a	O
hereditary	O
disease	O
with	O
signs	O
of	O
chronic	O
non-progressive	O
motor-sensory	O
neuropathy	O
which	O
is	O
characterised	O
by	O
symmetric	O
muscle	O
atrophy	O
and	O
weakness	O
of	O
the	O
distal	O
portion	O
of	O
lower	O
extremities	O
.	O

The	O
aim	O
is	O
to	O
present	O
two	O
cases	O
with	O
peroneal	O
muscular	O
atrophy	O
,	O
applied	O
rehabilitation	O
procedures	O
and	O
rehabilitation	O
outcome	O
.	O

Patient	O
DR	O
,	O
aged	O
51	O
,	O
and	O
patient	O
KH	O
,	O
aged	O
78	O
.	O

Both	O
patients	O
had	O
weakness	O
and	O
pronounced	O
atrophy	O
of	O
the	O
distal	O
portion	O
of	O
lower	O
extremities	O
,	O
numbness	O
down	O
the	O
legs	O
,	O
contractures	O
in	O
the	O
ankles	O
and	O
walking	O
difficulties	O
.	O

Evaluation	O
of	O
patients	O
included	O
a	O
clinical	O
examination	O
,	O
Barthel	O
Index	O
,	O
Time	B-P
Up	I-P
and	I-P
Go	I-P
test	I-P
,	O
measurement	O
of	O
the	O
ankle	O
range	O
of	O
motion	O
,	O
and	O
a	O
manual	B-P
muscle	I-P
test	I-P
.	O

On	O
admission	O
,	O
the	O
Barthel	O
Index	O
score	O
was	O
60	O
in	O
the	O
first	O
case	O
,	O
and	O
80	O
in	O
the	O
second	O
.	O

The	O
rehabilitation	O
program	O
included	O
exercise	O
therapy	O
with	O
for	O
lower	O
extremity	O
,	O
occupational	O
therapy	O
,	O
stationary	O
bicycle	O
riding	O
,	O
galvanic	O
current	O
,	O
water	O
exercises	O
,	O
and	O
ankle-foot	O
orthoses	O
for	O
both	O
legs	O
.	O

The	O
therapy	O
applied	O
had	O
no	O
significant	O
changes	O
in	O
the	O
clinical	O
neurological	O
status	O
of	O
the	O
patients	O
,	O
but	O
yet	O
it	O
provided	O
some	O
improvement	O
in	O
ankle	O
contractures	O
,	O
better	O
mobility	O
,	O
and	O
a	O
more	O
stable	O
gait	O
.	O

The	O
application	O
of	O
rehabilitation	O
procedures	O
in	O
patients	O
with	O
Charcot-Marie-Tooth	O
disease	O
can	O
improve	O
their	O
functional	O
status	O
and	O
walking	O
stability	O
.	O

Extended	O
Release	O
Guanfacine	O
in	O
Pediatric	O
Anxiety	O
Disorders	O
:	O
A	O
Pilot	O
,	O
Randomized	O
,	O
Placebo-Controlled	O
Trial	O
.	O

This	O
is	O
a	O
feasibility	O
study	O
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	O
of	O
the	O
α2	O
agonist	O
guanfacine	O
extended-release	O
(	O
GXR	O
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	O
disorder	O
(	O
GAD	O
)	O
,	O
separation	O
anxiety	O
disorder	O
(	O
SAD	O
)	O
,	O
or	O
social	O
phobia	O
/	O
social	O
anxiety	O
disorder	O
.	O

Youth	O
aged	O
6-17	O
years	O
with	O
a	O
primary	O
diagnosis	O
of	O
GAD	O
,	O
SAD	O
,	O
and/or	O
social	O
anxiety	O
disorder	O
were	O
treated	O
with	O
flexibly	O
dosed	O
GXR	O
(	O
1-6	O
mg	O
daily	O
,	O
n	O
=	O
62	O
)	O
or	O
placebo	O
(	O
n	O
=	O
21	O
)	O
for	O
12	O
weeks	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
GXR	O
in	O
youth	O
with	O
anxiety	O
disorders	O
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	O
-	O
emergent	O
adverse	O
events	O
(	O
TEAEs	O
)	O
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	O
and	O
behaviors	O
,	O
vital	O
signs	O
,	O
and	O
electrocardiographic	B-P
/	O
laboratory	O
parameters	O
.	O

Exploratory	O
efficacy	O
measures	O
included	O
dimensional	O
anxiety	O
scales	O
(	O
Pediatric	O
Anxiety	O
Rating	O
Scale	O
[	O
PARS	O
]	O
and	O
Screen	O
for	O
Child	O
Anxiety	O
Related	O
Emotional	O
Disorders	O
[	O
SCARED	O
]	O
)	O
,	O
as	O
well	O
as	O
the	O
Clinical	O
Global	O
Impression-Improvement	O
(	O
CGI-I	O
)	O
scale	O
.	O

As	O
this	O
was	O
an	O
exploratory	O
study	O
,	O
no	O
inferential	O
statistical	O
analyses	O
were	O
performed	O
.	O

GXR	O
was	O
safe	O
and	O
well	O
tolerated	O
.	O

Treatment	O
-related	O
mean	O
±	O
standard	O
deviation	O
changes	O
in	O
heart	O
rate	O
(	O
GXR	O
:	O
1.8	O
±	O
12	O
beats	O
per	O
minute	O
[	O
bpm	O
]	O
decrease	O
;	O
placebo	O
:	O
0.5	O
±	O
11	O
bpm	O
decrease	O
)	O
,	O
systolic	O
blood	O
pressure	O
(	O
GXR	O
:	O
2.3	O
±	O
11	O
mm	O
Hg	O
decrease	O
;	O
placebo	O
:	O
1.7	O
±	O
11	O
mm	O
Hg	O
decrease	O
)	O
,	O
or	O
diastolic	O
blood	O
pressure	O
(	O
GXR	O
:	O
1.3	O
±	O
9	O
mm	O
Hg	O
decrease	O
;	O
placebo	O
:	O
0.9	O
±	O
7	O
mm	O
Hg	O
increase	O
)	O
were	O
similar	O
between	O
treatment	O
groups	O
.	O

TEAEs	O
,	O
including	O
headache	O
,	O
somnolence	O
/	O
fatigue	O
,	O
abdominal	O
pain	O
,	O
and	O
dizziness	O
,	O
were	O
consistent	O
with	O
the	O
known	O
safety	O
profile	O
of	O
GXR	O
.	O

No	O
differences	O
were	O
observed	O
between	O
treatment	O
groups	O
for	O
PARS	O
and	O
SCARED	O
scores	O
,	O
although	O
at	O
endpoint	O
,	O
a	O
higher	O
proportion	O
of	O
subjects	O
receiving	O
GXR	O
versus	O
placebo	O
demonstrated	O
CGI-I	O
scores	O
≤2	O
(	O
54.2	O
%	O
vs.	O
31.6	O
%	O
)	O
,	O
as	O
rated	O
by	O
the	O
clinician	O
investigator	O
.	O

GXR	O
was	O
well	O
tolerated	O
in	O
pediatric	O
subjects	O
with	O
GAD	O
,	O
SAD	O
,	O
and/or	O
social	O
anxiety	O
disorder	O
.	O

ClinicalTrials.gov	O
Identifier	O
:	O
NCT01470469	O
.	O

Country	O
-	O
specific	O
chemical	O
signatures	O
of	O
persistent	O
organic	O
pollutants	O
(	O
POPs	O
)	O
in	O
breast	O
milk	O
of	O
French	O
,	O
Danish	O
and	O
Finnish	O
women	O
.	O

The	O
present	O
study	O
compares	O
concentrations	O
and	O
chemical	B-P
profiles	I-P
of	O
an	O
extended	O
range	O
of	O
persistent	O
organic	O
pollutants	O
(	O
dioxins	O
,	O
polychlorobiphenyls	O
,	O
brominated	O
flame	O
retardants	O
and	O
organochlorine	O
pesticides	O
)	O
in	O
breast	O
milk	O
samples	O
from	O
French	O
(	O
n	O
=	O
96	O
)	O
,	O
Danish	O
(	O
n	O
=	O
438	O
)	O
and	O
Finnish	O
(	O
n	O
=	O
22	O
)	O
women	O
.	O

Median	O
exposure	O
levels	O
observed	O
in	O
French	O
women	O
(	O
WHO	O
-	O
TEQ	O
2005	O
PCDD/F	O
=	O
6.1	O
pg/g	O
l.w.	O
,	O
WHO	O
-	O
TEQ	O
2005	O
dl-PCB	O
=	O
4.3	O
pg/g	O
l.w.	O
,	O
sum	O
of	O
6	O
ndl-PCB	O
=	O
85.2	O
ng/g	O
l.w.	O
,	O
sum	O
of	O
7	O
i-PBDE	O
=	O
1.5	O
ng/g	O
l.w	O
.	O
)	O

appeared	O
overall	O
lower	O
than	O
in	O
Danish	O
and	O
Finnish	O
women	O
for	O
all	O
examined	O
POPs	O
,	O
except	O
for	O
α-HBCD	O
(	O
2-fold	O
higher	O
level	O
at	O
0.6	O
ng/g	O
l.w.	O
)	O
.	O

Furthermore	O
,	O
the	O
observed	O
exposure	O
levels	O
of	O
dioxins	O
and	O
PCBs	O
were	O
higher	O
in	O
Danish	O
women	O
(	O
WHO	O
-	O
TEQ	O
2005	O
PCDD/F	O
=	O
13.2	O
pg/g	O
l.w.	O
,	O
WHO	O
-	O
TEQ	O
2005	O
dl-PCB	O
=	O
6.6	O
pg/g	O
l.w.	O
,	O
sum	O
of	O
6	O
ndl-PCB	O
=	O
162.8	O
ng/g	O
l.w	O
.	O
)	O

compared	O
to	O
Finnish	O
women	O
(	O
WHO	O
-	O
TEQ	O
2005	O
PCDD/F	O
=	O
9.0	O
pg/g	O
l.w.	O
,	O
WHO	O
-	O
TEQ	O
2005	O
dl-PCB	O
=	O
4.6	O
pg/g	O
l.w.	O
,	O
sum	O
of	O
6	O
ndl-PCB	O
=	O
104.0	O
ng/g	O
l.w	O
.	O

)	O
,	O
whereas	O
the	O
concentrations	O
of	O
PBDEs	O
were	O
similar	O
for	O
Danish	O
and	O
Finnish	O
women	O
(	O
sum	O
of	O
7	O
i-PBDE	O
=	O
4.9	O
and	O
5.2	O
ng/g	O
l.w	O
.	O

respectively	O
)	O
.	O

The	O
organochlorine	O
(	O
OC	O
)	O
pesticide	O
contamination	O
profile	O
,	O
determined	O
in	O
a	O
subset	O
of	O
French	O
samples	O
,	O
was	O
dominated	O
by	O
p	O
,	O
p'-DDE	O
(	O
56.6	O
%	O
)	O
,	O
followed	O
by	O
β-HCH	O
(	O
14.2	O
%	O
)	O
,	O
HCB	O
(	O
9.7	O
%	O
)	O
and	O
dieldrin	O
(	O
5.2	O
%	O
)	O
,	O
while	O
other	O
compounds	O
were	O
only	O
minor	O
contributors	O
(	O
<	O
5	O
%	O
)	O
.	O

The	O
three	O
countries	O
appeared	O
to	O
be	O
discriminated	O
by	O
the	O
observed	O
contamination	O
patterns	O
of	O
the	O
PCDD/F	O
versus	O
PCB	O
,	O
and	O
the	O
1,2,3,6,7,8-HxCDD	O
versus	O
1,2,3,4,7,8-HxCDD	O
ratios	O
,	O
in	O
addition	O
to	O
the	O
relative	O
contributions	O
of	O
specific	O
congeners	O
to	O
the	O
contamination	O
profile	O
(	O
PCBs	O
#	O
118	O
and	O
#	O
156	O
,	O
PBDEs	O
#	O
28	O
,	O
#	O
47	O
,	O
#	O
99	O
and	O
#	O
153	O
)	O
.	O

In	O
conclusion	O
,	O
unique	O
chemical	O
signatures	O
were	O
observed	O
for	O
each	O
country	O
on	O
the	O
basis	O
of	O
some	O
POP	O
congeners	O
.	O

Future	O
biomonitoring	O
studies	O
will	O
need	O
to	O
consider	O
the	O
high	O
variability	O
of	O
individual	O
exposure	O
profiles	O
in	O
relation	O
to	O
multiple	O
exposure	O
sources	O
but	O
also	O
physiological	O
and	O
metabolic	O
differences	O
.	O

Comparison	O
of	O
pulse	O
wave	O
velocity	O
derived	O
from	O
accelerometer	O
and	O
reflective	B-P
photo-plethysmography	I-P
signals	I-P
placed	O
at	O
the	O
carotid	O
and	O
femoral	O
artery	O
.	O

Carotid	O
-	O
femoral	O
pulse	O
wave	O
velocity	O
is	O
an	O
established	O
measure	O
to	O
assess	O
cardiovascular	O
risk	O
and	O
an	O
interesting	O
surrogate	O
parameter	O
towards	O
non-invasive	O
continuous	O
blood	O
pressure	O
inference	O
.	O

Due	O
to	O
progress	O
in	O
sensing	O
technologies	O
for	O
wearable	O
wrist	O
worn	O
sensors	O
,	O
there	O
are	O
low	O
cost	O
sensor	O
combinations	O
of	O
photo-plethysmography	B-P
and	O
high	O
fidelity	O
accelerometer	O
s	O
available	O
offering	O
access	O
to	O
pulse	O
information	O
from	O
larger	O
arteries	O
complemented	O
by	O
blood	O
volume	O
changes	O
in	O
the	O
superficial	O
tissue	O
.	O

In	O
this	O
work	O
we	O
compare	O
pulse	O
wave	O
velocities	O
derived	O
from	O
accelerometer	O
and	O
reflective	B-P
photo-plethysmography	I-P
signals	I-P
placed	O
at	O
the	O
carotid	O
and	O
femoral	O
artery	O
.	O

We	O
discuss	O
the	O
different	O
underlying	O
physiological	O
processes	O
for	O
the	O
two	O
sensing	O
principles	O
and	O
present	O
experimental	O
results	O
obtained	O
in	O
a	O
study	O
with	O
healthy	O
subjects	O
.	O

Dupuytren	O
in	O
a	O
Child	O
:	O
Rare	O
Presentation	O
of	O
a	O
Rare	O
Clinical	O
Entity	O
.	O

Dupuytren	O
disease	O
in	O
children	O
younger	O
than	O
10	O
years	O
is	O
rare	O
and	O
only	O
8	O
histologically	O
proven	O
cases	O
have	O
been	O
reported	O
.	O

A	O
histologically	O
proven	O
Dupuytren	O
disease	O
in	O
a	O
10-year-old	O
with	O
an	O
uncommon	O
clinical	O
presentation	O
as	O
a	O
nodule	O
on	O
the	O
radial	O
side	O
of	O
the	O
middle	O
phalanx	O
of	O
the	O
little	O
finger	O
is	O
documented	O
.	O

Dupuytren	O
's	O
disease	O
should	O
be	O
in	O
the	O
differential	B-P
diagnosis	I-P
in	O
cases	O
of	O
nodules	O
and	O
contractures	O
in	O
the	O
palm	O
and	O
fingers	O
of	O
children	O
.	O

Cardioprotective	O
kinase	O
signaling	O
to	O
subsarcolemmal	O
and	O
interfibrillar	O
mitochondria	O
is	O
mediated	O
by	O
caveolar	O
structures	O
.	O

The	O
demonstration	O
that	O
caveolin-3	O
overexpression	O
reduces	O
myocardial	O
ischemia	O
/	O
reperfusion	O
injury	O
and	O
our	O
own	O
finding	O
that	O
multiprotein	O
signaling	O
complexes	O
increase	O
in	O
mitochondria	O
in	O
association	O
with	O
caveolin-3	O
levels	O
,	O
led	O
us	O
to	O
investigate	O
the	O
contribution	O
of	O
caveolae	O
-driven	O
extracellular	O
signal-regulated	O
kinases	O
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
on	O
maintaining	O
the	O
function	O
of	O
cardiac	O
mitochondrial	O
subpopulations	O
from	O
reperfused	O
hearts	O
subjected	O
to	O
postconditioning	O
(	O
PostC	O
)	O
.	O

Rat	O
hearts	O
were	O
isolated	O
and	O
subjected	O
to	O
ischemia	O
/	O
reperfusion	O
and	O
to	O
PostC	O
.	O

Enhanced	O
cardiac	O
function	O
,	O
reduced	O
infarct	O
size	O
and	O
preserved	O
ultrastructure	O
of	O
cardiomyocytes	O
were	O
associated	O
with	O
increased	O
formation	O
of	O
caveolar	O
structures	O
,	O
augmented	O
levels	O
of	O
caveolin-3	O
and	O
mitochondrial	O
ERK1	O
/	O
2	O
activation	O
in	O
PostC	O
hearts	O
in	O
both	O
subsarcolemmal	O
(	O
SSM	O
)	O
and	O
interfibrillar	O
(	O
IFM	O
)	O
subpopulations	O
.	O

Disruption	O
of	O
caveolae	O
with	O
methyl-β-cyclodextrin	O
abolished	O
cardioprotection	O
in	O
PostC	O
hearts	O
and	O
diminished	O
pho-ERK1/2	O
gold	O
-	O
labeling	B-P
in	O
both	O
mitochondrial	O
subpopulations	O
in	O
correlation	O
with	O
suppression	O
of	O
resistance	O
to	O
permeability	O
transition	O
pore	O
opening	O
.	O

Also	O
,	O
differences	O
between	O
the	O
mitochondrial	O
subpopulations	O
in	O
the	O
setting	O
of	O
PostC	O
were	O
evaluated	O
.	O

Caveolae	O
disruption	O
with	O
methyl-β-cyclodextrin	O
abolished	O
the	O
cardioprotective	O
effect	O
of	O
postconditioning	O
by	O
inhibiting	O
the	O
interaction	O
of	O
ERK1	O
/	O
2	O
with	O
mitochondria	O
and	O
promoted	O
decline	O
in	O
mitochondrial	O
function	O
.	O

SSM	O
,	O
which	O
are	O
particularly	O
sensitive	O
to	O
reperfusion	O
damage	O
,	O
take	O
advantage	O
of	O
their	O
location	O
in	O
cardiomyocyte	O
boundary	O
and	O
benefit	O
from	O
the	O
cardioprotective	O
signaling	O
driven	O
by	O
caveolae	O
,	O
avoiding	O
injury	O
propagation	O
.	O

DT	B-P
MRI	I-P
microstructural	O
cortical	O
lesion	O
damage	O
does	O
not	O
explain	O
cognitive	O
impairment	O
in	O
MS.	O
We	O
combined	O
double	O
inversion	O
recovery	O
(	B-P
DIR	I-P
)	O
and	O
diffusion	O
tensor	O
(	O
DT	O
)	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
to	O
quantify	O
the	O
severity	O
of	O
cortical	O
lesion	O
(	O
CL	O
)	O
microstructural	O
tissue	O
abnormalities	O
in	O
a	O
large	O
cohort	O
of	O
relapse	O
-	O
onset	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
patients	O
and	O
its	O
contribution	O
to	O
cognitive	O
dysfunction	O
.	O

DIR	B-P
,	O
DT	B-P
,	O
dual-echo	B-P
,	O
and	O
three-dimensional	O
(	O
3D	O
)	O
T1-weighted	B-P
scans	I-P
were	O
acquired	O
from	O
149	O
MS	O
patients	O
and	O
40	O
controls	O
.	O

Cognitively	O
impaired	O
(	O
CI	O
)	O
patients	O
had	O
⩾2	O
abnormal	O
neuropsychological	B-P
tests	I-P
.	O

Diffusivity	O
values	O
in	O
CLs	O
,	O
cortex	O
,	O
white	O
matter	O
(	O
WM	O
)	O
lesions	O
,	O
and	O
normal-appearing	O
(	O
NA	O
)	O
WM	O
were	O
assessed	O
.	O

Predictors	O
of	O
cognitive	O
impairment	O
were	O
identified	O
using	O
a	O
random	O
forest	O
analysis	O
.	O

Compared	O
to	O
controls	O
,	O
MS	O
patients	O
had	O
lower	O
normalized	O
brain	O
volume	O
(	O
NBV	O
)	O
,	O
gray	O
matter	O
volume	O
(	O
GMV	O
)	O
,	O
WM	O
volume	O
,	O
lower	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
,	O
and	O
higher	O
mean	O
diffusivity	O
in	O
cortex	O
and	O
normal-appearing	O
white	O
matter	O
(	O
NAWM	O
)	O
.	O

A	O
total	O
of	O
44	O
(	O
29.5	O
%	O
)	O
patients	O
were	O
CI	O
.	O

Compared	O
to	O
cognitively	O
preserved	O
(	O
CP	O
)	O
,	O
CI	O
patients	O
had	O
higher	O
T2	O
WM	O
lesion	O
volume	O
(	O
LV	O
)	O
,	O
lower	O
NBV	O
and	O
GMV	O
,	O
and	O
more	O
severe	O
diffusivity	O
abnormalities	O
in	O
WM	O
lesions	O
,	O
cortex	O
,	O
and	O
NAWM	O
.	O

CL	O
measures	O
did	O
not	O
differ	O
between	O
CI	O
and	O
CP	O
patients	O
.	O

Cortex	O
FA	O
,	O
age	O
,	O
disease	O
duration	O
,	O
T2	O
WM	O
LV	O
,	O
and	O
GMV	O
best	O
predicted	O
MS	O
-related	O
cognitive	O
impairment	O
(	O
C-statistic	O
=	O
0.88	O
)	O
.	O
``	O

Diffuse	O
``	O
GM	O
and	O
NAWM	O
damage	O
and	O
WM	O
lesions	O
,	O
rather	O
than	O
intrinsic	O
CL	O
damage	O
,	O
contribute	O
to	O
cognitive	O
impairment	O
in	O
MS	O
.	O

Alanine	O
to	O
Serine	O
Variant	O
at	O
Position	O
986	O
of	O
Calcium	O
Sensing	O
Receptor	O
and	O
Colorectal	O
Cancer	O
Risk	O
.	O

With	O
regard	O
to	O
the	O
effect	O
of	O
calcium	O
against	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
and	O
considering	O
the	O
key	O
role	O
of	O
calcium	O
sensing	O
receptor	O
(	O
CaSR	O
)	O
in	O
calcium	O
homeostasis	O
,	O
this	O
study	O
investigated	O
whether	O
CaSR	O
gene	O
rs1801725	O
or	O
A986S	O
variant	O
was	O
associated	O
with	O
susceptibility	O
to	O
CRC	O
risk	O
.	O

This	O
study	O
was	O
conducted	O
as	O
a	O
case-control	O
study	O
and	O
303	O
cases	O
with	O
CRC	O
and	O
354	O
controls	O
were	O
enrolled	O
.	O

All	O
657	O
subjects	O
were	O
genotyped	O
for	O
CaSR	O
gene	O
A986S	O
variant	O
using	O
PCR	O
-	O
RFLP	B-P
method	I-P
.	O

No	O
significant	O
difference	O
was	O
observed	O
for	O
the	O
A986S	O
variant	O
of	O
CaSR	O
gene	O
in	O
either	O
genotype	O
or	O
allele	O
frequencies	O
between	O
the	O
cases	O
and	O
the	O
controls	O
and	O
this	O
lack	O
of	O
difference	O
remained	O
non-significant	O
even	O
after	O
adjustment	O
for	O
age	O
,	O
BMI	O
,	O
sex	O
,	O
smoking	O
status	O
,	O
and	O
family	O
history	O
of	O
CRC	O
.	O

No	O
evidence	O
for	O
the	O
effect	O
modification	O
of	O
the	O
association	O
A986S	O
variant	O
and	O
CRC	O
by	O
BMI	O
,	O
sex	O
,	O
or	O
tumor	O
site	O
was	O
also	O
observed	O
.	O

Furthermore	O
,	O
the	O
risk	O
of	O
obesity	O
in	O
relation	O
to	O
the	O
A986S	O
variant	O
in	O
the	O
controls	O
and	O
the	O
cases	O
was	O
separately	O
analyzed	O
and	O
we	O
observed	O
no	O
significant	O
difference	O
between	O
normal	O
weight	O
(	O
BMI	O
<	O
25kg/m	O
(	O
2	O
)	O
)	O
and	O
overweight	O
/	O
obese	O
(	O
BMI	O
≥	O
25kg/m	O
(	O
2	O
)	O
)	O
subjects	O
.	O

Our	O
findings	O
do	O
not	O
support	O
a	O
role	O
for	O
effect	O
of	O
the	O
CaSR	O
gene	O
A986S	O
variant	O
on	O
CRC	O
risk	O
;	O
nevertheless	O
,	O
this	O
finding	O
requires	O
confirmation	O
and	O
the	O
role	O
of	O
the	O
gene	O
variant	O
in	O
carcinogenesis	O
needs	O
to	O
be	O
further	O
investigated	O
.	O

Clinical	O
characteristics	O
and	O
viral	B-P
load	I-P
of	O
respiratory	O
syncytial	O
virus	O
and	O
human	O
metapneumovirus	O
in	O
children	O
hospitaled	O
for	O
acute	O
lower	O
respiratory	O
tract	O
infection	O
.	O

Respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
human	O
metapneumovirus	O
(	O
HMPV	O
)	O
are	O
two	O
common	O
viral	O
pathogens	O
in	O
acute	O
lower	O
respiratory	O
tract	O
infections	O
(	O
ALRTI	O
)	O
.	O

However	O
,	O
the	O
association	O
of	O
viral	B-P
load	I-P
with	O
clinical	O
characteristics	O
is	O
not	O
well-defined	O
in	O
ALRTI	O
.	O

To	O
explore	O
the	O
correlation	O
between	O
viral	B-P
load	I-P
and	O
clinical	O
characteristics	O
of	O
RSV	O
and	O
HMPV	O
in	O
children	O
hospitalized	O
for	O
ALRTI	O
in	O
Lanzhou	O
,	O
China	O
.	O

Three	O
hundred	O
and	O
eighty-seven	O
children	O
hospitalized	O
for	O
ALRTI	O
were	O
enrolled	O
.	O

Nasopharyngeal	O
aspirates	O
(	O
NPAs	O
)	O
were	O
sampled	O
from	O
each	O
children	O
.	O

Real-time	O
PCR	O
was	O
used	O
to	O
screen	O
RSV	O
,	O
HMPV	O
,	O
and	O
twelve	O
additional	O
respiratory	O
viruses	O
.	O

Bronchiolitis	O
was	O
the	O
leading	O
diagnoses	O
both	O
in	O
RSV	O
and	O
HMPV	O
positive	O
patients	O
.	O

A	O
significantly	O
greater	O
frequency	O
of	O
wheezing	O
(	O
52	O
%	O
vs.	O
33.52	O
%	O
,	O
P	O
=	O
0.000	O
)	O
was	O
noted	O
in	O
RSV	O
positive	O
and	O
negative	O
patients	O
.	O

The	O
RSV	O
viral	B-P
load	I-P
was	O
significant	O
higher	O
in	O
children	O
aged	O
<	O
1	O
year	O
(	O
P	O
=	O
0.003	O
)	O
,	O
children	O
without	O
fever	O
and	O
wheezing	O
(	O
P	O
=	O
0.015	O
and	O
P	O
=	O
0.000	O
)	O
,	O
days	O
of	O
illness	O
<	O
14	O
days	O
(	O
P	O
=	O
0.002	O
)	O
,	O
children	O
with	O
bronchiolitis	O
(	O
P	O
=	O
0.012	O
)	O
and	O
children	O
with	O
RSV	O
single	O
infections	O
(	O
P	O
=	O
0.000	O
)	O
.	O

No	O
difference	O
was	O
found	O
in	O
the	O
clinical	O
features	O
of	O
HMPV	O
positive	O
and	O
negative	O
patients	O
.	O

The	O
HMPV	O
viral	B-P
load	I-P
had	O
no	O
correlation	O
with	O
any	O
clinical	O
characteristics	O
.	O

The	O
incidences	O
of	O
severe	O
disease	O
were	O
similar	O
between	O
single	O
infection	O
and	O
coinfection	O
for	O
the	O
two	O
viruses	O
(	O
RSV	O
,	O
P	O
=	O
0.221	O
;	O
HMPV	O
,	O
P	O
=	O
0.764	O
)	O
and	O
there	O
has	O
no	O
statistical	O
significance	O
between	O
severity	O
and	O
viral	B-P
load	I-P
(	O
P	O
=	O
0.166	O
and	O
P	O
=	O
0.721	O
)	O
.	O

Bronchiolitis	O
is	O
the	O
most	O
common	O
disease	O
caused	O
by	O
RSV	O
and	O
HMPV	O
.	O

High	O
viral	B-P
load	I-P
or	O
co-infection	O
may	O
be	O
associated	O
with	O
some	O
symptoms	O
but	O
neither	O
has	O
a	O
significant	O
impact	O
on	O
disease	O
severity	O
for	O
the	O
two	O
viruses	O
.	O

J.	O
Med	O
.	O

Virol	O
.	O

89:589-597	O
,	O
2017	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Straight	O
configuration	O
saphenous	O
vein	O
transposition	O
to	O
popliteal	O
artery	O
for	O
vascular	O
access	O
.	O

The	O
saphenous	O
vein	O
is	O
commonly	O
used	O
as	O
a	O
vascular	O
graft	O
in	O
peripheral	O
artery	O
surgery	O
but	O
rarely	O
used	O
for	O
vascular	O
access	O
.	O

The	O
literature	O
on	O
straight	O
configuration	O
saphenous	O
vein	O
transposition	O
to	O
the	O
popliteal	O
artery	O
is	O
scarce	O
.	O

Here	O
we	O
present	O
two	O
cases	O
of	O
straight	O
configuration	O
saphenous	O
vein	O
transposition	O
to	O
the	O
popliteal	O
artery	O
for	O
vascular	O
access	O
,	O
the	O
surgical	B-P
technique	I-P
and	O
respective	O
follow-up	O
.	O

Two	O
young	O
men	O
,	O
aged	O
29	O
and	O
36	O
years	O
,	O
were	O
chosen	O
for	O
lower-limb	O
vascular	O
access	O
for	O
hemodialysis	O
.	O

The	O
first	O
patient	O
was	O
paraplegic	O
since	O
birth	O
.	O

He	O
used	O
his	O
arms	O
to	O
move	O
so	O
upper	O
extremity	O
vascular	O
access	O
was	O
avoided	O
.	O

The	O
second	O
patient	O
presented	O
with	O
an	O
infected	O
upper	O
extremity	O
arteriovenous	O
graft	O
(	O
AVG	O
)	O
and	O
after	O
multiple	O
closed	O
AVFs	O
he	O
had	O
no	O
more	O
available	O
arm	O
veins	O
.	O

Both	O
patients	O
received	O
autologous	O
lower	O
extremity	O
straight	O
configuration	O
saphenous	O
vein	O
transpositions	O
to	O
the	O
popliteal	O
artery	O
under	O
spinal	O
anesthesia	O
in	O
May	O
and	O
October	O
2012	O
,	O
respectively	O
.	O

Cannulation	O
of	O
the	O
fistula	O
was	O
allowed	O
after	O
one	O
month	O
.	O

There	O
were	O
no	O
early	O
complications	O
.	O

Slight	O
swelling	O
on	O
the	O
leg	O
appeared	O
in	O
one	O
of	O
the	O
patients	O
.	O

Both	O
fistulas	O
were	O
still	O
functional	O
after	O
36	O
and	O
32	O
months	O
,	O
respectively	O
.	O

The	O
straight	O
configuration	O
saphenous	O
vein	O
transposition	O
to	O
popliteal	O
artery	O
is	O
simple	O
to	O
perform	O
,	O
offers	O
a	O
long	O
and	O
straight	O
segment	O
for	O
cannulation	O
and	O
may	O
be	O
a	O
suitable	O
autologous	O
vascular	O
access	O
in	O
selected	O
patients	O
.	O

Microbiological	O
and	O
Clinical	O
Characteristics	O
of	O
Hypermucoviscous	O
Klebsiella	O
pneumoniae	O
Isolates	O
Associated	O
with	O
Invasive	O
Infections	O
in	O
China	O
.	O

A	O
distinctive	O
syndrome	O
caused	O
by	O
hypermucoviscous	O
Klebsiella	O
pneumoniae	O
(	O
HMKP	O
)	O
including	O
pyogenic	O
liver	O
abscess	O
(	O
PLA	O
)	O
is	O
now	O
becoming	O
a	O
globally	O
emerging	O
disease	O
.	O

In	O
the	O
present	O
study	O
,	O
22.8	O
%	O
(	O
84/369	O
)	O
of	O
K.	O
pneumoniae	O
clinical	O
isolates	O
associated	O
with	O
various	O
types	O
of	O
invasive	O
infections	O
were	O
identified	O
as	O
HMKP	O
,	O
with	O
45.2	O
%	O
associated	O
with	O
PLA	O
.	O

Multivariate	O
regression	O
analysis	O
showed	O
that	O
male	O
patients	O
with	O
41-50	O
years	O
,	O
PLA	O
,	O
diabetes	O
mellitus	O
,	O
and	O
hypertension	O
were	O
independent	O
risk	O
factors	O
for	O
HMKP	O
infections	O
.	O

K2	O
(	O
42.9	O
%	O
,	O
36/84	O
)	O
was	O
the	O
most	O
common	O
capsular	O
serotype	O
among	O
HMKP	O
isolates	O
,	O
followed	O
by	O
K1	O
(	O
23.8	O
%	O
,	O
20/84	O
)	O
.	O

Seventy-five	O
percentage	O
of	O
K1	O
HMKP	O
isolates	O
were	O
associated	O
with	O
PLA	O
,	O
while	O
K2	O
HMKP	O
isolates	O
accounted	O
for	O
more	O
types	O
of	O
invasive	O
infections	O
.	O

The	O
positive	O
rates	O
of	O
iutA	O
,	O
mrkD	O
,	O
aerobactin	O
,	O
iroN	O
,	O
and	O
rmpA	O
among	O
HMKP	O
isolates	O
were	O
significantly	O
higher	O
than	O
those	O
among	O
non-HMKP	O
isolates	O
(	O
p	O
<	O
0.05	O
)	O
.	O

There	O
was	O
a	O
correlation	O
between	O
magA	O
,	O
ybtS	O
,	O
alls	O
,	O
and	O
wcaG	O
and	O
K1	O
isolates	O
.	O

Interestingly	O
,	O
mrkD	O
was	O
exclusively	O
detected	O
among	O
HMKP	O
(	O
32.1	O
%	O
,	O
27/84	O
)	O
and	O
K2	O
isolates	O
(	O
65.9	O
%	O
,	O
27/41	O
)	O
.	O

All	O
K1	O
and	O
K2	O
HMKP	O
and	O
non-HMKP	O
isolates	O
were	O
positive	O
for	O
rmpA	O
.	O

Aerobactin	O
was	O
found	O
among	O
95.0	O
and	O
97.5	O
%	O
of	O
K1	O
and	O
K2	O
isolates	O
.	O

ST23	O
was	O
found	O
to	O
be	O
the	O
most	O
prevalent	O
ST	O
among	O
69	O
HMKP	O
isolates	O
with	O
K1	O
,	O
K2	O
,	O
K5	O
,	O
K20	O
,	O
and	O
K57	O
(	O
27.5	O
%	O
,	O
19/69	O
)	O
and	O
was	O
only	O
found	O
among	O
K1	O
isolates	O
.	O

ST65	O
was	O
the	O
second	O
most	O
prevalent	O
ST	O
(	O
26.1	O
%	O
,	O
18/69	O
)	O
and	O
was	O
also	O
only	O
found	O
among	O
K2	O
isolates	O
.	O

ST23-K1	O
HMKP	O
isolates	O
(	O
84.2	O
%	O
,	O
16/19	O
)	O
were	O
associated	O
with	O
PLA	O
,	O
while	O
ST65-K2	O
isolates	O
were	O
correlated	O
with	O
more	O
types	O
of	O
infections	O
relative	O
to	O
ST23-K1	O
isolates	O
.	O

PFGE	B-P
results	O
showed	O
that	O
the	O
homology	O
of	O
84	O
HMKP	O
isolates	O
was	O
diverse	O
.	O

Only	O
five	O
PFGE	B-P
clusters	O
with	O
more	O
than	O
75	O
%	O
similarity	O
accounted	O
for	O
more	O
than	O
three	O
isolates	O
.	O

These	O
five	O
PFGE	B-P
clusters	O
only	O
accounted	O
for	O
35	O
(	O
41.7	O
%	O
,	O
35/84	O
)	O
isolates	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
first	O
found	O
that	O
hypertension	O
and	O
male	O
patients	O
with	O
41-50	O
years	O
old	O
were	O
independent	O
risk	O
factors	O
.	O

The	O
composition	O
of	O
ST	O
types	O
and	O
PFGE	B-P
clusters	O
among	O
K.	O
pneumoniae	O
K2	O
isolates	O
was	O
more	O
diverse	O
than	O
K1	O
isolates	O
.	O

K1	O
and	O
K2	O
HMKP	O
isolates	O
had	O
respective	O
specific	O
profiles	O
of	O
virulence	O
-	O
associated	O
genes	O
.	O

Adequacy	O
of	O
initial	O
evaluation	O
of	O
fever	O
in	O
long-term	O
care	O
facilities	O
.	O

Febrile	O
residents	O
in	O
long-term	O
care	O
facilities	O
(	O
LTCF	O
)	O
might	O
be	O
inadequately	O
evaluated	O
by	O
caregivers	O
.	O

The	O
present	O
study	O
aimed	O
to	O
examine	O
the	O
factors	O
associated	O
with	O
inadequacy	O
of	O
initial	O
fever	O
evaluations	O
by	O
caregivers	O
at	O
night	O
in	O
LTCF	O
.	O

We	O
carried	O
out	O
a	O
cross-sectional	O
study	O
among	O
a	O
convenience	O
sample	O
of	O
caregivers	O
employed	O
at	O
11	O
LTCF	O
in	O
Japan	O
using	O
a	O
vignette-based	O
questionnaire	O
.	O

The	O
respondents	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
scenarios	O
describing	O
a	O
mild	O
or	O
severe	O
febrile	O
episode	O
in	O
an	O
LTCF	O
resident	O
at	O
night	O
.	O

The	O
respondents	O
'	O
thinking	O
patterns	O
were	O
classified	O
based	O
on	O
influential	O
factors	O
in	O
their	O
fever	O
evaluation	O
.	O

Associations	O
between	O
adequacy	O
of	O
evaluation	O
and	O
respondents	O
'	O
characteristics	O
were	O
evaluated	O
using	O
generalized	O
linear	O
mixed	O
models	O
.	O

A	O
total	O
of	O
34	O
%	O
of	O
fever	O
evaluations	O
among	O
caregivers	O
were	O
considered	O
to	O
be	O
inadequate	O
regarding	O
the	O
necessity	O
for	O
examination	O
by	O
a	O
physician	O
,	O
due	O
in	O
most	O
cases	O
to	O
underestimating	O
the	O
severity	O
of	O
the	O
fever	O
.	O

Respondents	O
'	O
thinking	O
patterns	O
in	O
fever	O
evaluation	O
were	O
significantly	O
associated	O
with	O
the	O
adequacy	O
of	O
the	O
evaluation	O
.	O

Caregivers	O
who	O
placed	O
particular	O
importance	O
on	O
the	O
preferences	O
of	O
residents	O
and	O
families	O
versus	O
other	O
factors	O
including	O
the	O
resident	O
's	O
febrile	O
condition	O
,	O
were	O
more	O
likely	O
to	O
make	O
an	O
inadequate	O
evaluation	O
than	O
those	O
who	O
did	O
not	O
.	O

Our	O
findings	O
here	O
suggest	O
that	O
eagerness	O
to	O
comply	O
with	O
residents	O
'	O
preference	O
in	O
fever	O
evaluation	O
could	O
prompt	O
caregivers	O
not	O
to	O
call	O
for	O
an	O
appropriate	O
diagnostic	B-P
procedure	I-P
.	O

Geriatr	O
Gerontol	O
Int	O
2016	O
;	O
••	O
:	O
••-••	O
.	O

Direct	O
effects	O
of	O
glucose	O
,	O
insulin	O
,	O
GLP-1	O
,	O
and	O
GIP	O
on	O
bulbospinal	O
neurons	O
in	O
the	O
rostral	O
ventrolateral	O
medulla	O
in	O
neonatal	O
wistar	O
rats	O
.	O

Although	O
patients	O
with	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
often	O
exhibit	O
hypertension	O
,	O
the	O
mechanisms	O
responsible	O
for	O
this	O
correlation	O
are	O
not	O
well	O
known	O
.	O

We	O
hypothesized	O
that	O
the	O
bulbospinal	O
neurons	O
in	O
the	O
rostral	O
ventrolateral	O
medulla	O
(	O
RVLM	O
)	O
are	O
affected	O
by	O
the	O
levels	O
of	O
glucose	O
,	O
insulin	O
,	O
or	O
incretins	O
(	O
glucagon	O
like	O
peptide-1	O
[	O
GLP-1	O
]	O
or	O
glucose-dependent	O
insulinotropic	O
peptide	O
[	O
GIP	O
]	O
)	O
in	O
patients	O
with	O
DM	O
.	O

To	O
investigate	O
whether	O
RVLM	O
neurons	O
are	O
activated	O
by	O
glucose	O
,	O
insulin	O
,	O
GLP-1	O
,	O
or	O
GIP	O
,	O
we	O
examined	O
changes	O
in	O
the	O
membrane	O
potentials	O
of	O
bulbospinal	O
RVLM	O
neurons	O
using	O
whole-cell	O
patch-clamp	O
technique	O
during	O
superfusion	O
with	O
various	O
levels	O
of	O
glucose	O
or	O
these	O
hormones	O
in	O
neonatal	O
Wistar	O
rats	O
.	O

A	O
brainstem	O
-	O
spinal	O
cord	O
preparation	O
was	O
used	O
for	O
the	O
experiments	O
.	O

A	O
low	O
level	O
of	O
glucose	O
stimulated	O
bulbospinal	O
RVLM	O
neurons	O
.	O

During	O
insulin	O
superfusion	O
,	O
almost	O
all	O
the	O
RVLM	O
neurons	O
were	O
depolarized	O
,	O
while	O
during	O
GLP-1	O
or	O
GIP	O
superfusion	O
,	O
almost	O
all	O
the	O
RVLM	O
neurons	O
were	O
hyperpolarized	O
.	O

Next	O
,	O
histological	B-P
examinations	I-P
were	O
performed	O
to	O
examine	O
transporters	O
for	O
glucose	O
and	O
receptors	O
for	O
insulin	O
,	O
GLP-1	O
,	O
and	O
GIP	O
on	O
RVLM	O
neurons	O
.	O

Low	O
-	O
level	O
glucose	O
-	O
depolarized	O
RVLM	O
neurons	O
exhibited	O
the	O
presence	O
of	O
glucose	O
transporter	O
3	O
(	O
GLUT3	O
)	O
.	O

Meanwhile	O
,	O
insulin	O
-	O
depolarized	O
,	O
GLP-1	O
-	O
hyperpolarized	O
,	O
and	O
GIP	O
-	O
hyperpolarized	O
RVLM	O
neurons	O
showed	O
each	O
of	O
the	O
respective	O
specific	O
receptor	O
.	O

These	O
results	O
indicate	O
that	O
a	O
low	O
level	O
of	O
glucose	O
stimulates	O
bulbospinal	O
RVLM	O
neurons	O
via	O
specific	O
transporters	O
on	O
these	O
neurons	O
,	O
inducing	O
hypertension	O
.	O

Furthermore	O
,	O
an	O
increase	O
in	O
insulin	O
or	O
a	O
reduction	O
in	O
incretins	O
may	O
also	O
activate	O
the	O
sympathetic	O
nervous	O
system	O
and	O
induce	O
hypertension	O
by	O
activating	O
RVLM	O
neurons	O
via	O
their	O
own	O
receptors	O
.	O

Detection	O
of	O
busulfan	O
adducts	O
on	O
proteins	O
.	O

Busulfan	O
is	O
a	O
bifunctional	O
alkyl	O
sulfonate	O
antineoplastic	O
drug	O
.	O

This	O
alkylating	O
agent	O
was	O
described	O
as	O
forming	O
covalent	O
adducts	O
on	O
proteins	O
.	O

However	O
,	O
only	O
limited	O
data	O
are	O
available	O
regarding	O
the	O
interaction	O
of	O
busulfan	O
with	O
proteins	O
.	O

Mass	B-P
spectrometry	I-P
and	O
bioinformatics	O
were	O
used	O
to	O
identify	O
busulfan	O
adducts	O
on	O
human	O
serum	O
albumin	O
and	O
hemoglobin	O
.	O

Albumin	O
and	O
hemoglobin	O
were	O
incubated	B-P
with	O
busulfan	O
or	O
control	O
compounds	O
,	O
digested	O
with	O
trypsin	O
and	O
analyzed	O
by	O
LC-MS	B-P
/	O
MS	B-P
on	O
a	O
Thermo	O
Fisher	O
LTQ	O
Orbitrap	O
Velos	O
Pro	O
.	O

MS	B-P
data	O
were	O
used	O
to	O
generate	O
spectral	O
libraries	O
of	O
non-modified	O
peptides	O
and	O
an	O
open	O
modification	O
search	O
was	O
performed	O
to	O
identify	O
potential	O
adduct	O
mass	O
shifts	O
and	O
possible	O
modification	O
sites	O
.	O

Results	O
were	O
confirmed	O
by	O
a	O
second	O
database	O
search	O
including	O
identified	O
mass	O
shifts	O
and	O
by	O
visual	O
inspection	O
of	O
annotated	O
tandem	O
mass	O
spectra	O
of	O
adduct	O
-carrying	O
peptides	O
.	O

Five	O
structures	O
of	O
busulfan	O
adducts	O
were	O
detected	O
and	O
a	O
chemical	O
structure	O
could	O
be	O
attributed	O
to	O
four	O
of	O
them	O
.	O

Two	O
were	O
primary	O
adducts	O
corresponding	O
to	O
busulfan	O
monoalkylation	O
and	O
alkylation	O
of	O
two	O
amino	O
acid	O
residues	O
by	O
a	O
single	O
busulfan	O
molecule	O
.	O

Two	O
others	O
corresponded	O
to	O
secondary	O
adducts	O
generated	O
during	O
sample	O
processing	O
.	O

Adducts	O
were	O
mainly	O
detected	O
on	O
Asp	O
,	O
Glu	O
,	O
and	O
His	O
residues	O
.	O

These	O
findings	O
were	O
confirmed	O
by	O
subsequent	O
database	O
searches	O
and	O
experiments	O
with	O
synthetic	O
peptides	O
.	O

The	O
combination	O
of	O
in	O
vitro	O
incubation	B-P
of	O
proteins	O
with	O
the	O
drug	O
of	O
interest	O
or	O
control	O
compounds	O
,	O
high-resolution	B-P
mass	I-P
spectrometry	I-P
,	O
and	O
open	O
modification	O
search	O
allowed	O
confirming	O
direct	O
interaction	O
of	O
busulfan	O
with	O
proteins	O
and	O
characterizing	O
resulting	O
adducts	O
.	O

Our	O
results	O
also	O
showed	O
that	O
careful	O
analysis	O
of	O
the	O
data	O
is	O
required	O
to	O
detect	O
experimental	O
artifacts	O
.	O

Impact	O
of	O
changes	O
in	O
pill	O
appearance	O
in	O
the	O
adherence	O
to	O
angiotensin	O
receptor	O
blockers	O
and	O
in	O
the	O
blood	O
pressure	O
levels	O
:	O
a	O
retrospective	O
cohort	O
study	O
.	O

To	O
assess	O
the	O
level	O
of	O
adherence	O
to	O
angiotensin	O
receptor	O
blockers	O
(	O
ARBs	O
)	O
in	O
patients	O
regularly	O
attending	O
a	O
community	O
pharmacy	O
and	O
the	O
influence	O
of	O
a	O
change	O
in	O
patients	O
'	O
adherence	O
to	O
pharmacological	O
treatment	O
.	O

Retrospective	O
cohort	O
study	O
of	O
a	O
random	O
sample	O
of	O
consecutive	O
patients	O
collecting	O
their	O
medication	O
.	O

40	O
community	O
pharmacies	O
in	O
Alicante	O
(	O
Southeast	O
Spain	O
)	O
.	O

602	O
consecutive	O
≥18	O
years	O
old	O
patients	O
following	O
treatment	O
with	O
ARBs	O
at	O
least	O
3	O
previous	O
refills	O
were	O
included	O
.	O

Prevalence	O
of	O
uncontrolled	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
adherence	O
to	O
prescribed	O
pharmacological	O
treatment	O
(	O
measured	O
through	O
both	O
the	O
Batalla	B-P
and	I-P
the	I-P
Morisky-Green	I-P
tests	I-P
)	O
.	O

A	O
multivariate	O
Poisson	O
regression	O
model	O
was	O
used	O
to	O
estimate	O
the	O
adjusted	O
risk	O
ratio	O
(	O
RRa	O
)	O
for	O
non-adherence	O
to	O
pharmacological	O
treatment	O
by	O
the	O
presence	O
of	O
a	O
change	O
in	O
patient	O
's	O
adherence	O
and	O
other	O
significant	O
variables	O
.	O

161/602	O
(	O
13.7	O
%	O
)	O
patients	O
presented	O
uncontrolled	O
BP	O
.	O

According	O
to	O
the	O
Morisky	B-P
test	I-P
,	O
410/602	O
(	O
68.2	O
%	O
)	O
patients	O
were	O
considered	O
adherent	O
to	O
pharmacological	O
treatment	O
and	O
231/602	O
(	O
38.4	O
%	O
)	O
patients	O
according	O
to	O
the	O
Batalla	B-P
test	I-P
.	O

According	O
to	O
the	O
Morisky-Green	B-P
test	I-P
,	O
in	O
the	O
multivariable	O
analysis	O
,	O
patients	O
with	O
a	O
previous	O
change	O
in	O
pill	O
appearance	O
were	O
less	O
likely	O
to	O
be	O
adherent	O
than	O
those	O
patients	O
with	O
no	O
change	O
in	O
their	O
pharmacological	O
treatment	O
(	O
RRa	O
0.45	O
;	O
CI	O
95	O
%	O
0.22	O
to	O
0.90	O
;	O
p=0.024	O
)	O
.	O

Systolic	O
BP	O
was	O
higher	O
in	O
patients	O
with	O
a	O
change	O
in	O
pill	O
appearance	O
in	O
the	O
previous	O
3	O
refills	O
(	O
median	O
BP	O
142	O
mm	O
Hg	O
;	O
IQR	O
136-148	O
)	O
than	O
in	O
those	O
who	O
did	O
not	O
have	O
a	O
change	O
(	O
median	O
BP	O
127	O
mm	O
Hg	O
;	O
IQR	O
118-135	O
;	O
p	O
<	O
0.001	O
)	O
.	O

There	O
was	O
a	O
low	O
percentage	O
of	O
adherence	O
and	O
nearly	O
15	O
%	O
of	O
uncontrolled	O
BP	O
in	O
patients	O
who	O
regularly	O
collected	O
their	O
medication	O
.	O

Switching	O
between	O
pills	O
of	O
different	O
appearances	O
was	O
associated	O
with	O
lower	O
patient	O
adherence	O
to	O
pharmacological	O
treatment	O
and	O
a	O
higher	O
uncontrolled	O
BP	O
than	O
no	O
change	O
in	O
pharmacological	O
treatment	O
or	O
change	O
only	O
in	O
package	O
but	O
not	O
in	O
pill	O
appearance	O
.	O

Surrogate	O
inaccuracy	O
in	O
predicting	O
older	O
adults	O
'	O
desire	O
for	O
life-sustaining	O
interventions	O
in	O
the	O
event	O
of	O
decisional	O
incapacity	O
:	O
is	O
it	O
due	O
in	O
part	O
to	O
erroneous	O
quality-of-life	B-P
assessments	I-P
?	O
.	O

Family	O
members	O
are	O
often	O
called	O
upon	O
to	O
make	O
decisions	O
for	O
an	O
incapacitated	O
relative	O
.	O

Yet	O
they	O
have	O
difficulty	O
predicting	O
a	O
loved	O
one	O
's	O
desire	O
to	O
receive	O
treatments	O
in	O
hypothetical	O
situations	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
this	O
difficulty	O
could	O
in	O
part	O
be	O
explained	O
by	O
discrepant	O
quality-of-life	B-P
assessments	I-P
.	O

The	O
data	O
come	O
from	O
235	O
community-dwelling	O
adults	O
aged	O
70	O
years	O
and	O
over	O
who	O
rated	O
their	O
quality	O
of	O
life	O
and	O
desire	O
for	O
specified	O
interventions	O
in	O
four	O
health	O
states	O
(	O
current	O
state	O
,	O
mild	O
to	O
moderate	O
stroke	O
,	O
incurable	O
brain	O
cancer	O
,	O
and	O
severe	O
dementia	O
)	O
.	O

All	O
ratings	O
were	O
made	O
on	O
Likert-type	O
scales	O
.	O

Using	O
identical	O
rating	O
scales	O
,	O
a	O
surrogate	O
chosen	O
by	O
the	O
older	O
adult	O
was	O
asked	O
to	O
predict	O
the	O
latter	O
's	O
responses	O
.	O

Linear	O
mixed	O
models	O
were	O
fitted	O
to	O
determine	O
whether	O
differences	O
in	O
quality-of-life	O
ratings	O
between	O
the	O
older	O
adult	O
and	O
surrogate	O
were	O
associated	O
with	O
surrogates	O
'	O
inaccuracy	O
in	O
predicting	O
desire	O
for	O
treatment	O
.	O

The	O
difference	O
in	O
quality-of-life	O
ratings	O
was	O
a	O
significant	O
predictor	O
of	O
prediction	O
inaccuracy	O
for	O
the	O
three	O
hypothetical	O
health	O
states	O
(	O
p	O
<	O
0.01	O
)	O
and	O
nearly	O
significant	O
for	O
the	O
current	O
health	O
state	O
(	O
p	O
=	O
0.077	O
)	O
.	O

All	O
regression	O
coefficients	O
were	O
negative	O
,	O
implying	O
that	O
the	O
more	O
the	O
surrogate	O
overestimated	O
quality	O
of	O
life	O
compared	O
to	O
the	O
older	O
adult	O
,	O
the	O
more	O
he	O
or	O
she	O
overestimated	O
the	O
older	O
adult	O
's	O
desire	O
to	O
be	O
treated	O
.	O

Discrepant	O
quality-of-life	O
ratings	O
are	O
associated	O
with	O
surrogates	O
'	O
difficulty	O
in	O
predicting	O
desire	O
for	O
life-sustaining	O
interventions	O
in	O
hypothetical	O
situations	O
.	O

This	O
finding	O
underscores	O
the	O
importance	O
of	O
discussing	O
anticipated	O
quality	O
of	O
life	O
in	O
states	O
of	O
cognitive	O
decline	O
,	O
to	O
better	O
prepare	O
family	O
members	O
for	O
making	O
difficult	O
decisions	O
for	O
their	O
loved	O
ones	O
.	O

ISRCTN89993391	O
.	O

Operative	O
surgical	O
nuances	O
of	O
modified	O
extradural	O
temporopolar	O
approach	O
with	O
mini-peeling	O
of	O
dura	O
propria	O
based	O
on	O
cadaveric	O
anatomical	O
study	O
of	O
lateral	O
cavernous	O
structures	O
.	O

Extradural	O
temporopolar	O
approach	O
(	O
ETA	O
)	O
has	O
been	O
modified	O
as	O
less	O
invasive	O
manner	O
and	O
named	O
as	O
trans-superior	O
orbital	O
fissure	O
(	O
SOF	O
)	O
approach	O
with	O
mini-peeling	O
technique	O
.	O

The	O
present	O
study	O
discusses	O
the	O
operative	O
nuances	O
of	O
this	O
modified	O
technique	O
on	O
the	O
basis	O
of	O
cadaveric	O
study	O
of	O
lateral	O
cavernous	O
structures	O
.	O

In	O
five	O
consecutive	O
cadaveric	O
specimens	O
,	O
we	O
performed	O
an	O
extradural	O
anterior	O
clinoidectomy	O
with	O
mini-peeling	O
of	O
the	O
dura	O
propria	O
to	O
expose	O
the	O
anterior	O
clinoid	O
process	O
entirely	O
.	O

We	O
also	O
investigated	O
the	O
histological	O
characteristics	O
of	O
the	O
lateral	O
cavernous	O
sinus	O
(	O
CS	O
)	O
between	O
the	O
dura	O
propria	O
and	O
periosteal	O
dura	O
at	O
the	O
SOF	O
,	O
foramen	O
rotundum	O
(	O
FR	O
)	O
,	O
and	O
foramen	O
ovale	O
(	O
FO	O
)	O
levels	O
,	O
and	O
of	O
each	O
trigeminal	O
nerve	O
division	O
.	O

Coronal	B-P
histological	I-P
examination	I-P
of	O
the	O
lateral	O
wall	O
of	O
the	O
CS	O
showed	O
invagination	O
of	O
the	O
dura	O
propria	O
and	O
periosteal	O
dura	O
into	O
the	O
SOF	O
.	O

In	O
contrast	O
,	O
no	O
such	O
invagination	O
was	O
observed	O
at	O
the	O
levels	O
of	O
the	O
FR	O
and	O
FO	O
.	O

This	O
finding	O
supports	O
the	O
technical	O
rationale	O
of	O
the	O
only	O
skeletonization	O
of	O
the	O
SOF	O
for	O
peeling	O
of	O
the	O
dura	O
propria	O
but	O
not	O
FR	O
.	O

In	O
addition	O
,	O
our	O
modified	O
ETA	O
method	O
needs	O
only	O
minimal	O
dural	O
incision	O
between	O
the	O
SOF	O
and	O
FR	O
where	O
no	O
cranial	O
nerves	O
are	O
present	O
.	O

Our	O
technical	O
modification	O
of	O
ETA	O
may	O
be	O
recommended	O
for	O
surgical	O
treatment	O
of	O
paraclinoid	O
lesions	O
to	O
reduce	O
the	O
risk	O
of	O
intraoperative	O
neurovascular	O
injury	O
.	O

Spermatocytic	O
Tumor	O
With	O
Sarcoma	O
:	O
A	O
Rare	O
Testicular	O
Neoplasm	O
.	O

Spermatocytic	O
tumor	O
,	O
formerly	O
known	O
as	O
spermatocytic	O
seminoma	O
,	O
is	O
an	O
uncommon	O
testicular	O
neoplasm	O
which	O
is	O
a	O
distinct	O
clinicopathologic	O
entity	O
from	O
classic	O
seminoma	O
.	O

These	O
tumors	O
are	O
not	O
associated	O
with	O
germ	O
cell	O
neoplasia	O
in	O
situ	O
,	O
other	O
germ	O
cell	O
tumors	O
,	O
or	O
isochromosome	O
12p	O
.	O

Although	O
typically	O
,	O
these	O
tumors	O
have	O
an	O
excellent	O
prognosis	O
occasional	O
cases	O
are	O
associated	O
with	O
sarcoma	O
and	O
have	O
a	O
very	O
poor	O
prognosis	O
.	O

We	O
present	O
a	O
case	O
of	O
spermatocytic	O
tumor	O
with	O
sarcoma	O
showing	O
a	O
chondrosarcomatous	O
component	O
,	O
discuss	O
the	O
pathologic	O
findings	O
and	O
differential	B-P
diagnosis	I-P
and	O
provide	O
follow-up	O
information	O
.	O

Comparison	O
of	O
methods	O
for	O
isolating	B-P
primary	O
hepatocytes	O
from	O
mini	O
pigs	O
.	O

Successful	O
porcine	O
hepatocyte	O
isolation	B-P
is	O
crucial	O
for	O
the	O
development	O
of	O
bioartificial	O
liver	O
devices	O
and	O
hepatocyte	O
transplantation	O
.	O

Serva	O
collagenase	O
NB	O
grades	O
are	O
formulated	O
collagenases	O
that	O
are	O
suitable	O
for	O
various	O
tissue	O
isolation	B-P
applications	O
.	O

N-acetylcysteine	O
(	O
NAC	O
)	O
can	O
improve	O
the	O
viability	O
of	O
human	O
hepatocytes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
two	O
collagenases	O
and	O
effect	O
of	O
NAC	O
on	O
hepatocyte	O
isolation	B-P
from	O
porcine	O
liver	O
tissue	O
.	O

Porcine	O
hepatocytes	O
were	O
isolated	B-P
using	O
the	O
perfusion	O
method	O
from	O
Bama	O
mini	O
pigs	O
assigned	O
to	O
the	O
Serva	O
NB	O
4	O
group	O
(	O
n=6	O
)	O
,	O
the	O
Serva	O
NB	O
8	O
group	O
(	O
n=6	O
)	O
,	O
or	O
the	O
NB	O
8	O
+	O
NAC	O
group	O
(	O
n=6	O
)	O
.	O

Viability	O
and	O
yield	O
were	O
defined	O
as	O
fresh	O
hepatocytes	O
and	O
their	O
spheroids	O
formation	O
after	O
24-hour	O
rocker	B-P
culture	I-P
in	O
serum-free	O
medium	O
.	O

Metabolic	O
function	O
was	O
assessed	O
by	O
gene	O
expression	O
,	O
albumin	O
,	O
and	O
urea	O
synthesis	O
.	O

All	O
procedures	O
resulted	O
in	O
successful	O
hepatocyte	O
isolation	B-P
.	O

Cells	O
from	O
the	O
NB	O
8	O
+	O
NAC	O
group	O
had	O
(	O
97.8±1.9	O
)	O
%	O
viability	O
,	O
which	O
was	O
higher	O
than	O
the	O
NB	O
8	O
group	O
with	O
(	O
94.4±2.4	O
)	O
%	O
and	O
the	O
NB	O
4	O
group	O
with	O
(	O
94.5±3.2	O
)	O
%	O
(	O
P	O
<	O
.001	O
)	O
.	O

The	O
final	O
cell	O
yield	O
reached	O
(	O
11.8±1.0	O
)	O
×10	O
(	O
9	O
)	O
cells	O
in	O
the	O
NB	O
8	O
+	O
NAC	O
group	O
,	O
compared	O
to	O
(	O
9.5±2.1	O
)	O
×10	O
(	O
9	O
)	O
cells	O
in	O
the	O
NB	O
8	O
group	O
(	O
P	O
<	O
.01	O
)	O
and	O
(	O
9.1±1.1	O
)	O
×10	O
(	O
9	O
)	O
cells	O
in	O
the	O
NB	O
4	O
group	O
(	O
P	O
<	O
.001	O
)	O
.	O

The	O
secretion	O
of	O
albumin	O
was	O
superior	O
in	O
the	O
NB	O
8	O
+	O
NAC	O
group	O
at	O
a	O
concentration	O
of	O
(	O
425.8±35.3	O
)	O
ng/mL	O
compared	O
to	O
the	O
NB	O
8	O
group	O
(	O
339.1±32.6	O
)	O
ng/mL	O
(	O
P	O
<	O
.001	O
)	O
and	O
NB	O
4	O
group	O
(	O
293.6±43.3	O
)	O
ng/mL	O
(	O
P	O
<	O
.01	O
)	O
.	O

The	O
injury	O
of	O
hepatocytes	O
also	O
decreased	O
in	O
the	O
NB	O
8	O
+	O
NAC	O
group	O
(	O
P	O
<	O
.01	O
)	O
.	O

The	O
data	O
are	O
presented	O
as	O
means	O
±	O
SD	O
.	O

Formulated	O
collagenase	O
Serva	O
NB	O
8	O
and	O
NAC	O
could	O
improve	O
the	O
porcine	O
hepatocyte	O
isolation	B-P
,	O
resulting	O
in	O
higher	O
yields	O
of	O
viable	O
cells	O
.	O

Salvage	O
Therapy	O
with	O
Ceftolozane-Tazobactam	O
for	O
Multidrug-Resistant	O
Pseudomonas	O
aeruginosa	O
Infections	O
.	O

Infections	O
caused	O
by	O
multidrug-resistant	O
Pseudomonas	O
aeruginosa	O
(	O
MDRPA	O
)	O
present	O
a	O
major	O
problem	O
for	O
therapeutic	O
management	O
.	O

We	O
report	O
here	O
our	O
experience	O
with	O
12	O
patients	O
with	O
a	O
severe	O
MDRPA	O
infection	O
(	O
6	O
of	O
which	O
were	O
pneumonia	O
)	O
who	O
received	O
salvage	O
therapy	O
with	O
ceftolozane-tazobactam	O
after	O
inappropriate	O
empirical	O
treatment	O
and/or	O
suboptimal	O
targeted	O
treatment	O
.	O

Although	O
10	O
of	O
the	O
12	O
patients	O
(	O
83.3	O
%	O
)	O
experienced	O
septic	O
shock	O
,	O
only	O
3	O
patients	O
(	O
25	O
%	O
)	O
died	O
during	O
the	O
follow-up	O
period	O
.	O

Microbiological	B-P
cure	O
in	O
7	O
patients	O
(	O
58.3	O
%	O
)	O
was	O
observed	O
.	O

MicroRNA	O
Expression	O
Signature	O
in	O
Degenerative	O
Aortic	O
Stenosis	O
.	O

Degenerative	O
aortic	O
stenosis	O
,	O
characterized	O
by	O
narrowing	O
of	O
the	O
exit	O
of	O
the	O
left	O
ventricle	O
of	O
the	O
heart	O
,	O
has	O
become	O
the	O
most	O
common	O
valvular	O
heart	O
disease	O
in	O
the	O
elderly	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
microRNA	O
(	O
miRNA	O
)	O
signature	O
in	O
degenerative	O
AS	O
.	O

Through	O
microarray	B-P
analysis	I-P
,	O
we	O
identified	O
the	O
miRNA	O
expression	O
signature	O
in	O
the	O
tissue	O
samples	O
from	O
healthy	O
individuals	O
(	O
n	O
=	O
4	O
)	O
and	O
patients	O
with	O
degenerative	O
AS	O
(	O
n	O
=	O
4	O
)	O
.	O

Six	O
miRNAs	O
(	O
hsa-miR-193a-3p	O
,	O
hsa-miR-29b-1-5p	O
,	O
hsa-miR-505-5p	O
,	O
hsa-miR-194-5p	O
,	O
hsa-miR-99b-3p	O
,	O
and	O
hsa-miR-200b-3p	O
)	O
were	O
overexpressed	O
and	O
14	O
(	O
hsa-miR-3663-3p	O
,	O
hsa-miR-513a-5p	O
,	O
hsa-miR-146b-5p	O
,	O
hsa-miR-1972	O
,	O
hsa-miR-718	O
,	O
hsa-miR-3138	O
,	O
hsa-miR-21-5p	O
,	O
hsa-miR-630	O
,	O
hsa-miR-575	O
,	O
hsa-miR-301a-3p	O
,	O
hsa-miR-636	O
,	O
hsa-miR-34a-3p	O
,	O
hsa-miR-21-3p	O
,	O
and	O
hsa-miR-516a-5p	O
)	O
were	O
downregulated	O
in	O
aortic	O
tissue	O
from	O
AS	O
patients	O
.	O

GeneSpring	O
13.1	O
was	O
used	O
to	O
identify	O
potential	O
human	O
miRNA	O
target	O
genes	O
by	O
comparing	O
a	O
3-way	O
comparison	O
of	O
predictions	O
from	O
TargetScan	O
,	O
PITA	O
,	O
and	O
microRNAorg	O
databases	O
.	O

Gene	O
Ontology	O
(	O
GO	O
)	O
and	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
analysis	O
were	O
performed	O
to	O
identify	O
potential	O
pathways	O
and	O
functional	O
annotations	O
associated	O
with	O
AS	O
.	O

Twenty	O
miRNAs	O
were	O
significantly	O
differentially	O
expressed	O
between	O
patients	O
with	O
AS	O
samples	O
and	O
normal	O
controls	O
and	O
identified	O
potential	O
miRNA	O
targets	O
and	O
molecular	O
pathways	O
associated	O
with	O
this	O
morbidity	O
.	O

This	O
study	O
describes	O
the	O
miRNA	O
expression	O
signature	O
in	O
degenerative	O
AS	O
and	O
provides	O
an	O
improved	O
understanding	O
of	O
the	O
molecular	O
pathobiology	O
of	O
this	O
disease	O
.	O

Electrocardiographic	O
appearance	O
of	O
aortic	O
stenosis	O
before	O
and	O
after	O
aortic	O
valve	O
replacement	O
.	O

So	O
far	O
,	O
the	O
specific	O
appearance	O
of	O
QRS	O
complex	O
,	O
ST-segment	O
,	O
and	O
T	O
wave	O
was	O
observed	O
in	O
aortic	O
stenosis	O
(	O
AS	O
)	O
.	O

S-wave	O
dynamic	O
change	O
in	O
leads	O
V1	O
-	O
V3	O
was	O
not	O
reported	O
in	O
AS	O
.	O

In	O
a	O
single-center	O
,	O
prospective	O
study	O
,	O
we	O
included	O
a	O
total	O
number	O
of	O
1.175	O
patients	O
who	O
underwent	O
surgical	O
aortic	O
valve	O
replacement	O
(	O
AVR	O
)	O
.	O

We	O
conducted	O
3-year	O
gathering	O
of	O
patients	O
with	O
symptomatic	O
and	O
asymptomatic	O
severe	O
AS	O
,	O
and	O
separated	O
them	O
by	O
hemodynamic	O
stability	O
into	O
groups	O
A	O
and	O
B	O
,	O
through	O
EFLV	O
(	O
of	O
more	O
or	O
less	O
than	O
50	O
%	O
)	O
,	O
AVA	O
(	O
of	O
more	O
or	O
less	O
than	O
0.9	O
cm	O
(	O
2	O
)	O
)	O
,	O
PG	O
(	O
between	O
55	O
and	O
75	O
mm	O
Hg	O
or	O
over	O
75	O
mm	O
Hg	O
)	O
,	O
and	O
end-diastolic	O
LV	O
dimension	O
(	O
of	O
more	O
or	O
less	O
than	O
56	O
mm	O
)	O
.	O

We	O
evaluated	O
the	O
impact	O
of	O
S-wave	O
magnitude	O
in	O
right	O
precordial	O
leads	O
before	O
and	O
after	O
AVR	O
in	O
all	O
patients	O
.	O

We	O
followed	O
S-wave	O
changes	O
in	O
electrocardiogram	O
altogether	O
with	O
hemodynamic	O
measurements	O
derived	O
from	O
echocardiography	B-P
.	O

Analysis	O
of	O
echocardiographic	B-P
parameters	O
,	O
measured	O
in	O
patients	O
before	O
surgery	O
,	O
did	O
not	O
show	O
statistical	O
significance	O
between	O
asymptomatic	O
and	O
symptomatic	O
group	O
.	O

The	O
statistical	O
significance	O
was	O
observed	O
in	O
the	O
change	O
in	O
S-wave	O
magnitude	O
in	O
the	O
right	O
precordial	O
leads	O
in	O
both	O
subsets	O
of	O
patients	O
before	O
AVR	O
.	O

We	O
found	O
statistically	O
significant	O
predictive	O
value	O
of	O
S-wave	O
magnitude	O
in	O
leads	O
V2	O
-	O
V3	O
for	O
dependent	O
variables	O
PG	O
and	O
end-diastolic	O
LV	O
dimension	O
.	O

S-wave	O
changes	O
in	O
right	O
precordial	O
leads	O
can	O
predict	O
increase	O
in	O
PG	O
and	O
critical	O
narrowing	O
of	O
AVA	O
,	O
suggestive	O
of	O
timely	O
referral	O
for	O
AVR	O
.	O

Sex	O
-Based	O
Differences	O
in	O
Cardiometabolic	O
Biomarkers	O
.	O

Few	O
data	O
are	O
available	O
comparing	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
biomarker	O
profiles	O
between	O
women	O
and	O
men	O
in	O
the	O
general	O
population	O
.	O

We	O
analyzed	O
sex	O
-based	O
differences	O
in	O
multiple	O
biomarkers	O
reflecting	O
distinct	O
pathophysiological	O
pathways	O
,	O
accounting	O
for	O
differences	O
between	O
women	O
and	O
men	O
in	O
CVD	O
risk	O
factors	O
,	O
body	O
composition	O
,	O
and	O
cardiac	O
morphology	O
.	O

A	O
cross-sectional	O
analysis	O
was	O
performed	O
using	O
data	O
from	O
the	O
Dallas	O
Heart	O
Study	O
,	O
a	O
multiethnic	O
population-based	O
study	O
.	O

Associations	O
between	O
sex	O
and	O
30	O
distinct	O
biomarkers	O
representative	O
of	O
6	O
pathophysiological	O
categories	O
were	O
evaluated	O
using	O
multivariable	O
linear	O
regression	O
adjusting	O
for	O
age	O
,	O
race	O
,	O
traditional	O
CVD	O
risk	O
factors	O
,	O
kidney	O
function	O
,	O
insulin	O
resistance	O
,	O
MRI	B-P
and	O
dual-energy	B-P
x-ray	I-P
absorptiometry	I-P
measures	O
of	O
body	O
composition	O
and	O
fat	O
distribution	O
,	O
and	O
left	O
ventricular	O
mass	O
.	O

After	O
excluding	O
participants	O
with	O
CVD	O
,	O
the	O
study	O
population	O
included	O
3439	O
individuals	O
,	O
mean	O
age	O
43	O
years	O
,	O
56	O
%	O
women	O
,	O
and	O
52	O
%	O
black	O
.	O

Significant	O
sex	O
-based	O
differences	O
were	O
seen	O
in	O
multiple	O
categories	O
of	O
biomarkers	O
,	O
including	O
lipids	O
,	O
adipokines	O
,	O
and	O
biomarkers	O
of	O
inflammation	O
,	O
endothelial	O
dysfunction	O
,	O
myocyte	O
injury	O
and	O
stress	O
,	O
and	O
kidney	O
function	O
.	O

In	O
fully	O
adjusted	O
models	O
,	O
women	O
had	O
higher	O
levels	O
of	O
high-density	O
lipoprotein	O
cholesterol	O
and	O
high-density	O
lipoprotein	O
particle	O
concentration	O
,	O
leptin	O
,	O
d-dimer	O
,	O
homoarginine	O
,	O
and	O
N-terminal	O
pro	O
B-type	O
natriuretic	O
peptide	O
,	O
and	O
lower	O
levels	O
of	O
low-density	O
lipoprotein	O
cholesterol	O
,	O
adiponectin	O
,	O
lipoprotein	O
-	O
associated	O
phospholipase	O
A2	O
mass	O
and	O
activity	O
,	O
monocyte	O
chemoattractant	O
protein-1	O
,	O
soluble	O
endothelial	O
cell	O
adhesion	O
molecule	O
,	O
symmetrical	O
dimethylarginine	O
,	O
asymmetrical	O
dimethylarginine	O
,	O
high-sensitivity	B-P
troponin	O
T	O
,	O
and	O
cystatin	O
C.	O
Biomarker	O
profiles	O
differ	O
significantly	O
between	O
women	O
and	O
men	O
in	O
the	O
general	O
population	O
.	O

Sex	O
differences	O
were	O
most	O
apparent	O
for	O
biomarkers	O
of	O
adiposity	O
,	O
endothelial	O
dysfunction	O
,	O
inflammatory	O
cell	O
recruitment	O
,	O
and	O
cardiac	O
stress	O
and	O
injury	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
characterize	O
whether	O
pathophysiological	O
processes	O
delineated	O
by	O
these	O
biomarkers	O
contribute	O
to	O
sex	O
-based	O
differences	O
in	O
the	O
development	O
and	O
complications	O
of	O
CVD	O
.	O

PCV13	O
serotype	O
decrease	O
in	O
Italian	O
adolescents	O
and	O
adults	O
in	O
the	O
post-	O
PCV13	O
era	O
:	O
Herd	O
protection	O
from	O
children	O
or	O
secular	O
trend	O
?	O
.	O

In	O
2010	O
PCV13	O
replaced	O
PCV7	O
in	O
the	O
pediatric	O
vaccination	O
schedule	O
for	O
Italian	O
children	O
.	O

While	O
a	O
strong	O
herd	O
effect	O
was	O
demonstrated	O
for	O
PCV7	O
,	O
a	O
possible	O
herd	O
effect	O
due	O
to	O
PCV13	O
is	O
still	O
under	O
debate	O
.	O

Our	O
aim	O
was	O
to	O
evaluate	O
differences	O
in	O
the	O
distribution	O
of	O
pneumococcal	O
serotypes	O
between	O
the	O
pre	O
and	O
post-	O
PCV13	O
eras	O
in	O
unvaccinated	O
Italian	O
adolescents	O
and	O
adults	O
with	O
laboratory-confirmed	B-P
pneumococcal	O
infection	O
from	O
3	O
Italian	O
Regions	O
with	O
a	O
high	O
rate	O
of	O
PCV13	O
vaccination	O
of	O
children	O
.	O

Adolescents	O
and	O
adults	O
admitted	O
with	O
laboratory-confirmed	B-P
pneumococcal	O
infection	O
in	O
the	O
hospitals	O
of	O
3	O
Italian	O
Regions	O
(	O
Friuli-Venezia	O
Giulia	O
,	O
Emilia	O
Romagna	O
,	O
and	O
Tuscany	O
)	O
between	O
April	O
2006	O
and	O
June	O
2016	O
were	O
included	O
in	O
the	O
study	O
.	O

Diagnosis	O
of	O
pneumococcal	O
infection	O
and	O
serotyping	O
were	O
performed	O
with	O
Real	O
Time	O
PCR	O
directly	O
on	O
normally	O
sterile	B-P
fluids	I-P
or	I-P
on	I-P
culture	I-P
isolates	I-P
.	O

523	O
patients	O
with	O
laboratory-confirmed	B-P
pneumococcal	O
infection	O
were	O
enrolled	O
(	O
Male	O
/	O
Female	O
ratio	O
was	O
300/223	O
,	O
1.3	O
;	O
median	O
age	O
67.1	O
,	O
IQR	O
53.4-74.9	O
)	O
.	O

None	O
of	O
the	O
patients	O
had	O
been	O
vaccinated	O
with	O
any	O
pneumococcal	O
vaccine	O
;	O
96.4	O
%	O
were	O
serotyped	O
.	O

Overall	O
,	O
the	O
most	O
frequent	O
serotypes	O
were	O
3	O
(	O
67/504	O
,	O
13.3	O
%	O
)	O
,	O
8	O
(	O
43/504	O
,	O
8.5	O
%	O
)	O
,	O
and	O
19A	O
(	O
38/504	O
,	O
7.5	O
%	O
)	O
.	O

Serotype	O
distribution	O
differed	O
among	O
age	O
classes	O
and	O
clinical	O
presentations	O
.	O

Overall	O
,	O
PCV13	O
serotypes	O
accounted	O
for	O
47.6	O
%	O
of	O
cases	O
:	O
62.3	O
%	O
in	O
the	O
pre-	O
PCV13	O
era	O
and	O
45.0	O
%	O
in	O
the	O
post-	O
PCV13	O
era	O
;	O
(	O
p=0.005	O
OR=2.03	O
;	O
CL	O
95	O
%	O
:	O
1.2-3.3	O
)	O
.	O

Serotype	O
7F	O
accounted	O
for	O
12/77	O
(	O
15.6	O
%	O
)	O
of	O
all	O
serotypes	O
in	O
the	O
pre-	O
PCV13	O
period	O
and	O
for	O
12/427	O
(	O
2.8	O
%	O
)	O
in	O
the	O
post-	O
PCV13	O
period	O
and	O
was	O
the	O
only	O
serotype	O
significantly	O
contributing	O
to	O
the	O
difference	O
in	O
percentage	O
between	O
pre	O
and	O
post-	O
PCV13	O
eras	O
.	O

Our	O
study	O
demonstrated	O
a	O
difference	O
in	O
percentage	O
in	O
serotype	O
distribution	O
in	O
adolescents	O
and	O
adults	O
laboratory-confirmed	B-P
pneumococcal	O
infection	O
between	O
the	O
pre	O
and	O
post-	O
PCV13	O
eras	O
.	O

This	O
difference	O
is	O
mainly	O
due	O
to	O
the	O
decrease	O
of	O
serotype	O
7F	O
.	O

Thus	O
,	O
in	O
order	O
to	O
decrease	O
disease	O
burden	O
,	O
adults	O
and	O
in	O
particular	O
the	O
elderly	O
should	O
be	O
offered	O
a	O
specific	O
vaccination	O
program	O
.	O

Low	O
implementation	O
of	O
Xpert	B-P
MTB/RIF	I-P
among	O
HIV	O
/	O
TB	O
co-infected	O
adults	O
in	O
the	O
International	O
epidemiologic	O
Databases	O
to	O
Evaluate	O
AIDS	O
(	O
IeDEA	O
)	O
program	O
.	O

Xpert	B-P
MTB/RIF	I-P
is	O
recommended	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
as	O
the	O
initial	O
tuberculosis	O
(	O
TB	O
)	O
diagnostic	B-P
test	I-P
in	O
individuals	O
suspected	O
of	O
HIV	O
-	O
associated	O
TB	O
.	O

We	O
sought	O
to	O
evaluate	O
field	O
implementation	O
of	O
Xpert	B-P
among	O
a	O
cohort	O
of	O
HIV	O
/	O
TB	O
co-infected	O
individuals	O
,	O
including	O
availability	O
,	O
utilization	O
and	O
outcomes	O
.	O

Observational	O
cohort	O
study	O
(	O
patient-level	O
data	O
)	O
and	O
cross-sectional	O
study	O
(	O
site-level	O
Xpert	B-P
availability	O
data	O
)	O
.	O

Data	O
were	O
collected	O
at	O
30	O
participating	O
International	O
epidemiologic	O
Databases	O
to	O
Evaluate	O
AIDS	O
(	O
IeDEA	O
)	O
sites	O
in	O
18	O
countries	O
from	O
January	O
2012-	O
January	O
2016	O
.	O

All	O
patients	O
were	O
HIV-infected	O
and	O
diagnosed	O
with	O
TB	O
,	O
either	O
bacteriologically	O
or	O
clinically	O
,	O
and	O
followed	O
until	O
a	O
determination	O
of	O
TB	O
treatment	O
outcome	O
.	O

We	O
used	O
multivariable	O
modified	O
Poisson	O
regression	O
to	O
estimate	O
adjusted	O
relative	O
risk	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
for	O
unfavorable	O
TB	O
treatment	O
outcomes	O
.	O

Most	O
sites	O
(	O
63	O
%	O
)	O
had	O
access	O
to	O
Xpert	B-P
,	O
either	O
in	O
the	O
clinic	O
(	O
13	O
%	O
)	O
,	O
in	O
the	O
same	O
facility	O
(	O
20	O
%	O
)	O
or	O
offsite	O
(	O
30	O
%	O
)	O
.	O

Among	O
2722	O
HIV	O
/	O
TB	O
patients	O
included	O
,	O
median	O
age	O
was	O
35.4	O
years	O
and	O
41	O
%	O
were	O
female	O
;	O
BMI	O
and	O
CD4	B-P
count	I-P
were	O
low	O
.	O

Overall	O
,	O
most	O
patients	O
(	O
76	O
%	O
)	O
received	O
at	O
least	O
one	O
TB	B-P
test	I-P
;	O
45	O
%	O
were	O
positive	O
.	O

Only	O
4	O
%	O
of	O
all	O
patients	O
were	O
tested	O
using	O
Xpert	B-P
:	O
64	O
%	O
were	O
Xpert	B-P
-	O
positive	O
,	O
13	O
%	O
showed	O
rifampicin	O
(	O
RIF	O
)	O
resistance	O
and	O
30	O
%	O
were	O
extrapulmonary	O
(	O
EPTB	O
)	O
or	O
both	O
pulmonary	O
-	O
EPTB	O
.	O

Treatment	O
outcomes	O
were	O
mostly	O
favorable	O
(	O
77	O
%	O
)	O
and	O
we	O
found	O
little	O
association	O
between	O
Xpert	B-P
use	O
and	O
an	O
unfavorable	O
TB	O
treatment	O
outcome	O
(	O
RR	O
1.25	O
,	O
95	O
%	O
CI	O
:	O
0.83	O
,	O
1.90	O
)	O
.	O

In	O
this	O
cohort	O
,	O
Xpert	B-P
utilization	O
was	O
low	O
even	O
though	O
the	O
majority	O
of	O
sites	O
had	O
access	O
to	O
the	O
test	O
.	O

Our	O
findings	O
show	O
the	O
need	O
for	O
expanded	O
implementation	O
and	O
further	O
research	O
exploring	O
barriers	O
to	O
use	O
in	O
low-resource	O
settings	O
.	O

Carboxymethyl	O
cellulase	O
production	O
optimization	O
from	O
newly	O
isolated	O
thermophilic	O
Bacillus	O
subtilis	O
K-18	O
for	O
saccharification	O
using	O
response	O
surface	O
methodology	O
.	O

In	O
this	O
study	O
,	O
a	O
novel	O
thermophilic	O
strain	O
was	O
isolated	O
from	O
soil	O
and	O
used	O
for	O
cellulase	O
production	O
in	O
submerged	O
fermentation	O
using	O
potato	O
peel	O
as	O
sole	O
carbon	O
source	O
.	O

The	O
bacterium	O
was	O
identified	O
by	O
16S	O
rRNA	O
gene	B-P
sequencing	I-P
technology	I-P
.	O

Central	O
composite	O
design	O
was	O
applied	O
for	O
enhanced	O
production	O
using	O
substrate	O
concentration	O
,	O
inoculum	O
size	O
,	O
yeast	O
extract	O
and	O
pH	O
as	O
dependent	O
variables	O
.	O

Highest	O
enzyme	O
titer	O
of	O
3.50	O
±	O
0.11	O
IU/ml	O
was	O
obtained	O
at	O
2	O
%	O
substrate	O
concentration	O
,	O
2	O
%	O
inoculum	O
size	O
,	O
1	O
%	O
yeast	O
extract	O
,	O
pH	O
5.0	O
,	O
incubation	B-P
temperature	O
of	O
50	O
°C	O
for	O
24	O
h	O
of	O
fermentation	O
period	O
.	O

The	O
crude	O
enzyme	O
was	O
characterized	O
having	O
optimum	O
pH	O
and	O
temperature	O
of	O
7.0	O
and	O
50	O
°C	O
,	O
respectively	O
.	O

The	O
efficiency	O
of	O
enzyme	O
was	O
checked	O
by	O
enzymatic	O
hydrolysis	O
of	O
acid	O
/	O
alkali	O
treated	O
pine	O
needles	O
which	O
revealed	O
that	O
54.389	O
%	O
saccharification	O
was	O
observed	O
in	O
acid	O
treated	O
pine	O
needles	O
.	O

These	O
results	O
indicated	O
that	O
the	O
cellulase	O
produced	O
by	O
the	O
Bacillus	O
subtilis	O
K-18	O
(	O
KX881940	O
)	O
could	O
be	O
effectively	O
used	O
for	O
industrial	O
processes	O
particularly	O
for	O
bioethanol	O
production	O
.	O

High-density	B-P
speckle	I-P
contrast	I-P
optical	I-P
tomography	I-P
(	O
SCOT	B-P
)	O
for	O
three	O
dimensional	O
tomographic	B-P
imaging	I-P
of	O
the	O
small	O
animal	O
brain	O
.	O

High-density	B-P
speckle	I-P
contrast	I-P
optical	I-P
tomography	I-P
(	O
SCOT	B-P
)	O
utilizing	O
tens	O
of	O
thousands	O
of	O
source	O
-	O
detector	O
pairs	O
,	O
was	O
developed	O
for	O
in	O
vivo	O
imaging	B-P
of	I-P
blood	I-P
flow	I-P
in	O
small	O
animals	O
.	O

The	O
reduction	O
in	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
due	O
to	O
local	O
ischemic	O
stroke	O
in	O
a	O
mouse	O
brain	O
was	O
transcanially	O
imaged	O
and	O
reconstructed	O
in	O
three	O
dimensions	O
.	O

The	O
reconstructed	O
volume	O
was	O
then	O
compared	O
with	O
corresponding	O
magnetic	O
resonance	O
images	O
demonstrating	O
that	O
the	O
volume	O
of	O
reduced	O
CBF	O
agrees	O
with	O
the	O
infarct	O
zone	O
at	O
twenty-four	O
hours	O
.	O

Mapping	B-P
how	O
local	O
perturbations	O
influence	O
systems-level	O
brain	O
dynamics	O
.	O

The	O
human	O
brain	O
exhibits	O
a	O
distinct	O
spatiotemporal	O
organization	O
that	O
supports	O
brain	O
function	O
and	O
can	O
be	O
manipulated	O
via	O
local	O
brain	O
stimulation	O
.	O

Such	O
perturbations	O
to	O
local	O
cortical	O
dynamics	O
are	O
globally	O
integrated	O
by	O
distinct	O
neural	O
systems	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
local	O
changes	O
in	O
neural	O
activity	O
affect	O
large-scale	O
system	O
dynamics	O
.	O

Here	O
,	O
we	O
briefly	O
review	O
empirical	O
and	O
computational	O
studies	O
addressing	O
how	O
localized	O
perturbations	O
affect	O
brain	O
activity	O
.	O

We	O
then	O
systematically	O
analyze	O
a	O
model	O
of	O
large-scale	O
brain	O
dynamics	O
,	O
assessing	O
how	O
localized	O
changes	O
in	O
brain	O
activity	O
at	O
the	O
different	O
sites	O
affect	O
whole-brain	O
dynamics	O
.	O

We	O
find	O
that	O
local	O
stimulation	O
induces	O
changes	O
in	O
brain	O
activity	O
that	O
can	O
be	O
summarized	O
by	O
relatively	O
smooth	O
tuning	O
curves	O
,	O
which	O
relate	O
a	O
region	O
's	O
effectiveness	O
as	O
a	O
stimulation	O
site	O
to	O
its	O
position	O
within	O
the	O
cortical	O
hierarchy	O
.	O

Our	O
results	O
also	O
support	O
the	O
notion	O
that	O
brain	O
hubs	O
,	O
operating	O
in	O
a	O
slower	O
regime	O
,	O
are	O
more	O
resilient	O
to	O
focal	O
perturbations	O
and	O
critically	O
contribute	O
to	O
maintain	O
stability	O
in	O
global	O
brain	O
dynamics	O
.	O

In	O
contrast	O
,	O
perturbations	O
of	O
peripheral	O
regions	O
,	O
characterized	O
by	O
faster	O
activity	O
,	O
have	O
greater	O
impact	O
on	O
functional	O
connectivity	O
.	O

As	O
a	O
parallel	O
with	O
this	O
region-level	O
result	O
,	O
we	O
also	O
find	O
that	O
peripheral	O
systems	O
such	O
as	O
the	O
visual	O
and	O
sensorimotor	O
networks	O
were	O
more	O
affected	O
by	O
local	O
perturbations	O
than	O
high-level	O
systems	O
such	O
as	O
the	O
cingulo-opercular	O
network	O
.	O

Our	O
findings	O
highlight	O
the	O
importance	O
of	O
a	O
periphery-to-core	O
hierarchy	O
to	O
determine	O
the	O
effect	O
of	O
local	O
stimulation	O
on	O
the	O
brain	O
network	O
.	O

This	O
study	O
also	O
provides	O
novel	O
resources	O
to	O
orient	O
empirical	O
work	O
aiming	O
at	O
manipulating	O
functional	O
connectivity	O
using	O
non-invasive	O
brain	O
stimulation	O
.	O

Impending	O
Atypical	O
Femoral	O
Fracture	O
in	O
Patients	O
With	O
Medullary	O
Thyroid	O
Cancer	O
With	O
Skeletal	O
Metastasis	O
Treated	O
With	O
Long-term	O
Bisphosphonate	O
and	O
Denosumab	O
.	O

Atypical	O
femoral	O
fractures	O
(	O
AFFs	O
)	O
occur	O
in	O
osteoporosis	O
patients	O
receiving	O
long-term	O
bisphosphonate	O
.	O

Atypical	O
femoral	O
fractures	O
also	O
occur	O
in	O
cancer	O
patients	O
receiving	O
long-term	O
bisphosphonate	O
or	O
denosumab	O
,	O
but	O
the	O
prevalence	O
is	O
low	O
.	O

We	O
describe	O
a	O
53-	O
year	O
-old	O
woman	O
with	O
a	O
history	O
of	O
medullary	O
thyroid	O
cancer	O
and	O
skull	O
metastasis	O
who	O
was	O
prescribed	O
bisphosphonate	O
for	O
6	O
years	O
and	O
denosumab	O
for	O
1.5	O
years	O
,	O
consecutively	O
.	O

Bone	B-P
scintigraphy	I-P
performed	O
because	O
of	O
spontaneous	O
groin	O
pain	O
showed	O
uptake	O
in	O
the	O
lateral	O
aspect	O
of	O
the	O
left	O
femur	O
,	O
which	O
was	O
confirmed	O
as	O
impending	O
AFF	O
.	O

In	O
oncological	O
patients	O
receiving	O
long-term	O
bisphosphonate	O
or	O
denosumab	O
,	O
AFF	O
should	O
be	O
included	O
as	O
a	O
differential	B-P
diagnosis	I-P
with	O
focal	O
femoral	O
findings	O
.	O

Lipid	B-P
levels	I-P
and	O
risk	O
of	O
recurrent	O
venous	O
thrombosis	O
:	O
results	O
from	O
the	O
MEGA	O
follow-up	O
study	O
.	O

Essentials	O
The	O
role	O
of	O
lipid	B-P
levels	I-P
in	O
the	O
risk	O
of	O
recurrent	O
venous	O
thrombosis	O
is	O
unclear	O
.	O

Lipids	O
were	O
assessed	O
in	O
patients	O
with	O
a	O
first	O
venous	O
thrombosis	O
(	O
n	O
=	O
2106	O
)	O
followed	O
for	O
6.9	O
years	O
.	O

Lipids	O
were	O
not	O
associated	O
with	O
recurrence	O
,	O
overall	O
or	O
in	O
patients	O
with	O
unprovoked	O
first	O
events	O
.	O

Testing	B-P
lipid	I-P
levels	I-P
is	O
not	O
useful	O
to	O
identify	O
patients	O
at	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O

Background	O
Knowledge	O
of	O
risk	O
factors	O
for	O
recurrent	O
venous	O
thrombosis	O
may	O
guide	O
decisions	O
on	O
duration	O
of	O
anticoagulation	O
.	O

The	O
association	O
between	O
lipid	B-P
levels	I-P
and	O
first	O
venous	O
thrombosis	O
has	O
been	O
studied	O
extensively	O
.	O

However	O
,	O
data	O
on	O
the	O
role	O
of	O
lipids	O
in	O
the	O
risk	O
of	O
recurrence	O
are	O
scarce	O
.	O

Objective	O
To	O
assess	O
the	O
association	O
between	O
lipid	B-P
levels	I-P
and	O
recurrent	O
venous	O
thrombosis	O
.	O

Patients	O
/Methods	O
Patients	O
with	O
a	O
first	O
venous	O
thrombosis	O
from	O
the	O
MEGA	O
study	O
were	O
included	O
.	O

Follow-up	O
started	O
at	O
the	O
date	O
of	O
end	O
of	O
anticoagulant	O
treatment	O
.	O

Percentile	O
categories	O
of	O
total	O
/	O
low-density	O
lipoprotein	O
/	O
high-density	O
lipoprotein	O
cholesterol	O
,	O
triglycerides	O
and	O
apolipoproteins	O
B	O
and	O
A1	O
were	O
established	O
(	O
<	O
10th	O
,	O
10th-25th	O
,	O
25th-75th	O
[	O
reference	O
]	O
,	O
75th-90th	O
,	O
>	O
90th	O
percentile	O
)	O
.	O

Lipids	O
were	O
measured	O
at	O
least	O
3	O
months	O
after	O
discontinuing	O
anticoagulation	O
.	O

Results	O
Of	O
2106	O
patients	O
followed	O
for	O
a	O
median	O
of	O
6.9	O
years	O
,	O
326	O
developed	O
recurrence	O
(	O
incidence	O
rate	O
,	O
2.7/100	O
patient	O
-	O
years	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
2.5-3.1	O
)	O
.	O

With	O
hazard	O
ratios	O
ranging	O
from	O
0.88	O
(	O
95	O
%	O
CI	O
,	O
0.55-1.42	O
)	O
to	O
1.33	O
(	O
95	O
%	O
CI	O
,	O
0.86-2.04	O
)	O
in	O
the	O
highest	O
percentile	O
category	O
vs.	O
the	O
reference	O
,	O
we	O
found	O
no	O
association	O
across	O
percentile	O
categories	O
between	O
recurrence	O
and	O
lipid	B-P
levels	I-P
in	O
age-	O
and	O
sex	O
-adjusted	O
models	O
,	O
nor	O
after	O
further	O
adjustments	O
for	O
body	O
mass	O
index	O
,	O
diabetes	O
,	O
estrogen	O
and	O
statin	O
use	O
,	O
and	O
duration	O
of	O
anticoagulation	O
.	O

Subgroup	O
analyses	O
stratified	O
by	O
unprovoked	O
or	O
provoked	O
first	O
events	O
,	O
location	O
(	O
deep	O
vein	O
thrombosis	O
or	O
pulmonary	O
embolism	O
)	O
and	O
sex	O
also	O
did	O
not	O
reveal	O
an	O
association	O
with	O
any	O
of	O
the	O
lipid	B-P
levels	I-P
studied	O
.	O

Conclusions	O
Testing	B-P
lipid	I-P
levels	I-P
did	O
not	O
identify	O
patients	O
at	O
an	O
increased	O
risk	O
of	O
recurrent	O
venous	O
thrombosis	O
in	O
this	O
study	O
,	O
including	O
those	O
with	O
unprovoked	O
first	O
events	O
,	O
and	O
these	O
should	O
not	O
influence	O
decisions	O
on	O
duration	O
of	O
anticoagulation	O
.	O

Temporal	O
and	O
Spatial	O
Variability	O
of	O
Fungal	O
Structures	O
and	O
Host	O
Responses	O
in	O
an	O
Incompatible	O
Rust-Wheat	O
Interaction	O
.	O

Information	O
about	O
temporal	O
and	O
spatial	O
variability	O
of	O
fungal	O
structures	O
and	O
host	O
responses	O
is	O
scarce	O
in	O
comparison	O
to	O
the	O
vast	O
amount	O
of	O
genetic	O
,	O
biochemical	O
,	O
and	O
physiological	O
studies	O
of	O
host-pathogen	O
interactions	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
avirulent	O
wild	O
type	O
and	O
virulent	O
mutant	O
isolates	O
of	O
Puccinia	O
striiformis	O
to	O
characterize	O
the	O
interactions	O
in	O
wheat	O
carrying	O
yellow	O
rust	O
Yr2	O
resistance	O
.	O

Both	O
conventional	O
and	O
advanced	O
microscopic	O
techniques	O
were	O
used	O
for	O
a	O
detailed	O
study	O
of	O
morphology	O
and	O
growth	O
of	O
fungal	O
colonies	O
and	O
associated	O
host	O
cell	O
responses	O
.	O

The	O
growth	O
of	O
the	O
wild	O
type	O
isolates	O
was	O
highly	O
restricted	O
due	O
to	O
hypersensitive	O
response	O
(	O
HR	O
,	O
plant	O
cell	O
death	O
)	O
indicated	O
by	O
autofluorescence	B-P
and	O
change	O
in	O
the	O
shape	O
of	O
the	O
affected	O
plant	O
cells	O
.	O

The	O
host	O
response	O
appeared	O
post	O
-	O
haustorial	O
,	O
but	O
large	O
variation	O
in	O
the	O
time	O
and	O
stage	O
of	O
arrest	O
was	O
observed	O
for	O
individual	O
fungal	O
colonies	O
,	O
probably	O
due	O
to	O
a	O
delay	O
between	O
detection	O
and	O
response	O
.	O

Some	O
colonies	O
were	O
stopped	O
right	O
after	O
the	O
formation	O
of	O
the	O
primary	O
infection	O
hyphae	O
whereas	O
others	O
formed	O
highly	O
branched	O
mycelia	O
.	O

HR	O
was	O
first	O
observed	O
in	O
host	O
cells	O
in	O
direct	O
contact	O
with	O
fungal	O
structures	O
,	O
after	O
which	O
the	O
defense	O
responses	O
spread	O
to	O
adjacent	O
host	O
cells	O
,	O
and	O
eventually	O
led	O
to	O
encasement	O
of	O
the	O
fungal	O
colony	O
.	O

Several	O
cells	O
with	O
HR	O
contained	O
haustoria	O
,	O
which	O
were	O
small	O
and	O
underdeveloped	O
,	O
but	O
some	O
cells	O
contained	O
normal	O
sized	O
haustoria	O
without	O
signs	O
of	O
hypersensitivity	O
.	O

The	O
growth	O
of	O
the	O
virulent	O
mutants	O
in	O
the	O
resistant	O
plants	O
was	O
similar	O
to	O
the	O
growth	O
in	O
plants	O
without	O
Yr2	O
resistance	O
,	O
which	O
is	O
a	O
strong	O
indication	O
that	O
the	O
incompatible	O
phenotype	O
was	O
associated	O
with	O
Yr2	O
.	O

The	O
interaction	O
between	O
P.	O
striiformis	O
and	O
wheat	O
with	O
Yr2	O
resistance	O
was	O
highly	O
variable	O
in	O
time	O
and	O
space	O
,	O
which	O
demonstrate	O
that	O
histological	O
studies	O
are	O
important	O
for	O
a	O
deeper	O
understanding	O
of	O
host-pathogen	O
interactions	O
and	O
plant	O
defense	O
mechanisms	O
in	O
general	O
.	O

The	O
impact	O
of	O
noninvasive	O
follicular	O
thyroid	O
neoplasm	O
with	O
papillary-like	O
nuclear	O
features	O
on	O
the	O
performance	O
of	O
the	O
Afirma	O
gene	O
expression	O
classifier	O
.	O

A	O
recent	O
revision	O
in	O
thyroid	O
tumor	O
nomenclature	O
has	O
resulted	O
in	O
a	O
change	O
from	O
a	O
malignant	O
diagnosis	O
(	O
noninvasive	O
follicular	O
variant	O
of	O
papillary	O
thyroid	O
carcinoma	O
)	O
to	O
one	O
that	O
is	O
nonmalignant	O
(	O
noninvasive	O
follicular	O
thyroid	O
neoplasm	O
with	O
papillary-like	O
nuclear	O
features	O
[	O
NIFTP	O
]	O
)	O
.	O

The	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
this	O
change	O
on	O
the	O
performance	O
of	O
the	O
Afirma	O
gene	O
expression	O
classifier	O
(	O
GEC	O
)	O
.	O

The	O
authors	O
retrospectively	O
analyzed	O
consecutive	O
thyroid	B-P
fine-needle	I-P
aspiration	I-P
specimens	O
with	O
indeterminate	O
diagnoses	B-P
on	O
which	O
GEC	O
was	O
performed	O
.	O

Surgical	O
pathology	O
material	O
was	O
reviewed	O
with	O
the	O
reclassification	O
of	O
nodules	O
into	O
NIFTP	O
.	O

GEC	O
testing	O
was	O
performed	O
on	O
384	O
fine-needle	B-P
aspiration	I-P
specimens	O
diagnosed	O
as	O
atypia	O
of	O
undetermined	O
significance	O
(	O
AUS	O
)	O
(	O
304	O
cases	O
)	O
and	O
suspicious	O
for	O
a	O
follicular	O
neoplasm	O
(	O
SFN	O
)	O
(	O
80	O
cases	O
)	O
and	O
yielded	O
a	O
suspicious	O
result	O
in	O
152	O
of	O
the	O
AUS	O
cases	O
(	O
50	O
%	O
)	O
and	O
50	O
of	O
the	O
SFN	O
cases	O
(	O
63	O
%	O
)	O
.	O

Thyroidectomy	O
was	O
performed	O
on	O
177	O
patients	O
.	O

After	O
reclassifying	O
NIFTP	O
,	O
the	O
positive	O
predictive	O
value	O
of	O
GEC	O
decreased	O
from	O
42	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
,	O
39	O
%	O
-45	O
%	O
)	O
to	O
24	O
%	O
(	O
95	O
%	O
CI	O
,	O
22	O
%	O
-26	O
%	O
)	O
in	O
the	O
AUS	O
group	O
and	O
from	O
23	O
%	O
(	O
95	O
%	O
CI	O
,	O
19	O
%	O
-27	O
%	O
)	O
to	O
13	O
%	O
(	O
95	O
%	O
CI	O
,	O
9	O
%	O
-18	O
%	O
)	O
in	O
the	O
SFN	O
group	O
.	O

Total	O
thyroidectomy	O
was	O
performed	O
more	O
frequently	O
than	O
a	O
partial	O
thyroidectomy	O
in	O
patients	O
with	O
AUS	O
with	O
a	O
suspicious	O
GEC	O
result	O
compared	O
with	O
pre-GEC	O
controls	O
(	O
68	O
%	O
vs	O
49	O
%	O
;	O
P	O
=	O
.037	O
)	O
.	O

Reclassification	O
of	O
NIFTP	O
significantly	O
decreases	O
the	O
positive	O
predictive	O
value	O
of	O
GEC	O
in	O
indeterminate	O
thyroid	O
nodules	O
.	O

Nevertheless	O
,	O
the	O
majority	O
of	O
patients	O
with	O
indeterminate	O
thyroid	O
nodules	O
with	O
a	O
suspicious	O
GEC	O
result	O
in	O
the	O
study	O
institution	O
have	O
undergone	O
total	O
thyroidectomy	O
.	O

This	O
finding	O
raises	O
concerns	O
over	O
reliance	O
on	O
a	O
suspicious	O
GEC	O
result	O
by	O
clinicians	O
to	O
justify	O
total	O
thyroidectomy	O
.	O

Cancer	O
Cytopathol	O
2017	O
.	O

©	O
2017	O
American	O
Cancer	O
Society	O
.	O

Cost-Effectiveness	O
of	O
the	O
'	O
One4All	B-P
'	O
HIV	O
Linkage	O
Intervention	O
in	O
Guangxi	O
Zhuang	O
Autonomous	O
Region	O
,	O
China	O
.	O

In	O
Guangxi	O
Zhuang	O
Autonomous	O
Region	O
,	O
China	O
,	O
an	O
estimated	O
80	O
%	O
of	O
newly-identified	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
-eligible	O
patients	O
are	O
not	O
engaged	O
in	O
ART	O
.	O

Delayed	O
ART	O
uptake	O
ultimately	O
translates	O
into	O
high	O
rates	O
of	O
HIV	O
morbidity	O
,	O
mortality	O
,	O
and	O
transmission	O
.	O

To	O
enhance	O
HIV	O
testing	O
receipt	O
and	O
subsequent	O
treatment	O
uptake	O
in	O
Guangxi	O
,	O
the	O
Chinese	O
Center	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
executed	O
a	O
cluster-randomized	O
trial	O
to	O
assess	O
the	O
effectiveness	O
and	O
cost-effectiveness	O
of	O
a	O
streamlined	O
HIV	O
testing	O
algorithm	O
(	O
the	O
One4All	B-P
intervention	O
)	O
in	O
12	O
county-level	O
hospitals	O
.	O

To	O
determine	O
the	O
incremental	O
cost-effectiveness	O
of	O
the	O
One4All	B-P
intervention	O
delivered	O
at	O
county	O
hospitals	O
in	O
Guangxi	O
,	O
China	O
,	O
compared	O
to	O
the	O
current	O
standard	O
of	O
care	O
(	O
SOC	O
)	O
.	O

Health	O
System	O
.	O

1-	O
,	O
5-and	O
25-years	O
.	O

We	O
adapted	O
a	O
dynamic	O
,	O
compartmental	O
HIV	O
transmission	O
model	O
to	O
simulate	O
HIV	O
transmission	O
and	O
progression	O
in	O
Guangxi	O
,	O
China	O
and	O
identify	O
the	O
economic	O
impact	O
and	O
health	O
benefits	O
of	O
implementing	O
the	O
One4All	B-P
intervention	O
in	O
all	O
Guangxi	O
hospitals	O
.	O

The	O
One4All	B-P
intervention	O
algorithm	O
entails	O
rapid	O
point-of-care	O
HIV	O
screening	B-P
,	O
CD4	O
and	O
viral	B-P
load	I-P
testing	O
of	O
individuals	O
presenting	O
for	O
HIV	O
screening	B-P
,	O
with	O
same-day	O
results	O
and	O
linkage	O
to	O
counselling	O
.	O

We	O
populated	O
the	O
model	O
with	O
data	O
from	O
the	O
One4All	B-P
trial	I-P
(	O
CTN-0056	B-P
)	O
,	O
China	O
CDC	O
HIV	O
registry	O
and	O
published	O
reports	O
.	O

Model	O
outcomes	O
were	O
HIV	O
incidence	O
,	O
mortality	O
,	O
costs	O
,	O
quality-adjusted	O
life	O
years	O
(	O
QALYs	O
)	O
,	O
and	O
the	O
incremental	O
cost-effectiveness	O
ratio	O
(	O
ICER	O
)	O
of	O
the	O
One4All	O
intervention	O
compared	O
to	O
SOC	O
.	O

The	O
One4All	O
testing	O
intervention	O
was	O
more	O
costly	O
than	O
SOC	O
(	O
CNY	O
2,182	O
vs.	O
CNY	O
846	O
)	O
,	O
but	O
facilitated	O
earlier	O
ART	O
access	O
,	O
resulting	O
in	O
delayed	O
disease	O
progression	O
and	O
mortality	O
.	O

Over	O
a	O
25-year	O
time	O
horizon	O
,	O
we	O
estimated	O
that	O
introducing	O
One4All	B-P
in	O
Guangxi	O
would	O
result	O
in	O
802	O
averted	O
HIV	O
cases	O
and	O
1629	O
averted	O
deaths	O
at	O
an	O
ICER	O
of	O
CNY	O
11,678	O
per	O
QALY	O
gained	O
.	O

Sensitivity	O
analysis	O
revealed	O
that	O
One4All	B-P
remained	O
cost-effective	O
at	O
even	O
minimal	O
levels	O
of	O
effectiveness	O
.	O

Results	O
were	O
robust	O
to	O
changes	O
to	O
a	O
range	O
of	O
parameters	O
characterizing	O
the	O
HIV	O
epidemic	O
over	O
time	O
.	O

The	O
One4All	B-P
HIV	O
testing	O
strategy	O
was	O
highly	O
cost-effective	O
by	O
WHO	O
standards	O
,	O
and	O
should	O
be	O
prioritized	O
for	O
widespread	O
implementation	O
in	O
Guangxi	O
,	O
China	O
.	O

Integrating	O
the	O
intervention	O
within	O
a	O
broader	O
combination	O
prevention	O
strategy	O
would	O
enhance	O
the	O
public	O
health	O
response	O
to	O
HIV	O
/	O
AIDS	O
in	O
Guangxi	O
.	O

Breast	O
Cancer	O
Detection	O
Rate	O
,	O
Incidence	O
,	O
Prevalence	O
and	O
Interval	O
Cancer	O
-related	O
Mammography	O
Screening	O
Times	O
among	O
Thai	O
Women	O
.	O

A	O
recent	O
guideline	O
by	O
the	O
American	O
Cancer	O
Society	O
recommended	O
that	O
mammography	B-P
(	O
MMG	B-P
)	O
should	O
be	O
done	O
for	O
women	O
starting	O
in	O
their	O
mid-40s	O
.	O

In	O
Thailand	O
,	O
information	O
on	O
opportunistic	O
mammography	O
screening	O
is	O
limited	O
and	O
data	O
on	O
the	O
total	O
incidence	O
of	O
breast	O
cancer	O
are	O
also	O
lacking	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
breast	O
cancer	O
detection	O
,	O
incident	O
and	O
prevalence	O
rates	O
among	O
Thai	O
women	O
.	O

We	O
retrospectively	O
reviewed	O
the	O
opportunistic	O
mammography	O
screening	O
of	O
normal	O
women	O
between	O
30	O
and	O
80	O
years	O
who	O
underwent	O
the	O
procedure	O
between	O
2001	O
and	O
2010	O
.	O

All	O
cases	O
were	O
followed	O
until	O
2012	O
.	O

The	O
detection	O
rate	O
was	O
calculated	O
for	O
the	O
whole	O
period	O
of	O
observation	O
using	O
'	O
number	O
of	O
women	O
with	O
positive	O
findings	O
'	O
divided	O
by	O
'	O
total	O
number	O
of	O
women	O
screened	B-P
'	O
.	O

The	O
incidence	O
rate	O
was	O
calculated	O
only	O
at	O
the	O
first	O
MMG	B-P
while	O
the	O
subsequence	O
rate	O
was	O
calculated	O
based	O
on	O
all	O
new	O
cases	O
detected	O
at	O
each	O
subsequent	O
MMG	B-P
.	O

Among	O
the	O
47,430	O
women	O
,	O
there	O
were	O
152,091	O
MMGs	B-P
or	O
approximately	O
3.2	O
occasions	O
per	O
person	O
(	O
range	O
,	O
1-10	O
)	O
.	O

The	O
average	O
duration	O
of	O
the	O
interval	O
between	O
each	O
subsequence	O
visit	O
was	O
1.8	O
years	O
.	O

Overall	O
,	O
breast	O
cancer	O
was	O
detected	O
in	O
543	O
women	O
,	O
with	O
a	O
detection	O
rate	O
of	O
10.3	O
per	O
1,000	O
persons	O
.	O

The	O
prevalence	O
rate	O
of	O
breast	O
cancer	O
at	O
the	O
first	O
visit	O
was	O
5.78	O
per	O
1,000	O
person	O
s.	O
The	O
incidence	O
or	O
new	O
cases	O
detected	O
at	O
any	O
follow-up	O
visit	O
was	O
10.4	O
per	O
1,000	O
person	O
s.	O
The	O
overall	O
interval	O
cancer	O
was	O
0.91	O
per	O
1,000	O
women	O
,	O
mainly	O
detected	O
before	O
their	O
second	O
and	O
third	O
MMG	B-P
,	O
with	O
a	O
rate	O
of	O
0.0.47	O
and	O
0.76	O
per	O
1,000	O
women	O
.	O

Opportunistic	O
mammography	O
screening	O
in	O
Thailand	O
detected	O
10	O
cases	O
of	O
breast	O
cancer	O
from	O
each	O
1,000	O
women	O
.	O

This	O
paper	O
indicated	O
a	O
high	O
rate	O
of	O
cancer	O
detection	O
during	O
a	O
two	O
year	O
interval	O
,	O
hence	O
,	O
a	O
screening	O
mammogram	O
should	O
be	O
performed	O
more	O
often	O
.	O

A	O
comparison	O
of	O
the	O
extent	O
and	O
pattern	O
of	O
cognitive	O
impairment	O
among	O
predialysis	O
,	O
dialysis	O
and	O
transplant	O
patients	O
:	O
a	O
cross	O
sectional	O
study	O
from	O
Australia	O
.	O

A	O
comparison	O
of	O
the	O
extent	O
and	O
pattern	O
of	O
cognitive	O
impairment	O
among	O
predialysis	O
,	O
dialysis	O
and	O
transplant	O
patients	O
:	O
a	O
cross	O
sectional	O
study	O
from	O
Australia	O
AIM	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
extent	O
of	O
cogntive	O
impairment	O
and	O
the	O
types	O
of	O
cognitive	O
deficits	O
in	O
an	O
Australian	O
cohort	O
of	O
four	O
patient	O
groups	O
with	O
end	O
stage	O
kidney	O
disease	O
.	O

Characteristics	O
predicting	O
the	O
presence	O
of	O
cognitive	O
impairment	O
were	O
also	O
evaluated	O
.	O

Observational	O
cross	O
sectional	O
study	O
of	O
one	O
hundred	O
and	O
fifty	O
five	O
patients	O
with	O
end	O
stage	O
kidney	O
disease	O
recruited	O
from	O
a	O
regional	O
Australian	O
renal	O
unit	O
.	O

Eligible	O
participants	O
included	O
those	O
whose	O
estimated	B-P
Glomerular	I-P
Filtration	I-P
Rate	I-P
was	O
<	O
30	O
ml/min/1.73	O
m	O
(	O
2	O
)	O
;	O
were	O
undertaking	O
peritoneal	O
or	O
hemodialysis	O
,	O
or	O
had	O
received	O
a	O
kidney	O
transplant	O
.	O

The	O
Montreal	O
Cognitive	O
Assessment	O
tool	O
was	O
used	O
to	O
screen	O
the	O
study	O
participants	O
for	O
cognitive	O
impairment	O
and	O
evaluate	O
cognitive	O
deficits	O
.	O

Cognitive	O
impairment	O
was	O
defined	O
as	O
a	O
total	O
Montreal	O
Cognitive	O
Assessment	O
tool	O
score	O
≤24/30	O
.	O

The	O
extent	O
of	O
cognitive	O
impairment	O
varied	O
between	O
the	O
four	O
groups	O
with	O
end	O
stage	O
kidney	O
disease	O
.	O

Factors	O
predicting	O
the	O
presence	O
of	O
cognitive	O
impairment	O
included	O
undertaking	O
dialysis	O
,	O
age	O
≥65	O
,	O
male	O
gender	O
,	O
and	O
the	O
presence	O
of	O
diabetes	O
or	O
cerebrovascular	O
disease	O
.	O

Deficits	O
in	O
executive	O
function	O
,	O
attention	O
,	O
language	O
,	O
visuospatial	O
skills	O
,	O
memory	O
and	O
orientation	O
were	O
common	O
amongst	O
the	O
study	O
participants	O
,	O
and	O
these	O
deficits	O
varied	O
according	O
to	O
which	O
end	O
stage	O
kidney	O
disease	O
group	O
the	O
participants	O
were	O
in	O
.	O

Limitations	O
to	O
the	O
study	O
included	O
the	O
cross	O
sectional	O
design	O
and	O
that	O
the	O
presence	O
of	O
confounders	O
like	O
depression	O
were	O
not	O
recorded	O
.	O

The	O
impact	O
of	O
disparities	O
in	O
the	O
cognitive	O
capabilities	O
identified	O
in	O
this	O
study	O
are	O
likely	O
to	O
be	O
far	O
reaching	O
.	O

Tailoring	O
of	O
education	O
and	O
self	O
management	O
programs	O
to	O
the	O
cognitive	O
deficits	O
of	O
individuals	O
is	O
required	O
.	O

Ideal	O
cardiovascular	O
health	O
and	O
inflammation	O
in	O
European	O
adolescents	O
:	O
The	O
HELENA	O
study	O
.	O

Inflammation	O
plays	O
a	O
key	O
role	O
in	O
atherosclerosis	O
and	O
this	O
process	O
seems	O
to	O
appear	O
in	O
childhood	O
.	O

The	O
ideal	O
cardiovascular	O
health	O
index	O
(	O
ICHI	O
)	O
has	O
been	O
inversely	O
related	O
to	O
atherosclerotic	O
plaque	O
in	O
adults	O
.	O

However	O
,	O
evidence	O
regarding	O
inflammation	O
and	O
ICHI	O
in	O
adolescents	O
is	O
scarce	O
.	O

The	O
aim	O
is	O
to	O
assess	O
the	O
association	O
between	O
ICHI	O
and	O
inflammation	O
in	O
European	O
adolescents	O
.	O

As	O
many	O
as	O
543	O
adolescents	O
(	O
251	O
boys	O
and	O
292	O
girls	O
)	O
from	O
the	O
Healthy	O
Lifestyle	O
in	O
Europe	O
by	O
Nutrition	O
in	O
Adolescence	O
(	O
HELENA	O
)	O
study	O
,	O
a	O
cross-sectional	O
multi-center	O
study	O
including	O
9	O
European	O
countries	O
,	O
were	O
measured	O
.	O

C-reactive	O
protein	O
(	O
CRP	O
)	O
,	O
complement	O
factors	O
C3	O
and	O
C4	O
,	O
leptin	O
and	O
white	O
blood	O
cell	O
counts	O
were	O
used	O
to	O
compute	O
an	O
inflammatory	O
score	O
.	O

Multilevel	O
linear	O
models	O
and	O
multilevel	O
logistic	O
regression	O
were	O
used	O
to	O
assess	O
the	O
association	O
between	O
ICHI	O
and	O
inflammation	O
controlling	O
by	O
covariates	O
.	O

Higher	O
ICHI	O
was	O
associated	O
with	O
a	O
lower	O
inflammatory	O
score	O
,	O
as	O
well	O
as	O
with	O
several	O
individual	O
components	O
,	O
both	O
in	O
boys	O
and	O
girls	O
(	O
p	O
<	O
0.01	O
)	O
.	O

In	O
addition	O
,	O
adolescents	O
with	O
at	O
least	O
4	O
ideal	O
components	O
of	O
the	O
ICHI	O
had	O
significantly	O
lower	O
inflammatory	O
score	O
and	O
lower	O
levels	O
of	O
the	O
study	O
biomarkers	O
,	O
except	O
CRP	O
.	O

Finally	O
,	O
the	O
multilevel	O
logistic	O
regression	O
showed	O
that	O
for	O
every	O
unit	O
increase	O
in	O
the	O
ICHI	O
,	O
the	O
probability	O
of	O
having	O
an	O
inflammatory	O
profile	B-P
decreased	O
by	O
28.1	O
%	O
in	O
girls	O
.	O

Results	O
from	O
this	O
study	O
suggest	O
that	O
a	O
better	O
ICHI	O
is	O
associated	O
with	O
a	O
lower	O
inflammatory	O
profile	B-P
already	O
in	O
adolescence	O
.	O

Improving	O
these	O
health	O
behaviors	O
,	O
and	O
health	O
factors	O
included	O
in	O
the	O
ICHI	O
,	O
could	O
play	O
an	O
important	O
role	O
in	O
CVD	O
prevention	O
.	O

Mesenchymal	O
stromal	O
cell	O
-	O
secreted	O
chemerin	O
is	O
a	O
novel	O
immunomodulatory	O
molecule	O
driving	O
the	O
migration	O
of	O
ChemR23	O
-	O
expressing	O
cells	O
.	O

Mesenchymal	O
stromal	O
cells	O
(	O
MSCs	O
)	O
are	O
multipotent	O
cells	O
characterized	O
by	O
broad	O
immunomodulatory	O
properties	O
exploited	O
for	O
the	O
treatment	O
of	O
inflammatory	O
disorders	O
.	O

However	O
,	O
the	O
efficacy	O
of	O
MSC	O
-based	O
therapy	O
is	O
highly	O
variable	O
and	O
tightly	O
linked	O
to	O
MSC	O
culture	B-P
conditions	I-P
and	O
treatment	O
schedule	O
.	O

Thus	O
,	O
the	O
identification	O
of	O
novel	O
key	O
molecules	O
regulating	O
MSC	O
immunomodulatory	O
activities	O
in	O
vivo	O
might	O
constitute	O
a	O
crucial	O
step	O
toward	O
the	O
optimization	O
of	O
currently	O
available	O
clinical	O
protocols	O
.	O

In	O
this	O
regard	O
,	O
herein	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
the	O
newly	O
identified	O
chemotactic	O
protein	O
,	O
chemerin	O
,	O
plays	O
a	O
role	O
in	O
MSC	O
-mediated	O
regulation	O
of	O
inflammation	O
.	O

Chemerin	O
production	O
by	O
human	O
MSCs	O
was	O
investigated	O
under	O
different	O
culture	B-P
conditions	I-P
using	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
(	O
ELISA	B-P
)	O
.	O

After	O
purification	O
,	O
MSC	O
-	O
secreted	O
chemerin	O
was	O
identified	O
using	O
mass	B-P
spectrometry	I-P
analysis	O
and	O
the	O
biological	O
activity	O
of	O
secreted	O
isoforms	O
was	O
evaluated	O
using	O
migration	B-P
assay	I-P
.	O

Bone	O
marrow	O
-	O
derived	O
MSCs	O
secrete	O
chemerin	O
and	O
express	O
its	O
receptors	O
ChemR23	O
and	O
CCRL2	O
.	O

Chemerin	O
production	O
is	O
dependent	O
on	O
culture	B-P
conditions	I-P
and	O
increases	O
upon	O
stimulation	O
with	O
inflammatory	O
cytokines	O
.	O

In	O
particular	O
,	O
platelet	O
lysate	O
(	O
PL	O
)	O
-	O
MSCs	O
produce	O
higher	O
levels	O
of	O
chemerin	O
compared	O
with	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
-	O
MSCs	O
.	O

Furthermore	O
,	O
chemerin	O
is	O
secreted	O
by	O
MSCs	O
as	O
an	O
inactive	O
precursor	O
,	O
which	O
can	O
be	O
converted	O
into	O
its	O
active	O
form	O
by	O
exogenous	O
chemerin	O
-	O
activating	O
serine	O
and	O
cysteine	O
proteases	O
.	O

Our	O
data	O
indicate	O
that	O
,	O
in	O
response	O
to	O
various	O
inflammatory	O
stimuli	O
,	O
MSCs	O
secrete	O
high	O
amounts	O
of	O
inactive	O
chemerin	O
,	O
which	O
can	O
then	O
be	O
activated	O
by	O
inflammation	O
-	O
induced	O
tissue	O
proteases	O
.	O

In	O
light	O
of	O
these	O
initial	O
findings	O
,	O
we	O
propose	O
that	O
further	O
analysis	O
of	O
chemerin	O
functions	O
in	O
vivo	O
might	O
constitute	O
a	O
crucial	O
step	O
toward	O
optimizing	O
MSC	O
-based	O
therapy	O
for	O
inflammatory	O
diseases	O
.	O

Prevalence	O
and	O
presentation	O
of	O
tuberculosis	O
among	O
hemodialysis	O
patients	O
in	O
Khartoum	O
,	O
Sudan	O
.	O

Tuberculosis	O
(	O
TB	O
)	O
is	O
a	O
major	O
health	O
problem	O
in	O
the	O
developing	O
countries	O
.	O

There	O
are	O
limited	O
data	O
about	O
the	O
prevalence	O
of	O
TB	O
patients	O
on	O
maintenance	O
hemodialysis	O
(	O
HD	O
)	O
in	O
Sudan	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
identify	O
the	O
prevalence	O
and	O
presentation	O
of	O
TB	O
among	O
Sudanese	O
maintenance	O
HD	O
patients	O
.	O

This	O
is	O
a	O
hospital	O
-based	O
descriptive	O
study	O
.	O

The	O
participants	O
of	O
the	O
study	O
are	O
all	O
HD	O
patients	O
distributed	O
in	O
13	O
HD	O
centers	O
in	O
Khartoum	O
and	O
Khartoum	O
North	O
Provinces	O
in	O
Sudan	O
.	O

All	O
patients	O
attended	O
the	O
HD	O
centers	O
from	O
November	O
1	O
,	O
2014	O
to	O
February	O
1	O
,	O
2015	O
,	O
were	O
interviewed	O
by	O
a	O
questionnaire	O
focused	O
on	O
personal	O
and	O
clinical	O
data	O
.	O

Those	O
who	O
were	O
diagnosed	O
as	O
having	O
active	O
TB	O
were	O
studied	O
regarding	O
their	O
clinical	O
presentation	O
,	O
presence	O
of	O
comorbidities	O
,	O
site	O
of	O
TB	O
,	O
and	O
methods	O
used	O
on	O
diagnosis	O
.	O

The	O
total	O
number	O
of	O
HD	O
patients	O
during	O
the	O
study	O
period	O
was	O
1328	O
patients	O
.	O

We	O
found	O
19	O
patients	O
who	O
already	O
diagnosed	O
and	O
treated	O
for	O
TB	O
infection	O
.	O

The	O
prevalence	O
rate	O
of	O
TB	O
among	O
HD	O
patients	O
is	O
1.4	O
%	O
.	O

The	O
mean	O
age	O
of	O
patient	O
was	O
44.53±8.69	O
years	O
,	O
89.5	O
%	O
of	O
them	O
were	O
males	O
.	O

The	O
majority	O
of	O
them	O
have	O
comorbidities	O
:	O
31.6	O
%	O
%	O
have	O
hypertension	O
and	O
21.1	O
%	O
have	O
diabetes	O
.	O

Extrapulmonary	O
TB	O
was	O
the	O
major	O
presentation	O
(	O
57.9	O
%	O
)	O
mainly	O
tuberculous	O
lymphadenitis	O
(	O
26.3	O
%	O
)	O
.	O

The	O
pulmonary	O
presentation	O
was	O
found	O
to	O
be	O
42.1	O
%	O
.	O

The	O
diagnosis	O
of	O
TB	O
was	O
supported	O
by	O
microbiological	O
evidence	O
of	O
alcohol	O
acid-fast	O
Bacilli	O
present	O
in	O
sputum	O
smear	O
(	O
21	O
%	O
)	O
,	O
histological	O
diagnosis	O
(	O
31.6	O
%	O
)	O
,	O
polymerase	O
chain	O
reaction	O
(	O
21	O
%	O
)	O
,	O
and	O
imaging	B-P
in	I-P
(	O
26.3	O
%	O
)	O
.	O

Patients	O
on	O
maintenance	O
HD	O
are	O
at	O
an	O
increased	O
risk	O
of	O
TB	O
and	O
diagnosis	O
of	O
TB	O
among	O
HD	O
patients	O
need	O
a	O
high	O
index	O
of	O
suspicion	O
.	O

There	O
is	O
a	O
great	O
need	O
for	O
establishing	O
a	O
screening	O
scheme	O
for	O
TB	O
among	O
HD	O
patients	O
and	O
further	O
epidemiological	O
studies	O
are	O
needed	O
to	O
fully	O
evaluate	O
this	O
problem	O
.	O

Sensitive	O
fluorescent	O
detection	O
of	O
DNA	O
methyltransferase	O
using	O
nicking	O
endonuclease	O
-mediated	O
multiple	O
primers	O
-like	O
rolling	O
circle	O
amplification	O
.	O

Sensitive	O
and	O
reliable	O
detection	O
of	O
DNA	O
methyltransferase	O
(	O
MTase	O
)	O
is	O
of	O
great	O
significance	O
for	O
both	O
early	O
tumor	O
diagnosis	O
and	O
therapy	O
.	O

In	O
this	O
study	O
,	O
a	O
simple	O
,	O
label	O
-free	O
and	O
sensitive	O
DNA	O
MTase	O
-	O
sensing	B-P
method	I-P
was	O
developed	O
on	O
the	O
basis	O
of	O
a	O
nicking	O
endonuclease	O
-mediated	O
multiple	O
primers	O
-like	O
rolling	O
circle	O
amplification	O
(	O
RCA	O
)	O
strategy	B-P
.	O

In	O
this	O
method	B-P
,	O
a	O
dumbbell	O
RCA	O
template	O
was	O
prepared	O
by	O
blunt-end	O
ligation	O
of	O
two	O
molecules	O
of	O
hairpin	O
DNA	O
.	O

In	O
addition	O
to	O
the	O
primer	O
-	O
binding	O
sequence	O
,	O
the	O
dumbbell	O
template	O
contained	O
another	O
three	O
important	O
parts	O
:	O
5'-CCGG-3	O
'	O
sequences	O
in	O
double-stranded	O
stems	O
,	O
nicking	O
endonuclease	O
recognition	O
sites	O
and	O
C-rich	O
sequences	O
in	O
single-stranded	O
loops	O
.	O

The	O
introduction	O
of	O
5'-CCGG-3	O
'	O
sequences	O
allows	O
the	O
dumbbell	O
template	O
to	O
be	O
destroyed	O
by	O
the	O
restriction	O
endonuclease	O
,	O
HpaII	O
,	O
but	O
is	O
not	O
destroyed	O
in	O
the	O
presence	O
of	O
the	O
target	O
MTase	O
-	O
M.SssI	O
MTase	O
.	O

The	O
introduction	O
of	O
nicking	O
endonuclease	O
recognition	O
sites	O
makes	O
the	O
M.SssI	O
MTase	O
-protected	O
dumbbell	O
template	O
-mediated	O
RCA	O
proceed	O
in	O
a	O
multiple	O
primers	O
-like	O
exponential	O
mode	O
,	O
thus	O
providing	O
the	O
RCA	O
with	O
high	O
amplification	O
efficiency	O
.	O

The	O
introduction	O
of	O
C-rich	O
sequences	O
may	O
promote	O
the	O
folding	O
of	O
amplification	O
products	O
into	O
a	O
G-quadruplex	O
structure	O
,	O
which	O
is	O
specifically	O
recognized	O
by	O
the	O
commercially	O
available	O
fluorescent	O
probe	O
thioflavin	O
T.	O
Improved	O
RCA	O
amplification	O
efficiency	O
and	O
specific	O
fluorescent	O
recognition	O
of	O
RCA	O
products	O
provide	O
the	O
M.SssI	O
MTase	O
-	O
sensing	B-P
platform	O
with	O
high	O
sensitivity	O
.	O

When	O
a	O
dumbbell	O
template	O
containing	O
four	O
nicking	O
endonuclease	O
sites	O
is	O
used	O
,	O
highly	O
specific	O
M.SssI	O
MTase	O
activity	O
detection	O
can	O
be	O
achieved	O
in	O
the	O
range	O
of	O
0.008-50U/mL	O
with	O
a	O
detection	O
limit	O
as	O
low	O
as	O
0.0011U/mL	O
.	O

Simple	O
experimental	B-P
operation	I-P
and	O
mix-and-detection	O
fluorescent	O
sensing	O
mode	O
ensures	O
that	O
M.SssI	O
MTase	O
quantitation	O
works	O
well	O
in	O
a	O
real-time	O
RCA	O
mode	O
,	O
thus	O
further	O
simplifying	O
the	O
sensing	O
performance	O
and	O
making	O
high	O
throughput	O
detection	O
possible	O
.	O

The	O
proposed	O
MTase	O
-	O
sensing	B-P
strategy	I-P
was	O
also	O
demonstrated	O
to	O
be	O
applicable	O
for	O
screening	O
and	O
evaluating	O
the	O
inhibitory	O
activity	O
of	O
MTase	O
inhibitors	O
.	O

Gleason	O
grade	O
grouping	O
of	O
prostate	O
cancer	O
is	O
of	O
prognostic	O
value	O
in	O
Asian	O
men	O
.	O

The	O
International	O
Society	O
of	O
Urological	O
Pathology	O
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade	O
Groups	O
(	O
GG	O
)	O
originally	O
described	O
by	O
Epstein	O
and	O
colleagues	O
over	O
Gleason	O
score	O
(	O
GS	O
)	O
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	O
by	O
the	O
WHO	O
classification	O
in	O
2016	O
.	O

The	O
majority	O
of	O
studies	O
validating	O
this	O
revision	O
have	O
been	O
in	O
Caucasian	O
populations	O
.	O

We	O
therefore	O
asked	O
whether	O
the	O
new	O
GG	O
system	O
was	O
retrospectively	O
associated	O
with	O
biochemical	O
disease-free	O
survival	O
in	O
a	O
mixed-ethnicity	O
cohort	O
of	O
Asian	O
men	O
.	O

A	O
total	O
of	O
680	O
radical	O
prostatectomies	O
(	O
RPs	O
)	O
from	O
2005	O
to	O
2014	O
were	O
included	O
.	O

GS	O
from	O
initial	O
biopsy	B-P
and	O
RP	O
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
GG	O
,	O
defined	O
as	O
:	O
1	O
(	O
GS	O
≤6	O
)	O
;	O
2	O
(	O
GS	O
3+4=7	O
)	O
;	O
3	O
(	O
GS	O
4+3=7	O
)	O
;	O
4	O
(	O
GS	O
4+4=8/5+3=8/3+5=8	O
)	O
and	O
5	O
(	O
GS	O
9-10	O
)	O
.	O

Biochemical	O
recurrence	O
was	O
defined	O
as	O
two	O
consecutive	O
post-	O
RP	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
levels	O
of	O
>	O
0.2	O
ng/mL	O
after	O
post-	O
RP	O
PSA	O
reaching	O
the	O
nadir	O
of	O
<	O
0.1	O
ng/mL	O
.	O

Our	O
data	O
showed	O
that	O
Kaplan-Meier	O
analysis	O
revealed	O
significant	O
differences	O
in	O
biochemical	O
recurrence	O
within	O
Gleason	O
GG	O
based	O
on	O
either	O
biopsy	B-P
or	O
prostatectomy	O
scoring	O
.	O

Multivariate	O
analysis	O
further	O
confirmed	O
that	O
a	O
higher	O
GG	O
was	O
significantly	O
associated	O
with	O
risk	O
of	O
biochemical	O
recurrence	O
.	O

This	O
GG	O
system	O
had	O
a	O
higher	O
prognostic	O
discrimination	O
for	O
both	O
initial	O
biopsy	B-P
and	O
RP	O
than	O
GS	O
.	O

Our	O
study	O
validates	O
the	O
use	O
of	O
the	O
revised	O
and	O
updated	O
GG	O
system	O
in	O
a	O
mixed-ethnicity	O
population	O
of	O
Asian	O
men	O
.	O

Higher	O
GG	O
was	O
significantly	O
associated	O
with	O
increased	O
risk	O
of	O
biochemical	O
recurrence	O
.	O

We	O
therefore	O
recommend	O
its	O
use	O
to	O
inform	O
clinical	O
management	O
for	O
patients	O
with	O
prostate	O
cancer	O
.	O

A	O
pH	O
-	O
Sensitive	O
Nanocarrier	O
for	O
Tumor	O
Targeting	O
:	O
Delivery	O
of	O
Ruthenium	O
Complex	O
for	O
Tumor	O
Theranostic	O
by	O
pH	O
-	O
Sensitive	O
Nanocapsule	O
.	O

Ruthenium	O
complex	O
is	O
a	O
potentially	O
theranostic	O
agent	O
for	O
cancer	B-P
imaging	I-P
and	O
therapy	O
,	O
however	O
its	O
application	O
is	O
limited	O
due	O
to	O
poor	O
water-solubility	O
and	O
lack	O
of	O
tumor	O
selectivity	O
.	O

To	O
overcome	O
the	O
above	O
drawbacks	O
,	O
pH	O
-	O
sensitive	O
nanocapsule	O
as	O
a	O
novel	O
targeting	O
carrier	O
was	O
designed	O
to	O
deliver	O
ruthenium	O
complex	O
for	O
treating	O
xenograft	O
tumor	O
of	O
mice	O
.	O

The	O
core	O
/	O
shell	O
structured	O
nanocapsule	O
with	O
ruthenium	O
complex	O
tris	O
(	O
1,10-phenanthroline	O
)	O
ruthenium	O
(	O
II	O
)	O
complex	O
(	O
3P-Ru	O
)	O
as	O
the	O
core	O
and	O
a	O
pH	O
-	O
sensitive	O
polymeric	O
material	O
poly	O
(	O
2-diisopropylaminoethyl	O
methacrylate	O
)	O
-block	O
poly	O
(	O
2-aminoethyl	O
methacrylate	O
hydrochloride	O
)	O
(	O
PbPS	O
)	O
as	O
the	O
shell	O
was	O
synthesized	O
and	O
characterized	O
.	O

Meanwhile	O
,	O
the	O
nanocapsule	O
was	O
used	O
to	O
investigate	O
cell	O
viability	O
and	O
evaluate	O
tissue	O
distribution	O
as	O
well	O
as	O
preventing	O
tumor	O
growth	O
efficacy	O
in	O
U251	O
stem	O
cells	O
tumor	O
-bearing	O
mouse	O
model	O
.	O

The	O
nanocapsule	O
had	O
a	O
size	O
of	O
103.1	O
±	O
11.3	O
nm	O
,	O
zeta	O
potential	O
of	O
-40	O
±	O
5.3	O
mV	O
,	O
EE	O
of	O
76.7	O
±	O
0.9	O
%	O
,	O
LE	O
of	O
25.4	O
±	O
0.6	O
%	O
and	O
it	O
could	O
control	O
drug	O
release	O
under	O
different	O
pH	O
conditions	O
.	O

The	O
results	O
of	O
cell	O
uptake	O
showed	O
that	O
the	O
fluorescent	O
3P-Ru	O
loaded	O
in	O
the	O
nanocapsule	O
could	O
be	O
delivered	O
into	O
cells	O
with	O
high	O
efficiency	O
,	O
and	O
then	O
significantly	O
inhibited	O
U251	O
proliferation	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

After	O
U251	O
stem	O
cells	O
were	O
transplanted	O
subcutaneously	O
into	O
mice	O
,	O
the	O
3P-Ru	O
/	O
PbPS	O
nanocapsule	O
(	O
PbPS	O
-	O
Ru	O
-	O
NC	O
)	O
via	O
intravenous	O
administration	O
could	O
concentrate	O
in	O
tumor	O
area	O
and	O
obviously	O
prevent	O
tumor	O
growth	O
.	O

The	O
pH	O
-	O
sensitive	O
nanocapsule	O
as	O
a	O
antitumor	O
agent	O
carrier	O
was	O
able	O
to	O
effectively	O
deliver	O
3P-Ru	O
into	O
gliomas	O
cells	O
,	O
and	O
cell	O
growth	O
was	O
significantly	O
inhibited	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Such	O
pH	O
-	O
sensitive	O
nanocapsule	O
for	O
ruthenium	O
complex	O
delivery	O
would	O
have	O
great	O
potential	O
application	O
in	O
tumor	O
theranostics	O
.	O

Heat-shock	O
protein	O
60	O
of	O
Porphyromonas	O
gingivalis	O
may	O
induce	O
dysfunction	O
of	O
human	O
umbilical	O
endothelial	O
cells	O
via	O
regulation	O
of	O
endothelial-nitric	O
oxide	O
synthase	O
and	O
vascular	O
endothelial-cadherin	O
.	O

Accumulating	O
evidence	O
has	O
established	O
that	O
periodontitis	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
coronary	O
heart	O
disease	O
(	O
CAD	O
)	O
.	O

Porphyromonus	O
gingivalis	O
(	O
P.	O
gingivalis	O
)	O
,	O
a	O
major	O
periodontal	O
pathogen	O
,	O
has	O
already	O
been	O
shown	O
to	O
have	O
a	O
significant	O
role	O
in	O
the	O
inflammatory	O
response	O
of	O
CAD	O
in	O
vivo	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
whether	O
P.	O
gingivalis	O
heat-shock	O
protein	O
60	O
(	O
HSP60	O
)	O
induced	O
the	O
dysfunction	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
in	O
vitro	O
.	O

HUVECs	O
were	O
stimulated	O
with	O
a	O
range	O
of	O
P.	O
gingivalis	O
HSP60	O
concentrations	O
(	O
1	O
,	O
10	O
and	O
100	O
ng/l	O
)	O
at	O
different	O
time-points	O
.	O

The	O
levels	O
of	O
vascular	O
endothelial	O
(	O
VE	O
)	O
-cadherin	O
,	O
endothelial	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
)	O
and	O
cysteinyl	O
aspartate-specific	O
protease-3	O
(	O
caspase-3	O
)	O
were	O
measured	O
using	O
western	B-P
blot	I-P
analysis	O
.	O

The	O
apoptotic	O
rate	O
of	O
HUVECs	O
was	O
detected	O
using	O
flow	B-P
cytometry	I-P
.	O

P.	O
gingivalis	O
HSP60	O
at	O
a	O
concentration	O
of	O
10	O
ng/l	O
significantly	O
decreased	O
the	O
expression	O
levels	O
of	O
VE-cadherin	O
and	O
eNOS	O
protein	O
at	O
24	O
h	O
stimulation	O
,	O
whereas	O
no	O
difference	O
in	O
these	O
proteins	O
was	O
identified	O
following	O
a	O
low	O
dose	O
of	O
P.	O
gingivalis	O
HSP60	O
(	O
1	O
ng/l	O
)	O
.	O

P.	O
gingivalis	O
HSP60	O
at	O
100	O
ng/l	O
significantly	O
downregulated	O
the	O
expression	O
levels	O
of	O
VE-cadherin	O
and	O
eNOS	O
protein	O
at	O
12	O
h	O
in	O
HUVECs	O
.	O

However	O
,	O
the	O
cleavage	O
of	O
caspase-3	O
showed	O
an	O
opposing	O
change	O
at	O
different	O
concentrations	O
.	O

Consistently	O
,	O
P.	O
gingivalis	O
HSP60	O
induced	O
apoptosis	O
of	O
HUVECs	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
indicated	O
that	O
P.	O
gingivalis	O
HSP60	O
may	O
induce	O
dysfunction	O
and	O
apoptosis	O
in	O
HUVECs	O
via	O
downregulating	O
the	O
expression	O
levels	O
of	O
VE-cadherin	O
and	O
eNOS	O
,	O
and	O
promoting	O
the	O
cleavage	O
of	O
caspase-3	O
.	O

A	O
Biomechanical	O
Modeling	O
Guided	O
CBCT	B-P
Estimation	O
Technique	O
.	O

Two-dimensional	O
-to-	O
three-dimensional	O
(	O
2D	O
-	O
3D	O
)	O
deformation	O
has	O
emerged	O
as	O
a	O
new	O
technique	O
to	O
estimate	O
cone-beam	B-P
computed	I-P
tomography	I-P
(	O
CBCT	B-P
)	O
images	O
.	O

The	O
technique	B-P
is	O
based	O
on	O
deforming	O
a	O
prior	O
high-quality	O
3D	O
CT	B-P
/	O
CBCT	B-P
image	O
to	O
form	O
a	O
new	O
CBCT	B-P
image	O
,	O
guided	O
by	O
limited-view	O
2D	O
projections	O
.	O

The	O
accuracy	O
of	O
this	O
intensity-based	O
technique	B-P
,	O
however	O
,	O
is	O
often	O
limited	O
in	O
low-contrast	O
image	O
regions	O
with	O
subtle	O
intensity	O
differences	O
.	O

The	O
solved	O
deformation	O
vector	O
fields	O
(	O
DVFs	O
)	O
can	O
also	O
be	O
biomechanical	O
ly	O
unrealistic	O
.	O

To	O
address	O
these	O
problems	O
,	O
we	O
have	O
developed	O
a	O
biomechanical	O
modeling	O
guided	O
CBCT	B-P
estimation	O
technique	O
(	O
Bio-CBCT-est	O
)	O
by	O
combining	O
2D	O
-	O
3D	O
deformation	O
with	O
finite	O
element	O
analysis	O
(	O
FEA	O
)	O
-based	O
biomechanical	O
modeling	O
of	O
anatomical	O
structures	O
.	O

Specifically	O
,	O
Bio-CBCT-est	O
first	O
extracts	O
the	O
2D	O
-	O
3D	O
deformation	O
-generated	O
displacement	O
vectors	O
at	O
the	O
high-contrast	O
anatomical	O
structure	O
boundaries	O
.	O

The	O
extracted	O
surface	O
deformation	O
fields	O
are	O
subsequently	O
used	O
as	O
the	O
boundary	O
conditions	O
to	O
drive	O
structure	O
-based	O
FEA	O
to	O
correct	O
and	O
fine-tune	O
the	O
overall	O
deformation	O
fields	O
,	O
especially	O
those	O
at	O
low-contrast	O
regions	O
within	O
the	O
structure	O
.	O

The	O
resulting	O
FEA	O
-corrected	O
deformation	O
fields	O
are	O
then	O
fed	O
back	O
into	O
2D	O
-	O
3D	O
deformation	O
to	O
form	O
an	O
iterative	O
loop	O
,	O
combining	O
the	O
benefits	O
of	O
intensity-based	O
deformation	O
and	O
biomechanical	O
modeling	O
for	O
CBCT	B-P
estimation	O
.	O

Using	O
eleven	O
lung	O
cancer	O
patient	O
cases	O
,	O
the	O
accuracy	O
of	O
the	O
Bio-CBCT-est	O
technique	B-P
has	O
been	O
compared	O
to	O
that	O
of	O
the	O
2D	O
-	O
3D	O
deformation	O
technique	O
and	O
the	O
traditional	O
CBCT	B-P
reconstruction	O
techniques	O
.	O

The	O
accuracy	O
was	O
evaluated	O
in	O
the	O
image	O
domain	O
,	O
and	O
also	O
in	O
the	O
DVF	O
domain	O
through	O
clinician	O
-tracked	O
lung	O
landmarks	O
.	O

Safety	O
and	O
function	O
of	O
a	O
prototype	O
microprocessor	O
-controlled	O
knee	O
prosthesis	O
for	O
low	O
active	O
transfemoral	O
amputees	O
switching	O
from	O
a	O
mechanic	O
knee	O
prosthesis	O
:	O
a	O
pilot	O
study	O
.	O

Aim	O
of	O
this	O
pilot	O
study	O
was	O
to	O
assess	O
safety	O
and	O
functioning	O
of	O
a	O
microprocessor	O
-controlled	O
knee	O
prosthesis	O
(	O
MPK	O
)	O
after	O
a	O
short	O
familiarization	O
time	O
and	O
no	O
structured	O
physical	O
therapy	O
.	O

Five	O
elderly	O
,	O
low-active	O
transfemoral	O
amputees	O
who	O
were	O
fitted	O
with	O
a	O
standard	O
non-microprocessor	O
controlled	O
knee	O
prosthesis	O
(	O
NMPK	O
)	O
performed	O
a	O
baseline	O
measurement	O
consisting	O
of	O
a	O
3	B-P
D	I-P
gait	I-P
analysis	I-P
,	O
functional	O
tests	O
and	O
questionnaires	O
.	O

The	O
first	O
follow-up	O
consisted	O
of	O
the	O
same	O
test	B-P
procedure	I-P
and	O
was	O
performed	O
with	O
the	O
MPK	O
after	O
4	O
to	O
6	O
weeks	O
of	O
familiarization	O
.	O

After	O
being	O
refitted	O
to	O
their	O
standard	O
NMPK	O
again	O
,	O
the	O
subjects	O
undertook	O
the	O
second	O
follow-up	O
which	O
consisted	O
of	O
solely	O
questionnaires	O
4	O
weeks	O
later	O
.	O

Questionnaires	O
and	O
functional	O
tests	O
showed	O
an	O
increase	O
in	O
the	O
perception	O
of	O
safety	O
.	O

Moreover	O
,	O
gait	B-P
analysis	I-P
revealed	O
more	O
physiologic	O
knee	O
and	O
hip	O
extension/flexion	O
patterns	O
when	O
using	O
the	O
MPK	O
.	O

Our	O
results	O
showed	O
that	O
although	O
the	O
Genium	O
with	O
Cenior-Leg	O
ruleset-MPK	O
(	O
GCL-MPK	O
)	O
might	O
help	O
to	O
improve	O
several	O
safety	O
-related	O
outcomes	O
as	O
well	O
as	O
gait	O
biomechanics	O
the	O
functional	O
potential	O
of	O
the	O
GCL-MPK	O
may	O
have	O
been	O
limited	O
without	O
specific	O
training	O
and	O
a	O
sufficient	O
acclimation	O
period	O
.	O

Implications	O
for	O
Rehabilitation	O
Elderly	O
transfemoral	O
amputees	O
are	O
often	O
limited	O
in	O
their	O
activity	O
by	O
safety	O
issues	O
as	O
well	O
as	O
insufficient	O
functioning	O
regarding	O
the	O
non	O
microprocessor	O
-controlled	O
knee	O
prostheses	O
(	O
NMPK	O
)	O
,	O
thing	O
that	O
could	O
be	O
eliminated	O
with	O
the	O
use	O
of	O
suitable	O
microprocessor	O
-controlled	O
prostheses	O
(	O
MPK	O
)	O
.	O

The	O
safety	O
and	O
functioning	O
of	O
a	O
prototype	O
MPK	O
(	O
GCL-MPK	O
)	O
specifically	O
designed	O
for	O
the	O
needs	O
of	O
older	O
and	O
low-active	O
transfemoral	O
amputees	O
was	O
assessed	O
in	O
this	O
pilot	O
study	O
.	O

The	O
GCL-MPK	O
showed	O
indicators	O
of	O
increased	O
safety	O
and	O
more	O
natural	O
walking	O
patterns	O
in	O
older	O
and	O
low-active	O
transfemoral	O
amputees	O
in	O
comparison	O
to	O
the	O
standard	O
NMPK	O
already	O
after	O
a	O
short	O
acclimatisation	O
time	O
and	O
no	O
structured	O
physical	O
therapy	O
.	O

Regarding	O
functional	O
performance	O
it	O
seems	O
as	O
if	O
providing	O
older	O
and	O
low-active	O
transfemoral	O
amputees	O
with	O
the	O
GCL-MPK	O
alone	O
without	O
prescribing	O
structured	O
prosthesis	O
training	O
might	O
be	O
insufficient	O
to	O
achieve	O
improvements	O
over	O
the	O
standard	O
NMPKs	O
.	O

Prognostic	O
significance	O
of	O
non-HPV16	O
genotypes	O
in	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
.	O

Recent	O
studies	O
have	O
found	O
that	O
cases	O
with	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
(	O
OPSCC	O
)	O
positive	O
for	O
HPV16	O
genotype	O
have	O
better	O
overall	O
survival	O
compared	O
with	O
cases	O
positive	O
for	O
other	O
HPV	O
genotypes	O
.	O

We	O
sought	O
to	O
further	O
replicate	O
these	O
studies	O
and	O
determine	O
if	O
this	O
relationship	O
is	O
modified	O
by	O
expression	O
of	O
p16	O
tumor	O
suppressor	O
protein	O
.	O

We	O
identified	O
238	O
OPSCC	O
cases	O
from	O
the	O
Carolina	O
Head	O
and	O
Neck	O
Cancer	O
Study	O
(	O
CHANCE	O
)	O
study	O
,	O
a	O
population	O
based	O
case-control	O
study	O
.	O

Tumors	O
that	O
tested	O
positive	O
solely	O
for	O
HPV16	O
genotype	O
and	O
no	O
other	O
genotypes	O
with	O
PCR	O
were	O
classified	O
as	O
HPV16-positive	O
.	O

Tumors	O
positive	O
for	O
any	O
other	O
high-risk	O
HPV	O
genotype	O
were	O
classified	O
as	O
non-HPV16-positive	O
.	O

Expression	O
of	O
p16	O
in	O
the	O
tumor	O
was	O
determined	O
with	O
immunohistochemistry	B-P
.	O

Follow-up	O
time	O
was	O
calculated	O
from	O
the	O
date	O
of	O
diagnosis	O
to	O
date	O
of	O
death	O
or	O
December	O
31	O
,	O
2013	O
.	O

Overall	O
survival	O
was	O
compared	O
with	O
the	O
Kaplan-Meier	O
curves	O
and	O
log-rank	O
test	O
.	O

Hazard	O
ratios	O
(	O
HR	O
)	O
adjusted	O
for	O
smoking	O
,	O
alcohol	O
use	O
,	O
sex	O
,	O
race	O
,	O
and	O
age	O
was	O
calculated	O
with	O
the	O
Cox	O
proportional	O
hazard	O
regression	O
.	O

Cases	O
with	O
HPV16-positive	O
OPSCC	O
had	O
better	O
overall	O
survival	O
than	O
cases	O
with	O
non-HPV16-positive	O
OPSCC	O
(	O
log-rank	O
p-value	O
:	O
0.010	O
)	O
.	O

When	O
restricted	O
to	O
OPSCC	O
cases	O
positive	O
for	O
p16	O
expression	O
,	O
the	O
same	O
trend	O
continued	O
(	O
log-rank	O
p-value	O
:	O
0.002	O
)	O
.	O

In	O
the	O
adjusted	O
model	O
,	O
cases	O
with	O
non-HPV16-positive	O
OPSCC	O
had	O
greater	O
risk	O
of	O
death	O
compared	O
to	O
cases	O
with	O
HPV16-positive	O
tumors	O
(	O
HR	O
:	O
1.92	O
;	O
95	O
%	O
CI	O
:	O
1.03	O
,	O
3.60	O
)	O
.	O

This	O
finding	O
indicates	O
that	O
HPV	O
genotyping	B-P
carries	O
valuable	O
prognostic	O
significance	O
in	O
addition	O
to	O
p16	O
status	O
and	O
future	O
survival	O
studies	O
of	O
OPSCC	O
should	O
take	O
into	O
account	O
differing	O
HPV	O
genotypes	O
.	O

Differential	B-P
proteomics	I-P
profiling	I-P
identifies	O
LDPs	O
and	O
biological	O
functions	O
in	O
high-fat	O
diet	O
-	O
induced	O
fatty	O
livers	O
.	O

Eukaryotic	O
cells	O
store	O
neutral	O
lipids	O
in	O
cytoplasmic	O
lipid	O
droplets	O
(	O
LDs	O
)	O
enclosed	O
in	O
a	O
monolayer	O
of	O
phospholipids	O
and	O
associated	O
proteins	O
[	O
LD	O
proteins	O
(	O
LDPs	O
)	O
]	O
.	O

Growing	O
evidence	O
has	O
demonstrated	O
that	O
LDPs	O
play	O
important	O
roles	O
in	O
the	O
pathogenesis	O
of	O
liver	O
diseases	O
.	O

However	O
,	O
the	O
composition	O
of	O
liver	O
LDPs	O
and	O
the	O
role	O
of	O
their	O
alterations	O
in	O
hepatosteatosis	O
are	O
not	O
well-understood	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
liver	O
proteome	O
and	O
LD	O
sub-proteome	B-P
profiling	I-P
to	O
identify	O
enriched	O
proteins	O
in	O
LDs	O
as	O
LDPs	O
,	O
and	O
quantified	O
their	O
changes	O
in	O
a	O
high-fat	O
diet	O
(	O
HFD	O
)	O
-	O
induced	O
fatty	O
liver	O
model	O
.	O

Among	O
5,000	O
quantified	O
liver	O
proteins	O
,	O
101	O
were	O
enriched	O
by	O
greater	O
than	O
10-fold	O
in	O
the	O
LD	O
sub-proteome	O
and	O
were	O
classified	O
as	O
LDPs	O
.	O

Differential	B-P
profiling	I-P
of	O
LDPs	O
in	O
HFD	O
-	O
induced	O
fatty	O
liver	O
provided	O
a	O
list	O
of	O
candidate	O
LDPs	O
for	O
functional	O
investigation	O
.	O

We	O
tested	O
the	O
function	O
of	O
an	O
upregulated	O
LDP	O
,	O
S100a10	O
,	O
in	O
vivo	O
with	O
adenovirus	O
-mediated	O
gene	O
silencing	O
and	O
found	O
,	O
unexpectedly	O
,	O
that	O
knockdown	O
of	O
S100a10	O
accelerated	O
progression	O
of	O
HFD	O
-	O
induced	O
liver	O
steatosis	O
.	O

The	O
S100A10	O
interactome	O
revealed	O
a	O
connection	O
between	O
S100A10	O
and	O
lipid	O
transporting	O
proteins	O
,	O
suggesting	O
that	O
S100A10	O
regulates	O
the	O
development	O
and	O
formation	O
of	O
LDs	O
by	O
transporting	O
and	O
trafficking	O
.	O

This	O
study	O
identified	O
LD	O
-enriched	O
sub-proteome	O
in	O
homeostatic	O
as	O
well	O
as	O
HFD	O
-	O
induced	O
fatty	O
livers	O
,	O
providing	O
a	O
rich	O
resource	O
for	O
the	O
LDP	O
research	O
field	O
.	O

Making	O
use	O
of	O
longitudinal	O
information	O
in	O
pattern	O
recognition	O
.	O

Longitudinal	O
designs	O
are	O
widely	O
used	O
in	O
medical	O
studies	O
as	O
a	O
means	O
of	O
observing	O
within-	O
subject	O
changes	O
over	O
time	O
in	O
groups	O
of	O
subjects	O
,	O
thereby	O
aiming	O
to	O
improve	O
sensitivity	O
for	O
detecting	O
disease	O
effects	O
.	O

Paralleling	O
an	O
increased	O
use	O
of	O
such	O
studies	O
in	O
neuroimaging	B-P
has	O
been	O
the	O
adoption	O
of	O
pattern	O
recognition	O
algorithms	O
for	O
making	O
individualized	O
predictions	O
of	O
disease	O
.	O

However	O
,	O
at	O
present	O
few	O
pattern	O
recognition	O
methods	O
exist	O
to	O
make	O
full	O
use	O
of	O
neuroimaging	B-P
data	O
that	O
have	O
been	O
collected	O
longitudinally	O
,	O
with	O
most	O
methods	O
relying	O
instead	O
on	O
cross-sectional	O
style	O
analysis	O
.	O

This	O
article	O
presents	O
a	O
principal	O
component	O
analysis	O
-based	O
feature	O
construction	O
method	O
that	O
uses	O
longitudinal	O
high-dimensional	O
data	O
to	O
improve	O
predictive	O
performance	O
of	O
pattern	O
recognition	O
algorithms	O
.	O

The	O
method	O
can	O
be	O
applied	O
to	O
data	O
from	O
a	O
wide	O
range	O
of	O
longitudinal	O
study	O
designs	O
and	O
permits	O
an	O
arbitrary	O
number	O
of	O
time-points	O
per	O
subject	O
.	O

We	O
apply	O
the	O
method	O
to	O
two	O
longitudinal	O
datasets	O
,	O
one	O
containing	O
subjects	O
with	O
mild	O
cognitive	O
impairment	O
along	O
with	O
healthy	O
controls	O
,	O
the	O
other	O
with	O
early	O
dementia	O
subjects	O
and	O
healthy	O
controls	O
.	O

Across	O
both	O
datasets	O
,	O
we	O
show	O
improvements	O
in	O
predictive	O
accuracy	O
relative	O
to	O
cross-sectional	O
classifiers	O
for	O
discriminating	O
disease	O
subjects	O
from	O
healthy	O
controls	O
on	O
the	O
basis	O
of	O
whole-	O
brain	O
structural	O
magnetic	B-P
resonance	I-P
image	I-P
-based	O
voxels	O
.	O

In	O
addition	O
,	O
we	O
can	O
transfer	O
longitudinal	O
information	O
from	O
one	O
set	O
of	O
subjects	O
to	O
make	O
disease	O
predictions	O
in	O
another	O
set	O
of	O
subjects	O
.	O

The	O
proposed	O
method	O
is	O
simple	O
and	O
,	O
as	O
a	O
feature	O
construction	O
method	O
,	O
flexible	O
with	O
respect	O
to	O
the	O
choice	O
of	O
classifier	O
and	O
image	O
registration	O
algorithm	O
.	O

Hum	O
Brain	O
Mapp	O
,	O
2016	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Multigenerational	O
effects	O
of	O
two	O
glucocorticoids	O
(	O
prednisolone	O
and	O
dexamethasone	O
)	O
on	O
life-history	O
parameters	O
of	O
crustacean	O
Ceriodaphnia	O
dubia	O
(	O
Cladocera	O
)	O
.	O

Synthetic	O
glucocorticoids	O
(	O
GCs	O
)	O
such	O
as	O
dexamethasone	O
(	O
DEX	O
)	O
and	O
prednisolone	O
(	O
PDS	O
)	O
have	O
been	O
used	O
since	O
the	O
1940s	O
to	O
cure	O
inflammatory	O
and	O
auto-immune	O
disorders	O
.	O

Their	O
use	O
has	O
been	O
linked	O
to	O
a	O
host	O
of	O
deleterious	O
effects	O
in	O
aquatic	O
ecosystems	O
such	O
as	O
osteoporosis	O
in	O
vertebrates	O
,	O
developmental	O
impairments	O
in	O
molluscs	O
and	O
reduced	O
fecundity	O
and	O
growth	O
in	O
cladocerans	O
.	O

Apart	O
from	O
these	O
handful	O
of	O
studies	O
,	O
the	O
effects	O
of	O
GCs	O
on	O
aquatic	O
biota	O
are	O
largely	O
unknown	O
.	O

The	O
present	O
study	O
is	O
a	O
first	O
of	O
its	O
kind	O
aiming	O
to	O
assess	O
the	O
multi-generational	O
exposure	O
effects	O
of	O
DEX	O
and	O
PDS	O
on	O
the	O
life	O
history	O
parameters	O
of	O
Ceriodaphnia	O
dubia	O
(	O
C.	O
dubia	O
)	O
.	O

Multigenerational	O
studies	O
have	O
proved	O
to	O
be	O
an	O
advantage	O
in	O
assessing	O
the	O
cumulative	O
damage	O
caused	O
by	O
aquatic	O
toxicants	O
at	O
the	O
population	O
level	O
of	O
the	O
exposed	O
organisms	O
over	O
a	O
period	O
of	O
successive	O
generations	O
using	O
multiple	O
biological	O
endpoints	O
.	O

Test	O
results	O
demonstrated	O
that	O
C.	O
dubia	O
exhibited	O
varied	O
sensitivities	O
towards	O
both	O
the	O
studied	O
chemicals	O
however	O
were	O
more	O
sensitive	O
to	O
DEX	O
with	O
48-h	O
EC50	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
of	O
0.75	O
mg/L	O
(	O
CI	O
:	O
0.59-0.92	O
)	O
in	O
comparison	O
to	O
PDS	O
[	O
19	O
mg/L	O
(	O
CI	O
:	O
15-23	O
)	O
]	O
.	O

EC10	O
values	O
for	O
F0	O
in	O
a	O
multigenerational	B-P
chronic	I-P
bioassays	I-P
were	O
48	O
μg/L	O
(	O
CI	O
:	O
37.4-61	O
)	O
for	O
DEX	O
and	O
460	O
μg/L	O
(	O
CI	O
:	O
341-606	O
)	O
for	O
PDS	O
and	O
in	O
F3	O
were	O
2.2	O
μg/L	O
(	O
CI	O
:	O
1.6-3.1	O
)	O
for	O
DEX	O
and	O
31	O
μg/L	O
(	O
CI	O
:	O
19.4-46	O
)	O
for	O
PDS	O
.	O

There	O
was	O
a	O
positive	O
trend	O
of	O
increased	O
toxicity	O
followed	O
by	O
reduced	O
life	O
history	O
traits	O
such	O
as	O
fecundity	O
,	O
brood	O
size	O
and	O
time	O
to	O
first	O
brood	O
and	O
intrinsic	O
rate	O
of	O
population	O
increase	O
and	O
body	O
growth	O
(	O
length	O
and	O
area	O
)	O
of	O
C.	O
dubia	O
in	O
the	O
case	O
of	O
both	O
studied	O
chemicals	O
.	O

The	O
results	O
from	O
the	O
current	O
work	O
highlighted	O
the	O
importance	O
of	O
multigenerational	O
studies	O
in	O
identifying	O
the	O
evolutionary	O
responses	O
of	O
stressed	O
non-target	O
aquatic	O
organisms	O
,	O
and	O
data	O
obtained	O
can	O
be	O
further	O
used	O
in	O
developing	O
water	O
quality	O
guidelines	O
.	O

Total	O
synthesis	O
and	O
neuroprotective	O
effect	O
of	O
O-methylmurrayamine	O
A	O
and	O
7-methoxymurrayacine	O
.	O

O-Methylmurrayamine	O
A	O
(	O
7	O
)	O
and	O
7-methoxymurrayacine	O
(	O
8	O
)	O
are	O
natural	O
products	O
isolated	O
from	O
Murraya	O
koenigii	O
and	O
Murraya	O
siamensis	O
,	O
respectively	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
synthesis	O
of	O
7	O
and	O
8	O
which	O
are	O
featured	O
in	O
the	O
key	O
step	O
of	O
cyclization	O
to	O
form	O
carbazole	O
intermediate	O
5	O
with	O
mild	O
conditions	O
.	O

The	O
structures	O
were	O
confirmed	O
by	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
,	O
(	B-P
13	I-P
)	I-P
C	I-P
NMR	I-P
,	O
and	O
HR-ESI-MS	B-P
.	O

In	O
addition	O
,	O
compounds	O
7	O
and	O
8	O
were	O
tested	O
for	O
their	O
neuroprotective	O
effects	O
against	O
H2O2	O
-induced	O
PC12	O
cell	O
damage	O
.	O

The	O
results	O
showed	O
that	O
compounds	O
7	O
and	O
8	O
have	O
neuroprotective	O
effect	O
.	O

A	O
case	O
of	O
bilateral	O
pneumothoraces	O
resulting	O
from	O
tracheostomy	O
for	O
advanced	O
laryngeal	O
cancer	O
.	O

Pneumothorax	O
is	O
a	O
possible	O
complication	O
of	O
tracheostomy	O
.	O

We	O
report	O
a	O
rare	O
case	O
of	O
bilateral	O
pneumothoraces	O
resulting	O
from	O
tracheostomy	O
in	O
an	O
advanced	O
laryngeal	O
cancer	O
patient	O
.	O

A	O
59-year-old	O
man	O
was	O
referred	O
to	O
our	O
clinic	O
for	O
evaluation	O
and	O
treatment	O
of	O
laryngeal	O
tumor	O
.	O

Laryngeal	B-P
endoscopy	I-P
showed	O
limited	O
movement	O
of	O
bilateral	O
vocal	O
cords	O
,	O
and	O
computed	B-P
tomography	I-P
revealed	O
a	O
tumor	O
lesion	O
extending	O
from	O
the	O
vocal	O
cords	O
to	O
the	O
subglottic	O
area	O
.	O

Three	O
days	O
after	O
the	O
first	O
visit	O
,	O
the	O
patient	O
developed	O
respiratory	O
difficulty	O
,	O
and	O
we	O
elected	O
to	O
perform	O
emergency	O
tracheostomy	O
for	O
airway	O
management	O
.	O

Immediately	O
after	O
the	O
start	O
of	O
the	O
procedure	O
,	O
he	O
began	O
hyperventilating	O
,	O
and	O
complained	O
of	O
respiratory	O
discomfort	O
and	O
chest	O
pain	O
.	O

We	O
then	O
recognized	O
a	O
mediastinal	O
air	O
leak	O
,	O
and	O
we	O
suspected	O
pneumothorax	O
resulting	O
from	O
the	O
tracheostomy	O
.	O

Chest	B-P
X-ray	I-P
showed	O
bilateral	O
pneumothoraces	O
;	O
therefore	O
,	O
we	O
inserted	O
bilateral	O
chest	O
drainage	O
tubes	O
,	O
which	O
stabilized	O
his	O
respiratory	O
condition	O
.	O

We	O
speculated	O
that	O
the	O
pathogenesis	O
of	O
the	O
bilateral	O
pneumothoraces	O
was	O
weakened	O
alveolar	O
walls	O
secondary	O
to	O
long-term	O
smoking	O
,	O
and	O
a	O
significant	O
rise	O
in	O
airway	O
pressure	O
because	O
of	O
airway	O
constriction	O
by	O
the	O
neck-extended	O
position	O
and	O
hyperventilation	O
,	O
during	O
tracheostomy	O
.	O

Thaw	B-P
-and-use	O
target	O
cells	O
pre-labeled	O
with	O
calcein	O
AM	O
for	O
antibody-dependent	B-P
cell-mediated	I-P
cytotoxicity	I-P
assays	I-P
.	O

In	O
vitro	O
antibody-dependent	B-P
cell-mediated	I-P
cytotoxicity	I-P
(	I-P
ADCC	I-P
)	I-P
assays	I-P
are	O
routinely	O
performed	O
to	O
support	O
the	O
research	O
and	O
development	O
of	O
therapeutic	O
antibodies	O
.	O

In	O
ADCC	B-P
assays	I-P
,	O
target	O
cells	O
bound	O
by	O
the	O
antibodies	O
are	O
lysed	O
by	O
activated	O
effector	O
cells	O
following	O
interactions	O
between	O
the	O
Fc	O
region	O
of	O
the	O
bound	O
antibody	O
and	O
Fcγ	O
receptors	O
on	O
effector	O
cells	O
.	O

Target	O
cell	O
lysis	O
is	O
typically	O
measured	O
by	O
quantification	O
of	O
released	O
endogenous	O
enzymes	O
,	O
e.g.	O
,	O
lactate	O
dehydrogenase	O
,	O
or	O
measurement	O
of	O
released	O
exogenous	O
labels	O
,	O
e.g.	O
,	O
(	O
51	O
)	O
Cr	O
,	O
europium	O
or	O
calcein	O
.	O

ADCC	B-P
assays	I-P
based	O
on	O
the	O
detection	O
of	O
exogenous	O
labels	O
released	O
from	O
lysed	O
target	O
cells	O
generally	O
show	O
higher	O
sensitivity	O
and	O
require	O
shorter	O
incubation	O
times	O
.	O

However	O
,	O
target	O
cells	O
are	O
usually	O
labeled	O
immediately	O
prior	O
to	O
assay	B-P
,	O
which	O
inadvertently	O
introduces	O
additional	O
assay	B-P
variations	O
due	O
to	O
differences	O
in	O
target	O
cell	O
conditions	O
and	O
labeling	B-P
/	O
handling	B-P
processes	I-P
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
use	O
of	O
thaw	B-P
-and-use	O
pre-labeled	O
target	O
cells	O
for	O
ADCC	B-P
assays	I-P
.	O

Thaw	B-P
-and-use	O
target	O
cells	O
in	O
our	O
experiments	O
were	O
pre-labeled	O
with	O
the	O
fluorescent	O
dye	O
calcein	O
AM	O
,	O
cryopreserved	B-P
in	O
single-use	O
aliquots	O
and	O
used	O
directly	O
in	O
assays	B-P
after	O
thawing	B-P
.	O

Upon	O
thaw	B-P
,	O
the	O
pre-labeled	O
cells	O
displayed	O
viability	O
and	O
label	O
retention	O
comparable	O
to	O
freshly	O
labeled	O
cells	O
,	O
responded	O
to	O
ADCC	O
mediated	O
by	O
both	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
engineered	O
natural	O
killer	O
cells	O
,	O
performed	O
stably	O
for	O
at	O
least	O
3	O
years	O
and	O
provided	O
favorable	O
precision	O
and	O
accuracy	O
to	O
ADCC	B-P
assays	I-P
.	O

Implementation	O
of	O
thaw	B-P
-and-use	O
pre-labeled	O
target	O
cells	O
in	O
ADCC	B-P
assays	I-P
can	O
help	O
to	O
alleviate	O
both	O
cell	B-P
culture	I-P
and	O
dye	B-P
labeling	I-P
derived	O
variability	O
,	O
increase	O
the	O
flexibility	O
of	O
assay	B-P
scheduling	O
and	O
improve	O
assay	O
consistency	O
and	O
robustness	O
.	O

Physical	O
Activity	O
and	O
Abnormal	O
Blood	O
Glucose	O
Among	O
Healthy	O
Weight	O
Adults	O
.	O

Physical	O
activity	O
has	O
been	O
linked	O
to	O
prevention	O
and	O
treatment	O
of	O
prediabetes	O
and	O
diabetes	O
in	O
overweight	O
and	O
obese	O
adults	O
.	O

This	O
study	O
examines	O
the	O
relationship	O
between	O
low	O
physical	O
activity	O
levels	O
and	O
risk	O
of	O
abnormal	O
blood	O
glucose	O
(	O
prediabetes	O
or	O
undiagnosed	O
diabetes	O
)	O
in	O
healthy	O
weight	O
adults	O
.	O

Data	O
from	O
the	O
2014	O
Health	O
Survey	O
for	O
England	O
were	O
analyzed	O
in	O
July	O
2016	O
,	O
focusing	O
on	O
adults	O
with	O
a	O
BMI	O
≥18.5	O
and	O
<	O
25	O
who	O
had	O
never	O
been	O
diagnosed	O
with	O
diabetes	O
(	O
N=1,153	O
)	O
.	O

Abnormal	O
blood	O
glucose	O
was	O
defined	O
as	O
hemoglobin	B-P
A1c	I-P
≥5.7	O
.	O

Physical	O
activity	O
was	O
measured	O
through	O
the	O
International	O
Physical	O
Activity	O
Questionnaire	O
.	O

Bivariate	O
analyses	O
and	O
Poisson	O
models	O
were	O
conducted	O
on	O
the	O
effect	O
of	O
physical	O
activity	O
on	O
abnormal	O
blood	O
glucose	O
,	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
waist	O
to	O
hip	O
ratio	O
,	O
sitting	O
time	O
,	O
age	O
X	O
physical	O
activity	O
interaction	O
,	O
sex	O
X	O
physical	O
activity	O
,	O
and	O
race	O
.	O

Abnormal	O
blood	O
glucose	O
was	O
detected	O
in	O
23.7	O
%	O
of	O
individuals	O
with	O
low	O
activity	O
levels	O
,	O
14.8	O
%	O
of	O
those	O
with	O
medium	O
activity	O
levels	O
,	O
and	O
12.2	O
%	O
of	O
those	O
with	O
high	O
activity	O
levels	O
(	O
p	O
<	O
0.003	O
)	O
.	O

Similarly	O
,	O
25.4	O
%	O
of	O
inactive	O
individuals	O
(	O
physically	O
active	O
for	O
<	O
30	O
minutes	O
per	O
week	O
)	O
were	O
more	O
likely	O
to	O
have	O
abnormal	O
blood	O
glucose	O
levels	O
than	O
active	O
individuals	O
(	O
13.4	O
%	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Higher	O
physical	O
activity	O
was	O
associated	O
with	O
a	O
lower	O
likelihood	O
of	O
abnormal	O
blood	O
glucose	O
in	O
an	O
adjusted	O
Poisson	O
regression	O
.	O

Among	O
healthy	O
weight	O
adults	O
,	O
low	O
physical	O
activity	O
levels	O
are	O
significantly	O
associated	O
with	O
abnormal	O
blood	O
glucose	O
(	O
prediabetes	O
and	O
undiagnosed	O
diabetes	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
healthy	O
weight	O
individuals	O
may	O
benefit	O
from	O
physical	O
exercise	O
.	O

Increased	O
dopamine	O
receptor	O
expression	O
and	O
anti-depressant	O
response	O
following	O
deep	O
brain	O
stimulation	O
of	O
the	O
medial	O
forebrain	O
bundle	O
.	O

Among	O
several	O
potential	O
neuroanatomical	O
targets	O
pursued	O
for	O
deep	O
brain	O
stimulation	O
(	O
DBS	O
)	O
for	O
treating	O
those	O
with	O
treatment-resistant	O
depression	O
(	O
TRD	O
)	O
,	O
the	O
superolateral-branch	O
of	O
the	O
medial	O
forebrain	O
bundle	O
(	O
MFB	O
)	O
is	O
emerging	O
as	O
a	O
privileged	O
location	O
.	O

We	O
investigated	O
the	O
antidepressant	B-P
-like	O
phenotypic	O
and	O
chemical	O
changes	O
associated	O
with	O
reward-processing	O
dopaminergic	O
systems	O
in	O
rat	O
brains	O
after	O
MFB	O
-	O
DBS	O
.	O

Male	O
Wistar	O
rats	O
were	O
divided	O
into	O
three	O
groups	O
:	O
sham-operated	O
,	O
DBS	O
-	O
Off	O
,	O
and	O
DBS	O
-On	O
.	O

For	O
DBS	O
,	O
a	O
concentric	O
bipolar	O
electrode	O
was	O
stereotactically	O
implanted	O
into	O
the	O
right	O
MFB	O
.	O

Exploratory	O
activity	O
and	O
depression-like	O
behavior	O
were	O
evaluated	O
using	O
the	O
open-field	O
and	O
forced-swimming	O
test	O
(	O
FST	O
)	O
,	O
respectively	O
.	O

MFB	O
-	O
DBS	O
effects	O
on	O
the	O
dopaminergic	O
system	O
were	O
evaluated	O
using	O
immunoblotting	B-P
for	O
tyrosine	O
hydroxylase	O
(	O
TH	O
)	O
,	O
dopamine	O
transporter	O
(	O
DAT	O
)	O
,	O
and	O
dopamine	O
receptors	O
(	O
D1-D5	O
)	O
,	O
and	O
high-performance	B-P
liquid	I-P
chromatography	I-P
for	O
quantifying	O
dopamine	O
,	O
3,4-dihydroxyphenylacetic	O
acid	O
(	O
DOPAC	O
)	O
,	O
and	O
homovanillic	O
acid	O
(	O
HVA	O
)	O
in	O
brain	O
homogenates	O
of	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
,	O
hippocampus	O
,	O
amygdala	O
,	O
and	O
nucleus	O
accumbens	O
(	O
NAc	O
)	O
.	O

Animals	O
receiving	O
MFB	O
-	O
DBS	O
showed	O
a	O
significant	O
increase	O
in	O
swimming	O
time	O
without	O
alterations	O
in	O
locomotor	O
activity	O
,	O
relative	O
to	O
the	O
DBS	O
-	O
Off	O
(	O
p	O
<	O
0.039	O
)	O
and	O
sham-operated	O
groups	O
(	O
p	O
<	O
0.014	O
)	O
,	O
indicating	O
an	O
antidepressant-like	O
response	O
.	O

MFB	O
-	O
DBS	O
led	O
to	O
a	O
striking	O
increase	O
in	O
protein	O
levels	O
of	O
dopamine	O
D2	O
receptors	O
and	O
DAT	O
in	O
the	O
PFC	O
and	O
hippocampus	O
,	O
respectively	O
.	O

However	O
,	O
we	O
did	O
not	O
observe	O
appreciable	O
differences	O
in	O
the	O
expression	O
of	O
other	O
dopamine	O
receptors	O
,	O
TH	O
,	O
or	O
in	O
the	O
concentrations	O
of	O
dopamine	O
,	O
DOPAC	O
,	O
and	O
HVA	O
in	O
PFC	O
,	O
hippocampus	O
,	O
amygdala	O
,	O
and	O
NAc	O
.	O

This	O
study	O
was	O
not	O
performed	O
on	O
an	O
animal	O
model	O
of	O
TRD	O
.	O

MFB	O
-	O
DBS	O
rescues	O
the	O
depression-like	O
phenotypes	O
and	O
selectively	O
activates	O
expression	O
of	O
dopamine	O
receptors	O
in	O
brain	O
regions	O
distant	O
from	O
the	O
target	O
area	O
of	O
stimulation	O
.	O

Vitamin	O
D	O
deficiency	O
and	O
interleukin-17	O
relationship	O
in	O
severe	O
obstructive	O
sleep	O
apnea-hypopnea	O
syndrome	O
.	O

We	O
aimed	O
to	O
assess	O
Vitamin	O
D	O
(	O
VD	O
)	O
abnormalities	O
in	O
patients	O
with	O
severe	O
obstructive	O
sleep	O
apnea-hypopnea	O
syndrome	O
(	O
OSAHS	O
)	O
,	O
to	O
study	O
its	O
association	O
with	O
clinical	O
and	O
polygraphic	O
data	O
,	O
and	O
to	O
correlate	O
VD	B-P
levels	I-P
with	O
interleukin-17	O
(	O
IL-17	O
)	O
.	O

Ninety-two	O
patients	O
with	O
severe	O
OSAHS	O
were	O
consecutively	O
enrolled	O
between	O
September	O
2014	O
and	O
February	O
2016	O
and	O
compared	O
to	O
age	O
-	O
,	O
sex	O
-	O
,	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
-matched	O
controls	O
.	O

Anthropometric	O
parameters	O
and	O
medical	O
history	O
were	O
collected	O
.	O

The	O
serum	B-P
levels	I-P
of	I-P
VD	I-P
and	O
IL-17	B-P
were	O
determined	O
by	O
radioimmunoassay	B-P
and	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
,	O
respectively	O
.	O

Ninety-two	O
severe	O
OSAHS	O
patients	O
and	O
thirty	O
controls	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

All	O
OSAHS	O
patients	O
had	O
VD	O
deficiency	O
.	O

The	O
mean	O
level	B-P
of	I-P
VD	I-P
was	O
at	O
7.9	O
ng/ml	O
among	O
OSAHS	O
group	O
versus	O
16.8	O
ng/ml	O
among	O
control	O
group	O
.	O

IL-17A	B-P
levels	I-P
were	O
elevated	O
(	O
20.3	O
pg/ml	O
)	O
in	O
OSAHS	O
group	O
compared	O
to	O
healthy	O
group	O
(	O
10.05	O
pg/ml	O
)	O
.	O

VD	B-P
levels	I-P
were	O
negatively	O
correlated	O
with	O
nocturia	O
severity	O
(	O
r	O
=	O
-0.26	O
;	O
P	O
=	O
0.01	O
)	O
and	O
positively	O
correlated	O
with	O
mean	O
O2	B-P
saturation	I-P
(	O
r	O
=	O
0.59	O
;	O
P	O
=	O
0.02	O
)	O
and	O
lowest	O
O2	B-P
saturation	I-P
(	O
r	O
=	O
0.3	O
;	O
P	O
=	O
0.03	O
)	O
.	O

IL-17	B-P
levels	I-P
were	O
positively	O
correlated	O
with	O
nocturia	O
severity	O
(	O
r	O
=	O
0.24	O
;	O
P	O
=	O
0.03	O
)	O
and	O
negatively	O
correlated	O
with	O
mean	O
O2	B-P
saturation	I-P
(	O
r	O
=	O
-0.42	O
;	O
P	O
=	O
0.03	O
)	O
.	O

A	O
significant	O
negative	O
association	O
was	O
observed	O
between	O
IL-7	B-P
and	O
VD	B-P
levels	I-P
(	O
r	O
=	O
-0.64	O
,	O
P	O
=	O
0.2	O
10	O
(	O
-4	O
)	O
)	O
.	O

The	O
magnitude	O
of	O
this	O
correlation	O
was	O
higher	O
for	O
important	O
nocturia	O
,	O
lower	O
MSaO2	B-P
,	O
or	O
higher	O
BMI	O
.	O

VD	O
deficiency	O
in	O
patients	O
with	O
severe	O
OSAHS	O
is	O
common	O
with	O
a	O
negative	O
association	O
between	O
IL-17	O
and	O
VD	B-P
serum	I-P
levels	I-P
.	O

Hypoxia	O
could	O
play	O
an	O
important	O
role	O
in	O
this	O
association	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
clarify	O
this	O
relationship	O
.	O

Modulation	O
of	O
gonadotrophin	O
induced	O
steroidogenic	O
enzymes	O
in	O
granulosa	O
cells	O
by	O
d-chiroinositol	O
.	O

d-chiroinositol	O
(	O
DCI	O
)	O
is	O
a	O
inositolphosphoglycan	O
(	O
IPG	O
)	O
involved	O
in	O
several	O
cellular	O
functions	O
that	O
control	O
the	O
glucose	O
metabolism	O
.	O

DCI	O
functions	O
as	O
second	O
messenger	O
in	O
the	O
insulin	O
signaling	O
pathway	O
and	O
it	O
is	O
considered	O
an	O
insulin	O
sensitizer	O
since	O
deficiency	O
in	O
tissue	O
availability	O
of	O
DCI	O
were	O
shown	O
to	O
cause	O
insulin	O
resistance	O
(	O
IR	O
)	O
.	O

Polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
is	O
a	O
pathological	O
condition	O
that	O
is	O
often	O
accompanied	O
with	O
insulin	O
resistance	O
.	O

DCI	O
can	O
positively	O
affects	O
several	O
aspect	O
of	O
PCOS	O
etiology	O
decreasing	O
the	O
total	B-P
and	I-P
free	I-P
testosterone	I-P
,	O
lowering	O
blood	O
pressure	O
,	O
improving	O
the	O
glucose	O
metabolism	O
and	O
increasing	O
the	O
ovulation	O
frequency	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
DCI	O
and	O
insulin	O
combined	O
with	O
gonadotrophins	O
namely	O
follicle-stimulating	O
hormone	O
(	O
FSH	O
)	O
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
on	O
key	O
steroidogenic	O
enzymes	O
genes	O
regulation	O
,	O
cytochrome	O
P450	O
family	O
19	O
subfamily	O
A	O
member	O
1	O
(	O
CYP19A1	O
)	O
and	O
cytochrome	O
P450	O
side-chain	O
cleavage	O
(	O
P450scc	O
)	O
in	O
primary	B-P
cultures	I-P
of	O
human	O
granulosa	O
cells	O
(	O
hGCs	O
)	O
.	O

We	O
also	O
investigated	O
whether	O
DCI	O
,	O
being	O
an	O
insulin-sensitizer	O
would	O
be	O
able	O
to	O
counteract	O
the	O
expected	O
stimulator	O
activity	O
of	O
insulin	O
on	O
human	O
granulosa	O
cells	O
(	O
hGCs	O
)	O
.	O

The	O
study	O
was	O
conducted	O
on	O
primary	B-P
cultures	I-P
of	O
hGCs	O
.	O

Gene	O
expression	O
was	O
evaluated	O
by	O
RT-qPCR	O
method	O
.	O

Statistical	O
analysis	O
was	O
performed	O
applying	O
student	O
t-test	O
,	O
as	O
appropriate	O
(	O
P	O
<	O
0.05	O
)	O
set	O
for	O
statistical	O
significance	O
.	O

DCI	O
is	O
able	O
to	O
reduce	O
the	O
gene	O
expression	O
of	O
CYP19A1	O
,	O
P450scc	O
and	O
insulin-like	O
growth	O
factor	O
1	O
receptor	O
(	O
IGF-1R	O
)	O
in	O
dose-response	O
manner	O
.	O

The	O
presence	O
of	O
DCI	O
impaired	O
the	O
increased	O
expression	O
of	O
steroidogenic	O
enzyme	O
genes	O
generated	O
by	O
the	O
insulin	O
treatment	O
in	O
gonadotrophin	O
-	O
stimulated	O
hGCs	O
.	O

Insulin	O
acts	O
as	O
co-gonadotrophin	O
increasing	O
the	O
expression	O
of	O
steroidogenic	O
enzymes	O
genes	O
in	O
gonadotrophin	O
-	O
stimulated	O
granulosa	O
cells	O
.	O

DCI	O
is	O
an	O
insulin-sensitizer	O
that	O
counteracts	O
this	O
action	O
by	O
reducing	O
the	O
expression	O
of	O
the	O
genes	O
CYP19A1	O
,	O
P450scc	O
and	O
IGF-1R	O
.	O

The	O
ability	O
of	O
DCI	O
to	O
modulate	O
in	O
vitro	O
ovarian	O
activity	O
of	O
insulin	O
could	O
in	O
part	O
explain	O
its	O
beneficial	O
effect	O
when	O
used	O
as	O
treatment	O
for	O
conditions	O
associated	O
to	O
insulin	O
resistance	O
.	O

Expression	O
of	O
WNT10A	O
Gene	O
in	O
Oral	O
Squamous	O
Cell	O
Carcinoma	O
.	O

Oral	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
constitutes	O
the	O
most	O
frequent	O
malignant	O
tumour	O
of	O
the	O
oral	O
cavity	O
.	O

Considering	O
the	O
significant	O
roles	O
the	O
Wnt	O
family	O
plays	O
in	O
physiological	O
and	O
pathological	O
events	O
,	O
this	O
study	O
aims	O
to	O
investigate	O
WNT10A	O
gene	O
expression	O
in	O
OSCC	O
.	O

The	O
cohort	O
was	O
composed	O
of	O
59	O
specimens	O
:	O
49	O
with	O
OSCC	O
and	O
10	O
controls	O
.	O

Total	O
RNA	O
from	O
the	O
samples	O
was	O
extracted	O
,	O
cDNA	O
was	O
synthesized	O
and	O
Real-time	B-P
PCR	I-P
analyses	I-P
were	O
performed	O
,	O
with	O
β-ACTIN	O
as	O
internal	O
control	O
.	O

The	O
number	O
of	O
OSCC	O
samples	O
for	O
the	O
4	O
TNM	O
stages	O
was	O
:	O
5	O
(	O
10.2	O
%	O
)	O
stage	O
I	O
,	O
10	O
(	O
20.4	O
%	O
)	O
stage	O
II	O
,	O
9	O
(	O
18.3	O
%	O
)	O
stage	O
III	O
,	O
and	O
25	O
(	O
51.1	O
%	O
)	O
stage	O
IV	O
.	O

For	O
Real-Time	B-P
PCR	I-P
analysis	I-P
,	O
significant	O
difference	O
was	O
found	O
between	O
control	O
samples	O
and	O
OSCC	O
stage	O
IV	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Higher	O
levels	O
of	O
WNT10A	O
expression	O
was	O
observed	O
in	O
OSCC	O
stage	O
IV	O
suggesting	O
a	O
potential	O
role	O
in	O
tumour	O
progression	O
.	O

Molecular	B-P
Imaging	I-P
of	O
Tumor	O
Angiogenesis	O
and	O
Therapeutic	O
Effects	O
with	O
Dual	O
Bioluminescence	O
.	O

Angiogenesis	O
is	O
critical	O
for	O
the	O
growth	O
of	O
tumor	O
by	O
supplying	O
nutrients	O
and	O
oxygen	O
that	O
exacerbates	O
the	O
metastasis	O
and	O
progression	O
of	O
cancer	O
.	O

Noninvasive	O
imaging	B-P
of	O
angiogenesis	O
during	O
the	O
tumor	O
therapeutic	O
processes	O
may	O
provide	O
novel	O
opportunities	O
for	O
image-guided	O
tumor	O
management	O
.	O

Here	O
,	O
we	O
want	O
to	O
develop	O
a	O
mouse	O
animal	O
model	O
for	O
assessing	O
cancer	O
progression	O
and	O
angiogenesis	O
in	O
the	O
same	O
individuals	O
by	O
molecular	B-P
imaging	I-P
.	O

Breast	O
cancer	O
model	O
was	O
developed	O
with	O
mouse	O
breast	O
cancer	O
cell	O
line	O
4T1	O
carrying	O
a	O
reporter	O
system	O
encoding	O
a	O
triple	O
fusion	O
(	O
TF	O
)	O
reporter	O
gene	O
consisting	O
of	O
renilla	O
luciferase	O
(	O
Rluc	O
)	O
,	O
red	O
fluorescent	O
protein	O
(	O
RFP	O
)	O
and	O
herpes	O
simplex	O
virus	O
truncated	O
thymidine	O
kinase	O
(	O
HSV-ttk	O
)	O
in	O
transgenic	O
mice	O
,	O
which	O
expressed	O
firefly	O
luciferase	O
(	O
Fluc	O
)	O
under	O
the	O
promoter	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
(	O
Vegfr2-luc	O
)	O
.	O

The	O
mice	O
were	O
subsequently	O
treated	O
with	O
ganciclovir	O
(	O
GCV	O
)	O
and	O
the	O
tumor	O
angiogenesis	O
was	O
tracked	O
by	O
Fluc	O
imaging	B-P
and	O
the	O
growth	O
status	O
of	O
tumor	O
was	O
monitored	O
by	O
imaging	B-P
of	O
Rluc	O
simultaneously	O
.	O

Overall	O
,	O
this	O
traceable	O
breast	O
cancer	O
model	O
can	O
simultaneously	O
image	O
the	O
tumor	O
growth	O
and	O
angiogenesis	O
in	O
single	O
individual	O
,	O
which	O
may	O
facilitate	O
a	O
better	O
understanding	O
the	O
mechanisms	O
of	O
angiogenesis	O
in	O
the	O
progression	O
and	O
regression	O
of	O
tumor	O
.	O

Evaluation	O
of	O
Spontaneous	O
Bone	O
Regeneration	O
after	O
Enucleation	O
of	O
Large	O
Cysts	O
of	O
the	O
Jaws	O
using	O
Radiographic	O
Computed	B-P
Software	O
.	O

Spontaneous	O
regeneration	O
of	O
bone	O
is	O
commonly	O
seen	O
in	O
the	O
small	O
surgical	O
defects	O
caused	O
by	O
enucleation	O
of	O
cysts	O
.	O

However	O
,	O
in	O
case	O
of	O
large	O
surgical	O
defects	O
caused	O
by	O
the	O
enucleation	O
,	O
spontaneous	O
regeneration	O
of	O
bone	O
is	O
a	O
rare	O
phenomenon	O
and	O
it	O
depends	O
on	O
factors	O
,	O
such	O
as	O
age	O
of	O
the	O
patient	O
,	O
intact	O
periosteum	O
,	O
and	O
proper	O
stabilization	O
.	O

The	O
study	O
included	O
16	O
patients	O
,	O
who	O
reported	O
to	O
the	O
department	O
of	O
oral	O
and	O
maxillofacial	O
surgery	O
with	O
the	O
complaint	O
of	O
pain	O
and	O
swelling	O
in	O
the	O
jaws	O
diagnosed	O
as	O
cyst	O
.	O

The	O
sample	O
included	O
equal	O
numbers	O
of	O
male	O
and	O
female	O
subjects	O
aged	O
between	O
15	O
and	O
40	O
years	O
.	O

Panoramic	B-P
radiographs	I-P
were	O
taken	O
pre-	O
and	O
postoperatively	O
on	O
day	O
2	O
of	O
the	O
enucleation	O
.	O

The	O
dimensions	O
of	O
the	O
cyst	O
were	O
evaluated	O
on	O
the	O
radiograph	B-P
according	O
to	O
the	O
proforma	O
.	O

Subsequent	O
radiographs	B-P
were	O
taken	O
at	O
regular	O
intervals	O
of	O
1.5	O
,	O
3	O
,	O
and	O
6	O
months	O
using	O
standard	O
parameters	O
and	O
were	O
analyzed	O
using	O
MCID™	O
analysis	O
software	O
of	O
imaging	B-P
research	I-P
.	O

Mean	O
reduction	O
was	O
seen	O
in	O
up	O
to	O
39	O
and	O
60	O
%	O
in	O
the	O
cystic	O
cavity	O
size	O
and	O
increase	O
in	O
the	O
mean	O
density	O
up	O
to	O
59	O
and	O
90.2	O
%	O
at	O
3	O
and	O
6	O
months	O
intervals	O
respectively	O
.	O

Spontaneous	O
bone	O
regeneration	O
was	O
seen	O
even	O
after	O
primary	O
closure	O
of	O
the	O
large	O
cystic	O
defect	O
without	O
the	O
need	O
for	O
placement	O
of	O
foreign	O
substances	O
or	O
grafts	O
and	O
it	O
also	O
eliminated	O
the	O
complications	O
resulting	O
from	O
placement	O
of	O
foreign	O
substance	O
.	O

Further	O
studies	O
are	O
required	O
in	O
a	O
larger	O
sample	O
with	O
longer	O
follow-up	O
durations	O
to	O
confirm	O
the	O
outcome	O
of	O
the	O
present	O
work	O
for	O
the	O
benefit	O
of	O
patients	O
.	O

The	O
present	O
study	O
depicted	O
that	O
spontaneous	O
bone	O
regeneration	O
can	O
occur	O
with	O
accepted	O
results	O
after	O
simple	O
enucleation	O
of	O
jaw	O
cyst	O
without	O
the	O
aid	O
of	O
any	O
graft	O
material	O
.	O

Hence	O
,	O
simple	O
enucleation	O
may	O
be	O
considered	O
as	O
a	O
first	O
line	O
of	O
treatment	O
modality	O
for	O
cystic	O
lesion	O
of	O
the	O
jaws	O
.	O

This	O
simplifies	O
the	O
surgical	O
procedure	O
,	O
decreases	O
the	O
economic	O
and	O
biologic	O
costs	O
,	O
and	O
reduces	O
the	O
risk	O
of	O
postoperative	O
complications	O
.	O

Follow-up	O
is	O
necessary	O
along	O
with	O
patient	O
's	O
compliance	O
for	O
the	O
success	O
of	O
treatment	O
.	O

Silent	O
strain	O
of	O
caregiving	O
:	O
exploring	O
the	O
best	O
predictors	O
of	O
distress	O
in	O
family	O
carers	O
of	O
geriatric	O
patients	O
.	O

The	O
aim	O
of	O
this	O
article	O
was	O
to	O
identify	O
the	O
best	O
predictors	O
of	O
distress	O
suffered	O
by	O
family	O
carers	O
(	O
FCs	O
)	O
of	O
geriatric	O
patients	O
.	O

A	O
cross-sectional	O
study	O
of	O
100	O
FC	O
-	O
geriatric	O
patient	O
dyads	O
was	O
conducted	O
.	O

The	O
negative	O
impact	O
of	O
care	O
(	O
NIoC	O
)	O
subscale	O
of	O
the	O
COPE	O
index	O
was	O
dichotomized	O
to	O
identify	O
lower	O
stress	O
(	O
score	O
of	O
≤15	O
on	O
the	O
scale	O
)	O
and	O
higher	O
stress	O
(	O
score	O
of	O
≥16	O
on	O
the	O
scale	O
)	O
exerted	O
on	O
FCs	O
by	O
the	O
process	O
of	O
providing	O
care	O
.	O

The	O
set	O
of	O
explanatory	O
variables	O
comprised	O
a	O
wide	O
range	O
of	O
sociodemographic	O
and	O
care-related	O
attributes	O
,	O
including	O
patient-related	O
results	O
from	O
comprehensive	O
geriatric	O
assessments	O
and	O
disease	O
profiles	O
.	O

The	O
best	O
combination	O
of	O
explanatory	O
variables	O
that	O
provided	O
the	O
highest	O
predictive	O
powe	O
r	O
for	O
distress	O
among	O
FCs	O
in	O
the	O
multiple	O
logistic	O
regression	O
(	O
LR	O
)	O
model	O
was	O
determined	O
according	O
to	O
statistical	O
information	O
criteria	O
.	O

The	O
statistical	O
robustness	O
of	O
the	O
observed	O
relationships	O
and	O
the	O
discriminative	O
power	O
of	O
the	O
model	O
were	O
verified	O
with	O
the	O
cross-validation	O
method	O
.	O

The	O
mean	O
age	O
of	O
FCs	O
was	O
57.2	O
(	O
±10.6	O
)	O
years	O
,	O
whereas	O
that	O
of	O
geriatric	O
patients	O
was	O
81.7	O
(	O
±6.4	O
)	O
years	O
.	O

Despite	O
the	O
broad	O
initial	O
set	O
of	O
potential	O
explanatory	O
variables	O
,	O
only	O
five	O
predictors	O
were	O
jointly	O
selected	O
for	O
the	O
best	O
statistical	O
model	O
.	O

A	O
higher	O
level	O
of	O
distress	O
was	O
independently	O
predicted	O
by	O
lower	O
self-evaluation	O
of	O
health	O
;	O
worse	O
self-appraisal	O
of	O
coping	O
well	O
as	O
a	O
caregiver	O
;	O
lower	O
sense	O
of	O
general	O
support	O
;	O
more	O
hours	O
of	O
care	O
per	O
week	O
;	O
and	O
the	O
motor	O
retardation	O
of	O
the	O
cared	O
-for	O
person	O
measured	O
with	O
the	O
speed	O
of	O
the	O
Timed	B-P
Up	I-P
and	I-P
Go	I-P
(	I-P
TUG	I-P
)	I-P
test	I-P
.	O

Worse	O
performance	O
on	O
the	O
TUG	B-P
test	I-P
was	O
only	O
the	O
patient	O
-related	O
predictor	O
of	O
distress	O
among	O
the	O
variables	O
examined	O
as	O
contributors	O
to	O
the	O
higher	O
NIoC	O
.	O

Enhancing	O
the	O
mobility	O
of	O
geriatric	O
patients	O
through	O
suitably	O
tailored	O
kinesitherapeutic	O
methods	O
during	O
their	O
hospital	O
stay	O
may	O
mitigate	O
the	O
burden	O
endured	O
by	O
FCs	O
.	O

Real-time	O
monitoring	O
of	O
vesicle	O
pH	O
in	O
an	O
endocytic	O
pathway	O
using	O
an	O
EGF	O
-	O
conjugated	O
two-photon	O
probe	O
.	O

Herein	O
,	O
we	O
developed	O
a	O
ratiometric	O
two-photon	O
probe	O
(	O
BHS3	O
-	O
EGF	O
)	O
,	O
derived	O
from	O
a	O
pH	O
sensitive	O
dye	O
and	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
,	O
for	O
real-time	O
monitoring	O
and	O
quantitative	O
analysis	O
of	O
acidic	O
luminal	O
pH	O
values	O
during	O
endocytic	O
pathway	O
activity	O
.	O

Two-photon	B-P
microscopy	I-P
imaging	I-P
with	O
BHS3	O
-	O
EGF	O
allows	O
the	O
quantitative	O
analysis	O
of	O
pH	O
distributions	O
of	O
single	O
vesicles	O
and	O
their	O
dynamics	O
in	O
receptor-mediated	O
endocytosis	O
in	O
real-time	O
.	O

LabRS	O
:	O
A	O
Rosetta	O
stone	O
for	O
retrospective	O
standardization	O
of	O
clinical	O
laboratory	O
test	O
results	O
.	O

Clinical	O
laboratories	O
in	O
the	O
United	O
States	O
do	O
not	O
have	O
an	O
explicit	O
result	O
standard	O
to	O
report	O
the	O
7	O
billion	O
laboratory	O
tests	O
results	O
they	O
produce	O
each	O
year	O
.	O

The	O
absence	O
of	O
standardized	O
test	O
results	O
creates	O
inefficiencies	O
and	O
ambiguities	O
for	O
secondary	O
data	O
users	O
.	O

We	O
developed	O
and	O
tested	O
a	O
tool	O
to	O
standardize	O
the	O
results	O
of	O
laboratory	O
tests	O
in	O
a	O
large	O
,	O
multicenter	O
clinical	O
data	O
warehouse	O
.	O

Laboratory	O
records	O
,	O
each	O
of	O
which	O
consisted	O
of	O
a	O
laboratory	O
result	O
and	O
a	O
test	O
identifier	O
,	O
from	O
27	O
diverse	O
facilities	O
were	O
captured	O
from	O
2000	O
through	O
2015	O
.	O

Each	O
record	O
underwent	O
a	O
standardization	O
process	O
to	O
convert	O
the	O
original	O
result	O
into	O
a	O
format	O
amenable	O
to	O
secondary	O
data	O
analysis	O
.	O

The	O
standardization	O
process	O
included	O
the	O
correction	O
of	O
typos	O
,	O
normalization	O
of	O
categorical	O
result	O
s	O
,	O
separation	O
of	O
inequalities	O
from	O
numbers	O
,	O
and	O
conversion	O
of	O
numbers	O
represented	O
by	O
words	O
(	O
eg	O
,	O
``	O
million	O
''	O
)	O
to	O
numerals	O
.	O

Quality	O
control	O
included	O
expert	O
review	O
.	O

We	O
obtained	O
1.266	O
×	O
10	O
9	O
laboratory	O
records	O
and	O
standardized	O
1.252	O
×	O
10	O
9	O
records	O
(	O
98.9	O
%	O
)	O
.	O

Of	O
the	O
unique	O
unstandardized	O
records	O
(	O
78.887	O
×	O
10	O
3	O
)	O
,	O
most	O
appeared	O
<	O
5	O
times	O
(	O
96	O
%	O
,	O
eg	O
,	O
typos	O
)	O
,	O
did	O
not	O
have	O
a	O
test	O
identifier	O
(	O
47	O
%	O
)	O
,	O
or	O
belonged	O
to	O
an	O
esoteric	O
test	B-P
with	O
<	O
100	O
results	O
(	O
2	O
%	O
)	O
.	O

Overall	O
,	O
these	O
3	O
reasons	O
accounted	O
for	O
nearly	O
all	O
unstandardized	O
results	O
(	O
98	O
%	O
)	O
.	O

Current	O
results	O
suggest	O
that	O
the	O
tool	O
is	O
both	O
scalable	O
and	O
generalizable	O
among	O
diverse	O
clinical	O
laboratories	O
.	O

Based	O
on	O
observed	O
trends	O
,	O
the	O
tool	O
will	O
require	O
ongoing	O
maintenance	O
to	O
stay	O
current	O
with	O
new	O
tests	B-P
and	O
result	O
formats	O
.	O

Future	O
work	O
to	O
develop	O
and	O
implement	O
an	O
explicit	O
standard	O
for	O
test	O
results	O
would	O
reduce	O
the	O
need	O
to	O
retrospective	O
ly	O
standardize	O
test	O
results	O
.	O

Lubiprostone	O
Accelerates	O
Intestinal	O
Transit	O
and	O
Alleviates	O
Small	O
Intestinal	O
Bacterial	O
Overgrowth	O
in	O
Patients	O
With	O
Chronic	O
Constipation	O
.	O

Lubiprostone	O
is	O
an	O
effective	O
treatment	O
for	O
chronic	O
constipation	O
(	O
CC	O
)	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
lubiprostone	O
is	O
through	O
increasing	O
fluid	O
secretion	O
and	O
lubrication	O
of	O
the	O
intestinal	O
lumen	O
.	O

The	O
effects	O
of	O
lubiprostone	O
on	O
gastrointestinal	O
transit	O
and	O
small	O
intestinal	O
bacterial	O
overgrowth	O
(	O
SIBO	O
)	O
have	O
not	O
been	O
adequately	O
explored	O
.	O

The	O
current	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
lubiprostone	O
(	O
1	O
)	O
alters	O
gastrointestinal	O
transit	O
and	O
(	O
2	O
)	O
affects	O
SIBO	O
in	O
patients	O
with	O
constipation	O
.	O

A	O
total	O
of	O
29	O
female	O
patients	O
(	O
mean	O
age	O
=	O
39	O
years	O
;	O
range	O
:	O
19-64	O
)	O
with	O
CC	O
received	O
2	O
weeks	O
of	O
lubiprostone	O
(	O
24mcg	O
b.i.d.	O
,	O
P.O.	O
)	O
.	O

Stool	O
consistency	O
based	O
on	O
Bristol	O
stool	O
scale	O
and	O
the	O
frequency	O
of	O
bowel	O
movements	O
(	O
BMs	O
)	O
were	O
recorded	O
.	O

Gastric	O
emptying	O
time	O
,	O
small	O
bowel	O
transit	O
time	O
,	O
colon	O
transit	O
time	O
(	O
CTT	O
)	O
,	O
combined	O
small	O
and	O
large	O
bowel	O
transit	O
time	O
(	O
SLBTT	O
)	O
and	O
whole	O
gut	O
transit	O
time	O
were	O
measured	O
using	O
wireless	B-P
motility	I-P
capsule	I-P
.	O

The	O
SIBO	O
status	O
was	O
assessed	O
by	O
the	O
lactulose	B-P
breath	I-P
test	I-P
.	O

Data	O
were	O
analyzed	O
using	O
Wilcoxon	O
rank	O
,	O
Mann-Whitney	O
U	O
,	O
Spearman׳s	O
rank	O
correlation	O
and	O
Chi-square	O
tests	O
.	O

Lubiprostone	O
significantly	O
softened	O
the	O
stool	O
and	O
increased	O
the	O
frequency	O
of	O
BM	O
from	O
median	O
of	O
2	O
to	O
4	O
times	O
per	O
week	O
.	O

The	O
CTT	O
and	O
SLBTT	O
were	O
significantly	O
shorter	O
in	O
responders	O
to	O
lubiprostone	O
(	O
i.e.	O
,	O
those	O
with	O
≥	O
2	O
times	O
increase	O
in	O
the	O
number	O
of	O
their	O
weekly	O
BM	O
)	O
compared	O
with	O
nonresponders	O
.	O

The	O
higher	O
frequency	O
of	O
BM	O
after	O
treatment	O
was	O
significantly	O
correlated	O
with	O
the	O
acceleration	O
of	O
CTT	O
,	O
SLBTT	O
and	O
whole	O
gut	O
transit	O
time	O
.	O

In	O
all	O
,	O
17	O
out	O
of	O
25	O
(	O
68	O
%	O
)	O
patients	O
,	O
who	O
were	O
tested	O
for	O
SIBO	O
at	O
baseline	O
,	O
were	O
positive	O
.	O

In	O
addition	O
,	O
7	O
out	O
of	O
17	O
(	O
41	O
%	O
)	O
SIBO	O
-	O
positive	O
patients	O
became	O
SIBO	O
-	O
negative	O
after	O
lubiprostone	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
CC	O
,	O
lubiprostone	O
improves	O
the	O
frequency	O
of	O
BMs	O
,	O
softens	O
the	O
stool	O
,	O
accelerates	O
intestinal	O
transit	O
and	O
decreases	O
accompanying	O
SIBO	O
.	O

The	O
improvement	O
of	O
SIBO	O
could	O
be	O
explained	O
by	O
the	O
cleansing	O
effect	O
of	O
increased	O
intestinal	O
fluid	O
and	O
mucus	O
combined	O
with	O
enhanced	O
intestinal	O
motility	O
with	O
lubiprostone	O
.	O

Sonic	O
hedgehog	O
in	O
oral	O
squamous	O
cell	O
carcinoma	O
:	O
An	O
immunohistochemical	B-P
study	O
.	O

Recent	O
studies	O
have	O
revealed	O
the	O
involvement	O
of	O
hedgehog	O
(	O
Hh	O
)	O
signaling	O
component	O
in	O
proliferation	O
and	O
invasive	O
behavior	O
of	O
many	O
carcinomas	O
.	O

This	O
study	O
aims	O
to	O
identify	O
the	O
expression	O
of	O
sonic	O
Hh	O
(	O
SHH	O
)	O
protein	O
of	O
SHH	O
pathway	O
in	O
oral	O
epithelial	O
dysplasia	O
and	O
oral	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
using	O
SHH	O
(	O
H-160	O
)	O
(	O
Santa	O
Cruz	O
,	O
sc-9042	O
)	O
which	O
could	O
have	O
therapeutic	O
implication	O
in	O
future	O
.	O

A	O
total	O
of	O
250	O
cases	O
comprising	O
50	O
normal	O
oral	O
mucosa	O
,	O
50	O
cases	O
of	O
oral	O
epithelial	O
dysplasia	O
,	O
50	O
well	O
,	O
50	O
moderate	O
and	O
50	O
poorly	O
differentiated	O
OSCCs	O
were	O
included	O
in	O
the	O
study	O
.	O

Immunohistochemical	B-P
evaluation	O
of	O
SHH	O
protein	O
expression	O
was	O
conducted	O
using	O
monoclonal	O
antibody	O
.	O

Interpretation	O
of	O
the	O
expression	O
was	O
done	O
by	O
immunoreactive	O
score	O
of	O
Remmele	O
and	O
Stegner	O
(	O
IRS	O
)	O
scoring	O
method	O
.	O

Chi-Square	O
test	O
was	O
used	O
to	O
analyze	O
the	O
results	O
.	O

The	O
study	O
showed	O
that	O
SHH	O
signaling	O
molecules	O
are	O
highly	O
expressed	O
in	O
OSCC	O
,	O
and	O
their	O
expression	O
was	O
mainly	O
in	O
the	O
cytoplasm	O
of	O
epithelial	O
cells	O
.	O

The	O
SHH	O
signaling	O
component	O
is	O
associated	O
with	O
the	O
pathological	O
parameter	O
in	O
OSCC	O
and	O
oral	O
epithelial	O
dysplasia	O
.	O

Spontaneous	O
activity	O
is	O
correlated	O
with	O
coding	O
density	O
in	O
primary	O
auditory	O
cortex	O
.	O

Sensory	O
neurons	O
across	O
sensory	O
modalities	O
and	O
specific	O
processing	O
areas	O
have	O
diverse	O
levels	O
of	O
spontaneous	O
firing	O
rates	O
(	O
SFRs	O
)	O
in	O
the	O
absence	O
of	O
sensory	O
stimuli	O
.	O

However	O
,	O
the	O
functional	O
significance	O
of	O
this	O
spontaneous	O
activity	O
is	O
not	O
well-understood	O
.	O

Previous	O
studies	O
in	O
the	O
auditory	O
system	O
have	O
demonstrated	O
that	O
different	O
levels	O
of	O
spontaneous	O
activity	O
are	O
correlated	O
with	O
a	O
variety	O
of	O
physiological	O
and	O
anatomic	O
properties	O
,	O
suggesting	O
that	O
neurons	O
with	O
differing	O
SFRs	O
make	O
unique	O
contributions	O
to	O
the	O
encoding	O
of	O
auditory	O
stimuli	O
.	O

Additionally	O
,	O
altered	O
SFRs	O
are	O
a	O
correlate	O
of	O
tinnitus	O
,	O
arising	O
in	O
several	O
auditory	O
areas	O
after	O
exposure	O
to	O
ototoxic	O
substances	O
and	O
noise	O
trauma	O
.	O

In	O
this	O
study	O
,	O
we	O
recorded	B-P
single-unit	I-P
activity	I-P
from	O
primary	O
auditory	O
cortex	O
of	O
awake	O
marmoset	O
monkeys	O
while	O
delivering	O
wide-band	O
random-spectrum	O
stimuli	O
and	O
white	O
Gaussian	O
noise	O
(	O
WGN	O
)	O
to	O
examine	O
any	O
divergences	O
in	O
stimulus	O
encoding	O
properties	O
across	O
SFR	O
classes	O
.	O

We	O
found	O
that	O
higher	O
levels	O
of	O
spontaneous	O
activity	O
were	O
associated	O
with	O
both	O
higher	O
levels	O
of	O
activation	O
relative	O
to	O
suppression	O
across	O
a	O
variety	O
of	O
wide-band	O
stimuli	O
and	O
higher	O
driven	O
rates	O
in	O
response	O
to	O
WGN	O
.	O

Moreover	O
,	O
response	O
latencies	O
to	O
WGN	O
were	O
negatively	O
correlated	O
with	O
the	O
level	O
of	O
activation	O
in	O
response	O
to	O
both	O
stimulus	O
types	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
a	O
novel	O
view	O
of	O
the	O
role	O
spontaneous	O
spiking	O
may	O
play	O
during	O
normal	O
stimulus	O
processing	O
in	O
primary	O
auditory	O
cortex	O
and	O
how	O
it	O
may	O
malfunction	O
in	O
cases	O
of	O
tinnitus	O
.	O

Three-dimensional	O
functional	O
human	O
neuronal	O
networks	O
in	O
uncompressed	O
low-density	O
electrospun	O
fiber	O
scaffolds	O
.	O

We	O
demonstrate	O
an	O
artificial	O
three-dimensional	O
(	O
3D	O
)	O
electrical	O
active	O
human	O
neuronal	O
network	O
system	O
,	O
by	O
the	O
growth	O
of	O
brain	O
neural	O
progenitors	O
in	O
highly	O
porous	O
low	O
density	O
electrospun	O
poly-ε-caprolactone	O
(	O
PCL	O
)	O
fiber	O
scaffolds	O
.	O

In	O
neuroscience	O
research	O
cell-based	B-P
assays	I-P
are	O
important	O
experimental	O
instruments	O
for	O
studying	O
neuronal	O
function	O
in	O
health	O
and	O
disease	O
.	O

Traditional	O
cell	B-P
culture	I-P
at	O
2D	O
-	O
surfaces	O
induces	O
abnormal	O
cell	O
-	O
cell	O
contacts	O
and	O
network	O
formation	O
.	O

Hence	O
,	O
there	O
is	O
a	O
tremendous	O
need	O
to	O
explore	O
in	O
vivo	O
-	O
resembling	O
3D	O
neural	O
cell	B-P
culture	I-P
approaches	O
.	O

We	O
present	O
an	O
improved	O
electrospinning	O
method	O
for	O
fabrication	O
of	O
scaffolds	O
that	O
promote	O
neuronal	O
differentiation	O
into	O
highly	O
3D	O
integrated	O
networks	O
,	O
formation	O
of	O
inhibitory	O
and	O
excitatory	O
synapses	O
and	O
extensive	O
neurite	O
growth	O
.	O

Notably	O
,	O
in	O
3D	O
scaffolds	O
in	O
vivo	O
-	O
resembling	O
intermixed	O
neuronal	O
and	O
glial	O
cell	O
network	O
were	O
formed	O
,	O
whereas	O
in	O
parallel	O
2D	O
cultures	B-P
a	O
neuronal	O
cell	O
layer	O
grew	O
separated	O
from	O
an	O
underlying	O
glial	O
cell	O
layer	O
.	O

Hence	O
,	O
the	O
use	O
of	O
the	O
3D	O
cell	B-P
assay	I-P
presented	O
will	O
most	O
likely	O
provide	O
more	O
physiological	O
relevant	O
results	O
.	O

Quercetin	O
attenuates	O
high	O
fructose	O
feeding	O
-	O
induced	O
atherosclerosis	O
by	O
suppressing	O
inflammation	O
and	O
apoptosis	O
via	O
ROS	O
-	O
regulated	O
PI3K/AKT	O
signaling	O
pathway	O
.	O

Quercetin	O
is	O
a	O
dietary	O
flavonoid	O
compound	O
extracted	O
from	O
various	O
plants	O
,	O
such	O
as	O
apple	O
and	O
onions	O
.	O

Previous	O
studies	O
have	O
revealed	O
its	O
anti-inflammatory	O
,	O
anti-cancer	O
,	O
antioxidant	O
and	O
anti-apoptotic	O
activities	O
.	O

This	O
study	O
investigated	O
the	O
ability	O
of	O
quercetin	O
to	O
inhibit	O
high	O
fructose	O
feeding	O
-	O
or	O
LPS	O
-	O
induced	O
atherosclerosis	O
through	O
regulating	O
oxidative	O
stress	O
,	O
apoptosis	O
and	O
inflammation	O
response	O
in	O
vivo	O
and	O
in	O
vitro	O
experiments	O
.	O

50	O
and	O
100mg/kg	O
quercetin	O
were	O
used	O
in	O
our	O
study	O
,	O
showing	O
significant	O
inhibitory	O
role	O
in	O
high	O
fructose	O
-	O
induced	O
atherosclerosis	O
via	O
reducing	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
levels	O
,	O
Caspase-3	O
activation	O
,	O
inflammatory	O
cytokines	O
releasing	O
,	O
the	O
number	O
of	O
terminal	O
deoxynucleotidyl	O
transferase	O
-mediated	O
dUTP	O
nick	O
end-labeling	O
(	O
TUNEL	O
)	O
-	O
positive	O
cells	O
and	O
collagen	O
contents	O
as	O
well	O
as	O
modulating	O
apoptosis	O
-	O
and	O
inflammation	O
-related	O
proteins	O
expression	O
.	O

We	O
also	O
explored	O
the	O
protective	O
effects	O
of	O
quercetin	O
on	O
atherosclerosis	O
by	O
phosphatidylinositide	O
3-kinases	O
(	O
PI3K	O
)	O
/	O
Protein	O
kinase	O
B	O
(	O
AKT	O
)	O
-associated	O
Bcl-2	O
/	O
Caspase-3	O
and	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-κB	O
)	O
signal	O
pathways	O
activation	O
,	O
promoting	O
AKT	O
and	O
Bcl-2	O
expression	O
and	O
reducing	O
Caspase-3	O
and	O
NF-κB	O
activation	O
.	O

Quercetin	O
reduced	O
the	O
atherosclerotic	O
plaque	O
size	O
in	O
vivo	O
in	O
high	O
fructose	O
feeding	O
-	O
induced	O
mice	O
assessed	O
by	O
oil	B-P
red	I-P
O	I-P
.	O

Also	O
,	O
in	O
vitro	O
experiments	O
,	O
quercetin	O
displayed	O
inhibitory	O
role	O
in	O
LPS	O
-	O
induced	O
ROS	O
production	O
,	O
inflammatory	O
response	O
and	O
apoptosis	O
,	O
which	O
were	O
linked	O
with	O
PI3K	O
/	O
AKT	O
-	O
regulated	O
Caspase-3	O
and	O
NF-κB	O
activation	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
showed	O
that	O
quercetin	O
inhibited	O
atherosclerotic	O
plaque	O
development	O
in	O
high	O
fructose	O
feeding	O
mice	O
via	O
PI3K	O
/	O
AKT	O
activation	O
regulated	O
by	O
ROS	O
.	O

THSD7A	O
expression	O
in	O
human	O
cancer	O
.	O

We	O
recently	O
described	O
a	O
case	O
of	O
a	O
Thrombospondin	O
Type-1	O
Domain	O
containing	O
7A	O
(	O
THSD7A	O
)	O
associated	O
membranous	O
nephropathy	O
in	O
a	O
female	O
patient	O
who	O
was	O
synchronously	O
suffering	O
from	O
a	O
THSD7A	O
-	O
positive	O
malignancy	O
.	O

We	O
here	O
investigated	O
the	O
role	O
of	O
THSD7A	O
as	O
a	O
new	O
potential	O
tumor	O
antigen	O
by	O
evaluating	O
over	O
20	O
000	O
tissue	O
spots	O
in	O
more	O
than	O
70	O
different	O
tumor	O
entities	O
by	O
immunohistochemistry	B-P
using	O
tissue	O
microarrays	O
.	O

THSD7A	O
expression	O
was	O
highly	O
variable	O
in	O
different	O
neoplasias	O
with	O
differing	O
staining	O
patterns	O
.	O

Both	O
gain	O
and	O
loss	O
of	O
THSD7A	O
expression	O
compared	O
to	O
expression	O
status	O
in	O
non-tumor	O
tissue	O
were	O
linked	O
to	O
tumor-specific	O
markers	O
in	O
the	O
different	O
tumor	O
entities	O
and	O
were	O
of	O
prognostic	O
value	O
.	O

The	O
potential	O
role	O
of	O
THSD7A	O
in	O
tumor	O
development	O
and	O
therapy	O
needs	O
further	O
investigation	O
.	O

Identification	O
of	O
a	O
peroxisomal	O
-targeted	O
aldolase	O
involved	O
in	O
chlorophyll	O
biosynthesis	O
and	O
sugar	O
metabolism	O
in	O
rice	O
.	O

Chlorophyll	O
plays	O
remarkable	O
and	O
critical	O
roles	O
in	O
photosynthetic	O
light-harvesting	O
,	O
energy	O
transduction	O
and	O
plant	O
development	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
a	O
rice	O
Chl	O
-deficient	O
mutant	O
,	O
ygdl-1	O
(	O
yellow	O
green	O
and	O
droopy	O
leaf-1	O
)	O
,	O
which	O
showed	O
yellow-green	O
leaves	O
throughout	O
plant	O
development	O
with	O
decreased	O
content	O
of	O
Chls	O
and	O
carotene	O
and	O
an	O
increased	O
Chl	O
a/b	O
ratio	O
.	O

The	O
ygdl-1	O
mutant	O
also	O
exhibited	O
severe	O
defects	O
in	O
chloroplast	O
development	O
,	O
including	O
disorganized	O
grana	O
stacks	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
the	O
mutant	O
contained	O
a	O
T-DNA	O
insertion	O
within	O
the	O
promoter	O
of	O
a	O
fructose-1,6-bisphosphate	O
aldolase	O
(	O
OsAld-Y	O
)	O
,	O
which	O
dramatically	O
reduced	O
the	O
OsAld-Y	O
mRNA	O
level	O
,	O
and	O
its	O
identity	O
was	O
verified	O
by	O
transgenic	O
complementation	O
.	O

Real-time	B-P
PCR	I-P
analysis	I-P
showed	O
that	O
the	O
expression	O
levels	O
of	O
genes	O
associated	O
with	O
chlorophyll	O
biosynthesis	O
and	O
chloroplast	O
development	O
were	O
concurrently	O
altered	O
in	O
the	O
ygdl-1	O
mutant	O
.	O

The	O
expression	O
of	O
OsAld-Y	O
-	O
GFP	O
fusion	O
protein	O
in	O
tobacco	O
epidermal	O
cells	O
showed	O
that	O
OsAld-Y	O
was	O
localized	O
to	O
the	O
peroxisome	O
.	O

In	O
addition	O
,	O
the	O
analysis	O
of	O
primary	O
carbon	O
metabolites	O
revealed	O
the	O
significantly	O
reduced	O
levels	O
of	O
sucrose	O
and	O
fructose	O
in	O
the	O
mutant	O
leaves	O
,	O
while	O
the	O
glucose	O
content	O
was	O
similar	O
to	O
wild-type	O
plants	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
OsAld-Y	O
participates	O
in	O
Chl	O
accumulation	O
,	O
chloroplast	O
development	O
and	O
plant	O
growth	O
by	O
influencing	O
the	O
photosynthetic	O
rate	O
of	O
leaves	O
and	O
the	O
sugar	O
metabolism	O
of	O
rice	O
.	O

Self-preserving	O
personal	O
care	O
products	O
.	O

As	O
questions	O
on	O
the	O
safety	O
of	O
some	O
popular	O
preservatives	O
are	O
on	O
the	O
rise	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
developing	O
'	O
self-preserving	O
'	O
personal	O
care	O
products	O
.	O

Use	O
of	O
multifunctional	O
ingredients	O
/	O
actives	O
with	O
antimicrobial	O
properties	O
has	O
been	O
explored	O
as	O
replacements	O
for	O
conventional	O
preservatives	O
.	O

This	O
study	O
explores	O
the	O
use	O
of	O
combinations	O
of	O
multifunctional	O
actives	O
(	O
MFA	O
)	O
and	O
other	O
cosmetic	O
ingredients	O
in	O
various	O
personal	O
care	O
formulations	O
,	O
to	O
deliver	O
microbiologically	O
safe	O
self-preserving	O
products	O
.	O

Products	O
studied	O
in	O
this	O
study	O
include	O
face	O
wash	O
,	O
gel-based	O
leave-on	O
skin	O
care	O
product	O
and	O
face	O
mask	O
.	O

Minimum	B-P
inhibitory	I-P
concentration	I-P
(	O
MIC	B-P
)	O
of	O
several	O
cosmetic	O
ingredients	O
was	O
determined	O
to	O
identify	O
multifunctional	O
actives	O
with	O
antimicrobial	O
activity	O
.	O

Personal	O
care	O
formulations	O
made	O
with	O
multifunctional	O
actives	O
and	O
other	O
cosmetic	O
ingredients	O
were	O
studied	O
for	O
preservative	O
efficacy	O
by	O
challenging	O
the	O
product	O
with	O
six	O
multiple	O
cycles	O
of	O
microbial	O
challenge	O
.	O

Formulations	O
with	O
combinations	O
of	O
multifunctional	O
actives	O
with	O
antioxidant	O
(	O
AO	O
)	O
and	O
chelators	O
(	O
CHL	O
)	O
were	O
found	O
to	O
work	O
synergistically	O
and	O
were	O
highly	O
efficacious	O
in	O
controlling	O
multiple	O
microbial	O
challenges	O
as	O
observed	O
in	O
the	O
preservative	O
efficacy	O
test	O
(	O
PET	O
)	O
studies	O
.	O

The	O
effective	O
combinations	O
were	O
able	O
to	O
withstand	O
up	O
to	O
six	O
multiple	O
microbial	O
challenges	O
without	O
product	O
degradation	O
.	O

The	O
preservative	O
efficacy	O
profile	B-P
was	O
similar	O
to	O
control	O
formula	O
containing	O
preservatives	O
.	O

Self-preserving	O
personal	O
care	O
/	O
cosmetic	O
products	O
can	O
be	O
developed	O
which	O
are	O
as	O
efficacious	O
as	O
preserved	O
products	O
by	O
a	O
prudent	O
selection	O
of	O
multifunctional	O
actives	O
,	O
antioxidants	O
and	O
chelators	O
as	O
a	O
part	O
of	O
the	O
formulation	O
.	O

Determining	O
putative	O
vectors	O
of	O
the	O
Bogia	O
Coconut	O
Syndrome	O
phytoplasma	O
using	O
loop-mediated	B-P
isothermal	I-P
amplification	I-P
of	O
single-insect	O
feeding	O
media	O
.	O

Phytoplasmas	O
are	O
insect	O
vectored	O
mollicutes	O
responsible	O
for	O
disease	O
in	O
many	O
economically	O
important	O
crops	O
.	O

Determining	O
which	O
insect	O
species	O
are	O
vectors	O
of	O
a	O
given	O
phytoplasma	O
is	O
important	O
for	O
managing	O
disease	O
but	O
is	O
methodologically	O
challenging	O
because	O
disease-free	O
plants	O
need	O
to	O
be	O
exposed	O
to	O
large	O
numbers	O
of	O
insects	O
,	O
often	O
over	O
many	O
months	O
.	O

A	O
relatively	O
new	O
method	O
to	O
detect	O
likely	O
transmission	O
involves	O
molecular	B-P
testing	I-P
for	O
phytoplasma	O
DNA	O
in	O
sucrose	O
solution	O
that	O
insects	O
have	O
fed	O
upon	O
.	O

In	O
this	O
study	O
we	O
combined	O
this	O
feeding	B-P
medium	I-P
method	I-P
with	O
a	O
loop-mediated	B-P
isothermal	I-P
amplification	I-P
(	I-P
LAMP	I-P
)	I-P
assay	I-P
to	O
study	O
627	O
insect	O
specimens	O
of	O
11	O
Hemiptera	O
taxa	O
sampled	O
from	O
sites	O
in	O
Papua	O
New	O
Guinea	O
affected	O
by	O
Bogia	O
coconut	O
syndrome	O
(	O
BCS	O
)	O
.	O

The	O
LAMP	B-P
assay	I-P
detected	O
phytoplasma	O
DNA	O
from	O
the	O
feeding	O
solution	O
and	O
head	O
tissue	O
of	O
insects	O
from	O
six	O
taxa	O
belonging	O
to	O
four	O
families	O
:	O
Derbidae	O
,	O
Lophopidae	O
,	O
Flatidae	O
and	O
Ricaniidae	O
.	O

Two	O
other	O
taxa	O
yielded	O
positives	O
only	O
from	O
the	O
heads	O
and	O
the	O
remainder	O
tested	O
negative	O
.	O

These	O
results	O
demonstrate	O
the	O
utility	O
of	O
combining	O
single-insect	B-P
feeding	I-P
medium	I-P
tests	I-P
with	O
LAMP	B-P
assays	I-P
to	O
identify	O
putative	O
vectors	O
that	O
can	O
be	O
the	O
subject	O
of	O
transmission	O
tests	O
and	O
to	O
better	O
understand	O
phytoplasma	O
pathosystems	O
.	O

Far-infrared	O
protects	O
vascular	O
endothelial	O
cells	O
from	O
advanced	O
glycation	O
end	O
products	O
-	O
induced	O
injury	O
via	O
PLZF	O
-mediated	O
autophagy	O
in	O
diabetic	O
mice	O
.	O

The	O
accumulation	O
of	O
advanced	O
glycation	O
end	O
products	O
(	O
AGEs	O
)	O
in	O
diabetic	O
patients	O
induces	O
vascular	O
endothelial	O
injury	O
.	O

Promyelocytic	O
leukemia	O
zinc	O
finger	O
protein	O
(	O
PLZF	O
)	O
is	O
a	O
transcription	O
factor	O
that	O
can	O
be	O
activated	O
by	O
low-temperature	O
far-infrared	O
(	O
FIR	O
)	O
irradiation	O
to	O
exert	O
beneficial	O
effects	O
on	O
the	O
vascular	O
endothelium	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
FIR	O
-	O
induced	O
PLZF	O
activation	O
on	O
AGE	O
-	O
induced	O
endothelial	O
injury	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

FIR	O
irradiation	O
inhibited	O
AGE	O
-	O
induced	O
apoptosis	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

PLZF	O
activation	O
increased	O
the	O
expression	O
of	O
phosphatidylinositol-3	O
kinases	O
(	O
PI3K	O
)	O
,	O
which	O
are	O
important	O
kinases	O
in	O
the	O
autophagic	O
signaling	O
pathway	O
.	O

FIR	O
-	O
induced	O
PLZF	O
activation	O
led	O
to	O
autophagy	O
in	O
HUVEC	O
,	O
which	O
was	O
mediated	O
through	O
the	O
upregulation	O
of	O
PI3K	O
.	O

Immunofluorescence	B-P
staining	B-P
showed	O
that	O
AGEs	O
were	O
engulfed	O
by	O
HUVECs	O
and	O
localized	O
to	O
lysosomes	O
.	O

FIR	O
-	O
induced	O
autophagy	O
promoted	O
AGEs	O
degradation	O
in	O
HUVECs	O
.	O

In	O
nicotinamide	O
/	O
streptozotocin	O
-	O
induced	O
diabetic	O
mice	O
,	O
FIR	O
therapy	O
reduced	O
serum	O
AGEs	O
and	O
AGEs	O
deposition	O
at	O
the	O
vascular	O
endothelium	O
.	O

FIR	O
therapy	O
also	O
reduced	O
diabetes	O
-	O
induced	O
inflammatory	O
markers	O
in	O
the	O
vascular	O
endothelium	O
and	O
improved	O
vascular	O
endothelial	O
function	O
.	O

These	O
protective	O
effects	O
of	O
FIR	O
therapy	O
were	O
not	O
found	O
in	O
PLZF	O
-	O
knockout	O
mice	O
.	O

Our	O
data	O
suggest	O
that	O
FIR	O
-	O
induced	O
PLZF	O
activation	O
in	O
vascular	O
endothelial	O
cells	O
protects	O
the	O
vascular	O
endothelium	O
in	O
diabetic	O
mice	O
from	O
AGE	O
-	O
induced	O
injury	O
.	O

Intraspinal	O
meningioma	O
with	O
malignant	O
transformation	O
and	O
distant	O
metastasis	O
.	O

Meningioma	O
is	O
typically	O
considered	O
to	O
be	O
a	O
benign	O
tumor	O
.	O

Malignant	O
transformation	O
and	O
metastasis	O
of	O
meningiomas	O
are	O
rare	O
.	O

Moreover	O
,	O
most	O
meningiomas	O
are	O
intracranial	O
,	O
and	O
there	O
are	O
few	O
reports	O
on	O
intraspinal	O
meningiomas	O
.	O

This	O
report	O
aimed	O
to	O
describe	O
the	O
clinical	O
features	O
and	O
pathological	O
findings	O
of	O
a	O
case	O
of	O
malignant	O
transformation	O
and	O
distant	O
metastasis	O
of	O
intraspinal	O
meningioma	O
,	O
with	O
a	O
review	O
of	O
the	O
literature	O
.	O

A	O
44-year-old	O
man	O
with	O
a	O
bilateral	O
lower	O
limb	O
paresis	O
was	O
diagnosed	O
with	O
an	O
intradural	O
extramedullary	O
tumor	O
of	O
the	O
thoracic	O
spine	O
.	O

Primary	O
tumor	O
resection	O
was	O
performed	O
,	O
and	O
the	O
histological	O
findings	O
revealed	O
atypical	O
meningioma	O
.	O

The	O
meningioma	O
recurred	O
2	O
years	O
after	O
the	O
primary	O
surgery	O
,	O
and	O
a	O
second	O
resection	O
was	O
performed	O
,	O
but	O
only	O
partial	O
resection	O
was	O
possible	O
because	O
of	O
decreased	O
motor	O
evoked	O
potential	O
.	O

At	O
age	O
48	O
,	O
the	O
patient	O
's	O
lower	O
limb	O
weakness	O
returned	O
,	O
and	O
a	O
third	O
resection	O
was	O
performed	O
,	O
and	O
the	O
histological	O
finding	O
remained	O
atypical	O
meningioma	O
.	O

At	O
age	O
54	O
,	O
the	O
tumor	O
increased	O
and	O
stereotactic	O
irradiation	O
was	O
performed	O
.	O

At	O
age	O
60	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
metastatic	O
tumors	O
of	O
the	O
rib	O
,	O
lumbar	O
vertebra	O
,	O
cervical	O
spine	O
,	O
and	O
sacrum	O
.	O

Biopsy	B-P
of	O
the	O
rib	O
metastatic	O
tumor	O
was	O
performed	O
,	O
and	O
the	O
histological	O
findings	O
revealed	O
anaplastic	O
meningioma	O
.	O

This	O
case	O
is	O
the	O
first	O
report	O
of	O
an	O
intraspinal	O
meningioma	O
that	O
transformed	O
from	O
atypical	O
to	O
anaplastic	O
meningioma	O
with	O
distant	O
hematogenous	O
metastasis	O
.	O

Basal	O
ryanodine	O
receptor	O
activity	O
suppresses	O
autophagic	O
flux	O
.	O

The	O
inositol	O
1,4,5-trisphosphate	O
receptors	O
(	O
IP3Rs	O
)	O
and	O
intracellular	O
Ca	O
(	O
2+	O
)	O
signaling	O
are	O
critically	O
involved	O
in	O
regulating	O
different	O
steps	O
of	O
autophagy	O
,	O
a	O
lysosomal	O
degradation	O
pathway	O
.	O

The	O
ryanodine	O
receptors	O
(	O
RyR	O
)	O
,	O
intracellular	O
Ca	O
(	O
2+	O
)	O
-release	O
channels	O
mainly	O
expressed	O
in	O
excitable	O
cell	O
types	O
including	O
muscle	O
and	O
neurons	O
,	O
have	O
however	O
not	O
yet	O
been	O
extensively	O
studied	O
in	O
relation	O
to	O
autophagy	O
.	O

Yet	O
,	O
aberrant	O
expression	O
and	O
excessive	O
activity	O
of	O
RyRs	O
in	O
these	O
tissues	O
has	O
been	O
implicated	O
in	O
the	O
onset	O
of	O
several	O
diseases	O
including	O
Alzheimer	O
's	O
disease	O
,	O
where	O
impaired	O
autophagy	O
regulation	O
contributes	O
to	O
the	O
pathology	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	B-P
whether	O
pharmacological	O
RyR	O
inhibition	O
could	O
modulate	O
autophagic	O
flux	O
in	O
ectopic	O
RyR	O
-	O
expressing	O
models	O
,	O
like	O
HEK293	O
cells	O
and	O
in	O
cell	O
types	O
that	O
endogenously	O
express	O
RyR	O
s	O
,	O
like	O
C2C12	O
myoblasts	O
and	O
primary	O
hippocampal	O
neurons	O
.	O

Importantly	O
,	O
RyR3	O
overexpression	O
in	O
HEK293	O
cells	O
impaired	O
the	O
autophagic	O
flux	O
.	O

Conversely	O
,	O
in	O
all	O
cell	O
models	O
tested	O
,	O
pharmacological	O
inhibition	O
of	O
endogenous	O
or	O
ectopically	O
expressed	O
RyRs	O
,	O
using	O
dantrolene	O
or	O
ryanodine	O
,	O
augmented	O
autophagic	O
flux	O
by	O
increasing	O
lysosomal	O
turn-over	O
(	O
number	O
of	O
autophagosomes	O
and	O
autolysosomes	O
measured	O
as	O
mCherry	O
-	O
LC3	O
punctae	O
/	O
cell	O
increased	O
from	O
70.37±7.81	O
in	O
control	O
HEK	O
RyR3	O
cells	O
to	O
111.18±7.72	O
and	O
98.14±7.31	O
after	O
dantrolene	O
and	O
ryanodine	O
treatments	O
,	O
respectively	O
)	O
.	O

Moreover	O
,	O
in	O
differentiated	O
C2C12	O
cells	O
,	O
transmission	B-P
electron	I-P
microscopy	I-P
demonstrated	O
that	O
dantrolene	O
treatment	O
decreased	O
the	O
number	O
of	O
early	O
autophagic	O
vacuoles	O
from	O
5.9±2.97	O
to	O
1.8±1.03	O
per	O
cellular	O
cross	O
section	O
.	O

The	O
modulation	O
of	O
the	O
autophagic	O
flux	O
could	O
be	O
linked	O
to	O
the	O
functional	O
inhibition	O
of	O
RyR	O
channels	O
as	O
both	O
RyR	O
inhibitors	O
efficiently	O
diminished	O
the	O
number	O
of	O
cells	O
showing	O
spontaneous	O
RyR3	O
activity	O
in	O
the	O
HEK293	O
cell	O
model	O
(	O
from	O
41.14	O
%	O
±2.12	O
in	O
control	O
cells	O
to	O
18.70	O
%	O
±2.25	O
and	O
9.74	O
%	O
±2.67	O
after	O
dantrolene	O
and	O
ryanodine	O
treatments	O
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
basal	O
RyR	O
-mediated	O
Ca	O
(	O
2+	O
)	O
-release	O
events	O
suppress	O
autophagic	O
flux	O
at	O
the	O
level	O
of	O
the	O
lysosomes	O
.	O

An	O
Inhibitory	O
Septum	O
to	O
Lateral	O
Hypothalamus	O
Circuit	O
That	O
Suppresses	O
Feeding	O
.	O

Feeding	O
behavior	O
is	O
orchestrated	O
by	O
neural	O
circuits	O
primarily	O
residing	O
in	O
the	O
hypothalamus	O
and	O
hindbrain	O
.	O

However	O
,	O
the	O
relative	O
influence	O
of	O
cognitive	O
and	O
emotional	O
brain	O
circuits	O
to	O
the	O
feeding	O
circuitry	O
in	O
the	O
hypothalamus	O
and	O
hindbrain	O
remains	O
unclear	O
.	O

Here	O
,	O
using	O
the	O
cell-type	O
selectivity	O
of	O
genetic	O
methods	O
,	O
circuit	B-P
mapping	I-P
,	O
and	O
behavior	O
assays	B-P
,	O
we	O
sought	O
to	O
decipher	O
neural	O
circuits	O
emanating	O
from	O
the	O
septal	O
nucleus	O
to	O
the	O
lateral	O
hypothalamus	O
(	O
LH	O
)	O
that	O
contribute	O
to	O
neural	O
regulation	O
of	O
food	O
intake	O
in	O
mice	O
.	O

We	O
found	O
that	O
chemogenetic	O
and	O
optogenetic	O
activation	O
of	O
septal	O
vesicular	O
GABA	O
transporter	O
(	O
vGAT	O
)	O
-	O
containing	O
neurons	O
or	O
their	O
projections	O
in	O
the	O
LH	O
reduced	O
food	O
intake	O
in	O
mice	O
.	O

Consistently	O
,	O
chemogenetic	O
inhibition	O
of	O
septal	O
vGAT	O
neurons	O
increased	O
food	O
intake	O
.	O

Furthermore	O
,	O
we	O
investigated	O
a	O
previously	O
unknown	O
neural	O
circuit	O
originating	O
from	O
septal	O
vGAT	O
neurons	O
to	O
a	O
subset	O
of	O
vGAT	O
neurons	O
in	O
the	O
LH	O
,	O
an	O
area	O
involved	O
in	O
homeostatic	O
and	O
hedonic	O
control	O
of	O
energy	O
states	O
.	O

Collectively	O
,	O
our	O
data	O
reveal	O
an	O
inhibitory	O
septohypothalamic	O
feeding	O
circuit	O
that	O
might	O
serve	O
as	O
a	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
eating	O
disorders	O
such	O
as	O
anorexia	O
nervosa	O
.	O

Our	O
results	O
demonstrate	O
that	O
top-down	O
projections	O
from	O
the	O
septum	O
to	O
the	O
hypothalamus	O
control	O
food	O
intake	O
negatively	O
.	O

Given	O
the	O
known	O
role	O
for	O
both	O
of	O
these	O
brain	O
regions	O
in	O
the	O
control	O
of	O
feeding	O
and	O
emotion	O
-	O
related	O
behaviors	O
,	O
these	O
findings	O
reveal	O
previously	O
unknown	O
neural	O
circuitry	O
that	O
is	O
likely	O
implicated	O
in	O
emotional	O
aspects	O
of	O
food	O
intake	O
and	O
provide	O
new	O
insights	O
into	O
the	O
development	O
of	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
eating	O
disorders	O
.	O

Pyomyositis	O
in	O
childhood	O
-	O
systemic	O
lupus	O
erythematosus	O
.	O

Pyomyositis	O
is	O
a	O
pyogenic	O
infection	O
of	O
skeletal	O
muscle	O
that	O
arises	O
from	O
hematogenous	O
spread	O
and	O
usually	O
presents	O
with	O
localized	O
abscess	O
.	O

This	O
muscle	O
infection	O
has	O
been	O
rarely	O
reported	O
in	O
adult-onset	O
systemic	O
lupus	O
erythematous	O
and	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
has	O
not	O
been	O
diagnosed	O
in	O
pediatric	O
lupus	O
population	O
.	O

Among	O
our	O
childhood-onset	O
systemic	O
lupus	O
erythematous	O
population	O
,	O
including	O
289	O
patients	O
,	O
one	O
presented	O
pyomyositis	O
.	O

This	O
patient	O
was	O
diagnosed	O
with	O
childhood-onset	O
systemic	O
lupus	O
erythematous	O
at	O
the	O
age	O
of	O
10	O
years-old	O
.	O

After	O
six	O
years	O
,	O
while	O
being	O
treated	O
with	O
prednisone	O
,	O
azathioprine	O
and	O
hydroxychloroquine	O
,	O
she	O
was	O
hospitalized	O
due	O
to	O
a	O
30-day	O
history	O
of	O
insidious	O
pain	O
in	O
the	O
left	O
thigh	O
and	O
no	O
apparent	O
trauma	O
or	O
fever	O
were	O
reported	O
.	O

Her	O
physical	O
examination	O
showed	O
muscle	O
tenderness	O
and	O
woody	O
induration	O
.	O

Laboratory	B-P
tests	I-P
revealed	O
anemia	O
,	O
increased	O
acute	O
phase	O
reactants	O
and	O
normal	O
muscle	O
enzymes	O
.	O

Computer	O
tomography	O
of	O
the	O
left	O
thigh	O
showed	O
collection	O
on	O
the	O
middle	O
third	O
of	O
the	O
vastus	O
intermedius	O
,	O
suggesting	O
purulent	O
stage	O
of	O
pyomyositis	O
.	O

Treatment	O
with	O
broad-spectrum	O
antibiotic	O
was	O
initiated	O
,	O
leading	O
to	O
a	O
complete	O
clinical	O
resolution	O
.	O

In	O
conclusion	O
,	O
we	O
described	O
the	O
first	O
case	O
of	O
pyomyositis	O
during	O
childhood	O
in	O
pediatric	O
lupus	O
population	O
.	O

This	O
report	O
reinforces	O
that	O
the	O
presence	O
of	O
localized	O
muscle	O
pain	O
in	O
immunocompromised	O
patients	O
,	O
even	O
without	O
elevation	O
of	O
muscle	B-P
enzymes	I-P
,	O
should	O
raise	O
the	O
suspicion	O
of	O
pyomyositis	O
.	O

A	O
prompt	O
antibiotic	O
therapy	O
is	O
strongly	O
recommended	O
.	O

Bacteria	O
from	O
Wheat	O
and	O
Cucurbit	O
Plant	O
Roots	O
Metabolize	O
PAHs	O
and	O
Aromatic	O
Root	O
Exudates	O
:	O
Implications	O
for	O
Rhizodegradation	O
.	O

The	O
chemical	O
interaction	O
between	O
plants	O
and	O
bacteria	O
in	O
the	O
root	O
zone	O
can	O
lead	O
to	O
soil	O
decontamination	O
.	O

Bacteria	O
which	O
degrade	O
PAHs	O
have	O
been	O
isolated	O
from	O
the	O
rhizospheres	O
of	O
plant	O
species	O
with	O
varied	O
biological	O
traits	O
,	O
however	O
,	O
it	O
is	O
not	O
known	O
what	O
phytochemicals	O
promote	O
contaminant	O
degradation	O
.	O

One	O
monocot	O
and	O
two	O
dicotyledon	O
plants	O
were	O
grown	O
in	O
PAH	O
-	O
contaminated	O
soil	O
from	O
a	O
manufactured	O
gas	O
plant	O
(	O
MGP	O
)	O
site	O
.	O

A	O
phytotoxicity	B-P
assay	I-P
confirmed	O
greater	O
soil	O
decontamination	O
in	O
rhizospheres	O
when	O
compared	O
to	O
bulk	O
soil	O
controls	O
.	O

Bacteria	O
were	O
isolated	O
from	O
plant	O
roots	O
(	O
rhizobacteria	O
)	O
and	O
selected	O
for	O
growth	O
on	O
anthracene	O
and	O
chrysene	O
on	O
PAH	O
-	O
amended	O
plates	O
.	O

Rhizosphere	O
isolates	O
metabolized	O
3-	O
and	O
4-ring	O
PAHs	O
and	O
PAH	O
catabolic	O
intermediates	O
in	O
liquid	B-P
incubations	I-P
.	O

Aromatic	O
root	O
exudate	O
compounds	O
,	O
namely	O
flavonoids	O
and	O
simple	O
phenols	O
,	O
were	O
also	O
substrates	O
for	O
isolated	O
rhizobacteria	O
.	O

In	O
particular	O
,	O
the	O
phenolic	O
compounds	O
-	O
morin	O
,	O
caffeic	O
acid	O
,	O
and	O
protocatechuic	O
acid	O
-	O
appear	O
to	O
be	O
linked	O
to	O
bacterial	O
degradation	O
of	O
3-	O
and	O
4-	O
ring	O
PAHs	O
in	O
the	O
rhizosphere	O
.	O

Crystal	O
Structure	O
of	O
Saccharomyces	O
cerevisiae	O
ECM4	O
,	O
a	O
Xi-Class	O
Glutathione	O
Transferase	O
that	O
Reacts	O
with	O
Glutathionyl-	O
(	O
hydro	O
)	O
quinones	O
.	O

Glutathionyl-hydroquinone	O
reductases	O
(	O
GHRs	O
)	O
belong	O
to	O
the	O
recently	O
characterized	O
Xi-class	O
of	O
glutathione	O
transferases	O
(	O
GSTXs	O
)	O
according	O
to	O
unique	O
structural	O
properties	O
and	O
are	O
present	O
in	O
all	O
but	O
animal	O
kingdoms	O
.	O

The	O
GHR	O
ScECM4	O
from	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
has	O
been	O
studied	O
since	O
1997	O
when	O
it	O
was	O
found	O
to	O
be	O
potentially	O
involved	O
in	O
cell-wall	O
biosynthesis	O
.	O

Up	O
to	O
now	O
and	O
in	O
spite	O
of	O
biological	O
studies	O
made	O
on	O
this	O
enzyme	O
,	O
its	O
physiological	O
role	O
remains	O
challenging	O
.	O

The	O
work	O
here	O
reports	O
its	O
crystallographic	B-P
study	O
.	O

In	O
addition	O
to	O
exhibiting	O
the	O
general	O
GSTX	O
structural	O
features	O
,	O
ScECM4	O
shows	O
extensions	O
including	O
a	O
huge	O
loop	O
which	O
contributes	O
to	O
the	O
quaternary	O
assembly	O
.	O

These	O
structural	O
extensions	O
are	O
probably	O
specific	O
to	O
Saccharomycetaceae	O
.	O

Soaking	O
of	O
ScECM4	O
crystals	O
with	O
GS-menadione	O
results	O
in	O
a	O
structure	O
where	O
glutathione	O
forms	O
a	O
mixed	O
disulfide	O
bond	O
with	O
the	O
cysteine	O
46	O
.	O

Solution	O
studies	O
confirm	O
that	O
ScECM4	O
has	O
reductase	O
activity	O
for	O
GS-menadione	O
in	O
presence	O
of	O
glutathione	O
.	O

Moreover	O
,	O
the	O
high	B-P
resolution	I-P
structures	O
allowed	O
us	O
to	O
propose	O
new	O
roles	O
of	O
conserved	O
residues	O
of	O
the	O
active	O
site	O
to	O
assist	O
the	O
cysteine	O
46	O
during	O
the	O
catalytic	O
act	O
.	O

Normal	O
Levels	O
of	O
Urinary	O
CC16	O
Protein	O
.	O

Comments	O
on	O
Beamer	O
et	O
al	O
.	O

Association	O
of	O
Children	O
's	O
Urinary	O
CC16	O
Levels	O
with	O
Arsenic	O
Concentrations	O
in	O
Multiple	O
Environmental	O
Media	O
.	O

Int	O
.	O

J.	O
Environ	O
.	O

Res	O
.	O

Public	O
Health	O
2016	O
,	O
13	O
,	O
521	O
.	O

In	O
1937	O
,	O
Max	O
Clara	O
described	O
a	O
new	O
type	O
of	O
cell	O
in	O
the	O
human	O
lung	O
,	O
which	O
was	O
later	O
determined	O
to	O
be	O
an	O
exocrine	O
secretory	O
cell	O
type	O
containing	O
granules	O
composed	O
of	O
proteins	O
[	O
1	O
]	O
.	O
[	O
...	O

]	O
.	O

Association	O
of	O
abdominal	O
fat	O
with	O
serum	O
amylase	O
in	O
an	O
older	O
cohort	O
:	O
The	O
Baltimore	O
Longitudinal	O
Study	O
of	O
Aging	O
.	O

Abdominal	O
fat	O
is	O
a	O
major	O
determinant	O
of	O
metabolic	O
diseases	O
in	O
older	O
individuals	O
.	O

Obesity	O
and	O
diabetes	O
are	O
associated	O
with	O
low	O
serum	O
amylase	O
(	O
SA	O
)	O
levels	O
,	O
but	O
the	O
association	O
between	O
SA	O
and	O
metabolic	O
disease	O
is	O
poorly	O
understood	O
.	O

We	O
investigated	O
the	O
association	O
of	O
low	O
SA	O
with	O
diabetes	O
and	O
sex	O
-	O
specific	O
associations	O
of	O
serum	O
amylase	O
with	O
abdominal	O
fat	O
in	O
older	O
adults	O
.	O

In	O
community-dwelling	O
volunteers	O
from	O
the	O
Baltimore	O
Longitudinal	O
Study	O
of	O
Aging	O
(	O
778	O
participants	O
,	O
age	O
66.8±13.6	O
years	O
)	O
,	O
we	O
assessed	O
abdominal	O
fat	O
by	O
computed	B-P
tomography	I-P
and	O
diabetes	O
status	O
using	O
the	O
American	O
Diabetes	O
Association	O
criteria	O
.	O

Linear	O
regression	O
analyses	O
assessed	O
the	O
cross-sectional	O
associations	O
between	O
abdominal	O
fat	O
and	O
SA	O
,	O
and	O
logistic	O
regression	O
assessed	O
the	O
odds	O
of	O
diabetes	O
,	O
given	O
low	O
SA	O
.	O

In	O
unadjusted	O
analyses	O
,	O
individuals	O
in	O
the	O
lowest	O
SA	O
quartile	O
(	O
<	O
48μ/L	O
)	O
had	O
1.97	O
greater	O
odds	O
of	O
diabetes	O
,	O
(	O
95	O
%	O
CI	O
,	O
1.01-3.83	O
)	O
than	O
those	O
in	O
the	O
highest	O
quartile	O
(	O
⩾80μ/L	O
)	O
.	O

This	O
association	O
was	O
no	O
longer	O
significant	O
after	O
adjusting	O
for	O
visceral	O
adipose	O
tissue	O
area	O
(	O
VAT	O
,	O
dm	O
(	O
2	O
)	O
)	O
,	O
abdominal	O
subcutaneous	O
adipose	O
tissue	O
(	O
SAT	O
,	O
dm	O
(	O
2	O
)	O
)	O
or	O
BMI	O
.	O

In	O
adjusted	O
analyses	O
,	O
VAT	O
and	O
SAT	O
were	O
significantly	O
associated	O
with	O
SA	O
in	O
both	O
sexes	O
.	O

Among	O
women	O
,	O
SA	O
was	O
more	O
strongly	O
associated	O
with	O
VAT	O
than	O
with	O
SAT	O
or	O
BMI	O
;	O
VAT	O
(	O
β=-0.117±0.048	O
,	O
P	O
<	O
0.001	O
)	O
,	O
SAT	O
(	O
β=-0.023±0.025	O
,	O
P=0.346	O
)	O
and	O
BMI	O
(	O
β=-0.0052±0.075	O
,	O
P=0.49	O
)	O
.	O

The	O
association	O
between	O
SA	O
and	O
diabetes	O
was	O
explained	O
mainly	O
by	O
abdominal	O
visceral	O
fat	O
.	O

In	O
women	O
,	O
SA	O
was	O
more	O
strongly	O
associated	O
with	O
VAT	O
than	O
with	O
BMI	O
or	O
SAT	O
.	O

These	O
findings	O
provide	O
motivation	O
for	O
future	O
mechanistic	O
studies	O
on	O
SA	O
's	O
role	O
in	O
metabolic	O
diseases	O
.	O

Activation	O
of	O
ephrinB-EphB	O
receptor	O
signalling	O
in	O
rat	O
spinal	O
cord	O
contributes	O
to	O
maintenance	O
of	O
diabetic	O
neuropathic	O
pain	O
.	O

Diabetic	O
neuropathic	O
pain	O
(	O
DNP	O
)	O
is	O
severe	O
and	O
intractable	O
in	O
clinic	O
.	O

The	O
specific	O
cellular	O
and	O
molecular	O
mechanisms	O
underlying	O
DNP	O
remain	O
elusive	O
and	O
its	O
treatment	O
are	O
limited	O
.	O

We	O
investigated	O
roles	O
of	O
EphB1	O
receptor	O
in	O
the	O
development	O
of	O
DNP	O
.	O

Diabetic	O
neuropathic	O
pain	O
was	O
produced	O
in	O
male	O
,	O
adult	O
,	O
Sprague-Dawley	O
rats	O
by	O
a	O
single	O
i.p	O
.	O

streptozotocin	O
(	O
STZ	O
)	O
or	O
alloxan	O
.	O

Western	B-P
blot	I-P
analysis	I-P
and	O
immunohistochemistry	B-P
were	O
used	O
to	O
analyse	O
expression	O
of	O
EphB1	O
receptor	O
as	O
well	O
as	O
the	O
activation	O
of	O
the	O
glial	O
cells	O
and	O
the	O
pro-inflammatory	O
cytokines	O
in	O
the	O
spinal	O
cord	O
.	O

DNP	O
manifested	O
as	O
mechanical	O
allodynia	O
,	O
which	O
was	O
determined	O
by	O
measuring	O
incidence	O
of	O
foot	O
withdrawal	O
in	O
response	O
to	O
mechanical	O
indentation	O
of	O
the	O
hind	O
paw	O
by	O
an	O
electro	O
von	O
Frey	O
filament	O
.	O

Diabetic	O
neuropathic	O
pain	O
and	O
high	O
blood	O
glucose	O
were	O
exhibited	O
simultaneously	O
in	O
around	O
70	O
%	O
of	O
animals	O
that	O
received	O
i.p	O
.	O

STZ	O
or	O
alloxan	O
.	O

Phosphorylation	O
of	O
EphB1	O
,	O
activation	O
of	O
the	O
astrocytes	O
and	O
microglial	O
cells	O
,	O
and	O
level	O
of	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-α	O
and	O
interleukin	O
(	O
IL	O
)	O
-1β	O
in	O
the	O
spinal	O
cord	O
were	O
significantly	O
increased	O
in	O
rats	O
with	O
DNP	O
.	O

Spinal	O
blocking	O
EphB1	O
receptor	O
activation	O
in	O
the	O
late	O
phase	O
after	O
STZ	O
injection	O
significantly	O
suppressed	O
the	O
established	O
mechanical	O
allodynia	O
as	O
well	O
as	O
activation	O
of	O
the	O
astrocytes	O
and	O
microglial	O
cells	O
and	O
activity	O
of	O
TNF-α	O
and	O
IL-1β	O
.	O

However	O
,	O
spinal	O
treatment	O
of	O
EphB1	O
-	O
Fc	O
in	O
the	O
early	O
phase	O
after	O
STZ	O
injection	O
did	O
not	O
prevent	O
the	O
induction	O
of	O
DNP	O
.	O

EphB1	O
receptor	O
activation	O
in	O
the	O
spinal	O
cord	O
is	O
critical	O
to	O
the	O
maintenance	O
,	O
but	O
not	O
induction	O
of	O
diabetic	O
pain	O
.	O

EphB1	O
receptor	O
may	O
be	O
a	O
potential	O
target	O
for	O
relieving	O
the	O
established	O
diabetic	O
pain	O
.	O

Activation	O
of	O
EphB1	O
receptor	O
in	O
the	O
spinal	O
cord	O
is	O
critical	O
to	O
maintaining	O
the	O
established	O
diabetic	O
neuropathic	O
pain	O
,	O
but	O
not	O
to	O
diabetic	O
pain	O
induction	O
.	O

Spinal	O
blocking	O
EphB1	O
receptor	O
activation	O
suppresses	O
ongoing	O
diabetic	O
neuropathic	O
pain	O
.	O

A	O
Variant	O
in	O
the	O
BACH2	O
Gene	O
Is	O
Associated	O
With	O
Susceptibility	O
to	O
Autoimmune	O
Addison	O
's	O
Disease	O
in	O
Humans	O
.	O

Autoimmune	O
Addison	O
's	O
disease	O
(	O
AAD	O
)	O
is	O
a	O
rare	O
but	O
highly	O
heritable	O
condition	O
.	O

The	O
BACH2	O
protein	O
plays	O
a	O
crucial	O
role	O
in	O
T	O
lymphocyte	O
maturation	O
,	O
and	O
allelic	O
variation	O
in	O
its	O
gene	O
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
autoimmune	O
conditions	O
.	O

We	O
aimed	O
to	O
determine	O
whether	O
alleles	O
of	O
the	O
rs3757247	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
the	O
BACH2	O
gene	O
are	O
associated	O
with	O
AAD	O
.	O

This	O
case-control	O
association	O
study	O
was	O
performed	O
in	O
two	O
phases	O
using	O
Taqman	B-P
chemistry	I-P
.	O

In	O
the	O
first	O
phase	O
,	O
the	O
rs3757247	O
SNP	O
was	O
genotyped	O
in	O
358	O
UK	O
AAD	O
subjects	O
and	O
166	O
local	O
control	O
subjects	O
.	O

Genotype	O
data	O
were	O
also	O
available	O
from	O
5154	O
healthy	O
UK	O
controls	O
from	O
the	O
Wellcome	O
Trust	O
(	O
WTCCC2	O
)	O
for	O
comparison	O
.	O

In	O
the	O
second	O
phase	O
,	O
the	O
SNP	O
was	O
genotyped	O
in	O
a	O
validation	O
cohort	O
comprising	O
317	O
Norwegian	O
AAD	O
subjects	O
and	O
365	O
controls	O
.	O

The	O
frequency	O
of	O
the	O
minor	O
T	O
allele	O
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
AAD	O
from	O
the	O
United	O
Kingdom	O
compared	O
to	O
both	O
the	O
local	O
and	O
WTCCC2	O
control	O
cohorts	O
(	O
58	O
%	O
vs	O
45	O
and	O
48	O
%	O
,	O
respectively	O
)	O
(	O
local	O
controls	O
,	O
P	O
=	O
1.1	O
×	O
10	O
(	O
-4	O
)	O
;	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.68	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.29-2.18	O
;	O
WTCCC2	O
controls	O
,	O
P	O
=	O
1.4	O
×	O
10	O
(	O
-6	O
)	O
;	O
OR	O
,	O
1.44	O
;	O
95	O
%	O
CI	O
,	O
1.23-1.69	O
)	O
.	O

This	O
finding	O
was	O
replicated	O
in	O
the	O
Norwegian	O
validation	O
cohort	O
(	O
P	O
=	O
.0015	O
;	O
OR	O
,	O
1.41	O
;	O
95	O
%	O
CI	O
,	O
1.14-1.75	O
)	O
.	O

Subgroup	O
analysis	O
showed	O
that	O
this	O
association	O
is	O
present	O
in	O
subjects	O
with	O
both	O
isolated	O
AAD	O
(	O
OR	O
,	O
1.53	O
;	O
95	O
%	O
CI	O
,	O
1.22-1.92	O
)	O
and	O
autoimmune	O
polyglandular	O
syndrome	O
type	O
2	O
(	O
OR	O
,	O
1.37	O
;	O
95	O
%	O
CI	O
,	O
1.12-1.69	O
)	O
in	O
the	O
UK	O
cohort	O
,	O
and	O
with	O
autoimmune	O
polyglandular	O
syndrome	O
type	O
2	O
in	O
the	O
Norwegian	O
cohort	O
(	O
OR	O
,	O
1.58	O
;	O
95	O
%	O
CI	O
,	O
1.22-2.06	O
)	O
.	O

We	O
have	O
demonstrated	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
allelic	O
variability	O
at	O
the	O
BACH2	O
locus	O
is	O
associated	O
with	O
susceptibility	O
to	O
AAD	O
.	O

Given	O
its	O
association	O
with	O
multiple	O
autoimmune	O
conditions	O
,	O
BACH2	O
can	O
be	O
considered	O
a	O
``	O
universal	O
''	O
autoimmune	O
susceptibility	O
locus	O
.	O

Design	O
,	O
synthesis	O
and	O
anti-tumor	O
activity	O
study	O
of	O
novel	O
histone	O
deacetylase	O
inhibitors	O
containing	O
isatin	O
-based	O
caps	O
and	O
o-phenylenediamine	O
-based	O
zinc	O
binding	O
groups	O
.	O

As	O
a	O
hot	O
topic	O
of	O
epigenetic	O
studies	O
,	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
are	O
related	O
to	O
lots	O
of	O
diseases	O
,	O
especially	O
cancer	O
.	O

Further	O
researches	O
indicated	O
that	O
different	O
HDAC	O
isoforms	O
played	O
various	O
roles	O
in	O
a	O
wide	O
range	O
of	O
tumor	O
types	O
.	O

Herein	O
a	O
novel	O
series	O
of	O
HDAC	O
inhibitors	O
with	O
isatin	O
-based	O
caps	O
and	O
o-phenylenediamine	O
-based	O
zinc	O
binding	O
groups	O
have	O
been	O
designed	O
and	O
synthesized	O
through	O
scaffold	B-P
hopping	I-P
strategy	I-P
.	O

Among	O
these	O
compounds	O
,	O
the	O
most	O
potent	O
compound	O
9n	O
exhibited	O
similar	O
if	O
not	O
better	O
HDAC	O
inhibition	O
and	O
antiproliferative	O
activities	O
against	O
multiple	O
tumor	O
cell	O
lines	O
compared	O
with	O
the	O
positive	O
control	O
entinostat	O
(	O
MS-275	O
)	O
.	O

Additionally	O
,	O
compared	O
with	O
MS-275	O
(	O
IC50	O
values	O
for	O
HDAC1	O
,	O
2	O
and	O
3	O
were	O
0.163	O
,	O
0.396	O
and	O
0.605µM	O
,	O
respectively	O
)	O
,	O
compound	O
9n	O
with	O
IC50	O
values	O
of	O
0.032	O
,	O
0.256	O
and	O
0.311µM	O
for	O
HDAC1	O
,	O
2	O
and	O
3	O
respectively	O
,	O
showed	O
a	O
moderate	O
HDAC1	O
selectivity	O
.	O

Snack	O
intake	O
is	O
reduced	O
using	O
an	O
implicit	O
,	O
high-level	O
construal	O
cue	O
.	O

Priming	O
a	O
high	O
level	O
construal	O
has	O
been	O
shown	O
to	O
enhance	O
self-control	O
and	O
reduce	O
preference	O
for	O
indulgent	O
food	O
.	O

Subtle	O
visual	O
cues	O
have	O
been	O
shown	O
to	O
enhance	O
the	O
effects	O
of	O
a	O
priming	O
procedure	O
.	O

The	O
current	O
study	O
therefore	O
examined	O
the	O
combined	O
impact	O
of	O
construal	O
level	O
and	O
a	O
visual	O
cue	O
reminder	O
on	O
the	O
consumption	O
of	O
energy-dense	O
snack	O
s.	O
A	O
student	O
and	O
community-based	O
adult	O
sample	O
with	O
a	O
wide	O
age	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
range	O
(	O
N	O
=	O
176	O
)	O
were	O
randomly	O
assigned	O
to	O
a	O
high	O
or	O
low	O
construal	O
condition	O
in	O
which	O
a	O
novel	O
symbol	O
was	O
embedded	O
.	O

Afterward	O
participants	O
completed	O
a	O
taste	O
test	B-P
of	O
ad	O
libitum	O
snack	O
foods	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
symbol	O
.	O

The	O
high	O
(	O
vs.	O
the	O
low	O
)	O
construal	O
level	O
prime	O
successfully	O
generated	O
more	O
abstract	O
responses	O
(	O
p	O
<	O
.0001	O
)	O
and	O
reduced	O
intake	O
when	O
the	O
cue	O
-	O
reminder	O
was	O
present	O
(	O
p	O
=	O
.02	O
)	O
but	O
not	O
when	O
it	O
was	O
absent	O
(	O
p	O
=	O
.40	O
)	O
.	O

Priming	O
high	O
construal	O
level	O
thinking	O
reduces	O
consumption	O
of	O
high	O
energy	O
dense	O
snacks	O
in	O
the	O
presence	O
of	O
a	O
visual	O
cue	O
-	O
reminder	O
.	O

This	O
may	O
be	O
a	O
practical	O
technique	O
for	O
reducing	O
overeating	O
and	O
has	O
the	O
potential	O
to	O
be	O
extended	O
to	O
other	O
unhealthy	O
behaviors	O
.	O

(	O
PsycINFO	O
Database	O
Record	O

Mammary	O
Gland	O
Pathology	O
Subsequent	O
to	O
Acute	O
Infection	O
with	O
Strong	O
versus	O
Weak	O
Biofilm	O
Forming	O
Staphylococcus	O
aureus	O
Bovine	O
Mastitis	O
Isolates	O
:	O
A	O
Pilot	O
Study	O
Using	O
Non-Invasive	O
Mouse	O
Mastitis	O
Model	O
.	O

Biofilm	O
formation	O
by	O
Staphylococcus	O
aureus	O
is	O
an	O
important	O
virulence	O
attribute	O
because	O
of	O
its	O
potential	O
to	O
induce	O
persistent	O
antibiotic	O
resistance	O
,	O
retard	O
phagocytosis	O
and	O
either	O
attenuate	O
or	O
promote	O
inflammation	O
,	O
depending	O
upon	O
the	O
disease	O
syndrome	O
,	O
in	O
vivo	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
potential	O
significance	O
of	O
strength	O
of	O
biofilm	O
formation	O
by	O
clinical	O
bovine	O
mastitis	O
-associated	O
S.	O
aureus	O
in	O
mammary	O
tissue	O
damage	O
by	O
using	O
a	O
mouse	O
mastitis	O
model	O
.	O

Two	O
S.	O
aureus	O
strains	O
of	O
the	O
same	O
capsular	O
phenotype	O
with	O
different	O
biofilm	O
forming	O
strengths	O
were	O
used	O
to	O
non-invasively	O
infect	O
mammary	O
glands	O
of	O
lactating	O
mice	O
.	O

Biofilm	O
forming	O
potential	O
of	O
these	O
strains	O
were	O
determined	O
by	O
tissue	B-P
culture	I-P
plate	I-P
method	I-P
,	O
ica	O
typing	O
and	O
virulence	O
gene	O
profile	O
per	O
detection	O
by	O
PCR	O
.	O

Delivery	O
of	O
the	O
infectious	O
dose	O
of	O
S.	O
aureus	O
was	O
directly	O
through	O
the	O
teat	O
lactiferous	O
duct	O
without	O
invasive	O
scraping	O
of	O
the	O
teat	O
surface	O
.	O

Both	O
bacteriological	B-P
and	O
histological	B-P
methods	I-P
were	O
used	O
for	O
analysis	O
of	O
mammary	O
gland	O
pathology	O
of	O
mice	O
post	O
-	O
infection	O
.	O

Histopathological	O
analysis	O
of	O
the	O
infected	O
mammary	O
glands	O
revealed	O
that	O
mice	O
inoculated	O
with	O
the	O
strong	O
biofilm	O
forming	O
S.	O
aureus	O
strain	O
produced	O
marked	O
acute	O
mastitic	O
lesions	O
,	O
showing	O
profuse	O
infiltration	O
predominantly	O
with	O
neutrophils	O
,	O
with	O
evidence	O
of	O
necrosis	O
in	O
the	O
affected	O
mammary	O
glands	O
.	O

In	O
contrast	O
,	O
the	O
damage	O
was	O
significantly	O
less	O
severe	O
in	O
mammary	O
glands	O
of	O
mice	O
infected	O
with	O
the	O
weak	O
biofilm-forming	O
S.	O
aureus	O
strain	O
.	O

Although	O
both	O
IL-1β	O
and	O
TNF-α	O
inflammatory	O
biomarkers	O
were	O
produced	O
in	O
infected	O
mice	O
,	O
level	O
of	O
TNF-α	O
produced	O
was	O
significantly	O
higher	O
(	O
p	O
<	O
0.05	O
)	O
in	O
mice	O
inoculated	O
with	O
strong	O
biofilm	O
forming	O
S.	O
aureus	O
than	O
the	O
weak	O
biofilm	O
forming	O
strain	O
.	O

This	O
finding	O
suggests	O
an	O
important	O
role	O
of	O
TNF-α	O
in	O
mammary	O
gland	O
pathology	O
post	O
-	O
infection	O
with	O
strong	O
biofilm-forming	O
S.	O
aureus	O
in	O
the	O
acute	O
mouse	O
mastitis	O
model	O
,	O
and	O
offers	O
an	O
opportunity	O
for	O
the	O
development	O
of	O
novel	O
strategies	O
for	O
reduction	O
of	O
mammary	O
tissue	O
damage	O
,	O
with	O
or	O
without	O
use	O
of	O
antimicrobials	O
and/or	O
anti-inflammatory	O
compounds	O
for	O
the	O
treatment	O
of	O
bovine	O
mastitis	O
.	O

Assessing	O
nitrous	O
oxide	O
effect	O
using	O
electroencephalographically	B-P
-based	O
depth	O
of	O
anesthesia	O
measures	O
cortical	O
state	O
and	O
cortical	O
input	O
.	O

Existing	O
electroencephalography	B-P
(	O
EEG	B-P
)	O
based	O
depth	O
of	O
anesthesia	O
monitors	O
can	O
not	O
reliably	O
track	O
sedative	O
or	O
anesthetic	O
states	O
during	O
n-methyl-D-aspartate	O
(	O
NMDA	O
)	O
receptor	O
antagonist	O
based	O
anesthesia	O
with	O
ketamine	O
or	O
nitrous	O
oxide	O
(	O
N2O	O
)	O
.	O

Here	O
,	O
a	O
physiologically	O
-motivated	O
depth	O
of	O
anesthesia	O
monitoring	O
algorithm	O
based	O
on	O
autoregressive-moving-average	O
(	O
ARMA	O
)	O
modeling	O
and	O
derivative	O
measures	O
of	O
interest	O
,	O
Cortical	O
State	O
(	O
CS	O
)	O
and	O
Cortical	O
Input	O
(	O
CI	O
)	O
,	O
is	O
retrospectively	O
applied	O
in	O
an	O
exploratory	O
manner	O
to	O
the	O
NMDA	O
receptor	O
antagonist	O
N2O	O
,	O
an	O
adjuvant	O
anesthetic	O
gas	O
used	O
in	O
clinical	O
practice	O
.	O

Composite	O
Cortical	O
State	O
(	O
CCS	O
)	O
and	O
Composite	O
Cortical	O
State	O
distance	O
(	O
CCSd	O
)	O
,	O
two	O
new	O
modifications	O
of	O
CS	O
,	O
along	O
with	O
CS	O
and	O
CI	O
were	O
evaluated	O
on	O
electroencephalographic	B-P
(	O
EEG	B-P
)	O
data	O
of	O
healthy	O
control	O
individuals	O
undergoing	O
N2O	O
inhalation	O
up	O
to	O
equilibrated	O
peak	O
gas	O
concentrations	O
of	O
20	O
,	O
40	O
or	O
60	O
%	O
N2O	O
/	O
O2	O
.	O

In	O
particular	O
,	O
CCSd	O
has	O
been	O
devised	O
to	O
vary	O
consistently	O
for	O
increasing	O
levels	O
of	O
anesthetic	O
concentration	O
independent	O
of	O
the	O
anesthetic	O
's	O
microscopic	O
mode	O
of	O
action	O
for	O
both	O
N2O	O
and	O
propofol	O
.	O

The	O
strongest	O
effects	O
were	O
observed	O
for	O
the	O
60	O
%	O
peak	O
gas	O
concentration	O
group	O
.	O

For	O
the	O
50-60	O
%	O
peak	O
gas	O
levels	O
,	O
individuals	O
showed	O
statistically	O
significant	O
reductions	O
in	O
responsiveness	O
compared	O
to	O
rest	O
,	O
and	O
across	O
the	O
group	O
CS	O
and	O
CCS	O
increased	O
by	O
39	O
and	O
42	O
%	O
,	O
respectively	O
,	O
while	O
CCSd	O
was	O
found	O
to	O
decrease	O
by	O
398	O
%	O
.	O

On	O
the	O
other	O
hand	O
a	O
clear	O
conclusion	O
regarding	O
the	O
changes	O
in	O
CI	O
could	O
not	O
be	O
reached	O
.	O

These	O
results	O
indicate	O
that	O
,	O
contrary	O
to	O
previous	O
depth	O
of	O
anesthesia	O
monitoring	O
measures	O
,	O
the	O
CS	O
,	O
CCS	O
,	O
and	O
especially	O
CCSd	O
measures	O
derived	O
from	O
frontal	O
EEG	B-P
are	O
potentially	O
useful	O
for	O
differentiating	O
gas	O
concentration	O
and	O
responsiveness	O
levels	O
in	O
people	O
under	O
N2O	O
.	O

On	O
the	O
other	O
hand	O
,	O
determining	O
the	O
utility	O
of	O
CI	O
in	O
this	O
regard	O
will	O
require	O
larger	O
sample	O
sizes	O
and	O
potentially	O
higher	O
gas	O
concentrations	O
.	O

Future	O
work	O
will	O
assess	O
the	O
sensitivity	O
of	O
CS	O
-based	O
and	O
CI	O
measures	O
to	O
other	O
anesthetics	O
and	O
their	O
utility	O
in	O
a	O
clinical	O
environment	O
.	O

Establishment	O
of	O
a	O
Novel	O
Simplified	O
Surgical	O
Model	O
of	O
Acute	O
Liver	O
Failure	O
in	O
the	O
Cynomolgus	O
Monkey	O
.	O

Models	O
using	O
large	O
animals	O
that	O
are	O
suitable	O
for	O
studying	O
artificial	O
liver	O
support	O
system	O
(	O
ALSS	O
)	O
are	O
urgently	O
needed	O
.	O

Presently	O
available	O
acute	O
liver	O
failure	O
(	O
ALF	O
)	O
models	O
mainly	O
involve	O
pigs	O
or	O
dogs	O
.	O

Establishment	O
of	O
current	O
surgical	O
ALF	O
models	O
(	O
hepatectomy	O
/	O
devascularization	O
)	O
requires	O
either	O
very	O
good	O
surgical	O
skills	O
or	O
multistep	O
processes-even	O
multiple	O
stages	O
of	O
surgery	O
.	O

Therefore	O
,	O
it	O
is	O
necessary	O
to	O
develop	O
a	O
simplified	O
surgical	O
method	O
.	O

Here	O
we	O
report	O
a	O
novel	O
simplified	O
surgical	O
ALF	O
model	O
using	O
cynomolgus	O
monkeys	O
.	O

Six	O
monkeys	O
underwent	O
portal-right	O
renal	O
venous	O
shunt	O
combined	O
with	O
common	O
bile	O
duct	O
ligation	O
and	O
transection	O
(	O
PRRS	O
+	O
CBDLT	O
)	O
.	O

Postoperatively	O
,	O
the	O
monkeys	O
had	O
progressively	O
increased	O
listlessness	O
,	O
loss	O
of	O
appetite	O
,	O
and	O
obvious	O
jaundice	O
.	O

Blood	O
biochemistry	O
levels	O
(	O
Amm	O
,	O
ALT	B-P
,	O
AST	B-P
,	O
TBiL	B-P
,	O
DBiL	B-P
,	O
ALP	B-P
,	O
LDH	B-P
,	O
CK	B-P
,	O
and	O
Cr	B-P
)	O
and	O
prothrombin	O
time	O
(	O
PT	O
)	O
were	O
significantly	O
increased	O
(	O
all	O
P	O
<	O
0.01	O
)	O
and	O
albumin	O
(	O
ALB	O
)	O
was	O
markedly	O
reduced	O
(	O
P	O
<	O
0.01	O
)	O
compared	O
with	O
baseline	O
values	O
.	O

Histological	O
examination	O
of	O
liver	O
specimens	O
on	O
postoperative	O
day	O
10	O
revealed	O
cholestasis	O
and	O
inflammation	O
.	O

PRRS	O
+	O
CBDLT	O
produced	O
ALF	O
that	O
closely	O
correlated	O
with	O
clinical	O
situations	O
.	O

Compared	O
with	O
other	O
surgical	O
or	O
drug	O
ALF	O
models	O
,	O
ours	O
was	O
simplified	O
and	O
animals	O
were	O
hemodynamically	O
stable	O
.	O

This	O
model	O
could	O
provide	O
a	O
good	O
platform	O
for	O
further	O
research	O
on	O
ALSS	O
,	O
especially	O
regarding	O
their	O
detoxification	O
functions	O
.	O

Production	O
of	O
bioactive	O
conjugated	O
linoleic	O
acid	O
by	O
the	O
multifunctional	O
enolase	O
from	O
Lactobacillus	O
plantarum	O
.	O

Lactobacillus	O
plantarum	O
α-enolase	O
,	O
a	O
multifunctional	O
-anchorless-	O
surface	O
protein	O
belonging	O
to	O
the	O
conserved	O
family	O
of	O
enolases	O
with	O
a	O
central	O
role	O
in	O
glycolytic	O
metabolism	O
,	O
was	O
characterized	O
to	O
have	O
a	O
side	O
role	O
in	O
the	O
intricate	O
metabolism	O
of	O
biohydrogenation	O
of	O
linoleic	O
acid	O
,	O
catalyzing	O
the	O
formation	O
of	O
bioactive	O
9-cis-11-trans-CLA	O
through	O
dehydration	O
and	O
isomerization	O
of	O
10-hydroxy-12-cis-octadecenoic	O
acid	O
.	O

The	O
identity	O
of	O
the	O
enolase	O
was	O
confirmed	O
through	O
mass	B-P
spectrometric	I-P
analysis	I-P
that	O
showed	O
the	O
characteristic	O
442	O
amino	O
acid	O
sequence	O
with	O
a	O
molecular	O
mass	O
of	O
48.03	O
kDa	O
.	O

The	O
enolase	O
was	O
not	O
capable	O
of	O
using	O
linoleic	O
acid	O
directly	O
as	O
a	O
substrate	O
but	O
instead	O
uses	O
its	O
hydroxyl	O
derivative	O
10-hydroxi-12-cis-octadecenoic	O
acid	O
to	O
finally	O
form	O
bioactive	O
conjugated	O
linoleic	O
acid	O
.	O

Biochemical	O
optimization	O
studies	O
were	O
carried	O
out	O
to	O
elucidate	O
the	O
conditions	O
for	O
maximum	O
production	O
of	O
9-cis-11-trans-CLA	O
and	O
maximum	O
stability	O
of	O
α-enolase	O
when	O
catalyzing	O
this	O
reaction	O
.	O

Furthermore	O
,	O
through	O
structural	O
analysis	O
of	O
the	O
protein	O
,	O
we	O
propose	O
the	O
binding	O
sites	O
of	O
substrate	O
and	O
product	O
molecules	O
that	O
were	O
characterized	O
as	O
two	O
hydrophobic	O
superficial	O
pockets	O
located	O
at	O
opposite	O
ends	O
of	O
the	O
enolase	O
connected	O
through	O
a	O
channel	O
where	O
the	O
catalysis	O
of	O
dehydration	O
and	O
isomerization	O
might	O
occur	O
.	O

These	O
results	O
prove	O
that	O
multifunctional	O
α-enolase	O
also	O
plays	O
a	O
role	O
in	O
cell	O
detoxification	O
from	O
polyunsaturated	O
fatty	O
acids	O
such	O
as	O
linoleic	O
acid	O
,	O
along	O
with	O
the	O
linoleate	O
isomerase	O
complex	O
.	O

Prevalence	O
of	O
gastrointestinal	O
parasites	O
in	O
dogs	O
of	O
Palampur	O
,	O
Himachal	O
Pradesh	O
.	O

A	O
total	O
of	O
246	O
faecal	O
/	O
scat	O
samples	O
of	O
the	O
dogs	O
were	O
screened	O
by	O
direct	O
and	O
floatation	B-P
concentration	I-P
technique	I-P
to	O
study	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tract	O
parasitism	O
in	O
dogs	O
of	O
Palampur	O
,	O
Himachal	O
Pradesh	O
,	O
India	O
.	O

Detailed	O
coprological	B-P
examination	I-P
targeting	O
different	O
seasons	O
,	O
age	O
groups	O
and	O
living	O
styles	O
of	O
the	O
dogs	O
revealed	O
an	O
overall	O
28.04	O
%	O
of	O
GI	O
parasitism	O
with	O
highest	O
prevalence	O
in	O
summer	O
season	O
(	O
37.87	O
%	O
)	O
.	O

Stray	O
dogs	O
harbored	O
47.29	O
%	O
GI	O
parasites	O
in	O
comparison	O
to	O
19.19	O
%	O
of	O
pet	O
dogs	O
.	O

Highest	O
prevalence	O
of	O
GI	O
parasitism	O
was	O
observed	O
in	O
the	O
pups	O
,	O
below	O
3	O
months	O
of	O
age	O
(	O
39.13	O
%	O
)	O
,	O
followed	O
by	O
the	O
dogs	O
with	O
the	O
age	O
ranging	O
from	O
3	O
months	O
to	O
1	O
year	O
(	O
26.38	O
%	O
)	O
and	O
lowest	O
in	O
dogs	O
of	O
the	O
age	O
ranging	O
from	O
1	O
to	O
3	O
years	O
(	O
6.77	O
%	O
)	O
.	O

Amongst	O
all	O
the	O
parasites	O
,	O
Toxocara	O
canis	O
(	O
44.93	O
%	O
)	O
infection	O
was	O
highest	O
,	O
followed	O
by	O
Dipylidium	O
caninum	O
(	O
17.39	O
%	O
)	O
and	O
hookworms	O
(	O
15.94	O
%	O
)	O
.	O

Challenging	O
Achievement	O
of	O
Bidirectional	O
Block	O
After	O
Linear	O
Ablation	O
Affects	O
the	O
Rhythm	O
Outcome	O
in	O
Patients	O
With	O
Persistent	O
Atrial	O
Fibrillation	O
.	O

It	O
is	O
not	O
clear	O
whether	O
bidirectional	O
block	O
(	O
BDB	O
)	O
of	O
linear	O
ablations	O
reduces	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
recurrence	O
after	O
radiofrequency	O
catheter	O
ablation	O
.	O

We	O
hypothesized	O
that	O
BDB	O
of	O
linear	O
ablation	O
has	O
prognostic	O
significance	O
after	O
radiofrequency	O
catheter	O
ablation	O
for	O
persistent	O
AF	O
.	O

Among	O
1793	O
consecutive	O
patients	O
in	O
the	O
Yonsei	O
AF	O
ablation	O
cohort	O
,	O
this	O
observational	O
cohort	O
study	O
included	O
398	O
patients	O
with	O
persistent	O
AF	O
(	O
75.6	O
%	O
male	O
;	O
age	O
,	O
59.8±10.3	O
years	O
)	O
who	O
underwent	O
catheter	O
ablation	O
with	O
a	O
consistent	O
ablation	O
protocol	O
of	O
the	O
Dallas	O
lesion	O
set	O
:	O
circumferential	O
pulmonary	O
vein	O
isolation	O
;	O
cavotricuspid	O
isthmus	O
ablation	O
(	O
CTI	O
)	O
;	O
roof	O
line	O
(	O
RL	O
)	O
;	O
posterior-inferior	O
line	O
(	O
PIL	O
)	O
;	O
and	O
anterior	O
line	O
(	O
AL	O
)	O
.	O

BDB	O
rates	O
of	O
de	O
novo	O
ablation	O
lines	O
were	O
100	O
%	O
in	O
circumferential	O
pulmonary	O
vein	O
isolation	O
,	O
100	O
%	O
in	O
CTI	O
,	O
84.7	O
%	O
in	O
RL	O
,	O
44.7	O
%	O
in	O
PIL	O
,	O
and	O
63.6	O
%	O
in	O
AL	O
.	O

During	O
29.0±18.4	O
months	O
of	O
follow-up	O
,	O
31.7	O
%	O
(	O
126/398	O
)	O
of	O
the	O
patients	O
showed	O
clinical	O
recurrence	O
.	O

Left	O
atrial	O
posterior	O
wall	O
(	O
LAPW	O
)	O
isolation	O
(	O
BDBs	O
of	O
RL	O
and	O
PIL	O
)	O
was	O
independently	O
associated	O
with	O
lower	O
clinical	O
AF	O
/	O
atrial	O
tachycardia	O
recurrence	O
(	O
hazard	O
ratio	O
,	O
0.68	O
;	O
95	O
%	O
CI	O
,	O
0.47-0.98	O
;	O
P=0.041	O
;	O
log-rank	O
,	O
P=0.017	O
)	O
,	O
whereas	O
BDBs	O
of	O
RL	O
or	O
AL	O
were	O
not	O
(	O
log-rank	O
,	O
P=0.178	O
for	O
RL	O
;	O
P=0.764	O
for	O
AL	O
)	O
.	O

Among	O
52	O
patients	O
who	O
underwent	O
repeat	O
procedures	O
(	O
23.0±16.1	O
months	O
after	O
de	B-P
novo	I-P
procedure	I-P
)	O
,	O
the	O
BDB	O
maintenance	O
rates	O
for	O
CTI	O
,	O
RL	O
,	O
PIL	O
,	O
and	O
AL	O
were	O
94.2	O
%	O
(	O
49	O
of	O
52	O
)	O
,	O
63.5	O
%	O
(	O
33	O
of	O
47	O
)	O
,	O
62.1	O
%	O
(	O
18	O
of	O
29	O
)	O
,	O
and	O
61.8	O
%	O
(	O
21	O
of	O
34	O
)	O
,	O
respectively	O
.	O

Although	O
PIL	O
crosses	O
the	O
esophageal	O
contact	O
area	O
,	O
LAPW	O
isolation	O
is	O
important	O
for	O
better	O
clinical	O
outcome	O
in	O
catheter	O
ablation	O
with	O
a	O
linear	O
ablation	O
strategy	O
for	O
patients	O
with	O
persistent	O
AF	O
.	O

Quality	O
Improvement	O
of	O
Liver	O
Ultrasound	B-P
Images	O
Using	O
Fuzzy	O
Techniques	O
.	O

Liver	O
ultrasound	B-P
images	O
are	O
so	O
common	O
and	O
are	O
applied	O
so	O
often	O
to	O
diagnose	O
diffuse	O
liver	O
diseases	O
like	O
fatty	O
liver	O
.	O

However	O
,	O
the	O
low	O
quality	O
of	O
such	O
images	O
makes	O
it	O
difficult	O
to	O
analyze	O
them	O
and	O
diagnose	O
diseases	O
.	O

The	O
purpose	O
of	O
this	O
study	O
,	O
therefore	O
,	O
is	O
to	O
improve	O
the	O
contrast	O
and	O
quality	O
of	O
liver	O
ultrasound	B-P
images	O
.	O

In	O
this	O
study	O
,	O
a	O
number	O
of	O
image	O
contrast	O
enhancement	O
algorithms	O
which	O
are	O
based	O
on	O
fuzzy	O
logic	O
were	O
applied	O
to	O
liver	O
ultrasound	B-P
images	O
-	O
in	O
which	O
the	O
view	O
of	O
kidney	O
is	O
observable	O
-	O
using	O
Matlab2013b	O
to	O
improve	O
the	O
image	O
contrast	O
and	O
quality	O
which	O
has	O
a	O
fuzzy	O
definition	O
;	O
just	O
like	O
image	O
contrast	O
improvement	O
algorithms	O
using	O
a	O
fuzzy	O
intensification	O
operator	O
,	O
contrast	O
improvement	O
algorithms	O
applying	O
fuzzy	O
image	O
histogram	O
hyperbolization	O
,	O
and	O
contrast	O
improvement	O
algorithms	O
by	O
fuzzy	O
IF-THEN	O
rules	O
.	O

With	O
the	O
measurement	O
of	O
Mean	O
Squared	O
Error	O
and	O
Peak	O
Signal	O
to	O
Noise	O
Ratio	O
obtained	O
from	O
different	O
images	O
,	O
fuzzy	O
methods	O
provided	O
better	O
results	O
,	O
and	O
their	O
implementation	O
-	O
compared	O
with	O
histogram	O
equalization	O
method	O
-	O
led	O
both	O
to	O
the	O
improvement	O
of	O
contrast	O
and	O
visual	O
quality	O
of	O
images	O
and	O
to	O
the	O
improvement	O
of	O
liver	O
segmentation	O
algorithms	O
results	O
in	O
images	O
.	O

Comparison	O
of	O
the	O
four	O
algorithms	O
revealed	O
the	O
power	O
of	O
fuzzy	O
logic	O
in	O
improving	O
image	O
contrast	O
compared	O
with	O
traditional	O
image	O
processing	O
algorithms	O
.	O

Moreover	O
,	O
contrast	O
improvement	O
algorithm	O
based	O
on	O
a	O
fuzzy	O
intensification	O
operator	O
was	O
selected	O
as	O
the	O
strongest	O
algorithm	O
considering	O
the	O
measured	O
indicators	O
.	O

This	O
method	O
can	O
also	O
be	O
used	O
in	O
future	O
studies	O
on	O
other	O
ultrasound	B-P
images	O
for	O
quality	O
improvement	O
and	O
other	O
image	O
processing	O
and	O
analysis	O
applications	O
.	O

Host	O
-	O
Induced	O
Silencing	O
of	O
Two	O
Pharyngeal	O
Gland	O
Genes	O
Conferred	O
Transcriptional	O
Alteration	O
of	O
Cell	O
Wall	O
-	O
Modifying	O
Enzymes	O
of	O
Meloidogyne	O
incognita	O
vis-à-vis	O
Perturbed	O
Nematode	O
Infectivity	O
in	O
Eggplant	O
.	O

The	O
complex	O
parasitic	O
strategy	O
of	O
Meloidogyne	O
incognita	O
appears	O
to	O
involve	O
simultaneous	O
expression	O
of	O
its	O
pharyngeal	O
gland	O
-	O
specific	O
effector	O
genes	O
in	O
order	O
to	O
colonize	O
the	O
host	O
plants	O
.	O

Research	O
reports	O
related	O
to	O
effector	O
crosstalk	O
in	O
phytonematodes	O
for	O
successful	O
parasitism	O
of	O
the	O
host	O
tissue	O
is	O
yet	O
underexplored	O
.	O

In	O
view	O
of	O
this	O
,	O
we	O
have	O
used	O
in	O
planta	O
effector	O
screening	O
approach	O
to	O
understand	O
the	O
possible	O
interaction	O
of	O
pioneer	O
genes	O
(	O
msp-18	O
and	O
msp-20	O
,	O
putatively	O
involved	O
in	O
late	O
and	O
early	O
stage	O
of	O
M.	O
incognita	O
parasitism	O
,	O
respectively	O
)	O
with	O
other	O
unrelated	O
effectors	O
such	O
as	O
cell-wall	O
modifying	O
enzymes	O
(	O
CWMEs	O
)	O
in	O
M.	O
incognita	O
.	O

Host	O
-	O
induced	O
gene	O
silencing	O
(	O
HIGS	O
)	O
strategy	O
was	O
used	O
to	O
generate	O
the	O
transgenic	O
eggplants	O
expressing	O
msp-18	O
and	O
msp-20	O
,	O
independently	O
.	O

Putative	O
transformants	O
were	O
characterized	O
via	O
qRT-PCR	O
and	O
Southern	O
hybridization	O
assay	O
.	O

SiRNAs	O
specific	O
to	O
msp-18	O
and	O
msp-20	O
were	O
also	O
detected	O
in	O
the	O
transformants	O
via	O
Northern	O
hybridization	O
assay	O
.	O

Transgenic	O
expression	O
of	O
the	O
RNAi	O
constructs	O
of	O
msp-18	O
and	O
msp-20	O
genes	O
resulted	O
in	O
43.64-69.68	O
%	O
and	O
41.74-67.30	O
%	O
reduction	O
in	O
M.	O
incognita	O
multiplication	O
encompassing	O
6	O
and	O
10	O
events	O
,	O
respectively	O
.	O

Additionally	O
,	O
transcriptional	O
oscillation	O
of	O
CWMEs	O
documented	O
in	O
the	O
penetrating	O
and	O
developing	O
nematodes	O
suggested	O
the	O
possible	O
interaction	O
among	O
CWMEs	O
and	O
pioneer	O
genes	O
.	O

The	O
rapid	O
assimilation	O
of	O
plant-derived	O
carbon	O
by	O
invading	O
nematodes	O
was	O
also	O
demonstrated	O
using	O
(	O
14	O
)	O
C	O
isotope	O
probing	B-P
approach	I-P
.	O

Our	O
data	O
suggests	O
that	O
HIGS	O
of	O
msp-18	O
and	O
msp-20	O
,	O
improves	O
nematode	O
resistance	O
in	O
eggplant	O
by	O
affecting	O
the	O
steady-state	O
transcription	O
level	O
of	O
CWME	O
genes	O
in	O
invading	O
nematodes	O
,	O
and	O
safeguard	O
the	O
plant	O
against	O
nematode	O
invasion	O
at	O
very	O
early	O
stage	O
because	O
nematodes	O
may	O
become	O
the	O
recipient	O
of	O
bioactive	O
RNA	O
species	O
during	O
the	O
process	O
of	O
penetration	O
into	O
the	O
plant	O
root	O
.	O

Defining	O
the	O
sham	O
environment	O
for	O
post-myocardial	O
infarction	O
studies	O
in	O
mice	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
sham	O
surgery	O
in	O
a	O
minimally	O
invasive	O
surgical	O
model	O
of	O
permanent	O
coronary	O
artery	O
occlusion	O
used	O
to	O
generate	O
myocardial	O
infarction	O
(	O
MI	O
)	O
in	O
mice	O
.	O

Adult	O
male	O
C57BL/6J	O
mice	O
(	O
3-6	O
mo	O
old	O
)	O
were	O
divided	O
into	O
five	O
groups	O
:	O
day	O
(	O
D	O
)	O
0	O
(	O
no	O
surgical	O
operation	O
)	O
,	O
D1	O
Sham	O
,	O
D1	O
MI	O
,	O
D7	O
Sham	O
,	O
and	O
D7	O
MI	O
.	O

A	O
refined	O
MI	O
surgery	O
technique	O
was	O
used	O
to	O
approach	O
the	O
coronary	O
artery	O
without	O
the	O
ribs	O
being	O
cut	O
.	O

Both	O
sham	O
and	O
MI	O
mice	O
had	O
the	O
left	O
ventricle	O
(	O
LV	O
)	O
exposed	O
through	O
a	O
small	O
incision	O
.	O

To	O
test	O
the	O
effects	O
of	O
surgery	O
alone	O
,	O
the	O
suture	O
was	O
passed	O
around	O
the	O
coronary	O
artery	O
but	O
not	O
ligated	O
.	O

The	O
MI	O
mice	O
were	O
subjected	O
to	O
permanent	O
coronary	O
artery	O
ligation	O
.	O

The	O
mice	O
were	O
killed	O
at	O
D1	O
or	O
D7	O
postsurgical	O
procedure	O
.	O

Compared	O
with	O
D0	O
no	O
surgery	O
controls	O
,	O
the	O
D1	O
and	O
D7	O
sham	O
groups	O
exhibited	O
no	O
surgical	O
mortality	O
and	O
similar	O
necropsy	B-P
and	O
echocardiographic	B-P
variables	O
.	O

Surgery	O
alone	O
did	O
not	O
induce	O
an	O
inflammatory	O
cell	O
response	O
,	O
as	O
evidenced	O
by	O
the	O
lack	O
of	O
leukocyte	O
infiltration	O
in	O
the	O
sham	O
groups	O
.	O

Analysis	O
of	O
165	O
inflammatory	O
cytokines	O
and	O
extracellular	O
matrix	O
factors	O
in	O
sham	O
revealed	O
that	O
a	O
minor	O
gene	O
response	O
was	O
initiated	O
but	O
not	O
translated	O
to	O
protein	O
levels	O
.	O

Collagen	O
deposition	O
did	O
not	O
occur	O
in	O
the	O
absence	O
of	O
MI	O
.	O

In	O
contrast	O
,	O
the	O
D1	O
and	O
D7	O
MI	O
groups	O
showed	O
the	O
expected	O
robust	O
inflammatory	O
and	O
scar	O
formation	O
responses	O
.	O

When	O
a	O
minimally	O
invasive	O
procedure	O
to	O
generate	O
MI	O
in	O
mice	O
was	O
used	O
,	O
the	O
D0	O
(	O
no	O
surgical	O
operation	O
)	O
control	O
was	O
an	O
adequate	O
replacement	O
for	O
the	O
use	O
of	O
sham	O
surgery	O
groups	O
.	O

Postprandial	O
anti-hyperglycemic	O
activity	O
of	O
marine	O
Streptomyces	O
coelicoflavus	O
SRBVIT13	O
mediated	O
gold	O
nanoparticles	O
in	O
streptozotocin	O
induced	O
diabetic	O
male	O
albino	O
Wister	O
rats	O
.	O

The	O
present	O
study	O
focuses	O
on	O
the	O
biosynthesis	O
of	O
gold	O
nanoparticles	O
(	O
AuNPs	O
)	O
using	O
Streptomyces	O
coelicoflavus	O
(	O
S.	O
coelicoflavus	O
)	O
SRBVIT13	O
isolated	O
from	O
marine	O
salt	O
pan	O
soils	O
collected	O
from	O
Ongole	O
,	O
Andhra	O
Pradesh	O
,	O
India	O
.	O

The	O
biosynthesised	O
AuNPs	O
are	O
characterised	O
by	O
UV-visible	B-P
spectroscopy	I-P
,	O
X-ray	B-P
diffraction	I-P
,	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
,	O
high-resolution	B-P
transmission	I-P
electron	I-P
microscopy	I-P
and	O
energy-dispersive	B-P
X-ray	I-P
analysis	I-P
.	O

Transmission	B-P
electron	I-P
microscopy	I-P
study	O
suggests	O
that	O
the	O
biosynthesised	O
AuNPs	O
are	O
spherical	O
in	O
shape	O
within	O
a	O
size	O
range	O
of	O
12-20	O
nm	O
(	O
mean	O
diameter	O
as	O
14	O
nm	O
)	O
.	O

The	O
anti-type	O
II	O
diabetes	O
activity	O
of	O
AuNPs	O
is	O
carried	O
out	O
by	O
testing	O
it	O
in	O
vitro	O
α-glucosidase	O
and	O
α-amylase	O
enzyme	O
inhibition	O
activity	O
and	O
in	O
vivo	O
postprandial	O
anti-hyperglycemic	O
activity	O
in	O
sucrose	O
and	O
glucose	O
-loaded	O
streptozotocin	O
induced	O
diabetic	O
albino	O
Wister	O
rats	O
.	O

AuNPs	O
has	O
shown	O
a	O
significant	O
inhibitory	O
activity	O
of	O
84.70	O
and	O
87.82	O
%	O
with	O
IC50	O
values	O
of	O
67.65	O
and	O
65.59	O
μg/mL	O
to	O
α-glucosidase	O
and	O
α-amylase	O
enzymes	O
,	O
while	O
the	O
diabetic	O
rats	O
have	O
shown	O
significant	O
reduction	O
in	O
the	O
post	O
postprandial	O
blood	O
glucose	O
level	O
by	O
57.80	O
and	O
88.09	O
%	O
,	O
respectively	O
compared	O
with	O
control	O
group	O
after	O
AuNPs	O
treatment	O
at	O
the	O
concentration	O
of	O
300	O
and	O
600	O
mg/kg	O
body	O
weight	O
.	O

Hence	O
,	O
this	O
biosynthesised	O
AuNPs	O
might	O
be	O
useful	O
in	O
combating	O
type	O
II	O
diabetes	O
mellitus	O
for	O
the	O
betterment	O
of	O
human	O
life	O
.	O

Effects	O
of	O
heat	O
treatment	O
on	O
conformation	O
and	O
cell	O
growth	O
activity	O
of	O
alpha-	O
lactalbumin	O
and	O
beta-lactoglobulin	O
from	O
market	O
milk	O
.	O

Heat	O
processes	O
,	O
low	O
temperature	O
for	O
long	O
time	O
(	O
LTLT	O
)	O
pasteurization	O
and	O
ultra-heat	O
treatment	O
(	O
UHT	O
)	O
sterilization	O
,	O
are	O
essential	O
for	O
commercial	O
market	O
milk	O
to	O
improve	O
the	O
shelf	O
life	O
of	O
raw	O
milk	O
and	O
ensure	O
microbial	O
safety	O
.	O

We	O
evaluated	O
the	O
effects	O
of	O
heat	O
experience	O
on	O
the	O
molecular	O
properties	O
of	O
α-lactalbumin	O
(	O
α-LA	O
)	O
and	O
β-lactoglobulin	O
(	O
β-LG	O
)	O
isolated	O
from	O
four	O
types	O
of	O
market	O
milk	O
such	O
as	O
LTLT-A	O
(	O
66°C	O
for	O
30	O
min	O
)	O
,	O
LTLT-B	O
(	O
65°C	O
for	O
30	O
min	O
)	O
,	O
UHT-I	O
(	O
130°C	O
for	O
2	O
s	O
,	O
indirect	O
heating	O
)	O
and	O
UHT-D	O
(	O
135°C	O
for	O
2	O
s	O
,	O
direct	O
heating	O
)	O
samples	O
.	O

We	O
examined	O
molecular	O
conformations	O
using	O
circular	B-P
dichroism	I-P
spectrum	I-P
measurement	I-P
and	O
cell	O
growth	O
activity	O
using	O
the	O
WST-1	O
method	O
for	O
the	O
proteins	O
.	O

α-LA	O
isolated	O
from	O
each	O
of	O
these	O
four	O
types	O
of	O
market	O
milk	O
displayed	O
no	O
significant	O
structural	O
difference	O
as	O
compared	O
to	O
raw	O
milk	O
α-LA	O
,	O
while	O
α-LA	O
of	O
UHT-I	O
only	O
inhibited	O
cell	O
growth	O
of	O
an	O
intestinal	O
epithelial	O
cell	O
line	O
more	O
potently	O
than	O
raw	O
milk	O
α-LA	O
.	O

In	O
the	O
case	O
of	O
β-LG	O
,	O
only	O
the	O
UHT-I	O
sample	O
demonstrated	O
a	O
drastic	O
change	O
in	O
structure	O
,	O
while	O
it	O
did	O
not	O
exhibit	O
any	O
cytotoxicity	O
.	O

We	O
found	O
that	O
cell	O
viability	O
effects	O
of	O
α-LA	O
and	O
β-LG	O
are	O
attributable	O
to	O
the	O
type	O
of	O
UHT	O
;	O
indirect	O
and	O
direct	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
effect	O
of	O
heat	O
treatment	O
on	O
whey	O
proteins	O
should	O
carefully	O
be	O
investigated	O
further	O
.	O

Relationship	O
between	O
polycythemia	O
and	O
in-hospital	O
mortality	O
in	O
chronic	O
obstructive	O
pulmonary	O
disease	O
patients	O
with	O
low-risk	O
pulmonary	O
embolism	O
.	O

Pulmonary	O
embolism	O
(	O
PE	O
)	O
is	O
frequent	O
in	O
subjects	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
and	O
associated	O
with	O
high	O
mortality	O
.	O

This	O
multi-center	O
retrospective	O
study	O
was	O
performed	O
to	O
investigate	O
if	O
secondary	O
polycythemia	O
is	O
associated	O
with	O
in-hospital	O
mortality	O
in	O
COPD	O
patients	O
with	O
low-risk	O
PE	O
.	O

We	O
identified	O
COPD	O
patients	O
with	O
proven	O
PE	O
between	O
October	O
,	O
2005	O
and	O
October	O
,	O
2015	O
.	O

Patients	O
in	O
risk	O
classes	O
III-V	O
on	O
the	O
basis	O
of	O
the	O
PESI	O
score	O
were	O
excluded	O
.	O

We	O
extracted	O
demographic	O
,	O
clinical	O
and	O
laboratory	O
information	O
at	O
the	O
time	O
of	O
admission	O
from	O
medical	O
records	O
.	O

All	O
subjects	O
were	O
followed	O
until	O
hospital	O
discharge	O
to	O
identify	O
all-cause	O
mortality	O
.	O

We	O
enrolled	O
629	O
consecutive	O
patients	O
with	O
COPD	O
and	O
PE	O
at	O
low	O
risk	O
:	O
132	O
of	O
them	O
(	O
21.0	O
%	O
)	O
with	O
and	O
497	O
(	O
79.0	O
%	O
)	O
without	O
secondary	O
polycythemia	O
.	O

Compared	O
with	O
those	O
without	O
polycythemia	O
,	O
the	O
polycythemia	O
group	O
had	O
significantly	O
lower	O
forced	B-P
expiratory	I-P
volume	I-P
in	I-P
one	I-P
second	I-P
(	I-P
FEV1	I-P
)	I-P
level	I-P
(	O
0.9±0.3	O
vs.	O
1.4±0.5	O
,	O
P=0.000	O
)	O
,	O
lower	O
PaO2	O
and	O
SpO2	O
as	O
well	O
as	O
higher	O
PaCO2	O
(	O
P=0.03	O
,	O
P=0.03	O
and	O
P=0.000	O
,	O
respectively	O
)	O
.	O

COPD	O
patients	O
with	O
polycythemia	O
had	O
a	O
higher	O
proportion	O
of	O
arrhythmia	O
in	O
electrocardiogram	O
(	O
ECG	O
)	O
(	O
49.5	O
%	O
vs.	O
35.7	O
%	O
,	O
P=0.02	O
)	O
,	O
a	O
longer	O
hospital	O
duration	O
time	O
(	O
15.3±10.1	O
vs.	O
9.7±9.1	O
,	O
P=0.001	O
)	O
,	O
a	O
higher	O
mechanical	O
ventilation	O
rate	O
(	O
noninvasive	O
and	O
invasive	O
,	O
51.7	O
%	O
vs.	O
30.3	O
%	O
,	O
P=0.04	O
and	O
31.0	O
%	O
vs.	O
7.9	O
%	O
,	O
P=0.04	O
,	O
respectively	O
)	O
,	O
and	O
a	O
higher	O
in-hospital	O
mortality	O
(	O
12.1	O
%	O
vs.	O
6.6	O
%	O
,	O
P=0.04	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
analysis	O
revealed	O
that	O
polycythemia	O
was	O
associated	O
with	O
mortality	O
in	O
COPD	O
patients	O
with	O
low-risk	O
PE	O
(	O
adjusted	O
OR	O
1.11	O
;	O
95	O
%	O
CI	O
,	O
1.04-1.66	O
)	O
.	O

Polycythemia	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
all-cause	O
in-hospital	O
mortality	O
in	O
COPD	O
patients	O
with	O
PE	O
at	O
low	O
risk	O
.	O

A	O
Rasch	O
Rating	O
Scale	O
Analysis	O
of	O
the	O
Presence	O
of	O
Nursing	O
Scale	O
-	O
RN	O
.	O

The	O
phenomenon	O
of	O
nursing	O
presence	O
encompasses	O
the	O
emotional	O
connection	O
between	O
nurse	O
and	O
patient	O
,	O
and	O
technical	O
skills	O
performed	O
by	O
the	O
nurse	O
.	O

The	O
Presence	O
of	O
Nursing	O
Scale	O
-	O
RN	O
version	O
(	O
PONS	O
-	O
RN	O
)	O
was	O
developed	O
to	O
measure	O
nurses	O
'	O
perceptions	O
of	O
their	O
ability	O
to	O
be	O
present	O
to	O
their	O
patients	O
.	O

This	O
study	O
summarizes	O
the	O
process	O
of	O
re-evaluation	O
of	O
the	O
psychometric	B-P
properties	I-P
of	O
the	O
PONS	O
-	O
RN	O
instrument	O
.	O

A	O
sample	O
of	O
76	O
registered	O
nurses	O
providing	O
direct	O
patient	O
care	O
responded	O
to	O
the	O
31-	O
item	O
questionnaire	O
.	O

The	O
Rasch	O
rating	O
scale	O
model	O
was	O
used	O
for	O
assessing	O
construct	O
validity	O
of	O
PONS	O
-	O
RN	O
data	O
.	O

A	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
of	O
residuals	O
supported	O
appropriateness	O
of	O
the	O
subscales	O
defined	O
by	O
a	O
2-dimensional	O
structure	O
.	O

The	O
results	O
of	O
item	O
and	O
person	O
fit	O
analysis	O
,	O
rating	O
scale	O
functioning	O
analysis	O
and	O
reliability	O
analysis	O
have	O
demonstrated	O
that	O
the	O
thirty-one	O
item	O
Presence	O
of	O
Nursing	O
Scale	O
-	O
RN	O
instrument	O
yielded	O
measures	O
with	O
high	O
validity	O
and	O
reliability	O
as	O
two	O
sub-scales	O
.	O

Jou	O
rn	O

Treatment	O
with	O
high	O
dose	O
of	O
atorvastatin	O
reduces	O
vascular	O
injury	O
in	O
diabetic	O
rats	O
.	O

Previous	O
reports	O
showed	O
conflicting	O
results	O
regarding	O
the	O
treatment	O
effects	O
of	O
statin	O
on	O
Diabetes	O
mellitus	O
(	O
DM	O
)	O
.	O

We	O
investigated	O
how	O
treatment	O
with	O
high	O
dose	O
of	O
atorvastatin	O
affects	O
the	O
impaired	O
vascular	O
function	O
in	O
diabetic	O
rats	O
.	O

Atorvastatin	O
(	O
80mg/kg/day	O
,	O
oral	O
gavage	O
,	O
4	O
weeks	O
)	O
or	O
its	O
vehicle	O
was	O
administered	O
to	O
male	O
control	O
or	O
streptozotocin	O
(	O
STZ	O
)	O
-induced	O
diabetic	O
rats	O
.	O

Aortic	O
segments	O
were	O
used	O
to	O
investigate	O
the	O
vascular	O
reactivity	O
,	O
protein	O
expression	O
of	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
and	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
oxidase	O
(	O
NADPH	O
oxidase	O
)	O
1	O
(	O
NOX1	O
)	O
and	O
superoxide	O
anions	O
levels	O
.	O

Atorvastatin	O
treatment	O
did	O
not	O
affect	O
glycemia	B-P
levels	I-P
.	O

In	O
diabetic	O
rats	O
,	O
the	O
vascular	O
reactivity	O
to	O
phenylephrine	O
increased	O
compared	O
with	O
controls	O
and	O
the	O
atorvastatin	O
treatment	O
reduced	O
this	O
response	O
.	O

Removal	O
of	O
the	O
endothelium	O
increased	O
the	O
response	O
to	O
phenylephrine	O
in	O
control	O
rats	O
,	O
but	O
not	O
in	O
the	O
diabetic	O
group	O
.	O

Atorvastatin	O
increased	O
the	O
endothelial	O
modulation	O
in	O
diabetic	O
rats	O
.	O

L-NAME	O
(	O
100μM	O
)	O
increased	O
the	O
reactivity	O
in	O
all	O
groups	O
,	O
but	O
this	O
effect	O
was	O
greater	O
in	O
atorvastatin	O
-treated	O
diabetic	O
rats	O
.	O

Indomethacin	O
(	O
10μM	O
)	O
and	O
NS398	O
(	O
1μM	O
)	O
decreased	O
the	O
contractile	O
response	O
in	O
diabetic	O
rats	O
and	O
atorvastatin	O
reversed	O
these	O
effects	O
,	O
without	O
changing	O
COX-2	O
expression	O
.	O

Apocynin	O
(	O
30μM	O
)	O
decreased	O
the	O
phenylephrine	O
response	O
in	O
diabetic	O
rats	O
,	O
which	O
also	O
showed	O
increased	O
NOX1	O
and	O
superoxide	O
anions	O
;	O
these	O
effects	O
were	O
prevented	O
by	O
atorvastatin	O
treatment	O
.	O

The	O
results	O
suggest	O
that	O
treatment	O
with	O
high	O
dose	O
of	O
atorvastatin	O
,	O
independent	O
of	O
glycemia	O
,	O
improves	O
endothelial	O
function	O
in	O
aortas	O
from	O
diabetic	O
rats	O
by	O
reducing	O
the	O
constrictor	O
prostanoids	O
derived	O
from	O
COX-2	O
and	O
by	O
reducing	O
the	O
oxidative	O
stress	O
by	O
NADPH	O
oxidase	O
,	O
as	O
well	O
as	O
a	O
possible	O
increasing	O
of	O
nitric	O
oxide	O
participation	O
.	O

Tobacco	O
Consumption	O
and	O
Toxicant	O
Exposure	O
of	O
Cigarette	O
Smokers	O
Using	O
Electronic	O
Cigarettes	O
.	O

There	O
is	O
considerable	O
debate	O
about	O
the	O
benefits	O
and	O
risks	O
of	O
electronic	O
cigarettes	O
(	O
ECs	O
)	O
.	O

To	O
better	O
understand	O
the	O
risk-benefit	O
ratio	O
of	O
ECs	O
,	O
more	O
information	O
is	O
needed	O
about	O
net	O
nicotine	O
consumption	O
and	O
toxicant	O
exposure	O
of	O
cigarette	O
smokers	O
switching	O
to	O
ECs	O
.	O

Forty	O
cigarette	O
smokers	O
(	O
>	O
1	O
year	O
of	O
smoking	O
)	O
interested	O
in	O
switching	O
to	O
ECs	O
but	O
not	O
necessarily	O
quitting	O
smoking	O
were	O
enrolled	O
in	O
a	O
four-	O
week	O
observational	O
study	O
and	O
provided	O
an	O
e-Go	O
C	O
non-variable	O
battery	O
and	O
refillable	O
atomizers	O
and	O
choice	O
of	O
8	O
flavors	O
in	O
12	O
or	O
24	O
mg	O
nicotine	O
dosage	O
.	O

Measurement	B-P
of	I-P
urinary	I-P
cotinine	I-P
(	O
metabolite	O
of	O
nicotine	O
)	O
,	O
4-	O
(	O
methylnitrosamino	O
)	O
-1-	O
(	O
3-pyridyl	O
)	O
-1-butanol	O
(	O
NNAL	O
;	O
a	O
pulmonary	O
carcinogen	O
)	O
,	O
and	O
eight	O
volatile	O
organic	O
compounds	O
(	O
VOCs	O
)	O
that	O
are	O
toxic	O
tobacco	O
smoke	O
constituents	O
was	O
conducted	O
at	O
baseline	O
and	O
Week	O
-4	O
.	O

All	O
participants	O
with	O
follow-up	O
data	O
(	O
92.5	O
%	O
)	O
reported	O
using	O
the	O
study	O
EC	O
.	O

Of	O
the	O
40	O
smokers	O
,	O
16	O
reported	O
no	O
cigarettes	O
at	O
Week	O
-2	O
(	O
40	O
%	O
)	O
and	O
6	O
continued	O
to	O
report	O
no	O
cigarettes	O
at	O
Week	O
-4	O
(	O
15	O
%	O
)	O
.	O

Change	O
in	O
nicotine	O
intake	O
over	O
the	O
4-	O
weeks	O
was	O
non-significant	O
(	O
p=0.90	O
)	O
.	O

Carbon	O
monoxide	O
(	O
p	O
<	O
0.001	O
)	O
,	O
NNAL	O
(	O
p	O
<	O
0.01	O
)	O
and	O
metabolites	O
of	O
benzene	O
(	O
p	O
<	O
0.01	O
)	O
and	O
acrylonitrile	O
(	O
p=0.001	O
)	O
were	O
significantly	O
decreased	O
in	O
the	O
study	O
sample	O
.	O

Smokers	O
switching	O
exclusively	O
to	O
ECs	O
for	O
at	O
least	O
half	O
of	O
the	O
study	O
period	O
demonstrated	O
significant	O
reductions	O
in	O
HEMA	O
(	O
p	O
>	O
=0.03	O
)	O
and	O
AAMA	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Smokers	O
using	O
ECs	O
over	O
4-	O
weeks	O
maintained	O
cotinine	B-P
levels	I-P
and	O
experienced	O
significant	O
reductions	O
in	O
carbon	O
monoxide	O
,	O
NNAL	O
,	O
and	O
two	O
out	O
of	O
eight	O
measured	O
VOC	O
metabolites	O
.	O

Those	O
who	O
switched	O
exclusively	O
to	O
ECs	O
for	O
at	O
least	O
half	O
of	O
the	O
study	O
period	O
significantly	O
reduced	O
two	O
additional	O
VOCs	O
.	O

This	O
study	O
extends	O
current	O
literature	O
by	O
measuring	O
change	O
in	O
smoking	O
dependence	O
and	O
disease-associated	O
biomarkers	O
,	O
4-	O
(	O
methylnitrosamino	O
)	O
-1-	O
(	O
3-pyridyl	O
)	O
-1-butanol	O
(	O
NNAL	O
)	O
and	O
a	O
panel	O
of	O
eight	O
common	O
volatile	O
organic	O
compounds	O
(	O
VOCs	O
)	O
that	O
are	O
toxic	O
tobacco	O
smoke	O
constituents	O
in	O
smokers	O
who	O
switch	O
to	O
electronic	O
cigarettes	O
.	O

The	O
findings	O
support	O
the	O
idea	O
of	O
harm	O
reduction	O
,	O
however	O
some	O
levels	O
of	O
toxicant	O
exposure	O
are	O
still	O
of	O
clinical	O
concern	O
,	O
particularly	O
for	O
dual	O
users	O
.	O

Extrapolation	O
of	O
these	O
results	O
must	O
be	O
careful	O
to	O
separate	O
the	O
different	O
toxic	O
exposure	O
results	O
for	O
exclusive	O
switchers	O
versus	O
dual	O
cigarette	O
+	O
EC	O
users	O
,	O
and	O
not	O
to	O
equate	O
harm	O
reduction	O
with	O
the	O
idea	O
that	O
using	O
ECs	O
is	O
harmless	O
.	O

Two-stage	O
reconstructive	O
overlapping	O
stent	O
LEO+	O
and	O
SILK	O
for	O
treatment	O
of	O
intracranial	O
circumferential	O
fusiform	O
aneurysms	O
in	O
the	O
posterior	O
circulation	O
.	O

Intracranial	O
circumferential	O
fusiform	O
aneurysms	O
of	O
the	O
posterior	O
circulation	O
involving	O
arterial	O
branches	O
or	O
perforating	O
vessels	O
are	O
difficult	O
to	O
treat	O
.	O

This	O
article	O
shows	O
an	O
endovascular	O
reconstruction	O
technique	O
not	O
yet	O
described	O
,	O
using	O
a	O
telescoping	O
self-expandable	O
stent	O
(	O
LEO+	O
)	O
and	O
flow-diverter	O
device	O
(	O
SILK	O
)	O
at	O
different	O
surgical	O
times	O
.	O

Two	O
patients	O
with	O
circumferential	O
fusiform	O
aneurysm	O
,	O
one	O
being	O
an	O
aneurysm	O
of	O
the	O
segments	O
P2	O
and	O
P3	O
of	O
the	O
posterior	O
cerebral	O
artery	O
,	O
diagnosed	O
after	O
a	O
headache	O
,	O
and	O
the	O
other	O
a	O
partially	O
thrombosed	O
aneurysm	O
of	O
the	O
lower	O
basilar	O
artery	O
,	O
diagnosed	O
following	O
ischemia	O
of	O
the	O
brain	O
stem	O
.	O

Endovascular	O
treatment	O
was	O
performed	O
by	O
means	O
of	O
a	O
vascular	O
reconstruction	O
technique	O
that	O
used	O
at	O
different	O
surgical	O
times	O
:	O
overlapping	O
;	O
a	O
telescoped	O
self-expandable	O
stent	O
,	O
LEO+	O
;	O
and	O
a	O
flow-diverter	O
device	O
,	O
SILK	O
.	O

Angiographic	B-P
control	O
was	O
carried	O
out	O
at	O
6	O
and	O
12	O
months	O
,	O
to	O
evaluate	O
arterial	O
patency	O
,	O
flow	O
maintenance	O
in	O
the	O
arterial	O
branches	O
and	O
perforating	O
vessels	O
,	O
and	O
thrombosis	O
of	O
the	O
aneurysm	O
.	O

The	O
combined	O
use	O
at	O
different	O
surgical	O
times	O
of	O
the	O
self-expandable	O
stent	O
and	O
flow-diverter	O
device	O
was	O
technically	O
successful	O
in	O
both	O
patients	O
.	O

There	O
were	O
no	O
complications	O
during	O
the	O
procedure	O
,	O
nor	O
in	O
the	O
long-term	O
follow-up	O
with	O
full	O
arterial	O
vascular	O
reconstruction	O
,	O
maintenance	O
of	O
cerebral	O
perfusion	O
and	O
complete	O
aneurysm	O
occlusion	O
at	O
the	O
6-	O
and	O
12-	O
month	O
angiographic	B-P
follow-up	O
.	O

There	O
was	O
no	O
aneurysm	O
recanalization	O
nor	O
intra-stent	O
stenosis	O
.	O

Circumferential	O
fusiform	O
aneurysm	O
of	O
the	O
posterior	O
circulation	O
involving	O
arterial	O
branches	O
or	O
perforating	O
vessels	O
to	O
the	O
brain	O
stem	O
may	O
be	O
treated	O
with	O
this	O
arterial	O
reconstruction	O
technique	O
at	O
different	O
surgical	O
times	O
,	O
using	O
the	O
self-expandable	O
stent	O
called	O
LEO+	O
and	O
the	O
flow-diverter	O
device	O
SILK	O
,	O
minimizing	O
the	O
risk	O
of	O
complications	O
and	O
failure	O
of	O
the	O
endovascular	O
technique	O
,	O
with	O
the	O
potential	O
for	O
arterial	O
reconstruction	O
with	O
thrombosis	O
of	O
the	O
aneurysmatic	O
sac	O
,	O
as	O
well	O
as	O
flow	O
maintenance	O
in	O
the	O
eloquent	O
arteries	O
,	O
in	O
this	O
type	O
of	O
cerebral	O
aneurysm	O
.	O

Laccase	O
-	O
immobilized	O
dendritic	O
nanofibrous	O
membranes	O
as	O
a	O
novel	O
approach	O
towards	O
the	O
removal	O
of	O
bisphenol	O
A.	O
Laccase	O
enzymes	O
from	O
Rhus	O
vernificera	O
were	O
covalently	O
bound	O
on	O
hyperbranched	O
polyethyleneimine	O
/	O
polyethersulfone	O
(	O
HPEI	O
/	O
PES	O
)	O
electrospun	O
nanofibrous	O
membranes	O
and	O
used	O
for	O
the	O
removal	O
of	O
bisphenol	O
A	O
(	O
BPA	O
)	O
from	O
water	O
.	O

The	O
laccase	O
enzyme	O
was	O
anchored	O
on	O
the	O
dendritic	O
membranes	O
through	O
the	O
abundant	O
peripheral	O
amine	O
groups	O
on	O
the	O
HPEI	O
using	O
glutaraldehyde	O
as	O
a	O
crosslinker	O
.	O

The	O
membranes	O
were	O
characterized	O
with	O
attenuated	O
total	O
reflectance-Fourier	O
transform	O
infrared	O
spectroscopy	O
,	O
scanning	B-P
electron	I-P
microscopy	I-P
coupled	O
with	O
energy-dispersive	B-P
X-ray	I-P
spectroscopy	I-P
(	O
SEM-EDS	B-P
)	O
and	O
ultraviolet-visible	B-P
spectroscopy	I-P
and	O
correlative	B-P
light	I-P
and	I-P
electron	I-P
microscopy	I-P
(	O
CLEM	B-P
)	O
.	O

Furthermore	O
,	O
contact-angle	O
analyses	O
,	O
pure	B-P
water	I-P
flux	I-P
measurements	I-P
and	O
rejection	O
analyses	O
were	O
carried	O
out	O
.	O

CLEM	B-P
showed	O
that	O
the	O
enzymes	O
were	O
uniformly	O
dispersed	O
on	O
the	O
nanofibres	O
while	O
SEM	B-P
analysis	O
revealed	O
that	O
the	O
nanofibres	O
had	O
an	O
average	O
diameter	O
of	O
354	O
±	O
37	O
nm	O
.	O

EDS	B-P
showed	O
the	O
presence	O
of	O
Cu	O
,	O
which	O
is	O
the	O
active	O
entity	O
in	O
laccase	O
enzymes	O
.	O

The	O
laccase	O
-modified	O
membranes	O
were	O
hydrophilic	O
(	O
50°-53°	O
contact	O
angle	O
)	O
and	O
exhibited	O
high	O
BPA	O
rejection	O
of	O
89.6	O
%	O
as	O
compared	O
to	O
the	O
52.4	O
%	O
demonstrated	O
by	O
pristine	O
PES	O
.	O

The	O
laccase	O
-modified	O
membranes	O
also	O
maintained	O
a	O
constant	B-P
permeate	I-P
flux	I-P
(	O
7.07	O
±	O
5.54	O
L/m	O
(	O
2	O
)	O
h	O
)	O
throughout	O
the	O
filtration	O
process	O
.	O

Recyclability	O
studies	O
indicated	O
that	O
the	O
membranes	O
still	O
maintained	O
a	O
high	O
BPA	O
removal	O
of	O
up	O
to	O
79	O
%	O
even	O
after	O
four	O
filtration	O
cycles	O
.	O

Associations	O
between	O
human	O
breast	O
milk	O
hormones	O
and	O
adipocytokines	O
and	O
infant	O
growth	O
and	O
body	O
composition	O
in	O
the	O
first	O
6	O
months	O
of	O
life	O
.	O

Much	O
is	O
to	O
be	O
learnt	O
about	O
human	O
breast	O
milk	O
(	O
HBM	O
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
extend	O
our	O
knowledge	O
of	O
HBM	O
by	O
investigating	O
the	O
role	O
of	O
maternal	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
,	O
sex	O
and	O
stage	O
of	O
lactation	O
(	O
month	O
1	O
vs.	O
6	O
)	O
on	O
HBM	O
insulin	O
,	O
glucose	O
,	O
leptin	O
,	O
IL-6	O
and	O
TNF-α	O
and	O
their	O
associations	O
with	O
infant	O
body	O
composition	O
.	O

Thirty-seven	O
exclusively	O
breastfeeding	O
infants	O
(	O
n	O
=	O
37	O
;	O
16♀	O
,	O
21♂	O
)	O
,	O
and	O
their	O
mothers	O
(	O
19-47	O
kg	O
m	O
(	O
-2	O
)	O
)	O
were	O
studied	O
at	O
1	O
and	O
6	O
months	O
of	O
lactation	O
.	O

Infants	O
had	O
body	O
composition	O
measured	O
(	O
using	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
)	O
and	O
HBM	O
collected	O
.	O

A	O
significant	O
interaction	O
between	O
maternal	O
BMI	O
and	O
infant	O
sex	O
on	O
insulin	B-P
levels	I-P
(	O
p	O
=	O
0.0322	O
)	O
was	O
observed	O
such	O
that	O
insulin	O
was	O
229	O
%	O
higher	O
in	O
obese	O
mothers	O
nursing	O
female	O
infants	O
than	O
in	O
normal	O
weight	O
mothers	O
nursing	O
female	O
infants	O
and	O
179	O
%	O
higher	O
than	O
obese	O
mothers	O
nursing	O
male	O
infants	O
.	O

For	O
leptin	O
,	O
a	O
significant	O
association	O
with	O
BMI	O
category	O
was	O
observed	O
(	O
p	O
<	O
0.0001	O
)	O
such	O
that	O
overweight	O
and	O
obese	O
mothers	O
had	O
96.5	O
%	O
and	O
315.1	O
%	O
higher	O
leptin	O
levels	O
than	O
normal	O
weight	O
mothers	O
,	O
respectively	O
.	O

Leptin	O
was	O
also	O
found	O
to	O
have	O
a	O
significant	O
(	O
p	O
=	O
0.0004	O
)	O
33.7	O
%	O
decrease	O
from	O
months	O
1	O
to	O
6	O
,	O
controlling	O
for	O
BMI	O
category	O
and	O
sex	O
.	O

A	O
significant	O
inverse	O
relationship	O
between	O
month	O
1	O
leptin	O
levels	O
and	O
infant	O
length	O
(	O
p	O
=	O
0.0257	O
)	O
,	O
percent	O
fat	O
(	O
p	O
=	O
0.0223	O
)	O
,	O
total	O
fat	O
mass	O
(	O
p	O
=	O
0.0226	O
)	O
and	O
trunk	O
fat	O
mass	O
(	O
p	O
=	O
0.0111	O
)	O
at	O
month	O
6	O
was	O
also	O
found	O
.	O

No	O
associations	O
or	O
interactions	O
were	O
observed	O
for	O
glucose	O
,	O
TNF-α	O
or	O
IL-6	O
.	O

These	O
data	O
demonstrate	O
that	O
maternal	O
BMI	O
,	O
infant	O
sex	O
and	O
stage	O
of	O
lactation	O
affect	O
the	O
compositional	O
make-up	O
of	O
insulin	O
and	O
leptin	O
.	O

Distinctive	O
pattern	O
of	O
let-7	O
family	O
microRNAs	O
in	O
aggressive	O
carcinoma	O
of	O
the	O
oral	O
tongue	O
in	O
young	O
patients	O
.	O

Oral	O
cavity	O
squamous	O
cell	O
carcinoma	O
may	O
be	O
more	O
aggressive	O
at	O
presentation	O
and	O
recurrence	O
in	O
young	O
patients	O
compared	O
with	O
older	O
patients	O
.	O

Dysregulation	O
of	O
microRNAs	O
(	O
miRNAs	O
or	O
miRs	O
)	O
has	O
been	O
associated	O
with	O
the	O
development	O
and	O
prognosis	O
of	O
oral	O
cavity	O
cancer	O
.	O

The	O
present	O
study	O
investigated	O
miRNA	O
expression	O
in	O
carcinoma	O
of	O
the	O
oral	O
tongue	O
in	O
young	O
patients	O
.	O

miRNA	O
expression	O
profiles	O
were	O
evaluated	O
in	O
formalin-fixed	O
,	O
paraffin-embedded	O
samples	O
of	O
tumor	O
and	O
normal	O
mucosa	O
from	O
12	O
patients	O
aged	O
<	O
30	O
years	O
old	O
with	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
tongue	O
.	O

The	O
levels	O
of	O
let-7f-5p	O
,	O
miR-30b-5p	O
and	O
let-7e-5p	O
were	O
upregulated	O
in	O
tumors	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
expression	O
of	O
let-7f-5p	O
was	O
upregulated	O
in	O
non-aggressive	O
tumors	O
,	O
while	O
the	O
expression	O
of	O
let-7e-5p	O
was	O
upregulated	O
in	O
aggressive	O
tumors	O
,	O
compared	O
with	O
the	O
corresponding	O
normal	O
tissue	O
.	O

Aggressive	O
tumors	O
had	O
higher	O
levels	O
of	O
let-7c	O
,	O
miR-130a-3p	O
,	O
miR-361-5p	O
,	O
miR-99a-5p	O
,	O
miR-29c-3p	O
and	O
let-7d-5p	O
than	O
non-aggressive	O
tumors	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
findings	O
remained	O
significant	O
for	O
let-7c	O
upon	O
false-discovery	O
rate	O
correction	O
.	O

An	O
excellent	O
correlation	O
was	O
noticed	O
on	O
validation	O
of	O
NanoString	O
counts	O
by	O
quantitative	B-P
polymerase	I-P
chain	I-P
reaction	I-P
.	O

The	O
comparison	O
with	O
published	O
findings	O
in	O
adults	O
demonstrated	O
a	O
unique	O
miRNA	O
signature	O
in	O
young	O
patients	O
with	O
aggressive	O
disease	O
.	O

Aggressive	O
oral	O
cavity	O
cancer	O
in	O
patients	O
<	O
30	O
years	O
old	O
is	O
associated	O
with	O
a	O
distinctive	O
expression	O
pattern	O
of	O
the	O
let-7	O
family	O
.	O

Larger	O
studies	O
including	O
direct	O
comparison	O
with	O
older	O
patients	O
are	O
warranted	O
.	O

TBL1XR1	O
predicts	O
isolated	O
tumor	O
cells	O
and	O
micrometastasis	O
in	O
patients	O
with	O
TNM	O
stage	O
I/II	O
colorectal	O
cancer	O
.	O

A	O
considerable	O
number	O
of	O
early	O
stage	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
patients	O
may	O
develop	O
cancer	O
relapse	O
or	O
metastasis	O
after	O
curative	O
surgery	O
.	O

Isolated	O
tumor	O
cells	O
(	O
ITC	O
)	O
and	O
micrometastasis	O
in	O
lymph	O
nodes	O
(	O
LNMM	O
)	O
,	O
which	O
are	O
undetectable	O
by	O
conventional	O
pathological	O
examination	O
,	O
may	O
be	O
one	O
primary	O
reason	O
.	O

Detection	O
of	O
ITC	O
/	O
LNMM	O
is	O
time-consuming	O
and	O
cost-ineffective	O
,	O
we	O
aimed	O
to	O
find	O
biomarkers	O
in	O
primary	O
CRC	O
tissues	O
to	O
help	O
predicting	O
ITC	O
/	O
LNMM	O
status	O
.	O

We	O
enrolled	O
137	O
node-negative	O
patients	O
with	O
early	O
stage	O
CRC	O
in	O
this	O
study	O
.	O

Existence	O
of	O
ITC	O
/	O
LNMM	O
was	O
identified	O
by	O
immunohistological	B-P
staining	I-P
with	O
cytokeratin	O
20	O
in	O
resected	O
lymph	O
nodes	O
.	O

Expression	O
of	O
transducin	O
(	O
β	O
)	O
-like	O
1	O
X-linked	O
receptor	O
1	O
(	O
TBL1XR1	O
)	O
in	O
primary	O
CRC	O
tissues	O
was	O
also	O
investigated	O
.	O

Chi-square	O
test	O
was	O
performed	O
to	O
reveal	O
the	O
correlations	O
between	O
ITC	O
/	O
LNMM	O
and	O
clinicopathological	O
characteristics	O
.	O

Univariate	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
determine	O
independent	O
prognostic	O
factors	O
.	O

Knock-down	O
experiment	O
together	O
with	O
proliferation	O
and	O
invasion	O
assays	B-P
were	O
carried	O
out	O
to	O
explore	O
molecular	O
mechanisms	O
between	O
TBL1XR1	O
and	O
ITC	O
/	O
LNMM	O
.	O

29.2	O
%	O
(	O
40/137	O
)	O
patients	O
were	O
identified	O
as	O
ITC	O
/	O
LNMM	O
positive	O
and	O
most	O
of	O
them	O
(	O
32/40	O
cases	O
,	O
80	O
%	O
)	O
showed	O
high	O
TBL1XR1	O
expression	O
in	O
primary	O
CRC	O
tissues	O
.	O

Both	O
ITC	O
/	O
LNMM	O
and	O
TBL1XR1	O
expression	O
were	O
independent	O
prognostic	O
factors	O
for	O
disease	O
relapse	O
or	O
metastasis	O
.	O

In	O
vitro	O
experiments	O
demonstrated	O
that	O
TBL1XR1	O
can	O
regulate	O
the	O
expression	O
of	O
VEGF-C	O
and	O
epithelial-mesenchymal	O
transition	O
proteins	O
,	O
thus	O
mediate	O
the	O
process	O
of	O
lymph	O
node	O
metastasis	O
.	O

Identification	O
of	O
ITC	O
/	O
LNMM	O
is	O
significant	O
in	O
evaluating	O
clinical	O
outcome	O
and	O
guiding	O
adjuvant	O
chemotherapy	O
for	O
early	O
stage	O
CRC	O
patients	O
.	O

TBL1XR1	O
overexpression	O
in	O
CRC	O
tissues	O
can	O
serve	O
as	O
an	O
efficient	O
biomarker	O
to	O
predict	O
the	O
status	O
of	O
ITC	O
/	O
LNMM	O
.	O

Serious	O
Games	O
for	O
Health	O
:	O
The	O
Potential	O
of	O
Metadata	O
.	O

Numerous	O
serious	O
games	O
and	O
health	O
games	O
exist	O
,	O
either	O
as	O
commercial	O
products	O
(	O
typically	O
with	O
a	O
focus	O
on	O
entertaining	O
a	O
broad	O
user	O
group	O
)	O
or	O
smaller	O
games	O
and	O
game	O
prototypes	O
,	O
often	O
resulting	O
from	O
research	O
projects	O
(	O
typically	O
tailored	O
to	O
a	O
smaller	O
user	O
group	O
with	O
a	O
specific	O
health	O
characteristic	O
)	O
.	O

A	O
major	O
drawback	O
of	O
existing	O
health	O
games	O
is	O
that	O
they	O
are	O
not	O
very	O
well	O
described	O
and	O
attributed	O
with	O
(	O
machine	O
-readable	O
,	O
quantitative	O
,	O
and	O
qualitative	O
)	O
metadata	O
such	O
as	O
the	O
characterizing	O
goal	O
of	O
the	O
game	O
,	O
the	O
target	O
user	O
group	O
,	O
or	O
expected	O
health	O
effects	O
well	O
proven	O
in	O
scientific	B-P
studies	I-P
.	O

This	O
makes	O
it	O
difficult	O
or	O
even	O
impossible	O
for	O
end	O
users	O
to	O
find	O
and	O
select	O
the	O
most	O
appropriate	O
game	O
for	O
a	O
specific	O
situation	O
(	O
e.g.	O
,	O
health	O
needs	O
)	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
article	O
was	O
to	O
motivate	O
the	O
need	O
and	O
potential	O
/	O
benefit	O
of	O
metadata	O
for	O
the	O
description	O
and	O
retrieval	O
of	O
health	O
games	O
and	O
to	O
describe	O
a	O
descriptive	O
model	O
for	O
the	O
qualitative	O
description	O
of	O
games	O
for	O
health	O
.	O

It	O
was	O
not	O
the	O
aim	O
of	O
the	O
article	O
to	O
describe	O
a	O
stable	O
,	O
running	O
system	O
(	O
portal	O
)	O
for	O
health	O
games	O
.	O

This	O
will	O
be	O
addressed	O
in	O
future	O
work	O
.	O

Building	O
on	O
previous	O
work	O
toward	O
a	O
metadata	O
format	O
for	O
serious	O
games	O
,	O
a	O
descriptive	O
model	O
for	O
the	O
formal	O
description	O
of	O
games	O
for	O
health	O
is	O
introduced	O
.	O

For	O
the	O
conceptualization	O
of	O
this	O
model	O
,	O
classification	O
schemata	O
of	O
different	O
existing	O
health	O
game	O
repositories	O
are	O
considered	O
.	O

The	O
classification	O
schema	O
consists	O
of	O
three	O
levels	O
:	O
a	O
core	O
set	O
of	O
mandatory	O
descriptive	O
fields	O
relevant	O
for	O
all	O
games	O
for	O
health	O
application	O
areas	O
,	O
a	O
detailed	O
level	O
with	O
more	O
comprehensive	O
,	O
optional	O
information	O
about	O
the	O
games	O
,	O
and	O
so-called	O
extension	O
as	O
level	O
three	O
with	O
specific	O
descriptive	O
elements	O
relevant	O
for	O
dedicated	O
health	O
games	O
application	O
areas	O
,	O
for	O
example	O
,	O
cardio	O
training	O
.	O

A	O
metadata	O
format	O
provides	O
a	O
technical	O
framework	O
to	O
describe	O
,	O
find	O
,	O
and	O
select	O
appropriate	O
health	O
games	O
matching	O
the	O
needs	O
of	O
the	O
end	O
user	O
.	O

Future	O
steps	O
to	O
improve	O
,	O
apply	O
,	O
and	O
promote	O
the	O
metadata	O
format	O
in	O
the	O
health	O
games	O
market	O
are	O
discussed	O
.	O

Blinking	O
Phase-Change	O
Nanocapsules	O
Enable	O
Background-Free	O
Ultrasound	B-P
Imaging	I-P
.	O

Microbubbles	O
are	O
widely	O
used	O
as	O
contrast	O
agents	O
to	O
improve	O
the	O
diagnostic	O
capability	O
of	O
conventional	O
,	O
highly	O
speckled	O
,	O
low-contrast	O
ultrasound	B-P
imaging	I-P
.	O

However	O
,	O
while	O
microbubbles	O
can	O
be	O
used	O
for	O
molecular	B-P
imaging	I-P
,	O
these	O
agents	O
are	O
limited	O
to	O
the	O
vascular	O
space	O
due	O
to	O
their	O
large	O
size	O
(	O
>	O
1	O
μm	O
)	O
.	O

Smaller	O
microbubbles	O
are	O
desired	O
but	O
their	O
ultrasound	O
visualization	O
is	O
limited	O
due	O
to	O
lower	O
echogenicity	O
or	O
higher	O
resonant	O
frequencies	O
.	O

Here	O
we	O
present	O
nanometer	O
scale	O
,	O
phase	O
changing	O
,	O
blinking	O
nanocapsules	O
(	O
BLInCs	O
)	O
,	O
which	O
can	O
be	O
repeatedly	O
optically	O
triggered	O
to	O
provide	O
transient	O
contrast	O
and	O
enable	O
background-free	B-P
ultrasound	I-P
imaging	I-P
.	O

In	O
response	O
to	O
irradiation	O
by	O
near-infrared	O
laser	O
pulses	O
,	O
the	O
BLInCs	O
undergo	O
cycles	O
of	O
rapid	O
vaporization	O
followed	O
by	O
recondensation	O
into	O
their	O
native	O
liquid	O
state	O
at	O
body	O
temperature	O
.	O

High	O
frame	O
rate	O
ultrasound	B-P
imaging	I-P
measures	O
the	O
dynamic	O
echogenicity	O
changes	O
associated	O
with	O
these	O
controllable	O
,	O
periodic	O
phase	O
transitions	O
.	O

Using	O
a	O
newly	O
developed	O
image	O
processing	O
algorithm	O
,	O
the	O
blinking	O
particles	O
are	O
distinguished	O
from	O
tissue	O
,	O
providing	O
a	O
background-free	O
image	O
of	O
the	O
BLInCs	O
while	O
the	O
underlying	O
B-mode	B-P
ultrasound	I-P
image	O
is	O
used	O
as	O
an	O
anatomical	O
reference	O
of	O
the	O
tissue	O
.	O

We	O
demonstrate	O
the	O
function	O
of	O
BLInCs	O
and	O
the	O
associated	O
imaging	B-P
technique	I-P
in	O
a	O
tissue	O
-mimicking	O
phantom	O
and	O
in	O
vivo	O
for	O
the	O
identification	O
of	O
the	O
sentinel	O
lymph	O
node	O
.	O

Our	O
studies	O
indicate	O
that	O
BLInCs	O
may	O
become	O
a	O
powerful	O
tool	O
to	O
identify	O
biological	O
targets	O
using	O
a	O
conventional	O
ultrasound	O
imaging	O
system	O
.	O

Predictors	O
of	O
neurologic	O
and	O
nonneurologic	O
death	O
in	O
patients	O
with	O
brain	O
metastasis	O
initially	O
treated	O
with	O
upfront	O
stereotactic	O
radiosurgery	O
without	O
whole-brain	O
radiation	O
therapy	O
.	O

In	O
this	O
study	O
we	O
attempted	O
to	O
discern	O
the	O
factors	O
predictive	O
of	O
neurologic	O
death	O
in	O
patients	O
with	O
brain	O
metastasis	O
treated	O
with	O
upfront	O
stereotactic	O
radiosurgery	O
(	O
SRS	O
)	O
without	O
whole	O
brain	O
radiation	O
therapy	O
(	O
WBRT	O
)	O
while	O
accounting	O
for	O
the	O
competing	O
risk	O
of	O
nonneurologic	O
death	O
.	O

We	O
performed	O
a	O
retrospective	O
single-institution	O
analysis	O
of	O
patients	O
with	O
brain	O
metastasis	O
treated	O
with	O
upfront	O
SRS	O
without	O
WBRT	O
.	O

Competing	O
risks	O
analysis	O
was	O
performed	O
to	O
estimate	O
the	O
subdistribution	O
hazard	O
ratios	O
(	O
HRs	O
)	O
for	O
neurologic	O
and	O
nonneurologic	O
death	O
for	O
predictor	O
variables	O
of	O
interest	O
.	O

Of	O
738	O
patients	O
treated	O
with	O
upfront	O
SRS	O
alone	O
,	O
neurologic	O
death	O
occurred	O
in	O
226	O
(	O
30.6	O
%	O
)	O
,	O
while	O
nonneurologic	O
death	O
occurred	O
in	O
309	O
(	O
41.9	O
%	O
)	O
.	O

Multivariate	O
competing	O
risks	O
analysis	O
identified	O
an	O
increased	O
hazard	O
of	O
neurologic	O
death	O
associated	O
with	O
diagnosis-specific	O
graded	O
prognostic	O
assessment	O
(	O
DS-GPA	O
)	O
≤	O
2	O
(	O
P	O
=	O
.005	O
)	O
,	O
melanoma	O
histology	B-P
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
increased	O
number	O
of	O
brain	O
metastases	O
(	O
P	O
<	O
.001	O
)	O
,	O
while	O
there	O
was	O
a	O
decreased	O
hazard	O
associated	O
with	O
higher	O
SRS	O
dose	O
(	O
P	O
=	O
.004	O
)	O
.	O

Targeted	O
agents	O
were	O
associated	O
with	O
a	O
decreased	O
HR	O
of	O
neurologic	O
death	O
in	O
the	O
first	O
1.5	O
years	O
(	O
P	O
=	O
.04	O
)	O
but	O
not	O
afterwards	O
.	O

An	O
increased	O
hazard	O
of	O
nonneurologic	O
death	O
was	O
seen	O
with	O
increasing	O
age	O
(	O
P	O
=.03	O
)	O
,	O
nonmelanoma	B-P
histology	I-P
(	O
P	O
<	O
.001	O
)	O
,	O
presence	O
of	O
extracranial	O
disease	O
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
progressive	O
systemic	O
disease	O
(	O
P	O
=.004	O
)	O
.	O

Melanoma	O
,	O
DS-GPA	O
,	O
number	O
of	O
brain	O
metastases	O
,	O
and	O
SRS	O
dose	O
are	O
predictive	O
of	O
neurologic	O
death	O
,	O
while	O
age	O
,	O
nonmelanoma	B-P
histology	I-P
,	O
and	O
more	O
advanced	O
systemic	O
disease	O
are	O
predictive	O
of	O
nonneurologic	O
death	O
.	O

Targeted	O
agents	O
appear	O
to	O
delay	O
neurologic	O
death	O
.	O

Myocardial	O
Blood	O
Flow	O
and	O
Inflammatory	O
Cardiac	O
Sarcoidosis	O
.	O

This	O
study	O
sought	O
to	O
evaluate	O
the	O
effects	O
of	O
inflammatory	O
sarcoid	O
disease	O
on	O
coronary	O
circulatory	O
function	O
and	O
the	O
response	O
to	O
immune-suppressive	O
treatment	O
.	O

Although	O
positron	B-P
emission	I-P
tomography	I-P
assessment	O
of	O
myocardial	O
inflammation	O
is	O
increasingly	O
applied	O
to	O
identify	O
active	O
cardiac	O
sarcoidosis	O
,	O
its	O
effect	O
on	O
coronary	O
flow	O
and	O
immune-suppressive	O
treatment	O
remains	O
to	O
be	O
characterized	O
.	O

Thirty-two	O
individuals	O
,	O
who	O
were	O
referred	O
for	O
positron	B-P
emission	I-P
tomography	I-P
/	O
computed	B-P
tomography	I-P
,	O
were	O
evaluated	O
for	O
known	O
or	O
suspected	O
cardiac	O
sarcoidosis	O
applying	O
(	O
18	O
)	O
F-fluorodeoxyglucose	O
to	O
determine	O
inflammation	O
and	O
(	O
13	O
)	O
N-ammonia	O
to	O
assess	O
for	O
perfusion	O
deficits	O
following	O
a	O
high-fat	O
/	O
low-carbohydrate	O
diet	O
and	O
fasting	O
state	O
>	O
12	O
h	O
to	O
suppress	O
myocardial	O
glucose	O
uptake	O
.	O

Inflammation	O
was	O
quantified	O
with	O
standardized	O
uptake	O
value	O
and	O
regional	O
myocardial	O
blood	O
flow	O
at	O
rest	O
and	O
during	O
regadenoson	O
-	O
stimulated	O
hyperemia	O
was	O
determined	O
in	O
ml/g/min	O
.	O

Positron	B-P
emission	I-P
tomography	I-P
studies	O
were	O
repeated	O
in	O
18	O
cases	O
with	O
a	O
median	O
follow-up	O
of	O
2.5	O
years	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
:1.3	O
to	O
3.4	O
years	O
)	O
.	O

Twenty-five	O
exams	O
had	O
normal	O
perfusion	O
but	O
evidence	O
of	O
regional	O
inflammation	O
(	O
group	O
1	O
)	O
,	O
and	O
21	O
exams	O
presented	O
a	O
regional	O
perfusion	O
deficit	O
associated	O
with	O
inflammation	O
(	O
group	O
2	O
)	O
.	O

Median	O
myocardial	O
blood	O
flow	O
did	O
not	O
differ	O
between	O
inflamed	O
and	O
noninflamed	O
myocardium	O
in	O
both	O
groups	O
(	O
0.86	O
ml/g/min	O
[	O
IQR	O
:	O
0.66	O
to	O
1.11	O
ml/g/min	O
]	O
vs.	O
0.83	O
ml/g/min	O
[	O
IQR	O
:	O
0.64	O
to	O
1.12	O
ml/g/min	O
]	O
and	O
0.74	O
ml/g/min	O
[	O
IQR	O
:	O
0.60	O
to	O
0.93	O
ml/g/min	O
]	O
vs.	O
0.77	O
ml/g/min	O
[	O
IQR	O
:	O
0.59	O
to	O
0.95	O
ml/g/min	O
]	O
,	O
respectively	O
)	O
.	O

As	O
regards	O
median	O
hyperemic	O
myocardial	O
blood	O
flows	O
,	O
they	O
were	O
significantly	O
lower	O
in	O
the	O
inflamed	O
than	O
in	O
the	O
remote	O
regions	O
in	O
group	O
1	O
and	O
2	O
(	O
2.31	O
ml/g/min	O
[	O
IQR	O
:	O
1.81	O
to	O
2.95	O
ml/g/min	O
]	O
vs.	O
2.70	O
ml/g/min	O
[	O
IQR	O
:	O
2.07	O
to	O
3.30	O
ml/g/min	O
]	O
and	O
1.61	O
ml/g/min	O
[	O
IQR	O
:	O
1.17	O
to	O
2.18	O
ml/g/min	O
]	O
vs.	O
1.94	O
ml/g/min	O
[	O
IQR	O
:	O
1.49	O
to	O
2.39	O
ml/g/min	O
]	O
;	O
p	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O

Immune-suppression	O
-mediated	O
decrease	O
in	O
inflammation	O
was	O
associated	O
with	O
preserved	O
myocardial	O
flow	O
reserve	O
(	O
MFR	O
)	O
at	O
follow-up	O
,	O
whereas	O
MFR	O
significantly	O
worsened	O
in	O
regions	O
without	O
changes	O
or	O
even	O
increases	O
in	O
inflammation	O
(	O
median	O
Δ	O
MFR	O
:	O
0.07	O
[	O
IQR	O
:	O
-0.29	O
to	O
0.45	O
]	O
vs.	O
-0.24	O
[	O
IQR	O
:	O
-0.84	O
to	O
0.21	O
]	O
;	O
p	O
<	O
0.001	O
)	O
.	O

There	O
was	O
an	O
inverse	O
correlation	O
between	O
pronounced	O
alterations	O
in	O
myocardial	O
inflammation	O
(	O
Δ	O
regional	O
myocardial	O
volume	O
with	O
standardized	O
uptake	O
value	O
>	O
4.1	O
)	O
and	O
Δ	O
MFR	O
(	O
r	O
=	O
-0.47	O
;	O
p	O
=	O
0.048	O
)	O
.	O

Sarcoid	O
-mediated	O
myocardial	O
inflammation	O
is	O
associated	O
with	O
a	O
regional	O
impairment	O
of	O
coronary	O
circulatory	O
function	O
.	O

The	O
association	O
between	O
immune-suppressive	O
treatment	O
-related	O
alterations	O
in	O
myocardial	O
inflammation	O
and	O
changes	O
in	O
coronary	O
vasodilator	O
capacity	O
suggests	O
direct	O
adverse	O
effect	O
of	O
inflammation	O
on	O
coronary	O
circulatory	O
function	O
in	O
cardiac	O
sarcoidosis	O
.	O

Identification	O
and	O
SAR	O
Evaluation	O
of	O
Hemozoin	O
-	O
Inhibiting	O
Benzamides	O
Active	O
against	O
Plasmodium	O
falciparum	O
.	O

Quinoline	O
antimalarials	O
target	O
hemozoin	O
formation	O
causing	O
a	O
cytotoxic	O
accumulation	O
of	O
ferriprotoporphyrin	O
IX	O
(	O
Fe	O
(	O
III	O
)	O
PPIX	O
)	O
.	O

Well-developed	O
SAR	O
models	O
exist	O
for	O
β-hematin	O
inhibition	O
,	O
parasite	O
activity	O
,	O
and	O
cellular	O
mechanisms	O
for	O
this	O
compound	O
class	O
,	O
but	O
no	O
comparably	O
detailed	O
investigations	O
exist	O
for	O
other	O
hemozoin	O
inhibiting	O
chemotypes	O
.	O

Here	O
,	O
benzamide	O
analogues	O
based	O
on	O
previous	O
HTS	B-P
hits	O
have	O
been	O
purchased	O
or	O
synthesized	O
.	O

Only	O
derivatives	O
containing	O
an	O
electron	O
deficient	O
aromatic	O
ring	O
and	O
capable	O
of	O
adopting	O
flat	O
conformations	O
,	O
optimal	O
for	O
π-π	O
interactions	O
with	O
Fe	O
(	O
III	O
)	O
PPIX	O
,	O
inhibited	O
β-hematin	O
formation	O
.	O

The	O
two	O
most	O
potent	O
analogues	O
showed	O
nanomolar	O
parasite	O
activity	O
,	O
with	O
little	O
CQ	O
cross-resistance	O
,	O
low	O
cytotoxicity	O
,	O
and	O
high	O
in	O
vitro	O
microsomal	O
stability	O
.	O

Selected	O
analogues	O
inhibited	O
hemozoin	O
formation	O
in	O
Plasmodium	O
falciparum	O
causing	O
high	O
levels	O
of	O
free	O
heme	O
.	O

In	O
contrast	O
to	O
quinolines	O
,	O
introduction	O
of	O
amine	O
side	O
chains	O
did	O
not	O
lead	O
to	O
benzamide	O
accumulation	O
in	O
the	O
parasite	O
.	O

These	O
data	O
reveal	O
complex	O
relationships	O
between	O
heme	O
binding	O
,	O
free	O
heme	O
levels	O
,	O
cellular	O
accumulation	O
,	O
and	O
in	O
vitro	O
activity	O
of	O
potential	O
novel	O
antimalarials	O
.	O

Towards	O
next-generation	O
sequencing	O
analytics	O
for	O
foodborne	O
RNA	O
viruses	O
:	O
Examining	O
the	O
effect	O
of	O
RNA	O
input	O
quantity	O
and	O
viral	O
RNA	O
purity	O
.	O

Detection	B-P
and	O
identification	B-P
of	O
viruses	O
in	O
food	O
samples	O
are	O
technically	O
challenging	O
due	O
largely	O
to	O
the	O
low	O
viral	O
copy	O
number	O
in	O
contaminated	O
food	O
items	O
,	O
and	O
the	O
lack	O
of	O
effective	O
culture	B-P
enrichment	I-P
methods	I-P
that	O
are	O
amenable	O
to	O
regulatory	O
applications	O
for	O
many	O
of	O
the	O
common	O
foodborne	O
viruses	O
.	O

Using	O
an	O
Illumina	O
MiSeq	O
platform	O
and	O
two	O
hepatitis	O
A	O
virus	O
(	O
HAV	O
)	O
cell-culture	B-P
adapted	O
strains	O
as	O
a	O
representative	O
enteric	O
virus	O
species	O
,	O
this	O
study	O
examined	O
the	O
limits	O
of	O
single-stranded	O
RNA	O
(	O
ssRNA	O
)	O
viral	B-P
detection	I-P
following	O
next-generation	O
sequencing	O
without	O
pre-amplification	O
of	O
the	O
viral	O
genome	O
.	O

Complete	O
viral	O
genome	O
sequences	O
were	O
obtained	O
from	O
HAV	O
samples	O
of	O
varying	O
purities	O
and	O
with	O
an	O
input	O
as	O
low	O
as	O
2ng	O
total	O
RNA	O
containing	O
1.4×10	O
(	O
5	O
)	O
copies	O
of	O
viral	O
RNA	O
.	O

In	O
addition	O
,	O
single	O
nucleotide	O
variations	O
were	O
reproducibly	O
detected	O
over	O
the	O
range	O
of	O
concentrations	O
examined	O
,	O
and	O
their	O
identity	O
confirmed	O
by	O
alternate	O
sequencing	O
technology	O
.	O

In	O
summary	O
,	O
next-generation	O
sequencing	O
technology	O
has	O
the	O
potential	O
for	O
sensitive	O
detection	B-P
/	O
identification	B-P
of	O
a	O
viral	O
genome	O
at	O
a	O
low	O
copy	O
number	O
.	O

This	O
study	O
provides	O
a	O
benchmark	O
for	O
metagenomic	O
sequencing	O
application	O
as	O
is	O
required	O
for	O
virus	B-P
detection	I-P
in	O
complex	O
food	O
matrices	O
using	O
a	O
culture	B-P
-independent	O
diagnostic	B-P
approach	I-P
.	O

The	O
antineoplastic	O
drug	O
,	O
trastuzumab	O
,	O
dysregulates	O
metabolism	O
in	O
iPSC	O
-derived	O
cardiomyocytes	O
.	O

The	O
targeted	O
ERBB2	O
therapy	O
,	O
trastuzumab	O
,	O
has	O
had	O
a	O
tremendous	O
impact	O
on	O
management	O
of	O
patients	O
with	O
HER2+	O
breast	O
cancer	O
,	O
leading	O
to	O
development	O
and	O
increased	O
use	O
of	O
further	O
HER2	O
targeted	O
therapies	O
.	O

The	O
major	O
clinical	O
side	O
effect	O
is	O
cardiotoxicity	O
but	O
the	O
mechanism	O
is	O
largely	O
unknown	O
.	O

On	O
the	O
basis	O
that	O
gene	O
expression	O
is	O
known	O
to	O
be	O
altered	O
in	O
multiple	O
models	O
of	O
heart	O
failure	O
,	O
we	O
examined	O
differential	O
gene	O
expression	O
of	O
iPSC	O
-derived	O
cardiomyocytes	O
treated	O
at	O
day	O
11	O
with	O
the	O
ERBB2	O
targeted	O
monoclonal	O
antibody	O
,	O
trastuzumab	O
for	O
48	O
h	O
and	O
the	O
small	O
molecule	O
tyrosine	O
kinase	O
inhibitor	O
of	O
EGFR	O
and	O
ERBB2	O
.	O

Transcriptome	B-P
sequencing	I-P
was	O
performed	O
on	O
four	O
replicates	O
from	O
each	O
group	O
(	O
48	O
h	O
untreated	O
,	O
48	O
h	O
trastuzumab	O
and	O
48	O
h	O
lapatinib	O
)	O
and	O
differential	O
gene	O
expression	O
analyses	O
were	O
performed	O
on	O
each	O
treatment	O
group	O
relative	O
to	O
untreated	O
cardiomyocytes	O
.	O

517	O
and	O
1358	O
genes	O
were	O
differentially	O
expressed	O
,	O
p	O
<	O
0.05	O
,	O
respectively	O
in	O
cardiomyocytes	O
treated	O
with	O
trastuzumab	O
and	O
lapatinib	O
.	O

Gene	O
ontology	O
analyses	O
revealed	O
in	O
cardiomyocytes	O
treated	O
with	O
trastuzumab	O
,	O
significant	O
down-regulation	O
of	O
genes	O
involved	O
in	O
small	O
molecule	O
metabolism	O
(	O
p	O
=	O
3.22	O
�—	O
10	O
(	O
-9	O
)	O
)	O
and	O
cholesterol	O
(	O
p	O
=	O
0.01	O
)	O
and	O
sterol	O
(	O
p	O
=	O
0.03	O
)	O
processing	O
.	O

We	O
next	O
measured	O
glucose	O
uptake	O
and	O
lactate	O
production	O
in	O
iPSC	O
-derived	O
cardiomyocytes	O
13	O
days	O
post-plating	O
,	O
treated	O
with	O
trastuzumab	O
up	O
to	O
96	O
h.	O
We	O
observed	O
significantly	O
decreased	O
glucose	O
uptake	O
from	O
the	O
media	O
of	O
iPSC	O
-derived	O
cardiomyocytes	O
treated	O
with	O
trastuzumab	O
as	O
early	O
as	O
24	O
h	O
(	O
p	O
=	O
0.001	O
)	O
and	O
consistently	O
up	O
to	O
96	O
h	O
(	O
p	O
=	O
0.03	O
)	O
.	O

Our	O
study	O
suggests	O
dysregulation	O
of	O
cardiac	O
gene	O
expression	O
and	O
metabolism	O
as	O
key	O
elements	O
of	O
ERBB2	O
signaling	O
that	O
could	O
potentially	O
be	O
early	O
biomarkers	O
of	O
cardiotoxicity	O
.	O

Diffusion	B-P
kurtosis	I-P
imaging	I-P
of	O
the	O
liver	O
at	O
3	O
Tesla	O
:	O
in	O
vivo	O
comparison	O
to	O
standard	O
diffusion-weighted	B-P
imaging	I-P
.	O

Background	O
Functional	O
techniques	B-P
like	O
diffusion-weighted	B-P
imaging	I-P
(	O
DWI	B-P
)	O
are	O
gaining	O
more	O
and	O
more	O
importance	O
in	O
liver	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
.	O

Diffusion	B-P
kurtosis	I-P
imaging	I-P
(	O
DKI	B-P
)	O
is	O
an	O
advanced	O
technique	B-P
that	O
might	O
help	O
to	O
overcome	O
current	O
limitations	O
of	O
DWI	B-P
.	O

Purpose	O
To	O
evaluate	O
DKI	B-P
for	O
the	O
differentiation	O
of	O
hepatic	O
lesions	O
in	O
comparison	O
to	O
conventional	O
DWI	B-P
at	O
3	O
Tesla	O
.	O

Material	O
and	O
Methods	O
Fifty-six	O
consecutive	O
patients	O
were	O
examined	O
using	O
a	O
routine	O
abdominal	B-P
MR	I-P
protocol	I-P
at	O
3	O
Tesla	O
which	O
included	O
DWI	B-P
with	O
b-values	O
of	O
50	O
,	O
400	O
,	O
800	O
,	O
and	O
1000	O
s/mm	O
(	O
2	O
)	O
.	O

Apparent	O
diffusion	O
coefficient	O
maps	O
were	O
calculated	O
applying	O
a	O
standard	O
mono-exponential	O
fit	O
,	O
while	O
a	O
non-Gaussian	O
kurtosis	O
fit	O
was	O
used	O
to	O
obtain	O
DKI	B-P
maps	O
.	O

ADC	O
as	O
well	O
as	O
Kurtosis-corrected	O
diffusion	O
(	O
D	O
)	O
values	O
were	O
quantified	O
by	O
region	O
of	O
interest	O
analysis	O
and	O
compared	O
between	O
lesions	O
.	O

Results	O
Sixty-eight	O
hepatic	O
lesions	O
(	O
hepatocellular	O
carcinoma	O
[	O
HCC	O
]	O
[	O
n	O
=	O
25	O
]	O
;	O
hepatic	O
adenoma	O
[	O
n	O
=	O
4	O
]	O
,	O
cysts	O
[	O
n	O
=	O
18	O
]	O
;	O
hepatic	O
hemangioma	O
[	O
HH	O
]	O
[	O
n	O
=	O
18	O
]	O
;	O
and	O
focal	O
nodular	O
hyperplasia	O
[	O
n	O
=	O
3	O
]	O
)	O
were	O
identified	O
.	O

Differentiation	O
of	O
malignant	O
and	O
benign	O
lesions	O
was	O
possible	O
based	O
on	O
both	O
DWI	B-P
ADC	O
as	O
well	O
as	O
DKI	B-P
D-values	O
(	O
P	O
values	O
were	O
in	O
the	O
range	O
of	O
0.04	O
to	O
<	O
0.0001	O
)	O
.	O

Conclusion	O
In	O
vivo	O
abdominal	O
DKI	B-P
calculated	O
using	O
standard	O
b-values	O
is	O
feasible	O
and	O
enables	O
quantitative	O
differentiation	O
between	O
malignant	O
and	O
benign	O
liver	O
lesions	O
.	O

Assessment	O
of	O
conventional	O
ADC	O
values	O
leads	O
to	O
similar	O
results	O
when	O
using	O
b-values	O
below	O
1000	O
s/mm	O
(	O
2	O
)	O
for	O
DKI	B-P
calculation	O
.	O

Ulnar	O
Osteotomy	O
with	O
2-Pin	O
Unilateral	O
Gradual	O
Distraction	O
for	O
Treatment	O
of	O
Chronic	O
Monteggia	O
Fracture	O
:	O
A	O
Case	O
Report	O
.	O

Missed	O
Monteggia	O
fracture	O
leading	O
to	O
chronic	O
radial	O
head	O
dislocation	O
is	O
a	O
known	O
complication	O
.	O

The	O
surgical	O
treatment	O
options	O
remain	O
challenging	O
.	O

The	O
aim	O
of	O
treatment	O
is	O
to	O
reduce	O
the	O
radial	O
head	O
and	O
to	O
maintain	O
the	O
stability	O
of	O
the	O
elbow	O
in	O
all	O
ranges	O
of	O
motion	O
.	O

A	O
few	O
surgical	B-P
techniques	I-P
have	O
been	O
described	O
with	O
complications	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
13	O
years	O
old	O
boy	O
with	O
chronic	O
radial	O
head	O
dislocation	O
as	O
a	O
result	O
of	O
an	O
unrecognised	O
Monteggia	O
fracture	O
-	O
dislocation	O
for	O
eight	O
years	O
.	O

We	O
successfully	O
reduced	O
the	O
radial	O
head	O
and	O
corrected	O
the	O
cubital	O
valgus	O
from	O
45	O
degrees	O
to	O
10	O
degrees	O
with	O
a	O
proximal	O
ulna	O
osteotomy	O
and	O
gradual	O
distraction	O
with	O
2-pin	O
Monotube	O
external	O
fixator	O
.	O

The	O
correction	O
was	O
uneventful	O
with	O
good	O
functional	O
outcome	O
.	O

Endoscopic	B-P
endonasal	O
surgery	O
for	O
remission	O
of	O
Cushing	O
's	O
Disease	O
caused	O
by	O
ectopic	O
intracavernous	O
macroadenoma	O
:	O
case	O
report	O
and	O
literature	O
review	O
.	O

Complete	O
surgical	O
resection	O
of	O
an	O
ACTH-secreting	O
pituitary	O
adenoma	O
is	O
the	O
gold	O
standard	O
of	O
treatment	O
of	O
Cushing	O
's	O
Disease	O
.	O

Ectopic	O
location	O
of	O
these	O
adenomas	O
is	O
an	O
extremely	O
rare	O
condition	O
that	O
may	O
compromise	O
the	O
diagnosis	O
and	O
surgical	O
success	O
.	O

We	O
present	O
the	O
first	O
case	O
of	O
an	O
ectopic	O
intracavernous	O
ACTH-secreting	O
macroadenoma	O
totally	O
resected	O
with	O
endoscopic	B-P
endonasal	O
surgery	O
(	O
EES	O
)	O
.	O

A	O
36	O
year	O
old	O
female	O
presented	O
with	O
Cushing	O
syndrome	O
.	O

Increased	O
ACTH	O
,	O
serum	O
cortisol	O
and	O
free	O
urine	O
cortisol	O
levels	O
were	O
identified	O
,	O
however	O
the	O
pituitary	B-P
MRI	I-P
failed	O
to	O
reveal	O
a	O
pituitary	O
tumor	O
;	O
instead	O
,	O
a	O
parasellar	O
lesion	O
in	O
the	O
left	O
cavernous	O
sinus	O
(	O
CS	O
)	O
was	O
noticed	O
.	O

Inferior	B-P
petrosal	I-P
sinus	I-P
sampling	I-P
demonstrated	O
a	O
significant	O
central	O
-to-	O
peripheral	O
and	O
lateralized	O
left-sided	O
ACTH	O
gradient	O
.	O

The	O
patient	O
underwent	O
EES	O
.	O

No	O
tumor	O
was	O
found	O
in	O
the	O
sella	O
,	O
however	O
,	O
the	O
left	O
CS	O
was	O
widely	O
explored	O
and	O
a	O
tumor	O
was	O
found	O
lateral	O
to	O
the	O
paraclival	O
segment	O
of	O
the	O
carotid	O
artery	O
.	O

There	O
were	O
no	O
complications	O
following	O
EES	O
.	O

Pathology	O
confirmed	O
the	O
diagnosis	O
of	O
an	O
ACTH-secreting	O
adenoma	O
.	O

During	O
the	O
immediately	O
postoperative	O
course	O
serum	O
cortisol	O
levels	O
dropped	O
below	O
5	O
mcg/dl	O
.	O

Postoperative	O
MRI	B-P
demonstrated	O
complete	O
tumor	O
resection	O
.	O

At	O
20	O
months	O
follow-up	O
,	O
the	O
patient	O
remains	O
in	O
clinical	O
and	O
biochemical	O
remission	O
of	O
Cushing	O
's	O
Disease	O
.	O

Only	O
12	O
cases	O
of	O
ectopic	O
intracavernous	O
ACTH-secreting	O
adenomas	O
have	O
been	O
reported	O
to	O
date	O
and	O
all	O
were	O
microadenomas	O
.	O

The	O
presence	O
of	O
an	O
ectopic	O
ACTH-secreting	O
macroadenoma	O
in	O
the	O
CS	O
represents	O
a	O
surgical	O
challenge	O
.	O

EES	O
is	O
the	O
ideal	O
approach	O
for	O
complete	O
resection	O
of	O
ectopic	O
intracavernous	O
adenomas	O
allowing	O
for	O
a	O
wide	O
exploration	O
of	O
the	O
CS	O
with	O
no	O
surgical	O
complications	O
.	O

Episomal	O
Nonviral	O
Gene	O
Therapy	O
Vectors	O
Slow	O
Progression	O
of	O
Atherosclerosis	O
in	O
a	O
Model	O
of	O
Familial	O
Hypercholesterolemia	O
.	O

Familial	O
hypercholesterolemia	O
(	O
FH	O
)	O
is	O
a	O
life-threatening	O
genetic	O
disorder	O
characterized	O
by	O
elevated	O
levels	B-P
of	I-P
plasma	I-P
low-density	I-P
lipoprotein	I-P
cholesterol	I-P
(	O
LDL-cholesterol	O
)	O
.	O

Current	O
attempts	O
at	O
gene	O
therapy	O
for	O
FH	O
have	O
been	O
limited	O
by	O
the	O
use	O
of	O
strong	O
heterologous	O
promoters	O
which	O
lack	O
genomic	O
DNA	O
elements	O
essential	O
for	O
regulated	O
expression	O
.	O

Here	O
,	O
we	O
have	O
combined	O
a	O
mini-gene	O
vector	O
expressing	O
the	O
human	O
LDLR	O
cDNA	O
from	O
a	O
10	O
kb	O
native	O
human	O
LDLR	O
locus	O
genomic	O
DNA	O
promoter	O
element	O
,	O
with	O
an	O
efficient	O
miRNA	O
targeting	O
3-hydroxy-3-methylgutaryl-coenzyme	O
A	O
reductase	O
(	O
Hmgcr	O
)	O
,	O
to	O
further	O
enhance	O
LDLR	O
expression	O
.	O

We	O
show	O
that	O
the	O
combined	O
vector	O
suppresses	O
endogenous	O
Hmgcr	O
transcripts	O
in	O
vivo	O
,	O
leading	O
to	O
an	O
increase	O
in	O
LDLR	O
transgene	O
expression	O
.	O

In	O
a	O
diet-induced	O
Ldlr	O
(	O
-/-	O
)	O
mouse	O
model	O
of	O
FH	O
,	O
we	O
show	O
that	O
administration	O
of	O
the	O
combined	O
vector	O
reduces	O
atherogenic	B-P
plasma	I-P
lipids	I-P
by	O
~32	O
%	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
our	O
episomal	O
nonviral	O
vectors	O
are	O
able	O
to	O
reduce	O
atherosclerosis	O
by	O
~40	O
%	O
after	O
12	O
weeks	O
in	O
vivo	O
.	O

Taken	O
together	O
,	O
the	O
vector	O
system	O
we	O
describe	O
exploits	O
the	O
normal	O
cellular	O
regulation	O
of	O
the	O
LDLR	O
to	O
provide	O
prolonged	O
expression	O
of	O
LDLR	O
through	O
targeted	O
knockdown	O
of	O
Hmgcr	O
.	O

This	O
novel	O
gene	O
therapy	O
system	O
could	O
act	O
alone	O
,	O
or	O
in	O
synergy	O
with	O
current	O
therapies	O
that	O
modulate	O
intracellular	O
cholesterol	O
,	O
such	O
as	O
statins	O
,	O
greatly	O
enhancing	O
its	O
therapeutic	O
application	O
for	O
FH	O
.	O

Progestin	O
suppressed	O
inflammation	O
and	O
cell	O
viability	O
of	O
tumor	O
necrosis	O
factor-α	O
-stimulated	O
endometriotic	O
stromal	O
cells	O
.	O

Endometriosis	O
is	O
an	O
estrogen	O
-	O
dependent	O
inflammatory	O
disease	O
.	O

Progestins	O
are	O
a	O
first-line	O
treatment	O
for	O
endometriosis	O
via	O
activation	O
of	O
pituitary	O
progesterone	O
receptors	O
and	O
suppression	O
of	O
systemic	O
estrogen	O
:	O
a	O
less	O
than	O
optimal	O
treatment	O
.	O

Increasing	O
evidence	O
is	O
beginning	O
to	O
show	O
that	O
progestins	O
may	O
also	O
influence	O
local	O
endometriotic	O
cells	O
,	O
which	O
may	O
contribute	O
to	O
their	O
clinical	O
efficacy	O
.	O

Endometrial	O
stromal	O
cells	O
(	O
ESC	O
)	O
isolated	O
from	O
women	O
with	O
endometriosis	O
were	O
cultured	B-P
with	O
TNF-α	O
to	O
simulate	O
an	O
inflammatory	O
environment	O
.	O

ESC	O
were	O
treated	O
with	O
the	O
progestins	O
,	O
medroxyprogesterone	O
acetate	O
(	O
MPA	O
)	O
,	O
norethisterone	O
acetate	O
(	O
NETA	O
)	O
,	O
or	O
dienogest	O
(	O
DNG	O
)	O
and	O
cytokine	O
mRNA	O
production	O
,	O
protein	O
secretion	O
,	O
and	O
cell	O
viability	O
measured	O
.	O

DNG	O
,	O
NETA	O
,	O
and	O
MPA	O
suppressed	O
the	O
secretion	O
of	O
interleukin	O
(	O
IL	O
)	O
-6	O
,	O
IL-8	O
,	O
and	O
monocyte	O
chemotactic	O
protein	O
(	O
MCP	O
)	O
-1	O
from	O
ESC	O
.	O

DNG	O
and	O
NETA	O
only	O
reduced	O
the	O
TNF-α	O
-stimulated	O
mRNA	O
production	O
.	O

All	O
three	O
progestins	O
suppressed	O
TNF-α	O
-stimulated	O
ESC	O
proliferation	O
.	O

Progestins	O
may	O
influence	O
endometriotic	O
stromal	O
cells	O
altering	O
the	O
inflammatory	O
microenvironment	O
and	O
their	O
clinical	O
efficacy	O
.	O

Evaluation	O
and	O
Treatment	O
of	O
Anemia	O
in	O
Premature	O
Infants	O
.	O

Anemia	O
in	O
preterm	O
infants	O
is	O
the	O
pathophysiological	O
process	O
with	O
greater	O
and	O
more	O
rapid	O
decline	O
in	O
hemoglobin	O
compared	O
to	O
the	O
physiological	O
anemia	O
in	O
infants	O
.	O

There	O
is	O
a	O
need	O
for	O
transfusions	O
and	O
administration	O
of	O
human	O
recombinant	O
erythropoietin	O
.	O

To	O
determine	O
the	O
frequency	O
of	O
anemia	O
in	O
premature	O
infants	O
at	O
the	O
Pediatric	O
Clinic	O
,	O
University	O
Clinical	O
Center	O
Sarajevo	O
,	O
as	O
well	O
as	O
parameter	O
values	O
in	O
the	O
blood	B-P
count	I-P
of	O
premature	O
infants	O
and	O
to	O
explore	O
a	O
relationship	O
between	O
blood	O
transfusions	O
with	O
the	O
advent	O
of	O
intraventricular	O
hemorrhage	O
(	O
determine	O
treatment	O
outcome	O
in	O
preterm	O
infants	O
)	O
.	O

Research	O
is	O
retrospective	O
study	O
and	O
it	O
included	O
the	O
period	O
of	O
six	O
months	O
in	O
year	O
2014	O
.	O

Research	O
included	O
100	O
patients	O
,	O
gestational	O
age	O
<	O
37	O
weeks	O
(	O
premature	O
infants	O
)	O
.	O

Data	O
were	O
collected	O
by	O
examining	O
the	O
medical	O
records	O
of	O
patients	O
at	O
the	O
Pediatric	O
Clinic	O
,	O
UCCS	O
.	O

The	O
first	O
group	O
of	O
patients	O
were	O
premature	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
(	O
62/100	O
)	O
and	O
the	O
second	O
group	O
were	O
premature	O
infants	O
of	O
gestational	O
age	O
33-37	O
weeks	O
(	O
38/100	O
)	O
.	O

Among	O
the	O
patients	O
,	O
5	O
%	O
were	O
boys	O
and	O
46	O
%	O
girls	O
.	O

There	O
was	O
significant	O
difference	O
in	O
birth	O
weight	O
and	O
APGAR	O
score	O
among	O
the	O
groups	O
.	O

In	O
the	O
first	O
group	O
,	O
there	O
were	O
27.42	O
%	O
of	O
deaths	O
,	O
while	O
in	O
the	O
second	O
group	O
,	O
there	O
were	O
only	O
10.53	O
%	O
of	O
deaths	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
length	O
of	O
treatment	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
difference	O
in	O
the	O
need	O
for	O
transfusion	O
among	O
the	O
groups	O
.	O

18	O
patients	O
in	O
the	O
first	O
group	O
required	O
a	O
transfusion	O
,	O
while	O
in	O
the	O
second	O
group	O
only	O
3	O
patients	O
.	O

Preterm	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
are	O
likely	O
candidates	O
for	O
blood	O
transfusion	O
during	O
treatment	O
.	O

Preterm	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
have	O
the	O
risk	O
of	O
intracranial	O
bleeding	O
associated	O
with	O
the	O
application	O
of	O
blood	O
transfusion	O
in	O
the	O
first	O
week	O
of	O
life	O
.	O

Development	O
and	O
validation	O
of	O
the	O
self-reported	O
PROMIS	O
pediatric	O
pain	O
behavior	O
item	O
bank	O
and	O
short	O
form	O
scale	O
.	O

Pain	O
behaviors	O
are	O
important	O
indicators	O
of	O
functioning	O
in	O
chronic	O
pain	O
;	O
however	O
,	O
no	O
self-reported	O
pain	O
behavior	O
instrument	O
has	O
been	O
developed	O
for	O
pediatric	O
populations	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
create	O
a	O
brief	O
pediatric	O
measure	O
of	O
patient-reported	O
pain	O
behaviors	O
as	O
part	O
of	O
the	O
Patient-	O
Reported	O
Outcome	O
Measurement	O
Information	O
System	O
(	O
PROMIS	O
)	O
.	O

A	O
pool	O
of	O
47	O
candidate	O
items	O
for	O
this	O
measure	O
had	O
been	O
previously	O
developed	O
through	O
qualitative	O
research	O
.	O

In	O
this	O
study	O
,	O
youth	O
with	O
chronic	O
pain	O
associated	O
with	O
juvenile	O
fibromyalgia	O
(	O
JFM	O
)	O
,	O
juvenile	O
idiopathic	O
arthritis	O
(	O
JIA	O
)	O
,	O
or	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
(	O
ages	O
8	O
to	O
18	O
years	O
)	O
from	O
three	O
pediatric	O
centers	O
completed	O
all	O
47	O
candidate	O
items	O
for	O
development	O
of	O
the	O
pain	O
behavior	O
item	O
bank	O
along	O
with	O
established	O
measures	O
of	O
pain	O
interference	O
,	O
depressive	O
symptoms	O
,	O
fatigue	O
,	O
average	O
pain	O
intensity	O
,	O
and	O
pain	O
catastrophizing	O
.	O

Caregivers	O
reported	O
on	O
socio-demographic	O
information	O
and	O
health	O
history	O
.	O

Psychometric	B-P
properties	O
of	O
the	O
pain	O
behavior	O
items	O
were	O
examined	O
using	O
an	O
item	O
response	O
theory	O
(	O
IRT	O
)	O
framework	O
with	O
confirmatory	O
factor	O
analysis	O
and	O
examination	O
of	O
differential	O
item	O
functioning	O
,	O
internal	O
consistency	O
,	O
and	O
test	O
information	O
curves	O
.	O

Results	O
were	O
used	O
,	O
along	O
with	O
expert	O
consensus	O
and	O
alignment	O
with	O
the	O
adult	O
PROMIS	O
pain	O
behavior	O
items	O
to	O
arrive	O
at	O
an	O
8-	O
item	O
pediatric	O
pain	O
behavior	O
short	O
form	O
,	O
and	O
all	O
47	O
items	O
were	O
retained	O
in	O
a	O
calibrated	O
item	O
bank	O
.	O

Confirmatory	O
factor	O
analysis	O
and	O
correlations	O
with	O
validated	O
measures	O
of	O
pain	O
,	O
pain	O
interference	O
,	O
and	O
psychosocial	O
functioning	O
provided	O
support	O
for	O
the	O
short	O
form	O
's	O
reliability	O
and	O
validity	O
.	O

The	O
new	O
PROMIS	O
pediatric	O
pain	O
behavior	O
scale	O
provides	O
a	O
reliable	O
,	O
precise	O
,	O
and	O
valid	O
measure	O
for	O
future	O
research	O
on	O
pain	O
behavior	O
in	O
school-age	O
children	O
with	O
chronic	O
pain	O
.	O

Reassembly	O
of	O
Excitable	O
Domains	O
after	O
CNS	O
Axon	O
Regeneration	O
.	O

Action	O
potential	O
initiation	O
and	O
propagation	O
in	O
myelinated	O
axons	O
require	O
ion	O
channel	O
clustering	O
at	O
axon	O
initial	O
segments	O
(	O
AIS	O
)	O
and	O
nodes	O
of	O
Ranvier	O
.	O

Disruption	O
of	O
these	O
domains	O
after	O
injury	O
impairs	O
nervous	O
system	O
function	O
.	O

Traditionally	O
,	O
injured	O
CNS	O
axons	O
are	O
considered	O
refractory	O
to	O
regeneration	O
,	O
but	O
some	O
recent	O
approaches	O
challenge	O
this	O
view	O
by	O
showing	O
robust	O
long-distance	O
regeneration	O
.	O

However	O
,	O
whether	O
these	O
approaches	O
allow	O
remyelination	O
and	O
promote	O
the	O
reestablishment	O
of	O
AIS	O
and	O
nodes	O
of	O
Ranvier	O
is	O
unknown	O
.	O

Using	O
mouse	O
optic	O
nerve	O
crush	O
as	O
a	O
model	O
for	O
CNS	O
traumatic	O
injury	O
,	O
we	O
performed	O
a	O
detailed	O
analysis	O
of	O
AIS	O
and	O
node	O
disruption	O
after	O
nerve	O
crush	O
.	O

We	O
found	O
significant	O
disruption	O
of	O
AIS	O
and	O
loss	O
of	O
nodes	O
within	O
days	O
of	O
the	O
crush	O
,	O
and	O
complete	O
loss	O
of	O
nodes	O
1	O
week	O
after	O
injury	O
.	O

Genetic	O
deletion	O
of	O
the	O
tumor	O
suppressor	O
phosphatase	O
and	O
tensin	O
homolog	O
(	O
Pten	O
)	O
in	O
retinal	O
ganglion	O
cells	O
(	O
RGCs	O
)	O
,	O
coupled	O
with	O
stimulation	O
of	O
RGCs	O
by	O
inflammation	O
and	O
cAMP	O
,	O
dramatically	O
enhanced	O
regeneration	O
.	O

With	O
this	O
treatmen	O
t	O
,	O
we	O
found	O
significant	O
reestablishment	O
of	O
RGC	O
AIS	O
,	O
remyelination	O
,	O
and	O
even	O
reassembly	O
of	O
nodes	O
in	O
regions	O
proximal	O
,	O
within	O
,	O
and	O
distal	O
to	O
the	O
crush	O
site	O
.	O

Remyelination	O
began	O
near	O
the	O
retina	O
,	O
progressed	O
distally	O
,	O
and	O
was	O
confirmed	O
by	O
electron	B-P
microscopy	I-P
.	O

Although	O
axons	O
grew	O
rapidly	O
,	O
remyelination	O
and	O
nodal	O
ion	O
channel	O
clustering	O
was	O
much	O
slower	O
.	O

Finally	O
,	O
genetic	O
deletion	O
of	O
ankyrinG	O
from	O
RGCs	O
to	O
block	O
AIS	O
reassembly	O
did	O
not	O
affect	O
axon	O
regeneration	O
,	O
indicating	O
that	O
preservation	O
of	O
neuronal	O
polarity	O
is	O
not	O
required	O
for	O
axon	O
regeneration	O
.	O

Together	O
,	O
our	O
results	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
regenerating	O
CNS	O
axons	O
can	O
be	O
remyelinated	O
and	O
reassemble	O
new	O
AIS	O
and	O
nodes	O
of	O
Ranvier	O
.	O

We	O
show	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
regenerated	O
CNS	O
axons	O
have	O
the	O
capacity	O
to	O
both	O
remyelinate	O
and	O
reassemble	O
the	O
axon	O
initial	O
segments	O
and	O
nodes	O
of	O
Ranvier	O
necessary	O
for	O
rapid	O
and	O
efficient	O
action	O
potential	O
propagation	O
.	O

New	O
sterols	O
with	O
anti-inflammatory	O
potentials	O
against	O
cyclooxygenase-2	O
and	O
5-lipoxygenase	O
from	O
Paphia	O
malabarica	O
.	O

Marine	O
bivalves	O
occupy	O
a	O
leading	O
share	O
in	O
the	O
total	O
edible	O
molluscs	O
at	O
the	O
coastline	O
regions	O
of	O
south-eastern	O
Asia	O
,	O
and	O
are	O
found	O
to	O
possess	O
significant	O
nutritional	O
and	O
biological	O
potential	O
.	O

Various	O
in	O
vitro	O
evaluation	O
(	O
antioxidant	O
and	O
anti-inflammatory	O
)	O
guided	O
purification	O
of	O
ethyl	O
acetate	O
-	O
methanol	O
(	O
EtOAc	O
-	O
MeOH	O
)	O
extract	O
of	O
bivalve	O
clam	O
,	O
Paphia	O
malabarica	O
characterised	O
two	O
new	O
sterol	O
derivatives	O
as	O
23-gem-dimethylcholesta-5-en-3β-ol	O
(	O
1	O
)	O
and	O
(	O
22E	O
)	O
-24	O
(	O
1	O
)	O
,24	O
(	O
2	O
)	O
-methyldihomocholest-5,22-dien-3β-ol	O
(	O
2	O
)	O
collected	O
from	O
the	O
south-west	O
coast	O
of	O
Arabian	O
Sea	O
.	O

Their	O
structures	O
were	O
unambiguously	O
assigned	O
on	O
the	O
basis	O
of	O
1D	B-P
,	O
2D	B-P
NMR	I-P
spectroscopy	I-P
and	O
mass	B-P
spectrometry	I-P
.	O

The	O
antioxidant	O
and	O
anti-inflammatory	O
activities	O
of	O
2	O
as	O
determined	O
by	O
DPPH	O
/	O
ABTS	O
(	O
+	O
)	O
radical	O
scavenging	O
and	O
anti-	O
cyclooxygenase-2	O
/	O
5-lipoxygenase	O
assays	B-P
were	O
significantly	O
greater	O
(	O
IC50	O
<	O
1	O
mg/mL	O
)	O
than	O
1	O
(	O
IC50	O
>	O
1	O
mg/mL	O
)	O
.	O

Structure-activity	O
relationship	O
analysis	O
revealed	O
that	O
the	O
bioactivities	O
of	O
these	O
compounds	O
were	O
directly	O
proportional	O
to	O
the	O
electronic	O
and	O
lipophilic	O
parameters	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
occurrence	O
and	O
characterisation	O
of	O
23-gem-dimethyl-3β-hydroxy-Δ	O
(	O
5	O
)	O
-cholestane	O
nucleus	O
and	O
C-30	O
dihomosterol	O
from	O
marine	O
organisms	O
.	O

Lipid	O
digestibility	O
and	O
energy	O
content	O
of	O
distillers	O
'	O
corn	O
oil	O
in	O
swine	O
and	O
poultry	O
.	O

Two	O
experiments	O
were	O
conducted	O
to	O
determine	O
the	O
DE	O
and	O
ME	O
and	O
apparent	O
total	O
tract	O
digestibility	O
of	O
ether	O
extract	O
of	O
3	O
distillers	O
'	O
corn	O
oil	O
(	O
DCO	O
;	O
4.9	O
,	O
12.8	O
,	O
or	O
13.9	O
%	O
free	O
fatty	O
acids	O
[	O
FFA	O
]	O
)	O
samplescompared	O
with	O
a	O
sample	O
of	O
refined	O
corn	O
oil	O
(	O
CO	O
;	O
0.04	O
%	O
FFA	O
)	O
and	O
an	O
industrially	O
hydrolyzed	O
high-FFA	O
DCO	O
(	O
93.8	O
%	O
FFA	O
)	O
in	O
young	O
pigs	O
and	O
growing	O
broilers	O
.	O

In	O
Exp	O
.	O

1	O
,	O
54	O
barrows	O
(	O
initial	O
age	O
=	O
28	O
d	O
)	O
were	O
fed	O
a	O
common	O
diet	O
for	O
7	O
d	O
and	O
then	O
fed	O
their	O
allotted	O
dietary	O
treatment	O
(	O
either	O
100	O
%	O
basal	O
diet	O
or	O
1	O
of	O
5	O
test	O
diets	O
consisting	O
of	O
90	O
%	O
basal	O
diet	O
plus	O
10	O
%	O
test	O
lipid	O
)	O
for	O
the	O
next	O
7	O
d	O
in	O
group	O
pens	O
(	O
9	O
pigs	O
/	O
pen	O
)	O
.	O

For	O
the	O
next	O
10	O
d	O
,	O
pigs	O
were	O
moved	O
to	O
individual	O
metabolism	O
crates	O
for	O
continued	O
diet	O
and	O
crate	O
adaptation	O
and	O
to	O
a	O
twice-daily	O
feeding	O
regimen	O
.	O

Pigs	O
remained	O
on	O
their	O
respective	O
diets	O
for	O
a	O
4-d	O
total	O
fecal	O
and	O
urine	B-P
collection	I-P
period	O
.	O

For	O
Exp	O
.	O

2	O
,	O
567	O
male	O
broilers	O
were	O
obtained	O
from	O
a	O
commercial	O
hatchery	O
(	O
1	O
d	O
of	O
age	O
)	O
and	O
reared	O
in	O
grower	O
battery	O
cages	O
that	O
contained	O
9	O
chicks	O
per	O
cage	O
.	O

Broilers	O
were	O
fed	O
a	O
common	O
corn	O
-	O
soybean	O
meal	O
starter	O
diet	O
from	O
placement	O
until	O
the	O
beginning	O
of	O
the	O
trial	O
(	O
19	O
d	O
of	O
age	O
)	O
.	O

Birds	O
were	O
then	O
randomly	O
assigned	O
to	O
1	O
of	O
6	O
dietary	O
treatments	O
(	O
94	O
%	O
basal	O
diet	O
plus	O
6	O
%	O
dextrose	O
or	O
94	O
%	O
basal	O
diet	O
plus	O
6	O
%	O
test	O
lipid	O
substituted	O
for	O
dextrose	O
)	O
on	O
d	O
19	O
and	O
were	O
allowed	O
an	O
8-d	O
dietary	O
acclimation	O
period	O
followed	O
by	O
a	O
48-h	O
energy	B-P
balance	I-P
assay	I-P
.	O

In	O
Exp	O
.	O

1	O
,	O
the	O
DCO	O
sample	O
with	O
12.8	O
%	O
FFA	O
contained	O
the	O
lowest	O
(	O
<	O
0.05	O
)	O
DE	O
(	O
8,036	O
kcal/kg	O
)	O
content	O
compared	O
with	O
the	O
0.04	O
%	O
refined	O
CO	O
sample	O
and	O
the	O
4.9	O
or	O
93.8	O
%	O
FFA	O
DCO	O
samples	O
(	O
8,814	O
,	O
8,828	O
,	O
and	O
8,921	O
kcal/kg	O
,	O
respectively	O
)	O
,	O
with	O
the	O
DCO	O
source	O
containing	O
13.9	O
%	O
FFA	O
having	O
intermediate	O
DE	O
(	O
8,465	O
kcal/kg	O
)	O
content	O
.	O

The	O
ME	O
content	O
of	O
these	O
lipid	O
sources	O
also	O
differed	O
among	O
treatments	O
(	O
<	O
0.01	O
)	O
,	O
following	O
trends	O
similar	O
to	O
their	O
DE	O
values	O
,	O
with	O
no	O
differences	O
noted	O
for	O
ME	O
as	O
a	O
percentage	O
of	O
DE	O
(	O
>	O
0.35	O
)	O
content	O
among	O
the	O
lipids	O
evaluated	O
.	O

In	O
Exp	O
.	O

2	O
,	O
lipids	O
containing	O
0.04	O
,	O
4.9	O
,	O
12.8	O
,	O
and	O
13.9	O
%	O
FFA	O
had	O
similar	O
nitrogen	O
corrected	O
apparent	O
ME	O
(	O
AME	O
)	O
values	O
(	O
8,072	O
,	O
7,936	O
,	O
8,036	O
,	O
and	O
7,694	O
respectively	O
)	O
,	O
except	O
for	O
the	O
industrially	O
hydrolyzed	O
DCO	O
sample	O
containing	O
93.8	O
%	O
FFA	O
,	O
which	O
contained	O
6,276	O
kcal/kg	O
(	O
<	O
0.01	O
)	O
.	O

Using	O
published	O
prediction	O
equations	O
,	O
the	O
predicted	O
DE	O
of	O
these	O
lipids	O
for	O
swine	O
was	O
3.5	O
%	O
greater	O
than	O
the	O
values	O
determined	O
in	O
Exp	O
.	O

1	O
for	O
all	O
lipid	O
sources	O
,	O
except	O
for	O
the	O
DCO	O
sample	O
containing	O
93.8	O
%	O
FFA	O
,	O
which	O
the	O
predicted	O
DE	O
was	O
underestimated	O
.	O

Likewise	O
,	O
the	O
predicted	O
AME	O
of	O
these	O
lipids	O
for	O
broilers	O
was	O
7.4	O
%	O
greater	O
than	O
the	O
determined	O
AMEn	O
(	O
Exp	O
.	O

2	O
)	O
for	O
all	O
lipid	O
sources	O
.	O

Antibacterial	O
Effect	O
of	O
Calcium	O
Hydroxide	O
With	O
or	O
Without	O
Chlorhexidine	O
as	O
Intracanal	O
Dressing	O
in	O
Primary	O
Teeth	O
With	O
Apical	O
Periodontitis	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
in	O
vivo	O
the	O
antibacterial	O
effect	O
of	O
calcium	O
hydroxide	O
(	O
CH	O
)	O
dressings	O
,	O
with	O
or	O
without	O
chlorhexidine	O
(	O
CHX	O
)	O
,	O
on	O
human	O
primary	O
teeth	O
with	O
apical	O
periodontitis	O
.	O

Forty	O
root	O
canals	O
in	O
40	O
children	O
were	O
selected	O
.	O

A	O
first	O
microbiological	O
sample	O
was	O
obtained	O
after	O
coronal	O
opening	O
,	O
and	O
the	O
teeth	O
were	O
randomly	O
assigned	O
to	O
Group	O
1	O
(	O
root	O
canals	O
filled	O
with	O
CH	O
paste	O
)	O
and	O
Group	O
2	O
(	O
CH	O
paste	O
plus	O
1.0	O
percent	O
CHX	O
)	O
.	O

After	O
30	O
days	O
,	O
the	O
dressing	O
was	O
removed	O
and	O
the	O
canals	O
were	O
allowed	O
to	O
remain	O
empty	O
for	O
72	O
hours	O
.	O

Subsequently	O
,	O
the	O
second	O
microbiological	O
sample	O
was	O
collected	O
.	O

After	O
performing	O
microbiological	B-P
tests	I-P
,	O
the	O
data	O
were	O
subjected	O
to	O
statistical	O
analysis	O
to	O
compare	O
the	O
two	O
CH	O
dressings	O
regarding	O
reducing	O
the	O
absolute	O
levels	O
of	O
microorganisms	O
and	O
with	O
respect	O
to	O
total	O
microbial	O
elimination	O
.	O

All	O
analyses	O
were	O
performed	O
with	O
a	O
significance	O
level	O
of	O
five	O
percent	O
.	O

Both	O
CH	O
dressings	O
provided	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
microorganisms	O
(	O
anaerobic	O
,	O
aerobic	O
,	O
black-pigmented	O
bacilli	O
,	O
streptococci	O
and	O
Streptococcus	O
mutans	O
)	O
in	O
a	O
similar	O
way	O
(	O
P	O
>	O
0.05	O
)	O
.	O

However	O
,	O
in	O
terms	O
of	O
complete	O
elimination	O
of	O
microbiota	O
,	O
CH	O
paste	O
alone	O
exhibited	O
greater	O
efficacy	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
addition	O
of	O
chlorhexidine	O
did	O
not	O
provide	O
additional	O
antimicrobial	O
benefits	O
compared	O
with	O
pure	O
calcium	O
hydroxide	O
paste	O
as	O
an	O
intracanal	O
dressing	O
in	O
primary	O
teeth	O
with	O
apical	O
periodontitis	O
.	O

Double-Network	O
Hydrogel	O
with	O
Tunable	O
Mechanical	O
Performance	O
and	O
Biocompatibility	O
for	O
the	O
Fabrication	O
of	O
Stem	O
Cells	O
-	O
Encapsulated	O
Fibers	O
and	O
3D	O
Assemble	O
.	O

Fabrication	O
of	O
cell	O
-	O
encapsulated	O
fibers	O
could	O
greatly	O
contribute	O
to	O
tissue	O
engineering	O
and	O
regenerative	O
medicine	O
.	O

However	O
,	O
existing	O
methods	O
suffered	O
from	O
not	O
only	O
unavoidability	O
of	O
cell	O
damaging	O
conditions	O
and/or	O
sophisticated	O
equipment	O
,	O
but	O
also	O
unavailability	O
of	O
proper	O
materials	O
to	O
satisfy	O
both	O
mechanical	O
and	O
biological	O
expectations	O
.	O

In	O
this	O
work	O
,	O
a	O
simple	O
method	O
is	O
proposed	O
to	O
prepare	O
cell	O
-	O
encapsulated	O
fibers	O
with	O
tunable	O
mechanical	O
strength	O
and	O
stretching	O
behavior	O
as	O
well	O
as	O
diameter	O
and	O
microstructure	O
.	O

The	O
hydrogel	O
fibers	O
are	O
made	O
from	O
optimal	O
combination	O
of	O
alginate	O
and	O
poly	O
(	O
N-iso-propylacrylamide	O
)	O
-poly	O
(	O
ethylene	O
glycol	O
)	O
,	O
characteristics	O
of	O
double-network	O
hydrogel	O
,	O
with	O
enough	O
stiffness	O
and	O
flexibility	O
to	O
create	O
a	O
variety	O
of	O
three	O
dimensional	O
structures	O
like	O
parallel	O
helical	O
and	O
different	O
knots	O
without	O
crack	O
.	O

Furthermore	O
,	O
such	O
hydrogel	O
fibers	O
exhibit	O
better	O
compatibility	O
as	O
indicated	O
by	O
the	O
viability	O
,	O
proliferation	O
and	O
expression	O
of	O
pluripotency	O
markers	O
of	O
embryonic	O
stem	O
cells	O
encapsulated	O
after	O
4-day	O
culture	B-P
.	O

The	O
double-network	O
hydrogel	O
possesses	O
specific	O
quick	O
responses	O
to	O
either	O
of	O
alginate	O
lyase	O
,	O
EDTA	O
or	O
lower	O
environmental	O
temperature	O
which	O
facilitate	O
the	O
optional	O
degradation	O
of	O
fibers	O
or	O
fibrous	O
assemblies	O
to	O
release	O
the	O
cells	O
encapsulated	O
for	O
subsequent	O
assay	B-P
or	O
treatment	O
.	O

The	O
Chinese	O
Herbal	O
Mixture	O
Tien-Hsien	O
Liquid	O
Augments	O
the	O
Anticancer	O
Immunity	O
in	O
Tumor	O
Cell	O
-	O
Vaccinated	O
Mice	O
.	O

Background	O
The	O
Chinese	O
herbal	O
mixture	O
,	O
Tien-Hsien	O
liquid	O
(	O
THL	O
)	O
,	O
has	O
been	O
used	O
as	O
an	O
anticancer	O
dietary	O
supplement	O
for	O
more	O
than	O
20	O
years	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
THL	O
can	O
modulate	O
immune	O
response	O
and	O
inhibit	O
tumor	O
growth	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
evaluated	O
the	O
effect	O
of	O
THL	O
on	O
anticancer	O
immune	O
response	O
in	O
mice	O
vaccinated	O
with	O
γ-ray	O
-	O
irradiated	O
tumor	O
cells	O
.	O

Methods	O
The	O
antitumor	O
effect	O
of	O
THL	O
was	O
determined	O
in	O
mice	O
vaccinated	O
with	O
low-tumorigenic	O
CT-26-low	O
colon	O
cancer	O
cells	O
or	O
γ-ray-irradiated	O
high-tumorigenic	O
CT-26-high	O
colon	O
cancer	O
cells	O
.	O

The	O
number	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
T	O
lymphocytes	O
in	O
the	O
spleen	O
was	O
analyzed	O
by	O
flow	B-P
cytometry	I-P
.	O

The	O
tumor	O
-	O
killing	O
activities	O
of	O
NK	O
cells	O
and	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
were	O
analyzed	O
by	O
flow	B-P
cytometry	I-P
using	O
YAC-1	O
and	O
CT-26-high	O
cells	O
,	O
respectively	O
,	O
as	O
target	O
cells	O
.	O

The	O
levels	O
of	O
IFN-γ	O
,	O
IL-2	O
,	O
and	O
TNF-α	O
were	O
determined	O
by	O
ELISA	B-P
.	O

Results	O
THL	O
suppressed	O
the	O
growth	O
of	O
CT-26-high	O
tumor	O
in	O
mice	O
previously	O
vaccinated	O
with	O
low-tumorigenic	O
CT-26-low	O
cells	O
or	O
γ-irradiated	O
CT-26-high	O
cells	O
.	O

THL	O
increased	O
the	O
populations	O
of	O
NK	O
cells	O
and	O
CD4+	O
T	O
lymphocytes	O
in	O
the	O
spleen	O
and	O
enhanced	O
the	O
tumor	O
-	O
killing	O
activities	O
of	O
NK	O
cells	O
and	O
CTL	O
in	O
mice	O
vaccinated	O
with	O
γ-irradiated	O
CT-26-high	O
cells	O
.	O

THL	O
increased	O
the	O
production	O
of	O
IFN-γ	O
,	O
IL-2	O
,	O
and	O
TNF-α	O
in	O
mice	O
vaccinated	O
with	O
γ-irradiated	O
CT-26-high	O
cells	O
.	O

Conclusion	O
THL	O
can	O
enhance	O
the	O
antitumor	O
immune	O
responses	O
in	O
mice	O
vaccinated	O
with	O
killed	O
tumor	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
THL	O
may	O
be	O
used	O
as	O
a	O
complementary	O
medicine	O
for	O
cancer	O
patients	O
previously	O
treated	O
with	O
killed	O
tumor	O
cell	O
vaccines	O
,	O
radiotherapy	O
,	O
or	O
chemotherapy	O
.	O

Utility	O
of	O
Post-Mortem	B-P
Genetic	O
Testing	O
in	O
Cases	O
of	O
Sudden	O
Arrhythmic	O
Death	O
Syndrome	O
.	O

Sudden	O
arrhythmic	O
death	O
syndrome	O
(	O
SADS	O
)	O
describes	O
a	O
sudden	O
death	O
with	O
negative	O
autopsy	B-P
and	O
toxicological	O
analysis	O
.	O

Cardiac	O
genetic	O
disease	O
is	O
a	O
likely	O
etiology	O
.	O

This	O
study	O
investigated	O
the	O
clinical	O
utility	O
and	O
combined	O
yield	O
of	O
post-mortem	B-P
genetic	O
testing	O
(	O
molecular	B-P
autopsy	I-P
)	O
in	O
cases	O
of	O
SADS	O
and	O
comprehensive	O
clinical	O
evaluation	O
of	O
surviving	O
relatives	O
.	O

We	O
evaluated	O
302	O
expertly	O
validated	O
SADS	O
cases	O
with	O
suitable	O
DNA	O
(	O
median	O
age	O
:	O
24	O
years	O
;	O
65	O
%	O
males	O
)	O
who	O
underwent	O
next-generation	O
sequencing	B-P
using	O
an	O
extended	O
panel	O
of	O
77	O
primary	O
electrical	O
disorder	O
and	O
cardiomyopathy	O
genes	O
.	O

Pathogenic	O
and	O
likely	O
pathogenic	O
variants	O
were	O
classified	O
using	O
American	O
College	O
of	O
Medical	O
Genetics	O
(	O
ACMG	O
)	O
consensus	O
guidelines	O
.	O

The	O
yield	O
of	O
combined	O
molecular	B-P
autopsy	I-P
and	O
clinical	O
evaluation	O
in	O
82	O
surviving	O
families	O
was	O
evaluated	O
.	O

A	O
gene-level	O
rare	O
variant	O
association	O
analysis	O
was	O
conducted	O
in	O
SADS	O
cases	O
versus	O
controls	O
.	O

A	O
clinically	O
actionable	O
pathogenic	O
or	O
likely	O
pathogenic	O
variant	O
was	O
identified	O
in	O
40	O
of	O
302	O
cases	O
(	O
13	O
%	O
)	O
.	O

The	O
main	O
etiologies	O
established	O
were	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia	O
and	O
long	O
QT	O
syndrome	O
(	O
17	O
[	O
6	O
%	O
]	O
and	O
11	O
[	O
4	O
%	O
]	O
,	O
respectively	O
)	O
.	O

Gene-based	O
rare	O
variants	O
association	O
analysis	O
showed	O
enrichment	O
of	O
rare	O
predicted	O
deleterious	O
variants	O
in	O
RYR2	O
(	O
p	O
=	O
5	O
×	O
10	O
(	O
-5	O
)	O
)	O
.	O

Combining	O
molecular	B-P
autopsy	I-P
with	O
clinical	O
evaluation	O
in	O
surviving	O
families	O
increased	O
diagnostic	O
yield	O
from	O
26	O
%	O
to	O
39	O
%	O
.	O

Molecular	B-P
autopsy	I-P
for	O
electrical	O
disorder	O
and	O
cardiomyopathy	O
genes	O
,	O
using	O
ACMG	O
guidelines	O
for	O
variant	O
classification	O
,	O
identified	O
a	O
modest	O
but	O
realistic	O
yield	O
in	O
SADS	O
.	O

Our	O
data	O
highlighted	O
the	O
predominant	O
role	O
of	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia	O
and	O
long	O
QT	O
syndrome	O
,	O
especially	O
the	O
RYR2	O
gene	O
,	O
as	O
well	O
as	O
the	O
minimal	O
yield	O
from	O
other	O
genes	O
.	O

Furthermore	O
,	O
we	O
showed	O
the	O
enhanced	O
utility	O
of	O
combined	O
clinical	O
and	O
genetic	O
evaluation	O
.	O

Biogeography	O
and	O
taxonomy	O
of	O
racket-tail	O
hummingbirds	O
(	O
Aves	O
:	O
Trochilidae	O
:	O
<	O
i	O
>	O
Ocreatus	O
<	O
/i	O
>	O
)	O
:	O
evidence	O
for	O
species	O
delimitation	O
from	O
morphology	O
and	O
display	O
behavior	O
.	O

We	O
analyzed	O
geographic	O
variation	O
,	O
biogeography	O
,	O
and	O
intrageneric	O
relationships	O
of	O
racket-tail	O
hummingbirds	O
Ocreatus	O
(	O
Aves	O
,	O
Trochilidae	O
)	O
.	O

Presently	O
,	O
the	O
genus	O
is	O
usually	O
considered	O
monospecific	O
,	O
with	O
O.	O
underwoodii	O
including	O
eight	O
subspecies	O
(	O
polystictus	O
,	O
discifer	O
,	O
underwoodii	O
,	O
incommodus	O
,	O
melanantherus	O
,	O
peruanus	O
,	O
annae	O
,	O
addae	O
)	O
,	O
although	O
up	O
to	O
three	O
species	O
have	O
been	O
recognized	O
by	O
some	O
authors	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
current	O
taxonomy	O
we	O
studied	O
geographic	O
variation	O
in	O
coloration	O
,	O
mensural	O
characters	O
,	O
and	O
behavioral	O
data	O
of	O
all	O
Ocreatus	O
taxa	O
.	O

We	O
briefly	O
review	O
the	O
taxonomic	O
history	O
of	O
the	O
genus	O
.	O

Applying	O
the	O
Biological	O
Species	O
Concept	O
,	O
species	O
delimitation	O
was	O
based	O
on	O
a	O
qualitative	O
-	O
quantitative	O
criteria	O
analysis	O
including	O
an	O
evaluation	O
of	O
character	O
states	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
genus	O
should	O
be	O
considered	O
a	O
superspecies	O
with	O
four	O
species	O
,	O
the	O
monotypic	O
Ocreatus	O
addae	O
,	O
O.	O
annae	O
,	O
and	O
O.	O
peruanus	O
,	O
and	O
the	O
polytypic	O
O.	O
underwoodii	O
(	O
including	O
the	O
subspecies	O
underwoodii	O
,	O
discifer	O
,	O
incommodus	O
,	O
melanantherus	O
,	O
polystictus	O
)	O
.	O

In	O
this	O
taxonomic	O
treatment	O
,	O
O.	O
annae	O
becomes	O
an	O
endemic	O
species	O
to	O
Peru	O
and	O
O.	O
addae	O
is	O
endemic	O
to	O
Bolivia	O
.	O

We	O
recommend	O
additional	O
sampling	B-P
of	O
distributional	O
,	O
ethological	O
,	O
and	O
molecular	O
data	O
for	O
an	O
improved	O
resolution	O
of	O
the	O
evolutionary	O
history	O
of	O
Ocreatus	O
.	O

Environmental	O
fate	O
and	O
effects	O
of	O
novel	O
quorum	O
sensing	O
inhibitors	O
that	O
can	O
control	O
biofilm	O
formation	O
.	O

The	O
formation	O
of	O
bacterial	O
biofilms	O
can	O
have	O
negative	O
impacts	O
on	O
industrial	O
processes	O
and	O
are	O
typically	O
difficult	O
to	O
control	O
.	O

The	O
increase	O
of	O
antibiotic	O
resistance	O
,	O
in	O
combination	O
with	O
the	O
requirement	O
for	O
more	O
environmentally	O
focused	O
approaches	O
,	O
has	O
placed	O
pressure	O
on	O
industry	O
and	O
the	O
scientific	O
community	O
to	O
reassess	O
biofilm	O
control	O
strategies	O
.	O

The	O
discovery	O
of	O
bacterial	O
quorum	O
sensing	O
,	O
as	O
an	O
important	O
mechanism	O
in	O
biofilm	O
formation	O
,	O
has	O
led	O
to	O
the	O
development	O
of	O
new	O
substances	O
(	O
such	O
as	O
halogenated	O
thiophenones	O
)	O
to	O
inhibit	O
the	O
quorum	O
sensing	O
process	O
.	O

However	O
,	O
there	O
are	O
currently	O
limited	O
data	O
regarding	O
the	O
biodegradability	O
or	O
ecotoxicity	O
of	O
these	O
substances	O
.	O

To	O
assess	O
the	O
environmental	O
fate	O
and	O
effects	O
of	O
thiophenones	O
capable	O
of	O
quorum	O
sensing	O
inhibition	O
,	O
candidate	O
substances	O
were	O
first	O
identified	O
that	O
have	O
potentially	O
high	O
biodegradability	O
and	O
low	O
ecotoxicity	O
using	O
quantitative	O
structure	O
activity	O
relationships	O
.	O

Subsequent	O
confirmatory	O
hazard	O
assessment	O
of	O
these	O
substances	O
,	O
using	O
a	O
marine	O
alga	O
and	O
a	O
marine	O
crustacean	O
,	O
indicated	O
that	O
these	O
estimates	O
were	O
significantly	O
under	O
predicted	O
with	O
acute	B-P
toxicity	I-P
values	O
more	O
than	O
three	O
orders	O
of	O
magnitude	O
lower	O
than	O
anticipated	O
combined	O
with	O
limited	O
biodegradability	O
.	O

Therefore	O
,	O
although	O
these	O
quorum	O
sensing	O
inhibitors	O
appear	O
a	O
promising	O
approach	O
to	O
control	O
biofilms	O
,	O
they	O
may	O
also	O
have	O
environmental	O
impacts	O
on	O
certain	O
aquatic	O
organisms	O
.	O

Quantification	O
of	O
apigenin	O
trimethyl	O
ether	O
in	O
rat	O
plasma	O
by	O
liquid	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
:	O
Application	O
to	O
a	O
pre-clinical	O
pharmacokinetic	O
study	O
.	O

Apigenin	O
trimethyl	O
ether	O
(	O
5,7,4'-trimethoxyflavone	O
,	O
ATE	O
)	O
is	O
a	O
naturally	O
occurring	O
polymethoxyflavone	O
with	O
a	O
wide	O
range	O
of	O
health-promoting	O
activities	O
.	O

In	O
this	O
study	O
,	O
a	O
sensitive	O
liquid	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
(	O
LC-MS/MS	B-P
)	O
method	O
was	O
developed	O
and	O
validated	O
for	O
the	O
quantification	O
of	O
ATE	O
in	O
rat	O
plasma	O
.	O

Protein	B-P
precipitation	I-P
was	O
applied	O
as	O
plasma	O
clean-up	O
procedure	O
;	O
the	O
electrospray	B-P
ionization	I-P
was	O
operated	O
in	O
its	O
positive	O
ion	O
mode	O
while	O
ATE	O
and	O
formononetin	O
(	O
internal	O
standard	O
)	O
were	O
measured	O
by	O
multiple	O
reactions	O
monitoring	O
(	O
ATE	O
:	O
m/z	O
313.1→298.1	O
;	O
formononetin	O
:	O
269.2→213.3	O
)	O
.	O

This	O
LC-MS/MS	B-P
method	I-P
displayed	O
good	O
selectivity	O
,	O
sensitivity	O
(	O
lower	O
limit	O
of	O
quantification	O
=2.5ng/ml	O
)	O
,	O
accuracy	O
(	O
both	O
intra-	O
and	O
inter-day	O
analytical	O
recovery	O
within	O
100±10	O
%	O
)	O
and	O
precision	O
(	O
both	O
intra-	O
and	O
inter-day	O
RSD	O
<	O
10	O
%	O
)	O
.	O

The	O
matrix	O
effect	O
was	O
found	O
to	O
be	O
insignificant	O
.	O

The	O
pharmacokinetic	O
profiles	O
of	O
ATE	O
were	O
subsequently	O
examined	O
in	O
Sprague-Dawley	O
rats	O
after	O
single	O
oral	O
administration	O
(	O
10mg/kg	O
)	O
.	O

When	O
given	O
in	O
an	O
aqueous	O
suspension	O
,	O
ATE	O
was	O
slowly	O
absorbed	O
with	O
quite	O
low	O
plasma	O
exposure	O
(	O
AUC	O
)	O
.	O

Fasting	O
further	O
attenuated	O
its	O
oral	O
absorption	O
and	O
led	O
to	O
∼70	O
%	O
drops	O
in	O
average	O
maximal	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
and	O
AUC	O
.	O

When	O
dosed	O
in	O
a	O
solution	O
formulated	O
with	O
2-hydroxypropyl-β-cyclodextrin	O
,	O
the	O
oral	O
absorption	O
of	O
ATE	O
was	O
substantially	O
improved	O
with	O
∼500	O
%	O
increases	O
in	O
average	O
Cmax	O
and	O
AUC	O
.	O

Clearly	O
,	O
aqueous	O
solubility	O
has	O
been	O
identified	O
as	O
a	O
barrier	O
to	O
the	O
oral	O
absorption	O
of	O
ATE	O
.	O

The	O
information	O
obtained	O
from	O
this	O
study	O
will	O
facilitate	O
further	O
medicinal	O
exploration	O
on	O
ATE	O
.	O

The	O
``	O
tight	O
orbit	O
''	O
:	O
Incidence	O
and	O
management	O
of	O
the	O
orbital	O
compartment	O
syndrome	O
.	O

The	O
orbital	O
compartment	O
syndrome	O
(	O
OCS	O
)	O
constitutes	O
a	O
severe	O
emergency	O
,	O
requiring	O
immediate	O
clinical	B-P
diagnosis	I-P
and	O
surgical	O
decompression	O
.	O

The	O
key	O
symptom	O
is	O
progressive	O
visual	O
impairment	O
caused	O
by	O
an	O
increase	O
in	O
intraorbital	O
pressure	O
,	O
impairing	O
the	O
perfusion	O
of	O
relevant	O
neurovascular	O
and	O
neurosensory	O
structures	O
.	O

Intraorbital	O
bleeding	O
due	O
to	O
trauma	O
and	O
surgical	O
intervention	O
is	O
known	O
to	O
be	O
the	O
main	O
etiological	O
factor	O
.	O

A	O
retrospective	O
analysis	O
of	O
all	O
patients	O
affected	O
by	O
an	O
OCS	O
between	O
January	O
1	O
,	O
2012	O
,	O
and	O
May	O
31	O
,	O
2015	O
,	O
was	O
performed	O
.	O

Patients	O
'	O
records	O
were	O
reviewed	O
with	O
regard	O
to	O
etiology	O
,	O
initial	O
ophthalmologic	O
status	O
,	O
fracture	O
pattern	O
,	O
concomitant	O
medication	O
,	O
surgical	O
management	O
,	O
and	O
postoperative	O
outcome	O
.	O

The	O
incidence	O
of	O
OCS	O
was	O
calculated	O
based	O
on	O
the	O
total	O
number	O
of	O
craniomaxillofacial	O
(	O
CMF	O
)	O
emergencies	O
.	O

Within	O
3.5	O
years	O
,	O
a	O
total	O
of	O
18,093	O
CMF	O
emergencies	O
were	O
registered	O
.	O

In	O
16	O
patients	O
,	O
an	O
OCS	O
was	O
documented	O
,	O
corresponding	O
to	O
an	O
incidence	O
of	O
0.088	O
%	O
.	O

The	O
mean	O
patient	O
age	O
was	O
67.31	O
±	O
23.86	O
years	O
,	O
ranging	O
from	O
22	O
to	O
102	O
years	O
.	O

The	O
etiology	O
varied	O
,	O
but	O
trauma	O
with	O
subsequent	O
intraorbital	O
bleeding	O
was	O
the	O
main	O
cause	O
.	O

The	O
use	O
of	O
anticoagulative	O
medication	O
was	O
documented	O
in	O
50	O
%	O
of	O
the	O
cases	O
.	O

In	O
14	O
patients	O
,	O
immediate	O
surgical	O
orbital	O
decompression	O
was	O
performed	O
:	O
in	O
10	O
patients	O
,	O
vision	O
could	O
be	O
preserved	B-P
;	O
in	O
three	O
patients	O
,	O
blindness	O
resulted	O
;	O
and	O
one	O
patient	O
was	O
lost	O
to	O
follow-up	O
.	O

Two	O
patients	O
were	O
managed	O
without	O
surgery	O
.	O

With	O
regard	O
to	O
the	O
total	O
number	O
of	O
CMF	O
emergencies	O
,	O
OCS	O
is	O
a	O
rare	O
condition	O
.	O

Early	O
clinical	B-P
diagnosis	I-P
and	O
surgical	O
decompression	O
are	O
required	O
to	O
prevent	O
permanent	O
vision	O
impairment	O
.	O

Anticoagulative	O
medication	O
must	O
be	O
considered	O
as	O
a	O
predisposing	O
factor	O
for	O
an	O
orbital	O
compartment	O
syndrome	O
in	O
patients	O
affected	O
by	O
periorbital	O
trauma	O
.	O

Metagenomic	O
recovery	O
of	O
phage	O
genomes	O
of	O
uncultured	O
freshwater	O
actinobacteria	O
.	O

Low	O
-	O
GC	O
Actinobacteria	O
are	O
among	O
the	O
most	O
abundant	O
and	O
widespread	O
microbes	O
in	O
freshwaters	O
and	O
have	O
largely	O
resisted	O
all	O
cultivation	B-P
efforts	O
.	O

Consequently	O
,	O
their	O
phages	O
have	O
remained	O
totally	O
unknown	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
used	O
deep	O
metagenomic	O
sequencing	O
to	O
assemble	O
eight	O
complete	O
genomes	O
of	O
the	O
first	O
tailed	O
phages	O
that	O
infect	O
freshwater	O
Actinobacteria	O
.	O

Their	O
genomes	O
encode	O
the	O
actinobacterial	O
-	O
specific	O
transcription	O
factor	O
whiB	O
,	O
frequently	O
found	O
in	O
mycobacteriophages	O
and	O
also	O
in	O
phages	O
infecting	O
marine	O
pelagic	O
Actinobacteria	O
.	O

Its	O
presence	O
suggests	O
a	O
common	O
and	O
widespread	O
strategy	O
of	O
modulation	O
of	O
host	O
transcriptional	O
machinery	O
upon	O
infection	O
via	O
this	O
transcriptional	O
switch	O
.	O

We	O
present	O
evidence	O
that	O
some	O
whiB	O
-	O
carrying	O
phages	O
infect	O
the	O
acI	O
lineage	O
of	O
Actinobacteria	O
.	O

At	O
least	O
one	O
of	O
them	O
encodes	O
the	O
ADP-ribosylating	O
component	O
of	O
the	O
widespread	O
bacterial	O
AB	O
toxins	O
family	O
(	O
for	O
example	O
,	O
clostridial	O
toxin	O
)	O
.	O

We	O
posit	O
that	O
the	O
presence	O
of	O
this	O
toxin	O
reflects	O
a	O
'trojan	O
horse	O
'	O
strategy	O
,	O
providing	O
protection	O
at	O
the	O
population	O
level	O
to	O
the	O
abundant	O
host	O
microbes	O
against	O
eukaryotic	O
predators	O
.	O

ACR	O
Appropriateness	O
Criteria	O
(	O
®	O
)	O
Radiologic	O
Management	O
of	O
Mesenteric	O
Ischemia	O
.	O

Mesenteric	O
vascular	O
insufficiency	O
is	O
a	O
serious	O
medical	O
condition	O
that	O
may	O
lead	O
to	O
bowel	O
infarction	O
,	O
morbidity	O
,	O
and	O
mortality	O
that	O
may	O
approach	O
50	O
%	O
.	O

Recommended	O
therapy	O
for	O
acute	O
mesenteric	O
ischemia	O
includes	O
aspiration	O
embolectomy	O
,	O
transcatheter	O
thrombolysis	O
,	O
and	O
angioplasty	O
with	O
or	O
without	O
stenting	O
for	O
the	O
treatment	O
of	O
underlying	O
arterial	O
stenosis	O
.	O

Nonocclusive	O
mesenteric	O
ischemia	O
may	O
respond	O
to	O
transarterial	O
infusion	O
of	O
vasodilators	O
such	O
as	O
nitroglycerin	O
,	O
papaverine	O
,	O
glucagon	O
,	O
and	O
prostaglandin	O
E1	O
.	O

Recommended	O
therapy	O
for	O
chronic	O
mesenteric	O
ischemia	O
includes	O
angioplasty	O
with	O
or	O
without	O
stent	O
placement	O
and	O
,	O
if	O
an	O
endovascular	O
approach	O
is	O
not	O
possible	O
,	O
surgical	O
bypass	O
or	O
endarterectomy	O
.	O

The	O
diagnosis	O
of	O
median	O
arcuate	O
ligament	O
syndrome	O
is	O
controversial	O
,	O
but	O
surgical	O
release	O
may	O
be	O
appropriate	O
depending	O
on	O
the	O
clinical	O
situation	O
.	O

Venous	O
mesenteric	O
ischemia	O
may	O
respond	O
to	O
systemic	O
anticoagulation	O
alone	O
.	O

Transhepatic	O
or	O
transjugular	O
superior	O
mesenteric	O
vein	O
catheterization	B-P
and	I-P
thrombolytic	I-P
infusion	I-P
can	O
be	O
offered	O
depending	O
on	O
the	O
severity	O
of	O
symptoms	O
,	O
condition	O
of	O
the	O
patient	O
,	O
and	O
response	O
to	O
systemic	O
anticoagulation	O
.	O

Adjunct	O
transjugular	O
intrahepatic	O
portosystemic	O
shunt	O
creation	O
can	O
be	O
considered	O
for	O
outflow	O
improvement	O
.	O

The	O
American	O
College	O
of	O
Radiology	O
Appropriateness	O
Criteria	O
are	O
evidence-based	O
guidelines	O
for	O
specific	O
clinical	O
conditions	O
that	O
are	O
reviewed	O
annually	O
by	O
a	O
multidisciplinary	O
expert	O
panel	O
.	O

The	O
guideline	O
development	O
and	O
revision	O
include	O
an	O
extensive	O
analysis	O
of	O
current	O
medical	O
literature	O
from	O
peer-reviewed	O
journals	O
and	O
the	O
application	O
of	O
well-established	O
methodologies	O
(	O
RAND	O
/	O
UCLA	O
Appropriateness	O
Method	O
and	O
Grading	O
of	O
Recommendations	O
Assessment	O
,	O
Development	O
,	O
and	O
Evaluation	O
or	O
GRADE	O
)	O
to	O
rate	O
the	O
appropriateness	O
of	O
imaging	B-P
and	O
treatment	O
procedures	O
for	O
specific	O
clinical	O
scenarios	O
.	O

In	O
those	O
instances	O
where	O
evidence	O
is	O
lacking	O
or	O
equivocal	O
,	O
expert	O
opinion	O
may	O
supplement	O
the	O
available	O
evidence	O
to	O
recommend	O
imaging	B-P
or	O
treatment	O
.	O

T1	O
and	O
T2	O
Mapping	O
in	O
Recognition	O
of	O
Early	O
Cardiac	O
Involvement	O
in	O
Systemic	O
Sarcoidosis	O
.	O

Purpose	O
To	O
determine	O
whether	O
quantitative	O
tissue	O
characterization	O
with	O
T1	O
and	O
T2	O
mapping	O
supports	O
recognition	O
of	O
myocardial	O
involvement	O
in	O
patients	O
with	O
systemic	O
sarcoidosis	O
.	O

Materials	O
and	O
Methods	O
Fifty-three	O
consecutive	O
patients	O
with	O
a	O
biopsy-proven	B-P
extracardiac	O
diagnosis	O
of	O
systemic	O
sarcoidosis	O
(	O
21	O
men	O
;	O
median	O
age	O
,	O
45	O
years	O
;	O
interquartile	O
range	O
,	O
22	O
years	O
)	O
and	O
36	O
normotensive	O
previously	O
healthy	O
control	O
subjects	O
(	O
14	O
men	O
;	O
median	O
age	O
,	O
43	O
years	O
;	O
interquartile	O
range	O
,	O
18	O
years	O
)	O
underwent	O
cardiovascular	O
magnetic	B-P
resonance	I-P
imaging	I-P
,	O
which	O
was	O
performed	O
to	O
assess	O
cardiac	O
function	O
and	O
late	B-P
gadolinium	I-P
enhancement	I-P
,	O
and	O
T1	O
and	O
T2	O
mapping	O
.	O

A	O
follow-up	O
substudy	O
was	O
performed	O
in	O
40	O
patients	O
(	O
mean	O
follow-up	O
interval	O
,	O
144	O
days	O
±	O
35	O
[	O
standard	O
deviation	O
]	O
)	O
;	O
of	O
these	O
40	O
patients	O
,	O
18	O
underwent	O
anti-inflammatory	O
treatment	O
for	O
systemic	O
symptoms	O
.	O

Binary	O
logistic	O
regression	O
and	O
receiver	O
operating	O
characteristic	O
curve	O
analyses	O
were	O
used	O
to	O
assess	O
discrimination	O
between	O
health	O
and	O
disease	O
;	O
Wilcoxon	O
signed	O
rank	O
test	O
was	O
used	O
to	O
assess	O
the	O
effect	O
of	O
treatment	O
.	O

Results	O
When	O
compared	O
with	O
control	O
subjects	O
,	O
patients	O
had	O
higher	O
ventricular	O
volume	O
,	O
higher	O
myocardial	O
native	O
T1	O
and	O
T2	O
,	O
and	O
lower	O
longitudinal	O
strain	O
and	O
ejection	O
fraction	O
(	O
P	O
<	O
.05	O
for	O
all	O
)	O
.	O

Myocardial	O
native	O
T1	O
and	O
T2	O
had	O
higher	O
discriminatory	O
accuracy	O
(	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
[	O
AUC	O
]	O
:	O
0.96	O
and	O
0.89	O
,	O
respectively	O
)	O
for	O
separation	O
between	O
control	O
subjects	O
and	O
patients	O
when	O
compared	O
with	O
the	O
standard	O
diagnostic	O
criteria	O
(	O
AUC	O
<	O
0.67	O
)	O
.	O

Native	O
T1	O
was	O
the	O
independent	O
discriminator	O
between	O
health	O
and	O
disease	O
(	O
specificity	O
,	O
90	O
%	O
;	O
sensitivity	O
,	O
96	O
%	O
;	O
accuracy	O
,	O
94	O
%	O
)	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
of	O
native	O
T1	O
and	O
T2	O
in	O
the	O
patients	O
who	O
underwent	O
treatment	O
(	O
z	O
score	O
:	O
-3.72	O
and	O
-2.88	O
;	O
P	O
<	O
.01	O
)	O
but	O
not	O
in	O
the	O
patients	O
who	O
did	O
not	O
(	O
z	O
score	O
,	O
-1.42	O
and	O
-1.38	O
;	O
P	O
>	O
.15	O
)	O
.	O

Conclusion	O
Quantitative	O
myocardial	O
tissue	O
characterization	O
with	O
T1	O
and	O
T2	O
mapping	O
may	O
enable	O
noninvasive	O
recognition	O
of	O
cardiac	O
involvement	O
and	O
activity	O
of	O
myocardial	O
inflammation	O
in	O
patients	O
with	O
systemic	O
sarcoidosis	O
.	O

Future	O
studies	O
will	O
be	O
performed	O
to	O
confirm	O
their	O
role	O
in	O
risk	O
stratification	O
and	O
guidance	O
of	O
clinical	O
management	O
.	O

(	O
©	O
)	O
RSNA	O
,	O
2017	O
Online	O
supplemental	O
material	O
is	O
available	O
for	O
this	O
article	O
.	O

Tumor-suppressive	O
function	O
of	O
long	O
noncoding	O
RNA	O
MALAT1	O
in	O
glioma	O
cells	O
by	O
suppressing	O
miR-155	O
expression	O
and	O
activating	O
FBXW7	O
function	O
.	O

The	O
human	O
metastasis	O
associated	O
lung	O
adenocarcinoma	O
transcript	O
1	O
(	O
MALAT1	O
)	O
is	O
a	O
long	O
non-coding	O
RNA	O
associated	O
with	O
metastasis	O
,	O
and	O
is	O
a	O
favorable	O
prognostic	O
factor	O
for	O
lung	O
cancer	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
MALAT1	O
plays	O
an	O
important	O
role	O
in	O
many	O
malignancies	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
MALAT1	O
in	O
glioma	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
expression	O
of	O
MALAT1	O
and	O
explored	O
its	O
prognostic	O
value	O
in	O
glioma	O
.	O

Further	O
,	O
we	O
investigated	O
the	O
regulatory	O
mechanism	O
of	O
MALAT1	O
in	O
glioma	O
progression	O
.	O

Our	O
results	O
showed	O
that	O
the	O
expression	O
of	O
MALAT1	O
was	O
significantly	O
decreased	O
in	O
glioma	O
specimens	O
than	O
in	O
noncancerous	O
brain	O
tissues	O
.	O

In	O
addition	O
,	O
MALAT1	O
expression	O
was	O
significantly	O
correlated	O
with	O
tumor	O
size	O
,	O
WHO	O
grade	O
and	O
Karnofsky	B-P
Performance	I-P
Status	I-P
(	O
KPS	B-P
)	O
,	O
and	O
was	O
an	O
independent	O
prognostic	O
factor	O
for	O
survival	O
of	O
glioma	O
patients	O
.	O

The	O
gain-	O
and	O
loss-of-function	O
experiments	O
revealed	O
miR-155	O
down-regulation	O
by	O
MALAT1	O
,	O
resulting	O
in	O
reciprocal	O
effects	O
.	O

Further	O
,	O
MALAT1	O
suppresses	O
cell	O
viability	O
by	O
down-regulating	O
miR-155	O
.	O

FBXW7	O
mRNA	O
was	O
identified	O
as	O
a	O
direct	O
target	O
of	O
miR-155	O
in	O
glioma	O
.	O

The	O
miR-155	O
-induced	O
tumorigenesis	O
is	O
mediated	O
through	O
FBXW7	O
function	O
.	O

Finally	O
,	O
we	O
found	O
that	O
MALAT1	O
positively	O
regulated	O
FBXW7	O
expression	O
,	O
which	O
was	O
responsible	O
for	O
glioma	O
progression	O
mediated	O
by	O
MALAT1	O
-	O
miR-155	O
pathway	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
demonstrated	O
that	O
MALAT1	O
may	O
be	O
a	O
novel	O
prognostic	O
biomarker	O
and	O
therapeutic	O
target	O
in	O
glioma	O
.	O

Restoration	O
of	O
MALAT1	O
levels	O
represents	O
a	O
novel	O
therapeutic	O
strategy	O
against	O
glioma	O
.	O

Do	O
post-trauma	O
symptoms	O
mediate	O
the	O
relation	O
between	O
neurobiological	O
stress	O
parameters	O
and	O
conduct	O
problems	O
in	O
girls	O
?	O
.	O

Attenuated	O
activity	O
of	O
stress-regulating	O
systems	O
has	O
consistently	O
been	O
reported	O
in	O
boys	O
with	O
conduct	O
problems	O
.	O

Results	O
in	O
studies	O
of	O
girls	O
are	O
inconsistent	O
,	O
which	O
may	O
result	O
from	O
the	O
high	O
prevalence	O
of	O
comorbid	O
post-trauma	O
symptoms	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
investigate	O
post-trauma	O
symptoms	O
as	O
a	O
potential	O
mediator	O
in	O
the	O
relation	O
between	O
stress-regulation	O
systems	O
functioning	O
and	O
conduct	O
problems	O
in	O
female	O
adolescents	O
.	O

The	O
sample	O
consisted	O
of	O
78	O
female	O
adolescents	O
(	O
mean	O
age	O
15.4	O
;	O
SD	O
1.1	O
)	O
admitted	O
to	O
a	O
closed	O
treatment	O
institution	O
.	O

The	O
diagnosis	B-P
of	O
disruptive	O
behaviour	O
disorder	O
(	O
DBD	O
)	O
was	O
assessed	O
by	O
a	O
structured	O
interview-	O
the	O
diagnostic	O
interview	O
schedule	O
for	O
children	O
version	O
IV	O
(	O
DISC-IV	O
)	O
.	O

To	O
assess	O
post-trauma	O
symptoms	O
and	O
externalizing	O
behaviour	O
problems	O
,	O
self-report	O
questionnaires	O
,	O
youth	O
self	O
report	O
(	O
YSR	O
)	O
and	O
the	O
trauma	O
symptom	O
checklist	O
for	O
Children	O
(	O
TSCC	O
)	O
were	O
used	O
.	O

The	O
cortisol	O
awakenings	O
response	O
(	O
CAR	O
)	O
measured	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
activity	O
,	O
whereas	O
autonomous	O
nervous	O
system	O
(	O
ANS	O
)	O
activity	O
was	O
assessed	O
by	O
heart	O
rate	O
(	O
HR	O
)	O
,	O
pre-ejection	O
period	O
(	O
PEP	O
)	O
and	O
respiratory	O
sinus	O
arrhythmia	O
(	O
RSA	O
)	O
.	O

Independent	O
t-tests	O
were	O
used	O
to	O
compare	O
girls	O
with	O
and	O
without	O
DBD	O
,	O
while	O
path	O
analyses	O
tested	O
for	O
the	O
mediating	O
role	O
of	O
post-	O
trauma	O
symptoms	O
in	O
the	O
relation	O
between	O
stress	O
regulating	O
systems	O
and	O
externalizing	O
behaviour	O
.	O

Females	O
with	O
DBD	O
(	O
n	O
=	O
37	O
)	O
reported	O
significantly	O
higher	O
rates	O
of	O
post-trauma	O
symptoms	O
and	O
externalizing	O
behaviour	O
problems	O
than	O
girls	O
without	O
DBD	O
(	O
n	O
=	O
39	O
)	O
.	O

Path	O
analysis	O
found	O
no	O
relation	O
between	O
CAR	O
and	O
externalizing	O
behaviour	O
problems	O
.	O

With	O
regard	O
to	O
ANS	O
activity	O
,	O
positive	O
direct	O
effects	O
on	O
externalizing	O
behaviour	O
problems	O
were	O
present	O
for	O
HR	O
(	O
standardized	O
β	O
=	O
0.306	O
,	O
p	O
=	O
0.020	O
)	O
and	O
PEP	O
(	O
standardized	O
β	O
=	O
-0.323	O
,	O
p	O
=	O
0.031	O
)	O
,	O
though	O
not	O
for	O
RSA	O
.	O

Furthermore	O
,	O
no	O
relation-whether	O
direct	O
or	O
indirect-could	O
be	O
determined	O
from	O
post-trauma	O
symptoms	O
.	O

Present	O
findings	O
demonstrate	O
that	O
the	O
neurobiological	O
characteristics	O
of	O
female	O
externalizing	O
behaviour	O
differ	O
from	O
males	O
,	O
since	O
girls	O
showed	O
heightened	O
instead	O
of	O
attenuated	O
ANS	O
activity	O
.	O

While	O
the	O
prevalence	O
of	O
post-trauma	O
symptoms	O
was	O
high	O
in	O
girls	O
with	O
DBD	O
,	O
it	O
did	O
not	O
mediate	O
the	O
relation	O
between	O
stress	O
parameters	O
and	O
externalizing	O
behaviour	O
.	O

Clinical	O
implications	O
and	O
future	O
directions	O
are	O
discussed	O
.	O

From	O
Homology	O
Models	O
to	O
a	O
Set	O
of	O
Predictive	O
Binding	O
Pockets	O
-a	O
5-HT1A	O
Receptor	O
Case	O
Study	O
.	O

Despite	O
its	O
remarkable	O
importance	O
in	O
the	O
arena	O
of	O
drug	O
design	O
,	O
serotonin	O
1A	O
receptor	O
(	O
5-HT1A	O
)	O
has	O
been	O
elusive	O
to	O
the	O
X-ray	B-P
crystallography	I-P
community	O
.	O

This	O
lack	O
of	O
direct	O
structural	O
information	O
not	O
only	O
hampers	O
our	O
knowledge	O
regarding	O
the	O
binding	O
modes	O
of	O
many	O
popular	O
ligands	O
(	O
including	O
the	O
endogenous	O
neurotransmitter	O
-	O
serotonin	O
)	O
,	O
but	O
also	O
limits	O
the	O
search	O
for	O
more	O
potent	O
compounds	O
.	O

In	O
this	O
paper	O
we	O
shed	O
new	O
light	O
on	O
the	O
3D	O
pharmacological	O
properties	O
of	O
the	O
5-HT1A	O
receptor	O
by	O
using	O
a	O
ligand-guided	O
approach	O
(	O
ALiBERO	O
)	O
grounded	O
in	O
the	O
Internal	O
Coordinate	O
Mechanics	O
(	O
ICM	O
)	O
docking	O
platform	O
.	O

Starting	O
from	O
a	O
homology	O
template	O
and	O
set	O
of	O
known	O
actives	O
,	O
the	O
method	O
introduces	O
receptor	O
flexibility	O
via	O
Normal	O
Mode	O
Analysis	O
and	O
Monte	O
Carlo	O
sampling	O
,	O
to	O
generate	O
a	O
subset	O
of	O
pockets	O
that	O
display	O
enriched	O
discrimination	O
of	O
actives	O
from	O
inactives	O
in	O
retrospective	O
docking	O
.	O

Here	O
,	O
we	O
thoroughly	O
investigated	O
the	O
repercussions	O
of	O
using	O
different	O
protein	O
templates	O
and	O
the	O
effect	O
of	O
compound	O
selection	O
on	O
screening	O
performance	O
.	O

Finally	O
,	O
the	O
best	O
resulting	O
protein	O
models	O
were	O
applied	O
prospectively	O
in	O
a	O
large	O
virtual	O
screening	O
campaign	O
,	O
in	O
which	O
two	O
new	O
active	O
compounds	O
were	O
identified	O
that	O
were	O
chemically	O
distinct	O
from	O
those	O
described	O
in	O
the	O
literature	O
.	O

Sensitivity	O
and	O
Specificity	O
of	O
Plasma	O
ALT	O
,	O
ALP	O
,	O
and	O
Bile	O
Acids	O
for	O
Hepatitis	O
in	O
Labrador	O
Retrievers	O
.	O

Biochemical	O
indicators	O
for	O
diagnosing	O
liver	O
disease	O
are	O
plasma	O
alanine	O
aminotransferase	O
activity	O
(	O
ALT	O
)	O
,	O
alkaline	O
phosphatase	O
activity	O
(	O
ALP	O
)	O
,	O
and	O
bile	B-P
acid	I-P
concentration	I-P
(	O
BA	O
)	O
.	O

To	O
determine	O
the	O
sensitivity	O
and	O
specificity	O
of	O
ALT	O
,	O
ALP	O
,	O
and	O
BA	O
for	O
detecting	O
primary	O
hepatitis	O
(	O
PH	O
)	O
in	O
clinically	O
healthy	O
Labrador	O
retrievers	O
and	O
investigate	O
whether	O
ALT	O
and	O
ALP	O
can	O
discriminate	O
between	O
dogs	O
with	O
PH	O
and	O
nonspecific	O
reactive	O
hepatitis	O
(	O
RH	O
)	O
.	O

191	O
clinically	O
healthy	O
and	O
51	O
clinically	O
ill	O
Labrador	O
retrievers	O
with	O
hepatic	O
histopathology	O
.	O

Retrospective	O
study	O
.	O

Medical	O
records	O
were	O
reviewed	O
for	O
ALT	O
,	O
ALP	O
,	O
preprandial	O
BA	O
,	O
liver	O
histopathology	O
,	O
and	O
hepatic	O
copper	O
concentrations	O
.	O

In	O
64	O
%	O
(	O
122/191	O
)	O
of	O
the	O
clinically	O
healthy	O
Labrador	O
retrievers	O
,	O
hepatic	O
histology	O
revealed	O
inflammatory	O
infiltrates	O
.	O

This	O
frequency	O
might	O
be	O
biased	O
because	O
part	O
of	O
them	O
was	O
included	O
as	O
first-line	O
relatives	O
of	O
dogs	O
with	O
copper-associated	O
hepatitis	O
.	O

Sensitivity	O
of	O
ALT	O
,	O
ALP	O
,	O
and	O
BA	O
in	O
this	O
population	O
for	O
detecting	O
acute	O
hepatitis	O
was	O
45	O
,	O
15	O
,	O
and	O
15	O
%	O
,	O
respectively	O
.	O

For	O
chronic	O
hepatitis	O
,	O
sensitivity	O
was	O
71	O
,	O
35	O
,	O
and	O
13	O
%	O
,	O
respectively	O
.	O

Specificity	O
of	O
ALT	O
,	O
ALP	O
,	O
and	O
BA	O
was	O
>	O
90	O
%	O
for	O
AH	O
,	O
CH	O
,	O
and	O
RH	O
.	O

When	O
increased	O
liver	O
enzymes	O
were	O
present	O
,	O
median	O
ALT	O
was	O
significantly	O
higher	O
in	O
PH	O
cases	O
(	O
312	O
U/L	O
,	O
range	O
38-1,369	O
)	O
compared	O
to	O
RH	O
cases	O
(	O
91	O
U/L	O
,	O
range	O
39-139	O
)	O
(	O
P	O
<	O
.001	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
ALP	O
between	O
dogs	O
with	O
a	O
PH	O
and	O
a	O
RH	O
(	O
P	O
=	O
.361	O
)	O
.	O

Histopathologic	O
abnormalities	O
in	O
the	O
liver	O
were	O
present	O
in	O
the	O
majority	O
of	O
apparent	O
clinically	O
healthy	O
Labrador	O
retrievers	O
.	O

The	O
sensitivity	O
of	O
ALT	O
,	O
ALP	O
,	O
and	O
BA	O
for	O
detecting	O
acute	O
and	O
chronic	O
hepatitis	O
in	O
this	O
population	O
was	O
low	O
.	O

More	O
sensitive	O
biomarkers	O
are	O
needed	O
for	O
early	B-P
detection	I-P
of	O
liver	O
disease	O
in	O
apparent	O
clinically	O
healthy	O
dogs	O
.	O

Validating	O
Signs	O
and	O
Symptoms	O
From	O
An	O
Actual	O
Mass	O
Casualty	O
Incident	O
to	O
Characterize	O
An	O
Irritant	O
Gas	O
Syndrome	O
Agent	O
(	O
IGSA	O
)	O
Exposure	O
:	O
A	O
First	O
Step	O
in	O
The	O
Development	O
of	O
a	O
Novel	O
IGSA	O
Triage	O
Algorithm	O
.	O

Chemical	O
exposures	O
can	O
pose	O
a	O
significant	O
threat	O
to	O
life	O
.	O

Rapid	O
assessment	O
by	O
first	O
responders	O
/	O
emergency	O
nurses	O
is	O
required	O
to	O
reduce	O
death	O
and	O
disability	O
.	O

Currently	O
,	O
no	O
informatics	O
tools	O
for	O
irritant	O
gas	O
syndrome	O
agent	O
s	O
(	O
IGSA	O
)	O
exposures	O
exist	O
to	O
process	O
victims	O
efficiently	O
,	O
continuously	O
monitor	O
for	O
latent	O
signs/symptoms	O
,	O
or	O
make	O
triage	O
recommendations	O
.	O

This	O
study	O
describes	O
the	O
first	O
step	O
in	O
developing	O
ED	O
informatics	O
tools	O
for	O
chemical	O
incidents	O
:	O
validation	O
of	O
signs/symptoms	O
that	O
characterize	O
an	O
IGSA	O
syndrome	O
.	O

Data	O
abstracted	O
from	O
146	O
patients	O
treated	O
for	O
chlorine	O
exposure	O
in	O
one	O
emergency	O
department	O
during	O
a	O
2005	O
train	O
derailment	O
and	O
152	O
patients	O
not	O
exposed	O
to	O
chlorine	O
(	O
a	O
comparison	O
group	O
)	O
were	O
mapped	O
to	O
93	O
possible	O
signs/symptoms	O
within	O
2	O
tools	O
(	O
WISER	O
and	O
CHEMM-IST	O
)	O
designed	O
to	O
assist	O
emergency	O
responders	O
/	O
emergency	O
nurses	O
with	O
managing	O
hazardous	O
material	O
exposures	O
.	O

Inferential	O
statistics	O
(	O
χ	O
(	O
2	O
)	O
/	O
Fisher	O
's	O
exact	O
test	O
)	O
and	O
diagnostics	B-P
tests	I-P
were	O
used	O
to	O
examine	O
mapped	O
signs/symptoms	O
of	O
persons	O
who	O
were	O
and	O
were	O
not	O
exposed	O
to	O
chlorine	O
.	O

Three	O
clusters	O
of	O
signs/symptoms	O
are	O
statistically	O
associated	O
with	O
an	O
IGSA	O
syndrome	O
(	O
P	O
<	O
.01	O
)	O
:	O
respiratory	O
(	O
shortness	O
of	O
breath	O
,	O
wheezing	O
,	O
coughing	O
,	O
and	O
choking	O
)	O
;	O
chest	O
discomfort	O
(	O
tightness	O
,	O
pain	O
,	O
and	O
burning	O
)	O
,	O
and	O
eye	O
,	O
nose	O
and/or	O
throat	O
(	O
pain	O
,	O
irritation	O
,	O
and	O
burning	O
)	O
.	O

The	O
syndrome	O
requires	O
the	O
presence	O
of	O
signs/symptoms	O
from	O
at	O
least	O
2	O
of	O
these	O
clusters	O
.	O

The	O
latency	O
period	O
must	O
also	O
be	O
considered	O
for	O
exposed	O
/	O
potentially	O
exposed	O
persons	O
.	O

This	O
study	O
uses	O
actual	O
patient	O
data	O
from	O
a	O
chemical	O
incident	O
to	O
characterize	O
and	O
validate	O
signs/symptoms	O
of	O
an	O
IGSA	O
syndrome	O
.	O

Validating	O
signs/symptoms	O
is	O
the	O
first	O
step	O
in	O
developing	O
new	O
ED	O
informatics	O
tools	O
with	O
the	O
potential	O
to	O
revolutionize	O
the	O
process	O
by	O
which	O
emergency	O
nurses	O
manage	O
triage	O
victims	O
of	O
chemical	O
incidents	O
.	O

The	O
effect	O
of	O
different	O
decline	O
angles	O
on	O
the	O
biomechanics	O
of	O
double	O
limb	O
squats	O
and	O
the	O
implications	O
to	O
clinical	O
and	O
training	O
practice	O
.	O

Bilateral	O
decline	O
squatting	O
has	O
been	O
well	O
documented	O
as	O
a	O
rehabilitation	O
exercise	O
,	O
however	O
,	O
little	O
information	O
exists	O
on	O
the	O
optimum	O
angle	O
of	O
decline	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
ankle	O
and	O
knee	O
angle	O
,	O
moments	O
,	O
the	O
patellofemoral	O
joint	O
load	O
,	O
patellar	O
tendon	O
load	O
and	O
associated	O
muscle	O
activity	O
while	O
performing	O
a	O
double	O
limb	O
squat	O
at	O
different	O
decline	O
angles	O
and	O
the	O
implications	O
to	O
rehabilitation	O
.	O

Eighteen	O
healthy	O
subjects	O
performed	O
double	O
limb	O
squats	O
at	O
6	O
angles	O
of	O
declination	O
:	O
0	O
,	O
5	O
,	O
10	O
,	O
15	O
,	O
20	O
and	O
25	O
degrees	O
.	O

The	O
range	O
of	O
motion	O
of	O
the	O
knee	O
and	O
ankle	O
joints	O
,	O
external	O
moments	O
,	O
the	O
patellofemoral	O
/	O
patellar	O
tendon	O
load	O
and	O
integrated	O
EMG	B-P
of	O
gastrocnemius	O
,	O
tibialis	O
anterior	O
,	O
rectus	O
femoris	O
and	O
biceps	O
femoris	O
were	O
evaluated	O
.	O

As	O
the	O
decline	O
angle	O
increased	O
up	O
to	O
20	O
degrees	O
,	O
the	O
range	O
of	O
motion	O
possible	O
at	O
the	O
ankle	O
and	O
knee	O
increased	O
.	O

The	O
joint	O
moments	O
showed	O
a	O
decrease	O
at	O
the	O
ankle	O
up	O
to	O
15	O
degrees	O
and	O
an	O
increase	O
at	O
the	O
knee	O
up	O
to	O
25	O
degrees	O
,	O
indicating	O
a	O
progressive	O
reduction	O
in	O
loading	O
around	O
the	O
ankle	O
with	O
a	O
corresponding	O
increase	O
of	O
the	O
load	O
in	O
the	O
patellar	O
tendon	O
and	O
patellofemoral	O
joint	O
.	O

These	O
trends	O
were	O
supported	O
by	O
a	O
decrease	O
in	O
tibialis	O
anterior	O
activity	O
and	O
an	O
increase	O
in	O
the	O
rectus	O
femoris	O
activity	O
up	O
to	O
15	O
degrees	O
declination	O
.	O

However	O
,	O
gastrocnemius	O
and	O
biceps	O
femoris	O
activity	O
increased	O
as	O
the	O
decline	O
angle	O
increased	O
above	O
15	O
degrees	O
.	O

The	O
action	O
of	O
gastrocnemius	O
and	O
biceps	O
femoris	O
stabilises	O
the	O
knee	O
against	O
an	O
anterior	O
displacement	O
of	O
the	O
femur	O
on	O
the	O
tibia	O
.	O

These	O
findings	O
would	O
suggest	O
that	O
there	O
is	O
little	O
benefit	O
in	O
using	O
a	O
decline	O
angle	O
greater	O
than	O
15-20	O
degrees	O
unless	O
the	O
purpose	O
is	O
to	O
offer	O
an	O
additional	O
stability	O
challenge	O
to	O
the	O
knee	O
joint	O
.	O

Intratympanic	O
steroid	O
delivery	O
by	O
an	O
indwelling	O
catheter	O
in	O
refractory	O
severe	O
sudden	O
sensorineural	O
hearing	O
loss	O
.	O

Many	O
studies	O
over	O
the	O
last	O
decade	O
showed	O
favorable	O
outcomes	O
with	O
intratympanic	O
(	O
IT	O
)	O
steroid	O
treatment	O
,	O
alone	O
as	O
salvage	O
treatment	O
or	O
in	O
combination	O
with	O
conventional	O
systemic	O
therapy	O
(	O
ST	O
)	O
.	O

However	O
,	O
in	O
severe	O
to	O
profound	O
sensorineural	O
hearing	O
loss	O
resistant	O
to	O
ST	O
,	O
the	O
optimal	O
infusion	O
mode	O
,	O
the	O
type	O
and	O
concentration	O
of	O
the	O
solution	O
,	O
the	O
preferable	O
drug	O
,	O
its	O
total	O
amount	O
,	O
and	O
the	O
duration	O
and	O
fractionation	O
of	O
the	O
treatment	O
are	O
still	O
debated	O
.	O

Aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
feasibility	O
and	O
the	O
outcomes	O
of	O
a	O
direct	O
and	O
constant	O
IT	O
delivery	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
by	O
means	O
of	O
a	O
new	O
indwelling	O
catheter	O
.	O

A	O
prospective	O
case-control	O
study	O
in	O
a	O
tertiary	O
referral	O
university	O
hospital	O
.	O

Ninety-nine	O
subjects	O
treated	O
with	O
ST	O
only	O
and	O
28	O
with	O
additional	O
IT	O
DEX	O
have	O
been	O
included	O
in	O
the	O
study	O
.	O

A	O
4	O
Fr	O
catheter	O
inserted	O
in	O
a	O
sub-annular	O
fashion	O
with	O
a	O
minimal	O
postero-inferior	O
tympanotomy	O
through	O
and	O
endocanalar	O
approach	O
under	O
local	O
anesthesia	O
.	O

DEX	O
4mg/ml	O
delivered	O
daily	O
,	O
up	O
to	O
7	O
days	O
.	O

Daily	O
bone	B-P
and	I-P
air-conducted	I-P
pure	I-P
tone	I-P
and	O
speech	B-P
audiometry	I-P
were	O
performed	O
with	O
a	O
follow-up	O
at	O
1	O
,	O
3	O
,	O
6	O
months	O
after	O
treatment	O
.	O

Twenty-one	O
out	O
of	O
28	O
patients	O
(	O
75	O
%	O
)	O
refractory	O
to	O
ST	O
gained	O
on	O
average	O
24.0dB±20.5dB	O
HL	O
after	O
IT	O
-	O
DEX	O
,	O
compared	O
to	O
35.4	O
%	O
(	O
average	O
6.7dB±16.6dB	O
HL	O
)	O
of	O
those	O
receiving	O
only	O
medical	O
ST	O
(	O
p	O
<	O
0.001	O
)	O
.	O

No	O
significant	O
side	O
effects	O
were	O
noted	O
.	O

In	O
severe	O
to	O
profound	O
sudden	O
deafness	O
refractory	O
to	O
conventional	O
ST	O
,	O
the	O
daily	O
perfusion	O
of	O
4mg/ml	O
DEX	O
through	O
an	O
intratympanic	O
catheter	O
is	O
an	O
easy	O
,	O
well	O
accepted	O
procedure	O
that	O
enables	O
patients	O
to	O
receive	O
a	O
drug	O
in	O
the	O
middle	O
ear	O
in	O
a	O
repeatable	O
or	O
sustained	O
form	O
,	O
with	O
minimal	O
discomfort	O
and	O
a	O
partial	O
rescue	O
(	O
67.86	O
%	O
)	O
and	O
a	O
speech	O
recognition	O
gain	O
of	O
39	O
%	O
.	O

A	O
Novel	O
BRCA1-Associated	O
Protein-1	O
Isoform	O
Affects	O
Response	O
of	O
Mesothelioma	O
Cells	O
to	O
Drugs	O
Impairing	O
BRCA1	O
-Mediated	O
DNA	O
Repair	O
.	O

BRCA1	O
associated	O
protein1	O
(	O
BAP1	O
)	O
is	O
a	O
tumor	O
suppressor	O
involved	O
in	O
multiple	O
cellular	O
processes	O
such	O
as	O
transcriptional	O
regulation	O
,	O
chromatin	O
modification	O
by	O
deubiquitinating	O
histone	O
2A	O
,	O
and	O
DNA	O
repair	O
.	O

BAP1	O
mutations	O
are	O
frequent	O
in	O
malignant	O
pleural	O
mesothelioma	O
(	O
MPM	O
)	O
.	O

Our	O
aim	O
was	O
to	O
functionally	O
characterize	O
a	O
newly	O
identified	O
isoform	O
of	O
BAP1	O
and	O
investigate	O
the	O
effects	O
of	O
its	O
expression	O
on	O
drug	O
sensitivity	O
in	O
MPM	O
.	O

Expression	O
of	O
BAP1	O
isoforms	O
was	O
detected	O
by	O
quantitative	B-P
polymerase	I-P
chain	I-P
reaction	I-P
in	O
MPM	O
and	O
normal	O
mesothelium	O
cell	O
lines	O
and	O
tumor	O
and	O
nontumor	O
samples	O
.	O

Histone	O
H2A	O
ubiquitination	O
levels	O
were	O
analyzed	O
by	O
Western	B-P
blot	I-P
after	O
acidic	B-P
extraction	I-P
of	O
core	O
histones	O
.	O

Subcellular	O
localization	O
of	O
BAP1	O
isoforms	O
was	O
examined	O
by	O
immunofluorescence	B-P
.	O

MPM	O
cell	O
survival	O
in	O
response	O
to	O
poly	O
(	O
adenosine	O
diphosphate-ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
and	O
dual	O
phosphoinositide	O
3-kinase	O
(	O
PI3K	O
)	O
-	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
inhibitors	O
was	O
analyzed	O
by	O
in	O
vitro	O
assays	O
.	O

We	O
have	O
identified	O
a	O
novel	O
alternative	O
splice	O
isoform	O
of	O
BAP1	O
(	O
BAP1Δ	O
)	O
that	O
misses	O
part	O
of	O
the	O
catalytic	O
domain	O
.	O

Cells	O
transfected	O
with	O
BAP1Δ	O
showed	O
reduced	O
deubiquitinating	O
activity	O
compared	O
with	O
full-length	O
BAP1	O
.	O

The	O
expression	O
of	O
BAP1Δ	O
transcript	O
is	O
more	O
abundant	O
in	O
nontumor	O
than	O
in	O
tumor	O
samples	O
.	O

MPM	O
cell	O
lines	O
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1Δ	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
PI3K	O
-	O
mTOR	O
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

These	O
observations	O
suggest	O
that	O
BAP1Δ	O
does	O
regulate	O
DNA	O
damage	O
response	O
and	O
influences	O
drug	O
sensitivity	O
.	O

It	O
might	O
therefore	O
be	O
relevant	O
to	O
investigate	O
whether	O
patients	O
with	O
high	O
expression	O
of	O
BAP1Δ	O
may	O
be	O
responsive	O
to	O
PARP	O
/	O
PI3K	O
-	O
mTOR	O
inhibitors	O
.	O

IFN-γ	O
-producing	O
Th1-like	O
regulatory	O
T	O
cells	O
may	O
limit	O
acute	O
cellular	O
renal	O
allograft	O
rejection	O
:	O
Paradoxical	O
post-transplantation	O
effects	O
of	O
IFN-γ	O
.	O

IFN-γ	O
is	O
a	O
protypical	O
proinflammatory	O
cytokine	O
that	O
plays	O
a	O
central	O
role	O
in	O
inflammation	O
and	O
acute	O
graft	O
rejection	O
.	O

Accumulating	O
evidence	O
indicates	O
that	O
IFN-γ	O
can	O
exert	O
previously	O
unexpected	O
immunoregulatory	O
activities	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
IFN-γ	O
secreted	O
by	O
Th1-like	O
regulatory	O
T	O
cells	O
in	O
human	O
kidney	O
transplantation	O
.	O

To	O
determine	O
the	O
function	O
of	O
IFN-γ	O
in	O
acute	O
T	O
cell-mediated	O
renal	O
allograft	O
rejection	O
(	O
ACR	O
)	O
,	O
we	O
examined	O
serum	O
cytokine	O
expression	O
profiles	O
in	O
ACR	O
patients	O
by	O
human	O
cytokine	O
multiplex	O
immunoassay	B-P
and	O
analyzed	O
the	O
cellular	O
origins	O
of	O
IFN-γ	O
in	O
peripheral	O
blood	O
and	O
renal	O
allograft	O
biopsies	B-P
from	O
ACR	O
cases	O
and	O
controls	O
by	O
flow	B-P
cytometry	I-P
and	O
immunohistochemistry	B-P
,	O
respectively	O
.	O

The	O
results	O
showed	O
significant	O
reduction	O
in	O
serum	O
concentrations	O
of	O
Th1	O
-inducing	O
cytokines	O
IL-12p70	O
and	O
IFN-γ	O
as	O
well	O
as	O
Th2	O
-related	O
cytokine	O
IL-4	O
in	O
ACR	O
patients	O
compared	O
with	O
stable	O
controls	O
.	O

However	O
,	O
levels	O
of	O
several	O
Th1	O
-	O
,	O
Th2	O
-	O
and	O
Th17	O
-related	O
cytokines	O
,	O
such	O
as	O
IL-2	O
,	O
TNF-α	O
,	O
TNF-β	O
,	O
IL-12	O
(	O
p40	O
)	O
,	O
IL-10	O
,	O
IL-15	O
,	O
IL-17	O
,	O
IL-21	O
,	O
and	O
IL-23	O
,	O
as	O
well	O
as	O
the	O
frequencies	O
of	O
Th1	O
and	O
Th17	O
cell	O
,	O
did	O
not	O
differ	O
between	O
ACR	O
cases	O
and	O
stable	O
controls	O
.	O

Moreover	O
,	O
we	O
found	O
the	O
levels	O
of	O
IFN-γ	O
were	O
correlated	O
with	O
those	O
of	O
the	O
anti-inflammatory	O
factor	O
,	O
IL-1	O
receptor	O
antagonist	O
(	O
IL-1Ra	O
)	O
in	O
ACR	O
.	O

Notably	O
,	O
the	O
Th1-like	O
Treg	O
cell	O
-to-	O
Foxp3	O
(	O
-	O
)	O
Th1	O
cell	B-P
ratio	I-P
was	O
significantly	O
lower	O
in	O
ACR	O
patients	O
compared	O
with	O
that	O
in	O
stable	O
controls	O
.	O

In	O
graft	O
biopsies	B-P
from	O
ACR	O
patients	O
,	O
Treg	O
cells	O
and	O
Th1-like	O
Treg	O
cells	O
were	O
less	O
abundant	O
than	O
those	O
without	O
ACR	O
.	O

Our	O
study	O
indicates	O
that	O
IFN-γ	O
secreted	O
from	O
Th1-like	O
Treg	O
cells	O
negatively	O
modulates	O
ACR	O
.	O

Heightened	O
HIV	O
antibody	O
responses	O
in	O
postpartum	O
women	O
as	O
exemplified	O
by	O
recent	O
infection	B-P
assays	I-P
:	O
implications	O
for	O
incidence	O
estimates	O
.	O

Laboratory	B-P
assays	I-P
that	O
identify	O
recent	O
HIV	O
infections	O
are	O
important	O
for	O
assessing	O
impacts	O
of	O
interventions	O
aimed	O
at	O
reducing	O
HIV	O
incidence	O
.	O

Kinetics	O
of	O
HIV	O
humoral	O
responses	O
can	O
vary	O
with	O
inherent	O
assay	O
properties	O
,	O
and	O
between	O
HIV	O
subtypes	O
,	O
populations	O
and	O
physiological	O
states	O
.	O

They	O
are	O
important	O
in	O
determining	O
mean	O
duration	O
of	O
recent	O
infection	O
(	O
MDRI	O
)	O
for	O
antibody-based	B-P
assays	I-P
for	O
detecting	O
recent	O
HIV	O
infections	O
.	O

We	O
determined	O
MDRIs	O
for	O
BED-CEIA	B-P
,	O
LAg	B-P
and	O
BRAI	B-P
assays	I-P
for	O
101	O
seroconverting	O
postpartum	O
women	O
,	O
recruited	O
in	O
Harare	O
in	O
1997-	O
2000	O
during	O
the	O
Zimbabwe	O
Vitamin	O
A	O
for	O
Mothers	O
and	O
Babies	O
(	O
ZVITAMBO	O
)	O
Trial	O
,	O
comparing	O
them	O
against	O
published	O
MDRIs	O
estimated	O
from	O
seroconverting	O
cases	O
in	O
the	O
general	O
population	O
.	O

We	O
also	O
compared	O
MDRIs	O
for	O
women	O
who	O
seroconverted	O
either	O
during	O
the	O
first	O
nine	O
months	O
,	O
or	O
at	O
later	O
stages	O
,	O
postpartum	O
.	O

At	O
cut-offs	O
(	O
C	O
)	O
of	O
0.8	O
for	O
BED	B-P
,	O
1.5	O
for	O
LAg	B-P
and	O
40	O
%	O
for	O
BRAI	B-P
,	O
estimated	O
MDRIs	O
for	O
postpartum	O
mothers	O
,	O
were	O
192	O
,	O
104	O
and	O
144	O
days	O
,	O
33	O
%	O
,	O
32-41	O
%	O
and	O
52	O
%	O
lower	O
than	O
published	O
estimates	O
of	O
287	O
,	O
152-177	O
and	O
298	O
days	O
,	O
respectively	O
,	O
for	O
clade	O
C	O
samples	O
from	O
general	O
populations	O
.	O

Point	O
estimates	O
of	O
MDRI	O
values	O
were	O
7	O
-	O
19	O
%	O
shorter	O
for	O
women	O
who	O
seroconverted	O
in	O
the	O
first	O
9-	O
months	O
postpartum	O
,	O
compared	O
with	O
those	O
seroconverting	O
later	O
.	O

MDRI	O
values	O
for	O
three	O
HIV	O
incidence	O
biomarkers	O
are	O
longer	O
in	O
the	O
general	O
population	O
than	O
among	O
postpartum	O
women	O
,	O
particularly	O
those	O
who	O
recently	O
gave	O
birth	O
,	O
consistent	O
with	O
heightened	O
immunologic	O
activation	O
soon	O
after	O
birth	O
.	O

Our	O
results	O
provide	O
a	O
caution	O
that	O
MDRI	O
may	O
vary	O
significantly	O
between	O
subjects	O
in	O
different	O
physiological	O
states	O
.	O

Clinicopathological	O
and	O
Immunohistochemical	B-P
Characteristics	O
of	O
Verruciform	O
Xanthoma	O
of	O
the	O
Lower	O
Gingiva	O
:	O
A	O
Case	O
Report	O
.	O

Verruciform	O
xanthoma	O
(	O
VX	O
)	O
is	O
a	O
rare	O
benign	O
lesion	O
and	O
mainly	O
effects	O
the	O
oral	O
mucosa	O
.	O

This	O
slow-growing	O
asymptomatic	O
lesion	O
typically	O
develops	O
along	O
the	O
gingival	O
margin	O
of	O
the	O
masticatory	O
mucosa	O
,	O
followed	O
by	O
the	O
hard	O
palate	O
,	O
tongue	O
,	O
buccal	O
mucosa	O
,	O
floor	O
of	O
the	O
mouth	O
,	O
alveolar	O
mucosa	O
,	O
soft	O
palate	O
and	O
junction	O
between	O
the	O
hard	O
and	O
soft	O
palate	O
.	O

Moreover	O
,	O
this	O
lesion	O
can	O
also	O
affect	O
the	O
skin	O
and	O
genital	O
organs	O
.	O

Clinically	O
,	O
VX	O
generally	O
presents	O
a	O
sessile	O
or	O
pedunculated	O
appearance	O
,	O
forming	O
a	O
papule	O
or	O
single	O
plaque	O
with	O
verrucous	O
or	O
papillomatous	O
mucosal	O
growth	O
.	O

The	O
colour	O
(	O
white	O
,	O
pink	O
,	O
grey	O
,	O
or	O
yellow	O
)	O
depends	O
on	O
the	O
thickness	O
of	O
the	O
overlying	O
epidermis	O
.	O

In	O
fact	O
,	O
the	O
clinical	O
findings	O
of	O
VX	O
are	O
similar	O
to	O
those	O
of	O
verrucous	O
carcinoma	O
and	O
other	O
benign	O
tumours	O
,	O
such	O
as	O
squamous	O
papilloma	O
,	O
verruca	O
vulgaris	O
and	O
mucosal	O
fibroma	O
.	O

For	O
this	O
reason	O
,	O
clinical	O
and	O
histopathological	O
examinations	O
are	O
essential	O
for	O
accurate	B-P
differential	I-P
diagnosis	I-P
.	O

Histologically	O
,	O
VX	O
is	O
characterized	O
by	O
parakeratosis	O
,	O
rete	O
ridges	O
of	O
uniform	O
depth	O
and	O
the	O
accumulation	O
of	O
foam	O
cells	O
,	O
which	O
are	O
also	O
called	O
``	O
xanthoma	O
cells	O
``	O
.	O

Here	O
,	O
we	O
describe	O
the	O
clinicopathological	O
and	O
immunohistochemical	B-P
findings	O
of	O
a	O
VX	O
located	O
on	O
the	O
lower	O
gingiva	O
of	O
a	O
64-year-old	O
male	O
patient	O
.	O

5-Bromo-2-aryl	O
benzimidazole	O
derivatives	O
as	O
non-cytotoxic	O
potential	O
dual	O
inhibitors	O
of	O
α-glucosidase	O
and	O
urease	O
enzymes	O
.	O

On	O
the	O
basis	O
of	O
previous	O
report	O
on	O
promising	O
α-glucosidase	O
inhibitory	O
activity	O
of	O
5-bromo-2-aryl	O
benzimidazole	O
derivatives	O
,	O
these	O
derivatives	O
were	O
further	O
screened	B-P
for	O
urease	O
inhibitory	O
and	O
cytotoxicity	B-P
activity	I-P
in	O
order	O
to	O
get	O
more	O
potent	O
and	O
non-cytotoxic	O
potential	O
dual	O
inhibitor	O
for	O
the	O
patients	O
suffering	O
from	O
diabetes	O
as	O
well	O
as	O
peptic	O
ulcer	O
.	O

In	O
this	O
study	O
,	O
all	O
compounds	O
showed	O
varying	O
degree	O
of	O
potency	O
in	O
the	O
range	O
of	O
(	O
IC50	O
=8.15±0.03-354.67±0.19μM	O
)	O
as	O
compared	O
to	O
standard	O
thiourea	O
(	O
IC50	O
=21.25±0.15μM	O
)	O
.	O

It	O
is	O
worth	O
mentioning	O
that	O
derivatives	O
7	O
(	O
IC50	O
=12.07±0.05μM	O
)	O
,	O
8	O
(	O
IC50	O
=10.57±0.12μM	O
)	O
,	O
11	O
(	O
IC50	O
=13.76±0.02μM	O
)	O
,	O
14	O
(	O
IC50	O
=15.70±0.12μM	O
)	O
and	O
22	O
(	O
IC50	O
=8.15±0.03μM	O
)	O
were	O
found	O
to	O
be	O
more	O
potent	O
inhibitors	O
than	O
standard	O
.	O

All	O
compounds	O
were	O
also	O
evaluated	O
for	O
cytotoxicity	B-P
towards	O
3T3	O
mouse	O
fibroblast	O
cell	O
line	O
and	O
found	O
to	O
be	O
completely	O
non-toxic	O
.	O

Previously	O
benzimidazole	O
1-25	O
were	O
also	O
showed	O
α-glucosidase	O
inhibitory	O
potential	O
.	O

In	O
silico	O
studies	O
were	O
performed	O
on	O
the	O
lead	O
molecules	O
i.e	O
.	O

2	O
,	O
7	O
,	O
8	O
,	O
11	O
,	O
14	O
,	O
and	O
22	O
,	O
in	O
order	O
to	O
rationalize	O
the	O
binding	O
interaction	O
of	O
compounds	O
with	O
the	O
active	O
site	O
of	O
urease	O
enzyme	O
.	O

Supercritical	O
processed	O
starch	O
nanosponge	O
as	O
a	O
carrier	O
for	O
enhancement	O
of	O
dissolution	B-P
and	O
pharmacological	O
efficacy	O
of	O
fenofibrate	O
.	O

In	O
current	O
study	O
,	O
supercritical	O
processed	O
starch	O
nanosponge	O
(	O
SSNS	O
)	O
used	O
as	O
a	O
carrier	O
for	O
poorly	O
water	O
soluble	O
drug	O
(	O
fenofibrate	O
)	O
to	O
enhance	O
its	O
in-vitro	O
and	O
in-vivo	O
performance	O
.	O

SSNS	O
was	O
prepared	O
by	O
using	O
sol-	B-P
gel	I-P
method	I-P
and	O
effective	O
supercritical	B-P
drying	I-P
technique	I-P
.	O

Fenofibrate	O
was	O
loaded	O
into	O
the	O
SSNS	O
by	O
using	O
solvent	B-P
immersion	I-P
method	I-P
with	O
selected	O
and	O
optimized	O
organic	O
solvent	O
.	O

BET	O
surface	O
area	O
of	O
SSNS	O
was	O
evaluated	O
by	O
nitrogen	B-P
adsorption/desorption	I-P
analysis	I-P
.	O

SSNS	O
and	O
drug	O
loaded	O
SSNS	O
were	O
characterized	O
by	O
DSC	B-P
,	O
XRPD	O
,	O
FTIR	O
,	O
SEM	B-P
,	O
Contact	O
angle	O
study	O
and	O
evaluated	O
for	O
in-vitro	O
,	O
in-vivo	O
studies	O
.	O

The	O
results	O
revealed	O
that	O
the	O
formed	O
SSNS	O
material	O
has	O
high	O
surface	O
area	O
(	O
180m2/gm	O
)	O
with	O
pore	O
size	O
(	O
40	O
nm	O
to	O
200nm	O
)	O
.	O

The	O
DSC	B-P
and	O
XRPD	O
study	O
revealed	O
the	O
amorphization	O
of	O
drug	O
within	O
a	O
SSNS	O
.	O

SEM	B-P
study	O
showed	O
the	O
continuous	O
porous	O
structure	O
with	O
differ	O
nanosized	O
pores	O
of	O
SSNS	O
.	O

Contact	O
angle	O
study	O
showed	O
improvement	O
in	O
aqueous	O
wetting	O
property	O
of	O
drug	O
within	O
a	O
SSNS	O
.	O

In-vitro	O
drug	O
release	O
study	O
showed	O
remarkable	O
dissolution	B-P
enhancement	O
of	O
SSNS	O
formulation	O
as	O
compared	O
to	O
plain	O
drug	O
.	O

In	O
vivo	O
pharmacodynamic	O
study	O
(	O
hyperlipidaemia	O
model	O
)	O
showed	O
SNSS	O
based	O
formulation	O
significantly	O
improved	O
the	O
bioavailability	O
of	O
drug	O
.	O

Thus	O
SSNS	O
carrier	O
system	O
has	O
good	O
potential	O
to	O
be	O
explored	O
as	O
a	O
delivery	O
system	O
for	O
poorly	O
water	O
soluble	O
drugs	O
.	O

Single-shot	O
real-time	O
video	O
recording	O
of	O
a	O
photonic	O
Mach	O
cone	O
induced	O
by	O
a	O
scattered	O
light	O
pulse	O
.	O

Ultrafast	O
video	O
recording	O
of	O
spatiotemporal	O
light	O
distribution	O
in	O
a	O
scattering	O
medium	O
has	O
a	O
significant	O
impact	O
in	O
biomedicine	O
.	O

Although	O
many	O
simulation	O
tools	O
have	O
been	O
implemented	O
to	O
model	O
light	O
propagation	O
in	O
scattering	O
media	O
,	O
existing	O
experimental	O
instruments	O
still	O
lack	O
sufficient	B-P
imaging	I-P
speed	I-P
to	O
record	O
transient	O
light-scattering	O
events	O
in	O
real	O
time	O
.	O

We	O
report	O
single-shot	O
ultrafast	O
video	O
recording	O
of	O
a	O
light	O
-	O
induced	O
photonic	O
Mach	O
cone	O
propagating	O
in	O
an	O
engineered	O
scattering	O
plate	O
assembly	O
.	O

This	O
dynamic	B-P
light-scattering	I-P
event	O
was	O
captured	O
in	O
a	O
single	O
camera	O
exposure	O
by	O
lossless-encoding	O
compressed	O
ultrafast	O
photography	O
at	O
100	O
billion	O
frames	O
per	O
second	O
.	O

Our	O
experimental	O
results	O
are	O
in	O
excellent	O
agreement	O
with	O
theoretical	O
predictions	O
by	O
time-resolved	O
Monte	O
Carlo	O
simulation	O
.	O

This	O
technology	O
holds	O
great	O
promise	O
for	O
next-generation	O
biomedical	O
imaging	O
instrumentation	O
.	O

Acute	O
Ph-negative	O
lymphoblastic	O
leukemias	O
in	O
adults	O
:	O
Risk	O
factors	O
in	O
the	O
use	O
of	O
the	O
ALL-2009	O
protocol	O
.	O

to	O
analyze	O
well-known	O
risk	O
factors	O
(	O
RFs	O
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	B-P
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	O
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
in	O
the	O
use	O
of	O
the	O
ALL-2009	O
protocol	O
.	O

The	O
protocol	O
covered	O
298	O
patients	O
(	O
137	O
women	O
(	O
including	O
13	O
pregnant	O
women	O
)	O
and	O
161	O
men	O
)	O
aged	O
15	O
to	O
55	O
years	O
(	O
median	O
age	O
28	O
years	O
)	O
with	O
Ph-negative	O
ALL	O
.	O

The	O
phenotype	O
was	O
unknown	O
in	O
6	O
patients	O
.	O

Three	O
(	O
1	O
%	O
)	O
were	O
ascertained	O
to	O
have	O
a	O
biphenotypic	O
variant	O
.	O

182	O
(	O
62.4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B-cell	O
ALL	O
(	O
early	O
pre-B	O
ALL	O
(	O
n=51	O
)	O
;	O
common	O
ALL	O
(	O
n=92	O
)	O
,	O
and	O
pre-B	O
ALL	O
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	O
had	O
T-cell	O
ALL	O
(	O
early	O
T-ALL	O
(	O
n=56	O
)	O
;	O
thymic	O
T-ALL	O
(	O
n=41	O
)	O
,	O
and	O
mature	O
T-ALL	O
(	O
n=10	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	O
of	O
30·109/l	O
and	O
more	O
for	O
B-ALL	O
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T-ALL	O
;	O
phenotype	O
В-I	O
for	O
B-ALL	O
,	O
phenotype	O
Т-I-II-IV	O
for	O
T-ALL	O
;	O
LDH	O
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t	O
(	O
4	O
;	O
11	O
)	O
)	O
,	O
the	O
high-risk	O
group	O
included	O
most	O
patients	O
with	O
B-ALL	O
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T-ALL	O
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

Thirty-five	O
patients	O
with	O
T-ALL	O
underwent	O
autologous	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
.	O

Allogeneic	O
BMT	O
was	O
performed	O
in	O
18	O
(	O
7	O
%	O
)	O
of	O
the	O
258	O
patients	O
who	O
had	O
undergone	O
an	O
induction	O
phase	O
.	O

Five-year	O
overall	O
survival	O
for	O
all	O
the	O
patients	O
included	O
in	O
the	O
investigation	O
was	O
59	O
%	O
;	O
relapse-free	O
survival	O
was	O
65	O
%	O
,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	O
with	O
B-ALL	O
and	O
in	O
those	O
with	O
T-ALL	O
:	O
the	O
overall	O
survival	O
rates	O
were	O
53.3	O
and	O
67.5	O
%	O
(	O
p=0.1	O
)	O
;	O
the	O
relapse-free	O
survival	O
was	O
56	O
and	O
79	O
%	O
(	O
p=0.005	O
)	O
,	O
respectively	O
.	O

Multivariate	O
analysis	O
including	O
the	O
well-known	O
RFs	O
demonstrated	O
that	O
the	O
latter	O
for	O
T-ALL	O
were	O
of	O
no	O
independent	O
prognostic	O
value	O
and	O
only	O
the	O
patient	O
's	O
age	O
was	O
identified	O
for	O
B-ALL	O
(	O
p=0.013	O
)	O
.	O

A	O
lower	O
chemotherapeutic	O
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	O
BMTs	O
did	O
not	O
affect	O
total	O
positive	O
treatment	O
results	O
in	O
adult	O
patients	O
with	O
ALL	O
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	O
effects	O
and	O
by	O
preserving	O
the	O
total	O
cytostatic	O
loading	O
dose	O
.	O

The	O
results	O
of	O
the	O
Russian	O
investigation	O
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	O
BMTs	O
in	O
adult	O
patients	O
with	O
ALL	O
.	O

Transcatheter	O
tricuspid	O
valve-in-valve	O
replacement	O
:	O
one-year	O
results	O
:	O
Alternative	O
to	O
surgery	O
in	O
high-risk	O
patients	O
.	O

Although	O
rheumatic	O
heart	O
disease	O
is	O
becoming	O
uncommon	O
in	O
industrialized	O
countries	O
,	O
its	O
global	O
burden	O
is	O
still	O
significant	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70-year-old	O
male	O
with	O
rheumatic	O
heart	O
disease	O
,	O
who	O
underwent	O
4	O
previous	O
heart	O
valve	O
replacement	O
surgeries	O
,	O
and	O
presented	O
to	O
our	O
hospital	O
with	O
refractory	O
heart	O
failure	O
(	O
NYHA	O
functional	O
class	O
IV	O
)	O
due	O
to	O
severe	O
stenosis	O
of	O
a	O
previously	O
implanted	O
tricuspid	O
bioprosthesis	O
.	O

The	O
Heart	O
Team	O
deemed	O
the	O
patient	O
as	O
inoperable	O
/	O
high-risk	O
for	O
surgery	O
.	O

As	O
an	O
alternative	O
,	O
a	O
transcatheter	O
tricuspid	O
valve-in-valve	O
replacement	O
was	O
decided	O
upon	O
and	O
later	O
executed	O
through	O
the	O
right	O
femoral	O
vein	O
,	O
with	O
the	O
insertion	O
of	O
an	O
Edwards	O
SAPIEN	O
XT	O
29	O
no	O
.	O

(	O
Edwards	O
Lifesciences	O
,	O
Irvine	O
,	O
CA	O
,	O
USA	O
)	O
through	O
the	O
inferior	O
vena	O
cava	O
,	O
towards	O
the	O
RV	O
,	O
followed	O
by	O
direct	O
implantation	O
in	O
the	O
tricuspid	O
bioprosthesis	O
(	O
valve-in-valve	O
)	O
,	O
under	O
rapid	O
pacing	O
,	O
without	O
complications	O
.	O

A	O
substantial	O
clinical	O
and	O
echocardiographic	B-P
improvement	O
was	O
noted	O
after	O
the	O
procedure	O
and	O
the	O
patient	O
was	O
subsequently	O
discharged	O
in	O
NYHA	O
functional	O
class	O
II	O
.	O

These	O
favourable	O
outcomes	O
persisted	O
through	O
the	O
1-year	O
follow-up	O
period	O
.	O

This	O
case	O
report	O
adds	O
to	O
the	O
current	O
body	O
of	O
evidence	O
that	O
tricuspid	O
valve	O
implantation	O
stands	O
as	O
a	O
viable	O
and	O
reliable	O
alternative	O
in	O
the	O
treatment	O
of	O
degenerated	O
bioprosthesis	O
in	O
high-surgical-risk	O
patients	O
.	O

Anatomic	O
variations	O
of	O
levator	O
scapulae	O
in	O
a	O
normal	O
cohort	O
:	O
an	O
MRI	B-P
study	I-P
.	O

Accessory	O
attachments	O
of	O
the	O
levator	O
scapulae	O
(	O
LS	O
)	O
muscle	O
have	O
been	O
described	O
in	O
the	O
literature	O
in	O
previous	O
cadaveric	O
studies	O
,	O
but	O
there	O
is	O
little	O
knowledge	O
about	O
the	O
incidence	O
and	O
distribution	O
.	O

Knowledge	O
of	O
LS	O
accessory	O
attachments	O
is	O
relevant	O
to	O
clinicians	O
working	O
in	O
the	O
fields	O
of	O
radiology	O
,	O
surgery	O
,	O
neurology	O
,	O
and	O
musculoskeletal	O
medicine	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
incidence	O
and	O
spectrum	O
of	O
LS	O
caudal	O
accessory	O
attachments	O
in	O
vivo	O
using	O
magnetic	B-P
resonance	I-P
(	I-P
MR	I-P
)	I-P
imaging	I-P
in	O
a	O
young	O
cohort	O
.	O

MR	B-P
images	O
of	O
the	O
cervical	O
spine	O
were	O
obtained	O
from	O
37	O
subjects	O
(	O
13	O
males	O
and	O
24	O
females	O
)	O
aged	O
18-36	O
years	O
using	O
an	O
axial	O
T1-weighted	O
spin	O
echo	O
sequence	O
acquired	O
from	O
a	O
3-Tesla	B-P
MR	I-P
scanner	I-P
.	O

The	O
LS	O
muscle	O
was	O
identified	O
,	O
and	O
the	O
presence	O
of	O
caudal	O
accessory	O
attachments	O
was	O
recorded	O
and	O
described	O
.	O

LS	O
caudal	O
accessory	O
attachments	O
were	O
identified	O
in	O
16	O
subjects	O
(	O
4	O
right	O
,	O
6	O
left	O
,	O
and	O
6	O
bilateral	O
;	O
12	O
female	O
)	O
.	O

Ten	O
had	O
unilateral	O
accessory	O
attachments	O
to	O
the	O
serratus	O
anterior	O
,	O
serratus	O
posterior	O
superior	O
or	O
the	O
first/second	O
rib	O
.	O

Four	O
had	O
bilateral	O
accessory	O
attachments	O
to	O
serratus	O
anterior	O
.	O

One	O
had	O
bilateral	O
accessory	O
attachments	O
to	O
serratus	O
posterior	O
superior	O
and	O
unilateral	O
accessory	O
attachment	O
to	O
serratus	O
anterior	O
.	O

One	O
had	O
bilateral	O
attachments	O
to	O
both	O
muscles	O
.	O

Both	O
unilateral	O
and	O
bilateral	O
LS	O
caudal	O
accessory	O
attachments	O
were	O
present	O
in	O
nearly	O
half	O
of	O
the	O
subjects	O
examined	O
.	O

They	O
were	O
relatively	O
more	O
frequent	O
in	O
females	O
than	O
males	O
.	O

The	O
findings	O
indicate	O
that	O
these	O
accessory	O
attachments	O
are	O
common	O
,	O
and	O
in	O
some	O
cases	O
,	O
those	O
accessory	O
attachments	O
can	O
occur	O
bilaterally	O
and	O
to	O
more	O
than	O
one	O
site	O
.	O

Variability	O
in	O
Saponin	O
Content	O
,	O
Cancer	O
Antiproliferative	O
Activity	O
and	O
Physicochemical	O
Properties	O
of	O
Concentrated	O
Agave	O
Sap	O
.	O

Concentrated	O
agave	O
sap	O
(	O
CAS	O
)	O
has	O
gained	O
popularity	O
as	O
an	O
unrefined	O
sweetener	O
.	O

It	O
is	O
obtained	O
by	O
boiling	O
``	O
aguamiel	O
``	O
that	O
contains	O
phytochemicals	O
with	O
diverse	O
bioactivities	O
.	O

Saponins	O
have	O
been	O
the	O
most	O
widely	O
studied	O
agave	O
phytochemicals	O
due	O
to	O
their	O
cancer	O
antiproliferative	O
effect	O
but	O
their	O
concentration	O
may	O
vary	O
due	O
to	O
maturity	O
of	O
the	O
agave	O
plant	O
and	O
collection	O
site	O
.	O

In	O
this	O
study	O
,	O
18	O
CAS	O
samples	O
produced	O
in	O
different	O
states	O
of	O
Mexico	O
were	O
analyzed	O
using	O
multivariate	O
methods	O
to	O
determine	O
which	O
physicochemical	O
or	O
phytochemical	O
parameters	O
were	O
responsible	O
for	O
variation	O
.	O

Additionally	O
,	O
extracts	O
with	O
different	O
saponin	O
profiles	B-P
were	O
tested	O
to	O
determine	O
possible	O
correlations	O
with	O
antiproliferative	O
activity	O
.	O

Total	O
soluble	O
solids	O
,	O
pH	O
,	O
and	O
water	O
activity	O
were	O
similar	O
to	O
those	O
reported	O
for	O
other	O
agave	O
sweeteners	O
.	O

Antioxidant	O
capacity	O
of	O
samples	O
was	O
correlated	O
to	O
browning	O
index	O
.	O

Eleven	O
steroidal	O
saponins	O
were	O
found	O
in	O
CAS	O
samples	O
and	O
they	O
were	O
the	O
main	O
source	O
of	O
variability	O
.	O

Magueyoside	O
B	O
,	O
a	O
kammogenin	O
tetraglycoside	O
,	O
was	O
the	O
most	O
abundant	O
saponin	O
in	O
all	O
samples	O
.	O

With	O
respect	O
to	O
bioactivity	O
,	O
multivariate	O
analysis	O
indicated	O
that	O
magueyoside	O
B	O
and	O
a	O
gentrogenin	O
tetraglycoside	O
were	O
compounds	O
strongly	O
related	O
with	O
bioactivity	O
.	O

CAS	O
from	O
Hidalgo	O
,	O
Puebla	O
,	O
and	O
Veracruz	O
had	O
higher	O
concentration	O
of	O
magueyoside	O
B	O
than	O
from	O
the	O
other	O
kamogenin	O
tetraglycoside	O
found	O
in	O
the	O
samples	O
from	O
other	O
Mexican	O
states	O
.	O

These	O
results	O
could	O
be	O
used	O
as	O
a	O
first	O
approach	O
to	O
characterize	O
and	O
standardize	O
CAS	O
to	O
validate	O
the	O
potential	O
health	O
benefits	O
derived	O
from	O
its	O
consumption	O
.	O

A	O
new	O
light	O
on	O
Alkaptonuria	O
:	O
A	O
Fourier-transform	B-P
infrared	I-P
microscopy	I-P
(	O
FTIRM	B-P
)	O
and	O
low	B-P
energy	I-P
X-ray	I-P
fluorescence	I-P
microscopy	I-P
(	O
LEXRF	B-P
)	O
correlative	O
study	O
on	O
a	O
rare	O
disease	O
.	O

Alkaptonuria	O
(	O
AKU	O
)	O
is	O
an	O
ultra-rare	O
disease	O
associated	O
to	O
the	O
lack	O
of	O
an	O
enzyme	O
involved	O
in	O
tyrosine	O
catabolism	O
.	O

This	O
deficiency	O
results	O
in	O
the	O
accumulation	O
of	O
homogentisic	O
acid	O
(	O
HGA	O
)	O
in	O
the	O
form	O
of	O
ochronotic	O
pigment	O
in	O
joint	O
cartilage	O
,	O
leading	O
to	O
a	O
severe	O
arthropathy	O
.	O

Secondary	O
amyloidosis	O
has	O
been	O
also	O
unequivocally	O
assessed	O
as	O
a	O
comorbidity	O
of	O
AKU	O
arthropathy	O
.	O

Composition	O
of	O
ochronotic	O
pigment	O
and	O
how	O
it	O
is	O
structurally	O
related	O
to	O
amyloid	O
is	O
still	O
unknown	O
.	O

We	O
exploited	O
Synchrotron	O
Radiation	O
Infrared	B-P
and	O
X-Ray	B-P
Fluorescence	I-P
microscopies	I-P
in	O
combination	O
with	O
conventional	O
bio-assays	B-P
and	O
analytical	O
tools	O
to	O
characterize	O
chemical	O
composition	O
and	O
morphology	O
of	O
AKU	O
cartilage	O
.	O

We	O
evinced	O
that	O
AKU	O
cartilage	O
is	O
characterized	O
by	O
proteoglycans	O
depletion	O
,	O
increased	O
Sodium	O
levels	O
,	O
accumulation	O
of	O
lipids	O
in	O
the	O
peri-lacunar	O
regions	O
and	O
amyloid	O
formation	O
.	O

We	O
also	O
highlighted	O
an	O
increase	O
of	O
aromatic	O
compounds	O
and	O
oxygen-containing	O
species	O
,	O
depletion	O
in	O
overall	O
Magnesium	O
content	O
(	O
although	O
localized	O
in	O
the	O
peri-lacunar	O
region	O
)	O
and	O
the	O
presence	O
of	O
calcium	O
carbonate	O
fragments	O
in	O
proximity	O
of	O
cartilage	O
lacunae	O
.	O

We	O
highlighted	O
common	O
features	O
between	O
AKU	O
and	O
arthropathy	O
,	O
but	O
also	O
specific	O
signatures	O
of	O
the	O
disease	O
,	O
like	O
presence	O
of	O
amyloids	O
and	O
peculiar	O
calcifications	O
.	O

Our	O
analyses	O
provide	O
a	O
unified	O
picture	O
of	O
AKU	O
cartilage	O
,	O
shedding	O
a	O
new	O
light	O
on	O
the	O
disease	O
and	O
opening	O
new	O
perspectives	O
.	O

Ochronotic	O
pigment	O
is	O
a	O
hallmark	O
of	O
AKU	O
and	O
responsible	O
of	O
tissue	O
degeneration	O
.	O

Conventional	O
bio-assays	B-P
have	O
not	O
yet	O
clarified	O
its	O
composition	O
and	O
its	O
structural	O
relationship	O
with	O
amyloids	O
.	O

The	O
present	O
work	O
proposes	O
new	O
strategies	O
for	O
filling	O
the	O
aforementioned	O
gap	O
that	O
encompass	O
the	O
integration	O
of	O
new	O
analytical	O
approaches	O
with	O
standardized	O
analyses	O
.	O

Critical	O
Aspects	O
for	O
Detection	O
of	O
Coxiella	O
burnetii	O
.	O

Coxiella	O
burnetii	O
is	O
a	O
globally	O
distributed	O
zoonotic	O
γ-proteobacterium	O
with	O
an	O
obligatory	O
intracellular	O
lifestyle	O
.	O

It	O
is	O
the	O
causative	O
agent	O
of	O
Q	O
fever	O
in	O
humans	O
and	O
of	O
coxiellosis	O
among	O
ruminants	O
,	O
although	O
the	O
agent	O
is	O
also	O
detected	O
in	O
ticks	O
,	O
birds	O
,	O
and	O
various	O
other	O
mammalian	O
species	O
.	O

Requirements	O
for	O
intracellular	O
multiplication	O
together	O
with	O
the	O
necessity	O
for	O
biosafety	O
level	O
3	O
facilities	O
restrict	O
the	O
cultivation	O
of	O
C.	O
burnetii	O
to	O
specialized	O
laboratories	O
.	O

Development	O
of	O
a	O
novel	O
medium	O
formulation	O
enabling	O
axenic	B-P
growth	I-P
of	O
C.	O
burnetii	O
has	O
facilitated	O
fundamental	O
genetic	O
studies	O
.	O

This	O
review	O
provides	O
critical	O
insights	O
into	O
direct	O
diagnostic	B-P
methods	I-P
currently	O
available	O
for	O
C.	O
burnetii	O
.	O

It	O
encompasses	O
molecular	O
detection	O
methods	O
,	O
isolation	B-P
,	O
and	O
propagation	B-P
of	I-P
the	I-P
bacteria	I-P
and	O
its	O
genetic	O
characterization	O
.	O

Differentiation	O
of	O
C.	O
burnetii	O
from	O
Coxiella-like	O
organisms	O
is	O
an	O
essential	O
diagnostic	O
prerequisite	O
,	O
particularly	O
when	O
handling	B-P
and	O
analyzing	O
ticks	O
.	O

Molecular	O
Mechanisms	O
of	O
Resistance	O
to	O
First-	O
and	O
Second-Generation	O
ALK	O
Inhibitors	O
in	O
ALK	O
-Rearranged	O
Lung	O
Cancer	O
.	O

Advanced	O
,	O
anaplastic	O
lymphoma	O
kinase	O
(	O
ALK	O
)	O
-positive	O
lung	O
cancer	O
is	O
currently	O
treated	O
with	O
the	O
first-generation	O
ALK	O
inhibitor	O
crizotinib	O
followed	O
by	O
more	O
potent	O
,	O
second-generation	O
ALK	O
inhibitors	O
(	O
e.g.	O
,	O
ceritinib	O
and	O
alectinib	O
)	O
upon	O
progression	O
.	O

Second-generation	O
inhibitors	O
are	O
generally	O
effective	O
even	O
in	O
the	O
absence	O
of	O
crizotinib	O
-	O
resistant	O
ALK	O
mutations	O
,	O
likely	O
reflecting	O
incomplete	O
inhibition	O
of	O
ALK	O
by	O
crizotinib	O
in	O
many	O
cases	O
.	O

Herein	O
,	O
we	O
analyzed	O
103	O
repeat	O
biopsies	B-P
from	O
ALK	O
-positive	O
patients	O
progressing	O
on	O
various	O
ALK	O
inhibitors	O
.	O

We	O
find	O
that	O
each	O
ALK	O
inhibitor	O
is	O
associated	O
with	O
a	O
distinct	O
spectrum	O
of	O
ALK	O
resistance	O
mutations	O
and	O
that	O
the	O
frequency	O
of	O
one	O
mutation	O
,	O
ALK	O
(	O
G1202R	O
)	O
,	O
increases	O
significantly	O
after	O
treatment	O
with	O
second-generation	O
agents	O
.	O

To	O
investigate	O
strategies	O
to	O
overcome	O
resistance	O
to	O
second-generation	O
ALK	O
inhibitors	O
,	O
we	O
examine	O
the	O
activity	O
of	O
the	O
third-generation	O
ALK	O
inhibitor	O
lorlatinib	O
in	O
a	O
series	O
of	O
ceritinib	O
-	O
resistant	O
,	O
patient	O
-derived	O
cell	O
lines	O
,	O
and	O
observe	O
that	O
the	O
presence	O
of	O
ALK	O
resistance	O
mutations	O
is	O
highly	O
predictive	O
for	O
sensitivity	O
to	O
lorlatinib	O
,	O
whereas	O
those	O
cell	O
lines	O
without	O
ALK	O
mutations	O
are	O
resistant	O
.	O

Secondary	O
ALK	O
mutations	O
are	O
a	O
common	O
resistance	O
mechanism	O
to	O
second-generation	O
ALK	O
inhibitors	O
and	O
predict	O
for	O
sensitivity	O
to	O
the	O
third-generation	O
ALK	O
inhibitor	O
lorlatinib	O
.	O

These	O
findings	O
highlight	O
the	O
importance	O
of	O
repeat	O
biopsies	B-P
and	O
genotyping	O
following	O
disease	O
progression	O
on	O
targeted	O
therapies	O
,	O
particularly	O
second-generation	O
ALK	O
inhibitors	O
.	O

Cancer	O
Discov	O
;	O
6	O
(	O
10	O
)	O
;	O
1118-33	O
.	O

©2016	O
AACRSee	O
related	O
commentary	O
by	O
Qiao	O
and	O
Lovly	O
,	O
p.	O
1084This	O
article	O
is	O
highlighted	O
in	O
the	O
In	O
This	O
Issue	O
feature	O
,	O
p.	O
1069	O
.	O

Harmonization	O
of	O
Clinical	O
Laboratory	O
Information	O
-	O
Current	O
and	O
Future	O
Strategies	O
.	O

According	O
to	O
a	O
patient	O
-centered	O
viewpoint	O
,	O
the	O
meaning	O
of	O
harmonization	O
in	O
the	O
context	O
of	O
laboratory	O
medicine	O
is	O
that	O
the	O
information	O
should	O
be	O
comparable	O
irrespective	O
of	O
the	O
measurement	O
procedure	O
used	O
and	O
where	O
and/or	O
when	O
a	O
measurement	O
is	O
made	O
.	O

Harmonization	O
represents	O
a	O
fundamental	O
aspect	O
of	O
quality	O
in	O
laboratory	O
medicine	O
as	O
its	O
ultimate	O
goal	O
is	O
to	O
improve	O
patient	O
outcomes	O
through	O
the	O
provision	O
of	O
an	O
accurate	O
and	O
actionable	O
laboratory	O
information	O
.	O

Although	O
the	O
initial	O
focus	O
has	O
to	O
a	O
large	O
extent	O
been	O
to	O
harmonize	O
and	O
standardize	O
analytical	O
processes	O
and	O
methods	O
,	O
the	O
scope	O
of	O
harmonization	O
goes	O
beyond	O
to	O
include	O
all	O
other	O
aspects	O
of	O
the	O
total	O
testing	O
process	O
(	O
TTP	O
)	O
,	O
such	O
as	O
terminology	O
and	O
units	O
,	O
report	O
formats	O
,	O
reference	O
intervals	O
and	O
decision	O
limits	O
,	O
as	O
well	O
as	O
tests	O
and	O
test	B-P
profiles	I-P
request	O
and	O
criteria	O
for	O
interpretation	O
.	O

Two	O
major	O
progresses	O
have	O
been	O
made	O
in	O
the	O
area	O
of	O
harmonization	O
in	O
laboratory	O
medicine	O
:	O
first	O
,	O
the	O
awareness	O
that	O
harmonization	O
should	O
take	O
into	O
consideration	O
not	O
only	O
the	O
analytical	O
phase	O
but	O
all	O
steps	O
of	O
the	O
TTP	O
,	O
thus	O
dealing	O
with	O
the	O
request	O
,	O
the	O
sample	O
,	O
the	O
measurement	O
,	O
and	O
the	O
report	O
.	O

Second	O
,	O
as	O
the	O
processes	O
required	O
to	O
achieve	O
harmonization	O
are	O
complicated	O
,	O
a	O
systematic	O
approach	O
is	O
needed	O
.	O

The	O
International	B-P
Federation	I-P
of	I-P
Clinical	I-P
Chemistry	I-P
and	I-P
Laboratory	I-P
Medicine	I-P
(	O
IFCC	B-P
)	O
has	O
played	O
a	O
fundamental	O
and	O
successful	O
role	O
in	O
the	O
development	O
of	O
standardized	O
and	O
harmonized	B-P
assays	I-P
,	O
and	O
now	O
it	O
should	O
continue	O
to	O
work	O
in	O
the	O
field	O
through	O
the	O
collaboration	O
and	O
cooperation	O
with	O
many	O
other	O
stakeholders	O
.	O

Historical	O
relationships	O
of	O
three	O
enigmatic	O
phasianid	O
genera	O
(	O
Aves	O
:	O
Galliformes	O
)	O
inferred	O
using	O
phylogenomic	O
and	O
mitogenomic	O
data	O
.	O

The	O
phylogeny	O
of	O
the	O
Phasianidae	O
(	O
pheasants	O
,	O
partridges	O
,	O
and	O
allies	O
)	O
has	O
been	O
studied	O
extensively	O
.	O

However	O
,	O
these	O
studies	O
have	O
largely	O
ignored	O
three	O
enigmatic	O
genera	O
because	O
of	O
scarce	O
DNA	O
source	O
material	O
and	O
limited	O
overlapping	O
phylogenetic	O
data	O
:	O
blood	O
pheasants	O
(	O
Ithaginis	O
)	O
,	O
snow	O
partridges	O
(	O
Lerwa	O
)	O
,	O
and	O
long-billed	O
partridges	O
(	O
Rhizothera	O
)	O
.	O

Thus	O
,	O
phylogenetic	O
positions	O
of	O
these	O
three	O
genera	O
remain	O
uncertain	O
in	O
what	O
is	O
otherwise	O
a	O
well-resolved	O
phylogeny	O
.	O

Previous	O
studies	O
using	O
different	O
data	O
types	O
place	O
Lerwa	O
and	O
Ithaginis	O
in	O
similar	O
positions	O
,	O
but	O
the	O
absence	O
of	O
overlapping	O
data	O
means	O
the	O
relationship	O
between	O
them	O
could	O
not	O
be	O
inferred	O
.	O

Rhizothera	O
was	O
originally	O
described	O
in	O
the	O
genus	O
Perdix	O
(	O
true	O
partridges	O
)	O
,	O
although	O
a	O
partial	O
cytochrome	O
b	O
(	O
CYB	O
)	O
sequence	O
suggests	O
it	O
is	O
sister	O
to	O
Pucrasia	O
(	O
koklass	O
pheasant	O
)	O
.	O

To	O
identify	O
robust	O
relationships	O
among	O
Ithaginis	O
,	O
Lerwa	O
,	O
Rhizothera	O
,	O
and	O
their	O
phasianid	O
relatives	O
,	O
we	O
used	O
3692	O
ultra-conserved	O
element	O
(	O
UCE	O
)	O
loci	O
and	O
complete	O
mitogenomes	O
from	O
19	O
species	O
including	O
previously	O
hypothesized	O
relatives	O
of	O
the	O
three	O
focal	O
genera	O
and	O
representatives	O
from	O
all	O
major	O
phasianid	O
clades	O
.	O

We	O
used	O
DNA	O
extracted	O
from	O
historical	O
specimen	O
toepads	O
for	O
species	O
that	O
lacked	O
fresh	O
tissue	O
in	O
museum	B-P
collections	I-P
.	O

Maximum	O
likelihood	O
and	O
multispecies	O
coalescent	O
UCE	O
analyses	O
strongly	O
supported	O
Lerwa	O
sister	O
to	O
a	O
large	O
clade	O
which	O
included	O
Ithaginis	O
at	O
its	O
base	O
,	O
and	O
also	O
including	O
turkey	O
,	O
grouse	O
,	O
typical	O
pheasants	O
,	O
tragopans	O
,	O
Pucrasia	O
,	O
and	O
Perdix	O
.	O

Rhizothera	O
was	O
also	O
in	O
this	O
clade	O
,	O
sister	O
to	O
a	O
diverse	O
group	O
comprising	O
Perdix	O
,	O
typical	O
pheasants	O
,	O
Pucrasia	O
,	O
turkey	O
and	O
grouse	O
.	O

Mitogenomic	O
genealogies	O
differed	O
from	O
UCEs	O
topologies	O
,	O
supporting	O
a	O
sister	O
relationship	O
between	O
Ithaginis	O
and	O
Lerwa	O
rather	O
than	O
a	O
grade	O
.	O

The	O
position	O
of	O
Rhizothera	O
using	O
mitogenomes	O
depended	O
on	O
analytical	O
choices	O
.	O

Unpartitioned	O
and	O
codon-based	O
analyses	O
placed	O
Rhizothera	O
sister	O
to	O
a	O
tragopan	O
clade	O
,	O
whereas	O
a	O
partitioned	O
DNA	O
model	O
of	O
the	O
mitogenome	O
was	O
congruent	O
with	O
UCE	O
results	O
.	O

In	O
all	O
mitogenome	B-P
analyses	I-P
,	O
Pucrasia	O
was	O
sister	O
to	O
a	O
clade	O
including	O
Perdix	O
and	O
the	O
typical	O
pheasants	O
with	O
high	O
support	O
,	O
in	O
contrast	O
to	O
UCEs	O
and	O
published	O
nuclear	O
intron	O
data	O
.	O

Due	O
to	O
the	O
strong	O
support	O
and	O
consistent	O
topology	O
provided	O
by	O
all	O
UCE	O
analyses	O
,	O
we	O
have	O
identified	O
phylogenetic	O
relationships	O
of	O
these	O
three	O
enigmatic	O
,	O
poorly-studied	O
,	O
phasianid	O
taxa	O
.	O

Conditional	O
reprogramming	O
and	O
long-term	O
expansion	O
of	O
normal	O
and	O
tumor	O
cells	O
from	O
human	O
biospecimens	O
.	O

Historically	O
,	O
it	O
has	O
been	O
difficult	O
to	O
propagate	O
cells	O
in	O
vitro	O
that	O
are	O
derived	O
directly	O
from	O
human	O
tumors	O
or	O
healthy	O
tissue	O
.	O

However	O
,	O
in	O
vitro	O
preclinical	O
models	O
are	O
essential	O
tools	O
for	O
both	O
the	O
study	O
of	O
basic	O
cancer	O
biology	O
and	O
the	O
promotion	O
of	O
translational	O
research	O
,	O
including	O
drug	O
discovery	O
and	O
drug	O
target	O
identification	O
.	O

This	O
protocol	O
describes	O
conditional	O
reprogramming	O
(	O
CR	O
)	O
,	O
which	O
involves	O
coculture	B-P
of	O
irradiated	O
mouse	O
fibroblast	O
feeder	O
cells	O
with	O
normal	O
and	O
tumor	O
human	O
epithelial	O
cells	O
in	O
the	O
presence	O
of	O
a	O
Rho	O
kinase	O
inhibitor	O
(	O
Y-27632	O
)	O
.	O

CR	O
cells	O
can	O
be	O
used	O
for	O
various	O
applications	O
,	O
including	O
regenerative	O
medicine	O
,	O
drug	B-P
sensitivity	I-P
testing	I-P
,	O
gene	O
expression	O
profiling	O
and	O
xenograft	O
studies	O
.	O

The	O
method	O
requires	O
a	O
pathologist	O
to	O
differentiate	O
healthy	O
tissue	O
from	O
tumor	O
tissue	O
,	O
and	O
basic	B-P
tissue	I-P
culture	I-P
skills	O
.	O

The	O
protocol	O
can	O
be	O
used	O
with	O
cells	O
derived	O
from	O
both	O
fresh	O
and	O
cryopreserved	O
tissue	O
samples	O
.	O

As	O
approximately	O
1	O
million	O
cells	O
can	O
be	O
generated	O
in	O
7	O
d	O
,	O
the	O
technique	O
is	O
directly	O
applicable	O
to	O
diagnostic	O
and	O
predictive	O
medicine	O
.	O

Moreover	O
,	O
the	O
epithelial	O
cells	O
can	O
be	O
propagated	O
indefinitely	O
in	O
vitro	O
,	O
yet	O
retain	O
the	O
capacity	O
to	O
become	O
fully	O
differentiated	O
when	O
placed	O
into	O
conditions	O
that	O
mimic	O
their	O
natural	O
environment	O
.	O

C4b	O
binding	O
protein	O
negatively	O
regulates	O
TLR1	O
/	O
2	O
response	O
.	O

TLR2	O
associates	O
with	O
TLR1	O
and	O
recognizes	O
microbial	O
lipoproteins	O
.	O

Pam3CSK4	O
,	O
a	O
triacylated	O
lipoprotein	O
,	O
is	O
anchored	O
to	O
the	O
extracellular	O
domain	O
of	O
TLR1	O
and	O
TLR2	O
and	O
induces	O
pro-inflammatory	O
signals	O
.	O

Here	O
we	O
show	O
that	O
C4b	O
binding	O
protein	O
(	O
C4BP	O
)	O
,	O
which	O
is	O
a	O
complement	O
pathway	O
inhibitor	O
,	O
is	O
a	O
TLR2	O
-associated	O
molecule	O
.	O

Immunoprecipitation	B-P
assay	I-P
using	O
anti-TLR2	O
mAb	O
shows	O
that	O
C4BP	O
binds	O
to	O
TLR2	O
.	O

In	O
C4BP-deficient	O
mice	O
,	O
Pam3CSK4	O
-	O
induced	O
IL-6	O
levels	O
were	O
increased	O
compared	O
with	O
wild	O
type	O
mice	O
.	O

In	O
C4BP	O
-	O
expressing	O
cells	O
,	O
Pam3CSK4	O
-	O
induced	O
IL-8	O
production	O
was	O
reduced	O
depending	O
on	O
the	O
C4BP	O
expression	O
levels	O
.	O

These	O
results	O
reveal	O
the	O
important	O
role	O
of	O
C4BP	O
in	O
negative	O
regulation	O
of	O
TLR1	O
/	O
2	O
-	O
dependent	O
pro-inflammatory	O
cytokine	O
production	O
.	O

Furthermore	O
,	O
using	O
a	O
fluorescent	O
conjugated	O
Pam3CSK4	O
,	O
we	O
show	O
that	O
C4BP	O
blocks	O
the	O
binding	O
of	O
Pam3CSK4	O
to	O
TLR1	O
/	O
2	O
.	O

Finally	O
,	O
we	O
show	O
that	O
exogenous	O
C4BP	O
also	O
inhibits	O
Pam3CSK4	O
-	O
induced	O
signaling	O
leading	O
to	O
IL-8	O
production	O
.	O

Our	O
results	O
indicate	O
C4BP	O
binding	O
to	O
TLR2	O
and	O
consequent	O
neutralization	O
of	O
its	O
activity	O
otherwise	O
inducing	O
pro-inflammatory	O
cytokine	O
production	O
.	O

C4BP	O
is	O
a	O
negative	O
regulator	O
of	O
TLR1	O
/	O
2	O
activity	O
.	O

The	O
genome	O
-scale	O
DNA-binding	O
profile	B-P
of	O
BarR	O
,	O
a	O
β-alanine	O
responsive	O
transcription	O
factor	O
in	O
the	O
archaeon	O
Sulfolobus	O
acidocaldarius	O
.	O

The	O
Leucine-responsive	O
Regulatory	O
Protein	O
(	O
Lrp	O
)	O
family	O
is	O
a	O
widespread	O
family	O
of	O
regulatory	O
transcription	O
factors	O
in	O
prokaryotes	O
.	O

BarR	O
is	O
an	O
Lrp	O
-like	O
transcription	O
factor	O
in	O
the	O
model	O
archaeon	O
Sulfolobus	O
acidocaldarius	O
that	O
activates	O
the	O
expression	O
of	O
a	O
β-alanine	O
aminotransferase	O
gene	O
,	O
which	O
is	O
involved	O
in	O
β-alanine	O
degradation	O
.	O

In	O
contrast	O
to	O
classical	O
Lrp	O
-like	O
transcription	O
factors	O
,	O
BarR	O
is	O
not	O
responsive	O
to	O
any	O
of	O
the	O
α-amino	O
acids	O
but	O
interacts	O
specifically	O
with	O
β-alanine	O
.	O

Besides	O
the	O
juxtaposed	O
β-alanine	O
aminotransferase	O
gene	O
,	O
other	O
regulatory	O
targets	O
of	O
BarR	O
have	O
not	O
yet	O
been	O
identified	O
although	O
β-alanine	O
is	O
the	O
precursor	O
of	O
coenzyme	O
A	O
and	O
thus	O
an	O
important	O
central	O
metabolite	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
extend	O
the	O
knowledge	O
of	O
the	O
DNA-binding	O
characteristics	O
of	O
BarR	O
and	O
of	O
its	O
corresponding	O
regulon	O
from	O
a	O
local	O
to	O
a	O
genome	O
-wide	O
perspective	O
.	O

We	O
characterized	O
the	O
genome-wide	B-P
binding	I-P
profile	I-P
of	O
BarR	O
using	O
chromatin	B-P
immunoprecipation	I-P
combined	O
with	O
high-throughput	O
sequencing	O
(	O
ChIP-seq	O
)	O
.	O

This	O
revealed	O
21	O
genomic	O
binding	O
loci	O
.	O

High-enrichment	O
binding	O
regions	O
were	O
validated	O
to	O
interact	O
with	O
purified	O
BarR	O
protein	O
in	O
vitro	O
using	O
electrophoretic	B-P
mobility	I-P
shift	I-P
assays	I-P
and	O
almost	O
all	O
targets	O
were	O
also	O
shown	O
to	O
harbour	O
a	O
conserved	O
semi-palindromic	O
binding	O
motif	O
.	O

Only	O
a	O
small	O
subset	O
of	O
enriched	O
genomic	O
sites	O
are	O
located	O
in	O
intergenic	O
regions	O
at	O
a	O
relative	O
short	O
distance	O
to	O
a	O
promoter	O
,	O
and	O
qRT-PCR	B-P
analysis	I-P
demonstrated	O
that	O
only	O
one	O
additional	O
operon	O
is	O
under	O
activation	O
of	O
BarR	O
,	O
namely	O
the	O
glutamine	O
synthase	O
operon	O
.	O

The	O
latter	O
is	O
also	O
a	O
target	O
of	O
other	O
Lrp	O
-like	O
transcription	O
factors	O
.	O

Detailed	O
inspection	O
of	O
the	O
BarR	O
ChIP-seq	O
profile	O
at	O
the	O
β-alanine	O
aminotransferase	O
promoter	O
region	O
in	O
combination	O
with	O
binding	O
motif	O
predictions	O
indicate	O
that	O
the	O
operator	O
structure	O
is	O
more	O
complicated	O
than	O
previously	O
anticipated	O
,	O
consisting	O
of	O
multiple	O
(	O
major	O
and	O
auxiliary	O
)	O
operators	O
.	O

BarR	O
has	O
a	O
limited	O
regulon	O
,	O
and	O
includes	O
also	O
glutamine	O
synthase	O
genes	O
besides	O
the	O
previously	O
characterized	O
β-alanine	O
aminotransferase	O
.	O

Regulation	O
of	O
glutamine	O
synthase	O
is	O
suggestive	O
of	O
a	O
link	O
between	O
β-alanine	O
and	O
α-amino	O
acid	O
metabolism	O
in	O
S.	O
acidocaldarius	O
.	O

Furthermore	O
,	O
this	O
work	O
reveals	O
that	O
the	O
BarR	O
regulon	O
overlaps	O
with	O
that	O
of	O
other	O
Lrp	O
-like	O
regulators	O
.	O

Ultra-low	O
activities	O
of	O
a	O
common	O
radioisotope	O
for	O
permission	O
-free	O
tracking	O
of	O
a	O
drosophilid	O
fly	O
in	O
its	O
natural	O
habitat	O
.	O

Knowledge	O
of	O
a	O
species	O
'	O
ecology	O
,	O
including	O
its	O
movement	O
in	O
time	O
and	O
space	O
,	O
is	O
key	O
for	O
many	O
questions	O
in	O
biology	O
and	O
conservation	O
.	O

While	O
numerous	O
tools	O
for	O
tracking	O
larger	O
animals	O
are	O
available	O
,	O
millimetre-sized	O
insects	O
are	O
averse	O
to	O
standard	O
tracking	O
and	O
labelling	O
procedures	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
applicability	O
of	O
ultra-low	O
,	O
permission	O
-	O
exempt	O
activities	O
of	O
the	O
metastable	O
isomer	O
of	O
the	O
radionuclide	O
Technetium-99	O
for	O
labelling	O
and	O
field	O
detection	O
of	O
the	O
mountain	O
fly	O
Drosophila	O
nigrosparsa	O
.	O

We	O
demonstrate	O
that	O
an	O
activity	O
of	O
less	O
than	O
10	O
MBq	O
is	O
sufficient	O
to	O
label	O
dozens	O
of	O
flies	O
and	O
detect	O
single	O
individuals	O
using	O
standard	O
radiation	O
protection	O
monitors	B-P
.	O

The	O
methodology	O
presented	O
here	O
is	O
applicable	O
to	O
many	O
small-sized	O
,	O
low-mobility	O
animals	O
as	O
well	O
as	O
independent	O
from	O
light	O
and	O
weather	O
conditions	O
and	O
visual	O
contact	O
with	O
the	O
target	O
organism	O
.	O

Somatic	O
molecular	B-P
subtyping	I-P
of	O
prostate	O
tumors	O
from	O
HOXB13	O
G84E	O
carriers	O
.	O

A	O
recurrent	O
germline	O
mutation	O
(	O
G84E	O
)	O
in	O
the	O
HOXB13	O
gene	O
is	O
associated	O
with	O
early	O
onset	O
and	O
family	O
history	O
-positive	O
prostate	O
cancer	O
in	O
patients	O
of	O
European	O
descent	O
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	O
cancer	O
families	O
.	O

To	O
date	O
,	O
the	O
molecular	O
features	O
of	O
prostate	O
tumors	O
occurring	O
in	O
HOXB13	O
G84E	O
carriers	O
have	O
not	O
been	O
studied	O
in	O
a	O
large	O
cohort	O
of	O
patients	O
.	O

We	O
identified	O
101	O
heterozygous	O
carriers	O
of	O
G84E	O
who	O
underwent	O
radical	O
prostatectomy	O
for	O
prostate	O
cancer	O
between	O
1985	O
and	O
2011	O
and	O
matched	O
these	O
men	O
by	O
race	O
,	O
age	O
and	O
tumor	O
grade	O
to	O
99	O
HOXB13	O
wild-type	O
controls	O
.	O

Immunostaining	B-P
for	O
HOXB13	O
,	O
PTEN	O
,	O
ERG	O
,	O
p53	O
and	O
SPINK1	O
as	O
well	O
as	O
RNA	O
in	O
situ	O
hybridization	O
for	O
ETV1	O
/	O
4	O
/	O
5	O
were	O
performed	O
using	O
genetically	B-P
validated	I-P
assays	I-P
.	O

Tumors	O
from	O
G84E	O
carriers	O
generally	O
expressed	O
HOXB13	O
protein	O
at	O
a	O
level	O
comparable	O
to	O
benign	O
and	O
wild-type	O
glands	O
.	O

ETS	O
gene	O
expression	O
(	O
either	O
ERG	O
or	O
ETV1	O
/	O
4	O
/	O
5	O
)	O
was	O
seen	O
in	O
36	O
%	O
(	O
36/101	O
)	O
of	O
tumors	O
from	O
G84E	O
carriers	O
compared	O
to	O
68	O
%	O
(	O
65/96	O
)	O
of	O
the	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

PTEN	O
was	O
lost	O
in	O
11	O
%	O
(	O
11/101	O
)	O
of	O
G84E	O
carriers	O
compared	O
to	O
25	O
%	O
(	O
25/99	O
)	O
of	O
the	O
controls	O
(	O
p	O
=	O
0.014	O
)	O
.	O

PTEN	O
loss	O
was	O
enriched	O
among	O
ERG	O
-	O
positive	O
compared	O
to	O
ERG	O
-	O
negative	O
tumors	O
in	O
both	O
groups	O
of	O
patients	O
.	O

Nuclear	O
accumulation	O
of	O
the	O
p53	O
protein	O
,	O
indicative	O
of	O
underlying	O
TP53	O
missense	O
mutations	O
,	O
was	O
uncommon	O
in	O
both	O
groups	O
,	O
occurring	O
in	O
1	O
%	O
(	O
1/101	O
)	O
of	O
the	O
G84E	O
carriers	O
versus	O
2	O
%	O
(	O
2/92	O
)	O
of	O
the	O
controls	O
(	O
p	O
=	O
NS	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
genes	O
other	O
than	O
ERG	O
and	O
PTEN	O
may	O
drive	O
carcinogenesis	O
/	O
progression	O
in	O
the	O
majority	O
of	O
men	O
with	O
germline	O
HOXB13	O
mutations	O
.	O

Single-cell	O
RNA-seq	O
enables	O
comprehensive	O
tumour	O
and	O
immune	B-P
cell	I-P
profiling	I-P
in	O
primary	O
breast	O
cancer	O
.	O

Single-cell	O
transcriptome	O
profiling	O
of	O
tumour	O
tissue	O
isolates	O
allows	O
the	O
characterization	O
of	O
heterogeneous	O
tumour	O
cells	O
along	O
with	O
neighbouring	O
stromal	O
and	O
immune	O
cells	O
.	O

Here	O
we	O
adopt	O
this	O
powerful	O
approach	O
to	O
breast	O
cancer	O
and	O
analyse	O
515	O
cells	O
from	O
11	O
patients	O
.	O

Inferred	O
copy	O
number	O
variations	O
from	O
the	O
single-cell	O
RNA-seq	O
data	O
separate	O
carcinoma	O
cells	O
from	O
non-cancer	O
cells	O
.	O

At	O
a	O
single-cell	O
resolution	O
,	O
carcinoma	O
cells	O
display	O
common	O
signatures	O
within	O
the	O
tumour	O
as	O
well	O
as	O
intratumoral	O
heterogeneity	O
regarding	O
breast	O
cancer	O
subtype	O
and	O
crucial	O
cancer-related	O
pathways	O
.	O

Most	O
of	O
the	O
non-cancer	O
cells	O
are	O
immune	O
cells	O
,	O
with	O
three	O
distinct	O
clusters	O
of	O
T	O
lymphocytes	O
,	O
B	O
lymphocytes	O
and	O
macrophages	O
.	O

T	O
lymphocytes	O
and	O
macrophages	O
both	O
display	O
immunosuppressive	O
characteristics	O
:	O
T	O
cells	O
with	O
a	O
regulatory	O
or	O
an	O
exhausted	O
phenotype	O
and	O
macrophages	O
with	O
an	O
M2	O
phenotype	O
.	O

These	O
results	O
illustrate	O
that	O
the	O
breast	O
cancer	O
transcriptome	O
has	O
a	O
wide	O
range	O
of	O
intratumoral	O
heterogeneity	O
,	O
which	O
is	O
shaped	O
by	O
the	O
tumour	O
cells	O
and	O
immune	O
cells	O
in	O
the	O
surrounding	O
microenvironment	O
.	O

Comprehensive	O
analysis	O
of	O
long	O
non-coding	O
RNAs	O
highlights	O
their	O
spatio-temporal	O
expression	O
patterns	O
and	O
evolutional	O
conservation	O
in	O
Sus	O
scrofa	O
.	O

Despite	O
modest	O
sequence	O
conservation	O
and	O
rapid	O
evolution	O
,	O
long	O
non-coding	O
RNAs	O
(	O
lncRNAs	O
)	O
appear	O
to	O
be	O
conserved	O
in	O
expression	O
pattern	O
and	O
function	O
.	O

However	O
,	O
analysis	O
of	O
lncRNAs	O
across	O
tissues	O
and	O
developmental	O
stages	O
remains	O
largely	O
uncharacterized	O
in	O
mammals	O
.	O

Here	O
,	O
we	O
systematically	O
investigated	O
the	O
lncRNAs	O
of	O
the	O
Guizhou	O
miniature	O
pig	O
(	O
Sus	O
scrofa	O
)	O
,	O
which	O
was	O
widely	O
used	O
as	O
biomedical	O
model	O
.	O

We	O
performed	O
RNA	O
sequencing	O
across	O
9	O
organs	O
and	O
3	O
developmental	O
skeletal	O
muscle	O
,	O
and	O
developed	O
a	O
filtering	O
pipeline	O
to	O
identify	O
10,813	O
lncRNAs	O
(	O
9,075	O
novel	O
)	O
.	O

Conservation	O
patterns	O
analysis	O
revealed	O
that	O
57	O
%	O
of	O
pig	O
lncRNAs	O
showed	O
homology	O
to	O
humans	O
and	O
mice	O
based	O
on	O
genome	O
alignment	O
.	O

5,455	O
lncRNAs	O
exhibited	O
typical	O
hallmarks	O
of	O
regulatory	O
molecules	O
,	O
such	O
as	O
high	O
spatio-temporal	O
specificity	O
.	O

Notably	O
,	O
conserved	O
lncRNAs	O
exhibited	O
higher	O
tissue	O
specificity	O
than	O
pig	O
-	O
specific	O
lncRNAs	O
and	O
were	O
significantly	O
enriched	O
in	O
testis	O
and	O
ovary	O
.	O

Weighted	O
co-expression	O
network	O
analysis	O
revealed	O
a	O
set	O
of	O
conserved	O
lncRNAs	O
that	O
are	O
likely	O
involved	O
in	O
postnatal	O
muscle	O
development	O
.	O

Based	O
on	O
the	O
high	O
degree	O
of	O
similarity	O
in	O
the	O
structure	O
,	O
organization	O
,	O
and	O
dynamic	O
expression	O
of	O
pig	O
lncRNAs	O
compared	O
with	O
human	O
and	O
mouse	O
lncRNAs	O
,	O
we	O
propose	O
that	O
these	O
lncRNAs	O
play	O
an	O
important	O
role	O
in	O
organ	O
physiology	O
and	O
development	O
in	O
mammals	O
.	O

Our	O
results	O
provide	O
a	O
resource	O
for	O
studying	B-P
animal	O
evolution	O
,	O
morphological	O
complexity	O
,	O
breeding	O
,	O
and	O
biomedical	O
research	O
.	O

Effect	O
of	O
endodontic	O
access	O
cavity	O
preparation	O
on	O
monolithic	O
and	O
ceramic	O
veneered	O
zirconia	O
restorations	O
.	O

Due	O
to	O
the	O
high	O
chipping	O
rates	O
observed	O
in	O
veneered	O
zirconia	O
ceramic	O
restorations	O
,	O
the	O
use	O
of	O
monolithic	O
zirconia	O
restorations	O
has	O
been	O
recommended	O
.	O

This	O
study	O
tried	O
to	O
compare	O
veneered	O
and	O
monolithic	O
zirconia	O
fixed	O
dental	O
prostheses	O
(	O
FDPs	O
)	O
with	O
respect	O
to	O
the	O
amount	O
of	O
damage	O
induced	O
by	O
endodontic	O
access	O
preparation	O
.	O

Monolithic	O
and	O
ceramic	O
veneered	O
(	O
n	O
=	O
10	O
)	O
three-unit	O
restorations	O
(	O
retainers	O
:	O
first	O
premolar	O
and	O
first	O
molar	O
;	O
pontic	O
:	O
second	O
premolar	O
)	O
were	O
subject	O
to	O
endodontic	O
access	O
cavity	O
preparation	O
in	O
both	O
retainers	O
using	O
a	O
diamond	O
rotary	O
instrument	O
under	O
continuous	O
water	O
cooling	O
.	O

The	O
number	O
of	O
chipping	O
fractures	O
and	O
microfractures	O
detected	O
using	O
the	O
fluorescent	B-P
penetrant	I-P
method	I-P
were	O
recorded	O
.	O

Statistical	O
analysis	O
was	O
based	O
on	O
Wilcoxon	O
rank	O
sum	O
tests	O
with	O
Bonferroni	O
correction	O
(	O
level	O
of	O
significance	O
α	O
=	O
.05	O
)	O
.	O

Only	O
one	O
microfracture	O
could	O
be	O
identified	O
in	O
the	O
group	O
of	O
monolithic	O
FDPs	O
while	O
a	O
maximum	O
of	O
seven	O
microfractures	O
and	O
three	O
chipping	O
fractures	O
per	O
retainer	O
crown	O
were	O
recorded	O
in	O
the	O
group	O
of	O
veneered	O
restorations	O
.	O

At	O
the	O
premolar	O
site	O
,	O
the	O
veneered	O
restorations	O
showed	O
significantly	O
more	O
microfractures	O
(	O
P	O
=	O
.0055	O
)	O
and	O
chipping	O
fractures	O
(	O
P	O
=	O
.0008	O
)	O
.	O

At	O
the	O
molar	O
site	O
,	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
microfractures	O
could	O
be	O
detected	O
(	O
P	O
=	O
.0767	O
)	O
,	O
while	O
significantly	O
more	O
chipping	O
fractures	O
occurred	O
in	O
the	O
veneered	O
samples	O
(	O
P	O
=	O
.0293	O
)	O
.	O

Monolithic	O
zirconia	O
restorations	O
seem	O
to	O
be	O
less	O
susceptible	O
to	O
damage	O
when	O
endodontic	O
access	O
cavities	O
have	O
to	O
be	O
prepared	O
as	O
compared	O
to	O
veneered	O
zirconia	O
reconstructions	O
.	O

However	O
,	O
no	O
conclusions	O
can	O
be	O
drawn	O
on	O
the	O
longterm	O
performance	O
of	O
a	O
specific	O
restoration	O
based	O
on	O
this	O
study	O
.	O

A	O
quantitative	O
method	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	O
in	O
myasthenia	O
gravis	O
.	O

Speech	O
and	O
voice	O
symptomatology	O
(	O
dysarthrophonia	O
)	O
are	O
often	O
reported	O
by	O
patients	O
with	O
myasthenia	O
gravis	O
(	O
MG	O
)	O
.	O

However	O
,	O
they	O
have	O
been	O
poorly	O
investigated	O
despite	O
their	O
significant	O
impact	O
on	O
quality	O
of	O
life	O
.	O

Quantitative	O
methods	O
for	O
the	O
assessment	O
of	O
dysarthrοphonia	O
could	O
facilitate	O
the	O
evaluation	O
of	O
these	O
common	O
MG	O
symptoms	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
phonatory	O
(	O
sustained	O
phonation	O
and	O
reading	O
)	O
and	O
speech	O
(	O
diadochokinesis	O
)	O
function	O
in	O
MG	O
patients	O
using	O
quantitative	O
measures	O
.	O

The	O
voice	O
/	O
speech	O
of	O
12	O
MG	O
patients	O
(	O
7	O
with	O
anti-AchR	O
and	O
5	O
with	O
anti-MuSK	B-P
antibodies	I-P
)	O
and	O
24	O
age-matched	O
healthy	O
controls	O
was	O
recorded	O
and	O
analyzed	O
using	O
electroglottography	B-P
(	O
EGG	B-P
)	O
and	O
speech	O
acoustics	O
.	O

For	O
the	O
analysis	O
of	O
voice	O
,	O
the	O
variables	O
that	O
were	O
found	O
to	O
distinguish	O
MG	O
patients	O
compared	O
to	O
healthy	O
controls	O
were	O
a	O
higher	O
average	O
fundamental	O
frequency	O
(	O
P	O
<	O
0.05	O
)	O
,	O
a	O
higher	O
standard	O
deviation	O
of	O
the	O
average	O
fundamental	O
frequency	O
(	O
P	O
<	O
0.001	O
)	O
,	O
a	O
higher	O
mean	O
fundamental	O
frequency	O
of	O
the	O
vibrating	O
vocal	O
folds	O
(	O
P	O
<	O
0.005	O
)	O
and	O
a	O
higher	O
fundamental	O
frequency	O
range	O
(	O
P	O
<	O
0.005	O
)	O
.	O

The	O
analysis	O
of	O
diadochokinesis	O
showed	O
that	O
MG	O
patients	O
had	O
a	O
higher	O
mean	O
duration	O
of	O
the	O
silent	O
interval	O
between	O
a	O
series	O
of	O
repetitive	O
/pa/	O
syllables	O
(	O
P	O
<	O
0.05	O
)	O
,	O
of	O
the	O
sound	O
/t/	O
(	O
P=0.05	O
)	O
and	O
of	O
the	O
silent	O
interval	O
between	O
a	O
series	O
of	O
repetitive	O
/ka/syllables	O
(	O
P	O
<	O
0.05	O
)	O
.	O

No	O
statistical	O
differences	O
were	O
found	O
in	O
any	O
of	O
these	O
variables	O
between	O
the	O
MG	O
subgroups	O
with	O
anti-AchR	O
or	O
anti-MuSK	B-P
antibodies	I-P
.	O

This	O
study	O
demonstrates	O
that	O
non-invasive	O
physiological	O
methods	O
(	O
EGG	B-P
and	O
speech	O
acoustics	O
)	O
offer	O
essential	O
tools	O
for	O
the	O
assessment	O
of	O
dysarthrophonia	O
in	O
MG	O
patients	O
.	O

An	O
abdominal	O
ectopic	O
pregnancy	O
following	O
a	O
frozen-thawed	O
ART	O
cycle	O
:	O
a	O
case	O
report	O
and	O
r	O
eview	O
of	O
the	O
literature	O
.	O

Ectopic	O
pregnancy	O
(	O
EP	O
)	O
occurs	O
in	O
1	O
%	O
of	O
pregnancies	O
and	O
is	O
reported	O
to	O
be	O
more	O
common	O
in	O
in	O
vitro	O
fertilization	O
/	O
intracytoplasmic	O
sperm	O
injection	O
(	O
IVF	O
/	O
ICSI	O
)	O
pregnancies	O
.	O

An	O
abdominal	O
ectopic	O
pregnancy	O
(	O
AEP	O
)	O
is	O
a	O
rare	O
form	O
of	O
EP	O
,	O
and	O
there	O
are	O
few	O
reports	O
of	O
an	O
AEP	O
after	O
IVF	O
/	O
ICSI	O
.	O

In	O
this	O
case	O
report	O
,	O
a	O
rare	O
case	O
of	O
AEP	O
after	O
frozen-thawed	O
cycle	O
of	O
ICSI	O
is	O
presented	O
.	O

After	O
a	O
frozen-thawed	O
cycle	O
of	O
ICSI	O
,	O
the	O
beta-human	O
chorionic	O
gonadotropin	O
(	O
HCG	O
)	O
level	O
at	O
4	O
weeks	O
0	O
days	O
of	O
gestation	O
was	O
3.4	O
IU/L	O
.	O

Subsequent	O
dysfunctional	O
uterine	O
bleeding	O
was	O
mistaken	O
for	O
menstruation	O
;	O
however	O
,	O
an	O
AEP	O
of	O
9	O
weeks	O
with	O
a	O
fetal	O
heart	O
beat	O
was	O
observed	O
by	O
ultrasound	B-P
.	O

After	O
the	O
AEP	O
was	O
observed	O
by	O
ultrasound	B-P
,	O
it	O
was	O
extracted	O
laparoscopically	B-P
.	O

A	O
rare	O
case	O
of	O
an	O
AEP	O
,	O
which	O
developed	O
after	O
frozen-thawed	O
cycle	O
of	O
ICSI	O
,	O
presented	O
with	O
a	O
very	O
low	O
serum	O
HCG	O
level	O
.	O

Even	O
if	O
the	O
HCG	O
titer	O
is	O
low	O
,	O
follow-up	O
HCG	O
levels	O
and	O
frequent	O
medical	O
examinations	O
are	O
necessary	O
.	O

Transcription	O
rate	O
and	O
transcript	O
length	O
drive	O
formation	O
of	O
chromosomal	O
interaction	O
domain	O
boundaries	O
.	O

Chromosomes	O
in	O
all	O
organisms	O
are	O
highly	O
organized	O
and	O
divided	O
into	O
multiple	O
chromosomal	O
interaction	O
domains	O
,	O
or	O
topological	O
domains	O
.	O

Regions	O
of	O
active	O
,	O
high	O
transcription	O
help	O
establish	O
and	O
maintain	O
domain	O
boundaries	O
,	O
but	O
precisely	O
how	O
this	O
occurs	O
remains	O
unclear	O
.	O

Here	O
,	O
using	O
fluorescence	B-P
microscopy	I-P
and	O
chromosome	O
conformation	O
capture	O
in	O
conjunction	O
with	O
deep	O
sequencing	O
(	O
Hi-C	O
)	O
,	O
we	O
show	O
that	O
in	O
Caulobacter	O
crescentus	O
,	O
both	O
transcription	O
rate	O
and	O
transcript	O
length	O
,	O
independent	O
of	O
concurrent	O
translation	O
,	O
drive	O
the	O
formation	O
of	O
domain	O
boundaries	O
.	O

We	O
find	O
that	O
long	O
,	O
highly	O
expressed	O
genes	O
do	O
not	O
form	O
topological	O
boundaries	O
simply	O
through	O
the	O
inhibition	O
of	O
supercoil	O
diffusion	O
.	O

Instead	O
,	O
our	O
results	O
support	O
a	O
model	O
in	O
which	O
long	O
,	O
active	O
regions	O
of	O
transcription	O
drive	O
local	O
decompaction	O
of	O
the	O
chromosome	O
,	O
with	O
these	O
more	O
open	O
regions	O
of	O
the	O
chromosome	O
forming	O
spatial	O
gaps	O
in	O
vivo	O
that	O
diminish	O
contacts	O
between	O
DNA	O
in	O
neighboring	O
domains	O
.	O

These	O
insights	O
into	O
the	O
molecular	O
forces	O
responsible	O
for	O
domain	O
formation	O
in	O
Caulobacter	O
likely	O
generalize	O
to	O
other	O
bacteria	O
and	O
possibly	O
eukaryotes	O
.	O

Argininosuccinic	O
Acid	O
Lyase	O
Deficiency	O
Missed	O
by	O
Newborn	B-P
Screen	I-P
.	O

Argininosuccinic	O
acid	O
lyase	O
(	O
ASL	O
)	O
deficiency	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
ASL	O
gene	O
(	O
OMIM	O
:	O
608310	O
)	O
is	O
a	O
urea	O
cycle	O
disorder	O
that	O
has	O
pleiotropic	O
presentations	O
.	O

On	O
the	O
mild	O
end	O
,	O
ASL	O
deficiency	O
can	O
manifest	O
as	O
nonspecific	O
neurocognitive	O
abnormalities	O
without	O
readily	O
identifiable	O
signs	O
to	O
differentiate	O
it	O
from	O
other	O
causes	O
of	O
intellectual	O
disability	O
or	O
learning	O
disabilities	O
.	O

Dietary	O
management	O
and	O
arginine	O
supplementation	O
,	O
if	O
initiated	O
early	O
,	O
may	O
ameliorate	O
symptoms	O
.Because	O
of	O
the	O
nonspecific	O
nature	O
of	O
the	O
symptoms	O
and	O
the	O
possibility	O
for	O
therapeutic	O
management	O
,	O
ASL	O
deficiency	O
is	O
part	O
of	O
the	O
recommended	O
uniform	B-P
screening	I-P
panel	I-P
for	O
newborn	B-P
screening	I-P
in	O
the	O
USA	O
.	O

We	O
report	O
here	O
a	O
case	O
of	O
ASL	O
deficiency	O
that	O
was	O
missed	O
on	O
newborn	B-P
screening	I-P
in	O
the	O
USA	O
.The	O
case	O
reported	O
here	O
has	O
two	O
known	O
pathogenic	O
mutations	O
-	O
one	O
with	O
no	O
residual	O
activity	O
and	O
one	O
with	O
reported	O
10	O
%	O
residual	O
activity	O
.	O

Review	O
of	O
this	O
newborn	B-P
screening	I-P
results	O
showed	O
subtle	O
elevation	O
of	O
citrulline	O
,	O
overlapping	O
the	O
normal	O
range	O
.	O

These	O
findings	O
suggest	O
that	O
newborn	B-P
screening	I-P
may	O
be	O
missing	O
other	O
patients	O
with	O
ASL	O
deficiency	O
with	O
at	O
least	O
one	O
hypomorphic	O
allele	O
.	O

This	O
case	O
was	O
diagnosed	O
incidentally	O
,	O
but	O
in	O
retrospect	O
had	O
symptoms	O
best	O
attributed	O
in	O
full	O
or	O
in	O
part	O
to	O
his	O
ASA	O
deficiency	O
,	O
including	O
protein	O
aversion	O
,	O
developmental	O
delay	O
,	O
and	O
seizures	O
.	O

This	O
case	O
highlights	O
the	O
importance	O
of	O
considering	O
ASL	O
deficiency	O
in	O
patients	O
with	O
nonspecific	O
abnormal	O
neurocognitive	O
signs	O
,	O
such	O
as	O
epilepsy	O
and	O
developmental	O
delay	O
,	O
even	O
when	O
newborn	B-P
screening	I-P
was	O
normal	O
.	O

Tzumin	O
A	O
and	O
B	O
,	O
two	O
new	O
lignan	O
derivatives	O
from	O
the	O
barks	O
of	O
Sassafras	O
tzumu	O
.	O

Two	O
new	O
lignan	O
compounds	O
,	O
5'-allyl-2,2'-dihydroxy-	O
[	O
1,1'-biphenyl	O
]	O
-5-carboxylic	O
acid	O
(	O
1	O
)	O
and	O
4,4'-diallyl-	O
[	O
1,1'-biphenyl	O
]	O
-2,2'-diol	O
(	O
2	O
)	O
,	O
together	O
with	O
four	O
known	O
compounds	O
(	O
3-6	O
)	O
,	O
were	O
isolated	O
from	O
the	O
barks	O
of	O
Sassafras	O
tzumu	O
.	O

The	O
new	O
compounds	O
were	O
determined	O
by	O
NMR	B-P
(	I-P
(	I-P
1	I-P
)	I-P
H	I-P
and	O
(	B-P
13	I-P
)	I-P
C	I-P
NMR	I-P
,	O
HSQC	B-P
,	O
HMBC	B-P
,	O
(	B-P
1	I-P
)	I-P
H-	I-P
(	I-P
1	I-P
)	I-P
H	I-P
COSY	I-P
,	O
NOESY	B-P
/	O
ROESY	B-P
)	O
,	O
and	O
MS	B-P
analysis	O
.	O

Compounds	O
1-3	O
showed	O
potent	O
AChE	O
inhibitory	O
activities	O
,	O
with	O
IC50	O
values	O
of	O
2.00	O
,	O
1.81	O
and	O
1.91	O
μM	O
,	O
respectively	O
.	O

EctD	O
-mediated	O
biotransformation	O
of	O
the	O
chemical	O
chaperone	O
ectoine	O
into	O
hydroxyectoine	O
and	O
its	O
mechanosensitive	O
channel	O
-independent	O
excretion	O
.	O

Ectoine	O
and	O
its	O
derivative	O
5-hydroxyectoine	O
are	O
cytoprotectants	O
widely	O
synthesized	O
by	O
microorganisms	O
as	O
a	O
defense	O
against	O
the	O
detrimental	O
effects	O
of	O
high	O
osmolarity	O
on	O
cellular	O
physiology	O
and	O
growth	O
.	O

Both	O
ectoines	O
possess	O
the	O
ability	O
to	O
preserve	O
the	O
functionality	O
of	O
proteins	O
,	O
macromolecular	O
complexes	O
,	O
and	O
even	O
entire	O
cells	O
,	O
attributes	O
that	O
led	O
to	O
their	O
description	O
as	O
chemical	O
chaperones	O
.	O

As	O
a	O
consequence	O
,	O
there	O
is	O
growing	O
interest	O
in	O
using	O
ectoines	O
for	O
biotechnological	O
purposes	O
,	O
in	O
skin	O
care	O
,	O
and	O
in	O
medical	O
applications	O
.	O

5-Hydroxyectoine	O
is	O
synthesized	O
from	O
ectoine	O
through	O
a	O
region-	O
and	O
stereo-specific	O
hydroxylation	O
reaction	O
mediated	O
by	O
the	O
EctD	O
enzyme	O
,	O
a	O
member	O
of	O
the	O
non-heme-containing	O
iron	O
(	O
II	O
)	O
and	O
2-oxoglutarate	O
-dependent	O
dioxygenases	O
.	O

This	O
chemical	O
modification	O
endows	O
the	O
newly	O
formed	O
5-hydroxyectoine	O
with	O
either	O
superior	O
or	O
different	O
stress-	O
protecting	O
and	O
stabilizing	O
properties	O
.	O

Microorganisms	O
producing	O
5-hydroxyectoine	O
typically	O
contain	O
a	O
mixture	O
of	O
both	O
ectoines	O
.	O

We	O
aimed	O
to	O
establish	O
a	O
recombinant	O
microbial	O
cell	O
factory	O
where	O
5-hydroxyectoine	O
is	O
(	O
i	O
)	O
produced	O
in	O
highly	O
purified	O
form	O
,	O
and	O
(	O
ii	O
)	O
secreted	O
into	O
the	O
growth	O
medium	O
.	O

We	O
used	O
an	O
Escherichia	O
coli	O
strain	O
(	O
FF4169	O
)	O
defective	O
in	O
the	O
synthesis	O
of	O
the	O
osmostress	O
protectant	O
trehalose	O
as	O
the	O
chassis	O
for	O
our	O
recombinant	O
cell	O
factory	O
.	O

We	O
expressed	O
in	O
this	O
strain	O
a	O
plasmid	O
-encoded	O
ectD	O
gene	O
from	O
Pseudomonas	O
stutzeri	O
A1501	O
under	O
the	O
control	O
of	O
the	O
anhydrotetracycline	O
-inducible	O
tet	O
promoter	O
.	O

We	O
chose	O
the	O
ectoine	O
hydroxylase	O
from	O
P.	O
stutzeri	O
A1501	O
for	O
our	O
cell	O
factory	O
after	O
a	O
careful	O
comparison	O
of	O
the	O
in	O
vivo	O
performance	O
of	O
seven	O
different	O
EctD	O
proteins	O
.	O

In	O
the	O
final	O
set-up	O
of	O
the	O
cell	O
factory	O
,	O
ectoine	O
was	O
provided	O
to	O
salt-stressed	B-P
cultures	I-P
of	O
strain	O
FF4169	O
(	O
pMP41	O
;	O
ectD	O
(	O
+	O
)	O
)	O
.	O

Ectoine	O
was	O
imported	O
into	O
the	O
cells	O
via	O
the	O
osmotically	O
inducible	O
ProP	O
and	O
ProU	O
transport	O
systems	O
,	O
intracellularly	O
converted	O
to	O
5-hydroxyectoine	O
,	O
which	O
was	O
then	O
almost	O
quantitatively	O
secreted	O
into	O
the	O
growth	O
medium	O
.	O

Experiments	O
with	O
an	O
E.	O
coli	O
mutant	O
lacking	O
all	O
currently	O
known	O
mechanosensitive	O
channels	O
(	O
MscL	O
,	O
MscS	O
,	O
MscK	O
,	O
MscM	O
)	O
revealed	O
that	O
the	O
release	O
of	O
5-hydroxyectoine	O
under	O
osmotic	O
steady-state	O
conditions	O
occurred	O
independently	O
of	O
these	O
microbial	O
safety	O
valves	O
.	O

In	O
shake-flask	B-P
experiments	I-P
,	O
2.13	O
g	O
l	O
(	O
-1	O
)	O
ectoine	O
(	O
15	O
mM	O
)	O
was	O
completely	O
converted	O
into	O
5-hydroxyectoine	O
within	O
24	O
h.	O
We	O
describe	O
here	O
a	O
recombinant	O
E.	O
coli	O
cell	O
factory	O
for	O
the	O
production	O
and	O
secretion	O
of	O
the	O
chemical	O
chaperone	O
5-hydroxyectoine	O
free	O
from	O
contaminating	O
ectoine	O
.	O

Comparison	O
of	O
visual	O
outcomes	O
and	O
reading	O
performance	O
after	O
bilateral	O
implantation	O
of	O
multifocal	O
intraocular	O
lenses	O
with	O
bilateral	O
monofocal	O
intraocular	O
lenses	O
.	O

To	O
compare	O
the	O
visual	O
acuity	O
outcomes	O
,	O
contrast	O
sensitivity	O
function	O
(	O
CS	O
)	O
and	O
reading	O
ability	O
in	O
patients	O
with	O
bilateral	O
multifocal	O
intraocular	O
lenses	O
and	O
patients	O
with	O
bilateral	O
monofocal	O
lenses	O
.	O

Vizyon	O
Eye	O
Center	O
,	O
Denizli	O
,	O
Turkey	O
.	O

Comparative	O
case	O
series	O
.	O

Consecutive	O
bilateral	O
cataract	O
patients	O
having	O
implantation	O
of	O
Acriva	O
Reviol	O
MFM	O
611	O
multifocal	O
IOLs	O
(	O
Group	O
A	O
)	O
or	O
Acriva	O
BB	O
UD	O
613	O
monofocal	O
IOLs	O
(	O
Group	O
B	O
)	O
were	O
included	O
.	O

Parameters	O
analyzed	O
6	O
months	O
postoperatively	O
included	O
monocular	O
uncorrected	O
distance	O
(	O
UDVA	O
)	O
,	O
binocular	O
uncorrected	O
intermediate	O
(	O
UIVA	O
)	O
,	O
binocular	O
uncorrected	O
near	O
(	O
UNVA	O
)	O
,	O
CS	O
and	O
bilateral	O
reading	O
performance	O
using	O
MN	B-P
Read	I-P
.	O

The	O
study	O
evaluated	O
42	O
eyes	O
in	O
Group	O
A	O
and	O
40	O
eyes	O
in	O
Group	O
B	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
UDVA	O
between	O
two	O
groups	O
postoperatively	O
(	O
p	O
=	O
.39	O
)	O
.	O

Binocular	O
UIVA	O
and	O
binocular	O
UNVA	O
are	O
better	O
in	O
Group	O
A	O
(	O
p	O
=	O
.00	O
,	O
p	O
=	O
.00	O
)	O
.	O

Under	O
photopic	O
and	O
scotopic	O
conditions	O
,	O
contrast	O
sensitivity	O
results	O
were	O
decreased	O
in	O
Group	O
A	O
,	O
especially	O
at	O
high	O
spatial	O
frequencies	O
.	O

No	O
statistically	O
difference	O
were	O
found	O
in	O
reading	O
acuity	O
,	O
critical	O
print	O
size	O
and	O
maximum	O
reading	O
speed	O
between	O
two	O
groups	O
(	O
p	O
=	O
.57	O
,	O
p	O
=	O
.62	O
,	O
p	O
=	O
.22	O
)	O
.	O

This	O
study	O
concludes	O
that	O
multifocal	O
lenses	O
are	O
reliable	O
and	O
efficient	O
replacements	O
for	O
reading	O
glasses	O
since	O
they	O
significantly	O
improve	O
the	O
vision	O
for	O
near	O
or	O
intermediate	O
distance	O
activities	O
.	O

Estradiol	O
prodrugs	O
(	O
EP	O
)	O
for	O
efficient	O
oral	O
estrogen	O
treatment	O
and	O
abolished	O
effects	O
on	O
estrogen	O
modulated	O
liver	O
functions	O
.	O

Oral	O
compared	O
to	O
parenteral	O
estrogen	O
administration	O
is	O
characterized	O
by	O
reduced	O
systemic	O
but	O
prominent	O
hepatic	O
estrogenic	O
effects	O
on	O
lipids	O
,	O
hemostatic	O
factors	O
,	O
GH	O
-/	O
IGF	O
I	O
axis	O
,	O
angiotensinogen	O
.	O

In	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	O
effects	O
of	O
oral	O
treatment	O
,	O
estradiol	O
(	O
E2	O
)	O
prodrugs	O
(	O
EP	O
)	O
were	O
designed	O
which	O
bypass	O
the	O
liver	O
tissue	O
as	O
inactive	O
molecules	O
.	O

Carbone17-OH	O
sulfonamide	O
[	O
-O2-NH2	O
]	O
substituted	O
esters	O
of	O
E2	O
(	O
EC508	O
,	O
others	O
)	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic	O
anhydrase	O
II	O
(	O
CA-II	O
)	O
binding	O
.	O

CA	O
II	O
in	O
erythrocytes	O
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
EP	O
from	O
portal	O
vein	O
blood	O
during	O
liver	O
passage	O
.	O

Ovariectomized	O
(	O
OVX	O
,	O
day	O
minus	O
14	O
)	O
rats	O
were	O
orally	O
treated	O
once	O
daily	O
from	O
day	O
1-3	O
.	O

Sacrifice	O
day	O
4	O
.	O

Uteri	O
were	O
dissected	O
and	O
weighed	B-P
.	O

Cholesterol	B-P
fractions	I-P
and	O
angiotensinogen	B-P
were	O
determined	O
in	O
plasma	O
.	O

Oral	O
E2	O
and	O
ethinyl	O
estradiol	O
(	O
EE	O
)	O
generated	O
dose	O
related	O
uterine	O
growth	O
and	O
important	O
hepatic	O
estrogenic	O
effects	O
.	O

EP	O
induced	O
uterine	O
growth	O
at	O
about	O
hundred-fold	O
lower	O
doses	O
.	O

This	O
was	O
possible	O
with	O
almost	O
absent	O
effects	O
on	O
plasma	O
cholesterol	O
or	O
angiotensinogen	O
.	O

Preliminary	O
pharmacokinetic	O
studies	O
with	O
EC508	O
used	O
intravenous	O
and	O
oral	O
administration	O
in	O
male	O
rats	O
.	O

Resulting	O
blood	O
levels	O
revealed	O
complete	O
oral	O
bioavailability	O
.	O

Further	O
high	O
blood	O
-	O
but	O
low	O
plasma	O
concentrations	O
indicated	O
erythrocyte	O
binding	O
of	O
EC508	O
in	O
vivo	O
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	O
passage	O
.	O

Very	O
high	O
systemic	O
estrogenicity	O
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	O
estrogenic	O
effects	O
is	O
evidence	O
for	O
a	O
systemic	O
release	O
of	O
E2	O
from	O
sulfonamide	O
EP	O
.	O

In	O
conclusion	O
,	O
tested	O
oral	O
EP	O
bypass	O
the	O
liver	O
in	O
erythrocytes	O
furnishing	O
systemic	O
estradiol	O
at	O
hydrolysis	O
.	O

This	O
mechanism	O
avoids	O
the	O
hepatic	O
estrogenic	O
impact	O
of	O
conventional	O
oral	O
estrogen	O
therapy	O
.	O

Comparison	O
of	O
true	O
unenhanced	O
and	O
virtual	O
unenhanced	O
(	O
VUE	O
)	O
attenuation	O
values	O
in	O
abdominopelvic	O
single-source	B-P
rapid	I-P
kilovoltage-switching	I-P
spectral	I-P
CT.	I-P
To	O
assess	O
the	O
agreement	O
between	O
the	O
true	O
non-contrast	O
(	O
TNC	O
)	O
attenuation	O
values	O
of	O
intra-abdominal	O
structures	O
and	O
attenuation	O
values	O
obtained	O
on	O
virtual-unenhanced	O
(	O
VUE	O
)	O
images	O
based	O
on	O
rapid	O
kVp-switching	O
dual-energy	O
CT	O
.	O

The	O
effects	O
of	O
contrast	O
phase	O
and	O
patient	O
characteristics	O
(	O
e.g.	O
,	O
BMI	O
,	O
hematocrit	O
,	O
hemoglobin	O
content	O
)	O
on	O
VUE	O
values	O
were	O
also	O
investigated	O
.	O

Ninety	O
four	O
patients	O
who	O
underwent	O
triphasic	B-P
abdominal	I-P
CT	I-P
(	O
liver	O
mass	O
protocol	O
,	O
n	O
=	O
47	O
;	O
pancreas	O
mass	O
protocol	O
,	O
n	O
=	O
47	O
)	O
between	O
August	O
2014	O
and	O
May	O
2015	O
were	O
retrospectively	O
reviewed	O
.	O

Unenhanced	O
series	O
was	O
performed	O
using	O
conventional	B-P
single-energy	I-P
mode	I-P
at	O
120	O
kVp	O
.	O

Late	O
arterial	O
and	O
venous	O
phase	O
post-contrast	O
series	O
were	O
obtained	O
utilizing	O
rapid	B-P
kVp-switching	I-P
dual-energy	I-P
CT	I-P
technique	I-P
.	O

VUE	O
images	O
were	O
processed	O
off	O
of	O
arterial	O
(	O
VUE-art	O
)	O
and	O
venous	O
(	O
VUE-ven	O
)	O
phase	O
series	O
.	O

Attenuation	O
values	O
of	O
liver	O
,	O
pancreas	O
,	O
kidneys	O
,	O
adrenal	O
glands	O
,	O
muscle	O
,	O
subcutaneous	O
fat	O
,	O
aorta	O
,	O
IVC	O
,	O
and	O
main	O
portal	O
vein	O
were	O
recorded	O
on	O
TNC	O
and	O
VUE	O
sets	O
of	O
images	O
.	O

Attenuation	O
values	O
were	O
compared	O
using	O
univariate	O
linear	O
regression	O
and	O
Student	O
two-tailed	O
paired	O
t	O
test	O
.	O

There	O
was	O
excellent	O
correlation	O
between	O
TNC	O
,	O
VUE-art	O
,	O
and	O
VUE-ven	O
attenuation	O
values	O
across	O
all	O
organs	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Paired	O
Student	O
t	O
test	O
,	O
however	O
,	O
showed	O
significant	O
difference	O
between	O
TNC	O
and	O
VUE-art	O
attenuation	O
of	O
kidneys	O
,	O
right	O
adrenal	O
gland	O
,	O
paraspinal	O
muscle	O
,	O
and	O
aorta	O
.	O

There	O
was	O
also	O
significant	O
difference	O
between	O
TNC	O
and	O
VUE-ven	O
attenuation	O
of	O
left	O
kidney	O
.	O

Percentage	O
of	O
cases	O
which	O
had	O
>	O
10	O
HU	O
difference	O
between	O
VUE	O
and	O
TNC	O
for	O
an	O
individual	O
was	O
calculated	O
which	O
ranged	O
between	O
13	O
%	O
(	O
right	O
kidney	O
)	O
and	O
42	O
%	O
(	O
right	O
adrenal	O
gland	O
)	O
.	O

Although	O
the	O
correlation	O
between	O
VUE	O
and	O
TNC	O
attenuation	O
values	O
was	O
excellent	O
and	O
mean	O
difference	O
between	O
TNC	O
and	O
VUE	O
attenuation	O
values	O
was	O
negligible	O
(	O
ranging	O
between	O
-5.94	O
HU	O
for	O
paraspinal	O
muscles	O
to	O
6.2	O
HU	O
in	O
aorta	O
)	O
,	O
intra-patient	O
analysis	O
showed	O
a	O
considerable	O
number	O
of	O
cases	O
which	O
had	O
>	O
10	O
HU	O
difference	O
between	O
VUE	O
and	O
TNC	O
.	O

VUE-ven	O
generally	O
offered	O
a	O
better	O
approximation	O
of	O
TNC	O
values	O
.	O

Further	O
optimization	O
of	O
post-processing	O
algorithms	O
might	O
be	O
necessary	O
before	O
complete	O
replacement	O
of	O
TNC	O
with	O
VUE	O
images	O
.	O

Pancreatic	O
Cystic	O
Lesions	O
:	O
Diagnostic	O
,	O
Management	O
and	O
Indications	O
for	O
Operation	O
.	O

Part	O
I	O
.	O

We	O
notice	O
an	O
increasing	O
frequency	O
in	O
the	O
detection	O
and	O
evaluation	O
of	O
pancreatic	O
cystic	O
lesions	O
(	O
PCLs	O
)	O
over	O
the	O
last	O
three	O
decades	O
.	O

They	O
show	O
awide	O
spectrum	O
of	O
imaging	B-P
and	O
clinical	O
features	O
.	O

The	O
diagnosis	O
and	O
discrimination	O
of	O
these	O
lesions	O
are	O
very	O
important	O
because	O
of	O
the	O
risk	O
for	O
concurrent	O
or	O
later	O
development	O
of	O
malignancy	O
.	O

The	O
main	O
reason	O
is	O
the	O
increased	O
awareness	O
of	O
these	O
lesions	O
and	O
the	O
extensive	O
use	O
of	O
cross-sectional	O
imaging	O
,	O
an	O
always	O
improving	O
technique	O
(	O
1	O
)	O
.	O

Commonly	O
,	O
PCLs	O
are	O
diagnosed	O
incidentally	O
during	O
investigation	O
for	O
often	O
unrelated	O
and	O
nonspecific	O
abdominal	O
complaints	O
using	O
state-of-the	O
art	O
abdominal	O
imaging	B-P
(	O
CT	B-P
,	O
MRT	B-P
)	O
.	O

The	O
term	O
PCN	O
denotes	O
a	O
histologically	O
heterogeneous	O
collection	O
of	O
neoplasms	O
showing	O
a	O
wide	O
spectrum	O
of	O
diagnoses	O
,	O
ranging	O
from	O
completely	O
benign	O
to	O
potentially	O
malignant	O
,	O
to	O
carcinoma	O
in	O
situ	O
,	O
to	O
frankly	O
invasive	O
and	O
malignant	O
(	O
2,3	O
)	O
.	O

In	O
1978	O
,	O
Compagno	O
and	O
Oertel	O
were	O
the	O
first	O
to	O
recognize	O
the	O
crucial	O
distinction	O
between	O
the	O
serous	O
and	O
the	O
mucinous	O
cystic	O
neoplasms	O
of	O
the	O
pancreas	O
by	O
explaining	O
the	O
importance	O
of	O
identifying	O
the	O
mucinous	O
neoplasms	O
because	O
of	O
their	O
overt	O
or	O
latent	O
malignant	O
potential	O
(	O
4,5	O
)	O
.	O

Since	O
then	O
,	O
the	O
interest	O
in	O
PCLs	O
increased	O
markedly	O
,	O
especially	O
so	O
with	O
the	O
recognition	O
of	O
the	O
importance	O
and	O
prevalence	O
of	O
intraductal	O
papillary	O
mucinous	O
neoplasms	O
(	O
IPMNs	O
)	O
.	O

Nowadays	O
,	O
PCLs	O
represent	O
a	O
common	O
and	O
often	O
difficult	O
challenge	O
in	O
clinical	O
practice	O
,	O
because	O
of	O
the	O
increase	O
in	O
their	O
detection	O
in	O
asymptomatic	O
patients	O
and	O
our	O
still	O
immature	O
understanding	O
of	O
some	O
aspects	O
of	O
their	O
biologic	O
behavior	O
.	O

Their	O
important	O
differences	O
regarding	O
their	O
outcome	O
and	O
the	O
fact	O
of	O
being	O
increasingly	O
often	O
identified	O
has	O
put	O
a	O
special	O
focus	O
on	O
these	O
neoplasms	O
by	O
surgeons	O
,	O
pathologists	O
,	O
gastroenterologists	O
,	O
radiologists	O
,	O
and	O
oncologists	O
alike	O
.	O

Management	O
of	O
patients	O
with	O
PCNs	O
can	O
be	O
challenging	O
and	O
varies	O
considerably	O
among	O
the	O
various	O
subtypes	O
of	O
PCNs	O
.	O

Their	O
treatment	O
ranges	O
from	O
resection	O
of	O
malignant	O
lesions	O
,	O
to	O
resection	O
and/or	O
surveillance	O
in	O
the	O
case	O
of	O
premalignant	O
lesions	O
,	O
to	O
simple	O
observation	O
in	O
the	O
case	O
of	O
benign	O
or	O
indolent	O
lesions	O
.	O

Under	O
these	O
circumstances	O
,	O
the	O
accurate	O
classification	O
of	O
PCNs	O
becomes	O
crucial	O
.	O

Therapeutic	O
decision	O
making	O
and	O
classification	O
rely	O
mainly	O
on	O
the	O
presenting	O
symptoms	O
and	O
radiologic	O
findings	O
,	O
often	O
without	O
actual	O
histologic	O
tissue	O
.	O

It	O
is	O
of	O
extreme	O
importance	O
to	O
identify	O
suspicious	O
features	O
indicating	O
potential	O
or	O
certain	O
malignancy	O
in	O
order	O
to	O
select	O
the	O
appropriate	O
treatment	O
.	O

The	O
risk	O
of	O
overtreatment	O
(	O
unnecessary	O
pancreatectomy	O
)	O
should	O
he	O
balanced	O
carefully	O
with	O
the	O
risk	O
of	O
under	O
treatment	O
(	O
missing	O
the	O
opportunity	O
to	O
cure	O
a	O
potentially	O
curable	O
malignant	O
or	O
premalignant	O
disease	O
)	O
.	O

Aspirin	O
-Based	O
Carbon	O
Dots	O
,	O
a	O
Good	O
Biocompatibility	O
of	O
Material	O
Applied	O
for	O
Bioimaging	O
and	O
Anti-Inflammation	O
.	O

The	O
emerging	O
photoluminescent	O
carbon	O
-based	O
nanomaterials	O
are	O
promising	O
in	O
various	O
fields	O
besides	O
cell	B-P
imaging	I-P
and	O
carrier	O
transport	O
.	O

Carbon	O
nanomaterials	O
with	O
specific	O
biological	O
functions	O
,	O
however	O
,	O
are	O
rarely	O
investigated	O
.	O

Aspirin	O
is	O
a	O
very	O
common	O
anti-inflammatory	O
medication	O
to	O
relieve	O
aches	O
and	O
pains	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
tried	O
to	O
create	O
a	O
carbon	O
nanoparticle	O
with	O
aspirin	O
,	O
and	O
we	O
expect	O
that	O
this	O
new	O
carbon	O
nanoparticle	O
will	O
have	O
both	O
anti-inflammatory	O
and	O
fluorescent	O
biomarker	O
functions	O
.	O

Fluorescent	O
aspirin	O
-based	O
carbon	O
dots	O
(	O
FACDs	O
)	O
were	O
synthesized	O
by	O
condensing	O
aspirin	O
and	O
hydrazine	O
through	O
a	O
one-step	O
microwave-assisted	B-P
method	I-P
.	O

Imaging	B-P
data	I-P
demonstrated	O
that	O
FACDs	O
efficiently	O
entered	O
into	O
human	O
cervical	O
carcinoma	O
and	O
mouse	O
monocyte	O
macrophage	O
cells	O
in	O
vitro	O
with	O
low	O
cell	O
toxicity	O
.	O

Results	O
from	O
quantitative	B-P
polymerase	I-P
chain	I-P
reaction	I-P
and	O
histological	B-P
analysis	I-P
indicated	O
that	O
FACDs	O
possessed	O
effective	O
anti-inflammatory	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
compared	O
to	O
aspirin	O
only	O
.	O

Hematology	B-P
,	O
serum	B-P
biochemistry	I-P
,	O
and	O
histology	B-P
results	O
suggested	O
that	O
FACDs	O
also	O
had	O
no	O
significant	O
toxicity	O
in	O
vivo	O
.	O

Our	O
results	O
clearly	O
demonstrate	O
that	O
FACDs	O
have	O
dual	O
functions	O
,	O
cellular	B-P
imaging	I-P
/	O
bioimaging	O
and	O
anti-inflammation	O
,	O
and	O
suggest	O
that	O
FACDs	O
have	O
great	O
potential	O
in	O
future	O
clinical	O
applications	O
.	O

Molecular	O
cytogenetic	O
characterization	O
of	O
mosaicism	O
for	O
a	O
small	O
supernumerary	O
marker	O
chromosome	O
derived	O
from	O
chromosome	O
8	O
or	O
r	O
(	O
8	O
)	O
(	O
:	O
:p11.22→q11.21	O
:	O
:	O
)	O
in	O
an	O
18-	O
year-old	O
female	O
with	O
short	O
stature	O
,	O
obesity	O
,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
,	O
and	O
intellectual	O
disability	O
.	O

We	O
present	O
molecular	O
cytogenetic	O
characterization	O
of	O
mosaicism	O
for	O
a	O
small	O
supernumerary	O
marker	O
chromosome	O
(	O
sSMC	O
)	O
derived	O
from	O
chromosome	O
8	O
.	O

An	O
18-	O
year-old	O
female	O
presented	O
with	O
short	O
stature	O
,	O
obesity	O
,	O
developmental	O
delay	O
,	O
speech	O
delay	O
,	O
dyslexia	O
,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
,	O
and	O
intellectual	O
disability	O
.	O

Cytogenetic	O
analysis	O
of	O
the	O
peripheral	O
blood	O
revealed	O
a	O
karyotype	B-P
of	I-P
47	I-P
,	I-P
XX	I-P
,	I-P
+mar	I-P
[	I-P
22	I-P
]	I-P
/46	I-P
,	I-P
XX	I-P
[	I-P
18	I-P
]	I-P
.	O

Array	O
comparative	O
genomic	O
hybridization	O
and	O
metaphase	O
fluorescence	O
in	O
situ	O
hybridization	O
analyses	O
were	O
performed	O
on	O
the	O
peripheral	O
blood	O
to	O
determine	O
the	O
origin	O
and	O
mosaicism	O
of	O
the	O
sSMC	O
,	O
and	O
quantitative	B-P
fluorescent	I-P
polymerase	I-P
chain	I-P
reaction	I-P
was	O
used	O
to	O
exclude	O
uniparental	O
disomy	O
.	O

Array	O
comparative	O
genomic	O
hybridization	O
analysis	O
of	O
the	O
blood	O
revealed	O
a	O
result	O
of	O
arr	O
8p11.22q11.21	O
(	O
39,136,065-49,725,726	O
)	O
×2.80	O
(	O
Log2	O
ratio	O
=0.49	O
)	O
,	O
consistent	O
with	O
70-80	O
%	O
mosaicism	O
,	O
encompassing	O
33	O
OMIM	O
genes	O
including	O
GOLGA7	O
,	O
AGPAT6	O
,	O
NKX6-3	O
,	O
KAT6A	O
,	O
and	O
FNTA	O
.	O

The	O
sSMC	O
(	O
8	O
)	O
was	O
r	O
(	O
8	O
)	O
(	O
:	O
:p11.22→q11.21	O
:	O
:	O
)	O
.	O

Metaphase	O
fluorescence	O
in	O
situ	O
hybridization	O
analysis	O
using	O
the	O
probes	O
of	O
RP11-754D24	O
(	O
8p11.21	O
)	O
and	O
RP11-769N21	O
(	O
8q11.21	O
)	O
showed	O
the	O
sSMC	O
(	O
8	O
)	O
in	O
12/27	O
of	O
cultured	O
lymphocytes	O
.	O

Quantitative	B-P
fluorescent	I-P
polymerase	I-P
chain	I-P
reaction	I-P
analysis	I-P
excluded	O
uniparental	O
disomy	O
8	O
.	O

Mosaic	O
sSMC	O
(	O
8	O
)	O
derived	O
from	O
r	O
(	O
8	O
)	O
(	O
:	O
:p11.22→q11.21	O
:	O
:	O
)	O
can	O
be	O
associated	O
with	O
obesity	O
,	O
intellectual	O
disability	O
,	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
.	O

Response	O
of	O
microbial	O
communities	O
colonizing	O
salt	O
marsh	O
plants	O
rhizosphere	O
to	O
copper	O
oxide	O
nanoparticles	O
contamination	O
and	O
its	O
implications	O
for	O
phytoremediation	O
processes	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
Cu	O
oxide	O
nanoparticles	O
(	O
CuO	O
NP	O
)	O
effect	O
on	O
microbial	O
communities	O
associated	O
with	O
salt	O
marsh	O
plants	O
(	O
Halimione	O
portulacoides	O
and	O
Pragmites	O
australis	O
)	O
rhizosphere	O
and	O
its	O
implications	O
for	O
phytoremediation	O
processes	O
.	O

Experiments	O
were	O
conducted	O
,	O
under	O
controlled	O
conditions	O
,	O
over	O
one	O
week	O
.	O

Rhizosediment	O
soaked	O
in	O
the	O
respective	O
elutriate	O
(	O
a	O
simplified	O
natural	O
medium	O
)	O
with	O
or	O
without	O
plants	O
,	O
was	O
doped	O
with	O
CuO	O
NP	O
or	O
with	O
Cu	O
in	O
ionic	O
form	O
.	O

Microbial	O
community	O
in	O
rhizosediments	O
was	O
characterized	O
in	O
terms	O
of	O
abundance	O
(	O
by	O
DAPI	O
)	O
and	O
structure	O
(	O
by	O
ARISA	O
)	O
.	O

Metal	O
uptake	O
by	O
plants	O
was	O
evaluated	O
by	O
measuring	O
Cu	O
in	O
plant	O
tissues	O
(	O
by	O
atomic	B-P
absorption	I-P
spectroscopy	I-P
)	O
.	O

Results	O
revealed	O
significant	O
metal	O
uptake	O
but	O
only	O
in	O
plant	O
roots	O
,	O
which	O
was	O
significantly	O
lower	O
(	O
H.	O
portulacoides	O
)	O
or	O
not	O
significant	O
(	O
P.	O
australis	O
)	O
when	O
the	O
metal	O
was	O
in	O
NP	O
form	O
.	O

Microbial	O
community	O
structure	O
was	O
significantly	O
changed	O
by	O
the	O
treatment	O
(	O
absence	O
/	O
presence	O
of	O
Cu	O
,	O
ionic	O
Cu	O
or	O
CuO	O
NP	O
)	O
as	O
showed	O
by	O
multivariate	O
analysis	O
of	O
ARISA	O
profiles	O
and	O
confirmed	O
by	O
analysis	O
of	O
similarities	O
(	O
Global	O
test	O
-	O
one	O
way	O
ANOSIM	O
)	O
.	O

Moreover	O
,	O
in	O
P.	O
australis	O
rhizosediments	O
microbial	O
abundance	O
,	O
bacterial	O
richness	O
and	O
diversity	O
indexes	O
were	O
significantly	O
affected	O
(	O
increased	O
or	O
decreased	O
)	O
due	O
to	O
metal	O
presence	O
whereas	O
in	O
H.	O
portulacoides	O
rhizosediment	O
microbial	O
abundance	O
showed	O
a	O
significant	O
decrease	O
,	O
particularly	O
when	O
the	O
metal	O
was	O
in	O
NP	O
form	O
.	O

Accordingly	O
,	O
Cu	O
presence	O
affected	O
the	O
response	O
of	O
the	O
rhizosphere	O
microbial	O
community	O
and	O
in	O
some	O
cases	O
that	O
response	O
was	O
significantly	O
different	O
when	O
Cu	O
was	O
in	O
NP	O
form	O
.	O

The	O
response	O
of	O
the	O
microbial	O
communities	O
to	O
Cu	O
NP	O
might	O
also	O
contribute	O
to	O
the	O
lower	O
metal	O
accumulation	O
by	O
plants	O
when	O
the	O
metal	O
was	O
in	O
this	O
form	O
.	O

So	O
,	O
Cu	O
NP	O
may	O
cause	O
disturbances	O
in	O
ecosystems	O
functions	O
,	O
ultimately	O
affecting	O
phytoremediation	O
processes	O
.	O

These	O
facts	O
should	O
be	O
considered	O
regarding	O
the	O
use	O
of	O
appropriate	O
salt	O
marshes	O
plants	O
to	O
remediate	O
moderately	O
impacted	O
areas	O
such	O
as	O
estuaries	O
,	O
where	O
NPs	O
can	O
be	O
found	O
.	O

Individual	O
differences	O
in	O
behavioral	O
activation	O
and	O
cardiac	O
vagal	O
control	O
influence	O
affective	O
startle	O
modification	O
.	O

The	O
startle	O
response	O
(	O
SR	O
)	O
has	O
a	O
close	O
relationship	O
with	O
stress	O
responses	O
.	O

Startle	O
modification	O
(	O
SRM	O
)	O
has	O
been	O
widely	O
used	O
to	O
study	O
stress	O
disorders	O
(	O
e.g.	O
,	O
posttraumatic	O
stress	O
disorder	O
)	O
.	O

The	O
framework	O
of	O
the	O
behavioral	O
inhibition	O
and	O
activation	O
systems	O
(	O
BIS	O
/	O
BAS	O
)	O
has	O
been	O
thought	O
to	O
correspond	O
with	O
withdrawal	O
and	O
approach	O
motivational	O
processes	O
underlying	O
affective	O
SRM	O
and	O
can	O
influence	O
stress	O
reactivity	O
.	O

Vagally-mediated	O
cardiac	O
activity	O
as	O
indexed	O
by	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
has	O
been	O
associated	O
with	O
SRM	O
and	O
regulatory	O
processes	O
during	O
stress	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
influence	O
of	O
individual	O
differences	O
in	O
the	O
BIS	O
/	O
BAS	O
and	O
resting	O
HRV	O
on	O
affective	O
SRM	O
were	O
examined	O
.	O

Eighty-six	O
subjects	O
viewed	O
affective	O
pictures	O
while	O
acoustic	O
SR	O
stimuli	O
were	O
delivered	O
.	O

Individual	O
differences	O
in	O
motivation	O
were	O
measured	O
by	O
the	O
BIS/BAS	O
scales	O
.	O

The	O
magnitude	O
of	O
SR	O
was	O
assessed	O
as	O
electromyographic	B-P
activity	O
of	O
the	O
SR	O
eyeblink	O
during	O
pictures	O
of	O
different	O
valences	O
.	O

Resting	O
HRV	O
was	O
derived	O
from	O
electrocardiography	B-P
.	O

In	O
contrast	O
to	O
previous	O
studies	O
,	O
the	O
present	O
results	O
showed	O
that	O
startle	O
inhibition	O
and	O
potentiation	O
were	O
related	O
to	O
BAS	O
and	O
HRV	O
,	O
but	O
not	O
to	O
BIS	O
.	O

There	O
was	O
also	O
an	O
interaction	O
of	O
BAS	O
and	O
HRV	O
,	O
indicating	O
that	O
the	O
relationship	O
between	O
HRV	O
and	O
SRM	O
strengthened	O
as	O
BAS	O
scores	O
decreased	O
.	O

The	O
present	O
findings	O
suggest	O
that	O
BAS	O
may	O
relate	O
to	O
both	O
withdrawal	O
and	O
approach	O
,	O
and	O
trait	O
stress	O
reactivity	O
is	O
influence	O
d	O
by	O
BAS	O
and	O
cardiac	O
vagal	O
activity	O
.	O

In	O
addition	O
,	O
BAS	O
moderates	O
the	O
relationship	O
between	O
cardiac	O
vagal	O
activity	O
and	O
SRM	O
.	O

These	O
findings	O
have	O
both	O
theoretical	O
and	O
practical	O
implications	O
for	O
the	O
study	O
of	O
SRM	O
,	O
stress	O
disorders	O
,	O
and	O
health	O
.	O

Moorean	O
and	O
Tahitian	O
Partula	O
tree	O
snail	O
survival	O
after	O
a	O
mass	O
extinction	O
:	O
New	O
genomic	O
insights	O
using	O
museum	O
specimens	O
.	O

Natural	O
history	O
museum	O
collections	O
provide	O
a	O
biodiversity	O
window	O
into	O
the	O
past	O
and	O
are	O
of	O
particular	O
importance	O
to	O
the	O
study	O
of	O
extinction	O
-impacted	O
clades	O
such	O
as	O
the	O
Pacific	O
Island	O
tree	O
snail	O
family	O
Partulidae	O
.	O

Deliberate	O
introduction	O
of	O
the	O
predatory	O
rosy	O
wolf	O
snail	O
Euglandina	O
rosea	O
in	O
the	O
late	O
20th	O
century	O
led	O
to	O
the	O
extinction	O
/	O
extirpation	O
of	O
55/61	O
Society	O
Island	O
Partulidae	O
species	O
.	O

In	O
this	O
study	O
,	O
we	O
phylogenomically	O
investigated	O
the	O
inter-relationships	O
of	O
the	O
three	O
surviving	O
Society	O
Island	O
valley	O
Partula	O
species	O
:	O
P.	O
taeniata	O
(	O
Moorea	O
)	O
,	O
P.	O
clara	O
and	O
P.	O
hyalina	O
(	O
Tahiti	O
)	O
.	O

All	O
three	O
formed	O
a	O
distinct	O
clade	O
in	O
earlier	O
mitochondrial	O
phylogenies	O
.	O

Using	O
Next	O
Generation	O
Sequencing	O
(	O
NGS	O
)	O
double	O
digested	O
Restriction	O
Associated	O
DNA	O
sequencing	O
(	O
ddRADseq	O
)	O
,	O
we	O
found	O
that	O
46-year-old	O
lyophilized	B-P
museum	O
specimens	O
produced	O
similar	O
numbers	O
of	O
reads	O
,	O
sequencing	O
depth	O
,	O
and	O
loci	O
as	O
10-year	O
old	O
ethanol	O
-preserved	O
collections	O
.	O

Phylogenomic	O
trees	O
indicated	O
that	O
Tahitian	O
P.	O
clara	O
and	O
P.	O
hyalina	O
are	O
the	O
result	O
of	O
a	O
single	O
founding	O
lineage	O
from	O
Moorea	O
,	O
contrasting	O
previous	O
mitochondrial	O
results	O
and	O
clarifying	O
the	O
enigmatic	O
taxonomic	O
status	O
of	O
P.	O
c.	O
incrassa	O
.	O

Our	O
study	O
highlights	O
the	O
utility	O
and	O
viability	O
of	O
NGS	O
techniques	O
for	O
museum	O
specimens	O
and	O
their	O
increased	O
resolution	O
of	O
evolutionary	O
patterns	O
.	O

Sampling	O
will	O
be	O
expanded	O
to	O
include	O
the	O
remaining	O
Society	O
Island	O
partulid	O
taxa	O
to	O
further	O
explore	O
the	O
evolutionary	O
history	O
of	O
this	O
radiation	O
.	O

A	O
framework	O
for	O
automatic	O
creation	O
of	O
gold	O
-	O
standard	O
rigid	O
3D-2D	O
registration	O
datasets	O
.	O

Advanced	O
image-guided	O
medical	O
procedures	O
incorporate	O
2D	O
intra-interventional	O
information	O
into	O
pre-interventional	O
3D	O
image	O
and	O
plan	O
of	O
the	O
procedure	O
through	O
3D	O
/	O
2D	O
image	O
registration	O
(	O
32R	O
)	O
.	O

To	O
enter	O
clinical	O
use	O
,	O
and	O
even	O
for	O
publication	O
purposes	O
,	O
novel	O
and	O
existing	O
32R	O
methods	O
have	O
to	O
be	O
rigorously	O
validated	O
.	O

The	O
performance	O
of	O
a	O
32R	O
method	O
can	O
be	O
estimated	O
by	O
comparing	O
it	O
to	O
an	O
accurate	O
reference	O
or	O
gold	B-P
standard	I-P
method	I-P
(	O
usually	O
based	O
on	O
fiducial	O
markers	O
)	O
on	O
the	O
same	O
set	O
of	O
images	O
(	O
gold	O
standard	O
dataset	O
)	O
.	O

Objective	O
validation	O
and	O
comparison	O
of	O
methods	O
are	O
possible	O
only	O
if	O
evaluation	O
methodology	O
is	O
standardized	O
,	O
and	O
the	O
gold	O
standard	O
dataset	O
is	O
made	O
publicly	O
available	O
.	O

Currently	O
,	O
very	O
few	O
such	O
datasets	O
exist	O
and	O
only	O
one	O
contains	O
images	O
of	O
multiple	O
patients	O
acquired	O
during	O
a	O
procedure	B-P
.	O

To	O
encourage	O
the	O
creation	O
of	O
gold	O
standard	O
32R	O
datasets	O
,	O
we	O
propose	O
an	O
automatic	O
framework	O
.	O

The	O
framework	O
is	O
based	O
on	O
rigid	O
registration	O
of	O
fiducial	O
markers	O
.	O

The	O
main	O
novelty	O
is	O
spatial	O
grouping	O
of	O
fiducial	O
markers	O
on	O
the	O
carrier	O
device	O
,	O
which	O
enables	O
automatic	O
marker	O
localization	O
and	O
identification	O
across	O
the	O
3D	O
and	O
2D	O
images	O
.	O

The	O
proposed	O
framework	O
was	O
demonstrated	O
on	O
clinical	O
angiograms	B-P
of	O
20	O
patients	O
.	O

Rigid	O
32R	O
computed	B-P
by	O
the	O
framework	O
was	O
more	O
accurate	O
than	O
that	O
obtained	O
manually	O
,	O
with	O
the	O
respective	O
target	O
registration	O
error	O
below	O
0.027	O
mm	O
compared	O
to	O
0.040	O
mm	O
.	O

The	O
framework	O
is	O
applicable	O
for	O
gold	O
standard	O
setup	O
on	O
any	O
rigid	O
anatomy	O
,	O
provided	O
that	O
the	O
acquired	O
images	O
contain	O
spatially	O
grouped	O
fiducial	O
markers	O
.	O

The	O
gold	O
standard	O
datasets	O
and	O
software	O
will	O
be	O
made	O
publicly	O
available	O
.	O

Technical	O
note	O
:	O
A	O
preliminary	O
comparative	O
study	O
between	O
classical	O
and	O
interventional	O
radiological	O
approaches	O
for	O
multi-phase	O
post-mortem	B-P
CT	I-P
angiography	B-P
.	O

Multi-phase	O
post-mortem	B-P
computed	I-P
tomography	I-P
angiography	I-P
(	O
MPMCTA	B-P
)	O
is	O
a	O
new	O
diagnostic	B-P
tool	I-P
,	O
used	O
in	O
forensic	O
pathology	O
.	O

On	O
the	O
one	O
hand	O
,	O
this	O
technique	O
allows	O
a	O
better	O
and	O
direct	O
visualization	O
of	O
vascular	O
and	O
solid	O
organ	O
lesions	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
invasiveness	O
of	O
the	O
procedure	O
-which	O
requires	O
surgical	O
denudation	O
(	O
inguinal	O
and/or	O
cervical	O
)	O
and	O
the	O
insertion	O
of	O
surgical	O
cannulas	O
-leads	O
to	O
many	O
relatives	O
refusing	O
scientific	B-P
autopsies	I-P
.	O

Our	O
hypothesis	O
states	O
that	O
a	O
minimally-invasive	O
procedure	O
combining	O
interventional	O
radiological	O
techniques	O
with	O
MPMCTA	B-P
(	O
replacement	O
of	O
surgical	O
cannulas	O
by	O
radiological	O
catheters	O
)	O
will	O
improve	O
the	O
approval	O
rate	O
of	O
scientific	B-P
autopsies	I-P
by	O
families	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
feasibility	O
of	O
the	O
minimally-invasive	O
MPMCTA	B-P
approach	O
and	O
to	O
compare	O
its	O
performance	O
to	O
the	O
current	O
reference-standard	O
(	O
the	O
conventional	O
approach	O
)	O
.	O

We	O
included	O
consecutively	O
16	O
corpses	O
divided	O
in	O
two	O
groups	O
according	O
to	O
the	O
contrast	O
enhancement	O
approach	O
:	O
radiological	O
catheters	O
(	O
n=8	O
)	O
,	O
and	O
surgical	O
cannulas	O
(	O
n=8	O
)	O
.	O

Corpses	O
were	O
chosen	O
and	O
assigned	O
randomly	O
from	O
our	O
local	O
data	O
.	O

The	O
quality	O
of	O
the	O
imaging	B-P
procedure	I-P
was	O
compared	O
according	O
to	O
four	O
items	O
:	O
global	O
vascular	O
opacification	O
,	O
cerebral	O
venous	O
opacification	O
,	O
and	O
lower	O
limbs	O
opacification	O
(	O
arterial	O
and	O
venous	O
)	O
.	O

A	O
minimally-invasive	O
approach	O
for	O
scientific	B-P
autopsies	I-P
is	O
feasible	O
through	O
a	O
radiological	O
catheter	O
.	O

Vascular	O
opacification	O
was	O
optimal	O
in	O
8	O
out	O
of	O
8	O
cases	O
and	O
was	O
no	O
less	O
effective	O
than	O
the	O
control	O
reference	O
group	O
using	O
surgical	O
cannula	O
incision	O
associated	O
with	O
their	O
non-occlusive	O
aspects	O
.	O

Prevalence	O
and	O
risk	O
factors	O
of	O
anxiety	O
and	O
depression	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
in	O
Southwest	O
China	O
.	O

Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
patients	O
have	O
high	O
risk	O
for	O
anxiety	O
and	O
depression	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
prevalence	O
and	O
risk	O
factors	O
of	O
anxiety	O
and	O
depression	O
in	O
SLE	O
patients	O
in	O
Southwest	O
China	O
.	O

Participants	O
were	O
recruited	O
by	O
convenience	O
sampling	B-P
from	O
Rheumatic	O
Outpatient	O
Clinic	O
of	O
West	O
China	O
Hospital	O
Sichuan	O
University	O
between	O
August	O
and	O
October	O
2014	O
.	O

The	O
prevalence	O
of	O
anxiety	O
and	O
depression	O
was	O
evaluated	O
using	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
(	O
HADS	O
)	O
.	O

Risk	O
factors	O
were	O
explored	O
by	O
multiple	O
logistic	O
regression	O
analyses	O
.	O

A	O
total	O
of	O
352	O
participants	O
were	O
enrolled	O
,	O
of	O
who	O
64	O
(	O
18.2	O
%	O
)	O
met	O
the	O
HADS	O
criteria	O
for	O
anxiety	O
and	O
82	O
(	O
23.3	O
%	O
)	O
for	O
depression	O
.	O

In	O
multivariable	O
analysis	O
,	O
higher	O
levels	O
of	O
pain	O
(	O
OR	O
=	O
1.17	O
,	O
P	O
=	O
0.02	O
)	O
and	O
fatigue	O
(	O
OR	O
=	O
1.19	O
,	O
P	O
<	O
0.01	O
)	O
predicted	O
a	O
higher	O
risk	O
of	O
anxiety	O
.	O

Similarly	O
,	O
a	O
higher	O
level	O
of	O
fatigue	O
(	O
OR	O
=	O
1.2	O
,	O
P	O
<	O
0.01	O
)	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
depression	O
.	O

The	O
results	O
suggest	O
that	O
anxiety	O
and	O
depression	O
are	O
common	O
in	O
patients	O
with	O
SLE	O
in	O
Southwest	O
China	O
.	O

Health	O
care	O
providers	O
and	O
SLE	O
patients	O
should	O
take	O
some	O
measures	O
to	O
cope	O
with	O
them	O
as	O
early	O
as	O
possible	O
.	O

Strengthening	O
management	O
of	O
pain	O
and	O
fatigue	O
may	O
be	O
useful	O
.	O

But	O
further	O
studies	O
are	O
needed	O
to	O
verify	O
these	O
findings	O
.	O

Proteomic	B-P
Analysis	I-P
of	O
Tung	O
Tree	O
(	O
Vernicia	O
fordii	O
)	O
Oilseeds	O
during	O
the	O
Developmental	O
Stages	O
.	O

The	O
tung	O
tree	O
(	O
Vernicia	O
fordii	O
)	O
,	O
a	O
non-model	O
woody	O
plant	O
belonging	O
to	O
the	O
Euphorbiaceae	O
family	O
,	O
is	O
a	O
promising	O
economic	O
plant	O
due	O
to	O
the	O
high	O
content	O
of	O
a	O
novel	O
high-value	O
oil	O
in	O
its	O
seeds	O
.	O

Many	O
metabolic	O
pathways	O
are	O
active	O
during	O
seed	O
development	O
.	O

Oil	O
(	O
triacylglycerols	O
(	O
TAGs	O
)	O
)	O
accumulates	O
in	O
oil	O
bodies	O
distributed	O
in	O
the	O
endosperm	O
cells	O
of	O
tung	O
tree	O
seeds	O
.	O

The	O
relationship	O
between	O
oil	O
bodies	O
and	O
oil	O
content	O
during	O
tung	O
tree	O
seed	O
development	O
was	O
analyzed	O
using	O
ultrastructural	O
observations	O
,	O
which	O
confirmed	O
that	O
oil	O
accumulation	O
was	O
correlated	O
with	O
the	O
volumes	O
and	O
numbers	O
of	O
oil	O
bodies	O
in	O
the	O
endosperm	O
cells	O
during	O
three	O
different	O
developmental	O
stages	O
.	O

For	O
a	O
deeper	O
understanding	O
of	O
seed	O
development	O
,	O
we	O
carried	O
out	O
proteomic	B-P
analyses	I-P
.	O

At	O
least	O
144	O
proteins	O
were	O
differentially	O
expressed	O
during	O
three	O
different	O
developmental	O
stages	O
.	O

A	O
total	O
of	O
76	O
proteins	O
were	O
successfully	O
identified	O
using	O
matrix-assisted	O
laser	O
desorption/ionization	O
time-of-flight	O
mass	O
spectrometry	O
/	O
mass	B-P
spectrometry	I-P
(	O
MALDI-TOF/MS	O
/	O
MS	B-P
)	O
.	O

These	O
proteins	O
were	O
grouped	O
into	O
11	O
classes	O
according	O
to	O
their	O
functions	O
.	O

The	O
major	O
groups	O
of	O
differentially	O
expressed	O
proteins	O
were	O
associated	O
with	O
energy	O
metabolism	O
(	O
25	O
%	O
)	O
,	O
fatty	O
acid	O
metabolism	O
(	O
15.79	O
%	O
)	O
and	O
defense	O
(	O
14.47	O
%	O
)	O
.	O

These	O
results	O
strongly	O
suggested	O
that	O
a	O
very	O
high	O
percentage	O
of	O
gene	O
expression	O
in	O
seed	O
development	O
is	O
dedicated	O
to	O
the	O
synthesis	O
and	O
accumulation	O
of	O
TAGs	O
.	O

Increased	O
childhood	O
body	O
mass	O
index	O
is	O
associated	O
with	O
young	O
adult	O
serum	B-P
uric	I-P
acid	I-P
levels	I-P
:	O
a	O
linkage	O
study	O
from	O
Japan	O
.	O

Growth	O
pattern	O
in	O
early	O
life	O
is	O
one	O
of	O
the	O
most	O
important	O
factors	O
affecting	O
the	O
pathogenesis	O
of	O
metabolic-associated	O
diseases	O
.	O

The	O
associations	O
between	O
serum	O
uric	O
acid	O
(	O
SUA	O
)	O
and	O
hypertension	O
,	O
kidney	O
disease	O
,	O
and	O
coronary	O
heart	O
disease	O
have	O
been	O
recognized	O
.	O

We	O
investigated	O
the	O
association	O
between	O
increased	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
during	O
childhood	O
and	O
adult	O
SUA	B-P
levels	I-P
in	O
Japan	O
.MethodsWe	O
included	O
298	O
children	O
with	O
health	O
examination	O
data	O
between	O
1981	O
and	O
2002	O
who	O
had	O
also	O
undergone	O
physical	O
examinations	O
after	O
reaching	O
early	O
adulthood	O
(	O
approximately	O
27	O
years	O
old	O
)	O
.	O

Subjects	O
were	O
divided	O
into	O
sex-specific	O
tertiles	O
based	O
on	O
the	O
difference	O
in	O
their	O
BMI	O
(	O
DBMI	O
)	O
over	O
a	O
6-	O
year	O
period	O
(	O
6-12	O
years	O
of	O
age	O
)	O
.	O

The	O
association	O
between	O
the	O
three	O
DBMI	O
groups	O
and	O
SUA	O
in	O
adults	O
was	O
analyzed	O
.	O

The	O
predicted	O
average	O
SUA	B-P
level	I-P
in	O
adults	O
from	O
the	O
high	O
DBMI	O
group	O
was	O
5.32	O
mg/dl	O
after	O
adjustment	O
for	O
related	O
factors	O
in	O
a	O
combined	O
sex	O
analysis	O
.	O

This	O
was	O
significantly	O
higher	O
than	O
among	O
the	O
low	O
DBMI	O
group	O
.	O

Excessive	O
BMI	O
increases	O
during	O
childhood	O
led	O
to	O
young	O
adult	O
SUA	O
elevation	O
even	O
after	O
adjusting	O
for	O
several	O
factors	O
.	O

Lifestyle	O
in	O
early	O
life	O
may	O
be	O
a	O
strong	O
predictor	O
of	O
future	O
uric	O
acid	O
metabolism	O
and	O
the	O
resulting	O
disease	O
risk	O
.	O

Influence	O
of	O
Surface	O
Properties	O
on	O
Adhesion	O
Forces	O
and	O
Attachment	O
of	O
Streptococcus	O
mutans	O
to	O
Zirconia	O
In	O
Vitro	O
.	O

Zirconia	O
is	O
becoming	O
a	O
prevalent	O
material	O
in	O
dentistry	O
.	O

However	O
,	O
any	O
foreign	O
bodies	O
inserted	O
may	O
provide	O
new	O
niches	O
for	O
the	O
bacteria	O
in	O
oral	O
cavity	O
.	O

The	O
object	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
effect	O
of	O
surface	O
properties	O
including	O
surface	O
roughness	O
and	O
hydrophobicity	O
on	O
the	O
adhesion	O
and	O
biofilm	O
formation	O
of	O
Streptococcus	O
mutans	O
(	O
S.	O
mutans	O
)	O
to	O
zirconia	O
.	O

Atomic	B-P
force	I-P
microscopy	I-P
was	O
employed	O
to	O
determine	O
the	O
zirconia	O
surface	O
morphology	O
and	O
the	O
adhesion	O
forces	O
between	O
the	O
S.	O
mutans	O
and	O
zirconia	O
.	O

The	O
results	O
showed	O
that	O
the	O
surface	O
roughness	O
was	O
nanoscale	O
and	O
significantly	O
different	O
among	O
tested	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
:	O
Coarse	O
(	O
23.94	O
±	O
2.52	O
nm	O
)	O
>	O
Medium	O
(	O
17.00	O
±	O
3.81	O
nm	O
)	O
>	O
Fine	O
(	O
11.89	O
±	O
1.68	O
nm	O
)	O
.	O

The	O
contact	O
angles	O
of	O
the	O
Coarse	O
group	O
were	O
the	O
highest	O
,	O
followed	O
by	O
the	O
Medium	O
and	O
the	O
Fine	O
groups	O
.	O

Increasing	O
the	O
surface	O
roughness	O
and	O
hydrophobicity	O
resulted	O
in	O
an	O
increase	O
of	O
adhesion	O
forces	O
and	O
early	O
attachment	O
(	O
2	O
h	O
and	O
4	O
h	O
)	O
of	O
S.	O
mutans	O
on	O
the	O
zirconia	O
but	O
no	O
influence	O
on	O
the	O
further	O
development	O
of	O
biofilm	O
(	O
6	O
h~24	O
h	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
surface	O
roughness	O
in	O
nanoscale	O
and	O
hydrophobicity	O
of	O
zirconia	O
had	O
influence	O
on	O
the	O
S.	O
mutans	O
initial	O
adhesion	O
force	O
and	O
early	O
attachment	O
instead	O
of	O
whole	O
stages	O
of	O
biofilm	O
formation	O
.	O

A	O
novel	O
combination	O
treatment	O
to	O
stimulate	O
bone	O
healing	O
and	O
regeneration	O
under	O
hypoxic	O
conditions	O
:	O
photobiomodulation	O
and	O
melatonin	O
.	O

Melatonin	O
has	O
anabolic	O
effects	O
on	O
the	O
bone	O
,	O
even	O
under	O
hypoxia	O
,	O
and	O
laser	O
irradiation	O
has	O
been	O
shown	O
to	O
improve	O
osteoblastic	O
differentiation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
laser	O
irradiation	O
and	O
melatonin	O
would	O
have	O
synergistic	O
effects	O
on	O
osteoblastic	O
differentiation	O
and	O
mineralization	O
under	O
hypoxic	O
conditions	O
.	O

MC3T3-E1	O
cells	O
were	O
exposed	O
to	O
1	O
%	O
oxygen	O
tension	O
for	O
the	O
hypoxia	O
condition	O
.	O

The	O
cells	O
were	O
divided	O
into	O
four	O
groups	O
:	O
G1	O
-	O
osteoblast	O
differentiation	O
medium	O
only	O
(	O
as	O
the	O
hypoxic	O
condition	O
)	O
,	O
G2	O
-	O
treatment	O
with	O
50	O
μM	O
melatonin	O
only	O
,	O
G3	O
-	O
laser	O
irradiation	O
(	O
808	O
nm	O
,	O
80	O
mW	O
,	O
GaAlAs	O
diode	O
)	O
only	O
,	O
and	O
G4	O
-	O
treatment	O
with	O
50	O
μM	O
melatonin	O
and	O
laser	O
irradiation	O
(	O
808	O
nm	O
,	O
80	O
mW	O
,	O
GaAlAs	O
diode	O
)	O
.	O

Immunoblotting	B-P
showed	O
that	O
osterix	O
expression	O
was	O
markedly	O
increased	O
in	O
the	O
melatonin	O
-	O
treated	O
and	O
laser-irradiated	O
cells	O
at	O
48	O
and	O
72	O
h.	O
In	O
addition	O
,	O
alkaline	O
phosphatase	O
activity	O
significantly	O
increased	O
and	O
continued	O
to	O
rise	O
throughout	O
the	O
experiment	O
.	O

Alizarin	B-P
Red	I-P
staining	I-P
showed	O
markedly	O
increased	O
mineralized	O
nodules	O
as	O
compared	O
with	O
only	O
melatonin	O
-	O
treated	O
or	O
laser-irradiated	O
cells	O
at	O
day	O
7	O
,	O
which	O
significantly	O
increased	O
by	O
day	O
14	O
.	O

Moreover	O
,	O
when	O
melatonin	O
-	O
treated	O
cells	O
were	O
laser-irradiated	O
,	O
the	O
differentiation	O
and	O
mineralization	O
of	O
cells	O
were	O
found	O
to	O
involve	O
p38	O
MAPK	O
and	O
PRKD1	O
signaling	O
mechanisms	O
.	O

However	O
,	O
the	O
enhanced	O
effects	O
of	O
laser	O
irradiation	O
with	O
melatonin	O
were	O
markedly	O
inhibited	O
when	O
the	O
cells	O
were	O
treated	O
with	O
luzindole	O
,	O
a	O
selective	O
melatonin	O
receptor	O
antagonist	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
laser	O
irradiation	O
could	O
promote	O
the	O
effect	O
of	O
melatonin	O
on	O
the	O
differentiation	O
and	O
mineralization	O
of	O
MC3T3-E1	O
cells	O
under	O
hypoxic	O
conditions	O
,	O
and	O
that	O
this	O
process	O
is	O
mediated	O
through	O
melatonin	O
1/2	O
receptors	O
and	O
PKRD	O
/	O
p38	O
signaling	O
pathways	O
.	O

Antinociceptive	O
effect	O
of	O
tebanicline	O
for	O
various	O
noxious	O
stimuli	O
-induced	O
behaviours	O
in	O
mice	O
.	O

Tebanicline	O
(	O
ABT-594	O
)	O
,	O
an	O
analogue	O
of	O
epibatidine	O
,	O
exhibits	O
potent	O
antinociceptive	O
effects	O
and	O
high	O
affinity	O
for	O
the	O
nicotinic	O
acetylcholine	O
receptor	O
in	O
the	O
central	O
nervous	O
system	O
.	O

We	O
assessed	O
whether	O
tebanicline	O
exerts	O
an	O
effect	O
on	O
various	O
noxious	O
stimuli	O
and	O
mediates	O
the	O
nicotine	O
receptor	O
or	O
opioid	O
receptor	O
through	O
stimulation	O
.	O

The	O
antinociceptive	O
effects	O
of	O
tebanicline	O
were	O
determined	O
by	O
noxious	O
chemical	O
,	O
thermal	O
and	O
mechanical	O
stimuli	O
-induced	O
behaviours	O
in	O
mice	O
.	O

Tebanicline	O
had	O
dose-dependent	O
analgesic	O
effects	O
in	O
formalin	O
,	O
hot-plate	B-P
and	I-P
tail-pressure	I-P
tests	I-P
.	O

By	O
contrast	O
,	O
the	O
antinociceptive	O
effect	O
of	O
tebanicline	O
was	O
not	O
demonstrated	O
in	O
the	O
tail-flick	B-P
assay	I-P
.	O

Pre-treatment	O
with	O
mecamylamine	O
,	O
a	O
nicotinic	O
acetylcholine	O
receptor	O
antagonist	O
,	O
blocked	O
the	O
effects	O
of	O
tebanicline	O
in	O
formalin	O
,	O
tail-pressure	B-P
and	I-P
hot-plate	I-P
tests	I-P
.	O

Moreover	O
,	O
pre-treatment	O
with	O
naloxone	O
,	O
an	O
opioid	O
receptor	O
antagonist	O
,	O
only	O
partially	O
inhibited	O
the	O
effects	O
of	O
tebanicline	O
in	O
formalin	O
and	O
tail-pressure	B-P
tests	I-P
.	O

Tebanicline	O
produced	O
antinociception	O
in	O
persistent	O
chemical	O
(	O
formalin	O
)	O
,	O
acute	O
thermal	O
(	O
hot-plate	B-P
,	O
but	O
not	O
tail-flick	O
)	O
and	O
mechanical	O
(	O
tail-pressure	B-P
)	O
pain	O
states	O
.	O

Moreover	O
,	O
tebanicline	O
stimulated	O
the	O
nicotinic	O
acetylcholine	O
receptor	O
and	O
opioid	O
receptor	O
.	O

The	O
value	O
of	O
lacrimal	B-P
scintillography	I-P
in	O
the	O
assessment	O
of	O
patients	O
with	O
epiphora	O
.	O

PurposeTo	O
assess	O
the	O
influence	O
of	O
dacryoscintillography	B-P
(	O
DSG	B-P
)	O
on	O
the	O
treatment	O
decision	O
for	O
patients	O
with	O
epiphora	O
and	O
clinically	O
patent	O
non-functioning	O
lacrimal	O
systems	O
.MethodsA	O
retrospective	O
3-year	O
review	O
.	O

Inclusion	O
:	O
patients	O
having	O
DSG	B-P
for	O
epiphora	O
with	O
delayed	O
tear	O
clearance	O
,	O
lacrimal	O
system	O
patency	O
on	O
syringing	O
,	O
and	O
no	O
visible	O
external	O
cause	O
for	O
watering	O
.	O

On	O
the	O
basis	O
of	O
regurgitation	O
during	O
syringing	O
,	O
tear	O
ducts	O
were	O
divided	O
into	O
freely	O
patent	O
(	O
FP	O
≤20	O
%	O
)	O
or	O
stenosed	O
.	O

The	O
DSG	B-P
results	O
were	O
examined	O
for	O
correlation	O
with	O
symptoms	O
and	O
clinical	O
examination	O
,	O
the	O
influence	O
on	O
decision	O
to	O
proceed	O
to	O
dacryocystorhinostomy	O
(	O
DCR	O
)	O
,	O
and	O
the	O
ability	O
to	O
predict	O
the	O
surgical	O
outcome	O
.ResultsA	O
total	O
of	O
242	O
eyes	O
were	O
examined	O
.	O

The	O
clinical	B-P
diagnosis	I-P
was	O
FP	O
in	O
45.5	O
%	O
,	O
nasolacrimal	O
duct	O
stenosis	O
(	O
NLDS	O
)	O
in	O
26.4	O
%	O
,	O
and	O
other	O
in	O
3.3	O
%	O
.	O

The	O
DSG	B-P
was	O
normal	O
in	O
30.9	O
%	O
of	O
FP	O
and	O
18.7	O
%	O
of	O
NLDS	O
eyes	O
.	O

Of	O
the	O
asymptomatic	O
eyes	O
,	O
46.7	O
%	O
had	O
an	O
abnormal	O
DSG	B-P
.	O

DSG	B-P
sensitivity	O
was	O
73.6	O
%	O
and	O
specificity	O
53.3	O
%	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
DSG	B-P
results	O
in	O
those	O
with	O
FP	O
or	O
NLDS	O
.	O

DCR	O
was	O
recommended	O
in	O
39.1	O
%	O
of	O
the	O
symptomatic	O
eyes	O
with	O
abnormal	O
DSG	B-P
.	O

DCR	O
surgery	O
was	O
considered	O
inappropriate	O
in	O
all	O
46	O
eyes	O
with	O
normal	O
DSG	B-P
.	O

DCR	O
was	O
successful	O
in	O
76.5	O
%	O
,	O
however	O
,	O
the	O
DSG	B-P
result	O
did	O
not	O
affect	O
the	O
success	O
of	O
surgery	O
.Conclusion	O
DSG	B-P
has	O
severe	O
limitations	O
due	O
to	O
lack	O
of	O
correlation	O
with	O
symptoms	O
and	O
clinical	O
examination	O
,	O
inability	O
to	O
separate	O
lacrimal	O
duct	O
narrowing	O
from	O
lacrimal	O
pump	O
function	O
,	O
and	O
inability	O
to	O
predict	O
the	O
results	O
of	O
surgery	O
.	O

DSG	B-P
can	O
at	O
best	O
provide	O
limited	O
guidance	O
on	O
whether	O
to	O
proceed	O
to	O
DCR	O
surgery	O
.Eye	O
advance	O
online	O
publication	O
,	O
3	O
March	O
2017	O
;	O
doi:10.1038/eye.2017.20	O
.	O

Short-term	O
effects	O
of	O
a	O
vibrotactile	O
neck	O
-based	O
treatment	O
device	O
for	O
positional	O
obstructive	O
sleep	O
apnea	O
:	O
preliminary	O
data	O
on	O
tolerability	O
and	O
efficacy	O
.	O

Positional	O
supine	O
obstructive	O
sleep	O
apnea	O
syndrome	O
(	O
OSAS	O
)	O
characterizes	O
a	O
subgroup	O
of	O
patients	O
suffering	O
from	O
OSAS	O
.	O

Several	O
devices	O
designed	O
to	O
limit	O
supine	O
position	O
have	O
been	O
developed	O
,	O
but	O
evidences	O
of	O
their	O
efficacy	O
and	O
safety	O
are	O
lacking	O
.	O

It	O
is	O
unclear	O
whether	O
a	O
neck-worn	O
vibrating	O
device	O
could	O
induce	O
positional	O
change	O
in	O
patients	O
with	O
positional	O
OSAS	O
.	O

We	O
evaluated	O
the	O
efficacy	O
of	O
a	O
neck	O
-worn	O
device	O
to	O
induce	O
supine	O
avoidance	O
positional	O
feedback	O
over	O
a	O
short-term	O
trial	O
in	O
OSAS	O
patients	O
and	O
its	O
impact	O
on	O
sleep	O
quality	O
and	O
polysomnographyc	B-P
indexes	I-P
.	O

Twenty	O
patients	O
with	O
positional	O
apneas	O
/	O
hypopneas	O
were	O
prospectively	O
studied	O
.	O

Baseline	O
characteristics	O
of	O
daytime	O
somnolence	O
and	O
risk	O
of	O
sleep	O
apnea	O
were	O
screened	B-P
and	O
the	O
efficacy	O
of	O
a	O
3-day	O
trial	O
of	O
supine	O
-	O
avoidance	O
therapy	O
by	O
vibrotactile	O
neck	O
worn	O
device	O
assessed	O
by	O
reporting	O
the	O
self-perceived	O
change	O
in	O
quality	O
of	O
sleep	O
and	O
performing	O
cardio-respiratory	B-P
polysomnography	I-P
.	O

Comparison	O
between	O
baseline	O
and	O
treatment	O
results	O
was	O
performed	O
.	O

The	O
neck	O
device	O
produced	O
a	O
reduction	O
in	O
overall	O
apnea-hypopnea	O
index	O
(	O
AHI	O
)	O
(	O
mean	O
AHI	O
pre	O
=16.8/h	O
and	O
post	O
=4.4/h	O
,	O
P	O
<	O
0.0001	O
)	O
,	O
oxygen	O
desaturation	O
(	O
pre	O
=13.7/h	O
and	O
post	O
=3.8/h	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
Respiratory	O
Disturbance	O
Indexes	O
(	O
RDI	O
)	O
(	O
20.0/h	O
vs.	O
5.2/h	O
;	O
P	O
<	O
0.0001	O
)	O
.The	O
time	O
spent	O
in	O
supine	O
position	O
decreased	O
from	O
62.1	O
%	O
to	O
33.7	O
%	O
of	O
the	O
total	O
(	O
P	O
<	O
0.001	O
)	O
.	O

However	O
,	O
the	O
impact	O
on	O
the	O
perceived	O
quality	O
of	O
sleep	O
was	O
unpredictable	O
.	O

The	O
neck	O
position	O
therapy	O
device	O
is	O
effective	O
in	O
restricting	O
supine	O
sleep	O
,	O
improving	O
AHI	O
and	O
related	O
polysomnographic	B-P
indexes	I-P
.	O

However	O
,	O
at	O
least	O
in	O
a	O
short-term	O
trial	O
,	O
it	O
seems	O
unable	O
to	O
improve	O
the	O
patient	O
's	O
sleep	O
quality	O
.	O

CS	O
-	O
PEG	O
decorated	O
PLGA	O
nano-prototype	O
for	O
delivery	O
of	O
bioactive	O
compounds	O
:	O
A	O
novel	O
approach	O
for	O
induction	O
of	O
apoptosis	O
in	O
HepG2	O
cell	O
line	O
.	O

Polymer	O
-	O
based	O
nanoparticles	O
are	O
used	O
as	O
vectors	O
for	O
cancer	O
drug	O
delivery	O
.	O

The	O
bioactive	O
compounds	O
(	O
quercetin	O
,	O
ellagic	O
acid	O
and	O
gallic	O
acid	O
)	O
are	O
well	O
known	O
to	O
be	O
not	O
only	O
antioxidants	O
but	O
also	O
chemopreventive	O
candidates	O
against	O
various	O
types	O
of	O
cancers	O
.	O

To	O
circumvent	O
the	O
low	O
bioavailability	O
and	O
the	O
short	O
half-life	O
time	O
obstacles	O
,	O
we	O
hypothesized	O
a	O
novel	O
PLGA	O
nano-platform	O
functionalized	O
with	O
CS	O
and	O
PEG	O
to	O
encapsulate	O
these	O
phytochemicals	O
.	O

This	O
encapsulation	O
will	O
protect	O
the	O
compounds	O
from	O
the	O
phagocytic	O
uptake	O
and	O
deliver	O
PLGA-CS-PEG	O
nano-prototype	O
with	O
high	O
biodegradability	O
and	O
biosafety	O
.	O

Three	O
consequent	O
types	O
of	O
PLGA-based	O
nanocomposites	O
were	O
prepared	O
and	O
characterized	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
newly	O
synthesized	O
nano-formulations	O
against	O
human	O
hepatocellular	O
carcinoma	O
(	O
HepG2	O
)	O
and	O
colorectal	O
cancer	O
(	O
HCT	O
116	O
)	O
cell	O
lines	O
using	O
cell	O
growth	O
inhibition	O
assays	B-P
,	O
followed	O
by	O
apoptosis	O
and	O
necrosis	O
assays	B-P
using	O
flow	B-P
cytometry	I-P
to	O
detect	B-P
the	O
underlying	O
mechanism	O
of	O
HepG2	O
cell	O
death	O
.	O

Through	O
Malvern	O
Zeta	O
Sizer	O
,	O
we	O
recorded	O
that	O
the	O
average	O
diameters	O
of	O
the	O
nano-prototypes	O
ranged	O
from	O
150	O
to	O
300nm	O
.	O

The	O
cytotoxic	B-P
activity	I-P
of	O
quercetin	O
,	O
ellagic	O
acid	O
,	O
and	O
gallic	O
acid	O
-	O
encapsulated	O
PLGA	O
,	O
PLGA-CS	O
,	O
and	O
PLGA-CS-PEG	O
nano-prototypes	O
it	O
has	O
been	O
found	O
that	O
they	O
reduce	O
the	O
IC50s	O
of	O
the	O
HepG2	O
cells	O
values	O
by	O
2.2	O
,	O
2.9	O
,	O
2.8-	O
folds	O
,	O
1	O
,	O
1.5	O
,	O
2.7-	O
folds	O
,	O
and	O
0.9	O
,	O
0.7	O
,	O
1.5-	O
folds	O
,	O
respectively	O
.	O

Mechanistically	O
,	O
the	O
nano-platforms	O
of	O
quercetin	O
seem	O
to	O
be	O
dependent	O
on	O
both	O
apoptosis	O
and	O
necrosis	O
,	O
while	O
those	O
of	O
ellagic	O
acid	O
and	O
gallic	O
acid	O
are	O
mainly	O
dependent	O
on	O
apoptosis	O
.	O

CS	O
-	O
PEG	O
-blended	O
PLGA	O
nano-delivery	O
system	O
of	O
quercetin	O
,	O
ellagic	O
acid	O
and	O
gallic	O
acid	O
can	O
potentiate	O
apoptosis-mediated	O
cell	O
death	O
in	O
HepG2	O
cell	O
line	O
.	O

In	O
vivo	O
assessment	O
of	O
periodontal	O
structures	O
and	O
measurement	O
of	O
gingival	O
sulcus	O
with	O
Optical	B-P
Coherence	I-P
Tomography	I-P
:	O
a	O
pilot	O
study	O
.	O

There	O
has	O
been	O
increasing	O
interest	O
on	O
the	O
development	O
of	O
clinically	O
acceptable	O
,	O
more	O
sensitive	O
and	O
specific	O
methods	O
for	O
non-invasive	O
diagnosis	O
in	O
Periodontics	O
.	O

In	O
this	O
pilot	O
study	O
,	O
the	O
performance	O
of	O
an	O
Optical	B-P
Coherence	I-P
Tomography	I-P
(	O
OCT	B-P
)	O
system	O
in	O
imaging	B-P
periodontal	O
structures	O
in	O
humans	O
was	O
evaluated	O
.	O

Gingival	O
sulcus	O
depth	O
measurements	O
were	O
obtained	O
and	O
compared	O
with	O
traditional	O
probes	O
.	O

In	O
total	O
,	O
445	O
sites	O
of	O
23	O
periodontally	O
healthy	O
individuals	O
were	O
measured	O
by	O
3	O
instruments	O
:	O
North	O
Carolina	O
manual	O
probe	O
,	O
Florida	O
automated	O
probe	O
and	O
OCT	B-P
at	O
1325	O
nm	O
.	O

To	O
obtain	O
quantitative	O
measurements	O
from	O
OCT	B-P
images	O
,	O
the	O
gingival	O
refractive	O
index	O
was	O
also	O
determined	O
.	O

Discomfort	O
/	O
pain	O
perception	O
and	O
the	O
duration	O
of	O
examinations	O
were	O
compared	O
among	O
the	O
instruments	O
.	O

The	O
analysis	O
of	O
OCT	B-P
images	O
allowed	O
the	O
identification	O
of	O
relevant	O
anatomic	O
dental	O
and	O
periodontal	O
regions	O
.	O

The	O
average	O
sulcus	O
depth	O
measured	O
by	O
OCT	B-P
,	O
0.85	O
±	O
0.27	O
mm	O
and	O
0.87	O
±	O
0.28	O
mm	O
,	O
was	O
lower	O
than	O
the	O
values	O
obtained	O
by	O
manual	O
and	O
automated	O
probing	O
.	O

Discomfort	O
/	O
pain	O
were	O
prevalent	O
for	O
traditional	O
probes	O
,	O
which	O
are	O
invasive	O
methods	O
,	O
than	O
for	O
the	O
non-invasive	O
OCT	B-P
technique	O
.	O

OCT	B-P
has	O
the	O
potential	O
to	O
be	O
a	O
reliable	O
tool	O
for	O
in	O
vivo	O
periodontal	O
tissues	O
evaluation	O
and	O
for	O
reproducible	O
sulcus	O
depth	O
measurements	O
in	O
healthy	O
sites	O
.	O

Further	O
technological	O
advances	O
are	O
required	O
to	O
reduce	O
the	O
procedure	O
time	O
and	O
promote	O
evaluation	O
of	O
posterior	O
oral	O
regions	O
.	O

Photonic	O
assessment	O
of	O
periodontal	O
tissue	O
with	O
OCT	B-P
(	O
top	O
)	O
in	O
a	O
clinical	O
environment	O
,	O
showing	O
tooth	O
/	O
gingiva	O
features	O
(	O
bottom	O
)	O
.	O

Epigenotype	O
,	O
genotype	O
,	O
and	O
phenotype	O
analysis	O
of	O
patients	O
in	O
Taiwan	O
with	O
Beckwith-Wiedemann	O
syndrome	O
.	O

Beckwith-Wiedemann	O
syndrome	O
(	O
BWS	O
)	O
is	O
a	O
congenital	O
overgrowth	O
disorder	O
predisposing	O
to	O
tumorigenesis	O
that	O
results	O
from	O
abnormal	O
expression	O
or	O
function	O
of	O
imprinted	O
genes	O
of	O
chromosome	O
11p15.5	O
.	O

Forty-seven	O
patients	O
in	O
Taiwan	O
with	O
clinical	O
suspicion	O
of	O
BWS	O
were	O
referred	O
for	O
diagnostic	O
testing	O
based	O
on	O
methylation	B-P
profiling	I-P
of	O
H19	O
-associated	O
imprinting	O
center	O
(	O
IC	O
)	O
1	O
and	O
KCNQ1OT1	O
-associated	O
IC2	O
using	O
high-resolution	B-P
melting	I-P
analysis	I-P
,	O
multiplex	O
ligation-dependent	O
probe	O
amplification	O
,	O
or	O
high-resolution	B-P
quantitative	I-P
methylation	I-P
profiling	I-P
.	O

Twenty-eight	O
patients	O
received	O
a	O
clinical	B-P
diagnosis	I-P
of	O
BWS	O
(	O
the	O
presence	O
of	O
3	O
major	O
features	O
or	O
2	O
major	O
features	O
and	O
at	O
least	O
1	O
minor	O
feature	O
)	O
,	O
18	O
had	O
suspected	O
BWS	O
(	O
the	O
presence	O
of	O
at	O
least	O
1	O
major	O
feature	O
)	O
,	O
and	O
1	O
had	O
isolated	O
Wilms	O
'	O
tumor	O
.	O

Nineteen	O
patients	O
were	O
identified	O
with	O
IC2	O
hypomethylation	O
(	O
including	O
1	O
with	O
isolated	O
Wilms	O
'	O
tumor	O
)	O
,	O
1	O
with	O
IC1	O
hypermethylation	O
,	O
2	O
with	O
paternal	O
uniparental	O
disomy	O
,	O
and	O
1	O
with	O
CDKN1C	O
mutation	O
.	O

Several	O
clinical	O
features	O
were	O
found	O
to	O
be	O
statistically	O
different	O
(	O
P	O
<	O
0.05	O
)	O
between	O
the	O
2	O
groups-	O
clinical	B-P
diagnosis	I-P
of	O
BWS	O
(	O
n=28	O
)	O
or	O
suspected	O
BWS	O
(	O
n=18	O
)	O
-including	O
macroglossia	O
,	O
pre-	O
or	O
postnatal	O
gigantism	O
,	O
abdominal	O
wall	O
defect	O
,	O
ear	O
creases	O
,	O
facial	O
nevus	O
flammeus	O
,	O
BWS	O
score	O
,	O
and	O
the	O
molecular	B-P
diagnosis	I-P
rate	O
.	O

Molecular	O
lesion	O
was	O
detected	O
in	O
81	O
%	O
of	O
patients	O
with	O
the	O
presence	O
of	O
three	O
major	O
features	O
,	O
compared	O
with	O
33	O
%	O
and	O
28	O
%	O
of	O
those	O
with	O
two	O
or	O
one	O
major	O
feature	O
,	O
respectively	O
.	O

The	O
mean	O
BWS	O
score	O
was	O
5.6	O
for	O
19	O
subjects	O
with	O
``	O
IC2	O
hypomethylation	O
``	O
,	O
compared	O
with	O
3.8	O
for	O
2	O
subjects	O
with	O
pUPD	O
.	O

The	O
BWS	O
score	O
of	O
one	O
subject	O
with	O
CDKN1C	O
mutation	O
and	O
one	O
with	O
IC1	O
hypermethylation	O
was	O
6	O
and	O
7	O
,	O
respectively	O
.	O

The	O
BWS	O
score	O
was	O
positively	O
correlated	O
with	O
the	O
molecular	B-P
diagnosis	I-P
rate	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
BWS	O
database	O
of	O
epigenotype	O
,	O
genotype	O
,	O
and	O
phenotype	O
is	O
expected	O
to	O
promote	O
better	O
genetic	O
counseling	O
and	O
medical	O
care	O
of	O
these	O
patients	O
.	O

Zebrafish	O
adult	O
pigment	O
stem	O
cells	O
are	O
multipotent	O
and	O
form	O
pigment	O
cells	O
by	O
a	O
progressive	O
fate	O
restriction	O
process	O
:	O
Clonal	B-P
analysis	I-P
identifies	O
shared	O
origin	O
of	O
all	O
pigment	O
cell	O
types	O
.	O

Skin	O
pigment	O
pattern	O
formation	O
is	O
a	O
paradigmatic	O
example	O
of	O
pattern	O
formation	O
.	O

In	O
zebrafish	O
,	O
the	O
adult	O
body	O
stripes	O
are	O
generated	O
by	O
coordinated	O
rearrangement	O
of	O
three	O
distinct	O
pigment	O
cell-types	O
,	O
black	O
melanocytes	O
,	O
shiny	O
iridophores	O
and	O
yellow	O
xanthophores	O
.	O

A	O
stem	O
cell	O
origin	O
of	O
melanocytes	O
and	O
iridophores	O
has	O
been	O
proposed	O
although	O
the	O
potency	O
of	O
those	O
stem	O
cells	O
has	O
remained	O
unclear	O
.	O

Xanthophores	O
,	O
however	O
,	O
seemed	O
to	O
originate	O
predominantly	O
from	O
proliferation	O
of	O
embryonic	O
xanthophores	O
.	O

Now	O
,	O
data	O
from	O
Singh	O
et	O
al	O
.	O

shows	O
that	O
all	O
three	O
cell-types	O
derive	O
from	O
shared	O
stem	O
cells	O
,	O
and	O
that	O
these	O
cells	O
generate	O
peripheral	O
neural	O
cell-types	O
too	O
.	O

Furthermore	O
,	O
clonal	O
compositions	O
are	O
best	O
explained	O
by	O
a	O
progressive	O
fate	O
restriction	O
model	O
generating	O
the	O
individual	O
cell-types	O
.	O

The	O
numbers	O
of	O
adult	O
pigment	O
stem	O
cells	O
associated	O
with	O
the	O
dorsal	O
root	O
ganglia	O
remain	O
low	O
,	O
but	O
progenitor	O
numbers	O
increase	O
significantly	O
during	O
larval	O
development	O
up	O
to	O
metamorphosis	O
,	O
likely	O
via	O
production	O
of	O
partially	O
restricted	O
progenitors	O
on	O
the	O
spinal	O
nerves	O
.	O

Analgesic	O
and	O
anti-inflammatory	O
actions	O
on	O
bradykinin	O
route	O
of	O
a	O
polysulfated	O
fraction	O
from	O
alga	O
Ulva	O
lactuca	O
.	O

We	O
investigated	O
structural	O
features	O
of	O
polysaccharides	O
from	O
Ulva	O
lactuca	O
and	O
their	O
effects	O
on	O
the	O
classical	O
models	O
of	O
nociception	O
and	O
inflammation	O
.	O

Crude	O
extract	O
was	O
obtained	O
by	O
enzymatic	B-P
digestion	I-P
and	O
isolated	O
by	O
ion	B-P
exchange	I-P
chromatography	I-P
on	O
DEAE-cellulose	O
.	O

The	O
fraction	O
with	O
higher	O
yield	O
was	O
used	O
in	O
the	O
tests	B-P
(	O
SP-Ul	O
)	O
.	O

Swiss	O
mice	O
received	O
SP-Ul	O
(	O
1	O
,	O
3	O
or	O
9mg/kg	O
;	O
i.v	O
.	O

)	O
,	O
30min	O
prior	O
to	O
injection	O
of	O
0.8	O
%	O
-	O
acetic	O
acid	O
or	O
1	O
%	O
-	O
formalin	O
or	O
prior	O
to	O
a	O
thermal	O
stimulus	O
.	O

At	O
same	O
doses	O
,	O
SP-Ul	O
was	O
tested	O
on	O
Wistar	O
rats	O
on	O
paw	O
edema	O
elicited	O
by	O
different	O
irritants	O
(	O
carrageenan	O
,	O
dextran	O
,	O
bradykinin	O
,	O
histamine	O
or	O
serotonin	O
)	O
.	O

The	O
results	O
of	O
infrared	O
characterization	O
indicated	O
the	O
presence	O
of	O
hydroxyl	O
groups	O
,	O
sulfate	O
,	O
uronic	O
acid	O
and	O
glycosidic	O
linkages	O
in	O
all	O
SP	O
fractions	O
spectrums	O
.	O

SP-Ul	O
decreased	O
significantly	O
the	O
antinociception	O
in	O
response	O
to	O
acetic	O
acid	O
or	O
formalin	O
(	O
second	O
phase	O
)	O
,	O
but	O
not	O
in	O
the	O
hot-plate	O
test	O
,	O
suggesting	O
that	O
its	O
analgesia	O
occurs	O
through	O
a	O
peripheral	O
mechanism	O
.	O

SP-Ul	O
did	O
not	O
reduce	O
carrageenan	O
-	O
induced	O
paw	O
edema	O
as	O
supported	O
by	O
both	O
histological	O
and	O
myeloperoxidase	O
activity	O
assessments	O
.	O

However	O
,	O
SP-Ul	O
(	O
1mg/kg	O
;	O
s.c.	O
)	O
reduced	O
dextran	O
-elicited	O
edema	O
,	O
showing	O
vascular	O
anti-inflammatory	O
effect	O
,	O
with	O
bradykinin	O
as	O
major	O
target	O
because	O
it	O
did	O
not	O
reduce	O
histamine	O
-	O
and	O
serotonin	O
-	O
induced	O
paw	O
edemas	O
.	O

Therefore	O
,	O
SP-Ul	O
acts	O
on	O
bradykinin	O
pathway	O
in	O
its	O
antinociceptive	O
and	O
anti-inflammatory	O
responses	O
.	O

Relationship	O
between	O
XspI	O
Site	O
Polymorphisms	O
of	O
LDL-R	O
Gene	O
and	O
Serum	O
IL-2	O
and	O
IL-10	O
in	O
Patients	O
with	O
Hypercholesterolemia	O
.	O

Relationship	O
has	O
been	O
identified	O
in	O
sporadic	O
reports	O
between	O
polymorphisms	O
and	O
hypercholesterolemia	O
.	O

However	O
,	O
the	O
relationship	O
between	O
inflammatory	O
cytokines	O
and	O
polymorphism	O
of	O
low-density	O
lipoprotein	O
receptor	O
(	O
LDL-R	O
)	O
gene	O
in	O
hypercholesterolemia	O
is	O
unclear	O
.	O

This	O
study	O
aimed	O
to	O
explore	O
the	O
relationship	O
and	O
significance	O
between	O
polymorphisms	O
of	O
LDL-R	O
gene	O
and	O
serum	O
Interleukin-2	O
(	O
IL-2	O
)	O
,	O
IL-10	O
in	O
patients	O
with	O
hypercholesterolemia	O
.	O

PCR-RFLP	B-P
and	O
direct	O
DNA	O
sequencing	O
assay	O
were	O
employed	O
to	O
determine	O
polymorphism	O
of	O
LDL-R	O
gene	O
in	O
900	O
patients	O
with	O
hypercholesterolemia	O
and	O
400	O
healthy	O
cases	O
.	O

ELISA	B-P
was	O
applied	O
to	O
assay	O
serum	O
concentration	O
of	O
IL-2	O
and	O
IL-10	O
.	O

Blood	O
lipid	O
indexes	O
were	O
tested	O
in	O
all	O
cases	O
.	O

Compared	O
with	O
the	O
healthy	O
controls	O
,	O
level	O
of	O
IL-2	O
increased	O
significantly	O
,	O
while	O
IL-10	O
decreased	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Correlation	O
analysis	O
showed	O
that	O
IL-2	O
was	O
positively	O
correlated	O
with	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
LDL-c	O
,	O
and	O
genotype	O
(	O
r	O
=	O
0.542	O
,	O
0.410	O
,	O
0.598	O
,	O
P	O
<	O
0.05	O
)	O
and	O
negatively	O
correlated	O
with	O
HDL-c	O
(	O
r	O
=	O
-0.352	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Negative	O
relationship	O
also	O
was	O
found	O
between	O
TC	O
,	O
LDL-c	O
,	O
genotype	O
,	O
and	O
IL-10	O
(	O
r	O
=	O
-0.452	O
,	O
-0.390	O
,	O
-0.613	O
,	O
P	O
<	O
0.05	O
)	O
,	O
and	O
positive	O
correlation	O
between	O
HDL-c	O
and	O
IL-10	O
(	O
r	O
=	O
0.398	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Multiple	O
linear	O
regression	O
showed	O
that	O
genotypes	O
and	O
TC	O
were	O
independent	O
factors	O
affecting	O
the	O
levels	B-P
of	I-P
IL-2	I-P
and	O
IL-10	B-P
(	O
P	O
<	O
0.05	O
)	O
.	O

IL-2	O
and	O
IL-10	O
were	O
related	O
to	O
gene	O
polymorphisms	O
of	O
LDL-R	O
,	O
which	O
might	O
be	O
involved	O
in	O
the	O
development	O
and	O
progress	O
of	O
hypercholesterolemia	O
.	O

Ag	O
nanoclusters	O
could	O
efficiently	O
quench	O
the	O
photoresponse	O
of	O
CdS	O
quantum	O
dots	O
for	O
novel	O
energy	O
transfer	O
-based	O
photoelectrochemical	O
bioanalysis	O
.	O

Herein	O
the	O
influence	O
of	O
ultrasmall	O
Ag	O
nanoclusters	O
(	O
Ag	O
NCs	O
)	O
against	O
CdS	O
quantum	O
dots	O
(	O
QDs	O
)	O
in	O
a	O
photoelectrochemical	O
(	O
PEC	O
)	O
nanosystem	O
was	O
exploited	O
for	O
the	O
first	O
time	O
,	O
based	O
on	O
which	O
a	O
novel	O
PEC	O
bioanalysis	O
was	O
successfully	O
developed	O
via	O
the	O
efficient	O
quenching	O
effect	O
of	O
Ag	O
NCs	O
against	O
the	O
CdS	O
QDs	O
.	O

In	O
a	O
model	O
system	O
,	O
DNA	B-P
assay	I-P
was	O
achieved	O
by	O
using	O
molecular	O
beacon	O
(	O
MB	O
)	O
probes	O
anchored	O
on	O
a	O
CdS	O
QDs	O
modified	O
electrode	O
,	O
and	O
the	O
MB	O
probes	O
contain	O
two	O
segments	O
that	O
can	O
hybridize	O
with	O
both	O
target	O
DNA	O
sequence	O
and	O
the	O
label	O
of	O
DNA	O
encapsulated	O
Ag	O
NCs	O
.	O

After	O
the	O
MB	O
probe	O
was	O
unfolded	O
by	O
the	O
target	O
DNA	O
sequence	O
,	O
the	O
labels	O
of	O
oligonucleotide	O
encapsulated	O
Ag	O
NCs	O
would	O
be	O
brought	O
in	O
close	O
proximity	O
to	O
the	O
CdS	O
QDs	O
electrode	O
surface	O
,	O
and	O
efficient	O
photocurrent	O
quenching	O
of	O
QDs	O
could	O
be	O
resulted	O
from	O
an	O
energy	O
transfer	O
process	O
that	O
originated	O
from	O
NCs	O
.	O

Thus	O
,	O
by	O
monitoring	O
the	O
attenuation	O
in	O
the	O
photocurrent	O
signal	O
,	O
an	O
elegant	O
and	O
sensitive	O
PEC	O
DNA	B-P
bioanalysis	I-P
could	O
be	O
accomplished	O
.	O

The	O
developed	O
biosensor	O
displayed	O
a	O
linear	O
range	O
from	O
1.0pM	O
to	O
10nM	O
and	O
the	O
detection	O
limit	O
was	O
experimentally	O
found	O
to	O
be	O
of	O
0.3pM	O
.	O

This	O
work	O
presents	O
a	O
feasible	O
signaling	O
principle	O
that	O
could	O
act	O
as	O
a	O
common	O
basis	O
for	O
general	O
PEC	O
bioanalysis	O
development	O
.	O

Effects	O
of	O
morphology	O
and	O
surface	O
hydroxyl	O
on	O
the	O
toxicity	O
of	O
BiOCl	O
in	O
human	O
HaCaT	O
cells	O
.	O

Recently	O
,	O
bismuth	O
oxychloride	O
nanomaterials	O
(	O
BiOCls	O
)	O
are	O
showing	O
great	O
promise	O
in	O
pollutant	O
removal	O
.	O

Residues	O
from	O
these	O
environmental	O
remediations	O
are	O
potential	O
hazardous	O
materials	O
.	O

Unfortunately	O
,	O
human	O
health	O
risks	O
of	O
BiOCls	O
are	O
still	O
unexplored	O
widely	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
focused	O
on	O
the	O
influence	O
of	O
physicochemical	O
properties	O
on	O
the	O
cytotoxicity	O
of	O
BiOCls	O
toward	O
a	O
human	O
skin	O
derived	O
cell	O
line	O
(	O
HaCaT	O
)	O
.	O

Results	O
showed	O
that	O
morphology	O
and	O
surface	O
hydroxyl	O
both	O
had	O
a	O
profound	O
effect	O
on	O
the	O
toxicity	O
of	O
BiOCls	O
.	O

Microsphere-shaped	O
BiOCl	O
caused	O
less	O
toxicity	O
than	O
nanosheet-shaped	O
BiOCl	O
because	O
of	O
weaker	O
particle-membrane	O
interactions	O
,	O
while	O
the	O
presence	O
of	O
surface	O
hydroxyl	O
on	O
microsphere-shaped	O
BiOCl	O
significantly	O
raised	O
the	O
toxicity	O
owing	O
to	O
the	O
increased	O
interaction	O
with	O
cell	O
membrane	O
.	O

Both	O
microsphere-shaped	O
BiOCl	O
with	O
surface	O
hydroxyl	O
and	O
nanosheet-shaped	O
BiOCl	O
caused	O
significant	O
cell	O
membrane	O
damage	O
(	O
PI	B-P
uptake	I-P
and	O
LDH	B-P
release	I-P
)	O
,	O
however	O
,	O
based	O
on	O
the	O
different	O
mechanism	O
.	O

The	O
former	O
may	O
be	O
a	O
predominant	O
``	O
chemical	O
''	O
mechanism	O
involved	O
an	O
oxidative	O
stress	O
paradigm	O
,	O
as	O
manifested	O
by	O
elevated	O
ROS	O
and	O
depleted	O
GSH	O
,	O
while	O
the	O
latter	O
is	O
mainly	O
due	O
to	O
a	O
direct	O
``	O
physical	O
``	O
damage	O
to	O
cell	O
membrane	O
.	O

Both	O
``	O
physical	O
``	O
and	O
``	O
chemical	O
''	O
response	O
led	O
to	O
cell	O
death	O
.	O

Furthermore	O
,	O
a	O
set	O
of	O
experiments	O
including	O
MMP	O
collapse	O
,	O
cell	O
cycle	O
arrest	O
,	O
and	O
apoptosis	O
/	O
necrosis	O
were	O
conducted	O
to	O
propose	O
a	O
scenario	O
for	O
toxicological	O
aspects	O
of	O
BiOCls	O
.	O

Data	O
presented	O
here	O
would	O
help	O
to	O
enable	O
the	O
rational	O
design	O
of	O
BiOCls	O
for	O
either	O
reducing	O
their	O
unintended	O
consequences	O
or	O
increasing	O
their	O
application	O
potentials	O
.	O

Serum	B-P
apolipoprotein	I-P
E	I-P
concentration	O
and	O
polymorphism	O
influence	O
serum	B-P
lipid	I-P
levels	I-P
in	O
Chinese	O
Shandong	O
Han	O
population	O
.	O

Apolipoprotein	O
E	O
(	O
ApoE	O
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
influence	O
serum	B-P
lipid	I-P
parameters	I-P
,	O
can	O
bind	O
to	O
multiple	O
types	O
of	O
lipids	O
and	O
plays	O
an	O
important	O
role	O
in	O
the	O
metabolism	O
and	O
homeostasis	O
of	O
lipids	O
and	O
lipoproteins	O
.	O

A	O
previous	O
study	O
showed	O
that	O
ApoE	O
concentration	O
significantly	O
affects	O
serum	B-P
lipid	I-P
levels	I-P
independently	O
of	O
ApoE	O
polymorphism	O
.	O

The	O
serum	B-P
lipid	I-P
levels	I-P
were	O
also	O
closely	O
correlated	O
with	O
dietary	O
habits	O
,	O
and	O
Shandong	O
cuisine	O
is	O
famous	O
for	O
its	O
high	O
salt	O
and	O
oil	O
contents	O
,	O
which	O
widely	O
differ	O
among	O
the	O
different	O
areas	O
in	O
China	O
.	O

Therefore	O
,	O
studying	O
the	O
effect	O
of	O
ApoE	O
polymorphism	O
on	O
ApoE	O
concentration	O
and	O
serum	B-P
lipid	I-P
levels	I-P
in	O
Shandong	O
province	O
is	O
very	O
important	O
.A	O
total	O
of	O
815	O
subjects	O
including	O
285	O
men	O
and	O
530	O
women	O
were	O
randomly	O
selected	O
and	O
studied	O
from	O
Jinan	O
,	O
Shandong	O
province	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
association	O
of	O
ApoE	O
polymorphism	O
and	O
serum	O
level	O
on	O
lipid	B-P
profiles	I-P
,	O
the	O
ApoE	O
genotypes	O
,	O
as	O
well	O
as	O
levels	O
of	O
fasting	O
serum	B-P
ApoE	I-P
and	O
other	O
lipid	B-P
parameters	I-P
,	O
were	O
detected	O
in	O
all	O
subjects	O
.The	O
frequency	O
of	O
the	O
ApoE	O
E3	O
allele	O
was	O
highest	O
(	O
83.1	O
%	O
)	O
,	O
while	O
those	O
of	O
E2	O
and	O
E4	O
were	O
9.4	O
%	O
and	O
7.5	O
%	O
,	O
respectively	O
,	O
which	O
are	O
similar	O
to	O
those	O
in	O
other	O
Asian	O
populations	O
.	O

ApoE2	O
allele	O
carriers	O
showed	O
significantly	O
increased	O
ApoE	B-P
levels	I-P
but	O
lower	O
levels	B-P
of	I-P
serum	I-P
total	I-P
cholesterol	I-P
(	O
TC	O
)	O
,	O
low-density	B-P
lipoprotein	I-P
cholesterol	I-P
(	O
LDL-C	B-P
)	O
,	O
and	O
Apolipoprotein	O
B	O
(	O
ApoB	O
)	O
.We	O
found	O
that	O
ApoE	O
level	O
is	O
influence	O
d	O
by	O
ApoE	O
polymorphism	O
in	O
a	O
gene	O
-	O
dependent	O
manner	O
.	O

The	O
ApoE	O
polymorphism	O
showed	O
different	O
influences	O
on	O
serum	B-P
lipid	I-P
parameters	I-P
with	O
increasing	O
age	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
in	O
our	O
Shandong	O
Han	O
population	O
.	O

Effect	O
of	O
nutritionally	O
induced	O
hyperlipidaemia	O
on	O
in	O
vitro	O
bovine	O
embryo	O
quality	O
depends	O
on	O
the	O
type	O
of	O
major	O
fatty	O
acid	O
in	O
the	O
diet	O
.	O

The	O
present	O
study	O
examined	O
whether	O
the	O
effects	O
of	O
dietary	O
-induced	O
hyperlipidaemia	O
on	O
preimplantation	O
embryo	O
development	O
depend	O
on	O
the	O
predominant	O
fatty	O
acid	O
(	O
FA	O
)	O
type	O
in	O
the	O
diet	O
.	O

In	O
a	O
combined	O
in	O
vivo	O
-	O
in	O
vitro	O
bovine	O
model	O
,	O
two	O
groups	O
of	O
cows	O
(	O
n=3	O
in	O
each	O
group	O
)	O
were	O
fed	O
with	O
three	O
diets	O
consecutively	O
(	O
4	O
weeks	O
feeding	O
for	O
each	O
)	O
:	O
(	O
1	O
)	O
a	O
maintenance	O
control	O
diet	O
(	O
CONT	O
)	O
;	O
(	O
2	O
)	O
a	O
high	O
-	O
starch	O
diet	O
rich	O
in	O
saturated	O
fat	O
(	O
SAT	O
)	O
;	O
and	O
(	O
3	O
)	O
a	O
high	O
-	O
starch	O
diet	O
rich	O
in	O
omega-3	O
unsaturated	O
fat	O
(	O
UNSAT	O
)	O
.	O

Two	O
feeding	O
sequences	O
were	O
used	O
to	O
test	O
for	O
carry-over	O
effects	O
:	O
Group	O
A	O
was	O
fed	O
CONT	O
,	O
SAT1	O
and	O
then	O
UNSAT2	O
,	O
whereas	O
Group	O
B	O
was	O
fed	O
CONT	O
,	O
UNSAT1	O
and	O
then	O
SAT2	O
.	O

Serum	O
was	O
collected	O
after	O
each	O
dietary	O
period	O
,	O
analysed	O
and	O
tested	O
in	O
bovine	O
in	O
vitro	O
embryo	B-P
culture	I-P
.	O

Introducing	O
SAT	O
and	O
UNSAT	O
diets	O
induced	O
hyperlipidaemia	O
(	O
specifically	O
hypercholesterolaemia	O
and	O
elevated	O
free	O
FAs	O
)	O
and	O
reduced	O
insulin	O
sensitivity	O
.	O

Carry-over	O
effects	O
in	O
serum	O
metabolites	O
and	O
FA	B-P
profile	I-P
were	O
dependent	O
on	O
the	O
diet	O
and	O
feeding	O
sequence	O
.	O

SAT1	O
and	O
SAT2	O
serum	O
decreased	O
blastocyst	O
rates	O
and	O
altered	O
blastocyst	O
mRNA	O
expression	O
related	O
to	O
apoptosis	O
and	O
oxidative	O
stress	O
.	O

UNSAT1	O
and	O
UNSAT2	O
serum	O
resulted	O
in	O
normal	O
embryo	O
development	O
and	O
quality	O
.	O

Other	O
in	O
vitro	O
effects	O
depended	O
on	O
the	O
sequence	O
of	O
feeding	O
.	O

In	O
conclusion	O
,	O
substitution	O
of	O
saturated	O
fat	O
with	O
omega-3	O
fat	O
in	O
a	O
high-caloric	O
diet	O
induced	O
hyperlipidaemia	O
with	O
an	O
FA	B-P
profile	I-P
yielding	O
similar	O
rates	O
and	O
quality	O
of	O
blastocysts	O
compared	O
with	O
normolipidaemic	O
controls	O
.	O

Whole-genome	O
sequencing	O
identifies	O
common-to-rare	O
variants	O
associated	O
with	O
human	O
blood	O
metabolites	O
.	O

Genetic	O
factors	O
modifying	O
the	O
blood	O
metabolome	O
have	O
been	O
investigated	O
through	O
genome-wide	O
association	O
studies	O
(	O
GWAS	O
)	O
of	O
common	O
genetic	O
variants	O
and	O
through	O
exome	O
sequencing	O
.	O

We	O
conducted	O
a	O
whole-genome	O
sequencing	O
study	O
of	O
common	O
,	O
low-frequency	O
and	O
rare	O
variants	O
to	O
associate	O
genetic	O
variations	O
with	O
blood	O
metabolite	O
levels	O
using	O
comprehensive	O
metabolite	O
profiling	B-P
in	O
1,960	O
adults	O
.	O

We	O
focused	O
the	O
analysis	O
on	O
644	O
metabolites	O
with	O
consistent	O
levels	O
across	O
three	O
longitudinal	O
data	O
collections	O
.	O

Genetic	O
sequence	O
variations	O
at	O
101	O
loci	O
were	O
associated	O
with	O
the	O
levels	O
of	O
246	O
(	O
38	O
%	O
)	O
metabolites	O
(	O
P	O
≤	O
1.9	O
×	O
10	O
(	O
-11	O
)	O
)	O
.	O

We	O
identified	O
113	O
(	O
10.7	O
%	O
)	O
among	O
1,054	O
unrelated	O
individuals	O
in	O
the	O
cohort	O
who	O
carried	O
heterozygous	O
rare	O
variants	O
likely	O
influencing	O
the	O
function	O
of	O
17	O
genes	O
.	O

Thirteen	O
of	O
the	O
17	O
genes	O
are	O
associated	O
with	O
inborn	O
errors	O
of	O
metabolism	O
or	O
other	O
pediatric	O
genetic	O
conditions	O
.	O

This	O
study	O
extends	O
the	O
map	O
of	O
loci	O
influencing	O
the	O
metabolome	O
and	O
highlights	O
the	O
importance	O
of	O
heterozygous	O
rare	O
variants	O
in	O
determining	O
abnormal	O
blood	O
metabolic	O
phenotypes	O
in	O
adults	O
.	O

Comparison	O
of	O
Colorado	O
Microdissection	B-P
Needle	O
Versus	O
Scalpel	O
Incision	O
for	O
Aesthetic	O
Upper	O
and	O
Lower	O
Eyelid	O
Blepharoplasty	O
.	O

Traditionally	O
,	O
eyelid	O
skin	O
incisions	O
with	O
electro-cautery	O
devices	O
have	O
been	O
avoided	O
due	O
to	O
the	O
concerns	O
of	O
aesthetically	O
unacceptable	O
scar	O
formation	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
compare	O
ecchymosis	O
,	O
cosmesis	O
,	O
and	O
histologic	O
tissue	O
damage	O
of	O
incisions	O
made	O
with	O
a	O
scalpel	O
or	O
Colorado	O
needle	O
in	O
patients	O
undergoing	O
upper	O
and	O
lower	O
aesthetic	O
blepharoplasty	O
.	O

To	O
the	O
best	O
of	O
authors	O
'	O
knowledge	O
,	O
no	O
previous	O
study	O
has	O
been	O
performed	O
before	O
to	O
compare	O
these	O
2	O
modalities	O
in	O
aesthetic	O
blepharoplasty	O
surgery	O
.	O

This	O
is	O
a	O
multicenter	O
,	O
prospective	O
,	O
interventional	O
,	O
comparative	O
case	O
series	O
.	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
Institutional	O
Review	O
Board	O
in	O
each	O
institution	O
.	O

Patients	O
underwent	O
bilateral	O
upper	O
and/or	O
transcutaneous	O
lower	O
blepharoplasty	O
with	O
1	O
side	O
randomly	O
selected	O
for	O
skin	O
incision	O
with	O
the	O
scalpel	O
,	O
the	O
other	O
side	O
with	O
the	O
Colorado	O
needle	O
.	O

Ecchymosis	O
was	O
evaluated	O
using	O
a	O
10-point	O
Likert	O
scale	O
and	O
the	O
wounds	O
using	O
a	O
Hollander	O
score	O
.	O

The	O
margins	O
of	O
excised	O
tissues	O
were	O
evaluated	O
histologically	O
.	O

A	O
total	O
of	O
254	O
eyelids	O
of	O
101	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
ecchymosis	O
on	O
postoperative	O
day	O
1	O
and	O
7	O
and	O
scar	O
cosmesis	O
on	O
day	O
30	O
and	O
180	O
between	O
the	O
2	O
techniques.	O
,	O
necrosis	O
was	O
noted	O
only	O
with	O
the	O
Colorado	O
needle	O
sides	O
(	O
p	O
=	O
0.001	O
)	O
.	O

No	O
adverse	O
events	O
occurred	O
on	O
the	O
Colorado	O
needle	O
side	O
at	O
any	O
time	O
after	O
surgery	O
.	O

No	O
clinical	O
difference	O
is	O
noted	O
between	O
Colorado	O
needle	O
and	O
scalpel	O
incisions	O
in	O
terms	O
of	O
ecchymosis	O
and	O
scar	O
cosmesis	O
after	O
aesthetic	O
blepharoplasty	O
.	O

Transition	O
From	O
Hospital	O
to	O
Home	O
in	O
Preterm	O
Infants	O
and	O
Their	O
Families	O
.	O

When	O
the	O
day	O
of	O
discharge	O
from	O
a	O
neonatal	O
intensive	O
care	O
unit	O
(	O
NICU	O
)	O
comes	O
for	O
the	O
parents	O
of	O
newborn	O
infants	O
,	O
they	O
are	O
filled	O
with	O
long-awaited	O
joy	O
and	O
happiness	O
.	O

They	O
go	O
home	O
feeling	O
as	O
parents	O
,	O
away	O
from	O
scheduled	O
routines	O
of	O
the	O
hospital	O
,	O
monitor	O
alarms	O
,	O
clinical	O
rounds	O
,	O
numerous	O
tests	B-P
,	O
and	O
so	O
on	O
.	O

What	O
do	O
we	O
know	O
about	O
what	O
happens	O
after	O
these	O
little	O
patients	O
and	O
their	O
families	O
leave	O
the	O
NICU	O
?	O

What	O
happens	O
from	O
the	O
point	O
of	O
leaving	O
the	O
hospital	O
until	O
when	O
things	O
get	O
settled	O
and	O
life	O
becomes	O
perceived	O
as	O
normal	O
?	O

This	O
article	O
presents	O
a	O
short	O
summary	O
of	O
research	O
conducted	O
with	O
the	O
vulnerable	O
population	O
of	O
high-risk	O
and	O
preterm	O
infants	O
and	O
their	O
families	O
postdischarge	O
.	O

Available	O
evidence	O
suggests	O
that	O
transition	O
to	O
home	O
after	O
hospital	O
discharge	O
,	O
a	O
phenomenon	O
that	O
many	O
families	O
experience	O
,	O
is	O
challenging	O
and	O
requires	O
attention	O
from	O
clinicians	O
and	O
researchers	O
if	O
we	O
are	O
to	O
provide	O
effective	O
,	O
efficient	O
,	O
and	O
high-quality	O
care	O
.	O

Prolyl-4-hydroxylase	O
2	O
and	O
3	O
coregulate	O
murine	O
erythropoietin	O
in	O
brain	O
pericytes	O
.	O

A	O
classic	O
response	O
to	O
systemic	O
hypoxia	O
is	O
the	O
increased	O
production	O
of	O
red	O
blood	O
cells	O
due	O
to	O
hypoxia-inducible	O
factor	O
(	O
HIF	O
)	O
-mediated	O
induction	O
of	O
erythropoietin	O
(	O
EPO	O
)	O
.	O

EPO	O
is	O
a	O
glycoprotein	O
hormone	O
that	O
is	O
essential	O
for	O
normal	O
erythropoiesis	O
and	O
is	O
predominantly	O
synthesized	O
by	O
peritubular	O
renal	O
interstitial	O
fibroblast-like	O
cells	O
,	O
which	O
express	O
cellular	O
markers	O
characteristic	O
of	O
neuronal	O
cells	O
and	O
pericytes	O
.	O

To	O
investigate	O
whether	O
the	O
ability	O
to	O
synthesize	O
EPO	O
is	O
a	O
general	O
functional	O
feature	O
of	O
pericytes	O
,	O
we	O
used	O
conditional	O
gene	O
targeting	O
to	O
examine	O
the	O
von	O
Hippel-Lindau	O
/	O
prolyl-4-hydroxylase	O
domain	O
(	O
PHD	O
)	O
/HIF	O
axis	O
in	O
cell	O
-	O
expressing	O
neural	O
glial	O
antigen	O
2	O
,	O
a	O
known	O
molecular	O
marker	O
of	O
pericytes	O
in	O
multiple	O
organs	O
.	O

We	O
found	O
that	O
pericytes	O
in	O
the	O
brain	O
synthesized	O
EPO	O
in	O
mice	O
with	O
genetic	O
HIF	O
activation	O
and	O
were	O
capable	O
of	O
responding	O
to	O
systemic	O
hypoxia	O
with	O
the	O
induction	O
of	O
Epo	O
.	O

Using	O
high-resolution	B-P
multiplex	O
in	O
situ	O
hybridization	O
,	O
we	O
determined	O
that	O
brain	O
pericytes	O
represent	O
an	O
important	O
cellular	O
source	O
of	O
Epo	O
in	O
the	O
hypoxic	O
brain	O
(	O
up	O
to	O
70	O
%	O
of	O
all	O
Epo	O
-	O
expressing	O
cells	O
)	O
.	O

We	O
furthermore	O
determined	O
that	O
Epo	O
transcription	O
in	O
brain	O
pericytes	O
was	O
HIF-2	O
dependent	O
and	O
cocontrolled	O
by	O
PHD2	O
and	O
PHD3	O
,	O
oxygen	O
-	O
and	O
2-oxoglutarate	O
-dependent	O
prolyl-4-hydroxylases	O
that	O
regulate	O
HIF	O
activity	O
.	O

In	O
summary	O
,	O
our	O
studies	O
provide	O
experimental	O
evidence	O
that	O
pericytes	O
in	O
the	O
brain	O
have	O
the	O
ability	O
to	O
function	O
as	O
oxygen	O
sensors	O
and	O
respond	O
to	O
hypoxia	O
with	O
EPO	O
synthesis	O
.	O

Our	O
findings	O
furthermore	O
suggest	O
that	O
the	O
ability	O
to	O
synthesize	O
EPO	O
may	O
represent	O
a	O
functional	O
feature	O
of	O
pericytes	O
in	O
the	O
brain	O
and	O
kidney	O
.	O

In	O
Vivo	O
Three-Dimensional	O
Patellar	O
Mechanics	O
:	O
Normal	O
Knees	O
Compared	O
with	O
Domed	O
and	O
Anatomic	O
Patellar	O
Components	O
.	O

Patellofemoral	O
complications	O
are	O
a	O
major	O
cause	O
of	O
revision	O
surgery	O
following	O
total	O
knee	O
arthroplasty	O
(	O
TKA	O
)	O
.	O

High	O
forces	O
occurring	O
at	O
the	O
patellofemoral	O
articulation	O
coupled	O
with	O
a	O
small	O
patellofemoral	O
contact	O
area	O
pose	O
substantial	O
design	O
challenges	O
.	O

In	O
this	O
study	O
,	O
the	O
three-dimensional	O
(	O
3D	O
)	O
in	O
vivo	O
mechanics	O
of	O
domed	O
and	O
anatomically	O
shaped	O
patellar	O
components	O
were	O
compared	O
with	O
those	O
of	O
native	O
patellae	O
.	O

Ten	O
normal	O
knees	O
,	O
10	O
treated	O
with	O
an	O
LCS-PS	O
(	O
low	O
contact	O
stress-posterior	O
stabilized	O
)	O
TKA	O
(	O
anatomically	O
shaped	O
patellar	O
component	O
)	O
,	O
and	O
10	O
treated	O
with	O
a	O
PFC	O
Sigma	O
RP-PS	O
(	O
press-fit	O
condylar	O
Sigma	O
rotating	O
platform-posterior	O
stabilized	O
)	O
TKA	O
(	O
domed	O
patellar	O
component	O
)	O
were	O
analyzed	O
under	O
fluoroscopic	B-P
surveillance	O
while	O
the	O
patient	O
performed	O
a	O
weight-bearing	O
deep	O
knee	O
bend	O
from	O
full	O
knee	O
extension	O
to	O
maximum	O
knee	O
flexion	O
.	O

Relevant	O
bone	O
geometries	O
were	O
segmented	O
out	O
from	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
scans	B-P
,	O
and	O
computer-assisted-design	O
(	O
CAD	O
)	O
models	O
of	O
the	O
implanted	O
components	O
were	O
obtained	O
from	O
the	O
manufacturer	O
.	O

Three-dimensional	O
patellofemoral	O
kinematics	O
were	O
obtained	O
using	O
a	O
3D	O
-to-	O
2D	O
registration	O
process	O
.	O

Contact	O
mechanics	O
were	O
calculated	O
using	O
a	O
distance	O
map	O
between	O
the	O
articulating	O
patellar	O
and	O
femoral	O
surfaces	O
.	O

Both	O
patellar	O
component	O
designs	O
exhibited	O
good	O
rotational	O
kinematics	O
and	O
tracked	O
well	O
within	O
the	O
femoral	O
trochlea	O
when	O
compared	O
with	O
the	O
normal	O
patella	O
.	O

The	O
contact	O
areas	O
in	O
the	O
TKA	O
groups	O
peaked	O
at	O
60°	O
of	O
knee	O
flexion	O
(	O
mean	O
and	O
standard	O
deviation	O
,	O
201	O
±	O
63.4	O
mm	O
for	O
the	O
LCS-PS	O
group	O
and	O
218	O
±	O
95.4	O
mm	O
for	O
the	O
Sigma	O
RP-PS	O
group	O
)	O
,	O
and	O
the	O
areas	O
were	O
substantially	O
smaller	O
than	O
those	O
previously	O
reported	O
for	O
the	O
normal	O
patella	O
.	O

Contact	O
points	O
in	O
the	O
TKA	O
groups	O
stayed	O
close	O
to	O
the	O
center	O
of	O
the	O
patellar	O
components	O
.	O

Both	O
designs	O
performed	O
satisfactorily	O
,	O
although	O
patellofemoral	O
contact	O
areas	O
were	O
reduced	O
in	O
comparison	O
with	O
those	O
in	O
the	O
native	O
patella	O
.	O

Therapeutic	O
Level	O
III	O
.	O

See	O
Instructions	O
for	O
Authors	O
for	O
a	O
complete	O
description	O
of	O
levels	O
of	O
evidence	O
.	O

JS	O
ISH-ECCR-3	O
A	O
NOVEL	O
ALGORITHM	O
FOR	O
THE	O
CASE	O
DETECTION	O
OF	O
THE	O
MOST	O
COMMON	O
FORM	O
OF	O
ENDOCRINE	O
HYPERTENSION	O
.	O

Primary	O
aldosteronism	O
(	O
PA	O
)	O
involves	O
more	O
than	O
11	O
%	O
of	O
patients	O
referred	O
to	O
specialized	O
hypertension	O
centers	O
and	O
,	O
therefore	O
,	O
is	O
much	O
more	O
common	O
than	O
commonly	O
held	O
.	O

Moreover	O
,	O
it	O
causes	O
a	O
damage	O
to	O
the	O
heart	O
,	O
blood	O
vessels	O
and	O
kidneys	O
,	O
which	O
translates	O
into	O
a	O
high	O
rate	O
of	O
cardiovascular	O
events	O
,	O
in	O
excess	O
to	O
the	O
degree	O
of	O
blood	O
pressure	O
raise	O
.	O

Along	O
with	O
the	O
notion	O
that	O
a	O
timely	O
diagnosis	B-P
entails	O
a	O
fundamental	O
step	O
for	O
the	O
choice	O
of	O
an	O
appropriate	O
therapy	O
,	O
which	O
can	O
correct	O
the	O
arterial	O
hypertension	O
and	O
the	O
hypokalemia	O
,	O
this	O
justifies	O
efforts	O
to	O
search	O
for	O
PA	O
in	O
the	O
majority	O
of	O
the	O
patients	O
with	O
hypertension	O
.	O

Unfortunately	O
,	O
because	O
of	O
the	O
lack	O
of	O
the	O
classical	O
signs	O
,	O
as	O
spontaneous	O
or	O
drug-induced	O
hypokalemia	O
and	O
related	O
symptoms	O
,	O
PA	O
deceives	O
diagnosis	B-P
in	O
the	O
majority	O
of	O
the	O
cases	O
.The	O
identification	O
of	O
a	O
curable	O
form	O
of	O
primary	O
aldosteronism	O
can	O
be	O
beneficial	O
particularly	O
in	O
some	O
subgroups	O
of	O
patients	O
,	O
namely	O
those	O
with	O
drug	O
-	O
resistant	O
hypertension	O
,	O
who	O
are	O
at	O
high	O
risk	O
of	O
primary	O
aldosteronism	O
.	O

An	O
aggressive	O
diagnostic	B-P
approach	I-P
is	O
necessary	O
in	O
these	O
patients	O
,	O
who	O
can	O
benefit	O
most	O
from	O
an	O
accurate	O
diagnosis	B-P
.	O

Knowledge	O
of	O
the	O
sodium	O
intake	O
and	O
drug	O
effects	O
on	O
the	O
aldosterone-renin	O
ratio	O
is	O
a	O
key	O
element	O
for	O
the	O
diagnosis	B-P
in	O
these	O
challenging	O
cases	O
.With	O
the	O
latest	O
work-up	B-P
endorsed	O
by	O
the	O
Endocrine	O
Society	O
Guidelines	O
and	O
supported	O
by	O
the	O
results	O
of	O
the	O
AQUARR	O
Study	O
,	O
the	O
diagnostic	O
algorithm	O
for	O
PA	O
can	O
be	O
substantially	O
simplified	O
.	O

This	O
means	O
skipping	O
the	O
so-called	O
confirmatory	O
tests	B-P
in	O
most	O
cases	O
and	O
thus	O
rendering	O
the	O
screening	B-P
of	O
PA	O
feasible	O
and	O
affordable	O
.	O

Hence	O
,	O
most	O
centers	O
can	O
nowadays	O
exploit	O
use	O
of	O
a	O
cost	O
-	O
effective	O
strategy	O
to	O
screen	O
for	O
patients	O
with	O
primary	O
aldosteronism	O
.	O

At	O
variance	O
,	O
the	O
identification	O
of	O
primary	O
aldosteronism	O
subtypes	O
,	O
which	O
involves	O
adrenal	B-P
vein	I-P
sampling	I-P
(	O
AVS	B-P
)	O
,	O
should	O
only	O
be	O
undertaken	O
at	O
tertiary	O
referral	O
centers	O
that	O
have	O
experience	O
in	O
performing	O
and	O
interpreting	O
this	O
minimally	B-P
invasive	I-P
test	I-P
.Overall	O
,	O
long-term	O
cure	O
biochemical	O
cure	O
can	O
be	O
consistently	O
achieved	O
when	O
adrenalectomy	O
is	O
based	O
on	O
AVS	B-P
-	O
based	O
identification	O
of	O
lateralized	O
aldosterone	O
excess	O
.	O

Moreover	O
,	O
long-term	O
cure	O
of	O
hypertension	O
,	O
defined	O
as	O
no	O
need	O
for	O
antihypertensive	O
drug	O
treatment	O
,	O
can	O
be	O
achieved	O
in	O
about	O
45	O
%	O
of	O
the	O
cases	O
,	O
with	O
an	O
additional	O
40	O
%	O
showing	O
a	O
marked	O
improvement	O
in	O
blood	O
pressure	O
control	O
.	O

Lack	O
of	O
blood	O
pressure	O
normalization	O
can	O
be	O
explained	O
by	O
misdiagnosis	O
and/or	O
concomitant	O
essential	O
hypertension	O
.	O

A	O
Giant	O
Intra	O
Abdominal	O
Mass	O
Mimicking	O
Renal	O
Cell	O
Carcinoma	O
:	O
A	O
Rare	O
Presentation	O
of	O
Renal	O
Angiomyolipoma	O
.	O

Angiomyolipoma	O
(	O
AML	O
)	O
is	O
a	O
benign	O
tumor	O
commonly	O
found	O
in	O
kidney	O
than	O
extra	O
renal	O
sites	O
.	O

Most	O
of	O
the	O
small	O
renal	O
angiomyolipomas	O
are	O
diagnosed	O
incidentally	O
on	O
ultrasound	B-P
and	O
other	O
imaging	B-P
studies	I-P
.	O

Some	O
renal	O
AMLs	O
present	O
clinically	O
when	O
become	O
very	O
big	O
,	O
giant	O
renal	O
angiomyolipoma	O
.	O

Although	O
almost	O
all	O
cases	O
are	O
benign	O
,	O
a	O
relatively	O
rare	O
variant	O
of	O
epitheloid	O
angiomyolipoma	O
has	O
got	O
malignant	O
potential	O
and	O
can	O
even	O
metastasize	O
.	O

Ultrasonography	B-P
,	O
CT	B-P
and	O
MRI	B-P
scan	I-P
are	O
usually	O
used	O
for	O
diagnosis	O
of	O
angiomyolipoma	O
with	O
high	O
level	O
of	O
accuracy	O
;	O
even	O
though	O
some	O
lesions	O
may	O
be	O
confused	O
as	O
renal	O
cell	O
carcinoma	O
on	O
imaging	B-P
studies	I-P
.	O

Here	O
,	O
a	O
48	O
year	O
old	O
man	O
presented	O
with	O
a	O
large	O
intra-abdominal	O
mass	O
preoperatively	O
diagnosed	O
as	O
a	O
case	O
of	O
right	O
renal	O
cell	O
carcinoma	O
and	O
radical	O
nephrectomy	O
was	O
performed	O
.	O

Histopathology	O
revealed	O
epitheloid	O
angiomyolipoma	O
(	O
EAML	O
)	O
.	O

DNA	O
methylation	O
detection	O
at	O
single	O
base	O
resolution	O
using	O
targeted	O
next	O
generation	O
bisulfite	O
sequencing	O
and	O
cross	O
validation	O
using	O
capillary	O
sequencing	O
.	O

With	O
a	O
purpose	O
of	O
accurate	O
and	O
simultaneous	O
determination	B-P
of	O
DNA	O
methylation	O
from	O
multiple	O
loci	O
in	O
multiple	O
samples	O
,	O
here	O
,	O
we	O
are	O
demonstrating	O
a	O
method	O
to	O
aid	O
rapid	O
DNA	O
methylation	O
detection	O
of	O
genomic	O
sequences	O
.	O

Using	O
genomic	O
DNA	O
of	O
peripheral	O
blood	O
from	O
14	O
healthy	O
individuals	O
,	O
DNA	O
methylation	O
in	O
465	O
CpG	O
sites	O
from	O
12	O
loci	O
of	O
genes	O
(	O
ADAM22	O
,	O
ATF2	O
,	O
BCR	O
,	O
CD83	O
,	O
CREBBP	O
,	O
IL12B	O
,	O
IL17RA	O
,	O
MAP2K2	O
,	O
RBM38	O
,	O
TGFBR2	O
,	O
TGFBR3	O
,	O
and	O
WNT5A	O
)	O
was	O
analysed	O
by	O
targeted	O
next	O
generation	O
bisulfite	O
sequencing	O
.	O

Analysed	O
region	O
for	O
three	O
genes	O
,	O
BCR	O
,	O
IL17RA	O
and	O
RBM38	O
showed	O
an	O
absolute	O
mean	O
DNA	O
methylation	O
of	O
25.6	O
%	O
,	O
89.2	O
%	O
and	O
38.9	O
%	O
respectively	O
.	O

Other	O
nine	O
gene	O
loci	O
were	O
unmethylated	O
and	O
exhibited	O
<	O
10	O
%	O
absolute	O
mean	O
DNA	O
methylation	O
.	O

Two	O
genes	O
,	O
IL17RA	O
and	O
RBM38	O
were	O
technically	O
validated	O
using	O
direct	O
capillary	O
sequencing	O
and	O
results	O
were	O
comparable	O
with	O
positive	O
correlation	O
(	O
P=0.0088	O
&	O
P	O
<	O
0.0001	O
respectively	O
)	O
in	O
the	O
CpG	O
sites	O
for	O
DNA	O
methylation	O
.	O

All	O
CpG	O
sites	O
analysed	O
from	O
RBM38	O
genes	O
locus	O
displayed	O
95	O
%	O
limits	O
of	O
agreement	O
for	O
DNA	O
methylation	O
measurements	O
from	O
the	O
two	O
methods	O
.	O

The	O
present	O
approach	O
provides	O
a	O
fast	O
and	O
reliable	O
DNA	O
methylation	O
quantitative	O
data	O
at	O
single	O
base	O
resolution	O
with	O
good	O
coverage	O
of	O
the	O
CpG	O
sites	O
under	O
analysis	O
in	O
multiple	O
loci	O
and	O
samples	O
simultaneously	O
.	O

Use	O
of	O
targeted	O
next	O
generation	O
bisulfite	O
sequencing	O
may	O
provide	O
an	O
opportunity	O
to	O
explore	O
genes	O
in	O
the	O
discovery	O
panel	O
for	O
biomarker	O
identification	O
and	O
facilitate	O
functional	O
validation	O
.	O

Function	O
analysis	O
of	O
Mef2c	O
promoter	O
in	O
muscle	O
differentiation	O
.	O

Regeneration	O
of	O
adult	O
skeletal	O
muscle	O
following	O
injury	O
occurs	O
through	O
the	O
activation	O
of	O
satellite	O
cells	O
,	O
that	O
proliferates	O
,	O
differentiates	O
,	O
and	O
fuses	O
with	O
injured	O
myofibers	O
.	O

Myocyte	O
enhancer	O
factor	O
2	O
(	O
MEF2	O
)	O
proteins	O
are	O
reported	O
that	O
they	O
have	O
the	O
potential	O
contributions	O
to	O
adult	O
muscle	O
regeneration	O
.	O

In	O
order	O
to	O
further	O
understand	O
Mef2c	O
gene	O
,	O
the	O
promoter	O
of	O
pig	O
Mef2c	O
gene	O
was	O
analyzed	O
in	O
this	O
paper	O
.	O

Quantitative	O
real-time	O
PCR	O
(	O
qRT-PCR	O
)	O
revealed	O
the	O
expression	O
pattern	O
of	O
Mef2c	O
gene	O
in	O
muscle	O
of	O
eight	O
tissues	O
.	O

The	O
Mef2c	O
promoter	O
had	O
the	O
higher	O
transcriptional	O
activity	O
in	O
differentiated	O
C2C12	O
cells	O
than	O
that	O
in	O
proliferating	O
C2C12	O
cells	O
,	O
which	O
was	O
accompanied	O
by	O
the	O
up-regulation	O
of	O
mRNA	O
expression	O
of	O
Mef2c	O
gene	O
.	O

Function	O
deletion	O
and	O
mutation	O
analyses	O
showed	O
that	O
MyoD	O
and	O
MEF2	O
binding	O
sites	O
within	O
the	O
Mef2c	O
promoter	O
were	O
responsible	O
for	O
the	O
regulation	O
of	O
Mef2c	O
transcription	O
.	O

MEF2C	O
could	O
up-regulate	O
the	O
transcriptional	O
activities	O
of	O
Mef2c	O
promoter	O
constructs	O
which	O
contained	O
a	O
3'-end	O
nucleotide	O
sequence	O
with	O
p300	O
binding	O
site	O
.	O

The	O
Electrophoretic	B-P
mobility	I-P
shift	I-P
assays	I-P
(	O
EMSA	B-P
)	O
and	O
chromatin	B-P
immunoprecipitation	I-P
(	I-P
ChIP	I-P
)	I-P
assays	I-P
determined	O
the	O
MyoD	O
binding	O
site	O
in	O
Mef2c	O
promoter	O
.	O

These	O
results	O
advanced	O
our	O
knowledge	O
of	O
the	O
promoter	O
of	O
the	O
pig	O
Mef2c	O
gene	O
.	O

And	O
the	O
study	O
of	O
Mef2c	O
promoter	O
regulator	O
elements	O
helped	O
to	O
elucidating	O
the	O
regulation	O
mechanisms	O
of	O
Mef2c	O
in	O
muscle	O
differentiation	O
or	O
muscle	O
repair	O
and	O
regeneration	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Predictive	O
biomarkers	O
and	O
effectiveness	O
of	O
MUC1	O
-targeted	O
dendritic-cell	O
-based	O
vaccine	O
in	O
patients	O
with	O
refractory	O
non-small	O
cell	O
lung	O
cancer	O
.	O

The	O
dendritic	O
cell	O
(	O
DC	O
)	O
-based	O
vaccine	O
targeting	O
the	O
highly	O
immunogenic	O
tumor	O
antigen	O
,	O
MUC1	O
,	O
has	O
been	O
promising	O
for	O
a	O
cancer	O
immunotherapy	O
;	O
however	O
,	O
predictive	O
biomarkers	O
for	O
beneficial	O
clinical	O
responses	O
of	O
the	O
vaccine	O
remain	O
to	O
be	O
determined	O
.	O

DCs	O
loaded	O
with	O
MUC1-derived	O
peptide	O
were	O
subcutaneously	O
administered	O
to	O
patients	O
with	O
MUC1-positive	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
that	O
was	O
refractory	O
to	O
standard	O
anticancer	O
therapies	O
,	O
every	O
2	O
weeks	O
.	O

The	O
effectiveness	O
and	O
tolerability	O
of	O
the	O
vaccine	O
were	O
evaluated	O
,	O
and	O
predictive	O
biomarkers	O
of	O
clinical	O
responses	O
were	O
explored	O
.	O

Between	O
August	O
2005	O
and	O
May	O
2015	O
,	O
40	O
patients	O
received	O
the	O
vaccines	O
.	O

The	O
median	O
survival	O
time	O
(	O
MST	O
)	O
after	O
the	O
initial	O
vaccination	O
was	O
7.4	O
months	O
,	O
and	O
the	O
1-year	O
survival	O
rate	O
was	O
25.0	O
%	O
.	O

The	O
MST	O
for	O
patients	O
who	O
received	O
more	O
than	O
six	O
vaccinations	O
was	O
9.5	O
months	O
,	O
and	O
the	O
1-year	O
survival	O
rate	O
was	O
39.3	O
%	O
.	O

In	O
this	O
cohort	O
,	O
patients	O
who	O
experienced	O
immune-related	O
adverse	O
events	O
,	O
including	O
skin	O
reactions	O
at	O
the	O
vaccination	O
site	O
and	O
fever	O
,	O
had	O
significantly	O
longer	O
survival	O
times	O
compared	O
with	O
patients	O
without	O
those	O
immune-related	O
adverse	O
events	O
(	O
12.6	O
versus	O
6.7	O
months	O
,	O
p	O
=	O
0.042	O
)	O
.	O

Longer	O
survival	O
times	O
were	O
also	O
observed	O
in	O
patients	O
whose	O
peripheral	B-P
white	I-P
blood	I-P
cells	I-P
contained	O
>	O
20.0	O
%	O
lymphocytes	B-P
(	O
12.6	O
versus	O
4.5	O
months	O
;	O
p	O
=	O
0.014	O
)	O
.	O

MUC1	O
-specific	O
cytotoxic	O
immune	O
responses	O
were	O
achieved	O
in	O
all	O
of	O
seven	O
patients	O
analyzed	O
who	O
received	O
six	O
vaccinations	O
.	O

The	O
MUC1	O
-targeted	O
DC	O
-based	O
vaccine	O
induced	O
an	O
antitumor	O
immune	O
response	O
that	O
promoted	O
prolonged	O
survival	O
of	O
patients	O
with	O
refractory	O
NSCLC	O
.	O

The	O
occurrence	O
of	O
immune-related	O
adverse	O
events	O
and	O
having	O
a	O
higher	O
percentage	O
of	O
peripheral	B-P
lymphocytes	I-P
were	O
predictive	O
biomarkers	O
of	O
a	O
beneficial	O
clinical	O
response	O
during	O
cancer	O
immunotherapy	O
for	O
NSCLC	O
.	O

The	O
Associated	O
Factors	O
and	O
Clinical	O
Features	O
of	O
Neuropathic	O
Pain	O
after	O
Brachial	O
Plexus	O
Injuries	O
:	O
A	O
Cross-sectional	O
Study	O
.	O

Neuropathic	O
pain	O
in	O
patients	O
with	O
brachial	O
plexus	O
injuries	O
brings	O
complicated	O
obstacles	O
to	O
the	O
treatment	O
and	O
recovery	O
for	O
both	O
surgeons	O
and	O
patients	O
.	O

The	O
clinical	O
features	O
of	O
neuropathic	O
pain	O
,	O
including	O
pain	O
intensity	O
,	O
type	O
and	O
time	O
phase	O
,	O
need	O
to	O
be	O
investigated	O
.	O

Moreover	O
,	O
possible	O
associated	O
factors	O
need	O
to	O
be	O
explored	O
.	O

A	O
cross-sectional	O
study	O
containing	O
77	O
participants	O
was	O
conducted	O
.	O

Their	O
baseline	O
information	O
and	O
injury-related	O
conditions	O
were	O
collected	O
.	O

The	O
Present	O
Pain	O
Index	O
evaluated	O
by	O
the	O
visual	B-P
analogue	I-P
scale	I-P
,	O
self-reports	O
using	O
the	O
specific	O
pain	O
questionnaires	O
were	O
used	O
for	O
screening	O
and	O
estimating	B-P
the	I-P
patients	I-P
'	I-P
pain	I-P
.	O

T-test	O
,	O
Chi-square	O
test	O
,	O
Logistic	O
Regression	O
and	O
correlation	O
coefficient	O
were	O
used	O
when	O
conducting	O
the	O
statistical	O
analyses	O
.	O

The	O
occurrence	O
rate	O
of	O
neuropathic	O
pain	O
in	O
our	O
study	O
was	O
54.5	O
%	O
.	O

Paraesthesia	O
/	O
dysaesthesia	O
had	O
the	O
highest	O
average	O
score	O
in	O
our	O
population	O
.	O

Among	O
potential	O
associated	O
factors	O
,	O
smoking	O
(	O
P=0.001	O
)	O
,	O
regular	O
alcohol	O
drinking	O
(	O
P=0.001	O
)	O
,	O
total	O
brachial	O
plexus	O
injuries	O
(	O
P=0.01	O
)	O
and	O
avulsions	O
(	O
P=0.019	O
)	O
were	O
related	O
to	O
the	O
development	O
of	O
neuropathic	O
pain	O
.	O

Patients	O
with	O
neuropathic	O
pain	O
experienced	O
significantly	O
poorer	O
function	O
of	O
the	O
upper	O
limbs	O
measured	O
by	O
the	O
Disabilities	O
of	O
Arm	O
,	O
Hand	O
and	O
Shoulder	O
questionnaire	O
(	O
P	O
<	O
0.01	O
)	O
.	O

There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
the	O
function	O
of	O
the	O
upper	O
limbs	O
and	O
pain	O
intensity	O
(	O
r=0.60	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Though	O
the	O
pain	O
type	O
and	O
time	O
phase	O
manifested	O
differently	O
across	O
patients	O
,	O
paraesthesia	O
/	O
dysaesthesia	O
occurred	O
most	O
commonly	O
in	O
our	O
study	O
.	O

Patients	O
were	O
more	O
likely	O
to	O
develop	O
neuropathic	O
pain	O
if	O
they	O
had	O
total	O
brachial	O
plexus	O
injuries	O
,	O
avulsion	O
and	O
bad	O
life	O
habits	O
.	O

Moreover	O
,	O
the	O
function	O
of	O
the	O
upper	O
limbs	O
was	O
affected	O
by	O
pain	O
.	O

A	O
New	O
Intraoperative	O
Protocol	O
for	O
Reducing	O
Perioperative	O
Transfusions	O
in	O
Cardiac	O
Surgery	O
.	O

Perioperative	O
anemia	O
and	O
blood	O
product	O
transfusion	O
increases	O
short-term	O
and	O
long-term	O
morbidity	O
and	O
mortality	O
during	O
cardiac	O
surgery	O
.	O

We	O
hypothesized	O
that	O
streamlined	O
cardiopulmonary	O
bypass	O
circuit	O
and	O
rotational	B-P
thromboelastometry	I-P
(	O
ROTEM	B-P
)	O
would	O
reduce	O
blood	O
product	O
usage	O
and	O
improve	O
outcomes	O
.	O

All	O
patients	O
with	O
Society	O
of	O
Thoracic	O
Surgeons	O
risk	O
scores	O
at	O
our	O
institution	O
from	O
January	O
2013	O
to	O
June	O
2015	O
were	O
included	O
.	O

Individuals	O
were	O
chronologically	O
stratified	O
into	O
2	O
groups	O
according	O
to	O
institutional	O
changes	O
to	O
a	O
streamlined	O
bypass	O
circuit	O
and	O
ROTEM	B-P
-guided	O
transfusion	O
.	O

Blood	O
product	O
transfusion	O
,	O
hematocrit	O
,	O
and	O
observed	O
to	O
expected	O
outcomes	O
(	O
O/E	O
)	O
were	O
compared	O
between	O
the	O
groups	O
.	O

Patients	O
were	O
defined	O
as	O
either	O
control	O
group	O
(	O
533	O
patients	O
,	O
12	O
months	O
)	O
or	O
intervention	O
group	O
(	O
804	O
patients	O
,	O
18	O
months	O
)	O
.	O

The	O
intervention	O
group	O
was	O
further	O
subdivided	O
into	O
streamlined	O
circuit	O
(	O
290	O
patients	O
,	O
6	O
months	O
)	O
and	O
ROTEM	B-P
(	O
514	O
patients	O
,	O
12	O
months	O
)	O
.	O

Use	O
of	O
streamlined	O
bypass	O
circuit	O
correlated	O
with	O
significantly	O
reduced	O
intraoperative	O
transfusion	O
of	O
packed	O
red	O
blood	O
cells	O
(	O
pRBCs	O
)	O
(	O
23.8	O
%	O
versus	O
17.9	O
%	O
;	O
p	O
=	O
0.05	O
)	O
and	O
platelets	O
(	O
28.0	O
%	O
versus	O
19.3	O
;	O
p	O
=	O
0.01	O
)	O
with	O
improvement	O
in	O
lowest	O
intraoperative	O
hematocrit	O
(	O
26.0	O
versus	O
26.9	O
;	O
p	O
=	O
0.02	O
)	O
.	O

ROTEM	B-P
was	O
associated	O
with	O
a	O
further	O
reduction	O
in	O
intraoperative	O
pRBCs	O
(	O
17.9	O
%	O
versus	O
11.28	O
%	O
;	O
p	O
=	O
0.01	O
)	O
and	O
postoperative	O
transfusion	O
pRBCs	O
(	O
38.3	O
%	O
versus	O
23.5	O
%	O
;	O
p	O
=	O
0.02	O
)	O
.	O

The	O
combination	O
was	O
associated	O
with	O
reduced	O
intraoperative	O
(	O
44.6	O
%	O
versus	O
34.1	O
;	O
p	O
<	O
0.001	O
)	O
and	O
postoperative	O
transfusions	O
(	O
45.6	O
%	O
versus	O
40.1	O
;	O
p	O
<	O
0.001	O
)	O
in	O
the	O
intervention	O
group	O
,	O
while	O
maintaining	O
a	O
higher	O
hematocrit	O
at	O
discharge	O
(	O
28.1	O
versus	O
29.1	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Finally	O
,	O
the	O
intervention	O
was	O
associated	O
with	O
a	O
statistically	O
significant	O
reduction	O
in	O
the	O
O/E	O
for	O
reoperation	O
(	O
p	O
=	O
0.003	O
)	O
.	O

Use	O
of	O
streamlined	O
cardiopulmonary	O
bypass	O
circuit	O
and	O
ROTEM	B-P
may	O
reduce	O
transfusion	O
and	O
reoperation	O
rates	O
and	O
improve	O
perioperative	O
anemia	O
in	O
cardiac	O
surgical	O
patients	O
.	O

This	O
study	O
demonstrates	O
reproducible	O
intraoperative	O
methods	O
for	O
reducing	O
blood	O
product	O
usage	O
and	O
improving	O
outcomes	O
.	O

Assessing	O
the	O
learning	O
potential	O
of	O
an	O
interactive	O
digital	O
game	O
versus	O
an	O
interactive-style	O
didactic	O
lecture	O
:	O
the	O
continued	O
importance	O
of	O
didactic	O
teaching	O
in	O
medical	O
student	O
education	O
.	O

Games	O
with	O
educational	O
intent	O
offer	O
a	O
possible	O
advantage	O
of	O
being	O
more	O
interactive	O
and	O
increasing	O
learner	O
satisfaction	O
.	O

We	O
conducted	O
a	O
two-armed	O
experiment	O
to	O
evaluate	O
student	O
satisfaction	O
and	O
content	O
mastery	O
for	O
an	O
introductory	O
pediatric	O
radiology	O
topic	O
,	O
taught	O
by	O
either	O
an	O
interactive	O
digital	O
game	O
or	O
with	O
a	O
traditional	O
didactic	O
lecture	O
.	O

Medical	O
students	O
participating	O
in	O
a	O
fourth-year	O
radiology	O
elective	O
were	O
invited	O
to	O
participate	O
.	O

Student	O
cohorts	O
were	O
alternatively	O
given	O
a	O
faculty	O
-	O
supervised	O
1h	O
session	O
playing	O
a	O
simple	O
interactive	O
digital	O
Tic-tac-toe	O
quiz	O
module	O
on	O
pediatric	B-P
gastrointestinal	I-P
radiology	I-P
or	O
a	O
1h	O
didactic	O
introductory	O
lecture	O
on	O
the	O
same	O
topic	O
.	O

Survey	O
questions	O
assessed	O
the	O
learners	O
'	O
perceived	O
ability	O
to	O
recall	O
the	O
material	O
as	O
well	O
as	O
their	O
satisfaction	O
with	O
the	O
educational	O
experience	O
.	O

Results	O
of	O
an	O
end-of-rotation	O
exam	O
were	O
reviewed	O
to	O
evaluate	O
a	O
quantitative	O
measure	O
of	O
learning	O
between	O
groups	O
.	O

Survey	O
responses	O
were	O
analyzed	O
with	O
a	O
chi-squared	O
test	O
.	O

Exam	O
results	O
for	O
both	O
groups	O
were	O
analyzed	O
with	O
a	O
paired	O
Student	O
's	O
t-test	O
.	O

Students	O
in	O
the	O
lecture	O
group	O
had	O
higher	O
test	O
scores	O
compared	O
to	O
students	O
in	O
the	O
game	O
group	O
(	O
4.0/5	O
versus	O
3.6/5	O
,	O
P	O
=	O
0.045	O
)	O
.	O

Students	O
in	O
the	O
lecture	O
group	O
reported	O
greater	O
understanding	O
and	O
recall	O
of	O
the	O
material	O
than	O
students	O
in	O
the	O
game	O
group	O
(	O
P	O
<	O
0.001	O
and	O
P	O
=	O
0.004	O
,	O
respectively	O
)	O
.	O

Students	O
in	O
the	O
lecture	O
group	O
perceived	O
the	O
lecture	O
to	O
be	O
more	O
enjoyable	O
and	O
a	O
better	O
use	O
of	O
their	O
time	O
compared	O
to	O
those	O
in	O
the	O
game	O
group	O
(	O
P	O
=	O
0.04	O
and	O
P	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
the	O
lecture	O
and	O
game	O
group	O
in	O
ability	O
to	O
maintain	O
interest	O
(	O
P	O
=	O
0.187	O
)	O
.	O

In	O
comparison	O
to	O
pre-survey	O
results	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
interest	O
for	O
further	O
digital	O
interactive	O
materials	O
reported	O
by	O
students	O
in	O
the	O
game	O
group	O
(	O
P	O
=	O
0.146	O
)	O
.	O

Our	O
experience	O
supported	O
the	O
use	O
of	O
a	O
traditional	O
lecture	O
over	O
a	O
digital	O
game	O
module	O
.	O

While	O
these	O
results	O
might	O
be	O
affected	O
by	O
the	O
specific	O
lecture	O
and	O
digital	O
content	O
in	O
any	O
given	O
comparison	O
,	O
a	O
digital	O
module	O
is	O
not	O
always	O
the	O
superior	O
option	O
.	O

Blubber	O
transcriptome	O
response	O
to	O
acute	O
stress	O
axis	O
activation	O
involves	O
transient	O
changes	O
in	O
adipogenesis	O
and	O
lipolysis	O
in	O
a	O
fasting	O
-adapted	O
marine	O
mammal	O
.	O

Stress	O
can	O
compromise	O
an	O
animal	O
's	O
ability	O
to	O
conserve	O
metabolic	O
stores	O
and	O
participate	O
in	O
energy	O
-demanding	O
activities	O
that	O
are	O
critical	O
for	O
fitness	O
.	O

Understanding	O
how	O
wild	O
animals	O
,	O
especially	O
those	O
already	O
experiencing	O
physiological	O
extremes	O
(	O
e.g	O
.	O

fasting	O
)	O
,	O
regulate	O
stress	O
responses	O
is	O
critical	O
for	O
evaluating	O
the	O
impacts	O
of	O
anthropogenic	O
disturbance	O
on	O
physiology	O
and	O
fitness	O
,	O
key	O
challenges	O
for	O
conservation	O
.	O

However	O
,	O
studies	O
of	O
stress	O
in	O
wildlife	O
are	O
often	O
limited	O
to	O
baseline	B-P
endocrine	I-P
measurements	I-P
and	O
few	O
have	O
investigated	O
stress	O
effects	O
in	O
fasting	O
-adapted	O
species	O
.	O

We	O
examined	O
downstream	B-P
molecular	I-P
consequences	I-P
of	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
activation	O
by	O
exogenous	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
)	O
in	O
blubber	O
of	O
northern	O
elephant	O
seals	O
due	O
to	O
the	O
ease	O
of	O
blubber	O
sampling	O
and	O
its	O
key	O
role	O
in	O
metabolic	O
regulation	O
in	O
marine	O
mammals	O
.	O

We	O
report	O
the	O
first	O
phocid	O
blubber	O
transcriptome	O
produced	O
by	O
RNAseq	O
,	O
containing	O
over	O
140,000	O
annotated	O
transcripts	O
,	O
including	O
metabolic	O
and	O
adipocytokine	O
genes	O
of	O
interest	O
.	O

The	O
acute	O
response	O
of	O
blubber	O
to	O
stress	O
axis	O
activation	O
,	O
measured	O
2	O
hours	O
after	O
ACTH	O
administration	O
,	O
involved	O
highly	O
specific	O
,	O
transient	O
(	O
lasting	O
<	O
24	O
hours	O
)	O
induction	O
of	O
gene	O
networks	O
that	O
promote	O
lipolysis	O
and	O
adipogenesis	O
in	O
mammalian	O
adipocytes	O
.	O

Differentially	O
expressed	O
genes	O
included	O
key	O
adipogenesis	O
factors	O
which	O
can	O
be	O
used	O
as	O
blubber	O
-specific	O
markers	O
of	O
acute	O
stress	O
in	O
marine	O
mammals	O
of	O
concern	O
for	O
which	O
sampling	O
of	O
other	O
tissues	O
is	O
not	O
possible	O
.	O

Effect	O
of	O
Low	O
-	O
Dose	O
MDCT	B-P
and	O
Iterative	B-P
Reconstruction	I-P
on	O
Trabecular	O
Bone	O
Microstructure	O
Assessment	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
low	O
-	O
dose	O
multi	B-P
detector	I-P
computed	I-P
tomography	I-P
(	O
MDCT	B-P
)	O
in	O
combination	O
with	O
statistical	B-P
iterative	I-P
reconstruction	I-P
algorithms	O
on	O
trabecular	O
bone	O
microstructure	O
parameters	O
.	O

Twelve	O
donated	O
vertebrae	O
were	O
scanned	B-P
with	O
the	O
routine	O
radiation	B-P
exposure	I-P
used	O
in	O
our	O
department	O
(	O
standard-dose	O
)	O
and	O
a	O
low	O
-	O
dose	O
protocol	O
.	O

Reconstructions	O
were	O
performed	O
with	O
filtered	B-P
backprojection	I-P
(	O
FBP	B-P
)	O
and	O
maximum-likelihood	O
based	O
statistical	B-P
iterative	I-P
reconstruction	I-P
(	O
SIR	B-P
)	O
.	O

Trabecular	O
bone	O
microstructure	O
parameters	O
were	O
assessed	O
and	O
statistically	O
compared	O
for	O
each	O
reconstruction	O
.	O

Moreover	O
,	O
fracture	O
loads	O
of	O
the	O
vertebrae	O
were	O
biomechanically	B-P
determined	O
and	O
correlated	O
to	O
the	O
assessed	O
microstructure	O
parameters	O
.	O

Trabecular	O
bone	O
microstructure	O
parameters	O
based	O
on	O
low	O
-	O
dose	O
MDCT	B-P
and	O
SIR	B-P
significantly	O
correlated	O
with	O
vertebral	O
bone	O
strength	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
microstructure	O
parameters	O
calculated	O
on	O
low	O
-	O
dose	O
SIR	B-P
and	O
standard	O
-	O
dose	O
FBP	B-P
images	O
.	O

However	O
,	O
the	O
results	O
revealed	O
a	O
strong	O
dependency	O
on	O
the	O
regularization	O
strength	O
applied	O
during	O
SIR	B-P
.	O

It	O
was	O
observed	O
that	O
stronger	O
regularization	O
might	O
corrupt	O
the	O
microstructure	O
analysis	O
,	O
because	O
the	O
trabecular	O
structure	O
is	O
a	O
very	O
small	O
detail	O
that	O
might	O
get	O
lost	O
during	O
the	O
regularization	O
process	O
.	O

As	O
a	O
consequence	O
,	O
the	O
introduction	O
of	O
SIR	B-P
for	O
trabecular	O
bone	O
microstructure	O
analysis	O
requires	O
a	O
specific	O
optimization	O
of	O
the	O
regularization	O
parameters	O
.	O

Moreover	O
,	O
in	O
comparison	O
to	O
other	O
approaches	O
,	O
superior	O
noise	O
-	O
resolution	O
trade-offs	O
can	O
be	O
found	O
with	O
the	O
proposed	O
methods	O
.	O

Netarsudil	O
Increases	O
Outflow	B-P
Facility	I-P
in	O
Human	O
Eyes	O
Through	O
Multiple	O
Mechanisms	O
.	O

Netarsudil	O
is	O
a	O
Rho	O
kinase/norepinephrine	O
transporter	O
inhibitor	O
currently	O
in	O
phase	O
3	O
clinical	O
development	O
for	O
glaucoma	O
treatment	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
its	O
active	O
metabolite	O
,	O
netarsudil-M1	O
,	O
on	O
outflow	B-P
facility	I-P
(	O
C	B-P
)	O
,	O
outflow	O
hydrodynamics	O
,	O
and	O
morphology	O
of	O
the	O
conventional	O
outflow	O
pathway	O
in	O
enucleated	O
human	O
eyes	O
.	O

Paired	O
human	O
eyes	O
(	O
n	O
=	O
5	O
)	O
were	O
perfused	O
with	O
either	O
0.3	O
μM	O
netarsudil-M1	O
or	O
vehicle	O
solution	O
at	O
constant	O
pressure	O
(	O
15	O
mm	O
Hg	O
)	O
.	O

After	O
3	O
hours	O
,	O
fluorescent	O
microspheres	O
were	O
added	O
to	O
perfusion	O
media	O
to	O
trace	O
the	O
outflow	O
patterns	O
before	O
perfusion	O
-	O
fixation	O
.	O

The	O
percentage	O
effective	O
filtration	O
length	O
(	O
PEFL	O
)	O
was	O
calculated	O
from	O
the	O
measured	O
lengths	O
of	O
tracer	O
distribution	O
in	O
the	O
trabecular	O
meshwork	O
(	O
TM	O
)	O
,	O
episcleral	O
veins	O
(	O
ESVs	O
)	O
,	O
and	O
along	O
the	O
inner	O
wall	O
(	O
IW	O
)	O
of	O
Schlemm	O
's	O
canal	O
after	O
global	O
and	O
confocal	B-P
imaging	I-P
.	O

Morphologic	O
changes	O
along	O
the	O
trabecular	O
outflow	O
pathway	O
were	O
investigated	O
by	O
confocal	B-P
,	O
light	B-P
,	O
and	O
electron	B-P
microscopy	I-P
.	O

Perfusion	O
with	O
netarsudil-M1	O
significantly	O
increased	O
C	B-P
when	O
compared	O
to	O
baseline	O
(	O
51	O
%	O
,	O
P	O
<	O
0.01	O
)	O
and	O
to	O
paired	O
controls	O
(	O
102	O
%	O
,	O
P	O
<	O
0.01	O
)	O
,	O
as	O
well	O
as	O
significantly	O
increased	O
PEFL	O
in	O
both	O
IW	O
(	O
P	O
<	O
0.05	O
)	O
and	O
ESVs	O
(	O
P	O
<	O
0.01	O
)	O
.	O

In	O
treated	O
eyes	O
,	O
PEFL	O
was	O
significantly	O
higher	O
in	O
ESVs	O
than	O
in	O
the	O
IW	O
(	O
P	O
<	O
0.01	O
)	O
and	O
was	O
associated	O
with	O
increased	O
cross-sectional	O
area	O
of	O
ESVs	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Percentage	O
effective	O
filtration	O
length	O
in	O
ESVs	O
positively	O
correlated	O
with	O
the	O
percentage	O
change	O
in	O
C	B-P
(	O
R2	O
=	O
0.58	O
,	O
P	O
=	O
0.01	O
)	O
.	O

A	O
significant	O
increase	O
in	O
juxtacanalicular	O
connective	O
tissue	O
(	O
JCT	O
)	O
thickness	O
(	O
P	O
<	O
0.05	O
)	O
was	O
found	O
in	O
treated	O
eyes	O
compared	O
to	O
controls	O
.	O

Netarsudil	O
acutely	O
increased	O
C	B-P
by	O
expansion	O
of	O
the	O
JCT	O
and	O
dilating	O
the	O
ESVs	O
,	O
which	O
led	O
to	O
redistribution	O
of	O
aqueous	O
outflow	O
through	O
a	O
larger	O
area	O
of	O
the	O
IW	O
and	O
ESVs	O
.	O

Clinical	O
and	O
angiographic	B-P
correlation	O
of	O
high-sensitivity	O
C-reactive	O
protein	O
with	O
acute	O
ST	O
elevation	O
myocardial	O
infarction	O
.	O

Vascular	O
inflammation	O
and	O
associated	O
ongoing	O
inflammatory	O
responses	O
are	O
considered	O
as	O
the	O
critical	O
culprits	O
in	O
the	O
pathogenesis	O
of	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
acute	O
coronary	O
syndrome	O
(	O
ACS	O
)	O
and	O
myocardial	O
infarction	O
(	O
MI	O
)	O
.	O

ST	O
segment	O
elevation	O
myocardial	O
infarction	O
(	O
STEMI	O
)	O
is	O
considered	O
as	O
one	O
of	O
the	O
prominent	O
clinical	O
forms	O
of	O
ACS	O
.	O

Moreover	O
,	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
is	O
an	O
important	O
acute	O
phase	O
prsotein	O
,	O
which	O
may	O
be	O
estimated	O
using	O
high-sensitivity	B-P
methods	I-P
(	O
hs-CRP	B-P
)	O
,	O
and	O
its	O
elevated	O
level	O
in	O
body	O
fluids	O
reflects	O
chronic	O
inflammatory	O
status	O
.	O

The	O
circulating	O
hs-CRP	B-P
level	O
has	O
been	O
proposed	O
as	O
a	O
promising	O
inflammatory	O
marker	O
of	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
.	O

The	O
present	O
study	O
investigated	O
the	O
correlation	O
of	O
hs-CRP	B-P
level	O
with	O
clinical	O
and	O
angiographic	B-P
features	O
of	O
STEMI	O
,	O
various	O
other	O
traditional	O
risk	O
factors	O
,	O
complications	O
of	O
myocardial	O
infarction	O
and	O
angiographically	O
significant	O
CAD	O
.	O

Out	O
of	O
190	O
patients	O
with	O
STEMI	O
that	O
were	O
analyzed	O
,	O
the	O
interval	O
between	O
symptom	O
onset	O
and	O
reperfusion	O
therapy	O
(	O
window	O
period	O
)	O
varied	O
from	O
0.5	O
to	O
24	O
h.	O
The	O
hs-CRP	B-P
value	O
was	O
found	O
to	O
be	O
higher	O
in	O
non-diabetic	O
patients	O
(	O
0.61	O
mg/dl	O
)	O
compared	O
with	O
diabetic	O
patients	O
(	O
0.87	O
mg/dl	O
)	O
.	O

Moreover	O
,	O
a	O
significant	O
correlation	O
between	O
hs-CRP	B-P
and	O
hs-troponin	B-P
T	I-P
was	O
also	O
recorded	O
(	O
P	O
<	O
0.001	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
mean	O
hs-CRP	B-P
values	O
in	O
patients	O
with	O
or	O
without	O
mortality	O
.	O

It	O
is	O
considered	O
that	O
the	O
present	O
study	O
will	O
increase	O
the	O
understanding	O
of	O
atherosclerosis	O
in	O
general	O
and	O
may	O
also	O
have	O
clinical	O
applications	O
in	O
the	O
targeting	O
of	O
therapy	O
for	O
this	O
harmful	O
disease	O
.	O

Mesenchymal	O
stem	O
cells	O
enhance	O
the	O
oncolytic	O
effect	O
of	O
Newcastle	O
disease	O
virus	O
in	O
glioma	O
cells	O
and	O
glioma	O
stem	O
cells	O
via	O
the	O
secretion	O
of	O
TRAIL	O
.	O

Newcastle	O
disease	O
virus	O
(	O
NDV	O
)	O
is	O
an	O
avian	O
paramyxovirus	O
,	O
which	O
selectively	O
exerts	O
oncolytic	O
effects	O
in	O
cancer	O
cells	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
have	O
been	O
reported	O
to	O
affect	O
tumor	O
growth	O
and	O
deliver	O
anti-tumor	O
agents	O
to	O
experimental	O
glioblastoma	O
(	O
GBM	O
)	O
.	O

Here	O
,	O
we	O
explored	O
the	O
effects	O
of	O
NDV	O
-	O
infected	O
MSCs	O
derived	O
from	O
different	O
sources	O
,	O
on	O
glioma	O
cells	O
and	O
glioma	O
stem	O
cells	O
(	O
GSCs	O
)	O
and	O
the	O
mechanisms	O
involved	O
in	O
their	O
effects	O
.	O

The	O
glioma	O
cell	O
lines	O
(	O
A172	O
and	O
U87	O
)	O
and	O
primary	O
GSCs	O
that	O
were	O
generated	O
from	O
GBM	O
tumors	O
were	O
used	O
in	O
this	O
study	O
.	O

MSCs	O
derived	O
from	O
bone	O
marrow	O
,	O
adipose	O
tissue	O
or	O
umbilical	O
cord	O
were	O
infected	O
with	O
NDV	O
(	O
MTH-68/H	O
)	O
.	O

The	O
ability	O
of	O
these	O
cells	O
to	O
deliver	O
the	O
virus	O
to	O
glioma	O
cell	O
lines	O
and	O
GSCs	O
and	O
the	O
effects	O
of	O
NDV	O
-	O
infected	O
MSCs	O
on	O
cell	O
death	O
and	O
on	O
the	O
stemness	O
and	O
self-renewal	O
of	O
GSCs	O
were	O
examined	O
.	O

The	O
mechanisms	O
involved	O
in	O
the	O
cytotoxic	O
effects	O
of	O
the	O
NDV	O
-	O
infected	O
MSCs	O
and	O
their	O
influence	O
on	O
the	O
radiation	O
sensitivity	O
of	O
GSCs	O
were	O
examined	O
as	O
well	O
.	O

NDV	O
induced	O
a	O
dose-dependent	O
cell	O
death	O
in	O
glioma	O
cells	O
and	O
a	O
low	O
level	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
self-renewal	O
in	O
GSCs	O
.	O

MSCs	O
derived	O
from	O
bone	O
marrow	O
,	O
adipose	O
and	O
umbilical	O
cord	O
that	O
were	O
infected	O
with	O
NDV	O
delivered	O
the	O
virus	O
to	O
co-cultured	B-P
glioma	O
cells	O
and	O
GSCs	O
.	O

Conditioned	O
medium	O
of	O
NDV	O
-	O
infected	O
MSCs	O
induced	O
higher	O
level	O
of	O
apoptosis	O
in	O
the	O
tumor	O
cells	O
compared	O
with	O
the	O
apoptosis	O
induced	O
by	O
their	O
direct	O
infection	O
with	O
similar	O
virus	O
titers	O
.	O

These	O
results	O
suggest	O
that	O
factor	O
(	O
s	O
)	O
secreted	O
by	O
the	O
infected	O
MSCs	O
sensitized	O
the	O
glioma	O
cells	O
to	O
the	O
cytotoxic	O
effects	O
of	O
NDV	O
.	O

We	O
identified	O
TRAIL	O
as	O
a	O
mediator	O
of	O
the	O
cytotoxic	O
effects	O
of	O
the	O
infected	O
MSCs	O
and	O
demonstrated	O
that	O
TRAIL	O
synergized	O
with	O
NDV	O
in	O
the	O
induction	O
of	O
cell	O
death	O
in	O
glioma	O
cells	O
and	O
GSCs	O
.	O

Moreover	O
,	O
conditioned	O
medium	O
of	O
infected	O
MSCs	O
enhanced	O
the	O
sensitivity	O
of	O
GSCs	O
to	O
γ-radiation	O
.	O

NDV	O
-	O
infected	O
umbilical	O
cord	O
-	O
derived	O
MSCs	O
may	O
provide	O
a	O
novel	O
effective	O
therapeutic	O
approach	O
for	O
targeting	O
GSCs	O
and	O
GBM	O
and	O
for	O
sensitizing	O
these	O
tumors	O
to	O
γ-radiation	O
.	O

Perlecan	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
encoding	O
DNA	O
-	O
loaded	O
chitosan	O
scaffolds	O
promote	O
angiogenesis	O
and	O
wound	O
healing	O
.	O

The	O
repair	O
of	O
dermal	O
wounds	O
,	O
particularly	O
in	O
the	O
diabetic	O
population	O
,	O
poses	O
a	O
significant	O
healthcare	O
burden	O
.	O

The	O
impaired	O
wound	O
healing	O
of	O
diabetic	O
wounds	O
is	O
attributed	O
to	O
low	O
levels	O
of	O
endogenous	O
growth	O
factors	O
,	O
including	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
that	O
normally	O
stimulate	O
multiple	O
phases	O
of	O
wound	O
healing	O
.	O

In	O
this	O
study	O
,	O
chitosan	O
scaffolds	O
were	O
prepared	O
via	O
freeze	B-P
drying	I-P
and	O
loaded	O
with	O
plasmid	O
DNA	O
encoding	O
perlecan	O
domain	O
I	O
and	O
VEGF189	O
and	O
analyzed	O
in	O
vivo	O
for	O
their	O
ability	O
to	O
promote	O
dermal	O
wound	O
healing	O
.	O

The	O
plasmid	O
DNA	O
encoding	O
perlecan	O
domain	O
I	O
and	O
VEGF189	O
loaded	O
scaffolds	O
promoted	O
dermal	O
wound	O
healing	O
in	O
normal	O
and	O
diabetic	O
rats	O
.	O

This	O
treatment	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
number	O
of	O
blood	O
vessels	O
and	O
sub-epithelial	O
connective	O
tissue	O
matrix	O
components	O
within	O
the	O
wound	O
beds	O
compared	O
to	O
wounds	O
treated	O
with	O
chitosan	O
scaffolds	O
containing	O
control	O
DNA	O
or	O
wounded	O
controls	O
.	O

These	O
results	O
suggest	O
that	O
chitosan	O
scaffolds	O
containing	O
plasmid	O
DNA	O
encoding	O
VEGF189	O
and	O
perlecan	O
domain	O
I	O
have	O
the	O
potential	O
to	O
induce	O
angiogenesis	O
and	O
wound	O
healing	O
.	O

Beneficial	O
effects	O
of	O
natural	O
eggshell	O
membrane	O
(	O
NEM	O
)	O
on	O
multiple	O
indices	O
of	O
arthritis	O
in	O
collagen-induced	O
arthritic	O
rats	O
.	O

This	O
study	O
was	O
performed	O
to	O
evaluate	O
the	O
potential	O
efficacy	O
of	O
natural	O
eggshell	O
membrane	O
(	O
NEM	O
)	O
in	O
collagen-induced	O
arthritic	O
rats	O
,	O
a	O
well-established	O
rodent	O
model	O
of	O
inflammation	O
and	O
rheumatoid	O
arthritis	O
.	O

Rats	O
with	O
developing	O
type	O
II	O
collagen-induced	O
arthritis	O
(	O
CIA	O
)	O
were	O
treated	O
once	O
daily	O
by	O
oral	O
gavage	O
on	O
study	O
days	O
-14	O
to	O
17	O
with	O
vehicle	O
or	O
NEM	O
(	O
52	O
mg/kg	O
body	O
weight	O
)	O
.	O

Rats	O
were	O
euthanized	O
on	O
study	O
day	O
17	O
.	O

Efficacy	O
was	O
assessed	O
by	O
daily	O
ankle	O
caliper	O
measurements	O
,	O
ankle	O
diameter	O
expressed	O
as	O
area	O
under	O
the	O
curve	O
(	O
AUCd0-17	O
)	O
,	O
and	O
histopathologic	O
evaluation	O
of	O
ankles	O
and	O
knees	O
.	O

Serum	O
biomarkers	O
of	O
cartilage	O
function	O
and	O
inflammation	O
[	O
collagen	B-P
type	I-P
II	I-P
C-telopeptide	I-P
(	O
CTXII	B-P
)	O
,	O
cartilage	B-P
oligomeric	I-P
matrix	I-P
protein	I-P
(	O
COMP	B-P
)	O
,	O
and	O
alpha-2-macroglobulin	B-P
(	O
A2M	B-P
)	O
]	O
were	O
measured	O
by	O
ELISA	B-P
.	O

Treatment	O
with	O
NEM	O
resulted	O
in	O
significant	O
beneficial	O
effects	O
on	O
the	O
daily	O
ankle	O
diameter	O
measurements	O
and	O
ankle	O
diameter	O
AUC	O
.	O

Ankle	O
and	O
knee	O
histopathology	O
scores	O
were	O
significantly	O
reduced	O
(	O
36	O
%	O
and	O
43	O
%	O
reduction	O
of	O
summed	O
individual	O
histopathology	O
scores	O
for	O
ankle	O
and	O
knee	O
,	O
respectively	O
;	O
p	O
<	O
0.05	O
)	O
toward	O
normal	O
for	O
rats	O
given	O
NEM	O
compared	O
to	O
vehicle	O
controls	O
.	O

The	O
percent	O
reduction	O
of	O
serum	O
CTXII	B-P
,	O
COMP	B-P
,	O
and	O
A2M	B-P
in	O
NEM	O
-	O
treated	O
rats	O
ranged	O
from	O
30	O
%	O
to	O
72	O
%	O
(	O
p	O
<	O
0.05	O
)	O
.	O

NEM	O
significantly	O
improved	O
multiple	O
aspects	O
of	O
inflammatory	O
arthritis	O
including	O
inflammation	O
,	O
pannus	O
,	O
cartilage	O
damage	O
,	O
bone	O
resorption	O
,	O
and	O
periosteal	O
bone	O
formation	O
.	O

This	O
study	O
provides	O
further	O
support	O
for	O
the	O
use	O
of	O
CTXII	O
,	O
COMP	O
,	O
and	O
A2M	O
as	O
relevant	O
biomarkers	O
that	O
were	O
responsive	O
to	O
NEM	O
.	O

Annexin	O
A1	O
restores	O
Aβ1-42	O
-induced	O
blood-brain	O
barrier	O
disruption	O
through	O
the	O
inhibition	O
of	O
RhoA-ROCK	O
signaling	O
pathway	O
.	O

The	O
blood-brain	O
barrier	O
(	O
BBB	O
)	O
is	O
composed	O
of	O
brain	O
capillary	O
endothelial	O
cells	O
and	O
has	O
an	O
important	O
role	O
in	O
maintaining	O
homeostasis	O
of	O
the	O
brain	O
separating	O
the	O
blood	O
from	O
the	O
parenchyma	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

It	O
is	O
widely	O
known	O
that	O
disruption	O
of	O
the	O
BBB	O
occurs	O
in	O
various	O
neurodegenerative	O
diseases	O
,	O
including	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Annexin	O
A1	O
(	O
ANXA1	O
)	O
,	O
an	O
anti-inflammatory	O
messenger	O
,	O
is	O
expressed	O
in	O
brain	O
endothelial	O
cells	O
and	O
regulates	O
the	O
BBB	O
integrity	O
.	O

However	O
,	O
its	O
role	O
and	O
mechanism	O
for	O
protecting	O
BBB	O
in	O
AD	O
have	O
not	O
been	O
identified	O
.	O

We	O
found	O
that	O
β-Amyloid	O
1-42	O
(	O
Aβ42	O
)	O
-induced	O
BBB	O
disruption	O
was	O
rescued	O
by	O
human	O
recombinant	O
ANXA1	O
(	O
hrANXA1	O
)	O
in	O
the	O
murine	O
brain	O
endothelial	O
cell	O
line	O
bEnd.3	O
.	O

Also	O
,	O
ANXA1	O
was	O
decreased	O
in	O
the	O
bEnd.3	O
cells	O
,	O
the	O
capillaries	O
of	O
5XFAD	O
mice	O
,	O
and	O
the	O
human	O
serum	O
of	O
patients	O
with	O
AD	O
.	O

To	O
find	O
out	O
the	O
mechanism	O
by	O
which	O
ANXA1	O
recovers	O
the	O
BBB	O
integrity	O
in	O
AD	O
,	O
the	O
RhoA-ROCK	O
signaling	O
pathway	O
was	O
examined	O
in	O
both	O
Aβ42	O
-treated	O
bEnd.3	O
cells	O
and	O
the	O
capillaries	O
of	O
5XFAD	O
mice	O
as	O
RhoA	O
was	O
activated	O
in	O
both	O
cases	O
.	O

RhoA	O
inhibitors	O
alleviated	O
Aβ42	O
-induced	O
BBB	O
disruption	O
and	O
constitutively	O
overexpressed	O
RhoA-GTP	O
(	O
active	O
form	O
of	O
RhoA	O
)	O
attenuated	O
the	O
protective	O
effect	O
of	O
ANXA1	O
.	O

When	O
pericytes	O
were	O
cocultured	B-P
with	O
bEnd.3	O
cells	O
,	O
Aβ42	O
-induced	O
RhoA	O
activation	O
of	O
bEnd.3	O
cells	O
was	O
inhibited	O
by	O
the	O
secretion	O
of	O
ANXA1	O
from	O
pericytes	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
ANXA1	O
restores	O
Aβ42	O
-induced	O
BBB	O
disruption	O
through	O
inhibition	O
of	O
RhoA-ROCK	O
signaling	O
pathway	O
and	O
we	O
propose	O
ANXA1	O
as	O
a	O
therapeutic	O
reagent	O
,	O
protecting	O
against	O
the	O
breakdown	O
of	O
the	O
BBB	O
in	O
AD	O
.	O

SY	O
17-1	O
DYNAMIC	O
REGULATION	O
OF	O
REDOX	O
REGULATING	O
FACTOR	O
APE1	O
/	O
REF-1	O
ON	O
THE	O
OXIDATIVE	O
STRESS	O
AND	O
VASCULAR	O
INFLAMMATION	O
.	O

Apurinic/apyrimidinic	O
endonuclease	O
1	O
/	O
redox	O
factor-1	O
(	O
APE1	O
/	O
Ref-1	O
)	O
is	O
a	O
multifunctional	O
protein	O
that	O
plays	O
a	O
central	O
role	O
in	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
and	O
redox	O
regulation	O
against	O
oxidative	O
stress	O
.	O

APE1	O
/	O
Ref-1	O
is	O
essential	O
for	O
cellular	O
survival	O
and	O
embryonic	O
lethal	O
in	O
knockout	O
mouse	O
models	O
.	O

Heterozygous	O
APE1	O
/	O
Ref-1	O
mice	O
showed	O
impaired	O
endothelium	O
-dependent	O
vasorelaxation	O
,	O
reduced	O
vascular	O
NO	B-P
levels	I-P
,	O
and	O
are	O
hypertensive	O
.	O

APE1	O
/	O
Ref-1	O
reduces	O
intracellular	O
reactive	O
oxygen	O
species	O
production	O
by	O
negatively	O
regulating	O
the	O
activity	O
of	O
the	O
NADPH	O
oxidase	O
.	O

APE1	O
/	O
Ref-1	O
is	O
predominantly	O
localized	O
in	O
the	O
nucleus	O
;	O
however	O
,	O
its	O
subcellular	O
localization	O
is	O
dynamically	O
regulated	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
APE1	O
/	O
Ref-1	O
is	O
secreted	O
in	O
response	O
to	O
hyperacetylation	O
at	O
specific	O
lysine	O
residues	O
.	O

We	O
investigated	O
the	O
functions	O
of	O
extracellular	O
APE1	O
/	O
Ref-1	O
with	O
respect	O
to	O
leading	O
anti-inflammatory	O
signaling	O
in	O
TNF-α	O
-stimulated	O
endothelial	O
cells	O
in	O
response	O
to	O
acetylation	O
.	O

Trichostatin	O
A	O
(	O
TSA	O
)	O
,	O
an	O
inhibitor	O
of	O
histone	O
deacetylase	O
,	O
considerably	O
suppressed	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
in	O
TNF-α	O
-stimulated	O
endothelial	O
cells	O
.	O

During	O
TSA	O
-mediated	O
acetylation	O
in	O
culture	B-P
,	O
a	O
time	O
-	O
dependent	O
increase	O
in	O
secreted	O
APE1	O
/	O
Ref-1	O
was	O
confirmed	O
.	O

Recombinant	O
human	O
APE1	O
/	O
Ref-1	O
with	O
reducing	O
activity	O
induced	O
a	O
conformational	O
change	O
in	O
TNFR1	O
by	O
thiol-disulfide	O
exchange	O
.	O

Following	O
treatment	O
with	O
the	O
neutralizing	O
anti-	O
APE1	O
/	O
Ref-1	O
antibody	O
,	O
inflammatory	O
signals	O
via	O
the	O
binding	O
of	O
TNF-α	O
to	O
TNFR1	O
were	O
remarkably	O
recovered	O
.	O

Furthermore	O
,	O
rh	O
APE1	O
/	O
Ref-1	O
inhibited	O
IL-1β	O
-	O
induced	O
VCAM-1	O
expression	O
in	O
endothelial	O
cells	O
,	O
and	O
it	O
inhibited	O
iNOS	O
or	O
COX-2	O
expression	O
in	O
lipopolysaccharide	O
-stimulated	O
RAW	O
264.7	O
macrophage	O
cells	O
.	O

These	O
results	O
strongly	O
indicate	O
that	O
anti-inflammatory	O
effects	O
of	O
secreted	O
APE1	O
/	O
Ref-1	O
and	O
its	O
property	O
of	O
secreted	O
APE1	O
/	O
Ref-1	O
may	O
be	O
useful	O
as	O
a	O
therapeutic	O
biomolecule	O
in	O
cardiovascular	O
disease	O
.	O

Direct	O
Repair	O
of	O
Lumbar	O
Pars	O
Interarticularis	O
Defects	O
by	O
Utilizing	O
Intraoperative	O
O-Arm-Based	O
Navigation	O
and	O
Microendoscopic	B-P
Techniques	I-P
.	O

A	O
retrospective	O
analysis	O
of	O
the	O
clinical	O
outcomes	O
of	O
eight	O
patients	O
with	O
the	O
lumbar	O
pars	O
interarticulars	O
defects	O
treated	O
by	O
direct	O
repair	O
with	O
the	O
aid	O
of	O
intraoperative	O
O-arm	O
based	O
navigation	O
and	O
microendoscopic	B-P
techniques	I-P
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
direct	O
screw	O
repair	O
by	O
using	O
minimally	O
invasive	O
surgery	O
for	O
the	O
lumbar	O
pars	O
interarticulars	O
defects	O
in	O
a	O
pilot	O
study	O
.	O

Direct	O
repair	O
of	O
pars	O
interarticulars	O
defects	O
has	O
been	O
used	O
to	O
treat	O
young	O
adult	O
patients	O
.	O

Reports	O
concerning	O
direct	O
repair	O
by	O
minimally	O
invasive	O
techniques	O
for	O
pars	O
interarticulars	O
defects	O
are	O
quite	O
rare	O
.	O

Review	O
of	O
medical	O
records	O
identified	O
eight	O
consecutive	O
patients	O
treated	O
with	O
intraoperative	O
O-arm	O
based	O
navigation	O
and	O
microendoscopic	B-P
techniques	I-P
.	O

Debridement	O
and	O
autograft	O
of	O
pars	O
interarticularis	O
defects	O
was	O
performed	O
under	O
microendoscopic	B-P
procedure	I-P
.	O

Then	O
,	O
percutaneous	O
bilateral	O
intralaminar	O
screws	O
were	O
inserted	O
by	O
utilizing	O
intraoperative	O
navigation	O
.	O

The	O
clinical	O
and	O
radiological	O
data	O
were	O
collected	O
and	O
analyzed	O
retrospectively	O
.	O

Eight	O
patients	O
had	O
a	O
mean	O
age	O
of	O
28.4	O
years	O
,	O
and	O
five	O
were	O
30	O
years	O
or	O
younger	O
at	O
the	O
time	O
of	O
treatment	O
.	O

Symptoms	O
included	O
axial	O
back	O
pain	O
in	O
100	O
%	O
of	O
patients	O
without	O
concomitant	O
radiculopathy	O
.	O

Autograft	O
was	O
used	O
in	O
all	O
cases	O
.	O

The	O
average	O
follow-up	O
duration	O
was	O
27.4	O
months	O
with	O
a	O
range	O
of	O
20	O
to	O
33	O
months	O
.	O

Symptoms	O
resolved	O
completely	O
or	O
partially	O
in	O
all	O
patients	O
.	O

Low	O
back	O
pain	O
visual	O
analog	O
scores	O
decrease	O
from	O
preoperative	O
6.8	O
to	O
postoperative	O
1.4	O
of	O
eight	O
cases	O
.	O

Of	O
16	O
pars	O
defects	O
,	O
healing	O
was	O
observed	O
in	O
13	O
(	O
81.3	O
%	O
)	O
at	O
last	O
radiological	O
follow-up	O
.	O

One	O
patient	O
with	O
bilateral	O
fusion	O
failure	O
refused	O
revision	O
surgery	O
because	O
of	O
mild	O
complaint	O
.	O

No	O
complications	O
such	O
as	O
dural	O
tear	O
,	O
nerve	O
root	O
injury	O
,	O
and	O
infection	O
occurred	O
.	O

Minimally	O
invasive	O
direct	O
repair	O
of	O
the	O
pars	O
interarticularis	O
defects	O
with	O
intralaminar	O
screws	O
by	O
using	O
microendoscopic	B-P
system	I-P
and	O
navigation	O
procedure	O
can	O
provide	O
safe	O
and	O
effective	O
treatment	O
of	O
spondylolysis	O
with	O
satisfactory	O
clinical	O
and	O
radiological	O
outcomes	O
,	O
which	O
need	O
some	O
special	O
tools	O
with	O
steep	O
learning	O
curve	O
.	O

4	O
.	O

Prevascularized	O
silicon	O
membranes	O
for	O
the	O
enhancement	O
of	O
transport	O
to	O
implanted	O
medical	O
devices	O
.	O

Recent	O
advances	O
in	O
drug	O
delivery	O
and	O
sensing	O
devices	O
for	O
in	O
situ	O
applications	O
are	O
limited	O
by	O
the	O
diffusion	O
-limiting	O
foreign	O
body	O
response	O
of	O
fibrous	O
encapsulation	O
.	O

In	O
this	O
study	O
,	O
we	O
fabricated	O
prevascularized	O
synthetic	O
device	O
ports	O
to	O
help	O
mitigate	O
this	O
limitation	O
.	O

Membranes	O
with	O
rectilinear	O
arrays	O
of	O
square	O
pores	O
with	O
widths	O
ranging	O
from	O
40	O
to	O
200	O
μm	O
were	O
created	O
using	O
materials	O
(	O
50	O
μm	O
thick	O
double-sided	O
polished	O
silicon	O
)	O
and	O
processes	O
(	O
photolithography	O
and	O
directed	O
reactive	O
ion	O
etching	O
)	O
common	O
in	O
the	O
manufacturing	O
of	O
microfabricated	O
sensors	O
.	O

Vascular	O
endothelial	O
cells	O
responded	O
to	O
membrane	O
geometry	O
by	O
either	O
forming	O
vascular	O
tubes	O
that	O
extended	O
through	O
the	O
pore	O
or	O
completely	O
filling	O
membrane	O
pores	O
after	O
4	O
days	O
in	O
culture	B-P
.	O

Although	O
tube	O
formation	O
began	O
to	O
predominate	O
overgrowth	O
around	O
75	O
μm	O
and	O
continued	O
to	O
increase	O
at	O
even	O
larger	O
pore	O
sizes	O
,	O
tubes	O
formed	O
at	O
these	O
large	O
pore	O
sizes	O
were	O
not	O
completely	O
round	O
and	O
had	O
relatively	O
thin	O
walls	O
.	O

Thus	O
,	O
the	O
optimum	O
range	O
of	O
pore	O
size	O
for	O
prevascularization	O
of	O
these	O
membranes	O
was	O
estimated	O
to	O
be	O
75-100	O
μm	O
.	O

This	O
study	O
lays	O
the	O
foundation	O
for	O
creating	O
a	O
prevascularized	O
port	O
that	O
can	O
be	O
used	O
to	O
reduce	O
fibrous	O
encapsulation	O
and	O
thus	O
enhance	O
diffusion	O
to	O
implanted	O
medical	O
devices	O
and	O
sensors	O
.	O

©	O
2015	O
Wiley	O
Periodicals	O
,	O
Inc.	O
J	O
Biomed	O
Mater	O
Res	O
Part	O
B	O
:	O
Appl	O
Biomater	O
,	O
104B	O
:	O
1602-1609	O
,	O
2016	O
.	O

GEORG-SCHMORL-PRIZE	O
OF	O
THE	O
GERMAN	O
SPINE	O
SOCIETY	O
(	O
DWG	O
)	O
2016	O
:	O
Comparison	O
of	O
in	O
vitro	O
osteogenic	O
potential	O
of	O
iliac	O
crest	O
and	O
degenerative	O
facet	O
joint	O
bone	O
autografts	O
for	O
intervertebral	O
fusion	O
in	O
lumbar	O
spinal	O
stenosis	O
.	O

The	O
promotion	O
of	O
spinal	O
fusion	O
using	O
bone	O
autografts	O
is	O
largely	O
mediated	O
by	O
the	O
osteoinductive	O
potential	O
of	O
progenitors	O
/	O
mesenchymal	O
stem	O
cells	O
(	O
MSC	O
)	O
that	O
reside	O
in	O
the	O
marrow	O
spaces	O
of	O
cancellous	O
bone	O
.	O

Iliac	O
crest	O
is	O
the	O
common	O
autograft	O
donor	O
site	O
,	O
but	O
its	O
use	O
presents	O
an	O
increased	O
risk	O
for	O
donor	O
site	O
pain	O
,	O
morbidity	O
and	O
infection	O
.	O

Degenerative	O
bone	O
samples	O
harvested	O
during	O
facetectomy	O
might	O
provide	O
an	O
alternative	O
viable	O
source	O
of	O
osteoinductive	O
autografts	O
.	O

In	O
this	O
study	O
,	O
we	O
conducted	O
an	O
intra-individual	O
comparison	O
of	O
the	O
osteogenic	O
potential	O
of	O
isolated	O
low	O
passage	O
MSC	O
from	O
both	O
sources	O
.	O

Iliac	O
crest	O
and	O
degenerative	O
facet	O
joints	O
were	O
harvested	O
from	O
eight	O
consecutive	O
patients	O
undergoing	O
transforaminal	O
lumbar	O
interspinal	O
fusion	O
due	O
to	O
lumbar	O
spinal	O
stenosis	O
.	O

MSC	O
were	O
isolated	O
by	O
collagenase	B-P
digestion	I-P
,	O
selected	O
by	O
plastic	O
adherence	O
and	O
minimally	O
expanded	O
for	O
downstream	B-P
assays	I-P
.	O

Clonogenic	O
and	O
osteogenic	O
potential	O
was	O
evaluated	O
by	O
colony	B-P
formation	I-P
assays	I-P
in	O
control	O
and	O
osteogenic	O
culture	O
medium	O
.	O

Osteogenic	O
properties	O
,	O
including	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
induction	O
,	O
matrix	O
mineralization	O
and	O
type	O
I	O
collagen	O
mRNA	O
and	O
protein	O
expression	O
were	O
characterized	O
using	O
quantitative	O
histochemical	B-P
staining	I-P
and	O
reverse	O
transcription	O
PCR	O
.	O

Spontaneous	O
adipogenesis	O
was	O
analysed	O
by	O
adipocyte	O
enumeration	O
and	O
gene	O
expression	O
analysis	O
of	O
adipogenic	O
markers	O
.	O

Average	O
colony-forming	O
efficiency	O
in	O
osteogenic	O
medium	O
was	O
equal	O
between	O
iliac	O
crest	O
(	O
38	O
±	O
12	O
%	O
)	O
and	O
facet	O
joint	O
(	O
36	O
±	O
11	O
%	O
)	O
.	O

Osteogenic	O
potential	O
at	O
the	O
clonal	O
level	O
was	O
55	O
±	O
26	O
and	O
68	O
±	O
17	O
%	O
for	O
iliac	O
crest	O
and	O
facet	O
joint	O
MSC	O
,	O
respectively	O
.	O

Clonogenic	O
and	O
osteogenic	O
potential	O
were	O
significantly	O
negatively	O
associated	O
with	O
donor	O
age	O
.	O

Osteogenic	O
differentiation	O
led	O
to	O
significant	O
induction	O
of	O
ALP	O
activity	O
in	O
iliac	O
crest	O
(	O
sixfold	O
)	O
and	O
facet	O
joint	O
(	O
eightfold	O
)	O
MSC	O
.	O

Matrix	O
mineralization	O
quantified	O
by	O
Alizarin	O
red	O
staining	B-P
was	O
increased	O
by	O
osteogenic	O
differentiation	O
,	O
yet	O
similar	O
between	O
both	O
MSC	O
sources	O
.	O

Protein	O
expression	O
of	O
type	O
I	O
collagen	O
was	O
enhanced	O
during	O
osteogenesis	O
and	O
significantly	O
greater	O
in	O
iliac	O
crest	O
MSC	O
.	O

Correspondingly	O
,	O
COL1A2	O
mRNA	O
expression	O
was	O
higher	O
in	O
osteogenically	O
differentiated	O
MSC	O
from	O
iliac	O
crest	O
.	O

Adipocyte	O
numbers	O
showed	O
significant	O
differences	O
between	O
iliac	O
crest	O
(	O
63	O
±	O
60	O
)	O
and	O
facet	O
joint	O
(	O
18	O
±	O
15	O
)	O
MSC	O
under	O
osteogenic	O
conditions	O
.	O

Negative	O
(	O
GREM1	O
)	O
and	O
positive	O
(	O
FABP4	O
)	O
adipogenic	O
markers	O
were	O
not	O
differentially	O
expressed	O
between	O
sources	O
.	O

MSC	O
from	O
iliac	O
crest	O
and	O
degenerative	O
facet	O
joints	O
largely	O
display	O
similar	O
clonogenic	O
and	O
osteogenic	O
properties	O
in	O
vitro	O
.	O

Differences	O
at	O
the	O
molecular	O
level	O
are	O
not	O
likely	O
to	O
impair	O
the	O
osteoinductive	O
capacity	O
of	O
facet	O
joint	O
MSC	O
.	O

Bone	O
autografts	O
from	O
facetectomy	O
would	O
be	O
viable	O
alternatives	O
as	O
bone	O
autografts	O
for	O
intervertebral	O
spinal	O
fusion	O
in	O
lumbar	O
spinal	O
stenosis	O
.	O

Crop	O
-to-	O
wild	O
gene	O
flow	O
and	O
its	O
fitness	O
consequences	O
for	O
a	O
wild	O
fruit	O
tree	O
:	O
Towards	O
a	O
comprehensive	O
conservation	O
strategy	O
of	O
the	O
wild	O
apple	O
in	O
Europe	O
.	O

Crop	O
-to-	O
wild	O
gene	O
flow	O
can	O
reduce	O
the	O
fitness	O
and	O
genetic	O
integrity	O
of	O
wild	O
species	O
.	O

Malus	O
sylvestris	O
,	O
the	O
European	O
crab-apple	O
fruit	O
tree	O
in	O
particular	O
,	O
is	O
threatened	O
by	O
the	O
disappearance	O
of	O
its	O
habitat	O
and	O
by	O
gene	O
flow	O
from	O
its	O
domesticated	O
relative	O
,	O
Malus	O
domestica	O
.	O

With	O
the	O
aims	O
of	O
evaluating	O
threats	O
for	O
M.	O
sylvestris	O
and	O
of	O
formulating	O
recommendations	O
for	O
its	O
conservation	O
,	O
we	O
studied	O
here	O
,	O
using	O
microsatellite	O
markers	O
and	O
growth	O
experiments	O
:	O
(	O
i	O
)	O
hybridization	O
rates	O
in	O
seeds	O
and	O
trees	O
from	O
a	O
French	O
forest	O
and	O
in	O
seeds	O
used	O
for	O
replanting	O
crab	O
apples	O
in	O
agrosystems	O
and	O
in	O
forests	O
,	O
(	O
ii	O
)	O
the	O
impact	O
of	O
the	O
level	O
of	O
M.	O
domestica	O
ancestry	O
on	O
individual	O
tree	O
fitness	O
and	O
(	O
iii	O
)	O
pollen	O
dispersal	O
abilities	O
in	O
relation	O
to	O
crop	O
-to-	O
wild	O
gene	O
flow	O
.	O

We	O
found	O
substantial	O
contemporary	O
crop	O
-to-	O
wild	O
gene	O
flow	O
in	O
crab-apple	O
tree	O
populations	O
and	O
superior	O
fitness	O
of	O
hybrids	O
compared	O
to	O
wild	O
seeds	O
and	O
seedlings	O
.	O

Using	O
paternity	B-P
analyses	I-P
,	O
we	O
showed	O
that	O
pollen	O
dispersal	O
could	O
occur	O
up	O
to	O
4	O
km	O
and	O
decreased	O
with	O
tree	O
density	O
.	O

The	O
seed	O
network	O
furnishing	O
the	O
wild	O
apple	O
reintroduction	O
agroforestry	O
programmes	O
was	O
found	O
to	O
suffer	O
from	O
poor	O
genetic	O
diversity	O
,	O
introgressions	O
and	O
species	O
misidentification	O
.	O

Overall	O
,	O
our	O
findings	O
indicate	O
supported	O
threats	O
for	O
the	O
European	O
wild	O
apple	O
steering	O
us	O
to	O
provide	O
precise	O
recommendations	O
for	O
its	O
conservation	O
.	O

Bromocriptine	O
Induces	O
Autophagy	O
-Dependent	O
Cell	O
Death	O
in	O
Pituitary	O
Adenomas	O
.	O

Bromocriptine	O
(	O
BRC	O
)	O
is	O
effective	O
in	O
patients	O
with	O
prolactinoma	O
.	O

However	O
,	O
the	O
cytotoxic	O
mechanism	O
of	O
BRC	O
remains	O
unknown	O
.	O

Slices	O
for	O
immunohistochemical	B-P
pathology	O
were	O
randomly	O
selected	O
from	O
37	O
paraffin-embedded	O
prolactinoma	O
tissue	O
sections	O
.	O

LC3	O
was	O
detected	O
by	O
immunohistochemistry	B-P
.	O

GH3	O
and	O
MMQ	O
cells	O
were	O
treated	O
by	O
BRC	O
and/or	O
rapamycin	O
(	O
RAPA	O
)	O
.	O

Cell	O
viability	O
and	O
the	O
cell	O
cycle	O
were	O
measured	O
by	O
CCK-8	O
and	O
flow	B-P
cytometry	I-P
,	O
respectively	O
.	O

Enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
measured	O
prolactin	O
secretion	O
.	O

Protein	O
expression	O
was	O
detected	O
by	O
Western	O
blot	O
or	O
immunofluorescence	B-P
.	O

LC3	O
was	O
significantly	O
expressed	O
in	O
prolactinoma	O
in	O
which	O
patients	O
were	O
treated	O
exclusively	O
with	O
BRC	O
.	O

LC3	O
expression	O
was	O
negative	O
in	O
normal	O
tissues	O
and	O
prolactinoma	O
in	O
which	O
patients	O
were	O
not	O
treated	O
with	O
BRC	O
.	O

Treatment	O
with	O
60	O
μM	O
BRC	O
for	O
24	O
hours	O
induced	O
cell	O
death	O
in	O
MMQ	O
cells	O
by	O
up	O
to	O
50	O
%	O
.	O

However	O
,	O
110	O
μM	O
BRC	O
was	O
required	O
to	O
produce	O
a	O
similar	O
effect	O
in	O
GH3	O
cells	O
.	O

The	O
cell	O
cycle	O
was	O
arrested	O
at	O
the	O
G0	O
-	O
G1	O
phase	O
and	O
S	O
phase	O
.	O

As	O
the	O
concentration	O
and	O
time	O
increased	O
,	O
the	O
conversion	O
ratio	O
of	O
LC3-I	O
to	O
LC3-II	O
increased	O
and	O
prolactin	O
secretion	O
decreased	O
.	O

In	O
addition	O
,	O
Bcl-2	O
and	O
BAX	O
expression	O
was	O
decreased	O
.	O

The	O
cell	O
viability	O
,	O
prolactin	O
level	O
,	O
and	O
G0-G1	O
cells	O
are	O
similar	O
in	O
MMQ	O
cells	O
treated	O
with	O
RAPA	O
and	O
a	O
low	O
concentration	O
of	O
BRC	O
and	O
MMQ	O
cells	O
treated	O
with	O
a	O
high	O
concentration	O
of	O
BRC	O
.	O

Compared	O
with	O
the	O
effects	O
of	O
a	O
high	O
concentration	O
of	O
BRC	O
,	O
treatment	O
with	O
RAPA	O
and	O
a	O
low	O
concentration	O
of	O
BRC	O
effectively	O
increase	O
the	O
conversion	O
rate	O
of	O
LC3-I	O
to	O
LC3-II	O
.	O

BRC	O
-	O
treated	O
pituitary	O
adenoma	O
cells	O
mainly	O
underwent	O
autophagic	O
cell	O
death	O
rather	O
than	O
apoptosis	O
.	O

Can	O
inorganic	O
phosphate	O
explain	O
sag	O
during	O
unfused	O
tetanic	O
contractions	O
of	O
skeletal	O
muscle	O
?	O
.	O

We	O
test	O
the	O
hypothesis	O
that	O
cytosolic	O
inorganic	O
phosphate	O
(	O
Pi	O
)	O
can	O
account	O
for	O
the	O
contraction	O
-	O
induced	O
reductions	O
in	O
twitch	O
duration	O
which	O
impair	O
summation	O
and	O
cause	O
force	O
to	O
decline	O
(	O
sag	O
)	O
during	O
unfused	O
tetanic	O
contractions	O
of	O
fast-twitch	O
muscle	O
.	O

A	O
five-state	O
model	O
of	O
crossbridge	O
cycling	O
was	O
used	O
to	O
simulate	O
twitch	O
and	O
unfused	O
tetanic	O
contractions	O
.	O

As	O
Pi	O
concentration	O
(	O
[	O
Pi	O
]	O
)	O
was	O
increased	O
from	O
0	O
to	O
30	O
mmol·L	O
(	O
-1	O
)	O
,	O
twitch	O
duration	O
decreased	O
,	O
with	O
progressive	O
reductions	O
in	O
sensitivity	O
to	O
Pi	O
as	O
[	O
Pi	O
]	O
was	O
increased	O
.	O

When	O
unfused	O
tetani	O
were	O
simulated	O
with	O
rising	O
[	O
Pi	O
]	O
,	O
sag	O
was	O
most	O
pronounced	O
when	O
initial	O
[	O
Pi	O
]	O
was	O
low	O
,	O
and	O
when	O
the	O
magnitude	O
of	O
[	O
Pi	O
]	O
increase	O
was	O
large	O
.	O

Fast-twitch	O
extensor	O
digitorum	O
longus	O
(	O
EDL	O
)	O
muscles	O
(	O
sag-prone	O
,	O
typically	O
low	O
basal	O
[	O
Pi	O
]	O
)	O
and	O
slow-twitch	O
soleus	O
muscles	O
(	O
sag	O
-	O
resistant	O
,	O
typically	O
high	O
basal	O
[	O
Pi	O
]	O
)	O
were	O
isolated	O
from	O
14	O
female	O
C57BL/6	O
mice	O
.	O

Muscles	O
were	O
sequentially	O
incubated	B-P
in	O
solutions	O
containing	O
either	O
glucose	O
or	O
pyruvate	O
to	O
create	O
typical	O
and	O
low	O
Pi	O
environments	O
,	O
respectively	O
.	O

Twitch	O
duration	O
was	O
greater	O
(	O
P	O
<	O
0.05	O
)	O
in	O
pyruvate	O
than	O
glucose	O
in	O
both	O
muscles	O
.	O

Stimuli	O
applied	O
at	O
intervals	O
approximately	O
three	O
times	O
the	O
time	O
to	O
peak	O
twitch	O
tension	O
resulted	O
in	O
sag	O
of	O
35.0	O
±	O
3.7	O
%	O
in	O
glucose	O
and	O
50.5	O
±	O
1.4	O
%	O
in	O
pyruvate	O
in	O
the	O
EDL	O
(	O
pyruvate	O
>	O
glucose	O
;	O
P	O
<	O
0.05	O
)	O
,	O
and	O
3.9	O
±	O
0.3	O
%	O
in	O
glucose	O
and	O
37.8	O
±	O
2.7	O
%	O
in	O
pyruvate	O
in	O
the	O
soleus	O
(	O
pyruvate	O
>	O
glucose	O
;	O
P	O
<	O
0.05	O
)	O
.	O

The	O
influence	O
of	O
Pi	O
on	O
crossbridge	O
cycling	O
provides	O
a	O
tenable	O
mechanism	O
for	O
sag	O
.	O

Moreover	O
,	O
the	O
low	O
basal	O
[	O
Pi	O
]	O
in	O
fast-twitch	O
relative	O
to	O
slow-twitch	O
muscle	O
has	O
promise	O
as	O
an	O
explanation	O
for	O
the	O
fiber-type	O
dependency	O
of	O
sag	O
.	O

Parasympathetic	O
Activity	O
and	O
Bronchial	O
Hyperresponsiveness	O
in	O
Athletes	O
.	O

A	O
high	O
prevalence	O
of	O
asthma	O
and	O
bronchial	O
hyperresponsiveness	O
(	O
BHR	O
)	O
is	O
reported	O
in	O
swimmers	O
and	O
cross-country	O
skiers	O
.	O

It	O
has	O
been	O
suggested	O
that	O
increased	O
parasympathetic	O
nervous	O
activity	O
is	O
involved	O
in	O
asthma	O
development	O
in	O
endurance	O
athletes	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
associations	O
of	O
BHR	O
to	O
parasympathetic	O
activity	O
in	O
healthy	O
and	O
asthmatic	O
swimmers	O
and	O
cross-country	O
skiers	O
and	O
healthy	O
non	O
athletes	O
.	O

Parasympathetic	O
activity	O
was	O
measured	O
by	O
pupillometry	B-P
and	O
heart	O
rate	O
variability	O
at	O
the	O
onset	O
of	O
exercise	O
with	O
the	O
cardiac	O
vagal	O
index	O
calculated	O
in	O
28	O
cross-country	O
skiers	O
(	O
♂18/♀10	O
)	O
,	O
29	O
swimmers	O
(	O
♂17/♀12	O
)	O
,	O
and	O
30	O
healthy	O
nonathlete	O
controls	O
(	O
♂14/♀16	O
)	O
on	O
two	O
different	O
days	O
.	O

All	O
subjects	O
performed	O
a	O
methacholine	O
bronchial	B-P
challenge	I-P
with	O
the	O
provocation	O
dose	O
causing	O
20	O
%	O
decrease	O
in	O
the	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
calculated	O
(	O
PD20met	O
)	O
.	O

Data	O
were	O
analyzed	O
by	O
robust	O
regression	O
analysis	O
and	O
presented	O
as	O
β	O
coefficients	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
.	O

PD20met	O
was	O
negatively	O
associated	O
with	O
cardiac	O
vagal	O
index	O
(	O
-13.9	O
,	O
95	O
%	O
CI	O
=	O
-26.8	O
to	O
-1.0	O
)	O
in	O
all	O
subjects	O
.	O

When	O
adjusted	O
to	O
the	O
type	O
of	O
sport	O
,	O
this	O
association	O
was	O
stronger	O
in	O
swimmers	O
(	O
-8.3	O
,	O
95	O
%	O
CI	O
=	O
-13.0	O
to	O
-3.6	O
)	O
as	O
compared	O
with	O
controls	O
and	O
nonsignificant	O
in	O
cross-country	O
skiers	O
.	O

Percent	O
pupil	O
constriction	O
was	O
significantly	O
associated	O
with	O
PD20met	O
in	O
swimmers	O
(	O
-9.4	O
,	O
95	O
%	O
CI	O
=	O
-15.4	O
to	O
-3.4	O
)	O
only	O
after	O
adjusting	O
for	O
the	O
type	O
of	O
sport	O
.	O

Fourteen	O
swimmers	O
(	O
48	O
%	O
)	O
and	O
16	O
cross-country	O
skiers	O
(	O
57	O
%	O
)	O
had	O
doctor-diagnosed	O
asthma	O
in	O
combination	O
with	O
current	O
BHR	O
and/or	O
current	O
use	O
of	O
asthma	O
drugs	O
.	O

Seventy-two	O
percent	O
swimmers	O
,	O
44	O
%	O
cross-country	O
skiers	O
,	O
and	O
39	O
%	O
controls	O
had	O
a	O
PD20met	O
≤8	O
μmol	O
(	O
P	O
=	O
0.015	O
)	O
.	O

Fourteen	O
swimmers	O
had	O
a	O
PD20met	O
≤2	O
μmol	O
as	O
compared	O
with	O
one	O
cross-country	O
skier	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Parasympathetic	O
activity	O
measured	O
in	O
the	O
heart	O
is	O
more	O
closely	O
related	O
to	O
BHR	O
as	O
compared	O
with	O
parasympathetic	O
activity	O
measured	O
in	O
the	O
pupils	O
.	O

The	O
type	O
of	O
sport	O
influences	O
BHR	O
severity	O
and	O
its	O
relationship	O
to	O
parasympathetic	O
activity	O
.	O

Intrinsic	O
inter-network	O
brain	O
dysfunction	O
correlates	O
with	O
symptom	O
dimensions	O
in	O
late-life	O
depression	O
.	O

Prior	O
studies	O
have	O
demonstrated	O
dysfunctions	O
within	O
the	O
core	O
neurocognitive	O
networks	O
(	O
the	O
executive	O
control	O
[	O
ECN	O
]	O
,	O
default	O
mode	O
[	O
DMN	O
]	O
and	O
salience	O
[	O
SN	O
]	O
networks	O
)	O
in	O
late-life	O
depression	O
(	O
LLD	O
)	O
.	O

Whether	O
inter-network	O
dysfunctional	O
connectivity	O
is	O
present	O
in	O
LLD	O
,	O
and	O
if	O
such	O
disruptions	O
are	O
associated	O
with	O
core	O
symptom	O
dimensions	O
is	O
unknown	O
.	O

A	O
cross-sectional	B-P
resting-state	I-P
functional	I-P
connectivity	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
investigation	O
was	O
conducted	O
of	O
LLD	O
(	O
n	O
=	O
39	O
)	O
and	O
age	O
-	O
and	O
gender	O
-equated	O
healthy	O
comparison	O
(	O
HC	O
)	O
(	O
n	O
=	O
29	O
)	O
participants	O
.	O

Dual	O
regression	O
independent	O
component	O
analysis	O
approach	O
was	O
used	O
to	O
identify	O
components	O
that	O
represented	O
the	O
ECN	O
,	O
DMN	O
and	O
SN	O
.	O

The	O
intrinsic	O
inter-network	O
connectivity	O
was	O
compared	O
between	O
LLD	O
and	O
HC	O
participants	O
and	O
the	O
relationship	O
of	O
inter-network	O
connectivity	O
abnormalities	O
with	O
dimensional	O
measures	O
was	O
examined	O
.	O

Relative	O
to	O
HC	O
participants	O
,	O
LLD	O
subjects	O
showed	O
decreased	O
inter-network	O
connectivity	O
between	O
the	O
bilateral	O
ECN	O
and	O
default	O
mode	O
subcortical	O
(	O
thalamus	O
,	O
basal	O
ganglia	O
and	O
ventral	O
striatum	O
)	O
networks	O
,	O
and	O
the	O
left	O
ECN	O
and	O
SN	O
insula	O
component	O
;	O
and	O
increased	O
inter-network	O
connections	O
between	O
the	O
left	O
ECN	O
and	O
posterior	O
DMN	O
and	O
salience	O
(	O
dorsal	O
anterior	O
cingulate	O
)	O
network	O
components	O
.	O

Distinct	O
inter-network	O
connectivity	O
abnormalities	O
correlated	O
with	O
depression	O
and	O
anxiety	O
severity	O
,	O
and	O
executive	O
dysfunction	O
in	O
LLD	O
participants	O
.	O

LLD	O
subjects	O
also	O
showed	O
pronounced	O
intra-network	O
connectivity	O
differences	O
within	O
the	O
ECN	O
,	O
whereas	O
fewer	O
but	O
significant	O
DMN	O
and	O
SN	O
disruptions	O
were	O
also	O
detected	O
.	O

Investigating	O
the	O
intrinsic	O
inter-network	O
functional	O
connectivity	O
could	O
provide	O
a	O
mechanistic	O
framework	O
to	O
better	O
understand	O
the	O
neural	O
basis	O
that	O
underlies	O
core	O
symptom	O
dimensions	O
in	O
LLD	O
.	O

Inter-network	O
connectivity	O
measures	O
have	O
the	O
potential	O
to	O
be	O
neuroimaging	O
biomarkers	O
of	O
symptom	O
dimensions	O
comprising	O
LLD	O
,	O
and	O
may	O
assist	O
in	O
developing	O
symptom	O
-specific	O
treatment	O
algorithms	O
.	O

Systematic	O
mapping	O
of	O
functional	O
enhancer	O
-	O
promoter	O
connections	O
with	O
CRISPR	B-P
interference	I-P
.	O

Gene	O
expression	O
in	O
mammals	O
is	O
regulated	O
by	O
noncoding	O
elements	O
that	O
can	O
affect	O
physiology	O
and	O
disease	O
,	O
yet	O
the	O
functions	O
and	O
target	O
genes	O
of	O
most	O
noncoding	O
elements	O
remain	O
unknown	O
.	O

We	O
present	O
a	O
high-throughput	O
approach	O
that	O
uses	O
clustered	B-P
regularly	I-P
interspaced	I-P
short	I-P
palindromic	I-P
repeats	I-P
(	I-P
CRISPR	I-P
)	I-P
interference	I-P
(	O
CRISPRi	B-P
)	O
to	O
discover	O
regulatory	O
elements	O
and	O
identify	O
their	O
target	O
genes	O
.	O

We	O
assess	O
>	O
1	O
megabase	O
of	O
sequence	O
in	O
the	O
vicinity	O
of	O
two	O
essential	O
transcription	O
factors	O
,	O
MYC	O
and	O
GATA1	O
,	O
and	O
identify	O
nine	O
distal	O
enhancers	O
that	O
control	O
gene	O
expression	O
and	O
cellular	O
proliferation	O
.	O

Quantitative	O
features	O
of	O
chromatin	O
state	O
and	O
chromosome	O
conformation	O
distinguish	O
the	O
seven	O
enhancers	O
that	O
regulate	O
MYC	O
from	O
other	O
elements	O
that	O
do	O
not	O
,	O
suggesting	O
a	O
strategy	O
for	O
predicting	O
enhancer	O
-	O
promoter	O
connectivity	O
.	O

This	O
CRISPRi	B-P
-based	O
approach	O
can	O
be	O
applied	O
to	O
dissect	O
transcriptional	O
networks	O
and	O
interpret	O
the	O
contributions	O
of	O
noncoding	O
genetic	O
variation	O
to	O
human	O
disease	O
.	O

Carbon	O
Monoxide	O
Improves	O
Efficacy	O
of	O
Mesenchymal	O
Stromal	O
Cells	O
During	O
Sepsis	O
by	O
Production	O
of	O
Specialized	O
Proresolving	O
Lipid	O
Mediators	O
.	O

Mesenchymal	O
stromal	O
cells	O
are	O
being	O
investigated	O
as	O
a	O
cell-based	O
therapy	O
for	O
a	O
number	O
of	O
disease	O
processes	O
,	O
with	O
promising	O
results	O
in	O
animal	O
models	O
of	O
systemic	O
inflammation	O
and	O
sepsis	O
.	O

Studies	O
are	O
ongoing	O
to	O
determine	O
ways	O
to	O
further	O
improve	O
the	O
therapeutic	O
potential	O
of	O
mesenchymal	O
stromal	O
cells	O
.	O

A	O
gas	O
molecule	O
that	O
improves	O
outcome	O
in	O
experimental	O
sepsis	O
is	O
carbon	O
monoxide	O
.	O

We	O
hypothesized	O
that	O
preconditioning	O
of	O
mesenchymal	O
stromal	O
cells	O
with	O
carbon	O
monoxide	O
ex	O
vivo	O
would	O
promote	O
further	O
therapeutic	O
benefit	O
when	O
cells	O
are	O
administered	O
in	O
vivo	O
after	O
the	O
onset	O
of	O
polymicrobial	O
sepsis	O
in	O
mice	O
.	O

Animal	O
study	O
and	O
primary	B-P
cell	I-P
culture	I-P
.	O

Laboratory	O
investigation	O
.	O

BALB/c	O
mice	O
.	O

Polymicrobial	O
sepsis	O
was	O
induced	O
by	O
cecal	O
ligation	O
and	O
puncture	O
.	O

Mesenchymal	O
stromal	O
cells	O
,	O
mesenchymal	O
stromal	O
cells	O
-	O
conditioned	O
with	O
carbon	O
monoxide	O
,	O
fibroblasts	O
,	O
or	O
fibroblasts	O
-	O
conditioned	O
with	O
carbon	O
monoxide	O
were	O
delivered	O
by	O
tail	O
vein	O
injections	O
to	O
septic	O
mice	O
.	O

The	O
mice	O
were	O
assessed	O
for	O
survival	O
,	O
bacterial	O
clearance	O
,	O
and	O
the	O
inflammatory	O
response	O
during	O
sepsis	O
in	O
each	O
of	O
the	O
groups	O
.	O

Mesenchymal	O
stromal	O
cells	O
were	O
also	O
assessed	O
for	O
their	O
ability	O
to	O
promote	O
bacterial	O
phagocytosis	O
by	O
neutrophils	O
,	O
the	O
production	O
of	O
specialized	O
proresolving	O
lipid	O
mediators	O
,	O
and	O
their	O
importance	O
for	O
mesenchymal	O
stromal	O
cells	O
function	O
using	O
gene	O
silencing	O
.	O

Ex	O
vivo	O
preconditioning	O
with	O
carbon	O
monoxide	O
allowed	O
mesenchymal	O
stromal	O
cells	O
to	O
be	O
administered	O
later	O
after	O
the	O
onset	O
of	O
sepsis	O
(	O
6	O
hr	O
)	O
,	O
and	O
yet	O
maintain	O
their	O
therapeutic	O
effect	O
with	O
increased	O
survival	O
.	O

Carbon	O
monoxide	O
preconditioned	O
mesenchymal	O
stromal	O
cells	O
were	O
also	O
able	O
to	O
alleviate	O
organ	O
injury	O
,	O
improve	O
bacterial	O
clearance	O
,	O
and	O
promote	O
the	O
resolution	O
of	O
inflammation	O
.	O

Mesenchymal	O
stromal	O
cells	O
exposed	O
to	O
carbon	O
monoxide	O
,	O
with	O
docosahexaenoic	O
acid	O
substrate	O
,	O
produced	O
specialized	O
proresolving	O
lipid	O
mediators	O
,	O
particularly	O
D-series	O
resolvins	O
,	O
which	O
promoted	O
survival	O
.	O

Silencing	O
of	O
lipoxygenase	O
pathways	O
(	O
5-lipoxygenase	O
and	O
12	O
/	O
15-lipoxygenase	O
)	O
,	O
which	O
are	O
important	O
enzymes	O
for	O
specialized	O
proresolving	O
lipid	O
mediator	O
biosynthesis	O
,	O
resulted	O
in	O
a	O
loss	O
of	O
therapeutic	O
benefit	O
bestowed	O
on	O
mesenchymal	O
stromal	O
cells	O
by	O
carbon	O
monoxide	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
production	O
of	O
specialized	O
proresolving	O
lipid	O
mediators	O
contribute	O
to	O
improved	O
mesenchymal	O
stromal	O
cell	O
efficacy	O
when	O
exposed	O
to	O
carbon	O
monoxide	O
,	O
resulting	O
in	O
an	O
improved	O
therapeutic	O
response	O
during	O
sepsis	O
.	O

Investigation	O
of	O
argyrophilic	O
nucleolar	O
organizing	O
region	O
.	O

Ischemia/reperfusion	O
(	O
I/R	O
)	O
injury	O
is	O
a	O
complex	O
event	O
frequently	O
observed	O
in	O
vascular	O
surgery	O
and	O
can	O
cause	O
functional	O
and	O
structural	O
cell	O
damage	O
.	O

Nucleolar-organizing	O
regions	O
(	O
NORs	O
)	O
are	O
sites	O
of	O
the	O
ribosomal	O
genes	O
located	O
on	O
chromosomes	O
and	O
can	O
be	O
stained	B-P
with	O
silver	O
when	O
they	O
are	O
active	O
.	O

Thus	O
these	O
proteins	O
are	O
named	O
as	O
argyrophilic-NOR	O
(	O
AgNOR	O
)	O
-associated	O
proteins	O
.	O

We	O
aimed	O
to	O
investigate	O
any	O
possible	O
effects	O
of	O
renal	O
I/R	O
injury	O
on	O
the	O
NOR	O
protein	O
synthesis	O
and	O
association	O
between	O
the	O
AgNOR	O
proteins	O
amount	O
and	O
histopathological	O
injuring	O
score	O
.	O

Nine	O
female	O
wistar-albino	O
rats	O
with	O
weight	O
of	O
200-250g	O
were	O
included	O
into	O
the	O
study	O
.	O

The	O
animals	O
were	O
randomly	O
divided	O
in	O
two	O
groups	O
,	O
a	O
Control	O
Group	O
and	O
an	O
I/R	O
Group	O
.	O

In	O
I/R	O
group	O
,	O
rats	O
were	O
subjected	O
to	O
45	O
minutes	O
of	O
renal	O
pedicle	O
occlusion	O
followed	O
by	O
24	O
hours	O
of	O
reperfusion	O
.	O

In	O
the	O
control	O
group	O
no	O
drug	O
injections	O
or	O
ischemia	O
reperfusion	O
were	O
performed	O
in	O
animals	O
.	O

Then	O
histopathological	O
injury	O
score	O
,	O
mean	O
AgNOR	O
number	O
and	O
total	O
AgNOR	O
area	O
/	O
nuclear	O
area	O
(	O
TAA	O
/	O
NA	O
)	O
were	O
detected	O
for	O
each	O
rat	O
.	O

The	O
differences	O
between	O
control	O
and	O
I/R	O
groups	O
were	O
significant	O
for	O
histopathological	O
injury	O
scores	O
(	O
p	O
=	O
0.016	O
)	O
.	O

Also	O
the	O
differences	O
between	O
control	O
group	O
and	O
I/R	O
group	O
were	O
significant	O
for	O
mean	O
AgNOR	O
number	O
(	O
p	O
=	O
0.000	O
)	O
and	O
TAA/NA	O
ratio	O
(	O
p	O
=	O
0.000	O
)	O
.	O

Additionally	O
,	O
there	O
was	O
a	O
positive	O
correlation	O
between	O
TAA/NA	O
ratio	O
and	O
histopathological	O
injury	O
score	O
(	O
r	O
=	O
0.728	O
;	O
p	O
=	O
0.026	O
)	O
and	O
between	O
mean	O
AgNOR	O
number	O
and	O
histopathological	O
injury	O
score	O
(	O
r	O
=	O
0.670	O
;	O
p	O
=	O
0.048	O
)	O
.	O

The	O
detection	O
of	O
AgNOR	O
proteins	O
amount	O
may	O
be	O
used	O
as	O
an	O
indicator	O
to	O
obtain	O
information	O
about	O
the	O
cellular	O
behaviour	O
(	O
self-protective	O
mechanism	O
of	O
tubular	O
epithelial	O
cells	O
)	O
against	O
I/R	O
injury	O
and	O
cellular	O
damage	O
levels	O
(	O
Tab	O
.	O

2	O
,	O
Fig	O
.	O

4	O
,	O
Ref	O
.	O

24	O
)	O
.	O

Sleep	O
Loss	O
Promotes	O
Astrocytic	O
Phagocytosis	O
and	O
Microglial	O
Activation	O
in	O
Mouse	O
Cerebral	O
Cortex	O
.	O

We	O
previously	O
found	O
that	O
Mertk	O
and	O
its	O
ligand	O
Gas6	O
,	O
astrocytic	O
genes	O
involved	O
in	O
phagocytosis	O
,	O
are	O
upregulated	O
after	O
acute	O
sleep	O
deprivation	O
.	O

These	O
results	O
suggested	O
that	O
astrocytes	O
may	O
engage	O
in	O
phagocytic	O
activity	O
during	O
extended	O
wake	O
,	O
but	O
direct	O
evidence	O
was	O
lacking	O
.	O

Studies	O
in	O
humans	O
and	O
rodents	O
also	O
found	O
that	O
sleep	O
loss	O
increases	O
peripheral	O
markers	O
of	O
inflammation	O
,	O
but	O
whether	O
these	O
changes	O
are	O
associated	O
with	O
neuroinflammation	O
and/or	O
activation	O
of	O
microglia	O
,	O
the	O
brain	O
's	O
resident	O
innate	O
immune	O
cells	O
,	O
was	O
unknown	O
.	O

Here	O
we	O
used	O
serial	B-P
block-face	I-P
scanning	I-P
electron	I-P
microscopy	I-P
to	O
obtain	O
3D	O
volume	O
measurements	O
of	O
synapses	O
and	O
surrounding	O
astrocytic	O
processes	O
in	O
mouse	O
frontal	O
cortex	O
after	O
6-8	O
h	O
of	O
sleep	O
,	O
spontaneous	O
wake	O
,	O
or	O
sleep	O
deprivation	O
(	O
SD	O
)	O
and	O
after	O
chronic	O
(	O
∼5	O
d	O
)	O
sleep	O
restriction	O
(	O
CSR	O
)	O
.	O

Astrocytic	O
phagocytosis	O
,	O
mainly	O
of	O
presynaptic	O
components	O
of	O
large	O
synapses	O
,	O
increased	O
after	O
both	O
acute	O
and	O
chronic	O
sleep	O
loss	O
relative	O
to	O
sleep	O
and	O
wake	O
.	O

MERTK	O
expression	O
and	O
lipid	O
peroxidation	O
in	O
synaptoneurosomes	O
also	O
increased	O
to	O
a	O
similar	O
extent	O
after	O
short	O
and	O
long	O
sleep	O
loss	O
,	O
suggesting	O
that	O
astrocytic	O
phagocytosis	O
may	O
represent	O
the	O
brain	O
's	O
response	O
to	O
the	O
increase	O
in	O
synaptic	O
activity	O
associated	O
with	O
prolonged	O
wake	O
,	O
clearing	O
worn	O
components	O
of	O
heavily	O
used	O
synapses	O
.	O

Using	O
confocal	B-P
microscopy	I-P
,	O
we	O
then	O
found	O
that	O
CSR	O
but	O
not	O
SD	O
mice	O
show	O
morphological	O
signs	O
of	O
microglial	O
activation	O
and	O
enhanced	O
microglial	O
phagocytosis	O
of	O
synaptic	O
elements	O
,	O
without	O
obvious	O
signs	O
of	O
neuroinflammation	O
in	O
the	O
CSF	O
.	O

Because	O
low	O
-	O
level	O
sustained	O
microglia	O
activation	O
can	O
lead	O
to	O
abnormal	O
responses	O
to	O
a	O
secondary	O
insult	O
,	O
these	O
results	O
suggest	O
that	O
chronic	O
sleep	O
loss	O
,	O
through	O
microglia	O
priming	O
,	O
may	O
predispose	O
the	O
brain	O
to	O
further	O
damage	O
.SIGNIFICANCE	O
STATEMENT	O
We	O
find	O
that	O
astrocytic	O
phagocytosis	O
of	O
synaptic	O
elements	O
,	O
mostly	O
of	O
presynaptic	O
origin	O
and	O
in	O
large	O
synapses	O
,	O
is	O
upregulated	O
already	O
after	O
a	O
few	O
hours	O
of	O
sleep	O
deprivation	O
and	O
shows	O
a	O
further	O
significant	O
increase	O
after	O
prolonged	O
and	O
severe	O
sleep	O
loss	O
,	O
suggesting	O
that	O
it	O
may	O
promote	O
the	O
housekeeping	O
of	O
heavily	O
used	O
and	O
strong	O
synapses	O
in	O
response	O
to	O
the	O
increased	O
neuronal	O
activity	O
of	O
extended	O
wake	O
.	O

By	O
contrast	O
,	O
chronic	O
sleep	O
restriction	O
but	O
not	O
acute	O
sleep	O
loss	O
activates	O
microglia	O
,	O
promotes	O
their	O
phagocytic	O
activity	O
,	O
and	O
does	O
so	O
in	O
the	O
absence	O
of	O
overt	O
signs	O
of	O
neuroinflammation	O
,	O
suggesting	O
that	O
like	O
many	O
other	O
stressors	O
,	O
extended	O
sleep	O
disruption	O
may	O
lead	O
to	O
a	O
state	O
of	O
sustained	O
microglia	O
activation	O
,	O
perhaps	O
increasing	O
the	O
brain	O
's	O
susceptibility	O
to	O
other	O
forms	O
of	O
damage	O
.	O

Mediastinal	O
mass	O
diagnosed	O
by	O
endobronchial	B-P
ultrasound	I-P
as	O
recurrent	O
hepatocellular	O
carcinoma	O
in	O
a	O
post	O
-	O
liver	O
transplantation	O
patient	O
.	O

We	O
presented	O
a	O
rare	O
case	O
of	O
recurrent	O
hepatocellular	O
carcinoma	O
after	O
liver	O
transplant	O
manifested	O
as	O
an	O
isolated	O
mediastinal	O
mass	O
.	O

A	O
62-	O
year	O
-	O
old	O
man	O
was	O
referred	O
for	O
evaluation	O
of	O
atypical	O
chest	O
pain	O
and	O
abnormal	O
finding	O
of	O
a	O
computed	B-P
tomography	I-P
of	I-P
the	I-P
chest	I-P
.	O

He	O
had	O
history	O
of	O
chronic	O
hepatitis	O
C	O
liver	O
cirrhosis	O
and	O
hepatocellular	O
carcinoma	O
underwent	O
orthotopic	O
liver	O
transplant	O
as	O
a	O
curative	O
treatment	O
three	O
years	O
earlier	O
.	O

The	O
computed	B-P
tomography	I-P
of	I-P
the	I-P
chest	I-P
demonstrated	O
paratracheal	O
mediastinal	O
lymphadenopathy	O
.	O

He	O
subsequently	O
underwent	O
endobronchial	B-P
ultrasound	I-P
with	I-P
transbronchial	I-P
needle	I-P
aspiration	I-P
(	O
EBUS-TBNA	B-P
)	O
.	O

The	O
right	O
paratracheal	O
lymph	O
node	O
station	O
4R	O
was	O
sampled	O
.	O

Rapid	O
on-site	O
cytology	O
evaluation	O
demonstrated	O
recurrent	O
metastatic	O
hepatocellular	O
carcinoma	O
.	O

Pulmonologist	O
should	O
be	O
cognizant	O
of	O
diagnostic	O
utility	O
of	O
EBUS-TBNA	B-P
in	O
this	O
clinical	O
setting	O
as	O
more	O
transplant	O
patients	O
on	O
immunosuppressive	O
medications	O
with	O
enlarged	O
mediastinal	O
lymphadenopathy	O
of	O
unknown	O
origin	O
will	O
be	O
referred	O
for	O
further	O
evaluation	O
.	O

Ecotoxicity	O
testing	O
and	O
environmental	O
risk	O
assessment	O
of	O
iron	O
nanomaterials	O
for	O
sub-surface	O
remediation	O
-	O
Recommendations	O
from	O
the	O
FP7	O
project	O
NanoRem	O
.	O

Nanoremediation	O
with	O
iron	O
(	O
Fe	O
)	O
nanomaterials	O
opens	O
new	O
doors	O
for	O
treating	O
contaminated	O
soil	O
and	O
groundwater	O
,	O
but	O
is	O
also	O
accompanied	O
by	O
new	O
potential	O
risks	O
as	O
large	O
quantities	O
of	O
engineered	O
nanomaterials	O
are	O
introduced	O
into	O
the	O
environment	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
assessed	O
the	O
ecotoxicity	O
of	O
four	O
engineered	O
Fe	O
nanomaterials	O
,	O
specifically	O
,	O
Nano-Goethite	O
,	O
Trap-Ox	O
Fe-zeolites	O
,	O
Carbo-Iron	O
(	O
®	O
)	O
and	O
FerMEG12	O
,	O
developed	O
within	O
the	O
European	O
FP7	O
project	O
NanoRem	O
for	O
sub-surface	O
remediation	O
towards	O
a	O
test	B-P
battery	I-P
consisting	O
of	O
eight	O
ecotoxicity	O
tests	B-P
on	O
bacteria	O
(	O
V.	O
fisheri	O
,	O
E.	O
coli	O
)	O
,	O
algae	O
(	O
P.	O
subcapitata	O
,	O
Chlamydomonas	O
sp	O
.	O

)	O
,	O
crustaceans	O
(	O
D.	O
magna	O
)	O
,	O
worms	O
(	O
E.	O
fetida	O
,	O
L.	O
variegatus	O
)	O
and	O
plants	O
(	O
R.	O
sativus	O
,	O
L.	O
multiflorum	O
)	O
.	O

The	O
tested	O
materials	O
are	O
commercially	O
available	O
and	O
include	O
Fe	O
oxide	O
and	O
nanoscale	O
zero	O
valent	O
iron	O
(	O
nZVI	O
)	O
,	O
but	O
also	O
hybrid	O
products	O
with	O
Fe	O
loaded	O
into	O
a	O
matrix	O
.	O

All	O
but	O
one	O
material	O
,	O
a	O
ball	O
milled	O
nZVI	O
(	O
FerMEG12	O
)	O
,	O
showed	O
no	O
toxicity	O
in	O
the	O
test	O
battery	O
when	O
tested	O
in	O
concentrations	O
up	O
to	O
100	O
mg/L	O
,	O
which	O
is	O
the	O
cutoff	O
for	O
hazard	O
labeling	O
in	O
chemicals	O
regulation	O
in	O
Europe	O
.	O

However	O
it	O
should	O
be	O
noted	O
that	O
Fe	O
nanomaterials	O
proved	O
challenging	O
to	O
test	O
adequately	O
due	O
to	O
their	O
turbidity	O
,	O
aggregation	O
and	O
sedimentation	O
behavior	O
in	O
aqueous	O
media	O
.	O

This	O
paper	O
provides	O
a	O
number	O
of	O
recommendations	O
concerning	O
future	O
testing	O
of	O
Fe	O
nanomaterials	O
and	O
discusses	O
environmental	O
risk	O
assessment	O
considerations	O
related	O
to	O
these	O
.	O

Derivation	O
of	O
a	O
Predictive	O
Score	O
for	O
Hemorrhagic	O
Progression	O
of	O
Cerebral	O
Contusions	O
in	O
Moderate	O
and	O
Severe	O
Traumatic	O
Brain	O
Injury	O
.	O

After	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
,	O
hemorrhagic	O
progression	O
of	O
contusions	O
(	O
HPCs	O
)	O
occurs	O
frequently	O
.	O

However	O
,	O
there	O
is	O
no	O
established	O
predictive	O
score	O
to	O
identify	O
high-risk	O
patients	O
for	O
HPC	O
.	O

Consecutive	O
patients	O
who	O
were	O
hospitalized	O
(	O
2008-2013	O
)	O
with	O
non-penetrating	O
moderate	O
or	O
severe	O
TBI	O
were	O
studied	O
.	O

The	O
primary	O
outcome	O
was	O
HPC	O
,	O
defined	O
by	O
both	O
a	O
relative	O
increase	O
in	O
contusion	O
volume	O
by	O
≥30	O
%	O
and	O
an	O
absolute	O
increase	O
by	O
≥10	O
mL	O
on	O
serial	O
imaging	O
.	O

Logistic	O
regression	O
models	O
were	O
created	O
to	O
identify	O
independent	O
risk	O
factors	O
for	O
HPC	O
.	O

The	O
HPC	O
Score	O
was	O
then	O
derived	O
based	O
on	O
the	O
final	O
model	O
.	O

Among	O
a	O
total	O
of	O
286	O
eligible	O
patients	O
,	O
61	O
(	O
21	O
%	O
)	O
patients	O
developed	O
HPC	O
.	O

On	O
univariate	O
analyses	O
,	O
HPC	O
was	O
associated	O
with	O
older	O
age	O
,	O
higher	O
initial	O
blood	O
pressure	O
,	O
antiplatelet	O
medications	O
,	O
anticoagulants	O
,	O
subarachnoid	O
hemorrhage	O
(	O
SAH	O
)	O
subdural	O
hematoma	O
(	O
SDH	O
)	O
,	O
skull	O
fracture	O
,	O
frontal	O
contusion	O
,	O
larger	O
contusion	O
volume	O
,	O
and	O
shorter	O
interval	O
from	O
injury	O
to	O
initial	B-P
CT	I-P
.	O

In	O
the	O
final	O
model	O
,	O
SAH	O
(	O
OR	O
6.33	O
,	O
95	O
%	O
CI	O
,	O
1.80-22.23	O
)	O
,	O
SDH	O
(	O
OR	O
3.46	O
,	O
95	O
%	O
CI	O
,	O
1.39-8.63	O
)	O
,	O
and	O
skull	O
fracture	O
(	O
OR	O
2.67	O
,	O
95	O
%	O
CI	O
,	O
1.28-5.58	O
)	O
were	O
associated	O
with	O
HPC	O
.	O

Based	O
on	O
these	O
factors	O
,	O
the	O
HPC	O
Score	O
was	O
derived	O
(	O
SAH	O
=	O
2	O
points	O
,	O
SDH	O
=	O
1	O
point	O
,	O
and	O
skull	O
fracture	O
=	O
1	O
point	O
)	O
.	O

This	O
score	O
had	O
an	O
area	O
under	O
the	O
receiver	O
operating	O
curve	O
of	O
0.77	O
.	O

Patients	O
with	O
a	O
score	O
of	O
0-2	O
had	O
a	O
4.0	O
%	O
incidence	O
of	O
HPC	O
,	O
while	O
patients	O
with	O
a	O
score	O
of	O
3-4	O
had	O
a	O
34.6	O
%	O
incidence	O
of	O
HPC	O
.	O

A	O
simple	O
HPC	O
Score	O
was	O
developed	O
for	O
early	O
risk	O
stratification	O
of	O
HPC	O
in	O
patients	O
with	O
moderate	O
or	O
severe	O
TBI	O
.	O

'	O
Yarn	O
with	O
me	O
'	O
:	O
applying	O
clinical	O
yarning	O
to	O
improve	O
clinician	O
-	O
patient	O
communication	O
in	O
Aboriginal	O
health	O
care	O
.	O

Although	O
successful	O
communication	O
is	O
at	O
the	O
heart	O
of	O
the	O
clinical	O
consultation	O
,	O
communication	O
between	O
Aboriginal	O
patients	O
and	O
practitioners	O
such	O
as	O
doctors	O
,	O
nurses	O
and	O
allied	O
health	O
professionals	O
,	O
continues	O
to	O
be	O
problematic	O
and	O
is	O
arguably	O
the	O
biggest	O
barrier	O
to	O
the	O
delivery	O
of	O
successful	O
health	O
care	O
to	O
Aboriginal	O
people	O
.	O

This	O
paper	O
presents	O
an	O
overarching	O
framework	O
for	O
practitioners	O
to	O
help	O
them	O
reorientate	O
their	O
communication	O
with	O
Aboriginal	O
patients	O
using	O
'	O
clinical	O
yarning	O
'	O
.	O

Clinical	O
yarning	O
is	O
a	O
patient	O
-centred	O
approach	O
that	O
marries	O
Aboriginal	O
cultural	O
communication	O
preferences	O
with	O
biomedical	O
understandings	O
of	O
health	O
and	O
disease	O
.	O

Clinical	O
yarning	O
consists	O
of	O
three	O
interrelated	O
areas	O
:	O
the	O
social	O
yarn	O
,	O
in	O
which	O
the	O
practitioner	O
aims	O
to	O
find	O
common	O
ground	O
and	O
develop	O
the	O
interpersonal	O
relationship	O
;	O
the	O
diagnostic	O
yarn	O
,	O
in	O
which	O
the	O
practitioner	O
facilitates	O
the	O
patient	O
's	O
health	O
story	O
while	O
interpreting	O
it	O
through	O
a	O
biomedical	O
or	O
scientific	B-P
lens	I-P
;	O
and	O
the	O
management	O
yarn	O
,	O
that	O
employs	O
stories	O
and	O
metaphors	O
as	O
tools	O
for	O
patients	O
to	O
help	O
them	O
understand	O
a	O
health	O
issue	O
so	O
a	O
collaborative	O
management	O
approach	O
can	O
be	O
adopted	O
.	O

There	O
is	O
cultural	O
and	O
research	O
evidence	O
that	O
supports	O
this	O
approach	O
.	O

Clinical	O
yarning	O
has	O
the	O
potential	O
to	O
improve	O
outcomes	O
for	O
patients	O
and	O
practitioners	O
.	O

The	O
association	O
between	O
maternal	O
hydronephrosis	O
and	O
acute	O
flank	O
pain	O
during	O
pregnancy	O
:	O
a	O
prospective	O
pilot-study	O
.	O

Maternal	O
hydronephrosis	O
may	O
cause	O
flank	O
pain	O
during	O
pregnancy	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
association	O
between	O
maternal	O
hydronephrosis	O
and	O
flank	O
pain	O
intensity	O
.	O

From	O
2014	O
to	O
2015	O
,	O
all	O
consecutive	O
women	O
with	O
singleton	O
pregnancies	O
,	O
who	O
presented	O
at	O
our	O
tertiary	O
center	O
due	O
to	O
acute	O
flank	O
pain	O
,	O
were	O
prospectively	O
evaluated	O
by	O
renal	O
ultrasonography	B-P
and	O
pain	O
questionnaires	O
.	O

A	O
visual	B-P
analogue	I-P
scale	I-P
was	O
used	O
to	O
assess	O
pain	O
intensity	O
.	O

The	O
study	O
had	O
90	O
%	O
power	O
to	O
detect	O
a	O
significant	O
correlation	O
between	O
hydronephrosis	O
and	O
flank	O
pain	O
(	O
Spearman	O
's	O
test	O
)	O
.	O

A	O
total	O
of	O
51	O
consecutive	O
women	O
with	O
left-sided	O
(	O
13.7	O
%	O
)	O
,	O
right-sided	O
(	O
64.7	O
%	O
)	O
or	O
bilateral	O
(	O
21.6	O
%	O
)	O
pain	O
were	O
enrolled	O
.	O

The	O
mean	O
gestational	O
age	O
of	O
these	O
women	O
,	O
who	O
presented	O
due	O
to	O
their	O
pain	O
,	O
was	O
27.5	O
±	O
6.8	O
weeks	O
at	O
the	O
time	O
of	O
consultation	O
.	O

The	O
mean	O
VAS	O
score	O
was	O
7.6	O
±	O
2.2	O
.	O

In	O
43/51	O
(	O
84.3	O
%	O
)	O
women	O
,	O
hydronephrosis	O
was	O
found	O
on	O
renal	O
sonograms	O
.	O

No	O
correlation	O
was	O
found	O
between	O
the	O
grade	O
of	O
hydronephrosis	O
and	O
pain	O
intensity	O
(	O
p	O
=	O
0.466	O
;	O
r=	O
-0.28	O
)	O
.	O

Women	O
delivered	O
at	O
a	O
mean	O
gestational	O
age	O
of	O
38.1	O
±	O
2.4	O
weeks	O
and	O
their	O
infants	O
had	O
a	O
mean	O
birthweight	O
of	O
3138	O
±	O
677	O
g.	O
Hydronephrosis	O
is	O
a	O
common	O
finding	O
among	O
pregnant	O
women	O
with	O
acute	O
flank	O
pain	O
.	O

The	O
grade	O
of	O
hydronephrosis	O
does	O
not	O
affect	O
pain	O
intensity	O
.	O

This	O
study	O
suggests	O
normal	O
pregnancy	O
outcomes	O
in	O
these	O
women	O
.	O

A	O
Microfluidic	O
Platform	O
to	O
design	O
crosslinked	O
Hyaluronic	O
Acid	O
Nanoparticles	O
(	O
cHANPs	O
)	O
for	O
enhanced	B-P
MRI	I-P
.	O

Recent	O
advancements	O
in	O
imaging	B-P
diagnostics	I-P
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	O
that	O
entrap	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
(	O
MRI	B-P
)	O
Contrast	O
Agents	O
(	O
CAs	O
)	O
,	O
without	O
the	O
need	O
to	O
chemically	O
modify	O
the	O
clinically	O
approved	O
compounds	O
.	O

Nevertheless	O
,	O
the	O
exploitation	O
of	O
microfluidic	O
platforms	O
for	O
their	O
controlled	O
and	O
continuous	O
production	O
is	O
still	O
missing	O
.	O

Here	O
,	O
a	O
microfluidic	O
platform	O
is	O
used	O
to	O
synthesize	O
crosslinked	O
Hyaluronic	O
Acid	O
NanoParticles	O
(	O
cHANPs	O
)	O
in	O
which	O
a	O
clinically	O
relevant	O
MRI	B-P
-	O
CAs	O
,	O
gadolinium	O
diethylenetriamine	O
penta-acetic	O
acid	O
(	O
Gd-DTPA	O
)	O
,	O
is	O
entrapped	O
.	O

This	O
microfluidic	O
process	O
facilitates	O
a	O
high	O
degree	O
of	O
control	O
over	O
particle	O
synthesis	O
,	O
enabling	O
the	O
production	O
of	O
monodisperse	O
particles	O
as	O
small	O
as	O
35	O
nm	O
.	O

Furthermore	O
,	O
the	O
interference	O
of	O
Gd-DTPA	O
during	O
polymer	O
precipitation	O
is	O
overcome	O
by	O
finely	O
tuning	O
process	O
parameters	O
and	O
leveraging	O
the	O
use	O
of	O
hydrophilic-lipophilic	O
balance	O
(	O
HLB	O
)	O
of	O
surfactants	O
and	O
pH	O
conditions	O
.	O

For	O
both	O
production	O
strategies	O
proposed	O
to	O
design	O
Gd	O
-loaded	O
cHANPs	O
,	O
a	O
boosting	O
of	O
the	O
relaxation	O
rate	O
T1	O
is	O
observed	O
since	O
a	O
T1	O
of	O
1562	O
is	O
achieved	O
with	O
a	O
10	O
μM	O
of	O
Gd	O
-loaded	O
cHANPs	O
while	O
a	O
similar	O
value	O
is	O
reached	O
with	O
100	O
μM	O
of	O
the	O
relevant	O
clinical	O
Gd-DTPA	O
in	O
solution	O
.	O

The	O
advanced	O
microfluidic	O
platform	O
to	O
synthesize	O
intravascularly	O
-	O
injectable	O
and	O
completely	O
biocompatible	O
hydrogel	O
nanoparticles	O
entrapping	O
clinically	O
approved	O
CAs	O
enables	O
the	O
implementation	O
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	O
and	O
therapy	O
applications	O
.	O

CD177	O
(	O
+	O
)	O
neutrophils	O
as	O
functionally	O
activated	O
neutrophils	O
negatively	O
regulate	O
IBD	O
.	O

Neutrophils	O
are	O
accumulated	O
in	O
inflamed	O
mucosa	O
of	O
IBD	O
and	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
.	O

CD177	O
is	O
expressed	O
in	O
neutrophils	O
specifically	O
and	O
upregulated	O
during	O
inflammation	O
.	O

However	O
,	O
the	O
role	O
of	O
CD177	O
(	O
+	O
)	O
neutrophils	O
in	O
pathogenesis	O
of	O
IBD	O
remains	O
elusive	O
.	O

Expression	O
of	O
CD177	O
was	O
analysed	O
in	O
peripheral	O
blood	O
and	O
intestinal	O
mucosa	O
from	O
patients	O
with	O
IBD	O
using	O
quantitative	O
RT-PCR	O
,	O
flow	B-P
cytometry	I-P
and	O
immunohistochemistry	B-P
.	O

CD177	O
(	O
+	O
)	O
and	O
CD177	O
(	O
-	O
)	O
neutrophils	O
were	O
isolated	O
to	O
determine	O
gene	O
differences	O
by	O
RNA	O
sequencing	O
.	O

Colitis	O
was	O
established	O
in	O
CD177	O
(	O
-/-	O
)	O
and	O
wild-type	O
mice	O
in	O
response	O
to	O
dextran	O
sulfate	O
sodium	O
(	O
DSS	O
)	O
insults	O
to	O
determine	O
the	O
role	O
of	O
CD177	O
(	O
+	O
)	O
neutrophils	O
in	O
IBD	O
.	O

CD177	O
(	O
+	O
)	O
neutrophils	O
were	O
markedly	O
increased	O
in	O
peripheral	O
blood	O
and	O
inflamed	O
mucosa	O
from	O
patients	O
with	O
active	O
IBD	O
compared	O
with	O
healthy	O
controls	O
.	O

RNA	O
sequencing	O
revealed	O
that	O
differential	O
gene	O
expression	O
between	O
CD177	O
(	O
+	O
)	O
and	O
CD177	O
(	O
-	O
)	O
neutrophils	O
from	O
patients	O
with	O
IBD	O
was	O
associated	O
with	O
response	O
to	O
bacterial	O
defence	O
,	O
hydrogen	O
peroxide	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

CD177	O
(	O
+	O
)	O
neutrophils	O
produced	O
lower	O
levels	O
of	O
proinflammatory	O
cytokines	O
(	O
ie	O
,	O
interferon-γ	O
,	O
interleukin	O
(	O
IL	O
)	O
-6	O
,	O
IL-17A	O
)	O
,	O
but	O
higher	O
levels	O
of	O
IL-22	O
and	O
transforming	O
growth	O
factor-β	O
,	O
and	O
exhibited	O
increased	O
bactericidal	O
activities	O
(	O
ie	O
,	O
ROS	O
,	O
antimicrobial	O
peptides	O
,	O
neutrophil	O
extracellular	O
trap	O
)	O
compared	O
with	O
CD177	O
(	O
-	O
)	O
subset	O
.	O

CD177	O
(	O
-/-	O
)	O
mice	O
developed	O
more	O
severe	O
colitis	O
on	O
DSS	O
insults	O
compared	O
with	O
wild-type	O
mice	O
.	O

Moreover	O
,	O
CD177	O
deficiency	O
led	O
to	O
compromised	O
intestinal	O
barrier	O
and	O
impaired	O
antibacterial	O
immunity	O
through	O
decreased	O
production	O
of	O
IL-22	O
by	O
CD177	O
(	O
-	O
)	O
neutrophils	O
.	O

CD177	O
(	O
+	O
)	O
neutrophils	O
represent	O
functionally	O
activated	O
population	O
and	O
play	O
a	O
protective	O
role	O
in	O
IBD	O
through	O
increased	O
bactericidal	O
activity	O
and	O
IL-22	O
production	O
.	O

Targeting	O
CD177	O
(	O
+	O
)	O
neutrophils	O
may	O
be	O
beneficial	O
for	O
treatment	O
of	O
IBD	O
.	O

Synaptic	O
NMDA	O
Receptor	O
Activation	O
Induces	O
Ubiquitination	O
and	O
Degradation	O
of	O
STEP61	O
.	O

NMDA	O
receptor	O
signaling	O
is	O
critical	O
for	O
the	O
development	O
of	O
synaptic	O
plasticity	O
,	O
learning	O
,	O
and	O
memory	O
,	O
and	O
dysregulation	O
of	O
NMDAR	O
signaling	O
is	O
implicated	O
in	O
a	O
number	O
of	O
neurological	O
disorders	O
including	O
schizophrenia	O
(	O
SZ	O
)	O
.	O

Previous	O
work	O
has	O
demonstrated	O
that	O
the	O
STriatal-Enriched	O
protein	O
tyrosine	O
Phosphatase	O
61	O
kDa	O
(	O
STEP61	O
)	O
is	O
elevated	O
in	O
human	O
SZ	O
postmortem	B-P
cortical	O
samples	O
and	O
after	O
administration	O
of	O
psychotomimetics	O
to	O
cultures	B-P
or	O
mice	O
.	O

Here	O
,	O
we	O
report	O
that	O
activation	O
of	O
synaptic	O
NMDAR	O
by	O
bicuculline	O
or	O
D-serine	O
results	O
in	O
the	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
of	O
STEP61	O
,	O
and	O
increased	O
surface	O
localization	O
of	O
GluN1	O
/	O
GluN2B	O
receptors	O
.	O

Moreover	O
,	O
bicuculline	O
or	O
D-serine	O
treatments	O
rescue	O
the	O
motor	O
and	O
cognitive	O
deficits	O
in	O
MK-801	O
-treated	O
mice	O
and	O
reduce	O
STEP61	O
in	O
mouse	O
frontal	O
cortex	O
.	O

These	O
results	O
suggest	O
that	O
STEP61	O
may	O
contribute	O
to	O
the	O
therapeutic	O
effects	O
of	O
D-serine	O
.	O

Epidemiological	O
patterns	O
of	O
bovine	O
besnoitiosis	O
in	O
an	O
endemic	O
beef	O
cattle	O
herd	O
reared	O
under	O
extensive	O
conditions	O
.	O

Bovine	O
besnoitiosis	O
is	O
a	O
parasitic	O
disease	O
caused	O
by	O
the	O
protozoan	O
Besnoitia	O
besnoiti	O
.	O

Described	O
many	O
decades	O
ago	O
,	O
recent	O
epidemiological	O
studies	O
reveal	O
its	O
important	O
spread	O
within	O
Europe	O
in	O
the	O
last	O
years	O
.	O

To	O
date	O
,	O
many	O
epidemiological	O
aspects	O
related	O
to	O
life	O
cycle	O
,	O
routes	O
of	O
transmission	O
,	O
incidence	O
rates	O
and	O
associated	O
risk	O
factors	O
are	O
lacking	O
;	O
hence	O
,	O
the	O
establishment	O
of	O
appropriate	O
disease	O
control	O
programmes	O
poses	O
an	O
important	O
challenge	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
epidemiological	O
pattern	O
of	O
the	O
disease	O
in	O
an	O
endemic	O
herd	O
reared	O
under	O
extensive	O
conditions	O
(	O
Spanish	O
Pyrenees	O
)	O
by	O
identifying	O
main	O
factors	O
associated	O
with	O
infection	O
and	O
clinical	O
disease	O
dynamics	O
.	O

The	O
study	O
population	O
consisted	O
of	O
276	O
Brown	O
Swiss	O
and	O
Pirenaica	O
adult	O
animals	O
and	O
145	O
calves	O
born	O
and	O
weaned	O
at	O
the	O
farm	O
during	O
the	O
study	O
.	O

Three	O
sampling	O
time	O
frames	O
were	O
used	O
:	O
January	O
2010	O
,	O
September	O
2010	O
and	O
February	O
2011	O
,	O
which	O
allowed	O
us	O
to	O
differentiate	O
two	O
periods	O
designated	O
as	O
mountain	O
and	O
valley	O
periods	O
.	O

The	O
data	O
related	O
to	O
animals	O
(	O
breed	O
,	O
sex	O
and	O
age	O
)	O
and	O
herd	O
management	O
(	O
animal	O
grouping	O
and	O
time	O
in	O
housing	O
)	O
were	O
recorded	O
.	O

The	O
data	O
collection	O
methodology	O
was	O
mainly	O
based	O
on	O
clinical	O
examinations	O
and	O
defining	O
the	O
serological	O
status	O
against	O
bovine	O
besnoitiosis	O
by	O
the	O
immunofluorescent	B-P
antibody	I-P
testing	I-P
of	O
blood	O
samples	O
.	O

The	O
total	O
prevalence	O
among	O
adult	O
animals	O
was	O
38.34	O
%	O
(	O
CI	O
95	O
%	O
:	O
34.53-42.07	O
)	O
,	O
with	O
18.54	O
%	O
of	O
seropositive	O
animals	O
showing	O
clinical	O
signs	O
.	O

In	O
regard	O
to	O
the	O
cumulative	O
incidence	O
,	O
34.57	O
%	O
of	O
new	O
infections	O
were	O
detected	O
during	O
the	O
mountain	O
period	O
,	O
in	O
contrast	O
to	O
the	O
24.59	O
%	O
observed	O
in	O
the	O
valley	O
period	O
.	O

The	O
incidence	O
density	O
was	O
0.058	O
and	O
0.061	O
new	O
infections	O
per	O
animal	O
-	O
month	O
for	O
the	O
mountain	O
and	O
valley	O
periods	O
,	O
respectively	O
.	O

According	O
to	O
the	O
seroepidemiological	O
study	O
,	O
the	O
seroconversion	O
probability	O
of	O
B.	O
besnoiti	O
infection	O
was	O
directly	O
associated	O
with	O
the	O
number	O
of	O
seropositive	O
cows	O
with	O
whom	O
an	O
animal	O
had	O
been	O
stabled	O
as	O
well	O
as	O
the	O
housing	O
period	O
duration	O
,	O
supporting	O
horizontal	O
transmission	O
by	O
close	O
contact	O
as	O
one	O
of	O
the	O
most	O
important	O
methods	O
of	O
disease	O
spread	O
.	O

In	O
addition	O
,	O
the	O
risk	O
of	O
developing	O
the	O
clinical	O
course	O
increased	O
with	O
age	O
,	O
and	O
the	O
presence	O
of	O
clinical	O
signs	O
was	O
related	O
to	O
higher	O
antibody	O
responses	O
.	O

Among	O
calves	O
(	O
from	O
3.1	O
to	O
7.1	O
months	O
old	O
)	O
sampled	O
once	O
at	O
weaning	O
,	O
the	O
total	O
seroprevalence	O
was	O
15.17	O
%	O
(	O
CI	O
95	O
%	O
:	O
9.36-21.04	O
)	O
,	O
and	O
the	O
chronic	O
stage	O
was	O
observed	O
in	O
three	O
animals	O
,	O
supporting	O
the	O
ability	O
of	O
B.	O
besnoiti	O
to	O
infect	O
and	O
even	O
cause	O
disease	O
in	O
animals	O
less	O
than	O
6	O
months	O
old	O
.	O

Finally	O
,	O
the	O
risk	O
of	O
calf	O
seroconversion	O
was	O
positively	O
related	O
to	O
the	O
serological	O
status	O
of	O
the	O
cows	O
,	O
suggesting	O
postnatal	O
transmission	O
between	O
dams	O
and	O
offspring	O
by	O
contact	O
during	O
the	O
suckling	O
period	O
.	O

Analyzing	O
Endosomal	O
Docking	O
,	O
Fusion	O
,	O
Sorting	O
,	O
and	O
Budding	O
Mechanisms	O
in	O
Isolated	O
Organelles	O
.	O

Due	O
to	O
their	O
central	O
role	O
in	O
the	O
reception	O
and	O
sorting	O
of	O
newly	O
internalized	O
material	O
,	O
early	O
endosomes	O
undergo	O
extensive	O
membrane	O
remodeling	O
.	O

They	O
dock	O
and	O
fuse	O
with	O
endocytic	O
carrier	O
vesicles	O
originating	O
from	O
the	O
plasma	O
membrane	O
,	O
sort	O
the	O
internalized	O
material	O
in	O
internal	O
microdomains	O
,	O
and	O
allow	O
the	O
budding	O
of	O
new	O
carrier	O
vesicles	O
from	O
their	O
membrane	O
,	O
destined	O
to	O
fuse	O
with	O
the	O
plasma	O
membrane	O
(	O
recycling	O
)	O
or	O
other	O
organelles	O
.	O

Early	O
endosomal	O
compartments	O
might	O
also	O
be	O
involved	O
in	O
the	O
recycling	O
of	O
synaptic	O
vesicles	O
in	O
nerve	O
terminals	O
.	O

The	O
present	O
protocol	O
describes	O
a	O
technique	O
allowing	O
to	O
assess	O
the	O
mechanistic	O
and	O
molecular	O
aspects	O
of	O
the	O
membrane	O
remodeling	O
processes	O
of	O
docking	O
,	O
fusion	O
,	O
sorting	O
,	O
and	O
budding	O
in	O
early	O
endosomes	O
of	O
neuron	O
-like	O
(	O
and	O
other	O
)	O
cells	O
.	O

It	O
involves	O
the	O
fluorescent	B-P
labeling	I-P
and	O
isolation	O
of	O
endosomal	O
organelles	O
,	O
the	O
setup	O
of	O
assays	B-P
allowing	O
for	O
docking	O
/	O
fusion	O
or	O
sorting	O
/	O
budding	O
in	O
vitro	O
,	O
and	O
finally	O
the	O
assessment	O
and	O
quantification	O
of	O
the	O
membrane	O
remodeling	O
events	O
by	O
fluorescent	B-P
microscopy	I-P
.	O

The	O
technique	O
can	O
be	O
easily	O
manipulated	O
by	O
the	O
addition	O
of	O
inhibitors	O
or	O
activators	O
,	O
and	O
can	O
be	O
combined	O
with	O
other	O
techniques	O
,	O
such	O
as	O
immunostaining	B-P
and	O
high-resolution	B-P
microscopy	I-P
,	O
expanding	O
the	O
experimental	O
possibilities	O
in	O
the	O
investigation	O
of	O
early	O
endosomal	O
characteristics	O
.	O

Inhibition	O
of	O
Sebum	O
Production	O
with	O
the	O
Acetyl	O
Coenzyme	O
A	O
Carboxylase	O
Inhibitor	O
Olumacostat	O
Glasaretil	O
.	O

Olumacostat	O
glasaretil	O
(	O
OG	O
)	O
is	O
a	O
small	O
molecule	O
inhibitor	O
of	O
acetyl	O
coenzyme	O
A	O
(	O
CoA	O
)	O
carboxylase	O
(	O
ACC	O
)	O
,	O
the	O
enzyme	O
that	O
controls	O
the	O
first	O
rate-limiting	O
step	O
in	O
fatty	O
acid	O
biosynthesis	O
.	O

Inhibition	O
of	O
ACC	O
activity	O
in	O
the	O
sebaceous	O
glands	O
is	O
designed	O
to	O
substantially	O
affect	O
sebum	O
production	O
,	O
because	O
over	O
80	O
%	O
of	O
human	O
sebum	O
components	O
contain	O
fatty	O
acids	O
.	O

OG	O
inhibits	O
de	O
novo	O
lipid	O
synthesis	O
in	O
primary	O
and	O
transformed	O
human	O
sebocytes	O
.	O

TrueMass	O
Sebum	O
Panel	O
analyses	O
showed	O
a	O
reduction	O
in	O
saturated	O
and	O
monounsaturated	O
fatty	O
acyl	O
chains	O
across	O
lipid	O
species	O
,	O
including	O
di-	O
and	O
triacylglycerols	O
,	O
phospholipids	O
,	O
cholesteryl	O
esters	O
,	O
and	O
wax	O
esters	O
in	O
OG	O
-	O
treated	O
sebocytes	O
.	O

There	O
was	O
no	O
shift	O
to	O
shorter	O
acyl	O
chain	O
lengths	O
observed	O
,	O
suggesting	O
that	O
the	O
fatty	O
acid	O
chain	O
elongation	O
process	O
was	O
not	O
affected	O
.	O

OG	O
is	O
a	O
pro-drug	O
of	O
the	O
ACC	O
inhibitor	O
5-	O
(	O
tetradecyloxy	O
)	O
-2-furoic	O
acid	O
and	O
was	O
designed	O
to	O
enhance	O
delivery	O
in	O
vivo	O
.	O

Topical	O
application	O
of	O
OG	O
but	O
not	O
5-	O
(	O
tetradecyloxy	O
)	O
-2-furoic	O
acid	O
significantly	O
reduced	O
hamster	O
ear	O
sebaceous	O
gland	O
size	O
,	O
indicating	O
that	O
this	O
pro-drug	O
approach	O
was	O
critical	O
to	O
obtain	O
the	O
desired	O
activity	O
in	O
vivo	O
.	O

High-performance	B-P
liquid	I-P
chromatography	I-P
analyses	I-P
of	O
hamster	O
ear	O
extracts	O
showed	O
that	O
OG	O
treatment	O
increased	O
ACC	O
levels	O
and	O
the	O
ratio	O
of	O
acetyl-CoA	O
to	O
free	O
CoA	O
in	O
these	O
animals	O
,	O
indicating	O
increased	O
fatty	O
acid	O
oxidation	O
.	O

These	O
changes	O
are	O
consistent	O
with	O
ACC	O
inhibition	O
.	O

Matrix-assisted	B-P
laser	I-P
desorption/ionization	I-P
imaging	B-P
showed	O
that	O
OG	O
applied	O
onto	O
Yorkshire	O
pig	O
ears	O
accumulated	O
in	O
sebaceous	O
glands	O
relative	O
to	O
the	O
surrounding	O
dermis	O
.	O

Sebaceous	O
gland	O
ACC	O
represents	O
an	O
attractive	O
therapeutic	O
target	O
given	O
its	O
central	O
role	O
in	O
formation	O
of	O
sebum	O
,	O
a	O
key	O
factor	O
in	O
acne	O
pathogenesis	O
.	O

Semi-preparative	B-P
HPLC	I-P
separation	I-P
followed	O
by	O
HPLC/UV	B-P
and	O
tandem	O
mass	O
spectrometric	O
analysis	O
of	O
phorbol	O
esters	O
in	O
Jatropha	O
seed	O
.	O

Phorbol	O
esters	O
(	O
PEs	O
)	O
are	O
well	O
known	O
as	O
the	O
main	O
toxic	O
compounds	O
in	O
Jatropha	O
curcas	O
Linnaeus	O
(	O
JCL	O
)	O
,	O
the	O
seed	O
oil	O
of	O
which	O
has	O
been	O
considered	O
as	O
a	O
major	O
feedstock	O
for	O
the	O
production	O
of	O
biodiesel	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
a	O
series	O
of	O
PEs	O
extracted	O
from	O
JCL	O
seed	O
kernels	O
with	O
methanol	O
(	O
MeOH	O
)	O
,	O
and	O
identified	O
more	O
than	O
seven	O
components	O
contained	O
in	O
the	O
PEs	O
.	O

The	O
isolation	O
of	O
main	O
five	O
components	O
of	O
a	O
series	O
of	O
PEs	O
was	O
revised	O
using	O
a	O
semi-preparative	B-P
reversed	I-P
phase	I-P
HPLC	I-P
analysis	I-P
of	O
ODS-3	O
column	O
.	O

The	O
five	O
peaks	O
of	O
components	O
were	O
successfully	O
isolated	O
,	O
and	O
peaks	O
of	O
J2	O
,	O
J3	O
,	O
J5	O
,	O
and	O
J7	O
were	O
assigned	O
to	O
be	O
Jatropha	O
factors	O
C1	O
,	O
C2	O
,	O
C3	O
,	O
and	O
C4/5	O
,	O
but	O
J6	O
was	O
a	O
mixture	O
of	O
Jatropha	O
factor	O
C6	O
and	O
its	O
isomer	O
based	O
on	O
the	O
data	O
of	O
UV	B-P
and	O
LC-MS	B-P
/	O
MS	B-P
,	O
and	O
J2	O
was	O
identified	O
using	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
analysis	I-P
.	O

By	O
characterization	O
using	O
LC-MS	B-P
/	O
MS	B-P
analysis	I-P
,	O
all	O
components	O
of	O
a	O
series	O
of	O
PEs	O
were	O
elucidated	O
to	O
be	O
the	O
12-deoxy-16-hydroxyphorbol	O
esters	O
composed	O
of	O
isomeric	O
form	O
of	O
dicarboxylic	O
groups	O
with	O
same	O
m/z	O
value	O
of	O
380	O
.	O

Gas	B-P
assisted	I-P
method	I-P
synthesis	O
nitrogen-doped	O
carbon	O
quantum	O
dots	O
and	O
Hg	O
(	O
II	O
)	O
sensing	O
.	O

Nitrogen-doped	O
fluorescent	O
carbon	O
quantum	O
dots	O
(	O
CQDs	O
)	O
was	O
prepared	O
by	O
gas-assisted	B-P
method	I-P
using	O
cellulose	O
as	O
precursors	O
under	O
ammonia	O
atmosphere	O
,	O
which	O
not	O
only	O
exhibited	O
excellent	O
photoluminescent	O
properties	O
,	O
but	O
also	O
showed	O
highly	O
selective	O
and	O
sensitive	O
detection	O
of	O
mercury	O
ion	O
.	O

The	O
nitrogen-doped	O
CQDs	O
displayed	O
excitation	O
wavelength	O
dependent	O
fluorescent	O
behavior	O
with	O
outstanding	O
dispersibility	O
.	O

Moreover	O
,	O
they	O
exhibited	O
high	O
tolerance	O
to	O
various	O
external	O
conditions	O
,	O
such	O
as	O
storage	O
time	O
,	O
pH	O
value	O
,	O
and	O
ionic	O
strength	O
.	O

The	O
rapid	O
detection	O
of	O
Hg	O
(	O
II	O
)	O
by	O
one-step	O
operation	O
within	O
1	O
min	O
and	O
the	O
good	O
linear	O
correlation	O
between	O
I0/I	O
and	O
Hg	O
(	O
II	O
)	O
concentration	O
in	O
the	O
range	O
of	O
10-100	O
nM	O
made	O
the	O
nitrogen-doped	O
CQDs	O
a	O
promising	O
nanoprobe	O
for	O
Hg	O
(	O
II	O
)	O
detection	O
.	O

The	O
detection	O
limit	O
of	O
the	O
nitrogen-doped	O
CQDs	O
is	O
about	O
7.7	O
nM	O
.	O

Such	O
a	O
nanoprobe	O
has	O
been	O
successfully	O
applied	O
for	O
the	O
analysis	O
of	O
Hg	O
(	O
II	O
)	O
in	O
natural	O
water	O
samples	O
,	O
demonstrating	O
excellent	O
practical	O
feasibility	O
.	O

Impact	O
of	O
antibiotic	O
de-escalation	O
on	O
clinical	O
outcomes	O
in	O
community-acquired	O
pneumococcal	O
pneumonia	O
.	O

Although	O
antibiotic	O
de-escalation	O
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	O
selection	O
pressure	O
,	O
adverse	O
drug	O
effects	O
and	O
costs	O
,	O
evidence	O
supporting	O
this	O
practice	O
in	O
community-acquired	O
pneumococcal	O
pneumonia	O
(	O
CAPP	O
)	O
is	O
lacking	O
.	O

We	O
carried	O
out	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
of	O
a	O
cohort	O
of	O
hospitalized	O
adults	O
with	O
CAPP	O
.	O

Pneumococcal	O
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	O
cultures	O
for	O
Streptococcus	O
pneumoniae	O
obtained	O
from	O
blood	O
,	O
sterile	O
fluids	O
or	O
sputum	O
,	O
and/or	O
a	O
positive	O
urinary	B-P
antigen	I-P
test	I-P
.	O

De-escalation	O
therapy	O
was	O
considered	O
when	O
the	O
initial	O
antibiotic	O
therapy	O
was	O
narrowed	O
to	O
penicillin	O
,	O
amoxicillin	O
or	O
amoxicillin/clavulanate	O
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
.	O

The	O
primary	O
outcomes	O
were	O
30	O
day	O
mortality	O
and	O
length	O
of	O
hospital	O
stay	O
(	O
LOS	O
)	O
.	O

Adjustment	O
for	O
confounders	O
was	O
performed	O
with	O
multivariate	O
and	O
propensity	O
score	O
analyses	O
.	O

Of	O
1410	O
episodes	O
of	O
CAPP	O
,	O
antibiotic	O
de-escalation	O
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
was	O
performed	O
in	O
166	O
cases	O
.	O

After	O
adjustment	O
,	O
antibiotic	O
de-escalation	O
was	O
not	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
mortality	O
(	O
OR	O
=	O
0.83	O
,	O
95	O
%	O
CI	O
=	O
0.24-2.81	O
)	O
,	O
but	O
it	O
was	O
found	O
to	O
be	O
a	O
protective	O
factor	O
for	O
prolonged	O
LOS	O
(	O
above	O
the	O
median	O
)	O
(	O
OR	O
=	O
0.46	O
,	O
95	O
%	O
CI	O
=	O
0.30-0.70	O
)	O
.	O

Similar	O
results	O
were	O
found	O
in	O
patients	O
classified	O
into	O
high-risk	O
pneumonia	O
severity	O
index	O
classes	O
(	O
IV-V	O
)	O
,	O
those	O
with	O
clinical	O
instability	O
and	O
those	O
with	O
bacteraemia	O
.	O

No	O
significant	O
differences	O
were	O
documented	O
in	O
adverse	O
drug	O
reactions	O
or	O
readmission	O
(	O
<	O
30	O
days	O
)	O
.	O

Antibiotic	O
de-escalation	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
duration	O
of	O
LOS	O
,	O
and	O
did	O
not	O
adversely	O
affect	O
outcomes	O
of	O
patients	O
with	O
CAPP	O
,	O
even	O
those	O
with	O
bacteraemia	O
and	O
severe	O
disease	O
,	O
and	O
those	O
who	O
were	O
clinically	O
unstable	O
.	O

Oral	O
health-related	O
quality	O
of	O
life	O
in	O
the	O
elderly	O
population	O
receiving	O
health	O
care	O
at	O
the	O
public	O
hospital	O
network	O
in	O
Medellín	O
,	O
Colombia	O
,	O
and	O
its	O
related	O
factors	O
.	O

Metrosalud	O
is	O
the	O
largest	O
public	O
hospital	O
network	O
in	O
the	O
city	O
of	O
Medellin	O
and	O
one	O
of	O
the	O
most	O
important	O
in	O
Colombia	O
providing	O
health	O
care	O
to	O
the	O
most	O
vulnerable	O
population	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
Oral	O
HealthRelated	O
Quality	O
of	O
Life	O
(	O
OHRQoL	O
)	O
and	O
its	O
related	O
factors	O
in	O
the	O
elderly	O
population	O
receiving	O
health	O
care	O
at	O
the	O
public	O
hospital	O
network	O
in	O
Medellin	O
(	O
Colombia	O
)	O
.	O

A	O
crosssectional	O
design	O
was	O
used	O
.	O

Men	O
and	O
women	O
≥	O
65	O
years	O
old	O
were	O
considered	O
for	O
this	O
research	O
,	O
selected	O
from	O
first	O
consultation	O
records	O
by	O
the	O
institution	O
's	O
statistical	O
unit	O
for	O
2011	O
,	O
who	O
accepted	O
to	O
participate	O
after	O
being	O
contacted	O
by	O
telephone	O
.	O

Sampling	O
was	O
performed	O
in	O
two	O
stages	O
:	O
simple	O
random	O
sampling	O
for	O
selecting	O
Hospital	O
Units	O
HU	O
and	O
Health	O
Centers	O
HC	O
throughout	O
the	O
hospital	O
network	O
in	O
the	O
city	O
,	O
followed	O
by	O
random	O
quota	O
sampling	O
in	O
proportion	O
to	O
the	O
number	O
of	O
elderly	O
population	O
assigned	O
to	O
each	O
HU	O
and	O
HC	O
.	O

A	O
total	O
342	O
patients	O
(	O
58.2	O
%	O
women	O
)	O
participated	O
in	O
the	O
study	O
.	O

The	O
project	O
involved	O
the	O
use	O
of	O
a	O
structured	O
questionnaire	O
and	O
complete	O
dental	O
examination	O
with	O
information	O
on	O
sociodemographic	O
data	O
,	O
selfperceived	O
health	O
variables	O
(	O
mental	O
,	O
general	O
and	O
oral	O
)	O
,	O
use	O
of	O
oral	O
health	O
services	O
,	O
Oral	O
HealthRelated	O
Quality	O
of	O
Life	O
(	O
OHRQoL	O
as	O
measured	O
with	O
GOHAI	O
index	O
)	O
,	O
temporomandibular	B-P
joint	I-P
test	I-P
,	O
oral	O
mucosa	O
,	O
soft	O
tissue	O
evaluation	O
,	O
periodontal	O
,	O
dental	B-P
and	O
prosthetic	O
examination	O
.	O

Descriptive	O
and	O
bivariate	O
analyses	O
were	O
conducted	O
to	O
determine	O
statistically	O
significant	O
differences	O
.	O

Multivariate	O
analysis	O
was	O
performed	O
,	O
using	O
logistic	O
regression	O
,	O
calculating	O
crude	O
and	O
adjusted	O
odds	O
ratios	O
(	O
OR	O
)	O
with	O
their	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
.	O

Impacts	O
were	O
found	O
to	O
be	O
generated	O
by	O
education	O
levels	O
,	O
differences	O
in	O
socioeconomic	O
status	O
and	O
urban	O
or	O
rural	O
housing	O
conditions	O
.	O

The	O
results	O
of	O
this	O
research	O
show	O
low	O
OHRQoL	O
levels	O
in	O
the	O
elderly	O
population	O
receiving	O
health	O
care	O
services	O
at	O
the	O
public	O
hospital	O
network	O
in	O
Medellin	O
.	O

SF2312	O
is	O
a	O
natural	O
phosphonate	O
inhibitor	O
of	O
enolase	O
.	O

Despite	O
being	O
crucial	O
for	O
energy	O
generation	O
in	O
most	O
forms	O
of	O
life	O
,	O
few	O
if	O
any	O
microbial	O
antibiotics	O
specifically	O
inhibit	O
glycolysis	O
.	O

To	O
develop	O
a	O
specific	O
inhibitor	O
of	O
the	O
glycolytic	O
enzyme	B-P
enolase	I-P
2	I-P
(	O
ENO2	B-P
)	O
for	O
the	O
treatment	O
of	O
cancers	O
with	O
deletion	O
of	O
ENO1	O
(	O
encoding	O
enolase	O
1	O
)	O
,	O
we	O
modeled	O
the	O
synthetic	O
tool	O
compound	O
inhibitor	O
phosphonoacetohydroxamate	O
(	O
PhAH	O
)	O
into	O
the	O
active	O
site	O
of	O
human	O
ENO2	B-P
.	O

A	O
ring-stabilized	O
analog	O
of	O
PhAH	O
,	O
in	O
which	O
the	O
hydroxamic	O
nitrogen	O
is	O
linked	O
to	O
Cα	O
by	O
an	O
ethylene	O
bridge	O
,	O
was	O
predicted	O
to	O
increase	O
binding	O
affinity	O
by	O
stabilizing	O
the	O
inhibitor	O
in	O
a	O
bound	O
conformation	O
.	O

Unexpectedly	O
,	O
a	O
structure-based	O
search	O
revealed	O
that	O
our	O
hypothesized	O
backbone-stabilized	O
PhAH	O
bears	O
strong	O
similarity	O
to	O
SF2312	O
,	O
a	O
phosphonate	O
antibiotic	O
of	O
unknown	O
mode	O
of	O
action	O
produced	O
by	O
the	O
actinomycete	O
Micromonospora	O
,	O
which	O
is	O
active	O
under	O
anaerobic	O
conditions	O
.	O

Here	O
,	O
we	O
present	O
multiple	O
lines	O
of	O
evidence	O
,	O
including	O
a	O
novel	O
X-ray	B-P
structure	O
,	O
that	O
SF2312	O
is	O
a	O
highly	O
potent	O
,	O
low	O
-	O
nanomolar	O
inhibitor	O
of	O
enolase	O
.	O

Axially	O
Chiral	O
Dimeric	O
Naphthalene	O
and	O
Naphthoquinone	O
Metabolites	O
,	O
from	O
Root	O
Cultures	B-P
of	O
the	O
West	O
African	O
Liana	O
Triphyophyllum	O
peltatum	O
.	O

Root	O
cultures	B-P
of	O
the	O
West	O
African	O
liana	O
Triphyophyllum	O
peltatum	O
were	O
initiated	O
from	O
stem	O
explants	O
of	O
in	O
vitro	O
cultivated	O
shoots	O
.	O

From	O
these	O
organ	B-P
cultures	I-P
,	O
three	O
new	O
binaphthalenes	O
,	O
one	O
binaphthoquinone	O
,	O
and	O
two	O
(	O
bi	O
)	O
naphthalene	O
glucosides	O
were	O
isolated	O
,	O
with	O
substitution	O
patterns	O
related	O
to	O
those	O
of	O
the	O
naphthylisoquinoline	O
alkaloids	O
,	O
which	O
are	O
the	O
``	O
normal	O
''	O
main	O
metabolites	O
of	O
T.	O
peltatum	O
.	O

The	O
structures	O
of	O
the	O
diglucoside	O
dioncoquinoside	O
A	O
(	O
1	O
)	O
and	O
of	O
the	O
axially	O
chiral	O
biaryls	O
triphyoquinols	O
A1	O
(	O
3	O
)	O
,	O
A2	O
(	O
4	O
)	O
,	O
and	O
B	O
(	O
5	O
)	O
,	O
triphyoquinoside	O
A	O
(	O
6	O
)	O
,	O
and	O
triphyoquinone	O
A	O
(	O
7	O
)	O
were	O
elucidated	O
by	O
spectroscopic	B-P
analysis	I-P
(	O
HRESIMS	B-P
,	O
1D	B-P
and	O
2D	B-P
NMR	I-P
)	O
and	O
by	O
application	O
of	O
electronic	O
circular	O
dichroism	O
(	O
ECD	O
)	O
spectroscopy	O
in	O
combination	O
with	O
the	O
exciton	O
chirality	O
method	O
and	O
quantum-chemical	B-P
ECD	I-P
calculations	I-P
.	O

The	O
root	O
cultures	B-P
likewise	O
produced	O
the	O
known	O
alkaloids	O
dioncophylline	O
A	O
(	O
8	O
)	O
,	O
5'-O-demethyldioncophylline	O
A	O
(	O
9	O
)	O
,	O
dioncopeltine	O
A	O
(	O
10	O
)	O
,	O
habropetaline	O
A	O
(	O
11	O
)	O
,	O
and	O
5'-O-methyldioncophylline	O
D	O
(	O
12a/b	O
)	O
,	O
the	O
naphthalene	O
glucoside	O
plumbaside	O
A	O
(	O
2	O
)	O
,	O
and	O
the	O
naphthoquinones	O
plumbagin	O
(	O
13	O
)	O
,	O
droserone	O
(	O
14	O
)	O
,	O
and	O
8-hydroxydroserone	O
(	O
15	O
)	O
.	O

Electromechanical	O
delays	O
during	O
a	O
fatiguing	O
exercise	O
and	O
recovery	O
in	O
patients	O
with	O
myotonic	O
dystrophy	O
type	O
1	O
.	O

The	O
partitioning	O
of	O
the	O
electromechanical	O
delay	O
by	O
an	O
electromyographic	B-P
(	O
EMG	B-P
)	O
,	O
mechanomyographic	B-P
(	O
MMG	B-P
)	O
and	O
force	O
combined	O
approach	O
can	O
provide	O
further	O
insight	O
into	O
the	O
electrochemical	O
and	O
mechanical	O
processes	O
involved	O
with	O
skeletal	O
muscle	O
contraction	O
and	O
relaxation	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
monitor	O
by	O
this	O
combined	O
approach	O
the	O
changes	O
in	O
delays	O
'	O
electrochemical	O
and	O
mechanical	O
components	O
throughout	O
a	O
fatiguing	O
task	O
and	O
during	O
recovery	O
in	O
patients	O
with	O
myotonic	O
dystrophy	O
type	O
1	O
(	O
DM1	O
)	O
,	O
who	O
present	O
at	O
the	O
skeletal	O
muscle	O
level	O
fibres	O
rearrangement	O
,	O
muscle	O
weakness	O
and	O
myotonia	O
,	O
especially	O
in	O
the	O
distal	O
muscles	O
.	O

After	O
assessing	O
maximum	O
voluntary	O
contraction	O
(	O
MVC	O
)	O
,	O
14	O
male	O
patients	O
with	O
DM1	O
and	O
14	O
healthy	O
controls	O
(	O
HC	O
)	O
performed	O
a	O
fatiguing	O
exercise	O
at	O
50	O
%	O
MVC	O
until	O
exhaustion	O
.	O

EMG	B-P
,	O
MMG	B-P
,	O
and	O
force	O
signals	O
were	O
recorded	O
from	O
tibialis	O
anterior	O
and	O
vastus	O
lateralis	O
muscles	O
.	O

The	O
electromechanical	O
delay	O
during	O
contraction	O
(	O
DelayTOT	O
)	O
and	O
relaxation	O
(	O
R-DelayTOT	O
)	O
components	O
,	O
EMG	B-P
and	O
MMG	B-P
root	O
mean	O
square	O
(	O
RMS	O
)	O
and	O
mean	O
frequency	O
(	O
MF	O
)	O
were	O
calculated	O
off-line	O
.	O

The	O
fatiguing	O
exercise	O
duration	O
was	O
similar	O
in	O
both	O
groups	O
.	O

In	O
patients	O
with	O
DM1	O
,	O
delays	O
components	O
were	O
significantly	O
longer	O
compared	O
to	O
HC	O
,	O
especially	O
in	O
the	O
distal	O
muscle	O
during	O
relaxation	O
.	O

Delays	O
components	O
recovered	O
quickly	O
from	O
the	O
fatiguing	O
exercise	O
in	O
HC	O
than	O
in	O
patients	O
with	O
DM1	O
in	O
both	O
muscles	O
.	O

The	O
alterations	O
in	O
delays	O
observed	O
in	O
DM1	O
during	O
the	O
fatiguing	O
exercise	O
may	O
indicate	O
that	O
also	O
the	O
lengthening	O
of	O
the	O
electrochemical	O
and	O
mechanical	O
processes	O
during	O
contraction	O
and	O
relaxation	O
could	O
play	O
a	O
role	O
in	O
explaining	O
exercise	O
intolerance	O
in	O
this	O
pathology	O
.	O

Chronic	O
adiponectin	O
deficiency	O
leads	O
to	O
Alzheimer	O
's	O
disease	O
-like	O
cognitive	O
impairments	O
and	O
pathologies	O
through	O
AMPK	O
inactivation	O
and	O
cerebral	O
insulin	O
resistance	O
in	O
aged	O
mice	O
.	O

Insulin	O
resistance	O
is	O
the	O
major	O
pathogenesis	O
underlying	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
and	O
these	O
patients	O
have	O
doubled	O
risk	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Increasing	O
evidence	O
suggests	O
that	O
insulin	O
resistance	O
plays	O
an	O
important	O
role	O
in	O
AD	O
pathogenesis	O
,	O
possibly	O
due	O
to	O
abnormal	O
GSK3β	O
activation	O
,	O
causing	O
intra-	O
and	O
extracellular	O
amyloid-beta	O
(	O
Aβ	O
)	O
accumulation	O
.	O

Adiponectin	O
(	O
APN	O
)	O
is	O
an	O
adipokine	O
with	O
insulin-sensitizing	O
and	O
anti-inflammatory	O
effects	O
.	O

Reduced	O
circulatory	O
APN	O
level	O
is	O
associated	O
with	O
insulin	O
resistance	O
and	O
T2DM	O
.	O

The	O
role	O
of	O
APN	O
in	O
AD	O
has	O
not	O
been	O
elucidated	O
.	O

In	O
this	O
study	O
,	O
we	O
aim	O
to	O
examine	O
if	O
adiponectin	O
deficiency	O
would	O
lead	O
to	O
cerebral	O
insulin	O
resistance	O
,	O
cognitive	O
decline	O
and	O
Alzheimer's-like	O
pathology	O
in	O
mice	O
.	O

To	O
study	O
the	O
role	O
of	O
adiponectin	O
in	O
cognitive	O
functions	O
,	O
we	O
employed	O
adiponectin-knockout	O
(	O
APN-KO	O
)	O
mice	O
and	O
demonstrated	O
chronic	O
APN	O
deficiency	O
in	O
their	O
CNS	O
.	O

Behavioral	B-P
tests	I-P
were	O
performed	O
to	O
study	O
the	O
cognitions	O
of	O
male	O
APN-KO	O
mice	O
.	O

Brains	O
and	O
tissue	O
lysates	O
were	O
collected	O
to	O
study	O
the	O
pathophysiological	O
and	O
molecular	O
changes	O
in	O
the	O
brain	O
of	O
APN-KO	O
mice	O
.	O

SH-SY5Y	O
neuroblastoma	O
cell	O
line	O
was	O
used	O
to	O
study	O
the	O
molecular	O
mechanism	O
upon	O
APN	O
and	O
insulin	O
treatment	O
.	O

Aged	O
APN	O
-deficient	O
mice	O
displayed	O
spatial	O
memory	O
and	O
learning	O
impairments	O
,	O
fear-conditioned	O
memory	O
deficit	O
as	O
well	O
as	O
anxiety	O
.	O

These	O
mice	O
also	O
developed	O
AD	O
pathologies	O
including	O
increased	O
cerebral	O
Aβ42	O
level	O
,	O
Aβ	O
deposition	O
,	O
hyperphosphorylated	O
Tau	O
proteins	O
,	O
microgliosis	O
and	O
astrogliosis	O
with	O
increased	O
cerebral	O
IL-1β	O
and	O
TNFα	O
levels	O
that	O
associated	O
with	O
increased	O
neuronal	O
apoptosis	O
and	O
reduced	O
synaptic	O
proteins	O
levels	O
,	O
suggesting	O
APN	O
deficiency	O
may	O
lead	O
to	O
neuronal	O
and	O
synaptic	O
loss	O
in	O
the	O
brain	O
.	O

AD	O
pathologies	O
-associated	O
APN	O
-	O
KO	O
mice	O
displayed	O
attenuated	O
AMPK	O
phosphorylation	O
and	O
impaired	O
insulin	O
signaling	O
including	O
decreased	O
Akt	O
induction	O
and	O
increased	O
GSK3β	O
activation	O
in	O
the	O
hippocampus	O
and	O
frontal	O
cortex	O
.	O

Aged	O
APN	O
-KO	O
mice	O
developed	O
hippocampal	O
insulin	O
resistance	O
with	O
reduced	O
pAkt	O
induction	O
upon	O
intracerebral	O
insulin	O
injection	O
.	O

Consistently	O
,	O
APN	O
treatment	O
in	O
SH-SY5Y	O
cells	O
with	O
insulin	O
resistance	O
and	O
overexpressing	O
Aβ	O
induce	O
higher	O
pAkt	O
levels	O
through	O
AdipoR1	O
upon	O
insulin	O
treatment	O
whereas	O
the	O
induction	O
was	O
blocked	O
by	O
compound	O
C	O
,	O
indicating	O
APN	O
can	O
enhance	O
neuronal	O
insulin	O
sensitivity	O
through	O
AMPK	O
activation	O
.	O

Our	O
results	O
indicated	O
that	O
chronic	O
APN	O
deficiency	O
inactivated	O
AMPK	O
causing	O
insulin	O
desensitization	O
and	O
elicited	O
AD-like	O
pathogenesis	O
in	O
aged	O
mice	O
which	O
also	O
developed	O
significant	O
cognitive	O
impairments	O
and	O
psychiatric	O
symptoms	O
.	O

The	O
adder	O
(	O
Vipera	O
berus	O
)	O
in	O
Southern	O
Altay	O
Mountains	O
:	O
population	O
characteristics	O
,	O
distribution	O
,	O
morphology	O
and	O
phylogenetic	O
position	O
.	O

As	O
the	O
most	O
widely	O
distributed	O
snake	O
in	O
Eurasia	O
,	O
the	O
adder	O
(	O
Vipera	O
berus	O
)	O
has	O
been	O
extensively	O
investigated	O
in	O
Europe	O
but	O
poorly	O
understood	O
in	O
Asia	O
.	O

The	O
Southern	O
Altay	O
Mountains	O
represent	O
the	O
adder	O
's	O
southern	O
distribution	O
limit	O
in	O
Central	O
Asia	O
,	O
whereas	O
its	O
population	O
status	O
has	O
never	O
been	O
assessed	O
.	O

We	O
conducted	O
,	O
for	O
the	O
first	O
time	O
,	O
field	O
surveys	O
for	O
the	O
adder	O
at	O
two	O
areas	O
of	O
Southern	O
Altay	O
Mountains	O
using	O
a	O
combination	O
of	O
line	O
transects	O
and	O
random	O
searches	O
.	O

We	O
also	O
described	O
the	O
morphological	O
characteristics	O
of	O
the	O
collected	B-P
specimens	I-P
and	O
conducted	O
analyses	O
of	O
external	O
morphology	O
and	O
molecular	O
phylogeny	O
.	O

The	O
results	O
showed	O
that	O
the	O
adder	O
distributed	O
in	O
both	O
survey	O
sites	O
and	O
we	O
recorded	O
a	O
total	O
of	O
34	O
sightings	O
.	O

In	O
Kanas	O
river	O
valley	O
,	O
the	O
estimated	O
encounter	O
rate	O
over	O
a	O
total	O
of	O
137	O
km	O
transects	O
was	O
0.15	O
±	O
0.05	O
sightings	O
/km	O
.	O

The	O
occurrence	O
of	O
melanism	O
was	O
only	O
17	O
%	O
.	O

The	O
small	O
size	O
was	O
typical	O
for	O
the	O
adders	O
in	O
Southern	O
Altay	O
Mountains	O
in	O
contrast	O
to	O
other	O
geographic	O
populations	O
of	O
the	O
nominate	O
subspecies	O
.	O

A	O
phylogenetic	O
tree	O
obtained	O
by	O
Bayesian	O
Inference	O
based	O
on	O
DNA	O
sequences	O
of	O
the	O
mitochondrial	O
cytochrome	O
b	O
(	O
1,023	O
bp	O
)	O
grouped	O
them	O
within	O
the	O
Northern	O
clade	O
of	O
the	O
species	O
but	O
failed	O
to	O
separate	O
them	O
from	O
the	O
subspecies	O
V.	O
b.	O
sachalinensis	O
.	O

Our	O
discovery	O
extends	O
the	O
distribution	O
range	O
of	O
V.	O
berus	O
and	O
provides	O
a	O
basis	O
for	O
further	O
researches	O
.	O

We	O
discuss	O
the	O
hypothesis	O
that	O
the	O
adder	O
expands	O
its	O
distribution	O
border	O
to	O
the	O
southwest	O
along	O
the	O
mountains	O
'	O
elevation	O
gradient	O
,	O
but	O
the	O
population	O
abundance	O
declines	O
gradually	O
due	O
to	O
a	O
drying	O
climate	O
.	O

Effect	O
of	O
emodin	O
on	O
mobility	O
signal	O
transduction	O
system	O
of	O
gallbladder	O
smooth	O
muscle	O
in	O
Guinea	O
pig	O
with	O
cholelithiasis	O
.	O

To	O
study	O
the	O
effect	O
of	O
emodin	O
on	O
protein	O
and	O
gene	O
expressions	O
of	O
the	O
massagers	O
in	O
mobility	O
signal	O
transduction	O
system	O
of	O
cholecyst	O
smooth	O
muscle	O
cells	O
in	O
guinea	O
pig	O
with	O
cholesterol	O
calculus	O
.	O

The	O
guinea	O
pigs	O
were	O
randomly	O
divided	O
into	O
4	O
groups	O
,	O
such	O
as	O
control	O
group	O
,	O
gall-stone	O
(	O
GS	O
)	O
group	O
,	O
emodin	O
group	O
and	O
ursodeoxycholic	O
acid	O
(	O
UA	O
)	O
group	O
.	O

Cholesterol	O
calculus	O
models	O
were	O
induced	O
in	O
guinea	O
pigs	O
of	O
GS	O
,	O
emodin	O
and	O
UA	O
groups	O
by	O
lithogenic	O
diet	O
,	O
while	O
emodin	O
or	O
UA	O
were	O
given	O
to	O
the	O
corresponding	O
group	O
for	O
7	O
weeks	O
.	O

The	O
histomorphological	O
and	O
ultrastructure	O
change	O
of	O
gallbladder	O
were	O
detected	O
by	O
microscope	O
and	O
electron	O
microscope	O
,	O
the	O
content	O
of	O
plasma	O
cholecystokinin	O
(	O
CCK	O
)	O
and	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
were	O
analyzed	O
successively	O
by	O
radioimmunoassay	B-P
and	O
flow	B-P
cytometry	I-P
.	O

The	O
protein	O
and	O
mRNA	O
of	O
Gsα	O
,	O
Giα	O
and	O
Cap	O
in	O
cholecyst	O
cells	O
were	O
determined	O
by	O
western	O
blotting	O
and	O
real	O
time	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

Emodin	O
or	O
UA	O
can	O
relieve	O
pathogenic	O
changes	O
in	O
epithelial	O
cells	O
and	O
muscle	O
cells	O
in	O
gallbladder	O
of	O
guinea	O
pig	O
with	O
cholesterol	O
calculus	O
by	O
microscope	O
and	O
transmission	O
electron	O
microscope	O
.	O

In	O
the	O
cholecyst	O
cells	O
of	O
GS	O
group	O
,	O
CCK	O
levels	O
in	O
plasma	O
and	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
decreased	O
,	O
the	O
protein	O
and	O
mRNA	O
of	O
GS	O
were	O
down-regulated	O
,	O
the	O
protein	O
and	O
mRNA	O
of	O
Gi	O
and	O
Cap	O
were	O
up-regulated	O
.	O

Emodin	O
significantly	O
decreased	O
the	O
formative	O
rate	O
of	O
gallstone	O
,	O
improved	O
the	O
pathogenic	O
change	O
in	O
epithelial	O
cells	O
and	O
muscle	O
cells	O
,	O
increased	O
CCK	O
levels	O
in	O
plasma	O
and	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
in	O
cholecyst	O
cells	O
,	O
enhanced	O
the	O
protein	O
and	O
mRNA	O
of	O
Gs	O
in	O
cholecyst	O
cells	O
,	O
reduced	O
the	O
protein	O
and	O
mRNA	O
of	O
Gi	O
and	O
Cap	O
in	O
cholecyst	O
cells	O
in	O
guinea	O
pig	O
with	O
cholesterol	O
calculus	O
.	O

The	O
dysfunction	O
of	O
gallbladder	O
contraction	O
gives	O
rise	O
to	O
the	O
disorders	O
of	O
mobility	O
signal	O
transduction	O
system	O
in	O
cholecyst	O
smooth	O
muscle	O
cells	O
,	O
including	O
low	O
content	O
of	O
plasma	O
CCK	O
and	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
in	O
cholecyst	O
cells	O
,	O
abnormal	O
protein	O
and	O
mRNA	O
of	O
Gs	O
,	O
Gi	O
and	O
Cap	O
.	O

Emodin	O
can	O
enhance	O
the	O
contractibility	O
of	O
gallbladder	O
and	O
alleviate	O
cholestasis	O
by	O
regulating	O
plasma	O
CCK	O
levels	O
,	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
in	O
cholecyst	O
cells	O
and	O
the	O
protein	O
and	O
mRNA	O
of	O
Gs	O
,	O
Gi	O
and	O
Cap	O
.	O

Negative	O
Psychological	O
Consequences	O
of	O
Breast	O
Cancer	O
among	O
Recently	O
Diagnosed	O
Ethnically	O
Diverse	O
Women	O
.	O

Breast	O
cancer	O
has	O
psychological	O
consequences	O
that	O
impact	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
.	O

We	O
examined	O
factors	O
associated	O
with	O
negative	O
psychological	O
consequences	O
of	O
a	O
breast	O
cancer	O
diagnosis	O
,	O
in	O
a	O
diverse	O
sample	O
of	O
910	O
recently	O
diagnosed	O
patients	O
(	O
378	O
African-American	O
,	O
372	O
White	O
,	O
and	O
160	O
Latina	O
)	O
.	O

Patients	O
completed	O
an	O
in-person	O
interview	O
as	O
part	O
of	O
the	O
Breast	O
Cancer	O
Care	O
in	O
Chicago	O
study	O
within	O
an	O
average	O
of	O
four	O
months	O
from	O
diagnosis	O
.	O

The	O
Cockburn	O
negative	O
psychological	O
consequences	O
of	O
breast	B-P
cancer	I-P
screening	I-P
scale	O
was	O
revised	O
to	O
focus	O
on	O
a	O
breast	O
cancer	O
diagnosis	O
.	O

Path	O
analysis	O
assessed	O
predictors	O
of	O
psychological	O
consequences	O
and	O
potential	O
mediators	O
between	O
race	O
/	O
ethnicity	O
and	O
psychological	O
consequences	O
.	O

Compared	O
to	O
White	O
counterparts	O
,	O
bivariate	O
analysis	O
showed	O
African-American	O
(	O
β	O
=	O
1.4	O
,	O
p	O
<	O
0.05	O
)	O
and	O
Latina	O
(	O
β	O
=	O
3.6	O
,	O
p	O
<	O
0.001	O
)	O
women	O
reported	O
greater	O
psychological	O
consequences	O
.	O

Strongest	O
predictors	O
(	O
P	O
<	O
0.05	O
for	O
all	O
)	O
included	O
unmet	O
social	O
support	O
(	O
β	O
=	O
0.38	O
)	O
,	O
and	O
provider	O
trust	O
(	O
β	O
=	O
0.12	O
)	O
,	O
followed	O
by	O
stage	O
at	O
diagnosis	O
(	O
β	O
=	O
0.10	O
)	O
and	O
perceived	O
neighborhood	O
social	O
disorder	O
(	O
β	O
=	O
0.09	O
)	O
.The	O
strongest	O
mediator	O
between	O
race	O
/	O
ethnicity	O
and	O
psychological	O
consequences	O
was	O
unmet	O
social	O
support	O
.	O

African-American	O
and	O
Latina	O
women	O
reported	O
greater	O
psychological	O
consequences	O
related	O
to	O
their	O
breast	O
cancer	O
diagnosis	O
;	O
this	O
disparity	O
was	O
mediated	O
by	O
differences	O
in	O
unmet	O
social	O
support	O
.	O

Social	O
support	O
represents	O
a	O
promising	O
point	O
of	O
intervention	O
.	O

In	O
Vitro	O
Assays	O
for	O
the	O
Discovery	O
of	O
PCSK9	O
Autoprocessing	O
Inhibitors	O
.	O

PCSK9	O
plays	O
a	O
significant	O
role	O
in	O
regulating	O
low-density	B-P
lipoprotein	I-P
(	I-P
LDL	I-P
)	I-P
cholesterol	I-P
levels	I-P
and	O
has	O
become	O
an	O
important	O
drug	O
target	O
for	O
treating	O
hypercholesterolemia	O
.	O

Although	O
a	O
member	O
of	O
the	O
serine	O
protease	O
family	O
,	O
PCSK9	O
only	O
catalyzes	O
a	O
single	O
reaction	O
,	O
the	O
autocleavage	O
of	O
its	O
prodomain	O
.	O

The	O
maturation	O
of	O
the	O
proprotein	O
is	O
an	O
essential	O
prerequisite	O
for	O
the	O
secretion	O
of	O
PCSK9	O
to	O
the	O
extracellular	O
space	O
where	O
it	O
binds	O
the	O
LDL	O
receptor	O
and	O
targets	O
it	O
for	O
degradation	O
.	O

We	O
have	O
found	O
that	O
a	O
construct	O
of	O
proPCSK9	O
where	O
the	O
C-terminal	O
domain	O
has	O
been	O
truncated	O
has	O
sufficient	O
stability	O
to	O
be	O
expressed	O
and	O
purified	O
from	O
Escherichia	O
coli	O
for	O
the	O
in	O
vitro	O
study	O
of	O
autoprocessing	O
.	O

Using	O
automated	O
Western	O
analysis	O
,	O
we	O
demonstrate	O
that	O
autoprocessing	O
exhibits	O
the	O
anticipated	O
first-order	O
kinetics	O
.	O

A	O
high-throughput	B-P
time-resolved	B-P
fluorescence	I-P
resonance	I-P
energy	I-P
transfer	I-P
assay	I-P
for	O
autocleavage	O
has	O
been	O
developed	O
using	O
a	O
PCSK9	O
monoclonal	O
antibody	O
that	O
is	O
sensitive	O
to	O
the	O
conformational	O
changes	O
that	O
occur	O
upon	O
maturation	O
of	O
the	O
proprotein	O
.	O

Kinetic	O
theory	O
has	O
been	O
developed	O
that	O
describes	O
the	O
behavior	O
of	O
both	O
reversible	O
and	O
irreversible	O
inhibitors	O
of	O
autocleavage	O
.	O

The	O
analysis	O
of	O
an	O
irreversible	O
lactone	O
inhibitor	O
validates	O
the	O
expected	O
relationship	O
between	O
potency	O
and	O
the	O
reaction	O
end	O
point	O
.	O

An	O
orthogonal	B-P
liquid	I-P
chromatography-mass	I-P
spectrometry	I-P
assay	I-P
has	O
also	O
been	O
implemented	O
for	O
the	O
confirmation	O
of	O
hits	O
from	O
the	O
antibody-based	B-P
assays	I-P
.	O

Leveraging	O
sequence	O
-based	O
faecal	O
microbial	O
community	O
survey	O
data	O
to	O
identify	O
a	O
composite	O
biomarker	O
for	O
colorectal	O
cancer	O
.	O

Colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
the	O
second	O
leading	O
cause	O
of	O
cancer-associated	O
mortality	O
in	O
the	O
USA	O
.	O

The	O
faecal	O
microbiome	O
may	O
provide	O
non-invasive	O
biomarkers	O
of	O
CRC	O
and	O
indicate	O
transition	O
in	O
the	O
adenoma-carcinoma	O
sequence	O
.	O

Re-analysing	O
raw	O
sequence	O
and	O
metadata	O
from	O
several	O
studies	B-P
uniformly	O
,	O
we	O
sought	O
to	O
identify	O
a	O
composite	O
and	O
generalisable	O
microbial	O
marker	O
for	O
CRC	O
.	O

Raw	O
16S	O
rRNA	O
gene	O
sequence	O
data	O
sets	O
from	O
nine	O
studies	B-P
were	O
processed	O
with	O
two	O
pipelines	O
,	O
(	O
1	O
)	O
QIIME	O
closed	O
reference	O
(	O
QIIME-CR	O
)	O
or	O
(	O
2	O
)	O
a	O
strain-specific	O
method	O
herein	O
termed	O
SS-UP	O
(	O
Strain	O
Select	O
,	O
UPARSE	O
bioinformatics	O
pipeline	O
)	O
.	O

A	O
total	O
of	O
509	O
samples	O
(	O
79	O
colorectal	O
adenoma	O
,	O
195	O
CRC	O
and	O
235	O
controls	O
)	O
were	O
analysed	O
.	O

Differential	O
abundance	O
,	O
meta-analysis	O
random	O
effects	O
regression	O
and	O
machine	O
learning	O
analyses	O
were	O
carried	O
out	O
to	O
determine	O
the	O
consistency	O
and	O
diagnostic	O
capabilities	O
of	O
potential	O
microbial	O
biomarkers	O
.	O

Definitive	O
taxa	O
,	O
including	O
Parvimonas	O
micra	O
ATCC	O
33270	O
,	O
Streptococcus	O
anginosus	O
and	O
yet-to-be-cultured	O
members	O
of	O
Proteobacteria	O
,	O
were	O
frequently	O
and	O
significantly	O
increased	O
in	O
stools	O
from	O
patients	O
with	O
CRC	O
compared	O
with	O
controls	O
across	O
studies	O
and	O
had	O
high	O
discriminatory	O
capacity	O
in	O
diagnostic	O
classification	O
.	O

Microbiome	O
-based	O
CRC	O
versus	O
control	O
classification	O
produced	O
an	O
area	O
under	O
receiver	O
operator	O
characteristic	O
(	O
AUROC	O
)	O
curve	O
of	O
76.6	O
%	O
in	O
QIIME-CR	O
and	O
80.3	O
%	O
in	O
SS-UP	O
.	O

Combining	O
clinical	O
and	O
microbiome	O
markers	O
gave	O
a	O
diagnostic	O
AUROC	O
of	O
83.3	O
%	O
for	O
QIIME-CR	O
and	O
91.3	O
%	O
for	O
SS-UP	O
.	O

Despite	O
technological	O
differences	O
across	O
studies	O
and	O
methods	O
,	O
key	O
microbial	O
markers	O
emerged	O
as	O
important	O
in	O
classifying	O
CRC	O
cases	O
and	O
such	O
could	O
be	O
used	O
in	O
a	O
universal	O
diagnostic	O
for	O
the	O
disease	O
.	O

The	O
choice	O
of	O
bioinformatics	O
pipeline	O
influenced	O
accuracy	O
of	O
classification	O
.	O

Strain	O
-	O
resolved	O
microbial	O
markers	O
might	O
prove	O
crucial	O
in	O
providing	O
a	O
microbial	O
diagnostic	O
for	O
CRC	O
.	O

Evaluation	O
of	O
DNMT1	O
gene	O
expression	O
profile	O
and	O
methylation	O
of	O
its	O
promoter	O
region	O
in	O
patients	O
with	O
ankylosing	O
spondylitis	O
.	O

Ankylosing	O
spondylitis	O
(	O
AS	O
)	O
is	O
an	O
autoimmune	O
disease	O
with	O
a	O
chronic	O
inflammatory	O
arthritis	O
.	O

The	O
critical	O
role	O
of	O
methylation	O
in	O
the	O
biology	O
of	O
immunocytes	O
has	O
increasingly	O
been	O
surveyed	O
to	O
discover	O
disease	O
etiology	O
.	O

DNA	O
methyltransferase	O
1	O
(	O
DNMT1	O
)	O
is	O
an	O
enzyme	O
,	O
which	O
establishes	O
and	O
regulates	O
patterns	O
of	O
methylated	O
cytosine	O
residues	O
.	O

The	O
aim	O
of	O
the	O
current	O
investigation	O
was	O
to	O
unveil	O
if	O
methylation	O
circumstances	O
of	O
CpG	O
sites	O
in	O
DNMT1	O
promoter	O
could	O
affect	O
the	O
mRNA	O
expression	O
level	O
of	O
this	O
gene	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
from	O
AS	O
patients	O
.	O

PBMCs	O
were	O
isolated	O
from	O
whole	O
blood	O
of	O
40	O
AS	O
patients	O
and	O
40	O
healthy	O
individuals	O
.	O

Total	O
RNA	O
and	O
DNA	O
contents	O
of	O
leukocytes	O
were	O
extracted	O
.	O

Afterward	O
,	O
quantitative	O
analysis	O
was	O
carried	O
out	O
by	O
real-time	O
PCR	O
using	O
the	O
SYBR	O
Green	O
PCR	O
Master	O
Mix	O
.	O

Finally	O
,	O
to	O
determine	O
the	O
methylation	O
level	O
,	O
PCR	O
products	O
of	O
bisulfite-treated	O
DNA	O
from	O
patients	O
and	O
controls	O
were	O
sequenced	B-P
.	O

Compared	O
with	O
healthy	O
controls	O
,	O
expression	O
level	O
of	O
DNMT1	O
in	O
AS	O
patients	O
was	O
significantly	O
downregulated	O
.	O

Methylation	O
of	O
DNMT1	O
promoter	O
was	O
significantly	O
higher	O
in	O
AS	O
patients	O
in	O
comparison	O
to	O
controls	O
.	O

While	O
a	O
negative	O
correlation	O
between	O
methylation	O
and	O
expression	O
level	O
of	O
DNMT1	O
was	O
observed	O
in	O
AS	O
patients	O
,	O
both	O
methylation	O
and	O
expression	O
level	O
of	O
DNMT1	O
did	O
not	O
correlate	O
with	O
clinical	O
manifestations	O
.	O

Considering	O
the	O
observation	O
that	O
decreased	O
expression	O
level	O
of	O
DNMT1	O
was	O
associated	O
with	O
hypermethylation	O
of	O
DNMT1	O
promoter	O
in	O
PBMCs	O
from	O
AS	O
patients	O
,	O
this	O
survey	O
suggests	O
that	O
dysregulation	O
of	O
DNMT1	O
expression	O
through	O
altered	O
methylation	O
level	O
of	O
other	O
target	O
genes	O
would	O
probably	O
contribute	O
to	O
AS	O
development	O
.	O

Incidence	O
of	O
Complex	O
Regional	O
Pain	O
Syndrome	O
I	O
Following	O
Foot	O
and	O
Ankle	O
Fractures	O
Using	O
the	O
Budapest	O
Criteria	O
.	O

OBJECTIVE	O
:	O
Fractures	O
are	O
a	O
well-recognized	O
inciting	O
event	O
in	O
the	O
development	O
of	O
complex	O
regional	O
pain	O
syndrome	O
.	O

This	O
study	O
aimed	O
to	O
prospectively	O
determine	O
the	O
incidence	O
of	O
complex	O
regional	O
pain	O
syndrome	O
following	O
foot	O
and	O
ankle	O
fractures	O
.	O

METHODS	O
:	O
A	O
prospective	O
study	O
was	O
conducted	O
of	O
patients	O
presenting	O
to	O
two	O
metropolitan	O
hospitals	O
with	O
plain	B-P
radiograph	I-P
diagnosis	O
of	O
fractures	O
to	O
the	O
foot	O
or	O
ankle	O
.	O

Patients	O
were	O
initially	O
screened	O
by	O
phone	O
3	O
months	O
after	O
injury	O
using	O
the	O
validated	O
International	O
Association	O
for	O
the	O
Study	O
of	O
Pain	O
Budapest	O
criteria	O
.	O

Patients	O
who	O
fulfilled	O
the	O
screening	O
criteria	O
were	O
then	O
physically	O
examined	O
by	O
a	O
pain	O
specialist	O
to	O
assess	O
clinical	O
signs	O
as	O
part	O
of	O
the	O
Budapest	O
criteria	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
306	O
consecutive	O
eligible	O
patients	O
were	O
included	O
.	O

One	O
hundred	O
and	O
ten	O
patients	O
reported	O
at	O
least	O
one	O
symptom	O
of	O
complex	O
regional	O
pain	O
syndrome	O
;	O
however	O
,	O
only	O
three	O
fulfilled	O
the	O
minimum	O
requirements	O
to	O
necessitate	O
clinical	O
review	O
.	O

Of	O
these	O
three	O
,	O
only	O
one	O
patient	O
fulfilled	O
the	O
combination	O
of	O
symptom	O
and	O
sign	O
criteria	O
for	O
a	O
positive	O
diagnosis	O
according	O
to	O
the	O
validated	O
Budapest	O
criteria	O
.	O

The	O
incidence	O
of	O
complex	O
regional	O
pain	O
syndrome	O
following	O
foot	O
and	O
ankle	O
fracture	O
in	O
this	O
study	O
was	O
0.3	O
%	O
.	O

CONCLUSION	O
:	O
Although	O
many	O
patients	O
may	O
experience	O
vasomotor	O
,	O
sensory	O
,	O
and	O
sudomotor	O
disturbance	O
following	O
a	O
fracture	O
to	O
the	O
foot	O
and	O
ankle	O
,	O
the	O
observed	O
incidence	O
of	O
complex	O
regional	O
pain	O
syndrome	O
using	O
a	O
prospectively	O
collected	O
validated	O
criteria	O
is	O
significantly	O
lower	O
than	O
previously	O
published	O
.	O

Visualization	B-P
for	O
Understanding	O
Uncertainty	O
in	O
Activation	O
Volumes	O
for	O
Deep	O
Brain	O
Stimulation	O
.	O

We	O
have	O
created	O
the	O
Neurostimulation	O
Uncertainty	O
Viewer	O
(	O
nuView	O
or	O
νView	O
)	O
tool	O
for	O
exploring	O
data	O
arising	O
from	O
deep	O
brain	O
stimulation	O
(	O
DBS	O
)	O
.	O

Simulated	O
volume	O
of	O
tissue	O
activated	O
(	O
VTA	O
)	O
,	O
using	O
clinical	B-P
electrode	I-P
placements	I-P
,	O
are	O
recorded	O
along	O
with	O
patient	O
outcomes	O
in	O
the	O
Unified	O
Parkinson	O
's	O
disease	O
rating	O
scale	O
(	O
UPDRS	O
)	O
.	O

The	O
data	O
is	O
volumetric	O
and	O
sparse	O
,	O
with	O
multi-value	O
patient	O
results	O
for	O
each	O
activated	O
voxel	O
in	O
the	O
simulation	O
.	O

νView	O
provides	O
a	O
collection	O
of	O
visual	O
methods	O
to	O
explore	O
the	O
activated	O
tissue	O
to	O
enhance	O
understanding	O
of	O
electrode	O
usage	O
for	O
improved	O
therapy	O
with	O
DBS	O
.	O

Subsolid	O
pulmonary	O
nodule	O
morphology	O
and	O
associated	O
patient	O
characteristics	O
in	O
a	O
routine	O
clinical	O
population	O
.	O

To	O
determine	O
the	O
presence	O
and	O
morphology	O
of	O
subsolid	O
pulmonary	O
nodules	O
(	O
SSNs	O
)	O
in	O
a	O
non-screening	O
setting	O
and	O
relate	O
them	O
to	O
clinical	O
and	O
patient	O
characteristics	O
.	O

A	O
total	O
of	O
16,890	O
reports	O
of	O
clinically	O
obtained	O
chest	B-P
CT	I-P
(	O
06/2011	O
to	O
11/2014	O
,	O
single-centre	O
)	O
were	O
searched	O
describing	O
an	O
SSN	O
.	O

Subjects	O
with	O
a	O
visually	O
confirmed	O
SSN	O
and	O
at	O
least	O
two	O
thin-slice	B-P
CTs	I-P
were	O
included	O
.	O

Nodule	O
volumes	O
were	O
measured	O
.	O

Progression	O
was	O
defined	O
as	O
volume	O
increase	O
exceeding	O
the	O
software	B-P
interscan	I-P
variation	O
.	O

Nodule	O
morphology	O
,	O
location	O
,	O
and	O
patient	O
characteristics	O
were	O
evaluated	O
.	O

Fifteen	O
transient	O
and	O
74	O
persistent	O
SSNs	O
were	O
included	O
(	O
median	O
follow-up	O
19.6	O
[	O
8.3-36.8	O
]	O
months	O
)	O
.	O

Subjects	O
with	O
an	O
SSN	O
were	O
slightly	O
older	O
than	O
those	O
without	O
(	O
62	O
vs.	O
58	O
years	O
;	O
p	O
=	O
0.01	O
)	O
,	O
but	O
no	O
gender	O
predilection	O
was	O
found	O
.	O

SSNs	O
were	O
mostly	O
located	O
in	O
the	O
upper	O
lobes	O
.	O

Women	O
showed	O
significantly	O
more	O
often	O
persistent	O
lesions	O
than	O
men	O
(	O
94	O
%	O
vs.	O
69	O
%	O
;	O
p	O
=	O
0.002	O
)	O
.	O

Part-solid	O
lesions	O
were	O
larger	O
(	O
1638	O
vs.	O
383	O
mm	O
(	O
3	O
)	O
;	O
p	O
<	O
0.001	O
)	O
and	O
more	O
often	O
progressive	O
(	O
68	O
%	O
vs.	O
38	O
%	O
;	O
p	O
=	O
0.02	O
)	O
,	O
compared	O
to	O
pure	O
ground-glass	O
nodules	O
.	O

Progressive	O
SSNs	O
were	O
rare	O
under	O
the	O
age	O
of	O
50	O
years	O
.	O

Logistic	O
regression	O
analysis	O
did	O
not	O
identify	O
additional	O
nodule	O
parameters	O
of	O
future	O
progression	O
,	O
apart	O
from	O
part-solid	O
nature	O
.	O

This	O
study	O
confirms	O
previously	O
reported	O
characteristics	O
of	O
SSNs	O
and	O
associated	O
factors	O
in	O
a	O
European	O
,	O
routine	O
clinical	O
population	O
.	O

•	O
SSNs	O
in	O
women	O
are	O
significantly	O
more	O
often	O
persistent	O
compared	O
to	O
men	O
.	O

•	O
SSN	O
persistence	O
is	O
not	O
associated	O
with	O
age	O
or	O
prior	O
malignancy	O
.	O

•	O
The	O
majority	O
of	O
(	O
persistent	O
)	O
SSNs	O
are	O
located	O
in	O
the	O
upper	O
lung	O
lobes	O
.	O

•	O
A	O
part-solid	O
nature	O
is	O
associated	O
with	O
future	O
nodule	O
growth	O
.	O

•	O
Progressive	O
solitary	O
SSNs	O
are	O
rare	O
under	O
the	O
age	O
of	O
50	O
years	O
.	O

Relationship	O
between	O
Occupational	O
Stress	O
,	O
5-HT2A	O
Receptor	O
Polymorphisms	O
and	O
Mental	O
Health	O
in	O
Petroleum	O
Workers	O
in	O
the	O
Xinjiang	O
Arid	O
Desert	O
:	O
A	O
Cross-Sectional	O
Study	O
.	O

At	O
present	O
,	O
there	O
is	O
growing	O
interest	O
in	O
research	O
examining	O
the	O
relationship	O
between	O
occupational	O
stress	O
and	O
mental	O
health	O
.	O

Owing	O
to	O
the	O
socioeconomic	O
impact	O
of	O
occupational	O
stress	O
and	O
the	O
unique	O
environment	O
of	O
petroleum	O
workers	O
in	O
Xinjiang	O
,	O
a	O
cross-sectional	O
study	O
was	O
carried	O
out	O
between	O
April	O
and	O
December	O
2015	O
to	O
investigate	O
the	O
relationship	O
between	O
occupational	O
stress	O
,	O
5-hydroxytryptamine	O
receptor	O
(	O
5-HTR2A	O
)	O
genotype	O
,	O
and	O
mental	O
health	O
.	O

A	O
total	O
of	O
1485	O
workers	O
were	O
selected	O
.	O

The	O
Symptom	O
Checklist	O
90	O
was	O
used	O
to	O
assess	O
nine	O
classes	O
of	O
psychological	O
symptoms	O
.	O

Work-related	O
stressors	O
were	O
evaluated	O
using	O
the	O
Occupational	O
Stress	O
Inventory-Revised	O
Edition	O
.	O

Levels	O
of	O
5-HTR2A	O
(	O
the	O
Tl02C	O
and	O
A-1438G	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
5-HTR2A	O
gene	O
)	O
were	O
measured	O
by	O
polymerase	O
chain	O
reaction	O
and	O
restriction	B-P
fragment	I-P
length	I-P
polymorphism	I-P
(	O
PCR	O
-	O
RFLP	B-P
)	O
.	O

The	O
findings	O
of	O
the	O
present	O
study	O
revealed	O
a	O
high	O
prevalence	O
rate	O
of	O
mental	O
health	O
problems	O
(	O
40.29	O
%	O
)	O
in	O
petroleum	O
workers	O
stationed	O
in	O
the	O
arid	O
desert	O
,	O
and	O
suggested	O
a	O
strong	O
correlation	O
between	O
occupational	O
stress	O
and	O
mental	O
health	O
.	O

The	O
TC	O
and	O
CC	O
genotype	O
of	O
Tl02C	O
were	O
found	O
to	O
be	O
protective	O
factors	O
against	O
mental	O
health	O
problems	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0.455	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
=	O
0.269-0.771	O
,	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0.340	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.162-0.716	O
)	O
.	O

AG	O
and	O
GG	O
genotype	O
of	O
A-1438G	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
1	O
=	O
2.729	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.433-5.195	O
;	O
odds	O
ratio	O
(	O
OR	O
)	O
2	O
=	O
2.480	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.221-5.037	O
]	O
were	O
revealed	O
as	O
risk	O
factors	O
.	O

These	O
data	O
provide	O
evidence	O
that	O
occupational	O
stress	O
and	O
5-HTR2A	O
gene	O
polymorphism	O
contributes	O
to	O
the	O
incidence	O
of	O
mental	O
health	O
problems	O
.	O

Gene	O
Expression	O
Profile	O
in	O
the	O
Liver	O
of	O
Sheep	O
Infected	O
with	O
Cystic	O
Echinococcosis	O
.	O

Cystic	O
Echinococcosis	O
(	O
CE	O
)	O
,	O
caused	O
by	O
infection	O
with	O
the	O
Echinococcus	O
granulosus	O
(	O
E.	O
granulosus	O
)	O
,	O
represents	O
considerable	O
health	O
problems	O
in	O
both	O
humans	O
and	O
livestock	O
.	O

Nevertheless	O
,	O
the	O
genetic	O
program	O
that	O
regulates	O
the	O
host	O
response	O
to	O
E.	O
granulosus	O
infection	O
is	O
largely	O
unknown	O
.	O

Previously	O
,	O
using	O
microarray	B-P
analysis	I-P
,	O
we	O
found	O
that	O
the	O
innate	O
immunity	O
played	O
a	O
vital	O
role	O
in	O
the	O
E.	O
granulosus	O
defense	O
of	O
the	O
intestine	O
tissue	O
where	O
E.	O
granulosus	O
first	O
invaded	O
.	O

Subsequently	O
,	O
we	O
turned	O
our	O
attention	O
to	O
investigating	O
the	O
molecular	O
immune	O
mechanism	O
in	O
its	O
organ	O
target	O
,	O
the	O
liver	O
,	O
which	O
is	O
where	O
the	O
E.	O
granulosus	O
metacestodes	O
are	O
established	O
and	O
live	O
for	O
very	O
long	O
periods	O
.	O

In	O
this	O
work	O
,	O
the	O
microarray-based	B-P
methodology	I-P
was	O
used	O
to	O
study	O
gene	O
expression	O
profiles	O
in	O
the	O
liver	O
of	O
sheep	O
infected	O
with	O
E.	O
granulosus	O
at	O
8	O
weeks	O
post	O
infection	O
,	O
corresponding	O
to	O
the	O
early	O
cystic	O
established	O
phase	O
.	O

A	O
total	O
of	O
6	O
female	O
-1-	O
year	O
-old	O
healthy	O
Kazakh	O
sheep	O
were	O
used	O
for	O
the	O
experiments	O
.	O

Three	O
Kazakh	O
sheep	O
were	O
orally	O
infected	O
with	O
E.	O
granulosus	O
eggs	O
,	O
and	O
the	O
others	O
remained	O
untreated	O
and	O
served	O
as	O
controls	O
.	O

Sheep	O
were	O
humanely	O
euthanized	O
and	O
necropsized	B-P
at	O
8	O
weeks	O
post	O
-	O
infection	O
(	O
the	O
early	O
stage	O
of	O
cyst	O
established	O
)	O
.	O

The	O
microarray	B-P
was	O
used	O
to	O
detect	O
differential	O
hepatic	O
gene	O
expression	O
between	O
CE	O
infection	O
sheep	O
and	O
healthy	O
controls	O
at	O
this	O
time	O
point	O
.	O

Real-time	O
PCR	O
was	O
used	O
to	O
validate	O
the	O
microarray	B-P
data	O
.	O

We	O
found	O
that	O
E.	O
granulosus	O
infection	O
induces	O
153	O
differentially	O
expressed	O
genes	O
in	O
the	O
livers	O
of	O
infected	O
sheep	O
compared	O
with	O
healthy	O
controls	O
.	O

Among	O
them	O
,	O
87	O
genes	O
were	O
up-regulated	O
,	O
and	O
66	O
genes	O
were	O
notably	O
down-regulated	O
.	O

Functional	O
analysis	O
showed	O
that	O
these	O
genes	O
were	O
associated	O
with	O
three	O
major	O
functional	O
categories	O
:	O
(	O
a	O
)	O
metabolism	O
,	O
(	O
b	O
)	O
the	O
immune	O
system	O
and	O
(	O
c	O
)	O
signaling	O
and	O
transport	O
.	O

Deeper	O
analysis	O
indicated	O
that	O
complement	O
together	O
with	O
other	O
genes	O
associated	O
with	O
metabolism	O
,	O
played	O
important	O
roles	O
in	O
the	O
defense	O
of	O
E.	O
granulosus	O
infection	O
.	O

The	O
present	O
study	O
identified	O
genes	O
profiling	O
in	O
the	O
liver	O
tissue	O
of	O
E.	O
granulosus	O
infection	O
in	O
sheep	O
.	O

The	O
expression	O
pattern	O
obtained	O
here	O
could	O
be	O
helpful	O
for	O
understanding	O
the	O
molecular	O
immunity	O
mechanisms	O
of	O
host	O
responses	O
to	O
E.	O
granulosus	O
infection	O
.	O

However	O
,	O
it	O
is	O
necessary	O
to	O
carry	O
out	O
further	O
studies	O
to	O
evalute	O
the	O
role	O
of	O
these	O
genes	O
.	O

Nonamplification	O
ERBB2	O
genomic	O
alterations	O
in	O
5605	O
cases	O
of	O
recurrent	O
and	O
metastatic	O
breast	O
cancer	O
:	O
An	O
emerging	O
opportunity	O
for	O
anti-HER2	O
targeted	O
therapies	O
.	O

Activating	O
,	O
nonamplification	O
ERBB2	O
mutations	O
(	O
ERBB2mut	O
)	O
are	O
not	O
detected	O
by	O
immunohistochemistry	B-P
(	O
IHC	B-P
)	O
or	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
,	O
but	O
are	O
detected	O
by	O
DNA	B-P
sequencing	I-P
and	O
may	O
predict	O
clinical	O
responses	O
to	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
HER2	O
)	O
-	O
targeted	O
therapy	O
.	O

The	O
authors	O
queried	O
5605	O
advanced/metastatic	O
breast	O
cancers	O
(	O
mBC	O
)	O
to	O
uncover	O
the	O
frequency	O
of	O
ERBB2mut	O
genomic	O
alterations	O
.	O

Clinical	O
responses	O
to	O
anti-HER2	O
therapeutics	O
were	O
identified	O
.	O

DNA	O
was	O
extracted	O
from	O
40	O
µm	O
of	O
formalin-fixed	O
paraffin-embedded	O
(	O
FFPE	O
)	O
sections	O
.	O

Comprehensive	B-P
genomic	I-P
profiling	I-P
(	O
CGP	B-P
)	O
was	O
used	O
to	O
evaluate	O
up	O
to	O
315	O
genes	O
(	O
592×	O
mean	O
coverage	O
depth	O
)	O
.	O

Results	O
were	O
analyzed	O
for	O
base	O
substitutions	O
,	O
short	O
indels	O
,	O
copy	O
number	O
changes	O
,	O
and	O
selected	O
rearrangements	O
.	O

Of	O
5605	O
cases	O
,	O
698	O
(	O
12.5	O
%	O
)	O
featured	O
ERBB2	O
alterations	O
,	O
including	O
596	O
(	O
10.6	O
%	O
)	O
ERBB2	O
amplifications	O
(	O
ERBB2amp	O
)	O
and	O
138	O
(	O
2.4	O
%	O
)	O
ERBB2mut	O
;	O
38	O
cases	O
(	O
0.7	O
%	O
)	O
had	O
co-occurring	O
ERBB2amp	O
and	O
ERBB2mut	O
.	O

ERBB2mut	O
predominantly	O
affected	O
the	O
kinase	O
(	O
124	O
cases	O
;	O
90	O
%	O
)	O
or	O
extracellular	O
(	O
15	O
cases	O
;	O
11	O
%	O
)	O
domains	O
.	O

Both	O
primary	O
BC	O
(	O
52	O
cases	O
;	O
38	O
%	O
)	O
and	O
metastatic	O
site	O
biopsies	B-P
(	O
86	O
cases	O
;	O
62	O
%	O
)	O
were	O
found	O
to	O
harbor	O
ERBB2mut	O
,	O
which	O
were	O
distributed	O
across	O
carcinoma	O
not	O
otherwise	O
specified	O
(	O
NOS	O
)	O
(	O
69	O
cases	O
;	O
50	O
%	O
)	O
,	O
invasive	O
ductal	O
carcinoma	O
(	O
IDC	O
)	O
(	O
40	O
cases	O
;	O
29	O
%	O
)	O
,	O
invasive	O
lobular	O
carcinoma	O
(	O
ILC	O
)	O
(	O
27	O
cases	O
;	O
20	O
%	O
)	O
,	O
and	O
mucinous	O
mBC	O
(	O
2	O
cases	O
;	O
1	O
%	O
)	O
.	O

Genes	O
commonly	O
coaltered	O
with	O
ERBB2	O
were	O
tumor	O
protein	O
53	O
(	O
TP53	O
)	O
(	O
49	O
%	O
)	O
;	O
phosphatidylinositol	O
3-kinase	O
catalytic	O
subunit	O
alpha	O
(	O
PIK3CA	O
)	O
(	O
42	O
%	O
)	O
;	O
cadherin	O
1	O
,	O
type	O
1	O
(	O
CDH1	O
)	O
(	O
37	O
%	O
)	O
;	O
MYC	O
(	O
17	O
%	O
)	O
;	O
and	O
cyclin	O
D1	O
protein	O
(	O
CCND1	O
)	O
(	O
16	O
%	O
)	O
.	O

CDH1	O
mutations	O
were	O
enriched	O
in	O
ERBB2mut	O
mBC	O
(	O
P	O
<	O
0.0006	O
)	O
and	O
associated	O
with	O
recurrent	O
mBC	O
.	O

Selected	O
patients	O
with	O
ERBB2mut	O
,	O
without	O
ERBB2amp	O
,	O
who	O
responded	O
to	O
anti-HER2	O
targeted	O
therapies	O
are	O
presented	O
herein	O
.	O

Within	O
this	O
large	O
series	O
,	O
1.8	O
%	O
of	O
cases	O
harbored	O
ERBB2mut	O
,	O
which	O
are	O
undetectable	O
by	O
standard-of-care	O
IHC	B-P
or	O
FISH	O
tests	O
.	O

Metastatic	O
BC	O
driven	O
by	O
ERBB2mut	O
respond	O
to	O
anti-HER2	O
targeted	O
therapies	O
,	O
and	O
expanding	O
clinical	O
trials	O
designed	O
to	O
detect	O
ERBB2mut	O
by	O
CGP	B-P
and	O
optimize	O
targeted	O
treatments	O
are	O
warranted	O
.	O

Cancer	O
2016	O
.	O

©	O
2016	O
American	O
Cancer	O
Society	O
.	O

Cancer	O
2016	O
;	O
122:2654-2662	O
.	O

©	O
2016	O
American	O
Cancer	O
Society	O
.	O

The	O
nitroxyl	O
donor	O
Angeli	O
's	O
salt	O
ameliorates	O
Staphylococcus	O
aureus	O
-induced	O
septic	O
arthritis	O
in	O
mice	O
.	O

Septic	O
arthritis	O
is	O
a	O
severe	O
and	O
rapidly	O
debilitating	O
disease	O
associated	O
with	O
severe	O
joint	O
pain	O
,	O
inflammation	O
and	O
oxidative	O
stress	O
.	O

Nitroxyl	O
(	O
HNO	O
)	O
has	O
become	O
a	O
nitrogen	O
oxide	O
of	O
significant	O
interest	O
due	O
to	O
its	O
pharmacological	O
endpoints	O
that	O
are	O
potentially	O
favorable	O
for	O
treating	O
varied	O
diseases	O
.	O

However	O
,	O
whether	O
HNO	O
also	O
serves	O
as	O
a	O
treatment	O
to	O
septic	O
arthritis	O
is	O
currently	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
HNO	O
donor	O
,	O
Angeli	O
's	O
salt	O
(	O
AS	O
)	O
,	O
in	O
the	O
outcome	O
of	O
chronic	O
Staphylococcus	O
aureus	O
(	O
S.	O
aureus	O
)	O
-induced	O
septic	O
arthritis	O
in	O
mice	O
.	O

Daily	O
treatment	O
with	O
AS	O
inhibited	O
mechanical	O
hyperalgesia	O
and	O
inflammation	O
(	O
edema	O
,	O
leukocyte	O
migration	O
,	O
cytokines	O
release	O
and	O
NF-κB	O
activation	O
,	O
and	O
oxidative	O
stress	O
)	O
resulting	O
in	O
reduced	O
disease	O
severity	O
(	O
clinical	O
course	O
,	O
histopathological	O
changes	O
,	O
proteoglycan	O
levels	O
in	O
the	O
joints	O
,	O
and	O
osteoclastogenesis	O
)	O
.	O

In	O
addition	O
,	O
AS	O
decreased	O
the	O
number	O
of	O
S.	O
aureus	O
colony	O
forming	O
unities	O
in	O
synovial	O
tissue	O
,	O
enhanced	O
the	O
bactericidal	O
effect	O
of	O
macrophages	O
and	O
inhibited	O
the	O
worsening	O
of	O
systemic	O
inflammatory	O
response	O
(	O
leukocyte	B-P
counts	I-P
in	O
the	O
lung	O
and	O
systemic	O
proinflammatory	O
cytokine	O
concentration	O
)	O
.	O

Our	O
results	O
suggest	O
for	O
the	O
first	O
time	O
the	O
therapeutic	O
potential	O
of	O
AS	O
in	O
a	O
model	O
of	O
septic	O
arthritis	O
by	O
mechanisms	O
involving	O
microbicidal	O
effects	O
,	O
anti-inflammatory	O
actions	O
and	O
reduction	O
of	O
disease	O
severity	O
.	O

An	O
Analysis	O
of	O
Systematic	O
Elemental	O
Changes	O
in	O
Decomposing	O
Bone	O
.	O

The	O
aim	O
of	O
this	O
pilot	O
study	O
was	O
to	O
investigate	O
compositional	O
changes	O
in	O
bone	O
during	O
decomposition	O
.	O

Elemental	O
concentrations	O
of	O
barium	O
,	O
calcium	O
,	O
iron	O
,	O
potassium	O
,	O
magnesium	O
,	O
zinc	O
and	O
phosphorus	O
in	O
porcine	O
bone	O
(	O
as	O
an	O
experimental	O
analog	O
for	O
human	O
bone	O
)	O
were	O
analyzed	O
by	O
inductively	B-P
coupled	I-P
plasma	I-P
optical	I-P
emission	I-P
spectroscopy	I-P
(	O
ICP-OES	B-P
)	O
.	O

The	O
samples	O
were	O
taken	O
from	O
porcine	O
bone	O
subjected	O
to	O
shallow	O
burial	O
and	O
surface	O
depositions	O
at	O
28-	O
day	O
intervals	O
for	O
a	O
period	O
of	O
140	O
days	O
.	O

Results	O
indicated	O
that	O
ICP-OES	B-P
elemental	O
profiling	O
has	O
potential	O
to	O
be	O
developed	O
as	O
a	O
forensic	B-P
test	I-P
for	O
determining	O
whether	O
a	O
bone	O
sample	O
originates	O
from	O
the	O
early	O
stages	O
of	O
soft	O
tissue	O
putrefaction	O
.	O

Significant	O
changes	O
in	O
iron	O
,	O
sodium	O
and	O
potassium	O
concentrations	O
were	O
found	O
over	O
140	O
days	O
.	O

These	O
elements	O
are	O
known	O
to	O
be	O
primarily	O
associated	O
with	O
proteins	O
and/or	O
tissue	O
fluids	O
within	O
the	O
bone	O
.	O

Changes	O
in	O
their	O
respective	O
concentrations	O
may	O
therefore	O
be	O
linked	O
to	O
dehydration	O
over	O
time	O
and	O
in	O
turn	O
may	O
be	O
indicative	O
of	O
time	O
since	O
deposition	O
.	O

Whole-body	O
strength	O
training	O
with	O
Huber	O
Motion	O
Lab	O
and	O
traditional	O
strength	O
training	O
in	O
cardiac	O
rehabilitation	O
:	O
A	O
randomized	O
controlled	O
study	O
.	O

Isometric	O
strengthening	O
has	O
been	O
rarely	O
studied	O
in	O
patients	O
with	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
,	O
mainly	O
because	O
of	O
possible	O
potential	O
side	O
effects	O
and	O
lack	O
of	O
appropriate	O
and	O
reliable	O
devices	O
.	O

We	O
aimed	O
to	O
compare	O
2	O
different	O
modes	O
of	O
resistance	O
training	O
,	O
an	O
isometric	O
mode	O
with	O
the	O
Huber	O
Motion	O
Lab	O
(	O
HML	O
)	O
and	O
traditional	O
strength	O
training	O
(	O
TST	O
)	O
,	O
in	O
CHD	O
patients	O
undergoing	O
a	O
cardiac	O
rehabilitation	O
program	O
.	O

We	O
randomly	O
assigned	O
50	O
patients	O
to	O
HML	O
or	O
TST	O
.	O

Patients	O
underwent	O
complete	O
blinded	O
evaluation	O
before	O
and	O
after	O
the	O
rehabilitation	O
program	O
,	O
including	O
testing	B-P
for	I-P
cardiopulmonary	I-P
exercise	I-P
,	O
maximal	B-P
isometric	I-P
voluntary	I-P
contraction	I-P
,	O
endothelial	O
function	O
and	O
body	O
composition	O
.	O

After	O
4	O
weeks	O
of	O
training	O
(	O
16	O
sessions	O
)	O
,	O
the	O
groups	O
did	O
not	O
differ	O
in	O
body	O
composition	O
,	O
anthropometric	O
characteristics	O
,	O
or	O
endothelial	O
function	O
.	O

With	O
HML	O
,	O
peak	O
power	O
output	O
(	O
P=0.035	O
)	O
,	O
maximal	O
heart	O
rate	O
(	O
P	O
<	O
0.01	O
)	O
and	O
gain	O
of	O
force	O
measured	O
in	O
the	O
chest	O
press	O
position	O
(	O
P	O
<	O
0.02	O
)	O
were	O
greater	O
after	O
versus	O
before	O
training	O
.	O

Both	O
protocols	O
appeared	O
to	O
be	O
well	O
tolerated	O
,	O
safe	O
and	O
feasible	O
for	O
these	O
CHD	O
patients	O
.	O

A	O
training	O
protocol	O
involving	O
6s	O
phases	O
of	O
isometric	O
contractions	O
with	O
10s	O
of	O
passive	O
recovery	O
on	O
an	O
HML	O
device	O
could	O
be	O
safely	O
implemented	O
in	O
rehabilitation	O
programs	O
for	O
patients	O
with	O
CHD	O
and	O
improve	O
functional	O
outcomes	O
.	O

Ultrasonic	B-P
computed	I-P
tomography	I-P
imaging	I-P
of	O
iron	O
oxide	O
nanoparticles	O
.	O

Iron	O
oxide	O
nanoparticles	O
(	O
IONPs	O
)	O
are	O
becoming	O
increasingly	O
used	O
and	O
intensively	O
investigated	O
in	O
the	O
field	O
of	O
medical	B-P
imaging	I-P
.	O

They	O
are	O
currently	O
FDA	O
approved	O
for	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
,	O
and	O
it	O
would	O
be	O
highly	O
desirable	O
to	O
visualize	O
them	O
by	O
ultrasound	O
as	O
well	O
.	O

Previous	O
reports	O
using	O
the	O
conventional	O
ultrasound	B-P
B-scan	I-P
(	I-P
pulse-echo	I-P
)	I-P
imaging	I-P
technique	I-P
have	O
shown	O
very	O
limited	O
detectability	O
of	O
these	O
particles	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
explore	O
the	O
feasibility	O
of	O
imaging	B-P
IONPs	O
using	O
the	O
through-transmission	O
ultrasound	O
methodology	O
and	O
demonstrate	O
their	O
detectability	O
using	O
ultrasonic	B-P
computed	I-P
tomography	I-P
(	O
UCT	B-P
)	O
.	O

Commercially	O
available	O
IONPs	O
were	O
acoustically	O
analysed	O
to	O
quantify	O
their	O
effect	O
on	O
the	O
speed	O
of	O
sound	O
(	O
SOS	O
)	O
and	O
acoustic	O
attenuation	O
as	O
a	O
function	O
of	O
concentration	O
.	O

Next	O
,	O
through-transmission	B-P
projection	I-P
and	O
UCT	B-P
imaging	I-P
were	O
performed	O
on	O
a	O
breast	O
mimicking	O
phantom	O
and	O
on	O
an	O
ex	O
vivo	O
tissue	O
model	O
,	O
to	O
which	O
IONPs	O
were	O
injected	O
.	O

Finally	O
,	O
an	O
MRI	B-P
scan	I-P
was	O
performed	O
to	O
verify	O
that	O
the	O
same	O
particles	O
examined	O
in	O
the	O
ultrasound	O
experiment	O
can	O
be	O
imaged	O
by	O
magnetic	O
resonance	O
,	O
using	O
the	O
same	O
clinically	O
relevant	O
concentrations	O
.	O

The	O
results	O
have	O
shown	O
a	O
consistent	O
concentration	O
dependent	O
speed	O
of	O
sound	O
increase	O
(	O
1.86	O
[	O
Formula	O
:	O
see	O
text	O
]	O
rise	O
per	O
100	O
µg	O
·	O
ml	O
(	O
-1	O
)	O
IONPs	O
)	O
.	O

Imaging	B-P
based	O
on	O
this	O
property	O
has	O
shown	O
a	O
substantial	O
contrast-to-noise	O
ratio	O
improvement	O
(	O
up	O
to	O
5	O
fold	O
,	O
p	O
<	O
0.01	O
)	O
.	O

The	O
SOS	O
-related	O
effect	O
generated	O
a	O
well	O
discernible	O
image	O
contrast	O
and	O
allowed	O
the	O
detection	O
of	O
the	O
particles	O
existence	O
and	O
location	O
,	O
in	O
both	O
raster-scan	B-P
projection	I-P
and	O
UCT	B-P
imaging	I-P
.	O

Conversely	O
,	O
no	O
significant	O
change	O
in	O
the	O
acoustic	O
attenuation	O
coefficient	O
was	O
noted	O
.	O

Based	O
on	O
these	O
findings	O
,	O
it	O
is	O
concluded	O
that	O
IONPs	O
can	O
be	O
used	O
as	O
an	O
effective	O
SOS	O
-	O
based	O
contrast	O
agent	O
,	O
potentially	O
useful	O
for	O
ultrasonic	O
breast	O
imaging	B-P
.	O

Furthermore	O
,	O
the	O
particle	O
offers	O
the	O
capacity	O
of	O
significantly	O
enhancing	O
diagnosis	O
accuracy	O
using	O
multimodal	B-P
MRI	B-P
-	O
ultrasound	B-P
imaging	I-P
capabilities	O
.	O

An	O
electrochemical	B-P
genosensor	O
for	O
Leishmania	O
major	O
detection	O
based	O
on	O
dual	O
effect	O
of	O
immobilization	B-P
and	O
electrocatalysis	O
of	O
cobalt-zinc	O
ferrite	O
quantum	O
dots	O
.	O

Identification	O
of	O
Leishmania	O
parasites	O
is	O
important	O
in	O
diagnosis	O
and	O
clinical	O
studies	O
of	O
leishmaniasis	O
.	O

Although	O
epidemiological	O
and	O
clinical	O
methods	O
are	O
available	O
,	O
they	O
are	O
not	O
sufficient	O
for	O
identification	O
of	O
causative	O
agents	O
of	O
leishmaniasis	O
.	O

In	O
the	O
present	O
study	O
,	O
quantum	O
dots	O
of	O
magnetic	O
cobalt-zinc	O
ferrite	O
(	O
Co0.5Zn0.5Fe2O4	O
)	O
were	O
synthesized	O
and	O
characterized	O
by	O
physicochemical	O
methods	O
.	O

The	O
quantum	O
dots	O
were	O
then	O
employed	O
as	O
an	O
electrode	O
modifier	O
to	O
immobilize	O
a	O
24-mer	O
specific	O
single	O
stranded	O
DNA	O
probe	O
,	O
and	O
fabrication	O
of	O
a	O
label-free	O
,	O
PCR-free	O
and	O
signal-on	O
electrochemical	B-P
genosensor	O
for	O
the	O
detection	O
of	O
Leishmania	O
major	O
.	O

Hybridization	O
of	O
the	O
complementary	O
single	O
stranded	O
DNA	O
sequence	O
with	O
the	O
probe	O
under	O
the	O
selected	O
conditions	O
was	O
explored	O
using	O
methylene	O
blue	O
as	O
a	O
redox	O
marker	O
,	O
utilizing	O
the	O
electrocatalytic	O
effect	O
of	O
the	O
quantum	O
dots	O
on	O
the	O
methylene	O
blue	O
electroreduction	O
process	O
.	O

The	O
genosensor	O
could	O
detect	O
a	O
synthetic	O
single	O
stranded	O
DNA	O
target	O
in	O
a	O
range	O
of	O
1.0×10	O
(	O
-11	O
)	O
to	O
1.0×10	O
(	O
-18	O
)	O
molL	O
(	O
-1	O
)	O
with	O
a	O
limit	O
of	O
detection	O
of	O
2.0×10	O
(	O
-19	O
)	O
molL	O
(	O
-1	O
)	O
,	O
and	O
genomic	O
DNA	O
in	O
a	O
range	O
of	O
7.31×10	O
(	O
-14	O
)	O
to	O
7.31×10	O
(	O
-6	O
)	O
ngμL	O
(	O
-1	O
)	O
with	O
a	O
limit	O
of	O
detection	O
of	O
1.80×10	O
(	O
-14	O
)	O
ngμL	O
(	O
-1	O
)	O
with	O
a	O
high	O
selectivity	O
and	O
sensitivity	O
.	O

Zinc	O
transporter	O
ZIP10	O
forms	O
a	O
heteromer	O
with	O
ZIP6	O
which	O
regulates	O
embryonic	O
development	O
and	O
cell	O
migration	O
.	O

There	O
is	O
growing	O
evidence	O
that	O
zinc	O
and	O
its	O
transporters	O
are	O
involved	O
in	O
cell	O
migration	O
during	O
development	O
and	O
in	O
cancer	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
zinc	O
transporter	O
ZIP10	O
(	O
SLC39A10	O
)	O
stimulates	O
cell	O
motility	O
and	O
proliferation	O
,	O
both	O
in	O
mammalian	O
cells	O
and	O
in	O
the	O
zebrafish	O
embryo	O
.	O

This	O
is	O
associated	O
with	O
inactivation	O
of	O
GSK-3α	O
and	O
-3ß	O
and	O
downregulation	O
of	O
E-cadherin	O
(	O
CDH1	O
)	O
.	O

Morpholino	O
-mediated	O
knock-down	O
of	O
zip10	O
causes	O
delayed	O
epiboly	O
and	O
deformities	O
of	O
the	O
head	O
,	O
eye	O
,	O
heart	O
and	O
tail	O
.	O

Furthermore	O
,	O
zip10	O
deficiency	O
results	O
in	O
overexpression	O
of	O
cdh1	O
,	O
zip6	O
and	O
stat3	O
,	O
the	O
latter	O
gene	O
product	O
driving	O
transcription	O
of	O
both	O
zip6	O
and	O
zip10	O
The	O
non-reduntant	O
requirement	O
of	O
Zip6	O
and	O
Zip10	O
for	O
epithelial	O
to	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
is	O
consistent	O
with	O
our	O
finding	O
that	O
they	O
exist	O
as	O
a	O
heteromer	O
.	O

We	O
postulate	O
that	O
a	O
subset	O
of	O
ZIPs	O
carrying	O
PrP-like	O
ectodomains	O
,	O
including	O
ZIP6	O
and	O
ZIP10	O
,	O
are	O
integral	O
to	O
cellular	B-P
pathways	O
and	O
plasticity	O
programs	O
,	O
such	O
as	O
EMT	O
.	O

Partial	O
tetrasomy	O
11q	O
resulting	O
from	O
an	O
intrachromosomal	O
triplication	O
of	O
a	O
22	O
Mb	O
region	O
of	O
chromosome	O
11	O
.	O

Intrachromosomal	O
triplications	O
are	O
complex	O
chromosomal	O
rearrangements	O
which	O
arise	O
during	O
meiosis	O
or	O
mitosis	O
and	O
lead	O
to	O
a	O
tetrasomic	O
dose	O
of	O
the	O
affected	O
genomic	O
regions	O
.	O

We	O
describe	O
a	O
female	O
patient	O
harboring	O
an	O
intrachromosomal	O
triplication	O
who	O
presented	O
to	O
the	O
Genetics	O
clinic	O
with	O
dysmorphic	O
features	O
,	O
including	O
telecanthus	O
,	O
flat	O
facial	O
profile	O
,	O
and	O
prognathism	O
,	O
short	O
stature	O
,	O
widely	O
spaced	O
nipples	O
,	O
multiple	O
allergy	O
complaints	O
,	O
loose	O
bowel	O
movements	O
,	O
and	O
mild	O
speech	O
delay	O
.	O

Microarray	B-P
analysis	I-P
showed	O
a	O
copy	O
number	O
gain	O
of	O
a	O
22.37	O
Mb	O
region	O
of	O
chromosome	O
11	O
between	O
bands	O
11q14.1	O
and	O
11q22.1	O
.	O

This	O
region	O
contains	O
95	O
genes	O
and	O
seven	O
microRNAs	O
,	O
none	O
of	O
which	O
have	O
been	O
implicated	O
in	O
a	O
disease	O
resulting	O
from	O
increased	O
gene	O
dosage	O
.	O

FISH	B-P
analysis	I-P
using	O
a	O
probe	O
targeted	O
to	O
the	O
middle	O
of	O
the	O
segment	O
of	O
the	O
copy	O
number	O
gain	O
yielded	O
a	O
pattern	O
indicative	O
of	O
a	O
tetrasomy	O
via	O
an	O
intrachromosomal	O
triplication	O
,	O
with	O
three	O
signals	O
on	O
the	O
long	O
arm	O
of	O
one	O
homologue	O
of	O
chromosome	O
11	O
and	O
the	O
fourth	O
on	O
the	O
other	O
homologue	O
.	O

Subsequent	O
FISH	B-P
analysis	I-P
showed	O
that	O
the	O
middle	O
triplicated	O
fragment	O
was	O
positioned	O
in	O
an	O
inverted	O
orientation	O
relative	O
to	O
the	O
outer	O
fragments	O
.	O

To	O
investigate	O
the	O
mechanism	O
by	O
which	O
the	O
intrachromosomal	O
triplication	O
occurred	O
,	O
SNP	B-P
microarray	I-P
analysis	I-P
was	O
performed	O
.	O

These	O
results	O
were	O
consistent	O
with	O
the	O
presence	O
of	O
multiple	O
haplotypes	O
in	O
the	O
tetrasomic	O
region	O
and	O
suggest	O
that	O
the	O
intrachromosomal	O
triplication	O
in	O
our	O
patient	O
arose	O
in	O
one	O
parent	O
during	O
meiosis	O
.	O

©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Investigation	O
of	O
the	O
mycobacterial	O
enzyme	O
HsaD	O
as	O
a	O
potential	O
novel	O
target	O
for	O
anti-tubercular	O
agents	O
using	O
a	O
fragment	O
-based	O
drug	O
design	O
approach	O
.	O

With	O
the	O
emergence	O
of	O
extensively	O
drug-resistant	O
tuberculosis	O
,	O
there	O
is	O
a	O
need	O
for	O
new	O
anti-tubercular	O
drugs	O
that	O
work	O
through	O
novel	O
mechanisms	O
of	O
action	O
.	O

The	O
meta	O
cleavage	O
product	O
hydrolase	O
,	O
HsaD	O
,	O
has	O
been	O
demonstrated	O
to	O
be	O
critical	O
for	O
the	O
survival	O
of	O
Mycobacterium	O
tuberculosis	O
in	O
macrophages	O
and	O
is	O
encoded	O
in	O
an	O
operon	O
involved	O
in	O
cholesterol	O
catabolism	O
,	O
which	O
is	O
identical	O
in	O
M.	O
tuberculosis	O
and	O
M.	O
bovis	O
BCG	O
.	O

We	O
generated	O
a	O
mutant	O
strain	O
of	O
M.	O
bovis	O
BCG	O
with	O
a	O
deletion	O
of	O
hsaD	O
and	O
tested	O
its	O
growth	O
on	O
cholesterol	O
.	O

Using	O
a	O
fragment	O
based	O
approach	O
,	O
over	O
1000	O
compounds	O
were	O
screened	B-P
by	O
a	O
combination	O
of	O
differential	B-P
scanning	I-P
fluorimetry	I-P
,	O
NMR	B-P
spectroscopy	I-P
and	O
enzymatic	B-P
assay	I-P
with	O
pure	O
recombinant	O
HsaD	O
to	O
identify	O
potential	O
inhibitors	O
.	O

We	O
used	O
enzymological	O
and	O
structural	O
studies	O
to	O
investigate	O
derivatives	O
of	O
the	O
inhibitors	O
identified	O
and	O
to	O
test	O
their	O
effects	O
on	O
growth	O
of	O
M.	O
bovis	O
BCG	O
and	O
M.	O
tuberculosis	O
.	O

The	O
hsaD	O
deleted	O
strain	O
was	O
unable	O
to	O
grow	O
on	O
cholesterol	O
as	O
sole	O
carbon	O
source	O
but	O
did	O
grow	O
on	O
glucose	O
.	O

Of	O
seven	O
chemically	O
distinct	O
'hits	O
'	O
from	O
the	O
library	O
,	O
two	O
chemical	O
classes	O
of	O
fragments	O
were	O
found	O
to	O
bind	O
in	O
the	O
vicinity	O
of	O
the	O
active	O
site	O
of	O
HsaD	O
by	O
X-ray	B-P
crystallography	I-P
.	O

The	O
compounds	O
also	O
inhibited	O
growth	O
of	O
M.	O
tuberculosis	O
on	O
cholesterol	O
.	O

The	O
most	O
potent	O
inhibitor	O
of	O
HsaD	O
was	O
also	O
found	O
to	O
be	O
the	O
best	O
inhibitor	O
of	O
mycobacterial	O
growth	O
on	O
cholesterol	O
-supplemented	O
minimal	O
medium	O
.	O

We	O
propose	O
that	O
HsaD	O
is	O
a	O
novel	O
therapeutic	O
target	O
,	O
which	O
should	O
be	O
fully	O
exploited	O
in	O
order	O
to	O
design	O
and	O
discover	O
new	O
anti-tubercular	O
drugs	O
.	O

A	O
new	O
approach	O
to	O
nasomaxillary	O
complex	O
type	O
of	O
nasal	O
bone	O
fracture	O
:	O
Clip	O
operation	O
.	O

Nasal	O
bone	O
fractures	O
comprise	O
almost	O
40	O
%	O
of	O
all	O
facial	O
injuries	O
.	O

Most	O
are	O
initially	O
reduced	O
using	O
closed	O
reduction	O
.	O

This	O
study	O
introduces	O
a	O
newly	O
developed	O
method	O
,	O
the	O
clip	O
operation	O
via	O
endonasal	O
approach	O
.	O

The	O
operation	O
was	O
performed	O
in	O
these	O
patients	O
by	O
a	O
single	O
surgeon	O
extensively	O
experienced	O
in	O
facial	O
bone	O
fractures	O
.	O

An	O
absorbable	O
mesh	O
plate	O
made	O
into	O
a	O
clip	O
was	O
used	O
for	O
fixation	O
after	O
open	O
reduction	O
via	O
the	O
endonasal	O
approach	O
.	O

No	O
screws	O
were	O
used	O
for	O
fixation	O
.	O

Nasal	O
packing	O
was	O
removed	O
the	O
first	O
day	O
after	O
surgery	O
;	O
aluminum	O
splinting	O
was	O
removed	O
the	O
third	O
week	O
after	O
surgery	O
.	O

Three-dimensional	O
facial	B-P
computed	I-P
tomography	I-P
and	O
cephalolateral	B-P
radiography	I-P
were	O
performed	O
preoperatively	O
and	O
postoperatively	O
.	O

Plastic	O
surgeon	O
satisfaction	O
and	O
postoperative	O
complications	O
were	O
assessed	O
.	O

Fracture	O
relapse	O
was	O
not	O
observed	O
.	O

Reduction	O
status	O
was	O
well	O
maintained	O
.	O

Postoperative	O
complications	O
occurred	O
,	O
with	O
a	O
low	O
final	O
incidence	O
of	O
1.8	O
%	O
in	O
the	O
third	O
postoperative	O
month	O
.	O

Plastic	O
surgeon	O
satisfaction	O
was	O
very	O
high	O
at	O
4.58	O
.	O

This	O
operation	O
takes	O
5-10	O
min	O
,	O
and	O
is	O
simple	O
to	O
perform	O
.	O

It	O
entails	O
a	O
short	O
hospitalization	O
,	O
and	O
the	O
duration	O
during	O
which	O
nasal	O
packing	O
and	O
aluminum	O
splint	O
are	O
maintained	O
is	O
comparable	O
.	O

Undesirable	O
functional	O
,	O
aesthetic	O
complications	O
and	O
secondary	O
surgery	O
resulting	O
from	O
inaccurate	O
relapse	O
were	O
reduced	O
.	O

The	O
clip	O
operation	O
is	O
a	O
useful	O
technique	O
for	O
correcting	O
nasal	O
bone	O
fractures	O
,	O
especially	O
nasomaxillary	O
complex	O
type	O
.	O

Frequency	O
distribution	O
of	O
interleukin-10	O
haplotypes	O
(	O
-1082	O
A	O
>	O
G	O
,	O
-819	O
C	O
>	O
T	O
,	O
and	O
-592	O
C	O
>	O
A	O
)	O
in	O
a	O
Mexican	O
population	O
.	O

Interleukin	O
10	O
(	O
IL-10	O
)	O
is	O
an	O
immunoregulatory	O
cytokine	O
with	O
multiple	O
roles	O
in	O
the	O
immune	O
system	O
.	O

Three	O
single	O
nucleotide	O
polymorphisms	O
at	O
positions	O
-1082	O
(	O
A	O
>	O
G	O
)	O
,	O
-819	O
(	O
C	O
>	O
T	O
)	O
,	O
and	O
-592	O
(	O
C	O
>	O
A	O
)	O
in	O
the	O
promoter	O
region	O
of	O
the	O
IL10	O
gene	O
are	O
believed	O
to	O
be	O
associated	O
with	O
different	O
inflammatory	O
,	O
infectious	O
,	O
and	O
autoimmune	O
diseases	O
.	O

These	O
polymorphisms	O
exhibit	O
a	O
strong	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
and	O
form	O
three	O
principal	O
haplotypes	O
(	O
GCC	O
,	O
ACC	O
,	O
and	O
ATA	O
)	O
.	O

The	O
GCC	O
and	O
ATA	O
haplotypes	O
have	O
been	O
associated	O
with	O
high	O
and	O
low	O
levels	O
of	O
IL-10	O
production	O
,	O
respectively	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
establish	O
the	O
allele	O
and	O
haplotype	O
frequencies	O
of	O
the	O
IL10	O
polymorphisms	O
in	O
Mestizos	O
from	O
western	O
Mexico	O
.	O

SNPs	O
were	O
analyzed	O
in	O
340	O
healthy	O
unrelated	O
Mestizos	O
from	O
western	O
Mexico	O
by	O
polymerase	O
chain	O
reaction	O
-	O
restriction	B-P
fragment	I-P
length	I-P
polymorphism	I-P
.	O

The	O
studied	O
population	O
presented	O
significant	O
differences	O
,	O
in	O
the	O
distribution	O
of	O
IL10	O
polymorphisms	O
,	O
from	O
the	O
Asian	O
,	O
African	O
,	O
and	O
European	O
populations	O
.	O

We	O
also	O
observed	O
a	O
strong	O
LD	O
within	O
-1082	O
A	O
>	O
G	O
,	O
-819	O
C	O
>	O
T	O
,	O
and	O
-592	O
C	O
>	O
A	O
(	O
100	O
%	O
pc	O
=	O
7.735	O
x	O
10	O
(	O
-18	O
)	O
)	O
.	O

The	O
haplotypes	O
ACC	O
(	O
45.4	O
%	O
)	O
,	O
ATA	O
(	O
22.0	O
%	O
)	O
,	O
GTA	O
(	O
14.9	O
%	O
)	O
,	O
and	O
GCC	O
(	O
13.9	O
%	O
)	O
were	O
most	O
frequently	O
observed	O
in	O
this	O
population	O
.	O

The	O
haplotype	O
frequencies	O
,	O
however	O
,	O
differed	O
from	O
those	O
reported	O
previously	O
in	O
Mestizos	O
from	O
central	O
Mexico	O
,	O
Asians	O
,	O
Africans	O
,	O
and	O
European	O
Caucasians	O
,	O
suggesting	O
a	O
differential	O
gene	O
flow	O
in	O
the	O
Mexican	O
Mestizo	O
population	O
.	O

This	O
could	O
account	O
for	O
the	O
genetic	O
variability	O
between	O
Mexicans	O
and	O
populations	O
of	O
other	O
ethnicities	O
.	O

The	O
study	O
of	O
these	O
polymorphisms	O
and	O
their	O
haplotypes	O
could	O
help	O
in	O
expanding	O
our	O
knowledge	O
to	O
design	O
future	O
disease	O
-	O
risk	O
studies	O
on	O
the	O
western	O
Mexican	O
population	O
.	O

Multilocus	O
sequence	O
typing	O
analyses	O
of	O
Clostridium	O
perfringens	O
type	O
A	O
strains	O
harboring	O
tpeL	O
and	O
netB	O
genes	O
.	O

Clostridium	O
perfringens	O
is	O
an	O
anaerobic	O
bacterium	O
ubiquitous	O
in	O
various	O
environments	O
,	O
especially	O
in	O
soil	O
and	O
the	O
gastrointestinal	O
tract	O
of	O
healthy	O
humans	O
and	O
animals	O
.	O

In	O
this	O
study	O
,	O
multilocus	O
sequence	O
typing	O
protocol	O
was	O
used	O
to	O
investigate	O
genotypic	O
relationships	O
among	O
40	O
C.	O
perfringens	O
strains	O
isolated	O
from	O
humans	O
and	O
broiler	O
chicken	O
with	O
necrotic	O
enteritis	O
[	O
NE	O
]	O
.	O

The	O
results	O
indicated	O
a	O
few	O
clonal	O
populations	O
,	O
mainly	O
observed	O
in	O
human	O
strains	O
,	O
with	O
32.5	O
%	O
of	O
all	O
strains	O
associated	O
with	O
one	O
of	O
three	O
clonal	O
complexes	O
and	O
30	O
sequences	O
types	O
.	O

The	O
CC-1	O
cluster	O
showed	O
an	O
interesting	O
and	O
unexpected	O
result	O
because	O
it	O
contained	O
seven	O
strains	O
[	O
six	O
from	O
animals	O
and	O
one	O
of	O
human	O
origin	O
]	O
.	O

Detection	O
assays	B-P
for	O
toxin	O
genes	O
tpeL	O
and	O
netB	O
were	O
also	O
performed	O
.	O

The	O
netB	O
gene	O
was	O
only	O
observed	O
in	O
7.5	O
%	O
of	O
the	O
strains	O
from	O
healthy	O
human	O
.	O

The	O
toxin	O
gene	O
tpeL	O
was	O
detected	O
in	O
22.5	O
%	O
of	O
the	O
C.	O
perfringens	O
strains	O
isolated	O
from	O
three	O
individuals	O
and	O
in	O
six	O
broilers	O
with	O
NE	O
.	O

Our	O
study	O
describes	O
the	O
role	O
of	O
some	O
C.	O
perfringens	O
strains	O
of	O
human	O
origin	O
acting	O
as	O
reservoirs	O
of	O
virulence	O
genes	O
and	O
sources	O
of	O
infection	O
.	O

In	O
addition	O
,	O
the	O
strains	O
of	O
human	O
and	O
animal	O
origin	O
were	O
found	O
to	O
be	O
genetically	O
distinct	O
but	O
phylogenetically	O
close	O
,	O
and	O
the	O
human	O
strains	O
showed	O
more	O
diversity	O
than	O
the	O
animal	O
strains	O
.	O

Effect	O
of	O
Core	O
Stability	O
Training	O
on	O
Trunk	O
Function	O
,	O
Standing	O
Balance	O
,	O
and	O
Mobility	O
in	O
Stroke	O
Patients	O
.	O

Trunk	O
function	O
is	O
important	O
for	O
standing	O
balance	O
,	O
mobility	O
,	O
and	O
functional	O
outcome	O
after	O
stroke	O
,	O
but	O
few	O
studies	O
have	O
evaluated	O
the	O
effects	O
of	O
exercises	O
aimed	O
at	O
improving	O
core	O
stability	O
in	O
stroke	O
patients	O
.	O

To	O
investigate	O
the	O
effectiveness	O
of	O
core	O
stability	O
training	O
on	O
trunk	O
function	O
,	O
standing	O
balance	O
,	O
and	O
mobility	O
in	O
stroke	O
patients	O
.	O

An	O
assessor-blinded	O
,	O
randomized	O
controlled	O
trial	O
was	O
undertaken	O
in	O
a	O
stroke	O
rehabilitation	O
ward	O
,	O
with	O
32	O
participants	O
randomly	O
assigned	O
to	O
an	O
experimental	O
group	O
or	O
a	O
control	O
group	O
(	O
n	O
=	O
16	O
each	O
)	O
.	O

The	O
experimental	O
group	O
received	O
400	O
minutes	O
of	O
core	O
stability	O
training	O
in	O
place	O
of	O
conventional	O
programs	O
within	O
total	O
training	O
time	O
,	O
while	O
the	O
control	O
group	O
received	O
only	O
conventional	O
programs	O
.	O

Primary	O
outcome	O
measures	O
were	O
evaluated	O
using	O
the	O
Trunk	O
Impairment	O
Scale	O
(	O
TIS	O
)	O
,	O
which	O
reflects	O
trunk	O
function	O
.	O

Secondary	O
outcome	O
measures	O
were	O
evaluated	O
by	O
pelvic	O
tilt	O
active	O
range	O
of	O
motion	O
in	O
the	O
sagittal	O
plane	O
,	O
the	O
Balance	O
Evaluation	O
Systems	O
Test-brief	O
version	O
(	O
Brief-BESTest	O
)	O
,	O
Functional	B-P
Reach	I-P
test	I-P
,	O
Timed	B-P
Up-and-Go	I-P
test	I-P
(	O
TUG	B-P
)	O
,	O
and	O
Functional	O
Ambulation	O
Categories	O
(	O
FAC	O
)	O
.	O

A	O
general	O
linear	O
repeated-measures	O
model	O
was	O
used	O
to	O
analyze	O
the	O
results	O
.	O

A	O
treatment	O
effect	O
was	O
found	O
for	O
the	O
experimental	O
group	O
on	O
the	O
dynamic	O
balance	O
subscale	O
and	O
total	O
score	O
of	O
the	O
TIS	O
(	O
P	O
=	O
.002	O
and	O
P	O
<	O
.001	O
,	O
respectively	O
)	O
,	O
pelvic	O
tilt	O
active	O
range	O
of	O
motion	O
(	O
P	O
<	O
.001	O
)	O
,	O
Brief-BESTest	O
(	O
P	O
<	O
.001	O
)	O
,	O
TUG	B-P
(	O
P	O
=	O
.008	O
)	O
,	O
and	O
FAC	O
(	O
P	O
=	O
.022	O
)	O
.	O

Core	O
stability	O
training	O
has	O
beneficial	O
effects	O
on	O
trunk	O
function	O
,	O
standing	O
balance	O
,	O
and	O
mobility	O
in	O
stroke	O
patients	O
.	O

Our	O
findings	O
might	O
provide	O
support	O
for	O
introducing	O
core	O
stability	O
training	O
in	O
stroke	O
rehabilitation	O
.	O

Impact	O
of	O
SPARC	O
expression	O
on	O
outcome	O
in	O
patients	O
with	O
advanced	O
pancreatic	O
cancer	O
not	O
receiving	O
nab-paclitaxel	O
:	O
a	O
pooled	O
analysis	O
from	O
prospective	O
clinical	O
and	O
translational	O
trials	O
.	O

Conflicting	O
results	O
on	O
the	O
role	O
of	O
secreted	O
protein	O
acidic	O
and	O
rich	O
in	O
cysteins	O
(	O
SPARC	O
)	O
expression	O
have	O
been	O
reported	O
in	O
resected	O
pancreatic	O
ductal	O
adenocarcinoma	O
(	O
PDAC	O
)	O
,	O
and	O
its	O
prognostic	O
and/or	O
predictive	O
role	O
in	O
advanced	O
PDAC	O
(	O
aPDAC	O
)	O
has	O
not	O
been	O
extensively	O
investigated	O
yet	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
SPARC	O
expression	O
as	O
a	O
biomarker	O
in	O
aPDAC	O
patients	O
(	O
pts	O
)	O
not	O
receiving	O
nab-paclitaxel	O
.	O

Using	O
immunohistochemistry	B-P
,	O
we	O
examined	O
the	O
stromal	O
as	O
well	O
as	O
the	O
tumoral	O
(	O
i.e.	O
,	O
cytoplasmic	O
)	O
SPARC	O
expression	O
in	O
tumour	O
tissue	O
(	O
primary	O
tumours	O
and	O
metastases	O
)	O
of	O
134	O
aPDAC	O
pts	O
participating	O
in	O
completed	O
prospective	O
clinical	O
and	O
biomarker	O
trials	O
.	O

The	O
SPARC	O
expression	O
levels	O
were	O
correlated	O
to	O
the	O
pts	O
'	O
clinicopathological	O
parameters	O
and	O
survival	O
times	O
.	O

Sixty-seven	O
per	O
cent	O
of	O
the	O
analysed	O
tumours	O
showed	O
high	O
stromal	O
SPARC	O
expression	O
,	O
which	O
was	O
not	O
associated	O
with	O
overall	O
survival	O
(	O
OS	O
,	O
median	O
9.1	O
vs	O
7.6	O
months	O
,	O
P=0.316	O
)	O
.	O

A	O
positive	O
cytoplasmic	O
SPARC	O
expression	O
was	O
detected	O
in	O
55	O
%	O
of	O
the	O
tumours	O
and	O
correlated	O
significantly	O
with	O
inferior	O
progression-free	O
survival	O
(	O
PFS	O
,	O
6.2	O
vs	O
8.6	O
months	O
,	O
P=0.004	O
)	O
and	O
OS	O
(	O
7.8	O
vs	O
8.4	O
months	O
,	O
P=0.032	O
)	O
.	O

This	O
association	O
was	O
strongest	O
for	O
pts	O
,	O
where	O
primary	O
tumour	O
tissue	O
was	O
examined	O
(	O
PFS	O
:	O
6.7	O
vs	O
10.8	O
months	O
,	O
P=0.004	O
;	O
OS	O
:	O
7.9	O
vs	O
11.9	O
months	O
,	O
P=0.030	O
)	O
,	O
whereas	O
no	O
significant	O
correlation	O
was	O
detected	O
for	O
pts	O
,	O
where	O
only	O
metastatic	O
tissue	O
was	O
available	O
(	O
PFS	O
:	O
5.8	O
vs	O
6.6	O
months	O
,	O
P=0.502	O
;	O
OS	O
:	O
7.0	O
vs	O
7.8	O
months	O
,	O
P=0.452	O
)	O
.	O

In	O
pts	O
receiving	O
gemcitabine	O
-based	O
chemotherapy	O
cytoplasmic	O
SPARC	O
expression	O
was	O
significantly	O
associated	O
with	O
an	O
inferior	O
PFS	O
and	O
OS	O
(	O
PFS	O
:	O
6.2	O
vs	O
9.2	O
months	O
,	O
P=0.002	O
;	O
OS	O
7.3	O
vs	O
9.9	O
months	O
,	O
P=0.012	O
)	O
,	O
whereas	O
no	O
such	O
association	O
was	O
detected	O
for	O
stromal	O
SPARC	O
expression	O
or	O
for	O
pts	O
receiving	O
fluoropyrimidine	O
-based	O
chemotherapy	O
.	O

We	O
identified	O
cytoplasmic	O
SPARC	O
expression	O
in	O
the	O
primary	O
tumour	O
as	O
a	O
biomarker	O
associated	O
with	O
inferior	O
PFS	O
and	O
OS	O
in	O
aPDAC	O
.	O

Cytoplasmic	O
SPARC	O
expression	O
may	O
furthermore	O
act	O
as	O
a	O
negative	O
predictive	O
biomarker	O
in	O
pts	O
treated	O
with	O
gemcitabine	O
-based	O
chemotherapy	O
.	O

IGF2BP3	O
functions	O
as	O
a	O
potential	O
oncogene	O
and	O
is	O
a	O
crucial	O
target	O
of	O
miR-34a	O
in	O
gastric	O
carcinogenesis	O
.	O

Gastric	O
cancer	O
(	O
GC	O
)	O
is	O
one	O
of	O
the	O
frequent	O
causes	O
of	O
cancer	O
-related	O
death	O
in	O
eastern	O
Asian	O
population	O
.	O

IGF2BP2	O
lists	O
in	O
the	O
top	O
rank	O
up-regulated	O
genes	O
in	O
GC	O
,	O
but	O
its	O
functional	O
role	O
is	O
unclear	O
.	O

The	O
expression	O
of	O
IGF2BP3	O
in	O
GC	O
cell	O
lines	O
and	O
primary	O
samples	O
was	O
examined	O
by	O
qRT-PCR	O
and	O
Western	B-P
blot	I-P
.	O

The	O
biological	O
role	O
of	O
IGF2BP3	O
was	O
revealed	O
by	O
a	O
series	O
of	O
functional	O
in	O
vitro	O
studies	O
.	O

Its	O
regulation	O
by	O
microRNAs	O
(	O
miRNAs	O
)	O
was	O
predicted	O
by	O
TargetScan	B-P
and	O
confirmed	O
by	O
luciferase	O
assays	O
and	O
rescue	O
experiments	O
.	O

IGF2BP3	O
ranked	O
the	O
No.1	O
of	O
the	O
up-regulated	O
genes	O
by	O
expression	O
microarray	B-P
analysis	I-P
in	O
GC	O
cell	O
line	O
s.	O
The	O
expression	O
level	O
of	O
IGF2BP3	O
was	O
observed	O
in	O
GC	O
tissues	O
comparing	O
with	O
non-tumorous	O
gastric	O
epitheliums	O
.	O

The	O
up-regulated	O
IGF2BP3	O
expression	O
was	O
associated	O
with	O
poor	O
disease	O
specific	O
survival	O
.	O

IGF2BP3	O
knockdown	O
significantly	O
inhibited	O
cell	O
proliferation	O
and	O
invasion	O
.	O

Apart	O
from	O
copy	O
number	O
gain	O
,	O
IGF2BP3	O
has	O
been	O
confirmed	O
to	O
be	O
negatively	O
regulated	O
by	O
tumor-suppressive	O
miRNA	O
,	O
namely	O
miR-34a	O
.	O

The	O
expression	O
of	O
miR-34a	O
showed	O
negative	O
correlation	O
with	O
IGF2BP3	O
mRNA	O
expression	O
in	O
primary	O
GC	O
samples	O
and	O
more	O
importantly	O
,	O
re-overexpression	O
of	O
IGF2BP3	O
rescued	O
the	O
inhibitory	O
effect	O
of	O
miR-34a	O
.	O

We	O
compressively	O
revealed	O
the	O
oncogenic	O
role	O
of	O
IGF2BP3	O
in	O
gastric	O
tumorigenesis	O
and	O
confirmed	O
its	O
activation	O
is	O
partly	O
due	O
to	O
the	O
silence	O
of	O
miR-34a	O
.	O

Our	O
findings	O
identified	O
useful	O
prognostic	O
biomarker	O
and	O
provided	O
clinical	O
translational	O
potential	O
.	O

Optimized	O
creation	O
of	O
glioblastoma	O
patient	O
derived	O
xenografts	O
for	O
use	O
in	O
preclinical	O
studies	O
.	O

Glioblastoma	O
multiforme	O
(	O
GBM	O
)	O
is	O
the	O
most	O
common	O
and	O
lethal	O
brain	O
tumor	O
in	O
adults	O
,	O
highlighting	O
the	O
need	O
for	O
novel	O
treatment	O
strategies	O
.	O

Patient	O
derived	O
xenografts	O
(	O
PDX	O
)	O
represent	O
a	O
valuable	O
tool	O
to	O
accomplish	O
this	O
task	O
.	O

PDX	O
were	O
established	O
by	O
implanting	O
GBM	O
tissue	O
subcutaneously	O
.	O

Engraftment	O
success	O
was	O
compared	O
between	O
NMRI	O
Foxn1	O
(	O
nu	O
)	O
and	O
NOD	O
/	O
SCID	O
as	O
well	O
as	O
between	O
fresh	O
and	O
cryopreserved	B-P
tissue	O
.	O

Established	O
PDX	O
were	O
analyzed	O
histologically	O
and	O
molecularly	O
.	O

Five	O
PDX	O
were	O
experimentally	O
treated	O
with	O
different	O
drugs	O
to	O
assess	O
their	O
potential	O
for	O
preclinical	O
drug	O
testing	O
.	O

Establishment	O
of	O
PDX	O
was	O
attempted	O
for	O
36	O
consecutive	O
GBM	O
cases	O
with	O
an	O
overall	O
success	O
rate	O
of	O
22.2	O
%	O
in	O
NMRI	O
Foxn1	O
(	O
nu	O
)	O
mice	O
.	O

No	O
difference	O
was	O
observed	O
between	O
fresh	O
or	O
cryopreserved	B-P
(	O
20-1057	O
days	O
)	O
tissue	O
in	O
direct	O
comparison	O
(	O
n	O
=	O
10	O
cases	O
)	O
.	O

Additionally	O
,	O
engraftment	O
was	O
better	O
in	O
NOD	O
/	O
SCID	O
mice	O
(	O
38.8	O
%	O
)	O
directly	O
compared	O
to	O
NMRI	O
Foxn1	O
(	O
nu	O
)	O
mice	O
(	O
27.7	O
%	O
)	O
(	O
n	O
=	O
18	O
cases	O
)	O
.	O

Molecular	O
data	O
and	O
histology	O
of	O
the	O
PDX	O
compare	O
well	O
to	O
the	O
primary	O
GBM	O
.	O

The	O
experimental	O
treatment	O
revealed	O
individual	O
differences	O
in	O
the	O
sensitivity	O
towards	O
several	O
clinically	O
relevant	O
drugs	O
.	O

The	O
use	O
of	O
vitally	O
frozen	O
GBM	O
tissue	O
allows	O
a	O
more	O
convenient	O
workflow	O
without	O
efficiency	O
loss	O
.	O

NOD	O
/	O
SCID	O
mice	O
appear	O
to	O
be	O
better	O
suited	O
for	O
initial	O
engraftment	O
of	O
tumor	O
tissue	O
compared	O
to	O
NMRI	O
Foxn1	O
(	O
nu	O
)	O
mice	O
.	O

Application	O
of	O
single	B-P
-	O
and	O
dual-energy	B-P
CT	I-P
brain	O
tissue	O
segmentation	O
to	O
PET	B-P
monitoring	O
of	O
proton	O
therapy	O
.	O

The	O
purpose	O
of	O
this	O
work	O
was	O
to	O
evaluate	O
the	O
ability	O
of	O
single	B-P
and	O
dual	B-P
energy	I-P
computed	I-P
tomography	I-P
(	O
SECT	B-P
,	O
DECT	B-P
)	O
to	O
estimate	O
tissue	O
composition	O
and	O
density	O
for	O
usage	O
in	O
Monte	O
Carlo	O
(	O
MC	O
)	O
simulations	O
of	O
irradiation	O
induced	O
β	O
(	O
+	O
)	O
activity	O
distributions	O
.	O

This	O
was	O
done	O
to	O
assess	O
the	O
impact	O
on	O
positron	B-P
emission	I-P
tomography	I-P
(	O
PET	B-P
)	O
range	O
verification	O
in	O
proton	O
therapy	O
.	O

A	O
DECT-based	B-P
brain	O
tissue	O
segmentation	O
method	O
was	O
developed	O
for	O
white	O
matter	O
(	O
WM	O
)	O
,	O
grey	O
matter	O
(	O
GM	O
)	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O

The	O
elemental	O
composition	O
of	O
reference	O
tissues	O
was	O
assigned	O
to	O
closest	O
CT	O
numbers	O
in	O
DECT	B-P
space	O
(	O
DECTdist	O
)	O
.	O

The	O
method	O
was	O
also	O
applied	O
to	O
SECT	B-P
data	O
(	O
SECTdist	O
)	O
.	O

In	O
a	O
validation	O
experiment	O
,	O
the	O
proton	O
irradiation	O
induced	O
PET	B-P
activity	O
of	O
three	O
brain	O
equivalent	O
solutions	O
(	O
BES	O
)	O
was	O
compared	O
to	O
simulations	O
based	O
on	O
different	O
tissue	O
segmentations	O
.	O

Five	O
patients	O
scanned	B-P
with	O
a	O
dual	O
source	O
DECT	B-P
scanner	O
were	O
analyzed	O
to	O
compare	O
the	O
different	O
segmentation	O
methods	O
.	O

A	O
single	O
magnetic	O
resonance	O
(	O
MR	O
)	O
scan	O
was	O
used	O
for	O
comparison	O
with	O
an	O
established	O
segmentation	O
toolkit	O
.	O

Additionally	O
,	O
one	O
patient	O
with	O
SECT	B-P
and	O
post-treatment	O
PET	B-P
scans	I-P
was	O
investigated	O
.	O

For	O
BES	O
,	O
DECTdist	O
and	O
SECTdist	O
reduced	O
differences	O
to	O
the	O
reference	O
simulation	O
by	O
up	O
to	O
62	O
%	O
when	O
compared	O
to	O
the	O
conventional	O
stoichiometric	O
segmentation	O
(	O
SECTSchneider	O
)	O
.	O

In	O
comparison	O
to	O
MR	O
brain	O
segmentation	O
,	O
Dice	O
similarity	O
coefficients	O
for	O
WM	O
,	O
GM	O
and	O
CSF	O
were	O
0.61	O
,	O
0.67	O
and	O
0.66	O
for	O
DECTdist	O
and	O
0.54	O
,	O
0.41	O
and	O
0.66	O
for	O
SECTdist	O
.	O

MC	O
simulations	O
of	O
PET	B-P
treatment	O
verification	O
in	O
patients	O
showed	O
important	O
differences	O
between	O
DECTdist	O
/	O
SECTdist	O
and	O
SECTSchneider	O
for	O
patients	O
with	O
large	O
CSF	O
areas	O
within	O
the	O
treatment	O
field	O
but	O
not	O
in	O
WM	O
and	O
GM	O
.	O

Differences	O
could	O
be	O
misinterpreted	O
as	O
PET	B-P
derived	O
range	O
shifts	O
of	O
up	O
to	O
4	O
mm	O
.	O

DECTdist	O
and	O
SECTdist	O
yielded	O
comparable	O
activity	O
distributions	O
,	O
and	O
comparison	O
of	O
SECTdist	O
to	O
a	O
measured	O
patient	O
PET	B-P
scan	I-P
showed	O
improved	O
agreement	O
when	O
compared	O
to	O
SECTSchneider	O
.	O

The	O
agreement	O
between	O
predicted	O
and	O
measured	O
PET	B-P
activity	O
distributions	O
was	O
improved	O
by	O
employing	O
a	O
brain	O
specific	O
segmentation	O
applicable	O
to	O
both	O
DECT	B-P
and	O
SECT	B-P
data	O
.	O

Comparison	O
of	O
Head	O
Elevation	O
Protocols	O
Following	O
Femoral	O
Artery	O
Sheath	O
Removal	O
After	O
Coronary	B-P
Angiography	I-P
.	O

To	O
compare	O
2	O
standard	O
protocols	O
for	O
head	O
elevation	O
following	O
removal	O
of	O
a	O
femoral	O
artery	O
sheath	O
after	O
coronary	B-P
angiography	I-P
and	O
their	O
effects	O
on	O
bleeding	O
complications	O
and	O
reported	O
levels	O
of	O
back	O
pain	O
.	O

One	O
protocol	O
involved	O
flat	O
supine	O
bed	O
rest	O
;	O
the	O
other	O
allowed	O
progressive	O
head	O
elevation	O
.	O

A	O
prospective	O
comparative	O
study	O
of	O
80	O
adult	O
patients	O
undergoing	O
coronary	B-P
angiography	I-P
via	O
the	O
femoral	O
approach	O
.	O

The	O
Numeric	O
Rating	O
Scale	O
was	O
used	O
as	O
the	O
measure	O
of	O
reported	O
pain	O
.	O

No	O
bleeding	O
complications	O
occurred	O
in	O
either	O
group	O
.	O

Both	O
groups	O
had	O
very	O
low	O
mean	O
pain	O
scores	O
.	O

Repeated-	O
measures	O
analysis	O
demonstrated	O
that	O
the	O
experience	O
of	O
pain	O
differed	O
significantly	O
over	O
time	O
by	O
location	O
(	O
F5,70	O
=	O
3.864	O
,	O
P	O
=	O
.004	O
)	O
,	O
with	O
a	O
notable	O
decrease	O
in	O
pain	O
scores	O
more	O
than	O
1	O
hour	O
after	O
sheath	O
removal	O
at	O
the	O
location	O
that	O
used	O
the	O
progressive	O
head	O
elevation	O
protocol	O
.	O

Patients	O
'	O
satisfaction	O
scores	O
after	O
discharge	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
2	O
groups	O
.	O

Patients	O
with	O
a	O
history	O
of	O
chronic	O
back	O
pain	O
had	O
consistently	O
higher	O
pain	O
scores	O
,	O
but	O
those	O
pain	O
scores	O
did	O
not	O
differ	O
significantly	O
by	O
location	O
(	O
or	O
protocol	O
)	O
.	O

It	O
appears	O
that	O
using	O
a	O
progressive	O
head	O
-	O
elevation	O
protocol	O
within	O
the	O
first	O
3	O
hours	O
after	O
diagnostic	O
angiography	B-P
is	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
bleeding	O
complications	O
at	O
the	O
access	O
site	O
and	O
warrants	O
further	O
exploration	O
in	O
the	O
mitigation	O
of	O
back	O
pain	O
associated	O
with	O
prolonged	O
supine	O
bed	O
rest	O
.	O

Lettuce	O
and	O
fruits	O
as	O
a	O
source	O
of	O
multidrug	O
resistant	O
Acinetobacter	O
spp	O
.	O

The	O
role	O
of	O
ready-to-eat	O
products	O
as	O
a	O
reservoir	O
of	O
pathogenic	O
species	O
of	O
Acinetobacter	O
remains	O
unclear	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
presence	O
of	O
Acinetobacter	O
species	O
in	O
lettuces	O
and	O
fruits	O
marketed	O
in	O
Portugal	O
,	O
and	O
their	O
susceptibility	O
to	O
antimicrobials	O
.	O

Acinetobacter	O
spp	O
.	O

were	O
isolated	O
from	O
77.9	O
%	O
of	O
the	O
samples	O
and	O
these	O
microorganisms	O
were	O
also	O
found	O
as	O
endophytes	O
(	O
i.e	O
.	O

present	O
within	O
the	O
plant	O
tissue	O
)	O
in	O
12	O
of	O
20	O
samples	O
of	O
lettuces	O
analysed	O
.	O

Among	O
253	O
isolates	O
that	O
were	O
identified	O
as	O
belonging	O
to	O
this	O
genus	O
,	O
181	O
presented	O
different	O
PFGE	B-P
profiles	O
,	O
representing	O
different	O
strains	O
.	O

Based	O
on	O
the	O
analysis	O
of	O
the	O
partial	O
sequence	O
of	O
rpoB	O
,	O
175	O
strains	O
were	O
identified	O
as	O
members	O
of	O
eighteen	O
distinct	O
species	O
and	O
the	O
remaining	O
six	O
strains	O
may	O
represent	O
five	O
new	O
candidate	O
species	O
since	O
their	O
rpoB	O
sequence	O
similarities	O
with	O
type	O
strains	O
were	O
less	O
than	O
95	O
%	O
.	O

Acinetobacter	O
calcoaceticus	O
and	O
Acinetobacter	O
johnsonii	O
were	O
the	O
most	O
common	O
species	O
,	O
both	O
with	O
the	O
frequency	O
of	O
26.5	O
%	O
;	O
and	O
11	O
%	O
of	O
the	O
strains	O
belong	O
to	O
the	O
Acinetobacter	O
baumannii	O
group	O
(	O
i.e	O
.	O

A.	O
baumannii	O
,	O
Acinetobacter	O
pittii	O
,	O
Acinetobacter	O
seifertii	O
and	O
Acinetobacter	O
nosocomialis	O
)	O
,	O
which	O
is	O
most	O
frequently	O
associated	O
with	O
nosocomial	O
infections	O
.	O

Overall	O
,	O
the	O
strains	O
were	O
least	O
susceptible	O
to	O
piperacillin	O
(	O
80.1	O
%	O
)	O
,	O
piperacillin-tazobactam	O
(	O
64.1	O
%	O
)	O
,	O
ceftazidime	O
(	O
43.1	O
%	O
)	O
,	O
ciprofloxacin	O
(	O
16.6	O
%	O
)	O
,	O
trimethoprim-sulfamethoxazole	O
(	O
14.9	O
%	O
)	O
,	O
imipenem	O
(	O
14.4	O
%	O
)	O
and	O
colistin	O
(	O
13.3	O
%	O
)	O
.	O

The	O
most	O
active	O
antimicrobials	O
were	O
minocycline	O
and	O
tetracycline	O
,	O
with	O
0.6	O
%	O
and	O
3.9	O
%	O
of	O
strains	O
resistant	O
,	O
respectively	O
.	O

About	O
29.8	O
%	O
of	O
the	O
strains	O
were	O
classified	O
as	O
multidrug-resistant	O
(	O
MDR	O
)	O
,	O
4.4	O
%	O
as	O
extensively	O
drug-resistant	O
(	O
XDR	O
)	O
and	O
the	O
prevalence	O
of	O
MDR	O
strains	O
within	O
the	O
A.	O
baumannii	O
group	O
(	O
25	O
%	O
)	O
was	O
similar	O
to	O
other	O
species	O
(	O
30.4	O
%	O
)	O
.	O

The	O
presence	O
of	O
clinically	O
important	O
species	O
as	O
well	O
as	O
MDR	O
strains	O
in	O
lettuces	O
and	O
fruits	O
may	O
be	O
a	O
threat	O
to	O
public	O
health	O
considering	O
that	O
they	O
may	O
transmit	O
these	O
pathogens	O
to	O
environments	O
such	O
as	O
the	O
community	O
and	O
hospital	O
settings	O
.	O

Osthole	O
attenuates	O
lipid	O
accumulation	O
,	O
regulates	O
the	O
expression	O
of	O
inflammatory	O
mediators	O
,	O
and	O
increases	O
antioxidants	O
in	O
FL83B	O
cells	O
.	O

Osthole	O
is	O
found	O
in	O
Cnidium	O
monnieri	O
(	O
L.	O
)	O
and	O
has	O
anti-inflammatory	O
and	O
anti-oxidative	O
properties	O
.	O

It	O
also	O
inhibits	O
the	O
proliferation	O
of	O
hepatocellular	O
carcinoma	O
cells	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
osthole	O
suppressive	O
nonalcoholic	O
fatty	O
liver	O
disease	O
effects	O
in	O
oleic	O
acid	O
(	O
OA	O
)	O
-	O
induced	O
hepatic	O
steatosis	O
and	O
if	O
it	O
can	O
modulate	O
inflammatory	O
responses	O
and	O
oxidative	O
stress	O
.	O

FL83B	O
cell	O
s	O
were	O
pretreated	O
with	O
OA	O
(	O
250μΜ	O
)	O
for	O
24h	O
,	O
and	O
then	O
added	O
different	O
concentrations	O
of	O
osthole	O
(	O
3-100μM	O
)	O
for	O
24h	O
.	O

Subsequently	O
,	O
lipolysis	O
and	O
transcription	O
factors	O
of	O
adipogenesis	O
and	O
phosphorylation	O
of	O
AMP-activated	O
protein	O
kinase	O
proteins	O
were	O
measured	O
.	O

In	O
addition	O
,	O
cells	O
with	O
OA	O
-	O
induced	O
steatosis	O
were	O
H2O2	O
-	O
stimulated	O
,	O
and	O
then	O
incubated	B-P
with	O
osthole	O
to	O
evaluated	O
if	O
it	O
could	O
suppress	O
its	O
progression	O
to	O
steatohepatitis	O
.	O

Osthole	O
significantly	O
enhanced	O
glycerol	O
release	O
and	O
lipolysis	O
protein	O
expression	O
.	O

Osthole	O
also	O
promoted	O
phosphorylation	O
of	O
AMP-activated	O
protein	O
kinases	O
and	O
increased	O
the	O
activity	O
of	O
triglyceride	O
lipase	O
and	O
hormone-	O
sensitive	O
lipase	O
.	O

Osthole	O
suppressed	O
the	O
nuclear	O
transcription	O
factor	O
kappa-B	O
and	O
the	O
p38	O
mitogen-activated	O
protein	O
kinase	O
pathway	O
,	O
and	O
decreased	O
the	O
malondialdehyde	O
concentration	O
in	O
FL83B	O
cells	O
with	O
OA	O
-	O
induced	O
steatosis	O
that	O
were	O
treated	O
with	O
H2O2	O
.	O

These	O
results	O
suggest	O
that	O
osthole	O
might	O
suppress	O
nonalcoholic	O
fatty	O
liver	O
disease	O
by	O
decreasing	O
lipid	O
accumulation	O
,	O
and	O
through	O
its	O
anti-oxidative	O
and	O
anti-inflammatory	O
effects	O
via	O
blocked	O
NF-κB	O
and	O
MAPK	O
signaling	O
pathways	O
.	O

ADHD	O
symptoms	O
in	O
non-treatment	O
seeking	O
young	O
adults	O
:	O
relationship	O
with	O
other	O
forms	O
of	O
impulsivity	O
.	O

Attention-deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
has	O
been	O
associated	O
with	O
various	O
manifestations	O
of	O
impulsivity	O
in	O
adults	O
,	O
including	O
elevated	O
rates	O
of	O
other	O
impulsive	O
disorders	O
,	O
substance	O
use	O
,	O
questionnaire	O
-based	O
impulsivity	O
scores	O
,	O
and	O
inhibitory	O
dysregulation	O
on	O
neurocognitive	B-P
tests	I-P
.	O

The	O
relationship	O
between	O
ADHD	O
and	O
all	O
these	O
other	O
forms	O
of	O
impulsivity	O
has	O
yet	O
to	O
be	O
explored	O
within	O
the	O
context	O
of	O
a	O
single	O
comprehensive	O
study	O
.	O

A	O
total	O
of	O
423	O
young	O
adults	O
,	O
who	O
gambled	O
≥5	O
times	O
in	O
the	O
preceding	O
year	O
,	O
were	O
recruited	O
using	O
media	O
advertisements	O
and	O
undertook	O
detailed	O
assessment	O
including	O
structured	O
psychiatric	O
interview	O
,	O
questionnaires	O
,	O
and	O
neurocognitive	B-P
tests	I-P
.	O

Participants	O
with	O
ADHD	O
symptoms	O
were	O
identified	O
using	O
the	O
Adult	O
ADHD	O
Self-Report	O
Scale	O
Screener	O
(	O
ASRS-V1.1	O
)	O
and	O
were	O
compared	O
to	O
controls	O
using	O
multivariate	O
analysis	O
of	O
variance	O
(	O
MANOVA	O
)	O
.	O

ADHD	O
symptoms	O
were	O
found	O
in	O
20.3	O
%	O
of	O
the	O
sample	O
,	O
but	O
only	O
7.3	O
%	O
of	O
these	O
subjects	O
had	O
ever	O
received	O
a	O
formal	O
diagnosis	O
.	O

ADHD	O
symptoms	O
were	O
associated	O
with	O
significantly	O
lower	O
quality	O
of	O
life	O
,	O
lower	O
self-esteem	O
,	O
higher	O
emotional	O
dysregulation	O
,	O
higher	O
impulsivity	O
questionnaire	O
scores	O
,	O
more	O
problematic	O
Internet	O
use	O
,	O
greater	O
occurrence	O
of	O
psychiatric	O
disorders	O
,	O
and	O
impaired	O
stop-signal	O
reaction	O
times	O
.	O

Of	O
these	O
variables	O
,	O
stop-signal	O
reaction	O
times	O
and	O
Barratt	O
attentional	O
impulsiveness	O
were	O
the	O
strongest	O
predictors	O
of	O
group	O
classification	O
.	O

ADHD	O
symptoms	O
are	O
common	O
and	O
under-diagnosed	O
in	O
young	O
adults	O
who	O
gamble	O
,	O
and	O
are	O
most	O
strongly	O
linked	O
with	O
certain	O
other	O
types	O
of	O
impulsivity	O
(	O
questionnaire	O
-	O
and	O
cognitive	O
-based	O
measures	O
)	O
and	O
with	O
emotional	O
dysregulation	O
,	O
suggesting	O
that	O
these	O
are	O
each	O
important	O
considerations	O
in	O
understanding	O
the	O
pathophysiology	O
of	O
the	O
disorder	O
,	O
but	O
also	O
potential	O
treatment	O
targets	O
.	O

It	O
is	O
necessary	O
to	O
question	O
whether	O
treatment	O
for	O
adult	O
ADHD	O
could	O
be	O
enhanced	O
by	O
considering	O
self-esteem	O
,	O
emotional	O
reactivity	O
,	O
and	O
impaired	O
inhibitory	O
control	O
as	O
specific	O
treatment	O
targets	O
,	O
in	O
addition	O
to	O
the	O
core	O
diagnostic	O
symptoms	O
of	O
the	O
disorder	O
.	O

The	O
Corneal	O
Epithelial	O
Barrier	O
and	O
Its	O
Developmental	O
Role	O
in	O
Isolating	O
Corneal	O
Epithelial	O
and	O
Conjunctival	O
Cells	O
From	O
One	O
Another	O
.	O

During	O
development	O
,	O
the	O
corneal	O
epithelium	O
(	O
CE	O
)	O
and	O
the	O
conjunctiva	O
are	O
derived	O
from	O
the	O
surface	O
ectoderm	O
.	O

Here	O
we	O
have	O
examined	O
how	O
,	O
during	O
development	O
,	O
the	O
cells	O
of	O
these	O
two	O
issues	O
become	O
isolated	O
from	O
each	O
other	O
.	O

Epithelia	O
from	O
the	O
anterior	O
eyes	O
of	O
chicken	O
embryos	O
were	O
labeled	O
with	O
the	O
fluorescent	O
,	O
lipophilic	O
dye	O
,	O
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine	O
perchlorate	O
(	O
DiI	O
)	O
.	O

DiI	O
was	O
placed	O
on	O
the	O
epithelial	O
surface	O
of	O
the	O
developing	O
anterior	O
eye	O
and	O
its	O
diffusion	O
was	O
monitored	O
by	O
fluorescence	B-P
microscopy	I-P
.	O

Concomitant	O
morphologic	O
changes	O
in	O
the	O
surface	O
cells	O
of	O
these	O
epithelial	O
were	O
examined	O
by	O
scanning	B-P
electron	I-P
microscopy	I-P
.	O

Immunofluorescence	B-P
was	O
used	O
to	O
analyze	O
the	O
expression	O
of	O
cytokeratin	O
K3	O
,	O
ZO-1	O
,	O
N-cadherin	O
and	O
Connexin-43	O
and	O
the	O
function	O
of	O
gap	O
junctions	O
was	O
analyzed	O
using	O
a	O
cut-loading	O
with	O
the	O
fluorescent	O
dye	O
rhodamine-dextran	O
.	O

Prior	O
to	O
embryonic	O
day	O
8	O
(	O
E	O
8	O
)	O
,	O
DiI	O
placed	O
on	O
the	O
surface	O
of	O
the	O
CE	O
spreads	O
throughout	O
all	O
the	O
epithelial	O
cells	O
of	O
the	O
anterior	O
eye	O
.	O

When	O
older	O
eyes	O
were	O
similarly	O
labeled	O
,	O
dye	O
diffusion	O
was	O
restricted	O
to	O
the	O
CE	O
.	O

Similarly	O
,	O
diffusion	O
of	O
DiI	O
placed	O
on	O
the	O
conjunctival	O
surface	O
after	O
E	O
8	O
was	O
restricted	O
to	O
the	O
conjunctiva	O
.	O

Scanning	B-P
electron	I-P
microscopy	I-P
showed	O
that	O
developmentally	O
(	O
1	O
)	O
physical	O
separations	O
progressively	O
form	O
between	O
the	O
cells	O
of	O
the	O
CE	O
and	O
those	O
of	O
the	O
conjunctiva	O
,	O
and	O
(	O
2	O
)	O
by	O
E	O
8	O
these	O
separations	O
form	O
a	O
ring	O
that	O
completely	O
encompasses	O
the	O
cornea	O
.	O

The	O
functional	O
restriction	O
of	O
gap	O
junctions	O
between	O
these	O
tissues	O
did	O
not	O
occur	O
until	O
E	O
14	O
.	O

During	O
ocular	O
development	O
,	O
a	O
barrier	O
to	O
the	O
diffusion	O
of	O
DiI	O
forms	O
between	O
the	O
contiguous	O
CE	O
and	O
conjunctiva	O
prior	O
to	O
the	O
differential	O
expression	O
of	O
gap	O
junctions	O
within	O
these	O
tissues	O
.	O

Low	O
Efficiency	O
Upconversion	O
Nanoparticles	O
for	O
High-Resolution	B-P
Coalignment	O
of	O
Near-Infrared	O
and	O
Visible	O
Light	O
Paths	O
on	O
a	O
Light	O
Microscope	O
.	O

The	O
combination	O
of	O
near-infrared	O
(	O
NIR	O
)	O
and	O
visible	O
wavelengths	O
in	O
light	B-P
microscopy	I-P
for	O
biological	B-P
studies	I-P
is	O
increasingly	O
common	O
.	O

For	O
example	O
,	O
many	O
fields	O
of	O
biology	O
are	O
developing	O
the	O
use	O
of	O
NIR	O
for	O
optogenetics	O
,	O
in	O
which	O
an	O
NIR	O
laser	O
induces	O
a	O
change	O
in	O
gene	O
expression	O
and/or	O
protein	O
function	O
.	O

One	O
major	O
technical	O
barrier	O
in	O
working	O
with	O
both	O
NIR	O
and	O
visible	O
light	O
on	O
an	O
optical	B-P
microscope	I-P
is	O
obtaining	O
their	O
precise	O
coalignment	O
at	O
the	O
imaging	O
plane	O
position	O
.	O

Photon	O
upconverting	O
particles	O
(	O
UCPs	O
)	O
can	O
bridge	O
this	O
gap	O
as	O
they	O
are	O
excited	O
by	O
NIR	O
light	O
but	O
emit	O
in	O
the	O
visible	O
range	O
via	O
an	O
anti-Stokes	O
luminescence	O
mechanism	O
.	O

Here	O
,	O
two	O
different	O
UCPs	O
have	O
been	O
identified	O
,	O
high-	O
efficiency	O
micro	O
(	O
540	O
)	O
-	O
UCPs	O
and	O
lower	O
efficiency	O
nano	O
(	O
545	O
)	O
-	O
UCPs	O
,	O
that	O
respond	O
to	O
NIR	O
light	O
and	O
emit	O
visible	O
light	O
with	O
high	O
photostability	O
even	O
at	O
very	O
high	O
NIR	O
power	O
densities	O
(	O
>	O
25	O
000	O
Suns	O
)	O
.	O

Both	O
of	O
these	O
UCPs	O
can	O
be	O
rapidly	O
and	O
reversibly	O
excited	O
by	O
visible	O
and	O
NIR	O
light	O
and	O
emit	O
light	O
at	O
visible	O
wavelengths	O
detectable	O
with	O
standard	O
emission	O
settings	O
used	O
for	O
Green	O
Fluorescent	O
Protein	O
(	O
GFP	O
)	O
,	O
a	O
commonly	O
used	O
genetically	O
encoded	O
fluorophore	O
.	O

However	O
,	O
the	O
high	O
efficiency	O
micro	O
(	O
540	O
)	O
-	O
UCPs	O
were	O
suboptimal	O
for	O
NIR	O
and	O
visible	O
light	O
coalignment	O
,	O
due	O
to	O
their	O
larger	O
size	O
and	O
spatial	O
broadening	O
from	O
particle	O
-to-	O
particle	O
energy	O
transfer	O
consistent	O
with	O
a	O
long-lived	O
excited	O
state	O
and	O
saturated	O
power	O
dependence	O
.	O

In	O
contrast	O
,	O
the	O
lower	O
efficiency	O
nano	O
-	O
UCPs	O
were	O
superior	O
for	O
precise	O
coalignment	O
of	O
the	O
NIR	O
beam	O
with	O
the	O
visible	O
light	O
path	O
(	O
∼2	O
μm	O
versus	O
∼8	O
μm	O
beam	O
broadening	O
,	O
respectively	O
)	O
consistent	O
with	O
limited	O
particle	O
-to-	O
particle	O
energy	O
transfer	O
,	O
superlinear	O
power	O
dependence	O
for	O
emission	O
,	O
and	O
much	O
smaller	O
particle	O
size	O
.	O

Furthermore	O
,	O
the	O
nano	O
-	O
UCPs	O
were	O
superior	O
to	O
a	O
traditional	O
two-	O
camera	O
method	O
for	O
NIR	O
and	O
visible	O
light	O
path	O
alignment	O
in	O
an	O
in	O
vivo	O
Infrared-Laser-Evoked	O
Gene	O
Operator	O
(	O
IR-LEGO	O
)	O
optogenetics	O
assay	O
in	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

In	O
summary	O
,	O
nano	O
-	O
UCPs	O
are	O
powerful	O
new	O
tools	O
for	O
coaligning	O
NIR	O
and	O
visible	O
light	O
paths	O
on	O
a	O
light	O
microscope	O
.	O

C1Q	B-P
Assay	I-P
Results	O
in	O
Complement-Dependent	B-P
Cytotoxicity	I-P
Crossmatch	B-P
Negative	O
Renal	O
Transplant	O
Candidates	O
with	O
Donor-Specific	O
Antibodies	O
:	O
High	O
Specificity	O
but	O
Low	O
Sensitivity	O
When	O
Predicting	O
Flow	B-P
Crossmatch	I-P
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
describe	O
the	O
association	O
of	O
positive	O
flow	B-P
cross	I-P
match	I-P
(	O
FXM	B-P
)	O
and	O
C1q-SAB	B-P
.	O

Methods	O
.	O

In	O
this	O
observational	O
,	O
cross-sectional	O
,	O
and	O
comparative	O
study	O
,	O
patients	O
included	O
had	O
negative	O
AHG-CDC-XM	B-P
and	O
donor	O
specific	O
antibodies	O
(	O
DSA	O
)	O
and	O
were	O
tested	O
with	O
FXM	B-P
.	O

All	O
pretransplant	O
sera	O
were	O
tested	O
with	O
C1q-SAB	B-P
assay	I-P
.	O

Results	O
.	O

A	O
total	O
of	O
50	O
donor	O
/	O
recipient	O
evaluations	O
were	O
conducted	O
;	O
half	O
of	O
them	O
had	O
at	O
least	O
one	O
C1q+	O
Ab	O
(	O
n	O
=	O
26	O
,	O
52	O
%	O
)	O
.	O

Ten	O
patients	O
(	O
20.0	O
%	O
)	O
had	O
DSA	O
C1q+	O
Ab	O
.	O

Twenty-five	O
(	O
50	O
%	O
)	O
FXMs	B-P
were	O
positive	O
.	O

Factors	O
associated	O
with	O
a	O
positive	O
FXM	B-P
were	O
the	O
presence	O
of	O
C1q+	O
Ab	O
(	O
DSA	O
C1q+	O
Ab	O
:	O
OR	O
27	O
,	O
2.80-259.56	O
,	O
P	O
=	O
0.004	O
,	O
and	O
no	O
DSA	O
C1q+	O
Ab	O
:	O
OR	O
5	O
,	O
1.27-19.68	O
,	O
P	O
=	O
0.021	O
)	O
and	O
the	O
DSA	O
LABScreen-SAB	O
MFI	O
(	O
OR	O
1.26	O
,	O
95	O
%	O
CI	O
1.06-1.49	O
,	O
P	O
=	O
0.007	O
)	O
.	O

The	O
cutoff	O
point	O
of	O
immunodominant	O
LABScreen	O
SAB	O
DSA	O
-	O
MFI	O
with	O
the	O
greatest	O
sensitivity	O
and	O
specificity	O
to	O
predict	O
FXM	B-P
was	O
2,300	O
(	O
sensitivity	O
:	O
72	O
%	O
and	O
specificity	O
:	O
75	O
%	O
)	O
.	O

For	O
FXM	B-P
prediction	O
,	O
DSA	O
C1q+	O
Ab	O
was	O
the	O
most	O
specific	O
(	O
95.8	O
%	O
,	O
85-100	O
)	O
and	O
the	O
combination	O
of	O
DSA	O
-	O
MFI	O
>	O
2,300	O
and	O
C1q+	O
Ab	O
was	O
the	O
most	O
sensitive	O
(	O
92.0	O
%	O
,	O
79.3-100	O
)	O
.	O

Conclusions	O
.	O

C1q+	O
Ab	O
and	O
LABScreen	O
SAB	O
DSA	O
-	O
MFI	O
were	O
significantly	O
associated	O
with	O
FXM	B-P
.	O

DSA	O
C1q+	O
Ab	O
was	O
highly	O
specific	O
but	O
with	O
low	O
sensitivity	O
.	O

Liver	O
Retransplantation	O
for	O
Hepatic	O
Abscess	O
Due	O
to	O
Hepatic	O
Artery	O
Thrombosis	O
:	O
A	O
Case	O
Report	O
.	O

Hepatic	O
artery	O
thrombosis	O
(	O
HAT	O
)	O
is	O
a	O
well-recognized	O
complication	O
of	O
liver	O
transplantation	O
(	O
LT	O
)	O
.	O

HAT	O
is	O
an	O
important	O
risk	O
factor	O
for	O
infectious	O
,	O
in	O
particular	O
hepatic	O
abscess	O
,	O
which	O
can	O
cause	O
graft	O
loss	O
and	O
increasing	O
morbidity	O
and	O
mortality	O
.	O

We	O
present	O
a	O
case	O
report	O
of	O
complicated	O
LT	O
in	O
a	O
52-	O
year-old	O
Caucasian	O
man	O
with	O
primary	O
sclerosing	O
cholangitis	O
.	O

In	O
2007	O
the	O
patient	O
was	O
included	O
on	O
the	O
waiting	O
list	O
in	O
Padua	O
for	O
LT	O
.	O

In	O
2012	O
the	O
patient	O
underwent	O
percutaneous	O
transhepatic	O
biliary	O
drainage	O
for	O
bile	O
duct	O
stricture	O
,	O
complicated	O
with	O
acute	O
pancreatitis	O
.	O

A	O
diagnostic	B-P
laparoscopy	I-P
was	O
performed	O
with	O
choledochotomy	O
and	O
Kehr	O
's	O
T	O
tube	O
drainage	O
.	O

On	O
February	O
14	O
,	O
2012	O
,	O
the	O
patient	O
underwent	O
LT	O
with	O
arterial	O
reconstruction	O
and	O
choledochojejunostomy	O
.	O

The	O
postoperative	O
course	O
was	O
complicated	O
with	O
HAT	O
,	O
multiple	O
liver	O
abscesses	O
,	O
and	O
sepsis	O
associated	O
with	O
bacteremia	O
due	O
to	O
Enterococcus	O
faecium	O
despite	O
massive	O
intravenous	O
antibiotic	O
therapy	O
and	O
percutaneous	O
drainages	O
.	O

On	O
November	O
28	O
,	O
2012	O
,	O
the	O
patient	O
underwent	O
retransplantation	O
.	O

Four	O
years	O
after	O
transplantation	O
the	O
patient	O
is	O
still	O
in	O
good	O
general	O
condition	O
.	O

Hepatic	O
abscess	O
formation	O
secondary	O
to	O
HAT	O
following	O
LT	O
is	O
a	O
major	O
complication	O
associated	O
with	O
important	O
morbidity	O
and	O
mortality	O
.	O

In	O
selected	O
cases	O
retransplantation	O
should	O
be	O
considered	O
as	O
our	O
case	O
demonstrates	O
.	O

Elicitation	B-P
of	O
Phenolics	O
from	O
the	O
Micropropagated	B-P
Endangered	O
Medicinal	O
Plant	O
Calligonum	O
polygonoides	O
L.	O
(	O
Polygonoaceae	O
)	O
.	O

Calligonum	O
polygonoides	O
L.	O
subsp	O
.	O

comosum	O
(	O
L'Hér	O
.	O
)	O

Sosk	O
.	O

is	O
a	O
plant	O
species	O
belonging	O
to	O
family	O
Polygonaceae	O
.	O

Susceptibility	O
to	O
threaten	O
,	O
presence	O
of	O
various	O
chemical	O
constituents	O
,	O
and	O
many	O
medicinal	O
effects	O
reported	O
for	O
this	O
plant	O
in	O
addition	O
to	O
rareness	O
of	O
in	O
vitro	O
culture	B-P
studies	I-P
have	O
fuelled	O
the	O
need	O
for	O
its	O
micropropagation	B-P
and	O
phytochemical	O
investigations	O
of	O
the	O
produced	O
cultures	B-P
.	O

To	O
employ	O
in	O
vitro	O
culture	B-P
technique	I-P
for	O
ex	B-P
situ	I-P
conservation	I-P
of	O
C.	O
polygonoides	O
,	O
using	O
the	O
fruit	O
as	O
an	O
explant	O
;	O
establish	O
callus	O
and	O
cell	B-P
suspension	I-P
cultures	I-P
from	O
in	O
vitro	O
germinated	O
plantlets	O
;	O
investigate	O
the	O
production	O
of	O
phenolics	O
through	O
callus	O
,	O
redifferentiated	O
shoot	O
,	O
and	O
cell	B-P
suspension	I-P
cultures	I-P
;	O
attempt	O
to	O
enhance	O
cell	O
capacity	O
to	O
accumulate	O
phenolics	O
using	O
salicylic	O
acid	O
and	O
yeast	O
extract	O
and	O
provide	O
a	O
brief	O
demonstration	O
of	O
biosynthetic	O
pathway	O
leading	O
to	O
phenolic	O
production	O
.	O

Modified	O
Murashige	O
and	O
Skoog	O
media	O
supplemented	O
with	O
growth	O
hormones	O
such	O
as	O
kinetin	O
,	O
1-naphthaleneacetic	O
acid	O
,	O
6-benzylaminopurine	O
,	O
and	O
indole-3-acetic	O
acid	O
were	O
used	O
to	O
establish	O
callus	O
,	O
redifferentiated	O
shoots	O
,	O
and	O
cell	B-P
suspension	I-P
cultures	I-P
.	O

Elicitation	B-P
of	O
cell	B-P
suspension	I-P
culture	I-P
was	O
performed	O
using	O
salicylic	O
acid	O
and	O
yeast	O
extracts	O
.	O

A	O
reversed	B-P
phase-high	I-P
performance	I-P
liquid	I-P
chromatography	I-P
method	O
for	O
determination	B-P
of	O
phenolic	O
content	O
in	O
the	O
aforementioned	B-P
cultures	I-P
was	O
developed	O
.	O

The	O
unorganized	O
callus	O
and	O
cell	B-P
suspension	I-P
cultures	I-P
contained	O
fewer	O
amounts	O
of	O
phenolic	O
compounds	O
than	O
redifferentiated	O
shoots	O
.	O

Elicitation	B-P
produced	O
massive	O
quantitative	O
reprogramming	O
of	O
phenolic	O
content	O
.	O

The	O
present	O
study	O
offers	O
an	O
alternative	O
and	O
renewable	O
source	O
for	O
this	O
valuable	O
natural	O
plant	O
,	O
provide	O
a	O
chance	O
to	O
improve	O
secondary	O
metabolite	O
yield	O
and	O
serve	O
as	O
a	O
useful	O
tool	O
for	O
studying	O
the	O
biosynthesis	O
of	O
these	O
compounds	O
and	O
its	O
regulation	O
in	O
plant	O
cells	O
.	O

In	O
vitro	O
culture	B-P
techniques	I-P
provided	O
a	O
strategy	O
for	O
ex	B-P
situ	I-P
conservation	I-P
of	O
the	O
endangered	O
C.	O
polygonoides	O
.Unorganized	O
callus	O
and	O
cell	B-P
suspension	I-P
cultures	I-P
accumulated	O
less	O
phenolic	O
content	O
than	O
re-differentiated	O
shoots	O
.	O

Elicitation	B-P
produced	O
massive	O
quantitative	O
reprogramming	O
of	O
phenolic	O
content	O
.	O

Phenolic	O
biosynthesis	O
was	O
discussed	O
briefly	O
.	O

Abbreviation	O
used	O
:	O
H2O2	O
:	O
Hydrogen	O
peroxide	O
,	O
Kin	O
:	O
Kinetin	O
,	O
NAA	O
:	O
Naphthaleneacetic	O
acid	O
,	O
BAP	O
:	O
6-benzylaminopurine	O
,	O
IAA	O
:	O
Indole-3-acetic	O
acid	O
,	O
HPLC	B-P
:	O
High-performance	B-P
liquid	I-P
chromatography	I-P
.	O

Methods	O
to	O
Study	O
Autophagy	O
in	O
Zebrafish	O
.	O

Autophagy	O
(	O
cellular	O
self-eating	O
)	O
is	O
a	O
highly	O
regulated	O
degradation	O
process	O
of	O
the	O
eukaryotic	O
cell	O
during	O
which	O
parts	O
of	O
the	O
cytoplasm	O
are	O
delivered	O
into	O
,	O
and	O
broken	O
down	O
within	O
,	O
the	O
lysosomal	O
compartment	O
.	O

The	O
process	O
serves	O
as	O
a	O
main	O
route	O
for	O
the	O
elimination	O
of	O
superfluous	O
and	O
damaged	O
cellular	O
constituents	O
,	O
thereby	O
mediating	O
macromolecular	O
and	O
organellar	O
turnover	O
.	O

In	O
addition	O
to	O
maintaining	O
cellular	O
homeostasis	O
,	O
autophagy	O
is	O
involved	O
in	O
various	O
other	O
cellular	O
and	O
developmental	O
processes	O
by	O
degrading	O
specific	O
regulatory	O
proteins	O
,	O
and	O
contributing	O
to	O
the	O
clearance	O
of	O
intracellular	O
pathogens	O
.	O

The	O
physiological	O
roles	O
and	O
pathological	O
involvement	O
of	O
autophagy	O
can	O
be	O
effectively	O
studied	O
in	O
divergent	O
eukaryotic	O
model	O
systems	O
ranging	O
from	O
yeast	O
to	O
mice	O
.	O

Such	O
a	O
tractable	O
animal	O
model	O
applied	O
only	O
recently	O
for	O
autophagy	O
researchis	O
the	O
zebrafish	O
Danio	O
rerio	O
,	O
which	O
also	O
facilitates	O
the	O
analysis	O
of	O
more	O
specific	O
biological	O
processes	O
such	O
as	O
tissue	O
regeneration	O
.	O

In	O
this	O
chapter	O
,	O
we	O
overview	O
the	O
main	O
methods	O
and	O
tools	O
that	O
are	O
used	O
to	O
monitor	O
autophagic	O
structures	O
and	O
to	O
assay	B-P
autophagic	O
responses	O
in	O
this	O
vertebrate	O
organism	O
.	O

We	O
place	O
emphasis	O
on	O
genetic	O
(	O
functional	O
)	O
approaches	O
applied	O
for	O
exploring	O
novel	O
cellular	O
and	O
developmental	O
roles	O
of	O
the	O
autophagic	O
process	O
.	O

Real-time	O
observation	O
of	O
protein	O
aggregates	O
in	O
pharmaceutical	O
formulations	O
using	O
liquid	B-P
cell	I-P
electron	I-P
microscopy	I-P
.	O

Understanding	O
the	O
properties	O
of	O
protein-based	O
therapeutics	O
is	O
a	O
common	O
goal	O
of	O
biologists	O
and	O
physicians	O
.	O

Technical	O
barriers	O
in	O
the	O
direct	O
observation	O
of	O
small	O
proteins	O
or	O
therapeutic	O
agents	O
can	O
limit	O
our	O
knowledge	O
of	O
how	O
they	O
function	O
in	O
solution	O
and	O
in	O
the	O
body	O
.	O

Electron	B-P
microscopy	I-P
(	O
EM	B-P
)	O
imaging	B-P
performed	O
in	O
a	O
liquid	O
environment	O
permits	O
us	O
to	O
peer	O
into	O
the	O
active	O
world	O
of	O
cells	O
and	O
molecules	O
at	O
the	O
nanoscale	O
.	O

Here	O
,	O
we	O
employ	O
liquid	B-P
cell	I-P
EM	I-P
to	O
directly	O
visualize	O
a	O
protein-based	O
therapeutic	O
in	O
its	O
native	O
conformation	O
and	O
aggregate	O
state	O
in	O
a	O
time-resolved	O
manner	O
.	O

In	O
combination	O
with	O
quantitative	B-P
analyses	I-P
,	O
information	O
from	O
this	O
work	O
contributes	O
new	O
molecular	O
insights	O
toward	O
understanding	O
the	O
behaviours	O
of	O
immunotherapies	O
in	O
a	O
solution	O
state	O
that	O
mimics	O
the	O
human	O
body	O
.	O

Identification	O
and	O
Functional	O
Characterization	O
of	O
a	O
Tonoplast	O
Dicarboxylate	O
Transporter	O
in	O
Tomato	O
(	O
Solanum	O
lycopersicum	O
)	O
.	O

Acidity	O
plays	O
an	O
important	O
role	O
in	O
flavor	O
and	O
overall	O
organoleptic	O
quality	O
of	O
fruit	O
and	O
is	O
mainly	O
due	O
to	O
the	O
presence	O
of	O
organic	O
acids	O
.	O

Understanding	O
the	O
molecular	O
basis	O
of	O
organic	O
acid	O
metabolism	O
is	O
thus	O
of	O
primary	O
importance	O
for	O
fruit	O
quality	O
improvement	O
.	O

Here	O
,	O
we	O
cloned	O
a	O
putative	O
tonoplast	O
dicarboxylate	O
transporter	O
gene	O
(	O
SlTDT	O
)	O
from	O
tomato	O
,	O
and	O
submitted	O
it	O
to	O
the	O
NCBI	O
database	O
(	O
GenBank	O
accession	O
number	O
:	O
KC733165	O
)	O
.	O

SlTDT	O
protein	O
contained	O
13	O
putative	O
transmembrane	O
domains	O
in	O
silico	O
analysis	O
.	O

Confocal	B-P
microscopic	I-P
study	O
using	O
green	O
fluorescent	O
fusion	O
proteins	O
revealed	O
that	O
SlTDT	O
was	O
localized	O
on	O
tonoplast	O
.	O

The	O
expression	O
patterns	O
of	O
SlTDT	O
in	O
tomato	O
were	O
analyzed	O
by	O
RT-qPCR	O
.	O

The	O
results	O
indicated	O
that	O
SlTDT	O
expressed	O
in	O
leaves	O
,	O
roots	O
,	O
flowers	O
and	O
fruits	O
at	O
different	O
ripening	O
stages	O
,	O
suggesting	O
SlTDT	O
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
different	O
tissues	O
.	O

To	O
further	O
explore	O
the	O
function	O
of	O
SlTDT	O
,	O
we	O
constructed	O
both	O
overexpression	O
and	O
RNAi	O
vectors	O
and	O
obtained	O
transgenic	O
tomato	O
plants	O
by	O
agrobacterium	O
-mediated	O
method	O
.	O

Gas	B-P
chromatography-mass	I-P
spectrometer	I-P
(	O
GC-MS	B-P
)	I-P
analysis	I-P
showed	O
that	O
overexpression	O
of	O
SlTDT	O
significantly	O
increased	O
malate	O
content	O
,	O
and	O
reduced	O
citrate	O
content	O
in	O
tomato	O
fruit	O
.	O

By	O
contrast	O
,	O
repression	O
of	O
SlTDT	O
in	O
tomato	O
reduced	O
malate	O
content	O
of	O
and	O
increased	O
citrate	O
content	O
.	O

These	O
results	O
indicated	O
that	O
SlTDT	O
played	O
an	O
important	O
role	O
in	O
remobilization	O
of	O
malate	O
and	O
citrate	O
in	O
fruit	O
vacuoles	O
.	O

Stromal	O
alterations	O
in	O
ovarian	O
cancers	O
via	O
wavelength	O
dependent	O
Second	B-P
Harmonic	I-P
Generation	I-P
microscopy	I-P
and	O
optical	O
scattering	O
.	O

Ovarian	O
cancer	O
remains	O
the	O
most	O
deadly	O
gynecological	O
cancer	O
with	O
a	O
poor	O
aggregate	O
survival	O
rate	O
;	O
however	O
,	O
the	O
specific	O
rates	O
are	O
highly	O
dependent	O
on	O
the	O
stage	O
of	O
the	O
disease	O
upon	O
diagnosis	O
.	O

Current	O
screening	O
and	O
imaging	O
tools	O
are	O
insufficient	O
to	O
detect	O
early	O
lesions	O
and	O
are	O
not	O
capable	O
of	O
differentiating	O
the	O
subtypes	O
of	O
ovarian	O
cancer	O
that	O
may	O
benefit	O
from	O
specific	O
treatments	O
.	O

As	O
an	O
alternative	O
to	O
current	O
screening	O
and	O
imaging	O
tools	O
,	O
we	O
utilized	O
wavelength	O
dependent	O
collagen	O
-specific	O
Second	B-P
Harmonic	I-P
Generation	I-P
(	I-P
SHG	I-P
)	I-P
imaging	I-P
microscopy	I-P
and	O
optical	B-P
scattering	I-P
measurements	I-P
to	O
probe	O
the	O
structural	O
differences	O
in	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
of	O
normal	O
stroma	O
,	O
benign	O
tumors	O
,	O
endometrioid	O
tumors	O
,	O
and	O
low	O
and	O
high-grade	O
serous	O
tumors	O
.	O

The	O
SHG	B-P
signatures	O
of	O
the	O
emission	O
directionality	O
and	O
conversion	O
efficiency	O
as	O
well	O
as	O
the	O
optical	O
scattering	O
are	O
related	O
to	O
the	O
organization	O
of	O
collagen	O
on	O
the	O
sub-micron	O
size	O
scale	O
and	O
encode	O
structural	O
information	O
.	O

The	O
wavelength	O
dependence	O
of	O
these	O
readouts	O
adds	O
additional	O
characterization	O
of	O
the	O
size	O
and	O
distribution	O
of	O
collagen	O
fibrils	O
/	O
fibers	O
relative	O
to	O
the	O
interrogating	O
wavelengths	O
.	O

We	O
found	O
a	O
strong	O
wavelength	O
dependence	O
of	O
these	O
metrics	O
that	O
are	O
related	O
to	O
significant	O
structural	O
differences	O
in	O
the	O
collagen	O
organization	O
and	O
are	O
consistent	O
with	O
the	O
dualistic	O
classification	O
of	O
type	O
I	O
and	O
II	O
serous	O
tumors	O
.	O

Moreover	O
,	O
type	O
I	O
endometrioid	O
tumors	O
have	O
strongly	O
differing	O
ECM	O
architecture	O
than	O
the	O
serous	O
malignancies	O
.	O

The	O
SHG	B-P
metrics	O
and	O
optical	B-P
scattering	I-P
measurements	I-P
were	O
used	O
to	O
form	O
a	O
linear	O
discriminant	O
model	O
to	O
classify	O
the	O
tissues	O
,	O
and	O
we	O
obtained	O
high	O
accuracy	O
(	O
>	O
90	O
%	O
)	O
between	O
high-grade	O
serous	O
tumors	O
from	O
the	O
other	O
tissue	O
types	O
.	O

High-grade	O
serous	O
tumors	O
account	O
for	O
~70	O
%	O
of	O
ovarian	O
cancers	O
,	O
and	O
this	O
delineation	O
has	O
potential	O
clinical	O
applications	O
in	O
terms	O
of	O
supplementing	O
histological	O
analysis	O
,	O
understanding	O
the	O
etiology	O
,	O
as	O
well	O
as	O
development	O
of	O
an	O
in	O
vivo	O
screening	O
tool	O
.	O

SHG	B-P
and	O
optical	B-P
scattering	I-P
measurements	I-P
provide	O
sub-resolution	O
information	O
and	O
when	O
combined	O
provide	O
superior	B-P
diagnostic	I-P
power	I-P
over	O
clinical	B-P
imaging	I-P
modalities	O
.	O

Additionally	O
the	O
measurements	O
are	O
able	O
to	O
delineate	O
the	O
different	O
subtypes	O
of	O
ovarian	O
cancer	O
and	O
may	O
potentially	O
assist	O
in	O
treatment	O
protocols	O
.	O

Understanding	O
the	O
altered	O
collagen	O
assembly	O
can	O
supplement	O
histological	O
analysis	O
and	O
provide	O
new	O
insight	O
into	O
the	O
etiology	O
.	O

These	O
methods	O
could	O
become	O
an	O
in	O
vivo	O
screening	O
tool	O
for	O
earlier	O
detection	O
which	O
is	O
important	O
since	O
ovarian	O
malignancies	O
can	O
metastasize	O
while	O
undetectable	O
by	O
current	O
clinical	B-P
imaging	I-P
resolution	O
.	O

Does	O
genistein	O
lower	O
plasma	B-P
lipids	I-P
and	O
homocysteine	B-P
levels	I-P
in	O
postmenopausal	O
women	O
?	O

A	O
meta-analysis	O
.	O

To	O
perform	O
a	O
meta-analysis	O
examining	O
the	O
effects	O
of	O
genistein	O
on	O
homocysteine	O
and	O
lipid	B-P
levels	I-P
in	O
postmenopausal	O
women	O
.	O

We	O
systematically	O
searched	O
the	O
PubMed	O
,	O
MEDLINE	O
,	O
and	O
Cochrane	O
Library	O
databases	O
and	O
the	O
ClinicalTrials.gov	O
website	O
for	O
studies	O
.	O

We	O
performed	O
a	O
meta-analysis	O
using	O
weighted	O
mean	O
differences	O
(	O
WMD	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
in	O
a	O
random-effects	O
model	O
.	O

We	O
assessed	O
between-	O
study	O
heterogeneity	O
using	O
the	O
Cochran	O
's	O
Q	O
and	O
I	O
(	O
2	O
)	O
statistics	O
.	O

Eight	O
randomized	O
,	O
controlled	O
trials	O
with	O
a	O
total	O
of	O
476	O
subjects	O
were	O
included	O
in	O
the	O
meta-analysis	O
.	O

Compared	O
with	O
placebos	O
,	O
genistein	O
was	O
effective	O
in	O
reducing	O
plasma	O
levels	O
of	O
homocysteine	O
(	O
WMD	O
,	O
-0.58	O
μmol/l	O
;	O
p	O
=	O
0.001	O
)	O
,	O
and	O
increasing	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
levels	O
(	O
WMD	O
,	O
4.9	O
mg/dl	O
;	O
p	O
=	O
0.0002	O
)	O
.	O

Subgroup	O
analyses	O
revealed	O
that	O
genistein	O
significantly	O
decreased	O
the	O
levels	O
of	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	O
(	O
WMD	O
,	O
-16.90	O
mg/dl	O
;	O
p	O
=	O
0.01	O
)	O
,	O
total	O
cholesterol	O
(	O
WMD	O
,	O
-15.83	O
mg/dl	O
;	O
p	O
=	O
0.008	O
)	O
,	O
and	O
triglycerides	O
(	O
WMD	O
,	O
-46.58	O
mg/dl	O
;	O
p	O
=	O
0.03	O
)	O
in	O
postmenopausal	O
women	O
with	O
metabolic	O
syndrome	O
,	O
but	O
had	O
no	O
significant	O
effects	O
in	O
those	O
with	O
no	O
metabolic	O
syndrome	O
.	O

Our	O
meta-analysis	O
demonstrates	O
that	O
genistein	O
significantly	O
reduces	O
homocysteine	B-P
levels	I-P
and	O
increases	O
HDL	B-P
cholesterol	I-P
levels	I-P
in	O
postmenopausal	O
women	O
.	O

Genistein	O
also	O
significantly	O
decreases	O
LDL	B-P
cholesterol	I-P
,	O
total	B-P
cholesterol	I-P
and	O
triglyceride	B-P
levels	I-P
in	O
postmenopausal	O
women	O
with	O
metabolic	O
syndrome	O
.	O

How	O
does	O
the	O
body	O
representation	O
system	O
develop	O
in	O
the	O
human	O
brain	O
?	O
.	O

Exploration	O
of	O
the	O
body	O
representation	O
system	O
(	O
BRS	O
)	O
from	O
kinaesthetic	O
illusions	O
in	O
fMRI	B-P
has	O
revealed	O
a	O
complex	O
network	O
composed	O
of	O
sensorimotor	O
and	O
frontoparietal	O
components	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
degree	O
of	O
maturity	O
of	O
this	O
network	O
in	O
children	O
aged	O
7-11	O
years	O
,	O
and	O
the	O
extent	O
to	O
which	O
structural	O
factors	O
account	O
for	O
network	O
differences	O
with	O
adults	O
.	O

Brain	O
activation	O
following	O
tendon	O
vibration	O
at	O
100Hz	O
(	O
'illusion	O
'	O
)	O
and	O
30Hz	O
(	O
'	O
no	O
illusion	O
'	O
)	O
were	O
analysed	O
using	O
the	O
two-stage	O
random	O
effects	O
model	O
,	O
with	O
or	O
without	O
white	O
and	O
grey	O
matter	O
covariates	O
.	O

The	O
BRS	O
was	O
already	O
well	O
established	O
in	O
children	O
as	O
revealed	O
by	O
the	O
contrast	O
'illusion	O
'	O
vs	O
'	O
no	O
illusion	O
'	O
,	O
although	O
still	O
immature	O
in	O
some	O
aspects	O
.	O

This	O
included	O
a	O
lower	O
level	O
of	O
activation	O
in	O
primary	O
somatosensory	O
and	O
posterior	O
parietal	O
regions	O
,	O
and	O
the	O
exclusive	O
activation	O
of	O
the	O
frontopolar	O
cortex	O
(	O
FPC	O
)	O
in	O
children	O
compared	O
to	O
adults	O
.	O

The	O
former	O
differences	O
were	O
related	O
to	O
structure	O
,	O
while	O
the	O
latter	O
difference	O
reflected	O
a	O
functional	O
strategy	O
where	O
the	O
FPC	O
may	O
serve	O
as	O
the	O
'top	O
'	O
in	O
top-down	O
modulation	O
of	O
the	O
activity	O
of	O
the	O
other	O
BRS	O
regions	O
to	O
facilitate	O
the	O
establishment	O
of	O
body	O
representations	O
.	O

Hence	O
,	O
the	O
development	O
of	O
the	O
BRS	O
not	O
only	O
relies	O
on	O
structural	O
maturation	O
,	O
but	O
also	O
involves	O
the	O
disengagement	O
of	O
an	O
executive	O
region	O
not	O
classically	O
involved	O
in	O
body	O
processing	O
.	O

The	O
FLASHE	O
Study	O
:	O
Survey	O
Development	O
,	O
Dyadic	O
Perspectives	O
,	O
and	O
Participant	O
Characteristics	O
.	O

The	O
National	O
Cancer	O
Institute	O
developed	O
the	O
Family	O
Life	O
,	O
Activity	O
,	O
Sun	O
,	O
Health	O
,	O
and	O
Eating	O
(	O
FLASHE	O
)	O
Study	O
to	O
examine	O
multiple	O
cancer	O
preventive	O
behaviors	O
within	O
parent	O
-	O
adolescent	O
dyads	O
.	O

The	O
purpose	O
of	O
creating	O
FLASHE	O
was	O
to	O
enable	O
the	O
examination	O
of	O
physical	O
activity	O
,	O
diet	O
,	O
and	O
other	O
cancer	O
preventive	O
behaviors	O
and	O
potential	O
correlates	O
among	O
parent	O
-	O
adolescent	O
dyads	O
.	O

FLASHE	O
surveys	O
were	O
developed	O
from	O
a	O
process	O
involving	O
literature	O
reviews	O
,	O
scientific	O
input	O
from	O
experts	O
in	O
the	O
field	O
,	O
cognitive	B-P
testing	I-P
,	O
and	O
usability	O
testing	O
.	O

This	O
cross-sectional	O
,	O
web-based	O
study	O
of	O
parents	O
and	O
their	O
adolescent	O
children	O
(	O
aged	O
12-17	O
years	O
)	O
was	O
administered	O
between	O
April	O
and	O
October	O
2014	O
.	O

The	O
nationwide	O
sample	O
consisted	O
of	O
1,573	O
parent	O
-	O
adolescent	O
dyads	O
(	O
1,699	O
parents	O
and	O
1,581	O
adolescents	O
)	O
who	O
returned	O
all	O
FLASHE	O
surveys	O
.	O

FLASHE	O
assessed	O
parent	O
and	O
adolescent	O
reports	O
of	O
several	O
intrapersonal	O
and	O
interpersonal	O
domains	O
(	O
including	O
psychosocial	O
variables	O
,	O
parenting	O
,	O
and	O
the	O
community	O
and	O
home	O
environments	O
)	O
.	O

On	O
a	O
subset	O
of	O
example	O
FLASHE	O
items	O
across	O
these	O
domains	O
,	O
responses	O
of	O
parents	O
and	O
adolescents	O
within	O
the	O
same	O
dyads	O
were	O
positively	O
and	O
significantly	O
correlated	O
(	O
r	O
=0.32-0.63	O
)	O
.	O

Analyses	O
were	O
run	O
in	O
2015-2016	O
.	O

FLASHE	O
data	O
present	O
multiple	O
opportunities	O
for	O
studying	O
research	O
questions	O
among	O
individuals	O
or	O
dyads	O
,	O
including	O
the	O
ability	O
to	O
examine	O
similarity	O
between	O
parents	O
and	O
adolescents	O
on	O
many	O
constructs	O
relevant	O
to	O
cancer	O
preventive	O
behaviors	O
.	O

FLASHE	O
data	O
are	O
publicly	O
available	O
for	O
researchers	O
and	O
practitioners	O
to	O
help	O
advance	O
research	O
on	O
cancer	O
preventive	O
health	O
behaviors	O
.	O

Inhibitory	O
effects	O
of	O
Lactobacillus	O
rhamnosus	O
and	O
Lactobacillus	O
casei	O
on	O
Candida	O
biofilm	O
of	O
denture	O
surface	O
.	O

Candida	O
albicans	O
biofilm	O
is	O
associated	O
with	O
denture-related	O
stomatitis	O
and	O
oral	O
candidiasis	O
of	O
elderly	O
.	O

Probiotics	O
are	O
beneficial	O
bacteria	O
and	O
have	O
antibacterial	O
activity	O
against	O
pathogenic	O
bacteria	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
antifungal	O
activity	O
of	O
various	O
probiotics	O
against	O
C.	O
albicans	O
and	O
the	O
inhibitory	O
effects	O
of	O
probiotics	O
on	O
Candida	O
biofilm	O
on	O
the	O
denture	O
surface	O
.	O

The	O
spent	O
culture	O
media	O
of	O
various	O
probiotics	O
were	O
investigated	O
the	O
antifungal	O
efficacy	O
against	O
C.	O
albicans	O
.	O

Candida	O
biofilm	O
was	O
formed	O
on	O
a	O
denture	O
base	O
resin	O
and	O
was	O
then	O
treated	O
with	O
Lactobacillus	O
rhamnosus	O
and	O
Lactobacillus	O
casei	O
.	O

Also	O
,	O
the	O
biofilm	O
s	O
of	O
L.	O
rhamnosus	O
and	O
L.	O
casei	O
were	O
formed	O
and	O
were	O
sequentially	O
treated	O
with	O
C.	O
albicans	O
.	O

Colony-forming	O
units	O
of	O
C.	O
albicans	O
on	O
the	O
denture	O
surface	O
were	O
counted	O
after	O
spreading	O
on	O
agar	O
plate	O
.	O

The	O
denture	O
base	O
resin	O
was	O
treated	O
with	O
the	O
spent	O
culture	O
media	O
for	O
30	O
days	O
,	O
after	O
which	O
the	O
denture	O
surface	O
roughness	O
was	O
analyzed	O
with	O
an	O
atomic	B-P
force	I-P
microscope	I-P
.	O

L.	O
rhamnosus	O
and	O
L.	O
casei	O
exhibited	O
stronger	O
antifungal	O
activity	O
than	O
other	O
probiotics	O
.	O

The	O
spent	O
culture	O
medium	O
of	O
L.	O
rhamnosus	O
and	O
L.	O
casei	O
exhibited	O
the	O
antifungal	O
activity	O
against	O
blastoconidia	O
and	O
biofilm	O
of	O
C.	O
albicans	O
.	O

L.	O
rhamnosus	O
and	O
L.	O
casei	O
showed	O
the	O
antifungal	O
activity	O
against	O
Candida	O
biofilm	O
,	O
and	O
the	O
biofilm	O
of	O
L.	O
rhamnosus	O
and	O
L.	O
casei	O
inhibited	O
formation	O
of	O
Candida	O
biofilm	O
on	O
denture	O
surface	O
.	O

Neither	O
of	O
the	O
probiotics	O
affected	O
the	O
surface	O
roughness	O
of	O
the	O
denture	O
base	O
resin	O
.	O

L.	O
rhamnosus	O
and	O
L.	O
casei	O
may	O
be	O
the	O
ideal	O
probiotics	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
denture-related	O
stomatitis	O
.	O

Antihyperalgesic	O
effect	O
of	O
CB1	O
receptor	O
activation	O
involves	O
the	O
modulation	O
of	O
P2X3	O
receptor	O
in	O
the	O
primary	O
afferent	O
neuron	O
.	O

Cannabinoid	O
system	O
is	O
a	O
potential	O
target	O
for	O
pain	O
control	O
.	O

Cannabinoid	O
receptor	O
1	O
(	O
CB1	O
)	O
activation	O
play	O
a	O
role	O
in	O
the	O
analgesic	O
effect	O
of	O
cannabinoids	O
once	O
it	O
is	O
expressed	O
in	O
primary	O
afferent	O
neurons	O
.	O

This	O
study	O
investigates	O
whether	O
the	O
anti-hyperalgesic	O
effect	O
of	O
CB1	O
receptor	O
activation	O
involves	O
P2X3	O
receptor	O
in	O
primary	O
afferent	O
neurons	O
.	O

Mechanical	O
hyperalgesia	O
was	O
evaluated	O
by	O
electronic	B-P
von	I-P
Frey	I-P
test	I-P
.	O

Cannabinoid	O
effect	O
was	O
evaluated	O
using	O
anandamide	O
or	O
ACEA	O
,	O
a	O
non-selective	O
or	O
a	O
selective	O
CB1	O
receptor	O
agonists	O
,	O
respectively	O
;	O
AM251	O
,	O
a	O
CB1	O
receptor	O
antagonist	O
,	O
and	O
antisense	O
ODN	O
for	O
CB1	O
receptor	O
.	O

Calcium	O
imaging	B-P
assay	I-P
was	O
performed	O
to	O
evaluated	O
α	O
,	O
β-meATP	O
-	O
responsive	O
cultured	O
DRG	O
neurons	O
pretreated	O
with	O
ACEA	O
.	O

Anandamide	O
or	O
ACEA	O
administered	O
in	O
peripheral	O
tissue	O
reduced	O
the	O
carrageenan	O
-induced	O
mechanical	O
hyperalgesia	O
.	O

The	O
reduction	O
in	O
the	O
carrageenan	O
-induced	O
hyperalgesia	O
induced	O
by	O
ACEA	O
was	O
completely	O
reversed	O
by	O
administration	O
of	O
AM251	O
as	O
well	O
as	O
by	O
the	O
intrathecal	O
treatment	O
with	O
antisense	O
ODN	O
for	O
CB1	O
receptor	O
.	O

Also	O
,	O
ACEA	O
reduced	O
the	O
mechanical	O
hyperalgesia	O
induced	O
by	O
bradykinin	O
and	O
by	O
α	O
,	O
β-meATP	O
,	O
a	O
P2X3	O
receptor	O
non-selective	O
agonist	O
,	O
but	O
not	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-α	O
)	O
,	O
interleukin-1	O
beta	O
(	O
IL-1β	O
)	O
and	O
chemokine	O
-induced	O
chemoattractant-1	O
(	O
CINC-1	O
)	O
.	O

Finally	O
,	O
CB1	O
receptor	O
s	O
are	O
co-localized	O
with	O
P2X3	O
receptors	O
in	O
DRG	O
small-diameter	O
neurons	O
and	O
the	O
treatment	O
with	O
ACEA	O
reduced	O
the	O
number	O
of	O
α	O
,	O
β-meATP	O
-	O
responsive	O
cultured	O
DRG	O
neurons	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
analgesic	O
effect	O
of	O
CB1	O
receptor	O
activation	O
is	O
mediated	O
by	O
a	O
negative	O
modulation	O
of	O
the	O
P2X3	O
receptor	O
in	O
the	O
primary	O
afferent	O
neurons	O
.	O

Gain-of-function	O
mutation	O
in	O
SCN5A	O
causes	O
ventricular	O
arrhythmias	O
and	O
early	O
onset	O
atrial	O
fibrillation	O
.	O

Mutations	O
in	O
SCN5A	O
,	O
the	O
gene	O
encoding	O
the	O
α-subunit	O
of	O
the	O
cardiac	O
sodium	O
channel	O
(	O
NaV1.5	O
)	O
,	O
are	O
associated	O
with	O
a	O
broad	O
spectrum	O
of	O
inherited	O
cardiac	O
arrhythmia	O
disorders	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
genetic	O
and	O
functional	O
determinants	O
underlying	O
a	O
Dutch	O
family	O
that	O
presented	O
with	O
a	O
combined	O
phenotype	O
of	O
ventricular	O
arrhythmias	O
with	O
a	O
likely	O
adrenergic	O
component	O
,	O
either	O
in	O
isolation	O
or	O
in	O
combination	O
with	O
a	O
mildly	O
decreased	O
heart	O
function	O
and	O
early	O
onset	O
(	O
<	O
55	O
years	O
)	O
atrial	O
fibrillation	O
.	O

We	O
performed	O
next	O
generation	O
sequencing	O
in	O
the	O
proband	O
of	O
a	O
two-	O
generation	O
Dutch	O
family	O
and	O
demonstrated	O
a	O
novel	O
missense	O
mutation	O
in	O
SCN5A-	O
(	O
p.M1851V	O
)	O
which	O
co-segregated	O
with	O
the	O
clinical	O
phenotype	O
in	O
the	O
family	O
.	O

We	O
functionally	O
evaluated	O
the	O
putative	O
genetic	O
defect	O
by	O
patch	O
clamp	O
electrophysiological	B-P
studies	I-P
in	O
human	O
embryonic	O
kidney	O
cells	O
transfected	O
with	O
mutant	O
or	O
wild-type	O
Nav1.5	O
.	O

The	O
current	O
inactivation	O
was	O
slower	O
and	O
recovery	O
from	O
inactivation	O
was	O
faster	O
in	O
SCN5A-M1851V	O
channels	O
.	O

The	O
voltage	O
dependence	O
of	O
inactivation	O
was	O
shifted	O
towards	O
more	O
positive	O
potentials	O
and	O
consequently	O
,	O
a	O
larger	O
TTX	O
-	O
sensitive	O
window	O
current	O
was	O
observed	O
in	O
SCN5A-M1851V	O
channels	O
.	O

Furthermore	O
,	O
a	O
higher	O
upstroke	O
velocity	O
was	O
observed	O
for	O
the	O
SCN5A-M1851V	O
channels	O
,	O
while	O
the	O
depolarization	O
voltage	O
was	O
more	O
negative	O
,	O
both	O
indicating	O
increased	O
excitability	O
.	O

This	O
mutation	O
leads	O
to	O
a	O
gain-of-function	O
mechanism	O
based	O
on	O
increased	O
channel	O
availability	O
and	O
increased	O
window	O
current	O
,	O
fitting	O
the	O
observed	O
clinical	O
phenotype	O
of	O
(	O
likely	O
adrenergic-induced	O
)	O
ventricular	O
arrhythmias	O
and	O
atrial	O
fibrillation	O
.	O

These	O
findings	O
further	O
expand	O
the	O
range	O
of	O
cardiac	O
arrhythmias	O
associated	O
with	O
mutations	O
in	O
SCN5A	O
.	O

Co-delivery	O
of	O
pemetrexed	O
and	O
miR-21	O
antisense	O
oligonucleotide	O
by	O
lipid	O
-	O
polymer	O
hybrid	O
nanoparticles	O
and	O
effects	O
on	O
glioblastoma	O
cells	O
.	O

Combination	O
therapy	O
using	O
anticancer	O
drugs	O
and	O
nucleic	O
acid	O
is	O
a	O
more	O
promising	O
strategy	O
to	O
overcome	O
multidrug	O
resistance	O
in	O
cancer	O
and	O
to	O
enhance	O
apoptosis	O
.	O

In	O
this	O
study	O
,	O
lipid	O
-	O
polymer	O
hybrid	O
nanoparticles	O
(	O
LPNs	O
)	O
,	O
which	O
contain	O
both	O
pemetrexed	O
and	O
miR-21	O
antisense	O
oligonucleotide	O
(	O
anti-miR-21	O
)	O
,	O
have	O
been	O
developed	O
for	O
treatment	O
of	O
glioblastoma	O
,	O
the	O
most	O
aggressive	O
type	O
of	O
brain	O
tumor	O
.	O

Prepared	O
LPNs	O
have	O
been	O
well	O
characterized	O
by	O
particle	O
size	O
distribution	O
and	O
zeta	O
potential	O
measurements	O
,	O
determination	O
of	O
encapsulation	O
efficiency	O
,	O
and	O
in	O
vitro	O
release	O
experiments	O
.	O

Morphology	O
of	O
LPNs	O
was	O
determined	O
by	O
transmission	B-P
electron	I-P
microscopy	I-P
.	O

LPNs	O
had	O
a	O
hydrodynamic	O
size	O
below	O
100	O
nm	O
and	O
exhibited	O
sustained	O
release	O
of	O
pemetrexed	O
up	O
to	O
10	O
h.	O
Encapsulation	O
of	O
pemetrexed	O
in	O
LPNs	O
increased	O
cellular	O
uptake	O
from	O
6	O
%	O
to	O
78	O
%	O
.	O

Results	O
of	O
confocal	B-P
microscopy	I-P
analysis	I-P
have	O
shown	O
that	O
co-delivery	O
of	O
anti-miR-21	O
significantly	O
improved	O
accumulation	O
of	O
LPNs	O
in	O
the	O
nucleus	O
of	O
U87MG	O
cells	O
.	O

Nevertheless	O
,	O
more	O
effective	O
cytotoxicity	O
results	O
could	O
not	O
be	O
obtained	O
due	O
to	O
low	O
concentration	O
of	O
anti-miR-21	O
,	O
loaded	O
in	O
LPNs	O
.	O

We	O
expect	O
that	O
the	O
effective	O
drug	O
delivery	O
systems	O
can	O
be	O
obtained	O
with	O
higher	O
concentration	O
of	O
anti-miR-21	O
for	O
the	O
treatment	O
of	O
glioblastoma	O
.	O

Multiplexing	O
Fluorescence	O
Anisotropy	O
Using	O
Frequency	B-P
Encoding	I-P
.	O

In	O
this	O
report	O
,	O
a	O
method	O
to	O
multiplex	O
fluorescence	O
anisotropy	O
measurements	O
is	O
described	O
using	O
frequency	B-P
encoding	I-P
.	O

As	O
a	O
demonstration	O
of	O
the	O
method	O
,	O
simultaneous	O
competitive	O
immunoassays	B-P
for	O
insulin	O
and	O
glucagon	O
were	O
performed	O
by	O
measuring	O
the	O
ratio	O
of	O
bound	O
and	O
free	O
Cy5-insulin	O
and	O
FITC-glucagon	O
in	O
the	O
presence	O
of	O
their	O
respective	O
antibodies	O
.	O

A	O
vertically	O
polarized	O
635	O
nm	O
laser	O
was	O
pulsed	O
at	O
73	O
Hz	O
and	O
used	O
to	O
excite	O
Cy5-insulin	O
,	O
while	O
a	O
vertically	O
polarized	O
488	O
nm	O
laser	O
pulsed	O
at	O
137	O
Hz	O
excited	O
FITC-glucagon	O
.	O

The	O
total	O
emission	O
was	O
split	O
into	O
parallel	O
and	O
perpendicular	O
polarizations	B-P
and	O
collected	O
onto	O
separate	O
photomultiplier	O
tubes	O
.	O

The	O
signals	O
from	O
each	O
channel	O
were	O
demodulated	O
using	O
a	O
fast	O
Fourier	O
transform	O
,	O
resolving	O
the	O
contributions	O
from	O
each	O
fluorophore	O
.	O

Anisotropy	O
calculations	B-P
were	O
carried	O
out	O
using	O
the	O
magnitude	O
of	O
the	O
peaks	O
in	O
the	O
frequency	O
domain	O
.	O

The	O
method	O
produced	O
the	O
expected	O
shape	O
of	O
the	O
calibration	O
curves	O
with	O
limits	O
of	O
detection	O
of	O
0.6	O
and	O
5	O
nM	O
for	O
insulin	O
and	O
glucagon	O
,	O
respectively	O
.	O

This	O
methodology	O
could	O
readily	O
be	O
expanded	O
to	O
other	O
biological	O
systems	O
and	O
further	O
multiplexed	O
to	O
monitor	O
increased	O
numbers	O
of	O
analytes	O
.	O

Effects	O
of	O
Inhalable	O
Microparticles	O
of	O
Seonpyejeongcheon-Tang	O
in	O
an	O
Asthma	O
Mouse	O
Model	O
:	O
-	O
Effects	O
of	O
Microparticles	O
of	O
SJT	O
.	O

Allergic	O
asthma	O
generally	O
presents	O
with	O
symptoms	O
of	O
wheezing	O
,	O
coughing	O
,	O
breathlessness	O
,	O
and	O
airway	O
inflammation	O
.	O

Seonpyejeongcheon-tang	O
(	O
SJT	O
)	O
consists	O
of	O
12	O
herbs	O
.	O

It	O
originated	O
from	O
Jeongcheon-tang	O
(	O
JT	O
)	O
,	O
also	O
known	O
as	O
Ding-chuan-tang	O
,	O
composed	O
of	O
7	O
herbs	O
,	O
in	O
She-sheng-zhong-miao-fang	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
effects	O
of	O
local	O
delivery	O
of	O
SJT	O
via	O
inhalable	O
microparticles	O
in	O
an	O
asthma	O
mouse	O
model	O
.	O

Microparticles	O
containing	O
SJT	O
were	O
produced	O
by	O
spray-drying	B-P
with	O
leucine	O
as	O
an	O
excipient	O
.	O

SJT	O
microparticles	O
were	O
evaluated	O
with	O
respect	O
to	O
their	O
aerodynamic	O
properties	O
,	O
in	O
vitro	O
cytotoxicity	B-P
,	O
in	O
vivo	O
toxicity	O
,	O
and	O
therapeutic	O
effects	O
on	O
ovalbumin	O
(	O
OVA	O
)	O
-	O
induced	O
asthma	O
in	O
comparison	O
with	O
orally-administered	O
SJT	O
.	O

SJT	O
microparticles	O
provided	O
desirable	O
aerodynamic	O
properties	O
(	O
fine	O
particle	O
fraction	O
of	O
48.9	O
%	O
±	O
6.4	O
%	O
and	O
mass	O
median	O
aerodynamic	O
diameter	O
of	O
3.7	O
±	O
0.3	O
μm	O
)	O
.	O

SJT	O
microparticles	O
did	O
not	O
show	O
any	O
cytotoxicity	B-P
against	O
RAW	O
264.7	O
macrophages	O
at	O
concentrations	O
of	O
0.01	O
-	O
3	O
mg/mL	O
.	O

Inhaled	O
SJT	O
microparticles	O
decreased	O
the	O
levels	O
of	O
IL-4	O
,	O
IL-5	O
,	O
IL-13	O
,	O
IL-17A	O
,	O
eotaxin	O
and	O
OVA-IgE	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
in	O
mice	O
with	O
OVA	O
-	O
induced	O
asthma	O
.	O

These	O
effects	O
were	O
verified	O
by	O
histological	O
evaluation	O
of	O
the	O
levels	O
of	O
infiltration	O
of	O
inflammatory	O
cells	O
and	O
collagen	O
,	O
destructions	O
of	O
alveoli	O
and	O
bronchioles	O
,	O
and	O
hyperplasia	O
of	O
goblet	O
cells	O
in	O
lung	O
tissues	O
.	O

The	O
effects	O
of	O
SJT	O
microparticles	O
in	O
the	O
asthma	O
model	O
were	O
equivalent	O
to	O
those	O
of	O
orally-administered	O
SJT	O
extract	O
.	O

This	O
study	O
suggests	O
that	O
SJT	O
is	O
a	O
promising	O
agent	O
for	O
inhalation	O
therapy	O
for	O
patients	O
with	O
asthma	O
.	O

Supramolecular	O
Recognition	O
of	O
Amino	O
Acids	O
by	O
Twisted	O
Cucurbit	O
[	O
14	O
]	O
uril	O
.	O

Binding	O
interactions	O
between	O
twisted	O
cucurbit	O
[	O
14	O
]	O
uril	O
(	O
tQ	O
[	O
14	O
]	O
)	O
and	O
twenty	O
standard	O
amino	O
acids	O
(	O
AAs	O
)	O
have	O
been	O
investigated	O
by	O
NMR	B-P
spectroscopy	I-P
and	O
isothermal	B-P
titration	I-P
calorimetry	I-P
(	B-P
ITC	I-P
)	I-P
in	O
aqueous	O
HCl	O
solutions	O
and	O
in	O
DMSO	O
.	O

The	O
results	O
showed	O
that	O
tQ	O
[	O
14	O
]	O
displays	O
clear	O
binding	O
affinity	O
for	O
AAs	O
with	O
a	O
positively	O
charged	O
side	O
chain	O
or	O
containing	O
an	O
aromatic	O
ring	O
,	O
but	O
weaker	O
binding	O
affinity	O
for	O
AAs	O
with	O
hydrophobic	O
or	O
polar	O
side	O
chains	O
,	O
with	O
the	O
binding	O
mode	O
depending	O
on	O
the	O
type	O
of	O
side	O
chain	O
present	O
in	O
the	O
AAs	O
.	O

Extremely	O
Giant	O
Liver	O
Hemangioma	O
(	O
50	O
cm	O
)	O
with	O
Kasabach-Merritt	O
Syndrome	O
.	O

A	O
33-	O
year	O
-	O
old	O
male	O
has	O
been	O
found	O
with	O
a	O
giant	O
liver	O
hemangioma	O
of	O
initial	O
size	O
29	O
cm	O
for	O
5	O
years	O
.	O

He	O
received	O
arterial	O
embolization	O
twice	O
in	O
order	O
to	O
shrink	O
the	O
tumor	O
;	O
however	O
,	O
no	O
effect	O
was	O
obtained	O
.	O

The	O
tumor	O
had	O
rapidly	O
grown	O
to	O
50	O
cm	O
and	O
caused	O
abnormalities	O
in	O
the	O
hematological	O
and	O
coagulative	O
systems	O
.	O

Preoperative	O
computed	B-P
tomography	I-P
revealed	O
that	O
the	O
right	O
hepatic	O
vein	O
,	O
right	O
hepatic	O
artery	O
,	O
and	O
right	O
portal	O
vein	O
were	O
not	O
involved	O
by	O
the	O
hemangioma	O
.	O

Resection	O
of	O
the	O
giant	O
liver	O
hemangioma	O
was	O
successfully	O
performed	O
after	O
intraoperative	O
intentional	O
bloodletting	O
with	O
concurrent	O
blood	O
salvage	O
.	O

All	O
hematological	O
and	O
coagulative	O
abnormalities	O
had	O
returned	O
to	O
normal	O
after	O
the	O
procedure	O
.	O

Body	O
mass	O
index	O
and	O
suicide	O
methods	O
.	O

Overweight	O
and	O
obesity	O
is	O
associated	O
with	O
lower	O
rates	O
of	O
suicide	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
association	O
with	O
different	O
suicide	O
methods	O
.	O

We	O
studied	O
the	O
association	O
between	O
groups	O
of	O
body	O
mass	O
index	O
and	O
suicide	O
methods	O
.	O

We	O
identified	O
all	O
medicolegal	O
autopsy	B-P
cases	O
with	O
a	O
cause	O
of	O
death	O
due	O
to	O
external	O
causes	O
in	O
Sweden	O
during	O
1999-2013	O
(	O
N	O
=	O
39,368	O
)	O
and	O
included	O
11,715	O
suicides	O
and	O
13,316	O
accidents	O
or	O
homicides	O
as	O
controls	O
.	O

We	O
applied	O
multinomial	O
regression	O
models	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
year	O
and	O
season	O
of	O
death	O
.	O

Obesity	O
was	O
associated	O
with	O
suicidal	O
intoxication	O
,	O
OR	O
1.15	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.02	O
,	O
1.30	O
]	O
and	O
negatively	O
associated	O
with	O
all	O
other	O
suicide	O
methods	O
studied	O
.	O

Underweight	O
showed	O
a	O
negative	O
association	O
with	O
suicidal	O
drowning	O
and	O
there	O
was	O
an	O
indication	O
towards	O
a	O
negative	O
association	O
with	O
hanging	O
in	O
men	O
OR	O
0.81	O
(	O
95	O
%	O
CI	O
0.65	O
,	O
1.01	O
)	O
.	O

We	O
conclude	O
that	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
is	O
associated	O
with	O
the	O
choice	O
of	O
suicide	O
method	O
.	O

This	O
may	O
be	O
of	O
importance	O
in	O
a	O
public	O
health	O
perspective	O
,	O
e.g	O
.	O

potential	O
for	O
prevention	O
of	O
intoxications	O
.	O

In	O
the	O
practice	O
of	O
forensic	O
medicine	O
,	O
the	O
physician	O
's	O
level	O
of	O
suspicion	O
may	O
rise	O
if	O
the	O
apparent	O
suicidal	O
method	O
is	O
less	O
common	O
for	O
the	O
individual	O
characteristics	O
of	O
the	O
deceased	O
,	O
such	O
as	O
BMI	O
.	O

Clinical	B-P
imaging	I-P
in	O
patients	O
with	O
fever	O
and	O
suspected	O
endocarditis	O
.	O

Echocardiography	B-P
remains	O
the	O
cornerstone	O
of	O
the	O
diagnostic	O
of	O
anatomic	O
lesions	O
and	O
consequences	O
on	O
cardiac	O
function	O
caused	O
by	O
infective	O
endocarditis	O
(	O
IE	O
)	O
.	O

There	O
is	O
now	O
evidence	O
that	O
other	O
imaging	B-P
techniques	I-P
are	O
useful	O
in	O
reducing	O
the	O
number	O
of	O
non-conclusive	O
diagnoses	O
,	O
in	O
particular	O
when	O
IE	O
is	O
suspected	O
on	O
prosthetic	O
material	O
or	O
devices	O
.	O

Besides	O
diagnosis	O
,	O
cardiac	B-P
imaging	I-P
strongly	O
contributes	O
to	O
prognostic	O
assessment	O
,	O
indications	O
for	O
early	O
surgery	O
and	O
patient	O
follow-up	O
.	O

It	O
is	O
required	O
a	O
specific	O
expertise	O
for	O
implementing	O
and	O
interpreting	O
all	O
imaging	B-P
techniques	I-P
and	O
the	O
complexity	O
of	O
decision-making	O
highlights	O
the	O
need	O
for	O
a	O
multidisciplinary	O
management	O
of	O
difficult	O
cases	O
in	O
specialized	O
endocarditis	O
teams	O
.	O

Propulsion	O
strategy	O
in	O
the	O
gait	O
of	O
primary	O
school	O
children	O
;	O
the	O
effect	O
of	O
age	O
and	O
speed	O
.	O

The	O
strategy	O
used	O
to	O
generate	O
power	O
for	O
forward	O
propulsion	O
in	O
walking	O
and	O
running	O
has	O
recently	O
been	O
highlighted	O
as	O
a	O
marker	O
of	O
gait	O
maturation	O
and	O
elastic	O
energy	O
recycling	O
.	O

This	O
study	O
investigated	O
ankle	O
and	O
hip	O
power	O
generation	O
as	O
a	O
propulsion	O
strategy	O
(	O
PS	O
)	O
during	O
the	O
late	O
stance	O
/	O
early	O
swing	O
phases	O
of	O
walking	O
and	O
running	O
in	O
typically	O
developing	O
(	O
TD	O
)	O
children	O
(	O
15	O
:	O
six	O
to	O
nine	O
years	O
;	O
17	O
:	O
nine	O
to	O
13	O
years	O
)	O
using	O
three-dimensional	O
gait	B-P
analysis	I-P
.	O

Peak	O
ankle	O
power	O
generation	O
at	O
push-off	O
(	O
peakA2	O
)	O
,	O
peak	O
hip	O
power	O
generation	O
in	O
early	O
swing	O
(	O
peakH3	O
)	O
and	O
propulsion	O
strategy	O
(	O
PS	O
)	O
[	O
peakA2	O
/	O
(	O
peakA2+peakH3	O
)	O
]	O
were	O
calculated	O
to	O
provide	O
the	O
relative	O
contribution	O
of	O
ankle	O
power	O
to	O
total	O
propulsion	O
.	O

Mean	O
PS	O
values	O
decreased	O
as	O
speed	O
increased	O
for	O
comfortable	O
walking	O
(	O
p	O
<	O
0.001	O
)	O
,	O
fast	O
walking	O
(	O
p	O
<	O
0.001	O
)	O
and	O
fast	O
running	O
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
less	O
consistently	O
during	O
jogging	O
(	O
p=0.054	O
)	O
.	O

PS	O
varied	O
with	O
age	O
(	O
p	O
<	O
0.001	O
)	O
only	O
during	O
fast	O
walking	O
.	O

At	O
any	O
speed	O
of	O
fast	O
walking	O
,	O
older	O
children	O
generated	O
more	O
peakA2	O
(	O
p=0.001	O
)	O
and	O
less	O
peakH3	O
(	O
p=0.001	O
)	O
than	O
younger	O
children	O
.	O

While	O
the	O
kinetics	O
of	O
running	O
propulsion	O
appear	O
to	O
be	O
developed	O
by	O
age	O
six	O
years	O
,	O
the	O
skills	O
of	O
fast	O
walking	O
appeared	O
to	O
require	O
additional	O
neuromuscular	O
maturity	O
.	O

These	O
findings	O
support	O
the	O
concept	O
that	O
running	O
is	O
a	O
skill	O
that	O
matures	O
early	O
for	O
TD	O
children	O
.	O

Percutaneous	O
forefoot	O
surgery	O
for	O
treatment	O
of	O
hallux	O
valgus	O
deformity	O
:	O
an	O
intermediate	O
prospective	O
study	O
.	O

This	O
study	O
aims	O
to	O
illustrate	O
the	O
results	O
of	O
percutaneous	O
forefoot	O
surgery	O
(	O
PFS	O
)	O
for	O
correction	O
of	O
hallux	O
valgus	O
.	O

A	O
prospective	O
study	O
of	O
108	O
patients	O
,	O
with	O
hallux	O
valgus	O
deformity	O
,	O
who	O
underwent	O
PFS	O
was	O
conducted	O
.	O

The	O
minimum	O
clinical	O
and	O
radiological	O
follow-up	O
was	O
two	O
years	O
(	O
mean	O
57.3	O
months	O
,	O
range	O
22-112	O
)	O
.	O

Preoperative	B-P
mean	I-P
visual	I-P
analog	I-P
scale	I-P
was	O
6.3	O
±	O
1.5	O
points	O
,	O
and	O
AOFAS	O
scores	O
were	O
50.6	O
±	O
11	O
points	O
.	O

At	O
the	O
last	O
follow-up	O
,	O
both	O
scores	O
improved	O
to	O
1.9	O
±	O
2.4	O
points	O
and	O
85.9	O
±	O
1.83	O
points	O
,	O
respectively	O
.	O

Mean	O
hallux	O
valgus	O
angle	O
changed	O
from	O
34.3°	O
±	O
9.3°	O
preoperatively	O
to	O
22.5°	O
±	O
11.1°	O
at	O
follow-up	O
.	O

At	O
follow-up	O
,	O
76.5	O
%	O
of	O
the	O
subjects	O
were	O
satisfied	O
or	O
very	O
satisfied	O
.	O

Recurrence	O
of	O
medial	O
1st	O
MT	O
head	O
pain	O
happened	O
in	O
22	O
cases	O
(	O
16.7	O
%	O
)	O
.	O

PFS	O
,	O
in	O
our	O
study	O
,	O
does	O
not	O
improve	O
the	O
radiological	O
and	O
patient	O
satisfaction	O
rate	O
results	O
compared	O
with	O
conventional	O
procedures	O
.	O

The	O
main	O
advantage	O
is	O
a	O
low	O
postoperative	O
pain	O
level	O
,	O
but	O
with	O
an	O
insufficient	O
HVA	O
correction	O
.	O

II	O
,	O
prospective	O
study	O
.	O

Contrasting	O
effects	O
of	O
intra	O
-	O
and	O
interspecific	O
identity	O
and	O
richness	O
of	O
ectomycorrhizal	O
fungi	O
on	O
host	O
plants	O
,	O
nutrient	O
retention	O
and	O
multifunctionality	O
.	O

A	O
major	O
gap	O
in	O
our	O
understanding	O
of	O
biodiversity	O
-	O
ecosystem	O
function	O
relationships	O
concerns	O
the	O
role	O
of	O
intra	O
-	O
and	O
interspecific	O
diversity	O
of	O
mycorrhizal	O
fungi	O
,	O
which	O
are	O
critical	O
for	O
plant	O
fitness	O
,	O
biogeochemical	O
cycling	O
and	O
other	O
processes	O
.	O

Here	O
,	O
we	O
test	O
the	O
hypothesis	O
that	O
the	O
identity	O
and	O
richness	O
of	O
ectomycorrhizal	O
(	O
ECM	O
)	O
fungi	O
at	O
the	O
intra-	O
and	O
interspecific	O
levels	O
affect	O
ecosystem	O
multifunctionality	O
by	O
regulating	O
plant	O
and	O
fungal	O
productivity	O
,	O
soil	O
CO2	O
efflux	O
and	O
nutrient	O
retention	O
.	O

Microcosms	O
containing	O
Scots	O
pine	O
(	O
Pinus	O
sylvestris	O
)	O
seedlings	O
colonized	O
by	O
different	O
ECM	O
fungal	O
isolates	O
,	O
in	O
monocultures	B-P
and	O
mixtures	B-P
,	O
enabled	O
us	O
to	O
test	O
for	O
both	O
intra-	O
and	O
interspecific	O
identity	O
and	O
richness	O
effects	O
,	O
and	O
transgressive	O
overyielding	O
.	O

Intra-	O
and	O
interspecific	O
identity	O
had	O
modest	O
but	O
significant	O
effects	O
on	O
plant	O
and	O
fungal	O
productivity	O
and	O
nutrient	O
retention	O
,	O
but	O
no	O
effect	O
on	O
CO2	O
efflux	O
.	O

Intraspecific	O
richness	O
increased	O
plant	O
root	O
productivity	O
and	O
ECM	O
root	O
tips	O
but	O
decreased	O
hyphal	O
length	O
,	O
whereas	O
interspecific	O
richness	O
had	O
no	O
effects	O
.	O

Interspecific	O
mixtures	O
outperformed	O
the	O
most	O
productive	O
monocultures	B-P
in	O
only	O
10	O
%	O
of	O
the	O
cases	O
,	O
compared	O
with	O
42	O
%	O
for	O
the	O
intraspecific	O
mixtures	O
.	O

Both	O
intra	O
-	O
and	O
interspecific	O
identity	O
and	O
richness	O
of	O
ECM	O
fungi	O
regulate	O
ecosystem	O
multifunctionality	O
,	O
but	O
their	O
effects	O
on	O
the	O
direction	O
and	O
magnitude	O
of	O
individual	O
variables	O
differ	O
.	O

Transgressive	O
overyielding	O
suggests	O
that	O
positive	O
niche	O
complementarity	O
effects	O
are	O
driving	O
some	O
of	O
the	O
responses	O
to	O
intraspecific	O
richness	O
.	O

Common	O
and	O
Uncommon	O
Anatomical	O
Variants	O
of	O
Intrahepatic	O
Bile	O
Ducts	O
in	O
Magnetic	B-P
Resonance	I-P
Cholangiopancreatography	I-P
and	O
its	O
Clinical	O
Implication	O
.	O

Preoperative	O
knowledge	O
of	O
intrahepatic	O
bile	O
duct	O
(	O
IHD	O
)	O
anatomy	O
is	O
critical	O
for	O
planning	O
liver	O
resections	O
,	O
liver	O
transplantations	O
and	O
complex	O
biliary	O
reconstructive	O
surgery	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
demonstrate	O
the	O
imaging	O
features	O
of	O
various	O
anatomical	O
variants	O
of	O
IHD	O
using	O
magnetic	B-P
resonance	I-P
cholangio-pancreatography	I-P
(	O
MRCP	B-P
)	O
and	O
their	O
prevalence	O
in	O
our	O
population	O
.	O

This	O
observational	O
clinical	O
evaluation	O
study	O
included	O
224	O
patients	O
who	O
were	O
referred	O
for	O
MRCP	B-P
.	O

MRCP	B-P
was	O
performed	O
in	O
a	O
1.5-Tesla	O
magnet	O
(	O
Philips	O
)	O
with	O
SSH	B-P
MRCP	I-P
3DHR	O
and	O
SSHMRCP	B-P
rad	O
protocol	O
.	O

A	O
senior	O
radiologist	O
assessed	O
the	O
biliary	O
passage	O
for	O
anatomical	O
variations	O
.	O

The	O
branching	O
pattern	O
of	O
the	O
right	O
hepatic	O
duct	O
(	O
RHD	O
)	O
was	O
typical	O
in	O
55.3	O
%	O
of	O
subjects	O
.	O

The	O
most	O
common	O
variant	O
was	O
right	O
posterior	O
sectoral	O
duct	O
(	O
RPSD	O
)	O
draining	O
into	O
the	O
left	O
hepatic	O
duct	O
(	O
LHD	O
)	O
in	O
27.6	O
%	O
of	O
subjects	O
.	O

Trifurcation	O
pattern	O
was	O
noted	O
in	O
9.3	O
%	O
of	O
subjects	O
.	O

In	O
4	O
%	O
of	O
subjects	O
,	O
RPSD	O
was	O
draining	O
into	O
the	O
common	O
hepatic	O
duct	O
(	O
CHD	O
)	O
and	O
in	O
0.8	O
%	O
of	O
subjects	O
into	O
the	O
cystic	O
duct	O
.	O

Other	O
variants	O
were	O
noted	O
in	O
2.6	O
%	O
of	O
subjects	O
.	O

In	O
4.9	O
%	O
of	O
cases	O
there	O
was	O
an	O
accessory	O
duct	O
.	O

The	O
most	O
common	O
type	O
of	O
LHD	O
branching	O
pattern	O
was	O
a	O
common	O
trunk	O
of	O
segment	O
2	O
and	O
3	O
ducts	O
joining	O
the	O
segment	O
4	O
duct	O
in	O
67.8	O
%	O
of	O
subjects	O
.	O

In	O
23.2	O
%	O
of	O
subjects	O
,	O
segment	O
2	O
duct	O
united	O
with	O
the	O
common	O
trunk	O
of	O
segment	O
3	O
and	O
4	O
and	O
in	O
3.4	O
%	O
of	O
subjects	O
segment	O
2	O
,	O
3	O
,	O
and	O
4	O
ducts	O
united	O
together	O
to	O
form	O
LHD	O
.	O

Other	O
uncommon	O
branching	O
patterns	O
of	O
LHD	O
were	O
seen	O
in	O
4.9	O
%	O
of	O
subjects	O
.	O

Intrahepatic	O
bile	O
duct	O
anatomy	O
is	O
complex	O
with	O
many	O
common	O
and	O
uncommon	O
variations	O
.	O

MRCP	B-P
is	O
a	O
reliable	O
non-invasive	O
imaging	B-P
method	I-P
for	O
demonstration	O
of	O
bile	O
duct	O
morpholog	O
y	O
,	O
which	O
is	O
useful	O
to	O
plan	O
complex	O
surgeries	O
and	O
to	O
prevent	O
iatrogenic	O
injuries	O
.	O

Chlamydia	O
pneumoniae	O
infection	O
promotes	O
vascular	O
endothelial	O
cell	O
angiogenesis	O
through	O
an	O
IQGAP1	O
-related	O
signaling	O
pathway	O
.	O

Chlamydia	O
pneumoniae	O
(	O
C.	O
pneumoniae	O
)	O
infection	O
plays	O
a	O
potential	O
role	O
in	O
angiogenesis	O
.	O

However	O
,	O
it	O
is	O
still	O
an	O
enigma	O
how	O
C.	O
pneumoniae	O
is	O
involved	O
in	O
this	O
process	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
C.	O
pneumoniae	O
infection	O
on	O
angiogenesis	O
,	O
and	O
then	O
explored	O
the	O
roles	O
of	O
IQGAP1	O
-related	O
signaling	O
in	O
C.	O
pneumoniae	O
infection	O
-	O
induced	O
angiogenesis	O
.	O

C.	O
pneumoniae	O
infection	O
significantly	O
enhanced	O
angiogenesis	O
as	O
assessed	O
by	O
the	O
tube	B-P
formation	I-P
assay	I-P
possibly	O
by	O
inducing	O
vascular	O
endothelial	O
cell	O
(	O
VEC	O
)	O
migration	O
in	O
the	O
wound	O
healing	O
and	O
Transwell	B-P
migration	I-P
assays	I-P
.	O

Subsequently	O
,	O
immunoprecipitation	B-P
,	O
Western	B-P
blot	I-P
and	O
tube	B-P
formation	I-P
assay	I-P
results	O
showed	O
that	O
the	O
phosphorylation	O
of	O
both	O
IQGAP1	O
and	O
N-WASP	O
was	O
required	O
for	O
the	O
angiogenesis	O
induced	O
by	O
C.	O
pneumoniae	O
infection	O
.	O

Our	O
co-immunoprecipitation	B-P
study	B-P
revealed	O
that	O
IQGAP1	O
physically	O
associated	O
with	O
N-WASP	O
after	O
C.	O
pneumoniae	O
infection	O
of	O
VECs	O
.	O

Actin	O
polymerization	O
assay	B-P
further	O
showed	O
that	O
in	O
C.	O
pneumoniae	O
-	O
infected	O
VECs	O
,	O
both	O
IQGAP1	O
and	O
N-WASP	O
were	O
recruited	O
to	O
filamentous	O
actin	O
,	O
and	O
shared	O
some	O
common	O
compartments	O
localized	O
at	O
the	O
leading	O
edge	O
of	O
lamellipodia	O
,	O
which	O
was	O
impaired	O
after	O
the	O
depletion	O
of	O
IQGAP1	O
by	O
using	O
the	O
small	O
interference	O
RNA	O
.	O

Moreover	O
,	O
the	O
knockdown	O
of	O
IQGAP1	O
also	O
significantly	O
decreased	O
N-WASP	O
phosphorylation	O
at	O
Tyr256	O
induced	O
by	O
C.	O
pneumoniae	O
infection	O
.	O

We	O
conclude	O
that	O
C.	O
pneumoniae	O
infection	O
promotes	O
VEC	O
migration	O
and	O
angiogenesis	O
presumably	O
through	O
the	O
IQGAP1	O
-related	O
signaling	O
pathway	O
.	O

Treatment	O
of	O
Carcinoma	O
In	O
Situ	O
of	O
the	O
Glans	O
Penis	O
With	O
Topical	O
Imiquimod	O
Followed	O
by	O
Carbon	O
Dioxide	O
Laser	O
Excision	O
.	O

Different	O
approaches	O
have	O
been	O
described	O
in	O
published	O
studies	O
for	O
carcinoma	O
in	O
situ	O
(	O
CIS	O
)	O
of	O
the	O
glans	O
penis	O
(	O
erythroplasia	O
of	O
Queyrat	O
)	O
,	O
including	O
topical	O
chemotherapy	O
or	O
immunotherapy	O
and	O
laser	O
or	O
surgical	O
excision	O
.	O

We	O
evaluated	O
the	O
efficacy	O
of	O
topical	O
imiquimod	O
(	O
IQ	O
)	O
followed	O
by	O
carbon	O
dioxide	O
laser	O
ablation	O
of	O
the	O
lesion	O
.	O

From	O
2010	O
to	O
2015	O
,	O
10	O
patients	O
affected	O
by	O
CIS	O
of	O
the	O
glans	O
were	O
treated	O
by	O
IQ	O
,	O
followed	O
by	O
carbon	O
dioxide	O
laser	O
ablation	O
.	O

For	O
every	O
patient	O
,	O
we	O
performed	O
histologic	B-P
examination	I-P
before	O
and	O
after	O
IQ	O
.	O

Local	O
toxicity	O
and	O
adverse	O
effects	O
were	O
recorded	O
.	O

After	O
treatment	O
,	O
histologic	B-P
examination	I-P
showed	O
no	O
residual	O
tumor	O
in	O
6	O
patients	O
(	O
complete	O
response	O
[	O
CR	O
]	O
)	O
,	O
stable	O
disease	O
in	O
2	O
patients	O
,	O
and	O
progressive	O
disease	O
in	O
2	O
patients	O
.	O

Those	O
with	O
a	O
CR	O
had	O
human	O
papillomavirus	O
-	O
related	O
lesions	O
,	O
and	O
they	O
had	O
no	O
experienced	O
relapses	O
after	O
a	O
mean	O
follow-up	O
of	O
26	O
months	O
.	O

The	O
2	O
patients	O
with	O
progressive	O
disease	O
underwent	O
total	O
penectomy	O
.	O

All	O
patients	O
were	O
alive	O
at	O
the	O
last	O
follow-up	O
examination	O
.	O

All	O
patients	O
experienced	O
a	O
mild	O
local	O
toxicity	O
(	O
burning	O
erythema	O
)	O
but	O
no	O
major	O
adverse	O
effects	O
.	O

Local	O
treatment	O
with	O
IQ	O
for	O
glans	O
CIS	O
is	O
effective	O
mainly	O
for	O
human	O
papillomavirus	O
-	O
related	O
lesions	O
.	O

The	O
present	O
study	O
is	O
the	O
first	O
to	O
record	O
the	O
histologic	B-P
examination	I-P
findings	O
before	O
and	O
after	O
IQ	O
treatment	O
.	O

The	O
small	O
number	O
of	O
patients	O
,	O
owing	O
to	O
the	O
rarity	O
of	O
this	O
disease	O
,	O
was	O
the	O
main	O
limitation	O
of	O
the	O
present	O
study	O
.	O

IQ	O
must	O
be	O
used	O
carefully	O
,	O
and	O
a	O
close	O
follow-up	O
protocol	O
is	O
mandatory	O
because	O
of	O
the	O
lack	O
of	O
long-term	O
efficacy	O
data	O
.	O

Characterization	O
of	O
electrocorticogram	B-P
high	O
-	O
gamma	O
signal	O
in	O
response	O
to	O
varying	O
upper	O
extremity	O
movement	O
velocity	O
.	O

The	O
mechanism	O
by	O
which	O
the	O
human	O
primary	O
motor	O
cortex	O
(	O
M1	O
)	O
encodes	O
upper	O
extremity	O
movement	O
kinematics	O
is	O
not	O
fully	O
understood	O
.	O

For	O
example	O
,	O
human	O
electrocorticogram	B-P
(	O
ECoG	B-P
)	O
signals	O
have	O
been	O
shown	O
to	O
modulate	O
with	O
upper	O
extremity	O
movement	O
s	O
;	O
however	O
,	O
this	O
relationship	O
has	O
not	O
been	O
explicitly	O
characterized	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
recorded	O
high	O
-	O
density	O
ECoG	B-P
signals	O
from	O
patients	O
undergoing	O
epilepsy	O
surgery	O
evaluation	O
as	O
they	O
performed	O
elementary	O
upper	O
extremity	O
movements	O
while	O
systematically	O
varying	O
movement	O
speed	O
and	O
duration	O
.	O

Specifically	O
,	O
subjects	O
performed	O
intermittent	O
pincer	O
grasp	O
/	O
release	O
,	O
elbow	O
flexion	O
/	O
extension	O
,	O
and	O
shoulder	O
flexion	O
/	O
extension	O
at	O
slow	O
,	O
moderate	O
,	O
and	O
fast	O
speeds	O
.	O

In	O
all	O
movements	O
,	O
bursts	O
of	O
power	O
in	O
the	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
band	O
(	O
80-160	O
Hz	O
)	O
were	O
observed	O
in	O
M1	O
.	O

In	O
addition	O
,	O
the	O
amplitude	O
of	O
these	O
power	O
bursts	O
and	O
the	O
area	O
of	O
M1	O
with	O
elevated	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
were	O
directly	O
proportional	O
to	O
the	O
movement	O
speed	O
.	O

Likewise	O
,	O
the	O
duration	O
of	O
elevated	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
increased	O
with	O
movement	O
duration	O
.	O

Based	O
on	O
linear	O
regression	O
,	O
M1	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
power	O
amplitude	O
and	O
duration	O
covaried	O
with	O
movement	O
speed	O
and	O
duration	O
,	O
respectively	O
,	O
with	O
an	O
average	O
[	O
Formula	O
:	O
see	O
text	O
]	O
of	O
[	O
Formula	O
:	O
see	O
text	O
]	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
encoding	O
of	O
upper	O
extremity	O
movement	O
speed	O
by	O
M1	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
is	O
primarily	O
linear	O
.	O

Also	O
,	O
the	O
fact	O
that	O
this	O
activity	O
remained	O
elevated	O
throughout	O
a	O
movement	O
suggests	O
that	O
M1	O
does	O
not	O
merely	O
generate	O
transient	O
instructions	O
for	O
a	O
specific	O
movement	O
duration	O
,	O
but	O
instead	O
is	O
responsible	O
for	O
the	O
entirety	O
of	O
the	O
movement	O
.	O

Finally	O
,	O
the	O
spatial	O
distribution	O
of	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
suggests	O
the	O
presence	O
of	O
a	O
recruitment	O
phenomenon	O
in	O
which	O
higher	O
speeds	O
or	O
increased	O
muscle	O
activity	O
involve	O
activation	O
of	O
larger	O
M1	O
area	O
s	O
.	O

Altered	O
interregional	O
correlations	O
between	O
serotonin	O
transporter	O
availability	O
and	O
cerebral	O
glucose	O
metabolism	O
in	O
schizophrenia	O
:	O
A	O
high-resolution	B-P
PET	I-P
study	O
using	O
[	O
(	O
11	O
)	O
C	O
]	O
DASB	O
and	O
[	O
(	O
18	O
)	O
F	O
]	O
FDG	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
patterns	O
of	O
interregional	O
correlations	O
of	O
serotonin	O
transporter	O
(	O
SERT	O
)	O
availability	O
with	O
glucose	O
metabolism	O
using	O
7-Tesla	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
and	O
high-resolution	B-P
positron	I-P
emission	I-P
tomography	I-P
(	O
PET	B-P
)	O
with	O
(	O
11	O
)	O
C-3-amino-4-	O
(	O
2-dimethylaminomethylphenylthio	O
)	O
benzonitrile	O
(	O
[	O
(	O
11	O
)	O
C	O
]	O
DASB	O
)	O
and	O
[	O
(	O
18	O
)	O
F	O
]	O
fluorodeoxyglucose	O
(	O
[	O
(	O
18	O
)	O
F	O
]	O
FDG	O
)	O
in	O
antipsychotic-free	O
patients	O
with	O
schizophrenia	O
in	O
order	O
to	O
shed	O
new	O
light	O
on	O
the	O
disrupted	O
functional	O
connectivity	O
in	O
schizophrenia	O
.	O

Nineteen	O
patients	O
with	O
schizophrenia	O
and	O
18	O
healthy	O
controls	O
underwent	O
high-resolution	B-P
PET	I-P
and	O
MRI	B-P
.	O

The	O
binding	O
potential	O
(	O
BPND	O
)	O
of	O
[	O
(	O
11	O
)	O
C	O
]	O
DASB	O
and	O
standardized	O
uptake	O
value	O
ratio	O
(	O
SUVR	O
)	O
of	O
[	O
(	O
18	O
)	O
F	O
]	O
FDG	O
were	O
obtained	O
.	O

In	O
SERT	O
availability	O
,	O
the	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
-based	O
analyses	O
showed	O
no	O
significant	O
group	O
differences	O
in	O
any	O
region	O
,	O
except	O
for	O
the	O
anterior	O
hippocampus	O
where	O
the	O
SERT	O
availability	O
was	O
lower	O
in	O
patients	O
with	O
schizophrenia	O
than	O
in	O
controls	O
.	O

The	O
ROI	O
-	O
and	O
voxel	O
-based	O
analyses	O
revealed	O
that	O
the	O
[	O
(	O
18	O
)	O
F	O
]	O
FDG	O
SUVR	O
values	O
were	O
significantly	O
lower	O
in	O
patients	O
than	O
in	O
controls	O
in	O
the	O
right	O
superior	O
frontal	O
gyrus	O
and	O
medial	O
part	O
of	O
the	O
left	O
superior	O
frontal	O
gyrus	O
.	O

Regarding	O
the	O
interregional	O
correlations	O
of	O
[	O
(	O
11	O
)	O
C	O
]	O
DASB	O
BPND	O
with	O
[	O
(	O
18	O
)	O
F	O
]	O
FDG	O
SUVR	O
,	O
more	O
widespread	O
positive	O
correlations	O
across	O
the	O
brain	O
regions	O
were	O
observed	O
in	O
control	O
subjects	O
than	O
in	O
patients	O
with	O
schizophrenia	O
.	O

Notably	O
,	O
the	O
patients	O
and	O
control	O
subjects	O
showed	O
statistically	O
significant	O
differences	O
in	O
correlations	O
between	O
the	O
SERT	O
availability	O
in	O
the	O
parietal	O
and	O
temporal	O
cortices	O
and	O
the	O
glucose	O
metabolism	O
in	O
the	O
posterior	O
cingulate	O
cortex	O
.	O

These	O
results	O
suggest	O
abnormal	O
functional	O
connectivity	O
between	O
the	O
higher-order	O
cortical	O
regions	O
in	O
schizophrenia	O
and	O
a	O
possible	O
important	O
role	O
of	O
the	O
posterior	O
cingulate	O
gyrus	O
and	O
its	O
related	O
circuitry	O
in	O
the	O
pathophysiology	O
of	O
schizophrenia	O
.	O

Trisaccharide	O
containing	O
α2,3-linked	O
sialic	O
acid	O
is	O
a	O
receptor	O
for	O
mumps	O
virus	O
.	O

Mumps	O
virus	O
(	O
MuV	O
)	O
remains	O
an	O
important	O
pathogen	O
worldwide	O
,	O
causing	O
epidemic	O
parotitis	O
,	O
orchitis	O
,	O
meningitis	O
,	O
and	O
encephalitis	O
.	O

Here	O
we	O
show	O
that	O
MuV	O
preferentially	O
uses	O
a	O
trisaccharide	O
containing	O
α2,3-linked	O
sialic	O
acid	O
in	O
unbranched	O
sugar	O
chains	O
as	O
a	O
receptor	O
.	O

Crystal	O
structures	O
of	O
the	O
MuV	O
attachment	O
protein	O
hemagglutinin-neuraminidase	O
(	O
MuV	O
-	O
HN	O
)	O
alone	O
and	O
in	O
complex	O
with	O
the	O
α2,3-sialylated	O
trisaccharide	O
revealed	O
that	O
in	O
addition	O
to	O
the	O
interaction	O
between	O
the	O
MuV	O
-	O
HN	O
active	O
site	O
residues	O
and	O
sialic	O
acid	O
,	O
other	O
residues	O
,	O
including	O
an	O
aromatic	O
residue	O
,	O
stabilize	O
the	O
third	O
sugar	O
of	O
the	O
trisaccharide	O
.	O

The	O
importance	O
of	O
the	O
aromatic	O
residue	O
and	O
the	O
third	O
sugar	O
in	O
the	O
MuV	O
-	O
HN	O
-	O
receptor	O
interaction	O
was	O
confirmed	O
by	O
computational	O
energy	O
calculations	O
,	O
isothermal	O
titration	O
calorimetry	O
studies	O
,	O
and	O
glycan-binding	B-P
assays	I-P
.	O

Furthermore	O
,	O
MuV	O
-	O
HN	O
was	O
found	O
to	O
bind	O
more	O
efficiently	O
to	O
unbranched	O
α2,3-sialylated	O
sugar	O
chains	O
compared	O
with	O
branched	O
ones	O
.	O

Important	O
ly	O
,	O
the	O
strategically	O
located	O
aromatic	O
residue	O
is	O
conserved	O
among	O
the	O
HN	O
protein	O
s	O
of	O
sialic	O
acid	O
-using	O
paramyxoviruses	O
,	O
and	O
alanine	O
substitution	O
compromised	O
their	O
ability	O
to	O
support	O
cell-cell	O
fusion	O
.	O

These	O
results	O
suggest	O
that	O
not	O
only	O
the	O
terminal	O
sialic	O
acid	O
but	O
also	O
the	O
adjacent	O
sugar	O
moiety	O
contribute	O
to	O
receptor	O
function	O
for	O
mumps	O
and	O
these	O
paramyxoviruses	O
.	O

The	O
distribution	O
of	O
structurally	O
different	O
sialylated	O
glycans	O
in	O
tissues	O
and	O
organs	O
may	O
explain	O
in	O
part	O
MuV	O
's	O
distinct	O
tropism	O
to	O
glandular	O
tissues	O
and	O
the	O
central	O
nervous	O
system	O
.	O

In	O
the	O
crystal	O
structure	O
,	O
the	O
epitopes	O
for	O
neutralizing	O
antibodies	O
are	O
located	O
around	O
the	O
α-helices	O
of	O
MuV	O
-	O
HN	O
that	O
are	O
not	O
well	O
conserved	O
in	O
amino	O
acid	O
sequences	O
among	O
different	O
genotypes	O
of	O
MuV	O
.	O

This	O
may	O
explain	O
the	O
fact	O
that	O
MuV	O
reinfection	O
sometimes	O
occurs	O
.	O

The	O
SmartOR	O
:	O
a	O
distributed	O
sensor	O
network	O
to	O
improve	O
operating	O
room	O
efficiency	O
.	O

Despite	O
the	O
significant	O
expense	O
of	O
OR	O
time	O
,	O
best	O
practice	O
achieves	O
only	O
70	O
%	O
efficiency	O
.	O

Compounding	O
this	O
problem	O
is	O
a	O
lack	O
of	O
real-time	O
data	O
.	O

Most	O
current	O
OR	O
utilization	O
programs	O
require	O
manual	O
data	O
entry	O
.	O

Automated	O
systems	O
require	O
installation	O
and	O
maintenance	O
of	O
expensive	O
tracking	O
hardware	O
throughout	O
the	O
institution	O
.	O

This	O
study	O
developed	O
an	O
inexpensive	O
,	O
automated	O
OR	O
utilization	O
system	O
and	O
analyzed	O
data	O
from	O
multiple	O
operating	O
rooms	O
.	O

OR	O
activity	O
was	O
deconstructed	O
into	O
four	O
room	O
states	O
.	O

A	O
sensor	O
network	O
was	O
then	O
developed	O
to	O
automatically	O
capture	O
these	O
states	O
using	O
only	O
three	O
sensors	O
,	O
a	O
local	O
wireless	O
network	O
,	O
and	O
a	O
data	O
capture	O
computer	O
.	O

Two	O
systems	O
were	O
then	O
installed	O
into	O
two	O
ORs	O
,	O
recordings	O
captured	O
24/7	O
.	O

The	O
SmartOR	O
recorded	O
the	O
following	O
events	O
:	O
any	O
room	O
activity	O
,	O
patient	O
entry/exit	O
time	O
,	O
anesthesia	O
time	O
,	O
laparoscopy	B-P
time	O
,	O
room	O
turnover	O
time	O
,	O
and	O
time	O
of	O
preoperative	O
patient	O
identification	O
by	O
the	O
surgeon	O
.	O

From	O
November	O
2014	O
to	O
December	O
2015	O
,	O
data	O
on	O
1003	O
cases	O
were	O
collected	O
.	O

The	O
mean	O
turnover	O
time	O
was	O
36	O
min	O
,	O
and	O
38	O
%	O
of	O
cases	O
met	O
the	O
institutional	O
goal	O
of	O
≤30	O
min	O
.	O

Data	O
analysis	O
also	O
identified	O
outlier	O
cases	O
(	O
>	O
1	O
SD	O
from	O
mean	O
)	O
in	O
the	O
domains	O
of	O
time	O
from	O
patient	O
entry	O
into	O
the	O
OR	O
to	O
intubation	O
(	O
11	O
%	O
of	O
cases	O
)	O
and	O
time	O
from	O
extubation	O
to	O
patient	O
exiting	O
the	O
OR	O
(	O
11	O
%	O
of	O
cases	O
)	O
.	O

Time	O
from	O
surgeon	O
identification	O
of	O
patient	O
to	O
scheduled	O
procedure	O
start	O
time	O
was	O
11	O
min	O
(	O
institution	O
bylaws	O
require	O
20	O
min	O
before	O
scheduled	O
start	O
time	O
)	O
,	O
yet	O
OR	O
teams	O
required	O
22	O
min	O
on	O
average	O
to	O
bring	O
a	O
patient	O
into	O
the	O
room	O
after	O
surgeon	O
identification	O
.	O

The	O
SmartOR	O
automatically	O
and	O
reliably	O
captures	O
data	O
on	O
OR	O
room	O
state	O
and	O
,	O
in	O
real	O
time	O
,	O
identifies	O
outlier	O
cases	O
that	O
may	O
be	O
examined	O
closer	O
to	O
improve	O
efficiency	O
.	O

As	O
no	O
manual	O
entry	O
is	O
required	O
,	O
the	O
data	O
are	O
indisputable	O
and	O
allow	O
OR	O
teams	O
to	O
maintain	O
a	O
patient	O
-centric	O
focus	O
.	O

In	O
vitro	O
antifungal	O
,	O
probiotic	O
,	O
and	O
antioxidant	O
functional	O
properties	O
of	O
a	O
novel	O
Lactobacillus	O
paraplantarum	O
isolated	O
from	O
fermented	O
dates	O
in	O
Saudi	O
Arabia	O
.	O

Fermented	O
foods	O
produced	O
using	O
dates	O
are	O
used	O
in	O
Gulf	O
countries	O
as	O
beneficial	O
and	O
healthful	O
foods	O
.	O

The	O
beneficial	O
microbial	O
flora	O
in	O
fermented	O
dates	O
contributes	O
to	O
maintaining	O
the	O
nutritional	O
properties	O
of	O
dates	O
by	O
preventing	O
the	O
growth	O
of	O
spoilage	O
fungi	O
.	O

Here	O
,	O
we	O
examined	O
the	O
antifungal	O
,	O
probiotic	O
,	O
and	O
antioxidant	O
properties	O
of	O
the	O
novel	O
Lactobacillus	O
strain	O
D-3	O
isolated	O
from	O
fermented	O
dates	O
.	O

Analyzing	O
the	O
morphological	O
,	O
physiological	O
,	O
and	O
biochemical	O
characteristics	O
of	O
this	O
strain	O
demonstrated	O
that	O
it	O
was	O
similar	O
to	O
Lactobacillus	O
species	O
,	O
and	O
molecular	O
level	O
amplification	O
of	O
the	O
16S	O
rRNA	O
gene	O
showed	O
that	O
it	O
belonged	O
to	O
Lactobacillus	O
paraplantarum	O
.	O

Under	O
shake	B-P
flask	I-P
cultivation	I-P
using	O
date	O
juice	O
,	O
the	O
strain	O
produced	O
significant	O
amounts	O
of	O
ethanol	O
and	O
lactic	O
,	O
succinic	O
,	O
and	O
acetic	O
acids	O
.	O

Purification	B-P
of	O
benzoic	O
acid	O
extracted	O
from	O
the	O
extracellular	O
fermentation	O
medium	O
was	O
confirmed	O
by	O
nuclear	B-P
magnetic	I-P
resonance	I-P
(	O
NMR	B-P
)	O
,	O
and	O
infrared	B-P
and	O
mass	B-P
spectral	I-P
data	O
revealed	O
minimum	B-P
inhibitory	I-P
concentration	I-P
(	O
MIC	B-P
)	O
values	O
of	O
10	O
,	O
20	O
,	O
10	O
,	O
5	O
,	O
and	O
10	O
mg	O
mL	O
(	O
-1	O
)	O
for	O
Aspergillus	O
fumigates	O
,	O
Curvularia	O
lunata	O
,	O
Fusarium	O
oxysporum	O
,	O
Gibberella	O
moniliformis	O
,	O
and	O
Penicillium	O
chrysogenum	O
,	O
respectively	O
.	O

The	O
strain	O
showed	O
several	O
advantages	O
,	O
including	O
the	O
ability	O
to	O
survive	O
under	O
conditions	O
similar	O
to	O
the	O
gastrointestinal	O
tract	O
(	O
low	O
pH	O
,	O
bile	O
salts	O
,	O
and	O
antimicrobial	O
susceptibility	O
)	O
and	O
high	O
levels	O
of	O
extracellular	O
enzyme	O
activities	O
.	O

The	O
strain	O
's	O
growth	O
patterns	O
under	O
various	O
concentrations	O
of	O
H2	O
O2	O
and	O
its	O
scavenging	O
properties	O
towards	O
hydroxyl	O
radical	O
(	O
64.85	O
%	O
)	O
and	O
DPPH	O
(	O
84.97	O
%	O
)	O
were	O
also	O
interesting	O
properties	O
.	O

The	O
antifungal	O
,	O
probiotic	O
,	O
and	O
antioxidant	O
properties	O
of	O
L.	O
paraplantarum	O
D3	O
may	O
provide	O
health	O
benefits	O
to	O
consumers	O
.	O

Impact	O
of	O
systemic	O
alitretinoin	O
treatment	O
on	O
skin	O
barrier	O
gene	O
and	O
protein	O
expression	O
in	O
patients	O
with	O
chronic	O
hand	O
eczema	O
.	O

Chronic	O
hand	O
eczema	O
(	O
CHE	O
)	O
is	O
a	O
common	O
inflammatory	O
skin	O
disease	O
that	O
affects	O
approximately	O
10	O
%	O
of	O
the	O
population	O
.	O

Systemic	O
alitretinoin	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
patients	O
with	O
CHE	O
who	O
are	O
refractory	O
to	O
topical	O
corticosteroids	O
.	O

To	O
analyse	O
the	O
impact	O
of	O
alitretinoin	O
on	O
the	O
skin	O
barrier	O
genes	O
and	O
protein	O
expression	O
in	O
the	O
skin	O
lesions	O
of	O
patients	O
with	O
CHE	O
.	O

Fifteen	O
patients	O
with	O
CHE	O
were	O
treated	O
with	O
30	O
mg	O
daily	O
of	O
alitretinoin	O
for	O
up	O
to	O
27	O
weeks	O
.	O

Disease	O
severity	O
was	O
assessed	O
using	O
a	O
clinical	O
score	O
.	O

Skin	B-P
biopsies	I-P
from	O
all	O
the	O
patients	O
were	O
evaluated	O
before	O
and	O
after	O
therapy	O
for	O
the	O
expression	O
of	O
Ki-67	O
,	O
various	O
skin	O
barrier	O
genes	O
and	O
thymic	O
stromal	O
lymphopoietin	O
(	O
TSLP	O
)	O
by	O
real-time	O
quantitative	O
polymerase	O
chain	O
reaction	O
and	O
immunohistochemistry	B-P
.	O

After	O
alitretinoin	O
application	O
,	O
an	O
improvement	O
in	O
the	O
clinical	O
severity	O
of	O
CHE	O
was	O
observed	O
in	O
the	O
majority	O
of	O
patients	O
.	O

Analysis	O
of	O
skin	B-P
biopsies	I-P
before	O
treatment	O
showed	O
a	O
significant	O
increase	O
in	O
Ki-67	O
-	O
positive	O
cells	O
in	O
the	O
suprabasal	O
layer	O
and	O
a	O
dysregulated	O
expression	O
of	O
various	O
skin	O
barrier	O
genes	O
,	O
such	O
as	O
claudin	O
1	O
,	O
loricrin	O
,	O
filaggrin	O
and	O
cytokeratin	O
10	O
,	O
which	O
were	O
normalized	O
after	O
treatment	O
.	O

TSLP	O
was	O
significantly	O
upregulated	O
in	O
patients	O
with	O
CHE	O
and	O
also	O
normalized	O
after	O
alitretinoin	O
treatment	O
and	O
negatively	O
correlated	O
with	O
filaggrin	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
barrier	O
genes	O
and	O
proteins	O
was	O
normalized	O
following	O
treatment	O
with	O
alitretinoin	O
in	O
patients	O
with	O
CHE	O
.	O

The	O
change	O
in	O
expression	O
levels	O
of	O
these	O
genes	O
correlated	O
with	O
the	O
clinical	O
efficacy	O
,	O
suggesting	O
that	O
alitretinoin	O
exhibits	O
a	O
disease	O
-	O
modifying	O
activity	O
.	O

TSLP	O
is	O
upregulated	O
in	O
CHE	O
and	O
seems	O
to	O
counteract	O
filaggrin	O
expression	O
in	O
the	O
skin	O
.	O

Palmitoylation	O
regulates	O
glutamate	O
receptor	O
distributions	O
in	O
postsynaptic	O
densities	O
through	O
control	O
of	O
PSD95	O
conformation	O
and	O
orientation	O
.	O

Postsynaptic	O
density	O
protein	O
95	O
(	O
PSD95	O
)	O
and	O
synapse-associated	O
protein	O
97	O
(	O
SAP97	O
)	O
are	O
homologous	O
scaffold	O
proteins	O
with	O
different	O
N-terminal	O
domains	O
,	O
possessing	O
either	O
a	O
palmitoylation	O
site	O
(	O
PSD95	O
)	O
or	O
an	O
L27	O
domain	O
(	O
SAP97	O
)	O
.	O

Here	O
,	O
we	O
measured	O
PSD95	O
and	O
SAP97	O
conformation	O
in	O
vitro	O
and	O
in	O
postsynaptic	O
densities	O
(	O
PSDs	O
)	O
using	O
FRET	B-P
and	O
EM	B-P
,	O
and	O
examined	O
how	O
conformation	O
regulated	O
interactions	O
with	O
AMPA-type	O
and	O
NMDA-type	O
glutamate	O
receptors	O
(	O
AMPARs	O
/	O
NMDARs	O
)	O
.	O

Palmitoylation	O
of	O
PSD95	O
changed	O
its	O
conformation	O
from	O
a	O
compact	O
to	O
an	O
extended	O
configuration	O
.	O

PSD95	O
associated	O
with	O
AMPARs	O
(	O
via	O
transmembrane	O
AMPAR	O
regulatory	O
protein	O
subunits	O
)	O
or	O
NMDARs	O
[	O
via	O
glutamate	O
ionotropic	O
receptor	O
NMDA-type	O
subunit	O
2B	O
(	O
GluN2B	O
)	O
subunits	O
]	O
only	O
in	O
its	O
palmitoylated	O
and	O
extended	O
conformation	O
.	O

In	O
contrast	O
,	O
in	O
its	O
extended	O
conformation	O
,	O
SAP97	O
associates	O
with	O
NMDARs	O
,	O
but	O
not	O
with	O
AMPARs	O
.	O

Within	O
PSDs	O
,	O
PSD95	O
and	O
SAP97	O
were	O
largely	O
in	O
the	O
extended	O
conformation	O
,	O
but	O
had	O
different	O
orientation	O
s.	O
PSD95	O
oriented	O
perpendicular	O
to	O
the	O
PSD	O
membrane	O
,	O
with	O
its	O
palmitoylated	O
,	O
N-terminal	O
domain	O
at	O
the	O
membrane	O
.	O

SAP97	O
oriented	O
parallel	O
to	O
the	O
PSD	O
membrane	O
,	O
likely	O
as	O
a	O
dimer	O
through	O
interactions	O
of	O
its	O
N-terminal	O
L27	O
domain	O
.	O

Changing	O
PSD95	O
palmitoylation	O
in	O
PSDs	O
altered	O
PSD95	O
and	O
AMPAR	O
levels	O
but	O
did	O
not	O
affect	O
NMDAR	O
levels	O
.	O

These	O
results	O
indicate	O
that	O
in	O
PSDs	O
,	O
PSD95	O
palmitoylation	O
,	O
conformation	O
,	O
and	O
its	O
interactions	O
are	O
dynamic	O
when	O
associated	O
with	O
AMPARs	O
and	O
more	O
stable	O
when	O
associated	O
with	O
NMDARs	O
.	O

Altogether	O
,	O
our	O
results	O
are	O
consistent	O
with	O
differential	O
regulation	O
of	O
PSD95	O
palmitoylation	O
in	O
PSDs	O
resulting	O
from	O
the	O
clustering	O
of	O
palmitoylating	O
and	O
depalmitoylating	O
enzymes	O
into	O
AMPAR	O
nanodomains	O
segregated	O
away	O
from	O
NMDAR	O
nanodomains	O
.	O

Low	O
Cytochrome	O
Oxidase	O
1	O
Links	O
Mitochondrial	O
Dysfunction	O
to	O
Atherosclerosis	O
in	O
Mice	O
and	O
Pigs	O
.	O

Cytochrome	O
oxidase	O
IV	O
complex	O
regulates	O
energy	O
production	O
in	O
mitochondria	O
.	O

Therefore	O
,	O
we	O
determined	O
the	O
relation	O
of	O
COX	O
genes	O
with	O
atherosclerosis	O
in	O
mice	O
and	O
pigs	O
.	O

First	O
,	O
we	O
compared	O
atherosclerosis	O
in	O
the	O
aortic	O
arch	O
of	O
age-matched	O
(	O
24	O
weeks	O
)	O
C57BL/6J	O
control	O
(	O
n	O
=	O
10	O
)	O
,	O
LDL-receptor	O
deficient	O
(	O
n	O
=	O
8	O
)	O
,	O
leptin	O
-	O
deficient	O
ob/ob	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
double	O
knock-out	O
(	O
lacking	O
LDL-receptor	O
and	O
leptin	O
)	O
mice	O
(	O
n	O
=	O
12	O
)	O
.	O

Low	O
aortic	O
mitochondria	O
-encoded	O
cytochrome	O
oxidase	O
1	O
in	O
obese	O
diabetic	O
double	O
knock-out	O
mice	O
was	O
associated	O
with	O
a	O
larger	O
plaque	O
area	O
and	O
higher	O
propensity	O
of	O
M1	O
macrophages	O
and	O
oxidized	O
LDL	O
.	O

Caloric	O
restriction	O
increased	O
mitochondria	O
-encoded	O
cytochrome	O
oxidase	O
1	O
and	O
reduced	O
plaque	O
area	O
and	O
oxidized	O
LDL	O
.	O

This	O
was	O
associated	O
with	O
a	O
reduction	O
of	O
titer	B-P
of	I-P
anti-oxidized	I-P
LDL	I-P
antibodies	I-P
,	O
a	O
proxy	O
of	O
systemic	O
oxidative	O
stress	O
.	O

Low	O
of	O
mitochondria	O
-encoded	O
cytochrome	O
oxidase	O
1	O
was	O
related	O
to	O
low	O
expression	O
of	O
peroxisome	O
proliferative	O
activated	O
receptors	O
α	O
,	O
δ	O
,	O
and	O
γ	O
and	O
of	O
peroxisome	O
proliferative	O
activated	O
receptor	O
,	O
gamma	O
,	O
co-activator	O
1	O
alpha	O
reflecting	O
mitochondrial	O
dysfunction	O
.	O

Caloric	O
restriction	O
increased	O
them	O
.	O

To	O
investigate	O
if	O
there	O
was	O
a	O
diabetic	O
/	O
obesity	O
requirement	O
for	O
mitochondria	O
-encoded	O
cytochrome	O
oxidase	O
1	O
to	O
be	O
down-regulated	O
,	O
we	O
then	O
studied	O
atherosclerosis	O
in	O
LAD	O
of	O
hypercholesterolemic	O
pigs	O
(	O
n	O
=	O
37	O
)	O
.	O

Pigs	O
at	O
the	O
end	O
of	O
the	O
study	O
were	O
divided	O
in	O
three	O
groups	O
based	O
on	O
increasing	O
LAD	O
plaque	O
complexity	O
according	O
to	O
Stary	O
(	O
Stary	O
I	O
:	O
n	O
=	O
12	O
;	O
Stary	O
II	O
:	O
n	O
=	O
13	O
;	O
Stary	O
III	O
:	O
n	O
=	O
12	O
)	O
.	O

Low	O
mitochondria	O
-encoded	O
cytochrome	O
oxidase	O
1	O
in	O
isolated	O
plaque	O
macrophages	O
was	O
associated	O
with	O
more	O
complex	O
coronary	O
plaques	O
and	O
oxidized	O
LDL	O
.	O

Nucleus	O
-encoded	O
cytochrome	O
oxidase	O
4I1	O
and	O
cytochrome	O
oxidase	O
10	O
did	O
not	O
correlate	O
with	O
plaque	O
complexity	O
and	O
oxidative	O
stress	O
.	O

In	O
mice	O
and	O
pigs	O
,	O
MT-COI	O
was	O
inversely	O
related	O
to	O
insulin	O
resistance	O
.	O

Low	O
MT-COI	O
is	O
related	O
to	O
mitochondrial	O
dysfunction	O
,	O
oxidative	O
stress	O
and	O
atherosclerosis	O
and	O
plaque	O
complexity	O
.	O

Metabolite	O
mapping	O
by	O
consecutive	O
nanostructure	O
and	O
silver-assisted	B-P
mass	I-P
spectrometry	I-P
imaging	I-P
on	O
tissue	O
sections	O
.	O

Nanostructure-based	B-P
mass	I-P
spectrometry	I-P
imaging	I-P
(	O
MSI	B-P
)	O
is	O
a	O
promising	O
technology	O
for	O
molecular	B-P
imaging	I-P
of	O
small	O
molecules	O
,	O
without	O
the	O
complex	O
chemical	O
background	O
typically	O
encountered	O
in	O
matrix-assisted	B-P
molecular	I-P
imaging	I-P
approaches	O
.	O

Here	O
,	O
we	O
have	O
enhanced	O
these	O
surfaces	O
with	O
silver	O
(	O
Ag	O
)	O
to	O
provide	O
a	O
second	O
tier	O
of	O
MSI	O
data	O
from	O
a	O
single	O
sample	O
.	O

MSI	O
data	O
was	O
acquired	O
through	O
the	O
application	O
of	O
laser	B-P
desorption/ionization	I-P
mass	I-P
spectrometry	I-P
to	O
biological	O
samples	O
imprinted	O
onto	O
desorption/ionization	O
on	O
silicon	O
(	O
DIOS	O
)	O
substrates	O
.	O

Following	O
initial	O
analysis	O
,	O
ultra-thin	O
Ag	O
layers	O
were	O
overlaid	O
onto	O
the	O
followed	O
by	O
MSI	B-P
analysis	I-P
(	O
Ag-DIOS	B-P
MSI	I-P
)	O
.	O

This	O
approach	O
was	O
first	O
demonstrated	O
for	O
fingermark	O
small	O
molecules	O
including	O
environmental	O
contaminants	O
and	O
sebum	O
components	O
.	O

Subsequently	O
,	O
this	O
bimodal	O
method	O
was	O
translated	O
to	O
lipids	O
and	O
metabolites	O
in	O
fore-stomach	O
sections	O
from	O
a	O
6-bromoisatin	O
chemopreventative	O
murine	O
mouse	O
model	O
.	O

DIOS	B-P
MSI	I-P
allowed	O
mapping	O
of	O
common	O
ions	O
in	O
fingermarks	O
as	O
well	O
as	O
6-bromoisatin	O
metabolites	O
and	O
lipids	O
in	O
murine	O
fore-stomach	O
.	O

Furthermore	O
,	O
DIOS	B-P
MSI	I-P
was	O
complemented	O
by	O
the	O
Ag-DIOS	B-P
MSI	I-P
of	O
Ag-adductable	O
lipids	O
such	O
as	O
wax	O
esters	O
in	O
fingermarks	O
and	O
cholesterol	O
in	O
murine	O
fore-stomach	O
.	O

Gastrointestinal	O
acid	O
condensation	O
products	O
of	O
6-bromoisatin	O
,	O
such	O
as	O
the	O
6,6'-dibromoindirubin	O
mapped	O
herein	O
,	O
are	O
very	O
challenging	O
to	O
isolate	B-P
and	O
characterize	O
.	O

By	O
re-analyzing	O
the	O
same	O
tissue	O
imprints	O
,	O
this	O
metabolite	O
was	O
readily	O
detected	O
by	O
DIOS	O
,	O
placed	O
in	O
a	O
tissue-specific	O
spatial	O
context	O
,	O
and	O
subsequently	O
overlaid	O
with	O
additional	O
lipid	O
distributions	O
acquired	O
using	O
Ag-DIOS	B-P
MSI	I-P
.	O

The	O
ability	O
to	O
place	O
metabolite	O
and	O
lipid	O
classes	O
in	O
a	O
tissue-specific	O
context	O
makes	O
this	O
novel	O
method	O
suited	O
to	O
MSI	B-P
analyses	I-P
where	O
the	O
collection	O
of	O
additional	O
information	O
from	O
the	O
same	O
sample	O
maximises	O
resource	O
use	O
,	O
and	O
also	O
maximises	O
the	O
number	O
of	O
annotated	O
small	O
molecules	O
,	O
in	O
particular	O
for	O
metabolites	O
that	O
are	O
typically	O
undetectable	O
with	O
traditional	O
platforms	O
.	O

Copyright	O
©	O
2017	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Development	O
of	O
the	O
pediatric	O
quality	O
of	O
life	O
inventory	O
neurofibromatosis	O
type	O
1	O
module	O
items	O
for	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
:	O
qualitative	O
methods	O
.	O

Health-related	O
quality	O
of	O
life	O
(	O
HRQOL	O
)	O
is	O
arguably	O
one	O
of	O
the	O
most	O
important	O
measures	O
in	O
evaluating	O
effectiveness	O
of	O
clinical	O
treatments	O
.	O

At	O
present	O
,	O
there	O
is	O
no	O
disease	O
-	O
specific	O
outcome	O
measure	O
to	O
assess	O
the	O
HRQOL	O
of	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
with	O
Neurofibromatosis	O
Type	O
1	O
(	O
NF1	O
)	O
.	O

This	O
study	O
aimed	O
to	O
develop	O
the	O
items	O
and	O
support	O
the	O
content	O
validity	O
for	O
the	O
Pediatric	O
Quality	O
of	O
Life	O
Inventory™	O
(	O
PedsQL™	O
)	O
NF1	O
Module	O
for	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
.	O

The	O
iterative	O
process	O
included	O
multiphase	O
qualitative	O
methods	O
including	O
a	O
literature	O
review	O
,	O
survey	O
of	O
expert	O
opinions	O
,	O
semi-structured	O
interviews	O
,	O
cognitive	O
interviews	O
and	O
pilot	O
testing	O
.	O

Fifteen	O
domains	O
were	O
derived	O
from	O
the	O
qualitative	O
methods	O
,	O
with	O
content	O
saturation	O
achieved	O
,	O
resulting	O
in	O
115	O
items	O
.	O

The	O
domains	O
include	O
skin	O
,	O
pain	O
,	O
pain	O
impact	O
,	O
pain	O
management	O
,	O
cognitive	O
functioning	O
,	O
speech	O
,	O
fine	O
motor	O
,	O
balance	O
,	O
vision	O
,	O
perceived	O
physical	O
appearance	O
,	O
communication	O
,	O
worry	O
,	O
treatment	O
,	O
medicines	O
and	O
gastrointestinal	O
symptoms	O
.	O

This	O
study	O
is	O
limited	O
because	O
all	O
participants	O
are	O
recruited	O
from	O
a	O
single	O
-	O
site	O
.	O

Qualitative	O
methods	O
support	O
the	O
content	O
validity	O
for	O
the	O
PedsQL™	O
NF1	O
Module	O
for	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
.	O

The	O
PedsQL™	O
NF1	O
Module	O
is	O
now	O
undergoing	O
national	O
multisite	O
field	O
testing	O
for	O
the	O
psychometric	B-P
validation	O
of	O
the	O
instrument	O
development	O
.	O

Triterpenoids	O
from	O
the	O
stems	O
of	O
Tripterygium	O
regelii	O
.	O

Three	O
new	O
triterpenoids	O
,	O
triregelolides	O
A	O
,	O
B	O
(	O
1	O
,	O
2	O
)	O
,	O
and	O
triregeloic	O
acid	O
(	O
3	O
)	O
,	O
were	O
isolated	O
from	O
the	O
stems	O
of	O
Tripterygium	O
regelii	O
along	O
with	O
twenty	O
known	O
triterpene	O
analogues	O
(	O
4-23	O
)	O
.	O

The	O
structures	O
of	O
three	O
new	O
compounds	O
were	O
identified	O
by	O
analyzing	O
their	O
NMR	B-P
spectroscopic	I-P
and	O
HRESIMS	B-P
data	O
.	O

Compounds	O
4	O
,	O
7	O
,	O
8	O
,	O
10	O
,	O
13	O
,	O
14	O
,	O
17	O
,	O
21-23	O
were	O
isolated	O
from	O
T.	O
regelii	O
for	O
the	O
first	O
time	O
.	O

Compounds	O
3	O
,	O
5	O
,	O
6	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
14	O
and	O
16	O
showed	O
inhibitory	O
effects	O
on	O
the	O
proliferation	O
of	O
human	O
breast	O
cancer	O
cells	O
MCF-7	O
by	O
24.1	O
%	O
,	O
69.6	O
%	O
,	O
72.8	O
%	O
,	O
21.6	O
%	O
,	O
23.1	O
%	O
,	O
43.3	O
%	O
,	O
25.5	O
%	O
and	O
23.5	O
%	O
(	O
p	O
<	O
0.05	O
)	O
at	O
a	O
concentration	O
of	O
10μM	O
,	O
respectively	O
.	O

Field	O
Measurements	O
and	O
Numerical	O
Simulations	O
of	O
Temperature	O
and	O
Moisture	O
in	O
Highway	O
Engineering	O
Using	O
a	O
Frequency	O
Domain	O
Reflectometry	O
Sensor	O
.	O

This	O
paper	O
presents	O
a	O
systematic	O
pioneering	O
study	O
on	O
the	O
use	O
of	O
agricultural	O
-	O
purpose	O
frequency	O
domain	O
reflectometry	O
(	O
FDR	O
)	O
sensors	O
to	O
monitor	O
temperature	O
and	O
moisture	O
of	O
a	O
subgrade	O
in	O
highway	O
extension	O
and	O
reconstruction	O
engineering	O
.	O

The	O
principle	O
of	O
agricultural	O
-	O
purpose	O
FDR	O
sensors	O
and	O
the	O
process	O
for	O
embedding	B-P
this	O
kind	O
of	O
sensors	O
for	O
subgrade	O
engineering	O
purposes	O
are	O
introduced	O
.	O

Based	O
on	O
field	O
measured	O
weather	O
data	O
,	O
a	O
numerical	O
analysis	O
model	O
for	O
temperature	O
and	O
moisture	O
content	O
in	O
the	O
subgrade	O
's	O
soil	O
is	O
built	O
.	O

Comparisons	O
of	O
the	O
temperature	O
and	O
moisture	O
data	O
obtained	O
from	O
numerical	O
simulation	O
and	O
FDR	O
-based	O
measurements	O
are	O
conducted	O
.	O

The	O
results	O
show	O
that	O
:	O
(	O
1	O
)	O
the	O
embedding	B-P
method	I-P
and	O
process	O
,	O
data	O
acquisition	O
,	O
and	O
remote	O
transmission	O
presented	O
are	O
reasonable	O
;	O
(	O
2	O
)	O
the	O
temperature	O
and	O
moisture	O
changes	O
are	O
coordinated	O
with	O
the	O
atmospheric	O
environment	O
and	O
they	O
are	O
also	O
in	O
close	O
agreement	O
with	O
numerical	O
calculations	O
;	O
(	O
3	O
)	O
the	O
change	O
laws	O
of	O
both	O
are	O
consistent	O
at	O
positions	O
where	O
the	O
subgrade	O
is	O
compacted	O
uniformly	O
.	O

These	O
results	O
suggest	O
that	O
the	O
data	O
measured	O
by	O
the	O
agricultural	O
-	O
purpose	O
FDR	O
sensors	O
are	O
reliable	O
.	O

The	O
findings	O
of	O
this	O
paper	O
enable	O
a	O
new	O
and	O
effective	O
real-time	O
monitoring	O
method	O
for	O
a	O
subgrade	O
's	O
temperature	O
and	O
moisture	O
changes	O
,	O
and	O
thus	O
broaden	O
the	O
application	O
of	O
agricultural	O
-	O
purpose	O
FDR	O
sensors	O
.	O

Vaginal	O
Infections	O
of	O
Albanian	O
women	O
Infected	O
with	O
HPV	O
and	O
their	O
impact	O
in	O
intraepithelial	O
cervical	O
lesions	O
evidenced	O
by	O
Pap	B-P
test	I-P
.	O

Cervical	B-P
cytology	I-P
is	O
the	O
best	O
single	O
method	O
for	O
large	O
screening	B-P
of	O
the	O
population	O
in	O
identifying	O
precancerous	O
lesions	O
of	O
the	O
uterine	O
cervix	O
.	O

To	O
estimate	O
the	O
frequency	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
positivity	O
in	O
a	O
group	O
of	O
Albanian	O
women	O
,	O
the	O
prevalence	O
of	O
vaginal	O
coinfections	O
,	O
and	O
the	O
relationship	O
of	O
coinfections	O
with	O
HPV	O
,	O
as	O
well	O
as	O
their	O
role	O
in	O
metaplasia	O
or	O
cervical	O
intraepithelial	O
lesions	O
(	O
CIN	O
)	O
.	O

In	O
this	O
retrospective	O
study	O
,	O
2075	O
vaginal	B-P
smears	I-P
were	O
examined	O
.	O

The	O
Papanicolaou	B-P
stain	I-P
was	O
used	O
for	O
all	O
slides	O
.	O

The	O
New	B-P
Bethesda	I-P
System	I-P
2001	O
was	O
used	O
for	O
the	O
interpretations	B-P
of	I-P
the	I-P
smears	I-P
.	O

Data	O
analysis	O
was	O
completed	O
using	O
the	O
Statistical	O
Package	O
for	O
the	O
Social	O
Sciences	O
version	O
19.0	O
.	O

Prevalence	O
of	O
HPV	O
positivity	O
was	O
43.9	O
%	O
with	O
an	O
average	O
age	O
of	O
35.48	O
±	O
9.27	O
years	O
.	O

Candida	O
coinfection	O
resulted	O
in	O
57.8	O
%	O
of	O
HPV	O
positive	O
women	O
with	O
a	O
significant	O
relationship	O
between	O
them	O
.	O

Gardnerella	O
coinfection	O
resulted	O
in	O
36	O
(	O
23	O
%	O
)	O
,	O
mixed	O
flora	O
in	O
34	O
(	O
8	O
%	O
)	O
,	O
and	O
Trichomonas	O
vaginalis	O
in	O
50	O
%	O
of	O
HPV	O
positive	O
woman	O
.	O

Among	O
the	O
women	O
with	O
positive	O
HPV	O
,	O
19	O
%	O
had	O
CIN	O
,	O
8	O
%	O
had	O
metaplasia	O
,	O
and	O
1	O
%	O
had	O
metaplasia	O
and	O
CIN	O
;	O
9	O
%	O
of	O
the	O
women	O
with	O
HPV	O
had	O
CIN1	O
and	O
one	O
of	O
the	O
coinfections	O
.	O

There	O
is	O
a	O
strong	O
relationship	O
between	O
CIN1	O
and	O
HPV	O
positivity	O
as	O
well	O
as	O
between	O
CIN1	O
and	O
coinfections	O
.	O

HPV	O
infection	O
is	O
a	O
major	O
factor	O
contributing	O
to	O
metaplasia	O
,	O
and	O
bacterial	O
coinfections	O
in	O
HPV	O
positive	O
women	O
have	O
a	O
statistically	O
significant	O
impact	O
in	O
the	O
development	O
of	O
metaplasia	O
.	O

Synthesis	O
and	O
characterization	O
of	O
acetylated	O
amylose	O
and	O
development	O
of	O
inclusion	O
complexes	O
with	O
rifampicin	O
.	O

Amylose	O
(	O
AM	O
)	O
tends	O
to	O
form	O
single	O
helical	O
inclusion	O
complexes	O
with	O
suitable	O
agents	O
.	O

These	O
complexes	O
are	O
considered	O
promising	O
biomaterial	O
carrier	O
since	O
the	O
guest	O
molecules	O
can	O
be	O
released	O
later	O
,	O
leading	O
to	O
many	O
applications	O
,	O
especially	O
in	O
the	O
pharmaceutical	O
industry	O
.	O

Rifampicin	O
(	O
RIF	O
)	O
has	O
long	O
been	O
recognized	O
as	O
an	O
active	O
drug	O
against	O
Mycobacterium	O
tuberculosis	O
,	O
however	O
,	O
the	O
administration	O
of	O
RIF	O
in	O
high	O
dosages	O
can	O
originate	O
unwanted	O
side-effects	O
.	O

Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	O
amylose	O
(	O
AM	O
)	O
in	O
the	O
formation	O
of	O
complexes	O
is	O
limited	O
by	O
their	O
low	O
water	O
solubility	O
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	O
of	O
substitution	O
(	O
DS	O
)	O
,	O
allowing	O
solubilizing	O
(	O
0.5gL	O
(	O
-1	O
)	O
)	O
acetylated	O
amylose	O
(	O
AMA	O
)	O
in	O
water	O
at	O
neutral	O
pH	O
,	O
in	O
opposition	O
to	O
that	O
observed	O
with	O
native	O
amylose	O
(	O
trace	O
solubility	O
)	O
.	O

The	O
resulting	O
acetylated	O
amylose	O
was	O
characterized	O
by	O
means	O
of	O
Fourier	O
Transform	O
Infrared	O
(	O
FT-IR	O
)	O
spectroscopy	O
and	O
Scanning	B-P
Electron	I-P
Microscopy	I-P
(	O
SEM	B-P
)	O
.	O

FT-IR	O
results	O
indicated	O
that	O
the	O
acetylation	O
of	O
anhydroglucose	O
units	O
of	O
amylose	O
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
SEM	B-P
results	O
suggested	O
that	O
the	O
smooth	O
surfaces	O
of	O
amylose	O
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	O
after	O
acetylation	O
.	O

Ultraviolet	B-P
absorption	I-P
spectroscopy	I-P
(	O
UV-vis	B-P
)	O
analysis	O
confirmed	O
the	O
formation	O
and	O
allowed	O
the	O
quantification	O
of	O
both	O
native	O
(	O
AM	O
-	O
RIF	O
)	O
and	O
acetylated	O
(	O
AMA	O
-	O
RIF	O
)	O
amylose	O
inclusion	O
complexes	O
.	O

Their	O
characterization	O
in	O
solution	O
was	O
performed	O
by	O
dynamic	B-P
light	I-P
scattering	I-P
(	O
DLS	B-P
)	O
and	O
zeta	O
potential	O
(	O
ZP	O
)	O
measurements	O
.	O

The	O
average	O
size	O
of	O
inclusion	O
complexes	O
as	O
determined	O
by	O
DLS	B-P
,	O
ranged	O
between	O
70	O
and	O
100nm	O
.	O

Besides	O
,	O
ZP	O
analysis	O
showed	O
that	O
both	O
complexes	O
are	O
more	O
stable	O
in	O
the	O
presence	O
of	O
RIF	O
.	O

This	O
study	O
may	O
lead	O
to	O
the	O
development	O
of	O
an	O
effective	O
method	O
for	O
the	O
preparation	O
of	O
amylose	O
inclusion	O
complexes	O
,	O
which	O
is	O
beneficial	O
to	O
their	O
further	O
application	O
in	O
drug	O
delivery	O
systems	O
.	O

Pupil	O
Sizes	O
Scale	O
with	O
Attentional	O
Load	O
and	O
Task	O
Experience	O
in	O
a	O
Multiple	O
Object	O
Tracking	O
Task	O
.	O

Previous	O
studies	O
have	O
related	O
changes	O
in	O
attentional	O
load	O
to	O
pupil	O
size	O
modulations	O
.	O

However	O
,	O
studies	O
relating	O
changes	O
in	O
attentional	O
load	O
and	O
task	O
experience	O
on	O
a	O
finer	O
scale	O
to	O
pupil	O
size	O
modulations	O
are	O
scarce	O
.	O

Here	O
,	O
we	O
investigated	O
how	O
these	O
changes	O
affect	O
pupil	O
sizes	O
.	O

To	O
manipulate	O
attentional	O
load	O
,	O
participants	O
covertly	O
tracked	O
between	O
zero	O
and	O
five	O
objects	O
among	O
several	O
randomly	O
moving	O
objects	O
on	O
a	O
computer	O
screen	O
.	O

To	O
investigate	O
effects	O
of	O
task	O
experience	O
,	O
the	O
experiment	O
was	O
conducted	O
on	O
three	O
consecutive	O
days	O
.	O

We	O
found	O
that	O
pupil	O
sizes	O
increased	O
with	O
each	O
increment	O
in	O
attentional	O
load	O
.	O

Across	O
days	O
,	O
we	O
found	O
systematic	O
pupil	O
size	O
reductions	O
.	O

We	O
compared	O
the	O
model	O
fit	O
for	O
predicting	O
pupil	O
size	O
modulations	O
using	O
attentional	O
load	O
,	O
task	O
experience	O
,	O
and	O
task	O
performance	O
as	O
predictors	O
.	O

We	O
found	O
that	O
a	O
model	O
which	O
included	O
attentional	O
load	O
and	O
task	O
experience	O
as	O
predictors	O
had	O
the	O
best	O
model	O
fit	O
while	O
adding	O
performance	O
as	O
a	O
predictor	O
to	O
this	O
model	O
reduced	O
the	O
overall	O
model	O
fit	O
.	O

Overall	O
,	O
results	O
suggest	O
that	O
pupillometry	B-P
provides	O
a	O
viable	O
metric	O
for	O
precisely	O
assessing	O
attentional	O
load	O
and	O
task	O
experience	O
in	O
visuospatial	O
tasks	O
.	O

Naphthohydroquinones	O
,	O
naphthoquinones	O
,	O
anthraquinones	O
,	O
and	O
a	O
naphthohydroquinone	O
dimer	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Morinda	O
parvifolia	O
and	O
their	O
cytotoxic	O
effects	O
through	O
up-regulation	O
of	O
p53	O
.	O

Five	O
unknown	O
compounds	O
,	O
morindaparvins	O
C-G	O
,	O
consisting	O
of	O
naphthohydroquinones	O
,	O
a	O
naphthoquinone	O
,	O
an	O
anthraquinone	O
,	O
and	O
a	O
naphthohydroquinone	O
dimer	O
,	O
together	O
with	O
three	O
known	O
quinones	O
and	O
seven	O
other	O
known	O
compounds	O
,	O
were	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Morinda	O
parvifolia	O
.	O

The	O
structures	O
of	O
morindaparvins	O
C	O
,	O
D	O
,	O
E	O
,	O
F	O
,	O
and	O
G	O
were	O
elucidated	O
on	O
the	O
basis	O
of	O
spectroscopic	B-P
or	O
X-ray	B-P
diffraction	I-P
analysis	I-P
as	O
methyl	O
4-hydroxy-1,6-dimethoxy-naphthalene-2-carboxylate	O
,	O
methyl	O
4,8-dihydroxy-1-methoxy-naphthalene-2-carboxylate	O
,	O
3-amino-6-methoxy-2-methoxycarbonyl-1,4-naphthoquinone	O
,	O
1,4-dihydroxy-7-hydroxymethyl-anthraquinone	O
,	O
and	O
dimethyl	O
1,1'-dihydroxy-4,4',7,7'-tetramethoxy-2,2'-binaphthalene-3,3'-dicarboxylate	O
,	O
respectively	O
.	O

Naphthoquinones	O
and	O
naphthohydroquinone	O
dimers	O
were	O
previously	O
unknown	O
in	O
the	O
genus	O
Morinda	O
.	O

In	O
addition	O
,	O
the	O
compounds	O
were	O
tested	O
for	O
cytotoxicity	O
against	O
four	O
human	O
cancer	O
cell	O
lines	O
HeLa	O
,	O
A2780	O
,	O
Ketr3	O
and	O
MCF-7	O
and	O
their	O
effects	O
on	O
p53	O
-	O
activated	O
transcription	O
.	O

Three	O
naphthoquinones	O
had	O
moderate	O
cytotoxic	O
effects	O
with	O
IC50	O
values	O
ranging	O
from	O
1.51	O
to	O
9.56	O
μM	O
,	O
through	O
up-regulation	O
of	O
p53	O
transcriptional	O
activity	O
.	O

The	O
duration	O
of	O
pregnancy	O
in	O
ecologically-challenged	O
area	O
.	O

The	O
effects	O
of	O
environmental	O
pollution	O
with	O
aromatic	O
hydrocarbons	O
on	O
the	O
angiogenesis	O
and	O
elements	O
of	O
the	O
mesenchymal	O
tissue	O
of	O
the	O
human	O
placenta	O
.	O

The	O
literature	O
presents	O
only	O
few	O
reports	O
regarding	O
the	O
effects	O
of	O
elevated	O
levels	O
of	O
aromatic	O
hydrocarbons	O
(	O
AH	O
)	O
on	O
the	O
functions	O
of	O
the	O
human	O
placenta	O
.	O

The	O
effects	O
of	O
environmental	O
contamination	O
with	O
AH	O
(	O
including	O
phenol	O
and	O
1-hydroxypyrene	O
)	O
have	O
certain	O
negative	O
effects	O
on	O
parenchymal	O
organs	O
such	O
as	O
human	O
placenta	O
.	O

The	O
paper	O
aimed	O
to	O
assess	O
the	O
effects	O
of	O
elevated	O
levels	O
of	O
AH	O
on	O
the	O
placental	O
angiogenesis	O
and	O
elements	O
of	O
the	O
mesenchymal	O
tissue	O
of	O
the	O
placenta	O
.	O

Tissue	O
material	O
from	O
50	O
afterbirths	O
from	O
Płock	O
constituted	O
a	O
study	O
group	O
,	O
whereas	O
50	O
afterbirths	O
from	O
Kutno	O
constituted	O
a	O
control	O
group	O
.	O

Immunohistochemical	B-P
reactions	I-P
with	I-P
the	I-P
peroxidase	I-P
method	I-P
using	O
LSAB	O
kits	O
(	O
DAKO	O
)	O
were	O
performed	O
.	O

The	O
extent	O
and	O
intensity	O
of	O
reactions	O
were	O
analysed	O
.	O

The	O
levels	O
of	O
phenols	O
and	O
1-hydroxypyrene	O
in	O
the	O
excreted	O
urine	O
of	O
pregnant	O
women	O
(	O
undergoing	O
delivery	O
)	O
were	O
detected	O
using	O
gas	B-P
chromatography	I-P
and	O
colorimetry	B-P
.	O

The	O
levels	O
of	O
phenol	O
and	O
1-hydroxypyrene	O
in	O
the	O
excreted	O
urine	O
were	O
demonstrated	O
to	O
be	O
statistically	O
significantly	O
higher	O
in	O
patients	O
living	O
in	O
the	O
area	O
of	O
Płock	O
.	O

Statistically	O
significantly	O
higher	O
expression	O
of	O
antibodies	O
indicating	O
placental	O
angiogenesis	O
was	O
observed	O
in	O
the	O
placentas	O
in	O
the	O
Płock	O
group	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Moreover	O
,	O
lower	O
expression	O
of	O
vimentin	O
indicating	O
reactions	O
with	O
proteins	O
in	O
mesenchymal	O
cells	O
was	O
observed	O
in	O
the	O
Kutno	O
group	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Pregnancy	O
in	O
the	O
environment	O
with	O
elevated	O
levels	O
of	O
aromatic	O
hydrocarbons	O
has	O
detrimental	O
effects	O
on	O
the	O
human	O
placenta	O
.	O

The	O
foetus	O
is	O
protected	O
by	O
activation	O
of	O
adaptation	O
and	O
compensation	O
mechanisms	O
that	O
are	O
manifested	O
as	O
significant	O
angiogenesis	O
and	O
greater	O
development	O
and	O
differentiation	O
of	O
mesenchymal	O
cells	O
compared	O
to	O
the	O
control	O
group	O
.	O

Chemisorption	O
of	O
Perfluorooctanoic	O
Acid	O
on	O
Powdered	O
Activated	O
Carbon	O
Initiated	O
by	O
Persulfate	O
in	O
Aqueous	O
Solution	O
.	O

Perfluorooctanoic	O
acid	O
(	O
PFOA	O
)	O
is	O
a	O
perfluorocarboxylic	O
acid	O
that	O
is	O
difficult	O
to	O
treat	O
by	O
most	O
conventional	O
methods	O
.	O

As	O
a	O
result	O
,	O
it	O
is	O
often	O
removed	O
from	O
solution	O
by	O
adsorption	B-P
on	O
powdered	O
activated	O
carbon	O
(	O
PAC	O
)	O
,	O
followed	O
by	O
incineration	O
of	O
the	O
spent	O
carbon	O
.	O

To	O
provide	O
a	O
new	O
approach	O
for	O
treatment	O
,	O
PFOA	O
was	O
exposed	O
to	O
sulfate	O
radicals	O
(	O
SO4	O
(	O
-•	O
)	O
)	O
produced	O
by	O
thermolysis	O
of	O
persulfate	O
(	O
S2O8	O
(	O
2-	O
)	O
)	O
in	O
the	O
presence	O
of	O
PAC	O
.	O

Under	O
acidic	O
conditions	O
,	O
thermal	O
activation	O
of	O
persulfate	O
resulted	O
in	O
transformation	O
of	O
PFOA	O
to	O
shorter-chain-length	O
perfluorinated	O
compounds	O
,	O
as	O
previously	O
reported	O
.	O

However	O
,	O
when	O
thermolysis	O
of	O
persulfate	O
occurred	O
under	O
circumneutral	O
pH	O
conditions	O
in	O
the	O
presence	O
of	O
PAC	O
,	O
a	O
new	O
removal	O
pathway	O
for	O
PFOA	O
was	O
observed	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
removal	O
of	O
PFOA	O
was	O
attributable	O
to	O
chemisorption	O
,	O
a	O
process	O
in	O
which	O
PAC	O
catalyzed	O
persulfate	O
decomposition	O
and	O
reacted	O
with	O
the	O
transformation	O
products	O
to	O
produce	O
covalently	O
bound	O
PFOA	O
.	O

At	O
PAC	O
concentrations	O
between	O
200	O
and	O
1000	O
mg/L	O
and	O
an	O
initial	O
PFOA	O
concentration	O
of	O
0.5	O
μM	O
,	O
covalent	O
bonding	O
resulted	O
in	O
removal	O
of	O
10-40	O
%	O
of	O
the	O
PFOA	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
process	O
resulted	O
in	O
removal	O
of	O
more	O
than	O
half	O
of	O
a	O
more	O
hydrophilic	O
perfluoroalkyl	O
acid	O
(	O
i.e.	O
,	O
perfluorobutanoic	O
acid	O
,	O
PFBA	O
)	O
,	O
which	O
was	O
greater	O
than	O
the	O
amount	O
of	O
PFBA	O
removed	O
by	O
physical	O
adsorption	B-P
on	O
PAC	O
.	O

Although	O
the	O
high	O
reaction	O
temperatures	O
(	O
i.e.	O
,	O
80	O
°C	O
)	O
and	O
relatively	O
high	O
doses	O
of	O
PAC	O
used	O
in	O
this	O
study	O
may	O
be	O
impractical	O
for	O
drinking	O
water	O
treatment	O
,	O
this	O
process	O
may	O
be	O
applied	O
to	O
the	O
treatment	O
of	O
these	O
recalcitrant	O
compounds	O
in	O
industrial	O
wastewater	O
,	O
reverse	O
osmosis	O
concentrate	O
,	O
and	O
other	O
waters	O
that	O
contain	O
high	O
concentrations	O
of	O
PFOA	O
and	O
other	O
perfluorocarboxylic	O
acids	O
.	O

Intracellular	O
distribution	O
and	O
stability	O
of	O
a	O
luminescent	O
rhenium	O
(	O
i	O
)	O
tricarbonyl	O
tetrazolato	O
complex	O
using	O
epifluorescence	B-P
microscopy	I-P
in	O
conjunction	O
with	O
X-ray	B-P
fluorescence	I-P
imaging	I-P
.	O

Optical	B-P
epifluorescence	I-P
microscopy	I-P
was	O
used	O
in	O
conjunction	O
with	O
X-ray	B-P
fluorescence	I-P
imaging	I-P
to	O
monitor	O
the	O
stability	O
and	O
intracellular	O
distribution	O
of	O
the	O
luminescent	O
rhenium	O
(	O
i	O
)	O
complex	O
fac-	O
[	O
Re	O
(	O
CO	O
)	O
3	O
(	O
phen	O
)	O
L	O
]	O
,	O
where	O
phen	O
=	O
1,10-phenathroline	O
and	O
L	O
=	O
5-	O
(	O
4-iodophenyl	O
)	O
tetrazolato	O
,	O
in	O
22Rv1	O
cells	O
.	O

The	O
rhenium	O
complex	O
showed	O
no	O
signs	O
of	O
ancillary	O
ligand	O
dissociation	O
,	O
a	O
conclusion	O
based	O
on	O
data	O
obtained	O
via	O
X-ray	B-P
fluorescence	I-P
imaging	I-P
aligning	O
iodine	O
and	O
rhenium	O
distributions	O
.	O

A	O
diffuse	O
reticular	O
localisation	O
was	O
detected	O
for	O
the	O
complex	O
in	O
the	O
nuclear	O
/	O
perinuclear	O
region	O
of	O
cells	O
,	O
by	O
either	O
optical	B-P
or	O
X-ray	B-P
fluorescence	I-P
imaging	I-P
techniques	O
.	O

X-ray	B-P
fluorescence	I-P
also	O
showed	O
that	O
the	O
rhenium	O
complex	O
disrupted	O
the	O
homeostasis	O
of	O
some	O
biologically	O
relevant	O
elements	O
,	O
such	O
as	O
chlorine	O
,	O
potassium	O
and	O
zinc	O
.	O

Reduced	O
Chest	O
and	O
Abdominal	O
Wall	O
Mobility	O
and	O
Their	O
Relationship	O
to	O
Lung	O
Function	O
,	O
Respiratory	O
Muscle	O
Strength	O
,	O
and	O
Exercise	O
Tolerance	O
in	O
Subjects	O
With	O
COPD	O
.	O

Advanced	O
air-flow	O
limitation	O
in	O
patients	O
with	O
COPD	O
leads	O
to	O
a	O
reduction	O
in	O
vital	O
capacity	O
,	O
respiratory	O
muscle	O
strength	O
,	O
and	O
exercise	O
capacity	O
.	O

However	O
,	O
its	O
impact	O
on	O
chest	O
and	O
abdominal	O
wall	O
mobility	O
is	O
unknown	O
.	O

This	O
study	O
aimed	O
to	O
ascertain	O
the	O
prevalence	O
of	O
patients	O
with	O
COPD	O
with	O
reduced	O
chest	O
and	O
abdominal	O
wall	O
mobility	O
and	O
to	O
investigate	O
the	O
effect	O
of	O
reduced	O
chest	O
and	O
abdominal	O
wall	O
mobility	O
on	O
pulmonary	O
function	O
,	O
respiratory	O
muscle	O
strength	O
,	O
and	O
exercise	O
capacity	O
.	O

In	O
51	O
elderly	O
male	O
subjects	O
with	O
COPD	O
,	O
chest	O
and	O
abdominal	O
wall	O
mobility	O
,	O
FVC	O
,	O
FEV1	B-P
,	O
FEV1/FVC	B-P
,	O
maximal	B-P
inspiratory	I-P
pressure	I-P
(	O
PImax	B-P
)	O
,	O
maximal	B-P
expiratory	I-P
pressure	I-P
(	O
PEmax	B-P
)	O
,	O
and	O
the	O
6-min	B-P
walk	I-P
distance	I-P
(	O
6MWD	B-P
)	O
were	O
assessed	O
.	O

Chest	O
and	O
abdominal	O
wall	O
mobility	O
were	O
measured	O
using	O
the	O
breathing	O
movement	B-P
scale	I-P
(	O
0-8	O
)	O
at	O
the	O
3	O
regions	O
(	O
upper	O
chest	O
,	O
lower	O
chest	O
,	O
and	O
abdomen	O
)	O
.	O

Reduced	O
mobility	O
was	O
defined	O
as	O
a	O
value	O
lower	O
than	O
the	O
lower	O
limit	O
of	O
the	O
normal	O
scale	O
.	O

The	O
unpaired	O
t	O
test	O
,	O
Mann-Whitney	O
test	O
,	O
and	O
multiple	O
regression	O
analysis	O
were	O
performed	O
.	O

The	O
percentages	O
of	O
subjects	O
with	O
reduced	O
mobility	O
were	O
78	O
%	O
for	O
the	O
upper	O
chest	O
,	O
76	O
%	O
for	O
the	O
lower	O
chest	O
,	O
and	O
53	O
%	O
for	O
the	O
abdomen	O
.	O

The	O
subjects	O
with	O
reduced	O
mobility	O
had	O
significantly	O
low	O
FVC	O
,	O
FEV1	B-P
,	O
and	O
6MWD	B-P
in	O
each	O
region	O
and	O
significantly	O
low	O
FEV1/FVC	B-P
,	O
PImax	B-P
,	O
and	O
PEmax	B-P
in	O
the	O
abdominal	O
region	O
compared	O
with	O
those	O
with	O
nonreduced	O
mobility	O
.	O

FVC	O
and	O
6MWD	B-P
were	O
independently	O
associated	O
with	O
the	O
scale	O
values	O
in	O
each	O
region	O
and	O
with	O
the	O
abdominal	O
scale	O
value	O
,	O
respectively	O
.	O

The	O
majority	O
of	O
subjects	O
with	O
COPD	O
had	O
reduced	O
chest	O
and	O
abdominal	O
wall	O
mobility	O
,	O
which	O
was	O
independently	O
associated	O
with	O
FVC	O
.	O

Even	O
though	O
abdominal	O
wall	O
mobility	O
was	O
relatively	O
preserved	O
compared	O
with	O
chest	O
wall	O
mobility	O
,	O
it	O
was	O
also	O
independently	O
associated	O
with	O
6MWD	B-P
.	O

Bone	O
-	O
Albumin	O
filling	O
decreases	O
donor	O
site	O
morbidity	O
and	O
enhances	O
bone	O
formation	O
after	O
anterior	O
cruciate	O
ligament	O
reconstruction	O
with	O
bone-patellar	O
tendon-bone	O
autografts	O
.	O

Donor	O
site	O
pain	O
affects	O
32-43	O
%	O
of	O
patients	O
after	O
anterior	O
cruciate	O
ligament	O
surgery	O
when	O
the	O
autograft	O
is	O
freshly	O
harvested	O
bone-patellar	O
tendon-bone	O
tissue	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
functional	O
and	O
morphological	O
differences	O
between	O
donor	O
sites	O
with	O
and	O
without	O
serum	O
albumin	O
-	O
coated	O
bone	O
allograft	O
filling	O
.	O

After	O
harvesting	O
and	O
implanting	O
the	O
graft	O
,	O
the	O
tibia	O
site	O
was	O
filled	O
with	O
either	O
fresh	O
autologous	O
cancellous	O
bone	O
enhanced	O
with	O
albumin	O
-	O
coated	O
allograft	O
or	O
autologous	O
bone	O
alone	O
.	O

The	O
patella	O
site	O
was	O
filled	O
either	O
with	O
albumin	O
-	O
coated	O
allograft	O
or	O
with	O
blood	O
clot	O
.	O

Knee	O
function	O
was	O
evaluated	O
by	O
the	O
VISA	O
,	O
Lysholm	O
and	O
IKDC	O
scores	O
and	O
a	O
visual	B-P
analog	I-P
scale	I-P
of	I-P
pain	I-P
during	O
standing	O
,	O
kneeling	O
and	O
crouching	O
after	O
six	O
weeks	O
and	O
six	O
months	O
.	O

Computed	B-P
tomography	I-P
was	O
performed	O
at	O
six	O
months	O
for	O
morphological	O
evaluation	O
.	O

At	O
six	O
weeks	O
,	O
both	O
groups	O
were	O
still	O
recovering	O
from	O
surgery	O
and	O
the	O
overall	O
knee	O
function	O
was	O
still	O
impaired	O
but	O
the	O
functional	O
scores	O
were	O
significantly	O
higher	O
in	O
the	O
Bone	O
-	O
Albumin	O
group	O
.	O

The	O
pain	O
with	O
crouching	O
and	O
kneeling	O
was	O
also	O
lower	O
as	O
compared	O
to	O
controls	O
.	O

At	O
six	O
months	O
,	O
the	O
knee	O
function	O
scores	O
were	O
close	O
to	O
normal	O
,	O
with	O
a	O
slight	O
decrease	O
in	O
the	O
controls	O
.	O

Pain	O
at	O
kneeling	O
was	O
still	O
prominent	O
in	O
the	O
controls	O
,	O
but	O
significantly	O
lower	O
in	O
the	O
Bone	O
-	O
Albumin	O
group	O
.	O

Computed	B-P
tomography	I-P
showed	O
significantly	O
smaller	O
bone	O
defects	O
and	O
higher	O
bone	O
density	O
in	O
the	O
Bone	O
-	O
Albumin	O
group	O
.	O

Results	O
from	O
the	O
present	O
study	O
indicate	O
that	O
donor	O
site	O
pain	O
,	O
a	O
disturbing	O
long-term	O
side	O
effect	O
of	O
bone-patellar	O
tendon-bone	O
surgery	O
,	O
is	O
significantly	O
reduced	O
if	O
bone	O
buildup	O
in	O
the	O
patella	O
and	O
the	O
tibia	O
is	O
augmented	O
by	O
serum	O
albumin	O
-	O
coated	O
bone	O
allografts	O
.	O

NF-κB	O
Links	O
TLR2	O
and	O
PAR1	O
to	O
Soluble	O
Immunomodulator	O
Factor	O
Secretion	O
in	O
Human	O
Platelets	O
.	O

The	O
primary	O
toll-like	O
receptor	O
(	O
TLR	O
)	O
-mediated	O
immune	O
cell	O
response	O
pathway	O
common	O
for	O
all	O
TLRs	O
is	O
MyD88	O
-dependent	O
activation	O
of	O
NF-κB	O
,	O
a	O
seminal	O
transcription	O
factor	O
for	O
many	O
chemokines	O
and	O
cytokines	O
.	O

Remarkably	O
,	O
anucleate	O
platelets	O
express	O
the	O
NF-κB	O
machinery	O
,	O
whose	O
role	O
in	O
platelets	O
remains	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
contribution	O
of	O
NF-κB	O
in	O
the	O
release	O
of	O
cytokines	O
and	O
serotonin	O
by	O
human	O
platelets	O
,	O
following	O
selective	O
stimulation	O
of	O
TLR2	O
and	O
protease	O
activated	O
receptor	O
1	O
(	O
PAR1	O
)	O
,	O
a	O
classical	O
and	O
non-classical	O
pattern-recognition	O
receptor	O
,	O
respectively	O
,	O
able	O
to	O
participate	O
to	O
the	O
innate	O
immune	O
system	O
.	O

We	O
discovered	O
that	O
platelet	O
PAR1	O
activation	O
drives	O
the	O
process	O
of	O
NF-κB	O
phosphorylation	O
,	O
in	O
contrast	O
to	O
TLR2	O
activation	O
,	O
which	O
induces	O
a	O
slower	O
phosphorylation	O
process	O
.	O

Conversely	O
,	O
platelet	O
PAR1	O
and	O
TLR2	O
activation	O
induces	O
similar	O
ERK1/2	O
,	O
p38	O
,	O
and	O
AKT	O
phosphorylation	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
engagement	O
of	O
platelet	O
TLR2	O
with	O
its	O
ligand	O
,	O
Pam3CSK4	O
,	O
significantly	O
increases	O
the	O
release	O
of	O
sCD62P	O
,	O
RANTES	O
,	O
and	O
sCD40L	O
;	O
this	O
effect	O
was	O
attenuated	O
by	O
incubating	B-P
platelets	O
with	O
a	O
blocking	O
anti-TLR2	O
antibody	O
.	O

This	O
effect	O
appeared	O
selective	O
since	O
no	O
modulation	O
of	O
serotonin	O
secretion	O
was	O
observed	O
following	O
platelet	O
TLR2	O
activation	O
.	O

Platelet	O
release	O
of	O
sCD62P	O
,	O
RANTES	O
,	O
and	O
sCD40L	O
following	O
TLR2	O
or	O
PAR1	O
triggering	O
was	O
abolished	O
in	O
the	O
presence	O
of	O
the	O
NF-κB	O
inhibitor	O
Bay11-7082	O
,	O
while	O
serotonin	O
release	O
following	O
PAR1	O
activation	O
was	O
significantly	O
decreased	O
.	O

These	O
new	O
findings	O
support	O
the	O
concept	O
that	O
NF-κB	O
is	O
an	O
important	O
player	O
in	O
platelet	O
immunoregulations	O
and	O
functions	O
.	O

Coexisting	O
cortical	O
atrophy	O
plays	O
a	O
crucial	O
role	O
in	O
cognitive	O
impairment	O
in	O
moderate	O
to	O
severe	O
cerebral	O
small	O
vessel	O
disease	O
patients	O
.	O

Whether	O
white	O
matter	O
lesion	O
(	O
WML	O
)	O
is	O
associated	O
with	O
vascular	O
cognitive	O
impairment	O
in	O
cerebral	O
small	O
vessel	O
disease	O
(	O
CSVD	O
)	O
remains	O
controversial	O
;	O
some	O
severe	O
CSVD	O
patients	O
retain	O
normal	O
cognitive	O
function	O
,	O
and	O
cortical	O
thinning	O
associated	O
with	O
WMLs	O
has	O
also	O
been	O
recently	O
reported	O
.	O

The	O
contribution	O
of	O
cortical	O
atrophy	O
to	O
vascular	O
cognitive	O
impairment	O
in	O
severe	O
CSVD	O
and	O
whether	O
WML	O
affects	O
cortical	O
atrophy	O
remain	O
unknown	O
.	O

From	O
November	O
2012	O
to	O
January	O
2015	O
,	O
50-	O
to	O
80-year-old	O
patients	O
with	O
moderate	O
to	O
severe	O
WMLs	O
or	O
more	O
than	O
four	O
lacunar	O
infarctions	O
and	O
cognitive	O
complaints	O
,	O
excluding	O
those	O
with	O
large	O
vascular	O
diseases	O
diagnosed	O
by	O
transcranial	B-P
cerebral	I-P
Doppler	I-P
,	O
were	O
recruited	O
.	O

The	O
patients	O
were	O
divided	O
into	O
CSVD	O
groups	O
with	O
or	O
without	O
vascular	O
cognitive	O
impairment	O
-	O
no	O
dementia	O
(	O
VCIND	O
)	O
according	O
to	O
scores	O
on	O
neuropsychological	B-P
tests	I-P
that	O
evaluated	O
five	O
cognitive	O
domains	O
.	O

Based	O
on	O
these	O
results	O
,	O
16	O
patients	O
were	O
included	O
in	O
the	O
CSVD	O
with	O
VCIND	O
group	O
,	O
and	O
12	O
were	O
included	O
in	O
the	O
CSVD	O
without	O
VCIND	O
group	O
.	O

T1	B-P
,	O
T2	B-P
,	O
3D-MPRAGE	B-P
,	O
and	O
diffusion	B-P
tensor	I-P
imaging	I-P
were	O
performed	O
,	O
and	O
gray	O
matter	O
volume	O
and	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
values	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

Gray	O
matter	O
volume	O
,	O
especially	O
in	O
the	O
frontal	O
cortex	O
,	O
bilateral	O
calcarine	O
sulcus	O
,	O
and	O
fusiform	O
gyrus	O
,	O
was	O
considerably	O
lower	O
in	O
the	O
CSVD	O
with	O
VCIND	O
patients	O
,	O
with	O
24,619	O
fewer	O
voxels	O
.	O

In	O
addition	O
,	O
the	O
FA	O
values	O
of	O
1,583	O
voxels	O
were	O
lower	O
in	O
the	O
CSVD	O
patients	O
with	O
VCIND	O
than	O
in	O
those	O
without	O
.	O

In	O
conclusion	O
,	O
cortical	O
atrophy	O
is	O
associated	O
with	O
cognitive	O
impairment	O
in	O
moderate	O
to	O
severe	O
WML	O
or	O
lacunar	O
infarction	O
patients	O
,	O
suggesting	O
that	O
cortical	O
atrophy	O
might	O
be	O
secondary	O
to	O
white	O
matter	O
damage	O
in	O
vascular	O
cognitive	O
impairment	O
caused	O
by	O
CSVD	O
.	O

A	O
novel	O
role	O
for	O
poly	O
(	O
C	O
)	O
binding	O
proteins	O
in	O
programmed	O
ribosomal	O
frameshifting	O
.	O

Translational	O
control	O
through	O
programmed	O
ribosomal	O
frameshifting	O
(	O
PRF	O
)	O
is	O
exploited	O
widely	O
by	O
viruses	O
and	O
increasingly	O
documented	O
in	O
cellular	O
genes	O
.	O

Frameshifting	O
is	O
induced	O
by	O
mRNA	O
secondary	O
structures	O
that	O
compromise	O
ribosome	O
fidelity	O
during	O
decoding	O
of	O
a	O
heptanucleotide	O
'slippery	O
'	O
sequence	O
.	O

The	O
nsp2	O
PRF	O
signal	O
of	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
is	O
distinctive	O
in	O
directing	O
both	O
-2	O
and	O
-1	O
PRF	O
and	O
in	O
its	O
requirement	O
for	O
a	O
trans-acting	O
protein	O
factor	O
,	O
the	O
viral	O
replicase	O
subunit	O
nsp1β	O
.	O

Here	O
we	O
show	O
that	O
the	O
the	O
trans-activation	O
of	O
frameshifting	O
is	O
carried	O
out	O
by	O
a	O
protein	O
complex	O
composed	O
of	O
nsp1β	O
and	O
a	O
cellular	O
poly	O
(	O
C	O
)	O
binding	O
protein	O
(	O
PCBP	O
)	O
.	O

From	O
the	O
results	O
of	O
in	O
vitro	O
translation	O
and	O
electrophoretic	B-P
mobility	I-P
shift	I-P
assays	I-P
,	O
we	O
demonstrate	O
that	O
a	O
PCBP	O
/	O
nsp1β	O
complex	O
binds	O
to	O
a	O
C-rich	O
sequence	O
downstream	O
of	O
the	O
slippery	O
sequence	O
and	O
here	O
mimics	O
the	O
activity	O
of	O
a	O
structured	O
mRNA	O
stimulator	O
of	O
PRF	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
role	O
for	O
a	O
trans-acting	O
cellular	O
protein	O
in	O
PRF	O
.	O

The	O
discovery	O
broadens	O
the	O
repertoire	O
of	O
activities	O
associated	O
with	O
poly	O
(	O
C	O
)	O
binding	O
proteins	O
and	O
prototypes	O
a	O
new	O
class	O
of	O
virus	O
-	O
host	O
interactions	O
.	O

Comparison	O
of	O
the	O
Effects	O
of	O
Subcutaneous	O
Versus	O
Continuous	O
Infusion	O
of	O
Heparin	O
on	O
Key	O
Inflammatory	O
Parameters	O
Following	O
Sepsis	O
.	O

Sepsis	O
is	O
the	O
result	O
of	O
the	O
interaction	O
between	O
inflammatory	O
mediators	O
and	O
coagulation	O
pathway	O
.	O

Unfractionated	O
heparin	O
may	O
play	O
a	O
role	O
as	O
an	O
anti-inflammatory	O
agent	O
beyond	O
its	O
anticoagulatory	O
effect	O
in	O
sepsis	O
.	O

As	O
a	O
result	O
,	O
it	O
may	O
cause	O
reduction	O
in	O
organ	O
failure	O
rate	O
in	O
patients	O
with	O
sepsis	O
due	O
to	O
its	O
impact	O
on	O
both	O
inflammatory	O
and	O
coagulation	O
process	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
anti-inflammatory	O
effects	O
of	O
heparin	O
in	O
sepsis	O
.	O

Plasma	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI-1	O
)	O
as	O
an	O
inflammatory	O
mediator	O
and	O
urinary	O
necoutrophil	O
gelatinase-associated	O
lipocalin	O
(	O
NGAL	O
)	O
as	O
a	O
marker	O
of	O
kidney	O
injury	O
were	O
investigated	O
.	O

This	O
prospective	O
,	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
in	O
a	O
32-	O
bed	O
intensive	O
care	O
unit	O
.	O

Thirty	O
patients	O
with	O
sepsis	O
were	O
randomized	O
to	O
receive	O
heparin	O
infusion	O
of	O
500	O
units/hour	O
or	O
5000	O
units	O
of	O
heparin	O
three	O
times	O
a	O
day	O
,	O
subcutaneously	O
.	O

The	O
plasma	O
level	O
of	O
PAI-1	O
and	O
urinary	O
level	O
of	O
NGAL	O
were	O
determined	O
at	O
day	O
0	O
,	O
2	O
and	O
7	O
.	O

The	O
infusion	O
group	O
had	O
a	O
lower	O
plasma	O
PAI-1	O
level	O
compared	O
to	O
the	O
subcutaneous	O
group	O
at	O
day	O
7	O
(	O
11.3	O
±	O
1.6	O
vs.	O
16.5	O
±	O
4.2	O
;	O
P	O
=	O
0.003	O
)	O
.	O

The	O
urinary	O
NGAL	O
level	O
was	O
lower	O
in	O
the	O
infusion	O
group	O
at	O
day	O
2	O
(	O
131.3	O
±	O
11.9	O
vs.	O
151.2	O
±	O
20.6	O
;	O
P	O
=	O
0.014	O
)	O
;	O
however	O
,	O
at	O
day	O
7	O
the	O
NGAL	O
level	O
was	O
decreased	O
in	O
the	O
subcutaneous	O
group	O
as	O
much	O
as	O
the	O
infusion	O
group	O
and	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
acute	B-P
physiology	I-P
and	I-P
chronic	I-P
health	I-P
evaluation	I-P
(	I-P
APACHE	I-P
)	I-P
II	I-P
and	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
scores	O
between	O
the	O
two	O
groups	O
at	O
day	O
0	O
,	O
2	O
and	O
7	O
.	O

Low-dose	O
heparin	O
infusion	O
compared	O
to	O
subcutaneous	O
heparin	O
can	O
decrease	O
the	O
plasma	O
PAI-1	O
and	O
urinary	O
NGAL	O
levels	O
more	O
rapidly	O
.	O

It	O
can	O
be	O
related	O
to	O
anti-inflammatory	O
effects	O
of	O
heparin	O
,	O
which	O
may	O
be	O
more	O
prominent	O
in	O
infusion	O
route	O
.	O

Chemotactic	O
Behaviors	O
of	O
Vibrio	O
cholerae	O
Cells	O
.	O

Vibrio	O
cholerae	O
,	O
the	O
causative	O
agent	O
of	O
cholera	O
,	O
swims	O
in	O
aqueous	O
environments	O
with	O
a	O
single	O
polar	O
flagellum	O
.	O

In	O
a	O
spatial	O
gradient	O
of	O
a	O
chemical	O
,	O
the	O
bacterium	O
can	O
migrate	O
in	O
``	O
favorable	O
``	O
directions	O
,	O
a	O
property	O
that	O
is	O
termed	O
chemotaxis	O
.	O

The	O
chemotaxis	O
of	O
V.	O
cholerae	O
is	O
not	O
only	O
critical	O
for	O
survival	O
in	O
various	O
environments	O
and	O
but	O
also	O
is	O
implicated	O
in	O
pathogenicity	O
.	O

In	O
this	O
chapter	O
,	O
we	O
describe	O
how	O
to	O
characterize	O
the	O
chemotactic	O
behaviors	O
of	O
V.	O
cholerae	O
:	O
these	O
methods	O
include	O
swarm	B-P
assay	I-P
,	O
temporal	B-P
stimulation	I-P
assay	I-P
,	O
capillary	B-P
assay	I-P
,	O
and	O
receptor	B-P
methylation	I-P
assay	I-P
.	O

FGF21	O
is	O
a	O
biomarker	O
for	O
mitochondrial	O
translation	O
and	O
mtDNA	O
maintenance	O
disorders	O
.	O

To	O
validate	O
new	O
mitochondrial	O
myopathy	O
serum	O
biomarkers	O
for	O
diagnostic	B-P
use	I-P
.	O

We	O
analyzed	O
serum	O
FGF21	O
(	O
S-FGF21	O
)	O
and	O
GDF15	O
from	O
patients	O
with	O
(	O
1	O
)	O
mitochondrial	O
diseases	O
and	O
(	O
2	O
)	O
nonmitochondrial	O
disorders	O
partially	O
overlapping	O
with	O
mitochondrial	O
disorder	O
phenotypes	O
.	O

We	O
(	O
3	O
)	O
did	O
a	O
meta-analysis	O
of	O
S-FGF21	O
in	O
mitochondrial	O
disease	O
and	O
(	O
4	O
)	O
analyzed	O
S-Fgf21	O
and	O
skeletal	O
muscle	O
Fgf21	O
expression	O
in	O
6	O
mouse	O
models	O
with	O
different	O
muscle	O
-	O
manifesting	O
mitochondrial	O
dysfunctions	O
.	O

We	O
report	O
that	O
S-FGF21	O
consistently	O
increases	O
in	O
primary	O
mitochondrial	O
myopathy	O
,	O
especially	O
in	O
patients	O
with	O
mitochondrial	O
translation	O
defects	O
or	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
deletions	O
(	O
675	O
and	O
347	O
pg/mL	O
,	O
respectively	O
;	O
controls	O
:	O
66	O
pg/mL	O
,	O
p	O
<	O
0.0001	O
for	O
both	O
)	O
.	O

This	O
is	O
corroborated	O
in	O
mice	O
(	O
mtDNA	O
deletions	O
1,163	O
vs	O
379	O
pg/mL	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

However	O
,	O
patients	O
and	O
mice	O
with	O
structural	O
respiratory	O
chain	O
subunit	O
or	O
assembly	O
factor	O
defects	O
showed	O
low	O
induction	O
(	O
human	O
335	O
pg/mL	O
,	O
p	O
<	O
0.05	O
;	O
mice	O
335	O
pg/mL	O
,	O
not	O
significant	O
)	O
.	O

Overall	O
specificities	O
of	O
FGF21	O
and	O
GDF15	O
to	O
find	O
patients	O
with	O
mitochondrial	O
myopathy	O
were	O
89.3	O
%	O
vs	O
86.4	O
%	O
,	O
and	O
sensitivities	O
67.3	O
%	O
and	O
76.0	O
%	O
,	O
respectively	O
.	O

However	O
,	O
GDF15	O
was	O
increased	O
also	O
in	O
a	O
wide	O
range	O
of	O
nonmitochondrial	O
conditions	O
.	O

S-FGF21	O
is	O
a	O
specific	O
biomarker	O
for	O
muscle	O
-	O
manifesting	O
defects	O
of	O
mitochondrial	O
translation	O
,	O
including	O
mitochondrial	O
transfer-RNA	O
mutations	O
and	O
primary	O
and	O
secondary	O
mtDNA	O
deletions	O
,	O
the	O
most	O
common	O
causes	O
of	O
mitochondrial	O
disease	O
.	O

However	O
,	O
normal	O
S-FGF21	O
does	O
not	O
exclude	O
structural	O
respiratory	O
chain	O
complex	O
or	O
assembly	O
factor	O
defects	O
,	O
important	O
to	O
acknowledge	O
in	O
diagnostics	B-P
.	O

This	O
study	O
provides	O
Class	O
III	O
evidence	O
that	O
elevated	O
S-FGF21	O
accurately	O
distinguishes	O
patients	O
with	O
mitochondrial	O
myopathies	O
from	O
patients	O
with	O
other	O
conditions	O
,	O
and	O
FGF21	O
and	O
GDF15	O
mitochondrial	O
myopathy	O
from	O
other	O
myopathies	O
.	O

Effect	O
of	O
Fusarium	O
-Derived	O
Metabolites	O
on	O
the	O
Barrier	O
Integrity	O
of	O
Differentiated	O
Intestinal	O
Porcine	O
Epithelial	O
Cells	O
(	O
IPEC-J2	O
)	O
.	O

The	O
human	O
,	O
animal	O
and	O
plant	O
pathogen	O
Fusarium	O
,	O
which	O
contaminates	O
agricultural	O
commodities	O
worldwide	O
,	O
produces	O
numerous	O
secondary	O
metabolites	O
.	O

An	O
example	O
is	O
the	O
thoroughly-investigated	O
deoxynivalenol	O
(	O
DON	O
)	O
,	O
which	O
severely	O
impairs	O
gastrointestinal	O
barrier	O
integrity	O
.	O

However	O
,	O
to	O
date	O
,	O
the	O
toxicological	B-P
profile	I-P
of	O
other	O
Fusarium	O
-derived	O
metabolites	O
,	O
such	O
as	O
enniatins	O
,	O
beauvericin	O
,	O
moniliformin	O
,	O
apicidin	O
,	O
aurofusarin	O
,	O
rubrofusarin	O
,	O
equisetin	O
and	O
bikaverin	O
,	O
are	O
poorly	O
characterized	O
.	O

Thus	O
we	O
examined	O
their	O
effects-as	O
metabolites	O
alone	O
and	O
as	O
metabolites	O
in	O
combination	O
with	O
DON	O
-on	O
the	O
intestinal	O
barrier	O
function	O
of	O
differentiated	O
intestinal	O
porcine	O
epithelial	O
cells	O
(	O
IPEC-J2	O
)	O
over	O
72	O
h.	O
Transepithelial	O
electrical	O
resistance	O
(	O
TEER	O
)	O
was	O
measured	O
at	O
24-h	O
intervals	O
,	O
followed	O
by	O
evaluation	O
of	O
cell	O
viability	O
using	O
neutral	B-P
red	I-P
(	I-P
NR	I-P
)	I-P
assay	I-P
.	O

Enniatins	O
A	O
,	O
A1	O
,	O
B	O
and	O
B1	O
,	O
apicidin	O
,	O
aurofusarin	O
and	O
beauvericin	O
significantly	O
reduced	O
TEER	O
.	O

Moniliformin	O
,	O
equisetin	O
,	O
bikaverin	O
and	O
rubrofusarin	O
had	O
no	O
effect	O
on	O
TEER	O
.	O

In	O
the	O
case	O
of	O
apicidin	O
,	O
aurofusarin	O
and	O
beauvericin	O
,	O
TEER	O
reductions	O
were	O
further	O
substantiated	O
by	O
the	O
addition	O
of	O
otherwise	O
no-effect	O
DON	O
concentrations	O
.	O

In	O
all	O
cases	O
,	O
viability	O
was	O
unaffected	O
,	O
confirming	O
that	O
TEER	O
reductions	O
were	O
not	O
due	O
to	O
compromised	O
viability	O
.	O

Considering	O
the	O
prevalence	O
of	O
mycotoxin	O
contamination	O
and	O
the	O
diseases	O
associated	O
with	O
intestinal	O
barrier	O
disruption	O
,	O
consumption	O
of	O
contaminated	O
food	O
or	O
feed	O
may	O
have	O
substantial	O
health	O
implications	O
.	O

Antigen	O
Masking	O
During	O
Fixation	B-P
and	O
Embedding	B-P
,	O
Dissected	O
.	O

Antigen	O
masking	O
in	O
routinely	O
processed	O
tissue	O
is	O
a	O
poorly	O
understood	O
process	O
caused	O
by	O
multiple	O
factors	O
.	O

We	O
sought	O
to	O
dissect	O
the	O
effect	O
on	O
antigenicity	O
of	O
each	O
step	O
of	O
processing	O
by	O
using	O
frozen	O
sections	O
as	O
proxies	O
of	O
the	O
whole	O
tissue	O
.	O

An	O
equivalent	O
extent	O
of	O
antigen	O
masking	O
occurs	O
across	O
variable	O
fixation	B-P
times	O
at	O
room	O
temperature	O
.	O

Most	O
antigens	O
benefit	O
from	O
longer	O
fixation	B-P
times	O
(	O
>	O
24	O
hr	O
)	O
for	O
optimal	O
detection	O
after	O
antigen	O
retrieval	O
(	O
AR	O
;	O
for	O
example	O
,	O
Ki-67	O
,	O
bcl-2	O
,	O
ER	O
)	O
.	O

The	O
transfer	O
to	O
a	O
graded	O
alcohol	O
series	O
results	O
in	O
an	O
enhanced	O
staining	O
effect	O
,	O
reproduced	O
by	O
treating	O
the	O
sections	O
with	O
detergents	O
,	O
possibly	O
because	O
of	O
a	O
better	O
access	O
of	O
the	O
polymeric	O
immunohistochemical	B-P
detection	O
system	O
to	O
tissue	O
structures	O
.	O

A	O
second	O
round	O
of	O
masking	O
occurs	O
upon	O
entering	O
the	O
clearing	O
agent	O
,	O
mostly	O
at	O
the	O
paraffin	O
embedding	B-P
step	O
.	O

This	O
may	O
depend	O
on	O
the	O
non-freezable	O
water	O
removal	O
.	O

AR	O
fully	O
reverses	O
the	O
masking	O
due	O
both	O
to	O
the	O
fixation	B-P
time	O
and	O
the	O
paraffin	O
embedding	B-P
.	O

AR	O
itself	O
destroys	O
some	O
epitopes	O
which	O
do	O
not	O
survive	O
routine	O
processing	O
.	O

Processed	O
frozen	O
sections	O
are	O
a	O
tool	O
to	O
investigate	O
fixation	B-P
and	O
processing	O
requirements	O
for	O
antigens	O
in	O
routine	O
specimens	O
.	O

Immunogenicity	O
and	O
protective	O
efficacy	O
of	O
recombinant	O
Bacille	O
Calmette-Guerin	O
strains	O
expressing	O
mycobacterium	O
antigens	O
Ag85A	O
,	O
CFP10	O
,	O
ESAT-6	O
,	O
GM-CSF	O
and	O
IL-12p70	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
immunogenicity	O
and	O
protective	O
efficacy	O
of	O
recombinant	O
bacille	O
calmette-guerin	O
(	O
rBCG	O
)	O
strains	O
expressing	O
Ag85A	O
(	O
A	O
)	O
,	O
CFP10	O
(	O
C	O
)	O
,	O
ESAT6	O
(	O
E	O
)	O
,	O
IL-12p70	O
(	O
I	O
)	O
,	O
and	O
fusion	O
protein	O
GM-CSF	O
(	O
G	O
)	O
.	O

rBCGs	O
were	O
established	O
by	O
integrating	O
of	O
A	O
,	O
C	O
,	O
E	O
,	O
I	O
,	O
G	O
,	O
AE	O
,	O
CE	O
,	O
IE	O
,	O
GC	O
,	O
GE	O
and	O
GCE	O
into	O
Mycobacterium	O
bovis	O
BCG-1173	O
and	O
BCG-SH	O
.	O

The	O
macro-	O
effects	O
of	O
rBCGs	O
on	O
mice	O
were	O
evaluated	O
by	O
phenotype	O
and	O
weight	O
.	O

The	O
immunogenicity	O
of	O
rBCGs	O
was	O
analyzed	O
by	O
lgG	O
,	O
lgG1	O
and	O
lgG2a	O
antibody	O
titers	O
,	O
and	O
IFN-γ	O
and	O
IL-4	O
contents	O
through	O
Enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
(	O
ELISA	B-P
)	O
.	O

Meanwhile	O
,	O
the	O
proportions	O
of	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	O
splenic	O
lymphocytes	O
were	O
determined	O
using	O
flow	B-P
cytometry	I-P
.	O

The	O
protective	O
efficacy	O
of	O
rBCGs	O
was	O
evaluated	O
by	O
bacterial	O
load	O
in	O
spleen	O
and	O
lung	O
tissues	O
from	O
immunized	O
mice	O
.	O

rBCGs	O
exhibited	O
no	O
obvious	O
side	O
effects	O
on	O
mice	O
.	O

The	O
antibody	O
titers	O
of	O
lgG	O
,	O
lgG1	O
and	O
lgG2a	O
,	O
proportion	O
of	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
,	O
and	O
concentrations	O
of	O
IFN-γ	O
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
multiple	O
-	O
gene	O
rBCGs	O
than	O
that	O
in	O
single-gene	O
rBCGs	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Bacterial	O
load	O
in	O
both	O
spleen	O
and	O
lung	O
tissues	O
from	O
mice	O
infected	O
with	O
M.	O
tuberculosis	O
H37Rv	O
were	O
significantly	O
reduced	O
by	O
rBCGs	O
.	O

A	O
significantly	O
lower	O
bacterial	O
load	O
was	O
revealed	O
in	O
rBCG	O
-1173	O
:	O
A	O
compared	O
with	O
multiple	O
-	O
gene	O
rBCGs	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Immunogenicity	O
was	O
better	O
on	O
multiple	O
-	O
gene	O
rBCGs	O
than	O
on	O
single-gene	O
rBCGs	O
,	O
while	O
excellent	O
protective	O
efficacy	O
was	O
exhibited	O
on	O
rBCG-1173	O
:	O
A	O
and	O
BCG-1173	O
.	O

Dyslipidaemia	O
and	O
Medical	O
Outcome	O
(	O
Health	O
Related	O
Quality	O
of	O
Life	O
)	O
in	O
Patients	O
with	O
Schizophrenia	O
Taking	O
Antipsychotics	O
in	O
Enugu	O
,	O
Nigeria	O
.	O

Aim	O
.	O

Determine	O
association	O
between	O
use	O
(	O
and	O
type	O
)	O
of	O
antipsychotics	O
and	O
dyslipidaemia	O
in	O
newly	O
diagnosed	O
schizophrenia	O
patients	O
attending	O
Federal	O
Neuropsychiatric	O
Hospital	O
,	O
Enugu	O
.	O

Methods	O
.	O

From	O
sixty	O
antipsychotic	O
naive	O
patients	O
with	O
schizophrenia	O
and	O
sixty	O
first-degree	O
relatives	O
matched	O
for	O
gender	O
and	O
age	O
,	O
fasting	B-P
blood	I-P
lipid	I-P
profiles	I-P
were	O
measured	O
at	O
baseline	O
and	O
after	O
twelve	O
weeks	O
.	O

Medical	O
Outcome	O
Study	O
Short	O
Form	O
General	O
Health	O
Survey	O
was	O
administered	O
to	O
patients	O
on	O
both	O
occasions	O
.	O

Fasting	B-P
lipid	I-P
profile	I-P
changes	O
of	O
both	O
groups	O
were	O
compared	O
.	O

Results	O
.	O

Mean	O
endpoint	O
of	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
low	O
density	O
lipoprotein	O
(	O
LD	O
)	O
,	O
and	O
triglycerides	O
(	O
TG	O
)	O
in	O
mmol/l	O
for	O
cases	O
was	O
significantly	O
higher	O
than	O
initial	O
values	O
(	O
TC	O
4.5	O
versus	O
4.3	O
,	O
t	O
=	O
4.3	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
(	O
LDL	O
2.8	O
versus	O
2.6	O
,	O
t	O
=	O
14.3	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
and	O
(	O
TG	O
1.3	O
versus	O
1.0	O
,	O
t	O
=	O
12.1	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Mean	O
endpoint	O
of	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
in	O
mmol/l	O
for	O
cases	O
was	O
significantly	O
lower	O
than	O
initial	O
values	O
(	O
1.1	O
versus	O
1.2	O
,	O
t	O
=	O
12.1	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Prevalence	O
of	O
dyslipidaemia	O
for	O
cases	O
was	O
13	O
%	O
.	O

Mean	O
endpoint	O
of	O
TC	O
,	O
LDL	O
,	O
TG	O
,	O
and	O
HDL	O
in	O
mmol/l	O
for	O
controls	O
was	O
not	O
significantly	O
different	O
from	O
initial	O
values	O
(	O
TC	O
4.30	O
versus	O
4.27	O
,	O
t	O
=	O
1.09	O
,	O
p	O
=	O
0.279	O
)	O
,	O
(	O
LDL	O
2.49	O
versus	O
2.46	O
,	O
t	O
=	O
1.28	O
,	O
p	O
=	O
0.205	O
)	O
,	O
(	O
TG	O
0.96	O
versus	O
0.94	O
,	O
t	O
=	O
1.27	O
,	O
p	O
=	O
0.207	O
)	O
,	O
and	O
(	O
HDL	O
1.37	O
versus	O
1.38	O
,	O
t	O
=	O
1.61	O
,	O
p	O
=	O
0.113	O
)	O
.	O

Subjects	O
on	O
atypical	O
antipsychotics	O
had	O
higher	O
risk	O
for	O
dyslipidaemia	O
.	O

Conclusion	O
.	O

Use	O
of	O
antipsychotics	O
was	O
significantly	O
associated	O
with	O
dyslipidaemia	O
.	O

Periprocedural	O
myocardial	O
infarction	O
during	O
percutaneous	O
coronary	O
intervention	O
in	O
an	O
academic	O
tertiary	O
centre	O
in	O
Johannesburg	O
.	O

Percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
is	O
effective	O
therapy	O
for	O
significant	O
atherosclerotic	O
coronary	O
artery	O
disease	O
.	O

Despite	O
medical	O
and	O
technological	O
advances	O
in	O
PCI	O
,	O
periprocedural	O
myocardial	O
infarction	O
(	O
PMI	O
)	O
remains	O
a	O
common	O
complication	O
.	O

The	O
frequency	O
and	O
factors	O
associated	O
with	O
PMI	O
have	O
been	O
well	O
investigated	O
in	O
the	O
developed	O
world	O
,	O
yet	O
there	O
is	O
a	O
paucity	O
of	O
data	O
from	O
the	O
developing	O
world	O
,	O
especially	O
Sub-Saharan	O
Africa	O
.	O

We	O
prospectively	O
enrolled	O
153	O
adult	O
patients	O
undergoing	O
PCI	O
at	O
the	O
Charlotte	O
Maxeke	O
Johannesburg	O
Academic	O
Hospital	O
from	O
the	O
1st	O
of	O
February	O
2014	O
to	O
31st	O
October	O
2014	O
.	O

Periprocedural	O
Creatinine	B-P
Kinase-MB	I-P
and	O
hs-Troponin	B-P
I	I-P
were	O
routinely	O
measured	O
before	O
PCI	O
and	O
at	O
16-24h	O
post-procedure	O
.	O

The	O
third	O
universal	O
definition	O
of	O
myocardial	O
infarction	O
was	O
used	O
to	O
define	O
a	O
PMI	O
event	O
.	O

152	O
participants	O
met	O
the	O
inclusion	O
criteria	O
and	O
were	O
analysed	O
for	O
PMI	O
.	O

70.4	O
%	O
participants	O
were	O
male	O
.	O

The	O
mean	O
age	O
was	O
58.8	O
(	O
SD	O
10.9	O
)	O
years	O
old	O
.	O

Sixteen	O
(	O
10.5	O
%	O
)	O
participants	O
fulfilled	O
the	O
criteria	O
for	O
PMI	O
.	O

Side	O
branch	O
pinching	O
with	O
preserved	O
TIMI	O
III	O
flow	O
was	O
noted	O
in	O
62.5	O
%	O
of	O
PMI	O
cases	O
.	O

Duration	O
of	O
procedure	O
(	O
P=0.007	O
)	O
,	O
right	O
coronary	O
artery	O
intervention	O
(	O
p=0.042	O
)	O
and	O
total	O
stent	O
length	O
(	O
p=0.045	O
)	O
were	O
independently	O
associated	O
with	O
PMI	O
.	O

PMI	O
occurred	O
in	O
10.5	O
%	O
of	O
cases	O
undergoing	O
PCI	O
.	O

This	O
is	O
consistent	O
with	O
the	O
prevalence	O
of	O
PMI	O
internationally	O
.	O

Larger	O
multicentre	O
studies	O
are	O
required	O
in	O
our	O
demographic	O
region	O
to	O
further	O
define	O
relevant	O
predictors	O
and	O
outcomes	O
associated	O
with	O
PMI	O
.	O

Lactate	O
induces	O
osteoblast	O
differentiation	O
by	O
stabilization	O
of	O
HIF1α	O
.	O

Aerobic	O
glycolysis	O
is	O
involved	O
in	O
osteoblast	O
differentiation	O
induced	O
by	O
Wnt	O
signaling	O
or	O
PTH	O
treatment	O
.	O

However	O
,	O
it	O
is	O
still	O
unclear	O
whether	O
lactate	O
,	O
the	O
end	O
product	O
of	O
aerobic	O
glycolysis	O
,	O
plays	O
any	O
role	O
in	O
osteoblast	O
differentiation	O
.	O

Herein	O
we	O
report	O
that	O
in	O
cultures	B-P
of	O
osteoblast-lineage	O
cells	O
,	O
lactate	O
promoted	O
alkaline	O
phosphatase	O
-positive	O
cell	O
formation	O
,	O
increased	O
the	O
activity	O
of	O
alkaline	O
phosphatase	O
,	O
and	O
induced	O
the	O
expression	O
of	O
osteocalcin	O
.	O

This	O
osteoblast	O
differentiation	O
-inducing	O
effect	O
of	O
lactate	O
can	O
be	O
inhibited	O
by	O
blocking	O
its	O
entry	O
into	O
cells	O
with	O
MCT1	O
siRNA	O
or	O
inhibitors	O
,	O
and	O
by	O
interfering	O
with	O
its	O
metabolism	O
by	O
using	O
specific	O
siRNAs	O
for	O
LDHB	O
and	O
PDH	O
.	O

Moreover	O
,	O
lactate	O
stabilized	O
HIF1α	O
expression	O
and	O
inhibited	O
HIF1α	O
activity	O
,	O
with	O
BAY87-2243	O
lowering	O
the	O
osteoblast	O
differentiation	O
-inducing	O
effect	O
of	O
lactate	O
.	O

Thus	O
,	O
these	O
findings	O
reveal	O
an	O
unrecognized	O
role	O
for	O
aerobic	O
glycolysis	O
in	O
osteoblast	O
differentiation	O
via	O
its	O
end	O
product	O
,	O
lactate	O
.	O

Effects	O
of	O
antrosterol	O
from	O
Antrodia	O
camphorata	O
submerged	O
whole	O
broth	O
on	O
lipid	O
homeostasis	O
,	O
antioxidation	O
,	O
alcohol	O
clearance	O
,	O
and	O
anti-inflammation	O
in	O
livers	O
of	O
chronic	O
-	O
alcohol	O
fed	O
mice	O
.	O

Antrodia	O
camphorata	O
is	O
a	O
functional	O
fungus	O
in	O
Taiwan	O
and	O
owns	O
several	O
pharmacological	O
functions	O
.	O

Antrosterol	O
,	O
a	O
bioactive	O
constitute	O
of	O
sterols	O
in	O
edible	O
Antrodia	O
camphorata	O
submerged	O
whole	O
broth	O
,	O
can	O
protect	O
liver	O
from	O
CCl4	O
damage	O
via	O
enhancing	O
antioxidant	O
and	O
anti-inflammatory	O
capacities	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
hepatoprotection	O
of	O
antrosterol	O
(	O
named	O
as	O
EK100	O
)	O
against	O
alcohol	O
consumption	O
.	O

A	O
Lieber-DeCarli	O
regular	O
EtOH	O
diet	O
(	O
EtOH	O
liquid	O
diet	O
,	O
5	O
%	O
(	O
v/v	O
)	O
alcohol	O
)	O
was	O
applied	O
to	O
induce	O
alcoholic	O
liver	O
damage	O
.	O

Mice	O
were	O
randomly	O
divided	O
into	O
5	O
groups	O
:	O
(	O
1	O
)	O
Control	O
:	O
control	O
liquid	O
diet	O
;	O
(	O
2	O
)	O
EtOH	O
:	O
EtOH	O
liquid	O
diet	O
;	O
(	O
3	O
)	O
EK100_1X	O
:	O
EtOH	O
liquid	O
diet	O
and	O
1mg	O
EK100	O
(	O
Antrosterol	O
)	O
/Kg	O
body	O
weight	O
(	O
bw	O
)	O
;	O
(	O
4	O
)	O
EK100_5X	O
:	O
EtOH	O
liquid	O
diet	O
and	O
5mg	O
EK100	O
/Kg	O
bw	O
;	O
(	O
5	O
)	O
EK100_10X	O
:	O
EtOH	O
liquid	O
diet	O
and	O
10mg	O
EK100	O
/Kg	O
bw	O
.	O

At	O
the	O
end	O
of	O
experiment	O
,	O
the	O
livers	O
were	O
collected	O
for	O
histo-pathological	O
analyses	O
,	O
RNA	B-P
and	O
protein	O
extraction	B-P
,	O
and	O
enzymatic	O
activities	O
.	O

Antrosterol	O
reduced	O
serum	O
/	O
liver	O
lipids	O
of	O
alcohol	O
-	O
diet	O
fed	O
mice	O
which	O
highly	O
related	O
to	O
upregulated	O
fatty	O
acid	O
β-oxidation	O
and	O
downregulated	O
lipogenesis	O
,	O
and	O
increased	O
fecal	O
lipid	O
/	O
bile-acid	O
outputs	O
.	O

Antrosterol	O
enhanced	O
hepatic	O
antioxidant	O
capabilities	O
in	O
alcohol	O
-	O
diet	O
fed	O
mice	O
while	O
it	O
also	O
lowered	O
serum	O
alcohol	O
level	O
,	O
as	O
well	O
as	O
increased	O
alcohol	O
dehydrogenase	O
(	O
ADH	O
)	O
and	O
catalase	O
(	O
CAT	O
)	O
activities	O
and	O
decreased	O
CYP2E1	O
protein	O
expression	O
in	O
livers	O
of	O
alcohol	O
-	O
diet	O
fed	O
mice	O
.	O

Besides	O
,	O
antrosterol	O
lowered	O
hepatic	O
inflammation	O
and	O
fibrosis	O
related	O
gene	O
expressions	O
,	O
as	O
well	O
as	O
serum	B-P
AST	I-P
/	O
ALT	B-P
values	O
and	O
TNF-α	O
/	O
IL-1β	O
contents	O
in	O
alcohol	O
-	O
diet	O
fed	O
mice	O
.	O

Based	O
on	O
the	O
results	O
,	O
hepatoprotection	O
of	O
antrosterol	O
is	O
mostly	O
attributed	O
to	O
its	O
regulations	O
of	O
lipid	O
homeostasis	O
,	O
antioxidant	O
capability	O
,	O
alcohol	O
metabolism	O
,	O
and	O
anti-inflammation	O
.	O

Development	O
of	O
Dual	B-P
Quantitative	I-P
Lateral	I-P
Flow	I-P
Immunoassay	I-P
for	O
the	O
Detection	O
of	O
Mycotoxins	O
.	O

Lateral	B-P
flow	I-P
immunoassays	I-P
have	O
been	O
widely	O
used	O
in	O
recent	O
years	O
for	O
detection	O
of	O
toxins	O
,	O
heavy	O
metals	O
,	O
and	O
biomarkers	O
.	O

To	O
improve	O
the	O
efficiency	O
of	O
individual	B-P
lateral	I-P
flow	I-P
immunoassays	I-P
,	O
multiplex	O
analytical	O
strips	O
play	O
an	O
important	O
role	O
in	O
the	O
detection	O
of	O
several	O
important	O
analytes	O
.	O

In	O
this	O
chapter	O
,	O
development	O
of	O
a	O
dual	B-P
lateral	I-P
flow	I-P
immunoassay	I-P
is	O
presented	O
for	O
detection	O
of	O
a	O
variety	O
of	O
low	O
molecular	O
weight	O
molecules	O
.	O

Various	O
buffers	O
,	O
additives	O
,	O
and	O
materials	O
are	O
introduced	O
and	O
evaluated	O
.	O

Depending	O
on	O
the	O
analyte	O
to	O
be	O
tested	O
,	O
the	O
technique	O
allows	O
for	O
selection	O
of	O
optimum	O
buffers	O
,	O
additives	O
,	O
and	O
other	O
materials	O
.	O

The	O
Daniel	O
K.	O
Inouye	O
College	O
of	O
Pharmacy	O
Scripts	O
:	O
Poha	O
Berry	O
(	O
Physalis	O
peruviana	O
)	O
with	O
Potential	O
Anti-inflammatory	O
and	O
Cancer	O
Prevention	O
Activities	O
.	O

The	O
Daniel	O
K.	O
Inouye	O
College	O
of	O
Pharmacy	O
,	O
during	O
a	O
historic	O
event	O
in	O
Spring	O
2016	O
,	O
graduated	O
the	O
first	O
two	O
students	O
in	O
the	O
Pacific	O
region	O
to	O
earn	O
a	O
PhD	O
in	O
pharmaceutical	O
sciences	O
at	O
the	O
University	O
of	O
Hawai	O
'	O
i	O
at	O
Hilo	O
.	O

The	O
college	O
offers	O
PhD	O
programs	O
in	O
these	O
five	O
disciplines	O
:	O
Cancer	O
Biology	O
,	O
Medicinal	O
Chemistry	O
,	O
Pharmaceutics	O
,	O
Pharmacognosy	O
,	O
and	O
Pharmacology	O
.	O

One	O
of	O
the	O
Pharmacognosy	O
dissertations	O
focused	O
on	O
plant-derived	O
natural	O
products	O
with	O
potential	O
anti-inflammatory	O
and	O
cancer	O
chemopreventive	O
activities	O
.	O

Physalis	O
peruviana	O
(	O
Pp	O
)	O
L.	O
originated	O
in	O
tropical	O
South	O
America	O
.	O

It	O
has	O
become	O
naturalized	O
and	O
is	O
found	O
readily	O
on	O
the	O
Island	O
of	O
Hawai	O
'	O
i	O
.	O

The	O
edible	O
fruits	O
are	O
commonly	O
known	O
as	O
cape	O
gooseberry	O
or	O
poha	O
in	O
Hawai	O
'	O
i	O
.	O

In	O
part	O
of	O
our	O
study	O
,	O
three	O
new	O
withanolides	O
,	O
physaperuvin	O
G	O
(	O
1	O
)	O
,	O
physaperuvins	O
I-J	O
(	O
2-3	O
)	O
,	O
along	O
with	O
four	O
known	O
withanolides	O
,	O
namely	O
,	O
4β-hydroxywithanolide	O
E	O
(	O
4	O
)	O
,	O
withaperuvin	O
C	O
(	O
5	O
)	O
,	O
and	O
physalactone	O
(	O
6	O
)	O
,	O
coagulin	O
(	O
7	O
)	O
were	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
P.	O
peruviana	O
.	O

In	O
addition	O
,	O
two	O
known	O
compounds	O
,	O
phyperunolide	O
F	O
(	O
8	O
)	O
,	O
and	O
withanolide	O
S	O
(	O
9	O
)	O
,	O
were	O
isolated	O
and	O
identified	O
from	O
the	O
poha	O
berry	O
fruits	O
.	O

The	O
structures	O
and	O
absolute	O
stereochemistry	O
of	O
new	O
compounds	O
from	O
poha	O
were	O
elucidated	O
by	O
several	O
spectroscopy	O
methods	O
:	O
Nuclear	B-P
Magnetic	I-P
Resonance	I-P
(	I-P
NMR	I-P
)	I-P
spectroscopy	I-P
,	O
X-ray	B-P
diffraction	I-P
,	O
and	O
mass	B-P
spectrometry	I-P
analyses	O
.	O

All	O
isolated	O
poha	O
compounds	O
(	O
aerial	O
parts	O
and	O
fruits	O
)	O
were	O
evaluated	O
for	O
their	O
anti-inflammatory	O
activity	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-activated	O
murine	O
macrophage	O
RAW	O
264.7	O
cells	O
,	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-α	O
)	O
-activated	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-κB	O
)	O
with	O
transfected	O
human	O
embryonic	O
kidney	O
cells	O
293	O
.	O

Most	O
of	O
the	O
isolated	O
natural	O
compounds	O
showed	O
activity	O
with	O
these	O
assays	B-P
.	O

Additional	O
studies	O
were	O
performed	O
with	O
models	O
of	O
colon	O
cancer	O
.	O

Specifically	O
,	O
4β-hydroxywithanolide	O
E	O
(	O
4HWE	O
)	O
inhibited	O
the	O
growth	O
of	O
colon	O
cancer	O
monolayer	B-P
and	O
spheroid	O
cultures	B-P
.	O

The	O
compound	O
induced	O
cell	O
cycle	O
arrest	O
at	O
low	O
concentrations	O
and	O
apoptosis	O
at	O
higher	O
concentrations	O
.	O

These	O
data	O
suggest	O
the	O
ingestion	O
of	O
poha	O
berries	O
may	O
have	O
some	O
effect	O
on	O
the	O
prevalence	O
of	O
colon	O
cancer	O
.	O

Additionally	O
,	O
poha	O
isolates	O
compounds	O
were	O
evaluated	O
for	O
their	O
growth	O
inhibitory	O
effects	O
with	O
U251MG	O
glioblastoma	O
and	O
MDA-MB-231	O
breast	O
cancer	O
cells	O
that	O
harbor	O
aberrantly-active	O
signal	O
transducer	O
and	O
activation	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
,	O
compared	O
to	O
normal	O
NIH-3T3	O
mouse	O
fibroblasts	O
.	O

This	O
work	O
has	O
led	O
to	O
the	O
filing	O
of	O
three	O
provisional	O
patents	O
with	O
the	O
University	O
of	O
Hawai	O
'	O
i	O
Office	O
of	O
Technology	O
Transfer	O
and	O
Economic	O
Development	O
.	O

An	O
efficient	O
approach	O
to	O
identify	O
different	O
chemical	O
markers	O
between	O
fibrous	O
root	O
and	O
rhizome	O
of	O
Anemarrhena	O
asphodeloides	O
by	O
ultra	B-P
high-performance	I-P
liquid	I-P
chromatography	I-P
quadrupole	I-P
time-of-flight	I-P
tandem	I-P
mass	I-P
spectrometry	I-P
with	O
multivariate	O
statistical	O
analysis	O
.	O

An	O
ultra	B-P
high-performance	I-P
liquid	I-P
chromatography	I-P
quadrupole	I-P
time-of-flight	I-P
tandem	I-P
mass	I-P
spectrometry	I-P
approach	O
coupled	O
with	O
multivariate	O
statistical	O
analysis	O
was	O
established	O
and	O
applied	O
to	O
rapidly	O
distinguish	O
the	O
chemical	O
differences	O
between	O
fibrous	O
root	O
and	O
rhizome	O
of	O
Anemarrhena	O
asphodeloides	O
.	O

The	O
datasets	O
of	O
tR-m/z	O
pairs	O
,	O
ion	O
intensity	O
and	O
sample	O
code	O
were	O
processed	O
by	O
principal	O
component	O
analysis	O
and	O
orthogonal	O
partial	O
least	O
squares	O
discriminant	O
analysis	O
.	O

Chemical	O
markers	O
could	O
be	O
identified	O
based	O
on	O
their	O
exact	O
mass	O
data	O
,	O
fragmentation	O
characteristics	O
,	O
and	O
retention	O
times	O
.	O

And	O
the	O
new	O
compounds	O
among	O
chemical	O
markers	O
could	O
be	O
isolated	O
rapidly	O
guided	O
by	O
the	O
ultra	B-P
high-performance	I-P
liquid	I-P
chromatography	I-P
quadrupole	I-P
time-of-flight	I-P
tandem	I-P
mass	I-P
spectrometry	I-P
and	O
their	O
definitive	O
structures	O
would	O
be	O
further	O
elucidated	O
by	O
NMR	B-P
spectra	I-P
.	O

Using	O
this	O
approach	O
,	O
twenty-four	O
markers	O
were	O
identified	O
on	O
line	O
including	O
nine	O
new	O
saponins	O
and	O
five	O
new	O
steroidal	O
saponins	O
of	O
them	O
were	O
obtained	O
in	O
pure	O
form	O
.	O

The	O
study	O
validated	O
this	O
proposed	O
approach	O
as	O
a	O
suitable	O
method	B-P
for	O
identification	O
of	O
the	O
chemical	O
differences	O
between	O
various	O
medicinal	O
parts	O
in	O
order	O
to	O
expand	O
medicinal	O
parts	O
and	O
increase	O
the	O
utilization	O
rate	O
of	O
resources	O
.	O

Liver	O
Fatty	O
Acid	O
Binding	O
Protein	O
Deficiency	O
Provokes	O
Oxidative	O
Stress	O
,	O
Inflammation	O
,	O
and	O
Apoptosis	O
-Mediated	O
Hepatotoxicity	O
Induced	O
by	O
Pyrazinamide	O
in	O
Zebrafish	O
Larvae	O
.	O

Pyrazinamide	O
(	O
PZA	O
)	O
is	O
an	O
essential	O
antitubercular	O
drug	O
,	O
but	O
little	O
is	O
still	O
known	O
about	O
its	O
hepatotoxicity	O
potential	O
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
PZA	O
exposure	O
on	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
larvae	O
and	O
the	O
mechanisms	O
underlying	O
its	O
hepatotoxicity	O
.	O

A	O
transgenic	O
line	O
of	O
zebrafish	O
larvae	O
that	O
expressed	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
in	O
the	O
liver	O
was	O
incubated	B-P
with	O
1	O
,	O
2.5	O
,	O
and	O
5	O
mM	O
PZA	O
from	O
72	O
h	O
postfertilization	O
(	O
hpf	O
)	O
.	O

Different	O
endpoints	O
such	O
as	O
mortality	O
,	O
morphology	O
changes	O
in	O
the	O
size	O
and	O
shape	O
of	O
the	O
liver	O
,	O
histological	O
changes	O
,	O
transaminase	B-P
analysis	I-P
and	O
apoptosis	O
,	O
markers	O
of	O
oxidative	O
and	O
genetic	O
damage	O
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
certain	O
genes	O
were	O
selected	O
to	O
evaluate	O
PZA	O
-	O
induced	O
hepatotoxicity	O
.	O

Our	O
results	O
confirm	O
the	O
manner	O
of	O
PZA	O
dose-dependent	O
hepatotoxicity	O
.	O

PZA	O
was	O
found	O
to	O
induce	O
marked	O
injury	O
in	O
zebrafish	O
larvae	O
,	O
such	O
as	O
liver	O
atrophy	O
,	O
elevations	O
of	O
transaminase	O
levels	O
,	O
oxidative	O
stress	O
,	O
and	O
hepatocyte	O
apoptosis	O
.	O

To	O
further	O
understand	O
the	O
mechanism	O
behind	O
PZA	O
-	O
induced	O
hepatotoxicity	O
,	O
changes	O
in	O
gene	O
expression	O
levels	O
in	O
zebrafish	O
larvae	O
exposed	O
to	O
PZA	O
for	O
72	O
h	O
postexposure	O
(	O
hpe	O
)	O
were	O
determined	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrated	O
that	O
PZA	O
decreased	O
the	O
expression	O
levels	O
of	O
liver	O
fatty	O
acid	O
binding	O
protein	O
(	O
L-FABP	O
)	O
and	O
its	O
target	O
gene	O
,	O
peroxisome	O
proliferator-activated	O
receptor	O
α	O
(	O
PPAR-α	O
)	O
,	O
and	O
provoked	O
more	O
severe	O
oxidative	O
stress	O
and	O
hepatitis	O
via	O
the	O
upregulation	O
of	O
inflammatory	O
cytokines	O
such	O
as	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-α	O
)	O
and	O
transforming	O
growth	O
factor	O
β	O
(	O
TGF-β	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
L-FABP	O
-mediated	O
PPAR-α	O
downregulation	O
appears	O
to	O
be	O
a	O
hepatotoxic	O
response	O
resulting	O
from	O
zebrafish	O
larva	O
liver	O
cell	O
apoptosis	O
,	O
and	O
L-FABP	O
can	O
be	O
used	O
as	O
a	O
biomarker	O
for	O
the	O
early	B-P
detection	I-P
of	O
PZA	O
-	O
induced	O
liver	O
damage	O
in	O
zebrafish	O
larvae	O
.	O

Molecular	O
Viability	O
Testing	O
of	O
UV	O
-	O
Inactivated	O
Bacteria	O
.	O

The	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
is	O
effective	O
at	O
detecting	O
bacterial	O
DNA	O
in	O
samples	O
,	O
but	O
it	O
is	O
unable	O
to	O
differentiate	O
viable	O
bacteria	O
from	O
inactivated	O
cells	O
or	O
free	O
DNA	O
fragments	O
.	O

New	O
PCR	O
-based	O
analytical	O
strategies	O
have	O
been	O
developed	O
to	O
address	O
this	O
limitation	O
.	O

Molecular	O
viability	O
testing	O
(	O
MVT	O
)	O
correlates	O
bacterial	O
viability	O
with	O
the	O
ability	O
to	O
rapidly	O
synthesize	O
species	O
-specific	O
ribosomal	O
RNA	O
precursor	O
(	O
pre-rRNA	O
)	O
in	O
response	O
to	O
brief	O
nutritional	O
stimulation	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
MVT	O
can	O
assess	O
bacterial	B-P
inactivation	I-P
by	O
chlorine	O
,	O
serum	O
,	O
and	O
low-temperature	O
pasteurization	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
MVT	O
can	O
detect	O
inactivation	B-P
of	O
Escherichia	O
coli	O
,	O
Aeromonas	O
hydrophila	O
,	O
and	O
Enterococcus	O
faecalis	O
cells	O
by	O
ultraviolet	O
(	O
UV	O
)	O
irradiation	O
.	O

Some	O
UV	O
-	O
inactivated	O
E.	O
coli	O
cells	O
transiently	O
retained	O
the	O
ability	O
to	O
synthesize	O
pre-rRNA	O
post-irradiation	O
(	O
generating	O
false-positive	O
MVT	O
results	O
)	O
,	O
but	O
this	O
activity	B-P
ceased	O
within	O
one	O
hour	O
following	O
UV	O
exposure	O
.	O

Viable	O
but	O
transiently	O
undetectable	O
(	O
by	O
culture	B-P
)	O
E.	O
coli	O
cells	O
were	O
consistently	O
detected	O
by	O
MVT	O
.	O

An	O
alternative	O
viability	O
testing	O
method	O
,	O
viability	O
PCR	O
(	O
vPCR	O
)	O
,	O
correlates	O
viability	O
with	O
cell	O
envelope	O
integrity	O
.	O

This	O
method	O
did	O
not	O
distinguish	O
viable	O
from	O
UV	O
-	O
inactivated	O
bacteria	O
under	O
some	O
conditions	O
,	O
indicating	O
that	O
the	O
inactivated	O
cells	O
retained	O
intact	O
cell	O
envelopes	O
.	O

MVT	O
holds	O
promise	O
as	O
a	O
means	O
to	O
rapidly	O
assess	O
microbial	B-P
inactivation	I-P
by	O
UV	O
treatment	O
.	O

IMPORTANCE	O
Ultraviolet	O
(	O
UV	O
)	O
irradiation	O
is	O
increasingly	O
used	O
to	O
disinfect	O
water	O
,	O
food	O
,	O
and	O
other	O
materials	O
for	O
human	O
use	O
.	O

Confirming	O
the	O
effectiveness	O
of	O
UV	O
disinfection	O
remains	O
a	O
challenging	O
task	O
.	O

In	O
particular	O
,	O
microbiological	O
methods	O
that	O
rely	O
on	O
rapid	O
detection	O
of	O
microbial	O
DNA	O
can	O
yield	O
misleading	O
results	O
.	O

This	O
is	O
due	O
to	O
the	O
detection	O
of	O
``	O
remnant	O
``	O
DNA	O
associated	O
with	O
dead	O
microbial	O
cells	O
.	O

This	O
report	O
describes	O
a	O
novel	O
method	O
that	O
rapidly	O
distinguishes	O
living	O
from	O
dead	O
microbial	O
cells	O
after	O
UV	O
disinfection	O
.	O

Adjunctive	O
aripiprazole	O
in	O
risperidone	O
-	O
induced	O
hyperprolactinaemia	O
:	O
double-blind	O
,	O
randomised	O
,	O
placebo-controlled	O
trial	O
.	O

Hyperprolactinaemia	O
is	O
a	O
troublesome	O
side-effect	O
of	O
treatment	O
with	O
antipsychotics	O
.	O

This	O
double-blind	O
,	O
placebo-controlled	O
study	O
aimed	O
at	O
examining	O
the	O
effect	O
of	O
adjunctive	O
treatment	O
with	O
10	O
mg	O
aripiprazole	O
on	O
prolactin	B-P
levels	I-P
and	O
sexual	O
side-effects	O
in	O
patients	O
with	O
schizophrenia	O
symptomatically	O
maintained	O
on	O
risperidone	O
.	O

Thirty	O
patients	O
taking	O
risperidone	O
were	O
enrolled	O
into	O
the	O
trial	O
(	O
CTRI/2012/11/003114	O
)	O
.	O

Aripiprazole	O
was	O
administered	O
at	O
a	O
fixed	O
daily	O
dose	O
of	O
10	O
mg/day	O
for	O
8	O
weeks	O
.	O

Serum	B-P
prolactin	I-P
was	O
measured	O
at	O
baseline	O
and	O
at	O
8	O
weeks	O
.	O

Hyperprolactinaemia	O
-related	O
problems	O
,	O
psychopathology	O
and	O
side-effects	O
were	O
evaluated	O
every	O
2	O
weeks	O
.	O

Prolactin	O
levels	O
decreased	O
by	O
58	O
%	O
in	O
the	O
aripiprazole	O
group	O
compared	O
with	O
an	O
increase	O
by	O
22	O
%	O
in	O
the	O
placebo	O
group	O
.	O

Prolactin	O
levels	O
normalised	O
in	O
46	O
%	O
of	O
patients	O
in	O
the	O
aripiprazole	O
group	O
(	O
number	O
needed	O
to	O
treat	O
,	O
NNT=2	O
)	O
.	O

Aripiprazole	O
improved	O
erectile	O
dysfunction	O
in	O
five	O
out	O
of	O
six	O
patients	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
change	O
in	O
psychopathology	O
or	O
side-effects	O
between	O
groups	O
.	O

Adjunctive	O
aripiprazole	O
reduced	O
prolactin	B-P
levels	I-P
in	O
those	O
treated	O
with	O
risperidone	O
,	O
with	O
no	O
effect	O
on	O
psychopathology	O
and	O
extrapyramidal	O
symptoms	O
.	O

This	O
is	O
a	O
potential	O
treatment	O
for	O
hyperprolactinaemia	O
observed	O
during	O
treatment	O
with	O
second-generation	O
antipsychotics	O
.	O

None	O
.	O

©	O
The	O
Royal	O
College	O
of	O
Psychiatrists	O
2015	O
.	O

This	O
is	O
an	O
open	O
access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Non-Commercial	O
,	O
No	O
Derivatives	O
(	O
CC	O
BY-NC-ND	O
)	O
licence	O
.	O

Folate	O
and	O
vitamin	O
B12	O
concentrations	O
are	O
associated	O
with	O
plasma	O
DHA	O
and	O
EPA	O
fatty	O
acids	O
in	O
European	O
adolescents	O
:	O
the	O
Healthy	O
Lifestyle	O
in	O
Europe	O
by	O
Nutrition	O
in	O
Adolescence	O
(	O
HELENA	O
)	O
study	O
.	O

This	O
study	O
aimed	O
to	O
examine	O
the	O
association	O
between	O
vitamin	O
B6	O
,	O
folate	O
and	O
vitamin	O
B12	O
biomarkers	O
and	O
plasma	O
fatty	O
acids	O
in	O
European	O
adolescents	O
.	O

A	O
subsample	O
from	O
the	O
Healthy	O
Lifestyle	O
in	O
Europe	O
by	O
Nutrition	O
in	O
Adolescence	O
study	O
with	O
valid	O
data	O
on	O
B-vitamins	O
and	O
fatty	O
acid	O
blood	O
parameters	O
,	O
and	O
all	O
the	O
other	O
covariates	O
used	O
in	O
the	O
analyses	O
such	O
as	O
BMI	O
,	O
Diet	O
Quality	O
Index	O
,	O
education	O
of	O
the	O
mother	O
and	O
physical	O
activity	O
assessed	O
by	O
a	O
questionnaire	O
,	O
was	O
selected	O
resulting	O
in	O
674	O
cases	O
(	O
43	O
%	O
males	O
)	O
.	O

B-vitamin	O
biomarkers	O
were	O
measured	O
by	O
chromatography	B-P
and	O
immunoassay	B-P
and	O
fatty	O
acids	O
by	O
enzymatic	B-P
analyses	O
.	O

Linear	O
mixed	O
models	O
elucidated	O
the	O
association	O
between	O
B-vitamins	O
and	O
fatty	O
acid	O
blood	O
parameters	O
(	O
changes	O
in	O
fatty	O
acid	O
profiles	B-P
according	O
to	O
change	O
in	O
10	O
units	O
of	O
vitamin	O
B	O
biomarkers	O
)	O
.	O

DHA	O
,	O
EPA	O
)	O
and	O
n-3	O
fatty	O
acids	O
showed	O
positive	O
associations	O
with	O
B-vitamin	O
biomarkers	O
,	O
mainly	O
with	O
those	O
corresponding	O
to	O
folate	O
and	O
vitamin	O
B12	O
.	O

Contrarily	O
,	O
negative	O
associations	O
were	O
found	O
with	O
n-6	O
:	O
n-3	O
ratio	O
,	O
trans-fatty	O
acids	O
and	O
oleic	O
:	O
stearic	O
ratio	O
.	O

With	O
total	O
homocysteine	O
(	O
tHcy	O
)	O
,	O
all	O
the	O
associations	O
found	O
with	O
these	O
parameters	O
were	O
opposite	O
(	O
for	O
instance	O
,	O
an	O
increase	O
of	O
10	O
nmol/l	O
in	O
red	O
blood	O
cell	O
folate	O
or	O
holotranscobalamin	O
in	O
females	O
produces	O
an	O
increase	O
of	O
15·85	O
µmol/l	O
of	O
EPA	O
(	O
P	O
value	O
<	O
0·01	O
)	O
,	O
whereas	O
an	O
increase	O
of	O
10	O
nmol/l	O
of	O
tHcy	O
in	O
males	O
produces	O
a	O
decrease	O
of	O
2·06	O
µmol/l	O
of	O
DHA	O
(	O
P	O
value	O
<	O
0·05	O
)	O
.	O

Positive	O
associations	O
between	O
B-vitamins	O
and	O
specific	O
fatty	O
acids	O
might	O
suggest	O
underlying	O
mechanisms	O
between	O
B-vitamins	O
and	O
CVD	O
and	O
it	O
is	O
worth	O
the	O
attention	O
of	O
public	O
health	O
policies	O
.	O

Assessment	O
of	O
Residual	O
Disease	O
With	O
Molecular	B-P
Breast	I-P
Imaging	I-P
in	O
Patients	O
Undergoing	O
Neoadjuvant	O
Therapy	O
:	O
Association	O
With	O
Molecular	O
Subtypes	O
.	O

Assessment	O
of	O
residual	O
disease	O
after	O
neoadjuvant	O
therapy	O
for	O
breast	O
cancer	O
is	O
an	O
ongoing	O
challenge	O
of	O
breast	O
imaging	B-P
.	O

This	O
study	O
evaluates	O
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	B-P
breast	I-P
imaging	I-P
(	O
MBI	B-P
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	O
zinc	O
telluride	O
detectors	O
in	O
assessing	O
residual	O
disease	O
after	O
neoadjuvant	O
therapy	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

Clinical	O
data	O
,	O
imaging	B-P
,	O
surgical	O
,	O
and	O
pathological	O
findings	O
of	O
51	O
women	O
with	O
breast	O
cancer	O
undergoing	O
neoadjuvant	O
therapy	O
were	O
recorded	O
.	O

MBI	B-P
findings	O
were	O
correlated	O
with	O
surgical	O
pathology	O
results	O
.	O

Accuracy	O
of	O
MBI	B-P
in	O
predicting	O
complete	O
pathological	O
response	O
and	O
size	O
of	O
residual	O
disease	O
was	O
assessed	O
according	O
to	O
molecular	O
subtypes	O
.	O

The	O
size	O
of	O
the	O
largest	O
focus	O
of	O
uptake	O
on	O
MBI	B-P
correlated	O
with	O
the	O
largest	O
dimension	O
measured	O
on	O
pathology	O
(	O
r	O
=	O
0.55	O
;	O
P	O
<	O
.001	O
)	O
.	O

This	O
correlation	O
was	O
stronger	O
for	O
triple	O
negative	O
and	O
HER2/neu	O
positive	O
subtypes	O
(	O
r	O
=	O
0.92	O
and	O
0.62	O
,	O
respectively	O
)	O
.	O

Sixteen	O
patients	O
(	O
31	O
%	O
)	O
had	O
complete	O
pathological	O
response	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
MBI	B-P
for	O
detecting	O
residual	O
disease	O
were	O
83	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
66-93	O
)	O
and	O
69	O
%	O
(	O
95	O
%	O
CI	O
,	O
42-88	O
)	O
,	O
respectively	O
.	O

For	O
triple	O
negative	O
or	O
HER2/neu	O
positive	O
disease	O
the	O
sensitivity	O
and	O
specificity	O
were	O
88	O
%	O
(	O
95	O
%	O
CI	O
,	O
62-98	O
)	O
and	O
75	O
%	O
(	O
95	O
%	O
CI	O
,	O
43-93	O
)	O
,	O
respectively	O
.	O

The	O
accuracy	O
of	O
MBI	B-P
in	O
assessing	O
residual	O
disease	O
after	O
neoadjuvant	O
treatment	O
might	O
be	O
related	O
to	O
the	O
molecular	O
subtype	O
.	O

Accuracy	O
is	O
highest	O
in	O
the	O
triple	O
negative	O
and	O
HER2/neu	O
positive	O
subtypes	O
.	O

HIF-1α	O
expression	O
and	O
high	O
microvessel	O
density	O
are	O
characteristic	O
features	O
in	O
serrated	O
colorectal	O
cancer	O
.	O

Serrated	O
colorectal	O
adenocarcinoma	O
(	O
SAC	O
)	O
is	O
a	O
morphologically	O
distinct	O
subtype	O
of	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
,	O
in	O
which	O
increased	O
HIF-1α	O
mRNA	O
expression	O
and	O
HIF-1α	O
protein	O
stabilization	O
are	O
typical	O
features	O
.	O

Here	O
we	O
aimed	O
to	O
further	O
elucidate	O
HIF-1α	O
protein	O
expression	O
in	O
serrated	O
and	O
non-serrated	O
colorectal	O
carcinomas	O
(	O
CRCs	O
)	O
and	O
their	O
precursor	O
lesions	O
and	O
its	O
association	O
with	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
microvascular	O
density	O
(	O
MVD	O
)	O
.	O

HIF-1α	O
and	O
VEGF	O
expressions	O
were	O
determined	O
immunohistochemically	B-P
in	O
134	O
serrated	O
polyps	O
(	O
SPs	O
)	O
,	O
104	O
non-serrated	O
adenomas	O
(	O
NSAs	O
)	O
,	O
81	O
SACs	O
,	O
and	O
74	O
matched	O
conventional	O
adenocarcinomas	O
(	O
CCs	O
)	O
and	O
were	O
correlated	O
with	O
morphology	O
,	O
clinicopathological	O
features	O
,	O
and	O
MVD	O
.	O

In	O
premalignant	O
lesions	O
,	O
both	O
HIF-1α	O
and	O
VEGF	O
were	O
expressed	O
in	O
the	O
vast	O
majority	O
of	O
SPs	O
and	O
NSAs	O
.	O

In	O
CRCs	O
,	O
HIF-1α	O
protein	O
was	O
also	O
present	O
in	O
77.8	O
%	O
of	O
SACs	O
,	O
while	O
only	O
20.3	O
%	O
of	O
CCs	O
were	O
HIF-1α	O
proficient	O
.	O

MVD	O
was	O
significantly	O
higher	O
in	O
SACs	O
,	O
but	O
the	O
serrated	O
morphology	O
was	O
the	O
only	O
significant	O
predictor	O
of	O
MVD	O
in	O
CRC	O
in	O
multivariate	O
analyses	O
.	O

HIF-1α	O
protein	O
is	O
often	O
stabilized	O
in	O
well-vascularized	O
SACs	O
,	O
suggesting	O
hypoxia	O
-	O
independent	O
stabilization	O
of	O
HIF-1α	O
.	O

Moreover	O
,	O
HIF-1α	O
stabilization	O
did	O
not	O
associate	O
with	O
oncogenic	O
activation	O
of	O
BRAF	O
or	O
KRAS	O
or	O
Von	O
Hippel-Lindau	O
(	O
VHL	O
)	O
mutation	O
.	O

Prevalent	O
HIF-1α	O
expression	O
in	O
SAC	O
and	O
its	O
precursors	O
support	O
the	O
importance	O
of	O
HIF-1α	O
-mediated	O
pathways	O
for	O
the	O
serrated	O
route	O
of	O
colorectal	O
carcinogenesis	O
.	O

Phenol	O
red	O
-	O
silk	O
tyrosine	O
cross-linked	O
hydrogels	O
.	O

Phenol	O
red	O
is	O
a	O
cytocompatible	O
pH	O
sensing	O
dye	O
that	O
is	O
commonly	O
added	O
to	O
cell	O
culture	O
media	O
,	O
but	O
removed	O
from	O
some	O
media	O
formulations	O
due	O
to	O
its	O
structural	O
mimicry	O
of	O
estrogen	O
.	O

Phenol	O
red	O
free	O
media	O
is	O
also	O
used	O
during	O
live	B-P
cell	I-P
imaging	I-P
,	O
to	O
avoid	O
absorbance	O
and	O
fluorescence	O
quenching	O
of	O
fluorophores	O
.	O

To	O
overcome	O
these	O
complications	O
,	O
we	O
developed	O
cytocompatible	O
and	O
degradable	O
phenol	O
red	O
-	O
silk	O
tyrosine	O
cross-linked	O
hydrogels	O
using	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
enzyme	O
and	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

Phenol	O
red	O
added	O
to	O
silk	O
during	O
tyrosine	O
crosslinking	O
accelerated	O
di-tyrosine	O
formation	O
in	O
a	O
concentration	O
-	O
dependent	O
reaction	O
.	O

Phenol	O
red	O
diffusion	O
studies	O
and	O
UV-Vis	B-P
spectra	I-P
of	O
phenol	O
red	O
-	O
silk	O
tyrosine	O
hydrogels	O
at	O
different	O
pHs	O
showed	O
altered	O
absorption	O
bands	O
,	O
confirming	O
entrapment	O
of	O
dye	O
within	O
the	O
hydrogel	O
network	O
.	O

LC-MS	B-P
of	O
HRP	O
-reacted	O
phenol	O
red	O
and	O
N-acetyl-l-tyrosine	O
reaction	O
products	O
confirmed	O
covalent	O
bonds	O
between	O
the	O
phenolic	O
hydroxyl	O
group	O
of	O
phenol	O
red	O
and	O
tyrosine	O
on	O
the	O
silk	O
.	O

At	O
lower	O
phenol	O
red	O
concentrations	O
,	O
leak-proof	O
hydrogels	O
which	O
did	O
not	O
release	O
phenol	O
red	O
were	O
fabricated	O
and	O
found	O
to	O
be	O
cytocompatible	O
based	O
on	O
live-dead	B-P
staining	I-P
and	O
alamar	O
blue	O
assessments	O
of	O
encapsulated	O
fibroblasts	O
.	O

Due	O
to	O
the	O
spectral	O
overlap	O
between	O
phenol	O
red	O
absorbance	O
at	O
415	O
nm	O
and	O
di-tyrosine	O
fluorescence	O
at	O
417	O
nm	O
,	O
phenol	O
red	O
-	O
silk	O
hydrogels	O
provide	O
both	O
absorbance	O
and	O
fluorescence	O
-based	O
pH	O
sensing	O
.	O

With	O
an	O
average	O
pKa	O
of	O
6.8	O
and	O
good	O
cytocompatibiltiy	O
,	O
phenol	O
red	O
-	O
silk	O
hydrogels	O
are	O
useful	O
for	O
pH	O
sensing	O
in	O
phenol	O
red	O
free	O
systems	O
,	O
cellular	O
microenvironments	O
and	O
bioreactors	O
.	O

Phenol	O
red	O
entrapped	O
within	O
hydrogels	O
facilitates	O
pH	O
sensing	O
in	O
phenol	O
red	O
free	O
environments	O
.	O

Leak-proof	O
phenol	O
red	O
based	O
pH	O
sensors	O
require	O
covalent	O
binding	O
techniques	O
,	O
but	O
are	O
complicated	O
due	O
to	O
the	O
lack	O
of	O
amino	O
or	O
carboxyl	O
groups	O
on	O
phenol	O
red	O
.	O

Currently	O
,	O
there	O
is	O
no	O
simple	O
,	O
reliable	O
technique	O
to	O
covalently	O
link	O
phenol	O
red	O
to	O
hydrogel	O
matrices	O
,	O
for	O
real-time	O
pH	O
sensing	O
in	O
cell	B-P
culture	I-P
environments	O
.	O

Herein	O
,	O
we	O
take	O
advantage	O
of	O
phenolic	O
groups	O
for	O
covalent	O
linkage	O
of	O
phenol	O
red	O
to	O
silk	O
tyrosine	O
in	O
the	O
presence	O
of	O
HRP	O
and	O
H2O2	O
.	O

The	O
novelty	O
of	O
the	O
current	O
system	O
stems	O
from	O
its	O
simplicity	O
and	O
the	O
use	O
of	O
silk	O
protein	O
to	O
create	O
a	O
cytocompatible	O
,	O
degradable	O
sensor	O
capable	O
of	O
real-time	O
pH	O
sensing	O
in	O
cell	O
culture	O
microenvironments	O
.	O

Is	O
focused	O
parathyroidectomy	O
appropriate	O
for	O
patients	O
with	O
primary	O
hyperparathyroidism	O
?	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
focused	O
or	O
complete	O
parathyroidectomy	O
was	O
more	O
appropriate	O
and	O
to	O
compare	O
follow-up	O
data	O
in	O
primary	O
hyperparathyroidism	O
(	O
PHPT	O
)	O
.	O

We	O
retrospectively	O
analyzed	O
225	O
operations	O
for	O
PHPT	O
at	O
Yonsei	O
University	O
Health	O
System	O
between	O
2000	O
and	O
2012	O
.	O

After	O
excluding	O
93	O
patients	O
,	O
the	O
remaining	O
132	O
were	O
divided	O
into	O
2	O
groups	O
:	O
those	O
who	O
underwent	O
focused	O
parathyroidectomy	O
(	O
FP	O
)	O
and	O
those	O
who	O
underwent	O
conventional	O
parathyroidectomy	O
(	O
CP	O
)	O
.	O

We	O
compared	O
clinicopathological	O
features	O
;	O
preoperative	O
calcium	B-P
,	O
parathyroid	B-P
hormone	I-P
(	O
PTH	B-P
)	O
,	O
phosphorus	B-P
,	O
vitamin	B-P
D	I-P
,	O
24-hour	B-P
urine	I-P
calcium	I-P
,	O
and	O
alkaline	O
phosphatase	O
levels	O
;	O
postoperative	O
calcium	B-P
and	O
PTH	B-P
levels	I-P
;	O
pathologic	O
diagnosis	O
;	O
multiplicity	O
;	O
and	O
results	O
of	O
a	O
localization	O
study	O
between	O
the	O
2	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
rates	O
of	O
development	O
of	O
postoperative	O
persistent	O
hyperparathyroidism	O
(	O
1/122	O
FP	O
patients	O
and	O
1/10	O
CP	O
patients	O
)	O
between	O
the	O
2	O
groups	O
due	O
to	O
a	O
technical	O
reason	O
(	O
FP	O
0.8	O
%	O
vs.	O
CP	O
10.0	O
%	O
,	O
P	O
=	O
0.146	O
)	O
.	O

Multiglandular	O
disease	O
(	O
MGD	O
)	O
was	O
uncommon	O
in	O
all	O
cases	O
(	O
6	O
of	O
132	O
,	O
4.5	O
%	O
)	O
.	O

All	O
MGD	O
cases	O
were	O
diagnosed	O
using	O
a	O
preoperative	O
localization	O
study	O
.	O

Sestamibi	B-P
scan	I-P
and	O
ultrasonography	B-P
sensitivity	O
were	O
94.2	O
%	O
and	O
90.2	O
%	O
,	O
respectively	O
.	O

We	O
suggest	O
that	O
FP	O
is	O
appropriate	O
in	O
PHPT	O
,	O
except	O
in	O
cases	O
of	O
MGD	O
if	O
detected	O
before	O
the	O
operation	O
using	O
preoperative	O
imaging	B-P
.	O

Knowledge	O
of	O
hereditary	O
PHPT	O
and	O
improved	O
preoperative	O
localization	O
studies	O
,	O
such	O
as	O
high-resolution	B-P
ultrasonography	I-P
,	O
contributed	O
to	O
the	O
decision	O
to	O
perform	O
FP	O
rather	O
than	O
CP	O
in	O
all	O
cases	O
of	O
unilateral	O
results	O
of	O
the	O
localizing	O
study	O
.	O

Neurotrophins	O
and	O
specific	O
receptors	O
in	O
the	O
oviduct	O
tracts	O
of	O
Japanese	O
quail	O
(	O
Coturnix	O
coturnix	O
japonica	O
)	O
.	O

Neurotrophins	O
(	O
NGF	O
,	O
BDNF	O
and	O
NT-3	O
)	O
and	O
their	O
specific	O
receptors	O
(	O
TrkA	O
,	O
TrkB	O
and	O
TrkC	O
)	O
were	O
studied	O
in	O
the	O
oviduct	O
of	O
egg	O
laying	O
quails	O
.	O

Neurotrophins	O
(	O
NTs	O
)	O
are	O
mainly	O
involved	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
neuronal	O
populations	O
in	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
,	O
but	O
also	O
in	O
reproductive	O
system	O
.	O

In	O
this	O
survey	O
,	O
we	O
first	O
studied	O
the	O
morphological	O
organization	O
of	O
the	O
quail	O
oviduct	O
,	O
distinguished	O
in	O
infundibulum	O
,	O
magnum	O
,	O
isthmus	O
,	O
uterus	O
and	O
vagina	O
,	O
and	O
then	O
we	O
analyzed	O
the	O
expression	O
and	O
localization	O
of	O
NTs	O
and	O
Trks	O
receptors	O
in	O
the	O
whole	O
tracts	O
.	O

By	O
western	O
blotting	O
we	O
detected	O
that	O
the	O
investigated	O
NTs	O
and	O
Trks	O
receptors	O
are	O
expressed	O
in	O
all	O
oviductal	O
tracts	O
.	O

By	O
immunohistochemistry	B-P
we	O
were	O
able	O
to	O
define	O
the	O
distribution	O
of	O
NTs	O
and	O
Trks	O
.	O

Specifically	O
,	O
NGF	O
,	O
BDNF	O
and	O
NT3	O
were	O
localized	O
in	O
lining	O
and	O
ductal	O
epithelial	O
cells	O
,	O
and	O
NGF	O
was	O
also	O
detected	O
in	O
secretory	O
cells	O
of	O
tubular	O
glands	O
and	O
in	O
nervous	O
fibers	O
of	O
vessel	O
wall	O
.	O

TrkA	O
and	O
TrkB	O
were	O
present	O
in	O
the	O
lining	O
and	O
ductal	O
epithelium	O
;	O
TrkA	O
and	O
TrkC	O
were	O
present	O
in	O
nervous	O
fibers	O
of	O
vessel	O
wall	O
in	O
all	O
oviductal	O
tracts	O
.	O

Furthermore	O
,	O
we	O
also	O
observed	O
NGF	O
and	O
BDNF	O
co-localized	O
with	O
TrkA	O
and	O
TrkB	O
in	O
cells	O
of	O
the	O
lining	O
and	O
ductal	O
epithelium	O
,	O
suggesting	O
an	O
autocrine	O
mechanism	O
of	O
action	O
.	O

Transcriptomic	O
and	O
Proteomic	B-P
Analysis	I-P
of	O
Oenococcus	O
oeni	O
Adaptation	O
to	O
Wine	O
Stress	O
Conditions	O
.	O

Oenococcus	O
oeni	O
,	O
the	O
main	O
lactic	O
acid	O
bacteria	O
responsible	O
for	O
malolactic	O
fermentation	O
in	O
wine	O
,	O
has	O
to	O
adapt	O
to	O
stressful	O
conditions	O
,	O
such	O
as	O
low	O
pH	O
and	O
high	O
ethanol	O
content	O
.	O

In	O
this	O
study	O
,	O
the	O
changes	O
in	O
the	O
transcriptome	O
and	O
the	O
proteome	O
of	O
O.	O
oeni	O
PSU-1	O
during	O
the	O
adaptation	O
period	O
before	O
MLF	O
start	O
have	O
been	O
studied	O
.	O

DNA	O
microarrays	O
were	O
used	O
for	O
the	O
transcriptomic	O
analysis	O
and	O
two	O
complementary	O
proteomic	B-P
techniques	I-P
,	O
2-D	B-P
DIGE	I-P
and	O
iTRAQ	B-P
labeling	I-P
were	O
used	O
to	O
analyze	O
the	O
proteomic	O
response	O
.	O

One	O
of	O
the	O
most	O
influenced	O
functions	O
in	O
PSU-1	O
due	O
to	O
inoculation	O
into	O
wine-like	O
medium	O
(	O
WLM	O
)	O
was	O
translation	O
,	O
showing	O
the	O
over-expression	O
of	O
certain	O
ribosomal	O
genes	O
and	O
the	O
corresponding	O
proteins	O
.	O

Amino	O
acid	O
metabolism	O
and	O
transport	O
was	O
also	O
altered	O
and	O
several	O
peptidases	O
were	O
up	O
regulated	O
both	O
at	O
gene	O
and	O
protein	O
level	O
.	O

Certain	O
proteins	O
involved	O
in	O
glutamine	O
and	O
glutamate	O
metabolism	O
showed	O
an	O
increased	O
abundance	O
revealing	O
the	O
key	O
role	O
of	O
nitrogen	O
uptake	O
under	O
stressful	O
conditions	O
.	O

A	O
strong	O
transcriptional	O
inhibition	O
of	O
carbohydrate	O
metabolism	O
related	O
genes	O
was	O
observed	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
transcriptional	O
up-regulation	O
of	O
malate	O
transport	O
and	O
citrate	B-P
consumption	I-P
was	O
indicative	O
of	O
the	O
use	O
of	O
L-malate	O
and	O
citrate	O
associated	O
to	O
stress	O
response	O
and	O
as	O
an	O
alternative	O
energy	O
source	O
to	O
sugar	O
metabolism	O
.	O

Regarding	O
the	O
stress	O
mechanisms	O
,	O
our	O
results	O
support	O
the	O
relevance	O
of	O
the	O
thioredoxin	O
and	O
glutathione	O
systems	O
in	O
the	O
adaptation	O
of	O
O.	O
oeni	O
to	O
wine	O
related	O
stress	O
.	O

Genes	O
and	O
proteins	O
related	O
to	O
cell	O
wall	O
showed	O
also	O
significant	O
changes	O
indicating	O
the	O
relevance	O
of	O
the	O
cell	O
envelop	O
as	O
protective	O
barrier	O
to	O
environmental	O
stress	O
.	O

The	O
differences	O
found	O
between	O
transcriptomic	O
and	O
proteomic	O
data	O
suggested	O
the	O
relevance	O
of	O
post-transcriptional	O
mechanisms	O
and	O
the	O
complexity	O
of	O
the	O
stress	O
response	O
in	O
O.	O
oeni	O
adaptation	O
.	O

Further	O
research	O
should	O
deepen	O
into	O
the	O
metabolisms	O
mostly	O
altered	O
due	O
to	O
wine	O
conditions	O
to	O
elucidate	O
the	O
role	O
of	O
each	O
mechanism	O
in	O
the	O
O.	O
oeni	O
ability	O
to	O
develop	O
MLF	O
.	O

Survival	O
of	O
ovarian	O
cancer	O
patients	O
in	O
Denmark	O
:	O
Results	O
from	O
the	O
Danish	O
gynaecological	O
cancer	O
group	O
(	O
DGCG	O
)	O
database	O
,	O
1995-2012	O
.	O

Ovarian	O
cancer	O
has	O
a	O
high	O
mortality	O
rate	O
,	O
especially	O
in	O
Denmark	O
where	O
mortality	O
rates	O
have	O
been	O
reported	O
higher	O
than	O
in	O
adjacent	O
countries	O
with	O
similar	O
demographics	O
.	O

This	O
study	O
therefore	O
examined	O
recent	O
survival	O
and	O
mortality	O
among	O
Danish	O
ovarian	O
cancer	O
patients	O
over	O
an	O
18-year	O
study	O
period	O
.	O

This	O
nationwide	O
registry-based	O
observational	O
study	O
used	O
data	O
from	O
the	O
Danish	O
Gynecology	O
Cancer	O
Database	O
,	O
Danish	O
Pathology	O
Registry	O
,	O
and	O
Danish	O
National	O
Patient	O
Registry	O
.	O

All	O
patients	O
with	O
ovarian	O
cancer	O
diagnosed	B-P
between	O
1995	O
and	O
2012	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
data	O
sources	O
were	O
linked	O
via	O
the	O
patients	O
'	O
personal	O
identification	O
number	O
and	O
the	O
analyses	O
included	O
data	O
on	O
cancer	B-P
stage	I-P
,	O
age	O
,	O
survival	O
,	O
surgery	O
status	O
and	O
comorbidity	O
.	O

The	O
computed	O
outcome	O
measures	O
were	O
age-adjusted	O
mortality	O
rates	O
and	O
age-adjusted	O
overall	O
and	O
relative	O
survival	O
rates	O
for	O
one	O
and	O
five	O
years	O
.	O

We	O
identified	O
9972	O
patients	O
diagnosed	O
with	O
ovarian	O
cancer	O
in	O
the	O
period	O
1995-2012	O
.	O

The	O
absolute	O
one-year	O
mortality	O
rate	O
decreased	O
from	O
42.8	O
(	O
CI	O
40.3-45.6	O
)	O
in	O
1995-1999	O
to	O
28.3	O
(	O
CI	O
25.9-30.9	O
)	O
in	O
2010-2012	O
,	O
and	O
the	O
five-year	O
mortality	O
rate	O
decreased	O
from	O
28.2	O
(	O
CI	O
27.0-29.5	O
)	O
in	O
1995-1999	O
to	O
23.9	O
(	O
CI	O
22.9-25.0	O
)	O
in	O
2005-2009	O
.	O

After	O
stratification	O
by	O
age	O
,	O
comorbidity	O
and	O
cancer	B-P
stage	I-P
,	O
the	O
decrease	O
in	O
one-year	O
mortality	O
was	O
most	O
substantial	O
in	O
the	O
65-74	O
year	O
old	O
age	O
group	O
41.1	O
(	O
CI	O
38.8-43.5	O
)	O
to	O
26.5	O
(	O
CI	O
24.4-28.7	O
)	O
and	O
for	O
stage	O
III	O
39.1	O
(	O
CI	O
35.1-43.6	O
)	O
to	O
22.9	O
(	O
CI	O
19.9-26.5	O
)	O
and	O
stage	O
IV	O
91.3	O
(	O
CI	O
80.8-103.2	O
)	O
to	O
41.9	O
(	O
CI	O
35.5-49.5	O
)	O
.	O

For	O
overall	O
survival	O
,	O
we	O
showed	O
an	O
increase	O
in	O
one-year	O
survival	O
from	O
68	O
%	O
(	O
CI	O
66-69	O
%	O
)	O
in	O
1995-1999	O
to	O
76	O
%	O
(	O
CI	O
74-78	O
%	O
)	O
in	O
2010-2012	O
and	O
an	O
increase	O
in	O
five-year	O
survival	O
from	O
33	O
%	O
(	O
CI	O
32-35	O
%	O
)	O
in	O
1995-1999	O
to	O
36	O
%	O
(	O
CI	O
34-38	O
%	O
)	O
in	O
2005-2009	O
.	O

Relative	O
survival	O
showed	O
similar	O
increases	O
through	O
the	O
period	O
.	O

Ovarian	O
cancer	O
survival	O
in	O
Denmark	O
has	O
improved	O
substantially	O
from	O
1995	O
to	O
2012	O
,	O
bringing	O
Denmark	O
closer	O
to	O
the	O
standards	O
set	O
by	O
adjacent	O
countries	O
.	O

Validity	O
and	O
reliability	O
of	O
fluoroscopy	B-P
for	O
digital	B-P
radiography	I-P
:	O
a	O
new	O
way	O
to	O
evaluate	O
diaphragmatic	O
mobility	O
.	O

Fluoroscopy	B-P
is	O
considered	O
the	O
most	O
accurate	O
method	O
to	O
evaluate	O
the	O
diaphragm	O
,	O
yet	O
most	O
existing	O
methods	O
for	O
measuring	O
diaphragmatic	O
mobility	O
using	O
fluoroscopy	B-P
are	O
complex	O
.	O

To	O
assess	O
the	O
validity	O
and	O
reliability	O
of	O
a	O
new	O
evaluation	O
method	O
of	O
diaphragmatic	O
motion	O
using	O
fluoroscopy	B-P
by	O
digital	B-P
radiography	I-P
of	O
healthy	O
adults	O
.	O

Twenty-six	O
adults	O
were	O
evaluated	O
,	O
according	O
to	O
the	O
parameters	O
:	O
anthropometry	O
and	O
pulmonary	B-P
function	I-P
test	I-P
.	O

The	O
evaluation	O
of	O
diaphragm	O
mobility	O
by	O
means	O
of	O
fluoroscopy	B-P
by	O
digital	B-P
radiography	I-P
method	O
was	O
randomly	O
conducted	O
by	O
two	O
raters	O
(	O
A	O
and	O
B	O
)	O
.	O

The	O
Pearson	O
correlation	O
coefficient	O
and	O
the	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
were	O
used	O
to	O
assess	O
the	O
concurrent	O
validity	O
.	O

The	O
inter-rater	O
and	O
intra-rater	O
reliability	O
of	O
the	O
measurement	O
of	O
diaphragmatic	O
motion	O
was	O
determined	O
using	O
ICC	O
and	O
a	O
confidence	O
interval	O
of	O
95	O
%	O
.	O

There	O
was	O
a	O
relationship	O
in	O
the	O
assessment	O
of	O
the	O
concurrent	O
validity	O
.	O

There	O
was	O
good	O
inter-rater	O
reliability	O
for	O
right	O
hemidiaphragm	O
mobility	O
and	O
moderate	O
reliability	O
for	O
left	O
hemidiaphragm	O
in	O
the	O
first	O
assessment	O
.	O

In	O
the	O
second	O
assessment	O
,	O
there	O
was	O
good	O
reliability	O
for	O
the	O
mobility	O
of	O
both	O
hemidiaphragms	O
.	O

There	O
was	O
good	O
intra-rater	O
reliability	O
in	O
the	O
mobility	O
of	O
both	O
hemidiaphragms	O
for	O
raters	O
A	O
and	O
B	O
.	O

The	O
evaluation	O
of	O
diaphragmatic	O
motion	O
using	O
fluoroscopy	B-P
by	O
digital	B-P
radiography	I-P
proved	O
to	O
be	O
a	O
valid	O
and	O
reliable	O
method	O
of	O
healthy	O
adults	O
.	O

Systems	B-P
Based	I-P
Study	I-P
of	O
the	O
Therapeutic	O
Potential	O
of	O
Small	O
Charged	O
Molecules	O
for	O
the	O
Inhibition	O
of	O
IL-1	O
Mediated	O
Cartilage	O
Degradation	O
.	O

Inflammatory	O
cytokines	O
are	O
key	O
drivers	O
of	O
cartilage	O
degradation	O
in	O
post-traumatic	O
osteoarthritis	O
.	O

Cartilage	O
degradation	O
mediated	O
by	O
these	O
inflammatory	O
cytokines	O
has	O
been	O
extensively	O
investigated	O
using	O
in	O
vitro	O
experimental	O
systems	O
.	O

Based	O
on	O
one	O
such	O
study	O
,	O
we	O
have	O
developed	O
a	O
computational	O
model	O
to	O
quantitatively	O
assess	O
the	O
impact	O
of	O
charged	O
small	O
molecules	O
intended	O
to	O
inhibit	O
IL-1	O
mediated	O
cartilage	O
degradation	O
.	O

We	O
primarily	O
focus	O
on	O
the	O
simplest	O
possible	O
computational	O
model	O
of	O
small	O
molecular	O
interaction	O
with	O
the	O
IL-1	O
system-direct	O
binding	O
of	O
the	O
small	O
molecule	O
to	O
the	O
active	O
site	O
on	O
the	O
IL-1	O
molecule	O
itself	O
.	O

We	O
first	O
use	O
the	O
model	O
to	O
explore	O
the	O
uptake	O
and	O
release	O
kinetics	O
of	O
the	O
small	O
molecule	O
inhibitor	O
by	O
cartilage	O
tissue	O
.	O

Our	O
results	O
show	O
that	O
negatively	O
charged	O
small	O
molecules	O
are	O
excluded	O
from	O
the	O
negatively	O
charged	O
cartilage	O
tissue	O
and	O
have	O
uptake	O
kinetics	O
in	O
the	O
order	O
of	O
hours	O
.	O

In	O
contrast	O
,	O
the	O
positively	O
charged	O
small	O
molecules	O
are	O
drawn	O
into	O
the	O
cartilage	O
with	O
uptake	O
and	O
release	O
timescales	O
ranging	O
from	O
hours	O
to	O
days	O
.	O

Using	O
our	O
calibrated	O
computational	O
model	O
,	O
we	O
subsequently	O
explore	O
the	O
effect	O
of	O
small	O
molecule	O
charge	O
and	O
binding	O
constant	O
on	O
the	O
rate	O
of	O
cartilage	O
degradation	O
.	O

The	O
results	O
from	O
this	O
analysis	O
indicate	O
that	O
the	O
small	O
molecules	O
are	O
most	O
effective	O
in	O
inhibiting	O
cartilage	O
degradation	O
if	O
they	O
are	O
either	O
positively	O
charged	O
and/or	O
bind	O
strongly	O
to	O
IL-1α	O
,	O
or	O
both	O
.	O

Furthermore	O
,	O
our	O
results	O
showed	O
that	O
the	O
cartilage	O
structural	O
homeostasis	O
can	O
be	O
restored	O
by	O
the	O
small	O
molecule	O
if	O
administered	O
within	O
six	O
days	O
following	O
initial	O
tissue	O
exposure	O
to	O
IL-1α	O
.	O

We	O
finally	O
extended	O
the	O
scope	O
of	O
the	O
computational	O
model	O
by	O
simulating	O
the	O
competitive	O
inhibition	O
of	O
cartilage	O
degradation	O
by	O
the	O
small	O
molecule	O
.	O

Results	O
from	O
this	O
model	O
show	O
that	O
small	O
molecules	O
are	O
more	O
efficient	O
in	O
inhibiting	O
cartilage	O
degradation	O
by	O
binding	O
directly	O
to	O
IL-1α	O
rather	O
than	O
binding	O
to	O
IL-1α	O
receptors	O
.	O

The	O
results	O
from	O
this	O
study	O
can	O
be	O
used	O
as	O
a	O
template	O
for	O
the	O
design	O
and	O
development	O
of	O
more	O
pharmacologically	O
effective	O
osteoarthritis	O
drugs	O
,	O
and	O
to	O
investigate	O
possible	O
therapeutic	O
options	O
.	O

Rate	O
-	O
equation	O
modelling	O
and	O
ensemble	O
approach	O
to	O
extraction	O
of	O
parameters	O
for	O
viral	O
infection	O
-	O
induced	O
cell	O
apoptosis	O
and	O
necrosis	O
.	O

We	O
develop	O
a	O
theoretical	O
approach	O
that	O
uses	O
physiochemical	O
kinetics	O
modelling	O
to	O
describe	O
cell	O
population	O
dynamics	O
upon	O
progression	O
of	O
viral	O
infection	O
in	O
cell	B-P
culture	I-P
,	O
which	O
results	O
in	O
cell	O
apoptosis	O
(	O
programmed	O
cell	O
death	O
)	O
and	O
necrosis	O
(	O
direct	O
cell	O
death	O
)	O
.	O

Several	O
model	O
parameters	O
necessary	O
for	O
computer	O
simulation	O
were	O
determined	O
by	O
reviewing	O
and	O
analyzing	O
available	O
published	O
experimental	O
data	O
.	O

By	O
comparing	O
experimental	O
data	O
to	O
computer	O
modelling	O
results	O
,	O
we	O
identify	O
the	O
parameters	O
that	O
are	O
the	O
most	O
sensitive	O
to	O
the	O
measured	O
system	O
properties	O
and	O
allow	O
for	O
the	O
best	O
data	O
fitting	O
.	O

Our	O
model	O
allows	O
extraction	O
of	O
parameters	O
from	O
experimental	O
data	O
and	O
also	O
has	O
predictive	O
power	O
.	O

Using	O
the	O
model	O
we	O
describe	O
interesting	O
time	O
-	O
dependent	O
quantities	O
that	O
were	O
not	O
directly	O
measured	O
in	O
the	O
experiment	O
and	O
identify	O
correlations	O
among	O
the	O
fitted	O
parameter	O
values	O
.	O

Numerical	O
simulation	O
of	O
viral	O
infection	O
progression	O
is	O
done	O
by	O
a	O
rate	O
-	O
equation	O
approach	O
resulting	O
in	O
a	O
system	O
of	O
``	O
stiff	O
''	O
equations	O
,	O
which	O
are	O
solved	O
by	O
using	O
a	O
novel	O
variant	O
of	O
the	O
stochastic	O
ensemble	O
modelling	O
approach	O
.	O

The	O
latter	O
was	O
originally	O
developed	O
for	O
coupled	O
chemical	O
reactions	O
.	O

Increased	O
RhoA	O
Activity	O
Predicts	O
Worse	O
Overall	O
Survival	O
in	O
Patients	O
Undergoing	O
Surgical	O
Resection	O
for	O
Lauren	O
Diffuse-Type	O
Gastric	O
Adenocarcinoma	O
.	O

Several	O
studies	O
have	O
reported	O
a	O
high	O
rate	O
of	O
RHOA	O
mutations	O
in	O
the	O
Lauren	O
diffuse-type	O
gastric	O
adenocarcinoma	O
(	O
GA	O
)	O
but	O
not	O
in	O
intestinal-type	O
GA	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
RhoA	O
activity	O
is	O
prognostic	O
for	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
patients	O
with	O
resectable	O
GA.	O
Retrospective	O
review	O
was	O
performed	O
on	O
a	O
prospective	O
database	O
of	O
GA	O
patients	O
who	O
underwent	O
potentially	O
curative	O
resection	O
between	O
2003	O
and	O
2012	O
at	O
a	O
single	O
institution	O
.	O

Tissue	O
microarrays	O
were	O
constructed	O
from	O
surgical	B-P
specimens	I-P
and	O
analyzed	O
for	O
phosphorylated	O
RhoA	O
,	O
a	O
marker	O
of	O
inactive	O
RhoA	O
signaling	O
.	O

OS	O
was	O
estimated	O
by	O
the	O
Kaplan-Meier	O
method	O
,	O
and	O
multivariate	O
analysis	O
was	O
performed	O
by	O
Cox	O
proportional	O
hazards	O
regression	O
modeling	O
.	O

One	O
hundred	O
thirty-six	O
patients	O
with	O
diffuse-type	O
GA	O
and	O
129	O
patients	O
with	O
intestinal-type	O
GA	O
were	O
examined	O
.	O

Compared	O
to	O
intestinal-type	O
GA	O
,	O
diffuse-type	O
GA	O
tumors	O
were	O
significantly	O
associated	O
with	O
increased	O
tumor	O
size	O
and	O
advanced	O
tumor	O
,	O
node	O
,	O
metastasis	O
(	O
TNM	O
)	O
classification	O
system	O
stage	O
.	O

In	O
patients	O
with	O
diffuse-type	O
GA	O
,	O
high	O
RhoA	O
activity	O
was	O
associated	O
with	O
significantly	O
worse	O
OS	O
when	O
compared	O
to	O
low	O
RhoA	O
activity	O
(	O
5-year	O
OS	O
52.5	O
vs.	O
81.0	O
%	O
,	O
p	O
=	O
0.017	O
)	O
.	O

This	O
difference	O
in	O
OS	O
was	O
not	O
observed	O
in	O
patients	O
with	O
intestinal-type	O
GA	O
(	O
5-year	O
OS	O
83.9	O
vs.	O
81.6	O
%	O
,	O
p	O
=	O
0.766	O
)	O
.	O

On	O
multivariate	O
analysis	O
of	O
diffuse-type	O
GA	O
patients	O
,	O
high	O
RhoA	O
activity	O
was	O
an	O
independent	O
negative	O
prognostic	O
factor	O
for	O
OS	O
(	O
hazard	O
ratio	O
2.38	O
,	O
95	O
%	O
confidence	O
interval	O
1.07-5.28	O
)	O
.	O

Increased	O
RhoA	O
activity	O
is	O
predictive	O
of	O
worse	O
OS	O
in	O
patients	O
with	O
diffuse-type	O
GA	O
who	O
undergo	O
potentially	O
curative	O
surgical	O
resection	O
.	O

Along	O
with	O
findings	O
from	O
genomic	O
studies	O
,	O
these	O
results	O
suggest	O
RhoA	O
may	O
be	O
a	O
novel	O
therapeutic	O
target	O
in	O
diffuse-type	O
GA	O
.	O

Evaluation	O
of	O
left	O
ventricular	O
diastolic	O
function	O
profile	O
in	O
patients	O
with	O
pulmonary	O
hypertension	O
due	O
to	O
heart	O
failure	O
with	O
preserved	O
ejection	O
fraction	O
.	O

Echocardiography	B-P
plays	O
an	O
important	O
role	O
in	O
the	O
diagnostic	O
work	B-P
up	I-P
of	O
heart	O
failure	O
with	O
preserved	O
ejection	O
fraction	O
(	O
HFpEF	O
)	O
.	O

We	O
sought	O
to	O
determine	O
the	O
left	O
ventricular	O
(	O
LV	O
)	O
diastolic	O
profile	O
by	O
echocardiography	B-P
in	O
patients	O
diagnosed	O
with	O
pulmonary	O
hypertension	O
(	O
PH	O
)	O
due	O
to	O
PH-HFpEF	O
.	O

The	O
study	O
of	O
LV	O
diastolic	O
function	O
by	O
echocardiography	B-P
has	O
limitations	O
in	O
patients	O
with	O
HFpEF	O
and	O
PH	O
,	O
and	O
certain	O
LV	O
diastolic	O
determinations	B-P
convey	O
a	O
worse	O
prognosis	O
.	O

We	O
included	O
patients	O
with	O
postcapillary	O
PH	O
and	O
diagnosis	O
of	O
PH-HFpEF	O
.	O

Investigators	O
reviewed	O
Doppler	B-P
echocardiograms	I-P
completed	O
within	O
3	O
months	O
of	O
the	O
diagnostic	O
right	B-P
heart	I-P
catheterization	I-P
.	O

We	O
included	O
149	O
patients	O
with	O
a	O
mean	O
±	O
standard	O
deviation	O
age	O
of	O
63	O
±	O
14	O
years	O
;	O
58	O
%	O
were	O
women	O
.	O

LV	O
diastolic	O
function	O
profile	O
was	O
determined	O
as	O
normal	O
(	O
41	O
%	O
)	O
,	O
grade	O
I	O
(	O
34	O
%	O
)	O
,	O
and	O
grade	O
II	O
and	O
grade	O
III	O
(	O
25	O
%	O
)	O
.	O

Pulmonary	O
artery	O
pressure	O
and	O
pulmonary	O
vascular	O
resistance	O
were	O
higher	O
and	O
cardiac	O
output	O
lower	O
in	O
patients	O
with	O
LV	O
diastolic	O
dysfunction	O
profile	O
;	O
however	O
,	O
pulmonary	O
artery	O
wedge	O
pressure	O
was	O
not	O
significantly	O
different	O
among	O
grades	O
of	O
LV	O
diastolic	O
function	O
.	O

Although	O
there	O
was	O
an	O
association	O
between	O
the	O
presence	O
of	O
LV	O
diastolic	O
dysfunction	O
profile	O
and	O
long-term	O
survival	O
(	O
P	O
=	O
0.03	O
)	O
,	O
it	O
disappeared	O
when	O
adjusting	O
for	O
age	O
and	O
gender	O
.	O

Right	O
ventricular	O
(	O
RV	O
)	O
dysfunction	O
,	O
paradoxical	O
septal	O
motion	O
,	O
and	O
higher	O
RV	O
systolic	O
pressure	O
remained	O
the	O
only	O
variables	O
significantly	O
associated	O
with	O
poor	O
survival	O
.	O

The	O
profile	O
of	O
LV	O
diastolic	O
dysfunction	O
by	O
conventional	O
echocardiography	B-P
is	O
highly	O
variable	O
in	O
patients	O
with	O
PH-HFpEF	O
and	O
has	O
no	O
significant	O
impact	O
on	O
long-term	O
survival	O
.	O

A	O
more	O
severe	O
RV	O
function	O
and	O
higher	O
right	O
ventricle	O
systolic	O
pressure	O
were	O
associated	O
with	O
worse	O
survival	O
.	O

Improving	O
protein	O
complex	O
prediction	O
by	O
reconstructing	O
a	O
high-confidence	O
protein-protein	O
interaction	O
network	O
of	O
Escherichia	O
coli	O
from	O
different	O
physical	O
interaction	O
data	O
sources	O
.	O

Although	O
different	O
protein-protein	O
physical	O
interaction	O
(	O
PPI	O
)	O
datasets	O
exist	O
for	O
Escherichia	O
coli	O
,	O
no	O
common	O
methodology	O
exists	O
to	O
integrate	O
these	O
datasets	O
and	O
extract	O
reliable	O
modules	O
reflecting	O
the	O
existing	O
biological	O
process	O
and	O
protein	O
complexes	O
.	O

Naïve	O
Bayesian	O
formula	O
is	O
the	O
highly	O
accepted	O
method	O
to	O
integrate	O
different	O
PPI	O
datasets	O
into	O
a	O
single	O
weighted	O
PPI	O
network	O
,	O
but	O
detecting	O
proper	O
weights	O
in	O
such	O
network	O
is	O
still	O
a	O
major	O
problem	O
.	O

In	O
this	O
paper	O
,	O
we	O
proposed	O
a	O
new	O
methodology	O
to	O
integrate	O
various	O
physical	O
PPI	O
datasets	O
into	O
a	O
single	O
weighted	O
PPI	O
network	O
in	O
a	O
way	O
that	O
the	O
detected	O
modules	O
in	O
PPI	O
network	O
exhibit	O
the	O
highest	O
similarity	O
to	O
available	O
functional	O
modules	O
.	O

We	O
used	O
the	O
co-expression	O
modules	O
as	O
functional	O
modules	O
,	O
and	O
we	O
shown	O
that	O
direct	O
functional	O
modules	O
detected	O
from	O
Gene	O
Ontology	O
terms	O
could	O
be	O
used	O
as	O
an	O
alternative	O
dataset	O
.	O

After	O
running	O
this	O
integrating	O
methodology	O
over	O
six	O
different	O
physical	O
PPI	O
datasets	O
,	O
orthologous	O
high-confidence	O
interactions	O
from	O
a	O
related	O
organism	O
and	O
two	O
AP-MS	B-P
PPI	O
datasets	O
gained	O
high	O
weights	O
in	O
the	O
integrated	O
networks	O
,	O
while	O
the	O
weights	O
for	O
one	O
AP-MS	B-P
PPI	O
dataset	O
and	O
two	O
other	O
datasets	O
derived	O
from	O
public	O
databases	O
have	O
converged	O
to	O
zero	O
.	O

The	O
majority	O
of	O
detected	O
modules	O
shaped	O
around	O
one	O
or	O
few	O
hub	O
protein	O
(	O
s	O
)	O
.	O

Still	O
,	O
a	O
large	O
number	O
of	O
highly	O
interacting	O
protein	O
modules	O
were	O
detected	O
which	O
are	O
functionally	O
relevant	O
and	O
are	O
likely	O
to	O
construct	O
protein	O
complexes	O
.	O

We	O
provided	O
a	O
new	O
high	O
confidence	O
protein	O
complex	O
prediction	O
method	O
supported	O
by	O
functional	O
studies	O
and	O
literature	O
mining	O
.	O

Human	O
Immunoglobulin	O
Heavy	O
Gamma	O
Chain	O
Polymorphisms	O
:	O
Molecular	O
Confirmation	O
Of	O
Proteomic	O
Assessment	O
.	O

Immunoglobulin	O
G	O
(	O
IgG	O
)	O
proteins	O
are	O
known	O
for	O
the	O
huge	O
diversity	O
of	O
the	O
variable	O
domains	O
of	O
their	O
heavy	O
and	O
light	O
chains	O
,	O
aimed	O
at	O
protecting	O
each	O
individual	O
against	O
foreign	O
antigens	O
.	O

The	O
IgG	O
also	O
harbor	O
specific	O
polymorphism	O
concentrated	O
in	O
the	O
CH2	O
and	O
CH3-CHS	O
constant	O
regions	O
located	O
on	O
the	O
Fc	O
fragment	O
of	O
their	O
heavy	O
chains	O
.	O

But	O
this	O
individual	O
particularity	O
relies	O
only	O
on	O
a	O
few	O
amino	O
acids	O
among	O
which	O
some	O
could	O
make	O
accurate	O
sequence	O
determination	O
a	O
challenge	O
for	O
mass	B-P
spectrometry	I-P
-	O
based	O
techniques	O
.The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
bring	O
a	O
molecular	O
validation	O
of	O
proteomic	O
results	O
by	O
the	O
sequencing	B-P
of	O
encoding	O
DNA	O
fragments	O
.	O

It	O
was	O
performed	O
using	O
ten	O
individual	O
samples	O
(	O
DNA	O
and	O
sera	O
)	O
selected	O
on	O
the	O
basis	O
of	O
their	O
Gm	O
(	O
gamma	O
marker	O
)	O
allotype	O
polymorphism	O
in	O
order	O
to	O
cover	O
the	O
main	O
immunoglobulin	O
heavy	O
gamma	O
(	O
IGHG	O
)	O
gene	O
diversity	O
.	O

Gm	O
allotypes	O
,	O
reflecting	O
part	O
of	O
this	O
diversity	O
,	O
were	O
determined	O
by	O
a	O
serological	B-P
method	I-P
.	O

On	O
its	O
side	O
,	O
the	O
IGH	O
locus	O
comprises	O
four	O
functional	O
IGHG	O
genes	O
totalizing	O
34	O
alleles	O
and	O
encoding	O
the	O
four	O
IgG	O
subclasses	O
.	O

The	O
genomic	O
study	O
focused	O
on	O
the	O
nucleotide	O
polymorphism	O
of	O
the	O
CH2	O
and	O
CH3-CHS	O
exons	O
and	O
of	O
the	O
intron	O
.	O

Despite	O
strong	O
sequence	O
identity	O
,	O
four	O
pairs	O
of	O
specific	O
gene	O
amplification	O
primers	O
could	O
be	O
designed	O
.	O

Additional	O
primers	O
were	O
identified	O
to	O
perform	O
the	O
subsequent	O
sequencing	B-P
.	O

The	O
nucleotide	O
sequences	O
obtained	O
were	O
first	O
assigned	O
to	O
a	O
specific	O
IGHG	O
gene	O
,	O
and	O
then	O
IGHG	O
alleles	O
were	O
deduced	O
using	O
a	O
home-made	O
decision	O
tree	O
reading	O
of	O
the	O
nucleotide	O
sequences	O
.	O

IGHG	O
amino	O
acid	O
(	O
AA	O
)	O
alleles	O
were	O
determined	O
by	O
mass	B-P
spectrometry	I-P
.	O

Identical	O
results	O
were	O
found	O
at	O
95	O
%	O
between	O
alleles	O
identified	O
by	O
proteomics	B-P
and	O
those	O
deduced	O
from	O
genomics	O
.	O

These	O
results	O
validate	O
the	O
proteomic	O
approach	O
which	O
could	O
be	O
used	O
for	O
diagnostic	O
purposes	O
,	O
namely	O
for	O
a	O
mother-and-child	O
differential	O
IGHG	O
detection	O
in	O
a	O
context	O
of	O
suspicion	O
of	O
congenital	O
infection	O
.	O

Aptamer	O
-based	O
surface-enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
sensor	O
for	O
thrombin	O
based	O
on	O
supramolecular	O
recognition	O
,	O
oriented	O
assembly	O
,	O
and	O
local	O
field	O
coupling	O
.	O

A	O
supramolecular	O
recognition	O
and	O
oriented	O
assembly	O
system	O
was	O
developed	O
on	O
chip	O
for	O
the	O
highly	O
selective	O
surface-enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
detection	O
of	O
thrombin	O
by	O
means	O
of	O
the	O
aptamer	O
-based	O
SERS	O
tag	O
method	O
.	O

A	O
15-base	O
thrombin-binding	O
aptamer	O
(	O
TBA15	O
)	O
with	O
a	O
thiol	O
end	O
was	O
first	O
immobilized	O
on	O
an	O
Ag	O
nanoprism	O
array	O
by	O
the	O
S-Ag	O
bond	O
.	O

This	O
aptamer	O
has	O
high	O
binding	O
affinity	O
with	O
thrombin	O
when	O
it	O
folds	O
into	O
a	O
G-quadruplex	O
structure	O
.	O

After	O
the	O
recognition	O
between	O
the	O
aptamer	O
and	O
thrombin	O
,	O
a	O
bridge	O
is	O
built	O
between	O
the	O
SERS	O
tag	O
(	O
4-mercaptobenzoic	O
acid	O
marked	O
Ag	O
nanoparticle	O
)	O
and	O
the	O
fixed	O
thrombin	O
based	O
on	O
the	O
activation	O
of	O
the	O
carboxylic	O
group	O
of	O
4-mercaptobenzoic	O
acid	O
.	O

Thus	O
,	O
the	O
quantitative	O
detection	O
of	O
thrombin	O
can	O
be	O
achieved	O
based	O
on	O
the	O
SERS	O
intensity	O
of	O
the	O
immobilized	O
SERS	O
tags	O
.	O

The	O
obvious	O
advantages	O
of	O
this	O
sensing	O
method	O
are	O
as	O
follows	O
:	O
(	O
1	O
)	O
remarkable	O
SERS	O
enhancement	O
due	O
to	O
the	O
high	O
electric	O
field	O
coupling	O
effect	O
via	O
the	O
gap	O
structure	O
formation	O
,	O
which	O
improves	O
the	O
sensitivity	O
of	O
the	O
SERS	O
detection	O
and	O
the	O
limit	O
of	O
detection	O
of	O
this	O
method	O
arrives	O
in	O
1.6	O
×	O
10	O
(	O
-11	O
)	O
M	O
,	O
(	O
2	O
)	O
high	O
selectivity	O
based	O
on	O
the	O
specific	O
aptamer	O
recognition	O
toward	O
thrombin	O
,	O
which	O
can	O
be	O
extended	O
to	O
other	O
enzymes	O
easily	O
by	O
changing	O
a	O
proper	O
sequence	O
,	O
(	O
3	O
)	O
high	O
repeatability	O
of	O
SERS	O
signals	O
according	O
to	O
a	O
highly	O
ordered	O
structure	O
,	O
and	O
(	O
4	O
)	O
highly	O
efficient	O
oriented	O
assembly	O
of	O
a	O
sandwich	O
structure	O
over	O
an	O
Ag	O
nanoprism	O
array	O
.	O

The	O
proposed	O
method	O
is	O
expected	O
to	O
be	O
a	O
practical	O
implement	O
in	O
medical	B-P
diagnosis	I-P
.	O

Graphical	O
Abstract	O
Illustration	O
of	O
the	O
aptamer	O
-based	O
SERS	O
sensor	O
for	O
thrombin	O
detection	O
.	O

In	O
Search	O
of	O
the	O
E.	O
coli	O
Compounds	O
that	O
Change	O
the	O
Antibiotic	O
Production	O
Pattern	O
of	O
Streptomyces	O
coelicolor	O
During	O
Inter-species	O
Interaction	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
interaction	O
between	O
E.coli	O
and	O
Streptomyces	O
coelicolor	O
A3	O
(	O
2	O
)	O
for	O
the	O
increased	O
production	O
of	O
undecylprodigiosin	O
and	O
identify	O
the	O
E.	O
coli	O
actives	O
mediating	O
this	O
inter-species	O
interaction	O
.	O

The	O
antibiotics	O
of	O
interest	O
were	O
the	O
red-pigmented	O
undecylprodigiosin	O
and	O
blue-pigmented	O
actinorhodin	O
.	O

Pure	O
cultures	B-P
of	O
S.	O
coelicolor	O
in	O
a	O
defined	O
medium	O
produced	O
higher	O
concentrations	O
of	O
actinorhodin	O
compared	O
to	O
those	O
of	O
undecylprodigiosin	O
.	O

The	O
latter	O
however	O
,	O
is	O
more	O
important	O
due	O
to	O
its	O
immunosuppressive	O
and	O
antitumor	O
properties	O
.	O

As	O
a	O
strategy	O
to	O
increase	O
undecylprodigiosin	O
production	O
,	O
we	O
added	O
separately	O
,	O
live	O
cells	O
and	O
heat-killed	O
cells	O
of	O
E.	O
coli	O
C600	O
,	O
and	O
the	O
cell-free	O
supernatant	O
of	O
E.	O
coli	O
culture	B-P
to	O
S.	O
coelicolor	O
cultures	B-P
in	I-P
shake	I-P
flasks	I-P
.	O

The	O
interaction	O
with	O
live	O
cells	O
of	O
E.	O
coli	O
altered	O
the	O
antibiotic	O
production	O
pattern	O
and	O
undecylprodigiosin	O
production	O
was	O
enhanced	O
by	O
3.5-fold	O
compared	O
to	O
the	O
pure	B-P
cultures	I-P
of	O
S.	O
coelicolor	O
and	O
actinorhodin	O
decreased	O
by	O
15-fold	O
.	O

The	O
heat-killed	O
cells	O
of	O
E.	O
coli	O
however	O
,	O
had	O
no	O
effect	O
on	O
antibiotic	O
production	O
.	O

In	O
all	O
cases	O
,	O
growth	O
and	O
glucose	O
consumption	O
of	O
S.	O
coelicolor	O
remained	O
almost	O
the	O
same	O
as	O
those	O
observed	O
in	O
the	O
pure	B-P
culture	I-P
indicating	O
that	O
the	O
changes	O
in	O
antibiotic	O
production	O
were	O
not	O
due	O
to	O
nutritional	O
stress	O
.	O

Results	O
with	O
cell-free	O
supernatant	O
of	O
E.	O
coli	O
culture	B-P
indicated	O
that	O
the	O
interaction	O
between	O
S.	O
coelicolor	O
and	O
E.	O
coli	O
was	O
mediated	O
via	O
diffusible	O
molecule	O
(	O
s	O
)	O
.	O

Using	O
a	O
set	O
of	O
extraction	B-P
procedures	I-P
and	O
agar-well	B-P
diffusion	I-P
bioassays	I-P
,	O
we	O
isolated	O
and	O
preliminarily	O
identified	O
a	O
class	O
of	O
compounds	O
.	O

For	O
the	O
preliminary	O
verification	O
,	O
we	O
added	O
the	O
compound	O
which	O
was	O
the	O
common	O
chemical	O
structural	O
moiety	O
in	O
this	O
class	O
of	O
compounds	O
to	O
the	O
pure	O
S.	O
coelicolor	O
cultures	B-P
.	O

We	O
observed	O
similar	O
effects	O
on	O
antibiotic	O
production	O
as	O
with	O
the	O
live	O
E.	O
coli	O
cells	O
and	O
their	O
supernatant	O
indicating	O
that	O
this	O
class	O
of	O
compounds	O
secreted	O
by	O
E.	O
coli	O
indeed	O
could	O
act	O
as	O
actives	O
during	O
interspecies	O
interaction	O
and	O
increase	O
the	O
production	O
of	O
undecylprodigiosin	O
.	O

On	O
the	O
identity	O
of	O
the	O
Palearctic	O
species	O
of	O
the	O
wolf	O
spider	O
genus	O
<	O
i	O
>	O
Trebacosa	O
<	O
/i	O
>	O
(	O
Araneae	O
:	O
Lycosidae	O
)	O
.	O

In	O
this	O
paper	O
we	O
propose	O
Trebacosa	O
brunhesi	O
Villepoux	O
,	O
2007	O
as	O
a	O
junior	O
synonym	O
of	O
Trebacosa	O
europaea	O
Szinetár	O
&	O
Kan-csal	O
,	O
2007	O
based	O
on	O
the	O
examination	O
of	O
specimens	O
from	O
all	O
the	O
localities	O
from	O
where	O
those	O
species	O
are	O
known	O
.	O

Illustration	O
of	O
the	O
type	O
species	O
of	O
the	O
genus	O
,	O
Trebacosa	O
marxi	O
(	O
Stone	O
,	O
1890	O
)	O
and	O
specimens	O
from	O
all	O
known	O
localities	O
of	O
T.	O
europaea	O
are	O
given	O
to	O
show	O
both	O
the	O
inter-	O
and	O
the	O
intraspecific	O
differences	O
of	O
the	O
genus	O
.	O

Scanning	B-P
electron	I-P
micrographs	I-P
were	O
used	O
to	O
illustrate	O
the	O
detailed	O
structure	O
of	O
the	O
female	O
's	O
genitalia	O
.	O

When	O
and	O
how	O
should	O
we	O
manage	O
thoracic	O
aortic	O
injuries	O
in	O
the	O
modern	O
era	O
?	O
.	O

A	O
best	O
evidence	O
topic	O
in	O
cardiovascular	O
surgery	O
was	O
written	O
according	O
to	O
a	O
structured	O
protocol	O
.	O

The	O
question	O
addressed	O
was	O
what	O
are	O
the	O
optimum	O
treatment	O
modality	O
and	O
timing	O
of	O
intervention	O
for	O
blunt	O
thoracic	O
aortic	O
injury	O
(	O
BTAI	O
)	O
in	O
the	O
modern	O
era	O
?	O

Of	O
the	O
697	O
papers	O
found	O
using	O
the	O
reported	O
search	O
,	O
14	O
(	O
5	O
meta-analyses	O
,	O
2	O
prospective	O
and	O
7	O
retrospective	O
studies	O
)	O
represented	O
the	O
best	O
evidence	O
to	O
answer	O
the	O
clinical	O
question	O
.	O

The	O
author	O
,	O
journal	O
,	O
country	O
,	O
date	O
of	O
publication	O
,	O
patient	O
group	O
studied	O
,	O
study	O
type	O
,	O
relevant	O
outcomes	O
,	O
results	O
and	O
weakness	O
of	O
these	O
papers	O
are	O
tabulated	O
.	O

All	O
five	O
meta-analyses	O
reported	O
a	O
reduction	O
in	O
mortality	O
with	O
thoracic	O
endovascular	O
aortic	O
repair	O
(	O
TEVAR	O
)	O
compared	O
with	O
open	O
repair	O
(	O
OR	O
)	O
,	O
but	O
only	O
four	O
found	O
the	O
same	O
benefit	O
on	O
paraplegia	O
rate	O
.	O

Similarly	O
,	O
the	O
two	O
prospective	O
and	O
four	O
retrospective	O
studies	O
showed	O
significantly	O
lower	O
mortality	O
with	O
TEVAR	O
than	O
with	O
OR	O
.	O

Only	O
one	O
study	O
(	O
a	O
meta-analysis	O
)	O
reported	O
a	O
significantly	O
lower	O
stroke	O
rate	O
with	O
TEVAR	O
than	O
with	O
OR	O
,	O
whereas	O
the	O
13	O
others	O
reported	O
a	O
similar	O
or	O
even	O
higher	O
stroke	O
rate	O
.	O

Other	O
complication	O
rates	O
were	O
identical	O
.	O

Four	O
studies	O
demonstrated	O
that	O
non-operative	O
management	O
(	O
NOM	O
)	O
as	O
a	O
treatment	O
option	O
for	O
BTAI	O
was	O
associated	O
with	O
increased	O
mortality	O
,	O
even	O
if	O
it	O
has	O
declined	O
in	O
recent	O
years	O
.	O

One	O
study	O
emphasized	O
that	O
some	O
cases	O
with	O
minimal	O
aortic	O
injuries	O
(	O
Grade	O
I	O
and	O
II	O
on	O
CT	B-P
scan	I-P
)	O
could	O
benefit	O
from	O
NOM	O
.	O

Regarding	O
the	O
timing	O
of	O
repair	O
,	O
only	O
three	O
studies	O
analysed	O
outcomes	O
of	O
delayed	O
repair	O
and	O
reported	O
significantly	O
lower	O
mortality	O
than	O
for	O
early	O
repair	O
.	O

We	O
conclude	O
that	O
with	O
lower	O
mortality	O
and	O
similar	O
overall	O
complications	O
including	O
paraplegia	O
but	O
higher	O
stroke	O
rate	O
,	O
TEVAR	O
is	O
the	O
most	O
suitable	O
treatment	O
for	O
BTAI	O
in	O
the	O
modern	O
era	O
,	O
where	O
expertise	O
exists	O
,	O
especially	O
for	O
cases	O
of	O
multiple	O
associated	O
injuries	O
and	O
in	O
the	O
older	O
age	O
group	O
.	O

Delayed	O
aortic	O
repair	O
can	O
be	O
proposed	O
based	O
on	O
CT	B-P
scan	I-P
analysis	I-P
,	O
but	O
emergent	O
repair	O
should	O
still	O
be	O
advocated	O
for	O
imminent	O
free	O
aortic	O
rupture	O
.	O

NOM	O
remains	O
a	O
therapeutic	O
option	O
but	O
only	O
with	O
selected	O
patients	O
.	O

A	O
novel	O
assay	B-P
to	O
measure	O
tertiary	O
and	O
quaternary	O
amines	O
in	O
wastewater	O
:	O
An	O
indicator	O
for	O
NDMA	O
wastewater	O
precursors	O
.	O

This	O
study	B-P
examined	O
the	O
potential	O
of	O
using	O
a	O
novel	O
bulk	B-P
amine	I-P
assay	I-P
as	O
an	O
approximation	O
for	O
the	O
tertiary	O
and	O
quaternary	O
amine	O
load	O
in	O
wastewaters	O
and	O
surface	O
water	O
samples	O
,	O
and	O
this	O
approximation	O
was	O
compared	O
to	O
N-nitrosodimethylamine	O
(	O
NDMA	O
)	O
formation	O
potential	O
using	O
chloramines	O
.	O

An	O
existing	O
colorimetric	B-P
method	I-P
was	O
examined	O
and	O
optimized	O
for	O
the	O
detection	O
of	O
amines	O
in	O
environmental	O
water	O
samples	O
.	O

The	O
method	B-P
consists	O
of	O
liquid-liquid	B-P
extraction	I-P
followed	O
by	O
a	O
catalyzed	O
reaction	O
to	O
form	O
a	O
yet-	O
undefined	O
product	O
that	O
is	O
known	O
to	O
be	O
both	O
a	O
strong	O
chromophore	O
and	O
fluorophore	O
.	O

Previous	O
work	O
verified	O
that	O
this	O
reaction	O
was	O
effectively	O
catalyzed	O
by	O
a	O
number	O
of	O
compounds	O
containing	O
tertiary	O
and	O
quaternary	O
amine	O
moieties	O
.	O

Many	O
tertiary	O
and	O
quaternary	O
compounds	O
are	O
also	O
efficient	O
producers	O
of	O
NDMA	O
under	O
chloramination	O
conditions	O
,	O
and	O
a	O
linear	O
correlation	O
was	O
consequently	O
derived	O
from	O
the	O
bulk	O
amine	O
signals	O
vs.	O
NDMA	O
formation	O
potential	O
in	O
various	O
wastewater	O
samples	O
(	O
R	O
(	O
2	O
)	O
=	O
0.74	O
;	O
n	O
=	O
24	O
;	O
p-value	O
<	O
0.05	O
)	O
.	O

The	O
results	O
provide	O
evidence	O
that	O
approximately	O
2	O
%	O
of	O
the	O
tertiary	O
and	O
quaternary	O
amines	O
measured	O
can	O
form	O
NDMA	O
and	O
an	O
estimated	O
0.01-1.3	O
%	O
of	O
nitrogen	O
in	O
dissolved	O
organic	O
nitrogen	O
originates	O
from	O
these	O
bulk	O
amines	O
.	O

The	O
normalization	O
of	O
NDMA	O
concentration	O
by	O
the	O
amine	O
measurement	O
revealed	O
that	O
ozone	O
effectively	O
destroyed	O
those	O
tertiary	O
and	O
quaternary	O
amine	O
structures	O
more	O
likely	O
to	O
form	O
NDMA	O
in	O
treated	O
wastewater	O
samples	O
.	O

This	O
bulk	B-P
amine	I-P
assay	I-P
illustrates	O
that	O
proxy	O
measurements	O
of	O
tertiary	O
and	O
quaternary	O
amines	O
can	O
be	O
linked	O
to	O
the	O
NDMA	O
formation	O
potential	O
of	O
a	O
given	O
sample	O
,	O
and	O
this	O
approach	O
may	O
prove	O
useful	O
as	O
a	O
characterizing	O
tool	O
for	O
NDMA	O
precursors	O
in	O
wastewater	O
.	O

Formation	O
of	O
an	O
Intraretinal	O
Fluid	O
Barrier	O
in	O
Cavitary	O
Optic	O
Disc	O
Maculopathy	O
.	O

Cavitary	O
optic	O
disc	O
maculopathy	O
develops	O
when	O
fluctuating	O
pressure	O
gradients	O
along	O
anomalous	O
communications	O
in	O
the	O
optic	O
nerve	O
head	O
induce	O
migration	O
of	O
fluid	O
into	O
the	O
adjacent	O
retinal	O
tissue	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
carefully	O
titrated	O
laser	O
photocoagulation	O
combined	O
with	O
vitrectomy	O
and	O
gas	O
tamponade	O
can	O
safely	O
create	O
an	O
effective	O
intraretinal	O
barrier	O
to	O
fluid	O
egress	O
from	O
the	O
optic	O
disc	O
cavitation	O
.	O

Retrospective	O
interventional	O
case	O
series	O
.	O

We	O
retrospectively	O
evaluated	O
medical	O
records	O
and	O
imaging	B-P
studies	I-P
of	O
22	O
consecutive	O
patients	O
with	O
cavitary	O
disc	O
maculopathy	O
evaluated	O
by	O
a	O
single	O
surgeon	O
between	O
1991	O
and	O
2014	O
.	O

Patients	O
requiring	O
surgery	O
underwent	O
carefully	O
titrated	O
juxtapapillary	O
laser	O
photocoagulation	O
followed	O
immediately	O
by	O
vitrectomy	O
and	O
gas	O
tamponade	O
.	O

Main	O
outcome	O
measures	O
were	O
change	O
in	O
visual	O
acuity	O
,	O
macular	O
fluid	O
resolution	O
,	O
and	O
recurrence	O
of	O
maculopathy	O
.	O

Eleven	O
patients	O
(	O
11	O
eyes	O
)	O
had	O
undergone	O
vitreous	O
surgery	O
and	O
were	O
included	O
in	O
the	O
study	O
.	O

No	O
preoperative	O
evidence	O
for	O
vitreous	O
traction	O
on	O
the	O
optic	O
disc	O
or	O
macula	O
was	O
seen	O
in	O
any	O
eye	O
.	O

Nine	O
patients	O
underwent	O
a	O
single	O
surgery	O
and	O
2	O
patients	O
required	O
additional	O
procedures	O
to	O
resolve	O
the	O
macular	O
fluid	O
.	O

Mean	O
length	O
of	O
follow-up	O
after	O
the	O
last	O
surgery	O
was	O
48.2	O
months	O
(	O
range	O
,	O
4-143	O
months	O
)	O
.	O

All	O
11	O
patients	O
(	O
100	O
%	O
)	O
had	O
complete	O
resolution	O
of	O
macular	O
fluid	O
,	O
with	O
an	O
average	O
time	O
to	O
resolution	O
of	O
8.5	O
months	O
(	O
range	O
,	O
1-18	O
months	O
)	O
.	O

Only	O
1	O
of	O
11	O
patients	O
(	O
9	O
%	O
)	O
had	O
recurrence	O
of	O
macular	O
fluid	O
(	O
14	O
months	O
postoperatively	O
)	O
.	O

The	O
average	O
preoperative	O
visual	O
acuity	O
of	O
20/125	O
(	O
logMAR	O
0.81	O
,	O
standard	O
deviation	O
[	O
SD	O
]	O
=	O
0.36	O
)	O
improved	O
by	O
nearly	O
4	O
lines	O
to	O
an	O
average	O
final	O
visual	O
acuity	O
of	O
20/57	O
(	O
logMAR	O
0.45	O
,	O
SD	O
=	O
0.37	O
)	O
(	O
P	O
=	O
.0072	O
)	O
.	O

A	O
possible	O
laser	O
-	O
induced	O
central	O
scotoma	O
was	O
suspected	O
in	O
only	O
1	O
patient	O
who	O
had	O
undergone	O
extensive	O
prior	O
laser	O
treatments	O
.	O

An	O
effective	O
intraretinal	O
barrier	O
to	O
fluid	O
migration	O
from	O
cavitary	O
optic	O
disc	O
anomalies	O
can	O
be	O
safely	O
achieved	O
in	O
most	O
patients	O
with	O
carefully	O
titrated	O
juxtapapillary	O
laser	O
photocoagulation	O
combined	O
with	O
vitrectomy	O
and	O
gas	O
tamponade	O
.	O

Once	O
achieved	O
,	O
the	O
barrier	O
facilitates	O
resolution	O
of	O
macular	O
fluid	O
and	O
long-term	O
avoidance	O
of	O
recurrent	O
maculopathy	O
.	O

Autologous	O
vs	O
Irradiated	O
Homologous	O
Costal	O
Cartilage	O
as	O
Graft	O
Material	O
in	O
Rhinoplasty	O
.	O

Studies	O
comparing	O
surgical	O
results	O
of	O
rhinoplasty	O
using	O
autologous	O
costal	O
cartilage	O
(	O
ACC	O
)	O
and	O
irradiated	O
homologous	O
costal	O
cartilage	O
(	O
IHCC	O
)	O
are	O
rare	O
.	O

To	O
compare	O
the	O
clinical	O
results	O
of	O
major	O
augmentation	O
rhinoplasty	O
using	O
ACC	O
vs	O
IHCC	O
and	O
analyze	O
the	O
histologic	O
properties	O
of	O
both	O
types	O
of	O
cartilage	O
.	O

A	O
retrospective	O
clinical	O
study	O
was	O
conducted	O
among	O
patients	O
who	O
had	O
undergone	O
rhinoseptoplasty	O
using	O
ACC	O
or	O
IHCC	O
from	O
January	O
1	O
,	O
2009	O
,	O
to	O
December	O
31	O
,	O
2014	O
.	O

Patients	O
were	O
followed	O
up	O
for	O
more	O
than	O
1	O
year	O
after	O
surgery	O
and	O
the	O
histologic	O
characteristics	O
of	O
ACC	O
and	O
IHCC	O
were	O
compared	O
.	O

The	O
details	O
of	O
the	O
surgical	O
procedures	O
and	O
complications	O
,	O
including	O
warping	O
,	O
infection	O
,	O
resorption	O
,	O
and/or	O
donor-site	O
morbidity	O
,	O
were	O
evaluated	O
by	O
reviewing	O
medical	O
records	O
and	O
facial	O
photographs	O
.	O

Patients	O
'	O
subjective	O
satisfaction	O
with	O
aesthetic	O
and	O
functional	O
results	O
was	O
evaluated	O
using	O
a	O
questionnaire	O
.	O

The	O
details	O
of	O
the	O
surgical	O
procedures	O
and	O
complications	O
,	O
including	O
warping	O
,	O
infection	O
,	O
resorption	O
,	O
and/or	O
donor-site	O
morbidity	O
;	O
patients	O
'	O
subjective	O
satisfaction	O
with	O
aesthetic	O
and	O
functional	O
results	O
'	O
objective	O
evaluation	O
of	O
surgical	O
outcomes	O
,	O
including	O
symmetry	O
,	O
dorsal	O
height	O
,	O
dorsal	O
length	O
,	O
dorsal	O
width	O
,	O
tip	O
projection	O
,	O
tip	O
rotation	O
,	O
tip	O
width	O
,	O
and	O
overall	O
result	O
;	O
and	O
histologic	O
structures	O
.	O

Objective	O
evaluation	O
of	O
surgical	O
outcomes	O
was	O
graded	O
using	O
the	O
Objective	O
Rhinoplasty	O
Outcome	O
Score	O
,	O
which	O
assessed	O
symmetry	O
,	O
dorsal	O
height	O
,	O
dorsal	O
length	O
,	O
dorsal	O
width	O
,	O
tip	O
projection	O
,	O
tip	O
rotation	O
,	O
tip	O
width	O
,	O
and	O
overall	O
result	O
.	O

Histologic	O
structures	O
were	O
evaluated	O
using	O
hematoxylin	B-P
and	I-P
eosin	I-P
,	O
Masson	B-P
trichrome	I-P
,	O
Alcian	B-P
blue	I-P
,	O
and	O
Verhoeff	B-P
elastic	I-P
stains	I-P
.	O

A	O
total	O
of	O
63	O
patients	O
(	O
27	O
males	O
and	O
36	O
females	O
;	O
mean	O
[	O
SD	O
]	O
age	O
,	O
30.6	O
[	O
9.5	O
]	O
years	O
)	O
had	O
rhinoseptoplasty	O
using	O
ACC	O
and	O
20	O
(	O
9	O
males	O
and	O
11	O
females	O
;	O
mean	O
[	O
SD	O
]	O
age	O
,	O
35.4	O
[	O
15.4	O
]	O
years	O
)	O
had	O
rhinoseptoplasty	O
using	O
IHCC	O
.	O

Among	O
observed	O
complications	O
,	O
only	O
notable	O
resorption	O
occurred	O
more	O
frequently	O
in	O
patients	O
using	O
IHCC	O
(	O
6	O
[	O
30	O
%	O
]	O
)	O
than	O
with	O
ACC	O
(	O
2	O
[	O
3	O
%	O
]	O
)	O
(	O
P	O
=	O
.002	O
)	O
.	O

In	O
subjective	O
evaluations	O
of	O
aesthetic	O
satisfaction	O
,	O
patients	O
who	O
received	O
ACC	O
showed	O
significantly	O
greater	O
satisfaction	O
(	O
37	O
of	O
51	O
patients	O
[	O
73	O
%	O
]	O
were	O
very	O
satisfied	O
)	O
than	O
did	O
those	O
who	O
received	O
IHCC	O
(	O
6	O
of	O
20	O
[	O
30	O
%	O
]	O
)	O
(	O
P	O
=	O
.001	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
between-group	O
difference	O
in	O
subjective	O
functional	O
outcomes	O
:	O
4	O
of	O
51	O
patients	O
receiving	O
ACC	O
(	O
8	O
%	O
)	O
and	O
5	O
of	O
20	O
receiving	O
IHCC	O
(	O
25	O
%	O
)	O
were	O
satisfied	O
(	O
P	O
=	O
.50	O
)	O
and	O
45	O
of	O
51	O
receiving	O
ACC	O
(	O
88	O
%	O
)	O
and	O
15	O
of	O
20	O
receiving	O
IHCC	O
(	O
75	O
%	O
)	O
were	O
very	O
satisfied	O
(	O
P	O
=	O
.15	O
)	O
.	O

Regarding	O
objective	O
aesthetic	O
outcomes	O
,	O
all	O
scores	O
for	O
both	O
ACC	O
and	O
IHCC	O
were	O
more	O
than	O
3.1	O
(	O
between	O
good	O
and	O
excellent	O
)	O
.	O

Histologic	B-P
analyses	I-P
showed	O
larger	O
,	O
more	O
evenly	O
distributed	O
,	O
uniform	O
chondrocytes	O
and	O
more	O
collagens	O
and	O
proteoglycan	O
contents	O
in	O
ACC	O
than	O
in	O
IHCC	O
.	O

Compared	O
with	O
patients	O
receiving	O
IHCC	O
,	O
those	O
receiving	O
ACC	O
for	O
rhinoseptoplasty	O
showed	O
superior	O
aesthetic	O
satisfaction	O
;	O
ACC	O
also	O
had	O
less	O
frequent	O
notable	O
resorption	O
.	O

Autologous	O
costal	O
cartilage	O
also	O
had	O
better	O
histologic	O
properties	O
than	O
IHCC	O
did	O
,	O
suggesting	O
it	O
as	O
an	O
ideal	O
graft	O
material	O
with	O
less	O
chance	O
of	O
long-term	O
resorption	O
.	O

3	O
.	O

The	O
Development	O
and	O
Psychometric	B-P
Properties	O
of	O
the	O
Children	O
's	O
Sleep	O
Assessment	O
Questionnaire	O
in	O
Taiwan	O
.	O

To	O
develop	O
and	O
examine	O
the	O
validity	O
and	O
reliability	O
of	O
the	O
Children	O
's	O
Sleep	O
Assessment	O
Questionnaire	O
(	O
CSAQ	O
)	O
for	O
school-aged	O
children	O
in	O
Taiwan	O
.	O

We	O
used	O
a	O
cross-sectional	O
study	O
design	O
with	O
stratified	O
random	O
sampling	O
.	O

Pairs	O
of	O
children	O
and	O
parents	O
were	O
recruited	O
from	O
a	O
school	O
-based	O
sample	O
of	O
third-	O
and	O
fourth-grade	O
students	O
,	O
enrolling	O
362	O
child	O
and	O
parent	O
pairs	O
.	O

The	O
content	O
validity	O
,	O
construct	O
validity	O
,	O
convergent	O
validity	O
,	O
internal	O
consistency	O
,	O
and	O
inter-rater	O
reliability	O
of	O
the	O
CSAQ	O
were	O
assessed	O
.	O

The	O
CSAQ	O
comprised	O
three	O
parts	O
:	O
sleep	O
hygiene	O
,	O
sleep	O
quality	O
,	O
and	O
sleep	O
disturbance	O
.	O

Sleep	O
hygiene	O
showed	O
a	O
moderate	O
intra-class	O
correlation	O
coefficient	O
(	O
0.37-0.66	O
)	O
between	O
children	O
and	O
parents	O
.	O

Results	O
of	O
exploratory	O
factor	O
analysis	O
suggested	O
a	O
four-factor	O
structure	O
model	O
for	O
sleep	O
quality	O
with	O
64.9	O
%	O
of	O
variance	O
and	O
a	O
two-factor	O
structure	O
for	O
sleep	O
disturbance	O
with	O
57.7	O
%	O
of	O
variance	O
.	O

These	O
two	O
models	O
also	O
demonstrated	O
good	O
fit	O
with	O
the	O
confirmatory	O
factor	O
analysis	O
.	O

The	O
CSAQ	O
is	O
a	O
valid	O
and	O
reliable	O
instrument	O
for	O
assessing	O
sleep	O
problems	O
in	O
school-aged	O
children	O
.	O

Both	O
clinicians	O
and	O
researchers	O
can	O
use	O
the	O
CSAQ	O
to	O
screen	O
or	O
elucidate	O
the	O
children	O
'	O
sleep	O
problems	O
.	O

Letter	O
to	O
the	O
Editor	O
]	O
NaOH	O
concentration	O
and	O
streptavidin	O
bead	O
type	O
are	O
key	O
factors	O
for	O
optimal	O
DNA	O
aptamer	O
strand	O
separation	B-P
and	O
isolation	B-P
.	O

Address	O
correspondence	O
to	O
Geoffrey	O
K.	O
Kilili	O
or	O
Christine	O
M.	O
Karbiwnyk	O
,	O
Winchester	O
Engineering	O
and	O
Analytical	O
Center	O
,	O
US	O
Food	O
and	O
Drug	O
Administration	O
,	O
Winchester	O
,	O
MA	O
,	O
01890	O
.	O

E-mail	O
:	O
Geoffrey.Kilili	O
@	O
fda.hhs.gov	O
or	O
Christine.Karbiwnyk	O
@	O
fda.hhs.gov	O
.	O

Does	O
infrared	O
visualization	O
improve	O
selection	O
of	O
venipuncture	B-P
sites	O
for	O
indwelling	O
needle	O
at	O
the	O
forearm	O
in	O
second-year	O
nursing	O
students	O
?	O
.	O

To	O
evaluate	O
the	O
effectiveness	O
of	O
a	O
vein	O
visualization	O
display	O
system	O
using	O
near-infrared	O
light	O
(	O
``	O
Vein	O
Display	O
``	O
)	O
for	O
the	O
safe	O
and	O
proper	O
selection	O
of	O
venipuncture	B-P
sites	O
for	O
indwelling	O
needle	O
placement	O
in	O
the	O
forearm	O
.	O

Ten	O
second	O
year	O
nursing	O
students	O
were	O
recruited	O
to	O
apply	O
an	O
indwelling	O
needle	O
line	O
with	O
and	O
without	O
Vein	O
Display	O
.	O

Another	O
ten	O
participants	O
were	O
recruited	O
from	O
various	O
faculty	O
to	O
serve	O
as	O
patients	O
.	O

The	O
quality	O
of	O
the	O
venipuncture	B-P
procedure	I-P
at	O
various	O
selected	O
sites	O
was	O
evaluated	O
according	O
to	O
a	O
scale	O
developed	O
by	O
the	O
authors	O
.	O

Time	O
,	O
scores	O
and	O
patterns	O
of	O
puncture	B-P
-	O
site	O
selection	O
were	O
compared	O
with	O
respect	O
to	O
three	O
different	O
methods	O
:	O
[	O
1	O
]	O
attempt	O
1	O
(	O
tourniquet	O
only	O
)	O
,	O
[	O
2	O
]	O
attempt	O
2	O
(	O
Vein	O
Display	O
only	O
)	O
and	O
[	O
3	O
]	O
attempt	O
3	O
(	O
both	O
)	O
.	O

To	O
validate	O
the	O
effectiveness	O
of	O
Vein	O
Display	O
,	O
52	O
trials	O
were	O
conducted	O
in	O
total	O
.	O

We	O
found	O
that	O
venipuncture	B-P
site	O
selection	O
time	O
was	O
significantly	O
improved	O
with	O
the	O
Vein	O
Display	O
,	O
particularly	O
in	O
the	O
case	O
of	O
difficult	O
to	O
administer	O
venipuncture	B-P
sites	O
.	O

Overall	O
,	O
we	O
found	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
venipuncture	B-P
quality	O
,	O
as	O
determined	O
by	O
our	O
scale	O
.	O

These	O
results	O
suggest	O
that	O
equipment	O
such	O
as	O
the	O
Vein	O
Display	O
can	O
contribute	O
immensely	O
to	O
the	O
improvement	O
of	O
practical	O
skills	O
,	O
such	O
as	O
venipuncture	B-P
,	O
especially	O
in	O
the	O
context	O
of	O
elderly	O
patients	O
.	O

Physiological	O
and	O
molecular	O
responses	O
of	O
juvenile	O
shortnose	O
sturgeon	O
(	O
Acipenser	O
brevirostrum	O
)	O
to	O
thermal	O
stress	O
.	O

The	O
shortnose	O
sturgeon	O
(	O
Acipenser	O
brevirostrum	O
LeSueur	O
,	O
1818	O
)	O
is	O
a	O
vulnerable	O
species	O
that	O
is	O
found	O
along	O
the	O
eastern	O
coast	O
of	O
North	O
America	O
.	O

Little	O
is	O
known	O
about	O
temperature	O
tolerance	O
in	O
this	O
species	O
and	O
with	O
a	O
rapidly	O
changing	O
global	O
climate	O
,	O
it	O
becomes	O
increasingly	O
important	O
to	O
define	O
the	O
thermal	O
tolerance	O
of	O
this	O
species	O
to	O
better	O
predict	O
population	O
distribution	O
.	O

Using	O
a	O
modified	B-P
critical	I-P
thermal	I-P
maximum	I-P
test	I-P
(	O
CTMax	B-P
)	O
,	O
the	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
impact	O
of	O
heating	O
rate	O
(	O
0.1	O
,	O
0.2	O
and	O
0.25°Cmin	O
(	O
-1	O
)	O
)	O
on	O
the	O
thermal	O
tolerance	O
,	O
associated	O
hematological	O
responses	O
,	O
and	O
oxygen	O
consumption	O
in	O
juvenile	O
sturgeon	O
.	O

In	O
addition	O
,	O
transcripts	O
associated	O
with	O
physiological	O
stress	O
and	O
heat	O
shock	O
(	O
i.e.	O
,	O
heat	O
shock	O
proteins	O
)	O
were	O
also	O
measured	O
.	O

Heating	O
rate	O
did	O
not	O
alter	O
the	O
CTMax	O
values	O
of	O
shortnose	O
sturgeon	O
.	O

Neither	O
heating	O
rate	O
nor	O
thermal	O
stress	O
affected	O
plasma	B-P
sodium	I-P
and	O
chloride	B-P
levels	I-P
,	O
nor	O
the	O
expression	O
of	O
transcripts	O
that	O
included	O
catalase	O
,	O
glucocorticoid	O
receptor	O
,	O
heat	O
shock	O
protein70	O
(	O
hsp70	O
)	O
,	O
heat	O
shock	O
protein	O
90α	O
(	O
hsp90α	O
)	O
and	O
cytochrome	O
P450	O
1a	O
(	O
cyp1a	O
)	O
.	O

However	O
,	O
regardless	O
of	O
heating	O
rate	O
,	O
thermal	O
stress	O
increased	O
both	O
plasma	O
potassium	O
and	O
lactate	O
concentrations	O
.	O

Glucose	O
levels	O
were	O
increased	O
at	O
heating	O
rates	O
of	O
0.2	O
and	O
0.25°Cmin	O
(	O
-1	O
)	O
,	O
but	O
not	O
at	O
0.1°Cmin	O
(	O
-1	O
)	O
.	O

Overall	O
,	O
oxygen	O
consumption	O
rates	O
increased	O
with	O
thermal	O
stress	O
,	O
but	O
the	O
response	O
patterns	O
were	O
not	O
affected	O
by	O
heating	O
rate	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
shortnose	O
sturgeon	O
can	O
tolerate	O
acute	O
heat	O
stress	O
,	O
as	O
many	O
physiological	O
and	O
molecular	O
parameters	O
measured	O
here	O
were	O
non-responsive	O
to	O
the	O
thermal	O
stress	O
.	O

Associations	O
of	O
NEUROD2	O
polymorphisms	O
and	O
change	O
of	O
cognitive	O
dysfunctions	O
in	O
schizophrenia	O
and	O
schizoaffective	O
disorder	O
after	O
eight	O
weeks	O
of	O
antipsychotic	O
treatment	O
.	O

NEUROD2	O
is	O
a	O
neurospecific	O
helix-loop-helix	O
transcription	O
factor	O
which	O
has	O
an	O
impact	O
on	O
the	O
regulation	O
of	O
glutamatergic	O
and	O
GABAergic	O
genes	O
.	O

We	O
investigated	O
an	O
association	O
of	O
NEUROD2	O
with	O
neurocognitive	O
dysfunctions	O
in	O
schizophrenia	O
and	O
schizoaffective	O
disorder	O
patients	O
before	O
and	O
during	O
treatment	O
with	O
different	O
second-generation	O
antipsychotics	O
.	O

Patients	O
were	O
genotyped	O
for	O
four	O
different	O
polymorphisms	O
of	O
the	O
NEUROD2	O
gene	O
(	O
(	O
rs9889354	O
(	O
A/G	O
)	O
,	O
rs1877032	O
(	O
C/T	O
)	O
,	O
rs12453682	O
(	O
C/T	O
)	O
and	O
rs11078918	O
(	O
C/G	O
)	O
)	O
.	O

Cognitive	O
function	O
was	O
assessed	O
at	O
baseline	O
and	O
week	O
8	O
.	O

Results	O
of	O
individual	O
neuropsychological	B-P
tests	I-P
were	O
assigned	O
to	O
six	O
cognitive	O
domains	O
(	O
reaction	O
time	O
and	O
quality	O
;	O
executive	O
function	O
;	O
working	O
,	O
verbal	O
and	O
visual	O
memory	O
)	O
and	O
a	O
general	O
cognitive	O
index	O
.	O

167	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
NEUROD2	O
exonic	O
polymorphism	O
rs11078918	O
showed	O
significant	O
associations	O
with	O
verbal	O
memory	O
and	O
executive	O
functions	O
,	O
whereas	O
the	O
NEUROD2	O
polymorphism	O
rs12453682	O
was	O
significantly	O
associated	O
with	O
working	O
and	O
verbal	O
memory	O
,	O
executive	O
functions	O
and	O
with	O
a	O
cognitive	O
index	O
.	O

Significant	O
associations	O
were	O
found	O
at	O
baseline	O
and	O
after	O
eight	O
weeks	O
.	O

Moreover	O
,	O
significant	O
associations	O
between	O
the	O
change	O
in	O
neuropsychological	B-P
test	I-P
results	O
during	O
antipsychotic	O
treatment	O
and	O
the	O
NEUROD2	O
polymorphisms	O
rs11078918	O
and	O
rs12453682	O
were	O
observed	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
NEUROD2	O
gene	O
could	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
neurocognitive	O
dysfunctions	O
as	O
well	O
as	O
in	O
the	O
change	O
of	O
cognitive	O
symptoms	O
under	O
antipsychotic	O
treatment	O
in	O
schizophrenia	O
and	O
schizoaffective	O
disorder	O
.	O

Reduced	O
susceptibilities	O
to	O
biocides	O
and	O
resistance	O
to	O
antibiotics	O
in	O
food	O
-	O
associated	O
bacteria	O
following	O
exposure	O
to	O
quaternary	O
ammonium	O
compounds	O
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
effects	O
of	O
step-wise	O
exposure	O
to	O
didecyl	O
dimethyl	O
ammonium	O
chloride	O
(	O
DDAC	O
)	O
on	O
the	O
antimicrobial	O
(	O
antibiotics	O
and	O
biocides	O
)	O
susceptibilities	O
of	O
food	O
-	O
associated	O
bacterial	O
strains	O
.	O

Adaptive	O
responses	O
of	O
bacterial	O
strains	O
were	O
investigated	O
by	O
exposing	O
the	O
strains	O
daily	O
to	O
increasing	O
subinhibitory	O
concentrations	O
of	O
DDAC	O
for	O
7	O
days	O
.	O

Following	O
adaptation	O
to	O
DDAC	O
,	O
a	O
threefold	O
increase	O
in	O
the	O
minimum	B-P
inhibitory	I-P
concentration	I-P
(	O
MIC	B-P
)	O
values	O
for	O
this	O
biocide	O
was	O
observed	O
in	O
48	O
%	O
of	O
the	O
Escherichia	O
coli	O
and	O
Listeria	O
monocytogenes	O
strains	O
,	O
and	O
3	O
%	O
of	O
the	O
Salmonella	O
strains	O
.	O

Reduced	O
susceptibility	O
to	O
other	O
biocides	O
was	O
found	O
with	O
the	O
most	O
important	O
increase	O
in	O
MIC	B-P
for	O
benzalkonium	O
chloride	O
(	O
BC	O
)	O
and	O
a	O
commercial	O
biocide	O
formulation	O
(	O
Galox	O
Horizon	O
)	O
containing	O
DDAC	O
and	O
glutaraldehyde	O
,	O
for	O
all	O
species	O
except	O
Salmonella	O
.	O

Increase	O
in	O
antibiotic	O
MIC	B-P
values	O
was	O
more	O
pronounced	O
in	O
E.	O
coli	O
in	O
terms	O
of	O
antibiotic	O
numbers	O
and	O
of	O
magnitude	O
(	O
from	O
4-	O
to	O
32-fold	O
increase	O
)	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
Salmonella	O
strains	O
.	O

Most	O
of	O
these	O
strains	O
had	O
acquired	O
resistance	O
to	O
ampicillin	O
,	O
cefotaxime	O
,	O
ceftazidime	O
,	O
chloramphenicol	O
and	O
ciprofloxacin	O
.	O

The	O
effects	O
of	O
exposure	O
to	O
DDAC	O
on	O
biocides	O
and	O
antibiotics	O
susceptibilities	O
depend	O
upon	O
the	O
bacteria	O
species	O
.	O

Extensive	O
use	O
of	O
DDAC	O
at	O
subinhibitory	O
concentrations	O
may	O
lead	O
to	O
the	O
development	O
of	O
antibiotic	O
-	O
resistant	O
bacteria	O
and	O
may	O
represent	O
a	O
public	O
health	O
issue	O
.	O

Association	O
of	O
Toll-Like	O
Receptor	O
4	O
on	O
Human	O
Monocyte	O
Subsets	O
and	O
Vulnerability	O
Characteristics	O
of	O
Coronary	O
Plaque	O
as	O
Assessed	O
by	O
64-Slice	B-P
Multidetector	I-P
Computed	I-P
Tomography	I-P
.	O

Although	O
Toll-like	O
receptor	O
4	O
(	O
TLR-4	O
)	O
is	O
involved	O
in	O
monocyte	O
activation	O
in	O
patients	O
with	O
accelerated	O
forms	O
of	O
atherosclerosis	O
,	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
TLR-4	O
on	O
circulating	O
monocyte	O
s	O
and	O
coronary	O
plaque	O
vulnerability	O
has	O
not	O
previously	O
been	O
evaluated	O
.	O

We	O
investigated	O
this	O
relationship	O
using	O
64-slice	B-P
multidetector	I-P
computed	I-P
tomography	I-P
(	O
MDCT	B-P
)	O
in	O
patients	O
with	O
stable	O
angina	O
pectoris	O
(	O
SAP	O
)	O
.Methods	O
and	O
Results	O
:	O
We	O
enrolled	O
65	O
patients	O
with	O
SAP	O
who	O
underwent	O
MDCT	B-P
.	O

Three	O
monocyte	O
subsets	O
(	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
-	O
)	O
,	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
+	O
)	O
,	O
and	O
CD14	O
(	O
+	O
)	O
CD16	O
(	O
+	O
)	O
)	O
and	O
expression	O
of	O
TLR-4	O
were	O
measured	O
by	O
flow	B-P
cytometry	I-P
.	O

Intracoronary	O
plaques	O
were	O
assessed	O
by	O
64-slice	B-P
MDCT	I-P
.	O

We	O
defined	O
vulnerability	O
of	O
intracoronary	O
plaques	O
according	O
to	O
the	O
presence	O
of	O
positive	O
remodeling	O
(	O
remodeling	O
index	O
>	O
1.05	O
)	O
and/or	O
low	O
CT	B-P
attenuation	O
(	O
<	O
35	O
HU	O
)	O
.	O

The	O
circulating	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
+	O
)	O
monocytes	O
more	O
frequently	O
expressed	O
TLR-4	O
than	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
-	O
)	O
and	O
CD14	O
(	O
+	O
)	O
CD16	O
(	O
+	O
)	O
monocytes	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
relative	O
proportion	O
of	O
the	O
expression	O
of	O
TLR-4	O
on	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
+	O
)	O
monocytes	O
was	O
significantly	O
greater	O
in	O
patients	O
with	O
vulnerable	O
plaque	O
compared	O
with	O
those	O
without	O
(	O
10.4	O
[	O
4.1-14.5	O
]	O
%	O
vs.	O
4.5	O
[	O
2.8-7.8	O
]	O
%	O
,	O
P=0.012	O
)	O
.	O

In	O
addition	O
,	O
the	O
relative	O
proportion	O
of	O
TLR-4	O
expression	O
on	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
+	O
)	O
monocytes	O
positively	O
correlated	O
with	O
the	O
remodeling	O
index	O
(	O
r=0.28	O
,	O
P=0.025	O
)	O
and	O
negatively	O
correlated	O
with	O
CT	B-P
attenuation	O
value	O
(	O
r=-0.31	O
,	O
P=0.013	O
)	O
.	O

Upregulation	O
of	O
TLR-4	O
on	O
CD14	O
(	O
++	O
)	O
CD16	O
(	O
+	O
)	O
monocytes	O
might	O
be	O
associated	O
with	O
coronary	O
plaque	O
vulnerability	O
in	O
patients	O
with	O
SAP	O
.	O

Hint1	O
suppresses	O
migration	O
and	O
invasion	O
of	O
hepatocellular	O
carcinoma	O
cells	O
in	O
vitro	O
by	O
modulating	O
girdin	O
activity	O
.	O

Histidine	O
triad	O
nucleotide-binding	O
protein	O
1	O
(	O
Hint1	O
)	O
is	O
a	O
haploinsufficient	O
tumor	O
suppressor	O
gene	O
.	O

Its	O
role	O
in	O
cancer	O
cell	O
migration	O
has	O
not	O
been	O
previously	O
speculated	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
examined	O
the	O
expression	O
of	O
Hint1	O
in	O
metastatic	O
and	O
non-metastatic	O
lymph	O
nodes	O
of	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
patients	O
and	O
further	O
elucidated	O
the	O
effect	O
of	O
Hint1	O
expression	O
on	O
girdin	O
expression	O
and	O
phosphorylation	O
of	O
AKT	O
and	O
ERK1	O
/	O
2	O
and	O
on	O
the	O
migration	O
of	O
HCC	O
cells	O
in	O
vitro	O
.	O

Expression	O
of	O
Hint1	O
and	O
girdin	O
in	O
primary	O
HCC	O
tissues	O
and	O
metastatic	O
and	O
non-metastatic	O
lymph	O
nodes	O
was	O
determined	O
by	O
RT-PCR	B-P
assays	I-P
.	O

HepG2	O
cells	O
were	O
transfected	O
with	O
plasmid	O
vectors	O
overexpressing	O
Hint1	O
or	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
targeting	O
Hint1	O
,	O
girdin	O
,	O
Hint1	O
plus	O
girdin	O
,	O
or	O
the	O
scrambled	O
RNA	O
.	O

Migration	O
and	O
invasion	O
of	O
HCC	O
cells	O
were	O
examined	O
by	O
wound	B-P
and	I-P
Transwell	I-P
assays	I-P
.	O

Protein	O
expression	O
was	O
detected	O
by	O
immunofluorescence	B-P
and	O
immunoblotting	B-P
assays	I-P
.	O

RT-PCR	B-P
assays	I-P
revealed	O
that	O
the	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
transcript	O
levels	O
of	O
Hint1	O
were	O
markedly	O
lower	O
than	O
those	O
of	O
primary	O
HCC	O
tissues	O
and	O
non-metastatic	O
lymph	O
nodes	O
(	O
P	O
<	O
0.01	O
)	O
.	O

By	O
contrast	O
,	O
the	O
mRNA	O
transcript	O
levels	O
of	O
girdin	O
were	O
significantly	O
higher	O
than	O
non-metastatic	O
lymph	O
nodes	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Furthermore	O
,	O
siRNA	O
knockdown	O
of	O
HINT1	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
mRNA	O
transcript	O
levels	O
of	O
girdin	O
in	O
HepG2	O
cells	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Wound	B-P
assays	I-P
and	I-P
Transwell	I-P
assays	I-P
showed	O
that	O
Hint1	O
knockdown	O
by	O
siRNA	O
significantly	O
enhanced	O
the	O
migration	O
and	O
invasion	O
of	O
HepG2	O
cells	O
compared	O
to	O
HepG2	O
cells	O
transfected	O
with	O
scrambled	O
siRNA	O
.	O

Hint1	O
knockdown	O
also	O
led	O
to	O
significantly	O
increased	O
phosphorylation	O
of	O
girdin	O
and	O
AKT	O
in	O
HepG2	O
cells	O
(	O
P	O
<	O
0.05	O
)	O
,	O
which	O
,	O
however	O
,	O
was	O
effectively	O
aborted	O
by	O
girdin	O
knockdown	O
by	O
siRNA	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Hint1	O
is	O
downregulated	O
in	O
metastatic	O
lymph	O
nodes	O
and	O
is	O
implicated	O
in	O
migration	O
and	O
invasion	O
of	O
HCC	O
cells	O
in	O
vitro	O
by	O
modulating	O
girdin	O
and	O
AKT	O
expression	O
and	O
phosphorylation	O
.	O

The	O
Hint1	O
-	O
girdin	O
-	O
AKT	O
signaling	O
axis	O
should	O
be	O
further	O
dissected	O
for	O
its	O
role	O
in	O
HCC	O
migration	O
and	O
invasion	O
and	O
may	O
be	O
therapeutically	O
targeted	O
to	O
suppress	O
tumor	O
growth	O
and	O
metastasis	O
.	O

Optimization	O
of	O
Early	O
Response	O
Monitoring	O
and	O
Prediction	O
of	O
Cancer	O
Antiangiogenesis	O
Therapy	O
via	O
Noninvasive	O
PET	B-P
Molecular	I-P
Imaging	I-P
Strategies	O
of	O
Multifactorial	O
Bioparameters	O
.	O

Objective	O
:	O
Antiangiogenesis	O
therapy	O
(	O
AAT	O
)	O
has	O
provided	O
substantial	O
benefits	O
regarding	O
improved	O
outcomes	O
and	O
survival	O
for	O
suitable	O
patients	O
in	O
clinical	O
settings	O
.	O

Therefore	O
,	O
the	O
early	O
definition	O
of	O
therapeutic	O
effects	O
is	O
urgently	O
needed	O
to	O
guide	O
cancer	O
AAT	O
.	O

We	O
aimed	O
to	O
optimize	O
the	O
early	O
response	O
monitoring	O
and	O
prediction	O
of	O
AAT	O
efficacy	O
,	O
as	O
indicated	O
by	O
the	O
multi-targeted	O
anti-angiogenic	O
drug	O
sunitinib	O
in	O
U87MG	O
tumors	O
,	O
using	O
noninvasive	O
positron	B-P
emission	I-P
computed	I-P
tomography	I-P
(	I-P
PET	I-P
)	I-P
molecular	I-P
imaging	I-P
strategies	O
of	O
multifactorial	O
bioparameters	O
.	O

Methods	O
:	O
U87MG	O
tumor	O
mice	O
were	O
treated	O
via	O
intragastric	O
injections	O
of	O
sunitinib	O
(	O
80	O
mg/kg	O
)	O
or	O
vehicle	O
for	O
7	O
consecutive	O
days	O
.	O

Longitudinal	O
MicroPET/CT	B-P
scans	I-P
with	O
(	O
18	O
)	O
F-FDG	O
,	O
(	O
18	O
)	O
F-FMISO	O
,	O
(	O
18	O
)	O
F-ML-10	O
and	O
(	O
18	O
)	O
F-Alfatide	O
II	O
were	O
acquired	O
to	O
quantitatively	O
measure	O
metabolism	O
,	O
hypoxia	O
,	O
apoptosis	O
and	O
angiogenesis	O
on	O
days	O
0	O
,	O
1	O
,	O
3	O
,	O
7	O
and	O
13	O
following	O
therapy	O
initiation	O
.	O

Tumor	O
tissues	O
from	O
a	O
dedicated	O
group	O
of	O
mice	O
were	O
collected	O
for	O
immunohistochemical	B-P
(	O
IHC	B-P
)	O
analysis	O
of	O
key	O
biomarkers	O
(	O
Glut-1	O
,	O
CA-IX	O
,	O
TUNEL	O
,	O
ανβ3	O
and	O
CD31	O
)	O
at	O
the	O
time	O
points	O
of	O
PET	B-P
imaging	I-P
.	O

The	O
tumor	O
sizes	O
and	O
mouse	O
weights	O
were	O
measured	O
throughout	O
the	O
study	O
.	O

The	O
tumor	O
uptake	O
(	O
ID	O
%	O
/gmax	O
)	O
,	O
the	O
ratios	O
of	O
the	O
tumor	O
/	O
muscle	O
(	O
T	O
/	O
M	O
)	O
for	O
each	O
probe	O
,	O
and	O
the	O
tumor	O
growth	O
ratios	O
(	O
TGR	O
)	O
were	O
calculated	O
and	O
used	O
for	O
statistical	O
analyses	O
of	O
the	O
differences	O
and	O
correlations	O
.	O

Results	O
:	O
Sunitinib	O
successfully	O
inhibited	O
U87MG	O
tumor	O
growth	O
with	O
significant	O
differences	O
in	O
the	O
tumor	O
size	O
from	O
day	O
9	O
after	O
sunitinib	O
treatment	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
uptakes	O
of	O
(	O
18	O
)	O
F-FMISO	O
(	O
reduced	O
hypoxia	O
)	O
,	O
(	O
18	O
)	O
F-ML-10	O
(	O
increased	O
apoptosis	O
)	O
and	O
(	O
18	O
)	O
F-Alfatide	O
II	O
(	O
decreased	O
angiogenesis	O
)	O
in	O
the	O
tumor	O
lesions	O
significantly	O
changed	O
during	O
the	O
early	O
stage	O
(	O
days	O
1	O
to	O
3	O
)	O
of	O
sunitinib	O
treatment	O
;	O
however	O
,	O
the	O
uptake	O
of	O
(	O
18	O
)	O
F-FDG	O
(	O
increased	O
glucose	O
metabolism	O
)	O
was	O
significantly	O
different	O
during	O
the	O
late	O
stage	O
.	O

The	O
PET	B-P
imaging	I-P
data	O
of	O
each	O
probe	O
were	O
all	O
confirmed	O
via	O
ex	O
vivo	O
IHC	B-P
of	O
the	O
relevant	O
biomarkers	O
.	O

Notably	O
,	O
the	O
PET	B-P
imaging	I-P
of	O
(	O
18	O
)	O
F-Alfatide	O
II	O
and	O
(	O
18	O
)	O
F-FMISO	O
was	O
significantly	O
correlated	O
(	O
all	O
P	O
<	O
0.05	O
)	O
with	O
TGR	O
,	O
whereas	O
the	O
imaging	O
of	O
(	O
18	O
)	O
F-FDG	O
and	O
(	O
18	O
)	O
F-ML-10	O
was	O
not	O
significantly	O
correlated	O
with	O
TGR	O
.	O

Conclusion	O
:	O
Based	O
on	O
the	O
tumor	O
uptake	O
of	O
the	O
PET	B-P
probes	O
and	O
their	O
correlations	O
with	O
MVD	O
and	O
TGR	O
,	O
(	O
18	O
)	O
F-Alfatide	O
II	O
PET	B-P
may	O
not	O
only	O
monitor	O
the	O
early	O
response	O
but	O
also	O
precisely	O
predict	O
the	O
therapeutic	O
efficacy	O
of	O
the	O
multi-targeted	O
,	O
anti-angiogenic	O
drug	O
sunitinib	O
in	O
U87MG	O
tumors	O
.	O

In	O
conclusion	O
,	O
it	O
is	O
feasible	O
to	O
optimize	O
the	O
early	O
response	O
monitoring	O
and	O
efficacy	O
prediction	O
of	O
cancer	O
AAT	O
using	O
noninvasive	O
PET	B-P
molecular	I-P
imaging	I-P
strategies	O
of	O
multifactorial	O
bioparameters	O
,	O
such	O
as	O
angiogenesis	O
imaging	B-P
with	O
(	O
18	O
)	O
F-Alfatide	O
II	O
,	O
which	O
represents	O
an	O
RGD	O
-based	O
probe	O
.	O

Functional	O
constituents	O
of	O
wild	O
and	O
cultivated	O
Goji	O
(	O
L.	O
barbarum	O
L.	O
)	O
leaves	O
:	O
phytochemical	O
characterization	O
,	O
biological	O
profile	O
,	O
and	O
computational	B-P
studies	I-P
.	O

Goji	O
(	O
Lycium	O
barbarum	O
L.	O
)	O
leaves	O
are	O
emphasized	O
as	O
a	O
functional	O
tea	O
or	O
as	O
dietary	O
supplements	O
.	O

The	O
phenolic	O
compound	O
profile	O
,	O
antioxidant	O
,	O
enzyme	O
inhibitory	O
,	O
antimicrobial	O
,	O
and	O
antimutagenic	O
activities	O
of	O
leaf	O
extracts	O
from	O
two	O
selected	O
cultivars	O
in	O
comparison	O
with	O
wild-growing	O
plants	O
have	O
been	O
evaluated	O
.	O

HPLC-DAD	B-P
/	O
ESI	B-P
-	O
ToF-MS	B-P
analysis	O
revealed	O
the	O
presence	O
of	O
phenolic	O
acids	O
and	O
flavonoids	O
with	O
chlorogenic	O
acid	O
and	O
rutin	O
being	O
the	O
dominant	O
compounds	O
in	O
the	O
cultivated	O
plants	O
,	O
whereas	O
rutin	O
and	O
kaempeferol-3-O-rutinoside	O
for	O
wild	O
growing	O
ones	O
.	O

In	O
particular	O
,	O
cv	O
.	O

Erma	O
contained	O
the	O
highest	O
amount	O
of	O
chlorogenic	O
acid	O
and	O
showed	O
a	O
strong	O
tyrosinase	O
-	O
inhibitory	O
effect	O
.	O

Staphylococcus	O
aureus	O
,	O
Listeria	O
monocytogenes	O
,	O
and	O
Penicillium	O
funiculosum	O
were	O
the	O
most	O
sensitive	O
strains	O
when	O
exposed	O
to	O
extracts	O
from	O
cultivated	O
plants	O
.	O

Antimutagenic	O
activity	O
was	O
evaluated	O
by	O
Ames	O
'	O
test	O
.	O

The	O
tested	O
extracts	O
provided	O
high	O
protection	O
against	O
mutagenicity	O
induced	O
by	O
2-anthramine	O
(	O
2-AA	O
)	O
to	O
Salmonella	O
typhimurium	O
strains	O
TA	O
98	O
and	O
TA	O
100	O
(	O
max	O
.	O

inhibition	O
(	O
%	O
)	O
88	O
%	O
and	O
74.2	O
%	O
,	O
respectively	O
)	O
.	O

Overall	O
,	O
Goji	O
leaves	O
are	O
a	O
rich	O
source	O
of	O
bioactive	O
compounds	O
with	O
functional	O
properties	O
that	O
need	O
further	O
risk/benefit	O
evaluation	O
when	O
used	O
in	O
foods	O
or	O
health-promoting	O
formulations	O
.	O

Proteomics	O
analysis	B-P
of	O
the	O
endogenous	O
,	O
constitutive	O
,	O
leaf	O
SUMOylome	O
.	O

SUMOylation	O
is	O
a	O
post-translational	O
modification	O
which	O
regulates	O
a	O
number	O
of	O
critical	O
biological	O
processes	O
in	O
,	O
for	O
example	O
mammals	O
,	O
yeast	O
and	O
plants	O
.	O

In	O
order	O
to	O
fully	O
understand	O
the	O
functional	O
effects	O
of	O
SUMOylation	O
an	O
essential	O
first	O
step	O
is	O
the	O
identification	O
of	O
endogenous	O
targets	O
for	O
SUMOylation	O
.	O

Here	O
we	O
report	O
the	O
results	O
of	O
using	O
a	O
recently	O
developed	O
proteomic	O
approach	O
based	O
on	O
the	O
use	O
of	O
3D	O
gels	O
to	O
identify	O
the	O
endogenous	O
SUMO	O
targets	O
in	O
leaves	O
of	O
Solanum	O
tuberosum	O
.	O

By	O
using	O
3D	O
gels	O
we	O
avoid	O
the	O
problem	O
of	O
co-migration	O
of	O
proteins	O
,	O
which	O
is	O
a	O
major	O
limitation	O
of	O
2D	O
gels	O
,	O
and	O
we	O
enable	O
the	O
use	O
of	O
the	O
highly	O
sensitive	O
CyDye	O
DIGE	O
fluor	O
saturation	O
dyes	O
.	O

Using	O
this	O
new	O
method	O
we	O
have	O
identified	O
39	O
individual	O
proteins	O
as	O
probable	O
SUMO	O
targets	O
in	O
leaves	O
of	O
Solanum	O
tuberosum	O
.	O

The	O
advantages	O
of	O
this	O
method	B-P
compared	O
with	O
other	O
approaches	O
are	O
discussed	O
,	O
and	O
possible	O
future	O
developments	O
are	O
outlined	O
.	O

The	O
authors	O
have	O
no	O
conflicts	O
of	O
interest	O
to	O
declare	O
.	O

All	O
authors	O
have	O
approved	O
the	O
manuscript	O
and	O
agree	O
with	O
submission	O
to	O
Journal	O
of	O
Proteomics	O
.	O

Reducing	O
neuroinflammation	O
by	O
delivery	O
of	O
IL-10	O
encoding	O
lentivirus	O
from	O
multiple-channel	O
bridges	O
.	O

The	O
spinal	O
cord	O
is	O
unable	O
to	O
regenerate	O
after	O
injury	O
largely	O
due	O
to	O
growth-inhibition	O
by	O
an	O
inflammatory	O
response	O
to	O
the	O
injury	O
that	O
fails	O
to	O
resolve	O
,	O
resulting	O
in	O
secondary	O
damage	O
and	O
cell	O
death	O
.	O

An	O
approach	O
that	O
prevents	O
inhibition	O
by	O
attenuating	O
the	O
inflammatory	O
response	O
and	O
promoting	O
its	O
resolution	O
through	O
the	O
transition	O
of	O
macrophages	O
to	O
anti-inflammatory	O
phenotypes	O
is	O
essential	O
for	O
the	O
creation	O
of	O
a	O
growth	O
permissive	O
microenvironment	O
.	O

Viral	O
gene	O
delivery	O
to	O
induce	O
the	O
expression	O
of	O
anti-inflammatory	O
factors	O
provides	O
the	O
potential	O
to	O
provide	O
localized	O
delivery	O
to	O
alter	O
the	O
host	O
inflammatory	O
response	O
.	O

Initially	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
the	O
biomaterial	O
and	O
viral	O
components	O
of	O
the	O
delivery	O
system	O
to	O
influence	O
the	O
extent	O
of	O
cell	O
infiltration	O
and	O
the	O
phenotype	O
of	O
these	O
cells	O
.	O

Bridge	O
implantation	O
reduces	O
antigen	O
-presenting	O
cell	O
infiltration	O
at	O
day	O
7	O
,	O
and	O
lentivirus	O
addition	O
to	O
the	O
bridge	O
induces	O
a	O
transient	O
increase	O
in	O
neutrophils	O
in	O
the	O
spinal	O
cord	O
at	O
day	O
7	O
and	O
macrophages	O
at	O
day	O
14	O
.	O

Delivery	O
of	O
a	O
lentivirus	O
encoding	O
IL-10	O
,	O
an	O
anti-inflammatory	O
factor	O
that	O
inhibits	O
immune	O
cell	O
activation	O
and	O
polarizes	O
the	O
macrophage	B-P
population	I-P
towards	O
anti-inflammatory	O
phenotypes	O
,	O
reduced	O
neutrophil	O
infiltration	O
at	O
both	O
day	O
7	O
and	O
day	O
28	O
.	O

Though	O
IL-10	O
lentivirus	O
did	O
not	O
affect	O
macrophages	B-P
number	I-P
,	O
it	O
skewed	O
the	O
macrophage	B-P
population	I-P
toward	O
an	O
anti-inflammatory	O
M2	O
phenotype	O
and	O
altered	O
macrophage	O
morphology	O
.	O

Additionally	O
,	O
IL-10	O
delivery	O
resulted	O
in	O
improved	O
motor	O
function	O
,	O
suggesting	O
reduced	O
secondary	O
damage	O
and	O
increased	O
sparing	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
localized	O
expression	O
of	O
anti-inflammatory	O
factors	O
,	O
such	O
as	O
IL-10	O
,	O
can	O
modulate	O
the	O
inflammatory	O
response	O
following	O
spinal	O
cord	O
injury	O
,	O
and	O
may	O
be	O
a	O
key	O
component	O
of	O
a	O
combinatorial	O
approach	O
that	O
targets	O
the	O
multiple	O
barriers	O
to	O
regeneration	O
and	O
functional	O
recovery	O
.	O

Longitudinal	O
study	O
of	O
bovine	O
rotavirus	O
group	O
A	O
in	O
newborn	O
calves	O
from	O
vaccinated	O
and	O
unvaccinated	O
dairy	O
herds	O
.	O

Reports	O
of	O
rotavirus	O
excretion	O
in	O
calves	O
usually	O
result	O
from	O
cross-sectional	O
studies	O
,	O
and	O
in	O
face	O
of	O
the	O
conflicting	O
results	O
regarding	O
protection	O
of	O
calves	O
born	O
to	O
vaccinated	O
dams	O
against	O
diarrhea	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
rotavirus	O
excretion	O
in	O
dairy	O
calves	O
born	O
to	O
vaccinated	O
or	O
unvaccinated	O
dams	O
,	O
to	O
identify	O
the	O
genotypes	O
of	O
bovine	O
rotavirus	O
group	O
A	O
(	O
RVA	O
)	O
strains	O
isolated	O
from	O
these	O
animals	O
as	O
well	O
as	O
to	O
investigate	O
characteristics	O
of	O
the	O
disease	O
in	O
naturally	O
occurring	O
circumstances	O
throughout	O
the	O
first	O
month	O
of	O
life	O
.	O

Five	O
hundred	O
fifty-two	O
fecal	O
samples	O
were	O
taken	O
from	O
56	O
calves	O
,	O
28	O
from	O
each	O
farm	O
and	O
,	O
in	O
the	O
vaccinated	O
herd	O
,	O
11/281	O
samples	O
(	O
3.91	O
%	O
)	O
taken	O
from	O
six	O
different	O
calves	O
tested	O
positive	O
for	O
RVA	O
while	O
in	O
the	O
unvaccinated	O
herd	O
,	O
3/271	O
samples	O
(	O
1.11	O
%	O
)	O
taken	O
from	O
3	O
different	O
calves	O
tested	O
positive	O
.	O

The	O
genotyping	B-P
of	O
the	O
VP7	O
genes	O
showed	O
91.2	O
%	O
nucleotide	O
sequence	O
identity	O
to	O
G6	O
genotype	O
(	O
NCDV	O
strain	O
)	O
,	O
and	O
for	O
the	O
VP4	O
gene	O
,	O
strains	O
from	O
the	O
vaccinated	O
herd	O
were	O
96.6	O
%	O
related	O
to	O
B223	O
strain	O
,	O
while	O
strains	O
from	O
the	O
unvaccinated	O
herd	O
were	O
88	O
%	O
related	O
to	O
P	O
[	O
5	O
]	O
genotype	O
(	O
UK	O
strain	O
)	O
.	O

Genotypes	O
found	O
in	O
this	O
study	O
were	O
G6P	O
[	O
11	O
]	O
in	O
the	O
vaccinated	O
herd	O
and	O
G6P	O
[	O
5	O
]	O
in	O
the	O
unvaccinated	O
herd	O
.	O

All	O
calves	O
infected	O
with	O
rotavirus	O
presented	O
an	O
episode	O
of	O
diarrhea	O
in	O
the	O
first	O
month	O
of	O
life	O
,	O
and	O
the	O
discrepancy	O
between	O
the	O
genotypes	O
found	O
in	O
the	O
commercial	O
vaccine	O
(	O
G6P	O
[	O
1	O
]	O
and	O
G10P	O
[	O
11	O
]	O
)	O
and	O
the	O
rotavirus	O
strains	O
circulating	O
in	O
both	O
vaccinated	O
and	O
unvaccinated	O
herds	O
show	O
the	O
importance	O
of	O
keeping	O
constant	O
surveillance	O
in	O
order	O
to	O
avoid	O
potential	O
causes	O
of	O
vaccination	O
failure	O
.	O

Comparative	O
Evaluation	O
for	O
Brain	O
Structural	O
Connectivity	O
Approaches	O
:	O
Towards	O
Integrative	O
Neuroinformatics	O
Tool	O
for	O
Epilepsy	O
Clinical	O
Research	O
.	O

Recent	O
advances	O
in	O
brain	O
fiber	O
tractography	O
algorithms	O
and	O
diffusion	B-P
Magnetic	I-P
Resonance	I-P
Imaging	I-P
(	O
MRI	B-P
)	O
data	O
collection	O
techniques	O
are	O
providing	O
new	O
approaches	O
to	O
study	O
brain	O
white	O
matter	O
connectivity	O
,	O
which	O
play	O
an	O
important	O
role	O
in	O
complex	O
neurological	O
disorders	O
such	O
as	O
epilepsy	O
.	O

Epilepsy	O
affects	O
approximately	O
50	O
million	O
persons	O
worldwide	O
and	O
it	O
is	O
often	O
described	O
as	O
a	O
disorder	O
of	O
the	O
cortical	O
network	O
organization	O
.	O

There	O
is	O
growing	O
recognition	O
of	O
the	O
need	O
to	O
better	O
understand	O
the	O
role	O
of	O
brain	O
structural	O
networks	O
in	O
the	O
onset	O
and	O
propagation	O
of	O
seizures	O
in	O
epilepsy	O
using	O
high	B-P
resolution	I-P
non-invasive	I-P
imaging	I-P
technologies	I-P
.	O

In	O
this	O
paper	O
,	O
we	O
perform	O
a	O
comparative	O
evaluation	O
of	O
two	O
techniques	B-P
to	O
compute	O
structural	O
connectivity	O
,	O
namely	O
probabilistic	O
fiber	O
tractography	O
and	O
statistics	O
derived	O
from	O
fractional	B-P
anisotropy	I-P
(	O
FA	B-P
)	O
,	O
using	O
diffusion	B-P
MRI	I-P
data	O
from	O
a	O
patient	O
with	O
rare	O
case	O
of	O
medically	O
intractable	O
insular	O
epilepsy	O
.	O

The	O
results	O
of	O
our	O
evaluation	O
demonstrate	O
that	O
probabilistic	O
fiber	O
tractography	O
provides	O
a	O
more	O
accurate	O
map	O
of	O
structural	O
connectivity	O
and	O
may	O
help	O
address	O
inherent	O
complexities	O
of	O
neural	O
fiber	O
layout	O
in	O
the	O
brain	O
,	O
such	O
as	O
fiber	O
crossings	O
.	O

This	O
work	O
provides	O
an	O
initial	O
result	O
towards	O
building	O
an	O
integrative	O
informatics	O
tool	O
for	O
neuroscience	O
that	O
can	O
be	O
used	O
to	O
accurately	O
characterize	O
the	O
role	O
of	O
fiber	O
tract	O
connectivity	O
in	O
neurological	O
disorders	O
such	O
as	O
epilepsy	O
.	O

Optimizing	O
Prone	O
Cardiopulmonary	O
Resuscitation	O
:	O
Identifying	O
the	O
Vertebral	O
Level	O
Correlating	O
With	O
the	O
Largest	O
Left	O
Ventricle	O
Cross-Sectional	O
Area	O
via	O
Computed	B-P
Tomography	I-P
Scan	I-P
.	O

Placing	O
the	O
patient	O
in	O
the	O
prone	O
position	O
frequently	O
is	O
required	O
for	O
some	O
surgical	O
procedures	O
.	O

If	O
cardiac	O
arrest	O
occurs	O
and	O
the	O
patient	O
can	O
not	O
be	O
safely	O
turned	O
supine	O
,	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	O
)	O
may	O
need	O
to	O
be	O
performed	O
with	O
the	O
patient	O
in	O
the	O
prone	O
position	O
.	O

Although	O
clear	O
landmarks	O
have	O
been	O
defined	O
for	O
supine	O
CPR	O
,	O
the	O
optimal	O
hand	O
position	O
for	O
CPR	O
in	O
the	O
prone	O
position	O
has	O
not	O
been	O
clearly	O
determined	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
anatomically	O
the	O
optimal	O
hand	O
position	O
for	O
CPR	O
in	O
the	O
prone	O
position	O
.	O

We	O
reviewed	O
retrospectively	O
the	O
chest	B-P
computed	I-P
tomography	I-P
images	O
of	O
100	O
patients	O
taken	O
in	O
the	O
prone	O
position	O
.	O

The	O
vertebral	O
body	O
levels	O
crossing	O
the	O
medial	O
angle	O
of	O
the	O
scapula	O
,	O
the	O
inferior	O
angle	O
of	O
the	O
scapula	O
,	O
and	O
the	O
spinous	O
process	O
of	O
the	O
vertebral	O
body	O
connected	O
to	O
the	O
most	O
inferior	O
rib	O
were	O
identified	O
,	O
and	O
we	O
selected	O
the	O
image	O
level	O
at	O
which	O
the	O
left	O
ventricular	O
(	O
LV	O
)	O
cross-sectional	O
area	O
was	O
the	O
largest	O
.	O

This	O
level	O
was	O
defined	O
as	O
the	O
optimal	O
compression	O
level	O
and	O
correlated	O
to	O
surface	O
anatomical	O
landmarks	O
.	O

We	O
calculated	B-P
the	O
ratio	O
of	O
the	O
distance	O
from	O
the	O
C7	O
spinous	O
process	O
to	O
the	O
level	O
of	O
the	O
largest	O
LV	O
cross-sectional	O
area	O
divided	O
by	O
the	O
distance	O
from	O
the	O
C7	O
spinous	O
process	O
to	O
the	O
spinous	O
process	O
of	O
the	O
vertebral	O
body	O
connected	O
with	O
the	O
most	O
inferior	O
rib	O
.	O

The	O
level	O
of	O
the	O
largest	O
LV	O
cross-sectional	O
area	O
in	O
the	O
prone	O
position	O
was	O
1	O
vertebral	O
segment	O
below	O
the	O
inferior	O
angle	O
of	O
the	O
scapula	O
in	O
45	O
%	O
(	O
99	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
33-58	O
)	O
of	O
patients	O
and	O
0	O
to	O
2	O
vertebral	O
segments	O
below	O
that	O
in	O
95	O
%	O
(	O
99	O
%	O
CI	O
,	O
86-98	O
)	O
of	O
patients	O
.	O

The	O
mean	O
(	O
SD	O
)	O
ratio	O
of	O
the	O
distance	O
from	O
the	O
C7	O
spinous	O
process	O
to	O
the	O
level	O
of	O
the	O
largest	O
LV	O
cross-sectional	O
area	O
divided	O
by	O
the	O
distance	O
from	O
the	O
C7	O
spinous	O
process	O
to	O
T12	O
spinous	O
process	O
was	O
67	O
%	O
±	O
7	O
%	O
(	O
99	O
%	O
CI	O
,	O
65-69	O
)	O
.	O

When	O
the	O
patient	O
is	O
positioned	O
prone	O
,	O
the	O
largest	O
LV	O
cross-sectional	O
area	O
is	O
0	O
to	O
2	O
vertebral	O
segments	O
below	O
the	O
inferior	O
angle	O
of	O
the	O
scapula	O
in	O
at	O
least	O
86	O
%	O
of	O
patients	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
whether	O
this	O
position	O
is	O
optimal	O
for	O
chest	O
compressions	O
in	O
the	O
prone	O
position	O
.	O

Transcriptional	O
analysis	O
of	O
blaNDM-1	O
and	O
copy	O
number	O
alteration	O
under	O
carbapenem	O
stress	O
.	O

New	O
Delhi	O
metallo	O
beta-lactamase	O
is	O
known	O
to	O
compromise	O
carbapenem	O
therapy	O
and	O
leading	O
to	O
treatment	O
failure	O
.	O

However	O
,	O
their	O
response	O
to	O
carbapenem	O
stress	O
is	O
not	O
clearly	O
known	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
transcriptional	O
response	O
of	O
blaNDM-1	O
and	O
plasmid	O
copy	O
number	O
alteration	O
under	O
carbapenem	O
exposure	O
.	O

Three	O
blaNDM-1	O
harboring	O
plasmids	O
representing	O
three	O
incompatibility	O
types	O
(	O
IncFIC	O
,	O
IncA/C	O
and	O
IncK	O
)	O
were	O
inoculated	O
in	O
LB	O
broth	O
with	O
and	O
without	O
imipenem	O
,	O
meropenem	O
and	O
ertapenem	O
.	O

After	O
each	O
1	O
h	O
total	O
RNA	O
was	O
isolated	O
,	O
immediately	O
reverse	O
transcribed	O
into	O
cDNA	O
and	O
quantitative	O
real	O
time	O
PCR	O
was	O
used	O
for	O
transcriptional	O
expression	O
of	O
blaNDM-1	O
.	O

Horizontal	O
transferability	O
and	O
stability	O
of	O
the	O
plasmids	O
encoding	O
blaNDM-1	O
were	O
also	O
determined	O
.	O

Changes	O
in	O
copy	O
number	O
of	O
blaNDM-1	O
harboring	O
plasmids	O
under	O
the	O
exposure	O
of	O
different	O
carbapenems	O
were	O
determined	O
by	O
real	O
time	O
PCR	O
.	O

Clonal	O
relatedness	O
among	O
the	O
isolates	O
was	O
determined	O
by	O
pulsed	B-P
field	I-P
gel	I-P
electrophoresis	I-P
.	O

Under	O
carbapenem	O
stress	O
over	O
an	O
interval	O
of	O
time	O
there	O
was	O
a	O
sharp	O
variation	O
in	O
the	O
transcriptional	O
expression	O
of	O
blaNDM-1	O
although	O
it	O
did	O
not	O
follow	O
a	O
specific	O
pattern	O
.	O

All	O
blaNDM-1	O
carrying	O
plasmids	O
were	O
transferable	O
by	O
conjugation	O
.	O

These	O
plasmids	O
were	O
highly	O
stable	O
and	O
complete	O
loss	O
was	O
observed	O
between	O
92	O
(	O
nd	O
)	O
to	O
96	O
(	O
th	O
)	O
serial	O
passages	O
when	O
antibiotic	O
pressure	O
was	O
withdrawn	O
.	O

High	O
copy	O
number	O
of	O
blaNDM-1	O
was	O
found	O
for	O
IncF	O
type	O
plasmids	O
compared	O
to	O
the	O
other	O
replicon	O
types	O
.	O

This	O
study	O
suggests	O
that	O
the	O
single	O
dose	O
of	O
carbapenem	O
pressure	O
does	O
not	O
significantly	O
influence	O
the	O
expression	O
of	O
blaNDM-1	O
and	O
also	O
focus	O
on	O
the	O
stability	O
of	O
this	O
gene	O
as	O
well	O
as	O
the	O
change	O
in	O
copy	O
number	O
with	O
respect	O
to	O
the	O
incompatible	O
type	O
of	O
plasmid	O
harboring	O
resistance	O
determinant	O
.	O

Multiparametric	O
estimation	O
of	O
brain	O
hemodynamics	O
with	O
MR	B-P
fingerprinting	I-P
ASL	I-P
.	O

Assessment	O
of	O
brain	O
hemodynamics	O
without	O
exogenous	O
contrast	O
agents	O
is	O
of	O
increasing	O
importance	O
in	O
clinical	O
applications	O
.	O

This	O
study	O
aims	O
to	O
develop	O
an	O
MR	B-P
perfusion	I-P
technique	I-P
that	O
can	O
provide	O
noncontrast	O
and	O
multiparametric	O
estimation	O
of	O
hemodynamic	O
markers	O
.	O

We	O
devised	O
an	O
arterial	B-P
spin	I-P
labeling	I-P
(	O
ASL	B-P
)	O
method	O
based	O
on	O
the	O
principle	O
of	O
MR	B-P
fingerprinting	I-P
(	O
MRF	B-P
)	O
,	O
referred	O
to	O
as	O
MRF-ASL	B-P
.	O

By	O
taking	O
advantage	O
of	O
the	O
rich	O
information	O
contained	O
in	O
MRF	B-P
sequence	I-P
,	O
up	O
to	O
seven	O
hemodynamic	O
parameters	O
can	O
be	O
estimated	O
concomitantly	O
.	O

Feasibility	O
demonstration	O
,	O
flip	O
angle	O
optimization	O
,	O
comparison	O
with	O
Look-Locker	B-P
ASL	I-P
,	O
reproducibility	O
test	O
,	O
sensitivity	O
to	O
hypercapnia	O
challenge	O
,	O
and	O
initial	O
clinical	O
application	O
in	O
an	O
intracranial	O
steno-occlusive	O
process	O
,	O
Moyamoya	O
disease	O
,	O
were	O
performed	O
to	O
evaluate	O
this	O
technique	O
.	O

Magnetic	B-P
resonance	I-P
fingerprinting	I-P
ASL	I-P
provided	O
estimation	O
of	O
up	O
to	O
seven	O
parameters	O
,	O
including	O
B1+	O
,	O
tissue	O
T1	O
,	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
,	O
tissue	O
bolus	O
arrival	O
time	O
(	O
BAT	O
)	O
,	O
pass-through	O
arterial	O
BAT	O
,	O
pass-through	O
blood	O
volume	O
,	O
and	O
pass-through	O
blood	B-P
travel	I-P
time	I-P
.	O

Coefficients	O
of	O
variation	O
of	O
the	O
estimated	O
parameters	O
ranged	O
from	O
0.2	O
to	O
9.6	O
%	O
.	O

Hypercapnia	O
resulted	O
in	O
an	O
increase	O
in	O
CBF	O
by	O
57.7	O
%	O
,	O
and	O
a	O
decrease	O
in	O
BAT	O
by	O
13.7	O
and	O
24.8	O
%	O
in	O
tissue	O
and	O
vessels	O
,	O
respectively	O
.	O

Patients	O
with	O
Moyamoya	O
disease	O
showed	O
diminished	O
CBF	O
and	O
lengthened	O
BAT	O
that	O
could	O
not	O
be	O
detected	O
with	O
regular	O
ASL	B-P
.	O

Magnetic	B-P
resonance	I-P
fingerprinting	I-P
ASL	I-P
is	O
a	O
promising	O
technique	O
for	O
noncontrast	O
,	O
multiparametric	O
perfusion	O
assessment	O
.	O

Magn	O
Reson	O
Med	O
,	O
2016	O
.	O

©	O
2016	O
International	O
Society	O
for	O
Magnetic	O
Resonance	O
in	O
Medicine	O
.	O

Engineering	O
anisotropic	O
biphasic	O
Janus-type	O
polymer	O
nanofiber	O
scaffold	O
networks	O
via	O
centrifugal	O
jet	O
spinning	O
.	O

Biphasic	O
materials	O
,	O
comprised	O
of	O
an	O
ordered	O
arrangement	O
of	O
two	O
different	O
material	O
phases	O
within	O
a	O
material	O
,	O
have	O
the	O
potential	O
for	O
a	O
wide	O
variety	O
of	O
applications	O
including	O
filtration	O
,	O
protective	O
clothing	O
and	O
tissue	O
engineering	O
.	O

This	O
study	O
reports	O
for	O
the	O
first	O
time	O
,	O
a	O
process	O
for	O
engineering	O
biphasic	O
Janus-type	O
polymeric	O
nanofiber	O
(	O
BJPNF	O
)	O
networks	O
via	O
the	O
centrifugal	O
jet	O
spinning	O
technique	O
.	O

BJPNF	O
alignment	O
and	O
fiber	O
diameter	O
was	O
dependent	O
on	O
fabrication	O
rotational	O
speed	O
as	O
well	O
as	O
solution	O
composition	O
.	O

The	O
biphasic	O
character	O
of	O
these	O
BJPNFs	O
,	O
which	O
was	O
controlled	O
via	O
the	O
rotational	O
speed	O
of	O
fabrication	O
,	O
was	O
confirmed	O
at	O
the	O
individual	O
nanofiber	O
scale	O
using	O
energy	B-P
dispersive	I-P
X-ray	I-P
spectroscopy	I-P
,	O
and	O
at	O
the	O
bulk	O
,	O
macro-scale	O
using	O
attenuated	O
total	O
reflectance	B-P
-	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
.	O

Biphasic	O
character	O
was	O
also	O
demonstrated	O
at	O
the	O
functional	O
level	O
via	O
differing	O
affinities	O
on	O
either	O
side	O
of	O
the	O
BJPNF	O
for	O
cell	O
attachment	O
.	O

Our	O
work	O
thus	O
presents	O
a	O
method	O
for	O
fabricating	O
BJPNF	O
scaffold	O
networks	O
where	O
there	O
might	O
be	O
a	O
need	O
for	O
different	O
properties	O
on	O
either	O
side	O
of	O
a	O
material	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
J	O
Biomed	O
Mater	O
Res	O
Part	O
B	O
:	O
Appl	O
Biomater	O
,	O
2016	O
.	O

A	O
novel	O
quantitative	O
PCR	O
detects	O
Babesia	O
infection	O
in	O
patients	O
not	O
identified	O
by	O
currently	O
available	O
non-nucleic	B-P
acid	I-P
amplification	I-P
tests	I-P
.	O

Ticks	O
transmit	O
Babesia	O
microti	O
,	O
the	O
causative	O
agents	O
of	O
babesiosis	O
in	O
North	O
America	O
and	O
Europe	O
.	O

Babesiosis	O
is	O
now	O
endemic	O
in	O
Northeastern	O
USA	O
and	O
affects	O
people	O
of	O
all	O
ages	O
.	O

Babesia	O
species	O
infect	O
erythrocytes	O
and	O
can	O
be	O
transmitted	O
through	O
blood	O
transfusion	O
.	O

Whole	O
blood	O
and	O
blood	O
products	O
,	O
which	O
are	O
not	O
tested	O
for	O
Babesia	O
,	O
can	O
cause	O
transfusion	O
-	O
transmitted	O
babesiosis	O
(	O
TTB	O
)	O
resulting	O
in	O
severe	O
consequences	O
in	O
the	O
immuno-compromised	O
patients	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
epidemiological	O
evaluation	O
of	O
babesiosis	O
in	O
a	O
tick-infested	O
state	O
.	O

We	O
examined	O
blood	O
samples	O
from	O
192	O
patients	O
who	O
visited	O
clinics	O
during	O
the	O
active	O
tick-borne	O
diseases	O
season	O
,	O
using	O
a	O
newly	O
developed	O
qPCR	O
assay	O
that	O
uses	O
the	O
specific	O
molecular	O
beacon	O
probe	O
.	O

Due	O
to	O
the	O
absence	O
of	O
clear	O
symptomology	O
,	O
clinical	O
laboratories	O
did	O
not	O
test	O
131	O
samples	O
by	O
IFA	B-P
,	O
FISH	O
or	O
microscopic	B-P
examination	I-P
of	O
Giemsa-stained	O
blood	B-P
smears	I-P
.	O

Babesia	O
infection	O
was	O
detected	O
in	O
all	O
age	O
groups	O
by	O
FISH	O
and	O
microscopy	B-P
;	O
notably	O
patients	O
>	O
40	O
years	O
of	O
age	O
represented	O
64	O
%	O
of	O
tested	O
samples	O
and	O
13	O
%	O
were	O
younger	O
patients	O
.	O

We	O
tested	O
all	O
samples	O
using	O
qPCR	O
and	O
found	O
that	O
38	O
%	O
were	O
positive	O
for	O
Babesia	O
.	O

Of	O
28	O
samples	O
that	O
were	O
positive	O
by	O
FISH	O
,	O
27	O
(	O
96	O
%	O
)	O
were	O
also	O
positive	O
by	O
qPCR	O
indicating	O
high	O
congruency	O
between	O
nucleic	B-P
acid	I-P
based	I-P
tests	I-P
.	O

Interestingly	O
,	O
of	O
78	O
asymptomatic	O
samples	O
not	O
tested	O
by	O
FISH	O
,	O
22	O
were	O
positive	O
by	O
our	O
qPCR	O
.	O

Direct	O
detection	O
of	O
Babesia	O
relies	O
upon	O
microscopic	B-P
examination	I-P
of	O
patient	O
blood	B-P
smears	I-P
,	O
which	O
is	O
labor	O
intensive	O
,	O
difficult	O
to	O
scale	O
up	O
,	O
requires	O
specific	O
expertise	O
and	O
is	O
hence	O
,	O
often	O
not	O
performed	O
.	O

In	O
fact	O
,	O
a	O
clinical	O
laboratory	O
examined	O
only	O
23	O
of	O
86	O
blood	O
samples	O
obtained	O
from	O
two	O
different	O
counties	O
by	O
microscopy	B-P
.	O

By	O
considering	O
individuals	O
positive	O
for	O
Babesia	O
infection	O
when	O
results	O
from	O
currently	O
available	O
microscopy	B-P
,	O
FISH	O
or	O
serological	B-P
tests	I-P
were	O
positive	O
,	O
we	O
found	O
that	O
our	O
qPCR	O
is	O
highly	O
sensitive	O
(	O
96.2	O
%	O
)	O
and	O
showed	O
a	O
specificity	O
of	O
70.5	O
%	O
for	O
Babesia	O
.	O

Robust	O
qPCR	O
using	O
specific	O
probes	O
can	O
be	O
highly	O
useful	O
for	O
efficient	O
and	O
appropriate	O
diagnosis	O
of	O
babesiosis	O
in	O
patients	O
in	O
conjunction	O
with	O
conventional	O
diagnostics	O
,	O
or	O
as	O
a	O
stand-alone	O
test	O
,	O
especially	O
for	O
donated	O
blood	B-P
screening	I-P
.	O

The	O
use	O
of	O
a	O
nucleic	B-P
acid	I-P
amplification	I-P
test	I-P
based	O
screening	B-P
of	I-P
blood	I-P
and	O
blood	O
products	O
could	O
prevent	O
TTB	O
.	O

Rational	O
use	O
of	O
rasburicase	O
for	O
the	O
treatment	O
and	O
management	O
of	O
tumor	O
lysis	O
syndrome	O
.	O

Purpose	O
There	O
is	O
a	O
lack	O
of	O
high-level	O
evidence	O
identifying	O
meaningful	O
outcomes	O
and	O
the	O
optimal	O
place	O
in	O
therapy	O
of	O
rasburicase	O
in	O
patients	O
with	O
,	O
or	O
at	O
high	O
risk	O
for	O
tumor	O
lysis	O
syndrome	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
characterize	O
outcomes	O
resulting	O
from	O
an	O
institution-specific	O
guideline	O
emphasizing	O
supportive	O
care	O
,	O
xanthine	O
oxidase	O
inhibitors	O
,	O
and	O
lower	O
doses	O
of	O
rasburicase	O
.	O

Methods	O
In	O
this	O
retrospective	O
chart	O
review	O
,	O
we	O
compared	O
conservative	O
rasburicase	O
dosing	O
,	O
in	O
accordance	O
with	O
newly	O
developed	O
UMHS	O
tumor	O
lysis	O
syndrome	O
guidelines	O
,	O
with	O
aggressive	O
rasburicase	O
in	O
adult	O
patients	O
(	O
≥	O
18	O
years	O
of	O
age	O
)	O
with	O
hematological	O
or	O
solid	O
tumor	O
malignancies	O
,	O
and	O
a	O
uric	B-P
acid	I-P
level	I-P
between	O
8	O
and	O
15	O
mg/dL	O
.	O

The	O
primary	O
efficacy	O
outcome	O
assessed	O
the	O
difference	O
in	O
the	O
proportion	O
of	O
patients	O
achieving	O
a	O
uric	B-P
acid	I-P
level	I-P
<	O
8	O
mg/dL	O
within	O
48	O
h	O
using	O
a	O
one-sided	O
noninferiority	O
test	O
.	O

The	O
principle	O
safety	O
outcomes	O
analyzed	O
included	O
incidence	O
of	O
acute	O
kidney	O
injury	O
and	O
hemodialysis	O
requirement	O
.	O

Results	O
One	O
hundred	O
sixty-one	O
patients	O
met	O
inclusion	O
criteria	O
and	O
were	O
included	O
in	O
the	O
study	O
.	O

Within	O
48	O
h	O
of	O
an	O
elevated	O
uric	O
acid	O
level	O
,	O
treatment	O
was	O
successful	O
in	O
97.03	O
%	O
of	O
patients	O
in	O
the	O
conservative	O
group	O
,	O
as	O
compared	O
with	O
98.33	O
%	O
in	O
the	O
aggressive	O
group	O
(	O
difference	O
,	O
1.3	O
percentage	O
points	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
-3.33	O
to	O
5.93	O
)	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
proportion	O
of	O
patients	O
requiring	O
hemodialysis	O
(	O
2.97	O
%	O
vs.	O
10.0	O
%	O
,	O
p-value	O
0.079	O
)	O
,	O
or	O
incidence	O
of	O
acute	O
kidney	O
injury	O
(	O
4.0	O
%	O
vs.	O
12.5	O
%	O
,	O
p-value	O
1.00	O
)	O
between	O
the	O
treatment	O
group	O
and	O
control	O
group	O
,	O
respectively	O
.	O

Conclusions	O
Conservative	O
rasburicase	O
use	O
was	O
noninferior	O
to	O
aggressive	O
rasburicase	O
use	O
in	O
patients	O
with	O
or	O
at	O
high	O
risk	O
for	O
tumor	O
lysis	O
syndrome	O
.	O

Comparative	O
analysis	O
of	O
macular	O
and	O
peripapillary	O
retinal	O
nerve	O
fiber	O
layer	O
thickness	O
in	O
normal	O
,	O
glaucoma	O
suspect	O
and	O
glaucomatous	O
eyes	O
by	O
optical	B-P
coherence	I-P
tomography	I-P
.	O

Peripapillary	O
retinal	O
nerve	O
fiber	O
layer	O
(	O
RNFL	O
)	O
thickness	O
analysis	O
is	O
a	O
subjective	B-P
method	I-P
of	I-P
analysis	I-P
of	O
glaucomatous	O
damage	O
.	O

As	O
almost	O
50	O
%	O
of	O
retinal	O
ganglion	O
cells	O
are	O
located	O
in	O
the	O
macula	O
,	O
assessment	O
of	O
macular	O
thickness	O
can	O
be	O
an	O
alternative	O
method	O
for	O
diagnosis	O
of	O
glaucoma	O
.	O

To	O
evaluate	O
the	O
changes	O
in	O
macular	O
and	O
retinal	O
nerve	O
fiber	O
layer	O
thickness	O
in	O
controls	O
,	O
glaucoma	O
suspects	O
and	O
glaucoma	O
patients	O
using	O
time	B-P
domain	I-P
optical	I-P
coherence	I-P
tomography	I-P
(	O
TD-OCT	B-P
)	O
.	O

Macular	O
and	O
peripapillary	O
RNFL	O
scans	B-P
were	O
performed	O
in	O
one	O
eye	O
of	O
70	O
controls	O
,	O
35	O
glaucoma	O
suspect	O
s	O
and	O
70	O
glaucoma	O
patients	O
by	O
TD-OCT	B-P
.	O

The	O
discriminating	O
power	O
of	O
each	O
parameter	O
between	O
the	O
groups	O
was	O
determined	O
by	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
(	O
AROC	O
)	O
curve	O
.	O

The	O
correlation	O
of	O
macula	O
r	O
thickness	O
and	O
RNFL	O
thickness	O
parameters	O
with	O
global	O
field	O
indices	O
were	O
also	O
performed	O
.	O

P-value	O
of	O
less	O
than	O
0.05	O
was	O
considered	O
statistically	O
significant	O
.	O

The	O
differences	O
in	O
all	O
the	O
macula	O
r	O
thickness	O
parameters	O
between	O
the	O
groups	O
were	O
statistically	O
significant	O
(	O
pless	O
than	O
0.05	O
)	O
except	O
foveal	O
thickness	O
(	O
FT	O
)	O
and	O
nasal	O
inner	O
(	O
NI	O
)	O
quadrant	O
thickness	O
.	O

The	O
temporal	O
outer	O
(	O
TO	O
)	O
macular	O
quadrant	O
produced	O
largest	O
AROC	O
curve	O
of	O
0.90	O
between	O
controls	O
and	O
glaucoma	O
patients	O
.	O

The	O
differences	O
in	O
all	O
the	O
RNFL	O
thickness	O
parameters	O
were	O
highly	O
significant	O
between	O
the	O
groups	O
(	O
pless	O
than	O
0.001	O
)	O
.	O

The	O
AROC	O
curve	O
between	O
control	O
group	O
and	O
glaucoma	O
patients	O
for	O
RNFL	O
average	O
thickness	O
was	O
0.99	O
.	O

Macular	O
thickness	O
as	O
detected	O
by	O
TD-OCT	B-P
had	O
high	O
discriminating	O
power	O
between	O
controls	O
,	O
glaucoma	O
suspects	O
and	O
glaucoma	O
patients	O
comparable	O
with	O
peripapillary	O
RNFL	O
thickness	O
parameters	O
.	O

Short-term	O
Variability	O
of	O
Vitamin	O
D	O
-Related	O
Biomarkers	O
.	O

Quantifying	O
the	O
variability	O
of	O
biomarkers	O
is	O
important	O
,	O
as	O
high	O
within-person	O
variability	O
can	O
lead	O
to	O
misclassification	O
of	O
individuals	O
.	O

Short-term	O
variability	O
of	O
important	O
markers	O
of	O
vitamin	O
D	O
metabolism	O
is	O
relatively	O
unknown	O
.	O

A	O
repeatability	O
study	O
was	O
conducted	O
in	O
160	O
Atherosclerosis	O
Risk	O
in	O
Communities	O
study	O
participants	O
(	O
60	O
%	O
female	O
,	O
28	O
%	O
black	O
,	O
mean	O
age	O
76	O
years	O
)	O
.	O

Fasting	O
serum	O
was	O
drawn	O
at	O
2	O
time	O
points	O
,	O
a	O
median	O
of	O
6	O
(	O
range	O
3-13	O
)	O
weeks	O
apart	O
.	O

Vitamin	O
D	O
binding	O
protein	O
(	O
VDBP	O
)	O
and	O
25-hydroxyvitamin	O
D	O
[	O
25	O
(	O
OH	O
)	O
D	O
]	O
were	O
measured	O
by	O
LC-MS	B-P
,	O
fibroblast	O
growth	O
factor	O
(	O
FGF23	O
)	O
and	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
by	O
enzyme-linked	B-P
immunoassay	I-P
,	O
and	O
calcium	O
and	O
phosphorus	O
by	O
Roche	B-P
Cobas	I-P
6000	I-P
.	O

Free	O
and	O
bioavailable	O
25	O
(	O
OH	O
)	O
D	O
were	O
calculated	O
.	O

We	O
calculated	O
the	O
within-person	O
CV	O
(	O
CVW	O
)	O
,	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
,	O
Spearman	O
rank	O
correlation	O
coefficient	O
(	O
r	O
)	O
,	O
and	O
percent	O
reclassified	O
.	O

The	O
CVW	O
was	O
lowest	O
for	O
calcium	O
(	O
2.0	O
%	O
)	O
,	O
albumin	O
(	O
3.6	O
%	O
)	O
,	O
25	O
(	O
OH	O
)	O
D	O
(	O
6.9	O
%	O
)	O
,	O
VDBP	O
(	O
7.0	O
%	O
)	O
and	O
phosphorus	O
(	O
7.6	O
%	O
)	O
;	O
intermediate	O
for	O
free	O
25	O
(	O
OH	O
)	O
D	O
(	O
9.0	O
%	O
)	O
and	O
bioavailable	O
25	O
(	O
OH	O
)	O
D	O
(	O
9.9	O
%	O
)	O
;	O
and	O
highest	O
for	O
PTH	O
(	O
16.7	O
%	O
)	O
and	O
FGF23	O
(	O
17.8	O
%	O
)	O
.	O

Reclassification	O
was	O
highest	O
for	O
PTH	O
,	O
VDBP	O
,	O
and	O
phosphorus	O
(	O
all	O
7.5	O
%	O
)	O
.	O

The	O
ICC	O
and	O
r	O
were	O
highest	O
(	O
≥0.80	O
)	O
for	O
25	O
(	O
OH	O
)	O
D	O
,	O
free	O
25	O
(	O
OH	O
)	O
D	O
,	O
bioavailable	O
25	O
(	O
OH	O
)	O
D	O
and	O
PTH	O
,	O
but	O
somewhat	O
lower	O
(	O
approximately	O
0.60-0.75	O
)	O
for	O
the	O
other	O
biomarkers	O
.	O

Six-	O
week	O
short-term	O
variability	O
,	O
as	O
assessed	O
by	O
CVW	O
,	O
was	O
quite	O
low	O
for	O
VDBP	O
,	O
calcium	O
and	O
phosphorus	O
,	O
but	O
fairly	O
high	O
for	O
FGF23	O
and	O
PTH	O
.	O

As	O
such	O
,	O
multiple	O
measurements	O
of	O
FGF23	O
and	O
PTH	O
may	O
be	O
needed	O
to	O
minimize	O
misclassification	O
.	O

These	O
results	O
provide	O
insight	O
into	O
the	O
extent	O
of	O
potential	O
misclassification	O
of	O
vitamin	O
D	O
markers	O
in	O
research	O
and	O
clinical	O
settings	O
.	O

A	O
rare	O
cause	O
of	O
gastric	O
obstruction	O
:	O
Lighters	O
swallowing	O
.	O

The	O
majority	O
of	O
swallowed	O
foreign	O
bodies	O
are	O
thrown	O
spontaneously	O
without	O
causing	O
complications	O
in	O
the	O
digestive	O
system	O
.	O

Multiple	O
number	O
of	O
foreign	O
bodies	O
may	O
be	O
swallowed	O
by	O
psychiatric	O
patients	O
which	O
delay	O
diagnosis	O
and	O
increase	O
the	O
complication	O
rate	O
.	O

Long	O
and	O
hard	O
objects	O
can	O
not	O
pass	O
through	O
the	O
pylorus	O
,	O
and	O
may	O
cause	O
obstruction	O
,	O
ulceration	O
,	O
bleeding	O
and	O
perforation	O
.	O

Endoscopy	B-P
is	O
used	O
as	O
an	O
effective	O
method	O
in	O
such	O
cases	O
.	O

An	O
exploratory	B-P
laparatomy	I-P
was	O
performed	O
after	O
unsuccessful	O
endoscopic	O
foreign	O
object	O
removal	O
in	O
a	O
28-year-old	O
schizophrenic	O
patient	O
with	O
gastric	O
outlet	O
obstruction	O
due	O
to	O
multiple	O
cigarette	O
lighter	O
swallowing	O
.	O

Ten	O
lighters	O
were	O
removed	O
from	O
the	O
stomach	O
through	O
gastrotomy	O
and	O
one	O
more	O
lighter	O
was	O
removed	O
from	O
the	O
descending	O
colon	O
by	O
milking	O
through	O
the	O
anus	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
discuss	O
encountered	O
difficulties	O
in	O
psychiatric	O
patients	O
who	O
underwent	O
surgery	O
due	O
to	O
intake	O
of	O
foreign	O
bodies	O
.	O

Helicobacter	O
pylori	O
prevalence	O
and	O
clinical	O
significance	O
in	O
patients	O
with	O
quiescent	O
Crohn	O
's	O
disease	O
.	O

Helicobacter	O
pylori	O
(	O
HP	O
)	O
infection	O
is	O
present	O
in	O
about	O
50	O
%	O
of	O
the	O
global	O
population	O
,	O
and	O
is	O
associated	O
with	O
chronic	O
gastritis	O
,	O
peptic	O
disease	O
and	O
gastric	O
malignancies	O
.	O

HP	O
prevalence	O
in	O
Crohn	O
's	O
disease	O
(	O
CD	O
)	O
patients	O
was	O
shown	O
to	O
be	O
low	O
compared	O
to	O
the	O
general	O
population	O
,	O
and	O
its	O
influence	O
on	O
disease	B-P
activity	I-P
is	O
yet	O
to	O
be	O
determined	O
.	O

Our	O
aims	O
were	O
to	O
determine	O
the	O
prevalence	O
of	O
HP	O
in	O
a	O
selected	O
group	O
of	O
CD	O
patients	O
with	O
quiescent	O
disease	O
,	O
and	O
to	O
assess	O
the	O
influence	O
of	O
its	O
eradication	O
on	O
disease	B-P
activity	I-P
and	O
endoscopic	B-P
and	O
laboratory	B-P
activity	I-P
measures	I-P
.	O

Consecutive	O
CD	O
patients	O
with	O
quiescent	O
disease	O
underwent	O
meticulous	O
disease	O
evaluation	O
with	O
MR	B-P
enterography	I-P
(	O
MRE	B-P
)	O
,	O
video	B-P
capsule	I-P
endoscopy	I-P
(	O
VCE	B-P
)	O
,	O
CRP	B-P
,	O
fecal	B-P
calprotectin	I-P
and	O
CDAI	O
.	O

All	O
patients	O
were	O
tested	O
for	O
the	O
presence	O
of	O
HP	O
using	O
stool	B-P
antigen	I-P
detection	I-P
kit	I-P
.	O

Patients	O
infected	O
with	O
HP	O
were	O
offered	O
eradication	O
treatment	O
with	O
sequential	O
therapy	O
.	O

HP	O
eradication	O
was	O
confirmed	O
using	O
urease	B-P
breath	I-P
test	I-P
and	O
stool	B-P
antigen	I-P
test	I-P
.	O

The	O
influence	O
of	O
HP	O
eradication	O
on	O
disease	B-P
activity	I-P
was	O
assessed	O
.	O

Out	O
of	O
56	O
patients	O
enrolled	O
,	O
six	O
patients	O
(	O
10.7	O
%	O
)	O
had	O
HP	O
infection	O
.	O

Of	O
them	O
,	O
five	O
patients	O
had	O
gastro-	O
duodenitis	O
per	O
VCE	B-P
.	O

All	O
HP	O
positive	O
patients	O
were	O
offered	O
eradication	O
treatment	O
and	O
underwent	O
successful	O
eradication	O
.	O

Notably	O
,	O
23	O
(	O
50	O
%	O
)	O
of	O
patients	O
had	O
proximal	O
disease	O
per	O
VCE	B-P
,	O
most	O
of	O
them	O
(	O
78	O
%	O
)	O
were	O
HP	O
negative	O
.	O

CDAI	O
,	O
CRP	B-P
,	O
fecal	B-P
calprotectin	I-P
and	O
VCE	B-P
Lewis	O
inflammatory	O
score	O
did	O
not	O
change	O
significantly	O
following	O
HP	O
eradication	O
,	O
Gastric	O
findings	O
on	O
VCE	B-P
were	O
not	O
impacted	O
by	O
HP	O
eradication	O
.	O

The	O
prevalence	O
of	O
HP	O
infection	O
in	O
patients	O
with	O
quiescent	O
CD	O
is	O
relatively	O
low	O
.	O

Eradication	O
of	O
the	O
bacteria	O
did	O
not	O
significantly	O
change	O
neither	O
disease	B-P
activity	I-P
measures	I-P
nor	O
the	O
presence	O
of	O
gastro-	O
duodenitis	O
per	O
VCE	B-P
,	O
suggesting	O
it	O
might	O
be	O
part	O
of	O
proximal	O
CD	O
.	O

The	O
influence	O
of	O
HP	O
on	O
CD	O
activity	O
merits	O
further	O
investigation	O
.	O

Abnormal	O
neural	O
precursor	O
cell	O
regulation	O
in	O
the	O
early	O
postnatal	O
Fragile	O
X	O
mouse	O
hippocampus	O
.	O

The	O
regulation	O
of	O
neural	O
precursor	O
cells	O
(	O
NPCs	O
)	O
is	O
indispensable	O
for	O
a	O
properly	O
functioning	O
brain	O
.	O

Abnormalities	O
in	O
NPC	O
proliferation	O
,	O
differentiation	O
,	O
survival	O
,	O
or	O
integration	O
have	O
been	O
linked	O
to	O
various	O
neurological	O
diseases	O
including	O
Fragile	O
X	O
syndrome	O
.	O

Yet	O
,	O
no	O
studies	O
have	O
examined	O
NPCs	O
from	O
the	O
early	O
postnatal	O
Fragile	O
X	O
mouse	O
hippocampus	O
despite	O
the	O
importance	O
of	O
this	O
developmental	O
time	O
point	O
,	O
which	O
marks	O
the	O
highest	O
expression	O
level	O
of	O
FMRP	O
,	O
the	O
protein	O
missing	O
in	O
Fragile	O
X	O
,	O
in	O
the	O
rodent	O
hippocampus	O
and	O
is	O
when	O
hippocampal	O
NPCs	O
have	O
migrated	O
to	O
the	O
dentate	O
gyrus	O
(	O
DG	O
)	O
to	O
give	O
rise	O
to	O
lifelong	O
neurogenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
NPCs	O
from	O
the	O
early	O
postnatal	O
hippocampus	O
and	O
DG	O
of	O
Fragile	O
X	O
mice	O
(	O
Fmr1	O
-	O
KO	O
)	O
.	O

Immunocytochemistry	B-P
on	O
neurospheres	O
showed	O
increased	O
Nestin	O
expression	O
and	O
decreased	O
Ki67	O
expression	O
,	O
which	O
collectively	O
indicated	O
aberrant	O
NPC	O
biology	O
.	O

Intriguingly	O
,	O
flow	B-P
cytometric	I-P
analysis	I-P
of	O
the	O
expression	O
of	O
the	O
antigens	O
CD15	O
,	O
CD24	O
,	O
CD133	O
,	O
GLAST	O
,	O
and	O
PSA-NCAM	O
showed	O
a	O
decreased	O
proportion	O
of	O
neural	O
stem	O
cells	O
(	O
GLAST	O
(	O
+	O
)	O
CD15	O
(	O
+	O
)	O
CD133	O
(	O
+	O
)	O
)	O
and	O
an	O
increased	O
proportion	O
of	O
neuroblasts	O
(	O
PSA-NCAM	O
(	O
+	O
)	O
CD15	O
(	O
+	O
)	O
)	O
in	O
the	O
DG	O
of	O
P7	O
Fmr1	O
-	O
KO	O
mice	O
.	O

This	O
was	O
mirrored	O
by	O
lower	O
expression	O
levels	O
of	O
Nestin	O
and	O
the	O
mitotic	O
marker	O
phospho-histone	O
H3	O
in	O
vivo	O
in	O
the	O
P9	O
hippocampus	O
,	O
as	O
well	O
as	O
a	O
decreased	O
proportion	O
of	O
cells	O
in	O
the	O
G2/M	O
phases	O
of	O
the	O
P7	O
DG	O
.	O

Thus	O
,	O
the	O
absence	O
of	O
FMRP	O
leads	O
to	O
fewer	O
actively	O
cycling	O
NPCs	O
,	O
coinciding	O
with	O
a	O
decrease	O
in	O
neural	O
stem	O
cells	O
and	O
an	O
increase	O
in	O
neuroblasts	O
.	O

Together	O
,	O
these	O
results	O
show	O
the	O
importance	O
of	O
FMRP	O
in	O
the	O
developing	O
hippocampal	O
formation	O
and	O
suggest	O
abnormalities	O
in	O
cell	O
cycle	O
regulation	O
in	O
Fragile	O
X	O
.	O

Truncated	O
Bovine	O
Integrin	O
Alpha-v/Beta-6	O
as	O
a	O
Universal	O
Capture	O
Ligand	O
for	O
FMD	O
Diagnosis	O
.	O

Foot-and-mouth	O
disease	O
(	O
FMD	O
)	O
is	O
endemic	O
in	O
many	O
regions	O
of	O
the	O
world	O
and	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
epizootic	O
animal	O
diseases	O
.	O

FMD	O
affects	O
livestock	O
,	O
such	O
as	O
cattle	O
,	O
sheep	O
,	O
goats	O
and	O
pigs	O
,	O
and	O
causes	O
enormous	O
economic	O
losses	O
due	O
to	O
reduced	O
productivity	O
and	O
trade	O
restrictions	O
.	O

Preparedness	O
and	O
early	B-P
diagnosis	I-P
are	O
essential	O
for	O
effective	O
control	O
of	O
FMD	O
.	O

Many	O
diagnostic	B-P
assays	I-P
are	O
dependent	O
on	O
raising	O
high-affinity	O
,	O
anti-FMD	O
virus	O
(	O
FMDV	O
)	O
serotype-specific	O
antibodies	O
in	O
small	O
animals	O
(	O
rabbits	O
and	O
guinea	O
pigs	O
)	O
that	O
give	O
broad	O
virus	O
coverage	O
.	O

Here	O
we	O
show	O
that	O
soluble	O
,	O
truncated	O
forms	O
of	O
bovine	O
αvβ6	O
bind	O
FMDV	O
in	O
an	O
authentic	O
RGD	O
and	O
divalent	O
cation	O
dependent	O
interaction	O
and	O
can	O
be	O
used	O
as	O
the	O
trapping	O
reagent	O
in	O
a	O
FMDV	O
sandwich	B-P
ELISA	I-P
.	O

In	O
addition	O
,	O
inclusion	O
of	O
FLAG	O
or	O
His	O
tags	O
facilitates	O
simple	O
purification	B-P
without	O
the	O
loss	O
of	O
virus	O
binding	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
when	O
combined	O
with	O
a	O
guinea	O
pig	O
polyclonal	O
serum	O
,	O
or	O
serotype-specific	O
monoclonal	O
antibodies	O
,	O
the	O
integrin	O
can	O
be	O
used	O
to	O
detect	O
viruses	O
representative	O
of	O
all	O
FMDV	O
serotypes	O
.	O

We	O
also	O
show	O
that	O
recombinant	O
FMDV	O
empty	O
capsids	O
,	O
with	O
stabilising	O
disulphide	O
bonds	O
,	O
can	O
serve	O
as	O
an	O
antigen	O
in	O
the	O
ELISA	B-P
and	O
can	O
therefore	O
replace	O
inactivated	O
virus	O
antigen	O
as	O
a	O
positive	O
control	O
for	O
the	O
assay	B-P
.	O

Our	O
results	O
demonstrate	O
the	O
potential	O
use	O
of	O
bovine	O
αvβ6	O
and	O
FMDV	O
empty	O
capsids	O
in	O
FMD	O
diagnostic	B-P
assays	I-P
.	O

Combinatorial	O
Library	O
Screening	O
Coupled	O
to	O
Mass	B-P
Spectrometry	I-P
to	O
Identify	O
Valuable	O
Cyclic	O
Peptides	O
.	O

Combinatorial	O
library	O
screening	O
coupled	O
to	O
mass	B-P
spectrometry	I-P
(	I-P
MS	I-P
)	I-P
analysis	I-P
is	O
a	O
practical	O
approach	O
to	O
identify	O
useful	O
peptides	O
.	O

Cyclic	O
peptides	O
can	O
have	O
high	O
biological	O
activity	O
,	O
selectivity	O
,	O
and	O
affinity	O
for	O
target	O
proteins	O
,	O
and	O
high	O
stability	O
against	O
proteolytic	O
degradation	O
.	O

Here	O
we	O
describe	O
two	O
strategies	O
to	O
prepare	O
combinatorial	O
libraries	O
suitable	O
for	O
MS	B-P
analysis	I-P
to	O
accelerate	O
the	O
discovery	O
of	O
cyclic	O
peptide	O
structures	O
.	O

Both	O
approaches	O
use	O
ChemMatrix	O
resin	O
and	O
the	O
linker	O
4-hydroxymethylbenzoic	O
acid	O
.	O

One	O
strategy	O
involves	O
the	O
synthesis	O
of	O
a	O
one-bead-two-peptides	O
library	O
in	O
which	O
each	O
bead	O
contains	O
both	O
the	O
cyclic	O
peptide	O
and	O
its	O
linear	O
counterpart	O
to	O
facilitate	O
MS	B-P
analysis	I-P
.	O

The	O
other	O
protocol	O
is	O
based	O
on	O
the	O
synthesis	O
of	O
a	O
cyclic	O
depsipeptide	O
library	O
in	O
which	O
a	O
glycolamidic	O
ester	O
group	O
is	O
incorporated	O
by	O
adding	O
glycolic	O
acid	O
.	O

After	O
library	O
screening	O
,	O
the	O
ring	O
is	O
opened	O
and	O
the	O
peptide	O
is	O
released	O
simultaneously	O
for	O
subsequent	O
MS	B-P
analysis	I-P
.	O

©	O
2016	O
by	O
John	O
Wiley	O
&	O
Sons	O
,	O
Inc	O
.	O

SARS	O
-	O
CoV	O
fusion	O
peptides	O
induce	O
membrane	O
surface	O
ordering	O
and	O
curvature	O
.	O

Viral	O
membrane	O
fusion	O
is	O
an	O
orchestrated	O
process	O
triggered	O
by	O
membrane-anchored	O
viral	O
fusion	O
glycoproteins	O
.	O

The	O
S2	O
subunit	O
of	O
the	O
spike	O
glycoprotein	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
contains	O
internal	O
domains	O
called	O
fusion	O
peptides	O
(	O
FP	O
)	O
that	O
play	O
essential	O
roles	O
in	O
virus	O
entry	O
.	O

Although	O
membrane	O
fusion	O
has	O
been	O
broadly	O
studied	O
,	O
there	O
are	O
still	O
major	O
gaps	O
in	O
the	O
molecular	O
details	O
of	O
lipid	O
rearrangements	O
in	O
the	O
bilayer	O
during	O
fusion	O
peptide	O
-	O
membrane	O
interactions	O
.	O

Here	O
we	O
employed	O
differential	B-P
scanning	I-P
calorimetry	I-P
(	O
DSC	B-P
)	O
and	O
electron	B-P
spin	I-P
resonance	I-P
(	O
ESR	B-P
)	O
to	O
gather	O
information	O
on	O
the	O
membrane	O
fusion	O
mechanism	O
promoted	O
by	O
two	O
putative	O
SARS	O
FPs	O
.	O

DSC	B-P
data	O
showed	O
the	O
peptides	O
strongly	O
perturb	O
the	O
structural	O
integrity	O
of	O
anionic	O
vesicles	O
and	O
support	O
the	O
hypothesis	O
that	O
the	O
peptides	O
generate	O
opposing	O
curvature	O
stresses	O
on	O
phosphatidylethanolamine	O
membranes	O
.	O

ESR	B-P
showed	O
that	O
both	O
FPs	O
increase	O
lipid	O
packing	O
and	O
head	O
group	O
ordering	O
as	O
well	O
as	O
reduce	O
the	O
intramembrane	O
water	O
content	O
for	O
anionic	O
membranes	O
.	O

Therefore	O
,	O
bending	O
moment	O
in	O
the	O
bilayer	O
could	O
be	O
generated	O
,	O
promoting	O
negative	O
curvature	O
.	O

The	O
significance	O
of	O
the	O
ordering	O
effect	O
,	O
membrane	O
dehydration	O
,	O
changes	O
in	O
the	O
curvature	O
properties	O
and	O
the	O
possible	O
role	O
of	O
negatively	O
charged	O
phospholipids	O
in	O
helping	O
to	O
overcome	O
the	O
high	O
kinetic	O
barrier	O
involved	O
in	O
the	O
different	O
stages	O
of	O
the	O
SARS	O
-	O
CoV	O
-mediated	O
membrane	O
fusion	O
are	O
discussed	O
.	O

Multi-hospital	O
occurrence	O
of	O
pan-resistant	O
Klebsiella	O
pneumoniae	O
ST147	O
with	O
an	O
ISEcp1	O
-directed	O
blaOXA-181	O
insertion	O
into	O
the	O
mgrB	O
gene	O
in	O
the	O
United	O
Arab	O
Emirates	O
.	O

The	O
emergence	O
of	O
pan-resistant	O
Klebsiella	O
pneumoniae	O
strains	O
is	O
an	O
increasing	O
concern	O
.	O

In	O
the	O
current	O
study	O
we	O
describe	O
a	O
cluster	O
of	O
9	O
pan-resistant	O
K.	O
pneumoniae	O
ST147	O
isolates	O
encountered	O
in	O
4	O
patients	O
over	O
nearly	O
one	O
year	O
in	O
3	O
hospitals	O
of	O
the	O
United	O
Arab	O
Emirates	O
.	O

The	O
isolates	O
exhibited	O
highly	O
similar	O
genotypes	O
.	O

All	O
produced	O
chromosomally	O
encoded	O
OXA-181	O
and	O
the	O
majority	O
also	O
produced	O
the	O
NDM-5	O
carbapenemase	O
.	O

Similarly	O
to	O
the	O
previously	O
described	O
single	O
isolate	O
from	O
the	O
UAE	O
,	O
MS6671	O
,	O
the	O
mgrB	O
was	O
disrupted	O
by	O
a	O
functional	O
,	O
ISEcp1	O
-driven	O
blaOXA-181	O
insertion	O
causing	O
resistance	O
to	O
carbapenems	O
.	O

The	O
mutation	O
was	O
successfully	O
complemented	O
with	O
an	O
intact	O
mgrB	O
gene	O
indicating	O
that	O
it	O
was	O
responsible	O
for	O
colistin	O
resistance	O
.	O

blaNDM-5	O
was	O
located	O
within	O
a	O
resistance	O
island	O
of	O
an	O
approximately	O
100	O
kb	O
IncFII	O
plasmid	O
carrying	O
ermB	O
,	O
mph	O
(	O
A	O
)	O
,	O
blaTEM-1B	O
,	O
rmtB	O
,	O
blaNDM-5	O
,	O
sul1	O
,	O
aadA2	O
and	O
dfrA12	O
resistance	O
genes	O
.	O

Sequencing	B-P
this	O
plasmid	O
(	O
pABC143-NDM	O
)	O
revealed	O
that	O
its	O
backbone	O
was	O
nearly	O
identical	O
to	O
that	O
of	O
plasmid	O
pMS6671E	O
from	O
which	O
several	O
resistance	O
genes	O
,	O
including	O
blaNDM-5	O
,	O
had	O
been	O
deleted	O
.	O

More	O
extensive	O
similarities	O
of	O
the	O
backbone	O
and	O
the	O
resistance	O
island	O
were	O
found	O
between	O
pABC143C-NDM	O
and	O
the	O
blaNDM-5	O
carrying	O
IncFII	O
plasmids	O
of	O
two	O
K.	O
pneumoniae	O
ST147	O
isolates	O
from	O
South	O
Korea	O
,	O
one	O
of	O
which	O
was	O
colistin	O
resistant	O
,	O
and	O
both	O
also	O
produced	O
OXA-181	O
.	O

Notably	O
one	O
of	O
these	O
strains	O
was	O
isolated	O
from	O
a	O
patient	O
transferred	O
from	O
the	O
UAE	O
.	O

Our	O
data	O
show	O
that	O
this	O
pan-resistant	O
clone	O
has	O
an	O
alarming	O
capacity	O
to	O
maintain	O
itself	O
over	O
an	O
extended	O
period	O
of	O
time	O
,	O
and	O
even	O
likely	O
to	O
be	O
transmitted	O
internationally	O
.	O

First	O
Draft	O
Genome	O
Sequence	O
of	O
Staphylococcus	O
condimenti	O
F-2T	O
.	O

This	O
report	O
describes	O
the	O
draft	O
genome	O
sequence	O
of	O
S.	O
condimenti	O
strain	O
F-2	O
(	O
T	O
)	O
(	O
DSM	O
11674	O
)	O
,	O
a	O
potential	O
starter	B-P
culture	I-P
.	O

The	O
genome	O
assembly	O
comprised	O
2,616,174	O
bp	O
with	O
34.6	O
%	O
GC	O
content	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
documentation	O
that	O
reports	O
the	O
whole-genome	O
sequence	O
of	O
S.	O
condimenti	O
.	O

Clinical	O
impact	O
of	O
postoperative	O
loss	O
in	O
psoas	O
major	O
muscle	O
and	O
nutrition	O
index	O
after	O
radical	O
cystectomy	O
for	O
patients	O
with	O
urothelial	O
carcinoma	O
of	O
the	O
bladder	O
.	O

Although	O
the	O
significance	O
of	O
preoperative	O
nutritional	O
status	O
has	O
been	O
investigated	O
,	O
there	O
is	O
no	O
report	O
regarding	O
the	O
relationship	O
of	O
their	O
postoperative	O
changes	O
on	O
outcomes	O
in	O
patients	O
who	O
underwent	O
radical	O
cystectomy	O
for	O
bladder	O
cancer	O
.	O

Here	O
,	O
we	O
report	O
the	O
clinical	O
impact	O
of	O
the	O
change	O
,	O
from	O
baseline	O
,	O
in	O
nutritional	O
status	O
and	O
volume	O
of	O
abdominal	O
skeletal	O
muscle	O
mass	O
and	O
adipose	O
tissue	O
after	O
radical	O
cystetomy	O
.	O

A	O
retrospective	O
analysis	O
of	O
89	O
patients	O
with	O
bladder	O
cancer	O
,	O
who	O
underwent	O
curative	O
radical	O
cystectomy	O
,	O
was	O
conducted	O
to	O
assess	O
the	O
time	O
course	O
of	O
change	O
,	O
from	O
baseline	O
,	O
in	O
body	O
composition	O
and	O
nutritional	O
status	O
at	O
1	O
,	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
24	O
months	O
,	O
after	O
surgery	O
.	O

Skeletal	O
muscle	O
mass	O
and	O
abdominal	O
adipose	O
tissue	O
mass	O
were	O
quantified	O
by	O
unenhanced	O
computed	B-P
tomography	I-P
images	O
.	O

Two	O
different	O
nutritional	O
indices	O
,	O
the	O
Prognostic	O
Nutritional	O
Index	O
and	O
the	O
Controlling	O
Nutritional	O
Status	O
score	O
were	O
calculated	O
from	O
laboratory	B-P
blood	I-P
tests	I-P
.	O

We	O
evaluated	O
the	O
prognostic	O
value	O
of	O
the	O
rate	O
of	O
change	O
in	O
the	O
body	O
composition	O
and	O
nutritional	O
status	O
after	O
radical	O
cystectomy	O
.	O

The	O
cross-sectional	O
area	O
at	O
the	O
level	O
of	O
the	O
third	O
lumbar	O
vertebra	O
of	O
the	O
psoas	O
major	O
muscle	O
and	O
nutritional	O
indices	O
showed	O
a	O
transient	O
deterioration	O
at	O
1	O
and	O
3	O
months	O
after	O
radical	O
cystectomy	O
,	O
with	O
a	O
return	O
to	O
baseline	O
values	O
from	O
6	O
to	O
24	O
months	O
.	O

A	O
≤	O
-10	O
%	O
loss	O
in	O
the	O
area	O
of	O
the	O
psoas	O
muscle	O
was	O
associated	O
with	O
a	O
shorter	O
overall	O
survival	O
,	O
compared	O
to	O
those	O
with	O
a	O
>	O
-10	O
change	O
[	O
hazard	O
ratio	O
(	O
HR	O
)	O
2.2	O
,	O
P	O
=	O
0.02	O
]	O
.	O

Multivariate	O
analyzes	O
identified	O
sarcopenia	O
status	O
at	O
baseline	O
(	O
HR	O
2.2	O
,	O
P	O
=	O
0.03	O
)	O
and	O
a	O
≤	O
-10	O
%	O
loss	O
in	O
the	O
psoas	O
muscle	O
(	O
HR	O
2.4	O
,	O
P	O
=	O
0.02	O
)	O
were	O
identified	O
as	O
independent	O
prognostic	O
factors	O
for	O
overall	O
survival	O
.	O

A	O
subanalysis	O
of	O
patients	O
without	O
sarcopenia	O
identified	O
a	O
worse	O
survival	O
outcome	O
for	O
patients	O
with	O
a	O
≤	O
-10	O
%	O
loss	O
in	O
the	O
psoas	O
muscle	O
(	O
HR	O
2.6	O
,	O
P	O
=	O
0.03	O
)	O
and	O
≤	O
-	O
5	O
change	O
in	O
the	O
Prognostic	O
Nutritional	O
Index	O
(	O
HR	O
3.6	O
,	O
P	O
=	O
0.01	O
)	O
.	O

Further	O
research	O
is	O
required	O
to	O
establish	O
appropriate	O
rehabilitation	O
protocols	O
and	O
nutritional	O
interventions	O
after	O
radical	O
cystectomy	O
for	O
maintaining	O
skeletal	O
muscle	O
mass	O
and	O
nutrition	O
status	O
which	O
could	O
counteract	O
physical	O
deterioration	O
and	O
improve	O
outcomes	O
.	O

Pyoderma	O
gangrenosum	O
:	O
A	O
clinician	O
's	O
nightmare	O
.	O

Pyoderma	O
gangrenosum	O
(	O
PG	O
)	O
is	O
a	O
rare	O
disease	O
and	O
that	O
affecting	O
specifically	O
the	O
sole	O
of	O
the	O
foot	O
,	O
is	O
even	O
rarer	O
.	O

Here	O
,	O
we	O
report	O
the	O
case	O
of	O
a	O
54-year-	O
old	O
female	O
admitted	O
with	O
a	O
painful	O
ulcer	O
on	O
the	O
sole	O
of	O
the	O
right	O
foot	O
which	O
was	O
initially	O
treated	O
with	O
empirical	O
antibiotics	O
and	O
debridement	O
.	O

The	O
disease	O
was	O
found	O
to	O
spread	O
rapidly	O
after	O
each	O
debridement	O
.	O

The	O
culture	O
reports	O
were	O
negative	O
;	O
rheumatology	O
workup	B-P
and	O
Doppler	B-P
study	I-P
were	O
within	O
normal	O
limits	O
.	O

A	O
clinical	O
suspicion	O
of	O
PG	O
was	O
made	O
and	O
was	O
confirmed	O
with	O
tissue	B-P
biopsy	I-P
.	O

She	O
was	O
started	O
on	O
oral	O
steroids	O
following	O
which	O
she	O
dramatically	O
improved	O
.	O

Thus	O
,	O
when	O
a	O
patient	O
presents	O
with	O
a	O
rapidly	O
expanding	O
painful	O
ulcer	O
in	O
a	O
vascular	O
limb	O
that	O
is	O
refractory	O
to	O
antibiotic	O
treatment	O
and	O
exacerbating	O
on	O
debridement	O
,	O
it	O
is	O
imperative	O
to	O
consider	O
the	O
possibility	O
of	O
PG	O
.	O

Sedation	O
of	O
Patients	O
With	O
Disorders	O
of	O
Consciousness	O
During	O
Neuroimaging	B-P
:	O
Effects	O
on	O
Resting	B-P
State	I-P
Functional	I-P
Brain	I-P
Connectivity	I-P
.	O

To	O
reduce	O
head	O
movement	O
during	O
resting	B-P
state	I-P
functional	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
,	O
post-coma	O
patients	O
with	O
disorders	O
of	O
consciousness	O
(	O
DOC	O
)	O
are	O
frequently	O
sedated	O
with	O
propofol	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
this	O
sedation	O
on	O
the	O
brain	O
connectivity	O
patterns	O
in	O
the	O
damaged	O
brain	O
essential	O
for	O
differential	B-P
diagnosis	I-P
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
assess	O
these	O
effects	O
.	O

Using	O
resting	B-P
state	I-P
functional	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
3T	O
data	O
obtained	O
over	O
several	O
years	O
of	O
scanning	B-P
patients	O
for	O
diagnostic	O
and	O
research	O
purposes	O
,	O
we	O
employed	O
a	O
seed-based	O
approach	O
to	O
examine	O
resting	O
state	O
connectivity	O
in	O
higher-order	O
(	O
default	O
mode	O
,	O
bilateral	O
external	O
control	O
,	O
and	O
salience	O
)	O
and	O
lower-order	O
(	O
auditory	O
,	O
sensorimotor	O
,	O
and	O
visual	O
)	O
resting	O
state	O
networks	O
and	O
connectivity	O
with	O
the	O
thalamus	O
,	O
in	O
20	O
healthy	O
unsedated	O
controls	O
,	O
8	O
unsedated	O
patients	O
with	O
DOC	O
,	O
and	O
8	O
patients	O
with	O
DOC	O
sedated	O
with	O
propofol	O
.	O

The	O
DOC	O
groups	O
were	O
matched	O
for	O
age	O
at	O
onset	O
,	O
etiology	O
,	O
time	O
spent	O
in	O
DOC	O
,	O
diagnosis	O
,	O
standardized	O
behavioral	O
assessment	O
scores	O
,	O
movement	O
intensities	O
,	O
and	O
pattern	O
of	O
structural	O
brain	O
injury	O
(	O
as	O
assessed	O
with	O
T1-based	B-P
voxel-based	I-P
morphometry	I-P
)	O
.	O

DOC	O
were	O
associated	O
with	O
severely	O
impaired	O
resting	O
state	O
network	O
connectivity	O
in	O
all	O
but	O
the	O
visual	O
network	O
.	O

Thalamic	O
connectivity	O
to	O
higher-order	O
network	O
regions	O
was	O
also	O
reduced	O
.	O

Propofol	O
administration	O
to	O
patients	O
was	O
associated	O
with	O
minor	O
further	O
decreases	O
in	O
thalamic	O
and	O
insular	O
connectivity	O
.	O

Our	O
findings	O
indicate	O
that	O
connectivity	O
decreases	O
associated	O
with	O
propofol	O
sedation	O
,	O
involving	O
the	O
thalamus	O
and	O
insula	O
,	O
are	O
relatively	O
small	O
compared	O
with	O
those	O
already	O
caused	O
by	O
DOC	O
-associated	O
structural	O
brain	O
injury	O
.	O

Nonetheless	O
,	O
given	O
the	O
known	O
importance	O
of	O
the	O
thalamus	O
in	O
brain	O
arousal	O
,	O
its	O
disruption	O
could	O
well	O
reflect	O
the	O
diminished	O
movement	O
obtained	O
in	O
these	O
patients	O
.	O

However	O
,	O
more	O
research	O
is	O
needed	O
on	O
this	O
topic	O
to	O
fully	O
address	O
the	O
research	O
question	O
.	O

High	O
Transferability	O
of	O
Homoeolog-Specific	O
Markers	O
between	O
Bread	O
Wheat	O
and	O
Newly	O
Synthesized	O
Hexaploid	O
Wheat	O
Lines	O
.	O

Bread	O
wheat	O
(	O
Triticum	O
aestivum	O
,	O
2n	O
=	O
6x	O
=	O
42	O
,	O
AABBDD	O
)	O
has	O
a	O
complex	O
allohexaploid	O
genome	O
,	O
which	O
makes	O
it	O
difficult	O
to	O
differentiate	O
between	O
the	O
homoeologous	O
sequences	O
and	O
assign	O
them	O
to	O
the	O
chromosome	O
A	O
,	O
B	O
,	O
or	O
D	O
subgenomes	O
.	O

The	O
chromosome	O
-based	O
draft	O
genome	O
sequence	O
of	O
the	O
'	O
Chinese	O
Spring	O
'	O
common	O
wheat	O
cultivar	O
enables	O
the	O
large-scale	O
development	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-based	O
markers	O
specific	O
for	O
homoeologs	O
.	O

Based	O
on	O
high-confidence	O
'	O
Chinese	O
Spring	O
'	O
genes	O
with	O
known	O
functions	O
,	O
we	O
developed	O
183	O
putative	O
homoeolog-specific	O
markers	O
for	O
chromosomes	O
4B	O
and	O
7B	O
.	O

These	O
markers	O
were	O
used	O
in	O
PCR	O
assays	O
for	O
the	O
4B	O
and	O
7B	O
nullisomes	O
and	O
their	O
euploid	O
synthetic	O
hexaploid	O
wheat	O
(	O
SHW	O
)	O
line	O
that	O
was	O
newly	O
generated	O
from	O
a	O
hybridization	O
between	O
Triticum	O
turgidum	O
(	O
AABB	O
)	O
and	O
the	O
wild	O
diploid	O
species	O
Aegilops	O
tauschii	O
(	O
DD	O
)	O
.	O

Up	O
to	O
64	O
%	O
of	O
the	O
markers	O
for	O
chromosomes	O
4B	O
or	O
7B	O
in	O
the	O
SHW	O
background	O
were	O
confirmed	O
to	O
be	O
homoeolog-specific	O
.	O

Thus	O
,	O
these	O
markers	O
were	O
highly	O
transferable	O
between	O
the	O
'	O
Chinese	O
Spring	O
'	O
bread	O
wheat	O
and	O
SHW	O
lines	O
.	O

Homoeolog-specific	O
markers	O
designed	O
using	O
genes	O
with	O
known	O
functions	O
may	O
be	O
useful	O
for	O
genetic	B-P
investigations	I-P
involving	O
homoeologous	O
chromosome	O
tracking	O
and	O
homoeolog	O
expression	O
and	O
interaction	O
analyses	O
.	O

Synthesis	O
of	O
1,2-Dioxetanes	O
as	O
Thermochemiluminescent	O
Labels	O
for	O
Ultrasensitive	B-P
Bioassays	I-P
:	O
Rational	O
Prediction	O
of	O
Olefin	O
Photooxygenation	O
Outcome	O
by	O
Using	O
a	O
Chemometric	B-P
Approach	I-P
.	O

Great	O
interest	O
in	O
new	O
thermochemiluminescent	O
(	O
TCL	O
)	O
molecules	O
,	O
for	O
example	O
,	O
in	O
bioanalytical	B-P
assays	I-P
,	O
has	O
prompted	O
the	O
design	O
and	O
synthesis	O
of	O
a	O
small	O
library	O
of	O
more	O
than	O
30	O
olefins	O
to	O
be	O
subjected	O
to	O
photooxygenation	O
,	O
with	O
the	O
aim	O
of	O
obtaining	O
new	O
1,2-dioxetane-based	O
TCL	O
labels	O
with	O
optimized	O
properties	O
.	O

Fluorine	O
atoms	O
on	O
the	O
acridan	O
system	O
remarkably	O
stabilize	O
1,2-dioxetanes	O
when	O
they	O
are	O
located	O
in	O
the	O
3-	O
and/or	O
6-position	O
(	O
4	O
h	O
and	O
4	O
i	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
2,7-difluorinated	O
acridan	O
dioxetane	O
(	O
4	O
j	O
)	O
showed	O
a	O
significantly	O
enhanced	O
fluorescence	O
quantum	O
yield	O
with	O
respect	O
to	O
the	O
unsubstituted	O
dioxetane	O
(	O
4	O
a	O
)	O
.	O

Some	O
of	O
the	O
synthesized	O
olefins	O
did	O
not	O
undergo	O
singlet	O
oxygen	O
addition	O
and	O
a	O
rationale	O
was	O
sought	O
to	O
ease	O
the	O
photooxygenation	O
step	O
,	O
leading	O
to	O
the	O
TCL	O
dioxetanes	O
.	O

A	O
chemometric	B-P
approach	I-P
has	O
been	O
adopted	O
to	O
exploit	O
principal	O
component	O
analysis	O
and	O
linear	O
discriminant	O
analysis	O
of	O
the	O
structural	O
and	O
electronic	O
molecular	O
descriptors	O
obtained	O
by	O
DFT	O
optimizations	O
of	O
olefins	O
3	O
.	O

This	O
approach	O
allows	O
the	O
steric	O
and	O
electronic	O
parameters	O
that	O
govern	O
dioxetane	O
formation	O
to	O
be	O
revealed	O
.	O

Executive	O
function	O
fails	O
to	O
predict	O
smoking	O
outcomes	O
in	O
a	O
clinical	O
trial	O
to	O
motivate	O
smokers	O
to	O
quit	O
.	O

Executive	O
function	O
(	O
EF	O
)	O
is	O
considered	O
an	O
important	O
mediator	O
of	O
health	O
outcomes	O
.	O

It	O
is	O
hypothesized	O
that	O
those	O
with	O
better	O
EF	O
are	O
more	O
likely	O
to	O
succeed	O
in	O
turning	O
their	O
intentions	O
into	O
actual	O
health	O
behaviors	O
.	O

Prior	O
studies	O
indicate	O
EF	O
is	O
associated	O
with	O
smoking	O
cessation	O
.	O

Experimental	O
and	O
longitudinal	O
studies	O
,	O
however	O
,	O
have	O
yielded	O
mixed	O
results	O
.	O

Few	O
studies	O
have	O
examined	O
whether	O
EF	O
predicts	O
post-treatment	O
smoking	O
behavior	O
.	O

Fewer	O
still	O
have	O
done	O
so	O
prospectively	O
in	O
a	O
large	O
trial	O
.	O

We	O
sought	O
to	O
determine	O
if	O
EF	O
predicts	O
quit	O
attempts	O
and	O
cessation	O
among	O
community	O
smokers	O
in	O
a	O
large	O
randomized	O
trial	O
evaluating	O
the	O
efficacy	O
of	O
motivational	O
interventions	O
for	O
encouraging	O
cessation	O
.	O

Participants	O
(	O
N=255	O
)	O
completed	O
a	O
baseline	O
assessment	O
that	O
included	O
a	O
cognitive	B-P
battery	I-P
to	I-P
assess	I-P
EF	O
(	O
Oral	O
Trail	O
Making	O
Test	O
B	O
,	O
Stroop	B-P
,	O
Controlled	O
Oral	O
Word	O
Association	O
Test	O
)	O
.	O

Participants	O
were	O
then	O
randomized	O
to	O
4	O
sessions	O
of	O
Motivational	O
Interviewing	O
or	O
Health	O
Education	O
or	O
one	O
session	O
of	O
Brief	O
Advice	O
to	O
quit	O
.	O

Quit	O
attempts	O
and	O
cessation	O
were	O
assessed	O
at	O
weeks	O
12	O
and	O
26	O
.	O

In	O
regression	O
analyses	O
,	O
none	O
of	O
the	O
EF	O
measures	O
were	O
statistically	O
significant	O
predictors	O
of	O
quit	O
attempts	O
or	O
cessation	O
(	O
all	O
ps	O
>	O
0.20	O
)	O
.	O

Our	O
data	O
did	O
not	O
support	O
models	O
of	O
health	O
behavior	O
that	O
emphasize	O
EF	O
as	O
a	O
mediator	O
of	O
health	O
outcomes	O
.	O

Methodological	O
shortcomings	O
weaken	O
the	O
existing	O
support	O
for	O
an	O
association	O
between	O
EF	O
and	O
smoking	O
behavior	O
.	O

We	O
suggest	O
methodological	O
improvements	O
that	O
could	O
help	O
move	O
this	O
potentially	O
important	O
area	O
of	O
research	O
forward	O
.	O

One-Pot	O
Hydrothermal	O
Synthesis	O
of	O
Carbon	O
Dots	O
with	O
Efficient	O
Up-	O
and	O
Down-Converted	O
Photoluminescence	O
for	O
the	O
Sensitive	O
Detection	O
of	O
Morin	O
in	O
a	O
Dual-Readout	B-P
Assay	I-P
.	O

Blue	O
luminescent	O
carbon	O
dots	O
(	O
CDs	O
)	O
with	O
a	O
high	O
photoluminescence	O
(	O
PL	O
)	O
quantum	O
yield	O
(	O
48.3	O
±	O
5.3	O
%	O
)	O
were	O
prepared	O
by	O
the	O
one-pot	O
hydrothermal	O
reaction	O
of	O
citric	O
acid	O
with	O
poly	O
(	O
ethylenimine	O
)	O
(	O
PEI	O
)	O
.	O

The	O
CDs	O
display	O
bright	O
PL	O
,	O
narrow	O
emission	O
spectra	O
,	O
pH	O
-dependent	O
PL	O
intensity	O
,	O
high	O
photostability	O
,	O
and	O
up-converted	O
luminescence	O
.	O

The	O
CDs	O
exhibit	O
a	O
quenching	O
of	O
both	O
down-	O
and	O
up-conversion	O
PL	O
in	O
the	O
presence	O
of	O
morin	O
and	O
thus	O
serve	O
as	O
useful	O
probes	O
for	O
morin	O
detection	O
.	O

Both	O
down-	O
and	O
up-conversion	O
measurements	O
allow	O
the	O
quantification	O
of	O
concentrations	O
from	O
0	O
to	O
300	O
μmol/L	O
with	O
a	O
detection	O
limit	O
of	O
0.6	O
μmol/L	O
,	O
and	O
this	O
dual-mode	B-P
detection	I-P
increases	O
the	O
reliability	O
of	O
the	O
measurement	O
.	O

The	O
proposed	O
method	O
of	O
determination	B-P
is	O
simple	O
,	O
sensitive	O
,	O
and	O
cost-effective	O
,	O
with	O
potential	O
applications	O
in	O
clinical	B-P
and	I-P
biochemical	I-P
assays	I-P
.	O

Complete	O
Genome	B-P
Sequence	I-P
Analysis	I-P
of	O
a	O
Naturally	O
Reassorted	O
Infectious	O
Bursal	O
Disease	O
Virus	O
from	O
India	O
.	O

The	O
novel	O
infectious	O
bursal	O
disease	O
virus	O
(	O
IBDV	O
)	O
isolate	O
BGE14/ABT1/MVC/India	O
is	O
a	O
very	O
virulent	O
IBDV	O
that	O
was	O
isolated	O
from	O
broiler	O
flocks	O
in	O
southern	O
parts	O
of	O
India	O
during	O
2014	O
.	O

Here	O
,	O
we	O
report	O
,	O
for	O
the	O
first	O
time	O
in	O
India	O
,	O
the	O
complete	O
genome	O
sequence	O
of	O
BGE14/ABT1/MVC/India	O
,	O
a	O
reassortment	O
strain	O
with	O
segments	O
A	O
and	O
B	O
derived	O
from	O
a	O
very	O
virulent	O
IBDV	O
strain	O
and	O
an	O
attenuated	O
IBDV	O
,	O
respectively	O
.	O

The	O
findings	O
from	O
this	O
study	O
provide	O
additional	O
insight	O
into	O
the	O
genetic	O
exchange	O
between	O
attenuated	O
and	O
very	O
virulent	O
strains	O
of	O
IBDV	O
circulating	O
in	O
the	O
field	O
.	O

Improved	O
diagnostic	O
yield	O
of	O
neuromuscular	O
disorders	O
applying	O
clinical	O
exome	O
sequencing	O
in	O
patients	O
arising	O
from	O
a	O
consanguineous	O
population	O
.	O

Neuromuscular	O
diseases	O
(	O
NMDs	O
)	O
include	O
a	O
broad	O
range	O
of	O
disorders	O
affecting	O
muscles	O
,	O
nerves	O
and	O
neuromuscular	O
junctions	O
.	O

Their	O
overlapping	O
phenotypes	O
and	O
heterogeneous	O
genetic	O
nature	O
have	O
created	O
challenges	O
in	O
diagnosis	O
which	O
calls	O
for	O
the	O
implementation	O
of	O
massive	O
parallel	O
sequencing	O
as	O
a	O
candidate	O
strategy	O
to	O
increase	O
the	O
diagnostic	O
yield	O
.	O

In	O
this	O
study	O
,	O
total	O
of	O
45	O
patients	O
,	O
mostly	O
offspring	O
of	O
consanguineous	O
marriages	O
were	O
examined	O
using	O
whole	O
exome	O
sequencing	O
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	O
rare	O
variants	O
in	O
known	O
NMD	O
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	O
(	O
73.3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	O
variants	O
were	O
detected	O
.	O

Today	O
,	O
the	O
advantage	O
of	O
whole	O
exome	O
sequencing	O
in	O
clinical	B-P
diagnostic	I-P
strategies	O
of	O
heterogeneous	O
disorders	O
is	O
clear	O
.	O

In	O
this	O
cohort	O
,	O
a	O
diagnostic	O
yield	O
of	O
73.3	O
%	O
was	O
achieved	O
which	O
is	O
quite	O
high	O
compared	O
to	O
the	O
overall	O
reported	O
diagnostic	O
yield	O
of	O
25	O
%	O
to	O
50	O
%	O
.	O

This	O
could	O
be	O
explained	O
by	O
the	O
consanguineous	O
background	O
of	O
these	O
patients	O
and	O
is	O
another	O
strong	O
advantage	O
of	O
offering	O
clinical	O
exome	O
sequencing	O
in	O
diagnostic	O
laboratories	O
,	O
especially	O
in	O
populations	O
with	O
high	O
rate	O
of	O
consanguinity	O
.	O

Association	O
of	O
kidney	O
disease	O
with	O
obstructive	O
sleep	O
apnea	O
in	O
a	O
population	O
study	O
of	O
men	O
.	O

To	O
determine	B-P
the	O
relationship	O
between	O
obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
and	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
.	O

Previous	O
population	O
studies	O
of	O
the	O
association	O
are	O
sparse	O
,	O
conflicting	O
and	O
confined	O
largely	O
to	O
studies	O
of	O
administrative	O
data	O
.	O

Cross-sectional	O
analysis	O
in	O
unselected	O
participants	O
of	O
the	O
Men	O
Androgens	O
Inflammation	O
Lifestyle	O
Environment	O
and	O
Stress	O
(	O
MAILES	O
)	O
study	O
,	O
aged	O
>	O
40	O
y.	O
Renal	O
data	O
were	O
available	O
on	O
812	O
men	O
without	O
a	O
prior	O
OSA	O
diagnosis	O
who	O
underwent	O
full	O
in-home	O
polysomnography	B-P
(	O
Embletta	O
X100	O
)	O
in	O
2010-2011	O
.	O

CKD	O
was	O
defined	O
as	O
an	O
estimated	B-P
glomerular	I-P
filtration	I-P
rate	I-P
(	O
eGFR	B-P
)	O
<	O
60	O
mL/min/1.73m2	O
or	O
eGFR	B-P
≥60	O
and	O
albuminuria	O
(	O
albumin	B-P
creatinine	I-P
ratio	I-P
≥3.0	O
mg/mmol	O
)	O
.	O

CKD	O
[	O
10.5	O
%	O
,	O
n=85	O
(	O
Stage	O
1-3	O
,	O
9.7	O
%	O
;	O
Stage	O
4-5	O
,	O
0.7	O
%	O
)	O
]	O
of	O
predominantly	O
mild	O
severity	O
showed	O
significant	O
association	O
s	O
with	O
OSA	O
(	O
AHI≥10	O
)	O
:	O
odds	O
ratio	O
(	O
OR	O
)	O
=1.9	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:1.02-3.5	O
,	O
severe	O
OSA	O
(	O
AHI	O
≥30/h	O
)	O
:	O
OR	O
=2.6	O
,	O
95	O
%	O
CI:1.1-6.2	O
,	O
and	O
respiratory	O
related	O
arousal	O
index	O
:	O
≥7.6/h	O
OR	O
=2.3	O
,	O
95	O
%	O
CI	O
:	O
1.1-4.7	O
,	O
but	O
not	O
measures	O
of	O
hypoxemia	O
after	O
adjustment	O
for	O
age	O
,	O
hypertension	O
,	O
diabetes	O
,	O
smoking	O
,	O
obesity	O
,	O
and	O
NSAID	O
use	O
.	O

There	O
was	O
no	O
association	O
of	O
CKD	O
with	O
daytime	O
sleepiness	O
.	O

In	O
men	O
with	O
CKD	O
,	O
those	O
with	O
OSA	O
were	O
not	O
significantly	O
more	O
likely	O
to	O
report	O
symptoms	O
(	O
sleepiness	O
,	O
snoring	O
,	O
apneas	O
)	O
or	O
be	O
identified	O
with	O
the	O
STOP	O
OSA	O
screening	O
questionnaire	O
,	O
compared	O
to	O
men	O
without	O
OSA	O
.	O

Predominantly	O
mild	O
CKD	O
is	O
associated	O
with	O
severe	O
OSA	O
and	O
arousals	O
.	O

Further	O
population	O
studies	O
examining	O
the	O
longitudinal	O
relationship	O
between	O
CKD	O
and	O
OSA	O
are	O
warranted	O
.	O

Better	O
methods	O
are	O
needed	O
to	O
identify	O
OSA	O
in	O
CKD	O
which	O
may	O
have	O
few	O
symptoms	O
.	O

Interobserver	O
and	O
Intraobserver	O
Reliability	O
of	O
Clinical	O
Assessments	O
in	O
Knee	O
Osteoarthritis	O
.	O

Clinical	O
examination	O
of	O
the	O
knee	O
is	O
subject	O
to	O
measurement	O
error	O
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
interobserver	O
and	O
intraobserver	O
reliability	O
of	O
commonly	O
used	O
clinical	O
tests	O
in	O
patients	O
with	O
knee	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

We	O
studied	O
subjects	O
with	O
symptomatic	O
knee	O
OA	O
who	O
were	O
participants	O
in	O
an	O
open-label	O
clinical	O
trial	O
of	O
intraarticular	O
steroid	O
therapy	O
.	O

Following	O
standardization	O
of	O
the	O
clinical	B-P
test	I-P
procedures	I-P
,	O
2	O
clinicians	O
assessed	O
25	O
subjects	O
independently	O
at	O
the	O
same	O
visit	O
,	O
and	O
the	O
same	O
clinician	O
assessed	O
88	O
subjects	O
over	O
an	O
interval	O
period	O
of	O
2-10	O
weeks	O
;	O
in	O
both	O
cases	O
prior	O
to	O
the	O
steroid	O
intervention	O
.	O

Clinical	O
examination	O
included	O
assessment	O
of	O
bony	O
enlargement	O
,	O
crepitus	O
,	O
quadriceps	O
wasting	O
,	O
knee	O
effusion	O
,	O
joint-line	O
and	O
anserine	O
tenderness	O
,	O
and	O
knee	O
range	O
of	O
movement	O
(	O
ROM	O
)	O
.	O

Intraclass	O
correlation	O
coefficients	O
(	O
ICC	O
)	O
,	O
estimated	O
kappa	O
(	O
κ	O
)	O
,	O
weighted	O
kappa	O
(	O
κω	O
)	O
,	O
and	O
Bland-Altman	O
plots	O
were	O
used	O
to	O
determine	O
interobserver	O
and	O
intraobserver	O
levels	O
of	O
agreement	O
.	O

Using	O
Landis	O
and	O
Koch	O
criteria	O
,	O
interobserver	O
κ	O
scores	O
were	O
moderate	O
for	O
patellofemoral	O
joint	O
(	O
κ	O
=	O
0.53	O
)	O
and	O
anserine	O
tenderness	O
(	O
κ	O
=	O
0.48	O
)	O
;	O
good	O
for	O
bony	O
enlargement	O
(	O
κ	O
=	O
0.66	O
)	O
,	O
quadriceps	O
wasting	O
(	O
κ	O
=	O
0.78	O
)	O
,	O
crepitus	O
(	O
κ	O
=	O
0.78	O
)	O
,	O
medial	O
tibiofemoral	O
joint	O
tenderness	O
(	O
κ	O
=	O
0.76	O
)	O
,	O
and	O
effusion	O
assessed	O
by	O
ballottement	O
(	O
κ	O
=	O
0.73	O
)	O
and	O
bulge	B-P
sign	I-P
(	O
κω	O
=	O
0.78	O
)	O
;	O
and	O
excellent	O
for	O
lateral	O
tibiofemoral	O
joint	O
tenderness	O
(	O
κ	O
=	O
1.00	O
)	O
,	O
flexion	O
(	O
ICC	O
=	O
0.97	O
)	O
,	O
and	O
extension	O
(	O
ICC	O
=	O
0.87	O
)	O
ROM	O
.	O

Intraobserver	O
κ	O
scores	O
were	O
moderate	O
for	O
lateral	O
tibiofemoral	O
joint	O
tenderness	O
(	O
κ	O
=	O
0.60	O
)	O
;	O
good	O
for	O
crepitus	O
(	O
κ	O
=	O
0.78	O
)	O
,	O
effusion	O
assessed	O
by	O
ballottement	O
test	O
(	O
κ	O
=	O
0.77	O
)	O
,	O
patellofemoral	O
joint	O
(	O
κ	O
=	O
0.66	O
)	O
,	O
medial	O
tibiofemoral	O
joint	O
(	O
κ	O
=	O
0.64	O
)	O
,	O
and	O
anserine	O
tenderness	O
(	O
κ	O
=	O
0.73	O
)	O
;	O
and	O
excellent	O
for	O
effusion	O
assessed	O
by	O
bulge	B-P
sign	I-P
(	O
κω	O
=	O
0.83	O
)	O
,	O
bony	O
enlargement	O
(	O
κ	O
=	O
0.98	O
)	O
,	O
quadriceps	O
wasting	O
(	O
κ	O
=	O
0.83	O
)	O
,	O
flexion	O
(	O
ICC	O
=	O
0.99	O
)	O
,	O
and	O
extension	O
(	O
ICC	O
=	O
0.96	O
)	O
ROM	O
.	O

Among	O
individuals	O
with	O
symptomatic	O
knee	O
OA	O
,	O
the	O
reliability	O
of	O
clinical	O
examination	O
of	O
the	O
knee	O
was	O
at	O
least	O
good	O
for	O
the	O
majority	O
of	O
clinical	O
signs	O
of	O
knee	O
OA	O
.	O

Epigenome-wide	O
analysis	O
links	O
SMAD3	O
methylation	O
at	O
birth	O
to	O
asthma	O
in	O
children	O
of	O
asthmatic	O
mothers	O
.	O

The	O
timing	O
and	O
mechanisms	O
of	O
asthma	O
inception	O
remain	O
imprecisely	O
defined	O
.	O

Although	O
epigenetic	O
mechanisms	O
likely	O
contribute	O
to	O
asthma	O
pathogenesis	O
,	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
asthma	O
inception	O
.	O

We	O
sought	O
to	O
assess	O
whether	O
the	O
trajectory	O
to	O
asthma	O
begins	O
already	O
at	O
birth	O
and	O
whether	O
epigenetic	O
mechanisms	O
,	O
specifically	O
DNA	O
methylation	O
,	O
contribute	O
to	O
asthma	O
inception	O
.	O

We	O
used	O
the	O
Methylated	B-P
CpG	I-P
Island	I-P
Recovery	I-P
Assay	I-P
chip	I-P
to	O
survey	O
DNA	O
methylation	O
in	O
cord	O
blood	O
mononuclear	O
cells	O
from	O
36	O
children	O
(	O
18	O
nonasthmatic	O
and	O
18	O
asthmatic	O
subjects	O
by	O
age	O
9	O
years	O
)	O
from	O
the	O
Infant	O
Immune	O
Study	O
(	O
IIS	O
)	O
,	O
an	O
unselected	O
birth	O
cohort	O
closely	O
monitored	O
for	O
asthma	O
for	O
a	O
decade	O
.	O

SMAD3	O
methylation	O
in	O
IIS	O
(	O
n	O
=	O
60	O
)	O
and	O
in	O
2	O
replication	O
cohorts	O
(	O
the	O
Manchester	O
Asthma	O
and	O
Allergy	B-P
Study	I-P
[	O
n	O
=	O
30	O
]	O
and	O
the	O
Childhood	O
Origins	O
of	O
Asthma	O
Study	O
[	O
n	O
=	O
28	O
]	O
)	O
was	O
analyzed	O
by	O
using	O
bisulfite	O
sequencing	O
or	O
Illumina	B-P
450K	I-P
arrays	I-P
.	O

Cord	O
blood	O
mononuclear	O
cell	O
-derived	O
IL-1β	O
levels	O
were	O
measured	O
by	O
means	O
of	O
ELISA	B-P
.	O

Neonatal	O
immune	O
cells	O
harbored	O
589	O
differentially	O
methylated	O
regions	O
that	O
distinguished	O
IIS	O
children	O
who	O
did	O
and	O
did	O
not	O
have	O
asthma	O
by	O
age	O
9	O
years	O
.	O

In	O
all	O
3	O
cohorts	O
methylation	O
in	O
SMAD3	O
,	O
the	O
most	O
connected	O
node	O
within	O
the	O
network	O
of	O
asthma	O
-	O
associated	O
,	O
differentially	O
methylated	O
regions	O
,	O
was	O
selectively	O
increased	O
in	O
asthmatic	O
children	O
of	O
asthmatic	O
mothers	O
and	O
was	O
associated	O
with	O
childhood	O
asthma	O
risk	O
.	O

Moreover	O
,	O
SMAD3	O
methylation	O
in	O
IIS	O
neonates	O
with	O
maternal	O
asthma	O
was	O
strongly	O
and	O
positively	O
associated	O
with	O
neonatal	O
production	O
of	O
IL-1β	O
,	O
an	O
innate	O
inflammatory	O
mediator	O
.	O

The	O
trajectory	O
to	O
childhood	O
asthma	O
begins	O
at	O
birth	O
and	O
involves	O
epigenetic	O
modifications	O
in	O
immunoregulatory	O
and	O
proinflammatory	O
pathways	O
.	O

Maternal	O
asthma	O
influences	O
epigenetic	O
mechanisms	O
that	O
contribute	O
to	O
the	O
inception	O
of	O
this	O
trajectory	O
.	O

Total	O
Fluorescence	O
Fingerprinting	O
of	O
Pesticides	O
:	O
A	O
Reliable	O
Approach	O
for	O
Continuous	O
Monitoring	O
of	O
Soils	O
and	O
Waters	O
.	O

The	O
present	O
work	O
relates	O
to	O
the	O
creation	O
/	O
extension	O
of	O
a	O
database	O
of	O
Total	B-P
Excitation-Emission	I-P
and	I-P
Total	I-P
Synchronous	I-P
Fluorescence	I-P
Matrices	I-P
(	O
TEEMs	B-P
and	I-P
TSFMs	I-P
)	O
along	O
with	O
optimal	B-P
Synchronous	I-P
Fluorescence	I-P
Spectra	I-P
(	O
SFS	B-P
)	O
to	O
fingerprint	O
pesticides	O
widely	O
used	O
in	O
Morocco	O
.	O

This	O
spectrometric	B-P
multi-component	I-P
fingerprinting	I-P
may	O
permit	O
the	O
direct	O
detection	B-P
of	I-P
pesticides	I-P
persisting	O
in	O
soil	O
or	O
water	O
.	O

The	O
objective	O
of	O
the	O
current	O
investigation	O
is	O
to	O
detect	B-P
four	I-P
pesticide	I-P
remains	O
in	O
agricultural	O
soils	O
by	O
applying	O
the	O
spectrometric	B-P
fingerprinting	I-P
results	O
.	O

They	O
are	O
the	O
commercial	O
:	O
i	O
)	O
insecticide	O
Axlera	O
5G	O
(	O
carbamate	O
)	O
,	O
ii	O
)	O
fungicide	O
Orsalis	O
5	O
%	O
SC	O
(	O
triazole	O
)	O
,	O
iii	O
)	O
insecticide	O
Force	O
0,5	O
G	O
(	O
pyrethrinoid	O
)	O
and	O
iv	O
)	O
insecticide	O
Proclaim	O
05	O
SG	O
(	O
non-assigned	O
)	O
.	O

The	O
agricultural	O
plantations	O
monitored	O
are	O
located	O
in	O
the	O
great	O
agricultural	O
Doukkala	O
region	O
at	O
the	O
western	O
Atlantic	O
side	O
of	O
Morocco	O
,	O
where	O
these	O
chemicals	O
are	O
in	O
large	O
sale	O
and	O
use	O
.	O

Nat1	O
promotes	O
translation	O
of	O
specific	O
proteins	O
that	O
induce	O
differentiation	O
of	O
mouse	O
embryonic	O
stem	O
cells	O
.	O

Novel	O
APOBEC1	O
target	O
1	O
(	O
Nat1	O
)	O
(	O
also	O
known	O
as	O
``	O
p97	O
,	O
''	O
``	O
Dap5	O
,	O
''	O
and	O
``	O
Eif4g2	O
``	O
)	O
is	O
a	O
ubiquitously	O
expressed	O
cytoplasmic	O
protein	O
that	O
is	O
homologous	O
to	O
the	O
C-terminal	O
two	O
thirds	O
of	O
eukaryotic	O
translation	O
initiation	O
factor	O
4G	O
(	O
Eif4g1	O
)	O
.	O

We	O
previously	O
showed	O
that	O
Nat1	O
-	O
null	O
mouse	O
embryonic	O
stem	O
cells	O
(	O
mES	O
cells	O
)	O
are	O
resistant	O
to	O
differentiation	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
found	O
that	O
NAT1	O
and	O
eIF4G1	O
share	O
many	O
binding	O
proteins	O
,	O
such	O
as	O
the	O
eukaryotic	O
translation	O
initiation	O
factors	O
eIF3	O
and	O
eIF4A	O
and	O
ribosomal	O
proteins	O
.	O

However	O
,	O
NAT1	O
did	O
not	O
bind	O
to	O
eIF4E	O
or	O
poly	O
(	O
A	O
)	O
-binding	O
proteins	O
,	O
which	O
are	O
critical	O
for	O
cap-dependent	O
translation	O
initiation	O
.	O

In	O
contrast	O
,	O
compared	O
with	O
eIF4G1	O
,	O
NAT1	O
preferentially	O
interacted	O
with	O
eIF2	O
,	O
fragile	O
X	O
mental	O
retardation	O
proteins	O
(	O
FMR	O
)	O
,	O
and	O
related	O
proteins	O
and	O
especially	O
with	O
members	O
of	O
the	O
proline-rich	O
and	O
coiled-coil-containing	O
protein	O
2	O
(	O
PRRC2	O
)	O
family	O
.	O

We	O
also	O
found	O
that	O
Nat1	O
-	O
null	O
mES	O
cells	O
possess	O
a	O
transcriptional	O
profile	O
similar	O
,	O
although	O
not	O
identical	O
,	O
to	O
the	O
ground	O
state	O
,	O
which	O
is	O
established	O
in	O
wild-type	O
mES	O
cells	O
when	O
treated	O
with	O
inhibitors	O
of	O
the	O
ERK	O
and	O
glycogen	O
synthase	O
kinase	O
3	O
(	O
GSK3	O
)	O
signaling	O
pathways	O
.	O

In	O
Nat1	O
-	O
null	O
mES	O
cells	O
,	O
the	O
ERK	O
pathway	O
is	O
suppressed	O
even	O
without	O
inhibitors	O
.	O

Ribosome	O
profiling	B-P
revealed	O
that	O
translation	O
of	O
mitogen-activated	O
protein	O
kinase	O
kinase	O
kinase	O
3	O
(	O
Map3k3	O
)	O
and	O
son	O
of	O
sevenless	O
homolog	O
1	O
(	O
Sos1	O
)	O
is	O
suppressed	O
in	O
the	O
absence	O
of	O
Nat1	O
Forced	O
expression	O
of	O
Map3k3	O
induced	O
differentiation	O
of	O
Nat1	O
-	O
null	O
mES	O
cells	O
.	O

These	O
data	O
collectively	O
show	O
that	O
Nat1	O
is	O
involved	O
in	O
the	O
translation	O
of	O
proteins	O
that	O
are	O
required	O
for	O
cell	O
differentiation	O
.	O

The	O
recognition	O
and	O
incidence	O
of	O
peroneal	O
tendon	O
dislocation	O
associated	O
with	O
a	O
fracture	O
of	O
the	O
talus	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
clarify	O
first	O
,	O
the	O
incidence	O
of	O
peroneal	O
tendon	O
dislocation	O
in	O
patients	O
with	O
a	O
fracture	O
of	O
the	O
talus	O
and	O
second	O
the	O
factors	O
associated	O
with	O
peroneal	O
tendon	O
dislocation	O
.	O

We	O
retrospectively	O
examined	O
30	O
patients	O
(	O
30	O
ankles	O
)	O
with	O
a	O
mean	O
age	O
of	O
37.5	O
years	O
,	O
who	O
had	O
undergone	O
internal	O
fixation	O
for	O
a	O
fracture	O
of	O
the	O
talus	O
.	O

Independent	O
examiners	O
assessed	O
for	O
peroneal	O
tendon	O
dislocation	O
using	O
the	O
pre-operative	O
CT	B-P
images	I-P
.	O

The	O
medical	O
records	O
were	O
also	O
reviewed	O
for	O
the	O
presence	O
of	O
peroneal	O
tendon	O
dislocation	O
.	O

The	O
associations	O
between	O
the	O
presence	O
of	O
dislocation	O
with	O
the	O
patient	O
characteristics	O
or	O
radiological	B-P
findings	O
,	O
including	O
age	O
,	O
mechanism	O
of	O
injury	O
,	O
severity	O
of	O
fracture	O
,	O
and	O
fleck	O
sign	O
,	O
were	O
assessed	O
using	O
Fisher	O
's	O
exact	O
tests	O
.	O

The	O
pre-operative	O
CT	B-P
images	I-P
showed	O
peroneal	O
tendon	O
dislocation	O
in	O
eight	O
out	O
of	O
30	O
patients	O
.	O

Dislocation	O
was	O
found	O
later	O
in	O
one	O
patient	O
whose	O
pre-operative	O
CT	B-P
image	I-P
had	O
not	O
shown	O
dislocation	O
.	O

The	O
overall	O
incidence	O
of	O
peroneal	O
tendon	O
dislocation	O
was	O
30	O
%	O
(	O
9/30	O
)	O
.	O

The	O
presence	O
of	O
dislocation	O
was	O
associated	O
with	O
the	O
presence	O
of	O
a	O
fleck	O
sign	O
(	O
p	O
=	O
0.03	O
)	O
.	O

Surprisingly	O
,	O
approximately	O
one-third	O
of	O
the	O
patients	O
who	O
underwent	O
internal	O
fixation	O
for	O
a	O
fracture	O
of	O
the	O
talus	O
had	O
peroneal	O
tendon	O
dislocation	O
.	O

This	O
was	O
associated	O
with	O
a	O
fleck	O
sign	O
.	O

Cite	O
this	O
article	O
:	O
Bone	O
Joint	O
J	O
2017	O
;	O
99-B:489-93	O
.	O

Clinical	O
Features	O
of	O
Smokers	O
With	O
Radiological	B-P
Emphysema	O
But	O
Without	O
Airway	O
Limitation	O
.	O

The	O
clinical	O
characteristics	O
of	O
patients	O
with	O
emphysema	O
but	O
without	O
airway	O
limitations	O
remain	O
unknown	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
clinical	O
features	O
of	O
current	O
and	O
former	O
smokers	O
without	O
airflow	O
limitation	O
who	O
have	O
radiologic	B-P
emphysema	O
on	O
chest	B-P
CT	I-P
scans	I-P
vs	O
a	O
control	O
group	O
of	O
current	O
and	O
ex-smokers	O
without	O
emphysema	O
.	O

Subjects	O
enrolled	O
had	O
anthropometric	B-P
characteristics	I-P
recorded	O
,	O
provided	O
a	O
medical	O
history	O
,	O
and	O
underwent	O
low-dose	O
chest	B-P
CT	I-P
scanning	I-P
.	O

The	O
following	O
parameters	O
were	O
also	O
evaluated	O
:	O
pulmonary	B-P
function	I-P
tests	I-P
including	O
diffusion	B-P
capacity	I-P
for	I-P
carbon	I-P
monoxide	I-P
(	O
Dlco	B-P
)	O
,	O
the	O
modified	O
Medical	O
Research	O
Council	O
dyspnea	O
score	O
,	O
COPD	O
assessment	O
test	O
(	O
CAT	O
)	O
,	O
and	O
6-min	B-P
walk	I-P
test	I-P
(	O
6MWT	B-P
)	O
.	O

A	O
comparison	O
was	O
conducted	O
between	O
those	O
with	O
and	O
without	O
CT	B-P
-	O
confirmed	O
emphysema	O
.	O

Of	O
the	O
203	O
subjects	O
,	O
154	O
had	O
emphysema	O
,	O
and	O
49	O
did	O
not	O
.	O

Adjusted	O
group	O
comparisons	O
revealed	O
that	O
a	O
higher	O
proportion	O
of	O
patients	O
with	O
emphysema	O
according	O
to	O
low-dose	O
chest	B-P
CT	I-P
scanning	I-P
had	O
an	O
abnormal	O
Dlco	O
value	O
(	O
<	O
80	O
%	O
)	O
(	O
46	O
%	O
vs	O
19	O
%	O
;	O
P	O
=	O
.02	O
)	O
,	O
a	O
decrease	O
in	O
percentage	O
of	O
oxygen	O
saturation	O
>	O
4	O
%	O
during	O
the	O
6MWT	B-P
(	O
8.5	O
%	O
vs	O
0	O
;	O
P	O
=	O
.04	O
)	O
,	O
and	O
an	O
altered	O
quality	O
of	O
life	O
(	O
CAT	O
score	O
≥	O
10	O
)	O
(	O
32	O
%	O
vs	O
14	O
%	O
;	O
P	O
=	O
.01	O
)	O
.	O

A	O
detailed	O
analysis	O
of	O
the	O
CAT	O
questionnaire	O
items	O
revealed	O
that	O
more	O
patients	O
with	O
emphysema	O
had	O
a	O
score	O
≥	O
1	O
in	O
the	O
``	O
chest	O
tightness	O
``	O
(	O
P	O
=	O
.05	O
)	O
and	O
``	O
limitation	O
when	O
doing	O
activities	O
at	O
home	O
``	O
(	O
P	O
<	O
.01	O
)	O
items	O
compared	O
with	O
those	O
with	O
no	O
emphysema	O
.	O

They	O
also	O
experienced	O
significantly	O
more	O
exacerbations	O
in	O
the	O
previous	O
year	O
(	O
0.19	O
vs	O
0.04	O
;	O
P	O
=	O
.02	O
)	O
.	O

A	O
significant	O
proportion	O
of	O
smokers	O
with	O
emphysema	O
according	O
to	O
low-dose	O
chest	B-P
CT	I-P
scanning	I-P
but	O
without	O
airway	O
limitation	O
had	O
alterations	O
in	O
their	O
quality	O
of	O
life	O
,	O
number	O
of	O
exacerbations	O
,	O
Dlco	B-P
values	O
,	O
and	O
oxygen	O
saturation	O
during	O
the	O
6MWT	B-P
test	I-P
.	O

Diagnosing	O
a	O
rare	O
case	O
of	O
desmoplastic	O
small	O
round	O
cell	O
tumour	O
on	O
liver	B-P
biopsy	I-P
.	O

A	O
50-	O
year	O
-old	O
male	O
of	O
Indian	O
descent	O
presented	O
with	O
jaundice	O
and	O
right	O
hypochondrium	O
pain	O
.	O

Following	O
a	O
computed	B-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
scan	I-P
of	O
the	O
abdomen	O
,	O
a	O
segment	O
7	O
liver	O
lesion	O
was	O
visualized	O
,	O
accompanied	O
by	O
extensive	O
peritoneal	O
tumour	O
deposits	O
.	O

An	O
ultrasound	B-P
guided	I-P
liver	I-P
biopsy	I-P
was	O
performed	O
and	O
histology	O
showed	O
loose	O
nests	O
and	O
sheets	O
of	O
tumour	O
cells	O
with	O
a	O
small	O
blue	O
round	O
cell	O
morphology	O
.	O

The	O
tumour	O
cells	O
showed	O
patchy	O
strong	O
immunopositivity	O
for	O
cytokeratins	O
(	O
AE1/3	O
,	O
CK7	O
,	O
CK19	O
)	O
and	O
synaptophysin	O
,	O
while	O
showing	O
diffuse	O
strong	O
perinuclear	O
positivity	O
for	O
desmin	O
.	O

Interphase	O
fluorescence	O
in-situ	O
hybridization	O
(	O
FISH	O
)	O
study	O
using	O
EWSR1	O
breakapart	O
probe	O
was	O
positive	O
for	O
EWSR1	O
gene	O
rearrangement	O
.	O

Desmoplastic	O
small	O
round	O
cell	O
tumour	O
is	O
a	O
rare	O
but	O
aggressive	O
intra-abdominal	O
mesenchymal	O
tumour	O
.	O

While	O
the	O
primary	O
sites	O
of	O
involvement	O
are	O
usually	O
the	O
peritoneum	O
and	O
omentum	O
,	O
visceral	O
involvement	O
can	O
occur	O
.	O

We	O
wish	O
to	O
highlight	O
the	O
importance	O
of	O
considering	O
this	O
entity	O
when	O
evaluating	O
a	O
liver	B-P
biopsy	I-P
especially	O
in	O
a	O
less	O
than	O
classical	O
clinical	O
context	O
.	O

Lithium	O
silicate	O
endocrown	O
fabricated	O
with	O
a	O
CAD-CAM	O
system	O
:	O
A	O
functional	O
and	O
esthetic	O
protocol	O
.	O

An	O
endocrown	O
restoration	O
is	O
an	O
alternative	O
approach	O
to	O
complete	O
crowns	O
with	O
intraradicular	O
cores	O
or	O
dowels	O
for	O
the	O
restoration	O
of	O
endodontically	O
treated	O
teeth	O
.	O

Endocrowns	O
conserve	O
tooth	O
structure	O
and	O
require	O
fewer	O
dental	O
visits	O
.	O

This	O
approach	O
has	O
been	O
widely	O
used	O
,	O
and	O
various	O
materials	O
and	O
techniques	O
have	O
been	O
reported	O
.	O

Computer-aided	O
design	O
and	O
computer-aided	O
manufacturing	O
(	O
CAD-CAM	O
)	O
systems	O
can	O
generate	O
and	O
store	O
libraries	O
of	O
teeth	O
with	O
various	O
anatomies	O
in	O
their	O
database	O
,	O
and	O
diagnostic	B-P
tooth	I-P
waxing	I-P
may	O
not	O
be	O
required	O
.	O

However	O
,	O
occlusal	O
adjustments	O
after	O
the	O
cementation	O
of	O
indirect	O
restorations	O
are	O
often	O
frustrating	O
.	O

Thus	O
,	O
a	O
rapid	O
and	O
efficient	O
way	O
of	O
addressing	O
this	O
challenge	O
is	O
necessary	O
.	O

This	O
clinical	O
report	O
presents	O
a	O
protocol	O
for	O
the	O
fabrication	O
and	O
delivery	O
of	O
an	O
endocrown	O
by	O
using	O
the	O
biogeneric	O
design	O
mode	O
with	O
lithium	O
silicate-based	O
ceramic	O
adjusted	O
before	O
its	O
complete	O
sintering	O
.	O

Long-term	O
lamivudine	O
therapy	O
in	O
chronic	O
hepatitis	O
B	O
.	O

One	O
to	O
5	O
years	O
of	O
therapy	O
of	O
chronic	O
hepatitis	O
B	O
with	O
oral	O
nucleoside	O
analogues	O
result	O
in	O
significant	O
clinical	O
improvements	O
,	O
but	O
effects	O
of	O
more	O
prolonged	O
therapy	O
are	O
not	O
well	O
defined	O
.	O

To	O
describe	O
outcomes	O
of	O
chronic	O
hepatitis	O
B	O
with	O
long-term	O
lamivudine	O
therapy	O
.	O

Forty-two	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
treated	O
with	O
lamivudine	O
were	O
followed	O
for	O
3.2-19.5	O
(	O
median	O
=	O
16.1	O
)	O
years	O
.	O

Therapy	O
was	O
switched	O
to	O
other	O
agents	O
(	O
n	O
=	O
16	O
)	O
if	O
patients	O
developed	O
lamivudine	O
resistance	O
and	O
relapse	O
of	O
disease	O
.	O

Among	O
22	O
HBeAg-positive	O
patients	O
,	O
17	O
(	O
77	O
%	O
)	O
became	O
HBeAg	O
negative	O
,	O
of	O
whom	O
5	O
(	O
23	O
%	O
)	O
subsequently	O
cleared	O
HBsAg	O
.	O

Among	O
20	O
HBeAg-negative	O
patients	O
,	O
10	O
(	O
50	O
%	O
)	O
cleared	O
HBsAg	O
.	O

The	O
time	O
to	O
HBsAg	O
clearance	O
ranged	O
from	O
0.9	O
to	O
16.8	O
(	O
median	O
=	O
9.3	O
)	O
years	O
.	O

Lamivudine	O
resistance	O
arose	O
in	O
24	O
patients	O
(	O
57	O
%	O
)	O
of	O
whom	O
6	O
(	O
25	O
%	O
)	O
lost	O
HBsAg	O
.	O

HBsAg	O
clearance	O
was	O
not	O
always	O
accompanied	O
by	O
seroconversion	O
;	O
anti-HBs	B-P
appearing	O
concurrently	O
in	O
only	O
five	O
patients	O
(	O
33	O
%	O
)	O
.	O

Nevertheless	O
,	O
HBsAg	O
loss	O
allowed	O
for	O
stopping	O
therapy	O
in	O
all	O
patients	O
,	O
none	O
re-developing	O
HBsAg	O
or	O
suffering	O
relapse	O
;	O
all	O
having	O
normal	O
alanine	B-P
aminotransferase	I-P
levels	I-P
and	O
no	O
(	O
n	O
=	O
13	O
)	O
or	O
unquantifiable	O
HBV	B-P
DNA	I-P
levels	I-P
(	O
n	O
=	O
2	O
)	O
when	O
last	O
seen	O
.	O

In	O
contrast	O
,	O
seven	O
of	O
27	O
patients	O
(	O
26	O
%	O
)	O
who	O
remained	O
HBsAg-positive	O
died	O
of	O
liver	O
disease	O
or	O
liver	O
cancer	O
or	O
underwent	O
liver	O
transplantation	O
,	O
all	O
of	O
whom	O
had	O
cirrhosis	O
.	O

Long-term	O
viral	O
suppression	O
with	O
nucleoside	O
analogues	O
leads	O
to	O
HBsAg	O
loss	O
in	O
a	O
substantial	O
proportion	O
of	O
patients	O
,	O
particularly	O
if	O
HBeAg-negative	O
.	O

Serious	O
outcomes	O
during	O
the	O
first	O
10-20	O
years	O
of	O
treatment	O
occur	O
largely	O
among	O
patients	O
with	O
pre-existing	O
cirrhosis	O
who	O
do	O
not	O
clear	O
HBsAg	O
with	O
therapy	O
.	O

Emergency	O
splenectomy	O
postelective	O
colonoscopy	B-P
.	O

Colonoscopy	B-P
is	O
the	O
gold	O
standard	O
for	O
investigation	O
of	O
colorectal	O
carcinoma	O
and	O
inflammatory	O
bowel	O
disease	O
.	O

Splenic	O
injury	O
is	O
a	O
rare	O
but	O
potentially	O
fatal	O
complication	O
of	O
colonoscopy	B-P
.	O

The	O
present	O
case	O
study	O
outlines	O
the	O
early	O
clinical	O
presentation	O
and	O
rapid	O
deterioration	O
of	O
a	O
patient	O
with	O
a	O
splenic	O
injury	O
after	O
an	O
elective	O
colonoscopy	B-P
.	O

A	O
70-year-old	O
female	O
underwent	O
a	O
colonoscopy	B-P
for	O
investigation	O
of	O
altered	O
bowel	O
habit	O
.	O

The	O
procedure	O
was	O
documented	O
as	O
difficult	O
due	O
to	O
the	O
presence	O
of	O
'	O
stiff	O
loopy	O
colon	O
'	O
.	O

In	O
recovery	O
,	O
patient	O
's	O
condition	O
deteriorated	O
and	O
she	O
was	O
moved	O
to	O
the	O
ward	O
for	O
further	O
assessment	O
.	O

She	O
gradually	O
became	O
haemodynamically	O
unstable	O
and	O
displayed	O
signs	O
of	O
peritoneal	O
irritation	O
.	O

Initial	O
attempts	O
of	O
fluid	O
resuscitation	O
failed	O
to	O
improve	O
patient	O
's	O
clinical	O
condition	O
.	O

Further	O
testing	O
revealed	O
a	O
significant	O
drop	O
in	O
haemoglobin	O
and	O
CT	B-P
confirmed	O
the	O
diagnosis	O
of	O
a	O
splenic	O
rupture	O
.	O

She	O
underwent	O
an	O
emergency	O
splenectomy	O
that	O
evening	O
.	O

Postoperatively	O
she	O
was	O
managed	O
in	O
the	O
high	O
dependency	O
unit	O
.	O

Xylan-based	O
temperature	O
/	O
pH	O
sensitive	O
hydrogels	O
for	O
drug	O
controlled	O
release	O
.	O

Xylan-based	O
temperature	O
/	O
pH	O
sensitive	O
hydrogels	O
were	O
prepared	O
by	O
the	O
crosslinking	O
copolymerization	O
of	O
xylan	O
with	O
N-isopropylacrylamide	O
(	O
NIPAm	O
)	O
and	O
acrylic	O
acid	O
(	O
AA	O
)	O
using	O
N	O
,	O
Ń-methylenebis-acrylamide	O
(	O
MBA	O
)	O
as	O
a	O
cross-linker	O
and	O
2,2-dimethoxy-2-phenylacetophenone	O
as	O
a	O
photoinitiator	O
via	O
ultraviolet	O
irradiation	O
.	O

The	O
influence	O
of	O
the	O
NIPAm	O
,	O
AA	O
and	O
MBA	O
amount	O
on	O
properties	O
of	O
xylan-based	O
hydrogels	O
was	O
discussed	O
.	O

The	O
morphology	O
and	O
interactions	O
of	O
hydrogels	O
were	O
characterized	O
by	O
SEM	B-P
and	O
FTIR	O
.	O

The	O
lower	O
critical	O
solution	O
temperature	O
(	O
LCST	O
)	O
of	O
hydrogels	O
was	O
investigated	O
by	O
DSC	B-P
.	O

The	O
results	O
indicated	O
that	O
the	O
LCST	O
of	O
hydrogels	O
emerged	O
at	O
around	O
34°C	O
and	O
increased	O
with	O
increasing	O
the	O
AA	O
content	O
.	O

The	O
drug	O
encapsulation	O
efficiency	O
of	O
as-prepared	O
hydrogels	O
reached	O
to	O
97.60	O
%	O
and	O
the	O
cumulative	O
release	O
rate	O
of	O
acetylsalicylic	O
acid	O
was	O
90.12	O
%	O
and	O
26.35	O
%	O
in	O
the	O
intestinal	O
and	O
gastric	O
fluid	O
,	O
respectively	O
.	O

Xylan-based	O
hydrogels	O
were	O
proved	O
to	O
be	O
biocompatible	O
with	O
NIH3T3	O
cell	O
by	O
MTT	O
assay	O
and	O
showed	O
the	O
promising	O
application	O
as	O
drug	O
carriers	O
for	O
the	O
intestinal	O
-	O
targeted	O
oral	O
drug	O
delivery	O
.	O

Dietary	O
grape	O
seed	O
proanthocyanidins	O
inactivate	O
regulatory	O
T	O
cells	O
by	O
promoting	O
NER	O
-	O
dependent	O
DNA	O
repair	O
in	O
dendritic	O
cells	O
in	O
UVB	O
-	O
exposed	O
skin	O
.	O

Ultraviolet	O
B	O
(	O
UVB	O
)	O
radiation	O
induces	O
regulatory	O
T	O
cells	O
(	O
Treg	O
cells	O
)	O
and	O
depletion	O
of	O
these	O
Treg	O
cells	O
alleviates	O
immunosuppression	O
and	O
inhibits	O
photocarcinogenesis	O
in	O
mice	O
.	O

Here	O
,	O
we	O
determined	O
the	O
effects	O
of	O
dietary	O
grape	O
seed	O
proanthocyanidins	O
(	O
GSPs	O
)	O
on	O
the	O
development	O
and	O
activity	O
of	O
UVB	O
-	O
induced	O
Treg	O
cells	O
.	O

C3H/HeN	O
mice	O
fed	O
a	O
GSPs	O
(	O
0.5	O
%	O
,	O
w/w	O
)	O
-	O
supplemented	O
or	O
control	O
diet	O
were	O
exposed	O
to	O
UVB	O
(	O
150	O
mJ/cm2	O
)	O
radiation	O
,	O
sensitized	O
to	O
2,4-dinitrofluorobenzene	O
(	O
DNFB	O
)	O
and	O
sacrificed	O
5	O
days	O
later	O
.	O

FACS	B-P
analysis	O
indicated	O
that	O
dietary	O
GSPs	O
decrease	O
the	O
numbers	O
of	O
UVB	O
-	O
induced	O
Treg	O
cells	O
.	O

ELISA	B-P
analysis	O
of	O
cultured	O
sorted	O
Treg	O
cells	O
indicated	O
that	O
secretion	O
of	O
immunosuppressive	O
cytokines	O
(	O
interleukin-10	O
,	O
TGF-β	O
)	O
was	O
significantly	O
lower	O
in	O
Treg	O
cells	O
from	O
GSPs	O
-	O
fed	O
mice	O
.	O

Dietary	O
GSPs	O
also	O
enhanced	O
the	O
ability	O
of	O
Treg	O
cells	O
from	O
wild-type	O
mice	O
to	O
stimulate	O
production	O
of	O
IFNγ	O
by	O
T	O
cells	O
.	O

These	O
effects	O
of	O
dietary	O
GSPs	O
on	O
Treg	O
cell	O
function	O
were	O
not	O
found	O
in	O
XPA	O
-	O
deficient	O
mice	O
,	O
which	O
are	O
incapable	O
of	O
repairing	O
UVB	O
-	O
induced	O
DNA	O
damage	O
.	O

Adoptive	O
transfer	O
experiments	O
revealed	O
that	O
naïve	O
recipients	O
that	O
received	O
Treg	O
cells	O
from	O
GSPs	O
-	O
fed	O
UVB	O
-	O
irradiated	O
wild-type	O
donors	O
that	O
had	O
been	O
sensitized	O
to	O
DNFB	O
exhibited	O
a	O
significantly	O
higher	O
contact	O
hypersensitivity	O
(	O
CHS	O
)	O
response	O
to	O
DNFB	O
than	O
mice	O
that	O
received	O
Treg	O
cells	O
from	O
UVB	O
-	O
exposed	O
mice	O
fed	O
the	O
control	O
diet	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
CHS	O
response	O
between	O
mice	O
that	O
received	O
Treg	O
cells	O
from	O
UVB	O
-	O
irradiated	O
XPA	O
-	O
deficient	O
donors	O
fed	O
GSPs	O
or	O
the	O
control	O
diet	O
.	O

Furthermore	O
,	O
dietary	O
GSPs	O
significantly	O
inhibited	O
UVB	O
-	O
induced	O
skin	O
tumor	O
development	O
in	O
wild-type	O
mice	O
but	O
not	O
in	O
XPA	O
-	O
deficient	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
GSPs	O
inactivate	O
Treg	O
cells	O
by	O
promoting	O
DNA	O
repair	O
in	O
dendritic	O
cells	O
in	O
UVB	O
-	O
exposed	O
skin	O
.	O

Salivary	O
protective	O
factors	O
in	O
patients	O
suffering	O
from	O
decompensated	O
type	O
2	O
diabetes	O
.	O

Defining	O
the	O
level	O
of	O
protective	O
factors	O
in	O
saliva	O
of	O
patients	O
suffering	O
from	O
decompensated	O
type	O
2	O
diabetes	O
.	O

50	O
Patients	O
with	O
diagnosis	O
of	O
decompensated	O
type	O
2	O
diabetes	O
,	O
including	O
32	O
women	O
and	O
18	O
men	O
at	O
the	O
age	O
of	O
57.9±9.2	O
years	O
.	O

The	O
control	O
group	O
consisted	O
of	O
50	O
people	O
among	O
whom	O
there	O
were	O
38	O
women	O
and	O
12	O
men	O
whose	O
average	O
age	O
was	O
estimated	O
at	O
51.2±9.9	O
years	O
.	O

It	O
was	O
stated	O
the	O
increased	O
concentration	O
of	O
total	O
protein	O
by	O
60	O
%	O
and	O
decreased	O
concentration	O
of	O
IgA	O
by	O
70	O
%	O
,	O
of	O
lysozyme	O
by	O
27	O
%	O
and	O
of	O
lactoferrin	O
by	O
40	O
%	O
in	O
resting	O
saliva	O
of	O
patients	O
with	O
type	O
2	O
diabetes	O
if	O
compared	O
to	O
the	O
control	O
group	O
.	O

These	O
outcomes	O
were	O
really	O
statistically	O
meaningful	O
.	O

The	O
evaluation	O
of	O
dependences	O
between	O
the	O
analyzed	O
protective	O
factors	O
and	O
the	O
indicator	O
of	O
oral	O
cavity	O
condition	O
proved	O
the	O
positive	O
correlation	O
between	O
the	O
concentration	O
of	O
total	B-P
protein	I-P
and	O
the	O
number	O
of	O
DMFT	O
(	O
i.e	O
.	O

the	O
rate	O
of	O
caries	O
intensity	O
)	O
.	O

The	O
remaining	O
coefficients	O
of	O
correlation	O
being	O
evaluated	O
proved	O
to	O
be	O
negative	O
and	O
statistically	O
meaningless	O
.	O

The	O
obtained	O
outcomes	O
prove	O
a	O
high	O
influence	O
of	O
proteins	O
included	O
in	O
saliva	O
on	O
the	O
prevalence	O
and	O
development	O
of	O
caries	O
at	O
patients	O
with	O
decompensated	O
type	O
2	O
diabetes	O
.	O

Does	O
adenomatous	O
polyposis	O
coli	O
gene	O
promoter	O
1A	O
methylation	B-P
increase	O
non-small	O
cell	O
lung	O
cancer	O
risk	O
?	O

A	O
meta-analysis	O
.	O

The	O
promoter	O
region	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
is	O
hypermethylated	O
in	O
several	O
types	O
of	O
cancers	O
,	O
including	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

The	O
prevalence	O
of	O
methylation	B-P
in	O
the	O
promoter	O
region	O
of	O
this	O
gene	O
in	O
tumor	O
tissues	O
and	O
autologous	B-P
controls	I-P
has	O
not	O
been	O
consistent	O
in	O
previous	O
studies	O
.	O

We	O
evaluated	O
the	O
frequency	O
of	O
APC	O
gene	O
promoter	O
1A	O
methylation	B-P
between	O
tumor	O
tissues	O
and	O
autologous	B-P
controls	I-P
in	O
NSCLC	O
patients	O
by	O
meta-analysis	O
.	O

Open	O
published	O
studies	O
of	O
APC	O
gene	O
promoter	O
1A	O
methylation	B-P
between	O
tumor	O
tissues	O
and	O
autologous	O
samples	O
in	O
NSCLC	O
patients	O
were	O
identified	O
using	O
a	O
systematic	O
search	O
.	O

Odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
of	O
APC	O
gene	O
promoter	O
1A	O
methylation	B-P
in	O
lung	O
cancer	O
tissues	O
versus	O
autologous	B-P
controls	I-P
were	O
calculated	O
.	O

Fourteen	O
studies	O
,	O
involving	O
a	O
total	O
of	O
1345	O
patients	O
and	O
2182	O
samples	O
,	O
were	O
finally	O
included	O
.	O

The	O
pooled	O
proportion	O
of	O
APC	O
promoter	O
1A	O
methylation	B-P
was	O
0.62	O
(	O
95	O
%	O
CI	O
0.52-072	O
)	O
and	O
0.34	O
(	O
95	O
%	O
CI	O
0.21-0.50	O
)	O
in	O
cancer	O
tissues	O
and	O
autologous	B-P
controls	I-P
,	O
respectively	O
.	O

The	O
APC	O
gene	O
promoter	O
1A	O
methylation	B-P
rate	O
in	O
cancer	O
tissues	O
was	O
much	O
higher	O
than	O
in	O
autologous	B-P
controls	I-P
,	O
with	O
a	O
pooled	O
OR	O
of	O
3.66	O
(	O
95	O
%	O
CI	O
2.12-6.33	O
)	O
.	O

A	O
strong	O
and	O
significant	O
correlation	O
of	O
APC	O
gene	O
promoter	O
1A	O
methylation	B-P
between	O
tumor	O
tissues	O
and	O
autologous	B-P
controls	I-P
was	O
detected	O
(	O
correlation	O
coefficient	O
rpearson	O
=	O
0.77	O
;	O
P	O
=	O
0.0013	O
)	O
.	O

The	O
proportion	O
of	O
APC	O
promoter	O
1A	O
methylation	B-P
in	O
lung	O
cancer	O
tissues	O
was	O
higher	O
than	O
in	O
autologous	B-P
controls	I-P
,	O
indicating	O
that	O
promoter	O
1A	O
methylation	B-P
of	O
the	O
APC	O
gene	O
may	O
play	O
an	O
important	O
role	O
in	O
NSCLC	O
carcinogenesis	O
.	O

Cyanate	O
-	O
Impaired	O
Angiogenesis	O
:	O
Association	O
With	O
Poor	O
Coronary	O
Collateral	O
Growth	O
in	O
Patients	O
With	O
Stable	O
Angina	O
and	O
Chronic	O
Total	O
Occlusion	O
.	O

Cyanate	O
has	O
recently	O
gained	O
attention	O
for	O
its	O
role	O
in	O
the	O
pathogenesis	O
of	O
vascular	O
injury	O
.	O

Nonetheless	O
,	O
the	O
effect	O
of	O
cyanate	O
on	O
angiogenesis	O
remains	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
oral	O
administration	O
of	O
cyanate	O
impaired	O
blood	O
perfusion	O
recovery	O
in	O
a	O
mouse	O
hind-limb	O
ischemia	O
model	O
.	O

A	O
reduction	O
in	O
blood	O
perfusion	O
recovery	O
at	O
day	O
21	O
was	O
observed	O
in	O
the	O
ischemic	O
tissue	O
of	O
cyanate	O
-	O
treated	O
mice	O
.	O

Likewise	O
,	O
there	O
were	O
fewer	O
capillaries	O
in	O
the	O
ischemic	O
hind-limb	O
tissue	O
of	O
cyanate	O
-	O
exposed	O
mice	O
.	O

Our	O
in	O
vitro	O
study	O
showed	O
that	O
cyanate	O
,	O
together	O
with	O
its	O
carbamylated	O
products	O
,	O
inhibited	O
the	O
migration	O
,	O
proliferation	O
,	O
and	O
tube-formation	O
abilities	O
of	O
endothelial	O
cells	O
.	O

Further	O
research	O
revealed	O
that	O
cyanate	O
regulated	O
angiogenesis	O
partly	O
by	O
interrupting	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
/	O
phosphatidylinositol	O
3-kinase	O
/	O
Akt	O
pathway	O
.	O

The	O
serum	O
concentrations	O
of	O
homocitrulline	O
,	O
a	O
marker	O
of	O
cyanate	O
exposure	O
,	O
were	O
determined	O
in	O
117	O
patients	O
with	O
stable	O
angina	O
and	O
chronic	O
total	O
occlusion	O
.	O

Consistent	O
with	O
the	O
antiangiogenic	O
role	O
of	O
cyanate	O
,	O
homocitrulline	B-P
levels	I-P
were	O
increased	O
in	O
patients	O
with	O
poor	O
coronary	O
collateralization	O
(	O
n=58	O
)	O
compared	O
with	O
those	O
with	O
high	O
collateralization	O
(	O
n=59	O
;	O
21.09±13.08	O
versus	O
15.54±9.02	O
ng/mL	O
,	O
P=0.009	O
)	O
.	O

In	O
addition	O
,	O
elevated	O
homocitrulline	O
concentration	O
was	O
a	O
strong	O
predictor	O
of	O
poor	O
coronary	O
collateral	O
growth	O
.	O

Impaired	O
angiogenesis	O
induced	O
by	O
cyanate	O
might	O
contribute	O
to	O
poor	O
coronary	O
collateral	O
growth	O
.	O

Peripheral	O
interactions	O
between	O
cannabinoid	O
and	O
opioid	O
receptor	O
agonists	O
in	O
a	O
model	O
of	O
inflammatory	O
mechanical	O
hyperalgesia	O
.	O

Activation	O
of	O
opioid	O
and	O
cannabinoid	O
receptors	O
expressed	O
in	O
nociceptors	O
induces	O
effective	O
antihyperalgesia	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
combinations	O
of	O
opioid	O
and	O
cannabinoid	O
receptor	O
agonists	O
directed	O
at	O
the	O
injured	O
site	O
would	O
enhance	O
therapeutic	O
effectiveness	O
.	O

Behavioral	O
pharmacology	O
experiments	O
were	O
performed	O
to	O
compare	O
the	O
effects	O
of	O
DAMGO	O
,	O
a	O
selective	O
agonist	O
for	O
μ-opioid	O
receptor	O
(	O
MOR	O
)	O
,	O
ACPA	O
,	O
a	O
specific	O
agonist	O
for	O
CB1	O
,	O
and	O
combinations	O
of	O
DAMGO	O
and	O
ACPA	O
in	O
attenuating	O
complete	O
Freund	O
's	O
adjuvant	O
(	O
CFA	O
)	O
-induced	O
mechanical	O
hyperalgesia	O
in	O
the	O
rat	O
hindpaw	O
.	O

DAMGO	O
(	O
1μg-1mg	O
)	O
or	O
ACPA	O
(	O
1μg-2mg	O
)	O
was	O
administered	O
into	O
the	O
inflamed	O
paw	O
when	O
mechanical	O
hyperalgesia	O
was	O
fully	O
developed	O
.	O

When	O
administered	O
individually	O
,	O
DAMGO	O
and	O
ACPA	O
dose	O
-dependently	O
reversed	O
the	O
mechanical	O
hyperalgesia	O
.	O

DAMGO	O
displayed	O
a	O
lower	O
ED50	O
value	O
(	O
57.4±2.49μg	O
)	O
than	O
ACPA	O
(	O
111.6±2.18μg	O
)	O
,	O
but	O
ACPA	O
produced	O
longer	O
lasting	O
antihyperalgesic	O
effects	O
.	O

Combinations	O
of	O
DAMGO	O
and	O
ACPA	O
also	O
dose	O
-dependently	O
attenuated	O
mechanical	O
hyperalgesia	O
,	O
but	O
the	O
antihyperalgesic	O
effects	O
were	O
partial	O
and	O
transient	O
even	O
at	O
high	O
doses	O
.	O

Using	O
isobolographic	B-P
analysis	I-P
,	O
we	O
determined	O
that	O
combined	O
treatment	O
with	O
DAMGO	O
and	O
ACPA	O
produced	O
antagonistic	O
effects	O
with	O
the	O
observed	O
ED50	O
of	O
128.4±2.28μg	O
.	O

Our	O
findings	O
showed	O
that	O
MOR	O
and	O
CB1	O
agonists	O
directed	O
at	O
the	O
inflamed	O
site	O
effectively	O
attenuate	O
mechanical	O
hyperalgesia	O
when	O
administered	O
individually	O
,	O
but	O
exert	O
opposing	O
effects	O
when	O
administered	O
together	O
.	O

The	O
antagonistic	O
interactions	O
between	O
the	O
two	O
classes	O
of	O
drugs	O
at	O
the	O
inflamed	O
site	O
suggest	O
distinct	O
mechanisms	O
unique	O
to	O
peripheral	O
nociceptors	O
or	O
inflamed	O
tissue	O
,	O
and	O
therefore	O
require	O
further	O
studies	O
to	O
investigate	O
whether	O
the	O
therapeutic	O
utility	O
of	O
the	O
combined	O
drug	O
treatments	O
in	O
chronic	O
pain	O
conditions	O
can	O
be	O
optimized	O
.	O

Quantitative	B-P
Susceptibility	I-P
Mapping	I-P
using	O
Structural	O
Feature	O
based	O
Collaborative	O
Reconstruction	O
(	O
SFCR	O
)	O
in	O
the	O
Human	O
Brain	O
.	O

The	O
reconstruction	O
of	O
MR	O
quantitative	B-P
susceptibility	I-P
mapping	I-P
(	O
QSM	B-P
)	O
from	O
local	O
phase	O
measurements	O
is	O
an	O
ill	O
posed	O
inverse	O
problem	O
and	O
different	O
regularization	O
strategies	O
incorporating	O
a	O
priori	O
information	O
extracted	O
from	O
magnitude	O
and	O
phase	O
images	O
have	O
been	O
proposed	O
.	O

However	O
,	O
the	O
anatomy	O
observed	O
in	O
magnitude	O
and	O
phase	O
images	O
does	O
not	O
always	O
coincide	O
spatially	O
with	O
that	O
in	O
susceptibility	O
maps	O
,	O
which	O
could	O
give	O
erroneous	O
estimation	O
in	O
the	O
reconstructed	O
susceptibility	O
map	O
.	O

In	O
this	O
paper	O
,	O
we	O
develop	O
a	O
structural	O
feature	O
based	O
collaborative	O
reconstruction	O
(	O
SFCR	O
)	O
method	O
for	O
QSM	B-P
including	O
both	O
magnitude	O
and	O
susceptibility	O
based	O
information	O
.	O

The	O
SFCR	O
algorithm	O
is	O
composed	O
of	O
two	O
consecutive	O
steps	O
corresponding	O
to	O
complementary	O
reconstruction	O
models	O
,	O
each	O
with	O
a	O
structural	O
feature	O
based	O
l1	O
norm	O
constraint	O
and	O
a	O
voxel	O
fidelity	O
based	O
l2	O
norm	O
constraint	O
,	O
which	O
allows	O
both	O
the	O
structure	O
edges	O
and	O
tiny	O
features	O
to	O
be	O
recovered	O
,	O
whereas	O
the	O
noise	O
and	O
artifacts	O
could	O
be	O
reduced	O
.	O

In	O
the	O
M-step	O
,	O
the	O
initial	O
susceptibility	O
map	O
is	O
reconstructed	O
by	O
employing	O
a	O
k-space	O
based	O
compressed	O
sensing	O
model	O
incorporating	O
magnitude	O
prior	O
.	O

In	O
the	O
S-step	O
,	O
the	O
susceptibility	O
map	O
is	O
fitted	O
in	O
spatial	O
domain	O
using	O
weighted	O
constraints	O
derived	O
from	O
the	O
initial	O
susceptibility	O
map	O
from	O
the	O
M-step	O
.	O

Simulations	O
and	O
in	O
vivo	O
human	O
experiments	O
at	O
7T	O
MRI	B-P
show	O
that	O
the	O
SFCR	O
method	O
provides	O
high	O
quality	O
susceptibility	O
maps	O
with	O
improved	O
RMSE	O
and	O
MSSIM	O
.	O

Finally	O
,	O
the	O
susceptibility	O
values	O
of	O
deep	O
gray	O
matter	O
are	O
analyzed	O
in	O
multiple	O
head	O
positions	O
,	O
with	O
the	O
supine	O
position	O
most	O
approximate	O
to	O
the	O
gold	O
standard	O
COSMOS	O
result	O
.	O

Cognitive	O
impairment	O
in	O
first-episode	O
drug-naïve	O
patients	O
with	O
schizophrenia	O
:	O
Relationships	O
with	O
serum	O
concentrations	O
of	O
brain-derived	O
neurotrophic	O
factor	O
and	O
glial	O
cell	O
line-derived	O
neurotrophic	O
factor	O
.	O

Evidence	O
suggests	O
that	O
brain-derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
and	O
glial	O
cell	O
line	O
-derived	O
neurotrophic	O
factor	O
(	O
GDNF	O
)	O
are	O
important	O
in	O
the	O
regulation	O
of	O
synaptic	O
plasticity	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
cognitive	O
processes	O
in	O
psychiatric	O
disorders	O
.	O

Our	O
work	O
aimed	O
at	O
exploring	O
the	O
associations	O
between	O
serum	O
BDNF	O
and	O
GDNF	O
levels	O
and	O
cognitive	O
functions	O
in	O
first-episode	O
drug-naïve	O
(	O
FEDN	O
)	O
patients	O
with	O
schizophrenia	O
.	O

The	O
BDNF	O
and	O
GDNF	O
levels	O
of	O
58	O
FEDN	O
patients	O
and	O
55	O
age	O
-	O
and	O
sex	O
-matched	O
healthy	O
controls	O
were	O
measured	O
and	O
test	O
subjects	O
were	O
examined	O
using	O
several	O
neurocognitive	B-P
tests	I-P
including	O
the	O
verbal	B-P
fluency	I-P
test	I-P
(	O
VFT	B-P
)	O
,	O
the	O
trail	O
making	O
test	O
(	O
TMT	O
)	O
,	O
the	O
digit	O
span	O
test	O
(	O
DST	O
)	O
,	O
and	O
the	O
Stroop	B-P
test	I-P
.	O

Patients	O
performed	O
significantly	O
worse	O
than	O
controls	O
in	O
nearly	O
all	O
neurocognitive	B-P
performances	I-P
except	O
the	O
forward	O
subscale	O
part	O
of	O
the	O
DST	O
.	O

BDNF	O
levels	O
were	O
inversely	O
correlated	O
to	O
TMT-part	O
B	O
scores	O
and	O
positively	O
correlated	O
to	O
VFT-action	B-P
in	O
the	O
FEDN	O
group	O
.	O

GDNF	O
levels	O
showed	O
a	O
positive	O
correlation	O
with	O
VFT-action	O
scores	O
and	O
a	O
negative	O
correlation	O
with	O
TMT-part	O
B	O
scores	O
of	O
these	O
patients	O
.	O

Current	O
data	O
suggests	O
that	O
cognitive	O
dysfunction	O
widely	O
exists	O
in	O
the	O
early	O
stages	O
of	O
schizophrenia	O
.	O

BDNF	O
and	O
GDNF	O
may	O
be	O
jointly	O
contributed	O
to	O
the	O
pathological	O
mechanisms	O
involved	O
in	O
cognitive	O
impairment	O
in	O
FEDN	O
patients	O
with	O
schizophrenia	O
.	O

Monitoring	O
proteolytic	O
processing	O
events	O
by	O
quantitative	B-P
mass	I-P
spectrometry	I-P
.	O

Protease	O
activity	O
plays	O
a	O
key	O
role	O
in	O
a	O
wide	O
variety	O
of	O
biological	O
processes	O
including	O
gene	O
expression	O
,	O
protein	O
turnover	O
and	O
development	O
.	O

misregulation	O
of	O
these	O
proteins	O
has	O
been	O
associated	O
with	O
many	O
cancer	O
types	O
such	O
as	O
prostate	O
,	O
breast	O
,	O
and	O
skin	O
cancer	O
.	O

thus	O
,	O
the	O
identification	O
of	O
protease	O
substrates	O
will	O
provide	O
key	O
information	O
to	O
understand	O
proteolysis	O
-related	O
pathologies	O
.	O

Areas	O
covered	O
:	O
Proteomics	O
-based	O
methods	O
to	O
investigate	O
proteolysis	O
activity	O
,	O
focusing	O
on	O
substrate	O
identification	O
,	O
protease	O
specificity	O
and	O
their	O
applications	O
in	O
systems	O
biology	O
are	O
reviewed	O
.	O

Their	O
quantification	O
strategies	O
,	O
challenges	O
and	O
pitfalls	O
are	O
underlined	O
and	O
the	O
biological	O
implications	O
of	O
protease	O
malfunction	O
are	O
highlighted	O
.	O

Expert	O
commentary	O
:	O
Dysregulated	O
protease	O
activity	O
is	O
a	O
hallmark	O
for	O
some	O
disease	O
pathologies	O
such	O
as	O
cancer	O
.	O

Current	O
biochemical	O
approaches	O
are	O
low	O
throughput	O
and	O
some	O
are	O
limited	O
by	O
the	O
amount	O
of	O
sample	O
required	O
to	O
obtain	O
reliable	O
results	O
.	O

Mass	B-P
spectrometry	I-P
based	O
proteomics	O
provides	O
a	O
suitable	O
platform	O
to	O
investigate	O
protease	O
activity	O
,	O
providing	O
information	O
about	O
substrate	O
specificity	O
and	O
mapping	B-P
cleavage	O
sites	O
.	O

Interleukin-15	O
as	O
a	O
potential	O
new	O
target	O
in	O
Sjögren	O
's	O
syndrome	O
-	O
associated	O
inflammation	O
.	O

IL-15	O
is	O
a	O
key	O
regulatory	O
cytokine	O
that	O
shares	O
many	O
biological	O
properties	O
with	O
IL-2	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
IL-15	O
could	O
be	O
up-regulated	O
in	O
T	O
cell	O
-mediated	O
inflammatory	O
disorders	O
,	O
such	O
as	O
rheumatoid	O
arthritis	O
and	O
inflammatory	O
bowel	O
diseases	O
.	O

However	O
,	O
the	O
role	O
and	O
expression	O
of	O
IL-15	O
in	O
the	O
inflammatory	O
autoimmune	O
disease	O
Sjögren	O
's	O
syndrome	O
(	O
SS	O
)	O
has	O
not	O
been	O
investigated	O
.	O

In	O
the	O
present	O
study	O
we	O
evaluated	O
the	O
expression	O
of	O
IL-15	O
mRNA	O
and	O
protein	O
in	O
minor	O
salivary	O
gland	O
(	O
MSG	O
)	O
biopsy	O
specimens	O
and	O
in	O
human	O
salivary	O
gland	O
epithelial	O
cell	O
(	O
SGEC	O
)	O
cultures	B-P
obtained	O
from	O
patients	O
with	O
primary	O
SS	O
(	O
pSS	O
)	O
and	O
compared	O
their	O
expression	O
with	O
that	O
seen	O
in	O
normal	O
healthy	O
control	O
subjects	O
.	O

IL-15	O
gene	O
and	O
protein	O
analysis	O
revealed	O
that	O
SGEC	O
are	O
able	O
to	O
produce	O
IL-15	O
.	O

Results	O
obtained	O
demonstrated	O
that	O
the	O
number	O
of	O
IL-15	O
(	O
+	O
)	O
cultured	O
SGEC	O
was	O
significantly	O
higher	O
in	O
cells	O
derived	O
from	O
patients	O
with	O
pSS	O
in	O
comparison	O
with	O
SGEC	O
from	O
healthy	O
subjects	O
;	O
similar	O
results	O
were	O
obtained	O
for	O
IL-15	O
immunoreactivity	O
by	O
using	O
immunohistochemistry	B-P
that	O
revealed	O
a	O
strong	O
expression	O
both	O
in	O
acinar	O
and	O
in	O
ductal	O
cells	O
from	O
pSS	O
MSG	O
.	O

These	O
studies	O
could	O
provide	O
a	O
rational	O
basis	O
to	O
determine	O
whether	O
IL-15	O
could	O
be	O
a	O
good	O
candidate	O
for	O
anti-cytokine	O
therapy	O
in	O
chronic	O
inflammatory	O
pSS	O
diseases	O
.	O

LDLR	O
,	O
ApoB	O
and	O
ApoE	O
genes	O
polymorphisms	O
and	O
classical	O
risk	O
factors	O
in	O
premature	O
coronary	O
artery	O
disease	O
.	O

Lipoproteins	O
play	O
a	O
central	O
role	O
in	O
the	O
development	O
of	O
atherosclerotic	O
disease	O
.	O

So	O
,	O
with	O
their	O
ability	O
to	O
affect	O
lipid	O
levels	O
,	O
the	O
LDLR	O
,	O
ApoB	O
and	O
ApoE	O
polymorphisms	O
could	O
be	O
one	O
of	O
the	O
factors	O
influencing	O
development	O
of	O
atherosclerosis	O
.	O

This	O
hypothesis	O
has	O
been	O
tested	O
in	O
different	O
populations	O
with	O
conflicting	O
results	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
the	O
LDLR	O
,	O
ApoB	O
and	O
ApoE	O
genes	O
polymorphisms	O
with	O
premature	O
CAD	O
(	O
PCAD	O
)	O
in	O
Egyptians	O
.	O

One	O
hundred	O
thirty-five	O
patients	O
of	O
PCAD	O
and	O
one	O
hundred	O
thirty-two	O
ages	O
and	O
sex	O
matched	O
control	O
subjects	O
were	O
included	O
in	O
the	O
study	O
.	O

LDLR	O
and	O
ApoB	O
genes	O
polymorphisms	O
were	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

The	O
ApoE	O
genotypes	O
were	O
identified	O
by	O
multiplex	B-P
amplification	I-P
refractory	I-P
mutation	I-P
system	I-P
(	O
multi-AMRS	B-P
)	O
.	O

We	O
found	O
that	O
LDLR	O
A	O
(	O
+	O
)	O
A	O
(	O
+	O
)	O
genotype	O
,	O
ApoB	O
X	O
(	O
+	O
)	O
allele	O
and	O
ApoE	O
E4	O
allele	O
increased	O
the	O
risk	O
of	O
PCAD	O
by	O
1.8	O
,	O
2.1	O
and	O
12.1	O
respectively	O
.	O

The	O
present	O
study	O
proved	O
that	O
smoking	O
,	O
metabolic	O
syndrome	O
,	O
ApoB	O
X	O
(	O
+	O
)	O
X	O
(	O
+	O
)	O
genotype	O
and	O
ApoE	O
E4	O
allele	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
PCAD	O
.	O

This	O
is	O
the	O
first	O
study	O
investigate	O
the	O
association	O
between	O
low	O
density	O
lipoprotein	O
receptor	O
,	O
apolipoprotein	O
B	O
and	O
apolipoprotein	O
E	O
genes	O
polymorphisms	O
with	O
PCAD	O
and	O
lipid	O
levels	O
in	O
Egyptians	O
and	O
we	O
concluded	O
that	O
the	O
LDLR	O
A	O
(	O
+	O
)	O
A	O
(	O
+	O
)	O
genotype	O
,	O
ApoB	O
X	O
(	O
+	O
)	O
allele	O
and	O
ApoE	O
E4	O
allele	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
development	O
of	O
PCAD	O
by	O
elevated	O
levels	B-P
of	I-P
total	I-P
cholesterol	I-P
(	I-P
TC	I-P
)	I-P
and	O
low	B-P
density	I-P
lipoprotein	I-P
(	O
LDLc	B-P
)	O
.	O

The	O
coexistence	O
of	O
CAD	O
risk	O
factors	O
with	O
LDLR	O
A	O
(	O
+	O
)	O
A	O
(	O
+	O
)	O
genotype	O
,	O
ApoB	O
X	O
(	O
+	O
)	O
allele	O
and	O
ApoE	O
E4	O
allele	O
may	O
increase	O
the	O
risk	O
of	O
the	O
development	O
of	O
PCAD	O
in	O
Egyptian	O
patients	O
.	O

Analyzing	O
the	O
clinical	O
profile	B-P
of	O
swine	O
flu	O
/	O
influenza	O
A	O
H1N1	O
infection	O
in	O
central	O
India	O
:	O
a	O
retrospective	O
study	O
.	O

Recently	O
,	O
India	O
reported	O
an	O
increase	O
in	O
swine	O
flu	O
(	O
influenza	O
A	O
H1N1	O
)	O
activity	O
.	O

There	O
are	O
limited	O
studies	B-P
on	O
epidemiology	O
of	O
swine	O
flu	O
in	O
Indian	O
context	O
.	O

This	O
study	B-P
aims	O
to	O
analyze	O
clinical	O
and	O
epidemiological	O
profile	O
of	O
suspected	O
swine	O
flu	O
cases	O
in	O
central	O
India	O
.	O

171	O
cases	O
were	O
included	O
in	O
a	O
hospital	O
based	O
,	O
observational	O
,	O
descriptive	O
study	O
conducted	O
from	O
December	O
2014	O
to	O
April	O
2015	O
.	O

Demographics	O
,	O
clinical	O
presentation	O
and	O
outcome	O
of	O
positive	O
and	O
negative	O
cases	O
were	O
compared	O
.	O

Data	O
was	O
analyzed	O
using	O
STATA	O
software	O
.	O

Distribution	O
by	O
age	O
,	O
sex	O
and	O
residence	O
was	O
found	O
similar	O
(	O
p	O
>	O
0.05	O
)	O
in	O
positive	O
and	O
negative	O
cases	O
.	O

Cough	O
(	O
89	O
%	O
)	O
,	O
fever	O
(	O
85	O
%	O
)	O
and	O
throat	O
irritation	O
(	O
51	O
%	O
)	O
were	O
chief	O
complaints	O
(	O
avg	O
.	O

duration	O
=	O
4.9	O
days	O
)	O
.	O

History	O
of	O
travel	O
,	O
history	O
of	O
contact	O
with	O
swine	O
flu	O
cases	O
(	O
p	O
=	O
0.002	O
)	O
and	O
history	O
of	O
visiting	O
crowded	O
places	O
(	O
p	O
=	O
0.098	O
)	O
was	O
reported	O
considerably	O
in	O
higher	O
proportion	O
in	O
positive	O
cases	O
as	O
compared	O
to	O
negative	O
cases	O
.	O

There	O
were	O
14	O
deaths	O
and	O
they	O
occurred	O
significantly	O
in	O
younger	O
age	O
among	O
positive	O
cases	O
as	O
compared	O
to	O
negatives	O
(	O
Mean	O
±	O
SD	O
:	O
34	O
±	O
2.8	O
vs	O
47	O
±	O
8.4	O
years	O
)	O
.	O

Case	O
fatality	O
ratio	O
(	O
CFR	O
)	O
in	O
positive	O
cases	O
showing	O
history	O
of	O
travel	O
,	O
contact	O
with	O
swine	O
flu	O
cases	O
,	O
requiring	O
invasive	O
ventilator	O
support	O
and	O
>	O
3	O
X-ray	O
zones	O
involvement	O
were	O
significantly	O
higher	O
.	O

Outbreak	O
in	O
later	O
part	O
of	O
winter	O
,	O
high	O
case	O
fatality	O
and	O
younger	O
population	O
is	O
more	O
affected	O
.	O

In	O
this	O
study	B-P
,	O
swine	O
flu	O
infection	O
and	O
outbreaks	O
started	O
later	O
in	O
the	O
year	O
Hospital	O
stay	O
and	O
CFR	O
were	O
increased	O
.	O

Understanding	O
the	O
swine	O
flu	O
infection	O
,	O
changing	O
clinical	O
presentation	O
of	O
swine	O
flu	O
and	O
formulate	O
new	O
strategies	O
for	O
its	O
prevention	O
and	O
management	O
.	O

Inactivation	O
of	O
Cancer	O
Mutations	O
Utilizing	O
CRISPR/Cas9	O
.	O

Although	O
whole-genome	O
sequencing	O
has	O
uncovered	O
a	O
large	O
number	O
of	O
mutations	O
that	O
drive	O
tumorigenesis	O
,	O
functional	O
ratification	O
for	O
most	O
mutations	O
remains	O
sparse	O
.	O

Here	O
,	O
we	O
present	O
an	O
approach	O
to	O
test	O
functional	O
relevance	O
of	O
tumor	O
mutations	O
employing	O
CRISPR/Cas9	O
.	O

Combining	O
comprehensive	O
sgRNA	O
design	O
and	O
an	O
efficient	O
reporter	O
assay	B-P
to	O
nominate	O
efficient	O
and	O
selective	O
sgRNAs	O
,	O
we	O
establish	O
a	O
pipeline	O
to	O
dissect	O
roles	O
of	O
cancer	O
mutations	O
with	O
potential	O
applicability	O
to	O
personalized	O
medicine	O
and	O
future	O
therapeutic	O
use	O
.	O

Anterolateral	O
entorhinal	O
cortex	O
volume	O
predicted	O
by	O
altered	O
intra-item	O
configural	O
processing	O
.	O

Recent	O
functional	O
imaging	B-P
studies	I-P
have	O
proposed	O
that	O
the	O
human	O
entorhinal	O
cortex	O
is	O
subdivided	O
into	O
functionally	O
distinct	O
anterolateral	O
(	O
alERC	O
)	O
and	O
posteromedial	O
(	O
pmERC	O
)	O
subregions	O
.	O

The	O
alERC	O
overlaps	O
with	O
regions	O
that	O
are	O
affected	O
earliest	O
by	O
Alzheimer	O
's	O
disease	O
pathology	O
,	O
yet	O
its	O
cognitive	O
function	O
remains	O
poorly	O
understood	O
.	O

Previous	O
human	O
fMRI	B-P
studies	I-P
have	O
focused	O
on	O
its	O
role	O
in	O
object	O
memory	O
,	O
but	O
rodent	O
studies	O
on	O
the	O
putatively	O
homologous	O
lateral	O
entorhinal	O
cortex	O
suggest	O
that	O
it	O
also	O
plays	O
an	O
important	O
role	O
in	O
representing	O
spatial	O
properties	O
of	O
objects	O
.	O

In	O
order	O
to	O
investigate	O
the	O
cognitive	O
effects	O
of	O
human	O
alERC	O
volume	O
differences	O
,	O
we	O
developed	O
an	O
eyetracking-based	O
task	O
to	O
evaluate	O
intra-item	O
configural	O
processing	O
(	O
i.e.	O
,	O
processing	O
the	O
arrangement	O
of	O
an	O
object	O
's	O
features	O
)	O
,	O
and	O
used	O
manual	O
segmentation	O
based	O
on	O
a	O
recently-	O
developed	O
protocol	O
to	O
delineate	O
the	O
alERC	O
/	O
pmERC	O
as	O
well	O
as	O
other	O
medial	O
temporal	O
lobe	O
(	O
MTL	O
)	O
subregions	O
.	O

In	O
a	O
group	O
of	O
older	O
adult	O
men	O
and	O
women	O
at	O
varying	O
stages	O
of	O
brain	O
atrophy	O
and	O
cognitive	O
decline	O
,	O
we	O
found	O
that	O
intra-item	O
configural	O
processing	O
-	O
regardless	O
of	O
an	O
object	O
's	O
novelty	O
-	O
was	O
strongly	O
predicted	O
by	O
alERC	O
volume	O
,	O
but	O
not	O
by	O
the	O
volume	O
of	O
any	O
other	O
MTL	O
subregion	O
.	O

These	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
the	O
human	O
alERC	O
plays	O
a	O
role	O
in	O
supporting	O
a	O
distinct	O
aspect	O
of	O
object	O
processing	O
,	O
namely	O
attending	O
to	O
the	O
arrangement	O
of	O
an	O
object	O
's	O
component	O
features.SIGNIFICANCE	O
STATEMENT	O
Alzheimer	O
's	O
disease	O
pathology	O
appears	O
earliest	O
in	O
brain	O
regions	O
that	O
overlap	O
with	O
the	O
anterolateral	O
entorhinal	O
cortex	O
(	O
alERC	O
)	O
.	O

However	O
,	O
the	O
cognitive	O
role	O
of	O
the	O
alERC	O
is	O
poorly	O
understood	O
.	O

Previous	O
human	O
studies	O
treat	O
the	O
alERC	O
as	O
an	O
extension	O
of	O
the	O
neighboring	O
perirhinal	O
cortex	O
,	O
supporting	O
object	O
memory	O
.	O

Animal	O
studies	O
suggest	O
that	O
the	O
alERC	O
may	O
support	O
the	O
spatial	O
properties	O
of	O
objects	O
.	O

In	O
a	O
group	O
of	O
older	O
adult	O
humans	O
at	O
the	O
earliest	O
stages	O
of	O
cognitive	O
decline	O
,	O
we	O
show	O
that	O
alERC	O
volume	O
selectively	O
predicted	O
configural	O
processing	O
(	O
attention	O
to	O
the	O
spatial	O
arrangement	O
of	O
an	O
object	O
's	O
parts	O
)	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
a	O
cognitive	O
role	O
related	O
to	O
alERC	O
volume	O
in	O
humans	O
.	O

This	O
task	O
can	O
be	O
adapted	O
to	O
serve	O
as	O
an	O
early	O
detection	O
method	O
for	O
Alzheimer	O
's	O
disease	O
pathology	O
.	O

Antidepressant	O
-like	O
effects	O
of	O
scopolamine	O
in	O
mice	O
are	O
enhanced	O
by	O
the	O
group	O
II	O
mGlu	O
receptor	O
antagonist	O
LY341495	O
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
the	O
muscarinic	O
receptor	O
antagonist	O
scopolamine	O
induces	O
a	O
potent	O
and	O
rapid	O
antidepressant	O
effect	O
relative	O
to	O
conventional	O
antidepressants	O
.	O

However	O
,	O
potential	O
undesirable	O
effects	O
,	O
including	O
memory	O
impairment	O
,	O
partially	O
limit	O
the	O
use	O
of	O
scopolamine	O
in	O
psychiatry	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
propose	O
to	O
overcome	O
these	O
limitations	O
and	O
enhance	O
the	O
therapeutic	O
effects	O
of	O
scopolamine	O
via	O
administration	O
in	O
combination	O
with	O
the	O
group	O
II	O
metabotropic	O
glutamate	O
(	O
mGlu	O
)	O
receptor	O
antagonist	O
,	O
LY341495	O
.	O

Joint	O
administration	O
of	O
sub-effective	O
doses	O
of	O
scopolamine	O
(	O
0.03	O
or	O
0.1	O
mg/kg	O
,	O
i.p	O
.	O
)	O

with	O
a	O
sub-effective	O
dose	O
of	O
LY341495	O
(	O
0.1	O
mg/kg	O
,	O
i.p	O
.	O
)	O

induced	O
a	O
profound	O
antidepressant	O
effect	O
in	O
the	O
tail	B-P
suspension	I-P
test	I-P
(	O
TST	B-P
)	O
and	O
in	O
the	O
forced	B-P
swim	I-P
test	I-P
(	O
FST	B-P
)	O
in	O
mice	O
.	O

This	O
drug	O
combination	O
did	O
not	O
impair	O
memory	O
,	O
as	O
measured	O
using	O
the	O
Morris	B-P
water	I-P
maze	I-P
(	O
MWM	B-P
)	O
,	O
and	O
did	O
not	O
influence	O
the	O
locomotor	O
activity	O
of	O
mice	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
an	O
AMPA	O
receptor	O
antagonist	O
,	O
NBQX	O
(	O
10	O
mg/kg	O
)	O
,	O
completely	O
reversed	O
the	O
antidepressant-like	O
activity	O
of	O
a	O
mixture	O
of	O
scopolamine	O
and	O
LY341495	O
in	O
the	O
TST	B-P
.	O

However	O
,	O
this	O
effect	O
was	O
not	O
influenced	O
by	O
para-chlorophenylalanine	O
(	O
PCPA	O
)	O
pre-treatment	O
,	O
indicating	O
a	O
lack	O
of	O
involvement	O
of	O
serotonergic	O
system	O
activation	O
in	O
the	O
antidepressant-like	O
effects	O
of	O
jointly	O
given	O
scopolamine	O
and	O
LY341495	O
.	O

Therefore	O
,	O
the	O
combined	O
administration	O
of	O
low	O
doses	O
of	O
the	O
antimuscarinic	O
drug	O
scopolamine	O
and	O
the	O
group	O
II	O
mGlu	O
receptor	O
antagonist	O
LY341495	O
might	O
be	O
a	O
new	O
,	O
effective	O
and	O
safe	O
strategy	O
in	O
the	O
therapy	O
of	O
depression	O
.	O

Repeatability	O
and	O
agreement	O
of	O
ultrasonography	B-P
with	O
computed	B-P
tomography	I-P
for	O
evaluating	O
forefoot	O
structure	O
in	O
the	O
coronal	O
plane	O
.	O

Forefoot	O
structure	O
is	O
important	O
to	O
understand	O
some	O
foot	O
problems	O
such	O
as	O
hallux	O
valgus	O
and	O
metatarsalgia	O
.	O

Ultrasonography	B-P
(	O
US	B-P
)	O
is	O
a	O
highly	O
portable	O
,	O
noninvasive	O
,	O
low	O
cost	O
,	O
and	O
fast	O
imaging	O
method	O
,	O
especially	O
when	O
compared	O
to	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
,	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
,	O
and	O
radiography	B-P
.	O

As	O
the	O
use	O
of	O
US	B-P
for	O
evaluating	O
forefoot	O
bony	O
structure	O
has	O
not	O
been	O
validated	O
,	O
except	O
for	O
the	O
presence	O
of	O
synovitis	O
,	O
erosions	O
and	O
bursitis	O
within	O
the	O
forefoot	O
in	O
people	O
with	O
inflammatory	O
arthritis	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
US	B-P
is	O
a	O
reliable	O
method	O
for	O
evaluating	O
forefoot	O
structure	O
.	O

Sixty	O
feet	O
(	O
30	O
women	O
,	O
age	O
=	O
40.1	O
±	O
11.8	O
years	O
)	O
were	O
examined	O
by	O
US	B-P
and	O
CT	B-P
to	O
assess	O
agreement	O
with	O
CT	B-P
and	O
repeatability	O
of	O
US	B-P
evaluation	O
of	O
the	O
2nd	O
metatarsal	O
head	O
height	O
,	O
length	O
between	O
the	O
medial	O
sesamoid	O
bone	O
and	O
5th	O
metatarsal	O
head	O
,	O
transverse	O
arch	O
height	O
,	O
transverse	O
arch	O
index	O
,	O
sesamoid	O
rotation	O
angle	O
,	O
and	O
area	O
under	O
the	O
transverse	O
arch	O
.	O

The	O
measurement	O
data	O
were	O
evaluated	O
for	O
agreement	O
with	O
CT	B-P
using	O
the	O
intra-class	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
3	O
,	O
1	O
,	O
Pearson	O
correlation	O
coefficient	O
,	O
and	O
Bland-Altman	O
plot	O
,	O
and	O
with	O
ICC1	O
,	O
1	O
for	O
repeatability	O
.	O

The	O
ICC3	O
,	O
1	O
values	O
of	O
0.78-0.89	O
,	O
Pearson	O
correlation	O
coefficient	O
of	O
0.78-0.90	O
,	O
and	O
Bland-Altman	O
plots	O
showed	O
almost	O
perfect	O
agreements	O
between	O
the	O
US	B-P
and	O
CT	B-P
method	O
for	O
all	O
parameters	O
,	O
except	O
the	O
area	O
under	O
the	O
transverse	O
arch	O
(	O
AUTA	O
)	O
.	O

The	O
ICC1	O
,	O
1	O
also	O
showed	O
perfect	O
agreements	O
(	O
0.84-0.92	O
)	O
between	O
two	O
sets	O
of	O
US	B-P
measurements	O
in	O
all	O
parameters	O
.	O

The	O
US	B-P
evaluation	O
of	O
forefoot	O
structure	O
in	O
the	O
coronal	O
plane	O
showed	O
good	O
agreement	O
with	O
CT	B-P
and	O
repeatability	O
of	O
two	O
ultrasonograms	O
in	O
adult	O
women	O
.	O

This	O
reliable	O
evaluation	O
method	O
of	O
forefoot	O
structure	O
can	O
contribute	O
to	O
a	O
quick	O
clinical	O
assessment	O
screening	O
for	O
risk	O
factors	O
of	O
foot	O
problems	O
such	O
as	O
hallux	O
valgus	O
and	O
metatarsalgia	O
.	O

However	O
,	O
because	O
of	O
some	O
limitations	O
such	O
as	O
a	O
lack	O
of	O
inter-observer	O
reliability	O
,	O
more	O
research	O
is	O
needed	O
to	O
validate	O
US	B-P
evaluation	O
of	O
forefoot	O
structure	O
.	O

The	O
current	O
study	O
(	O
trial	O
registration	O
number	O
:	O
R0297	O
)	O
was	O
approved	O
by	O
the	O
Ethical	O
Committee	O
for	O
Human	O
Experiments	O
of	O
Kyoto	O
University	O
(	O
http	O
:	O
//www.ec.med.kyoto-u.ac.jp	O
)	O
on	O
December	O
3	O
,	O
2015	O
.	O

The	O
first	O
participant	O
in	O
this	O
study	O
was	O
enrolled	O
on	O
November	O
17	O
,	O
2015	O
and	O
retrospectively	O
registered	O
.	O

Design	O
,	O
synthesis	O
,	O
molecular	O
docking	O
,	O
anti-Proteus	O
mirabilis	O
and	O
urease	O
inhibition	O
of	O
new	O
fluoroquinolone	O
carboxylic	O
acid	O
derivatives	O
.	O

New	O
hydroxamic	O
acid	O
,	O
hydrazide	O
and	O
amide	O
derivatives	O
of	O
ciprofloxacin	O
in	O
addition	O
to	O
their	O
analogues	O
of	O
levofloxacin	O
were	O
prepared	O
and	O
identified	O
by	O
different	O
spectroscopic	O
techniques	O
.	O

Some	O
of	O
the	O
prepared	O
compounds	O
revealed	O
good	O
activity	O
against	O
the	O
urease	O
splitting	O
bacteria	O
,	O
Proteus	O
mirabilis	O
.	O

The	O
urease	O
inhibitory	O
activity	O
was	O
investigated	O
using	O
indophenol	B-P
method	I-P
.	O

Most	O
of	O
the	O
tested	O
compounds	O
showed	O
better	O
activity	O
than	O
the	O
reference	O
acetohydroxamic	O
acid	O
(	O
AHA	O
)	O
.	O

The	O
ciprofloxacin	O
hydrazide	O
derivative	O
3a	O
and	O
levofloxacin	O
hydroxamic	O
acid	O
7	O
experienced	O
the	O
highest	O
activity	O
(	O
IC50	O
=1.22μM	O
and	O
2.20μM	O
,	O
respectively	O
)	O
.	O

Molecular	O
docking	O
study	O
revealed	O
high	O
spontaneous	O
binding	O
ability	O
of	O
the	O
tested	O
compounds	O
to	O
the	O
active	O
site	O
of	O
urease	O
.	O

Biochemical	O
and	O
molecular	O
characterization	O
of	O
a	O
lipase	O
from	O
an	O
Algerian	O
isolated	O
Staphylococcus	O
aureus	O
strain	O
.	O

A	O
Staphylococcus	O
aureus	O
strain	O
,	O
isolated	O
from	O
an	O
Algerian	O
biotope	O
,	O
secretes	O
a	O
non-induced	O
lipase	O
in	O
the	O
culture	O
medium	O
.	O

The	O
S.	O
aureus	O
lipase	O
(	O
SAL	O
)	O
was	O
purified	O
to	O
homogeneity	O
.	O

Pure	O
SAL	O
is	O
a	O
monomeric	O
protein	O
(	O
43	O
kDa	O
)	O
.	O

The	O
20	O
N-terminal	O
amino	O
acid	O
residues	O
showed	O
a	O
high	O
degree	O
of	O
homology	O
with	O
other	O
staphylococcal	O
lipase	O
sequences	O
.	O

SAL	O
presents	O
specific	O
activities	O
of	O
about	O
1600	O
and	O
555	O
U	O
mg	O
(	O
-1	O
)	O
using	O
tributyrin	O
and	O
olive	O
oil	O
emulsion	O
as	O
substrates	O
,	O
respectively	O
.	O

In	O
contrast	O
to	O
other	O
staphylococcal	O
lipases	O
previously	O
characterized	O
,	O
SAL	O
was	O
stable	O
at	O
a	O
pH	O
range	O
from	O
6	O
to	O
9	O
after	O
1	O
h	O
incubation	O
,	O
and	O
retained	O
50	O
%	O
of	O
its	O
activity	O
after	O
10	O
min	O
incubation	O
at	O
50	O
°C	O
.	O

The	O
purified	O
enzyme	O
was	O
also	O
characterized	O
using	O
monolayer	B-P
technique	I-P
.	O

Lipase	O
activity	O
can	O
be	O
measured	O
only	O
when	O
the	O
surface	O
pressure	O
exceeds	O
15	O
mN	O
m	O
(	O
-1	O
)	O
.	O

The	O
critical	O
surface	O
pressure	O
(	O
πc	O
)	O
measured	O
with	O
egg-PC	O
films	O
was	O
estimated	O
at	O
33	O
mN	O
m	O
(	O
-1	O
)	O
.	O

SAL	O
showed	O
a	O
preference	O
for	O
the	O
distal	O
ester	O
groups	O
of	O
the	O
diglyceride	O
isomers	O
at	O
low	O
surface	O
pressure	O
,	O
for	O
the	O
adjacent	O
ester	O
groups	O
at	O
high	O
surface	O
pressure	O
and	O
a	O
preference	O
for	O
the	O
sn-3	O
position	O
of	O
the	O
2,3-sn-enantiomer	O
of	O
dicaprin	O
.	O

Cloned	O
and	O
sequenced	O
gene	O
part	O
,	O
encoding	O
the	O
mature	O
lipase	O
shows	O
,	O
in	O
comparison	O
with	O
S.	O
aureus	O
lipase	O
3	O
(	O
SAL3	O
)	O
,	O
a	O
deletion	O
of	O
three	O
residues	O
(	O
LKA	O
)	O
at	O
the	O
N-terminal	O
extremity	O
and	O
a	O
substitution	O
of	O
glycine	O
208	O
and	O
isoleucine	O
226	O
with	O
an	O
arginine	O
and	O
leucine	O
,	O
respectively	O
.	O

Effect	O
of	O
single-dose	O
carbapenem	O
exposure	O
on	O
transcriptional	O
expression	O
of	O
blaNDM-1	O
and	O
mexA	O
in	O
Pseudomonas	O
aeruginosa	O
.	O

The	O
therapeutic	O
option	O
of	O
a	O
carbapenem	O
antibiotic	O
is	O
compromised	O
in	O
Pseudomonas	O
aeruginosa	O
owing	O
both	O
to	O
acquired	O
and	O
intrinsic	O
resistance	O
mechanisms	O
.	O

In	O
recent	O
years	O
,	O
New	O
Delhi	O
metallo-β-lactamase	O
has	O
been	O
the	O
focus	O
as	O
a	O
predominant	O
carbapenem	O
resistance	O
determinant	O
.	O

However	O
,	O
it	O
is	O
unclear	O
which	O
of	O
the	O
mechanisms	O
might	O
be	O
adopted	O
by	O
a	O
P.	O
aeruginosa	O
strain	O
possessing	O
both	O
blaNDM-1	O
and	O
an	O
overexpressed	O
MexAB-OprM	O
system	O
during	O
carbapenem	O
therapy	O
.	O

This	O
study	O
investigated	O
the	O
interplay	O
of	O
both	O
mechanisms	O
in	O
clinical	O
isolates	O
of	O
P.	O
aeruginosa	O
when	O
exposed	O
to	O
meropenem	O
.	O

Five	O
strains	O
were	O
used	O
:	O
(	O
i	O
)	O
strain	O
overexpressing	O
MexAB-OprM	O
but	O
with	O
no	O
blaNDM-1	O
;	O
(	O
ii	O
)	O
strain	O
harbouring	O
blaNDM-1	O
but	O
expressing	O
MexAB-OprM	O
at	O
basal	O
level	O
;	O
(	O
iii	O
)	O
strain	O
possessing	O
blaNDM-1	O
and	O
overexpressing	O
MexAB-OprM	O
;	O
(	O
iv	O
)	O
P.	O
aeruginosa	O
PAO1	O
;	O
and	O
(	O
v	O
)	O
P.	O
aeruginosa	O
K2733-PAO1	O
(	O
ΔMexAB-OprM	O
ΔMexCD-OprJ	O
ΔMexEF-OprN	O
ΔMexXY-OprM	O
)	O
into	O
which	O
blaNDM-1	O
was	O
cloned	O
.	O

Strains	O
were	O
incubated	O
in	O
Luria-Bertani	O
broth	O
with	O
and	O
without	O
1μg/mL	O
meropenem	O
.	O

Total	B-P
RNA	I-P
was	O
isolated	O
at	O
45-min	O
intervals	O
and	O
was	O
immediately	O
reverse	O
transcribed	O
to	O
cDNA	O
.	O

This	O
was	O
repeated	O
for	O
6h	O
.	O

Quantitative	O
real-time	O
PCR	O
was	O
performed	O
for	O
both	O
resistance	O
mechanisms	O
.	O

Meropenem	O
exposure	O
did	O
not	O
significantly	O
elevate	O
transcription	O
of	O
either	O
the	O
blaNDM-1	O
or	O
mexA	O
gene	O
.	O

However	O
,	O
an	O
interesting	O
finding	O
was	O
that	O
upon	O
single-dose	O
exposure	O
to	O
carbapenem	O
,	O
the	O
efflux	O
pump	O
system	O
played	O
a	O
major	O
role	O
in	O
bacterial	O
survival	O
compared	O
with	O
NDM-1	O
.	O

This	O
study	O
gives	O
an	O
insight	O
into	O
the	O
bacterial	O
response	O
to	O
carbapenem	O
antibiotic	O
when	O
two	O
different	O
resistance	O
mechanisms	O
coexist	O
.	O

This	O
type	O
of	O
study	O
would	O
be	O
helpful	O
in	O
designing	O
future	O
antimicrobials	O
.	O

Design	O
and	O
synthesis	O
of	O
phosphoryl-substituted	O
diphenylpyrimidines	O
(	O
Pho-DPPYs	O
)	O
as	O
potent	O
Bruton	O
's	O
tyrosine	O
kinase	O
(	O
BTK	O
)	O
inhibitors	O
:	O
Targeted	O
treatment	O
of	O
B	O
lymphoblastic	O
leukemia	O
cell	O
lines	O
.	O

A	O
family	O
of	O
phosphoryl-substituted	O
diphenylpyrimidine	O
derivatives	O
(	O
Pho-DPPYs	O
)	O
were	O
synthesized	O
and	O
biologically	O
evaluated	O
as	O
potent	O
BTK	O
inhibitors	O
in	O
this	O
study	O
.	O

Compound	O
7b	O
was	O
found	O
to	O
markedly	O
inhibit	O
BTK	O
activity	O
at	O
concentrations	O
of	O
0.82nmol/L	O
,	O
as	O
well	O
as	O
to	O
suppress	O
the	O
proliferations	O
of	O
B-cell	O
leukemia	O
cell	O
lines	O
(	O
Ramos	O
and	O
Raji	O
)	O
expressing	O
high	O
levels	O
of	O
BTK	O
at	O
concentrations	O
of	O
3.17μM	O
and	O
6.69μM	O
.	O

Moreover	O
,	O
flow	B-P
cytometry	I-P
analysis	I-P
results	O
further	O
indicated	O
that	O
7b	O
promoted	O
cell	O
apoptosis	O
to	O
a	O
substantial	O
degree	O
.	O

In	O
a	O
word	O
,	O
compound	O
7b	O
is	O
a	O
promising	O
BTK	O
inhibitor	O
for	O
the	O
treatment	O
of	O
B-cell	O
lymphoblastic	O
leukemia	O
.	O

Transplacental	O
Passage	O
of	O
Acetaminophen	O
in	O
Term	O
Pregnancy	O
.	O

Objective	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maternal	O
and	O
fetal	O
pharmacokinetic	O
(	O
PK	O
)	O
profiles	B-P
of	O
acetaminophen	O
after	O
administration	O
of	O
a	O
therapeutic	O
oral	O
dose	O
.	O

Study	O
Design	O
After	O
obtaining	O
Institutional	O
Review	O
Board	O
approval	O
and	O
their	O
written	O
informed	O
consent	O
,	O
pregnant	O
women	O
were	O
given	O
a	O
single	O
oral	O
dose	O
(	O
1,000	O
mg	O
)	O
of	O
acetaminophen	O
upon	O
admission	O
for	O
scheduled	O
cesarean	O
delivery	O
.	O

Maternal	O
venous	O
blood	O
and	O
fetal	O
cord	O
blood	O
were	O
obtained	O
at	O
the	O
time	O
of	O
delivery	O
and	O
acetaminophen	B-P
levels	I-P
were	O
measured	O
using	O
gas	B-P
chromatography-mass	I-P
spectroscopy	I-P
.	O

PK	O
parameters	O
were	O
calculated	O
by	O
noncompartmental	O
analysis	O
.	O

Nonparametric	O
correlation	O
of	O
maternal	O
/	O
fetal	O
acetaminophen	B-P
levels	I-P
and	O
PK	O
curves	O
were	O
calculated	O
.	O

Results	O
In	O
this	O
study	O
,	O
34	O
subjects	O
were	O
enrolled	O
(	O
median	O
,	O
32	O
years	O
;	O
range	O
,	O
25-39	O
years	O
)	O
.	O

The	O
median	O
maternal	O
weight	O
was	O
82	O
kg	O
(	O
range	O
,	O
62-100	O
kg	O
)	O
.	O

All	O
but	O
two	O
subjects	O
were	O
delivered	O
beyond	O
39	O
weeks	O
'	O
gestation	O
.	O

The	O
median	O
newborn	O
birth	O
weight	O
was	O
3,590	O
g	O
(	O
interquartile	O
range	O
,	O
3,403-3,848	O
g	O
)	O
.	O

Noncompartmental	O
analysis	O
described	O
similar	O
PK	O
parameters	O
in	O
the	O
maternal	O
(	O
T1/2	O
,	O
84	O
minutes	O
;	O
apparent	O
clearance	O
[	O
Cl/F	O
]	O
,	O
28.8	O
L/h	O
;	O
apparent	O
volume	O
of	O
distribution	O
[	O
Vd/F	O
]	O
,	O
57.5	O
L	O
)	O
and	O
fetal	O
compartments	O
(	O
T1/2	O
,	O
82	O
minutes	O
;	O
Cl/F	O
,	O
31.2	O
L/h	O
;	O
Vd/F	O
,	O
61.2	O
L	O
)	O
.	O

Paired	O
maternal	O
/	O
fetal	O
acetaminophen	B-P
levels	I-P
were	O
highly	O
correlated	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Conclusion	O
Fetal	O
acetaminophen	O
PKs	O
in	O
the	O
fetus	O
parallels	O
that	O
in	O
the	O
mother	O
suggesting	O
that	O
placental	O
transfer	O
is	O
flow	O
limited	O
.	O

Maternal	O
acetaminophen	B-P
levels	I-P
can	O
be	O
used	O
as	O
a	O
surrogate	O
for	O
fetal	O
exposure	O
.	O

Can	O
LDL	O
cholesterol	O
be	O
too	O
low	O
?	O

Possible	O
risks	O
of	O
extremely	O
low	O
levels	O
.	O

Following	O
the	O
continuous	O
accumulation	O
of	O
evidence	O
supporting	O
the	O
beneficial	O
role	O
of	O
reducing	O
low-density	B-P
lipoprotein	I-P
cholesterol	I-P
(	I-P
LDL-C	I-P
)	I-P
levels	I-P
in	O
the	O
treatment	O
and	O
prevention	O
of	O
atherosclerotic	O
cardiovascular	O
disease	O
and	O
its	O
complications	O
,	O
therapeutic	O
possibilities	O
now	O
exist	O
to	O
lower	O
LDL-C	B-P
to	O
very	O
low	O
levels	O
,	O
similar	O
to	O
or	O
even	O
lower	O
than	O
those	O
seen	O
in	O
newborns	O
and	O
nonhuman	O
species	O
.	O

In	O
addition	O
to	O
the	O
important	O
task	O
of	O
evaluating	O
potential	O
side	O
effects	O
of	O
such	O
treatments	O
,	O
the	O
question	O
arises	O
whether	O
extremely	O
low	O
LDL-C	B-P
levels	I-P
per	O
se	O
may	O
provoke	O
adverse	O
effects	O
in	O
humans	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
information	O
from	O
studies	O
of	O
human	O
cellular	O
and	O
organ	O
physiology	O
,	O
phenotypic	O
characterization	O
of	O
rare	O
genetic	O
diseases	O
of	O
lipid	O
metabolism	O
,	O
and	O
experience	O
from	O
clinical	O
trials	O
.	O

Specifically	O
,	O
we	O
emphasize	O
the	O
importance	O
of	O
the	O
robustness	O
of	O
the	O
regulatory	O
systems	O
that	O
maintain	O
balanced	O
fluxes	O
and	O
levels	O
of	O
cholesterol	O
at	O
both	O
cellular	O
and	O
organismal	O
levels	O
.	O

Even	O
at	O
extremely	O
low	O
LDL-C	B-P
levels	I-P
,	O
critical	O
capacities	O
of	O
steroid	O
hormone	O
and	O
bile	O
acid	O
production	O
are	O
preserved	B-P
,	O
and	O
the	O
presence	O
of	O
a	O
cholesterol	O
blood-brain	O
barrier	O
protects	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Apparent	O
relationships	O
sometimes	O
reported	O
between	O
less	O
pronounced	O
low	O
LDL-C	B-P
levels	I-P
and	O
disease	O
states	O
such	O
as	O
cancer	O
,	O
depression	O
,	O
infectious	O
disease	O
and	O
others	O
can	O
generally	O
be	O
explained	O
as	O
secondary	O
phenomena	O
.	O

Drug-related	O
side	O
effects	O
including	O
an	O
increased	O
propensity	O
for	O
development	O
of	O
type	O
2	O
diabetes	O
occur	O
during	O
statin	O
treatment	O
,	O
whilst	O
further	O
evaluation	O
of	O
more	O
potent	O
LDL	O
-	O
lowering	O
treatments	O
such	O
as	O
PCSK9	O
inhibitors	O
is	O
needed	O
.	O

Experience	O
from	O
the	O
recently	O
reported	O
and	O
ongoing	O
large	O
event-driven	O
trials	O
are	O
of	O
great	O
interest	O
,	O
and	O
further	O
evaluation	O
including	O
careful	O
analysis	O
of	O
cognitive	O
functions	O
will	O
be	O
important	O
.	O

Role	O
of	O
vision	O
in	O
sighted	O
and	O
blind	O
soccer	O
players	O
in	O
adapting	O
to	O
an	O
unstable	O
balance	B-P
task	I-P
.	O

This	O
study	O
tested	O
whether	O
a	O
compensatory	O
hypothesis	O
exists	O
on	O
postural	O
control	O
during	O
standing	O
unstable	O
balance	B-P
tasks	I-P
comparing	O
blind	O
soccer	O
players	O
(	O
n	O
=	O
7	O
)	O
to	O
sighted	O
soccer	O
players	O
(	O
n	O
=	O
15	O
)	O
and	O
sighted	O
sedentary	O
individuals	O
(	O
n	O
=	O
6	O
)	O
.	O

All	O
subjects	O
performed	O
a	O
pre	O
-	O
test	B-P
,	O
a	O
training	O
of	O
ten	O
practice	O
trials	O
on	O
a	O
single	O
day	O
,	O
and	O
a	O
post	O
-	O
test	B-P
balance	B-P
test	I-P
.	O

All	O
tests	B-P
were	O
performed	O
on	O
an	O
unstable	O
surface	O
placed	O
on	O
a	O
force	O
platform	O
and	O
under	O
closed-eyes	O
conditions	O
,	O
and	O
a	O
final	O
test	B-P
was	O
performed	O
with	O
open	O
eyes	O
.	O

Balance	O
performance	O
was	O
assessed	O
by	O
resultant	O
distance	O
(	O
RD	O
)	O
and	O
the	O
magnitude	O
of	O
mean	O
velocity	O
(	O
MV	O
)	O
of	O
the	O
centre	O
of	O
pressure	O
(	O
CoP	O
)	O
displacement	O
,	O
and	O
EMG	B-P
signals	O
from	O
the	O
gastrocnemius	O
lateralis	O
,	O
tibialis	O
anterior	O
,	O
rectus	O
femoris	O
,	O
and	O
peroneus	O
longus	O
were	O
measured	O
with	O
surface	B-P
electromyography	I-P
.	O

Principal	O
component	O
analysis	O
(	O
PCA	O
)	O
on	O
EMG	B-P
muscular	O
activation	O
was	O
used	O
to	O
assess	O
EMG	O
pattern	O
differences	O
during	O
the	O
balance	B-P
tasks	I-P
.	O

All	O
groups	O
improved	O
their	O
performance	O
,	O
obtaining	O
low	O
scores	O
for	O
the	O
closed-eyes	O
condition	O
balance	B-P
task	I-P
after	O
the	O
training	O
period	O
in	O
RD	O
,	O
VM	O
,	O
and	O
aids	O
received	O
to	O
keep	O
balance	O
in	O
the	O
novel	O
task	O
,	O
and	O
no	O
differences	O
were	O
found	O
between	O
groups	O
or	O
in	O
interaction	O
effects	O
.	O

Sighted	O
individuals	O
and	O
the	O
control	O
group	O
showed	O
significantly	O
lower	O
RD	O
and	O
VM	O
scores	O
under	O
open-eyes	O
conditions	O
than	O
blind	O
participants	O
.	O

As	O
regards	O
neuromuscular	O
behaviour	O
,	O
three	O
principal	O
patterns	O
explained	O
84.15	O
%	O
of	O
the	O
variability	O
in	O
the	O
measured	O
data	O
.	O

The	O
theoretical	O
improvement	O
of	O
the	O
other	O
senses	O
caused	O
by	O
visual	O
deprivation	O
does	O
not	O
allow	O
blind	O
individuals	O
to	O
obtain	O
better	O
balance	O
than	O
sighted	O
individuals	O
under	O
closed-eyes	O
conditions	O
,	O
thereby	O
reinforcing	O
the	O
prominent	O
role	O
of	O
vision	O
in	O
integrating	O
and	O
processing	O
the	O
other	O
sensory	O
inputs	O
.	O

In	O
addition	O
,	O
blind	O
individuals	O
seem	O
to	O
increase	O
their	O
muscular	O
co-activation	O
as	O
a	O
safety	O
strategy	O
,	O
but	O
this	O
behaviour	O
is	O
not	O
different	O
to	O
that	O
shown	O
by	O
sighted	O
people	O
under	O
closed-eyes	O
conditions	O
.	O

The	O
Peptidoglycan	O
Pattern	O
of	O
Staphylococcus	O
carnosus	O
TM300	O
-	O
Detailed	O
Analysis	O
and	O
Variations	O
Due	O
to	O
Genetic	O
and	O
Metabolic	O
Influences	O
.	O

The	O
Gram-positive	O
bacterium	O
Staphylococcus	O
carnosus	O
(	O
S.	O
carnosus	O
)	O
TM300	O
is	O
an	O
apathogenic	O
staphylococcal	O
species	O
commonly	O
used	O
in	O
meat	O
starter	B-P
cultures	I-P
.	O

As	O
with	O
all	O
Gram-positive	O
bacteria	O
,	O
its	O
cytoplasmic	O
membrane	O
is	O
surrounded	O
by	O
a	O
thick	O
peptidoglycan	O
(	O
PGN	O
)	O
or	O
murein	O
sacculus	O
consisting	O
of	O
several	O
layers	O
of	O
glycan	O
strands	O
cross-linked	O
by	O
peptides	O
.	O

In	O
contrast	O
to	O
pathogenic	O
staphylococci	O
,	O
mainly	O
Staphylococcus	O
aureus	O
(	O
S.	O
aureus	O
)	O
,	O
the	O
chemical	O
composition	O
of	O
S.	O
carnosus	O
PGN	O
is	O
not	O
well	O
studied	O
so	O
far	O
.	O

UPLC/MS	B-P
analysis	I-P
of	O
enzymatically	B-P
digested	I-P
S.	O
carnosus	O
TM300	O
PGN	O
revealed	O
substantial	O
differences	O
in	O
its	O
composition	O
compared	O
to	O
the	O
known	O
pattern	O
of	O
S.	O
aureus	O
.	O

While	O
in	O
S.	O
aureus	O
the	O
uncross-linked	O
stem	O
peptide	O
consists	O
of	O
a	O
pentapeptide	O
,	O
in	O
S.	O
carnosus	O
,	O
this	O
part	O
of	O
the	O
PGN	O
is	O
shortened	O
to	O
tripeptides	O
.	O

Furthermore	O
,	O
we	O
found	O
the	O
PGN	O
composition	O
to	O
vary	O
when	O
cells	O
were	O
incubated	B-P
under	O
certain	O
conditions	O
.	O

The	O
collective	O
overproduction	O
of	O
HlyD	O
,	O
FtsE	O
and	O
FtsX	O
-a	O
putative	O
protein	O
complex	O
interacting	O
with	O
penicillin-binding	O
protein	O
2	O
(	O
PBP2	O
)	O
-caused	O
the	O
reappearance	O
of	O
classical	O
penta	O
stem	O
peptides	O
.	O

In	O
addition	O
,	O
under	O
high	O
sugar	O
conditions	O
,	O
tetra	O
stem	O
peptides	O
occur	O
due	O
to	O
overflow	O
metabolism	O
.	O

This	O
indicates	O
that	O
S.	O
carnosus	O
TM300	O
cells	O
adapt	O
to	O
various	O
conditions	O
by	O
modification	O
of	O
their	O
PGN	O
.	O

A	O
brief	O
comparative	O
review	O
of	O
primate	O
posterior	O
parietal	O
cortex	O
:	O
A	O
novel	O
hypothesis	O
on	O
the	O
human	O
toolmaker	O
.	O

The	O
primate	O
visual	O
system	O
contains	O
two	O
major	O
cortical	O
pathways	O
:	O
a	O
ventral-temporal	O
pathway	O
that	O
has	O
been	O
associated	O
with	O
object	O
processing	O
and	O
recognition	O
,	O
and	O
a	O
dorsal-parietal	O
pathway	O
that	O
has	O
been	O
associated	O
with	O
spatial	O
processing	O
and	O
action	O
guidance	O
.	O

Our	O
understanding	O
of	O
the	O
role	O
of	O
the	O
dorsal	O
pathway	O
,	O
in	O
particular	O
,	O
has	O
greatly	O
evolved	O
within	O
the	O
framework	O
of	O
the	O
two-pathway	O
hypothesis	O
since	O
its	O
original	O
conception	O
.	O

Here	O
,	O
we	O
present	O
a	O
comparative	O
review	O
of	O
the	O
primate	O
dorsal	O
pathway	O
in	O
humans	O
and	O
monkeys	O
based	O
on	O
electrophysiological	B-P
,	O
neuroimaging	B-P
,	O
neuropsychological	B-P
,	O
and	O
neuroanatomical	B-P
studies	I-P
.	O

We	O
consider	O
similarities	O
and	O
differences	O
across	O
species	O
in	O
terms	O
of	O
the	O
topographic	O
representation	O
of	O
visual	O
space	O
;	O
specificity	O
for	O
eye	O
,	O
reaching	O
,	O
or	O
grasping	O
movements	O
;	O
multi-modal	O
response	O
properties	O
;	O
and	O
the	O
representation	O
of	O
objects	O
and	O
tools	O
.	O

We	O
also	O
review	O
the	O
relative	O
anatomical	O
location	O
of	O
functionally	O
-	O
and	O
topographically-defined	O
regions	O
of	O
the	O
posterior	O
parietal	O
cortex	O
.	O

An	O
emerging	O
theme	O
from	O
this	O
comparative	O
analysis	O
is	O
that	O
non-spatial	O
information	O
is	O
represented	O
to	O
a	O
greater	O
degree	O
,	O
and	O
with	O
increased	O
complexity	O
,	O
in	O
the	O
human	O
dorsal	O
visual	O
system	O
.	O

We	O
propose	O
that	O
non-spatial	O
information	O
in	O
the	O
primate	O
parietal	O
cortex	O
contributes	O
to	O
the	O
perception-to-action	O
system	O
aimed	O
at	O
manipulating	O
objects	O
in	O
peripersonal	O
space	O
.	O

In	O
humans	O
,	O
this	O
network	O
has	O
expanded	O
in	O
multiple	O
ways	O
,	O
including	O
the	O
development	O
of	O
a	O
dorsal	O
object	O
vision	O
system	O
mirroring	O
the	O
complexity	O
of	O
the	O
ventral	O
stream	O
,	O
the	O
integration	O
of	O
object	O
information	O
with	O
parietal	O
working	O
memory	O
systems	O
,	O
and	O
the	O
emergence	O
of	O
tool-specific	O
object	O
representations	O
in	O
the	O
anterior	O
intraparietal	O
sulcus	O
and	O
regions	O
of	O
the	O
inferior	O
parietal	O
lobe	O
.	O

We	O
propose	O
that	O
these	O
evolutionary	O
changes	O
have	O
enabled	O
the	O
emergence	O
of	O
human-specific	O
behaviors	O
,	O
such	O
as	O
the	O
sophisticated	O
use	O
of	O
tools	O
.	O

Vaccination	O
of	O
piglets	O
at	O
2	O
and	O
3	O
weeks	O
of	O
age	O
with	O
Ingelvac	O
PRRSFLEX®	O
EU	O
provides	O
protection	O
against	O
heterologous	O
field	O
challenge	O
in	O
the	O
face	O
of	O
homologous	O
maternally	O
derived	O
antibodies	O
.	O

Due	O
to	O
difficulties	O
in	O
eradicating	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
(	O
PRRS	O
)	O
linked	O
to	O
biosecurity	O
challenges	O
,	O
transmission	O
of	O
the	O
virus	O
and	O
the	O
lack	O
of	O
efficient	O
DIVA	O
vaccines	O
,	O
successful	O
control	O
of	O
PRRS	O
requires	O
a	O
combination	O
of	O
strict	O
management	O
measures	O
and	O
vaccination	O
of	O
both	O
sows	O
and	O
piglets	O
.	O

The	O
present	O
study	O
aimed	O
to	O
assess	O
the	O
efficacy	O
of	O
a	O
recently	O
developed	O
MLV	O
vaccine	O
(	O
Ingelvac	O
PRRSFLEX®	O
EU	O
)	O
in	O
piglets	O
at	O
2	O
and	O
3-weeks	O
of	O
age	O
in	O
the	O
presence	O
of	O
homologous	O
maternally	O
derived	O
antibodies	O
as	O
the	O
dams	O
were	O
vaccinated	O
with	O
the	O
same	O
vaccine	O
strain	O
(	O
ReproCyc®	O
PRRS	O
EU	O
)	O
.	O

The	O
study	O
was	O
carried	O
out	O
on	O
a	O
Hungarian	O
farrow	O
to	O
finish	O
farm	O
naturally	O
infected	O
with	O
PRRSv	O
.	O

The	O
study	O
was	O
designed	O
as	O
a	O
blind	O
,	O
placebo	O
controlled	O
side	O
by	O
side	O
trial	O
.	O

ORF5	O
sequence	O
similarity	O
of	O
the	O
vaccine	O
strain	O
and	O
the	O
resident	O
field	O
strain	O
was	O
87.8	O
%	O
.	O

PRRS	O
specific	O
real-time	O
quantitative	O
PCR	O
was	O
performed	O
from	O
serum	O
samples	O
to	O
measure	O
both	O
the	O
viral	B-P
load	I-P
and	O
the	O
frequency	O
of	O
virus	O
positive	O
animals	O
.	O

At	O
the	O
time	O
of	O
the	O
natural	O
infection	O
observed	O
in	O
the	O
control	O
group	O
at	O
10-12	O
weeks	O
of	O
age	O
,	O
the	O
number	O
of	O
viraemic	O
animals	O
did	O
not	O
increase	O
significantly	O
in	O
the	O
vaccinated	O
group	O
.	O

To	O
understand	O
the	O
infection	O
dynamics	O
,	O
positive	O
PCR	O
samples	O
with	O
low	O
Ct	O
values	O
were	O
sequenced	O
(	O
ORF5	O
)	O
and	O
the	O
data	O
analysis	O
indicated	O
the	O
circulation	O
of	O
wild	O
type	O
virus	O
in	O
both	O
groups	O
,	O
however	O
wild	O
type	O
virus	O
was	O
only	O
found	O
in	O
non-vaccinated	O
animals	O
.	O

Our	O
data	O
indicate	O
that	O
piglets	O
vaccinated	O
at	O
as	O
early	O
as	O
2	O
weeks	O
of	O
age	O
with	O
Ingelvac	O
PRRSFLEX®	O
EU	O
were	O
protected	O
both	O
in	O
terms	O
of	O
proportion	O
of	O
viraemic	O
animals	O
and	O
viraemia	O
levels	O
.	O

It	O
has	O
to	O
be	O
highlighted	O
that	O
these	O
results	O
were	O
achieved	O
in	O
piglets	O
with	O
high	O
levels	O
of	O
homologous	O
maternally	O
derived	O
antibodies	O
(	O
MDA	O
)	O
at	O
the	O
time	O
of	O
vaccination	O
.	O

Effects	O
of	O
pulmonary	O
static	O
inflation	O
with	O
50	O
%	O
xenon	O
on	O
oxygen	O
impairment	O
during	O
cardiopulmonary	O
bypass	O
for	O
stanford	O
type	O
A	O
acute	O
aortic	O
dissection	O
:	O
A	O
pilot	O
study	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
pulmonary	O
static	O
inflation	O
with	O
50	O
%	O
xenon	O
on	O
postoperative	O
oxygen	O
impairment	O
during	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
for	O
Stanford	O
type	O
A	O
acute	O
aortic	O
dissection	O
(	O
AAD	O
)	O
.	O

This	O
prospective	O
single-center	O
nonrandomized	O
controlled	O
clinical	O
trial	O
included	O
100	O
adult	O
patients	O
undergoing	O
surgery	O
for	O
Stanford	O
type	O
A	O
AAD	O
at	O
an	O
academic	O
hospital	O
in	O
China	O
.	O

Fifty	O
subjects	O
underwent	O
pulmonary	O
static	O
inflation	O
with	O
50	O
%	O
oxygen	O
from	O
January	O
2013	O
to	O
January	O
2014	O
,	O
and	O
50	O
underwent	O
inflation	O
with	O
50	O
%	O
xenon	O
from	O
January	O
2014	O
to	O
December	O
2014	O
.	O

During	O
CPB	O
,	O
the	O
lungs	O
were	O
inflated	O
with	O
either	O
50	O
%	O
xenon	O
(	O
xenon	O
group	O
)	O
or	O
50	O
%	O
oxygen	O
(	O
control	O
group	O
)	O
to	O
maintain	O
an	O
airway	O
pressure	O
of	O
5	O
cm	O
H2O	O
.	O

The	O
primary	O
outcome	O
was	O
oxygenation	B-P
index	I-P
(	O
OI	B-P
)	O
value	O
after	O
intubation	O
,	O
and	O
10	O
minutes	O
and	O
6	O
hours	O
after	O
the	O
operation	O
.	O

The	O
second	O
outcome	O
was	O
cytokine	O
and	O
reactive	O
oxygen	O
species	O
levels	O
after	O
intubation	O
and	O
10	O
minutes	O
,	O
6	O
hours	O
,	O
and	O
24	O
hours	O
after	O
the	O
operation	O
.	O

Patients	O
treated	O
with	O
xenon	O
had	O
lower	O
OI	B-P
levels	O
compared	O
to	O
the	O
control	O
group	O
before	O
surgery	O
(	O
P	O
=	O
0.002	O
)	O
;	O
however	O
,	O
there	O
was	O
no	O
difference	O
in	O
postoperative	O
values	O
between	O
the	O
2	O
groups	O
.	O

Following	O
surgery	O
,	O
mean	O
maximal	O
OI	B-P
values	O
decreased	O
by	O
18.8	O
%	O
and	O
33.8	O
%	O
,	O
respectively	O
,	O
in	O
the	O
xenon	O
and	O
control	O
groups	O
.	O

After	O
surgery	O
,	O
the	O
levels	O
of	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
and	O
thromboxane	O
B2	O
decreased	O
by	O
23.5	O
%	O
,	O
9.1	O
%	O
,	O
and	O
30.2	O
%	O
,	O
respectively	O
,	O
in	O
the	O
xenon	O
group	O
,	O
but	O
increased	O
by	O
10.8	O
%	O
,	O
26.2	O
%	O
,	O
and	O
26.4	O
%	O
,	O
respectively	O
,	O
in	O
the	O
control	O
group	O
.	O

Moreover	O
,	O
IL-10	O
levels	O
increased	O
by	O
28	O
%	O
in	O
the	O
xenon	O
group	O
and	O
decreased	O
by	O
7.5	O
%	O
in	O
the	O
control	O
group	O
.	O

There	O
were	O
significant	O
time	O
and	O
treatment	O
-	O
time	O
interaction	O
effects	O
on	O
methane	O
dicarboxylic	O
aldehyde	O
(	O
P	O
=	O
0.000	O
and	O
P	O
=	O
0.050	O
,	O
respectively	O
)	O
and	O
myeloperoxidase	O
(	O
P	O
=	O
0.000	O
and	O
P	O
=	O
0.001	O
in	O
xenon	O
and	O
control	O
groups	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
hospital	O
mortality	O
and	O
1-year	O
survival	O
rate	O
between	O
the	O
2	O
groups	O
.	O

Pulmonary	O
static	O
inflation	O
with	O
50	O
%	O
xenon	O
during	O
CPB	O
could	O
attenuate	O
OI	B-P
decreases	O
at	O
the	O
end	O
of	O
surgery	O
for	O
Stanford	O
type	O
A	O
AAD	O
.	O

Thus	O
,	O
xenon	O
may	O
function	O
by	O
triggering	O
anti-inflammatory	O
responses	O
and	O
suppressing	O
pro-inflammatory	O
and	O
oxidative	O
effects	O
.	O

Ecology	O
and	O
Feeding	O
Habits	O
Drive	O
Infection	O
of	O
Water	O
Bugs	O
with	O
Mycobacterium	O
ulcerans	O
.	O

Mycobacterium	O
ulcerans	O
(	O
MU	O
)	O
,	O
the	O
causative	O
agent	O
of	O
Buruli	O
ulcer	O
,	O
is	O
present	O
in	O
a	O
wide	O
spectrum	O
of	O
environments	O
,	O
including	O
terrestrial	O
and	O
aquatic	O
ecosystems	O
in	O
tropical	O
regions	O
.	O

The	O
most	O
promising	O
studies	B-P
on	O
the	O
epidemiological	O
risk	O
of	O
this	O
disease	O
suggest	O
that	O
some	O
ecological	O
settings	O
may	O
favor	O
infection	O
of	O
animals	O
with	O
MU	O
including	O
human	O
.	O

A	O
species	O
'	O
needs	O
and	O
impacts	O
on	O
resources	O
and	O
the	O
environment	O
,	O
i.e.	O
,	O
its	O
ecological	O
niche	O
,	O
may	O
influence	O
its	O
susceptibility	O
to	O
be	O
infected	O
by	O
this	O
microbial	O
form	O
.	O

For	O
example	O
,	O
some	O
Naucoridae	O
may	O
dive	O
in	O
fresh	O
waters	O
to	O
prey	O
upon	O
infected	O
animals	O
and	O
thus	O
may	O
get	O
infected	O
with	O
MU	O
.	O

However	O
,	O
these	O
studies	B-P
have	O
rarely	O
considered	O
that	O
inference	O
on	O
the	O
ecological	O
settings	O
favoring	O
infection	O
and	O
transmission	O
may	O
be	O
confounded	O
because	O
host	O
carrier	O
sister	O
species	O
have	O
similar	O
ecological	O
niches	O
,	O
and	O
potentially	O
the	O
same	O
host	O
-	O
microbe	O
interactions	O
.	O

Hence	O
,	O
a	O
relationship	O
between	O
the	O
ecological	O
niche	O
of	O
Naucoridae	O
and	O
its	O
infection	O
with	O
MU	O
may	O
be	O
due	O
to	O
a	O
symbiotic	O
relationship	O
between	O
the	O
host	O
and	O
the	O
pathogen	O
,	O
rather	O
than	O
its	O
ecological	O
niche	O
.	O

To	O
account	O
for	O
this	O
confounding	O
effect	O
,	O
we	O
investigated	O
the	O
relationships	O
between	O
surrogates	O
of	O
the	O
ecological	O
niche	O
of	O
water	O
bug	O
species	O
and	O
their	O
susceptibility	O
to	O
MU	O
,	O
by	O
performing	O
phylogenetic	O
comparative	O
analyses	O
on	O
a	O
large	O
dataset	O
of	O
11	O
families	O
of	O
water	O
bugs	O
collected	O
in	O
10	O
different	O
sites	O
across	O
Cameroon	O
,	O
central	O
Africa	O
.	O

Our	O
results	O
indicate	O
that	O
MU	O
circulates	O
and	O
infects	O
a	O
couple	O
of	O
host	O
taxa	O
,	O
i.e.	O
,	O
Belostomatidae	O
,	O
Naucoridae	O
,	O
living	O
both	O
in	O
the	O
aquatic	O
vegetation	O
and	O
as	O
predators	O
inside	O
the	O
trophic	O
network	O
and	O
sister	O
species	O
of	O
water	O
bugs	O
have	O
indeed	O
similar	O
host	O
-	O
microbe	O
interactions	O
with	O
MU	O
.	O

Transforming	O
Growth	O
Factor	O
Beta	O
1	O
(	O
TGF-β1	O
)	O
in	O
Thyroid	O
Cancer	O
Patients	O
:	O
a	O
View	O
from	O
the	O
Peripheral	O
Blood	O
.	O

Transforming	O
growth	O
factor	O
beta	O
(	O
TGF-β	O
)	O
plays	O
an	O
important	O
role	O
in	O
many	O
pathophysiological	O
conditions	O
,	O
including	O
cancer	O
.	O

The	O
level	O
of	O
TGF-β	O
in	O
patients	O
with	O
differentiated	O
thyroid	O
cancer	O
(	O
DTC	O
)	O
has	O
not	O
been	O
examined	O
so	O
far	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
measure	O
TGF-β	O
concentration	O
in	O
serum	O
samples	O
and	O
in	O
PHA	O
-	O
stimulated	O
whole	O
blood	O
culture	B-P
in	O
vitro	O
and	O
to	O
analyze	O
possible	O
associations	O
of	O
TGF-β1	O
levels	O
with	O
leukocyte	O
,	O
lymphocyte	O
and	O
platelets	O
counts	B-P
,	O
the	O
histological	O
type	O
of	O
thyroid	O
cancer	O
,	O
and	O
stage	B-P
of	I-P
disease	I-P
.	O

TGF-β1	O
was	O
measured	O
in	O
22	O
DTC	O
patients	O
and	O
20	O
healthy	O
controls	O
using	O
the	O
duoSet	O
ELISA	O
Development	O
kit	O
for	O
human	O
TGF-β1	O
.	O

The	O
concentration	O
of	O
TGF-β1	O
in	O
serum	O
samples	O
from	O
both	O
groups	O
correlated	O
positively	O
with	O
the	O
platelet	O
counts	B-P
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
serum	O
concentrations	O
of	O
TGF-β1	O
between	O
DTC	O
patients	O
and	O
control	O
subjects	O
,	O
but	O
PHA	O
stimulated	O
whole	O
blood	O
cultures	B-P
of	O
DTC	O
patients	O
produced	O
less	O
TGF-β1	O
than	O
those	O
from	O
controls	O
.	O

Additional	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
significance	O
of	O
these	O
in	O
vitro	O
findings	O
.	O

Successful	O
Fetal	B-P
Tele-Echo	I-P
at	O
a	O
Small	O
Regional	O
Hospital	O
.	O

Prenatal	B-P
diagnosis	I-P
of	O
complex	O
congenital	O
heart	O
disease	O
(	O
CHD	O
)	O
has	O
been	O
shown	O
to	O
improve	O
newborn	O
outcomes	O
.	O

The	O
rate	O
of	O
prenatal	B-P
diagnosis	I-P
and	O
access	O
to	O
fetal	B-P
echocardiography	I-P
vary	O
widely	O
across	O
the	O
United	O
States	O
.	O

A	O
clinical	B-P
fetal	I-P
tele-echo	I-P
service	O
was	O
established	O
at	O
King	O
's	O
Daughters	O
Medical	O
Center	O
(	O
KDMC	O
)	O
in	O
Ashland	O
,	O
KY	O
,	O
a	O
region	O
in	O
eastern	O
Kentucky	O
that	O
is	O
3	O
h	O
from	O
the	O
nearest	O
congenital	O
heart	O
surgeon	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
fetal	B-P
tele-echo	I-P
utilizing	O
local	O
sonographers	O
at	O
a	O
small	O
regional	O
hospital	O
can	O
accurately	O
and	O
efficiently	O
identify	O
fetuses	O
with	O
complex	O
CHD	O
.	O

Medical	O
records	O
were	O
reviewed	O
for	O
all	O
mother-infant	O
pairs	O
who	O
had	O
fetal	B-P
tele-echoes	I-P
performed	O
at	O
KDMC	O
and	O
interpreted	O
by	O
University	O
of	O
Louisville	O
pediatric	O
cardiology	O
between	O
March	O
2011	O
and	O
December	O
2013	O
.	O

Findings	O
on	O
fetal	B-P
tele-echo	I-P
were	O
compared	O
to	O
newborn	O
echo	B-P
and	O
clinical	O
course	O
,	O
and	O
divided	O
into	O
four	O
groups	O
:	O
(	O
1	O
)	O
Correct	O
-	O
no	O
difference	O
between	O
fetal	B-P
tele-echo	I-P
and	O
newborn	O
echo	B-P
,	O
(	O
2	O
)	O
Likely	O
Correct-normal	O
fetal	B-P
tele-echo	I-P
and	O
benign	O
newborn	O
course	O
,	O
(	O
3	O
)	O
Major	O
Difference	O
-one	O
that	O
affected	O
newborn	O
clinical	O
course	O
,	O
and	O
(	O
4	O
)	O
Minor	O
Difference	O
-did	O
not	O
affect	O
clinical	O
course	O
.	O

Seventy-five	O
mother-infant	O
pairs	O
were	O
analyzed	O
.	O

Fetal	B-P
tele-echoes	I-P
were	O
Correct	O
in	O
21	O
%	O
,	O
Likely	O
Correct	O
in	O
56	O
%	O
,	O
showed	O
Major	O
Differences	O
in	O
0	O
%	O
,	O
and	O
showed	O
Minor	O
Differences	O
in	O
23	O
%	O
.	O

For	O
identifying	O
complex	O
CHD	O
,	O
fetal	B-P
tele-echo	I-P
had	O
a	O
sensitivity	O
and	O
specificity	O
of	O
100	O
%	O
.	O

The	O
average	O
number	O
of	O
fetal	B-P
echocardiograms	I-P
per	O
mother-infant	O
pair	O
was	O
1.1	O
.	O

Fetal	B-P
tele-echocardiography	I-P
performed	O
by	O
local	O
sonographers	O
at	O
a	O
small	O
regional	O
hospital	O
can	O
accurately	O
and	O
efficiently	O
identify	O
fetuses	O
with	O
complex	O
CHD	O
.	O

Hypovitaminosis	O
D	O
and	O
Associated	O
Cardiometabolic	O
Risk	O
in	O
Women	O
with	O
PCOS	O
.	O

Women	O
with	O
Polycystic	O
Ovary	O
Syndrome	O
(	O
PCOS	O
)	O
frequently	O
suffer	O
from	O
metabolic	O
disturbances	O
like	O
insulin	O
resistance	O
,	O
hypertension	O
and	O
atherogenic	O
dyslipidemia	O
.	O

Accumulating	O
evidences	O
suggest	O
that	O
Vitamin	O
D	O
deficiency	O
is	O
common	O
in	O
PCOS	O
and	O
may	O
be	O
associated	O
with	O
metabolic	O
and	O
endocrinal	O
dysfunctions	O
in	O
PCOS	O
.	O

Thus	O
women	O
with	O
PCOS	O
may	O
be	O
at	O
elevated	O
risk	O
of	O
cardiovascular	O
disease	O
.	O

Present	O
study	O
aims	O
to	O
evaluate	O
Vitamin	O
D	O
status	O
and	O
to	O
assess	O
its	O
association	O
with	O
metabolic	O
and	O
endocrinal	O
dysregulations	O
in	O
women	O
with	O
PCOS	O
,	O
which	O
might	O
help	O
in	O
early	O
identification	O
and	O
prevention	O
of	O
future	O
symptomatic	O
cardiac	O
disease	O
.	O

A	O
total	O
of	O
44	O
women	O
with	O
PCOS	O
,	O
diagnosed	O
by	O
Rotterdam	O
criteria	O
and	O
45	O
healthy	O
control	O
without	O
PCOS	O
,	O
were	O
evaluated	O
for	O
Vitamin	O
D	O
and	O
cardiometabolic	O
risk	O
factors	O
,	O
including	O
fasting	O
plasma	O
glucose	O
,	O
insulin	O
resistance	O
,	O
dyslipidemia	O
,	O
hs-CRP	O
.	O

That	O
apart	O
,	O
several	O
endocrinal	O
parameters	O
of	O
hyperandrogenism	O
were	O
also	O
examined	O
.	O

Several	O
correlation	O
studies	O
were	O
determined	O
to	O
establish	O
the	O
role	O
of	O
Vitamin	O
D	O
as	O
a	O
cardiometabolic	O
risk	O
factor	O
in	O
PCOS	O
.	O

Results	O
were	O
expressed	O
as	O
mean±SD	O
and	O
were	O
statistically	O
analysed	O
using	O
SPSS	O
software	O
version	O
16	O
,	O
unpaired	O
student	O
's	O
t-test	O
and	O
Pearson	O
's	O
correlation	O
coefficient	O
.	O

We	O
found	O
lower	O
levels	O
of	O
Vitamin	O
D	O
,	O
which	O
was	O
statistically	O
significant	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

Hyperinsulinemia	O
,	O
rise	O
in	O
insulin	O
resistance	O
and	O
marked	O
dyslipidemia	O
was	O
observed	O
in	O
the	O
present	O
study	O
.	O

Another	O
relevant	O
finding	O
was	O
significant	O
correlation	O
of	O
Vitamin	O
D	O
with	O
insulin	O
and	O
Homeostatic	B-P
Model	I-P
of	I-P
Assessment-	I-P
Insulin	I-P
Resistance	I-P
Index	I-P
(	O
HOMA-IR	B-P
)	O
.	O

Hypovitaminosis	O
D	O
was	O
prevalent	O
in	O
PCOS	O
.	O

This	O
was	O
related	O
to	O
metabolic	O
and	O
hormonal	O
disorders	O
in	O
PCOS	O
.	O

Possibly	O
this	O
combined	O
with	O
impaired	O
fasting	O
glucose	O
,	O
IR	O
and	O
dyslipidemia	O
,	O
could	O
account	O
for	O
Cardio	O
vascular	O
risks	O
in	O
PCOS	O
.	O

Further	O
prospective	O
observational	O
studies	O
and	O
randomized	O
control	O
trials	O
are	O
required	O
to	O
explore	O
the	O
above	O
hypothesis	O
.	O

Activation	O
of	O
general	O
control	O
nonderepressible	O
2	O
kinase	O
protects	O
human	O
glomerular	O
endothelial	O
cells	O
from	O
harmful	O
high-glucose	O
-	O
induced	O
molecular	O
pathways	O
.	O

Considering	O
the	O
referred	O
beneficial	O
effects	O
of	O
protein	O
restriction	O
on	O
diabetic	O
nephropathy	O
(	O
DN	O
)	O
and	O
the	O
role	O
of	O
renal	O
endothelium	O
in	O
its	O
pathogenesis	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
general	O
control	O
nonderepressible	O
2	O
(	O
GCN2	O
)	O
kinase	O
activation	O
,	O
a	O
sensor	O
of	O
amino	O
acid	O
deprivation	O
,	O
on	O
known	O
detrimental	O
molecular	O
pathways	O
in	O
primary	O
human	O
glomerular	O
endothelial	O
cells	O
(	O
GEnC	O
)	O
.	O

GEnC	O
were	O
cultured	B-P
under	O
normal	O
or	O
high	O
-glucose	O
conditions	O
in	O
the	O
presence	O
or	O
not	O
of	O
the	O
GCN2	O
kinase	O
activator	O
,	O
tryptophanol	O
.	O

Glucose	O
transporter	O
1	O
(	O
GLUT1	O
)	O
expression	O
was	O
assessed	O
by	O
western	O
blotting	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
using	O
a	O
fluorogenic	O
probe	O
.	O

Activities	O
of	O
glyceraldehyde	O
3-phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
were	O
assessed	O
by	O
commercial	B-P
activity	I-P
assays	I-P
,	O
sorbitol	O
colorimetrically	B-P
,	O
methylglyoxal	O
by	O
ELISA	B-P
and	O
O-linked	O
β-N-acetyl	O
glucosamine	O
(	O
O-GlcNAc	O
)	O
-modified	O
proteins	O
by	O
western	O
blotting	O
.	O

High	O
glucose	O
induced	O
GLUT1	O
expression	O
,	O
increased	O
ROS	O
and	O
inhibited	O
GAPDH	O
.	O

Also	O
it	O
increased	O
the	O
polyol	O
pathway	O
product	O
sorbitol	O
,	O
PKC	O
activity	O
,	O
the	O
level	O
of	O
the	O
O-GlcNAc-modified	O
proteins	O
that	O
produced	O
by	O
the	O
hexosamine	O
pathway	O
and	O
the	O
advanced	O
glycation	O
endproducts	O
'	O
precursor	O
methylglyoxal	O
.	O

Co-treatment	O
of	O
GEnC	O
with	O
tryptophanol	O
restored	O
the	O
above	O
high-glucose	O
-	O
induced	O
alterations	O
.	O

Activation	O
of	O
GCN2	O
kinase	O
protects	O
GEnC	O
from	O
high-glucose	O
-	O
induced	O
harmful	O
molecular	O
pathways	O
.	O

By	O
inhibiting	O
concurrently	O
many	O
pathways	O
involved	O
in	O
DN	O
pathogenesis	O
,	O
GCN2	O
kinase	O
may	O
serve	O
as	O
a	O
pharmaceutical	O
target	O
for	O
the	O
treatment	O
of	O
DN	O
.	O

Vasopressin	O
regulates	O
the	O
growth	O
of	O
the	O
biliary	O
epithelium	O
in	O
polycystic	O
liver	O
disease	O
.	O

The	O
neurohypophysial	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
acts	O
by	O
three	O
distinct	O
receptor	O
subtypes	O
:	O
V1a	O
,	O
V1b	O
,	O
and	O
V2	O
.	O

In	O
the	O
liver	O
,	O
AVP	O
is	O
involved	O
in	O
ureogenesis	O
,	O
glycogenolysis	O
,	O
neoglucogenesis	O
and	O
regeneration	O
.	O

No	O
data	O
exist	O
about	O
the	O
presence	O
of	O
AVP	O
in	O
the	O
biliary	O
epithelium	O
.	O

Cholangiocytes	O
are	O
the	O
target	O
cells	O
in	O
a	O
number	O
of	O
animal	O
models	O
of	O
cholestasis	O
,	O
including	O
bile	O
duct	O
ligation	O
(	O
BDL	O
)	O
,	O
and	O
in	O
several	O
human	O
pathologies	O
,	O
such	O
as	O
polycystic	O
liver	O
disease	O
characterized	O
by	O
the	O
presence	O
of	O
cysts	O
that	O
bud	O
from	O
the	O
biliary	O
epithelium	O
.	O

In	O
vivo	O
,	O
liver	O
fragments	O
from	O
normal	O
and	O
BDL	O
mice	O
and	O
rats	O
as	O
well	O
as	O
liver	O
samples	O
from	O
normal	O
and	O
ADPKD	O
patients	O
were	O
collected	O
to	O
evaluate	O
:	O
(	O
i	O
)	O
intrahepatic	O
bile	O
duct	O
mass	O
by	O
immunohistochemistry	B-P
for	O
cytokeratin-19	O
;	O
and	O
(	O
ii	O
)	O
expression	O
of	O
V1a	O
,	O
V1b	O
and	O
V2	O
by	O
immunohistochemistry	B-P
,	O
immunofluorescence	B-P
and	O
real-time	O
PCR	O
.	O

In	O
vitro	O
,	O
small	O
and	O
large	O
mouse	O
cholangiocytes	O
,	O
H69	O
(	O
non-malignant	O
human	O
cholangiocytes	O
)	O
and	O
LCDE	O
(	O
human	O
cholangiocytes	O
from	O
the	O
cystic	O
epithelium	O
)	O
were	O
stimulated	O
with	O
vasopressin	O
in	O
the	O
absence/	O
presence	O
of	O
AVP	O
antagonists	O
such	O
as	O
OPC-31260	O
and	O
Tolvaptan	O
,	O
before	O
assessing	O
cellular	O
growth	O
by	O
MTT	B-P
assay	I-P
and	O
cAMP	O
levels	O
.	O

Cholangiocytes	O
express	O
V2	O
receptor	O
that	O
was	O
upregulated	O
following	O
BDL	O
and	O
in	O
ADPKD	O
liver	O
samples	O
.	O

Administration	O
of	O
AVP	O
increased	O
proliferation	O
and	O
cAMP	O
levels	O
of	O
small	O
cholangiocytes	O
and	O
LCDE	O
cells	O
.	O

We	O
found	O
no	O
effect	O
in	O
the	O
proliferation	O
of	O
large	O
mouse	O
cholangiocytes	O
and	O
H69	O
cells	O
.	O

Increases	O
were	O
blocked	O
by	O
preincubation	B-P
with	O
the	O
AVP	O
antagonists	O
.	O

These	O
results	O
showed	O
that	O
AVP	O
and	O
its	O
receptors	O
may	O
be	O
important	O
in	O
the	O
modulation	O
of	O
the	O
proliferation	O
rate	O
of	O
the	O
biliary	O
epithelium	O
.	O

MALDI-TOF	O
mass	O
spectrometry	O
for	O
the	O
identification	O
of	O
lactic	O
acid	O
bacteria	O
isolated	O
from	O
a	O
French	O
cheese	O
:	O
The	O
Maroilles	O
.	O

In	O
this	O
study	O
we	O
identified	O
the	O
culturable	B-P
population	O
of	O
mesophilic	O
lactic	O
acid	O
bacteria	O
(	O
LAB	O
)	O
from	O
a	O
French	O
cheese	O
Maroilles	O
made	O
either	O
with	O
raw	O
or	O
pasteurized	O
milk	O
using	O
MALDI-TOF	O
mass	O
spectrometry	O
(	O
MS	B-P
)	O
.	O

Samples	O
from	O
rind	O
and	O
heart	O
of	O
Maroilles	O
cheese	O
were	O
used	O
,	O
the	O
LAB	O
were	O
selected	O
on	O
MRS	O
agar	O
at	O
30°C	O
and	O
197	O
Gram-positive	O
and	O
catalase-negative	O
strains	O
were	O
subjected	O
to	O
identification	O
by	O
MALDI-TOF	O
MS	O
profiling	O
.	O

All	O
strains	O
were	O
unambiguously	O
identified	O
:	O
105	O
strains	O
from	O
Maroilles	O
made	O
with	O
raw	O
milk	O
(	O
38	O
on	O
the	O
rind	O
and	O
67	O
in	O
the	O
heart	O
)	O
and	O
92	O
strains	O
from	O
Maroilles	O
made	O
with	O
pasteurized	O
milk	O
(	O
39	O
on	O
the	O
rind	O
and	O
53	O
in	O
the	O
heart	O
)	O
.	O

MALDI-TOF	O
MS	O
identification	O
allowed	O
identification	O
of	O
three	O
genera	O
belonging	O
to	O
LAB	O
including	O
Lactobacillus	O
,	O
Enterococcus	O
and	O
Leuconostoc	O
.	O

Lactobacillus	O
was	O
the	O
most	O
represented	O
genus	O
with	O
seven	O
species	O
:	O
Lactobacillus	O
plantarum	O
(	O
L.	O
plantarum	O
)	O
,	O
L.	O
paracasei	O
,	O
L.	O
curvatus	O
,	O
L.	O
rhamnosus	O
,	O
L.	O
fructivorans	O
,	O
L.	O
parabuchneri	O
,	O
L.	O
brevis	O
found	O
in	O
Maroilles	O
made	O
with	O
both	O
kind	O
of	O
milk	O
.	O

The	O
correlation	O
between	O
the	O
16S	O
rDNA	O
-based	O
identification	O
performed	O
on	O
selected	O
strains	O
and	O
those	O
obtained	O
by	O
MALDI-TOF-MS	O
demonstrates	O
that	O
this	O
fast	O
,	O
economically	O
affordable	O
,	O
robust	O
and	O
reliable	O
method	O
for	O
bacteria	O
characterisation	O
stands	O
as	O
an	O
attractive	O
alternative	O
to	O
the	O
commonly-used	O
methods	O
and	O
its	O
application	O
in	O
food	O
industry	O
is	O
discussed	O
.	O

Variation	O
in	O
the	O
Use	O
of	O
Vestibular	B-P
Diagnostic	I-P
Testing	I-P
for	O
Patients	O
Presenting	O
to	O
Otolaryngology	O
Clinics	O
with	O
Dizziness	O
.	O

We	O
used	O
a	O
national	O
otolaryngology	O
practice-based	O
research	O
network	O
database	O
to	O
characterize	O
the	O
utilization	O
of	O
vestibular	B-P
function	I-P
testing	I-P
in	O
patients	O
diagnosed	O
with	O
dizziness	O
and/or	O
a	O
vestibular	O
disorder	O
.	O

Database	O
review	O
.	O

The	O
Creating	O
Healthcare	O
Excellence	O
through	O
Education	O
and	O
Research	O
(	O
CHEER	O
)	O
practice-based	O
research	O
network	O
of	O
academic	O
and	O
community	O
providers	O
Dizzy	O
patients	O
in	O
the	O
CHEER	O
retrospective	O
database	O
were	O
identified	O
through	O
ICD-9	O
codes	O
;	O
vestibular	B-P
testing	I-P
procedures	I-P
were	O
identified	O
with	O
CPT	O
codes	O
.	O

Demographics	O
and	O
procedures	B-P
per	I-P
patient	I-P
were	O
tabulated	O
.	O

Analysis	O
included	O
number	O
and	O
type	O
of	O
vestibular	B-P
tests	I-P
ordered	O
,	O
stratified	O
by	O
individual	O
clinic	O
and	O
by	O
practice	O
type	O
(	O
community	O
vs	O
academic	O
)	O
.	O

Chi-square	O
tests	O
were	O
performed	O
to	O
assess	O
if	O
the	O
percentage	O
of	O
patients	O
receiving	O
testing	O
was	O
statistically	O
significant	O
across	O
clinics	O
.	O

A	O
logistic	O
regression	O
model	O
was	O
used	O
to	O
examine	O
the	O
association	O
between	O
receipt	O
of	O
testing	O
and	O
being	O
tested	O
on	O
initial	O
visit	O
.	O

A	O
total	O
of	O
12,468	O
patients	O
diagnosed	O
with	O
dizziness	O
and/or	O
a	O
vestibular	O
disorder	O
were	O
identified	O
from	O
7	O
community	O
and	O
5	O
academic	O
CHEER	O
network	O
clinics	O
across	O
the	O
country	O
.	O

One-fifth	O
of	O
these	O
patients	O
had	O
at	O
least	O
1	O
vestibular	B-P
function	I-P
test	I-P
.	O

The	O
percentage	O
of	O
patients	O
tested	O
varied	O
widely	O
by	O
site	O
,	O
from	O
3	O
%	O
to	O
72	O
%	O
;	O
academic	O
clinics	O
were	O
twice	O
as	O
likely	O
to	O
test	O
.	O

Initial	O
visit	O
vestibular	B-P
testing	I-P
also	O
varied	O
,	O
from	O
0	O
%	O
to	O
96	O
%	O
of	O
dizzy	O
patients	O
,	O
and	O
was	O
15	O
times	O
more	O
likely	O
in	O
academic	O
clinics	O
.	O

There	O
is	O
significant	O
variation	O
in	O
use	O
and	O
timing	O
of	O
vestibular	B-P
diagnostic	I-P
testing	I-P
across	O
otolaryngology	O
clinics	O
.	O

The	O
CHEER	O
network	O
research	O
database	O
does	O
not	O
contain	O
outcome	O
data	O
.	O

These	O
results	O
illustrate	O
the	O
critical	O
need	O
for	O
research	O
that	O
examines	O
outcomes	O
as	O
related	O
to	O
vestibular	B-P
testing	I-P
.	O

Verification	O
of	O
respiratory-gated	O
radiotherapy	O
with	O
new	O
real-time	O
tumour	O
-tracking	O
radiotherapy	O
system	O
using	O
cine	O
EPID	O
images	O
and	O
a	O
log	O
file	O
.	O

A	O
combined	O
system	O
comprising	O
the	O
TrueBeam	O
linear	O
accelerator	O
and	O
a	O
new	O
real-time	O
tumour	O
-tracking	O
radiotherapy	O
system	O
,	O
SyncTraX	O
,	O
was	O
installed	O
at	O
our	O
institution	O
.	O

The	O
objectives	O
of	O
this	O
study	O
are	O
to	O
develop	O
a	O
method	O
for	O
the	O
verification	O
of	O
respiratory-gated	O
radiotherapy	O
with	O
SyncTraX	O
using	O
cine	O
electronic	O
portal	O
image	O
device	O
(	O
EPID	O
)	O
images	O
and	O
a	O
log	O
file	O
and	O
to	O
verify	O
this	O
treatment	O
in	O
clinical	O
cases	O
.	O

Respiratory-gated	O
radiotherapy	O
was	O
performed	O
using	O
TrueBeam	O
and	O
the	O
SyncTraX	O
system	O
.	O

Cine	O
EPID	O
images	O
and	O
a	O
log	O
file	O
were	O
acquired	O
for	O
a	O
phantom	O
and	O
three	O
patients	O
during	O
the	O
course	O
of	O
the	O
treatment	O
.	O

Digitally	O
reconstructed	O
radiographs	O
(	O
DRRs	O
)	O
were	O
created	O
for	O
each	O
treatment	O
beam	O
using	O
a	O
planning	B-P
CT	I-P
set	O
.	O

The	O
cine	O
EPID	O
images	O
,	O
log	O
file	O
,	O
and	O
DRRs	O
were	O
analysed	O
using	O
a	O
developed	O
software	O
.	O

For	O
the	O
phantom	O
case	O
,	O
the	O
accuracy	O
of	O
the	O
proposed	O
method	O
was	O
evaluated	O
to	O
verify	O
the	O
respiratory-gated	O
radiotherapy	O
.	O

For	O
the	O
clinical	O
cases	O
,	O
the	O
intra-	O
and	O
inter-fractional	O
variations	O
of	O
the	O
fiducial	O
marker	O
used	O
as	O
an	O
internal	O
surrogate	O
were	O
calculated	O
to	O
evaluate	O
the	O
gating	O
accuracy	O
and	O
set-up	O
uncertainty	O
in	O
the	O
superior	O
-	O
inferior	O
(	O
SI	O
)	O
,	O
anterior-posterior	O
(	O
AP	O
)	O
,	O
and	O
left-right	O
(	O
LR	O
)	O
directions	O
.	O

The	O
proposed	O
method	O
achieved	O
high	O
accuracy	O
for	O
the	O
phantom	O
verification	O
.	O

For	O
the	O
clinical	O
cases	O
,	O
the	O
intra-	O
and	O
inter-fractional	O
variations	O
of	O
the	O
fiducial	O
marker	O
were	O
⩽3	O
mm	O
and	O
±3	O
mm	O
in	O
the	O
SI	O
,	O
AP	O
,	O
and	O
LR	O
directions	O
.	O

We	O
proposed	O
a	O
method	O
for	O
the	O
verification	O
of	O
respiratory-gated	O
radiotherapy	O
with	O
SyncTraX	O
using	O
cine	O
EPID	O
images	O
and	O
a	O
log	O
file	O
and	O
showed	O
that	O
this	O
treatment	O
is	O
performed	O
with	O
high	O
accuracy	O
in	O
clinical	O
cases	O
.	O

New	O
Diterpenoids	O
from	O
Clerodendranthus	O
spicatus	O
.	O

Two	O
new	O
diterpenoids	O
,	O
neoorthosiphonones	O
B	O
and	O
C	O
(	O
1	O
and	O
2	O
)	O
,	O
and	O
one	O
known	O
diterpenoid	O
,	O
were	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Clerodendranthus	O
spicatus	O
.	O

Their	O
structures	O
including	O
absolute	O
configurations	O
were	O
determined	O
by	O
comprehensive	O
spectroscopic	B-P
analyses	I-P
and	O
X-ray	B-P
crystallographic	I-P
methods	I-P
.	O

No	O
compound	O
was	O
found	O
to	O
inhibit	O
fibronectin	O
production	O
at	O
the	O
concentration	O
of	O
20	O
μM	O
.	O

Coordinated	O
Asthma	O
Program	O
Improves	O
Asthma	O
Outcomes	O
in	O
High-Risk	O
Children	O
.	O

Innovative	O
approaches	O
within	O
primary	O
care	O
are	O
needed	O
to	O
reduce	O
fragmented	O
care	O
,	O
increase	O
continuity	O
of	O
care	O
,	O
and	O
improve	O
asthma	O
outcomes	O
in	O
children	O
with	O
asthma	O
.	O

Our	O
objective	O
was	O
to	O
assess	O
the	O
impact	O
of	O
coordinated	O
team	O
-based	O
asthma	O
care	O
on	O
unplanned	O
asthma	O
-related	O
health	O
care	O
utilization	O
.	O

A	O
multidisciplinary	O
asthma	O
team	O
was	O
developed	O
to	O
provide	O
coordinated	O
care	O
to	O
high-risk	O
asthma	O
patients	O
.	O

Patients	O
received	O
an	O
in-depth	B-P
diagnostic	I-P
and	O
family	O
needs	O
assessment	O
,	O
asthma	O
education	O
,	O
and	O
coordinated	O
referral	O
to	O
social	O
and	O
community	O
services	O
.	O

Over	O
a	O
2-	O
year	O
period	O
,	O
141	O
patients	O
were	O
followed	O
.	O

At	O
both	O
1	O
and	O
2	O
years	O
postintervention	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
from	O
preintervention	O
rates	O
in	O
urgent	O
care	O
visits	O
(	O
40	O
%	O
,	O
P	O
=	O
.002	O
;	O
50	O
%	O
,	O
P	O
<	O
.0001	O
)	O
,	O
emergency	O
department	O
visits	O
(	O
63	O
%	O
,	O
P	O
<	O
.0001	O
;	O
70	O
%	O
,	O
P	O
<	O
.0001	O
)	O
,	O
and	O
inpatient	O
hospitalization	O
(	O
69	O
%	O
,	O
P	O
=	O
.002	O
;	O
54	O
%	O
,	O
P	O
=	O
.04	O
)	O
.	O

Our	O
coordinated	O
asthma	O
care	O
program	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
urgent	O
care	O
visits	O
,	O
emergency	O
department	O
visits	O
,	O
and	O
inpatient	O
hospitalizations	O
among	O
high-risk	O
children	O
with	O
asthma	O
.	O

The	O
relationship	O
between	O
anthropometry	O
and	O
body	O
composition	O
from	O
computed	B-P
tomography	I-P
:	O
The	O
Mediators	O
of	O
Atherosclerosis	O
in	O
South	O
Asians	O
Living	O
in	O
America	O
Study	O
.	O

Few	O
studies	O
examine	O
the	O
relationships	O
between	O
anthropometry	O
and	O
the	O
body	O
composition	O
measures	O
they	O
approximate	O
,	O
or	O
whether	O
they	O
differ	O
by	O
sex	O
,	O
and	O
no	O
studies	O
have	O
examined	O
these	O
relationships	O
in	O
South	O
Asians	O
living	O
in	O
the	O
US	O
.	O

We	O
conducted	O
a	O
cross-sectional	O
study	O
of	O
871	O
participants	O
in	O
the	O
Mediators	O
of	O
Atherosclerosis	O
in	O
South	O
Asians	O
Living	O
in	O
America	O
(	O
MASALA	O
)	O
Study	O
who	O
had	O
BMI	O
<	O
40	O
kg/m	O
(	O
2	O
)	O
and	O
underwent	O
abdominal	B-P
CT	I-P
scans	I-P
for	O
measurement	O
of	O
visceral	O
and	O
subcutaneous	O
fat	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
model	O
the	O
associations	O
between	O
anthropometric	O
measures	O
and	O
naturally	O
log-transformed	O
body	O
composition	O
measures	O
.	O

All	O
measures	O
of	O
anthropometry	O
,	O
except	O
height	O
,	O
were	O
significantly	O
associated	O
with	O
visceral	O
fat	O
and	O
had	O
a	O
significant	O
non-linear	O
component	O
(	O
p	O
<	O
.05	O
)	O
.	O

The	O
only	O
associations	O
for	O
visceral	O
fat	O
that	O
exhibited	O
significant	O
heterogeneity	O
by	O
sex	O
were	O
waist	O
circumference	O
(	O
%	O
difference	O
in	O
visceral	O
fat	O
slope	O
:	O
women	O
1.92	O
,	O
men	O
2.74	O
,	O
p	O
=	O
.007	O
for	O
interaction	O
)	O
and	O
waist-to-hip	O
ratio	O
(	O
women	O
25.9	O
,	O
men	O
717.4	O
,	O
p	O
<	O
.001	O
)	O
.	O

Except	O
for	O
height	O
,	O
all	O
measures	O
of	O
anthropometry	O
were	O
significantly	O
associated	O
with	O
subcutaneous	O
fat	O
,	O
had	O
a	O
significant	O
quadratic	O
component	O
,	O
and	O
significant	O
heterogeneity	O
by	O
sex	O
(	O
weight	O
(	O
kg	O
)	O
:	O
2.74	O
for	O
women	O
,	O
4.08	O
for	O
men	O
;	O
BMI	O
(	O
kg/m	O
(	O
2	O
)	O
)	O
:	O
10.3	O
,	O
14.0	O
;	O
waist	O
circumference	O
(	O
cm	O
)	O
:	O
1.51	O
,	O
3.36	O
;	O
hip	O
circumference	O
(	O
cm	O
)	O
:	O
2.53	O
,	O
4.50	O
)	O
with	O
p	O
<	O
.001	O
for	O
each	O
.	O

In	O
MASALA	O
participants	O
,	O
the	O
relationships	O
of	O
anthropometric	O
measures	O
with	O
visceral	O
and	O
subcutaneous	O
fat	O
appear	O
similar	O
to	O
other	O
race	O
/	O
ethnic	O
groups	O
,	O
but	O
with	O
weaker	O
non-linearity	O
and	O
heterogeneity	O
by	O
sex	O
.	O

Given	O
these	O
results	O
,	O
researchers	O
should	O
consider	O
separate	O
models	O
by	O
sex	O
for	O
US	O
South	O
Asians	O
when	O
approximating	O
subcutaneous	O
fat	O
or	O
when	O
using	O
waist	O
circumference	O
to	O
approximate	O
visceral	O
fat	O
.	O

A	O
92-	O
year	O
-	O
old	O
man	O
with	O
primary	O
cutaneous	O
diffuse	O
large	O
B-cell	O
non-Hodgkin	O
's	O
lymphoma	O
manifesting	O
as	O
a	O
giant	O
scalp	O
mass	O
:	O
A	O
case	O
report	O
.	O

Primary	O
cutaneous	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
is	O
an	O
uncommon	O
entity	O
,	O
representing	O
10	O
%	O
of	O
all	O
extranodal	O
NHLs	O
.	O

Among	O
all	O
cutaneous	O
sites	O
,	O
the	O
scalp	O
is	O
a	O
rare	O
site	O
of	O
representation	O
.	O

A	O
92-	O
year	O
-old	O
Chinese	O
man	O
visited	O
our	O
hospital	O
with	O
a	O
multiple-nodular	O
huge	O
scalp	O
mass	O
on	O
the	O
right	O
parieto-occipital	O
regions	O
.	O

The	O
mass	O
was	O
of	O
7-	O
month	O
duration	O
and	O
progressively	O
enlarging	O
in	O
size	O
.	O

On	O
the	O
basis	O
of	O
the	O
result	O
of	O
biopsy	B-P
,	O
diffuse	O
large	O
B-cell	O
NHL	O
was	O
diagnosed	O
.	O

The	O
mass	O
was	O
partially	O
resected	O
by	O
surgery	O
and	O
no	O
further	O
treatment	O
was	O
conducted	O
due	O
to	O
the	O
advanced	O
age	O
and	O
poor	O
physical	O
status	O
.	O

The	O
tumor	O
relapsed	O
in	O
situ	O
after	O
6	O
months	O
and	O
the	O
patient	O
died	O
after	O
2	O
years	O
.	O

This	O
case	O
highlighted	O
the	O
limited	O
access	O
to	O
standard	O
treatment	O
options	O
in	O
patients	O
with	O
advanced	O
age	O
.	O

A	O
thorough	O
examination	O
is	O
necessary	O
to	O
decide	O
upon	O
the	O
treatment	O
for	O
the	O
primary	O
cutaneous	O
lymphoma	O
.	O

Prenatal	B-P
Diagnosis	I-P
of	O
Lysosomal	O
Storage	O
Disorders	O
Using	O
Chorionic	O
Villi	O
.	O

Prenatal	B-P
enzymatic	I-P
diagnosis	I-P
for	O
an	O
array	O
of	O
lysosomal	O
storage	O
disorders	O
(	O
LSDs	O
)	O
can	O
be	O
performed	O
accurately	O
,	O
provided	O
that	O
a	O
confirmed	O
diagnosis	O
by	O
biochemical/molecular	O
study	O
in	O
the	O
index	O
case	O
is	O
available	O
and	O
a	O
strict	O
defined	O
protocol	O
,	O
specific	O
to	O
each	O
individual	O
disorder	O
is	O
followed	O
.	O

The	O
present	O
chapter	O
describes	O
the	O
protocols	O
for	O
reliable	O
and	O
accurate	O
prenatal	B-P
enzymatic	I-P
diagnoses	I-P
by	O
fluorometric	B-P
and	O
spectrophotometric	B-P
methods	I-P
of	O
lysosomal	O
storage	O
disorders	O
:	O
Gaucher	O
,	O
Fabry	O
,	O
Pompe	O
,	O
Niemann	O
Pick	O
A/B	O
,	O
Tay	O
Sach	O
,	O
Sandhoff	O
,	O
GM1	O
,	O
Mucoplysaccharidoses	O
,	O
Wolman	O
,	O
Krabbe	O
,	O
Metachromatic	O
leukodystrophy	O
,	O
and	O
Batten	O
diseases	O
using	O
uncultured	O
chorionic	O
villi	O
samples	O
.	O

The	O
biological	O
reference	O
intervals	O
for	O
enzyme	B-P
levels	I-P
in	O
normal	O
and	O
affected	O
fetuses	O
are	O
given	O
for	O
interpretation	O
of	O
prenatal	O
results	O
.	O

It	O
is	O
imperative	O
to	O
establish	O
normal	O
reference	O
interval	O
in	O
each	O
laboratory	O
to	O
take	O
into	O
account	O
the	O
local	O
environment	O
,	O
technical	O
variations	O
,	O
and	O
different	O
ethnicities	O
.	O

Besides	O
,	O
enzyme	O
activity	O
in	O
the	O
fetus	O
should	O
be	O
represented	O
as	O
percentage	O
of	O
the	O
mean	O
activity	O
of	O
enzyme	O
of	O
normal	O
fetuses	O
.	O

The	O
pitfalls	O
and	O
challenges	O
in	O
prenatal	B-P
diagnosis	I-P
as	O
well	O
as	O
technical	O
problems	O
in	O
performing	O
enzyme	B-P
assays	I-P
are	O
also	O
discussed	O
to	O
help	O
the	O
reader	O
in	O
standardization	O
and	O
performing	O
the	O
assays	B-P
for	O
correct	O
diagnosis	O
.	O

Reduced	O
compensatory	O
responses	O
to	O
maintain	O
central	O
blood	O
volume	O
during	O
hypovolemic	O
stress	O
in	O
women	O
with	O
vasovagal	O
syncope	O
.	O

Although	O
vasovagal	O
syncope	O
(	O
VVS	O
)	O
is	O
a	O
common	O
clinical	O
condition	O
the	O
underlying	O
pathophysiology	O
is	O
not	O
fully	O
understood	O
.	O

A	O
decrease	O
in	O
cardiac	O
output	O
has	O
recently	O
been	O
suggested	O
as	O
a	O
determinant	O
factor	O
for	O
orthostatic	O
VVS	O
.	O

The	O
aim	O
was	O
to	O
investigate	O
compensatory	O
mechanisms	O
to	O
maintain	O
central	O
blood	O
volume	O
and	O
venous	O
return	O
during	O
hypovolemic	O
stress	O
in	O
women	O
with	O
VVS	O
.	O

14	O
VVS	O
women	O
(	O
25.7±5.0	O
years	O
)	O
and	O
15	O
matched	O
controls	O
(	O
22.8±3.2	O
years	O
)	O
were	O
investigated	O
.	O

Single	O
step	O
and	O
graded	O
lower	O
body	O
negative	O
pressure	O
(	O
LBNP	O
)	O
to	O
presyncope	O
was	O
used	O
to	O
create	O
hypovolemic	O
stress	O
.	O

Peripheral	O
mobilization	O
of	O
venous	O
blood	O
from	O
the	O
arm	O
(	O
capacitance	O
response	O
and	O
net	O
capillary	O
fluid	O
absorption	O
)	O
and	O
lower	O
limb	O
blood	O
pooling	O
(	O
calf	O
capacitance	O
response	O
)	O
were	O
evaluated	O
with	O
volumetric	B-P
technique	I-P
.	O

Cardiovascular	O
responses	O
and	O
plasma	B-P
norepinephrine	I-P
(	I-P
P-NE	I-P
)	I-P
were	I-P
measured	I-P
.	O

Resting	O
P-NE	B-P
was	I-P
elevated	I-P
in	O
VVS	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Despite	O
similar	O
hypovolemic	O
stimulus	O
,	O
VVS	O
displayed	O
blunted	O
increase	B-P
in	I-P
P-NE	I-P
(	O
P	O
<	O
0.01	O
)	O
and	O
reduced	O
maximal	O
percentage	O
increase	O
in	O
TPR	O
(	O
P	O
<	O
0.05	O
)	O
during	O
graded	O
LBNP	O
.	O

Arm	O
capacitance	O
response	O
was	O
slower	O
(	O
P	O
<	O
0.05	O
)	O
and	O
reduced	O
in	O
VVS	O
at	O
higher	O
levels	O
of	O
LBNP	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Capillary	O
fluid	O
absorption	O
from	O
extra-	O
to	O
intravascular	O
space	O
was	O
reduced	O
by	O
almost	O
40	O
%	O
in	O
VVS	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Accordingly	O
,	O
a	O
more	O
pronounced	O
reduction	O
in	O
CO	O
was	O
found	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
conclusion	O
,	O
women	O
with	O
VVS	O
presented	O
with	O
decreased	O
mobilization	O
of	O
peripheral	O
venous	O
blood	O
and	O
decreased	O
net	O
fluid	O
absorption	O
from	O
tissue	O
to	O
blood	O
during	O
hypovolemic	O
stress	O
,	O
partly	O
explained	O
by	O
an	O
attenuated	O
vasoconstrictor	O
response	O
.	O

This	O
may	O
seriously	O
impede	O
maintenance	O
of	O
cardiac	O
output	O
during	O
hypovolemic	O
stress	O
and	O
could	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
VVS	O
.	O

Deep	O
Sequencing	O
of	O
the	O
Hepatitis	O
B	O
Virus	O
Genome	O
:	O
Analysis	O
of	O
Multiple	O
Samples	O
by	O
Implementation	O
of	O
the	O
Illumina	O
Platform	O
.	O

The	O
quasispecies	O
variation	O
of	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
was	O
believed	O
to	O
be	O
a	O
viral	O
response	O
to	O
antiviral	O
treatment	O
and	O
host	O
immune	O
pressure	O
.	O

Sanger	O
sequencing	O
was	O
previously	O
the	O
classic	O
approach	O
for	O
quasispecies	O
analysis	O
,	O
but	O
this	O
method	O
was	O
also	O
time-consuming	O
and	O
laborious	O
.	O

Ultra-deep	O
sequencing	O
has	O
been	O
widely	O
used	O
in	O
viral	O
quasispecies	O
research	O
,	O
especially	O
for	O
low-frequency	O
mutation	B-P
detection	I-P
.	O

Here	O
we	O
present	O
a	O
multiple	O
samples	O
deep	O
sequencing	O
method	O
employing	O
the	O
Illumina	O
platform	O
to	O
detect	O
HBV	O
quasispecies	O
variation	O
in	O
patient-derived	O
samples	O
.	O

The	O
effect	O
of	O
total	O
hip	O
arthroplasty	O
on	O
sagittal	O
spinal	O
-	O
pelvic-leg	O
alignment	O
and	O
low	O
back	O
pain	O
in	O
patients	O
with	O
severe	O
hip	O
osteoarthritis	O
.	O

Sagittal	O
spinopelvic	O
malalignment	O
has	O
been	O
reported	O
in	O
spinal	O
disorders	O
such	O
as	O
low	O
back	O
pain	O
(	O
LBP	O
)	O
,	O
and	O
restoration	O
of	O
normal	O
alignment	O
is	O
targeted	O
when	O
treating	O
these	O
disorders	O
.	O

Abnormal	O
sagittal	O
spinal	O
-	O
pelvic-leg	O
alignment	O
has	O
been	O
reported	O
in	O
patients	O
with	O
severe	O
hip	O
osteoarthritis	O
(	O
OA	O
)	O
,	O
who	O
have	O
a	O
high	O
prevalence	O
of	O
associated	O
LBP	O
.	O

This	O
prospective	O
longitudinal	O
study	O
aimed	O
to	O
investigate	O
changes	O
in	O
sagittal	O
spinal	O
-	O
pelvic-leg	O
alignment	O
after	O
total	O
hip	O
arthroplasty	O
(	O
THA	O
)	O
in	O
patients	O
with	O
severe	O
hip	O
OA	O
,	O
and	O
whether	O
these	O
changes	O
contribute	O
to	O
LBP	O
relief	O
.	O

Patients	O
undergoing	O
primary	O
THA	O
due	O
to	O
severe	O
unilateral	O
hip	O
OA	O
were	O
recruited	O
.	O

Physical	O
examination	O
and	O
X-ray	O
films	O
were	O
taken	O
to	O
rule	O
out	O
any	O
spinal	O
disorder	O
.	O

Sagittal	O
alignment	O
of	O
pelvis	O
,	O
hip	O
,	O
and	O
spine	O
was	O
analyzed	O
on	O
lateral	B-P
radiographs	I-P
taken	O
before	O
(	O
baseline	O
)	O
and	O
1	O
year	O
after	O
(	O
follow-up	O
)	O
THA	O
.	O

Functional	O
instruments	O
were	O
completed	O
by	O
patients	O
including	O
:	O
visual	B-P
analog	I-P
scale	I-P
(	O
VAS	B-P
)	O
for	O
LBP	O
,	O
Roland-Morris	O
Disability	O
Questionnaire	O
(	O
RMDQ	O
)	O
,	O
and	O
Harris	O
Hip	O
Score	O
(	O
HHS	O
)	O
.	O

Comparisons	O
were	O
carried	O
out	O
at	O
baseline	O
and	O
follow-up	O
,	O
and	O
between	O
patients	O
with	O
and	O
without	O
LBP	O
.	O

The	O
recruited	O
69	O
patients	O
showed	O
significantly	O
reduced	O
hip	O
flexion	O
and	O
improved	O
global	O
spinal	O
balance	O
at	O
follow-up	O
compared	O
with	O
baseline	O
.	O

LBP	O
was	O
reported	O
by	O
39	O
patients	O
(	O
56.5	O
%	O
)	O
before	O
surgery	O
;	O
at	O
follow-up	O
,	O
17	O
reported	O
complete	O
resolution	O
,	O
while	O
22	O
reported	O
significant	O
relief	O
.	O

Significant	O
decreases	O
in	O
VAS	O
and	O
RMDQ	O
scores	O
in	O
lumbar	O
spine	O
and	O
increase	O
in	O
hip	O
HHS	O
were	O
observed	O
.	O

THA	O
in	O
patients	O
with	O
severe	O
hip	O
OA	O
could	O
help	O
correct	O
abnormal	O
sagittal	O
spinal	O
-	O
pelvic-leg	O
alignment	O
and	O
relieve	O
comorbid	O
LBP	O
.	O

Improvements	O
in	O
hip	O
flexion	O
and	O
global	O
spinal	O
balance	O
might	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
LBP	O
relief	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
characterization	O
of	O
anodised	O
zirconium	O
as	O
a	O
potential	O
material	O
for	O
biomedical	O
applications	O
.	O

In	O
vitro	O
studies	O
offer	O
the	O
insights	O
for	O
the	O
understanding	O
of	O
the	O
mechanisms	O
at	O
the	O
tissue-implant	O
interface	O
that	O
will	O
provide	O
an	O
effective	O
functioning	O
in	O
vivo	O
.	O

The	O
good	O
biocompatibility	O
of	O
zirconium	O
makes	O
a	O
good	O
candidate	O
for	O
biomedical	O
applications	O
and	O
the	O
attractive	O
in	O
vivo	O
performance	O
is	O
mainly	O
due	O
to	O
the	O
presence	O
of	O
a	O
protective	O
oxide	O
layer	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
by	O
in	O
vitro	O
and	O
in	O
vivo	O
approach	O
,	O
the	O
influence	O
of	O
surface	O
modification	O
achieved	O
by	O
anodisation	O
at	O
30	O
and	O
60V	O
on	O
zirconium	O
implants	O
on	O
the	O
first	O
steps	O
of	O
the	O
osseointegration	O
process	O
.	O

In	O
this	O
study	O
cell	O
attachment	O
,	O
proliferation	O
and	O
morphology	O
of	O
mouse	O
myoblast	O
C2C12-GFP	O
and	O
in	O
mouse	O
osteoprogenitor	O
MC3T3-E1	O
cells	O
was	O
evaluated	O
.	O

Also	O
,	O
together	O
with	O
the	O
immune	O
system	O
response	O
,	O
osteoclast	O
differentiation	O
and	O
morphology	O
with	O
RAW	O
264.7	O
murine	O
cell	O
line	O
were	O
analysed	O
.	O

It	O
was	O
found	O
that	O
anodisation	O
treatment	O
at	O
60V	O
enhanced	O
cell	O
spreading	O
and	O
the	O
osteoblastic	O
and	O
osteoclastic	O
cells	O
morphology	O
,	O
showing	O
a	O
strong	O
dependence	O
on	O
the	O
surface	O
characteristics	O
.	O

In	B-P
vivo	I-P
tests	I-P
were	O
performed	O
in	O
a	O
rat	O
femur	O
osteotomy	O
model	O
.	O

Dynamical	O
and	O
static	O
histological	B-P
and	O
histomorphometric	B-P
analyses	I-P
were	O
developed	O
15	O
and	O
30	O
days	O
after	O
surgery	O
.	O

Newly	O
formed	O
bone	O
around	O
Zr60V	O
implants	O
showed	O
a	O
continuous	O
newly	O
compact	O
and	O
homogeneous	O
bone	O
just	O
15	O
after	O
surgery	O
,	O
as	O
judged	O
by	O
the	O
enhanced	O
thickness	O
and	O
mineralization	O
rate	O
.	O

The	O
results	O
indicate	O
that	O
anodising	O
treatment	O
at	O
60V	O
could	O
be	O
an	O
effective	O
improvement	O
in	O
the	O
osseointegration	O
of	O
zirconium	O
by	O
stimulating	O
adhesion	O
,	O
proliferation	O
,	O
morphology	O
,	O
new	O
bone	O
thickness	O
and	O
bone	O
mineral	O
apposition	O
,	O
making	O
zirconium	O
an	O
emerging	O
candidate	O
material	O
for	O
biomedical	O
applications	O
.	O

Turkey	O
herpesvirus	O
with	O
an	O
insertion	O
in	O
the	O
UL3-4	O
region	O
displays	O
an	O
appropriate	O
balance	O
between	O
growth	O
activity	O
and	O
antibody	O
-eliciting	O
capacity	O
and	O
is	O
suitable	O
for	O
the	O
establishment	O
of	O
a	O
recombinant	O
vaccine	O
.	O

We	O
constructed	O
turkey	O
herpesvirus	O
(	O
HVT	O
)	O
vector	O
vaccines	O
in	O
which	O
the	O
VP2	O
gene	O
of	O
infectious	O
bursal	O
disease	O
virus	O
(	O
IBDV	O
)	O
was	O
inserted	O
into	O
the	O
HVT	O
genome	O
in	O
the	O
following	O
regions	O
:	O
UL3-4	O
,	O
UL22-23	O
,	O
UL45-46	O
,	O
and	O
US10-SORF3	O
.	O

We	O
then	O
evaluated	O
the	O
relationship	O
between	O
the	O
gene	O
insertion	O
site	O
and	O
the	O
capacity	O
of	O
the	O
virus	O
to	O
elicit	O
antibodies	O
.	O

rHVT/IBD	O
(	O
US10	O
)	O
showed	O
good	O
growth	O
activity	O
in	O
vitro	O
,	O
with	O
growth	O
comparable	O
to	O
that	O
of	O
the	O
parent	O
HVT	O
.	O

On	O
the	O
other	O
hand	O
,	O
rHVT/IBD	O
(	O
UL3-4	O
)	O
,	O
rHVT/IBD	O
(	O
UL22-23	O
)	O
,	O
and	O
rHVT/IBD	O
(	O
UL45-46	O
)	O
exhibited	O
decreased	O
growth	O
activity	O
in	O
chicken	O
embryo	O
fibroblast	O
(	O
CEF	O
)	O
cells	O
compared	O
to	O
the	O
parent	O
HVT	O
.	O

However	O
,	O
the	O
rHVT/IBD	O
(	O
US10	O
)	O
elicited	O
lower	O
levels	O
of	O
virus-neutralizing	O
(	O
VN	O
)	O
antibodies	O
compared	O
to	O
the	O
other	O
constructs	O
.	O

rHVT/IBD	O
(	O
UL3-4	O
)	O
and	O
rHVT/IBD	O
(	O
UL45-46	O
)	O
appeared	O
to	O
be	O
similar	O
in	O
their	O
ability	O
to	O
elicit	O
VN	O
antibodies	O
.	O

Based	O
on	O
the	O
results	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
assays	O
,	O
rHVT/IBD	O
(	O
UL3-4	O
)	O
was	O
selected	O
for	O
further	O
testing	O
.	O

In	O
a	O
challenge	O
assay	B-P
,	O
rHVT/IBD	O
(	O
UL3-4	O
)	O
protected	O
chickens	O
from	O
challenge	O
with	O
virulent	O
Marek	O
's	O
disease	O
virus	O
serotype	O
1	O
and	O
IBDV	O
.	O

In	O
conclusion	O
,	O
the	O
site	O
of	O
gene	O
insertion	O
may	O
have	O
a	O
strong	O
effect	O
on	O
the	O
growth	O
of	O
the	O
vector	O
virus	O
in	O
vitro	O
and	O
its	O
antibody	O
-eliciting	O
capacity	O
.	O

Insertions	O
in	O
the	O
UL3-4	O
region	O
permitted	O
a	O
balance	O
between	O
growth	O
activity	O
and	O
VN-antibody	O
-eliciting	O
capacity	O
,	O
and	O
this	O
region	O
might	O
therefore	O
be	O
an	O
appropriate	O
insertion	O
site	O
for	O
IBDV	O
VP2	O
.	O

Salmonella	O
enterica	O
serovar	O
Typhi	O
and	O
gallbladder	O
cancer	O
:	O
a	O
case-control	O
study	O
and	O
meta-analysis	O
.	O

In	O
Chile	O
,	O
where	O
gallbladder	O
cancer	O
(	O
GBC	O
)	O
rates	O
are	O
high	O
and	O
typhoid	O
fever	O
was	O
endemic	O
until	O
the	O
1990s	O
,	O
we	O
evaluated	O
the	O
association	O
between	O
Salmonella	O
enterica	O
serovar	O
Typhi	O
(	O
S.	O
Typhi	O
)	O
antibodies	O
and	O
GBC	O
.	O

We	O
tested	O
39	O
GBC	O
cases	O
,	O
40	O
gallstone	O
controls	O
,	O
and	O
39	O
population-based	O
controls	O
for	O
S.	O
Typhi	O
Vi	O
antibodies	O
and	O
performed	O
culture	O
and	O
quantitative	O
polymerase	O
chain	O
reaction	O
for	O
the	O
subset	O
with	O
bile	O
,	O
gallstone	O
,	O
tissue	O
,	O
and	O
stool	O
samples	O
available	O
.	O

We	O
calculated	O
gender	O
and	O
education-adjusted	O
odds	O
ratios	O
(	O
ORs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
for	O
the	O
association	O
with	O
GBC	O
.	O

We	O
also	O
conducted	O
a	O
meta-analysis	O
of	O
>	O
1000	O
GBC	O
cases	O
by	O
combining	O
our	O
results	O
with	O
previous	O
studies	O
.	O

GBC	O
cases	O
were	O
more	O
likely	O
to	O
have	O
high	O
Vi	O
antibody	O
titer	O
levels	O
than	O
combined	O
controls	O
(	O
OR	O
:	O
4.0	O
,	O
95	O
%	O
CI	O
:	O
0.9-18.3	O
)	O
,	O
although	O
S.	O
Typhi	O
was	O
not	O
recovered	O
from	O
bile	O
,	O
gallstone	O
,	O
tissue	O
,	O
or	O
stool	O
samples	O
.	O

In	O
our	O
meta-analysis	O
,	O
the	O
summary	O
relative	O
risk	O
was	O
4.6	O
(	O
95	O
%	O
CI	O
:	O
3.1-6.8	O
,	O
P	O
heterogeneity	O
=0.6	O
)	O
for	O
anti-Vi	O
and	O
5.0	O
(	O
95	O
%	O
CI	O
:	O
2.7-9.3	O
,	O
P	O
heterogeneity	O
=	O
0.2	O
)	O
for	O
bile	O
or	O
stool	B-P
culture	I-P
.	O

Our	O
results	O
are	O
consistent	O
with	O
the	O
meta-analysis	O
.	O

Despite	O
differences	O
in	O
study	O
methods	O
(	O
e.g.	O
,	O
S.	O
Typhi	O
detection	B-P
assay	I-P
)	O
,	O
most	O
studies	O
found	O
a	O
positive	O
association	O
between	O
S.	O
Typhi	O
and	O
GBC	O
.	O

However	O
,	O
the	O
mechanism	O
underlying	O
this	O
association	O
requires	O
further	O
investigation	O
.	O

Progressive	O
Occlusion	O
and	O
Recanalization	O
after	O
Endovascular	O
Treatment	O
for	O
287	O
Unruptured	O
Small	O
Aneurysms	O
(	O
<	O
5mm	O
)	O
:	O
A	O
Single-Center	O
6-Year	O
Experience	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
coiling	O
for	O
small	O
unruptured	O
intracranial	O
aneurysms	O
(	O
UIAs	O
)	O
﹤5mm	O
)	O
on	O
progressive	O
occlusio	O
n	O
and	O
recanalization	O
,	O
and	O
the	O
dubious	O
factors	O
related	O
to	O
progressive	O
occlusion	O
and	O
recanalization	O
among	O
UIAs	O
without	O
complete	O
occlusion	O
.	O

A	O
total	O
of	O
264	O
patients	O
with	O
287	O
small	O
UIAs	O
were	O
coiled	O
in	O
our	O
institute	O
between	O
June	O
2009	O
and	O
December	O
2014	O
.	O

All	O
UIAs	O
enrolled	O
were	O
divided	O
into	O
small	O
(	O
3-5mm	O
)	O
and	O
very	O
small	O
(	O
<	O
3mm	O
)	O
group	O
s	O
,	O
and	O
UIAs	O
without	O
initial	O
complete	O
occlusion	O
were	O
divided	O
into	O
progressive	O
,	O
stable	O
and	O
recanalization	O
groups	O
.	O

Baseline	O
characteristics	O
,	O
procedure	O
-related	O
complications	O
,	O
angiographic	B-P
follow-up	O
results	O
,	O
and	O
clinical	O
outcomes	O
were	O
statistically	O
analyzed	O
.	O

Among	O
287	O
aneurysms	O
,	O
211	O
aneurysms	O
(	O
73.5	O
%	O
)	O
were	O
completely	O
coiled	O
,	O
three	O
(	O
1.2	O
%	O
)	O
intraoperative	O
ruptures	O
and	O
12	O
(	O
4.2	O
%	O
)	O
perioperative	O
thromboembolic	O
events	O
occurred	O
.	O

Angiographic	B-P
follow-up	O
was	O
available	O
for	O
174	O
patients	O
(	O
65.9	O
%	O
)	O
,	O
the	O
incidence	O
of	O
recanalization	O
was	O
5.7	O
%	O
.	O

Among	O
56	O
aneurysms	O
without	O
complete	O
occlusion	O
,	O
43	O
(	O
76.8	O
%	O
)	O
had	O
progressive	O
occlusion	O
and	O
6	O
(	O
10.7	O
%	O
)	O
had	O
recanalization	O
.	O

Anatomic	O
results	O
of	O
initial	O
and	O
follow-up	O
between	O
small	O
and	O
very	O
small	O
groups	O
were	O
similar	O
in	O
both	O
groups	O
.	O

On	O
logistic	O
regression	O
analysis	O
,	O
smaller	O
size	O
(	O
<	O
3mm	O
)	O
without	O
complete	O
occlusion	O
related	O
to	O
recanalization	O
(	O
OR	O
,	O
8.0	O
,	O
95	O
%	O
CI	O
,	O
1.3-50.0	O
,	O
P=0.026	O
)	O
.	O

Our	O
study	O
suggested	O
that	O
coil	O
embolization	O
of	O
small	O
UIAs	O
can	O
achieve	O
a	O
high	O
rate	O
of	O
progressive	O
occlusion	O
and	O
low	O
rate	O
of	O
recanalization	O
during	O
follow-up	O
.	O

Anatomic	O
results	O
of	O
initial	O
and	O
follow-up	O
between	O
small	O
(	O
3-5mm	O
)	O
and	O
very	O
small	O
(	O
<	O
3mm	O
)	O
groups	O
were	O
similar	O
in	O
both	O
groups	O
.	O

What	O
's	O
more	O
,	O
smaller	O
size	O
(	O
<	O
3mm	O
)	O
without	O
complete	O
occlusion	O
may	O
relate	O
to	O
recanalization	O
.	O

Entrapment	O
of	O
the	O
posterior	O
femoral	O
cutaneous	O
nerve	O
and	O
its	O
inferior	O
cluneal	O
branches	O
:	O
anatomical	O
basis	O
of	O
surgery	O
for	O
inferior	O
cluneal	O
neuralgia	O
.	O

The	O
apparent	O
failure	O
of	O
pudendal	O
nerve	O
surgery	O
in	O
some	O
patients	O
has	O
led	O
us	O
to	O
suggest	O
the	O
possibility	O
of	O
entrapment	O
of	O
other	O
adjacent	O
nerve	O
structures	O
,	O
leading	O
to	O
the	O
concept	O
of	O
inferior	O
cluneal	O
neuralgia	O
.	O

Via	O
its	O
numerous	O
collateral	O
branches	O
,	O
the	O
posterior	O
femoral	O
cutaneous	O
nerve	O
innervates	O
a	O
very	O
extensive	O
territory	O
including	O
the	O
posterior	O
surface	O
of	O
the	O
thigh	O
,	O
the	O
infragluteal	O
fold	O
,	O
the	O
skin	O
over	O
the	O
ischial	O
tuberosity	O
,	O
but	O
also	O
the	O
lateral	O
anal	O
region	O
,	O
scrotum	O
or	O
labium	O
majus	O
via	O
its	O
perineal	O
branch	O
.	O

We	O
described	O
the	O
pathophysiological	O
features	O
of	O
cluneal	O
neuralgia	O
,	O
the	O
surgical	B-P
technique	I-P
and	O
our	O
preliminary	O
results	O
.	O

We	O
performed	O
a	O
transmuscular	O
approach	O
leading	O
to	O
the	O
fat	O
of	O
the	O
deep	O
gluteal	O
region	O
.	O

Exploration	O
was	O
continued	O
cranially	O
underneath	O
the	O
piriformis	O
,	O
looking	O
for	O
potential	O
entrapments	O
affecting	O
the	O
posterior	O
femoral	O
cutaneous	O
nerve	O
and	O
the	O
sciatic	O
nerve	O
.	O

Nerve	O
decompression	O
on	O
the	O
lateral	O
surface	O
of	O
the	O
ischial	O
tuberosity	O
was	O
then	O
performed	O
.	O

A	O
constant	O
anatomical	O
finding	O
must	O
be	O
highlighted	O
:	O
the	O
presence	O
of	O
a	O
lateral	O
fibrous	O
expansion	O
from	O
the	O
ischium	O
passing	O
behind	O
the	O
nerves	O
and	O
vessels	O
,	O
especially	O
the	O
posterior	O
femoral	O
cutaneous	O
nerve	O
and	O
its	O
perineal	O
branches	O
.	O

In	O
our	O
patients	O
,	O
release	O
of	O
this	O
expansion	O
allowed	O
decompression	O
of	O
the	O
nerve	O
trapped	O
by	O
this	O
expansion	O
.	O

Cluneal	O
neuralgia	O
constitutes	O
a	O
distinct	O
entity	O
of	O
perineal	O
pain	O
,	O
which	O
must	O
be	O
identified	O
and	O
distinguished	O
from	O
pudendal	O
neuralgia	O
.	O

Surgery	O
should	O
be	O
performed	O
via	O
a	O
transgluteal	O
approach	O
.	O

A	O
lateral	O
ischial	O
obstacle	O
must	O
be	O
investigated	O
,	O
in	O
the	O
form	O
of	O
a	O
constant	O
fibrous	O
expansion	O
,	O
which	O
,	O
like	O
a	O
retinaculum	O
,	O
can	O
cause	O
nerve	O
entrapment	O
.	O

MRI	B-P
-based	O
prostate	O
cancer	O
detection	O
with	O
high-level	O
representation	O
and	O
hierarchical	O
classification	O
.	O

Extracting	O
the	O
high-level	O
feature	O
representation	O
by	O
using	O
deep	O
neural	O
networks	O
for	O
detection	O
of	O
prostate	O
cancer	O
,	O
and	O
then	O
based	O
on	O
high-level	O
feature	O
representation	O
constructing	O
hierarchical	O
classification	O
to	O
refine	O
the	O
detection	O
results	O
.	O

High-level	O
feature	O
representation	O
is	O
first	O
learned	O
by	O
a	O
deep	O
learning	O
network	O
,	O
where	O
multiparametric	B-P
MR	I-P
images	O
are	O
used	O
as	O
the	O
input	O
data	O
.	O

Then	O
,	O
based	O
on	O
the	O
learned	O
high-level	O
features	O
,	O
a	O
hierarchical	O
classification	O
method	O
is	O
developed	O
,	O
where	O
multiple	O
random	O
forest	O
classifiers	O
are	O
iteratively	O
constructed	O
to	O
refine	O
the	O
detection	O
results	O
of	O
prostate	O
cancer	O
.	O

The	O
experiments	O
were	O
carried	O
on	O
21	O
real	O
patient	O
subjects	O
,	O
and	O
the	O
proposed	O
method	O
achieves	O
an	O
averaged	O
section-based	O
evaluation	O
(	O
SBE	O
)	O
of	O
89.90	O
%	O
,	O
an	O
averaged	O
sensitivity	O
of	O
91.51	O
%	O
,	O
and	O
an	O
averaged	O
specificity	O
of	O
88.47	O
%	O
.	O

The	O
high-level	O
features	O
learned	O
from	O
our	O
proposed	O
method	O
can	O
achieve	O
better	O
performance	O
than	O
the	O
conventional	O
handcrafted	O
features	O
(	O
e.g.	O
,	O
LBP	O
and	O
Haar-like	O
features	O
)	O
in	O
detecting	O
prostate	O
cancer	O
regions	O
,	O
also	O
the	O
context	O
features	O
obtained	O
from	O
the	O
proposed	O
hierarchical	O
classification	O
approach	O
are	O
effective	O
in	O
refining	O
cancer	O
detection	O
result	O
.	O

Gut	O
microbiome	O
alterations	O
in	O
patients	O
with	O
stage	O
4	O
hepatitis	O
C.	O
Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
causes	O
debilitating	O
liver	O
diseases	O
,	O
which	O
may	O
progress	O
to	O
cirrhosis	O
and	O
cancer	O
,	O
and	O
claims	O
500,000	O
annual	O
lives	O
worldwide	O
.	O

While	O
HCV	O
epidemiology	O
,	O
pathophysiology	O
,	O
and	O
therapy	O
are	O
being	O
deeply	O
studied	O
,	O
rare	O
attention	O
is	O
given	O
to	O
reciprocal	O
interactions	O
between	O
HCV	O
infection	O
,	O
HCV	O
-induced	O
chronic	O
liver	O
diseases	O
,	O
and	O
the	O
human	O
gut	O
microbiome	O
.	O

As	O
Egypt	O
has	O
the	O
world	O
's	O
highest	O
prevalence	O
of	O
HCV	O
infections	O
,	O
we	O
launched	O
this	O
study	O
to	O
monitor	O
differences	O
in	O
the	O
gut	O
microbial	O
community	O
composition	O
of	O
Egyptian	O
HCV	O
patients	O
that	O
may	O
affect	O
,	O
or	O
result	O
from	O
,	O
the	O
patients	O
'	O
liver	O
state	O
.	O

To	O
this	O
end	O
,	O
we	O
analyzed	O
stool	O
samples	O
from	O
six	O
stage	O
4	O
-	O
HCV	O
patients	O
and	O
eight	O
healthy	O
individuals	O
by	O
high-throughput	B-P
16S	B-P
rRNA	I-P
gene	I-P
sequencing	I-P
using	O
Illumina	O
MiSeq	O
.	O

Overall	O
,	O
the	O
alpha-diversity	O
of	O
the	O
healthy	O
persons	O
'	O
gut	O
microbiomes	O
was	O
higher	O
than	O
those	O
of	O
the	O
HCV	O
patients	O
.	O

Whereas	O
members	O
of	O
phylum	O
Bacteroidetes	O
were	O
more	O
abundant	O
in	O
HCV	O
patients	O
,	O
healthy	O
individuals	O
had	O
higher	O
abundance	O
of	O
Firmicutes	O
,	O
Proteobacteria	O
,	O
and	O
Actinobacteria	O
.	O

Genus	O
-level	O
analysis	O
showed	O
differential	O
abundance	O
of	O
Prevotella	O
and	O
Faecalibacterium	O
(	O
higher	O
in	O
HCV	O
patients	O
)	O
vs.	O
Ruminococcus	O
and	O
Clostridium	O
(	O
healthy	O
group	O
)	O
,	O
indicating	O
that	O
the	O
higher	O
abundance	O
of	O
Bacteroidetes	O
in	O
HCV	O
patients	O
is	O
most	O
likely	O
due	O
to	O
Prevotella	O
overabundance	O
.	O

The	O
probiotic	O
genus	O
,	O
Bifidobacterium	O
,	O
was	O
only	O
observed	O
in	O
the	O
microbiotas	O
of	O
healthy	O
individuals	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	O
provides	O
a	O
first	O
overview	O
of	O
major	O
phyla	O
and	O
genera	O
differentiating	O
stage	O
4	O
-	O
HCV	O
patients	O
from	O
healthy	O
individuals	O
and	O
suggests	O
possible	O
microbiome	O
remodeling	O
in	O
chronic	O
hepatitis	O
C	O
,	O
possibly	O
shaped	O
by	O
bacterial	O
translocation	O
as	O
well	O
as	O
the	O
liver	O
's	O
impaired	O
role	O
in	O
digestion	O
and	O
protein	O
synthesis	O
.	O

Future	O
studies	O
will	O
investigate	O
the	O
microbiome	O
composition	O
and	O
functional	O
capabilities	O
in	O
more	O
patients	O
while	O
tracing	O
some	O
potential	O
biomarker	O
taxa	O
(	O
e.g.	O
,	O
Prevotella	O
,	O
Faecalibacterium	O
vs.	O
Bifidobacterium	O
)	O
.	O

The	O
clinical	O
and	O
economic	O
burden	O
of	O
significant	O
bleeding	O
during	O
lung	O
resection	O
surgery	O
:	O
A	O
retrospective	O
matched	O
cohort	O
analysis	O
of	O
real	O
-	O
world	O
data	O
.	O

The	O
objective	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
quantify	O
the	O
clinical	O
and	O
economic	O
burden	O
of	O
significant	O
bleeding	O
in	O
lung	O
resection	O
surgery	O
in	O
the	O
US	O
.	O

This	O
study	O
utilized	O
2009-2012	O
data	O
from	O
the	O
Premier	O
Perspective	O
Database	O
(	O
TM	O
)	O
.	O

Adult	O
patients	O
with	O
primary	O
pulmonary	O
lobectomy	O
or	O
segmentectomy	O
procedures	O
were	O
categorized	O
by	O
the	O
surgical	O
approach	O
(	O
VATS	O
vs	O
open	O
)	O
and	O
primary	O
diagnosis	O
(	O
primary	B-P
or	O
metastatic	B-P
lung	I-P
cancer	I-P
vs	O
non-lung	B-P
cancer	I-P
)	O
.	O

Patients	O
requiring	O
≥3	O
units	O
of	O
blood	O
products	O
with	O
at	O
least	O
1	O
unit	O
of	O
PRBCs	O
:	O
``	O
significant	O
bleeding	O
``	O
cohort	O
;	O
those	O
requiring	O
<	O
3	O
units	O
:	O
``	O
non-significant	O
bleeding	O
``	O
cohort	O
;	O
and	O
those	O
not	O
requiring	O
blood	O
products	O
:	O
``	O
no	O
bleeding	O
``	O
cohort	O
.	O

A	O
matched	O
cohort	O
analysis	O
was	O
performed	O
between	O
the	O
``	O
significant	O
bleeding	O
``	O
and	O
the	O
``	O
no	O
bleeding	O
cohort	O
``	O
using	O
matching	O
variables	O
:	O
hospital	O
,	O
lung	B-P
cancer	I-P
diagnosis	I-P
,	O
year	O
of	O
surgery	O
,	O
APR-DRG	O
severity	O
score	O
,	O
procedure	O
type	O
and	O
approach	O
,	O
age	O
,	O
and	O
gender	O
.	O

The	O
``	O
All	O
-	O
patient	O
``	O
cohort	O
comprised	O
21,429	O
patients	O
:	O
213	O
``	O
significant	O
bleeding	O
``	O
;	O
2,780	O
``	O
non-significant	O
bleeding	O
``	O
;	O
and	O
18,436	O
``	O
no	O
bleeding	O
``	O
.	O

Overall	O
incidence	O
of	O
significant	O
chest	O
bleeding	O
was	O
0.99	O
%	O
.	O

Patients	O
from	O
``	O
significant	O
bleeding	O
``	O
cohort	O
and	O
``	O
non-significant	O
bleeding	O
``	O
cohort	O
had	O
2.5	O
days	O
and	O
2	O
days	O
(	O
p	O
<	O
0.0001	O
)	O
longer	O
length	O
of	O
stay	O
in	O
the	O
hospital	O
compared	O
to	O
those	O
in	O
the	O
``	O
no	O
bleeding	O
``	O
cohort	O
,	O
respectively	O
.	O

Overall	O
,	O
hospital	O
costs	O
for	O
``	O
significant	O
bleeding	O
``	O
cohort	O
were	O
higher	O
than	O
``	O
no	O
bleeding	O
``	O
cohort	O
for	O
those	O
who	O
were	O
covered	O
under	O
Medicare	O
(	O
$	O
59,871	O
vs	O
$	O
23,641	O
)	O
,	O
were	O
≥76	O
years	O
of	O
age	O
(	O
$	O
64,010	O
vs	O
$	O
24,243	O
)	O
,	O
had	O
greater	O
severity	O
of	O
illness	O
(	O
$	O
97,813	O
vs	O
$	O
51,871	O
)	O
and	O
underwent	O
open	O
segmentectomy	O
(	O
$	O
74,220	O
vs	O
$	O
21,903	O
)	O
.	O

Hospital	O
costs	O
for	O
``	O
significant	O
bleeding	O
``	O
cohort	O
and	O
``	O
non-significant	O
bleeding	O
``	O
were	O
significantly	O
higher	O
(	O
$	O
11,589	O
and	O
$	O
5,280	O
,	O
respectively	O
,	O
p	O
<	O
0.0001	O
)	O
than	O
no	O
bleeding	O
cohort	O
.	O

Although	O
significant	O
bleeding	O
during	O
lung	O
resection	O
surgery	O
is	O
rare	O
,	O
patients	O
with	O
such	O
complication	O
could	O
stay	O
longer	O
at	O
the	O
hospital	O
and	O
cost	O
an	O
average	O
of	O
$	O
13,103	O
more	O
than	O
those	O
without	O
.	O

Elimination	B-P
and	O
molecular	B-P
identification	I-P
of	O
endophytic	O
bacterial	O
contaminants	O
during	O
in	O
vitro	O
propagation	B-P
of	O
Bambusa	O
balcooa	O
.	O

Bambusa	O
balcooa	O
is	O
an	O
economically	O
important	O
,	O
multipurpose	O
bamboo	O
species	O
,	O
decidedly	O
used	O
in	O
construction	O
industry	O
.	O

Availability	O
of	O
natural	O
bamboo	O
is	O
depleting	O
very	O
rapidly	O
due	O
to	O
accelerated	O
deforestation	O
and	O
its	O
unrestrained	O
use	O
.	O

The	O
large	O
number	O
and	O
timely	O
supply	O
of	O
saplings	O
are	O
the	O
need	O
of	O
the	O
hour	O
for	O
the	O
restoration	O
of	O
bamboo	O
stands	O
.	O

Micropropagation	B-P
,	O
being	O
the	O
potent	O
alternative	O
for	O
season	O
independent	O
rapid	O
regeneration	O
,	O
is	O
restricted	O
in	O
bamboo	O
because	O
of	O
endophytic	O
contamination	O
.	O

An	O
in	O
vitro	O
attempt	O
has	O
been	O
taken	O
to	O
overcome	O
the	O
endophytic	O
contamination	O
by	O
using	O
broad	O
spectrum	O
antibiotics	O
as	O
surface	O
sterilant	O
as	O
well	O
as	O
a	O
media	O
component	O
.	O

Ampicillin	O
sodium	O
salt	O
(	O
5	O
mg/ml	O
for	O
30	O
min	O
)	O
as	O
a	O
surface	O
sterilant	O
was	O
found	O
as	O
the	O
best	O
treatment	O
for	O
high	O
bud	O
breaking	O
(	O
80	O
%	O
)	O
coupled	O
with	O
high	O
branching	O
and	O
low	O
contamination	O
(	O
20	O
%	O
)	O
but	O
it	O
was	O
found	O
ineffective	O
to	O
control	O
the	O
contamination	O
during	O
multiplication	O
stage	O
.	O

Then	O
,	O
two	O
endophytes	O
were	O
isolated	O
and	O
minimum	B-P
inhibitory	I-P
concentration	I-P
was	O
determined	O
through	O
antibiotic	O
susceptibility	B-P
test	I-P
for	O
successful	O
eradication	O
at	O
multiplication	O
stage	O
.	O

Finally	O
,	O
contamination	O
free	O
cultures	B-P
were	O
obtained	O
when	O
streptocycline	O
(	O
100	O
μg/ml	O
)	O
and	O
gentamicin	O
sulphate	O
(	O
75	O
μg/ml	O
)	O
were	O
added	O
into	O
the	O
medium	O
.	O

The	O
two	O
isolated	O
endophytes	O
,	O
BB1	O
and	O
BB2	O
,	O
were	O
identified	O
through	O
16S	O
rDNA	O
techniques	B-P
and	O
NCBI-BLAST	O
algorithm	O
with	O
99	O
%	O
sequence	O
similarity	O
with	O
those	O
of	O
Janibacter	O
sp	O
.	O

(	O
KX423734	O
)	O
and	O
Serratia	O
marcescens	O
strain	O
(	O
KX423735	O
)	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
for	O
B.	O
balcooa	O
where	O
antibiotics	O
were	O
used	O
as	O
surface	O
sterilant	O
as	O
well	O
as	O
medium	O
component	O
,	O
to	O
control	O
endophytic	O
bacterial	O
contaminants	O
,	O
followed	O
by	O
their	O
identification	O
.	O

Multifunctional	O
theranostic	O
Pluronic	O
mixed	O
micelles	O
improve	O
targeted	O
photoactivity	O
of	O
Verteporfin	O
in	O
cancer	O
cells	O
.	O

Nanotechnology	O
development	O
provides	O
new	O
strategies	O
to	O
treat	O
cancer	O
by	O
integration	O
of	O
different	O
treatment	O
modalities	O
in	O
a	O
single	O
multifunctional	O
nanoparticle	O
.	O

In	O
this	O
scenario	O
,	O
we	O
applied	O
the	O
multifunctional	O
Pluronic	O
P123	O
/	O
F127	O
mixed	O
micelles	O
for	O
Verteporfin	O
-mediated	O
photodynamic	O
therapy	O
in	O
PC3	O
and	O
MCF-7	O
cancer	O
cells	O
.	O

Micelles	O
functionalization	O
aimed	O
the	O
targeted	O
delivery	O
by	O
the	O
insertion	O
of	O
biotin	O
moiety	O
on	O
micelle	O
surface	O
and	O
fluorescence	B-P
image	I-P
-based	O
through	O
rhodamine-B	O
dye	O
conjugation	O
in	O
the	O
polymer	O
chains	O
.	O

Multifunctional	O
Pluronics	O
formed	O
spherical	O
nanoparticulated	O
micelles	O
that	O
efficiently	O
encapsulated	O
the	O
photosensitizer	O
Verteporfin	O
maintaining	O
its	O
favorable	O
photophysical	O
properties	O
.	O

Lyophilized	O
formulations	O
were	O
stable	O
at	O
least	O
for	O
6	O
months	O
and	O
readily	O
reconstituted	O
in	O
aqueous	O
media	O
.	O

The	O
multifunctional	O
micelles	O
were	O
stable	O
in	O
protein	O
-rich	O
media	O
due	O
to	O
the	O
dual	O
Pluronic	O
mixed	O
micelles	O
characteristic	O
:	O
high	O
drug	O
loading	O
capacity	O
provided	O
by	O
its	O
micellar	O
core	O
and	O
high	O
kinetic	O
stability	O
due	O
its	O
biocompatible	O
shell	O
.	O

Biotin	O
surface	O
functionalized	O
micelles	O
showed	O
higher	O
internalization	O
rates	O
due	O
biotin	O
-mediated	O
endocytosis	O
,	O
as	O
demonstrated	O
by	O
competitive	O
cellular	O
uptake	O
studies	O
.	O

Rhodamine	O
B	O
-tagged	O
micelles	O
allowed	O
monitoring	O
cellular	O
uptake	O
and	O
intracellular	O
distribution	O
of	O
the	O
formulations	O
.	O

Confocal	B-P
microscopy	I-P
studies	O
demonstrated	O
a	O
larger	O
intracellular	O
distribution	O
of	O
the	O
formulation	O
and	O
photosensitizer	O
,	O
which	O
could	O
drive	O
Verteporfin	O
to	O
act	O
on	O
multiple	O
cell	O
sites	O
.	O

Formulations	O
were	O
not	O
toxic	O
in	O
the	O
dark	O
condition	O
,	O
but	O
showed	O
high	O
Verteporfin	O
-induced	O
phototoxicity	O
against	O
both	O
cancer	O
cell	O
lines	O
at	O
low	O
drug	O
and	O
light	O
doses	O
.	O

These	O
results	O
point	O
Verteporfin	O
-loaded	O
multifunctional	O
micelles	O
as	O
a	O
promising	O
tool	O
to	O
further	O
developments	O
in	O
photodynamic	O
therapy	O
of	O
cancer	O
.	O

Sensitivity	O
and	O
Specificity	O
of	O
Metal	O
Ion	O
Levels	O
in	O
Predicting	O
``	O
Pseudotumors	O
``	O
due	O
to	O
Taper	O
Corrosion	O
in	O
Patients	O
With	O
Dual	O
Taper	O
Modular	O
Total	O
Hip	O
Arthroplasty	O
.	O

Currently	O
,	O
no	O
serum	O
metal	O
ion	O
threshold	O
exists	O
to	O
identify	O
adverse	O
tissue	O
reactions	O
in	O
total	O
hip	O
arthroplasty	O
(	O
THA	O
)	O
patients	O
with	O
taper	O
corrosion	O
.	O

Our	O
study	O
aims	O
to	O
investigate	O
the	O
sensitivity	O
and	O
specificity	O
of	O
serum	O
metal	O
ions	O
in	O
detecting	O
taper	O
corrosion	O
related	O
pseudotumors	O
in	O
patients	O
with	O
dual	O
taper	O
modular	O
THA	O
.	O

A	O
total	O
of	O
148	O
patients	O
with	O
dual	O
taper	O
modular	O
THA	O
were	O
investigated	O
:	O
(	O
1	O
)	O
90	O
patients	O
with	O
pseudotumors	O
detected	O
with	O
metal	B-P
artifact	I-P
reduction	I-P
sequence-magnetic	I-P
resonance	I-P
imaging	I-P
(	O
MARS-MRI	B-P
)	O
and	O
(	O
2	O
)	O
58	O
patients	O
without	O
pseudotumors	O
on	O
MARS-MRI	B-P
.	O

Receiver	O
operating	O
characteristic	O
curves	O
were	O
constructed	O
to	O
determine	O
the	O
sensitivity	O
and	O
specificity	O
using	O
different	O
metal	O
ion	O
thresholds	O
.	O

The	O
severity	O
of	O
intraoperative	O
tissue	O
damage	O
was	O
correlated	O
with	O
preoperative	O
metal	O
ion	O
levels	O
.	O

Pseudotumor	O
was	O
associated	O
with	O
higher	O
cobalt	O
(	O
5.0	O
μg/L	O
vs	O
3.7	O
μg/L	O
,	O
P	O
<	O
.01	O
)	O
and	O
Co	O
/	O
Cr	O
ratio	O
(	O
6.0	O
vs	O
3.7	O
,	O
P	O
<	O
.01	O
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
for	O
cobalt	O
level	O
of	O
2.8	O
μg/L	O
and	O
Co	O
/	O
Cr	O
ratio	O
of	O
3.8	O
in	O
detecting	O
taper	O
corrosion	O
-related	O
pseudotumors	O
on	O
MARS-MRI	B-P
was	O
88	O
%	O
and	O
32	O
%	O
and	O
70	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Higher	O
intraoperative	O
tissue	O
damage	O
grades	O
demonstrated	O
significantly	O
higher	O
Co	O
/	O
Cr	O
ratios	O
(	O
8.6	O
vs	O
3.4	O
,	O
P	O
=	O
.03	O
)	O
.	O

Although	O
metal	O
ion	O
levels	O
alone	O
should	O
not	O
be	O
relied	O
on	O
as	O
the	O
sole	O
parameter	O
to	O
determine	O
revision	O
surgery	O
,	O
cobalt	O
level	O
>	O
2.8	O
μg/L	O
and	O
the	O
Co	O
/	O
Cr	O
ratio	O
>	O
3.8	O
are	O
useful	O
clinical	O
diagnostic	O
adjuncts	O
in	O
the	O
systematic	O
clinical	O
evaluation	O
for	O
taper	O
corrosion	O
-related	O
adverse	O
tissue	O
reactions	O
in	O
patients	O
with	O
dual	O
modular	O
taper	O
THA	O
.	O

Optimization	O
of	O
techniques	O
for	O
multiple	O
platform	B-P
testing	I-P
in	O
small	O
,	O
precious	O
samples	O
such	O
as	O
human	O
chorionic	B-P
villus	I-P
sampling	I-P
.	O

Multiple	O
testing	B-P
to	O
understand	O
global	O
changes	O
in	O
gene	O
expression	O
based	O
on	O
genetic	O
and	O
epigenetic	O
modifications	O
is	O
evolving	O
.	O

Chorionic	O
villi	O
,	O
obtained	O
for	O
prenatal	O
testing	O
,	O
is	O
limited	O
,	O
but	O
can	O
be	O
used	O
to	O
understand	O
ongoing	O
human	O
pregnancies	O
.	O

However	O
,	O
optimal	O
storage	O
,	O
processing	O
and	O
utilization	O
of	O
CVS	B-P
for	O
multiple	O
platform	B-P
testing	I-P
have	O
not	O
been	O
established	O
.	O

Leftover	O
CVS	B-P
samples	O
were	O
flash-frozen	O
or	O
preserved	O
in	O
RNAlater	O
.	O

Modifications	O
to	O
standard	O
isolation	O
kits	O
were	O
performed	O
to	O
isolate	O
quality	O
DNA	O
and	O
RNA	O
from	O
samples	O
as	O
small	O
as	O
2-5	O
mg.	O
RNAlater	O
samples	O
had	O
significantly	O
higher	O
RNA	O
yields	O
and	O
quality	O
and	O
were	O
successfully	O
used	O
in	O
microarray	O
and	O
RNA-sequencing	O
(	O
RNA-seq	O
)	O
.	O

RNA-seq	O
libraries	O
generated	O
using	O
200	O
versus	O
800-ng	O
RNA	O
showed	O
similar	O
biological	O
coefficients	O
of	O
variation	O
.	O

RNAlater	O
samples	O
had	O
lower	O
DNA	O
yields	O
and	O
quality	O
,	O
which	O
improved	O
by	O
heating	O
the	O
elution	O
buffer	O
to	O
70	O
°C	O
.	O

Purification	B-P
of	I-P
DNA	I-P
was	O
not	O
necessary	O
for	O
bisulfite-conversion	O
and	O
genome-wide	O
methylation	O
profiling	O
.	O

CVS	B-P
cells	O
were	O
propagated	O
and	O
continue	O
to	O
express	O
genes	O
found	O
in	O
freshly	O
isolated	O
chorionic	O
villi	O
.	O

CVS	B-P
samples	O
preserved	O
in	O
RNAlater	O
are	O
superior	O
.	O

Our	O
optimized	O
techniques	O
provide	O
specimens	O
for	O
genetic	O
,	O
epigenetic	O
and	O
gene	O
expression	O
studies	O
from	O
a	O
single	O
small	O
sample	O
which	O
can	O
be	O
used	O
to	O
develop	O
diagnostics	B-P
and	O
treatments	O
using	O
a	O
systems	O
biology	O
approach	O
in	O
the	O
prenatal	O
period	O
.	O

©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Antimicrobial	O
and	O
antioxidant	O
activities	O
of	O
a	O
new	O
metabolite	O
from	O
Quercus	O
incana	O
.	O

Phytochemical	O
investigations	O
of	O
Quercus	O
incana	O
led	O
to	O
the	O
isolation	O
of	O
a	O
new	O
catechin	O
derivative	O
quercuschin	O
(	O
1	O
)	O
,	O
along	O
with	O
six	O
known	O
compounds	O
:	O
quercetin	O
(	O
2	O
)	O
,	O
methyl	O
gallate	O
(	O
3	O
)	O
,	O
gallic	O
acid	O
(	O
4	O
)	O
,	O
betulinic	O
acid	O
(	O
5	O
)	O
,	O
(	O
Z	O
)	O
-9-octadecenoic	O
acid	O
methyl	O
ester	O
(	O
6	O
)	O
and	O
β-sitosterol	O
glucoside	O
(	O
7	O
)	O
from	O
the	O
ethyl	O
acetate	O
fraction	O
of	O
methanolic	O
extract	O
of	O
the	O
bark	O
.	O

Compound	O
1	O
was	O
screened	O
for	O
its	O
antibacterial	O
,	O
antifungal	O
and	O
antioxidant	O
potential	O
.	O

Antibacterial	O
and	O
antifungal	O
activities	O
of	O
the	O
compound	O
were	O
tested	O
against	O
different	O
bacterial	O
and	O
fungal	O
strains	O
,	O
employing	O
the	O
agar	B-P
well	I-P
diffusion	I-P
methods	I-P
.	O

The	O
antibacterial	O
activity	O
was	O
the	O
highest	O
against	O
Streptococcus	O
pyogenes	O
with	O
80.0	O
%	O
inhibition	O
,	O
while	O
the	O
antifungal	O
activity	O
of	O
the	O
compound	O
was	O
the	O
highest	O
against	O
Candida	O
glabrata	O
with	O
80.5	O
%	O
inhibition	O
.	O

The	O
results	O
of	O
the	O
antioxidant	O
activity	O
indicated	O
that	O
the	O
compound	O
exhibited	O
antioxidant	O
activity	O
comparable	O
to	O
that	O
of	O
standard	O
,	O
butylated	O
hydroxyanisole	O
(	O
51.2	O
μg/10	O
μl	O
versus	O
45.9	O
μg/10	O
μl	O
)	O
.	O

The	O
Effect	O
of	O
Image	O
Review	O
before	O
Patient	O
Discharge	O
on	O
Study	O
Completeness	O
and	O
Sonographer	O
Job	O
Satisfaction	O
in	O
a	O
Pediatric	B-P
Echocardiographic	I-P
Laboratory	O
.	O

Incomplete	O
echocardiographic	B-P
assessment	O
accounts	O
for	O
approximately	O
10	O
%	O
of	O
preventable	O
diagnostic	O
errors	O
and	O
may	O
place	O
children	O
at	O
risk	O
for	O
adverse	O
outcomes	O
or	O
increased	O
testing	B-P
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
physician	O
review	O
of	O
images	O
improves	O
study	O
completeness	O
.	O

A	O
prospective	O
quality	O
improvement	O
(	O
QI	O
)	O
study	O
initiated	O
physician	O
review	O
of	O
first-time	O
echocardiographic	B-P
studies	O
for	O
completeness	O
before	O
patient	O
discharge	O
.	O

Studies	O
were	O
incomplete	O
if	O
not	O
all	O
anatomic	O
structures	O
were	O
diagnostically	O
demonstrated	O
.	O

QI	O
examinations	O
were	O
compared	O
with	O
controls	O
obtained	O
before	O
study	O
initiation	O
.	O

Demographic	O
and	O
clinical	O
information	O
and	O
duration	O
of	O
scan	B-P
were	O
collected	O
during	O
the	O
control	O
and	O
QI	O
periods	O
.	O

An	O
anonymous	O
survey	O
was	O
administered	O
to	O
the	O
sonographers	O
to	O
assess	O
perceptions	O
of	O
the	O
intervention	O
.	O

There	O
were	O
no	O
differences	O
between	O
the	O
QI	O
(	O
n	O
=	O
63	O
)	O
and	O
control	O
(	O
n	O
=	O
63	O
)	O
groups	O
in	O
age	O
,	O
height	O
,	O
weight	O
,	O
and	O
technical	O
barriers	O
.	O

After	O
study	O
completion	O
,	O
35	O
%	O
of	O
control	O
scans	B-P
versus	O
5	O
%	O
of	O
QI	O
scans	B-P
were	O
incomplete	O
(	O
P	O
<	O
.001	O
)	O
.	O

In	O
the	O
QI	O
group	O
,	O
the	O
sonographer	O
,	O
physician	O
,	O
or	O
both	O
returned	O
to	O
scan	B-P
in	O
12	O
(	O
19	O
%	O
)	O
,	O
nine	O
(	O
14	O
%	O
)	O
,	O
and	O
two	O
(	O
3	O
%	O
)	O
studies	O
,	O
respectively	O
.	O

QI	O
studies	O
were	O
longer	O
than	O
control	O
studies	O
(	O
44	O
vs	O
36	O
min	O
,	O
P	O
=	O
.003	O
)	O
before	O
review	O
.	O

Physician	O
review	O
added	O
a	O
median	O
of	O
6	O
min	O
(	O
range	O
,	O
1-28	O
min	O
)	O
.	O

The	O
majority	O
of	O
sonographers	O
believed	O
that	O
immediate	O
review	O
improved	O
communication	O
,	O
and	O
50	O
%	O
believed	O
that	O
it	O
improved	O
their	O
job	O
satisfaction	O
.	O

Review	O
of	O
initial	O
outpatient	O
echocardiographic	B-P
examinations	O
before	O
patient	O
discharge	O
significantly	O
improves	O
study	O
completeness	O
.	O

Review	O
adds	O
a	O
nominal	O
amount	O
of	O
time	O
to	O
total	O
study	O
duration	O
,	O
improves	O
sonographer	O
-	O
physician	O
communication	O
,	O
and	O
may	O
prevent	O
unnecessary	O
testing	B-P
,	O
potentially	O
reducing	O
the	O
cost	O
of	O
care	O
.	O

Is	O
there	O
a	O
role	O
for	O
surgical	O
resection	O
in	O
patients	O
with	O
pancreatic	O
cancer	O
with	O
liver	O
metastases	O
responding	O
to	O
chemotherapy	O
?	O
.	O

New	O
chemotherapeutic	O
regimens	O
have	O
improved	O
survival	O
for	O
stage	O
IV	O
pancreatic	O
ductal	O
adenocarcinoma	O
and	O
occasionally	O
major	O
response	O
of	O
liver	O
metastases	O
can	O
be	O
observed	O
.	O

Aim	O
of	O
this	O
work	O
is	O
to	O
analyze	O
the	O
outcomes	O
of	O
patients	O
undergoing	O
primary	O
chemotherapy	O
for	O
liver	O
metastases	O
from	O
pancreatic	O
cancer	O
and	O
to	O
evaluate	O
the	O
results	O
of	O
surgical	O
resection	O
.	O

Retrospective	O
analysis	O
.	O

patients	O
with	O
extra-hepatic	O
metastases	O
,	O
patients	O
with	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
≥3	O
,	O
patients	O
undergoing	O
supportive	O
care	O
alone	O
.	O

127	O
patients	O
were	O
identified	O
.	O

Liver	O
metastases	O
were	O
unilobar	O
in	O
28.5	O
%	O
of	O
patients	O
.	O

Chemotherapy	O
regimens	O
included	O
gemcitabine	O
alone	O
or	O
in	O
association	O
with	O
other	O
agents	O
(	O
44	O
%	O
)	O
,	O
oxaliplatin	O
,	O
irinotecan	O
,	O
fluorouracil	O
and	O
leucovorin	O
(	O
FOLFIRINOX	O
8	O
%	O
)	O
,	O
and	O
cisplatin	O
,	O
gemcitabine	O
plus	O
capecitabine	O
and	O
epirubicin	O
(	O
PEXG	O
)	O
or	O
capecitabine	O
and	O
docetaxel	O
(	O
PDXG	O
)	O
or	O
epirubicin	O
and	O
fluorouracil	O
(	O
PEFG	O
)	O
(	O
48	O
%	O
)	O
.	O

56	O
patients	O
(	O
44	O
%	O
)	O
had	O
a	O
complete	O
(	O
7	O
%	O
)	O
or	O
partial	O
response	O
(	O
37	O
%	O
)	O
.	O

surgical	O
resection	O
was	O
carried	O
out	O
in	O
11	O
patients	O
(	O
8.5	O
%	O
)	O
.	O

Median	O
overall	O
survival	O
was	O
11	O
months	O
for	O
the	O
entire	O
cohort	O
and	O
15	O
months	O
for	O
those	O
with	O
partial	O
/	O
complete	O
response	O
.	O

In	O
this	O
sub-group	O
median	O
survival	O
was	O
significantly	O
longer	O
(	O
46	O
versus	O
11	O
months	O
)	O
for	O
patients	O
undergoing	O
resection	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

Independent	O
predictors	O
of	O
overall	O
survival	O
were	O
chemotherapy	O
with	O
multiple	O
agents	O
(	O
HR	O
:	O
0.512	O
)	O
,	O
surgical	O
resection	O
(	O
HR	O
:	O
0.360	O
)	O
,	O
>	O
5	O
liver	O
metastases	O
at	O
diagnosis	O
(	O
HR	O
:	O
3.515	O
)	O
,	O
and	O
CA	B-P
19.9	I-P
reduction	O
<	O
50	O
%	O
of	O
baseline	O
value	O
(	O
HR	O
:	O
2.708	O
)	O
.	O

Surgical	O
resection	O
of	O
primary	O
pancreatic	O
tumor	O
with	O
or	O
without	O
residual	O
liver	O
disease	O
can	O
be	O
considered	O
in	O
selected	O
cases	O
after	O
primary	O
chemotherapy	O
and	O
it	O
is	O
associated	O
with	O
improved	O
survival	O
.	O

Cdc45	O
-	O
induced	O
loading	O
of	O
human	O
RPA	O
onto	O
single-stranded	O
DNA	O
.	O

Cell	O
division	O
cycle	O
protein	O
45	O
(	O
Cdc45	O
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
eukaryotic	O
replicative	O
DNA	O
helicase	O
.	O

We	O
found	O
that	O
human	O
Cdc45	O
forms	O
a	O
complex	O
with	O
the	O
single-stranded	O
DNA	O
(	O
ssDNA	O
)	O
binding	O
protein	O
RPA	O
.	O

Moreover	O
,	O
it	O
actively	O
loads	O
RPA	O
onto	O
nascent	O
ssDNA	O
.	O

Pull-down	B-P
assays	I-P
and	O
surface	O
plasmon	O
resonance	O
studies	O
revealed	O
that	O
Cdc45	O
-	O
bound	O
RPA	O
complexed	O
with	O
ssDNA	O
in	O
the	O
8-10	O
nucleotide	O
binding	O
mode	O
,	O
but	O
dissociated	O
when	O
RPA	O
covered	O
a	O
30-mer	O
.	O

Real-time	B-P
analysis	I-P
of	O
RPA	O
-	O
ssDNA	O
binding	O
demonstrated	O
that	O
Cdc45	O
catalytically	O
loaded	O
RPA	O
onto	O
ssDNA	O
.	O

This	O
placement	O
reaction	O
required	O
physical	O
contacts	O
of	O
Cdc45	O
with	O
the	O
RPA70A	O
subdomain	O
.	O

Our	O
results	O
imply	O
that	O
Cdc45	O
controlled	O
stabilization	O
of	O
the	O
8-	O
nt	O
RPA	O
binding	O
mode	O
,	O
the	O
subsequent	O
RPA	O
transition	O
into	O
30-mer	O
mode	O
and	O
facilitated	O
an	O
ordered	O
binding	O
to	O
ssDNA	O
.	O

We	O
propose	O
that	O
a	O
Cdc45	O
-mediated	O
loading	O
guarantees	O
a	O
seamless	O
deposition	O
of	O
RPA	O
on	O
newly	O
emerging	O
ssDNA	O
at	O
the	O
nascent	O
replication	O
fork	O
.	O

Hyperandrogenemia	O
in	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
:	O
prevalence	O
,	O
characteristics	O
and	O
association	O
with	O
body	O
mass	O
index	O
.	O

Hyperandrogenemia	O
is	O
one	O
of	O
the	O
major	O
diagnostic	O
features	O
for	O
the	O
diagnosis	O
of	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
prevalence	O
and	O
the	O
characteristics	O
of	O
hyperandrogenemia	O
in	O
women	O
with	O
PCOS	O
and	O
to	O
investigate	O
the	O
association	O
of	O
clinical	O
and	O
biochemical	O
characteristics	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
according	O
to	O
the	O
presence	O
of	O
hyperandrogenemia	O
.	O

We	O
studied	O
266	O
women	O
diagnosed	O
with	O
PCOS	O
.	O

Hyperandrogenemia	O
was	O
defined	O
by	O
testosterone	O
(	O
T	O
)	O
and/or	O
free	O
testosterone	O
(	O
FT	O
)	O
and/or	O
∆4	O
androstenedione	O
(	O
Δ4-A	O
)	O
higher	O
than	O
75	O
%	O
of	O
the	O
upper	O
limits	O
of	O
each	O
hormone	O
.	O

Patients	O
were	O
stratified	O
in	O
two	O
groups	O
according	O
to	O
a	O
BMI	O
threshold	O
of	O
25	O
kg/m2	O
.	O

Hyperandrogenemia	O
was	O
present	O
in	O
78.2	O
%	O
of	O
the	O
patients	O
.	O

Elevated	O
levels	O
of	O
T	O
were	O
found	O
in	O
58.4	O
%	O
,	O
while	O
elevated	O
levels	O
of	O
FT	O
and	O
Δ4-A	O
were	O
found	O
in	O
42.5	O
%	O
and	O
34.1	O
%	O
of	O
patients	O
.	O

In	O
normal	O
weight	O
women	O
(	O
BMI	O
≤25	O
kg/m2	O
)	O
with	O
hyperandrogenemia	O
lower	O
values	O
of	O
hip	O
circumference	O
and	O
HOMA-IR	B-P
and	O
increased	O
levels	O
of	O
T	O
,	O
FT	O
,	O
Δ4-A	O
,	O
17-hydroxyprogesterone	O
(	O
17-OHP	O
)	O
,	O
dehydroepiandrosterone	O
sulfate	O
(	O
DHEAS	O
)	O
,	O
white	O
blood	O
cells	O
(	O
WBC	O
)	O
and	O
neutrophils	O
were	O
observed	O
compared	O
to	O
women	O
without	O
hyperandrogenemia	O
.	O

Also	O
,	O
in	O
overweight	O
women	O
higher	O
levels	O
of	O
T	O
,	O
FT	O
,	O
Δ4-A	O
,	O
17-OHP	O
,	O
DHEAS	O
and	O
cortisol	O
were	O
measured	O
,	O
while	O
lower	O
thyroid-stimulating	B-P
hormone	I-P
(	I-P
TSH	I-P
)	I-P
levels	I-P
were	O
comparable	O
to	O
women	O
without	O
hyperandrogenemia	O
.	O

This	O
study	O
showed	O
high	O
prevalence	O
of	O
hyperandrogenemia	O
in	O
PCOS	O
women	O
.	O

Women	O
with	O
BMI	O
≤25	O
kg/m2	O
have	O
significant	O
differences	O
in	O
androgens	O
,	O
WBC	O
,	O
neutrophils	O
and	O
HOMA-IR	B-P
and	O
women	O
with	O
BMI	O
≥25	O
kg/m2	O
in	O
androgens	O
,	O
TSH	O
and	O
cortisol	O
according	O
to	O
the	O
presence	O
or	O
not	O
of	O
hyperandrogenemia	O
.	O

Differential	O
Immunohistochemical	B-P
Profiles	B-P
for	O
Distinguishing	O
Prostate	O
Carcinoma	O
and	O
Urothelial	O
Carcinoma	O
.	O

The	O
pathologic	O
distinction	O
between	O
high-grade	O
prostate	O
adenocarcinoma	O
(	O
PAC	O
)	O
involving	O
the	O
urinary	O
bladder	O
and	O
high-grade	O
urothelial	O
carcinoma	O
(	O
UC	O
)	O
infiltrating	O
the	O
prostate	O
can	O
be	O
difficult	O
.	O

However	O
,	O
making	O
this	O
distinction	O
is	O
clinically	O
important	O
because	O
of	O
the	O
different	O
treatment	O
modalities	O
for	O
these	O
two	O
entities	O
.	O

A	O
total	O
of	O
249	O
patient	O
cases	O
(	O
PAC	O
,	O
111	O
cases	O
;	O
UC	O
,	O
138	O
cases	O
)	O
collected	O
between	O
June	O
1995	O
and	O
July	O
2009	O
at	O
Seoul	O
St.	O
Mary	O
's	O
Hospital	O
were	O
studied	O
.	O

An	O
immunohistochemical	B-P
evaluation	B-P
of	O
prostatic	O
markers	O
(	O
prostate-specific	O
antigen	O
[	O
PSA	O
]	O
,	O
prostate-specific	O
membrane	O
antigen	O
[	O
PSMA	O
]	O
,	O
prostate	O
acid	O
phosphatase	O
[	O
PAP	O
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-methylacyl	O
coenzyme	O
A	O
racemase	O
[	O
AMACR	O
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34βE12	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	O
protein	O
3	O
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

The	O
sensitivities	O
of	O
prostatic	O
markers	O
in	O
PAC	O
were	O
100	O
%	O
for	O
PSA	O
,	O
83.8	O
%	O
for	O
PSMA	O
,	O
91.9	O
%	O
for	O
PAP	O
,	O
93.7	O
%	O
for	O
P501s	O
,	O
88.3	O
%	O
for	O
NKX	O
3.1	O
,	O
and	O
66.7	O
%	O
for	O
AMACR	O
.	O

However	O
,	O
the	O
urothelial	O
markers	O
CK34βE12	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA3	O
were	O
also	O
positive	O
in	O
1.8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3.6	O
%	O
,	O
and	O
0	O
%	O
of	O
PAC	O
,	O
respectively	O
.	O

The	O
sensitivities	O
of	O
urothelial	O
markers	O
in	O
UC	O
were	O
75.4	O
%	O
for	O
CK34βE12	O
,	O
73.9	O
%	O
for	O
p63	O
,	O
45.7	O
%	O
for	O
thrombomodulin	O
,	O
22.5	O
%	O
for	O
S100P	O
,	O
and	O
84.8	O
%	O
for	O
GATA3	O
.	O

Conversely	O
,	O
the	O
prostatic	O
markers	O
PSA	O
,	O
PSMA	O
,	O
PAP	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
AMACR	O
were	O
also	O
positive	O
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
UC	O
s	O
,	O
respectively	O
.	O

Prostatic	O
and	O
urothelial	O
markers	O
,	O
including	O
PSA	O
,	O
NKX3.1	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
and	O
GATA3	O
are	O
very	O
useful	O
for	O
differentiating	O
PAC	O
from	O
UC	O
.	O

The	O
optimal	O
combination	O
of	O
prostatic	O
and	O
urothelial	O
markers	O
could	O
improve	O
the	O
ability	O
to	O
differentiate	O
PAC	O
from	O
UC	O
pathologically	O
.	O

Relationship	O
between	O
interpersonal	O
trauma	O
exposure	O
and	O
addictive	O
behaviors	O
:	O
a	O
systematic	O
review	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
systematically	O
summarize	O
knowledge	O
on	O
the	O
association	O
between	O
exposure	O
to	O
interpersonal	O
trauma	O
and	O
addictive	O
behaviors	O
.	O

Extant	O
reviews	O
on	O
this	O
association	O
focused	O
on	O
a	O
restricted	O
range	O
of	O
substance-related	O
addictions	O
,	O
and/or	O
used	O
a	O
narrative	O
instead	O
of	O
a	O
systematic	O
approach	O
.	O

Systematic	O
searches	O
of	O
8	O
databases	O
yielded	O
29,841	O
studies	O
,	O
of	O
which	O
3054	O
studies	O
were	O
included	O
and	O
subsequently	O
classified	O
in	O
relation	O
to	O
study	O
design	O
(	O
scoping	O
review	O
)	O
.	O

A	O
subset	O
of	O
observational	O
studies	O
(	O
N	O
=	O
181	O
)	O
prospectively	O
investigating	O
the	O
relationship	O
between	O
exposure	O
to	O
interpersonal	O
traumata	O
and	O
subsequent	O
behavioral	O
or	O
substance-related	O
addiction	O
problems	O
were	O
characterized	O
.	O

Heterogeneity	O
in	O
study	O
methodologies	O
and	O
types	O
of	O
addictive	O
behaviors	O
and	O
traumatic	O
experiences	O
assessed	O
precluded	O
meta-analysis	O
.	O

Instead	O
,	O
the	O
proportions	O
of	O
associations	O
tested	O
in	O
this	O
literature	O
that	O
revealed	O
positive	O
,	O
negative	O
,	O
or	O
null	O
relationships	O
between	O
trauma	O
exposure	O
and	O
subsequent	O
addictive	O
behaviors	O
were	O
recorded	O
,	O
along	O
with	O
other	O
methodological	O
features	O
.	O

Of	O
3054	O
included	O
studies	O
,	O
70.7	O
%	O
(	O
n	O
=	O
2160	O
)	O
used	O
a	O
cross-sectional	O
design	O
.	O

In	O
the	O
181	O
prospective	O
observational	O
studies	O
(	O
407,041	O
participants	O
,	O
98.8	O
%	O
recruited	O
from	O
developed	O
countries	O
)	O
,	O
35.1	O
%	O
of	O
the	O
tested	O
associations	O
between	O
trauma	O
exposure	O
and	O
later	O
addictive	O
behaviors	O
was	O
positive	O
,	O
1.3	O
%	O
was	O
negative	O
,	O
and	O
63.6	O
%	O
was	O
non-significant	O
.	O

These	O
results	O
were	O
primarily	O
obtained	O
among	O
non-treatment	O
seeking	O
samples	O
(	O
80.7	O
%	O
of	O
studies	O
;	O
n	O
=	O
146	O
)	O
,	O
using	O
single	O
and	O
multi-item	O
measures	O
of	O
addictive	O
behaviors	O
of	O
unknown	O
psychometric	B-P
quality	O
(	O
46.4	O
%	O
of	O
studies	O
)	O
.	O

Positive	O
associations	O
were	O
more	O
frequently	O
observed	O
in	O
studies	O
examining	O
childhood	O
versus	O
adult	O
traumatization	O
(	O
39.7	O
%	O
vs.	O
29.7	O
%	O
)	O
.	O

Longitudinal	O
research	O
in	O
this	O
area	O
emphasizes	O
alcohol	O
abuse	O
,	O
and	O
almost	O
no	O
research	O
has	O
examined	O
behavioral	O
addictions	O
.	O

Results	O
provide	O
some	O
support	O
for	O
a	O
positive	O
association	O
between	O
exposure	O
to	O
interpersonal	O
trauma	O
and	O
subsequent	O
addictive	O
behaviors	O
but	O
this	O
relationship	O
was	O
not	O
consistently	O
reported	O
.	O

Longitudinal	O
studies	O
typically	O
assessed	O
trauma	O
exposure	O
retrospectively	O
,	O
often	O
after	O
addictive	O
behavior	O
onset	O
,	O
thus	O
precluding	O
robust	O
inferences	O
about	O
whether	O
traumatization	O
affects	O
initial	O
onset	O
of	O
addictive	O
behaviors	O
.	O

Functional	O
analyses	O
of	O
OcRhS1	O
and	O
OcUER1	O
involved	O
in	O
UDP-L-rhamnose	O
biosynthesis	O
in	O
Ornithogalum	O
caudatum	O
.	O

UDP-L-rhamnose	O
(	O
UDP-Rha	O
)	O
is	O
an	O
important	O
sugar	O
donor	O
for	O
the	O
synthesis	O
of	O
rhamnose	O
-containing	O
compounds	O
in	O
plants	O
.	O

However	O
,	O
only	O
a	O
few	O
enzymes	O
and	O
their	O
encoding	O
genes	O
involved	O
in	O
UDP-Rha	O
biosynthesis	O
are	O
available	O
in	O
plants	O
.	O

Here	O
,	O
two	O
genes	O
encoding	O
rhamnose	O
synthase	O
(	O
RhS	O
)	O
and	O
bi-functional	O
UDP-4-keto-6-deoxy-D-glucose	O
(	O
UDP-4K6DG	O
)	O
3	O
,	O
5-epimerase/UDP-4-keto-L-rhamnose	O
(	O
UDP-4KR	O
)	O
4-keto-reductase	O
(	O
UER	O
)	O
were	O
isolated	O
from	O
Ornithogalum	O
caudatum	O
based	O
on	O
the	O
RNA	O
-	O
Seq	O
data	O
.	O

The	O
OcRhS1	O
gene	O
has	O
an	O
ORF	O
(	O
open	O
reading	O
frame	O
)	O
of	O
2019	O
bp	O
encoding	O
a	O
tri-functional	O
RhS	O
enzyme	O
.	O

In	O
vitro	O
enzymatic	B-P
assays	I-P
revealed	O
OcRhS1	O
can	O
really	O
convert	O
UDP-D-glucose	O
(	O
UDP-Glc	O
)	O
into	O
UDP-Rha	O
via	O
three	O
consecutive	O
reactions	O
.	O

Biochemical	O
evidences	O
indicated	O
that	O
the	O
recombinant	O
OcRhS1	O
was	O
active	O
in	O
the	O
pH	O
range	O
of	O
5-11	O
and	O
over	O
the	O
temperature	O
range	O
of	O
0-60	O
°C	O
.	O

The	O
Km	O
value	O
of	O
OcRhS1	O
for	O
UDP-Glc	O
was	O
determined	O
to	O
be	O
1.52	O
×	O
10	O
(	O
-4	O
)	O
M.	O
OcRhS1	O
is	O
a	O
multi-domain	O
protein	O
with	O
two	O
sets	O
of	O
cofactor-binding	O
motifs	O
.	O

The	O
cofactors	O
dependent	O
properties	O
of	O
OcRhS1	O
were	O
thus	O
characterized	O
in	O
this	O
research	O
.	O

Moreover	O
,	O
the	O
N-terminal	O
portion	O
of	O
OcRhS1	O
(	O
OcRhS1-N	O
)	O
was	O
observed	O
to	O
metabolize	O
UDP-Glc	O
to	O
form	O
intermediate	O
UDP-4K6DG	O
.	O

OcUER1	O
contains	O
an	O
ORF	O
of	O
906	O
bp	O
encoding	O
a	O
polypeptide	O
of	O
301	O
aa	O
.	O

OcUER1	O
shared	O
high	O
similarity	O
with	O
the	O
carboxy-terminal	O
domain	O
of	O
OcRhS1	O
(	O
OcRhS1-C	O
)	O
,	O
suggesting	O
its	O
intrinsic	O
ability	O
of	O
converting	O
UDP-4K6DG	O
into	O
UDP-Rha	O
.	O

It	O
was	O
thus	O
reasonably	O
inferred	O
that	O
UDP-Glc	O
could	O
be	O
bio-transformed	O
into	O
UDP-Rha	O
under	O
the	O
collaborating	O
action	O
of	O
OcRhS1-N	O
and	O
OcUER1	O
.	O

The	O
subsequently	O
biochemical	B-P
assay	I-P
verified	O
this	O
notion	O
.	O

Importantly	O
,	O
expression	O
profiles	O
of	O
OcRhS1	O
and	O
OcUER1	O
revealed	O
their	O
possible	O
involvement	O
in	O
the	O
biosynthesis	O
of	O
rhamnose	O
-containing	O
polysaccharides	O
in	O
O.	O
caudatum	O
.	O

Design	O
,	O
Synthesis	O
,	O
and	O
Cytotoxic	O
Evaluation	O
of	O
Certain	O
7-Chloro-4-	O
(	O
piperazin-1-yl	O
)	O
quinoline	O
Derivatives	O
as	O
VEGFR-II	O
Inhibitors	O
.	O

Signaling	O
pathway	O
inhibition	O
of	O
VEGFR-II	O
is	O
visualized	O
as	O
valuable	O
tool	O
in	O
cancer	O
management	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
synthesis	O
of	O
novel	O
1-4-	O
(	O
7-chloroquinolin-4-yl	O
)	O
piperazin-1-yl	O
)	O
-2-	O
(	O
N-substituted-amino	O
)	O
-ethanone	O
derivatives	O
(	O
4a-t	O
)	O
was	O
achieved	O
through	O
the	O
amination	O
of	O
2-chloro-1-	O
(	O
4-	O
(	O
7-chloroquinolin-4-yl	O
)	O
piperazin-1-yl	O
)	O
ethanone	O
(	O
3	O
)	O
with	O
different	O
secondary	O
amines	O
.	O

The	O
structures	O
of	O
the	O
target	O
compounds	O
were	O
confirmed	O
by	O
IR	B-P
,	O
(	B-P
1	I-P
)	I-P
H-NMR	I-P
,	O
(	B-P
13	I-P
)	I-P
C-NMR	I-P
,	O
HRMS	B-P
,	O
and	O
microanalysis	B-P
.	O

Compounds	O
4a-t	O
were	O
subjected	O
to	O
in	O
vitro	O
anticancer	O
screening	O
against	O
human	O
breast	O
cancer	O
(	O
MCF-7	O
)	O
and	O
prostate	O
cancer	O
(	O
PC3	O
)	O
cell	O
lines	O
.	O

The	O
highest	O
cytotoxicty	O
against	O
both	O
cell	O
lines	O
was	O
displayed	O
by	O
2-	O
(	O
4-	O
(	O
4-bromobenzyl	O
)	O
piperazin-1-yl	O
)	O
-1-	O
(	O
4-	O
(	O
7-chloroquinolin-4-yl	O
)	O
piperazin-1-yl	O
)	O
ethanone	O
(	O
4q	O
)	O
,	O
with	O
IC50	O
values	O
of	O
6.502	O
and	O
11.751	O
μM	O
against	O
MCF-7	O
and	O
PC3	O
cells	O
,	O
respectively	O
,	O
compared	O
with	O
the	O
standard	O
drug	O
doxorubicin	O
(	O
MCF-7	O
:	O
6.774	O
μM	O
,	O
PC3	O
:	O
7.7316	O
μM	O
)	O
.	O

Due	O
to	O
its	O
notable	O
activity	O
toward	O
MCF-7	O
cells	O
,	O
4q	O
was	O
further	O
evaluated	O
as	O
VEGFR-II	O
inhibitor	O
,	O
showing	O
an	O
IC50	O
of	O
1.38	O
μM	O
compared	O
to	O
sorafenib	O
(	O
0.33	O
μM	O
)	O
.	O

The	O
docking	O
study	O
proved	O
that	O
4q	O
has	O
a	O
binding	O
mode	O
akin	O
to	O
that	O
of	O
VEGFR-II	O
inhibitors	O
.	O

Mutation	O
profiles	O
of	O
synchronous	O
colorectal	O
cancers	O
from	O
a	O
patient	O
with	O
Lynch	O
syndrome	O
suggest	O
distinct	O
oncogenic	O
pathways	O
.	O

Patients	O
with	O
Lynch	O
syndrome	O
often	O
present	O
with	O
multiple	O
synchronous	O
or	O
metachronous	O
colorectal	O
cancers	O
(	O
CRCs	O
)	O
.	O

The	O
presence	O
of	O
multiple	O
CRCs	O
with	O
distinct	O
genetic	B-P
profiles	I-P
and	O
driver	O
mutations	O
could	O
complicate	O
treatment	O
as	O
each	O
cancer	O
may	O
respond	O
differently	O
to	O
therapy	O
.	O

Studies	O
of	O
sporadic	O
CRCs	O
suggested	O
that	O
synchronous	O
tumors	O
have	O
distinct	O
etiologies	O
,	O
but	O
could	O
not	O
rule	O
out	O
differences	O
in	O
genetic	O
background	O
.	O

The	O
presence	O
of	O
multiple	O
cancers	O
in	O
a	O
patient	O
with	O
a	O
predisposing	O
mutation	O
provides	O
an	O
opportunity	O
to	O
profile	O
synchronous	O
cancers	O
in	O
the	O
same	O
genetic	O
background	O
.	O

Here	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
patient	O
with	O
Lynch	O
syndrome	O
that	O
presented	O
with	O
six	O
synchronous	O
CRCs	O
.	O

Microsatellite	O
instability	O
(	O
MSI	O
)	O
and	O
genomic	B-P
profiling	I-P
indicated	O
that	O
each	O
lesion	O
had	O
a	O
unique	O
pattern	O
of	O
instability	O
and	O
a	O
distinct	O
profile	O
of	O
affected	O
genes	O
.	O

These	O
findings	O
support	O
the	O
idea	O
that	O
in	O
Lynch	O
syndrome	O
,	O
synchronous	O
CRCs	O
can	O
develop	O
in	O
parallel	O
with	O
distinct	O
mutation	O
profiles	O
and	O
that	O
these	O
differences	O
may	O
inform	O
treatment	O
decisions	O
.	O

Association	O
between	O
neutrophil	O
-to-	O
lymphocyte	O
ratio	O
and	O
differentiated	O
thyroid	O
cancer	O
:	O
a	O
meta-analysis	O
.	O

The	O
association	O
between	O
neutrophil	O
-to-	O
lymphocyte	O
ratio	O
(	O
NLR	O
)	O
and	O
differentiated	O
thyroid	O
cancer	O
(	O
DTC	O
)	O
is	O
undecided	O
.	O

To	O
rectify	O
this	O
question	O
,	O
we	O
conducted	O
a	O
systematic	O
meta-analysis	O
based	O
on	O
7	O
prospective	O
cohort	O
studies	O
published	O
between	O
2013	O
and	O
2015	O
,	O
comprising	O
7349	O
patients	O
.	O

Six	O
of	O
these	O
cohorts	O
included	O
pretreatment	O
(	O
baseline	O
)	O
NLR	O
data	O
for	O
patients	O
with	O
thyroid	O
nodules	O
.	O

The	O
meta-analysis	O
of	O
these	O
6	O
cohorts	O
showed	O
that	O
the	O
NLR	O
of	O
patients	O
with	O
DTC	O
(	O
4617	O
cases	O
)	O
was	O
statistically	O
similar	O
to	O
patients	O
with	O
benign	O
nodules	O
only	O
(	O
1666	O
cases	O
)	O
,	O
with	O
a	O
mean	O
difference	O
(	O
MD	O
)	O
of	O
0.19	O
(	O
95	O
%	O
CI	O
:	O
-0.09	O
to	O
0.46	O
;	O
I	O
(	O
2	O
)	O
=	O
93	O
%	O
;	O
P	O
<	O
0.001	O
)	O
.	O

No	O
significant	O
difference	O
in	O
NLR	O
was	O
found	O
between	O
patients	O
with	O
DTC	O
and	O
patients	O
with	O
benign	O
nodules	O
.	O

Two	O
studies	B-P
addressed	O
an	O
association	O
between	O
NLR	O
and	O
papillary	O
thyroid	O
carcinoma	O
in	O
patients	O
stratified	O
by	O
age	O
<	O
45	O
and	O
≥45	O
years	O
(	O
496	O
and	O
891	O
cases	O
,	O
respectively	O
)	O
;	O
the	O
pooled	O
MD	O
was	O
0.09	O
(	O
95	O
%	O
CI	O
:	O
-0.37	O
to	O
0.55	O
;	O
I	O
(	O
2	O
)	O
=	O
92.2	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O

An	O
elevated	O
NLR	O
seems	O
not	O
a	O
reliable	O
indicator	O
of	O
progressing	O
DTC	O
in	O
patients	O
with	O
goiters	O
,	O
and	O
there	O
was	O
no	O
difference	O
in	O
NLR	O
between	O
patients	O
aged	O
<	O
45	O
years	O
and	O
those	O
aged	O
≥45	O
years	O
.	O

Well-designed	O
and	O
large-scale	O
investigations	O
are	O
warranted	O
to	O
understand	O
the	O
value	O
of	O
NLR	O
in	O
the	O
prognosis	O
of	O
DTC	O
.	O

A	O
novel	O
functional	O
full-fat	O
hard	O
cheese	O
containing	O
liposomal	O
nanoencapsulated	O
green	O
tea	O
catechins	O
:	O
manufacture	O
and	O
recovery	O
following	O
simulated	O
digestion	O
.	O

(	O
+	O
)	O
-Catechin	O
or	O
green	O
tea	O
extract	O
were	O
encapsulated	O
in	O
soy	O
lecithin	O
nanoliposomes	O
and	O
incorporated	O
into	O
a	O
full-fat	O
cheese	O
,	O
then	O
ripened	O
at	O
8	O
°C	O
for	O
90	O
days	O
.	O

Cheese	O
samples	O
were	O
subjected	O
to	O
simulated	O
gastrointestinal	O
digestion	O
to	O
measure	O
total	O
phenolic	O
conten	O
t	O
(	O
TPC	O
)	O
and	O
antioxidant	O
activity	O
of	O
the	O
cheese	O
digesta	O
,	O
and	O
to	O
determine	O
the	O
catechin	O
recovery	O
after	O
digestion	O
by	O
high	B-P
performance	I-P
liquid	I-P
chromatography	I-P
(	O
HPLC	B-P
)	O
.	O

Addition	O
of	O
catechin	O
or	O
green	O
tea	O
extract	O
significantly	O
(	O
P	O
≤	O
0.05	O
)	O
increased	O
TPC	O
and	O
antioxidant	O
activity	O
(	O
measured	O
by	O
ferric	B-P
reducing	I-P
antioxidant	I-P
power	I-P
and	O
oxygen	B-P
radical	I-P
absorbance	I-P
capacity	I-P
)	O
of	O
the	O
full-fat	O
cheese	O
without	O
affecting	O
pH	O
or	O
proximate	O
composition	O
.	O

HPLC	B-P
analysis	I-P
confirmed	O
retention	O
of	O
encapsulated	O
catechins	O
in	O
the	O
cheese	O
curd	O
;	O
however	O
,	O
individual	O
catechins	O
were	O
recovered	O
in	O
differing	O
amounts	O
(	O
15-52	O
%	O
)	O
from	O
cheese	O
digesta	O
after	O
6	O
h	O
of	O
digestion	O
.	O

Transmission	B-P
electron	I-P
microscopy	I-P
and	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
provided	O
evidence	O
for	O
association	O
of	O
nanoliposomes	O
with	O
the	O
surface	O
of	O
milk	O
fat	O
globules	O
inside	O
the	O
cheese	O
matrix	O
.	O

The	O
study	O
shows	O
the	O
potential	O
for	O
using	O
cheese	O
as	O
a	O
delivery	O
vehicle	O
for	O
green	O
tea	O
antioxidants	O
.	O

Monosubstituted	O
Benzene	O
Derivatives	O
from	O
Fruits	O
of	O
Ficus	O
hirta	O
and	O
Their	O
Antifungal	O
Activity	O
against	O
Phytopathogen	O
Penicillium	O
italicum	O
.	O

Ficus	O
hirta	O
,	O
a	O
widely	O
consumed	O
food	O
by	O
Hakka	O
people	O
,	O
has	O
been	O
reported	O
to	O
show	O
potent	O
antifungal	O
activity	O
against	O
phytopathogen	O
Penicillium	O
italicum	O
.	O

However	O
,	O
there	O
is	O
no	O
report	O
of	O
chemical	O
constituents	O
responsible	O
for	O
the	O
antifungal	O
activity	O
.	O

In	O
the	O
current	O
study	O
,	O
nine	O
monosubstituted	O
benzene	O
derivatives	O
,	O
including	O
three	O
new	O
derivatives	O
(	O
1-3	O
)	O
,	O
were	O
isolated	O
from	O
the	O
fruits	O
of	O
F.	O
hirta	O
.	O

The	O
structures	O
of	O
these	O
isolates	O
were	O
elucidated	O
on	O
the	O
basis	O
of	O
the	O
analysis	O
of	O
spectroscopic	O
data	O
(	O
mass	B-P
spectrometry	I-P
and	O
nuclear	O
magnetic	O
resonance	O
)	O
.	O

All	O
of	O
the	O
isolates	O
were	O
evaluated	O
for	O
antifungal	O
activities	O
against	O
P.	O
italicum	O
.	O

At	O
an	O
equivalent	O
concentration	O
,	O
compound	O
1	O
exhibited	O
stronger	O
antifungal	O
activity	O
than	O
that	O
of	O
the	O
ethanol	O
extract	O
of	O
F.	O
hirta	O
fruits	O
.	O

The	O
prognostic	O
value	O
of	O
cytotoxic	O
T-lymphocyte	O
antigen	O
4	O
in	O
cancers	O
:	O
a	O
systematic	O
review	O
and	O
meta-analysis	O
.	O

The	O
outcomes	O
of	O
studies	O
analyzing	O
the	O
prognostic	O
role	O
of	O
CTLA-4	O
in	O
cancers	O
are	O
controversial	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
our	O
meta-analysis	O
was	O
to	O
clarify	O
the	O
correlation	O
between	O
CTLA-4	O
expression	O
and	O
OS	O
in	O
different	O
cancer	O
cases	O
.	O

Relevant	O
literature	O
was	O
searched	O
using	O
PubMed	O
,	O
EMBASE	O
,	O
Web	O
of	O
Science	O
,	O
and	O
the	O
Cochrane	O
Library	O
.	O

The	O
clinicopathological	O
features	O
,	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
collected	O
from	O
these	O
studies	O
and	O
were	O
analyzed	O
using	O
Stata	O
version	O
12.0	O
software	O
.	O

The	O
pooled	O
HR	O
values	O
showed	O
no	O
significant	O
correlation	O
between	O
CTLA-4	O
expression	O
levels	O
and	O
OS	O
in	O
relation	O
to	O
tumors	O
(	O
HR	O
:	O
1.24	O
,	O
95	O
%	O
CI	O
:	O
0.98-1.56	O
,	O
I2	O
=	O
71.7	O
%	O
,	O
P	O
=	O
0.000	O
)	O
.	O

Further	O
subgroup	O
analyses	O
were	O
conducted	O
and	O
categorized	O
by	O
experimental	O
methods	O
,	O
CTLA-4	O
sources	O
and	O
cancer	O
types	O
.	O

The	O
survey	O
showed	O
a	O
significant	O
correlation	O
(	O
HR	O
:	O
1.47	O
,	O
95	O
%	O
CI	O
:	O
1.14-1.89	O
)	O
between	O
high	O
expression	O
of	O
CTLA-4	O
and	O
OS	O
in	O
the	O
SNP	O
subgroup	O
,	O
and	O
subgroups	O
analyzing	O
by	O
PCR	O
(	O
HR	O
:	O
1.50	O
,	O
95	O
%	O
CI	O
:	O
1.20-1.86	O
)	O
and	O
flow	B-P
cytometry	I-P
(	O
HR	O
:	O
2.76	O
,	O
95	O
%	O
CI	O
:	O
1.49-5.14	O
)	O
.	O

In	O
addition	O
,	O
our	O
analysis	O
observed	O
significant	O
differences	O
between	O
patients	O
and	O
controls	O
in	O
in	O
CTLA-4+	O
CD4+	O
lymphocytes	O
,	O
sur	O
CTLA-4+	O
CD4+	O
lymphocytes	O
,	O
in	O
CTLA-4+	O
CD8+	O
lymphocytes	O
,	O
and	O
sur	O
CTLA-4+	O
CD8+	O
lymphocytes	O
.	O

Knowledge	O
of	O
the	O
effects	O
of	O
CTLA-4	O
could	O
potentially	O
be	O
used	O
to	O
effectively	O
guide	O
appropriate	O
prognosis	O
and	O
therapeutic	O
strategies	O
in	O
cancer	O
patients	O
.	O

Endoscopic	O
Fundoplication	O
:	O
Effectiveness	O
for	O
Controlling	O
Symptoms	O
of	O
Gastroesophageal	O
Reflux	O
Disease	O
.	O

Transoral	O
incisionless	O
fundoplication	O
(	O
TIF	O
)	O
is	O
a	O
completely	O
endoscopic	B-P
approach	I-P
to	O
treat	O
gastroesophageal	O
reflux	O
disease	O
(	O
GERD	O
)	O
.	O

We	O
previously	O
reported	O
our	O
initial	O
results	O
demonstrating	O
safety	O
and	O
early	O
effectiveness	O
.	O

We	O
now	O
present	O
an	O
updated	O
experience	O
describing	O
outcomes	O
with	O
longer	O
follow-up	O
.	O

For	O
a	O
three-year	O
period	O
,	O
TIF	O
procedures	O
were	O
performed	O
on	O
80	O
patients	O
.	O

Preoperative	O
workup	O
routinely	O
consisted	O
of	O
contrast	B-P
esophagram	I-P
and	O
manometry	B-P
.	O

PH	O
testing	O
was	O
reserved	O
for	O
patients	O
with	O
either	O
atypical	O
symptoms	O
or	O
typical	O
symptoms	O
unresponsive	O
to	O
proton-pump	O
inhibitors	O
(	O
PPIs	O
)	O
.	O

Heartburn	O
severity	O
was	O
longitudinally	O
assessed	O
using	O
the	O
GERD	O
health-related	O
quality	O
of	O
life	O
index	O
.	O

Safety	O
analysis	O
was	O
performed	O
on	O
all	O
80	O
patients	O
,	O
and	O
an	O
effectiveness	O
analysis	O
was	O
performed	O
on	O
patients	O
with	O
at	O
least	O
6-month	O
follow-up	O
.	O

Mean	O
procedure	O
time	O
was	O
75	O
minutes	O
.	O

There	O
were	O
seven	O
(	O
8.75	O
%	O
)	O
grade	O
2	O
complications	O
and	O
one	O
(	O
1.25	O
%	O
)	O
grade	O
3	O
complication	O
(	O
aspiration	O
pneumonia	O
)	O
.	O

The	O
median	O
length	O
of	O
stay	O
was	O
1	O
day	O
(	O
mean	O
,	O
1.4	O
)	O
.	O

Forty-one	O
patients	O
had	O
a	O
minimum	O
of	O
6-month	O
of	O
follow-up	O
(	O
mean	O
,	O
24	O
months	O
;	O
range	O
,	O
6-68	O
months	O
)	O
.	O

The	O
mean	O
satisfaction	O
scores	O
at	O
follow-up	O
improved	O
significantly	O
from	O
baseline	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Sixty-three	O
percent	O
of	O
patients	O
had	O
completely	O
stopped	O
or	O
reduced	O
their	O
PPI	O
dose	O
.	O

Results	O
were	O
not	O
impacted	O
by	O
impaired	O
motility	O
;	O
however	O
,	O
the	O
presence	O
of	O
a	O
small	O
hiatal	O
hernia	O
or	O
a	O
Hill	O
grade	O
2/4	O
valve	O
was	O
associated	O
with	O
reduced	O
GERD	O
health-related	O
quality	O
of	O
life	O
scores	O
postoperatively	O
.	O

At	O
a	O
mean	O
follow-up	O
of	O
24	O
months	O
,	O
TIF	O
is	O
effective	O
.	O

Although	O
symptoms	O
and	O
satisfaction	O
improved	O
significantly	O
,	O
many	O
patients	O
continued	O
to	O
take	O
PPIs	O
.	O

Future	O
studies	O
should	O
focus	O
on	O
longer-term	O
durability	O
and	O
comparisons	O
with	O
laparoscopic	O
techniques	O
.	O

Neuroticism	O
and	O
Fatigue	O
3	O
Months	O
After	O
Ischemic	O
Stroke	O
:	O
A	O
Cross-Sectional	O
Study	O
.	O

To	O
examine	O
the	O
relation	O
between	O
neuroticism	O
and	O
fatigue	O
in	O
Chinese	O
patients	O
with	O
stroke	O
.	O

Cross-sectional	O
study	O
.	O

Acute	O
stroke	O
unit	O
.	O

Survivors	O
of	O
ischemic	O
stroke	O
(	O
N=191	O
)	O
recruited	O
from	O
the	O
acute	O
stroke	O
unit	O
between	O
May	O
1	O
,	O
2010	O
,	O
and	O
September	O
1	O
,	O
2011	O
.	O

Not	O
applicable	O
.	O

The	O
personality	O
trait	O
of	O
neuroticism	O
was	O
measured	O
with	O
the	O
neuroticism	O
subscale	O
of	O
the	O
Chinese	O
version	O
of	O
the	O
NEO	B-P
Five-Factor	I-P
Inventory	I-P
.	O

The	O
level	O
of	O
fatigue	O
was	O
measured	O
with	O
the	O
Fatigue	O
Assessment	O
Scale	O
.	O

The	O
National	O
Institutes	O
of	O
Health	O
Stroke	O
Scale	O
,	O
Geriatric	O
Depression	O
Scale	O
,	O
Barthel	O
Index	O
,	O
and	O
Mini-Mental	B-P
State	I-P
Examination	I-P
were	O
administered	O
to	O
obtain	O
demographic	O
and	O
clinical	O
information	O
.	O

Fatigue	O
severity	O
3	O
months	O
after	O
stroke	O
positively	O
correlated	O
with	O
Geriatric	O
Depression	O
Scale	O
and	O
NEO	B-P
Five-Factor	I-P
Inventory	I-P
neuroticism	O
scores	O
and	O
negatively	O
correlated	O
with	O
the	O
Barthel	O
Index	O
score	O
.	O

Neuroticism	O
,	O
independent	O
of	O
depressive	O
symptoms	O
,	O
is	O
a	O
predictor	O
of	O
fatigue	O
severity	O
3	O
months	O
after	O
stroke	O
.	O

Interventions	O
such	O
as	O
psychological	O
screening	O
programs	O
are	O
warranted	O
for	O
early	O
detection	O
of	O
patients	O
at	O
high	O
risk	O
of	O
poststroke	O
depression	O
.	O

Phosphodiesterase	O
Type	O
5	O
Inhibitors	O
and	O
Risk	O
of	O
Malignant	O
Melanoma	O
:	O
Matched	O
Cohort	O
Study	O
Using	O
Primary	O
Care	O
Data	O
from	O
the	O
UK	O
Clinical	O
Practice	O
Research	O
Datalink	O
.	O

Laboratory	O
evidence	O
suggests	O
that	O
reduced	O
phosphodiesterase	O
type	O
5	O
(	O
PDE5	O
)	O
expression	O
increases	O
the	O
invasiveness	O
of	O
melanoma	O
cells	O
;	O
hence	O
,	O
pharmacological	O
inhibition	O
of	O
PDE5	O
could	O
affect	O
melanoma	O
risk	O
.	O

Two	O
major	O
epidemiological	O
studies	O
have	O
investigated	O
this	O
and	O
come	O
to	O
differing	O
conclusions	O
.	O

We	O
therefore	O
aimed	O
to	O
investigate	O
whether	O
PDE5	O
inhibitor	O
use	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
malignant	O
melanoma	O
,	O
and	O
whether	O
any	O
increase	O
in	O
risk	O
is	O
likely	O
to	O
represent	O
a	O
causal	O
relationship	O
.	O

We	O
conducted	O
a	O
matched	O
cohort	O
study	O
using	O
primary	O
care	O
data	O
from	O
the	O
UK	O
Clinical	O
Practice	O
Research	O
Datalink	O
.	O

All	O
men	O
initiating	O
a	O
PDE5	O
inhibitor	O
and	O
with	O
no	O
prior	O
cancer	B-P
diagnosis	I-P
were	O
identified	O
and	O
matched	O
on	O
age	O
,	O
diabetes	O
status	O
,	O
and	O
general	O
practice	O
to	O
up	O
to	O
four	O
unexposed	O
controls	O
.	O

Ever	O
use	O
of	O
a	O
PDE5	O
inhibitor	O
and	O
time-updated	O
cumulative	O
number	O
of	O
PDE5	O
inhibitor	O
prescriptions	O
were	O
investigated	O
as	O
exposures	O
,	O
and	O
the	O
primary	O
outcome	O
was	O
malignant	O
melanoma	O
.	O

Basal	O
cell	O
carcinoma	O
,	O
solar	O
keratosis	O
,	O
and	O
colorectal	O
cancer	O
were	O
investigated	O
as	O
negative	O
control	O
outcomes	O
to	O
exclude	O
bias	O
.	O

Hazard	O
ratios	O
(	O
HRs	O
)	O
were	O
estimated	O
from	O
Cox	O
models	O
stratified	O
by	O
matched	O
set	O
and	O
adjusted	O
for	O
potential	O
confounders	O
.	O

145,104	O
men	O
with	O
≥1	O
PDE5	O
inhibitor	O
prescription	O
,	O
and	O
560,933	O
unexposed	O
matched	O
controls	O
were	O
included	O
.	O

In	O
total	O
,	O
1,315	O
incident	O
malignant	O
melanoma	O
diagnoses	O
were	O
observed	O
during	O
3.44	O
million	O
person-years	O
of	O
follow-up	O
(	O
mean	O
4.9	O
y	O
per	O
person	O
)	O
.	O

After	O
adjusting	O
for	O
potential	O
confounders	O
,	O
there	O
was	O
weak	O
evidence	O
of	O
a	O
small	O
positive	O
association	O
between	O
PDE5	O
inhibitor	O
use	O
and	O
melanoma	O
risk	O
(	O
HR	O
=	O
1.14	O
,	O
95	O
%	O
CI	O
1.01-1.29	O
,	O
p	O
=	O
0.04	O
)	O
.	O

A	O
similar	O
increase	O
in	O
risk	O
was	O
seen	O
for	O
the	O
two	O
negative	O
control	O
outcomes	O
related	O
to	O
sun	O
exposure	O
(	O
HR	O
=	O
1.15	O
,	O
95	O
%	O
CI	O
1.11-1.19	O
,	O
p	O
<	O
0.001	O
,	O
for	O
basal	O
cell	O
carcinoma	O
;	O
HR	O
=	O
1.21	O
,	O
95	O
%	O
CI	O
1.17-1.25	O
,	O
p	O
<	O
0.001	O
,	O
for	O
solar	O
keratosis	O
)	O
,	O
but	O
there	O
was	O
no	O
increased	O
risk	O
for	O
colorectal	O
cancer	O
(	O
HR	O
=	O
0.91	O
,	O
95	O
%	O
CI	O
0.85-0.98	O
,	O
p	O
=	O
0.01	O
)	O
.	O

There	O
was	O
no	O
evidence	O
that	O
risk	O
increased	O
with	O
number	O
of	O
prescriptions	O
received	O
(	O
p-trend	O
=	O
0.83	O
)	O
.	O

In	O
a	O
post	O
hoc	O
analysis	O
,	O
there	O
was	O
strong	O
evidence	O
that	O
solar	O
keratosis	O
was	O
associated	O
with	O
future	O
PDE5	O
inhibitor	O
use	O
(	O
odds	O
ratio	O
=	O
1.28	O
,	O
95	O
%	O
CI	O
1.23-1.34	O
,	O
p	O
<	O
0.001	O
)	O
,	O
suggesting	O
that	O
men	O
with	O
higher	O
sun	O
exposure	O
were	O
more	O
likely	O
to	O
become	O
PDE5	O
inhibitor	O
users	O
.	O

However	O
,	O
a	O
limitation	O
of	O
our	O
study	O
was	O
that	O
we	O
did	O
not	O
have	O
individual-level	O
data	O
on	O
sun	O
exposure	O
,	O
so	O
we	O
could	O
not	O
directly	O
control	O
for	O
this	O
in	O
the	O
primary	O
analysis	O
.	O

Our	O
results	O
were	O
not	O
consistent	O
with	O
PDE5	O
inhibitors	O
being	O
causally	O
associated	O
with	O
melanoma	O
risk	O
,	O
and	O
strongly	O
suggest	O
that	O
observed	O
risk	O
increases	O
are	O
driven	O
by	O
greater	O
sun	O
exposure	O
among	O
patients	O
exposed	O
to	O
a	O
PDE5	O
inhibitor	O
.	O

An	O
investigation	O
of	O
fungal	O
contamination	O
on	O
the	O
surface	O
of	O
medicinal	O
herbs	O
in	O
China	O
.	O

The	O
dried	O
parts	O
of	O
medicinal	O
herbs	O
are	O
susceptible	O
to	O
the	O
infection	O
of	O
fungi	O
during	O
p	O
re-	O
or	O
post-harvest	O
procedure	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
presence	O
of	O
fungi	O
and	O
their	O
metabolites	O
mycotoxins	O
on	O
the	O
surface	O
of	O
medicinal	O
herbs	O
collected	O
from	O
China	O
.	O

Forty-five	O
retail	O
samples	O
of	O
15	O
different	O
medicinal	O
herbs	O
were	O
collected	O
from	O
3	O
different	O
regions	O
in	O
China	O
.	O

Then	O
the	O
potential	O
fungi	O
were	O
immediately	O
washed	O
off	O
from	O
the	O
surface	O
of	O
each	O
sample	O
with	O
0.1	O
%	O
Tween-20	O
followed	O
by	O
incubation	B-P
of	O
the	O
rinse	O
on	O
petri-dish	O
with	O
potato	O
dextrose	O
agar	O
containing	O
chloramphenicol	O
at	O
28	O
°C	O
.	O

The	O
obtained	O
fungi	O
were	O
isolated	O
as	O
single	O
colonies	O
and	O
then	O
characterized	O
by	O
morphology	O
and	O
molecular	B-P
identification	I-P
using	O
internal	B-P
transcribed	I-P
spacer	I-P
(	I-P
ITS	I-P
)	I-P
sequencing	I-P
with	O
extracted	O
DNA	O
.	O

Meanwhile	O
,	O
the	O
mycotoxin	O
-producing	O
potential	O
of	O
the	O
isolates	O
was	O
studied	O
by	O
liquid	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
(	O
LC-MS	B-P
/	O
MS	B-P
)	O
.	O

A	O
total	O
of	O
126	O
fungi	O
were	O
identified	O
from	O
the	O
surface	O
of	O
samples	O
by	O
morphology	O
and	O
ITS	B-P
sequencing	I-P
,	O
with	O
Aspergillus	O
and	O
Penicillium	O
genera	O
as	O
the	O
predominant	O
contaminants	O
.	O

The	O
mycotoxin	O
-producing	O
potential	O
analysis	O
showed	O
that	O
6	O
of	O
8	O
A.	O
versicolor	O
isolates	O
could	O
produce	O
sterigmatocystin	O
.	O

All	O
3	O
A.	O
aculeatus	O
isolates	O
produced	O
ochratoxin	O
A	O
,	O
but	O
only	O
1	O
of	O
3	O
A.	O
flavus	O
strains	O
produced	O
aflatoxins	O
B1	O
and	O
B2	O
without	O
G1	O
and	O
G2	O
.	O

Although	O
the	O
sample	O
contamination	O
ratios	O
were	O
high	O
(	O
≥95.6	O
%	O
)	O
,	O
there	O
was	O
no	O
significant	O
difference	O
(	O
χ	O
(	O
2	O
)	O
=	O
1.05	O
,	O
P	O
=	O
1.0	O
)	O
among	O
the	O
samples	O
from	O
3	O
regions	O
,	O
which	O
demonstrates	O
the	O
prevalent	O
fungal	O
contamination	O
in	O
the	O
herbal	O
medicines	O
.	O

The	O
prevalent	O
contamination	O
phenomenon	O
of	O
fungi	O
and	O
high	O
potential	O
risk	O
of	O
sterigmatocystin	O
and	O
ochratoxin	O
A	O
were	O
observed	O
in	O
45	O
medicinal	O
herbs	O
collected	O
from	O
China	O
.	O

From	O
chemotherapy	O
to	O
target	O
therapies	O
associated	O
with	O
radiation	O
in	O
the	O
treatment	O
of	O
NSCLC	O
:	O
a	O
durable	O
marriage	O
?	O
.	O

The	O
integration	O
between	O
radiotherapy	O
and	O
drugs	O
,	O
from	O
chemotherapy	O
to	O
recently	O
available	O
target	O
therapies	O
,	O
continues	O
to	O
have	O
a	O
relevant	O
role	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	O
and	O
metastatic	O
Non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

Aim	O
of	O
the	O
present	O
review	O
is	O
to	O
evaluate	O
the	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	O
and	O
new	O
modalities	O
of	O
radiotherapy	O
.	O

Areas	O
covered	O
:	O
We	O
searched	O
Medline	O
,	O
Google	O
Scholar	O
,	O
PubMed	O
,	O
ProQuest	O
Dissertation	O
,	O
and	O
Theses	O
databases	O
for	O
reports	O
published	O
in	O
English	O
.	O

A	O
study	O
was	O
included	O
when	O
it	O
reported	O
on	O
cancer-related	O
radiotherapy	O
and	O
included	O
patients	O
with	O
NSCLC	O
treated	O
with	O
chemo	O
and/or	O
target	O
therapies	O
.	O

Review	O
articles	O
were	O
excluded	O
from	O
the	O
analysis	O
.	O

Expert	O
commentary	O
:	O
Chemo-radiotherapy	O
still	O
represents	O
the	O
standard	O
of	O
choice	O
in	O
locally	O
advanced	O
NSCLC	O
,	O
while	O
to	O
date	O
the	O
addition	O
of	O
target	O
therapies	O
to	O
chemo-radiotherapy	O
did	O
not	O
demonstrate	O
any	O
robust	O
advantage	O
in	O
this	O
stage	B-P
of	I-P
disease	I-P
.	O

Considering	O
the	O
absence	O
of	O
randomized	O
controlled	O
trials	O
,	O
the	O
role	O
of	O
target	O
therapies	O
in	O
early	O
stage	O
adjuvant	O
NSCLC	O
is	O
not	O
yet	O
recommended	O
in	O
clinical	O
practice	O
.	O

On	O
the	O
contrary	O
,	O
in	O
the	O
setting	O
of	O
oligometastatic	O
and	O
oligoprogressive	O
disease	O
,	O
new	O
molecules	O
demonstrated	O
to	O
be	O
safe	O
and	O
effective	O
,	O
opening	O
to	O
a	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	O
and	O
new	O
modalities	O
of	O
radiotherapy	O
.	O

Diagnostic	O
value	O
of	O
diffusion	B-P
weighted	I-P
MRI	I-P
and	O
ADC	O
in	O
differential	B-P
diagnosis	I-P
of	O
cavernous	O
hemangioma	O
of	O
the	O
liver	O
.	O

To	O
investigate	O
the	O
use	O
of	O
diffusion	B-P
weighted	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
DWI	B-P
)	O
and	O
the	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
values	O
in	O
the	O
diagnosis	O
of	O
hemangioma	O
.	O

The	O
study	O
population	O
consisted	O
of	O
72	O
patients	O
with	O
liver	O
masses	O
larger	O
than	O
1	O
cm	O
(	O
72	O
focal	O
lesions	O
)	O
.	O

DWI	B-P
examination	O
with	O
a	O
b	O
value	O
of	O
600	O
s/mm2	O
was	O
carried	O
out	O
for	O
all	O
patients	O
.	O

After	O
DWI	B-P
examination	O
,	O
an	O
ADC	O
map	O
was	O
created	O
and	O
ADC	O
values	O
were	O
measured	O
for	O
72	O
liver	O
masses	O
and	O
normal	O
liver	O
tissue	O
(	O
control	O
group	O
)	O
.	O

The	O
average	O
ADC	O
values	O
of	O
normal	O
liver	O
tissue	O
and	O
focal	O
liver	O
lesions	O
,	O
the	O
``	O
cut-off	O
``	O
ADC	O
values	O
,	O
and	O
the	O
diagnostic	O
sensitivity	O
and	O
specificity	O
of	O
the	O
ADC	O
map	O
in	O
diagnosing	O
hemangioma	O
,	O
benign	O
and	O
malignant	O
lesions	O
were	O
researched	O
.	O

Of	O
the	O
72	O
liver	O
masses	O
,	O
51	O
were	O
benign	O
and	O
21	O
were	O
malignant	O
.	O

Benign	O
lesions	O
comprised	O
38	O
hemangiomas	O
and	O
13	O
simple	O
cysts	O
.	O

Malignant	O
lesions	O
comprised	O
9	O
hepatocellular	O
carcinomas	O
,	O
and	O
12	O
metastases	O
.	O

The	O
highest	O
ADC	O
values	O
were	O
measured	O
for	O
cysts	O
(	O
3.782±0.53×10	O
(	O
-3	O
)	O
mm	O
(	O
2	O
)	O
/s	O
)	O
and	O
hemangiomas	O
(	O
2.705±0.63×10	O
(	O
-3	O
)	O
mm	O
(	O
2	O
)	O
/s	O
)	O
.	O

The	O
average	O
ADC	O
value	O
of	O
hemangiomas	O
was	O
significantly	O
higher	O
than	O
malignant	O
lesions	O
and	O
the	O
normal	O
control	O
group	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
average	O
ADC	O
value	O
of	O
cysts	O
were	O
significantly	O
higher	O
when	O
compared	O
to	O
hemangiomas	O
and	O
normal	O
control	O
group	O
(	O
p	O
<	O
0.001	O
)	O
.	O

To	O
distinguish	O
hemangiomas	O
from	O
malignant	O
liver	O
lesions	O
,	O
the	O
``	O
cut-off	O
``	O
ADC	O
value	O
of	O
1.800×10	O
(	O
-3	O
)	O
mm	O
(	O
2	O
)	O
/s	O
had	O
a	O
sensitivity	O
of	O
97.4	O
%	O
and	O
a	O
specificity	O
of	O
90.9	O
%	O
.	O

To	O
distinguish	O
hemangioma	O
from	O
normal	O
liver	O
parenchyma	O
the	O
``	O
cut-off	O
''	O
value	O
of	O
1.858×10	O
(	O
-3	O
)	O
mm	O
(	O
2	O
)	O
/s	O
had	O
a	O
sensitivity	O
of	O
97.4	O
%	O
and	O
a	O
specificity	O
of	O
95.7	O
%	O
.	O

To	O
distinguish	O
benign	O
liver	O
lesions	O
from	O
malignant	O
liver	O
lesions	O
the	O
``	O
cut-off	O
''	O
value	O
of	O
1.800×10	O
(	O
-3	O
)	O
mm	O
(	O
2	O
)	O
/s	O
had	O
a	O
sensitivity	O
of	O
96.1	O
%	O
and	O
a	O
specificity	O
of	O
90.0	O
%	O
.	O

DWI	B-P
and	O
quantitative	O
measurement	O
of	O
ADC	O
values	O
can	O
be	O
used	O
in	O
differential	B-P
diagnosis	I-P
of	O
benign	O
and	O
malignant	O
liver	O
lesions	O
and	O
also	O
in	O
the	O
diagnosis	O
and	O
differentiation	O
of	O
hemangiomas	O
.	O

When	O
dynamic	O
examination	O
can	O
not	O
distinguish	O
cases	O
with	O
vascular	O
metastasis	O
and	O
lesions	O
from	O
hemangioma	O
,	O
DWI	B-P
and	O
ADC	O
values	O
can	O
be	O
useful	O
in	O
the	O
primary	O
diagnosis	O
and	O
differential	B-P
diagnosis	I-P
.	O

The	O
technique	O
does	O
not	O
require	O
contrast	O
material	O
,	O
so	O
it	O
can	O
safely	O
be	O
used	O
in	O
patients	O
with	O
renal	O
failure	O
.	O

Anti-bacterial	O
and	O
Anti-biofilm	O
Evaluation	O
of	O
Thiazolopyrimidinone	O
Derivatives	O
Targeting	O
the	O
Histidine	O
Kinase	O
YycG	O
Protein	O
of	O
Staphylococcus	O
epidermidis	O
.	O

Staphylococcus	O
epidermidis	O
is	O
one	O
of	O
the	O
most	O
important	O
opportunistic	O
pathogens	O
in	O
nosocomial	O
infections	O
.	O

The	O
main	O
pathogenicity	O
associated	O
with	O
S.	O
epidermidis	O
involves	O
the	O
formation	O
of	O
biofilms	O
on	O
implanted	O
medical	O
devices	O
,	O
biofilms	O
dramatically	O
decrease	O
the	O
efficacy	O
of	O
conventional	O
antibiotics	O
and	O
the	O
host	O
immune	O
system	O
.	O

This	O
emphasizes	O
the	O
urgent	O
need	O
for	O
designing	O
novel	O
anti-staphylococcal	O
biofilm	O
agents	O
.	O

Based	O
on	O
the	O
findings	O
that	O
compound	O
5	O
,	O
targeting	O
the	O
histidine	O
kinase	O
domain	O
of	O
S.	O
epidermidis	O
YycG	O
,	O
possessed	O
bactericidal	O
activity	O
against	O
staphylococci	O
,	O
39	O
derivatives	O
of	O
compound	O
5	O
with	O
intact	O
thiazolopyrimidinone	O
core	O
structures	O
were	O
newly	O
designed	O
,	O
7	O
derivatives	O
were	O
further	O
screened	B-P
to	O
explore	O
their	O
anti-bacterial	O
and	O
anti-biofilm	O
activities	O
.	O

The	O
seven	O
derivatives	O
strongly	O
inhibited	O
the	O
growth	O
of	O
S.	O
epidermidis	O
and	O
Staphylococcus	O
aureus	O
in	O
the	O
minimal	B-P
inhibitory	I-P
concentration	I-P
range	O
of	O
1.56-6.25	O
μM	O
.	O

All	O
the	O
derivatives	O
reduced	O
the	O
proportion	O
of	O
viable	O
cells	O
in	O
mature	O
biofilms	O
.	O

They	O
all	O
displayed	O
low	O
cytotoxicity	O
on	O
mammalian	O
cells	O
and	O
were	O
not	O
hemolytic	O
to	O
human	O
erythrocytes	O
.	O

The	O
biofilm	O
inhibition	O
activities	O
of	O
four	O
derivatives	O
(	O
H5-32	O
,	O
H5-33	O
,	O
H5-34	O
,	O
and	O
H5-35	O
)	O
were	O
further	O
investigated	O
under	O
shearing	O
forces	O
,	O
they	O
all	O
led	O
to	O
significant	O
decreases	O
in	O
the	O
biofilm	O
formation	O
of	O
S.	O
epidermidis	O
.	O

These	O
results	O
were	O
suggestive	O
that	O
the	O
seven	O
derivatives	O
of	O
compound	O
5	O
have	O
the	O
potential	O
to	O
be	O
developed	O
into	O
agents	O
for	O
eradicating	O
biofilm	O
-associated	O
infections	O
.	O

A	O
Whole-Body	O
Approach	O
to	O
Point	O
of	O
Care	O
Ultrasound	B-P
.	O

Ultrasonography	B-P
is	O
an	O
essential	O
imaging	O
modality	O
in	O
the	O
ICU	O
used	O
to	O
diagnose	O
and	O
guide	O
the	O
treatment	O
of	O
cardiopulmonary	O
failure	O
.	O

Critical	O
care	O
ultrasonography	B-P
requires	O
that	O
all	O
image	O
acquisition	O
,	O
image	O
interpretation	O
,	O
and	O
clinical	O
applications	O
of	O
ultrasonography	B-P
are	O
personally	O
performed	O
by	O
the	O
critical	O
care	O
clinician	O
at	O
the	O
point	O
of	O
care	O
and	O
that	O
the	O
information	O
obtained	O
is	O
combined	O
with	O
the	O
history	O
,	O
physical	O
,	O
and	O
laboratory	O
information	O
.	O

Point-of-care	O
ultrasonography	B-P
is	O
often	O
compartmentalized	O
such	O
that	O
the	O
clinician	O
will	O
focus	O
on	O
one	O
body	O
system	O
while	O
performing	O
the	O
critical	O
care	O
ultrasonography	B-P
examination	O
.	O

We	O
suggest	O
a	O
change	O
from	O
this	O
compartmentalized	O
approach	O
to	O
a	O
systematic	O
whole-body	O
ultrasonography	B-P
approach	I-P
.	O

The	O
standard	O
whole-body	O
ultrasonography	B-P
examination	O
includes	O
thoracic	O
,	O
cardiac	O
,	O
limited	O
abdominal	O
,	O
and	O
an	O
evaluation	O
for	O
DVT	O
.	O

Other	O
elements	O
of	O
ultrasonography	B-P
are	O
used	O
when	O
clinically	O
indicated	O
.	O

Each	O
of	O
these	O
elements	O
is	O
reviewed	O
in	O
this	O
article	O
and	O
are	O
accompanied	O
by	O
a	O
link	O
to	O
pertinent	O
cases	O
from	O
the	O
Ultrasound	O
Corner	O
section	O
of	O
CHEST	O
.	O

The	O
relationship	O
of	O
serum	O
vitamins	O
A	O
,	O
D	O
,	O
E	O
and	O
LL-37	O
levels	O
with	O
allergic	O
status	O
,	O
tonsillar	O
virus	B-P
detection	I-P
and	O
immune	O
response	O
.	O

Tonsils	O
have	O
an	O
active	O
role	O
in	O
immune	O
defence	O
and	O
inducing	O
and	O
maintaining	O
tolerance	O
to	O
allergens	O
.	O

Vitamins	O
A	O
,	O
D	O
,	O
and	O
E	O
,	O
and	O
antimicrobial	O
peptide	O
LL-37	O
may	O
have	O
immunomodulatory	O
effects	O
.	O

We	O
studied	O
how	O
their	O
serum	O
levels	O
were	O
associated	O
with	O
allergy	O
status	O
,	O
intratonsillar	O
/	O
nasopharyngeal	O
virus	B-P
detection	I-P
and	O
intratonsillar	O
expression	O
of	O
T	O
cell	O
-	O
and	O
innate	O
immune	O
response	O
-specific	O
cytokines	O
,	O
transcription	O
factors	O
and	O
type	O
I	O
/	O
II	O
/	O
III	O
interferons	O
in	O
patients	O
undergoing	O
tonsillectomy	O
.	O

110	O
elective	O
tonsillectomy	O
patients	O
participated	O
.	O

Serum	O
levels	O
of	O
vitamins	O
A	O
,	O
25	O
(	O
OH	O
)	O
D	O
,	O
and	O
E	O
,	O
LL-37	O
and	O
allergen-specific	O
IgE	O
as	O
well	O
as	O
nasopharyngeal	O
/	O
intratonsillar	O
respiratory	O
viruses	O
were	O
analyzed	O
.	O

The	O
mRNA	O
expression	O
of	O
IFN-α	O
,	O
IFN-β	O
,	O
IFN-γ	O
,	O
IL-10	O
,	O
IL-13	O
,	O
IL-17	O
,	O
IL-28	O
,	O
IL-29	O
,	O
IL-37	O
,	O
TGF-β	O
,	O
FOXP3	O
,	O
GATA3	O
,	O
RORC2	O
and	O
Tbet	O
in	O
tonsils	O
were	O
analyzed	O
by	O
quantitative	O
RT-PCR	O
.	O

The	O
median	O
age	O
of	O
the	O
patients	O
was	O
16	O
years	O
(	O
range	O
3-60	O
)	O
,	O
28	O
%	O
of	O
subjects	O
had	O
atopy	O
,	O
and	O
57	O
%	O
carried	O
≥1	O
respiratory	O
virus	O
in	O
nasopharynx	O
.	O

Detection	B-P
of	I-P
viruses	I-P
decreased	O
by	O
age	O
.	O

Higher	O
vitamin	O
A	O
levels	O
showed	O
borderline	O
significance	O
with	O
less	O
viral	B-P
detection	I-P
(	O
P	O
=	O
0.056	O
)	O
.	O

Higher	O
25	O
(	O
OH	O
)	O
D	O
was	O
associated	O
with	O
less	O
allergic	O
rhinitis	O
and	O
atopy	O
(	O
P	O
<	O
0.05	O
)	O
and	O
higher	O
vitamin	O
E	O
with	O
less	O
self-reported	O
allergy	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
gene	O
expression	O
analyses	O
,	O
25	O
(	O
OH	O
)	O
D	O
was	O
associated	O
with	O
higher	O
IL-37	O
,	O
vitamin	O
A	O
with	O
higher	O
IFN-γ	O
and	O
vitamin	O
E	O
with	O
less	O
IL-28	O
(	O
P	O
<	O
0.05	O
)	O
.	O

LL-37	O
was	O
associated	O
with	O
less	O
FOXP3	O
,	O
RORC2	O
and	O
IL-17	O
in	O
tonsils	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Vitamin	O
D	O
and	O
E	O
levels	O
were	O
associated	O
with	O
less	O
allergic	O
disorders	O
.	O

Vitamin	O
A	O
was	O
linked	O
to	O
antiviral	O
and	O
vitamin	O
D	O
with	O
anti-inflammatory	O
activity	O
.	O

LL-37	O
and	O
was	O
linked	O
to	O
T	O
regulatory	O
cell	O
effects	O
.	O

Stimulation	O
of	O
cell	O
proliferation	O
by	O
glutathione	O
monoethyl	O
ester	O
in	O
aged	O
bone	O
marrow	O
stromal	O
cells	O
is	O
associated	O
with	O
the	O
assistance	O
of	O
TERT	O
gene	O
expression	O
and	O
telomerase	O
activity	O
.	O

The	O
proliferation	O
and	O
differentiation	O
potential	O
of	O
aged	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSCs	O
)	O
are	O
significantly	O
reduced	O
.	O

In	O
order	O
to	O
improve	O
the	O
performance	O
of	O
the	O
aged	O
BMSCs	O
,	O
these	O
cells	O
were	O
treated	O
with	O
2	O
mM	O
glutathione	O
monoethyl	O
ester	O
(	O
GSH-MEE	O
)	O
for	O
24	O
h.	O
Proliferation	O
rate	O
,	O
telomerase	O
activity	O
,	O
telomere	O
length	O
,	O
and	O
differentiation	O
to	O
cholinergic	O
neuron-like	O
cells	O
(	O
CNLCs	O
)	O
were	O
observed	O
to	O
increase	O
.	O

Though	O
,	O
the	O
expression	O
level	O
of	O
telomerase	O
reverse	O
transcriptase	O
gene	O
increased	O
,	O
but	O
CTC1	O
and	O
TEN1	O
genes	O
from	O
Ctc1-Stn1-Ten1	O
complex	O
encoding	O
proteins	O
with	O
regulatory	O
function	O
significantly	O
decreased	O
.	O

Trypan	B-P
blue	I-P
exclusion	I-P
assay	I-P
was	O
used	O
to	O
analyze	O
the	O
proliferation	O
and	O
,	O
while	O
telomere	O
length	O
,	O
its	O
several	O
related	O
gene	O
expressions	O
,	O
and	O
telomerase	O
activity	O
were	O
measured	O
using	O
the	O
real	O
time	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
and	O
polymerase	O
chain	O
reaction	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
techniques	I-P
,	O
respectively	O
.	O

CNLCs	O
differentiation	O
potential	O
was	O
evaluated	O
by	O
estimating	O
the	O
percentage	O
of	O
choline	O
acetyltransferase	O
immunereactive	O
cells	O
.The	O
results	O
suggested	O
that	O
GSH-MEE	O
could	O
improve	O
aged	O
rat	O
BMSC	O
properties	O
and	O
would	O
be	O
of	O
potential	O
benefit	O
for	O
enhancing	O
the	O
performance	O
of	O
aged	O
people	O
's	O
BMSCs	O
.	O

Histopathology	O
of	O
the	O
filum	O
terminale	O
in	O
children	O
with	O
and	O
without	O
tethered	O
cord	O
syndrome	O
with	O
attention	O
to	O
the	O
elastic	O
tissue	O
within	O
the	O
filum	O
.	O

To	O
compare	O
histologically	O
transected	O
fila	O
from	O
pediatric	O
patients	O
with	O
tethered	O
cord	O
syndrome	O
(	O
TCS	O
)	O
,	O
with	O
and	O
without	O
a	O
low	O
conus	O
,	O
with	O
controls	O
,	O
focusing	O
on	O
collagenous	O
and	O
elastic	O
tissue	O
.	O

Thirty	O
fila	O
from	O
patients	O
with	O
TCS	O
,	O
including	O
5	O
where	O
minimal	O
cautery	O
was	O
used	O
prior	O
to	O
filum	O
section	B-P
,	O
were	O
compared	O
with	O
fila	O
from	O
27	O
pediatric	O
cadavers	O
without	O
TCS	O
(	O
controls	O
)	O
.	O

Sections	O
of	O
fila	O
were	O
stained	B-P
with	O
H	B-P
&	I-P
E	I-P
,	O
Masson	B-P
trichrome	I-P
and	O
Verhoeff	B-P
von	I-P
Gieson	I-P
elastic	I-P
stains	I-P
,	O
and	O
7	O
with	O
Gordon	B-P
and	I-P
Sweet	I-P
's	I-P
reticulin	I-P
stain	I-P
.	O

Fila	O
from	O
controls	O
showed	O
loose	O
fibrous	O
connective	O
tissue	O
(	O
FCT	O
)	O
with	O
thin	O
and	O
evenly	O
dispersed	O
elastic	O
fibers	O
(	O
EFs	O
)	O
.	O

Reticulin	O
fibers	O
(	O
RFs	O
)	O
were	O
seen	O
in	O
blood	O
vessel	O
walls	O
and	O
nerve	O
twigs	O
.	O

Fat	O
was	O
identified	O
microscopically	O
in	O
2	O
fila	O
.	O

All	O
fila	O
from	O
patients	O
with	O
TCS	O
had	O
dense	O
FCT	O
.	O

The	O
EFs	O
were	O
in	O
normal	O
numbers	O
in	O
17	O
,	O
and	O
focally	O
or	O
diffusely	O
decreased	O
in	O
13	O
.	O

All	O
25	O
patients	O
where	O
the	O
fila	O
were	O
cauterized	O
during	O
resection	O
had	O
thick	O
and	O
coiled	O
EFs	O
.	O

Coiling	O
was	O
not	O
seen	O
when	O
minimal	O
cautery	O
was	O
applied	O
.	O

RFs	O
were	O
seen	O
in	O
blood	O
vessel	O
walls	O
and	O
nerve	O
twigs	O
.	O

Fat	O
was	O
identified	O
in	O
19	O
patients	O
.	O

Findings	O
were	O
similar	O
,	O
whether	O
the	O
conus	O
termination	O
was	O
normal	O
or	O
low	O
.	O

The	O
fila	O
of	O
all	O
patients	O
with	O
TCS	O
,	O
whether	O
or	O
not	O
the	O
conus	O
was	O
low	O
,	O
showed	O
abnormal	O
FCT	O
.	O

EFs	O
were	O
decreased	O
in	O
48	O
%	O
of	O
patients	O
;	O
however	O
,	O
there	O
were	O
thick	O
and	O
coiled	O
EFs	O
in	O
all	O
patients	O
.	O

Coiling	O
of	O
EFs	O
,	O
initially	O
thought	O
to	O
be	O
an	O
abnormality	O
in	O
patients	O
,	O
is	O
considered	O
most	O
likely	O
to	O
be	O
a	O
result	O
of	O
cautery	O
(	O
i.e.	O
,	O
artifactual	O
/	O
iatrogenic	O
coiling	O
)	O
.	O

Interaction	O
of	O
the	O
Antimicrobial	O
Peptides	O
Rhesus	O
θ-Defensin	O
and	O
Porcine	O
Protegrin-1	O
with	O
Anionic	O
Phospholipid	O
Monolayers	O
.	O

A	O
combination	O
of	O
Langmuir	O
isotherm	O
,	O
Brewster	B-P
angle	I-P
microscopy	I-P
(	O
BAM	B-P
)	O
,	O
and	O
neutron	O
reflectivity	O
studies	O
have	O
been	O
performed	O
to	O
gain	O
insight	O
into	O
the	O
effects	O
on	O
model	O
bacterial	O
cell	O
membranes	O
of	O
the	O
antimicrobial	O
peptides	O
,	O
Rhesus	O
θ-defensin	O
1	O
(	O
RTD-1	O
)	O
,	O
and	O
porcine	O
protegrin	O
1	O
(	O
PG-1	O
)	O
.	O

The	O
peptides	O
were	O
interacted	O
with	O
monolayers	O
spread	O
at	O
the	O
air	O
-	O
water	O
interface	O
and	O
prepared	O
from	O
a	O
3:1	O
molar	O
mixture	O
of	O
phosphatidylethanolamine	O
and	O
phosphatidylglycerol	O
used	O
to	O
approximate	O
the	O
cell	O
membranes	O
of	O
Gram	O
positive	O
bacteria	O
.	O

The	O
Langmuir	O
film	O
balance	O
measurements	O
show	O
that	O
both	O
peptides	O
perturb	O
the	O
lipid	O
monolayers	O
causing	O
an	O
increase	O
in	O
surface	O
pressure	O
,	O
and	O
the	O
BAM	B-P
studies	O
show	O
that	O
each	O
results	O
in	O
the	O
formation	O
of	O
small	O
domains	O
within	O
the	O
lipid	O
films	O
,	O
around	O
5	O
μm	O
diameter	O
.	O

The	O
overall	O
change	O
in	O
monolayer	O
surface	O
pressure	O
caused	O
by	O
PG-1	O
,	O
however	O
,	O
is	O
a	O
little	O
more	O
pronounced	O
than	O
that	O
due	O
to	O
RTD-1	O
(	O
+8.5	O
mN·m	O
(	O
-1	O
)	O
vs	O
+5.5	O
mN·m	O
(	O
-1	O
)	O
)	O
,	O
and	O
the	O
rate	O
of	O
its	O
initial	O
interaction	O
with	O
the	O
monolayer	O
is	O
a	O
little	O
more	O
rapid	O
than	O
that	O
for	O
RTD-1	O
.	O

The	O
neutron	O
reflectivity	O
studies	O
also	O
show	O
differences	O
for	O
PG-1	O
and	O
RTD-1	O
,	O
with	O
the	O
model	O
fits	O
to	O
these	O
data	O
showing	O
that	O
the	O
more	O
amphiphilic	O
PG-1	O
becomes	O
fully	O
embedded	B-P
within	O
the	O
lipid	O
film	O
-causing	O
an	O
extension	O
of	O
the	O
lipid	O
acyl	O
chains	O
but	O
leaving	O
the	O
thickness	O
of	O
the	O
lipid	O
headgroup	O
layer	O
unaffected-while	O
RTD-1	O
is	O
seen	O
to	O
insert	O
less	O
deeply-causing	O
the	O
same	O
extension	O
of	O
the	O
lipid	O
acyl	O
chains	O
as	O
PG-1	O
but	O
also	O
causing	O
a	O
significant	O
increase	O
in	O
thickness	O
of	O
the	O
lipid	O
headgroup	O
layer	O
.	O

The	O
various	O
differing	O
effects	O
of	O
the	O
two	O
peptides	O
on	O
anionic	O
lipid	O
monolayers	O
are	O
discussed	O
in	O
the	O
context	O
of	O
their	O
differing	O
hemolytic	B-P
activities	I-P
,	O
and	O
their	O
proposed	O
differing	O
propensities	O
to	O
form	O
transmembrane	O
pores	O
.	O

Mass	B-P
spectrometric	I-P
analysis	O
of	O
protein	O
-	O
ligand	O
interactions	O
.	O

The	O
interactions	O
of	O
small	O
molecules	O
with	O
proteins	O
(	O
protein	O
-	O
ligand	O
interactions	O
)	O
mediate	O
various	O
biological	O
phenomena	O
including	O
signal	O
transduction	O
and	O
protein	O
transcription	O
and	O
translation	O
.	O

Synthetic	O
compounds	O
such	O
as	O
drugs	O
can	O
also	O
bind	O
to	O
target	O
proteins	O
,	O
leading	O
to	O
the	O
inhibition	O
of	O
protein	O
-	O
ligand	O
interactions	O
.	O

These	O
interactions	O
typically	O
accompany	O
association	O
-	O
dissociation	O
equilibrium	O
according	O
to	O
the	O
free	O
energy	O
difference	O
between	O
free	O
and	O
bound	O
states	O
;	O
therefore	O
,	O
the	O
quantitative	O
biophysical	O
analysis	O
of	O
the	O
interactions	O
,	O
which	O
uncovers	O
the	O
stoichiometry	O
and	O
dissociation	O
constant	O
,	O
is	O
important	O
for	O
understanding	O
biological	O
reactions	O
as	O
well	O
as	O
for	O
rational	O
drug	O
development	O
.	O

Mass	B-P
spectrometry	I-P
(	O
MS	B-P
)	O
has	O
been	O
used	O
to	O
determine	O
the	O
precise	O
molecular	O
masses	O
of	O
molecules	O
.	O

Recent	O
advancements	O
in	O
MS	B-P
enable	O
us	O
to	O
determine	O
the	O
molecular	O
masses	O
of	O
protein	O
-	O
ligand	O
complexes	O
without	O
disrupting	O
the	O
non-covalent	O
interactions	O
through	O
the	O
gentle	O
desolvation	O
of	O
the	O
complexes	O
by	O
increasing	O
the	O
vacuum	O
pressure	O
of	O
a	O
chamber	O
in	O
a	O
mass	O
spectrometer	O
.	O

This	O
method	O
is	O
called	O
MS	B-P
under	O
non-denaturing	O
conditions	O
or	O
native	O
MS	B-P
and	O
allows	O
the	O
unambiguous	O
determination	O
of	O
protein	O
-	O
ligand	O
interactions	O
.	O

Under	O
a	O
few	O
assumptions	O
,	O
MS	B-P
has	O
also	O
been	O
applied	O
to	O
determine	O
the	O
dissociation	O
constants	O
for	O
protein	O
-	O
ligand	O
interactions	O
.	O

The	O
structural	O
information	O
of	O
a	O
protein	O
-	O
ligand	O
interaction	O
,	O
such	O
as	O
the	O
location	O
of	O
the	O
interaction	O
and	O
conformational	O
change	O
in	O
a	O
protein	O
,	O
can	O
also	O
be	O
analyzed	O
using	O
hydrogen	O
/	O
deuterium	B-P
exchange	I-P
MS	B-P
.	O

In	O
this	O
paper	O
,	O
we	O
briefly	O
describe	O
the	O
history	O
,	O
principle	O
,	O
and	O
recent	O
applications	O
of	O
MS	B-P
for	O
the	O
study	O
of	O
protein	O
-	O
ligand	O
interactions	O
.	O

γ-Butenolide	O
and	O
furanone	O
derivatives	O
from	O
the	O
soil	O
-derived	O
fungus	O
Aspergillus	O
sclerotiorum	O
PSU-RSPG178	O
.	O

Chromatographic	B-P
separation	I-P
of	O
the	O
broth	O
extract	O
of	O
the	O
soil	O
-derived	O
fungus	O
Aspergillus	O
sclerotiorum	O
PSU-RSPG178	O
resulted	O
in	O
isolation	O
of	O
four	O
γ-butenolide-furanone	O
dimers	O
,	O
aspersclerotiorones	O
A-D	O
,	O
a	O
furanone	O
derivative	O
,	O
aspersclerotiorone	O
E	O
,	O
and	O
two	O
γ-butenolide	O
derivatives	O
,	O
aspersclerotiorones	O
F	O
and	O
G	O
,	O
together	O
with	O
six	O
known	O
compounds	O
,	O
penicillic	O
acid	O
,	O
dihydropenicillic	O
acid	O
,	O
5,6-dihydro-6-hydroxypenicillic	O
acid	O
,	O
6-methoxy-5,6-dihydropenicillic	O
acid	O
,	O
coculnol	O
and	O
(	O
4R,5R	O
)	O
-4,5-dihydroxy-3-methoxy-5-methylcyclohex-2-en-1-one	O
.	O

Their	O
structures	O
were	O
determined	O
by	O
spectroscopic	B-P
evidence	I-P
.	O

For	O
aspersclerotiorones	O
A	O
and	O
B	O
,	O
the	O
structures	O
were	O
confirmed	O
by	O
single-crystal	B-P
X-ray	I-P
diffraction	I-P
crystallography	I-P
.	O

Penicillic	O
acid	O
displayed	O
weak	O
antibacterial	O
activity	O
against	O
Staphylococcus	O
aureus	O
and	O
Escherichia	O
coli	O
with	O
equal	O
MIC	O
values	O
of	O
128	O
μg/mL	O
,	O
and	O
it	O
was	O
noncytotoxic	O
towards	O
African	O
green	O
monkey	O
kidney	O
fibroblast	O
cells	O
.	O

Embryonic	O
Mutant	O
Huntingtin	O
Aggregate	O
Formation	O
in	O
Mouse	O
Models	O
of	O
Huntington	O
's	O
Disease	O
.	O

The	O
role	O
of	O
aggregate	O
formation	O
in	O
the	O
pathophysiology	O
of	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
remains	O
uncertain	O
.	O

However	O
,	O
the	O
temporal	O
appearance	O
of	O
aggregates	O
tends	O
to	O
correlate	O
with	O
the	O
onset	O
of	O
symptoms	O
and	O
the	O
numbers	O
of	O
neuropil	O
aggregates	O
correlate	O
with	O
the	O
progression	O
of	O
clinical	O
disease	O
.	O

Using	O
highly	O
sensitive	O
immunohistochemical	B-P
methods	I-P
we	O
have	O
detected	O
the	O
appearance	O
of	O
diffuse	O
aggregates	O
during	O
embryonic	O
development	O
in	O
the	O
R6/2	O
and	O
YAC128	O
mouse	O
models	O
of	O
HD	O
.	O

These	O
are	O
initially	O
seen	O
in	O
developing	O
axonal	O
tracts	O
and	O
appear	O
to	O
spread	O
throughout	O
the	O
cerebrum	O
in	O
the	O
early	O
neonate	O
.	O

Prevalence	O
and	O
correlates	O
of	O
binge	O
eating	O
disorder	O
related	O
features	O
in	O
the	O
community	O
.	O

Binge	O
eating	O
disorder	O
(	O
BED	O
)	O
is	O
associated	O
with	O
high	O
levels	O
of	O
obesity	O
and	O
psychological	O
suffering	O
,	O
but	O
little	O
is	O
known	O
about	O
1	O
)	O
the	O
distribution	O
of	O
features	O
of	O
BED	O
in	O
the	O
general	O
population	O
and	O
2	O
)	O
their	O
consequences	O
for	O
weight	O
development	O
and	O
psychological	O
distress	O
in	O
young	O
adulthood	O
.	O

We	O
investigated	O
the	O
prevalence	O
of	O
features	O
of	O
BED	O
and	O
their	O
association	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
psychological	O
distress	O
among	O
men	O
(	O
n	O
=	O
2423	O
)	O
and	O
women	O
(	O
n	O
=	O
2825	O
)	O
from	O
the	O
longitudinal	O
community-based	O
FinnTwin16	O
cohort	O
(	O
born	O
1975-1979	O
)	O
.	O

Seven	O
eating	O
-related	O
cognitions	O
and	O
behaviors	O
similar	O
to	O
the	O
defining	O
features	O
of	O
BED	O
were	O
extracted	O
from	O
the	O
Eating	O
Disorder	O
Inventory-2	O
and	O
were	O
assessed	O
at	O
a	O
mean	O
age	O
of	O
24	O
.	O

BMI	O
and	O
psychological	O
distress	O
,	O
measured	O
with	O
the	O
General	B-P
Health	I-P
Questionnaire	I-P
,	O
were	O
assessed	O
at	O
ages	O
24	O
and	O
34	O
.	O

We	O
assessed	O
prevalence	O
of	O
the	O
features	O
and	O
their	O
association	O
with	O
BMI	O
and	O
psychological	O
distress	O
cross-sectionally	O
and	O
prospectively	O
.	O

More	O
than	O
half	O
of	O
our	O
participants	O
reported	O
at	O
least	O
one	O
feature	O
of	O
BED	O
;	O
clustering	O
of	O
several	O
features	O
in	O
one	O
individual	O
was	O
less	O
common	O
,	O
particularly	O
among	O
men	O
.	O

The	O
most	O
frequently	O
reported	O
feature	O
was	O
'	O
stuffing	O
oneself	O
with	O
food	O
'	O
,	O
whereas	O
the	O
least	O
common	O
was	O
'	O
eating	O
or	O
drinking	O
in	O
secrecy	O
'	O
.	O

All	O
individual	O
features	O
of	O
BED	O
and	O
their	O
clustering	O
particularly	O
were	O
associated	O
with	O
higher	O
BMI	O
and	O
more	O
psychological	O
distress	O
cross-sectionally	O
.	O

Prospectively	O
,	O
the	O
clustering	O
of	O
features	O
of	O
BED	O
predicted	O
increase	O
in	O
psychological	O
distress	O
but	O
not	O
additional	O
weight	O
gain	O
when	O
baseline	O
BMI	O
was	O
accounted	O
for	O
.	O

In	O
summary	O
,	O
although	O
some	O
features	O
of	O
BED	O
were	O
common	O
,	O
the	O
clustering	O
of	O
several	O
features	O
in	O
one	O
individual	O
was	O
not	O
.	O

The	O
features	O
were	O
cumulatively	O
associated	O
with	O
BMI	O
and	O
psychological	O
distress	O
and	O
predicted	O
further	O
increase	O
in	O
psychological	O
distress	O
over	O
ten	O
years	O
of	O
follow-up	O
.	O

Design	O
and	O
synthesis	O
of	O
pH	O
-	O
sensitive	O
polymeric	O
micelles	O
for	O
oral	O
delivery	O
of	O
poorly	O
water	O
-	O
soluble	O
drugs	O
.	O

pH	O
-	O
sensitive	O
polymer	O
poly	O
(	O
polylactide-co-methacrylic	O
acid	O
)	O
-b-poly	O
(	O
acrylic	O
acid	O
)	O
was	O
synthesized	O
using	O
atom	O
transfer	O
radical	O
polymerization	O
and	O
ring-opening	O
polymerization	O
and	O
characterized	O
by	O
gel	B-P
permeation	I-P
chromatography	I-P
and	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
.	O

The	O
polymers	O
can	O
self-assemble	O
to	O
form	O
micelles	O
in	O
aqueous	O
medium	O
,	O
which	O
respond	O
rapidly	O
to	O
pH	O
change	O
within	O
the	O
gastrointestinal	O
relevant	O
pH	O
range	O
.	O

Critical	O
micelle	O
concentrations	O
and	O
pH	O
response	O
behavior	O
of	O
the	O
polymeri	O
c	O
micelle	O
were	O
investigated	O
.	O

Water	O
-	O
insoluble	O
drug	O
nifedipine	O
was	O
loaded	O
and	O
the	O
drug	O
-	O
loading	O
content	O
can	O
be	O
controlled	O
by	O
tuning	O
the	O
composition	O
of	O
the	O
polymers	O
.	O

The	O
in	O
vitro	O
release	O
studies	O
indicate	O
pH	O
sensitivity	O
enabled	O
rapid	O
drug	O
release	O
at	O
the	O
environment	O
of	O
simulated	O
intestinal	O
fluid	O
(	O
pH	O
7.36	O
)	O
,	O
the	O
cumulative	O
released	O
amount	O
of	O
NFD	O
reached	O
more	O
than	O
80	O
%	O
within	O
24	O
h	O
,	O
while	O
only	O
35	O
%	O
in	O
the	O
simulated	O
gastric	O
fluid	O
(	O
pH	O
1.35	O
)	O
.	O

All	O
the	O
results	O
showed	O
that	O
the	O
pH	O
-	O
sensitive	O
P	O
(	O
PLAMA-co-MAA	O
)	O
-b-PAA	O
micelle	O
may	O
be	O
a	O
prospective	O
candidate	O
as	O
oral	O
drug	O
delivery	O
carrier	O
for	O
hydrophobic	O
drugs	O
with	O
controlled	O
release	O
behavior	O
.	O

Estimation	O
of	O
Split	O
Renal	O
Function	O
With	O
(	O
99m	O
)	O
Tc-DMSA	O
SPECT	B-P
:	O
Comparison	O
Between	O
3D	O
Volumetric	O
Assessment	O
and	O
2D	O
Coronal	B-P
Projection	I-P
Imaging	I-P
.	O

Split	O
renal	O
function	O
(	O
SRF	O
)	O
can	O
be	O
estimated	O
with	O
(	O
99m	O
)	O
Tc-labeled	O
dimercaptosuccinic	O
acid	O
(	O
DMSA	O
)	O
SPECT	B-P
cortical	O
renal	O
scintigraphy	B-P
on	O
either	O
2D	O
projected	O
images	O
or	O
3D	O
images	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
there	O
is	O
a	O
significant	O
difference	O
between	O
SRF	O
values	O
calculated	O
with	O
the	O
2D	O
method	B-P
and	O
those	O
calculated	O
with	O
the	O
3D	O
method	B-P
.	O

This	O
retrospective	O
study	O
was	O
performed	O
with	O
(	O
99m	O
)	O
Tc-DMSA	O
SPECT	B-P
images	O
of	O
316	O
patients	O
(	O
age	O
range	O
,	O
1-26	O
years	O
)	O
.	O

All	O
images	O
were	O
reconstructed	O
by	O
filtered	B-P
back	I-P
projection	I-P
.	O

An	O
automated	B-P
computational	I-P
method	I-P
was	O
developed	O
to	O
estimate	O
SRF	O
using	O
both	O
2D	O
projection	O
images	O
and	O
direct	O
3D	O
images	O
.	O

A	O
paired	O
t	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
difference	O
between	O
SRFs	O
determined	O
with	O
the	O
two	O
methods	B-P
and	O
the	O
association	O
between	O
the	O
magnitude	O
of	O
the	O
differences	O
and	O
kidney	O
size	O
,	O
patient	O
age	O
,	O
and	O
SRF	O
.	O

There	O
was	O
strong	O
correlation	O
between	O
SRFs	O
estimated	O
with	O
the	O
2D	O
and	O
3D	O
methods	B-P
(	O
r	O
=	O
0.94	O
,	O
p	O
<	O
0.001	O
)	O
.	O

There	O
was	O
small	O
significant	O
difference	O
(	O
0.14	O
%	O
±	O
0.86	O
%	O
,	O
p	O
=	O
0.003	O
)	O
in	O
SRFs	O
obtained	O
with	O
the	O
two	O
methods	B-P
.	O

The	O
difference	O
was	O
clinically	O
negligible	O
and	O
independent	O
of	O
renal	O
length	O
(	O
p	O
=	O
0.698	O
)	O
,	O
volume	O
(	O
p	O
=	O
0.297	O
)	O
,	O
and	O
patient	O
age	O
(	O
p	O
=	O
0.768	O
)	O
but	O
was	O
associated	O
with	O
SRF	O
(	O
p	O
=	O
0.018	O
)	O
.	O

For	O
determination	B-P
of	O
split	O
renal	O
function	O
,	O
(	O
99m	O
)	O
Tc-DMSA	O
SPECT	B-P
renal	O
scintigraphy	B-P
2D	O
coronal	O
projection	O
images	O
perform	O
as	O
well	O
as	O
and	O
are	O
simpler	O
to	O
analyze	O
than	O
3D	O
images	O
.	O

Hypocretin/Orexin	O
Peptides	O
Excite	O
Rat	O
Neuroendocrine	O
Dopamine	O
Neurons	O
through	O
Orexin	O
2	O
Receptor	O
-Mediated	O
Activation	O
of	O
a	O
Mixed	O
Cation	O
Current	O
.	O

Hypocretin/Orexin	O
(	O
H/O	O
)	O
neurons	O
of	O
the	O
lateral	O
hypothalamus	O
are	O
compelling	O
modulator	O
candidates	O
for	O
the	O
chronobiology	O
of	O
neuroendocrine	O
output	O
and	O
,	O
as	O
a	O
consequence	O
,	O
hormone	O
release	O
from	O
the	O
anterior	O
pituitary	O
.	O

Here	O
we	O
investigate	O
the	O
effects	O
of	O
H/O	O
peptides	O
upon	O
tuberoinfundibular	O
dopamine	O
(	O
TIDA	O
)	O
neurons	O
-	O
cells	O
which	O
control	O
,	O
via	O
inhibition	O
,	O
the	O
pituitary	O
secretion	O
of	O
prolactin	O
.	O

In	O
whole	O
cell	O
recordings	O
performed	O
in	O
male	O
rat	O
hypothalamic	O
slices	O
,	O
application	O
of	O
H/O-A	O
,	O
as	O
well	O
as	O
H/O-B	O
,	O
excited	O
oscillating	O
TIDA	O
neurons	O
,	O
inducing	O
a	O
reversible	O
depolarising	O
switch	O
from	O
phasic	O
to	O
tonic	O
discharge	O
.	O

The	O
H/O	O
-	O
induced	O
inward	O
current	O
underpinning	O
this	O
effect	O
was	O
post-synaptic	O
(	O
as	O
it	O
endured	O
in	O
the	O
presence	O
of	O
tetrodotoxin	O
)	O
,	O
appeared	O
to	O
be	O
carried	O
by	O
a	O
Na	O
(	O
+	O
)	O
-	O
dependent	O
transient	O
receptor	O
potential-like	O
channel	O
(	O
as	O
it	O
was	O
blocked	O
by	O
2-APB	O
and	O
was	O
diminished	O
by	O
removal	O
of	O
extracellular	O
Na	O
(	O
+	O
)	O
)	O
,	O
and	O
was	O
a	O
consequence	O
of	O
OX2R	O
receptor	O
activation	O
(	O
as	O
it	O
was	O
blocked	O
by	O
the	O
OX2R	O
receptor	O
antagonist	O
TCS	O
OX2	O
29	O
,	O
but	O
not	O
the	O
OX1R	O
receptor	O
antagonist	O
SB	O
334867	O
)	O
.	O

Application	O
of	O
the	O
hormone	O
,	O
melatonin	O
,	O
failed	O
to	O
alter	O
TIDA	O
membrane	O
potential	O
or	O
oscillatory	O
activity	O
.	O

This	O
first	O
description	O
of	O
the	O
electrophysiological	B-P
effects	I-P
of	O
H/Os	O
upon	O
the	O
TIDA	O
network	O
identifies	O
cellular	O
mechanisms	O
that	O
may	O
contribute	O
to	O
the	O
circadian	O
rhythmicity	O
of	O
prolactin	O
secretion	O
.	O

A	O
modified	O
ESBL	B-P
Nordmann/Dortet/Poirel-based	I-P
protocol	I-P
to	O
optimize	O
early	O
sepsis	O
management	O
.	O

We	O
evaluated	O
a	O
modification	O
of	O
a	O
colorimetric	B-P
test	I-P
recently	O
described	O
by	O
Dortet	O
et	O
al	O
.	O

(	O
2015	O
)	O
for	O
the	O
rapid	O
detection	O
of	O
ESBL	O
-producing	O
Enterobacteriaceae	O
directly	O
from	O
positive	O
blood	B-P
cultures	I-P
that	O
requires	O
less	O
manipulation	B-P
,	O
materials	O
and	O
hands-on	O
time	O
.	O

The	O
simplified	O
protocol	B-P
showed	O
a	O
sensitivity	O
and	O
specificity	O
of	O
100	O
%	O
and	O
95.7	O
%	O
respectively	O
.	O

Angiotensin-converting	O
enzyme	O
insertion/deletion	O
polymorphism	O
association	O
with	O
obesity	O
and	O
some	O
related	O
disorders	O
in	O
Egyptian	O
females	O
:	O
a	O
case-control	O
observational	O
study	O
.	O

According	O
to	O
the	O
WHO	O
report	O
in	O
2015	O
,	O
obesity	O
is	O
the	O
fifth	O
leading	O
cause	O
of	O
death	O
worldwide	O
,	O
and	O
the	O
prevalence	O
of	O
Egyptian	O
female	O
obesity	O
is	O
37.5	O
%	O
.	O

Since	O
obesity	O
is	O
highly	O
influenced	O
by	O
genetics	O
,	O
and	O
adipose	O
tissue	O
renin-angiotensin	O
system	O
is	O
over-activated	O
in	O
obesity	O
,	O
the	O
effect	O
of	O
angiotensin-converting	O
enzyme	O
(	O
ACE	O
)	O
insertion/deletion	O
(	O
I/D	O
)	O
polymorphism	O
on	O
obesity	O
and	O
related	O
disorders	O
was	O
studied	O
in	O
several	O
populations	O
,	O
because	O
of	O
its	O
effect	O
on	O
ACE	O
activity	O
.	O

Our	O
objective	O
was	O
to	O
study	O
the	O
association	O
of	O
ACE	O
I/D	O
polymorphism	O
with	O
obesity	O
and	O
certain	O
related	O
disorders	O
,	O
namely	O
hypertension	O
,	O
insulin	O
resistance	O
and	O
metabolic	O
syndrome	O
,	O
in	O
Egyptian	O
females	O
.	O

Eighty	O
female	O
volunteers	O
were	O
recruited	O
,	O
blood	O
pressure	O
and	O
body	B-P
measurements	I-P
were	O
recorded	O
and	O
a	O
fasting	O
blood	O
sample	O
was	O
obtained	O
for	O
the	O
quantitation	O
of	O
glucose	O
,	O
lipid	B-P
profile	I-P
,	O
insulin	O
,	O
leptin	O
and	O
identification	O
of	O
ACE	O
I/D	O
polymorphs	O
.	O

Subjects	O
were	O
grouped	O
based	O
on	O
hypertension	O
and	O
obesity	O
states	O
.	O

Comparisons	O
of	O
continuous	O
parameters	O
were	O
made	O
with	O
independent	O
sample	O
t-test	O
between	O
two	O
groups	O
.	O

The	O
frequencies	O
of	O
ACE	O
genotypes	O
and	O
alleles	O
,	O
and	O
the	O
association	O
between	O
gene	O
polymorphism	O
and	O
metabolic	O
parameters	O
were	O
assessed	O
using	O
chi-square	O
or	O
Fisher	O
's	O
exact	O
test	O
.	O

Genotype	O
frequencies	O
were	O
in	O
Hardy-Weinberg	O
equilibrium	O
for	O
all	O
groups	O
.	O

Genotype	O
distribution	O
did	O
not	O
differ	O
significantly	O
between	O
controls	O
and	O
cases	O
of	O
all	O
the	O
studied	O
disorders	O
.	O

Although	O
DD	O
carriers	O
had	O
apparently	O
higher	O
parameters	O
of	O
blood	O
pressure	O
,	O
lipid	B-P
profile	I-P
and	O
insulin	O
resistance	O
,	O
only	O
diastolic	O
blood	O
pressure	O
was	O
almost	O
significant	O
(	O
p	O
=	O
0.057	O
)	O
.	O

I-carriers	O
were	O
significantly	O
less	O
susceptible	O
to	O
hypertension	O
than	O
DD	O
carriers	O
having	O
normal	O
waist/hip	O
ratio	O
(	O
p	O
=	O
0.007	O
,	O
OR	O
=	O
17.29	O
,	O
CI	O
=	O
1.81-164.96	O
)	O
and	O
normal	O
conicity	O
index	O
(	O
p	O
=	O
0.024	O
,	O
OR	O
=	O
7.00	O
,	O
CI	O
=	O
1.36-35.93	O
)	O
.	O

In	O
DD	O
genotype	O
carriers	O
,	O
a	O
significant	O
association	O
was	O
found	O
between	O
insulin	O
resistance	O
and	O
high	O
body	O
mass	O
index	O
(	O
p	O
=	O
0.004	O
,	O
OR	O
=	O
8.89	O
,	O
CI	O
=	O
1.94-40.71	O
)	O
,	O
waist	O
circumference	O
(	O
p	O
=	O
0.003	O
,	O
OR	O
=	O
9.63	O
,	O
CI	O
=	O
2.14-43.36	O
)	O
and	O
waist/height	O
ratio	O
(	O
p	O
=	O
0.034	O
,	O
OR	O
=	O
6.86	O
,	O
CI	O
=	O
1.25-37.61	O
)	O
,	O
although	O
the	O
variations	O
in	O
percentages	O
between	O
DD	O
and	O
I-carriers	O
were	O
not	O
high	O
enough	O
to	O
conclude	O
an	O
effect	O
of	O
ACE	O
I/D	O
on	O
such	O
an	O
association	O
.	O

In	O
this	O
sample	O
of	O
Egyptian	O
females	O
,	O
ACE	O
I/D	O
polymorphism	O
was	O
not	O
significantly	O
associated	O
with	O
obesity	O
nor	O
with	O
any	O
of	O
its	O
related	O
disorders	O
studied	O
.	O

The	O
I	O
allele	O
seemed	O
protective	O
against	O
hypertension	O
in	O
subjects	O
with	O
normal	O
,	O
not	O
high	O
,	O
waist/hip	O
ratio	O
and	O
conicity	O
index	O
compared	O
to	O
DD	O
genotype	O
carriers	O
.	O

22q11.2q13	O
duplication	O
including	O
SOX10	O
causes	O
sex-reversal	O
and	O
peripheral	O
demyelinating	O
neuropathy	O
,	O
central	O
dysmyelinating	O
leukodystrophy	O
,	O
Waardenburg	O
syndrome	O
,	O
and	O
Hirschsprung	O
disease	O
.	O

Diagnosis	O
of	O
genetic	O
syndromes	O
may	O
be	O
difficult	O
when	O
specific	O
components	O
of	O
a	O
disorder	O
manifest	O
at	O
a	O
later	O
age	O
.	O

We	O
present	O
a	O
follow	O
up	O
of	O
a	O
previous	O
report	O
[	O
Seeherunvong	O
et	O
al.	O
,	O
(	O
2004	O
)	O
;	O
AJMGA	O
127	O
:	O
149-151	O
]	O
,	O
of	O
an	O
individual	O
with	O
22q	O
duplication	O
and	O
sex-reversal	O
syndrome	O
.	O

The	O
subject	O
's	O
phenotype	O
evolved	O
to	O
include	O
peripheral	O
and	O
central	O
demyelination	O
,	O
Waardenburg	O
syndrome	O
type	O
IV	O
,	O
and	O
Hirschsprung	O
disease	O
(	O
PCWH	O
;	O
MIM	O
609136	O
)	O
.	O

DNA	O
microarray	O
analysis	O
defined	O
the	O
duplication	O
at	O
22q11.2q13	O
,	O
including	O
SOX10	O
.	O

Sequencing	B-P
of	O
the	O
coding	O
region	O
of	O
SOX10	O
did	O
not	O
reveal	O
any	O
mutations	O
.	O

Our	O
data	O
suggest	O
that	O
SOX10	O
duplication	O
can	O
cause	O
disorders	O
of	O
sex	O
development	O
and	O
PCWH	O
,	O
supporting	O
the	O
hypothesis	O
that	O
SOX10	O
toxic	O
gain	O
of	O
function	O
rather	O
than	O
dominant	O
negative	O
activity	O
underlies	O
PCWH	O
.	O

Evolution	O
of	O
Fitness	O
Cost-Neutral	O
Mutant	O
PfCRT	O
Conferring	O
P.	O
falciparum	O
4-Aminoquinoline	O
Drug	O
Resistance	O
Is	O
Accompanied	O
by	O
Altered	O
Parasite	O
Metabolism	O
and	O
Digestive	O
Vacuole	O
Physiology	O
.	O

Southeast	O
Asia	O
is	O
an	O
epicenter	O
of	O
multidrug-resistant	O
Plasmodium	O
falciparum	O
strains	O
.	O

Selective	O
pressures	O
on	O
the	O
subcontinent	O
have	O
recurrently	O
produced	O
several	O
allelic	O
variants	O
of	O
parasite	O
drug	O
resistance	O
genes	O
,	O
including	O
the	O
P.	O
falciparum	O
chloroquine	O
resistance	O
transporter	O
(	O
pfcrt	O
)	O
.	O

Despite	O
significant	O
reductions	O
in	O
the	O
deployment	O
of	O
the	O
4-aminoquinoline	O
drug	O
chloroquine	O
(	O
CQ	O
)	O
,	O
which	O
selected	O
for	O
the	O
mutant	O
pfcrt	O
alleles	O
that	O
halted	O
CQ	O
efficacy	O
decades	O
ago	O
,	O
the	O
parasite	O
pfcrt	O
locus	O
is	O
continuously	O
evolving	O
.	O

This	O
is	O
highlighted	O
by	O
the	O
presence	O
of	O
a	O
highly	O
mutated	O
allele	O
,	O
Cam734	O
pfcrt	O
,	O
which	O
has	O
acquired	O
the	O
singular	O
ability	O
to	O
confer	O
parasite	O
CQ	O
resistance	O
without	O
an	O
associated	O
fitness	O
cost	O
.	O

Here	O
,	O
we	O
used	O
pfcrt	O
-specific	O
zinc-finger	O
nucleases	O
to	O
genetically	O
dissect	O
this	O
allele	O
in	O
the	O
pathogenic	O
setting	O
of	O
asexual	O
blood-stage	O
infection	O
.	O

Comparative	O
analysis	O
of	O
drug	O
resistance	O
and	O
growth	O
profiles	O
of	O
recombinant	O
parasites	O
that	O
express	O
Cam734	O
or	O
variants	O
thereof	O
,	O
Dd2	O
(	O
the	O
most	O
common	O
Southeast	O
Asian	O
variant	O
)	O
,	O
or	O
wild-type	O
pfcrt	O
,	O
revealed	O
previously	O
unknown	O
roles	O
for	O
PfCRT	O
mutations	O
in	O
modulating	O
parasite	O
susceptibility	O
to	O
multiple	O
antimalarial	O
agents	O
.	O

These	O
results	O
were	O
generated	O
in	O
the	O
GC03	O
strain	O
,	O
used	O
in	O
multiple	O
earlier	O
pfcrt	O
studies	O
,	O
and	O
might	O
differ	O
in	O
natural	O
isolates	O
harboring	O
this	O
allele	O
.	O

Results	O
presented	O
herein	O
show	O
that	O
Cam734	O
-mediated	O
CQ	O
resistance	O
is	O
dependent	O
on	O
the	O
rare	O
A144F	O
mutation	O
that	O
has	O
not	O
been	O
observed	O
beyond	O
Southeast	O
Asia	O
,	O
and	O
reveal	O
distinct	O
impacts	O
of	O
this	O
and	O
other	O
Cam734	O
-specific	O
mutations	O
on	O
CQ	O
resistance	O
and	O
parasite	O
growth	O
rates	O
.	O

Biochemical	B-P
assays	I-P
revealed	O
a	O
broad	O
impact	O
of	O
mutant	O
PfCRT	O
isoforms	O
on	O
parasite	O
metabolism	O
,	O
including	O
nucleoside	O
triphosphate	O
levels	O
,	O
hemoglobin	O
catabolism	O
and	O
disposition	O
of	O
heme	O
,	O
as	O
well	O
as	O
digestive	O
vacuole	O
volume	O
and	O
pH	O
.	O

Results	O
from	O
our	O
study	O
provide	O
new	O
insights	O
into	O
the	O
complex	O
molecular	O
basis	O
and	O
physiological	O
impact	O
of	O
PfCRT	O
-mediated	O
antimalarial	O
drug	O
resistance	O
,	O
and	O
inform	O
ongoing	O
efforts	O
to	O
characterize	O
novel	O
pfcrt	O
alleles	O
that	O
can	O
undermine	O
the	O
efficacy	O
of	O
first-line	O
antimalarial	O
drug	O
regimens	O
.	O

Sonochemical	O
Effect	O
on	O
Activity	O
and	O
Conformation	O
of	O
Commercial	O
Lipases	O
.	O

The	O
enzyme	O
under	O
lower-intensity	O
ultrasonic	O
irradiation	O
leads	O
to	O
favourable	O
conformational	O
changes	O
,	O
thereby	O
enhancing	O
its	O
activity	O
.	O

The	O
augmentation	O
of	O
activity	O
of	O
ultrasound	O
-	O
treated	O
enzyme	O
is	O
strongly	O
dependent	O
on	O
ultrasound	O
intensity	O
,	O
duty	O
cycle	O
and	O
exposure	O
time	O
,	O
which	O
was	O
investigated	O
for	O
commercial	O
lipases	O
.	O

Thermomyces	O
lanuginosus	O
(	O
TL	O
)	O
lipase	O
showed	O
a	O
1.3-fold	O
enhanced	O
activity	O
after	O
irradiating	O
at	O
22	O
kHz	O
and	O
11.38	O
W	O
cm	O
(	O
-2	O
)	O
with	O
50	O
%	O
duty	O
cycle	O
for	O
25-min	O
ultrasonic	O
treatment	O
and	O
1.5-fold	O
enhanced	O
activity	O
was	O
observed	O
for	O
lipozyme	O
(	O
candida	O
antarctica	O
lipase	O
B	O
(	O
CALB	O
)	O
)	O
lipase	O
,	O
at	O
22	O
kHz	O
and	O
15.48	O
W	O
cm	O
(	O
-2	O
)	O
with	O
66.67	O
%	O
duty	O
cycle	O
for	O
20-min	O
ultrasonic	O
treatment	O
.	O

After	O
sonication	O
,	O
thermodynamic	O
parameters	O
viz	O
.	O

E	O
a	O
,	O
ΔH	O
,	O
ΔS	O
and	O
ΔG	O
were	O
evaluated	O
and	O
values	O
were	O
found	O
to	O
be	O
significantly	O
lower	O
for	O
both	O
lipases	O
.	O

In	O
addition	O
,	O
the	O
changes	O
in	O
secondary	O
structure	O
due	O
to	O
sonication	O
were	O
investigated	O
by	O
using	O
Fourier	B-P
transform	I-P
infrared	I-P
(	O
FT-IR	B-P
)	O
,	O
which	O
revealed	O
increase	O
in	O
a	O
certain	O
number	O
of	O
random	O
coiled	O
structure	O
,	O
loss	O
of	O
β-sheets	O
,	O
β-turns	O
and	O
α-helix	O
content	O
in	O
TL	O
lipase	O
and	O
CALB	O
lipase	O
.	O

Also	O
,	O
fluorescence	B-P
spectroscopy	I-P
exhibited	O
the	O
increased	O
number	O
of	O
tryptophan	O
on	O
surface	O
of	O
both	O
lipases	O
.	O

Moreover	O
,	O
particle	O
size	O
distribution	O
after	O
sonication	O
also	O
helped	O
to	O
improve	O
surface	O
area	O
and	O
enhanced	O
mass	O
transfer	O
,	O
which	O
contributed	O
to	O
improvement	O
in	O
lipase	O
activity	O
.	O

Temperature	O
and	O
Plant	O
Genotype	O
Alter	O
Alkaloid	O
Concentrations	O
in	O
Ryegrass	O
Infected	O
with	O
an	O
Epichloë	O
Endophyte	O
and	O
This	O
Affects	O
an	O
Insect	O
Herbivore	O
.	O

Asexual	O
Epichloë	O
endophytes	O
colonize	O
agricultural	O
forage	O
grasses	O
in	O
a	O
relationship	O
which	O
is	O
mutually	O
beneficial	O
and	O
provides	O
the	O
host	O
plant	O
with	O
protection	O
against	O
herbivorous	O
insects	O
.	O

The	O
endophyte	O
strain	O
AR37	O
(	O
Epichloë	O
festucae	O
var	O
.	O

lolii	O
)	O
produces	O
epoxy-janthitrem	O
alkaloids	O
and	O
is	O
the	O
only	O
endophyte	O
known	O
to	O
provide	O
ryegrass	O
with	O
resistance	O
against	O
porina	O
larvae	O
(	O
Wiseana	O
cervinata	O
(	O
Walker	O
)	O
)	O
,	O
a	O
major	O
pasture	O
pest	O
in	O
cooler	O
areas	O
of	O
New	O
Zealand	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
temperature	O
on	O
concentrations	O
of	O
epoxy-janthitrems	O
in	O
AR37	O
-	O
infected	O
ryegrass	O
and	O
determined	O
how	O
the	O
resulting	O
variations	O
in	O
concentration	O
affected	O
consumption	O
,	O
growth	O
and	O
survival	O
of	O
porina	O
larvae	O
.	O

Twenty	O
replicate	O
pairs	O
of	O
perennial	O
(	O
Lolium	O
perenne	O
L.	O
)	O
and	O
Italian	O
ryegrass	O
(	O
L.	O
multiflorum	O
Lam	O
.	O
)	O

plants	O
with	O
and	O
without	O
endophyte	O
were	O
prepared	O
by	O
cloning	O
,	O
with	O
one	O
of	O
each	O
pair	O
grown	O
at	O
either	O
high	O
(	O
20°C	O
)	O
or	O
low	O
(	O
7°C	O
)	O
temperature	O
.	O

After	O
10	O
weeks	O
,	O
herbage	O
on	O
each	O
plant	O
was	O
harvested	O
,	O
divided	O
into	O
leaf	O
and	O
pseudostem	O
,	O
then	O
freeze	B-P
dried	I-P
and	O
ground	O
.	O

Leaf	O
and	O
pseudostem	O
material	O
was	O
then	O
incorporated	O
separately	O
into	O
semi	O
-	O
synthetic	O
diets	O
which	O
were	O
fed	O
to	O
porina	O
larvae	O
in	O
a	O
bioassay	B-P
over	O
3	O
weeks	O
.	O

Epoxy-janthitrem	O
concentrations	O
within	O
the	O
plant	O
materials	O
and	O
the	O
semi	O
-	O
synthetic	O
diets	O
were	O
analyzed	O
by	O
high	O
performance	O
liquid	B-P
chromatography	I-P
.	O

AR37	O
-	O
infected	O
ryegrass	O
grown	O
at	O
high	O
temperature	O
contained	O
high	O
in	O
plant	O
a	O
concentrations	O
of	O
epoxy-janthitrem	O
(	O
30.6	O
μg/g	O
in	O
leaves	O
and	O
83.9	O
μg/g	O
in	O
pseudostems	O
)	O
that	O
had	O
a	O
strong	O
anti-feedant	O
effect	O
on	O
porina	O
larvae	O
when	O
incorporated	O
into	O
their	O
diets	O
,	O
reducing	O
their	O
survival	O
by	O
25-42	O
%	O
on	O
pseudostems	O
.	O

In	O
comparison	O
,	O
in	O
planta	O
epoxy-janthitrem	O
concentrations	O
in	O
AR37	O
-	O
infected	O
ryegrass	O
grown	O
at	O
low	O
temperature	O
were	O
very	O
low	O
(	O
0.67	O
μg/g	O
in	O
leaves	O
and	O
7.4	O
μg/g	O
in	O
pseudostems	O
)	O
resulting	O
in	O
a	O
small	O
anti-feedant	O
effect	O
in	O
perennial	O
but	O
not	O
in	O
Italian	O
ryegrass	O
.	O

Although	O
alkaloid	O
concentrations	O
were	O
greatly	O
reduced	O
by	O
low	O
temperature	O
this	O
reduction	O
did	O
not	O
occur	O
until	O
after	O
4	O
weeks	O
of	O
exposure	O
.	O

Alkaloid	O
concentrations	O
were	O
slightly	O
lower	O
in	O
Italian	O
than	O
in	O
perennial	O
ryegrass	O
and	O
concentrations	O
were	O
higher	O
in	O
the	O
pseudostems	O
when	O
compared	O
with	O
the	O
leaves	O
.	O

In	O
conclusion	O
,	O
epoxy-janthitrems	O
expressed	O
by	O
the	O
AR37	O
endophyte	O
show	O
strong	O
activity	O
against	O
porina	O
larvae	O
.	O

However	O
,	O
when	O
ryegrass	O
plants	O
are	O
grown	O
at	O
a	O
constant	O
low	O
temperature	O
for	O
an	O
extended	O
period	O
of	O
time	O
in	O
planta	O
epoxy-janthitrem	O
concentrations	O
are	O
greatly	O
reduced	O
and	O
are	O
less	O
effective	O
against	O
this	O
pasture	O
pest	O
.	O

Influence	O
of	O
ozone	O
and	O
paracetic	O
acid	O
disinfection	O
on	O
adhesion	O
of	O
resilient	O
liners	O
to	O
acrylic	O
resin	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
paracetic	O
acid	O
(	O
PAA	O
)	O
and	O
ozone	O
disinfection	O
on	O
the	O
tensile	O
bond	O
strength	O
(	O
TBS	O
)	O
of	O
silicone-based	O
resilient	O
liners	O
to	O
acrylic	O
resins	O
.	O

One	O
hundred	O
and	O
twenty	O
dumbbell	O
shaped	O
heat-polymerized	O
acrylic	O
resins	O
were	O
prepared	O
.	O

From	O
the	O
mid	O
segment	O
of	O
the	O
specimens	O
,	O
3	O
mm	O
of	O
acrylic	O
were	O
grinded	O
off	O
and	O
separated	O
parts	O
were	O
reattached	O
by	O
resilient	O
liners	O
.	O

The	O
specimens	O
were	O
divided	O
into	O
2	O
control	O
(	O
control1	O
,	O
control7	O
)	O
and	O
4	O
test	O
groups	O
of	O
PAA	O
and	O
ozone	O
disinfection	O
(	O
PAA1	O
,	O
PAA7	O
,	O
ozone1	O
and	O
ozone7	O
;	O
n=10	O
)	O
.	O

While	O
control	O
groups	O
were	O
immersed	O
in	O
distilled	O
water	O
for	O
10	O
min	O
(	O
control1	O
)	O
and	O
7	O
days	O
(	O
control7	O
)	O
,	O
test	O
groups	O
were	O
subjected	O
to	O
PAA	O
(	O
16	O
g/L	O
)	O
or	O
ozone	O
rich	O
water	O
(	O
4	O
mg/L	O
)	O
for	O
1	O
cycle	O
(	O
10	O
min	O
for	O
PAA	O
and	O
60	O
min	O
for	O
ozone	O
)	O
per	O
day	O
for	O
7	O
days	O
prior	O
to	O
tensile	O
tests	B-P
.	O

Measurements	O
of	O
the	O
TBS	O
were	O
analyzed	O
using	O
3-way	O
ANOVA	O
and	O
Tukey	B-P
's	I-P
HSD	I-P
test	I-P
.	O

Adhesive	O
strength	O
of	O
Mollosil	O
decreased	O
significantly	O
by	O
application	O
of	O
ozone	O
disinfection	O
.	O

PAA	O
disinfection	O
had	O
no	O
negative	O
effect	O
on	O
the	O
TBS	O
values	O
of	O
Mollosil	O
and	O
Molloplast	O
B	O
to	O
acrylic	O
resin	O
.	O

Single	O
application	O
of	O
ozone	O
disinfection	O
did	O
not	O
have	O
any	O
negative	O
effect	O
on	O
TBS	O
values	O
of	O
Molloplast	O
B	O
,	O
but	O
prolonged	O
exposure	O
to	O
ozone	O
decreased	O
its	O
adhesive	O
strength	O
.	O

The	O
adhesion	O
of	O
resilient	O
liners	O
to	O
acrylic	O
was	O
not	O
adversely	O
affected	O
by	O
PAA	O
disinfection	O
.	O

Immersion	O
in	O
ozonated	O
water	O
significantly	O
decreased	O
TBS	O
of	O
Mollosil	O
.	O

Prolonged	O
exposure	O
to	O
ozone	O
negatively	O
affects	O
adhesion	O
of	O
Molloplast	O
B	O
to	O
denture	O
base	O
materials	O
.	O

Rapidly	O
Progressive	O
and	O
Almost	O
Lethal	O
Pneumonia	O
.	O

We	O
herein	O
describe	O
the	O
case	O
of	O
a	O
65-	O
year	O
-old	O
male	O
patient	O
who	O
presented	O
with	O
Osler	O
's	O
triad	O
,	O
which	O
is	O
the	O
combination	O
of	O
endocarditis	O
,	O
pneumonia	O
,	O
and	O
meningitis	O
.	O

This	O
report	O
is	O
even	O
more	O
unusual	O
since	O
the	O
pathogen	O
isolated	O
was	O
the	O
invasive	O
and	O
virulent	O
strain	O
of	O
Streptococcus	O
pneumoniae	O
serotype	O
3	O
.	O

The	O
clinical	O
entity	O
described	O
is	O
also	O
called	O
Austrian	O
syndrome	O
.	O

Even	O
though	O
rare	O
in	O
this	O
antibiotic	O
era	O
,	O
the	O
syndrome	O
remains	O
one	O
of	O
high	O
morbidity	O
and	O
mortality	O
.	O

This	O
particular	O
case	O
is	O
of	O
paramount	O
importance	O
for	O
the	O
clinician	O
reader	O
.	O

First	O
,	O
it	O
documents	O
the	O
clinical	O
features	O
associated	O
with	O
invasive	O
pneumococcal	O
disease	O
and	O
the	O
Austrian	O
syndrome	O
.	O

Second	O
,	O
and	O
equally	O
important	O
,	O
it	O
highlights	O
why	O
following	O
the	O
Surviving	O
Sepsis	O
Campaign	O
guidelines	O
saves	O
lives	O
.	O

For	O
this	O
case	O
,	O
the	O
following	O
steps	O
were	O
taken	O
:	O
1	O
.	O

As	O
a	O
surrogate	O
for	O
perfusion	O
,	O
early	O
and	O
aggressive	O
fluid	O
resuscitation	O
therapy	O
(	O
guided	O
by	O
lactic	B-P
acid	I-P
levels	I-P
)	O
was	O
instituted	O
;	O
2.	O
also	O
early	O
in	O
the	O
treatment	O
,	O
broad	O
spectrum	O
antibiotics	O
were	O
administered	O
;	O
3.	O
to	O
guide	O
antibiotic	O
therapy	O
,	O
microbiological	B-P
cultures	I-P
were	O
obtained	O
.	O

The	O
patient	O
subsequently	O
improved	O
and	O
was	O
transferred	O
to	O
the	O
internal	O
medicine	O
ward	O
to	O
complete	O
4	O
weeks	O
of	O
antibiotic	O
therapy	O
.	O

Human	O
Umbilical	O
Cord	O
Blood	O
-	O
Derived	O
Neural	O
Stem	O
Cell	O
Line	O
as	O
a	O
Screening	O
Model	O
for	O
Toxicity	O
.	O

The	O
aim	O
was	O
to	O
investigate	O
whether	O
a	O
human	O
neural	O
stem	O
cell	O
(	O
NSC	O
)	O
line	O
derived	O
from	O
human	O
umbilical	O
cord	O
blood	O
(	O
hUCB	O
)	O
can	O
be	O
used	O
for	O
toxicity	O
study	O
.	O

Toxicity	O
of	O
both	O
neurotoxic	O
environmental	O
xenobiotics	O
,	O
methyl	O
mercury	O
chloride	O
(	O
CH3HgCl	O
)	O
,	O
lead	O
acetate	O
(	O
CH3COOPb	O
)	O
,	O
and	O
chlorpyrifos	O
(	O
CP	O
)	O
,	O
and	O
non-neurotoxic	O
insecticide	O
,	O
dichlorvos	O
,	O
as	O
well	O
as	O
non-neurotoxic	O
drugs	O
,	O
theophylline	O
and	O
acetaminophen	O
were	O
assessed	O
.	O

Additionally	O
,	O
differentiation	O
of	O
neuronal	O
and	O
glial	O
cell	O
lines	O
derived	O
from	O
hUCB	O
was	O
elucidated	O
.	O

It	O
was	O
observed	O
that	O
CH3HgCl	O
was	O
more	O
toxic	O
to	O
human	O
NSCs	O
in	O
comparison	O
to	O
CH3COOPb	O
and	O
CP	O
.	O

The	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
value	O
against	O
NSCs	O
was	O
3	O
,	O
10	O
,	O
and	O
300	O
mg/L	O
,	O
in	O
each	O
staining	B-P
process	I-P
,	O
acridine	O
orange	O
/	O
ethidium	O
bromide	O
(	O
AO	O
/	O
EB	O
)	O
staining	B-P
,	O
3-	O
(	O
4,5-dimethylthiazol-2-yl	O
)	O
2,5-diphenyl	O
tetrazolium	O
bromide	O
(	O
MTT	O
)	O
assay	B-P
,	O
and	O
Hoechst	B-P
staining	I-P
,	O
for	O
CH3HgCl	O
,	O
CP	O
,	O
and	O
CH3COOPb	O
,	O
respectively	O
.	O

CH3HgCl	O
had	O
the	O
LC25	O
value	O
as	O
10.0	O
,	O
14.4	O
,	O
and	O
12.7	O
mg/L	O
,	O
by	O
staining	B-P
method	I-P
mentioned	O
in	O
succession	O
.	O

CP	O
had	O
the	O
LC25	O
value	O
as	O
21.9	O
,	O
23.7	O
,	O
and	O
18.4	O
mg/L	O
;	O
similarly	O
,	O
CH3COOPb	O
had	O
LC25	O
values	O
,	O
successively	O
as	O
616.9	O
,	O
719.2	O
,	O
and	O
890.3	O
mg/L	O
.	O

LC50	O
values	O
ranged	O
from	O
18.2	O
to	O
21.7	O
mg/L	O
for	O
CH3HgCl	O
,	O
56.4	O
to	O
60.2	O
mg/L	O
for	O
CP	O
,	O
and	O
1000	O
to	O
1460.1	O
for	O
CH3COOPb	O
.	O

Theophylline	O
,	O
acetaminophen	O
,	O
and	O
dichlorvos	O
had	O
no	O
impact	O
on	O
the	O
viability	O
of	O
NSCs	O
.	O

This	O
work	O
justified	O
that	O
hUCB	O
-	O
NSC	O
model	O
can	O
be	O
used	O
for	O
toxicity	O
study	O
.	O

Risk	O
Factors	O
for	O
Infection	O
After	O
Knee	B-P
Arthroscopy	I-P
:	O
Analysis	O
of	O
595,083	O
Cases	O
From	O
3	O
United	O
States	O
Databases	O
.	O

To	O
identify	O
and	O
quantify	O
patient-	O
and	O
procedure-related	O
risk	O
factors	O
for	O
post-arthroscopic	O
knee	O
infections	O
using	O
a	O
large	O
dataset	O
.	O

An	O
administrative	O
health	O
care	O
database	O
including	O
8	O
years	O
of	O
records	O
from	O
2	O
large	O
commercial	O
insurers	O
and	O
Medicare	O
(	O
a	O
5	O
%	O
random	O
sample	O
)	O
was	O
queried	O
to	O
identify	O
all	O
knee	B-P
arthroscopies	I-P
performed	O
on	O
patients	O
aged	O
at	O
least	O
15	O
years	O
using	O
Current	O
Procedural	O
Terminology	O
(	O
CPT	O
)	O
codes	O
.	O

Each	O
CPT	O
code	O
was	O
designated	O
as	O
a	O
high-	O
or	O
low-complexity	O
procedure	O
,	O
with	O
the	O
former	O
typically	O
requiring	O
accessory	O
incisions	O
or	O
increased	O
operative	O
time	O
.	O

Deep	O
infections	O
were	O
identified	O
by	O
a	O
CPT	O
code	O
for	O
incision	O
and	O
drainage	O
within	O
90	O
days	O
of	O
surgery	O
.	O

Superficial	O
infections	O
were	O
identified	O
by	O
International	O
Classification	O
of	O
Diseases	O
,	O
Ninth	O
Revision	O
infection	O
codes	O
without	O
any	O
record	O
of	O
incision	O
and	O
drainage	O
.	O

Patients	O
were	O
compared	O
based	O
on	O
age	O
,	O
sex	O
,	O
body	O
mass	O
index	O
,	O
tobacco	O
use	O
,	O
presence	O
of	O
diabetes	O
,	O
and	O
Charlson	O
Comorbidity	O
Index	O
.	O

A	O
total	O
of	O
526,537	O
patients	O
underwent	O
595,083	O
arthroscopic	B-P
knee	I-P
procedures	I-P
.	O

Deep	O
postoperative	O
infections	O
occurred	O
at	O
a	O
rate	O
of	O
0.22	O
%	O
.	O

Superficial	O
infections	O
occurred	O
at	O
a	O
rate	O
of	O
0.29	O
%	O
.	O

Tobacco	O
use	O
and	O
morbid	O
obesity	O
were	O
the	O
largest	O
risk	O
factors	O
for	O
deep	O
and	O
superficial	O
infections	O
,	O
respectively	O
(	O
P	O
<	O
.001	O
;	O
relative	O
risk	O
of	O
1.90	O
and	O
2.19	O
,	O
respectively	O
)	O
.	O

There	O
were	O
also	O
higher	O
infection	O
rates	O
among	O
patients	O
undergoing	O
relatively	O
high-complexity	B-P
arthroscopies	I-P
,	O
men	O
,	O
obese	O
patients	O
,	O
diabetic	O
patients	O
,	O
and	O
younger	O
patients	O
(	O
in	O
order	O
of	O
decreasing	O
relative	O
risk	O
)	O
.	O

Increased	O
Charlson	O
Comorbidity	O
Index	O
was	O
associated	O
with	O
superficial	O
and	O
total	O
infections	O
(	O
P	O
<	O
.001	O
)	O
.	O

Post-arthroscopic	O
knee	O
infections	O
were	O
more	O
frequent	O
among	O
morbidly	O
obese	O
patients	O
,	O
tobacco	O
users	O
,	O
patients	O
undergoing	O
relatively	O
complex	O
procedures	O
,	O
men	O
,	O
obese	O
patients	O
,	O
diabetic	O
patients	O
,	O
relatively	O
young	O
patients	O
,	O
and	O
patients	O
with	O
increased	O
comorbidity	O
burdens	O
in	O
this	O
study	O
population	O
.	O

This	O
knowledge	O
may	O
allow	O
more	O
informed	O
preoperative	O
counseling	O
,	O
aid	O
surgeons	O
in	O
patient	O
selection	O
,	O
and	O
facilitate	O
infection	O
prevention	O
by	O
targeting	O
individuals	O
with	O
higher	O
inherent	O
risk	O
.	O

Level	O
IV	O
,	O
cross-sectional	O
study	O
.	O

Identification	O
of	O
Predictive	O
DNA	O
Methylation	O
Biomarkers	O
for	O
Chemotherapy	O
Response	O
in	O
Colorectal	O
Cancer	O
.	O

Resistance	O
to	O
5-Fluorouracil	O
(	O
5-FU	O
)	O
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	O
of	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
and	O
posed	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O

DNA	O
methylation	O
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
underlying	O
mechanisms	O
for	O
recurrent	O
disease	O
and	O
its	O
contribution	O
to	O
the	O
development	O
of	O
drug	O
resistance	O
remains	O
to	O
be	O
clarified	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
methylation	O
phenotype	O
in	O
CRC	O
for	O
identification	O
of	O
predictive	O
markers	O
for	O
chemotherapy	O
response	O
.	O

We	O
performed	O
DNA	O
methylation	O
profiling	O
on	O
43	O
non-recurrent	O
and	O
five	O
recurrent	O
CRC	O
patients	O
using	O
the	O
Illumina	O
Infinium	O
HumanMethylation450	O
Beadchip	O
assay	O
.	O

In	O
addition	O
,	O
CRC	O
cells	O
with	O
different	O
genetic	O
backgrounds	O
,	O
response	O
to	O
5-FU	O
and	O
global	O
methylation	O
levels	O
(	O
HT29	O
and	O
SW48	O
)	O
were	O
treated	O
with	O
5-FU	O
and	O
DNA	O
methylation	O
inhibitor	O
5-aza-2'-deoxycytidine	O
(	O
5-azadC	O
)	O
.	O

The	O
singular	O
and	O
combined	O
effects	O
of	O
these	O
two	O
drug	O
classes	O
on	O
cell	O
viability	O
and	O
global	O
methylation	O
profiles	B-P
were	O
investigated	O
.	O

Our	O
genome-wide	O
methylation	O
study	O
on	O
the	O
clinical	O
specimens	O
showed	O
that	O
recurrent	O
CRCs	O
exhibited	O
higher	O
methylation	O
levels	O
compared	O
to	O
non-recurrent	O
CRCs	O
.	O

We	O
identified	O
4787	O
significantly	O
differentially	O
methylated	O
genes	O
(	O
P	O
<	O
0.05	O
)	O
;	O
3112	O
genes	O
were	O
hyper	O
-	O
while	O
1675	O
genes	O
were	O
hypomethylated	O
in	O
the	O
recurrent	O
group	O
compared	O
to	O
the	O
non-recurrent	O
.	O

Fifty	O
eight	O
and	O
47	O
of	O
the	O
significantly	O
hypermethylated	O
and	O
hypomethylated	O
genes	O
have	O
an	O
absolute	O
recurrent	O
/	O
non-recurrent	O
methylation	O
difference	O
of	O
≥20	O
%	O
.	O

Most	O
of	O
the	O
hypermethylated	O
genes	O
were	O
involved	O
in	O
the	O
MAPK	O
signaling	O
pathway	O
which	O
is	O
a	O
key	O
regulator	O
for	O
apoptosis	O
while	O
the	O
hypomethylated	O
genes	O
were	O
involved	O
in	O
the	O
PI3K-AKT	O
signaling	O
pathway	O
and	O
proliferation	O
process	O
.	O

We	O
also	O
demonstrate	O
that	O
5-azadC	O
treatment	O
enhanced	O
response	O
to	O
5-FU	O
which	O
resulted	O
in	O
significant	O
growth	O
inhibition	O
compared	O
to	O
5-FU	O
alone	O
in	O
hypermethylated	O
cell	O
lines	O
SW48	O
.	O

In	O
conclusion	O
,	O
we	O
found	O
the	O
evidence	O
of	O
five	O
potentially	O
biologically	O
important	O
genes	O
in	O
recurrent	O
CRCs	O
that	O
could	O
possibly	O
serve	O
as	O
a	O
new	O
potential	O
therapeutic	O
targets	O
for	O
patients	O
with	O
chemoresistance	O
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	O
of	O
CCNEI	O
,	O
CCNDBP1	O
,	O
PON3	O
,	O
DDX43	O
,	O
and	O
CHL1	O
in	O
CRC	O
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
CRC	O
and	O
5-azadC	O
-mediated	O
restoration	O
of	O
5-FU	O
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	O
signaling	O
pathway	O
.	O

Evolutionary	O
History	O
and	O
Ongoing	O
Transmission	O
of	O
Phylogenetic	O
Sublineages	O
of	O
Mycobacterium	O
tuberculosis	O
Beijing	O
Genotype	O
in	O
China	O
.	O

Mycobacterium	O
tuberculosis	O
Beijing	O
genotype	O
originated	O
in	O
China	O
and	O
has	O
undergone	O
a	O
dramatic	O
population	O
growth	O
and	O
global	O
spread	O
in	O
the	O
last	O
century	O
.	O

Here	O
,	O
a	O
collection	B-P
of	O
M.	O
tuberculosis	O
Beijing	O
family	O
isolates	O
from	O
different	O
provinces	O
across	O
all	O
China	O
was	O
genotyped	O
by	O
high-resolution	O
(	O
24-MIRU-VNTR	O
)	O
and	O
low-resolution	O
,	O
high-rank	O
(	O
modern	O
and	O
ancient	O
sublineages	O
)	O
markers	O
.	O

The	O
molecular	O
profiles	O
and	O
global	O
and	O
local	O
phylogenies	O
were	O
compared	O
to	O
the	O
strain	O
phenotype	O
and	O
patient	O
data	O
.	O

The	O
phylogeographic	O
patterns	O
observed	O
in	O
the	O
studied	B-P
collection	B-P
demonstrate	O
that	O
large-scale	O
(	O
but	O
not	O
middle/small-scale	O
)	O
distance	O
remains	O
one	O
of	O
the	O
decisive	O
factors	O
of	O
the	O
genetic	O
divergence	O
of	O
M.	O
tuberculosis	O
populations	O
.	O

Analysis	O
of	O
diversity	O
and	O
network	O
topology	O
of	O
the	O
local	O
collections	B-P
appears	O
to	O
corroborate	O
a	O
recent	O
intriguing	O
hypothesis	O
about	O
Beijing	O
genotype	O
originating	O
in	O
South	O
China	O
.	O

Placing	O
our	O
results	O
within	O
the	O
Eurasian	O
context	O
suggested	O
that	O
important	O
Russian	O
B0/W148	O
and	O
Asian	O
/	O
Russian	O
A0/94-32	O
epidemic	O
clones	O
of	O
the	O
Beijing	O
genotype	O
could	O
trace	O
their	O
origins	O
to	O
the	O
northeastern	O
and	O
northwestern	O
regions	O
of	O
China	O
,	O
respectively	O
.	O

The	O
higher	O
clustering	O
of	O
the	O
modern	O
isolates	O
in	O
children	O
and	O
lack	O
of	O
increased	O
MDR	O
rate	O
in	O
any	O
sublineage	O
suggest	O
that	O
not	O
association	O
with	O
drug	O
resistance	O
but	O
other	O
(	O
e.g.	O
,	O
speculatively	O
,	O
virulence	O
-related	O
)	O
properties	O
underlie	O
an	O
enhanced	O
dissemination	O
of	O
the	O
evolutionarily	O
recent	O
,	O
modern	O
sublineage	O
of	O
the	O
Beijing	O
genotype	O
in	O
China	O
.	O

Extract	O
of	O
Caulis	O
Spatholobi	O
,	O
a	O
novel	O
blocker	O
targeting	O
tumor	O
cell	O
‑induced	O
platelet	O
aggregation	O
,	O
inhibits	O
breast	O
cancer	O
metastasis	O
.	O

Metastasis	O
of	O
breast	O
cancer	O
is	O
the	O
vital	O
step	O
for	O
malignant	O
progression	O
.	O

During	O
such	O
a	O
process	O
,	O
hematogenous	O
metastasis	O
is	O
an	O
indispensable	O
approach	O
for	O
the	O
dissemination	O
of	O
cancer	O
cells	O
.	O

A	O
platelet	O
,	O
contributes	O
to	O
hypercoagulable	O
state	O
,	O
and	O
is	O
also	O
identified	O
the	O
crucial	O
factor	O
in	O
the	O
coagulation	O
system	O
for	O
supporting	O
metastasis	O
.	O

Therefore	O
,	O
the	O
relationship	O
of	O
a	O
platelet	O
and	O
a	O
tumor	O
cell	O
plays	O
a	O
critical	O
role	O
in	O
tumor	O
cell	O
metastasis	O
.	O

Consequently	O
,	O
inhibiting	O
tumor	O
cell	O
‑induced	O
platelet	O
aggregation	O
(	O
TCIPA	O
)	O
is	O
recongnized	O
as	O
a	O
crucial	O
target	O
on	O
suppression	O
of	O
tumor	O
metastasis	O
such	O
as	O
aspirin	O
(	O
ASA	O
)	O
.	O

Under	O
such	O
circumstance	O
,	O
here	O
we	O
report	O
that	O
,	O
through	O
dissociating	O
the	O
tumor‑platelet	O
(	O
T‑P	O
)	O
complex	O
,	O
80	O
%	O
ethanol	O
extracts	O
of	O
Caulis	O
Spatholobi	O
(	O
SET	O
)	O
successfully	O
alleviated	O
the	O
hypercoagulation	O
state	O
,	O
thereby	O
reducing	O
tumor	O
metastasis	O
and	O
improving	O
the	O
prospects	O
of	O
survival	O
in	O
breast	O
cancer	O
cell	O
model	O
.	O

Through	O
MTT	B-P
and	O
anti‑aggregation	B-P
assay	I-P
stimulated	I-P
by	I-P
ADP	I-P
,	O
we	O
detected	O
the	O
optimum	O
treatment	O
time	O
and	O
the	O
optimum	O
dose	O
of	O
SET	O
.	O

By	O
using	O
confocal	B-P
microscopy	I-P
,	O
we	O
observed	O
that	O
SET	O
can	O
strongly	O
block	O
the	O
formation	O
of	O
T‑P	O
complex	O
i	O
n	O
vitro	O
.	O

The	O
result	O
was	O
further	O
quantified	O
and	O
confirmed	O
by	O
the	O
FACS	B-P
analysis	I-P
.	O

The	O
fluorescent	O
value	O
of	O
T‑P	O
complex	O
was	O
obviously	O
decreased	O
in	O
the	O
drug‑treated	O
groups	O
.	O

In	O
vivo	O
,	O
4T1	O
cells	O
were	O
injected	O
through	O
the	O
mouse	O
tail	O
vein	O
for	O
dynamic	B-P
visualization	I-P
by	O
small	O
animal	O
imaging	O
system	O
.	O

The	O
metastatic	O
intensity	O
was	O
quantified	O
and	O
the	O
survival	O
curve	O
was	O
analyzed	O
.	O

Additionally	O
,	O
general	O
observation	O
and	O
hematoxylin	B-P
and	I-P
eosin	I-P
(	I-P
H	I-P
&	I-P
E	I-P
)	I-P
staining	I-P
of	O
lung	O
tissue	O
was	O
performed	O
.	O

SET	O
exerted	O
an	O
obvious	O
effect	O
on	O
the	O
inhibition	O
of	O
metastasis	O
and	O
increasing	O
the	O
survival	O
rate	O
of	O
mice	O
.	O

For	O
the	O
molecular	O
mechanism	O
study	O
of	O
anti‑TCIPA	B-P
,	O
zymography	O
and	O
R	O
T‑PCR	O
assay	O
preliminarily	O
revealed	O
the	O
molecular	O
mechanism	O
of	O
SET	O
in	O
the	O
regulation	O
of	O
P	O
‑T	O
interaction	O
.	O

Collectively	O
,	O
through	O
drug	O
efficacy	O
identification	O
and	O
pharmacological	O
revealing	O
,	O
we	O
have	O
obtained	O
a	O
promising	O
candidate	O
for	O
the	O
interference	O
of	O
breast	O
metastasis	O
by	O
suppressing	O
TCIPA	O
,	O
which	O
will	O
be	O
beneficial	O
for	O
clinical	O
cancer	O
treatment	O
.	O

Involvement	O
of	O
apoptotic	O
pathways	O
in	O
docosahexaenoic	O
acid	O
-induced	O
benefit	O
in	O
prostate	O
cancer	O
:	O
Pathway-focused	O
gene	O
expression	O
analysis	O
using	O
RT	O
(	O
2	O
)	O
Profile	O
PCR	O
Array	O
System	O
.	O

Present	O
study	O
aimed	O
to	O
better	O
understand	O
the	O
potential	O
apoptotic	O
pathways	O
that	O
involved	O
in	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
-induced	O
apoptosis	O
of	O
prostate	O
cancer	O
cells	O
.	O

Human	O
prostate	O
cancer	O
DU145	O
cells	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
fish	O
oil	O
,	O
omega-3	O
PUFA	O
(	O
DHA	O
,	O
and	O
Eicosapentaenoic	O
acid	O
,	O
EPA	O
)	O
,	O
or	O
omega-6	O
PUFA	O
(	O
Arachidonic	O
acid	O
,	O
AA	O
)	O
.	O

Cell	O
viability	O
and	O
apoptosis	O
were	O
evaluated	O
by	O
MTT	O
assay	O
and	O
Hoechst	B-P
staining	I-P
.	O

Pathway-focused	O
gene	O
expression	O
profiling	O
of	O
DU145	O
cells	O
was	O
analyzed	O
with	O
the	O
RT	O
(	O
2	O
)	O
Profile	O
PCR	O
Array	O
System	O
.	O

The	O
results	O
were	O
verified	O
by	O
real	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT-qPCR	O
)	O
.	O

AA	O
exposure	O
showed	O
no	O
obvious	O
effect	O
on	O
viability	O
of	O
DU145	O
cells	O
.	O

However	O
,	O
exposure	O
with	O
fish	O
oil	O
,	O
EPA	O
,	O
or	O
DHA	O
for	O
24	O
h	O
significantly	O
affected	O
cell	O
viability	O
.	O

The	O
growth	O
inhibition	O
of	O
DHA	O
was	O
more	O
pronounced	O
than	O
that	O
of	O
EPA	O
and	O
showed	O
a	O
time-dependent	O
increase	O
.	O

DHA	O
exposure	O
caused	O
typical	O
apoptotic	O
characteristics	O
.	O

Ten	O
genes	O
were	O
more	O
expressed	O
,	O
while	O
5	O
genes	O
were	O
less	O
expressed	O
following	O
DHA	O
exposure	O
.	O

RT-qPCR	O
confirmed	O
the	O
time	O
dependent	O
effect	O
of	O
DHA	O
on	O
the	O
expression	O
of	O
these	O
differentially	O
expressed	O
genes	O
.	O

KEGG	O
pathway	O
analysis	O
showed	O
that	O
DHA	O
may	O
induce	O
the	O
apoptosis	O
of	O
cancer	O
cells	O
preferentially	O
through	O
mediating	O
P53	O
,	O
MAPK	O
,	O
TNF	O
,	O
PI3K/AKT	O
,	O
and	O
NF-κB	O
signaling	O
pathways	O
.	O

Our	O
study	O
demonstrated	O
the	O
beneficial	O
action	O
of	O
DHA	O
on	O
human	O
prostate	O
carcinoma	O
cell	O
line	O
DU145	O
.	O

The	O
pro-apoptotic	O
effect	O
of	O
DHA	O
on	O
DU145	O
cells	O
may	O
involve	O
mediation	O
various	O
pathways	O
,	O
especially	O
P53	O
,	O
MAPK	O
,	O
TNF	O
,	O
PI3K/AKT	O
,	O
and	O
NF-κB	O
signaling	O
pathways	O
.	O

Molecular	O
mechanisms	O
of	O
DHA	O
on	O
apoptosis	O
of	O
cancer	O
cells	O
still	O
need	O
to	O
be	O
further	O
clarified	O
.	O

In	O
Vivo	O
3-Dimensional	O
Strain	O
Mapping	O
Confirms	O
Large	O
Optic	O
Nerve	O
Head	O
Deformations	O
Following	O
Horizontal	O
Eye	O
Movements	O
.	O

To	O
measure	O
lamina	O
cribrosa	O
(	O
LC	O
)	O
strains	O
(	O
deformations	O
)	O
following	O
abduction	O
and	O
adduction	O
in	O
healthy	O
subjects	O
and	O
to	O
compare	O
them	O
with	O
those	O
resulting	O
from	O
a	O
relatively	O
high	O
acute	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
elevation	O
.	O

A	O
total	O
of	O
16	O
eyes	O
from	O
8	O
healthy	O
subjects	O
were	O
included	O
.	O

Among	O
the	O
16	O
eyes	O
,	O
11	O
had	O
peripapillary	O
atrophy	O
(	O
PPA	O
)	O
.	O

For	O
each	O
subject	O
,	O
both	O
optic	O
nerve	O
heads	O
(	O
ONHs	O
)	O
were	O
imaged	O
using	O
optical	B-P
coherence	I-P
tomography	I-P
(	O
OCT	B-P
)	O
at	O
baseline	O
(	O
twice	O
)	O
,	O
in	O
different	O
gaze	O
positions	O
(	O
adduction	O
and	O
abduction	O
of	O
20°	O
)	O
and	O
following	O
an	O
acute	O
IOP	O
elevation	O
of	O
approximately	O
20	O
mm	O
Hg	O
from	O
baseline	O
(	O
via	O
ophthalmodynamometry	B-P
)	O
.	O

Strains	O
of	O
LC	O
for	O
all	O
loading	O
scenarios	O
were	O
mapped	O
using	O
a	O
three-dimensional	O
tracking	O
algorithm	O
.	O

In	O
all	O
16	O
eyes	O
,	O
LC	O
strains	O
induced	O
by	O
adduction	O
and	O
abduction	O
were	O
5.83	O
%	O
±	O
3.78	O
%	O
and	O
3.93	O
%	O
±	O
2.57	O
%	O
,	O
respectively	O
,	O
and	O
both	O
significantly	O
higher	O
than	O
the	O
control	O
strains	O
measured	O
from	O
the	O
repeated	O
baseline	O
acquisitions	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Strains	O
of	O
LC	O
in	O
adduction	O
were	O
on	O
average	O
higher	O
than	O
those	O
in	O
abduction	O
,	O
but	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0.07	O
)	O
.	O

Strains	O
of	O
LC	O
induced	O
by	O
IOP	O
elevations	O
(	O
on	O
average	O
21.13	O
±	O
7.61	O
mm	O
Hg	O
)	O
were	O
6.41	O
%	O
±	O
3.21	O
%	O
and	O
significantly	O
higher	O
than	O
the	O
control	O
strains	O
(	O
P	O
<	O
0.0005	O
)	O
.	O

Gaze	O
-	O
induced	O
LC	O
strains	O
in	O
the	O
PPA	O
group	O
were	O
on	O
average	O
larger	O
than	O
those	O
in	O
the	O
non-PPA	O
group	O
;	O
however	O
,	O
the	O
relationship	O
was	O
not	O
statistically	O
significant	O
.	O

Our	O
results	O
confirm	O
that	O
horizontal	O
eye	O
movements	O
generate	O
significant	O
ONH	O
strains	O
,	O
which	O
is	O
consistent	O
with	O
our	O
previous	O
estimations	O
using	O
finite	O
element	O
analysis	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
explore	O
a	O
possible	O
link	O
between	O
ONH	O
strains	O
induced	O
by	O
eye	O
movements	O
and	O
axonal	O
loss	O
in	O
optic	O
neuropathies	O
.	O

Medial	O
Patellofemoral	O
Ligament	O
Reconstruction	O
Femoral	O
Tunnel	O
Accuracy	O
:	O
Relationship	O
to	O
Disease	O
-	O
Specific	O
Quality	O
of	O
Life	O
.	O

Medial	O
patellofemoral	O
ligament	O
(	O
MPFL	O
)	O
reconstruction	O
is	O
a	O
procedure	O
aimed	O
to	O
reestablish	O
the	O
checkrein	O
to	O
lateral	O
patellar	O
translation	O
in	O
patients	O
with	O
symptomatic	O
patellofemoral	O
instability	O
.	O

Correct	O
femoral	O
tunnel	O
position	O
is	O
thought	O
to	O
be	O
crucial	O
to	O
successful	O
MPFL	O
reconstruction	O
,	O
but	O
the	O
accuracy	O
of	O
this	O
statement	O
in	O
terms	O
of	O
patient	O
outcomes	O
has	O
not	O
been	O
tested	O
.	O

To	O
assess	O
the	O
accuracy	O
of	O
femoral	O
tunnel	O
placement	O
in	O
an	O
MPFL	O
reconstruction	O
cohort	O
and	O
to	O
determine	O
the	O
correlation	O
between	O
tunnel	O
accuracy	O
and	O
a	O
validated	O
disease	O
-	O
specific	O
,	O
patient	O
-reported	O
quality-of-life	O
outcome	O
measure	O
.	O

Case	O
series	O
;	O
Level	O
of	O
evidence	O
,	O
4	O
.	O

Between	O
June	O
2008	O
and	O
February	O
2014	O
,	O
a	O
total	O
of	O
206	O
subjects	O
underwent	O
an	O
MPFL	O
reconstruction	O
.	O

Lateral	O
radiographs	B-P
were	O
measured	O
to	O
determine	O
the	O
accuracy	O
of	O
the	O
femoral	O
tunnel	O
by	O
measuring	O
the	O
distance	O
from	O
the	O
center	O
of	O
the	O
femoral	O
tunnel	O
to	O
the	O
Schöttle	O
point	O
.	O

Banff	O
Patella	O
Instability	O
Instrument	O
(	O
BPII	O
)	O
scores	O
were	O
collected	O
a	O
mean	O
24	O
months	O
postoperatively	O
.	O

A	O
total	O
of	O
155	O
(	O
79.5	O
%	O
)	O
subjects	O
had	O
adequate	O
postoperative	O
lateral	O
radiographs	B-P
and	O
complete	O
BPII	O
scores	O
.	O

The	O
mean	O
duration	O
of	O
follow-up	O
(	O
±	O
SD	O
)	O
was	O
24.4	O
±	O
8.2	O
months	O
(	O
range	O
,	O
12-74	O
months	O
)	O
.	O

Measurement	O
from	O
the	O
center	O
of	O
the	O
femoral	O
tunnel	O
to	O
the	O
Schöttle	O
point	O
resulted	O
in	O
143	O
(	O
92.3	O
%	O
)	O
tunnel	O
s	O
being	O
categorized	O
as	O
``	O
good	O
``	O
or	O
``	O
ideal	O
.	O
''	O

There	O
were	O
8	O
failures	O
in	O
the	O
cohort	O
,	O
none	O
of	O
which	O
occurred	O
in	O
malpositioned	O
tunnels	O
.	O

The	O
mean	O
distance	O
from	O
the	O
center	O
of	O
the	O
MPFL	O
tunnel	O
to	O
the	O
center	O
of	O
the	O
Schöttle	O
point	O
was	O
5.9	O
±	O
4.2	O
mm	O
(	O
range	O
,	O
0.5-25.9	O
mm	O
)	O
.	O

The	O
mean	O
postoperative	O
BPII	O
score	O
was	O
65.2	O
±	O
22.5	O
(	O
range	O
,	O
9.2-100	O
)	O
.	O

Pearson	O
r	O
correlation	O
demonstrated	O
no	O
statistically	O
significant	O
relationship	O
between	O
accuracy	O
of	O
femoral	O
tunnel	O
position	O
and	O
BPII	O
score	O
(	O
r	O
=	O
-0.08	O
;	O
95	O
%	O
CI	O
,	O
-0.24	O
to	O
0.08	O
)	O
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
correlation	O
between	O
the	O
accuracy	O
of	O
MPFL	O
reconstruction	O
femoral	O
tunnel	O
in	O
relation	O
to	O
the	O
Schöttle	O
point	O
and	O
disease	O
-	O
specific	O
quality-of-life	O
scores	O
.	O

Graft	O
failure	O
was	O
not	O
related	O
to	O
femoral	O
tunnel	O
placement	O
.	O

The	O
patellofemoral	O
instability	O
population	O
is	O
complex	O
,	O
and	O
patients	O
present	O
with	O
multiple	O
risk	O
factors	O
that	O
,	O
in	O
addition	O
to	O
the	O
accuracy	O
of	O
femoral	O
tunnel	O
position	O
,	O
contribute	O
to	O
quality	O
of	O
life	O
and	O
warrant	O
further	O
investigation	O
.	O

Morphogenetic	O
Alterations	O
of	O
Alternaria	O
alternata	O
Exposed	O
to	O
Dicarboximide	O
Fungicide	O
,	O
Iprodione	O
.	O

Fungicide-resistant	O
Alternaria	O
alternata	O
impede	O
the	O
practical	O
control	O
of	O
the	O
Alternaria	O
diseases	O
in	O
crop	O
fields	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
cytological	O
fungicide	O
resistance	O
mechanisms	O
of	O
A.	O
alternata	O
against	O
dicarboximide	O
fungicide	O
iprodione	O
.	O

A.	O
alternata	O
isolated	O
from	O
cactus	O
brown	O
spot	O
was	O
cultured	B-P
on	O
potato-dextrose	O
agar	O
(	O
PDA	O
)	O
with	O
or	O
without	O
iprodione	O
,	O
and	O
the	O
fungal	B-P
cultures	I-P
with	O
different	O
growth	O
characteristics	O
from	O
no	O
,	O
initial	O
and	O
full	O
growth	O
were	O
observed	O
by	O
light	B-P
and	O
electron	B-P
microscopy	I-P
.	O

Mycelia	O
began	O
to	O
grow	O
from	O
one	O
day	O
after	O
incubation	O
(	O
DAI	O
)	O
and	O
continued	O
to	O
be	O
in	O
full	O
growth	O
(	O
control-growth	O
,	O
Con-G	O
)	O
on	O
PDA	O
without	O
fungicide	O
,	O
while	O
on	O
PDA	O
with	O
iprodione	O
,	O
no	O
fungal	O
growth	O
(	O
iprodione-no	O
growth	O
,	O
Ipr-N	O
)	O
occurred	O
for	O
the	O
first	O
3	O
DAI	O
,	O
but	O
once	O
the	O
initial	O
growth	O
(	O
iprodione-initial	O
growth	O
,	O
Ipr-I	O
)	O
began	O
at	O
4-5	O
DAI	O
,	O
the	O
colonies	O
grew	O
and	O
expanded	O
continuously	O
to	O
be	O
in	O
full	O
growth	O
(	O
iprodione-growth	O
,	O
Ipr-G	O
)	O
,	O
suggesting	O
Ipr-I	O
may	O
be	O
a	O
turning	O
moment	O
of	O
the	O
morphogenetic	O
changes	O
resisting	O
fungicidal	O
toxicity	O
.	O

Con-G	O
formed	O
multicellular	O
conidia	O
with	O
cell	O
walls	O
and	O
septa	O
and	O
intact	O
dense	O
cytoplasm	O
.	O

In	O
Ipr-N	O
,	O
fungal	O
sporulation	O
was	O
inhibited	O
by	O
forming	O
mostly	O
undeveloped	O
unicellular	O
conidia	O
with	O
degraded	O
and	O
necrotic	O
cytoplasm	O
.	O

However	O
,	O
in	O
Ipr-I	O
,	O
conspicuous	O
cellular	O
changes	O
occurred	O
during	O
sporulation	O
by	O
forming	O
multicellular	O
conidia	O
with	O
double	O
layered	O
(	O
thickened	O
)	O
cell	O
walls	O
and	O
accumulation	O
of	O
proliferated	O
lipid	O
bodies	O
in	O
the	O
conidial	O
cytoplasm	O
,	O
which	O
may	O
inhibit	O
the	O
penetration	O
of	O
the	O
fungicide	O
into	O
conidial	O
cells	O
,	O
reducing	O
fungicide	O
-	O
associated	O
toxicity	O
,	O
and	O
may	O
be	O
utilized	O
as	O
energy	O
and	O
nutritional	O
sources	O
,	O
respectively	O
,	O
for	O
the	O
further	O
fungal	O
growth	O
to	O
form	O
mature	O
colonies	O
as	O
in	O
Ipr-G	O
that	O
formed	O
multicellular	O
conidia	O
with	O
cell	O
walls	O
and	O
intact	O
cytoplasm	O
with	O
lipid	O
bodies	O
as	O
in	O
Con-G	O
.	O

Cardiovascular	O
comorbidity	O
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
in	O
the	O
Canary	O
Islands	O
(	O
CCECAN	O
study	O
)	O
.	O

Numerous	O
studies	B-P
have	O
shown	O
a	O
high	O
prevalence	O
of	O
cardiovascular	O
disease	O
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyse	O
the	O
prevalence	O
of	O
cardiovascular	O
risk	O
factors	O
and	O
comorbidity	O
in	O
a	O
Canary	O
Islands	O
population	O
diagnosed	O
with	O
COPD	O
,	O
and	O
compared	O
it	O
with	O
data	O
from	O
the	O
general	O
population	O
.	O

A	O
cross-sectional	O
study	O
was	O
carried	O
out	O
in	O
300	O
patients	O
with	O
COPD	O
and	O
524	O
subjects	O
without	O
respiratory	O
disease	O
(	O
control	O
group	O
)	O
.	O

The	O
two	O
groups	O
were	O
compared	O
using	O
standard	O
bivariate	O
methods	O
.	O

Logistic	O
regression	O
models	O
were	O
used	O
to	O
estimate	O
the	O
cardiovascular	O
risks	O
in	O
COPD	O
patients	O
compared	O
to	O
control	O
group	O
.	O

Patients	O
with	O
COPD	O
showed	O
a	O
high	O
prevalence	O
of	O
hypertension	O
(	O
72	O
%	O
)	O
,	O
dyslipidaemia	O
(	O
73	O
%	O
)	O
,	O
obesity	O
(	O
41	O
%	O
)	O
,	O
diabetes	O
type	O
2	O
(	O
39	O
%	O
)	O
,	O
and	O
sleep	O
apnoea	O
syndrome	O
(	O
30	O
%	O
)	O
from	O
mild	O
stages	B-P
of	I-P
the	I-P
disease	I-P
(	O
GOLD	O
2009	O
)	O
.	O

There	O
was	O
a	O
22	O
%	O
prevalence	O
of	O
cardiac	O
arrhythmia	O
,	O
16	O
%	O
of	O
ischaemic	O
heart	O
disease	O
,	O
16	O
%	O
heart	O
failure	O
,	O
12	O
%	O
peripheral	O
vascular	O
disease	O
,	O
and	O
8	O
%	O
cerebrovascular	O
disease	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
patients	O
with	O
COPD	O
had	O
a	O
higher	O
risk	O
of	O
dyslipidaemia	O
(	O
OR	O
3.24	O
,	O
95	O
%	O
CI	O
;	O
2.21-4.75	O
)	O
,	O
diabetes	O
type	O
2	O
(	O
OR	O
1.52	O
,	O
95	O
%	O
CI	O
;	O
1.01-2,28	O
)	O
,	O
and	O
ischaemic	O
heart	O
disease	O
(	O
OR	O
2.34	O
,	O
95	O
%	O
CI	O
;	O
1.22-4.49	O
)	O
.	O

In	O
the	O
case	O
of	O
dyslipidaemia	O
,	O
an	O
increased	O
risk	O
was	O
obtained	O
when	O
adjusted	O
for	O
age	O
,	O
gender	O
,	O
and	O
consumption	O
of	O
tobacco	O
(	O
OR	O
5.04	O
,	O
95	O
%	O
CI	O
;	O
2.36-10.74	O
)	O
.	O

Patients	O
with	O
COPD	O
resident	O
in	O
the	O
Canary	O
Islands	O
have	O
a	O
high	O
prevalence	O
of	O
hypertension	O
,	O
dyslipidaemia	O
,	O
ischaemic	O
heart	O
disease	O
,	O
and	O
cardiac	O
arrhythmia	O
.	O

Compared	O
to	O
general	O
population	O
,	O
patients	O
with	O
COPD	O
have	O
a	O
significant	O
increase	O
in	O
the	O
risk	O
of	O
dyslipidaemia	O
.	O

Higher	O
copeptin	O
levels	O
are	O
associated	O
with	O
worse	O
outcome	O
in	O
patients	O
with	O
hypertrophic	O
cardiomyopathy	O
.	O

Correlation	O
of	O
increased	O
copeptin	O
levels	O
with	O
various	O
cardiovascular	O
diseases	O
has	O
been	O
described	O
.	O

The	O
clinical	O
use	O
of	O
copeptin	O
levels	O
in	O
patients	O
with	O
hypertrophic	O
cardiomyopathy	O
(	O
HCM	O
)	O
has	O
not	O
been	O
investigated	O
before	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
prognostic	O
value	O
of	O
copeptin	O
levels	O
in	O
patients	O
with	O
hypertrophic	O
cardiomyopathy	O
(	O
HCM	O
)	O
.	O

HCM	O
was	O
defined	O
as	O
presence	O
of	O
left	O
ventricular	O
wall	O
thickness	O
≥15	O
mm	O
in	O
a	O
subject	O
without	O
any	O
concomitant	O
disease	O
that	O
may	O
cause	O
left	O
ventricular	O
hypertrophy	O
.	O

Levels	O
of	O
copeptin	O
and	O
plasma	B-P
N-terminal	I-P
probrain	I-P
natriuretic	I-P
peptide	I-P
(	O
NT-proBNP	B-P
)	O
were	O
evaluated	O
prospectively	O
in	O
24	O
obstructive	O
HCM	O
patients	O
,	O
36	O
nonobstructive	O
HCM	O
patients	O
,	O
and	O
36	O
age	O
-	O
and	O
sex	O
-	O
matched	O
control	O
subjects	O
.	O

Blood	O
samples	O
were	O
collected	O
in	O
the	O
morning	O
between	O
7	O
and	O
9	O
am	O
after	O
overnight	O
fasting	O
.	O

Patients	O
were	O
followed	O
for	O
24	O
months	O
.	O

Hospitalization	O
with	O
diagnosis	O
of	O
heart	O
failure	O
/	O
arrhythmia	O
,	O
implantable	O
cardioverter-defibrillator	O
implantation	O
,	O
and	O
cardiac	O
mortality	O
were	O
accepted	O
as	O
adverse	O
cardiac	O
events	O
.	O

Copeptin	O
and	O
NT-proBNP	B-P
levels	O
were	O
higher	O
in	O
the	O
HCM	O
group	O
compared	O
with	O
controls	O
(	O
14.1	O
vs	O
8.4	O
pmol/L	O
,	O
P	O
<	O
0.01	O
;	O
and	O
383	O
vs	O
44	O
pg/mL	O
,	O
P	O
<	O
0.01	O
,	O
respectively	O
)	O
.	O

Copeptin	O
and	O
NT-proBNP	B-P
levels	O
were	O
higher	O
in	O
the	O
obstructive	O
HCM	O
subgroup	O
compared	O
with	O
the	O
nonobstructive	O
HCM	O
subgroup	O
(	O
18.3	O
vs	O
13.1	O
pmol/L	O
,	O
P	O
<	O
0.01	O
;	O
and	O
717	O
vs	O
223	O
pg/mL	O
,	O
P	O
<	O
0.01	O
,	O
respectively	O
)	O
.	O

In	O
multivariable	O
logistic	O
regression	O
analysis	O
,	O
copeptin	O
and	O
NT-proBNP	B-P
levels	O
remained	O
as	O
independent	O
predictors	O
of	O
heart	O
failure	O
(	O
P	O
<	O
0.01	O
for	O
both	O
)	O
and	O
adverse	O
cardiac	O
events	O
(	O
P	O
<	O
0.01	O
for	O
both	O
)	O
.	O

Copeptin	O
and	O
NT-proBNP	B-P
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
obstructive	O
HCM	O
,	O
and	O
higher	O
levels	O
were	O
associated	O
with	O
worse	O
outcome	O
.	O

Long-term	O
antibiofilm	O
activity	O
of	O
carboxymethyl	O
chitosan	O
on	O
mixed	O
biofilm	O
on	O
silicone	O
.	O

Silicone	O
voice	O
prostheses	O
are	O
most	O
frequently	O
used	O
in	O
voice	O
rehabilitation	O
of	O
laryngectomized	O
patients	O
.	O

However	O
,	O
the	O
functional	O
device	O
lifetimes	O
are	O
limited	O
due	O
to	O
formation	O
of	O
mixed	O
biofilms	O
.	O

Existing	O
in	O
vitro	O
models	O
simulating	O
biofilm	O
formation	O
are	O
restricted	O
to	O
only	O
short-term	O
periods	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
carboxymethyl	O
chitosan	O
on	O
mixed	O
biofilm	O
formation	O
of	O
fungi	O
and	O
bacteria	O
on	O
silicone	O
over	O
a	O
long-term	O
period	O
.	O

Mixed	O
species	O
biofilms	O
of	O
Candida	O
albicans	O
,	O
Candida	O
tropicalis	O
,	O
Lactobacillus	O
gasseri	O
,	O
Streptococcus	O
salivarius	O
,	O
Rothia	O
dentocariosa	O
,	O
and	O
Staphylococcus	O
epidermidis	O
were	O
cultivated	O
on	O
the	O
surfaces	O
of	O
medical-grade	O
silicone	O
with	O
and	O
without	O
addition	O
of	O
carboxymethyl	O
chitosan	O
.	O

Biofilm	O
kinetics	O
was	O
monitored	O
using	O
specially	O
designed	O
image	O
analysis	O
software	O
to	O
calculate	O
the	O
percentual	O
surface	O
covering	O
of	O
each	O
platelet	O
.	O

Biofilm	O
architecture	O
was	O
investigated	O
by	O
scanning	B-P
electron	I-P
microscopy	I-P
.	O

A	O
cover	O
of	O
living	O
mixed	O
biofilm	O
could	O
be	O
generated	O
over	O
22	O
days	O
on	O
silicone	O
and	O
the	O
maximum	O
of	O
22	O
%	O
biofilm	O
surface	O
covering	O
at	O
day	O
22	O
.	O

However	O
,	O
less	O
than	O
4	O
%	O
surface	O
coverage	O
was	O
observed	O
on	O
the	O
carboxymethyl	O
chitosan	O
-	O
treated	O
plates	O
in	O
the	O
testing	O
period	O
.	O

Scanning	B-P
electron	I-P
microscopy	I-P
confirms	O
that	O
,	O
on	O
surfaces	O
treated	O
by	O
carboxymethyl	O
chitosan	O
,	O
the	O
biofilm	O
was	O
less	O
dense	O
.	O

In	O
addition	O
,	O
there	O
were	O
fewer	O
layers	O
of	O
cells	O
and	O
profuse	O
cellular	O
debris	O
,	O
together	O
with	O
degrading	O
and	O
morphologically	O
altered	O
yeast	O
cells	O
.	O

Carboxymethyl	O
chitosan	O
may	O
serve	O
as	O
a	O
possible	O
antibiofilm	O
agent	O
to	O
limit	O
biofilm	O
formation	O
on	O
voice	O
prostheses	O
.	O

NA	O
Laryngoscope	O
,	O
126	O
:	O
E404-E408	O
,	O
2016	O
.	O

Bone	O
Marrow	O
-Derived	O
Mesenchymal	O
Stem	O
Cells	O
-Derived	O
Exosomes	O
Promote	O
Survival	O
of	O
Retinal	O
Ganglion	O
Cells	O
Through	O
miRNA	O
-Dependent	O
Mechanisms	O
.	O

The	O
loss	O
of	O
retinal	O
ganglion	O
cells	O
(	O
RGC	O
)	O
and	O
their	O
axons	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
blindness	O
and	O
includes	O
traumatic	O
(	O
optic	O
neuropathy	O
)	O
and	O
degenerative	O
(	O
glaucoma	O
)	O
eye	O
diseases	O
.	O

Although	O
no	O
clinical	O
therapies	O
are	O
in	O
use	O
,	O
mesenchymal	O
stem	O
cells	O
(	O
MSC	O
)	O
have	O
demonstrated	O
significant	O
neuroprotective	O
and	O
axogenic	O
effects	O
on	O
RGC	O
in	O
both	O
of	O
the	O
aforementioned	O
models	O
.	O

Recent	O
evidence	O
has	O
shown	O
that	O
MSC	O
secrete	O
exosomes	O
,	O
membrane	O
enclosed	O
vesicles	O
(	O
30-100	O
nm	O
)	O
containing	O
proteins	O
,	O
mRNA	O
and	O
miRNA	O
which	O
can	O
be	O
delivered	O
to	O
nearby	O
cells	O
.	O

The	O
present	O
study	O
aimed	O
to	O
isolate	O
exosomes	O
from	O
bone	O
marrow	O
-derived	O
MSC	O
(	O
BMSC	O
)	O
and	O
test	O
them	O
in	O
a	O
rat	O
optic	O
nerve	O
crush	O
(	O
ONC	O
)	O
model	O
.	O

Treatment	O
of	O
primary	B-P
retinal	I-P
cultures	I-P
with	O
BMSC	O
-	O
exosomes	O
demonstrated	O
significant	O
neuroprotective	O
and	O
neuritogenic	O
effects	O
.	O

Twenty-one	O
days	O
after	O
ONC	O
and	O
weekly	O
intravitreal	O
exosome	O
injections	O
;	O
optical	B-P
coherence	I-P
tomography	I-P
,	O
electroretinography	B-P
,	O
and	O
immunohistochemistry	B-P
was	O
performed	O
.	O

BMSC	O
-derived	O
exosomes	O
promoted	O
statistically	O
significant	O
survival	O
of	O
RGC	O
and	O
regeneration	O
of	O
their	O
axons	O
while	O
partially	O
preventing	O
RGC	O
axonal	O
loss	O
and	O
RGC	O
dysfunction	O
.	O

Exosomes	O
successfully	O
delivered	O
their	O
cargo	O
into	O
inner	O
retinal	O
layers	O
and	O
the	O
effects	O
were	O
reliant	O
on	O
miRNA	O
,	O
demonstrated	O
by	O
the	O
diminished	O
therapeutic	O
effects	O
of	O
exosomes	O
derived	O
from	O
BMSC	O
after	O
knockdown	O
of	O
Argonaute-2	O
,	O
a	O
key	O
miRNA	O
effector	O
molecule	O
.	O

This	O
study	O
supports	O
the	O
use	O
of	O
BMSC	O
-derived	O
exosomes	O
as	O
a	O
cell-free	O
therapy	O
for	O
traumatic	O
and	O
degenerative	O
ocular	O
disease	O
.	O

Stem	O
Cells	O
Translational	O
Medicine	O
2017	O
;	O
6:1273-1285	O
.	O

Readily	O
Accessible	O
and	O
Predictable	O
Naphthalene	O
-Based	O
Two-Photon	O
Fluorophore	O
with	O
Full	O
Visible	O
-	O
Color	O
Coverage	O
.	O

Herein	O
we	O
report	O
22	O
acedan	O
-derived	O
,	O
two-photon	O
fluorophores	O
with	O
synthetic	O
feasibility	O
and	O
full	O
coverage	O
of	O
visible	O
wavelength	O
emission	O
.	O

The	O
emission	O
wavelengths	O
were	O
predicted	O
by	O
computational	B-P
analysis	I-P
,	O
which	O
enabled	O
us	O
to	O
visualize	O
multicolor	O
images	O
by	O
two-photon	O
excitation	O
with	O
single	O
wavelength	O
,	O
and	O
to	O
design	O
a	O
turn-on	O
,	O
two-photon	O
fluorescence	O
sensor	O
for	O
endogenous	O
H2	O
O2	O
in	O
Raw	O
264.7	O
macrophage	O
and	O
rat	O
brain	O
hippocampus	O
ex	O
vivo	O
.	O

Low	O
Soluble	O
Syndecan-1	O
Precedes	O
Preeclampsia	O
.	O

Syndecan-1	O
(	O
Sdc1	O
;	O
CD138	O
)	O
is	O
a	O
major	O
transmembrane	O
heparan	O
sulfate	O
proteoglycan	O
expressed	O
on	O
the	O
extracellular	O
,	O
luminal	O
surface	O
of	O
epithelial	O
cells	O
and	O
syncytiotrophoblast	O
,	O
thus	O
comprising	O
a	O
major	O
component	O
of	O
the	O
glycocalyx	O
of	O
these	O
cells	O
.	O

The	O
``	O
soluble	O
``	O
(	O
shed	O
)	O
form	O
of	O
Sdc1	O
has	O
paracrine	O
and	O
autocrine	O
functions	O
and	O
is	O
normally	O
produced	O
in	O
a	O
regulated	O
fashion	O
.	O

We	O
compared	O
plasma	O
soluble	O
Sdc1	O
concentrations	O
,	O
in	O
relation	O
to	O
placental	O
Sdc1	O
expression	O
,	O
in	O
uncomplicated	O
(	O
control	O
)	O
and	O
preeclamptic	O
pregnancies	O
.	O

We	O
evaluated	O
soluble	O
Sdc1	O
across	O
uncomplicated	O
pregnancy	O
,	O
and	O
between	O
preeclamptic	O
,	O
gestational	O
hypertensive	O
and	O
control	O
patients	O
at	O
mid-pregnancy	O
(	O
20	O
weeks	O
)	O
and	O
3rd	O
trimester	O
by	O
ELISA	B-P
.	O

Placental	O
expression	O
level	O
of	O
Sdc1	O
was	O
compared	O
between	O
groups	O
in	O
relation	O
to	O
pre-delivery	O
plasma	O
soluble	O
Sdc1	O
.	O

Participants	O
were	O
recruited	O
from	O
Magee-Womens	O
Hospital	O
.	O

In	O
uncomplicated	O
pregnancy	O
,	O
plasma	O
soluble	O
Sdc1	O
rose	O
significantly	O
in	O
the	O
1st	O
trimester	O
,	O
and	O
reached	O
an	O
approximate	O
50-fold	O
increase	O
at	O
term	O
compared	O
to	O
post	O
pregnancy	O
levels	O
.	O

Soluble	O
Sdc1	O
was	O
lower	O
at	O
mid-pregnancy	O
in	O
women	O
who	O
later	O
developed	O
preeclampsia	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
not	O
gestational	O
hypertension	O
,	O
compared	O
to	O
controls	O
,	O
and	O
remained	O
lower	O
at	O
late	O
pregnancy	O
in	O
preeclampsia	O
(	O
P	O
<	O
0.01	O
)	O
compared	O
to	O
controls	O
.	O

Sdc1	O
was	O
prominently	O
expressed	O
on	O
syncytiotrophoblast	O
of	O
microvilli	O
.	O

Syncytiotrophoblast	O
Sdc1	O
immunostaining	B-P
intensities	I-P
,	O
and	O
mRNA	O
content	O
in	O
villous	O
homogenates	O
,	O
were	O
lower	O
in	O
preeclampsia	O
vs.	O
controls	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Soluble	O
Sdc1	O
and	O
Sdc1	O
immunostaining	B-P
scores	O
were	O
inversely	O
associated	O
with	O
systolic	O
blood	O
pressures	O
,	O
and	O
positively	O
correlated	O
with	O
infant	O
birth	O
weight	O
percentile	O
.	O

Soluble	O
Sdc1	O
is	O
significantly	O
lower	O
before	O
the	O
clinical	O
onset	O
of	O
preeclampsia	O
,	O
with	O
reduced	O
expression	O
of	O
Sdc1	O
in	O
the	O
delivered	O
placenta	O
,	O
suggesting	O
a	O
role	O
for	O
glycocalyx	O
disturbance	O
in	O
preeclampsia	O
pathophysiology	O
.	O

Clonal	O
and	O
serotype	O
dynamics	O
of	O
serogroup	O
6	O
isolates	O
causing	O
invasive	O
pneumococcal	O
disease	O
in	O
Portugal	O
:	O
1999-2012	O
.	O

Although	O
serogroup	O
6	O
was	O
among	O
the	O
first	O
to	O
be	O
recognized	O
among	O
Streptococcus	O
pneumoniae	O
,	O
several	O
new	O
serotypes	O
were	O
identified	O
since	O
the	O
introduction	O
of	O
pneumococcal	O
conjugate	O
vaccines	O
(	O
PCVs	O
)	O
.	O

A	O
decrease	O
of	O
the	O
6B-2	O
variant	O
among	O
invasive	O
pneumococcal	O
disease	O
(	O
IPD	O
)	O
,	O
but	O
not	O
6B-1	O
,	O
was	O
noted	O
post	O
conjugate	O
vaccine	O
introduction	O
,	O
underpinned	O
by	O
a	O
decrease	O
of	O
CC273	O
isolates	O
.	O

Serotype	O
6C	O
was	O
associated	O
with	O
adult	O
IPD	O
and	O
increased	O
in	O
this	O
age	O
group	O
representing	O
two	O
lineages	O
(	O
CC315	O
and	O
CC395	O
)	O
,	O
while	O
the	O
same	O
lineages	O
expressed	O
other	O
serogroup	O
6	O
serotypes	O
in	O
children	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
a	O
potential	O
cross-protection	O
of	O
PCVs	O
against	O
serotype	O
6C	O
IPD	O
among	O
vaccinated	O
children	O
but	O
not	O
among	O
adults	O
.	O

Serotype	O
6A	O
became	O
the	O
most	O
important	O
serogroup	O
6	O
serotype	O
in	O
children	O
but	O
it	O
decreased	O
in	O
adult	O
IPD	O
.	O

No	O
other	O
serogroup	O
6	O
serotypes	O
were	O
detected	O
,	O
so	O
available	O
phenotypic	O
or	O
simple	O
genotypic	O
assays	B-P
remain	O
adequate	O
for	O
distinguishing	O
serotypes	O
within	O
serogroup	O
6	O
isolates	O
.	O

Sleep	O
characteristics	O
in	O
type	O
1	O
diabetes	O
and	O
associations	O
with	O
glycemic	O
control	O
:	O
systematic	O
review	O
and	O
meta-analysis	O
.	O

The	O
association	O
between	O
inadequate	O
sleep	O
and	O
type	O
2	O
diabetes	O
has	O
garnered	O
much	O
attention	O
,	O
but	O
little	O
is	O
known	O
about	O
sleep	O
and	O
type	O
1	O
diabetes	O
(	O
T1D	O
)	O
.	O

Our	O
objectives	O
were	O
to	O
conduct	O
a	O
systematic	O
review	O
and	O
meta-analysis	O
comparing	O
sleep	O
in	O
persons	O
with	O
and	O
without	O
T1D	O
,	O
and	O
to	O
explore	O
relationships	O
between	O
sleep	O
and	O
glycemic	O
control	O
in	O
T1D	O
.	O

Studies	O
were	O
identified	O
from	O
Medline	O
and	O
Scopus	O
.	O

Studies	O
reporting	O
measures	O
of	O
sleep	O
in	O
T1D	O
patients	O
and	O
controls	O
,	O
and/or	O
associations	O
between	O
sleep	O
and	O
glycemic	O
control	O
,	O
were	O
selected	O
.	O

A	O
total	O
of	O
22	O
studies	O
were	O
eligible	O
for	O
the	O
meta-analysis	O
.	O

Children	O
with	O
T1D	O
had	O
shorter	O
sleep	O
duration	O
(	O
mean	O
difference	O
[	O
MD	O
]	O
=	O
-26.4	O
minutes	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
-35.4	O
,	O
-17.7	O
)	O
than	O
controls	O
.	O

Adults	O
with	O
T1D	O
reported	O
poorer	O
sleep	O
quality	O
(	O
MD	O
in	O
standardized	O
sleep	O
quality	O
score	O
=	O
0.51	O
;	O
95	O
%	O
CI	O
=	O
0.33	O
,	O
0.70	O
)	O
,	O
with	O
higher	O
scores	O
reflecting	O
worse	O
sleep	O
quality	O
)	O
than	O
controls	O
,	O
but	O
there	O
was	O
no	O
difference	O
in	O
self	O
-	O
reported	O
sleep	O
duration	O
.	O

Adults	O
with	O
TID	O
who	O
reported	O
sleeping	O
>	O
6	O
hours	O
had	O
lower	O
hemoglobin	B-P
A1c	I-P
(	I-P
HbA1c	I-P
)	I-P
levels	I-P
than	O
those	O
sleeping	O
≤6	O
hours	O
(	O
MD	O
=	O
-0.24	O
%	O
;	O
95	O
%	O
CI	O
=	O
-0.47	O
,	O
-0.02	O
)	O
,	O
and	O
participants	O
reporting	O
good	O
sleep	O
quality	O
had	O
lower	O
HbA1c	O
than	O
those	O
with	O
poor	O
sleep	O
quality	O
(	O
MD	O
=	O
-0.19	O
%	O
;	O
95	O
%	O
CI	O
=	O
-0.30	O
,	O
-0.08	O
)	O
.	O

The	O
estimated	O
prevalence	O
of	O
obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
in	O
adults	O
with	O
TID	O
was	O
51.9	O
%	O
(	O
95	O
%	O
CI	O
=	O
31.2	O
,	O
72.6	O
)	O
.	O

Patients	O
with	O
moderate-to-severe	O
OSA	O
had	O
a	O
trend	O
toward	O
higher	O
HbA1c	O
(	O
MD	O
=	O
0.39	O
%	O
,	O
95	O
%	O
CI	O
=	O
-0.08	O
,	O
0.87	O
)	O
.	O

T1D	O
was	O
associated	O
with	O
poorer	O
sleep	O
and	O
high	O
prevalence	O
of	O
OSA	O
.	O

Poor	O
sleep	O
quality	O
,	O
shorter	O
sleep	O
duration	O
,	O
and	O
OSA	O
were	O
associated	O
with	O
suboptimal	O
glycemic	O
control	O
in	O
T1D	O
patients	O
.	O

Preoperative	O
ultrasonographic	B-P
findings	O
of	O
internal	O
jugular	O
veins	O
and	O
carotid	O
arteries	O
in	O
kidney	O
transplant	O
recipients	O
.	O

Hemodialysis	O
via	O
the	O
internal	O
jugular	O
vein	O
(	O
IJV	O
)	O
has	O
been	O
widely	O
used	O
for	O
patients	O
with	O
end	O
stage	O
renal	O
disease	O
(	O
ESRD	O
)	O
patients	O
,	O
as	O
they	O
have	O
a	O
higher	O
risk	O
of	O
arterial	O
diseases	O
.	O

We	O
investigated	O
the	O
ultrasonographic	B-P
findings	O
of	O
the	O
IJV	O
and	O
carotid	O
artery	O
(	O
CA	O
)	O
in	O
recipients	O
of	O
kidney	O
transplantation	O
(	O
KT	O
)	O
and	O
identified	O
factors	O
influencing	O
IJV	O
/	O
CA	O
abnormalities	O
.	O

We	O
enrolled	O
120	O
adult	O
KT	O
recipients	O
.	O

Patients	O
in	O
group	O
A	O
(	O
n	O
=	O
57	O
)	O
had	O
a	O
history	O
of	O
IJV	O
hemodialysis	O
,	O
while	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
63	O
)	O
were	O
not	O
yet	O
on	O
dialysis	O
or	O
undergoing	O
dialysis	O
methods	O
not	O
involving	O
the	O
IJV	O
.	O

The	O
day	O
before	O
surgery	O
,	O
we	O
evaluated	O
the	O
state	O
of	O
the	O
IJV	O
and	O
CA	O
using	O
ultrasonography	B-P
.	O

We	O
followed	O
patients	O
with	O
IJV	O
stenosis	O
for	O
six	O
months	O
after	O
KT	O
.	O

Ultrasonography	B-P
revealed	O
that	O
four	O
patients	O
(	O
7	O
%	O
)	O
in	O
group	O
A	O
had	O
IJV	O
abnormalities	O
,	O
while	O
no	O
patients	O
in	O
group	O
B	O
had	O
abnormalities	O
(	O
P	O
=	O
0.118	O
)	O
.	O

Of	O
the	O
four	O
patients	O
with	O
abnormalities	O
,	O
one	O
with	O
57.4	O
%	O
stenosis	O
normalized	O
during	O
follow-	O
up	O
.	O

However	O
,	O
another	O
patient	O
with	O
90.1	O
%	O
stenosis	O
progressed	O
to	O
occlusion	O
,	O
while	O
the	O
two	O
patients	O
with	O
total	O
occlusion	O
remained	O
the	O
same	O
.	O

Twenty	O
patients	O
in	O
group	O
A	O
(	O
n	O
=	O
11	O
)	O
and	O
B	O
(	O
n	O
=	O
9	O
)	O
had	O
several	O
CA	O
abnormalities	O
(	O
P	O
=	O
0.462	O
)	O
.	O

Upon	O
multivariate	O
analysis	O
with	O
stepwise	O
selection	O
,	O
height	O
and	O
age	O
were	O
significantly	O
correlated	O
with	O
IJV	O
stenosis	O
(	O
P	O
=	O
0.043	O
,	O
odds	O
ratio	O
=	O
0.9	O
)	O
and	O
CA	O
abnormality	O
(	O
P	O
=	O
0.012	O
,	O
odds	O
ratio	O
=	O
1.1	O
)	O
,	O
respectively	O
.	O

IJV	O
abnormalities	O
(	O
especially	O
with	O
a	O
history	O
of	O
IJV	O
hemodialysis	O
)	O
and	O
CA	O
abnormalities	O
may	O
be	O
present	O
in	O
ESRD	O
patients	O
.	O

Therefore	O
,	O
we	O
recommend	O
ultrasonographic	B-P
evaluation	O
before	O
catheterization	O
.	O

Simultaneous	O
edited	O
MRS	B-P
of	O
GABA	O
and	O
glutathione	O
.	O

Edited	O
MRS	B-P
allows	O
the	O
detection	O
of	O
low	O
-	O
concentration	O
metabolites	O
,	O
whose	O
signals	O
are	O
not	O
resolved	O
in	O
the	O
MR	B-P
spectrum	I-P
.	O

Tailored	O
acquisitions	O
can	O
be	O
designed	O
to	O
detect	O
,	O
for	O
example	O
,	O
the	O
inhibitory	O
neurotransmitter	O
γ-aminobutyric	O
acid	O
(	O
GABA	O
)	O
,	O
or	O
the	O
reduction-oxidation	O
(	O
redox	O
)	O
compound	O
glutathione	O
(	O
GSH	O
)	O
,	O
and	O
single	O
-	O
voxel	O
edited	O
experiments	O
are	O
generally	O
acquired	O
at	O
a	O
rate	O
of	O
one	O
metabolite	O
-	O
per-experiment	O
.	O

We	O
demonstrate	O
that	O
simultaneous	O
detection	O
of	O
the	O
overlapping	O
signals	O
of	O
GABA	O
and	O
GSH	O
is	O
possible	O
using	O
Hadamard	B-P
Encoding	I-P
and	I-P
Reconstruction	I-P
of	I-P
Mega-Edited	I-P
Spectroscopy	I-P
(	O
HERMES	B-P
)	O
.	O

HERMES	B-P
applies	O
orthogonal	O
editing	O
encoding	O
(	O
following	O
a	O
Hadamard	O
scheme	O
)	O
,	O
such	O
that	O
GSH-	O
and	O
GABA	O
-	O
edited	O
difference	O
spectra	O
can	O
be	O
reconstructed	O
from	O
a	O
single	O
multiplexed	O
experiment	O
.	O

At	O
a	O
TE	O
of	O
80ms	O
,	O
20-ms	O
editing	O
pulses	O
are	O
applied	O
at	O
4.56ppm	O
(	O
on	O
GSH	O
)	O
,1.9ppm	O
(	O
on	O
GABA	O
)	O
,	O
both	O
offsets	O
(	O
using	O
a	O
dual-lobe	O
cosine-modulated	O
pulse	O
)	O
or	O
neither	O
.	O

Hadamard	O
combinations	O
of	O
the	O
four	O
sub-experiments	O
yield	O
GABA	O
and	O
GSH	O
difference	O
spectra	O
.	O

It	O
is	O
shown	O
that	O
HERMES	B-P
gives	O
excellent	O
separation	O
of	O
the	O
edited	O
GABA	O
and	O
GSH	O
signals	O
in	O
phantoms	O
,	O
and	O
resulting	O
edited	O
lineshapes	O
agree	O
well	O
with	O
separate	O
Mescher-Garwood	B-P
Point-resolved	I-P
Spectroscopy	I-P
(	O
MEGA-PRESS	B-P
)	O
acquisitions	O
.	O

In	O
vivo	O
,	O
the	O
quality	O
and	O
signal-to-noise	O
ratio	O
(	O
SNR	O
)	O
of	O
HERMES	B-P
spectra	O
are	O
similar	O
to	O
those	O
of	O
sequentially	O
acquired	O
MEGA-PRESS	B-P
spectra	O
,	O
with	O
the	O
benefit	O
of	O
saving	O
half	O
the	O
acquisition	O
time	O
.	O

Clinical	O
comparison	O
of	O
oral	O
administration	O
and	O
viscosupplementation	O
of	O
hyaluronic	O
acid	O
(	O
HA	O
)	O
in	O
early	O
knee	O
osteoarthritis	O
.	O

Osteoarthritis	O
(	O
OA	O
)	O
is	O
a	O
progressive	O
,	O
chronic	O
and	O
degenerative	O
joint	O
disease	O
characterized	O
by	O
a	O
loss	O
of	O
articular	O
cartilage	O
.	O

Treatment	O
of	O
OA	O
is	O
largely	O
palliative	O
based	O
on	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
opioids	O
and	O
injections	O
of	O
steroids	O
.	O

Regarding	O
conservative	O
treatment	O
,	O
intra-articular	O
injections	O
of	O
hyaluronic	O
acid	O
(	O
HA	O
)	O
can	O
play	O
a	O
role	O
in	O
early	O
symptomatic	O
knee	O
OA	O
.	O

Between	O
August	O
2015	O
and	O
September	O
2015	O
,	O
sixty	O
patients	O
(	O
32	O
males	O
and	O
28	O
females	O
)	O
between	O
40	O
and	O
70	O
years	O
old	O
were	O
randomly	O
allocated	O
into	O
two	O
groups	O
:	O
Half	O
were	O
treated	O
with	O
three	O
weekly	O
intra-articular	O
injections	O
of	O
hyaluronic	O
acid	O
1.6	O
%	O
(	O
group	O
A	O
)	O
,	O
while	O
the	O
others	O
were	O
treated	O
with	O
Syalox	O
300	O
Plus	O
(	O
®	O
)	O
(	O
hyaluronic	O
acid	O
300	O
mg	O
+	O
Boswellia	O
serrata	O
extract	O
100	O
mg	O
)	O
1	O
tab	O
/	O
die	O
for	O
20	O
days	O
and	O
afterward	O
Syalox	O
150	O
(	O
®	O
)	O
(	O
hyaluronic	O
acid	O
150	O
mg	O
)	O
1	O
tab	O
/	O
die	O
for	O
other	O
20	O
days	O
(	O
group	O
B	O
)	O
.	O

All	O
patients	O
were	O
evaluated	O
clinically	O
with	O
American	O
Knee	O
Society	O
Score	O
(	O
AKSS	O
)	O
and	O
visual	B-P
analogue	I-P
scale	I-P
(	O
VAS	B-P
)	O
for	O
the	O
pain	O
before	O
the	O
treatment	O
and	O
after	O
3	O
months	O
.	O

AKSS	O
of	O
the	O
patients	O
in	O
both	O
groups	O
was	O
significantly	O
increased	O
by	O
the	O
treatment	O
,	O
and	O
VAS	B-P
score	O
was	O
significantly	O
reduced	O
.	O

In	O
both	O
groups	O
,	O
two	O
subgroups	O
were	O
created	O
with	O
patients	O
older	O
than	O
60	O
years	O
and	O
patients	O
younger	O
than	O
60	O
years	O
.	O

Better	O
results	O
are	O
reported	O
in	O
younger	O
patients	O
of	O
group	O
A	O
and	O
older	O
subjects	O
in	O
group	O
B	O
.	O

Despite	O
several	O
limitations	O
,	O
the	O
results	O
of	O
the	O
study	O
have	O
shown	O
that	O
HA	O
injection	O
and	O
oral	O
administration	O
may	O
have	O
beneficial	O
therapeutic	O
effects	O
on	O
patients	O
with	O
early	O
osteoarthritis	O
.	O

Different	O
outcomes	O
in	O
younger	O
and	O
older	O
subject	O
suggested	O
a	O
combined	O
therapy	O
first	O
with	O
local	O
infiltrations	O
and	O
then	O
with	O
oral	O
composition	O
.	O

An	O
innovative	O
method	O
of	O
ocular	O
prosthesis	O
fabrication	O
by	O
bio-CAD	O
and	O
rapid	O
3-D	O
printing	O
technology	O
:	O
A	O
pilot	O
study	O
.	O

Ocular	O
prosthesis	O
is	O
either	O
a	O
readymade	O
stock	O
shell	O
or	O
custom	O
made	O
prosthesis	O
(	O
CMP	O
)	O
.	O

Presently	O
,	O
there	O
is	O
no	O
other	O
technology	O
available	O
,	O
which	O
is	O
either	O
superior	O
or	O
even	O
comparable	O
to	O
the	O
conventional	O
CMP	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
fabricate	O
ocular	O
prosthesis	O
using	O
computer	O
aided	O
design	O
(	O
CAD	O
)	O
and	O
rapid	O
manufacturing	O
(	O
RM	O
)	O
technology	O
and	O
to	O
compare	O
it	O
with	O
custom	O
made	O
prosthesis	O
(	O
CMP	O
)	O
.	O

The	O
ocular	O
prosthesis	O
prepared	O
by	O
CAD	O
was	O
compared	O
with	O
conventional	O
CMP	O
in	O
terms	O
of	O
time	O
taken	O
for	O
fabrication	O
,	O
weight	O
,	O
cosmesis	O
,	O
comfort	O
,	O
and	O
motility	O
.	O

Two	O
eyes	O
of	O
two	O
patients	O
were	O
included	O
.	O

Computerized	B-P
tomography	I-P
scan	I-P
of	O
wax	O
model	O
of	O
socket	O
was	O
converted	O
into	O
three	O
dimensional	O
format	O
using	O
Materialize	O
Interactive	O
Medical	O
Image	O
Control	O
System	O
(	O
MIMICS	O
)	O
software	O
and	O
further	O
refined	O
.	O

This	O
was	O
given	O
as	O
an	O
input	O
to	O
rapid	O
manufacturing	O
machine	O
(	O
Polyjet	O
3-D	O
printer	O
)	O
.	O

The	O
final	O
painting	O
on	O
prototype	O
was	O
done	O
by	O
an	O
ocularist	O
.	O

The	O
average	O
effective	O
time	O
required	O
for	O
fabrication	O
of	O
CAD	O
prosthesis	O
was	O
2.5	O
hours	O
;	O
and	O
weight	O
2.9	O
grams	O
.	O

The	O
same	O
for	O
CMP	O
were	O
10	O
hours	O
;	O
and	O
4.4	O
grams	O
.	O

CAD	O
prosthesis	O
was	O
more	O
comfortable	O
for	O
both	O
the	O
patients	O
.	O

The	O
study	O
demonstrates	O
the	O
first	O
ever	O
attempt	O
of	O
fabricating	O
a	O
complete	O
ocular	O
prosthesis	O
using	O
CAD	O
and	O
rapid	O
manufacturing	O
and	O
comparing	O
it	O
with	O
conventional	O
CMP	O
.	O

This	O
prosthesis	O
takes	O
lesser	O
time	O
for	O
fabrication	O
,	O
and	O
is	O
more	O
comfortable	O
.	O

Studies	O
with	O
larger	O
sample	O
size	O
will	O
be	O
required	O
to	O
further	O
validate	O
this	O
technique	O
.	O

Quantitative	O
determination	B-P
of	O
five	O
metabolites	O
of	O
aspirin	O
by	O
UHPLC-MS	B-P
/	O
MS	B-P
coupled	O
with	O
enzymatic	O
reaction	O
and	O
its	O
application	O
to	O
evaluate	O
the	O
effects	O
of	O
aspirin	O
dosage	O
on	O
the	O
metabolic	O
profile	O
.	O

Acetylsalicylic	O
acid	O
(	O
Aspirin	O
,	O
ASA	O
)	O
is	O
a	O
famous	O
drug	O
for	O
cardiovascular	O
diseases	O
in	O
recent	O
years	O
.	O

Effects	O
of	O
ASA	O
dosage	O
on	O
the	O
metabolic	O
profile	O
have	O
not	O
been	O
fully	O
understood	O
.	O

The	O
purpose	O
of	O
our	O
study	O
is	O
to	O
establish	O
a	O
rapid	O
and	O
reliable	O
method	B-P
to	O
quantify	O
ASA	O
metabolites	O
in	O
biological	O
matrices	O
,	O
especially	O
for	O
glucuronide	O
metabolites	O
whose	O
standards	O
are	O
not	O
commercially	O
available	O
.	O

Then	O
we	O
applied	O
this	O
method	B-P
to	O
evaluate	O
the	O
effects	O
of	O
ASA	O
dosage	O
on	O
the	O
metabolic	O
and	O
excretion	O
profile	O
of	O
ASA	O
metabolites	O
in	O
rat	O
urine	O
.	O

Salicylic	O
acid	O
(	O
SA	O
)	O
,	O
gentisic	O
acid	O
(	O
GA	O
)	O
and	O
salicyluric	O
acid	O
(	O
SUA	O
)	O
were	O
determined	O
directly	O
by	O
UHPLC-MS	B-P
/	O
MS	B-P
,	O
while	O
salicyl	O
phenolic	O
glucuronide	O
(	O
SAPG	O
)	O
and	O
salicyluric	O
acid	O
phenolic	O
glucuronide	O
(	O
SUAPG	O
)	O
were	O
quantified	O
indirectly	O
by	O
measuring	O
the	O
released	O
SA	O
and	O
SUA	O
from	O
SAPG	O
and	O
SUAPG	O
after	O
β-glucuronidase	O
digestion	O
.	O

SUA	O
and	O
SUAPG	O
were	O
the	O
major	O
metabolites	O
of	O
ASA	O
in	O
rat	O
urine	O
24	O
h	O
after	O
ASA	O
administration	O
,	O
which	O
accounted	O
for	O
50	O
%	O
(	O
SUA	O
)	O
and	O
26	O
%	O
(	O
SUAPG	O
)	O
.	O

When	O
ASA	O
dosage	O
was	O
increased	O
,	O
the	O
contributions	O
dropped	O
to	O
32	O
%	O
and	O
18	O
%	O
,	O
respectively	O
.	O

The	O
excretion	O
of	O
other	O
three	O
metabolites	O
(	O
GA	O
,	O
SA	O
and	O
SAPG	O
)	O
however	O
showed	O
remarkable	O
increases	O
by	O
16	O
%	O
,	O
6	O
%	O
and	O
4	O
%	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
SUA	O
and	O
SUAPG	O
were	O
mainly	O
excreted	O
in	O
the	O
time	O
period	O
of	O
12-24	O
h	O
,	O
while	O
GA	O
was	O
excreted	O
in	O
the	O
earlier	O
time	O
periods	O
(	O
0-4	O
h	O
and	O
4-8	O
h	O
)	O
.	O

SA	O
was	O
mainly	O
excreted	O
in	O
the	O
time	O
period	O
of	O
0-4	O
h	O
and	O
12-24	O
h.	O
And	O
the	O
excretion	O
of	O
SAPG	O
was	O
equally	O
distributed	O
in	O
the	O
four	O
time	O
periods	O
.	O

We	O
went	O
further	O
to	O
show	O
that	O
the	O
excretion	O
of	O
five	O
metabolites	O
in	O
rat	O
urine	O
was	O
delayed	O
when	O
ASA	O
dosage	O
was	O
increased	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
developed	O
a	O
rapid	O
and	O
sensitive	O
method	B-P
to	O
determine	O
the	O
five	O
ASA	O
metabolites	O
(	O
SA	O
,	O
GA	O
,	O
SUA	O
,	O
SAPG	O
and	O
SUAPG	O
)	O
in	O
rat	O
urine	O
.	O

We	O
showed	O
that	O
ASA	O
dosage	O
could	O
significantly	O
influence	O
the	O
metabolic	O
and	O
excretion	O
profile	O
of	O
ASA	O
metabolites	O
in	O
rat	O
urine	O
.	O

High-fidelity	O
Glucagon-CreER	O
mouse	O
line	O
generated	O
by	O
CRISPR-Cas9	O
assisted	O
gene	O
targeting	O
.	O

α-cells	O
are	O
the	O
second	O
most	O
prominent	O
cell	O
type	O
in	O
pancreatic	O
islets	O
and	O
are	O
responsible	O
for	O
producing	O
glucagon	O
to	O
increase	O
plasma	O
glucose	O
levels	O
in	O
times	O
of	O
fasting	O
.	O

α-cell	O
dysfunction	O
and	O
inappropriate	O
glucagon	O
secretion	O
occur	O
in	O
both	O
type	O
1	O
and	O
type	O
2	O
diabetes	O
.	O

Thus	O
,	O
there	O
is	O
growing	O
interest	O
in	O
studying	O
both	O
normal	O
function	O
and	O
pathophysiology	O
of	O
α-cells	O
.	O

However	O
,	O
tools	O
to	O
target	O
gene	O
ablation	O
or	O
activation	O
specifically	O
of	O
α-cells	O
have	O
been	O
limited	O
,	O
compared	O
to	O
those	O
available	O
for	O
β-cells	O
.	O

Previous	O
Glucagon-Cre	O
and	O
Glucagon-CreER	O
transgenic	O
mouse	O
lines	O
have	O
suffered	O
from	O
transgene	O
silencing	O
,	O
and	O
the	O
only	O
available	O
Glucagon-CreER	O
``	O
knock-in	O
''	O
mouse	O
line	O
results	O
in	O
glucagon	O
haploinsufficiency	O
,	O
which	O
can	O
confound	O
the	O
interpretation	O
of	O
gene	B-P
deletion	I-P
analyses	I-P
.	O

Therefore	O
,	O
we	O
sought	O
to	O
develop	O
a	O
Glucagon-CreER	O
(	O
T2	O
)	O
mouse	O
line	O
that	O
would	O
maintain	O
normal	O
glucagon	O
expression	O
and	O
would	O
be	O
less	O
susceptible	O
to	O
transgene	O
silencing	O
.	O

We	O
utilized	O
CRISPR-Cas9	O
technology	O
to	O
insert	O
an	O
IRES-CreER	O
(	O
T2	O
)	O
sequence	O
into	O
the	O
3	O
'	O
UTR	O
of	O
the	O
Glucagon	O
(	O
Gcg	O
)	O
locus	O
in	O
mouse	O
embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
.	O

Targeted	O
ESC	O
clones	O
were	O
then	O
injected	O
into	O
mouse	O
blastocysts	O
to	O
obtain	O
Gcg-CreER	O
(	O
T2	O
)	O
mice	O
.	O

Recombination	O
efficiency	O
in	O
GCG	O
(	O
+	O
)	O
pancreatic	O
α-cells	O
and	O
glucagon-like	O
peptide	O
1	O
positive	O
(	O
GLP1	O
(	O
+	O
)	O
)	O
enteroendocrine	O
L-cells	O
was	O
measured	O
in	O
Gcg-CreER	O
(	O
T2	O
)	O
;	O
Rosa26-LSL-YFP	O
mice	O
injected	O
with	O
tamoxifen	O
during	O
fetal	O
development	O
and	O
adulthood	O
.	O

Tamoxifen	O
injection	O
of	O
Gcg-CreER	O
(	O
T2	O
)	O
;	O
Rosa26-LSL-YFP	O
mice	O
induced	O
high	O
recombination	O
efficiency	O
of	O
the	O
Rosa26-LSL-YFP	O
locus	O
in	O
perinatal	O
and	O
adult	O
α-cells	O
(	O
88	O
%	O
and	O
95	O
%	O
,	O
respectively	O
)	O
,	O
as	O
well	O
as	O
in	O
first-wave	O
fetal	O
α-cells	O
(	O
36	O
%	O
)	O
and	O
adult	O
enteroendocrine	O
L-cells	O
(	O
33	O
%	O
)	O
.	O

Mice	O
homozygous	O
for	O
the	O
Gcg-CreER	O
(	O
T2	O
)	O
allele	O
were	O
phenotypically	O
normal	O
.	O

We	O
successfully	O
derived	O
a	O
Gcg-CreER	O
(	O
T2	O
)	O
mouse	O
line	O
that	O
expresses	O
CreER	O
(	O
T2	O
)	O
in	O
pancreatic	O
α-cells	O
and	O
enteroendocrine	O
L-cells	O
without	O
disrupting	O
preproglucagon	O
gene	O
expression	O
.	O

These	O
mice	O
will	O
be	O
a	O
useful	O
tool	O
for	O
performing	O
temporally	O
controlled	O
genetic	O
manipulation	O
specifically	O
in	O
these	O
cell	O
types	O
.	O

Impact	O
of	O
alcohol	O
use	O
on	O
EEG	B-P
dynamics	I-P
of	O
response	O
inhibition	O
:	O
a	O
cotwin	O
control	O
analysis	O
.	O

Research	O
indicates	O
that	O
alcohol	O
misuse	O
is	O
associated	O
with	O
behavioral	O
disinhibition	O
,	O
but	O
the	O
neurophysiological	O
mechanisms	O
governing	O
this	O
relationship	O
remain	O
largely	O
unknown	O
.	O

Recent	O
work	O
suggests	O
that	O
successful	O
inhibition	O
and	O
cognitive	O
control	O
involve	O
electrophysiological	B-P
theta-band	I-P
dynamics	I-P
,	O
including	O
medial	O
frontal	O
cortex	O
(	O
MFC	O
)	O
power	O
enhancement	O
and	O
functional	O
connectivity	O
between	O
the	O
MFC	O
and	O
dorsal	O
prefrontal	O
cortex	O
(	O
dPFC	O
)	O
regions	O
,	O
which	O
may	O
be	O
disrupted	O
by	O
alcohol	O
misuse	O
.	O

In	O
addition	O
,	O
research	O
suggests	O
that	O
,	O
compared	O
to	O
men	O
,	O
women	O
are	O
at	O
heightened	O
risk	O
of	O
experiencing	O
the	O
negative	O
physical	O
and	O
neurocognitive	O
correlates	O
of	O
drinking	O
.	O

The	O
present	O
study	O
tested	O
the	O
hypothesis	O
that	O
alcohol	O
misuse	O
has	O
a	O
deleterious	O
effect	O
on	O
theta-band	O
response	O
inhibition	O
EEG	B-P
dynamics	I-P
in	O
a	O
sample	O
of	O
300	O
24-year-old	O
same-sex	O
twins	O
.	O

A	O
cotwin	O
control	O
(	O
CTC	O
)	O
design	O
was	O
used	O
to	O
disentangle	O
premorbid	O
risk	O
for	O
alcohol	O
use	O
from	O
the	O
causal	O
effects	O
of	O
alcohol	O
exposure	O
.	O

Drinking	O
was	O
negatively	O
associated	O
with	O
theta-band	O
MFC	O
power	O
and	O
MFC	O
-	O
dPFC	O
connectivity	O
during	O
response	O
inhibition	O
,	O
and	O
this	O
effect	O
was	O
stronger	O
among	O
women	O
.	O

The	O
CTC	O
analysis	O
suggested	O
that	O
,	O
for	O
women	O
,	O
reduced	O
nogo-related	O
theta-band	O
MFC	O
power	O
and	O
MFC	O
-	O
dPFC	O
connectivity	O
were	O
both	O
consistent	O
with	O
the	O
potential	O
deleterious	O
causal	O
effects	O
of	O
alcohol	O
exposure	O
.	O

These	O
findings	O
suggest	O
that	O
diminished	O
theta-band	O
MFC	O
power	O
and	O
MFC	O
-	O
dPFC	O
connectivity	O
may	O
be	O
neurophysiological	O
mechanisms	O
underlying	O
alcohol-related	O
disinhibition	O
.	O

Although	O
preliminary	O
,	O
these	O
results	O
suggest	O
that	O
normative	O
levels	O
of	O
alcohol	O
use	O
during	O
emerging	O
adulthood	O
have	O
potential	O
sex-specific	O
causal	O
effects	O
on	O
response	O
inhibition	O
EEG	B-P
dynamics	I-P
,	O
and	O
thus	O
have	O
potentially	O
significant	O
public	O
health	O
implications	O
.	O

The	O
Use	O
of	O
a	O
Software	O
-	O
Assisted	O
Method	O
to	O
Estimate	O
Fetal	O
Weight	O
at	O
and	O
Near	O
Term	O
Using	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
apply	O
a	O
semi-automated	O
calculation	O
method	O
of	O
fetal	O
body	O
volume	O
and	O
,	O
thus	O
,	O
of	O
magnetic	O
resonance-estimated	O
fetal	O
weight	O
(	O
MR-EFW	O
)	O
prior	O
to	O
planned	O
delivery	O
and	O
to	O
evaluate	O
whether	O
the	O
technique	O
of	O
measurement	O
could	O
be	O
simplified	O
while	O
remaining	O
accurate	O
.	O

MR-EFW	O
was	O
calculated	O
using	O
a	O
semi-automated	O
method	O
at	O
38.6	O
weeks	O
of	O
gestation	O
in	O
36	O
patients	O
and	O
compared	O
to	O
the	O
picture	O
archiving	O
and	O
communication	O
system	O
(	O
PACS	O
)	O
.	O

Per	O
patient	O
,	O
8	O
sequences	O
were	O
acquired	O
with	O
a	O
slice	O
thickness	O
of	O
4-8	O
mm	O
and	O
an	O
intersection	O
gap	O
of	O
0	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
or	O
20	O
mm	O
.	O

The	O
median	O
absolute	O
relative	O
errors	O
for	O
MR-EFW	O
and	O
the	O
time	O
of	O
planimetric	O
measurements	O
were	O
calculated	O
for	O
all	O
8	O
sequences	O
and	O
for	O
each	O
method	O
(	O
assisted	O
vs.	O
PACS	O
)	O
,	O
and	O
the	O
difference	O
between	O
the	O
methods	O
was	O
calculated	O
.	O

The	O
median	O
delivery	O
weight	O
was	O
3,280	O
g.	O
The	O
overall	O
median	O
relative	O
error	O
for	O
all	O
288	O
MR-EFW	O
calculations	O
was	O
2.4	O
%	O
using	O
the	O
semi-automated	O
method	O
and	O
2.2	O
%	O
for	O
the	O
PACS	O
method	O
.	O

Measurements	O
did	O
not	O
differ	O
between	O
the	O
8	O
sequences	O
using	O
the	O
assisted	O
method	O
(	O
p	O
=	O
0.313	O
)	O
or	O
the	O
PACS	O
(	O
p	O
=	O
0.118	O
)	O
,	O
while	O
the	O
time	O
of	O
planimetric	O
measurement	O
decreased	O
significantly	O
with	O
a	O
larger	O
gap	O
(	O
p	O
<	O
0.001	O
)	O
and	O
in	O
the	O
assisted	O
method	O
compared	O
to	O
the	O
PACS	O
method	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Our	O
simplified	O
MR-EFW	O
measurement	O
showed	O
a	O
dramatic	O
decrease	O
in	O
time	O
of	O
planimetric	O
measurement	O
without	O
a	O
decrease	O
in	O
the	O
accuracy	O
of	O
weight	O
estimates	O
.	O

High-Throughput	O
Genotyping	O
with	O
TaqMan	O
Allelic	O
Discrimination	O
and	O
Allele-Specific	O
Genotyping	O
Assays	O
.	O

Real-time	O
PCR	O
-based	O
genotyping	O
methods	O
,	O
such	O
as	O
TaqMan	O
allelic	O
discrimination	O
assays	O
and	O
allele-specific	O
genotyping	O
,	O
are	O
particularly	O
useful	O
when	O
screening	B-P
a	O
handful	O
of	O
single	O
nucleotide	O
polymorphisms	O
in	O
hundreds	O
of	O
samples	O
;	O
either	O
derived	O
from	O
different	O
individuals	O
,	O
tissues	O
,	O
or	O
pre	O
-	O
amplified	O
DNA	O
.	O

Although	O
real-time	O
PCR	O
-	O
based	O
methods	O
such	O
as	O
TaqMan	O
are	O
well-established	O
,	O
alternative	O
methods	O
,	O
like	O
allele-specific	O
genotyping	O
,	O
are	O
powerful	O
alternatives	O
,	O
especially	O
for	O
genotyping	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
length	O
polymorphisms	O
.	O

Here	O
,	O
we	O
describe	O
all	O
relevant	O
aspects	O
when	O
developing	O
an	O
assay	B-P
for	O
a	O
new	O
SNP	O
or	O
STR	O
using	O
either	O
TaqMan	O
or	O
allele-specific	O
genotyping	O
,	O
respectively	O
,	O
such	O
as	O
primer	O
and	O
probe	O
design	O
,	O
optimization	O
of	O
reaction	O
conditions	O
,	O
the	O
experimental	O
procedure	O
for	O
typing	O
hundreds	O
of	O
samples	O
,	O
and	O
finally	O
the	O
data	O
evaluation	O
.	O

Our	O
goal	O
is	O
to	O
provide	O
a	O
guideline	O
for	O
developing	O
genotyping	O
assays	O
using	O
these	O
two	O
approaches	O
that	O
render	O
reliable	O
and	O
reproducible	O
genotype	O
calls	O
involving	O
minimal	O
optimization	O
.	O

Autoimmune	O
Myelofibrosis	O
in	O
Systemic	O
Lupus	O
Erythematosus	O
Report	O
of	O
Two	O
Cases	O
and	O
Review	O
of	O
the	O
Literature	O
.	O

Autoimmune	O
myelofibrosis	O
(	O
AIMF	O
)	O
is	O
a	O
rare	O
entity	O
of	O
steroid	O
-	O
responsive	O
bone	O
marrow	O
fibrosis	O
that	O
accompanies	O
a	O
variety	O
of	O
autoimmune	O
diseases	O
,	O
particularly	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
.	O

Rarely	O
it	O
may	O
occur	O
in	O
patients	O
with	O
autoimmune	O
markers	O
but	O
no	O
definable	O
autoimmune	O
disease	O
(	O
Primary-AIMF	O
)	O
.	O

We	O
report	O
the	O
cases	O
of	O
two	O
young	O
women	O
with	O
SLE	O
-	O
associated	O
AIMF	O
(	O
SLE	O
-	O
AIMF	O
)	O
.	O

The	O
first	O
patient	O
was	O
a	O
young	O
woman	O
who	O
had	O
pancytopenia	O
,	O
massive	O
splenomegaly	O
and	O
reticulin	O
fibrosis	O
in	O
the	O
marrow	B-P
biopsy	I-P
.	O

The	O
pancytopenia	O
and	O
splenomegaly	O
resolved	O
completely	O
within	O
weeks	O
of	O
treatment	O
with	O
corticosteroids	O
.	O

Repeat	O
marrow	B-P
biopsy	I-P
showed	O
marked	O
regression	O
of	O
marrow	O
fibrosis	O
.	O

The	O
second	O
patient	O
was	O
a	O
young	O
woman	O
with	O
fever	O
,	O
anasarca	O
,	O
bicytopenia	O
and	O
reticulin	O
fibrosis	O
in	O
the	O
marrow	B-P
biopsy	I-P
.	O

Steroid	O
therapy	O
resulted	O
in	O
rapid	O
clinical	O
improvement	O
and	O
resolution	O
of	O
pancytopenia	O
.	O

A	O
review	O
of	O
the	O
literature	O
revealed	O
a	O
total	O
of	O
30	O
patients	O
with	O
SLE	O
-	O
AIMF	O
reported	O
to-	O
date	O
.	O

Patients	O
with	O
SLE	O
-	O
AIMF	O
are	O
young	O
women	O
with	O
SLE	O
and	O
blood	O
cytopenia	O
who	O
are	O
found	O
to	O
have	O
increased	O
bone	O
marrow	O
reticulin	O
on	O
marrow	B-P
biopsy	I-P
.	O

Steroid	O
therapy	O
results	O
in	O
rapid	O
hematological	O
recovery	O
and	O
regression	O
of	O
marrow	O
fibrosis	O
.	O

Whether	O
AIMF	O
is	O
one	O
of	O
several	O
hematological	O
complications	O
of	O
SLE	O
,	O
or	O
represents	O
a	O
unique	O
and	O
distinct	O
subset	O
of	O
patients	O
with	O
SLE	O
in	O
not	O
clear	O
.	O

Prospective	O
studies	O
with	O
longer	O
follow-up	O
are	O
needed	O
to	O
better	O
define	O
the	O
prevalence	O
and	O
clinical	O
spectrum	O
of	O
SLE	O
-	O
AIMF	O
.	O

Clinical	O
application	O
of	O
a	O
gadolinium	O
-based	O
capsule	O
as	O
an	O
MRI	O
contrast	O
agent	O
in	O
slow	O
transit	O
constipation	O
diagnostics	O
.	O

As	O
a	O
traditional	O
method	O
for	O
the	O
assessment	O
of	O
colon	O
dynamics	O
,	O
radio-opaque	O
markers	O
(	O
ROMs	O
)	O
are	O
limited	O
in	O
clinical	O
use	O
because	O
of	O
their	O
ionizing	O
radiation	O
.	O

We	O
compared	O
the	O
accuracy	O
and	O
applicability	O
of	O
gadolinium	O
-based	O
capsules	O
with	O
ROMs	O
in	O
the	O
measurement	O
of	O
colon	O
dynamics	O
in	O
healthy	O
controls	O
and	O
slow	O
transit	O
constipation	O
(	O
STC	O
)	O
patients	O
.	O

Seven	O
patients	O
with	O
STC	O
and	O
nine	O
healthy	O
controls	O
under	O
a	O
normal	O
diet	O
orally	O
consumed	O
ROMs	O
and	O
gadolinium	O
-based	O
capsules	O
simultaneously	O
.	O

All	O
subjects	O
underwent	O
X-ray	B-P
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
.	O

Healthy	O
control	O
images	O
were	O
acquired	O
at	O
12	O
,	O
24	O
,	O
and	O
48	O
h	O
,	O
and	O
STC	O
patient	O
images	O
were	O
acquired	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
h.	O
The	O
scores	O
based	O
on	O
the	O
position	O
of	O
the	O
labeling	O
capsules	O
and	O
ROMs	O
in	O
the	O
colon	O
and	O
the	O
colon	B-P
transit	I-P
times	I-P
(	O
CTTs	B-P
)	O
in	O
the	O
two	O
groups	O
were	O
compared	O
.	O

The	O
CTTs	B-P
obtained	O
via	O
the	O
ROMs	O
were	O
34.7±17.4	O
and	O
67.3±6.5	O
h	O
in	O
the	O
healthy	O
controls	O
and	O
STC	O
patients	O
,	O
respectively	O
(	O
P	O
<	O
.05	O
)	O
.	O

The	O
CTTs	B-P
obtained	O
via	O
MRI	B-P
were	O
30.9±15.9	O
and	O
74.1±7.2	O
h	O
in	O
the	O
healthy	O
controls	O
and	O
STC	O
patients	O
,	O
respectively	O
(	O
P	O
<	O
.05	O
)	O
.	O

The	O
CTTs	B-P
of	O
the	O
STC	O
patients	O
were	O
significantly	O
longer	O
than	O
the	O
healthy	O
controls	O
.	O

The	O
correlation	O
(	O
rs	O
)	O
between	O
the	O
scores	O
based	O
on	O
the	O
position	O
of	O
the	O
labeling	O
capsule	O
and	O
ROMs	O
in	O
the	O
healthy	O
group	O
and	O
the	O
STC	O
patients	O
was	O
.880	O
(	O
P	O
<	O
.05	O
)	O
and	O
.889	O
(	O
P	O
<	O
.05	O
)	O
,	O
respectively	O
.	O

As	O
a	O
MRI	O
contrast	O
label	O
,	O
gadolinium	O
-based	O
capsules	O
exhibit	O
results	O
comparable	O
to	O
ROMs	O
in	O
colon	O
motility	O
measurements	O
.	O

The	O
next	O
frontier	O
of	O
office	O
-based	O
inferior	O
vena	O
cava	O
filter	O
placement	O
.	O

There	O
is	O
an	O
increasing	O
number	O
of	O
procedures	O
that	O
traditionally	O
were	O
performed	O
in	O
the	O
inpatient	O
setting	O
that	O
are	O
now	O
becoming	O
office	O
-based	O
procedures	O
.	O

These	O
include	O
peripheral	O
endovascular	O
procedures	O
such	O
as	O
angiograms	B-P
,	O
angioplasties	O
,	O
dialysis	O
access	O
interventions	O
,	O
and	O
treatment	O
for	O
venous	O
insufficiency	O
.	O

We	O
chose	O
to	O
evaluate	O
the	O
feasibility	O
,	O
safety	O
of	O
inferior	O
vena	O
cava	O
(	O
IVC	O
)	O
filter	O
placement	O
in	O
the	O
office-based	O
setting	O
.	O

All	O
procedures	O
were	O
performed	O
using	O
local	O
anesthesia	O
,	O
and	O
ultrasound	B-P
guidance	I-P
for	O
puncture	O
.	O

All	O
venograms	B-P
were	O
performed	O
with	O
manual	O
injection	O
of	O
iodinated	O
contrast	O
.	O

An	O
IVC	O
filter	O
was	O
placed	O
in	O
the	O
cases	O
(	O
except	O
one	O
failure	O
of	O
placement	O
)	O
using	O
fluoroscopy	B-P
in	O
the	O
infrarenal	O
position	O
.	O

Patients	O
were	O
observed	O
in	O
a	O
recovery	O
area	O
and	O
then	O
discharged	O
.	O

Follow-up	O
data	O
were	O
obtained	O
through	O
an	O
interview	O
,	O
physical	O
examination	O
,	O
and	O
24-hour	O
postoperative	O
phone	O
call	O
.	O

Over	O
the	O
course	O
of	O
27	O
months	O
,	O
29	O
Greenfield	O
filters	O
(	O
Boston	O
Scientific	O
,	O
Marlborough	O
,	O
Mass	O
)	O
and	O
three	O
Celect	O
temporary	O
filters	O
(	O
Cook	O
,	O
Bloomington	O
,	O
Ind	O
)	O
were	O
placed	O
in	O
the	O
infrarenal	O
IVC	O
for	O
18	O
women	O
and	O
14	O
men	O
,	O
with	O
an	O
average	O
age	O
of	O
75.3	O
±	O
15.6	O
years	O
(	O
range	O
,	O
38-97	O
years	O
)	O
.	O

Twenty-four	O
acute	O
,	O
6	O
recent	O
(	O
<	O
6	O
months	O
ago	O
)	O
and	O
three	O
subacute	O
lower	O
extremity	O
deep	O
vein	O
thromboses	O
(	O
DVTs	O
)	O
were	O
identified	O
.	O

The	O
indications	O
for	O
the	O
procedure	O
were	O
patients	O
with	O
:	O
DVT	O
who	O
were	O
to	O
undergo	O
surgery	O
(	O
n	O
=	O
6	O
)	O
,	O
acute	O
large	O
free-floating	O
iliofemoral	O
DVT	O
(	O
deemed	O
high-risk	O
for	O
long-term	O
anticoagulation	O
)	O
(	O
n	O
=	O
7	O
)	O
,	O
new	O
DVT	O
during	O
anticoagulation	O
therapy	O
(	O
n	O
=	O
6	O
)	O
,	O
DVT	O
with	O
gastrointestinal	O
bleeding	O
(	O
n	O
=	O
4	O
)	O
,	O
DVT	O
with	O
hematuria	O
(	O
n	O
=	O
2	O
)	O
,	O
recent	O
DVT	O
(	O
which	O
extended	O
during	O
full	O
dose	O
anticoagulation	O
treatment	O
)	O
while	O
undergoing	O
a	O
long	O
flight	O
(	O
n	O
=	O
1	O
)	O
(	O
temporary	O
filter	O
placement	O
)	O
,	O
DVT	O
with	O
arm	O
hematoma	O
(	O
n	O
=	O
1	O
)	O
,	O
DVT	O
with	O
unsteady	O
gait	O
and	O
history	O
of	O
falls	O
(	O
n	O
=	O
2	O
)	O
,	O
DVT	O
with	O
nose	O
bleeding	O
(	O
n	O
=	O
1	O
)	O
,	O
DVT	O
with	O
dementia	O
and	O
inability	O
to	O
receive	O
anticoagulation	O
treatment	O
(	O
n	O
=	O
1	O
)	O
,	O
DVT	O
and	O
receiving	O
chemotherapy	O
and	O
with	O
thrombocytopenia	O
(	O
n	O
=	O
1	O
)	O
,	O
and	O
DVT	O
and	O
refusal	O
to	O
take	O
anticoagulation	O
medication	O
(	O
n	O
=	O
1	O
)	O
.	O

One	O
patient	O
had	O
a	O
failure	O
to	O
place	O
a	O
filter	O
because	O
of	O
chronic	O
IVC	O
occlusion	O
found	O
on	O
venogram	B-P
.	O

One	O
patient	O
with	O
history	O
of	O
gastrointestinal	O
bleeding	O
,	O
acute	O
DVT	O
,	O
and	O
atrial	O
fibrillation	O
suffered	O
IVC	O
filter	O
thrombosis	O
1	O
month	O
after	O
the	O
procedure	O
.	O

We	O
attempted	O
removal	O
of	O
the	O
temporary	O
filters	O
in	O
the	O
hospital	O
in	O
two	O
patients	O
but	O
failed	O
to	O
retrieve	O
the	O
filter	O
in	O
these	O
two	O
cases	O
.	O

We	O
noted	O
no	O
insertion	O
site	O
DVT	O
,	O
extension	O
of	O
DVT	O
,	O
or	O
pulmonary	O
embolism	O
.	O

Our	O
preliminary	O
experience	O
suggests	O
that	O
placement	O
of	O
IVC	O
filters	O
for	O
treatment	O
of	O
venous	O
thrombotic	O
events	O
in	O
an	O
office-based	O
facility	O
is	O
safe	O
and	O
efficacious	O
with	O
basic	O
endovascular	O
equipment	O
.	O

Long-term	O
outcome	O
can	O
not	O
be	O
determined	O
at	O
this	O
point	O
.	O

Objective	O
Assessment	O
of	O
Vergence	O
after	O
Treatment	O
of	O
Concussion	O
-	O
Related	O
CI	O
:	O
A	O
Pilot	O
Study	O
.	O

To	O
evaluate	O
changes	O
in	O
objective	O
measures	O
of	O
disparity	O
vergence	O
after	O
office-based	O
vision	O
therapy	O
(	O
OBVT	O
)	O
for	O
concussion	O
-	O
related	O
convergence	O
insufficiency	O
(	O
CI	O
)	O
and	O
determine	O
the	O
feasibility	O
of	O
using	O
this	O
objective	O
assessment	O
as	O
an	O
outcome	O
measure	O
in	O
a	O
clinical	O
trial	O
.	O

This	O
was	O
a	O
prospective	O
,	O
observational	O
trial	O
.	O

All	O
participants	O
were	O
treated	O
with	O
weekly	O
OBVT	O
with	O
home	O
reinforcement	O
.	O

Participants	O
included	O
two	O
adolescents	O
and	O
three	O
young	O
adults	O
with	O
concussion	O
-	O
related	O
,	O
symptomatic	O
CI	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
average	O
peak	O
velocity	O
for	O
4°	O
symmetrical	O
convergence	O
steps	O
.	O

Other	O
objective	O
outcome	O
measures	O
of	O
disparity	O
vergence	O
included	O
time	O
to	O
peak	O
velocity	O
,	O
latency	O
,	O
accuracy	O
,	O
settling	O
time	O
,	O
and	O
main	O
sequence	O
.	O

We	O
also	O
evaluated	O
saccadic	O
eye	O
movements	O
using	O
the	O
same	O
outcome	O
measures	O
.	O

Changes	O
in	O
clinical	O
measures	O
(	O
near	O
point	O
of	O
convergence	O
,	O
positive	O
fusional	O
vergence	O
at	O
near	O
,	O
Convergence	O
Insufficiency	O
Symptom	O
Survey	O
[	O
CISS	O
]	O
score	O
)	O
were	O
evaluated	O
.	O

There	O
were	O
statistically	O
significant	O
and	O
clinically	O
meaningful	O
changes	O
in	O
all	O
clinical	O
measures	O
for	O
convergence	O
.	O

Four	O
of	O
the	O
five	O
subjects	O
met	O
clinical	O
success	O
criteria	O
.	O

For	O
the	O
objective	O
measures	O
,	O
we	O
found	O
a	O
statistically	O
significant	O
increase	O
in	O
peak	O
velocity	O
,	O
response	O
accuracy	O
to	O
4°	O
symmetrical	O
convergence	O
and	O
divergence	O
step	O
stimuli	O
,	O
and	O
the	O
main	O
sequence	O
ratio	O
for	O
convergence	O
step	O
stimuli	O
.	O

Objective	O
saccadic	O
eye	O
movements	O
(	O
5	O
and	O
10°	O
)	O
appeared	O
normal	O
pre-	O
OBVT	O
and	O
did	O
not	O
show	O
any	O
significant	O
change	O
after	O
treatment	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
use	O
of	O
objective	O
measures	O
of	O
disparity	O
vergence	O
as	O
outcome	O
measures	O
for	O
concussion	O
-	O
related	O
convergence	O
insufficiency	O
.	O

These	O
measures	O
provide	O
additional	O
information	O
that	O
is	O
not	O
accessible	O
with	O
clinical	B-P
tests	I-P
about	O
underlying	O
physiological	O
mechanisms	O
leading	O
to	O
changes	O
in	O
clinical	O
findings	O
and	O
symptoms	O
.	O

The	O
study	O
results	O
also	O
demonstrate	O
that	O
patients	O
with	O
concussion	O
can	O
tolerate	O
the	O
visual	O
demands	O
(	O
over	O
200	O
vergence	O
and	O
versional	O
eye	O
movements	O
)	O
during	O
the	O
25-minute	O
testing	O
time	O
and	O
suggest	O
that	O
these	O
measures	O
could	O
be	O
used	O
in	O
a	O
large-scale	O
randomized	O
clinical	O
trial	O
of	O
concussion	O
-	O
related	O
CI	O
as	O
outcome	O
measures	O
.	O

Cardiovascular	B-P
magnetic	I-P
resonance	I-P
features	O
of	O
mechanical	O
dyssynchrony	O
in	O
patients	O
with	O
left	O
bundle	O
branch	O
block	O
.	O

Patients	O
with	O
left	O
bundle	O
branch	O
block	O
(	O
LBBB	O
)	O
can	O
exhibit	O
mechanical	O
dyssynchrony	O
which	O
may	O
contribute	O
to	O
heart	O
failure	O
;	O
such	O
patients	O
may	O
benefit	O
from	O
cardiac	O
resynchronization	O
treatment	O
(	O
CRT	O
)	O
.	O

While	O
cardiac	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
CMR	B-P
)	O
has	O
become	O
a	O
common	O
part	O
of	O
heart	O
failure	O
work-up	B-P
,	O
CMR	B-P
features	O
of	O
mechanical	O
dyssynchrony	O
in	O
patients	O
with	O
LBBB	O
have	O
not	O
been	O
well	O
characterized	O
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
potential	O
of	O
CMR	B-P
to	O
characterize	O
mechanical	O
features	O
of	O
LBBB	O
.	O

CMR	B-P
examinations	O
from	O
43	O
patients	O
with	O
LBBB	O
on	O
their	O
electrocardiogram	O
,	O
but	O
without	O
significant	O
focal	O
structural	O
abnormalities	O
,	O
and	O
from	O
43	O
age-	O
and	O
gender	O
-matched	O
normal	O
controls	O
were	O
retrospectively	O
reviewed	O
.	O

The	O
following	O
mechanical	O
features	O
of	O
LBBB	O
were	O
evaluated	O
:	O
septal	O
flash	O
(	O
SF	O
)	O
,	O
apical	O
rocking	O
(	O
AR	O
)	O
,	O
delayed	O
aortic	O
valve	O
opening	O
measured	O
relative	O
to	O
both	O
end-diastole	O
(	O
AVOED	O
)	O
and	O
pulmonic	O
valve	O
opening	O
(	O
AVOPVO	O
)	O
,	O
delayed	O
left-ventricular	O
(	O
LV	O
)	O
free-wall	O
contraction	O
,	O
and	O
curvatures	O
of	O
the	O
septum	O
and	O
LV	O
free-wall	O
.	O

Septal	O
displacement	O
curves	O
were	O
also	O
generated	O
,	O
using	O
feature	O
-tracking	O
techniques	O
.	O

The	O
echocardiographic	B-P
findings	O
of	O
LBBB	O
were	O
also	O
reviewed	O
in	O
those	O
subjects	O
for	O
whom	O
they	O
were	O
available	O
.	O

LBBB	O
was	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
SF	O
and	O
AR	O
;	O
within	O
the	O
LBBB	O
group	O
,	O
79	O
%	O
had	O
SF	O
and	O
65	O
%	O
had	O
AR	O
.	O

Delayed	O
AVOED	O
,	O
AVOPVO	O
,	O
and	O
delayed	O
LV	O
free-wall	O
contraction	O
were	O
significantly	O
associated	O
with	O
LBBB	O
.	O

AVOED	O
and	O
AVOPVO	O
positively	O
correlated	O
with	O
QRS	O
duration	O
and	O
negatively	O
correlated	O
with	O
ejection	B-P
fraction	I-P
.	O

Hearts	O
with	O
electrocardiographic	B-P
evidence	O
of	O
LBBB	O
showed	O
lower	O
septal-to-LV	O
free-wall	O
curvature	O
ratios	O
at	O
end-diastole	O
compared	O
to	O
normal	O
controls	O
.	O

CMR	B-P
can	O
be	O
used	O
to	O
identify	O
and	O
evaluate	O
mechanical	O
dyssynchrony	O
in	O
patients	O
with	O
LBBB	O
.	O

None	O
of	O
the	O
normal	O
controls	O
showed	O
the	O
mechanical	O
features	O
associated	O
with	O
LBBB	O
.	O

Moreover	O
,	O
not	O
all	O
patients	O
with	O
LBBB	O
showed	O
the	O
same	O
degree	O
of	O
mechanical	O
dyssynchrony	O
,	O
which	O
could	O
have	O
implications	O
for	O
CRT	O
.	O

Microcapillary	O
sign	O
of	O
flap	O
alignment	O
in	O
femtosecond	O
laser	O
-assisted	O
in	O
situ	O
keratomileusis	O
.	O

We	O
present	O
an	O
observational	B-P
sign	O
that	O
ensures	O
perfect	O
alignment	O
during	O
femtosecond	O
laser	O
-assisted	O
in	O
situ	O
keratomileusis	O
(	O
FS	O
LASIK	O
)	O
.	O

Alignment	O
is	O
assured	O
when	O
a	O
microsponge	O
is	O
used	O
to	O
dry	O
the	O
flap	O
and	O
the	O
area	O
of	O
dryness	O
exceeds	O
the	O
area	O
of	O
direct	O
touch	O
of	O
the	O
microsponge	O
.	O

The	O
area	O
might	O
even	O
reach	O
the	O
whole	O
circumference	O
of	O
the	O
flap	O
at	O
the	O
first	O
touch	O
.	O

This	O
sign	O
of	O
alignment	O
can	O
be	O
explained	O
by	O
microcapillary	O
action	O
.	O

This	O
sign	O
was	O
not	O
elicited	O
in	O
flaps	O
created	O
by	O
a	O
microkeratome	O
.	O

Molecular	O
profile	O
of	O
5-fluorouracil	O
pathway	O
genes	O
in	O
colorectal	O
carcinoma	O
.	O

This	O
study	O
addresses	O
involvement	O
of	O
major	O
5-fluorouracil	O
(	O
5-FU	O
)	O
pathway	O
genes	O
in	O
the	O
prognosis	O
of	O
colorectal	O
carcinoma	O
patients	O
.	O

Testing	O
set	O
and	O
two	O
validation	O
sets	O
comprising	O
paired	O
tumor	O
and	O
adjacent	O
mucosa	O
tissue	O
samples	O
from	O
151	O
patients	O
were	O
used	O
for	O
transcript	O
profiling	O
of	O
15	O
5-FU	O
pathway	O
genes	O
by	O
quantitative	O
real-time	O
PCR	O
and	O
DNA	O
methylation	O
profiling	O
by	O
high	O
resolution	O
melting	O
analysis	O
.	O

Intratumoral	O
molecular	O
profiles	O
were	O
correlated	O
with	O
clinical	O
data	O
of	O
patients	O
.	O

Protein	O
levels	O
of	O
two	O
most	O
relevant	O
candidate	O
markers	O
were	O
assessed	O
by	O
immunoblotting	B-P
.	O

Downregulation	O
of	O
DPYD	O
and	O
upregulation	O
of	O
PPAT	O
,	O
UMPS	O
,	O
RRM2	O
,	O
and	O
SLC29A1	O
transcripts	O
were	O
found	O
in	O
tumors	O
compared	O
to	O
adjacent	O
mucosa	O
in	O
testing	O
and	O
validation	O
sets	O
of	O
patients	O
.	O

Low	O
RRM2	O
transcript	O
level	O
significantly	O
associated	O
with	O
poor	O
response	O
to	O
the	O
first-line	O
palliative	O
5-FU	O
-based	O
chemotherapy	O
in	O
the	O
testing	O
set	O
and	O
with	O
poor	O
disease-free	O
interval	O
of	O
patients	O
in	O
the	O
validation	O
set	O
irrespective	O
of	O
5-FU	O
treatment	O
.	O

UPP2	O
was	O
strongly	O
methylated	O
while	O
its	O
transcript	O
absent	O
in	O
both	O
tumors	O
and	O
adjacent	O
mucosa	O
.	O

DPYS	O
methylation	O
level	O
was	O
significantly	O
higher	O
in	O
tumor	O
tissues	O
compared	O
to	O
adjacent	O
mucosa	O
samples	O
.	O

Low	O
intratumoral	O
level	O
of	O
UPB1	O
methylation	O
was	O
prognostic	O
for	O
poor	O
disease-free	O
interval	O
of	O
the	O
patients	O
(	O
P	O
=	O
0.0002	O
)	O
.	O

The	O
rest	O
of	O
the	O
studied	O
5-FU	O
genes	O
were	O
not	O
methylated	O
in	O
tumors	O
or	O
adjacent	O
mucosa	O
.	O

The	O
observed	O
overexpression	O
of	O
several	O
5-FU	O
activating	O
genes	O
and	O
DPYD	O
downregulation	O
deduce	O
that	O
chemotherapy	O
naïve	O
colorectal	O
tumors	O
share	O
favorable	O
gene	O
expression	O
profile	O
for	O
5-FU	O
therapy	O
.	O

Low	O
RRM2	O
transcript	O
and	O
UPB1	O
methylation	O
levels	O
present	O
separate	O
poor	O
prognosis	O
factors	O
for	O
colorectal	O
carcinoma	O
patients	O
and	O
should	O
be	O
further	O
investigated	O
.	O

The	O
role	O
of	O
the	O
hippocampus	O
and	O
the	O
function	O
of	O
calcitonin	O
gene-related	O
peptide	O
in	O
the	O
mechanism	O
of	O
traumatic	O
brain	O
injury	O
accelerating	O
fracture-healing	O
.	O

This	O
research	O
attempts	O
to	O
identify	O
the	O
part	O
the	O
hippocampus	O
plays	O
in	O
accelerated	O
fracture-healing	O
after	O
traumatic	O
brain	O
injury	O
as	O
well	O
as	O
to	O
test	O
functions	O
of	O
calcitonin	O
gene-related	O
peptide	O
(	O
CGRP	O
)	O
during	O
this	O
process	O
.	O

Experiments	O
were	O
carried	O
out	O
on	O
Male	O
Sprague-Dawley	O
rats	O
that	O
were	O
split	O
into	O
four	O
groups	O
at	O
random	O
:	O
TBI	O
-	O
fracture	O
group	O
,	O
fracture	O
-	O
only	O
group	O
,	O
TBI	O
-	O
only	O
group	O
,	O
and	O
control	O
group	O
.	O

In	O
the	O
first	O
week	O
,	O
blood	O
specimen	O
would	O
be	O
drawn	O
from	O
rats	O
among	O
the	O
groups	O
except	O
those	O
of	O
the	O
control	O
group	O
at	O
three-time	O
points	O
(	O
24	O
,	O
72	O
and	O
168	O
hours	O
)	O
post	O
-	O
damage	O
.	O

These	O
rats	O
would	O
be	O
assessed	O
from	O
the	O
neurological	O
perspective	O
based	O
on	O
their	O
grades	O
of	O
performance	O
in	O
a	O
sequence	O
of	O
tests	O
24	O
hours	O
before	O
and	O
12	O
hours	O
after	O
brain	O
injury	O
.	O

Blood	B-P
samples	I-P
were	O
also	O
taken	O
from	O
the	O
control	O
group	O
24	O
hours	O
before	O
the	O
injury	O
,	O
and	O
whole	O
brain	O
tissues	O
in	O
the	O
injured	O
groups	O
were	O
harvested	O
at	O
72	O
and	O
168	O
hours	O
post	O
-	O
injury	O
.	O

We	O
compared	O
the	O
serum	O
CGRP	O
concentration	O
,	O
the	O
distribution	O
of	O
CGRP	O
,	O
the	O
CGRP	O
expression	O
,	O
and	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
hippocampus	O
,	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
hippocampus	O
,	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
hippocampus	O
,	O
and	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
brain	O
by	O
immunohistochemistry	B-P
,	O
Western	B-P
blotting	I-P
,	O
RT	O
-	O
Of	O
CGRP	O
RNA	O
expression	O
levels	O
.	O

Neurological	B-P
examinations	I-P
suggested	O
that	O
the	O
functions	O
of	O
the	O
cerebral	O
cortex	O
,	O
cerebellum	O
,	O
and	O
brain	O
stem	O
showed	O
significant	O
differences	O
pre	O
-	O
and	O
post	O
-	O
injury	O
(	O
p	O
<	O
0.001	O
)	O
.	O

ELISA	B-P
analysis	I-P
indicated	O
a	O
great	O
density	O
of	O
CGRP	O
in	O
TBI	O
-	O
fracture	O
group	O
at	O
different	O
time	O
points	O
.	O

Furthermore	O
,	O
in	O
the	O
TBI	O
-	O
fracture	O
group	O
,	O
CGRP	O
in	O
both	O
hippocampus	O
and	O
the	O
whole	O
brain	O
showed	O
a	O
noticeable	O
augment	O
in	O
RT-PCR	O
and	O
western	B-P
blot	I-P
analysis	I-P
at	O
72	O
and	O
168	O
h	O
post	O
-	O
injury	O
,	O
and	O
only	O
in	O
this	O
group	O
,	O
immunohistochemistry	B-P
analysis	I-P
indicated	O
that	O
CGRP	O
was	O
present	O
in	O
the	O
hippocampus	O
at	O
168	O
hours	O
post	O
-	O
injury	O
.	O

We	O
observed	O
that	O
the	O
hippocampus	O
and	O
CGRP	O
were	O
responsible	O
for	O
quick	O
bone-healing	O
mechanisms	O
.	O

We	O
suggest	O
a	O
role	O
for	O
the	O
hippocampus	O
in	O
accelerated	O
fracture	O
healing	O
.	O

CGRP	O
expression	O
,	O
as	O
determined	O
by	O
IHC	B-P
,	O
can	O
not	O
be	O
observed	O
in	O
other	O
groups	O
,	O
indicating	O
that	O
the	O
hippocampus	O
may	O
be	O
the	O
specific	O
component	O
of	O
the	O
brain	O
that	O
responds	O
to	O
``	O
big	O
stress	O
``	O
.	O

Glycated	O
Hemoglobin	O
(	O
HbA1c	O
)	O
Correlation	O
with	O
Severity	O
of	O
Coronary	O
Artery	O
Disease	O
in	O
Non-diabetic	O
Patients	O
-	O
A	O
Hospital	O
based	O
Study	O
from	O
North-Eastern	O
India	O
.	O

Glycated	O
Hemoglobin	O
(	O
HbA1c	O
)	O
levels	O
are	O
predictive	O
of	O
cardiovascular	O
disease	O
and	O
mortality	O
in	O
patients	O
with	O
diabetes	O
mellitus	O
,	O
however	O
,	O
association	O
of	O
HbA1c	O
with	O
Coronary	O
Artery	O
Disease	O
(	O
CAD	O
)	O
in	O
non-diabetics	O
is	O
inconsistent	O
.	O

To	O
evaluate	O
the	O
correlation	O
between	O
HbA1c	O
level	O
and	O
severity	O
of	O
CAD	O
in	O
non-diabetic	O
patients	O
using	O
SYNTAX	O
score	O
in	O
a	O
cohort	O
of	O
proven	O
CAD	O
on	O
angiography	B-P
at	O
Gauhati	O
Medical	O
College	O
,	O
Guwahati	O
,	O
Assam	O
,	O
India	O
,	O
which	O
is	O
a	O
major	O
tertiary	O
care	O
hospital	O
of	O
North-Eastern	O
India	O
.	O

We	O
prospectively	O
collected	O
data	O
of	O
non-diabetic	O
patients	O
with	O
proven	O
CAD	O
on	O
angiography	B-P
from	O
June	O
2014	O
to	O
June	O
2015	O
.	O

Patients	O
were	O
divided	O
into	O
four	O
groups	O
(	O
interquartiles	O
)	O
according	O
to	O
HbA1c	O
levels	O
,	O
less	O
than	O
4.8	O
%	O
,	O
4.8	O
%	O
to	O
5.1	O
%	O
,	O
5.1	O
%	O
to	O
5.6	O
%	O
,	O
and	O
5.6	O
%	O
to	O
6.5	O
%	O
.	O

Severity	O
of	O
CAD	O
was	O
assessed	O
using	O
SYNTAX	O
score	O
and	O
the	O
number	O
of	O
coronary	O
vessels	O
diseased	O
.	O

We	O
compared	O
different	O
quartiles	O
of	O
HbA1c	O
with	O
regard	O
to	O
SYNTAX	O
score	O
and	O
number	O
of	O
diseased	O
vessels	O
.	O

A	O
total	O
of	O
346	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O

Mean	O
age	O
was	O
58.1±10.4	O
years	O
.	O

Of	O
the	O
total	O
91.9	O
%	O
(	O
318	O
)	O
were	O
males	O
,	O
44.8	O
%	O
(	O
155	O
)	O
were	O
hypertensives	O
,	O
29.2	O
%	O
(	O
101	O
)	O
were	O
smokers	O
and	O
34.7	O
%	O
(	O
120	O
)	O
were	O
dyslipidemic	O
.	O

We	O
found	O
that	O
CAD	O
severity	O
by	O
SYNTAX	O
score	O
as	O
well	O
as	O
number	O
of	O
vessels	O
involved	O
was	O
significantly	O
different	O
among	O
quartiles	O
(	O
p-values	O
<	O
0.001	O
and	O
<	O
0.001	O
respectively	O
)	O
.	O

Increase	O
in	O
HbA1c	O
level	O
was	O
strongly	O
correlated	O
with	O
disease	O
severity	O
and	O
higher	O
SYNTAX	O
score	O
.	O

A	O
significant	O
increase	O
was	O
noted	O
in	O
the	O
mean	O
number	O
of	O
diseased	O
vessels	O
(	O
p-value	O
<	O
0.001	O
)	O
as	O
HbA1c	O
level	O
increases	O
.	O

Age	O
,	O
gender	O
,	O
hypertension	O
and	O
dyslipidemia	O
did	O
not	O
show	O
significant	O
difference	O
among	O
quartiles	O
however	O
smoking	O
was	O
found	O
to	O
be	O
an	O
independent	O
predictor	O
of	O
severity	O
of	O
CAD	O
by	O
SYNTAX	O
score	O
(	O
p	O
<	O
0.05	O
)	O
.	O

From	O
this	O
clinical	O
study	O
,	O
we	O
can	O
conclude	O
that	O
a	O
significant	O
correlation	O
exists	O
between	O
HbA1c	O
and	O
severity	O
of	O
CAD	O
by	O
SYNTAX	O
score	O
as	O
well	O
as	O
number	O
of	O
vessels	O
involved	O
in	O
non-	O
diabetes	O
.	O

Phishing	O
suspiciousness	O
in	O
older	O
and	O
younger	O
adults	O
:	O
The	O
role	O
of	O
executive	O
functioning	O
.	O

Phishing	O
is	O
the	O
spoofing	O
of	O
Internet	O
websites	O
or	O
emails	O
aimed	O
at	O
tricking	O
users	O
into	O
entering	O
sensitive	O
information	O
,	O
with	O
such	O
goals	O
as	O
financial	O
or	O
identity	O
theft	O
.	O

The	O
current	O
study	O
sought	O
to	O
determine	O
whether	O
age	O
is	O
associated	O
with	O
increased	O
susceptibility	O
to	O
phishing	O
and	O
whether	O
tests	O
of	O
executive	O
functioning	O
can	O
predict	O
phishing	O
susceptibility	O
.	O

A	O
total	O
of	O
193	O
cognitively	O
intact	O
participants	O
,	O
91	O
younger	O
adults	O
and	O
102	O
older	O
adults	O
,	O
were	O
primarily	O
recruited	O
through	O
a	O
Psychology	O
department	O
undergraduate	O
subject	O
pool	O
and	O
a	O
gerontology	O
research	O
registry	O
,	O
respectively	O
.	O

The	O
Executive	O
Functions	O
Module	O
from	O
the	O
Neuropsychological	O
Assessment	O
Battery	O
and	O
the	O
Iowa	O
Gambling	O
Task	O
were	O
the	O
primary	O
cognitive	O
predictors	O
of	O
reported	O
phishing	O
suspiciousness	O
.	O

Other	O
predictors	O
included	O
age	O
group	O
(	O
older	O
vs.	O
younger	O
)	O
,	O
sex	O
,	O
education	O
,	O
race	O
,	O
ethnicity	O
,	O
prior	O
knowledge	O
of	O
phishing	O
,	O
prior	O
susceptibility	O
to	O
phishing	O
,	O
and	O
whether	O
or	O
not	O
browsing	O
behaviors	O
were	O
reportedly	O
different	O
in	O
the	O
laboratory	O
setting	O
versus	O
at	O
home	O
.	O

A	O
logistic	O
regression	O
,	O
which	O
accounted	O
for	O
a	O
22.7	O
%	O
reduction	O
in	O
error	O
variance	O
compared	O
to	O
the	O
null	O
model	O
and	O
predicted	O
phishing	O
suspiciousness	O
with	O
73.1	O
%	O
(	O
95	O
%	O
CI	O
[	O
66.0	O
,	O
80.3	O
]	O
)	O
accuracy	O
,	O
revealed	O
three	O
statistically	O
significant	O
predictors	O
:	O
the	O
main	O
effect	O
of	O
education	O
(	O
b	O
=	O
0.58	O
,	O
SE	O
=	O
0.27	O
)	O
and	O
the	O
interactions	O
of	O
age	O
group	O
with	O
prior	O
awareness	O
of	O
phishing	O
(	O
b	O
=	O
2.31	O
,	O
SE	O
=	O
1.12	O
)	O
and	O
performance	O
on	O
the	O
Neuropsychological	B-P
Assessment	I-P
Battery	I-P
Mazes	I-P
test	I-P
(	O
b	O
=	O
0.16	O
,	O
SE	O
=	O
0.07	O
)	O
.	O

Whether	O
or	O
not	O
older	O
adults	O
reported	O
being	O
suspicious	O
of	O
the	O
phishing	O
attacks	O
used	O
in	O
this	O
study	O
was	O
partially	O
explained	O
by	O
educational	O
history	O
and	O
prior	O
phishing	O
knowledge	O
.	O

This	O
suggests	O
that	O
simple	O
educational	O
interventions	O
may	O
be	O
effective	O
in	O
reducing	O
phishing	O
vulnerability	O
.	O

Although	O
one	O
test	O
of	O
executive	O
functioning	O
was	O
found	O
useful	O
for	O
identifying	O
those	O
at	O
risk	O
of	O
phishing	O
susceptibility	O
,	O
four	O
tests	O
were	O
not	O
found	O
to	O
be	O
useful	O
;	O
these	O
results	O
speak	O
to	O
the	O
need	O
for	O
more	O
ecologically	O
valid	O
tools	O
in	O
clinical	O
neuropsychology	O
.	O

Breakthrough	O
viridans	O
streptococcal	O
bacteremia	O
in	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplant	O
recipients	O
receiving	O
levofloxacin	O
prophylaxis	O
in	O
a	O
Japanese	O
hospital	O
.	O

Breakthrough	O
viridans	O
streptococcal	O
bacteremia	O
(	O
VSB	O
)	O
in	O
patients	O
with	O
hematological	O
malignancy	O
receiving	O
levofloxacin	O
prophylaxis	O
is	O
a	O
major	O
blood	O
stream	O
infection	O
(	O
BSI	O
)	O
occurring	O
during	O
febrile	O
neutropenia	O
.	O

However	O
,	O
clinical	O
data	O
focused	O
on	O
VSB	O
in	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplant	O
(	O
allo-HSCT	O
)	O
recipients	O
are	O
lacking	O
.	O

The	O
medical	O
records	O
of	O
allo-HSCT	O
recipients	O
who	O
received	O
oral	O
levofloxacin	O
prophylaxis	O
between	O
January	O
2011	O
and	O
August	O
2013	O
at	O
Toranomon	O
Hospital	O
were	O
reviewed	O
to	O
evaluate	O
breakthrough	O
VSB	O
.	O

Stored	O
viridans	O
streptococcal	O
(	O
VGS	O
)	O
species	O
were	O
identified	O
by	O
using	O
sodA	O
gene	O
sequencing	B-P
,	O
and	O
were	O
assessed	O
for	O
drug	O
susceptibility	O
.	O

Among	O
the	O
184	O
allo-HSCT	O
recipients	O
on	O
levofloxacin	O
prophylaxis	O
,	O
28	O
(	O
15.2	O
%	O
)	O
experienced	O
breakthrough	O
VSB	O
.	O

All	O
of	O
the	O
28	O
recipients	O
with	O
VSB	O
were	O
treated	O
with	O
a	O
cefepime	O
-	O
based	O
or	O
piperacillin/tazobactam	O
-	O
based	O
regimen	O
.	O

The	O
susceptibility	O
rates	O
of	O
the	O
VGS	O
strains	O
for	O
levofloxacin	O
,	O
cefepime	O
,	O
piperacillin/tazobactam	O
,	O
meropenem	O
,	O
and	O
vancomycin	O
were	O
0	O
%	O
,	O
95	O
%	O
,	O
100	O
%	O
,	O
100	O
%	O
,	O
and	O
100	O
%	O
,	O
respectively	O
.	O

Both	O
the	O
MIC50	B-P
(	O
minimum	B-P
inhibitory	I-P
concentration	I-P
)	O
and	O
the	O
MIC90	B-P
of	O
ceftazidim	O
(	O
0.5	O
μg/mL	O
and	O
2	O
μg/mL	O
,	O
respectively	O
)	O
were	O
higher	O
than	O
the	O
MIC90	B-P
of	O
all	O
the	O
other	O
anti-pseudomonal	O
beta-lactams	O
(	O
APBLs	O
)	O
.	O

Only	O
1	O
VGS	O
strain	O
had	O
a	O
penicillin	O
MIC	B-P
≥	O
2	O
μg/mL	O
by	O
the	O
Etest	B-P
(	O
3.6	O
%	O
)	O
.	O

There	O
were	O
no	O
cases	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
that	O
was	O
associated	O
with	O
VSB	O
,	O
although	O
the	O
rate	O
of	O
viridans	O
group	O
streptococcal	O
shock	O
syndrome	O
was	O
high	O
(	O
26	O
%	O
)	O
.	O

The	O
crude	O
30-day	O
mortality	O
rate	O
in	O
the	O
VSB	O
group	O
(	O
10.7	O
%	O
)	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
in	O
the	O
BSI	O
without	O
VSB	O
group	O
(	O
9.3	O
%	O
)	O
or	O
non	O
-	O
BSI	O
group	O
(	O
7.0	O
%	O
)	O
(	O
P	O
=	O
0.77	O
)	O
.	O

Also	O
,	O
VSB	O
was	O
not	O
a	O
risk	O
factor	O
for	O
all-cause	O
mortality	O
up	O
to	O
60	O
days	O
following	O
allo-HSCT	O
(	O
P	O
=	O
0.43	O
)	O
.	O

APBL	O
with	O
increased	O
anti-VGS	O
activity	O
(	O
APBL-VA	O
)	O
monotherapy	O
would	O
typically	O
be	O
optimal	O
for	O
treating	O
the	O
VGS	O
strains	O
in	O
this	O
setting	O
.	O

Indication	O
of	O
adding	O
an	O
empiric	O
anti-gram-positive	O
agent	O
to	O
APBL-VA	O
for	O
treating	O
VSB	O
should	O
depend	O
on	O
local	O
factors	O
,	O
such	O
as	O
the	O
susceptibility	O
results	O
.	O

In	O
addition	O
,	O
breakthrough	O
VSB	O
is	O
probably	O
not	O
a	O
major	O
cause	O
of	O
death	O
in	O
allo-HSCT	O
settings	O
,	O
where	O
beta-lactam	O
non-susceptible	O
VGS	O
and	O
the	O
ARDS	O
are	O
rare	O
.	O

Regeneration	O
of	O
mandibular	O
ameloblastoma	O
defect	O
with	O
the	O
help	O
of	O
autologous	O
dental	O
pulp	O
stem	O
cells	O
and	O
buccal	O
pad	O
of	O
fat	O
stromal	O
vascular	O
fraction	O
.	O

Ameloblastoma	O
is	O
benign	O
odontogenic	O
tumor	O
,	O
which	O
is	O
locally	O
aggressive	O
in	O
behavior	O
.	O

Till	O
date	O
,	O
the	O
treatment	O
of	O
choice	O
is	O
resection	O
and	O
reconstruction	O
using	O
a	O
variety	O
of	O
modalities	O
.	O

Inadequate	O
resection	O
may	O
lead	O
to	O
many	O
complications	O
such	O
as	O
bone	O
deformity	O
and	O
dysfunction	O
.	O

This	O
report	O
is	O
about	O
a	O
14-	O
year-old	O
male	O
with	O
ameloblastoma	O
treated	O
with	O
autologous	O
dental	O
pulp	O
stem	O
cells	O
(	O
DPSCs	O
)	O
and	O
stromal	O
vascular	O
fraction	O
(	O
SVF	O
)	O
and	O
evidence	O
of	O
bone	O
regeneration	O
.	O

Marsupialization	O
was	O
performed	O
;	O
tooth	O
was	O
extracted	O
and	O
sent	O
for	O
DPSC	O
cultivation	O
.	O

On	O
the	O
day	O
of	O
surgery	O
,	O
SVF	O
was	O
processed	O
from	O
buccal	O
pad	O
of	O
fat	O
,	O
and	O
platelet-rich	O
fibrin	O
(	O
PRF	O
)	O
was	O
prepared	O
from	O
patient	O
's	O
peripheral	O
blood	O
.	O

During	O
the	O
procedure	O
,	O
labial	O
plate	O
resection	O
and	O
curating	O
of	O
tumor	O
lining	O
were	O
done	O
.	O

After	O
which	O
,	O
a	O
mesh	O
packed	O
with	O
SyboGraft	O
T-plug	O
,	O
prepared	O
SVF	O
,	O
DPSCs	O
,	O
and	O
PRF	O
were	O
placed	O
over	O
lingual	O
cortex	O
and	O
pressure	O
dressing	O
was	O
done	O
.	O

After	O
the	O
1	O
(	O
st	O
)	O
month	O
of	O
surgery	O
the	O
postoperative	O
course	O
was	O
uneventful	O
,	O
the	O
wound	O
shrinkage	O
led	O
to	O
exposure	O
of	O
mesh	O
in	O
the	O
intraoral	O
region	O
.	O

Removal	O
of	O
exposed	O
mesh	O
was	O
done	O
.	O

The	O
correction	O
surgery	O
with	O
removal	O
of	O
part	O
of	O
mesh	O
and	O
primary	O
closure	O
was	O
achieved	O
with	O
SyboGraft	O
plug	O
,	O
SVF	O
and	O
PRF	O
.	O

Enhanced	O
bone	O
formation	O
was	O
seen	O
in	O
post-operative	O
OPG	B-P
and	O
CT	B-P
Scan	I-P
after	O
10	O
(	O
th	O
)	O
month	O
.	O

In	O
this	O
article	O
,	O
we	O
propose	O
an	O
innovative	O
approach	O
to	O
manage	O
these	O
cases	O
by	O
using	O
a	O
combination	O
of	O
autologous	O
DPSC	O
and	O
buccal	O
pad	O
of	O
fat	O
SVF	O
to	O
regenerate	O
a	O
mandibular	O
defect	O
left	O
by	O
the	O
resection	O
of	O
an	O
ameloblastoma	O
with	O
1.5	O
year	O
follow-up	O
.	O

We	O
were	O
able	O
to	O
demonstrate	O
bone	O
regeneration	O
using	O
this	O
technique	O
with	O
no	O
recurrence	O
of	O
tumor	O
.	O

The	O
Relationship	O
Between	O
Thyroid	O
Function	O
and	O
the	O
Prevalence	O
of	O
Type	O
2	O
Diabetes	O
Mellitus	O
in	O
Euthyroid	O
Subjects	O
.	O

Thyroid	O
hormones	O
(	O
THs	O
)	O
are	O
primarily	O
responsible	O
for	O
the	O
regulation	O
of	O
energy	O
balance	O
and	O
metabolism	O
,	O
suggesting	O
that	O
TH	B-P
levels	I-P
may	O
contribute	O
to	O
the	O
development	O
of	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

However	O
,	O
few	O
studies	O
have	O
investigated	O
the	O
relationship	O
between	O
TH	O
and	O
T2DM	O
in	O
a	O
general	O
population	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
serum	O
TH	B-P
levels	I-P
within	O
the	O
reference	O
range	O
are	O
related	O
to	O
T2DM	O
.	O

A	O
cross-sectional	O
study	O
(	O
n	O
=	O
15,296	O
)	O
was	O
performed	O
in	O
Tianjin	O
,	O
China	O
.	O

Serum	O
free	O
triiodothyronine	O
(	O
FT3	O
)	O
,	O
free	O
thyroxine	O
(	O
FT4	O
)	O
,	O
and	O
thyroid-stimulating	O
hormone	O
(	O
TSH	O
)	O
levels	O
were	O
measured	O
by	O
chemiluminescence	B-P
immunoassay	I-P
,	O
and	O
T2DM	O
was	O
defined	O
according	O
to	O
the	O
American	O
Diabetes	O
Association	O
criteria	O
.	O

Multiple	O
logistic	O
regression	O
models	O
were	O
used	O
to	O
assess	O
the	O
sex	O
-	O
specific	O
relationships	O
between	O
FT3	O
,	O
FT4	O
,	O
FT3	O
/	O
FT4	O
ratios	O
,	O
and	O
TSH	O
quintiles	O
and	O
T2DM	O
.	O

The	O
prevalence	O
of	O
T2DM	O
was	O
16.2	O
%	O
in	O
males	O
and	O
7.7	O
%	O
in	O
females	O
.	O

In	O
males	O
,	O
the	O
multivariable-adjusted	O
odds	O
ratios	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
of	O
T2DM	O
for	O
increasing	O
quintiles	O
of	O
FT3	O
,	O
FT4	O
,	O
and	O
FT3	O
/	O
FT4	O
ratios	O
were	O
1.00	O
,	O
0.75	O
(	O
0.63	O
to	O
0.89	O
)	O
,	O
0.70	O
(	O
0.58	O
to	O
0.84	O
)	O
,	O
0.63	O
(	O
0.52	O
to	O
0.76	O
)	O
,	O
0.56	O
(	O
0.46	O
to	O
0.68	O
;	O
P	O
for	O
trend	O
<	O
0.0001	O
)	O
;	O
1.00	O
,	O
1.05	O
(	O
0.87	O
to	O
1.27	O
)	O
,	O
1.16	O
(	O
0.96	O
to	O
1.40	O
)	O
,	O
1.09	O
(	O
0.90	O
to	O
1.31	O
)	O
,	O
1.29	O
(	O
1.07	O
to	O
1.56	O
;	O
P	O
for	O
trend	O
=	O
0.01	O
)	O
;	O
and	O
1.00	O
,	O
0.69	O
(	O
0.58	O
to	O
0.83	O
)	O
,	O
0.72	O
(	O
0.60	O
to	O
0.86	O
)	O
,	O
0.59	O
(	O
0.48	O
to	O
0.71	O
)	O
,	O
and	O
0.55	O
(	O
0.46	O
to	O
0.66	O
;	O
P	O
for	O
trend	O
<	O
0.0001	O
)	O
,	O
respectively	O
.	O

Similar	O
results	O
also	O
were	O
observed	O
in	O
females	O
.	O

In	O
contrast	O
,	O
a	O
strong	O
negative	O
correlation	O
between	O
TSH	O
and	O
T2DM	O
was	O
observed	O
in	O
males	O
,	O
but	O
not	O
in	O
females	O
.	O

This	O
study	O
demonstrated	O
that	O
decreased	O
FT3	O
,	O
FT3	O
/	O
FT4	O
ratios	O
,	O
and	O
increased	O
FT4	O
levels	O
are	O
independently	O
related	O
to	O
a	O
higher	O
prevalence	O
of	O
T2DM	O
in	O
both	O
males	O
and	O
females	O
,	O
and	O
TSH	O
is	O
inversely	O
related	O
to	O
T2DM	O
in	O
males	O
only	O
.	O

Osseointegration	O
behavior	O
of	O
novel	O
Ti-Nb-Zr-Ta-Si	O
alloy	O
for	O
dental	O
implants	O
:	O
an	O
in	O
vivo	O
study	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
effects	O
of	O
Ti-Nb-Zr-Ta-Si	O
alloy	O
implants	O
on	O
mineral	O
apposition	O
rate	O
and	O
new	O
BIC	O
contact	O
in	O
rabbits	O
.	O

Twelve	O
Ti-Nb-Zr-Ta-Si	O
alloy	O
implants	O
were	O
fabricated	O
and	O
placed	O
into	O
the	O
right	O
femur	O
sites	O
in	O
six	O
rabbits	O
,	O
and	O
commercially	O
pure	O
titanium	O
implants	O
were	O
used	O
as	O
controls	O
in	O
the	O
left	O
femur	O
.	O

Tetracycline	O
and	O
alizarin	O
red	O
were	O
administered	O
3	O
weeks	O
and	O
1	O
week	O
before	O
euthanization	O
,	O
respectively	O
.	O

At	O
4	O
weeks	O
and	O
8	O
weeks	O
after	O
implantation	O
,	O
animals	O
were	O
euthanized	O
,	O
respectively	O
.	O

Surface	O
characterization	O
and	O
implant-bone	O
contact	O
surface	O
analysis	O
were	O
performed	O
by	O
using	O
a	O
scanning	O
electron	O
microscope	O
and	O
an	O
energy	O
dispersive	O
X-ray	O
detector	O
.	O

Mineral	O
apposition	O
rate	O
was	O
evaluated	O
using	O
a	O
confocal	B-P
laser	I-P
scanning	I-P
microscope	I-P
.	O

Toluidine	B-P
blue	I-P
staining	I-P
was	O
performed	O
on	O
undecalcified	O
sections	O
for	O
histology	O
and	O
histomorphology	O
evaluation	O
.	O

Scanning	O
electron	O
microscope	O
and	O
histomorphology	O
observation	O
revealed	O
a	O
direct	O
contact	O
between	O
implants	O
and	O
bone	O
of	O
all	O
groups	O
.	O

After	O
a	O
healing	O
period	O
of	O
4	O
weeks	O
,	O
Ti-Nb-Zr-Ta-Si	O
alloy	O
implants	O
showed	O
significantly	O
higher	O
mineral	O
apposition	O
rate	O
compared	O
to	O
commercially	O
pure	O
titanium	O
implants	O
(	O
P	O
<	O
0.05	O
)	O
,	O
whereas	O
there	O
was	O
no	O
significant	O
difference	O
between	O
Ti-Nb-Zr-Ta-Si	O
alloy	O
implants	O
and	O
commercially	O
pure	O
titanium	O
implants	O
(	O
P	O
>	O
0.05	O
)	O
at	O
8	O
weeks	O
.	O

No	O
significant	O
difference	O
of	O
bone-to-implant	O
contact	O
was	O
observed	O
between	O
Ti-Nb-Zr-Ta-Si	O
alloy	O
implants	O
and	O
commercially	O
pure	O
titanium	O
implants	O
implants	O
after	O
a	O
healing	O
period	O
of	O
4	O
weeks	O
and	O
8	O
weeks	O
.	O

This	O
study	O
showed	O
that	O
Ti-Nb-Zr-Ta-Si	O
alloy	O
implants	O
could	O
establish	O
a	O
close	O
direct	O
contact	O
comparedto	O
commercially	O
pure	O
titanium	O
implants	O
implants	O
,	O
improved	O
mineral	O
matrix	O
apposition	O
rate	O
,	O
and	O
may	O
someday	O
be	O
an	O
alternative	O
as	O
a	O
material	O
for	O
dental	O
implants	O
.	O

Antibacterial	O
Activity	O
of	O
Polyaniline	O
Coated	O
Silver	O
Nanoparticles	O
Synthesized	O
from	O
Piper	O
Betle	O
Leaves	O
Extract	O
.	O

Plants	O
or	O
natural	O
resources	O
have	O
been	O
found	O
to	O
be	O
a	O
good	O
alternative	O
method	O
for	O
nanoparticles	O
synthesis	O
.	O

In	O
this	O
study	O
,	O
polyaniline	O
coated	O
silver	O
nanoparticles	O
(	O
AgNPs	O
)	O
synthesized	O
from	O
Piper	O
betle	O
leaves	O
extract	O
were	O
investigated	O
for	O
their	O
antibacterial	O
activity	O
.	O

Silver	O
nanoparticles	O
were	O
prepared	O
from	O
the	O
reduction	O
of	O
silver	O
nitrate	O
and	O
NaBH4	O
was	O
used	O
as	O
reducing	O
agent	O
.	O

Silver	O
nanoparticles	O
and	O
extracts	O
were	O
mixed	O
thoroughly	O
and	O
then	O
coated	O
by	O
polyaniline	O
.	O

Prepared	O
nanoparticles	O
were	O
characterized	O
by	O
Visual	O
inspection	O
,	O
Ultraviolet-visible	B-P
spectroscopy	I-P
(	O
UV	B-P
)	O
,	O
Fourier	O
transform	O
infrared	O
Spectroscopy	O
(	O
FT-IR	O
)	O
,	O
Transmission	B-P
Electron	I-P
Microscopy	I-P
(	I-P
TEM	I-P
)	I-P
techniques	I-P
.	O

Antibacterial	O
activities	O
of	O
the	O
synthesized	O
silver	O
nanoparticles	O
were	O
tested	O
against	O
Staphylococcus	O
aureus	O
ATCC	O
25923	O
,	O
Salmonella	O
typhi	O
ATCC	O
14028	O
,	O
Escherichia	O
coli	O
ATCC	O
25922	O
and	O
Pseudomonas	O
aeruginosa	O
ATCC	O
27853	O
.	O

UV-Vis	B-P
spectrum	I-P
of	O
reaction	O
mixture	O
showed	O
strong	O
absorption	O
peak	O
with	O
centering	O
at	O
400	O
nm	O
.	O

The	O
FT-IR	O
results	O
imply	O
that	O
Ag-NPs	O
were	O
successfully	O
synthesized	O
and	O
capped	O
with	O
bio-compounds	O
present	O
in	O
P.	O
betle	O
.	O

TEM	B-P
image	O
showed	O
that	O
Ag-NPs	O
formed	O
were	O
well	O
dispersed	O
with	O
a	O
spherical	O
structures	O
and	O
particle	O
size	O
ranging	O
from	O
10	O
to	O
30	O
nm	O
.	O

The	O
result	O
revealed	O
that	O
Ag-Extract	O
NPs	O
showed	O
32.78±0.64	O
mm	O
zone	O
of	O
inhibition	O
against	O
S.	O
aureus	O
,	O
whereas	O
norfloxacin	O
(	O
positive	O
control	O
)	O
showed	O
maximum	O
32.15±0.40	O
mm	O
zone	O
of	O
inhibition	O
for	O
S.	O
aureus	O
.	O

Again	O
,	O
maximum	O
zone	O
of	O
inhibition	O
29.55±0.45	O
mm	O
was	O
found	O
for	O
S.	O
typhi	O
,	O
27.12±0.38	O
mm	O
for	O
E.	O
coli	O
and	O
21.95±0.45	O
mm	O
for	O
P.	O
aeruginosa	O
.	O

The	O
results	O
obtained	O
by	O
this	O
study	O
ca	O
n't	O
be	O
directly	O
extrapolated	O
to	O
human	O
;	O
so	O
further	O
studies	O
should	O
be	O
undertaken	O
to	O
established	O
the	O
strong	O
antimicrobial	O
activity	O
of	O
Ag-Extract	O
NPs	O
for	O
drug	O
development	O
program	O
.	O

Early	O
assessment	O
of	O
bilateral	O
inguinal	O
hernia	O
repair	O
:	O
A	O
comparison	O
between	O
the	O
laparoscopic	O
total	O
extraperitoneal	O
and	O
Stoppa	O
approaches	O
.	O

The	O
present	O
clinical	O
trial	O
was	O
designed	O
to	O
compare	O
the	O
results	O
of	O
bilateral	O
inguinal	O
hernia	O
repair	O
between	O
patients	O
who	O
underwent	O
the	O
conventional	O
Stoppa	O
technique	O
and	O
laparoscopic	O
total	O
extraperitoneal	O
repair	O
(	O
LTE	O
)	O
with	O
a	O
single	O
mesh	O
and	O
without	O
staple	O
fixation	O
.	O

This	O
controlled	O
,	O
randomised	O
clinical	O
trial	O
was	O
conducted	O
at	O
General	O
Surgery	O
and	O
Trauma	O
of	O
the	O
Clinics	O
Hospital	O
,	O
Medical	O
School	O
,	O
the	O
University	O
of	O
Sγo	O
Paulo	O
between	O
September	O
2010	O
and	O
February	O
2011	O
.	O

Totally	O
,	O
50	O
male	O
patients	O
,	O
with	O
a	O
bilateral	O
inguinal	O
hernia	O
,	O
older	O
than	O
25	O
years	O
were	O
considered	O
eligible	O
for	O
the	O
study	O
.	O

The	O
following	O
parameters	O
were	O
analysed	O
during	O
the	O
early	O
post-operative	O
period	O
:	O
(	O
1	O
)	O
The	O
intensity	O
of	O
surgical	O
trauma	O
,	O
operation	O
time	O
,	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
levels	O
,	O
white	B-P
blood	I-P
cell	I-P
count	I-P
,	O
bleeding	O
and	O
pain	O
intensity	O
;	O
(	O
2	O
)	O
quality	O
of	O
life	O
assessment	O
;	O
and	O
(	O
3	O
)	O
post-operative	O
complications	O
.	O

LTE	O
procedure	O
was	O
longer	O
than	O
the	O
Stoppa	O
procedure	O
(	O
134.6	O
min	O
΁	O
38.3	O
vs.	O
90.6	O
min	O
΁	O
41.3	O
;	O
P	O
<	O
0.05	O
)	O
.	O

The	O
levels	O
of	O
CRP	O
were	O
higher	O
in	O
the	O
Stoppa	O
group	O
(	O
P	O
<	O
0.05	O
)	O
but	O
the	O
number	O
of	O
leucocytes	O
,	O
haematocrit	O
,	O
and	O
haemoglobin	O
were	O
similar	O
between	O
the	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
pain	O
during	O
the	O
1	O
st	O
and	O
7	O
th	O
post-operative	O
,	O
physical	O
functioning	O
,	O
physical	O
limitation	O
,	O
the	O
impact	O
of	O
pain	O
on	O
daily	O
activities	O
,	O
and	O
the	O
Carolinas	O
Comfort	O
Scale	O
during	O
the	O
7	O
th	O
and	O
15	O
th	O
post-operative	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Complications	O
occurred	O
in	O
88	O
%	O
of	O
Stoppa	O
group	O
(	O
22	O
patients	O
)	O
and	O
64	O
%	O
in	O
LTE	O
group	O
(	O
16	O
patients	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
comparative	O
study	O
between	O
the	O
Stoppa	O
and	O
LTE	O
approaches	O
for	O
the	O
bilateral	O
inguinal	O
hernia	O
repair	O
demonstrated	O
that	O
:	O
(	O
1	O
)	O
The	O
LTE	O
approach	O
showed	O
less	O
surgical	O
trauma	O
despite	O
the	O
longer	O
operation	O
time	O
;	O
(	O
2	O
)	O
Quality	O
of	O
life	O
during	O
the	O
early	O
post-operative	O
period	O
were	O
similar	O
;	O
and	O
(	O
3	O
)	O
Complication	O
rates	O
were	O
higher	O
in	O
the	O
Stoppa	O
group	O
.	O

Minocycline	O
reduces	O
mechanical	O
allodynia	O
and	O
depressive-like	O
behaviour	O
in	O
type-1	O
diabetes	O
mellitus	O
in	O
the	O
rat	O
.	O

A	O
common	O
and	O
devastating	O
complication	O
of	O
diabetes	O
mellitus	O
is	O
painful	O
diabetic	O
neuropathy	O
(	O
PDN	O
)	O
that	O
can	O
be	O
accompanied	O
by	O
emotional	O
disorders	O
such	O
as	O
depression	O
.	O

A	O
few	O
studies	O
have	O
suggested	O
that	O
minocycline	O
that	O
inhibits	O
microglia	O
may	O
attenuate	O
pain	O
hypersensitivity	O
in	O
PDN	O
.	O

Moreover	O
,	O
a	O
recent	O
study	O
reported	O
that	O
minocycline	O
has	O
an	O
acute	O
antidepressive-like	O
effect	O
in	O
diabetic	O
animals	O
.	O

Here	O
we	O
studied	O
whether	O
(	O
i	O
)	O
prolonged	O
minocycline	O
treatment	O
suppresses	O
pain	O
behaviour	O
in	O
PDN	O
,	O
(	O
ii	O
)	O
the	O
minocycline	O
effect	O
varies	O
with	O
submodality	O
of	O
pain	O
,	O
and	O
(	O
iii	O
)	O
the	O
suppression	O
of	O
pain	O
behaviour	O
by	O
prolonged	O
minocycline	O
treatment	O
is	O
associated	O
with	O
antidepressive-like	O
effect	O
.	O

The	O
experiments	O
were	O
performed	O
in	O
streptozotocin	O
-	O
induced	O
rat	O
model	O
of	O
type-1	O
diabetes	O
.	O

Pain	O
behaviour	O
was	O
evoked	O
by	O
innocuous	O
(	O
monofilaments	O
)	O
and	O
noxious	O
(	O
paw	O
pressure	O
)	O
mechanical	O
stimulation	O
,	O
innocuous	O
cold	O
(	O
acetone	O
drops	O
)	O
and	O
noxious	O
heat	O
(	O
radiant	O
heat	O
)	O
.	O

Depression-like	O
behaviour	O
was	O
assessed	O
using	O
forced	B-P
swimming	I-P
test	I-P
.	O

Minocycline	O
treatment	O
(	O
daily	O
80	O
mg/kg	O
per	O
os	O
)	O
of	O
three-	O
week	O
duration	O
started	O
four	O
weeks	O
after	O
induction	O
of	O
diabetes	O
.	O

Diabetes	O
induced	O
mechanical	O
allodynia	O
and	O
hyperalgesia	O
,	O
cold	O
allodynia	O
,	O
heat	O
hypoalgesia	O
,	O
and	O
depression-like	O
behaviour	O
.	O

Minocycline	O
treatment	O
significantly	O
attenuated	O
mechanical	O
allodynia	O
and	O
depression-like	O
behaviour	O
,	O
while	O
it	O
failed	O
to	O
produce	O
significant	O
changes	O
in	O
mechanical	O
hyperalgesia	O
,	O
cold	O
allodynia	O
or	O
heat	O
hypoalgesia	O
.	O

The	O
results	O
indicate	O
that	O
prolonged	O
per	O
oral	O
treatment	O
with	O
minocycline	O
has	O
a	O
sustained	O
mechanical	O
antiallodynic	O
and	O
antidepressive-like	O
effect	O
in	O
PDN	O
.	O

These	O
results	O
support	O
the	O
proposal	O
that	O
minocycline	O
might	O
provide	O
a	O
treatment	O
option	O
for	O
attenuating	O
sensory	O
and	O
comorbid	O
emotional	O
symptoms	O
in	O
chronic	O
PDN	O
.	O

Sustained	O
delivery	O
of	O
vincristine	O
inside	O
an	O
orthotopic	O
mouse	O
sarcoma	O
model	O
decreases	O
tumor	O
growth	O
.	O

Sarcoma	O
accounts	O
for	O
20	O
%	O
of	O
solid	O
tumors	O
in	O
children	O
.	O

Surgery	O
has	O
significant	O
morbidity	O
.	O

We	O
hypothesized	O
that	O
delivering	O
chemotherapy	O
directly	O
into	O
tumors	O
through	O
sustained	O
release	O
silk	O
systems	O
could	O
slow	O
tumor	O
growth	O
.	O

Human	O
Ewing	O
sarcoma	O
cells	O
A673	O
were	O
cultured	B-P
with	O
vincristine	O
and	O
doxorubicin	O
to	O
determine	O
half	O
maximal	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
.	O

Cells	O
were	O
injected	O
into	O
mouse	O
hind	O
leg	O
to	O
create	O
orthotopic	O
tumors	O
.	O

Tumor	O
volumes	O
were	O
measured	O
using	O
ultrasound	B-P
.	O

When	O
volume	O
reached	O
>	O
250mm	O
(	O
3	O
,	O
)	O
interventions	O
included	O
:	O
implantation	O
of	O
drug-free	O
silk	O
foam	O
(	O
Control	O
-F	O
)	O
,	O
doxorubicin	O
400μg	O
foam	O
(	O
Dox400	O
-F	O
)	O
,	O
vincristine	O
50μg	O
foam	O
(	O
Vin50	O
-F	O
)	O
,	O
drug-free	O
silk	O
gel	O
(	O
Control	O
-G	O
)	O
,	O
vincristine	O
50μg	O
gel	O
(	O
Vin50	O
-G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	O
vincristine	O
50μg	O
(	O
Vin50	O
-IV	O
)	O
.	O

End-point	O
was	O
volume	O
>	O
1000mm	O
(	O
3	O
)	O
.	O

Kaplan	O
Meier	O
and	O
ANOVA	O
were	O
used	O
.	O

IC50	O
for	O
vincristine	O
and	O
doxorubicin	O
was	O
0.5ng/mL	O
and	O
200ng/mL	O
,	O
respectively	O
.	O

There	O
was	O
no	O
difference	O
between	O
Dox400	O
-F	O
[	O
6±	O
1days	O
to	O
end	O
point	O
(	O
DTEP	O
)	O
]	O
and	O
Control	O
-F	O
(	O
5±1.3	O
DTEP	O
)	O
.	O

Vin50	O
-F	O
(	O
12.4±3.5	O
DTEP	O
)	O
had	O
slower	O
growth	O
compared	O
to	O
Control	O
-F	O
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
there	O
was	O
no	O
difference	O
between	O
Vin50	O
-F	O
and	O
Vin50	O
-IV	O
(	O
14±0	O
DTEP	O
)	O
.	O

Growth	O
was	O
slowest	O
with	O
Vin50	O
-G	O
,	O
28±10.3	O
DTEP	O
compared	O
to	O
all	O
other	O
treatment	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Sustained	O
delivery	O
of	O
vincristine	O
inside	O
the	O
sarcoma	O
tumor	O
with	O
silk	O
gel	O
decreased	O
tumor	O
growth	O
.	O

Applying	O
this	O
intratumoral	O
treatment	O
strategy	O
may	O
potentially	O
decrease	O
the	O
extent	O
of	O
surgical	O
excision	O
.	O

Evaluation	O
of	O
function	O
and	O
recovery	B-P
of	O
adipose	O
-derived	O
stem	O
cells	O
after	O
exposure	O
to	O
paclitaxel	O
.	O

Adipose	O
-derived	O
stem	O
cells	O
(	O
ASCs	O
)	O
are	O
considered	O
to	O
play	O
a	O
positive	O
role	O
in	O
wound	O
healing	O
as	O
evidenced	O
by	O
their	O
increasing	O
use	O
in	O
breast	O
reconstructive	O
procedures	O
.	O

After	O
chemotherapy	O
for	O
breast	O
cancer	O
,	O
poor	O
soft	O
tissue	O
wound	O
healing	O
is	O
a	O
major	O
problem	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
functional	O
capabilities	O
and	O
recovery	B-P
of	O
ASCs	O
after	O
exposure	O
to	O
chemotherapeutic	O
agent	O
paclitaxel	O
(	O
PTX	O
)	O
using	O
in	O
vitro	O
and	O
ex	O
vivo	O
models	O
were	O
demonstrated	O
.	O

Human	O
ASCs	O
were	O
isolated	O
from	O
periumbilical	O
fat	O
tissue	O
and	O
treated	O
with	O
PTX	O
at	O
various	O
concentrations	O
.	O

Adult	O
Sprague-Dawley	O
rats	O
were	O
given	O
intravenous	O
injections	O
with	O
PTX	O
.	O

Two	O
and	O
four	O
weeks	O
after	O
the	O
initial	O
PTX	O
treatment	O
,	O
ASCs	O
were	O
isolated	O
from	O
rat	O
adipose	O
tissue	O
.	O

Proliferation	O
,	O
cell	O
viability	O
,	O
apoptosis	O
and	O
cell	O
migration	O
rates	O
were	O
measured	O
by	O
growth	O
curves	O
,	O
MTT	O
assays	O
,	O
flow	B-P
cytometry	I-P
and	O
scratch	B-P
assays	I-P
.	O

ASCs	O
were	O
cultured	O
in	O
derivative-specific	O
differentiation	O
media	O
with	O
or	O
without	O
PTX	O
for	O
3	O
weeks	O
.	O

Adipogenic	O
,	O
osteogenic	O
and	O
endothelial	O
differentiation	O
levels	O
were	O
measured	O
by	O
quantitative	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
and	O
histological	B-P
staining	B-P
.	O

PTX	O
induced	O
apoptosis	O
,	O
decreased	O
the	O
proliferation	O
and	O
cell	O
migration	O
rates	O
of	O
ASCs	O
and	O
inhibited	O
ASCs	O
multipotent	O
differentiation	O
in	O
both	O
in	O
vitro	O
human	O
ASC	O
populations	O
and	O
ex	O
vivo	O
rat	O
ASC	O
populations	O
with	O
PTX	O
treatment	O
.	O

Furthermore	O
,	O
after	O
cessation	O
of	O
PTX	O
,	O
ASCs	O
exhibited	O
recovery	B-P
potential	O
of	O
differentiation	O
capacity	O
in	O
both	O
in	O
vitro	O
and	O
animal	O
studies	O
.	O

Our	O
results	O
provide	O
insight	O
into	O
poor	O
soft	O
tissue	O
wound	O
healing	O
and	O
promote	O
further	O
understanding	O
of	O
the	O
potential	O
capability	O
of	O
ASCs	O
to	O
serve	O
as	O
a	O
cell	O
source	O
for	O
fat	O
grafting	O
and	O
reconstruction	O
in	O
cancer	O
patients	O
undergoing	O
chemotherapy	O
treatment	O
.	O

Three-Dimensional	O
HyCoSy	B-P
With	O
Perfluoropropane-Albumin	O
Microspheres	O
as	O
Contrast	O
Agents	O
and	O
Normal	O
Saline	O
Injections	O
Into	O
the	O
Pelvic	O
Cavity	O
for	O
Morphological	O
Assessment	O
of	O
the	O
Fallopian	O
Tube	O
in	O
Infertile	O
Women	O
.	O

To	O
apply	O
the	O
three-dimensional	O
(	O
3D	O
)	O
hysterosalpingo-contrast	B-P
sonography	I-P
(	O
HyCoSy	B-P
)	O
with	O
perfluoropropane-albumin	O
microspheres	O
as	O
contrast	O
agents	O
and	O
normal	O
saline	O
injections	O
into	O
the	O
pelvic	O
cavity	O
for	O
assessment	B-P
of	I-P
the	I-P
tubal	I-P
patency	I-P
and	O
adhesions	O
of	O
fimbrial	O
parts	O
.	O

Fifty-five	O
infertile	O
female	O
patients	O
were	O
recruited	O
to	O
undergo	O
3D	O
HyCoSy	B-P
with	O
normal	O
saline	O
injected	O
into	O
the	O
pelvic	O
cavity	O
,	O
in	O
which	O
the	O
tubal	O
patency	O
was	O
observed	O
by	O
visualizing	O
the	O
spillage	O
of	O
contrast	O
agents	O
from	O
the	O
fimbriae	O
,	O
and	O
the	O
fimbrial	O
adhesion	O
was	O
confirmed	O
by	O
the	O
finger-like	O
projections	O
of	O
the	O
fimbriae	O
and	O
their	O
floating	O
and	O
moving	O
status	O
.	O

Of	O
the	O
55	O
patients	O
,	O
bilateral	O
tubal	O
patency	O
was	O
observed	O
in	O
44	O
(	O
80.0	O
%	O
)	O
,	O
unilateral	O
tubal	O
patency	O
and	O
the	O
other	O
partial	O
occlusion	O
in	O
7	O
(	O
12.7	O
%	O
)	O
,	O
unilateral	O
partial	O
occlusion	O
and	O
the	O
other	O
complete	O
occlusion	O
in	O
3	O
(	O
5.4	O
%	O
)	O
,	O
and	O
bilateral	O
complete	O
occlusion	O
in	O
1	O
(	O
1.8	O
%	O
)	O
.	O

The	O
fimbrial	O
parts	O
were	O
observed	O
in	O
105	O
fallopian	O
tubes	O
,	O
among	O
which	O
101	O
were	O
seen	O
with	O
the	O
finger-like	O
fimbriae	O
floated	O
and	O
moved	O
in	O
the	O
pelvic	O
cavity	O
,	O
whereas	O
4	O
tubes	O
were	O
not	O
because	O
of	O
adhesion	O
to	O
the	O
pelvic	O
cavity	O
(	O
n	O
=	O
3	O
)	O
or	O
the	O
ovary	O
and	O
intestine	O
(	O
n	O
=	O
1	O
)	O
.	O

More	O
than	O
three	O
visible	O
,	O
quite	O
long	O
,	O
and	O
distributed	O
evenly	O
finger-like	O
projection	O
s	O
were	O
present	O
for	O
the	O
patent	O
fimbrial	O
parts	O
;	O
however	O
,	O
fewer	O
,	O
flat	O
,	O
and	O
not	O
evenly	O
distributed	O
finger-like	O
projection	O
s	O
were	O
present	O
for	O
the	O
adhesive	O
tubes	O
.	O

No	O
serious	O
complications	O
occurred	O
during	O
or	O
after	O
this	O
procedure	B-P
.	O

Combination	O
of	O
3D	O
HyCoSy	B-P
with	O
normal	O
saline	O
injected	O
into	O
the	O
pelvic	O
cavity	O
may	O
be	O
a	O
feasible	O
and	O
safe	O
procedure	B-P
to	O
assess	O
tubal	O
patency	O
and	O
adhesions	O
of	O
the	O
fimbrial	O
parts	O
.	O

Ketogenic	O
diets	O
improve	O
behaviors	O
associated	O
with	O
autism	O
spectrum	O
disorder	O
in	O
a	O
sex	O
-	O
specific	O
manner	O
in	O
the	O
EL	O
mouse	O
.	O

The	O
core	O
symptoms	O
of	O
autism	O
spectrum	O
disorder	O
are	O
poorly	O
treated	O
with	O
current	O
medications	O
.	O

Symptoms	O
of	O
autism	O
spectrum	O
disorder	O
are	O
frequently	O
comorbid	O
with	O
a	O
diagnosis	B-P
of	O
epilepsy	O
and	O
vice	O
versa	O
.	O

Medically	O
-	O
supervised	O
ketogenic	O
diets	O
are	O
remarkably	O
effective	O
nonpharmacological	O
treatments	O
for	O
epilepsy	O
,	O
even	O
in	O
drug	O
-refractory	O
cases	O
.	O

There	O
is	O
accumulating	O
evidence	O
that	O
supports	O
the	O
efficacy	O
of	O
ketogenic	O
diets	O
in	O
treating	O
the	O
core	O
symptoms	O
of	O
autism	O
spectrum	O
disorders	O
in	O
animal	O
models	O
as	O
well	O
as	O
limited	O
reports	O
of	O
benefits	O
in	O
patients	O
.	O

This	O
study	O
tests	B-P
the	O
behavioral	O
effects	O
of	O
ketogenic	O
diet	O
feeding	O
in	O
the	O
EL	O
mouse	O
,	O
a	O
model	O
with	O
behavioral	O
characteristics	O
of	O
autism	O
spectrum	O
disorder	O
and	O
comorbid	O
epilepsy	O
.	O

Male	O
and	O
female	O
EL	O
mice	O
were	O
fed	O
control	O
diet	O
or	O
one	O
of	O
two	O
ketogenic	O
diet	O
formulas	O
ad	O
libitum	O
starting	O
at	O
5weeks	O
of	O
age	O
.	O

Beginning	O
at	O
8weeks	O
of	O
age	O
,	O
diet	O
protocols	O
continued	O
and	O
performance	O
of	O
each	O
group	O
on	O
tests	O
of	O
sociability	O
and	O
repetitive	O
behavior	O
was	O
assessed	O
.	O

A	O
ketogenic	O
diet	O
improved	O
behavioral	O
characteristics	O
of	O
autism	O
spectrum	O
disorder	O
in	O
a	O
sex	O
-	O
and	O
test	O
-	O
specific	O
manner	O
;	O
ketogenic	O
diet	O
never	O
worsened	O
relevant	O
behaviors	O
.	O

Ketogenic	O
diet	O
feeding	O
improved	O
multiple	O
measures	O
of	O
sociability	O
and	O
reduced	O
repetitive	O
behavior	O
in	O
female	O
mice	O
,	O
with	O
limited	O
effects	O
in	O
males	O
.	O

Additional	O
experiments	O
in	O
female	O
mice	O
showed	O
that	O
a	O
less	O
strict	O
,	O
more	O
clinically	O
-	O
relevant	O
diet	O
formula	O
was	O
equally	O
effective	O
in	O
improving	O
sociability	O
and	O
reducing	O
repetitive	O
behavior	O
.	O

Taken	O
together	O
these	O
results	O
add	O
to	O
the	O
growing	O
number	O
of	O
studies	O
suggesting	O
that	O
ketogenic	O
and	O
related	O
diets	O
may	O
provide	O
significant	O
relief	O
from	O
the	O
core	O
symptoms	O
of	O
autism	O
spectrum	O
disorder	O
,	O
and	O
suggest	O
that	O
in	O
some	O
cases	O
there	O
may	O
be	O
increased	O
efficacy	O
in	O
females	O
.	O

The	O
Abundance	O
of	O
Endofungal	O
Bacterium	O
Rhizobium	O
radiobacter	O
(	O
syn	O
.	O

Agrobacterium	O
tumefaciens	O
)	O
Increases	O
in	O
Its	O
Fungal	O
Host	O
Piriformospora	O
indica	O
during	O
the	O
Tripartite	O
Sebacinalean	O
Symbiosis	O
with	O
Higher	O
Plants	O
.	O

Rhizobium	O
radiobacter	O
(	O
syn	O
.	O

Agrobacterium	O
tumefaciens	O
,	O
syn.	O
``	O

Agrobacterium	O
fabrum	O
``	O
)	O
is	O
an	O
endofungal	O
bacterium	O
of	O
the	O
fungal	O
mutualist	O
Piriformospora	O
(	O
syn	O
.	O

Serendipita	O
)	O
indica	O
(	O
Basidiomycota	O
)	O
,	O
which	O
together	O
form	O
a	O
tripartite	O
Sebacinalean	O
symbiosis	O
with	O
a	O
broad	O
range	O
of	O
plants	O
.	O

R.	O
radiobacter	O
strain	O
F4	O
(	O
RrF4	O
)	O
,	O
isolated	O
from	O
P.	O
indica	O
DSM	O
11827	O
,	O
induces	O
growth	O
promotion	O
and	O
systemic	O
resistance	O
in	O
cereal	O
crops	O
,	O
including	O
barley	O
and	O
wheat	O
,	O
suggesting	O
that	O
R.	O
radiobacter	O
contributes	O
to	O
a	O
successful	O
symbiosis	O
.	O

Here	O
,	O
we	O
studied	O
the	O
impact	O
of	O
endobacteria	O
on	O
the	O
morphology	O
and	O
the	O
beneficial	O
activity	O
of	O
P.	O
indica	O
during	O
interactions	O
with	O
plants	O
.	O

Low	O
numbers	O
of	O
endobacteria	O
were	O
detected	O
in	O
the	O
axenically	B-P
grown	I-P
P.	O
indica	O
(	O
long	O
term	O
lab-cultured	B-P
,	O
lcPiri	O
)	O
whereas	O
mycelia	O
colonizing	O
the	O
plant	O
root	O
contained	O
increased	O
numbers	O
of	O
bacteria	O
.	O

Higher	O
numbers	O
of	O
endobacteria	O
were	O
also	O
found	O
in	O
axenic	B-P
cultures	I-P
of	O
P.	O
indica	O
that	O
was	O
freshly	O
re-isolated	O
(	O
riPiri	O
)	O
from	O
plant	O
roots	O
,	O
though	O
numbers	O
dropped	O
during	O
repeated	O
axenic	B-P
re-cultivation	I-P
.	O

Prolonged	O
treatments	O
of	O
P.	O
indica	O
cultures	B-P
with	O
various	O
antibiotics	O
could	O
not	O
completely	O
eliminate	O
the	O
bacterium	O
,	O
though	O
the	O
number	O
of	O
detectable	O
endobacteria	O
decreased	O
significantly	O
,	O
resulting	O
in	O
partial-cured	O
P.	O
indica	O
(	O
pcPiri	O
)	O
.	O

pcPiri	O
showed	O
reduced	O
growth	O
in	O
axenic	B-P
cultures	I-P
and	O
poor	O
sporulation	O
.	O

Consistent	O
with	O
this	O
,	O
pcPiri	O
also	O
showed	O
reduced	O
plant	O
growth	O
promotion	O
and	O
reduced	O
systemic	O
resistanc	O
e	O
against	O
powdery	O
mildew	O
infection	O
as	O
compared	O
with	O
riPiri	O
and	O
lcPiri	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
assumption	O
that	O
the	O
endobacterium	O
R.	O
radiobacter	O
improves	O
P.	O
indica	O
's	O
fitness	O
and	O
thus	O
contributes	O
to	O
the	O
success	O
of	O
the	O
tripartite	O
Sebacinalean	O
symbiosis	O
.	O

Flash	B-P
visual	I-P
evoked	I-P
potentials	I-P
in	O
diurnal	O
birds	O
of	O
prey	O
.	O

The	O
objective	O
of	O
this	O
pilot	O
study	O
was	O
to	O
evaluate	O
the	O
feasibility	O
of	O
Flash	B-P
Visual	I-P
Evoked	I-P
Potentials	I-P
(	O
FVEPs	B-P
)	O
testing	O
in	O
birds	O
of	O
prey	O
in	O
a	O
clinical	O
setting	O
and	O
to	O
describe	O
the	O
protocol	O
and	O
the	O
baseline	O
data	O
for	O
normal	O
vision	O
in	O
this	O
species	O
.	O

FVEP	B-P
recordings	O
were	O
obtained	O
from	O
6	O
normal	O
adult	O
birds	O
of	O
prey	O
:	O
n.	O
2	O
Harris	O
's	O
Hawks	O
(	O
Parabuteo	O
unicinctus	O
)	O
,	O
n.	O
1	O
Lanner	O
Falcon	O
(	O
Falco	O
biarmicus	O
)	O
,	O
n.	O
2	O
Gyrfalcons	O
(	O
Falco	O
rusticolus	O
)	O
and	O
n.	O
1	O
Saker	O
Falcon	O
(	O
Falco	O
cherrug	O
)	O
.	O

Before	O
carrying	O
out	O
VEP	B-P
tests	I-P
,	O
all	O
animals	O
underwent	O
neurologic	B-P
and	O
ophthalmic	O
routine	O
examination	O
.	O

Waveforms	O
were	O
analysed	O
to	O
identify	O
reproducible	O
peaks	O
from	O
random	O
variation	O
of	O
baseline	O
.	O

At	O
least	O
three	O
positive	O
and	O
negative	O
peaks	O
were	O
highlighted	O
in	O
all	O
tracks	O
with	O
elevated	O
repeatability	O
.	O

Measurements	O
consisted	O
of	O
the	O
absolute	O
and	O
relative	O
latencies	O
of	O
these	O
peaks	O
(	O
P1	O
,	O
N1	O
,	O
P2	O
,	O
N2	O
,	O
P3	O
,	O
and	O
N3	O
)	O
and	O
their	O
peak-to-peak	O
amplitudes	O
.	O

Both	O
the	O
peak	O
latency	O
and	O
wave	O
morphology	O
achieved	O
from	O
normal	O
animals	O
were	O
similar	O
to	O
those	O
obtained	O
previously	O
in	O
other	O
animal	O
species	O
.	O

This	O
test	B-P
can	O
be	O
easily	O
and	O
safely	O
performed	O
in	O
a	O
clinical	O
setting	O
in	O
birds	O
of	O
prey	O
and	O
could	O
be	O
useful	O
for	O
an	O
objective	O
assessment	O
of	O
visual	O
function	O
.	O

Perfusion	O
deconvolution	O
in	O
DSC-MRI	B-P
with	O
dispersion-compliant	O
bases	O
.	O

Perfusion	B-P
imaging	I-P
of	O
the	O
brain	O
via	O
Dynamic	B-P
Susceptibility	I-P
Contrast	I-P
MRI	I-P
(	O
DSC-MRI	B-P
)	O
allows	O
tissue	O
perfusion	O
characterization	O
by	O
recovering	O
the	O
tissue	O
impulse	O
response	O
function	O
and	O
scalar	O
parameters	O
such	O
as	O
the	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
,	O
blood	O
volume	O
(	O
CBV	O
)	O
,	O
and	O
mean	O
transit	O
time	O
(	O
MTT	O
)	O
.	O

However	O
,	O
the	O
presence	O
of	O
bolus	O
dispersion	O
causes	O
the	O
data	O
to	O
reflect	O
macrovascular	O
properties	O
,	O
in	O
addition	O
to	O
tissue	O
perfusion	O
.	O

In	O
this	O
case	O
,	O
when	O
performing	O
deconvolution	O
of	O
the	O
measured	O
arterial	O
and	O
tissue	O
concentration	O
time-curves	O
it	O
is	O
only	O
possible	O
to	O
recover	O
the	O
effective	O
,	O
i.e	O
.	O

dispersed	O
,	O
response	O
function	O
and	O
parameters	O
.	O

We	O
introduce	O
Dispersion-Compliant	O
Bases	O
(	O
DCB	O
)	O
to	O
represent	O
the	O
response	O
function	O
in	O
the	O
presence	O
and	O
absence	O
of	O
dispersion	O
.	O

We	O
perform	O
in	O
silico	O
and	O
in	O
vivo	O
experiments	O
,	O
and	O
show	O
that	O
DCB	O
deconvolution	O
outperforms	O
oSVD	O
and	O
the	O
state-of-the-art	O
CPI+VTF	O
techniques	O
in	O
the	O
estimation	O
of	O
effective	O
perfusion	O
parameters	O
,	O
regardless	O
of	O
the	O
presence	O
and	O
amount	O
of	O
dispersion	O
.	O

We	O
also	O
show	O
that	O
DCB	O
deconvolution	O
can	O
be	O
used	O
as	O
a	O
pre-processing	O
step	O
to	O
improve	O
the	O
estimation	O
of	O
dispersion	O
-free	O
parameters	O
computed	B-P
with	O
CPI+VTF	O
,	O
which	O
employs	O
a	O
model	O
of	O
the	O
vascular	O
transport	O
function	O
to	O
characterize	O
dispersion	O
.	O

Indeed	O
,	O
in	O
silico	O
results	O
show	O
a	O
reduction	O
of	O
relative	O
errors	O
up	O
to	O
50	O
%	O
for	O
dispersion	O
-free	O
CBF	O
and	O
MTT	O
.	O

Moreover	O
,	O
the	O
DCB	O
method	O
recovers	O
effective	O
response	O
functions	O
that	O
comply	O
with	O
healthy	O
and	O
pathological	O
scenarios	O
,	O
and	O
offers	O
the	O
advantage	O
of	O
making	O
no	O
assumptions	O
about	O
the	O
presence	O
,	O
amount	O
,	O
and	O
nature	O
of	O
dispersion	O
.	O

Profiles	B-P
,	O
sources	O
and	O
potential	O
exposures	O
of	O
parent	O
,	O
chlorinated	O
and	O
brominated	O
polycyclic	O
aromatic	O
hydrocarbons	O
in	O
haze	O
associated	O
atmosphere	O
.	O

Profiles	B-P
,	O
sources	O
and	O
potential	O
exposures	O
of	O
chlorinated	O
and	O
brominated	O
polycyclic	O
aromatic	O
hydrocarbons	O
(	O
ClPAHs	O
and	O
BrPAHs	O
)	O
in	O
haze	O
associated	O
atmosphere	O
remain	O
unclear	O
.	O

Haze	O
events	O
happened	O
frequently	O
during	O
heating	O
period	O
in	O
Beijing	O
provided	O
a	O
typical	O
urban	O
context	O
to	O
investigate	O
the	O
concentrations	O
,	O
profiles	B-P
,	O
sources	O
and	O
potential	O
exposures	O
of	O
ClPAHs	O
,	O
BrPAHs	O
and	O
their	O
non-halogenated	O
parent	O
compounds	O
(	O
PAHs	O
)	O
in	O
air	O
samples	O
.	O

Average	O
concentrations	O
of	O
PAHs	O
,	O
ClPAHs	O
and	O
BrPAHs	O
during	O
heating	O
periods	O
(	O
with	O
more	O
frequent	O
haze	O
events	O
)	O
were	O
about	O
3-9	O
times	O
higher	O
than	O
during	O
non-heating	O
periods	O
.	O

Concentrations	O
of	O
particulate	O
matter	O
(	O
PM	O
)	O
-	O
associated	O
ClPAHs	O
and	O
BrPAHs	O
were	O
higher	O
in	O
heating	O
period	O
than	O
in	O
non-heating	O
period	O
,	O
while	O
for	O
gas	O
-	O
associated	O
ClPAHs	O
and	O
BrPAHs	O
,	O
this	O
distinction	O
was	O
not	O
significant	O
.	O

Congener	O
patterns	O
and	O
congener	B-P
profiles	I-P
indicated	O
that	O
with	O
increasing	O
coal	O
combustion	O
during	O
the	O
heating	O
period	O
,	O
concentrations	O
of	O
PAHs	O
and	O
ClPAHs	O
in	O
air	O
were	O
elevated	O
in	O
comparison	O
to	O
the	O
non-heating	O
period	O
.	O

Inhalation	O
of	O
PM	O
-	O
associated	O
PAHs	O
,	O
ClPAHs	O
and	O
BrPAHs	O
accounted	O
for	O
higher	O
exposure	O
than	O
inhalation	O
of	O
gas	O
phase	O
and	O
dermal	O
contact	O
of	O
both	O
gas	O
phase	O
and	O
particulate	O
phase	O
.	O

In	O
this	O
study	O
we	O
found	O
that	O
the	O
particulate	O
phase	O
is	O
the	O
dominant	O
exposure	O
pathway	O
of	O
atmospheric	O
PAHs	O
,	O
ClPAHs	O
and	O
BrPAHs	O
during	O
haze	O
days	O
,	O
which	O
is	O
different	O
from	O
previous	O
studies	O
.	O

Vitamin	O
D	O
deficiency	O
in	O
pregnancy	O
may	O
affect	O
fetal	O
thymus	O
development	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
association	O
of	O
vitamin	O
D	O
deficiency	O
(	O
VDD	O
)	O
during	O
pregnancy	O
with	O
thymus	O
size	O
in	O
full-term	O
fetuses	O
.	O

In	O
this	O
prospective	O
study	O
,	O
we	O
evaluated	O
mid-pregnancy	O
serum	O
25-hydroxyvitamin	B-P
D3	I-P
(	I-P
25	I-P
(	I-P
OH	I-P
)	I-P
D3	I-P
)	I-P
concentrations	I-P
.	O

The	O
fetal	O
thymus	O
size	O
was	O
measured	O
by	O
ultrasound	B-P
in	O
the	O
third	O
trimester	O
.	O

Neonatal	O
25	B-P
(	I-P
OH	I-P
)	I-P
D3	I-P
levels	I-P
were	O
evaluated	O
by	O
umbilical	O
cord	O
blood	B-P
sampling	I-P
.	O

Correlation	O
of	O
maternal	O
and	O
neonatal	O
vitamin	B-P
D	I-P
levels	I-P
and	O
association	O
between	O
thymus	O
size	O
and	O
both	O
,	O
maternal	O
and	O
neonatal	O
vitamin	B-P
D	I-P
concentrations	I-P
were	O
investigated	O
.	O

Serum	B-P
25	I-P
(	I-P
OH	I-P
)	I-P
D3	I-P
concentrations	I-P
were	O
within	O
the	O
normal	O
range	O
in	O
48	O
(	O
29.8	O
%	O
)	O
mothers	O
and	O
10	O
(	O
13.1	O
%	O
)	O
new-borns	O
.	O

A	O
strong	O
correlation	O
between	O
mid-pregnancy	O
maternal	O
and	O
neonatal	O
25	B-P
(	I-P
OH	I-P
)	I-P
D3	I-P
concentration	I-P
(	O
r	O
=	O
0.8	O
,	O
p	O
<	O
0.001	O
)	O
was	O
found	O
.	O

A	O
significant	O
linear	O
correlation	O
was	O
observed	O
between	O
both	O
,	O
maternal	O
and	O
neonatal	O
25	B-P
(	I-P
OH	I-P
)	I-P
D3	I-P
concentrations	I-P
and	O
thymus	O
perimeter	O
length	O
(	O
r	O
=	O
0.45	O
,	O
p	O
=	O
0.04	O
and	O
r	O
=	O
0.43	O
,	O
p	O
<	O
0.01	O
,	O
respectively	O
)	O
.	O

Both	O
,	O
maternal	O
and	O
fetal	O
VDDs	O
were	O
associated	O
with	O
decreased	O
thymus	O
perimeter	O
(	O
p	O
=	O
0.04	O
,	O
p	O
=	O
0.03	O
)	O
.	O

Vitamin	O
D	O
deficiency	O
during	O
pregnancy	O
may	O
be	O
associated	O
with	O
smaller	O
fetal	O
thymus	O
.	O

Our	O
data	O
suggest	O
that	O
VDD	O
in	O
pregnancy	O
may	O
lead	O
to	O
systemic	O
inflammatory	O
response	O
in	O
the	O
fetus	O
.	O

Fully	O
automated	O
disc	B-P
diffusion	I-P
for	O
rapid	O
antibiotic	B-P
susceptibility	I-P
test	I-P
results	O
:	O
a	O
proof-of-principle	O
study	O
.	O

Antibiotic	O
resistance	O
poses	O
a	O
significant	O
threat	O
to	O
patients	O
suffering	O
from	O
infectious	O
diseases	O
.	O

Early	O
readings	O
of	O
antibiotic	B-P
susceptibility	I-P
test	I-P
(	O
AST	B-P
)	O
results	O
could	O
be	O
of	O
critical	O
importance	O
to	O
ensure	O
adequate	O
treatment	O
.	O

Disc	B-P
diffusion	I-P
is	O
a	O
well-standardized	O
,	O
established	O
and	O
cost	O
-	O
efficient	O
AST	B-P
procedure	I-P
;	O
however	O
,	O
its	O
use	O
in	O
the	O
clinical	O
laboratory	O
is	O
hampered	O
by	O
the	O
many	O
manual	O
steps	O
involved	O
,	O
and	O
an	O
incubation	O
time	O
of	O
16-18	O
h	O
,	O
which	O
is	O
required	O
to	O
achieve	O
reliable	O
test	O
results	O
.	O

We	O
have	O
evaluated	O
a	O
fully	O
automated	O
system	O
for	O
its	O
potential	O
for	O
early	O
reading	O
of	O
disc	B-P
diffusion	I-P
diameters	O
after	O
6-12	O
h	O
of	O
incubation	B-P
.	O

We	O
assessed	O
availability	O
of	O
results	O
,	O
methodological	O
precision	O
,	O
categorical	O
agreement	O
and	O
interpretation	O
errors	O
as	O
compared	O
with	O
an	O
18	O
h	O
standard	O
.	O

In	O
total	O
,	O
1028	O
clinical	O
strains	O
(	O
291	O
Escherichia	O
coli	O
,	O
272	O
Klebsiella	O
pneumoniae	O
,	O
176	O
Staphylococcus	O
aureus	O
and	O
289	O
Staphylococcus	O
epidermidis	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

Disc	B-P
diffusion	I-P
plates	O
were	O
streaked	O
,	O
incubated	B-P
and	O
imaged	O
using	O
the	O
WASPLab	O
TM	O
automation	O
system	O
.	O

Our	O
results	O
demonstrate	O
that	O
:	O
(	O
i	O
)	O
early	O
AST	B-P
reading	O
is	O
possible	O
for	O
important	O
pathogens	O
;	O
(	O
ii	O
)	O
methodological	O
precision	O
is	O
not	O
hampered	O
at	O
early	O
timepoints	O
;	O
and	O
(	O
iii	O
)	O
species	O
-	O
specific	O
reading	O
times	O
must	O
be	O
selected	O
.	O

As	O
inhibition	O
zone	O
diameters	O
change	O
over	O
time	O
and	O
are	O
phenotype	O
/	O
drug	O
combination	O
dependent	O
,	O
specific	O
cut-offs	O
and	O
expert	O
rules	O
will	O
be	O
essential	O
to	O
ensure	O
reliable	O
interpretation	O
and	O
reporting	O
of	O
early	O
susceptibility	O
testing	O
results	O
.	O

Corn	O
oil	O
intake	O
favorably	O
impacts	O
lipoprotein	O
cholesterol	O
,	O
apolipoprotein	B-P
and	O
lipoprotein	B-P
particle	O
levels	O
compared	O
with	O
extra-virgin	O
olive	O
oil	O
.	O

Corn	O
oil	O
(	O
CO	O
)	O
and	O
extra-virgin	O
olive	O
oil	O
(	O
EVOO	O
)	O
are	O
rich	O
sources	O
of	O
unsaturated	O
fatty	O
acids	O
(	O
UFA	O
)	O
,	O
but	O
UFA	O
profiles	O
differ	O
among	O
oils	O
,	O
which	O
may	O
affect	O
lipoprotein	B-P
levels	I-P
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
CO	O
versus	O
EVOO	O
intake	O
on	O
fasting	O
lipoprotein	B-P
and	O
subfraction	O
cholesterol	B-P
levels	I-P
,	O
apolipoprotein	B-P
(	I-P
apo	I-P
)	I-P
A1	I-P
,	O
apo	B-P
B	I-P
,	O
and	O
low-density	B-P
lipoprotein	I-P
particle	O
concentrations	O
in	O
men	O
and	O
women	O
.	O

As	O
part	O
of	O
a	O
weight	O
maintenance	O
diet	O
,	O
men	O
and	O
women	O
were	O
provided	O
with	O
food	O
items	O
prepared	O
with	O
54	O
g	O
per	O
day	O
of	O
CO	O
or	O
EVOO	O
(	O
21-day	O
treatment	O
,	O
21-day	O
washout	O
)	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
controlled-feeding	O
,	O
crossover	O
trial	O
.	O

Fasting	O
lipoprotein	O
cholesterol	O
and	O
related	O
variables	O
were	O
determined	O
with	O
density	B-P
gradient	I-P
ultracentrifugation	I-P
.	O

Among	O
the	O
54	O
completers	O
,	O
CO	O
reduced	O
total	O
cholesterol	O
,	O
low-density	B-P
lipoprotein	I-P
cholesterol	I-P
(	O
LDL-C	B-P
)	O
,	O
very	B-P
low-density	I-P
lipoprotein	I-P
cholesterol	I-P
(	O
VLDL-C	B-P
)	O
,	O
non-high-density	B-P
lipoprotein	I-P
cholesterol	I-P
(	O
non-HDL-C	B-P
)	O
,	O
apo	B-P
B	I-P
and	O
LDL	B-P
particle	O
concentration	O
to	O
a	O
greater	O
extent	O
compared	O
with	O
EVOO	O
intake	O
.	O

Changes	O
in	O
LDL-C	B-P
and	O
VLDL-C	B-P
contributed	O
to	O
the	O
larger	O
reduction	O
in	O
non-HDL-C	B-P
with	O
CO	O
compared	O
with	O
EVOO	O
intake	O
(	O
-0.39	O
mmol/l	O
vs	O
-0.04	O
mmol/l	O
;	O
P	O
<	O
0.001	O
)	O
.	O

The	O
larger	O
reduction	O
in	O
LDL-C	B-P
by	O
CO	O
intake	O
was	O
attributable	O
to	O
changes	O
(	O
P	O
<	O
0.05	O
)	O
caused	O
by	O
CO	O
vs	O
EVOO	O
in	O
large	O
LDL1+2-C	B-P
(	O
-0.22	O
mmol/l	O
)	O
and	O
intermediate-density	B-P
lipoprotein	I-P
cholesterol	I-P
(	O
-0.12	O
mmol/l	O
)	O
.	O

HDL-C	B-P
responses	O
did	O
not	O
differ	O
between	O
treatments	O
,	O
but	O
apo	B-P
A1	I-P
increased	O
more	O
with	O
EVOO	O
compared	O
with	O
CO	O
intake	O
(	O
4.6	O
versus	O
0.7	O
mg/dl	O
,	O
respectively	O
,	O
P=0.016	O
)	O
.	O

CO	O
intake	O
reduced	O
atherogenic	O
lipoprotein	O
cholesterol	O
and	O
particle	O
concentrations	O
to	O
a	O
larger	O
extent	O
than	O
did	O
EVOO	O
,	O
which	O
may	O
have	O
implications	O
for	O
cardiovascular	O
disease	O
risk	O
.	O

Naphthoquinone	O
glycosides	O
for	O
bioelectroanalytical	O
enumeration	O
of	O
the	O
faecal	O
indicator	O
Escherichia	O
coli	O
.	O

Microbial	O
water	O
quality	O
monitoring	O
for	O
the	O
presence	O
of	O
faecal	O
indicator	O
bacteria	O
(	O
FIB	O
)	O
is	O
a	O
mandatory	O
activity	O
in	O
many	O
countries	O
and	O
is	O
key	O
in	O
public	O
health	O
protection	O
.	O

Despite	O
technological	O
advances	O
and	O
a	O
need	O
for	O
methodological	O
improvements	O
,	O
chromogenic	B-P
and	O
fluorogenic	O
enzymatic	O
techniques	O
remain	O
the	O
mainstays	O
of	O
water	O
quality	O
monitoring	O
for	O
both	O
public	O
health	O
agencies	O
and	O
regulated	O
utilities	O
.	O

We	O
demonstrated	O
that	O
bioelectroanalytical	O
approaches	O
to	O
FIB	O
enumeration	O
are	O
possible	O
and	O
can	O
be	O
achieved	O
using	O
commercially	O
available	O
enzyme	O
-	O
specific	O
resorufin	O
glycosides	O
,	O
although	O
these	O
are	O
expensive	O
,	O
not	O
widely	O
available	O
or	O
designed	O
for	O
purpose	O
.	O

Following	O
this	O
,	O
we	O
designed	O
two	O
naphthoquinone	O
glycosides	O
which	O
performed	O
better	O
,	O
achieving	O
Escherichia	B-P
coli	I-P
detection	I-P
in	O
the	O
range	O
5.0	O
×	O
10	O
(	O
2	O
)	O
to	O
5.0	O
×	O
10	O
(	O
5	O
)	O
CFU	O
ml	O
(	O
-1	O
)	O
22-54	O
%	O
quicker	O
than	O
commercially	O
available	O
resorufin	O
glycosides	O
.	O

The	O
molecular	O
design	O
of	O
the	O
naphthoquinone	O
glycosides	O
requires	O
fewer	O
synthetic	O
steps	O
allowing	O
them	O
to	O
be	O
produced	O
for	O
as	O
little	O
as	O
US	O
$	O
50	O
per	O
kg	O
.	O

Tests	O
with	O
environmental	O
samples	O
demonstrated	O
the	O
low	O
tendency	O
for	O
abiotic	O
interference	O
and	O
that	O
,	O
despite	O
specificity	O
being	O
maintained	O
between	O
β-glucuronidase	O
and	O
β-galactosidase	O
,	O
accurate	O
enumeration	O
of	O
E.	O
coli	O
in	O
environmental	O
samples	O
necessitates	O
development	O
of	O
a	O
selective	O
medium	O
.	O

In	O
comparison	O
to	O
a	O
commercially	O
available	O
detection	O
method	O
,	O
which	O
has	O
U.S.	O
Environmental	O
Protection	O
Agency	O
(	O
EPA	O
)	O
approval	O
,	O
our	O
approach	O
performed	O
better	O
at	O
high	O
organism	O
concentrations	O
,	O
detecting	O
500	O
organisms	O
in	O
9	O
h	O
compared	O
with	O
13.5	O
h	O
for	O
the	O
commercial	B-P
method	I-P
.	O

Bioelectroanalytical	O
detection	O
is	O
comparable	O
to	O
current	B-P
approved	I-P
methods	I-P
and	O
with	O
further	O
development	O
could	O
result	O
in	O
improved	O
detection	O
times	O
.	O

A	O
recent	O
trend	O
for	O
low-cost	O
open-source	O
hardware	O
means	O
that	O
automated	O
,	O
potentiostatically	O
controlled	O
E.	B-P
coli	I-P
detection	I-P
systems	O
could	O
be	O
constructed	O
for	O
less	O
than	O
US	O
$	O
100	O
per	O
channel	O
.	O

Opportunistic	O
screening	O
for	O
osteoporosis	O
by	O
routine	O
CT	B-P
in	O
Southern	O
Europe	O
.	O

Feasibility	O
evaluation	O
of	O
early	B-P
detection	I-P
of	O
osteoporosis	O
in	O
oncologic	O
patients	O
by	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
on	O
abdominal	B-P
computed	I-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
scans	I-P
performed	O
for	O
other	O
clinical	O
indications	O
,	O
by	O
using	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
(	O
DXA	B-P
)	O
as	O
reference	O
.	O

Abdominal	B-P
CT	I-P
images	O
can	O
identify	O
patients	O
with	O
osteoporosis	O
BMD	O
without	O
additional	O
radiation	O
exposure	O
or	O
cost	O
.	O

The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
evaluate	O
the	O
feasibility	O
of	O
early	B-P
detection	I-P
of	O
osteoporosis	O
by	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
on	O
abdominal	B-P
computed	I-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
scans	I-P
performed	O
in	O
oncologic	O
patients	O
,	O
comparing	O
calibrated	O
and	O
uncalibrated	O
measurements	O
by	O
using	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
(	O
DXA	B-P
)	O
as	O
reference	O
.	O

We	O
also	O
performed	O
an	O
external	O
validation	O
of	O
a	O
threshold	O
of	O
160	O
Hounsfield	O
units	O
(	O
HU	O
)	O
,	O
proposed	O
as	O
highly	O
sensitive	O
.	O

Cohort	O
comprised	O
CT	B-P
-	O
DXA	B-P
pairs	O
within	O
a	O
6-month	O
period	O
performed	O
for	O
any	O
indication	O
on	O
326	O
consecutive	O
adults	O
,	O
aged	O
62.4	O
±	O
12.38	O
years	O
(	O
mean	O
±	O
standard	O
deviation	O
)	O
.	O

CT	B-P
attenuation	O
of	O
trabecular	O
bone	O
in	O
HU	O
was	O
measured	O
at	O
the	O
axial	O
cross	O
sections	O
of	O
L1	O
,	O
L2	O
,	O
L3	O
,	O
and	O
L4	O
vertebrae	O
.	O

Vertebral	O
compression	O
fractures	O
were	O
assessed	O
by	O
sagittal	B-P
reconstruction	I-P
view	O
.	O

Diagnostic	O
performance	O
measures	O
and	O
the	O
area	O
under	O
the	O
receiver	O
operator	O
characteristic	O
curve	O
(	O
AUC	O
)	O
for	O
diagnosing	O
osteoporosis	O
were	O
calculated	B-P
.	O

BMD	O
values	O
were	O
statistical	O
significantly	O
lower	O
at	O
any	O
vertebral	O
level	O
from	O
L1	O
to	O
L4	O
for	O
patients	O
with	O
osteoporosis	O
defined	O
by	O
DXA	B-P
(	O
p	O
<	O
0.001	O
)	O
.	O

Calibrated	O
and	O
uncalibrated	O
BMD	O
values	O
were	O
significantly	O
correlated	O
(	O
R	O
(	O
2	O
)	O
=	O
0.833	O
,	O
p	O
<	O
0.01	O
)	O
.	O

An	O
uncalibrated	O
L1	O
CT	B-P
attenuation	O
threshold	O
of	O
160	O
HU	O
was	O
more	O
than	O
90	O
%	O
sensitive	O
,	O
and	O
a	O
threshold	O
of	O
73	O
HU	O
was	O
more	O
than	O
90	O
%	O
specific	O
for	O
distinguishing	O
osteoporosis	O
BMD	O
.	O

Fifty-nine	O
percent	O
of	O
patients	O
with	O
vertebral	O
compression	O
fracture	O
had	O
non	O
-	O
osteoporotic	O
DXA	O
T-scores	O
.	O

Abdominal	B-P
CT	I-P
images	O
obtained	O
for	O
other	O
reasons	O
can	O
identify	O
patients	O
with	O
osteoporosis	O
BMD	O
without	O
additional	O
radiation	O
exposure	O
or	O
cost	O
.	O

Uncalibrated	O
values	O
at	O
L1	O
can	O
detect	O
more	O
osteoporosis	O
patients	O
with	O
spinal	O
compression	O
fractures	O
than	O
DXA	B-P
in	O
oncologic	O
patients	O
.	O

Passive	O
case	O
detection	O
of	O
malaria	O
in	O
Ratanakiri	O
Province	O
(	O
Cambodia	O
)	O
to	O
detect	O
villages	O
at	O
higher	O
risk	O
for	O
malaria	O
.	O

Cambodia	O
reduced	O
malaria	O
incidence	O
by	O
more	O
than	O
75	O
%	O
between	O
2000	O
and	O
2015	O
,	O
a	O
target	O
of	O
the	O
Millennium	O
Development	O
Goal	O
6	O
.	O

The	O
Cambodian	O
Government	O
aims	O
to	O
eliminate	O
all	O
forms	O
of	O
malaria	O
by	O
2025	O
.	O

The	O
country	O
's	O
malaria	O
incidence	O
is	O
highly	O
variable	O
at	O
provincial	O
level	O
,	O
but	O
less	O
is	O
known	O
at	O
village	O
level	O
.	O

This	O
study	O
used	O
passive	O
case	O
detection	O
(	O
PCD	O
)	O
data	O
at	O
village	O
level	O
in	O
Ratanakiri	O
Province	O
from	O
2010	O
to	O
2014	O
to	O
describe	O
incidence	O
trends	O
and	O
identify	O
high-risk	O
areas	O
of	O
malaria	O
to	O
be	O
primarily	O
targeted	O
towards	O
malaria	O
elimination	O
.	O

In	O
2010	O
,	O
the	O
Cambodian	O
malaria	O
programme	O
created	O
a	O
Malaria	O
Information	O
System	O
(	O
MIS	O
)	O
to	O
capture	O
malaria	O
information	O
at	O
village	O
level	O
through	O
PCD	O
by	O
village	O
malaria	O
workers	O
and	O
health	O
facilities	O
.	O

The	O
MIS	O
data	O
of	O
Ratanakiri	O
Province	O
2010-2014	O
were	O
used	O
to	O
calculate	O
annual	O
incidence	O
rates	O
by	O
Plasmodium	O
species	O
at	O
province	O
and	O
commune	O
levels	O
.	O

For	O
estimating	O
the	O
trend	O
at	O
provincial	O
level	O
only	O
villages	O
reporting	O
each	O
year	O
were	O
selected	O
.	O

The	O
communal	O
incidences	O
and	O
the	O
number	O
of	O
cases	O
per	O
village	O
were	O
visualized	O
on	O
a	O
map	O
per	O
Plasmodium	O
species	O
and	O
per	O
year	O
.	O

Analysis	O
of	O
spatial	O
clustering	O
of	O
village	O
malaria	O
cases	O
by	O
Plasmodium	O
species	O
was	O
performed	O
by	O
year	O
.	O

Overall	O
,	O
malaria	O
annual	O
incidence	O
rates	O
per	O
1000	O
inhabitants	O
decreased	O
from	O
86	O
(	O
2010	O
)	O
to	O
30	O
(	O
2014	O
)	O
.	O

Falciparum	O
incidence	O
decreased	O
(	O
by	O
79	O
%	O
in	O
2014	O
compared	O
to	O
2010	O
;	O
CI	O
95	O
%	O
76-82	O
%	O
)	O
more	O
rapidly	O
than	O
vivax	O
incidence	O
(	O
by	O
19	O
%	O
in	O
2014	O
compared	O
to	O
2010	O
;	O
CI	O
95	O
%	O
5-32	O
%	O
)	O
.	O

There	O
were	O
ten	O
to	O
16	O
significant	O
spatial	O
clusters	O
each	O
year	O
.	O

Big	O
clusters	O
tended	O
to	O
extend	O
along	O
the	O
Cambodian-Vietnamese	O
border	O
and	O
along	O
the	O
Sesan	O
River	O
.	O

Three	O
clusters	O
appeared	O
throughout	O
all	O
years	O
(	O
2010-2014	O
)	O
:	O
one	O
with	O
21	O
villages	O
appeared	O
each	O
year	O
,	O
the	O
second	O
shrunk	O
progressively	O
from	O
2012	O
to	O
2014	O
and	O
the	O
third	O
was	O
split	O
into	O
two	O
smaller	O
clusters	O
in	O
2013	O
and	O
2014	O
.	O

The	O
decline	O
of	O
malaria	O
burden	O
can	O
be	O
attributed	O
to	O
intensive	O
malaria	O
control	O
activities	O
implemented	O
in	O
the	O
areas	O
:	O
distribution	O
of	O
a	O
long-lasting	O
insecticidal	O
net	O
per	O
person	O
and	O
early	B-P
diagnosis	I-P
and	O
prompt	O
treatment	O
.	O

Dihydro-artemisinin	O
piperaquine	O
was	O
the	O
only	O
first-line	O
treatment	O
for	O
all	O
malaria	O
cases	O
.	O

No	O
radical	O
treatment	O
with	O
primaquine	O
was	O
provided	O
for	O
Plasmodium	O
vivax	O
cases	O
,	O
which	O
could	O
explain	O
the	O
slow	O
decrease	O
of	O
P.	O
vivax	O
due	O
to	O
relapses	O
.	O

To	O
achieve	O
malaria	O
elimination	O
by	O
2025	O
,	O
priority	O
should	O
be	O
given	O
to	O
the	O
control	O
of	O
stable	O
malaria	O
clusters	O
appearing	O
over	O
time	O
.	O

Potential	O
Utility	O
of	O
Diffusion-Weighted	B-P
Magnetic	I-P
Resonance	I-P
Imaging	I-P
in	O
Diagnosis	O
of	O
Residual	O
Bladder	O
Cancer	O
before	O
Second	O
Transurethral	O
Resection	O
.	O

The	O
study	O
aimed	O
to	O
investigate	O
the	O
diagnostic	O
utility	O
of	O
diffusion-weighted	B-P
MRI	I-P
(	O
DW-MRI	B-P
)	O
in	O
differentiating	O
residual	O
bladder	O
cancer	O
from	O
benign	O
postoperative	O
changes	O
before	O
a	O
second	O
transurethral	O
resection	O
of	O
the	O
bladder	O
(	O
TURB	O
)	O
.	O

Of	O
the	O
75	O
bladder	O
cancer	O
patients	O
who	O
underwent	O
a	O
second	O
TURB	O
from	O
2013	O
to	O
2015	O
,	O
23	O
patients	O
who	O
underwent	O
multi-sequence	O
bladder	B-P
MRI	I-P
after	O
their	O
initial	O
TURB	O
were	O
retrospectively	O
evaluated	O
.	O

Thirty	O
lesions	O
were	O
histologically	O
examined	O
at	O
the	O
second	O
TURB	O
and	O
the	O
results	O
of	O
them	O
were	O
compared	O
with	O
the	O
findings	O
obtained	O
through	O
T2-weighted	B-P
MRI	I-P
,	O
dynamic	B-P
contrast-enhanced	I-P
MRI	I-P
(	O
DCE-MRI	B-P
)	O
,	O
and	O
DW-MRI	B-P
.	O

Positive	O
findings	O
of	O
27	O
,	O
28	O
,	O
and	O
15	O
lesions	O
showed	O
up	O
on	O
T2W-	B-P
,	O
DCE	B-P
-	O
,	O
and	O
DW-MRI	B-P
,	O
respectively	O
.	O

Thirteen	O
lesions	O
were	O
confirmed	O
histologically	O
to	O
constitute	O
residual	O
cancer	O
.	O

The	O
sensitivity	O
/	O
specificity	O
/	O
accuracy	O
of	O
T2W-	B-P
,	O
DCE	B-P
-	O
,	O
and	O
DW-MRI	B-P
were	O
100/18/53	O
,	O
100/12/50	O
,	O
and	O
92/82/87	O
%	O
,	O
respectively	O
.	O

DW-MRI	B-P
was	O
significantly	O
superior	O
in	O
specificity	O
and	O
accuracy	O
to	O
T2W-	B-P
(	O
p	O
<	O
0.01	O
for	O
both	O
)	O
and	O
DCE-MRI	B-P
(	O
p	O
<	O
0.01	O
for	O
both	O
)	O
.	O

This	O
study	O
first	O
showed	O
the	O
superiority	O
of	O
DW-MRI	B-P
to	O
T2W-	B-P
and	O
DCE-MRI	B-P
in	O
differentiating	O
residual	O
cancer	O
before	O
a	O
second	O
TURB	O
.	O

PROTECTIVE	O
EFFECTS	O
OF	O
DIPEPTIDYL	O
PEPTIDASE-4	O
INHIBITORS	O
ON	O
PROGRESSION	O
OF	O
DIABETIC	O
RETINOPATHY	O
IN	O
PATIENTS	O
WITH	O
TYPE	O
2	O
DIABETES	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
dipeptidyl	O
peptidase-4	O
inhibitors	O
(	O
DPP4	O
)	O
on	O
the	O
progression	O
of	O
diabetic	O
retinopathy	O
(	O
DR	O
)	O
in	O
patients	O
with	O
Type	O
2	O
diabetes	O
based	O
on	O
the	O
DR	O
severity	O
scale	O
.	O

The	O
medical	O
records	O
of	O
82	O
patients	O
with	O
Type	O
2	O
diabetes	O
enrolled	O
from	O
2005	O
to	O
2015	O
were	O
retrospectively	O
reviewed	O
.	O

Fundus	B-P
photographs	I-P
were	O
graded	O
using	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
methods	O
.	O

The	O
associations	O
between	O
baseline	O
risk	O
factors	O
and	O
progression	O
of	O
DR	O
were	O
investigated	O
.	O

Seven	O
of	O
28	O
patients	O
treated	O
with	O
DPP4	O
inhibitors	O
and	O
26	O
of	O
54	O
treated	O
with	O
other	O
hypoglycemic	O
agents	O
showed	O
progression	O
of	O
retinopathy	O
,	O
defined	O
as	O
one	O
or	O
more	O
steps	O
on	O
the	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
scale	O
(	O
P	O
=	O
0.043	O
)	O
.	O

Only	O
treatment	O
with	O
DPP4	O
inhibitors	O
significantly	O
reduced	O
the	O
progression	O
of	O
DR	O
in	O
patients	O
after	O
propensity	O
score	O
matching	O
(	O
P	O
=	O
0.009	O
)	O
.	O

Treatment	O
with	O
DPP4	O
inhibitors	O
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
DR	O
progression	O
(	O
P	O
=	O
0.011	O
)	O
.	O

Treatment	O
with	O
DPP4	O
inhibitors	O
was	O
the	O
independent	O
protective	O
factor	O
against	O
the	O
progression	O
of	O
DR	O
,	O
aside	O
from	O
improving	O
glycemic	O
control	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
show	O
the	O
benefits	O
of	O
DPP4	O
inhibitors	O
in	O
reducing	O
DR	O
progression	O
,	O
and	O
provides	O
encouraging	O
preliminary	O
data	O
for	O
further	O
evaluation	O
of	O
DPP4	O
inhibitors	O
in	O
the	O
progression	O
of	O
DR	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

Association	O
of	O
Traumatic	O
and	O
Atraumatic	O
Posterior	O
Shoulder	O
Instability	O
With	O
Glenoid	O
Retroversion	O
and	O
Outcomes	O
After	O
Arthroscopic	O
Capsulolabral	O
Repair	O
.	O

To	O
compare	O
glenoid	O
retroversion	O
and	O
functional	O
outcomes	O
between	O
patients	O
with	O
traumatic	O
onset	O
of	O
posterior	O
shoulder	O
instability	O
(	O
PSI	O
)	O
and	O
patients	O
with	O
atraumatic	O
onset	O
of	O
PSI	O
.	O

Patients	O
with	O
PSI	O
who	O
underwent	O
arthroscopic	O
posterior	O
capsulolabral	O
anchor	O
repair	O
,	O
were	O
active	O
in	O
sports	O
,	O
and	O
had	O
undergone	O
surgery	O
a	O
minimum	O
of	O
2	O
years	O
earlier	O
were	O
included	O
.	O

Traumatic	O
onset	O
was	O
defined	O
as	O
PSI	O
that	O
occurred	O
after	O
a	O
trauma	O
with	O
the	O
shoulder	O
in	O
adduction	O
,	O
flexion	O
,	O
and	O
internal	O
rotation	O
in	O
patients	O
with	O
no	O
history	O
of	O
instability	O
.	O

Subjective	O
evaluations	O
were	O
obtained	O
with	O
the	O
American	O
Shoulder	O
and	O
Elbow	O
Surgeons	O
(	O
ASES	O
)	O
;	O
Quick	O
Disabilities	O
of	O
the	O
Arm	O
,	O
Shoulder	O
and	O
Hand	O
;	O
Single	O
Assessment	O
Numeric	O
Evaluation	O
(	O
SANE	O
)	O
;	O
and	O
Short	O
Form	O
12	O
Physical	O
Component	O
Summary	O
scores	O
preoperatively	O
and	O
after	O
a	O
minimum	O
2-year	O
follow-up	O
postoperatively	O
.	O

Additional	O
questions	O
assessed	O
return	O
to	O
sport	O
and	O
shoulder	O
stability	O
.	O

Glenoid	O
version	O
was	O
measured	O
with	O
a	O
2-dimensional	B-P
glenoid	I-P
vault	I-P
method	I-P
on	O
magnetic	B-P
resonance	I-P
imaging	I-P
.	O

A	O
total	O
of	O
41	O
shoulders	O
in	O
38	O
patients	O
were	O
eligible	O
for	O
inclusion	O
(	O
3	O
female	O
and	O
35	O
male	O
patients	O
;	O
mean	O
age	O
,	O
27.6	O
years	O
;	O
age	O
range	O
,	O
13	O
to	O
66	O
years	O
)	O
.	O

Three	O
patients	O
refused	O
participation	O
,	O
and	O
2	O
patients	O
required	O
subsequent	O
surgery	O
for	O
failure	O
.	O

Postoperative	O
outcomes	O
were	O
available	O
for	O
32	O
of	O
the	O
remaining	O
36	O
shoulders	O
(	O
89	O
%	O
)	O
with	O
a	O
mean	O
follow-up	O
of	O
4.1	O
years	O
(	O
range	O
,	O
2.0	O
to	O
7.8	O
years	O
;	O
20	O
atraumatic	O
and	O
12	O
traumatic	O
)	O
.	O

The	O
ASES	O
score	O
improved	O
significantly	O
in	O
both	O
groups	O
(	O
P	O
<	O
.03	O
)	O
,	O
whereas	O
the	O
SANE	O
;	O
Quick	O
Disabilities	O
of	O
the	O
Arm	O
,	O
Shoulder	O
and	O
Hand	O
;	O
and	O
Short	O
Form	O
12	O
Physical	O
Component	O
Summary	O
scores	O
only	O
significantly	O
improved	O
for	O
patients	O
with	O
traumatic	O
PSI	O
(	O
P	O
<	O
.02	O
)	O
.	O

Baseline	O
score-adjusted	O
comparison	O
between	O
groups	O
showed	O
that	O
the	O
postoperative	O
median	O
ASES	O
scores	O
(	O
atraumatic	O
,	O
95.8	O
;	O
traumatic	O
,	O
99.9	O
)	O
and	O
SANE	O
scores	O
(	O
atraumatic	O
,	O
86.5	O
;	O
traumatic	O
,	O
98.0	O
)	O
were	O
significantly	O
more	O
improved	O
in	O
patients	O
with	O
traumatic	O
PSI	O
(	O
P	O
=	O
.01	O
and	O
P	O
=	O
.012	O
,	O
respectively	O
)	O
.	O

Atraumatic	O
PSI	O
was	O
associated	O
with	O
significantly	O
higher	O
glenoid	O
retroversion	O
(	O
-21.8°	O
±	O
4.2°	O
vs	O
-17.7°	O
±	O
5.5°	O
,	O
P	O
=	O
.032	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
regarding	O
return	O
to	O
sport	O
(	O
P	O
=	O
.375	O
)	O
or	O
postoperative	O
re-dislocations	O
(	O
P	O
=	O
.99	O
)	O
between	O
the	O
groups	O
.	O

Atraumatic	O
onset	O
of	O
PSI	O
was	O
associated	O
with	O
higher	O
degrees	O
of	O
glenoid	O
retroversion	O
and	O
less	O
favorable	O
functional	O
outcomes	O
of	O
arthroscopic	O
posterior	O
capsulolabral	O
anchor	O
repair	O
than	O
traumatic	O
PSI	O
.	O

Level	O
III	O
,	O
retrospective	O
case-control	O
study	O
.	O

Recurrent	O
noncoding	O
regulatory	O
mutations	O
in	O
pancreatic	O
ductal	O
adenocarcinoma	O
.	O

The	O
contributions	O
of	O
coding	O
mutations	O
to	O
tumorigenesis	O
are	O
relatively	O
well	O
known	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
somatic	O
alterations	O
in	O
noncoding	O
DNA	O
.	O

Here	O
we	O
describe	O
GECCO	O
(	O
Genomic	O
Enrichment	O
Computational	O
Clustering	O
Operation	O
)	O
to	O
analyze	O
somatic	O
noncoding	O
alterations	O
in	O
308	O
pancreatic	O
ductal	O
adenocarcinomas	O
(	O
PDAs	O
)	O
and	O
identify	O
commonly	O
mutated	O
regulatory	O
regions	O
.	O

We	O
find	O
recurrent	O
noncoding	O
mutations	O
to	O
be	O
enriched	O
in	O
PDA	O
pathways	O
,	O
including	O
axon	O
guidance	O
and	O
cell	O
adhesion	O
,	O
and	O
newly	O
identified	O
processes	O
,	O
including	O
transcription	O
and	O
homeobox	O
genes	O
.	O

We	O
identified	O
mutations	O
in	O
protein	O
binding	O
sites	O
correlating	O
with	O
differential	O
expression	O
of	O
proximal	O
genes	O
and	O
experimentally	O
validated	O
effects	O
of	O
mutations	O
on	O
expression	O
.	O

We	O
developed	O
an	O
expression	O
modulation	O
score	O
that	O
quantifies	O
the	O
strength	O
of	O
gene	O
regulation	O
imposed	O
by	O
each	O
class	O
of	O
regulatory	O
elements	O
,	O
and	O
found	O
the	O
strongest	O
elements	O
were	O
most	O
frequently	O
mutated	O
,	O
suggesting	O
a	O
selective	O
advantage	O
.	O

Our	O
detailed	O
single-cancer	B-P
analysis	I-P
of	O
noncoding	O
alterations	O
identifies	O
regulatory	O
mutations	O
as	O
candidates	O
for	O
diagnostic	O
and	O
prognostic	O
markers	O
,	O
and	O
suggests	O
new	O
mechanisms	O
for	O
tumor	O
evolution	O
.	O

High	B-P
throughput	I-P
selection	O
of	O
antibiotic-resistant	O
transgenic	O
Arabidopsis	O
plants	O
.	O

Kanamycin	O
resistance	O
is	O
the	O
most	O
frequently	O
used	O
antibiotic-resistance	O
marker	O
for	O
Arabidopsis	O
transformations	O
,	O
however	O
,	O
this	O
method	O
frequently	O
causes	O
escape	O
of	O
untransformed	O
plants	O
,	O
particularly	O
at	O
the	O
high	O
seedling	O
density	O
during	O
the	O
selection	O
.	O

Here	O
we	O
developed	O
a	O
robust	O
high	O
-	O
density	O
selection	O
method	O
using	O
top	O
agar	O
for	O
Arabidopsis	O
thaliana	O
.	O

Top	O
agar	O
effectively	O
suppressed	O
growth	O
of	O
untransformed	O
wild-type	O
plants	O
on	O
selection	O
media	O
at	O
high	O
density	O
.	O

Survival	O
of	O
the	O
transformed	O
plants	O
during	O
the	O
selection	O
were	O
confirmed	O
by	O
production	O
of	O
green	O
true	O
leaves	O
and	O
expression	O
of	O
a	O
firefly	O
luciferase	O
reporter	O
gene	O
.	O

Top	O
agar	O
method	O
allowed	O
selection	O
using	O
a	O
large	O
amount	O
of	O
seeds	O
in	O
Arabidopsis	O
transformation	O
.	O

Everolimus	O
for	O
Treatment	O
of	O
Pseudomyogenic	O
Hemangioendothelioma	O
.	O

Pseudomyogenic	O
hemangioendothelioma	O
(	O
PMH	O
)	O
is	O
a	O
recently	O
described	O
vascular	O
neoplasm	O
that	O
occurs	O
most	O
commonly	O
in	O
the	O
soft	O
tissue	O
of	O
the	O
distal	O
extremities	O
of	O
young	O
adults	O
.	O

Metastatic	O
PMH	O
can	O
be	O
fatal	O
and	O
there	O
are	O
no	O
effective	O
medications	O
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
15-year-old	O
boy	O
with	O
metastatic	O
PMH	O
,	O
who	O
responded	O
to	O
treatment	O
with	O
everolimus	O
,	O
a	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitor	O
.	O

Immunohistochemistry	B-P
showed	O
that	O
mammalian	O
target	O
of	O
rapamycin	O
was	O
expressed	O
in	O
PMH	O
biopsy	O
specimens	O
,	O
which	O
may	O
explain	O
the	O
reduction	O
in	O
PMH	O
tumor	O
size	O
following	O
treatment	O
.	O

``	O
Predictors	O
of	O
provider	O
-	O
initiated	O
HIV	B-P
testing	I-P
and	O
counseling	O
refusal	O
by	O
outpatient	O
department	O
clients	O
in	O
Wolaita	O
zone	O
,	O
Southern	O
Ethiopia	O
:	O
a	O
case	O
control	O
study	O
``	O
.	O

``	O
Despite	O
different	O
strategies	O
designed	O
to	O
rapidly	O
identify	O
HIV	O
infected	O
individuals	O
,	O
majority	O
of	O
HIV	O
-infected	O
people	O
are	O
unaware	O
of	O
their	O
sero-status	O
in	O
developing	O
countries	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
predictors	O
of	O
provider	O
-initiated	O
HIV	B-P
testing	I-P
and	O
counseling	O
(	O
PITC	O
)	O
refusal	O
by	O
outpatient	O
department	O
(	O
OPD	O
)	O
clients	O
in	O
Wolaita	O
zone	O
,	O
Southern	O
Ethiopia	O
.	O

Facility	O
based	O
unmatched	O
case	O
control	O
study	O
was	O
conducted	O
on	O
outpatient	O
department	O
clients	O
in	O
randomly	O
selected	O
seven	O
health	O
facilities	O
in	O
Wolaita	O
zone	O
,	O
Southern	O
Ethiopia	O
in	O
February	O
2012	O
.	O

A	O
total	O
of	O
291	O
participants	O
(	O
97	O
cases	O
and	O
194	O
controls	O
)	O
were	O
included	O
in	O
our	O
study	O
.	O

Cases	O
were	O
patients	O
who	O
refused	O
HIV	B-P
test	I-P
while	O
controls	O
were	O
patients	O
who	O
tested	O
for	O
HIV	O
after	O
provider	O
-initiated	O
HIV	B-P
testing	I-P
and	O
counseling	O
(	O
PITC	O
)	O
recommendation	O
by	O
outpatient	O
department	O
(	O
OPD	O
)	O
clinicians	O
.	O

We	O
used	O
both	O
quantitative	O
and	O
qualitative	O
methods	O
of	O
data	O
collection	O
.	O

Pretested	O
interviewer	O
administered	O
questionnaires	O
were	O
used	O
to	O
collect	O
quantitative	O
data	O
by	O
trained	O
nurses	O
,	O
and	O
in-depth	O
interview	O
with	O
14	O
OPD	O
clinicians	O
was	O
conducted	O
by	O
principal	O
investigator	O
to	O
supplement	O
quantitative	O
findings	O
.	O

Bivariate	O
and	O
multivariate	O
analyses	O
were	O
done	O
to	O
identify	O
independent	O
predictors	O
of	O
provider	O
-initiated	O
HIV	B-P
testing	I-P
and	O
counseling	O
refusal	O
by	O
OPD	O
clients	O
.	O

Study	O
participants	O
who	O
had	O
stigmatizing	O
attitude	O
[	O
AOR	O
=6.09	O
,	O
(	O
95	O
%	O
CI	O
:	O
1.70	O
,	O
21.76	O
)	O
]	O
,	O
who	O
had	O
perceived	O
risk	O
for	O
HIV	O
infection	O
[	O
AOR	O
=5.23	O
,	O
(	O
95	O
%	O
CI	O
:	O
2.22	O
,	O
12.32	O
)	O
]	O
,	O
who	O
did	O
not	O
perceive	O
the	O
benefits	O
of	O
provider	O
-initiated	O
HIV	B-P
testing	I-P
and	O
counseling	O
[	O
AOR	O
=4.64	O
,	O
(	O
95	O
%	O
CI	O
:	O
1.79	O
,	O
12.01	O
)	O
]	O
,	O
who	O
did	O
not	O
get	O
minimum	O
recommended	O
pretest	O
information	O
from	O
their	O
providers	O
[	O
AOR	O
=2.98	O
,	O
(	O
95	O
%	O
CI	O
:	O
1.06	O
,	O
8.35	O
)	O
]	O
,	O
who	O
ever	O
not	O
heard	O
of	O
provider	O
-initiated	O
HIV	B-P
testing	I-P
and	O
counseling	O
service	O
[	O
AOR	O
=2.41	O
,	O
(	O
95	O
%	O
CI	O
:	O
1.14	O
,	O
5.09	O
)	O
]	O
,	O
and	O
who	O
were	O
from	O
urban	O
area	O
[	O
AOR	O
=2.40	O
,	O
(	O
95	O
%	O
CI	O
=1.26	O
,	O
4.57	O
)	O
]	O
were	O
more	O
likely	O
to	O
refuse	O
provider	O
-initiated	O
HIV	B-P
testing	I-P
and	O
counseling	O
service	O
than	O
their	O
counterparts	O
.	O

Knowledge	O
on	O
HIV	O
/AIDS	O
,	O
attitude	O
towards	O
people	O
living	O
with	O
HIV	O
/AIDS	O
and	O
perceived	O
risk	O
for	O
HIV	O
infection	O
by	O
clients	O
were	O
the	O
major	O
barriers	O
for	O
provider	O
-initiated	O
HIV	B-P
testing	I-P
and	O
counseling	O
acceptance	O
.	O

Health	O
professionals	O
working	O
at	O
outpatient	O
department	O
should	O
give	O
due	O
attention	O
to	O
overcome	O
these	O
barriers	O
so	O
as	O
to	O
enhance	O
HIV	B-P
testing	I-P
acceptance	O
by	O
their	O
clients	O
.	O
''	O

``	O
JOURNAL	O
ARTICLE	O
''	O

Gender	O
and	O
Direction	O
of	O
Effect	O
of	O
Alcohol	O
Problems	O
and	O
Internalizing	O
Symptoms	O
in	O
a	O
Longitudinal	O
Sample	O
of	O
College	O
Students	O
.	O

Alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
are	O
consistently	O
found	O
to	O
be	O
associated	O
but	O
how	O
they	O
relate	O
to	O
each	O
other	O
is	O
unclear	O
.	O

The	O
present	O
study	O
aimed	O
to	O
address	O
limitations	O
in	O
the	O
literature	O
of	O
comorbidity	O
of	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
by	O
investigating	O
the	O
direction	O
of	O
effect	O
between	O
the	O
phenotypes	O
and	O
possible	O
gender	O
differences	O
in	O
college	O
students	O
.	O

We	O
utilized	O
data	O
from	O
a	O
large	O
longitudinal	O
study	O
of	O
college	O
students	O
from	O
the	O
United	O
States	O
(	O
N	O
=	O
2607	O
)	O
.	O

Three	O
waves	O
of	O
questionnaire-based	O
data	O
were	O
collected	O
over	O
the	O
first	O
two	O
years	O
of	O
college	O
(	O
in	O
2011-2013	O
)	O
.	O

Cross-lagged	O
models	O
were	O
applied	O
to	O
examine	O
the	O
possible	O
direction	O
of	O
effect	O
of	O
internalizing	O
symptoms	O
and	O
alcohol	O
problems	O
.	O

Possible	O
effects	O
of	O
gender	O
were	O
investigated	O
using	O
multigroup	O
modeling	O
.	O

There	O
were	O
significant	O
correlations	O
between	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
.	O

A	O
direction	O
of	O
effect	O
was	O
found	O
between	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
but	O
differed	O
between	O
genders	O
.	O

A	O
unidirectional	O
relationship	O
varying	O
with	O
age	O
was	O
identified	O
for	O
males	O
where	O
alcohol	O
problems	O
initially	O
predicted	O
internalizing	O
symptoms	O
followed	O
by	O
internalizing	O
symptoms	O
predicting	O
alcohol	O
problems	O
.	O

For	O
females	O
,	O
a	O
unidirectional	O
relationship	O
existed	O
wherein	O
alcohol	O
problems	O
predicted	O
internalizing	O
symptoms	O
.	O

Conclusions/Importance	O
:	O
We	O
conclude	O
that	O
the	O
relationship	O
between	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
is	O
complex	O
and	O
differ	O
between	O
genders	O
.	O

In	O
males	O
,	O
both	O
phenotypes	O
are	O
predictive	O
of	O
each	O
other	O
,	O
while	O
in	O
females	O
the	O
relationship	O
is	O
driven	O
by	O
alcohol	O
problems	O
.	O

Importantly	O
,	O
our	O
study	O
examines	O
a	O
population-based	O
sample	O
,	O
revealing	O
that	O
the	O
observed	O
relationships	O
between	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
are	O
not	O
limited	O
to	O
individuals	O
with	O
clinically	B-P
diagnosed	I-P
mental	O
health	O
or	O
substance	O
use	O
problems	O
.	O

Atheroprotective	O
effects	O
of	O
pure	O
tocotrienol	O
supplementation	O
in	O
the	O
treatment	O
of	O
rabbits	O
with	O
experimentally	O
induced	O
early	O
and	O
established	O
atherosclerosis	O
.	O

Atherosclerosis	O
is	O
the	O
main	O
cause	O
of	O
coronary	O
artery	O
disease	O
-related	O
deaths	O
worldwide	O
.	O

The	O
atheroprotective	O
properties	O
of	O
pure	O
tocotrienols	O
(	O
T3	O
)	O
in	O
the	O
absence	O
of	O
alpha-tocopherol	O
(	O
α-TCP	O
)	O
in	O
vitamin	O
E	O
has	O
not	O
been	O
extensively	O
examined	O
.	O

To	O
determine	O
the	O
atheroprotective	O
properties	O
of	O
T3	O
in	O
early	O
and	O
established	O
atherosclerosis	O
rabbits	O
.	O

Thirty	O
New	O
Zealand	O
white	O
rabbits	O
were	O
divided	O
into	O
two	O
groups	O
,	O
B1	O
and	O
B2	O
which	O
represent	O
early	O
[	O
fed	O
1	O
%	O
high	O
cholesterol	O
diet	O
(	O
HCD	O
)	O
for	O
2	O
weeks	O
]	O
and	O
established	O
(	O
fed	O
1	O
%	O
HCD	O
for	O
8	O
weeks	O
)	O
atherosclerosis	O
.	O

Each	O
group	O
was	O
subdivided	O
into	O
three	O
intervention	O
arms	O
:	O
1	O
)	O
T3	O
-4	O
mg/kg	O
,	O
2	O
)	O
T3	O
-15	O
mg/kg	O
and	O
3	O
)	O
vehicle	O
without	O
T3	O
(	O
T3	O
negative	O
)	O
for	O
8	O
weeks	O
.	O

Serial	O
fasting	O
blood	O
samples	O
were	O
obtained	O
for	O
lipid	B-P
profile	I-P
,	O
and	O
whole	O
lengths	O
of	O
aorta	O
were	O
used	O
to	O
determine	O
tissue	O
markers	O
of	O
endothelial	O
activation	O
,	O
inflammation	O
and	O
plaque	O
stability	O
.	O

In	O
B1	O
,	O
atherosclerotic	O
lesion	O
in	O
T3	O
-4	O
mg/kg	O
group	O
was	O
significantly	O
reduced	O
(	O
p=0.008	O
)	O
,	O
while	O
aortic	O
tissue	O
expression	O
of	O
vascular	O
cellular	O
adhesion	O
molecule	O
1	O
(	O
VCAM-1	O
)	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
and	O
matrix	O
metalloproteinase	O
(	O
MMP-12	O
)	O
was	O
reduced	O
in	O
T3	O
-4	O
mg/kg	O
compared	O
to	O
T3	O
-negative	O
rabbits	O
group	O
(	O
0.2±0.1	O
vs.	O
28.5±3.1	O
%	O
;	O
3.0±1.6	O
vs.	O
14.0±1.7	O
%	O
;	O
and	O
5.2±2.2	O
vs.	O
27.7±0.8	O
%	O
,	O
respectively	O
,	O
p	O
<	O
0.05	O
)	O
.	O

T3	O
-15	O
mg/kg	O
group	O
showed	O
reduction	O
in	O
VCAM-1	O
,	O
E-selectin	O
,	O
IL-6	O
and	O
MMP-12	O
(	O
3.9±1.9	O
vs.	O
28.5±3.1	O
%	O
;	O
10.3±0.5	O
vs.	O
59.8±8.5	O
%	O
;	O
2.6±1.7	O
vs.	O
14.0±1.7	O
%	O
;	O
and	O
16.2±3.2	O
vs.	O
27.7	O
0.8	O
%	O
,	O
respectively	O
,	O
p	O
<	O
0.05	O
)	O
.	O

In	O
B2	O
,	O
T3	O
-4	O
mg/kg	O
group	O
reduced	O
aortic	O
tissue	O
expression	O
of	O
intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM-1	O
)	O
,	O
E-selectin	O
,	O
IL-6	O
,	O
MMP-12	O
and	O
MMP-9	O
compared	O
to	O
T3	O
-negative	O
rabbits	O
group	O
(	O
29.9±2.4	O
vs.	O
55.3±1.3	O
%	O
;	O
26.7±1.5	O
vs.	O
60.5±7.6	O
%	O
;	O
15.7±0.7	O
vs.	O
27.7±4.8	O
%	O
;	O
34.8±2.7	O
vs.	O
46.5±3.4	O
%	O
;	O
and	O
25.89±3.9	O
vs.	O
45.9±1.7	O
%	O
,	O
respectively	O
,	O
p	O
<	O
0.05	O
)	O
.	O

T3	O
-15	O
mg/kg	O
group	O
showed	O
reduced	O
VCAM-1	O
,	O
ICAM-1	O
,	O
E-selectin	O
,	O
IL-6	O
,	O
MMP-12	O
and	O
MMP-9	O
(	O
20.5±3.3	O
vs.	O
35.6±2.5	O
%	O
;	O
24.9±1.3	O
vs.	O
55.3±1.3	O
%	O
;	O
29.9±6.7	O
vs.	O
60.5±7.6	O
;	O
11.3±2.2	O
vs.	O
27.7±4.8	O
%	O
;	O
23.0±1.7	O
vs.	O
46.5±3.4	O
%	O
;	O
and	O
17.6±1.9	O
vs.	O
45.9±1.7	O
%	O
,	O
respectively	O
,	O
p	O
<	O
0.05	O
.	O

These	O
findings	O
suggest	O
the	O
possible	O
atheroprotective	O
role	O
T3	O
plays	O
as	O
an	O
adjunct	O
supplementation	O
to	O
standard	O
treatment	O
in	O
the	O
prevention	O
of	O
CAD	O
.	O

Insecticidal	O
effects	O
of	O
deltamethrin	O
in	O
laboratory	O
and	O
field	O
populations	O
of	O
Culicoides	O
species	O
:	O
how	O
effective	O
are	O
host	O
-	O
contact	O
reduction	O
methods	O
in	O
India	O
?	O
.	O

Bluetongue	O
virus	O
(	O
BTV	O
)	O
is	O
transmitted	O
by	O
Culicoides	O
biting	O
midges	O
and	O
causes	O
bluetongue	O
(	O
BT	O
)	O
,	O
a	O
clinical	O
disease	O
observed	O
primarily	O
in	O
sheep	O
.	O

BT	O
has	O
a	O
detrimental	O
effect	O
on	O
subsistence	O
farmers	O
in	O
India	O
,	O
where	O
hyperendemic	O
outbreaks	O
impact	O
on	O
smallholdings	O
in	O
the	O
southern	O
states	O
of	O
the	O
country	O
.	O

In	O
this	O
study	O
,	O
we	O
establish	O
a	O
reliable	O
method	O
for	O
testing	O
the	O
toxic	O
effects	O
of	O
deltamethrin	O
on	O
Culicoides	O
and	O
then	O
compare	O
deltamethrin	O
with	O
traditional	O
control	O
methods	O
used	O
by	O
farmers	O
in	O
India	O
.	O

Effects	O
of	O
deltamethrin	O
were	O
initially	O
tested	O
using	O
a	O
colonised	O
strain	O
of	O
Culicoides	O
nubeculosus	O
Meigen	O
and	O
a	O
modified	O
World	O
Health	O
Organisation	O
exposure	B-P
assay	I-P
.	O

This	O
method	O
was	O
then	O
applied	O
to	O
field	O
populations	O
of	O
Culicoides	O
spp	O
.	O

in	O
India	O
.	O

The	O
field	O
population	O
of	O
C.	O
oxystoma	O
in	O
India	O
had	O
a	O
greater	O
LC50	O
(	O
0.012	O
±	O
0.009	O
%	O
)	O
for	O
deltamethrin	O
than	O
laboratory-reared	B-P
C.nubeculosus	O
(	O
0.0013	O
±	O
0.0002	O
%	O
)	O
.	O

Exposure	O
of	O
C.	O
nubeculosus	O
to	O
deltamethrin	O
at	O
higher	O
ambient	O
temperatures	O
resulted	O
in	O
greater	O
rates	O
of	O
knockdown	O
but	O
a	O
lower	O
mortality	O
rate	O
at	O
24	O
h	O
post-exposure	O
.	O

Behavioural	B-P
assays	I-P
with	O
C.	O
nubeculosus	O
in	O
WHO	O
tubes	O
provided	O
evidence	O
for	O
contact	O
irritancy	O
and	O
spatial	O
repellence	O
caused	O
by	O
deltamethrin	O
.	O

The	O
field	O
experiments	O
in	O
India	O
,	O
however	O
,	O
provided	O
no	O
evidence	O
for	O
repellent	O
or	O
toxic	O
effects	O
of	O
deltamethrin	O
.	O

Traditional	O
methods	O
such	O
as	O
the	O
application	O
of	O
neem	O
oil	O
and	O
burning	O
of	O
neem	O
leaves	O
also	O
provided	O
no	O
protection	O
.	O

Our	O
study	O
demonstrates	O
that	O
field	O
-collected	O
Culicoides	O
in	O
India	O
are	O
less	O
susceptible	O
to	O
deltamethrin	O
exposure	O
than	O
laboratory-bred	B-P
C.	O
nubeculosus	O
and	O
traditional	O
methods	O
of	O
insect	O
control	O
do	O
not	O
provide	O
protection	O
to	O
sheep	O
.	O

These	O
low	O
levels	O
of	O
susceptibility	O
to	O
deltamethrin	O
have	O
not	O
been	O
recorded	O
before	O
in	O
field	O
populations	O
of	O
Culicoides	O
and	O
suggest	O
resistance	O
to	O
synthetic	O
pyrethrioids	O
.	O

Alternative	O
insect	O
control	O
methods	O
,	O
in	O
addition	O
to	O
vaccination	O
,	O
may	O
be	O
needed	O
to	O
protect	O
Indian	O
livestock	O
from	O
BTV	O
transmission	O
.	O

Antiviral	O
activities	O
of	O
selected	O
antimalarials	O
against	O
dengue	O
virus	O
type	O
2	O
and	O
Zika	O
virus	O
.	O

In	O
a	O
previous	O
study	O
,	O
twelve	O
antimalarial	O
compounds	O
,	O
amodiaquine	O
(	O
AQ	O
)	O
and	O
derivatives	O
,	O
were	O
shown	O
to	O
have	O
potent	O
anti-dengue	O
viral	O
(	O
DENV	O
)	O
activity	O
by	O
using	O
the	O
stable	O
DENV2	O
Renilla	O
luciferase	O
reporter	O
replicon	O
expressing	O
BHK-21	O
cells	O
,	O
infectivity	O
(	O
plaque	B-P
)	O
,	O
and	O
the	O
qRT-PCR	O
assays	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
molecular	O
modeling	O
on	O
these	O
compounds	O
to	O
determine	O
their	O
stereo-electronic	O
properties	O
required	O
for	O
optimal	O
antiviral	O
activity	O
.	O

Based	O
on	O
the	O
similarity	O
of	O
calculated	O
stereo-electronic	O
profiles	O
,	O
specifically	O
the	O
electrostatic	O
potential	O
profiles	O
of	O
the	O
compounds	O
,	O
and	O
in	O
silico	O
screening	O
of	O
related	O
compounds	O
from	O
literature	O
,	O
we	O
identified	O
three	O
additional	O
compounds	O
,	O
Quinacrine	O
(	O
QC	O
)	O
,	O
Mefloquine	O
(	O
MQ	O
)	O
,	O
and	O
GSK369796	O
.	O

Analysis	O
of	O
their	O
antiviral	O
activities	O
indicated	O
that	O
all	O
three	O
compounds	O
have	O
high	O
anti-DENV	O
activity	O
in	O
the	O
DENV2	O
replicon	O
expressing	O
cells	O
with	O
EC50	O
values	O
of	O
5.30	O
±	O
1.31	O
μM	O
(	O
QC	O
)	O
,	O
3.22	O
±	O
0.37	O
μM	O
(	O
MQ	O
)	O
,	O
and	O
5.06	O
±	O
0.86	O
μM	O
(	O
GSK369796	O
)	O
.	O

The	O
infectivity	B-P
assays	I-P
revealed	O
the	O
EC50	O
values	O
of	O
7.09	O
±	O
1.67	O
μM	O
(	O
QC	O
)	O
,	O
4.36	O
±	O
0.31	O
μM	O
(	O
MQ	O
)	O
and	O
3.03	O
±	O
0.35	O
μM	O
(	O
GSK369796	O
)	O
.	O

The	O
mode	O
of	O
action	O
of	O
these	O
compounds	O
is	O
through	O
inhibition	O
of	O
autophagy	O
,	O
thereby	O
affecting	O
DENV2	O
replication	O
.	O

Moreover	O
,	O
these	O
compounds	O
also	O
showed	O
antiviral	O
activity	O
against	O
the	O
rapidly	O
emerging	O
Zika	O
virus	O
(	O
ZIKV	O
)	O
with	O
EC50	O
values	O
of	O
2.27	O
±	O
0.14	O
μM	O
(	O
QC	O
)	O
,	O
3.95	O
±	O
0.21	O
μM	O
(	O
MQ	O
)	O
,	O
and	O
2.57	O
±	O
0.09	O
μM	O
(	O
GSK369796	O
)	O
.	O

Deficient	O
cMyBP-C	O
protein	O
expression	O
during	O
cardiomyocyte	O
differentiation	O
underlies	O
human	O
hypertrophic	O
cardiomyopathy	O
cellular	B-P
phenotypes	O
in	O
disease	O
specific	O
human	O
ES	O
cell	O
derived	O
cardiomyocytes	O
.	O

Mutations	O
of	O
cardiac	O
sarcomere	O
genes	O
have	O
been	O
identified	O
to	O
cause	O
HCM	O
,	O
but	O
the	O
molecular	O
mechanisms	O
that	O
lead	O
to	O
cardiomyocyte	O
hypertrophy	O
and	O
risk	O
for	O
sudden	O
death	O
are	O
uncertain	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
HCM	O
disease	O
mechanisms	O
at	O
play	O
during	O
cardiac	O
differentiation	O
of	O
human	O
HCM	O
specific	O
pluripotent	O
stem	O
cells	O
.	O

We	O
generated	O
a	O
human	O
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
line	O
carrying	O
a	O
naturally	O
occurring	O
mutation	O
of	O
MYPBC3	O
(	O
c.2905	O
+1	O
G	O
>	O
A	O
)	O
to	O
study	O
HCM	O
pathogenesis	O
during	O
cardiac	O
differentiation	O
.	O

HCM	O
-	O
specific	O
hESC	O
-	O
derived	O
cardiomyocytes	O
(	O
hESC	O
-CMs	O
)	O
displayed	O
hallmark	O
aspects	O
of	O
HCM	O
including	O
sarcomere	O
disarray	O
,	O
hypertrophy	O
and	O
impaired	O
calcium	O
impulse	O
propagation	O
.	O

HCM	O
hESC	O
-CMs	O
presented	O
a	O
transient	O
haploinsufficiency	O
of	O
cMyBP-C	O
during	O
cardiomyocyte	O
differentiation	O
,	O
but	O
by	O
day	O
30	O
post	O
-	O
differentiation	O
cMyBP-C	O
levels	O
were	O
similar	O
to	O
control	O
hESC	O
-CMs	O
.	O

Gene	O
transfer	O
of	O
full-length	O
MYBPC3	O
during	O
differentiation	O
prevented	O
hypertrophy	O
,	O
sarcomere	O
disarray	O
and	O
improved	O
calcium	O
impulse	O
propagation	O
in	O
HCM	O
hESC	O
-CMs	O
.	O

These	O
findings	O
point	O
to	O
the	O
critical	O
role	O
of	O
MYBPC3	O
during	O
sarcomere	O
assembly	O
in	O
cardiac	O
myocyte	O
differentiation	O
and	O
suggest	O
developmental	O
influences	O
of	O
MYBPC3	O
truncating	O
mutations	O
on	O
the	O
mature	O
hypertrophic	O
phenotype	O
.	O

Crude	O
4-methylcyclohexanemethanol	O
(	O
MCHM	O
)	O
did	O
not	O
cause	O
skin	O
irritation	O
in	O
humans	O
in	O
48-h	O
patch	B-P
test	I-P
.	O

Crude	O
4-methylcyclohexanemethanol	O
(	O
MCHM	O
)	O
is	O
an	O
industrial	O
chemical	O
used	O
to	O
wash	O
and	O
clean	O
coal	O
.	O

On	O
January	O
9th	O
,	O
2014	O
approximately	O
10,000	O
gallons	O
of	O
a	O
mixture	O
containing	O
crude	O
MCHM	O
were	O
released	O
into	O
the	O
Elk	O
River	O
near	O
Charleston	O
,	O
West	O
Virginia	O
,	O
contaminating	O
the	O
local	O
water	O
supply	O
.	O

Following	O
the	O
spill	O
,	O
residents	O
reported	O
numerous	O
health	O
complaints	O
,	O
and	O
sought	O
medical	O
attention	O
for	O
ailments	O
including	O
rashes	O
and	O
itching	O
.	O

The	O
relationship	O
between	O
the	O
complaints	O
and	O
the	O
spill	O
were	O
unknown	O
,	O
as	O
such	O
symptoms	O
are	O
reported	O
frequently	O
in	O
the	O
background	O
.	O

In	O
this	O
study	O
,	O
the	O
primary	O
irritation	O
potential	O
of	O
crude	O
MCHM	O
was	O
evaluated	O
in	O
206	O
individuals	O
who	O
underwent	O
48	O
hour	O
semi-occluded	O
patch	B-P
testing	I-P
.	O

MCHM	O
concentrations	O
assessed	O
in	O
this	O
study	O
were	O
1	O
,	O
5	O
,	O
15	O
,	O
and	O
100	O
ppm	O
.	O

No	O
appreciable	O
skin	O
reactions	O
were	O
observed	O
in	O
individuals	O
at	O
any	O
concentration	O
.	O

Three	O
of	O
the	O
five	O
concentrations	O
evaluated	O
were	O
above	O
the	O
highest	O
measured	O
concentration	O
of	O
MCHM	O
in	O
the	O
tap	O
water	O
of	O
residents	O
in	O
West	O
Virginia	O
(	O
3.7	O
ppm	O
)	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
crude	O
MCHM	O
would	O
not	O
be	O
a	O
dermal	O
irritant	O
for	O
the	O
vast	O
majority	O
,	O
if	O
not	O
all	O
,	O
potentially	O
exposed	O
persons	O
at	O
the	O
concentrations	O
in	O
the	O
water	O
reported	O
after	O
the	O
spill	O
.	O

Harmful	O
effects	O
of	O
Dinophysis	O
to	O
the	O
ciliate	O
Mesodinium	O
rubrum	O
:	O
Implications	O
for	O
prey	O
capture	O
.	O

Toxigenic	O
Dinophysis	O
spp	O
.	O

are	O
obligate	O
mixotrophic	O
dinoflagellates	O
that	O
require	O
a	O
constant	O
supply	O
of	O
prey	O
-	O
Mesodinium	O
rubrum	O
-to	O
achieve	O
long-term	O
growth	O
by	O
means	O
of	O
kleptoplasty	O
.	O

Mesodinium	O
rubrum	O
is	O
,	O
however	O
,	O
a	O
fast	O
moving	O
,	O
jumping	O
ciliate	O
exhibiting	O
an	O
effective	O
escape	O
response	O
from	O
suspensivorous	O
predators	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
series	O
of	O
laboratory	B-P
experiments	I-P
evaluating	O
the	O
motility	O
and	O
survival	O
of	O
M.	O
rubrum	O
in	O
the	O
presence	O
of	O
Dinophysis	O
cells	O
and/or	O
substances	O
contained	O
in	O
their	O
culture	O
medium	O
was	O
designed	O
,	O
in	O
order	O
to	O
assess	O
the	O
mechanisms	O
involved	O
in	O
prey	O
capture	O
by	O
Dinophysis	O
spp	O
.	O

Cell	O
abundance	O
of	O
M.	O
rubrum	O
decreased	O
in	O
the	O
presence	O
of	O
Dinophysis	O
cf	O
.	O

ovum	O
cells	O
producing	O
okadaic	O
acid	O
(	O
OA	O
;	O
up	O
to	O
7.94±2.67pgcell	O
(	O
-1	O
)	O
)	O
and	O
smaller	O
amounts	O
of	O
dinophysistoxin-1	O
(	O
DTX-1	O
)	O
and	O
pectenotoxin-2	O
(	O
PTX-2	O
)	O
.	O

Prey	O
capture	O
was	O
often	O
observed	O
after	O
the	O
ciliate	O
had	O
been	O
attached	O
to	O
adhesive	O
``	O
mucus	O
traps	O
``	O
,	O
which	O
only	O
appeared	O
in	O
the	O
presence	O
of	O
Dinophysis	O
cells	O
.	O

Before	O
being	O
attached	O
to	O
the	O
mucus	O
traps	O
,	O
M.	O
rubrum	O
cells	O
reduced	O
significantly	O
their	O
swimming	O
frequency	O
(	O
from	O
∼41	O
to	O
19±3	O
jumps	O
min	O
(	O
-1	O
)	O
)	O
after	O
only	O
4h	O
of	O
initial	O
contact	O
with	O
D.	O
cf	O
.	O

ovum	O
cells	O
.	O

M.	O
rubrum	O
survival	O
was	O
not	O
affected	O
in	O
contact	O
with	O
purified	O
OA	O
,	O
DTX-1	O
and	O
PTX-2	O
solutions	O
,	O
but	O
decreased	O
significantly	O
when	O
the	O
ciliate	O
was	O
exposed	O
to	O
cell-free	O
or	O
filtered	O
culture	O
medium	O
from	O
both	O
D.	O
cf	O
.	O

ovum	O
and	O
D.	O
caudata	O
,	O
the	O
latter	O
containing	O
moderate	O
concentrations	O
of	O
free	O
eicosapentaenoic	O
acid	O
and	O
docosahexaenoic	O
acid	O
.	O

The	O
results	O
thus	O
indicate	O
that	O
Dinophysis	O
combines	O
the	O
release	O
of	O
toxic	O
compounds	O
other	O
than	O
shellfish	O
toxins	O
,	O
possibly	O
free	O
PUFAs	O
,	O
and	O
a	O
``	O
mucus	O
trap	O
``	O
to	O
enhance	O
its	O
prey	O
capture	O
success	O
by	O
immobilizing	O
and	O
subsequently	O
arresting	O
M.	O
rubrum	O
cells	O
.	O

The	O
Crystal	O
Structure	O
of	O
the	O
C-Terminal	O
Domain	O
of	O
the	O
Salmonella	O
enterica	O
PduO	O
Protein	O
:	O
An	O
Old	O
Fold	O
with	O
a	O
New	O
Heme-Binding	O
Mode	O
.	O

The	O
two-domain	O
protein	O
PduO	O
,	O
involved	O
in	O
1,2-propanediol	O
utilization	O
in	O
the	O
pathogenic	O
Gram-negative	O
bacterium	O
Salmonella	O
enterica	O
is	O
an	O
ATP	O
:	O
Cob	O
(	O
I	O
)	O
alamin	O
adenosyltransferase	O
,	O
but	O
this	O
is	O
a	O
function	O
of	O
the	O
N-terminal	O
domain	O
alone	O
.	O

The	O
role	O
of	O
its	O
C-terminal	O
domain	O
(	O
PduOC	O
)	O
is	O
,	O
however	O
,	O
unknown	O
.	O

In	O
this	O
study	O
,	O
comparative	O
growth	B-P
assays	I-P
with	O
a	O
set	O
of	O
Salmonella	O
mutant	O
strains	O
showed	O
that	O
this	O
domain	O
is	O
necessary	O
for	O
effective	O
in	O
vivo	O
catabolism	O
of	O
1,2-propanediol	O
.	O

It	O
was	O
also	O
shown	O
that	O
isolated	O
,	O
recombinantly-expressed	O
PduOC	O
binds	O
heme	O
in	O
vivo	O
.	O

The	O
structure	O
of	O
PduOC	O
co-crystallized	O
with	O
heme	O
was	O
solved	O
(	O
1.9	O
Å	O
resolution	O
)	O
showing	O
an	O
octameric	O
assembly	O
with	O
four	O
heme	O
moieities	O
.	O

The	O
four	O
heme	O
groups	O
are	O
highly	O
solvent-exposed	O
and	O
the	O
heme	O
iron	O
is	O
hexa-coordinated	O
with	O
bis-His	O
ligation	O
by	O
histidines	O
from	O
different	O
monomers	O
.	O

Static	B-P
light	I-P
scattering	I-P
confirmed	O
the	O
octameric	O
assembly	O
in	O
solution	O
,	O
but	O
a	O
mutation	O
of	O
the	O
heme	O
-	O
coordinating	O
histidine	O
caused	O
dissociation	O
into	O
dimers	O
.	O

Isothermal	B-P
titration	I-P
calorimetry	I-P
using	O
the	O
PduOC	O
apoprotein	O
showed	O
strong	O
heme	O
binding	O
(	O
K	O
d	O
=	O
1.6	O
×	O
10	O
(	O
-7	O
)	O
M	O
)	O
.	O

Biochemical	O
experiments	O
showed	O
that	O
the	O
absence	O
of	O
the	O
C-terminal	O
domain	O
in	O
PduO	O
did	O
not	O
affect	O
adenosyltransferase	O
activity	O
in	O
vitro	O
.	O

The	O
evidence	O
suggests	O
that	O
PduOC	O
:	O
heme	O
plays	O
an	O
important	O
role	O
in	O
the	O
set	O
of	O
cobalamin	O
transformations	O
required	O
for	O
effective	O
catabolism	O
of	O
1,2-propanediol	O
.	O

Salmonella	O
PduO	O
is	O
one	O
of	O
the	O
rare	O
proteins	O
which	O
binds	O
the	O
redox-active	O
metabolites	O
heme	O
and	O
cobalamin	O
,	O
and	O
the	O
heme-binding	O
mode	O
of	O
the	O
C-terminal	O
domain	O
differs	O
from	O
that	O
in	O
other	O
members	O
of	O
this	O
protein	O
family	O
.	O

Detection	O
and	O
Characterization	O
of	O
Flat	O
Aberrant	O
Crypt	O
Foci	O
(	O
Flat	O
ACF	O
)	O
in	O
the	O
Novel	O
A/J	O
Min/+	O
Mouse	O
.	O

Flat	O
aberrant	O
crypt	O
foci	O
(	O
flat	O
ACF	O
)	O
and	O
mucin-depleted	O
foci	O
(	O
MDF	O
)	O
have	O
previously	O
been	O
described	O
as	O
preneoplastic	O
colonic	O
lesions	O
.	O

We	O
used	O
the	O
novel	O
A/J	O
Min/+	O
mouse	O
model	O
,	O
that	O
demonstrates	O
extensive	O
spontaneous	O
colon	O
carcinogenesis	O
to	O
refine	O
the	O
method	O
of	O
detection	O
of	O
flat	O
ACF	O
and	O
further	O
characterize	O
and	O
define	O
them	O
as	O
early	O
lesions	O
by	O
histological	B-P
examination	I-P
and	O
comparison	O
with	O
MDF	O
.	O

Colons	O
were	O
stained	B-P
with	I-P
methylene	I-P
blue	I-P
(	O
MB	O
)	O
for	O
flat	O
ACF	O
detection	O
and	O
restained	B-P
with	O
high-iron	O
diamine-alcian	O
blue	O
(	O
HID-AB	O
)	O
for	O
MDF	O
detection	O
.	O

Optimal	O
flat	O
ACF	O
recognition	O
required	O
at	O
least	O
24	O
h	O
of	O
storage	O
post-	O
MB	B-P
staining	I-P
and	O
adherence	O
to	O
a	O
set	O
of	O
characteristics	O
.	O

The	O
fraction	O
of	O
flat	O
ACF	O
corresponding	O
with	O
MDF	O
was	O
93	O
%	O
.	O

Flat	O
ACF	O
/	O
MDF	O
displayed	O
the	O
same	O
picture	O
of	O
severe	O
dysplasia	O
,	O
lack	O
of	O
mucus	O
and	O
goblet	O
cells	O
and	O
accumulation	O
of	O
cytoplasmic	O
β-catenin	O
.	O

The	O
easily	O
detectable	O
flat	O
ACF	O
are	O
reliable	O
surface	O
biomarkers	O
of	O
Apc	O
-driven	O
colon	O
carcinogenesis	O
.	O

Effectiveness	O
of	O
workers	O
'	O
general	B-P
health	I-P
examination	I-P
in	O
Korea	O
by	O
health	O
examination	O
period	O
and	O
compliance	O
:	O
retrospective	O
cohort	O
study	O
using	O
nationwide	O
data	O
.	O

Our	O
study	O
evaluated	O
the	O
effectiveness	O
of	O
the	O
Workers	O
'	O
General	B-P
Health	I-P
Examination	I-P
by	O
health	O
examination	O
period	O
and	O
compliance	O
.	O

A	O
retrospective	O
cohort	O
of	O
the	O
health	O
examination	O
participants	O
in	O
2006	O
(	O
baseline	O
year	O
:	O
N�€‰=�€‰6,527,045	O
)	O
was	O
used	O
.	O

We	O
identified	O
newly	O
occurring	O
cardio	O
-	O
cerebrovascular	O
disease	O
over	O
7	O
years	O
(	O
from	O
2007	O
to	O
2013	O
)	O
.	O

After	O
stratification	O
by	O
age	O
,	O
sex	O
,	O
and	O
national	O
health	O
insurance	O
type	O
,	O
we	O
identified	O
7	O
years	O
'	O
cumulative	O
incidence	O
of	O
cardio	O
-	O
cerebrovascular	O
disease	O
by	O
health	O
examination	O
compliance	O
and	O
estimated	O
its	O
relative	O
risk	O
by	O
health	O
examination	O
period	O
and	O
compliance	O
.	O

The	O
compliant	O
group	O
presented	O
a	O
lower	O
cumulative	O
incidence	O
of	O
cardio	O
-	O
cerebrovascular	O
disease	O
than	O
the	O
non-compliant	O
group	O
;	O
this	O
result	O
was	O
consistent	O
across	O
sex	O
,	O
working	O
age	O
(	O
40s	O
and	O
50s	O
)	O
,	O
and	O
workplace	O
policyholder	O
.	O

Relative	O
risk	O
of	O
cardio	O
-	O
cerebrovascular	O
disease	O
by	O
health	O
examination	O
period	O
(	O
1	O
and	O
2	O
years	O
)	O
showed	O
statistically	O
significant	O
results	O
in	O
ischemic	O
heart	O
disease	O
for	O
male	O
participants	O
.	O

Of	O
men	O
in	O
their	O
40s	O
,	O
office	O
workers	O
(	O
over	O
a	O
2-year	O
period	O
)	O
presented	O
statistically	O
higher	O
relative	O
risk	O
of	O
ischemic	O
heart	O
disease	O
than	O
non-office	O
workers	O
(	O
over	O
a	O
1-year	O
period	O
:	O
1.03	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.02-1.03	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
consistent	O
results	O
in	O
ischemic	O
cerebrovascular	O
disease	O
and	O
hemorrhagic	O
cerebrovascular	O
disease	O
for	O
men	O
or	O
cardio	O
-	O
cerebrovascular	O
disease	O
for	O
women	O
.	O

A	O
1-year	O
period	O
of	O
Workers	O
'	O
General	B-P
Health	I-P
Examinations	I-P
in	O
non-office	O
workers	O
had	O
a	O
more	O
significant	O
prevention	O
effect	O
on	O
ischemic	O
heart	O
disease	O
than	O
a	O
2-year	O
period	O
in	O
office	O
workers	O
among	O
working	O
age	O
(	O
40s-50s	O
)	O
men	O
.	O

It	O
is	O
,	O
however	O
,	O
necessary	O
to	O
consider	O
that	O
prevention	O
of	O
cardio	O
-	O
cerebrovascular	O
disease	O
can	O
be	O
partially	O
explained	O
by	O
their	O
occupational	O
characteristics	O
rather	O
than	O
by	O
health	O
examination	O
period	O
.	O

Histological	O
evidence	O
of	O
inflammatory	O
reaction	O
associated	O
with	O
fibrosis	O
in	O
the	O
atrial	O
and	O
ventricular	O
walls	O
in	O
a	O
case-control	O
study	O
of	O
patients	O
with	O
history	O
of	O
atrial	O
fibrillation	O
.	O

Chronic	O
inflammation	O
in	O
the	O
atrial	O
myocardium	O
was	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
atrial	O
fibrosis	O
in	O
patients	O
with	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
to	O
what	O
extent	O
atrial	O
inflammatory	O
reaction	O
associated	O
with	O
AF	O
extends	O
on	O
the	O
ventricular	O
myocardium	O
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
extent	O
of	O
fibrosis	O
and	O
lymphomononuclear	O
infiltration	O
in	O
human	O
ventricular	O
myocardium	O
and	O
explore	O
its	O
association	O
with	O
AF	O
.	O

Medical	O
records	O
from	O
consecutive	O
autopsies	B-P
were	O
checked	O
for	O
presence	O
of	O
AF	O
.	O

Heart	O
specimens	O
from	O
30	O
patients	O
died	O
from	O
cardiovascular	O
causes	O
(	O
64	O
±	O
12	O
years	O
,	O
17	O
men	O
)	O
were	O
collected	O
in	O
three	O
equal	O
groups	O
:	O
no	O
AF	O
,	O
paroxysmal	O
AF	O
,	O
and	O
permanent	O
AF	O
.	O

Tissue	O
samples	O
were	O
taken	O
from	O
the	O
Bachmann	O
's	O
bundle	O
,	O
crista	O
terminalis	O
,	O
posterior	O
left	O
atrium	O
,	O
left	O
ventricle	O
and	O
right	O
ventricle	O
free	O
walls	O
and	O
stained	B-P
with	I-P
Masson	I-P
's	I-P
trichrome	I-P
for	O
analysis	O
of	O
fibrosis	O
extent	O
.	O

Immunohistochemistry	B-P
was	O
performed	O
using	O
antibodies	O
against	O
CD3-	O
and	O
CD45-antigens	O
and	O
quantified	O
as	O
number	O
of	O
antigen-positive	O
cells	O
per	O
1	O
mm	O
(	O
2	O
)	O
.	O

Fibrosis	O
extent	O
,	O
CD3+	O
and	O
CD45+	O
cell	B-P
counts	I-P
were	O
elevated	O
in	O
AF	O
patients	O
at	O
all	O
sites	O
(	O
P	O
<	O
0.001	O
for	O
all	O
)	O
.	O

Fibrosis	O
extent	O
demonstrated	O
correlation	O
with	O
both	O
CD3+	O
and	O
CD45+	O
cell	B-P
counts	I-P
in	O
the	O
right	O
(	O
r	O
=	O
0.781	O
,	O
P	O
<	O
0.001	O
for	O
CD45+	O
and	O
r	O
=	O
0.720	O
,	O
P	O
<	O
0.001	O
for	O
CD3+	O
)	O
and	O
the	O
left	O
(	O
r	O
=	O
0.515	O
,	O
P	O
=	O
0.004	O
for	O
CD45+	O
and	O
r	O
=	O
0.573	O
,	O
P	O
=	O
0.001	O
for	O
CD3+	O
)	O
ventricles	O
.	O

Neither	O
fibrosis	O
nor	O
inflammatory	O
cell	B-P
count	I-P
showed	O
association	O
with	O
either	O
age	O
or	O
comorbidities	O
.	O

Histological	O
signs	O
of	O
chronic	O
inflammation	O
affecting	O
ventricular	O
myocardium	O
are	O
strongly	O
associated	O
with	O
AF	O
and	O
demonstrate	O
significant	O
correlation	O
with	O
fibrosis	O
extent	O
that	O
can	O
not	O
be	O
explained	O
by	O
cardiovascular	O
comorbidities	O
otherwise	O
.	O

Structural	O
properties	O
and	O
psychometric	B-P
improvements	O
of	O
the	O
Health	O
Literacy	O
Questionnaire	O
in	O
a	O
Slovak	O
population	O
.	O

Health	O
literacy	O
is	O
an	O
important	O
determinant	O
of	O
health	O
and	O
health	O
equity	O
and	O
therefore	O
requires	O
robust	O
measurement	O
.	O

The	O
aim	O
was	O
to	O
examine	O
the	O
psychometric	B-P
properties	O
of	O
the	O
Slovak	O
version	O
of	O
the	O
Health	O
Literacy	O
Questionnaire	O
(	O
HLQ	O
)	O
including	O
revised	O
wording	O
of	O
response	O
categories	O
.	O

A	O
cross-sectional	O
survey	O
of	O
the	O
general	O
Slovak	O
adult	O
population	O
(	O
N	O
=	O
360	O
,	O
mean	O
age	O
39	O
)	O
was	O
conducted	O
with	O
the	O
HLQ	O
following	O
its	O
translation	O
and	O
cultural	O
adaptation	O
.	O

Psychometric	B-P
tests	O
(	O
confirmatory	O
factor	O
analysis	O
,	O
Cronbach	O
's	O
alpha	O
,	O
composite	O
reliability	O
)	O
and	O
association	O
(	O
linear	O
regression	O
,	O
ANOVA	O
)	O
with	O
sociodemographic	O
variables	O
were	O
undertaken	O
.	O

The	O
performance	O
of	O
alternative	O
version	O
of	O
response	O
options	O
were	O
explored	O
with	O
the	O
Mann-Whittney	O
U	O
test	O
and	O
item	O
response	O
theory	O
.	O

A	O
highly	O
restrictive	O
nine-factor	O
confirmatory	O
factor	O
analysis	O
showed	O
acceptable	O
fit	O
[	O
χ	O
(	O
2	O
)	O
WLSMV	O
=	O
1684	O
(	O
df	O
=	O
866	O
)	O
,	O
p	O
<	O
0.0001	O
;	O
CFI	O
=	O
0.943	O
,	O
TLI	O
=	O
0.938	O
,	O
RMSEA	O
=	O
0.051	O
,	O
WRMR	O
=	O
1.297	O
]	O
and	O
reliability	O
was	O
acceptable	O
(	O
range	O
0.73-0.84	O
)	O
.	O

The	O
revised	O
response	O
categories	O
had	O
a	O
better	O
distribution	O
with	O
lower	O
average	O
scores	O
in	O
three	O
domains	O
,	O
compared	O
with	O
the	O
original	O
,	O
and	O
improved	O
item	O
information	O
curves	O
.	O

The	O
nine	O
HLQ	O
scales	O
are	O
robust	O
,	O
providing	O
a	O
fine-grained	O
assessment	O
of	O
health	O
literacy	O
.	O

The	O
revised	O
response	O
options	O
improve	O
psychometric	B-P
properties	O
and	O
are	O
recommended	O
for	O
future	O
studies	O
.	O

Identification	O
of	O
MiR-21-5p	O
as	O
a	O
Functional	O
Regulator	O
of	O
Mesothelin	O
Expression	O
Using	O
MicroRNA	O
Capture	O
Affinity	O
Coupled	O
with	O
Next	O
Generation	O
Sequencing	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
non-coding	O
RNAs	O
that	O
regulate	O
mRNA	O
expression	O
mainly	O
by	O
silencing	O
target	O
transcripts	O
via	O
binding	O
to	O
miRNA	O
recognition	O
elements	O
(	O
MREs	O
)	O
in	O
the	O
3'untranslated	O
region	O
(	O
3'UTR	O
)	O
.	O

The	O
identification	O
of	O
bona	O
fide	O
targets	O
is	O
challenging	O
for	O
researchers	O
working	O
on	O
the	O
functional	O
aspect	O
of	O
miRNAs	O
.	O

Recently	O
,	O
we	O
developed	O
a	O
method	O
(	O
miR-CATCH	O
)	O
based	O
on	O
biotinylated	O
DNA	O
antisense	O
oligonucleotides	O
that	O
capture	O
the	O
mRNA	O
of	O
interest	O
and	O
facilitates	O
the	O
characterisation	O
of	O
miRNAs	O
:	O
:mRNA	O
interactions	O
in	O
a	O
physiological	O
cellular	O
context	O
.	O

Here	O
,	O
the	O
miR-CATCH	O
technique	O
was	O
applied	O
to	O
the	O
mesothelin	O
(	O
MSLN	O
)	O
gene	O
and	O
coupled	O
with	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
,	O
to	O
identify	O
miRNAs	O
that	O
regulate	O
MSLN	O
mRNA	O
and	O
that	O
may	O
be	O
responsible	O
for	O
its	O
increased	O
protein	O
levels	O
found	O
in	O
malignant	O
pleural	O
mesothelioma	O
(	O
MPM	O
)	O
.	O

Biotinylated	O
MSLN	O
oligos	O
were	O
employed	O
to	O
isolate	O
miRNA	O
:	O
:MSLN	O
mRNA	O
complexes	O
from	O
a	O
normal	O
cell	O
line	O
(	O
Met-5A	O
)	O
which	O
expresses	O
low	O
levels	O
of	O
MSLN	O
.	O

MiRNAs	O
targeting	O
the	O
MSLN	O
mRNA	O
were	O
identified	O
by	O
NGS	O
and	O
miR-21-5p	O
and	O
miR-100-5p	O
were	O
selected	O
for	O
further	O
validation	O
analyses	O
.	O

MiR-21-5p	O
was	O
shown	O
to	O
be	O
able	O
to	O
modulate	O
MSLN	O
expression	O
in	O
miRNA	O
mimic	O
experiments	O
in	O
a	O
panel	O
of	O
malignant	O
and	O
non-malignant	O
cell	O
lines	O
.	O

Further	O
miRNA	O
inhibitor	O
experiments	O
and	O
luciferase	O
assays	B-P
in	O
Mero-14	O
cells	O
validated	O
miR-21-5p	O
as	O
a	O
true	O
regulator	O
of	O
MSLN	O
.	O

Moreover	O
,	O
in	O
vitro	O
experiments	O
showed	O
that	O
treatment	O
with	O
miR-21-5p	O
mimic	O
reduced	O
proliferation	O
of	O
MPM	O
cell	O
lines	O
.	O

Altogether	O
,	O
this	O
work	O
shows	O
that	O
the	O
miR-CATCH	O
technique	O
,	O
coupled	O
with	O
NGS	O
and	O
in	O
vitro	O
validation	O
,	O
represents	O
a	O
reliable	O
method	O
to	O
identify	O
native	O
miRNA	O
:	O
:mRNA	O
interactions	O
.	O

MiR-21-5p	O
is	O
suggested	O
as	O
novel	O
regulator	O
of	O
MSLN	O
with	O
a	O
possible	O
functional	O
role	O
in	O
cellular	O
growth	O
.	O

An	O
ancient	O
role	O
for	O
nitric	O
oxide	O
in	O
regulating	O
the	O
animal	O
pelagobenthic	O
life	O
cycle	O
:	O
evidence	O
from	O
a	O
marine	O
sponge	O
.	O

In	O
many	O
marine	O
invertebrates	O
,	O
larval	O
metamorphosis	O
is	O
induced	O
by	O
environmental	O
cues	O
that	O
activate	O
sensory	O
receptors	O
and	O
signalling	O
pathways	O
.	O

Nitric	O
oxide	O
(	O
NO	O
)	O
is	O
a	O
gaseous	O
signalling	O
molecule	O
that	O
regulates	O
metamorphosis	O
in	O
diverse	O
bilaterians	O
.	O

In	O
most	O
cases	O
NO	O
inhibits	O
or	O
represses	O
this	O
process	O
,	O
although	O
it	O
functions	O
as	O
an	O
activator	O
in	O
some	O
species	O
.	O

Here	O
we	O
demonstrate	O
that	O
NO	O
positively	O
regulates	O
metamorphosis	O
in	O
the	O
poriferan	O
Amphimedon	O
queenslandica	O
.	O

High	O
rates	O
of	O
A.	O
queenslandica	O
metamorphosis	O
normally	O
induced	O
by	O
a	O
coralline	O
alga	O
are	O
inhibited	O
by	O
an	O
inhibitor	O
of	O
nitric	O
oxide	O
synthase	O
(	O
NOS	O
)	O
and	O
by	O
a	O
NO	O
scavenger	O
.	O

Consistent	O
with	O
this	O
,	O
an	O
artificial	O
donor	O
of	O
NO	O
induces	O
metamorphosis	O
even	O
in	O
the	O
absence	O
of	O
the	O
alga	O
.	O

Inhibition	O
of	O
the	O
ERK	O
signalling	O
pathway	O
prevents	O
metamorphosis	O
in	O
concert	O
with	O
,	O
or	O
downstream	O
of	O
,	O
NO	O
signalling	O
;	O
a	O
NO	O
donor	O
can	O
not	O
override	O
the	O
ERK	O
inhibitor	O
.	O

NOS	O
gene	O
expression	O
is	O
activated	O
late	O
in	O
embryogenesis	O
and	O
in	O
larvae	O
,	O
and	O
is	O
enriched	O
in	O
specific	O
epithelial	O
and	O
subepithelial	O
cell	O
types	O
,	O
including	O
a	O
putative	O
sensory	O
cell	O
,	O
the	O
globular	O
cell	O
;	O
DAF-FM	O
staining	B-P
supports	O
these	O
cells	O
being	O
primary	O
sources	O
of	O
NO	O
.	O

Together	O
,	O
these	O
results	O
are	O
consistent	O
with	O
NO	O
playing	O
an	O
activating	O
role	O
in	O
induction	O
of	O
A.	O
queenslandica	O
metamorphosis	O
,	O
evidence	O
of	O
its	O
highly	O
conserved	O
regulatory	O
role	O
in	O
metamorphosis	O
throughout	O
the	O
Metazoa	O
.	O

Threshold	O
Dose	O
Distribution	O
in	O
Walnut	O
Allergy	O
.	O

In	O
food	O
allergy	O
,	O
eliciting	O
doses	O
(	O
EDs	O
)	O
of	O
foods	O
on	O
a	O
population	O
level	O
can	O
improve	O
risk	O
management	O
and	O
labeling	O
strategies	O
for	O
the	O
food	O
industry	O
and	O
regulatory	O
authorities	O
.	O

Previously	O
,	O
data	O
available	O
for	O
walnut	O
were	O
unsuitable	O
to	O
determine	O
EDs	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
EDs	O
for	O
walnut	O
allergic	O
adults	O
and	O
to	O
compare	O
with	O
previously	O
established	O
threshold	O
data	O
for	O
peanut	O
and	O
tree	O
nuts	O
.	O

Prospectively	O
,	O
adult	O
subjects	O
with	O
a	O
suspected	O
walnut	O
allergy	O
underwent	O
a	O
low-dose	O
double-blind	O
,	O
placebo-controlled	O
food	O
challenge	O
.	O

Individual	O
no	B-P
observed	I-P
and	I-P
lowest	I-P
observed	I-P
adverse	I-P
effect	I-P
levels	I-P
were	O
determined	O
and	O
log-normal	O
,	O
log-logistic	O
,	O
and	O
Weibull	O
models	O
were	O
fit	O
to	O
the	O
data	O
.	O

Estimated	O
ED	O
values	O
were	O
calculated	O
for	O
the	O
ED5	O
,	O
ED10	O
,	O
and	O
ED50	O
,	O
the	O
dose	O
respectively	O
predicted	O
to	O
provoke	O
an	O
allergic	O
reaction	O
in	O
5	O
%	O
,	O
10	O
%	O
,	O
and	O
50	O
%	O
of	O
the	O
walnut	O
allergic	O
population	O
.	O

Fifty-seven	O
subjects	O
were	O
challenged	B-P
and	O
33	O
subjects	O
were	O
confirmed	O
to	O
be	O
walnut	O
allergic	O
.	O

Objective	O
symptoms	O
occurred	O
in	O
20	O
of	O
the	O
positive	B-P
challenges	I-P
(	O
61	O
%	O
)	O
.	O

The	O
cumulative	O
EDs	O
in	O
the	O
distribution	O
models	O
ranged	O
from	O
3.1	O
to	O
4.1	O
mg	O
for	O
the	O
ED05	O
,	O
from	O
10.6	O
to	O
14.6	O
mg	O
walnut	O
protein	O
for	O
the	O
ED10	O
,	O
and	O
from	O
590	O
to	O
625	O
mg	O
of	O
walnut	O
protein	O
for	O
the	O
ED50	O
.	O

Our	O
data	O
indicate	O
that	O
population	O
EDs	O
for	O
walnut	O
are	O
slightly	O
higher	O
compared	O
with	O
those	O
for	O
peanut	O
and	O
hazelnut	O
allergy	O
.	O

Currently	O
available	O
data	O
indicate	O
that	O
the	O
ED	O
values	O
for	O
hazelnut	O
could	O
be	O
used	O
as	O
a	O
conservative	O
temporary	O
placeholder	O
when	O
implementing	O
risk	O
management	O
strategies	O
for	O
other	O
tree	O
nuts	O
where	O
little	O
or	O
no	O
food	B-P
challenge	I-P
data	O
are	O
available	O
.	O

Graphene	O
/	O
Nafion	O
composite	O
film	O
modified	O
glassy	O
carbon	O
electrode	O
for	O
simultaneous	O
determination	B-P
of	O
paracetamol	O
,	O
aspirin	O
and	O
caffeine	O
in	O
pharmaceutical	O
formulations	O
.	O

A	O
graphene	O
-	O
Nafion	O
composite	O
film	O
was	O
fabricated	O
on	O
the	O
glassy	O
carbon	O
electrode	O
(	O
GR-NF/GCE	O
)	O
,	O
and	O
used	O
for	O
simultaneous	O
determination	B-P
of	O
paracetamol	O
(	O
PAR	O
)	O
,	O
aspirin	O
(	O
ASA	O
)	O
and	O
caffeine	O
(	O
CAF	O
)	O
.	O

The	O
electrochemical	O
behaviors	O
of	O
PAR	O
,	O
ASA	O
and	O
CAF	O
were	O
investigated	O
by	O
cyclic	O
voltammetry	O
and	O
square-wave	B-P
adsorptive	I-P
anodic	I-P
stripping	I-P
voltammetry	I-P
.	O

By	O
using	O
stripping	B-P
one	O
for	O
simultaneous	O
determination	B-P
of	O
PAR	O
,	O
ASA	O
and	O
CAF	O
,	O
their	O
electrochemical	O
oxidation	O
peaks	O
appeared	O
at	O
+0.64	O
,	O
1.04	O
and	O
1.44V	O
,	O
and	O
good	O
linear	O
current	O
responses	O
were	O
obtained	O
with	O
the	O
detection	O
limits	O
of	O
18ngmL	O
(	O
-1	O
)	O
(	O
1.2×10	O
(	O
-9	O
)	O
M	O
)	O
,	O
11.7ngmL	O
(	O
-1	O
)	O
(	O
6.5×10	O
(	O
-8	O
)	O
M	O
)	O
and	O
7.3ngmL	O
(	O
-1	O
)	O
(	O
3.8×10	O
(	O
-8	O
)	O
M	O
)	O
,	O
respectively	O
.	O

Finally	O
,	O
the	O
proposed	O
electrochemical	O
sensor	O
was	O
successfully	O
applied	O
for	O
quantifying	O
PAR	O
,	O
ASA	O
and	O
CAF	O
in	O
commercial	O
tablet	O
formulations	O
.	O

The	O
cancer	O
Warburg	O
effect	O
may	O
be	O
a	O
testable	O
example	O
of	O
the	O
minimum	O
entropy	O
production	O
rate	O
principle	O
.	O

Cancer	O
cells	O
consume	O
more	O
glucose	O
by	O
glycolytic	O
fermentation	O
to	O
lactate	O
than	O
by	O
respiration	O
,	O
a	O
characteristic	O
known	O
as	O
the	O
Warburg	O
effect	O
.	O

In	O
contrast	O
with	O
the	O
34	O
moles	O
of	O
ATP	O
produced	O
by	O
respiration	O
,	O
fermentation	O
produces	O
two	O
moles	O
of	O
ATP	O
per	O
mole	O
of	O
glucose	O
consumed	O
,	O
which	O
poses	O
a	O
puzzle	O
on	O
the	O
function	O
of	O
the	O
Warburg	O
effect	O
.	O

Productions	O
of	O
free	O
energy	O
(	O
ΔG	O
)	O
,	O
enthalpy	O
(	O
ΔH	O
)	O
and	O
entropy	O
(	O
ΔS	O
)	O
per	O
mole	O
linearly	O
vary	O
with	O
the	O
fraction	O
(	O
x	O
)	O
of	O
glucose	O
consumed	O
by	O
fermentation	O
that	O
is	O
frequently	O
estimated	O
around	O
0.9	O
.	O

Hence	O
,	O
calculation	O
shows	O
that	O
,	O
in	O
respect	O
to	O
pure	O
respiration	O
,	O
the	O
predominant	O
fermentative	O
metabolism	O
decreases	O
around	O
10	O
%	O
the	O
production	O
of	O
entropy	O
per	O
mole	O
of	O
glucose	O
consumed	O
in	O
cancer	O
cells	O
.	O

We	O
hypothesize	O
that	O
increased	O
fermentation	O
could	O
allow	O
cancer	O
cells	O
to	O
accomplish	O
the	O
Prigogine	O
theorem	O
of	O
the	O
trend	O
to	O
minimize	O
the	O
rate	O
of	O
production	O
of	O
entropy	O
.	O

According	O
the	O
theorem	O
,	O
open	O
cellular	O
systems	O
near	O
the	O
steady	O
state	O
could	O
evolve	O
to	O
minimize	O
the	O
rates	O
of	O
entropy	O
production	O
that	O
may	O
be	O
reached	O
by	O
modified	O
replicating	O
cells	O
producing	O
entropy	O
at	O
low	O
rate	O
.	O

Remarkably	O
,	O
at	O
CO2	O
concentrations	O
above	O
930	O
ppm	O
,	O
glucose	O
respiration	O
produces	O
less	O
entropy	O
than	O
fermentation	O
,	O
which	O
suggests	O
experimental	O
tests	B-P
to	O
validate	O
the	O
hypothesis	O
of	O
minimization	O
of	O
the	O
rate	O
of	O
entropy	O
production	O
through	O
the	O
Warburg	O
effect	O
.	O

Generation	O
of	O
High-Quality	O
SWATH	O
(	O
®	O
)	O
Acquisition	O
Data	O
for	O
Label-free	O
Quantitative	O
Proteomics	O
Studies	O
Using	O
TripleTOF	O
(	O
®	O
)	O
Mass	O
Spectrometers	O
.	O

Data	O
-	O
independent	O
acquisition	O
is	O
a	O
powerful	O
mass	B-P
spectrometry	I-P
technique	I-P
that	O
enables	O
comprehensive	O
MS	B-P
and	O
MS/MS	O
analysis	O
of	O
all	O
detectable	O
species	O
,	O
providing	O
an	O
information	O
rich	O
data	O
file	O
that	O
can	O
be	O
mined	O
deeply	O
.	O

Here	O
,	O
we	O
describe	O
how	O
to	O
acquire	O
high-quality	O
SWATH	O
(	O
®	O
)	O
Acquisition	O
data	O
to	O
be	O
used	O
for	O
large	O
quantitative	O
proteomic	O
studies	O
.	O

We	O
specifically	O
focus	O
on	O
using	O
variable	O
sized	O
Q1	O
windows	O
for	O
acquisition	O
of	O
MS/MS	O
data	O
for	O
generating	O
higher	O
specificity	O
quantitative	O
data	O
.	O

Association	O
of	O
Exclusive	O
Breastfeeding	O
Duration	O
With	O
Systemic	O
Inflammation	O
Markers	O
in	O
Adolescents	O
:	O
A	O
Cross-Sectional	O
Study	O
.	O

Breastfeeding	O
duration	O
has	O
been	O
associated	O
with	O
less	O
low-grade	O
inflammation	O
in	O
healthy	O
adolescents	O
,	O
but	O
there	O
is	O
scarce	O
information	O
regarding	O
obese	O
subjects	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
whether	O
exclusive	O
breastfeeding	O
is	O
related	O
to	O
serum	O
concentrations	O
of	O
inflammatory	O
markers	O
in	O
a	O
population	O
of	O
Spanish	O
adolescents	O
.	O

A	O
cross-sectional	O
study	O
was	O
performed	O
on	O
1,001	O
adolescents	O
(	O
13.2	O
±	O
1.2	O
years	O
)	O
randomly	O
recruited	O
from	O
schools	O
in	O
southeast	O
Spain	O
.	O

Data	O
on	O
breastfeeding	O
duration	O
were	O
collected	O
via	O
a	O
parental	O
questionnaire	O
.	O

Interleukin-6	O
(	O
IL-6	O
)	O
and	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-α	O
)	O
were	O
determined	O
by	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
.	O

C-reactive	O
protein	O
(	O
CRP	O
)	O
was	O
determined	O
by	O
solid-phase	B-P
chemiluminescent	I-P
immunometric	I-P
assay	I-P
.	O

Nonadjusted	O
and	O
adjusted	O
multivariate	O
correlation	O
analyses	O
confirmed	O
a	O
strong	O
association	O
(	O
p	O
<	O
.001	O
,	O
95	O
%	O
confidence	O
interval	O
)	O
between	O
the	O
three	O
markers	O
of	O
inflammation	O
and	O
exclusive	O
breastfeeding	O
duration	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
for	O
IL-6	O
,	O
TNF-α	O
,	O
and	O
CRP	O
serum	O
concentrations	O
among	O
normal	O
weight	O
,	O
overweight	O
,	O
and	O
obese	O
adolescents	O
,	O
except	O
for	O
IL-6	O
between	O
normal	O
weight	O
and	O
obese	O
subjects	O
.	O

Likewise	O
,	O
no	O
significant	O
association	O
was	O
found	O
between	O
these	O
markers	O
of	O
inflammation	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
z-score	O
.	O

We	O
found	O
a	O
possible	O
association	O
between	O
inflammatory	O
markers	O
and	O
exclusive	O
breastfeeding	O
duration	O
in	O
adolescents	O
,	O
regardless	O
of	O
their	O
BMI	O
.	O

This	O
finding	O
suggests	O
that	O
increased	O
body	O
weight	O
or	O
obesity	O
might	O
not	O
mediate	O
the	O
association	O
between	O
breastfeeding	O
and	O
inflammation	O
.	O

These	O
results	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
relationship	O
between	O
breastfeeding	O
and	O
inflammatory	O
markers	O
in	O
adolescents	O
.	O

Pulmonary	O
function	O
and	O
health-related	O
quality	O
of	O
life	O
1-	O
year	O
follow	O
up	O
after	O
cardiac	O
surgery	O
.	O

Pulmonary	O
function	O
is	O
severely	O
reduced	O
in	O
the	O
early	O
period	O
after	O
cardiac	O
surgery	O
,	O
and	O
impairments	O
have	O
been	O
described	O
up	O
to	O
4-6	O
months	O
after	O
surgery	O
.	O

Evaluation	O
of	O
pulmonary	O
function	O
in	O
a	O
longer	O
perspective	O
is	O
lacking	O
.	O

In	O
this	O
prospective	O
study	O
pulmonary	O
function	O
and	O
health-related	O
quality	O
of	O
life	O
were	O
investigated	O
1	O
year	O
after	O
cardiac	O
surgery	O
.	O

Pulmonary	O
function	O
measurements	O
,	O
health-related	O
quality	O
of	O
life	O
(	O
SF-36	O
)	O
,	O
dyspnoea	O
,	O
subjective	O
breathing	O
and	O
coughing	O
ability	O
and	O
pain	O
were	O
evaluated	O
before	O
and	O
1	O
year	O
after	O
surgery	O
in	O
150	O
patients	O
undergoing	O
coronary	O
artery	O
bypass	O
grafting	O
,	O
valve	O
surgery	O
or	O
combined	O
surgery	O
.	O

One	O
year	O
after	O
surgery	O
the	O
forced	O
vital	O
capacity	O
and	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
were	O
significantly	O
decreased	O
(	O
by	O
4-5	O
%	O
)	O
compared	O
to	O
preoperative	O
values	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Saturation	O
of	O
peripheral	O
oxygen	O
was	O
unchanged	O
1	O
year	O
postoperatively	O
compared	O
to	O
baseline	O
.	O

A	O
significantly	O
improved	O
health-related	O
quality	O
of	O
life	O
was	O
found	O
1	O
year	O
after	O
surgery	O
,	O
with	O
improvements	O
in	O
all	O
eight	O
aspects	O
of	O
SF-36	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Sternotomy	O
-related	O
pain	O
was	O
low	O
1	O
year	O
postoperatively	O
at	O
rest	O
(	O
median	O
0	O
[	O
min-max	O
;	O
0-7	O
]	O
)	O
,	O
while	O
taking	O
a	O
deep	O
breath	O
(	O
0	O
[	O
0-4	O
]	O
)	O
and	O
while	O
coughing	O
(	O
0	O
[	O
0-8	O
]	O
)	O
.	O

A	O
more	O
pronounced	O
decrease	O
in	O
pulmonary	O
function	O
was	O
associated	O
with	O
dyspnoea	O
limitations	O
and	O
impaired	O
subjective	O
breathing	O
and	O
coughing	O
ability	O
.	O

One	O
year	O
after	O
cardiac	O
surgery	O
static	O
and	O
dynamic	O
lung	B-P
function	I-P
measurements	I-P
were	O
slightly	O
decreased	O
,	O
while	O
health-related	O
quality	O
of	O
life	O
was	O
improved	O
in	O
comparison	O
to	O
preoperative	O
values	O
.	O

Measured	O
levels	O
of	O
pain	O
were	O
low	O
and	O
saturation	O
of	O
peripheral	O
oxygen	O
was	O
same	O
as	O
preoperatively	O
.	O

Tailor-made	O
drug	O
carrier	O
:	O
Comparison	O
of	O
formation-dependent	O
physicochemical	O
properties	O
within	O
self-assembled	O
aggregates	O
for	O
an	O
optimal	O
drug	O
carrier	O
.	O

Self-assembled	O
surfactant	O
aggregates	O
,	O
such	O
as	O
micelles	O
and	O
vesicles	O
,	O
have	O
been	O
investigated	O
for	O
their	O
application	O
as	O
drug	O
carriers	O
in	O
the	O
treatment	O
of	O
various	O
diseases	O
.	O

However	O
,	O
the	O
characteristics	O
that	O
decide	O
which	O
aggregate	O
is	O
the	O
best	O
drug	O
carrier	O
for	O
each	O
disease	O
have	O
not	O
yet	O
been	O
clarified	O
.	O

In	O
order	O
to	O
design	O
an	O
optimal	O
drug	O
carrier	O
for	O
each	O
disease	O
,	O
various	O
kinds	O
of	O
self-assembled	O
aggregates	O
,	O
such	O
as	O
spherical	O
micelles	O
,	O
lens-like	O
vesicles	O
,	O
and	O
tube-like	O
vesicles	O
,	O
were	O
evaluated	O
by	O
``	O
multiple	O
techniques	O
``	O
including	O
dynamic	B-P
light	I-P
scattering	I-P
,	O
differential	B-P
scanning	I-P
calorimetry	I-P
,	O
nuclear	B-P
magnetic	I-P
resonance	I-P
spectroscopy	I-P
,	O
and	O
fluorescence	B-P
measurement	I-P
using	O
the	O
Laurdan	O
probe	O
.	O

These	O
studies	O
led	O
to	O
the	O
compilation	O
of	O
a	O
database	O
on	O
the	O
formation-dependent	O
properties	O
of	O
self-assembled	O
aggregates	O
.	O

As	O
the	O
relationship	O
between	O
physicochemical	O
properties	O
of	O
self-assembled	O
aggregates	O
and	O
their	O
functions	O
as	O
drug	O
carriers	O
have	O
been	O
extensively	O
reported	O
,	O
this	O
database	O
can	O
be	O
utilized	O
for	O
designing	O
an	O
optimal	O
drug	O
carrier	O
,	O
i.e.	O
,	O
a	O
tailor-made	O
drug	O
carrier	O
.	O

A	O
R2R3-MYB	O
transcription	O
factor	O
from	O
Lablab	O
purpureus	O
induced	O
by	O
drought	O
increases	O
tolerance	O
to	O
abiotic	O
stress	O
in	O
Arabidopsis	O
.	O

Few	O
regulators	O
for	O
drought	O
tolerance	O
have	O
been	O
identified	O
in	O
Lablab	O
purpureus	O
which	O
is	O
a	O
multipurpose	O
leguminous	O
crop	O
.	O

The	O
transcription	O
factor	O
MYB	O
is	O
involved	O
in	O
regulatory	O
networks	O
in	O
response	O
to	O
abiotic	O
and	O
biotic	O
stresses	O
in	O
plants	O
.	O

A	O
novel	O
R2R3-MYB	O
factor	O
in	O
L.	O
purpureus	O
has	O
been	O
identified	O
.	O

An	O
suppression	O
subtraction	O
hybridization	O
(	O
SSH	O
)	O
library	O
was	O
constructed	O
using	O
root	O
tissues	O
of	O
L.	O
purpureus	O
MEIDOU	O
2012	O
from	O
well-watered	O
and	O
water-stress	O
treatments	O
that	O
were	O
subjected	O
to	O
drought	O
stress	O
for	O
10	O
days	O
.	O

In	O
addition	O
,	O
the	O
cDNA	O
of	O
LpMYB1	O
was	O
identified	O
based	O
on	O
the	O
SSH	O
library	O
.	O

The	O
cDNA	O
of	O
LpMYB1	O
is	O
858	O
bp	O
and	O
encodes	O
a	O
285-	O
amino	O
acid	O
protein	O
with	O
a	O
calculated	B-P
mass	O
of	O
33.4	O
kDa	O
.	O

The	O
LpMYB1	O
protein	O
localizes	O
to	O
the	O
nucleus	O
and	O
has	O
transactivation	O
activity	O
with	O
the	O
activation	O
domain	O
in	O
the	O
C	O
terminal	O
region	O
of	O
the	O
protein	O
.	O

In	O
LpMYB1	O
overexpressed	O
Arabidopsis	O
,	O
the	O
tolerance	O
of	O
transgenic	O
seedlings	O
to	O
drought	O
and	O
salt	O
was	O
improved	O
,	O
and	O
the	O
germination	O
potential	O
of	O
transgenic	O
seeds	O
increase	O
in	O
the	O
presence	O
of	O
NaCl	O
or	O
ABA	O
.	O

LpMYB1	O
is	O
a	O
drought	O
-	O
responsive	O
R2R3-MYB	O
factor	O
that	O
can	O
increase	O
the	O
drought	O
and	O
salt	O
tolerance	O
of	O
LpMYB1	O
-	O
overexpressed	O
Arabidopsis	O
.	O

The	O
evolutionary	O
history	O
of	O
bears	O
is	O
characterized	O
by	O
gene	O
flow	O
across	O
species	O
.	O

Bears	O
are	O
iconic	O
mammals	O
with	O
a	O
complex	O
evolutionary	O
history	O
.	O

Natural	O
bear	O
hybrids	O
and	O
studies	O
of	O
few	O
nuclear	O
genes	O
indicate	O
that	O
gene	O
flow	O
among	O
bears	O
may	O
be	O
more	O
common	O
than	O
expected	O
and	O
not	O
limited	O
to	O
polar	O
and	O
brown	O
bears	O
.	O

Here	O
we	O
present	O
a	O
genome	B-P
analysis	I-P
of	O
the	O
bear	O
family	O
with	O
representatives	O
of	O
all	O
living	O
species	O
.	O

Phylogenomic	O
analyses	O
of	O
869	O
mega	O
base	O
pairs	O
divided	O
into	O
18,621	O
genome	O
fragments	O
yielded	O
a	O
well-resolved	O
coalescent	O
species	O
tree	O
despite	O
signals	O
for	O
extensive	O
gene	O
flow	O
across	O
species	O
.	O

However	O
,	O
genome	B-P
analyses	I-P
using	O
different	O
statistical	O
methods	O
show	O
that	O
gene	O
flow	O
is	O
not	O
limited	O
to	O
closely	O
related	O
species	O
pairs	O
.	O

Strong	O
ancestral	O
gene	O
flow	O
between	O
the	O
Asiatic	O
black	O
bear	O
and	O
the	O
ancestor	O
to	O
polar	O
,	O
brown	O
and	O
American	O
black	O
bear	O
explains	O
uncertainties	O
in	O
reconstructing	O
the	O
bear	O
phylogeny	O
.	O

Gene	O
flow	O
across	O
the	O
bear	O
clade	O
may	O
be	O
mediated	O
by	O
intermediate	O
species	O
such	O
as	O
the	O
geographically	O
wide-spread	O
brown	O
bears	O
leading	O
to	O
large	O
amounts	O
of	O
phylogenetic	O
conflict	O
.	O

Genome-scale	B-P
analyses	I-P
lead	O
to	O
a	O
more	O
complete	O
understanding	O
of	O
complex	O
evolutionary	O
processes	O
.	O

Evidence	O
for	O
extensive	O
inter-specific	O
gene	O
flow	O
,	O
found	O
also	O
in	O
other	O
animal	O
species	O
,	O
necessitates	O
shifting	O
the	O
attention	O
from	O
speciation	O
processes	O
achieving	O
genome	O
-wide	O
reproductive	O
isolation	O
to	O
the	O
selective	O
processes	O
that	O
maintain	O
species	O
divergence	O
in	O
the	O
face	O
of	O
gene	O
flow	O
.	O

Beyond	O
``	O
Median	O
Waiting	O
Time	O
``	O
:	O
Development	O
and	O
Validation	O
of	O
a	O
Competing	O
Risk	O
Model	O
to	O
Predict	O
Outcomes	O
on	O
the	O
Kidney	O
Transplant	O
Waiting	O
List	O
.	O

Median	O
historical	O
time	O
to	O
kidney	O
transplant	O
is	O
misleading	O
because	O
it	O
does	O
not	O
convey	O
the	O
competing	O
risks	O
of	O
death	O
or	O
removal	O
from	O
the	O
waiting	O
list	O
.	O

We	O
developed	O
and	O
validated	O
a	O
competing	O
risk	O
model	O
to	O
calculate	O
likelihood	O
of	O
outcomes	O
for	O
kidney	O
transplant	O
candidates	O
and	O
demonstrate	O
how	O
this	O
information	O
differs	O
from	O
median	O
time	O
to	O
transplant	O
.	O

Data	O
were	O
obtained	O
from	O
the	O
US	O
Scientific	O
Registry	O
of	O
Transplant	O
Recipients	O
.	O

The	O
retrospective	O
cohort	O
included	O
163	O
636	O
adults	O
listed	O
for	O
kidney	O
transplant	O
before	O
December	O
31	O
,	O
2011	O
.	O

Predictors	O
were	O
age	O
,	O
sex	O
,	O
blood	O
type	O
,	O
calculated	B-P
panel-reactive	B-P
antibodies	I-P
,	O
donation	O
service	O
area	O
,	O
dialysis	O
duration	O
,	O
comorbid	O
conditions	O
,	O
and	O
body	O
mass	O
index	O
.	O

Outcomes	O
were	O
deceased	O
or	O
living	O
donor	O
transplant	O
,	O
death	O
or	O
removal	O
from	O
the	O
list	O
due	O
to	O
deteriorating	O
medical	O
condition	O
,	O
or	O
removal	O
due	O
to	O
other	O
reasons	O
.	O

We	O
calculated	O
hazards	O
for	O
the	O
possible	O
outcomes	O
,	O
then	O
the	O
cumulative	O
incidence	O
function	O
for	O
a	O
given	O
candidate	O
using	O
competing	O
risk	O
methodology	O
.	O

Discrimination	O
and	O
calibration	O
were	O
assessed	O
through	O
C	O
statistics	O
and	O
calibration	O
plots	O
for	O
each	O
cause	O
-	O
specific	O
Cox	O
proportional	O
hazard	O
model	O
.	O

C	O
statistics	O
ranged	O
from	O
0.64	O
to	O
0.73	O
.	O

Calibration	O
plots	O
showed	O
good	O
calibration	O
.	O

The	O
competing	O
risk	O
model	O
shows	O
probability	O
of	O
all	O
possible	O
outcomes	O
for	O
up	O
to	O
12	O
years	O
given	O
a	O
candidate	O
's	O
characteristics	O
,	O
contrasted	O
with	O
the	O
median	O
waiting	O
time	O
for	O
that	O
candidate	O
's	O
donation	O
service	O
area	O
.	O

A	O
competing	O
risk	O
model	O
conveys	O
more	O
relevant	O
information	O
than	O
the	O
median	O
waiting	O
time	O
for	O
a	O
given	O
transplant	O
center	O
.	O

This	O
model	O
will	O
be	O
updated	O
to	O
create	O
a	O
calculator	O
reflecting	O
the	O
most	O
recent	O
outcomes	O
and	O
changes	O
in	O
allocation	O
policy	O
.	O

It	O
illustrates	O
the	O
conversations	O
that	O
should	O
be	O
initiated	O
with	O
transplant	O
candidates	O
.	O

How	O
Integrated	B-P
Management	I-P
Strategies	I-P
Promote	O
Protein	O
Quality	O
of	O
Cotton	O
Embryos	O
:	O
High	O
Levels	O
of	O
Soil	O
Available	O
N	O
,	O
N	O
Assimilation	O
and	O
Protein	O
Accumulation	O
Rate	O
.	O

Cottonseed	O
is	O
widely	O
used	O
as	O
a	O
source	O
of	O
ruminant	O
feed	O
and	O
for	O
industrial	O
purposes	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
tremendous	O
need	O
to	O
improve	O
the	O
nutritional	O
value	O
of	O
cotton	O
embryos	O
.	O

In	O
this	O
study	O
,	O
a	O
conventional	B-P
management	I-P
(	O
CM	B-P
)	O
and	O
two	O
integrated	O
cotton	O
management	B-P
strategies	I-P
(	O
IMS1	B-P
,	O
IMS2	B-P
)	O
were	O
performed	O
at	O
two	O
soil	O
fertility	O
levels	O
to	O
study	O
the	O
relationships	O
among	O
soil	O
N	O
,	O
N	O
assimilation	O
,	O
embryonic	O
protein	O
accumulation	O
and	O
protein	O
quality	O
.	O

The	O
levels	B-P
of	I-P
proteins	I-P
,	O
essential	B-P
amino	I-P
acids	I-P
,	O
and	O
semi-essential	B-P
amino	I-P
acids	I-P
,	O
especially	O
those	O
of	O
glutamate	B-P
,	O
lysine	B-P
,	O
and	O
methionine	B-P
,	O
were	O
higher	O
in	O
IMS1	B-P
and	O
IMS2	B-P
embryos	O
than	O
in	O
CM	B-P
embryos	O
.	O

These	O
changes	O
were	O
significantly	O
positively	O
correlated	O
with	O
the	O
soil	O
-	O
available	O
N	B-P
content	I-P
,	O
glutamine	O
synthetase	O
activity	O
and	O
peak	O
value	O
of	O
protein	O
accumulation	O
rate	O
and	O
were	O
negatively	O
correlated	O
with	O
the	O
free	O
amino	B-P
acid	I-P
level	I-P
.	O

These	O
results	O
illustrated	O
that	O
integrated	B-P
management	I-P
strategies	I-P
,	O
especially	O
the	O
rates	O
and	O
timing	O
of	O
N	O
application	O
,	O
raise	O
the	O
level	O
of	O
soil	O
available	O
N	O
,	O
which	O
is	O
beneficial	O
for	O
N	O
assimilation	O
in	O
developing	O
cotton	O
embryos	O
.	O

The	O
protein	B-P
content	I-P
was	O
limited	O
by	O
the	O
rate	O
of	O
protein	O
accumulation	O
rather	O
than	O
by	O
the	O
free	O
amino	B-P
acid	I-P
content	I-P
.	O

The	O
combination	O
of	O
target	O
yield	O
fertilization	O
,	O
a	O
growth	O
-driven	O
N	O
application	O
schedule	O
,	O
a	O
high	O
plant	O
density	O
and	O
the	O
seedling	O
raising	O
with	O
bio-organic	O
fertilizer	O
can	O
substantially	O
improve	O
protein	O
quality	O
in	O
cotton	O
embryos	O
,	O
especially	O
at	O
a	O
soil	O
with	O
low	O
soil	O
organic	O
matter	O
and	O
total	O
nitrogen	O
.	O

BAG3	O
is	O
involved	O
in	O
neuronal	O
differentiation	O
and	O
migration	O
.	O

Bcl2-associated	O
athanogene	O
3	O
(	O
BAG3	O
)	O
protein	O
belongs	O
to	O
the	O
family	O
of	O
co-chaperones	O
interacting	O
with	O
several	O
heat	O
shock	O
proteins	O
.	O

It	O
plays	O
a	O
key	O
role	O
in	O
protein	O
quality	O
control	O
and	O
mediates	O
the	O
clearance	O
of	O
misfolded	O
proteins	O
.	O

Little	O
is	O
known	O
about	O
the	O
expression	O
and	O
cellular	O
localization	O
of	O
BAG3	O
during	O
nervous	O
system	O
development	O
and	O
differentiation	O
.	O

Therefore	O
,	O
we	O
analyze	O
the	O
subcellular	O
distribution	O
and	O
expression	O
of	O
BAG3	O
in	O
nerve-growth-factor	O
-induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
and	O
in	O
developing	O
and	O
adult	O
cortex	O
of	O
mouse	O
brain	O
.	O

In	O
differentiated	O
PC12	O
cells	O
,	O
BAG3	O
was	O
localized	O
mainly	O
in	O
the	O
neuritic	O
domain	O
rather	O
than	O
the	O
cell	O
body	O
,	O
whereas	O
in	O
control	O
cells	O
,	O
it	O
appeared	O
to	O
be	O
confined	O
to	O
the	O
cytoplasm	O
near	O
the	O
nuclear	O
membrane	O
.	O

Interestingly	O
,	O
the	O
change	O
of	O
BAG3	O
localization	O
during	O
neuronal	O
differentiation	O
was	O
associated	O
only	O
with	O
a	O
slight	O
increase	O
in	O
total	O
BAG3	O
expression	O
.	O

These	O
data	O
were	O
coroborated	O
by	O
transmission	B-P
electron	I-P
microscopy	I-P
showing	O
that	O
BAG3	O
was	O
confined	O
mainly	O
within	O
large	O
dense-core	O
vesicles	O
of	O
the	O
axon	O
in	O
differentiated	O
PC12	O
cells	O
.	O

In	O
mouse	O
developing	O
cortex	O
,	O
BAG3	O
appeared	O
to	O
be	O
intensely	O
expressed	O
in	O
cellular	O
processes	O
of	O
migrating	O
cells	O
,	O
whereas	O
in	O
adult	O
brain	O
,	O
a	O
diffuse	O
expression	O
of	O
low	O
to	O
medium	O
intensity	O
was	O
detected	O
in	O
neuronal	O
cell	O
bodies	O
.	O

These	O
findings	O
suggest	O
that	O
BAG3	O
expression	O
is	O
required	O
for	O
neuronal	O
differentiation	O
and	O
migration	O
and	O
that	O
its	O
role	O
is	O
linked	O
to	O
a	O
change	O
in	O
its	O
distribution	O
pattern	O
rather	O
than	O
to	O
an	O
increase	O
in	O
its	O
protein	O
expression	O
levels	O
.	O

Determinants	O
of	O
On-Road	O
Driving	O
in	O
Multiple	O
Sclerosis	O
.	O

To	O
investigate	O
the	O
cognitive	O
,	O
visual	O
,	O
and	O
motor	O
deficits	O
underlying	O
poor	O
performance	O
on	O
different	O
dimensions	O
of	O
on-road	O
driving	O
in	O
individuals	O
with	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

Prospective	O
cross-sectional	O
study	O
.	O

MS	O
clinic	O
and	O
driving	O
simulator	O
lab	O
.	O

Active	O
drivers	O
(	O
N=102	O
)	O
with	O
various	O
types	O
of	O
MS.	O
Not	O
applicable	O
.	O

Off-road	O
cognitive	O
,	O
visual	O
,	O
and	O
motor	O
functions	O
,	O
as	O
well	O
as	O
13	O
specific	O
driving	O
skills	O
.	O

These	O
skills	O
were	O
categorized	O
into	O
hierarchic	O
clusters	O
of	O
operational	O
,	O
tactical	O
,	O
visuo-integrative	O
,	O
and	O
mixed	O
driving	O
.	O

Stepwise	O
regression	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
off-road	O
functions	O
influencing	O
performance	O
on	O
the	O
on-road	O
test	O
and	O
each	O
cluster	O
.	O

Visuospatial	O
function	O
(	O
P=.002	O
)	O
,	O
inhibition	O
(	O
P=.008	O
)	O
,	O
binocular	O
acuity	O
(	O
P=.04	O
)	O
,	O
vertical	B-P
visual	I-P
field	I-P
(	O
P=.02	O
)	O
,	O
and	O
stereopsis	O
(	O
P=.03	O
)	O
best	O
determined	O
variance	O
in	O
total	O
on-road	O
score	O
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=.37	O
)	O
.	O

Attentional	O
shift	O
(	O
P=.0004	O
)	O
,	O
stereopsis	O
(	O
P=.007	O
)	O
,	O
glare	B-P
recovery	I-P
(	O
P=.047	O
)	O
,	O
and	O
use	O
of	O
assistive	O
devices	O
(	O
P=.03	O
)	O
best	O
predicted	O
the	O
operational	O
cluster	O
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=.28	O
)	O
.	O

Visuospatial	O
function	O
(	O
P=.002	O
)	O
,	O
inhibition	O
(	O
P=.002	O
)	O
,	O
reasoning	O
(	O
P=.003	O
)	O
,	O
binocular	O
acuity	O
(	O
P=.04	O
)	O
,	O
and	O
stereopsis	O
(	O
P=.005	O
)	O
best	O
determined	O
the	O
tactical	O
cluster	O
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=.41	O
)	O
.	O

The	O
visuo-integrative	O
mode	O
l	O
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=.12	O
)	O
comprised	O
binocular	O
acuity	O
(	O
P=.007	O
)	O
and	O
stereopsis	O
(	O
P=.045	O
)	O
.	O

Inhibition	O
(	O
P=.0001	O
)	O
and	O
binocular	O
acuity	O
(	O
P=.001	O
)	O
provided	O
the	O
best	O
model	O
of	O
the	O
mixed	O
cluster	O
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=.25	O
)	O
.	O

Our	O
results	O
provide	O
more	O
insights	O
into	O
the	O
specific	O
impairments	O
that	O
influence	O
different	O
dimensions	O
of	O
on-road	O
driving	O
and	O
may	O
be	O
used	O
as	O
a	O
framework	O
for	O
targeted	O
driving	O
intervention	O
programs	O
in	O
MS	O
.	O

Presumptive	O
Spontaneous	O
Lysosomal	O
Storage-Like	O
Disease	O
in	O
a	O
Crl	O
:	O
CD1	O
(	O
ICR	O
)	O
Mouse	O
.	O

A	O
clinically	O
unremarkable	O
4.5-mo-old	O
female	O
Crl	O
:	O
CD1	O
(	O
ICR	O
)	O
VAF/Elite	O
mouse	O
was	O
euthanized	O
for	O
scheduled	O
sentinel	O
processing	O
.	O

Gross	B-P
necropsy	I-P
findings	O
included	O
significant	O
hepatosplenomegaly	O
and	O
visceral	O
lymphadenomegaly	O
,	O
resulting	O
in	O
a	O
preliminarygross	O
diagnosis	O
of	O
lymphoma	O
.	O

Histology	O
revealed	O
florid	O
accumulations	O
of	O
large	O
,	O
'foamy	O
'	O
macrophages	O
present	O
in	O
the	O
bone	O
marrow	O
,	O
small	O
intestines	O
,	O
and	O
viscera	O
including	O
liver	O
,	O
spleen	O
,	O
lymph	O
nodes	O
,	O
thymus	O
,	O
uterus	O
,	O
and	O
ovaries	O
.	O

The	O
cytoplasm	O
of	O
these	O
cells	O
was	O
abundant	O
,	O
stained	O
pale	O
blue	O
with	O
Wright-Giemsa	B-P
and	O
was	O
periodic	B-P
acid-Schiff	I-P
positive	O
.	O

Given	O
these	O
characteristic	O
gross	O
and	O
histologic	B-P
findings	O
,	O
a	O
spontaneous	O
lysosomal	O
storage-like	O
disease	O
was	O
diagnosed	O
in	O
this	O
mouse	O
.	O

Cholesterol	O
ester	O
storage	O
disease	O
is	O
likely	O
,	O
because	O
of	O
the	O
visceral	O
involvement	O
with	O
sparing	O
of	O
the	O
CNS	O
,	O
but	O
could	O
not	O
be	O
diagnosed	O
definitively	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
report	O
is	O
the	O
first	O
to	O
describe	O
a	O
case	O
of	O
spontaneous	O
lysosomal	O
storage	O
disease	O
in	O
an	O
outbred	O
mouse	O
of	O
the	O
CD1	O
(	O
ICR	O
)	O
background	O
.	O

Sinogram	B-P
-based	O
coil	O
selection	O
for	O
streak	O
artifact	O
reduction	O
in	O
undersampled	O
radial	B-P
real-time	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
.	O

Streak	O
artifacts	O
are	O
a	O
common	O
problem	O
in	O
radial	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
.	O

We	O
therefore	O
developed	O
a	O
method	O
for	O
automatically	O
excluding	O
receiver	O
coil	O
elements	O
which	O
lead	O
to	O
these	O
artifacts	O
.	O

The	O
proposed	O
coil	O
selection	O
relates	O
to	O
real-time	B-P
MRI	I-P
data	O
based	O
on	O
highly	O
undersampled	O
radial	O
acquisitions	O
.	O

It	O
exploits	O
differences	O
between	O
high-	B-P
and	O
low-resolution	O
sinograms	B-P
reconstructed	O
from	O
datasets	O
acquired	O
during	O
preparatory	O
scans	B-P
.	O

Apart	O
from	O
phantom	O
validations	O
,	O
the	O
performance	O
was	O
assessed	O
for	O
real-time	B-P
MRI	I-P
studies	O
of	O
different	O
human	O
organ	O
systems	O
in	O
vivo	O
.	O

The	O
algorithm	O
greatly	O
reduces	O
streak	O
artifact	O
strength	O
without	O
compromising	O
image	O
quality	O
in	O
other	O
parts	O
of	O
the	O
image	O
.	O

It	O
is	O
robust	O
with	O
respect	O
to	O
different	O
experimental	O
settings	O
and	O
fast	O
to	O
be	O
included	O
in	O
the	O
online	O
reconstruction	O
pipeline	O
for	O
real-time	B-P
MRI	I-P
.	O

The	O
proposed	O
method	O
enables	O
a	O
fast	O
reduction	O
of	O
streak	O
artifacts	O
in	O
radial	B-P
real-time	I-P
MRI	I-P
.	O

Considerations	O
on	O
the	O
Relevance	O
of	O
Cerebral	O
Fusiform	O
Aneurysms	O
Observed	O
During	O
HIV	O
Infection	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-associated	O
ectatic	O
cerebral	O
vasculitis	O
(	O
HIV	O
-	O
AECV	O
)	O
is	O
a	O
rare	O
form	O
of	O
vasculitis	O
with	O
diffuse	O
fusiform	O
aneurysms	O
.	O

Its	O
pathophysiology	O
remains	O
poorly	O
understood	O
.	O

Although	O
extensively	O
described	O
in	O
children	O
,	O
it	O
is	O
still	O
incompletely	O
studied	O
in	O
adults	O
.	O

Our	O
objective	O
was	O
to	O
present	O
five	O
adult	O
cases	O
with	O
emphasis	O
on	O
imaging	O
findings	O
and	O
long-term	O
evolution	O
.	O

From	O
2006	O
to	O
2014	O
,	O
we	O
included	O
5	O
HIV	O
-	O
infected	O
patients	O
presenting	O
with	O
fusiform	O
cerebral	O
aneurysms	O
.	O

Vessels	O
abnormalities	O
were	O
assessed	O
with	O
brain	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
angiography	B-P
,	O
magnetic	B-P
resonance	I-P
angiography	I-P
(	O
MRA	B-P
)	O
and/or	O
digital	B-P
subtraction	I-P
angiography	I-P
(	O
DSA	B-P
)	O
.	O

All	O
patients	O
had	O
MR	B-P
assessment	O
of	O
the	O
brain	O
.	O

Clinical	O
and	O
biological	O
data	O
were	O
analyzed	O
.	O

Fusiform	O
aneurysms	O
of	O
carotid	O
terminations	O
extending	O
to	O
middle	O
and	O
anterior	O
cerebral	O
arteries	O
were	O
bilateral	O
in	O
three	O
patients	O
and	O
unilateral	O
in	O
one	O
.	O

More	O
distal	O
fusiform	O
aneurysms	O
were	O
observed	O
in	O
four	O
patients	O
and	O
saccular	O
aneurysms	O
in	O
two	O
patients	O
,	O
two	O
patients	O
suffered	O
from	O
ischemic	O
lesions	O
while	O
none	O
experienced	O
hemorrhage	O
.	O

Unlike	O
recent	O
reviews	O
,	O
our	O
study	O
underlines	O
the	O
low	O
hemorrhagic	O
potential	O
of	O
HIV	O
-	O
AECV	O
and	O
long-term	O
follow-up	O
suggests	O
a	O
monophasic	O
evolution	O
under	O
antiretroviral	O
medication	O
.	O

Repeated	O
local	O
emergence	O
of	O
carbapenem-resistant	O
Acinetobacter	O
baumannii	O
in	O
a	O
single	O
hospital	O
ward	O
.	O

We	O
recently	O
reported	O
a	O
dramatic	O
increase	O
in	O
the	O
prevalence	O
of	O
carbapenem-resistant	O
Acinetobacter	O
baumannii	O
infections	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
of	O
a	O
Vietnamese	O
hospital	O
.	O

This	O
upsurge	O
was	O
associated	O
with	O
a	O
specific	O
oxa23	O
-positive	O
clone	O
that	O
was	O
identified	O
by	O
multilocus	B-P
VNTR	I-P
analysis	I-P
.	O

Here	O
,	O
we	O
used	O
whole-genome	B-P
sequence	I-P
analysis	I-P
to	O
dissect	O
the	O
emergence	O
of	O
carbapenem-resistant	O
A.	O
baumannii	O
causing	O
ventilator-associated	O
pneumonia	O
(	O
VAP	O
)	O
in	O
the	O
ICU	O
during	O
2009-2012	O
.	O

To	O
provide	O
historical	O
context	O
and	O
distinguish	O
microevolution	O
from	O
strain	O
introduction	O
,	O
we	O
compared	O
these	O
genomes	O
with	O
those	O
of	O
A.	O
baumannii	O
asymptomatic	O
carriage	O
and	O
VAP	O
isolates	O
from	O
this	O
same	O
ICU	O
collected	O
during	O
2003-2007	O
.	O

We	O
identified	O
diverse	O
lineages	O
co-circulating	O
over	O
many	O
years	O
.	O

Carbapenem	O
resistance	O
was	O
associated	O
with	O
the	O
presence	O
of	O
oxa23	O
,	O
oxa40	O
,	O
oxa58	O
and	O
ndm1	O
genes	O
in	O
multiple	O
lineages	O
.	O

The	O
majority	O
of	O
resistant	O
isolates	O
were	O
oxa23	O
-positive	O
global	O
clone	O
GC2	O
;	O
fine-scale	O
phylogenomic	O
analysis	O
revealed	O
five	O
distinct	O
GC2	O
sublineages	O
within	O
the	O
ICU	O
that	O
had	O
evolved	O
locally	O
via	O
independent	O
chromosomal	O
insertions	O
of	O
oxa23	O
transposons	O
.	O

The	O
increase	O
in	O
infections	O
caused	O
by	O
carbapenem-resistant	O
A.	O
baumannii	O
was	O
associated	O
with	O
transposon	O
-mediated	O
transmission	O
of	O
a	O
carbapenemase	O
gene	O
,	O
rather	O
than	O
clonal	O
expansion	O
or	O
spread	O
of	O
a	O
carbapenemase	O
-harbouring	O
plasmid	O
.	O

Additionally	O
,	O
we	O
found	O
evidence	O
of	O
homologous	O
recombination	O
creating	O
diversity	O
within	O
the	O
local	O
GC2	O
population	O
,	O
including	O
several	O
events	O
resulting	O
in	O
replacement	O
of	O
the	O
capsule	O
locus	O
.	O

We	O
identified	O
likely	O
donors	O
of	O
the	O
imported	O
capsule	O
locus	O
sequences	O
amongst	O
the	O
A.	O
baumannii	O
isolated	O
on	O
the	O
same	O
ward	O
,	O
suggesting	O
that	O
diversification	O
was	O
largely	O
facilitated	O
via	O
reassortment	O
and	O
sharing	O
of	O
genetic	O
material	O
within	O
the	O
localized	O
A.	O
baumannii	O
population	O
.	O

UHPLC-MS/MS	B-P
method	I-P
for	O
the	O
quantitation	O
of	O
penicillin	O
G	O
and	O
metabolites	O
in	O
citrus	O
fruit	O
using	O
internal	O
standards	O
.	O

Penicillin	O
G	O
has	O
been	O
applied	O
to	O
citrus	O
trees	O
as	O
a	O
potential	O
treatment	O
in	O
the	O
fight	O
against	O
Huanglongbing	O
(	O
HLB	O
)	O
.	O

Here	O
,	O
we	O
have	O
developed	O
and	O
validated	O
a	O
method	O
to	O
identify	O
and	O
quantitate	O
penicillin	O
G	O
and	O
two	O
of	O
its	O
metabolites	O
,	O
penillic	O
acid	O
and	O
penilloic	O
acid	O
,	O
in	O
citrus	O
fruit	O
using	O
ultra	B-P
high	I-P
performance	I-P
liquid	I-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
(	O
UHPLC-MS/MS	B-P
)	O
.	O

This	O
method	O
improves	O
upon	O
a	O
previous	O
method	O
by	O
incorporating	O
isotopically	O
labeled	O
internal	O
standards	O
,	O
namely	O
,	O
penillic	O
acid-D5	O
,	O
and	O
penilloic	O
acid-D5	O
.	O

These	O
standards	O
greatly	O
enhanced	O
the	O
accuracy	O
and	O
precision	O
of	O
our	O
measurements	O
by	O
compensating	O
for	O
recovery	O
losses	O
,	O
degradation	O
,	O
and	O
matrix	O
effects	O
.	O

When	O
2g	O
of	O
citrus	O
fruit	O
sample	O
is	O
extracted	O
,	O
the	O
limits	O
of	O
detection	O
(	O
LOD	O
)	O
were	O
determined	O
to	O
be	O
0.1ng/g	O
for	O
penicillin	O
G	O
and	O
penilloic	O
acid	O
,	O
and	O
0.25ng/g	O
for	O
penillic	O
acid	O
.	O

At	O
fortification	O
levels	O
of	O
0.1	O
,	O
0.25	O
,	O
1	O
,	O
and	O
10ng/g	O
,	O
absolute	O
recoveries	O
for	O
penillic	O
and	O
penilloic	O
acids	O
were	O
generally	O
between	O
50-70	O
%	O
.	O

Recoveries	O
corrected	O
with	O
the	O
isotopically	O
labeled	O
standards	O
were	O
approximately	O
90-110	O
%	O
.	O

This	O
method	O
will	O
be	O
useful	O
for	O
the	O
identification	O
and	O
quantitation	O
of	O
drug	O
residues	O
and	O
their	O
degradation	O
products	O
using	O
isotopically	O
labeled	O
standards	O
and	O
UHPLC-MS/MS	B-P
.	O

Pitfalls	O
in	O
interpretation	O
of	O
FDG	O
PET/CT	B-P
:	O
Septic	O
pulmonary	O
emboli	O
mimicking	O
metastases	O
in	O
a	O
case	O
of	O
gastric	O
carcinoma	O
.	O

Inflammatory	O
lesions	O
may	O
sometimes	O
show	O
intense	O
tracer	O
uptake	O
and	O
mimic	O
neoplastic	O
lesions	O
on	O
(	O
18	O
)	O
F-fluoro-deoxyglucose	O
(	O
FDG	O
)	O
positron	B-P
emission	I-P
tomography/computed	I-P
tomography	I-P
(	O
PET/CT	B-P
)	O
.	O

We	O
report	O
one	O
such	O
false	O
positive	O
case	O
on	O
FDG	O
PET/CT	B-P
,	O
where	O
septic	O
pulmonary	O
emboli	O
(	O
SPE	O
)	O
mimicked	O
pulmonary	O
metastases	O
.	O

A	O
45-	O
year-old	O
man	O
with	O
stomach	O
cancer	O
had	O
an	O
indwelling	O
central	O
venous	O
catheter	O
(	O
CVC	O
)	O
in	O
situ	O
while	O
on	O
neoadjuvant	O
chemotherapy	O
.	O

He	O
underwent	O
FDG	O
PET/CT	B-P
scan	I-P
for	O
response	O
assessment	O
and	O
the	O
images	O
revealed	O
multiple	O
,	O
intensely	O
FDG	O
avid	O
,	O
peripheral	O
,	O
lung	O
nodules	O
with	O
feeding	O
vessels	O
,	O
which	O
were	O
suspicious	O
for	O
pulmonary	O
metastases	O
.	O

A	O
day	O
later	O
,	O
the	O
patient	O
developed	O
fever	O
with	O
chills	O
and	O
his	O
blood	B-P
culture	I-P
showed	O
bacterial	O
growth	O
(	O
Enterobacter	O
cloacae	O
)	O
.	O

A	O
provisional	O
diagnosis	O
of	O
SPE	O
from	O
an	O
infected	O
CVC	O
was	O
made	O
.	O

Chemotherapy	O
was	O
withheld	O
,	O
CVC	O
removed	O
,	O
and	O
the	O
catheter	O
tip	O
was	O
sent	O
for	O
bacterial	B-P
culture	I-P
.	O

Following	O
a	O
4-week	O
course	O
of	O
antibiotic	O
treatment	O
,	O
the	O
patient	O
became	O
afebrile	O
.	O

Culture	B-P
from	O
the	O
CVC	O
tip	O
grew	O
the	O
same	O
organism	O
,	O
as	O
was	O
seen	O
earlier	O
in	O
the	O
patient	O
's	O
blood	B-P
culture	I-P
,	O
thus	O
pin-pointing	O
the	O
source	O
of	O
infection	O
in	O
our	O
case	O
.	O

Diagnosis	O
of	O
SPE	O
was	O
clinched	O
when	O
follow-up	O
CT	B-P
chest	O
done	O
after	O
completion	O
of	O
antibiotic	O
course	O
showed	O
complete	O
resolution	O
of	O
the	O
lung	O
lesions	O
.	O

Numerical	O
simulation	O
of	O
emitted	O
particle	O
characteristics	O
and	O
airway	O
deposition	O
distribution	O
of	O
Symbicort	O
(	O
®	O
)	O
Turbuhaler	O
(	O
®	O
)	O
dry	O
powder	O
fixed	O
combination	O
aerosol	O
drug	O
.	O

One	O
of	O
the	O
most	O
widespread	O
dry	O
powder	O
fixed	O
combinations	O
used	O
in	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
management	O
is	O
Symbicort	O
(	O
®	O
)	O
Turbuhaler	O
(	O
®	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
simulate	O
the	O
deposition	O
distribution	O
of	O
both	O
components	O
of	O
this	O
drug	O
within	O
the	O
airways	O
based	O
on	O
realistic	O
airflow	B-P
measurements	I-P
.	O

Breathing	O
parameters	O
of	O
25	O
healthy	O
adults	O
(	O
11	O
females	O
and	O
14	O
males	O
)	O
were	O
acquired	O
while	O
inhaling	O
through	O
Turbuhaler	O
(	O
®	O
)	O
.	O

Individual	O
specific	O
emitted	O
doses	O
and	O
particle	O
size	O
distributions	O
of	O
Symbicort	O
(	O
®	O
)	O
Turbuhaler	O
(	O
®	O
)	O
were	O
determined	O
.	O

A	O
self-developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	O
corticosteroid	O
;	O
ICS	O
)	O
and	O
formoterol	O
(	O
long	O
acting	O
β2	O
agonist	O
;	O
LABA	O
)	O
in	O
the	O
upper	O
airways	O
and	O
lungs	O
of	O
the	O
healthy	O
volunteers	O
.	O

Based	O
on	O
current	O
simulations	O
the	O
emitted	O
doses	O
varied	O
between	O
50.4	O
%	O
and	O
92.5	O
%	O
of	O
the	O
metered	O
dose	O
for	O
the	O
ICS	O
,	O
and	O
between	O
38	O
%	O
and	O
96.1	O
%	O
in	O
case	O
of	O
LABA	O
component	O
depending	O
on	O
the	O
individual	O
inhalation	O
flow	O
rate	O
.	O

This	O
variability	O
induced	O
a	O
notable	O
inter-	O
individual	O
spread	O
of	O
the	O
deposited	O
lung	O
doses	O
(	O
mean	O
:	O
33.6	O
%	O
,	O
range	O
:	O
20.4	O
%	O
-48.8	O
%	O
for	O
budesonide	O
and	O
mean	O
:	O
29.8	O
%	O
,	O
range	O
:	O
16.4	O
%	O
-42.9	O
%	O
for	O
formoterol	O
)	O
.	O

Significant	O
inter-gender	O
differences	O
were	O
also	O
observed	O
.	O

Average	O
lung	O
dose	O
of	O
budesonide	O
was	O
29.2	O
%	O
of	O
the	O
metered	O
dose	O
for	O
females	O
and	O
37	O
%	O
for	O
males	O
,	O
while	O
formoterol	O
deposited	O
with	O
26.4	O
%	O
efficiency	O
for	O
females	O
and	O
32.5	O
%	O
for	O
males	O
.	O

Present	O
results	O
also	O
highlighted	O
the	O
importance	O
of	O
breath-holding	O
after	O
inhalation	O
of	O
the	O
drug	O
.	O

About	O
a	O
half	O
of	O
the	O
total	O
lung	O
deposition	O
occurred	O
during	O
breath-hold	O
at	O
9.6s	O
average	O
breath-hold	O
time	O
.	O

Calculated	O
depositions	O
confirmed	O
appropriate	O
lung	O
deposition	O
of	O
Symbicort	O
(	O
®	O
)	O
Turbuhaler	O
(	O
®	O
)	O
for	O
both	O
genders	O
,	O
however	O
more	O
effort	O
for	O
optimal	O
inhalation	O
technique	O
is	O
advised	O
for	O
persons	O
with	O
low	O
vital	O
capacity	O
.	O

This	O
study	O
demonstrated	O
the	O
possibility	O
of	O
personalized	O
prediction	O
of	O
airway	O
deposition	O
of	O
aerosol	O
drugs	O
by	O
numerical	O
simulations	O
.	O

The	O
methodology	O
developed	O
in	O
this	O
study	O
will	O
be	O
applicable	O
also	O
to	O
other	O
marketed	O
drugs	O
in	O
the	O
future	O
.	O

Dynamic	O
Cross-Entropy	O
.	O

Complexity	O
measures	O
for	O
time	O
series	O
have	O
been	O
used	O
in	O
many	O
applications	O
to	O
quantify	O
the	O
regularity	O
of	O
one	O
dimensional	O
time	O
series	O
,	O
however	O
many	O
dynamical	O
systems	O
are	O
spatially	O
distributed	O
multidimensional	O
systems	O
.	O

We	O
introduced	O
Dynamic	O
Cross-Entropy	O
(	O
DCE	O
)	O
a	O
novel	O
multidimensional	O
complexity	O
measure	O
that	O
quantifies	O
the	O
degree	O
of	O
regularity	O
of	O
EEG	B-P
signals	O
in	O
selected	O
frequency	O
bands	O
.	O

Time	O
series	O
generated	O
by	O
discrete	O
logistic	O
equations	O
with	O
varying	O
control	O
parameter	O
r	O
are	O
used	O
to	O
test	O
DCE	O
measures	O
.	O

Sliding	O
window	O
DCE	O
analyses	O
are	O
able	O
to	O
reveal	O
specific	O
period	O
doubling	O
bifurcations	O
that	O
lead	O
to	O
chaos	O
.	O

A	O
similar	O
behavior	O
can	O
be	O
observed	O
in	O
seizures	O
triggered	O
by	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
.	O

Sample	O
entropy	O
data	O
show	O
the	O
level	O
of	O
signal	O
complexity	O
in	O
different	O
phases	O
of	O
the	O
ictal	O
ECT	O
.	O

The	O
transition	O
to	O
irregular	O
activity	O
is	O
preceded	O
by	O
the	O
occurrence	O
of	O
cyclic	O
regular	O
behavior	O
.	O

A	O
significant	O
increase	O
of	O
DCE	O
values	O
in	O
successive	O
order	O
from	O
high	O
frequencies	O
in	O
gamma	O
to	O
low	O
frequencies	O
in	O
delta	O
band	O
reveals	O
several	O
phase	O
transitions	O
into	O
less	O
ordered	O
states	O
,	O
possible	O
chaos	O
in	O
the	O
human	O
brain	O
.	O

To	O
our	O
knowledge	O
there	O
are	O
no	O
reliable	O
techniques	O
able	O
to	O
reveal	O
the	O
transition	O
to	O
chaos	O
in	O
case	O
of	O
multidimensional	O
times	O
series	O
.	O

In	O
addition	O
,	O
DCE	O
based	O
on	O
sample	O
entropy	O
appears	O
to	O
be	O
robust	O
to	O
EEG	O
artifacts	O
compared	O
to	O
DCE	O
based	O
on	O
Shannon	O
entropy	O
.	O

The	O
applied	O
technique	O
may	O
offer	O
new	O
approaches	O
to	O
better	O
understand	O
nonlinear	O
brain	O
activity	O
.	O

Retrospective	O
study	O
of	O
24	O
cases	O
of	O
acute	O
appendiceal	O
diverticulitis	O
:	O
CT	B-P
findings	O
and	O
pathological	O
correlations	O
.	O

Appendiceal	O
diverticulitis	O
is	O
relatively	O
rare	O
and	O
is	O
difficult	O
to	O
distinguish	O
clinically	O
and	O
radiologically	O
from	O
acute	O
appendicitis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
computed	B-P
tomography	I-P
(	B-P
CT	I-P
)	O
findings	O
of	O
acute	O
appendiceal	O
diverticulitis	O
.	O

Among	O
the	O
1329	O
patients	O
who	O
underwent	O
appendectomy	O
at	O
our	O
institution	O
between	O
January	O
2010	O
and	O
July	O
2015	O
,	O
28	O
were	O
diagnosed	O
pathologically	O
with	O
appendiceal	O
diverticulitis	O
,	O
including	O
24	O
patients	O
who	O
were	O
evaluated	O
by	O
preoperative	O
CT	B-P
.	O

The	O
control	O
group	O
consisted	O
of	O
38	O
patients	O
without	O
diverticulitis	O
.	O

Average	O
age	O
of	O
patients	O
,	O
ratio	O
of	O
males	O
to	O
females	O
,	O
appendiceal	O
diameter	O
,	O
presence	O
of	O
a	O
diverticulum	O
,	O
diverticular	O
enhancement	O
,	O
peri-appendiceal	O
fat	O
stranding	O
,	O
peri-appendiceal	O
loculated	O
fluid	O
and	O
perforation	O
,	O
and	O
the	O
presence	O
of	O
appendicolith	O
were	O
evaluated	O
retrospectively	O
.	O

Peri-appendiceal	O
fat	O
stranding	O
(	O
p	O
<	O
0.005	O
)	O
,	O
appendiceal	O
diameter	O
(	O
p	O
<	O
0.005	O
)	O
,	O
and	O
peri-appendiceal	O
loculated	O
fluid	O
differed	O
significantly	O
between	O
the	O
diverticulitis	O
and	O
non	O
-	O
diverticulitis	O
groups	O
(	O
p	O
<	O
0.005	O
)	O
.	O

Although	O
relatively	O
uncommon	O
,	O
appendiceal	O
diverticulitis	O
should	O
be	O
included	O
in	O
the	O
differential	B-P
diagnosis	I-P
of	O
acute	O
appendicitis	O
.	O

It	O
differs	O
from	O
typical	O
acute	O
appendicitis	O
by	O
the	O
presence	O
of	O
an	O
inflamed	O
diverticulum	O
,	O
seen	O
on	O
CT	B-P
.	O

These	O
patients	O
are	O
also	O
more	O
likely	O
to	O
have	O
peri-appendiceal	O
extra-luminal	O
loculated	O
fluid	O
,	O
peri-appendiceal	O
fat	O
stranding	O
,	O
and	O
a	O
larger	O
diameter	O
of	O
the	O
appendix	O
.	O

The	O
latter	O
finding	O
is	O
likely	O
due	O
to	O
the	O
increased	O
intraluminal	O
pressure	O
.	O

Development	O
of	O
delineation	O
for	O
the	O
left	O
anterior	O
descending	O
coronary	O
artery	O
region	O
in	O
left	O
breast	O
cancer	O
radiotherapy	O
:	O
An	O
optimized	O
organ	O
at	O
risk	O
.	O

The	O
left	O
anterior	O
descending	O
coronary	O
artery	O
(	O
LAD	O
)	O
and	O
diagonal	O
branches	O
(	O
DBs	O
)	O
are	O
blurred	O
on	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
.	O

We	O
aimed	O
to	O
define	O
the	O
LAD	O
region	O
(	O
LADR	O
)	O
with	O
adequate	O
inclusion	O
of	O
the	O
LAD	O
and	O
DBs	O
and	O
contouring	O
consistency	O
.	O

The	O
LADR	O
was	O
defined	O
using	O
coronary	O
CT	B-P
angiograms	I-P
.	O

The	O
inclusion	O
ratio	O
was	O
used	O
to	O
assess	O
the	O
LAD	O
and	O
DBs	O
inclusion	O
by	O
the	O
LADR	O
.	O

Four	O
radiation	O
oncologists	O
delineated	O
the	O
LAD	O
and	O
LADR	O
,	O
using	O
contrast-enhanced	B-P
CT	I-P
of	O
15	O
patients	O
undergoing	O
left	O
breast	O
radiotherapy	O
.	O

The	O
Sørensen-Dice	O
similarity	O
index	O
(	O
DSI	O
)	O
,	O
Jaccard	O
similarity	O
index	O
(	O
JSI	O
)	O
,	O
and	O
Hausdorff	O
distance	O
(	O
HD	O
)	O
were	O
calculated	O
to	O
assess	O
similarity	O
.	O

The	O
mean	O
dose	O
(	O
Dmean	O
)	O
and	O
maximum	O
dose	O
(	O
Dmax	O
)	O
to	O
the	O
LAD	O
and	O
LADR	O
were	O
calculated	O
to	O
compare	O
consistency	O
.	O

Correlations	O
were	O
evaluated	O
using	O
Pearson	O
's	O
correlation	O
coefficient	O
.	O

The	O
inclusion	O
ratio	O
of	O
the	O
LAD	O
by	O
the	O
LADR	O
was	O
96	O
%	O
.	O

The	O
mean	O
DSI	O
,	O
JSI	O
,	O
and	O
HD	O
values	O
were	O
respectively	O
27.9	O
%	O
,	O
16.7	O
%	O
,	O
and	O
0.42mm	O
for	O
the	O
LAD	O
,	O
and	O
83.1	O
%	O
,	O
73.0	O
%	O
,	O
and	O
0.18mm	O
for	O
the	O
LADR	O
.	O

The	O
Dmean	O
between	O
the	O
LAD	O
and	O
LADR	O
were	O
strongly	O
correlated	O
(	O
r=0.93	O
)	O
.	O

Delineation	O
of	O
the	O
LADR	O
significantly	O
improved	O
contouring	O
similarity	O
and	O
consistency	O
for	O
dose	O
reporting	O
.	O

This	O
could	O
optimize	O
dose	O
estimation	O
for	O
breast	O
radiotherapy	O
.	O

A	O
sensitive	O
method	B-P
for	O
the	O
determination	B-P
of	O
Sulfonamides	O
in	O
seawater	O
samples	O
by	O
Solid	B-P
Phase	I-P
Extraction	I-P
and	O
UV-Visible	B-P
spectrophotometry	I-P
.	O

The	O
authors	O
have	O
developed	O
a	O
sensitive	O
spectrophotometric	B-P
method	I-P
for	O
determination	B-P
of	O
sulfonamide	O
derivatives	O
such	O
as	O
sulfanilamide	O
(	O
SAA	O
)	O
,	O
sulfadiazine	O
(	O
SDZ	O
)	O
,	O
sulfacetamide	O
(	O
SCT	O
)	O
sulfamethoxazole	O
(	O
SMX	O
)	O
,	O
sulfamerazine	O
(	O
SMR	O
)	O
,	O
sulfadimethoxine	O
(	O
SDX	O
)	O
,	O
sulfamethiazole	O
(	O
SMT	O
)	O
and	O
Sulfathiazole	O
(	O
STZ	O
)	O
.	O

This	O
method	B-P
is	O
based	O
on	O
the	O
Bratton-Marshall	O
reaction	O
,	O
which	O
involves	O
the	O
diazotization	O
of	O
sulfonamides	O
with	O
sodium	O
nitrite	O
under	O
acidic	O
conditions	O
,	O
followed	O
by	O
coupling	O
with	O
N-	O
(	O
1-naphtyl	O
)	O
ethylenediamine	O
dihydrochloride	O
(	O
NED	O
)	O
to	O
form	O
a	O
pink	O
colored	O
compound	O
.	O

Therefore	O
,	O
the	O
Bratton-Marshall	O
method	O
was	O
modified	O
by	O
optimizing	O
the	O
reaction	O
conditions	O
,	O
which	O
allows	O
us	O
to	O
determine	B-P
a	O
low	O
concentration	O
range	O
of	O
sulfonamides	O
compared	O
to	O
the	O
reported	O
methods	B-P
.	O

The	O
limits	O
of	O
detection	O
and	O
quantification	O
obtained	O
were	O
0.019-0.05	O
and	O
0.06-0.16μgmL	O
(	O
-1	O
)	O
,	O
respectively	O
.	O

In	O
comparison	O
with	O
other	O
reported	O
methods	B-P
using	O
different	O
coupling	O
agents	O
,	O
the	O
proposed	O
method	B-P
was	O
found	O
to	O
be	O
the	O
most	O
simple	O
and	O
sensitive	O
for	O
sulfonamides	O
determination	B-P
.	O

In	O
this	O
paper	O
,	O
the	O
modified	O
method	B-P
was	O
successfully	O
employed	O
for	O
the	O
determination	B-P
of	O
sulfonamides	O
in	O
drinking	O
water	O
,	O
seawater	O
and	O
pharmaceutical	O
and	O
veterinary	O
formulations	O
.	O

The	O
purpose	O
of	O
this	O
work	O
is	O
to	O
optimize	O
and	O
develop	O
a	O
simple	O
method	B-P
for	O
extraction	B-P
and	O
concentration	O
of	O
sulfonamides	O
present	O
as	O
residues	O
in	O
seawater	O
and	O
their	O
quantification	O
with	O
the	O
recommended	O
spectrophotometric	B-P
method	I-P
.	O

Solid	B-P
phase	I-P
extraction	I-P
(	O
SPE	B-P
)	O
of	O
sulfonamides	O
from	O
seawater	O
samples	O
was	O
evaluated	O
using	O
Oasis	O
HLB	O
cartridges	O
(	O
3mL	O
,	O
540mg	O
)	O
.	O

The	O
recovery	O
efficiency	O
was	O
investigated	O
in	O
the	O
sulfonamides	O
concentration	O
range	O
comprised	O
between	O
0.19	O
and	O
126ngmL	O
(	O
-1	O
)	O
.	O

The	O
ease	O
of	O
use	O
of	O
this	O
extraction	B-P
method	B-P
makes	O
it	O
very	O
useful	O
for	O
routine	O
laboratory	O
work	O
.	O

Intranasal	O
Insulin	O
Prevents	O
Anesthesia	O
-	O
Induced	O
Cognitive	O
Impairment	O
and	O
Chronic	O
Neurobehavioral	O
Changes	O
.	O

General	O
anesthesia	O
increases	O
the	O
risk	O
for	O
cognitive	O
impairment	O
post	O
operation	O
,	O
especially	O
in	O
the	O
elderly	O
and	O
vulnerable	O
individuals	O
.	O

Recent	O
animal	O
studies	O
on	O
the	O
impact	O
of	O
anesthesia	O
on	O
postoperative	O
cognitive	O
impairment	O
have	O
provided	O
some	O
valuable	O
insights	O
,	O
but	O
much	O
remains	O
to	O
be	O
understood	O
.	O

Here	O
,	O
by	O
using	O
mice	O
of	O
various	O
ages	O
and	O
conditions	O
,	O
we	O
found	O
that	O
anesthesia	O
with	O
propofol	O
and	O
sevoflurane	O
caused	O
significant	O
deficits	O
in	O
spatial	O
learning	O
and	O
memory	O
,	O
as	O
tested	O
using	O
Morris	B-P
Water	I-P
Maze	I-P
(	O
MWM	B-P
)	O
2-6	O
days	O
after	O
anesthesia	O
exposure	O
,	O
in	O
aged	O
(	O
17-18	O
months	O
old	O
)	O
wild-type	O
(	O
WT	O
)	O
mice	O
and	O
in	O
adult	O
(	O
7-8	O
months	O
old	O
)	O
3xTg-AD	O
mice	O
(	O
a	O
triple	O
transgenic	O
mouse	O
model	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
)	O
,	O
but	O
not	O
in	O
adult	O
WT	O
mice	O
.	O

Anesthesia	O
resulted	O
in	O
long-term	O
neurobehavioral	O
changes	O
in	O
the	O
fear	O
conditioning	O
task	O
carried	O
out	O
65	O
days	O
after	O
exposure	O
to	O
anesthesia	O
in	O
3xTg-AD	O
mice	O
.	O

Importantly	O
,	O
daily	O
intranasal	O
administration	O
of	O
insulin	O
(	O
1.75	O
U/	O
mouse	O
/	O
day	O
)	O
for	O
only	O
3	O
days	O
prior	O
to	O
anesthesia	O
completely	O
prevented	O
the	O
anesthesia	O
-	O
induced	O
deficits	O
in	O
spatial	O
learning	O
and	O
memory	O
and	O
the	O
long-term	O
neurobehavioral	O
changes	O
tested	O
65	O
days	O
after	O
exposure	O
to	O
anesthesia	O
in	O
3xTg-AD	O
mice	O
.	O

These	O
results	O
indicate	O
that	O
aging	O
and	O
AD	O
-like	O
brain	O
pathology	O
increase	O
the	O
vulnerability	O
to	O
cognitive	O
impairment	O
after	O
anesthesia	O
and	O
that	O
intranasal	O
treatment	O
with	O
insulin	O
can	O
prevent	O
anesthesia	O
-	O
induced	O
cognitive	O
impairment	O
.	O

Different	O
Susceptibilities	O
between	O
Apoe	O
-	O
and	O
Ldlr	O
-	O
Deficient	O
Mice	O
to	O
Inflammation	O
-	O
Associated	O
Colorectal	O
Carcinogenesis	O
.	O

Hypercholesterolemia	O
resulting	O
in	O
atherosclerosis	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ischemic	O
heart	O
disease	O
and	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.	O

However	O
,	O
the	O
roles	O
of	O
apoliprotein	O
(	O
Apo	O
)	O
E	O
(	O
Apoe	O
)	O
and	O
low-density	O
lipoprotein	O
(	O
Ldl	O
)	O
receptor	O
(	O
Ldlr	O
)	O
in	O
colorectal	O
carcinogenesis	O
have	O
not	O
yet	O
been	O
investigated	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
susceptibility	O
of	O
Apoe	O
-	O
deficient	O
and	O
Ldlr	O
-	O
deficient	O
mice	O
,	O
which	O
are	O
genetic	O
animal	O
models	O
of	O
atherosclerosis	O
to	O
azoxymethane	O
(	O
AOM	O
)	O
/	O
dextran	O
sodium	O
sulfate	O
(	O
DSS	O
)	O
-	O
induced	O
colorectal	O
carcinogenesis	O
.	O

In	O
Experiment	O
1	O
,	O
male	O
Apoe	O
-	O
deficient	O
(	O
n	O
=	O
20	O
)	O
and	O
wild	O
type	O
(	O
WT	O
)	O
mice	O
(	O
C57BL/6J	O
,	O
n	O
=	O
21	O
)	O
were	O
treated	O
with	O
a	O
single	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O

injection	O
of	O
AOM	O
(	O
10	O
mg/kg	O
body	O
weight	O
)	O
and	O
then	O
given	O
1.5	O
%	O
DSS	O
in	O
drinking	O
water	O
for	O
seven	O
days	O
.	O

They	O
were	O
maintained	O
up	O
to	O
week	O
20	O
and	O
sacrificed	O
for	O
the	O
histopathological	O
examination	O
of	O
colorectal	O
tumors	O
.	O

The	O
mRNA	O
expression	O
of	O
cyclooxygenase	O
(	O
Cox	O
)	O
-2	O
,	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
Nos2	O
)	O
,	O
tumor	O
necrosis	O
factor	O
(	O
Tnf	O
)	O
-α	O
interleukin	O
(	O
Il	O
)	O
-1β	O
,	O
and	O
Il-6	O
was	O
assayed	O
in	O
the	O
colorectal	O
mucosa	O
.	O

In	O
Experiment	O
2	O
,	O
male	O
Ldlr	O
-	O
deficient	O
(	O
n	O
=	O
14	O
)	O
and	O
WT	O
mice	O
(	O
C57BL/6J	O
,	O
n	O
=	O
10	O
)	O
were	O
given	O
a	O
single	O
i.p	O
.	O

injection	O
of	O
AOM	O
(	O
10	O
mg/kg	O
body	O
weight	O
)	O
and	O
then	O
given	O
2	O
%	O
DSS	O
in	O
drinking	O
water	O
for	O
seven	O
days	O
.	O

They	O
were	O
sacrificed	O
at	O
week	O
20	O
to	O
evaluate	O
their	O
colorectum	O
histopathologically	O
.	O

In	O
Experiment	O
1	O
,	O
the	O
multiplicity	O
of	O
CRCs	O
was	O
significantly	O
higher	O
in	O
the	O
Apoe	O
-	O
deficient	O
mice	O
(	O
2.75	O
±	O
1.48	O
)	O
than	O
in	O
the	O
WT	O
mice	O
(	O
0.62	O
±	O
0.67	O
)	O
.	O

The	O
serum	B-P
lipoprotein	I-P
levels	I-P
in	O
the	O
Apoe	O
-	O
deficient	O
mice	O
were	O
also	O
significantly	O
higher	O
than	O
in	O
the	O
WT	O
mice	O
.	O

In	O
Experiment	O
2	O
,	O
the	O
incidence	O
(	O
29	O
%	O
)	O
and	O
multiplicity	O
(	O
0.50	O
±	O
0.94	O
)	O
of	O
CRCs	O
in	O
the	O
Ldlr	O
mice	O
were	O
significantly	O
lower	O
than	O
in	O
the	O
WT	O
mice	O
(	O
80	O
%	O
incidence	O
and	O
3.10	O
±	O
2.38	O
multiplicity	O
)	O
.	O

The	O
mRNA	O
expression	O
of	O
two	O
inducible	O
enzymes	O
and	O
certain	O
pro-inflammatory	O
cytokines	O
in	O
the	O
colorectum	O
of	O
each	O
genotype	O
was	O
greater	O
than	O
in	O
the	O
respective	O
WT	O
mice	O
.	O

The	O
values	O
in	O
the	O
Apoe	O
-	O
deficient	O
mice	O
were	O
much	O
greater	O
than	O
in	O
the	O
Ldlr	O
mice	O
.	O

These	O
findings	O
suggest	O
that	O
Apoe	O
-	O
deficient	O
mice	O
showed	O
increased	O
susceptibility	O
to	O
inflammation	O
-	O
associated	O
colorectal	O
carcinogenesis	O
due	O
to	O
their	O
high	O
reactivity	O
to	O
inflammatory	O
stimuli	O
.	O

Ultrathin	O
Au	O
nanowires	O
assisted	O
magnetic	O
graphene	O
-	O
silica	O
ZIC-HILIC	O
composites	O
for	O
highly	O
specific	O
enrichment	O
of	O
N-linked	O
glycopeptides	O
.	O

Protein	O
glycosylation	O
has	O
been	O
proven	O
to	O
participate	O
in	O
a	O
variety	O
of	O
complex	O
biological	O
processes	O
;	O
however	O
,	O
the	O
low	O
abundance	O
of	O
glycopeptides	O
in	O
natural	O
samples	O
makes	O
it	O
essential	O
to	O
develop	O
methods	O
to	O
isolate	O
and	O
enrich	O
glycopeptides	O
.	O

In	O
this	O
study	O
,	O
a	O
novel	O
ultrathin	O
Au	O
nanowire	O
assisted	O
zwitterionic	O
hydrophilic	O
magnetic	O
graphene	O
oxide	O
(	O
GO	O
-	O
Fe3O4	O
/	O
SiO2	O
/	O
AuNWs	O
/	O
L-Cys	O
)	O
was	O
synthesized	O
with	O
the	O
good	O
biocompatibility	O
of	O
GO	O
,	O
strong	O
magnetic	O
responses	O
of	O
Fe3O4	O
,	O
large	O
surface	O
area	O
of	O
ultrathin	O
Au	O
nanowires	O
and	O
excellent	O
hydrophilicity	O
of	O
L-Cys	O
via	O
four	O
simple	O
and	O
rapid	O
steps	O
.	O

The	O
ultrathin	O
Au	O
nanowires	O
have	O
a	O
one-dimensional	O
structure	O
and	O
were	O
easily	O
grafted	O
with	O
an	O
abundant	O
amount	O
of	O
L-Cys	O
for	O
the	O
enrichment	O
of	O
glycopeptides	O
.	O

After	O
the	O
GO	O
-	O
Fe3O4	O
/	O
SiO2	O
/	O
AuNWs	O
/	O
L-Cys	O
composites	O
were	O
applied	O
to	O
glycopeptide	O
enrichment	O
,	O
26	O
glycopeptides	O
from	O
a	O
human	O
IgG	O
digest	O
could	O
be	O
identified	O
,	O
with	O
a	O
detection	O
limit	O
as	O
low	O
as	O
10	O
fmol	O
.	O

Due	O
to	O
the	O
abundant	O
amount	O
of	O
grafted	O
L-Cys	O
,	O
the	O
composites	O
also	O
showed	O
a	O
large	O
binding	O
capacity	O
(	O
150	O
μg	O
mg	O
(	O
-1	O
)	O
)	O
.	O

Furthermore	O
,	O
the	O
composites	O
were	O
applied	O
for	O
the	O
analysis	O
of	O
real	O
biological	O
samples	O
.	O

A	O
total	O
of	O
793	O
glycopeptides	O
from	O
467	O
glycoproteins	O
were	O
identified	O
in	O
three	O
replicate	B-P
analyses	I-P
of	O
40	O
μg	O
of	O
mouse	O
liver	O
proteins	O
.	O

The	O
results	O
demonstrated	O
the	O
great	O
potential	O
of	O
GO	O
-	O
Fe3O4	O
/	O
SiO2	O
/	O
AuNWs	O
/	O
L-Cys	O
composites	O
for	O
the	O
analysis	O
of	O
glycoproteins	O
.	O

Dual-color	B-P
STED	I-P
microscopy	I-P
reveals	O
a	O
sandwich	O
structure	O
of	O
Bassoon	O
and	O
Piccolo	O
in	O
active	O
zones	O
of	O
adult	O
and	O
aged	O
mice	O
.	O

Presynaptic	O
active	O
zones	O
play	O
a	O
pivotal	O
role	O
as	O
synaptic	O
vesicle	O
release	O
sites	O
for	O
synaptic	O
transmission	O
,	O
but	O
the	O
molecular	O
architecture	O
of	O
active	O
zones	O
in	O
mammalian	O
neuromuscular	O
junctions	O
(	O
NMJs	O
)	O
at	O
sub-diffraction	O
limited	O
resolution	O
remains	O
unknown	O
.	O

Bassoon	O
and	O
Piccolo	O
are	O
active	O
zone	O
specific	O
cytosolic	O
proteins	O
essential	O
for	O
active	O
zone	O
assembly	O
in	O
NMJs	O
,	O
ribbon	O
synapses	O
,	O
and	O
brain	O
synapses	O
.	O

These	O
proteins	O
are	O
thought	O
to	O
colocalize	O
and	O
share	O
some	O
functions	O
at	O
active	O
zones	O
.	O

Here	O
,	O
we	O
report	O
an	O
unexpected	O
finding	O
of	O
non-overlapping	O
localization	O
of	O
these	O
two	O
proteins	O
in	O
mouse	O
NMJs	O
revealed	O
using	O
dual-color	O
stimulated	O
emission	O
depletion	O
(	O
STED	O
)	O
super	B-P
resolution	I-P
microscopy	I-P
.	O

Piccolo	O
puncta	O
sandwiched	O
Bassoon	O
puncta	O
and	O
aligned	O
in	O
a	O
Piccolo	O
-	O
Bassoon	O
-	O
Piccolo	O
structure	O
in	O
adult	O
NMJs	O
.	O

P/Q-type	O
voltage-gated	O
calcium	O
channel	O
(	O
VGCC	O
)	O
puncta	O
colocalized	O
with	O
Bassoon	O
puncta	O
.	O

The	O
P/Q-type	O
VGCC	O
and	O
Bassoon	O
protein	O
levels	O
decreased	O
significantly	O
in	O
NMJs	O
from	O
aged	O
mouse	O
.	O

In	O
contrast	O
,	O
the	O
Piccolo	O
levels	O
in	O
NMJs	O
from	O
aged	O
mice	O
were	O
comparable	O
to	O
levels	O
in	O
adult	O
mice	O
.	O

This	O
study	O
revealed	O
the	O
molecular	O
architecture	O
of	O
active	O
zones	O
in	O
mouse	O
NMJs	O
at	O
sub-diffraction	O
limited	O
resolution	O
,	O
and	O
described	O
the	O
selective	O
degeneration	O
mechanism	O
of	O
active	O
zone	O
proteins	O
in	O
NMJs	O
from	O
aged	O
mice	O
.	O

Interestingly	O
,	O
the	O
localization	O
pattern	O
of	O
active	O
zone	O
proteins	O
described	O
herein	O
is	O
similar	O
to	O
active	O
zone	O
structures	O
described	O
using	O
electron	B-P
microscope	I-P
tomography	I-P
.	O

Immobilization	O
of	O
Lipase	O
from	O
Pseudomonas	O
fluorescens	O
on	O
Porous	O
Polyurea	O
and	O
Its	O
Application	O
in	O
Kinetic	B-P
Resolution	I-P
of	O
Racemic	O
1-Phenylethanol	O
.	O

A	O
porous	O
polyurea	O
(	O
PPU	O
)	O
was	O
prepared	O
through	O
a	O
simple	O
protocol	O
by	O
reacting	O
toluene	O
diisocyanate	O
with	O
water	O
in	O
binary	O
solvent	O
of	O
water	O
-	O
acetone	O
.	O

Its	O
amine	O
group	O
was	O
determined	O
through	O
spectrophotometric	B-P
absorbance	O
based	O
on	O
its	O
iminization	O
with	O
p-nitrobenzaldehyde	O
amines	O
.	O

PPU	O
was	O
then	O
used	O
as	O
a	O
novel	O
polymer	O
support	O
for	O
enzyme	O
immobilization	O
,	O
through	O
activation	O
by	O
glutaraldehyde	O
followed	O
by	O
immobilization	O
of	O
an	O
enzyme	O
,	O
lipase	O
from	O
Pseudomonas	O
fluorescens	O
(	O
PFL	O
)	O
,	O
via	O
covalent	O
bonding	O
with	O
the	O
amine	O
groups	O
of	O
lipase	O
molecules	O
.	O

Influences	O
of	O
glutaraldehyde	O
and	O
enzyme	O
concentration	O
and	O
pH	O
in	O
the	O
process	O
were	O
studied	O
.	O

The	O
results	O
revealed	O
that	O
the	O
activity	O
of	O
the	O
immobilized	O
PFL	O
reached	O
a	O
maximum	O
at	O
GA	O
concentration	O
of	O
0.17	O
mol/L	O
and	O
at	O
pH	O
8	O
.	O

Immobilization	O
rate	O
of	O
60	O
%	O
or	O
higher	O
for	O
PFL	O
was	O
obtained	O
under	O
optimized	O
condition	O
with	O
an	O
enzyme	O
activity	O
of	O
283	O
U/mg	O
.	O

The	O
porous	O
structure	O
of	O
PPU	O
,	O
prior	O
to	O
and	O
after	O
GA	O
activation	O
and	O
PFL	O
immobilization	O
,	O
was	O
characterized	O
.	O

The	O
activity	O
of	O
the	O
immobilized	O
PFL	O
at	O
different	O
temperature	O
and	O
pH	O
and	O
its	O
stability	O
at	O
40	O
°C	O
as	O
well	O
as	O
its	O
reusability	O
were	O
tested	O
.	O

The	O
immobilized	O
enzyme	O
was	O
finally	O
used	O
as	O
enantioselective	O
catalyst	O
in	O
kinetic	B-P
resolution	I-P
of	O
racemic	O
1-	O
ph	O
enylethanol	O
(	O
1-PEOH	O
)	O
,	O
and	O
its	O
performance	O
compared	O
with	O
the	O
free	O
PFL	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
enzyme	O
activity	O
and	O
stability	O
were	O
greatly	O
improved	O
for	O
the	O
immobilized	O
PFL	O
,	O
and	O
highly	O
pure	O
enantiomers	O
from	O
racemic	O
1-PEOH	O
were	O
effectively	O
achieved	O
using	O
the	O
immobilized	O
PFL	O
.	O

Noticeable	O
deactivation	O
of	O
PFL	O
in	O
the	O
resolution	B-P
was	O
observed	O
by	O
acetaldehyde	O
in	O
situ	O
formed	O
.	O

In	O
addition	O
,	O
the	O
immobilized	O
PFL	O
was	O
readily	O
recovered	O
from	O
the	O
reaction	O
system	O
for	O
reuse	O
.	O

A	O
total	O
of	O
73	O
%	O
of	O
the	O
initial	O
activity	O
was	O
retained	O
after	O
5	O
repeated	O
reuse	O
cycles	O
.	O

This	O
work	O
provides	O
a	O
novel	O
route	O
to	O
preparation	O
of	O
a	O
polyurea	O
porous	O
material	O
and	O
its	O
enzyme	O
immobilization	O
,	O
leading	O
to	O
a	O
novel	O
type	O
of	O
immobilized	O
enzyme	O
for	O
efficient	O
kinetic	B-P
resolution	I-P
of	O
racemic	O
molecules	O
.	O

CHOROIDAL	O
VASCULARITY	O
INDEX	O
:	O
A	O
Novel	O
Optical	B-P
Coherence	I-P
Tomography	I-P
Based	O
Parameter	O
in	O
Patients	O
With	O
Exudative	O
Age-Related	O
Macular	O
Degeneration	O
.	O

To	O
evaluate	O
choroidal	O
structural	O
changes	O
in	O
exudative	O
age-related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
using	O
choroidal	O
vascularity	O
index	O
computed	O
from	O
image	O
binarization	O
on	O
spectral	B-P
domain	I-P
optical	I-P
coherence	I-P
tomography	I-P
with	O
enhanced	O
depth	B-P
imaging	I-P
.	O

This	O
prospective	O
case	O
series	O
included	O
42	O
consecutive	O
patients	O
with	O
unilateral	O
exudative	O
AMD	O
.	O

Choroidal	O
images	B-P
were	O
segmented	O
into	O
luminal	O
area	O
and	O
stromal	O
area	O
.	O

Choroidal	O
vascularity	O
index	O
was	O
defined	O
as	O
the	O
ratio	O
of	O
luminal	O
area	O
to	O
total	O
choroid	O
area	O
.	O

Mean	O
choroidal	O
vascularity	O
index	O
and	O
mean	O
choroidal	O
thickness	O
between	O
study	O
and	O
fellow	O
eyes	O
of	O
the	O
same	O
patient	O
with	O
dry	O
AMD	O
were	O
compared	O
using	O
Student	O
's	O
t-test	O
.	O

There	O
was	O
a	O
significantly	O
lower	O
choroidal	O
vascularity	O
index	O
in	O
eyes	O
with	O
exudative	O
AMD	O
(	O
60.14	O
±	O
4.55	O
vs.	O
62.75	O
±	O
4.82	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Luminal	O
area	O
(	O
P	O
<	O
0.01	O
)	O
was	O
decreased	O
in	O
eyes	O
with	O
exudative	O
AMD	O
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
total	O
choroid	O
area	O
(	O
P	O
=	O
0.05	O
)	O
and	O
choroidal	O
thickness	O
(	O
P	O
=	O
0.93	O
)	O
between	O
study	O
and	O
fellow	O
eyes	O
.	O

Eyes	O
with	O
exudative	O
AMD	O
demonstrated	O
reduced	O
choroidal	O
vascularity	O
index	O
but	O
insignificant	O
differences	O
in	O
choroidal	O
thickness	O
compared	O
with	O
their	O
fellow	O
eyes	O
.	O

Choroidal	O
vascularity	O
index	O
may	O
be	O
a	O
potential	O
noninvasive	O
tool	O
for	O
studying	O
structural	O
changes	O
in	O
choroid	O
and	O
monitoring	O
choroidal	O
disease	O
in	O
exudative	O
AMD	O
.	O

Toxicity	O
mechanism	O
of	O
titanium	O
dioxide	O
and	O
zinc	O
oxide	O
nanoparticles	O
against	O
food	O
pathogens	O
.	O

Food	O
preservation	O
is	O
an	O
important	O
field	O
of	O
research	O
.	O

It	O
extends	O
the	O
shelf	O
life	O
of	O
major	O
food	O
products	O
.	O

Our	O
current	O
study	O
is	O
based	O
on	O
food	O
preservation	O
through	O
TiO2	O
and	O
ZnO	O
nanoparticles	O
.	O

TiO2	O
and	O
ZnO	O
are	O
biocompatible	O
nanomaterial	O
.	O

The	O
biocompatibility	O
of	O
the	O
materials	O
were	O
established	O
through	O
toxicity	O
studies	O
on	O
cell	O
lines	O
.	O

Titanium	O
dioxide	O
and	O
Zinc	O
Oxide	O
nanoparticle	O
were	O
synthesized	O
by	O
wet	O
chemical	O
process	O
.	O

They	O
are	O
characterized	O
by	O
X-Ray	B-P
diffraction	I-P
and	O
TEM	B-P
.	O

The	O
antibacterial	O
activities	O
of	O
both	O
the	O
materials	O
were	O
analysed	O
to	O
ensure	O
their	O
effectiveness	O
as	O
food	O
preservative	O
against	O
Salmonella	O
typhi	O
,	O
Klebsiella	O
pneumoniae	O
and	O
Shigella	O
flexneri	O
.	O

The	O
results	O
indicates	O
that	O
TiO2	O
and	O
ZnO	O
nanoparticle	O
inhibits	O
Salmonella	O
,	O
Klebsiella	O
and	O
Shigella	O
.	O

The	O
mode	O
of	O
action	O
is	O
by	O
the	O
generation	O
of	O
ROS	O
in	O
cases	O
of	O
Salmonella	O
,	O
Klebsiella	O
.	O

Mode	O
of	O
action	O
in	O
Shigella	O
is	O
still	O
unclear	O
.	O

It	O
was	O
also	O
proved	O
that	O
TiO2	O
and	O
ZnO	O
nanoparticle	O
are	O
biocompatible	O
materials	O
.	O

Pregnancy	O
and	O
Kidney	O
Outcomes	O
in	O
Patients	O
With	O
IgA	O
Nephropathy	O
:	O
A	O
Cohort	O
Study	O
.	O

The	O
outcomes	O
of	O
pregnancy	O
in	O
immunoglobulin	O
A	O
nephropathy	O
(	O
IgAN	O
)	O
are	O
controversial	O
.	O

This	O
cohort	O
study	O
assessed	O
the	O
effects	O
of	O
pregnancy	O
on	O
kidney	O
disease	O
progression	O
and	O
risk	O
factors	O
for	O
adverse	O
pregnancy	O
outcomes	O
in	O
patients	O
with	O
IgAN	O
.	O

A	O
cohort	O
study	O
.	O

Women	O
of	O
child-bearing	O
age	O
with	O
IgAN	O
and	O
minimum	O
follow-up	O
of	O
1	O
year	O
after	O
biopsy	B-P
from	O
December	O
2003	O
to	O
September	O
2014	O
.	O

Pregnancy	O
,	O
treated	O
as	O
a	O
time-dependent	O
variable	O
;	O
baseline	O
(	O
at	O
time	O
of	O
biopsy	B-P
)	O
estimated	O
glomerular	B-P
filtration	I-P
rate	I-P
(	O
eGFR	B-P
)	O
,	O
proteinuria	O
,	O
blood	O
pressure	O
,	O
and	O
kidney	O
pathology	O
(	O
Oxford	O
MEST	O
classification	O
)	O
.	O

Kidney	O
disease	O
progression	O
event	O
,	O
defined	O
as	O
30	O
%	O
decline	O
in	O
eGFR	B-P
or	O
end-stage	O
kidney	O
disease	O
;	O
rate	O
of	O
eGFR	B-P
decline	O
;	O
and	O
adverse	O
pregnancy	O
outcomes	O
,	O
including	O
severe	O
preeclampsia	O
and	O
fetal	O
loss	O
.	O

Of	O
413	O
patients	O
enrolled	O
,	O
266	O
(	O
64.4	O
%	O
)	O
,	O
101	O
(	O
24.5	O
%	O
)	O
,	O
40	O
(	O
9.6	O
%	O
)	O
,	O
and	O
6	O
(	O
1.5	O
%	O
)	O
had	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
stages	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
,	O
respectively	O
.	O

During	O
follow-up	O
,	O
104	O
had	O
116	O
pregnancies	O
,	O
of	O
which	O
110	O
continued	O
beyond	O
week	O
20	O
;	O
309	O
patients	O
did	O
not	O
become	O
pregnant	O
.	O

After	O
adjustment	O
for	O
age	O
,	O
eGFR	B-P
,	O
mean	O
arterial	O
pressure	O
,	O
proteinuria	O
,	O
and	O
pathology	O
class	O
at	O
the	O
time	O
of	O
biopsy	B-P
,	O
subsequent	O
pregnancy	O
among	O
patients	O
with	O
CKD	O
stages	O
3	O
to	O
4	O
,	O
but	O
not	O
CKD	O
stages	O
1	O
to	O
2	O
,	O
was	O
associated	O
with	O
faster	O
eGFR	B-P
decline	O
(	O
-7.44	O
vs	O
-3.90mL/min/1.73m	O
(	O
2	O
)	O
per	O
year	O
;	O
P=0.007	O
)	O
and	O
increased	O
incidence	O
of	O
kidney	O
progression	O
events	O
(	O
HR	O
,	O
5.14	O
;	O
95	O
%	O
CI	O
,	O
1.16-22.74	O
)	O
compared	O
with	O
patients	O
who	O
did	O
not	O
become	O
pregnant	O
.	O

Relatively	O
small	O
sample	O
size	O
and	O
single-center	O
experience	O
.	O

Pregnancy	O
accelerated	O
kidney	O
disease	O
progression	O
in	O
women	O
with	O
IgAN	O
and	O
CKD	O
stage	O
3	O
,	O
but	O
not	O
in	O
those	O
at	O
stage	O
1	O
or	O
2	O
.	O

Assessment	O
of	O
Early	O
Treatment	O
Response	O
With	O
DWI	B-P
After	O
CT	B-P
-Guided	O
Radiofrequency	O
Ablation	O
of	O
Functioning	O
Adrenal	O
Adenomas	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
establish	O
the	O
suitability	O
of	O
the	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
as	O
a	O
parameter	O
for	O
evaluating	O
early	O
treatment	O
response	O
after	O
percutaneous	O
ablation	O
of	O
functional	O
adrenal	O
adenomas	O
.	O

Seventeen	O
adult	O
patients	O
with	O
functioning	O
adrenal	O
adenomas	O
underwent	O
radiofrequency	O
ablation	O
.	O

Serum	O
hormone	O
levels	O
were	O
analyzed	O
before	O
and	O
up	O
to	O
6	O
months	O
after	O
ablation	O
.	O

MRI	B-P
findings	O
(	O
nodule	O
size	O
in	O
cm	O
,	O
signal	O
intensity	O
index	O
,	O
ADC	O
maps	O
,	O
and	O
nodule-to-muscle	O
ADC	O
ratio	O
)	O
were	O
analyzed	O
before	O
and	O
up	O
to	O
30	O
days	O
after	O
ablation	O
.	O

A	O
consensus	O
review	O
of	O
all	O
scans	B-P
was	O
performed	O
by	O
two	O
attending	O
abdominal	O
imaging	O
radiologists	O
.	O

The	O
procedure	O
was	O
considered	O
successful	O
if	O
serum	O
hormone	O
levels	O
normalized	O
and	O
no	O
contrast	O
enhancement	O
of	O
the	O
adrenal	O
lesion	O
was	O
seen	O
on	O
follow-up	O
MRI	B-P
.	O

Of	O
17	O
patients	O
who	O
underwent	O
radiofrequency	O
ablation	O
,	O
complete	O
response	O
was	O
achieved	O
in	O
16	O
patients	O
with	O
partial	O
response	O
in	O
one	O
patient	O
.	O

Of	O
the	O
four	O
parameters	O
of	O
interest	O
,	O
only	O
ADC	O
maps	O
and	O
nodule-to-muscle	O
ADC	O
ratio	O
showed	O
statistically	O
significant	O
differences	O
(	O
p	O
<	O
0.05	O
)	O
.	O

This	O
prospective	O
study	O
suggests	O
that	O
apparent	O
diffusion	O
coefficient	O
values	O
may	O
help	O
radiologists	O
monitor	O
early	O
treatment	O
response	O
after	O
CT	B-P
-guided	O
radiofrequency	O
ablation	O
of	O
functioning	O
adrenal	O
adenomas	O
.	O

Clinical	O
course	O
and	O
therapeutic	O
outcomes	O
of	O
operatively	O
and	O
non-operatively	O
managed	O
patients	O
with	O
denosumab	O
-related	O
osteonecrosis	O
of	O
the	O
jaw	O
(	O
DRONJ	O
)	O
.	O

Details	O
regarding	O
risk	O
factors	O
,	O
onset	O
,	O
and	O
outcomes	O
for	O
denosumab	O
-related	O
osteonecrosis	O
(	O
DRONJ	O
)	O
are	O
sparse	O
.	O

This	O
study	O
examines	O
the	O
clinical	O
characteristics	O
and	O
operative	O
and	O
non-operative	O
therapeutic	O
outcomes	O
in	O
patients	O
with	O
DRONJ	O
not	O
previously	O
exposed	O
to	O
other	O
antiresorptives	O
.	O

A	O
retrospective	O
medical	O
record	O
review	O
was	O
conducted	O
,	O
and	O
data	O
were	O
collected	O
,	O
including	O
clinical	O
findings	O
,	O
management	O
,	O
healing	O
outcomes	O
,	O
and	O
radiologic	O
,	O
histologic	O
,	O
and	O
micro-computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
analyses	O
.	O

Seventeen	O
patients	O
were	O
treated	O
with	O
denosumab	O
,	O
with	O
14.1	O
±	O
8.3	O
doses	O
before	O
DRONJ	O
onset	O
.	O

The	O
majority	O
of	O
lesions	O
were	O
observed	O
at	O
sites	O
of	O
dental	O
prostheses	O
(	O
41	O
%	O
)	O
and	O
dental	O
extractions	O
(	O
35	O
%	O
)	O
.	O

Sixteen	O
patients	O
were	O
managed	O
non-operatively	O
(	O
10/16	O
)	O
or	O
operatively	O
(	O
6/16	O
)	O
with	O
either	O
major	O
(	O
5/6	O
)	O
or	O
minor	O
surgery	O
(	O
1/6	O
)	O
and	O
included	O
in	O
the	O
follow-up	O
analysis	O
.	O

Complete	O
healing	O
was	O
significant	O
in	O
patients	O
treated	O
with	O
major	O
surgery	O
(	O
80	O
%	O
)	O
compared	O
to	O
the	O
non-operative	O
group	O
(	O
20	O
%	O
;	O
p	O
<	O
0.035	O
)	O
.	O

Denosumab	O
was	O
discontinued	O
in	O
60	O
%	O
of	O
non-operative	O
patients	O
and	O
major	O
surgery	O
patients	O
with	O
no	O
effect	O
on	O
healing	O
.	O

Histologic	O
findings	O
of	O
4	O
patients	O
analyzed	O
exhibited	O
a	O
decreased	O
number	O
of	O
osteocyte	O
lacunae	O
,	O
and	O
micro-CT	B-P
of	O
3	O
patients	O
scanned	B-P
revealed	O
trabecular	O
thickening	O
.	O

DRONJ	O
lesions	O
occurred	O
mostly	O
at	O
sites	O
of	O
prostheses	O
sores	O
after	O
a	O
mean	O
of	O
14	O
doses	O
of	O
denosumab	O
.	O

Major	O
surgery	O
demonstrated	O
more	O
complete	O
healing	O
than	O
non-operative	O
management	O
,	O
and	O
denosumab	O
cessation	O
did	O
not	O
improve	O
healing	O
outcomes	O
.	O

Anticholinergic	O
premedication	O
to	O
prevent	O
bradycardia	O
in	O
combined	O
spinal	O
anesthesia	O
and	O
dexmedetomidine	O
sedation	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

When	O
dexmedetomidine	O
is	O
used	O
in	O
patients	O
undergoing	O
spinal	O
anesthesia	O
,	O
high	O
incidence	O
of	O
bradycardia	O
in	O
response	O
to	O
parasympathetic	O
activation	O
is	O
reported	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
atropine	O
premedication	O
for	O
preventing	O
the	O
incidence	O
of	O
bradycardia	O
and	O
the	O
hemodynamic	O
effect	O
on	O
patients	O
undergoing	O
spinal	O
anesthesia	O
with	O
sedation	O
by	O
dexmedetomidine	O
.	O

Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

Operating	O
room	O
.	O

One	O
hundred	O
fourteen	O
patients	O
(	O
age	O
range	O
,	O
2-65	O
years	O
;	O
American	O
Society	O
of	O
Anesthesiology	O
class	O
I-II	O
)	O
participated	O
in	O
this	O
study	O
,	O
willing	O
to	O
be	O
sedated	O
and	O
to	O
undergo	O
spinal	O
anesthesia	O
.	O

The	O
patients	O
were	O
divided	O
into	O
2	O
groups	O
:	O
group	O
A	O
and	O
group	O
C.	O
After	O
performing	O
spinal	O
anesthesia	O
,	O
dexmedetomidine	O
was	O
infused	O
at	O
a	O
loading	O
dose	O
of	O
0.6	O
μg/kg	O
for	O
10	O
minutes	O
,	O
followed	O
by	O
an	O
infusion	O
at	O
0.25	O
μg/	O
(	O
kg	O
h	O
)	O
.	O

Simultaneously	O
with	O
the	O
loading	O
dose	O
of	O
dexmedetomidine	O
,	O
patients	O
in	O
group	O
A	O
received	O
an	O
intravenous	O
bolus	O
of	O
0.5	O
mg	O
atropine	O
,	O
whereas	O
patients	O
in	O
group	O
C	O
received	O
an	O
intravenous	O
normal	O
saline	O
bolus	O
.	O

Data	O
on	O
administration	O
of	O
atropine	O
and	O
ephedrine	O
were	O
collected	O
.	O

Hemodynamic	B-P
data	O
including	O
heart	O
rate	O
,	O
systolic	O
blood	O
pressure	O
,	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
,	O
and	O
mean	O
blood	O
pressure	O
(	O
MBP	O
)	O
were	O
also	O
recorded	O
.	O

The	O
incidence	O
of	O
bradycardia	O
requiring	O
atropine	O
treatment	O
was	O
significantly	O
higher	O
in	O
group	O
C	O
than	O
group	O
A	O
(	O
P=.035	O
)	O
.	O

However	O
,	O
the	O
incidence	O
of	O
hypotension	O
needing	O
ephedrine	O
treatment	O
showed	O
no	O
significant	O
difference	O
between	O
the	O
2	O
groups	O
(	O
P=.7	O
)	O
.	O

Systolic	O
blood	O
pressure	O
and	O
heart	O
rate	O
showed	O
no	O
significant	O
differences	O
between	O
the	O
2	O
groups	O
(	O
P=.138	O
and	O
.464	O
,	O
respectively	O
)	O
.	O

However	O
,	O
group	O
A	O
showed	O
significant	O
increases	O
in	O
DBP	O
and	O
MBP	O
,	O
and	O
group	O
C	O
did	O
not	O
(	O
P=.014	O
and	O
.008	O
,	O
respectively	O
)	O
.	O

Prophylactic	O
atropine	O
reduces	O
the	O
incidence	O
of	O
bradycardia	O
in	O
patients	O
undergoing	O
spinal	O
anesthesia	O
with	O
dexmedetomidine	O
sedation	O
.	O

However	O
,	O
DBP	O
and	O
MBP	O
showed	O
significant	O
increases	O
in	O
patients	O
when	O
prophylactic	O
atropine	O
was	O
administrated	O
.	O

Therefore	O
,	O
atropine	O
premedication	O
should	O
be	O
administered	O
cautiously	O
.	O

Randomized	O
Trial	O
of	O
Long-Acting	O
Insulin	O
Glargine	O
Titration	B-P
Web	O
Tool	O
(	O
LTHome	O
)	O
Versus	O
Enhanced	O
Usual	O
Therapy	O
of	O
Glargine	O
Titration	B-P
(	O
INNOVATE	O
Trial	O
)	O
.	O

Basal	O
insulin	O
titration	B-P
in	O
the	O
real	O
world	O
is	O
often	O
unsuccessful	O
.	O

LTHome	O
,	O
a	O
web	O
tool	O
,	O
applies	O
a	O
rules	O
engine-based	O
algorithm	O
providing	O
insulin	O
titration	B-P
advice	O
directly	O
to	O
the	O
patient	O
.	O

This	O
pilot	O
,	O
randomized	O
trial	O
evaluates	O
basal	O
insulin	O
glargine	O
titration	B-P
by	O
LTHome	O
compared	O
to	O
enhanced	O
usual	O
therapy	O
(	O
[	O
EUT	O
]	O
-	O
diabetes	O
education	O
program	O
)	O
over	O
12	O
weeks	O
.	O

Important	O
inclusion	O
criteria	O
:	O
18-75	O
years	O
,	O
type	O
2	O
diabetes	O
,	O
computer	O
literacy	O
,	O
and	O
HbA1c	O
>	O
7.0	O
%	O
.	O

Trial	O
protocol	O
was	O
approved	O
by	O
ethics	O
board	O
.	O

We	O
randomized	O
139	O
subjects	O
.	O

The	O
achievement	O
of	O
primary	O
composite	O
outcome	O
(	O
four	O
out	O
of	O
seven	O
fasting	O
plasma	O
glucose	O
[	O
FPG	O
]	O
within	O
5-7.2	O
mmol/L	O
+	O
mean	O
for	O
three	O
consecutive	O
FPG	O
within	O
5-7.2	O
mmol/L	O
+	O
no	O
severe	O
hypoglycemia	O
)	O
was	O
15	O
%	O
in	O
LTHome	O
versus	O
41	O
%	O
in	O
EUT	O
(	O
noninferiority	O
not	O
met	O
,	O
P-value	O
=	O
0.92	O
)	O
.	O

Other	O
outcomes	O
were	O
similar	O
between	O
the	O
LTHome	O
and	O
EUT	O
arms	O
:	O
alternate	O
composite	O
outcome	O
achievement	O
(	O
last	O
five	O
FPG	O
mean	O
within	O
the	O
range	O
of	O
5-7.2	O
mmol/L	O
+	O
no	O
hypoglycemia	O
,	O
47	O
%	O
and	O
51	O
%	O
,	O
P	O
=	O
0.73	O
)	O
;	O
A1c	O
reduction	O
(	O
-1.0	O
%	O
and	O
-1.1	O
%	O
,	O
P	O
=	O
0.66	O
)	O
;	O
proportion	O
achieving	O
A1c	O
≤7	O
%	O
(	O
14	O
%	O
and	O
20	O
%	O
,	O
P	O
=	O
0.36	O
)	O
;	O
and	O
hypoglycemia	O
incidence	O
(	O
31	O
%	O
and	O
37	O
%	O
,	O
P	O
=	O
0.4	O
)	O
,	O
respectively	O
.	O

Patient	O
satisfaction	O
score	O
improvements	O
were	O
greater	O
in	O
LTHome	O
versus	O
EUT	O
(	O
change	O
in	O
fear	O
of	O
hypoglycemia	O
score	O
P	O
=	O
0.04	O
and	O
change	O
in	O
diabetes	O
distress	O
score	O
P	O
=	O
0.04	O
)	O
.	O

The	O
mean	O
number	O
of	O
additional	O
healthcare	O
provider	O
visits	O
was	O
0.13	O
for	O
LTHome	O
and	O
1.22	O
for	O
EUT	O
(	O
P	O
<	O
0.01	O
)	O
.	O

INNOVATE	O
trial	O
suggests	O
clinical	O
utility	O
of	O
LTHome	O
compared	O
to	O
EUT	O
in	O
real-life	O
settings	O
.	O

Further	O
research	O
is	O
needed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
automated	O
insulin	O
titration	B-P
algorithms	O
.	O

HIV-1	O
integrase	O
inhibitor	O
resistance	O
among	O
treatment	O
naïve	O
patients	O
in	O
the	O
West	O
of	O
Scotland	O
.	O

Transmitted	O
integrase	O
inhibitor	O
resistance	O
is	O
rare	O
,	O
with	O
only	O
a	O
small	O
number	O
of	O
cases	O
reported	O
world-wide	O
to	O
date	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
whether	O
transmitted	O
integrase	O
inhibitor	O
resistance	O
has	O
occurred	O
in	O
Scotland	O
and	O
if	O
so	O
,	O
could	O
there	O
be	O
a	O
case	O
for	O
performing	O
genotypic	B-P
integrase	I-P
resistance	I-P
testing	I-P
at	O
baseline	O
.	O

The	O
study	O
population	O
consisted	O
of	O
106	O
treatment	O
naïve	O
,	O
newly	O
diagnosed	O
,	O
HIV	O
positive	O
patients	O
.	O

The	O
patient	O
samples	O
were	O
collected	O
between	O
October	O
2015	O
and	O
March	O
2016	O
at	O
the	O
time	O
of	O
HIV	B-P
diagnosis	I-P
and	O
prior	O
to	O
initiation	O
of	O
anti-retroviral	O
therapy	O
.	O

The	O
integrase	O
region	O
was	O
amplified	O
and	O
sequenced	B-P
.	O

We	O
detected	O
integrase	O
inhibitor	O
resistance	O
(	O
T66I/T	O
)	O
at	O
baseline	O
in	O
one	O
patient	O
sample	O
.	O

This	O
is	O
a	O
non-polymorphic	O
mutation	O
seen	O
in	O
patients	O
receiving	O
elvitegravir	O
which	O
confers	O
high-level	O
resistance	O
to	O
elvitegravir	O
and	O
intermediate	O
resistance	O
to	O
raltegravir	O
.	O

A	O
further	O
10	O
patients	O
had	O
accessory	O
mutations	O
which	O
have	O
minimal	O
or	O
no	O
effect	O
on	O
susceptibility	O
to	O
integrase	O
inhibitors	O
.	O

Transmitted	O
integrase	O
inhibitor	O
resistance	O
remains	O
rare	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
do	O
not	O
support	O
performing	O
integrase	O
resistance	O
testing	O
at	O
baseline	O
.	O

Regulatory	O
role	O
of	O
cytosolic	O
phospholipase	O
A2	O
alpha	O
in	O
the	O
induction	O
of	O
CD40	O
in	O
microglia	O
.	O

The	O
aberrant	O
expression	O
of	O
CD40	O
,	O
a	O
co-stimulatory	O
receptor	O
found	O
on	O
the	O
antigen-presenting	O
cells	O
,	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
various	O
degenerative	O
diseases	O
.	O

Our	O
previous	O
study	O
demonstrated	O
that	O
the	O
reduction	O
of	O
cytosolic	O
phospholipase	O
A2	O
alpha	O
(	O
cPLA2α	O
)	O
protein	O
overexpression	O
and	O
activation	O
in	O
the	O
spinal	O
cord	O
of	O
a	O
mouse	O
model	O
of	O
ALS	O
,	O
hmSOD1	O
G93A	O
,	O
inhibited	O
CD40	O
upregulation	O
in	O
microglia	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
cPLA2α	O
has	O
a	O
direct	O
,	O
participatory	O
role	O
in	O
the	O
molecular	O
events	O
leading	O
to	O
CD40	O
induction	O
.	O

Cultures	B-P
of	O
primary	O
mouse	O
microglia	O
or	O
BV-2	O
microglia	O
cell	O
line	O
exposed	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
interferon	O
gamma	O
(	O
IFNγ	O
)	O
for	O
different	O
periods	O
of	O
time	O
,	O
in	O
order	O
to	O
study	O
the	O
role	O
of	O
cPLA2α	O
in	O
the	O
events	O
leading	O
to	O
CD40	O
protein	O
induction	O
.	O

Addition	O
of	O
LPS	O
or	O
IFNγ	O
caused	O
a	O
significant	O
upregulation	O
of	O
cPLA2α	O
and	O
of	O
CD40	O
,	O
while	O
prevention	O
of	O
cPLA2α	O
upregulation	O
by	O
a	O
specific	O
oligonucleotide	O
antisense	O
(	O
AS	O
)	O
prevented	O
the	O
induction	O
of	O
CD40	O
,	O
suggesting	O
a	O
role	O
of	O
cPLA2α	O
in	O
the	O
induction	O
of	O
CD40	O
.	O

Addition	O
of	O
LPS	O
to	O
microglia	O
caused	O
an	O
immediate	O
activation	O
of	O
cPLA2α	O
detected	O
by	O
its	O
phosphorylated	O
form	O
,	O
while	O
addition	O
of	O
IFNγ	O
induced	O
cPLA2α	O
activation	O
at	O
a	O
later	O
time	O
scale	O
(	O
4	O
h	O
)	O
.	O

The	O
activation	O
of	O
cPLA2α	O
is	O
mediated	O
by	O
ERK	O
activity	O
.	O

Suppression	O
of	O
cPLA2α	O
activity	O
inhibited	O
superoxide	O
production	O
by	O
NOX2-NADPH	O
oxidase	O
and	O
activation	O
of	O
NF-κB	O
detected	O
by	O
the	O
phosphorylation	O
of	O
p65	O
on	O
serine	O
536	O
at	O
15	O
min	O
by	O
LPS	O
and	O
at	O
4	O
h	O
by	O
IFNγ	O
.	O

Inhibition	O
of	O
NOX2	O
prevented	O
NF-κB	O
activation	O
and	O
CD40	O
induction	O
but	O
did	O
not	O
affect	O
cPLA2α	O
activation	O
,	O
suggesting	O
cPLA2α	O
is	O
located	O
upstream	O
to	O
NOX2	O
and	O
NF-κB	O
.	O

The	O
activation	O
of	O
cPLA2	O
by	O
LPS	O
was	O
mediated	O
by	O
both	O
adaptor	O
proteins	O
downstream	O
to	O
LPS	O
receptor	O
;	O
TRIF	O
and	O
MyD88	O
,	O
while	O
the	O
activation	O
of	O
cPLA2α	O
by	O
IFNγ	O
was	O
mediated	O
by	O
the	O
secreted	O
TNF-α	O
at	O
4	O
h.	O
The	O
early	O
activation	O
of	O
STAT1α	O
(	O
detected	O
by	O
phospho-serine727	O
and	O
phoshpo-tyrosine701	O
)	O
by	O
IFNγ	O
and	O
the	O
late	O
activation	O
of	O
STAT1α	O
by	O
LPS	O
were	O
not	O
affected	O
in	O
the	O
presence	O
of	O
cPLA2α	O
inhibitors	O
,	O
indicating	O
that	O
STAT1α	O
is	O
not	O
under	O
cPLA2α	O
regulation	O
.	O

Our	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
cPLA2	O
upregulates	O
CD40	O
protein	O
expression	O
induced	O
by	O
either	O
LPS	O
or	O
IFNγ	O
,	O
and	O
this	O
regulatory	O
effect	O
is	O
mediated	O
via	O
the	O
activation	O
of	O
NOX2-NADPH	O
oxidase	O
and	O
NF-κB	O
.	O

Cumulatively	O
,	O
our	O
results	O
indicate	O
that	O
cPLA2α	O
may	O
serve	O
as	O
a	O
pivotal	O
amplifier	O
of	O
the	O
inflammatory	O
response	O
in	O
the	O
CNS	O
.	O

Identification	O
of	O
markers	O
for	O
quiescent	O
pancreatic	O
stellate	O
cells	O
in	O
the	O
normal	O
human	O
pancreas	O
.	O

Pancreatic	O
stellate	O
cells	O
(	O
PSCs	O
)	O
play	O
a	O
central	O
role	O
as	O
source	O
of	O
fibrogenic	O
cells	O
in	O
pancreatic	O
cancer	O
and	O
chronic	O
pancreatitis	O
.	O

In	O
contrast	O
to	O
quiescent	O
hepatic	O
stellate	O
cells	O
(	O
qHSCs	O
)	O
,	O
a	O
specific	O
marker	O
for	O
quiescent	O
PSCs	O
(	O
qPSCs	O
)	O
that	O
can	O
be	O
used	O
in	O
formalin-fixed	O
and	O
paraffin	O
embedded	O
(	O
FFPE	O
)	O
normal	O
human	O
pancreatic	O
tissue	O
has	O
not	O
been	O
identified	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
a	O
marker	O
enabling	O
the	O
identification	O
of	O
qPSCs	O
in	O
normal	O
human	O
FFPE	O
pancreatic	O
tissue	O
.	O

Immunohistochemical	B-P
(	O
IHC	B-P
)	O
,	O
double-IHC	B-P
,	O
immunofluorescence	B-P
(	O
IF	B-P
)	O
and	O
double-IF	B-P
analyses	I-P
were	O
carried	O
out	O
using	O
a	O
tissue	O
microarray	O
consisting	O
of	O
cores	O
with	O
normal	O
human	O
pancreatic	O
tissue	O
.	O

Cores	O
with	O
normal	O
human	O
liver	O
served	O
as	O
control	O
.	O

Antibodies	O
directed	O
against	O
adipophilin	O
,	O
α-SMA	O
,	O
CD146	O
,	O
CRBP-1	O
,	O
cytoglobin	O
,	O
desmin	O
,	O
GFAP	O
,	O
nestin	O
,	O
S100A4	O
and	O
vinculin	O
were	O
examined	O
,	O
with	O
special	O
emphasis	O
on	O
their	O
expression	O
in	O
periacinar	O
cells	O
in	O
the	O
normal	O
human	O
pancreas	O
and	O
perisinusoidal	O
cells	O
in	O
the	O
normal	O
human	O
liver	O
.	O

The	O
immunolabelling	B-P
capacity	O
was	O
evaluated	O
according	O
to	O
a	O
semiquantitative	O
scoring	O
system	O
.	O

Double-IF	B-P
of	O
the	O
markers	O
of	O
interest	O
together	O
with	O
markers	O
for	O
other	O
periacinar	O
cells	O
was	O
performed	O
.	O

Moreover	O
,	O
the	O
utility	O
of	O
histochemical	B-P
stains	I-P
for	O
the	O
identification	O
of	O
human	O
qPSCs	O
was	O
examined	O
,	O
and	O
their	O
ultrastructure	O
was	O
revisited	O
by	O
electron	B-P
microscopy	I-P
.	O

Adipophilin	O
,	O
CRBP-1	O
,	O
cytoglobin	O
and	O
vinculin	O
were	O
expressed	O
in	O
qHSCs	O
in	O
the	O
liver	O
,	O
whereas	O
cytoglobin	O
and	O
adipophilin	O
were	O
expressed	O
in	O
qPSCs	O
in	O
the	O
pancreas	O
.	O

Adipophilin	O
immunohistochemistry	B-P
was	O
highly	O
dependent	O
on	O
the	O
preanalytical	O
time	O
interval	O
(	O
PATI	O
)	O
from	O
removal	O
of	O
the	O
tissue	O
to	O
formalin	B-P
fixation	I-P
.	O

Cytoglobin	O
,	O
S100A4	O
and	O
vinculin	O
were	O
expressed	O
in	O
periacinar	O
fibroblasts	O
(	O
FBs	O
)	O
.	O

The	O
other	O
examined	O
markers	O
were	O
negative	O
in	O
human	O
qPSCs	O
.	O

Our	O
data	O
indicate	O
that	O
cytoglobin	O
and	O
adipophilin	O
are	O
markers	O
of	O
qPSCs	O
in	O
the	O
normal	O
human	O
pancreas	O
.	O

However	O
,	O
the	O
use	O
of	O
adipophilin	O
as	O
a	O
qPSC	O
marker	O
may	O
be	O
limited	O
due	O
to	O
its	O
high	O
dependence	O
on	O
optimal	O
PATI	O
.	O

Cytoglobin	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
a	O
sensitive	O
marker	O
for	O
qPSCs	O
but	O
is	O
expressed	O
in	O
FBs	O
as	O
well	O
.	O

Isolation	B-P
,	O
structural	B-P
analysis	I-P
,	O
and	O
expression	O
characteristics	O
of	O
the	O
maize	O
nuclear	O
factor	O
Y	O
gene	O
families	O
.	O

NUCLEAR	O
FACTOR-Y	O
(	O
NF-Y	O
)	O
has	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
growth	O
,	O
development	O
,	O
and	O
response	O
to	O
environmental	O
stress	O
.	O

A	O
NF-Y	O
complex	O
,	O
which	O
consists	O
of	O
three	O
subunits	O
,	O
NF-YA	O
,	O
NF-YB	O
,	O
and	O
,	O
NF-YC	O
,	O
binds	O
to	O
CCAAT	O
sequences	O
in	O
a	O
promoter	O
to	O
control	O
the	O
expression	O
of	O
target	O
genes	O
.	O

Although	O
NF-Y	O
proteins	O
have	O
been	O
reported	O
in	O
Arabidopsis	O
and	O
rice	O
,	O
a	O
comprehensive	O
and	O
systematic	O
analysis	O
of	O
ZmNF-Y	O
genes	O
has	O
not	O
yet	O
been	O
performed	O
.	O

To	O
examine	O
the	O
functions	O
of	O
ZmNF-Y	O
genes	O
in	O
this	O
family	O
,	O
we	O
isolated	O
and	O
characterized	O
50	O
ZmNF-Y	O
(	O
14	O
ZmNF-YA	O
,	O
18	O
ZmNF-YB	O
,	O
and	O
18	O
ZmNF-YC	O
)	O
genes	O
in	O
an	O
analysis	O
of	O
the	O
maize	O
genome	O
.	O

The	O
50	O
ZmNF-Y	O
genes	O
were	O
distributed	O
on	O
all	O
10	O
maize	O
chromosomes	O
,	O
and	O
12	O
paralogs	O
were	O
identified	O
.	O

Multiple	O
alignments	O
showed	O
that	O
maize	O
ZmNF-Y	O
family	O
proteins	O
had	O
conserved	O
regions	O
and	O
relatively	O
variable	O
N-terminal	O
or	O
C-terminal	O
domains	O
.	O

The	O
comparative	O
syntenic	O
map	O
illustrated	O
40	O
paralogous	O
NF-Y	O
gene	O
pairs	O
among	O
the	O
10	O
maize	O
chromosomes	O
.	O

Microarray	B-P
data	O
showed	O
that	O
the	O
ZmNF-Y	O
genes	O
had	O
tissue-specific	O
expression	O
patterns	O
in	O
various	O
maize	O
developmental	O
stages	O
and	O
in	O
response	O
to	O
biotic	O
and	O
abiotic	O
stresses	O
.	O

The	O
results	O
suggested	O
that	O
ZmNF-YB2	O
,	O
4	O
,	O
8	O
,	O
10	O
,	O
13	O
,	O
and	O
16	O
and	O
ZmNF-YC6	O
,	O
8	O
,	O
and	O
15	O
were	O
induced	O
,	O
while	O
ZmNF-YA1	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
7	O
,	O
10	O
,	O
12	O
,	O
and	O
13	O
,	O
ZmNF-YB15	O
,	O
and	O
ZmNF-YC3	O
and	O
9	O
were	O
suppressed	O
by	O
drought	O
stress	O
.	O

ZmNF-YA3	O
,	O
ZmNF-YA8	O
and	O
ZmNF-YA12	O
were	O
upregulated	O
after	O
infection	O
by	O
the	O
three	O
pathogens	O
,	O
while	O
ZmNF-YA1	O
and	O
ZmNF-YB2	O
were	O
suppressed	O
.	O

These	O
results	O
indicate	O
that	O
the	O
ZmNF-Ys	O
may	O
have	O
significant	O
roles	O
in	O
the	O
response	O
to	O
abiotic	O
and	O
biotic	O
stresses	O
.	O

Involvement	O
of	O
NF-κB	O
in	O
regulation	O
of	O
Actinobacillus	O
pleuropneumoniae	O
exotoxin	O
ApxI	O
-induced	O
proinflammatory	O
cytokine	O
production	O
in	O
porcine	O
alveolar	O
macrophages	O
.	O

Actinobacillus	O
pleuropneumoniae	O
is	O
a	O
crucial	O
respiratory	O
pathogen	O
that	O
causes	O
fibrinous	O
,	O
hemorrhagic	O
,	O
necrotizing	O
pleuropneumonia	O
in	O
pigs	O
.	O

A.	O
pleuropneumoniae	O
exotoxins	O
(	O
ApxI	O
to	O
IV	O
)	O
are	O
the	O
major	O
virulence	O
factors	O
contributing	O
to	O
A.	O
pleuropneumoniae	O
pathogenesis	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
ApxI	O
induces	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
in	O
porcine	O
alveolar	O
macrophages	O
(	O
PAMs	O
)	O
via	O
the	O
mitogen-activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
p38	O
and	O
cJun	O
NH2-terminal	O
kinase	O
(	O
JNK	O
)	O
.	O

Nonetheless	O
,	O
the	O
role	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-κB	O
-a	O
transcription	O
factor	O
widely	O
implicated	O
in	O
immune	O
and	O
inflammatory	O
responses	O
-in	O
ApxI	O
-elicited	O
cytokine	O
production	O
has	O
yet	O
to	O
be	O
defined	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
involvement	O
of	O
NF-κB	O
in	O
ApxI	O
-elicited	O
production	O
of	O
interleukin	O
(	O
IL	O
)	O
-1β	O
,	O
IL-8	O
,	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-α	O
in	O
PAMs	O
and	O
investigated	O
the	O
correlation	O
between	O
NF-κB	O
and	O
MAPK	O
(	O
p38	O
and	O
JNK	O
)	O
pathways	O
in	O
this	O
event	O
.	O

The	O
results	O
of	O
Western	B-P
blot	I-P
analysis	I-P
,	O
confocal	B-P
microscopy	I-P
,	O
and	O
a	O
DNA	O
binding	O
activity	B-P
assay	I-P
revealed	O
that	O
the	O
classical	O
NF-κB	O
pathway	O
was	O
activated	O
by	O
ApxI	O
,	O
as	O
evidenced	O
by	O
the	O
decreased	O
levels	O
of	O
IκB	O
and	O
subsequent	O
NF-κB	O
translocation	O
and	O
activation	O
in	O
ApxI	O
-stimulated	O
PAMs	O
.	O

Moreover	O
,	O
the	O
blocking	O
of	O
ApxI	O
-induced	O
NF-κB	O
activation	O
significantly	O
attenuated	O
the	O
levels	O
of	O
mRNA	O
and	O
protein	O
secretion	O
of	O
IL-1β	O
,	O
IL-8	O
,	O
and	O
TNF-α	O
in	O
PAMs	O
.	O

Notably	O
,	O
the	O
attenuation	O
of	O
JNK	O
activation	O
by	O
a	O
specific	O
inhibitor	O
(	O
SP600125	O
)	O
reduced	O
ApxI	O
-induced	O
NF-κB	O
activation	O
,	O
whereas	O
a	O
p38	O
blocker	O
(	O
SB203580	O
)	O
had	O
no	O
effect	O
on	O
the	O
NF-κB	O
pathway	O
.	O

Further	O
examination	O
revealed	O
that	O
the	O
level	O
of	O
phosphorylation	O
at	O
serine	O
536	O
on	O
the	O
NF-κB	O
p65	O
subunit	O
was	O
dependent	O
on	O
JNK	O
activity	O
.	O

Collectively	O
,	O
this	O
study	O
,	O
for	O
the	O
first	O
time	O
,	O
demonstrates	O
a	O
pivotal	O
role	O
of	O
NF-κB	O
in	O
ApxI	O
-induced	O
IL-1β	O
,	O
IL-8	O
,	O
and	O
TNF-α	O
production	O
;	O
JNK	O
,	O
but	O
not	O
p38	O
,	O
may	O
positively	O
affect	O
the	O
activation	O
of	O
the	O
classical	O
NF-κB	O
pathway	O
.	O

Expression	O
of	O
caspase	O
3	O
in	O
ovarian	O
follicle	O
cells	O
of	O
the	O
lizard	O
Podarcis	O
sicula	O
.	O

In	O
this	O
study	O
,	O
our	O
aim	O
was	O
to	O
determine	O
whether	O
caspase	O
3	O
plays	O
a	O
role	O
,	O
during	O
previtellogenesis	O
,	O
in	O
the	O
ovarian	O
follicular	O
epithelium	O
of	O
the	O
lizard	O
Podarcis	O
sicula	O
.	O

We	O
investigated	O
the	O
presence	O
and	O
localization	O
of	O
proform	O
and	O
active	O
caspase	O
3	O
by	O
enzyme	B-P
assay	I-P
,	O
Western	O
blotting	O
and	O
immunocytochemistry	B-P
.	O

In	O
parallel	O
,	O
a	O
fragment	O
of	O
caspase	O
3	O
was	O
cloned	O
for	O
the	O
first	O
time	O
in	O
this	O
species	O
,	O
sequenced	O
and	O
used	O
for	O
in	O
situ	O
hybridization	O
to	O
localize	O
messengers	O
and	O
analysed	O
by	O
a	O
phylogenetic	O
survey	O
to	O
shed	O
light	O
on	O
its	O
homology	O
with	O
reptilian	O
caspases	O
.	O

Results	O
demonstrated	O
that	O
:	O
(	O
1	O
)	O
the	O
follicle	O
cells	O
expressed	O
a	O
caspase	O
of	O
the	O
3/7	O
group	O
and	O
the	O
mRNA	O
for	O
caspase	O
3	O
was	O
transcribed	O
in	O
the	O
stem	O
phase	O
and	O
was	O
completely	O
translated	O
during	O
cell	O
differentiation	O
;	O
(	O
2	O
)	O
the	O
proform	O
protein	O
was	O
stored	O
during	O
the	O
differentiated	O
(	O
nurse	O
)	O
stage	O
and	O
activated	O
at	O
the	O
end	O
of	O
previtellogenesis	O
provoking	O
the	O
degeneration	O
of	O
cells	O
;	O
(	O
3	O
)	O
the	O
predicted	O
protein	O
sequence	O
,	O
although	O
partial	O
,	O
had	O
a	O
strong	O
similarity	O
with	O
the	O
known	O
reptilian	O
caspases	O
3	O
.	O

The	O
epithelial	O
cells	O
of	O
the	O
ovarian	O
follicle	O
,	O
therefore	O
,	O
do	O
not	O
employ	O
caspase	O
3	O
during	O
the	O
nurse	O
stage	O
but	O
,	O
instead	O
,	O
prepare	O
for	O
apoptosis	O
long	O
before	O
the	O
process	O
actually	O
begins	O
.	O

The	O
relevance	O
of	O
this	O
strategy	O
is	O
discussed	O
.	O

Malignancy	O
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	B-P
,	O
but	O
not	O
with	O
Hashimoto	O
's	O
thyroiditis	O
in	O
histopathology	B-P
in	O
patients	O
with	O
thyroid	O
nodules	O
evaluated	O
as	O
Bethesda	O
Category	O
III	O
(	O
AUS	O
/	O
FLUS	O
)	O
in	O
cytology	B-P
.	O

The	O
predictors	O
of	O
malignancy	O
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	O
in	O
nodules	O
with	O
atypia	O
of	O
undetermined	O
significance	O
/	O
follicular	O
lesion	O
of	O
undetermined	O
significance	O
(	O
AUS	O
/	O
FLUS	O
)	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
predictors	O
of	O
malignancy	O
in	O
these	O
patients	O
.	O

A	O
total	O
of	O
427	O
patients	O
with	O
cytologically	O
Bethesda	O
Category	O
III	O
(	O
AUS	O
/	O
FLUS	O
)	O
thyroid	O
nodules	O
were	O
included	O
in	O
this	O
retrospective	O
study	O
.	O

We	O
divided	O
the	O
nodules	O
into	O
two	O
subgroups	O
according	O
to	O
the	O
histopathology	B-P
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
findings	O
.	O

In	O
overall	O
,	O
427	O
patients	O
with	O
449	O
AUS	O
/	O
FLUS	O
nodules	O
who	O
had	O
undergone	O
surgery	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
23.4	O
%	O
(	O
105/449	O
)	O
.	O

When	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
25.8	O
%	O
in	O
nodules	O
with	O
AUS	O
(	O
82/318	O
)	O
and	O
17.6	O
%	O
in	O
nodules	O
with	O
FLUS	O
(	O
23/131	O
)	O
(	O
p	O
=	O
0.061	O
)	O
.	O

The	O
vast	O
majority	O
of	O
malignant	O
specimens	O
in	O
histopathology	B-P
consisted	O
of	O
papillary	O
thyroid	O
carcinoma	O
(	O
PTC	O
)	O
(	O
n	O
=	O
91	O
,	O
86.7	O
%	O
)	O
.	O

Preoperative	O
ultrasonographic	O
features	O
of	O
105	O
malignant	O
nodules	O
in	O
histopathology	B-P
were	O
compared	O
with	O
the	O
344	O
benign	O
nodules	O
in	O
histopathology	B-P
.	O

Anteroposterior/Transverse	O
(	O
AP/T	O
)	O
ratio	O
was	O
significantly	O
higher	O
in	O
malignant	O
group	O
compared	O
to	O
benign	O
group	O
(	O
p	O
=	O
0.013	O
)	O
.	O

In	O
multiple	O
logistic	O
analysis	O
,	O
we	O
found	O
that	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	O
were	O
independently	O
associated	O
with	O
malignancy	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
malignancy	O
-associated	O
cut-off	O
value	O
of	O
AP/T	O
ratio	O
at	O
maximum	O
sensitivity	O
and	O
specificity	O
was	O
≥0.81	O
.	O

We	O
did	O
not	O
find	O
any	O
correlation	O
between	O
malignancy	O
and	O
Hashimoto	O
's	O
thyroiditis	O
in	O
histopathology	B-P
in	O
multivariate	O
analysis	O
(	O
p	O
>	O
0.05	O
)	O
.	O

In	O
Bethesda	O
Category	O
III	O
nodules	O
with	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	O
,	O
surgery	O
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine-needle	B-P
aspiration	I-P
biopsy	I-P
or	O
observation	O
.	O

PUMILIO	O
/	O
FOXP1	O
signaling	O
drives	O
expansion	O
of	O
hematopoietic	O
stem/progenitor	O
and	O
leukemia	O
cells	O
.	O

RNA-binding	O
proteins	O
(	O
RBPs	O
)	O
have	O
emerged	O
as	O
important	O
regulators	O
of	O
invertebrate	O
adult	O
stem	O
cells	O
,	O
but	O
their	O
activities	O
remain	O
poorly	O
appreciated	O
in	O
mammals	O
.	O

Using	O
a	O
short	O
hairpin	O
RNA	O
strategy	O
,	O
we	O
demonstrate	O
here	O
that	O
the	O
2	O
mammalian	O
RBPs	O
,	O
PUMILIO	O
(	O
PUM	O
)	O
1	O
and	O
PUM2	O
,	O
members	O
of	O
the	O
PUF	O
family	O
of	O
posttranscriptional	O
regulators	O
,	O
are	O
essential	O
for	O
hematopoietic	O
stem/progenitor	O
cell	O
(	O
HSPC	O
)	O
proliferation	O
and	O
survival	O
in	O
vitro	O
and	O
in	O
vivo	O
upon	O
reconstitution	B-P
assays	I-P
.	O

Moreover	O
,	O
we	O
found	O
that	O
PUM1	O
/	O
2	O
sustain	O
myeloid	O
leukemic	O
cell	O
growth	O
.	O

Through	O
a	O
proteomic	O
approach	O
,	O
we	O
identified	O
the	O
FOXP1	O
transcription	O
factor	O
as	O
a	O
new	O
target	O
of	O
PUM1	O
/	O
2	O
.	O

Contrary	O
to	O
its	O
canonical	O
repressive	O
activity	O
,	O
PUM1	O
/	O
2	O
rather	O
promote	O
FOXP1	O
expression	O
by	O
a	O
direct	O
binding	O
to	O
2	O
canonical	O
PUM	O
responsive	O
elements	O
present	O
in	O
the	O
FOXP1	O
-	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
.	O

Expression	O
of	O
FOXP1	O
strongly	O
correlates	O
with	O
PUM1	O
and	O
PUM2	O
levels	O
in	O
primary	O
HSPCs	O
and	O
myeloid	O
leukemia	O
cells	O
.	O

We	O
demonstrate	O
that	O
FOXP1	O
by	O
itself	O
supports	O
HSPC	O
and	O
leukemic	O
cell	O
growth	O
,	O
thus	O
mimicking	O
PUM	O
activities	O
.	O

Mechanistically	O
,	O
FOXP1	O
represses	O
the	O
expression	O
of	O
the	O
p21	O
(	O
-CIP1	O
)	O
and	O
p27	O
(	O
-KIP1	O
)	O
cell	O
cycle	O
inhibitors	O
.	O

Enforced	O
FOXP1	O
expression	O
reverses	O
shPUM	O
antiproliferative	O
and	O
proapoptotic	O
activities	O
.	O

Altogether	O
,	O
our	O
results	O
reveal	O
a	O
novel	O
regulatory	O
pathway	O
,	O
underscoring	O
a	O
previously	O
unknown	O
and	O
interconnected	O
key	O
role	O
of	O
PUM1	O
/	O
2	O
and	O
FOXP1	O
in	O
regulating	O
normal	O
HSPC	O
and	O
leukemic	O
cell	O
growth	O
.	O

Combination	O
of	O
diagnostic	B-P
laparoscopy	I-P
and	O
intraoperative	O
indocyanine	B-P
green	I-P
fluorescence	I-P
angiography	I-P
for	O
the	O
early	B-P
detection	I-P
of	O
intestinal	O
ischemia	O
not	O
detectable	O
at	O
CT	B-P
scan	I-P
.	O

Acute	O
mesenteric	O
ischemia	O
is	O
the	O
most	O
severe	O
gastrointestinal	O
complication	O
of	O
acute	O
aortic	O
dissection	O
.	O

The	O
timing	O
of	O
diagnosis	O
is	O
of	O
major	O
importance	O
,	O
in	O
fact	O
the	O
recognition	O
of	O
acute	O
mesenteric	O
ischemia	O
often	O
occurs	O
too	O
late	O
due	O
to	O
the	O
presence	O
of	O
unspecific	O
symptoms	O
and	O
lack	O
of	O
reliable	O
exams	O
.	O

Recently	O
,	O
indocyanine	B-P
green	I-P
fluorescence	I-P
angiography	I-P
has	O
been	O
adopted	O
in	O
order	O
to	O
measure	O
blood	O
perfusion	O
and	O
microcirculation	O
.	O

We	O
decided	O
to	O
perform	O
a	O
diagnostic	B-P
laparoscopy	I-P
with	O
the	O
support	O
of	O
intra-operative	O
near-infrared	O
indocyanine	B-P
green	I-P
fluorescence	I-P
angiography	I-P
,	O
in	O
order	O
to	O
detect	O
an	O
initial	O
intestinal	O
ischemia	O
in	O
a	O
68-year-old	O
patient	O
previously	O
treated	O
with	O
a	O
TEVAR	O
procedure	O
for	O
a	O
type-B	O
aortic	O
dissection	O
.	O

The	O
fluorescence	B-P
system	I-P
demonstrated	O
an	O
hypoperfused	O
area	O
in	O
the	O
ascending	O
colon	O
,	O
therefore	O
an	O
ileocholic	O
resection	O
was	O
thus	O
performed	O
.	O

Opening	O
the	O
operatory	O
specimen	O
,	O
the	O
mucosa	O
of	O
the	O
colon	O
appeared	O
totally	O
ischemic	O
,	O
whilst	O
the	O
serosa	O
was	O
normal	O
.	O

When	O
ischemia	O
occurs	O
,	O
the	O
oxygen	O
supply	O
is	O
interrupted	O
,	O
hence	O
the	O
necrosis	O
of	O
the	O
enteral	O
mucosa	O
occurs	O
within	O
3h	O
,	O
whilst	O
the	O
necrosis	O
of	O
the	O
full	O
thickness	O
of	O
the	O
bowel	O
wall	O
occurs	O
within	O
6h	O
.	O

A	O
diagnosis	O
during	O
these	O
``	O
golden	O
hours	O
``	O
is	O
of	O
major	O
importance	O
for	O
a	O
successful	O
treatment	O
.	O

The	O
combination	O
of	O
laparoscopy	B-P
and	O
UV	O
light	O
and	O
fluorescein	O
dye	O
should	O
be	O
considered	O
as	O
an	O
invaluable	O
diagnostic	B-P
procedure	I-P
for	O
the	O
diagnosis	O
of	O
early	O
stage	O
acute	O
bowel	O
ischemia	O
which	O
is	O
not	O
visible	O
at	O
instrumental	O
examinations	O
nor	O
with	O
diagnostic	B-P
laparoscopy	I-P
.	O

Ventricular	O
tachycardia	O
score	O
-	O
A	O
novel	O
method	B-P
for	O
wide	O
QRS	O
complex	O
tachycardia	O
differentiation	O
-	O
Explained	O
.	O

Philosophy	O
,	O
merits	O
and	O
limitations	O
of	O
a	O
novel	O
method	B-P
for	O
wide	O
QRS	O
complex	O
tachycardia	O
differentiation	O
,	O
based	O
on	O
a	O
scoring	O
system	O
and	O
called	O
the	O
ventricular	O
tachycardia	O
(	O
VT	O
)	O
score	O
,	O
were	O
explained	O
.	O

The	O
following	O
criteria	O
were	O
assigned	O
one	O
point	O
:	O
initial	O
dominant	O
R	O
wave	O
in	O
V1	O
;	O
initial	O
r	O
>	O
40	O
ms	O
in	O
V1	O
or	O
V2	O
;	O
notched	O
S	O
in	O
V1	O
;	O
initial	O
R	O
wave	O
in	O
a	O
VR	O
;	O
lead	O
II	O
RWPT	O
≥50	O
ms	O
;	O
and	O
absence	O
of	O
an	O
RS	O
in	O
leads	O
V1-V6	O
.	O

Atrioventricular	O
dissociation	O
(	O
including	O
fusion	O
/	O
capture	O
beats	O
and	O
partial	O
dissociation	O
)	O
was	O
assigned	O
two	O
points	O
.	O

We	O
recommend	O
≥3	O
VT	O
score	O
points	O
for	O
a	O
firm	O
diagnosis	B-P
of	O
VT.	O
A	O
cut-off	O
≥1	O
point	O
can	O
be	O
used	O
for	O
diagnosis	B-P
of	O
VT	O
when	O
highest	O
overall	O
accuracy	O
rather	O
than	O
error	O
-	O
free	O
diagnosis	B-P
is	O
desired	O
.	O

However	O
,	O
in	O
case	O
of	O
VT	O
score	O
of	O
0-2	O
(	O
i.e.	O
,	O
not	O
fully	O
diagnostic	B-P
ECG	I-P
)	O
,	O
we	O
recommend	O
using	O
other	O
options	O
(	O
electrophysiological	B-P
study	I-P
,	O
clinical	O
data	O
,	O
previous	O
and	O
following	O
ECGs	B-P
,	O
etc	O
.	O
)	O

for	O
confirming	O
the	O
diagnosis	B-P
.	O

Genome-wide	O
association	O
mapping	O
in	O
winter	O
barley	O
for	O
grain	O
yield	O
and	O
culm	O
cell	O
wall	O
polymer	O
content	O
using	O
the	O
high-throughput	O
CoMPP	B-P
technique	I-P
.	O

A	O
collection	O
of	O
112	O
winter	O
barley	O
varieties	O
(	O
Hordeum	O
vulgare	O
L.	O
)	O
was	O
grown	O
in	O
the	O
field	O
for	O
two	O
years	O
(	O
2008/09	O
and	O
2009/10	O
)	O
in	O
northern	O
Italy	O
and	O
grain	O
and	O
straw	O
yields	O
recorded	O
.	O

In	O
the	O
first	O
year	O
of	O
the	O
trial	O
,	O
a	O
severe	O
attack	O
of	O
barley	O
yellow	O
mosaic	O
virus	O
(	O
BaYMV	O
)	O
strongly	O
influenced	O
final	O
performances	O
with	O
an	O
average	O
reduction	O
of	O
~	O
50	O
%	O
for	O
grain	O
and	O
straw	O
harvested	O
in	O
comparison	O
to	O
the	O
second	O
year	O
.	O

The	O
genetic	B-P
determination	I-P
(	O
GD	B-P
)	O
for	O
grain	O
yield	O
was	O
0.49	O
and	O
0.70	O
,	O
for	O
the	O
two	O
years	O
respectively	O
,	O
and	O
for	O
straw	O
yield	O
GD	B-P
was	O
low	O
in	O
2009	O
(	O
0.09	O
)	O
and	O
higher	O
in	O
2010	O
(	O
0.29	O
)	O
.	O

Cell	O
wall	O
polymers	O
in	O
culms	O
were	O
quantified	O
by	O
means	O
of	O
the	O
monoclonal	O
antibodies	O
LM6	O
,	O
LM11	O
,	O
JIM13	O
and	O
BS-400-3	O
and	O
the	O
carbohydrate-binding	O
module	O
CBM3a	O
using	O
the	O
high-throughput	O
CoMPP	B-P
technique	I-P
.	O

Of	O
these	O
,	O
LM6	O
,	O
which	O
detects	O
arabinan	O
components	O
,	O
showed	O
a	O
relatively	O
high	O
GD	B-P
in	O
both	O
years	O
and	O
a	O
significantly	O
negative	O
correlation	O
with	O
grain	O
yield	O
(	O
GYLD	O
)	O
.	O

Overall	O
,	O
heritability	O
(	O
H2	O
)	O
was	O
calculated	O
for	O
GYLD	O
,	O
LM6	O
and	O
JIM	O
and	O
resulted	O
to	O
be	O
0.42	O
,	O
0.32	O
and	O
0.20	O
,	O
respectively	O
.	O

A	O
total	O
of	O
4,976	O
SNPs	O
from	O
the	O
9K	O
iSelect	O
array	O
were	O
used	O
in	O
the	O
study	O
for	O
the	O
analysis	O
of	O
population	O
structure	O
,	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
and	O
genome-wide	O
association	O
study	O
(	O
GWAS	O
)	O
.	O

Marker-trait	O
associations	O
(	O
MTA	O
)	O
were	O
analyzed	O
for	O
grain	O
yield	O
and	O
cell	O
wall	O
determination	O
by	O
LM6	O
and	O
JIM13	O
as	O
these	O
were	O
the	O
traits	O
showing	O
significant	O
correlations	O
between	O
the	O
years	O
.	O

A	O
single	O
QTL	O
for	O
GYLD	O
containing	O
three	O
MTAs	O
was	O
found	O
on	O
chromosome	O
3H	O
located	O
close	O
to	O
the	O
Hv-eIF4E	O
gene	O
,	O
which	O
is	O
known	O
to	O
regulate	O
resistance	O
to	O
BaYMV	O
.	O

Subsequently	O
the	O
QTL	O
was	O
shown	O
to	O
be	O
tightly	O
linked	O
to	O
rym4	O
,	O
a	O
locus	O
for	O
resistance	O
to	O
the	O
virus	O
.	O

GWAs	O
on	O
arabinans	O
quantified	O
by	O
LM6	O
resulted	O
in	O
the	O
identification	O
of	O
major	O
QTLs	O
closely	O
located	O
on	O
3H	O
and	O
hypotheses	O
regarding	O
putative	O
candidate	O
genes	O
were	O
formulated	O
through	O
the	O
study	O
of	O
gene	O
expression	O
levels	O
based	O
on	O
bioinformatics	O
tools	O
.	O

The	O
Effect	O
of	O
Sodium	O
Fluoride	O
on	O
Cell	O
Apoptosis	O
and	O
the	O
Mechanism	O
of	O
Human	O
Lung	O
BEAS-2B	O
Cells	O
In	O
Vitro	O
.	O

Sodium	O
fluoride	O
(	O
NaF	O
)	O
is	O
a	O
source	O
of	O
fluoride	O
ions	O
used	O
in	O
many	O
applications	O
.	O

Previous	O
studies	O
found	O
that	O
NaF	O
suppressed	O
the	O
proliferation	O
of	O
osteoblast	O
MC3T3	O
E1	O
cells	O
and	O
induced	O
the	O
apoptosis	O
of	O
chondrocytes	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
NaF	O
on	O
human	O
lung	O
BEAS-2B	O
cells	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
mode	O
of	O
cell	O
death	O
induced	O
by	O
NaF	O
and	O
its	O
underlying	O
molecular	O
mechanisms	O
.	O

BEAS-2B	O
cells	O
were	O
treated	O
with	O
NaF	O
at	O
concentrations	O
of	O
0	O
,	O
0.25	O
,	O
0.5	O
,	O
1.0	O
,	O
2.0	O
,	O
and	O
4.0	O
mmol/L	O
.	O

Cell	O
viability	O
decreased	O
and	O
apoptotic	O
cells	O
significantly	O
increased	O
as	O
concentrations	O
of	O
NaF	O
increased	O
over	O
specific	O
periods	O
of	O
time	O
.	O

The	O
IC50	O
of	O
NaF	O
was	O
1.9	O
and	O
0.9	O
mM	O
after	O
24	O
and	O
48	O
h	O
,	O
respectively	O
.	O

The	O
rates	O
of	O
apoptosis	O
increased	O
from	O
4.8	O
to	O
37.7	O
%	O
after	O
NaF	O
exposure	O
.	O

HE	B-P
staining	I-P
,	O
electron	B-P
microscopy	I-P
,	O
and	O
single	O
cell	O
gel	O
electrophoresis	O
revealed	O
that	O
morphological	O
changes	O
of	O
apoptosis	O
increased	O
with	O
exposure	O
concentrations	O
.	O

RT-PCR	O
and	O
Western	O
blotting	O
were	O
used	O
to	O
detect	O
the	O
apoptotic	O
pathways	O
.	O

The	O
expressions	O
of	O
bax	O
,	O
caspase-3	O
,	O
caspase-9	O
,	O
p53	O
,	O
and	O
the	O
cytoplasmic	O
CytC	O
of	O
the	O
NaF	O
groups	O
increased	O
,	O
while	O
bcl-2	O
and	O
mitochondrial	O
CytC	O
decreased	O
compared	O
with	O
that	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Further	O
,	O
the	O
fluorescence	O
intensities	O
of	O
ROS	O
in	O
the	O
NaF	O
groups	O
were	O
higher	O
than	O
those	O
in	O
the	O
control	O
group	O
,	O
and	O
the	O
membrane	O
potential	O
of	O
mitochondria	O
in	O
the	O
NaF	O
group	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

These	O
findings	O
suggested	O
that	O
NaF	O
induced	O
apoptosis	O
in	O
the	O
BEAS-2B	O
cells	O
through	O
mitochondria	O
-mediated	O
signal	O
pathways	O
.	O

Our	O
study	O
provides	O
the	O
theoretical	O
foundation	O
and	O
experimental	O
basis	O
for	O
exploring	O
the	O
mechanisms	O
of	O
human	O
lung	O
epithelial	O
cell	O
damage	O
and	O
cytotoxicity	O
induced	O
by	O
fluorine	O
.	O

Salivary	O
Colony	O
Stimulating	O
Factor-1	O
,	O
Interleukin-34	O
,	O
and	O
Matrix	O
Metalloproteinase-8	O
as	O
Markers	O
of	O
Periodontal	O
Disease	O
.	O

Colony-stimulating	O
factor	O
(	O
CSF	O
)	O
-1	O
and	O
interleukin	O
(	O
IL	O
)	O
-34	O
are	O
macrophage	O
growth	O
factors	O
and	O
regulators	O
of	O
osteoclastogenesis	O
.	O

The	O
potential	O
involvement	O
of	O
CSF-1	O
and	O
IL-34	O
in	O
periodontal	O
disease	O
is	O
yet	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
presence	O
of	O
CSF-1	O
and	O
IL-34	O
in	O
whole	O
saliva	O
in	O
relation	O
to	O
periodontal	O
disease	O
.	O

Protocol	O
validation	O
was	O
assessed	O
in	O
saliva	O
of	O
healthy	O
donors	O
(	O
n=21	O
)	O
by	O
ELISA	B-P
.	O

Salivary	O
CSF-1	O
,	O
IL-34	O
,	O
and	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-8	O
,	O
a	O
biomarker	O
candidate	O
of	O
periodontitis	O
,	O
were	O
determined	O
in	O
48	O
patients	O
(	O
29	O
periodontitis	O
,	O
12	O
gingivitis	O
,	O
7	O
healthy	O
)	O
and	O
related	O
to	O
the	O
clinical	O
periodontal	O
parameters	O
bleeding	O
on	O
probing	O
(	O
BOP	O
)	O
,	O
probing	O
depth	O
(	O
PD	O
)	O
,	O
clinical	O
attachment	O
loss	O
(	O
AL	O
)	O
,	O
and	O
plaque	O
index	O
(	O
PI	O
)	O
.	O

An	O
additional	O
separate	O
group	O
of	O
gingivitis	O
(	O
n=21	O
)	O
and	O
part	O
of	O
periodontitis	O
patients	O
(	O
n=11	O
)	O
were	O
subjected	O
to	O
non-surgical	O
periodontal	O
treatment	O
whereupon	O
changes	O
in	O
salivary	O
CSF-1	O
,	O
IL-34	O
,	O
and	O
MMP-8	O
levels	O
were	O
determined	O
and	O
related	O
to	O
periodontal	O
outcome	O
.	O

Periodontitis	O
patients	O
displayed	O
higher	O
CSF-1	O
and	O
MMP-8	O
levels	O
in	O
saliva	O
compared	O
to	O
healthy	O
,	O
while	O
IL-34	O
levels	O
were	O
lower	O
.	O

Higher	O
CSF-1	O
/	O
IL-34	O
ratio	O
was	O
observed	O
in	O
periodontitis	O
patients	O
compared	O
to	O
healthy	O
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
CSF-1	O
and	O
MMP-8	O
which	O
both	O
correlated	O
negatively	O
to	O
IL-34	O
,	O
in	O
gingivitis	O
and	O
periodontitis	O
.	O

Clinical	O
periodontal	O
parameters	O
correlated	O
positively	O
to	O
CSF-1	O
,	O
MMP-8	O
,	O
and	O
to	O
the	O
CSF-1	O
/	O
IL-34	O
ratio	O
and	O
negatively	O
to	O
IL-34	O
in	O
periodontitis	O
patients	O
.	O

Following	O
treatment	O
CSF-1	O
and	O
MMP-8	O
levels	O
decreased	O
along	O
with	O
clinical	O
improvement	O
in	O
gingivitis	O
patients	O
.	O

CSF-1	O
and	O
IL-34	O
are	O
present	O
in	O
saliva	O
and	O
seem	O
to	O
have	O
complementary	O
roles	O
in	O
periodontal	O
disease	O
,	O
IL-34	O
in	O
steady-state	O
and	O
CSF-1	O
in	O
inflammation	O
.	O

A	O
Concurrent	O
Case	O
of	O
Ménétrier	O
's	O
Disease	O
and	O
Signet	O
Ring	O
Carcinoma	O
.	O

Ménétrier	O
's	O
disease	O
,	O
also	O
known	O
as	O
hyperplastic	O
protein-losing	O
gastropathy	O
,	O
is	O
a	O
rare	O
,	O
idiopathic	O
,	O
acquired	O
,	O
premalignant	O
condition	O
associated	O
with	O
gastric	O
carcinoma	O
.	O

Its	O
association	O
with	O
signet	O
ring	O
cell	O
cancer	O
of	O
the	O
stomach	O
has	O
been	O
previously	O
reported	O
only	O
twice	O
.	O

We	O
present	O
the	O
third	O
case	O
of	O
histologically	O
confirmed	O
concurrent	O
Ménétrier	O
's	O
disease	O
with	O
signet	O
ring	O
carcinoma	O
of	O
the	O
stomach	O
,	O
interrogated	O
by	O
esophagogastroduodenoscopy	B-P
and	O
endoscopic	B-P
ultrasound	I-P
.	O

Bilateral	O
Sensory	O
Changes	O
and	O
High	O
Burden	O
of	O
Disease	O
in	O
Patients	O
with	O
Chronic	O
Pain	O
and	O
Unilateral	O
Nondermatomal	O
Somatosensory	O
Deficits	O
:	O
A	O
Quantitative	B-P
Sensory	I-P
Testing	I-P
and	O
Clinical	O
Study	O
.	O

Widespread	O
sensory	O
deficits	O
resembling	O
hemihypoaesthesia	O
occur	O
in	O
20-40	O
%	O
of	O
chronic	O
pain	O
patients	O
on	O
the	O
side	O
of	O
pain	O
,	O
independent	O
of	O
pain	O
aetiology	O
,	O
and	O
have	O
been	O
termed	O
nondermatomal	O
sensory	O
deficits	O
(	O
NDSD	O
)	O
.	O

Sensory	O
profiles	O
have	O
rarely	O
been	O
investigated	O
in	O
NDSD	O
.	O

Quantitative	B-P
sensory	I-P
testing	I-P
(	O
QST	B-P
)	O
according	O
to	O
the	O
protocol	O
of	O
the	O
German	O
Research	O
Network	O
on	O
Neuropathic	O
Pain	O
(	O
DFNS	O
)	O
was	O
performed	O
in	O
the	O
face	O
,	O
hand	O
and	O
foot	O
of	O
the	O
painful	O
body	O
side	O
and	O
in	O
contralateral	O
regions	O
in	O
chronic	O
pain	O
patients	O
.	O

Twenty-five	O
patients	O
with	O
NDSD	O
and	O
23	O
without	O
NDSD	O
(	O
termed	O
pain-only	O
group	O
)	O
were	O
included	O
after	O
exclusion	O
of	O
neuropathic	O
pain	O
.	O

Comprehensive	O
clinical	O
and	O
psychiatric	B-P
evaluations	I-P
were	O
done	O
.	O

NDSD	O
in	O
chronic	O
pain	O
was	O
associated	O
with	O
high	O
burden	O
of	O
disease	O
and	O
more	O
widespread	O
pain	O
.	O

Only	O
in	O
the	O
NDSD	O
group	O
significantly	O
higher	O
thresholds	O
for	O
mechanical	O
and	O
painful	O
stimuli	O
were	O
found	O
in	O
at	O
least	O
2	O
of	O
3	O
regions	O
ipsilateral	O
to	O
pain	O
.	O

In	O
addition	O
,	O
we	O
found	O
a	O
bilateral	O
loss	O
of	O
function	O
for	O
temperature	O
and	O
vibration	O
detection	O
,	O
and	O
a	O
gain	O
of	O
function	O
for	O
pressure	O
pain	O
in	O
certain	O
regions	O
in	O
patients	O
with	O
NDSD	O
.	O

Sensory	O
loss	O
and	O
gain	O
of	O
function	O
for	O
pressure	O
pain	O
correlated	O
with	O
pain	O
intensity	O
in	O
several	O
regions	O
.	O

This	O
may	O
indicate	O
a	O
distinct	O
sensory	O
profile	O
in	O
chronic	O
non	O
-	O
neuropathic	O
pain	O
and	O
NDSD	O
,	O
probably	O
attributable	O
to	O
altered	O
central	O
pain	O
processing	O
and	O
sensitisation	O
.	O

The	O
presence	O
of	O
NDSD	O
in	O
chronic	O
non	O
-	O
neuropathic	O
pain	O
may	O
be	O
regarded	O
as	O
a	O
marker	O
for	O
higher	O
burden	O
of	O
pain	O
disease	O
.	O

Highest	O
dominant	O
frequency	O
and	O
rotor	O
positions	O
are	O
robust	O
markers	O
of	O
driver	O
location	O
during	O
noninvasive	B-P
mapping	I-P
of	O
atrial	O
fibrillation	O
:	O
A	O
computational	B-P
study	I-P
.	O

Dominant	B-P
frequency	I-P
(	O
DF	B-P
)	O
and	O
rotor	B-P
mapping	I-P
have	O
been	O
proposed	O
as	O
noninvasive	B-P
techniques	I-P
to	O
guide	O
localization	O
of	O
drivers	O
maintaining	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
robustness	O
of	O
both	O
techniques	B-P
in	O
identifying	O
atrial	O
drivers	O
noninvasively	O
under	O
the	O
effect	O
of	O
electrical	O
noise	O
or	O
model	O
uncertainties	O
.	O

Inverse	O
-	O
computed	O
DFs	O
and	O
phase	O
maps	O
were	O
obtained	O
from	O
30	O
different	O
mathematical	O
AF	O
simulations	O
.	O

Epicardial	O
highest	O
dominant	O
frequency	O
(	O
HDF	O
)	O
regions	O
and	O
rotor	O
location	O
were	O
compared	O
with	O
the	O
same	O
inverse	O
-	O
computed	O
measurements	O
after	O
addition	O
of	O
noise	O
to	O
the	O
ECG	B-P
,	O
size	O
variations	O
of	O
the	O
atria	O
,	O
and	O
linear	O
or	O
angular	O
deviations	O
in	O
the	O
atrial	O
location	O
inside	O
the	O
thorax	O
.	O

Inverse	O
-	O
computed	O
electrograms	O
(	O
EGMs	O
)	O
individually	O
correlated	O
poorly	O
with	O
the	O
original	O
EGMs	O
in	O
the	O
absence	O
of	O
induced	O
uncertainties	O
(	O
0.45	O
±	O
0.12	O
)	O
and	O
were	O
worse	O
with	O
10-dB	O
noise	O
(	O
0.22	O
±	O
0.11	O
)	O
,	O
3-cm	O
displacement	O
(	O
0.01	O
±	O
0.02	O
)	O
,	O
or	O
36°	O
rotation	O
(	O
0.02	O
±	O
0.03	O
)	O
.	O

However	O
,	O
inverse	O
-	O
computed	O
HDF	O
regions	O
showed	O
robustness	O
against	O
induced	O
uncertainties	O
:	O
from	O
82	O
%	O
±	O
18	O
%	O
match	O
for	O
the	O
best	O
conditions	O
,	O
down	O
to	O
73	O
%	O
±	O
23	O
%	O
for	O
10-dB	O
noise	O
,	O
77	O
%	O
±	O
21	O
%	O
for	O
5-cm	O
displacement	O
,	O
and	O
60	O
%	O
±	O
22	O
%	O
for	O
36°	O
rotation	O
.	O

The	O
distance	O
from	O
the	O
inverse	O
-	O
computed	O
rotor	O
to	O
the	O
original	O
rotor	O
was	O
also	O
affected	O
by	O
uncertainties	O
:	O
0.8	O
±	O
1.61	O
cm	O
for	O
the	O
best	O
conditions	O
,	O
2.4	O
±	O
3.6	O
cm	O
for	O
10-dB	O
noise	O
,	O
4.3	O
±	O
3.2	O
cm	O
for	O
4-cm	O
displacement	O
,	O
and	O
4.0	O
±	O
2.1	O
cm	O
for	O
36°	O
rotation	O
.	O

Restriction	O
of	O
rotor	O
detections	O
to	O
the	O
HDF	O
area	O
increased	O
rotor	O
detection	O
accuracy	O
from	O
4.5	O
±	O
4.5	O
cm	O
to	O
3.2	O
±	O
3.1	O
cm	O
(	O
P	O
<	O
.05	O
)	O
with	O
0-dB	O
noise	O
.	O

The	O
combination	O
of	O
frequency	O
and	O
phase-	O
derived	O
measurements	O
increases	O
the	O
accuracy	O
of	O
noninvasive	O
localization	O
of	O
atrial	O
rotors	O
driving	O
AF	O
in	O
the	O
presence	O
of	O
noise	O
and	O
uncertainties	O
in	O
atrial	O
location	O
or	O
size	O
.	O

pH	O
affects	O
bacterial	O
community	O
composition	O
in	O
soils	O
across	O
the	O
Huashan	O
Watershed	O
,	O
China	O
.	O

To	O
investigate	O
soil	O
bacterial	O
richness	O
and	O
diversity	O
and	O
to	O
determine	O
the	O
correlations	O
between	O
bacterial	O
communities	O
and	O
soil	O
properties	O
,	O
8	O
soil	O
samples	O
were	O
collected	O
from	O
the	O
Huashan	O
watershed	O
in	O
Anhui	O
,	O
China	O
.	O

Subsequently	O
,	O
454	O
high-throughput	B-P
pyrosequencing	I-P
and	O
bioinformatics	O
analyses	O
were	O
performed	O
to	O
examine	O
the	O
soil	O
bacterial	O
community	O
compositions	O
.	O

The	O
operational	O
taxonomic	O
unit	O
richness	O
of	O
the	O
bacterial	O
community	O
ranged	O
from	O
3664	O
to	O
5899	O
,	O
and	O
the	O
diversity	O
indices	O
,	O
including	O
Chao1	O
,	O
Shannon-Wiener	O
,	O
and	O
Faith	O
's	O
phylogenetic	O
diversity	O
ranged	O
from	O
7751	O
to	O
15	O
204	O
,	O
7.386	O
to	O
8.327	O
,	O
and	O
415.77	O
to	O
679.11	O
,	O
respectively	O
.	O

The	O
2	O
most	O
dominant	O
phyla	O
in	O
the	O
soil	O
samples	O
were	O
Actinobacteria	O
and	O
Proteobacteria	O
.	O

The	O
richness	O
and	O
diversity	O
of	O
the	O
bacterial	O
community	O
were	O
positively	O
correlated	O
with	O
soil	O
pH	O
.	O

The	O
Mantel	O
test	O
revealed	O
that	O
the	O
soil	O
pH	O
was	O
the	O
dominant	O
factor	O
influencing	O
the	O
bacterial	O
community	O
.	O

The	O
positive	O
modular	O
structure	O
of	O
co-occurrence	O
patterns	O
at	O
the	O
genus	O
level	O
was	O
discovered	O
by	O
network	O
analysis	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	O
provide	O
useful	O
information	O
that	O
enhances	O
our	O
understanding	O
of	O
the	O
effects	O
of	O
soil	O
properties	O
on	O
the	O
bacterial	O
communities	O
.	O

NLRP3	O
inflammasome	O
activation	O
contributes	O
to	O
long-term	O
behavioral	O
alterations	O
in	O
mice	O
injected	O
with	O
lipopolysaccharide	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
might	O
affect	O
the	O
central	O
nervous	O
system	O
by	O
causing	O
neuroinflammation	O
,	O
which	O
subsequently	O
leads	O
to	O
brain	O
damage	O
and	O
dysfunction	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
role	O
of	O
nod-like	O
receptor	O
pyrin	O
domain-containing	O
protein	O
3	O
(	O
NLRP3	O
)	O
inflammasome	O
activation	O
in	O
long-term	O
behavioral	O
alterations	O
of	O
8-	O
week	O
-old	O
male	O
C57BL/6	O
mice	O
injected	O
intraperitoneally	O
with	O
LPS	O
(	O
5mg/kg	O
)	O
.	O

At	O
different	O
time	O
points	O
after	O
injection	O
,	O
we	O
assessed	O
locomotor	O
function	O
with	O
a	O
24-point	O
neurologic	O
deficit	O
scoring	O
system	O
and	O
the	O
rotarod	O
test	O
;	O
assessed	O
recognition	O
memory	O
with	O
the	O
novel	O
object	O
recognition	O
test	O
;	O
and	O
assessed	O
emotional	O
abnormality	O
(	O
anhedonia	O
and	O
behavioral	O
despair	O
)	O
with	O
the	O
tail	B-P
suspension	I-P
test	I-P
,	O
forced	B-P
swim	I-P
test	I-P
,	O
and	O
sucrose	B-P
preference	I-P
test	I-P
.	O

We	O
also	O
assessed	O
protein	O
expression	O
of	O
NLRP3	O
,	O
apoptosis-associated	O
speck-like	O
protein	O
(	O
ASC	O
)	O
,	O
and	O
caspase-1	O
p10	O
in	O
hippocampus	O
by	O
Western	O
blotting	O
;	O
measured	O
levels	O
of	O
interleukin	O
(	O
IL	O
)	O
-1β	O
,	O
IL-18	O
,	O
tumor	O
necrosis	O
factor	O
α	O
(	O
TNFα	O
)	O
,	O
and	O
IL-10	O
in	O
hippocampus	O
;	O
measured	O
TNFα	O
and	O
IL-1β	O
in	O
serum	O
by	O
ELISA	B-P
;	O
and	O
evaluated	O
microglial	O
activity	O
in	O
hippocampus	O
by	O
Iba1	B-P
immunofluorescence	I-P
.	O

We	O
found	O
that	O
LPS	O
-	O
injected	O
mice	O
displayed	O
long-term	O
depression	O
-like	O
behaviors	O
and	O
recognition	O
memory	O
deficit	O
;	O
elevated	O
expression	O
of	O
NLRP3	O
,	O
ASC	O
,	O
and	O
caspase-1	O
p10	O
;	O
increased	O
levels	O
of	O
IL-1β	O
,	O
IL-18	O
,	O
and	O
TNFα	O
;	O
decreased	O
levels	O
of	O
IL-10	O
;	O
and	O
increased	O
microglial	O
activation	O
.	O

These	O
effects	O
were	O
blocked	O
by	O
the	O
NLRP3	O
inflammasome	O
inhibitor	O
Ac-Tyr-Val-Ala-Asp-chloromethylketone	O
.	O

The	O
results	O
demonstrate	O
proof	O
of	O
concept	O
that	O
NLRP3	O
inflammasome	O
activation	O
contributes	O
to	O
long-term	O
behavioral	O
alterations	O
in	O
LPS	O
-	O
exposed	O
mice	O
,	O
probably	O
through	O
enhanced	O
inflammation	O
,	O
and	O
that	O
NLRP3	O
inflammasome	O
inhibition	O
might	O
alleviate	O
peripheral	O
and	O
brain	O
inflammation	O
and	O
thereby	O
ameliorate	O
long-term	O
behavioral	O
alterations	O
in	O
LPS	O
-	O
exposed	O
mice	O
.	O

Inhibition	O
of	O
ectopic	O
microtubule	O
assembly	O
by	O
the	O
kinesin-13	O
KLP-7	O
prevents	O
chromosome	O
segregation	O
and	O
cytokinesis	O
defects	O
in	O
oocytes	O
.	O

In	O
most	O
species	O
,	O
oocytes	O
lack	O
centrosomes	O
.	O

Accurate	O
meiotic	O
spindle	O
assembly	O
and	O
chromosome	O
segregation	O
-	O
essential	O
to	O
prevent	O
miscarriage	O
or	O
developmental	O
defects	O
-	O
thus	O
occur	O
through	O
atypical	O
mechanisms	O
that	O
are	O
not	O
well	O
characterized	O
.	O

Using	O
quantitative	O
in	O
vitro	O
and	O
in	O
vivo	O
functional	O
assays	B-P
in	O
the	O
C.	O
elegans	O
oocyte	O
,	O
we	O
provide	O
novel	O
evidence	O
that	O
the	O
kinesin-13	O
KLP-7	O
promotes	O
destabilization	O
of	O
the	O
whole	O
cellular	O
microtubule	O
network	O
.	O

By	O
counteracting	O
ectopic	O
microtubule	O
assembly	O
and	O
disorganization	O
of	O
the	O
microtubule	O
network	O
,	O
this	O
function	O
is	O
strictly	O
required	O
for	O
spindle	O
organization	O
,	O
chromosome	O
segregation	O
and	O
cytokinesis	O
in	O
meiotic	O
cells	O
.	O

Strikingly	O
,	O
when	O
centrosome	O
activity	O
was	O
experimentally	O
reduced	O
,	O
the	O
absence	O
of	O
KLP-7	O
or	O
the	O
mammalian	O
kinesin-13	O
protein	O
MCAK	O
(	O
KIF2C	O
)	O
also	O
resulted	O
in	O
ectopic	O
microtubule	O
asters	O
during	O
mitosis	O
in	O
C.	O
elegans	O
zygotes	O
or	O
HeLa	O
cells	O
,	O
respectively	O
.	O

Our	O
results	O
highlight	O
the	O
general	O
function	O
of	O
kinesin-13	O
microtubule	O
depolymerases	O
in	O
preventing	O
ectopic	O
,	O
spontaneous	O
microtubule	O
assembly	O
when	O
centrosome	O
activity	O
is	O
defective	O
or	O
absent	O
,	O
which	O
would	O
otherwise	O
lead	O
to	O
spindle	O
microtubule	O
disorganization	O
and	O
aneuploidy	O
.	O

4-Anilino-2-pyridylquinazolines	O
and	O
-	O
pyrimidines	O
as	O
Highly	O
Potent	O
and	O
Nontoxic	O
Inhibitors	O
of	O
Breast	O
Cancer	O
Resistance	O
Protein	O
(	O
ABCG2	O
)	O
.	O

Multidrug	O
resistance	O
(	O
MDR	O
)	O
mediated	O
by	O
ATP-binding	O
cassette	O
(	O
ABC	O
)	O
transport	O
proteins	O
remains	O
a	O
major	O
problem	O
in	O
the	O
chemotherapeutic	O
treatment	O
of	O
cancer	O
and	O
might	O
be	O
overcome	O
by	O
inhibition	O
of	O
the	O
transporter	O
.	O

Because	O
of	O
the	O
lack	O
of	O
understanding	O
,	O
the	O
complex	O
mechanisms	O
involved	O
in	O
the	O
transport	O
process	O
,	O
in	O
particular	O
for	O
breast	O
cancer	O
resistance	O
protein	O
(	O
BCRP	O
/	O
ABCG2	O
)	O
,	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	O
of	O
ABCG2	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
a	O
systematic	O
series	O
of	O
4-substituted-2-pyridylquinazolines	O
in	O
terms	O
of	O
their	O
inhibitory	O
potency	O
as	O
well	O
as	O
selectivity	O
toward	O
ABCG2	O
.	O

For	O
comparison	O
,	O
the	O
quinazoline	O
scaffold	O
was	O
reduced	O
to	O
the	O
significantly	O
smaller	O
4-methylpyrimidine	O
basic	O
structure	O
.	O

Furthermore	O
,	O
the	O
cytotoxicity	O
and	O
the	O
ability	O
to	O
reverse	O
MDR	O
was	O
tested	O
with	O
the	O
chemotherapeutic	O
agents	O
SN-38	O
and	O
mitoxantrone	O
(	O
MX	O
)	O
.	O

Interaction	O
of	O
the	O
compounds	O
with	O
ABCG2	O
was	O
investigated	O
by	O
a	O
colorimetric	B-P
ATPase	O
assay	B-P
.	O

Enzyme	O
kinetic	O
studies	O
were	O
carried	O
out	O
with	O
Hoechst	O
33342	O
as	O
fluorescent	O
dye	O
and	O
substrate	O
of	O
ABCG2	O
to	O
elucidate	O
the	O
compounds	O
binding	O
modes	O
.	O

How	O
do	O
wettability	O
,	O
zeta	O
potential	O
and	O
hydroxylation	O
degree	O
affect	O
the	O
biological	O
response	O
of	O
biomaterials	O
?	O
.	O

It	O
is	O
well	O
known	O
that	O
composition	O
,	O
electric	O
charge	O
,	O
wettability	O
and	O
roughness	O
of	O
implant	O
surfaces	O
have	O
great	O
influence	O
on	O
their	O
interaction	O
with	O
the	O
biological	O
fluids	O
and	O
tissues	O
,	O
but	O
systematic	O
studies	O
of	O
different	O
materials	O
in	O
the	O
same	O
experimental	O
conditions	O
are	O
still	O
lacking	O
in	O
the	O
scientific	O
literature	O
.	O

The	O
aim	O
of	O
this	O
research	O
is	O
to	O
investigate	O
the	O
correlations	O
between	O
some	O
surface	O
characteristics	O
(	O
wettability	O
,	O
zeta	O
potential	O
and	O
hydroxylation	O
degree	O
)	O
and	O
the	O
biological	O
response	O
(	O
protein	O
adsorption	O
,	O
blood	O
wettability	O
,	O
cell	O
and	O
bacterial	O
adhesion	O
)	O
to	O
some	O
model	O
biomaterials	O
.	O

The	O
resulting	O
knowledge	O
can	O
be	O
applied	O
for	O
the	O
development	O
of	O
future	O
innovative	O
surfaces	O
for	O
implantable	O
biomaterials	O
.	O

Roughness	O
was	O
not	O
considered	O
as	O
a	O
variable	O
because	O
it	O
is	O
a	O
widely	O
explored	O
feature	O
:	O
smooth	O
surfaces	O
prepared	O
by	O
a	O
controlled	O
protocol	O
were	O
compared	O
in	O
order	O
to	O
have	O
no	O
roughness	O
effects	O
.	O

Three	O
oxides	O
(	O
ZrO2	O
,	O
Al2O3	O
,	O
SiO2	O
)	O
,	O
three	O
metals	O
(	O
316LSS	O
steel	O
,	O
Ti	O
,	O
Nb	O
)	O
and	O
two	O
polymers	O
(	O
corona	O
treated	O
polystyrene	O
for	O
cell	B-P
culture	I-P
and	O
untreated	O
polystyrene	O
for	O
bacteria	B-P
culture	I-P
)	O
,	O
widely	O
used	O
for	O
biomedical	O
applications	O
,	O
were	O
considered	O
.	O

The	O
surfaces	O
were	O
characterized	O
by	O
contact	O
profilometry	O
,	O
SEM	B-P
-	O
EDS	B-P
,	O
XPS	B-P
,	O
FTIR	O
,	O
zeta	O
potential	O
and	O
wettability	O
with	O
different	O
fluids	O
.	O

Protein	O
adsorption	O
,	O
blood	O
wettability	O
,	O
bacterial	O
and	O
cell	O
adhesion	O
were	O
evaluated	O
in	O
order	O
to	O
investigate	O
the	O
correlations	O
between	O
the	O
surface	O
physiochemical	O
properties	O
and	O
biological	O
responses	O
.	O

From	O
a	O
methodological	O
standpoint	O
,	O
XPS	B-P
and	O
electrokinetic	O
measurements	O
emerged	O
as	O
the	O
more	O
suitable	O
techniques	O
respectively	O
for	O
the	O
evaluation	O
of	O
hydroxylation	O
degree	O
and	O
surface	O
charge	O
/	O
isoelectric	O
point	O
.	O

Moreover	O
,	O
determination	O
of	O
wettability	O
by	O
blood	O
appeared	O
a	O
specific	O
and	O
crucial	O
test	O
,	O
the	O
results	O
of	O
which	O
are	O
not	O
easily	O
predictable	O
by	O
using	O
other	O
type	O
of	O
tests	O
.	O

Hydroxylation	O
degree	O
resulted	O
correlated	O
to	O
the	O
wettability	O
by	O
water	O
,	O
but	O
not	O
directly	O
to	O
surface	O
charge	O
.	O

Wetting	O
tests	O
with	O
different	O
media	O
showed	O
the	O
possibility	O
to	O
highlight	O
some	O
differences	O
among	O
look-alike	O
materials	O
.	O

A	O
dependence	O
of	O
protein	O
absorption	O
on	O
hydroxylation	O
degree	O
,	O
charge	O
and	O
wettability	O
was	O
evidenced	O
and	O
its	O
maximum	O
was	O
registered	O
for	O
surfaces	O
with	O
low	O
wettability	O
in	O
both	O
water	O
based	O
and	O
protein	O
containing	O
media	O
and	O
a	O
moderate	O
surface	O
charge	O
.	O

As	O
far	O
as	O
bacterial	O
adhesion	O
is	O
concerned	O
,	O
no	O
effect	O
of	O
surface	O
charge	O
or	O
protein	O
adsorption	O
was	O
evidenced	O
,	O
while	O
the	O
presence	O
of	O
a	O
high	O
acid	O
component	O
of	O
the	O
surface	O
energy	O
appeared	O
significant	O
.	O

Finally	O
,	O
the	O
combination	O
of	O
hydroxylation	O
degree	O
,	O
wettability	O
,	O
surface	O
charge	O
and	O
energy	O
(	O
polar	O
component	O
)	O
emerged	O
as	O
a	O
key	O
parameter	O
for	O
cell	O
adhesion	O
and	O
viability	O
.	O

Diverse	O
Colletotrichum	O
species	O
cause	O
anthracnose	O
of	O
tea	O
plants	O
(	O
Camellia	O
sinensis	O
(	O
L.	O
)	O
O.	O
Kuntze	O
)	O
in	O
China	O
.	O

Anthracnose	O
caused	O
by	O
Colletotrichum	O
is	O
one	O
of	O
the	O
most	O
severe	O
diseases	O
that	O
can	O
afflict	O
Camellia	O
sinensis	O
.	O

However	O
,	O
research	O
on	O
the	O
diversity	O
and	O
geographical	O
distribution	O
of	O
Colletotrichum	O
in	O
China	O
remain	O
limited	O
.	O

In	O
this	O
study	O
,	O
106	O
Colletotrichum	O
isolates	O
were	O
collected	O
from	O
diseased	O
leaves	O
of	O
Ca	O
.	O

sinensis	O
cultivated	O
in	O
the	O
15	O
main	O
tea	O
production	O
provinces	O
in	O
China	O
.	O

Multi-locus	O
phylogenetic	O
analysis	O
coupled	O
with	O
morphological	B-P
identification	I-P
showed	O
that	O
the	O
collected	O
isolates	O
belonged	O
to	O
11	O
species	O
,	O
including	O
6	O
known	O
species	O
(	O
C.	O
camelliae	O
,	O
C.	O
cliviae	O
,	O
C.	O
fioriniae	O
,	O
C.	O
fructicola	O
,	O
C.	O
karstii	O
,	O
and	O
C.	O
siamense	O
)	O
,	O
3	O
new	O
record	O
species	O
(	O
C.	O
aenigma	O
,	O
C.	O
endophytica	O
,	O
and	O
C.	O
truncatum	O
)	O
,	O
1	O
novel	O
species	O
(	O
C.	O
wuxiense	O
)	O
,	O
and	O
1	O
indistinguishable	O
strain	O
,	O
herein	O
described	O
as	O
Colletotrichum	O
sp	O
.	O

Of	O
these	O
species	O
,	O
C.	O
camelliae	O
and	O
C.	O
fructicola	O
were	O
the	O
dominant	O
species	O
causing	O
anthracnose	O
in	O
Ca	O
.	O

sinensis	O
.	O

In	O
addition	O
,	O
our	O
study	O
provided	O
further	O
evidence	O
that	O
phylogenetic	O
analysis	O
using	O
a	O
combination	O
of	O
ApMat	O
and	O
GS	O
sequences	O
can	O
be	O
used	O
to	O
effectively	O
resolve	O
the	O
taxonomic	O
relationships	O
within	O
the	O
C.	O
gloeosporioides	O
species	O
complex	O
.	O

Finally	O
,	O
pathogenicity	O
tests	B-P
suggested	O
that	O
C.	O
camelliae	O
,	O
C.	O
aenigma	O
,	O
and	O
C.	O
endophytica	O
are	O
more	O
invasive	O
than	O
other	O
species	O
after	O
the	O
inoculation	O
of	O
the	O
leaves	O
of	O
Ca	O
.	O

sinensis	O
.	O

Quantitative	O
assessment	O
of	O
passive	O
electrical	O
properties	O
of	O
the	O
cardiac	O
T-tubular	O
system	O
by	O
FRAP	B-P
microscopy	B-P
.	O

Well-coordinated	O
activation	O
of	O
all	O
cardiomyocytes	O
must	O
occur	O
on	O
every	O
heartbeat	O
.	O

At	O
the	O
cell	O
level	O
,	O
a	O
complex	O
network	O
of	O
sarcolemmal	O
invaginations	O
,	O
called	O
the	O
transverse-axial	O
tubular	O
system	O
(	O
TATS	O
)	O
,	O
propagates	O
membrane	O
potential	O
changes	O
to	O
the	O
cell	O
core	O
,	O
ensuring	O
synchronous	O
and	O
uniform	O
excitation-contraction	O
coupling	O
.	O

Although	O
myocardial	O
conduction	O
of	O
excitation	O
has	O
been	O
widely	O
described	O
,	O
the	O
electrical	O
properties	O
of	O
the	O
TATS	O
remain	O
mostly	O
unknown	O
.	O

Here	O
,	O
we	O
exploit	O
the	O
formal	O
analogy	O
between	O
diffusion	O
and	O
electrical	O
conductivity	O
to	O
link	O
the	O
latter	O
with	O
the	O
diffusional	O
properties	O
of	O
TATS	O
.	O

Fluorescence	B-P
recovery	I-P
after	I-P
photobleaching	I-P
(	O
FRAP	B-P
)	O
microscopy	B-P
is	O
used	O
to	O
probe	O
the	O
diffusion	O
properties	O
of	O
TATS	O
in	O
isolated	O
rat	O
cardiomyocytes	O
:	O
A	O
fluorescent	O
dextran	O
inside	O
TATS	O
lumen	O
is	O
photobleached	O
,	O
and	O
signal	O
recovery	O
by	O
diffusion	O
of	O
unbleached	O
dextran	O
from	O
the	O
extracellular	O
space	O
is	O
monitored	O
.	O

We	O
designed	O
a	O
mathematical	O
model	O
to	O
correlate	O
the	O
time	O
constant	O
of	O
fluorescence	B-P
recovery	I-P
with	O
the	O
apparent	O
diffusion	O
coefficient	O
of	O
the	O
fluorescent	O
molecules	O
.	O

Then	O
,	O
apparent	O
diffusion	O
is	O
linked	O
to	O
electrical	O
conductivity	O
and	O
used	O
to	O
evaluate	O
the	O
efficiency	O
of	O
the	O
passive	O
spread	O
of	O
membrane	O
depolarization	O
along	O
TATS	O
.	O

The	O
method	O
is	O
first	O
validated	O
in	O
cells	O
where	O
most	O
TATS	O
elements	O
are	O
acutely	O
detached	O
by	O
osmotic	O
shock	O
and	O
then	O
applied	O
to	O
probe	O
TATS	O
electrical	O
conductivity	O
in	O
failing	O
heart	O
cells	O
.	O

We	O
find	O
that	O
acute	O
and	O
pathological	O
tubular	O
remodeling	O
significantly	O
affect	O
TATS	O
electrical	O
conductivity	O
.	O

This	O
may	O
explain	O
the	O
occurrence	O
of	O
defects	O
in	O
action	O
potential	O
propagation	O
at	O
the	O
level	O
of	O
single	O
T-tubules	O
,	O
recently	O
observed	O
in	O
diseased	O
cardiomyocytes	O
.	O

Artificial	O
spatiotemporal	O
touch	O
inputs	O
reveal	O
complementary	O
decoding	O
in	O
neocortical	O
neurons	O
.	O

Investigations	O
of	O
the	O
mechanisms	O
of	O
touch	O
perception	O
and	O
decoding	O
has	O
been	O
hampered	O
by	O
difficulties	O
in	O
achieving	O
invariant	O
patterns	O
of	O
skin	O
sensor	O
activation	O
.	O

To	O
obtain	O
reproducible	O
spatiotemporal	O
patterns	O
of	O
activation	O
of	O
sensory	O
afferents	O
,	O
we	O
used	O
an	O
artificial	O
fingertip	O
equipped	O
with	O
an	O
array	O
of	O
neuromorphic	O
sensors	O
.	O

The	O
artificial	O
fingertip	O
was	O
used	O
to	O
transduce	O
real-world	O
haptic	O
stimuli	O
into	O
spatiotemporal	O
patterns	O
of	O
spikes	O
.	O

These	O
spike	O
patterns	O
were	O
delivered	O
to	O
the	O
skin	O
afferents	O
of	O
the	O
second	O
digit	O
of	O
rats	O
via	O
an	O
array	O
of	O
stimulation	O
electrodes	O
.	O

Combined	O
with	O
low	O
-	O
noise	O
intra	O
-	O
and	O
extracellular	O
recordings	O
from	O
neocortical	O
neurons	O
in	O
vivo	O
,	O
this	O
approach	O
provided	O
a	O
previously	O
inaccessible	O
high	B-P
resolution	I-P
analysis	O
of	O
the	O
representation	O
of	O
tactile	O
information	O
in	O
the	O
neocortical	O
neuronal	O
circuitry	O
.	O

The	O
results	O
indicate	O
high	O
information	O
content	O
in	O
individual	O
neurons	O
and	O
reveal	O
multiple	O
novel	O
neuronal	O
tactile	O
coding	O
features	O
such	O
as	O
heterogeneous	O
and	O
complementary	O
spatiotemporal	O
input	O
selectivity	O
also	O
between	O
neighboring	O
neurons	O
.	O

Such	O
neuronal	O
heterogeneity	O
and	O
complementariness	O
can	O
potentially	O
support	O
a	O
very	O
high	O
decoding	O
capacity	O
in	O
a	O
limited	O
population	O
of	O
neurons	O
.	O

Our	O
results	O
also	O
indicate	O
a	O
potential	O
neuroprosthetic	O
approach	O
to	O
communicate	O
with	O
the	O
brain	O
at	O
a	O
very	O
high	B-P
resolution	I-P
and	O
provide	O
a	O
potential	O
novel	O
solution	O
for	O
evaluating	O
the	O
degree	O
or	O
state	O
of	O
neurological	O
disease	O
in	O
animal	O
models	O
.	O

Risk	O
stratification	O
for	O
major	O
adverse	O
cardiac	O
events	O
and	O
ventricular	O
tachyarrhythmias	O
by	O
cardiac	B-P
MRI	I-P
in	O
patients	O
with	O
cardiac	O
sarcoidosis	O
.	O

The	O
presence	O
of	O
myocardial	O
fibrosis	O
by	O
cardiac	B-P
MRI	I-P
has	O
prognostic	O
value	O
in	O
cardiac	O
sarcoidosis	O
,	O
and	O
localisation	O
may	O
be	O
equally	O
relevant	O
to	O
clinical	O
outcomes	O
.	O

We	O
aimed	O
to	O
analyse	O
cardiac	O
damage	O
and	O
function	O
in	O
detail	O
and	O
explore	O
the	O
relationship	O
with	O
clinical	O
outcomes	O
in	O
patients	O
with	O
cardiac	O
sarcoidosis	O
using	O
cardiac	B-P
MRI	I-P
.	O

We	O
included	O
81	O
consecutive	O
patients	O
with	O
cardiac	O
sarcoidosis	O
undergoing	O
cardiac	B-P
MR.	I-P
Left	O
ventricular	O
mass	O
and	O
fibrosis	O
mass	O
were	O
calculated	O
,	O
and	O
localisation	O
was	O
analysed	O
using	O
a	O
17-segment	O
model	O
.	O

Participants	O
underwent	O
follow-up	O
through	O
2015	O
,	O
and	O
the	O
development	O
of	O
major	O
adverse	O
cardiac	O
events	O
including	O
ventricular	O
tachyarrhythmias	O
was	O
recorded	O
.	O

Increased	O
left	O
ventricular	O
fibrosis	O
mass	O
was	O
associated	O
with	O
increased	O
prevalence	O
of	O
ventricular	O
tachyarrhythmias	O
(	O
p	O
<	O
0.001	O
)	O
.	O

When	O
localisation	O
was	O
defined	O
as	O
the	O
sum	O
of	O
late	O
gadolinium	O
enhancement	O
in	O
the	O
left	O
ventricular	O
basal	O
anterior	O
and	O
basal	O
anteroseptal	O
area	O
s	O
,	O
or	O
the	O
right	O
ventricular	O
area	O
,	O
it	O
was	O
associated	O
with	O
ventricular	O
tachyarrhythmias	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Kaplan-Meier	O
analysis	O
during	O
a	O
median	O
follow-up	O
of	O
22.1	O
months	O
showed	O
that	O
both	O
the	O
mass	O
and	O
localisation	O
groupings	O
for	O
fibrosis	O
were	O
significantly	O
associated	O
with	O
major	O
adverse	O
cardiac	O
events	O
or	O
ventricular	O
tachyarrhythmias	O
and	O
that	O
when	O
combined	O
,	O
the	O
risk	O
stratification	O
was	O
better	O
than	O
for	O
each	O
variable	O
alone	O
(	O
p	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O

By	O
Cox-proportional	O
hazard	O
risk	O
analysis	O
,	O
the	O
localisation	O
grouping	O
was	O
an	O
independent	O
predictor	O
for	O
the	O
both	O
.	O

In	O
patients	O
with	O
cardiac	O
sarcoidosis	O
,	O
both	O
fibrosis	O
mass	O
and	O
its	O
localisation	O
to	O
the	O
basal	O
anterior	O
/	O
anteroseptal	O
left	O
ventricle	O
,	O
or	O
right	O
ventricle	O
was	O
associated	O
with	O
the	O
development	O
of	O
major	O
adverse	O
cardiac	O
events	O
or	O
ventricular	O
tachyarrhythmias	O
.	O

Cardiac	B-P
MR	I-P
with	O
late	O
gadolinium	O
enhancement	O
may	O
be	O
useful	O
for	O
improving	O
risk	O
stratification	O
in	O
patients	O
with	O
cardiac	O
sarcoidosis	O
.	O

Prostate	O
external	O
beam	O
radiotherapy	O
combined	O
with	O
high-dose-rate	O
brachytherapy	O
:	O
dose	O
-	O
volume	O
parameters	O
from	O
deformably-registered	O
plans	O
correlate	O
with	O
late	O
gastrointestinal	O
complications	O
.	O

Derivation	O
of	O
dose	O
-	O
volume	O
correlated	O
with	O
toxicity	O
for	O
multi-modal	O
treatments	O
can	O
be	O
difficult	O
due	O
to	O
the	O
perceived	O
need	O
for	O
voxel-by-voxel	B-P
dose	I-P
accumulation	I-P
.	O

With	O
data	O
available	O
for	O
a	O
single	O
-	O
institution	O
cohort	O
with	O
long	O
follow-up	O
,	O
an	O
investigation	O
was	O
undertaken	O
into	O
rectal	O
dose	O
-	O
volume	O
effects	O
for	O
gastrointestinal	O
toxicities	O
after	O
deformably-registering	O
each	O
phase	O
of	O
a	O
combined	O
external	O
beam	O
radiotherapy	O
(	O
EBRT	O
)	O
/	O
high-dose-rate	O
(	O
HDR	O
)	O
brachytherapy	O
prostate	O
treatment	O
.	O

One	O
hundred	O
and	O
eighteen	O
patients	O
received	O
EBRT	O
in	O
23	O
fractions	O
of	O
2	O
Gy	O
and	O
HDR	O
(	O
TG43	O
algorithm	O
)	O
in	O
3	O
fractions	O
of	O
6.5	O
Gy	O
.	O

Results	O
for	O
the	O
Late	O
Effects	O
of	O
Normal	O
Tissues	O
-	O
Subjective	O
,	O
Objective	O
,	O
Management	O
and	O
Analytic	O
toxicity	O
assessments	O
were	O
available	O
with	O
a	O
median	O
follow-up	O
of	O
72	O
months	O
.	O

The	O
HDR	O
CT	B-P
was	O
deformably-registered	O
to	O
the	O
EBRT	O
CT.	B-P
Doses	O
were	O
corrected	O
for	O
dose	O
fractionation	O
.	O

Rectum	O
dose-volume	O
histogram	O
(	O
DVH	O
)	O
parameters	O
were	O
calculated	O
in	O
two	O
ways	O
.	O

(	O
1	O
)	O
Distribution-adding	O
:	O
parameters	O
were	O
calculated	O
after	O
the	O
EBRT	O
dose	O
distribution	O
was	O
3D-summed	O
with	O
the	O
registered	O
HDR	O
dose	O
distribution	O
.	O

(	O
2	O
)	O
Parameter-adding	O
:	O
the	O
EBRT	O
DVH	O
parameters	O
were	O
added	O
to	O
HDR	O
DVH	O
parameters	O
.	O

Logistic	O
regressions	O
and	O
Mann-Whitney	O
U-tests	O
were	O
used	O
to	O
correlate	O
parameters	O
with	O
late	O
peak	O
toxicity	O
(	O
dichotomised	O
at	O
grade	O
1	O
or	O
2	O
)	O
.	O

The	O
48-80	O
,	O
40-63	O
and	O
49-55	O
Gy	O
dose	O
regions	O
from	O
distribution-adding	O
were	O
significantly	O
correlated	O
with	O
rectal	O
bleeding	O
,	O
urgency	O
/	O
tenesmus	O
and	O
stool	O
frequency	O
respectively	O
.	O

Additionally	O
,	O
urgency	O
/	O
tenesmus	O
and	O
anorectal	O
pain	O
were	O
associated	O
with	O
the	O
25-26	O
Gy	O
and	O
44-48	O
Gy	O
dose	O
regions	O
from	O
distribution-adding	O
respectively	O
.	O

Parameter-adding	O
also	O
indicated	O
the	O
low	O
-	O
mid	O
dose	O
region	O
was	O
significantly	O
correlated	O
with	O
stool	O
frequency	O
and	O
proctitis	O
.	O

This	O
study	O
confirms	O
significant	O
dose-histogram	O
effects	O
for	O
gastrointestinal	O
toxicities	O
after	O
including	O
deformable	O
registration	O
to	O
combine	O
phases	O
of	O
EBRT	O
/	O
HDR	O
prostate	O
cancer	O
treatment	O
.	O

The	O
findings	O
from	O
distribution-adding	O
were	O
in	O
most	O
cases	O
consistent	O
with	O
those	O
from	O
parameter-adding	O
.	O

The	O
mid	O
-	O
high	O
dose	O
range	O
and	O
near	O
maximum	O
doses	O
were	O
important	O
for	O
rectal	O
bleeding	O
.	O

The	O
distribution-adding	O
mid	O
-	O
high	O
dose	O
range	O
was	O
also	O
important	O
for	O
stool	O
frequency	O
and	O
urgency	O
/	O
tenesmus	O
.	O

We	O
encourage	O
additional	O
studies	O
in	O
a	O
variety	O
of	O
institutions	O
using	O
a	O
variety	O
of	O
dose	B-P
accumulation	I-P
methods	I-P
with	O
appropriate	O
inter-fraction	O
motion	O
management	O
.	O

NCT	O
NCT00193856	O
.	O

Retrospectively	O
registered	O
12	O
September	O
2005	O
.	O

Altered	O
Effects	O
of	O
Perspective-Taking	O
on	O
Functional	O
Connectivity	O
during	O
Self-	O
and	O
Other-Referential	O
Processing	O
in	O
Adults	O
with	O
Autism	O
Spectrum	O
Disorder	O
.	O

In	O
interactive	O
social	O
situations	O
,	O
it	O
is	O
often	O
crucial	O
to	O
be	O
able	O
to	O
take	O
another	O
person	O
's	O
perspective	O
when	O
evaluating	O
one	O
's	O
own	O
or	O
another	O
person	O
's	O
specific	O
trait	O
;	O
individuals	O
with	O
ASD	O
critically	O
lack	O
this	O
social	O
skill	O
.	O

To	O
examine	O
how	O
perspective	O
-	O
dependent	O
self-	O
and	O
other-	O
evaluation	O
processes	O
modulate	O
functional	O
connectivity	O
in	O
ASD	O
,	O
we	O
conducted	O
an	O
fMRI	B-P
study	O
in	O
which	O
26	O
high-functioning	O
adults	O
with	O
ASD	O
and	O
24	O
typically	O
developed	O
(	O
TD	O
)	O
controls	O
were	O
asked	O
to	O
decide	O
whether	O
an	O
adjective	O
describing	O
a	O
personality	O
trait	O
correctly	O
described	O
the	O
participant	O
himself/herself	O
(	O
``	O
self	O
``	O
)	O
or	O
the	O
participant	O
's	O
mother	O
(	O
``	O
other	O
''	O
)	O
by	O
taking	O
either	O
the	O
first	O
(	O
1P	O
)	O
or	O
third	O
person	O
(	O
3P	O
)	O
perspective	O
.	O

We	O
observed	O
that	O
functional	O
connectivity	O
between	O
the	O
left	O
sensorimotor	O
cortex	O
and	O
the	O
left	O
middle	O
cingulate	O
cortex	O
was	O
enhanced	O
in	O
TD	O
taking	O
the	O
3P	O
perspective	O
,	O
this	O
enhancement	O
was	O
significantly	O
reduced	O
in	O
ASD	O
,	O
and	O
the	O
degree	O
of	O
reduction	O
was	O
significantly	O
correlated	O
with	O
the	O
severity	O
of	O
autistic	O
traits	O
.	O

Furthermore	O
,	O
the	O
self-reference	O
effect	O
on	O
functional	O
connectivity	O
between	O
the	O
left	O
inferior	O
frontal	O
cortex	O
and	O
frontopolar	O
cortices	O
was	O
significantly	O
enhanced	O
in	O
TD	O
taking	O
the	O
3P	O
perspective	O
,	O
whereas	O
such	O
effect	O
was	O
reversed	O
in	O
ASD	O
.	O

These	O
findings	O
indicate	O
altered	O
effects	O
of	O
perspective	O
on	O
the	O
functional	O
connectivity	O
,	O
which	O
may	O
underlie	O
the	O
deficits	O
in	O
social	O
interaction	O
and	O
communication	O
observed	O
in	O
individuals	O
with	O
ASD	O
.	O

Relationship	O
Between	O
Femur	O
and	O
Femoral	O
Arteries	O
for	O
Identifying	O
Risk	O
Factors	O
for	O
Vascular	O
Injury	O
.	O

BACKGROUND	O
This	O
study	O
aimed	O
to	O
identify	O
risk	O
factors	O
for	O
vascular	O
injury	O
in	O
proximal	O
femoral	O
fracture	O
through	O
identifying	O
frequency	O
and	O
distances	O
between	O
femur	O
and	O
femoral	O
arteries	O
with	O
computed	B-P
tomography	I-P
angiography	I-P
and	O
3-dimensional	B-P
reconstruction	I-P
.	O

MATERIAL	O
AND	O
METHODS	O
In	O
a	O
series	O
of	O
400	O
participants	O
,	O
based	O
on	O
measurement	O
results	O
regarding	O
the	O
distribution	O
of	O
femoral	O
arteries	O
in	O
the	O
medial	O
femur	O
,	O
the	O
femoral	O
portion	O
covering	O
that	O
part	O
was	O
divided	O
into	O
levels	O
A-E	O
.	O

The	O
center	O
region	O
,	O
margin	O
region	O
,	O
and	O
risky	O
area	O
in	O
the	O
medial	O
femur	O
were	O
defined	O
.	O

The	O
frequency	O
of	O
femoral	O
arteries	O
and	O
interested	O
shortest	O
distance	O
between	O
the	O
outer	O
femur	O
and	O
superficial	O
,	O
deep	O
,	O
and	O
perforating	O
femoral	O
arteries	O
(	O
SFAs	O
,	O
DFAs	O
,	O
and	O
PFAs	O
)	O
in	O
the	O
center	O
region	O
,	O
margin	O
region	O
,	O
and	O
risky	O
area	O
at	O
each	O
level	O
were	O
recorded	O
.	O

RESULTS	O
There	O
were	O
173	O
males	O
and	O
227	O
females	O
(	O
average	O
age	O
:	O
63.61±19.18	O
years	O
)	O
in	O
this	O
study	O
.	O

The	O
starting	O
point	O
and	O
end	O
point	O
for	O
femoral	O
arteries	O
in	O
the	O
medial	O
femur	O
were	O
from	O
22.55±4.23	O
%	O
to	O
54.56±8.39	O
%	O
of	O
the	O
whole	O
femur	O
.	O

The	O
femoral	O
arteries	O
in	O
the	O
medial	O
femur	O
mainly	O
were	O
distributed	O
at	O
levels	O
B	O
(	O
88.2	O
%	O
)	O
,	O
C	O
(	O
65.9	O
%	O
)	O
,	O
and	O
D	O
(	O
40.6	O
%	O
)	O
.	O

The	O
femoral	O
arteries	O
in	O
center	O
regions	O
in	O
the	O
risky	O
area	O
,	O
most	O
of	O
which	O
were	O
DFAs	O
and	O
PFAs	O
,	O
were	O
mainly	O
concentrated	O
at	O
levels	O
B	O
(	O
26.93	O
%	O
)	O
and	O
C	O
(	O
11.81	O
%	O
)	O
.	O

CONCLUSIONS	O
The	O
mid-shaft	O
level	O
was	O
the	O
most	O
risky	O
level	O
,	O
and	O
the	O
DFAs	O
and	O
PFAs	O
were	O
easier	O
to	O
injure	O
than	O
the	O
SFAs	O
when	O
performing	O
internal	O
fixation	O
of	O
proximal	O
femoral	O
fracture	O
.	O

We	O
recommended	O
that	O
great	O
attention	O
be	O
paid	O
to	O
drill	O
and	O
screw	O
insertion	O
around	O
the	O
mid-shaft	O
level	O
for	O
prevention	O
of	O
iatrogenic	O
vascular	O
injury	O
.	O

The	O
A312	O
Allele	O
(	O
c.280A	O
>	O
T	O
)	O
Is	O
Responsible	O
for	O
the	O
Weak	O
A	O
Phenotype	O
.	O

The	O
ABO*A312	O
allele	O
was	O
found	O
in	O
a	O
71-	O
year-old	O
Korean	O
male	O
with	O
ABO	O
discrepancy	O
and	O
in	O
his	O
two	O
sons	O
.	O

Although	O
the	O
ABO*A312	O
allele	O
(	O
c.280A	O
>	O
T	O
,	O
I94F	O
)	O
in	O
an	O
AwB	O
case	O
was	O
registered	O
in	O
GenBank	O
,	O
the	O
impact	O
of	O
the	O
I94F	O
mutation	O
of	O
the	O
ABO	O
gene	O
on	O
the	O
activity	O
of	O
A	O
transferase	O
has	O
not	O
been	O
studied	O
.	O

Transient	B-P
transfection	I-P
experiments	I-P
were	O
performed	O
in	O
HeLa	O
cells	O
using	O
A101	O
,	O
A102	O
,	O
and	O
A312	O
alleles	O
synthesized	O
by	O
site-directed	O
mutagenesis	O
,	O
and	O
the	O
functional	O
expression	O
level	O
of	O
A	O
antigen	O
was	O
assessed	O
by	O
flow	B-P
cytometry	I-P
.	O

The	O
results	O
showed	O
that	O
the	O
A102	O
and	O
A312	O
alleles	O
expressed	O
A	O
antigen	O
levels	O
that	O
were	O
80.28	O
%	O
and	O
19.32	O
%	O
,	O
respectively	O
,	O
of	O
that	O
of	O
the	O
A101	O
allele	O
.	O

Our	O
study	O
results	O
demonstrate	O
that	O
the	O
c.280A	O
>	O
T	O
variant	O
is	O
responsible	O
for	O
the	O
weakened	O
expression	O
of	O
A	O
antigen	O
.	O

Bioenergetic	O
status	O
modulates	O
motor	O
neuron	O
vulnerability	O
and	O
pathogenesis	O
in	O
a	O
zebrafish	O
model	O
of	O
spinal	O
muscular	O
atrophy	O
.	O

Degeneration	O
and	O
loss	O
of	O
lower	O
motor	O
neurons	O
is	O
the	O
major	O
pathological	O
hallmark	O
of	O
spinal	O
muscular	O
atrophy	O
(	O
SMA	O
)	O
,	O
resulting	O
from	O
low	O
levels	O
of	O
ubiquitously-expressed	O
survival	O
motor	O
neuron	O
(	O
SMN	O
)	O
protein	O
.	O

One	O
remarkable	O
,	O
yet	O
unresolved	O
,	O
feature	O
of	O
SMA	O
is	O
that	O
not	O
all	O
motor	O
neurons	O
are	O
equally	O
affected	O
,	O
with	O
some	O
populations	O
displaying	O
a	O
robust	O
resistance	O
to	O
the	O
disease	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
selective	O
vulnerability	O
of	O
distinct	O
motor	O
neuron	O
pools	O
arises	O
from	O
fundamental	O
modifications	O
to	O
their	O
basal	O
molecular	O
profiles	O
.	O

Comparative	O
gene	O
expression	O
profiling	O
of	O
motor	O
neurons	O
innervating	O
the	O
extensor	O
digitorum	O
longus	O
(	O
disease-resistant	O
)	O
,	O
gastrocnemius	O
(	O
intermediate	O
vulnerability	O
)	O
,	O
and	O
tibialis	O
anterior	O
(	O
vulnerable	O
)	O
muscles	O
in	O
mice	O
revealed	O
that	O
disease	O
susceptibility	O
correlates	O
strongly	O
with	O
a	O
modified	O
bioenergetic	O
profile	B-P
.	O

Targeting	O
of	O
identified	O
bioenergetic	O
pathways	O
by	O
enhancing	O
mitochondrial	O
biogenesis	O
rescued	O
motor	O
axon	O
defects	O
in	O
SMA	O
zebrafish	O
.	O

Moreover	O
,	O
targeting	O
of	O
a	O
single	O
bioenergetic	O
protein	O
,	O
phosphoglycerate	O
kinase	O
1	O
(	O
Pgk1	O
)	O
,	O
was	O
found	O
to	O
modulate	O
motor	O
neuron	O
vulnerability	O
in	O
vivo	O
.	O

Knockdown	O
of	O
pgk1	O
alone	O
was	O
sufficient	O
to	O
partially	O
mimic	O
the	O
SMA	O
phenotype	O
in	O
wild-type	O
zebrafish	O
.	O

Conversely	O
,	O
Pgk1	O
overexpression	O
,	O
or	O
treatment	O
with	O
terazosin	O
(	O
an	O
FDA	O
-approved	O
small	O
molecule	O
that	O
binds	O
and	O
activates	O
Pgk1	O
)	O
,	O
rescued	O
motor	O
axon	O
phenotypes	O
in	O
SMA	O
zebrafish	O
.	O

We	O
conclude	O
that	O
global	O
bioenergetics	O
pathways	O
can	O
be	O
therapeutically	O
manipulated	O
to	O
ameliorate	O
SMA	O
motor	O
neuron	O
phenotypes	O
in	O
vivo	O
.	O

Decomposition	O
of	O
xenobiotics	O
during	O
visible	O
light	O
irradiation	O
in	O
the	O
presence	O
of	O
immobilised	O
photosensitisers	O
:	O
kinetics	O
study	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
study	O
the	O
photosensitised	O
oxidation	O
of	O
the	O
xenobiotics	O
benzylparaben	O
(	O
BeP	O
)	O
and	O
2,4dichlorophenol	O
(	O
2,4DCP	O
)	O
in	O
aqueous	O
solutions	O
using	O
photosensitisers	O
immobilised	O
into	O
chitosan	O
carrier	O
particles	O
and	O
visible	O
light	O
radiation	O
.	O

Zn	O
(	O
II	O
)	O
phthalocyanine	O
tetrasulfonate	O
tetrasodium	O
salt	O
and	O
Al	O
(	O
III	O
)	O
phthalocyanine	O
chloride	O
tetrasulfonic	O
acid	O
were	O
used	O
as	O
photosensitisers	O
.	O

The	O
major	O
role	O
of	O
the	O
singlet	O
oxygen	O
during	O
photodegradation	O
was	O
proven	O
by	O
using	O
scavengers	O
of	O
reactive	O
oxygen	O
species	O
.	O

The	O
influence	O
of	O
initial	O
xenobiotic	O
concentration	O
and	O
temperature	O
on	O
degradation	O
rate	O
was	O
examined	O
.	O

The	O
investigations	O
were	O
focused	O
on	O
kinetics	O
(	O
Langmuir-Hinshelwood	O
model	O
)	O
as	O
well	O
as	O
activation	O
energy	O
determination	B-P
.	O

Moreover	O
,	O
the	O
adsorption	O
isotherms	O
of	O
BeP	O
and	O
2,4DCP	O
into	O
chitosan	O
carrier	O
were	O
determined	O
using	O
the	O
Brunauer-Emmett-Teller	O
model	O
.	O

Assessing	O
the	O
manipulative	O
potentials	O
of	O
monkeys	O
,	O
apes	O
and	O
humans	O
from	O
hand	O
proportions	O
:	O
implications	O
for	O
hand	O
evolution	O
.	O

The	O
hand	O
structure	O
possesses	O
a	O
greater	O
potential	O
for	O
performing	O
manipulative	O
skills	O
than	O
is	O
typically	O
observed	O
,	O
whether	O
in	O
humans	O
or	O
non-human	O
anthropoids	O
.	O

However	O
,	O
a	O
precise	O
assessment	O
of	O
the	O
potential	O
manipulative	O
skills	O
of	O
hands	O
has	O
been	O
challenging	O
,	O
which	O
hampers	O
our	O
understanding	O
of	O
the	O
evolution	O
of	O
manipulative	O
abilities	O
in	O
anthropoid	O
hands	O
.	O

Here	O
,	O
we	O
establish	O
a	O
functional	O
model	O
to	O
quantitatively	O
infer	O
the	O
manipulative	O
potentials	O
of	O
anthropoid	O
hands	O
based	O
on	O
hand	O
proportions	O
.	O

Our	O
results	O
reveal	O
a	O
large	O
disparity	O
of	O
manipulative	O
potentials	O
among	O
anthropoid	O
hands	O
.	O

From	O
the	O
aspect	O
of	O
hand	O
proportions	O
,	O
the	O
human	O
hand	O
has	O
the	O
best	O
manipulative	O
potential	O
among	O
anthropoids	O
.	O

However	O
,	O
the	O
species	O
with	O
a	O
manipulative	O
potential	O
closer	O
to	O
that	O
of	O
humans	O
are	O
not	O
our	O
nearest	O
relatives	O
,	O
chimpanzees	O
,	O
but	O
rather	O
,	O
are	O
certain	O
monkey	O
species	O
.	O

In	O
combination	O
with	O
the	O
phylogenetically	B-P
informed	I-P
morphometric	I-P
analyses	I-P
,	O
our	O
results	O
suggest	O
that	O
the	O
morphological	O
changes	O
of	O
non-human	O
anthropoid	O
hands	O
did	O
not	O
coevolve	O
with	O
the	O
brain	O
to	O
facilitate	O
the	O
manipulative	O
ability	O
during	O
the	O
evolutionary	O
process	O
,	O
although	O
the	O
manipulative	O
ability	O
is	O
a	O
survival	O
skill	O
.	O

The	O
changes	O
in	O
non-human	O
anthropoid	O
hands	O
may	O
have	O
more	O
likely	O
evolved	O
under	O
selective	O
pressure	O
for	O
locomotion	O
than	O
manipulation	O
.	O

The	O
impact	O
of	O
childhood	O
maltreatment	O
on	O
the	O
differential	O
efficacy	O
of	O
CBASP	O
versus	O
escitalopram	O
in	O
patients	O
with	O
chronic	O
depression	O
:	O
A	O
secondary	O
analysis	O
.	O

Childhood	O
maltreatment	O
(	O
CM	O
)	O
has	O
been	O
indicated	O
as	O
a	O
predictor	O
of	O
a	O
differential	O
response	O
to	O
antidepressant	O
treatment	O
with	O
psychotherapy	O
compared	O
to	O
medication	O
.	O

In	O
this	O
secondary	O
analysis	O
,	O
we	O
investigated	O
whether	O
the	O
presence	O
of	O
CM	O
results	O
in	O
a	O
differential	O
indication	O
for	O
the	O
Cognitive	O
Behavioral	O
Analysis	O
System	O
of	O
Psychotherapy	O
(	O
CBASP	O
)	O
or	O
escitalopram	O
plus	O
clinical	O
management	O
(	O
ESC	O
)	O
.	O

Sixty	O
patients	O
with	O
chronic	O
depression	O
were	O
randomized	O
to	O
either	O
22	O
sessions	O
of	O
CBASP	O
or	O
ESC	O
over	O
the	O
course	O
of	O
8	O
weeks	O
of	O
acute	O
and	O
20	O
weeks	O
of	O
extended	O
treatment	O
at	O
2	O
German	O
treatment	O
sites	O
.	O

CM	O
was	O
assessed	O
using	O
the	O
Childhood	O
Trauma	O
Questionnaire	O
and	O
the	O
clinician	O
rated	O
Early	O
Trauma	O
Inventory	O
.	O

Intention-to-treat	O
analyses	O
were	O
used	O
to	O
examine	O
the	O
impact	O
of	O
CM	O
on	O
depression	O
,	O
global	B-P
functioning	I-P
,	O
and	O
quality	O
of	O
life	O
.	O

The	O
presence	O
of	O
CM	O
did	O
not	O
result	O
in	O
significant	O
differences	O
in	O
treatment	O
response	O
to	O
CBASP	O
or	O
ESC	O
on	O
any	O
outcome	O
measure	O
after	O
28	O
weeks	O
of	O
treatment	O
independent	O
of	O
the	O
type	O
of	O
CM	O
assessment	O
.	O

After	O
8	O
weeks	O
,	O
a	O
significant	O
CM	O
×	O
treatment	O
interaction	O
was	O
found	O
for	O
scores	O
on	O
the	O
Montgomery-Asberg	O
Depression	O
Rating	O
Scale	O
.	O

Patients	O
with	O
a	O
history	O
of	O
CM	O
receiving	O
CBASP	O
had	O
a	O
significantly	O
lower	O
response	O
rate	O
compared	O
to	O
patients	O
without	O
CM	O
and	O
to	O
those	O
receiving	O
ESC	O
after	O
8	O
weeks	O
.	O

Conclusively	O
,	O
CBASP	O
and	O
ESC	O
are	O
equally	O
effective	O
treatment	O
options	O
for	O
the	O
difficult	O
to	O
treat	O
subgroup	O
of	O
patients	O
with	O
chronic	O
depression	O
and	O
a	O
history	O
of	O
CM	O
.	O

CM	O
may	O
be	O
a	O
predictor	O
of	O
a	O
longer	O
latency	O
of	O
treatment	O
response	O
in	O
the	O
case	O
of	O
psychotherapy	O
.	O

CBASP	O
and	O
escitalopram	O
are	O
equally	O
effective	O
treatment	O
options	O
for	O
chronic	O
depression	O
.	O

Both	O
treatments	O
are	O
also	O
equally	O
effective	O
for	O
the	O
difficult	O
to	O
treat	O
subgroup	O
of	O
patients	O
with	O
chronic	O
depression	O
and	O
a	O
history	O
of	O
childhood	O
maltreatment	O
.	O

Childhood	O
maltreatment	O
may	O
result	O
in	O
a	O
longer	O
latency	O
of	O
treatment	O
response	O
in	O
the	O
case	O
of	O
psychotherapy	O
.	O

Starvation	O
-	O
and	O
antibiotics	O
-induced	O
formation	O
of	O
persister	O
cells	O
in	O
Pseudomonas	O
aeruginosa	O
.	O

Planktonic	O
stationary	B-P
and	I-P
exponential	I-P
cultures	I-P
of	O
Pseudomonas	O
aeruginosa	O
are	O
highly	O
resistant	O
to	O
killing	O
by	O
bactericidal	O
antimicrobials	O
because	O
of	O
the	O
presence	O
of	O
persisters	O
,	O
cells	O
that	O
are	O
multidrug	O
tolerant	O
and	O
play	O
a	O
key	O
role	O
in	O
the	O
recalcitrance	O
of	O
biofilm	O
infections	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
formation	O
of	O
persister	O
cells	O
in	O
P.	O
aeruginosa	O
stationary	B-P
vs.	O
exponential	B-P
cultures	I-P
using	O
different	O
class	O
antimicrobials	O
.	O

The	O
susceptibilities	O
of	O
P.	O
aeruginosa	O
PAO1	O
wild-type	O
and	O
mutant	O
strains	O
to	O
antimicrobials	O
were	O
determined	O
by	O
standard	B-P
microtiter	I-P
broth	I-P
dilution	I-P
method	I-P
.	O

In	O
order	O
to	O
determine	O
persister	O
formation	O
,	O
dose	O
-	O
and	O
time	O
-dependent	O
killing	B-P
experiments	I-P
were	O
performed	O
with	O
antibiotics	O
.	O

Ceftazidime	O
(	O
Cephalosporin	O
)	O
showed	O
little	O
efficacy	O
against	O
either	O
culture	B-P
.	O

Stationary-phase	O
cells	O
were	O
more	O
tolerant	O
to	O
imipenem	O
(	O
Carbapenem	O
)	O
than	O
exponential	O
cells	O
,	O
leaving	O
a	O
small	O
fraction	O
of	O
persisters	O
at	O
high	O
imipenem	O
concentration	O
in	O
both	O
populations	O
.	O

Polymyxin	O
B	O
(	O
Polymyxin	O
)	O
appeared	O
to	O
be	O
ineffective	O
at	O
low	O
concentrations	O
against	O
both	O
cell	O
populations	O
.	O

Very	O
high	O
polymyxin	O
B	O
concentration	O
completely	O
eradicated	O
exponential	O
cells	O
and	O
regrowth	O
was	O
seen	O
in	O
a	O
stationary	O
population	O
.	O

Stationary	O
cells	O
were	O
more	O
tolerant	O
to	O
tobramycin	O
(	O
Aminoglycoside	O
)	O
than	O
exponential	O
cells	O
but	O
a	O
higher	O
concentration	O
of	O
tobramycin	O
completely	O
eliminated	O
survivors	O
.	O

Ciprofloxacin	O
(	O
Fluoroquinolone	O
)	O
at	O
a	O
low	O
concentration	O
resulted	O
in	O
killing	O
of	O
both	O
cultures	B-P
of	O
P.	O
aeruginosa	O
,	O
producing	O
persisters	O
that	O
were	O
invulnerable	O
to	O
killing	O
.	O

Stationary	O
cells	O
appear	O
to	O
be	O
somewhat	O
more	O
tolerant	O
than	O
exponential	O
cells	O
in	O
all	O
of	O
these	O
assays	B-P
.	O

We	O
also	O
showed	O
that	O
nutrient	O
deprivation	O
(	O
serine	O
starvation	O
)	O
regulated	O
by	O
stringent	O
and	O
general	O
stress	O
response	O
,	O
contribute	O
to	O
the	O
increased	O
tolerance	O
of	O
P.	O
aeruginosa	O
exponential	O
and	O
stationary	O
planktonic	O
cells	O
via	O
production	O
of	O
persisters	O
.	O

BRG1	O
in	O
the	O
Nucleus	O
Accumbens	O
Regulates	O
Cocaine-Seeking	O
Behavior	O
.	O

Drug	O
addiction	O
is	O
defined	O
as	O
a	O
chronic	O
disease	O
characterized	O
by	O
compulsive	O
drug	O
seeking	O
and	O
episodes	O
of	O
relapse	O
despite	O
prolonged	O
periods	O
of	O
drug	O
abstinence	O
.	O

Neurobiological	O
adaptations	O
,	O
including	O
transcriptional	O
and	O
epigenetic	O
alterations	O
in	O
the	O
nucleus	O
accumbens	O
,	O
are	O
thought	O
to	O
contribute	O
to	O
this	O
life-long	O
disease	O
state	O
.	O

We	O
previously	O
demonstrated	O
that	O
the	O
transcription	O
factor	O
SMAD3	O
is	O
increased	O
after	O
7	O
days	O
of	O
withdrawal	O
from	O
cocaine	O
self-administration	O
.	O

However	O
,	O
it	O
is	O
still	O
unknown	O
which	O
additional	O
factors	O
participate	O
in	O
the	O
process	O
of	O
chromatin	O
remodeling	O
and	O
facilitate	O
the	O
binding	O
of	O
SMAD3	O
to	O
promoter	O
regions	O
of	O
target	O
genes	O
.	O

Here	O
,	O
we	O
examined	O
the	O
possible	O
interaction	O
of	O
BRG1	O
-also	O
known	O
as	O
SMARCA4	O
,	O
an	O
adenosine	O
triphosphatase	O
-containing	O
chromatin	O
remodeler	O
-and	O
SMAD3	O
in	O
response	O
to	O
cocaine	O
exposure	O
.	O

The	O
expression	O
of	O
BRG1	O
,	O
as	O
well	O
as	O
its	O
binding	O
to	O
SMAD3	O
and	O
target	O
gene	O
promoter	O
regions	O
,	O
was	O
evaluated	O
in	O
the	O
nucleus	O
accumbens	O
and	O
dorsal	O
striatum	O
of	O
rats	O
using	O
western	O
blotting	O
,	O
co-immunoprecipitation	B-P
,	O
and	O
chromatin	B-P
immunoprecipitation	I-P
following	O
abstinence	O
from	O
cocaine	O
self-administration	O
.	O

Rats	O
were	O
assessed	O
for	O
cocaine-seeking	O
behaviors	O
after	O
either	O
intra-accumbal	O
injections	O
of	O
the	O
BRG1	O
inhibitor	O
PFI3	O
or	O
viral-mediated	O
overexpression	O
of	O
BRG1	O
.	O

After	O
withdrawal	O
from	O
cocaine	O
self-administration	O
,	O
BRG1	O
expression	O
and	O
complex	O
formation	O
with	O
SMAD3	O
are	O
increased	O
in	O
the	O
nucleus	O
accumbens	O
,	O
resulting	O
in	O
increased	O
binding	O
of	O
BRG1	O
to	O
the	O
promoter	O
regions	O
of	O
Ctnnb1	O
,	O
Mef2d	O
,	O
and	O
Dbn1	O
.	O

Intra-accumbal	O
infusion	O
of	O
PFI3	O
attenuated	O
,	O
whereas	O
viral	O
overexpression	O
of	O
Brg1	O
enhanced	O
,	O
cocaine-reinstatement	O
behavior	O
.	O

BRG1	O
is	O
a	O
key	O
mediator	O
of	O
the	O
SMAD3	O
-dependent	O
regulation	O
of	O
cellular	O
and	O
behavioral	O
plasticity	O
that	O
mediates	O
cocaine	O
seeking	O
after	O
a	O
period	O
of	O
withdrawal	O
.	O

Theranostic	O
Upconversion	O
Nanobeacons	O
for	O
Tumor	O
mRNA	O
Ratiometric	B-P
Fluorescence	I-P
Detection	I-P
and	O
Imaging	B-P
-	O
Monitored	O
Drug	O
Delivery	O
.	O

Remote	O
optical	O
detection	O
and	O
imaging	B-P
of	O
specific	O
tumor	O
-related	O
biomarkers	O
and	O
simultaneous	O
activation	O
of	O
therapy	O
according	O
to	O
the	O
expression	O
level	O
of	O
the	O
biomarkers	O
in	O
tumor	O
site	O
with	O
theranostic	O
probes	O
should	O
be	O
an	O
effective	O
modality	O
for	O
treatment	O
of	O
cancers	O
.	O

Herein	O
,	O
an	O
upconversion	O
nanobeacon	O
(	O
UCNPs	O
-	O
MB	O
/	O
Dox	O
)	O
is	O
proposed	O
as	O
a	O
new	O
theranostic	O
nanoprobe	O
to	O
ratiometrically	O
detect	O
and	O
visualize	O
the	O
thymidine	O
kinase	O
1	O
(	O
TK1	O
)	O
mRNA	O
that	O
can	O
simultaneously	O
trigger	O
the	O
Dox	O
release	O
to	O
activate	O
the	O
chemotherapy	O
accordingly	O
.	O

UCNPs	O
-	O
MB	O
/	O
Dox	O
is	O
constructed	O
with	O
the	O
conjugation	O
of	O
a	O
TK1	O
mRNA	O
-specific	O
molecular	O
beacon	O
(	O
MB	O
)	O
bearing	O
a	O
quencher	O
(	O
BHQ-1	O
)	O
and	O
an	O
alkene	O
handle	O
modified	O
upconversion	O
nanoparticle	O
(	O
UCNP	O
)	O
through	O
click	O
reaction	O
and	O
subsequently	O
loading	O
with	O
a	O
chemotherapy	O
drug	O
(	O
Dox	O
)	O
.	O

With	O
this	O
nanobeacon	O
,	O
quantitative	O
ratiometric	O
upconversion	O
detection	O
of	O
the	O
target	O
with	O
high	O
sensitivity	O
and	O
selectivity	O
as	O
well	O
as	O
the	O
target	O
triggered	O
Dox	O
release	O
in	O
vitro	O
is	O
demonstrated	B-P
.	O

The	O
sensitive	O
and	O
selective	O
ratiometric	O
detection	O
and	O
imaging	B-P
of	O
TK1	O
mRNA	O
under	O
the	O
irradiation	O
of	O
near	O
infrared	O
light	O
(	O
980	O
nm	O
)	O
and	O
the	O
mRNA	O
-dependent	O
release	O
of	O
Dox	O
for	O
chemotherapy	O
in	O
the	O
tumor	O
MCF-7	O
cells	O
and	O
A549	O
cells	O
are	O
also	O
shown	O
.	O

This	O
work	O
provides	O
a	O
smart	O
and	O
robust	O
platform	O
for	O
gene	O
-related	O
tumor	O
theranostics	O
.	O

Influence	O
of	O
increased	O
epicardial	O
adipose	O
tissue	O
volume	O
on	O
1-year	O
in-stent	O
restenosis	O
in	O
patients	O
who	O
received	O
coronary	O
stent	O
implantation	O
.	O

Epicardial	O
adipose	O
tissue	O
(	O
EAT	O
)	O
is	O
significantly	O
associated	O
with	O
the	O
formation	O
and	O
composition	O
of	O
coronary	O
atherosclerotic	O
plaque	O
,	O
cardiac	O
events	O
and	O
the	O
clinical	O
prognosis	O
of	O
coronary	O
heart	O
disease	O
.	O

But	O
,	O
whether	O
increased	O
EAT	O
deposition	O
may	O
affect	O
the	O
incidence	O
of	O
in-stent	O
restenosis	O
(	O
ISR	O
)	O
is	O
currently	O
unclear	O
.	O

This	O
study	O
used	O
coronary	B-P
computed	I-P
tomography	I-P
angiography	I-P
(	O
CCTA	B-P
)	O
as	O
a	O
mean	O
to	O
investigate	O
whether	O
increased	O
EAT	O
volume	O
was	O
associated	O
with	O
ISR	O
.	O

A	O
total	O
of	O
364	O
patients	O
who	O
underwent	O
64-slice	B-P
CCTA	I-P
examination	O
for	O
the	O
evaluation	O
of	O
suspected	O
coronary	O
artery	O
disease	O
,	O
and	O
subsequently	O
underwent	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
for	O
the	O
first	O
time	O
,	O
and	O
then	O
accepted	O
coronary	B-P
angiography	I-P
(	O
CA	B-P
)	O
follow-up	O
for	O
ISR	O
examination	O
in	O
one	O
year	O
,	O
were	O
retrospectively	O
included	O
in	O
this	O
study	O
.	O

EAT	O
volume	O
was	O
measured	O
by	O
CCTA	B-P
examination	O
.	O

CA	B-P
follow-up	O
was	O
obtained	O
between	O
9	O
and	O
15	O
months	O
.	O

ISR	O
was	O
deﬁned	O
as	O
≥	O
50	O
%	O
luminal	O
diameter	O
narrowing	O
of	O
the	O
stent	O
segment	O
or	O
peri-stent	O
segment	O
.	O

EAT	O
volume	O
was	O
compared	O
between	O
patients	O
with	O
and	O
without	O
ISR	O
and	O
additional	O
well-known	O
predictors	O
of	O
ISR	O
were	O
compared	O
.	O

EAT	O
volume	O
was	O
signiﬁcantly	O
increased	O
in	O
patients	O
with	O
ISR	O
compared	O
with	O
those	O
without	O
ISR	O
(	O
154.5	O
±	O
74.6	O
mL	O
vs.	O
131.0	O
±	O
52.2	O
mL	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
relation	O
between	O
ISR	O
and	O
EAT	O
volume	O
remained	O
signiﬁcant	O
after	O
adjustment	O
for	O
conventional	O
cardiovascular	O
risk	O
factors	O
and	O
angiographic	O
parameters	O
.	O

EAT	O
volume	O
was	O
related	O
with	O
ISR	O
and	O
may	O
provide	O
additional	O
information	O
for	O
future	O
ISR	O
.	O

Effect	O
of	O
ultrasound	O
and	O
enzymatic	O
pre-treatment	O
on	O
yield	O
and	O
properties	O
of	O
banana	O
juice	O
.	O

Effect	O
of	O
ultrasound	O
and	O
enzymatic	O
pre-treatments	O
with	O
cellulase	O
and	O
pectinase	O
on	O
yield	O
and	O
properties	O
of	O
banana	O
juice	O
were	O
investigated	O
.	O

A	O
two-level	O
full	O
factorial	O
design	O
was	O
employed	O
.	O

The	O
factors	O
selected	O
were	O
ultrasonication	O
time	O
(	O
0	O
and	O
30	O
min	O
)	O
,	O
cellulase	O
concentration	O
(	O
0	O
and	O
0.2	O
%	O
)	O
and	O
pectinase	O
concentration	O
(	O
0	O
and	O
0.2	O
%	O
)	O
.	O

The	O
responses	O
studied	O
were	O
yield	O
,	O
viscosity	O
,	O
clarity	B-P
,	O
total	O
soluble	O
solids	O
(	O
TSS	O
)	O
and	O
pH	O
.	O

It	O
was	O
observed	O
that	O
pectinase	O
was	O
more	O
effective	O
in	O
increasing	O
the	O
yield	O
of	O
juice	O
compared	O
to	O
cellulase	O
.	O

Ultrasonic	O
pre-treatment	O
alone	O
did	O
not	O
significantly	O
increase	O
the	O
yield	O
of	O
juice	O
.	O

When	O
ultrasound	O
was	O
combined	O
with	O
pre-treatment	O
with	O
both	O
the	O
enzymes	O
maximum	O
yield	O
of	O
89.40	O
%	O
was	O
obtained	O
compared	O
to	O
47.30	O
%	O
in	O
the	O
control	O
.	O

The	O
viscosity	O
of	O
the	O
juice	O
decreased	O
with	O
addition	O
of	O
enzymes	O
and	O
with	O
application	O
of	O
ultrasound	O
.	O

The	O
clarity	O
of	O
the	O
juice	O
was	O
not	O
affected	O
by	O
cellulase	O
treatment	O
,	O
but	O
improved	O
with	O
pectinase	O
treatment	O
.	O

Ultrasonication	O
alone	O
was	O
found	O
to	O
be	O
more	O
effective	O
than	O
pectinase	O
or	O
cellulase	O
treatment	O
in	O
improving	O
the	O
clarity	O
of	O
the	O
juice	O
.	O

The	O
TSS	O
increased	O
with	O
enzymatic	O
treatment	O
,	O
ultrasonication	O
and	O
their	O
combination	O
.	O

pH	O
was	O
not	O
affected	O
by	O
treatment	O
type	O
,	O
but	O
was	O
found	O
to	O
be	O
lower	O
for	O
the	O
treated	O
juices	O
.	O

Significant	O
correlations	O
were	O
observed	O
between	O
the	O
various	O
responses	O
.	O

Investigating	O
Effects	O
of	O
Acidic	O
pH	O
on	O
Proliferation	O
,	O
Invasion	O
and	O
Drug	O
-	O
Induced	O
Apoptosis	O
in	O
Lymphoblastic	O
Leukemia	O
.	O

Some	O
studies	O
have	O
shown	O
that	O
extracellular	O
pH	O
in	O
tumors	O
,	O
which	O
results	O
in	O
tumor	O
progression	O
,	O
is	O
less	O
than	O
that	O
in	O
normal	O
tissues	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
extracellular	O
acidic	O
pH	O
on	O
proliferation	O
,	O
invasion	O
,	O
and	O
drug	O
-	O
induced	O
apoptosis	O
in	O
acute	O
lymphoblastic	O
cells	O
.	O

The	O
cells	O
were	O
cultured	O
in	O
different	O
pH	O
(	O
pH	O
6.6	O
and	O
pH	O
7.4	O
)	O
for	O
12	O
days	O
.	O

Cell	O
proliferation	O
was	O
assessed	O
by	O
MTT	O
assay	O
and	O
cell	O
invasion	O
was	O
assayed	O
by	O
invasion	B-P
assay	I-P
and	O
gene	O
expression	O
analysis	O
of	O
MMP-9	O
.	O

Drug	O
-	O
induced	O
apoptosis	O
was	O
evaluated	O
after	O
exposure	O
to	O
doxorubicin	O
for	O
24	O
hours	O
by	O
annexin	O
V	O
/	O
PI	O
staining	B-P
and	O
gene	O
expression	O
analysis	O
of	O
BAX	O
pro-apoptotic	O
protein	O
.	O

The	O
results	O
indicated	O
the	O
enhanced	O
growth	O
and	O
invasion	O
of	O
leukemic	O
cells	O
at	O
pH	O
6.6	O
(	O
P	O
≤	O
0.05	O
)	O
.	O

Furthermore	O
,	O
the	O
cells	O
at	O
pH	O
6.6	O
were	O
resistant	O
to	O
apoptosis	O
by	O
doxorubicin	O
(	O
P	O
≤	O
0.05	O
)	O
.	O

It	O
can	O
be	O
concluded	O
that	O
acidic	O
pH	O
increases	O
the	O
proliferation	O
,	O
invasion	O
and	O
reduces	O
the	O
drug	O
-	O
induced	O
apoptosis	O
in	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Extracellular	O
acidity	O
can	O
influence	O
the	O
behavior	O
of	O
leukemic	O
cells	O
and	O
therefore	O
,	O
the	O
manipulation	O
of	O
extracellular	O
liquid	O
can	O
be	O
selected	O
as	O
a	O
therapeutic	O
strategy	O
for	O
leukemia	O
,	O
especially	O
for	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Extracellular	O
Self-Assembly	O
of	O
Functional	O
and	O
Tunable	O
Protein	O
Conjugates	O
from	O
Bacillus	O
subtilis	O
.	O

The	O
ability	O
to	O
stably	O
and	O
specifically	O
conjugate	O
recombinant	O
proteins	O
to	O
one	O
another	O
is	O
a	O
powerful	O
approach	O
for	O
engineering	O
multifunctional	O
enzymes	O
,	O
protein	O
therapeutics	O
,	O
and	O
novel	O
biological	O
materials	O
.	O

While	O
many	O
of	O
these	O
applications	O
have	O
been	O
illustrated	O
through	O
in	O
vitro	O
and	O
in	O
vivo	O
intracellular	O
protein	O
conjugation	O
methods	O
,	O
extracellular	O
self-assembly	O
of	O
protein	O
conjugates	O
offers	O
unique	O
advantages	O
:	O
simplifying	O
purification	B-P
,	O
reducing	O
toxicity	O
and	O
burden	O
,	O
and	O
enabling	O
tunability	O
.	O

Exploiting	O
the	O
recently	O
described	O
SpyTag-SpyCatcher	B-P
system	I-P
,	O
we	O
describe	O
here	O
how	O
enzymes	O
and	O
structural	O
proteins	O
can	O
be	O
genetically	O
encoded	O
to	O
covalently	O
conjugate	O
in	O
culture	O
media	O
following	O
programmable	O
secretion	O
from	O
Bacillus	O
subtilis	O
.	O

Using	O
this	O
approach	O
,	O
we	O
demonstrate	O
how	O
self-conjugation	O
of	O
a	O
secreted	O
industrial	O
enzyme	O
,	O
XynA	O
,	O
dramatically	O
increases	O
its	O
resilience	O
to	O
boiling	O
,	O
and	O
we	O
show	O
that	O
cellular	O
consortia	O
can	O
be	O
engineered	O
to	O
self-assemble	O
functional	O
protein-protein	O
conjugates	O
with	O
tunable	O
composition	O
.	O

This	O
novel	O
genetically	O
encoded	O
modular	O
system	O
provides	O
a	O
flexible	O
strategy	O
for	O
protein	O
conjugation	O
harnessing	O
the	O
substantial	O
advantages	O
of	O
extracellular	O
self-assembly	O
.	O

Alpha-particle	O
fluence	O
in	O
radiobiological	O
experiments	O
.	O

Two	O
methods	O
were	O
proposed	O
for	O
determining	O
alpha-particle	O
fluence	O
for	O
radiobiological	O
experiments	O
.	O

The	O
first	O
involved	O
calculating	O
the	O
probabilities	O
of	O
hitting	O
the	O
target	O
for	O
alpha	O
particles	O
emitted	O
from	O
a	O
source	O
through	O
Monte	O
Carlo	O
simulations	O
,	O
which	O
when	O
multiplied	O
by	O
the	O
activity	O
of	O
the	O
source	O
gave	O
the	O
fluence	O
at	O
the	O
target	O
.	O

The	O
second	O
relied	O
on	O
the	O
number	O
of	O
chemically	O
etched	O
alpha-particle	O
tracks	O
developed	O
on	O
a	O
solid-state	O
nuclear	O
track	O
detector	O
(	O
SSNTD	O
)	O
that	O
was	O
irradiated	O
by	O
an	O
alpha-particle	O
source	O
.	O

The	O
etching	O
efficiencies	O
(	O
defined	O
as	O
percentages	O
of	O
latent	O
tracks	O
created	O
by	O
alpha	O
particles	O
from	O
the	O
source	O
that	O
could	O
develop	O
to	O
become	O
visible	O
tracks	O
upon	O
chemical	O
etching	O
)	O
were	O
computed	B-P
through	O
Monte	O
Carlo	O
simulations	O
,	O
which	O
when	O
multiplied	O
by	O
the	O
experimentally	O
counted	O
number	O
of	O
visible	O
tracks	O
would	O
also	O
give	O
the	O
fluence	O
at	O
the	O
target	O
.	O

We	O
studied	O
alpha	O
particles	O
with	O
an	O
energy	O
of	O
5.486	O
MeV	O
emitted	O
from	O
an	O
241Am	O
source	O
,	O
and	O
considered	O
the	O
alpha-particle	O
tracks	O
developed	O
on	O
polyallyldiglycol	O
carbonate	O
film	O
,	O
which	O
is	O
a	O
common	O
SSNTD	O
.	O

Our	O
results	O
showed	O
that	O
the	O
etching	O
efficiencies	O
were	O
equal	O
to	O
one	O
for	O
source	O
-	O
film	O
distances	O
of	O
from	O
0.6	O
to	O
3.5	O
cm	O
for	O
a	O
circular	O
film	O
of	O
radius	O
of	O
1	O
cm	O
,	O
and	O
for	O
source	O
-	O
film	O
distances	O
of	O
from	O
1	O
to	O
3	O
cm	O
for	O
circular	O
film	O
of	O
radius	O
of	O
2	O
cm	O
.	O

For	O
circular	O
film	O
with	O
a	O
radius	O
of	O
3	O
cm	O
,	O
the	O
etching	O
efficiencies	O
never	O
reached	O
1	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
hit	O
probability	O
decreased	O
monotonically	O
with	O
increase	O
in	O
the	O
source	O
-	O
target	O
distance	O
,	O
and	O
fell	O
to	O
zero	O
when	O
the	O
source	O
-	O
target	O
distance	O
was	O
larger	O
than	O
the	O
particle	O
range	O
in	O
air	O
.	O

Why	O
being	O
an	O
expert	O
-	O
despite	O
xpert	B-P
-remains	O
crucial	O
for	O
children	O
in	O
high	O
TB	O
burden	O
settings	O
.	O

As	O
access	O
to	O
Xpert	B-P
expands	O
in	O
high	O
TB-burden	O
settings	O
,	O
its	O
performance	O
against	O
clinically	B-P
diagnosed	I-P
TB	O
as	O
a	O
reference	O
standard	O
provides	O
important	O
insight	O
as	O
the	O
majority	O
of	O
childhood	O
TB	O
is	O
bacteriologically	O
unconfirmed	O
.	O

We	O
aim	O
to	O
describe	O
the	O
characteristics	O
and	O
outcomes	O
of	O
children	O
with	O
presumptive	O
TB	O
and	O
TB	O
disease	O
,	O
and	O
assess	O
performance	O
of	O
Xpert	B-P
under	O
programmatic	O
conditions	O
against	O
a	O
clinical	B-P
diagnosis	I-P
of	O
TB	O
as	O
a	O
reference	O
standard	O
.	O

Retrospective	O
review	O
of	O
children	O
evaluated	O
for	O
presumptive	O
TB	O
in	O
Mbeya	O
,	O
Tanzania	O
.	O

Baseline	O
characteristics	O
were	O
compared	O
by	O
TB	O
disease	O
status	O
and	O
,	O
for	O
patients	O
diagnosed	B-P
with	O
TB	O
,	O
by	O
TB	O
confirmation	O
status	O
using	O
Wilcoxon	O
rank	O
sum	O
test	O
for	O
continuous	O
variables	O
and	O
the	O
Chi-square	O
test	O
for	O
categorical	O
variables	O
.	O

Sensitivity	O
and	O
specificity	O
were	O
calculated	O
to	O
assess	O
the	O
performance	O
of	O
Xpert	B-P
,	O
smear	B-P
,	O
and	O
culture	B-P
against	O
clinical	O
TB	O
.	O

Kappa	O
statistics	O
were	O
calculated	O
to	O
assess	O
agreement	O
between	O
Xpert	B-P
and	O
smear	B-P
to	O
culture	B-P
.	O

Among	O
children	O
(	O
N	O
=	O
455	O
)	O
evaluated	O
for	O
presumptive	O
TB	O
,	O
70.3	O
%	O
(	O
320/455	O
)	O
had	O
Xpert	B-P
and	O
62.8	O
%	O
(	O
286/455	O
)	O
had	O
culture	B-P
performed	O
on	O
sputa	O
.	O

34.5	O
%	O
(	O
157/455	O
)	O
were	O
diagnosed	B-P
with	O
TB	O
:	O
80.3	O
%	O
(	O
126/157	O
)	O
pulmonary	O
TB	O
,	O
13.4	O
%	O
(	O
21/157	O
)	O
bacteriologically	O
confirmed	O
,	O
53.5	O
%	O
(	O
84/157	O
)	O
HIV	O
positive	O
,	O
and	O
48.4	O
%	O
(	O
76/157	O
)	O
inpatients	O
.	O

Compared	O
to	O
the	O
reference	O
standard	O
of	O
clinical	B-P
diagnosis	I-P
,	O
sensitivity	O
of	O
Xpert	B-P
was	O
8	O
%	O
(	O
95	O
%	O
CI	O
4-15	O
)	O
,	O
smear	B-P
6	O
%	O
(	O
95	O
%	O
CI	O
3-12	O
)	O
and	O
culture	B-P
16	O
%	O
(	O
95	O
%	O
CI	O
9-24	O
)	O
,	O
and	O
did	O
not	O
differ	O
based	O
on	O
patient	O
disposition	O
,	O
nutrition	O
or	O
HIV	O
status	O
.	O

Despite	O
access	O
to	O
Xpert	B-P
,	O
the	O
majority	O
of	O
children	O
with	O
presumptive	O
TB	O
were	O
treated	O
based	O
on	O
clinical	B-P
diagnosis	I-P
.	O

Reflecting	O
the	O
reality	O
of	O
clinical	O
practice	O
in	O
resource	O
limited	O
settings	O
,	O
new	O
diagnostics	B-P
such	O
as	O
Xpert	B-P
serve	O
as	O
important	O
adjunctive	O
tests	O
but	O
will	O
not	O
obviate	O
the	O
need	O
for	O
astute	O
clinicians	O
and	O
comprehensive	O
diagnostic	O
algorithms	O
.	O

Development	O
and	O
Validation	O
of	O
a	O
New	O
Reliable	O
Method	B-P
for	O
the	O
Diagnosis	O
of	O
Avian	O
Botulism	O
.	O

Liver	O
is	O
a	O
reliable	O
matrix	O
for	O
laboratory	B-P
confirmation	O
of	O
avian	O
botulism	O
using	O
real-time	O
PCR	O
.	O

Here	O
,	O
we	O
developed	O
,	O
optimized	O
,	O
and	O
validated	O
the	O
analytical	O
steps	O
preceding	O
PCR	O
to	O
maximize	O
the	O
detection	O
of	O
Clostridium	O
botulinum	O
group	O
III	O
in	O
avian	O
liver	O
.	O

These	O
pre	O
-	O
PCR	O
steps	O
included	O
enrichment	O
incubation	B-P
of	O
the	O
whole	O
liver	O
(	O
maximum	O
25	O
g	O
)	O
at	O
37°C	B-P
for	O
at	O
least	O
24	O
h	O
in	O
an	O
anaerobic	O
chamber	O
and	O
DNA	O
extraction	O
using	O
an	O
enzymatic	B-P
digestion	I-P
step	O
followed	O
by	O
a	O
DNA	B-P
purification	I-P
step	O
.	O

Conditions	O
of	O
sample	O
storage	O
before	O
analysis	O
appear	O
to	O
have	O
a	O
strong	O
effect	O
on	O
the	O
detection	O
of	O
group	O
III	O
C.	O
botulinum	O
strains	O
and	O
our	O
results	O
recommend	O
storage	O
at	O
temperatures	O
below	O
-18°C	O
.	O

Short-term	O
storage	O
at	O
5°C	O
is	O
possible	O
for	O
up	O
to	O
24	O
h	O
,	O
but	O
a	O
decrease	O
in	O
sensitivity	O
was	O
observed	O
at	O
48	O
h	O
of	O
storage	O
at	O
this	O
temperature	O
.	O

Analysis	O
of	O
whole	O
livers	O
(	O
maximum	O
25	O
g	O
)	O
is	O
required	O
and	O
pooling	O
samples	O
before	O
enrichment	B-P
culturing	I-P
must	O
be	O
avoided	O
.	O

Pooling	O
is	O
however	O
possible	O
before	O
or	O
after	O
DNA	O
extraction	O
under	O
certain	O
conditions	O
.	O

Whole	O
livers	O
should	O
be	O
10-fold	O
diluted	O
in	O
enrichment	O
medium	O
and	O
homogenized	O
using	O
a	O
Pulsifier®	O
blender	O
(	O
Microgen	O
,	O
Surrey	O
,	O
UK	O
)	O
instead	O
of	O
a	O
conventional	O
paddle	O
blender	O
.	O

Spiked	O
liver	O
samples	O
showed	O
a	O
limit	O
of	O
detection	O
of	O
5	O
spores	O
/g	O
liver	O
for	O
types	O
C	O
and	O
D	O
and	O
250	O
spores	O
/g	O
for	O
type	O
E.	O
Using	O
the	O
method	B-P
developed	O
here	O
,	O
the	O
analysis	O
of	O
268	O
samples	O
from	O
73	O
suspected	O
outbreaks	O
showed	O
100	O
%	O
specificity	O
and	O
95.35	O
%	O
sensitivity	O
compared	O
with	O
other	O
PCR	O
-based	O
methods	B-P
considered	O
as	O
reference	O
.	O

The	O
mosaic	O
type	O
C	O
/	O
D	O
was	O
the	O
most	O
common	O
neurotoxin	O
type	O
found	O
in	O
examined	O
samples	O
,	O
which	O
included	O
both	O
wild	O
and	O
domestic	O
birds	O
.	O

Sewage	O
sludge	O
pretreatment	O
by	O
microwave	O
irradiation	O
combined	O
with	O
activated	O
carbon	O
fibre	O
at	O
alkaline	O
pH	O
for	O
anaerobic	O
digestion	O
.	O

This	O
research	O
focuses	O
on	O
the	O
effects	O
of	O
microwave	O
-assisted	O
activated	O
carbon	O
fibre	O
(	O
ACF	O
)	O
(	O
MW	O
-	O
ACF	O
)	O
treatment	O
on	O
sewage	O
sludge	O
at	O
alkaline	O
pH	O
.	O

The	O
disintegration	O
and	O
biodegradability	O
of	O
sewage	O
sludge	O
were	O
studied	O
.	O

It	O
was	O
found	O
that	O
the	O
MW-ACF	O
process	O
at	O
alkaline	O
pH	O
provided	O
a	O
rapid	O
and	O
efficient	O
process	O
to	O
disrupt	O
the	O
microbial	O
cells	O
in	O
the	O
sludge	O
.	O

The	O
results	O
suggested	O
that	O
when	O
irradiated	O
at	O
800	O
W	O
MW	O
for	O
110	O
s	O
with	O
a	O
dose	O
of	O
1.0	O
g	O
ACF	O
/g	O
solid	O
concentration	O
(	O
SS	O
)	O
at	O
pH	O
10.5	O
,	O
the	O
MW	O
-	O
ACF	O
pretreatment	O
achieved	O
55	O
%	O
SS	O
disintegration	O
,	O
23	O
%	O
greater	O
than	O
the	O
value	O
of	O
MW	O
alone	O
(	O
32	O
%	O
)	O
.	O

The	O
concentration	O
of	O
total	B-P
nitrogen	I-P
,	O
total	B-P
phosphorus	I-P
,	O
supernatant	B-P
soluble	I-P
chemical	I-P
oxygen	I-P
demand	I-P
,	O
protein	B-P
,	O
and	O
polysaccharide	O
increased	O
by	O
60	O
%	O
,	O
144	O
%	O
,	O
145	O
%	O
,	O
74	O
%	O
,	O
and	O
77	O
%	O
,	O
respectively	O
.	O

An	O
increase	O
in	O
biogas	O
production	O
by	O
63.7	O
%	O
was	O
achieved	O
after	O
20	O
days	O
of	O
anaerobic	O
digestion	O
(	O
AD	O
)	O
,	O
compared	O
to	O
the	O
control	O
.	O

The	O
results	O
indicated	O
that	O
the	O
MW-ACF	O
pretreatment	O
process	O
at	O
alkaline	O
pH	O
provides	O
novel	O
sludge	O
management	O
options	O
in	O
disintegration	O
of	O
sewage	O
sludge	O
for	O
further	O
AD	O
.	O

Estrogen	O
deficiency	O
accelerates	O
lumbar	O
facet	O
joints	O
arthritis	O
.	O

Dramatic	O
increase	O
in	O
the	O
prevalence	O
of	O
lumbar	O
facet	O
joint	O
(	O
LFJ	O
)	O
arthritis	O
in	O
women	O
around	O
the	O
age	O
of	O
menopause	O
indicates	O
a	O
protective	O
role	O
for	O
estrogen	O
in	O
LFJ	O
arthritis	O
.	O

To	O
date	O
,	O
there	O
is	O
no	O
evidence	O
for	O
this	O
indication	O
and	O
the	O
mechanism	O
of	O
such	O
an	O
effect	O
remains	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
ovariectomized	O
(	O
OVX	O
)	O
mice	O
were	O
used	O
to	O
mimic	O
the	O
estrogen	O
-	O
deficient	O
status	O
of	O
post-menopausal	O
women	O
.	O

Micro-CT	B-P
and	O
immunohistochemistry	B-P
was	O
employed	O
to	O
assess	O
the	O
morphological	O
and	O
molecular	O
changes	O
in	O
ovariectomy	O
-	O
induced	O
LFJ	O
arthritis	O
.	O

The	O
results	O
show	O
that	O
the	O
LFJ	O
subchondral	O
bone	O
mass	O
was	O
significantly	O
decreased	O
in	O
OVX	O
mice	O
,	O
with	O
increased	O
cavities	O
on	O
the	O
interface	O
of	O
the	O
subchondral	O
bone	O
.	O

Severe	O
cartilage	O
degradation	O
was	O
observed	O
in	O
ovariectomy	O
-	O
induced	O
LFJ	O
arthritis	O
.	O

Increased	O
blood	O
vessels	O
and	O
innervations	O
were	O
also	O
found	O
in	O
degenerated	O
LFJ	O
,	O
particularly	O
in	O
the	O
subchondral	O
bone	O
area	O
.	O

17β-Estradiol	O
treatment	O
efficiently	O
suppressed	O
LFJ	O
subchondral	O
bone	O
turnover	O
,	O
markedly	O
inhibited	O
cartilage	O
degradation	O
,	O
and	O
increased	O
blood	O
vessel	O
and	O
nerve	O
ending	O
growth	O
in	O
degenerated	O
LFJ	O
in	O
OVX	O
mice	O
.	O

Our	O
study	O
reveals	O
that	O
estrogen	O
is	O
a	O
key	O
factor	O
in	O
regulating	O
LFJ	O
metabolism	O
.	O

Severe	O
LFJ	O
degeneration	O
occurs	O
when	O
estrogen	O
is	O
absent	O
in	O
vivo	O
.	O

Collapsed	O
subchondral	O
bone	O
may	O
be	O
the	O
initiation	O
of	O
this	O
process	O
,	O
and	O
estrogen	O
replacement	O
therapy	O
can	O
effectively	O
prevent	O
degeneration	O
of	O
LFJ	O
under	O
estrogen	O
-	O
deficient	O
conditions	O
.	O

Transcriptome	B-P
sequencing	I-P
and	O
de	O
novo	O
characterization	O
of	O
Korean	O
endemic	O
land	O
snail	O
,	O
Koreanohadra	O
kurodana	O
for	O
functional	O
transcripts	O
and	O
SSR	O
markers	O
.	O

The	O
Korean	O
endemic	O
land	O
snail	O
Koreanohadra	O
kurodana	O
(	O
Gastropoda	O
:	O
Bradybaenidae	O
)	O
found	O
in	O
humid	O
areas	O
of	O
broadleaf	O
forests	O
and	O
shrubs	O
have	O
been	O
considered	O
vulnerable	O
as	O
the	O
number	O
of	O
individuals	O
are	O
declining	O
in	O
recent	O
years	O
.	O

The	O
species	O
is	O
poorly	O
characterized	O
at	O
the	O
genomic	O
level	O
that	O
limits	O
the	O
understanding	O
of	O
functions	O
at	O
the	O
molecular	O
and	O
genetics	O
level	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
performed	O
de	O
novo	O
transcriptome	B-P
sequencing	I-P
to	O
produce	O
a	O
comprehensive	O
transcript	O
dataset	O
of	O
visceral	O
mass	O
tissue	O
of	O
K.	O
kurodana	O
by	O
the	O
Illumina	O
paired-end	O
sequencing	O
technology	O
.	O

Over	O
234	O
million	O
quality	O
reads	O
were	O
assembled	O
to	O
a	O
total	O
of	O
315,924	O
contigs	O
and	O
191,071	O
unigenes	O
,	O
with	O
an	O
average	O
and	O
N50	O
length	O
of	O
585.6	O
and	O
715	O
bp	O
and	O
678	O
and	O
927	O
bp	O
,	O
respectively	O
.	O

Overall	O
,	O
36.32	O
%	O
of	O
the	O
unigenes	O
found	O
matches	O
to	O
known	O
protein	O
/	O
nucleotide	O
sequences	O
in	O
the	O
public	O
databases	O
.	O

The	O
direction	O
of	O
the	O
unigenes	O
to	O
functional	O
categories	O
was	O
determined	O
using	O
COG	O
,	O
GO	O
,	O
KEGG	O
,	O
and	O
InterProScan	O
protein	O
domain	O
search	O
.	O

The	O
GO	O
analysis	O
search	O
resulted	O
in	O
22,967	O
unigenes	O
(	O
12.02	O
%	O
)	O
being	O
categorized	O
into	O
40	O
functional	O
groups	O
.	O

The	O
KEGG	O
annotation	O
revealed	O
that	O
metabolism	O
pathway	O
genes	O
were	O
enriched	O
.	O

The	O
most	O
prominent	O
protein	O
motifs	O
include	O
the	O
zinc	O
finger	O
,	O
ribonuclease	O
H	O
,	O
reverse	O
transcriptase	O
,	O
and	O
ankyrin	O
repeat	O
domains	O
.	O

The	O
simple	O
sequence	O
repeats	O
(	O
SSRs	O
)	O
identified	O
from	O
>	O
1	O
kb	O
length	O
of	O
unigenes	O
show	O
a	O
dominancy	O
of	O
dinucleotide	O
repeat	O
motifs	O
followed	O
with	O
tri-	O
and	O
tetranucleotide	O
motifs	O
.	O

A	O
number	O
of	O
unigenes	O
were	O
putatively	O
assessed	O
to	O
belong	O
to	O
adaptation	O
and	O
defense	O
mechanisms	O
including	O
heat	O
shock	O
proteins	O
70	O
,	O
Toll-like	O
receptor	O
4	O
,	O
AMP-activated	O
protein	O
kinase	O
,	O
aquaporin-2	O
,	O
etc	O
.	O

Our	O
data	O
provide	O
a	O
rich	O
source	O
for	O
the	O
identification	O
and	O
functional	O
characterization	O
of	O
new	O
genes	O
and	O
candidate	O
polymorphic	O
SSR	O
markers	O
in	O
K.	O
kurodana	O
.	O

The	O
availability	O
of	O
transcriptome	O
information	O
(	O
http	O
:	O
//bioinfo.sch.ac.kr/submission/	O
)	O
would	O
promote	O
the	O
utilization	O
of	O
the	O
resources	O
for	O
phylogenetics	O
study	O
and	O
genetic	O
diversity	O
assessment	O
.	O

Pre-existing	O
renal	O
lesions	O
revealed	O
after	O
renal	O
trauma	O
,	O
Difficulties	O
in	O
diagnosis	O
and	O
accountability	O
:	O
About	O
14	O
cases	O
.	O

Pre-existing	O
renal	O
lesions	O
(	O
PERL	O
)	O
may	O
interfere	O
with	O
the	O
patho-physiology	O
of	O
trauma	O
,	O
alter	O
the	O
radiographic	B-P
imaging	I-P
and	O
influence	O
the	O
therapeutic	O
approach	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
record	O
the	O
PERL	O
found	O
incidentally	O
during	O
blunt	O
renal	O
trauma	O
,	O
to	O
specify	O
the	O
place	O
for	O
effective	O
conservative	O
management	O
and	O
to	O
determin	O
the	O
estimated	O
partial	O
permanent	O
disability	O
(	O
PPD	O
)	O
.	O

The	O
medical	O
records	O
of	O
14	O
patients	O
with	O
PERL	O
and	O
blunt	O
renal	O
trauma	O
were	O
reviewed	O
.	O

In	O
each	O
patient	O
,	O
pre-existing	O
renal	O
abnormalities	O
,	O
clinical	O
symptoms	O
,	O
CT	B-P
scan	I-P
study	O
findings	O
,	O
associated	O
injuries	O
,	O
therapeutic	O
approach	O
,	O
the	O
accountability	O
criteria	O
and	O
the	O
estimated	O
PPD	O
were	O
recorded	O
.	O

There	O
were	O
11	O
men	O
and	O
3	O
women	O
with	O
a	O
mean	O
age	O
of	O
35,6	O
years	O
(	O
range	O
19-66	O
years	O
)	O
.	O

Renal	O
trauma	O
was	O
due	O
to	O
a	O
traffic	O
accident	O
in	O
8	O
patients	O
.	O

Renal	O
damage	O
appeared	O
to	O
be	O
disproportionate	O
to	O
the	O
severity	O
of	O
the	O
trauma	O
(	O
minor	O
trauma	O
)	O
.	O

They	O
had	O
a	O
lower	O
rate	O
of	O
associated	O
trauma	O
to	O
other	O
abdominal	O
organs	O
(	O
four	O
patients	O
only	O
)	O
.	O

Urinary	O
stones	O
were	O
present	O
in	O
5	O
patients	O
,	O
pelvi-ureteric	O
junction	O
obstruction	O
in	O
3	O
,	O
horseshoe	O
kidny	O
in	O
3	O
,	O
ectopic	O
kidney	O
in	O
2	O
and	O
upper	O
urinary	O
tract	O
carcinoma	O
in	O
one	O
case	O
.	O

Early	O
nephrectomy	O
was	O
required	O
in	O
three	O
cases	O
for	O
hemodynamic	O
instability	O
.	O

Ureteral	O
stenting	O
was	O
indicated	O
in	O
3	O
cases	O
.	O

Six	O
patients	O
were	O
operated	O
later	O
because	O
of	O
their	O
underlying	O
renal	O
pathology	B-P
.	O

A	O
conservative	O
treatment	O
was	O
possible	O
only	O
in	O
7	O
of	O
cases	O
.	O

The	O
PPD	O
related	O
to	O
renal	O
trauma	O
varide	O
from	O
0	O
to	O
13	O
%	O
in	O
all	O
cases	O
.	O

PERL	O
may	O
complicate	O
a	O
negligible	O
renal	O
trauma	O
while	O
in	O
some	O
cases	O
they	O
may	O
be	O
of	O
vital	O
importance	O
for	O
the	O
patient	O
's	O
final	O
outcome	O
.	O

The	O
imaging	O
findings	O
are	O
crucial	O
but	O
may	O
be	O
confusing	O
.	O

The	O
therapeutic	O
approach	O
is	O
,	O
to	O
a	O
large	O
extent	O
,	O
dependent	O
on	O
the	O
type	O
of	O
PERL	O
and	O
the	O
severity	O
of	O
damage	O
,	O
and	O
is	O
often	O
conservative	O
in	O
the	O
hemo-dynamically	O
stable	O
patient	O
.	O

Accountability	O
link	O
may	O
be	O
difficult	O
to	O
establish	O
and	O
the	O
PPD	O
depends	O
on	O
the	O
PERL	O
and	O
the	O
renal	O
injuries	O
severity	O
.	O

We	O
have	O
no	O
involvement	O
with	O
funding	O
in	O
this	O
case	O
.	O

Ethical	O
approval	O
:	O
Not	O
required	O
Conflicts	O
of	O
interest	O
:	O
None	O
.	O

The	O
sensitivity	O
and	O
specifity	O
of	O
DR-70	O
immunoassay	B-P
as	O
a	O
tumor	O
marker	O
for	O
non-small	O
cell	O
lung	O
cancer	O
.	O

Lung	O
cancer	O
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	O
related	O
mortality	O
.	O

Patients	O
with	O
lung	O
cancer	O
are	O
usually	O
diagnosed	B-P
at	O
advanced	O
or	O
locally	O
advanced	O
stage	O
,	O
for	O
this	O
reason	O
early	B-P
diagnosis	I-P
of	O
lung	O
cancer	O
is	O
very	O
important	O
.	O

For	O
early	B-P
detection	I-P
of	O
lung	O
cancer	O
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low-dose	B-P
computed	I-P
tomography	I-P
or	O
tumor	O
biomarkers	O
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	O
DR-70	O
sensitivity	O
and	O
specificity	O
as	O
a	O
tumor	O
marker	O
in	O
detection	O
of	O
non-small	O
cell	O
lung	O
cancers	O
.	O

Between	O
May	O
2013	O
and	O
April	O
2014	O
,	O
the	O
serum	O
samples	O
from	O
88	O
non	O
lung	O
cancer	O
patients	O
,	O
86	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disesase	O
were	O
obtained	O
.	O

Blood	O
samples	O
from	O
each	O
participant	O
were	O
analyzed	O
for	O
DR-70	O
level	O
.	O

Totally	O
174	O
patients	O
were	O
enrolled	O
to	O
the	O
study	O
(	O
152	O
male	O
,	O
22	O
female	O
)	O
.	O

Histopathologically	O
47	O
(	O
53.4	O
%	O
)	O
patients	O
were	O
diagnosed	B-P
with	O
squamous	O
cell	O
lung	O
cancer	O
,	O
34	O
(	O
38.6	O
%	O
)	O
with	O
adenocarcinoma	O
,	O
and	O
7	O
(	O
8	O
%	O
)	O
with	O
non-small	O
cell	O
lung	O
cancer	O
.	O

The	O
mean	O
serum	O
DR-70	O
levels	O
in	O
lung	O
cancer	O
patients	O
(	O
2.43	O
±	O
1.82	O
µg/mL	O
)	O
was	O
significantly	O
higher	O
compared	O
to	O
the	O
86	O
non-cancerous	O
subjects	O
(	O
1.15	O
±	O
0.70	O
µg/mL	O
)	O
(	O
p	O
<	O
0.01	O
)	O
.	O

DR-70	O
exhibited	O
clinical	O
sensitivity	O
and	O
specificity	O
of	O
54.5	O
and	O
83.7	O
%	O
,	O
respectively	O
,	O
at	O
an	O
optimal	O
cut	O
off	O
at	O
1.98	O
µg/mL	O
.	O

It	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	O
is	O
6.171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
DR-70	O
level	O
is	O
1.98	O
µg/mL	O
and	O
higher	O
.	O

DR-70	O
,	O
a	O
marker	O
used	O
to	O
measure	O
fibrin	O
degradation	O
products	O
,	O
generated	O
by	O
all	O
major	O
cancers	O
,	O
may	O
helps	O
to	O
find	O
high	O
risk	O
lung	O
cancer	O
patients	O
.	O

Complete	O
Genome	O
Sequence	O
of	O
the	O
Largest	O
Known	O
Flavi-Like	O
Virus	O
,	O
Diaphorina	O
citri	O
flavi-like	O
virus	O
,	O
a	O
Novel	O
Virus	O
of	O
the	O
Asian	O
Citrus	O
Psyllid	O
,	O
Diaphorina	O
citri	O
.	O

A	O
novel	O
flavi-like	O
virus	O
tentatively	O
named	O
Diaphorina	O
citri	O
flavi-like	O
virus	O
(	O
DcFLV	O
)	O
was	O
identified	O
in	O
field	O
populations	O
of	O
Diaphorina	O
citri	O
through	O
small	O
RNA	O
and	O
transcriptome	B-P
sequencing	I-P
followed	O
by	O
reverse	O
transcription	O
(	O
RT	O
)	O
-PCR	O
.	O

We	O
report	O
here	O
the	O
complete	O
nucleotide	O
sequence	O
and	O
genome	O
organization	O
of	O
DcFLV	O
,	O
the	O
largest	O
flavi-like	O
virus	O
identified	O
to	O
date	O
.	O

Dural	O
Venous	O
Sinus	O
Diameters	O
in	O
Children	O
with	O
Sickle	O
Cell	O
Disease	O
:	O
Correlation	O
with	O
History	O
of	O
Stroke	O
in	O
a	O
Case-Control	O
Study	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
diameters	O
of	O
the	O
dural	O
venous	O
sinuses	O
(	O
DVSs	O
)	O
in	O
children	O
with	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
with	O
healthy	O
controls	O
and	O
determine	O
whether	O
the	O
size	O
has	O
any	O
correlation	O
to	O
history	O
of	O
cerebral	O
infarct	O
among	O
children	O
with	O
SCD	O
.	O

A	O
retrospective	O
review	O
compared	O
demographics	O
,	O
medical	O
history	O
and	O
magnetic	B-P
resonance	I-P
venography	I-P
(	O
MRV	B-P
)	O
findings	O
in	O
children	O
with	O
SCD	O
with	O
those	O
in	O
controls	O
.	O

Venous	O
sinus	O
diameters	O
were	O
measured	O
on	O
MRV	B-P
in	O
all	O
subjects	O
by	O
the	O
authors	O
,	O
who	O
were	O
blinded	O
to	O
the	O
children	O
's	O
clinical	O
history	O
.	O

The	O
study	O
cohort	O
included	O
38	O
MRVs	B-P
in	O
children	O
with	O
SCD	O
and	O
38	O
control	O
subjects	O
.	O

Statistical	O
comparison	O
showed	O
children	O
with	O
SCD	O
had	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
larger	O
DVS	O
diameters	O
than	O
controls	O
.	O

Among	O
children	O
with	O
SCD	O
with	O
a	O
history	O
of	O
stroke	O
or	O
silent	O
infarct	O
,	O
DVS	O
diameters	O
were	O
not	O
significantly	O
different	O
.	O

Children	O
with	O
SCD	O
had	O
larger	O
DVS	O
diameters	O
than	O
did	O
controls	O
,	O
regardless	O
of	O
the	O
former	O
group	O
's	O
history	O
of	O
cerebral	O
infarct	O
.	O

The	O
difference	O
in	O
size	O
of	O
venous	O
sinuses	O
is	O
important	O
to	O
be	O
aware	O
of	O
during	O
the	O
interpretation	O
of	O
neuroimaging	B-P
studies	O
to	O
avoid	O
unneeded	O
additional	O
imaging	B-P
or	O
referral	O
.	O

Genomic	B-P
analysis	I-P
of	O
nontypeable	O
pneumococci	O
causing	O
invasive	O
pneumococcal	O
disease	O
in	O
South	O
Africa	O
,	O
2003-2013	O
.	O

The	O
capsular	O
polysaccharide	O
is	O
the	O
principal	O
virulence	O
factor	O
of	O
Streptococcus	O
pneumoniae	O
and	O
a	O
target	O
for	O
current	O
pneumococcal	O
vaccines	O
.	O

However	O
,	O
some	O
pathogenic	O
pneumococci	O
are	O
serologically	O
nontypeable	O
[	O
nontypeable	O
pneumococci	O
(	O
NTPn	O
)	O
]	O
.	O

Due	O
to	O
their	O
relative	O
rarity	O
,	O
NTPn	O
are	O
poorly	O
characterized	O
,	O
and	O
,	O
as	O
such	O
,	O
limited	O
data	O
exist	O
which	O
describe	O
these	O
organisms	O
.	O

We	O
aimed	O
to	O
describe	O
disease	O
and	O
genotypically	O
characterize	O
NTPn	O
causing	O
invasive	O
pneumococcal	O
disease	O
in	O
South	O
Africa	O
.	O

Isolates	O
were	O
detected	O
through	O
national	O
,	O
laboratory	O
-	O
based	O
surveillance	O
for	O
invasive	O
pneumococcal	O
disease	O
in	O
South	O
Africa	O
and	O
characterized	O
by	O
whole	O
genome	B-P
analysis	I-P
.	O

We	O
predicted	O
ancestral	O
serotypes	O
(	O
serotypes	O
from	O
which	O
NTPn	O
may	O
have	O
originated	O
)	O
for	O
Group	O
I	O
NTPn	O
using	O
multilocus	O
sequence	O
typing	O
and	O
capsular	O
region	O
sequence	O
analyses	O
.	O

Antimicrobial	O
resistance	O
patterns	O
and	O
mutations	O
potentially	O
causing	O
nontypeability	O
were	O
identified	O
.	O

From	O
2003-2013	O
,	O
39	O
(	O
0.1	O
%	O
,	O
39/32,824	O
)	O
NTPn	O
were	O
reported	O
.	O

Twenty-two	O
(	O
56	O
%	O
)	O
had	O
partial	O
capsular	O
genes	O
(	O
Group	O
I	O
)	O
and	O
17	O
(	O
44	O
%	O
)	O
had	O
complete	O
capsular	O
deletion	O
of	O
which	O
15	O
had	O
replacement	O
by	O
other	O
genes	O
(	O
Group	O
II	O
)	O
.	O

Seventy-nine	O
percent	O
(	O
31/39	O
)	O
of	O
our	O
NTPn	O
isolates	O
were	O
derived	O
from	O
encapsulated	O
S.	O
pneumoniae	O
.	O

Ancestral	O
serotypes	O
1	O
(	O
27	O
%	O
,	O
6/22	O
)	O
and	O
8	O
(	O
14	O
%	O
,	O
3/22	O
)	O
were	O
most	O
prevalent	O
,	O
and	O
59	O
%	O
(	O
13/22	O
)	O
of	O
ancestral	O
serotypes	O
were	O
serotypes	O
included	O
in	O
the	O
13-valent	O
pneumococcal	O
conjugate	O
vaccine	O
.	O

We	O
identified	O
a	O
variety	O
of	O
mutations	O
within	O
the	O
capsular	O
region	O
of	O
Group	O
I	O
NTPn	O
,	O
some	O
of	O
which	O
may	O
be	O
responsible	O
for	O
the	O
nontypeable	O
phenotype	O
.	O

Nonsusceptibility	O
to	O
tetracycline	O
and	O
erythromycin	O
was	O
higher	O
in	O
NTPn	O
than	O
encapsulated	O
S.	O
pneumoniae	O
.	O

NTPn	O
are	O
currently	O
a	O
rare	O
cause	O
of	O
invasive	O
pneumococcal	O
disease	O
in	O
South	O
Africa	O
and	O
represent	O
a	O
genetically	O
diverse	O
collection	O
of	O
isolates	O
.	O

Locating	O
the	O
Seventh	O
Cervical	O
Spinous	O
Process	O
:	O
Development	O
and	O
Validation	O
of	O
a	O
Multivariate	O
Model	O
Using	O
Palpation	B-P
and	O
Personal	O
Information	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
validate	O
a	O
multivariate	O
prediction	O
model	O
,	O
guided	O
by	O
palpation	B-P
and	O
personal	O
information	O
,	O
for	O
locating	O
the	O
seventh	O
cervical	O
spinous	O
process	O
(	O
C7SP	O
)	O
.	O

A	O
single-blinded	O
,	O
cross-sectional	O
study	O
at	O
a	O
primary	O
to	O
tertiary	O
health	O
care	O
center	O
was	O
conducted	O
for	O
model	O
development	O
and	O
temporal	O
validation	O
.	O

One-hundred	O
sixty	O
participants	O
were	O
prospectively	O
included	O
for	O
model	O
development	O
(	O
n	O
=	O
80	O
)	O
and	O
time-split	O
validation	O
stages	O
(	O
n	O
=	O
80	O
)	O
.	O

The	O
C7SP	O
was	O
located	O
using	O
the	O
thorax-rib	B-P
static	I-P
method	I-P
(	O
TRSM	B-P
)	O
.	O

Participants	O
underwent	O
chest	B-P
radiography	I-P
for	O
assessment	O
of	O
the	O
inner	O
body	O
structure	O
located	O
with	O
TRSM	B-P
and	O
using	O
radio-opaque	O
markers	O
placed	O
over	O
the	O
skin	O
.	O

Age	O
,	O
sex	O
,	O
height	O
,	O
body	O
mass	O
,	O
body	O
mass	O
index	O
,	O
and	O
vertex-marker	O
distanc	O
e	O
(	O
DV-M	O
)	O
were	O
used	O
to	O
predict	O
the	O
distance	O
from	O
the	O
C7SP	O
to	O
the	O
vertex	O
(	O
DV-C7	O
)	O
.	O

Multivariate	O
linear	O
regression	O
modeling	O
,	O
limits	O
of	O
agreement	O
plot	O
,	O
histogram	O
of	O
residues	O
,	O
receiver	O
operating	O
characteristic	O
curves	O
,	O
and	O
confusion	O
tables	O
were	O
analyzed	O
.	O

The	O
multivariate	O
linear	O
prediction	O
model	O
for	O
DV-C7	O
(	O
in	O
centimeters	O
)	O
was	O
DV-C7	O
=	O
0.986DV-M	O
+	O
0.018	O
(	O
mass	O
)	O
+	O
0.014	O
(	O
age	O
)	O
-	O
1.008	O
.	O

Receiver	O
operating	O
characteristic	O
curves	O
had	O
better	O
discrimination	O
of	O
DV-C7	O
(	O
area	O
under	O
the	O
curve	O
=	O
0.661	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
0.541-0.782	O
;	O
P	O
=	O
.015	O
)	O
than	O
DV-M	O
(	O
area	O
under	O
the	O
curve	O
=	O
0.480	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
0.345-0.614	O
;	O
P	O
=	O
.761	O
)	O
,	O
with	O
respective	O
cutoff	O
points	O
at	O
23.40	O
cm	O
(	O
sensitivity	O
=	O
41	O
%	O
,	O
specificity	O
=	O
63	O
%	O
)	O
and	O
24.75	O
cm	O
(	O
sensitivity	O
=	O
69	O
%	O
,	O
specificity	O
=	O
52	O
%	O
)	O
.	O

The	O
C7SP	O
was	O
correctly	O
located	O
more	O
often	O
when	O
using	O
predicted	O
DV-C7	O
in	O
the	O
validation	O
sample	O
than	O
when	O
using	O
the	O
TRSM	B-P
in	O
the	O
development	O
sample	O
:	O
n	O
=	O
53	O
(	O
66	O
%	O
)	O
vs	O
n	O
=	O
32	O
(	O
40	O
%	O
)	O
,	O
P	O
<	O
.001	O
.	O

Better	O
accuracy	O
was	O
obtained	O
when	O
locating	O
the	O
C7SP	O
by	O
use	O
of	O
a	O
multivariate	O
model	O
that	O
incorporates	O
palpation	B-P
and	O
personal	O
information	O
.	O

Dissociation	O
between	O
complete	O
hippocampal	O
context	O
memory	O
formation	O
and	O
context	O
fear	O
acquisition	O
.	O

Rodents	O
require	O
a	O
minimal	O
time	O
period	O
to	O
explore	O
a	O
context	O
prior	O
to	O
footshock	O
to	O
display	O
plateau	O
-	O
level	O
context	O
fear	O
at	O
test	B-P
.	O

To	O
investigate	O
whether	O
this	O
rapid	O
fear	O
plateau	O
reflects	O
complete	O
memory	O
formation	O
within	O
that	O
short	O
time-frame	O
,	O
we	O
used	O
the	O
immediate-early	O
gene	O
product	O
Arc	O
as	O
an	O
indicator	O
of	O
hippocampal	O
context	O
memory	O
formation	O
-related	O
activity	O
.	O

We	O
found	O
that	O
hippocampal	O
Arc	O
expression	O
continued	O
to	O
increase	O
well	O
past	O
the	O
minimal	O
time	O
required	O
for	O
plateau	O
-	O
level	O
fear	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
context	O
fear	O
conditioning	O
occurs	O
more	O
rapidly	O
than	O
complete	O
memory	O
formation	O
.	O

Thus	O
,	O
animals	O
may	O
be	O
able	O
to	O
condition	O
robustly	O
to	O
both	O
complete	O
and	O
incomplete	O
contextual	O
representations	O
.	O

Structural	O
Remodeling	O
of	O
Sympathetic	O
Innervation	O
in	O
Atherosclerotic	O
Blood	O
Vessels	O
:	O
Role	O
of	O
Atherosclerotic	O
Disease	O
Progression	O
and	O
Chronic	O
Social	O
Stress	O
.	O

The	O
sympathetic	O
nervous	O
system	O
(	O
SNS	O
)	O
can	O
undergo	O
dramatic	O
structural	O
plasticity	O
in	O
response	O
to	O
behavioral	O
factors	O
and/or	O
the	O
presence	O
of	O
disease	O
,	O
leading	O
to	O
SNS	O
hyperinnervation	O
of	O
peripheral	O
tissues	O
.	O

The	O
SNS	O
has	O
been	O
proposed	O
as	O
an	O
important	O
mediator	O
between	O
stressful	O
behavior	O
and	O
the	O
progression	O
of	O
atherosclerosis	O
in	O
the	O
vasculature	O
.	O

The	O
present	O
study	O
examined	O
whether	O
structural	O
remodeling	O
of	O
the	O
SNS	O
occurs	O
in	O
the	O
vasculature	O
in	O
a	O
genetically	O
hyperlipidemic	O
animal	O
model	O
of	O
atherosclerosis	O
,	O
the	O
Watanabe	O
heritable	O
hyperlipidemic	O
rabbit	O
(	O
WHHL	O
;	O
relative	O
to	O
normolipidemic	O
New	O
Zealand	O
white	O
rabbits	O
[	O
NZW	O
]	O
)	O
,	O
and	O
whether	O
SNS	O
plasticity	O
is	O
driven	O
by	O
the	O
progression	O
of	O
disease	O
and/or	O
by	O
stressful	O
social	O
behavior	O
.	O

WHHL	O
and	O
NZW	O
rabbits	O
were	O
assigned	O
to	O
an	O
unstable	O
or	O
stable	O
social	O
environment	O
for	O
4	O
months	O
.	O

Aortic	O
atherosclerosis	O
was	O
assessed	O
and	O
SNS	O
aortic	O
innervation	O
quantified	O
using	O
immunofluorescent	B-P
microscopy	I-P
.	O

Numerous	O
SNS	O
varicosities	O
were	O
observed	O
throughout	O
the	O
aorta	O
in	O
WHHLs	O
and	O
NZWs	O
,	O
extending	O
into	O
the	O
vascular	O
media	O
and	O
intima	O
,	O
an	O
innervation	O
pattern	O
not	O
previously	O
reported	O
.	O

WHHLs	O
exhibited	O
significantly	O
greater	O
innervation	O
than	O
NZWs	O
(	O
F	O
(	O
1,41	O
)	O
=	O
55.3	O
,	O
p	O
<	O
.001	O
)	O
,	O
with	O
extensive	O
innervation	O
of	O
the	O
atherosclerotic	O
neointima	O
.	O

The	O
innervation	O
density	O
was	O
highly	O
correlated	O
with	O
the	O
extent	O
of	O
disease	O
in	O
the	O
WHHLs	O
(	O
r	O
(	O
21	O
)	O
=	O
0.855	O
,	O
p	O
<	O
.001	O
)	O
.	O

Social	O
environment	O
did	O
not	O
influence	O
innervation	O
in	O
NZWs	O
(	O
aortic	O
arch	O
:	O
p	O
=	O
.078	O
,	O
thoracic	O
aorta	O
:	O
p	O
=	O
.34	O
)	O
or	O
WHHLs	O
(	O
arch	O
:	O
p	O
=	O
.97	O
,	O
thoracic	O
:	O
p	O
=	O
.61	O
)	O
.	O

The	O
findings	O
suggest	O
that	O
hyperinnervation	O
is	O
driven	O
largely	O
by	O
the	O
progression	O
of	O
disease	O
rather	O
than	O
social	O
environment	O
.	O

SNS	O
innervation	O
patterns	O
observed	O
in	O
atherosclerotic	O
human	O
and	O
mouse	O
aortas	O
were	O
consistent	O
with	O
the	O
rabbit	O
,	O
suggesting	O
that	O
SNS	O
hyperinnervation	O
of	O
the	O
diseased	O
vessel	O
wall	O
is	O
a	O
general	O
feature	O
across	O
mammalian	O
species	O
.	O

Effects	O
of	O
an	O
early	O
intervention	O
using	O
human	O
amniotic	O
epithelial	O
cells	O
in	O
a	O
COPD	O
rat	O
model	O
.	O

The	O
study	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
an	O
early	O
intervention	O
using	O
human	O
amniotic	O
epithelial	O
cell	O
(	O
hAEC	O
)	O
in	O
a	O
rat	O
model	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O

Twenty-four	O
specific	O
pathogen-free	O
Wistar	O
rats	O
were	O
randomized	O
to	O
the	O
control	O
,	O
COPD	O
,	O
and	O
COPD	O
+	O
hAEC	O
groups	O
.	O

COPD	O
was	O
established	O
by	O
intratracheal	O
LPS	O
injection	O
combined	O
with	O
smoke	O
fumigation	O
over	O
30	O
days	O
.	O

On	O
the	O
first	O
day	O
of	O
model	O
establishment	O
rats	O
in	O
the	O
AEC	O
group	O
also	O
received	O
intratracheal	O
instillation	O
of	O
500,000	O
hAECs	O
isolated	O
from	O
the	O
placenta	O
of	O
healthy	O
donors	O
.	O

The	O
mean	O
linear	O
intercept	O
(	O
MLI	O
)	O
and	O
mean	O
alveolar	O
number	O
(	O
MAN	O
)	O
were	O
used	O
to	O
assess	O
the	O
degree	O
of	O
lung	O
emphysema	O
.	O

IL-8	O
was	O
measured	O
using	O
a	O
radioimmunoassay	B-P
,	O
surfactant	O
protein	O
D	O
(	O
SP-D	O
)	O
was	O
measured	O
by	O
ELISA	B-P
,	O
and	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
2	O
and	O
MMP8	O
expression	O
was	O
assessed	O
by	O
PCR	O
.	O

Smoke	O
fumigation	O
combined	O
to	O
LPS	O
injection	O
successfully	O
established	O
a	O
COPD	O
rat	O
model	O
with	O
significant	O
emphysema	O
and	O
airway	O
inflammation	O
,	O
elevated	O
MLI	O
and	O
MAN	O
,	O
elevated	O
systemic	O
and	O
lung	O
tissue	O
levels	O
of	O
IL-8	O
and	O
SP-D	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
high	O
expression	O
of	O
MMP2	O
and	O
MMP8	O
.	O

Rats	O
in	O
the	O
COPD	O
+	O
hAEC	O
group	O
exhibited	O
alleviated	O
lung	O
damage	O
,	O
MLI	O
and	O
MAN	O
(	O
P	O
<	O
0.05	O
)	O
,	O
reduced	O
systemic	O
and	O
lung	O
tissue	O
levels	O
of	O
IL-8	O
and	O
SP-D	O
(	O
P	O
<	O
0.05	O
)	O
and	O
MMP2	O
and	O
MMP8	O
expression	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Early	O
intervention	O
using	O
hAECs	O
could	O
delay	O
disease	O
progression	O
in	O
rats	O
with	O
COPD	O
.	O

Okanin	O
,	O
effective	O
constituent	O
of	O
the	O
flower	O
tea	O
Coreopsis	O
tinctoria	O
,	O
attenuates	O
LPS	O
-induced	O
microglial	O
activation	O
through	O
inhibition	O
of	O
the	O
TLR4	O
/	O
NF-κB	O
signaling	O
pathways	O
.	O

The	O
EtOAc	O
extract	O
of	O
Coreopsis	O
tinctoria	O
Nutt	O
.	O

significantly	O
inhibited	O
LPS	O
-induced	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
,	O
as	O
judged	O
by	O
the	O
Griess	O
reaction	O
,	O
and	O
attenuated	O
the	O
LPS	O
-induced	O
elevation	O
in	O
iNOS	O
,	O
COX-2	O
,	O
IL-1β	O
,	O
IL-6	O
and	O
TNF-α	O
mRNA	O
levels	O
,	O
as	O
determined	O
by	O
quantitative	O
real-time	O
PCR	O
,	O
when	O
incubated	O
with	O
BV-2	O
microglial	O
cells	O
.	O

Immunohistochemical	B-P
results	I-P
showed	O
that	O
the	O
EtOAc	O
extract	O
significantly	O
decreased	O
the	O
number	O
of	O
Iba-1-positive	O
cells	O
in	O
the	O
hippocampal	O
region	O
of	O
LPS	O
-	O
treated	O
mouse	O
brains	O
.	O

The	O
major	O
effective	O
constituent	O
of	O
the	O
EtOAc	O
extract	O
,	O
okanin	O
,	O
was	O
further	O
investigated	O
.	O

Okanin	O
significantly	O
suppressed	O
LPS	O
-induced	O
iNOS	O
expression	O
and	O
also	O
inhibited	O
IL-6	O
and	O
TNF-α	O
production	O
and	O
mRNA	O
expression	O
in	O
LPS	O
-	O
stimulated	O
BV-2	O
cells	O
.	O

Western	B-P
blot	I-P
analysis	I-P
indicated	O
that	O
okanin	O
suppressed	O
LPS	O
-induced	O
activation	O
of	O
the	O
NF-κB	O
signaling	O
pathway	O
by	O
inhibiting	O
the	O
phosphorylation	O
of	O
IκBα	O
and	O
decreasing	O
the	O
level	O
of	O
nuclear	O
NF-κB	O
p65	O
after	O
LPS	O
treatment	O
.	O

Immunofluorescence	B-P
staining	I-P
results	O
showed	O
that	O
okanin	O
inhibited	O
the	O
translocation	O
of	O
the	O
NF-κB	O
p65	O
subunit	O
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
.	O

Moreover	O
,	O
okanin	O
significantly	O
inhibited	O
LPS	O
-induced	O
TLR4	O
expression	O
in	O
BV-2	O
cells	O
.	O

In	O
summary	O
,	O
okanin	O
attenuates	O
LPS	O
-induced	O
activation	O
of	O
microglia	O
.	O

This	O
effect	O
may	O
be	O
associated	O
with	O
its	O
capacity	O
to	O
inhibit	O
the	O
TLR4	O
/	O
NF-κB	O
signaling	O
pathways	O
.	O

These	O
results	O
suggest	O
that	O
okanin	O
may	O
have	O
potential	O
as	O
a	O
nutritional	O
preventive	O
strategy	O
for	O
neurodegenerative	O
disorders	O
.	O

Biofunctional	O
polyethylene	O
glycol	O
coatings	O
on	O
titanium	O
:	O
An	O
in	O
vitro	O
-based	O
comparison	O
of	O
functionalization	O
methods	O
.	O

Three	O
methods	O
for	O
the	O
production	O
of	O
Polyethylene	O
glycol	O
(	O
PEG	O
)	O
coatings	O
on	O
titanium	O
are	O
compared	O
,	O
i.e	O
.	O

plasma	O
polymerization	O
,	O
electrodeposition	O
and	O
silanization	O
.	O

The	O
compared	O
deposition	O
methods	O
presented	O
similar	O
wettability	O
(	O
hydrophilic	O
coatings	O
)	O
,	O
chemical	O
composition	O
assessed	O
by	O
XPS	B-P
and	O
thickness	O
around	O
1nm	O
.	O

The	O
coatings	O
lowered	O
albumin	O
adsorption	B-P
and	O
presented	O
a	O
decreased	O
fibroblast	O
,	O
Streptococcus	O
sanguinis	O
and	O
Lactobacillus	O
salivarius	O
adhesion	O
.	O

Immobilization	O
of	O
a	O
cell	O
adhesion	O
peptide	O
(	O
RGD	O
)	O
presented	O
a	O
higher	O
fibroblast	O
adhesion	O
and	O
no	O
alteration	O
of	O
the	O
bacterial	O
adhesion	O
,	O
giving	O
three	O
methods	O
for	O
the	O
biofunctionalization	O
of	O
titanium	O
for	O
dental	O
implants	O
.	O

The	O
feasibility	O
of	O
each	O
methodology	O
is	O
compared	O
in	O
terms	O
of	O
the	O
process	O
parameters	O
in	O
order	O
to	O
provide	O
a	O
guide	O
for	O
the	O
election	O
of	O
the	O
methodology	O
.	O

Demonstration	O
and	O
validation	O
of	O
a	O
new	O
pressure	O
-based	O
MRI	O
-safe	O
pain	O
tolerance	O
device	O
.	O

One	O
of	O
the	O
barriers	O
to	O
studying	O
the	O
behavioral	O
and	O
emotional	O
effects	O
of	O
pain	O
using	O
functional	B-P
Magnetic	I-P
Resonance	I-P
Imaging	I-P
(	O
fMRI	B-P
)	O
is	O
the	O
absence	O
of	O
a	O
commercially	O
available	O
,	O
MRI	O
-	O
compatible	O
,	O
pressure	O
-based	O
algometer	O
to	O
elicit	O
pain	O
.	O

The	O
present	O
study	O
sought	O
to	O
address	O
this	O
barrier	O
through	O
creation	O
and	O
validation	O
of	O
a	O
novel	O
MRI	O
-safe	O
apparatus	O
capable	O
of	O
delivering	O
incremental	O
,	O
measurable	O
amounts	O
of	O
pressure	O
inside	O
a	O
scanning	O
bore	O
.	O

We	O
introduced	O
an	O
MR-safe	O
device	O
used	O
to	O
administer	O
pressure	O
-based	O
pain	O
.	O

To	O
test	B-P
against	O
a	O
commercially	O
available	O
,	O
MRI	O
-	O
incompatible	O
algometer	O
(	O
AlgoMed	O
)	O
,	O
199	O
participants	O
reported	O
their	O
pain	O
tolerance	O
for	O
both	O
devices	O
.	O

A	O
second	O
experiment	O
tested	B-P
the	O
validity	O
of	O
pressure	O
-based	O
pain	O
in	O
an	O
MRI	O
environment	O
by	O
comparing	O
brain	O
activation	O
with	O
established	O
neural	O
networks	O
for	O
pain	O
.	O

10	O
participants	O
performed	O
an	O
identical	O
procedure	O
to	O
test	B-P
for	O
pain	O
tolerance	O
while	O
being	O
scanned	B-P
in	O
a	O
7T	O
MRI	O
scanner	O
.	O

Results	O
support	O
the	O
validity	O
and	O
reliability	O
of	O
our	O
novel	O
device	O
.	O

In	O
Study	O
1	O
,	O
pain	O
tolerance	O
with	O
this	O
device	O
was	O
strongly	O
correlated	O
with	O
pain	O
tolerance	O
as	O
measured	O
by	O
a	O
commercially	O
available	O
algometer	O
(	O
r=0.78	O
)	O
.	O

In	O
Study	O
2	O
,	O
this	O
device	O
yielded	O
BOLD	O
activation	O
within	O
the	O
insula	O
(	O
BA	O
13	O
)	O
and	O
anterior	O
cingulate	O
gyrus	O
(	O
BA	O
24	O
)	O
;	O
as	O
pressure	O
increased	O
,	O
activation	O
in	O
these	O
areas	O
parametrically	O
increased	O
.	O

These	O
findings	O
correspond	O
to	O
other	O
studies	O
using	O
thermal	O
,	O
electrical	O
,	O
or	O
mechanical	O
pain	O
applications	O
.	O

Behavioral	O
and	O
functional	O
data	O
demonstrate	O
that	O
this	O
new	O
device	O
is	O
a	O
valid	O
method	O
of	O
administering	O
pressure	O
-related	O
pain	O
in	O
MRI	O
environments	O
.	O

Our	O
novel	O
MRI	O
-safe	O
device	O
is	O
a	O
valid	O
instrument	O
to	O
measure	O
and	O
administer	O
pressure	O
-based	O
pain	O
.	O

The	O
effect	O
of	O
green	O
tea	O
extract	O
supplementation	O
on	O
sputum	B-P
smear	I-P
conversion	O
and	O
weight	O
changes	O
in	O
pulmonary	O
TB	O
patients	O
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

Acceleration	O
in	O
sputum	B-P
smear	I-P
conversion	O
helps	O
faster	O
improvement	O
and	O
decreased	O
probability	O
of	O
the	O
transfer	O
of	O
TB	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
green	O
tea	O
extract	O
supplementation	O
on	O
sputum	B-P
smear	I-P
conversion	O
and	O
weight	O
changes	O
in	O
smear	O
positive	O
pulmonary	O
TB	O
patients	O
in	O
Iran	O
.	O

In	O
this	O
double	O
blind	O
clinical	O
study	O
,	O
TB	O
patients	O
were	O
divided	O
into	O
intervention	O
,	O
(	O
n=43	O
)	O
receiving	O
500	O
mg	O
green	O
tea	O
extract	O
(	O
GTE	O
)	O
,	O
and	O
control	O
groups	O
(	O
n=40	O
)	O
receiving	O
placebo	O
for	O
two	O
months	O
,	O
using	O
balanced	O
randomization	O
.	O

Random	O
allocation	O
and	O
allocation	O
concealment	O
were	O
observed	O
.	O

Height	O
and	O
weight	O
were	O
measured	O
at	O
the	O
beginning	O
,	O
and	O
two	O
and	O
six	O
months	O
post-treatment	O
.	O

Evaluations	O
were	O
performed	O
on	O
three	O
slides	O
,	O
using	O
the	O
ZiehlNeelsen	B-P
method	I-P
.	O

Independent	O
and	O
paired	O
t	O
test	O
,	O
McNemar	O
's	O
,	O
Wilcoxon	O
,	O
Kaplan-Meier	O
,	O
Cox	O
regression	O
model	O
and	O
Log-Rank	O
test	O
were	O
utilized	O
.	O

Statistical	O
significance	O
was	O
set	O
at	O
p	O
<	O
0.05	O
.	O

This	O
trial	O
was	O
registered	O
under	O
IRCT201212232602N11	O
.	O

The	O
interventional	O
changes	O
and	O
the	O
interactive	O
effect	O
of	O
intervention	O
on	O
weight	O
were	O
not	O
significant	O
(	O
p	O
>	O
0.05	O
)	O
.	O

In	O
terms	O
of	O
shortening	O
the	O
duration	O
of	O
conversion	O
,	O
the	O
case	O
to	O
control	O
proportion	O
showed	O
a	O
significant	O
difference	O
(	O
p=0.032	O
)	O
.	O

Based	O
on	O
the	O
Cox	O
regression	O
model	O
,	O
the	O
hazard	O
ratio	O
of	O
the	O
relative	O
risk	O
of	O
delay	O
in	O
sputum	B-P
smear	I-P
conversion	O
was	O
3.7	O
(	O
p=0.002	O
)	O
in	O
the	O
higher	O
microbial	O
load	O
group	O
compared	O
to	O
the	O
placebo	O
group	O
and	O
0.54	O
(	O
95	O
%	O
CI	O
:	O
0.31-0.94	O
)	O
in	O
the	O
intervention	O
compared	O
to	O
the	O
placebo	O
group	O
.	O

GTE	O
decreases	O
the	O
risk	O
of	O
delay	O
in	O
sputum	B-P
smear	I-P
conversion	O
,	O
but	O
has	O
no	O
effect	O
on	O
weight	O
gain	O
.	O

Moreover	O
,	O
it	O
may	O
be	O
used	O
as	O
an	O
adjuvant	O
therapy	O
for	O
faster	O
rehabilitation	O
for	O
pulmonary	O
TB	O
patients	O
.	O

Ocular	O
toxicity	O
of	O
AUY922	O
in	O
pigmented	O
and	O
albino	O
rats	O
.	O

AUY922	O
,	O
a	O
heat	O
shock	O
protein	O
90	O
inhibitor	O
is	O
associated	O
with	O
ocular	O
adverse	O
events	O
(	O
AEs	O
)	O
.	O

To	O
provide	O
a	O
better	O
understanding	O
of	O
ocular	O
AEs	O
in	O
patients	O
,	O
4	O
investigative	O
studies	O
were	O
performed	O
in	O
a	O
step-wise	O
approach	O
to	O
assess	O
retinal	O
structure	O
and	O
function	O
in	O
pigmented	O
(	O
Brown	O
Norway	O
)	O
and	O
albino	O
(	O
Wistar	O
)	O
rats	O
.	O

In	O
rats	O
administered	O
30mg/kg	O
of	O
AUY922	O
,	O
the	O
AUC	O
0-24	O
h	O
and	O
Cmax	O
are	O
comparable	O
to	O
that	O
in	O
patients	O
at	O
70mg/m	O
(	O
2	O
)	O
.	O

AUY922	O
at	O
≥30mg/kg	O
was	O
poorly	O
tolerated	O
by	O
rats	O
with	O
morbidity	O
or	O
mortality	O
generally	O
after	O
the	O
third	O
weekly	O
treatment	O
.	O

Electroretinography	B-P
(	O
ERG	B-P
)	O
changes	O
were	O
observed	O
at	O
doses	O
≥30mg/kg	O
.	O

The	O
ERG	B-P
changes	O
were	O
dose	O
dependent	O
,	O
consistent	O
with	O
an	O
effect	O
on	O
the	O
photoreceptors	O
,	O
and	O
fully	O
reversible	O
.	O

The	O
ERG	B-P
effects	O
could	O
not	O
be	O
minimized	O
by	O
decreasing	O
the	O
Cmax	O
while	O
maintaining	O
AUC	O
.	O

Histopathological	O
changes	O
were	O
seen	O
mainly	O
when	O
rats	O
were	O
administered	O
AUY922	O
at	O
100mg/kg	O
.	O

The	O
2-	O
hour	O
infusion	O
of	O
AUY922	O
at	O
100mg/kg	O
caused	O
disorganization	O
of	O
the	O
outer	O
segment	O
photoreceptor	O
morphology	O
in	O
male	O
Brown	O
Norway	O
rats	O
;	O
the	O
severity	O
of	O
the	O
disorganization	O
increased	O
with	O
the	O
number	O
of	O
administrations	O
,	O
but	O
was	O
reversible	O
during	O
a	O
4-	O
week	O
posttreatment	O
period	O
.	O

There	O
was	O
no	O
major	O
difference	O
in	O
ocular	O
response	O
between	O
Brown	O
Norway	O
and	O
Wistar	O
rats	O
.	O

No	O
changes	O
in	O
serum	O
iron	O
levels	O
,	O
and	O
no	O
changes	O
in	O
rhodopsin	O
,	O
PDE6α	O
,	O
β-transducin	O
concentrations	O
,	O
or	O
retinal	O
pigment	O
epithelium-specific	O
protein	O
RPE65	O
expression	O
were	O
observed	O
after	O
single	O
and	O
multiple	O
infusions	O
of	O
AUY922	O
at	O
100mg/kg	O
compared	O
to	O
vehicle-treated	O
controls	O
.	O

AUY922	O
retinal	O
toxicity	O
in	O
rats	O
recapitulates	O
and	O
further	O
characterizes	O
that	O
reported	O
in	O
patients	O
and	O
is	O
shown	O
to	O
be	O
reversible	O
,	O
while	O
a	O
precise	O
molecular	O
mechanism	O
for	O
the	O
effect	O
was	O
not	O
determined	O
.	O

Antiproliferative	O
and	O
apoptotic	O
effects	O
of	O
a	O
specific	O
anti-insulin-like	O
growth	O
factor	O
I	O
receptor	O
single	O
chain	O
antibody	O
on	O
breast	O
cancer	O
cells	O
.	O

Insulin-like	O
growth	O
factor	O
I	O
receptor	O
(	O
IGF-IR	O
)	O
is	O
expressed	O
on	O
breast	O
cancer	O
cells	O
and	O
involves	O
in	O
metastasis	O
,	O
survival	O
,	O
and	O
proliferation	O
.	O

Currently	O
,	O
application	O
of	O
IGF-IR	O
-targeting	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
drugs	O
,	O
is	O
a	O
promising	O
strategy	O
for	O
breast	O
cancer	O
therapy	O
.	O

Single-chain	O
fragment	O
variable	O
(	O
scFv	O
)	O
antibodies	O
have	O
been	O
introduced	O
as	O
appropriate	O
tools	O
for	O
tumor-targeting	O
purposes	O
because	O
of	O
their	O
advantages	O
over	O
whole	O
antibodies	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
employed	O
a	O
naïve	O
phage	O
library	O
and	O
isolated	O
scFvs	O
against	O
a	O
specific	O
epitope	O
from	O
extracellular	O
domain	O
of	O
IGF-IR	O
by	O
panning	O
process	O
.	O

The	O
selected	O
scFvs	O
were	O
further	O
characterized	O
using	O
polyclonal	B-P
and	O
monoclonal	B-P
phage	I-P
ELISA	I-P
,	O
soluble	O
monoclonal	B-P
ELISA	I-P
,	O
and	O
colony	O
PCR	O
and	O
sequencing	O
.	O

Antiproliferative	O
and	O
apoptotic	O
effects	O
of	O
selected	O
scFv	O
antibodies	O
on	O
breast	O
cancer	O
cell	O
lines	O
were	O
also	O
evaluated	O
by	O
MTT	O
and	O
Annexin	B-P
V/PI	I-P
assays	I-P
.	O

The	O
results	O
of	O
ELISA	B-P
indicated	O
specific	O
reactions	O
of	O
the	O
isolated	O
scFvs	O
against	O
the	O
IGF-IR	O
peptide	O
,	O
and	O
analyses	B-P
of	I-P
PCR	I-P
product	I-P
and	O
sequencing	O
confirmed	O
the	O
presence	O
of	O
full	O
length	O
VH	O
and	O
Vκ	O
inserts	O
.	O

Treatment	O
of	O
MCF7	O
and	O
SKBR3	O
cells	O
with	O
anti-IGF-IR	O
scFv	O
led	O
to	O
a	O
significant	O
growth	O
inhibition	O
.	O

The	O
results	O
also	O
showed	O
that	O
scFv	O
treatment	O
significantly	O
augmented	O
trastuzumab	O
growth	O
inhibitory	O
effects	O
on	O
SKBR3	O
cells	O
.	O

The	O
percentage	O
of	O
the	O
apoptotic	O
MCF7	O
and	O
SKBR3	O
cells	O
after	O
24-h	O
treatment	O
with	O
scFv	O
was	O
39	O
and	O
30.70	O
%	O
,	O
respectively	O
.	O

Twenty-four-hour	O
treatment	O
with	O
scFv	O
in	O
combination	O
with	O
trastuzumab	O
resulted	O
in	O
44.75	O
%	O
apoptosis	O
of	O
SKBR3	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
the	O
targeting	O
of	O
IGF-IR	O
by	O
scFv	O
can	O
be	O
an	O
effective	O
strategy	O
in	O
the	O
treatment	O
of	O
breast	O
cancer	O
and	O
provide	O
further	O
evidence	O
for	O
effectiveness	O
of	O
dual	O
targeting	O
of	O
HER2	O
and	O
IGF-IR	O
in	O
breast	O
cancer	O
therapy	O
.	O

Depot	O
Dependent	O
Effects	O
of	O
Dexamethasone	O
on	O
Gene	O
Expression	O
in	O
Human	O
Omental	O
and	O
Abdominal	O
Subcutaneous	O
Adipose	O
Tissues	O
from	O
Obese	O
Women	O
.	O

Glucocorticoids	O
promote	O
fat	O
accumulation	O
in	O
visceral	O
compared	O
to	O
subcutaneous	O
depots	O
,	O
but	O
the	O
molecular	O
mechanisms	O
involved	O
remain	O
poorly	O
understood	O
.	O

To	O
identify	O
long-term	O
changes	O
in	O
gene	O
expression	O
that	O
are	O
differentially	O
sensitive	O
or	O
responsive	O
to	O
glucocorticoids	O
in	O
these	O
depots	O
,	O
paired	O
samples	O
of	O
human	O
omental	O
(	O
Om	O
)	O
and	O
abdominal	O
subcutaneous	O
(	O
Abdsc	O
)	O
adipose	O
tissues	O
obtained	O
from	O
obese	O
women	O
during	O
elective	O
surgery	O
were	O
cultured	B-P
with	O
the	O
glucocorticoid	O
receptor	O
agonist	O
dexamethasone	O
(	O
Dex	O
,	O
0	O
,	O
1	O
,	O
10	O
,	O
25	O
and	O
1000	O
nM	O
)	O
for	O
7	O
days	O
.	O

Dex	O
regulated	O
32	O
%	O
of	O
the	O
19,741	O
genes	O
on	O
the	O
array	O
,	O
while	O
53	O
%	O
differed	O
by	O
Depot	O
and	O
2.5	O
%	O
exhibited	O
a	O
Depot	O
*	O
Dex	O
concentration	O
interaction	O
.	O

Gene	O
set	O
enrichment	O
analysis	O
showed	O
Dex	O
regulation	O
of	O
the	O
expected	O
metabolic	O
and	O
inflammatory	O
pathways	O
in	O
both	O
depots	O
.	O

Cluster	O
analysis	O
of	O
the	O
460	O
transcripts	O
that	O
exhibited	O
an	O
interaction	O
of	O
Depot	O
and	O
Dex	O
concentration	O
revealed	O
sets	O
of	O
mRNAs	O
for	O
which	O
the	O
responses	O
to	O
Dex	O
differed	O
in	O
magnitude	O
,	O
sensitivity	O
or	O
direction	O
between	O
the	O
two	O
depots	O
as	O
well	O
as	O
mRNAs	O
that	O
responded	O
to	O
Dex	O
only	O
in	O
one	O
depot	O
.	O

These	O
transcripts	O
were	O
also	O
clearly	O
depot	O
different	O
in	O
fresh	O
adipose	O
tissue	O
and	O
are	O
implicated	O
in	O
processes	O
that	O
could	O
affect	O
adipose	O
tissue	O
distribution	O
or	O
functions	O
(	O
e.g	O
.	O

adipogenesis	O
,	O
triacylglycerol	O
synthesis	O
and	O
storage	O
,	O
insulin	O
action	O
)	O
.	O

Elucidation	O
of	O
the	O
mechanisms	O
underlying	O
the	O
depot	O
differences	O
in	O
the	O
effect	O
of	O
Dex	O
on	O
the	O
expression	O
of	O
specific	O
genes	O
and	O
pathways	O
that	O
regulate	O
adipose	O
function	O
may	O
offer	O
novel	O
insights	O
into	O
understanding	O
the	O
biology	O
of	O
visceral	O
adipose	O
tissues	O
and	O
their	O
links	O
to	O
metabolic	O
health	O
.	O

Results	O
of	O
a	O
Single	O
Institution	O
Experience	O
with	O
Dose-Escalated	O
Chemoradiation	O
for	O
Locally	O
Advanced	O
Unresectable	O
Non-Small	O
Cell	O
Lung	O
Cancer	O
.	O

We	O
determined	O
factors	O
associated	O
with	O
morbidity	O
and	O
outcomes	O
of	O
a	O
series	O
of	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
patients	O
treated	O
with	O
dose-escalated	O
chemoradiotherapy	O
at	O
the	O
University	O
of	O
Pittsburgh	O
Lung	O
Cancer	O
Program	O
.	O

The	O
records	O
of	O
170	O
stage	O
III	O
NSCLC	O
patients	O
treated	O
with	O
definitive	O
intent	O
were	O
retrospectively	O
reviewed	O
.	O

All	O
patients	O
received	O
four-dimensional	B-P
CT	I-P
simulation	I-P
scan	I-P
and	O
had	O
respiratory	O
gating	O
if	O
tumor	O
movement	O
exceeded	O
5	O
mm	O
.	O

Overall	O
survival	O
(	O
OS	O
)	O
,	O
locoregional	O
control	O
(	O
LRC	O
)	O
,	O
and	O
freedom	O
from	O
distant	O
metastasis	O
(	O
FFDM	O
)	O
were	O
calculated	O
using	O
log-rank	O
and	O
Cox	O
regression	O
analysis	O
.	O

For	O
the	O
present	O
series	O
of	O
patients	O
,	O
median	O
follow-up	O
was	O
36.6	O
months	O
,	O
median	O
survival	O
27.4	O
months	O
,	O
and	O
the	O
2-	O
and	O
4-	O
year	O
OS	O
was	O
56.0	O
and	O
30.7	O
%	O
,	O
respectively	O
.	O

The	O
4-	O
year	O
LRC	O
and	O
FFDM	O
were	O
43.9	O
and	O
40.7	O
%	O
,	O
respectively	O
.	O

No	O
benefit	O
was	O
associated	O
with	O
irradiation	O
doses	O
above	O
66	O
Gy	O
in	O
OS	O
(	O
p	O
=	O
0.586	O
)	O
,	O
LRC	O
(	O
p	O
=	O
0.440	O
)	O
,	O
or	O
FFDM	O
(	O
p	O
=	O
0.230	O
)	O
.	O

On	O
univariate	O
analysis	O
,	O
variables	O
associated	O
with	O
worse	O
survival	O
included	O
:	O
clinical	O
stage	O
IIIB	O
(	O
p	O
=	O
0.037	O
)	O
,	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
over	O
450	O
cc	O
(	O
p	O
<	O
0.001	O
)	O
,	O
heart	O
V30	O
over	O
40	O
%	O
(	O
p	O
=	O
-0.048	O
)	O
,	O
and	O
esophageal	O
mean	O
dose	O
over	O
20	O
%	O
(	O
p	O
=	O
0.024	O
)	O
,	O
V5	O
(	O
p	O
=	O
-0.015	O
)	O
,	O
and	O
V60	O
(	O
p	O
=	O
-0.011	O
)	O
.	O

On	O
multivariable	O
analysis	O
,	O
PTV	O
above	O
450	O
cc	O
(	O
52.2	O
vs.	O
25.3	O
months	O
,	O
p	O
<	O
0.001	O
)	O
and	O
esophageal	O
V60	O
>	O
20	O
%	O
(	O
43.8	O
vs.	O
21.3	O
months	O
,	O
p	O
=	O
-0.01	O
)	O
were	O
associated	O
with	O
lower	O
survival	O
.	O

Grade	O
2	O
or	O
higher	O
acute	O
lung	O
toxicity	O
and	O
esophagitis	O
were	O
detected	O
in	O
9.5	O
and	O
59.7	O
%	O
,	O
respectively	O
of	O
patients	O
.	O

Grade	O
2	O
or	O
higher	O
acute	O
lung	O
toxicity	O
was	O
reduced	O
if	O
lung	O
V5	O
was	O
≤65	O
(	O
7.4	O
vs.	O
23.8	O
%	O
,	O
p	O
=	O
0.03	O
)	O
.	O

Grade	O
2	O
or	O
higher	O
acute	O
esophagitis	O
was	O
reduced	O
if	O
V60	O
≤	O
20	O
%	O
(	O
62	O
vs.	O
81.3	O
%	O
,	O
p	O
=	O
0.018	O
)	O
.	O

The	O
use	O
of	O
intensity-modulated	O
radiation	O
therapy	O
was	O
more	O
frequent	O
in	O
stage	O
IIIB	O
compared	O
to	O
stage	O
IIIA	O
patients	O
(	O
56.5	O
vs.	O
39.5	O
%	O
,	O
p	O
=	O
0.048	O
)	O
and	O
was	O
associated	O
with	O
a	O
higher	O
lung	O
V5	O
and	O
V10	O
.	O

The	O
outcomes	O
of	O
a	O
program	O
of	O
dose-escalated	O
chemoradiotherapy	O
for	O
unresectable	O
stage	O
IIIA	O
and	O
IIIB	O
NSCLC	O
patients	O
were	O
consistent	O
with	O
other	O
studies	O
and	O
showed	O
no	O
benefit	O
to	O
radiation	O
doses	O
above	O
66	O
Gy	O
.	O

Furthermore	O
,	O
maintaining	O
low	O
esophageal	O
V60	O
and	O
lung	O
V5	O
were	O
associated	O
with	O
lower	O
morbidity	O
and	O
mortality	O
.	O

Performance	O
of	O
loop-mediated	B-P
isothermal	I-P
amplification	I-P
(	O
LAMP	B-P
)	O
for	O
the	O
diagnosis	O
of	O
malaria	O
among	O
malaria	O
suspected	O
pregnant	O
women	O
in	O
Northwest	O
Ethiopia	O
.	O

Malaria	O
is	O
a	O
major	O
public	O
health	O
problem	O
and	O
an	O
important	O
cause	O
of	O
maternal	O
and	O
infant	O
morbidity	O
in	O
sub-Saharan	O
Africa	O
,	O
including	O
Ethiopia	O
.	O

Early	B-P
and	O
accurate	O
diagnosis	O
of	O
malaria	O
with	O
effective	O
treatment	O
is	O
the	O
best	O
strategy	O
for	O
prevention	O
and	O
control	O
of	O
complications	O
during	O
pregnancy	O
and	O
infant	O
morbidity	O
and	O
mortality	O
.	O

However	O
,	O
laboratory	B-P
diagnosis	I-P
has	O
relied	O
on	O
the	O
identification	O
of	O
malaria	O
parasites	O
and	O
parasite	O
antigens	O
in	O
peripheral	O
blood	O
using	O
Giemsa-stained	B-P
microscopy	I-P
or	O
rapid	B-P
diagnostic	I-P
tests	I-P
(	O
RDTs	B-P
)	O
which	O
lack	O
analytical	O
and	O
clinical	O
sensitivity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
loop-mediated	B-P
isothermal	I-P
amplification	I-P
(	O
LAMP	B-P
)	O
for	O
the	O
diagnosis	O
of	O
malaria	O
among	O
malaria	O
suspected	O
pregnant	O
women	O
in	O
Northwest	O
Ethiopia	O
.	O

A	O
cross	O
sectional	O
study	O
was	O
conducted	O
from	O
January	O
to	O
April	O
2016	O
.	O

Pregnant	O
women	O
(	O
n	O
=	O
87	O
)	O
suspected	O
of	O
having	O
malaria	O
at	O
six	O
health	O
centres	O
were	O
enrolled	O
.	O

A	O
venous	O
blood	O
sample	O
was	O
collected	O
from	O
each	O
study	O
subject	O
,	O
and	O
analysed	O
for	O
Plasmodium	O
parasites	O
by	O
microscopy	B-P
,	O
RDT	B-P
,	O
and	O
LAMP	B-P
.	O

Diagnostic	O
accuracy	O
outcome	O
measures	O
(	O
sensitivity	O
,	O
specificity	O
,	O
predictive	O
values	O
,	O
and	O
Kappa	O
scores	O
)	O
of	O
microscopy	B-P
,	O
RDT	B-P
and	O
LAMP	B-P
were	O
compared	O
to	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
nPCR	O
)	O
as	O
the	O
gold	O
standard	O
.	O

Specimen	B-P
processing	I-P
and	O
reporting	O
times	O
were	O
documented	O
.	O

Using	O
nPCR	O
as	O
the	O
gold	O
standard	O
technique	O
,	O
the	O
sensitivity	O
of	O
microscopy	B-P
and	O
RDT	B-P
was	O
90	O
and	O
70	O
%	O
,	O
and	O
the	O
specificity	O
was	O
98.7	O
and	O
97.4	O
%	O
,	O
respectively	O
.	O

LAMP	B-P
assay	B-P
was	O
100	O
%	O
sensitive	O
and	O
93.5	O
%	O
specific	O
compared	O
to	O
nPCR	O
.	O

This	O
study	O
showed	O
higher	O
sensitivity	O
of	O
LAMP	B-P
compared	O
to	O
microscopy	B-P
and	O
RDT	B-P
for	O
the	O
detection	O
of	O
malaria	O
in	O
pregnancy	O
.	O

Increased	O
sensitivity	O
and	O
ease	O
of	O
use	O
with	O
LAMP	B-P
in	O
point-of-care	O
testing	O
for	O
malaria	O
in	O
pregnancy	O
was	O
noted	O
.	O

LAMP	B-P
warrants	O
further	O
evaluation	O
in	O
intermittent	O
screening	O
and	O
treatment	O
programmes	O
in	O
pregnancy	O
.	O

Chikungunya	O
Virus	O
Infection	O
Manifesting	O
as	O
Intermediate	O
Uveitis	O
.	O

To	O
describe	O
a	O
case	O
of	O
intermediate	O
uveitis	O
caused	O
by	O
chikungunya	O
virus	O
infection	O
in	O
the	O
Western	O
Hemisphere	O
.	O

Case	O
report	O
of	O
a	O
patient	O
diagnosed	O
with	O
chikungunya	O
infection	O
presenting	O
with	O
blurry	O
vision	O
and	O
floaters	O
.	O

Exam	O
revealed	O
a	O
unilateral	O
intermediate	O
uveitis	O
,	O
with	O
an	O
extensive	O
work-up	B-P
positive	O
for	O
chikungunya	O
virus	O
immunoglobulin	O
M	O
and	O
G	O
titers	O
.	O

The	O
patient	O
responded	O
to	O
oral	O
corticosteroids	O
with	O
signs	O
and	O
symptoms	O
resolving	O
over	O
the	O
course	O
of	O
3	O
months	O
'	O
treatment	O
.	O

While	O
anterior	O
uveitis	O
and	O
retinitis	O
are	O
the	O
most	O
common	O
ocular	O
manifestations	O
of	O
chikungunya	O
infection	O
,	O
we	O
report	O
here	O
a	O
case	O
of	O
chikungunya	O
infection	O
presenting	O
as	O
an	O
intermediate	O
uveitis	O
,	O
responding	O
well	O
to	O
oral	O
corticosteroids	O
.	O

This	O
case	O
demonstrates	O
the	O
varied	O
presentation	O
of	O
chikungunya	O
-related	O
uveitis	O
and	O
highlights	O
its	O
consideration	O
in	O
the	O
differential	B-P
diagnoses	I-P
of	O
those	O
who	O
have	O
had	O
preceding	O
systemic	O
viral	O
symptoms	O
and	O
uveitis	O
.	O

Selection	O
of	O
an	O
Artificial	O
Diet	O
for	O
Laboratory	O
Rearing	B-P
of	O
Opogona	O
sacchari	O
(	O
Lepidoptera	O
:	O
Tineidae	O
)	O
(	O
Bojer	O
,	O
1856	O
)	O
.	O

The	O
banana	O
moth	O
Opogona	O
sacchari	O
(	O
Bojer	O
)	O
(	O
Lepidoptera	O
:	O
Tineidae	O
)	O
is	O
a	O
polyphagous	O
pest	O
that	O
can	O
cause	O
serious	O
damage	O
,	O
in	O
particular	O
to	O
banana	O
crops	O
in	O
southern	O
Brazil	O
.	O

The	O
insect	O
is	O
a	O
quarantine	O
pest	O
in	O
several	O
countries	O
,	O
including	O
Argentina	O
,	O
the	O
main	O
consumer	O
market	O
for	O
bananas	O
from	O
southern	O
Brazil	O
.	O

Little	O
information	O
is	O
available	O
about	O
the	O
biology	O
and	O
ecology	O
of	O
this	O
moth	O
,	O
such	O
as	O
a	O
suitable	O
diet	O
for	O
laboratory	O
rearing	B-P
.	O

In	O
order	O
to	O
provide	O
support	O
for	O
integrated	O
pest	O
management	O
of	O
the	O
pest	O
,	O
this	O
study	O
furnished	O
data	O
for	O
selecting	O
two	O
diets	O
suitable	O
for	O
continuous	O
laboratory	O
rearing	B-P
of	O
O.	O
sacchari	O
,	O
one	O
based	O
on	O
dried	O
beans	O
,	O
wheat	O
germ	O
,	O
soy	O
bran	O
,	O
brewer	O
's	O
yeast	O
,	O
and	O
casein	O
and	O
another	O
diet	O
with	O
wheat	O
germ	O
and	O
casein	O
as	O
protein	O
sources	O
.	O

With	O
both	O
diets	O
,	O
the	O
viability	O
of	O
the	O
egg	O
-	O
adult	O
period	O
exceeded	O
68	O
%	O
,	O
with	O
fertility	O
over	O
338	O
eggs	O
per	O
female	O
.	O

A	O
corrected	O
biotic	O
potential	O
analysis	O
gave	O
similar	O
values	O
for	O
the	O
two	O
diets	O
.	O

Living	O
on	O
the	O
edge	O
:	O
substrate	O
competition	O
explains	O
loss	O
of	O
robustness	O
in	O
mitochondrial	O
fatty-acid	O
oxidation	O
disorders	O
.	O

Defects	O
in	O
genes	O
involved	O
in	O
mitochondrial	O
fatty-acid	O
oxidation	O
(	O
mFAO	O
)	O
reduce	O
the	O
ability	O
of	O
patients	O
to	O
cope	O
with	O
metabolic	O
challenges	O
.	O

mFAO	O
enzymes	O
accept	O
multiple	O
substrates	O
of	O
different	O
chain	O
length	O
,	O
leading	O
to	O
molecular	O
competition	O
among	O
the	O
substrates	O
.	O

Here	O
,	O
we	O
combined	O
computational	B-P
modeling	I-P
with	O
quantitative	O
mouse	O
and	O
patient	O
data	O
to	O
investigate	O
whether	O
substrate	O
competition	O
affects	O
pathway	O
robustness	O
in	O
mFAO	O
disorders	O
.	O

First	O
,	O
we	O
used	O
comprehensive	O
biochemical	O
analyses	O
of	O
wild-type	O
mice	O
and	O
mice	O
deficient	O
for	O
medium-chain	O
acyl-CoA	O
dehydrogenase	O
(	O
MCAD	O
)	O
to	O
parameterize	O
a	O
detailed	O
computational	O
model	O
of	O
mFAO	O
.	O

Model	O
simulations	O
predicted	O
that	O
MCAD	O
deficiency	O
would	O
have	O
no	O
effect	O
on	O
the	O
pathway	O
flux	O
at	O
low	O
concentrations	O
of	O
the	O
mFAO	O
substrate	O
palmitoyl-CoA	O
.	O

However	O
,	O
high	O
concentrations	O
of	O
palmitoyl-CoA	O
would	O
induce	O
a	O
decline	O
in	O
flux	O
and	O
an	O
accumulation	O
of	O
intermediate	O
metabolites	O
.	O

We	O
proved	O
computationally	O
that	O
the	O
predicted	O
overload	O
behavior	O
was	O
due	O
to	O
substrate	O
competition	O
in	O
the	O
pathway	O
.	O

Second	O
,	O
to	O
study	O
the	O
clinical	O
relevance	O
of	O
this	O
mechanism	O
,	O
we	O
used	O
patients	O
'	O
metabolite	O
profiles	O
and	O
generated	O
a	O
humanized	O
version	O
of	O
the	O
computational	O
model	O
.	O

While	O
molecular	O
competition	O
did	O
not	O
affect	O
the	O
plasma	O
metabolite	O
profiles	O
during	O
MCAD	O
deficiency	O
,	O
it	O
was	O
a	O
key	O
factor	O
in	O
explaining	O
the	O
characteristic	O
acylcarnitine	O
profiles	O
of	O
multiple	O
acyl-CoA	O
dehydrogenase	O
deficient	O
patients	O
.	O

The	O
patient-specific	O
computational	O
models	O
allowed	O
us	O
to	O
predict	O
the	O
severity	O
of	O
the	O
disease	O
phenotype	O
,	O
providing	O
a	O
proof	O
of	O
principle	O
for	O
the	O
systems	O
medicine	O
approach	O
.	O

We	O
conclude	O
that	O
substrate	O
competition	O
is	O
at	O
the	O
basis	O
of	O
the	O
physiology	O
seen	O
in	O
patients	O
with	O
mFAO	O
disorders	O
,	O
a	O
finding	O
that	O
may	O
explain	O
why	O
these	O
patients	O
run	O
a	O
risk	O
of	O
a	O
life-threatening	O
metabolic	O
catastrophe	O
.	O

Reduction	O
in	O
Hospital-Wide	O
Clinical	B-P
Laboratory	I-P
Specimen	I-P
Identification	I-P
Errors	O
following	O
Process	O
Interventions	O
:	O
A	O
10-	O
Year	O
Retrospective	O
Observational	O
Study	O
.	O

Accurate	O
patient	O
identification	O
and	O
specimen	O
labeling	O
at	O
the	O
time	O
of	O
collection	O
are	O
crucial	O
steps	O
in	O
the	O
prevention	O
of	O
medical	O
errors	O
,	O
thereby	O
improving	O
patient	O
safety	O
.	O

All	O
patient	O
specimen	O
identification	O
errors	O
that	O
occurred	O
in	O
the	O
outpatient	O
department	O
(	O
OPD	O
)	O
,	O
emergency	O
department	O
(	O
ED	O
)	O
,	O
and	O
inpatient	O
department	O
(	O
IPD	O
)	O
of	O
a	O
3,800-	O
bed	O
academic	O
medical	O
center	O
in	O
Taiwan	O
were	O
documented	O
and	O
analyzed	O
retrospectively	O
from	O
2005	O
to	O
2014	O
.	O

To	O
reduce	O
such	O
errors	O
,	O
the	O
following	O
series	O
of	O
strategies	O
were	O
implemented	O
:	O
a	O
restrictive	O
specimen	O
acceptance	O
policy	O
for	O
the	O
ED	O
and	O
IPD	O
in	O
2006	O
;	O
a	O
computer-assisted	B-P
barcode	O
positive	O
patient	O
identification	O
system	O
for	O
the	O
ED	O
and	O
IPD	O
in	O
2007	O
and	O
2010	O
,	O
and	O
automated	O
sample	O
labeling	O
combined	O
with	O
electronic	O
identification	O
systems	O
introduced	O
to	O
the	O
OPD	O
in	O
2009	O
.	O

Of	O
the	O
2000345	O
specimens	O
collected	O
in	O
2005	O
,	O
1023	O
(	O
0.0511	O
%	O
)	O
were	O
identified	O
as	O
having	O
patient	O
identification	O
errors	O
,	O
compared	O
with	O
58	O
errors	O
(	O
0.0015	O
%	O
)	O
among	O
3761238	O
specimens	O
collected	O
in	O
2014	O
,	O
after	O
serial	O
interventions	O
;	O
this	O
represents	O
a	O
97	O
%	O
relative	O
reduction	O
.	O

The	O
total	O
number	O
(	O
rate	O
)	O
of	O
institutional	O
identification	O
errors	O
contributed	O
from	O
the	O
ED	O
,	O
IPD	O
,	O
and	O
OPD	O
over	O
a	O
10-	O
year	O
period	O
were	O
423	O
(	O
0.1058	O
%	O
)	O
,	O
556	O
(	O
0.0587	O
%	O
)	O
,	O
and	O
44	O
(	O
0.0067	O
%	O
)	O
errors	O
before	O
the	O
interventions	O
,	O
and	O
3	O
(	O
0.0007	O
%	O
)	O
,	O
52	O
(	O
0.0045	O
%	O
)	O
and	O
3	O
(	O
0.0001	O
%	O
)	O
after	O
interventions	O
,	O
representing	O
relative	O
99	O
%	O
,	O
92	O
%	O
and	O
98	O
%	O
reductions	O
,	O
respectively	O
.	O

Accurate	O
patient	O
identification	O
is	O
a	O
challenge	O
of	O
patient	O
safety	O
in	O
different	O
health	O
settings	O
.	O

The	O
data	O
collected	O
in	O
our	O
study	O
indicate	O
that	O
a	O
restrictive	O
specimen	O
acceptance	O
policy	O
,	O
computer-generated	B-P
positive	O
identification	O
systems	O
,	O
and	O
interdisciplinary	O
cooperation	O
can	O
significantly	O
reduce	O
patient	O
identification	O
errors	O
.	O

Multimodality	B-P
imaging	I-P
approach	O
in	O
the	O
diagnosis	O
of	O
chronic	O
myocarditis	O
with	O
preserved	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
MCpEF	O
)	O
:	O
The	O
role	O
of	O
2D	B-P
speckle-tracking	I-P
echocardiography	I-P
.	O

Up	O
to	O
one	O
third	O
of	O
patients	O
with	O
chronic	O
myocarditis	O
(	O
MC	O
)	O
have	O
preserved	O
left	O
ventricular	O
(	O
LV	O
)	O
ejection	O
fraction	O
(	O
MCpEF	O
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
role	O
of	O
adding	O
2D	B-P
speckle-tracking	I-P
echocardiography	I-P
(	O
STE	B-P
)	O
to	O
cardiac	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
cMRI	B-P
)	O
in	O
the	O
diagnosis	O
of	O
patients	O
with	O
MCpEF	O
.	O

We	O
analyzed	O
67	O
patients	O
with	O
suspected	O
MCpEF	O
who	O
underwent	O
endomyocardial	B-P
biopsy	I-P
(	O
EMB	B-P
)	O
.	O

Thirty-two	O
patients	O
with	O
confirmed	O
chronic	O
myocardial	O
inflammation	O
by	O
EMB	B-P
served	O
as	O
study	O
group	O
(	O
MCpEF	O
)	O
and	O
the	O
remaining	O
patients	O
(	O
n=35	O
)	O
served	O
as	O
control	O
group	O
.	O

In	O
all	O
patients	O
,	O
2D	B-P
STE	I-P
and	O
cMRI	B-P
were	O
performed	O
within	O
48h	O
before	O
EMB	B-P
.	O

Patients	O
with	O
MCpEF	O
had	O
significantly	O
lower	O
LV	O
global	O
longitudinal	O
systolic	O
strain	O
(	O
GLS	O
)	O
than	O
controls	O
(	O
GLS	O
:	O
-17.01±2.42	O
%	O
vs.	O
-19.39±3.81	O
%	O
,	O
p	O
<	O
0.001	O
;	O
respectively	O
)	O
.	O

In	O
line	O
,	O
an	O
abnormal	O
GLS	O
had	O
adequate	O
diagnostic	O
performance	O
to	O
detect	O
MCpEF	O
(	O
sensitivity	O
,	O
specificity	O
,	O
and	O
accuracy	O
of	O
82	O
%	O
,	O
70	O
%	O
,	O
and	O
76	O
%	O
,	O
respectively	O
)	O
,	O
which	O
was	O
superior	O
to	O
cMRI	B-P
based	O
on	O
the	O
Lake-Louise	O
criteria	O
(	O
sensitivity	O
,	O
specificity	O
,	O
and	O
accuracy	O
54	O
%	O
,	O
71	O
%	O
,	O
and	O
67	O
%	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
adding	O
GLS	O
to	O
the	O
Lake-Louise	O
criteria	O
improved	O
significantly	O
the	O
diagnostic	O
performance	O
of	O
cMRI	B-P
to	O
detect	O
MCpEF	O
(	O
sensitivity	O
,	O
specificity	O
,	O
and	O
accuracy	O
96	O
%	O
,	O
55	O
%	O
,	O
and	O
75	O
%	O
,	O
respectively	O
)	O
.	O

The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
GLS	O
using	O
2D	B-P
STE	I-P
could	O
play	O
an	O
important	O
role	O
in	O
the	O
diagnostic	O
evaluation	O
of	O
patients	O
with	O
suspected	O
chronic	O
myocarditis	O
with	O
preserved	O
LV	O
ejection	O
fraction	O
(	O
MCpEF	O
)	O
.	O

IN	O
VITRO	O
ANTIMICROBIAL	O
SCREENING	O
OF	O
AQUILARIA	O
AGALLOCHA	O
ROOTS	O
.	O

It	O
was	O
previously	O
shown	O
that	O
some	O
parts	O
of	O
Aquilaria	O
agallocha	O
,	O
which	O
is	O
commonly	O
known	O
as	O
oud	O
or	O
oodh	O
,	O
such	O
as	O
roots	O
have	O
been	O
used	O
as	O
a	O
traditional	O
medical	O
herbal	O
in	O
different	O
countries	O
.	O

In	O
Turkey	O
A.	O
agallocha	O
is	O
one	O
of	O
the	O
ingredients	O
while	O
preparing	O
famous	O
Mesir	O
paste	O
,	O
which	O
was	O
invented	O
as	O
a	O
medicinal	O
paste	O
and	O
used	O
from	O
the	O
Ottoman	O
period	O
to	O
now	O
at	O
least	O
for	O
500	O
years	O
.	O

The	O
identification	O
the	O
in	O
vitro	O
antimicrobial	O
activity	O
of	O
ethanol	O
extract	O
of	O
A.	O
agallocha	O
roots	O
is	O
main	O
purpose	O
of	O
this	O
analysis	O
.	O

By	O
using	O
17	O
bacteria	O
and	O
1	O
fungi	O
,	O
which	O
include	O
Bacillus	O
,	O
Candida	O
,	O
Enterobacter	O
,	O
Enterococcus	O
,	O
Escherichia	O
,	O
Klebsiella	O
,	O
Listeria	O
,	O
Pseudomonas	O
,	O
Salmonella	O
and	O
Staphylococcus	O
genera	O
,	O
the	O
activity	O
of	O
A.	O
agallocha	O
root	O
extracts	O
were	O
analysed	O
by	O
the	O
help	O
of	O
the	O
disk	B-P
diffusion	I-P
method	I-P
,	O
that	O
is	O
one	O
of	O
the	O
methods	B-P
commonly	O
used	O
to	O
determine	O
antimicrobial	O
activities	O
.	O

As	O
a	O
result	O
of	O
the	O
study	O
it	O
was	O
observed	O
that	O
ethanol	O
extracts	O
of	O
A.	O
agallocha	O
roots	O
have	O
a	O
clear	O
antimicrobial	O
activity	O
against	O
nearly	O
all	O
microorganism	O
used	O
in	O
the	O
study	O
,	O
but	O
only	O
two	O
bacteria	O
namely	O
E.	O
coli	O
ATCC	O
25922	O
and	O
S.	O
typhimurium	O
SL	O
1344	O
.	O

According	O
to	O
the	O
disk	B-P
diffusion	I-P
test	I-P
results	O
it	O
may	O
be	O
possible	O
to	O
propose	O
that	O
A.	O
agallocha	O
roots	O
should	O
have	O
a	O
medicinal	O
uses	O
especially	O
against	O
E.	O
faecium	O
,	O
L.	O
monocytogenes	O
ATCC	O
7644	O
,	O
B.	O
subtilis	O
DSMZ	O
1971	O
,	O
C.	O
albicans	O
DSMZ	O
1386	O
,	O
S.	O
epidermidis	O
DSMZ	O
20044	O
and	O
S.	O
aureus	O
ATCC	O
25923	O
.	O

MiR	O
221	O
/	O
222	O
as	O
new	O
players	O
in	O
tamoxifen	O
resistance	O
.	O

Breast	O
cancer	O
is	O
the	O
most	O
frequent	O
cancer	O
in	O
women	O
.	O

Despite	O
advances	O
in	O
early	B-P
detection	I-P
and	O
treatment	O
,	O
it	O
has	O
the	O
second	O
highest	O
mortality	O
rate	O
after	O
lung	O
cancer	O
.	O

Around	O
85	O
%	O
of	O
breast	O
carcinomas	O
are	O
ER+	O
;	O
thus	O
,	O
antiestrogens	O
like	O
tamoxifen	O
are	O
beneficial	O
.	O

Although	O
,	O
tamoxifen	O
is	O
useful	O
for	O
many	O
patients	O
,	O
plenty	O
of	O
patients	O
respond	O
poorly	O
to	O
initial	O
therapy	O
or	O
recurrence	O
occurs	O
in	O
about	O
30	O
%	O
of	O
cases	O
,	O
because	O
tamoxifen	O
resistance	O
happens	O
.	O

Drug	O
resistance	O
remains	O
a	O
major	O
clinical	O
obstacle	O
to	O
successful	O
treatment	O
of	O
breast	O
cancer	O
and	O
more	O
than	O
90	O
%	O
of	O
unsuccessful	O
treatments	O
are	O
because	O
of	O
acquired	O
resistance	O
and	O
MultiDrug	O
Resistance	O
(	O
MDR	O
)	O
is	O
a	O
major	O
contributor	O
.	O

MicroRNAs	O
are	O
members	O
of	O
a	O
novel	O
class	O
of	O
short	O
noncoding	O
RNAs	O
.	O

Besides	O
to	O
their	O
various	O
roles	O
in	O
gene	O
expression	O
,	O
miRNAs	O
are	O
considered	O
as	O
important	O
cancer	O
therapeutic	O
targets	O
and	O
biomarkers	O
.	O

Since	O
2005	O
,	O
when	O
miRNA	O
deregulation	O
was	O
first	O
reported	O
in	O
breast	O
cancer	O
,	O
more	O
than	O
1000	O
reports	O
have	O
been	O
published	O
about	O
miRNAs	O
.	O

Increasing	O
number	O
of	O
studies	O
showed	O
the	O
importance	O
of	O
miRNAs	O
in	O
antiestrogen	O
therapy	O
,	O
especially	O
on	O
tamoxifen	O
;	O
thus	O
,	O
it	O
is	O
not	O
surprising	O
that	O
these	O
tiny	O
molecules	O
are	O
involved	O
in	O
drug	O
resistance	O
.	O

Due	O
to	O
the	O
pivotal	O
role	O
of	O
these	O
known	O
RNA	O
molecules	O
,	O
in	O
this	O
review	O
,	O
we	O
tried	O
to	O
illustrate	O
the	O
importance	O
of	O
the	O
miRNAs	O
as	O
a	O
new	O
player	O
in	O
breast	O
cancer	O
pathogenesis	O
.	O

We	O
have	O
also	O
focused	O
on	O
cancer	O
drug	O
resistance	O
mechanisms	O
highlighting	O
the	O
role	O
of	O
important	O
oncomirs	O
,	O
miR	O
221	O
/	O
222	O
,	O
involved	O
in	O
cell	O
cycle	O
deregulation	O
in	O
breast	O
cancer	O
.	O

The	O
relationship	O
between	O
these	O
oncomiRs	O
with	O
resistance	O
to	O
tamoxifen	O
is	O
also	O
emphasized	O
.	O

Unaffected	O
twins	O
discordant	O
for	O
affective	O
disorders	O
show	O
changes	O
in	O
anterior	O
callosal	O
white	O
matter	O
microstructure	O
.	O

The	O
neurobiological	O
mechanisms	O
mediating	O
an	O
increased	O
risk	O
to	O
develop	O
affective	O
disorders	O
remain	O
poorly	O
understood	O
.	O

In	O
a	O
group	O
of	O
individuals	O
with	O
a	O
family	O
history	O
of	O
major	O
depressive	O
(	O
MDD	O
)	O
or	O
bipolar	O
disorder	O
(	O
BD	O
)	O
,	O
we	O
investigated	O
the	O
microstructural	O
properties	O
of	O
white	O
matter	O
fiber	O
tracts	O
,	O
that	O
is	O
,	O
cingulum	O
bundle	O
,	O
uncinate	O
fasciculus	O
,	O
anterior	O
limb	O
of	O
the	O
internal	O
capsule	O
,	O
and	O
corpus	O
callosum	O
,	O
that	O
facilitate	O
the	O
communication	O
between	O
brain	O
regions	O
implicated	O
in	O
affective	O
disorders	O
.	O

Eighty-nine	O
healthy	O
mono	O
-	O
or	O
dizygotic	O
twins	O
with	O
a	O
co-twin	O
diagnosed	O
with	O
MDD	O
or	O
BD	O
(	O
high-risk	O
)	O
and	O
57	O
healthy	O
twins	O
with	O
a	O
co-twin	O
with	O
no	O
familial	O
history	O
of	O
affective	O
disorders	O
(	O
low-risk	O
)	O
were	O
included	O
in	O
a	O
diffusion	B-P
tensor	I-P
imaging	I-P
study	I-P
.	O

The	O
high-risk	O
group	O
showed	O
decreased	O
fractional	B-P
anisotropy	I-P
(	O
FA	B-P
)	O
,	O
a	O
measure	O
of	O
water	O
diffusion	O
directionality	O
,	O
and	O
increased	O
radial	O
diffusivity	O
in	O
the	O
anterior	O
region	O
of	O
corpus	O
callosum	O
compared	O
to	O
the	O
low-risk	O
group	O
.	O

This	O
abnormality	O
was	O
not	O
associated	O
with	O
zygosity	O
or	O
type	O
of	O
depressive	O
disorder	O
of	O
co-twin	O
.	O

The	O
observed	O
decreased	O
anterior	O
callosal	O
fiber	O
FA	B-P
in	O
the	O
high-risk	O
group	O
may	O
be	O
indicative	O
of	O
a	O
compromised	O
interhemispheric	O
communication	O
between	O
left	O
and	O
right	O
frontal	O
regions	O
critically	O
involved	O
in	O
mood	O
regulation	O
.	O

Reduced	O
anterior	O
callosal	O
FA	B-P
may	O
act	O
as	O
a	O
vulnerability	O
marker	O
for	O
affective	O
disorders	O
in	O
individuals	O
at	O
familial	O
risk	O
.	O

Polyanionic	O
carbosilane	O
dendrimers	O
prevent	O
hepatitis	O
C	O
virus	O
infection	O
in	O
cell	B-P
culture	I-P
.	O

Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
is	O
a	O
major	O
biomedical	O
problem	O
worldwide	O
.	O

Although	O
new	O
direct	O
antiviral	O
agents	O
(	O
DAAs	O
)	O
have	O
been	O
developed	O
for	O
the	O
treatment	O
of	O
chronic	O
HCV	O
infection	O
,	O
the	O
potential	O
emergence	O
of	O
resistant	O
virus	O
variants	O
and	O
the	O
difficulties	O
to	O
implement	O
their	O
administration	O
worldwide	O
make	O
the	O
development	O
of	O
novel	O
antiviral	O
agents	O
an	O
urgent	O
need	O
.	O

Moreover	O
,	O
no	O
effective	O
vaccine	O
is	O
available	O
against	O
HCV	O
and	O
transmission	O
of	O
the	O
virus	O
still	O
occurs	O
particularly	O
when	O
prophylactic	O
measures	O
are	O
not	O
taken	O
.	O

We	O
used	O
a	O
cell-based	O
system	O
to	O
screen	O
a	O
battery	O
of	O
polyanionic	O
carbosilane	O
dendrimers	O
(	O
PCDs	O
)	O
to	O
identify	O
compounds	O
with	O
antiviral	O
activity	O
against	O
HCV	O
and	O
show	O
that	O
they	O
inhibit	O
effective	O
virus	O
adsorption	O
of	O
major	O
HCV	O
genotypes	O
.	O

Interestingly	O
,	O
one	O
of	O
the	O
PCDs	O
irreversibly	O
destabilized	O
infectious	O
virions	O
.	O

This	O
compound	O
displays	O
additive	O
effect	O
in	O
combination	O
with	O
a	O
clinically	O
relevant	O
DAA	O
,	O
sofosbuvir	O
.	O

Our	O
results	O
support	O
further	O
characterization	O
of	O
these	O
molecules	O
as	O
nanotools	O
for	O
the	O
control	O
of	O
hepatitis	O
C	O
virus	O
spread	O
.	O

Enhancing	O
Comparative	O
Effectiveness	O
Research	O
With	O
Automated	O
Pediatric	O
Pneumonia	O
Detection	O
in	O
a	O
Multi-Institutional	O
Clinical	O
Repository	O
:	O
A	O
PHIS	O
+	O
Pilot	O
Study	O
.	O

Community-acquired	O
pneumonia	O
is	O
a	O
leading	O
cause	O
of	O
pediatric	O
morbidity	O
.	O

Administrative	O
data	O
are	O
often	O
used	O
to	O
conduct	O
comparative	O
effectiveness	O
research	O
(	O
CER	O
)	O
with	O
sufficient	O
sample	O
sizes	O
to	O
enhance	O
detection	O
of	O
important	O
outcomes	O
.	O

However	O
,	O
such	O
studies	O
are	O
prone	O
to	O
misclassification	O
errors	O
because	O
of	O
the	O
variable	O
accuracy	O
of	O
discharge	O
diagnosis	O
codes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
an	O
automated	O
,	O
scalable	O
,	O
and	O
accurate	O
method	O
to	O
determine	O
the	O
presence	O
or	O
absence	O
of	O
pneumonia	O
in	O
children	O
using	O
chest	B-P
imaging	I-P
reports	O
.	O

The	O
multi-institutional	O
PHIS	O
+	O
clinical	O
repository	O
was	O
developed	O
to	O
support	O
pediatric	O
CER	O
by	O
expanding	O
an	O
administrative	O
database	O
of	O
children	O
's	O
hospitals	O
with	O
detailed	O
clinical	O
data	O
.	O

To	O
develop	O
a	O
scalable	O
approach	O
to	O
find	O
patients	O
with	O
bacterial	O
pneumonia	O
more	O
accurately	O
,	O
we	O
developed	O
a	O
Natural	O
Language	O
Processing	O
(	O
NLP	O
)	O
application	O
to	O
extract	O
relevant	O
information	O
from	O
chest	B-P
diagnostic	I-P
imaging	I-P
reports	O
.	O

Domain	O
experts	O
established	O
a	O
reference	O
standard	O
by	O
manually	O
annotating	O
282	O
reports	O
to	O
train	O
and	O
then	O
test	O
the	O
NLP	O
application	O
.	O

Findings	O
of	O
pleural	O
effusion	O
,	O
pulmonary	O
infiltrate	O
,	O
and	O
pneumonia	O
were	O
automatically	O
extracted	O
from	O
the	O
reports	O
and	O
then	O
used	O
to	O
automatically	O
classify	O
whether	O
a	O
report	O
was	O
consistent	O
with	O
bacterial	O
pneumonia	O
.	O

Compared	O
with	O
the	O
annotated	O
diagnostic	B-P
imaging	I-P
reports	O
reference	O
standard	O
,	O
the	O
most	O
accurate	O
implementation	O
of	O
machine	O
learning	O
algorithms	O
in	O
our	O
NLP	O
application	O
allowed	O
extracting	O
relevant	O
findings	O
with	O
a	O
sensitivity	O
of	O
.939	O
and	O
a	O
positive	O
predictive	O
value	O
of	O
.925	O
.	O

It	O
allowed	O
classifying	O
reports	O
with	O
a	O
sensitivity	O
of	O
.71	O
,	O
a	O
positive	O
predictive	O
value	O
of	O
.86	O
,	O
and	O
a	O
specificity	O
of	O
.962	O
.	O

When	O
compared	O
with	O
each	O
of	O
the	O
domain	O
experts	O
manually	O
annotating	O
these	O
reports	O
,	O
the	O
NLP	O
application	O
allowed	O
for	O
significantly	O
higher	O
sensitivity	O
(	O
.71	O
vs	O
.527	O
)	O
and	O
similar	O
positive	O
predictive	O
value	O
and	O
specificity	O
.	O

NLP	O
-based	O
pneumonia	O
information	O
extraction	O
of	O
pediatric	O
diagnostic	B-P
imaging	I-P
reports	O
performed	O
better	O
than	O
domain	O
experts	O
in	O
this	O
pilot	O
study	O
.	O

NLP	O
is	O
an	O
efficient	O
method	O
to	O
extract	O
information	O
from	O
a	O
large	O
collection	O
of	O
imaging	O
reports	O
to	O
facilitate	O
CER	O
.	O

Radiation	O
risk	O
of	O
breast	O
screening	O
in	O
England	O
with	O
digital	B-P
mammography	I-P
.	O

To	O
estimate	O
the	O
risks	O
and	O
benefits	O
of	O
breast	O
screening	O
in	O
terms	O
of	O
number	O
of	O
deaths	O
due	O
to	O
radiation-induced	O
cancers	O
and	O
the	O
number	O
of	O
lives	O
saved	O
owing	O
to	O
modern	O
screening	O
in	O
the	O
National	O
Health	O
Service	O
Breast	O
Screening	O
Programme	O
(	O
NHSBSP	O
)	O
in	O
England	O
.	O

Radiation	O
risk	O
model	O
,	O
patient	O
dose	O
data	O
and	O
data	O
from	O
national	O
screening	O
statistics	O
were	O
used	O
to	O
estimate	O
the	O
number	O
of	O
deaths	O
due	O
to	O
radiation-induced	O
breast	O
cancers	O
in	O
the	O
NHSBSP	O
in	O
England	O
.	O

Dose	O
and	O
dose	O
effectiveness	O
factors	O
(	O
DDREFs	O
)	O
equal	O
to	O
one	O
and	O
two	O
were	O
assumed	O
.	O

The	O
breast	O
cancer	O
mortality	O
reduction	O
in	O
the	O
invited	O
population	O
due	O
to	O
screening	O
and	O
the	O
percentage	O
of	O
females	O
diagnosed	O
with	O
symptomatic	O
breast	O
cancer	O
,	O
who	O
die	O
from	O
breast	O
cancer	O
,	O
were	O
collated	O
from	O
the	O
literature	O
.	O

The	O
number	O
of	O
lives	O
saved	O
owing	O
to	O
screening	O
was	O
calculated	O
.	O

Assuming	O
,	O
a	O
total	O
of	O
1,770,436	O
females	O
between	O
the	O
ages	O
of	O
50-70	O
years	O
were	O
screened	O
each	O
year	O
,	O
and	O
a	O
breast	O
cancer	O
mortality	O
reduction	O
of	O
20	O
%	O
due	O
to	O
screening	O
in	O
the	O
invited	O
population	O
,	O
the	O
number	O
of	O
screen-detected	O
cancers	O
were	O
14,872	O
annually	O
,	O
resulting	O
in	O
1071	O
lives	O
saved	O
.	O

Conversely	O
,	O
for	O
the	O
same	O
mortality	O
reduction	O
,	O
the	O
number	O
of	O
radiation-induced	O
cancer	O
s	O
was	O
36	O
and	O
18	O
for	O
DDREFs	O
of	O
1	O
and	O
2	O
,	O
respectively	O
.	O

This	O
resulted	O
in	O
seven	O
and	O
three	O
deaths	O
due	O
to	O
radiation-induced	O
cancers	O
annually	O
for	O
DDREFs	O
of	O
1	O
and	O
2	O
,	O
respectively	O
.	O

The	O
ratios	O
of	O
lives	O
saved	O
owing	O
to	O
screening	O
to	O
radiation-induced	O
cancers	O
were	O
30	O
:	O
1	O
and	O
60	O
:	O
1	O
for	O
DDREFs	O
of	O
1	O
and	O
2	O
.	O

The	O
ratios	O
of	O
lives	O
saved	O
owing	O
to	O
screening	O
to	O
deaths	O
due	O
to	O
radiation-induced	O
cancer	O
s	O
were	O
156	O
:	O
1	O
and	O
312	O
:	O
1	O
for	O
DDREFs	O
of	O
1	O
and	O
2	O
.	O

For	O
the	O
1.8	O
%	O
of	O
the	O
screening	O
population	O
with	O
very	O
thick	O
breasts	O
,	O
the	O
latter	O
ratios	O
decrease	O
to	O
94	O
:	O
1	O
and	O
187	O
:	O
1	O
for	O
DDREFs	O
of	O
1	O
and	O
2	O
.	O

The	O
breast	O
cancer	O
mortality	O
reduction	O
due	O
to	O
screening	O
greatly	O
outweighs	O
the	O
risk	O
of	O
death	O
due	O
to	O
radiation-induced	O
cancer	O
s.	O
Advances	O
in	O
knowledge	O
:	O
Estimation	O
of	O
the	O
radiation	O
risk	O
for	O
modern	O
breast	O
screening	O
in	O
England	O
using	O
digital	B-P
mammography	I-P
.	O

Metabolic	O
responses	O
of	O
the	O
growing	O
Daphnia	O
similis	O
to	O
chronic	O
AgNPs	O
exposure	O
as	O
revealed	O
by	O
GC-Q-TOF/MS	B-P
and	O
LC-Q-TOF/MS	B-P
.	O

Silver	O
nanoparticles	O
(	O
AgNPs	O
)	O
are	O
one	O
of	O
the	O
most	O
widely	O
used	O
nanomaterials	O
.	O

Their	O
fast-growing	O
utilization	O
has	O
increased	O
the	O
occurrence	O
of	O
AgNPs	O
in	O
the	O
environment	O
,	O
posing	O
potential	O
health	O
and	O
ecological	O
risks	O
.	O

In	O
this	O
study	O
,	O
we	O
conducted	O
chronic	B-P
toxicity	I-P
tests	I-P
and	O
investigated	O
the	O
metabolic	O
changes	O
of	O
the	O
growing	O
Daphna	O
similis	O
with	O
exposure	O
to	O
0	O
,	O
0.02	O
,	O
and	O
1	O
ppb	O
AgNPs	O
,	O
using	O
non-targeted	B-P
mass	I-P
spectrometry	I-P
-based	O
metabolomics	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
baseline	O
metabolite	O
change	O
of	O
a	O
common	O
aquatic	O
organism	O
Daphnia	O
crustacean	O
through	O
its	O
life-cycle	O
.	O

The	O
results	O
show	O
a	O
dynamic	O
kinetic	O
pattern	O
of	O
the	O
growing	O
Daphnia	O
's	O
metabolome	O
underwent	O
a	O
cycle	O
from	O
day	O
0	O
to	O
day	O
21	O
,	O
with	O
the	O
level	O
of	O
metabolites	O
gradually	O
increasing	O
from	O
day	O
0	O
to	O
day	O
13	O
,	O
before	O
falling	O
back	O
to	O
the	O
baseline	O
level	O
of	O
day	O
0	O
on	O
day	O
21	O
.	O

As	O
for	O
the	O
samples	O
exposed	O
to	O
environmental	O
concentrations	O
of	O
AgNPs	O
,	O
although	O
without	O
morphological	O
or	O
structural	O
changes	O
,	O
numerous	O
metabolite	O
changes	O
occurred	O
abruptly	O
during	O
the	O
first	O
10	O
days	O
,	O
and	O
these	O
changes	O
reached	O
steady	O
state	O
by	O
day	O
13	O
.	O

The	O
significant	O
changes	O
in	O
certain	O
metabolites	O
,	O
such	O
as	O
amino	O
acids	O
(	O
serine	O
,	O
threonine	O
and	O
tyrosine	O
)	O
,	O
sugars	O
(	O
d-allose	O
)	O
and	O
fatty	O
acids	O
(	O
arachidonic	O
acid	O
)	O
revealed	O
new	O
insights	O
into	O
how	O
these	O
metabolites	O
in	O
Daphnia	O
respond	O
to	O
chronic	O
AgNPs	O
stress	O
.	O

These	O
findings	O
highlight	O
the	O
capability	O
of	O
metabolomics	O
to	O
discover	O
early	O
metabolic	O
responses	O
to	O
environmental	O
silver	O
nanoparticles	O
.	O

Histomorphometric	B-P
and	O
transcriptome	O
evaluation	O
of	O
early	O
healing	O
bone	O
treated	O
with	O
a	O
novel	O
human	O
particulate	O
dentin	O
powder	O
.	O

Human	O
particulate	O
dentin	O
(	O
HPD	O
)	O
shows	O
potential	O
as	O
an	O
alternative	O
bone	O
grafting	O
material	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
bone	O
healing	O
at	O
the	O
molecular	O
level	O
after	O
grafting	O
with	O
HPD	O
is	O
unclear	O
.	O

This	O
study	O
assessed	O
the	O
histological	O
and	O
global	O
gene	O
expression	O
of	O
bone	O
tissues	O
grafted	O
with	O
HPD	O
.	O

The	O
HPD	O
was	O
prepared	O
to	O
250-500	O
µm	O
in	O
size	O
.	O

X-ray	B-P
diffraction	I-P
(	O
XRD	B-P
)	O
and	O
energy	B-P
dispersive	I-P
x-ray	I-P
spectroscopy	I-P
(	O
EDX	B-P
)	O
were	O
performed	O
to	O
confirm	O
the	O
crystal	O
structure	O
,	O
organic	O
compound	O
residues	O
,	O
and	O
surface	O
morphology	O
,	O
respectively	O
.	O

Bony	O
defects	O
were	O
created	O
on	O
the	O
heads	O
of	O
24	O
New	O
Zealand	O
White	O
rabbits	O
.	O

Sterilized	O
HPD	O
was	O
used	O
as	O
the	O
grafting	O
material	O
.	O

The	O
quality	O
and	O
quantity	O
of	O
new	O
bone	O
formation	O
was	O
evaluated	O
using	O
micro-CT	B-P
and	O
histologic	O
analyses	O
during	O
the	O
8	O
week	O
experimental	O
periods	O
.	O

For	O
microarray	B-P
assay	I-P
,	O
bone	O
tissue	O
and	O
blood	O
samples	O
were	O
taken	O
at	O
3	O
,	O
5	O
and	O
7	O
d	O
post-implantation	O
.	O

The	O
results	O
of	O
XRD	B-P
and	O
EDX	B-P
showed	O
that	O
HPD	O
exhibited	O
physical	O
and	O
chemical	O
properties	O
similar	O
to	O
natural	O
hydroxyapatite	O
.	O

New	O
bone	O
formation	O
was	O
observed	O
after	O
HPD	O
implantation	O
compared	O
to	O
the	O
controls	O
,	O
as	O
shown	O
on	O
hematoxylin	B-P
and	I-P
eosin	I-P
staining	I-P
and	O
micro-CT	B-P
.	O

The	O
bone	O
volume	O
of	O
HPD	O
treated	O
animals	O
was	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
at	O
all	O
observation	O
times	O
.	O

Microarray	B-P
analysis	I-P
showed	O
that	O
vascular	O
development	O
coupled	O
with	O
immune	O
and	O
inflammatory	O
related	O
genes	O
were	O
expressed	O
in	O
the	O
early	O
healing	O
stage	O
.	O

The	O
gene	O
coding	O
for	O
the	O
IL-1	O
antagonist	O
,	O
IL1RN	O
,	O
was	O
expressed	O
to	O
inhibit	O
the	O
inflammatory	O
response	O
,	O
and	O
at	O
the	O
same	O
time	O
,	O
the	O
CCL2	O
gene	O
was	O
activated	O
to	O
2.3	O
times	O
the	O
normal	O
level	O
.	O

BMP2	O
,	O
RUNX2	O
,	O
COL1A	O
,	O
and	O
OPN	O
expression	O
were	O
also	O
up-regulated	O
.	O

CCL2	O
predominated	O
in	O
osteoblastogenesis	O
of	O
the	O
HPD	O
-	O
treated	O
bony	O
defect	O
in	O
the	O
early	O
stage	O
of	O
healing	O
.	O

HPD	O
accelerated	O
bone	O
regeneration	O
and	O
augmentation	O
.	O

These	O
results	O
suggested	O
that	O
HPD	O
provided	O
potential	O
as	O
a	O
bone	O
graft	O
resource	O
during	O
the	O
bone	O
healing	O
process	O
.	O

Cannabis	O
use	O
is	O
associated	O
with	O
reduced	O
prevalence	O
of	O
non-alcoholic	O
fatty	O
liver	O
disease	O
:	O
A	O
cross-sectional	O
study	O
.	O

Cannabis	O
use	O
is	O
associated	O
with	O
reduced	O
prevalence	O
of	O
obesity	O
and	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
in	O
humans	O
and	O
mouse	O
disease	O
models	O
.	O

Obesity	O
and	O
DM	O
are	O
a	O
well-established	O
independent	O
risk	O
factor	O
for	O
non-alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
,	O
the	O
most	O
prevalent	O
liver	O
disease	O
globally	O
.	O

The	O
effects	O
of	O
cannabis	O
use	O
on	O
NAFLD	O
prevalence	O
in	O
humans	O
remains	O
ill-defined	O
.	O

Our	O
objective	O
is	O
to	O
determine	O
the	O
relationship	O
between	O
cannabis	O
use	O
and	O
the	O
prevalence	O
of	O
NAFLD	O
in	O
humans	O
.	O

We	O
conducted	O
a	O
population-based	O
case-control	O
study	O
of	O
5,950,391	O
patients	O
using	O
the	O
2014	O
Healthcare	O
Cost	O
and	O
Utilization	O
Project	O
(	O
HCUP	O
)	O
,	O
Nationwide	O
Inpatient	O
Survey	O
(	O
NIS	O
)	O
discharge	O
records	O
of	O
patients	O
18	O
years	O
and	O
older	O
.	O

After	O
identifying	O
patients	O
with	O
NAFLD	O
(	O
1	O
%	O
of	O
all	O
patients	O
)	O
,	O
we	O
next	O
identified	O
three	O
exposure	O
groups	O
:	O
non-cannabis	O
users	O
(	O
98.04	O
%	O
)	O
,	O
non-dependent	O
cannabis	O
users	O
(	O
1.74	O
%	O
)	O
,	O
and	O
dependent	O
cannabis	O
users	O
(	O
0.22	O
%	O
)	O
.	O

We	O
adjusted	O
for	O
potential	O
demographics	O
and	O
patient	O
related	O
confounders	O
and	O
used	O
multivariate	O
logistic	O
regression	O
(	O
SAS	O
9.4	O
)	O
to	O
determine	O
the	O
odds	O
of	O
developing	O
NAFLD	O
with	O
respects	O
to	O
cannabis	O
use	O
.	O

Our	O
findings	O
revealed	O
that	O
cannabis	O
users	O
(	O
dependent	O
and	O
non-dependent	O
)	O
showed	O
significantly	O
lower	O
NAFLD	O
prevalence	O
compared	O
to	O
non-users	O
(	O
AOR	O
:	O
0.82	O
[	O
0.76-0.88	O
]	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

The	O
prevalence	O
of	O
NAFLD	O
was	O
15	O
%	O
lower	O
in	O
non-dependent	O
users	O
(	O
AOR	O
:	O
0.85	O
[	O
0.79-0.92	O
]	O
;	O
p	O
<	O
0.0001	O
)	O
and	O
52	O
%	O
lower	O
in	O
dependent	O
users	O
(	O
AOR	O
:	O
0.49	O
[	O
0.36-0.65	O
]	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

Among	O
cannabis	O
users	O
,	O
dependent	O
patients	O
had	O
43	O
%	O
significantly	O
lower	O
prevalence	O
of	O
NAFLD	O
compared	O
to	O
non-dependent	O
patients	O
(	O
AOR	O
:	O
0.57	O
[	O
0.42-0.77	O
]	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

Our	O
observations	O
suggest	O
that	O
cannabis	O
use	O
is	O
associated	O
with	O
lower	O
prevalence	O
of	O
NAFLD	O
in	O
patients	O
.	O

These	O
novel	O
findings	O
suggest	O
additional	O
molecular	B-P
mechanistic	I-P
studies	I-P
to	O
explore	O
the	O
potential	O
role	O
of	O
cannabis	O
use	O
in	O
NAFLD	O
development	O
.	O

Proximal	B-P
Soil	I-P
Sensing	I-P
-	O
A	O
Contribution	O
for	O
Species	O
Habitat	O
Distribution	O
Modelling	O
of	O
Earthworms	O
in	O
Agricultural	O
Soils	O
?	O
.	O

Earthworms	O
are	O
important	O
for	O
maintaining	O
soil	O
ecosystem	O
functioning	O
and	O
serve	O
as	O
indicators	O
of	O
soil	O
fertility	O
.	O

However	O
,	O
detection	O
of	O
earthworms	O
is	O
time-consuming	O
,	O
which	O
hinders	O
the	O
assessment	O
of	O
earthworm	O
abundances	O
with	O
high	O
sampling	O
density	O
over	O
entire	O
fields	O
.	O

Recent	O
developments	O
of	O
mobile	O
terrestrial	O
sensor	O
platforms	O
for	O
proximal	B-P
soil	I-P
sensing	I-P
(	O
PSS	B-P
)	O
provided	O
new	O
tools	O
for	O
collecting	O
dense	O
spatial	O
information	O
of	O
soils	O
using	O
various	O
sensing	O
principles	O
.	O

Yet	O
,	O
the	O
potential	O
of	O
PSS	B-P
for	O
assessing	O
earthworm	O
habitats	O
is	O
largely	O
unexplored	O
.	O

This	O
study	O
investigates	O
whether	O
PSS	B-P
data	O
contribute	O
to	O
the	O
spatial	O
prediction	O
of	O
earthworm	O
abundances	O
in	O
species	O
distribution	O
models	O
of	O
agricultural	O
soils	O
.	O

Proximal	B-P
soil	I-P
sensing	I-P
data	O
,	O
e.g.	O
,	O
soil	O
electrical	O
conductivity	O
(	O
EC	O
)	O
,	O
pH	O
,	O
and	O
near	B-P
infrared	I-P
absorbance	I-P
(	O
NIR	B-P
)	O
,	O
were	O
collected	O
in	O
real-time	O
in	O
a	O
field	O
with	O
two	O
management	O
strategies	O
(	O
reduced	O
tillage	O
/	O
conventional	O
tillage	O
)	O
and	O
sandy	O
to	O
loam	O
soils	O
.	O

PSS	B-P
was	O
related	O
to	O
observations	O
from	O
a	O
long-term	O
(	O
11	O
years	O
)	O
earthworm	O
observation	O
study	O
conducted	O
at	O
42	O
plots	O
.	O

Earthworms	O
were	O
sampled	O
from	O
0.5	O
x	O
0.5	O
x	O
0.2	O
m³	O
soil	O
blocks	O
and	O
identified	O
to	O
species	O
level	O
.	O

Sensor	O
data	O
were	O
highly	O
correlated	O
with	O
earthworm	O
abundances	O
observed	O
in	O
reduced	O
tillage	O
but	O
less	O
correlated	O
with	O
earthworm	O
abundances	O
observed	O
in	O
conventional	O
tillage	O
.	O

This	O
may	O
indicate	O
that	O
management	O
influences	O
the	O
sensor	O
-	O
earthworm	O
relationship	O
.	O

Generalized	O
additive	O
models	O
and	O
state-space	O
models	O
showed	O
that	O
modelling	O
based	O
on	O
data	O
fusion	O
from	O
EC	O
,	O
pH	O
,	O
and	O
NIR	B-P
sensors	O
produced	O
better	O
results	O
than	O
modelling	O
without	O
sensor	O
data	O
or	O
data	O
from	O
just	O
a	O
single	O
sensor	O
.	O

Regarding	O
the	O
individual	O
earthworm	O
species	O
,	O
particular	O
sensor	O
combinations	O
were	O
more	O
appropriate	O
than	O
others	O
due	O
to	O
the	O
different	O
habitat	O
requirements	O
of	O
the	O
earthworms	O
.	O

Earthworm	O
species	O
with	O
soil	O
-specific	O
habitat	O
preferences	O
were	O
spatially	O
predicted	O
with	O
higher	O
accuracy	O
by	O
PSS	B-P
than	O
more	O
ubiquitous	O
species	O
.	O

Our	O
findings	O
suggest	O
that	O
PSS	B-P
contributes	O
to	O
the	O
spatial	O
modelling	O
of	O
earthworm	O
abundances	O
at	O
field	O
scale	O
and	O
that	O
it	O
will	O
support	O
species	O
distribution	O
modelling	O
in	O
the	O
attempt	O
to	O
understand	O
the	O
soil	O
-	O
earthworm	O
relationships	O
in	O
agroecosystems	O
.	O

The	O
use	O
of	O
informativity	O
in	O
the	O
development	O
of	O
robust	O
viromics	O
-based	O
examinations	O
.	O

Metagenomics	O
-based	O
studies	O
have	O
provided	O
insight	O
into	O
many	O
of	O
the	O
complex	O
microbial	O
communities	O
responsible	O
for	O
maintaining	O
life	O
on	O
this	O
planet	O
.	O

Sequencing	O
efforts	O
often	O
uncover	O
novel	O
genetic	O
content	O
;	O
this	O
is	O
most	O
evident	O
for	O
phage	O
communities	O
,	O
in	O
which	O
upwards	O
of	O
90	O
%	O
of	O
all	O
sequences	O
exhibit	O
no	O
similarity	O
to	O
any	O
sequence	O
in	O
current	O
data	O
repositories	O
.	O

For	O
the	O
small	O
fraction	O
that	O
can	O
be	O
identified	O
,	O
the	O
top	O
BLAST	O
hit	O
is	O
generally	O
posited	O
as	O
being	O
representative	O
of	O
a	O
viral	O
taxon	O
present	O
in	O
the	O
sample	O
of	O
origin	O
.	O

Homology	O
-based	O
classification	O
,	O
however	O
,	O
can	O
be	O
misleading	O
as	O
sequence	O
repositories	O
capture	O
but	O
a	O
small	O
fraction	O
of	O
phage	O
diversity	O
.	O

Furthermore	O
,	O
lateral	O
gene	O
transfer	O
is	O
pervasive	O
within	O
phage	O
communities	O
.	O

As	O
such	O
,	O
the	O
presence	O
of	O
a	O
particular	O
gene	O
may	O
not	O
be	O
indicative	O
of	O
the	O
presence	O
of	O
a	O
particular	O
viral	O
species	O
.	O

Rather	O
,	O
it	O
is	O
just	O
that	O
:	O
an	O
indication	O
of	O
the	O
presence	O
of	O
a	O
specific	O
gene	O
.	O

To	O
circumvent	O
this	O
limitation	O
,	O
we	O
have	O
developed	O
a	O
new	O
method	O
for	O
the	O
analysis	B-P
of	I-P
viral	I-P
metagenomic	I-P
datasets	I-P
.	O

BLAST	O
hits	O
are	O
weighted	O
,	O
integrating	O
the	O
sequence	O
identity	O
and	O
length	O
of	O
alignments	O
as	O
well	O
as	O
a	O
taxonomic	O
signal	O
,	O
such	O
that	O
each	O
gene	O
is	O
evaluated	O
with	O
respect	O
to	O
its	O
information	O
content	O
.	O

Through	O
this	O
quantifiable	O
metric	O
,	O
predictions	O
of	O
viral	O
community	O
structure	O
can	O
be	O
made	O
with	O
confidence	O
.	O

As	O
a	O
proof-of-concept	O
,	O
the	O
approach	O
presented	O
here	O
was	O
implemented	O
and	O
applied	O
to	O
seven	O
freshwater	O
viral	O
metagenomes	O
.	O

While	O
providing	O
a	O
robust	O
method	O
for	O
evaluating	O
viral	O
metagenomic	O
data	O
,	O
the	O
tool	O
is	O
versatile	O
and	O
can	O
easily	O
be	O
customized	O
to	O
investigations	O
of	O
any	O
environment	O
or	O
biome	O
.	O

Fragment	O
-Based	O
Discovery	O
of	O
5-Arylisatin	O
-Based	O
Inhibitors	O
of	O
Matrix	O
Metalloproteinases	O
2	O
and	O
13	O
.	O

Matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
are	O
well-established	O
targets	O
for	O
several	O
pathologies	O
.	O

In	O
particular	O
,	O
MMP-2	O
and	O
MMP-13	O
play	O
a	O
prominent	O
role	O
in	O
cancer	O
progression	O
.	O

In	O
this	O
study	O
,	O
a	O
structure-based	O
screening	O
campaign	O
was	O
applied	O
to	O
prioritize	O
metalloproteinase	O
-oriented	O
fragments	O
.	O

This	O
computational	O
model	O
was	O
applied	O
to	O
a	O
representative	O
fragment	O
set	O
from	O
the	O
publically	O
available	O
EDASA	O
Scientific	O
compound	O
library	O
.	O

These	O
fragments	O
were	O
prioritized	O
,	O
and	O
the	O
top-ranking	O
hits	O
were	O
tested	O
in	O
a	O
biological	B-P
assay	I-P
to	O
validate	O
the	O
model	O
.	O

Two	O
scaffolds	O
showed	O
consistent	O
activity	O
in	O
the	O
assay	B-P
,	O
and	O
the	O
isatin-based	O
compounds	O
were	O
the	O
most	O
interesting	O
.	O

These	O
latter	O
fragments	O
have	O
significant	O
potential	O
as	O
tools	O
for	O
the	O
design	O
and	O
realization	O
of	O
novel	O
MMP	O
inhibitors	O
.	O

In	O
addition	O
to	O
their	O
micromolar	O
activity	O
,	O
the	O
chemical	O
synthesis	O
affords	O
flexible	O
and	O
creative	O
access	O
to	O
their	O
analogues	O
.	O

Silk	O
I	O
and	O
Silk	O
II	O
studied	O
by	O
fast	B-P
scanning	I-P
calorimetry	I-P
.	O

Using	O
fast	B-P
scanning	I-P
calorimetry	I-P
(	O
FSC	B-P
)	O
,	O
we	O
investigated	O
the	O
glass	O
transition	O
and	O
crystal	O
melting	O
of	O
samples	O
of	O
B.	O
mori	O
silk	O
fibroin	O
containing	O
Silk	O
I	O
and/or	O
Silk	O
II	O
crystal	O
s.	O
Due	O
to	O
the	O
very	O
short	O
residence	O
times	O
at	O
high	O
temperatures	O
during	O
such	O
measurements	O
,	O
thermal	O
decomposition	O
of	O
silk	O
protein	O
can	O
be	O
significantly	O
suppressed	O
.	O

FSC	B-P
was	O
performed	O
at	O
2000K/s	O
using	O
the	O
Mettler	B-P
Flash	I-P
DSC1	I-P
on	O
fibroin	O
films	O
with	O
masses	O
around	O
130-270ng	O
.	O

Films	O
were	O
prepared	O
with	O
different	O
crystalline	O
fractions	O
(	O
ranging	O
from	O
0.26	O
to	O
0.50	O
)	O
and	O
with	O
different	O
crystal	O
structures	O
(	O
Silk	O
I	O
,	O
Silk	O
II	O
,	O
or	O
mixed	O
)	O
by	O
varying	O
the	O
processing	O
conditions	O
.	O

These	O
included	O
water	O
annealing	O
at	O
different	O
temperatures	O
,	O
exposure	O
to	O
50	O
%	O
MeOH	O
in	O
water	O
,	O
or	O
autoclaving	O
.	O

The	O
resulting	O
crystal	O
structure	O
was	O
examined	O
using	O
wide	O
angle	O
X-ray	B-P
scattering	I-P
.	O

Degree	O
of	O
crystallinity	O
was	O
evaluated	O
from	O
Fourier	O
transform	O
infrared	O
(	O
FTIR	O
)	O
spectroscopy	O
and	O
from	O
analysis	O
of	O
the	O
heat	O
capacity	O
increment	O
at	O
the	O
glass	O
transition	O
temperature	O
.	O

Silk	O
fibroin	O
films	O
prepared	O
by	O
water	O
annealing	O
at	O
25°C	O
were	O
the	O
least	O
crystalline	O
and	O
had	O
Silk	O
I	O
structure	O
.	O

FTIR	O
and	O
FSC	B-P
studies	O
showed	O
that	O
films	O
prepared	O
by	O
autoclaving	O
or	O
50	O
%	O
MeOH	O
exposure	O
were	O
the	O
most	O
crystalline	O
and	O
had	O
Silk	O
II	O
structure	O
.	O

Intermediate	O
crystalline	O
fraction	O
and	O
mixed	O
Silk	O
I	O
/	O
Silk	O
II	O
structure	O
s	O
were	O
found	O
in	O
films	O
prepared	O
by	O
water	O
annealing	O
at	O
37°C	O
.	O

FSC	B-P
results	O
indicate	O
that	O
Silk	O
I	O
I	O
crystals	O
exhibit	O
endotherms	O
of	O
narrower	O
width	O
and	O
have	O
higher	O
mean	O
melting	O
temperature	O
Tm	O
(	O
II	O
)	O
=351±2.6°C	O
,	O
compared	O
to	O
Silk	O
I	O
crystals	O
which	O
melt	O
at	O
Tm	O
(	O
I	O
)	O
=292±3.8°C	O
.	O

Films	O
containing	O
mixed	O
Silk	O
I	O
/	O
Silk	O
II	O
structure	O
showed	O
two	O
clearly	O
separated	O
endothermic	O
peaks	O
.	O

Evidence	O
suggests	O
that	O
the	O
two	O
types	O
of	O
crystal	O
s	O
melt	O
separately	O
and	O
do	O
not	O
thermal	O
ly	O
interconvert	O
on	O
the	O
extremely	O
short	O
time	O
scale	O
(	O
0.065s	O
between	O
onset	O
and	O
end	O
of	O
melting	O
)	O
of	O
the	O
FSC	B-P
experiment	I-P
.	O

Silkworm	O
silk	O
is	O
a	O
naturally	O
occurring	O
biomaterial	O
.	O

The	O
fibroin	O
component	O
of	O
silk	O
forms	O
two	O
types	O
of	O
crystals	O
.	O

Silk	O
properties	O
depend	O
upon	O
the	O
amount	O
and	O
type	O
of	O
crystals	O
,	O
and	O
their	O
stability	O
.	O

One	O
measure	O
of	O
stability	O
is	O
crystal	O
melting	O
temperature	O
.	O

Crystal	O
s	O
which	O
are	O
more	O
stable	O
have	O
a	O
higher	O
melting	O
temperature	O
.	O

Until	O
now	O
,	O
it	O
has	O
been	O
challenging	O
to	O
study	O
thermal	O
behavior	O
of	O
silk	O
crystal	O
s	O
because	O
they	O
degrade	O
at	O
high	O
temperature	O
.	O

To	O
avoid	O
degradation	O
,	O
and	O
study	O
the	O
melting	O
properties	O
of	O
silk	O
biomaterial	O
,	O
we	O
heated	O
silk	O
at	O
a	O
very	O
fast	O
rate	O
of	O
2000K/s	O
using	O
a	O
special	O
calorimeter	O
.	O

We	O
have	O
shown	O
that	O
the	O
two	O
crystal	O
types	O
have	O
very	O
different	O
melting	O
temperature	O
s	O
,	O
indicating	O
that	O
one	O
crystal	O
type	O
is	O
much	O
more	O
stable	O
than	O
the	O
other	O
.	O

Maternal	O
vascular	O
responses	O
to	O
hypoxia	O
in	O
a	O
rat	O
model	O
of	O
intrauterine	O
growth	O
restriction	O
.	O

Intrauterine	O
growth	O
restriction	O
(	O
IUGR	O
)	O
is	O
a	O
common	O
pregnancy	O
complication	O
and	O
is	O
a	O
leading	O
cause	O
of	O
fetal	O
morbidity	O
and	O
mortality	O
.	O

Placental	O
hypoxia	O
contributes	O
to	O
adverse	O
fetal	O
consequences	O
,	O
such	O
as	O
IUGR	O
.	O

Exposing	O
pregnant	O
rats	O
to	O
hypoxia	O
can	O
lead	O
to	O
IUGR	O
;	O
however	O
,	O
assessment	O
of	O
maternal	O
vascular	O
function	O
in	O
a	O
rat	O
model	O
of	O
hypoxia	O
,	O
and	O
the	O
mechanisms	O
that	O
may	O
contribute	O
to	O
adverse	O
pregnancy	O
outcomes	O
,	O
has	O
not	O
been	O
extensively	O
studied	O
.	O

We	O
hypothesized	O
that	O
exposing	O
pregnant	O
rats	O
to	O
hypoxia	O
will	O
affect	O
maternal	O
systemic	O
vascular	O
function	O
and	O
increase	O
the	O
uterine	O
artery	O
resistance	O
index	O
(	O
RI	O
)	O
,	O
which	O
will	O
be	O
associated	O
with	O
IUGR	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
pregnant	O
rats	O
were	O
kept	O
in	O
normoxia	O
(	O
21	O
%	O
O2	O
)	O
or	O
hypoxia	O
(	O
11	O
%	O
O2	O
)	O
from	O
gestational	O
day	O
(	O
GD	O
)	O
6	O
to	O
20	O
Maternal	O
blood	O
pressure	O
,	O
uteroplacental	O
resistance	O
index	O
(	O
RI	O
)	O
(	O
ultrasound	B-P
biomicroscopy	I-P
)	O
,	O
and	O
vascular	O
function	O
(	O
wire	B-P
myography	I-P
)	O
were	O
assessed	O
in	O
uterine	O
and	O
mesenteric	O
arteries	O
.	O

Fetal	O
weight	O
was	O
significantly	O
reduced	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
maternal	O
blood	O
pressure	O
was	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
rats	O
exposed	O
to	O
hypoxia	O
.	O

Maternal	O
vascular	O
function	O
was	O
also	O
affected	O
after	O
exposure	O
to	O
hypoxia	O
,	O
including	O
impaired	O
endothelium	O
-dependent	O
vasodilation	O
responses	O
to	O
methacholine	O
in	O
isolated	O
uterine	O
arteries	O
(	O
pEC50	O
normoxia	O
:	O
6.55	O
±	O
0.23	O
vs.	O
hypoxia	O
:	O
5.02	O
±	O
0.35	O
,	O
P	O
<	O
0.01	O
)	O
and	O
a	O
reduced	O
uterine	O
artery	O
RI	O
in	O
vivo	O
(	O
normoxia	O
:	O
0.63	O
±	O
0.04	O
vs.	O
hypoxia	O
:	O
0.53	O
±	O
0.01	O
,	O
P	O
<	O
0.05	O
)	O
;	O
associated	O
with	O
an	O
increase	O
in	O
umbilical	O
vein	O
RI	O
(	O
normoxia	O
:	O
0.35	O
±	O
0.02	O
vs.	O
hypoxia	O
:	O
0.45	O
±	O
0.04	O
,	O
P	O
<	O
0.05	O
)	O
.	O

These	O
data	O
demonstrate	O
maternal	O
and	O
fetal	O
alterations	O
in	O
vascular	O
function	O
due	O
to	O
prenatal	O
exposure	O
to	O
hypoxia	O
.	O

Further	O
,	O
although	O
there	O
was	O
a	O
compensatory	O
reduction	O
in	O
uterine	O
artery	O
RI	O
in	O
the	O
hypoxia	O
groups	O
,	O
this	O
was	O
not	O
sufficient	O
to	O
prevent	O
IUGR	O
.	O

Association	O
of	O
interleukin-2	O
,	O
-4	O
and	O
-10	O
with	O
dengue	O
severity	O
.	O

Dengue	O
is	O
an	O
arboviral	O
disease	O
caused	O
by	O
four	O
distinct	O
serotypes	O
of	O
dengue	O
virus	O
.	O

The	O
pathogenesis	O
of	O
dengue	O
is	O
not	O
very	O
clearly	O
understood	O
.	O

Various	O
pro-	O
and	O
anti-inflammatory	O
cytokines	O
are	O
involved	O
in	O
the	O
immune	O
pathogenesis	O
of	O
dengue	O
.	O

Interleukin	O
(	O
IL	O
)	O
-2	O
/	O
IL-2	O
receptor	O
interaction	O
is	O
supposed	O
to	O
play	O
a	O
protective	O
role	O
,	O
while	O
IL-4	O
acts	O
as	O
pro-inflammatory	O
whereas	O
IL-10	O
acts	O
as	O
anti-inflammatory	O
cytokines	O
.	O

So	O
far	O
,	O
not	O
much	O
information	O
is	O
available	O
regarding	O
the	O
established	O
role	O
of	O
these	O
cytokines	O
with	O
dengue	O
infection	O
and	O
severity	O
.	O

our	O
study	O
aimed	O
to	O
show	O
the	O
association	O
of	O
IL-2	O
,	O
-4	O
,	O
and	O
-10	O
with	O
severity	O
of	O
dengue	O
infection	O
.	O

This	O
was	O
a	O
cross-sectional	O
study	O
.	O

The	O
study	O
was	O
conducted	O
in	O
the	O
year	O
2015	O
;	O
150	O
blood	O
samples	O
from	O
suspected	O
dengue	O
cases	O
were	O
confirmed	O
for	O
dengue	O
and	O
then	O
with	O
an	O
equal	O
number	O
of	O
healthy	O
control	O
samples	O
were	O
tested	O
for	O
cytokines	B-P
levels	I-P
(	O
IL-2	O
,	O
-4	O
,	O
and	O
-10	O
)	O
by	O
ELISA	B-P
.	O

Severity	O
of	O
the	O
dengue	O
infection	O
was	O
determined	O
on	O
the	O
basis	O
of	O
clinical	O
manifestations	O
based	O
on	O
the	O
WHO	O
criteria	O
.	O

for	O
statistical	O
analysis	O
,	O
SPSS	O
version	O
21	O
(	O
IBM	O
,	O
New	O
York	O
,	O
United	O
States	O
)	O
was	O
used	O
.	O

Out	O
of	O
150	O
samples	O
,	O
56	O
samples	O
came	O
to	O
be	O
dengue	O
positive	O
.	O

Thirty-eight	O
(	O
67.85	O
%	O
)	O
cases	O
were	O
classified	O
as	O
nonsevere	O
dengue	O
and	O
18	O
(	O
32.15	O
%	O
)	O
were	O
severe	O
dengue	O
.	O

The	O
serum	O
levels	B-P
of	I-P
IL-4	I-P
and	O
-10	B-P
were	O
significantly	O
raised	O
in	O
severe	O
dengue	O
cases	O
as	O
compared	O
to	O
nonsevere	O
dengue	O
cases	O
.	O

No	O
significant	O
association	O
was	O
observed	O
between	O
serum	O
IL-2	B-P
levels	I-P
and	O
the	O
severity	O
of	O
dengue	O
.	O

IL-4	B-P
and	O
-10	B-P
levels	I-P
can	O
be	O
used	O
as	O
marker	O
of	O
severe	O
dengue	O
and	O
help	O
in	O
early	O
preparedness	O
to	O
start	O
the	O
treatment	O
in	O
the	O
line	O
of	O
severe	O
dengue	O
.	O

Up-Regulation	O
of	O
Claudin-6	O
in	O
the	O
Distal	O
Lung	O
Impacts	O
Secondhand	O
Smoke	O
-Induced	O
Inflammation	O
.	O

It	O
has	O
long	O
been	O
understood	O
that	O
increased	O
epithelial	O
permeability	O
contributes	O
to	O
inflammation	O
observed	O
in	O
many	O
respiratory	O
diseases	O
.	O

Recently	O
,	O
evidence	O
has	O
revealed	O
that	O
environmental	O
exposure	O
to	O
noxious	O
material	O
such	O
as	O
cigarette	O
smoke	O
reduces	O
tight	O
junction	O
barrier	O
integrity	O
,	O
thus	O
enhancing	O
inflammatory	O
conditions	O
.	O

Claudin-6	O
(	O
Cldn6	O
)	O
is	O
a	O
tetraspanin	O
transmembrane	O
protein	O
found	O
within	O
the	O
tight	O
junctional	O
complex	O
and	O
is	O
implicated	O
in	O
maintaining	O
lung	O
epithelial	O
barriers	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
increased	O
Cldn6	O
ameliorates	O
inflammation	O
at	O
the	O
respiratory	O
barrier	O
,	O
we	O
utilized	O
the	O
Tet-On	O
inducible	O
transgenic	O
system	O
to	O
conditionally	O
over-express	O
Clnd6	O
in	O
the	O
distal	O
lung	O
.	O

Cldn6	O
transgenic	O
(	O
TG	O
)	O
and	O
control	O
mice	O
were	O
continuously	O
provided	O
doxycycline	O
from	O
postnatal	O
day	O
(	O
PN	O
)	O
30	O
until	O
euthanasia	O
date	O
at	O
PN90	O
.	O

A	O
subset	O
of	O
Cldn6	O
TG	O
and	O
control	O
mice	O
were	O
also	O
subjected	O
to	O
daily	O
secondhand	O
tobacco	O
smoke	O
(	O
SHS	O
)	O
via	O
a	O
nose	O
only	O
inhalation	O
system	O
from	O
PN30-90	O
and	O
compared	O
to	O
room	O
air	O
(	O
RA	O
)	O
controls	O
.	O

Animals	O
were	O
euthanized	O
on	O
PN90	O
and	O
lungs	O
were	O
harvested	O
for	O
histological	O
and	O
molecular	O
characterization	O
.	O

Bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
was	O
procured	O
for	O
the	O
assessment	O
of	O
inflammatory	O
cells	O
and	O
molecules	O
.	O

Quantitative	O
RT-PCR	O
and	O
immunoblotting	B-P
revealed	O
increased	O
Cldn6	O
expression	O
in	O
TG	O
vs.	O
control	O
animals	O
and	O
SHS	O
decreased	O
Cldn6	O
expression	O
regardless	O
of	O
genetic	O
up-regulation	O
.	O

Histological	O
evaluations	O
revealed	O
no	O
adverse	O
pulmonary	O
remodeling	O
via	O
Hematoxylin	B-P
and	I-P
Eosin	I-P
(	I-P
H	I-P
&	I-P
amp	I-P
;	I-P
E	I-P
)	I-P
staining	I-P
or	O
any	O
qualitative	O
alterations	O
in	O
the	O
abundance	O
of	O
type	O
II	O
pneumocytes	O
or	O
proximal	O
non-ciliated	O
epithelial	O
cells	O
via	O
staining	B-P
for	O
cell	O
specific	O
propeptide	O
of	O
Surfactant	O
Protein-C	O
(	O
proSP-C	O
)	O
or	O
Club	O
Cell	O
Secretory	O
Protein	O
(	O
CCSP	O
)	O
,	O
respectively	O
.	O

Immunoblotting	B-P
and	O
qRT-PCR	O
confirmed	O
the	O
differential	O
expression	O
of	O
Cldn6	O
and	O
the	O
pro-inflammatory	O
cytokines	O
TNF-α	O
and	O
IL-1β	O
.	O

As	O
a	O
general	O
theme	O
,	O
inflammation	O
induced	O
by	O
SHS	O
exposure	O
was	O
influenced	O
by	O
the	O
availability	O
of	O
Cldn6	O
.	O

These	O
data	O
reveal	O
captivating	O
information	O
suggesting	O
a	O
role	O
for	O
Cldn6	O
in	O
lungs	O
exposed	O
to	O
tobacco	O
smoke	O
.	O

Further	O
research	O
is	O
critically	O
necessary	O
in	O
order	O
to	O
fully	O
explain	O
roles	O
for	O
tight	O
junctional	O
components	O
such	O
as	O
Cldn6	O
and	O
other	O
related	O
molecules	O
in	O
lungs	O
coping	O
with	O
exposure	O
.	O

Enhanced	O
Performance	O
of	O
Colorimetric	B-P
Biosensing	B-P
on	O
Paper	O
Microfluidic	B-P
Platforms	I-P
Through	O
Chemical	O
Modification	O
and	O
Incorporation	O
of	O
Nanoparticles	O
.	O

This	O
chapter	O
describes	O
two	O
different	O
methodologies	O
used	O
to	O
improve	O
the	O
analytical	O
performance	O
of	O
colorimetric	B-P
paper	O
-based	O
biosensors	O
.	O

Microfluidic	O
paper-based	O
analytical	O
devices	O
(	O
μPADs	O
)	O
have	O
been	O
produced	O
by	O
a	O
stamping	O
process	O
and	O
CO2	O
laser	O
ablation	O
and	O
modified	O
,	O
respectively	O
,	O
through	O
an	O
oxidation	O
step	O
and	O
incorporation	O
of	O
silica	O
nanoparticles	O
on	O
the	O
paper	O
structure	O
.	O

Both	O
methods	O
are	O
employed	O
in	O
order	O
to	O
overcome	O
the	O
largest	O
problem	O
associated	O
with	O
colorimetric	B-P
detection	I-P
,	O
the	O
heterogeneity	O
of	O
the	O
color	O
distribution	O
in	O
the	O
detection	O
zones	O
.	O

The	O
modification	O
steps	O
are	O
necessary	O
to	O
improve	O
the	O
interaction	O
between	O
the	O
paper	O
surface	O
and	O
the	O
selected	O
enzymes	O
.	O

The	O
enhanced	O
performance	O
has	O
ensured	O
reliability	O
for	O
quantitative	O
analysis	O
of	O
clinically	O
relevant	O
compounds	O
.	O

Anti-inflammatory	O
activity	O
of	O
Elaeagnus	O
angustifolia	O
fruit	O
extract	O
on	O
rat	O
paw	O
edema	O
.	O

The	O
Elaeagnus	O
angustifolia	O
fruit	O
has	O
been	O
traditionally	O
used	O
in	O
Iranian	O
herbal	O
medicine	O
to	O
treat	O
diarrhea	O
and	O
rheumatoid	O
arthritis	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
E.	O
angustifolia	O
fruit	O
extract	O
on	O
the	O
acute	O
and	O
chronic	O
phases	O
of	O
formalin	O
-	O
induced	O
rat	O
paw	O
edema	O
were	O
examined	O
.	O

The	O
acute	O
and	O
chronic	O
anti-inflammatory	O
effects	O
of	O
E.	O
angustifolia	O
fruit	O
extract	O
were	O
investigated	O
through	O
the	O
subcutaneous	O
injection	O
of	O
100	O
μL	O
of	O
formalin	O
(	O
2.5	O
%	O
)	O
into	O
a	O
rat	O
's	O
hind	O
paw	O
.	O

Thirty	O
minutes	O
before	O
the	O
procedure	O
,	O
the	O
experimental	O
groups	O
were	O
treated	O
intraperitoneally	O
with	O
hydroalcoholic	O
fruit	O
extracts	O
of	O
E.	O
angustifolia	O
(	O
concentrations	O
of	O
100	O
,	O
300	O
,	O
700	O
,	O
and	O
1000	O
mg/kg	O
)	O
;	O
sodium	O
salicylate	O
(	O
SS	O
,	O
400	O
mg/kg	O
)	O
and	O
distilled	O
water	O
were	O
used	O
as	O
positive	O
and	O
negative	O
control	O
groups	O
,	O
respectively	O
.	O

Treatment	O
with	O
SS	O
and	O
the	O
fruit	O
extracts	O
were	O
performed	O
daily	O
for	O
8	O
days	O
,	O
and	O
the	O
degree	O
of	O
edema	O
was	O
measured	O
by	O
using	O
mercury	O
plethysmometer	O
and	O
digital	O
caliper	O
.	O

In	O
the	O
acute	O
anti-inflammatory	O
study	O
,	O
the	O
extract	O
showed	O
a	O
significant	O
anti-inflammatory	O
effect	O
in	O
a	O
dose-dependent	O
manner	O
.	O

The	O
results	O
of	O
1000	O
mg/kg	O
of	O
the	O
extract	O
was	O
significantly	O
different	O
compared	O
with	O
the	O
negative	O
control	O
group	O
(	O
p	O
<	O
0.05	O
)	O
and	O
was	O
comparable	O
to	O
sodium	O
salicylate	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Results	O
from	O
the	O
chronic	O
study	O
suggested	O
that	O
E.	O
angustifolia	O
extract	O
significantly	O
reduced	O
paw	O
edema	O
and	O
inflammation	O
in	O
a	O
dose-dependent	O
manner	O
.	O

The	O
results	O
also	O
showed	O
that	O
the	O
measurement	O
by	O
digital	O
caliper	O
and	O
mercury	O
plethysmometer	O
were	O
both	O
reliable	O
and	O
might	O
be	O
applied	O
interchangeably	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Phytochemical	B-P
tests	I-P
indicated	O
that	O
the	O
hydroalcoholic	O
fruit	O
extract	O
of	O
E.	O
angustifolia	O
was	O
positive	O
for	O
cardiac	O
glycosides	O
,	O
flavonoids	O
,	O
terpenoids	O
,	O
and	O
saponins	O
.	O

Based	O
on	O
our	O
findings	O
,	O
the	O
E.	O
angustifolia	O
fruit	O
extract	O
probably	O
has	O
acute	O
and	O
chronic	O
anti-inflammatory	O
activities	O
to	O
support	O
its	O
applications	O
in	O
folk	O
medicine	O
.	O

A	O
Recombinant	O
Human	O
Anti-Platelet	O
scFv	O
Antibody	O
Produced	O
in	O
Pichia	O
pastoris	O
for	O
Atheroma	O
Targeting	O
.	O

Cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	O
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	O
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	O
disease	O
,	O
cerebrovascular	O
disease	O
and	O
peripheral	O
arterial	O
disease	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single-chain	O
variable	O
fragment	O
(	O
scFv	O
)	O
derived	O
from	O
a	O
human	O
anti-αIIbβ3	O
antibody	O
(	O
HuAb	O
)	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O

Indeed	O
,	O
platelets	O
within	O
atheroma	O
plaques	O
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	O
,	O
in	O
platelet	O
-	O
leucocyte	O
aggregates	O
and	O
in	O
thrombi	O
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	O
of	O
atherosclerotic	O
progression	O
.	O

The	O
DNA	O
sequence	O
that	O
encodes	O
the	O
anti-αIIbβ3	O
TEG4	O
scFv	O
previously	O
obtained	O
from	O
a	O
phage-display	O
selection	O
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
(	O
pPICZαA	O
)	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	O
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	B-P
experiments	I-P
.	O

The	O
recombinant	O
protein	O
was	O
expressed	O
at	O
high	O
yields	O
in	O
Pichia	O
pastoris	O
(	O
30	O
mg/L	O
culture	O
)	O
.	O

The	O
advantage	O
of	O
P.	O
pastoris	O
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	O
proteins	O
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	O
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	O
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
)	O
.	O

The	O
improved	O
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	O
active	O
scFv	O
fragments	O
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	O
-directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	B-P
of	O
atherosclerotic	O
plaques	O
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	O
risk	O
of	O
instability	O
.	O

Identification	O
of	O
Left	O
Ventricle	O
Failure	O
on	O
Pulmonary	O
Artery	O
CTA	B-P
:	O
Diagnostic	O
Significance	O
of	O
Decreased	O
Aortic	O
&	O
Left	O
Ventricle	O
Enhancement	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
findings	O
on	O
non-	O
ECG	O
-	O
gated	O
CT	B-P
pulmonary	I-P
angiography	I-P
(	O
CTPA	B-P
)	O
indicating	O
decreased	O
left	O
ventricle	O
(	O
LV	O
)	O
systolic	O
function	O
,	O
later	O
confirmed	O
by	O
echocardiogram	O
.	O

After	O
obtaining	O
institutional	O
review	O
board	O
approval	O
,	O
review	O
was	O
performed	O
of	O
emergency	O
department	O
(	O
ED	O
)	O
patients	O
who	O
had	O
CTPA	B-P
and	O
follow-up	O
echocardiogram	O
within	O
48	O
h	O
,	O
over	O
18	O
months	O
.	O

Patients	O
with	O
pulmonary	O
embolus	O
,	O
suboptimal	O
CTPA	B-P
,	O
arrhythmias	O
or	O
pericardial	O
tamponade	O
were	O
excluded	O
.	O

One	O
hundred	O
thirty-seven	O
patients	O
were	O
identified	O
and	O
divided	O
into	O
cases	O
(	O
LVEF	O
<	O
40	O
%	O
,	O
n	O
=	O
52	O
)	O
and	O
controls	O
(	O
LVEF	O
>	O
50	O
%	O
,	O
n	O
=	O
85	O
)	O
.	O

Two	O
reviewers	O
performed	O
these	O
analyses	O
:	O
measurement	O
of	O
enhancement	O
in	O
main	O
pulmonary	O
artery	O
(	O
MPA	O
)	O
,	O
LV	O
,	O
and	O
aorta	O
;	O
subjective	O
enhancement	O
of	O
LV	O
and	O
aorta	O
(	O
Ao	O
)	O
relative	O
to	O
MPA	O
using	O
a	O
four-point	O
Likert	O
scale	O
;	O
contrast	O
transit	O
time	O
(	O
TD	O
)	O
to	O
trigger	O
CTPA	B-P
and	O
LV	O
short	O
&	O
long	O
axis	O
dimensions	O
.	O

When	O
available	O
,	O
the	O
most	O
recent	O
N-terminal	O
pro-B-type	O
natriuretic	O
peptide	O
(	O
NT-proBNP	O
)	O
level	O
was	O
recorded	O
.	O

Decreased	O
aortic	O
and	O
LV	O
subjective	O
enhancement	O
were	O
the	O
best	O
predictors	O
of	O
LV	O
systolic	O
dysfunction	O
.	O

For	O
Ao	O
/	O
MPA	O
ratio	O
,	O
an	O
optimal	O
cutoff	O
value	O
of	O
0.20	O
resulted	O
in	O
a	O
sensitivity	O
of	O
0.54	O
and	O
specificity	O
of	O
0.93	O
(	O
AUC	O
=	O
0.83	O
,	O
0.78-0.88	O
95	O
%	O
CI	O
)	O
.	O

A	O
threshold	O
of	O
86.7	O
HU	O
for	O
Ao	O
enhancement	O
resulted	O
in	O
a	O
sensitivity	O
of	O
0.68	O
and	O
specificity	O
of	O
0.90	O
(	O
AUC	O
=	O
0.82	O
,	O
0.77-0.88	O
95	O
%	O
CI	O
)	O
.	O

A	O
LV	O
short	O
axis	O
diameter	O
of	O
more	O
than	O
54.3	O
mm	O
had	O
a	O
sensitivity	O
of	O
0.62	O
and	O
specificity	O
of	O
0.98	O
(	O
AUC	O
=	O
0.88	O
,	O
0.83-0.92	O
95	O
%	O
CI	O
)	O
.	O

For	O
the	O
LV	O
long	O
axis	O
diameter	O
,	O
a	O
cutoff	O
of	O
87.5	O
mm	O
resulted	O
in	O
a	O
sensitivity	O
of	O
0.66	O
and	O
specificity	O
of	O
0.84	O
(	O
AUC	O
=	O
0.78	O
,	O
0.72-0.84	O
95	O
%	O
CI	O
)	O
.	O

With	O
bolus	O
timing	O
,	O
cases	O
had	O
a	O
longer	O
TD	O
(	O
13.4	O
vs.	O
10.4	O
s	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Unsuspected	O
LV	O
systolic	O
dysfunction	O
can	O
be	O
recognized	O
on	O
a	O
CTPA	B-P
by	O
identification	O
of	O
decreased	O
aortic	O
enhancement	O
,	O
LV	O
enlargement	O
and	O
increased	O
TD	O
.	O

This	O
has	O
important	O
diagnostic	O
implications	O
for	O
the	O
patient	O
presenting	O
with	O
shortness	O
of	O
breath	O
,	O
chest	O
pain	O
,	O
or	O
dyspnea	O
.	O

Heart	O
beat	O
characterization	O
from	O
ballistocardiogram	B-P
signals	I-P
using	O
extended	O
functions	O
of	O
multiple	O
instances	O
.	O

A	O
multiple	O
instance	O
learning	O
(	O
MIL	O
)	O
method	O
,	O
extended	O
Function	O
of	O
Multiple	O
Instances	O
(	O
eFUMI	O
)	O
,	O
is	O
applied	O
to	O
ballistocardiogram	B-P
(	O
BCG	B-P
)	O
signals	O
produced	O
by	O
a	O
hydraulic	O
bed	O
sensor	O
.	O

The	O
goal	O
of	O
this	O
approach	O
is	O
to	O
learn	O
a	O
personalized	O
heartbeat	O
``	O
concept	O
``	O
for	O
an	O
individual	O
.	O

This	O
heartbeat	O
concept	O
is	O
a	O
prototype	O
(	O
or	O
``	O
signature	O
``	O
)	O
that	O
characterizes	O
the	O
heartbeat	O
pattern	O
for	O
an	O
individual	O
in	O
ballistocardiogram	B-P
data	O
.	O

The	O
eFUMI	O
method	O
models	O
the	O
problem	O
of	O
learning	O
a	O
heartbeat	O
concept	O
from	O
a	O
BCG	B-P
signal	I-P
as	O
a	O
MIL	O
problem	O
.	O

This	O
approach	O
elegantly	O
addresses	O
the	O
uncertainty	O
inherent	O
in	O
a	O
BCG	B-P
signal	I-P
(	O
e.	O
g.	O
,	O
misalignment	O
between	O
training	O
data	O
and	O
ground	O
truth	O
,	O
mis-collection	O
of	O
heartbeat	O
by	O
some	O
transducers	O
,	O
etc.	O
)	O
.	O

Given	O
a	O
BCG	B-P
training	O
signal	O
coupled	O
with	O
a	O
ground	O
truth	O
signal	O
(	O
e.g.	O
,	O
a	O
pulse	O
finger	O
sensor	O
)	O
,	O
training	O
``	O
bags	O
''	O
labeled	O
with	O
only	O
binary	O
labels	O
denoting	O
if	O
a	O
training	O
bag	O
contains	O
a	O
heartbeat	O
signal	O
or	O
not	O
can	O
be	O
generated	O
.	O

Then	O
,	O
using	O
these	O
bags	O
,	O
eFUMI	O
learns	O
a	O
personalized	O
concept	O
of	O
heartbeat	O
for	O
a	O
subject	O
as	O
well	O
as	O
several	O
non-	O
heartbeat	O
background	O
concepts	O
.	O

After	O
learning	O
the	O
heartbeat	O
concept	O
,	O
heartbeat	O
detection	O
and	O
heart	O
rate	O
estimation	O
can	O
be	O
applied	O
to	O
test	O
data	O
.	O

Experimental	O
results	O
show	O
that	O
the	O
estimated	O
heartbeat	O
concept	O
found	O
by	O
eFUMI	O
is	O
more	O
representative	O
and	O
a	O
more	O
discriminative	O
prototype	O
of	O
the	O
heartbeat	O
signals	O
than	O
those	O
found	O
by	O
comparison	O
MIL	O
methods	O
in	O
the	O
literature	O
.	O

An	O
Anatomic	O
Investigation	O
Into	O
the	O
Relationship	O
Between	O
Posterior	O
Condylar	O
Offset	O
and	O
Posterior	O
Tibial	O
Slope	O
of	O
One	O
Thousand	O
One	O
Hundred	O
Thirty-Eight	O
Cadaveric	O
Knees	O
.	O

Posterior	O
condylar	O
offset	O
(	O
PCO	O
)	O
and	O
posterior	O
tibial	O
slope	O
(	O
PTS	O
)	O
have	O
critical	O
consequences	O
in	O
total	O
knee	O
arthroplasty	O
,	O
especially	O
with	O
regards	O
to	O
sagittal	O
plane	O
balancing	O
.	O

However	O
,	O
there	O
has	O
only	O
been	O
limited	O
investigation	O
into	O
the	O
functional	O
consequences	O
of	O
each	O
,	O
and	O
there	O
have	O
only	O
been	O
anecdotal	O
observations	O
regarding	O
any	O
associations	O
between	O
PCO	O
and	O
PTS	O
.	O

In	O
a	O
large	O
osteological	O
study	O
of	O
1138	O
knees	O
,	O
standardized	O
measurements	O
of	O
PCO	O
and	O
PTS	O
were	O
taken	O
using	O
previously	O
described	O
techniques	O
on	O
specimens	O
of	O
different	O
age	O
,	O
race	O
,	O
and	O
gender	O
.	O

Multiple	O
linear	O
regression	O
was	O
performed	O
to	O
determine	O
the	O
independent	O
predictors	O
of	O
medial	O
and	O
lateral	O
PTS	O
.	O

Mean	O
standardized	O
medial	O
PCO	O
was	O
greater	O
than	O
lateral	O
PCO	O
(	O
1.22	O
±	O
0.16	O
vs	O
1.15	O
±	O
0.19	O
mm	O
,	O
P	O
<	O
.001	O
)	O
and	O
medial	O
PTS	O
was	O
greater	O
than	O
lateral	O
PTS	O
(	O
7.3	O
±	O
3.8°	O
vs	O
5.7	O
±	O
3.7°	O
,	O
P	O
<	O
.001	O
)	O
.	O

Decreasing	O
PCO	O
,	O
female	O
gender	O
,	O
and	O
African-American	O
race	O
were	O
associated	O
with	O
both	O
increased	O
medial	O
and	O
lateral	O
PTS	O
.	O

Neither	O
age	O
nor	O
femoral	O
length	O
correlated	O
with	O
medial	O
or	O
lateral	O
PTS	O
.	O

These	O
data	O
are	O
the	O
first	O
to	O
quantify	O
that	O
an	O
inverse	O
correlation	O
between	O
PCO	O
and	O
PTS	O
exists	O
.	O

This	O
relationship	O
represents	O
an	O
important	O
area	O
for	O
future	O
biomechanical	B-P
and	O
clinical	O
studies	O
.	O

An	O
environment	O
-	O
dependent	O
transcriptional	O
network	O
specifies	O
human	O
microglia	O
identity	O
.	O

Microglia	O
play	O
essential	O
roles	O
in	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
homeostasis	O
and	O
influence	O
diverse	O
aspects	O
of	O
neuronal	O
function	O
.	O

However	O
,	O
the	O
transcriptional	O
mechanisms	O
that	O
specify	O
human	O
microglia	O
phenotypes	O
are	O
largely	O
unknown	O
.	O

We	O
examined	O
the	O
transcriptomes	O
and	O
epigenetic	O
landscapes	O
of	O
human	O
microglia	O
isolated	O
from	O
surgically	O
resected	O
brain	O
tissue	O
ex	O
vivo	O
and	O
following	O
transition	O
to	O
an	O
in	O
vitro	O
environment	O
.	O

Transfer	O
to	O
a	O
tissue	B-P
culture	I-P
environment	O
results	O
in	O
rapid	O
and	O
extensive	O
downregulation	O
of	O
microglia	O
-specific	O
genes	O
that	O
are	O
induced	O
in	O
primitive	O
mouse	O
macrophages	O
following	O
migration	O
into	O
the	O
fetal	O
brain	O
.	O

Substantial	O
subsets	O
of	O
these	O
genes	O
exhibit	O
altered	O
expression	O
in	O
neurodegenerative	O
and	O
behavioral	O
diseases	O
and	O
are	O
associated	O
with	O
non-coding	O
risk	O
variants	O
.	O

These	O
findings	O
reveal	O
an	O
environment	O
-dependent	O
transcriptional	O
network	O
specifying	O
microglia	O
-specific	O
programs	O
of	O
gene	O
expression	O
and	O
facilitate	O
efforts	O
to	O
understand	O
the	O
roles	O
of	O
microglia	O
in	O
human	O
disease	O
.	O

Comparative	O
kinematic	B-P
gait	I-P
analysis	I-P
in	O
young	O
and	O
old	O
Beagle	O
dogs	O
.	O

Age-related	O
involution	O
in	O
dogs	O
involves	O
loss	O
of	O
muscle	O
mass	O
and	O
changes	O
in	O
connective	O
tissue	O
and	O
articular	O
cartilage	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
an	O
age-related	O
influence	O
on	O
joint	O
mobility	O
can	O
be	O
detected	O
in	O
the	O
absence	O
of	O
diseases	O
.	O

Five	O
young	O
(	O
Ø	O
2.0	O
years	O
)	O
and	O
five	O
old	O
(	O
Ø	O
10.4	O
years	O
)	O
healthy	O
and	O
sound	O
Beagle	O
dogs	O
were	O
measured	O
during	O
locomotion	O
on	O
a	O
treadmill	O
by	O
computer-assisted	B-P
gait	B-P
analysis	I-P
.	O

Angles	O
of	O
the	O
shoulder	O
,	O
elbow	O
,	O
carpal	O
,	O
hip	O
,	O
stifle	O
and	O
tarsal	O
joints	O
were	O
analyzed	O
,	O
including	O
joint	O
angle	O
progression	O
curves	O
,	O
minimum	O
and	O
maximum	O
joint	O
angles	O
and	O
range	O
of	O
motion	O
(	O
ROM	O
)	O
.	O

The	O
old	O
group	O
showed	O
a	O
smaller	O
maximum	O
joint	O
angle	O
(	O
p	O
=	O
0.037	O
)	O
and	O
ROM	O
(	O
p	O
=	O
0.037	O
)	O
of	O
the	O
carpal	O
joint	O
and	O
similar	O
tendencies	O
in	O
the	O
shoulder	O
,	O
elbow	O
and	O
carpal	O
joint	O
.	O

The	O
descriptive	O
analysis	O
of	O
the	O
progression	O
curves	O
revealed	O
less	O
flexion	O
and	O
extension	O
of	O
the	O
joints	O
of	O
the	O
forelimb	O
.	O

This	O
indicates	O
restricted	O
joint	O
mobility	O
of	O
the	O
forelimb	O
but	O
primarily	O
of	O
the	O
carpal	O
joint	O
.	O

Findings	O
in	O
the	O
joints	O
of	O
the	O
hindlimb	O
were	O
not	O
consistent	O
;	O
contrasting	O
alterations	O
may	O
be	O
due	O
to	O
a	O
compensatory	O
mechanism	O
.	O

As	O
most	O
alterations	O
were	O
found	O
in	O
the	O
distal	O
joints	O
,	O
these	O
should	O
receive	O
particular	O
attention	O
when	O
examining	O
elderly	O
dogs	O
.	O

Bacteriology	B-P
of	O
Urine	O
Specimens	O
Obtained	O
from	O
Men	O
with	O
Symptomatic	O
Benign	O
Prostatic	O
Hyperplasia	O
.	O

Bacteriuria	O
and	O
urinary	O
tract	O
infections	O
are	O
common	O
sequelae	O
of	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
.	O

Thus	O
,	O
the	O
knowledge	O
of	O
urine	O
bacteriology	B-P
in	O
men	O
with	O
symptomatic	O
BPH	O
in	O
our	O
environment	O
may	O
play	O
a	O
complementary	O
role	O
in	O
management	O
.	O

To	O
determine	O
the	O
incidence	O
of	O
bacteriuria	O
and	O
the	O
antibiotic	O
sensitivity	O
pattern	O
of	O
bacterial	O
isolates	O
in	O
cultured	B-P
urine	I-P
samples	O
of	O
men	O
with	O
symptomatic	O
BPH	O
.	O

This	O
was	O
a	O
1	O
year	O
prospective	O
study	O
.	O

All	O
patients	O
who	O
presented	O
with	O
lower	O
urinary	O
tract	O
symptoms	O
due	O
to	O
BPH	O
and	O
who	O
met	O
the	O
inclusion	O
criteria	O
were	O
studied	O
.	O

Urine	O
samples	O
were	O
obtained	O
from	O
the	O
patients	O
for	O
microscopy	B-P
,	O
culture	B-P
,	O
and	O
sensitivity	O
following	O
standard	O
protocol	O
.	O

Ninety-four	O
patients	O
were	O
studied	O
.	O

The	O
age	O
range	O
was	O
53-80	O
years	O
with	O
a	O
mean	O
of	O
65.5	O
±	O
7.8	O
years	O
.	O

Bacterial	O
isolates	O
were	O
noted	O
in	O
42	O
(	O
44.7	O
%	O
)	O
patients	O
.	O

Six	O
of	O
these	O
had	O
two	O
different	O
species	O
of	O
bacterial	O
organisms	O
isolated	O
.	O

Escherichia	O
coli	O
noted	O
in	O
20	O
(	O
47.6	O
%	O
)	O
specimens	O
was	O
the	O
most	O
common	O
organism	O
isolated	O
while	O
the	O
least	O
common	O
,	O
Providencia	O
species	O
,	O
was	O
noted	O
in	O
1	O
(	O
2.4	O
%	O
)	O
.	O

The	O
bacterial	O
isolates	O
were	O
mostly	O
sensitive	O
to	O
imipenem	O
,	O
meropenem	O
,	O
and	O
nitrofurantoin	O
,	O
but	O
showed	O
greater	O
resistance	O
to	O
cefuroxime	O
,	O
gentamicin	O
,	O
and	O
ofloxacin	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
means	O
for	O
age	O
(	O
P	O
=	O
0.80	O
)	O
,	O
duration	O
of	O
symptoms	O
(	O
P	O
=	O
0.09	O
)	O
,	O
and	O
prostate	O
size	O
(	O
P	O
=	O
0.52	O
)	O
in	O
the	O
patients	O
with	O
and	O
those	O
without	O
bacteriuria	O
.	O

Bacteriuria	O
is	O
a	O
common	O
finding	O
in	O
patients	O
with	O
symptomatic	O
BPH	O
in	O
our	O
setting	O
.	O

The	O
bacterial	O
isolates	O
showed	O
high	O
level	O
of	O
resistance	O
to	O
oral	O
cephalosporins	O
and	O
fluoroquinolones	O
.	O

There	O
is	O
a	O
need	O
to	O
update	O
guidelines	O
in	O
empiric	O
use	O
of	O
antibiotics	O
in	O
this	O
group	O
of	O
patients	O
.	O

Maternal	O
dietary	O
intake	O
during	O
pregnancy	O
and	O
offspring	O
body	O
composition	O
:	O
The	O
Healthy	O
Start	O
Study	O
.	O

Consistent	O
evidence	O
of	O
an	O
influence	O
of	O
maternal	O
dietary	O
intake	O
during	O
pregnancy	O
on	O
infant	O
body	O
size	O
and	O
composition	O
in	O
human	O
populations	O
is	O
lacking	O
,	O
despite	O
robust	O
evidence	O
in	O
animal	O
models	O
.	O

We	O
sought	O
to	O
evaluate	O
the	O
influence	O
of	O
maternal	O
macronutrient	O
intake	O
and	O
balance	O
during	O
pregnancy	O
on	O
neonatal	O
body	O
size	O
and	O
composition	O
,	O
including	O
fat	O
mass	O
and	O
fat-free	O
mass	O
.	O

The	O
analysis	O
was	O
conducted	O
among	O
1040	O
mother	O
-	O
offspring	O
pairs	O
enrolled	O
in	O
the	O
prospective	O
prebirth	O
observational	O
cohort	O
:	O
the	O
Healthy	O
Start	O
Study	O
.	O

Diet	O
during	O
pregnancy	O
was	O
collected	O
using	O
repeated	O
24-	O
hour	O
dietary	O
recalls	O
(	O
up	O
to	O
8	O
)	O
.	O

Direct	O
measures	O
of	O
body	O
composition	O
were	O
obtained	O
using	O
air	B-P
displacement	I-P
plethysmography	I-P
.	O

The	O
National	O
Cancer	O
Institute	O
measurement	O
error	O
model	O
was	O
used	O
to	O
estimate	O
usual	O
dietary	O
intake	O
during	O
pregnancy	O
.	O

Multivariable	O
partition	O
(	O
nonisocaloric	O
)	O
and	O
nutrient	O
density	O
(	O
isocaloric	O
)	O
linear	O
regression	O
models	O
were	O
used	O
to	O
test	O
the	O
associations	O
between	O
maternal	O
dietary	O
intake	O
and	O
neonatal	O
body	O
composition	O
.	O

The	O
median	O
macronutrient	O
composition	O
during	O
pregnancy	O
was	O
32.2	O
%	O
from	O
fat	O
,	O
15.0	O
%	O
from	O
protein	O
,	O
and	O
47.8	O
%	O
from	O
carbohydrates	O
.	O

In	O
the	O
partition	O
multivariate	O
regression	O
model	O
,	O
individual	O
macronutrient	O
intake	O
values	O
were	O
not	O
associated	O
with	O
birthweight	O
or	O
fat-free	O
mass	O
,	O
but	O
were	O
associated	O
with	O
fat	O
mass	O
.	O

Respectively	O
,	O
418	O
kJ	O
increases	O
in	O
total	O
fat	O
,	O
saturated	O
fat	O
,	O
unsaturated	O
fat	O
,	O
and	O
total	O
carbohydrates	O
were	O
associated	O
with	O
4.2-g	O
(	O
P	O
=	O
.03	O
)	O
,	O
11.1-g	O
(	O
P	O
=	O
.003	O
)	O
,	O
5.9-g	O
(	O
P	O
=	O
.04	O
)	O
,	O
and	O
2.9-g	O
(	O
P	O
=	O
.02	O
)	O
increases	O
in	O
neonatal	O
fat	O
mass	O
,	O
independent	O
of	O
prepregnancy	O
body	O
mass	O
index	O
.	O

In	O
the	O
nutrient	O
density	O
multivariate	O
regression	O
model	O
,	O
macronutrient	O
balance	O
was	O
not	O
associated	O
with	O
fat	O
mass	O
,	O
fat-free	O
mass	O
,	O
or	O
birthweight	O
after	O
adjustment	O
for	O
prepregnancy	O
body	O
mass	O
index	O
.	O

Neonatal	O
adiposity	O
,	O
but	O
not	O
birthweight	O
,	O
is	O
independently	O
associated	O
with	O
increased	O
maternal	O
intake	O
of	O
total	O
fat	O
,	O
saturated	O
fat	O
,	O
unsaturated	O
fat	O
,	O
and	O
total	O
carbohydrates	O
,	O
but	O
not	O
protein	O
,	O
suggesting	O
that	O
most	O
forms	O
of	O
increased	O
caloric	O
intake	O
contribute	O
to	O
fetal	O
fat	O
accretion	O
.	O

Low	O
energy	O
cost	O
for	O
optimal	O
speed	O
and	O
control	O
of	O
membrane	O
fusion	O
.	O

Membrane	O
fusion	O
is	O
the	O
cell	O
's	O
delivery	O
process	O
,	O
enabling	O
its	O
many	O
compartments	O
to	O
receive	O
cargo	O
and	O
machinery	O
for	O
cell	O
growth	O
and	O
intercellular	O
communication	O
.	O

The	O
overall	O
activation	O
energy	O
of	O
the	O
process	O
must	O
be	O
large	O
enough	O
to	O
prevent	O
frequent	O
and	O
nonspecific	O
spontaneous	O
fusion	O
events	O
,	O
yet	O
must	O
be	O
low	O
enough	O
to	O
allow	O
it	O
to	O
be	O
overcome	O
upon	O
demand	O
by	O
specific	O
fusion	O
proteins	O
[	O
such	O
as	O
soluble	O
N-ethylmaleimide-sensitive	O
factor	O
attachment	O
protein	O
receptors	O
(	O
SNAREs	O
)	O
]	O
.	O

Remarkably	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
activation	O
energy	O
for	O
spontaneous	O
bilayer	O
fusion	O
has	O
never	O
been	O
measured	O
.	O

Multiple	O
models	O
have	O
been	O
developed	O
and	O
refined	O
to	O
estimate	O
the	O
overall	O
activation	O
energy	O
and	O
its	O
component	O
parts	O
,	O
and	O
they	O
span	O
a	O
very	O
broad	O
range	O
from	O
20	O
kBT	O
to	O
150	O
kBT	O
,	O
depending	O
on	O
the	O
assumptions	O
.	O

In	O
this	O
study	O
,	O
using	O
a	O
bulk	O
lipid-mixing	B-P
assay	I-P
at	O
various	O
temperatures	O
,	O
we	O
report	O
that	O
the	O
activation	O
energy	O
of	O
complete	O
membrane	O
fusion	O
is	O
at	O
the	O
lowest	O
range	O
of	O
these	O
theoretical	O
values	O
.	O

Typical	O
lipid	O
vesicles	O
were	O
found	O
to	O
slowly	O
and	O
spontaneously	O
fully	O
fuse	O
with	O
activation	O
energies	O
of	O
∼30	O
kBT	O
Our	O
data	O
demonstrate	O
that	O
the	O
merging	B-P
of	O
membranes	O
is	O
not	O
nearly	O
as	O
energy	O
consuming	O
as	O
anticipated	O
by	O
many	O
models	O
and	O
is	O
ideally	O
positioned	O
to	O
minimize	O
spontaneous	O
fusion	O
while	O
enabling	O
rapid	O
,	O
SNARE	O
-	O
dependent	O
fusion	O
upon	O
demand	O
.	O

Sleep	O
architecture	O
in	O
Pierre-Robin	O
sequence	O
:	O
The	O
effect	O
of	O
mandibular	O
distraction	O
osteogenesis	O
.	O

Pierre-Robin	O
Sequence	O
(	O
PRS	O
)	O
,	O
a	O
triad	O
of	O
micro	O
/	O
retrognathia	O
,	O
glossoptosis	O
,	O
and	O
upper	O
airway	O
obstruction	O
,	O
usually	O
in	O
conjunction	O
with	O
a	O
cleft	O
palate	O
is	O
frequently	O
associated	O
with	O
significant	O
morbidity	O
.	O

Mandibular	O
distraction	O
osteogenesis	O
(	O
MDO	O
)	O
is	O
an	O
effective	O
treatment	O
modality	O
to	O
address	O
retroglossal	O
upper	O
airway	O
obstruction	O
by	O
increasing	O
the	O
anterior-posterior	O
diameter	O
of	O
the	O
infant	O
airway	O
.	O

Although	O
MDO	O
has	O
been	O
shown	O
to	O
improve	O
the	O
apnea-hypopnea	O
index	O
(	O
AHI	O
)	O
in	O
children	O
with	O
PRS	O
,	O
the	O
consequences	O
of	O
MDO	O
on	O
other	O
aspects	O
of	O
infant	O
sleep	O
,	O
including	O
hypercapnea	O
,	O
hypoxia	O
,	O
the	O
REM	O
to	O
Non-REM	O
ratio	O
,	O
as	O
well	O
as	O
its	O
effect	O
on	O
central	O
and	O
mixed	O
apneas	O
has	O
not	O
been	O
investigated	O
with	O
an	O
adequate	O
sample	O
size	O
.	O

To	O
characterize	O
the	O
effect	O
of	O
MDO	O
on	O
key	O
components	O
of	O
sleep	O
architecture	O
in	O
infants	O
with	O
PRS	O
.	O

Charts	O
from	O
32	O
infants	O
with	O
PRS	O
that	O
were	O
addressed	O
with	O
MDO	O
at	O
our	O
tertiary-care	O
children	O
's	O
hospital	O
were	O
retrospectively	O
reviewed	O
.	O

Of	O
these	O
,	O
26	O
infants	O
(	O
57.7	O
%	O
male	O
;	O
mean	O
age	O
=	O
4.1	O
weeks	O
,	O
SD	O
=	O
5.0	O
)	O
had	O
pre-	O
and	O
post-operative	O
polysomnograms	B-P
(	O
PSG	B-P
)	O
.	O

Paired	O
samples	O
t-tests	O
were	O
used	O
to	O
compare	O
pre-	O
and	O
post	O
-	O
MDO	O
sleep	O
architecture	O
mean	O
score	O
differences	O
.	O

Among	O
the	O
26	O
infants	O
,	O
73.1	O
%	O
demonstrated	O
severe	O
pre	O
-	O
MDO	O
sleep	O
apnea	O
(	O
AHI	O
>	O
10	O
)	O
.	O

Several	O
aspects	O
of	O
sleep	O
architecture	O
were	O
found	O
to	O
improve	O
post-operatively	O
.	O

Significant	O
improvements	O
were	O
found	O
in	O
AHI	O
(	O
30.3	O
vs.	O
8.7	O
;	O
t	O
=	O
4.1	O
,	O
p	O
<	O
0.001	O
)	O
,	O
obstructive	O
apneas	O
(	O
79.3	O
vs.	O
5.8	O
;	O
t	O
=	O
4.0	O
,	O
p	O
<	O
0.001	O
)	O
,	O
hypopneas	O
(	O
48.1	O
vs.	O
22.1	O
;	O
t	O
=	O
2.2	O
,	O
p	O
=	O
0.040	O
)	O
,	O
time	O
spent	O
below	O
90	O
%	O
SpO2	B-P
(	O
3.9	O
%	O
vs.	O
0.7	O
%	O
;	O
t	O
=	O
3.3	O
,	O
p	O
=	O
0.003	O
)	O
,	O
and	O
lowest	O
SpO2	B-P
nadir	O
(	O
75.4	O
%	O
vs.	O
82.9	O
%	O
;	O
3.4	O
,	O
p	O
=	O
0.002	O
)	O
.	O

In	O
addition	O
,	O
a	O
marginally	O
significant	O
improvement	O
was	O
found	O
for	O
mixed	O
apnea	O
(	O
6.3	O
vs.	O
1.6	O
;	O
t	O
=	O
1.99	O
,	O
p	O
=	O
0.058	O
)	O
.	O

MDO	O
improve	O
s	O
several	O
sleep	O
architecture	O
parameters	O
in	O
this	O
sample	O
of	O
infants	O
with	O
PRS	O
.	O

Statistically	O
significant	O
improvement	O
was	O
seen	O
in	O
obstructive	O
apneas	O
,	O
hypopneas	O
,	O
AHI	O
,	O
obstructive	O
AHI	O
,	O
and	O
several	O
indicators	O
of	O
hypoxia	O
during	O
sleep	O
.	O

Propensity	O
-	O
matched	O
Analysis	O
of	O
Outcomes	O
and	O
Hospital	O
Charges	O
for	O
Anterior	O
Versus	O
Posterior	O
Cervical	O
Fusion	O
for	O
Cervical	O
Spondylotic	O
Myelopathy	O
.	O

Retrospective	O
analysis	O
of	O
data	O
from	O
the	O
Nationwide	O
Inpatient	O
Sample	O
,	O
a	O
nationally	O
representative	O
,	O
all-payer	O
database	O
of	O
inpatient	O
diagnoses	B-P
and	I-P
procedures	I-P
in	O
the	O
United	O
States	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
compare	O
anterior	O
cervical	O
fusion	O
(	O
ACF	O
)	O
to	O
posterior	O
cervical	O
fusion	O
(	O
PCF	O
)	O
in	O
the	O
treatment	O
of	O
cervical	O
spondylotic	O
myelopathy	O
(	O
CSM	O
)	O
.	O

Previous	O
studies	O
used	O
retrospective	O
single	O
-	O
institution	O
level	O
data	O
to	O
quantify	O
outcomes	O
for	O
CSM	O
patients	O
fusion	O
.	O

It	O
is	O
unclear	O
whether	O
ACF	O
or	O
PCF	O
is	O
superior	O
with	O
regards	O
to	O
charges	O
or	O
outcomes	O
for	O
the	O
treatment	O
of	O
CSM	O
.	O

We	O
used	O
Nationwide	O
Inpatient	O
Sample	O
data	O
to	O
compare	O
ACF	O
to	O
PCF	O
in	O
the	O
management	O
of	O
CSM	O
.	O

All	O
patients	O
18	O
years	O
or	O
older	O
with	O
a	O
diagnosis	B-P
of	O
CSM	O
between	O
1998	O
and	O
2011	O
were	O
included	O
.	O

ACF	O
patients	O
were	O
matched	O
to	O
PCF	O
patients	O
using	O
propensity	O
scores	O
based	O
on	O
patient	O
characteristics	O
(	O
number	O
of	O
levels	O
fused	O
,	O
spine	O
alignment	O
,	O
comorbidities	O
)	O
,	O
hospital	O
characteristics	O
,	O
and	O
patient	O
demographics	O
.	O

Multivariable	O
regression	O
was	O
used	O
to	O
measure	O
the	O
effect	O
of	O
treatment	O
assignment	O
on	O
in-	O
hospital	O
charges	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
in-hospital	O
mortality	O
,	O
discharge	O
disposition	O
,	O
and	O
dysphagia	O
diagnosis	B-P
.	O

From	O
1998	O
to	O
2011	O
,	O
we	O
identified	O
109,728	O
hospitalizations	O
with	O
a	O
CSM	O
diagnosis	B-P
.	O

Of	O
these	O
patients	O
,	O
45,629	O
(	O
41.6	O
%	O
)	O
underwent	O
ACF	O
and	O
14,439	O
(	O
13.2	O
%	O
)	O
underwent	O
PCF	O
.	O

The	O
PCF	O
cohort	O
incurred	O
an	O
average	O
of	O
$	O
41,683	O
more	O
in-hospital	O
charges	O
(	O
P	O
<	O
0.001	O
,	O
inflation	O
adjusted	O
to	O
2011	O
dollars	O
)	O
and	O
remained	O
in	O
hospital	O
an	O
average	O
of	O
2.4	O
days	O
longer	O
(	O
P	O
<	O
0.001	O
)	O
than	O
the	O
ACF	O
cohort	O
.	O

The	O
ACF	O
cohort	O
was	O
just	O
as	O
likely	O
to	O
die	O
in	O
the	O
hospital	O
[	O
odds	O
ratio	O
0.91	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
0.68-1.2	O
]	O
,	O
3.0	O
times	O
more	O
likely	O
to	O
be	O
discharged	O
to	O
home	O
or	O
self-care	O
(	O
95	O
%	O
CI	O
,	O
2.9-3.2	O
)	O
,	O
and	O
2.5	O
times	O
more	O
likely	O
to	O
experience	O
dysphagia	O
(	O
95	O
%	O
CI	O
,	O
2.0-3.1	O
)	O
than	O
the	O
PCF	O
cohort	O
.	O

In	O
treating	O
CSM	O
,	O
ACF	O
led	O
to	O
lower	O
hospital	O
charges	O
,	O
shorter	O
hospital	O
stays	O
,	O
and	O
an	O
increased	O
likelihood	O
of	O
being	O
discharged	O
to	O
home	O
relative	O
to	O
PCF	O
.	O

Analysis	O
of	O
patients	O
with	O
diabetes	O
and	O
complicated	O
intra-abdominal	O
infection	O
or	O
complicated	O
urinary	O
tract	O
infection	O
in	O
phase	O
3	O
trials	O
of	O
ceftolozane/tazobactam	O
.	O

Diabetes	O
mellitus	O
and	O
hyperglycemia	O
are	O
associated	O
with	O
increased	O
susceptibility	O
to	O
bacterial	O
infections	O
and	O
poor	O
treatment	O
outcomes	O
.	O

This	O
post	O
hoc	O
evaluation	O
of	O
the	O
treatment	O
of	O
complicated	O
intra-abdominal	O
infections	O
(	O
cIAI	O
)	O
and	O
complicated	O
urinary	O
tract	O
infections	O
(	O
cUTI	O
)	O
aimed	O
to	O
evaluate	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
in	O
patients	O
with	O
and	O
without	O
diabetes	O
treated	O
with	O
ceftolozane/tazobactam	O
and	O
comparators	O
.	O

Ceftolozane/tazobactam	O
is	O
an	O
antibacterial	O
with	O
potent	O
activity	O
against	O
Gram-negative	O
pathogens	O
and	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
cIAI	O
(	O
with	O
metronidazole	O
)	O
and	O
cUTI	O
(	O
including	O
pyelonephritis	O
)	O
.	O

Patients	O
from	O
the	O
phase	O
3	O
ASPECT	O
studies	O
with	O
(	O
n	O
=	O
245	O
)	O
and	O
without	O
(	O
n	O
=	O
1802	O
)	O
diabetes	O
were	O
compared	O
to	O
evaluate	O
the	O
baseline	O
characteristics	O
,	O
efficacy	O
,	O
and	O
safety	O
of	O
ceftolozane/tazobactam	O
and	O
active	O
comparators	O
.	O

Significantly	O
more	O
patients	O
with	O
than	O
without	O
diabetes	O
were	O
65	O
years	O
of	O
age	O
or	O
older	O
;	O
patients	O
with	O
diabetes	O
were	O
also	O
more	O
likely	O
to	O
weigh	O
≥75	O
kg	O
at	O
baseline	O
(	O
57.1	O
%	O
vs	O
44.5	O
%	O
)	O
,	O
to	O
have	O
renal	O
impairment	O
(	O
48.5	O
%	O
vs	O
30.2	O
%	O
)	O
,	O
or	O
to	O
have	O
APACHE	B-P
II	I-P
scores	I-P
≥10	O
(	O
33.8	O
%	O
vs	O
17.0	O
%	O
)	O
.	O

More	O
patients	O
with	O
diabetes	O
had	O
comorbidities	O
and	O
an	O
increased	O
incidence	O
of	O
complicating	O
factors	O
in	O
both	O
cIAI	O
and	O
cUTI	O
.	O

Clinical	O
cIAI	O
and	O
composite	O
cure	O
cUTI	O
rates	O
across	O
study	O
treatments	O
were	O
lower	O
in	O
patients	O
with	O
than	O
without	O
diabetes	O
(	O
cIAI	O
,	O
75.4	O
%	O
vs	O
86.1	O
%	O
,	O
P	O
=	O
0.0196	O
;	O
cUTI	O
,	O
62.4	O
%	O
vs	O
74.7	O
%	O
,	O
P	O
=	O
0.1299	O
)	O
but	O
were	O
generally	O
similar	O
between	O
the	O
ceftolozane/tazobactam	O
and	O
active	O
comparator	O
treatment	O
groups	O
.	O

However	O
,	O
significantly	O
higher	O
composite	O
cure	O
rates	O
were	O
reported	O
with	O
ceftolozane/tazobactam	O
than	O
with	O
levofloxacin	O
in	O
patients	O
without	O
diabetes	O
with	O
cUTI	O
(	O
79.5	O
%	O
vs	O
69.9	O
%	O
;	O
P	O
=	O
0.0048	O
)	O
.	O

Significantly	O
higher	O
rates	O
of	O
adverse	O
events	O
observed	O
in	O
patients	O
with	O
diabetes	O
were	O
likely	O
due	O
to	O
comorbidities	O
because	O
treatment	O
-related	O
adverse	O
events	O
were	O
similar	O
between	O
groups	O
.	O

In	O
this	O
post	O
hoc	O
analysis	O
,	O
patients	O
with	O
diabetes	O
in	O
general	O
were	O
older	O
,	O
heavier	O
,	O
and	O
had	O
a	O
greater	O
number	O
of	O
complicating	O
comorbidities	O
.	O

Patients	O
with	O
diabetes	O
had	O
lower	O
cure	O
rates	O
and	O
a	O
significantly	O
higher	O
frequency	O
of	O
adverse	O
events	O
than	O
patients	O
without	O
diabetes	O
,	O
likely	O
because	O
of	O
the	O
higher	O
rates	O
of	O
medical	O
complications	O
in	O
this	O
subgroup	O
.	O

Ceftolozane/tazobactam	O
was	O
shown	O
to	O
be	O
at	O
least	O
as	O
effective	O
as	O
comparators	O
in	O
treating	O
cUTI	O
and	O
cIAI	O
in	O
this	O
population	O
.	O

cIAI	O
,	O
NCT01445665	O
and	O
NCT01445678	O
(	O
both	O
trials	O
registered	O
prospectively	O
on	O
September	O
26	O
,	O
2011	O
)	O
;	O
cUTI	O
,	O
NCT01345929	O
and	O
NCT01345955	O
(	O
both	O
trials	O
registered	O
prospectively	O
on	O
April	O
28	O
,	O
2011	O
)	O
.	O

Sensory	O
coding	O
and	O
cognitive	O
processing	O
of	O
sound	O
in	O
Veterans	O
with	O
blast	O
exposure	O
.	O

Recent	O
anecdotal	O
reports	O
from	O
VA	O
audiology	O
clinics	O
as	O
well	O
as	O
a	O
few	O
published	O
studies	O
have	O
identified	O
a	O
sub-population	O
of	O
Service	O
Members	O
seeking	O
treatment	O
for	O
problems	O
communicating	O
in	O
everyday	O
,	O
noisy	O
listening	O
environments	O
despite	O
having	O
normal	O
to	O
near-normal	O
hearing	O
thresholds	O
.	O

Because	O
of	O
their	O
increased	O
risk	O
of	O
exposure	O
to	O
dangerous	O
levels	O
of	O
prolonged	O
noise	O
and	O
transient	O
explosive	O
blast	O
events	O
,	O
communication	O
problems	O
in	O
these	O
soldiers	O
could	O
be	O
due	O
to	O
either	O
hearing	O
loss	O
(	O
traditional	O
or	O
``	O
hidden	O
''	O
)	O
in	O
the	O
auditory	O
sensory	O
periphery	O
or	O
from	O
blast-induced	O
injury	O
to	O
cortical	O
networks	O
associated	O
with	O
attention	O
.	O

We	O
found	O
that	O
out	O
of	O
the	O
14	O
blast-exposed	O
Service	O
Members	O
recruited	O
for	O
this	O
study	O
,	O
12	O
had	O
hearing	O
thresholds	O
in	O
the	O
normal	O
to	O
near-normal	O
range	O
.	O

A	O
majority	O
of	O
these	O
participants	O
reported	O
having	O
problems	O
specifically	O
related	O
to	O
failures	O
with	O
selective	O
attention	O
.	O

Envelope	B-P
following	I-P
responses	I-P
(	O
EFRs	B-P
)	O
measuring	O
neural	O
coding	O
fidelity	O
of	O
the	O
auditory	O
brainstem	O
to	O
suprathreshold	O
sounds	O
were	O
similar	O
between	O
blast-exposed	O
and	O
non-blast	O
controls	O
.	O

Blast-exposed	O
subjects	O
performed	O
substantially	O
worse	O
than	O
non-blast	O
controls	O
in	O
an	O
auditory	O
selective	O
attention	O
task	O
in	O
which	O
listeners	O
classified	O
the	O
melodic	O
contour	O
(	O
rising	O
,	O
falling	O
,	O
or	O
``	O
zig-zagging	O
``	O
)	O
of	O
one	O
of	O
three	O
simultaneous	O
,	O
competing	O
tone	O
sequences	O
.	O

Salient	O
pitch	O
and	O
spatial	O
differences	O
made	O
for	O
easy	O
segregation	O
of	O
the	O
three	O
concurrent	O
melodies	O
.	O

Poor	O
performance	O
in	O
the	O
blast-exposed	O
subjects	O
was	O
associated	O
with	O
weaker	O
evoked	B-P
response	I-P
potentials	I-P
(	O
ERPs	B-P
)	O
in	O
frontal	B-P
EEG	I-P
channels	I-P
,	O
as	O
well	O
as	O
a	O
failure	O
of	O
attention	O
to	O
enhance	O
the	O
neural	O
responses	O
evoked	O
by	O
a	O
sequence	O
when	O
it	O
was	O
the	O
target	O
compared	O
to	O
when	O
it	O
was	O
a	O
distractor	O
.	O

These	O
results	O
suggest	O
that	O
communication	O
problems	O
in	O
these	O
listeners	O
can	O
not	O
be	O
explained	O
by	O
compromised	O
sensory	O
representations	O
in	O
the	O
auditory	O
periphery	O
,	O
but	O
rather	O
point	O
to	O
lingering	O
blast-induced	O
damage	O
to	O
cortical	O
networks	O
implicated	O
in	O
the	O
control	O
of	O
attention	O
.	O

Because	O
all	O
study	O
participants	O
also	O
suffered	O
from	O
post-traumatic	O
disorder	O
(	O
PTSD	O
)	O
,	O
follow-up	O
studies	O
are	O
required	O
to	O
tease	O
apart	O
the	O
contributions	O
of	O
PTSD	O
and	O
blast-induced	O
injury	O
on	O
cognitive	O
performance	O
.	O

The	O
N-Methyl	O
d-Aspartate	O
Glutamate	O
Receptor	O
Antagonist	O
Ketamine	O
Disrupts	O
the	O
Functional	O
State	O
of	O
the	O
Corticothalamic	O
Pathway	O
.	O

The	O
non-competitive	O
N-methyl	O
d-aspartate	O
glutamate	O
receptor	O
(	O
NMDAR	O
)	O
antagonist	O
ketamine	O
elicits	O
a	O
brain	O
state	O
resembling	O
high-risk	O
states	O
for	O
developing	O
psychosis	O
and	O
early	O
stages	O
of	O
schizophrenia	O
characterized	O
by	O
sensory	O
and	O
cognitive	O
deficits	O
and	O
aberrant	O
ongoing	O
gamma	O
oscillations	O
(	O
30-80	O
Hz	O
)	O
in	O
cortical	O
and	O
subcortical	O
structures	O
,	O
including	O
the	O
thalamus	O
.	O

The	O
underlying	O
mechanisms	O
are	O
unknown	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
a	O
ketamine	O
-	O
induced	O
psychotic	O
-	O
relevant	O
state	O
disturbs	O
the	O
functional	O
state	O
of	O
the	O
corticothalamic	O
(	O
CT	O
)	O
pathway	O
.	O

Multisite	B-P
field	I-P
recordings	I-P
were	O
performed	O
in	O
the	O
somatosensory	O
CT	O
system	O
of	O
the	O
sedated	O
rat	O
.	O

Baseline	O
activity	O
was	O
challenged	O
by	O
activation	O
of	O
vibrissa	O
-	O
related	O
prethalamic	O
inputs	O
.	O

The	O
sensory	O
-	O
evoked	O
thalamic	O
response	O
was	O
characterized	O
by	O
a	O
short	O
-	O
latency	O
(	O
∼4	O
ms	O
)	O
prethalamic	O
-mediated	O
negative	O
sharp	O
potential	O
and	O
a	O
longer	O
latency	O
(	O
∼10	O
ms	O
)	O
CT	O
-mediated	O
negative	O
potential	O
.	O

Following	O
a	O
single	O
subcutaneous	O
injection	O
of	O
ketamine	O
(	O
2.5	O
mg/kg	O
)	O
,	O
spontaneously	O
occurring	O
and	O
sensory	O
-	O
evoked	O
thalamic	O
gamma	O
oscillations	O
increased	O
and	O
decreased	O
in	O
power	O
,	O
respectively	O
.	O

The	O
power	O
of	O
the	O
sensory	O
-related	O
gamma	O
oscillations	O
was	O
positively	O
correlated	O
with	O
both	O
the	O
amplitude	O
and	O
the	O
area	O
under	O
the	O
curve	O
of	O
the	O
corresponding	O
CT	O
potential	O
but	O
not	O
with	O
the	O
prethalamic	O
potential	O
.	O

The	O
present	O
results	O
show	O
that	O
the	O
layer	O
VI	O
CT	O
pathway	O
significantly	O
contributes	O
in	O
thalamic	O
gamma	O
oscillations	O
,	O
and	O
they	O
support	O
the	O
hypothesis	O
that	O
reduced	O
NMDAR	O
activation	O
disturbs	O
the	O
functional	O
state	O
of	O
CT	O
and	O
corticocortical	O
networks	O
.	O

Rubinstein-Taybi	O
Syndrome	O
Associated	O
with	O
Pituitary	O
Macroadenoma	O
:	O
A	O
Case	O
Report	O
.	O

Rubinstein-Taybi	O
Syndrome	O
(	O
RSTS	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
that	O
is	O
classically	O
characterized	O
by	O
prenatal	O
and	O
postnatal	O
growth	O
restriction	O
,	O
microcephaly	O
,	O
dysmorphic	O
craniofacial	O
features	O
,	O
broad	O
thumbs	O
and	O
toes	O
,	O
and	O
intellectual	O
disability	O
.	O

We	O
describe	O
the	O
first	O
reported	O
case	O
of	O
a	O
pituitary	O
macroadenoma	O
associated	O
with	O
RSTS	O
.	O

A	O
39-year-old	O
Caucasian	O
female	O
with	O
a	O
past	O
medical	O
history	O
of	O
RSTS	O
diagnosed	O
at	O
age	O
two	O
was	O
found	O
to	O
have	O
a	O
gadolinium	O
-enhancing	O
pituitary	O
mass	O
on	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
of	O
the	O
brain	O
three	O
years	O
ago	O
during	O
workup	O
for	O
migraine-like	O
headaches	O
.	O

Subsequent	O
serial	O
imaging	B-P
showed	O
radiographic	O
evidence	O
of	O
growth	O
up	O
to	O
11.5	O
x	O
14.0	O
x	O
10.0	O
mm	O
in	O
size	O
.	O

The	O
pituitary	O
sellar	O
lesion	O
was	O
resected	O
through	O
an	O
endoscopic	O
transnasal	O
transsphenoidal	O
approach	O
and	O
was	O
found	O
to	O
be	O
a	O
thyrotroph	O
adenoma	O
.	O

RSTS	O
is	O
a	O
rare	O
,	O
neurodevelopmental	O
genetic	O
disease	O
where	O
most	O
patients	O
with	O
disabilities	O
survive	O
into	O
adulthood	O
.	O

The	O
disorder	O
is	O
associated	O
with	O
an	O
increased	O
predisposition	O
for	O
development	O
of	O
nervous	O
system	O
tumors	O
,	O
including	O
pituitary	O
adenomas	O
.	O

A	O
helical	O
segment	O
makes	O
potassium	O
channels	O
go-go	O
.	O

More	O
than	O
500	O
variants	O
in	O
the	O
KCNH2	O
gene	O
,	O
which	O
encodes	O
the	O
cardiac	O
human	O
ether-a-go-go	O
(	O
hERG	O
)	O
ion	O
channel	O
,	O
have	O
been	O
associated	O
with	O
sudden	O
cardiac	O
death	O
,	O
but	O
only	O
a	O
subset	O
of	O
these	O
variants	O
have	O
been	O
investigated	O
.	O

Matthew	O
D.	O
Perry	O
and	O
colleagues	O
now	O
combine	O
NMR	B-P
spectroscopy	I-P
and	O
electrophysiological	B-P
experiments	I-P
to	O
explore	O
the	O
functional	O
properties	O
of	O
mutations	O
within	O
an	O
overlooked	O
hERG	O
helix	O
,	O
finding	O
important	O
contributions	O
to	O
channel	O
function	O
.	O

Characterization	O
and	O
Ectopic	O
Expression	O
of	O
CoWRI1	O
,	O
an	O
AP2/EREBP	O
Domain-Containing	O
Transcription	O
Factor	O
from	O
Coconut	O
(	O
Cocos	O
nucifera	O
L	O
.	O
)	O

Endosperm	O
,	O
Changes	O
the	O
Seeds	O
Oil	O
Content	O
in	O
Transgenic	O
Arabidopsis	O
thaliana	O
and	O
Rice	O
(	O
Oryza	O
sativa	O
L	O
.	O
)	O
.	O

Coconut	O
(	O
Cocos	O
nucifera	O
L.	O
)	O
is	O
a	O
key	O
tropical	O
crop	O
and	O
a	O
member	O
of	O
the	O
monocotyledonous	O
family	O
Arecaceae	O
(	O
Palmaceae	O
)	O
.	O

Few	O
genes	O
and	O
related	O
metabolic	O
processes	O
involved	O
in	O
coconut	O
endosperm	O
development	O
have	O
been	O
investigated	O
.	O

In	O
this	O
study	O
,	O
a	O
new	O
member	O
of	O
the	O
WRI1	O
gene	O
family	O
was	O
isolated	O
from	O
coconut	O
endosperm	O
and	O
was	O
named	O
CoWRI1	O
.	O

Its	O
transcriptional	O
activities	O
and	O
interactions	O
with	O
the	O
acetyl-CoA	O
carboxylase	O
(	O
BCCP2	O
)	O
promoter	O
of	O
CoWRI1	O
were	O
confirmed	O
by	O
the	O
yeast	O
two-hybrid	O
and	O
yeast	O
one-hybrid	O
approaches	O
,	O
respectively	O
.	O

Functional	O
characterization	O
was	O
carried	O
out	O
through	O
seed	O
-specific	O
expression	O
in	O
Arabidopsis	O
and	O
endosperm	O
-specific	O
expression	O
in	O
rice	O
.	O

In	O
transgenic	O
Arabidopsis	O
,	O
high	O
over-expressions	O
of	O
CoWRI1	O
in	O
seven	O
independent	O
T2	O
lines	O
were	O
detected	O
by	O
quantitative	O
real-time	O
PCR	O
.	O

The	O
relative	O
mRNA	O
accumulation	O
of	O
genes	O
encoding	O
enzymes	O
involved	O
in	O
either	O
fatty	O
acid	O
biosynthesis	O
or	O
triacylglycerols	O
assembly	O
(	O
BCCP2	O
,	O
KASI	O
,	O
MAT	O
,	O
ENR	O
,	O
FATA	O
,	O
and	O
GPDH	O
)	O
were	O
also	O
assayed	B-P
in	O
mature	O
seeds	O
.	O

Furthermore	O
,	O
lipid	O
and	O
fatty	O
acids	O
C16:0	O
and	O
C18:0	O
significantly	O
increased	O
.	O

In	O
two	O
homozygous	O
T2	O
transgenic	O
rice	O
lines	O
(	O
G5	O
and	O
G2	O
)	O
,	O
different	O
CoWRI1	O
expression	O
levels	O
were	O
detected	O
,	O
but	O
no	O
CoWRI1	O
transcripts	O
were	O
detected	O
in	O
the	O
wild	O
type	O
.	O

Analyses	O
of	O
the	O
seed	O
oil	O
content	O
,	O
starch	O
content	O
,	O
and	O
total	O
protein	O
content	O
indicated	O
that	O
the	O
two	O
T2	O
transgenic	O
lines	O
showed	O
a	O
significant	O
increase	O
(	O
P	O
<	O
0.05	O
)	O
in	O
seed	O
oil	O
content	O
.	O

The	O
transgenic	O
lines	O
also	O
showed	O
a	O
significant	O
increase	O
in	O
starch	O
content	O
,	O
whereas	O
total	O
protein	O
content	O
decreased	O
significantly	O
.	O

Further	O
analysis	O
of	O
the	O
fatty	O
acid	O
composition	O
revealed	O
that	O
palmitic	O
acid	O
(	O
C16:0	O
)	O
and	O
linolenic	O
acid	O
(	O
C18:3	O
)	O
increased	O
significantly	O
in	O
the	O
seeds	O
of	O
the	O
transgenic	O
rice	O
lines	O
,	O
but	O
oleic	O
acid	O
(	O
C18:1	O
)	O
levels	O
significantly	O
declined	O
.	O

Mitochondrial	O
Ultrastructure	O
and	O
Glucose	O
Signaling	O
Pathways	O
Attributed	O
to	O
the	O
Kv1.3	O
Ion	O
Channel	O
.	O

Gene-targeted	O
deletion	O
of	O
the	O
potassium	O
channel	O
Kv1.3	O
(	O
Kv1.3	O
(	O
-∕-	O
)	O
)	O
results	O
i	O
n	O
``	O
S	O
uper-smeller	O
''	O
mice	O
with	O
a	O
se	O
nsory	O
p	O
h	O
enotype	O
t	O
hat	O
includes	O
an	O
increased	O
olfactory	O
ability	O
linked	O
to	O
changes	O
in	O
olfactory	O
circuitry	O
,	O
increased	O
abundance	O
of	O
olfactory	O
cilia	O
,	O
and	O
increased	O
expression	O
of	O
odorant	O
receptors	O
and	O
the	O
G-protein	O
,	O
Golf	O
.	O

Kv1.3	O
(	O
-∕-	O
)	O
mice	O
a	O
lso	O
have	O
a	O
metabolic	O
p	O
h	O
enotype	O
i	O
ncluding	O
lo	O
wer	O
b	O
o	O
dy	O
weight	O
a	O
nd	O
de	O
creased	O
a	O
d	O
iposity	O
,	O
in	O
creased	O
total	O
energy	O
expenditure	O
(	O
TEE	O
)	O
,	O
increased	O
locomotor	O
activity	O
,	O
and	O
resistance	O
to	O
both	O
diet	O
-	O
and	O
genetic-induced	O
obesity	O
.	O

We	O
explored	O
two	O
cellular	O
aspects	O
to	O
elucidate	O
the	O
mechanism	O
by	O
which	O
loss	O
of	O
Kv1.3	O
channel	O
in	O
the	O
olfactory	O
bulb	O
(	O
OB	O
)	O
may	O
enhance	O
glucose	O
utilization	O
and	O
metabolic	O
rate	O
.	O

First	O
,	O
using	O
in	O
situ	O
hybridization	O
we	O
find	O
that	O
Kv1.3	O
and	O
the	O
insulin	O
-	O
dependent	O
glucose	O
transporter	O
type	O
4	O
(	O
GLUT4	O
)	O
are	O
co-localized	O
to	O
the	O
mitral	O
cell	O
layer	O
of	O
the	O
OB	O
.	O

Disruption	O
of	O
Kv1.3	O
conduction	O
via	O
construction	O
of	O
a	O
pore	O
mutation	O
(	O
W386F	O
Kv1.3	O
)	O
was	O
sufficient	O
to	O
independently	O
translocate	O
GLUT4	O
to	O
the	O
plasma	O
membrane	O
in	O
HEK	O
293	O
cells	O
.	O

Because	O
olfactory	O
sensory	O
perception	O
and	O
the	O
maintenance	O
of	O
action	O
potential	O
(	O
AP	O
)	O
firing	O
frequency	O
by	O
mitral	O
cells	O
of	O
the	O
OB	O
is	O
highly	O
energy	O
demanding	O
and	O
Kv1.3	O
is	O
also	O
expressed	O
in	O
mitochondria	O
,	O
we	O
next	O
explored	O
the	O
structure	O
of	O
this	O
organelle	O
in	O
mitral	O
cells	O
.	O

We	O
challenged	O
wildtype	O
(	O
WT	O
)	O
and	O
Kv1.3	O
(	O
-∕-	O
)	O
male	O
mice	O
with	O
a	O
m	O
oderately	O
high-fat	O
diet	O
(	O
M	O
HF	O
,	O
31.8	O
%	O
kcal	O
fat	O
)	O
for	O
4	O
months	O
and	O
then	O
examined	O
OB	O
ultrastructure	O
using	O
transmission	B-P
electron	I-P
microscopy	I-P
.	O

In	O
WT	O
mice	O
,	O
mitochondria	O
were	O
significantly	O
enlarged	O
following	O
diet-induced	O
obesity	O
(	O
DIO	O
)	O
and	O
there	O
were	O
fewer	O
mitochondria	O
,	O
likely	O
due	O
to	O
mitophagy	O
.	O

Interestingly	O
,	O
mitochondria	O
were	O
significantly	O
smaller	O
in	O
Kv1.3	O
(	O
-∕-	O
)	O
mice	O
c	O
ompared	O
with	O
that	O
of	O
W	O
T	O
mice	O
.	O

Similar	O
to	O
their	O
m	O
etabolic	O
r	O
esistance	O
to	O
D	O
IO	O
,	O
the	O
K	O
v1.3	O
(	O
-∕-	O
)	O
mice	O
ha	O
d	O
unchanged	O
mit	O
ochondria	O
in	O
terms	O
of	O
cros	O
s	O
sectional	O
area	O
and	O
abundance	O
following	O
a	O
challenge	O
with	O
modified	O
diet	O
.	O

We	O
are	O
very	O
interested	O
to	O
understand	O
how	O
targeted	O
disruption	O
of	O
the	O
Kv1.3	O
channel	O
in	O
the	O
OB	O
can	O
modify	O
TEE	O
.	O

Our	O
study	O
demonstrates	O
that	O
Kv1.3	O
regulates	O
mitochondrial	O
structure	O
and	O
alters	O
glucose	O
utilization	O
;	O
two	O
important	O
metabolic	O
changes	O
that	O
could	O
drive	O
whole	O
system	O
changes	O
in	O
metabolism	O
initiated	O
at	O
the	O
OB	O
.	O

Methylation	O
Analysis	O
of	O
BRCA1	O
and	O
APC	O
in	O
Breast	O
Cancer	O
and	O
It	O
's	O
Relationship	O
to	O
Clinicopathological	O
Features	O
.	O

Promoter	O
methylation	O
of	O
tumor	O
suppressor	O
genes	O
is	O
an	O
important	O
epigenetic	O
alteration	O
that	O
occurs	O
in	O
the	O
primary	O
stages	O
of	O
human	O
tumors	O
,	O
including	O
breast	O
cancer	O
.	O

Identification	O
of	O
methylated	O
genes	O
and	O
their	O
relationship	O
to	O
clinical	O
features	O
can	O
contribute	O
to	O
the	O
prognosis	O
and	O
early	B-P
detection	I-P
of	O
tumors	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
methylation	O
status	O
of	O
APC	O
and	O
BRCA1	O
genes	O
and	O
their	O
relationship	O
to	O
clinical	O
factors	O
in	O
breast	O
cancer	O
patients	O
.	O

BRCA1	O
and	O
APC	O
promoter	O
methylation	O
was	O
examined	O
by	O
methylation	O
-	O
specific	O
multiplex	O
ligation-dependent	O
probe	O
amplification	O
(	O
MS-MLPA	O
)	O
assay	B-P
in	O
formalin-fixed	O
paraffin	O
embedded	O
(	O
FFPE	O
)	O
breast	O
tissue	O
from	O
75	O
patients	O
.	O

APC	O
promoter	O
methylation	O
was	O
detected	O
in	O
30.67	O
%	O
breast	O
cancer	O
tissues	O
and	O
BRCA1	O
was	O
methylated	O
in	O
9.33	O
%	O
of	O
breast	O
tumors	O
.	O

Methylation	O
of	O
APC	O
was	O
associated	O
with	O
low	O
histological	O
grade	O
(	O
p	O
=	O
0.006	O
)	O
and	O
methylation	O
of	O
BRCA1	O
was	O
related	O
with	O
lymph	O
node	O
metastasis	O
(	O
p	O
=	O
0.017	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
methylation	O
status	O
of	O
APC	O
and	O
BRCA1	O
can	O
be	O
a	O
predictive	O
marker	O
for	O
early	B-P
detection	I-P
and	O
better	O
management	O
of	O
breast	O
cancer	O
patients	O
.	O

Invasive	O
fungal	O
infections	O
in	O
renal	O
transplant	O
patients	O
:	O
a	O
single	O
center	O
study	O
.	O

Timely	O
diagnosis	O
of	O
invasive	O
fungal	O
infections	O
(	O
IFI	O
)	O
in	O
renal	O
transplant	O
(	O
RT	O
)	O
patients	O
on	O
immunosuppression	O
is	O
often	O
difficult	O
,	O
jeopardizing	O
their	O
life	O
and	O
graft	O
.	O

We	O
reported	O
IFI	O
and	O
their	O
causative	O
fungal	O
agents	O
in	O
post-	O
RT	O
patients	O
.	O

This	O
was	O
a	O
retrospective	O
6-year	O
clinical	O
study	O
carried	O
out	O
from	O
2010	O
to	O
2015	O
on	O
1900	O
RT	O
patients	O
.	O

Clinical	O
data	O
included	O
patient	O
-	O
donor	O
demographics	O
,	O
time	O
to	O
onset	O
of	O
infection	O
,	O
risk	O
factors	O
and	O
graft	O
function	O
in	O
terms	O
of	O
serum	B-P
creatinine	I-P
(	O
SCr	B-P
)	O
.	O

To	O
identify	O
IFI	O
,	O
we	O
examined	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
,	O
blood	O
,	O
tissue	O
,	O
and	O
wound	O
swab	O
samples	O
by	O
conventional	O
mycological	B-P
methods	I-P
.	O

IFI	O
were	O
diagnosed	O
in	O
30	O
(	O
1.56	O
%	O
)	O
patients	O
on	O
triple	O
immunosuppression	O
,	O
mainly	O
males	O
(	O
n	O
=	O
25	O
)	O
with	O
mean	O
age	O
of	O
36.57	O
±	O
11.9	O
years	O
at	O
13.12	O
±	O
18.35	O
months	O
post-	O
RT	O
.	O

Aspergillus	O
species	O
was	O
identified	O
in	O
11	O
BAL	O
,	O
one	O
tissue	O
,	O
and	O
one	O
wound	O
specimen	O
each	O
,	O
30.76	O
%	O
of	O
these	O
were	O
fatal	O
and	O
15.38	O
%	O
caused	O
graft	O
loss	O
;	O
Candida	O
albicans	O
was	O
in	O
nine	O
BAL	O
,	O
four	O
blood	O
,	O
two	O
wound	O
swab	O
,	O
and	O
one	O
tissue	O
specimens	O
,	O
25	O
%	O
of	O
these	O
were	O
fatal	O
and	O
25	O
%	O
had	O
graft	O
loss	O
and	O
one	O
mucor	O
in	O
BAL	O
which	O
was	O
fatal	O
.	O

Seven	O
patients	O
were	O
diabetic	O
,	O
10	O
had	O
superadded	O
cytomegalovirus	O
infection	O
,	O
and	O
15	O
were	O
anti-rejected	O
.	O

IFI	O
are	O
associated	O
with	O
increased	O
morbidity	O
and	O
mortality	O
in	O
RT	O
patients	O
.	O

Triple	O
immunosuppression	O
,	O
broad	O
spectrum	O
antibiotics	O
for	O
≥	O
two	O
weeks	O
,	O
diabetes	O
and	O
superadded	O
infection	O
are	O
added	O
risks	O
for	O
these	O
patients	O
.	O

Prevention	O
,	O
early	O
diagnosis	O
,	O
and	O
appropriate	O
management	O
are	O
necessary	O
to	O
improve	O
their	O
prognosis	O
.	O

Characterization	O
and	O
phylogenetic	O
analysis	O
of	O
complete	O
mitochondrial	O
genomes	O
for	O
two	O
desert	O
cyprinodontoid	O
fishes	O
,	O
Empetrichthys	O
latos	O
and	O
Crenichthys	O
baileyi	O
.	O

The	O
Pahrump	O
poolfish	O
(	O
Empetrichthys	O
latos	O
)	O
and	O
White	O
River	O
springfish	O
(	O
Crenichthys	O
baileyi	O
)	O
are	O
small-bodied	O
teleost	O
fishes	O
(	O
order	O
Cyprinodontiformes	O
)	O
endemic	O
to	O
the	O
arid	O
Great	O
Basin	O
and	O
Mojave	O
Desert	O
regions	O
of	O
western	O
North	O
America	O
.	O

These	O
taxa	O
survive	O
as	O
small	O
,	O
isolated	O
populations	O
in	O
remote	O
streams	O
and	O
springs	O
and	O
evolved	O
to	O
tolerate	O
extreme	O
conditions	O
of	O
high	O
temperature	O
and	O
low	O
dissolved	O
oxygen	O
.	O

Both	O
species	O
have	O
experienced	O
severe	O
population	O
declines	O
over	O
the	O
last	O
50-60years	O
that	O
led	O
to	O
some	O
subspecies	O
being	O
categorized	O
with	O
protected	O
status	O
under	O
the	O
U.S	O
.	O

Endangered	O
Species	O
Act	O
.	O

Here	O
we	O
report	O
the	O
first	O
sequencing	B-P
of	O
the	O
complete	O
mitochondrial	O
DNA	O
genomes	O
for	O
both	O
E.	O
l.	O
latos	O
and	O
the	O
moapae	O
subspecies	O
of	O
C.	O
baileyi	O
.	O

Complete	O
mitogenomes	O
of	O
16,546bp	O
nucleotides	O
were	O
obtained	O
from	O
two	O
E.	O
l.	O
latos	O
individuals	O
collected	O
from	O
introduced	O
populations	O
at	O
Spring	O
Mountain	O
Ranch	O
State	O
Park	O
and	O
Shoshone	O
Ponds	O
Natural	O
Area	O
,	O
Nevada	O
,	O
USA	O
,	O
while	O
a	O
single	O
mitogenome	O
of	O
16,537bp	O
was	O
sequenced	O
for	O
C.	O
b.	O
moapae	O
.	O

The	O
mitogenomes	O
of	O
both	O
species	O
contain	O
13	O
protein	O
-	O
encoding	O
genes	O
,	O
twenty-two	O
tRNAs	O
,	O
and	O
two	O
rRNAs	O
(	O
12S	O
and	O
18S	O
)	O
following	O
the	O
syntenic	O
arrangement	O
typical	O
of	O
Actinopterygiian	O
fish	O
mitogenomes	O
,	O
as	O
well	O
as	O
D-loop	O
control	O
regions	O
of	O
858bp	O
for	O
E.	O
latos	O
and	O
842bp	O
for	O
C.	O
baileyi	O
moapae	O
.	O

The	O
two	O
E.	O
latos	O
individuals	O
exhibited	O
only	O
0.0181	O
%	O
nucleotide	O
sequence	O
divergence	O
across	O
the	O
entire	O
mitogenome	O
,	O
implying	O
little	O
intraspecific	O
mtDNA	O
genetic	O
variation	O
.	O

Comparative	O
phylogenetic	O
analysis	O
of	O
the	O
poolfish	O
and	O
springfish	O
mitochondrial	O
genomes	O
to	O
available	O
mitogenomes	O
of	O
other	O
Cyprinodontoid	O
fishes	O
confirmed	O
the	O
close	O
relationship	O
of	O
these	O
oviparous	O
Empetrichthys	O
and	O
Crenichthys	O
genera	O
to	O
the	O
viviparous	O
goodeid	O
fishes	O
of	O
central	O
Mexico	O
,	O
and	O
showed	O
the	O
combined	O
clade	O
of	O
these	O
fishes	O
to	O
be	O
a	O
sister	O
group	O
to	O
the	O
Profundulidae	O
killifishes	O
.	O

Despite	O
several	O
significant	O
life	O
history	O
and	O
morphological	O
differences	O
between	O
the	O
Empetrichthyinae	O
and	O
Goodienae	O
,	O
estimates	O
of	O
evolutionary	O
genetic	O
distances	O
using	O
two	O
partial	O
regions	O
of	O
mtDNA	O
point	O
to	O
inclusion	O
of	O
the	O
Empetrichthys	O
and	O
Crenichthys	O
genera	O
within	O
the	O
family	O
Goodeidae	O
along	O
with	O
the	O
goodeid	O
fishes	O
of	O
central	O
Mexico	O
.	O

Assessment	O
the	O
Exposure	O
Level	O
of	O
Rare	O
Earth	O
Elements	O
in	O
Workers	O
Producing	O
Cerium	O
,	O
Lanthanum	O
Oxide	O
Ultrafine	O
and	O
Nanoparticles	O
.	O

In	O
order	O
to	O
assess	O
occupational	O
exposure	O
level	O
of	O
15	O
rare	O
earth	O
elements	O
(	O
REEs	O
)	O
and	O
identify	O
the	O
associated	O
influence	O
,	O
we	O
used	O
inductively	B-P
coupled	I-P
plasma	I-P
mass	I-P
spectrometry	I-P
(	O
ICP-MS	B-P
)	O
based	O
on	O
closed	O
-	O
vessel	O
microwave	O
-	O
assisted	O
wet	O
digestion	O
procedure	O
to	O
determinate	B-P
the	O
concentration	O
of	O
Y	O
,	O
La	O
,	O
Ce	O
,	O
Pr	O
,	O
Nd	O
,	O
Sm	O
,	O
Eu	O
,	O
Gd	O
,	O
Tb	O
,	O
Dy	O
,	O
Ho	O
,	O
Er	O
,	O
Tm	O
,	O
Yb	O
and	O
Lu	O
in	O
urinary	O
samples	O
obtained	O
from	O
workers	O
producing	O
ultrafine	O
and	O
nanoparticles	O
containing	O
cerium	O
and	O
lanthanum	O
oxide	O
.	O

The	O
results	O
suggest	O
that	O
La	O
and	O
Ce	O
were	O
the	O
primary	O
component	O
,	O
together	O
accounting	O
for	O
97	O
%	O
of	O
total	O
REEs	O
in	O
workers	O
.	O

The	O
urinary	O
levels	O
of	O
La	O
,	O
and	O
Ce	O
among	O
the	O
workers	O
(	O
6.36	O
,	O
15.32	O
μg.g	O
(	O
-1	O
)	O
creatinine	O
,	O
respectively	O
)	O
were	O
significantly	O
enriched	O
compared	O
to	O
those	O
levels	O
measured	O
in	O
the	O
control	O
subjects	O
(	O
1.52	O
,	O
4.04	O
μg.g	O
(	O
-1	O
)	O
creatinine	O
,	O
respectively	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O

This	O
study	O
simultaneously	O
identified	O
the	O
associated	O
individual	O
factors	O
,	O
the	O
results	O
indicate	O
that	O
the	O
concentrations	O
in	O
over	O
5	O
years	O
group	O
(	O
11.64	O
±	O
10.93	O
for	O
La	O
,	O
27.83	O
±	O
24.38	O
for	O
Ce	O
)	O
were	O
significantly	O
elevated	O
compared	O
to	O
1-5	O
years	O
group	O
(	O
2.58	O
±	O
1.51	O
for	O
La	O
,	O
6.87	O
±	O
3.90	O
for	O
Ce	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Compared	O
the	O
urinary	O
levels	O
of	O
La	O
and	O
Ce	O
at	O
the	O
separation	O
and	O
packaging	O
locations	O
(	O
9.10	O
±	O
9.51	O
for	O
La	O
,	O
22.29	O
±	O
21.01	O
for	O
Ce	O
)	O
with	O
the	O
other	O
locations	O
(	O
2.85	O
±	O
0.98	O
for	O
La	O
,	O
6.37	O
±	O
2.12	O
for	O
Ce	O
)	O
,	O
the	O
results	O
show	O
urinary	O
concentrations	O
were	O
significantly	O
higher	O
in	O
workers	O
at	O
separation	O
and	O
packaging	O
locations	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Inter	O
-	O
individual	O
variation	O
in	O
levels	O
of	O
La	O
and	O
Ce	O
in	O
urine	O
is	O
the	O
result	O
of	O
multi-factorial	O
comprehensive	O
action	O
.	O

Further	O
researches	O
should	O
focus	O
on	O
the	O
multiple	O
factors	O
contributing	O
to	O
the	O
REEs	O
levels	O
of	O
the	O
occupationally	O
exposed	O
workers	O
.	O

Conventional	O
and	O
Iontophoresis	O
Corneal	O
Cross-Linking	O
for	O
Keratoconus	O
:	O
Efficacy	O
and	O
Assessment	O
by	O
Optical	B-P
Coherence	I-P
Tomography	I-P
and	O
Confocal	B-P
Microscopy	I-P
.	O

To	O
compare	O
the	O
efficacy	O
,	O
safety	O
,	O
and	O
microstructural	O
corneal	O
changes	O
during	O
2	O
years	O
after	O
conventional	O
corneal	O
collagen	O
cross-linking	O
(	O
C	O
-	O
CXL	O
)	O
and	O
transepithelial	O
corneal	O
CXL	O
by	O
iontophoresis	O
(	O
I	O
-	O
CXL	O
)	O
for	O
keratoconus	O
.	O

Eighty	O
eyes	O
of	O
80	O
patients	O
with	O
progressive	O
keratoconus	O
were	O
treated	O
by	O
C	O
-	O
CXL	O
(	O
n	O
=	O
40	O
)	O
or	O
I	O
-	O
CXL	O
(	O
n	O
=	O
40	O
)	O
.	O

Patients	O
were	O
investigated	O
before	O
surgery	O
and	O
1	O
,	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
24	O
months	O
after	O
treatment	O
.	O

We	O
measured	O
central	O
corneal	O
thickness	O
and	O
maximal	O
simulated	O
keratometry	O
values	O
(	O
Kmax	O
)	O
and	O
performed	O
specular	B-P
microscopy	I-P
and	O
in	O
vivo	O
confocal	B-P
microscopy	I-P
at	O
each	O
time	O
point	O
.	O

The	O
demarcation	O
line	O
was	O
assessed	O
1	O
month	O
after	O
treatment	O
.	O

Kmax	O
remained	O
stable	O
after	O
I	O
-	O
CXL	O
during	O
the	O
entire	O
study	O
period	O
(	O
P	O
=	O
0.56	O
)	O
,	O
whereas	O
the	O
average	O
keratometry	O
increased	O
by	O
0.2	O
diopter	O
(	O
50.9	O
±	O
5.6-51.1	O
±	O
5.2	O
)	O
.	O

Kmax	O
significantly	O
decreased	O
1	O
(	O
P	O
=	O
0.02	O
)	O
to	O
2	O
years	O
(	O
P	O
<	O
0.01	O
)	O
after	O
C	O
-	O
CXL	O
,	O
with	O
an	O
average	O
decrease	O
of	O
1.1	O
diopters	O
(	O
49.9	O
±	O
4.5-48.8	O
±	O
4.2	O
)	O
.	O

The	O
failure	O
rate	O
of	O
I	O
-	O
CXL	O
was	O
20	O
%	O
and	O
that	O
of	O
C	O
-	O
CXL	O
7.5	O
%	O
.	O

The	O
demarcation	O
line	O
was	O
superficially	O
visible	O
in	O
35	O
%	O
of	O
cases	O
after	O
I	O
-	O
CXL	O
compared	O
with	O
95	O
%	O
of	O
cases	O
after	O
C	O
-	O
CXL	O
.	O

Endothelial	O
cell	O
density	O
and	O
central	O
corneal	O
thickness	O
remained	O
stable	O
during	O
the	O
entire	O
study	O
period	O
.	O

The	O
change	O
in	O
Kmax	O
2	O
years	O
after	O
C	O
-	O
CXL	O
and	O
I	O
-	O
CXL	O
and	O
the	O
preoperative	O
Kmax	O
were	O
negatively	O
correlated	O
(	O
r	O
=	O
0.14	O
,	O
P	O
=	O
0.013	O
,	O
and	O
r	O
=	O
0.17	O
,	O
P	O
=	O
0.007	O
,	O
respectively	O
)	O
.	O

I	O
-	O
CXL	O
halted	O
progression	O
of	O
keratoconus	O
less	O
efficiently	O
than	O
did	O
C	O
-	O
CXL	O
after	O
2	O
years	O
of	O
follow-up	O
.	O

Longer	O
prospective	O
studies	O
are	O
still	O
needed	O
to	O
ensure	O
I	O
-	O
CXL	O
efficacy	O
.	O

Efficacy	O
and	O
safety	O
of	O
cisplatin	O
,	O
dexamethasone	O
,	O
gemcitabine	O
and	O
pegaspargase	O
(	O
DDGP	O
)	O
regimen	O
in	O
newly	O
diagnosed	O
,	O
advanced-stage	O
extranodal	O
natural	O
killer/T-cell	O
lymphoma	O
:	O
interim	O
analysis	O
of	O
a	O
phase	O
4	O
study	O
NCT01501149	O
.	O

To	O
explore	O
a	O
more	O
effective	O
treatment	O
for	O
newly	O
diagnosed	O
,	O
advanced-stage	O
extranodal	O
natural	O
killer/T-cell	O
lymphoma	O
,	O
nasal	O
type	O
(	O
ENKTL	O
)	O
,	O
we	O
conducted	O
a	O
phase	O
4	O
study	O
of	O
the	O
cisplatin	O
,	O
dexamethasone	O
,	O
gemcitabine	O
,	O
pegaspargase	O
(	O
DDGP	O
)	O
regimen	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
2-year	O
progression-free	O
survival	O
(	O
PFS	O
)	O
after	O
the	O
protocol	O
treatment	O
.	O

Secondary	O
endpoints	O
included	O
response	O
rate	O
(	O
RR	O
)	O
,	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
median	O
survival	O
time	O
(	O
MST	O
)	O
.	O

The	O
interim	O
analysis	O
included	O
data	O
only	O
from	O
March	O
2011	O
to	O
September	O
2013	O
,	O
who	O
received	O
six	O
cycles	O
of	O
DDGP	O
chemotherapy	O
.	O

A	O
total	O
of	O
25	O
eligible	O
patients	O
were	O
enrolled	O
.	O

Seventeen	O
patients	O
(	O
17/24	O
,	O
70.83	O
%	O
)	O
achieved	O
complete	O
response	O
(	O
CR	O
)	O
and	O
four	O
(	O
4/24	O
,	O
16.67	O
%	O
)	O
achieved	O
partial	O
response	O
(	O
PR	O
)	O
,	O
three	O
(	O
3/24	O
,	O
12.50	O
%	O
)	O
had	O
progressive	O
disease	O
(	O
PD	O
)	O
.	O

The	O
RR	O
after	O
treatment	O
was	O
87.50	O
%	O
.	O

After	O
a	O
median	O
follow-up	O
duration	O
of	O
24.67	O
months	O
(	O
range	O
4-48	O
months	O
)	O
.	O

The	O
2-year	O
PFS	O
and	O
OS	O
rate	O
were	O
61.80	O
%	O
(	O
95	O
%	O
CI	O
,	O
42.00	O
%	O
to	O
81.60	O
%	O
)	O
and	O
68.50	O
%	O
(	O
95	O
%	O
CI	O
,	O
48.70	O
%	O
to	O
88.30	O
%	O
)	O
,	O
respectively	O
.	O

The	O
MST	O
was	O
36.55	O
months	O
(	O
95	O
%	O
CI	O
,	O
29.41	O
months	O
to	O
43.70	O
months	O
)	O
.	O

Grade	O
3/4	O
leukopenia	O
occurred	O
in	O
fourteen	O
patients	O
(	O
58.33	O
%	O
)	O
and	O
grade	O
3/4	O
thrombocytopenia	O
occurred	O
in	O
eleven	O
patients	O
(	O
45.83	O
%	O
)	O
.	O

Twelve	O
patients	O
(	O
50.00	O
%	O
)	O
experienced	O
Activated	B-P
Partial	I-P
Phromboplastin	I-P
Ptime	I-P
(	O
APTT	B-P
)	O
elongation	O
and	O
fourteen	O
patients	O
(	O
58.33	O
%	O
)	O
experienced	O
hypofibrinogenemia	O
.	O

In	O
conclusion	O
,	O
DDGP	O
regimen	O
is	O
an	O
effective	O
and	O
tolerated	O
treatment	O
for	O
newly	O
diagnosed	O
,	O
advanced-stage	O
ENKTL	O
.	O

This	O
trial	O
was	O
registered	O
at	O
www.ClinicalTrials.gov	O
as	O
#	O
NCT01501149	O
.	O

Radiation	O
-	O
induced	O
Parotid	O
Gland	O
Atrophy	O
in	O
Patients	O
with	O
Head	O
and	O
Neck	O
Cancer	O
After	O
Carbon-ion	O
Radiotherapy	O
.	O

This	O
study	O
aimed	O
to	O
clarify	O
the	O
relationship	O
between	O
dosimetric	B-P
factors	O
and	O
parotid	O
gland	O
(	O
PG	O
)	O
atrophy	O
after	O
carbon	O
ion	O
radiotherapy	O
(	O
C-ion	O
RT	O
)	O
.	O

Fifty-four	O
patients	O
with	O
head	O
and	O
neck	O
tumours	O
were	O
enrolled	O
and	O
93	O
irradiated	O
PGs	O
were	O
analyzed	O
.	O

Thirty	O
and	O
24	O
patients	O
were	O
treated	O
with	O
total	O
doses	O
[	O
relative	O
biological	O
effectiveness	O
(	O
RBE	O
)	O
]	O
of	O
57.6	O
Gy	O
and	O
64.0	O
Gy	O
,	O
respectively	O
,	O
in	O
16	O
fractions	O
.	O

PG	O
volumes	O
were	O
measured	B-P
using	O
computed	O
tomographic	O
images	O
obtained	O
before	O
C-ion	O
RT	O
and	O
every	O
3-6	O
months	O
thereafter	O
.	O

The	O
median	O
follow-up	O
period	O
was	O
46.4	O
months	O
(	O
range	O
=24.0-123.0	O
months	O
)	O
.	O

Univariate	O
analysis	O
showed	O
that	O
PG	O
volumes	O
receiving	O
more	O
than	O
5	O
,	O
10	O
,	O
15	O
,	O
and	O
20	O
Gy	O
RBE	O
(	O
V5	O
,	O
V10	O
,	O
V15	O
and	O
V20	O
,	O
respectively	O
)	O
,	O
mean	O
dose	O
,	O
and	O
maximum	O
dose	O
were	O
significantly	O
associated	O
with	O
PG	O
atrophy	O
.	O

Multivariate	O
analysis	O
indicated	O
that	O
only	O
V5	O
was	O
significantly	O
associated	O
with	O
atrophy	O
.	O

Increasing	O
V5	O
was	O
a	O
significant	O
risk	O
factor	O
for	O
PG	O
atrophy	O
after	O
C-ion	O
RT	O
.	O

Methylation	O
status	O
of	O
the	O
promoter	O
region	O
of	O
the	O
human	O
frizzled	O
9	O
gene	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

The	O
FZD9	O
gene	O
is	O
located	O
at	O
chromosome	O
7q11.23	O
,	O
and	O
has	O
been	O
indicated	O
to	O
be	O
a	O
tumor	O
suppressor	O
gene	O
.	O

The	O
present	O
study	O
examined	O
the	O
involvement	O
of	O
FZD9	O
promoter	O
methylation	O
in	O
the	O
downregulation	O
of	O
FZD9	O
expression	O
in	O
leukemia	O
cells	O
.	O

The	O
expression	O
of	O
the	O
FZD9	O
gene	O
was	O
absent	O
in	O
various	O
leukemic	O
cell	O
lines	O
,	O
while	O
it	O
was	O
restored	O
following	O
treatment	O
with	O
DNA	O
demethylating	O
agent	O
5-aza-2'-deoxycytidine	O
.	O

Bisulfite	O
sequencing	O
analysis	O
of	O
the	O
FZD9	O
promoter	O
region	O
showed	O
that	O
it	O
was	O
partially	O
methylated	O
in	O
cell	O
lines	O
in	O
which	O
FZD9	O
gene	O
was	O
not	O
expressed	O
.	O

Thus	O
,	O
DNA	O
methylation	O
in	O
the	O
promoter	O
region	O
may	O
lead	O
to	O
inactivation	O
of	O
the	O
FZD9	O
gene	O
,	O
which	O
may	O
represent	O
and	O
aberration	O
associated	O
with	O
leukemia	O
,	O
since	O
DNA	O
was	O
not	O
methylated	O
in	O
normal	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Methylation	O
-specific	O
polymerase	O
chain	O
reaction	O
analysis	O
revealed	O
that	O
the	O
promoter	O
region	O
of	O
the	O
FZD9	O
gene	O
was	O
frequently	O
methylated	O
in	O
primary	O
or	O
relapse	O
acute	O
myeloid	O
leukemia	O
(	O
52.9	O
%	O
;	O
excluding	O
acute	O
promyelocytic	O
leukemia	O
)	O
;	O
however	O
,	O
methylation	O
was	O
infrequent	O
in	O
B-cell	O
acute	O
lymphocytic	O
leukemia	O
(	O
5.6	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
indicated	O
that	O
the	O
methylation	O
profile	B-P
of	O
the	O
FZD9	O
gene	O
corresponded	O
to	O
that	O
of	O
a	O
candidate	O
tumor-suppressor	O
gene	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

Coxiella	O
burnetii	O
isolates	O
originating	O
from	O
infected	O
cattle	O
induce	O
a	O
more	O
pronounced	O
proinflammatory	O
cytokine	O
response	O
compared	O
to	O
isolates	O
from	O
infected	O
goats	O
and	O
sheep	O
.	O

Coxiella	O
burnetii	O
is	O
the	O
causative	O
agent	O
of	O
Q	O
fever	O
.	O

Although	O
the	O
prevalence	O
of	O
C.	O
burnetii	O
in	O
cattle	O
is	O
much	O
higher	O
than	O
in	O
goats	O
and	O
sheep	O
,	O
infected	O
cattle	O
are	O
rarely	O
associated	O
with	O
human	O
outbreaks	O
.	O

We	O
investigated	O
whether	O
the	O
immune	O
response	O
of	O
humans	O
differs	O
after	O
contact	O
with	O
C.	O
burnetii	O
isolates	O
from	O
different	O
host	O
origins	O
or	O
with	O
different	O
multilocus	B-P
variable	I-P
number	I-P
of	I-P
tandem	I-P
repeat	I-P
analysis	I-P
(	O
MLVA	B-P
)	O
genotypes	O
.	O

Cytokine	O
responses	O
were	O
measured	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
stimulated	O
with	O
16	O
C.	O
burnetii	O
isolates	O
with	O
known	O
MLVA	B-P
genotype	O
from	O
goats	O
,	O
sheep	O
,	O
cattle	O
,	O
acute	O
and	O
chronic	O
Q	O
fever	O
patients	O
.	O

Coxiella	O
burnetii	O
isolates	O
originating	O
from	O
cattle	O
induce	O
significantly	O
more	O
IL-1β	O
,	O
TNF-α	O
and	O
IL-22	O
than	O
the	O
isolates	O
from	O
goats	O
,	O
sheep	O
or	O
chronic	O
Q	O
fever	O
patients	O
.	O

Comparing	O
the	O
cytokine	O
induction	O
of	O
the	O
isolates	O
based	O
on	O
their	O
MVLA	B-P
genotype	O
did	O
not	O
reveal	O
differences	O
in	O
response	O
between	O
the	O
MLVA	B-P
genotypes	O
.	O

The	O
proinflammatory	O
cytokine	O
response	O
induced	O
in	O
human	O
PBMCs	O
by	O
C.	O
burnetii	O
isolates	O
from	O
cattle	O
may	O
explain	O
the	O
low	O
incidence	O
of	O
human	O
Q	O
fever	O
outbreaks	O
caused	O
by	O
cattle	O
.	O

The	O
cytokine	O
profile	O
of	O
PBMCs	O
stimulated	O
with	O
C.	O
burnetii	O
isolates	O
from	O
chronic	O
Q	O
fever	O
patients	O
resembles	O
isolates	O
from	O
goats	O
.	O

Furthermore	O
,	O
cytokine	O
responses	O
seem	O
to	O
be	O
depending	O
on	O
host	O
origin	O
than	O
on	O
MLVA	B-P
genotype	O
.	O

The	O
short-term	O
effects	O
of	O
farmed	O
fish	O
food	O
consumed	O
by	O
wild	O
fish	O
congregating	O
outside	O
the	O
farms	O
.	O

We	O
simulated	O
in	O
the	O
laboratory	O
the	O
possible	O
effects	O
on	O
fatty	O
acids	O
and	O
immune	O
status	O
of	O
wild	O
fish	O
arriving	O
for	O
the	O
first	O
time	O
in	O
the	O
vicinity	O
of	O
a	O
sea-cage	O
fish	O
farm	O
,	O
shifting	O
their	O
natural	O
diet	O
to	O
commercial	O
feed	O
consumption	O
,	O
rich	O
in	O
fatty	O
acids	O
of	O
vegetable	O
origin	O
.	O

The	O
flesh	O
fatty	O
acid	O
profile	O
of	O
golden	O
mullet	O
specimens	O
was	O
altered	O
after	O
2weeks	O
of	O
commercial	O
feed	O
consumption	O
,	O
showing	O
an	O
increase	O
in	O
fatty	O
acids	O
of	O
vegetable	O
origin	O
.	O

The	O
serum	B-P
peroxidase	I-P
and	O
bactericidal	O
activities	O
,	O
and	O
head-kidney	O
leucocyte	O
phagocytic	O
capacity	O
,	O
increased	O
after	O
eight	O
weeks	O
of	O
the	O
new	O
diet	O
,	O
while	O
the	O
respiratory	O
burst	O
activity	O
decreased	O
.	O

The	O
extent	O
of	O
these	O
changes	O
can	O
not	O
be	O
considered	O
large	O
enough	O
to	O
regard	O
them	O
as	O
compromising	O
the	O
health	O
status	O
of	O
fish	O
.	O

More	O
research	O
is	O
needed	O
in	O
order	O
to	O
elucidate	O
whether	O
the	O
rapid	O
assimilation	O
of	O
the	O
dietary	O
fatty	O
acids	O
could	O
harm	O
the	O
immune	O
status	O
of	O
fish	O
when	O
feeding	O
for	O
longer	O
periods	O
than	O
two	O
months	O
.	O

Atmospheric	O
wet	O
deposition	O
of	O
dissolved	O
trace	O
elements	O
to	O
Jiaozhou	O
Bay	O
,	O
North	O
China	O
:	O
Fluxes	O
,	O
sources	O
and	O
potential	O
effects	O
on	O
aquatic	O
environments	O
.	O

To	O
analyze	O
the	O
fluxes	O
,	O
seasonal	O
variations	O
,	O
sources	O
and	O
potential	O
ecological	O
effects	O
of	O
dissolved	O
trace	O
elements	O
(	O
TEs	O
)	O
in	O
atmospheric	O
wet	O
deposition	O
(	O
AWD	O
)	O
,	O
one-year	O
wet	O
precipitation	O
samples	O
were	O
collected	O
and	O
determined	O
for	O
nine	O
TEs	O
in	O
Jiaozhou	O
Bay	O
(	O
JZB	O
)	O
between	O
June	O
2015	O
and	O
May	O
2016	O
.	O

Both	O
the	O
volume-weighted	B-P
mean	O
(	O
VWM	O
)	O
concentration	O
and	O
flux	O
sequence	O
for	O
the	O
measured	O
TEs	O
was	O
Al	O
>	O
Mn	O
>	O
Zn	O
>	O
Fe	O
>	O
Pb	O
>	O
Se	O
>	O
Cr	O
>	O
Cd	O
>	O
Co.	O
Al	O
was	O
the	O
most	O
abundant	O
TE	O
with	O
a	O
VWM	O
concentration	O
and	O
wet	O
flux	O
of	O
33.8	O
μg	O
L	O
(	O
-1	O
)	O
and	O
29.2	O
mg	O
m	O
(	O
-2	O
)	O
yr	O
(	O
-1	O
)	O
,	O
which	O
were	O
2	O
and	O
3	O
orders	O
of	O
magnitude	O
higher	O
than	O
those	O
of	O
Co	O
,	O
respectively	O
.	O

The	O
emission	O
intensities	O
of	O
pollutants	O
,	O
rainfall	O
amount	O
and	O
wind	O
speed	O
were	O
the	O
dominating	O
factors	O
influencing	O
seasonal	O
variations	O
of	O
TEs	O
in	O
AWD	O
.	O

Based	O
on	O
enrichment	O
factors	O
,	O
correlation	O
analysis	O
and	O
principal	O
component	O
analysis	O
,	O
most	O
of	O
the	O
TEs	O
in	O
AWD	O
were	O
primarily	O
originated	O
from	O
anthropogenic	O
activities	O
except	O
for	O
Al	O
and	O
Fe	O
,	O
which	O
are	O
typically	O
derived	O
from	O
re-suspended	O
soil	O
dusts	O
.	O

Although	O
the	O
TE	O
inputs	O
by	O
AWD	O
were	O
significantly	O
lower	O
than	O
those	O
by	O
rivers	O
,	O
the	O
TE	O
inputs	O
via	O
short-term	O
heavy	O
rains	O
would	O
distinctly	O
increase	O
surface	O
seawater	O
TE	O
concentrations	O
and	O
then	O
pollute	O
the	O
marine	O
environment	O
of	O
JZB	O
.	O

AWD	O
would	O
have	O
both	O
profound	O
impacts	O
on	O
the	O
biogeochemical	O
cycles	O
of	O
TEs	O
and	O
dual	O
ecological	O
effects	O
(	O
nutrient	O
and	O
toxicity	O
)	O
on	O
aquatic	O
organisms	O
.	O

Anatomic	O
assessment	O
of	O
the	O
left	O
main	O
bifurcation	O
and	O
dynamic	O
bifurcation	O
angles	O
using	O
computed	B-P
tomography	I-P
angiography	I-P
.	O

An	O
understanding	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
(	O
LMCA	O
)	O
anatomy	O
is	O
important	O
for	O
accurate	O
diagnosis	O
and	O
therapeutic	O
.	O

We	O
aimed	O
to	O
investigate	O
LMCA	O
anatomy	O
via	O
128-multisliced	B-P
coronary	I-P
computed-tomography-angiography	I-P
(	O
CCTA	B-P
)	O
in	O
patients	O
with	O
normal	O
LMCA	O
.	O

A	O
total	O
of	O
201	O
CCTA	B-P
studies	O
were	O
included	O
in	O
this	O
study	O
.	O

Anatomical	O
features	O
of	O
LMCA	O
including	O
cross-sectional	O
areas	O
of	O
the	O
LMCA	O
ostial	O
,	O
LMCA	O
distal	O
,	O
LAD	O
ostial	O
and	O
LCX	O
ostial	O
,	O
and	O
degree	O
of	O
tapering	O
and	O
LMCA	O
bifurcation	O
angles	O
(	O
BA	O
)	O
in	O
the	O
form	O
of	O
LMCA	O
-	O
LCX	O
BA	O
,	O
LMCA	O
-	O
LAD	O
BA	O
,	O
LAD	O
-	O
LCX	O
BA	O
at	O
end-diastole	O
and	O
end-systole	O
.	O

The	O
mean	O
age	O
was	O
55	O
±	O
11	O
with	O
55.7	O
%	O
males	O
.	O

RCA	O
was	O
dominant	O
in	O
173	O
(	O
86.1	O
%	O
)	O
patients	O
.	O

Mean	O
LMCA	O
length	O
was	O
10.0±4.5	O
mm	O
.	O

The	O
mean	O
values	O
of	O
LMCA	O
ostial	O
,	O
LMCA	O
distal	O
,	O
LAD	O
ostial	O
and	O
LCX	O
ostial	O
areas	O
were	O
18.2±5.1	O
mm²	O
,	O
13.2±4.0	O
,	O
9.0±3.2	O
mm²	O
and	O
7.6±2.8	O
mm²	O
,	O
respectively	O
.	O

LMCA	O
ostial	O
-	O
distal	O
area	O
,	O
LMCA	O
distal	O
-	O
LAD	O
ostial	O
area	O
and	O
LMCA	O
distal	O
-	O
LCX	O
ostial	O
area	O
ratios	O
were	O
≥1.44	O
-	O
<	O
1.69	O
in	O
47	O
(	O
23.4	O
%	O
)	O
,	O
53	O
(	O
26.4	O
%	O
)	O
,	O
47	O
(	O
23.4	O
%	O
)	O
patients	O
,	O
respectively	O
,	O
and	O
were	O
≥1.69-	O
<	O
1.96	O
in	O
19	O
(	O
9.5	O
%	O
)	O
,	O
24	O
(	O
11.9	O
%	O
)	O
,	O
40	O
(	O
19.9	O
%	O
)	O
patients	O
respectively	O
.	O

Systolic	O
motion	O
modifies	O
LMCA	O
BAs	O
;	O
systolic	O
motion	O
begets	O
an	O
increment	O
of	O
LMCA	O
-	O
LAD	O
angle	O
in	O
72.6	O
%	O
of	O
patients	O
and	O
decrement	O
of	O
LAD	O
-	O
LCX	O
angle	O
in	O
75.6	O
%	O
of	O
the	O
patients	O
.	O

Patients	O
with	O
T-shaped	O
LAD	O
-	O
LCX	O
BA	O
was	O
shown	O
to	O
have	O
significantly	O
longer	O
LMCA	O
,	O
larger	O
LAD	O
ostial	O
area	O
,	O
larger	O
LCX	O
ostial	O
area	O
and	O
higher	O
diastolic-to-systolic	O
range	O
(	O
DSR	O
)	O
of	O
LAD	O
-	O
LCX	O
BA	O
compared	O
to	O
patients	O
with	O
Y-shaped	O
LAD	O
-	O
LCX	O
BA	O
.	O

LMCA	O
with	O
T-shaped	O
distal	O
BA	O
was	O
found	O
to	O
have	O
significantly	O
longer	O
LMCA	O
,	O
larger	O
LAD	O
ostial	O
area	O
,	O
larger	O
LCX	O
ostial	O
area	O
and	O
higher	O
DSR	O
of	O
distal	O
BA	O
compared	O
to	O
patients	O
with	O
Y-shaped	O
distal	O
BA	O
.	O

These	O
findings	O
may	O
provide	O
useful	O
information	O
for	O
LMCA	O
bifurcation	O
stenting	O
or	O
designing	O
dedicated	O
stents	O
for	O
LMCA	O
.	O

Mapping	B-P
mitochondrial	I-P
heteroplasmy	I-P
in	O
a	O
Leydig	O
tumor	O
by	O
laser	B-P
capture	I-P
micro-dissection	I-P
and	O
cycling	B-P
temperature	I-P
capillary	I-P
electrophoresis	I-P
.	O

The	O
growth	O
of	O
tumor	O
cells	O
is	O
accompanied	O
by	O
mutations	O
in	O
nuclear	O
and	O
mitochondrial	O
genomes	O
creating	O
marked	O
genetic	O
heterogeneity	O
.	O

Tumors	O
also	O
contain	O
non-tumor	O
cells	O
of	O
various	O
origins	O
.	O

An	O
observed	O
somatic	O
mitochondrial	O
mutation	O
would	O
have	O
occurred	O
in	O
a	O
founding	O
cell	O
and	O
spread	O
through	O
cell	O
division	O
.	O

Micro-anatomical	B-P
dissection	I-P
of	O
a	O
tumor	O
coupled	O
with	O
assays	B-P
for	O
mitochondrial	O
point	O
mutations	O
permits	O
new	O
insights	O
into	O
this	O
growth	O
process	O
.	O

More	O
generally	O
,	O
the	O
ability	O
to	O
detect	O
and	O
trace	O
,	O
at	O
a	O
histological	O
level	O
,	O
somatic	O
mitochondrial	O
mutations	O
in	O
human	O
tissues	O
and	O
tumors	O
,	O
makes	O
these	O
mutations	O
into	O
markers	O
for	O
lineage	O
tracing	O
.	O

A	O
tumor	O
was	O
first	O
sampled	B-P
by	O
a	O
large	O
punch	B-P
biopsy	I-P
and	O
scanned	B-P
for	O
any	O
significant	O
degree	O
of	O
heteroplasmy	O
in	O
a	O
set	O
of	O
sequences	O
containing	O
known	O
mutational	O
hotspots	O
of	O
the	O
mitochondrial	O
genome	O
.	O

A	O
heteroplasmic	O
tumor	O
was	O
sliced	O
at	O
a	O
12	O
μm	O
thickness	O
and	O
placed	O
on	O
membranes	O
.	O

Laser	B-P
capture	I-P
micro-dissection	I-P
was	O
used	O
to	O
take	O
25000	O
μm	O
(	O
2	O
)	O
subsamples	O
or	O
spots	O
.	O

After	O
DNA	O
amplification	O
,	O
cycling	B-P
temperature	I-P
capillary	I-P
electrophoresis	I-P
(	O
CTCE	B-P
)	O
was	O
used	O
on	O
the	O
laser	O
captured	O
samples	O
to	O
quantify	O
mitochondrial	O
mutant	O
fractions	O
.	O

Of	O
six	O
testicular	O
tumors	O
studied	O
,	O
one	O
,	O
a	O
Leydig	O
tumor	O
,	O
was	O
discovered	O
to	O
carry	O
a	O
detectable	O
degree	O
of	O
heteroplasmy	O
for	O
two	O
separate	O
point	O
mutations	O
:	O
a	O
C	O
→	O
T	O
mutation	O
at	O
bp	O
64	O
and	O
a	O
T	O
→	O
C	O
mutation	O
found	O
at	O
bp	O
152	O
.	O

From	O
this	O
tumor	O
,	O
381	O
spots	O
were	O
sampled	B-P
with	O
laser	B-P
capture	I-P
micro-dissection	I-P
.	O

The	O
ordered	O
distribution	O
of	O
spots	O
exhibited	O
a	O
wide	O
range	O
of	O
fractions	O
of	O
the	O
mutant	O
sequences	O
from	O
0	O
to	O
100	O
%	O
mutant	O
copies	O
.	O

The	O
two	O
mutations	O
co-distributed	O
in	O
the	O
growing	O
tumor	O
indicating	O
they	O
were	O
present	O
on	O
the	O
same	O
genome	O
copies	O
in	O
the	O
founding	O
cell	O
.	O

Laser	B-P
capture	I-P
micro-dissection	I-P
of	O
sliced	O
tumor	O
samples	O
coupled	O
with	O
CTCE	B-P
-based	O
point	O
mutation	O
assays	B-P
provides	O
an	O
effective	O
and	O
practical	O
means	O
to	O
obtain	O
maps	O
of	O
mitochondrial	O
mutational	O
heteroplasmy	O
within	O
human	O
tumors	O
.	O

Indications	O
for	O
embolization	O
in	O
a	O
French	O
level	O
1	O
trauma	O
center	O
.	O

Abdominal	O
trauma	O
accounts	O
for	O
nearly	O
20	O
%	O
of	O
all	O
traumatic	O
injuries	O
.	O

It	O
often	O
involves	O
young	O
patients	O
sustaining	O
multiple	O
injuries	O
,	O
with	O
a	O
high	O
associated	O
mortality	O
rate	O
.	O

Management	O
should	O
begin	O
at	O
the	O
scene	O
of	O
injury	O
and	O
relies	O
on	O
a	O
structured	O
chain	O
of	O
care	O
in	O
order	O
to	O
transport	O
the	O
trauma	O
patient	O
to	O
the	O
appropriate	O
hospital	O
center	O
.	O

Management	O
is	O
multi-disciplinary	O
,	O
involving	O
intensive	O
care	O
specialists	O
,	O
surgeons	O
and	O
radiologists	O
.	O

Imaging	O
to	O
precisely	O
define	O
injury	O
is	O
best	O
performed	O
with	O
whole	B-P
body	I-P
dual	I-P
phase	I-P
computed	I-P
tomography	I-P
,	O
which	O
can	O
also	O
identify	O
the	O
source	O
of	O
bleeding	O
.	O

Non-operative	O
management	O
has	O
developed	O
considerably	O
over	O
the	O
years	O
:	O
this	O
includes	O
selective	O
embolization	O
in	O
case	O
of	O
active	O
bleeding	O
or	O
vascular	O
anomalies	O
in	O
stable	O
or	O
stabilized	O
patients	O
after	O
resuscitation	O
.	O

Embolization	O
has	O
become	O
one	O
of	O
the	O
corner	O
stones	O
of	O
abdominal	O
trauma	O
management	O
and	O
interventional	O
radiologists	O
must	O
play	O
an	O
active	O
role	O
on	O
the	O
trauma	O
team	O
.	O

This	O
overview	O
details	O
the	O
different	O
embolization	O
procedures	O
according	O
to	O
the	O
involved	O
organ	O
and	O
embolic	O
agent	O
used	O
.	O

The	O
nanocomposite	O
nature	O
of	O
bone	O
drives	O
its	O
strength	O
and	O
damage	O
resistance	O
.	O

In	O
human	O
bone	O
,	O
an	O
amorphous	O
mineral	O
serves	O
as	O
a	O
precursor	O
to	O
the	O
formation	O
of	O
a	O
highly	O
substituted	O
nanocrystalline	O
apatite	O
.	O

However	O
,	O
the	O
precise	O
role	O
of	O
this	O
amorphous	O
mineral	O
remains	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
by	O
using	O
transmission	B-P
electron	I-P
microscopy	I-P
that	O
100-300	O
nm	O
amorphous	O
calcium	O
phosphate	O
regions	O
are	O
present	O
in	O
the	O
disordered	O
phase	O
of	O
trabecular	O
bone	O
.	O

Nanomechanical	O
experiments	O
on	O
cylindrical	O
samples	O
,	O
with	O
diameters	O
between	O
250	O
nm	O
and	O
3,000	O
nm	O
,	O
of	O
the	O
bone	O
's	O
ordered	O
and	O
disordered	O
phases	O
revealed	O
a	O
transition	O
from	O
plastic	O
deformation	O
to	O
brittle	O
failure	O
and	O
at	O
least	O
a	O
factor-of-2	O
higher	O
strength	O
in	O
the	O
smaller	O
samples	O
.	O

We	O
postulate	O
that	O
this	O
transition	O
in	O
failure	O
mechanism	O
is	O
caused	O
by	O
the	O
suppression	O
of	O
extrafibrillar	O
shearing	O
in	O
the	O
smaller	O
samples	O
,	O
and	O
that	O
the	O
emergent	O
smaller	O
-is-	O
stronger	O
size	O
effect	O
is	O
related	O
to	O
the	O
sample-size	O
scaling	O
of	O
the	O
distribution	O
of	O
flaws	O
.	O

Our	O
findings	O
should	O
help	O
in	O
the	O
understanding	O
of	O
the	O
multi-scale	O
nature	O
of	O
bone	O
and	O
provide	O
insights	O
into	O
the	O
biomineralization	O
process	O
.	O

Characterization	O
and	O
antimicrobial	B-P
evaluation	I-P
of	O
SpPR-AMP1	O
,	O
a	O
proline-rich	O
antimicrobial	O
peptide	O
from	O
the	O
mud	O
crab	O
Scylla	O
paramamosain	O
.	O

Antimicrobial	O
peptide	O
(	O
AMP	O
)	O
is	O
an	O
important	O
molecule	O
in	O
the	O
innate	O
immune	O
system	O
.	O

Here	O
,	O
we	O
report	O
the	O
cloning	O
and	O
functional	O
studies	O
of	O
proline-rich	O
AMPs	O
(	O
PR-AMPs	O
)	O
from	O
the	O
three	O
species	O
of	O
mud	O
crab	O
:	O
Scylla	O
paramamosain	O
,	O
S.	O
serrata	O
,	O
and	O
the	O
swimming	O
crab	O
Portunus	O
pelagicus	O
.	O

The	O
deduced	O
peptides	O
revealed	O
that	O
they	O
contain	O
the	O
putative	O
signal	O
peptides	O
and	O
encode	O
for	O
mature	O
peptides	O
,	O
which	O
contain	O
sequence	O
architecture	O
similar	O
to	O
a	O
6.5-kDa	O
proline-rich	O
AMP	O
of	O
the	O
shore	O
crab	O
,	O
Carcinus	O
maenas	O
which	O
showed	O
similarity	O
with	O
the	O
bactenecin7	O
.	O

Tissue	O
distribuction	O
analysis	O
indicated	O
that	O
the	O
SpPR-AMP1	O
was	O
expressed	O
in	O
a	O
wide	O
range	O
of	O
adult	O
tissues	O
,	O
with	O
the	O
highest	O
expression	O
levels	O
in	O
the	O
crab	O
hemocyte	O
.	O

Challenge	O
experiments	O
showed	O
that	O
the	O
levels	O
of	O
SpPR-AMP1	O
mRNA	O
expression	O
were	O
up-regulated	O
in	O
the	O
hemocyte	O
after	O
peptidoglycan	O
stimulation	O
.	O

To	O
evaluate	O
the	O
biological	O
properties	O
of	O
mature	O
SpPR-AMP1	O
,	O
peptides	O
were	O
chemically	O
synthesized	O
and	O
recombinantly	O
expressed	O
.	O

SpPR-AMP1	O
showed	O
strong	O
antibacterial	O
activity	O
against	O
both	O
Gram-positive	O
bacteria	O
Micrococcus	O
luteus	O
and	O
Gram-negative	O
bacteria	O
Vibrio	O
harveyi	O
.	O

The	O
results	O
indicate	O
that	O
the	O
SpPR-AMP1	O
plays	O
a	O
role	O
in	O
crab	O
immunity	O
.	O

Cluster	O
-	O
dependent	O
colistin	O
hetero-resistance	O
in	O
Enterobacter	O
cloacae	O
complex	O
.	O

Aims	O
of	O
this	O
study	O
were	O
to	O
:	O
(	O
i	O
)	O
evaluate	O
whether	O
the	O
cluster	O
membership	O
could	O
have	O
an	O
impact	O
on	O
hetero-resistance	O
phenotype	O
to	O
colistin	O
in	O
the	O
Enterobacter	O
cloacae	O
complex	O
(	O
ECC	O
)	O
;	O
and	O
(	O
ii	O
)	O
determine	O
the	O
genetic	O
mechanism	O
of	O
colistin	O
hetero-resistance	O
in	O
ECC	O
.	O

A	O
collection	O
of	O
124	O
clinical	O
isolates	O
belonging	O
to	O
13	O
clusters	O
were	O
used	O
to	O
analyse	O
the	O
hetero-resistance	O
phenotype	O
(	O
MICs	B-P
were	O
determined	O
using	O
the	O
broth	B-P
microdilution	I-P
method	I-P
,	O
Etest	B-P
and	O
population	B-P
analysis	I-P
profiling	I-P
)	O
.	O

Different	O
mutants	O
(	O
ΔphoP	O
,	O
ΔphoQ	O
,	O
ΔphoPQ	O
,	O
ΔpmrA	O
,	O
ΔpmrB	O
,	O
ΔpmrAB	O
,	O
ΔarnE	O
,	O
ΔarnF	O
and	O
ΔarnBCADTEF	O
)	O
were	O
constructed	O
and	O
tested	O
for	O
their	O
colistin	O
hetero-resistance	O
phenotype	O
.	O

Based	O
on	O
broth	B-P
microdilution	I-P
and	O
Etest	B-P
results	O
,	O
it	O
was	O
shown	O
that	O
the	O
hetero-resistance	O
to	O
colistin	O
depended	O
on	O
the	O
cluster	O
:	O
strains	O
from	O
clusters	O
I	O
,	O
II	O
,	O
IV	O
,	O
VII	O
,	O
IX	O
,	O
X	O
,	O
XI	O
and	O
XII	O
were	O
usually	O
hetero-resistant	O
,	O
whereas	O
those	O
from	O
clusters	O
III	O
,	O
V	O
,	O
VI	O
,	O
VIII	O
and	O
XIII	O
were	O
categorized	O
as	O
susceptible	O
.	O

However	O
,	O
for	O
some	O
cluster	O
V	O
and	O
VIII	O
strains	O
,	O
a	O
small	O
proportion	O
(	O
<	O
10	O
(	O
-7	O
)	O
)	O
of	O
cells	O
appeared	O
resistant	O
when	O
tested	O
by	O
population	O
analysis	O
profiling	O
.	O

From	O
a	O
mechanistic	O
point	O
of	O
view	O
,	O
analysis	O
of	O
mutants	O
revealed	O
that	O
the	O
mechanism	O
of	O
hetero-resistance	O
was	O
mainly	O
due	O
to	O
the	O
expression	O
of	O
the	O
arn	O
operon	O
and	O
the	O
phoP	O
/	O
phoQ	O
two-component	O
regulatory	O
system	O
.	O

Because	O
the	O
colistin	O
hetero-resistance	O
appeared	O
cluster	O
-	O
dependent	O
in	O
the	O
ECC	O
,	O
it	O
should	O
be	O
advocated	O
to	O
determine	O
the	O
cluster	O
of	O
the	O
strain	O
associated	O
with	O
the	O
infection	O
in	O
parallel	O
with	O
the	O
MIC	B-P
of	O
colistin	O
.	O

The	O
resistance	O
mechanism	O
may	O
not	O
be	O
similar	O
to	O
other	O
Enterobacteriaceae	O
since	O
only	O
the	O
two-component	O
regulatory	O
system	O
PhoP	O
/	O
PhoQ	O
(	O
and	O
not	O
PmrA	O
/	O
PmrB	O
)	O
seemed	O
to	O
play	O
a	O
role	O
in	O
resistance	O
regulation	O
.	O

Neurokinin	O
3	O
Receptor	O
Antagonism	O
Reveals	O
Roles	O
for	O
Neurokinin	O
B	O
in	O
the	O
Regulation	O
of	O
Gonadotropin	O
Secretion	O
and	O
Hot	O
Flashes	O
in	O
Postmenopausal	O
Women	O
.	O

Neurokinin	O
B	O
(	O
NKB	O
)	O
and	O
kisspeptin	O
are	O
obligate	O
for	O
normal	O
gonadotropin	O
secretion	O
,	O
and	O
links	O
between	O
GnRH	O
pulsatility	O
and	O
vasomotor	O
symptoms	O
have	O
been	O
proposed	O
.	O

Using	O
a	O
selective	O
NKB	O
receptor	O
(	O
NK3R	O
)	O
antagonist	O
,	O
the	O
role	O
of	O
NKB	O
in	O
the	O
hypergonadotropic	O
state	O
in	O
menopausal	O
women	O
was	O
explored	O
.	O

Eleven	O
postmenopausal	O
women	O
were	O
administered	O
the	O
NK3R	O
antagonist	O
MLE4901	O
,	O
40	O
mg	O
twice	O
daily	O
orally	O
for	O
7	O
days	O
.	O

10-	O
min	O
blood	B-P
sampling	I-P
for	O
8	O
h	O
was	O
performed	O
before	O
and	O
on	O
the	O
last	O
day	O
of	O
NK3R	O
antagonist	O
treatment	O
for	O
LH	O
pulsatility	O
analysis	O
with	O
kisspeptin-10	O
(	O
0.3	O
µg/kg	O
iv	O
bolus	O
)	O
administered	O
at	O
6	O
h	O
on	O
both	O
days	O
.	O

Hot	O
flash	O
frequency	O
and	O
severity	O
were	O
self-reported	O
for	O
7	O
days	O
before	O
and	O
during	O
NK3R	O
antagonist	O
administration	O
.	O

LH	O
fell	O
from	O
29.3	O
±	O
4.1	O
to	O
24.4	O
±	O
3.8	O
IU/l	O
(	O
p	O
<	O
0.05	O
)	O
after	O
7	O
days	O
of	O
NK3R	O
antagonist	O
,	O
with	O
no	O
change	O
in	O
FSH	O
.	O

Basal	O
(	O
nonpulsatile	O
)	O
LH	O
secretion	O
was	O
reduced	O
(	O
549.0	O
±	O
70.8	O
vs.	O
366.1	O
±	O
92.1	O
IU/L/6	O
h	O
,	O
p	O
=	O
0.006	O
)	O
and	O
while	O
LH	O
pulse	O
frequency	O
did	O
not	O
change	O
in	O
the	O
group	O
as	O
a	O
whole	O
(	O
0.8	O
±	O
0.1	O
to	O
0.7	O
±	O
0.1	O
pulses	O
/h	O
,	O
ns	O
)	O
,	O
it	O
did	O
fall	O
in	O
the	O
8/11	O
women	O
with	O
hot	O
flashes	O
,	O
(	O
1.0	O
±	O
0.1	O
to	O
0.7	O
±	O
0.1	O
pulses	O
/h	O
,	O
p	O
<	O
0.05	O
)	O
.	O

These	O
women	O
also	O
reported	O
a	O
reduction	O
in	O
hot	O
flash	O
frequency	O
(	O
3.4	O
±	O
1.2	O
to	O
1.0	O
±	O
0.6	O
hot	O
flashes	O
/	O
day	O
,	O
p	O
=	O
0.008	O
)	O
whist	O
taking	O
NK3R	O
antagonist	O
.	O

Kisspeptin-10	O
did	O
not	O
affect	O
LH	O
secretion	O
with	O
or	O
without	O
NK3R	O
antagonist	O
.	O

The	O
administration	O
of	O
a	O
NK3R	O
antagonist	O
indicates	O
a	O
role	O
for	O
NKB	O
in	O
the	O
regulation	O
of	O
LH	O
/	O
GnRH	O
in	O
postmenopausal	O
women	O
whereas	O
the	O
lack	O
of	O
response	O
to	O
kisspeptin	O
may	O
reflect	O
the	O
hypoestrogenic	O
state	O
.	O

These	O
data	O
support	O
a	O
link	O
between	O
LH	O
/	O
GnRH	O
pulsatility	O
and	O
vasomotor	O
symptoms	O
and	O
NK3R	O
antagonism	O
as	O
a	O
potential	O
therapeutic	O
approach	O
.	O

Untypeable	O
hepatitis	O
C	O
virus	O
subtypes	O
in	O
Pakistan	O
:	O
A	O
neglected	O
section	O
.	O

Diagnostically	O
untypeable	O
subtypes	O
contribute	O
a	O
considerable	O
percent	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
subtypes	O
in	O
Pakistan	O
.	O

In	O
the	O
present	O
study	O
,	O
chronically	O
infected	O
HCV	O
patients	O
with	O
known	O
viremia	O
were	O
subjected	O
to	O
HCV	O
genotyping	B-P
.	O

Among	O
the	O
total	O
retrieved	O
samples	O
,	O
92.7	O
%	O
(	O
64/69	O
)	O
were	O
found	O
typeable	O
while	O
7.24	O
%	O
(	O
5/69	O
)	O
were	O
diagnostically	O
untypeable	O
.	O

In	O
conclusion	O
,	O
the	O
presence	O
of	O
large	O
number	O
of	O
untypeable	O
HCV	O
subtypes	O
emphasizes	O
the	O
need	O
of	O
an	O
updated	O
type	O
-	O
specific	O
genotyping	B-P
assay	B-P
and	O
consideration	O
of	O
primers	O
for	O
proportionally	O
rare	O
subtypes	O
to	O
minimize	O
the	O
number	O
of	O
untypeable	O
HCV	O
subtypes	O
.	O

An	O
assessment	O
of	O
the	O
importance	O
of	O
exposure	O
routes	O
to	O
the	O
uptake	O
and	O
internal	O
localisation	O
of	O
fluorescent	O
nanoparticles	O
in	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
,	O
using	O
light	B-P
sheet	I-P
microscopy	I-P
.	O

A	O
major	O
challenge	O
in	O
nanoecotoxicology	O
is	O
finding	O
suitable	O
methods	O
to	O
determine	O
the	O
uptake	O
and	O
localisation	O
of	O
nanoparticles	O
on	O
a	O
whole-organism	O
level	O
.	O

Some	O
uptake	O
methods	O
have	O
been	O
associated	O
with	O
artefacts	O
induced	O
by	O
sample	O
preparation	O
,	O
including	O
staining	O
for	O
electron	B-P
microscopy	I-P
.	O

This	O
study	O
used	O
light	B-P
sheet	I-P
microscopy	I-P
(	O
LSM	B-P
)	O
to	O
define	O
the	O
uptake	O
and	O
localisation	O
of	O
fluorescently	O
labelled	O
nanoparticles	O
in	O
living	O
organisms	O
with	O
minimal	O
sample	O
preparation	O
.	O

Zebrafish	O
(	O
Danio	O
rerio	O
)	O
were	O
exposed	O
to	O
fluorescent	O
gold	O
nanoparticles	O
(	O
Au	O
NPs	O
)	O
and	O
fluorescent	O
polystyrene	O
NPs	O
via	O
aqueous	O
or	O
dietary	O
exposure	O
.	O

The	O
in	O
vivo	O
uptake	O
and	O
localisation	O
of	O
NPs	O
were	O
investigated	O
using	O
LSM	B-P
at	O
different	O
time	O
points	O
(	O
1	O
,	O
3	O
and	O
7	O
days	O
)	O
.	O

A	O
time	O
-	O
dependent	O
increase	O
in	O
fluorescence	O
was	O
observed	O
in	O
the	O
gut	O
after	O
dietary	O
exposure	O
to	O
both	O
Au	O
NPs	O
and	O
polystyrene	O
NPs	O
.	O

No	O
fluorescence	O
was	O
observed	O
within	O
gut	O
epithelia	O
regardless	O
of	O
the	O
NP	O
exposure	O
route	O
indicating	O
no	O
or	O
limited	O
uptake	O
via	O
intestinal	O
villi	O
.	O

Fish	O
exposed	O
to	O
polystyrene	O
NPs	O
through	O
the	O
aqueous	O
phase	O
emitted	O
fluorescence	O
signals	O
from	O
the	O
gills	O
and	O
intestine	O
.	O

Fluorescence	O
was	O
also	O
detected	O
in	O
the	O
head	O
region	O
of	O
the	O
fish	O
after	O
aqueous	O
exposure	O
to	O
polystyrene	O
NPs	O
.	O

This	O
was	O
not	O
observed	O
for	O
Au	O
NPs	O
.	O

Aqueous	O
exposure	O
to	O
Au	O
NPs	O
resulted	O
in	O
increased	O
relative	O
swimming	O
distance	O
,	O
while	O
no	O
effect	O
was	O
observed	O
for	O
other	O
exposures	O
.	O

This	O
study	O
supports	O
that	O
the	O
route	O
of	O
exposure	O
is	O
essential	O
for	O
the	O
uptake	O
and	O
subsequent	O
localisation	O
of	O
nanoparticles	O
in	O
zebrafish	O
.	O

Furthermore	O
,	O
it	O
demonstrates	O
that	O
the	O
localisation	O
of	O
NPs	O
in	O
whole	O
living	O
organisms	O
can	O
be	O
visualised	O
in	O
real-time	O
,	O
using	O
LSM	B-P
.	O

Geometric	O
morphometrics	B-P
reveals	O
restrictions	O
on	O
the	O
shape	O
of	O
the	O
female	O
os	O
coxae	O
.	O

The	O
methodology	O
for	O
sex	O
determination	O
in	O
human	O
skeletal	O
remains	O
depends	O
on	O
the	O
different	O
bone	O
morphologies	O
presented	O
by	O
men	O
and	O
women	O
.	O

Due	O
to	O
their	O
direct	O
implications	O
in	O
reproduction	O
,	O
the	O
whole	O
pelvis	O
,	O
particularly	O
the	O
os	O
coxae	O
,	O
shows	O
different	O
characteristics	O
in	O
either	O
sex	O
.	O

The	O
sacrum	O
and	O
the	O
os	O
coxae	O
constitute	O
the	O
birth	O
cana	O
l.	O
In	O
this	O
research	O
study	O
,	O
the	O
os	O
coxae	O
shape	O
is	O
analyzed	O
using	O
geometric	O
morphometrics	B-P
,	O
providing	O
information	O
on	O
morphology	O
,	O
regardless	O
of	O
size	O
or	O
any	O
other	O
factor	O
beyond	O
the	O
geometry	O
itself	O
.	O

A	O
total	O
of	O
46	O
adult	O
ossa	O
coxae	O
from	O
a	O
Spanish	O
archaeological	O
collection	B-P
were	O
studied	O
using	O
geometric	O
morphometrics	B-P
.	O

The	O
results	O
show	O
that	O
there	O
is	O
a	O
restriction	O
on	O
the	O
shape	O
of	O
female	O
os	O
coxae	O
.	O

In	O
contrast	O
,	O
male	O
os	O
coxae	O
presents	O
a	O
greater	O
range	O
of	O
variation	O
.	O

The	O
biological	O
reason	O
for	O
this	O
difference	O
is	O
the	O
obstetrical	O
dilemma	O
;	O
a	O
concept	O
defined	O
as	O
the	O
anatomical	O
conflict	O
between	O
bipedalism	O
and	O
the	O
full-term	O
birth	O
of	O
a	O
neonate	O
whose	O
large	O
head	O
requires	O
greater	O
dimensions	O
in	O
the	O
pelvic	O
cavity	O
.	O

Our	O
experimental	O
data	O
reinforce	O
the	O
validity	O
of	O
the	O
obstetrical	O
dilemma	O
as	O
source	O
of	O
the	O
restriction	O
on	O
the	O
shape	O
of	O
female	O
ossa	O
coxae	O
.	O

Additionally	O
,	O
according	O
to	O
the	O
results	O
obtained	O
,	O
size	O
itself	O
does	O
not	O
represent	O
a	O
condition	O
for	O
belonging	O
to	O
one	O
sex	O
or	O
another	O
.	O

Expression	O
and	O
Purification	B-P
of	O
E2	O
Glycoprotein	O
from	O
Insect	O
Cells	O
(	O
Sf9	O
)	O
for	O
Use	O
in	O
Serology	B-P
.	O

Chikungunya	O
virus	O
(	O
CHIKV	O
)	O
is	O
a	O
mosquito	O
-	O
borne	O
arbovirus	O
which	O
poses	O
a	O
major	O
threat	O
to	O
global	O
public	O
health	O
.	O

Definitive	O
CHIKV	O
diagnosis	O
is	O
crucial	O
,	O
especially	O
in	O
distinguishing	O
the	O
disease	O
from	O
dengue	O
virus	O
,	O
which	O
co-circulates	O
in	O
endemic	O
areas	O
and	O
shares	O
the	O
same	O
mosquito	O
vectors	O
.	O

Laboratory	B-P
diagnosis	I-P
is	O
mainly	O
based	O
on	O
serological	O
or	O
molecular	O
approaches	O
.	O

The	O
E2	O
glycoprotein	O
is	O
a	O
good	O
candidate	O
for	O
serological	B-P
diagnosis	I-P
since	O
it	O
is	O
the	O
immunodominant	O
antigen	O
during	O
the	O
course	O
of	O
infection	O
,	O
and	O
reacts	O
with	O
seropositive	O
CHIKV	O
sera	O
.	O

In	O
this	O
chapter	O
,	O
we	O
describe	O
the	O
generation	O
of	O
stable	O
clone	O
Sf9	O
(	O
Spodoptera	O
frugiperda	O
)	O
cells	O
expressing	O
secreted	O
,	O
soluble	O
,	O
and	O
native	O
recombinant	O
CHIKV	O
E2	O
glycoprotein	O
.	O

We	O
use	O
direct	O
plasmid	O
expression	O
in	O
insect	O
cells	O
,	O
rather	O
than	O
the	O
traditional	O
technique	O
of	O
generating	O
recombinant	O
baculovirus	O
.	O

This	O
recombinant	O
protein	O
is	O
useful	O
for	O
serological	B-P
diagnosis	I-P
of	O
CHIKV	O
infection	O
.	O

Safety	O
of	O
transradial	B-P
diagnostic	I-P
cardiac	I-P
catheterization	I-P
in	O
patients	O
under	O
oral	O
anticoagulant	O
therapy	O
.	O

Cardiac	O
catheterization	O
in	O
anticoagulated	O
patients	O
is	O
usually	O
performed	O
after	O
the	O
anticoagulation	O
has	O
been	O
withdrawn	O
,	O
at	O
least	O
in	O
the	O
previous	O
48h	O
,	O
and	O
sometimes	O
bridging	O
therapy	O
with	O
heparin	O
is	O
used	O
.	O

A	O
prospective	O
observational	O
study	O
including	O
489	O
patients	O
undergoing	O
transradial	O
catheterization	O
was	O
conducted	O
.	O

A	O
total	O
of	O
140	O
patients	O
were	O
under	O
acenocoumarol	O
(	O
group	O
A	O
)	O
and	O
they	O
were	O
compared	O
with	O
the	O
remainder	O
(	O
group	O
B	O
)	O
for	O
complications	O
after	O
the	O
procedure	O
(	O
bleeding	O
and	O
vascular	O
access	O
complications	O
)	O
.	O

Patients	O
in	O
group	O
A	O
were	O
older	O
(	O
74±12	O
years	O
vs.	O
68±17	O
years	O
,	O
p	O
<	O
0.01	O
)	O
and	O
the	O
main	O
indication	O
for	O
anticoagulation	O
was	O
atrial	O
fibrillation	O
(	O
58.6	O
%	O
)	O
.	O

No	O
complications	O
occurred	O
during	O
the	O
procedures	O
.	O

There	O
were	O
no	O
acute	O
bleedings	O
just	O
after	O
the	O
bandage	O
removal	O
.	O

During	O
the	O
first	O
24h	O
,	O
only	O
3	O
(	O
2.1	O
%	O
)	O
radial	O
occlusions	O
in	O
group	O
A	O
and	O
2	O
(	O
0.6	O
%	O
)	O
in	O
group	O
B	O
(	O
p=0.14	O
)	O
were	O
recorded	O
.	O

Hematomas	O
between	O
5	O
and	O
10cm	O
appeared	O
in	O
5	O
%	O
of	O
the	O
group	O
A	O
vs.	O
4.6	O
%	O
in	O
group	O
B	O
.	O

During	O
the	O
1-month	O
follow-up	O
period	O
,	O
one	O
more	O
radial	O
occlusion	O
in	O
each	O
group	O
was	O
recorded	O
and	O
there	O
were	O
4	O
(	O
1.1	O
%	O
)	O
additional	O
mild	O
hematomas	O
in	O
group	O
B	O
and	O
none	O
in	O
group	O
A	O
(	O
p=0.48	O
)	O
.	O

Performing	O
a	O
transradial	B-P
diagnostic	I-P
cardiac	I-P
catheterization	I-P
without	O
removal	O
of	O
the	O
oral	O
chronic	O
anticoagulation	O
appears	O
safe	O
in	O
patients	O
under	O
acenocumarol	O
therapy	O
.	O

Hounsfield	O
unit	O
recovery	O
in	O
clinical	O
cone	B-P
beam	I-P
CT	I-P
images	O
of	O
the	O
thorax	O
acquired	O
for	O
image	O
guided	O
radiation	O
therapy	O
.	O

A	O
comprehensive	O
artefact	O
correction	O
method	O
for	O
clinical	O
cone	B-P
beam	I-P
CT	I-P
(	O
CBCT	B-P
)	O
images	O
acquired	O
for	O
image	O
guided	O
radiation	O
therapy	O
(	O
IGRT	O
)	O
on	O
a	O
commercial	O
system	O
is	O
presented	O
.	O

The	O
method	O
is	O
demonstrated	O
to	O
reduce	O
artefacts	O
and	O
recover	O
CT	B-P
-like	O
Hounsfield	O
units	O
(	O
HU	O
)	O
in	O
reconstructed	O
CBCT	B-P
images	O
of	O
five	O
lung	O
cancer	O
patients	O
.	O

Projection	O
image	O
based	O
artefact	O
corrections	O
of	O
image	O
lag	O
,	O
detector	O
scatter	O
,	O
body	O
scatter	O
and	O
beam	O
hardening	O
are	O
described	O
and	O
applied	O
to	O
CBCT	B-P
images	O
of	O
five	O
lung	O
cancer	O
patients	O
.	O

Image	O
quality	O
is	O
evaluated	O
through	O
visual	O
appearance	O
of	O
the	O
reconstructed	O
images	O
,	O
HU	O
-correspondence	O
with	O
the	O
planning	O
CT	B-P
images	O
,	O
and	O
total	O
volume	O
HU	O
error	O
.	O

Artefacts	O
are	O
reduced	O
and	O
CT	B-P
-like	O
HUs	O
are	O
recovered	O
in	O
the	O
artefact	O
corrected	O
CBCT	B-P
images	O
.	O

Visual	O
inspection	O
confirms	O
that	O
artefacts	O
are	O
indeed	O
suppressed	O
by	O
the	O
proposed	O
method	O
,	O
and	O
the	O
HU	O
root	O
mean	O
square	O
difference	O
between	O
reconstructed	O
CBCTs	B-P
and	O
the	O
reference	O
CT	B-P
images	O
are	O
reduced	O
by	O
31	O
%	O
when	O
using	O
the	O
artefact	O
corrections	O
compared	O
to	O
the	O
standard	O
clinical	O
CBCT	B-P
reconstruction	O
.	O

A	O
versatile	O
artefact	O
correction	O
method	O
for	O
clinical	O
CBCT	B-P
images	O
acquired	O
for	O
IGRT	O
has	O
been	O
developed	O
.	O

HU	O
values	O
are	O
recovered	O
in	O
the	O
corrected	O
CBCT	B-P
images	O
.	O

The	O
proposed	O
method	O
relies	O
on	O
post	O
processing	O
of	O
clinical	O
projection	O
images	O
,	O
and	O
does	O
not	O
require	O
patient	O
specific	O
optimisation	O
.	O

It	O
is	O
thus	O
a	O
powerful	O
tool	O
for	O
image	O
quality	O
improvement	O
of	O
large	O
numbers	O
of	O
CBCT	B-P
images	O
.	O

Cerebrospinal	O
fluid	O
biomarkers	O
as	O
a	O
measure	O
of	O
disease	O
activity	O
and	O
treatment	O
efficacy	O
in	O
relapsing-remitting	O
multiple	O
sclerosis	O
.	O

Cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
biomarkers	O
can	O
reflect	O
different	O
aspects	O
of	O
the	O
pathophysiology	O
of	O
relapsing-remitting	O
multiple	O
sclerosis	O
(	O
RRMS	O
)	O
.	O

Understanding	O
the	O
impact	O
of	O
different	O
disease	O
modifying	O
therapies	O
on	O
the	O
CSF	O
biomarker	O
profile	B-P
may	O
increase	O
their	O
implementation	O
in	O
clinical	O
practice	O
and	O
their	O
appropriateness	O
for	O
monitoring	O
treatment	O
efficacy	O
.	O

This	O
study	O
investigated	O
the	O
influence	O
of	O
first-line	O
(	O
interferon	O
beta	O
)	O
and	O
second-line	O
(	O
natalizumab	O
)	O
therapies	O
on	O
seven	O
CSF	O
biomarkers	O
in	O
RRMS	O
and	O
their	O
correlation	O
with	O
clinical	O
and	O
radiological	O
outcomes	O
.	O

We	O
included	O
59	O
RRMS	O
patients	O
and	O
39	O
healthy	O
controls	O
.	O

The	O
concentrations	O
of	O
C-X-C	O
motif	O
chemokine	O
13	O
(	O
CXCL13	O
)	O
,	O
C-C	O
motif	O
chemokine	O
ligand	O
2	O
(	O
CCL2	O
)	O
,	O
chitinase-3-like	O
protein	O
1	O
(	O
CHI3L1	O
)	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
neurofilament	O
light	O
protein	O
(	O
NFL	O
)	O
,	O
and	O
neurogranin	O
were	O
determined	O
by	O
ELISA	B-P
,	O
and	O
chitotriosidase	O
(	O
CHIT1	O
)	O
was	O
analyzed	O
by	O
spectrofluorometry	B-P
.	O

RRMS	O
patients	O
had	O
higher	O
levels	O
of	O
NFL	O
,	O
CXCL13	O
,	O
CHI3L1	O
,	O
and	O
CHIT1	O
than	O
controls	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Subgroup	O
analysis	O
revealed	O
higher	O
NFL	O
,	O
CXCL13	O
and	O
CHIT1	O
levels	O
in	O
patients	O
treated	O
with	O
first-line	O
therapy	O
compared	O
to	O
second-line	O
therapy	O
(	O
p	O
=	O
0.008	O
,	O
p	O
=	O
0.001	O
and	O
p	O
=	O
0.026	O
,	O
respectively	O
)	O
.	O

NFL	O
and	O
CHIT1	O
levels	O
correlated	O
with	O
relapse	O
status	O
,	O
and	O
NFL	O
and	O
CXCL13	O
levels	O
correlated	O
with	O
the	O
formation	O
of	O
new	O
magnetic	B-P
resonance	I-P
imaging	I-P
lesions	O
.	O

Furthermore	O
,	O
we	O
found	O
an	O
association	O
between	O
inflammatory	O
and	O
degenerative	O
biomarkers	O
.	O

The	O
results	O
indicate	O
that	O
CSF	O
levels	O
of	O
NFL	O
,	O
CXCL13	O
,	O
CHI3L1	O
,	O
and	O
CHIT1	O
correlate	O
with	O
the	O
clinical	O
and/or	O
radiological	O
disease	O
activity	O
,	O
providing	O
additional	O
dimensions	O
in	O
the	O
assessment	O
of	O
treatment	O
efficacy	O
.	O

Complete	O
study	O
demonstrating	O
the	O
absence	O
of	O
rhabdovirus	O
in	O
a	O
distinct	O
Sf9	O
cell	O
line	O
.	O

A	O
putative	O
novel	O
rhabdovirus	O
(	O
SfRV	O
)	O
was	O
previously	O
identified	O
in	O
a	O
Spodoptera	O
frugiperda	O
cell	O
line	O
(	O
Sf9	O
cells	O
[	O
ATCC	O
CRL-1711	O
lot	O
58078522	O
]	O
)	O
by	O
next	O
generation	O
sequencing	O
and	O
extensive	O
bioinformatic	O
analysis	O
.	O

We	O
performed	O
an	O
extensive	O
analysis	O
of	O
our	O
Sf9	O
cell	O
bank	O
(	O
ATCC	O
CRL-1711	O
lot	O
5814	O
[	O
Sf9L5814	O
]	O
)	O
to	O
determine	O
whether	O
this	O
virus	O
was	O
already	O
present	O
in	O
cells	O
obtained	O
from	O
ATCC	O
in	O
1987	O
.	O

Inverse	O
PCR	O
of	O
DNA	O
isolated	O
from	O
Sf9	O
L5814	O
cellular	O
DNA	O
revealed	O
integration	O
of	O
SfRV	O
sequences	O
in	O
the	O
cellular	O
genome	O
.	O

RT-PCR	O
of	O
total	O
RNA	O
showed	O
a	O
deletion	O
of	O
320	O
nucleotides	O
in	O
the	O
SfRV	O
RNA	O
that	O
includes	O
the	O
transcriptional	O
motifs	O
for	O
genes	O
X	O
and	O
L.	O
Concentrated	O
cell	B-P
culture	I-P
supernatant	O
was	O
analyzed	O
by	O
sucrose	B-P
density	I-P
gradient	I-P
centrifugation	I-P
and	O
revealed	O
a	O
single	O
band	O
at	O
a	O
density	O
of	O
1.14	O
g/ml	O
.	O

This	O
fraction	O
was	O
further	O
analysed	O
by	O
electron	B-P
microscopy	I-P
and	O
showed	O
amorphous	O
and	O
particulate	O
debris	O
that	O
did	O
not	O
resemble	O
a	O
rhabdovirus	O
in	O
morphology	O
or	O
size	O
.	O

SDS-PAGE	O
analysis	O
confirmed	O
that	O
the	O
protein	O
composition	O
did	O
not	O
contain	O
the	O
typical	O
five	O
rhabdovirus	O
structural	O
proteins	O
and	O
LC-MS/MS	B-P
analysis	I-P
revealed	O
primarily	O
of	O
exosomal	O
marker	O
proteins	O
,	O
the	O
SfRV	O
N	O
protein	O
,	O
and	O
truncated	O
forms	O
of	O
SfRV	O
N	O
,	O
P	O
,	O
and	O
G	O
proteins	O
.	O

The	O
SfRV	O
L	O
gene	O
fragment	O
RNA	O
sequence	O
was	O
recovered	O
from	O
the	O
supernatant	O
after	O
ultracentrifugation	B-P
of	O
the	O
1.14	O
g/ml	O
fraction	O
treated	O
with	O
diethyl	O
ether	O
suggesting	O
that	O
the	O
SfRV	O
L	O
gene	O
fragment	O
sequence	O
is	O
not	O
associated	O
with	O
a	O
diethyl	O
ether	O
resistant	O
nucleocapsid	O
.	O

Interestingly	O
,	O
the	O
1.14	O
g/ml	O
fraction	O
was	O
able	O
to	O
transfer	O
baculovirus	O
DNA	O
into	O
Sf9L5814	O
cells	O
,	O
consistent	O
with	O
the	O
presence	O
of	O
functional	O
exosomes	O
.	O

Our	O
results	O
demonstrate	O
the	O
absence	O
of	O
viral	O
particles	O
in	O
ATCC	O
CRL-1711	O
lot	O
5814	O
Sf9	O
cells	O
in	O
contrast	O
to	O
a	O
previous	O
study	O
that	O
suggested	O
the	O
presence	O
of	O
infectious	O
rhabdoviral	O
particles	O
in	O
Sf9	O
cells	O
from	O
a	O
different	O
lot	O
.	O

This	O
study	O
highlights	O
how	O
cell	O
lines	O
with	O
different	O
lineages	O
may	O
present	O
different	O
virosomes	O
and	O
therefore	O
no	O
general	O
conclusions	O
can	O
be	O
drawn	O
across	O
Sf9	O
cells	O
from	O
different	O
laboratories	O
.	O

Risks	O
and	O
benefits	O
of	O
reducing	O
target	O
volume	O
margins	O
in	O
breast	O
tangent	O
radiotherapy	O
.	O

This	O
study	O
investigates	O
the	O
potential	O
benefits	O
of	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
margin	O
reduction	O
for	O
whole	O
breast	O
radiotherapy	O
in	O
relation	O
to	O
dose	O
received	O
by	O
organs	O
at	O
risk	O
(	O
OARs	O
)	O
,	O
as	O
well	O
as	O
reductions	O
in	O
radiation	O
-	O
induced	O
secondary	O
cancer	O
risk	O
.	O

Such	O
benefits	O
were	O
compared	O
to	O
the	O
increased	O
radiation	O
-	O
induced	O
secondary	O
cancer	O
risk	O
attributed	O
from	O
increased	O
ionizing	B-P
radiation	I-P
imaging	I-P
doses	O
.	O

Ten	O
retrospective	O
patients	O
'	O
computed	B-P
tomography	I-P
datasets	O
were	O
considered	O
.	O

Three	O
computerized	O
treatment	O
plans	O
with	O
varied	O
PTV	O
margins	O
(	O
0	O
,	O
5	O
and	O
10	O
mm	O
)	O
were	O
created	O
for	O
each	O
patient	O
complying	O
with	O
the	O
Radiation	O
Therapy	O
Oncology	O
Group	O
(	O
RTOG	O
)	O
1005	O
protocol	O
requirements	O
.	O

The	O
BEIR	O
VII	O
lifetime	O
attributable	O
risk	O
(	O
LAR	O
)	O
model	O
was	O
used	O
to	O
estimate	O
secondary	O
cancer	O
risk	O
to	O
OARs	O
.	O

The	O
LAR	O
was	O
assessed	O
for	O
all	O
treatment	O
plans	O
considering	O
(	O
a	O
)	O
doses	O
from	O
PTV	O
margin	O
variation	O
and	O
(	O
b	O
)	O
doses	O
from	O
two	O
(	O
daily	O
and	O
weekly	O
)	O
kilovoltage	B-P
cone	I-P
beam	I-P
computed	I-P
tomography	I-P
(	O
kV	B-P
CBCT	I-P
)	O
imaging	B-P
protocols	O
during	O
the	O
course	O
of	O
treatment	O
.	O

We	O
found	O
PTV	O
margins	O
from	O
largest	O
to	O
smallest	O
resulted	O
in	O
a	O
mean	O
OAR	O
relative	O
dose	O
reduction	O
of	O
31	O
%	O
(	O
heart	O
)	O
,	O
28	O
%	O
(	O
lung	O
)	O
and	O
23	O
%	O
(	O
contralateral	O
breast	O
)	O
and	O
the	O
risk	O
of	O
radiation	O
-	O
induced	O
secondary	O
cancer	O
by	O
a	O
relative	O
23	O
%	O
(	O
contralateral	O
breast	O
)	O
and	O
22	O
%	O
(	O
contralateral	O
lung	O
)	O
.	O

Daily	O
image-guidance	O
using	O
kV	B-P
CBCT	I-P
increased	O
the	O
risk	O
of	O
radiation	O
induced	O
secondary	O
cancer	O
to	O
the	O
contralateral	O
breast	O
and	O
contralateral	O
lung	O
by	O
a	O
relative	O
1.6-1.9	O
%	O
and	O
1.9-2.5	O
%	O
respectively	O
.	O

Despite	O
the	O
additional	O
dose	O
from	O
kV	B-P
CBCT	I-P
for	O
the	O
two	O
considered	O
imaging	B-P
protocols	O
,	O
smaller	O
PTV	O
margins	O
would	O
still	O
result	O
in	O
an	O
overall	O
reduction	O
in	O
secondary	O
cancer	O
risk	O
.	O

Impact	O
of	O
AAC	O
(	O
6	O
'	O
)	O
-Ib-cr	O
in	O
combination	O
with	O
chromosomal	O
-mediated	O
mechanisms	O
on	O
clinical	O
quinolone	O
resistance	O
in	O
Escherichia	O
coli	O
.	O

aac	O
(	O
6	O
'	O
)	O
-Ib-cr	O
is	O
the	O
most	O
prevalent	O
plasmid	O
-mediated	O
fluoroquinolone	O
(	O
FQ	O
)	O
resistance	O
mechanism	O
in	O
Enterobacteriaceae	O
.	O

We	O
aimed	O
to	O
analyse	O
the	O
interplay	O
between	O
this	O
plasmid	O
-mediated	O
gene	O
and	O
chromosomal	O
-mediated	O
quinolone	O
resistance	O
mechanisms	O
on	O
both	O
FQ	O
resistance	O
and	O
bacterial	O
fitness	O
in	O
Escherichia	O
coli	O
.	O

E.	O
coli	O
ATCC	O
25922	O
and	O
derived	O
isogenic	O
strains	O
carrying	O
chromosomal	O
-mediated	O
quinolone	O
resistance	O
modifications	O
(	O
Ser83Leu-Asp87Asn	O
in	O
GyrA	O
,	O
Ser80Arg	O
in	O
ParC	O
and/or	O
a	O
marR	O
gene	O
deletion	O
)	O
were	O
electroporated	B-P
with	O
a	O
pBK-CMV	O
vector	O
encoding	O
AAC	O
(	O
6	O
'	O
)	O
-Ib-cr	O
.	O

The	O
MICs	O
of	O
FQs	O
were	O
determined	O
by	O
microdilution	B-P
and	O
bactericidal	O
activity	O
was	O
determined	O
using	O
time-kill	O
curves	O
.	O

A	O
peritoneal	O
sepsis	O
murine	O
model	O
was	O
used	O
to	O
evaluate	O
the	O
in	O
vivo	O
impact	O
.	O

Bacterial	O
fitness	O
was	O
analysed	O
using	O
growth	O
curves	O
and	O
competition	B-P
assays	I-P
.	O

The	O
presence	O
of	O
the	O
aac	O
(	O
6	O
'	O
)	O
-Ib-cr	O
gene	O
increased	O
the	O
MICs	O
of	O
ciprofloxacin	O
and	O
norfloxacin	O
4-8-fold	O
for	O
all	O
E.	O
coli	O
genotypes	O
,	O
independently	O
of	O
the	O
initial	O
resistance	O
level	O
.	O

Combination	O
of	O
the	O
aac	O
(	O
6	O
'	O
)	O
-Ib-cr	O
gene	O
with	O
three	O
or	O
four	O
chromosomal	O
mechanisms	O
was	O
necessary	O
to	O
reach	O
MIC	O
values	O
above	O
the	O
susceptible	O
category	O
.	O

Killing	O
curve	O
assays	O
showed	O
a	O
clear	O
selective	O
advantage	O
for	O
survival	O
in	O
strains	O
harbouring	O
the	O
aac	O
(	O
6	O
'	O
)	O
-Ib-cr	O
gene	O
(	O
up	O
to	O
7	O
log10	O
cfu/mL	O
after	O
24	O
h	O
)	O
.	O

AAC	O
(	O
6	O
'	O
)	O
-Ib-cr	O
significantly	O
reduced	O
the	O
ciprofloxacin	O
efficacy	O
in	O
vivo	O
.	O

In	O
terms	O
of	O
bacterial	O
fitness	O
cost	O
,	O
maximal	O
OD	O
was	O
significantly	O
lower	O
for	O
all	O
strains	O
harbouring	O
the	O
aac	O
(	O
6	O
'	O
)	O
-Ib-cr	O
gene	O
,	O
independently	O
of	O
chromosomal	O
mutations	O
associated	O
.	O

The	O
aac	O
(	O
6	O
'	O
)	O
-Ib-cr	O
gene	O
,	O
in	O
spite	O
of	O
producing	O
low-level	O
resistance	O
by	O
itself	O
,	O
plays	O
a	O
relevant	O
role	O
in	O
acquisition	O
of	O
a	O
clinical	O
level	O
of	O
ciprofloxacin	O
and	O
norfloxacin	O
resistance	O
,	O
when	O
combined	O
with	O
three	O
or	O
four	O
chromosomal	O
mutations	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Macrophages	O
modulate	O
the	O
growth	O
and	O
differentiation	O
of	O
rhesus	O
monkey	O
embryonic	O
trophoblasts	O
.	O

Immune	O
cells	O
within	O
the	O
endometrium	O
at	O
implantation	O
are	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
implantation	O
,	O
although	O
their	O
exact	O
role	O
is	O
not	O
well	O
understood	O
.	O

A	O
co-culture	B-P
system	I-P
of	O
rhesus	O
monkey	O
embryos	O
and	O
maternal	O
immune	O
cells	O
was	O
established	O
.	O

Blastocysts	O
obtained	O
by	O
in	O
vitro	O
fertilization	O
were	O
co-cultured	B-P
with	O
peripheral	O
blood	O
cells	O
or	O
decidual	O
macrophages	O
.	O

Culture	O
media	O
were	O
collected	O
to	O
assess	O
secretions	O
.	O

Embryo	O
growth	O
was	O
monitored	O
,	O
and	O
trophoblasts	O
were	O
evaluated	O
for	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
differentiation	O
.	O

Embryonic	O
trophoblast	O
outgrowths	O
were	O
visible	O
within	O
6	O
days	O
of	O
culture	B-P
,	O
and	O
the	O
area	O
of	O
embryo	O
outgrowth	O
was	O
reduced	O
when	O
blastocysts	O
were	O
cultured	B-P
with	O
peripheral	O
-	O
derived	O
or	O
decidual	O
macrophages	O
.	O

Trophoblast	O
proliferation	O
was	O
not	O
significantly	O
affected	O
with	O
macrophage	O
co-culture	B-P
while	O
chorionic	O
gonadotropin	O
secretion	O
was	O
increased	O
.	O

Trophoblast	O
expression	O
of	O
CDH	O
11	O
and	O
GJA1	O
was	O
increased	O
,	O
suggesting	O
that	O
macrophages	O
accelerate	O
differentiation	O
of	O
peri-implantation	O
trophoblasts	O
.	O

These	O
results	O
indicate	O
an	O
important	O
role	O
of	O
macrophages	O
in	O
placentation	O
and	O
pregnancy	O
success	O
.	O

Chemical	O
Composition	O
and	O
Biological	O
Activity	O
of	O
Essential	O
Oils	O
from	O
Different	O
Species	O
of	O
Piper	O
from	O
Panama	O
.	O

The	O
chemical	O
composition	O
of	O
leaf	O
essential	O
oils	O
from	O
11	O
species	O
of	O
Piper	O
from	O
Panama	O
was	O
analyzed	O
by	O
a	O
combination	O
GC-FID	B-P
and	O
GC-MS	B-P
procedures	I-P
.	O

Six	O
of	O
them	O
had	O
sesquiterpene	O
hydrocarbons	O
as	O
major	O
constituents	O
,	O
three	O
were	O
characterized	O
by	O
monoterpene	O
hydrocarbons	O
,	O
one	O
by	O
a	O
diterpene	O
,	O
and	O
one	O
by	O
a	O
phenylpropanoid	O
,	O
dillapiole	O
.	O

The	O
main	O
components	O
identified	O
in	O
each	O
species	O
were	O
:	O
cembratrienol	O
(	O
25.4	O
%	O
)	O
in	O
Piper	O
augustum	O
;	O
β-pinene	O
(	O
26.6	O
%	O
)	O
in	O
Piper	O
corrugatum	O
;	O
α-pinene	O
(	O
19.4	O
%	O
)	O
in	O
Piper	O
curtispicum	O
;	O
trans-β-farnesene	O
(	O
63.7	O
%	O
)	O
in	O
Piper	O
darienense	O
;	O
p-cymene	O
(	O
43.9	O
%	O
)	O
in	O
Piper	O
grande	O
;	O
dillapiole	O
(	O
57.7	O
%	O
)	O
in	O
Piper	O
hispidum	O
;	O
linalool	O
(	O
14.5	O
%	O
)	O
,	O
α-phellandrene	O
(	O
13.8	O
%	O
)	O
,	O
and	O
limonene	O
(	O
12.2	O
%	O
)	O
in	O
Piper	O
jacquemontianum	O
;	O
β-caryophyllene	O
(	O
45.2	O
%	O
)	O
in	O
Piper	O
longispicum	O
;	O
linalool	O
(	O
16.5	O
%	O
)	O
,	O
α-phellandrene	O
(	O
11.8	O
%	O
)	O
,	O
limonene	O
(	O
11.4	O
%	O
)	O
,	O
and	O
p-cymene	O
(	O
9.0	O
%	O
)	O
in	O
Piper	O
multiplinervium	O
;	O
β-selinene	O
(	O
19.0	O
%	O
)	O
,	O
β-elemene	O
(	O
16.1	O
%	O
)	O
,	O
and	O
α-selinene	O
(	O
15.5	O
%	O
)	O
in	O
Piper	O
reticulatum	O
;	O
and	O
germacrene	O
D	O
(	O
19.7	O
%	O
)	O
in	O
Piper	O
trigonum	O
.	O

The	O
essential	O
oils	O
of	O
P.	O
hispidum	O
and	O
P.	O
longispicum	O
at	O
a	O
concentration	O
of	O
250	O
µg/mL	O
showed	O
larvicidal	O
activity	O
against	O
Aedes	O
aegypti	O
,	O
while	O
the	O
oils	O
from	O
P.	O
curtispicum	O
,	O
P.	O
multiplinervium	O
,	O
P.	O
reticulatum	O
,	O
and	O
P.	O
trigonum	O
were	O
inactive	O
(	O
LC100	O
≥	O
500	O
µg/mL	O
)	O
.	O

The	O
essential	O
oils	O
of	O
P.	O
grande	O
,	O
P.	O
jacquemontianum	O
,	O
and	O
P.	O
multiplinervium	O
showed	O
no	O
significant	O
antifungal	O
activity	O
(	O
MIC	O
>	O
250	O
µg/mL	O
)	O
against	O
several	O
yeasts	O
and	O
filamentous	O
fungal	O
strains	O
.	O

Clinical	O
significance	O
of	O
human	O
intestinal	O
spirochetosis	O
:	O
a	O
retrospective	O
study	O
.	O

The	O
clinical	O
and	O
pathological	O
features	O
of	O
human	O
intestinal	O
spirochetosis	O
(	O
HIS	O
)	O
are	O
not	O
well	O
known	O
.	O

Here	O
we	O
report	O
55	O
patients	O
with	O
HIS	O
who	O
were	O
diagnosed	O
at	O
our	O
institution	O
during	O
the	O
past	O
5	O
years	O
.	O

Seven	O
patients	O
presented	O
with	O
symptoms	O
such	O
as	O
abdominal	O
pain	O
or	O
diarrhea	O
,	O
while	O
the	O
others	O
were	O
incidentally	O
diagnosed	O
during	O
screening	B-P
colonoscopy	I-P
.	O

Most	O
patients	O
had	O
non-specific	O
endoscopic	B-P
findings	O
,	O
including	O
intestinal	O
edema	O
or	O
erosion	O
.	O

The	O
diagnosis	O
of	O
HIS	O
was	O
histologically	O
confirmed	O
via	O
hematoxylin	B-P
and	I-P
eosin	I-P
staining	I-P
,	O
periodic	B-P
acid-Schiff	I-P
staining	I-P
,	O
and/or	O
immunohistochemistry	B-P
using	O
anti-Treponema	O
pallidum	O
antibody	O
.	O

Among	O
the	O
55	O
patients	O
,	O
five	O
were	O
diagnosed	O
with	O
diseases	O
other	O
than	O
HIS	O
(	O
amoebic	O
colitis	O
,	O
three	O
;	O
ulcerative	O
colitis	O
,	O
one	O
)	O
.	O

Sixteen	O
patients	O
were	O
treated	O
with	O
either	O
amoxicillin	O
or	O
metronidazole	O
;	O
only	O
metronidazole	O
proved	O
to	O
be	O
effective	O
.	O

The	O
clinical	O
significance	O
of	O
asymptomatic	O
HIS	O
remains	O
unknown	O
.	O

Some	O
case	O
reports	O
suggest	O
a	O
risk	O
for	O
increased	O
severity	O
in	O
patients	O
with	O
immunodeficiency	O
and/or	O
sexually	O
transmitted	O
diseases	O
.	O

Therefore	O
,	O
aggressive	O
treatment	O
for	O
HIS	O
should	O
be	O
considered	O
,	O
particularly	O
in	O
high-risk	O
patients	O
.	O

Hydroxysafflor	O
yellow	O
A	O
attenuates	O
the	O
expression	O
of	O
inflammatory	O
cytokines	O
in	O
acute	O
soft	O
tissue	O
injury	O
.	O

We	O
examined	O
the	O
effect	O
of	O
hydroxysafflor	O
yellow	O
A	O
(	O
HSYA	O
)	O
on	O
the	O
inflammatory	O
response	O
to	O
strike	O
-	O
induced	O
acute	O
soft	O
tissue	O
injury	O
in	O
rats	O
.	O

Soft	O
tissue	O
injury	O
was	O
induced	O
in	O
rat	O
leg	O
muscles	O
using	O
a	O
strike	O
hammer	O
,	O
followed	O
by	O
intraperitoneal	O
administration	O
of	O
HSYA	O
at	O
16	O
,	O
32	O
,	O
or	O
64	O
mg/kg	O
.	O

After	O
24	O
h	O
,	O
the	O
rats	O
were	O
anaesthetized	O
,	O
blood	O
and	O
muscle	O
samples	O
were	O
taken	O
.	O

Plasma	O
levels	B-P
of	I-P
interleukin	I-P
(	I-P
IL	I-P
)	I-P
-6	I-P
,	O
IL-1β	B-P
,	O
and	O
tumour	B-P
necrosis	I-P
factor	I-P
(	I-P
TNF	I-P
)	I-P
-α	I-P
were	O
measured	O
by	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
.	O

Total	O
RNA	O
and	O
protein	O
were	O
isolated	O
from	O
muscle	O
tissue	O
to	O
determine	O
the	O
mRNA	O
levels	B-P
of	I-P
IL-6	I-P
,	O
IL-1β	B-P
,	O
TNF-α	B-P
,	O
vascular	B-P
cell	I-P
adhesion	I-P
molecule	I-P
(	I-P
VCAM	I-P
)	I-P
-1	I-P
,	O
and	O
intercellular	B-P
adhesion	I-P
molecule	I-P
(	I-P
ICAM	I-P
)	I-P
-1	I-P
,	O
and	O
the	O
protein	O
level	O
of	O
phosphorylated	O
p38	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
.	O

Nuclear	O
factor	O
(	O
NF	O
)	O
-κB	O
expression	O
was	O
determined	O
by	O
muscle	O
histopathology	B-P
and	O
immunohistochemistry	B-P
.	O

HSYA	O
attenuated	O
pathologic	O
changes	O
in	O
strike	O
-	O
induced	O
soft	O
tissue	O
inflammation	O
.	O

Treatment	O
with	O
HSYA	O
also	O
alleviated	O
strike	O
-	O
induced	O
increases	O
in	O
TNF-α	B-P
,	O
IL-1β	B-P
,	O
IL-6	B-P
,	O
VCAM-1	B-P
,	O
and	O
ICAM-1	B-P
mRNA	O
levels	O
and	O
inhibited	O
the	O
increased	O
activation	O
of	O
NF-κB	O
and	O
phosphorylation	O
of	O
p38	O
MAPK	O
in	O
muscle	O
tissue	O
.	O

These	O
findings	O
suggest	O
that	O
HSYA	O
effectively	O
inhibits	O
strike	O
-	O
induced	O
inflammatory	O
signal	O
transduction	O
in	O
rats	O
.	O

Serum	B-P
ferritin	I-P
levels	I-P
as	O
a	O
useful	O
diagnostic	O
marker	O
for	O
the	O
distinction	O
of	O
systemic	O
juvenile	O
idiopathic	O
arthritis	O
and	O
Kawasaki	O
disease	O
.	O

The	O
clinical	O
features	O
and	O
laboratory	B-P
parameters	I-P
of	O
patients	O
with	O
Kawasaki	O
disease	O
(	O
KD	O
)	O
and	O
systemic	O
juvenile	O
idiopathic	O
arthritis	O
(	O
s-JIA	O
)	O
tend	O
to	O
overlap	O
.	O

Furthermore	O
,	O
there	O
have	O
been	O
no	O
definitive	O
biomarkers	O
for	O
these	O
disease	O
s	O
,	O
making	O
clinical	B-P
diagnosis	I-P
difficult	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
diagnostic	O
value	O
of	O
serum	B-P
ferritin	I-P
levels	I-P
for	O
differentiating	O
KD	O
from	O
s-JIA	O
and	O
predicting	O
the	O
disease	O
severity	O
of	O
KD	O
.	O

We	O
analyzed	O
228	O
patients	O
with	O
KD	O
and	O
81	O
patients	O
with	O
s-JIA	O
.	O

Serum	B-P
ferritin	I-P
levels	I-P
were	O
compared	O
between	O
patients	O
with	O
s-JIA	O
and	O
KD	O
.	O

Furthermore	O
,	O
serum	B-P
ferritin	I-P
levels	I-P
in	O
patients	O
with	O
KD	O
were	O
compared	O
with	O
respect	O
to	O
clinical	O
features	O
such	O
as	O
responsiveness	O
to	O
intravenous	O
immunoglobulin	O
(	O
IVIG	O
)	O
therapy	O
.	O

Serum	B-P
ferritin	I-P
levels	I-P
in	O
KD	O
patients	O
with	O
no	O
response	O
to	O
IVIG	O
therapy	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
KD	O
patients	O
with	O
a	O
good	O
response	O
to	O
IVIG	O
therapy	O
.	O

Serum	B-P
ferritin	I-P
levels	I-P
in	O
patients	O
with	O
KD	O
needing	O
plasma	O
exchange	O
(	O
PE	O
)	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
patients	O
not	O
needing	O
PE	O
.	O

However	O
,	O
serum	B-P
ferritin	I-P
levels	I-P
overlapped	O
between	O
severe	O
KD	O
patients	O
with	O
nonresponsiveness	O
to	O
IVIG	O
therapy	O
or	O
needing	O
PE	O
and	O
other	O
patients	O
with	O
mild	O
KD	O
.	O

Furthermore	O
,	O
patients	O
with	O
s-JIA	O
showed	O
a	O
distinct	O
elevation	O
of	O
serum	B-P
ferritin	I-P
levels	I-P
compared	O
with	O
KD	O
patients	O
.	O

The	O
cutoff	O
value	O
of	O
serum	B-P
ferritin	I-P
levels	I-P
for	O
differentiating	O
KD	O
from	O
s-JIA	O
was	O
369.6	O
ng/ml	O
.	O

Serum	B-P
ferritin	I-P
levels	I-P
were	O
significantly	O
elevated	O
in	O
s-JIA	O
patients	O
compared	O
with	O
KD	O
patients	O
.	O

Measurement	B-P
of	I-P
serum	I-P
ferritin	I-P
levels	I-P
can	O
be	O
useful	O
for	O
differentiating	O
s-JIA	O
from	O
KD	O
.	O

Enhancement	O
of	O
brain	O
plasticity	O
and	O
recovery	O
of	O
locomotive	O
function	O
after	O
lumbar	O
spinal	O
cord	O
stimulation	O
in	O
combination	O
with	O
gait	O
training	O
with	O
partial	O
weight	O
support	O
in	O
rats	O
with	O
cerebral	O
ischemia	O
.	O

Lumbar	O
spinal	O
cord	O
stimulation	O
(	O
LSCS	O
)	O
is	O
reportedly	O
effective	O
for	O
the	O
recovery	O
of	O
locomotive	O
intraspinal	O
neural	O
network	O
,	O
motor	O
cortex	O
and	O
basal	O
ganglia	O
in	O
animals	O
with	O
complete	O
spinal	O
cord	O
injury	O
and	O
parkinsonism	O
.	O

We	O
evaluated	O
the	O
effect	O
of	O
LSCS	O
in	O
combination	O
with	O
gait	O
training	O
on	O
the	O
recovery	O
of	O
locomotive	O
function	O
and	O
brain	O
plasticity	O
using	O
a	O
rat	O
model	O
of	O
brain	O
ischemia	O
.	O

Adult	O
male	O
Sprague	O
Dawley	O
rats	O
with	O
ischemia	O
were	O
randomly	O
assigned	O
into	O
one	O
of	O
four	O
groups	O
:	O
sham	O
treatment	O
(	O
group	O
1	O
)	O
,	O
LSCS	O
only	O
(	O
group	O
2	O
)	O
,	O
LSCS	O
with	O
gait	O
training	O
and	O
50	O
%	O
(	O
group	O
3	O
)	O
and	O
80	O
%	O
(	O
group	O
4	O
)	O
of	O
body	O
weight	O
support	O
.	O

Evaluations	O
before	O
randomization	O
and	O
4	O
weeks	O
after	O
intervention	O
included	O
motor	O
scoring	O
index	O
,	O
real-time	O
PCR	O
and	O
Western	B-P
blot	I-P
.	O

Motor	O
scoring	O
index	O
was	O
significantly	O
improved	O
after	O
the	O
intervention	O
in	O
groups	O
2	O
and	O
3	O
.	O

The	O
ratio	O
of	O
phospho-protein	O
kinase	O
C	O
(	O
PKC	O
)	O
to	O
PKC	O
measured	O
in	O
the	O
infarcted	O
area	O
tended	O
to	O
be	O
higher	O
in	O
groups	O
3	O
and	O
4	O
.	O

Protein	O
expression	O
of	O
mGluR2	O
and	O
mRNA	O
expression	O
of	O
mGluR1	O
measured	O
in	O
the	O
contralateral	O
cortex	O
were	O
lower	O
in	O
groups	O
3	O
and	O
4	O
.	O

The	O
ratio	O
of	O
phospho-Akt	O
to	O
Akt	O
and	O
mRNA	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
measured	O
in	O
the	O
ischemic	O
border	O
zone	O
were	O
higher	O
in	O
group	O
2	O
.	O

The	O
mRNA	O
expression	O
of	O
MAP1b	O
measured	O
in	O
the	O
infarcted	O
area	O
was	O
significantly	O
higher	O
in	O
group	O
2	O
.	O

The	O
findings	O
suggest	O
that	O
LSCS	O
and	O
gait	O
training	O
with	O
an	O
adequate	O
amount	O
of	O
body	O
weight	O
support	O
may	O
promote	O
brain	O
plasticity	O
and	O
facilitate	O
the	O
functional	O
recovery	O
.	O

Effect	O
of	O
organic	O
and	O
inorganic	O
selenium	O
supplementation	O
on	O
semen	B-P
quality	I-P
and	O
blood	O
enzymes	O
in	O
buffalo	O
bulls	O
.	O

The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
effect	O
of	O
organic	O
and	O
inorganic	O
selenium	O
(	O
Se	O
)	O
supplementation	O
on	O
semen	B-P
quality	I-P
and	O
blood	O
serum	O
profiles	B-P
of	O
buffalo	O
bulls	O
.	O

Nine	O
mature	O
buffalo	O
bulls	O
were	O
divided	O
into	O
three	O
groups	O
:	O
control	O
(	O
non-supplemented	O
)	O
;	O
organic	O
Se	O
(	O
10	O
mg	O
Sel-Plex	O
®/head	O
twice	O
weekly	O
)	O
and	O
inorganic	O
Se	O
(	O
10	O
mg	O
sodium	O
selenite	O
/head	O
twice	O
weekly	O
)	O
.	O

Semen	O
was	O
collected	O
twice	O
a	O
week	O
for	O
3	O
months	O
during	O
Se	O
supplementation	O
.	O

Semen	O
properties	O
were	O
evaluated	O
from	O
fresh	O
ejaculate	O
.	O

Moreover	O
,	O
fructose	O
concentration	O
,	O
aspartate	O
and	O
alanine	O
transaminase	O
(	O
AST	O
and	O
ALT	O
)	O
activities	O
,	O
total	B-P
protein	I-P
and	O
total	B-P
cholesterol	I-P
were	O
assayed	B-P
in	O
seminal	O
plasma	O
.	O

Additionally	O
AST	O
,	O
ALT	O
,	O
testosterone	O
and	O
Se	O
levels	O
were	O
determined	O
in	O
the	O
blood	O
serum	O
.	O

Results	O
showed	O
that	O
Se	O
supplementation	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
influences	O
the	O
semen	O
parameters	O
during	O
3	O
months	O
of	O
treatment	O
.	O

Organic	O
Se	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
increased	O
the	O
percentage	O
of	O
viable	O
sperms	O
compared	O
to	O
inorganic	O
Se	O
and	O
the	O
control	O
group	O
.	O

Fructose	O
concentration	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0.05	O
)	O
in	O
the	O
seminal	O
plasma	O
of	O
organic	O
Se	O
-	O
treated	O
bulls	O
.	O

Serum	O
testosterone	O
and	O
Se	O
concentrations	O
were	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
increased	O
in	O
the	O
Se	O
supplemented	O
groups	O
than	O
the	O
control	O
group	O
.	O

In	O
conclusion	O
,	O
Se	O
supplementation	O
improved	O
the	O
parameters	O
of	O
buffalo	O
bull	O
semen	O
and	O
more	O
precisely	O
,	O
organic	O
Se	O
was	O
more	O
effective	O
for	O
the	O
improvement	O
of	O
semen	B-P
quality	I-P
and	O
some	O
blood	O
components	O
than	O
inorganic	O
Se	O
.	O

metabolic	O
profiling	O
of	O
Parkinson	O
's	O
disease	O
and	O
mild	O
cognitive	O
impairment	O
.	O

Early	B-P
diagnosis	I-P
of	O
Parkinson	O
's	O
disease	O
and	O
mild	O
cognitive	O
impairment	O
is	O
important	O
to	O
enable	O
prompt	O
treatment	O
and	O
improve	O
patient	O
welfare	O
,	O
yet	O
no	O
standard	B-P
diagnostic	I-P
test	I-P
is	O
available	O
.	O

Metabolomics	O
is	O
a	O
powerful	O
tool	O
used	O
to	O
elucidate	O
disease	O
mechanisms	O
and	O
identify	O
potential	O
biomarkers	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
use	O
metabolic	O
profiling	O
to	O
understand	O
the	O
pathoetiology	O
of	O
Parkinson	O
's	O
disease	O
and	O
to	O
identify	O
potential	O
disease	O
biomarkers	O
.	O

This	O
study	O
compared	O
the	O
serological	O
metabolomic	O
profiles	O
of	O
early-stage	O
Parkinson	O
's	O
patients	O
(	O
diagnosed	O
<	O
12	O
months	O
)	O
to	O
asymptomatic	O
matched	O
controls	O
using	O
an	O
established	O
array	O
based	O
detection	O
system	O
(	O
DiscoveryHD4™	O
,	O
Metabolon	O
,	O
UK	O
)	O
,	O
correlating	O
metabolite	O
levels	O
to	O
clinical	O
measurements	O
of	O
cognitive	O
impairment	O
.	O

A	O
total	O
of	O
1434	O
serological	O
metabolites	O
were	O
assessed	O
in	O
early-stage	O
Parkinson	O
's	O
disease	O
cases	O
(	O
n	O
=	O
41	O
)	O
and	O
asymptomatic	O
matched	O
controls	O
(	O
n	O
=	O
40	O
)	O
.	O

Post-quality	O
control	O
,	O
statistical	O
analysis	O
identified	O
n	O
=	O
20	O
metabolites	O
,	O
predominantly	O
metabolites	O
of	O
the	O
fatty	O
acid	O
oxidation	O
pathway	O
,	O
associated	O
with	O
Parkinson	O
's	O
disease	O
and	O
mild	O
cognitive	O
impairment	O
.	O

Receiver	O
operator	O
curve	O
assessment	O
confirmed	O
that	O
the	O
nine	O
fatty	O
acid	O
oxidation	O
metabolites	O
had	O
good	O
predictive	O
accuracy	O
(	O
area	O
under	O
curve	O
=	O
0.857	O
)	O
for	O
early-stage	O
Parkinson	O
's	O
disease	O
and	O
mild	O
cognitive	O
impairment	O
(	O
area	O
under	O
curve	O
=	O
0.759	O
)	O
.	O

Our	O
study	O
indicates	O
that	O
fatty	O
acid	O
oxidation	O
may	O
be	O
an	O
important	O
component	O
in	O
the	O
pathophysiology	O
of	O
Parkinson	O
's	O
disease	O
and	O
may	O
have	O
potential	O
as	O
a	O
diagnostic	B-P
biomarker	I-P
for	O
disease	O
onset	O
and	O
mild	O
cognitive	O
impairment	O
.	O

©	O
2017	O
The	O
Authors	O
.	O

Movement	O
Disorders	O
published	O
by	O
Wiley	O
Periodicals	O
,	O
Inc.	O
on	O
behalf	O
of	O
International	O
Parkinson	O
and	O
Movement	O
Disorder	O
Society	O
.	O

Striatal	O
dopamine	O
modulates	O
timing	O
of	O
self-initiated	O
saccades	O
.	O

The	O
ability	O
to	O
adjust	O
movement	O
timing	O
is	O
essential	O
in	O
daily	O
life	O
.	O

Explorations	O
of	O
the	O
underlying	O
neural	O
mechanisms	O
have	O
reported	O
a	O
gradual	O
increase	O
or	O
decrease	O
in	O
neuronal	O
activity	O
prior	O
to	O
self-timed	O
movements	O
within	O
the	O
cortico	O
-	O
basal	O
ganglia	O
loop	O
.	O

Previous	O
studies	O
in	O
both	O
humans	O
and	O
animals	O
have	O
shown	O
that	O
endogenous	O
dopamine	O
(	O
DA	O
)	O
plays	O
a	O
modulatory	O
role	O
in	O
self-timing	O
.	O

However	O
,	O
the	O
specific	O
site	O
of	O
dopaminergic	O
regulation	O
remains	O
elusive	O
because	O
the	O
systemic	O
application	O
of	O
DA	O
-	O
related	O
substances	O
can	O
directly	O
alter	O
both	O
cortical	O
and	O
subcortical	O
neuronal	O
activities	O
.	O

To	O
investigate	O
the	O
role	O
of	O
striatal	O
DA	O
in	O
self-timing	O
,	O
we	O
locally	O
injected	O
DA	O
receptor	O
agonists	O
or	O
antagonists	O
into	O
the	O
striatum	O
of	O
two	O
female	O
monkeys	O
(	O
Macaca	O
fuscata	O
)	O
while	O
they	O
performed	O
two	O
versions	O
of	O
the	O
memory-guided	B-P
saccade	I-P
(	I-P
MS	I-P
)	I-P
task	I-P
.	O

In	O
the	O
conventional	O
,	O
triggered	O
MS	B-P
task	I-P
,	O
animals	O
made	O
a	O
saccade	O
to	O
the	O
location	O
of	O
a	O
previously	O
flashed	O
visual	O
cue	O
in	O
response	O
to	O
the	O
fixation	O
point	O
offset	O
.	O

In	O
the	O
self-timed	O
MS	B-P
task	I-P
,	O
monkeys	O
were	O
rewarded	O
for	O
making	O
a	O
self-initiated	O
saccade	O
within	O
a	O
predetermined	O
time	O
interval	O
following	O
the	O
cue	O
.	O

Infusion	O
of	O
a	O
small	O
amount	O
of	O
a	O
D1	O
or	O
D2	O
antagonist	O
led	O
to	O
early	O
saccades	O
in	O
the	O
self-timed	O
,	O
but	O
not	O
the	O
triggered	O
MS	B-P
tasks	I-P
,	O
while	O
infusion	O
of	O
DA	O
agonists	O
produced	O
no	O
consistent	O
effect	O
.	O

We	O
also	O
found	O
that	O
local	O
administration	O
of	O
nicotinic	O
but	O
not	O
muscarinic	O
acetylcholine	O
receptor	O
agonists	O
and	O
antagonists	O
altered	O
the	O
timing	O
of	O
self-initiated	O
saccades	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
timing	O
of	O
self-initiated	O
movements	O
may	O
be	O
regulated	O
by	O
the	O
balance	O
of	O
signals	O
in	O
the	O
direct	O
and	O
indirect	O
basal	O
ganglia	O
pathways	O
,	O
as	O
well	O
as	O
that	O
between	O
both	O
hemispheres	O
of	O
the	O
brain	O
.	O

Functional	O
Characterization	O
of	O
Pneumocystis	O
carinii	O
Inositol	O
Transporter	O
1	O
.	O

Fungi	O
in	O
the	O
genus	O
Pneumocystis	O
live	O
in	O
the	O
lungs	O
of	O
mammals	O
,	O
where	O
they	O
can	O
cause	O
a	O
fatal	O
pneumonia	O
(	O
PCP	O
[	O
Pneumocystis	O
pneumonia	O
]	O
)	O
in	O
hosts	O
with	O
compromised	O
immune	O
systems	O
.	O

The	O
absence	O
of	O
a	O
continuous	O
in	O
vitro	O
culture	B-P
system	I-P
for	O
any	O
species	O
of	O
Pneumocystis	O
has	O
led	O
to	O
limited	O
understanding	O
of	O
these	O
fungi	O
,	O
especially	O
for	O
the	O
discovery	O
of	O
new	O
therapies	O
.	O

We	O
recently	O
reported	O
that	O
Pneumocystis	O
carinii	O
,	O
Pneumocystis	O
murina	O
,	O
and	O
most	O
significantly	O
,	O
Pneumocystis	O
jirovecii	O
lack	O
both	O
enzymes	O
necessary	O
for	O
myo-inositol	O
biosynthesis	O
but	O
contain	O
genes	O
with	O
homologies	O
to	O
fungal	O
myo-inositol	O
transporters	O
.	O

Since	O
myo-inositol	O
is	O
essential	O
for	O
eukaryotic	O
viability	O
,	O
the	O
primary	O
transporter	O
,	O
ITR1	O
,	O
was	O
functionally	O
and	O
structurally	O
characterized	O
in	O
P.	O
carinii	O
The	O
predicted	O
structure	O
of	O
P.	O
carinii	O
ITR1	O
(	O
PcITR1	O
)	O
contained	O
12	O
transmembrane	O
alpha-helices	O
with	O
intracellular	O
C	O
and	O
N	O
termini	O
,	O
consistent	O
with	O
other	O
inositol	O
transporters	O
.	O

The	O
apparent	O
Km	O
was	O
0.94	O
±	O
0.08	O
(	O
mean	O
±	O
standard	O
deviation	O
)	O
,	O
suggesting	O
that	O
myo-inositol	O
transport	O
in	O
P.	O
carinii	O
is	O
likely	O
through	O
a	O
low-affinity	O
,	O
highly	O
selective	O
transport	O
system	O
,	O
as	O
no	O
other	O
sugars	O
or	O
inositol	O
stereoisomers	O
were	O
significant	O
competitive	O
inhibitors	O
.	O

Glucose	O
transport	O
was	O
shown	O
to	O
use	O
a	O
different	O
transport	O
system	O
.	O

The	O
myo-inositol	O
transport	O
was	O
distinct	O
from	O
mammalian	O
transporters	O
,	O
as	O
it	O
was	O
not	O
sodium	O
dependent	O
and	O
was	O
cytochalasin	O
B	O
resistant	O
.	O

Inositol	O
transport	O
in	O
these	O
fungi	O
offers	O
an	O
attractive	O
new	O
drug	O
target	O
because	O
of	O
the	O
reliance	O
of	O
the	O
fungi	O
on	O
its	O
transport	O
,	O
clear	O
differences	O
between	O
the	O
mammalian	O
and	O
fungal	O
transporters	O
,	O
and	O
the	O
ability	O
of	O
the	O
host	O
to	O
both	O
synthesize	O
and	O
transport	O
this	O
critical	O
nutrient	O
,	O
predicting	O
low	O
toxicity	O
of	O
potential	O
inhibitors	O
to	O
the	O
fungal	O
transporter	O
.	O

myo-Inositol	O
is	O
a	O
sugarlike	O
nutrient	O
that	O
is	O
essential	O
for	O
life	O
in	O
most	O
organisms	O
.	O

Humans	O
and	O
microbes	O
alike	O
can	O
obtain	O
it	O
by	O
making	O
it	O
,	O
which	O
involves	O
only	O
2	O
enzymes	O
,	O
by	O
taking	O
it	O
from	O
the	O
environment	O
by	O
a	O
transport	O
process	O
,	O
or	O
by	O
recycling	O
it	O
from	O
other	O
cellular	O
constituents	O
.	O

Inspection	O
of	O
the	O
genomes	O
of	O
the	O
pathogenic	O
fungi	O
of	O
the	O
genus	O
Pneumocystis	O
showed	O
that	O
these	O
pneumonia	O
-	O
causing	O
parasites	O
could	O
not	O
make	O
myo-inositol	O
,	O
as	O
they	O
lacked	O
the	O
2	O
enzymes	O
.	O

Instead	O
,	O
we	O
found	O
evidence	O
of	O
inositol	O
transporters	O
,	O
which	O
would	O
import	O
the	O
sugar	O
from	O
the	O
lungs	O
where	O
the	O
fungi	O
reside	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
characterized	O
the	O
transport	O
of	O
myo-inositol	O
in	O
the	O
fungus	O
and	O
found	O
that	O
the	O
transporter	O
was	O
highly	O
selective	O
for	O
myo-inositol	O
and	O
did	O
not	O
transport	O
any	O
other	O
molecules	O
.	O

The	O
transport	O
was	O
distinct	O
from	O
that	O
in	O
mammalian	O
cells	O
,	O
and	O
since	O
mammals	O
can	O
both	O
make	O
and	O
transport	O
myo-inositol	O
,	O
while	O
Pneumocystis	O
fungi	O
must	O
transport	O
it	O
,	O
this	O
process	O
offers	O
a	O
potential	O
new	O
drug	O
target	O
.	O

Torsed	O
and	O
Nontorsed	O
Inguinal	O
Undescended	O
Testis	O
:	O
Comparison	O
of	O
Computed	B-P
Tomography	I-P
Findings	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
computed	B-P
tomography	I-P
imaging	I-P
features	O
of	O
a	O
torsed	O
inguinal	O
testis	O
with	O
nontorsed	O
inguinal	O
testes	O
.	O

Computed	B-P
tomography	I-P
scans	I-P
of	O
patients	O
with	O
undescended	O
testes	O
were	O
retrospectively	O
collected	O
(	O
2011-2016	O
)	O
.	O

Imaging	B-P
features	O
of	O
nontorsed	O
undescended	O
testis	O
were	O
compared	O
with	O
a	O
case	O
of	O
an	O
inguinal	O
torsed	O
testis	O
.	O

Observations	O
included	O
location	O
of	O
the	O
undescended	O
testis	O
,	O
size	O
(	O
length	O
×	O
width	O
)	O
and	O
texture	O
of	O
each	O
testis	O
,	O
peritesticular	O
findings	O
,	O
position	O
of	O
testicular	O
vessels	O
,	O
and	O
enhancement	O
patterns	O
.	O

Twelve	O
nontorsed	O
inguinal	O
undescended	O
testes	O
were	O
compared	O
with	O
1	O
torsed	O
undescended	O
testicle	O
.	O

Torsed	O
testis	O
was	O
larger	O
than	O
nontorsed	O
(	O
44	O
×	O
27	O
mm	O
vs	O
32.9	O
±	O
6.1	O
×	O
22.9	O
±	O
4.9	O
mm	O
)	O
,	O
surrounded	O
by	O
fat	O
stranding	O
and	O
fluid	O
,	O
with	O
heterogeneous	O
texture	O
,	O
enhancement	O
of	O
its	O
outer	O
layers	O
,	O
and	O
an	O
upward	O
kink	O
of	O
its	O
vessels	O
.	O

Because	O
torsed	O
undescended	O
testis	O
can	O
mimic	O
a	O
groin	O
abscess	O
and	O
because	O
torsion	O
is	O
a	O
medical	O
emergency	O
,	O
radiologists	O
should	O
be	O
aware	O
of	O
this	O
entity	O
and	O
its	O
distinguishing	O
imaging	B-P
features	O
.	O

Color	B-P
Doppler	I-P
examination	I-P
can	O
ascertain	O
absence	O
/	O
reduction	O
of	O
blood	O
flow	O
.	O

Granulomatous	O
prostatitis	O
:	O
clinical	O
and	O
histomorphologic	O
survey	O
of	O
the	O
disease	O
in	O
a	O
tertiary	O
care	O
hospital	O
.	O

Granulomatous	O
prostatitis	O
is	O
an	O
uncommon	O
entity	O
that	O
is	O
diagnosed	O
incidentally	O
on	O
histopathology	O
and	O
is	O
broadly	O
classified	O
as	O
nonspecific	O
,	O
specific	O
,	O
postsurgical	O
(	O
post-transurethral	O
resection	O
)	O
,	O
or	O
secondary	O
to	O
other	O
rare	O
systemic	O
granulomatous	O
diseases	O
.	O

Only	O
very	O
few	O
studies	O
are	O
available	O
in	O
the	O
literature	O
that	O
describe	O
the	O
clinical	O
and	O
histomorphological	B-P
spectrum	I-P
of	O
the	O
disease	O
.	O

A	O
retrospective	O
analysis	O
of	O
histopathological	O
records	O
of	O
1,181	O
prostatic	O
specimens	O
received	O
in	O
the	O
pathology	O
department	O
was	O
done	O
over	O
a	O
period	O
of	O
13	O
years	O
(	O
January	O
2003	O
to	O
January	O
2016	O
)	O
.	O

All	O
histologically	B-P
proven	O
cases	O
of	O
granulomatous	O
prostatitis	O
were	O
retrieved	O
,	O
and	O
relevant	O
clinical	O
data	O
were	O
collected	O
from	O
patients	O
'	O
records	O
.	O

Epstein	O
and	O
Hutchins	O
classification	O
was	O
used	O
to	O
categorize	O
these	O
cases	O
.	O

Twenty-two	O
cases	O
of	O
granulomatous	O
prostatitis	O
were	O
identified	O
,	O
accounting	O
for	O
an	O
incidence	O
of	O
1.86	O
%	O
.	O

Among	O
these	O
,	O
nonspecific	O
granulomatous	O
prostatitis	O
(	O
n	O
=	O
10	O
)	O
was	O
the	O
most	O
common	O
followed	O
by	O
tubercular	O
prostatitis	O
(	O
n	O
=	O
5	O
)	O
,	O
posttransurethral	O
resection	O
of	O
the	O
prostate	O
(	O
n	O
=	O
3	O
)	O
,	O
allergic	O
(	O
n	O
=	O
2	O
)	O
,	O
and	O
xanthogranulomatous	O
prostatitis	O
(	O
n	O
=	O
2	O
)	O
.	O

The	O
age	O
range	O
of	O
these	O
patients	O
was	O
between	O
41	O
and	O
75	O
years	O
,	O
with	O
the	O
majority	O
of	O
patients	O
in	O
their	O
7	O
(	O
th	O
)	O
decade	O
.	O

Serum	B-P
prostate-specific	I-P
antigen	I-P
levels	I-P
ranged	O
between	O
0.88	O
ng/mL	O
and	O
19.22	O
ng/mL	O
.	O

Hard	O
and	O
fixed	O
nodules	O
were	O
observed	O
on	O
digital	B-P
rectal	I-P
examination	I-P
in	O
14	O
cases	O
.	O

Transrectal	B-P
ultrasound	I-P
revealed	O
hypoechoic	O
shadows	O
in	O
five	O
cases	O
.	O

Despite	O
present-day	O
advances	O
in	O
imaging	O
modalities	O
and	O
serological	B-P
investigations	I-P
,	O
it	O
is	O
virtually	O
impossible	O
to	O
identify	O
granulomatous	O
prostatitis	O
clinically	O
.	O

Histopathology	O
remains	O
the	O
gold	O
standard	O
in	O
diagnosing	O
the	O
disease	O
.	O

However	O
,	O
assigning	O
an	O
etiologic	O
cause	O
to	O
the	O
wide	O
spectrum	O
of	O
granulomas	O
in	O
granulomatous	O
prostatitis	O
requires	O
a	O
pathologist	O
's	O
expertise	O
and	O
proper	O
clinical	O
correlation	O
for	O
appropriate	O
patient	O
management	O
.	O

Blur	O
perception	O
throughout	O
the	O
visual	O
field	O
in	O
myopia	O
and	O
emmetropia	O
.	O

We	O
evaluated	O
the	O
ability	O
of	O
emmetropic	O
and	O
myopic	O
observers	O
to	O
detect	O
and	O
discriminate	O
blur	O
across	O
the	O
retina	O
under	O
monocular	O
or	O
binocular	O
viewing	O
conditions	O
.	O

We	O
recruited	O
39	O
young	O
(	O
23-30	O
years	O
)	O
healthy	O
adults	O
(	O
n	O
=	O
19	O
myopes	O
)	O
with	O
best-corrected	O
visual	O
acuity	O
0.0	O
LogMAR	O
(	O
20/20	O
)	O
or	O
better	O
in	O
each	O
eye	O
and	O
no	O
binocular	O
or	O
accommodative	O
dysfunction	O
.	O

Monocular	O
and	O
binocular	O
blur	O
discrimination	O
thresholds	O
were	O
measured	O
as	O
a	O
function	O
of	O
pedestal	O
blur	O
using	O
naturalistic	O
stimuli	O
with	O
an	O
adaptive	B-P
4AFC	I-P
procedure	I-P
.	O

Stimuli	O
were	O
presented	O
in	O
a	O
46°	O
diameter	O
window	O
at	O
40	O
cm	O
.	O

Gaussian	O
blur	O
pedestals	O
were	O
confined	O
to	O
an	O
annulus	O
at	O
either	O
0°	O
,	O
4°	O
,	O
8°	O
,	O
or	O
12°	O
eccentricity	O
,	O
with	O
a	O
blur	O
increment	O
applied	O
to	O
only	O
one	O
quadrant	O
of	O
the	O
image	O
.	O

The	O
adaptive	B-P
procedure	I-P
efficiently	O
estimated	O
a	O
dipper	O
shaped	O
blur	O
discrimination	O
threshold	O
function	O
with	O
two	O
parameters	O
:	O
intrinsic	O
blur	O
and	O
blur	O
sensitivity	O
.	O

The	O
amount	O
of	O
intrinsic	O
blur	O
increased	O
for	O
retinal	O
eccentricities	O
beyond	O
4°	O
(	O
p	O
<	O
0.001	O
)	O
and	O
was	O
lower	O
in	O
binocular	O
than	O
monocular	O
conditions	O
(	O
p	O
<	O
0.001	O
)	O
,	O
but	O
was	O
similar	O
across	O
refractive	O
groups	O
(	O
p	O
=	O
0.47	O
)	O
.	O

Blur	O
sensitivity	O
decreased	O
with	O
retinal	O
eccentricity	O
(	O
p	O
<	O
0.001	O
)	O
and	O
was	O
highest	O
for	O
binocular	O
viewing	O
,	O
but	O
only	O
for	O
central	O
vision	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Myopes	O
showed	O
worse	O
blur	O
sensitivity	O
than	O
emmetropes	O
monocularly	O
(	O
p	O
<	O
0.05	O
)	O
but	O
not	O
binocularly	O
(	O
p	O
=	O
0.66	O
)	O
.	O

As	O
expected	O
,	O
blur	O
perception	O
worsens	O
in	O
the	O
visual	O
periphery	O
and	O
binocular	O
summation	O
is	O
most	O
evident	O
in	O
central	O
vision	O
.	O

Furthermore	O
,	O
myopes	O
exhibit	O
a	O
monocular	O
impairment	O
in	O
blur	O
sensitivity	O
that	O
improves	O
under	O
binocular	O
conditions	O
.	O

Implications	O
for	O
the	O
development	O
of	O
myopia	O
are	O
discussed	O
.	O

Antibacterial	O
effect	O
of	O
PEO	O
coating	O
with	O
silver	O
on	O
AA7075	O
.	O

In	O
this	O
work	O
,	O
plasma	O
electrolytic	O
oxidation	O
(	O
PEO	O
)	O
coatings	O
were	O
produced	O
on	O
AA7075	O
using	O
alkaline	O
solution	O
containing	O
silicates	O
compounds	O
and	O
silver	O
micrometric	O
particles	O
in	O
order	O
to	O
give	O
to	O
the	O
coating	O
an	O
antimicrobial	O
effect	O
.	O

In	O
the	O
optic	O
of	O
circular	O
economy	O
,	O
silver	O
chloride	O
derived	O
from	O
the	O
acid	O
pre-treatment	O
of	O
electronic	O
scraps	O
was	O
used	O
as	O
raw	O
material	O
and	O
successively	O
silver	O
powders	O
were	O
synthesized	O
from	O
silver	O
chloride	O
solution	O
using	O
glucose	O
syrup	O
as	O
reducing	O
agent	O
.	O

The	O
coatings	O
were	O
characterized	O
by	O
scanning	O
electron	O
microscope	O
(	O
SEM	O
)	O
,	O
X-ray	B-P
diffraction	I-P
analysis	I-P
(	O
XRD	B-P
)	O
,	O
X-ray	B-P
photoelectron	I-P
spectroscopy	I-P
(	O
XPS	B-P
)	O
,	O
potentiodynamic	B-P
polarization	I-P
test	I-P
and	O
antimicrobial	B-P
tests	I-P
.	O

The	O
results	O
evidenced	O
that	O
the	O
obtained	O
coatings	O
were	O
homogenous	O
and	O
give	O
to	O
the	O
samples	O
higher	O
corrosion	O
resistance	O
than	O
untreated	O
alloy	O
.	O

The	O
silver	O
particles	O
,	O
found	O
both	O
inside	O
and	O
outside	O
of	O
the	O
pores	O
that	O
characterize	O
the	O
PEO	O
layer	O
,	O
produced	O
an	O
efficacious	O
antimicrobial	O
effect	O
both	O
against	O
E.	O
coli	O
and	O
S.	O
aureus	O
.	O

An	O
Efficient	O
and	O
Reliable	O
Statistical	O
Method	O
for	O
Estimating	O
Functional	O
Connectivity	O
in	O
Large	O
Scale	O
Brain	O
Networks	O
Using	O
Partial	O
Correlation	O
.	O

Currently	O
,	O
network-oriented	O
analysis	O
of	O
fMRI	B-P
data	O
has	O
become	O
an	O
important	O
tool	O
for	O
understanding	O
brain	O
organization	O
and	O
brain	O
networks	O
.	O

Among	O
the	O
range	O
of	O
network	O
modeling	O
methods	O
,	O
partial	O
correlation	O
has	O
shown	O
great	O
promises	O
in	O
accurately	O
detecting	O
true	O
brain	O
network	O
connections	O
.	O

However	O
,	O
the	O
application	O
of	O
partial	O
correlation	O
in	O
investigating	O
brain	O
connectivity	O
,	O
especially	O
in	O
large-scale	O
brain	O
networks	O
,	O
has	O
been	O
limited	O
so	O
far	O
due	O
to	O
the	O
technical	O
challenges	O
in	O
its	O
estimation	O
.	O

In	O
this	O
paper	O
,	O
we	O
propose	O
an	O
efficient	O
and	O
reliable	O
statistical	O
method	O
for	O
estimating	O
partial	O
correlation	O
in	O
large-scale	O
brain	O
network	O
modeling	O
.	O

Our	O
method	O
derives	O
partial	O
correlation	O
based	O
on	O
the	O
precision	O
matrix	O
estimated	O
via	O
Constrained	O
L1-minimization	O
Approach	O
(	O
CLIME	O
)	O
,	O
which	O
is	O
a	O
recently	O
developed	O
statistical	O
method	O
that	O
is	O
more	O
efficient	O
and	O
demonstrates	O
better	O
performance	O
than	O
the	O
existing	O
methods	O
.	O

To	O
help	O
select	O
an	O
appropriate	O
tuning	O
parameter	O
for	O
sparsity	O
control	O
in	O
the	O
network	O
estimation	O
,	O
we	O
propose	O
a	O
new	O
Dens-based	O
selection	O
method	O
that	O
provides	O
a	O
more	O
informative	O
and	O
flexible	O
tool	O
to	O
allow	O
the	O
users	O
to	O
select	O
the	O
tuning	O
parameter	O
based	O
on	O
the	O
desired	O
sparsity	O
level	O
.	O

Another	O
appealing	O
feature	O
of	O
the	O
Dens-based	O
method	O
is	O
that	O
it	O
is	O
much	O
faster	O
than	O
the	O
existing	O
methods	O
,	O
which	O
provides	O
an	O
important	O
advantage	O
in	O
neuroimaging	B-P
applications	I-P
.	O

Simulation	O
studies	O
show	O
that	O
the	O
Dens-based	O
method	O
demonstrates	O
comparable	O
or	O
better	O
performance	O
with	O
respect	O
to	O
the	O
existing	O
methods	O
in	O
network	O
estimation	O
.	O

We	O
applied	O
the	O
proposed	O
partial	O
correlation	O
method	O
to	O
investigate	O
resting	B-P
state	I-P
functional	I-P
connectivity	I-P
using	I-P
rs-fMRI	I-P
data	I-P
from	O
the	O
Philadelphia	O
Neurodevelopmental	O
Cohort	O
(	O
PNC	O
)	O
study	O
.	O

Our	O
results	O
show	O
that	O
partial	O
correlation	O
analysis	O
removed	O
considerable	O
between-module	O
marginal	O
connections	O
identified	O
by	O
full	O
correlation	O
analysis	O
,	O
suggesting	O
these	O
connections	O
were	O
likely	O
caused	O
by	O
global	O
effects	O
or	O
common	O
connection	O
to	O
other	O
nodes	O
.	O

Based	O
on	O
partial	O
correlation	O
,	O
we	O
find	O
that	O
the	O
most	O
significant	O
direct	O
connections	O
are	O
between	O
homologous	O
brain	O
locations	O
in	O
the	O
left	O
and	O
right	O
hemisphere	O
.	O

When	O
comparing	O
partial	O
correlation	O
derived	O
under	O
different	O
sparse	O
tuning	O
parameters	O
,	O
an	O
important	O
finding	O
is	O
that	O
the	O
sparse	O
regularization	O
has	O
more	O
shrinkage	O
effects	O
on	O
negative	O
functional	O
connections	O
than	O
on	O
positive	O
connections	O
,	O
which	O
supports	O
previous	O
findings	O
that	O
many	O
of	O
the	O
negative	O
brain	O
connections	O
are	O
due	O
to	O
non-neurophysiological	O
effects	O
.	O

An	O
R	O
package	O
``	O
DensParcorr	O
''	O
can	O
be	O
downloaded	O
from	O
CRAN	O
for	O
implementing	O
the	O
proposed	O
statistical	O
methods	O
.	O

C-MYC	O
-	O
induced	O
upregulation	O
of	O
lncRNA	O
SNHG12	O
regulates	O
cell	O
proliferation	O
,	O
apoptosis	O
and	O
migration	O
in	O
triple-negative	O
breast	O
cancer	O
.	O

Triple-negative	O
breast	O
cancer	O
(	O
TNBC	O
)	O
is	O
one	O
of	O
the	O
most	O
aggressive	O
subtypes	O
of	O
breast	O
cancer	O
,	O
with	O
a	O
significantly	O
higher	O
recurrence	O
and	O
mortality	O
rate	O
.	O

There	O
is	O
an	O
urgent	O
need	O
to	O
uncover	O
the	O
mechanism	O
underlying	O
TNBC	O
and	O
establish	O
therapeutic	O
targets	O
.	O

Long	O
non-coding	O
RNAs	O
(	O
lncRNAs	O
)	O
are	O
involved	O
in	O
a	O
series	O
of	O
biological	O
functions	O
and	O
provide	O
novel	O
insights	O
into	O
the	O
molecular	O
mechanism	O
of	O
cancer	O
.	O

Based	O
on	O
their	O
expression	O
specificity	O
and	O
large	O
number	O
,	O
lncRNAs	O
are	O
likely	O
to	O
serve	O
as	O
the	O
basis	O
for	O
clinical	O
applications	O
in	O
oncology	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
utilized	O
RNA	O
sequencing	B-P
(	O
RNA-seq	B-P
)	O
to	O
explore	O
the	O
lncRNAs	O
expression	O
profiles	O
in	O
TNBC	O
and	O
identified	O
that	O
small	O
nucleolar	O
RNA	O
host	O
gene	O
12	O
(	O
SNHG12	O
)	O
was	O
remarkably	O
increased	O
in	O
TNBC	O
.	O

However	O
,	O
the	O
role	O
of	O
SNHG12	O
in	O
TNBC	O
has	O
not	O
been	O
clarified	O
.	O

Herein	O
,	O
we	O
determine	O
that	O
SNHG12	O
is	O
upregulated	O
in	O
TNBC	O
,	O
and	O
its	O
high	O
expression	O
is	O
significantly	O
correlated	O
with	O
tumor	O
size	O
and	O
lymph	O
node	O
metastasis	O
.	O

Mechanistic	O
investigations	O
show	O
that	O
SNHG12	O
is	O
a	O
direct	O
transcriptional	O
target	O
of	O
c-MYC	O
.	O

Silencing	O
SNHG12	O
expression	O
inhibits	O
TNBC	O
cells	O
proliferation	O
and	O
apoptosis	O
promotion	O
,	O
whereas	O
SNHG12	O
overexpression	O
has	O
the	O
opposite	O
effect	O
.	O

In	O
addition	O
,	O
we	O
reveal	O
that	O
SNHG12	O
may	O
promote	O
cells	O
migration	O
by	O
regulating	O
MMP13	O
expression	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
it	O
is	O
the	O
first	O
report	O
indicating	O
that	O
SNHG12	O
is	O
involved	O
in	O
breast	O
cancer	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
SNHG12	O
contributes	O
to	O
the	O
oncogenic	O
potential	O
of	O
TNBC	O
and	O
may	O
be	O
a	O
promising	O
therapeutic	O
target	O
.	O

Dynamic	O
disorder	O
can	O
explain	O
non-exponential	O
kinetics	O
of	O
fast	O
protein	O
mechanical	O
unfolding	O
.	O

Protein	O
unfolding	O
often	O
does	O
not	O
obey	O
a	O
simple	O
two-state	O
behavior	O
.	O

Previous	O
single	B-P
molecule	I-P
force	I-P
spectroscopy	I-P
studies	B-P
demonstrated	O
stretched	O
exponential	O
kinetics	O
of	O
protein	O
unfolding	O
under	O
a	O
constant	O
pulling	O
force	O
,	O
the	O
molecular	O
origin	O
of	O
which	O
remains	O
subject	O
to	O
debate	O
.	O

We	O
here	O
set	O
out	O
to	O
extensively	O
sample	O
the	O
mechanical	O
unfolding	O
of	O
ubiquitin	O
and	O
NuG2	O
by	O
Molecular	O
Dynamics	O
(	O
MD	O
)	O
simulations	O
.	O

Both	O
proteins	O
show	O
kinetics	O
best	O
fit	O
by	O
stretched	O
exponentials	O
,	O
with	O
stretching	O
exponents	O
similar	O
to	O
those	O
found	O
in	O
experiments	O
,	O
even	O
though	O
static	O
disorder	O
is	O
absent	O
in	O
our	O
short	O
MD	O
simulations	O
.	O

Instead	O
,	O
we	O
can	O
ascribe	O
non-exponential	O
kinetics	O
to	O
dynamic	O
disorder	O
,	O
due	O
to	O
conformational	O
fluctuations	O
on	O
the	O
nanosecond	O
timescale	O
.	O

Our	O
study	O
highlights	O
the	O
general	O
role	O
of	O
dynamic	O
disorder	O
in	O
protein	O
kinetics	O
on	O
a	O
broad	O
range	O
of	O
time	O
scales	O
even	O
including	O
those	O
probed	O
in	O
MD	O
simulations	O
.	O

Alleviation	O
of	O
hepatic	O
fat	O
accumulation	O
by	O
betaine	O
involves	O
reduction	O
of	O
homocysteine	O
via	O
up-regulation	O
of	O
betaine-homocysteine	O
methyltransferase	O
(	O
BHMT	O
)	O
.	O

We	O
investigated	O
the	O
anti-lipogenic	O
effect	O
of	O
betaine	O
in	O
rats	O
fed	O
methionine	O
and	O
choline	O
-	O
deficient	O
diet	O
(	O
MCD	O
)	O
.	O

Intake	O
of	O
MCD	O
for	O
3	O
wk	O
resulted	O
in	O
a	O
significant	O
accumulation	O
of	O
hepatic	O
lipids	O
,	O
which	O
was	O
prevented	O
by	O
betaine	O
supplementation	O
in	O
drinking	O
water	O
(	O
1	O
%	O
)	O
.	O

Phosphorylation	O
of	O
AMP-activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
,	O
acetyl-CoA	O
carboxylase	O
(	O
ACC	O
)	O
,	O
sterol	O
regulatory	O
element-binding	O
protein	O
1c	O
(	O
SREBP-1c	O
)	O
,	O
and	O
liver	O
kinase	O
B1	O
(	O
LKB1	O
)	O
was	O
inhibited	O
by	O
MCD	O
intake	O
,	O
and	O
these	O
changes	O
were	O
all	O
inhibited	O
by	O
betaine	O
feeding	O
.	O

Meanwhile	O
,	O
betaine	O
supplementation	O
reversed	O
the	O
reduction	O
of	O
methionine	O
and	O
S-adenosylmethionine	O
(	O
SAM	O
)	O
,	O
and	O
the	O
elevation	O
of	O
homocysteine	B-P
levels	I-P
in	O
the	O
liver	O
,	O
which	O
could	O
be	O
attributable	O
to	O
the	O
induction	O
of	O
betaine-homocysteine	O
methyltransfease	O
(	O
BHMT	O
)	O
and	O
methionine	O
adenosyltransferase	O
(	O
MAT	O
)	O
.	O

Different	O
cell	O
lines	O
were	O
used	O
to	O
clarify	O
the	O
role	O
of	O
homocysteine	O
on	O
activation	O
of	O
the	O
AMPK	O
pathway	O
.	O

Homocysteine	O
treatment	O
decreased	O
pAMPK	O
,	O
pACC	O
,	O
pSREBP-1c	O
and	O
pLKB1	O
in	O
HepG2	O
cells	O
.	O

Metformin	O
-	O
induced	O
activation	O
of	O
AMPK	O
was	O
also	O
inhibited	O
by	O
homocysteine	O
.	O

Treatment	O
with	O
hydroxylamine	O
,	O
a	O
cystathionine	O
β-synthase	O
inhibitor	O
,	O
resulted	O
in	O
a	O
reduction	O
of	O
pAMPK	O
,	O
pACC	O
and	O
pSREBP-1c	O
,	O
accompanied	O
by	O
an	O
elevation	O
of	O
intracellular	O
homocysteine	O
.	O

Betaine	O
treatment	O
prevented	O
the	O
homocysteine	O
-	O
induced	O
reduction	O
of	O
pAMPK	O
,	O
pACC	O
,	O
pSREBP-1c	O
and	O
pLKB1	O
in	O
H4IIE	O
cells	O
,	O
but	O
not	O
in	O
HepG2	O
cells	O
.	O

Also	O
the	O
elevation	O
of	O
cellular	O
homocysteine	O
and	O
inhibition	O
of	O
protein	O
expression	O
of	O
BHMT	O
were	O
prevented	O
by	O
betaine	O
only	O
in	O
H4IIE	O
cells	O
which	O
express	O
BHMT	O
.	O

The	O
results	O
suggest	O
that	O
the	O
beneficial	O
effect	O
of	O
betaine	O
against	O
hepatic	O
lipid	O
accumulation	O
may	O
be	O
attributed	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
depletion	O
of	O
homocysteine	O
via	O
up-regulation	O
of	O
BHMT	O
in	O
hepatocytes	O
.	O

Novel	O
antibody	O
probes	O
for	O
the	O
characterization	O
of	O
endosialin	O
/	O
TEM-1	O
.	O

Endosialin	O
(	O
Tumor	O
Endothelial	O
Marker-1	O
(	O
TEM-1	O
)	O
,	O
CD248	O
)	O
is	O
primarily	O
expressed	O
on	O
pericytes	O
of	O
tumor	O
-	O
associated	O
microvasculature	O
,	O
tumor	O
-	O
associated	O
stromal	O
cells	O
and	O
directly	O
on	O
tumors	O
of	O
mesenchymal	O
origin	O
,	O
including	O
sarcoma	O
and	O
melanoma	O
.	O

While	O
the	O
function	O
of	O
endosialin/TEM-1	O
is	O
incompletely	O
understood	O
,	O
studies	O
have	O
suggested	O
a	O
role	O
in	O
supporting	O
tumor	O
growth	O
and	O
invasion	O
thus	O
making	O
it	O
an	O
attractive	O
therapeutic	O
target	O
.	O

In	O
an	O
effort	O
to	O
further	O
understand	O
its	O
role	O
in	O
cancer	O
,	O
we	O
previously	O
developed	O
a	O
humanized	O
anti-endosialin/TEM-1	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
,	O
called	O
ontuxizumab	O
(	O
MORAb-004	O
)	O
for	O
testing	O
in	O
preclinical	O
and	O
clinical	O
studies	O
.	O

We	O
herein	O
report	O
on	O
the	O
generation	O
of	O
an	O
extensive	O
panel	O
of	O
recombinant	O
endosialin/TEM-1	O
protein	O
extracellular	O
domain	O
(	O
ECD	O
)	O
fragments	O
and	O
novel	O
mAbs	O
against	O
ECD	O
motifs	O
.	O

The	O
domain-specific	O
epitopes	O
were	O
mapped	O
against	O
ECD	O
sub-domains	O
to	O
identify	O
those	O
that	O
can	O
detect	O
distinct	O
structural	O
motifs	O
and	O
can	O
be	O
potentially	O
formatted	O
as	O
probes	O
suitable	O
for	O
diagnostic	O
and	O
functional	O
studies	O
.	O

A	O
number	O
of	O
mAbS	O
were	O
shown	O
to	O
cross-react	B-P
with	O
the	O
murine	O
and	O
human	O
protein	O
,	O
potentially	O
allowing	O
their	O
use	O
in	O
human	O
animal	O
models	O
and	O
corresponding	O
clinical	O
trials	O
.	O

In	O
addition	O
,	O
pairing	O
of	O
several	O
mAbs	O
supported	O
their	O
use	O
in	O
immunoassays	B-P
that	O
can	O
detect	O
soluble	O
endosialin/TEM-1	O
(	O
sEND	O
)	O
in	O
the	O
serum	O
of	O
healthy	O
subjects	O
and	O
cancer	O
patients	O
.	O

Transparent	O
nanostructured	O
cellulose	O
acetate	O
films	O
based	O
on	O
the	O
self	O
assembly	O
of	O
PEO-b-PPO-b-PEO	O
block	O
copolymer	O
.	O

In	O
this	O
study	O
fabrication	O
and	O
characterization	O
of	O
transparent	O
nanostructured	O
composite	O
films	O
based	O
on	O
cellulose	O
triacetate	O
(	O
CTA	O
)	O
and	O
poly	O
(	O
ethylene	O
oxide	O
)	O
-b-poly	O
(	O
propylene	O
oxide	O
)	O
-b-poly	O
(	O
ethylene	O
oxide	O
)	O
(	O
EPE	O
)	O
triblock	O
copolymer	O
were	O
presented	O
.	O

The	O
effect	O
of	O
the	O
addition	O
of	O
EPE	O
triblock	O
copolymer	O
on	O
the	O
thermal	B-P
stability	I-P
,	O
morphology	O
,	O
and	O
mechanical	O
properties	O
of	O
cellulose	O
triacetate	O
films	O
was	O
investigated	O
.	O

The	O
triblock	O
EPE	O
was	O
chosen	O
since	O
PEO	O
blocks	O
interact	O
favorably	O
with	O
CTA	O
,	O
whereas	O
,	O
PPO	O
blocks	O
remain	O
immiscible	O
which	O
provokes	O
a	O
microphase	O
separation	O
.	O

This	O
allows	O
to	O
obtain	O
EPE	O
/	O
CTA	O
composite	O
films	O
with	O
ordered	O
microphase-separated	O
structures	O
where	O
PPO	O
spherical	O
microdomains	O
are	O
well-dispersed	O
in	O
PEO	O
/	O
CTA	O
matrix	O
by	O
simple	O
solvent	O
-	O
evaporation	O
process	O
.	O

During	O
this	O
process	O
,	O
PEO	O
block	O
chains	O
selectively	O
interact	O
with	O
CTA	O
by	O
strong	O
interpolymer	O
hydrogen-bonding	O
while	O
PPO	O
block	O
microseparated	O
.	O

The	O
addition	O
even	O
40wt	O
%	O
of	O
EPE	O
leads	O
to	O
nanostructured	O
EPE	O
/	O
CTA	O
composite	O
.	O

The	O
cytotoxicity	B-P
assay	I-P
of	O
CTA	O
and	O
EPE	O
/	O
CTA	O
composite	O
films	O
confirm	O
non-toxic	O
character	O
of	O
designed	O
transparent	O
nanostructured	O
composites	O
based	O
on	O
sustainable	O
matrices	O
.	O

Bactec™	O
blood	O
culture	O
bottles	O
allied	O
to	O
MALDI-TOF	O
mass	O
spectrometry	O
:	O
rapid	O
etiologic	O
diagnosis	O
of	O
bacterial	O
endophthalmitis	O
.	O

Matrix-assisted	O
laser	O
desorption	O
ionization-time	O
of	O
flight	O
(	O
MALDI-TOF	O
)	O
mass	O
spectrometry	O
(	O
MS	O
)	O
has	O
been	O
used	O
for	O
direct	O
identification	O
of	O
pathogens	O
from	O
blood-inoculated	B-P
blood	O
culture	O
bottles	O
(	O
BCBs	O
)	O
.	O

We	O
showed	O
that	O
MALDI-TOF	O
MS	O
is	O
an	O
useful	O
technique	O
for	O
rapid	O
identification	O
of	O
the	O
causative	O
agents	O
of	O
endophthalmitis	O
from	O
vitreous	O
humor	O
-	O
inoculated	O
BCBs	O
with	O
a	O
simple	O
protocol	O
.	O

Effective	O
mercury	O
(	O
II	O
)	O
bioremoval	O
from	O
aqueous	O
solution	O
,	O
and	O
its	O
electrochemical	O
determination	O
.	O

This	O
work	O
proposed	O
mercury	O
elimination	O
using	O
agricultural	O
waste	O
(	O
Allium	O
Cepa	O
L	O
.	O
)	O
.	O

The	O
biomass	O
removed	O
99.4	O
%	O
of	O
mercury	O
,	O
following	O
a	O
pseudo-second	O
order	O
kinetics	O
(	O
r	O
(	O
2	O
)	O
=	O
0.9999	O
)	O
.	O

The	O
Langmuir	O
model	O
was	O
adequately	O
fitted	O
to	O
the	O
adsorption	O
isotherm	O
,	O
thereby	O
obtaining	O
the	O
maximum	O
mercury	O
adsorption	B-P
capacity	O
of	O
111.1	O
±	O
0.3	O
mg	O
g	O
(	O
-1	O
)	O
.	O

The	O
biomass	O
showed	O
high	O
density	O
of	O
strong	O
mercury	O
chelating	O
groups	O
,	O
thus	O
making	O
it	O
economically	O
attractive	O
.	O

Also	O
,	O
the	O
implementation	O
of	O
a	O
mercury	O
-	O
selective	B-P
electrode	I-P
for	O
continuous	O
determination	B-P
in	O
real	O
time	O
is	O
proposed	O
;	O
this	O
electrode	O
replaces	O
techniques	O
like	O
atomic	B-P
absorption	I-P
spectroscopy	I-P
,	O
thus	O
it	O
can	O
be	O
applied	O
to	O
real	O
time	O
studies	O
.	O

This	O
work	O
therefore	O
presents	O
a	O
new	O
perspective	O
for	O
removing	O
mercury	O
(	O
II	O
)	O
from	O
contaminated	O
water	O
for	O
environmental	O
remediation	O
.	O

Zebrafish	O
akt2	O
is	O
essential	O
for	O
survival	O
,	O
growth	O
,	O
bone	O
development	O
,	O
and	O
glucose	O
homeostasis	O
.	O

As	O
one	O
of	O
three	O
akt	O
isoforms	O
,	O
akt2	O
plays	O
a	O
key	O
role	O
in	O
the	O
regulation	O
of	O
widely	O
divergent	O
cellular	O
processes	O
in	O
mammals	O
.	O

However	O
,	O
its	O
role	O
and	O
underlying	O
mechanisms	O
in	O
zebrafish	O
remain	O
largely	O
unknown	O
.	O

To	O
elucidate	O
the	O
function	O
of	O
akt2	O
in	O
zebrafish	O
,	O
we	O
generated	O
zebrafish	O
lacking	O
akt2	O
gene	O
via	O
CRISPR/Cas9	O
technology	O
.	O

Akt2	O
-	O
null	O
zebrafish	O
exhibit	O
partial	O
lethality	O
and	O
severe	O
growth	O
deficiency	O
,	O
which	O
is	O
different	O
from	O
those	O
observed	O
in	O
akt2	O
-	O
null	O
mice	O
.	O

Furthermore	O
,	O
akt2	O
-	O
null	O
zebrafish	O
display	O
deficiency	O
in	O
fin	O
ray	O
development	O
,	O
but	O
their	O
cartilage	O
is	O
not	O
affected	O
.	O

Similar	O
to	O
observations	O
in	O
akt2	O
-	O
null	O
mice	O
,	O
akt2	O
-	O
null	O
zebrafish	O
display	O
impaired	O
glucose	O
homeostasis	O
.	O

However	O
,	O
in	O
contrast	O
to	O
that	O
in	O
akt2	O
-	O
null	O
mice	O
,	O
insulin	B-P
level	I-P
is	O
lower	O
in	O
akt2	O
-	O
null	O
zebrafish	O
,	O
implicating	O
the	O
symptoms	O
of	O
type	O
I	O
diabetes	O
exhibited	O
in	O
akt2	O
-	O
null	O
zebrafish	O
.	O

In	O
addition	O
,	O
transcriptome	O
analysis	O
reveals	O
that	O
the	O
genes	O
involved	O
in	O
metabolism	O
and	O
osteogenesis	O
are	O
disturbed	O
in	O
akt2	O
-	O
null	O
zebrafish	O
.	O

Taken	O
together	O
,	O
these	O
data	O
not	O
only	O
support	O
an	O
important	O
role	O
of	O
akt2	O
in	O
zebrafish	O
survival	O
,	O
growth	O
,	O
bone	O
development	O
and	O
glucose	O
homeostasis	O
,	O
but	O
also	O
suggest	O
that	O
akt2	O
has	O
divergent	O
functions	O
between	O
mice	O
and	O
zebrafish	O
,	O
even	O
though	O
they	O
are	O
evolutionarily	O
conserved	O
.	O

Combination	O
of	O
telmisartan	O
with	O
sildenafil	O
ameliorate	O
progression	O
of	O
diabetic	O
nephropathy	O
in	O
streptozotocin	O
-	O
induced	O
diabetic	O
model	O
.	O

Diabetic	O
nephropathy	O
(	O
DN	O
)	O
is	O
a	O
leading	O
cause	O
of	O
end-stage	O
renal	O
disease	O
in	O
the	O
world	O
.	O

Several	O
signaling	O
pathways	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
DN	O
including	O
elevation	O
in	O
level	O
of	O
angiotensin	O
II	O
,	O
formation	O
of	O
advanced	O
glycation	O
end	O
products	O
(	O
AGE	O
)	O
,	O
activation	O
of	O
protein	O
kinase	O
c	O
(	O
PKC	O
)	O
,	O
and	O
lipid	O
accumulation	O
.	O

These	O
pathways	O
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	O
stress	O
,	O
increasing	O
expression	O
of	O
transforming	O
growth	O
factor	O
beta-1	O
(	O
TGF-β	O
1	O
)	O
and	O
release	O
of	O
interleukins	O
and	O
adhesion	O
molecules	O
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	O
pathway	O
to	O
ameliorate	O
the	O
progression	O
of	O
DN	O
.	O

In	O
the	O
present	O
study	O
,	O
white	O
male	O
rats	O
(	O
N=48	O
)	O
were	O
divided	O
into	O
six	O
groups	O
(	O
8	O
rats	O
each	O
)	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	O
control	O
and	O
a	O
control	O
vehicle	O
group	O
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	O
by	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
Streptozotocin	O
(	O
STZ	O
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
DN	O
.	O

Thereafter	O
,	O
the	O
rats	O
were	O
divided	O
into	O
DN	O
group	O
,	O
DN	O
group	O
receiving	O
Telmisartan	O
or	O
Sildenafil	O
or	O
Telmisartan	O
Sildenafil	O
combination	O
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	O
samples	O
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	O
,	O
animals	O
were	O
then	O
euthanized	O
,	O
blood	O
and	O
tissue	O
samples	O
were	O
collected	O
for	O
measurement	B-P
of	I-P
Blood	I-P
glucose	I-P
,	O
BUN	B-P
,	O
S.Cr	B-P
,	O
LDL	B-P
,	O
NO	B-P
,	O
TGF-β1	B-P
,	O
IL-1β	B-P
,	O
AGEPs	B-P
,	O
and	O
SOD	B-P
.	O

The	O
combination	O
therapy	O
showed	O
significant	O
decrease	O
in	O
BUN	O
,	O
S.Cr	O
,	O
LDL	O
,	O
TGF-β1	O
,	O
IL-1β	O
,	O
Proteinuria	O
and	O
AGEPs	O
and	O
significant	O
increase	O
in	O
SOD	O
and	O
NO	O
.	O

The	O
findings	O
showed	O
that	O
combination	O
therapy	O
was	O
able	O
to	O
ameliorate	O
DN	O
and	O
that	O
the	O
effects	O
were	O
superior	O
to	O
the	O
single	O
drugs	O
alone	O
.	O

Transparent	O
bactericidal	O
ZnO	O
nanocoatings	O
.	O

Thin	O
bactericidal	O
ZnO	O
coatings	O
prepared	O
with	O
the	O
polymer-salt	O
method	O
are	O
shown	O
to	O
be	O
highly	O
transparent	O
in	O
the	O
visible	O
.	O

The	O
spectral	O
measurements	O
and	O
XRD	B-P
analysis	I-P
data	O
show	O
that	O
coatings	O
prepared	O
are	O
formed	O
by	O
ZnO	O
nanoparticles	O
~	O
10	O
nm	O
in	O
size	O
.	O

The	O
coatings	O
demonstrate	O
the	O
bactericidal	O
effect	O
against	O
the	O
gram-positive	O
Staphylococcus	O
aureus	O
ATCC	O
209P	O
and	O
gram-negative	O
Escherichia	O
coli	O
ATCC	O
25922	O
bacteria	O
both	O
under	O
the	O
natural	O
light	O
and	O
in	O
the	O
darkness	O
.	O

Identification	O
of	O
potential	O
predictive	O
markers	O
of	O
dexamethasone	O
resistance	O
in	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Response	O
to	O
dexamethasone	O
(	O
DEXA	O
)	O
,	O
as	O
a	O
hallmark	O
drug	O
in	O
the	O
treatment	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
is	O
one	O
of	O
the	O
pivotal	O
prognostic	O
factors	O
in	O
the	O
prediction	O
of	O
outcome	O
in	O
ALL	O
.	O

Identification	O
of	O
predictive	O
markers	O
of	O
chemoresistance	O
is	O
beneficial	O
to	O
selecting	O
of	O
the	O
best	O
therapeutic	O
protocol	O
with	O
the	O
lowest	O
effect	O
adverse	O
.	O

Hence	O
,	O
we	O
aimed	O
to	O
find	O
drug	O
targets	O
using	O
the	O
2DE	B-P
/	O
MS	B-P
proteomics	B-P
study	I-P
of	O
a	O
DEXA	O
-	O
resistant	O
cell	O
line	O
(	O
REH	O
)	O
as	O
a	O
model	O
for	O
poor	O
DEXA	O
responding	O
patients	O
before	O
and	O
after	O
drug	O
treatment	O
.	O

Using	O
the	O
proteomic	B-P
methods	I-P
,	O
three	O
differentially	O
expressed	O
proteins	O
were	O
detected	O
,	O
including	O
voltage	O
dependent	O
anion	O
channel	O
1	O
(	O
VDAC1	O
)	O
,	O
sorting	O
Nexin	O
3	O
(	O
SNX3	O
)	O
,	O
and	O
prefoldin	O
subunit	O
6	O
(	O
PFDN6	O
)	O
.	O

We	O
observed	O
low	O
expression	O
of	O
three	O
proteins	O
after	O
DEXA	O
treatment	O
in	O
REH	O
cells	O
.	O

We	O
subsequently	O
verified	O
low	O
expression	O
of	O
resulted	O
proteins	O
at	O
the	O
mRNA	O
level	O
using	O
the	O
quantitative	B-P
PCR	I-P
method	I-P
.	O

These	O
proteins	O
are	O
promising	O
proteins	O
because	O
of	O
their	O
important	O
roles	O
in	O
drug	O
resistance	O
and	O
regulation	O
of	O
apoptosis	O
(	O
VDAC1	O
)	O
,	O
protein	O
trafficking	O
(	O
SNX3	O
)	O
,	O
and	O
protein	O
folding	O
(	O
PFDN6	O
)	O
.	O

Additionally	O
,	O
mRNA	O
expression	O
level	O
of	O
these	O
proteins	O
was	O
assessed	O
in	O
17	O
bone	O
marrow	O
samples	O
from	O
children	O
with	O
newly	O
diagnosed	O
ALL	O
and	O
7	O
non-cancerous	O
samples	O
as	O
controls	O
.	O

The	O
results	O
indicated	O
that	O
independent	O
of	O
the	O
molecular	O
subtypes	O
of	O
leukemia	O
,	O
mRNA	O
expression	O
of	O
VDAC1	O
,	O
SNX3	O
,	O
and	O
PFDN6	O
decreased	O
in	O
ALL	O
samples	O
compared	O
with	O
non-cancerous	O
samples	O
particularly	O
in	O
VDAC1	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Additionally	O
,	O
mRNA	O
expression	O
of	O
three	O
proteins	O
was	O
also	O
declined	O
in	O
high-risk	O
samples	O
compared	O
with	O
standard	O
risk	O
cases	O
.	O

These	O
results	O
demonstrated	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
these	O
proteins	O
in	O
childhood	O
ALL	O
.	O

Furthermore	O
,	O
investigation	O
of	O
protein-protein	O
interaction	O
using	O
STRING	O
database	O
indicated	O
that	O
these	O
proteins	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
NR3C1	O
as	O
dexamethasone	O
target	O
.	O

In	O
conclusion	O
,	O
our	O
proteomic	B-P
study	I-P
in	O
DEXA	O
resistant	O
leukemic	O
cells	O
revealed	O
VDAC1	O
,	O
SNX3	O
,	O
and	O
PFDN6	O
are	O
promising	O
proteins	O
that	O
might	O
serve	O
as	O
potential	O
biomarkers	O
of	O
prognosis	O
and	O
chemotherapy	O
in	O
childhood	O
ALL	O
.	O

Radiologic	B-P
assessment	I-P
of	O
quality	O
of	O
root	O
canal	O
fillings	O
and	O
periapical	O
status	O
in	O
an	O
Austrian	O
subpopulation	O
-	O
An	O
observational	O
study	O
.	O

Progress	O
in	O
endodontic	O
techniques	O
and	O
methodological	O
advances	O
have	O
altered	O
root	O
canal	O
therapy	O
over	O
the	O
last	O
decades	O
.	O

These	O
techniques	O
and	O
methods	O
need	O
periodical	O
documentation	O
.	O

This	O
observational	O
study	O
determined	O
the	O
current	O
prevalence	O
of	O
endodontic	O
treatments	O
,	O
and	O
investigated	O
the	O
relationship	O
of	O
various	O
factors	O
with	O
the	O
periapical	O
status	O
in	O
a	O
Lower	O
Austrian	O
subpopulation	O
.	O

One	O
thousand	O
orthopantomograms	B-P
of	O
first-time	O
university	O
adult	O
patients	O
radiographed	B-P
at	O
an	O
outpatient	O
clinic	O
were	O
evaluated	O
.	O

For	O
each	O
tooth	O
,	O
the	O
presence	O
of	O
periradicular	O
pathosis	O
and/or	O
endodontic	O
treatment	O
was	O
recorded	O
,	O
as	O
was	O
the	O
quality	O
of	O
(	O
post-	O
)	O
endodontic	O
treatment	O
(	O
homogeneity	O
and	O
length	O
of	O
root	O
canal	O
fillings	O
;	O
preparation	O
failures	O
;	O
posts	O
/	O
screws	O
;	O
apicoectomies	O
;	O
coronal	O
restorations	O
)	O
.	O

Two	O
evaluators	O
,	O
blinded	O
to	O
each	O
other	O
,	O
scored	O
all	O
teeth	O
.	O

In	O
cases	O
of	O
disagreement	O
,	O
they	O
joined	O
for	O
a	O
consensus	O
score	O
.	O

In	O
all	O
,	O
22,586	O
teeth	O
were	O
counted	O
.	O

Of	O
these	O
,	O
2,907	O
teeth	O
(	O
12.9	O
%	O
)	O
had	O
periapical	O
pathosis	O
,	O
while	O
2,504	O
teeth	O
had	O
undergone	O
root	O
canal	O
treatment	O
.	O

Of	O
the	O
endodontically	O
treated	O
teeth	O
,	O
52	O
%	O
showed	O
no	O
radiographic	O
signs	O
of	O
apical	O
periodontitis	O
,	O
while	O
44.9	O
%	O
had	O
overt	O
apical	O
lesions	O
,	O
and	O
3,1	O
%	O
revealed	O
widened	O
periodontal	O
ligament	O
space	O
.	O

The	O
majority	O
of	O
the	O
root	O
canal	O
fillings	O
was	O
inhomogeneous	O
(	O
70.4	O
%	O
)	O
;	O
75.4	O
%	O
were	O
rated	O
too	O
short	O
,	O
and	O
3.8	O
%	O
too	O
long	O
.	O

The	O
presence	O
of	O
apical	O
pathosis	O
was	O
significantly	O
correlated	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
2.556	O
[	O
confidence	O
interval	O
(	O
CI	O
)	O
2.076-3.146	O
]	O
;	O
P	O
<	O
0.0001	O
)	O
with	O
poor	O
root	O
canal	O
fillings	O
(	O
length	O
and	O
homogeneity	O
)	O
.	O

Posts	O
or	O
screws	O
positively	O
affected	O
periapical	O
status	O
(	O
OR	O
1.853	O
[	O
CI	O
1.219-2.819	O
]	O
;	O
P	O
=	O
0.004	O
)	O
,	O
but	O
endodontically	O
treated	O
posterior	O
teeth	O
were	O
infrequently	O
restored	O
(	O
posts	O
,	O
7.5	O
%	O
;	O
screws	O
,	O
2.7	O
%	O
)	O
.	O

Best	O
results	O
were	O
found	O
for	O
teeth	O
with	O
both	O
appropriate	O
endodontic	O
treatment	O
and	O
adequate	O
coronal	O
restoration	O
.	O

A	O
high	O
prevalence	O
of	O
periradicular	O
radiolucencies	O
was	O
observed	O
with	O
root	O
canal	O
filled	O
teeth	O
,	O
along	O
with	O
high	O
numbers	O
of	O
unmet	O
treatment	O
needs	O
.	O

Periapical	O
health	O
was	O
associated	O
with	O
adequate	O
root	O
canal	O
obturation	O
and	O
high-grade	O
postendodontic	O
restorations	O
,	O
and	O
quality	O
regarding	O
these	O
latter	O
aspects	O
is	O
considered	O
mandatory	O
to	O
promote	O
periapical	O
health	O
.	O

Comparison	O
of	O
semiologies	O
between	O
tilt-induced	O
psychogenic	O
nonsyncopal	O
collapse	O
and	O
psychogenic	O
nonepileptic	O
seizures	O
.	O

We	O
sought	O
to	O
characterize	O
the	O
clinical	O
features	O
of	O
tilt-induced	O
psychogenic	O
nonsyncopal	O
collapse	O
(	O
PNSC	O
)	O
from	O
a	O
cohort	O
of	O
young	O
patients	O
and	O
to	O
compare	O
the	O
semiologies	O
between	O
PNSC	O
and	O
EEG	B-P
-confirmed	O
psychogenic	O
nonepileptic	O
seizures	O
(	O
PNES	O
)	O
.	O

A	O
PNSC	O
diagnosis	O
was	O
made	O
if	O
a	O
clinical	O
event	O
occurred	O
during	O
tilt-table	B-P
testing	I-P
that	O
the	O
patient	O
regarded	O
as	O
fainting	O
,	O
but	O
neither	O
hypotension	O
nor	O
EEG	B-P
changes	O
were	O
present	O
.	O

A	O
diagnosis	O
of	O
PNSC	O
was	O
made	O
in	O
17.6	O
%	O
of	O
all	O
patients	O
referred	O
during	O
the	O
15-month	O
study	O
period	O
.	O

Cohorts	O
with	O
psychogenic	O
nonsyncopal	O
collapse	O
(	O
n=40	O
)	O
and	O
PNES	O
(	O
n=40	O
)	O
did	O
not	O
differ	O
in	O
age	O
(	O
15.5±2.2	O
versus	O
14.6±2.7	O
,	O
p=.11	O
)	O
or	O
female	O
gender	O
(	O
80	O
%	O
versus	O
72.5	O
%	O
,	O
p=.43	O
)	O
.	O

Psychogenic	O
nonsyncopal	O
collapse	O
events	O
were	O
briefer	O
than	O
PNES	O
events	O
(	O
median	O
:	O
45	O
versus	O
201.5s	O
,	O
p	O
<	O
.001	O
)	O
.	O

Negative	O
motor	O
signs	O
(	O
head	O
drop	O
,	O
body	O
limpness	O
)	O
predominated	O
in	O
PNSC	O
(	O
85	O
%	O
versus	O
20	O
%	O
,	O
p	O
<	O
.001	O
)	O
,	O
while	O
the	O
positive	O
motor	O
signs	O
of	O
convulsion	O
occurred	O
more	O
often	O
with	O
PNES	O
(	O
90	O
%	O
versus	O
30	O
%	O
,	O
p	O
<	O
.001	O
)	O
.	O

Behavioral	O
arrest	O
(	O
25	O
%	O
versus	O
32.5	O
%	O
,	O
p=.46	O
)	O
and	O
eye	O
closure	O
(	O
85	O
%	O
versus	O
72.5	O
%	O
,	O
p=.21	O
)	O
did	O
not	O
differ	O
between	O
PNSC	O
and	O
PNES	O
.	O

Patients	O
with	O
PNSC	O
were	O
more	O
likely	O
to	O
be	O
tearful	O
before	O
(	O
30	O
%	O
versus	O
7.5	O
%	O
,	O
p=.02	O
)	O
and	O
after	O
(	O
62.5	O
%	O
versus	O
7.5	O
%	O
,	O
p	O
<	O
.001	O
)	O
an	O
event	O
.	O

In	O
conclusion	O
,	O
although	O
overlap	O
exists	O
,	O
the	O
features	O
of	O
PNSC	O
generally	O
appear	O
similar	O
to	O
neurally	O
mediated	O
syncope	O
,	O
while	O
the	O
features	O
of	O
PNES	O
generally	O
appear	O
similar	O
to	O
epileptic	O
seizures	O
.	O

Psychogenic	O
nonsyncopal	O
collapse	O
and	O
PNES	O
likely	O
represent	O
similar	O
disorders	O
that	O
differ	O
primarily	O
by	O
clinical	O
semiologies	O
and	O
referral	O
patterns	O
.	O

MicroRNA	O
101b	O
Is	O
Downregulated	O
in	O
the	O
Prefrontal	O
Cortex	O
of	O
a	O
Genetic	O
Model	O
of	O
Depression	O
and	O
Targets	O
the	O
Glutamate	O
Transporter	O
SLC1A1	O
(	O
EAAT3	O
)	O
in	O
Vitro	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
regulatory	O
molecules	O
that	O
cause	O
translational	O
repression	O
by	O
base	O
pairing	O
with	O
target	O
mRNAs	O
.	O

Cumulative	O
evidence	O
suggests	O
that	O
changes	O
in	O
miRNA	O
expression	O
may	O
in	O
part	O
underlie	O
the	O
pathophysiology	O
and	O
treatment	O
of	O
neuropsychiatric	O
disorders	O
,	O
including	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

A	O
miRNA	O
expression	O
assay	B-P
that	O
can	O
simultaneously	O
detect	O
423	O
rat	O
miRNAs	O
(	O
miRBase	O
v.17	O
)	O
was	O
used	O
to	O
profile	B-P
the	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
of	O
a	O
genetic	O
rat	O
model	O
of	O
MDD	O
(	O
the	O
Flinders	O
Sensitive	O
Line	O
[	O
FSL	O
]	O
)	O
and	O
the	O
controls	O
,	O
the	O
Flinders	O
Resistant	O
Line	O
(	O
FRL	O
)	O
.	O

Gene	O
expression	O
data	O
from	O
the	O
PFC	O
of	O
FSL	O
/	O
FRL	O
animals	O
(	O
GEO	O
accession	O
no	O
.	O

GSE20388	O
)	O
were	O
used	O
to	O
guide	O
mRNA	O
target	O
selection	O
.	O

Luciferase	B-P
reporter	I-P
assays	I-P
were	O
used	O
to	O
verify	O
miRNA	O
targets	O
in	O
vitro	O
.	O

We	O
identified	O
23	O
miRNAs	O
that	O
were	O
downregulated	O
in	O
the	O
PFC	O
of	O
the	O
FSL	O
model	O
compared	O
with	O
controls	O
.	O

Interestingly	O
,	O
one	O
of	O
the	O
identified	O
miRNAs	O
(	O
miR-101b	O
)	O
is	O
highly	O
conserved	O
between	O
rat	O
and	O
human	O
and	O
was	O
recently	O
found	O
to	O
be	O
downregulated	O
in	O
the	O
PFC	O
of	O
depressed	O
suicide	O
subjects	O
.	O

Using	O
a	O
combination	O
of	O
in	O
silico	O
and	O
in	O
vitro	O
analyses	O
,	O
we	O
found	O
that	O
miR-101b	O
targets	O
the	O
neuronal	O
glutamate	O
transporter	O
SLC1A1	O
(	O
also	O
known	O
as	O
EAAC1	O
or	O
EAAT3	O
)	O
.	O

Accordingly	O
,	O
both	O
mRNA	O
and	O
protein	O
levels	O
of	O
SLC1A1	O
were	O
found	O
to	O
be	O
upregulated	O
in	O
the	O
PFC	O
of	O
the	O
FSL	O
model	O
.	O

Besides	O
providing	O
a	O
list	O
of	O
novel	O
miRNAs	O
associated	O
with	O
depression-like	O
states	O
,	O
this	O
preclinical	O
study	O
replicated	O
the	O
human	O
association	O
of	O
miR-101	O
with	O
depression	O
.	O

In	O
addition	O
,	O
since	O
one	O
of	O
the	O
targets	O
of	O
miR-101b	O
appears	O
to	O
be	O
a	O
glutamate	O
transporter	O
,	O
our	O
preclinical	O
data	O
support	O
the	O
hypothesis	O
of	O
a	O
glutamatergic	O
dysregulation	O
being	O
implicated	O
in	O
the	O
etiology	O
of	O
depression	O
.	O

A	O
Feasibility	O
Study	O
of	O
Telementoring	O
for	O
Identifying	O
the	O
Appendix	O
Using	O
Smartphone	O
-Based	O
Telesonography	B-P
.	O

We	O
investigated	O
the	O
feasibility	O
of	O
the	O
clinical	O
application	O
of	O
novice	O
-	O
practitioner	O
-	O
performed	O
/	O
offsite	O
-	O
mentor	O
-guided	O
ultrasonography	B-P
for	O
identifying	O
the	O
appendix	O
.	O

A	O
randomized	O
crossover	O
study	O
was	O
conducted	O
using	O
a	O
telesonography	O
system	O
that	O
can	O
transmit	O
the	O
ultrasound	B-P
images	O
displayed	O
on	O
the	O
ultrasound	O
monitor	O
(	O
ultrasound	O
sequence	O
video	O
)	O
and	O
images	O
showing	O
the	O
practitioner	O
's	O
operations	O
(	O
background	O
video	O
)	O
to	O
a	O
smartphone	O
without	O
any	O
interruption	O
in	O
motion	O
over	O
a	O
Long-Term	O
Evolution	O
(	O
LTE	O
)	O
network	O
.	O

Thirty	O
novice	O
practitioners	O
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
.	O

The	O
subjects	O
in	O
group	O
A	O
(	O
n	O
=	O
15	O
)	O
performed	O
ultrasonography	B-P
for	O
the	O
identification	O
of	O
the	O
appendix	O
under	O
mentoring	O
by	O
an	O
onsite	O
expert	O
,	O
whereas	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
15	O
)	O
performed	O
the	O
same	O
procedure	B-P
under	O
mentoring	O
by	O
an	O
offsite	O
expert	O
.	O

Each	O
subject	O
performed	O
the	O
procedure	B-P
on	O
three	O
simulated	O
patients	O
.	O

After	O
a	O
4-	O
week	O
interval	O
,	O
they	O
performed	O
the	O
procedure	B-P
again	O
under	O
the	O
other	O
type	O
of	O
mentoring	O
.	O

A	O
total	O
of	O
90	O
ultrasound	B-P
examinations	O
were	O
performed	O
in	O
each	O
scenario	O
.	O

The	O
primary	O
outcomes	O
were	O
the	O
success	O
rate	O
for	O
identifying	O
the	O
appendix	O
and	O
the	O
time	O
required	O
to	O
identify	O
the	O
appendix	O
.	O

The	O
success	O
rates	O
for	O
identifying	O
the	O
appendix	O
were	O
91.1	O
%	O
(	O
82/90	O
)	O
in	O
onsite	O
-	O
mentored	O
ultrasonography	B-P
and	O
87.8	O
%	O
(	O
79/90	O
)	O
in	O
offsite	O
-	O
mentored	O
ultrasonography	B-P
;	O
both	O
rates	O
were	O
high	O
,	O
and	O
there	O
was	O
no	O
significant	O
difference	O
(	O
p	O
=	O
0.468	O
)	O
between	O
them	O
.	O

The	O
time	O
required	O
in	O
the	O
case	O
of	O
offsite	O
mentoring	O
(	O
median	O
,	O
242.9	O
s	O
;	O
interquartile	O
range	O
(	O
IQR	O
)	O
,	O
238.2	O
)	O
was	O
longer	O
than	O
that	O
for	O
onsite	O
mentoring	O
(	O
median	O
,	O
291.4	O
s	O
;	O
IQR	O
,	O
200.9	O
)	O
;	O
however	O
,	O
the	O
difference	O
was	O
not	O
significant	O
(	O
p	O
=	O
0.051	O
)	O
.	O

It	O
appears	O
that	O
offsite	O
mentoring	O
can	O
allow	O
novice	O
onsite	O
practitioners	O
to	O
perform	O
ultrasonography	B-P
as	O
effectively	O
as	O
they	O
can	O
under	O
onsite	O
mentoring	O
,	O
even	O
for	O
examinations	O
that	O
require	O
proficiency	O
in	O
rather	O
complex	O
practices	O
,	O
such	O
as	O
identifying	O
the	O
appendix	O
.	O

Evaluation	O
of	O
analytical	O
methods	O
for	O
the	O
determination	B-P
of	O
the	O
physicochemical	O
properties	O
of	O
fermented	O
,	O
granulated	O
,	O
and	O
roasted	O
cassava	O
pulp	O
-	O
gari	O
.	O

Simple	O
but	O
reliable	O
methods	O
for	O
the	O
determination	B-P
of	O
the	O
physicochemical	O
properties	O
of	O
gari	O
were	O
evaluated	O
for	O
the	O
parameters	O
,	O
such	O
as	O
grain	O
size	O
,	O
bulk	O
density	O
,	O
swelling	O
index	O
,	O
moisture	O
content	O
,	O
gross	O
calorific	O
value	O
,	O
cyanide	O
content	O
,	O
and	O
acidity	O
content	O
.	O

The	O
grain	O
sizes	O
were	O
between	O
525	O
and	O
928	O
μm	O
(	O
weighted	O
means	O
)	O
,	O
the	O
bulk	O
densities	O
between	O
0.541	O
and	O
0.699	O
g/cm³	O
,	O
and	O
the	O
swelling	O
indices	O
between	O
3.21	O
and	O
4.33	O
.	O

The	O
moisture	O
contents	O
ranged	O
from	O
4.30	O
to	O
9.19	O
%	O
.	O

The	O
gross	O
calorific	O
values	O
were	O
found	O
between	O
15.45	O
and	O
15.82	O
kJ/g	O
.	O

The	O
cyanide	O
contents	O
were	O
between	O
0	O
and	O
4.8	O
ppm	O
.	O

The	O
acidity	O
contents	O
varied	O
among	O
0.55	O
and	O
1.62	O
%	O
.	O

Correlation	O
tests	O
verified	O
the	O
influences	O
of	O
the	O
grain	O
size	O
and	O
the	O
moisture	O
content	O
on	O
the	O
acidity	O
content	O
with	O
a	O
probability	O
of	O
99.9	O
%	O
.	O

The	O
methods	O
were	O
regarded	O
as	O
suitable	O
and	O
adaptable	O
for	O
the	O
application	O
in	O
small	O
and	O
medium	O
cassava	O
-	O
processing	O
industries	O
with	O
special	O
regard	O
to	O
the	O
respect	O
of	O
the	O
consumer	O
`	O
s	O
health	O
safety	O
.	O

Implementing	O
Non-Invasive	O
Prenatal	B-P
Diagnosis	I-P
(	O
NIPD	B-P
)	O
in	O
a	O
National	O
Health	O
Service	O
Laboratory	O
;	O
From	O
Dominant	O
to	O
Recessive	O
Disorders	O
.	O

Our	O
UK	O
National	O
Health	O
Service	O
regional	O
genetics	O
laboratory	O
offers	O
NIPD	B-P
for	O
autosomal	O
dominant	O
and	O
de	O
novo	O
conditions	O
(	O
achondroplasia	O
,	O
thanataphoric	O
dysplasia	O
,	O
Apert	O
syndrome	O
)	O
,	O
paternal	O
mutation	O
exclusion	O
for	O
cystic	O
fibrosis	O
and	O
a	O
range	O
of	O
bespoke	B-P
tests	I-P
.	O

NIPD	B-P
avoids	O
the	O
risks	O
associated	O
with	O
invasive	B-P
testing	I-P
,	O
making	O
prenatal	B-P
diagnosis	I-P
more	O
accessible	O
to	O
families	O
at	O
high	O
genetic	O
risk	O
.	O

However	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	O
diagnosis	O
for	O
autosomal	O
recessive	O
diseases	O
,	O
which	O
is	O
complicated	O
by	O
the	O
predominance	O
of	O
the	O
maternal	O
mutant	O
allele	O
in	O
the	O
cell-free	O
DNA	O
sample	O
and	O
thus	O
requires	O
a	O
variety	O
of	O
different	O
approaches	O
.	O

Validation	O
and	O
diagnostic	O
implementation	O
for	O
NIPD	B-P
of	O
congenital	O
adrenal	O
hyperplasia	O
(	O
CAH	O
)	O
is	O
further	O
complicated	O
by	O
presence	O
of	O
a	O
pseudogene	O
that	O
requires	O
a	O
different	O
approach	O
.	O

We	O
have	O
used	O
an	O
assay	B-P
targeting	O
approximately	O
6700	O
heterozygous	O
SNPs	O
around	O
the	O
CAH	O
gene	O
(	O
CYP21A2	O
)	O
to	O
construct	O
the	O
high-risk	O
parental	O
haplotypes	O
and	O
tested	O
this	O
approach	O
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	O
of	O
the	O
parental	O
alleles	O
can	O
be	O
correctly	O
identified	O
using	O
NIPD	B-P
.	O

We	O
are	O
evaluating	O
various	O
measures	O
of	O
the	O
fetal	O
fraction	O
to	O
help	O
determine	O
inheritance	O
of	O
parental	O
mutations	O
.	O

We	O
are	O
currently	O
exploring	O
the	O
utility	O
of	O
an	O
NIPD	B-P
multi-disorder	B-P
panel	I-P
for	O
autosomal	O
recessive	O
disease	O
,	O
to	O
make	O
testing	O
more	O
widely	O
applicable	O
to	O
families	O
with	O
a	O
variety	O
of	O
serious	O
genetic	O
conditions	O
.	O

Expression	O
of	O
the	O
Mir-133	O
and	O
Bcl-2	O
could	O
be	O
affected	O
by	O
swimming	O
training	O
in	O
the	O
heart	O
of	O
ovariectomized	O
rats	O
.	O

The	O
beneficial	O
and	O
more	O
potent	O
role	O
of	O
exercise	O
to	O
prevent	O
heart	O
apoptosis	O
in	O
ovariectomized	O
rats	O
has	O
been	O
known	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
swimming	O
training	O
on	O
cardiac	O
expression	O
of	O
Bcl-2	O
,	O
and	O
Mir-133	O
levels	O
and	O
glycogen	O
changes	O
in	O
the	O
myocyte	O
.	O

Forty	O
animals	O
were	O
separated	O
into	O
four	O
groups	O
as	O
control	O
,	O
sham	O
,	O
ovariectomy	O
(	O
OVX	O
)	O
and	O
ovariectomized	O
group	O
with	O
8	O
weeks	O
swimming	O
training	O
(	O
OVX.E	O
)	O
.	O

Training	O
effects	O
were	O
evaluated	O
by	O
measuring	O
lipid	B-P
profiles	I-P
,	O
Bcl-2	O
and	O
Mir-133	O
expression	O
levels	O
in	O
the	O
cardiac	O
tissue	O
.	O

Grafts	O
were	O
analyzed	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
for	O
Bcl-2	O
mRNA	O
and	O
Mir-133	O
and	O
by	O
Western	O
blot	O
for	O
Bcl-2	O
protein	O
.	O

Ovariectomy	O
down-regulated	O
Bcl-2	O
and	O
Mir-133	O
expression	O
levels	O
in	O
the	O
cardiac	O
tissue	O
,	O
and	O
swimming	O
training	O
up-regulated	O
their	O
expression	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Our	O
results	O
showed	O
that	O
regular	O
exercise	O
as	O
a	O
physical	O
replacement	O
therapy	O
could	O
prevent	O
and	O
improve	O
the	O
effects	O
of	O
estrogen	O
deficiency	O
in	O
the	O
cardia	O
.	O

Evaluation	O
of	O
a	O
New	O
Brain	O
Tissue	O
Probe	O
for	O
Cerebral	O
Blood	O
Flow	O
Monitoring	O
in	O
an	O
Experimental	O
Pig	O
Model	O
.	O

Bedside	O
monitoring	O
of	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
may	O
provide	O
new	O
insights	O
into	O
the	O
pathophysiology	O
of	O
brain	O
injury	O
,	O
allow	O
early	O
detection	O
of	O
secondary	O
ischemia	O
,	O
and	O
help	O
guide	O
therapy	O
.	O

To	O
evaluate	O
a	O
new	O
brain	O
tissue	O
probe	O
for	O
serial	O
CBF	O
monitoring	O
using	O
near-infrared	B-P
spectroscopy	I-P
and	O
indocyanine	O
green	O
dye	B-P
dilution	I-P
(	O
NeMo	O
Probe	O
)	O
compared	O
with	O
the	O
existing	O
thermal	O
diffusion	O
probe	O
(	O
QFlow	O
500	O
Probe	O
)	O
.	O

In	O
7	O
pigs	O
,	O
the	O
NeMo	O
Probe	O
and	O
QFlow	O
500	O
Probe	O
were	O
inserted	O
into	O
the	O
subcortical	O
white	O
matter	O
.	O

Parallel	O
measurements	O
were	O
recorded	O
during	O
(	O
1	O
)	O
baseline	O
,	O
(	O
2	O
)	O
hypotension	O
,	O
(	O
3	O
)	O
hypertension	O
,	O
and	O
(	O
4	O
)	O
hyperventilation	O
.	O

Thereafter	O
,	O
protocol	O
points	O
1	O
through	O
4	O
were	O
repeated	O
once	O
.	O

The	O
Spearman	O
correlation	O
(	O
rs	O
)	O
,	O
Bland-Altman	O
plot	O
,	O
concordance	O
rate	O
,	O
and	O
coefficient	O
of	O
variation	O
were	O
used	O
for	O
statistical	O
analysis	O
.	O

There	O
was	O
poor	O
agreement	O
between	O
56	O
pairs	O
of	O
absolute	O
CBF	O
values	O
(	O
rs	O
=	O
0.52	O
,	O
P	O
<	O
.001	O
)	O
.	O

The	O
mean	O
bias	O
was	O
10.7	O
mL·100	O
g·min	O
with	O
limits	O
of	O
agreement	O
of	O
-33.0	O
to	O
54.3	O
mL·100	O
g·min	O
.	O

The	O
analysis	O
of	O
49	O
pairs	O
of	O
changes	O
in	O
CBF	O
showed	O
a	O
good	O
correlation	O
(	O
rs	O
=	O
0.83	O
,	O
P	O
<	O
.001	O
)	O
,	O
and	O
the	O
concordance	O
rate	O
was	O
93.3	O
%	O
.	O

The	O
coefficient	O
of	O
variation	O
from	O
repeated	O
measurements	O
under	O
comparable	O
physiological	O
conditions	O
was	O
51.6	O
%	O
for	O
the	O
QFlow	O
500	O
Probe	O
and	O
12.9	O
%	O
for	O
the	O
NeMo	O
Probe	O
.	O

Absolute	O
CBF	O
values	O
obtained	O
with	O
the	O
NeMo	O
Probe	O
and	O
QFlow	O
500	O
Probe	O
can	O
not	O
be	O
interpreted	O
as	O
equivalent	O
.	O

However	O
,	O
the	O
NeMo	O
Probe	O
provides	O
acceptable	O
trending	O
ability	O
and	O
reproducibility	O
from	O
repeated	O
measurements	O
,	O
whereas	O
the	O
reproducibility	O
of	O
the	O
QFlow	O
500	O
Probe	O
was	O
poor	O
.	O

Future	O
clinical	O
studies	O
are	O
warranted	O
to	O
evaluate	O
the	O
NeMo	O
Probe	O
in	O
the	O
setting	O
of	O
acute	O
brain	O
injury	O
.	O

CBF	O
,	O
cerebral	O
blood	O
flow	O
CBV	O
,	O
cerebral	O
blood	O
volume	O
ICG	O
,	O
indocyanine	O
green	O
ICP	O
,	O
intracranial	O
pressure	O
MAP	O
,	O
mean	O
arterial	O
pressure	O
mttICG	O
,	O
mean	O
transit	O
time	O
of	O
indocyanine	O
green	O
NIRS	B-P
,	O
near-infrared	B-P
spectroscopy	I-P
.	O

Complex	O
patterns	O
of	O
multiple	O
biomineralization	O
in	O
single-celled	O
plant	O
trichomes	O
of	O
the	O
Loasaceae	O
.	O

Plants	O
of	O
the	O
family	O
Loasaceae	O
are	O
characterized	O
by	O
a	O
usually	O
dense	O
indument	O
of	O
various	O
trichome	O
types	O
,	O
including	O
two	O
basically	O
different	O
types	O
of	O
mineralized	O
,	O
unicellular	O
trichomes	O
(	O
stinging	O
hairs	O
or	O
setae	O
and	O
scabrid-glochidiate	O
trichomes	O
)	O
.	O

Mineralized	O
trichomes	O
have	O
long	O
been	O
known	O
to	O
have	O
silicified	O
or	O
calcified	O
walls	O
,	O
but	O
recent	O
studies	O
demonstrated	O
that	O
trichomes	O
of	O
Loasaceae	O
may	O
also	O
contain	O
calcium	O
phosphate	O
.	O

The	O
current	O
study	O
investigates	O
the	O
distribution	O
of	O
different	O
biominerals	O
in	O
the	O
mineralized	O
trichomes	O
across	O
several	O
different	O
taxa	O
.	O

Plants	O
from	O
cultivation	O
were	O
studied	O
with	O
scanning	B-P
electron	I-P
microscopy	I-P
including	O
energy	B-P
dispersive	I-P
x-ray	I-P
analyses	I-P
and	O
element	O
mapping	O
.	O

The	O
vast	O
majority	O
of	O
the	O
31	O
species	O
investigated	O
had	O
at	O
least	O
two	O
different	O
biominerals	O
in	O
their	O
trichomes	O
,	O
and	O
22	O
had	O
three	O
different	O
biominerals	O
in	O
their	O
trichomes	O
.	O

Thirty	O
of	O
the	O
species	O
had	O
calcium	O
phosphate	O
in	O
their	O
trichomes	O
.	O

Loasa	O
was	O
mostly	O
free	O
of	O
silica	O
,	O
but	O
contained	O
calcium	O
phosphate	O
in	O
trichome	O
tips	O
and	O
barbs	O
,	O
whereas	O
calcium	O
phosphate	O
and	O
silica	O
were	O
found	O
in	O
representatives	O
of	O
other	O
genera	O
of	O
the	O
family	O
(	O
Blumenbachia	O
,	O
Caiophora	O
,	O
Nasa	O
)	O
.	O

Biomineralization	O
is	O
remarkably	O
diversified	O
between	O
species	O
,	O
different	O
trichome	O
types	O
and	O
parts	O
of	O
the	O
same	O
trichome	O
.	O

Individual	O
genera	O
largely	O
had	O
different	O
patterns	O
of	O
biomineralization	O
.	O

The	O
presence	O
of	O
three	O
biominerals	O
in	O
the	O
trichomes	O
of	O
the	O
basally	O
branching	O
Eucnide	O
urens	O
indicates	O
either	O
an	O
early	O
evolution	O
and	O
subsequent	O
loss	O
or	O
several	O
independent	O
origins	O
of	O
multiple	O
biomineralization	O
.	O

Differential	O
biomineralization	O
of	O
the	O
parts	O
of	O
individual	O
,	O
unicellular	O
trichomes	O
clearly	O
indicates	O
an	O
extraordinary	O
degree	O
of	O
physiological	O
control	O
over	O
this	O
process	O
.	O

MinorityReport	O
,	O
software	O
for	O
generalized	O
analysis	O
of	O
causal	O
genetic	B-P
variants	I-P
.	O

The	O
widespread	O
availability	O
of	O
next	O
generation	O
genome	O
sequencing	O
technologies	O
has	O
enabled	O
a	O
wide	O
range	O
of	O
variant	B-P
detection	I-P
applications	O
,	O
especially	O
in	B-P
cancer	I-P
and	O
inborn	O
genetic	O
disorders	O
.	O

For	O
model	O
systems	O
and	O
microorganisms	O
,	O
the	O
same	O
technology	O
may	O
be	O
used	O
to	O
discover	O
the	O
causative	O
mutations	O
for	O
any	O
phenotype	B-P
,	O
including	O
those	O
generated	O
in	O
response	O
to	O
chemical	O
perturbation	O
.	O

In	O
the	O
case	O
of	O
pathogenic	O
organisms	O
,	O
these	O
approaches	O
have	O
allowed	O
the	O
determination	B-P
of	I-P
drug	O
targets	O
by	O
means	O
of	O
resistance	O
selection	O
followed	O
by	O
genome	O
sequencing	O
.	O

MinorityReport	O
is	O
open	O
source	O
software	O
written	O
in	O
python	O
that	O
facilitates	O
the	O
comparison	O
of	O
any	O
two	O
sets	O
of	O
genome	O
alignments	O
for	O
the	O
purpose	O
of	O
rapidly	O
identifying	O
the	O
spectrum	O
of	O
nonsynonymous	O
changes	O
,	O
insertions	O
or	O
deletions	O
,	O
and	O
copy	O
number	O
variations	O
in	O
a	O
presumed	O
mutant	O
relative	O
to	O
its	O
parent	O
.	O

Specifically	O
,	O
MinorityReport	O
relates	O
mapped	O
sequence	O
reads	O
in	O
SAM	O
format	O
output	O
from	O
any	O
alignment	O
tool	O
for	O
both	O
the	O
mutant	O
and	O
parent	O
genome	O
,	O
relative	O
to	O
a	O
reference	O
genome	O
,	O
and	O
produces	O
the	O
set	O
of	O
variants	O
that	O
distinguishes	O
the	O
mutant	O
from	O
the	O
parent	O
,	O
all	O
presented	O
in	O
an	O
intuitive	O
,	O
straightforward	O
report	O
format	O
.	O

MinorityReport	O
features	O
tunable	O
parameters	O
for	O
evaluating	O
evidence	O
and	O
a	O
scoring	O
system	O
that	O
prioritizes	O
reported	O
variants	O
based	O
on	O
relative	O
proportions	O
of	O
read	O
counts	O
supporting	O
the	O
variant	O
in	O
the	O
mutant	O
versus	O
parent	O
data	O
sets	O
.	O

The	O
utility	O
of	O
MinorityReport	O
is	O
demonstrated	O
using	O
previously	O
published	O
publicly	O
available	O
data	O
sets	O
to	O
find	O
the	O
determinants	B-P
of	I-P
resistance	I-P
for	O
novel	O
anti-malarial	O
drugs	O
.	O

MinorityReport	O
is	O
readily	O
available	O
(	O
github	O
:	O
JeremyHorst/	O
MinorityReport	O
)	O
to	O
identify	O
the	O
genetic	O
mechanisms	O
of	O
drug	O
resistance	O
in	O
Plasmodium	O
,	O
genotype-phenotype	O
relationships	O
in	O
human	O
diads	O
,	O
or	O
genomic	O
variations	O
between	O
any	O
two	O
related	O
organisms	O
.	O

Multicentric	O
Castleman	O
disease	O
of	O
hyaline	O
vascular	O
variant	O
presenting	O
with	O
unusual	O
systemic	O
manifestations	O
:	O
a	O
case	O
report	O
.	O

Castleman	O
disease	O
is	O
a	O
rare	O
lymphoproliferative	O
disorder	O
presenting	O
with	O
localized	O
or	O
disseminated	O
lymphadenopathy	O
and	O
systemic	O
manifestations	O
.	O

It	O
can	O
be	O
categorized	O
in	O
numerous	O
ways	O
,	O
such	O
as	O
unicentric	O
versus	O
multicentric	O
,	O
histopathological	O
variants	O
(	O
hyaline	O
-	O
vascular	O
,	O
plasma	O
cell	O
,	O
and	O
mixed	O
)	O
,	O
or	O
subtypes	O
based	O
on	O
causative	O
viral	O
infections	O
(	O
human	O
immunodeficiency	O
virus	O
,	O
human	O
herpesvirus-8	O
,	O
or	O
Kaposi	O
sarcoma	O
herpesvirus	O
)	O
.	O

Presentation	O
ranges	O
from	O
asymptomatic	O
to	O
symptoms	O
involving	O
multiple	O
organs	O
.	O

Even	O
though	O
the	O
exact	O
mechanism	O
of	O
pathogenesis	O
is	O
unknown	O
,	O
treatment	O
is	O
directed	O
toward	O
possible	O
etiologies	O
such	O
as	O
interleukin-6	O
,	O
cluster	O
of	O
differentiation	O
20	O
,	O
and	O
viral	O
agents	O
.	O

A	O
36-	O
year	O
-old	O
Sri	O
Lankan	O
woman	O
presented	O
with	O
generalized	O
body	O
swelling	O
and	O
foamy	O
urine	O
of	O
2	O
weeks	O
'	O
duration	O
.	O

Examination	O
revealed	O
pallor	O
;	O
generalized	O
edema	O
;	O
axillary	O
,	O
cervical	O
,	O
and	O
inguinal	O
lymphadenopathy	O
;	O
hypertension	O
;	O
and	O
hepatomegaly	O
.	O

Investigations	O
showed	O
bicytopenia	O
,	O
nephrotic	O
range	O
proteinuria	O
with	O
hypoalbuminemia	O
,	O
hypogammaglobulinemia	O
,	O
and	O
features	O
of	O
hyaline	O
-	O
vascular	O
type	O
Castleman	O
disease	O
in	O
a	O
lymph	B-P
node	I-P
biopsy	I-P
.	O

She	O
was	O
managed	O
with	O
rituximab	O
and	O
had	O
good	O
clinical	O
improvement	O
.	O

Castleman	O
disease	O
has	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
,	O
disease	O
pathogeneses	O
,	O
and	O
associations	O
and/or	O
complications	O
.	O

Medical	O
professionals	O
need	O
to	O
be	O
familiar	O
with	O
this	O
spectrum	O
because	O
timely	O
diagnosis	O
and	O
aggressive	O
targeted	O
therapy	O
are	O
the	O
cornerstones	O
of	O
managing	O
these	O
patients	O
.	O

Lack	O
of	O
Effect	O
of	O
Oral	O
Sulforaphane	O
Administration	O
on	O
Nrf2	O
Expression	O
in	O
COPD	O
:	O
A	O
Randomized	O
,	O
Double-Blind	O
,	O
Placebo	O
Controlled	O
Trial	O
.	O

COPD	O
patients	O
have	O
high	O
pulmonary	O
and	O
systemic	O
oxidative	O
stress	O
that	O
correlates	O
with	O
severity	O
of	O
disease	O
.	O

Sulforaphane	O
has	O
been	O
shown	O
to	O
induce	O
expression	O
of	O
antioxidant	O
genes	O
via	O
activation	O
of	O
a	O
transcription	O
factor	O
,	O
nuclear	O
factor	O
erythroid-2	O
related	O
factor	O
2	O
(	O
Nrf2	O
)	O
.	O

This	O
parallel	O
,	O
placebo-controlled	O
,	O
phase	O
2	O
,	O
randomized	O
trial	O
was	O
conducted	O
at	O
three	O
US	O
academic	O
medical	O
centers	O
.	O

Patients	O
who	O
met	O
GOLD	O
criteria	O
for	O
COPD	O
and	O
were	O
able	O
to	O
tolerate	O
bronchoscopies	B-P
were	O
randomly	O
assigned	O
(	O
1:1:1	O
)	O
to	O
receive	O
placebo	O
,	O
25	O
μmoles	O
,	O
or	O
150	O
μmoles	O
sulforaphane	O
daily	O
by	O
mouth	O
for	O
four	O
weeks	O
.	O

The	O
primary	O
outcomes	O
were	O
changes	O
in	O
Nrf2	O
target	O
gene	O
expression	O
(	O
NQ01	O
,	O
HO1	O
,	O
AKR1C1	O
and	O
AKR1C3	O
)	O
in	O
alveolar	O
macrophages	O
and	O
bronchial	O
epithelial	O
cells	O
.	O

Secondary	O
outcomes	O
included	O
measures	O
of	O
oxidative	O
stress	O
and	O
airway	O
inflammation	O
,	O
and	O
pulmonary	B-P
function	I-P
tests	I-P
.	O

Between	O
July	O
2011	O
and	O
May	O
2013	O
,	O
89	O
patients	O
were	O
enrolled	O
and	O
randomized	O
.	O

Sulforaphane	O
was	O
absorbed	O
in	O
the	O
patients	O
as	O
evident	O
from	O
their	O
plasma	O
metabolite	O
levels	O
.	O

Changes	O
in	O
Nrf2	O
target	O
gene	O
expression	O
relative	O
to	O
baseline	O
ranged	O
from	O
0.79	O
to	O
1.45	O
and	O
there	O
was	O
no	O
consistent	O
pattern	O
among	O
the	O
three	O
groups	O
;	O
the	O
changes	O
were	O
not	O
statistically	O
significantly	O
different	O
from	O
baseline	O
.	O

Changes	O
in	O
measures	O
of	O
inflammation	O
and	O
pulmonary	B-P
function	I-P
tests	I-P
were	O
not	O
different	O
among	O
the	O
groups	O
.	O

Sulforaphane	O
was	O
well	O
tolerated	O
at	O
both	O
dose	O
levels	O
.	O

Sulforaphane	O
administered	O
for	O
four	O
weeks	O
at	O
doses	O
of	O
25	O
μmoles	O
and	O
150	O
μmoles	O
to	O
patients	O
with	O
COPD	O
did	O
not	O
stimulate	O
the	O
expression	O
of	O
Nrf2	O
target	O
genes	O
or	O
have	O
an	O
effect	O
on	O
levels	O
of	O
other	O
anti-oxidants	O
or	O
markers	O
of	O
inflammation	O
.	O

Clinicaltrials.gov	O
:	O
NCT01335971	O
.	O

Multivariate	O
Imaging	B-P
Genetics	O
Study	O
of	O
MRI	B-P
Gray	O
Matter	O
Volume	O
and	O
SNPs	O
Reveals	O
Biological	O
Pathways	O
Correlated	O
with	O
Brain	O
Structural	O
Differences	O
in	O
Attention	O
Deficit	O
Hyperactivity	O
Disorder	O
.	O

Attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
is	O
a	O
prevalent	O
neurodevelopmental	O
disorder	O
affecting	O
children	O
,	O
adolescents	O
,	O
and	O
adults	O
.	O

Its	O
etiology	O
is	O
not	O
well	O
understood	O
,	O
but	O
it	O
is	O
increasingly	O
believed	O
to	O
result	O
from	O
diverse	O
pathophysiologies	O
that	O
affect	O
the	O
structure	O
and	O
function	O
of	O
specific	O
brain	O
circuits	O
.	O

Although	O
one	O
of	O
the	O
best-studied	O
neurobiological	O
abnormalities	O
in	O
ADHD	O
is	O
reduced	O
fronto-striatal-cerebellar	O
gray	O
matter	O
(	O
GM	O
)	O
volume	O
,	O
its	O
specific	O
genetic	O
correlates	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
T1-weighted	B-P
MR	I-P
images	I-P
of	I-P
brain	I-P
structure	I-P
were	O
collected	O
from	O
198	O
adolescents	O
(	O
63	O
ADHD	O
-	O
diagnosed	O
)	O
.	O

A	O
multivariate	O
parallel	O
independent	O
component	O
analysis	O
(	O
Para-ICA	O
)	O
technique	O
-identified	O
imaging	B-P
genetic	O
relationships	O
between	O
regional	O
GM	O
volume	O
and	O
single	O
nucleotide	O
polymorphism	O
data	O
.	O

Para-ICA	O
analyses	O
extracted	O
14	O
components	O
from	O
genetic	O
data	O
and	O
9	O
from	O
MR	B-P
data	O
.	O

An	O
iterative	O
cross-validation	O
using	O
randomly	O
chosen	O
subsamples	O
indicated	O
acceptable	O
stability	O
of	O
these	O
ICA	O
solutions	O
.	O

A	O
series	O
of	O
partial	O
correlation	O
analyses	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
and	O
ethnicity	O
revealed	O
two	O
genotype-phenotype	O
component	O
pairs	O
significantly	O
differed	O
between	O
ADHD	O
and	O
non-ADHD	O
groups	O
,	O
after	O
a	O
Bonferroni	O
correction	O
for	O
multiple	O
comparisons	O
.	O

The	O
brain	O
phenotype	O
component	O
not	O
only	O
included	O
structures	O
frequently	O
found	O
to	O
have	O
abnormally	O
low	O
volume	O
in	O
previous	O
ADHD	O
studies	O
but	O
was	O
also	O
significantly	O
associated	O
with	O
ADHD	O
differences	O
in	O
symptom	O
severity	O
and	O
performance	O
on	O
cognitive	O
tests	O
frequently	O
found	O
to	O
be	O
impaired	O
in	O
patients	O
diagnosed	O
with	O
the	O
disorder	O
.	O

Pathway	O
analysis	O
of	O
the	O
genotype	O
component	O
identified	O
several	O
different	O
biological	O
pathways	O
linked	O
to	O
these	O
structural	O
abnormalities	O
in	O
ADHD	O
.	O

Some	O
of	O
these	O
pathways	O
implicate	O
well-known	O
dopaminergic	O
neurotransmission	O
and	O
neurodevelopment	O
hypothesized	O
to	O
be	O
abnormal	O
in	O
ADHD	O
.	O

Other	O
more	O
recently	O
implicated	O
pathways	O
included	O
glutamatergic	O
and	O
GABA-eric	O
physiological	O
systems	O
;	O
others	O
might	O
reflect	O
sources	O
of	O
shared	O
liability	O
to	O
disturbances	O
commonly	O
found	O
in	O
ADHD	O
,	O
such	O
as	O
sleep	O
abnormalities	O
.	O

Quantitative	B-P
fetal	I-P
fibronectin	I-P
and	O
cervical	B-P
length	I-P
to	O
predict	O
preterm	O
birth	O
in	O
asymptomatic	O
women	O
with	O
previous	O
cervical	O
surgery	O
.	O

Quantitative	B-P
fetal	I-P
fibronectin	I-P
testing	I-P
has	O
demonstrated	B-P
accuracy	O
for	O
prediction	O
of	O
spontaneous	O
preterm	O
birth	O
in	O
asymptomatic	O
women	O
with	O
a	O
history	O
of	O
preterm	O
birth	O
.	O

Predictive	O
accuracy	O
in	O
women	O
with	O
previous	O
cervical	O
surgery	O
(	O
a	O
potentially	O
different	O
risk	O
mechanism	O
)	O
is	O
not	O
known	O
.	O

We	O
sought	O
to	O
compare	O
the	O
predictive	O
accuracy	O
of	O
cervicovaginal	O
fluid	O
quantitative	B-P
fetal	I-P
fibronectin	I-P
and	O
cervical	B-P
length	I-P
testing	I-P
in	O
asymptomatic	O
women	O
with	O
previous	O
cervical	O
surgery	O
to	O
that	O
in	O
women	O
with	O
1	O
previous	O
preterm	O
birth	O
.	O

We	O
conducted	O
a	O
prospective	O
blinded	O
secondary	O
analysis	O
of	O
a	O
larger	O
observational	O
study	O
of	O
cervicovaginal	O
fluid	O
quantitative	B-P
fetal	I-P
fibronectin	I-P
concentration	O
in	O
asymptomatic	O
women	O
measured	O
with	O
a	O
Hologic	O
10Q	O
system	O
(	O
Hologic	O
,	O
Marlborough	O
,	O
MA	O
)	O
.	O

Prediction	O
of	O
spontaneous	O
preterm	O
birth	O
(	O
<	O
30	O
,	O
<	O
34	O
,	O
and	O
<	O
37	O
weeks	O
)	O
with	O
cervicovaginal	O
fluid	O
quantitative	B-P
fetal	I-P
fibronectin	I-P
concentration	O
in	O
primiparous	O
women	O
who	O
had	O
undergone	O
at	O
least	O
1	O
invasive	O
cervical	B-P
procedure	I-P
(	O
n	O
=	O
473	O
)	O
was	O
compared	O
with	O
prediction	O
in	O
women	O
who	O
had	O
previous	O
spontaneous	O
preterm	O
birth	O
,	O
preterm	O
prelabor	O
rupture	O
of	O
membranes	O
,	O
or	O
late	O
miscarriage	O
(	O
n	O
=	O
821	O
)	O
.	O

Relationship	O
with	O
cervical	O
length	O
was	O
explored	O
.	O

The	O
rate	O
of	O
spontaneous	O
preterm	O
birth	O
<	O
34	O
weeks	O
in	O
the	O
cervical	O
surgery	O
group	O
was	O
3	O
%	O
compared	O
with	O
9	O
%	O
in	O
previous	O
spontaneous	O
preterm	O
birth	O
group	O
.	O

Receiver	O
operating	O
characteristic	O
curves	O
comparing	O
quantitative	B-P
fetal	I-P
fibronectin	I-P
for	O
prediction	O
at	O
all	O
3	O
gestational	O
end	O
points	O
were	O
comparable	O
between	O
the	O
cervical	O
surgery	O
and	O
previous	O
spontaneous	O
preterm	O
birth	O
groups	O
(	O
34	O
weeks	O
:	O
area	O
under	O
the	O
curve	O
,	O
0.78	O
[	O
95	O
%	O
confidence	O
interval	O
0.64-0.93	O
]	O
vs	O
0.71	O
[	O
95	O
%	O
confidence	O
interval	O
0.64-0.78	O
]	O
;	O
P	O
=	O
.39	O
)	O
.	O

Prediction	O
of	O
spontaneous	O
preterm	O
birth	O
using	O
cervical	B-P
length	I-P
compared	O
with	O
quantitative	B-P
fetal	I-P
fibronectin	I-P
for	O
prediction	O
of	O
preterm	O
birth	O
<	O
34	O
weeks	O
of	O
gestation	O
offered	O
similar	O
prediction	O
(	O
area	O
under	O
the	O
curve	O
,	O
0.88	O
[	O
95	O
%	O
confidence	O
interval	O
0.79-0.96	O
]	O
vs	O
0.77	O
[	O
95	O
%	O
confidence	O
interval	O
0.62-0.92	O
]	O
,	O
P	O
=	O
.12	O
in	O
the	O
cervical	O
surgery	O
group	O
;	O
and	O
0.77	O
[	O
95	O
%	O
confidence	O
interval	O
0.70-0.84	O
]	O
vs	O
0.74	O
[	O
95	O
%	O
confidence	O
interval	O
0.67-0.81	O
]	O
,	O
P	O
=	O
.32	O
in	O
the	O
previous	O
spontaneous	O
preterm	O
birth	O
group	O
)	O
.	O

Prediction	O
of	O
spontaneous	O
preterm	O
birth	O
using	O
cervicovaginal	O
fluid	O
quantitative	B-P
fetal	I-P
fibronectin	I-P
in	O
asymptomatic	O
women	O
with	O
cervical	O
surgery	O
is	O
valid	O
,	O
and	O
has	O
comparative	O
accuracy	O
to	O
that	O
in	O
women	O
with	O
a	O
history	O
of	O
spontaneous	O
preterm	O
birth	O
.	O

miR-27b	O
inhibits	O
gastric	O
cancer	O
metastasis	O
by	O
targeting	O
NR2F2	O
.	O

Increasing	O
attention	O
is	O
focused	O
on	O
the	O
down-regulation	O
of	O
miRNAs	O
in	O
cancer	O
process	O
.	O

Nuclear	O
receptor	O
subfamily	O
2	O
(	O
NR2F2	O
,	O
also	O
known	O
as	O
COUP-TFII	O
)	O
is	O
involved	O
in	O
the	O
development	O
of	O
many	O
types	O
of	O
cancers	O
,	O
but	O
its	O
role	O
in	O
gastric	O
cancer	O
remains	O
elusive	O
.	O

In	O
this	O
experiment	O
,	O
oncomine	O
and	O
Kaplan-meier	O
database	O
revealed	O
that	O
NR2F2	O
was	O
up-regulated	O
in	O
gastric	O
cancer	O
and	O
that	O
the	O
high	O
NR2F2	O
expression	O
contributed	O
to	O
poor	O
survival	O
.	O

MicroRNA-27b	O
was	O
targeted	O
and	O
down-regulated	O
by	O
NR2F2	O
in	O
human	O
gastric	O
cancer	O
tissues	O
and	O
cells	O
.	O

The	O
ectopic	O
expression	O
of	O
miR-27b	O
inhibited	O
gastric	O
cancer	O
cell	O
proliferation	O
and	O
tumor	O
growth	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Assays	B-P
suggested	O
that	O
the	O
overexpression	O
of	O
miR-27b	O
could	O
promote	O
MGC-803	O
cells	O
'	O
migration	O
and	O
invasion	O
and	O
retard	O
their	O
metastasis	O
to	O
the	O
liver	O
.	O

In	O
addition	O
,	O
down-regulation	O
of	O
miR-27b	O
enhanced	O
GES-1	O
cells	O
'	O
proliferation	O
and	O
metastasis	O
in	O
vitro	O
.	O

These	O
findings	O
reveal	O
that	O
miR-27b	O
is	O
a	O
tumor	O
suppressor	O
in	O
gastric	O
cancer	O
and	O
a	O
biomarker	O
for	O
improving	O
patients	O
'	O
survival	O
.	O

Did	O
FIDELIS	O
projects	O
contribute	O
to	O
the	O
detection	O
of	O
new	O
smear	B-P
-	O
positive	O
pulmonary	O
tuberculosis	O
cases	O
in	O
China	O
?	O
.	O

Setting	O
:	O
The	O
first	O
phase	O
of	O
the	O
Fund	O
for	O
Innovative	O
DOTS	O
Expansion	O
through	O
Local	O
Initiatives	O
to	O
Stop	O
TB	O
(	O
FIDELIS	O
)	O
projects	O
in	O
China	O
started	O
in	O
2003	O
.	O

Objective	O
:	O
To	O
determine	O
whether	O
the	O
FIDELIS	O
projects	O
contribute	O
d	O
to	O
the	O
increased	O
case	O
detection	O
rate	O
for	O
new	O
smear	B-P
-	O
positive	O
pulmonary	O
tuberculosis	O
(	O
PTB	O
)	O
in	O
China	O
.	O

Methods	O
:	O
We	O
compared	O
the	O
case	O
notification	O
rates	O
(	O
CNRs	O
)	O
in	O
the	O
intervention	O
year	O
with	O
those	O
of	O
the	O
previous	O
year	O
in	O
the	O
FIDELIS	O
areas	O
,	O
then	O
compared	O
the	O
difference	O
between	O
the	O
CNRs	O
of	O
the	O
intervention	O
year	O
and	O
the	O
previous	O
year	O
in	O
the	O
FIDELIS	O
areas	O
with	O
those	O
in	O
the	O
non-FI-DELIS	O
areas	O
within	O
the	O
province	O
.	O

Results	O
:	O
There	O
was	O
an	O
increase	O
in	O
the	O
CNR	O
in	O
the	O
intervention	O
year	O
compared	O
with	O
the	O
previous	O
year	O
for	O
all	O
the	O
project	O
sites	O
.	O

The	O
differences	O
between	O
the	O
CNR	O
in	O
the	O
intervention	O
year	O
and	O
the	O
previous	O
year	O
ranged	O
from	O
6.4	O
to	O
31.1	O
per	O
100	O
000	O
population	O
in	O
the	O
FIDELIS	O
areas	O
and	O
from	O
2.9	O
to	O
20.4/100	O
000	O
in	O
the	O
non-FIDELIS	O
areas	O
.	O

Differences	O
-in-	O
differences	O
analysis	O
shows	O
that	O
the	O
differences	O
in	O
the	O
CNRs	O
in	O
the	O
FIDELIS	O
areas	O
were	O
not	O
statistically	O
significantly	O
different	O
from	O
those	O
in	O
the	O
non-	O
FIDELIS	O
areas	O
(	O
P	O
=	O
0.393	O
)	O
.	O

Conclusion	O
:	O
The	O
FIDELIS	O
projects	O
may	O
have	O
contributed	O
to	O
the	O
increase	O
in	O
case	O
detection	O
of	O
new	O
smear	B-P
-	O
positive	O
PTB	O
in	O
China	O
,	O
but	O
the	O
level	O
of	O
evidence	O
is	O
low	O
.	O

Minor	O
physical	O
anomalies	O
and	O
dermatoglyphic	O
signs	O
in	O
affective	O
disorders	O
:	O
A	O
systematic	O
review	O
.	O

The	O
increased	O
prevalence	O
of	O
minor	O
physical	O
anomalies	O
(	O
MPAs	O
)	O
and	O
the	O
abnormalities	O
of	O
dermatoglyphic	O
patterns	O
may	O
be	O
physical	O
manifestations	O
of	O
neurodevelopmental	O
disruption	O
in	O
affective	O
disorders	O
.	O

This	O
paper	O
aims	O
to	O
review	O
the	O
current	O
state	O
of	O
knowledge	O
on	O
the	O
frequency	O
of	O
MPAs	O
and	O
dermatoglyphic	O
abnormalities	O
in	O
mood	O
disorders	O
.	O

A	O
MEDLINE	O
,	O
PsychInfo	O
and	O
Web	O
of	O
Science	O
search	O
was	O
carried	O
out	O
to	O
collect	O
all	O
publications	O
on	O
the	O
frequency	O
of	O
MPAs	O
and	O
on	O
dermatoglyphic	O
traits	O
in	O
bipolar	O
disorder	O
and	O
unipolar	O
depression	O
.	O

24	O
studies	O
on	O
MPAs	O
,	O
19	O
on	O
dermatoglyphics	B-P
,	O
and	O
5	O
dealing	O
with	O
both	O
were	O
found	O
with	O
discrepant	O
findings	O
.	O

The	O
relative	O
contribution	O
of	O
neurodevelopmental	O
retardation	O
to	O
the	O
aetiology	O
of	O
affective	O
disorders	O
remains	O
undetermined	O
,	O
the	O
field	O
is	O
open	O
for	O
further	O
research	O
.	O

Increased	O
recognition	O
of	O
neurodevelopmental	O
processes	O
in	O
the	O
origin	O
of	O
affective	O
disorders	O
may	O
allow	O
for	O
earlier	O
and	O
more	O
effective	O
intervention	O
and	O
prevention	O
.	O

TNF	O
and	O
IL-18	O
cytokines	O
may	O
regulate	O
liver	O
fat	O
storage	O
under	O
homeostasis	O
conditions	O
.	O

The	O
inflammation	O
induced	O
by	O
obesogenic	O
diets	O
is	O
associated	O
with	O
deposition	O
of	O
fat	O
in	O
the	O
liver	O
.	O

On	O
the	O
other	O
hand	O
,	O
anti-inflammatory	O
and	O
immunosuppressive	O
therapies	O
may	O
impact	O
in	O
body	O
fat	O
storage	O
and	O
in	O
liver	O
lipid	O
dynamics	O
.	O

It	O
is	O
important	O
to	O
study	O
specific	O
inflammatory	O
mediators	O
in	O
this	O
context	O
,	O
since	O
their	O
role	O
on	O
hepatic	O
damage	O
is	O
not	O
fully	O
clarified	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
interleukin	O
(	O
IL	O
)	O
-18	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
in	O
liver	O
dysfunction	O
induced	O
by	O
diet	O
.	O

Male	O
C57BL/6	O
wild-type	O
(	O
WT	O
)	O
,	O
IL-18	O
,	O
and	O
TNF	O
receptor	O
1	O
knockout	O
mice	O
(	O
IL-18	O
(	O
-/-	O
)	O
and	O
TNFR1	O
(	O
-/-	O
)	O
)	O
were	O
divided	O
according	O
to	O
the	O
experimental	O
diets	O
:	O
chow	O
diet	O
or	O
a	O
high-refined	O
carbohydrate-containing	O
diet	O
.	O

Alanine	O
aminotransferase	O
was	O
quantified	O
by	O
colorimetric	B-P
analysis	I-P
.	O

Total	O
fat	O
content	O
in	O
the	O
liver	O
was	O
determined	O
by	O
Folch	B-P
methods	I-P
.	O

Levels	O
of	O
TNF	O
,	O
IL-6	O
,	O
IL-4	O
,	O
and	O
IL-13	O
in	O
liver	O
samples	O
were	O
measured	O
by	O
ELISA	B-P
assay	I-P
.	O

IL-18	O
and	O
TNFR	O
knockout	O
mice	O
fed	O
with	O
chow	O
diet	O
showed	O
higher	O
liver	O
triglycerides	O
deposition	O
than	O
WT	O
mice	O
fed	O
with	O
the	O
same	O
diet	O
(	O
WT	O
:	O
131.9	O
±	O
24.5	O
;	O
IL-18	O
(	O
-/-	O
)	O
:	O
239.4	O
±	O
38.12*	O
;	O
TNF	O
(	O
-/-	O
)	O
:	O
179.6	O
±	O
50.45*	O
;	O
*P	O
<	O
0.01	O
)	O
.	O

Furthermore	O
,	O
these	O
animals	O
also	O
showed	O
a	O
worse	O
liver	O
histopathological	O
score	O
and	O
lower	O
levels	O
of	O
TNF	O
,	O
IL-6	O
,	O
IL-4	O
,	O
and	O
IL-13	O
in	O
the	O
liver	O
.	O

Interestingly	O
,	O
treatment	O
with	O
a	O
high-carbohydrate	O
diet	O
did	O
not	O
exacerbate	O
liver	O
damage	O
in	O
IL-18	O
(	O
-/-	O
)	O
and	O
TNFR1	O
(	O
-/-	O
)	O
mice	O
.	O

Our	O
data	O
suggest	O
that	O
IL-18	O
and	O
TNF	O
may	O
be	O
involved	O
on	O
hepatic	O
homeostasis	O
mainly	O
in	O
a	O
context	O
of	O
a	O
healthy	O
diet	O
.	O

Permanence	O
can	O
be	O
Defended	O
.	O

In	O
donation	O
after	O
the	O
circulatory-respiratory	B-P
determination	I-P
of	I-P
death	I-P
(	O
DCDD	B-P
)	O
,	O
the	O
dead	O
donor	O
rule	O
requires	O
that	O
the	O
donor	O
be	O
dead	O
before	O
organ	O
procurement	O
can	O
proceed	O
.	O

Under	O
the	O
relevant	O
limb	O
of	O
the	O
Uniform	O
Determination	O
of	O
Death	O
Act	O
1981	O
(	O
USA	O
)	O
,	O
a	O
person	O
is	O
dead	O
when	O
the	O
cessation	O
of	O
circulatory-respiratory	O
function	O
is	O
'	O
irreversible	O
'	O
.	O

Critics	O
of	O
current	O
practice	O
in	O
DCDD	B-P
have	O
argued	O
that	O
the	O
donor	O
is	O
not	O
dead	O
at	O
the	O
time	O
organs	O
are	O
procured	O
,	O
and	O
so	O
the	O
procurement	O
of	O
organs	O
from	O
these	O
donors	O
violates	O
the	O
dead	O
donor	O
rule	O
.	O

We	O
offer	O
a	O
new	O
argument	O
here	O
in	O
defence	O
of	O
current	O
DCDD	B-P
practice	O
,	O
and	O
,	O
in	O
particular	O
,	O
of	O
the	O
interpretation	O
of	O
the	O
requirement	O
of	O
'	O
irreversibility	O
'	O
as	O
permanence	O
.	O

Evaluation	O
of	O
MIF	O
-173	O
G/C	O
Polymorphism	O
in	O
Turkish	O
Patients	O
with	O
Ankylosing	O
Spondylitis	O
.	O

Ankylosing	O
spondylitis	O
(	O
AS	O
)	O
is	O
a	O
chronic	O
inflammatory	O
disease	O
mainly	O
affecting	O
the	O
spine	O
and	O
sacroiliac	O
joints	O
.	O

Macrophage	O
migration	O
inhibitory	O
(	O
MIF	O
)	O
factor	O
is	O
a	O
regulatory	O
cytokine	O
that	O
inhibits	O
random	O
immune	O
cell	O
migration	O
.	O

MIF	O
gene	O
promoter	O
polymorphisms	O
play	O
a	O
role	O
in	O
the	O
progression	O
of	O
several	O
inflammatory	O
disorders	O
.	O

To	O
investigate	O
the	O
relationship	O
between	O
the	O
MIF	O
gene	O
-173	O
G/C	O
single-nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
and	O
AS	O
.	O

Cross-sectional	O
study	O
.	O

In	O
this	O
study	O
,	O
a	O
total	O
of	O
161	O
AS	O
and	O
194	O
normal	O
controls	O
were	O
recruited	O
.	O

The	O
MIF	O
gene	O
-173	O
G/C	O
SNP	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
using	O
the	O
restriction	B-P
fragment	I-P
length	I-P
polymorphism	I-P
method	I-P
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
terms	O
of	O
genotype	O
distribution	O
(	O
p	O
>	O
0.05	O
)	O
.	O

When	O
wild-type	O
G/G	O
and	O
G/C+C/C	O
genotypes	O
are	O
compared	O
in	O
terms	O
of	O
clinical	O
characteristics	O
,	O
there	O
is	O
a	O
significant	O
difference	O
between	O
the	O
average	O
age	O
and	O
the	O
duration	O
of	O
disease	O
in	O
AS	O
patients	O
(	O
p	O
<	O
0.05	O
)	O
.	O

No	O
significant	O
relationship	O
between	O
AS	O
disease	O
and	O
MIF	O
-173	O
G/C	O
polymorphism	O
was	O
found	O
.	O

MIF	O
-173	O
G/C	O
polymorphism	O
(	O
C	O
allele	O
)	O
may	O
affect	O
the	O
time	O
of	O
onset	O
and	O
the	O
duration	O
of	O
disease	O
in	O
AS	O
patients	O
.	O

Demonstration	O
of	O
a	O
bronchobiliary	O
fistula	O
using	O
magnetic	B-P
resonance	I-P
image	I-P
with	O
hepatospecific	O
contrast	O
agent	O
.	O

Bronchobiliary	O
fistulas	O
are	O
a	O
rare	O
entity	O
of	O
difficult	O
diagnosis	O
.	O

The	O
utility	O
of	O
magnetic	B-P
resonance	I-P
image	I-P
(	O
MRI	B-P
)	O
with	O
hepatospecific	O
contrast	O
agents	O
to	O
demonstrate	O
such	O
condition	O
is	O
seldom	O
described	O
in	O
the	O
literature	O
.	O

This	O
case	O
reports	O
a	O
patient	O
with	O
pulmonary	O
infection	O
with	O
a	O
past	O
history	O
of	O
hepatic	O
surgery	O
for	O
hydatid	O
disease	O
in	O
whom	O
the	O
presence	O
of	O
bile	O
in	O
the	O
sputum	O
rose	O
the	O
suspicious	O
of	O
a	O
bronchobiliary	O
fistula	O
.	O

MRI	B-P
with	O
hepatospecific	O
contrast	O
agents	O
showed	O
the	O
communication	O
between	O
the	O
biliary	O
and	O
bronchial	O
tree	O
and	O
provided	O
anatomic	O
data	O
to	O
allow	O
a	O
therapeutic	O
approach	O
.	O

Rifampicin	O
-	O
induced	O
adrenal	O
crisis	O
in	O
a	O
patient	O
with	O
tuberculosis	O
:	O
a	O
therapeutic	O
challenge	O
.	O

A	O
55-year-old	O
Indian	O
man	O
presented	O
with	O
productive	O
cough	O
and	O
a	O
large	O
left	O
pleural	O
effusion	O
.	O

Pleural	B-P
fluid	I-P
culture	I-P
grew	O
Mycobacterium	O
tuberculosis	O
,	O
and	O
he	O
was	O
started	O
on	O
antituberculosis	O
therapy	O
.	O

One	O
week	O
later	O
,	O
the	O
patient	O
presented	O
to	O
hospital	O
with	O
drowsiness	O
,	O
dehydration	O
and	O
hypotension	O
.	O

He	O
was	O
transferred	O
to	O
critical	O
care	O
and	O
only	O
improved	O
after	O
starting	O
hydrocortisone	O
and	O
stopping	O
rifampicin	O
.	O

His	O
short	B-P
synACTHen	I-P
test	I-P
subsequently	O
confirmed	O
primary	O
adrenal	O
insufficiency	O
,	O
and	O
a	O
CT	B-P
of	O
the	O
abdomen	O
showed	O
bilateral	O
adrenal	O
enlargement	O
.	O

Rifampicin	O
is	O
known	O
to	O
accelerate	O
cortisol	O
metabolism	O
.	O

We	O
report	O
the	O
rare	O
case	O
of	O
a	O
rifampicin	O
-	O
induced	O
adrenal	O
crisis	O
as	O
a	O
first	O
presentation	O
of	O
Addison	O
's	O
disease	O
in	O
a	O
patient	O
with	O
tuberculous	O
infiltration	O
of	O
the	O
adrenal	O
glands	O
.	O

The	O
correlation	O
of	O
the	O
results	O
of	O
the	O
survey	O
SNOT-20	O
of	O
objective	O
studies	O
of	O
nasal	O
obstruction	O
and	O
the	O
geometry	O
of	O
the	O
nasal	O
cavities	O
.	O

In	O
this	O
paper	O
were	O
verified	O
the	O
correlation	O
between	O
the	O
results	O
of	O
the	O
survey	O
SNOT-20	O
and	O
the	O
results	O
of	O
the	O
objective	O
tests	O
of	O
nasal	O
obstruction	O
which	O
are	O
rhinomanometry	B-P
and	O
acoustic	B-P
rhinometry	I-P
before	O
and	O
after	O
surgical	O
treatment	O
,	O
such	O
as	O
septoplasty	O
,	O
septoconchoplasty	B-P
,	O
ethmoidectomy	O
and	O
septoethmoidectomy	B-P
.	O

The	O
material	O
used	O
in	O
this	O
study	O
was	O
233	O
patients	O
diagnosed	O
routinely	O
in	O
the	O
Rhinomanometry	B-P
Laboratory	O
of	O
the	O
Department	O
of	O
Otolaryngology	O
at	O
the	O
Medical	O
University	O
of	O
Warsaw	O
,	O
reporting	O
rhinological	O
problems	O
.	O

Data	O
were	O
obtained	O
from	O
70	O
women	O
(	O
31,4	O
%	O
)	O
ranging	O
in	O
ages	O
from	O
18	O
to	O
81	O
years	O
of	O
age	O
and	O
153	O
men	O
(	O
68,6	O
%	O
)	O
ranging	O
in	O
ages	O
from	O
16	O
to	O
81	O
years	O
of	O
age	O
.	O

The	O
researches	O
presented	O
in	O
the	O
study	O
were	O
made	O
using	O
the	O
device	O
RhinoMetrics	O
SRE	O
2100	O
which	O
combines	O
the	O
Rhinomanometer	O
(	O
RhinoStream	O
)	O
and	O
Acoustic	O
Rhinometer	O
(	O
RhinoScan	O
)	O
Interacoustics	O
AS	O
(	O
Denmark	O
)	O
.	O

Survey	O
SNOT-20	O
(	O
Sino-Nasal	O
Outcome	O
Test-20	O
)	O
in	O
Polish	O
was	O
completed	O
by	O
patients	O
before	O
surgery	O
and	O
during	O
the	O
postoperative	O
control	O
visits	O
.	O

The	O
calculated	O
correlations	O
between	O
the	O
objective	O
parameter	O
,	O
which	O
was	O
the	O
resistance	O
to	O
the	O
flow	O
of	O
air	O
through	O
the	O
nasal	O
cavity	O
,	O
and	O
the	O
subjective	O
feelings	O
of	O
respondents	O
expressed	O
in	O
the	O
survey	O
SNOT-20	O
were	O
generally	O
weak	O
,	O
and	O
statistical	O
significance	O
was	O
achieved	O
with	O
respect	O
to	O
the	O
first	O
question	O
survey	O
(	O
the	O
severity	O
of	O
the	O
nose	O
obstruction	O
)	O
for	O
all	O
components	O
of	O
resistance	O
flow	O
.	O

The	O
feeling	O
of	O
nasal	O
obstruction	O
is	O
the	O
most	O
reproducible	O
and	O
reliable	O
complaint	O
reported	O
by	O
the	O
patient	O
with	O
rhinological	O
problems	O
.	O

Distal	O
posterior	O
cerebral	O
artery	O
revascularization	O
for	O
a	O
fusiform	O
PCA	O
aneurysm	O
:	O
A	O
lesson	O
learned	O
.	O

The	O
need	O
for	O
revascularization	O
with	O
proximal	O
posterior	O
cerebral	O
artery	O
occlusion	O
in	O
the	O
treatment	O
of	O
giant	O
and	O
fusiform	O
aneurysms	O
is	O
unclear	O
.	O

While	O
early	O
series	O
demonstrated	O
only	O
about	O
a	O
10	O
%	O
chance	O
of	O
infarction	O
following	O
posterior	O
cerebral	O
artery	O
occlusion	O
,	O
recently	O
several	O
authors	O
have	O
advocated	O
a	O
bypass	O
prior	O
to	O
parent	O
vessel	O
sacrifice	O
in	O
all	O
cases	O
.	O

We	O
present	O
the	O
case	O
of	O
an	O
adult	O
man	O
with	O
a	O
fusiform	O
aneurysm	O
of	O
the	O
right	O
posterior	O
cerebral	O
artery	O
at	O
the	O
P2-P3	O
junction	O
.	O

He	O
clinically	O
failed	O
a	O
balloon	O
test	O
occlusion	O
preoperatively	O
and	O
therefore	O
underwent	O
an	O
occipital	O
artery	O
to	O
distal	O
posterior	O
cerebral	O
artery	O
bypass	O
with	O
subsequent	O
endovascular	O
occlusion	O
of	O
the	O
parent	O
vessel	O
and	O
aneurysm	O
.	O

Despite	O
the	O
fact	O
that	O
the	O
immediate	O
and	O
6	O
month	O
follow	O
up	O
cerebral	B-P
angiography	I-P
confirmed	O
a	O
patent	O
bypass	O
,	O
the	O
patient	O
still	O
developed	O
a	O
posterior	O
cerebral	O
artery	O
territory	O
stroke	O
.	O

We	O
believe	O
this	O
case	O
demonstrates	O
that	O
successful	O
distal	O
revascularization	O
in	O
the	O
setting	O
of	O
proximal	O
posterior	O
cerebral	O
artery	O
occlusion	O
does	O
not	O
guarantee	O
against	O
cerebral	O
ischemia	O
and	O
infarction	O
even	O
in	O
those	O
patients	O
that	O
fail	O
a	O
test	O
occlusion	O
.	O

Untoward	O
events	O
associated	O
with	O
aberrant	O
fluid	O
infusion	O
during	O
cataract	O
surgery	O
:	O
Laboratory	B-P
study	I-P
with	O
corroborative	O
clinical	O
observations	O
.	O

To	O
determine	O
the	O
relationship	O
between	O
untoward	O
events	O
noted	O
during	O
phacoemulsification	O
surgery	O
associated	O
with	O
aberrant	O
infusion	O
misdirection	O
and	O
their	O
causal	O
relationship	O
to	O
current	O
infusion	O
sleeve	O
design	O
.	O

The	O
New	O
York	O
Eye	O
&	O
Ear	O
Infirmary	O
of	O
Mt	O
.	O

Sinai	O
,	O
New	O
York	O
,	O
New	O
York	O
,	O
USA	O
.	O

Retrospective	O
case	O
reports	O
and	O
experimental	O
study	O
.	O

Observations	O
of	O
live	O
cataract	O
surgery	O
were	O
documented	O
with	O
high-definition	O
videography	O
using	O
3	O
commercial	O
phacoemulsification	O
platforms	O
.	O

Laboratory	B-P
studies	I-P
using	O
a	O
Photron	O
MC2	O
high-speed	O
camera	O
and	O
the	O
Kitaro	O
cataract	O
surgical	O
system	O
were	O
used	O
to	O
simulate	O
surgical	B-P
maneuvers	I-P
and	O
assess	O
flow	O
patterns	O
and	O
visualize	O
the	O
dynamics	O
of	O
fluid	O
movement	O
in	O
the	O
anterior	O
chamber	O
.	O

Color-flow	B-P
Doppler	I-P
ultrasound	I-P
studies	I-P
were	O
used	O
to	O
demonstrate	O
the	O
effect	O
of	O
infusion	O
fluid	O
on	O
the	O
iris	O
during	O
surgery	O
.	O

Misdirected	O
infusion	O
and	O
floppy-iris	O
leaflets	O
were	O
determined	O
to	O
be	O
secondary	O
to	O
a	O
fulcrum	O
effect	O
at	O
the	O
corneal	O
wound	O
that	O
constrained	O
movement	O
of	O
the	O
standard	O
silicone	O
sleeves	O
.	O

The	O
phacoemulsification	O
needles	O
could	O
therefore	O
decenter	O
independently	O
of	O
the	O
infusion	O
sleeve	O
,	O
attenuating	O
infusion	O
volume	O
down	O
1	O
side	O
of	O
the	O
sleeve	O
and	O
,	O
as	O
a	O
result	O
,	O
obstructing	O
fluid	O
exiting	O
the	O
ipsilateral	O
port	O
.	O

Untoward	O
events	O
associated	O
with	O
aberrant	O
fluid	O
infusion	O
during	O
phacoemulsification	O
surgery	O
were	O
secondary	O
to	O
a	O
fulcrum	O
effect	O
at	O
the	O
corneal	O
wound	O
.	O

Complications	O
included	O
misdirected	O
infusion	O
that	O
facilitated	O
the	O
transport	O
of	O
retained	O
nuclear	O
fragments	O
to	O
the	O
vitreous	O
,	O
inconsistent	O
lens	O
followability	O
during	O
phacoemulsification	O
,	O
and	O
exaggerated	O
movements	O
of	O
the	O
iris	O
particularly	O
consistent	O
with	O
intraoperative	O
floppy-iris	O
syndrome	O
and	O
pseudoexfoliation	O
.	O

None	O
of	O
the	O
authors	O
has	O
a	O
financial	O
or	O
proprietary	O
interest	O
in	O
any	O
material	O
or	O
method	O
mentioned	O
.	O

Pedicle	O
Screw	O
Combined	O
With	O
Lateral	O
Mass	O
Screw	O
Fixation	O
in	O
the	O
Treatment	O
of	O
Basilar	O
Invagination	O
and	O
Congenital	O
C2-C3	O
Fusion	O
.	O

Clinical	O
evaluation	O
of	O
a	O
surgical	O
fixation	O
technique	O
featuring	O
combined	O
use	O
of	O
pedicle	O
screw	O
and	O
lateral	O
mass	O
screw	O
(	O
LMS	O
)	O
.	O

Introduction	O
of	O
a	O
novel	O
technique	O
for	O
the	O
treatment	O
of	O
congenital	O
C2-C3	O
fusion	O
and	O
basilar	O
invagination	O
(	O
BI	O
)	O
.	O

Posterior	O
occipitocervical	O
fixation	O
using	O
C2	O
pedicle	O
screw	O
was	O
widely	O
used	O
for	O
BI	O
.	O

However	O
,	O
in	O
cases	O
where	O
BI	O
is	O
concurrent	O
with	O
congenital	O
C2-C3	O
fusion	O
,	O
the	O
C2	O
pedicles	O
tend	O
to	O
be	O
thinner	O
than	O
that	O
in	O
normal	O
population	O
and	O
hence	O
more	O
likely	O
to	O
fail	O
.	O

We	O
prompted	O
to	O
tackle	O
the	O
issue	O
by	O
combining	O
the	O
pedicle	O
screw	O
with	O
the	O
additional	O
use	O
of	O
LMS	O
in	O
attempt	O
to	O
strengthen	O
the	O
fixation	O
.	O

Twenty-five	O
patients	O
who	O
underwent	O
combined	O
pedicle	O
screw	O
with	O
LMS	O
fixation	O
were	O
retrospectively	O
studied	O
.	O

The	O
instrument	O
position	O
,	O
fusion	O
status	O
,	O
and	O
complications	O
were	O
analyzed	O
.	O

None	O
had	O
spinal	O
cord	O
or	O
vertebral	O
artery	O
injury	O
.	O

The	O
average	O
follow-up	O
time	O
was	O
20	O
months	O
.	O

Solid	O
fusion	O
was	O
achieved	O
in	O
23	O
patients	O
(	O
92	O
%	O
)	O
as	O
detected	O
radiologically	B-P
.	O

Two	O
cases	O
suffered	O
from	O
recurred	O
BI	O
and	O
instrument	O
failure	O
but	O
eventually	O
achieved	O
solid	O
fusion	O
between	O
the	O
occiput	O
and	O
C2	O
was	O
after	O
revision	O
.	O

Among	O
all	O
25	O
patients	O
,	O
4	O
suffered	O
from	O
complications	O
including	O
instrument	O
s	O
failure	O
,	O
cerebrospinal	O
fluid	O
leakage	O
,	O
and	O
intracranial	O
infection	O
.	O

The	O
clinical	O
outcome	O
indicates	O
that	O
the	O
technique	O
is	O
reliable	O
for	O
the	O
treatment	O
of	O
BI	O
with	O
congenital	O
C2-C3	O
fusion	O
.	O

Map	O
learning	O
and	O
working	O
memory	O
:	O
Multimodal	O
learning	O
strategies	O
.	O

The	O
current	O
research	O
investigated	O
whether	O
learning	O
spatial	O
information	O
from	O
a	O
map	O
involves	O
different	O
modalities	O
,	O
which	O
are	O
managed	O
by	O
discrete	O
components	O
in	O
working	O
memory	O
.	O

In	O
four	O
experiments	O
,	O
participants	O
studied	O
a	O
map	O
either	O
while	O
performing	O
a	O
simultaneous	O
interference	O
task	O
(	O
high	O
cognitive	O
load	O
)	O
or	O
without	O
interference	O
(	O
low	O
cognitive	O
load	O
)	O
.	O

The	O
modality	O
of	O
interference	O
varied	O
between	O
experiments	O
.	O

Experiment	O
1	O
used	O
a	O
tapping	O
task	O
(	O
visuospatial	O
)	O
,	O
Experiment	O
2	O
a	O
backwards	O
counting	O
task	O
(	O
verbal	O
)	O
,	O
Experiment	O
3	O
an	O
articulatory	O
suppression	B-P
task	I-P
(	O
verbal	O
)	O
and	O
Experiment	O
4	O
an	O
n-back	O
task	O
(	O
central	O
executive	O
)	O
.	O

Spatial	O
recall	O
was	O
assessed	O
in	O
two	O
tests	O
,	O
directional	O
judgements	O
and	O
map	O
drawing	O
.	O

Cognitive	O
load	O
was	O
found	O
to	O
affect	O
spatial	O
recall	O
detrimentally	O
regardless	O
of	O
interference	O
modality	O
.	O

The	O
findings	O
suggest	O
that	O
when	O
learning	O
maps	O
people	O
use	O
a	O
multimodal	O
learning	O
strategy	O
,	O
utilising	O
resources	O
from	O
all	O
components	O
of	O
working	O
memory	O
.	O

RBBP6	O
:	O
a	O
potential	O
biomarker	O
of	O
apoptosis	O
induction	O
in	O
human	O
cervical	O
cancer	O
cell	O
lines	O
.	O

Overexpression	O
of	O
RBBP6	O
in	O
cancers	O
of	O
the	O
colon	O
,	O
lung	O
,	O
and	O
esophagus	O
makes	O
it	O
a	O
potential	O
target	O
in	O
anticancer	O
therapy	O
.	O

This	O
is	O
especially	O
important	O
because	O
RBBP6	O
associates	O
with	O
the	O
tumor	O
suppressor	O
gene	O
p53	O
,	O
the	O
inactivation	O
of	O
which	O
has	O
been	O
linked	O
to	O
over	O
50	O
%	O
of	O
all	O
cancer	O
types	O
.	O

However	O
,	O
the	O
expression	O
of	O
RBBP6	O
in	O
cancer	O
and	O
its	O
interaction	O
with	O
p53	O
are	O
yet	O
to	O
be	O
understood	O
in	O
order	O
to	O
determine	O
whether	O
or	O
not	O
RBBP6	O
is	O
cancer	O
promoting	O
and	O
therefore	O
a	O
potential	O
biomarker	O
.	O

In	O
this	O
study	B-P
,	O
we	O
manipulated	O
RBBP6	O
expression	O
levels	O
followed	O
by	O
treatment	O
with	O
either	O
camptothecin	O
or	O
γ-aminobutyric	O
acid	O
in	O
cervical	O
cancer	O
cells	O
to	O
induce	O
apoptosis	O
or	O
cell	O
cycle	O
arrest	O
.	O

We	O
began	O
by	O
staining	B-P
human	O
cervical	O
cancer	O
tissue	O
sections	O
with	O
anti-RBBP6	O
monoclonal	O
antibody	O
to	O
evaluate	O
the	O
extent	O
of	O
expression	O
of	O
RBBP6	O
in	O
patients	O
'	O
specimens	O
.	O

We	O
followed	O
on	O
with	O
silencing	O
the	O
overexpression	O
of	O
RBBP6	O
and	O
treatment	O
with	O
anticancer	O
agents	O
to	O
evaluate	O
how	O
the	O
specimens	O
respond	O
to	O
combinational	O
therapy	O
.	O

Apoptosis	O
induction	O
was	O
evaluated	O
through	O
confocal	O
microscope	O
,	O
and	O
flow	B-P
cytometry	I-P
using	O
annexin	O
V	O
staining	B-P
,	O
and	O
also	O
by	O
checking	O
the	O
mitochondrial	O
and	O
caspase-3/7	O
activity	O
.	O

Cell	O
cycle	O
arrest	O
was	O
evaluated	O
using	O
flow	B-P
cytometry	I-P
through	O
staining	B-P
with	O
propidium	O
iodide	O
.	O

RBBP6	O
was	O
highly	O
expressed	O
in	O
cervical	O
cancer	O
tissue	O
sections	O
that	O
were	O
in	O
stage	O
II	O
or	O
III	O
of	O
development	O
.	O

Silencing	O
RBBP6	O
followed	O
by	O
treatment	O
with	O
γ-aminobutyric	O
acid	O
and	O
camptothecin	O
seems	O
to	O
sensitize	O
cells	O
to	O
apoptosis	O
induction	O
rather	O
than	O
cell	O
cycle	O
arrest	O
.	O

Overexpression	O
of	O
RBBP6	O
seems	O
to	O
promote	O
S-phase	O
in	O
cell	O
cycle	O
and	O
cell	O
proliferation	O
.	O

These	O
results	O
predict	O
a	O
proliferative	O
role	O
of	O
RBBP6	O
in	O
cancer	O
progression	O
rather	O
than	O
as	O
a	O
cancer-causing	O
gene	O
.	O

Furthermore	O
,	O
sensitization	O
of	O
cells	O
to	O
camptothecin	O
-	O
induced	O
apoptosis	O
by	O
RBBP6	O
targeting	O
suggests	O
a	O
promising	O
tool	O
for	O
halting	O
cervical	O
cancer	O
progression	O
.	O

Detection	O
of	O
AMA-M2	O
in	O
human	O
saliva	O
:	O
Potentials	O
in	O
diagnosis	O
and	O
monitoring	O
of	O
primary	O
biliary	O
cholangitis	O
.	O

Serum	O
anti-mitochondrial	O
antibody	O
type	O
2	O
(	O
AMA-M2	O
)	O
is	O
considered	O
as	O
a	O
pivotal	O
biomarker	O
for	O
the	O
diagnosis	O
of	O
primary	O
biliary	O
cholangitis	O
(	O
PBC	O
)	O
.	O

However	O
,	O
serological	B-P
tests	I-P
have	O
many	O
limitations	O
,	O
including	O
inconvenience	O
,	O
invasiveness	O
,	O
and	O
infection	O
risks	O
.	O

Thus	O
,	O
a	O
less	O
invasive	O
approach	O
to	O
detect	O
AMA-M2	B-P
titer	I-P
is	O
desirable	O
.	O

We	O
examined	O
salivary	O
AMA-M2	O
of	O
potential	O
PBC	O
patients	O
and	O
found	O
that	O
AMA-M2	O
could	O
be	O
detected	O
only	O
in	O
saliva	O
of	O
serum	O
AMA-M2-positive	O
PBC	O
patients	O
,	O
but	O
not	O
in	O
saliva	O
of	O
serum	O
AMA-M2-negative	O
PBC	O
patients	O
,	O
oral	O
lichen	O
planus	O
patients	O
(	O
OLP	O
)	O
patients	O
,	O
or	O
healthy	O
controls	O
.	O

Furthermore	O
,	O
the	O
concentration	O
of	O
salivary	O
AMA-M2	O
was	O
positively	O
correlated	O
with	O
the	O
amount	O
of	O
serum	O
AMA-M2	O
in	O
patients	O
.	O

The	O
salivary	O
inflammatory	O
cytokines	O
were	O
increased	O
in	O
the	O
PBC	O
,	O
consistent	O
with	O
the	O
results	O
of	O
serum	O
test	B-P
.	O

These	O
findings	O
indicated	O
that	O
saliva	O
might	O
be	O
a	O
less	O
invasive	O
and	O
cost-effective	O
medium	O
to	O
accurately	O
test	O
for	O
AMA-M2	B-P
levels	I-P
and	O
this	O
is	O
a	O
promising	O
development	O
for	O
the	O
diagnosis	O
and	O
monitoring	O
of	O
PBC	O
.	O

L1	O
retrotransposon	O
expression	O
in	O
circulating	O
tumor	O
cells	O
.	O

Long	O
interspersed	O
nuclear	O
element	O
1	O
(	O
LINE-1	O
or	O
L1	O
)	O
belongs	O
to	O
the	O
non-long	O
terminal	O
repeat	O
(	O
non-LTR	O
)	O
retrotransposon	O
family	O
,	O
which	O
has	O
been	O
implicated	O
in	O
carcinogenesis	O
and	O
disease	O
progression	O
.	O

Circulating	O
tumor	O
cells	O
(	O
CTCs	O
)	O
are	O
also	O
known	O
to	O
be	O
involved	O
in	O
cancer	O
progression	O
.	O

The	O
present	O
study	O
aimed	O
to	O
compare	O
the	O
L1	O
expression	O
between	O
circulating	O
tumor	O
cells	O
and	O
non-cancerous	O
samples	O
.	O

Blood	O
samples	O
were	O
collected	O
from	O
10	O
healthy	O
individuals	O
and	O
22	O
patients	O
with	O
different	O
types	O
of	O
cancer	O
.	O

The	O
whole	O
blood	O
cells	O
were	O
isolated	O
using	O
enrichment	O
protocols	O
and	O
the	O
DNA	O
and	O
RNA	O
were	O
extracted	O
.	O

RT-qPCR	O
was	O
performed	O
for	O
L1-ORF1	O
(	O
open	O
reading	O
frame	O
1	O
)	O
and	O
L1-ORF2	O
,	O
using	O
18S	O
rRNA	O
as	O
the	O
reference	O
gene	O
.	O

The	O
data	O
were	O
analyzed	O
with	O
the	O
Livak	O
method	O
and	O
statistical	O
analyses	O
were	O
carried	O
out	O
with	O
the	O
Mann-Whitney	O
and	O
Kruskal-Wallis	O
tests	O
.	O

In	O
parallel	O
with	O
the	O
above	O
molecular	O
biology	O
experiments	O
,	O
FISH	O
experiments	O
were	O
performed	O
on	O
the	O
interphase	O
nuclei	O
of	O
the	O
cells	O
for	O
the	O
detection	O
of	O
ORF2	O
RNA	O
.	O

DNA	B-P
analysis	I-P
revealed	O
the	O
presence	O
of	O
both	O
ORF1	O
and	O
ORF2	O
in	O
all	O
samples	O
.	O

RNA	O
expression	O
experiments	O
demonstrated	O
that	O
ORF1	O
was	O
not	O
expressed	O
in	O
all	O
samples	O
,	O
while	O
ORF2	O
was	O
expressed	O
at	O
varying	O
levels	O
in	O
the	O
non-cancer	O
samples	O
and	O
the	O
samples	O
representing	O
the	O
different	O
cancer	O
types	O
.	O

A	O
significant	O
difference	O
in	O
ORF2	O
expression	O
was	O
observed	O
between	O
the	O
CTCs	O
and	O
non-cancer	O
samples	O
(	O
p	O
=	O
0,00043	O
)	O
,	O
and	O
significant	O
differences	O
were	O
also	O
observed	O
between	O
normal	O
and	O
lung	O
(	O
p	O
=	O
0,034	O
)	O
,	O
pancreatic	O
(	O
p	O
=	O
0,022	O
)	O
,	O
prostate	O
(	O
p	O
=	O
0,014	O
)	O
,	O
and	O
unknown	O
primary	O
of	O
origin	O
(	O
p	O
=	O
0,0039	O
)	O
cancer	O
samples	O
.	O

Cytogenetic	O
analysis	O
revealed	O
higher	O
levels	O
of	O
ORF2	O
in	O
the	O
nuclei	O
of	O
CTCs	O
than	O
in	O
normal	O
samples	O
.	O

This	O
study	O
highlights	O
the	O
significant	O
difference	O
in	O
L1-ORF2	O
expression	O
between	O
CTCs	O
and	O
normal	O
samples	O
.	O

The	O
increased	O
expression	O
levels	O
observed	O
for	O
CTCs	O
may	O
be	O
correlated	O
with	O
the	O
characteristic	O
features	O
of	O
these	O
cells	O
.	O

Fluoride	O
concentration	O
in	O
saliva	O
and	O
biofilm	O
fluid	O
following	O
the	O
application	O
of	O
three	O
fluoride	O
varnishes	O
.	O

Most	O
of	O
the	O
commercially	O
available	O
fluoride	O
varnishes	O
(	O
FV	O
)	O
have	O
not	O
been	O
evaluated	O
for	O
their	O
cariostatic	O
properties	O
.	O

Consequently	O
,	O
the	O
aim	O
of	O
this	O
in	O
vivo	O
study	O
was	O
to	O
investigate	O
intra	O
-	O
oral	O
fluoride	O
retention	O
and	O
clearance	O
patterns	O
from	O
three	O
different	O
FV	O
.	O

Eighteen	O
subjects	O
(	O
7-11	O
years	O
)	O
participated	O
in	O
a	O
laboratory	O
analyst	O
-	O
blinded	O
,	O
randomized	O
,	O
crossover	O
study	O
comparing	O
the	O
ability	O
of	O
5	O
%	O
sodium	O
fluoride	O
varnishes	O
(	O
CavityShield-CS	O
,	O
Enamel	O
Pro-EP	O
,	O
Vanish-V	O
)	O
to	O
enhance	O
fluoride	O
concentrations	O
in	O
biofilm	O
fluid	O
,	O
centrifuged	O
and	O
whole	O
saliva	O
over	O
a	O
period	O
of	O
48h	O
after	O
a	O
single	O
FV	O
application	O
.	O

Similar	O
fluoride	O
concentration	O
×	O
time	O
patterns	O
were	O
noted	O
for	O
all	O
investigated	O
FV	O
and	O
studied	O
variables	O
,	O
with	O
the	O
highest	O
fluoride	O
concentrations	O
observed	O
for	O
the	O
first	O
biological	O
sample	O
collected	O
after	O
FV	O
application	O
(	O
30min	O
)	O
.	O

Mean±SE	O
(	O
area	O
under	O
fluoride	O
clearance	O
curve	O
)	O
values	O
were	O
(	O
μg	O
F/g	O
or	O
ml×min	O
)	O
:	O
biofilm	O
fluid	O
-	O
CS	O
(	O
472±191	O
)	O
,	O
EP	O
(	O
423±75	O
)	O
,	O
V	O
(	O
1264±279	O
)	O
;	O
centrifuged	O
saliva	O
-	O
CS	O
(	O
42±7	O
)	O
,	O
EP	O
(	O
19±3	O
)	O
,	O
V	O
(	O
41±8	O
)	O
;	O
whole	O
saliva	O
-	O
CS	O
(	O
68±11	O
)	O
,	O
EP	O
(	O
64±10	O
)	O
,	O
V	O
(	O
60±7	O
)	O
.	O

V	O
delivered	O
more	O
fluoride	O
to	O
biofilm	O
fluid	O
than	O
CS	O
(	O
p=0.0116	O
)	O
and	O
EP	O
(	O
p=0.0065	O
)	O
,	O
which	O
did	O
not	O
differ	O
(	O
p=0.27	O
)	O
.	O

For	O
centrifuged	O
saliva	O
,	O
CS	O
and	O
V	O
were	O
not	O
significantly	O
different	O
(	O
p=0.86	O
)	O
,	O
but	O
resulted	O
in	O
higher	O
fluoride	O
retention	O
than	O
EP	O
(	O
p	O
<	O
0.0008	O
)	O
.	O

No	O
significant	O
differences	O
among	O
FV	O
were	O
observed	O
for	O
whole	O
saliva	O
(	O
p=0.79	O
)	O
.	O

The	O
present	O
study	O
has	O
shown	O
that	O
FV	O
vary	O
in	O
their	O
ability	O
to	O
deliver	O
fluoride	O
intra	O
-	O
orally	O
potentially	O
related	O
to	O
formulation	O
differences	O
.	O

To	O
what	O
extent	O
the	O
present	O
findings	O
relate	O
to	O
clinical	O
efficacy	O
remains	O
,	O
however	O
,	O
to	O
be	O
determined	B-P
.	O

Clinical	O
research	O
that	O
investigates	O
fluoride	O
release	O
patterns	O
into	O
saliva	O
and	O
biofilm	O
fluid	O
from	O
different	O
FV	O
products	O
is	O
insufficient	O
.	O

More	O
research	O
is	O
needed	O
to	O
investigate	O
different	O
FV	O
formulations	O
for	O
their	O
efficacy	O
in	O
order	O
to	O
help	O
clinicians	O
make	O
better	O
evidence	O
based	O
treatment	O
choices	O
.	O

TGFβ	O
Contributes	O
to	O
the	O
Anti-inflammatory	O
Effects	O
of	O
Tauroursodeoxycholic	O
Acid	O
on	O
an	O
Animal	O
Model	O
of	O
Acute	O
Neuroinflammation	O
.	O

The	O
bile	O
acid	O
conjugate	O
tauroursodeoxycholic	O
acid	O
(	O
TUDCA	O
)	O
is	O
a	O
neuroprotective	O
agent	O
in	O
various	O
animal	O
models	O
of	O
neuropathologies	O
.	O

We	O
have	O
previously	O
shown	O
the	O
anti-inflammatory	O
properties	O
of	O
TUDCA	O
in	O
an	O
animal	O
model	O
of	O
acute	O
neuroinflammation	O
.	O

Here	O
,	O
we	O
present	O
a	O
new	O
anti-inflammatory	O
mechanism	O
of	O
TUDCA	O
through	O
the	O
regulation	O
of	O
transforming	O
growth	O
factor	O
β	O
(	O
TGFβ	O
)	O
pathway	O
.	O

The	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
was	O
injected	O
intravenously	O
(	O
iv	O
)	O
on	O
TGFβ	O
reporter	O
mice	O
(	O
Smad-binding	O
element	O
(	O
SBE	O
)	O
/Tk-Luc	O
)	O
to	O
study	O
in	O
their	O
brains	O
the	O
real-time	B-P
activation	I-P
profile	I-P
of	O
the	O
TGFβ	O
pathway	O
in	O
a	O
non-invasive	O
way	O
.	O

The	O
activation	O
of	O
the	O
TGFβ	O
pathway	O
in	O
the	O
brain	O
of	O
SBE/Tk-Luc	O
mice	O
increased	O
24	O
h	O
after	O
LPS	O
injection	O
,	O
compared	O
to	O
control	O
animals	O
.	O

This	O
activation	O
peak	O
increased	O
further	O
in	O
mice	O
treated	O
with	O
both	O
LPS	O
and	O
TUDCA	O
than	O
in	O
mice	O
treated	O
with	O
LPS	O
only	O
.	O

The	O
enhanced	O
TGFβ	O
activation	O
in	O
mice	O
treated	O
with	O
LPS	O
and	O
TUDCA	O
correlated	O
with	O
both	O
an	O
increase	O
in	O
TGFβ3	O
transcript	O
in	O
mouse	O
brain	O
and	O
an	O
increase	O
in	O
TGFβ3	O
immunoreactivity	O
in	O
microglia	O
/	O
macrophages	O
,	O
endothelial	O
cells	O
,	O
and	O
neurons	O
.	O

Inhibition	O
of	O
the	O
TGFβ	O
receptor	O
with	O
SB431542	O
drug	O
reverted	O
the	O
effect	O
of	O
TUDCA	O
on	O
microglia	O
/	O
macrophages	O
activation	O
and	O
on	O
TGFβ3	O
immunoreactivity	O
.	O

Under	O
inflammatory	O
conditions	O
,	O
treatment	O
with	O
TUDCA	O
enhanced	O
further	O
the	O
activation	O
of	O
TGFβ	O
pathway	O
in	O
mouse	O
brain	O
and	O
increased	O
the	O
expression	O
of	O
TGFβ3	O
.	O

Therefore	O
,	O
the	O
induction	O
of	O
TGFβ3	O
by	O
TUDCA	O
might	O
act	O
as	O
a	O
positive	O
feedback	O
,	O
increasing	O
the	O
initial	O
activation	O
of	O
the	O
TGFβ	O
pathway	O
by	O
the	O
inflammatory	O
stimulus	O
.	O

Our	O
findings	O
provide	O
proof-of-concept	O
that	O
TGFβ	O
contributes	O
to	O
the	O
anti-inflammatory	O
effect	O
of	O
TUDCA	O
under	O
neuroinflammatory	O
conditions	O
.	O

Systemic	O
matrix	O
metalloproteinase-8	O
response	O
in	O
chronic	O
tonsillitis	O
.	O

The	O
development	O
of	O
several	O
life-long	O
diseases	O
,	O
such	O
as	O
coronary	O
heart	O
disease	O
,	O
is	O
affected	O
by	O
low-grade	O
systemic	O
inflammation	O
.	O

Data	O
on	O
the	O
potential	O
long-term	O
health	O
effects	O
of	O
chronic	O
tonsillitis	O
are	O
limited	O
.	O

Many	O
inflammatory	O
conditions	O
present	O
with	O
enhanced	O
systemic	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-8	O
response	O
.	O

In	O
head	O
and	O
neck	O
cancer	O
,	O
high	O
plasma	O
level	O
of	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
(	O
TIMP	O
)	O
-1	O
predicts	O
poor	O
prognosis	O
.	O

We	O
analyzed	O
S-MMP-8	O
with	O
immunofluorometric	B-P
assay	I-P
and	O
S-TIMP-1	O
with	O
an	O
immunosorbent	B-P
assay	I-P
in	O
175	O
consecutive	O
patients	O
undergoing	O
tonsillectomy	O
for	O
benign	O
tonsillar	O
disease	O
,	O
and	O
in	O
33	O
control	O
patients	O
with	O
tonsillar	O
squamous	O
cell	O
carcinoma	O
.	O

Tonsillar	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
status	O
was	O
determined	O
by	O
PCR	O
.	O

In	O
patients	O
with	O
benign	O
tonsillar	O
disease	O
,	O
chronic	O
tonsillitis	O
without	O
hypertrophy	O
was	O
associated	O
with	O
enhanced	O
systemic	O
MMP-8	O
response	O
.	O

Compared	O
to	O
patients	O
with	O
benign	O
tonsillar	O
disease	O
,	O
patients	O
with	O
tonsillar	O
squamous	O
cell	O
carcinoma	O
had	O
significantly	O
higher	O
concentrations	O
of	O
S-MMP-8	O
and	O
S-TIMP-1	O
.	O

Neither	O
S-MMP-8	O
nor	O
S-TIMP-1	O
correlated	O
with	O
tonsillar	O
HPV	O
positivity	O
.	O

Evidence	O
of	O
toothpick	O
groove	O
formation	O
in	O
Neandertal	O
anterior	O
and	O
posterior	O
teeth	O
.	O

During	O
the	O
microscopic	B-P
examination	I-P
of	O
the	O
Neandertal	O
dentitions	O
from	O
El	O
Sidrón	O
(	O
Spain	O
)	O
and	O
Hortus	O
(	O
France	O
)	O
,	O
we	O
found	O
unusual	O
fine	O
parallel	O
microstriations	O
on	O
the	O
mesial	O
and	O
distal	O
sides	O
of	O
all	O
tooth	O
types	O
,	O
near	O
the	O
cervix	O
.	O

As	O
its	O
appearance	O
was	O
similar	O
to	O
toothpick	O
grooves	O
described	O
in	O
other	O
Homo	O
species	O
,	O
it	O
could	O
correspond	O
to	O
early	O
stages	O
on	O
its	O
formation	O
.	O

To	O
test	O
this	O
hypothesis	O
we	O
developed	O
an	O
experimental	O
replication	O
of	O
a	O
groove	O
using	O
grass	O
stalks	O
.	O

Comparisons	O
between	O
204	O
isolated	O
Neandertal	O
teeth	O
and	O
the	O
two	O
experimental	O
dental	O
specimens	O
corroborate	O
that	O
the	O
marks	O
correspond	O
to	O
initial	O
stages	O
of	O
toothpick	O
groove	O
formation	O
,	O
and	O
we	O
propose	O
a	O
five-grade	O
recording	O
scale	O
that	O
summarized	O
the	O
groove	O
formation	O
process	O
.	O

Using	O
this	O
new	O
recording	O
procedure	O
,	O
we	O
found	O
that	O
Hortus	O
individuals	O
have	O
higher	O
incidence	O
of	O
this	O
trait	O
(	O
eight	O
individuals	O
out	O
of	O
nine	O
)	O
than	O
the	O
El	O
Sidrón	O
individuals	O
(	O
nine	O
out	O
of	O
11	O
)	O
.	O

Toothpick	O
grooves	O
from	O
El	O
Sidrón	O
show	O
the	O
earliest	O
stages	O
of	O
development	O
,	O
whereas	O
the	O
grooves	O
found	O
on	O
Hortus	O
Neandertals	O
were	O
well-developed	O
.	O

Toothpick	O
grooves	O
were	O
also	O
found	O
in	O
21	O
incisors	O
and	O
canines	O
.	O

These	O
differences	O
could	O
be	O
due	O
to	O
the	O
more	O
advanced	O
occlusal	O
dental	O
wear	O
in	O
Hortus	O
individuals	O
,	O
maybe	O
age	O
-related	O
and	O
with	O
a	O
more	O
meat	O
-based	O
diet	O
maybe	O
favoring	O
the	O
inclusion	O
of	O
food	O
debris	O
and	O
thus	O
probing	O
as	O
the	O
cleaning	O
methodology	O
.	O

Our	O
results	O
allow	O
the	O
identification	O
and	O
characterization	O
of	O
incipient	O
toothpick	O
grooves	O
on	O
the	O
human	O
fossil	O
record	O
and	O
contribute	O
to	O
increase	O
our	O
knowledge	O
on	O
Neandertals	O
behavioral	O
and	O
oral	O
care	O
habits	O
.	O

Expression	O
IRF	O
/	O
MUM1	O
>	O
25	O
%	O
Predictor	O
to	O
Three-	O
year	O
Survival	O
of	O
Diffuse	O
Large	O
B	O
Cell	O
Lymphoma	O
in	O
the	O
Immunochemotherapy	O
Era	O
.	O

Non	O
Hodgkin	O
lymphoma	O
-	O
Diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
DLBC	O
)	O
is	O
composed	O
of	O
more	O
varieties	O
of	O
one	O
disease	O
.	O

Analysis	O
and	O
understanding	O
of	O
a	O
wide	O
range	O
of	O
characteristics	O
of	O
the	O
disease	O
,	O
which	O
include	O
:	O
clinical	O
,	O
immunohistochemical	B-P
,	O
cytogenetic	O
and	O
molecular	O
characteristics	O
may	O
improve	O
treatment	O
results	O
.	O

achieving	O
the	O
estimated	O
three-	O
year	O
survival	O
and	O
influence	O
of	O
IRF	O
/	O
MUM1	O
expression	O
to	O
three-	O
year	O
survival	O
.	O

A	O
study	O
was	O
retrospective-prospective	O
,	O
patients	O
were	O
followed	O
for	O
seven	O
years	O
a	O
period	O
of	O
dine	O
.	O

The	O
study	O
included	O
60	O
patients	O
de	O
novo	O
DLBCL	O
.	O

Age	O
was	O
18-72	O
years	O
old	O
,	O
the	O
average	O
age	O
45	O
years	O
,	O
male	O
31	O
(	O
51,7	O
%	O
)	O
and	O
female	O
29	O
(	O
48.3	O
%	O
)	O
.	O

Median	O
follow-up	O
was	O
47	O
months	O
(	O
3-91	O
months	O
)	O
.	O

To	O
determine	O
differentiation	O
immunophenotype	B-P
antibodies	O
those	O
were	O
used	O
anti-CD20	O
,	O
anti-CD10	O
,	O
anti-Bcl-6	O
,	O
IRF-4	O
/	O
MUM1	O
,	O
CD	O
138	O
.	O

Included	O
the	O
GCB	O
type	O
was	O
65	O
%	O
.	O

Impact	O
prognostic	O
index	O
IPI	O
>	O
2	O
GBC	O
vs	O
non	O
GBC	O
p=0,038	O
X	O
(	O
2	O
)	O
.	O

Statistically	O
significant	O
difference	O
was	O
confirmed	O
compared	O
to	O
the	O
IPI	O
>	O
2	O
to	O
3	O
year	O
OS	O
p	O
<	O
0,0005	O
X	O
(	O
2	O
)	O
.	O

Significantly	O
longer	O
three-	O
year	O
survival	O
was	O
provided	O
in	O
the	O
group	O
GCB	O
36	O
(	O
92,3	O
%	O
)	O
vs.	O
non	O
GCB	O
8	O
(	O
38,1	O
%	O
)	O
p=0,003	O
X	O
(	O
2	O
)	O
.	O

Clinical	O
and	O
immunohistochemical	O
factors	O
showed	O
a	O
significant	O
impact	O
to	O
three-	O
year	O
survival	O
by	O
univariate	O
:	O
LDH	O
p=0,005	O
,	O
MUM1	O
p=0,003	O
,	O
while	O
CD10	O
p=0,069	O
was	O
confirmed	O
on	O
the	O
level	O
of	O
borderline	O
impact	O
.	O

Using	O
multivariate	O
analysis	O
,	O
expression	O
MUM1	O
has	O
the	O
greatest	O
impact	O
p	O
<	O
0.0005	O
OR=0.083	O
(	O
95	O
%	O
CI	O
0.23-0.303	O
)	O
on	O
the	O
disease	O
outcome	O
-	O
three-	O
year	O
survival	O
.	O

expression	O
MUM1	O
>	O
25	O
%	O
has	O
the	O
greatest	O
impact	O
on	O
the	O
disease	O
outcome	O
-	O
three-	O
year	O
survival	O
.	O

Outcome	O
of	O
obese	O
and	O
diabetic	O
patients	O
underwent	O
laparoscopic	O
gastric	O
bypass	O
:	O
when	O
the	O
surgery	O
fails	O
.	O

The	O
beneficial	O
effects	O
of	O
bariatric	O
surgery	O
on	O
diabetes	O
and	O
obesity	O
have	O
been	O
widely	O
demonstrated	O
in	O
literature	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
rate	O
of	O
failure	O
of	O
laparoscopic	O
gastric	O
bypass	O
both	O
in	O
terms	O
of	O
weight	O
loss	O
and	O
metabolic	O
remission	O
after	O
one	O
follow-up	O
year	O
.	O

A	O
longitudinal	O
,	O
multicentric	O
prospective	O
study	O
was	O
carried	O
out	O
on	O
771	O
patients	O
affected	O
by	O
pathological	O
obesity	O
.	O

The	O
following	O
parameters	O
were	O
recorded	O
for	O
each	O
patient	O
before	B-P
surgery	I-P
:	O
anthropometric	O
,	O
metabolic	O
,	O
social	O
,	O
smoking	O
habits	O
and	O
previous	O
failure	O
of	O
other	O
bariatric	O
procedures	O
.	O

After	O
1	O
follow-up	O
year	O
,	O
final	O
weight	O
,	O
final	O
BMI	O
,	O
final	O
percentage	O
of	O
lost	O
excess	O
body	O
weight	O
and	O
percentage	O
of	O
lost	O
BMI	O
were	O
evaluated	O
.	O

Statistical	O
analysis	O
showed	O
a	O
correlation	O
between	O
BMI	O
>	O
50	O
Kg/m2	O
,	O
presence	O
of	O
metabolic	O
syndrome	O
,	O
presence	O
of	O
diabetes	O
,	O
gastric	O
pouch	O
volume	O
greater	O
than	O
60	O
ml	O
and	O
failure	O
of	O
weight	O
loss	O
outcome	O
.	O

Statistical	O
analysis	O
of	O
metabolic	O
failure	O
has	O
recognized	O
a	O
high	O
preoperative	O
HbA1c	O
%	O
value	O
as	O
a	O
statistically	O
significant	O
negative	O
predictive	O
factor	O
.	O

Bariatric	O
Surgery	O
is	O
the	O
most	O
effective	O
treatment	O
for	O
weight	O
loss	O
and	O
metabolic	O
improvement	O
.	O

However	O
,	O
in	O
our	O
study	O
,	O
surgery	O
did	O
not	O
achieve	O
the	O
expected	O
outcome	O
in	O
patients	O
with	O
specific	O
metabolic	O
,	O
anthropometric	O
and	O
surgical	O
characteristics	O
(	O
BMI	O
>	O
50	O
Kg/m2	O
,	O
presence	O
of	O
metabolic	O
syndrome	O
,	O
presence	O
of	O
T2DM	O
with	O
high	O
preoperative	O
HbA1c	O
%	O
level	O
and	O
gastric	O
pouch	O
volume	O
greater	O
than	O
60	O
ml	O
)	O
.	O

Sepsis	O
Clinical	O
Criteria	O
in	O
Emergency	O
Department	O
Patients	O
Admitted	O
to	O
an	O
Intensive	O
Care	O
Unit	O
:	O
An	O
External	O
Validation	O
Study	O
of	O
Quick	O
Sequential	O
Organ	O
Failure	O
Assessment	O
.	O

Quick	O
Sequential	O
Organ	O
Failure	O
Assessment	O
(	O
qSOFA	O
)	O
is	O
a	O
prognostic	O
score	O
for	O
patients	O
with	O
sepsis	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
the	O
area	O
under	O
the	O
receiver	O
operating	O
curve	O
(	O
AUROC	O
)	O
,	O
sensitivity	O
,	O
specificity	O
,	O
and	O
likelihood	O
ratios	O
of	O
qSOFA	O
vs.	O
systemic	O
inflammation	O
response	O
syndrome	O
(	O
SIRS	O
)	O
in	O
predicting	O
in-hospital	O
mortality	O
among	O
emergency	O
department	O
(	O
ED	O
)	O
patients	O
with	O
suspected	O
infection	O
admitted	O
to	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	O
chart	O
review	O
study	O
of	O
ED	O
patients	O
admitted	O
to	O
an	O
ICU	O
with	O
suspected	O
infection	O
from	O
August	O
1	O
,	O
2012	O
to	O
February	O
28	O
,	O
2015	O
.	O

We	O
included	O
all	O
patients	O
with	O
body	O
fluid	O
cultures	O
sampled	O
either	O
during	O
their	O
ED	O
stay	O
without	O
antibiotic	O
administration	O
or	O
within	O
24	O
h	O
of	O
antibiotics	O
administered	O
in	O
the	O
ED	O
.	O

Trained	O
chart	O
abstractors	O
blinded	O
to	O
the	O
study	O
hypothesis	O
double-entered	O
data	O
from	O
each	O
patient	O
's	O
electronic	O
medical	O
record	O
including	O
demographic	O
characteristics	O
,	O
vital	O
signs	O
,	O
laboratory	B-P
study	I-P
results	I-P
,	O
physical	O
examination	O
findings	O
,	O
and	O
in-hospital	O
mortality	O
.	O

We	O
then	O
calculated	O
the	O
AUROC	O
,	O
sensitivity	O
,	O
specificity	O
,	O
and	O
likelihood	O
ratios	O
for	O
qSOFA	O
and	O
SIRS	O
for	O
predicting	O
in-hospital	O
mortality	O
.	O

Of	O
214	O
patients	O
admitted	O
to	O
an	O
ICU	O
with	O
presumed	O
sepsis	O
,	O
39	O
(	O
18.2	O
%	O
)	O
died	O
during	O
hospitalization	O
.	O

The	O
AUROC	O
value	O
was	O
0.65	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
0.56-0.74	O
)	O
for	O
SIRS	O
vs.	O
0.66	O
(	O
95	O
%	O
CI	O
0.57-0.76	O
)	O
for	O
qSOFA	O
;	O
2+	O
qSOFA	O
criteria	O
predicted	O
in-hospital	O
mortality	O
with	O
89.7	O
%	O
sensitivity	O
,	O
27.4	O
%	O
specificity	O
,	O
1.2	O
positive	O
likelihood	O
ratio	O
,	O
and	O
0.4	O
negative	O
likelihood	O
ratio	O
.	O

Among	O
ED	O
patients	O
admitted	O
to	O
an	O
ICU	O
,	O
the	O
SIRS	O
and	O
qSOFA	O
criteria	O
had	O
comparable	O
prognostic	O
value	O
for	O
predicting	O
in-hospital	O
mortality	O
.	O

These	O
prognostic	O
values	O
are	O
similar	O
to	O
those	O
reported	O
by	O
the	O
Sepsis-3	O
guidelines	O
for	O
ICU	O
encounters	O
.	O

Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Shedding	O
and	O
Antibody	O
Response	O
in	O
Swine	O
Farms	O
:	O
A	O
Longitudinal	O
Study	O
.	O

The	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
causes	O
an	O
acute	O
and	O
highly	O
contagious	O
enteric	O
disease	O
characterized	O
by	O
severe	O
enteritis	O
,	O
vomiting	O
,	O
watery	O
diarrhea	O
,	O
and	O
a	O
high	O
mortality	O
rate	O
in	O
seronegative	O
neonatal	O
piglets	O
.	O

In	O
the	O
last	O
few	O
years	O
,	O
PED	O
had	O
a	O
large	O
economic	O
impact	O
on	O
the	O
swine	O
industries	O
in	O
Asia	O
and	O
the	O
US	O
,	O
and	O
in	O
2014	O
,	O
the	O
PEDV	O
also	O
re-emerged	O
in	O
Europe	O
.	O

Two	O
main	O
PEDV	O
variants	O
circulate	O
worldwide	O
but	O
only	O
the	O
S	O
INDEL	O
variant	O
,	O
considered	O
a	O
mild	O
strain	O
,	O
is	O
spreading	O
in	O
Europe	O
.	O

To	O
gain	O
insights	O
into	O
the	O
pathogenicity	O
of	O
this	O
variant	O
,	O
its	O
viral	B-P
load	I-P
and	O
temporal	O
shedding	O
pattern	O
were	O
evaluated	O
in	O
piglets	O
from	O
infected	O
farms	O
.	O

Quantitative	O
real-time	O
PCR	O
(	O
qPCR	O
)	O
targeting	O
the	O
spike	O
gene	O
,	O
was	O
validated	O
according	O
to	O
the	O
minimum	O
information	O
for	O
quantitative	O
real-time	O
PCR	O
experiments	O
guidelines	O
.	O

The	O
qPCR	O
was	O
applied	O
to	O
longitudinal	O
studies	O
conducted	O
in	O
four	O
swine	O
farms	O
naturally	O
infected	O
with	O
the	O
PEDV	O
S	O
INDEL	O
variant	O
.	O

Clinical	O
data	O
,	O
fecal	O
swabs	O
,	O
and	O
blood	O
samples	O
were	O
collected	O
from	O
103	O
piglets	O
at	O
15-30-day	O
intervals	O
for	O
2-5	O
months	O
.	O

On	O
all	O
four	O
farms	O
,	O
diarrhea	O
was	O
observed	O
in	O
sows	O
during	O
gestation	O
and	O
in	O
farrowing	O
units	O
,	O
and	O
the	O
mortality	O
rates	O
of	O
piglets	O
were	O
18	O
,	O
25	O
,	O
30	O
,	O
and	O
35	O
%	O
.	O

Different	O
clinical	O
pictures	O
(	O
0-50	O
%	O
of	O
diarrhea	O
positivity	O
)	O
,	O
viral	O
titer	O
levels	O
(	O
mean	O
5.3-7.2	O
log10	O
genome	O
copies	O
/mL	O
)	O
,	O
and	O
antibody	O
conditions	O
(	O
30-80	O
%	O
of	O
positivity	O
)	O
were	O
registered	O
among	O
sows	O
on	O
the	O
four	O
farms	O
.	O

The	O
percentage	O
of	O
qPCR	O
positive	O
piglets	O
varied	O
greatly	O
from	O
the	O
beginning	O
(	O
63-100	O
%	O
)	O
to	O
the	O
end	O
(	O
0	O
%	O
)	O
of	O
the	O
infection	O
course	O
.	O

Clinical	O
signs	O
were	O
present	O
in	O
96	O
%	O
of	O
the	O
qPCR	O
positive	O
animals	O
.	O

Viral	O
loads	O
ranged	O
from	O
8.5	O
log10	O
to	O
4	O
log10	O
genome	O
copies	O
/mL	O
in	O
suckling	O
pigs	O
at	O
3-6	O
days	O
of	O
age	O
and	O
were	O
not	O
statistically	O
different	O
among	O
farms	O
,	O
despite	O
the	O
different	O
patterns	O
observed	O
in	O
sows	O
.	O

After	O
2-3	O
weeks	O
,	O
only	O
a	O
few	O
piglets	O
still	O
showed	O
detectable	O
viral	O
levels	O
and	O
clinical	O
signs	O
,	O
and	O
they	O
developed	O
antibody	O
responses	O
.	O

Moreover	O
,	O
co-infections	O
with	O
other	O
pathogens	O
and	O
biosecurity	O
procedures	O
limiting	O
the	O
circulation	O
of	O
the	O
virus	O
could	O
have	O
influenced	O
the	O
severity	O
of	O
PED	O
infection	O
.	O

QPCR	O
and	O
clinical	O
data	O
were	O
useful	O
in	O
understanding	O
the	O
dynamics	O
of	O
PEDV	O
infections	O
and	O
,	O
therefore	O
,	O
in	O
implementing	O
appropriate	O
control	O
measures	O
.	O

Fabrication	O
of	O
Lab-on-Paper	O
Using	O
Porous	O
Au-Paper	O
Electrode	O
:	O
Application	O
to	O
Tumor	O
Marker	O
Electrochemical	B-P
Immunoassays	I-P
.	O

A	O
simple	O
,	O
low-cost	O
,	O
and	O
sensitive	O
electrochemical	B-P
lab-on-paper	I-P
assay	I-P
is	O
developed	O
based	O
on	O
a	O
novel	O
gold	O
nanoparticle	O
modified	O
porous	O
paper	O
working	O
electrode	O
for	O
use	O
in	O
point-of-care	O
testing	O
(	O
POCT	O
)	O
.	O

Electrochemical	B-P
methods	I-P
are	O
introduced	O
for	O
lab-on-paper	O
based	O
on	O
screen-printed	O
paper	O
electrodes	O
.	O

To	O
further	O
improve	O
specificity	O
,	O
performance	O
,	O
and	O
sensitivity	O
for	O
point-of-care	O
testing	O
,	O
a	O
novel	O
porous	O
Au-paper	O
working	O
electrode	O
(	O
Au-PWE	O
)	O
is	O
designed	O
for	O
lab-on-paper	O
using	O
growth	O
of	O
an	O
interconnected	O
Au	O
nanoparticle	O
(	O
NP	O
)	O
layer	O
on	O
the	O
surface	O
of	O
cellulose	O
fibers	O
in	O
order	O
to	O
enhance	O
the	O
conductivity	O
of	O
the	O
paper	O
sample	O
zone	O
and	O
immobilize	O
the	O
primary	O
antibodies	O
(	O
Ab1	O
)	O
.	O

With	O
a	O
sandwich-type	O
immunoassay	O
format	O
,	O
Pd	O
-	O
Au	O
bimetallic	O
nanoparticles	O
possessing	O
peroxidase-like	O
activity	O
are	O
used	O
as	O
a	O
matrix	O
to	O
immobilize	O
secondary	O
antibodies	O
(	O
Ab2	O
)	O
for	O
rapid	O
detection	O
of	O
targets	O
.	O

This	O
lab-on-paper	O
based	O
immunodevice	O
is	O
applied	O
to	O
the	O
diagnosis	O
of	O
a	O
cancer	O
biomarker	O
in	O
clinical	O
serum	O
samples	O
.	O

An	O
easy	O
to	O
produce	O
and	O
economical	O
three-dimensional	O
brain	O
phantom	O
for	O
stereotactic	B-P
computed	I-P
tomographic-guided	I-P
brain	I-P
biopsy	I-P
training	O
in	O
the	O
dog	O
.	O

To	O
develop	O
and	O
validate	O
a	O
three-dimensional	O
(	O
3D	O
)	O
brain	O
phantom	O
that	O
can	O
be	O
incorporated	O
into	O
existing	O
stereotactic	O
headframes	O
to	O
simulate	O
stereotactic	B-P
brain	I-P
biopsy	I-P
(	O
SBB	B-P
)	O
and	O
train	O
veterinary	O
surgeons	O
.	O

Experimental	O
study	O
.	O

Canine	O
brain	O
phantoms	O
were	O
fabricated	O
from	O
osteological	O
skull	O
specimens	O
,	O
agarose	O
brain	O
parenchyma	O
,	O
and	O
cheddar	O
and	O
mozzarella	O
cheese	O
molds	O
(	O
simulating	O
meningiomas	O
and	O
gliomas	O
)	O
.	O

The	O
neuroradiologic	O
and	O
viscoelastic	O
properties	O
of	O
phantoms	O
were	O
quantified	O
with	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
and	O
oscillatory	O
compression	O
tests	O
,	O
respectively	O
.	O

Phantoms	O
were	O
validated	O
by	O
experienced	O
and	O
novice	O
operators	O
performing	O
SBB	B-P
on	O
phantoms	O
containing	O
randomly	O
placed	O
,	O
focal	O
targets	O
.	O

Target	O
yield	O
and	O
needle	O
placement	O
error	O
(	O
NPE	O
)	O
were	O
compared	O
between	O
operators	O
.	O

Phantoms	O
were	O
produced	O
in	O
<	O
4	O
hours	O
,	O
at	O
an	O
average	O
cost	O
of	O
$	O
92	O
.	O

The	O
CT	B-P
appearances	O
of	O
the	O
phantom	O
skull	O
,	O
agarose	O
,	O
and	O
cheese	O
components	O
approximated	O
the	O
in	O
vivo	O
features	O
of	O
skull	O
,	O
brain	O
parenchyma	O
,	O
and	O
contrast-enhancing	B-P
tumors	O
of	O
meningeal	O
and	O
glial	O
origin	O
,	O
respectively	O
.	O

The	O
complex	O
moduli	O
of	O
the	O
agarose	O
and	O
cheeses	O
were	O
comparable	O
to	O
the	O
viscoelastic	O
properties	O
of	O
in	O
vivo	O
brain	O
tissues	O
and	O
brain	O
tumors	O
.	O

The	O
overall	O
diagnostic	O
yield	O
of	O
SBB	B-P
was	O
88	O
%	O
.	O

Although	O
NPE	O
did	O
not	O
differ	O
between	O
novice	O
(	O
median	O
3.68	O
mm	O
;	O
range	O
,	O
1.46-14.54	O
mm	O
)	O
and	O
experienced	O
surgeons	O
(	O
median	O
1.17	O
mm	O
,	O
range	O
,	O
0.78-1.58	O
mm	O
)	O
,	O
our	O
results	O
support	O
the	O
relevance	O
of	O
the	O
learning	O
curve	O
associated	O
with	O
the	O
SBB	B-P
procedure	I-P
.	O

This	O
3D	O
phantom	O
replicates	O
anatomical	O
,	O
CT	B-P
,	O
and	O
tactile	O
features	O
of	O
brain	O
tissues	O
and	O
tumors	O
and	O
can	O
be	O
used	O
to	O
develop	O
the	O
technical	O
skills	O
required	O
to	O
perform	O
SBB	B-P
.	O

Experience	O
of	O
Varied	O
Presentation	O
of	O
Chronic	O
Progressive	O
Disseminated	O
Histoplasmosis	O
in	O
Immunocompetent	O
Patients	O
:	O
A	O
Diagnostic	O
Conundrum	O
.	O

We	O
report	O
two	O
cases	O
of	O
chronic	O
progressive	O
disseminated	O
histoplasmosis	O
with	O
unusual	O
and	O
rare	O
clinical	O
picture	O
in	O
a	O
patient	O
with	O
no	O
underlying	O
risk	O
factor	O
.	O

One	O
50-year-old	O
male	O
,	O
presented	O
with	O
hoarseness	O
of	O
voice	O
,	O
chronic	O
cough	O
,	O
with	O
a	O
history	O
of	O
nonresponding	O
anti-tubercular	O
therapy	O
,	O
revealed	O
mucocutaneous	O
lesions	O
on	O
examination	O
.	O

Fungating	O
vocal	O
cord	O
lesions	O
were	O
visualized	O
on	O
bronchoscopy	B-P
,	O
raised	O
suspicion	O
of	O
carcinoma	O
.	O

The	O
second	O
case	O
,	O
a	O
22-year-	O
old	O
female	O
,	O
referred	O
to	O
hospital	O
with	O
suspected	O
vasculitis	O
,	O
with	O
complaints	O
of	O
``	O
off	O
and	O
on	O
''	O
fever	O
with	O
decreased	O
oral	O
intake	O
,	O
arthralgia	O
,	O
who	O
later	O
developed	O
generalized	O
nodular	O
skin	O
eruptions	O
.	O

On	O
investigation	O
,	O
human	B-P
immunodeficiency	I-P
virus	I-P
test	I-P
was	O
found	O
to	O
be	O
negative	O
in	O
both	O
the	O
cases	O
.	O

Histopathological	O
findings	O
of	O
skin	B-P
biopsy	I-P
,	O
adrenal	O
and	O
bone	O
marrow	O
aspirates	O
raised	O
suspicion	O
,	O
whereas	O
fungal	B-P
cultures	I-P
confirmed	O
Histoplasma	O
infection	O
.	O

Although	O
diagnosis	O
was	O
delayed	O
,	O
but	O
both	O
of	O
them	O
were	O
successfully	O
treated	O
with	O
amphotericin	O
B	O
.	O

Radiolabeled	O
B9958	O
Derivatives	O
for	O
Imaging	B-P
Bradykinin	O
B1	O
Receptor	O
Expression	O
with	O
Positron	B-P
Emission	I-P
Tomography	I-P
:	O
Effect	O
of	O
the	O
Radiolabel	O
-	O
Chelator	O
Complex	O
on	O
Biodistribution	O
and	O
Tumor	O
Uptake	O
.	O

Bradykinin	O
B1	O
receptor	O
(	O
B1R	O
)	O
,	O
which	O
is	O
upregulated	O
in	O
a	O
variety	O
of	O
malignancies	O
,	O
is	O
an	O
attractive	O
cancer	B-P
imaging	I-P
biomarker	O
.	O

In	O
this	O
study	O
we	O
optimized	O
the	O
selection	O
of	O
radiolabel	O
-	O
chelator	O
complex	O
to	O
improve	O
tumor	O
uptake	O
and	O
tumor	O
-to-background	O
contrast	O
of	O
radiolabeled	O
analogues	O
of	O
B9958	O
(	O
Lys-Lys-Arg-Pro-Hyp-Gly-Cpg-Ser-d-Tic-Cpg	O
)	O
,	O
a	O
potent	O
B1R	O
antagonist	O
.	O

Peptide	O
sequences	O
were	O
assembled	O
on	O
solid	O
phase	O
.	O

Cold	O
standards	O
were	O
prepared	O
by	O
incubating	O
DOTA	O
-/	O
NODA	O
-	O
conjugated	O
peptides	O
with	O
GaCl3	O
,	O
and	O
by	O
incubating	O
AlOH	O
-	O
NODA	O
-conjugated	O
peptide	O
with	O
NaF	O
.	O

Binding	O
affinities	O
were	O
measured	O
via	O
in	B-P
vitro	I-P
competition	I-P
binding	I-P
assays	I-P
.	O

(	O
68	O
)	O
Ga	O
and	O
(	O
18	O
)	O
F	O
labeling	O
experiments	O
were	O
performed	O
in	O
acidic	O
buffer	O
and	O
purified	O
by	O
HPLC	B-P
.	O

Imaging	B-P
/	O
biodistribution	O
studies	O
were	O
performed	O
in	O
mice	O
bearing	O
both	O
B1R-positive	O
(	O
B1R+	O
)	O
HEK293T	O
:	O
:	O
hB1R	O
and	O
B1R-negative	O
(	O
B1R-	O
)	O
HEK293T	O
tumors	O
.	O

Z02176	O
(	O
Ga-DOTA-Pip-B9958	O
;	O
Pip	O
:	O
4-amino-	O
(	O
1-carboxymethyl	O
)	O
piperidine	O
)	O
,	O
Z02137	O
(	O
Ga-NODA-Mpaa-Pip-B9958	O
;	O
Mpaa	O
:	O
4-methylphenylacetic	O
acid	O
)	O
,	O
and	O
Z04139	O
(	O
AlF-NODA-Mpaa-Pip-B9958	O
)	O
bound	O
h	O
B1R	O
with	O
high	O
affinity	O
(	O
Ki	O
=	O
1.4-2.5	O
nM	O
)	O
.	O

(	O
68	O
)	O
Ga	O
-/	O
(	O
18	O
)	O
F	O
-	O
labeled	O
peptides	O
were	O
obtained	O
on	O
average	O
in	O
≥32	O
%	O
decay-corrected	O
radiochemical	O
yield	O
with	O
>	O
99	O
%	O
radiochemical	O
purity	O
and	O
100-261	O
GBq/μmol	O
specific	O
activity	O
.	O

Biodistribution	O
/	O
imaging	B-P
studies	O
at	O
1	O
h	O
postinjection	O
showed	O
that	O
all	O
tracers	O
cleared	O
rapidly	O
from	O
background	O
tissues	O
(	O
except	O
kidneys	O
)	O
and	O
were	O
excreted	O
predominantly	O
via	O
the	O
renal	O
pathway	O
.	O

Only	O
kidneys	O
,	O
bladders	O
,	O
and	O
B1R+	O
tumors	O
were	O
clearly	O
visualized	O
in	O
PET	B-P
images	O
.	O

Uptake	O
in	O
B1R+	O
tumor	O
was	O
higher	O
by	O
using	O
(	O
68	O
)	O
Ga	O
-	O
Z02176	O
(	O
28.9	O
±	O
6.21	O
%	O
ID/g	O
)	O
and	O
(	O
18	O
)	O
F	O
-	O
Z04139	O
(	O
22.6	O
±	O
3.41	O
%	O
ID/g	O
)	O
than	O
(	O
68	O
)	O
Ga	O
-	O
Z02137	O
(	O
14.0	O
±	O
4.86	O
%	O
ID/g	O
)	O
.	O

The	O
B1R+	O
tumor-to-blood	O
and	O
B1R+	O
tumor-to-muscle	O
contrast	O
ratios	O
were	O
also	O
higher	O
for	O
(	O
68	O
)	O
Ga	O
-	O
Z02176	O
(	O
56.1	O
±	O
17.3	O
and	O
167	O
±	O
57.6	O
)	O
and	O
(	O
18	O
)	O
F	O
-	O
Z04139	O
(	O
58.0	O
±	O
20.9	O
and	O
173	O
±	O
42.9	O
)	O
than	O
(	O
68	O
)	O
Ga	O
-	O
Z02137	O
(	O
34.3	O
±	O
15.2	O
and	O
103	O
±	O
30.2	O
)	O
.	O

With	O
improved	O
target-to-background	O
contrast	O
(	O
68	O
)	O
Ga	O
-	O
Z02176	O
and	O
(	O
18	O
)	O
F	O
-	O
Z04139	O
are	O
promising	O
for	O
imaging	B-P
B1R	O
expression	O
in	O
cancers	O
with	O
PET	B-P
.	O

A	O
sequential	O
approach	O
with	O
imatinib	O
,	O
chemotherapy	O
and	O
transplant	O
for	O
adult	O
Ph+	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Final	O
results	O
of	O
the	O
GIMEMA	O
LAL	O
0904	O
study	O
.	O

In	O
the	O
GIMEMA	O
LAL	O
0904	O
protocol	O
,	O
adult	O
Ph+	O
acute	O
lymphoblastic	O
leukemia	O
patients	O
were	O
treated	O
with	O
chemotherapy	O
for	O
induction	O
and	O
consolidation	O
,	O
followed	O
by	O
maintenance	O
with	O
imatinib	O
.	O

The	O
protocol	O
was	O
subsequently	O
amended	O
and	O
imatinib	O
was	O
incorporated	O
in	O
the	O
induction	O
and	O
post	O
-	O
remission	O
phase	O
together	O
with	O
chemotherapy	O
.	O

Due	O
to	O
the	O
toxicity	O
of	O
this	O
combined	O
approach	O
,	O
the	O
protocol	O
was	O
further	O
amended	O
to	O
a	O
sequential	O
scheme	O
based	O
on	O
imatinib	O
plus	O
steroids	O
as	O
induction	O
,	O
followed	O
by	O
consolidation	O
with	O
chemotherapy	O
plus	O
imatinib	O
and	O
,	O
when	O
applicable	O
,	O
by	O
a	O
hematopoietic	O
stem	O
cell	O
transplant	O
.	O

Fifty-one	O
patients	O
(	O
median	O
age	O
:	O
45.9	O
years	O
)	O
were	O
enrolled	O
in	O
the	O
final	O
sequential	O
protocol	O
,	O
hereby	O
reported	O
.	O

At	O
the	O
end	O
of	O
induction	O
(	O
day	O
+50	O
)	O
,	O
96	O
%	O
of	O
evaluable	O
patients	O
(	O
n=49	O
)	O
achieved	O
a	O
complete	O
hematologic	O
remission	O
;	O
after	O
consolidation	O
,	O
all	O
were	O
in	O
complete	O
hematologic	O
remission	O
.	O

No	O
deaths	O
in	O
induction	O
were	O
recorded	O
.	O

Overall	O
survival	O
and	O
disease-free	O
survival	O
at	O
60	O
months	O
are	O
48.8	O
%	O
and	O
45.8	O
%	O
,	O
respectively	O
.	O

At	O
day	O
+50	O
(	O
end	O
of	O
the	O
imatinib	O
induction	O
)	O
,	O
a	O
log	O
-	O
reduction	O
of	O
BCR-ABL1	O
levels	O
>	O
1.3	O
was	O
associated	O
with	O
a	O
significantly	O
more	O
prolonged	O
disease-free	O
survival	O
(	O
55.6	O
%	O
,	O
C.I	O
.	O

95	O
%	O
:	O
39.0-79.3	O
vs	O
20	O
%	O
,	O
C.I	O
.	O

95	O
%	O
:	O
5.8-69.1	O
;	O
p	O
=0.03	O
)	O
,	O
overall	O
survival	O
(	O
59.1	O
%	O
,	O
C.I	O
.	O

95	O
%	O
:	O
42.3-82.6	O
vs	O
20	O
%	O
,	O
C.I	O
.	O

95	O
%	O
:	O
5.8-69.1	O
,	O
p	O
=0.02	O
)	O
and	O
lower	O
relapse	O
incidence	O
(	O
20.5	O
%	O
,	O
C.I	O
.	O

95	O
%	O
:	O
7.2-38.6	O
vs	O
60.0	O
%	O
,	O
C.I	O
.	O

95	O
%	O
:	O
21.6-84.3	O
,	O
p	O
=0.01	O
)	O
.	O

Mean	O
BCR-ABL1	O
levels	O
remained	O
significantly	O
higher	O
in	O
patients	O
who	O
subsequently	O
relapsed	O
.	O

Finally	O
,	O
BCR-ABL1p190	O
patients	O
showed	O
a	O
significantly	O
faster	O
molecular	O
response	O
than	O
BCR-ABL1p210	O
patients	O
(	O
p	O
=0.023	O
)	O
.	O

Thought	O
the	O
study	O
was	O
not	O
powered	O
to	O
evaluate	O
the	O
role	O
of	O
allogeneic	O
stem	O
cell	O
transplant	O
,	O
allografting	O
positively	O
impacted	O
on	O
overall	O
survival	O
and	O
disease-free	O
survival	O
.	O

A	O
sequential	O
approach	O
with	O
imatinib	O
alone	O
in	O
induction	O
,	O
consolidated	O
by	O
chemotherapy	O
plus	O
imatinib	O
followed	O
by	O
a	O
stem	O
cell	O
transplant	O
is	O
a	O
feasible	O
,	O
well-tolerated	O
and	O
effective	O
strategy	O
for	O
adult	O
Ph+	O
acute	O
lymphoblastic	O
leukemia	O
,	O
leading	O
to	O
the	O
best	O
long-term	O
survival	O
rates	O
so	O
far	O
reported	O
.	O

Trial	O
ID	O
:	O
NCT00458848	O
.	O

Abstract	O
and	O
Effector-Selective	O
Decision	O
Signals	O
Exhibit	O
Qualitatively	O
Distinct	O
Dynamics	O
before	O
Delayed	O
Perceptual	O
Reports	O
.	O

Electrophysiological	B-P
research	I-P
has	O
isolated	O
neural	O
signatures	O
of	O
decision	O
formation	O
in	O
a	O
variety	O
of	O
brain	O
regions	O
.	O

Studies	B-P
in	O
rodents	O
and	O
monkeys	O
have	O
focused	O
primarily	O
on	O
effector-selective	O
signals	O
that	O
translate	O
the	O
emerging	O
decision	O
into	O
a	O
specific	O
motor	O
plan	O
,	O
but	O
,	O
more	O
recently	O
,	O
research	O
on	O
the	O
human	O
brain	O
has	O
identified	O
an	O
abstract	O
signature	O
of	O
evidence	O
accumulation	O
that	O
does	O
not	O
appear	O
to	O
play	O
any	O
direct	O
role	O
in	O
action	O
preparation	O
.	O

The	O
functional	O
dissociations	O
between	O
these	O
distinct	O
signal	O
types	O
have	O
only	O
begun	O
to	O
be	O
characterized	O
,	O
and	O
their	O
dynamics	O
during	O
decisions	O
with	O
deferred	O
actions	O
with	O
or	O
without	O
foreknowledge	O
of	O
stimulus-effector	O
mapping	O
,	O
a	O
commonly	O
studied	O
task	O
scenario	O
in	O
single-unit	B-P
and	O
functional	B-P
imaging	I-P
investigations	O
,	O
have	O
not	O
been	O
established	O
.	O

Here	O
we	O
traced	O
the	O
dynamics	O
of	O
distinct	O
abstract	O
and	O
effector-selective	O
decision	O
signals	O
in	O
the	O
form	O
of	O
the	O
broad-band	O
centro-parietal	O
positivity	O
(	O
CPP	O
)	O
and	O
limb-selective	O
β-band	O
(	O
8-16	O
and	O
18-30	O
Hz	O
)	O
EEG	B-P
activity	O
,	O
respectively	O
,	O
during	O
delayed	O
-	O
reported	O
motion	O
direction	O
decisions	O
with	O
and	O
without	O
foreknowledge	O
of	O
direction	O
-	O
response	O
mapping	O
.	O

With	O
foreknowledge	O
,	O
the	O
CPP	O
and	O
β-band	O
signals	O
exhibited	O
a	O
similar	O
gradual	O
build-up	O
following	O
evidence	O
onset	O
,	O
but	O
whereas	O
choice	O
-	O
predictive	O
β-band	O
activity	O
persisted	O
up	O
until	O
the	O
delayed	O
response	O
,	O
the	O
CPP	O
dropped	O
toward	O
baseline	O
after	O
peaking	O
.	O

Without	O
foreknowledge	O
,	O
the	O
CPP	O
exhibited	O
identical	O
dynamics	O
,	O
whereas	O
choice	O
-	O
selective	O
β-band	O
activity	O
was	O
eliminated	O
.	O

These	O
findings	O
highlight	O
qualitative	O
functional	O
distinctions	O
between	O
effector-selective	O
and	O
abstract	O
decision	O
signals	O
and	O
are	O
of	O
relevance	O
to	O
the	O
assumptions	O
founding	O
functional	O
neuroimaging	O
investigations	O
of	O
decision-making	O
.	O

Neural	O
signatures	O
of	O
evidence	O
accumulation	O
have	O
been	O
isolated	O
in	O
numerous	O
brain	O
regions	O
.	O

Although	O
animal	O
neurophysiology	O
has	O
largely	O
concentrated	O
on	O
effector-selective	O
decision	O
signals	O
that	O
translate	O
the	O
emerging	O
decision	O
into	O
a	O
specific	O
motor	O
plan	O
,	O
recent	O
research	O
on	O
the	O
human	O
brain	O
has	O
isolated	O
abstract	O
neural	O
signatures	O
of	O
decision	O
formation	O
that	O
are	O
independent	O
of	O
specific	O
sensory	O
and	O
motor	O
requirements	O
.	O

Here	O
,	O
we	O
examine	O
the	O
functional	O
distinctions	O
between	O
the	O
two	O
distinct	O
classes	O
of	O
decision	O
variable	O
signal	O
during	O
decisions	O
with	O
deferred	O
actions	O
with	O
and	O
without	O
foreknowledge	O
of	O
stimulus-effector	O
mapping	O
.	O

We	O
find	O
salient	O
distinctions	O
in	O
the	O
dynamics	O
of	O
abstract	O
versus	O
effector-selective	O
decision	O
signals	O
in	O
the	O
human	O
brain	O
,	O
in	O
terms	O
of	O
sustainment	O
through	O
response	O
delays	O
and	O
contingency	O
on	O
foreknowledge	O
of	O
stimulus-response	O
mapping	O
.	O

The	O
use	O
of	O
Ocimum	O
americanum	O
essential	O
oil	O
against	O
the	O
pathogens	O
Aeromonas	O
hydrophila	O
and	O
Gyrodactylus	O
sp	O
.	O

in	O
silver	O
catfish	O
(	O
Rhamdia	O
quelen	O
)	O
.	O

The	O
bactericidal	O
activity	O
(	O
MIC-test	B-P
)	O
of	O
Ocimum	O
americanum	O
(	O
inflorescences	O
)	O
essential	O
oil	O
(	O
OAEO	O
)	O
against	O
Aeromonas	O
hydrophila	O
was	O
determined	O
in	O
this	O
study	O
.	O

It	O
was	O
also	O
investigated	O
the	O
potential	O
of	O
OAEO	O
and	O
the	O
main	O
compound	O
found	O
in	O
the	O
oil	O
(	O
linalool	O
)	O
at	O
subinhibitory	O
concentrations	O
to	O
be	O
inhibitors	O
of	O
hemolysis	O
caused	O
by	O
Aer	O
.	O

hydrophila	O
in	O
fish	O
erythrocytes	O
.	O

An	O
in	O
vivo	O
experiment	O
was	O
conducted	O
to	O
evaluate	O
survival	O
of	O
fish	O
(	O
Rhamdia	O
quelen	O
)	O
experimentally	O
infected	O
with	O
Aer	O
.	O

hydrophila	O
and	O
exposed	O
to	O
OAEO	O
.	O

A	O
second	O
experiment	O
was	O
conducted	O
to	O
evaluate	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
activity	O
of	O
OAEO	O
(	O
mix	O
from	O
inflorescences	O
and	O
leaves	O
)	O
against	O
the	O
parasite	O
Gyrodactylus	O
sp	O
.	O

The	O
OAEO	O
showed	O
weak	O
in	O
vitro	O
activity	O
against	O
Aer	O
.	O

hydrophila	O
(	O
6400	O
μg	O
ml	O
(	O
-1	O
)	O
)	O
.	O

At	O
subinhibitory	O
concentrations	O
OAEO	O
(	O
100	O
μg	O
ml	O
(	O
-1	O
)	O
)	O
inhibited	O
hemolysis	O
(	O
90	O
%	O
)	O
caused	O
by	O
Aer	O
.	O

hydrophila	O
in	O
fish	O
erythrocytes	O
,	O
however	O
,	O
linalool	O
did	O
not	O
present	O
hemolysis	O
inhibition	O
activity	O
.	O

At	O
low	O
concentrations	O
(	O
10	O
and	O
20	O
mg	O
l	O
(	O
-1	O
)	O
)	O
added	O
to	O
the	O
water	O
OAEO	O
promoted	O
survival	O
of	O
experimentally	O
infected	O
fish	O
with	O
Aer	O
.	O

hydrophila	O
.	O

Lastly	O
,	O
OAEO	O
-mix	O
(	O
50	O
mg	O
l	O
(	O
-1	O
)	O
)	O
was	O
effective	O
against	O
Gyrodactylus	O
sp	O
.	O

significantly	O
reducing	O
(	O
60	O
%	O
)	O
the	O
number	O
of	O
parasites	O
in	O
the	O
fish	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Consistent	O
tracer	O
administration	O
profile	O
improves	O
test-retest	O
repeatability	O
of	O
myocardial	O
blood	O
flow	O
quantification	O
with	O
(	O
82	O
)	O
Rb	O
dynamic	B-P
PET	I-P
imaging	B-P
.	O

Quantification	O
of	O
myocardial	O
blood	O
flow	O
(	O
MBF	O
)	O
and	O
stress	O
/	O
rest	O
flow	O
reserve	O
is	O
used	O
increasingly	O
to	O
diagnose	O
multi-vessel	O
coronary	O
artery	O
disease	O
and	O
micro-vascular	O
disease	O
with	O
PET	B-P
imaging	B-P
.	O

However	O
,	O
variability	O
in	O
the	O
measurements	O
may	O
limit	O
physician	O
confidence	O
to	O
direct	O
revascularization	O
therapies	O
based	O
on	O
specific	O
threshold	O
values	O
.	O

This	O
study	O
evaluated	O
the	O
effects	O
of	O
rubidium-82	O
(	O
(	O
82	O
)	O
Rb	O
)	O
tracer	O
injection	O
profile	O
using	O
a	O
constant	O
-	O
activity-rate	O
(	O
CA	O
)	O
vs	O
a	O
constant	O
-	O
flow-rate	O
(	O
CF	O
)	O
infusion	O
to	O
improve	O
test-retest	O
repeatability	O
of	O
MBF	O
measurements	O
.	O

22	O
participants	O
underwent	O
single-session	O
(	O
82	O
)	O
Rb	O
dynamic	B-P
PET	I-P
imaging	B-P
during	O
rest	O
and	O
dipyridamole	B-P
stress	I-P
using	O
one	O
of	O
2	O
test-retest	O
infusion	O
protocols	O
:	O
CA	O
-	O
CA	O
(	O
n	O
=	O
12	O
)	O
or	O
CA	O
-	O
CF	O
(	O
n	O
=	O
10	O
)	O
.	O

MBF	O
was	O
quantified	O
using	O
a	O
single-tissue-compartment	O
model	O
(	O
1TCM	O
)	O
and	O
a	O
simplified	O
retention	O
model	O
(	O
SRM	O
)	O
.	O

Non-parametric	O
test-retest	O
repeatability	O
coefficients	O
(	O
RPCnp	O
)	O
were	O
compared	O
between	O
groups	O
.	O

Myocardium-to-blood	O
contrast	O
and	O
signal-to-noise	O
ratios	O
of	O
the	O
late	O
uptake	O
images	O
(	O
2	O
to	O
6	O
minutes	O
)	O
were	O
also	O
compared	O
to	O
evaluate	O
standard	O
myocardial	O
perfusion	O
image	O
(	O
MPI	O
)	O
quality	O
.	O

MBF	O
values	O
in	O
the	O
CA	O
-	O
CA	O
group	O
were	O
more	O
repeatable	O
(	O
smaller	O
RPCnp	O
)	O
than	O
the	O
CA	O
-	O
CF	O
group	O
using	O
the	O
1TCM	O
at	O
rest	O
alone	O
,	O
rest	O
and	O
stress	O
combined	O
,	O
and	O
stress	O
/	O
rest	O
reserve	O
(	O
21	O
%	O
vs	O
36	O
%	O
,	O
16	O
%	O
vs	O
19	O
%	O
,	O
and	O
20	O
%	O
vs	O
27	O
%	O
,	O
P	O
<	O
0.05	O
,	O
respectively	O
)	O
,	O
and	O
using	O
the	O
SRM	O
at	O
Rest	O
and	O
Stress	O
alone	O
,	O
Rest	O
and	O
Stress	O
combined	O
,	O
and	O
stress	O
/	O
rest	O
reserve	O
(	O
21	O
%	O
vs	O
38	O
%	O
,	O
15	O
%	O
vs	O
25	O
%	O
,	O
22	O
%	O
vs	O
38	O
%	O
,	O
and	O
23	O
%	O
vs	O
49	O
%	O
,	O
P	O
<	O
0.05	O
,	O
respectively	O
)	O
.	O

In	O
terms	O
of	O
image	O
quality	O
,	O
myocardium-to-blood	O
contrast	O
and	O
signal-to-noise	O
ratios	O
were	O
not	O
significantly	O
different	O
between	O
groups	O
.	O

Constant	O
-	O
activity-rate	O
'square-wave	O
'	O
infusion	O
of	O
(	O
82	O
)	O
Rb	O
produces	O
more	O
repeatable	O
tracer	O
injection	O
profiles	O
and	O
decreases	O
the	O
test-retest	O
variability	O
of	O
MBF	O
measurements	O
,	O
when	O
compared	O
to	O
a	O
constant-	O
flow-rate	O
'bolus	O
'	O
administration	O
of	O
(	O
82	O
)	O
Rb	O
,	O
especially	O
with	O
SRM	O
,	O
and	O
without	O
compromising	O
standard	O
MPI	O
quality	O
.	O

STRANGULATION	O
-INDUCED	O
CENTRAL	O
RETINAL	O
ARTERY	O
OCCLUSION	O
:	O
CASE	O
REPORT	O
AND	O
REVIEW	O
OF	O
THE	O
LITERATURE	O
.	O

To	O
describe	O
a	O
patient	O
with	O
central	O
retinal	O
artery	O
occlusion	O
following	O
an	O
episode	O
of	O
mechanical	O
strangulation	O
.	O

A	O
retrospective	O
case	O
report	O
.	O

An	O
83-	O
year-old	O
man	O
presented	O
with	O
acute	O
vision	O
loss	O
in	O
his	O
right	O
eye	O
after	O
a	O
strangling	O
episode	O
.	O

Multimodal	B-P
clinical	I-P
imaging	I-P
was	O
performed	O
.	O

Visual	O
acuity	O
in	O
the	O
affected	O
right	O
eye	O
was	O
no	O
light	O
perception	O
.	O

Examination	O
revealed	O
optic	O
nerve	O
edema	O
and	O
optic	O
nerve	O
pallor	O
and	O
also	O
severe	O
vascular	O
attenuation	O
and	O
a	O
cherry-red	O
spot	O
in	O
the	O
macula	O
.	O

Mechanical	O
disruption	O
of	O
carotid	O
plaque	O
can	O
lead	O
to	O
occlusion	O
of	O
the	O
central	O
retinal	O
artery	O
,	O
which	O
may	O
portend	O
a	O
dismal	O
visual	O
prognosis	O
.	O

Does	O
orthodontic	O
debonding	O
lead	O
to	O
tooth	O
sensitivity	O
?	O

Comparison	O
of	O
teeth	O
with	O
and	O
without	O
visible	O
enamel	O
microcracks	O
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
possible	O
changes	O
in	O
sensitivity	O
of	O
teeth	O
with	O
and	O
without	O
visible	O
enamel	O
microcracks	O
(	O
EMCs	O
)	O
up	O
to	O
1	O
week	O
after	O
the	O
removal	O
of	O
metal	O
brackets	O
.	O

After	O
debonding	O
,	O
15	O
patients	O
possessing	O
teeth	O
with	O
visible	O
EMCs	O
and	O
15	O
subjects	O
whose	O
teeth	O
were	O
free	O
of	O
EMCs	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

For	O
each	O
experimental	O
group	O
,	O
a	O
control	O
group	O
was	O
formed	O
.	O

The	O
assessments	O
of	O
tooth	O
sensitivity	O
elicited	O
by	O
compressed	O
air	O
and	O
cold	O
testing	O
were	O
performed	O
5	O
times	O
:	O
just	O
before	O
debonding	O
,	O
immediately	O
after	O
debonding	O
,	O
and	O
at	O
1	O
,	O
3	O
,	O
and	O
7	O
days	O
after	O
debonding	O
.	O

Tooth	O
sensitivity	O
was	O
recorded	O
on	O
a	O
100-mm	O
visual	B-P
analog	I-P
scale	I-P
.	O

For	O
the	O
patients	O
without	O
visible	O
EMCs	O
,	O
discomfort	O
peaked	O
immediately	O
after	O
debonding	O
and	O
started	O
to	O
decrease	O
on	O
day	O
1	O
;	O
at	O
1	O
week	O
after	O
debonding	O
,	O
the	O
visual	B-P
analog	I-P
scale	I-P
scores	O
were	O
lower	O
than	O
just	O
before	O
debonding	O
and	O
immediately	O
after	O
debonding	O
.	O

For	O
the	O
subjects	O
possessing	O
teeth	O
with	O
visible	O
EMCs	O
,	O
the	O
pattern	O
of	O
sensitivity	O
dynamic	O
was	O
inherently	O
the	O
same	O
.	O

However	O
,	O
the	O
patients	O
with	O
visible	O
EMCs	O
showed	O
higher	O
visual	B-P
analog	I-P
scale	I-P
values	O
at	O
each	O
time	O
interval	O
.	O

Debonding	O
leads	O
to	O
a	O
short-term	O
increase	O
in	O
tooth	O
sensitivity	O
.	O

EMCs	O
,	O
a	O
form	O
of	O
enamel	O
damage	O
,	O
do	O
not	O
predispose	O
to	O
greater	O
sensitivity	O
perception	O
in	O
relation	O
to	O
bracket	O
removal	O
.	O

Unusual	O
axillary	O
metastasis	O
of	O
recurrent	O
nasopharyngeal	O
cancer	O
:	O
A	O
case	O
report	O
.	O

Nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
has	O
a	O
high	O
propensity	O
of	O
metastasis	O
.	O

The	O
most	O
commonly	O
described	O
sites	O
of	O
distant	O
metastasis	O
are	O
the	O
bones	O
,	O
lungs	O
,	O
and	O
liver	O
,	O
whereas	O
axillary	O
metastasis	O
is	O
seldom	O
reported	O
.	O

We	O
hereby	O
present	O
the	O
case	O
of	O
a	O
66-year-old	O
man	O
with	O
NPC	O
,	O
cT2N2M0	O
,	O
at	O
diagnosis	O
.	O

He	O
had	O
completed	O
chemoradiotherapy	O
and	O
been	O
disease-free	O
for	O
7	O
years	O
.	O

After	O
that	O
period	O
,	O
late	O
recurrence	O
in	O
the	O
form	O
of	O
a	O
solitary	O
axillary	O
lymph	O
node	O
metastasis	O
was	O
detected	O
and	O
confirmed	O
by	O
core-needle	B-P
biopsy	I-P
.	O

The	O
lesion	O
was	O
chemoresistant	O
but	O
responded	O
to	O
salvage	O
radiotherapy	O
at	O
a	O
dose	O
of	O
65	O
Gy	O
in	O
21	O
fractions	O
.	O

Post-radiotherapy	O
positron	B-P
emission	I-P
tomography	I-P
scan	I-P
showed	O
no	O
evidence	O
of	O
disease	O
.	O

We	O
suggested	O
that	O
long-term	O
follow-up	O
of	O
NPC	O
patients	O
is	O
important	O
because	O
a	O
late	O
relapse	O
may	O
occur	O
at	O
an	O
unusual	O
site	O
.	O

Aggressive	O
management	O
of	O
solitary	O
metastasis	O
may	O
achieve	O
good	O
outcome	O
.	O

Uncoupling	O
of	O
Vascular	O
Nitric	O
Oxide	O
Synthase	O
Caused	O
by	O
Intermittent	O
Hypoxia	O
.	O

Objective	O
.	O

Obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
,	O
characterized	O
by	O
chronic	O
intermittent	O
hypoxia	O
(	O
CIH	O
)	O
,	O
is	O
often	O
present	O
in	O
diabetic	O
(	O
DB	O
)	O
patients	O
.	O

Both	O
conditions	O
are	O
associated	O
with	O
endothelial	O
dysfunction	O
and	O
cardiovascular	O
disease	O
.	O

We	O
hypothesized	O
that	O
diabetic	O
endothelial	O
dysfunction	O
is	O
further	O
compromised	O
by	O
CIH	O
.	O

Methods	O
.	O

Adult	O
male	O
diabetic	O
(	O
BKS.Cg-Dock7	O
(	O
m	O
)	O
+/+	O
Lepr	O
(	O
db	O
)	O
/J	O
)	O
(	O
db/db	O
)	O
mice	O
(	O
10	O
weeks	O
old	O
)	O
and	O
their	O
heterozygote	O
littermates	O
were	O
subjected	O
to	O
CIH	O
or	O
intermittent	O
air	O
(	O
IA	O
)	O
for	O
8	O
weeks	O
.	O

Mice	O
were	O
separated	O
into	O
4	O
groups	O
:	O
IA	O
(	O
intermittent	O
air	O
nondiabetic	O
)	O
,	O
IH	O
(	O
intermittent	O
hypoxia	O
nondiabetic	O
)	O
,	O
IADB	O
(	O
intermittent	O
air	O
diabetic	O
)	O
,	O
and	O
IHDB	O
(	O
intermittent	O
hypoxia	O
diabetic	O
)	O
groups	O
.	O

Endothelium	O
-dependent	O
and	O
endothelium	O
-independent	O
relaxation	O
and	O
modulation	O
by	O
basal	O
nitric	O
oxide	O
(	O
NO	O
)	O
were	O
analyzed	O
using	O
wire	O
myograph	O
.	O

Plasma	O
8-isoprostane	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
and	O
asymmetric	O
dimethylarginine	O
(	O
ADMA	O
)	O
were	O
measured	O
using	O
ELISA	B-P
.	O

Uncoupling	O
of	O
eNOS	O
was	O
measured	O
using	O
dihydroethidium	O
(	O
DHE	O
)	O
staining	B-P
.	O

Results	O
.	O

Endothelium	O
-dependent	O
vasodilation	O
and	O
basal	O
NO	O
production	O
were	O
significantly	O
impaired	O
in	O
the	O
IH	O
and	O
IADB	O
group	O
compared	O
to	O
IA	O
group	O
but	O
was	O
more	O
pronounced	O
in	O
IHDB	O
group	O
.	O

Levels	O
of	O
8-isoprostane	O
,	O
IL-6	O
,	O
ADMA	O
,	O
and	O
eNOS	O
uncoupling	O
were	O
≈2-fold	O
higher	O
in	O
IH	O
and	O
IADB	O
groups	O
and	O
were	O
further	O
increased	O
in	O
the	O
IHDB	O
group	O
.	O

Conclusion	O
.	O

Endothelial	O
dysfunction	O
is	O
more	O
pronounced	O
in	O
diabetic	O
mice	O
subjected	O
to	O
CIH	O
compared	O
to	O
diabetic	O
or	O
CIH	O
mice	O
alone	O
.	O

Oxidative	O
stress	O
,	O
ADMA	O
,	O
and	O
eNOS	O
uncoupling	O
were	O
exacerbated	O
by	O
CIH	O
in	O
diabetic	O
mice	O
.	O

Association	O
of	O
Fat	O
Mass	O
and	O
Obesity	O
-	O
associated	O
Gene	O
Variant	O
with	O
Lifestyle	O
Factors	O
and	O
Body	O
Fat	O
in	O
Indian	O
Children	O
.	O

Common	O
intronic	O
variants	O
of	O
the	O
fat	O
mass	O
and	O
obesity	O
-	O
associated	O
(	O
FTO	O
)	O
gene	O
have	O
been	O
associated	O
with	O
obesity	O
-related	O
traits	O
in	O
humans	O
.	O

(	O
1	O
)	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
study	O
the	O
distribution	O
of	O
FTO	O
gene	O
variants	O
across	O
different	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
categories	O
and	O
(	O
2	O
)	O
to	O
explore	O
the	O
association	O
between	O
FTO	O
gene	O
variants	O
and	O
lifestyle	O
factors	O
in	O
obese	O
and	O
normal	O
weight	O
Indian	O
children	O
.	O

Fifty-six	O
children	O
(	O
26	O
boys	O
,	O
mean	O
age	O
10.3	O
±	O
2.2	O
years	O
)	O
were	O
studied	O
.	O

Height	O
,	O
weight	O
,	O
and	O
waist	O
and	O
hip	O
circumference	O
were	O
measured	O
.	O

Physical	O
activity	O
(	O
questionnaire	O
)	O
and	O
food	O
intake	O
(	O
food	O
frequency	O
questionnaire	O
)	O
were	O
assessed	O
.	O

Body	O
fat	O
percentage	O
(	O
%	O
BF	O
)	O
was	O
measured	O
by	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
.	O

FTO	O
allelic	O
variants	O
at	O
rs9939609	O
site	O
were	O
detected	O
by	O
SYBR	O
Green	O
Amplification	O
Refractory	O
Mutation	O
System	O
real-time	O
polymerase	O
chain	O
reaction	O
using	O
allele	O
-	O
specific	O
primers	O
.	O

Generalized	O
linear	O
model	O
was	O
used	O
to	O
investigate	O
the	O
simultaneous	O
influence	O
of	O
genetic	O
and	O
lifestyle	O
factors	O
on	O
%	O
BF	O
.	O

Mean	O
height	O
,	O
weight	O
,	O
and	O
BMI	O
of	O
normal	O
and	O
obese	O
children	O
were	O
130.6	O
±	O
7.1	O
versus	O
143.2	O
±	O
15.6	O
,	O
24.0	O
±	O
5.2	O
versus	O
53.1	O
±	O
15.8	O
,	O
and	O
13.9	O
±	O
2.1	O
versus	O
25.3	O
±	O
3.2	O
,	O
respectively	O
.	O

The	O
frequency	O
of	O
AA	O
allele	O
was	O
57	O
%	O
among	O
obese	O
children	O
and	O
35	O
%	O
in	O
normal	O
weight	O
children	O
.	O

Children	O
with	O
the	O
AA	O
allele	O
who	O
were	O
obese	O
had	O
least	O
physical	O
activity	O
,	O
whereas	O
children	O
with	O
AT	O
allele	O
and	O
obesity	O
had	O
the	O
highest	O
intake	O
of	O
calories	O
when	O
compared	O
to	O
children	O
who	O
had	O
AT	O
allele	O
and	O
were	O
normal	O
.	O

%	O
BF	O
was	O
positively	O
associated	O
with	O
AA	O
alleles	O
and	O
junk	O
food	O
intake	O
and	O
negatively	O
with	O
healthy	O
food	O
intake	O
and	O
moderate	O
physical	O
activity	O
.	O

Healthy	O
lifestyle	O
with	O
high	O
physical	O
activity	O
and	O
diet	O
low	O
in	O
calories	O
and	O
fat	O
may	O
help	O
in	O
modifying	O
the	O
risk	O
imposed	O
by	O
FTO	O
variants	O
in	O
children	O
.	O

Hormonal	B-P
and	O
testicular	O
changes	O
in	O
rats	O
submitted	O
to	O
congenital	O
hypothyroidism	O
in	O
early	O
life	O
.	O

The	O
goal	O
of	O
this	O
study	B-P
was	O
to	O
evaluate	O
the	O
influence	O
of	O
hypothyroidism	O
induced	O
by	O
MMI	O
,	O
during	O
gestation	O
(	O
G	O
)	O
or	O
gestation	O
plus	O
lactation	O
(	O
GL	O
)	O
on	O
testis	O
and	O
its	O
relation	O
with	O
leptin	O
in	O
rats	O
.	O

Six	O
to	O
eight	O
pups	O
were	O
killed	O
at	O
90	O
days	O
of	O
age	O
.	O

For	O
statistical	O
analysis	O
One-way	O
ANOVA	O
followed	O
by	O
the	O
Holm-Sìdak	O
post	O
hoc	O
test	O
was	O
used	O
.	O

Hypothyroidism	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
LH	O
,	O
FSH	O
and	O
testosterone	O
and	O
an	O
increase	O
in	O
leptin	O
serum	O
levels	O
(	O
p	O
<	O
0.04	O
)	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
StAR	O
,	O
AR	O
,	O
FSHR	O
,	O
LHR	O
,	O
pSTAT3	O
and	O
SOCS3	O
(	O
p	O
<	O
0.04	O
)	O
protein	O
expression	O
and	O
in	O
the	O
fertility	O
parameters	O
(	O
p	O
<	O
0.04	O
)	O
.	O

We	O
can	O
conclude	O
that	O
hypothyroidism	O
is	O
associated	O
with	O
reduction	O
of	O
steroidogenesis	O
and	O
spermatogenesis	O
leading	O
to	O
a	O
low	O
fertility	O
potential	O
in	O
these	O
animals	O
.	O

This	O
outcome	O
could	O
be	O
a	O
consequence	O
of	O
low	O
pituitary	O
stimulus	O
and	O
testicular	O
response	O
and	O
probably	O
are	O
not	O
related	O
with	O
leptin	O
hormone	O
since	O
its	O
signaling	O
pathway	O
is	O
down-regulated	O
in	O
the	O
testis	O
.	O

Aberrant	O
LncRNA	O
Expression	O
Profile	O
in	O
a	O
Contusion	O
Spinal	O
Cord	O
Injury	O
Mouse	O
Model	O
.	O

Long	O
noncoding	O
RNAs	O
(	O
LncRNAs	O
)	O
play	O
a	O
crucial	O
role	O
in	O
cell	O
growth	O
,	O
development	O
,	O
and	O
various	O
diseases	O
related	O
to	O
the	O
central	O
nervous	O
system	O
.	O

However	O
,	O
LncRNA	O
differential	O
expression	O
profiles	O
in	O
spinal	O
cord	O
injury	O
are	O
yet	O
to	O
be	O
reported	O
.	O

In	O
this	O
study	O
,	O
we	O
profiled	O
the	O
expression	O
pattern	O
of	O
LncRNAs	O
using	O
a	O
microarray	B-P
method	I-P
in	O
a	O
contusion	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
mouse	O
model	O
.	O

Compared	O
with	O
a	O
spinal	O
cord	O
without	O
injury	O
,	O
few	O
changes	O
in	O
LncRNA	O
expression	O
levels	O
were	O
noted	O
1	O
day	O
after	O
injury	O
.	O

The	O
differential	O
changes	O
in	O
LncRNA	O
expression	O
peaked	O
1	O
week	O
after	O
SCI	O
and	O
subsequently	O
declined	O
until	O
3	O
weeks	O
after	O
injury	O
.	O

Quantitative	O
real-time	O
polymerase	O
chain	O
reaction	O
(	O
qRT-PCR	O
)	O
was	O
used	O
to	O
validate	O
the	O
reliability	O
of	O
the	O
microarray	O
,	O
demonstrating	O
that	O
the	O
results	O
were	O
reliable	O
.	O

Gene	O
ontology	O
(	O
GO	O
)	O
analysis	O
indicated	O
that	O
differentially	O
expressed	O
mRNAs	O
were	O
involved	O
in	O
transport	O
,	O
cell	O
adhesion	O
,	O
ion	O
transport	O
,	O
and	O
metabolic	O
processes	O
,	O
among	O
others	O
.	O

Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
enrichment	O
analysis	O
showed	O
that	O
the	O
neuroactive	O
ligand-receptor	O
interaction	O
,	O
the	O
PI3K	O
-	O
Akt	O
signaling	O
pathway	O
,	O
and	O
focal	O
adhesions	O
were	O
potentially	O
implicated	O
in	O
SCI	O
pathology	O
.	O

We	O
constructed	O
a	O
dynamic	O
LncRNA	O
-	O
mRNA	O
network	O
containing	O
264	O
LncRNAs	O
and	O
949	O
mRNAs	O
to	O
elucidate	O
the	O
interactions	O
between	O
the	O
LncRNAs	O
and	O
mRNAs	O
.	O

Overall	O
,	O
the	O
results	O
from	O
this	O
study	O
indicate	O
for	O
the	O
first	O
time	O
that	O
LncRNAs	O
are	O
differentially	O
expressed	O
in	O
a	O
contusion	O
SCI	O
mouse	O
model	O
.	O

Retroperitoneal	O
hemorrhage	O
after	O
ureteroscopy	B-P
without	O
laser	O
lithotripsy	O
:	O
an	O
extreme	O
example	O
of	O
an	O
underreported	O
event	O
?	O
.	O

Retroperitoneal	O
hemorrhage	O
and	O
an	O
associated	O
hematoma	O
are	O
uncommon	O
but	O
potentially	O
serious	O
complications	O
following	O
ureteroscopy	B-P
with	O
laser	O
lithotripsy	O
.	O

However	O
,	O
no	O
reports	O
of	O
serious	O
bleeding	O
complications	O
have	O
been	O
published	O
regarding	O
ureteroscopy	B-P
without	O
laser	O
lithotripsy	O
in	O
the	O
management	O
of	O
stone	O
disease	O
.	O

We	O
report	O
of	O
such	O
a	O
case	O
here	O
and	O
then	O
review	O
the	O
current	O
literature	O
in	O
order	O
to	O
discuss	O
the	O
incidence	O
,	O
risk	O
factors	O
,	O
and	O
management	O
of	O
such	O
events	O
.	O

Size	O
-selective	O
separation	O
and	O
overall	O
-	O
amplification	O
of	O
cell-free	B-P
fetal	I-P
DNA	I-P
fragments	O
using	O
PCR	B-P
-based	I-P
enrichment	I-P
.	O

This	O
study	O
aimed	O
to	O
establish	O
a	O
method	O
for	O
the	O
selective	O
amplification	O
of	O
cell-free	B-P
fetal	I-P
DNA	I-P
(	O
cffDNA	B-P
)	O
in	O
maternal	O
plasma	O
and	O
preserve	O
the	O
integrity	O
of	O
DNA	O
fragments	O
during	O
amplification	O
,	O
thereby	O
providing	O
a	O
sufficient	O
amount	O
of	O
cffDNA	B-P
to	O
meet	O
the	O
requirement	O
of	O
routine	O
non-invasive	O
prenatal	O
testing	O
.	O

We	O
amplified	O
DNA	O
molecules	O
in	O
a	O
one-reaction	O
system	O
without	O
considering	O
their	O
particular	O
sequences	O
and	O
lengths	O
(	O
overall	O
amplification	O
)	O
by	O
using	O
PCR	B-P
-based	I-P
enrichment	I-P
.	O

We	O
then	O
modified	O
PCR	O
conditions	O
to	O
verify	O
the	O
effect	O
of	O
denaturation	O
temperature	O
on	O
DNA	O
amplification	O
on	O
various	O
lengths	O
of	O
DNA	O
(	O
selective	O
overall	O
amplification	O
)	O
.	O

Finally	O
,	O
we	O
used	O
an	O
optimum	O
temperature	O
range	O
to	O
amplify	O
cffDNA	B-P
selectively	O
.	O

Amplification	O
results	O
were	O
validated	O
by	O
electrophoresis	B-P
and	O
real-time	O
quantitative	O
PCR	O
.	O

Our	O
PCR	B-P
-based	I-P
enrichment	I-P
efficiently	O
amplified	O
all	O
DNA	O
fragments	O
with	O
differing	O
lengths	O
within	O
a	O
single	O
reaction	O
system	O
,	O
as	O
well	O
as	O
preserving	O
the	O
integrity	O
of	O
the	O
DNA	O
fragments	O
.	O

cffDNA	B-P
was	O
significantly	O
amplified	O
along	O
with	O
the	O
selective	O
amplification	O
of	O
small	O
fragment	O
maternal	O
plasma	O
DNA	O
in	O
an	O
appropriate	O
range	O
of	O
denaturation	O
temperatures	O
.	O

We	O
have	O
established	O
a	O
PCR-based	O
method	O
for	O
the	O
simultaneous	O
enrichment	B-P
and	O
amplification	O
of	O
cffDNA	B-P
in	O
order	O
to	O
meet	O
the	O
requirements	O
of	O
high	O
cffDNA	B-P
quantity	O
for	O
routine	O
non-invasive	O
prenatal	O
testing	O
.	O

Lipids	O
and	O
lipid	O
changes	O
with	O
synthetic	O
and	O
biologic	O
disease-modifying	O
antirheumatic	O
drug	O
therapy	O
in	O
rheumatoid	O
arthritis	O
:	O
implications	O
for	O
cardiovascular	O
risk	O
.	O

To	O
highlight	O
recently	O
published	O
studies	O
addressing	O
lipid	O
changes	O
with	O
disease-modifying	O
antirheumatic	O
drug	O
use	O
and	O
outline	O
implications	O
on	O
cardiovascular	O
outcomes	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

Growing	O
evidence	O
suggests	O
lower	O
lipid	O
levels	O
are	O
present	O
in	O
patients	O
with	O
active	O
RA	O
vs.	O
general	O
population	O
,	O
and	O
significant	O
modifications	O
of	O
lipid	B-P
profile	I-P
with	O
inflammation	O
suppression	O
.	O

Increase	O
in	O
lipid	O
levels	O
in	O
patients	O
with	O
RA	O
on	O
synthetic	O
and	O
biological	O
disease-modifying	O
antirheumatic	O
drugs	O
may	O
be	O
accompanied	O
by	O
antiatherogenic	O
changes	O
in	O
lipid	O
composition	O
and	O
function	O
.	O

The	O
impact	O
of	O
lipid	O
changes	O
on	O
cardiovascular	O
outcomes	O
in	O
RA	O
is	O
a	O
subject	O
of	O
active	O
research	O
.	O

The	O
role	O
of	O
lipids	O
in	O
cardiovascular	O
risk	O
in	O
RA	O
may	O
be	O
overpowered	O
by	O
the	O
benefits	O
of	O
inflammation	O
suppression	O
with	O
antirheumatic	O
medication	O
use	O
.	O

Recommendations	O
on	O
lipid	O
management	O
in	O
RA	O
are	O
evolving	O
but	O
uncertainty	O
exists	O
regarding	O
frequency	O
of	O
lipid	B-P
testing	I-P
and	O
goals	O
of	O
treatment	O
.	O

Knowledge	O
about	O
quantitative	O
and	O
qualitative	O
lipid	O
changes	O
in	O
RA	O
is	O
expanding	O
.	O

The	O
relative	O
role	O
of	O
lipids	O
in	O
cardiovascular	O
risk	O
in	O
the	O
context	O
of	O
systemic	O
inflammation	O
and	O
antirheumatic	O
therapy	O
remains	O
uncertain	O
,	O
delaying	O
development	O
of	O
effective	O
strategies	O
for	O
cardiovascular	O
risk	O
management	O
in	O
RA	O
.	O

Studies	O
are	O
underway	O
to	O
address	O
these	O
knowledge	O
gaps	O
and	O
may	O
be	O
expected	O
to	O
inform	O
cardiovascular	O
risk	O
management	O
in	O
RA	O
and	O
the	O
general	O
population	O
.	O

Undiagnosed	O
Primary	O
Open-Angle	O
Glaucoma	O
in	O
Korea	O
:	O
The	O
Korean	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
2008-2009	O
.	O

To	O
evaluate	O
the	O
characteristics	O
of	O
patients	O
with	O
previously	O
undiagnosed	O
primary	O
open-angle	O
glaucoma	O
(	O
POAG	O
)	O
in	O
Korea	O
.	O

This	O
study	O
examined	O
data	O
from	O
391	O
subjects	O
obtained	O
from	O
the	O
2008-2009	O
Korean	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
KNHANES	O
)	O
.	O

The	O
KNHANES	O
is	O
a	O
population-based	O
,	O
cross-sectional	O
epidemiological	O
survey	O
.	O

Participants	O
aged	O
19	O
years	O
or	O
older	O
completed	O
standardized	O
interviews	O
and	O
dilated	O
ocular	O
examinations	O
,	O
including	O
measurement	O
of	O
intraocular	O
pressure	O
,	O
visual	O
fields	O
with	O
frequency	B-P
doubling	I-P
perimetry	I-P
,	O
and	O
fundus	B-P
photography	I-P
.	O

Data	O
from	O
the	O
361	O
patients	O
with	O
previously	O
undiagnosed	O
POAG	O
were	O
analyzed	O
and	O
compared	O
with	O
data	O
from	O
the	O
30	O
patients	O
with	O
previously	O
diagnosed	O
glaucoma	O
.	O

A	O
total	O
of	O
92.3	O
%	O
of	O
POAG	O
cases	O
were	O
undiagnosed	O
before	O
this	O
study	O
.	O

Adjusted	O
for	O
age	O
and	O
sex	O
,	O
the	O
strongest	O
risk	O
factor	O
for	O
undiagnosed	O
glaucoma	O
was	O
longer	O
elapsed	O
time	O
since	O
last	O
eye	O
doctor	O
visit	O
.	O

Glaucoma	O
patients	O
who	O
had	O
not	O
visited	O
an	O
eye	O
specialist	O
in	O
the	O
last	O
3	O
years	O
were	O
22	O
times	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
CI	O
,	O
4.49-105.64	O
,	O
p	O
<	O
0.001	O
)	O
more	O
likely	O
to	O
have	O
undiagnosed	O
disease	O
compared	O
with	O
patients	O
who	O
had	O
visited	O
an	O
eye	O
specialist	O
in	O
the	O
last	O
month	O
.	O

Another	O
significant	O
factor	O
for	O
previously	O
undiagnosed	O
glaucoma	O
was	O
smaller	O
cup-to-disc	O
ratio	O
(	O
odds	O
ratio	O
,	O
OR	O
,	O
0.60/0.1	O
units	O
,	O
95	O
%	O
CI	O
0.43-0.85/0.1	O
units	O
,	O
p	O
=	O
0.004	O
)	O
.	O

The	O
higher	O
vertical	O
cup-to-disc	O
ratio	O
of	O
a	O
subject	O
's	O
two	O
eyes	O
was	O
significantly	O
different	O
between	O
those	O
with	O
previously	O
undiagnosed	O
(	O
0.69	O
)	O
and	O
diagnosed	O
(	O
0.78	O
)	O
POAG	O
(	O
p	O
=	O
0.001	O
)	O
.	O

The	O
undiagnosed	O
POAG	O
group	O
had	O
a	O
longer	O
interval	O
from	O
last	O
eye	O
doctor	O
visit	O
and	O
smaller	O
vertical	O
cup-to-disc	O
ratio	O
compared	O
to	O
the	O
diagnosed	O
group	O
.	O

Low-dose	B-P
dynamic	I-P
myocardial	I-P
perfusion	I-P
CT	I-P
image	I-P
reconstruction	O
using	O
pre-contrast	B-P
normal-dose	I-P
CT	I-P
scan	I-P
induced	O
structure	B-P
tensor	I-P
total	I-P
variation	I-P
regularization	I-P
.	O

Dynamic	B-P
myocardial	I-P
perfusion	I-P
CT	I-P
(	O
DMP-CT	B-P
)	O
imaging	O
provides	O
quantitative	O
functional	O
information	O
for	O
diagnosis	O
and	O
risk	O
stratification	O
of	O
coronary	O
artery	O
disease	O
by	O
calculating	O
myocardial	O
perfusion	O
hemodynamic	O
parameter	O
(	O
MPHP	O
)	O
maps	O
.	O

However	O
,	O
the	O
level	O
of	O
radiation	O
delivered	O
by	O
dynamic	B-P
sequential	I-P
scan	I-P
protocol	I-P
can	O
be	O
potentially	O
high	O
.	O

The	O
purpose	O
of	O
this	O
work	O
is	O
to	O
develop	O
a	O
pre-contrast	O
normal-dose	O
scan	O
induced	O
structure	O
tensor	O
total	O
variation	O
regularization	O
based	O
on	O
the	O
penalized	O
weighted	O
least-squares	O
(	O
PWLS	O
)	O
criteria	O
to	O
improve	O
the	O
image	O
quality	O
of	O
DMP-CT	B-P
with	O
a	O
low-mAs	B-P
CT	I-P
acquisition	I-P
.	O

For	O
simplicity	O
,	O
the	O
present	O
approach	O
was	O
termed	O
as	O
'	O
PWLS-ndiSTV	O
'	O
.	O

Specifically	O
,	O
the	O
ndiSTV	O
regularization	O
takes	O
into	O
account	O
the	O
spatial-temporal	O
structure	O
information	O
of	O
DMP-CT	B-P
data	O
and	O
further	O
exploits	O
the	O
higher	O
order	O
derivatives	O
of	O
the	O
objective	O
images	O
to	O
enhance	O
denoising	O
performance	O
.	O

Subsequently	O
,	O
an	O
effective	O
optimization	O
algorithm	O
based	O
on	O
the	O
split-Bregman	O
approach	O
was	O
adopted	O
to	O
minimize	O
the	O
associative	O
objective	O
function	O
.	O

Evaluations	O
with	O
modified	O
dynamic	O
XCAT	O
phantom	O
and	O
preclinical	O
porcine	O
datasets	O
have	O
demonstrated	O
that	O
the	O
proposed	O
PWLS-ndiSTV	O
approach	O
can	O
achieve	O
promising	O
gains	O
over	O
other	O
existing	O
approaches	O
in	O
terms	O
of	O
noise-induced	O
artifacts	O
mitigation	O
,	O
edge	O
details	O
preservation	O
,	O
and	O
accurate	O
MPHP	O
maps	O
calculation	O
.	O

Low	O
efficacy	O
of	O
albendazole	O
against	O
Trichuris	O
trichiura	O
infection	O
in	O
schoolchildren	O
from	O
Port	O
Elizabeth	O
,	O
South	O
Africa	O
.	O

Albendazole	O
is	O
one	O
of	O
two	O
standard	O
drugs	O
for	O
the	O
control	O
of	O
soil-transmitted	O
helminthiasis	O
.	O

A	O
total	O
of	O
149	O
schoolchildren	O
from	O
Port	O
Elizabeth	O
,	O
South	O
Africa	O
,	O
were	O
examined	O
for	O
soil-transmitted	O
helminth	O
infections	O
using	O
duplicate	B-P
Kato-Katz	I-P
thick	I-P
smears	I-P
before	O
and	O
2	O
weeks	O
after	O
administration	O
of	O
albendazole	O
(	O
400	O
mg	O
)	O
.	O

Trichuris	O
trichiura	O
was	O
the	O
predominant	O
soil-transmitted	O
helminth	O
species	O
(	O
prevalence	O
60.4	O
%	O
)	O
,	O
followed	O
by	O
Ascaris	O
lumbricoides	O
(	O
47.7	O
%	O
)	O
.	O

While	O
albendazole	O
was	O
highly	O
efficacious	O
against	O
A.	O
lumbricoides	O
(	O
cure	O
rate	O
[	O
CR	O
]	O
97.2	O
%	O
;	O
egg	O
reduction	O
rate	O
[	O
ERR	O
]	O
94.3	O
%	O
)	O
,	O
it	O
lacked	O
efficacy	O
against	O
T.	O
trichiura	O
(	O
CR	O
1.1	O
%	O
;	O
ERR	O
46.0	O
%	O
)	O
.	O

Our	O
study	O
confirms	O
low	O
efficacy	O
of	O
single	O
dose	O
albendazole	O
against	O
T.	O
trichiura	O
.	O

There	O
is	O
a	O
need	O
for	O
safe	O
and	O
efficacious	O
drugs	O
against	O
T.	O
trichiura	O
.	O

A	O
Systematic	O
Review	O
on	O
Infliximab	O
and	O
Adalimumab	O
Drug	O
Monitoring	O
:	O
Levels	O
,	O
Clinical	O
Outcomes	O
and	O
Assays	B-P
.	O

Immunogenicity	O
to	O
therapeutic	O
proteins	O
has	O
been	O
linked	O
to	O
loss	O
of	O
response	O
by	O
a	O
large	O
percentage	O
of	O
patients	O
taking	O
anti-tumor	O
necrosis	O
factor-alpha	O
agents	O
.	O

Drug	O
monitoring	O
can	O
be	O
extremely	O
useful	O
,	O
allowing	O
physicians	O
to	O
adjust	O
the	O
therapeutic	O
scheme	O
individually	O
.	O

This	O
article	O
aims	O
to	O
systematically	O
review	O
the	O
published	O
data	O
with	O
respect	O
to	O
cutoff	O
levels	O
of	O
infliximab	O
(	O
IFX	O
)	O
and	O
adalimumab	O
(	O
ADA	O
)	O
and	O
relate	O
them	O
to	O
the	O
methodology	O
adopted	O
for	O
quantification	O
of	O
IFX	O
and	O
ADA	O
levels	O
and	O
clinical	O
outcomes	O
.	O

The	O
PubMed	O
database	O
was	O
searched	O
to	O
identify	O
studies	O
focusing	O
on	O
the	O
association	O
between	O
IFX	O
or	O
ADA	O
cutoff	O
levels	O
and	O
clinical	O
outcomes	O
in	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
.	O

Of	O
the	O
1654	O
articles	O
initially	O
selected	O
by	O
queries	O
,	O
20	O
were	O
included	O
.	O

A	O
receiver	O
operating	O
characteristic	O
curve	O
analysis	O
was	O
performed	O
to	O
identify	O
cutoff	O
levels	O
of	O
IFX	O
or	O
ADA	O
that	O
correlated	O
with	O
a	O
clinical	O
outcome	O
,	O
but	O
only	O
6	O
studies	O
performed	O
the	O
same	O
analysis	O
for	O
antidrug	O
antibody	O
levels	O
.	O

Cutoff	O
levels	O
were	O
different	O
between	O
studies	O
.	O

The	O
methodology	O
chosen	O
for	O
level	O
quantifications	O
,	O
clinical	O
outcomes	O
,	O
and	O
sample	O
size	O
and	O
characteristics	O
were	O
also	O
different	O
.	O

Nevertheless	O
,	O
measurement	B-P
of	I-P
drug	I-P
levels	I-P
should	O
be	O
performed	O
during	O
maintenance	O
,	O
and	O
with	O
loss	O
of	O
response	O
,	O
with	O
persistent	O
high	O
levels	O
of	O
C-reactive	O
protein	O
,	O
and	O
when	O
mucosal	O
lesions	O
are	O
still	O
present	O
.	O

In	O
these	O
scenarios	O
,	O
drug	O
and	O
antidrug	O
levels	O
were	O
correlated	O
with	O
clinical	O
outcomes	O
.	O

Concerning	O
drug	O
levels	O
monitoring	O
any	O
methodology	O
is	O
adequate	O
.	O

With	O
respect	O
to	O
antidrug	O
antibody	O
levels	O
,	O
it	O
will	O
be	O
necessary	O
to	O
define	O
a	O
gold	O
standard	O
method	O
or	O
to	O
establish	O
different	O
cutoff	O
levels	O
for	O
different	O
methodologies	O
.	O

Human	O
Leucocyte	O
Antigen	O
B50	O
Is	O
Associated	O
with	O
Conversion	O
to	O
Generalized	O
Myasthenia	O
Gravis	O
in	O
Patients	O
with	O
Pure	O
Ocular	O
Onset	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
associations	O
between	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
and	O
II	O
alleles	O
and	O
disease	O
characteristics	O
in	O
Turkish	O
patients	O
with	O
myasthenia	O
gravis	O
(	O
MG	O
)	O
.	O

The	O
MHC	O
class	O
I	O
and	O
II	O
alleles	O
of	O
108	O
unrelated	O
MG	O
patients	O
were	O
genotyped	B-P
.	O

The	O
human	O
leucocyte	O
antigen	O
(	O
HLA	O
)	O
distribution	O
of	O
all	O
MG	O
patients	O
and	O
subgroups	O
of	O
MG	O
patients	O
(	O
grouped	O
according	O
to	O
disease	O
characteristics	O
)	O
was	O
compared	O
to	O
that	O
of	O
250	O
healthy	O
controls	O
.	O

Overall	O
distributions	O
of	O
HLA-B*61	O
and	O
C*05	O
were	O
more	O
frequent	O
in	O
MG	O
patients	O
(	O
7.4	O
vs.	O
2.0	O
%	O
and	O
14.8	O
vs.	O
6.8	O
%	O
,	O
respectively	O
)	O
than	O
in	O
non-MG	O
patients	O
.	O

Subgroup	O
analyses	O
revealed	O
that	O
HLA-DRB1*14	O
and	O
DQB1*02	O
alleles	O
were	O
more	O
frequent	O
in	O
early-onset	O
MG	O
[	O
n	O
=	O
10	O
(	O
20.8	O
%	O
)	O
vs.	O
n	O
=	O
25	O
(	O
10.0	O
%	O
)	O
and	O
n	O
=	O
21	O
(	O
43.8	O
%	O
)	O
vs.	O
n	O
=	O
59	O
(	O
23.6	O
%	O
)	O
]	O
.	O

In	O
patients	O
seropositive	O
for	O
anti-AchR	O
antibodies	O
,	O
the	O
frequencies	O
of	O
HLA-B*50	O
and	O
C*05	O
were	O
higher	O
.	O

HLA-C*05	O
,	O
DRB1*01	O
,	O
and	O
DRB1*11	O
were	O
higher	O
in	O
patients	O
with	O
ocular	O
MG	O
.	O

In	O
addition	O
,	O
HLA-A*01	O
,	O
A*31	O
,	O
B*08	O
,	O
and	O
DRB1*14	O
were	O
higher	O
among	O
patients	O
with	O
thymic	O
hyperplasia	O
,	O
whereas	O
DQB1*03	O
was	O
lower	O
.	O

However	O
,	O
all	O
of	O
these	O
differences	O
lost	O
significance	O
after	O
correction	O
of	O
the	O
p	O
value	O
for	O
multiple	O
comparisons	O
.	O

No	O
allele	O
association	O
was	O
found	O
among	O
patients	O
with	O
thymoma	O
.	O

Strikingly	O
,	O
patients	O
with	O
generalized	O
MG	O
who	O
had	O
pure	O
ocular	O
symptoms	O
at	O
disease	O
onset	O
had	O
significantly	O
increased	O
HLA-B*50	O
compared	O
to	O
the	O
controls	O
(	O
corrected	O
p	O
<	O
0.001	O
,	O
OR	O
=	O
9.92	O
;	O
95	O
%	O
CI	O
3.05-32.22	O
)	O
.	O

The	O
HLA-B*50	O
allele	O
was	O
associated	O
with	O
conversion	O
to	O
generalized	O
disease	O
in	O
patients	O
with	O
pure	O
ocular	O
symptoms	O
at	O
disease	O
onset	O
.	O

This	O
finding	O
could	O
extend	O
our	O
understanding	O
of	O
the	O
complex	O
interactions	O
between	O
the	O
pathogenesis	O
of	O
MG	O
and	O
genetic	O
heritage	O
.	O

Determination	B-P
of	O
eight	O
pesticides	O
in	O
Lycium	O
barbarum	O
by	O
LC-MS/MS	B-P
and	O
dietary	O
risk	O
assessment	O
.	O

A	O
LC-MS/MS	B-P
method	O
for	O
determination	B-P
of	O
eight	O
pesticides	O
(	O
triadimefon	O
,	O
sulfoxaflor	O
,	O
flusilazole	O
,	O
tebuconazole	O
,	O
difenoconazole	O
,	O
amitraz	O
,	O
azoxystrobin	O
,	O
and	O
thiophanate-methyl	O
)	O
in	O
Lycium	O
barbarum	O
was	O
established	O
.	O

The	O
samples	O
were	O
extracted	B-P
with	O
acetonitrile	O
,	O
and	O
then	O
cleaned	O
up	O
by	O
primary	O
secondary	O
amine	O
.	O

The	O
extracts	O
were	O
diluted	O
with	O
0.1	O
%	O
formic	O
acid	O
in	O
water	O
.	O

The	O
results	O
showed	O
that	O
at	O
the	O
fortified	O
levels	O
of	O
0.01-10mg/kg	O
,	O
the	O
average	O
recoveries	O
of	O
these	O
pesticides	O
ranged	O
from	O
82.1	O
%	O
to	O
96.2	O
%	O
with	O
the	O
relative	O
standard	O
deviations	O
lower	O
than	O
7	O
%	O
.	O

The	O
half-lives	O
of	O
eight	O
pesticides	O
were	O
1.3-5.0days	O
in	O
Lycium	O
barbarum	O
fruits	O
.	O

The	O
pre-harvest	O
interval	O
of	O
all	O
pesticides	O
mentioned	O
above	O
were	O
investigated	O
.	O

Tebuconazole	O
(	O
14days	O
)	O
,	O
sulfoxaflor	O
(	O
14days	O
)	O
and	O
flusilazole	O
(	O
28days	O
)	O
have	O
longer	O
pre-harvest	O
interval	O
than	O
the	O
others	O
which	O
have	O
7days	O
.	O

The	O
dietary	O
risks	O
,	O
assessed	O
as	O
hazard	O
quotients	O
,	O
were	O
far	O
below	O
100	O
%	O
.	O

The	O
results	O
showed	O
that	O
the	O
eight	O
pesticides	O
applied	O
to	O
Lycium	O
barbarum	O
were	O
comparably	O
safe	O
for	O
the	O
consumer	O
.	O

Anterior	O
single	O
implants	O
with	O
different	O
neck	O
designs	O
:	O
5	O
Year	O
results	O
of	O
a	O
randomized	O
clinical	O
trial	O
.	O

The	O
design	O
of	O
the	O
implant	O
neck	O
might	O
be	O
significant	O
for	O
preservation	B-P
of	O
marginal	O
bone	O
.	O

To	O
compare	O
the	O
5-year	O
radiographic	O
and	O
clinical	O
outcome	O
of	O
single	O
anterior	O
implants	O
provided	O
with	O
a	O
smooth	O
neck	O
,	O
a	O
rough	O
neck	O
or	O
a	O
scalloped	O
rough	O
neck	O
.	O

93	O
Patients	O
with	O
a	O
missing	O
anterior	O
tooth	O
in	O
the	O
maxilla	O
were	O
included	O
.	O

At	O
random	O
,	O
patients	O
received	O
an	O
implant	O
with	O
a	O
1.5	O
mm	O
smooth	O
neck	O
(	O
``	O
smooth	O
group	O
``	O
)	O
,	O
a	O
rough	O
neck	O
with	O
grooves	O
(	O
``	O
rough	O
group	O
``	O
)	O
or	O
a	O
scalloped	O
rough	O
neck	O
with	O
grooves	O
(	O
``	O
scalloped	O
group	O
``	O
)	O
.	O

Implants	O
were	O
installed	O
in	O
healed	O
sites	O
.	O

Follow-up	O
visits	O
were	O
conducted	O
after	O
final	O
crown	O
delivery	O
and	O
1	O
year	O
and	O
5	O
years	O
later	O
.	O

Scalloped	O
implants	O
showed	O
significantly	O
more	O
initial	O
marginal	O
bone	O
resorption	O
.	O

The	O
total	O
amount	O
of	O
bone	O
loss	O
was	O
1.26	O
±	O
0.90	O
mm	O
in	O
the	O
smooth	O
group	O
,	O
1.20	O
±	O
1.1	O
mm	O
in	O
the	O
rough	O
group	O
and	O
2.28	O
±	O
0.97	O
mm	O
in	O
the	O
scalloped	O
group	O
(	O
P	O
<	O
.05	O
)	O
.	O

Survival	O
rates	O
were	O
96.2	O
%	O
for	O
the	O
smooth	O
and	O
scalloped	O
group	O
and	O
100	O
%	O
for	O
the	O
rough	O
group	O
.	O

Scalloped	O
implants	O
showed	O
deeper	O
pocket	O
depths	O
,	O
more	O
bleeding	O
and	O
more	O
technical	O
complications	O
.	O

There	O
were	O
no	O
differences	O
in	O
esthetic	O
outcome	O
nor	O
in	O
patient	O
satisfaction	O
.	O

For	O
anterior	O
single	O
tooth	O
replacements	O
,	O
scalloped	O
implants	O
show	O
less	O
favorable	O
radiographic	O
and	O
clinical	O
outcome	O
compared	O
to	O
regular	O
implants	O
with	O
a	O
smooth	O
neck	O
or	O
rough	O
neck	O
.	O

Discontinued	O
Splenogonadal	O
Fusion	O
and	O
Bilateral	O
Empty	O
Scrotum	O
in	O
an	O
18-	O
Month	O
-Old	O
Boy	O
.	O

Splenogonadal	O
fusion	O
is	O
a	O
rare	O
benign	O
congenital	O
anomaly	O
defined	O
as	O
the	O
presence	O
of	O
splenic	O
tissue	O
adherent	O
to	O
gonads	O
.	O

It	O
was	O
first	O
described	O
in	O
1883	O
by	O
Bostroem	O
,	O
a	O
German	O
pathologist	O
.	O

We	O
present	O
a	O
case	O
of	O
an	O
18-	O
month	O
-old	O
boy	O
who	O
was	O
referred	O
as	O
a	O
case	O
of	O
bilateral	O
empty	O
scrotum	O
since	O
birth	O
.	O

During	O
routine	O
laparoscopic	B-P
exploration	O
,	O
right	O
vas	O
deferens	O
and	O
testicular	O
vessels	O
were	O
entering	O
the	O
right	O
internal	O
inguinal	O
ring	O
so	O
right	O
inguinal	O
exploration	O
was	O
done	O
,	O
which	O
revealed	O
blind	O
ending	O
vas	O
deferens	O
and	O
testicular	O
vessels	O
and	O
the	O
left	O
testis	O
was	O
found	O
intra-abdominally	O
near	O
the	O
left	O
internal	O
ring	O
with	O
a	O
mass	O
on	O
its	O
upper	O
pole	O
.	O

Wedge	B-P
biopsy	I-P
was	O
taken	O
from	O
the	O
upper	O
pole	O
of	O
the	O
testicle	O
(	O
site	O
of	O
the	O
mass	O
)	O
for	O
tissue	O
diagnosis	O
followed	O
by	O
orchidopexy	O
.	O

Histology	B-P
showed	O
splenic	O
tissue	O
.	O

Although	O
splenogonadal	O
fusion	O
is	O
a	O
rare	O
condition	O
,	O
surgeons	O
should	O
be	O
aware	O
of	O
this	O
rare	O
disease	O
entity	O
to	O
avoid	O
unnecessary	O
aggressive	O
interventions	O
such	O
as	O
orchiectomy	O
.	O

Silk	O
fibroin	O
based	O
carrier	O
system	O
for	O
delivery	O
of	O
fibrinogen	O
and	O
thrombin	O
as	O
coagulant	O
supplements	O
.	O

The	O
control	O
of	O
bleeding	O
is	O
one	O
of	O
the	O
most	O
important	O
interventions	O
after	O
a	O
traumatic	O
injury	O
.	O

Hemostatic	O
devices	O
delivering	O
blood	O
clotting	O
accelerating	O
agents	O
such	O
as	O
fibrinogen	O
are	O
increasingly	O
used	O
due	O
to	O
their	O
efficacy	O
and	O
their	O
ease	O
of	O
application	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
a	O
method	O
to	O
incorporate	O
the	O
coagulant	O
supplements	O
fibrinogen	O
and	O
thrombin	O
in	O
silk	O
protein	O
sponges	O
by	O
mixing	O
the	O
coagulants	O
with	O
an	O
aqueous	O
silk	O
solution	O
,	O
followed	O
by	O
molding	B-P
,	O
freeze-drying	B-P
and	O
water	B-P
annealing	I-P
.	O

In	O
this	O
combination	O
system	O
we	O
demonstrate	O
the	O
delivery	O
of	O
fibrinogen	O
while	O
maintaining	O
its	O
hemostatic	O
potential	O
.	O

Concentration	O
ratios	O
of	O
silk	O
to	O
fibrinogen	O
of	O
1.0	O
%	O
/2.8	O
%	O
,	O
2.3	O
%	O
/1.5	O
%	O
and	O
3.0	O
%	O
/0.8	O
%	O
were	O
used	O
.	O

The	O
thrombin	O
-induced	O
fibrin	O
polymeric	O
network	O
filled	O
the	O
space	O
in	O
and	O
next	O
to	O
the	O
silk	O
spongy	O
structure	O
but	O
also	O
remained	O
interconnected	O
to	O
the	O
silk	O
,	O
providing	O
an	O
intact	O
network	O
.	O

The	O
mechanical	O
characterization	O
of	O
the	O
fibrinogen-releasing	O
silk	O
sponges	O
before	O
and	O
after	O
the	O
induction	O
of	O
the	O
fibrinogen	O
polymerization	O
demonstrated	O
that	O
the	O
fibrin	O
network	O
resulted	O
in	O
reduced	O
permanent	O
deformation	O
from	O
21.1	O
%	O
to	O
6.5	O
%	O
,	O
19.6	O
%	O
to	O
5.7	O
%	O
and	O
12.7	O
%	O
to	O
9.4	O
%	O
for	O
the	O
2.8	O
%	O
,	O
1.5	O
%	O
and	O
0.8	O
%	O
fibrinogen	O
-containing	O
silk	O
sponges	O
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
fibrin	O
formation	O
lead	O
to	O
a	O
more	O
linear	O
elastic	O
behavior	O
over	O
longer	O
strain	O
ranges	O
.	O

In	O
combination	O
,	O
the	O
Calcein-AM	O
/	O
PI	O
stainings	O
and	O
MTT	O
assay	O
results	O
indicate	O
uniform	O
cell	O
adhesion	O
on	O
the	O
surface	O
and	O
cytocompatibility	O
of	O
the	O
silk	O
/	O
fibrin	O
sponges	O
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
co-delivery	O
of	O
thrombin	O
with	O
fibrinogen	O
via	O
silk	O
as	O
carrier	O
material	O
is	O
described	O
,	O
offering	O
a	O
more	O
mechanically	O
robust	O
and	O
durable	O
system	O
while	O
preserving	O
hemostatic	O
features	O
of	O
the	O
coagulant	O
substances	O
for	O
the	O
generation	O
of	O
hemostatic	O
devices	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Evaluation	O
of	O
Outcome	O
Following	O
Coronectomy	O
for	O
the	O
Management	O
of	O
Mandibular	O
Third	O
Molars	O
in	O
Close	O
Proximity	O
to	O
Inferior	O
Alveolar	O
Nerve	O
.	O

Iatrogenic	O
damage	O
to	O
Inferior	O
Alveolar	O
Nerve	O
(	O
IAN	O
)	O
is	O
a	O
significant	O
risk	O
factor	O
following	O
prophylactic	O
or	O
therapeutic	O
removal	O
of	O
impacted	O
mandibular	O
third	O
molar	O
.	O

The	O
risk	O
to	O
IAN	O
injury	O
increases	O
many	O
fold	O
,	O
when	O
the	O
third	O
molar	O
root	O
overlaps	O
the	O
nerve	O
canal	O
as	O
identified	O
by	O
the	O
radiographic	B-P
imaging	I-P
.	O

Various	O
methods	O
like	O
orthodontic	O
assisted	O
extraction	O
,	O
staged	O
removal	O
of	O
tooth	O
or	O
coronectomy	O
have	O
been	O
advocated	O
to	O
reduce	O
the	O
incidence	O
of	O
IAN	O
injury	O
in	O
high	O
risk	O
cases	O
with	O
variable	O
outcome	O
.	O

The	O
aim	O
of	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
fate	O
of	O
the	O
root	O
(	O
resorbed	O
,	O
exfoliated	O
,	O
covered	O
by	O
bone	O
)	O
after	O
coronectomy	O
or	O
intentional	O
root	O
retention	O
of	O
impacted	O
mandibular	O
3	O
(	O
rd	O
)	O
molars	O
in	O
patients	O
with	O
high	O
risk	O
for	O
inferior	O
alveolar	O
nerve	O
damage	O
as	O
evaluated	O
by	O
the	O
intra	B-P
oral	I-P
periapical	I-P
radiograph	I-P
.	O

Twenty	O
impacted	O
mandibular	O
third	O
molar	O
teeth	O
,	O
in	O
18	O
patients	O
with	O
high	O
risk	O
of	O
injury	O
to	O
IAN	O
based	O
on	O
Rood	O
's	O
Criteria	O
in	O
an	O
intra	B-P
oral	I-P
periapical	I-P
radiographic	I-P
examination	I-P
,	O
between	O
the	O
age	O
group	O
of	O
18	O
to	O
40	O
years	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O

Preoperatively	O
the	O
impacted	O
third	O
molars	O
were	O
evaluated	O
clinically	O
as	O
well	O
as	O
radiographically	O
.	O

Pederson	O
Difficulty	O
Index	O
and	O
Winter	O
's	O
Classification	O
of	O
impacted	O
tooth	O
was	O
recorded	O
.	O

Coronectomy	O
was	O
done	O
at	O
the	O
cemento	O
enamel	O
junction	O
leaving	O
the	O
roots	O
2-3mm	O
below	O
the	O
alveolar	O
crest	O
and	O
primary	O
closure	O
was	O
done	O
.	O

Patients	O
were	O
evaluated	O
periodically	O
for	O
two	O
years	O
at	O
six	O
months	O
interval	O
.	O

Post	O
operative	O
pain	O
,	O
swelling	O
,	O
IAN	O
injury	O
or	O
any	O
other	O
complications	O
were	O
observed	O
and	O
recorded	O
.	O

None	O
of	O
the	O
patients	O
had	O
IAN	O
injury	O
and	O
none	O
required	O
second	O
surgical	O
removal	O
.	O

There	O
was	O
no	O
incidence	O
of	O
post-operative	O
infection	O
and	O
none	O
required	O
second	O
surgical	O
intervention	O
.	O

However	O
,	O
two	O
of	O
our	O
patients	O
had	O
failed	O
coronectomy	O
(	O
10	O
%	O
)	O
due	O
to	O
mobilization	O
of	O
roots	O
intra	O
operatively	O
and	O
the	O
roots	O
were	O
removed	O
.	O

One	O
patient	O
developed	O
profuse	O
bleeding	O
intra-operatively	O
in	O
the	O
failed	O
coronectomy	O
case	O
.	O

One	O
patient	O
had	O
temporary	O
lingual	O
nerve	O
paresthesia	O
.	O

Coronectomy	O
procedure	O
is	O
effective	O
in	O
controlling	O
inferior	O
alveolar	O
nerve	O
injury	O
following	O
third	O
molar	O
surgery	O
,	O
in	O
radiographically	O
evaluated	O
high	O
risk	O
cases	O
and	O
it	O
has	O
very	O
low	O
incidence	O
of	O
complications	O
.	O

DNA	O
annealing	O
by	O
Redβ	O
is	O
insufficient	O
for	O
homologous	O
recombination	O
and	O
the	O
additional	O
requirements	O
involve	O
intra-	O
and	O
inter-molecular	O
interactions	O
.	O

Single	O
strand	O
annealing	O
proteins	O
(	O
SSAPs	O
)	O
like	O
Redβ	O
initiate	O
homologous	O
recombination	O
by	O
annealing	O
complementary	O
DNA	O
strands	O
.	O

We	O
show	O
that	O
C-terminally	O
truncated	O
Redβ	O
,	O
whilst	O
still	O
able	O
to	O
promote	O
annealing	O
and	O
nucleoprotein	O
filament	O
formation	O
,	O
is	O
unable	O
to	O
mediate	O
homologous	O
recombination	O
.	O

Mutations	O
of	O
the	O
C-terminal	O
domain	O
were	O
evaluated	O
using	O
both	O
single	O
-	O
and	O
double	O
stranded	O
(	O
ss	O
and	O
ds	O
)	O
substrates	O
in	O
recombination	O
assays	B-P
.	O

Mutations	O
of	O
critical	O
amino	O
acids	O
affected	O
either	O
dsDNA	O
recombination	O
or	O
both	O
ssDNA	O
and	O
dsDNA	O
recombination	O
indicating	O
two	O
separable	O
functions	O
,	O
one	O
of	O
which	O
is	O
critical	O
for	O
dsDNA	O
recombination	O
and	O
the	O
second	O
for	O
recombination	O
per	O
se	O
.	O

As	O
evaluated	O
by	O
co-immunoprecipitation	B-P
experiments	I-P
,	O
the	O
dsDNA	O
recombination	O
function	O
relates	O
to	O
the	O
Redα	O
-	O
Redβ	O
protein-protein	O
interaction	O
,	O
which	O
requires	O
not	O
only	O
contacts	O
in	O
the	O
C-terminal	O
domain	O
but	O
also	O
a	O
region	O
near	O
the	O
N-terminus	O
.	O

Because	O
the	O
nucleoprotein	O
filament	O
formed	O
with	O
C-terminally	O
truncated	O
Redβ	O
has	O
altered	O
properties	O
,	O
the	O
second	O
C-terminal	O
function	O
could	O
be	O
due	O
to	O
an	O
interaction	O
required	O
for	O
functional	O
filaments	O
.	O

Alternatively	O
the	O
second	O
C-terminal	O
function	O
could	O
indicate	O
a	O
requirement	O
for	O
a	O
Redβ	O
-	O
host	O
factor	O
interaction	O
.	O

These	O
data	O
further	O
advance	O
the	O
model	O
for	O
Red	O
recombination	O
and	O
the	O
proposition	O
that	O
Redβ	O
and	O
RAD52	O
SSAPs	O
share	O
ancestral	O
and	O
mechanistic	O
roots	O
.	O

Visualization	O
and	O
targeting	O
of	O
LGR5	O
(	O
+	O
)	O
human	O
colon	O
cancer	O
stem	O
cells	O
.	O

The	O
cancer	O
stem	O
cell	O
(	O
CSC	O
)	O
theory	O
highlights	O
a	O
self-renewing	O
subpopulation	O
of	O
cancer	O
cells	O
that	O
fuels	O
tumour	O
growth	O
.	O

The	O
existence	O
of	O
human	O
CSCs	O
is	O
mainly	O
supported	O
by	O
xenotransplantation	O
of	O
prospectively	O
isolated	O
cells	O
,	O
but	O
their	O
clonal	O
dynamics	O
and	O
plasticity	O
remain	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
human	O
LGR5	O
(	O
+	O
)	O
colorectal	O
cancer	O
cells	O
serve	O
as	O
CSCs	O
in	O
growing	O
cancer	O
tissues	O
.	O

Lineage	O
-	O
tracing	B-P
experiments	I-P
with	O
a	O
tamoxifen	O
-inducible	O
Cre	O
knock-in	O
allele	O
of	O
LGR5	O
reveal	O
the	O
self-renewal	O
and	O
differentiation	O
capacity	O
of	O
LGR5	O
(	O
+	O
)	O
tumour	O
cells	O
.	O

Selective	O
ablation	O
of	O
LGR5	O
(	O
+	O
)	O
CSCs	O
in	O
LGR5	O
-i	O
Caspase9	O
knock-in	O
organoids	O
leads	O
to	O
tumour	O
regression	O
,	O
followed	O
by	O
tumour	O
regrowth	O
driven	O
by	O
re-emerging	O
LGR5	O
(	O
+	O
)	O
CSCs	O
.	O

KRT20	O
knock-in	O
reporter	O
marks	O
differentiated	O
cancer	O
cells	O
that	O
constantly	O
diminish	O
in	O
tumour	O
tissues	O
,	O
while	O
reverting	O
to	O
LGR5	O
(	O
+	O
)	O
CSCs	O
and	O
contributing	O
to	O
tumour	O
regrowth	O
after	O
LGR5	O
(	O
+	O
)	O
CSC	O
ablation	O
.	O

We	O
also	O
show	O
that	O
combined	O
chemotherapy	O
potentiates	O
targeting	O
of	O
LGR5	O
(	O
+	O
)	O
CSCs	O
.	O

These	O
data	O
provide	O
insights	O
into	O
the	O
plasticity	O
of	O
CSCs	O
and	O
their	O
potential	O
as	O
a	O
therapeutic	O
target	O
in	O
human	O
colorectal	O
cancer	O
.	O

Assessment	O
of	O
demographic	O
and	O
pathoanatomic	O
risk	O
factors	O
in	O
recurrent	O
patellofemoral	O
instability	O
.	O

The	O
WARPS/STAID	O
classification	O
employs	O
clinical	O
assessment	O
of	O
presenting	O
features	O
and	O
anatomic	O
characteristics	O
to	O
identify	O
two	O
distinct	O
subsets	O
of	O
patients	O
within	O
the	O
patellofemoral	O
instability	O
population	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
further	O
define	O
the	O
specific	O
demographics	O
and	O
the	O
prevalence	O
of	O
risky	O
pathoanatomies	O
in	O
patients	O
classified	O
as	O
either	O
WARPS	O
or	O
STAID	O
presenting	O
with	O
recurrent	O
patellofemoral	O
instability	O
.	O

A	O
secondary	O
purpose	O
was	O
to	O
further	O
validate	O
the	O
WARPS/STAID	O
classification	O
with	O
the	O
Banff	O
Patella	O
Instability	O
Instrument	O
(	O
BPII	O
)	O
,	O
the	O
Marx	O
activity	O
scale	O
and	O
the	O
Patellar	O
Instability	O
Severity	O
Score	O
(	O
ISS	O
)	O
.	O

A	O
convenience	O
sample	O
of	O
50	O
patients	O
with	O
recurrent	O
patellofemoral	O
instability	O
,	O
including	O
25	O
WARPS	O
and	O
25	O
STAID	O
subtype	O
patients	O
,	O
were	O
assessed	O
.	O

Clinical	O
data	O
were	O
collected	O
including	O
assessment	O
of	O
demographic	O
risk	O
factors	O
(	O
sex	O
,	O
BMI	O
,	O
bilaterality	O
of	O
symptoms	O
,	O
affected	O
limb	O
side	O
and	O
age	O
at	O
first	O
dislocation	O
)	O
and	O
pathoanatomic	O
risk	O
factors	O
(	O
TT-TG	O
distance	O
,	O
patella	O
height	O
,	O
patellar	O
tilt	O
,	O
grade	O
of	O
trochlear	O
dysplasia	O
,	O
Beighton	O
score	O
and	O
rotational	O
abnormalities	O
of	O
the	O
tibia	O
or	O
femur	O
)	O
.	O

Patients	O
completed	O
the	O
BPII	O
and	O
the	O
Marx	O
activity	O
scale	O
.	O

The	O
ISS	O
was	O
calculated	B-P
from	O
the	O
clinical	O
assessment	O
data	O
.	O

Patients	O
were	O
stratified	O
into	O
the	O
WARPS	O
or	O
STAID	O
subtypes	O
for	O
comparative	O
analysis	O
.	O

An	O
independent	O
t	O
test	O
was	O
used	O
to	O
compare	O
demographics	O
,	O
the	O
pathoanatomic	O
risk	O
factors	O
and	O
subjective	O
measures	O
between	O
the	O
groups	O
.	O

Convergent	O
validity	O
was	O
tested	O
with	O
a	O
Pearson	O
r	O
correlation	O
coefficient	O
between	O
the	O
WARPS/STAID	O
and	O
ISS	O
scores	O
.	O

Demographic	O
risk	O
factors	O
statistically	O
associated	O
with	O
a	O
WARPS	O
subtype	O
included	O
female	O
sex	O
,	O
age	O
at	O
first	O
dislocation	O
and	O
bilaterality	O
.	O

Pathoanatomic	O
risk	O
factors	O
statistically	O
associated	O
with	O
a	O
WARPS	O
subtype	O
included	O
trochlear	O
dysplasia	O
,	O
TT-TG	O
distance	O
,	O
generalized	O
ligamentous	O
laxity	O
,	O
patellar	O
tilt	O
and	O
rotational	O
abnormalities	O
.	O

The	O
independent	O
t	O
test	O
revealed	O
a	O
significant	O
difference	O
between	O
the	O
ISS	O
scores	O
:	O
WARPS	O
subtype	O
(	O
M	O
=	O
4.4	O
,	O
SD	O
=	O
1.1	O
)	O
and	O
STAID	O
subtype	O
(	O
M	O
=	O
2.5	O
,	O
SD	O
=	O
1.5	O
)	O
;	O
t	O
(	O
48	O
)	O
=	O
5.2	O
,	O
p	O
<	O
0.001	O
.	O

The	O
relationship	O
between	O
the	O
WARPS/STAID	O
and	O
the	O
ISS	O
scores	O
,	O
measured	O
using	O
a	O
Pearson	O
r	O
correlation	O
coefficient	O
,	O
demonstrated	O
a	O
strong	O
relationship	O
:	O
r	O
=	O
-0.61	O
,	O
n	O
=	O
50	O
,	O
p	O
<	O
0.001	O
.	O

This	O
study	O
has	O
demonstrated	O
statistically	O
significant	O
evidence	O
that	O
certain	O
demographics	O
and	O
pathoanatomies	O
are	O
more	O
prevalent	O
in	O
each	O
of	O
the	O
WARPS	O
and	O
STAID	O
patellofemoral	O
instability	O
subtypes	O
.	O

There	O
was	O
no	O
difference	O
in	O
quality-of-life	O
or	O
activity	O
level	O
between	O
the	O
subtypes	O
.	O

The	O
WARPS/STAID	O
score	O
demonstrated	O
convergent	O
validity	O
to	O
the	O
ISS	O
and	O
divergent	O
validity	O
to	O
the	O
BPII	O
score	O
and	O
the	O
Marx	O
activity	O
scale	O
.	O

This	O
study	O
has	O
further	O
validated	O
both	O
the	O
WARPS/STAID	O
classification	O
and	O
the	O
ISS	O
of	O
patients	O
that	O
present	O
with	O
recurrent	O
patellofemoral	O
instability	O
.	O

III	O
.	O

Molecular	O
diversity	O
of	O
α-gliadin	O
expressed	O
genes	O
in	O
genetically	O
contrasted	O
spelt	O
(	O
Triticum	O
aestivum	O
ssp	O
.	O

spelta	O
)	O
accessions	O
and	O
comparison	O
with	O
bread	O
wheat	O
(	O
T.	O
aestivum	O
ssp	O
.	O

aestivum	O
)	O
and	O
related	O
diploid	O
Triticum	O
and	O
Aegilops	O
species	O
.	O

The	O
gluten	O
proteins	O
of	O
cereals	O
such	O
as	O
bread	O
wheat	O
(	O
Triticum	O
aestivum	O
ssp	O
.	O

aestivum	O
)	O
and	O
spelt	O
(	O
T.	O
aestivum	O
ssp	O
.	O

spelta	O
)	O
are	O
responsible	O
for	O
celiac	O
disease	O
(	O
CD	O
)	O
.	O

The	O
α-gliadins	O
constitute	O
the	O
most	O
immunogenic	O
class	O
of	O
gluten	O
proteins	O
as	O
they	O
include	O
four	O
main	O
T-cell	O
stimulatory	O
epitopes	O
that	O
affect	O
CD	O
patients	O
.	O

Spelt	O
has	O
been	O
less	O
studied	O
than	O
bread	O
wheat	O
and	O
could	O
constitute	O
a	O
source	O
of	O
valuable	O
diversity	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
study	O
the	O
genetic	O
diversity	O
of	O
spelt	O
α-gliadin	O
transcripts	O
and	O
to	O
compare	O
it	O
with	O
those	O
of	O
bread	O
wheat	O
.	O

Genotyping	B-P
data	O
from	O
85	O
spelt	O
accessions	O
obtained	O
with	O
19	O
simple	O
sequence	O
repeat	O
(	O
SSR	O
)	O
markers	O
were	O
used	O
to	O
select	O
11	O
contrasted	O
accessions	O
,	O
from	O
which	O
446	O
full	O
open	O
reading	O
frame	O
α-gliadin	O
genes	O
were	O
cloned	O
and	O
sequenced	B-P
,	O
which	O
revealed	O
a	O
high	O
allelic	O
diversity	O
.	O

High	O
variations	O
among	O
the	O
accessions	O
were	O
highlighted	O
,	O
in	O
terms	O
of	O
the	O
proportion	O
of	O
α-gliadin	O
sequences	O
from	O
each	O
of	O
the	O
three	O
genomes	O
(	O
A	O
,	O
B	O
and	O
D	O
)	O
,	O
and	O
their	O
composition	O
in	O
the	O
four	O
T-cell	O
stimulatory	O
epitopes	O
.	O

An	O
accession	O
from	O
Tajikistan	O
stood	O
out	O
,	O
having	O
a	O
particularly	O
high	O
proportion	O
of	O
α-gliadins	O
from	O
the	O
B	O
genome	O
and	O
a	O
low	O
immunogenic	O
content	O
.	O

Even	O
if	O
no	O
clear	O
separation	O
between	O
spelt	O
and	O
bread	O
wheat	O
sequences	O
was	O
shown	O
,	O
spelt	O
α-gliadins	O
displayed	O
specific	O
features	O
concerning	O
e.g	O
.	O

the	O
frequencies	O
of	O
some	O
amino	O
acid	O
substitutions	O
.	O

Given	O
this	O
observation	O
and	O
the	O
variations	O
in	O
toxicity	O
revealed	O
in	O
the	O
spelt	O
accessions	O
in	O
this	O
study	O
,	O
the	O
high	O
genetic	O
diversity	O
held	O
in	O
spelt	O
germplasm	O
collections	O
could	O
be	O
a	O
valuable	O
resource	O
in	O
the	O
development	O
of	O
safer	O
varieties	O
for	O
CD	O
patients	O
.	O

Use	O
of	O
Platelet	B-P
Function	I-P
Testing	I-P
Before	O
Pipeline	O
Embolization	O
Device	O
Placement	O
:	O
A	O
Multicenter	O
Cohort	O
Study	O
.	O

Thromboembolic	O
complications	O
constitute	O
a	O
significant	O
source	O
of	O
morbidity	O
after	O
neurointerventional	O
procedures	O
.	O

Flow	O
diversion	O
using	O
the	O
pipeline	O
embolization	O
device	O
for	O
the	O
treatment	O
of	O
intracranial	O
aneurysms	O
necessitates	O
the	O
use	O
of	O
dual	O
antiplatelet	O
therapy	O
to	O
reduce	O
this	O
risk	O
.	O

The	O
use	O
of	O
platelet	B-P
function	I-P
testing	I-P
before	O
pipeline	O
embolization	O
device	O
placement	O
remains	O
controversial	O
.	O

A	O
retrospective	O
review	O
of	O
prospectively	O
maintained	O
databases	O
at	O
3	O
academic	O
institutions	O
was	O
performed	O
from	O
the	O
years	O
2009	O
to	O
2016	O
to	O
identify	O
patients	O
with	O
intracranial	O
aneurysms	O
treated	O
with	O
pipeline	O
embolization	O
device	O
placement	O
.	O

Clinical	O
and	O
radiographic	O
data	O
were	O
analyzed	O
with	O
emphasis	O
on	O
thromboembolic	O
complications	O
and	O
clopidogrel	O
responsiveness	O
.	O

A	O
total	O
of	O
402	O
patients	O
underwent	O
414	O
pipeline	O
embolization	O
device	O
procedures	O
for	O
the	O
treatment	O
of	O
465	O
intracranial	O
aneurysms	O
.	O

Thromboembolic	O
complications	O
were	O
encountered	O
in	O
9.2	O
%	O
of	O
procedures	O
and	O
were	O
symptomatic	O
in	O
5.6	O
%	O
.	O

Clopidogrel	O
nonresponders	O
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
compared	O
with	O
clopidogrel	O
responders	O
(	O
17.4	O
%	O
versus	O
5.6	O
%	O
)	O
.	O

This	O
risk	O
was	O
significantly	O
lower	O
in	O
nonresponders	O
who	O
were	O
switched	O
to	O
ticagrelor	O
when	O
compared	O
with	O
patients	O
who	O
remained	O
on	O
clopidogrel	O
(	O
2.7	O
%	O
versus	O
24.4	O
%	O
)	O
.	O

In	O
patients	O
who	O
remained	O
on	O
clopidogrel	O
,	O
the	O
rate	O
of	O
thromboembolic	O
complications	O
was	O
significantly	O
lower	O
in	O
those	O
who	O
received	O
a	O
clopidogrel	O
boost	O
within	O
24	O
hours	O
pre-procedure	O
when	O
compared	O
with	O
those	O
who	O
did	O
not	O
(	O
9.8	O
%	O
versus	O
51.9	O
%	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
rate	O
of	O
hemorrhagic	O
complications	O
between	O
groups	O
.	O

Clopidogrel	O
nonresponders	O
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
when	O
compared	O
with	O
clopidogrel	O
responders	O
.	O

However	O
,	O
this	O
risk	O
seems	O
to	O
be	O
mitigated	O
in	O
nonresponders	O
who	O
were	O
switched	O
to	O
ticagrelor	O
or	O
received	O
a	O
clopidogrel	O
boost	O
within	O
24	O
hours	O
pre-procedure	O
.	O

A	O
screening	B-P
assay	B-P
for	O
the	O
identification	O
of	O
host	O
cell	O
requirements	O
and	O
antiviral	O
targets	O
for	O
hepatitis	O
D	O
virus	O
infection	O
.	O

Hepatitis	O
delta	O
virus	O
(	O
HDV	O
)	O
is	O
a	O
minimalistic	O
satellite	O
virus	O
of	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
.	O

HBV	O
/	O
HDV	O
co-infection	O
,	O
i.e.	O
``	O

hepatitis	O
D	O
``	O
,	O
is	O
the	O
most	O
severe	O
form	O
of	O
viral	O
hepatitis	O
.	O

No	O
effective	O
therapy	O
for	O
HDV	O
infection	O
is	O
available	O
partly	O
due	O
to	O
the	O
fact	O
that	O
HDV	O
is	O
a	O
highly	O
host	O
-	O
dependent	O
virus	O
devoid	O
of	O
any	O
potentially	O
drugable	O
enzyme	O
encoded	O
in	O
its	O
small	O
genome	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
semi-automated	O
method	O
to	O
evaluate	O
HDV	O
infection	O
and	O
replication	O
under	O
the	O
influence	O
of	O
different	O
drugs	O
.	O

We	O
utilized	O
a	O
Huh-7/hNTCP	O
cell	O
culture	O
based	O
system	O
in	O
a	O
96-	O
well	O
plate	O
format	O
,	O
an	O
automated	O
microscope	O
and	O
image	O
acquisition	O
as	O
well	O
as	O
analysis	O
with	O
the	O
CellProfiler	O
software	O
to	O
quantify	O
the	O
impact	O
of	O
these	O
drugs	O
on	O
HDV	O
infection	O
.	O

For	O
validation	O
,	O
three	O
groups	O
of	O
potential	O
anti-HDV	O
agents	O
were	O
evaluated	O
:	O
To	O
target	O
ribozyme	O
activity	O
of	O
HDV	O
RNA	O
,	O
we	O
screened	B-P
ribozyme	O
inhibitors	O
but	O
only	O
observed	O
marked	O
toxicity	O
.	O

Testing	O
innate	O
antiviral	O
mediators	O
showed	O
that	O
interferons	O
alpha-2a	O
and	O
beta-1a	O
had	O
a	O
specific	O
inhibitory	O
effect	O
on	O
HDV	O
infection	O
.	O

Finally	O
,	O
we	O
screened	B-P
a	O
library	O
of	O
160	O
human	O
kinase	O
inhibitors	O
covering	O
all	O
parts	O
of	O
the	O
human	O
kinome	O
.	O

Overall	O
,	O
only	O
inhibitors	O
targeting	O
the	O
tyrosine	O
kinase-like	O
group	O
had	O
significant	O
average	O
anti-HDV	O
activity	O
.	O

Looking	O
at	O
individual	O
substances	O
,	O
kenpaullone	O
,	O
a	O
GSK-3β	O
and	O
Cdk	O
inhibitor	O
,	O
had	O
the	O
highest	O
selective	O
index	O
of	O
3.44	O
.	O

Thus	O
,	O
we	O
provide	O
a	O
potentially	O
useful	O
tool	O
to	O
screen	O
for	O
substances	O
with	O
anti-HDV	O
activity	O
and	O
novel	O
insights	O
into	O
interactions	O
between	O
HDV	O
replication	O
and	O
the	O
human	O
kinome	O
.	O

Correcting	O
Concavity	O
of	O
Rabbit	O
Auricular	O
Cartilage	O
:	O
Comparison	O
of	O
Single	O
Scoring	O
Incisions	O
with	O
Butyl	O
Cyanoacrylate	O
-Aided	O
Techniques	O
.	O

The	O
authors	O
present	O
the	O
results	O
of	O
an	O
experimental	O
study	O
in	O
which	O
four	O
different	O
techniques	O
were	O
used	O
for	O
the	O
correction	O
of	O
concave	O
rabbit	O
auricular	O
cartilage	O
.	O

Sixteen	O
New	O
Zealand	O
adult	O
male	O
rabbits	O
were	O
used	O
in	O
the	O
study	O
.	O

Butyl	O
cyanoacrylate	O
-aided	O
cartilage	O
graft	O
fixation	O
and	O
butyl	O
cyanoacrylate	O
-aided	O
bone	O
graft	O
fixation	O
and	O
scoring	O
technique	O
,	O
alone	O
or	O
combined	O
with	O
butyl	O
cyanoacrylate	O
application	O
,	O
were	O
performed	O
to	O
correct	O
the	O
concavity	O
of	O
rabbit	O
auricular	O
cartilage	O
.	O

Angle	O
measurements	O
showed	O
that	O
all	O
four	O
techniques	O
were	O
efficient	O
for	O
correction	O
of	O
the	O
cartilage	O
concavities	O
.	O

However	O
,	O
the	O
mean	O
postsacrifice	O
angles	O
of	O
the	O
graft	O
fixation	O
groups	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
other	O
study	O
groups	O
,	O
reflecting	O
the	O
fact	O
that	O
graft	O
fixation	O
with	O
butyl	O
cyanoacrylate	O
application	O
was	O
more	O
efficient	O
for	O
preserving	O
the	O
final	O
cartilage	O
shape	O
.	O

Furthermore	O
,	O
in	O
the	O
ninth	O
month	O
,	O
graft	O
fixation	O
groups	O
had	O
the	O
lowest	O
chondrocyte	O
densities	O
,	O
the	O
highest	O
degree	O
of	O
inflammation	O
,	O
the	O
highest	O
degree	O
of	O
foreign	O
body	O
reaction	O
,	O
and	O
the	O
highest	O
butyl	O
cyanoacrylate	O
density	O
.	O

Fibrosis	O
or	O
chondrocyte	O
proliferation	O
on	O
scoring	O
incision	O
lines	O
is	O
not	O
an	O
associated	O
feature	O
of	O
this	O
technique	O
.	O

When	O
the	O
incision	O
depths	O
were	O
standardized	O
,	O
the	O
scoring	O
technique	O
provided	O
efficacy	O
similar	O
to	O
that	O
of	O
the	O
scoring	O
incisions	O
combined	O
with	O
butyl	O
cyanoacrylate	O
application	O
for	O
correction	O
of	O
the	O
cartilage	O
concavity	O
.	O

The	O
scoring	O
incision	O
plus	O
butyl	O
cyanoacrylate	O
group	O
showed	O
less	O
toxicity	O
than	O
the	O
graft	O
fixation	O
groups	O
because	O
of	O
rapid	O
removal	O
of	O
toxic	O
breakdown	O
products	O
.	O

Graft	O
fixation	O
techniques	O
were	O
superior	O
to	O
other	O
corrective	O
procedures	O
with	O
regard	O
to	O
preservation	B-P
of	O
the	O
final	O
cartilage	O
shape	O
.	O

Although	O
they	O
resulted	O
in	O
greater	O
toxicity	O
,	O
the	O
cartilage	O
correction	O
was	O
not	O
affected	O
unfavorably	O
.	O

Detection	O
of	O
circulating	O
tumour	O
cells	O
may	O
add	O
value	O
in	O
endometrial	O
cancer	O
management	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
circulating	O
tumour	O
cells	O
(	O
CTCs	O
)	O
in	O
patients	O
with	O
endometrial	O
cancer	O
(	O
EC	O
)	O
.	O

This	O
study	O
included	O
40	O
patients	O
with	O
a	O
pre-operative	O
diagnosis	O
of	O
high-risk	O
EC	O
between	O
April	O
2015	O
and	O
May	O
2016	O
.	O

Patients	O
were	O
further	O
divided	O
into	O
high-risk	O
(	O
grade	O
3	O
,	O
non-endometrioid	O
,	O
myometrial	O
invasion	O
≥1/2	O
and	O
stage	O
III-IV	O
)	O
and	O
high-intermediate-risk	O
(	O
grade	O
2-3	O
,	O
endometrioid	O
,	O
myometrial	O
invasion	O
<	O
1/2	O
and	O
stage	O
I-II	O
)	O
groups	O
according	O
to	O
postoperative	O
pathological	O
results	O
.	O

CTCs	O
were	O
detected	O
using	O
the	O
CellSearch	B-P
system	I-P
,	O
and	O
CTC	O
results	O
were	O
correlated	O
with	O
standard	O
clinicopathological	O
characteristics	O
and	O
serum	O
tumour	O
marker	O
CA125	O
/	O
HE4	O
status	O
using	O
Chi-squared	B-P
test	I-P
,	O
continuity	O
correction	O
or	O
Fisher	O
's	O
exact	O
test	O
.	O

The	O
pharmacodynamic	O
effect	O
was	O
detected	O
after	O
the	O
first	O
cycle	O
of	O
adjuvant	O
therapy	O
.	O

Patients	O
were	O
followed	O
up	O
for	O
13	O
months	O
to	O
assess	O
outcomes	O
.	O

Fifteen	O
percent	O
of	O
patients	O
had	O
one	O
or	O
more	O
CTCs	O
.	O

The	O
presence	O
of	O
CTCs	O
was	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
cervical	O
involvement	O
(	O
83.33	O
%	O
vs	O
11.76	O
%	O
,	O
p=0.00	O
)	O
.	O

No	O
significant	O
difference	O
in	O
CTC	O
-	O
positive	O
rates	O
was	O
detected	O
between	O
the	O
high-risk	O
and	O
high-intermediate-risk	O
groups	O
,	O
and	O
no	O
significant	O
correlation	O
was	O
found	O
between	O
CTCs	O
and	O
serum	O
CA125	O
/	O
HE4	O
,	O
either	O
by	O
positive	O
rates	O
or	O
exact	O
serum	O
levels	O
of	O
the	O
conventional	O
tumour	O
markers	O
.	O

No	O
more	O
CTCs	O
were	O
detected	O
after	O
the	O
first	O
cycle	O
of	O
standard	O
chemotherapy	O
in	O
this	O
study	O
,	O
and	O
no	O
distant	O
metastases	O
or	O
recurrence	O
were	O
found	O
in	O
the	O
CTC	O
-	O
positive	O
patients	O
during	O
the	O
follow-up	O
period	O
.	O

The	O
presence	O
of	O
CTC	O
s	O
was	O
correlated	O
with	O
cervical	O
involvement	O
.	O

Early-stage	O
EC	O
patients	O
with	O
CTCs	O
may	O
benefit	O
from	O
additional	O
adjuvant	O
therapies	O
.	O

Assessment	O
of	O
CTCs	O
may	O
be	O
useful	O
in	O
the	O
management	O
of	O
high-risk	O
EC	O
patients	O
.	O

Is	O
the	O
inactivation	O
of	O
dentin	O
proteases	O
by	O
crosslinkers	O
reversible	O
?	O
.	O

Inactivation	O
of	O
dentin	O
proteases	O
by	O
crosslinkers	O
has	O
been	O
suggested	O
as	O
a	O
way	O
to	O
prevent	O
the	O
degradation	O
of	O
dentin	O
collagen	O
in	O
the	O
hybrid	O
layer	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
if	O
the	O
inhibition	O
is	O
reversible	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
inactivation	O
effect	O
of	O
various	O
crosslinkers	O
on	O
dentin	O
protease	O
activity	O
over	O
a	O
period	O
of	O
6	O
months	O
.	O

Demineralized	O
dentin	O
beams	O
(	O
1×2×6mm	O
,	O
n=10/group	O
)	O
were	O
treated	O
with	O
(	O
1	O
)	O
1	O
%	O
glutaraldehyde	O
(	O
GA1	O
)	O
,	O
(	O
2	O
)	O
5	O
%	O
glutaraldehyde	O
(	O
GA5	O
)	O
,	O
(	O
3	O
)	O
1	O
%	O
grape	O
seed	O
extract	O
(	O
GS1	O
)	O
,	O
(	O
4	O
)	O
5	O
%	O
grape	O
seed	O
extract	O
(	O
GS5	O
)	O
,	O
(	O
5	O
)	O
10	O
%	O
sumac	O
berry	O
extract	O
(	O
S	O
)	O
,	O
(	O
6	O
)	O
20μM	O
curcumin	O
(	O
CR20	O
)	O
,	O
and	O
(	O
7	O
)	O
200μM	O
curcumin	O
(	O
CR200	O
)	O
for	O
5min	O
.	O

Untreated	O
beams	O
served	O
as	O
control	O
.	O

The	O
beams	O
were	O
incubated	B-P
up	O
to	O
6	O
months	O
and	O
incubation	O
media	O
were	O
used	O
to	O
analyze	O
solubilized	O
telopeptide	O
(	O
ICTP	O
and	O
CTX	O
)	O
fragments	O
as	O
indicators	O
of	O
MMP	O
-	O
and	O
cathepsin	O
K	O
-mediated	O
degradation	O
after	O
1	O
,	O
3	O
and	O
6	O
months	O
of	O
incubation	B-P
.	O

The	O
relative	O
MMP	O
activity	O
of	O
dentin	O
beams	O
was	O
tested	O
using	O
a	O
generic	O
MMP	O
assay	B-P
.	O

Data	O
were	O
analyzed	O
using	O
repeated-measures	O
ANOVA	O
,	O
α=0.05	O
.	O

All	O
treated	O
groups	O
showed	O
significant	O
decrease	O
in	O
CTX	O
release	O
(	O
32.2-469.5pg/mg	O
dentin	O
)	O
and	O
ICTP	O
(	O
1.8-47.6ng/mg	O
dentin	O
)	O
fragments	O
during	O
the	O
first	O
month	O
of	O
incubation	B-P
compared	O
to	O
control	O
(	O
1159pg/mg	O
and	O
72.9ng/mg	O
dentin	O
,	O
respectively	O
)	O
.	O

GA5	O
,	O
GS5	O
and	O
CR200	O
maintained	O
their	O
inhibitory	O
effect	O
during	O
6-month	O
incubation	B-P
.	O

The	O
results	O
were	O
confirmed	O
by	O
dry	O
mass	O
loss	O
and	O
relative	O
MMP	O
activity	O
following	O
6	O
months	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
the	O
long-term	O
effect	O
is	O
both	O
crosslinker	O
and	O
dose	O
dependent	O
.	O

The	O
effect	O
of	O
Nigella	O
sativa	O
on	O
inflammation	O
-	O
induced	O
myocardial	O
fibrosis	O
in	O
male	O
rats	O
.	O

Nigella	O
sativa	O
(	O
NS	O
)	O
(	O
Ranunculaceae	O
)	O
used	O
as	O
a	O
protective	O
and	O
therapeutic	O
traditional	O
medicine	O
.	O

This	O
study	O
evaluates	O
the	O
effect	O
of	O
NS	O
on	O
inflammation	O
-	O
induced	O
myocardial	O
fibrosis	O
,	O
serum	O
and	O
tissue	O
inflammatory	O
markers	O
,	O
and	O
oxidative	O
stress	O
status	O
in	O
male	O
rats	O
.	O

Fifty	O
male	O
Wistar	O
rats	O
were	O
divided	O
into	O
five	O
groups	O
:	O
(	O
1	O
)	O
control	O
;	O
(	O
2	O
)	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
1	O
mg/kg/day	O
;	O
(	O
3	O
)	O
LPS	O
+	O
NS	O
(	O
hydroalcoholic	O
extract	O
)	O
,	O
100	O
mg/kg/day	O
;	O
(	O
4	O
)	O
LPS	O
+	O
NS	O
,	O
200	O
mg/kg/day	O
;	O
(	O
5	O
)	O
LPS	O
+	O
NS	O
,	O
400	O
mg/kg/day	O
(	O
n	O
=	O
10	O
in	O
each	O
group	O
)	O
.	O

The	O
duration	O
of	O
LPS	O
administration	O
was	O
two	O
weeks	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
blood	O
samples	O
were	O
taken	O
and	O
ventricles	O
were	O
homogenized	B-P
and	O
stained	B-P
for	O
histological	B-P
evaluation	O
.	O

Serum	O
nitrite	B-P
levels	I-P
were	O
lower	O
in	O
LPS	O
group	O
than	O
the	O
control	O
group	O
(	O
22.98	O
±	O
1.03	O
vs	O
28.5	O
±	O
0.93	O
μmol/L	O
)	O
,	O
in	O
which	O
they	O
were	O
significantly	O
increased	O
by	O
NS	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Higher	O
levels	B-P
of	I-P
heart	I-P
interlukine-6	I-P
(	O
IL-6	B-P
)	O
and	O
tumor	B-P
necrosis	I-P
factor-α	I-P
(	O
TNF-α	B-P
)	O
were	O
observed	O
in	O
LPS	O
group	O
compared	O
to	O
the	O
controls	O
(	O
IL-6	B-P
:	O
6805	O
±	O
656	O
vs	O
4733	O
±	O
691	O
pg/mL	O
;	O
TNF-α	B-P
:	O
6504	O
±	O
501	O
vs	O
5309	O
±	O
452	O
pg/mL	O
)	O
,	O
in	O
which	O
they	O
were	O
reduced	O
by	O
NS	O
400	O
mg/kg	O
compared	O
to	O
LPS	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

A	O
significant	O
increment	O
of	O
malondialdehyde	O
and	O
reduction	O
in	O
heart	O
total	O
thiol	O
,	O
superoxide	O
dismutase	O
and	O
catalase	O
concentrations	O
were	O
observed	O
in	O
LPS	O
group	O
(	O
p	O
<	O
0.05	O
)	O
which	O
significantly	O
restored	O
with	O
treatment	O
by	O
three	O
doses	O
of	O
NS	O
.	O

Histopathological	O
studies	O
showed	O
higher	O
inflammatory	O
cell	O
infiltrates	O
,	O
cardiac	O
fibrosis	O
,	O
and	O
collagen	O
deposition	O
in	O
LPS	O
group	O
,	O
which	O
were	O
reduced	O
by	O
the	O
administration	O
of	O
NS	O
.	O

Treatment	O
by	O
NS	O
reduced	O
myocardial	O
fibrosis	O
in	O
inflammation	O
-	O
induced	O
fibrosis	O
,	O
possibly	O
through	O
improving	O
oxidative	O
/	O
anti-oxidative	O
balance	O
.	O

A	O
Window	O
on	O
the	O
Study	O
of	O
Aversive	O
Instrumental	O
Learning	O
:	O
Strains	O
,	O
Performance	O
,	O
Neuroendocrine	O
,	O
and	O
Immunologic	O
Systems	O
.	O

The	O
avoidance	O
response	O
is	O
present	O
in	O
pathological	O
anxiety	O
and	O
interferes	O
with	O
normal	O
daily	O
functions	O
.	O

The	O
aim	O
of	O
this	O
article	O
is	O
to	O
shed	O
light	O
on	O
performance	O
markers	O
of	O
active	O
avoidance	O
(	O
AA	O
)	O
using	O
two	O
different	O
rat	O
strains	O
,	O
Sprague-Dawley	O
(	O
SD	O
)	O
and	O
Wistar	O
.	O

Specifically	O
,	O
good	O
and	O
poor	O
performers	O
were	O
evaluated	O
regarding	O
anxiety	O
traits	O
exhibited	O
in	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
and	O
corticosterone	B-P
levels	I-P
and	O
motor	O
activity	O
in	O
the	O
open	B-P
field	I-P
test	I-P
.	O

In	O
addition	O
,	O
the	O
plasma	B-P
levels	I-P
of	O
Interleukin-6	O
(	O
IL-6	O
)	O
,	O
Interleukin-1Beta	O
(	O
IL-1beta	O
)	O
,	O
Nerve	O
Growth	O
Factor	O
Beta	O
(	O
NGF-beta	O
)	O
,	O
Tumor	O
Necrosis	O
Factor-Alpha	O
(	O
TNF-alpha	O
)	O
and	O
cytokine-induced	O
neutrophil	O
chemoattractant	O
1	O
(	O
CINC-1	O
)	O
were	O
compared	O
in	O
the	O
good	O
and	O
poor	O
performers	O
to	O
better	O
understand	O
the	O
role	O
of	O
the	O
immunologic	O
system	O
in	O
aversive	O
learning	O
.	O

Behavioral	O
criteria	O
were	O
employed	O
to	O
identify	O
subpopulations	O
of	O
SD	O
and	O
Wistar	O
rats	O
based	O
on	O
their	O
behavioral	O
scores	O
during	O
a	O
two-way	O
AA	O
test	O
.	O

The	O
animals	O
were	O
tested	O
for	O
anxiety	O
-like	O
behavior	O
in	O
the	O
EPM	O
and	O
motor	O
activity	O
in	O
the	O
open-field	B-P
test	I-P
.	O

Plasma	B-P
corticosterone	I-P
levels	I-P
were	O
measured	O
at	O
the	O
end	O
of	O
the	O
avoidance	O
test	O
.	O

Cytokine	B-P
levels	I-P
of	O
IL-6	O
,	O
IL-1beta	O
,	O
NGF-beta	O
,	O
TNF-alpha	O
,	O
and	O
CINC-1	O
were	O
measured	O
in	O
the	O
plasma	O
of	O
the	O
Wistar	O
rats	O
.	O

Sixty-six	O
percent	O
of	O
the	O
Wistar	O
rats	O
and	O
35	O
%	O
of	O
the	O
SD	O
rats	O
exhibited	O
a	O
poor	O
performance	O
.	O

This	O
feature	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
anxiety	O
-like	O
behavior	O
in	O
the	O
EPM	O
.	O

The	O
poor	O
and	O
good	O
performers	O
exhibited	O
lower	O
levels	B-P
of	I-P
corticosterone	I-P
compared	O
with	O
the	O
control	O
animals	O
,	O
which	O
suggests	O
that	O
training	O
alters	O
corticosterone	B-P
levels	I-P
,	O
thereby	O
leading	O
to	O
hypocortisolism	O
,	O
independent	O
of	O
the	O
performance	O
.	O

The	O
CINC-1	O
levels	O
were	O
increased	O
in	O
the	O
poor	O
performers	O
,	O
which	O
reinforces	O
the	O
role	O
of	O
immunologic	O
system	O
activation	O
in	O
learning	O
deficits	O
.	O

Our	O
study	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
complex	O
interactions	O
that	O
underlie	O
neuroimmune	O
consequences	O
and	O
their	O
implications	O
for	O
performance	O
.	O

Proteome	O
changes	O
in	O
rat	O
serum	O
after	O
a	O
chronic	O
ingestion	O
of	O
enriched	O
uranium	O
:	O
Toward	O
a	O
biological	O
signature	O
of	O
internal	O
contamination	O
and	O
radiological	O
effect	O
.	O

The	O
civilian	O
and	O
military	O
use	O
of	O
uranium	O
results	O
in	O
an	O
increased	O
risk	O
of	O
human	O
exposure	O
.	O

The	O
toxicity	O
of	O
uranium	O
results	O
from	O
both	O
its	O
chemical	O
and	O
radiological	O
properties	O
that	O
vary	O
with	O
isotopic	O
composition	O
.	O

Validated	O
biomarkers	O
of	O
health	O
effects	O
associated	O
with	O
exposure	O
to	O
uranium	O
are	O
neither	O
sensitive	O
nor	O
specific	O
to	O
uranium	O
radiotoxicity	O
and/or	O
radiological	O
effect	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
if	O
serum	O
proteins	O
could	O
be	O
useful	O
as	O
biomarkers	O
of	O
both	O
uranium	O
exposure	O
and	O
radiological	O
effect	O
.	O

Male	O
Sprague-Dawley	O
rats	O
were	O
chronically	O
exposed	O
through	O
drinking	O
water	O
to	O
low	O
levels	O
(	O
40mg/L	O
,	O
corresponding	O
to	O
1mg	O
of	O
uranium	O
per	O
animal	O
per	O
day	O
)	O
of	O
either	O
4	O
%	O
(	O
235	O
)	O
U-enriched	O
uranium	O
(	O
EU	O
)	O
or	O
12	O
%	O
EU	O
during	O
6	O
weeks	O
.	O

A	O
proteomics	O
approach	O
based	O
on	O
two-dimensional	O
electrophoresis	O
(	O
2D-DIGE	B-P
)	O
and	O
mass	B-P
spectrometry	I-P
(	O
MS	B-P
)	O
was	O
used	O
to	O
establish	O
protein	O
expression	O
profiles	B-P
that	O
could	O
be	O
relevant	O
for	O
discriminating	O
between	O
groups	O
,	O
and	O
to	O
identify	O
some	O
differentially	O
expressed	O
proteins	O
following	O
uranium	O
ingestion	O
.	O

It	O
demonstrated	O
that	O
the	O
expressions	O
of	O
174	O
protein	O
spots	O
over	O
1045	O
quantified	O
spots	O
were	O
altered	O
after	O
uranium	O
exposure	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Using	O
both	O
inferential	O
and	O
non-supervised	O
multivariate	O
statistics	O
,	O
we	O
show	O
sets	O
of	O
spots	O
features	O
that	O
lead	O
to	O
a	O
clear	O
discrimination	O
between	O
controls	O
and	O
EU	O
exposed	O
groups	O
on	O
the	O
one	O
hand	O
(	O
21	O
spots	O
)	O
,	O
and	O
between	O
4	O
%	O
EU	O
and	O
12	O
%	O
EU	O
on	O
the	O
other	O
hand	O
(	O
7	O
spots	O
)	O
,	O
showing	O
that	O
investigation	O
of	O
the	O
serum	O
proteome	O
may	O
possibly	O
be	O
of	O
relevance	O
to	O
address	O
both	O
uranium	O
contamination	O
and	O
radiological	O
effect	O
.	O

Finally	O
,	O
using	O
bioinformatics	O
tools	O
,	O
pathway	O
analyses	O
of	O
differentially	O
expressed	O
MS	B-P
-	O
identified	O
proteins	O
find	O
that	O
acute	O
phase	O
,	O
inflammatory	O
and	O
immune	O
responses	O
as	O
well	O
as	O
oxidative	O
stress	O
are	O
likely	O
involved	O
in	O
the	O
response	O
to	O
contamination	O
,	O
suggesting	O
a	O
physiological	O
perturbation	O
,	O
but	O
that	O
does	O
not	O
necessarily	O
lead	O
to	O
a	O
toxic	O
effect	O
.	O

Phototoxic	O
action	O
of	O
a	O
zinc	O
(	O
II	O
)	O
phthalocyanine	O
encapsulated	O
into	O
poloxamine	O
polymeric	O
micelles	O
in	O
2D	O
and	O
3D	O
colon	O
carcinoma	O
cell	B-P
cultures	I-P
.	O

Photodynamic	O
therapy	O
is	O
emerging	O
as	O
a	O
hopeful	O
method	O
for	O
the	O
treatment	O
of	O
oncological	O
diseases	O
.	O

In	O
the	O
search	O
of	O
novel	O
therapeutic	O
strategies	O
for	O
colorectal	O
cancer	O
,	O
in	O
this	O
work	O
we	O
reported	O
the	O
photocytotoxic	O
activity	O
of	O
a	O
lipophilic	O
zinc	O
(	O
II	O
)	O
phthalocyanine	O
on	O
a	O
murine	O
colon	O
adenocarcinoma	O
cell	O
line	O
(	O
CT26	O
cells	O
)	O
.	O

The	O
2,9	O
(	O
10	O
)	O
,16	O
(	O
17	O
)	O
,23	O
(	O
24	O
)	O
tetrakis	O
[	O
(	O
2-dimethylamino	O
)	O
ethylsulfanyl	O
]	O
phthalocyaninatozinc	O
(	O
II	O
)	O
,	O
named	O
Pc9	O
,	O
was	O
encapsulated	O
into	O
Tetronic®	O
1107	O
polymeric	O
poloxamine	O
micelles	O
(	O
T1107	O
)	O
and	O
assayed	O
in	O
2D	O
and	O
3D	O
cell	B-P
cultures	I-P
.	O

We	O
showed	O
that	O
the	O
formulation	O
Pc9	O
-	O
T1107	O
was	O
efficient	O
to	O
reduce	O
cell	O
viability	O
after	O
photodynamic	O
treatment	O
both	O
in	O
2D	O
cultures	B-P
(	O
IC50	O
10±2nM	O
)	O
as	O
well	O
as	O
in	O
CT26	O
spheroids	O
(	O
IC50	O
370±11nM	O
)	O
.	O

Cellular	O
uptake	O
of	O
Pc9	O
-	O
T1107	O
was	O
a	O
time-	O
and	O
concentration-dependent	O
process	O
,	O
being	O
the	O
phthalocyanine	O
formulation	O
mainly	O
incorporated	O
into	O
lysosomal	O
vesicles	O
and	O
endoplasmic	O
reticulum	O
cisterns	O
,	O
but	O
not	O
in	O
mitochondria	O
.	O

Pc9	O
-	O
T1107	O
also	O
induced	O
the	O
formation	O
of	O
reactive	O
oxygen	O
species	O
immediately	O
after	O
cell	O
irradiation	O
.	O

We	O
also	O
found	O
that	O
the	O
phototoxic	O
action	O
of	O
Pc9	O
-	O
T1107	O
was	O
partially	O
reversed	O
in	O
the	O
presence	O
of	O
antioxidants	O
,	O
such	O
as	O
TROLOX	O
and	O
N-acetyl-cysteine	O
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
Pc9	O
-	O
T1107	O
treatment	O
triggered	O
an	O
apoptotic	O
cell	O
death	O
,	O
as	O
suggested	O
by	O
the	O
detection	O
of	O
pyknotic	O
nuclei	O
,	O
the	O
reduction	O
in	O
the	O
expression	O
levels	O
of	O
procaspase-3	O
and	O
the	O
increase	O
in	O
caspase-3	O
enzymatic	O
activity	O
.	O

Diagnosing	O
neonatal	O
transphyseal	O
fractures	O
of	O
the	O
distal	O
humerus	O
.	O

A	O
traumatic	O
birth	O
can	O
cause	O
significant	O
upper	O
limb	O
injury	O
;	O
the	O
presenting	O
features	O
are	O
non-specific	O
and	O
the	O
differential	O
diagnosis	O
long	O
.	O

Transphyseal	O
fractures	O
of	O
the	O
distal	O
humerus	O
are	O
a	O
rare	O
but	O
clinically	O
important	O
birth	O
injury	O
.	O

This	O
injury	O
has	O
typical	O
radiographic	O
findings	O
,	O
which	O
due	O
to	O
the	O
un-ossified	O
nature	O
of	O
the	O
distal	O
humeral	O
epiphysis	O
can	O
easily	O
be	O
misinterpreted	O
.	O

This	O
article	O
presents	O
the	O
radiographic	O
appearance	O
correlated	O
with	O
arthrography	B-P
,	O
ultrasound	B-P
and	O
MRI	B-P
obtained	O
from	O
four	O
cases	O
of	O
neonatal	O
transphyseal	O
fracture	O
of	O
the	O
distal	O
humerus	O
.	O

We	O
hope	O
that	O
by	O
demonstrating	O
the	O
appearances	O
for	O
each	O
of	O
these	O
imaging	B-P
techniques	I-P
in	O
relation	O
to	O
the	O
underlying	O
pathology	O
will	O
reduce	O
errors	O
of	O
interpretation	O
that	O
may	O
lead	O
to	O
inappropriate	O
diagnosis	O
and	O
management	O
of	O
these	O
children	O
.	O

Methods	O
,	O
tools	O
and	O
current	O
perspectives	O
in	O
proteogenomics	O
.	O

With	O
combined	O
technological	O
advancements	O
in	O
high-throughput	O
next-generation	O
sequencing	O
and	O
deep	B-P
mass	I-P
spectrometry	I-P
-based	O
proteomics	O
,	O
proteogenomics	O
,	O
i.e.	O
,	O
the	O
integrative	O
analysis	O
of	O
proteomic	O
and	O
genomic	O
data	O
,	O
has	O
emerged	O
as	O
a	O
new	O
research	O
field	O
.	O

Early	O
efforts	O
in	O
the	O
field	O
were	O
focused	O
on	O
improving	O
protein	O
identification	O
using	O
sample-specific	O
genomic	O
and	O
transcriptomic	O
sequencing	O
data	O
.	O

More	O
recently	O
,	O
integrative	O
analysis	O
of	O
quantitative	O
measurements	O
from	O
genomic	O
and	O
proteomic	O
studies	O
have	O
identified	O
novel	O
insights	O
into	O
gene	O
expression	O
regulation	O
,	O
cell	O
signaling	O
,	O
and	O
disease	O
.	O

Many	O
methods	O
and	O
tools	O
have	O
been	O
developed	O
or	O
adapted	O
to	O
enable	O
an	O
array	O
of	O
integrative	O
proteogenomic	O
approaches	O
and	O
in	O
this	O
article	O
,	O
we	O
systematically	O
classify	O
published	O
methods	O
and	O
tools	O
into	O
four	O
major	O
categories	O
,	O
(	O
1	O
)	O
Sequence	O
-centric	O
proteogenomics	O
;	O
(	O
2	O
)	O
Analysis	O
of	O
proteogenomic	O
relationships	O
;	O
(	O
3	O
)	O
Integrative	O
modeling	O
of	O
proteogenomic	O
data	O
;	O
and	O
(	O
4	O
)	O
Data	O
sharing	O
and	O
visualization	O
.	O

We	O
provide	O
a	O
comprehensive	O
review	O
of	O
methods	O
and	O
available	O
tools	O
in	O
each	O
category	O
and	O
highlight	O
their	O
typical	O
applications	O
.	O

Spine	O
fracture	O
prevalence	O
in	O
a	O
nationally	O
representative	O
sample	O
of	O
US	O
women	O
and	O
men	O
aged	O
≥40	O
years	O
:	O
results	O
from	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
)	O
2013-2014	O
.	O

Spine	O
fracture	O
prevalence	O
is	O
similar	O
in	O
men	O
and	O
women	O
,	O
increasing	O
from	O
<	O
5	O
%	O
in	O
those	O
<	O
60	O
to	O
11	O
%	O
in	O
those	O
70-79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years	O
.	O

Prevalence	O
was	O
higher	O
with	O
age	O
,	O
lower	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
,	O
and	O
in	O
those	O
meeting	O
criteria	O
for	O
spine	B-P
imaging	I-P
.	O

Most	O
subjects	O
with	O
spine	O
fractures	O
were	O
unaware	O
of	O
them	O
.	O

Spine	O
fractures	O
have	O
substantial	O
medical	O
significance	O
but	O
are	O
seldom	O
recognized	O
.	O

This	O
study	O
collected	O
contemporary	O
nationally	O
representative	O
spine	O
fracture	O
prevalence	O
data	O
.	O

Cross-sectional	O
analysis	O
of	O
3330	O
US	O
adults	O
aged	O
≥40	O
years	O
participating	O
in	O
NHANES	O
2013-2014	O
with	O
evaluable	O
Vertebral	O
Fracture	O
Assessment	O
(	O
VFA	B-P
)	O
.	O

VFA	B-P
was	O
graded	O
by	O
semiquantitative	O
measurement	O
.	O

BMD	O
and	O
an	O
osteoporosis	O
questionnaire	O
were	O
collected	O
.	O

Overall	O
spine	O
fracture	O
prevalence	O
was	O
5.4	O
%	O
and	O
similar	O
in	O
men	O
and	O
women	O
.	O

Prevalence	O
increased	O
with	O
age	O
from	O
<	O
5	O
%	O
in	O
those	O
<	O
60	O
to	O
11	O
%	O
in	O
those	O
70-79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years	O
.	O

Fractures	O
were	O
more	O
common	O
in	O
non-Hispanic	O
whites	O
and	O
in	O
people	O
with	O
lower	O
body	O
mass	O
index	O
and	O
BMD	O
.	O

Among	O
subjects	O
with	O
spine	O
fracture	O
,	O
26	O
%	O
met	O
BMD	O
criteria	O
for	O
osteoporosis	O
.	O

Prevalence	O
was	O
higher	O
in	O
subjects	O
who	O
met	O
National	O
Osteoporosis	O
Foundation	O
(	O
NOF	O
)	O
criteria	O
for	O
spine	B-P
imaging	I-P
(	O
14	O
vs	O
4.7	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Only	O
8	O
%	O
of	O
people	O
with	O
a	O
spine	O
fracture	O
diagnosed	O
by	O
VFA	B-P
had	O
a	O
self-reported	O
fracture	O
,	O
and	O
among	O
those	O
who	O
self-reported	O
a	O
spine	O
fracture	O
,	O
only	O
21	O
%	O
were	O
diagnosed	O
with	O
fracture	O
by	O
VFA	B-P
.	O

Spine	O
fracture	O
prevalence	O
is	O
similar	O
in	O
women	O
and	O
men	O
and	O
increases	O
with	O
age	O
and	O
lower	O
BMD	O
,	O
although	O
most	O
subjects	O
with	O
spine	O
fracture	O
do	O
not	O
meet	O
BMD	O
criteria	O
for	O
osteoporosis	O
.	O

Since	O
most	O
(	O
>	O
90	O
%	O
)	O
individuals	O
were	O
unaware	O
of	O
their	O
spine	O
fractures	O
,	O
lateral	O
spine	B-P
imaging	I-P
is	O
needed	O
to	O
identify	O
these	O
women	O
and	O
men	O
.	O

Spine	O
fracture	O
prevalence	O
was	O
threefold	O
higher	O
in	O
individuals	O
meeting	O
NOF	O
criteria	O
for	O
spine	B-P
imaging	I-P
(	O
∼1	O
in	O
7	O
undergoing	O
VFA	B-P
)	O
.	O

Identifying	O
spine	O
fractures	O
as	O
part	O
of	O
comprehensive	O
risk	O
assessment	O
may	O
improve	O
clinical	B-P
decision	I-P
making	I-P
.	O

In	O
vitro	O
affinity	O
of	O
Deinococcus	O
radiodurans	O
MutS	O
towards	O
mismatched	O
DNA	O
exceeds	O
that	O
of	O
its	O
orthologues	O
from	O
Escherichia	O
coli	O
and	O
Thermus	O
thermophilus	O
.	O

The	O
mismatch	O
binding	O
protein	O
MutS	O
is	O
responsible	O
for	O
the	O
recognition	O
of	O
mispaired	O
and	O
unpaired	O
bases	O
,	O
which	O
is	O
the	O
initial	O
step	O
in	O
DNA	O
repair	O
.	O

Among	O
the	O
MutS	O
proteins	O
most	O
extensively	O
studied	O
in	O
vitro	O
are	O
those	O
derived	O
from	O
Thermus	O
thermophilus	O
,	O
Thermus	O
aquaticus	O
and	O
Escherichia	O
coli	O
.	O

Here	O
,	O
we	O
present	O
the	O
first	O
report	O
on	O
the	O
in	O
vitro	O
examination	O
of	O
DNA	O
mismatch	O
binding	O
activity	O
of	O
MutS	O
protein	O
from	O
Deinococcus	O
radiodurans	O
and	O
confront	O
this	O
with	O
the	O
properties	O
of	O
those	O
from	O
E.	O
coli	O
and	O
T.	O
thermophilus	O
.	O

The	O
analyses	O
which	O
included	O
mobility	B-P
gel-shift	I-P
assay	I-P
,	O
colorimetric	B-P
and	O
qPCR	B-P
estimation	I-P
of	O
MutS	O
-bound	O
DNA	O
clearly	O
showed	O
that	O
D.	O
radiodurans	O
MutS	O
exhibited	O
much	O
higher	O
affinity	O
towards	O
mismatched	O
DNA	O
in	O
vitro	O
than	O
its	O
counterparts	O
from	O
E.	O
coli	O
and	O
T.	O
thermophilus	O
.	O

In	O
addition	O
,	O
D.	O
radiodurans	O
MutS	O
displayed	O
a	O
significantly	O
higher	O
specificity	O
of	O
DNA	O
mismatch	O
binding	O
than	O
the	O
two	O
other	O
orthologues	O
.	O

The	O
specificity	O
expressed	O
as	O
the	O
ratio	O
of	O
mismatched	O
to	O
fully	O
complementary	O
DNA	O
bound	O
reached	O
over	O
4	O
and	O
20-fold	O
higher	O
values	O
for	O
D.	O
radiodurans	O
than	O
for	O
T.	O
thermophilus	O
and	O
E.	O
coli	O
MutS	O
,	O
respectively	O
.	O

The	O
results	O
demonstrate	O
mainly	O
the	O
biotechnological	O
potential	O
of	O
D.	O
radiodurans	O
MutS	O
but	O
the	O
in	O
vitro	O
characteristics	O
of	O
the	O
MutS	O
orthologues	O
could	O
reflect	O
substantial	O
differences	O
in	O
DNA	O
mismatch	O
binding	O
activities	O
existing	O
in	O
vivo	O
.	O

P-glycoprotein	O
traffics	O
from	O
the	O
nucleus	O
to	O
the	O
plasma	O
membrane	O
in	O
rat	O
brain	O
endothelium	O
during	O
inflammatory	O
pain	O
.	O

P-glycoprotein	O
(	O
PgP	O
)	O
,	O
a	O
drug	O
efflux	O
pump	O
in	O
blood-brain	O
barrier	O
endothelial	O
cells	O
,	O
is	O
a	O
major	O
clinical	O
obstacle	O
for	O
effective	O
central	O
nervous	O
system	O
drug	O
delivery	O
.	O

Identifying	O
PgP	O
regulatory	O
pathways	O
that	O
can	O
be	O
exploited	O
clinically	O
is	O
critical	O
for	O
improving	O
central	O
nervous	O
system	O
drug	O
delivery	O
.	O

We	O
previously	O
found	O
that	O
PgP	O
activity	O
increases	O
in	O
rat	O
brain	O
microvessels	O
concomitant	O
with	O
decreased	O
central	O
nervous	O
system	O
drug	O
delivery	O
in	O
response	O
to	O
acute	O
peripheral	O
inflammatory	O
pain	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
PgP	O
traffics	O
to	O
the	O
luminal	O
plasma	O
membrane	O
of	O
the	O
microvessel	O
endothelial	O
cells	O
from	O
intracellular	O
stores	O
during	O
peripheral	O
inflammatory	O
pain	O
.	O

Using	O
immunofluorescence	B-P
microscopy	I-P
,	O
we	O
detected	O
PgP	O
in	O
endothelial	O
cell	O
nuclei	O
and	O
in	O
the	O
luminal	O
plasma	O
membrane	O
in	O
control	O
animals	O
.	O

Following	O
peripheral	O
inflammatory	O
pain	O
,	O
luminal	O
PgP	O
staining	B-P
increased	O
while	O
staining	B-P
in	O
the	O
nucleus	O
decreased	O
.	O

Biochemical	B-P
analysis	I-P
of	O
nuclear	O
PgP	O
content	O
confirmed	O
our	O
visual	O
observations	O
.	O

Peripheral	O
inflammatory	O
pain	O
also	O
increased	O
endothelial	O
cell	O
luminal	O
staining	B-P
of	O
polymerase	O
1	O
and	O
transcript	O
release	O
factor	O
/	O
cavin1	O
and	O
serum	O
deprivation	O
response	O
protein	O
/	O
cavin2	O
,	O
two	O
caveolar	O
scaffold	O
proteins	O
,	O
without	O
changing	O
caveolin1	O
or	O
protein	O
kinase	O
C	O
delta	O
binding	O
protein	O
/	O
cavin3	O
location	O
.	O

Our	O
data	O
(	O
a	O
)	O
indicate	O
that	O
PgP	O
traffics	O
from	O
stores	O
in	O
the	O
nucleus	O
to	O
the	O
endothelial	O
cell	O
luminal	O
membrane	O
in	O
response	O
to	O
peripheral	O
inflammatory	O
pain	O
;	O
(	O
b	O
)	O
provide	O
an	O
explanation	O
for	O
our	O
previous	O
observation	O
that	O
peripheral	O
inflammatory	O
pain	O
inhibits	O
central	O
nervous	O
system	O
drug	O
uptake	O
;	O
and	O
(	O
c	O
)	O
suggest	O
a	O
novel	O
regulatory	O
mechanism	O
for	O
PgP	O
activity	O
in	O
rat	O
brain	O
.	O

Case	O
Report	O
of	O
Necrotizing	O
Fasciitis	O
Associated	O
with	O
Streptococcus	O
pneumoniae	O
.	O

Necrotizing	O
fasciitis	O
,	O
caused	O
by	O
Streptococcus	O
pneumoniae	O
,	O
is	O
an	O
extremely	O
rare	O
and	O
life-threatening	O
bacterial	O
soft	O
tissue	O
infection	O
.	O

We	O
report	O
a	O
case	O
of	O
early	O
necrotizing	O
fasciitis	O
associated	O
with	O
Streptococcus	O
pneumoniae	O
infection	O
in	O
a	O
26-	O
year	O
-old	O
man	O
who	O
was	O
immunocompromised	O
with	O
mixed	O
connective	O
tissue	O
disease	O
.	O

The	O
patient	O
presented	O
with	O
acute	O
,	O
painful	O
,	O
erythematous	O
,	O
and	O
edematous	O
skin	O
lesions	O
of	O
his	O
right	O
lower	O
back	O
,	O
which	O
rapidly	O
progressed	O
to	O
the	O
right	O
knee	O
.	O

The	O
patient	O
underwent	O
surgical	B-P
exploration	I-P
,	O
and	O
a	O
diagnosis	O
of	O
necrotizing	O
fasciitis	O
was	O
confirmed	O
by	O
pathological	O
evidence	O
of	O
necrosis	O
of	O
the	O
fascia	O
and	O
neutrophil	O
infiltration	O
in	O
tissue	B-P
biopsies	I-P
.	O

Cultures	B-P
of	O
fascial	O
tissue	B-P
biopsies	I-P
and	O
blood	O
samples	O
were	O
positive	O
for	O
Streptococcus	O
pneumoniae	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
necrotizing	O
fasciitis	O
resulting	O
from	O
Streptococcus	O
pneumoniae	O
diagnosed	O
at	O
early	O
phase	O
;	O
the	O
patient	O
recovered	O
well	O
without	O
surgical	O
debridement	O
.	O

Right	O
Ventricular	O
Response	O
During	O
Exercise	O
in	O
Patients	O
with	O
Chronic	O
Obstructive	O
Pulmonary	O
Disease	O
.	O

Right	O
ventricular	O
(	O
RV	O
)	O
pump	O
function	O
is	O
of	O
essential	O
clinical	O
and	O
prognostic	O
importance	O
in	O
a	O
variety	O
of	O
heart	O
and	O
lung	O
diseases	O
.	O

While	O
the	O
evaluation	O
of	O
RV	O
performance	O
at	O
rest	O
has	O
been	O
implemented	O
in	O
the	O
clinical	O
setting	O
,	O
it	O
is	O
unknown	O
whether	O
this	O
assessment	O
during	O
exercise	O
may	O
provide	O
additional	O
benefit	O
.	O

With	O
this	O
aim	O
,	O
we	O
evaluated	O
the	O
exercise	O
-	O
induced	O
pulmonary	B-P
arterial	I-P
systolic	I-P
pressure	I-P
(	O
PASP	B-P
)	O
increase	O
during	O
exercise	O
in	O
patients	O
with	O
severe	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
as	O
an	O
expression	O
of	O
RV	O
contractile	O
reserve	O
.	O

Cardiopulmonary	B-P
exercise	I-P
testing	I-P
(	O
CPET	B-P
)	O
with	O
synchronic	B-P
echocardiography	I-P
was	O
performed	O
in	O
81	O
patients	O
.	O

Patients	O
were	O
classified	O
into	O
two	O
groups	O
according	O
to	O
an	O
exercise	O
-	O
induced	O
PASP	B-P
increase	O
above	O
30mmHg	O
(	O
High	O
PSAP	B-P
)	O
or	O
below	O
30mmHg	O
(	O
Low	O
PSAP	B-P
)	O
during	O
maximal	O
exercise	O
.	O

Patients	O
were	O
then	O
followed	O
for	O
three	O
years	O
.	O

Sixteen	O
patients	O
(	O
20	O
%	O
)	O
had	O
low	O
PSAP	B-P
and	O
65	O
(	O
80	O
%	O
)	O
showed	O
high	O
PSAP	B-P
.	O

These	O
were	O
not	O
significant	O
clinical	O
and	O
functional	O
differences	O
.	O

Low	O
PSAP	B-P
was	O
associated	O
with	O
a	O
significantly	O
lower	O
peak	O
VO2	O
(	O
mean	O
(	O
SD	O
)	O
,	O
35	O
(	O
2	O
)	O
%	O
predicted	O
)	O
compared	O
to	O
high	O
PSAP	B-P
response	O
(	O
peak	O
VO2	O
45	O
(	O
3	O
)	O
%	O
predicted	O
)	O
,	O
p=0.045	O
.	O

Factors	O
associated	O
with	O
mortality	O
were	O
age	O
and	O
exercise	O
-	O
induced	O
PASP	B-P
.	O

Seventeen	O
patients	O
died	O
during	O
the	O
three	O
years	O
of	O
follow-up	O
(	O
7	O
(	O
39	O
%	O
)	O
in	O
the	O
low	O
PSAP	B-P
group	O
and	O
only	O
10	O
(	O
1	O
%	O
)	O
in	O
the	O
high	O
PSAP	B-P
group	O
,	O
p=0.041	O
)	O
.	O

Cardiopulmonary	B-P
exercise	I-P
testing	I-P
with	O
a	O
synchronic	B-P
echocardiography	I-P
may	O
be	O
a	O
useful	O
tool	O
for	O
the	O
assessment	O
of	O
RV	O
contractile	O
reserve	O
in	O
severe	O
COPD	O
patients	O
.	O

Exercise	O
-	O
induced	O
PSAP	B-P
emerges	O
as	O
a	O
possible	O
prognostic	O
factor	O
in	O
these	O
patients	O
.	O

MiR-424-5p	O
participates	O
in	O
esophageal	O
squamous	O
cell	O
carcinoma	O
invasion	O
and	O
metastasis	O
via	O
SMAD7	O
pathway	O
mediated	O
EMT	O
.	O

ESCC	O
is	O
a	O
life-threatening	O
disease	O
due	O
to	O
invasion	O
and	O
metastasis	O
in	O
the	O
early	O
stage	O
.	O

Great	O
efforts	O
had	O
been	O
made	O
to	O
detect	O
the	O
molecular	O
mechanisms	O
which	O
led	O
to	O
the	O
invasion	O
and	O
metastasis	O
in	O
ESCC	O
.	O

Recent	O
evidence	O
had	O
suggested	O
that	O
deregulation	O
of	O
miR-424-5p	O
took	O
an	O
important	O
role	O
in	O
cancers	O
.	O

However	O
,	O
its	O
role	O
and	O
functional	O
mechanism	O
in	O
ESCC	O
had	O
seldom	O
been	O
elucidated	O
.	O

The	O
expression	O
levels	O
of	O
miR-424-5p	O
were	O
detected	O
in	O
ESCC	O
tissues	O
and	O
cell	O
lines	O
by	O
real-time	O
PCR	O
methods	O
.	O

Then	O
,	O
the	O
invasion	O
,	O
metastasis	O
and	O
proliferation	O
ability	O
of	O
ESCC	O
cell	O
lines	O
transfected	O
with	O
miR-424-5p	O
mimics	O
were	O
analyzed	O
separately	O
by	O
transwell	B-P
invasion	I-P
assay	I-P
,	O
wound	B-P
healing	I-P
assay	I-P
and	O
cell	O
proliferation	O
assay	O
.	O

Finally	O
,	O
the	O
target	O
gene	O
of	O
miR-424-5p	O
was	O
studied	O
and	O
verified	O
by	O
luciferase	B-P
activity	I-P
assay	I-P
.	O

And	O
the	O
role	O
of	O
miR-424-5p	O
in	O
EMT	O
was	O
also	O
investigated	O
by	O
real-time	O
PCR	O
and	O
western	B-P
blot	I-P
assay	I-P
.	O

We	O
showed	O
that	O
the	O
expression	O
levels	O
of	O
miR-424-5p	O
were	O
decreased	O
both	O
in	O
ESCC	O
tissues	O
and	O
cell	O
lines	O
.	O

Furthermore	O
,	O
the	O
expression	O
levels	O
of	O
miR-424-5p	O
were	O
negatively	O
linked	O
to	O
lymph	O
node	O
metastasis	O
in	O
ESCC	O
tissues	O
.	O

Restoration	O
of	O
miR-424-5p	O
in	O
EC-1	O
cells	O
by	O
using	O
miR-424-5p	O
mimics	O
could	O
decrease	O
the	O
invasion	O
,	O
metastasis	O
and	O
proliferation	O
of	O
EC-1	O
cells	O
,	O
indicating	O
its	O
role	O
in	O
inhibition	O
on	O
the	O
invasion	O
and	O
metastasis	O
ability	O
of	O
ESCC	O
cells	O
and	O
tissues	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
SMAD7	O
was	O
a	O
specific	O
target	O
gene	O
for	O
miR-424-5p	O
by	O
luciferase	B-P
activity	I-P
assay	I-P
and	O
miR-424-5p	O
could	O
not	O
only	O
negatively	O
regulate	O
SMAD7	O
expression	O
but	O
also	O
participate	O
in	O
EMT	O
via	O
SMAD7	O
,	O
because	O
overexpression	O
of	O
SMAD7	O
could	O
partly	O
enhance	O
the	O
miR-424-5p	O
anti-EMT	O
function	O
.	O

Our	O
results	O
described	O
that	O
miR-424-5p	O
-	O
SMAD7	O
pathway	O
contributed	O
to	O
ESCC	O
invasion	O
and	O
metastasis	O
and	O
up-regulation	O
of	O
miR-424-5p	O
perhaps	O
provided	O
a	O
strategy	O
for	O
preventing	O
tumor	O
invasion	O
,	O
metastasis	O
.	O

Are	O
TMCs	O
the	O
Mechanotransduction	O
Channels	O
of	O
Vertebrate	O
Hair	O
Cells	O
?	O
.	O

Sensory	O
transduction	O
in	O
vertebrate	O
hair	O
cells	O
and	O
the	O
molecules	O
that	O
mediate	O
it	O
have	O
long	O
been	O
of	O
great	O
interest	O
.	O

Some	O
components	O
of	O
the	O
mechanotransduction	O
apparatus	O
have	O
been	O
identified	O
,	O
most	O
as	O
deafness	O
gene	O
products	O
.	O

Although	O
prior	O
candidates	O
for	O
the	O
mechanotransduction	O
channel	O
have	O
been	O
proposed	O
,	O
each	O
has	O
faded	O
with	O
new	O
evidence	O
.	O

Now	O
,	O
two	O
strong	O
candidates	O
,	O
TMC1	O
and	O
TMC2	O
(	O
transmembrane	O
channel-like	O
)	O
,	O
have	O
emerged	O
from	O
discovery	O
of	O
deafness	O
genes	O
in	O
humans	O
and	O
mice	O
.	O

They	O
are	O
expressed	O
at	O
the	O
right	O
time	O
during	O
development	O
:	O
exactly	O
at	O
the	O
onset	O
of	O
mechanosensitivity	O
.	O

They	O
are	O
expressed	O
in	O
the	O
right	O
place	O
:	O
in	O
hair	O
cells	O
but	O
not	O
surrounding	O
cells	O
.	O

Fluorescently	B-P
tagged	I-P
TMCs	O
localize	O
to	O
the	O
tips	O
of	O
stereocilia	O
,	O
the	O
site	O
of	O
the	O
transduction	O
channels	O
.	O

TMCs	O
bind	O
other	O
proteins	O
essential	O
for	O
mechanosensation	O
,	O
suggesting	O
a	O
larger	O
transduction	O
complex	O
.	O

Although	O
TMC1	O
and	O
TMC2	O
can	O
substitute	O
for	O
each	O
other	O
,	O
genetic	O
deletion	O
of	O
both	O
renders	O
mouse	O
hair	O
cells	O
mechanically	O
insensitive	O
.	O

Finally	O
,	O
the	O
conductance	O
and	O
Ca	O
(	O
2+	O
)	O
selectivity	O
of	O
the	O
transduction	O
channels	O
depend	O
on	O
the	O
TMC	O
proteins	O
,	O
differing	O
when	O
hair	O
cells	O
express	O
one	O
or	O
the	O
other	O
TMC	O
,	O
and	O
differing	O
if	O
TMC1	O
harbors	O
a	O
point	O
mutation	O
.	O

Some	O
contrary	O
evidence	O
has	O
emerged	O
:	O
a	O
current	O
activated	O
in	O
hair	O
cells	O
by	O
negative	O
pressure	O
,	O
with	O
some	O
similarity	O
to	O
the	O
transduction	O
current	O
,	O
persists	O
in	O
TMC	O
knock-outs	O
.	O

But	O
it	O
is	O
not	O
clear	O
that	O
this	O
anomalous	O
current	O
is	O
carried	O
by	O
the	O
same	O
proteins	O
.	O

Further	O
evidence	O
is	O
desired	O
,	O
such	O
as	O
production	O
of	O
a	O
mechanically	O
gated	O
conductance	O
by	O
pure	O
TMCs	O
.	O

But	O
the	O
great	O
majority	O
of	O
evidence	O
is	O
consistent	O
with	O
these	O
TMCs	O
as	O
pore-forming	O
subunits	O
of	O
the	O
long-sought	O
hair-cell	O
transduction	O
channel	O
.	O

Cytokine	O
IL-10	O
,	O
activators	O
of	O
PI3-kinase	O
,	O
agonists	O
of	O
α-2	O
adrenoreceptor	O
and	O
antioxidants	O
prevent	O
ischemia	O
-	O
induced	O
cell	O
death	O
in	O
rat	O
hippocampal	O
cultures	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL-10	O
with	O
the	O
action	O
of	O
a	O
PI3-kinase	O
selective	O
activator	O
740	O
Y-P	O
,	O
selective	O
agonists	O
of	O
alpha-2	O
adrenoreceptor	O
,	O
guanfacine	O
and	O
UK-14,304	O
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	O
:	O
recombinant	O
human	O
peroxiredoxin	O
6	O
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	O
(	O
ischemia-like	O
conditions	O
)	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
response	O
of	O
cells	O
to	O
OGD	O
in	O
the	O
control	O
includes	O
two	O
phases	O
.	O

The	O
first	O
phase	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
frequency	O
of	O
spontaneous	O
synchronous	O
Ca	O
(	O
2+	O
)	O
-oscillations	O
(	O
SSCO	O
)	O
in	O
neurons	O
and	O
Ca	O
(	O
2+	O
)	O
-	O
pulse	O
in	O
astrocytes	O
.	O

Spontaneous	O
Ca	O
(	O
2+	O
)	O
events	O
in	O
astrocytes	O
during	O
ischemia	O
in	O
control	O
experiments	O
disappeared	O
.	O

The	O
second	O
phase	O
started	O
after	O
a	O
few	O
minutes	O
of	O
OGD	O
and	O
looked	O
like	O
a	O
sharp/avalanche	O
,	O
global	O
synchronic	O
(	O
within	O
20	O
s	O
)	O
increase	O
in	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
in	O
many	O
cells	O
.	O

Within	O
1	O
h	O
after	O
OGD	O
,	O
a	O
mass	O
death	O
of	O
cells	O
,	O
primarily	O
astrocytes	O
,	O
was	O
observed	O
.	O

To	O
study	O
the	O
protective	O
action	O
of	O
the	O
compounds	O
,	O
cells	O
were	O
incubated	B-P
in	O
the	O
presence	O
of	O
the	O
neuroprotective	O
agents	O
for	O
10-40	O
min	O
or	O
24	O
h	O
before	O
ischemia	O
.	O

All	O
the	O
neuroprotective	O
agents	O
delayed	O
a	O
global	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
increase	O
during	O
OGD	O
or	O
completely	O
inhibited	O
this	O
process	O
and	O
increased	O
cell	O
survival	O
.	O

Adenoviral	O
Delivery	O
of	O
Tumor	O
Necrosis	O
Factor-α	O
and	O
Interleukin-2	O
Enables	O
Successful	O
Adoptive	O
Cell	O
Therapy	O
of	O
Immunosuppressive	O
Melanoma	O
.	O

Adoptive	O
T-cell	O
transfer	O
is	O
a	O
promising	O
treatment	O
approach	O
for	O
metastatic	O
cancer	O
,	O
but	O
efficacy	O
in	O
solid	O
tumors	O
has	O
only	O
been	O
achieved	O
with	O
toxic	O
pre-	O
and	O
postconditioning	O
regimens	O
.	O

Thus	O
,	O
adoptive	O
T-cell	O
therapies	O
would	O
benefit	O
from	O
complementary	O
modalities	O
that	O
enable	O
their	O
full	O
potential	O
without	O
excessive	O
toxicity	O
.	O

We	O
aimed	O
to	O
improve	O
the	O
efficacy	O
and	O
safety	O
of	O
adoptive	O
T-cell	O
transfer	O
by	O
using	O
adenoviral	O
vectors	O
for	O
direct	O
delivery	O
of	O
immunomodulatory	O
murine	O
cytokines	O
into	O
B16.OVA	O
melanoma	O
tumors	O
with	O
concomitant	O
T-cell	O
receptor	O
transgenic	O
OT-I	O
T-cell	O
transfer	O
.	O

Armed	O
adenoviruses	O
expressed	O
high	O
local	O
and	O
low	O
systemic	O
levels	O
of	O
cytokine	O
when	O
injected	O
into	O
B16.OVA	O
tumors	O
,	O
suggesting	O
safety	O
of	O
virus-mediated	O
cytokine	O
delivery	O
.	O

Antitumor	O
efficacy	O
was	O
significantly	O
enhanced	O
with	O
adenoviruses	O
coding	O
for	O
murine	O
interleukin-2	O
(	O
mIL-2	O
)	O
and	O
tumor	O
necrosis	O
factor-α	O
(	O
mTNFα	O
)	O
when	O
compared	O
with	O
T-cell	O
transfer	O
alone	O
or	O
viruses	O
alone	O
.	O

Further	O
improvement	O
in	O
efficacy	O
was	O
achieved	O
with	O
a	O
triple	O
combination	O
of	O
mIL-2	O
,	O
mTNFα	O
,	O
and	O
OT-I	O
T-cells	O
.	O

Mechanistic	O
studies	O
suggest	O
that	O
mIL-2	O
has	O
an	O
important	O
role	O
in	O
activating	O
T-cells	O
at	O
the	O
tumor	O
,	O
while	O
mTNFα	O
induces	O
chemokine	O
expression	O
.	O

Furthermore	O
,	O
adenovirus	O
treatments	O
enhanced	O
tumor	O
-	O
infiltration	O
of	O
OT-I	O
T-cells	O
as	O
demonstrated	O
by	O
SPECT/CT	B-P
imaging	I-P
of	O
(	O
111	O
)	O
In-labeled	O
cells	O
.	O

Our	O
results	O
suggest	O
the	O
utility	O
of	O
cytokine-coding	O
adenoviruses	O
for	O
improving	O
the	O
efficacy	O
of	O
adoptive	O
T-cell	O
therapies	O
.	O

Components	O
of	O
treatment	O
delay	O
in	O
rheumatoid	O
arthritis	O
differ	O
according	O
to	O
autoantibody	O
status	O
:	O
validation	O
of	O
a	O
single-centre	O
observation	O
using	O
national	O
audit	O
data	O
.	O

To	O
determine	O
whether	O
time	O
to	O
treatment	O
following	O
symptom	O
onset	O
differs	O
between	O
RA	O
patients	O
according	O
to	O
autoantibody	O
status	O
.	O

A	O
single-centre	O
retrospective	O
analysis	O
of	O
a	O
UK	O
early	O
RA	O
inception	O
cohort	O
was	O
first	O
undertaken	O
to	O
identify	O
those	O
components	O
of	O
the	O
patient	O
journey	O
that	O
differed	O
by	O
serological	O
subtype	O
.	O

Data	O
from	O
a	O
UK	O
national	O
audit	O
of	O
early	O
inflammatory	O
arthritis	O
patients	O
was	O
accessed	O
to	O
replicate	O
the	O
key	O
finding	O
.	O

A	O
total	O
of	O
173	O
RA	O
patients	O
were	O
diagnosed	B-P
over	O
a	O
31-	O
month	O
period	O
,	O
of	O
whom	O
80	O
(	O
46	O
%	O
)	O
were	O
ACPA/RF	O
double-seropositive	O
(	O
ACPA	O
(	O
+	O
)	O
/RF	O
(	O
+	O
)	O
)	O
,	O
53	O
(	O
31	O
%	O
)	O
ACPA	O
(	O
-	O
)	O
/RF	O
(	O
-	O
)	O
,	O
17	O
(	O
10	O
%	O
)	O
ACPA	O
(	O
+	O
)	O
/RF	O
(	O
-	O
)	O
and	O
23	O
(	O
13	O
%	O
)	O
RF	O
(	O
+	O
)	O
/ACPA	O
(	O
-	O
)	O
Overall	O
,	O
ACPA	O
(	O
+	O
)	O
/RF	O
(	O
+	O
)	O
patients	O
experienced	O
significantly	O
longer	O
symptom	O
duration	O
before	O
DMARD	O
initiation	O
.	O

This	O
was	O
accounted	O
for	O
by	O
delays	O
in	O
their	O
presentation	O
to	O
primary	O
care	O
following	O
symptom	O
onset	O
-a	O
finding	O
that	O
was	O
robustly	O
confirmed	O
in	O
an	O
independent	O
dataset	O
of	O
2192	O
UK	O
early	O
RA	O
patients	O
.	O

In	O
contrast	O
,	O
ACPA	O
(	O
-	O
)	O
/RF	O
(	O
-	O
)	O
patients	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
delays	O
in	O
DMARD	O
initiation	O
after	O
presenting	O
to	O
secondary	O
care	O
.	O

Causes	O
of	O
treatment	O
delays	O
in	O
early	O
RA	O
differ	O
according	O
to	O
patients	O
'	O
autoantibody	O
status	O
.	O

More	O
insidious	O
symptom	O
onset	O
and/or	O
distinct	O
health-seeking	O
behaviours	O
among	O
ACPA	O
(	O
+	O
)	O
/RF	O
(	O
+	O
)	O
patients	O
may	O
contribute	O
to	O
late	O
presentations	O
in	O
primary	O
care	O
,	O
whereas	O
ACPA	O
(	O
-	O
)	O
/RF	O
(	O
-	O
)	O
patients	O
experience	O
delayed	O
diagnosis	O
and	O
treatment	O
in	O
secondary	O
care	O
.	O

These	O
observations	O
inform	O
the	O
research	O
agenda	O
,	O
potentially	O
influencing	O
the	O
design	O
of	O
service	O
delivery	O
for	O
early	O
arthritis	O
patients	O
.	O

Interferon	O
gamma	O
and	O
interleukin	O
10	O
polymorphisms	O
in	O
Chinese	O
children	O
with	O
hemophagocytic	O
lymphohistiocytosis	O
.	O

The	O
aim	O
of	O
the	O
study	O
is	O
to	O
investigate	O
the	O
association	O
of	O
interferon	O
gamma	O
(	O
IFN-γ	O
)	O
and	O
interleukin-10	O
(	O
IL-10	O
)	O
gene	O
single	O
nucleotide	O
polymorphisms	O
with	O
the	O
susceptibility	O
of	O
hemophagocytic	O
lymphohistiocytosis	O
(	O
HLH	O
)	O
in	O
Chinese	O
children	O
without	O
known	O
family	O
history	O
of	O
HLH	O
.	O

Forty	O
children	O
with	O
HLH	O
and	O
160	O
age	O
-	O
and	O
gender	O
-matched	O
healthy	O
controls	O
from	O
Xuzhou	O
Children	O
's	O
Hospital	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Serum	O
IFN-γ	O
and	O
IL-10	O
levels	O
were	O
measured	O
by	O
enzyme	B-P
linked-immunosorbent	I-P
assay	I-P
.	O

Polymorphisms	O
of	O
the	O
IFN-γ	O
gene	O
at	O
position	O
+874	O
and	O
+2109	O
,	O
and	O
IL-10	O
at	O
position	O
-1082	O
were	O
analyzed	O
by	O
allele	O
-	O
specific	O
PCR	O
.	O

Median	O
serum	O
concentrations	O
of	O
IFN	O
-γ	O
and	O
IL-10	O
were	O
significantly	O
higher	O
in	O
children	O
with	O
HLH	O
compared	O
to	O
healthy	O
controls	O
.	O

The	O
frequencies	O
of	O
IFN-γ	O
+874	O
T/A	O
and	O
T/T	O
genotypes	O
,	O
as	O
well	O
as	O
T	O
allele	O
,	O
were	O
significantly	O
higher	O
in	O
the	O
HLH	O
group	O
compared	O
with	O
those	O
in	O
the	O
control	O
group	O
.	O

The	O
frequencies	O
of	O
IL-10	O
-1082	O
G/A	O
genotype	O
and	O
G	O
allele	O
were	O
significantly	O
increased	O
in	O
HLH	O
patients	O
compared	O
with	O
healthy	O
controls	O
.	O

No	O
significant	O
difference	O
was	O
found	O
in	O
the	O
distribution	O
of	O
IFN-γ	O
+2109	O
G/A	O
genotypes	O
between	O
children	O
with	O
HLH	O
and	O
controls	O
.	O

This	O
study	O
presents	O
preliminary	O
evidence	O
for	O
the	O
association	O
between	O
IFN	O
+874	O
T/A	O
,	O
T/T	O
,	O
IL-10	O
-1082	O
A/G	O
genotypes	O
,	O
and	O
HLH	O
susceptibility	O
in	O
Chinese	O
children	O
with	O
HLH	O
.	O

Analysis	O
of	O
occupant	O
kinematics	O
and	O
dynamics	O
in	O
nearside	O
oblique	O
impacts	O
.	O

The	O
objective	O
of	O
this	O
article	O
is	O
to	O
analyze	O
the	O
kinematics	O
and	O
dynamics	O
of	O
restrained	O
postmortem	B-P
human	O
surrogates	O
(	O
PMHS	O
)	O
exposed	O
to	O
a	O
nearside	O
oblique	O
impact	O
and	O
the	O
injuries	O
that	O
were	O
found	O
after	O
the	O
tests	O
.	O

Three	O
male	O
PMHS	O
of	O
similar	O
age	O
(	O
64	O
±	O
4	O
years	O
)	O
and	O
anthropometry	O
(	O
weight	O
:	O
61	O
±	O
9.6	O
kg	O
;	O
stature	O
:	O
172	O
±	O
2.7	O
cm	O
)	O
were	O
exposed	O
to	O
a	O
30°	O
nearside	O
oblique	O
impact	O
at	O
34	O
km/h	O
.	O

The	O
test	O
fixture	O
approximated	O
the	O
seating	O
position	O
of	O
a	O
front	O
seat	O
occupant	O
.	O

A	O
rigid	O
seat	O
was	O
designed	O
to	O
match	O
the	O
pelvic	O
displacement	O
in	O
a	O
vehicle	O
seat	O
.	O

Surrogates	O
were	O
restrained	O
by	O
a	O
3-point	O
seat	O
belt	O
consisting	O
of	O
a	O
2	O
kN	O
pretensioner	O
(	O
PT	O
)	O
,	O
4.5	O
kN	O
force-limiting	O
shoulder	O
belt	O
,	O
and	O
a	O
3.5	O
kN	O
PT	O
lap	O
belt	O
.	O

The	O
shoulder	O
belt	O
PT	O
was	O
not	O
fired	O
in	O
one	O
of	O
the	O
tests	O
.	O

Trajectories	O
of	O
the	O
head	O
,	O
shoulder	O
,	O
and	O
hip	O
joint	O
(	O
bilaterally	O
)	O
were	O
recorded	O
at	O
1,000	O
Hz	O
by	O
a	O
3D	O
motion	O
capture	O
system	O
.	O

The	O
3D	O
acceleration	O
and	O
angular	O
rate	O
of	O
the	O
head	O
,	O
T1	O
,	O
and	O
pelvis	O
,	O
and	O
the	O
3D	O
acceleration	O
of	O
selected	O
spinal	O
locations	O
was	O
measured	O
at	O
10,000	O
Hz	O
.	O

Seat	O
belt	O
load	O
cells	O
measured	O
the	O
belt	O
tension	O
at	O
4	O
locations	O
.	O

PMHS	O
donation	O
and	O
handling	O
were	O
performed	O
with	O
the	O
approval	O
of	O
the	O
relevant	O
regional	O
ethics	O
review	O
board	O
.	O

Activation	O
of	O
the	O
shoulder	O
PT	O
reduced	O
substantially	O
the	O
peak	O
forward	O
excursion	O
of	O
the	O
head	O
but	O
did	O
not	O
influence	O
the	O
lateral	O
displacement	O
of	O
the	O
head	O
center	O
of	O
gravity	O
(	O
CG	O
)	O
.	O

In	O
all	O
3	O
subjects	O
,	O
the	O
lateral	O
excursion	O
of	O
the	O
head	O
CG	O
(	O
291.1	O
,	O
290	O
,	O
292.1	O
mm	O
)	O
was	O
greater	O
than	O
the	O
forward	O
displacement	O
(	O
271.4	O
,	O
216.7	O
,	O
171.5	O
mm	O
)	O
.	O

The	O
hip	O
joint	O
excursion	O
of	O
the	O
PMHS	O
that	O
was	O
not	O
exposed	O
to	O
the	O
shoulder	O
PT	O
seat	O
belt	O
was	O
twice	O
the	O
magnitude	O
observed	O
for	O
the	O
other	O
2	O
subjects	O
.	O

The	O
3	O
PMHS	O
sustained	O
clavicle	O
fractures	O
on	O
the	O
shoulder	O
loaded	O
by	O
the	O
seat	O
belt	O
and	O
2	O
of	O
them	O
were	O
diagnosed	O
atlantoaxial	O
subluxation	O
in	O
the	O
radiologist	O
examination	O
.	O

Avulsion	O
fractures	O
of	O
the	O
right	O
lamina	O
of	O
T1	O
,	O
T2	O
,	O
T3	O
,	O
and	O
T4	O
were	O
found	O
when	O
the	O
PT	O
was	O
not	O
used	O
.	O

The	O
3	O
PMHS	O
received	O
multiple	O
fractures	O
spread	O
over	O
both	O
aspects	O
of	O
the	O
rib	O
cage	O
and	O
involving	O
the	O
posterior	O
aspect	O
of	O
it	O
.	O

In	O
this	O
study	O
of	O
nearside	O
oblique	O
impact	O
loading	O
,	O
the	O
PMHS	O
exhibited	O
kinematics	O
characterized	O
by	O
reduced	O
torso	O
pitching	O
and	O
increased	O
lateral	O
head	O
excursion	O
as	O
compared	O
to	O
previous	O
frontal	O
impact	O
results	O
.	O

These	O
kinematics	O
resulted	O
in	O
potential	O
cervical	O
and	O
thoracic	O
spinal	O
injuries	O
and	O
in	O
complete	O
,	O
displaced	O
fractures	O
of	O
the	O
lateral	O
and	O
posterior	O
aspects	O
of	O
the	O
rib	O
cage	O
.	O

Though	O
this	O
is	O
a	O
limited	O
number	O
of	O
subjects	O
,	O
it	O
shows	O
the	O
necessity	O
of	O
further	O
understanding	O
of	O
the	O
kinematics	O
of	O
occupants	O
exposed	O
to	O
this	O
loading	O
mode	O
.	O

Triceps	O
and	O
Subscapular	O
Skinfold	O
Thickness	O
Percentiles	O
and	O
Cut-Offs	O
for	O
Overweight	O
and	O
Obesity	O
in	O
a	O
Population-Based	O
Sample	O
of	O
Schoolchildren	O
and	O
Adolescents	O
in	O
Bogota	O
,	O
Colombia	O
.	O

The	O
assessment	O
of	O
skinfold	B-P
thickness	I-P
is	O
an	O
objective	O
measure	O
of	O
adiposity	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
establish	O
Colombian	O
smoothed	O
centile	O
charts	O
and	O
LMS	O
L	O
(	O
Box-Cox	O
transformation	O
)	O
,	O
M	O
(	O
median	O
)	O
,	O
and	O
S	O
(	O
coefficient	O
of	O
variation	O
)	O
tables	O
for	O
triceps	O
,	O
subscapular	O
,	O
and	O
triceps	O
+	O
subscapular	O
skinfolds	O
;	O
appropriate	O
cut-offs	O
were	O
selected	O
using	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
based	O
on	O
a	O
population-based	O
sample	O
of	O
children	O
and	O
adolescents	O
in	O
Bogotá	O
,	O
Colombia	O
.	O

A	O
cross-sectional	O
study	O
was	O
conducted	O
in	O
9618	O
children	O
and	O
adolescents	O
(	O
55.7	O
%	O
girls	O
;	O
age	O
range	O
of	O
9-17.9	O
years	O
)	O
.	O

Triceps	O
and	O
subscapular	O
skinfold	O
measurements	O
were	O
obtained	O
using	O
standardized	O
methods	O
.	O

We	O
calculated	O
the	O
triceps	O
+	O
subscapular	O
skinfold	O
(	O
T	O
+	O
SS	O
)	O
sum	O
.	O

Smoothed	O
percentile	O
curves	O
for	O
triceps	O
and	O
subscapular	O
skinfold	O
thickness	O
were	O
derived	O
using	O
the	O
LMS	O
method	O
.	O

ROC	O
curve	O
analyses	O
were	O
used	O
to	O
evaluate	O
the	O
optimal	O
cut-off	O
point	O
of	O
skinfold	B-P
thickness	I-P
for	O
overweight	O
and	O
obesity	O
,	O
based	O
on	O
the	O
International	O
Obesity	O
Task	O
Force	O
definitions	O
.	O

Subscapular	O
and	O
triceps	O
skinfolds	O
and	O
T	O
+	O
SS	O
were	O
significantly	O
higher	O
in	O
girls	O
than	O
in	O
boys	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
ROC	O
analysis	O
showed	O
that	O
subscapular	O
and	O
triceps	O
skinfolds	O
and	O
T	O
+	O
SS	O
have	O
a	O
high	O
discriminatory	O
power	O
in	O
the	O
identification	O
of	O
overweight	O
and	O
obesity	O
in	O
the	O
sample	O
population	O
in	O
this	O
study	O
.	O

Our	O
results	O
provide	O
sex	O
-	O
and	O
age	O
-specific	O
normative	O
reference	O
standards	O
for	O
skinfold	B-P
thickness	I-P
values	O
from	O
a	O
population	O
from	O
Bogotá	O
,	O
Colombia	O
.	O

Circulating	O
CXCR5	O
+	O
PD-1	O
+	O
ICOS	O
+	O
Follicular	O
T	O
Helper	O
Cells	O
Are	O
Increased	O
Close	O
to	O
the	O
Diagnosis	O
of	O
Type	O
1	O
Diabetes	O
in	O
Children	O
With	O
Multiple	O
Autoantibodies	O
.	O

Although	O
type	O
1	O
diabetes	O
(	O
T1D	O
)	O
is	O
primarily	O
perceived	O
as	O
a	O
T	O
cell	O
-driven	O
autoimmune	O
disease	O
,	O
islet	O
autoantibodies	O
are	O
the	O
best	O
currently	O
available	O
biomarker	O
for	O
autoimmunity	O
and	O
disease	O
risk	O
.	O

These	O
antibodies	O
are	O
produced	O
by	O
autoreactive	O
B	O
cells	O
,	O
the	O
activation	O
of	O
which	O
is	O
largely	O
dependent	O
on	O
the	O
function	O
of	O
CD4	O
(	O
+	O
)	O
CXCR5	O
(	O
+	O
)	O
follicular	O
T	O
helper	O
cells	O
(	O
Tfh	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
comprehensively	O
characterized	O
the	O
Tfh	O
-	O
as	O
well	O
as	O
B-cell	O
compartments	O
in	O
a	O
large	O
cohort	O
of	O
children	O
with	O
newly	O
diagnosed	O
T1D	O
or	O
at	O
different	O
stages	O
of	O
preclinical	O
T1D	O
.	O

We	O
demonstrate	B-P
that	O
the	O
frequency	O
of	O
CXCR5	O
(	O
+	O
)	O
PD-1	O
(	O
+	O
)	O
ICOS	O
(	O
+	O
)	O
-	O
activated	O
circulating	O
Tfh	O
cells	O
is	O
increased	O
both	O
in	O
children	O
with	O
newly	O
diagnosed	O
T1D	O
and	O
in	O
autoantibody	O
-positive	O
at-risk	O
children	O
with	O
impaired	O
glucose	O
tolerance	O
.	O

Interestingly	O
,	O
this	O
increase	O
was	O
only	O
evident	O
in	O
children	O
positive	O
for	O
two	O
or	O
more	O
biochemical	O
autoantibodies	O
.	O

No	O
alterations	O
in	O
the	O
circulating	O
B-cell	O
compartment	O
were	O
observed	O
in	O
children	O
with	O
either	O
prediabetes	O
or	O
diabetes	O
.	O

Our	O
results	O
demonstrate	B-P
that	O
Tfh	O
activation	O
is	O
detectable	O
in	O
the	O
peripheral	O
blood	O
close	O
to	O
the	O
presentation	O
of	O
clinical	O
T1D	O
but	O
only	O
in	O
a	O
subgroup	O
of	O
children	O
identifiable	O
by	O
positivity	O
for	O
multiple	O
autoantibodies	O
.	O

These	O
findings	O
suggest	O
a	O
role	O
for	O
Tfh	O
cells	O
in	O
the	O
pathogenesis	O
of	O
human	O
T1D	O
and	O
carry	O
important	O
implications	O
for	O
targeting	O
Tfh	O
cells	O
and/or	O
B	O
cells	O
therapeutically	O
.	O

Low	O
Concentration	O
of	O
Sodium	O
Butyrate	O
from	O
Ultrabraid	O
+	O
NaBu	O
suture	O
,	O
Promotes	O
Angiogenesis	O
and	O
Tissue	O
Remodelling	O
in	O
Tendon	O
-	O
bones	O
Injury	O
.	O

Sodium	O
butyrate	O
(	O
NaBu	O
)	O
,	O
a	O
form	O
of	O
short-chain	O
fatty	O
acid	O
(	O
SCFA	O
)	O
,	O
acts	O
classically	O
as	O
a	O
potent	O
anti-angiogenic	O
agent	O
in	O
tumour	O
angiogenesis	O
models	O
,	O
some	O
authors	O
demonstrated	O
that	O
low	O
concentrations	O
of	O
NaBu	O
may	O
contribute	O
to	O
healing	O
of	O
tendon	O
-	O
bone	O
injury	O
in	O
part	O
at	O
least	O
through	O
promotion	O
of	O
tissue	O
remodelling	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
low	O
-range	O
concentrations	O
of	O
NaBu	O
using	O
in	O
vitro	O
and	O
in	O
vivo	O
assays	B-P
using	O
angiogenesis	O
as	O
the	O
primary	O
outcome	O
measure	O
and	O
the	O
mechanisms	O
through	O
which	O
it	O
acts	O
.	O

We	O
demonstrated	O
that	O
NaBu	O
,	O
alone	O
or	O
perfused	O
from	O
the	O
UltraBraid	O
+	O
NaBu	O
suture	O
was	O
pro-angiogenic	O
at	O
very	O
low	O
-range	O
doses	O
promoting	O
migration	O
,	O
tube	O
formation	O
and	O
cell	O
invasion	O
in	O
bovine	O
aortic	O
endothelial	O
cells	O
(	O
BAECs	O
)	O
.	O

Furthermore	O
,	O
cell	O
exposure	O
to	O
low	O
NaBu	O
concentrations	O
increased	O
expression	O
of	O
proteins	O
involved	O
in	O
angiogenic	O
cell	O
signalling	O
,	O
including	O
p-PKCβ1	O
,	O
p-FAK	O
,	O
p-ERK1	O
/	O
2	O
,	O
p-NFκβ	O
,	O
p-PLCγ1	O
and	O
p-VEGFR2	O
.	O

In	O
addition	O
,	O
inhibitors	O
of	O
both	O
VEGFR2	O
and	O
PKCβ1	O
blocked	O
the	O
angiogenic	O
response	O
.	O

In	O
in	O
vivo	O
assays	B-P
,	O
low	O
concentrations	O
of	O
NaBu	O
induced	O
neovascularization	O
in	O
sponge	O
implants	O
in	O
mice	O
,	O
evidenced	O
by	O
increased	O
numbers	O
of	O
vessels	O
and	O
haemoglobin	O
content	O
in	O
these	O
implants	O
.	O

The	O
findings	O
in	O
this	O
study	O
indicate	O
that	O
low	O
concentrations	O
of	O
NaBu	O
could	O
be	O
an	O
important	O
compound	O
to	O
stimulate	O
angiogenesis	O
at	O
a	O
site	O
where	O
vasculature	O
is	O
deficient	O
and	O
healing	O
is	O
compromised	O
.	O

Plantar	O
fascia	O
segmentation	O
and	O
thickness	O
estimation	O
in	O
ultrasound	O
images	O
.	O

Ultrasound	B-P
(	I-P
US	I-P
)	I-P
imaging	I-P
offers	O
significant	O
potential	O
in	O
diagnosis	O
of	O
plantar	O
fascia	O
(	O
PF	O
)	O
injury	O
and	O
monitoring	O
treatment	O
.	O

In	O
particular	O
US	B-P
imaging	I-P
has	O
been	O
shown	O
to	O
be	O
reliable	O
in	O
foot	O
and	O
ankle	O
assessment	O
and	O
offers	O
a	O
real-time	O
effective	O
imaging	B-P
technique	I-P
that	O
is	O
able	O
to	O
reliably	O
confirm	O
structural	O
changes	O
,	O
such	O
as	O
thickening	O
,	O
and	O
identify	O
changes	O
in	O
the	O
internal	O
echo	O
structure	O
associated	O
with	O
diseased	O
or	O
damaged	O
tissue	O
.	O

Despite	O
the	O
advantages	O
of	O
US	B-P
imaging	I-P
,	O
images	O
are	O
difficult	O
to	O
interpret	O
during	O
medical	O
assessment	O
.	O

This	O
is	O
partly	O
due	O
to	O
the	O
size	O
and	O
position	O
of	O
the	O
PF	O
in	O
relation	O
to	O
the	O
adjacent	O
tissues	O
.	O

It	O
is	O
therefore	O
a	O
requirement	O
to	O
devise	O
a	O
system	O
that	O
allows	O
better	O
and	O
easier	O
interpretation	O
of	O
PF	O
ultrasound	O
images	O
during	O
diagnosis	O
.	O

This	O
study	O
proposes	O
an	O
automatic	B-P
segmentation	I-P
approach	I-P
which	O
for	O
the	O
first	O
time	O
extracts	O
ultrasound	O
data	O
to	O
estimate	O
size	O
across	O
three	O
sections	O
of	O
the	O
PF	O
(	O
rearfoot	O
,	O
midfoot	O
and	O
forefoot	O
)	O
.	O

This	O
segmentation	B-P
method	I-P
uses	O
artificial	O
neural	O
network	O
module	O
(	O
ANN	O
)	O
in	O
order	O
to	O
classify	O
small	O
overlapping	O
patches	O
as	O
belonging	O
or	O
not-belonging	O
to	O
the	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
of	O
the	O
PF	O
tissue	O
.	O

Features	O
ranking	O
and	O
selection	O
techniques	O
were	O
performed	O
as	O
a	O
post-processing	O
step	O
for	O
features	O
extraction	O
to	O
reduce	O
the	O
dimension	O
and	O
number	O
of	O
the	O
extracted	O
features	O
.	O

The	O
trained	O
ANN	O
classifies	O
the	O
image	O
overlapping	O
patches	O
into	O
PF	O
and	O
non-	O
PF	O
tissue	O
,	O
and	O
then	O
it	O
is	O
used	O
to	O
segment	O
the	O
desired	O
PF	O
region	O
.	O

The	O
PF	O
thickness	O
was	O
calculated	O
using	O
two	O
different	O
methods	O
:	O
distance	O
transformation	O
and	O
area-length	O
calculation	O
algorithms	O
.	O

This	O
new	O
approach	O
is	O
capable	O
of	O
accurately	O
segmenting	O
the	O
PF	O
region	O
,	O
differentiating	O
it	O
from	O
surrounding	O
tissues	O
and	O
estimating	O
its	O
thickness	O
.	O

Assessment	O
of	O
periodontal	O
bone	O
level	O
revisited	O
:	O
a	O
controlled	O
study	O
on	O
the	O
diagnostic	O
accuracy	O
of	O
clinical	O
evaluation	O
methods	O
and	O
intra-oral	B-P
radiography	I-P
.	O

The	O
accuracy	O
of	O
analogue	B-P
and	O
especially	O
digital	B-P
intra-oral	I-P
radiography	I-P
in	O
assessing	O
interdental	O
bone	O
level	O
needs	O
further	O
documentation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
clinical	O
and	O
radiographic	B-P
bone	O
level	O
assessment	O
to	O
intra-surgical	O
bone	O
level	O
registration	O
(	O
1	O
)	O
and	O
to	O
identify	O
the	O
clinical	O
variables	O
rendering	O
interdental	O
bone	O
level	O
assessment	O
inaccurate	O
(	O
2	O
)	O
.	O

The	O
study	O
sample	O
included	O
49	O
interdental	O
sites	O
in	O
17	O
periodontitis	O
patients	O
.	O

Evaluation	O
methods	O
included	O
vertical	O
relative	O
probing	O
attachment	O
level	O
(	O
RAL-V	O
)	O
,	O
analogue	B-P
and	O
digital	B-P
intra-oral	I-P
radiography	I-P
and	O
bone	B-P
sounding	I-P
without	O
and	O
with	O
flap	O
elevation	O
.	O

The	O
latter	O
was	O
considered	O
the	O
true	O
bone	O
level	O
.	O

Five	O
examiners	O
evaluated	O
all	O
radiographs	B-P
.	O

Significant	O
underestimation	O
of	O
the	O
true	O
bone	O
level	O
was	O
observed	O
for	O
all	O
evaluation	O
methods	O
pointing	O
to	O
2.7	O
mm	O
on	O
average	O
for	O
analogue	B-P
radiography	I-P
,	O
2.5	O
mm	O
for	O
digital	B-P
radiography	I-P
,	O
1.8	O
mm	O
for	O
RAL-V	O
and	O
0.6	O
mm	O
for	O
bone	B-P
sounding	I-P
without	O
flap	O
elevation	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Radiographic	B-P
underestimation	O
of	O
the	O
true	O
bone	O
level	O
was	O
higher	O
in	O
the	O
(	O
pre	O
)	O
molar	O
region	O
(	O
p	O
≤	O
0.047	O
)	O
and	O
increased	O
with	O
defect	O
depth	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Variation	O
between	O
clinicians	O
was	O
huge	O
(	O
range	O
analogue	B-P
radiography	I-P
2.2-3.2	O
mm	O
;	O
range	O
digital	B-P
radiography	I-P
2.1-3.0	O
mm	O
)	O
.	O

All	O
evaluation	O
methods	O
significantly	O
underestimated	O
the	O
true	O
bone	O
level	O
.	O

Bone	B-P
sounding	I-P
was	O
most	O
accurate	O
,	O
whereas	O
intra-oral	B-P
radiographs	I-P
were	O
least	O
accurate	O
.	O

Deep	O
periodontal	O
defects	O
in	O
the	O
(	O
pre	O
)	O
molar	O
region	O
were	O
most	O
underrated	O
by	O
intra-oral	B-P
radiography	I-P
.	O

Bone	B-P
sounding	I-P
had	O
the	O
highest	O
accuracy	O
in	O
assessing	O
interdental	O
bone	O
level	O
.	O

Options	O
in	O
treating	O
trigeminal	O
neuralgia	O
:	O
Experience	O
with	O
195	O
patients	O
.	O

For	O
patients	O
with	O
medically	O
unresponsive	O
trigeminal	O
neuralgia	O
(	O
TN	O
)	O
,	O
surgical	O
options	O
include	O
microvascular	O
decompression	O
(	O
MVD	O
)	O
,	O
radiofrequency	O
rhizotomy	O
(	O
RF	O
)	O
,	O
and	O
stereotactic	O
radiosurgery	O
(	O
SRS	O
)	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
the	O
risks	O
and	O
benefits	O
and	O
cost	O
inherent	O
with	O
each	O
of	O
the	O
three	O
modalities	O
,	O
we	O
performed	O
a	O
retrospective	O
review	O
of	O
our	O
experience	O
with	O
195	O
cases	O
of	O
TN	O
treated	O
over	O
the	O
past	O
15	O
years	O
.	O

Since	O
2001	O
,	O
195	O
patients	O
with	O
previously	O
untreated	O
TN	O
were	O
managed	O
:	O
with	O
MVD	O
in	O
79	O
,	O
RF	O
in	O
36	O
,	O
and	O
SRS	O
in	O
80	O
.	O

All	O
patients	O
reported	O
herein	O
underwent	O
preoperative	O
MRI	B-P
.	O

Women	O
outnumbered	O
men	O
122/73	O
(	O
p=0.045	O
)	O
.	O

Follow-up	O
after	O
surgery	O
was	O
32±46	O
months	O
.	O

The	O
patients	O
qualifying	O
for	O
MVD	O
were	O
generally	O
healthier	O
and	O
younger	O
,	O
with	O
a	O
mean	O
age	O
±	O
SD	O
of	O
57±14	O
,	O
compared	O
to	O
those	O
undergoing	O
RF	O
(	O
75±15	O
)	O
or	O
SRS	O
(	O
73±13	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

In	O
case	O
of	O
relapse	O
,	O
medical	O
treatment	O
was	O
always	O
tried	O
and	O
failed	O
prior	O
to	O
consideration	O
of	O
surgical	O
intervention	O
.	O

A	O
second	O
surgical	O
procedure	O
was	O
necessary	O
in	O
2	O
,	O
23	O
,	O
and	O
18	O
patients	O
initially	O
treated	O
with	O
MVD	O
,	O
RF	O
,	O
and	O
SRS	O
respectively	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

In	O
the	O
patients	O
treated	O
with	O
MVD	O
,	O
RF	O
,	O
and	O
SRS	O
,	O
the	O
average	O
number	O
of	O
procedures	O
per	O
patient	O
necessary	O
to	O
achieve	O
pain	O
control	O
was	O
1.1	O
,	O
2.0	O
,	O
and	O
1.3	O
respectively	O
(	O
p=0.001	O
)	O
.	O

There	O
were	O
7	O
complications	O
in	O
the	O
patients	O
treated	O
with	O
MVD	O
but	O
no	O
deaths	O
.	O

Numbness	O
was	O
present	O
in	O
13	O
,	O
18	O
,	O
and	O
29	O
patients	O
treated	O
with	O
MVD	O
,	O
RF	O
,	O
and	O
SRS	O
respectively	O
(	O
p=0.008	O
)	O
.	O

MVD	O
for	O
TN	O
is	O
the	O
treatment	O
least	O
likely	O
to	O
fail	O
or	O
require	O
additional	O
treatment	O
.	O

Patients	O
who	O
underwent	O
MVD	O
were	O
younger	O
than	O
those	O
undergoing	O
RF	O
or	O
SRS	O
.	O

The	O
highest	O
rate	O
of	O
recurrence	O
of	O
TN	O
was	O
encountered	O
in	O
patients	O
undergoing	O
RF	O
(	O
64	O
%	O
)	O
.	O

Facial	O
numbness	O
was	O
least	O
likely	O
to	O
occur	O
with	O
MVD	O
(	O
16	O
%	O
)	O
compared	O
to	O
RF	O
and	O
SRS	O
(	O
50	O
%	O
and	O
36	O
%	O
respectively	O
)	O
.	O

Bi-layered	O
constructs	O
of	O
poly	O
(	O
glycerol-sebacate	O
)	O
-	O
β-tricalcium	O
phosphate	O
for	O
bone-soft	O
tissue	O
interface	O
applications	O
.	O

This	O
study	O
aims	O
to	O
establish	O
a	O
facile	O
protocol	O
for	O
the	O
preparation	O
of	O
a	O
bi-layered	O
poly	O
(	O
glycerol-sebacate	O
)	O
(	O
PGS	O
)	O
/	O
β-tricalcium	O
phosphate	O
(	O
β-TCP	O
)	O
construct	O
and	O
to	O
investigate	O
its	O
potential	O
for	O
bone-soft	O
tissue	O
engineering	O
applications	O
.	O

The	O
layered	O
structure	O
was	O
prepared	O
by	O
distributing	O
the	O
ceramic	O
particles	O
within	O
a	O
prepolymer	O
synthesized	O
in	O
a	O
microwave	O
reactor	O
followed	O
by	O
a	O
cross-linking	O
of	O
the	O
final	O
construct	O
in	O
vacuum	O
(	O
<	O
10mbar	O
)	O
.	O

The	O
vacuum	O
stage	O
led	O
to	O
the	O
separation	O
of	O
cross-linked	O
elastomer	O
(	O
top	O
)	O
and	O
ceramic	O
(	O
bottom	O
)	O
phases	O
.	O

Results	O
showed	O
that	O
addition	O
of	O
β-TCP	O
particles	O
to	O
the	O
elastomer	O
matrix	O
after	O
the	O
polymerization	O
led	O
to	O
an	O
increase	O
in	O
compression	O
strength	O
(	O
up	O
to	O
14±2.3MPa	O
)	O
.	O

Tensile	O
strength	O
(	O
σ	O
)	O
,	O
Young	O
's	O
modulus	O
(	O
E	O
)	O
,	O
and	O
elongation	O
at	O
break	O
(	O
%	O
)	O
values	O
were	O
calculated	O
as	O
0.29±0.03MPa	O
and	O
0.21±0.03	O
;	O
0.38±0.02	O
and	O
1.95±0.4	O
;	O
and	O
240±50	O
%	O
and	O
24±2	O
%	O
for	O
PGS	O
and	O
PGS	O
/	O
β-TCP	O
bi-layered	O
constructs	O
,	O
respectively	O
.	O

Morphology	O
was	O
characterized	O
by	O
using	O
Scanning	B-P
Electron	I-P
Microscopy	I-P
(	O
SEM	B-P
)	O
and	O
micro-computed	B-P
tomography	I-P
(	O
μ-CT	B-P
)	O
.	O

Tomography	B-P
data	O
revealed	O
an	O
open	O
porosity	O
of	O
35	O
%	O
for	O
the	O
construct	O
,	O
mostly	O
contributed	O
from	O
the	O
ceramic	O
phase	O
since	O
the	O
elastomer	O
side	O
has	O
no	O
pore	O
.	O

Homogeneous	O
β-TCP	O
distribution	O
within	O
the	O
elastomeric	O
structure	O
was	O
observed	O
.	O

Cell	O
culture	O
studies	O
confirmed	O
biocompatibility	O
with	O
poor	O
elastomer	O
-	O
side	O
and	O
good	O
bone	O
-	O
side	O
cell	O
attachment	O
.	O

In	O
a	O
further	O
study	O
to	O
investigate	O
the	O
osteogenic	O
properties	O
,	O
the	O
construct	O
were	O
loaded	O
with	O
BMP-2	O
and/or	O
TGF-β1	O
.	O

The	O
PGS	O
/	O
β-TCP	O
bi-layered	O
constructs	O
with	O
improved	O
mechanical	O
and	O
biological	O
properties	O
have	O
the	O
potential	O
to	O
be	O
used	O
in	O
bone-soft	O
tissue	O
interface	O
applications	O
where	O
soft	O
tissue	O
penetration	O
is	O
a	O
problem	O
.	O

Dosimetry	O
software	O
Hermes	O
Internal	O
Radiation	O
Dosimetry	O
:	O
from	O
quantitative	O
image	O
reconstruction	O
to	O
voxel	O
-level	O
absorbed	O
dose	O
distribution	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
validate	O
a	O
software	O
package	O
called	O
Hermes	O
Internal	O
Radiation	O
Dosimetry	O
(	O
HIRD	O
)	O
for	O
internal	O
dose	O
assessment	O
tailored	O
for	O
clinical	O
practice	O
.	O

The	O
software	O
includes	O
all	O
the	O
necessary	O
steps	O
to	O
perform	O
voxel	O
-level	O
absorbed	O
dose	O
calculations	O
including	O
quantitative	O
reconstruction	O
,	O
image	O
coregistration	O
and	O
volume	O
of	O
interest	O
tools	O
.	O

The	O
basics	O
of	O
voxel	O
-level	O
dosimetry	O
methods	O
and	O
implementations	O
to	O
HIRD	O
software	O
are	O
reviewed	O
.	O

Then	O
,	O
HIRD	O
is	O
validated	O
using	O
simulated	O
SPECT	B-P
/	O
CT	B-P
data	O
and	O
data	O
from	O
Lu-DOTATATE	O
-	O
treated	O
patients	O
by	O
comparing	O
absorbed	O
kidney	O
doses	O
with	O
OLINDA/EXM	O
-based	O
dosimetry	O
.	O

In	O
addition	O
,	O
electron	O
and	O
photon	O
dose	O
components	O
are	O
studied	O
separately	O
in	O
an	O
example	O
patient	O
case	O
.	O

The	O
simulation	O
study	O
showed	O
that	O
HIRD	O
can	O
reproduce	O
time-activity	O
curves	O
accurately	O
and	O
produce	O
absorbed	O
doses	O
with	O
less	O
than	O
10	O
%	O
error	O
for	O
the	O
kidneys	O
,	O
liver	O
and	O
spleen	O
.	O

From	O
the	O
patient	O
data	O
,	O
the	O
absorbed	O
kidney	O
doses	O
calculated	O
using	O
HIRD	O
and	O
using	O
OLINDA/EXM	O
were	O
highly	O
correlated	O
(	O
Pearson	O
's	O
correlation	O
coefficient	O
,	O
r=0.98	O
)	O
.	O

From	O
Bland-Altman	O
plot	O
analysis	O
,	O
an	O
average	O
absorbed	O
dose	O
difference	O
of	O
-2	O
%	O
was	O
found	O
between	O
the	O
methods	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
in	O
Lu-DOTATATE	O
-	O
treated	O
patients	O
,	O
photons	O
can	O
contribute	O
over	O
10	O
%	O
of	O
the	O
kidney	O
's	O
total	O
dose	O
and	O
is	O
partly	O
because	O
of	O
cross-irradiation	O
from	O
high	O
-	O
uptake	O
lesions	O
close	O
to	O
the	O
kidneys	O
.	O

HIRD	O
is	O
a	O
straightforward	O
voxel	O
-level	O
internal	O
dosimetry	O
software	O
.	O

Its	O
clinical	O
utility	O
was	O
verified	O
with	O
simulated	O
and	O
clinical	O
Lu-DOTATATE	O
-	O
treated	O
patient	O
data	O
.	O

Patient	O
studies	O
also	O
showed	O
that	O
photon	O
contribution	O
towards	O
the	O
total	O
dose	O
can	O
be	O
relatively	O
high	O
and	O
voxel	O
-level	O
dose	O
calculations	O
can	O
be	O
valuable	O
in	O
cases	O
where	O
the	O
target	O
organ	O
is	O
in	O
close	O
proximity	O
to	O
high-	O
uptake	O
organs	O
.	O

Correlation	O
between	O
the	O
histopathology	O
of	O
chronic	O
urticaria	O
and	O
its	O
clinical	O
picture	O
.	O

Chronic	O
urticaria	O
is	O
characterized	O
by	O
transient	O
,	O
pruritic	O
lesions	O
of	O
varying	O
sizes	O
,	O
with	O
central	O
pallor	O
and	O
well-defined	O
edges	O
,	O
with	O
disease	O
duration	O
longer	O
than	O
six	O
weeks	O
.	O

Its	O
cellular	O
infiltrate	O
consists	O
of	O
neutrophils	O
,	O
lymphocytes	O
and	O
eosinophils	O
.	O

There	O
is	O
a	O
subgroup	O
of	O
patients	O
with	O
eosinophilic	O
or	O
neutrophilic	O
urticaria	O
,	O
resistant	O
to	O
the	O
treatment	O
with	O
antihistamines	O
,	O
but	O
that	O
respond	O
to	O
a	O
combination	O
of	O
antihistamine	O
with	O
other	O
drugs	O
.	O

To	O
evaluate	O
the	O
present	O
infiltration	O
in	O
chronic	O
urticaria	O
biopsies	B-P
and	O
correlate	O
it	O
with	O
the	O
clinical	O
disease	O
activity	O
and	O
response	O
to	O
treatment	O
.	O

Forty-one	O
patients	O
with	O
chronic	O
urticaria	O
were	O
classified	O
according	O
to	O
the	O
score	O
of	O
severity	O
of	O
the	O
disease	O
,	O
response	O
to	O
treatment	O
and	O
type	O
of	O
perivascular	O
infiltrate	O
.	O

Inflammatory	O
infiltrates	O
were	O
divided	O
in	O
eosinophilic	O
(	O
46.30	O
%	O
)	O
,	O
neutrophilic	O
and	O
mixed	O
.	O

An	O
association	O
was	O
found	O
between	O
the	O
eosinophilic	O
infiltrate	O
and	O
clinical	O
scores	O
of	O
greater	O
severity	O
(	O
p	O
=	O
0.002	O
)	O
.	O

This	O
association	O
shows	O
that	O
the	O
eosinophilic	O
inflammatory	O
infiltrates	O
denote	O
high	O
clinical	O
activity	O
,	O
which	O
means	O
more	O
severe	O
and	O
exuberant	O
clinical	O
pictures	O
of	O
the	O
disease	O
.	O

Os	O
subtibiale	O
:	O
Mimicking	O
medial	O
malleolar	O
fracture	O
a	O
report	O
of	O
three	O
cases	O
and	O
review	O
of	O
literature	O
.	O

There	O
are	O
numerous	O
sesamoids	O
and	O
accessory	O
ossicles	O
around	O
the	O
foot	O
which	O
can	O
easily	O
be	O
misdiagnosed	O
as	O
fractures	O
.	O

Os	O
subtibiale	O
is	O
a	O
very	O
rare	O
normal	O
variant	O
of	O
the	O
medial	O
malleolus	O
which	O
is	O
usually	O
diagnosed	O
incidentally	O
in	O
routine	O
ankle	O
radiographs	B-P
.	O

In	O
this	O
report	O
,	O
we	O
present	O
a	O
case	O
series	O
of	O
3	O
patients	O
with	O
os	O
subtibiale	O
who	O
were	O
admitted	O
to	O
the	O
emergency	O
department	O
with	O
ankle	O
sprains	O
and	O
misdiagnosed	O
as	O
medial	O
malleolar	O
fractures	O
.	O

We	O
would	O
like	O
to	O
raise	O
awareness	O
to	O
the	O
very	O
rare	O
and	O
usually	O
asymptomatic	O
os	O
subtibiale	O
as	O
a	O
diagnostic	O
pitfall	O
.	O

Variant	O
2	O
of	O
KIAA0101	O
,	O
antagonizing	O
its	O
oncogenic	O
variant	O
1	O
,	O
might	O
be	O
a	O
potential	O
therapeutic	O
strategy	O
in	O
hepatocellular	O
carcinoma	O
.	O

Hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
is	O
one	O
of	O
the	O
most	O
lethal	O
malignant	O
tumors	O
worldwide	O
and	O
effective	O
therapies	O
,	O
including	O
molecular	O
therapy	O
,	O
remain	O
elusive	O
.	O

Our	O
previous	O
work	O
demonstrates	O
that	O
oncogenic	O
KIAA0101	O
transcript	O
variant	O
(	O
tv	O
)	O
1	O
promotes	O
HCC	O
development	O
and	O
might	O
be	O
a	O
HCC	O
therapeutic	O
target	O
.	O

However	O
,	O
the	O
function	O
of	O
another	O
KIAA0101	O
variant	O
,	O
KIAA0101	O
tv2	O
,	O
remains	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
reported	O
that	O
KIAA0101	O
tv2	O
was	O
highly	O
expressed	O
in	O
adjacent	O
non-tumorous	O
liver	O
tissues	O
(	O
NTs	O
)	O
compared	O
to	O
HCC	O
tissues	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
results	O
showed	O
that	O
KIAA0101	O
tv2	O
decreased	O
cell	O
survival	O
,	O
colony	O
formation	O
,	O
tumor	B-P
xenografts	I-P
,	O
migration	O
,	O
and	O
invasion	O
,	O
as	O
well	O
as	O
induced	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
.	O

Interestingly	O
,	O
it	O
could	O
inhibit	O
the	O
function	O
of	O
KIAA0101	O
tv1	O
by	O
partially	O
down-regulating	O
KIAA0101	O
tv1	O
,	O
acting	O
similar	O
to	O
KIAA0101	O
tv1	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
.	O

Further	O
studies	O
illustrated	O
that	O
KIAA0101	O
tv2	O
could	O
increase	O
the	O
activity	O
of	O
p53	O
by	O
competing	O
with	O
KIAA0101	O
tv1	O
for	O
P53	O
binding	O
.	O

In	O
conclusion	O
,	O
KIAA0101	O
tv2	O
exerts	O
anti-tumor	O
activity	O
in	O
HCC	O
and	O
acts	O
as	O
an	O
endogenous	O
competitor	O
of	O
tumor-associated	O
KIAA0101	O
tv1	O
.	O

KIAA0101	O
tv2	O
has	O
a	O
potential	O
to	O
work	O
as	O
a	O
therapeutic	O
drug	O
targeting	O
the	O
KIAA0101	O
tv1	O
in	O
HCC	O
.	O

The	O
AGES-Reykjavik	O
study	O
atlases	O
:	O
Non-linear	O
multi-spectral	O
template	O
and	O
atlases	O
for	O
studies	O
of	O
the	O
ageing	O
brain	O
.	O

Quantitative	O
analyses	O
of	O
brain	O
structures	O
from	O
Magnetic	B-P
Resonance	I-P
(	O
MR	B-P
)	O
image	B-P
data	O
are	O
often	O
performed	O
using	O
automatic	O
segmentation	O
algorithms	O
.	O

Many	O
of	O
these	O
algorithms	O
rely	O
on	O
templates	O
and	O
atlases	O
in	O
a	O
common	O
coordinate	O
space	O
.	O

Most	O
freely	O
available	O
brain	O
atlases	O
are	O
generated	O
from	O
relatively	O
young	O
individuals	O
and	O
not	O
always	O
derived	O
from	O
well-defined	O
cohort	O
studies	O
.	O

In	O
this	O
paper	O
,	O
we	O
introduce	O
a	O
publicly	O
available	O
multi-spectral	O
template	O
with	O
corresponding	O
tissue	O
probability	O
atlases	O
and	O
regional	O
atlases	O
,	O
optimised	O
to	O
use	O
in	O
studies	O
of	O
ageing	O
cohorts	O
(	O
mean	O
age	O
75	O
±	O
5	O
years	O
)	O
.	O

Furthermore	O
,	O
we	O
provide	O
validation	O
data	O
from	O
a	O
regional	O
segmentation	O
pipeline	O
to	O
assure	O
the	O
integrity	O
of	O
the	O
dataset	O
.	O

In	O
vitro	O
screening	B-P
and	O
in	O
silico	O
validation	O
revealed	O
key	O
microbes	O
for	O
higher	O
production	O
of	O
significant	O
therapeutic	O
enzyme	O
l-asparaginase	O
.	O

l-asparaginase	O
is	O
an	O
enzyme	O
of	O
medical	O
prominence	O
and	O
reputable	O
as	O
a	O
chemotherapeutic	O
agent	O
.	O

It	O
also	O
has	O
immense	O
potential	O
to	O
cure	O
autoimmune	O
and	O
infectious	O
diseases	O
.	O

The	O
vast	O
application	O
of	O
this	O
enzyme	O
in	O
healthcare	O
sector	O
increases	O
its	O
market	O
demand	O
.	O

However	O
,	O
presently	O
the	O
huge	O
market	O
demand	O
is	O
not	O
achieved	O
completely	O
.	O

This	O
serves	O
the	O
basis	O
to	O
explore	O
better	O
producer	O
microbial	O
strains	O
to	O
bridge	O
the	O
gap	O
between	O
huge	O
demand	O
and	O
supply	O
of	O
this	O
therapeutic	O
enzyme	O
.	O

The	O
present	O
study	O
deals	O
with	O
the	O
successful	O
screening	B-P
of	O
potent	O
microorganisms	O
producing	O
l-asparaginase	O
.	O

47	O
microorganisms	O
were	O
screened	B-P
including	O
bacteria	O
,	O
fungi	O
,	O
and	O
yeasts	O
.	O

Among	O
all	O
,	O
Penicillium	O
lilacinum	O
showed	O
the	O
highest	O
enzyme	O
activity	O
i.e.	O
,	O
39.67	O
IU/ml	O
.	O

Shigella	O
flexneri	O
has	O
23.21	O
IU/ml	O
of	O
enzyme	O
activity	O
(	O
highest	O
among	O
all	O
the	O
bacterial	O
strain	O
tested	O
)	O
.	O

Further	O
,	O
the	O
3-D	O
structure	O
of	O
l-asparaginase	O
from	O
higher	O
producer	O
strains	O
was	O
developed	O
and	O
validated	O
in	O
silico	O
for	O
its	O
activity	O
.	O

l-asparagine	O
(	O
substrate	O
for	O
l-asparaginase	O
)	O
was	O
docked	O
inside	O
the	O
binding	O
pocket	O
of	O
P.	O
lilacinum	O
and	O
S.	O
flexneri	O
.	O

Docking	O
score	O
for	O
the	O
most	O
common	O
substrate	O
l-asparagine	O
is	O
-6.188	O
(	O
P.	O
lilacinum	O
)	O
,	O
-5.576	O
(	O
S.	O
flexneri	O
)	O
which	O
is	O
quite	O
good	O
.	O

Moreover	O
,	O
the	O
chemical	O
property	O
of	O
the	O
binding	O
pocket	O
revealed	O
that	O
amino	O
acid	O
residues	O
Phe	O
243	O
,	O
Gln	O
260	O
,	O
Gly	O
365	O
,	O
Asp	O
386	O
in	O
P.	O
lilacinum	O
and	O
residues	O
Asp	O
181	O
,	O
Thr	O
318	O
,	O
Asn	O
320	O
in	O
S.	O
flexneri	O
have	O
an	O
important	O
role	O
in	O
H-bonding	O
.	O

The	O
in	O
silico	O
results	O
supports	O
and	O
strengthen	O
the	O
wet	O
lab	O
results	O
.	O

The	O
outcome	O
obtained	O
motivates	O
to	O
take	O
the	O
present	O
study	O
result	O
from	O
lab	O
to	O
industry	O
for	O
the	O
economic	O
/	O
massive	O
production	O
of	O
this	O
enzyme	O
for	O
the	O
diverse	O
therapeutic	O
application	O
.	O

Digital	O
Myopericytoma	O
:	O
A	O
Case	O
Report	O
and	O
Systematic	O
Literature	O
Review	O
.	O

A	O
myopericytoma	O
(	O
MP	O
)	O
is	O
an	O
exceedingly	O
rare	O
perivascular	O
tumor	O
of	O
unknown	O
etiology	O
.	O

Given	O
their	O
potential	O
for	O
mimicry	O
and	O
malignancy	O
,	O
MP	O
tumors	O
pose	O
a	O
unique	O
challenge	O
for	O
surgeons	O
and	O
may	O
be	O
overlooked	O
on	O
differential	B-P
diagnosis	I-P
.	O

We	O
present	O
a	O
case	O
report	O
of	O
an	O
otherwise	O
healthy	O
33-year-old	O
right-hand	O
dominant	O
male	O
who	O
presented	O
to	O
our	O
outpatient	O
clinic	O
with	O
a	O
2-month	O
history	O
of	O
painless	O
swelling	O
and	O
erythema	O
of	O
the	O
pulp	O
of	O
his	O
left	O
index	O
finger	O
.	O

Subsequent	O
plain	B-P
film	I-P
X-ray	I-P
showed	O
near-complete	O
bony	O
destruction	O
of	O
his	O
distal	O
phalanx	O
.	O

Pathological	O
evaluation	O
of	O
an	O
incisional	B-P
biopsy	I-P
showed	O
a	O
benign	O
variant	O
of	O
MP	O
.	O

The	O
lesion	O
was	O
treated	O
by	O
excision	O
with	O
tumor	O
shelling	O
,	O
and	O
there	O
was	O
no	O
evidence	O
of	O
recurrence	O
81	O
days	O
postoperatively	O
.	O

A	O
systematic	O
literature	O
review	O
of	O
the	O
management	O
and	O
outcome	O
of	O
all	O
known	O
cases	O
of	O
hand	O
and	O
wrist	O
MP	O
is	O
presented	O
.	O

Appearance	O
Differences	O
Between	O
Lots	O
and	O
Brands	O
of	O
Similar	O
Shade	O
Designations	O
of	O
Dental	O
Composite	O
Resins	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
investigate	O
differences	O
in	O
two	O
inherent	O
appearance	O
characteristics	O
between	O
lots	O
of	O
an	O
enamel	O
dental	O
composite	O
resin	O
of	O
the	O
same	O
shade	O
and	O
brand	O
,	O
and	O
to	O
further	O
compare	O
these	O
differences	O
to	O
those	O
of	O
similar	O
shade	O
designation	O
of	O
a	O
different	O
brand	O
of	O
dental	O
composite	O
resins	O
.	O

Appearance	O
analyses	O
proceeded	O
for	O
three	O
different	O
lots	O
of	O
shades	O
A1	O
,	O
B2	O
,	O
and	O
D3	O
manufactured	O
by	O
one	O
company	O
and	O
for	O
one	O
lot	O
of	O
shade	O
EA1	O
manufactured	O
by	O
another	O
.	O

Samples	O
were	O
measured	O
on	O
black	O
,	O
white	O
,	O
and	O
gray	O
backings	O
using	O
spectroradiometry	B-P
.	O

Kubelka-Munk	O
theory	O
was	O
used	O
to	O
determine	O
reflectivity	O
of	O
each	O
lot	O
studied	O
.	O

CIELAB	O
values	O
and	O
color	O
differences	O
between	O
shades	O
and	O
lots	O
were	O
analyzed	O
.	O

Translucency	O
indicators	O
were	O
compared	O
between	O
lots	O
over	O
thicknesses	O
from	O
0.5	O
to	O
3.0	O
mm	O
.	O

Differences	O
in	O
inherent	O
color	O
between	O
some	O
lots	O
of	O
same	O
shade	O
designations	O
within	O
a	O
brand	O
were	O
found	O
to	O
be	O
above	O
the	O
acceptability	O
threshold	O
.	O

Color	O
difference	O
between	O
an	O
enamel	O
composite	O
resin	O
of	O
shade	O
A1	O
and	O
a	O
composite	O
resin	O
of	O
shade	O
EA1	O
was	O
also	O
above	O
the	O
acceptability	O
threshold	O
.	O

Statistically	O
significant	O
differences	O
in	O
the	O
translucency	O
were	O
found	O
between	O
some	O
lots	O
of	O
one	O
shade	O
over	O
the	O
entire	O
range	O
of	O
thicknesses	O
studied	O
.	O

Appearance	O
analyses	O
indicate	O
substantial	O
variation	O
between	O
lots	O
of	O
same	O
shade	O
designations	O
as	O
well	O
as	O
between	O
brands	O
of	O
similar	O
shade	O
designations	O
.	O

Optical	O
principles	O
applied	O
to	O
important	O
clinical	O
appearance	O
attributes	O
are	O
described	O
which	O
characterize	O
inherent	O
appearance	O
attributes	O
and	O
provide	O
aid	O
in	O
the	O
appearance	O
matching	O
process	O
for	O
dental	O
composite	O
resins	O
used	O
in	O
restorative	O
and	O
operative	O
dental	O
procedures	O
.	O

(	O
J	O
Esthet	O
Restor	O
Dent	O
29	O
:	O
E6-E14	O
,	O
2017	O
)	O
.	O

The	O
genetic	O
basis	O
for	O
variation	O
in	O
resistance	O
to	O
infection	O
in	O
the	O
Drosophila	O
melanogaster	O
genetic	O
reference	O
panel	O
.	O

Individuals	O
vary	O
extensively	O
in	O
the	O
way	O
they	O
respond	O
to	O
disease	O
but	O
the	O
genetic	O
basis	O
of	O
this	O
variation	O
is	O
not	O
fully	O
understood	O
.	O

We	O
found	O
substantial	O
individual	O
variation	O
in	O
resistance	O
and	O
tolerance	O
to	O
the	O
fungal	O
pathogen	O
Metarhizium	O
anisopliae	O
Ma549	O
using	O
the	O
Drosophila	O
melanogaster	O
Genetic	O
Reference	O
Panel	O
(	O
DGRP	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
host	O
defense	O
to	O
Ma549	O
was	O
correlated	O
with	O
defense	O
to	O
the	O
bacterium	O
Pseudomonas	O
aeruginosa	O
Pa14	O
,	O
and	O
several	O
previously	O
published	O
DGRP	O
phenotypes	O
including	O
oxidative	O
stress	O
sensitivity	O
,	O
starvation	O
stress	O
resistance	O
,	O
hemolymph	O
glucose	B-P
levels	I-P
,	O
and	O
sleep	O
indices	O
.	O

We	O
identified	O
polymorphisms	O
associated	O
with	O
differences	O
between	O
lines	O
in	O
both	O
their	O
mean	O
survival	O
times	O
and	O
microenvironmental	O
plasticity	O
,	O
suggesting	O
that	O
lines	O
differ	O
in	O
their	O
ability	O
to	O
adapt	O
to	O
variable	O
pathogen	O
exposures	O
.	O

The	O
majority	O
of	O
polymorphisms	O
increasing	O
resistance	O
to	O
Ma549	O
were	O
sex	O
biased	O
,	O
located	O
in	O
non-coding	O
regions	O
,	O
had	O
moderately	O
large	O
effect	O
and	O
were	O
rare	O
,	O
suggesting	O
that	O
there	O
is	O
a	O
general	O
cost	O
to	O
defense	O
.	O

Nevertheless	O
,	O
host	O
defense	O
was	O
not	O
negatively	O
correlated	O
with	O
overall	O
longevity	O
and	O
fecundity	O
.	O

In	O
contrast	O
to	O
Ma549	O
,	O
minor	O
alleles	O
were	O
concentrated	O
in	O
the	O
most	O
Pa14	O
-	O
susceptible	O
as	O
well	O
as	O
the	O
most	O
Pa14	O
-	O
resistant	O
lines	O
.	O

A	O
pathway	O
based	O
analysis	O
revealed	O
a	O
network	O
of	O
Pa14	O
and	O
Ma549	O
-	O
resistance	O
genes	O
that	O
are	O
functionally	O
connected	O
through	O
processes	O
that	O
encompass	O
phagocytosis	O
and	O
engulfment	O
,	O
cell	O
mobility	O
,	O
intermediary	O
metabolism	O
,	O
protein	O
phosphorylation	O
,	O
axon	O
guidance	O
,	O
response	O
to	O
DNA	O
damage	O
,	O
and	O
drug	O
metabolism	O
.	O

Functional	O
testing	O
with	O
insertional	O
mutagenesis	O
lines	O
indicates	O
that	O
12/13	O
candidate	O
genes	O
tested	O
influence	O
susceptibility	O
to	O
Ma549	O
.	O

Many	O
candidate	O
genes	O
have	O
homologs	O
identified	O
in	O
studies	O
of	O
human	O
disease	O
,	O
suggesting	O
that	O
genes	O
affecting	O
variation	O
in	O
susceptibility	O
are	O
conserved	O
across	O
species	O
.	O

Cyclic	O
thrombocytopenia	O
synchronizing	O
with	O
the	O
menstrual	O
cycle	O
showing	O
periodic	O
phases	O
of	O
thrombocytopenia	O
and	O
rebound	O
thrombocytosis	O
.	O

A	O
37-	O
year	O
-old	O
woman	O
was	O
admitted	O
to	O
our	O
hospital	O
for	O
purpura	O
involving	O
the	O
extremities	O
and	O
thrombocytopenia	O
.	O

Prednisolone	O
(	O
PSL	O
)	O
was	O
administered	O
based	O
on	O
a	O
diagnosis	O
of	O
idiopathic	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
)	O
,	O
but	O
was	O
not	O
effective	O
for	O
maintaining	O
her	O
platelet	B-P
count	I-P
within	O
the	O
normal	O
range	O
,	O
which	O
showed	O
cyclic	O
fluctuation	O
corresponding	O
to	O
the	O
menstrual	O
cycle	O
.	O

Therefore	O
,	O
we	O
discontinued	O
PSL	O
,	O
and	O
cyclic	O
thrombocytopenia	O
(	O
CTP	O
)	O
was	O
diagnosed	O
.	O

CTP	O
is	O
a	O
rare	O
disease	O
which	O
is	O
usually	O
treated	O
as	O
ITP	O
but	O
with	O
no	O
response	O
.	O

Although	O
the	O
exact	O
cause	O
of	O
CTP	O
is	O
uncertain	O
,	O
in	O
our	O
case	O
,	O
a	O
hormonal	O
mechanism	O
may	O
be	O
responsible	O
for	O
fluctuating	O
platelet	B-P
count	I-P
.	O

Craving	O
behavioral	O
intervention	O
for	O
internet	O
gaming	O
disorder	O
:	O
remediation	O
of	O
functional	O
connectivity	O
of	O
the	O
ventral	O
striatum	O
.	O

Psychobehavioral	O
intervention	O
is	O
an	O
effective	O
treatment	O
of	O
Internet	O
addiction	O
,	O
including	O
Internet	O
gaming	O
disorder	O
(	O
IGD	O
)	O
.	O

However	O
,	O
the	O
neural	O
mechanisms	O
underlying	O
its	O
efficacy	O
remain	O
unclear	O
.	O

Cortical	O
-	O
ventral	O
striatum	O
(	O
VS	O
)	O
circuitry	O
is	O
a	O
common	O
target	O
of	O
psychobehavioral	O
interventions	O
in	O
drug	O
addiction	O
,	O
and	O
cortical	O
-	O
VS	O
dysfunction	O
has	O
been	O
reported	O
in	O
IGD	O
;	O
hence	O
,	O
the	O
primary	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
how	O
the	O
VS	O
circuitry	O
responds	O
to	O
psychobehavioral	O
interventions	O
in	O
IGD	O
.	O

In	O
a	O
cross-sectional	O
study	O
,	O
we	O
examined	O
resting-state	O
functional	O
connectivity	O
of	O
the	O
VS	O
in	O
74	O
IGD	O
subjects	O
(	O
IGDs	O
)	O
and	O
41	O
healthy	O
controls	O
(	O
HCs	O
)	O
.	O

In	O
a	O
follow-up	O
craving	O
behavioral	O
intervention	O
(	O
CBI	O
)	O
study	O
,	O
of	O
the	O
74	O
IGD	O
subjects	O
,	O
20	O
IGD	O
subjects	O
received	O
CBI	O
(	O
CBI+	O
)	O
and	O
16	O
IGD	O
subjects	O
did	O
not	O
(	O
CBI-	O
)	O
.	O

All	O
participants	O
were	O
scanned	B-P
twice	O
with	O
similar	O
time	O
interval	O
to	O
assess	O
the	O
effects	O
of	O
CBI	O
.	O

IGD	O
subjects	O
showed	O
greater	O
resting-state	O
functional	O
connectivity	O
of	O
the	O
VS	O
to	O
left	O
inferior	O
parietal	O
lobule	O
(	O
lIPL	O
)	O
,	O
right	O
inferior	O
frontal	O
gyrus	O
and	O
left	O
middle	O
frontal	O
gyrus	O
,	O
in	O
positive	O
association	O
with	O
the	O
severity	O
of	O
IGD	O
.	O

Moreover	O
,	O
compared	O
with	O
CBI-	O
,	O
CBI+	O
showed	O
significantly	O
greater	O
decrease	O
in	O
VS	O
-	O
lIPL	O
connectivity	O
,	O
along	O
with	O
amelioration	O
in	O
addiction	O
severity	O
following	O
the	O
intervention	O
.	O

These	O
findings	O
demonstrated	O
that	O
functional	O
connectivity	O
between	O
VS	O
and	O
lIPL	O
,	O
each	O
presumably	O
mediating	O
gaming	O
craving	O
and	O
attentional	O
bias	O
,	O
may	O
be	O
a	O
potential	O
biomarker	O
of	O
the	O
efficacy	O
of	O
psychobehavioral	O
intervention	O
.	O

These	O
results	O
also	O
suggested	O
that	O
non-invasive	O
techniques	O
such	O
as	O
transcranial	O
magnetic	O
or	O
direct	O
current	O
stimulation	O
targeting	O
the	O
VS	O
-	O
lIPL	O
circuitry	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
Internet	O
gaming	O
disorders	O
.	O

Inflammatory	O
pain	O
-related	O
traits	O
of	O
sensory	O
DRG	O
neurons	O
innervating	O
the	O
hip	O
joints	O
.	O

Hip	O
pain	O
is	O
transmitted	O
to	O
the	O
dorsal	O
horn	O
of	O
the	O
spinal	O
cord	O
via	O
the	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
,	O
which	O
contains	O
two	O
types	O
of	O
neurons	O
with	O
differential	O
sensitivity	O
to	O
neurotrophic	O
factors	O
.	O

If	O
either	O
type	O
predominantly	O
innervates	O
the	O
hip	O
joint	O
,	O
it	O
may	O
represent	O
a	O
good	O
target	O
for	O
hip	O
joint	O
pain	O
treatment	O
.	O

Inflammation	O
was	O
induced	O
in	O
the	O
left	O
hip	O
joint	O
of	O
rats	O
(	O
n	O
=	O
10	O
)	O
by	O
using	O
complete	O
Freund	O
's	O
adjuvant	O
.	O

Fluoro-Gold	O
(	O
FG	O
)	O
was	O
applied	O
to	O
the	O
hip	O
joint	O
after	O
7	O
days	O
,	O
and	O
T12	O
-	O
L6	O
DRGs	O
were	O
double-stained	B-P
for	O
calcitonin	O
gene-related	O
peptide	O
(	O
CGRP	O
)	O
and	O
isolection-IB4	O
1	O
week	O
later	O
.	O

FG	O
-labeled	O
neurons	O
in	O
the	O
control	O
group	O
were	O
distributed	O
throughout	O
the	O
left	O
DRG	O
from	O
T13	O
to	O
L5	O
,	O
primarily	O
in	O
L2	O
to	O
L4	O
,	O
and	O
CGRP	O
-positive	O
neurons	O
were	O
significantly	O
more	O
frequent	O
than	O
IB4	O
-	O
binding	O
neurons	O
.	O

In	O
the	O
inflammatory	O
group	O
,	O
FG	O
-labeled	O
neurons	O
were	O
similarly	O
distributed	O
,	O
primarily	O
at	O
L3	O
and	O
L4	O
,	O
and	O
CGRP	O
-positive	O
neurons	O
were	O
significantly	O
more	O
frequent	O
than	O
IB4	O
-	O
binding	O
neurons	O
.	O

The	O
percentage	O
of	O
CGRP	O
-positive	O
neurons	O
was	O
significantly	O
greater	O
in	O
the	O
inflammatory	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Most	O
small	O
neurons	O
innervating	O
the	O
hip	O
joint	O
express	O
CGRP	O
.	O

Furthermore	O
,	O
hip	O
joint	O
inflammation	O
caused	O
an	O
increase	O
in	O
CGRP	O
-positive	O
neurons	O
,	O
but	O
not	O
in	O
IB4	O
-	O
binding	O
neurons	O
.	O

Our	O
results	O
suggest	O
that	O
CGRP	O
-	O
expressing	O
nerve	O
growth	O
factor	O
-dependent	O
neurons	O
are	O
primarily	O
responsible	O
for	O
hip	O
joint	O
pain	O
and	O
may	O
represent	O
therapeutic	O
targets	O
.	O

Quantifying	O
Nonlinear	O
Contributions	O
to	O
Cortical	B-P
Responses	I-P
Evoked	I-P
by	O
Continuous	O
Wrist	O
Manipulation	O
.	O

Cortical	B-P
responses	I-P
to	O
continuous	O
stimuli	O
as	O
recorded	O
using	O
either	O
magneto-	B-P
or	O
electroencephalography	B-P
(	O
EEG	B-P
)	O
have	O
shown	O
power	O
at	O
harmonics	O
of	O
the	O
stimulated	O
frequency	O
,	O
indicating	O
nonlinear	O
behavior	O
.	O

Even	O
though	O
the	O
selection	O
of	O
analysis	O
techniques	O
depends	O
on	O
the	O
linearity	O
of	O
the	O
system	O
under	O
study	O
,	O
the	O
importance	O
of	O
nonlinear	O
contributions	O
to	O
cortical	B-P
responses	I-P
has	O
not	O
been	O
formally	O
addressed	O
.	O

The	O
goal	O
of	O
this	O
paper	O
is	O
to	O
quantify	O
the	O
nonlinear	O
contributions	O
to	O
the	O
cortical	B-P
response	I-P
obtained	O
from	O
continuous	O
sensory	O
stimulation	O
.	O

EEG	B-P
was	O
used	O
to	O
record	O
the	O
cortical	B-P
response	I-P
evoked	I-P
by	O
continuous	O
movement	O
of	O
the	O
wrist	O
joint	O
of	O
healthy	O
subjects	O
applied	O
with	O
a	O
robotic	O
manipulator	O
.	O

Multisine	O
stimulus	O
signals	O
(	O
i.e.	O
,	O
the	O
sum	O
of	O
several	O
sinusoids	O
)	O
elicit	O
a	O
periodic	O
cortical	B-P
response	I-P
and	O
allow	O
to	O
assess	O
the	O
nonlinear	O
contributions	O
to	O
the	O
response	O
.	O

Wrist	O
dynamics	O
(	O
relation	O
between	O
joint	O
angle	O
and	O
torque	O
)	O
were	O
successfully	O
linearized	O
,	O
explaining	O
99	O
%	O
of	O
the	O
response	O
.	O

In	O
contrast	O
,	O
the	O
cortical	B-P
response	I-P
revealed	O
a	O
highly	O
nonlinear	O
relation	O
;	O
where	O
most	O
power	O
(	O
∼	O
80	O
%	O
)	O
occurred	O
at	O
non-stimulated	O
frequencies	O
.	O

Moreover	O
,	O
only	O
10	O
%	O
of	O
the	O
response	O
could	O
be	O
explained	O
using	O
a	O
nonparametric	O
linear	O
model	O
.	O

These	O
results	O
indicate	O
that	O
the	O
recorded	O
evoked	B-P
cortical	I-P
responses	I-P
are	O
governed	O
by	O
nonlinearities	O
and	O
that	O
linear	O
methods	O
do	O
not	O
suffice	O
when	O
describing	O
the	O
relation	O
between	O
mechanical	O
stimulus	O
and	O
cortical	O
response	O
.	O

Insulin	O
-mediated	O
hypoglycaemia	O
secondary	O
to	O
recurrent	O
clear	O
cell	O
renal	O
carcinoma	O
.	O

Renal	O
cell	O
carcinoma	O
has	O
previously	O
been	O
associated	O
with	O
hypoglycaemia	O
in	O
the	O
setting	O
of	O
non-islet	O
cell	O
tumours	O
,	O
caused	O
by	O
a	O
paraneoplastic	O
phenomenon	O
relating	O
to	O
the	O
production	O
of	O
insulin-like	O
growth	O
factor	O
type	O
II	O
.	O

We	O
present	O
a	O
case	O
of	O
recurrent	O
clear	O
cell	O
renal	O
cell	O
carcinoma	O
,	O
leading	O
to	O
an	O
insulin	O
-mediated	O
paraneoplastic	O
phenomenon	O
causing	O
severe	O
recurrent	O
hypoglycaemia	O
.	O

Hypoglycaemina	O
was	O
managed	O
successfully	O
using	O
diazoxide	O
therapy	O
,	O
in	O
conjunction	O
with	O
pazopanib	O
and	O
radiotherapy	O
to	O
reduce	O
tumour	B-P
burden	I-P
.	O

Clinical	O
and	O
therapeutic	O
implications	O
of	O
BRAF	O
mutation	O
heterogeneity	O
in	O
metastatic	O
melanoma	O
.	O

Heterogeneity	O
of	O
BRAF	O
mutation	O
in	O
melanoma	O
has	O
been	O
a	O
controversial	O
subject	O
.	O

Quantitative	O
data	O
on	O
BRAF	O
allele	O
frequency	O
(	O
AF	O
)	O
are	O
sparse	O
,	O
and	O
the	O
potential	O
relationship	O
with	O
response	O
to	O
BRAF	O
inhibitors	O
(	O
BRAFi	O
)	O
in	O
patients	O
with	O
metastatic	O
melanoma	O
is	O
unknown	O
.	O

We	O
quantitatively	O
measured	O
BRAF	O
AF	O
in	O
a	O
cohort	O
of	O
treatment	O
naïve	O
metastatic	O
melanoma	O
samples	O
by	O
pyrosequencing	B-P
and	O
correlated	O
with	O
survival	O
data	O
in	O
patients	O
treated	O
with	O
BRAFi	O
as	O
part	O
of	O
their	O
clinical	O
care	O
.	O

Fifty-two	O
samples	O
from	O
50	O
patients	O
were	O
analysed	O
.	O

BRAF	O
V600E	O
mutations	O
were	O
detected	O
in	O
71.1	O
%	O
of	O
samples	O
followed	O
by	O
V600K	O
(	O
25	O
%	O
)	O
and	O
V600R	O
(	O
3.9	O
%	O
)	O
.	O

There	O
was	O
a	O
wide	O
range	O
of	O
AF	O
from	O
3.9	O
%	O
to	O
80.3	O
%	O
(	O
median	O
41.3	O
%	O
)	O
.	O

In	O
33	O
patients	O
treated	O
with	O
BRAFi	O
,	O
there	O
was	O
no	O
difference	O
in	O
overall	O
or	O
progression-free	O
survival	O
when	O
the	O
patients	O
were	O
categorized	O
into	O
high	O
or	O
low	O
AF	O
groups	O
.	O

There	O
was	O
no	O
correlation	O
between	O
AF	O
and	O
degree	O
of	O
response	O
,	O
and	O
no	O
difference	O
in	O
survival	O
based	O
on	O
genotype	O
.	O

Investigating	O
Synthetic	O
Oligonucleotide	O
Targeting	O
of	O
Mir31	O
in	O
Duchenne	O
Muscular	O
Dystrophy	O
.	O

Exon-skipping	O
via	O
synthetic	O
antisense	O
oligonucleotides	O
represents	O
one	O
of	O
the	O
most	O
promising	O
potential	O
therapies	O
for	O
Duchenne	O
muscular	O
dystrophy	O
(	O
DMD	O
)	O
,	O
yet	O
this	O
approach	O
is	O
highly	O
sequence-specific	O
and	O
thus	O
each	O
oligonucleotide	O
is	O
of	O
benefit	O
to	O
only	O
a	O
subset	O
of	O
patients	O
.	O

The	O
discovery	O
that	O
dystrophin	O
mRNA	O
is	O
subject	O
to	O
translational	O
suppression	O
by	O
the	O
microRNA	O
miR31	O
,	O
and	O
that	O
miR31	O
is	O
elevated	O
in	O
the	O
muscle	O
of	O
DMD	O
patients	O
,	O
raises	O
the	O
possibility	O
that	O
the	O
same	O
oligonucleotide	O
chemistries	O
employed	O
for	O
exon	O
skipping	O
could	O
be	O
directed	O
toward	O
relieving	O
this	O
translational	O
block	O
.	O

This	O
approach	O
would	O
act	O
synergistically	O
with	O
exon	O
skipping	O
where	O
possible	O
,	O
but	O
by	O
targeting	O
the	O
3'UTR	O
it	O
would	O
further	O
be	O
of	O
benefit	O
to	O
the	O
many	O
DMD	O
patients	O
who	O
express	O
low	O
levels	O
of	O
in-frame	O
transcript	O
.	O

We	O
here	O
present	O
investigations	O
into	O
the	O
feasibility	O
of	O
combining	O
exon	O
skipping	O
with	O
several	O
different	O
strategies	O
for	O
miR31	O
-	O
modulation	O
,	O
using	O
both	O
in	O
vitro	O
models	O
and	O
the	O
mdx	O
mouse	O
(	O
the	O
classical	O
animal	O
model	O
of	O
DMD	O
)	O
,	O
and	O
monitoring	O
effects	O
on	O
dystrophin	O
at	O
the	O
transcriptional	O
and	O
translational	O
level	O
.	O

We	O
show	O
that	O
despite	O
promising	O
results	O
from	O
our	O
cell	B-P
culture	I-P
model	O
,	O
our	O
in	O
vivo	O
data	O
failed	O
to	O
demonstrate	O
similarly	O
reproducible	O
enhancement	O
of	O
dystrophin	O
translation	O
,	O
suggesting	O
that	O
miR31	O
-	O
modulation	O
may	O
not	O
be	O
practical	O
under	O
current	O
oligonucleotide	O
approaches	O
.	O

Possible	O
explanations	O
for	O
this	O
disappointing	O
outcome	O
are	O
discussed	O
,	O
along	O
with	O
suggestions	O
for	O
future	O
investigations	O
.	O

Staphylococcus	O
pseudintermedius	O
Human	O
Infection	O
Cases	O
in	O
Spain	O
:	O
Dog	O
-to-	O
Human	O
Transmission	O
.	O

Staphylococcus	O
pseudintermedius	O
is	O
an	O
opportunistic	O
pathogen	O
that	O
has	O
been	O
identified	O
as	O
infectious	O
agent	O
or	O
colonizer	O
mainly	O
in	O
dogs	O
.	O

S.	O
pseudintermedius	O
has	O
been	O
also	O
detected	O
in	O
humans	O
and	O
more	O
specifically	O
in	O
people	O
in	O
contact	O
with	O
dogs	O
.	O

In	O
this	O
study	O
,	O
the	O
possible	O
S.	O
pseudintermedius	O
pet	O
-to-	O
human	O
transmission	O
was	O
analyzed	O
in	O
four	O
clinical	O
human	O
cases	O
.	O

Two	O
patients	O
were	O
dog	O
owners	O
and	O
S.	O
pseudintermedius	O
was	O
also	O
detected	O
as	O
colonizer	O
in	O
these	O
healthy	O
animals	O
.	O

S.	O
pseudintermedius	O
isolates	O
from	O
patients	O
and	O
dogs	O
of	O
the	O
same	O
household	O
showed	O
identical	O
pulsed-field	B-P
gel	I-P
electrophoresis	I-P
patterns	O
,	O
sequence	O
types	O
(	O
STs	O
)	O
,	O
and	O
antimicrobial	O
resistance	O
phenotypes	O
and	O
genotypes	O
,	O
and	O
were	O
methicillin	O
susceptible	O
.	O

Resistance	O
to	O
erythromycin	O
,	O
clindamycin	O
,	O
tetracycline	O
,	O
trimetoprim-sulfamethoxazole	O
,	O
and/or	O
ciprofloxacin	O
was	O
identified	O
among	O
S.	O
pseudintermedius	O
strains	O
.	O

The	O
lineages	O
ST241	O
and	O
the	O
new	O
ST521	O
were	O
detected	O
in	O
the	O
strains	O
of	O
the	O
two	O
dog	O
-	O
owner	O
patients	O
,	O
respectively	O
.	O

The	O
strains	O
from	O
the	O
other	O
two	O
patients	O
presented	O
two	O
new	O
STs	O
,	O
ST719	O
and	O
ST720	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
description	O
of	O
human	O
infections	O
caused	O
by	O
S.	O
pseudintermedius	O
in	O
Spain	O
.	O

Investigation	O
on	O
evaluation	O
criteria	O
of	O
backwashing	O
effects	O
for	O
a	O
pilot-scale	O
BAF	O
treating	O
petrochemical	O
wastewater	O
.	O

Parameters	O
for	O
evaluation	O
criteria	O
of	O
air	O
-	O
water	O
backwashing	O
effect	O
s	O
of	O
a	O
pilot-scale	O
biological	O
aerated	O
filter	O
(	O
BAF	O
)	O
treating	O
petrochemical	O
wastewater	O
were	O
investigated	O
.	O

The	O
parameters	O
included	O
the	O
suspended	O
solids	O
(	O
SS	O
)	O
and	O
specific	O
oxygen	O
uptake	O
rate	O
(	O
SOUR	O
)	O
of	O
the	O
backwashing	O
effluent	O
,	O
recovery	O
of	O
the	O
BAF	O
after	O
backwashing	O
,	O
and	O
the	O
removal	O
of	O
the	O
biomass	O
/	O
bioactivity	O
attached	O
on	O
the	O
filter	O
media	O
after	O
backwashing	O
.	O

Results	O
showed	O
that	O
the	O
weight	O
of	O
the	O
total	O
sludge	O
produced	O
in	O
the	O
backwashing	O
effluent	O
increased	O
with	O
the	O
increase	O
in	O
water	O
-	O
backwashing	O
intensity	O
,	O
while	O
the	O
total	O
SOUR	O
of	O
backwashing	O
effluent	O
rose	O
notably	O
with	O
the	O
increase	O
of	O
air	O
-	O
backwashing	O
intensity	O
.	O

The	O
optimal	O
backwashing	O
intensity	O
of	O
14	O
L/	O
(	O
m	O
(	O
2	O
)	O
·s	O
)	O
for	O
air	O
and	O
4	O
L/	O
(	O
m	O
(	O
2	O
)	O
·s	O
)	O
for	O
water	O
were	O
obtained	O
.	O

When	O
the	O
BAF	O
was	O
backwashed	O
on	O
this	O
condition	O
,	O
the	O
BAF	O
recovered	O
with	O
high	O
average	O
removal	O
of	O
chemical	O
oxygen	O
demand	O
(	O
COD	O
)	O
and	O
ammonia	O
nitrogen	O
[	O
Formula	O
:	O
see	O
text	O
]	O
of	O
14.3	O
%	O
and	O
50.3	O
%	O
,	O
respectively	O
.	O

High	O
amount	O
of	O
biomass	O
removal	O
at	O
15.8	O
%	O
and	O
low	O
level	O
of	O
bioactivity	O
removal	O
at	O
8.8	O
%	O
attached	O
on	O
the	O
filter	O
media	O
were	O
also	O
found	O
.	O

Concentrations	O
of	O
the	O
benzene	O
,	O
toluene	O
,	O
ethylbenzene	O
and	O
(	O
o-	O
,	O
m-	O
,	O
p-	O
)	O
xylenes	O
(	O
BTEX	O
)	O
and	O
phenol	O
in	O
the	O
backwashed	O
sludge	O
were	O
analyzed	O
,	O
showing	O
that	O
the	O
backwashing	O
was	O
essential	O
to	O
remove	O
some	O
aromatic	O
compounds	O
adsorbed	B-P
in	O
the	O
microorganisms	O
.	O

Leprosy	O
reactions	O
:	O
The	O
predictive	O
value	O
of	O
Mycobacterium	O
leprae	O
-	O
specific	O
serology	O
evaluated	O
in	O
a	O
Brazilian	O
cohort	O
of	O
leprosy	O
patients	O
(	O
U-MDT	O
/	O
CT-BR	O
)	O
.	O

Leprosy	O
reactions	O
,	O
reversal	O
reactions	O
/	O
RR	O
and	O
erythema	O
nodosum	O
leprosum	O
/	O
ENL	O
,	O
can	O
cause	O
irreversible	O
nerve	O
damage	O
,	O
handicaps	O
and	O
deformities	O
.	O

The	O
study	O
of	O
Mycobacterium	O
leprae	O
-	O
specific	O
serologic	O
responses	O
at	O
diagnosis	O
in	O
the	O
cohort	O
of	O
patients	O
enrolled	O
at	O
the	O
Clinical	O
Trial	O
for	O
Uniform	O
Multidrug	O
Therapy	O
Regimen	O
for	O
Leprosy	O
Patients	O
in	O
Brazil	O
/	O
U-MDT	O
/	O
CT-BR	O
is	O
suitable	O
to	O
evaluate	O
its	O
prognostic	O
value	O
for	O
the	O
development	O
of	O
reactions	O
.	O

IgM	O
and	O
IgG	O
antibody	O
responses	O
to	O
PGL-I	O
,	O
LID-1	O
,	O
ND-O-LID	O
were	O
evaluated	O
by	O
ELISA	B-P
in	O
452	O
reaction-free	O
leprosy	O
patients	O
at	O
diagnosis	O
,	O
enrolled	O
and	O
monitored	O
for	O
the	O
development	O
of	O
leprosy	O
reactions	O
during	O
a	O
total	O
person	O
-	O
time	O
of	O
780,930	O
person	O
-	O
days	O
,	O
i.e	O
.	O

2139.5	O
person	O
-	O
years	O
,	O
with	O
a	O
maximum	O
of	O
6.66	O
years	O
follow-up	O
time	O
.	O

Among	O
these	O
patients	O
,	O
36	O
%	O
(	O
160/452	O
)	O
developed	O
reactions	O
during	O
follow-up	O
:	O
26	O
%	O
(	O
119/452	O
)	O
RR	O
and	O
10	O
%	O
(	O
41/452	O
)	O
had	O
ENL	O
.	O

At	O
baseline	O
higher	O
anti-PGL-I	O
,	O
anti-LID-1	O
and	O
anti-ND-O-LID	O
seropositivity	O
rates	O
were	O
seen	O
in	O
patients	O
who	O
developed	O
ENL	O
and	O
RR	O
compared	O
to	O
reaction-free	O
patients	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Seroreactivity	O
in	O
reactional	O
and	O
reaction-free	O
patients	O
was	O
stratified	O
by	O
bacilloscopic	O
index	O
/	O
BI	O
categories	O
.	O

Among	O
BI	O
negative	O
patients	O
,	O
higher	O
anti-PGL-I	O
levels	O
were	O
seen	O
in	O
RR	O
compared	O
to	O
reaction-free	O
patients	O
(	O
p	O
=	O
0.014	O
)	O
.	O

In	O
patients	O
with	O
0	O
<	O
BI	O
<	O
3	O
,	O
(	O
36	O
RR	O
,	O
36	O
reaction-free	O
)	O
,	O
higher	O
antibody	O
levels	O
to	O
PGL-I	O
(	O
p	O
=	O
0.014	O
)	O
and	O
to	O
LID-1	O
(	O
p	O
=	O
0.035	O
)	O
were	O
seen	O
in	O
RR	O
while	O
difference	O
in	O
anti-ND-O-LID	O
positivity	O
was	O
borderline	O
(	O
p	O
=	O
0.052	O
)	O
.	O

Patients	O
with	O
BI	O
≥3	O
that	O
developed	O
ENL	O
had	O
higher	O
levels	O
of	O
anti-LID-1	O
antibodies	O
(	O
p	O
=	O
0.028	O
)	O
compared	O
to	O
reaction-free	O
patients	O
.	O

Anti-PGL-I	O
serology	B-P
had	O
a	O
limited	O
predictive	O
value	O
for	O
RR	O
according	O
to	O
receiver	O
operating	O
curve	O
/	O
ROC	O
analyses	O
(	O
area-under-the-curve	O
/	O
AUC	O
=	O
0.7	O
)	O
.	O

Anti	O
LID-1	O
serology	B-P
at	O
baseline	O
showed	O
the	O
best	O
performance	O
to	O
predict	O
ENL	O
(	O
AUC	O
0.85	O
)	O
.	O

Overall	O
,	O
detection	O
of	O
anti-PGL-I	O
,	O
anti-LID-1	O
and	O
anti-ND-O-LID	O
antibodies	O
at	O
diagnosis	O
,	O
showed	O
low	O
sensitivity	O
and	O
specificity	O
for	O
RR	O
prediction	O
,	O
indicating	O
low	O
applicability	O
of	O
serological	B-P
tests	I-P
for	O
RR	O
prognosis	O
.	O

On	O
the	O
other	O
hand	O
,	O
anti-LID-1	O
serology	B-P
at	O
diagnosis	O
has	O
shown	O
prognostic	O
value	O
for	O
ENL	O
development	O
in	O
BI	O
positive	O
patients	O
.	O

ClinicalTrials.gov	O
NCT00669643	O
.	O

Fully	O
Automated	O
Lipid	O
Pool	O
Detection	O
Using	O
Near	B-P
Infrared	I-P
Spectroscopy	I-P
.	O

Background	O
.	O

Detecting	O
and	O
identifying	O
vulnerable	O
plaque	O
,	O
which	O
is	O
prone	O
to	O
rupture	O
,	O
is	O
still	O
a	O
challenge	O
for	O
cardiologist	O
.	O

Such	O
lipid	O
core	O
-containing	O
plaque	O
is	O
still	O
not	O
identifiable	O
by	O
everyday	O
angiography	B-P
,	O
thus	O
triggering	O
the	O
need	O
to	O
develop	O
a	O
new	O
tool	O
where	O
NIRS	B-P
-	O
IVUS	B-P
can	O
visualize	O
plaque	O
characterization	O
in	O
terms	O
of	O
its	O
chemical	O
and	O
morphologic	O
characteristic	O
.	O

The	O
new	O
tool	O
can	O
lead	O
to	O
the	O
development	O
of	O
new	O
methods	O
of	O
interpreting	O
the	O
newly	O
obtained	O
data	O
.	O

In	O
this	O
study	O
,	O
the	O
algorithm	O
to	O
fully	O
automated	O
lipid	O
pool	O
detection	O
on	O
NIRS	B-P
images	O
is	O
proposed	O
.	O

Method	O
.	O

Designed	O
algorithm	O
is	O
divided	O
into	O
four	O
stages	O
:	O
preprocessing	O
(	O
image	O
enhancement	O
)	O
,	O
segmentation	O
of	O
artifacts	O
,	O
detection	O
of	O
lipid	O
areas	O
,	O
and	O
calculation	O
of	O
Lipid	O
Core	O
Burden	O
Index	O
.	O

Results	O
.	O

A	O
total	O
of	O
31	O
NIRS	B-P
chemograms	B-P
were	O
analyzed	O
by	O
two	O
methods	O
.	O

The	O
metrics	O
,	O
total	O
LCBI	O
,	O
maximal	O
LCBI	O
in	O
4	O
mm	O
blocks	O
,	O
and	O
maximal	O
LCBI	O
in	O
2	O
mm	O
blocks	O
,	O
were	O
calculated	O
to	O
compare	O
presented	O
algorithm	O
with	O
commercial	O
available	O
system	O
.	O

Both	O
intraclass	O
correlation	O
(	O
ICC	O
)	O
and	O
Bland-Altman	O
plots	O
showed	O
good	O
agreement	O
and	O
correlation	O
between	O
used	O
methods	O
.	O

Conclusions	O
.	O

Proposed	O
algorithm	O
is	O
fully	O
automated	O
lipid	O
pool	O
detection	O
on	O
near	B-P
infrared	I-P
spectroscopy	I-P
images	O
.	O

It	O
is	O
a	O
tool	O
developed	O
for	O
offline	O
data	O
analysis	O
,	O
which	O
could	O
be	O
easily	O
augmented	O
for	O
newer	O
functions	O
and	O
projects	O
.	O

Characterization	O
and	O
Genomic	B-P
Analysis	I-P
of	O
a	O
Highly	O
Efficient	O
Dibutyl	O
Phthalate	O
-	O
Degrading	O
Bacterium	O
Gordonia	O
sp	O
.	O

Strain	O
QH-12	O
.	O

A	O
bacterial	O
strain	O
QH-12	O
isolated	O
from	O
activated	O
sludge	O
was	O
identified	O
as	O
Gordonia	O
sp	O
.	O

based	O
on	O
analysis	O
of	O
16S	O
rRNA	O
gene	O
sequence	O
and	O
was	O
found	O
to	O
be	O
capable	O
of	O
utilizing	O
dibutyl	O
phthalate	O
(	O
DBP	O
)	O
and	O
other	O
common	O
phthalate	O
esters	O
(	O
PAEs	O
)	O
as	O
the	O
sole	O
carbon	O
and	O
energy	O
source	O
.	O

The	O
degradation	O
kinetics	O
of	O
DBP	O
under	O
different	O
concentrations	O
by	O
the	O
strain	O
QH-12	O
fit	O
well	O
with	O
the	O
modified	O
Gompertz	O
model	O
(	O
R²	O
>	O
0.98	O
)	O
.	O

However	O
,	O
strain	O
QH-12	O
could	O
not	O
utilize	O
the	O
major	O
intermediate	O
product	O
phthalate	O
(	O
phthalic	O
acid	O
;	O
PA	O
)	O
as	O
the	O
sole	O
carbon	O
and	O
energy	O
source	O
,	O
and	O
only	O
a	O
little	O
amount	O
of	O
PA	O
was	O
detected	O
.	O

The	O
QH-12	O
genome	B-P
analysis	I-P
revealed	O
the	O
presence	O
of	O
putative	O
hydrolase	O
/	O
esterase	O
genes	O
involved	O
in	O
PAEs	O
-	O
degradation	O
but	O
no	O
phthalic	O
acid	O
catabolic	O
gene	O
cluster	O
was	O
found	O
,	O
suggesting	O
that	O
a	O
novel	O
degradation	O
pathway	O
of	O
PAEs	O
was	O
present	O
in	O
Gordonia	O
sp	O
.	O

QH-12	O
.	O

This	O
information	O
will	O
be	O
valuable	O
for	O
obtaining	O
a	O
more	O
holistic	O
understanding	O
on	O
diverse	O
genetic	O
mechanisms	O
of	O
PAEs	O
-degrading	O
Gordonia	O
sp	O
.	O

strains	O
.	O

Knee	O
joint	O
kinematics	O
with	O
dynamic	O
augmentation	O
of	O
primary	O
anterior	O
cruciate	O
ligament	O
repair	O
-	O
a	O
biomechanical	O
study	O
.	O

Dynamic	O
augmentation	O
of	O
anterior	O
cruciate	O
ligament	O
tears	O
seems	O
to	O
reduce	O
anteroposterior	O
knee	O
translation	O
close	O
to	O
the	O
pre	O
-	O
injury	O
level	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
biomechanically	O
investigate	O
the	O
course	O
of	O
translation	O
during	O
a	O
simulated	O
early	O
post-operative	O
phase	O
.	O

It	O
is	O
hypothesized	O
that	O
anteroposterior	O
translation	O
is	O
maintained	O
at	O
the	O
immediate	O
post-operative	O
level	O
over	O
a	O
simulated	O
rehabilitation	O
period	O
of	O
50'000	O
gait	O
cycles	O
.	O

Eight	O
fresh	O
-	O
frozen	O
human	O
cadaveric	O
knee	O
joints	O
from	O
donors	O
with	O
a	O
mean	O
age	O
of	O
35.5	O
(	O
range	O
25-40	O
)	O
years	O
were	O
subjected	O
to	O
50'000	O
cycles	O
of	O
0°-70°-0°	O
flexion-extension	O
movements	O
in	O
a	O
custom-made	O
test	B-P
setup	I-P
.	O

Anteroposterior	O
translation	O
was	O
assessed	O
with	O
simulated	O
Lachman/KT-1000	B-P
testing	I-P
in	O
0°	O
,	O
15°	O
,	O
30°	O
,	O
60°	O
and	O
90°	O
of	O
flexion	O
in	O
knee	O
joints	O
treated	O
with	O
the	O
novel	O
technique	O
initially	O
and	O
after	O
50'000	O
cycles	O
testing	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Wilcoxon	O
Signed-Rank	O
Test	O
.	O

The	O
level	O
of	O
significance	O
was	O
set	O
at	O
p	O
=	O
0.05	O
.	O

Anteroposterior	O
translation	O
changed	O
non	O
-	O
significantly	O
for	O
all	O
flexion	O
angles	O
between	O
cycle	O
0	O
and	O
50'000	O
(	O
p	O
=	O
0.39	O
to	O
p	O
=	O
0.89	O
)	O
,	O
except	O
for	O
30°	O
flexion	O
,	O
where	O
a	O
significant	O
increase	O
by	O
1.4	O
mm	O
was	O
found	O
(	O
p	O
=	O
0.03	O
)	O
.	O

Increase	O
in	O
anteroposterior	O
translation	O
of	O
knees	O
treated	O
with	O
this	O
dynamic	O
augmentation	O
procedure	O
is	O
low	O
.	O

The	O
procedure	O
maintains	O
translation	O
close	O
to	O
the	O
immediate	O
post-operative	O
level	O
over	O
a	O
simulated	O
rehabilitation	O
period	O
of	O
50'000	O
gait	O
cycles	O
and	O
therefore	O
supports	O
anterior	O
cruciate	O
ligament	O
repair	O
during	O
biological	O
healing	O
.	O

Annexin	O
A1	O
nuclear	O
translocation	O
induces	O
retinal	O
ganglion	O
cell	O
apoptosis	O
after	O
ischemia-reperfusion	O
injury	O
through	O
the	O
p65/IL-1β	O
pathway	O
.	O

The	O
degeneration	O
of	O
retinal	O
ganglion	O
cells	O
(	O
RGCs	O
)	O
has	O
been	O
identified	O
as	O
a	O
major	O
problem	O
in	O
glaucoma	O
.	O

Previous	O
studies	O
have	O
indicated	O
an	O
association	O
between	O
annexin	O
A1	O
(	O
ANXA1	O
)	O
and	O
neuronal	O
cell	O
apoptosis	O
,	O
and	O
RGCs	O
apoptosis	O
in	O
acute	O
ischemia-reperfusion	O
was	O
attributed	O
to	O
an	O
increased	O
production	O
of	O
IL-1β	O
.	O

We	O
found	O
that	O
the	O
expression	O
and	O
nuclear	O
translocation	O
of	O
ANXA1	O
were	O
upregulated	O
in	O
models	O
of	O
acute	O
ischemia-reperfusion	O
in	O
RGCs	O
in	O
vivo	O
.	O

ANXA1	O
was	O
found	O
to	O
have	O
a	O
promoting	O
effect	O
on	O
the	O
expression	O
of	O
IL-1β	O
in	O
primary	B-P
cultured	I-P
RGCs	O
,	O
which	O
could	O
be	O
inhibited	O
by	O
treatment	O
with	O
ANXA1	O
shRNA	O
or	O
the	O
p65	O
inhibitor	O
BAY	O
11-7082	O
.	O

ANXA1	O
interacted	O
with	O
p65	O
,	O
and	O
recruited	O
it	O
into	O
the	O
nucleus	O
.	O

Chromatin	B-P
immunoprecipitation	I-P
assay	I-P
revealed	O
that	O
ANXA1	O
accumulated	O
at	O
the	O
IL-1β	O
gene	O
promoter	O
.	O

The	O
reduction	O
of	O
p65	O
nuclear	O
translocation	O
using	O
a	O
membrane-permeable	O
ANXA1	O
peptide	O
containing	O
a	O
Ser5Ala	O
mutation	O
led	O
to	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
IL-1β	O
,	O
and	O
acute	O
ischemia-reperfusion	O
induced	O
RGCs	O
apoptosis	O
in	O
vivo	O
.	O

These	O
results	O
indicate	O
that	O
in	O
RGCs	O
,	O
ANXA1	O
increases	O
IL-1β	O
expression	O
by	O
recruiting	O
p65	O
to	O
the	O
nucleus	O
,	O
which	O
induces	O
cell	O
apoptosis	O
.	O

The	O
obtained	O
results	O
may	O
help	O
the	O
development	O
of	O
a	O
novel	O
treatment	O
strategy	O
against	O
RGCs	O
apoptosis	O
in	O
acute	O
ischemia-reperfusion	O
injury	O
.	O

The	O
anatomical	O
mummies	O
of	O
Mombello	O
:	O
detection	O
of	O
cocaine	O
,	O
nicotine	O
,	O
and	O
caffeine	O
in	O
the	O
hair	O
of	O
psychiatric	O
patients	O
of	O
the	O
early	O
20th	O
century	O
.	O

The	O
Mombello	O
Psychiatric	O
Hospital	O
in	O
Limbiate	O
,	O
near	O
Milan	O
,	O
replaced	O
the	O
old	O
Senavra	O
Hospital	O
as	O
the	O
Psychiatric	O
Hospital	O
for	O
the	O
Province	O
of	O
Milan	O
in	O
the	O
19th	O
century	O
.	O

During	O
the	O
early	O
20th	O
century	O
,	O
bodies	O
of	O
several	O
Mombello	O
patients	O
were	O
dissected	O
and	O
preserved	B-P
by	O
Giuseppe	O
Paravicini	O
,	O
an	O
anatomist	O
who	O
operated	O
within	O
the	O
asylum	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
and	O
memorialize	O
this	O
important	O
assemblage	O
.	O

To	O
this	O
end	O
,	O
we	O
were	O
allowed	O
to	O
sample	O
the	O
head	O
hair	O
of	O
six	O
such	O
preparations	O
for	O
toxicological	O
analysis	O
.	O

By	O
means	O
of	O
high	B-P
performance	I-P
liquid	I-P
chromatography	I-P
,	O
cocaine	O
and	O
its	O
main	O
metabolite	O
,	O
benzoylecgonine	O
,	O
were	O
detected	O
in	O
two	O
out	O
of	O
six	O
hair	O
samples	O
.	O

The	O
concentrations	O
for	O
cocaine	O
were	O
0.151	O
and	O
0.09ng/mg	O
and	O
for	O
benzoylecgonine	O
0.103	O
and	O
0.147ng/mg	O
,	O
respectively	O
.	O

Given	O
that	O
cocaine	O
was	O
a	O
commonly	O
used	O
medicine	O
,	O
beginning	O
in	O
the	O
mid-19th	O
century	O
and	O
persisting	O
into	O
the	O
20th	O
century	O
,	O
it	O
is	O
not	O
surprising	O
that	O
some	O
patients	O
may	O
have	O
ingested	O
this	O
drug	O
.	O

In	O
addition	O
to	O
the	O
detection	O
of	O
cocaine	O
,	O
these	O
analyses	O
also	O
provided	O
evidence	O
of	O
nicotine	O
and	O
caffeine	O
intake	O
.	O

Stem	O
cells	O
and	O
their	O
role	O
in	O
pituitary	O
tumorigenesis	O
.	O

The	O
presence	O
of	O
adult	O
pituitary	O
stem	O
cells	O
(	O
PSCs	O
)	O
has	O
been	O
described	O
in	O
murine	O
systems	O
by	O
comprehensive	O
cellular	O
profiling	O
and	O
genetic	O
lineage	O
tracing	O
experiments	O
.	O

PSCs	O
are	O
thought	O
to	O
maintain	O
multipotent	O
capacity	O
throughout	O
life	O
and	O
give	O
rise	O
to	O
all	O
hormone	O
-producing	O
cell	O
lineages	O
,	O
playing	O
a	O
role	O
in	O
pituitary	O
gland	O
homeostasis	O
.	O

Additionally	O
,	O
PSCs	O
have	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
pituitary	O
tumorigenesis	O
,	O
in	O
both	O
adenomas	O
and	O
adamantinomatous	O
craniopharyngiomas	O
.	O

In	O
this	O
manuscript	O
,	O
we	O
discuss	O
the	O
different	O
approaches	O
used	O
to	O
demonstrate	O
the	O
presence	O
of	O
PSCs	O
in	O
the	O
murine	O
adult	O
pituitary	O
,	O
from	O
marker	B-P
analyses	I-P
to	O
genetic	B-P
tracing	I-P
.	O

In	O
addition	O
,	O
we	O
review	O
the	O
published	O
literature	O
suggesting	O
the	O
existence	O
of	O
tumor	O
stem	O
cells	O
in	O
mouse	O
and	O
human	O
pituitary	O
tumors	O
.	O

Finally	O
,	O
we	O
discuss	O
the	O
potential	O
role	O
of	O
PSCs	O
in	O
pituitary	O
tumorigenesis	O
in	O
the	O
context	O
of	O
current	O
models	O
of	O
carcinogenesis	O
and	O
present	O
evidence	O
showing	O
that	O
in	O
contrast	O
to	O
pituitary	O
adenoma	O
,	O
which	O
follows	O
a	O
classical	O
cancer	O
stem	O
cell	O
paradigm	O
,	O
a	O
novel	O
mechanism	O
has	O
been	O
revealed	O
for	O
paracrine	O
,	O
non-cell	O
autonomous	O
tumor	O
initiation	O
in	O
adamantinomatous	O
craniopharyngioma	O
,	O
a	O
benign	O
but	O
clinically	O
aggressive	O
pediatric	O
tumor	O
.	O

Long-term	O
outcomes	O
of	O
stereotactic	O
body	O
radiation	O
therapy	O
(	O
SBRT	O
)	O
with	O
fiducial	O
tracking	O
for	O
inoperable	O
stage	O
I	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

Stereotactic	O
body	O
radiation	O
therapy	O
(	O
SBRT	O
)	O
for	O
stage	O
I	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
is	O
considered	O
standard	O
of	O
care	O
in	O
the	O
medically	O
inoperable	O
patient	O
population	O
.	O

Multiple	O
methods	O
of	O
SBRT	O
delivery	O
exist	O
including	O
fiducial	O
-based	O
tumor	O
tracking	O
,	O
which	O
allows	O
for	O
smaller	O
treatment	O
margins	O
and	O
avoidance	O
of	O
patient	O
immobilization	O
devices	O
.	O

We	O
explore	O
the	O
long-term	O
clinical	O
outcomes	O
of	O
this	O
novel	O
fiducial	O
-based	O
SBRT	O
method	O
.	O

In	O
this	O
single	O
institutional	O
retrospective	O
review	O
,	O
we	O
detail	O
the	O
outcomes	O
of	O
medically	O
inoperable	O
pathologically	O
confirmed	O
stage	O
I	O
NSCLC	O
.	O

Patients	O
were	O
treated	O
with	O
the	O
Cyberknife	O
SBRT	O
system	O
using	O
a	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
defined	O
as	O
a	O
5-mm	O
expansion	O
from	O
gross	O
tumor	O
volume	O
(	O
GTV	O
)	O
without	O
creation	O
of	O
an	O
internal	O
target	O
volume	O
(	O
ITV	O
)	O
.	O

Dose	O
was	O
delivered	O
in	O
three	O
or	O
five	O
equal	O
fractions	O
of	O
10	O
to	O
20	O
Gy	O
.	O

Pretreatment	O
and	O
posttreatment	O
pulmonary	B-P
function	I-P
test	I-P
(	O
PFT	B-P
)	O
changes	O
and	O
evidence	O
of	O
late	O
radiological	B-P
rib	O
fractures	O
were	O
analyzed	O
for	O
the	O
majority	O
of	O
patients	O
.	O

Actuarial	O
local	O
control	O
,	O
locoregional	O
control	O
,	O
distant	O
control	O
,	O
and	O
overall	O
survival	O
were	O
calculated	O
using	O
the	O
Kaplan-Meier	O
method	O
.	O

Sixty-one	O
patients	O
with	O
a	O
median	O
age	O
of	O
75	O
years	O
were	O
available	O
for	O
analysis	O
.	O

The	O
majority	O
(	O
80	O
%	O
)	O
of	O
patients	O
were	O
deemed	O
to	O
be	O
medically	O
inoperable	O
due	O
to	O
underlying	O
pulmonary	O
dysfunction	O
.	O

Eleven	O
patients	O
(	O
18	O
%	O
)	O
developed	O
symptomatic	O
pneumothoraces	O
secondary	O
to	O
fiducial	O
placement	O
under	O
CT	B-P
guidance	I-P
,	O
which	O
precipitously	O
dropped	O
to	O
0	O
%	O
following	O
transition	O
to	O
bronchoscopic	O
fiducial	O
placement	O
.	O

The	O
2-year	O
rib	O
fracture	O
risk	O
was	O
21.4	O
%	O
with	O
a	O
median	O
time	O
to	O
rib	O
fracture	O
of	O
2.9	O
years	O
.	O

PFTs	B-P
averaged	O
over	O
all	O
patients	O
and	O
parameters	O
demonstrated	O
small	O
absolute	O
declines	O
,	O
5.7	O
%	O
averaged	O
PFT	B-P
decline	O
,	O
at	O
approximately	O
1	O
year	O
of	O
follow-up	O
,	O
but	O
only	O
the	O
diffusing	O
capacity	O
of	O
lung	O
for	O
carbon	O
monoxide	O
(	O
DLCO	O
)	O
demonstrated	O
a	O
statistically	O
significant	O
decline	O
(	O
10.29	O
vs.	O
9.01	O
mL/min/mmHg	O
,	O
p	O
=	O
0.01	O
)	O
.	O

Five-year	O
local	O
control	O
,	O
locoregional	O
control	O
,	O
and	O
overall	O
surviva	O
l	O
were	O
87.6	O
,	O
71.8	O
,	O
and	O
39.3	O
%	O
,	O
respectively	O
.	O

Despite	O
reduced	O
treatment	O
margins	O
and	O
lack	O
of	O
patient	O
immobilization	O
,	O
SBRT	O
with	O
fiducial	O
-based	O
tumor	O
tracking	O
achieves	O
clinically	O
comparable	O
long-term	O
outcomes	O
to	O
other	O
linac	O
-based	O
SBRT	O
approaches	O
.	O

Can	O
diaphragmatic	B-P
ultrasonography	I-P
performed	O
during	O
the	O
T-tube	O
trial	O
predict	O
weaning	O
failure	O
?	O

The	O
role	O
of	O
diaphragmatic	O
rapid	O
shallow	O
breathing	O
index	O
.	O

The	O
rapid	O
shallow	O
breathing	O
index	O
(	O
RSBI	O
)	O
,	O
which	O
is	O
the	O
ratio	O
between	O
respiratory	O
rate	O
(	O
RR	O
)	O
and	O
tidal	O
volume	O
(	O
VT	O
)	O
,	O
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
indices	O
to	O
predict	O
weaning	O
outcome	O
.	O

Whereas	O
the	O
diaphragm	O
plays	O
a	O
fundamental	O
role	O
in	O
generating	O
VT	O
,	O
in	O
the	O
case	O
of	O
diaphragmatic	O
dysfunction	O
the	O
inspiratory	O
accessory	O
muscles	O
may	O
contribute	O
.	O

If	O
this	O
occurs	O
during	O
a	O
weaning	O
trial	O
,	O
delayed	O
weaning	O
failure	O
is	O
likely	O
since	O
the	O
accessory	O
muscles	O
are	O
more	O
fatigable	O
than	O
the	O
diaphragm	O
.	O

Hence	O
,	O
we	O
hypothesised	O
that	O
the	O
traditional	O
RSBI	O
could	O
be	O
implemented	O
by	O
substituting	O
VT	O
with	O
the	O
ultrasonographic	B-P
evaluation	I-P
of	O
diaphragmatic	O
displacement	O
(	O
DD	O
)	O
.	O

We	O
named	O
the	O
new	O
index	O
the	O
diaphragmatic	O
-	O
RSBI	O
(	O
D	O
-	O
RSBI	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
ability	O
of	O
the	O
traditional	O
RSBI	O
and	O
D	O
-	O
RSBI	O
to	O
predict	O
weaning	O
failure	O
in	O
ready-to-wean	O
patients	O
.	O

We	O
performed	O
a	O
prospective	O
observational	O
study	O
.	O

During	O
a	O
T-tube	O
spontaneous	O
breathing	O
trial	O
(	O
SBT	O
)	O
we	O
simultaneously	O
evaluated	O
right	O
hemidiaphragm	O
displacement	O
(	O
i.e.	O
,	O
DD	O
)	O
by	O
using	O
M-mode	B-P
ultrasonography	I-P
as	O
well	O
as	O
the	O
RSBI	O
.	O

Outcome	O
of	O
the	O
weaning	O
attempt	O
,	O
length	O
of	O
mechanical	O
ventilation	O
,	O
length	O
of	O
intensive	O
care	O
unit	O
and	O
hospital	O
stay	O
,	O
and	O
hospital	O
mortality	O
were	O
recorded	O
.	O

Receiver	O
operator	O
characteristic	O
(	O
ROC	O
)	O
curves	O
were	O
used	O
to	O
evaluate	O
the	O
diagnostic	O
accuracy	O
of	O
D	O
-	O
RSBI	O
and	O
RSBI	O
.	O

We	O
enrolled	O
51	O
patients	O
requiring	O
mechanical	O
ventilation	O
for	O
more	O
than	O
48	O
h	O
who	O
were	O
ready	O
to	O
perform	O
a	O
SBT	O
.	O

Most	O
of	O
the	O
patients	O
,	O
34	O
(	O
66	O
%	O
)	O
,	O
were	O
successfully	O
weaned	O
from	O
mechanical	O
ventilation	O
.	O

When	O
considering	O
the	O
17	O
patients	O
that	O
failed	O
the	O
weaning	O
attempt	O
,	O
11	O
(	O
64	O
%	O
)	O
had	O
to	O
be	O
reconnected	O
to	O
the	O
ventilator	O
during	O
the	O
SBT	O
,	O
three	O
(	O
18	O
%	O
)	O
had	O
to	O
be	O
re-intubated	O
within	O
48	O
h	O
of	O
extubation	O
,	O
and	O
three	O
(	O
18	O
%	O
)	O
required	O
non-invasive	O
ventilation	O
support	O
within	O
48	O
h	O
of	O
extubation	O
.	O

The	O
areas	O
under	O
the	O
ROC	O
curves	O
for	O
D	O
-	O
RSBI	O
and	O
RSBI	O
were	O
0.89	O
and	O
0.72	O
,	O
respectively	O
(	O
P	O
=	O
0.006	O
)	O
.	O

D	O
-	O
RSBI	O
(	O
RR	O
/	O
DD	O
)	O
was	O
more	O
accurate	O
than	O
traditional	O
RSBI	O
(	O
RR	O
/	O
VT	O
)	O
in	O
predicting	O
the	O
weaning	O
outcome	O
.	O

Our	O
clinical	O
trial	O
was	O
retrospectively	O
registered	O
with	O
ClinicalTrials.gov	O
(	O
identifier	O
:	O
NCT02696018	O
)	O
.	O

ClinicalTrials.gov	O
processed	O
our	O
record	O
on	O
25	O
February	O
2016	O
.	O

Molecular	O
mechanisms	O
of	O
thermal	O
resistance	O
of	O
the	O
insect	O
trypanosomatid	O
Crithidia	O
thermophila	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
molecular	O
mechanisms	O
governing	O
thermal	O
resistance	O
of	O
a	O
monoxenous	O
trypanosomatid	O
Crithidia	O
luciliae	O
thermophila	O
,	O
which	O
we	O
reclassified	O
as	O
a	O
separate	O
species	O
C.	O
thermophila	O
.	O

We	O
analyzed	O
morphology	O
,	O
growth	O
kinetics	O
,	O
and	O
transcriptomic	O
profiles	O
of	O
flagellates	O
cultivated	O
at	O
low	O
(	O
23°C	O
)	O
and	O
elevated	O
(	O
34°C	O
)	O
temperature	O
.	O

When	O
maintained	O
at	O
high	O
temperature	O
,	O
they	O
grew	O
significantly	O
faster	O
,	O
became	O
shorter	O
,	O
with	O
genes	O
involved	O
in	O
sugar	B-P
metabolism	I-P
and	O
mitochondrial	O
stress	O
protection	O
significantly	O
upregulated	O
.	O

Comparison	O
with	O
another	O
thermoresistant	O
monoxenous	O
trypanosomatid	O
,	O
Leptomonas	O
seymouri	O
,	O
revealed	O
dramatic	O
differences	O
in	O
transcription	O
profiles	O
of	O
the	O
two	O
species	O
with	O
only	O
few	O
genes	O
showing	O
the	O
same	O
expression	O
pattern	O
.	O

This	O
disparity	O
illustrates	O
differences	O
in	O
the	O
biology	O
of	O
these	O
two	O
parasites	O
and	O
distinct	O
mechanisms	O
of	O
their	O
thermotolerance	O
,	O
a	O
prerequisite	O
for	O
living	O
in	O
warm-blooded	O
vertebrates	O
.	O

Novel	O
High-grade	O
Endometrial	O
Stromal	O
Sarcoma	O
:	O
A	O
Morphologic	O
Mimicker	O
of	O
Myxoid	O
Leiomyosarcoma	O
.	O

Endometrial	O
stromal	O
sarcomas	O
(	O
ESS	O
)	O
are	O
often	O
underpinned	O
by	O
recurrent	O
chromosomal	O
translocations	O
resulting	O
in	O
the	O
fusion	O
of	O
genes	O
involved	O
in	O
epigenetic	O
regulation	O
.	O

To	O
date	O
,	O
only	O
YWHAE-NUTM2	O
rearrangements	O
are	O
associated	O
with	O
distinctive	O
high-grade	O
morphology	O
and	O
aggressive	O
clinical	O
behavior	O
.	O

We	O
identified	O
3	O
ESS	O
morphologically	O
mimicking	O
myxoid	O
leiomyosarcoma	O
of	O
the	O
uterus	O
and	O
sought	O
to	O
describe	O
their	O
unique	O
histopathologic	O
features	O
and	O
identify	O
genetic	O
alterations	O
using	O
next-generation	O
sequencing	O
.	O

All	O
cases	O
displayed	O
predominantly	O
spindled	O
cells	O
associated	O
with	O
abundant	O
myxoid	O
stroma	O
and	O
brisk	O
mitotic	O
activity	O
.	O

Tumors	O
involved	O
the	O
endometrium	O
and	O
demonstrated	O
tongue-like	O
myometrial	O
infiltration	O
.	O

All	O
3	O
were	O
associated	O
with	O
an	O
aggressive	O
clinical	O
course	O
,	O
including	O
multisite	O
bony	O
metastases	O
in	O
1	O
patient	O
,	O
progressive	O
peritoneal	O
disease	O
after	O
chemotherapy	O
in	O
another	O
,	O
and	O
metastases	O
to	O
the	O
lung	O
and	O
skin	O
in	O
the	O
last	O
patient	O
.	O

All	O
3	O
ESS	O
were	O
found	O
to	O
harbor	O
ZC3H7B	O
-	O
BCOR	O
gene	O
fusions	O
by	O
targeted	B-P
sequencing	I-P
and	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

On	O
the	O
basis	O
of	O
the	O
review	O
of	O
these	O
cases	O
,	O
we	O
find	O
that	O
ESS	O
with	O
ZC3H7B	O
-	O
BCOR	O
fusion	O
constitutes	O
a	O
novel	O
type	O
of	O
high-grade	O
ESS	O
and	O
shares	O
significant	O
morphologic	O
overlap	O
with	O
myxoid	O
leiomyosarcoma	O
.	O

Association	O
of	O
vitamin	O
D	O
deficiency	O
with	O
poor	O
glycaemic	O
control	O
in	O
diabetic	O
patients	O
.	O

An	O
association	O
between	O
serum	B-P
levels	I-P
of	I-P
vitamin	I-P
D	I-P
and	O
glycaemic	O
control	O
in	O
type-2	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
patients	O
has	O
been	O
reported	O
in	O
some	O
of	O
the	O
studies	O
carried	O
out	O
in	O
the	O
West	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
on	O
this	O
relationship	O
in	O
Pakistani	O
diabetic	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
ascertain	O
whether	O
vitamin	B-P
D	I-P
levels	I-P
have	O
any	O
influence	O
on	O
glycaemic	O
control	O
in	O
Pakistani	O
patients	O
with	O
type-2	O
DM	O
.	O

In	O
a	O
cross-sectional	O
survey	O
,	O
relationship	O
between	O
serum	O
levels	B-P
of	I-P
25-hydroxy	I-P
vitamin	I-P
D	I-P
(	O
25	O
(	O
OH	O
)	O
D	O
)	O
and	O
glycated	B-P
haemoglobin	I-P
(	O
HbA1C	O
)	O
was	O
examined	O
in	O
141	O
type-2	O
diabetic	O
patients	O
including	O
102	O
males	O
and	O
39	O
females	O
;	O
age	O
range	O
22	O
to	O
70	O
years	O
,	O
visiting	O
the	O
Aga	O
Khan	O
University	O
Hospital	O
during	O
July	O
2013-	O
April	O
2014	O
.	O

Venous	O
blood	O
was	O
collected	O
and	O
analyzed	O
for	O
serum	O
/	O
plasma	O
levels	B-P
of	I-P
25	I-P
(	I-P
OH	I-P
)	I-P
D	I-P
and	O
related	O
biomarkers	O
using	O
kit	B-P
methods	I-P
.	O

HbA1C	B-P
levels	I-P
<	O
7.0	O
%	O
and	O
>	O
7.0	O
%	O
were	O
taken	O
as	O
indicators	O
of	O
good	O
and	O
poor	O
glycaemic	O
control	O
,	O
respectively	O
.	O

An	O
association	O
between	O
25	O
(	O
OH	O
)	O
D	O
and	O
HbA1C	O
was	O
investigated	O
using	O
regression	O
analysis	O
.	O

Percent	O
vitamin	O
D	O
deficiency	O
(	O
serum	O
level	B-P
of	I-P
25	I-P
(	I-P
OH	I-P
)	I-P
D	I-P
<	O
20	O
ng/ml	O
)	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
poor	O
glycaemic	O
control	O
compared	O
to	O
patients	O
with	O
good	O
glycaemic	O
control	O
(	O
58.7	O
%	O
vs.	O
30.6	O
%	O
;	O
p-value=0.006	O
)	O
.	O

Binary	O
logistic	O
regression	O
analysis	O
revealed	O
positive	O
association	O
between	O
vitamin	O
D	O
deficiency	O
and	O
poor	O
glycaemic	O
control	O
while	O
adjusting	O
for	O
BMI	O
,	O
serum	O
levels	O
of	O
albumin	O
,	O
alanine	B-P
aminotransferase	I-P
and	O
alkaline	B-P
phosphatase	I-P
(	O
OR	O
,	O
4.86	O
(	O
95	O
%	O
CI	O
,	O
1.9-11.9	O
;	O
p-value	O
<	O
0.001	O
)	O
.	O

The	O
association	O
between	O
vitamin	O
D	O
deficiency	O
and	O
abnormal	O
HbA1C	O
in	O
Pakistani	O
diabetic	O
patients	O
is	O
suggestive	O
that	O
patients	O
with	O
hypovitaminosis	O
D	O
could	O
benefit	O
from	O
vitamin	O
D	O
supplementation	O
.	O

Generation	O
of	O
a	O
Three-Dimensional	O
Retinal	O
Tissue	O
from	O
Self-Organizing	O
Human	O
ESC	O
Culture	O
.	O

A	O
three-dimensional	O
(	O
3D	O
)	O
tissue	O
generated	O
in	O
vitro	O
is	O
a	O
promising	O
source	O
to	O
study	O
developmental	O
biology	O
and	O
regenerative	O
medicine	O
.	O

In	O
the	O
last	O
decade	O
,	O
Yoshiki	O
Sasai	O
's	O
group	O
have	O
developed	O
a	O
3D	O
stem	O
cell	O
culture	B-P
technique	I-P
known	O
as	O
SFEBq	B-P
and	O
demonstrated	O
that	O
embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
have	O
an	O
ability	O
to	O
self-organize	O
stratified	O
neural	O
tissue	O
including	O
3D	O
-	O
retina	O
.	O

Furthermore	O
,	O
we	O
have	O
reported	O
that	O
ESC-derived	O
retinal	O
tissue	O
can	O
form	O
an	O
optic	O
cup	O
and	O
a	O
ciliary	O
margin	O
,	O
which	O
are	O
unique	O
structures	O
in	O
the	O
developing	O
retina	O
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
self-organizing	O
culture	B-P
technique	I-P
to	O
generate	O
3D	O
-	O
retina	O
from	O
human	O
ESCs	O
.	O

Atorvastatin	O
-induced	O
dermatomyositis	O
.	O

A	O
49-year-	O
old	O
man	O
with	O
no	O
previous	O
history	O
of	O
musculoskeletal	O
or	O
cutaneous	O
problems	O
who	O
had	O
a	O
myocardial	O
infarction	O
(	O
MI	O
)	O
was	O
treated	O
with	O
atorvastatin	O
,	O
prasugrel	O
,	O
enoxaparine	O
,	O
and	O
diltiazem	O
following	O
percutaneous	O
coronary	O
intervention	O
.	O

He	O
was	O
referred	O
to	O
our	O
rheumatology	O
outpatient	O
clinic	O
for	O
rash	O
and	O
papules	O
on	O
the	O
knuckles	O
,	O
face	O
,	O
and	O
neck	O
,	O
as	O
well	O
as	O
proximal	O
muscle	O
weakness	O
.	O

In	O
the	O
physical	O
examination	O
,	O
a	O
reddish	O
rash	O
on	O
the	O
face	O
and	O
Gottron	O
's	O
papules	O
on	O
the	O
knuckles	O
were	O
detected	O
.	O

The	O
skin	B-P
biopsy	I-P
performed	O
indicated	O
interface	O
dermatitis	O
with	O
hydropic	O
degeneration	O
of	O
basal	O
keratinocytes	O
,	O
supporting	O
the	O
clinical	O
impression	O
of	O
dermatomyositis	O
.	O

He	O
was	O
started	O
on	O
prednisolone	O
1	O
mg/kg/day	O
.	O

After	O
30	O
days	O
of	O
prednisolone	O
therapy	O
,	O
all	O
symptoms	O
disappeared	O
.	O

High	O
molecular	O
weight	O
PEGylation	O
of	O
human	O
pancreatic	O
polypeptide	O
at	O
position	O
22	O
improves	O
stability	O
and	O
reduces	O
food	O
intake	O
in	O
mice	O
.	O

Human	O
pancreatic	O
polypeptide	O
(	O
hPP	O
)	O
is	O
known	O
to	O
suppress	O
appetite	O
and	O
food	O
intake	O
,	O
thereby	O
representing	O
a	O
potential	O
therapeutic	O
approach	O
against	O
obesity	O
and	O
associated	O
metabolic	O
disorders	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
improve	O
hPP	O
stability	O
by	O
covalent	O
PEGylation	O
with	O
diverse	O
molecular	O
weight	O
polyethylene	O
glycols	O
(	O
PEGs	O
)	O
at	O
two	O
positions	O
using	O
promising	O
lead	O
structures	O
while	O
maintaining	O
target	O
activity	O
.	O

Modified	O
peptides	O
were	O
synthesized	O
by	O
combined	O
solid-phase	O
and	O
solution-phase	O
peptide	O
synthesis	O
.	O

Their	O
potency	O
was	O
investigated	O
in	O
constitutively	O
expressing	O
human	O
epithelial	O
cells	O
and	O
isolated	O
human	O
colonic	O
mucosa	O
as	O
well	O
as	O
receptor-transfected	O
artificial	O
cell	O
lines	O
.	O

Human	O
blood	O
plasma	O
and	O
porcine	O
liver	O
homogenates	O
were	O
used	O
to	O
examine	O
the	O
in	O
vitro	O
stability	O
of	O
the	O
analogues	O
.	O

The	O
most	O
promising	O
variants	O
were	O
injected	O
s.c.	O
in	O
C57BL/6JRj	O
mice	O
to	O
monitor	O
fasting-induced	O
food	O
intake	O
and	O
bioavailability	O
.	O

In	O
human	O
epithelia	O
and	O
colonic	O
mucosal	O
preparations	O
,	O
activity	O
of	O
the	O
modified	O
hPP	O
peptides	O
depended	O
on	O
the	O
core	O
sequence	O
and	O
latency	O
of	O
the	O
peptides	O
was	O
related	O
to	O
PEG	O
size	O
.	O

Peptides	O
modified	O
with	O
a	O
22	O
kDa	O
PEG	O
(	O
PEG22	O
)	O
remained	O
intact	O
in	O
blood	O
plasma	O
and	O
on	O
incubation	B-P
with	O
liver	O
homogenates	O
for	O
more	O
than	O
96	O
h.	O
Finally	O
,	O
hPP2-36	O
,	O
[	O
K	O
(	O
22	O
)	O
(	O
PEG22	O
)	O
]	O
hPP2-36	O
and	O
[	O
K	O
(	O
22	O
)	O
(	O
PEG22	O
)	O
,	O
Q	O
(	O
34	O
)	O
]	O
hPP	O
significantly	O
reduced	O
cumulative	O
food	O
intake	O
in	O
mice	O
over	O
16	O
h	O
after	O
s.c.	O
administration	O
.	O

Modification	O
with	O
PEG22	O
at	O
position	O
22	O
stabilizes	O
hPP	O
significantly	O
while	O
extending	O
its	O
biological	O
activities	O
and	O
could	O
be	O
used	O
in	O
drug	O
development	O
prospectively	O
.	O

Hip	O
segmentation	O
from	O
MRI	B-P
volumes	O
in	O
infants	O
for	O
DDH	O
diagnosis	O
and	O
treatment	O
planning	O
.	O

Diagnosis	O
and	O
surgical	O
management	O
of	O
Developmental	O
Dysplasia	O
of	O
the	O
Hip	O
(	O
DDH	O
)	O
relies	O
on	O
physical	O
examination	O
and	O
2D	O
ultrasound	B-P
scanning	I-P
.	O

Magnetic	B-P
Resonance	I-P
Imaging	I-P
(	O
MRI	B-P
)	O
can	O
be	O
used	O
to	O
complement	O
existing	O
techniques	O
and	O
could	O
be	O
advantageous	O
in	O
treatment	O
planning	O
due	O
to	O
its	O
larger	O
field	O
of	O
view	O
.	O

In	O
this	O
paper	O
we	O
propose	O
a	O
semi-automatic	O
method	O
to	O
segment	O
surface	O
models	O
of	O
the	O
acetabulum	O
from	O
MRI	B-P
images	O
.	O

The	O
method	O
incorporates	O
clinical	O
knowledge	O
in	O
the	O
form	O
of	O
intensity	O
priors	O
which	O
are	O
integrated	O
into	O
a	O
Random	O
Walker	O
(	O
RW	O
)	O
formulation	O
.	O

We	O
use	O
a	O
modified	O
RW	O
framework	O
which	O
compensates	O
for	O
incomplete	O
or	O
blurred	O
boundaries	O
in	O
the	O
image	O
by	O
using	O
information	O
from	O
neighboring	O
slices	O
in	O
the	O
sequence	O
incorporated	O
as	O
node	O
weights	O
.	O

We	O
conducted	O
a	O
pilot	O
study	O
to	O
evaluate	O
the	O
segmentation	O
on	O
a	O
set	O
of	O
10	O
infant	O
hip	O
MRI	B-P
sequences	O
using	O
a	O
1.5	O
Tesla	O
MR	O
scanner	O
.	O

Contours	O
obtained	O
from	O
the	O
semi-automated	O
segmentation	O
were	O
compared	O
against	O
manually	O
segmented	O
hip	O
contours	O
using	O
Dice	O
Ratio	O
(	O
DR	O
)	O
,	O
Hausdorff	O
Distance	O
(	O
HD	O
)	O
and	O
Root	O
Mean	O
Square	O
(	O
RMS	O
)	O
distance	O
.	O

The	O
proposed	O
method	O
gave	O
values	O
of	O
(	O
DR	O
=	O
0.84	O
±	O
0.5	O
,	O
HD	O
=3.0	O
±	O
0.7	O
,	O
RMS	O
=1.9	O
±	O
0.3	O
)	O
and	O
(	O
DR	O
=0.86	O
±	O
0.2	O
,	O
HD	O
=3.0	O
±	O
0.1	O
,	O
RMS	O
=	O
2.0	O
±	O
0.6	O
)	O
for	O
right	O
and	O
left	O
acetabular	O
contours	O
respectively	O
which	O
was	O
higher	O
than	O
the	O
corresponding	O
values	O
obtained	O
from	O
conventional	O
RW	O
segmentation	O
.	O

The	O
execution	O
time	O
of	O
the	O
segmentation	O
algorithm	O
was	O
less	O
than	O
~4	O
seconds	O
on	O
a	O
3.5	O
GHz	O
CPU	O
.	O

Enzymatic	O
biosynthesis	O
of	O
novel	O
neobavaisoflavone	O
glucosides	O
via	O
Bacillus	O
UDP	O
-	O
glycosyltransferase	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
perform	O
structural	O
modifications	O
of	O
of	O
neobavaisoflavone	O
(	O
NBIF	O
)	O
,	O
using	O
an	O
in	O
vitro	O
enzymatic	O
glycosylation	O
reaction	O
,	O
in	O
order	O
to	O
improve	O
its	O
water-solubility	O
.	O

Two	O
novel	O
glucosides	O
of	O
NBIF	O
were	O
obtained	O
from	O
an	O
enzymatic	O
glycosylation	O
by	O
UDP	O
-	O
glycosyltransferase	O
.	O

The	O
glycosylated	O
products	O
were	O
elucidated	O
by	O
LC-MS	B-P
,	O
HR-ESI-MS	B-P
,	O
and	O
NMR	O
analysis	O
.	O

The	O
HPLC	B-P
peaks	O
were	O
integrated	O
and	O
the	O
concentrations	O
in	O
sample	O
solutions	O
were	O
calculated	O
.	O

The	O
MTT	B-P
assay	I-P
was	O
used	O
to	O
detect	O
the	O
cytotoxic	O
activity	O
of	O
compounds	O
in	O
cancer	O
cell	O
lines	O
.	O

Based	O
on	O
the	O
spectroscopic	O
analyses	O
,	O
the	O
two	O
novel	O
glucosides	O
were	O
identified	O
as	O
neobavaisoflavone-4'-O-β-D-glucopyranoside	O
(	O
1	O
)	O
and	O
neobavaisoflavone-4	O
'	O
,	O
7-di-O-β-D-glucopyranoside	O
(	O
2	O
)	O
.	O

Additionally	O
,	O
the	O
water-solubilities	O
of	O
compounds	O
1	O
and	O
2	O
were	O
approximately	O
175.1-	O
and	O
4	O
031.9-fold	O
higher	O
than	O
that	O
of	O
the	O
substrate	O
,	O
respectively	O
.	O

Among	O
the	O
test	O
compounds	O
,	O
only	O
NBIF	O
exhibited	O
weak	O
cytotoxicity	O
against	O
four	O
human	O
cancer	O
cell	O
lines	O
,	O
with	O
IC50	O
values	O
ranging	O
from	O
63.47	O
to	O
72.81	O
µmol·L	O
(	O
-1	O
)	O
.	O

These	O
results	O
suggest	O
that	O
in	O
vitro	O
enzymatic	O
glycosylation	O
is	O
a	O
powerful	O
approach	O
to	O
structural	O
modification	O
,	O
improving	O
water-solubility	O
.	O

Gastrointestinal	O
disorders	O
in	O
Curry-Jones	O
syndrome	O
:	O
Clinical	O
and	O
molecular	O
insights	O
from	O
an	O
affected	O
newborn	O
.	O

Curry-Jones	O
syndrome	O
(	O
CJS	O
)	O
is	O
a	O
pattern	O
of	O
malformation	O
that	O
includes	O
craniosynostosis	O
,	O
pre-axial	O
polysyndactyly	O
,	O
agenesis	O
of	O
the	O
corpus	O
callosum	O
,	O
cutaneous	O
and	O
gastrointestinal	O
abnormalities	O
.	O

A	O
recurrent	O
,	O
mosaic	O
mutation	O
of	O
SMO	O
(	O
c.1234	O
C	O
>	O
T	O
;	O
p.Leu412Phe	O
)	O
causes	O
CJS	O
.	O

This	O
report	O
describes	O
the	O
gastrointestinal	O
and	O
surgical	O
findings	O
in	O
a	O
baby	O
with	O
CJS	O
who	O
presented	O
with	O
abdominal	O
obstruction	O
and	O
reviews	O
the	O
spectrum	O
of	O
gastrointestinal	O
malformations	O
in	O
this	O
rare	O
disorder	O
.	O

A	O
41-	O
week	O
,	O
4,165	O
g	O
,	O
female	O
presented	O
with	O
craniosynostosis	O
,	O
pre-axial	O
polysyndactyly	O
,	O
and	O
cutaneous	O
findings	O
consistent	O
with	O
a	O
clinical	B-P
diagnosis	I-P
of	O
CJS	O
.	O

The	O
infant	O
developed	O
abdominal	O
distension	O
beginning	O
on	O
the	O
second	O
day	O
of	O
life	O
.	O

Surgical	B-P
exploration	I-P
revealed	O
an	O
intestinal	O
malrotation	O
for	O
which	O
she	O
underwent	O
a	O
Ladd	O
procedure	O
.	O

Multiple	O
small	O
nodules	O
were	O
found	O
on	O
the	O
surface	O
of	O
the	O
small	O
and	O
large	O
bowel	O
in	O
addition	O
to	O
an	O
apparent	O
intestinal	O
duplication	O
that	O
seemed	O
to	O
originate	O
posterior	O
to	O
the	O
pancreas	O
.	O

Histopathology	O
of	O
serosal	O
nodules	O
revealed	O
bundles	O
of	O
smooth	O
muscle	O
with	O
associated	O
ganglion	O
cells	O
.	O

Molecular	O
analysis	O
demonstrated	O
the	O
SMO	O
c.1234	O
C	O
>	O
T	O
mutation	O
in	O
varying	O
amounts	O
in	O
affected	O
skin	O
(	O
up	O
to	O
35	O
%	O
)	O
and	O
intestinal	O
hamartoma	O
(	O
26	O
%	O
)	O
.	O

Gastrointestinal	O
features	O
including	O
structural	O
malformations	O
,	O
motility	O
disorders	O
,	O
and	O
upper	O
GI	O
bleeding	O
are	O
major	O
causes	O
of	O
morbidity	O
in	O
CJS	O
.	O

Smooth	O
muscle	O
hamartomas	O
are	O
a	O
recognized	O
feature	O
of	O
children	O
with	O
CJS	O
typically	O
presenting	O
with	O
abdominal	O
obstruction	O
requiring	O
surgical	O
intervention	O
.	O

A	O
somatic	O
mutation	O
in	O
SMO	O
likely	O
accounts	O
for	O
the	O
structural	O
malformations	O
and	O
predisposition	O
to	O
form	O
bowel	O
hamartomas	O
and	O
myofibromas	O
.	O

The	O
mutation	O
burden	O
in	O
the	O
involved	O
tissues	O
likely	O
accounts	O
for	O
the	O
variable	O
manifestations	O
.	O

Dominant	O
and	O
Non-	O
Dominant	O
Frequency	O
Structure	O
of	O
Evoked	O
Ventricular	O
Fibrillation	O
in	O
Dogs	O
with	O
Myocardial	O
Ischemia	O
.	O

The	O
first	O
10	O
min	O
of	O
electrically	O
provoked	O
ventricular	O
fibrillation	O
in	O
dogs	O
with	O
ischemic	O
heart	O
disease	O
were	O
characterized	O
by	O
organized	O
myocardial	O
activity	O
evidenced	O
by	O
the	O
dominant	O
ECG	O
frequency	O
structure	O
.	O

During	O
the	O
first	O
2	O
min	O
of	O
ventricular	O
fibrillation	O
,	O
low-frequency	O
oscillations	O
(	O
4-7	O
Hz	O
)	O
dominated	O
,	O
while	O
on	O
min	O
3	O
to	O
10	O
after	O
the	O
onset	O
of	O
fibrillation	O
,	O
the	O
dominant	O
frequencies	O
were	O
low	O
and	O
medium	O
(	O
4-12	O
Hz	O
)	O
.	O

After	O
10-min	O
fibrillation	O
,	O
the	O
oscillations	O
became	O
non-	O
dominant	O
.	O

Thus	O
,	O
ischemic	O
myocardium	O
maintains	O
the	O
organized	O
structure	O
of	O
ventricular	O
fibrillation	O
for	O
the	O
first	O
10	O
min	O
,	O
which	O
is	O
important	O
for	O
the	O
development	O
of	O
automatic	B-P
diagnostics	I-P
of	O
abnormal	O
cardiac	O
activity	O
in	O
humans	O
.	O

Clinical	O
Relevance	O
of	O
Pleural	O
Effusion	O
in	O
Patients	O
with	O
Pulmonary	O
Embolism	O
.	O

Data	O
regarding	O
pleural	O
effusion	O
due	O
to	O
pulmonary	O
embolism	O
(	O
PE	O
)	O
are	O
limited	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
clinical	O
characteristics	O
of	O
PE	O
patients	O
with	O
pleural	O
effusion	O
caused	O
by	O
PE	O
.	O

Patients	O
with	O
PE	O
were	O
retrospectively	O
analyzed	O
and	O
divided	O
into	O
2	O
groups	O
based	O
on	O
computed	B-P
tomography	I-P
:	O
a	O
group	O
with	O
pleural	O
effusion	O
due	O
to	O
PE	O
(	O
effusion	O
group	O
)	O
and	O
a	O
group	O
without	O
pleural	O
effusion	O
(	O
control	O
group	O
)	O
.	O

Clinical	O
characteristics	O
were	O
compared	O
between	O
the	O
2	O
groups	O
.	O

The	O
study	O
population	O
consisted	O
of	O
the	O
effusion	O
group	O
(	O
n	O
=	O
127	O
)	O
and	O
the	O
control	O
group	O
(	O
n	O
=	O
651	O
)	O
.	O

Serum	B-P
C-reactive	I-P
protein	I-P
(	I-P
CRP	I-P
)	I-P
level	I-P
was	O
significantly	O
higher	O
in	O
the	O
effusion	O
group	O
than	O
in	O
the	O
control	O
group	O
.	O

The	O
percentages	O
of	O
high-risk	O
Simplified	O
PE	O
Severity	O
Index	O
(	O
57	O
vs.	O
47	O
%	O
,	O
p	O
=	O
0.008	O
)	O
,	O
central	O
PE	O
(	O
84	O
vs.	O
73	O
%	O
,	O
p	O
=	O
0.013	O
)	O
,	O
right	O
ventricular	O
dilation	O
(	O
45	O
vs.	O
36	O
%	O
,	O
p	O
=	O
0.053	O
)	O
,	O
and	O
pulmonary	O
infarction	O
(	O
40	O
vs.	O
8	O
%	O
,	O
p	O
<	O
0.001	O
)	O
were	O
higher	O
in	O
the	O
effusion	O
group	O
than	O
in	O
the	O
control	O
group	O
.	O

Multivariate	O
analysis	O
demonstrated	O
that	O
pulmonary	O
infarction	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
6.20	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
3.49-10.91	O
,	O
p	O
<	O
0.001	O
)	O
and	O
CRP	O
level	O
(	O
OR	O
1.05	O
,	O
95	O
%	O
CI	O
1.101-1.09	O
,	O
p	O
=	O
0.023	O
)	O
were	O
independent	O
predictors	O
of	O
pleural	O
effusion	O
due	O
to	O
PE	O
.	O

The	O
presence	O
of	O
pleural	O
effusion	O
was	O
not	O
a	O
predictor	O
of	O
short-term	O
outcomes	O
or	O
length	O
of	O
hospital	O
stay	O
.	O

Patients	O
with	O
more	O
severe	O
PE	O
are	O
likely	O
to	O
have	O
pleural	O
effusion	O
caused	O
by	O
PE	O
.	O

However	O
,	O
pleural	O
effusion	O
was	O
not	O
a	O
proven	O
predictor	O
of	O
short-term	O
outcome	O
or	O
length	O
of	O
hospital	O
stay	O
.	O

Pulmonary	O
infarction	O
and	O
CRP	O
levels	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
pleural	O
effusion	O
.	O

Chemoprevention	O
of	O
spontaneous	O
ovarian	O
cancer	O
in	O
the	O
domestic	O
hen	O
.	O

The	O
hen	O
is	O
an	O
attractive	O
animal	O
model	O
for	O
in	B-P
vivo	I-P
testing	I-P
of	O
agents	O
that	O
thwart	O
ovarian	O
carcinogenesis	O
because	O
ovarian	O
cancer	O
in	O
the	O
domestic	O
hen	O
features	O
clinical	O
and	O
molecular	O
alterations	O
that	O
are	O
similar	O
to	O
ovarian	O
cancer	O
in	O
humans	O
,	O
including	O
a	O
high	O
incidence	O
of	O
p53	O
mutations	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
test	O
the	O
potential	O
ovarian	O
cancer	O
chemopreventive	O
effect	O
of	O
the	O
p53	O
stabilizing	O
compound	O
CP-31398	O
on	O
hens	O
that	O
spontaneously	O
present	O
the	O
ovarian	O
cancer	O
phenotype	O
.	O

Beginning	O
at	O
79	O
wk	O
of	O
age	O
,	O
576	O
egg-laying	O
hens	O
(	O
Gallus	O
domesticus	O
)	O
were	O
randomized	O
to	O
diets	O
containing	O
different	O
amounts	O
of	O
CP-31398	O
for	O
94	O
wk	O
,	O
5	O
d	O
,	O
comprising	O
a	O
control	O
group	O
(	O
C	O
)	O
(	O
n	O
=	O
144	O
)	O
,	O
which	O
was	O
fed	O
a	O
diet	O
containing	O
0	O
ppm	O
(	O
mg/kg	O
)	O
of	O
CP-31398	O
;	O
a	O
low-dose	O
treatment	O
(	O
LDT	O
)	O
group	O
(	O
n	O
=	O
144	O
)	O
,	O
which	O
was	O
fed	O
a	O
diet	O
containing	O
100	O
ppm	O
of	O
CP-31398	O
;	O
a	O
moderate-dose	O
treatment	O
(	O
MDT	O
)	O
group	O
(	O
n	O
=	O
144	O
)	O
which	O
was	O
fed	O
a	O
diet	O
containing	O
200	O
ppm	O
of	O
CP-31398	O
;	O
and	O
a	O
high-dose	O
treatment	O
(	O
HDT	O
)	O
group	O
(	O
n	O
=	O
144	O
)	O
,	O
which	O
was	O
fed	O
a	O
diet	O
containing	O
300	O
ppm	O
of	O
CP-31398	O
.	O

Hens	O
were	O
killed	O
at	O
174	O
wk	O
of	O
age	O
to	O
determine	O
the	O
incidence	O
of	O
ovarian	O
and	O
oviductal	O
adenocarcinomas	O
.	O

Whereas	O
the	O
incidence	O
of	O
localized	O
and	O
metastatic	O
ovarian	O
cancers	O
in	O
the	O
MDT	O
and	O
HDT	O
groups	O
was	O
significantly	O
lower	O
(	O
up	O
to	O
77	O
%	O
)	O
compared	O
to	O
levels	O
in	O
the	O
C	O
and	O
LDT	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
,	O
the	O
incidence	O
of	O
oviductal	O
cancer	O
was	O
unaffected	O
by	O
CP-31398	O
.	O

CP-31398	O
appears	O
to	O
be	O
an	O
effective	O
tool	O
for	O
chemoprevention	O
against	O
ovarian	O
malignancies	O
,	O
but	O
does	O
not	O
appear	O
to	O
affect	O
oviductal	O
malignancies	O
.	O

Live	B-P
imaging	I-P
of	O
the	O
genetically	O
intractable	O
obligate	O
intracellular	O
bacteria	O
Orientia	O
tsutsugamushi	O
using	O
a	O
panel	O
of	O
fluorescent	O
dyes	O
.	O

Our	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
of	O
bacterial	O
infection	O
and	O
pathogenesis	O
are	O
disproportionally	O
derived	O
from	O
a	O
small	O
number	O
of	O
well-characterised	O
species	O
and	O
strains	O
.	O

One	O
reason	O
for	O
this	O
is	O
the	O
enormous	O
time	O
and	O
resources	O
required	O
to	O
develop	O
a	O
new	O
organism	O
into	O
experimental	O
system	O
that	O
can	O
be	O
interrogated	O
at	O
the	O
molecular	O
level	O
,	O
in	O
particular	O
with	O
regards	O
to	O
the	O
development	O
of	O
genetic	O
tools	O
.	O

Live	B-P
cell	I-P
imaging	I-P
by	O
fluorescence	B-P
microscopy	I-P
is	O
a	O
powerful	O
technique	O
to	O
study	O
biological	O
processes	O
such	O
as	O
bacterial	O
motility	O
,	O
host	O
cell	O
invasion	O
,	O
and	O
bacterial	O
growth	O
and	O
division	O
.	O

In	O
the	O
absence	O
of	O
genetic	O
tools	O
that	O
enable	O
exogenous	O
expression	O
of	O
fluorescent	O
proteins	O
,	O
fluorescent	O
chemical	O
probes	O
can	O
be	O
used	O
to	O
label	O
and	O
track	O
living	O
cells	O
.	O

A	O
large	O
number	O
of	O
fluorescent	O
chemical	O
probes	O
are	O
commercially	O
available	O
,	O
but	O
these	O
have	O
overwhelmingly	O
been	O
applied	O
to	O
the	O
study	O
of	O
eukaryotic	O
cell	O
systems	O
.	O

Here	O
,	O
we	O
present	O
a	O
methodical	O
analysis	O
of	O
four	O
different	O
classes	O
of	O
probes	O
,	O
which	O
can	O
be	O
used	O
to	O
delineate	O
the	O
cytoplasm	O
,	O
nucleic	O
acids	O
,	O
cell	O
membrane	O
or	O
peptidoglycan	O
of	O
living	O
bacterial	O
cells	O
.	O

We	O
have	O
tested	O
these	O
in	O
the	O
context	O
of	O
the	O
important	O
but	O
neglected	O
human	O
pathogen	O
Orientia	O
tsutsugamushi	O
but	O
expect	O
that	O
the	O
methodology	O
would	O
be	O
broadly	O
applicable	O
to	O
other	O
bacterial	O
species	O
.	O

Relations	O
between	O
doses	O
cumulated	O
in	O
bone	O
marrow	O
and	O
dose	O
delivery	O
techniques	O
during	O
radiation	O
therapy	O
of	O
cervical	O
and	O
endometrial	O
cancer	O
.	O

To	O
compare	O
normal	O
tissue	O
complication	O
probability	O
(	O
NTCP	O
)	O
and	O
average	O
doses	O
in	O
the	O
bone	O
marrow	O
(	O
BM	O
)	O
,	O
obtained	O
for	O
five	O
different	O
radiotherapy	O
delivery	O
and	O
planning	O
strategies	O
of	O
cervical	O
and	O
endometrial	O
cancer	O
.	O

50	O
patients	O
were	O
taken	O
to	O
analysis	O
.	O

For	O
each	O
case	O
,	O
3	O
different	O
dose	O
delivery	O
techniques	O
were	O
used	O
:	O
4-field	O
,	O
X15MV	O
,	O
3DCRT	O
;	O
7-field	O
,	O
X6MV	O
,	O
IMRT	O
;	O
and	O
2-arc	O
,	O
X6MV	O
,	O
VMAT	O
.	O

Two	O
optimization	O
scenarios	O
were	O
used	O
for	O
the	O
IMRT	O
and	O
VMAT	O
plans	O
generation	O
:	O
with	O
(	O
+	O
)	O
and	O
without	O
(	O
-	O
)	O
the	O
inclusion	O
of	O
the	O
BM	O
as	O
an	O
optimized	O
structure	O
.	O

Average	O
doses	O
and	O
dose-volume	O
histogram	O
parameters	O
for	O
the	O
PTV	O
,	O
BM	O
,	O
bladder	O
,	O
rectum	O
,	O
bowels	O
and	O
femoral	O
heads	O
were	O
compared	O
.	O

In	O
addition	O
,	O
the	O
BM	O
doses	O
were	O
analyzed	O
with	O
respect	O
to	O
the	O
PTV	O
and/or	O
volume	O
of	O
the	O
BM	O
,	O
and	O
NTCP	O
for	O
the	O
BM	O
were	O
computed	B-P
.	O

The	O
dose	O
in	O
PTV	O
for	O
evaluated	O
plans	O
was	O
similar	O
.	O

The	O
worst	O
doses	O
in	O
organs	O
at	O
risk	O
were	O
obtained	O
for	O
3DCRT	O
.	O

Using	O
the	O
BM	O
during	O
the	O
optimization	O
of	O
IMRT	O
and	O
VMAT	O
reduces	O
an	O
average	O
dose	O
in	O
BM	O
without	O
increasing	O
the	O
doses	O
in	O
the	O
bladder	O
,	O
rectum	O
and	O
bowels	O
.	O

Differences	O
between	O
doses	O
in	O
BM	O
for	O
IMRT	O
(	O
+	O
)	O
and	O
VMAT	O
(	O
+	O
)	O
plans	O
were	O
similar	O
while	O
NTCP	O
was	O
lower	O
for	O
VMAT	O
(	O
+	O
)	O
.	O

A	O
correlation	O
between	O
average	O
dose	O
in	O
BM	O
and	O
the	O
volume	O
ratio	O
of	O
BM	O
and	O
PTV	O
was	O
found	O
for	O
each	O
technique	O
.	O

Using	O
the	O
BM	O
during	O
the	O
optimization	O
of	O
the	O
IMRT	O
and	O
VMAT	O
plans	O
effectively	O
reduces	O
the	O
dose	O
in	O
BM	O
without	O
increasing	O
the	O
dose	O
in	O
the	O
bladder	O
,	O
rectum	O
and	O
bowels	O
.	O

The	O
VMAT	O
(	O
+	O
)	O
plans	O
were	O
characterized	O
by	O
the	O
lowest	O
NTCP	O
.	O

A	O
Fluorescent	O
Split	O
Aptamer	O
for	O
Visualizing	O
RNA-RNA	O
Assembly	O
In	O
Vivo	O
.	O

RNA-RNA	O
assembly	O
governs	O
key	O
biological	O
processes	O
and	O
is	O
a	O
powerful	O
tool	O
for	O
engineering	O
synthetic	O
genetic	O
circuits	O
.	O

Characterizing	O
RNA	O
assembly	O
in	O
living	O
cells	O
often	O
involves	O
monitoring	O
fluorescent	O
reporter	O
proteins	O
,	O
which	O
are	O
at	O
best	O
indirect	O
measures	O
of	O
underlying	O
RNA-RNA	O
hybridization	O
events	O
and	O
are	O
subject	O
to	O
additional	O
temporal	O
and	O
load	O
constraints	O
associated	O
with	O
translation	O
and	O
activation	O
of	O
reporter	O
proteins	O
.	O

In	O
contrast	O
,	O
RNA	O
aptamers	O
that	O
sequester	O
small	O
molecule	O
dyes	O
and	O
activate	O
their	O
fluorescence	O
are	O
increasingly	O
utilized	O
in	O
genetically	O
encoded	O
strategies	O
to	O
report	O
on	O
RNA	O
-	O
level	O
events	O
.	O

Split-aptamer	O
systems	O
have	O
been	O
rationally	O
designed	O
to	O
generate	O
signal	O
upon	O
hybridization	B-P
of	O
two	O
or	O
more	O
discrete	O
RNA	O
transcripts	O
,	O
but	O
none	O
directly	O
function	O
when	O
expressed	O
in	O
vivo	O
.	O

We	O
reasoned	O
that	O
the	O
improved	O
physiological	O
properties	O
of	O
the	O
Broccoli	O
aptamer	O
enable	O
construction	O
of	O
a	O
split-aptamer	O
system	O
that	O
could	O
function	O
in	O
living	O
cells	O
.	O

Here	O
we	O
present	O
the	O
Split-Broccoli	O
system	O
,	O
in	O
which	O
self-assembly	O
is	O
nucleated	O
by	O
a	O
thermostable	O
,	O
three-way	O
junction	O
RNA	O
architecture	O
and	O
fluorescence	O
activation	O
requires	O
both	O
strands	O
.	O

Functional	O
assembly	O
of	O
the	O
system	O
approximately	O
follows	O
second-order	O
kinetics	O
in	O
vitro	O
and	O
improves	O
when	O
cotranscribed	O
,	O
rather	O
than	O
when	O
assembled	O
from	O
purified	O
components	O
.	O

Split-Broccoli	O
fluorescence	O
is	O
digital	O
in	O
vivo	O
and	O
retains	O
functional	O
modularity	O
when	O
fused	O
to	O
RNAs	O
that	O
regulate	O
circuit	O
function	O
through	O
RNA-RNA	O
hybridization	O
,	O
as	O
demonstrated	O
with	O
an	O
RNA	O
Toehold	O
switch	O
.	O

Split-Broccoli	O
represents	O
the	O
first	O
functional	O
split-aptamer	O
system	O
to	O
operate	O
in	O
vivo	O
.	O

It	O
offers	O
a	O
genetically	O
encoded	O
and	O
nondestructive	O
platform	O
to	O
monitor	O
and	O
exploit	O
RNA-RNA	O
hybridization	O
,	O
whether	O
as	O
an	O
all-	O
RNA	O
,	O
stand-alone	O
AND	O
gate	O
or	O
as	O
a	O
tool	O
for	O
monitoring	O
assembly	O
of	O
RNA-RNA	O
hybrids	O
.	O

When	O
water	O
is	O
thicker	O
than	O
blood	O
:	O
recognising	O
a	O
systemic	O
cause	O
of	O
haemoptysis	O
.	O

The	O
case	O
of	O
an	O
11-	O
year-old	O
child	O
presenting	O
with	O
acute	O
haemoptysis	O
and	O
breathlessness	O
is	O
described	O
.	O

The	O
girl	O
was	O
Malaysian	O
and	O
had	O
recently	O
arrived	O
in	O
the	O
UK	O
.	O

She	O
subsequently	O
deteriorated	O
,	O
developing	O
respiratory	O
failure	O
.	O

The	O
course	O
of	O
the	O
illness	O
is	O
described	O
,	O
with	O
reference	O
to	O
the	O
diagnostic	B-P
process	I-P
at	O
each	O
stage	O
.	O

The	O
case	O
demonstrates	O
the	O
importance	O
of	O
having	O
a	O
broad	O
investigatory	O
approach	O
in	O
acute	O
haemoptysis	O
.	O

Safety	O
and	O
Efficacy	O
of	O
Flexible	O
Ureteroscopy	O
in	O
Combination	O
with	O
Holmium	O
Laser	O
Lithotripsy	O
for	O
the	O
Treatment	O
of	O
Bilateral	O
Upper	O
Urinary	O
Tract	O
Calculi	O
.	O

To	O
retrospectively	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
flexible	O
ureteroscopy	O
(	O
FURS	O
)	O
in	O
combination	O
with	O
holmium	O
laser	O
lithotripsy	O
for	O
the	O
treatment	O
of	O
bilateral	O
upper	O
urinary	O
calculi	O
.	O

The	O
stone-free	O
status	O
was	O
defined	O
as	O
the	O
absence	O
of	O
any	O
stones	O
or	O
asymptomatic	O
status	O
,	O
or	O
the	O
presence	O
of	O
clinically	O
insignificant	O
residual	O
fragments	O
<	O
4	O
mm	O
,	O
and	O
was	O
assessed	O
by	O
plain	O
kidney	O
,	O
ureter	O
,	O
and	O
bladder	B-P
X-ray	I-P
.	O

The	O
operative	O
time	O
,	O
stone-free	O
rates	O
(	O
SFRs	O
)	O
,	O
serum	B-P
creatinine	I-P
(	O
SCr	B-P
)	O
,	O
and	O
complications	O
were	O
recorded	O
.	O

During	O
the	O
operation	O
,	O
there	O
was	O
no	O
bleeding	O
,	O
ureteral	O
perforation	O
,	O
avulsion	O
,	O
and	O
rupture	O
.	O

Postoperative	O
hematuria	O
was	O
observed	O
in	O
2	O
patients	O
.	O

SCr	B-P
increased	O
significantly	O
on	O
the	O
first	O
day	O
after	O
the	O
procedure	O
compared	O
with	O
the	O
preoperative	O
SCr	B-P
,	O
but	O
after	O
4	O
weeks	O
,	O
the	O
renal	O
function	O
significantly	O
improved	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
SFR	O
was	O
71.6	O
%	O
(	O
63/88	O
)	O
on	O
the	O
first	O
day	O
after	O
the	O
first	O
surgical	O
procedure	O
;	O
it	O
then	O
increased	O
to	O
86.4	O
%	O
(	O
76/88	O
)	O
in	O
the	O
fourth	O
week	O
,	O
and	O
rose	O
to	O
97.4	O
%	O
(	O
76/78	O
)	O
after	O
the	O
second	O
operation	O
.	O

The	O
results	O
demonstrated	O
that	O
FURS	O
in	O
combination	O
with	O
holmium	O
laser	O
lithotripsy	O
represented	O
a	O
favorable	O
less-invasive	O
alternative	O
with	O
high	O
SFR	O
and	O
acceptable	O
complication	O
rates	O
in	O
the	O
treatment	O
of	O
bilateral	O
upper	O
urinary	O
tract	O
calculi	O
.	O

Artemisinin	O
loaded	O
chitosan	O
magnetic	O
nanoparticles	O
for	O
the	O
efficient	O
targeting	O
to	O
the	O
breast	O
cancer	O
.	O

Artemisinin	O
,	O
a	O
natural	O
anti-malarial	O
agent	O
,	O
also	O
possesses	O
anti-proliferative	O
and	O
anti-angiogenic	O
activity	O
in	O
cancer	O
cells	O
with	O
very	O
low	O
toxicity	O
to	O
normal	O
healthy	O
cells	O
.	O

Drug	O
loaded	O
magnetic	O
nanoparticles	O
by	O
using	O
external	O
magnetic	O
field	O
could	O
selectively	O
accumulate	O
the	O
drug	O
at	O
the	O
target	O
site	O
and	O
thereby	O
reduce	O
the	O
doses	O
required	O
to	O
achieve	O
therapeutic	O
concentration	O
which	O
may	O
otherwise	O
produce	O
serious	O
side	O
effects	O
on	O
healthy	O
cells	O
.	O

In	O
the	O
present	O
study	O
the	O
artemisinin	O
magnetic	O
nanoparticles	O
were	O
successfully	O
formulated	O
using	O
chitosan	O
by	O
ionic-gelation	B-P
method	I-P
.	O

The	O
developed	O
magnetic	O
nanoparticles	O
of	O
artemisinin	O
were	O
smooth	O
and	O
spherical	O
in	O
nature	O
and	O
their	O
size	O
was	O
in	O
the	O
range	O
of	O
349-445nm	O
.	O

The	O
polydispersity	O
index	O
(	O
PDI	O
)	O
and	O
zeta	O
potential	O
of	O
the	O
formulated	O
nanoparticles	O
were	O
in	O
the	O
range	O
of	O
0.373-0.908	O
and	O
-9.34	O
to	O
-33.3	O
respectively	O
.	O

They	O
showed	O
55	O
%	O
to	O
62.5	O
%	O
of	O
drug	O
encapsulation	O
efficiency	O
and	O
20	O
%	O
to	O
25	O
%	O
drug	O
loading	O
capacity	O
.	O

Around	O
62	O
%	O
to	O
78	O
%	O
of	O
artemisinin	O
was	O
released	O
from	O
the	O
artemisinin	O
magnetic	O
nanoparticles	O
over	O
the	O
period	O
of	O
48h	O
.	O

On	O
application	O
of	O
physiologically	O
acceptable	O
external	O
magnetic	O
field	O
,	O
FITC	O
conjugated	O
artemisinin	O
magnetic	O
nanoparticles	O
showed	O
an	O
enhanced	O
accumulation	O
of	O
nanoparticles	O
in	O
the	O
4T1	O
breast	O
tumour	O
tissues	O
of	O
BALB/c	O
mice	O
model	O
.	O

Comparison	O
of	O
left	O
ventricular	O
ejection	O
fraction	O
values	O
obtained	O
using	O
invasive	O
contrast	B-P
left	I-P
ventriculography	I-P
,	O
two-dimensional	B-P
echocardiography	I-P
,	O
and	O
gated	B-P
single-photon	B-P
emission	I-P
computed	I-P
tomography	I-P
.	O

Left	O
ventricular	O
ejection	O
fraction	O
can	O
be	O
measured	O
by	O
a	O
variety	O
of	O
invasive	O
and	O
non-invasive	O
cardiac	B-P
techniques	I-P
.	O

This	O
study	O
assesses	O
the	O
relation	O
of	O
three	O
diagnostic	O
modalities	O
to	O
each	O
other	O
in	O
the	O
measurement	O
of	O
left	O
ventricular	O
ejection	O
fraction	O
:	O
invasive	O
contrast	B-P
left	I-P
ventriculography	I-P
,	O
two-dimensional	B-P
echocardiography	I-P
,	O
and	O
quantitative	O
gated	B-P
single-photon	B-P
emission	I-P
computed	I-P
tomography	I-P
.	O

Retrospective	O
chart	O
review	O
was	O
conducted	O
on	O
58	O
patients	O
hospitalized	O
with	O
chest	O
pain	O
,	O
who	O
underwent	O
left	O
ventricular	O
ejection	O
fraction	O
evaluation	O
using	O
each	O
of	O
the	O
aforementioned	O
modalities	O
within	O
a	O
3-month	O
period	O
not	O
interrupted	O
by	O
myocardial	O
infarction	O
or	O
revascularization	O
.	O

The	O
mean	O
left	O
ventricular	O
ejection	O
fraction	O
values	O
were	O
as	O
follows	O
:	O
invasive	O
contrast	B-P
left	I-P
ventriculography	I-P
(	O
0.44±0.15	O
)	O
,	O
two-dimensional	B-P
echocardiography	I-P
(	O
0.46±0.13	O
)	O
,	O
and	O
gated	B-P
single-photon	B-P
emission	I-P
computed	I-P
tomography	I-P
(	O
0.37±0.10	O
)	O
.	O

Correlations	O
coefficients	O
and	O
associated	O
p	O
values	O
were	O
as	O
follows	O
:	O
invasive	O
contrast	B-P
left	I-P
ventriculography	I-P
versus	O
two-dimensional	B-P
echocardiography	I-P
(	O
r=0.69	O
,	O
p	O
<	O
0.001	O
)	O
,	O
invasive	O
contrast	B-P
left	I-P
ventriculography	I-P
versus	O
gated	B-P
single-photon	B-P
emission	I-P
computed	I-P
tomography	I-P
(	O
r=0.80	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
and	O
gated	B-P
single-photon	B-P
emission	I-P
computed	I-P
tomography	I-P
versus	O
two-dimensional	B-P
echocardiography	I-P
(	O
r=0.69	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
strong	O
positive	O
correlations	O
exist	O
among	O
the	O
three	O
techniques	B-P
studied	O
.	O

Immunoassays	B-P
for	O
riboflavin	O
and	O
flavin	O
mononucleotide	O
using	O
antibodies	O
specific	O
to	O
d-ribitol	O
and	O
d-ribitol-5-phosphate	O
.	O

Riboflavin	O
(	O
vitamin	O
B2	O
)	O
,	O
a	O
water-soluble	O
vitamin	O
,	O
plays	O
a	O
key	O
role	O
in	O
maintaining	O
human	O
health	O
.	O

Though	O
,	O
numerous	O
methods	O
have	O
been	O
reported	O
for	O
the	O
determination	B-P
of	O
total	B-P
riboflavin	I-P
(	I-P
TRF	I-P
)	I-P
content	I-P
in	O
foods	O
and	O
biological	O
samples	O
,	O
very	O
few	O
methods	O
are	O
reported	O
for	O
quantifying	O
riboflavin	O
and	O
its	O
coenzymes	O
[	O
flavin	O
mononucleotide	O
(	O
FMN	O
)	O
;	O
flavin	O
adenine	O
dinucleotide	O
(	O
FAD	O
)	O
]	O
individually	O
.	O

Recently	O
,	O
we	O
have	O
demonstrated	O
that	O
antibodies	O
specific	O
to	O
d-ribitol	O
and	O
d-ribitol-5-phosphate	O
also	O
recognize	O
riboflavin	O
and	O
FMN	O
,	O
respectively	O
,	O
and	O
not	O
vice-versa	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
evaluated	O
these	O
two	O
antibodies	O
for	O
the	O
analysis	O
of	O
riboflavin	O
and	O
FMN	O
by	O
indirect	O
competitive	O
ELISA	B-P
(	O
icELISA	B-P
)	O
in	O
selected	O
foods	O
and	O
pharmaceuticals	O
.	O

Under	O
the	O
optimal	O
assay	B-P
conditions	O
,	O
50	O
%	O
inhibition	O
concentration	O
(	O
IC50	O
)	O
and	O
limit	O
of	O
detection	O
(	O
LOD	O
,	O
IC10	O
)	O
were	O
3.41ng/mL	O
and	O
0.02ng/mL	O
for	O
riboflavin	O
,	O
and	O
7.84ng/mL	O
and	O
0.24ng/mL	O
for	O
FMN	O
,	O
respectively	O
,	O
with	O
detectable	O
concentration	O
range	O
between	O
0.1	O
and	O
100ng	O
of	O
analytes	O
and	O
<	O
0.1	O
%	O
cross-reactivity	O
with	O
other	O
water-soluble	O
vitamins	O
.	O

The	O
amounts	O
of	O
TRF	O
in	O
food	O
samples	O
,	O
as	O
analyzed	O
by	O
icELISA	B-P
using	O
ribitol	O
antibody	O
,	O
were	O
90-95	O
%	O
of	O
the	O
reported	O
values	O
in	O
the	O
literature	O
or	O
label	O
values	O
.	O

Quantification	O
of	O
individual	O
flavins	O
(	O
riboflavin	O
and	O
FMN	O
)	O
from	O
the	O
same	O
food	O
samples	O
showed	O
variation	O
in	O
their	O
values	O
compared	O
to	O
TRF	O
,	O
and	O
were	O
in	O
good	O
agreement	O
with	O
values	O
obtained	O
from	O
HPLC	B-P
and	O
AOAC	B-P
methods	O
.	O

Further	O
,	O
spiking	O
and	O
recovery	O
analysis	O
of	O
food	O
samples	O
and	O
pharmaceuticals	O
showed	O
no	O
significant	O
matrix	O
effects	O
.	O

The	O
immunoassays	B-P
were	O
validated	O
in	O
terms	O
of	O
accuracy	O
and	O
precision	O
using	O
inter-	B-P
and	O
intra-assays	B-P
.	O

The	O
immunoassays	B-P
developed	O
in	O
this	O
study	O
are	O
sensitive	O
and	O
appears	O
feasible	O
for	O
screening	O
a	O
large	O
number	O
of	O
samples	O
in	O
the	O
quantification	O
of	O
riboflavin	O
and	O
FMN	O
in	O
various	O
biological	O
samples	O
,	O
pharmaceuticals	O
and	O
natural	O
/	O
processed	O
foods	O
.	O

Applicability	O
of	O
drinking	O
water	O
treatment	O
residue	O
for	O
lake	O
restoration	O
in	O
relation	O
to	O
metal	O
/	O
metalloid	O
risk	O
assessment	O
.	O

Drinking	O
water	O
treatment	O
residue	O
(	O
DWTR	O
)	O
,	O
a	O
byproduct	O
generated	O
during	O
potable	O
water	O
production	O
,	O
exhibits	O
a	O
high	O
potential	O
for	O
recycling	O
to	O
control	O
eutrophication	O
.	O

However	O
,	O
this	O
beneficial	O
recycling	O
is	O
hampered	O
by	O
unclear	O
metal	O
/	O
metalloid	O
pollution	O
risks	O
related	O
to	O
DWTR	O
.	O

In	O
this	O
study	O
,	O
the	O
pollution	O
risks	O
of	O
Al	O
,	O
As	O
,	O
Ba	O
,	O
Be	O
,	O
Cd	O
,	O
Co	O
,	O
Cr	O
,	O
Cu	O
,	O
Fe	O
,	O
Mn	O
,	O
Mo	O
,	O
Ni	O
,	O
Pb	O
,	O
and	O
Zn	O
due	O
to	O
DWTR	O
application	O
were	O
first	O
evaluated	O
for	O
lake	O
water	O
based	O
on	O
human	O
health	O
risk	O
assessment	O
models	O
and	O
comparison	O
of	O
regulatory	O
standards	O
.	O

The	O
risks	O
of	O
DWTR	O
were	O
also	O
evaluated	O
for	O
sediments	O
on	O
the	O
basis	O
of	O
toxicity	O
characteristics	O
leaching	O
procedure	O
and	O
fractionation	O
in	O
relation	O
to	O
risk	O
assessment	O
code	O
.	O

Variations	O
in	O
the	O
biological	O
behaviors	O
of	O
metal	O
/	O
metalloid	O
in	O
sediments	O
caused	O
by	O
DWTR	O
were	O
assessed	O
using	O
Chironomus	O
plumosus	O
larvae	O
and	O
Hydrilla	O
verticillata	O
.	O

Kinetic	B-P
luminescent	I-P
bacteria	I-P
test	I-P
(	O
using	O
Aliivibrio	O
fischeri	O
)	O
was	O
conducted	O
to	O
analyze	O
the	O
possibility	O
of	O
acute	O
and	O
chronic	O
detrimental	O
effects	O
of	O
sediment	O
with	O
DWTR	O
application	O
.	O

According	O
to	O
the	O
obtained	O
results	O
,	O
we	O
identify	O
a	O
potential	O
undesirable	O
effect	O
of	O
DWTR	O
related	O
to	O
Fe	O
and	O
Mn	O
(	O
typically	O
under	O
anaerobic	O
conditions	O
)	O
;	O
roughly	O
present	O
a	O
dosage	O
threshold	O
calculation	O
model	O
;	O
and	O
recommend	O
a	O
procedure	O
for	O
DWTR	O
prescreening	O
to	O
ensure	O
safe	O
application	O
.	O

Overall	O
,	O
managed	O
DWTR	O
application	O
is	O
necessary	O
for	O
successful	O
eutrophication	O
control	O
.	O

Mucosal	O
and	O
cutaneous	O
human	O
papillomaviruses	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
papillomas	O
.	O

Conflicting	O
data	O
exist	O
regarding	O
the	O
contribution	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
to	O
the	O
development	O
of	O
head	O
and	O
neck	O
squamous	O
cell	O
papillomas	O
.	O

Formalin-fixed	O
paraffin-embedded	O
papillomas	O
were	O
tested	O
for	O
28	O
mucosal	O
and	O
79	O
cutaneous	O
HPVs	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-based	O
methods	O
.	O

Eighty-three	O
papillomas	O
(	O
43	O
oropharyngeal	O
,	O
31	O
oral	O
,	O
6	O
laryngeal	O
,	O
and	O
3	O
nasopharyngeal	O
)	O
were	O
analyzed	O
.	O

Twenty-four	O
samples	O
(	O
28.9	O
%	O
)	O
harbored	O
mucosal	O
HPVs	O
:	O
3	O
oropharyngeal	O
(	O
6.9	O
%	O
)	O
,	O
15	O
oral	O
(	O
48.3	O
%	O
)	O
,	O
4	O
laryngeal	O
(	O
66.7	O
%	O
)	O
,	O
and	O
2	O
nasopharyngeal	O
papillomas	O
(	O
66.7	O
%	O
)	O
.	O

Eighty-one	O
cases	O
were	O
also	O
tested	O
for	O
cutaneous	O
HPVs	O
,	O
detected	O
in	O
16	O
lesions	O
(	O
19.7	O
%	O
)	O
:	O
11	O
(	O
13.5	O
%	O
)	O
harbored	O
only	O
cutaneous	O
types	O
,	O
and	O
5	O
(	O
6.2	O
%	O
)	O
were	O
positive	O
for	O
both	O
cutaneous	O
and	O
mucosal	O
HPVs	O
.	O

Among	O
these	O
81	O
cases	O
,	O
prevalence	O
of	O
mucosal	O
and/or	O
cutaneous	O
HPV	O
infection	O
was	O
43.2	O
%	O
.	O

HPV	B-P
DNA	I-P
detection	I-P
in	O
a	O
fraction	O
of	O
head	O
and	O
neck	O
papillomas	O
supports	O
the	O
role	O
of	O
HPV	O
in	O
their	O
development	O
.	O

However	O
,	O
other	O
markers	O
need	O
to	O
be	O
considered	O
to	O
confirm	O
the	O
association	O
of	O
HPV	O
infection	O
with	O
these	O
lesions	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Head	O
Neck	O
39	O
:	O
254-259	O
,	O
2017	O
.	O

Bilateral	O
C1	O
laminar	O
hooks	O
combined	O
with	O
C2	O
pedicle	O
screw	O
fixation	O
in	O
the	O
treatment	O
of	O
atlantoaxial	O
subluxation	O
after	O
Grisel	O
syndrome	O
.	O

Many	O
etiologies	O
can	O
lead	O
to	O
atlantoaxial	O
subluxaion	O
.	O

In	O
Grisel	O
syndrome	O
(	O
GS	O
)	O
,	O
this	O
subluxation	O
occurs	O
spontaneously	O
after	O
inflammatory	O
processes	O
of	O
the	O
head	O
and	O
neck	O
.	O

Diagnosis	O
is	O
typically	O
based	O
on	O
clinical	O
history	O
and	O
a	O
strong	O
suspicion	O
of	O
this	O
syndrome	O
.	O

Nonsurgical	O
treatment	O
most	O
often	O
resolves	O
the	O
symptoms	O
;	O
however	O
,	O
in	O
some	O
cases	O
surgical	O
treatment	O
is	O
necessary	O
to	O
repair	O
the	O
subluxation	O
.	O

Various	O
surgical	B-P
techniques	I-P
and	O
instrumentation	O
systems	O
have	O
been	O
used	O
to	O
treat	O
atlantoaxial	O
subluxation	O
,	O
although	O
there	O
is	O
no	O
consensus	O
regarding	O
the	O
best	O
treatment	O
method	O
for	O
the	O
pediatric	O
population	O
.	O

To	O
describe	O
a	O
case	O
of	O
atlantoaxial	O
subluxation	O
in	O
a	O
child	O
with	O
GS	O
treated	O
surgically	O
with	O
an	O
alternative	O
construct	O
.	O

This	O
is	O
a	O
case	O
report	O
and	O
literature	O
review	O
.	O

Our	O
case	O
study	O
involves	O
a	O
5-	O
year	O
-old	O
girl	O
with	O
a	O
6-	O
month	O
history	O
of	O
unresolved	O
Fielding	O
type	O
II	O
atlantoaxial	O
subluxation	O
caused	O
by	O
GS	O
.	O

Despite	O
conservative	O
treatment	O
,	O
the	O
patient	O
's	O
symptoms	O
continued	O
to	O
progress	O
.	O

After	O
two	O
failed	O
closed	O
reduction	O
attempts	O
,	O
open	O
reduction	O
and	O
C1-C2	O
fusion	O
were	O
performed	O
with	O
atlas	O
laminar	O
hook	O
and	O
axis	O
pedicle	O
polyaxial	O
screws	O
.	O

A	O
literature	O
review	O
of	O
the	O
surgical	O
treatment	O
of	O
GS	O
was	O
also	O
performed	O
.	O

After	O
surgery	O
,	O
the	O
patient	O
exhibited	O
full	O
clinical	O
and	O
functional	O
recovery	O
with	O
complete	O
resolution	O
of	O
symptoms	O
.	O

At	O
the	O
36-	O
month	O
follow-up	O
examination	O
,	O
there	O
was	O
continual	O
evidence	O
of	O
satisfactory	O
reduction	O
and	O
fusion	O
.	O

No	O
complications	O
were	O
observed	O
.	O

Upon	O
completion	O
of	O
the	O
literature	O
review	O
,	O
eight	O
GS	O
cases	O
were	O
found	O
to	O
have	O
been	O
treated	O
surgically	O
with	O
the	O
minimum	O
patient	O
age	O
being	O
9	O
years	O
.	O

Conservative	O
management	O
of	O
GS	O
is	O
the	O
most	O
common	O
and	O
effective	O
treatment	O
;	O
however	O
,	O
a	O
few	O
surgical	O
cases	O
have	O
been	O
reported	O
in	O
the	O
literature	O
with	O
good	O
results	O
.	O

Satisfactory	O
clinical	O
results	O
and	O
fusion	O
at	O
36	O
months	O
post	O
surgery	O
were	O
seen	O
in	O
a	O
pediatric	O
patient	O
with	O
atlantoaxial	O
subluxation	O
and	O
instability	O
using	O
atlas	O
laminar	O
hook	O
and	O
axis	O
pedicle	O
polyaxial	O
screws	O
.	O

Fracture	O
of	O
the	O
os	O
trigonum	O
:	O
A	O
report	O
of	O
two	O
cases	O
and	O
review	O
of	O
the	O
literature	O
.	O

We	O
report	O
two	O
cases	O
of	O
acute	O
fractures	O
of	O
the	O
os	O
trigonum	O
.	O

The	O
os	O
trigonum	O
fracture	O
related	O
to	O
the	O
first	O
case	O
was	O
sustained	O
following	O
a	O
hyper-plantar	O
flexion	O
injury	O
during	O
a	O
game	O
of	O
soccer	O
.	O

The	O
second	O
case	O
involved	O
a	O
patient	O
who	O
fell	O
from	O
height	O
and	O
also	O
sustained	O
open	O
fractures	O
of	O
the	O
left	O
distal	O
tibia	O
and	O
lateral	O
malleolus	O
as	O
well	O
as	O
the	O
right	O
calcaneus	O
.	O

In	O
both	O
cases	O
,	O
a	O
preliminary	O
diagnosis	O
of	O
a	O
posterior	O
talar	O
process	O
fracture	O
was	O
made	O
from	O
the	O
initial	O
radiographs	B-P
of	O
the	O
ankle	O
.	O

The	O
correct	O
diagnosis	O
of	O
an	O
os	O
trigonum	O
fracture	O
rather	O
than	O
a	O
fracture	O
of	O
the	O
posterior	O
talar	O
process	O
was	O
only	O
made	O
following	O
further	O
assessment	O
with	O
CT	B-P
imaging	I-P
.	O

Given	O
that	O
the	O
course	O
of	O
treatment	O
is	O
largely	O
determined	O
by	O
imaging	B-P
findings	O
,	O
CT	B-P
for	O
further	O
imaging	B-P
evaluation	O
should	O
be	O
performed	O
in	O
cases	O
of	O
suspected	O
acute	O
bony	O
injuries	O
of	O
the	O
posterior	O
ankle	O
,	O
particularly	O
when	O
the	O
limitations	O
of	O
using	O
radiographs	B-P
for	O
the	O
assessment	O
of	O
such	O
injuries	O
are	O
expected	O
to	O
be	O
encountered	O
.	O

Molecular	O
Characterization	O
of	O
Equine	O
APRIL	O
and	O
its	O
Expression	B-P
Analysis	I-P
During	O
the	O
Adipogenic	O
Differentiation	O
of	O
Equine	O
Adipose	O
-	O
Derived	O
Stem	O
Cell	O
In	O
Vitro	O
.	O

A	O
proliferation	O
inducing	O
ligand	O
(	O
APRIL	O
)	O
is	O
a	O
member	O
of	O
the	O
TNF	O
superfamily	O
.	O

It	O
shares	O
two	O
receptors	O
with	O
B-cell	O
activating	O
factor	O
(	O
BAFF	O
)	O
,	O
B-cell	O
maturation	O
antigen	O
(	O
BCMA	O
)	O
,	O
and	O
transmembrane	O
activator	O
and	O
CAML	O
interactor	O
(	O
TACI	O
)	O
.	O

Herein	O
,	O
the	O
equine	O
APRIL	O
was	O
identified	O
from	O
equine	O
adipose-derived	O
stem	O
cell	O
(	O
ASC	O
)	O
,	O
and	O
the	O
protein	O
expression	O
of	O
APRIL	O
and	O
its	O
related	O
molecules	O
were	O
detected	O
during	O
the	O
adipogenic	O
differentiation	O
of	O
equine	O
ASC	O
in	O
vitro	O
.	O

The	O
equine	O
APRIL	O
gene	O
was	O
located	O
on	O
chromosome	O
11	O
,	O
spans	O
1852	O
base	O
pairs	O
(	O
bp	O
)	O
.	O

Its	O
open	O
reading	O
frame	O
covers	O
753	O
bp	O
,	O
encoding	O
a	O
250-amino	O
acid	O
protein	O
with	O
the	O
typical	O
TNF	O
structure	O
domain	O
.	O

During	O
the	O
two	O
weeks	O
'	O
adipogenic	O
differentiation	O
of	O
equine	O
ASC	O
,	O
although	O
the	O
protein	O
expression	O
of	O
APRIL	O
and	O
TACI	O
had	O
an	O
insignificant	O
change	O
,	O
that	O
of	O
BCMA	O
increased	O
significantly	O
.	O

Moreover	O
,	O
with	O
the	O
addition	O
of	O
recombinant	O
protein	O
His6-sAPRIL	O
,	O
a	O
reduced	O
differentiation	O
of	O
equine	O
ASC	O
toward	O
adipocyte	O
was	O
detected	O
.	O

These	O
results	O
may	O
provide	O
the	O
basis	O
for	O
investigating	O
the	O
role	O
of	O
APRIL	O
in	O
ASC	O
adipogenic	O
differentiation	O
.	O

Effect	O
of	O
Xenotransplantation	O
Site	O
on	O
MicroRNA	O
Expression	O
of	O
Human	O
Colon	O
Cancer	O
Stem	O
Cells	O
.	O

Cancer	O
stem	O
cells	O
(	O
CSCs	O
)	O
have	O
a	O
high	O
tumorigenic	O
ability	O
to	O
form	O
patient-derived	O
tumor	O
xenografts	O
(	O
PDXs	O
)	O
.	O

PDXs	O
are	O
an	O
attractive	O
pre-clinical	O
model	O
,	O
but	O
gene	O
expression	O
and	O
biological	O
behavior	O
of	O
cancer	O
cells	O
in	O
the	O
tumor	O
will	O
change	O
during	O
establishment	O
and	O
passage	O
of	O
PDXs	O
.	O

Human	O
colon	O
cancer	O
PDX	O
was	O
established	O
and	O
passaged	B-P
either	O
subcutaneously	O
or	O
orthotopically	O
into	O
the	O
murine	O
intestine	O
.	O

Histology	O
and	O
flow	B-P
cytometric	I-P
profile	B-P
of	O
the	O
surgical	O
specimen	O
and	O
the	O
PDX	O
were	O
analyzed	O
.	O

CSCs	O
were	O
then	O
isolated	O
from	O
the	O
tumors	O
and	O
their	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
was	O
analyzed	O
by	O
semi-quantitative	B-P
polymerase	I-P
chain	I-P
reaction	I-P
.	O

The	O
surgical	O
specimens	O
and	O
PDXs	O
were	O
histologically	O
similar	O
.	O

The	O
size	O
of	O
CSC	O
population	O
increased	O
and	O
expression	O
of	O
miRNA	O
s	O
in	O
CSCs	O
changed	O
in	O
the	O
passaged	B-P
PDXs	O
.	O

Expression	O
of	O
oncogenic	O
miRNAs	O
was	O
highly	O
up-regulated	O
in	O
the	O
CSCs	O
of	O
the	O
orthotopically	O
passaged	B-P
PDXs	O
.	O

The	O
xenotransplantation	O
site	O
and	O
the	O
number	O
of	O
tumor	O
passages	B-P
affect	O
the	O
miRNA	O
expression	O
of	O
human	O
colon	O
CSCs	O
.	O

Dynamin-related	O
protein	O
1	O
mediates	O
low	O
glucose	O
-	O
induced	O
endothelial	O
dysfunction	O
in	O
human	O
arterioles	O
.	O

Intensive	O
glycemic	O
regulation	O
has	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
hypoglycemia	O
.	O

Hypoglycemic	O
burden	O
correlates	O
with	O
adverse	O
cardiovascular	O
complications	O
and	O
contributes	O
acutely	O
and	O
chronically	O
to	O
endothelial	O
dysfunction	O
.	O

Prior	O
data	O
indicate	O
that	O
mitochondrial	O
dysfunction	O
contributes	O
to	O
hypoglycemia	O
-	O
induced	O
endothelial	O
dysfunction	O
,	O
but	O
the	O
mechanisms	O
behind	O
this	O
linkage	O
remain	O
unknown	O
.	O

We	O
attempt	O
to	O
determine	O
whether	O
clinically	O
relevant	O
low-glucose	O
(	O
LG	O
)	O
exposures	O
acutely	O
induce	O
endothelial	O
dysfunction	O
through	O
activation	O
of	O
the	O
mitochondrial	O
fission	O
process	O
.	O

Characterization	O
of	O
mitochondrial	O
morphology	O
was	O
carried	O
out	O
in	O
cultured	O
endothelial	O
cells	O
by	O
using	O
confocal	B-P
microscopy	I-P
.	O

Isolated	O
human	O
arterioles	O
were	O
used	O
to	O
explore	O
the	O
effect	O
LG	O
-	O
induced	O
mitochondrial	O
fission	O
has	O
on	O
the	O
formation	O
of	O
detrimental	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
bioavailability	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
,	O
and	O
endothelial-dependent	O
vascular	O
relaxation	O
.	O

Fluorescence	B-P
microscopy	I-P
was	O
employed	O
to	O
visualize	O
changes	O
in	O
mitochondrial	O
ROS	O
and	O
NO	O
levels	O
and	O
videomicroscopy	B-P
applied	O
to	O
measure	O
vasodilation	O
response	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	O
Drp1	O
with	O
Mdivi-1	O
during	O
LG	O
exposure	O
reduced	O
mitochondrial	O
fragmentation	O
among	O
vascular	O
endothelial	O
cells	O
(	O
LG	O
:	O
0.469	O
;	O
LG	O
+	O
Mdivi-1	O
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
LG	O
:	O
2.036	O
;	O
LG	O
+	O
Mdivi-1	O
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
NO	O
(	O
LG	O
:	O
1.352	O
;	O
LG	O
+	O
Mdivi-1	O
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	O
response	O
to	O
acetylcholine	O
(	O
LG	O
:	O
31.6	O
%	O
;	O
LG	O
+	O
Mdivi-1	O
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Additionally	O
,	O
decreased	O
expression	O
of	O
Drp1	O
via	O
siRNA	O
knockdown	O
during	O
LG	O
conditions	O
also	O
improved	O
vascular	O
relaxation	O
.	O

Exposure	O
to	O
LG	O
imparts	O
endothelial	O
dysfunction	O
coupled	O
with	O
altered	O
mitochondrial	O
phenotypes	O
among	O
isolated	O
human	O
arterioles	O
.	O

Disruption	O
of	O
Drp1	O
and	O
subsequent	O
mitochondrial	O
fragmentation	O
events	O
prevents	O
impaired	O
vascular	O
dilation	O
,	O
restores	O
mitochondrial	O
phenotype	O
,	O
and	O
implicates	O
mitochondrial	O
fission	O
as	O
a	O
primary	O
mediator	O
of	O
LG	O
-	O
induced	O
endothelial	O
dysfunction	O
.NEW	O
&	O
NOTEWORTHY	O
Acute	O
low-glucose	O
exposure	O
induces	O
mitochondrial	O
fragmentation	O
in	O
endothelial	O
cells	O
via	O
Drp1	O
and	O
is	O
associated	O
with	O
impaired	O
endothelial	O
function	O
in	O
human	O
arterioles	O
.	O

Targeting	O
of	O
Drp1	O
prevents	O
fragmentation	O
,	O
improves	O
vasofunction	O
,	O
and	O
may	O
provide	O
a	O
therapeutic	O
target	O
for	O
improving	O
cardiovascular	O
complications	O
among	O
diabetics	O
.Listen	O
to	O
this	O
article	O
's	O
corresponding	O
podcast	O
@	O
http	O
:	O
//ajpheart.podbean.com/e/mitochondrial-dynamics-impact-endothelial-function/	O
.	O

EEG	B-P
Monitoring	O
Technique	O
Influences	O
the	O
Management	O
of	O
Hypoxic-Ischemic	O
Seizures	O
in	O
Neonates	O
Undergoing	O
Therapeutic	O
Hypothermia	O
.	O

Electroencephalogram	O
(	O
EEG	O
)	O
monitoring	O
techniques	O
for	O
neonatal	O
hypoxia-ischemia	O
(	O
HI	O
)	O
are	O
evolving	O
over	O
time	O
,	O
and	O
the	O
specific	O
type	O
of	O
EEG	O
utilized	O
could	O
influence	O
seizure	O
diagnosis	O
and	O
management	O
.	O

We	O
examined	O
whether	O
the	O
type	O
of	O
EEG	B-P
performed	O
affected	O
seizure	O
treatment	O
decisions	O
(	O
e.g.	O
,	O
the	O
choice	O
and	O
number	O
of	O
antiseizure	O
drugs	O
[	O
ASDs	O
]	O
)	O
in	O
therapeutic	O
hypothermia-treated	O
neonates	O
with	O
HI	O
from	O
2007	O
to	O
2015	O
in	O
the	O
Johns	O
Hopkins	O
Hospital	O
Neonatal	O
Intensive	O
Care	O
Unit	O
.	O

During	O
this	O
period	O
,	O
3	O
different	O
EEG	O
monitoring	O
protocols	O
were	O
utilized	O
:	O
Period	O
1	O
(	O
2007-2009	O
)	O
,	O
single	O
,	O
brief	O
conventional	O
EEG	B-P
(	O
1	O
h	O
duration	O
)	O
at	O
a	O
variable	O
time	O
during	O
therapeutic	O
hypothermia	O
treatment	O
,	O
i.e.	O
,	O
ordered	O
when	O
a	O
seizure	O
was	O
suspected	O
;	O
Period	O
2	O
(	O
2009-2013	O
)	O
,	O
single	O
,	O
brief	O
conventional	O
EEG	B-P
followed	O
by	O
amplitude-integrated	B-P
EEG	I-P
for	O
the	O
duration	O
of	O
therapeutic	O
hypothermia	O
treatment	O
and	O
another	O
brief	O
conventional	O
EEG	B-P
after	O
rewarming	O
;	O
and	O
Period	O
3	O
(	O
2014-2015	O
)	O
,	O
continuous	B-P
video-EEG	I-P
(	O
cEEG	B-P
)	O
for	O
the	O
duration	O
of	O
therapeutic	O
hypothermia	O
treatment	O
(	O
72	O
h	O
)	O
plus	O
for	O
an	O
additional	O
12	O
h	O
during	O
and	O
after	O
rewarming	O
.	O

One	O
hundred	O
and	O
sixty-two	O
newborns	O
were	O
included	O
in	O
this	O
retrospective	O
cohort	O
study	O
.	O

As	O
a	O
function	O
of	O
the	O
type	O
and	O
duration	O
of	O
EEG	O
monitoring	O
,	O
we	O
assessed	O
the	O
risk	O
(	O
likelihood	O
)	O
of	O
receiving	O
no	O
ASD	O
,	O
at	O
least	O
1	O
ASD	O
,	O
or	O
≥2	O
ASDs	O
.	O

We	O
found	O
that	O
the	O
risk	O
of	O
a	O
neonate	O
being	O
prescribed	O
an	O
ASD	O
was	O
46	O
%	O
less	O
during	O
Period	O
3	O
(	O
cEEG	B-P
)	O
than	O
during	O
Period	O
1	O
(	O
brief	O
conventional	O
EEG	B-P
only	O
)	O
(	O
95	O
%	O
CI	O
6-69	O
%	O
,	O
p	O
=	O
0.03	O
)	O
.	O

After	O
adjusting	O
for	O
initial	O
EEG	B-P
and	O
MRI	B-P
results	O
,	O
compared	O
with	O
Period	O
1	O
,	O
there	O
was	O
a	O
38	O
%	O
lower	O
risk	O
of	O
receiving	O
an	O
ASD	O
during	O
Period	O
2	O
(	O
95	O
%	O
CI	O
:	O
9-58	O
%	O
,	O
p	O
=	O
0.02	O
)	O
and	O
a	O
67	O
%	O
lower	O
risk	O
during	O
Period	O
3	O
(	O
95	O
%	O
CI	O
:	O
23-86	O
%	O
,	O
p	O
=	O
0.01	O
)	O
.	O

The	O
risk	O
ratio	O
of	O
receiving	O
≥2	O
ASDs	O
was	O
not	O
significantly	O
different	O
across	O
the	O
3	O
periods	O
.	O

In	O
conclusion	O
,	O
in	O
addition	O
to	O
the	O
higher	O
sensitivity	O
and	O
specificity	O
of	O
continuous	B-P
video-EEG	I-P
monitoring	O
,	O
fewer	O
infants	O
are	O
prescribed	O
an	O
ASD	O
when	O
undergoing	O
continuous	O
forms	O
of	O
EEG	O
monitoring	O
(	O
aEEG	B-P
or	O
cEEG	B-P
)	O
than	O
those	O
receiving	O
conventional	O
EEG	B-P
.	O

We	O
recommend	O
that	O
use	O
of	O
continuous	B-P
video-EEG	I-P
be	O
considered	O
whenever	O
possible	O
,	O
both	O
to	O
treat	O
seizures	O
more	O
specifically	O
and	O
to	O
avoid	O
overtreatment	O
.	O

Risk	O
of	O
advanced	O
lesions	O
at	O
the	O
first	O
follow-up	O
colonoscopy	B-P
after	O
polypectomy	O
of	O
diminutive	O
versus	O
small	O
adenomatous	O
polyps	O
of	O
low-grade	O
dysplasia	O
.	O

The	O
current	O
guidelines	O
for	O
surveillance	O
after	O
polypectomy	O
do	O
not	O
distinguish	O
between	O
diminutive	O
(	O
1-5	O
mm	O
)	O
and	O
small	O
(	O
6-9	O
mm	O
)	O
polyps	O
with	O
low-grade	O
dysplasia	O
(	O
LGD	O
)	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
risk	O
for	O
advanced	O
neoplasia	O
on	O
follow-up	O
colonoscopy	B-P
.	O

We	O
retrospectively	O
analyzed	O
443	O
patients	O
whose	O
worst	O
finding	O
at	O
index	O
colonoscopy	O
was	O
polypectomy	O
of	O
1	O
to	O
5	O
or	O
6	O
to	O
9	O
mm	O
polyps	O
with	O
LGD	O
and	O
those	O
who	O
underwent	O
a	O
follow-up	O
colonoscopy	B-P
.	O

During	O
a	O
mean	O
follow-up	O
of	O
32.0	O
months	O
(	O
interquartile	O
range	O
13-48	O
months	O
)	O
,	O
advanced	O
neoplasia	O
was	O
found	O
in	O
26	O
patients	O
(	O
5.9	O
%	O
)	O
.	O

Among	O
all	O
included	O
patients	O
(	O
n	O
=	O
443	O
)	O
,	O
advanced	O
neoplasia	O
was	O
found	O
in	O
13	O
of	O
310	O
patients	O
(	O
4.2	O
%	O
)	O
of	O
the	O
1-	O
to	O
5-mm	O
group	O
versus	O
13	O
of	O
133	O
patients	O
(	O
9.8	O
%	O
)	O
of	O
the	O
6-	O
to	O
9-mm	O
group	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
3.49	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.6-7.6	O
)	O
.	O

Among	O
the	O
patients	O
with	O
1	O
to	O
2	O
polyps	O
resected	O
(	O
n	O
=	O
313	O
)	O
,	O
advanced	O
neoplasia	O
was	O
found	O
in	O
8	O
of	O
231	O
patients	O
(	O
3.5	O
%	O
)	O
of	O
the	O
1-	O
to	O
5-mm	O
group	O
versus	O
8	O
of	O
82	O
patients	O
(	O
9.8	O
%	O
)	O
of	O
the	O
6-	O
to	O
9-mm	O
group	O
(	O
HR	O
3.97	O
;	O
95	O
%	O
CI	O
,	O
1.47-10.7	O
)	O
.	O

Among	O
the	O
patients	O
with	O
≥3	O
polyps	O
resected	O
(	O
n	O
=	O
130	O
)	O
,	O
advanced	O
neoplasia	O
was	O
found	O
in	O
5	O
of	O
79	O
patients	O
(	O
6.3	O
%	O
)	O
of	O
the	O
1-	O
to	O
5-mm	O
group	O
versus	O
5	O
of	O
51	O
patients	O
(	O
9.8	O
%	O
)	O
of	O
the	O
6-	O
to	O
9-mm	O
group	O
(	O
HR	O
2.4	O
;	O
95	O
%	O
CI	O
,	O
0.7-8.36	O
)	O
.	O

Fair	O
bowel	O
preparation	O
also	O
was	O
associated	O
with	O
the	O
risk	O
for	O
advanced	O
neoplasia	O
at	O
follow-up	O
(	O
HR	O
3.87	O
,	O
95	O
%	O
CI	O
,	O
1.70-8.82	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
among	O
patients	O
with	O
up	O
to	O
9-mm	O
adenomatous	O
polyps	O
,	O
a	O
polyp	O
size	O
of	O
6	O
to	O
9	O
mm	O
,	O
>	O
2	O
polyps	O
,	O
and	O
fair	O
bowel	O
preparation	O
are	O
associated	O
with	O
advanced	O
neoplasia	O
.	O

Application	O
of	O
Laparoscopic	B-P
Lumbar	O
Discectomy	O
and	O
Artificial	O
Disc	O
Replacement	O
:	O
At	O
Least	O
Two	O
Years	O
of	O
Follow-Up	O
.	O

This	O
prospective	O
observational	O
study	O
included	O
22	O
patients	O
who	O
were	O
diagnosed	O
with	O
symptomatic	O
degenerative	O
disc	O
disease	O
treated	O
via	O
artificial	O
disc	O
replacement	O
(	O
ADR	O
)	O
with	O
a	O
laparoscopic	B-P
technique	O
.	O

The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
ADR	O
using	O
a	O
laparoscopic	B-P
technique	O
for	O
lumbar	O
disc	O
herniation	O
.	O

Symptomatic	O
degenerative	O
disc	O
disease	O
is	O
the	O
major	O
cause	O
of	O
low	O
back	O
pain	O
with	O
lumbar	O
segmental	O
instability	O
.	O

ADR	O
has	O
increased	O
in	O
popularity	O
as	O
an	O
alternative	O
treatment	O
for	O
lumbar	O
disc	O
herniation	O
.	O

However	O
,	O
the	O
traditional	O
approach	O
to	O
spinal	O
surgery	O
carries	O
the	O
risk	O
of	O
catastrophic	O
bleeding	O
from	O
injury	O
to	O
major	O
vessels	O
,	O
as	O
well	O
as	O
iatrogenic	O
injury	O
to	O
the	O
viscera	O
and	O
associated	O
structures	O
.	O

Therefore	O
,	O
laparoscopic	B-P
lumbar	O
discectomy	O
and	O
ADR	O
may	O
represent	O
a	O
useful	O
alternative	O
.	O

Twenty-two	O
patients	O
(	O
8	O
males	O
and	O
14	O
females	O
)	O
who	O
were	O
diagnosed	O
with	O
symptomatic	O
degenerative	O
disc	O
disease	O
were	O
included	O
in	O
this	O
study	O
.	O

Seven	O
cases	O
involved	O
the	O
L4/5	O
level	O
,	O
and	O
15	O
cases	O
involved	O
the	O
L5/S1	O
level	O
.	O

All	O
patients	O
were	O
ineffective	O
after	O
at	O
least	O
6	O
months	O
of	O
conservative	O
treatments	O
;	O
all	O
patients	O
were	O
informed	O
of	O
the	O
surgery	O
before	O
the	O
operation	O
and	O
provided	O
consent	O
.	O

Three-dimensional	O
computed	B-P
tomographic	I-P
angiography	I-P
(	O
3D	O
-	O
CTA	B-P
)	O
of	O
the	O
iliac	O
great	O
blood	O
vessels	O
was	O
completed	O
before	O
the	O
surgery	O
.	O

All	O
surgical	O
procedures	O
were	O
performed	O
under	O
a	O
laparoscope	O
.	O

All	O
patients	O
were	O
followed	O
up	O
.	O

All	O
surgeries	O
were	O
successfully	O
completed	O
.	O

The	O
average	O
operation	O
time	O
was	O
120	O
minutes	O
(	O
range	O
110-150	O
min	O
)	O
,	O
and	O
the	O
average	O
hemorrhage	O
was	O
145	O
mL	O
(	O
range	O
80-360	O
mL	O
)	O
.	O

All	O
cases	O
underwent	O
X-rays	B-P
at	O
3	O
days	O
,	O
3	O
months	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
and	O
the	O
final	O
postoperative	O
follow-up	O
.	O

The	O
outcome	O
indicated	O
that	O
there	O
was	O
no	O
mobilization	O
,	O
displacement	O
,	O
or	O
subsidence	O
in	O
all	O
patients	O
with	O
the	O
exception	O
of	O
one	O
case	O
with	O
prosthesis	O
migration	O
.	O

The	O
follow-up	O
time	O
was	O
43.8	O
months	O
(	O
range	O
24-64	O
months	O
)	O
.	O

The	O
mean	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
and	O
Oswestry	O
scores	O
were	O
decreased	O
postoperatively	O
.	O

The	O
mean	O
improvement	O
rate	O
of	O
the	O
VAS	O
score	O
was	O
73.5	O
%	O
.	O

Lumbar	O
ADR	O
using	O
a	O
laparoscope	O
represents	O
a	O
novel	O
,	O
minimally	O
invasive	O
treatment	O
for	O
symptomatic	O
degenerative	O
disc	O
disease	O
and	O
severe	O
lumbar	O
discogenic	O
pain	O
.	O

Recommendations	O
for	O
CSF	O
AD	O
biomarkers	O
in	O
the	O
diagnostic	B-P
evaluation	O
of	O
dementia	O
.	O

This	O
article	O
presents	O
recommendations	O
,	O
based	O
on	O
the	O
Grading	O
of	O
Recommendations	O
,	O
Assessment	O
,	O
Development	O
,	O
and	O
Evaluation	O
method	O
,	O
for	O
the	O
clinical	O
application	O
of	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
amyloid-β1-42	O
,	O
tau	O
,	O
and	O
phosphorylated	O
tau	O
in	O
the	O
diagnostic	B-P
evaluation	O
of	O
patients	O
with	O
dementia	O
.	O

The	O
recommendations	O
were	O
developed	O
by	O
a	O
multidisciplinary	O
working	O
group	O
based	O
on	O
the	O
available	O
evidence	O
and	O
consensus	O
from	O
focused	O
discussions	O
for	O
(	O
i	O
)	O
identification	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
as	O
the	O
cause	O
of	O
dementia	O
,	O
(	O
ii	O
)	O
prediction	O
of	O
rate	O
of	O
decline	O
,	O
(	O
iii	O
)	O
cost-effectiveness	O
,	O
and	O
(	O
iv	O
)	O
interpretation	O
of	O
results	O
.	O

The	O
working	O
group	O
found	O
sufficient	O
evidence	O
to	O
support	O
a	O
recommendation	O
to	O
use	O
CSF	O
AD	O
biomarkers	O
as	O
a	O
supplement	O
to	O
clinical	O
evaluation	O
,	O
particularly	O
in	O
uncertain	O
and	O
atypical	O
cases	O
,	O
to	O
identify	O
or	O
exclude	O
AD	O
as	O
the	O
cause	O
of	O
dementia	O
.	O

Because	O
of	O
insufficient	O
evidence	O
,	O
it	O
was	O
uncertain	O
whether	O
CSF	O
AD	O
biomarkers	O
outperform	O
imaging	O
biomarkers	O
.	O

Operational	O
recommendations	O
for	O
the	O
interpretation	O
of	O
ambiguous	O
CSF	O
biomarker	O
results	O
were	O
also	O
provided	O
.	O

Capsular	O
Polysaccharide	O
Types	O
and	O
Virulence-Related	O
Traits	O
of	O
Epidemic	O
KPC	O
-	O
Producing	O
Klebsiella	O
pneumoniae	O
Isolates	O
in	O
a	O
Chinese	O
University	O
Hospital	O
.	O

Klebsiella	O
pneumoniae	O
is	O
an	O
important	O
human	O
pathogen	O
associated	O
with	O
a	O
variety	O
of	O
diseases	O
and	O
the	O
prevalence	O
of	O
blaKPC	O
carrying	O
K.	O
pneumoniae	O
(	O
KPC-Kp	O
)	O
is	O
rapidly	O
increasing	O
.	O

Capsule	O
is	O
an	O
important	O
virulence	O
factor	O
in	O
K.	O
pneumoniae	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
to	O
first	O
systematically	O
characterize	O
capsular	O
polysaccharide	O
(	O
CPS	O
)	O
and	O
virulence	O
traits	O
in	O
KPC-Kp	O
strains	O
.	O

A	O
total	O
of	O
56	O
KPC-Kp	O
isolates	O
were	O
recovered	O
from	O
clinical	O
samples	O
in	O
a	O
Chinese	O
hospital	O
,	O
which	O
were	O
assigned	O
to	O
clonal	O
lineages	O
by	O
multilocus	O
sequence	O
typing	O
(	O
MLST	O
)	O
.	O

Capsule	O
typing	O
(	O
wzi	B-P
sequencing	I-P
and	O
wzc	O
polymerase	O
chain	O
reaction	O
[	O
PCR	O
]	O
)	O
and	O
virulence	O
genes	O
were	O
characterized	O
by	O
molecular	B-P
approaches	I-P
.	O

The	O
virulence	O
of	O
these	O
strains	O
was	O
determined	O
by	O
biofilm	O
formation	O
,	O
serum	O
killing	O
resistance	O
,	O
phagocytosis	O
,	O
and	O
infection	O
models	O
.	O

Six	O
different	O
STs	O
were	O
found	O
among	O
56	O
KPC-Kp	O
isolates	O
:	O
76.8	O
%	O
(	O
43	O
of	O
56	O
isolates	O
)	O
belonged	O
to	O
ST11	O
,	O
6	O
isolates	O
belonged	O
to	O
ST147	O
,	O
4	O
isolates	O
belonged	O
to	O
ST15	O
,	O
1	O
isolate	O
belonged	O
to	O
ST1456	O
,	O
1	O
isolate	O
belonged	O
to	O
ST65	O
,	O
and	O
1	O
isolate	O
was	O
ST23	O
.	O

Based	O
on	O
the	O
wzi	B-P
gene	I-P
DNA	I-P
sequences	I-P
and	O
wzc	O
PCR	O
,	O
these	O
56	O
strains	O
were	O
classified	O
as	O
capsular	O
type	O
wzi47-K47	O
(	O
n	O
=	O
37	O
)	O
,	O
wzi64-K64	O
(	O
n	O
=	O
8	O
)	O
,	O
wzi8-K8	O
(	O
n	O
=	O
4	O
)	O
,	O
wzi37-K37	O
(	O
n	O
=	O
4	O
)	O
,	O
wzi53-K53	O
(	O
n	O
=	O
1	O
)	O
,	O
wzi125-K2	O
(	O
n	O
=	O
1	O
)	O
,	O
and	O
wzi1-K1	O
(	O
n	O
=	O
1	O
)	O
.	O

Heterogeneity	O
was	O
detected	O
in	O
biofilm	O
formation	O
and	O
phagocytosis	O
among	O
different	O
CPS	O
types	O
.	O

ST11	O
strains	O
were	O
less	O
virulent	O
than	O
other	O
ST	O
strains	O
.	O

KPC-Kp	O
strains	O
exhibit	O
variability	O
of	O
virulence-associated	O
traits	O
.	O

Differences	O
were	O
associated	O
with	O
the	O
ST	O
types	O
and	O
CPS	O
.	O

Pulmonary	O
homograft	O
stenosis	O
in	O
the	O
Ross	O
procedure	O
:	O
Incidence	O
,	O
clinical	O
impact	O
and	O
predictors	O
in	O
long-term	O
follow-up	O
.	O

The	O
Ross	O
procedure	O
is	O
used	O
in	O
the	O
treatment	O
of	O
selected	O
patients	O
with	O
aortic	O
valve	O
disease	O
.	O

Pulmonary	O
graft	O
stenosis	O
can	O
appear	O
in	O
the	O
long-term	O
follow-up	O
after	O
the	O
Ross	O
intervention	O
,	O
but	O
the	O
factors	O
involved	O
and	O
its	O
clinical	O
implications	O
are	O
not	O
fully	O
known	O
.	O

To	O
describe	O
the	O
incidence	O
,	O
clinical	O
impact	O
and	O
predictors	O
of	O
homograft	O
stenosis	O
and	O
reintervention	O
after	O
the	O
Ross	O
procedure	O
in	O
a	O
prospective	O
series	O
in	O
a	O
tertiary	O
referral	O
hospital	O
.	O

From	O
1997	O
to	O
2009	O
,	O
107	O
patients	O
underwent	O
the	O
Ross	O
procedure	O
(	O
mean	O
age	O
:	O
30±11	O
years	O
;	O
69	O
%	O
men	O
;	O
21	O
aged	O
<	O
18	O
years	O
)	O
,	O
and	O
were	O
followed	O
for	O
echocardiographic	B-P
homograft	O
stenosis	O
(	O
peak	O
gradient	O
>	O
36mmHg	O
)	O
and	O
surgical	O
or	O
percutaneous	O
homograft	O
reintervention	O
.	O

After	O
15	O
years	O
of	O
follow-up	O
(	O
median	O
:	O
11	O
years	O
)	O
,	O
echocardiographic	B-P
and	O
clinical	O
data	O
were	O
available	O
in	O
91	O
(	O
85	O
%	O
)	O
and	O
104	O
(	O
98	O
%	O
)	O
patients	O
,	O
respectively	O
:	O
26/91	O
(	O
29	O
%	O
)	O
patients	O
developed	O
homograft	O
stenosis	O
;	O
10/104	O
(	O
10	O
%	O
)	O
patients	O
underwent	O
13	O
homograft	O
reintervention	O
procedures	O
(	O
three	O
patients	O
underwent	O
surgical	O
replacement	O
,	O
three	O
received	O
a	O
percutaneous	O
pulmonary	O
valve	O
and	O
one	O
needed	O
stent	O
implantation	O
)	O
.	O

The	O
other	O
three	O
patients	O
underwent	O
two	O
consecutive	O
procedures	O
in	O
follow-up	O
;	O
one	O
died	O
because	O
of	O
a	O
procedure-related	O
myocardial	O
infarction	O
.	O

Rates	O
of	O
survival	O
free	O
from	O
homograft	O
stenosis	O
and	O
reintervention	O
at	O
1	O
,	O
5	O
and	O
10	O
years	O
were	O
96	O
%	O
,	O
82	O
%	O
and	O
75	O
%	O
and	O
99	O
%	O
,	O
94	O
%	O
and	O
91	O
%	O
,	O
respectively	O
.	O

Paediatric	O
patients	O
had	O
worse	O
survival	O
free	O
from	O
homograft	O
stenosis	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
3.50	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.56-7.90	O
;	O
P=0.002	O
)	O
,	O
although	O
there	O
were	O
no	O
significant	O
differences	O
regarding	O
reintervention	O
(	O
HR	O
:	O
2.01	O
,	O
95	O
%	O
CI	O
:	O
0.52-7.78	O
;	O
P=0.31	O
)	O
.	O

Younger	O
age	O
of	O
homograft	O
donor	O
was	O
also	O
a	O
stenosis	O
predictor	O
(	O
HR	O
:	O
0.97	O
,	O
95	O
%	O
CI	O
:	O
0.94-0.99	O
;	O
P=0.046	O
)	O
.	O

The	O
probabilities	O
of	O
homograft	O
stenosis	O
and	O
reintervention	O
10	O
years	O
after	O
the	O
Ross	O
procedure	O
were	O
29	O
%	O
and	O
10	O
%	O
,	O
respectively	O
;	O
only	O
one	O
patient	O
had	O
a	O
reintervention	O
-related	O
death	O
.	O

Younger	O
donor	O
and	O
recipient	O
age	O
were	O
associated	O
with	O
a	O
higher	O
rate	O
of	O
stenosis	O
.	O

Extensor	O
indicis	O
proprius	O
tendon	O
transfer	O
using	O
shear	B-P
wave	I-P
elastography	I-P
.	O

The	O
means	O
for	O
judging	O
optimal	O
tension	O
during	O
tendon	O
transfers	O
are	O
approximate	O
and	O
not	O
very	O
quantifiable	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
demonstrate	O
the	O
feasibility	O
of	O
quantitatively	O
assessing	O
muscular	O
mechanical	O
properties	O
intraoperatively	O
using	O
ultrasound	B-P
elastography	I-P
(	O
shear	B-P
wave	I-P
elastography	I-P
[	O
SWE	B-P
]	O
)	O
during	O
extensor	O
indicis	O
proprius	O
(	O
EIP	O
)	O
transfer	O
.	O

We	O
report	O
two	O
cases	O
of	O
EIP	O
transfer	O
for	O
post-traumatic	O
rupture	O
of	O
the	O
extensor	O
pollicis	O
longus	O
muscle	O
.	O

Ultrasound	O
acquisitions	O
measured	O
the	O
elasticity	O
modulus	O
of	O
the	O
EIP	O
muscle	O
at	O
different	O
stages	O
:	O
rest	O
,	O
active	O
extension	O
,	O
active	O
extension	O
against	O
resistance	O
,	O
EIP	O
section	O
,	O
distal	O
passive	O
traction	O
of	O
the	O
tendon	O
,	O
after	O
tendon	O
transfer	O
at	O
rest	O
and	O
then	O
during	O
active	O
extension	O
.	O

A	O
preliminary	O
analysis	O
was	O
conducted	O
of	O
the	O
distribution	O
of	O
values	O
for	O
this	O
modulus	O
at	O
the	O
various	O
transfer	O
steps	O
.	O

Different	O
shear	O
wave	O
velocity	O
and	O
elasticity	O
modulus	O
values	O
were	O
observed	O
at	O
the	O
various	O
transfer	O
steps	O
.	O

The	O
tension	O
applied	O
during	O
the	O
transfer	O
seemed	O
close	O
to	O
the	O
resting	O
tension	O
if	O
a	O
traditional	O
protocol	O
were	O
followed	O
.	O

The	O
elasticity	O
modulus	O
varied	O
by	O
a	O
factor	O
of	O
37	O
between	O
the	O
active	O
extension	O
against	O
resistance	O
step	O
(	O
565.1	O
kPa	O
)	O
and	O
after	O
the	O
tendon	O
section	O
(	O
15.3	O
kPa	O
)	O
.	O

The	O
elasticity	O
modulus	O
values	O
were	O
distributed	O
in	O
the	O
same	O
way	O
for	O
each	O
patient	O
.	O

The	O
therapeutic	O
benefit	O
of	O
SWE	B-P
elastography	B-P
was	O
studied	O
for	O
the	O
first	O
time	O
in	O
tendon	O
transfers	O
.	O

Quantitative	O
data	O
on	O
the	O
elasticity	O
modulus	O
during	O
this	O
test	O
may	O
make	O
it	O
an	O
effective	O
means	O
of	O
improving	O
intraoperative	O
adjustments	O
.	O

Correlation	O
of	O
Technetium-99m	O
Macroaggregated	O
Albumin	O
and	O
Yttrium-90	O
Glass	O
Microsphere	O
Biodistribution	O
in	O
Hepatocellular	O
Carcinoma	O
:	O
A	O
Retrospective	O
Review	O
of	O
Pretreatment	B-P
Single	I-P
Photon	I-P
Emission	I-P
CT	I-P
and	O
Posttreatment	B-P
Positron	I-P
Emission	I-P
Tomography/CT	I-P
.	O

To	O
evaluate	O
whether	O
technetium-99	O
(	O
(	O
99m	O
)	O
Tc	O
)	O
-labeled	O
macroaggregated	O
albumin	O
(	O
MAA	O
)	O
can	O
predict	O
subsequent	O
yttrium-90	O
(	O
(	O
90	O
)	O
Y	O
)	O
distribution	O
and	O
imaging	B-P
response	O
in	O
patients	O
with	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
.	O

Retrospective	O
review	O
was	O
performed	O
of	O
records	O
of	O
83	O
patients	O
with	O
HCC	O
who	O
underwent	O
(	O
90	O
)	O
Y	O
glass	O
microsphere	O
radioembolization	O
with	O
(	O
99m	O
)	O
Tc-MAA	O
single	B-P
photon	I-P
emission	I-P
computed	I-P
tomography	I-P
(	O
SPECT	B-P
)	O
and	O
(	O
90	O
)	O
Y	O
positron	B-P
emission	I-P
tomography	I-P
(	B-P
PET	I-P
)	I-P
/CT	I-P
between	O
January	O
2013	O
and	O
December	O
2014	O
.	O

Images	O
were	O
fused	O
to	O
segment	O
the	O
whole	O
liver	O
normal	O
tissue	O
(	O
WLNT	O
)	O
and	O
the	O
largest	O
tumors	O
.	O

Fused	O
images	O
were	O
reviewed	O
and	O
analyzed	O
for	O
comparison	O
of	O
absorbed	O
dose	O
(	O
AD	O
)	O
to	O
tumors	O
and	O
WLNT	O
as	O
calculated	O
from	O
(	O
99m	O
)	O
Tc-MAA	O
SPECT	B-P
and	O
from	O
(	O
90	O
)	O
Y	O
PET/CT	B-P
,	O
subjective	O
imaging	B-P
comparison	O
of	O
(	O
99m	O
)	O
Tc-MAA	O
SPECT	B-P
and	O
(	O
90	O
)	O
Y	O
PET	B-P
for	O
tumors	O
and	O
WLNT	O
,	O
and	O
correlation	O
of	O
tumoral	O
AD	O
with	O
response	O
on	O
follow-up	O
CT	B-P
.	O

Final	O
analysis	O
included	O
73	O
and	O
63	O
patients	O
for	O
WLNT	O
and	O
tumor	O
(	O
99m	O
)	O
Tc-MAA	O
/	O
(	O
90	O
)	O
Y	O
correlation	O
,	O
respectively	O
,	O
and	O
62	O
patients	O
for	O
AD	O
vs	O
response	O
.	O

(	O
99m	O
)	O
Tc-MAA	O
/	O
(	O
90	O
)	O
Y	O
limit	O
of	O
agreement	O
for	O
each	O
reviewer	O
was	O
viewed	O
as	O
clinically	O
acceptable	O
only	O
for	O
WLNT	O
(	O
-15	O
to	O
15	O
Gy	O
)	O
.	O

AD	O
interreviewer	O
variability	O
was	O
clinically	O
acceptable	O
for	O
WLNT	O
but	O
was	O
too	O
broad	O
for	O
tumor	O
.	O

Mean	O
tumor	O
AD	O
for	O
objective	O
response	O
(	O
78	O
%	O
)	O
was	O
313	O
Gy	O
vs	O
234	O
Gy	O
for	O
nonresponders	O
.	O

No	O
threshold	O
was	O
found	O
between	O
tumor	O
AD	O
and	O
response	O
(	O
P	O
>	O
.1	O
)	O
.	O

Catheter	O
mismatch	O
between	O
(	O
99m	O
)	O
Tc-MAA	O
and	O
(	O
90	O
)	O
Y	O
had	O
a	O
direct	O
impact	O
on	O
AD	O
mismatch	O
between	O
the	O
2	O
image	O
sets	O
.	O

(	O
99m	O
)	O
Tc-MAA	O
was	O
found	O
to	O
be	O
a	O
poor	O
surrogate	O
to	O
quantitatively	O
predict	O
subsequent	O
(	O
90	O
)	O
Y	O
AD	O
to	O
hepatocellular	O
tumors	O
.	O

(	O
99m	O
)	O
Tc-MAA	O
distribution	O
correlated	O
with	O
(	O
90	O
)	O
Y	O
distribution	O
in	O
the	O
normal	O
hepatic	O
parenchyma	O
.	O

Outlining	O
a	O
Population	O
``	O
at	O
Risk	O
''	O
of	O
Parkinson	O
's	O
Disease	O
:	O
Evidence	O
from	O
a	O
Case-Control	O
Study	O
.	O

The	O
multifactorial	O
pathogenesis	O
of	O
Parkinson	O
's	O
Disease	O
(	O
PD	O
)	O
requires	O
a	O
careful	O
identification	O
of	O
populations	O
``	O
at	O
risk	O
''	O
of	O
developing	O
the	O
disease	O
.	O

In	O
this	O
case-control	O
study	O
we	O
analyzed	O
a	O
large	O
Italian	O
population	O
,	O
in	O
an	O
attempt	O
to	O
outline	O
general	O
criteria	O
to	O
define	O
a	O
population	O
``	O
at	O
risk	O
''	O
of	O
PD	O
.	O

We	O
enrolled	O
300	O
PD	O
patients	O
and	O
300	O
controls	O
,	O
gender	O
and	O
age	O
matched	O
,	O
from	O
the	O
same	O
urban	O
geographical	O
area	O
.	O

All	O
subjects	O
were	O
interviewed	O
on	O
demographics	O
,	O
family	O
history	O
of	O
PD	O
,	O
occupational	O
and	O
environmental	O
toxicants	O
exposure	O
,	O
smoking	O
status	O
,	O
and	O
alcohol	O
consumption	O
.	O

A	O
sample	O
of	O
65	O
patients	O
and	O
65	O
controls	O
also	O
underwent	O
serum	O
dosing	O
of	O
iron	B-P
,	O
copper	B-P
,	O
mercury	B-P
,	O
and	O
manganese	B-P
by	O
means	O
of	O
Inductively	B-P
Coupled-Plasma-Mass-Spectrometry	I-P
(	O
ICP-MS	B-P
)	O
.	O

Positive	O
family	O
history	O
,	O
toxicants	O
exposure	O
,	O
non-current-smoker	O
,	O
and	O
alcohol	O
nonconsumer	O
status	O
occurred	O
as	O
significant	O
risk	O
factors	O
in	O
our	O
population	O
.	O

The	O
number	O
of	O
concurring	O
risk	O
factors	O
overlapping	O
in	O
the	O
same	O
subject	O
impressively	O
increased	O
the	O
overall	O
risk	O
.	O

No	O
significant	O
differences	O
were	O
measured	O
in	O
the	O
metal	O
serum	O
levels	O
.	O

Our	O
findings	O
indicate	O
that	O
combination	O
of	O
three	O
to	O
four	O
concurrent	O
PD	O
-	O
risk	O
factors	O
defines	O
a	O
condition	O
``	O
at	O
risk	O
``	O
of	O
PD	O
.	O

A	O
simple	O
stratification	O
,	O
based	O
on	O
these	O
questionnaires	O
,	O
might	O
be	O
of	O
help	O
in	O
identifying	O
subjects	O
suitable	O
for	O
neuroprotective	O
strategies	O
.	O

Noncommunicable	O
disease	O
in	O
rural	O
India	O
:	O
Are	O
we	O
seriously	O
underestimating	O
the	O
risk	O
?	O

The	O
Nallampatti	O
noncommunicable	O
disease	O
study	O
.	O

To	O
assess	O
the	O
prevalence	O
of	O
noncommunicable	O
diseases	O
in	O
a	O
true	O
rural	O
farming	O
population	O
in	O
South	O
India	O
and	O
compare	O
the	O
data	O
with	O
the	O
landmark	O
contemporary	O
Indian	O
Council	O
of	O
Medical	O
Research-India	O
Diabetes	O
(	O
ICMR-INDIAB	O
)	O
study	O
.	O

Local	O
Ethics	O
Committee	O
approval	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	O
.	O

Inclusion	O
criteria	O
were	O
participants	O
,	O
aged	O
≥20	O
and	O
≤85	O
years	O
,	O
from	O
Nallampatti	O
,	O
a	O
classical	O
farming	O
village	O
from	O
Tamil	O
Nadu	O
state	O
,	O
India	O
.	O

All	O
participants	O
were	O
administered	O
a	O
detailed	O
questionnaire	O
,	O
had	O
anthropometric	O
measurements	O
including	O
height	O
,	O
weight	O
,	O
and	O
waist	O
circumference	O
.	O

Bloods	O
were	O
drawn	O
for	O
random	B-P
blood	I-P
glucose	I-P
,	O
glycated	B-P
hemoglobin	I-P
(	O
HbA1c	B-P
)	O
,	O
nonfasting	B-P
lipid	I-P
profile	I-P
,	O
Cystatin	B-P
C	I-P
,	O
uric	B-P
acid	I-P
,	O
and	O
hemoglobin	B-P
.	O

All	O
participants	O
had	O
carotid	O
intima-media	O
thickness	O
(	O
CIMT	O
)	O
done	O
by	O
high-resolution	B-P
B-mode	B-P
carotid	I-P
ultrasound	I-P
.	O

More	O
than	O
50	O
%	O
of	O
the	O
population	O
had	O
either	O
diabetes	O
or	O
prediabetes	O
based	O
on	O
HbA1c	O
.	O

Nearly	O
,	O
40	O
%	O
of	O
the	O
population	O
had	O
hypertension	O
with	O
suboptimal	O
control	O
in	O
those	O
with	O
known	O
hypertension	O
.	O

Nearly	O
,	O
a	O
third	O
of	O
the	O
population	O
had	O
dyslipidemia	O
,	O
elevated	B-P
cystatin	I-P
C	I-P
levels	I-P
,	O
and	O
abnormal	O
CIMT	O
.	O

The	O
burden	O
was	O
higher	O
than	O
the	O
comparable	O
ICMR-INDIAB	O
study	O
in	O
rural	O
Tamil	O
Nadu	O
.	O

One-third	O
to	O
one-half	O
of	O
this	O
rural	O
farming	O
population	O
is	O
at	O
risk	O
of	O
cardiovascular	O
disease	O
,	O
with	O
poor	O
control	O
of	O
preexisting	O
cardiovascular	O
risk	O
factors	O
.	O

Current	O
Indian	O
data	O
may	O
underestimate	O
the	O
risk	O
in	O
different	O
ethnic	O
populations	O
and	O
regions	O
of	O
India	O
.	O

Long-term	O
follow-up	O
of	O
this	O
cohort	O
for	O
the	O
incident	O
cardiovascular	O
disease	O
will	O
shed	O
light	O
on	O
the	O
true	O
cardiovascular	O
risk	O
in	O
a	O
typical	O
South	O
Indian	O
rural	O
farming	O
population	O
.	O

A	O
miniature	O
bird	O
-borne	O
passive	O
air	O
sampler	O
for	O
monitoring	O
halogenated	O
flame	O
retardants	O
.	O

Birds	O
have	O
been	O
used	O
intensively	O
as	O
biomonitors	O
of	O
halogenated	O
flame	O
retardants	O
(	O
HFRs	O
)	O
,	O
and	O
several	O
studies	O
have	O
reported	O
elevated	O
tissue	O
concentrations	O
and	O
inter-	O
individual	O
variability	O
for	O
these	O
contaminants	O
.	O

While	O
diet	O
is	O
known	O
to	O
be	O
an	O
important	O
exposure	O
pathway	O
for	O
HFRs	O
in	O
birds	O
,	O
it	O
has	O
been	O
suggested	O
that	O
exposure	O
through	O
air	O
may	O
represent	O
an	O
underestimated	O
source	O
of	O
HFRs	O
for	O
certain	O
species	O
.	O

However	O
,	O
a	O
method	O
was	O
not	O
available	O
for	O
measuring	O
the	O
atmospheric	O
exposure	O
of	O
individual	O
birds	O
to	O
HFRs	O
or	O
other	O
semi-volatile	O
contaminants	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
bird	O
-borne	O
passive	O
air	O
sampler	O
(	O
PAS	O
)	O
enabling	O
the	O
determination	B-P
of	O
individual	O
atmospheric	O
exposure	O
to	O
gas	O
-	O
and	O
particle-phase	O
HFRs	O
using	O
the	O
ring-billed	O
gull	O
(	O
Larus	O
delawarensis	O
)	O
nesting	O
in	O
the	O
Montreal	O
area	O
(	O
QC	O
,	O
Canada	O
)	O
.	O

The	O
new	O
miniaturized	O
elliptical-shaped	O
PAS	O
(	O
mean	O
weight	O
:	O
2.72g	O
)	O
was	O
tested	O
using	O
two	B-P
sorbent	I-P
types	I-P
during	O
three	O
exposure	O
periods	O
(	O
one	O
,	O
two	O
and	O
three	O
weeks	O
)	O
.	O

Results	O
showed	O
that	O
PAS	O
using	O
polyurethane	O
foam	O
(	O
PUF	O
)	O
combined	O
with	O
a	O
glass	O
fiber	O
filter	O
collected	O
all	O
major	O
polybrominated	O
diphenyl	O
ethers	O
(	O
PBDEs	O
)	O
and	O
exhibited	O
better	O
performance	O
for	O
collecting	O
highly	O
hydrophobic	O
DecaBDE	O
mixture	O
congeners	O
compared	O
to	O
the	O
PAS	O
using	O
polydimethylsiloxane	O
(	O
PDMS	O
)	O
.	O

Emerging	O
HFRs	O
including	O
hexabromobenzene	O
,	O
Dechlorane	O
604	O
Component	O
B	O
,	O
and	O
Dechlorane	O
plus	O
(	O
DP	O
)	O
isomers	O
also	O
were	O
sampled	B-P
by	O
the	O
PUF	O
-based	O
PAS	O
.	O

Sampling	B-P
rates	O
for	O
most	O
HFRs	O
were	O
comparable	O
between	O
the	O
three	O
exposure	O
periods	O
.	O

This	O
novel	O
bird	O
-borne	O
PAS	O
provides	O
valuable	O
information	O
on	O
the	O
non-dietary	O
exposure	O
of	O
free-ranging	O
birds	O
to	O
HFRs	O
.	O

Perceived	O
image	O
quality	O
with	O
simulated	O
segmented	O
bifocal	O
corrections	O
.	O

Bifocal	O
contact	O
or	O
intraocular	O
lenses	O
use	O
the	O
principle	O
of	O
simultaneous	O
vision	O
to	O
correct	O
for	O
presbyopia	O
.	O

A	O
modified	O
two-channel	O
simultaneous	O
vision	O
simulator	O
provided	O
with	O
an	O
amplitude	O
transmission	O
spatial	O
light	O
modulator	O
was	O
used	O
to	O
optically	O
simulate	O
14	O
segmented	O
bifocal	O
patterns	O
(	O
+	O
3	O
diopters	O
addition	O
)	O
with	O
different	O
far/near	O
pupillary	O
distributions	O
of	O
equal	O
energy	O
.	O

Five	O
subjects	O
with	O
paralyzed	O
accommodation	O
evaluated	O
image	O
quality	O
and	O
subjective	O
preference	O
through	O
the	O
segmented	O
bifocal	O
corrections	O
.	O

There	O
are	O
strong	O
and	O
systematic	O
perceptual	O
differences	O
across	O
the	O
patterns	O
,	O
subjects	O
and	O
observation	B-P
distances	I-P
:	O
48	O
%	O
of	O
the	O
conditions	O
evaluated	O
were	O
significantly	O
preferred	O
or	O
rejected	O
.	O

Optical	O
simulations	O
(	O
in	O
terms	O
of	O
through-	O
focus	O
Strehl	O
ratio	O
from	O
Hartmann-Shack	O
aberrometry	O
)	O
accurately	O
predicted	O
the	O
pattern	O
producing	O
the	O
highest	O
perceived	O
quality	O
in	O
4	O
out	O
of	O
5	O
patients	O
,	O
both	O
for	O
far	O
and	O
near	O
vision	O
.	O

These	O
perceptual	O
differences	O
found	O
arise	O
primarily	O
from	O
optical	O
grounds	O
,	O
but	O
have	O
an	O
important	O
neural	O
component	O
.	O

3D	O
printing	O
scaffold	O
coupled	O
with	O
low	O
level	O
light	O
therapy	O
for	O
neural	O
tissue	O
regeneration	O
.	O

3D	O
printing	O
has	O
shown	O
promise	O
for	O
neural	O
regeneration	O
by	O
providing	O
customized	O
nerve	O
scaffolds	O
to	O
structurally	O
support	O
and	O
bridge	O
the	O
defect	O
gap	O
as	O
well	O
as	O
deliver	O
cells	O
or	O
various	O
bioactive	O
substances	O
.	O

Low-level	O
light	O
therapy	O
(	O
LLLT	O
)	O
exhibits	O
positive	O
effects	O
on	O
rehabiliation	O
of	O
degenerative	O
nerves	O
and	O
neural	O
disorders	O
.	O

With	O
this	O
in	O
mind	O
,	O
we	O
postulate	O
that	O
3D	O
printed	O
neural	O
scaffold	O
coupling	O
with	O
LLLT	O
will	O
generate	O
a	O
new	O
strategy	O
to	O
repair	O
neural	O
degeneration	O
.	O

To	O
achieve	O
this	O
goal	O
,	O
we	O
applied	O
red	O
laser	O
light	O
to	O
stimualte	O
neural	O
stem	O
cells	O
on	O
3D	O
printed	O
scaffolds	O
and	O
investigated	O
the	O
subsequent	O
cell	O
response	O
with	O
respect	O
to	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Here	O
we	O
show	O
that	O
cell	O
prolifeartion	O
rate	O
and	O
intracellular	O
reactive	O
oxgen	O
species	O
synthesis	O
were	O
significantly	O
increased	O
after	O
15	O
s	O
laser	O
stimulation	O
follwed	O
by	O
1	O
d	O
culture	B-P
.	O

Over	O
culturing	B-P
time	O
of	O
14	O
d	O
in	O
vitro	O
,	O
the	O
laser	O
stimulation	O
promoted	O
neuronal	O
differentiation	O
of	O
neural	O
stem	O
cells	O
,	O
while	O
the	O
glial	O
differentiation	O
was	O
suppressed	O
based	O
on	O
results	O
of	O
both	O
immunocytochemistry	B-P
studies	O
and	O
real-time	O
quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
testing	O
.	O

These	O
findings	O
suggest	O
that	O
integration	O
of	O
3D	O
printing	O
and	O
LLLT	O
might	O
provide	O
a	O
powerful	O
methodology	O
for	O
neural	O
tissue	O
engineering	O
.	O

Bi-directional	O
DNA	O
Walking	O
Machine	O
and	O
Its	O
Application	O
in	O
an	O
Enzyme-Free	B-P
Electrochemiluminescence	I-P
Biosensor	O
for	O
Sensitive	O
Detection	O
of	O
MicroRNAs	O
.	O

Herein	O
,	O
a	O
dual	O
microRNA	O
(	O
miRNA	O
)	O
powered	O
bi-directional	O
DNA	O
walking	O
machine	O
with	O
precise	O
control	O
was	O
developed	O
to	O
fabricate	O
an	O
enzyme-free	O
biosensor	O
on	O
the	O
basis	O
of	O
distance-based	O
electrochemiluminescence	B-P
(	O
ECL	B-P
)	O
energy	O
transfer	O
for	O
multiple	O
detection	O
of	O
miRNAs	O
.	O

By	O
using	O
miRNA-21	O
as	O
the	O
driving	O
force	O
,	O
the	O
DNA	O
walker	O
could	O
move	O
forth	O
along	O
the	O
track	O
and	O
generated	O
quenching	O
of	O
ECL	B-P
response	O
due	O
to	O
the	O
proximity	O
between	O
Au	O
nanoparticles	O
(	O
AuNPs	O
)	O
and	O
Mn	O
(	O
2+	O
)	O
doped	O
CdS	O
nanocrystals	O
(	O
CdS	O
:	O
Mn	O
NCs	O
)	O
film	O
as	O
the	O
ECL	B-P
emitters	O
,	O
realizing	O
ultrasensitive	O
determination	B-P
of	O
miRNA-21	O
.	O

Impressively	O
,	O
once	O
miRNA-155	O
was	O
introduced	O
as	O
the	O
driving	O
force	O
,	O
the	O
walker	O
could	O
move	O
back	O
along	O
the	O
track	O
automatically	O
,	O
and	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
occurred	O
owing	O
to	O
the	O
appropriate	O
large	O
separation	O
between	O
AuNPs	O
and	O
CdS	O
:	O
Mn	O
NCs	O
,	O
achieving	O
an	O
ECL	B-P
enhancement	O
and	O
realizing	O
ultrasensitive	O
detection	O
of	O
miRNA-155	O
.	O

The	O
bi-directiona	O
l	O
movement	O
of	O
the	O
DNA	O
walker	O
on	O
the	O
track	O
led	O
to	O
continuous	O
distance-based	O
energy	O
transfer	O
from	O
CdS	O
:	O
Mn	O
NCs	O
film	O
by	O
AuNPs	O
,	O
which	O
resulted	O
in	O
significant	O
ECL	B-P
signal	O
variation	O
of	O
CdS	O
:	O
Mn	O
NCs	O
for	O
multiple	O
detection	O
of	O
miRNA-21	O
and	O
miRNA-155	O
down	O
to	O
1.51	O
fM	O
and	O
1.67	O
fM	O
,	O
respectively	O
.	O

Amazingly	O
,	O
the	O
elaborated	O
biosensor	O
provided	O
a	O
new	O
chance	O
for	O
constructing	O
controllable	O
molecular	O
nanomachines	O
in	O
biosensing	B-P
,	O
disease	O
diagnosis	O
,	O
and	O
clinical	O
analysis	O
.	O

CD169	O
identifies	O
an	O
activated	O
CD8	O
(	O
+	O
)	O
T	O
cell	O
subset	O
in	O
regional	O
lymph	O
nodes	O
that	O
predicts	O
favorable	O
prognosis	O
in	O
colorectal	O
cancer	O
patients	O
.	O

CD169	O
was	O
first	O
identified	O
on	O
macrophages	O
(	O
Mϕ	O
)	O
and	O
linked	O
to	O
antigen	O
presentation	O
.	O

Here	O
,	O
we	O
showed	O
CD169	O
expression	O
on	O
some	O
CD8	O
(	O
+	O
)	O
T	O
lymphocytes	O
in	O
regional	O
lymph	O
nodes	O
(	O
LNs	O
)	O
and	O
investigated	O
the	O
function	O
and	O
clinical	O
relevance	O
of	O
CD169	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
in	O
tumor-draining	O
LNs	O
of	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
patients	O
.	O

Fresh	O
tumor-draining	O
LN	O
tissues	O
from	O
39	O
randomly	O
enrolled	O
patients	O
were	O
assessed	O
by	O
flow	B-P
cytometry	I-P
for	O
activation	O
and	O
differentiation	O
of	O
CD169	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
and	O
T	O
cell-mediated	O
killing	O
of	O
tumor	O
cells	O
.	O

In	O
total	O
,	O
114	O
tumor-draining	O
LN	O
paraffin	O
sections	O
from	O
CRC	O
patients	O
were	O
analyzed	O
by	O
multiple-color	B-P
immunofluorescence	I-P
for	O
CD169	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
T	O
cell	O
distribution	O
and	O
clinical	O
values	O
.	O

The	O
prognostic	O
significance	O
of	O
CD169	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
was	O
evaluated	O
by	O
Kaplan-Meier	O
analysis	O
.	O

A	O
fraction	O
of	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
in	O
regional	O
LNs	O
,	O
but	O
not	O
peripheral	O
blood	O
,	O
tonsils	O
,	O
or	O
tumors	O
,	O
expressed	O
surface	O
CD169	O
.	O

In	O
situ	O
detection	O
of	O
draining	O
LNs	O
revealed	O
preferential	O
localization	O
of	O
CD169	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
to	O
subcapsular	O
sinus	O
and	O
interfollicular	O
regions	O
,	O
closely	O
associated	O
with	O
CD169	O
(	O
+	O
)	O
Mϕ	O
.	O

CD169	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
T	O
cell	O
ratios	O
were	O
significantly	O
lower	O
in	O
peri-tumor	O
LNs	O
than	O
distant-tumor	O
LNs	O
.	O

CD169	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
predominantly	O
expressed	O
activation	O
markers	O
(	O
CD69	O
,	O
HLA-DR	O
,	O
PD-1	O
)	O
with	O
slightly	O
lower	O
CD45RA	O
and	O
CD62L	O
levels	O
.	O

They	O
produced	O
high	O
granzyme	O
B	O
,	O
perforin	O
,	O
TNF-α	O
,	O
and	O
IFNγ	O
levels	O
,	O
and	O
promoted	O
tumor-killing	O
efficiency	O
ex	O
vitro	O
.	O

Moreover	O
,	O
CD169	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
infiltrating	O
tumor-draining	O
LNs	O
decreased	O
with	O
disease	O
progression	O
and	O
were	O
strongly	O
associated	O
with	O
CRC	O
patient	O
survival	O
.	O

We	O
identified	O
novel	O
activated	O
/	O
cytolytic	O
CD169	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
selectively	O
present	O
in	O
regional	O
LNs	O
,	O
potentially	O
serving	O
as	O
a	O
powerful	O
prognostic	O
factor	O
and	O
indicator	O
for	O
selecting	O
patients	O
for	O
immunotherapy	O
.	O

Radiofrequency	O
ablation	O
of	O
posteroseptal	O
accessory	O
pathways	O
associated	O
with	O
coronary	O
sinus	O
diverticula	O
.	O

Posteroseptal	O
accessory	O
pathways	O
may	O
be	O
associated	O
with	O
a	O
coronary	O
sinus	O
(	O
CS	O
)	O
diverticulum	O
.	O

Our	O
purpose	O
was	O
to	O
describe	O
the	O
clinical	O
characteristics	O
,	O
mapping	O
and	O
ablation	O
of	O
these	O
pathways	O
.	O

This	O
was	O
a	O
retrospective	O
study	O
of	O
all	O
patients	O
who	O
underwent	O
ablation	O
of	O
posteroseptal	O
accessory	O
pathways	O
in	O
a	O
single	O
centre	O
.	O

Patients	O
with	O
a	O
diverticulum	O
of	O
the	O
CS	O
or	O
one	O
of	O
its	O
tributaries	O
were	O
included	O
in	O
group	O
I	O
,	O
while	O
the	O
other	O
patients	O
formed	O
group	O
II	O
.	O

Clinical	O
presentation	O
,	O
ablation	O
procedure	O
and	O
outcome	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

A	O
total	O
of	O
51	O
patients	O
were	O
included	O
,	O
16	O
in	O
group	O
I	O
and	O
35	O
in	O
group	O
II	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
age	O
or	O
sex	O
distribution	O
.	O

Atrial	O
fibrillation	O
(	O
AF	O
)	O
and	O
previous	O
unsuccessful	O
ablation	O
were	O
more	O
common	O
in	O
group	O
I	O
.	O

A	O
negative	O
delta	O
wave	O
in	O
lead	O
II	O
was	O
the	O
ECG	B-P
finding	O
with	O
best	O
sensitivity	O
and	O
specificity	O
for	O
the	O
presence	O
of	O
a	O
diverticulum	O
.	O

A	O
pathway	O
potential	O
was	O
common	O
at	O
the	O
successful	O
site	O
in	O
group	O
I	O
,	O
and	O
the	O
interval	O
between	O
local	B-P
ventricular	I-P
electrogram	I-P
and	O
delta	O
wave	O
onset	O
was	O
shorter	O
(	O
19.5	O
±	O
8	O
vs	O
33.1	O
±	O
7.6	O
ms	O
,	O
p	O
<	O
0.001	O
)	O
.	O

There	O
was	O
a	O
trend	O
toward	O
lower	O
procedural	O
success	O
rate	O
and	O
higher	O
recurrence	O
rate	O
in	O
group	O
I	O
,	O
although	O
this	O
was	O
not	O
significant	O
.	O

CS	O
diverticula	O
should	O
be	O
suspected	O
in	O
patients	O
with	O
manifest	O
posteroseptal	O
accessory	O
pathways	O
who	O
have	O
a	O
previous	O
failed	O
ablation	O
,	O
documented	O
AF	O
or	O
typical	O
electrocardiographic	O
signs	O
.	O

A	O
discrete	O
potential	O
is	O
frequently	O
seen	O
at	O
the	O
successful	O
site	O
,	O
but	O
the	O
local	B-P
ventricular	I-P
electrogram	I-P
is	O
not	O
as	O
early	O
as	O
in	O
other	O
accessory	O
pathways	O
.	O

Enhancing	O
the	O
genome	O
editing	O
toolbox	O
:	O
genome	O
wide	O
CRISPR	O
arrayed	O
libraries	O
.	O

CRISPR-Cas9	O
technology	O
has	O
accelerated	O
biological	O
research	O
becoming	O
routine	O
for	O
many	O
laboratories	O
.	O

It	O
is	O
rapidly	O
replacing	O
conventional	O
gene	O
editing	O
techniques	O
and	O
has	O
high	O
utility	O
for	O
both	O
genome-wide	O
and	O
gene-focussed	O
applications	O
.	O

Here	O
we	O
present	O
the	O
first	O
individually	O
cloned	O
CRISPR-Cas9	O
genome	O
wide	O
arrayed	O
sgRNA	O
libraries	O
covering	O
17,166	O
human	O
and	O
20,430	O
mouse	O
genes	O
at	O
a	O
complexity	O
of	O
34,332	O
sgRNAs	O
for	O
human	O
and	O
40,860	O
sgRNAs	O
for	O
the	O
mouse	O
genome	O
.	O

For	O
flexibility	O
in	O
generating	O
stable	O
cell	O
lines	O
the	O
sgRNAs	O
have	O
been	O
cloned	O
in	O
a	O
lentivirus	O
backbone	O
containing	O
PiggyBac	O
transposase	O
recognition	O
elements	O
together	O
with	O
fluorescent	O
and	O
drug	O
selection	O
markers	O
.	O

Over	O
95	O
%	O
of	O
tested	O
sgRNA	O
induced	O
specific	O
DNA	O
cleavage	O
as	O
measured	O
by	O
CEL-1	O
assays	B-P
.	O

Furthermore	O
,	O
sgRNA	O
targeting	O
GPI	O
anchor	O
protein	O
pathway	O
genes	O
induced	O
loss	O
of	O
function	O
mutations	O
in	O
human	O
and	O
mouse	O
cell	O
lines	O
measured	O
by	O
FLAER	O
labelling	O
.	O

These	O
arrayed	O
libraries	O
offer	O
the	O
prospect	O
for	O
performing	O
screens	O
on	O
individual	O
genes	O
,	O
combinations	O
as	O
well	O
as	O
larger	O
gene	O
sets	O
.	O

They	O
also	O
facilitate	O
rapid	O
deconvolution	O
of	O
signals	O
from	O
genome-wide	O
screens	O
.	O

This	O
set	O
of	O
vectors	O
provide	O
an	O
organized	O
comprehensive	O
gene	O
editing	O
toolbox	O
of	O
considerable	O
scientific	O
value	O
.	O

Pentraxin	O
3	O
in	O
neonates	O
with	O
and	O
without	O
diagnosis	O
of	O
pulmonary	O
hypertension	O
.	O

Pentraxin	O
3	O
is	O
a	O
novel	O
biomarker	O
produced	O
by	O
vascular	O
endothelial	O
cells	O
and	O
macrophages	O
.	O

In	O
recent	O
studies	O
involving	O
adults	O
,	O
pentraxin	O
3	O
has	O
been	O
introduced	O
as	O
a	O
reliable	O
biomarker	O
in	O
the	O
evaluation	O
of	O
cardiovascular	O
disease	O
and	O
pulmonary	O
hypertension	O
.	O

This	O
study	O
was	O
conducted	O
with	O
an	O
aim	O
to	O
measure	O
the	O
level	O
of	O
pentraxin	O
3	O
in	O
neonates	O
with	O
pulmonary	O
hypertension	O
and	O
comparing	O
with	O
normal	O
healthy	O
controls	O
.	O

In	O
a	O
case-control	O
study	O
,	O
plasma	O
pentraxin	O
3	O
levels	O
were	O
evaluated	O
in	O
3	O
groups	O
of	O
neonates	O
including	O
neonates	O
with	O
pulmonary	O
arterial	O
hypertension	O
(	O
PAH	O
)	O
,	O
neonates	O
with	O
congenital	O
heart	O
disease	O
without	O
pulmonary	O
arterial	O
hypertension	O
(	O
CHD-PAH	O
)	O
and	O
normal	O
healthy	O
neonates	O
.	O

Plasma	O
pentraxin	O
3	O
levels	O
in	O
72	O
neonates	O
(	O
21	O
in	O
PAH	O
,	O
19	O
in	O
CHD-PAH	O
,	O
and	O
32	O
in	O
control	O
group	O
)	O
were	O
measured	O
.	O

Demographic	O
characteristics	O
had	O
no	O
significant	O
statistical	O
difference	O
among	O
the	O
3	O
groups	O
.	O

Pentraxin	O
3	O
levels	O
in	O
PAH	O
group	O
was	O
significantly	O
higher	O
than	O
CHD-PAH	O
and	O
control	O
groups	O
(	O
2.12±2.32	O
vs.	O
0.58±0.57	O
and	O
1.03±1.38ng/mL	O
,	O
P=0.008	O
,	O
respectively	O
)	O
.	O

No	O
significant	O
correlation	O
was	O
found	O
between	O
concentrations	O
of	O
pentraxin	O
3	O
and	O
cardiac	O
ejection	O
fractions	O
between	O
PAH	O
and	O
CHD-PAH	O
(	O
r=0.009	O
,	O
P=0.97	O
)	O
.	O

However	O
,	O
significant	O
positive	O
correlation	O
was	O
detected	O
between	O
PTX3	O
concentrations	O
and	O
pulmonary	B-P
pressures	I-P
between	O
these	O
two	O
groups	O
(	O
r=0.499	O
,	O
P=0.001	O
)	O
.	O

Results	O
from	O
our	O
study	O
showed	O
that	O
pentraxin	O
3	O
levels	O
were	O
increased	O
in	O
newborn	O
infants	O
with	O
pulmonary	O
hypertension	O
.	O

Plasma	O
pentraxin	O
3	O
could	O
be	O
considered	O
as	O
a	O
novel	O
adjunct	O
diagnostic	O
tool	O
in	O
the	O
evaluation	O
of	O
pulmonary	O
hypertension	O
in	O
combination	O
with	O
echocardiography	B-P
or	O
as	O
a	O
diagnostic	O
tool	O
when	O
echocardiography	B-P
is	O
not	O
readily	O
available	O
for	O
confirmation	O
of	O
increased	O
pulmonary	O
pressure	O
.	O

Interleukin-1β	O
induced	O
Stress	O
Granules	O
Sequester	O
COX-2	O
mRNA	O
and	O
Regulates	O
its	O
Stability	O
and	O
Translation	O
in	O
Human	O
OA	O
Chondrocytes	O
.	O

Enhanced	O
and	O
immediate	O
expression	O
of	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
mRNA	O
is	O
observed	O
in	O
IL-1β	O
-	O
stimulated	O
OA	O
chondrocytes	O
but	O
the	O
synthesis	O
of	O
protein	O
found	O
significantly	O
delayed	O
.	O

Here	O
we	O
investigated	O
the	O
role	O
of	O
stress	O
granules	O
(	O
SGs	O
)	O
,	O
ribonucleoprotein	O
complexes	O
that	O
regulate	O
mRNA	O
translation	O
,	O
in	O
the	O
delayed	O
translation	O
of	O
COX-2	O
mRNAs	O
in	O
IL-1β	O
-	O
stimulated	O
OA	O
chondrocytes	O
.	O

Stimulation	O
of	O
human	O
chondrocytes	O
with	O
IL-1β	O
activated	O
the	O
stress	O
response	O
genes	O
and	O
the	O
phosphorylation	O
of	O
eIF2α	O
that	O
triggered	O
the	O
assembly	O
of	O
SGs	O
.	O

Using	O
combined	O
immunofluorescence	B-P
staining	I-P
of	O
SGs	O
markers	O
and	O
COX-2	O
protein	O
,	O
RNA	O
fluorescence	O
in	O
situ	O
hybridization	O
and	O
RNA	O
immunoprecipitation	B-P
,	O
the	O
COX-2	O
mRNAs	O
were	O
found	O
sequestered	O
in	O
SGs	O
in	O
IL-1β	O
-	O
stimulated	O
OA	O
chondrocytes	O
.	O

No	O
increase	O
in	O
COX-2	O
protein	O
expression	O
was	O
observed	O
during	O
the	O
persistence	O
of	O
SGs	O
but	O
enhanced	O
expression	O
of	O
COX-2	O
protein	O
was	O
noted	O
upon	O
clearance	O
of	O
the	O
SGs	O
.	O

Inhibition	O
of	O
SGs	O
clearance	O
blocked	O
COX-2	O
mRNA	O
translation	O
whereas	O
blocking	O
the	O
assembly	O
of	O
SGs	O
by	O
TIA-1	O
depletion	O
resulted	O
in	O
rapid	O
and	O
increased	O
production	O
of	O
COX-2	O
and	O
PGE2	O
.	O

Our	O
findings	O
show	O
for	O
the	O
first	O
time	O
assembly	O
of	O
SGs	O
and	O
sequestration	O
of	O
COX-2	O
mRNAs	O
in	O
human	O
OA	O
chondrocytes	O
under	O
pathological	O
conditions	O
.	O

Post-transcriptional	O
regulation	O
of	O
COX-2	O
mRNAs	O
translation	O
by	O
SGs	O
indicates	O
a	O
role	O
in	O
IL-1β	O
-mediated	O
catabolic	O
response	O
that	O
could	O
be	O
therapeutically	O
targeted	O
in	O
OA	O
.	O

Quantitative	O
in	O
vivo	O
assessment	O
of	O
bone	O
microarchitecture	O
in	O
the	O
human	O
knee	O
using	O
HR-pQCT	B-P
.	O

High-resolution	B-P
peripheral	I-P
quantitative	I-P
computed	I-P
tomography	I-P
(	O
HR-pQCT	B-P
)	O
is	O
a	O
novel	O
imaging	O
modality	O
capable	O
of	O
visualizing	B-P
bone	O
microarchitecture	O
in	O
vivo	O
at	O
human	O
peripheral	O
sites	O
such	O
as	O
the	O
distal	O
radius	O
and	O
distal	O
tibia	O
.	O

This	O
research	O
has	O
extended	O
the	O
technology	O
to	O
provide	O
a	O
non-invasive	O
assessment	O
of	O
bone	O
microarchitecture	O
at	O
the	O
human	O
knee	O
by	O
establishing	O
new	O
hardware	O
,	O
imaging	B-P
protocols	O
and	O
data	O
analysis	O
.	O

A	O
custom	O
leg	O
holder	O
was	O
developed	O
to	O
stabilize	O
a	O
human	O
knee	O
centrally	O
within	O
a	O
second	B-P
generation	I-P
HR-pQCT	I-P
field	O
of	O
view	O
.	O

Five	O
participants	O
with	O
anterior	O
cruciate	O
ligament	O
reconstructions	O
had	O
their	O
knee	O
joint	O
imaged	B-P
in	O
a	O
continuous	O
scan	B-P
of	O
6cm	O
axially	O
.	O

The	O
nominal	O
isotropic	O
voxel	O
size	O
was	O
60.7μm	O
.	O

Bone	O
mineral	O
density	O
and	O
microarchitecture	O
were	O
assessed	O
within	O
the	O
weight-bearing	O
regions	O
of	O
medial	O
and	O
lateral	O
compartments	O
of	O
the	O
knee	O
at	O
three	O
depths	O
from	O
the	O
weight-bearing	O
articular	O
bone	O
surface	O
,	O
including	O
both	O
the	O
cortical	O
and	O
trabecular	O
bone	O
regions	O
.	O

Scan	O
duration	O
was	O
approximately	O
18min	O
per	O
knee	O
and	O
produced	O
5GB	O
of	O
projection	O
data	O
and	O
10GB	O
of	O
reconstructed	O
image	O
data	O
(	O
2304×2304	O
image	O
matrix	O
,	O
1008	O
slices	O
)	O
.	O

Motion	O
during	O
the	O
scan	B-P
was	O
minimized	O
by	O
the	O
leg	O
holder	O
and	O
was	O
similar	O
in	O
magnitude	O
as	O
a	O
scan	B-P
of	O
the	O
distal	O
tibia	O
.	O

Bone	O
mineral	O
density	O
and	O
microarchitectural	O
parameters	O
were	O
assessed	O
for	O
16	O
volumes	O
of	O
interest	O
in	O
the	O
tibiofemoral	O
joint	O
.	O

This	O
is	O
a	O
new	O
non-invasive	O
in	O
vivo	O
assessment	O
tool	O
for	O
bone	O
microarchitecture	O
in	O
the	O
human	O
knee	O
that	O
provides	O
an	O
opportunity	O
to	O
gain	O
insight	O
into	O
normal	O
,	O
injured	O
and	O
surgically	O
reconstructed	O
human	O
knee	O
bone	O
architecture	O
in	O
cross-sectional	O
or	O
longitudinal	O
studies	O
.	O

Cloning	O
and	O
sequence	O
analysis	O
of	O
Wild	O
Argali	O
short	O
palate	O
,	O
lung	O
and	O
nasal	O
epithelium	O
clone	O
1	O
cDNA	O
.	O

Experiments	O
were	O
conducted	O
to	O
clone	O
the	O
sequence	O
of	O
Wild	O
Argali	O
short	O
palate	O
,	O
lung	O
and	O
nasal	O
epithelium	O
clone	O
1	O
(	O
SPLUNC1	O
)	O
cDNA	O
,	O
and	O
to	O
lay	O
the	O
foundation	O
for	O
further	O
study	O
the	O
biological	O
function	O
of	O
Wild	O
Argali	O
SPLUNC1	O
.	O

The	O
complete	O
sequence	O
of	O
Wild	O
Argali	O
SPLUNC1	O
cDNA	O
was	O
generated	O
by	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
.	O

The	O
entire	O
coding	O
sequence	O
was	O
inserted	O
into	O
the	O
pPIC9K	O
vector	O
and	O
expressed	O
in	O
Pichia	O
pastoris	O
(	O
P.	O
pastoris	O
)	O
GS115	O
.	O

The	O
recombinant	O
SPLUNC1	O
protein	O
was	O
detected	O
by	O
Western	B-P
blot	I-P
and	O
purified	O
by	O
Ni	B-P
(	I-P
2+	I-P
)	I-P
chelate	I-P
affinity	I-P
chromatography	I-P
.	O

The	O
test	O
of	O
effect	O
of	O
the	O
protein	O
on	O
Mycoplasma	O
ovipneumoniae	O
(	O
MO	O
)	O
was	O
performed	O
with	O
real-time	O
polymerase	O
chain	O
reaction	O
.	O

The	O
Wild	O
Argali	O
SPLUNC1	O
cDNA	O
was	O
1,076	O
bp	O
with	O
an	O
open	O
reading	O
frame	O
of	O
768	O
bp	O
,	O
which	O
encoded	O
a	O
26.49	O
kDa	O
protein	O
composed	O
of	O
255	O
amino	O
acids	O
.	O

Its	O
amino	O
acid	O
sequence	O
shared	O
98.4	O
%	O
,	O
96.9	O
%	O
,	O
94.5	O
%	O
,	O
90.2	O
%	O
,	O
80.8	O
%	O
,	O
78.4	O
%	O
,	O
78.3	O
%	O
,	O
72.5	O
%	O
,	O
72.3	O
%	O
,	O
68.8	O
%	O
identity	O
with	O
those	O
of	O
SPLUNC1	O
cDNA	O
from	O
Ovis	O
aries	O
(	O
accession	O
no	O
.	O

NP_001288334.1	O
)	O
,	O
Capra	O
hircus	O
(	O
accession	O
no	O
.	O

XP_005688516.1	O
)	O
,	O
Pantholops	O
hodgsonii	O
(	O
accession	O
no	O
.	O

XP_005979709.1	O
)	O
,	O
Bos	O
taurus	O
(	O
accession	O
no	O
.	O

NP_776851.1	O
)	O
,	O
Felis	O
catus	O
(	O
accession	O
no	O
.	O

XP_006929910.1	O
)	O
,	O
Homo	O
sapiens	O
(	O
accession	O
no	O
.	O

NP_001230122.1	O
)	O
,	O
Sus	O
scrofa	O
(	O
accession	O
no	O
.	O

NP_001005727.1	O
)	O
,	O
Chinchilla	O
lanigera	O
(	O
accession	O
no	O
.	O

NP_001269294.1	O
)	O
,	O
Mus	O
musculus	O
(	O
accession	O
no	O
.	O

NP_035256.2	O
)	O
,	O
and	O
Rattus	O
norvegicus	O
(	O
accession	O
no	O
.	O

NP_742028.1	O
)	O
,	O
respectively	O
.	O

The	O
recombinant	O
protein	O
corresponded	O
to	O
the	O
expected	O
molecular	O
mass	O
of	O
25.47	O
kDa	O
as	O
judged	O
by	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
,	O
and	O
it	O
was	O
detected	O
in	O
the	O
supernatant	O
of	O
P.	O
pastoris	O
,	O
and	O
it	O
could	O
be	O
purified	O
.	O

The	O
results	O
from	O
the	O
test	O
of	O
inhibition	O
effect	O
of	O
argali	O
recombinant	O
SPLUNC1	O
protein	O
on	O
MO	O
showed	O
that	O
the	O
product	O
could	O
inhibit	O
MO	O
very	O
well	O
(	O
p	O
<	O
0.01	O
)	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
Wild	O
Argali	O
SPLUNC1	O
was	O
different	O
from	O
other	O
organisms	O
.	O

The	O
recombinant	O
SPLUNC1	O
protein	O
has	O
good	O
biological	O
activity	O
.	O

Biochemical	O
and	O
proteomic	O
analyses	O
of	O
the	O
physiological	O
response	O
induced	O
by	O
individual	O
housing	O
in	O
gilts	O
provide	O
new	O
potential	O
stress	O
markers	O
.	O

The	O
objective	O
assessment	O
of	O
animal	O
stress	O
and	O
welfare	O
requires	O
proper	O
laboratory	O
biomarkers	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
analyzed	O
the	O
changes	O
in	O
serum	O
composition	O
in	O
gilts	O
after	O
switching	O
their	O
housing	O
,	O
from	O
pen	O
to	O
individual	O
stalls	O
,	O
which	O
is	O
generally	O
accepted	O
to	O
cause	O
animal	O
discomfort	O
.	O

Blood	O
and	O
saliva	O
samples	O
were	O
collected	O
a	O
day	O
before	O
and	O
up	O
to	O
four	O
days	O
after	O
changing	O
the	O
housing	O
system	O
.	O

Biochemical	O
analyses	O
showed	O
adaptive	O
changes	O
in	O
lipid	O
and	O
protein	O
metabolism	O
after	O
the	O
housing	O
switch	O
,	O
whereas	O
cortisol	O
and	O
muscular	O
markers	O
showed	O
a	O
large	O
variability	O
between	O
animals	O
.	O

2D-DIGE	B-P
and	O
iTRAQ	O
proteomic	O
approaches	O
revealed	O
variations	O
in	O
serum	O
protein	O
composition	O
after	O
changing	O
housing	O
and	O
diet	O
of	O
gilts	O
.	O

Both	O
techniques	O
showed	O
alterations	O
in	O
two	O
main	O
homeostatic	O
mechanisms	O
:	O
the	O
innate	O
immune	O
and	O
redox	O
systems	O
.	O

The	O
acute	O
phase	O
proteins	O
haptoglobin	O
,	O
apolipoprotein	O
A-I	O
and	O
α1-antichymotrypsin	O
3	O
,	O
and	O
the	O
antioxidant	O
enzyme	O
peroxiredoxin	O
2	O
were	O
found	O
differentially	O
expressed	O
by	O
2D-DIGE	B-P
.	O

Other	O
proteins	O
related	O
to	O
the	O
innate	O
immune	O
system	O
,	O
including	O
lactotransferrin	O
,	O
protegrin	O
3	O
and	O
galectin	O
1	O
were	O
also	O
identified	O
by	O
iTRAQ	O
,	O
as	O
well	O
as	O
oxidative	O
stress	O
enzymes	O
such	O
as	O
peroxiredoxin	O
2	O
and	O
glutathione	O
peroxidase	O
3	O
.	O

Proteomics	O
also	O
revealed	O
the	O
decrease	O
of	O
apolipoproteins	O
,	O
and	O
the	O
presence	O
of	O
intracellular	O
proteins	O
in	O
serum	O
,	O
which	O
may	O
indicate	O
physical	O
injury	O
to	O
tissues	O
.	O

Housing	O
of	O
gilts	O
in	O
individual	O
stalls	O
and	O
diet	O
change	O
increase	O
lipid	O
and	O
protein	O
catabolism	O
,	O
oxidative	O
stress	O
,	O
activate	O
the	O
innate	O
immune	O
system	O
and	O
cause	O
a	O
certain	O
degree	O
of	O
tissue	O
damage	O
.	O

We	O
propose	O
that	O
valuable	O
assays	O
for	O
stress	B-P
assessment	I-P
in	O
gilts	O
may	O
be	O
based	O
on	O
a	O
score	O
composed	O
by	O
a	O
combination	O
of	O
salivary	O
cortisol	O
,	O
lipid	O
metabolites	O
,	O
innate	O
immunity	O
and	O
oxidative	O
stress	O
markers	O
and	O
intracellular	O
proteins	O
.	O

Personalized	O
Medicine	O
Approaches	O
in	O
Prostate	O
Cancer	O
Employing	O
Patient	O
Derived	O
3D	O
Organoids	O
and	O
Humanized	O
Mice	O
.	O

Prostate	O
cancer	O
(	O
PCa	O
)	O
is	O
the	O
most	O
common	O
malignancy	O
and	O
the	O
second	O
most	O
common	O
cause	O
of	O
cancer	O
death	O
in	O
Western	O
men	O
.	O

Despite	O
its	O
prevalence	O
,	O
PCa	O
has	O
proven	O
very	O
difficult	O
to	O
propagate	O
in	O
vitro	O
.	O

PCa	O
represents	O
a	O
complex	O
organ-like	O
multicellular	O
structure	O
maintained	O
by	O
the	O
dynamic	O
interaction	O
of	O
tumoral	O
cells	O
with	O
parenchymal	O
stroma	O
,	O
endothelial	O
and	O
immune	O
cells	O
,	O
and	O
components	O
of	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
.	O

The	O
lack	O
of	O
PCa	O
models	O
that	O
recapitulate	O
this	O
intricate	O
system	O
has	O
hampered	O
progress	O
toward	O
understanding	O
disease	O
progression	O
and	O
lackluster	O
therapeutic	O
responses	O
.	O

Tissue	O
slices	O
,	O
monolayer	B-P
cultures	I-P
and	O
genetically	O
engineered	O
mouse	O
models	O
(	O
GEMM	O
)	O
fail	O
to	O
mimic	O
the	O
complexities	O
of	O
the	O
PCa	O
microenvironment	O
or	O
reproduce	O
the	O
diverse	O
mechanisms	O
of	O
therapy	O
resistance	O
.	O

Moreover	O
,	O
patient	O
derived	O
xenografts	O
(	O
PDXs	O
)	O
are	O
expensive	O
,	O
time	O
consuming	O
,	O
difficult	O
to	O
establish	O
for	O
prostate	O
cancer	O
,	O
lack	O
immune	O
cell-tumor	O
regulation	O
,	O
and	O
often	O
tumors	O
undergo	O
selective	O
engraftments	O
.	O

Here	O
,	O
we	O
describe	O
an	O
interdisciplinary	O
approach	O
using	O
primary	O
PCa	O
and	O
tumor	O
initiating	O
cells	O
(	O
TICs	O
)	O
,	O
three-dimensional	O
(	O
3D	O
)	O
tissue	O
engineering	O
,	O
genetic	B-P
and	O
morphometric	B-P
profiling	I-P
,	O
and	O
humanized	O
mice	O
to	O
generate	O
patient	O
-	O
derived	O
organoids	O
for	O
examining	O
personalized	O
therapeutic	O
responses	O
in	O
vitro	O
and	O
in	O
mice	O
co-engrafted	O
with	O
a	O
human	O
immune	O
system	O
(	O
HIS	O
)	O
,	O
employing	O
adaptive	O
T-cell-	O
and	O
chimeric	O
antigen	O
receptor-	O
(	O
CAR	O
)	O
immunotherapy	O
.	O

The	O
development	O
of	O
patient	O
specific	O
therapies	O
targeting	O
the	O
vulnerabilities	O
of	O
cancer	O
,	O
when	O
combined	O
with	O
antiproliferative	O
and	O
immunotherapy	O
approaches	O
could	O
help	O
to	O
achieve	O
the	O
full	O
transformative	O
power	O
of	O
cancer	O
precision	O
medicine	O
.	O

Acute	O
Gout	O
Following	O
Dermofasciectomy	O
in	O
a	O
Patient	O
With	O
Dupuytren	O
Disease	O
.	O

A	O
62-	O
year	O
-	O
old	O
man	O
underwent	O
uncomplicated	O
dermofasciectomy	O
of	O
the	O
right	O
little	O
finger	O
.	O

In	O
the	O
week	O
after	O
surgery	O
,	O
he	O
presented	O
with	O
erythema	O
,	O
tenderness	O
,	O
reduced	O
range	O
of	O
movement	O
,	O
and	O
a	O
chalklike	O
discharge	O
from	O
the	O
suture	O
line	O
.	O

Investigations	O
revealed	O
a	O
raised	O
serum	B-P
urate	I-P
level	I-P
accompanied	O
with	O
a	O
borderline	O
rise	O
in	O
inflammatory	O
markers	O
.	O

A	O
diagnosis	O
of	O
acute	O
gout	O
was	O
made	O
.	O

The	O
patient	O
was	O
managed	O
with	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
.	O

Clinicians	O
should	O
consider	O
the	O
diagnosis	O
of	O
gout	O
when	O
patients	O
present	O
after	O
surgery	O
with	O
redness	O
,	O
pain	O
,	O
and	O
swelling	O
and	O
also	O
consider	O
measuring	O
urate	O
levels	O
before	O
surgery	O
and	O
initiating	O
colchicine	O
prophylaxis	O
when	O
there	O
is	O
a	O
known	O
diagnosis	O
of	O
gout	O
before	O
surgery	O
.	O

Accurate	O
diagnosis	O
may	O
prevent	O
unnecessary	O
antibiotic	O
use	O
.	O

F901318	O
represents	O
a	O
novel	O
class	O
of	O
antifungal	O
drug	O
that	O
inhibits	O
dihydroorotate	O
dehydrogenase	O
.	O

There	O
is	O
an	O
important	O
medical	O
need	O
for	O
new	O
antifungal	O
agents	O
with	O
novel	O
mechanisms	O
of	O
action	O
to	O
treat	O
the	O
increasing	O
number	O
of	O
patients	O
with	O
life-threatening	O
systemic	O
fungal	O
disease	O
and	O
to	O
overcome	O
the	O
growing	O
problem	O
of	O
resistance	O
to	O
current	O
therapies	O
.	O

F901318	O
,	O
the	O
leading	O
representative	O
of	O
a	O
novel	O
class	O
of	O
drug	O
,	O
the	O
orotomides	O
,	O
is	O
an	O
antifungal	O
drug	O
in	O
clinical	O
development	O
that	O
demonstrates	O
excellent	O
potency	O
against	O
a	O
broad	O
range	O
of	O
dimorphic	O
and	O
filamentous	O
fungi	O
.	O

In	O
vitro	O
susceptibility	B-P
testing	I-P
of	O
F901318	O
against	O
more	O
than	O
100	O
strains	O
from	O
the	O
four	O
main	O
pathogenic	O
Aspergillus	O
spp	O
.	O

revealed	O
minimal	O
inhibitory	O
concentrations	O
of	O
≤0.06	O
µg/mL-	O
greater	O
potency	O
than	O
the	O
leading	O
antifungal	O
classes	O
.	O

An	O
investigation	O
into	O
the	O
mechanism	O
of	O
action	O
of	O
F901318	O
found	O
that	O
it	O
acts	O
via	O
inhibition	O
of	O
the	O
pyrimidine	O
biosynthesis	O
enzyme	O
dihydroorotate	O
dehydrogenase	O
(	O
DHODH	O
)	O
in	O
a	O
fungal	O
-	O
specific	O
manner	O
.	O

Homology	O
modeling	O
of	O
Aspergillus	O
fumigatus	O
DHODH	O
has	O
identified	O
a	O
predicted	O
binding	O
mode	O
of	O
the	O
inhibitor	O
and	O
important	O
interacting	O
amino	O
acid	O
residues	O
.	O

In	O
a	O
murine	O
pulmonary	O
model	O
of	O
aspergillosis	O
,	O
F901318	O
displays	O
in	O
vivo	O
efficacy	O
against	O
a	O
strain	O
of	O
A.	O
fumigatus	O
sensitive	O
to	O
the	O
azole	O
class	O
of	O
antifungals	O
and	O
a	O
strain	O
displaying	O
an	O
azole	O
-	O
resistant	O
phenotype	O
.	O

F901318	O
is	O
currently	O
in	O
late	O
Phase	O
1	O
clinical	O
trials	O
,	O
offering	O
hope	O
that	O
the	O
antifungal	O
armamentarium	O
can	O
be	O
expanded	O
to	O
include	O
a	O
class	O
of	O
agent	O
with	O
a	O
mechanism	O
of	O
action	O
distinct	O
from	O
currently	O
marketed	O
antifungals	O
.	O

Identification	B-P
of	O
yeasts	O
isolated	O
from	O
raffia	O
wine	O
(	O
Raphia	O
hookeri	O
)	O
produced	O
in	O
Côte	O
d'Ivoire	O
and	O
genotyping	B-P
of	O
Saccharomyces	O
cerevisiae	O
strains	O
by	O
PCR	O
inter-delta	O
.	O

Raffia	O
wine	O
is	O
a	O
traditional	O
alcoholic	O
beverage	O
produced	O
in	O
several	O
African	O
countries	O
where	O
it	O
plays	O
a	O
significant	O
role	O
in	O
traditional	O
customs	O
and	O
population	O
diet	O
.	O

Alcoholic	O
fermentation	O
of	O
this	O
beverage	O
is	O
ensured	O
by	O
a	O
complex	O
natural	O
yeast	O
flora	O
which	O
plays	O
a	O
decisive	O
role	O
in	O
the	O
quality	O
of	O
the	O
final	O
product	O
.	O

This	O
present	O
study	O
aims	O
to	O
evaluate	O
the	O
distribution	O
and	O
the	O
diversity	O
of	O
the	O
yeast	O
strains	O
isolated	O
in	O
raffia	O
wine	O
from	O
four	O
sampling	O
areas	O
(	O
Abengourou	O
,	O
Alépé	O
,	O
Grand-Lahou	O
and	O
Adzopé	O
)	O
in	O
Côte	O
d'Ivoire	O
.	O

Based	O
on	O
the	O
D1/D2	O
domain	O
of	O
the	O
LSU	O
rDNA	O
sequence	O
analysis	O
,	O
nine	O
species	O
belonging	O
to	O
six	O
genera	O
were	O
distinguished	O
.	O

With	O
a	O
percentage	O
of	O
69.5	O
%	O
out	O
of	O
171	O
yeast	O
isolates	O
,	O
Saccharomyces	O
cerevisiae	O
was	O
the	O
predominant	O
species	O
in	O
the	O
raffia	O
wine	O
,	O
followed	O
by	O
Kodamaea	O
ohmeri	O
(	O
20.4	O
%	O
)	O
.	O

The	O
other	O
species	O
isolated	O
were	O
Candida	O
haemulonii	O
(	O
4.1	O
%	O
)	O
,	O
Candida	O
phangngensis	O
(	O
1.8	O
%	O
)	O
,	O
Pichia	O
kudriavzevii	O
(	O
1.2	O
%	O
)	O
,	O
Hanseniaspora	O
jakobsenii	O
(	O
1.2	O
%	O
)	O
,	O
Candida	O
silvae	O
(	O
0.6	O
%	O
)	O
,	O
Hanseniaspora	O
guilliermondii	O
(	O
0.6	O
%	O
)	O
and	O
Meyerozyma	O
caribbica	O
(	O
0.6	O
%	O
)	O
.	O

The	O
molecular	O
characterization	O
of	O
S.	O
cerevisiae	O
isolates	O
at	O
the	O
strain	O
level	O
using	O
the	O
PCR-interdelta	O
method	O
revealed	O
the	O
presence	O
of	O
21	O
profiles	B-P
(	O
named	O
I	O
to	O
XXI	O
)	O
within	O
115	O
isolates	O
.	O

Only	O
four	O
profiles	B-P
(	O
I	O
,	O
III	O
,	O
V	O
and	O
XI	O
)	O
were	O
shared	O
by	O
the	O
four	O
areas	O
under	O
study	O
.	O

Phenotypic	O
characterization	O
of	O
K.	O
ohmeri	O
strains	O
showed	O
two	O
subgroups	O
for	O
sugar	O
fermentation	O
and	O
no	O
diversity	O
for	O
the	O
nitrogen	O
compound	O
assimilations	O
and	O
the	O
growth	O
at	O
different	O
temperatures	O
.	O

Medication	O
Intervention	O
for	O
Chronic	O
Kidney	O
Disease	O
Patients	O
Transitioning	O
from	O
Hospital	O
to	O
Home	O
:	O
Study	O
Design	O
and	O
Baseline	O
Characteristics	O
.	O

The	O
hospital	O
readmission	O
rate	O
in	O
the	O
population	O
with	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
is	O
high	O
and	O
strategies	O
to	O
reduce	O
this	O
risk	O
are	O
urgently	O
needed	O
.	O

The	O
CKD	O
-	O
Medication	O
Intervention	O
Trial	O
(	O
CKD	O
-	O
MIT	O
;	O
www.clinicaltrials.gov	O
;	O
NCTO1459770	O
)	O
is	O
a	O
single-blind	O
(	O
investigators	O
)	O
,	O
randomized	O
,	O
clinical	O
trial	O
conducted	O
at	O
Providence	O
Health	O
Care	O
in	O
Spokane	O
,	O
Washington	O
.	O

Study	O
participants	O
are	O
hospitalized	O
patients	O
with	O
CKD	O
stages	O
3-5	O
(	O
not	O
treated	O
with	O
kidney	O
replacement	O
therapy	O
)	O
and	O
acute	O
illness	O
.	O

The	O
study	O
intervention	O
is	O
a	O
pharmacist-led	O
,	O
home-based	O
,	O
medication	O
management	O
intervention	O
delivered	O
within	O
7	O
days	O
after	O
hospital	O
discharge	O
.	O

The	O
primary	O
outcome	O
is	O
a	O
composite	O
of	O
hospital	O
readmissions	O
and	O
visits	O
to	O
emergency	O
departments	O
and	O
urgent	O
care	O
centers	O
for	O
90	O
days	O
following	O
hospital	O
discharge	O
.	O

Secondary	O
outcomes	O
are	O
achievements	O
of	O
guideline-based	O
targets	O
for	O
CKD	O
risk	O
factors	O
and	O
complications	O
.	O

Enrollment	O
began	O
in	O
February	O
2012	O
and	O
ended	O
in	O
May	O
2015	O
.	O

At	O
baseline	O
,	O
the	O
age	O
of	O
participants	O
was	O
69	O
±	O
11	O
years	O
(	O
mean	O
±	O
SD	O
)	O
,	O
50	O
%	O
(	O
77	O
of	O
155	O
)	O
were	O
women	O
,	O
83	O
%	O
(	O
117	O
of	O
141	O
)	O
had	O
hypertension	O
and	O
56	O
%	O
(	O
79	O
of	O
141	O
)	O
had	O
diabetes	O
.	O

At	O
baseline	O
,	O
the	O
estimated	B-P
glomerular	I-P
filtration	I-P
rate	O
was	O
41	O
±	O
14	O
ml/min/1.73	O
m2	O
and	O
urine	B-P
albumin-to-creatinine	I-P
ratio	I-P
was	O
43	O
mg/g	O
(	O
interquartile	O
range	O
8-528	O
mg/g	O
)	O
.	O

The	O
most	O
frequent	O
diagnosis	O
category	O
for	O
the	O
index	O
hospital	O
admission	O
was	O
cardiovascular	O
diseases	O
at	O
34	O
%	O
(	O
53	O
of	O
155	O
)	O
,	O
but	O
the	O
most	O
common	O
single	O
diagnosis	O
for	O
admission	O
was	O
community-acquired	O
acute	O
kidney	O
injury	O
at	O
10	O
%	O
(	O
16	O
of	O
155	O
)	O
.	O

Participants	O
in	O
CKD	O
-	O
MIT	O
are	O
typical	O
of	O
acutely	O
ill	O
hospitalized	O
patients	O
with	O
CKD	O
.	O

A	O
medication	O
management	O
intervention	O
after	O
hospital	O
discharge	O
is	O
under	O
study	O
to	O
reduce	O
post	O
-	O
hospitalization	O
acute	O
care	O
utilization	O
and	O
to	O
improve	O
CKD	O
management	O
.	O

Subchondral	O
bone	O
microarchitecture	O
and	O
failure	O
mechanism	O
under	O
compression	O
:	O
A	O
finite	O
element	O
study	O
.	O

Subchondral	O
bone	O
(	O
SCB	O
)	O
microdamage	O
is	O
commonly	O
observed	O
in	O
traumatic	O
joint	O
injuries	O
and	O
has	O
been	O
strongly	O
associated	O
with	O
post-traumatic	O
osteoarthritis	O
(	O
PTOA	O
)	O
.	O

Knowledge	O
of	O
the	O
three-dimensional	O
stress	O
and	O
strain	O
distribution	O
within	O
the	O
SCB	O
tissue	O
helps	O
to	O
understand	O
the	O
mechanism	O
of	O
SCB	O
failure	O
,	O
and	O
may	O
lead	O
to	O
an	O
improved	O
understanding	O
of	O
mechanisms	O
of	O
PTOA	O
initiation	O
,	O
prevention	O
and	O
treatment	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
high-resolution	B-P
micro-computed	I-P
tomography	I-P
(	O
µCT	B-P
)	O
-based	O
finite	O
element	O
(	O
FE	O
)	O
modelling	O
of	O
cartilage-bone	O
to	O
evaluate	O
the	O
failure	O
mechanism	O
and	O
the	O
locations	O
of	O
SCB	O
tissue	O
at	O
high-risk	O
of	O
initial	O
failure	O
under	O
compression	O
.	O

The	O
µCT	O
images	O
of	O
five	O
cartilage-bone	O
specimens	O
with	O
an	O
average	O
SCB	O
thickness	O
of	O
1.23±0.20mm	O
were	O
used	O
to	O
develop	O
five	O
µCT-based	B-P
FE	O
models	O
.	O

The	O
FE	O
models	O
were	O
analysed	O
under	O
axial	O
compressions	O
of	O
approximately	O
30MPa	O
applied	O
to	O
the	O
cartilage	O
surface	O
while	O
the	O
bone	O
edges	O
were	O
constrained	O
.	O

Strain	O
and	O
stress-based	O
failure	O
criteria	O
were	O
then	O
applied	O
to	O
evaluate	O
the	O
failure	O
mechanism	O
of	O
the	O
SCB	O
tissue	O
under	O
excessive	O
compression	O
through	O
articular	O
cartilage	O
.	O

µCT-based	B-P
FE	O
models	O
predicted	O
two	O
locations	O
in	O
the	O
SCB	O
at	O
high-risk	O
of	O
initial	O
failure	O
:	O
(	O
1	O
)	O
the	O
interface	O
of	O
the	O
calcified	O
-	O
uncalcified	O
cartilage	O
due	O
to	O
excessive	O
tension	O
,	O
and	O
(	O
2	O
)	O
the	O
trabecular	O
bone	O
beneath	O
the	O
subchondral	O
plate	O
due	O
to	O
excessive	O
compression	O
.	O

µCT-based	B-P
FE	O
models	O
of	O
cartilage-bone	O
enabled	O
us	O
to	O
quantify	O
the	O
distribution	O
of	O
the	O
applied	O
compression	O
which	O
was	O
transferred	O
through	O
the	O
articular	O
cartilage	O
to	O
its	O
underlying	O
SCB	O
,	O
and	O
to	O
investigate	O
the	O
mechanism	O
and	O
the	O
mode	O
of	O
SCB	O
tissue	O
failure	O
.	O

Ultimately	O
,	O
the	O
results	O
will	O
help	O
to	O
understand	O
the	O
mechanism	O
of	O
injury	O
formation	O
in	O
relation	O
to	O
PTOA	O
.	O

The	O
Prevalence	O
of	O
Sleep	O
Apnea	O
in	O
Type	O
B	O
Aortic	O
Dissection	O
:	O
Implications	O
for	O
False	O
Lumen	O
Thrombosis	O
.	O

Obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
has	O
been	O
implicated	O
in	O
aortic	O
dissection	O
.	O

Thrombosis	O
of	O
the	O
false	O
lumen	O
is	O
associated	O
with	O
a	O
prognosis	O
of	O
type	O
B	O
aortic	O
dissection	O
(	O
AoD	O
)	O
,	O
and	O
partial	O
thrombosis	O
has	O
been	O
reported	O
to	O
be	O
an	O
independent	O
predictor	O
of	O
mortality	O
.	O

This	O
study	O
sought	O
to	O
explore	O
whether	O
the	O
severity	O
of	O
OSA	O
is	O
associated	O
with	O
false	O
lumen	O
thrombosis	O
.	O

In	O
this	O
observational	O
study	O
,	O
151	O
type	O
B	O
AoD	O
patients	O
were	O
recruited	O
consecutively	O
from	O
2013	O
to	O
2015	O
.	O

The	O
status	O
of	O
the	O
false	O
lumen	O
was	O
classified	O
as	O
patent	O
,	O
partially	O
thrombosed	O
,	O
or	O
completely	O
thrombosed	O
based	O
on	O
a	O
computer	B-P
tomography	I-P
angiography	I-P
image	O
.	O

Patients	O
were	O
divided	O
into	O
non-OSA	O
group	O
(	O
apnea-hypopnea	O
index	O
[	O
AHI	O
]	O
<	O
5	O
)	O
,	O
and	O
mild	O
(	O
5	O
≤	O
AHI	O
≤	O
15	O
)	O
,	O
moderate	O
(	O
15	O
<	O
AHI	O
≤	O
30	O
)	O
,	O
and	O
severe	O
OSA	O
groups	O
(	O
AHI	O
>	O
30	O
)	O
using	O
the	O
AHI	O
.	O

The	O
prevalence	O
of	O
OSA	O
in	O
type	O
B	O
dissection	O
was	O
66.2	O
%	O
.	O

Among	O
151	O
cases	O
,	O
51	O
patients	O
(	O
33.8	O
%	O
)	O
were	O
in	O
the	O
non-OSA	O
group	O
,	O
56	O
(	O
37.1	O
%	O
)	O
were	O
in	O
the	O
mild	O
group	O
,	O
21	O
(	O
13.9	O
%	O
)	O
were	O
in	O
the	O
moderate	O
group	O
,	O
and	O
23	O
(	O
15.2	O
%	O
)	O
were	O
in	O
the	O
severe	O
group	O
.	O

Additionally	O
,	O
a	O
partially	O
thrombosed	O
false	O
lumen	O
was	O
observed	O
in	O
88	O
patients	O
(	O
58.3	O
%	O
)	O
.	O

Multivariable	O
analysis	O
revealed	O
that	O
OSA	O
severity	O
was	O
positively	O
associated	O
with	O
partial	O
thrombosis	O
(	O
odds	O
ratio	O
,	O
1.784	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
1.182-2.691	O
,	O
P	O
=	O
.006	O
)	O
after	O
adjusting	O
for	O
other	O
confounding	O
factors	O
.	O

OSA	O
was	O
present	O
in	O
two-thirds	O
of	O
patients	O
with	O
type	O
B	O
AoD	O
.	O

The	O
severity	O
of	O
OSA	O
was	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
partial	O
false	O
lumen	O
thrombosis	O
.	O

OSA	O
may	O
therefore	O
be	O
implicated	O
in	O
both	O
the	O
etiology	O
and	O
prognosis	O
of	O
AoD	O
.	O

Phytoplankton	O
production	O
and	O
taxon	O
-	O
specific	O
growth	O
rates	O
in	O
the	O
Costa	O
Rica	O
Dome	O
.	O

During	O
summer	O
2010	O
,	O
we	O
investigated	O
phytoplankton	O
production	O
and	O
growth	O
rates	O
at	O
19	O
stations	O
in	O
the	O
eastern	O
tropical	O
Pacific	O
,	O
where	O
winds	O
and	O
strong	O
opposing	O
currents	O
generate	O
the	O
Costa	O
Rica	O
Dome	O
(	O
CRD	O
)	O
,	O
an	O
open	O
-	O
ocean	O
upwelling	O
feature	O
.	O

Primary	O
production	O
(	O
(	O
14	O
)	O
C	O
-	O
incorporation	O
)	O
and	O
group-specific	O
growth	O
and	O
net	O
growth	O
rates	O
(	O
two-treatment	O
seawater	O
dilution	B-P
method	I-P
)	O
were	O
estimated	O
from	O
samples	O
incubated	B-P
in	O
situ	O
at	O
eight	O
depths	O
.	O

Our	O
cruise	O
coincided	O
with	O
a	O
mild	O
El	O
Niño	O
event	O
,	O
and	O
only	O
weak	O
upwelling	O
was	O
observed	O
in	O
the	O
CRD	O
.	O

Nevertheless	O
,	O
the	O
highest	O
phytoplankton	O
abundances	O
were	O
found	O
near	O
the	O
dome	O
center	O
.	O

However	O
,	O
mixed-layer	O
growth	O
rates	O
were	O
lowest	O
in	O
the	O
dome	O
center	O
(	O
∼0.5-0.9	O
day	O
(	O
-1	O
)	O
)	O
,	O
but	O
higher	O
on	O
the	O
edge	O
of	O
the	O
dome	O
(	O
∼0.9-1.0	O
day	O
(	O
-1	O
)	O
)	O
and	O
in	O
adjacent	O
coastal	O
waters	O
(	O
0.9-1.3	O
day	O
(	O
-1	O
)	O
)	O
.	O

We	O
found	O
good	O
agreement	O
between	O
independent	O
methods	O
to	O
estimate	O
growth	O
rates	O
.	O

Mixed-layer	O
growth	O
rates	O
of	O
Prochlorococcus	O
and	O
Synechococcus	O
were	O
largely	O
balanced	O
by	O
mortality	O
,	O
whereas	O
eukaryotic	O
phytoplankton	O
showed	O
positive	O
net	O
growth	O
(	O
∼0.5-0.6	O
day	O
(	O
-1	O
)	O
)	O
,	O
that	O
is	O
,	O
growth	O
available	O
to	O
support	O
larger	O
(	O
mesozooplankton	O
)	O
consumer	O
biomass	O
.	O

These	O
are	O
the	O
first	O
group-specific	O
phytoplankton	O
rate	O
estimates	O
in	O
this	O
region	O
,	O
and	O
they	O
demonstrate	O
that	O
integrated	O
primary	O
production	O
is	O
high	O
,	O
exceeding	O
1	O
g	O
C	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
on	O
average	O
,	O
even	O
during	O
a	O
period	O
of	O
reduced	O
upwelling	O
.	O

Simultaneous	O
determination	B-P
of	O
eight	O
metabolites	O
of	O
organophosphate	O
and	O
pyrethroid	O
pesticides	O
in	O
urine	O
.	O

A	O
simultaneous	O
method	O
for	O
quantifying	O
eight	O
metabolites	O
of	O
organophosphate	O
pesticides	O
and	O
pyrethroid	O
pesticides	O
in	O
urine	O
samples	O
has	O
been	O
established	O
.	O

The	O
analytes	O
were	O
extracted	B-P
using	O
liquid-liquid	B-P
extraction	I-P
coupled	O
with	O
WCX	O
solid	B-P
phase	I-P
extraction	I-P
(	I-P
SPE	I-P
)	I-P
cartridges	O
.	O

Eight	O
metabolites	O
were	O
chemically	O
derivatized	O
before	O
analysis	O
using	O
gas	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
(	O
GC-MS-MS	B-P
)	O
.	O

The	O
separation	B-P
was	O
performed	O
on	O
a	O
HP-5MS	O
capillary	O
column	O
(	O
30	O
m	O
×	O
0.25	O
mm	O
×	O
0.25	O
µm	O
)	O
with	O
temperature	O
programming	O
.	O

The	O
detection	O
was	O
performed	O
under	O
electro-spray	B-P
ionization	I-P
(	O
ESI	B-P
)	O
in	O
multiple	O
reaction	O
monitoring	O
(	O
MRM	O
)	O
mode	O
.	O

An	O
internal	O
standard	O
method	O
was	O
used	O
.	O

The	O
extraction	B-P
solvent	O
,	O
types	O
of	O
SPE	B-P
cartridges	O
and	O
eluents	O
were	O
optimized	O
by	O
comparing	O
the	O
sample	O
recoveries	O
under	O
different	O
conditions	O
.	O

The	O
results	O
showed	O
that	O
the	O
calibration	O
curves	O
of	O
the	O
five	O
organophosphorus	O
pesticides	O
metabolites	O
were	O
linear	O
in	O
the	O
range	O
of	O
0.2-200	O
μg/L	O
(	O
r	O
(	O
2	O
)	O
≥	O
0.992	O
)	O
and	O
that	O
of	O
the	O
three	O
pyrethroid	O
pesticides	O
metabolites	O
were	O
linear	O
in	O
the	O
range	O
of	O
0.025-250	O
μg/L	O
(	O
r	O
(	O
2	O
)	O
≥	O
0.991	O
)	O
.	O

The	O
limits	O
of	O
detection	O
(	O
LODs	O
,	O
S/N	O
≥	O
3	O
)	O
and	O
the	O
limits	O
of	O
quantification	O
(	O
LOQs	O
,	O
S/N	O
≥	O
10	O
)	O
of	O
the	O
eight	O
metabolites	O
were	O
0.008-0.833	O
μg/L	O
and	O
0.25-2.5	O
μg/L	O
,	O
respectively	O
.	O

The	O
recoveries	O
of	O
the	O
eight	O
metabolites	O
ranged	O
from	O
54.08	O
%	O
to	O
82.49	O
%	O
.	O

This	O
efficient	O
,	O
stable	O
,	O
and	O
cost-effective	O
method	O
is	O
adequate	O
to	O
handle	O
the	O
large	O
number	O
of	O
samples	O
required	O
for	O
surveying	O
the	O
exposure	O
level	O
of	O
organophosphorus	O
and	O
pyrethroid	O
pesticides	O
in	O
the	O
general	O
population	O
.	O

Improvement	O
in	O
advanced	O
pancreatic	O
cancer	O
survival	O
with	O
novel	O
chemotherapeutic	O
strategies	O
-	O
experience	O
of	O
a	O
community	O
based	O
hospital	O
.	O

Background	O
:	O
New	O
chemotherapeutic	O
strategies	O
for	O
locally	O
advanced	O
or	O
metastatic	O
pancreatic	O
ductal	O
adenocarcinoma	O
(	O
PDAC	O
)	O
have	O
been	O
shown	O
to	O
improve	O
survival	O
in	O
randomized	O
clinical	O
trials	O
.	O

Little	O
is	O
known	O
about	O
the	O
use	O
of	O
such	O
chemotherapies	O
and	O
their	O
benefit	O
in	O
community-based	O
hospitals	O
.	O

This	O
retrospective	O
study	O
analyzes	O
the	O
overall	O
survival	O
of	O
these	O
patients	O
under	O
``	O
real	O
life	O
conditions	O
``	O
before	O
and	O
after	O
the	O
introduction	O
of	O
FOLFIRINOX	O
in	O
2011	O
.	O

Methods	O
:	O
We	O
retrospectively	O
identified	O
consecutive	O
patients	O
with	O
PDAC	O
who	O
were	O
treated	O
at	O
our	O
hospital	O
from	O
2011	O
to	O
June	O
2014	O
(	O
2011+	O
cohort	O
)	O
and	O
2004	O
to	O
2010	O
(	O
historical	O
cohort	O
)	O
.	O

Patients	O
were	O
included	O
if	O
PDAC	O
was	O
diagnosed	B-P
in	O
a	O
locally	O
advanced	O
or	O
metastatic	O
state	O
and	O
at	O
least	O
1	O
cycle	O
of	O
chemotherapy	O
was	O
given	O
.	O

Survival	O
was	O
assessed	O
until	O
April	O
2016	O
.	O

Patients	O
with	O
FOLFIRINOX	O
were	O
further	O
analyzed	O
regarding	O
drug	O
administration	O
and	O
side	O
effects	O
.	O

Results	O
:	O
128	O
patients	O
met	O
the	O
inclusion	O
criteria	O
.	O

Of	O
the	O
74	O
patients	O
in	O
the	O
historical	O
cohort	O
,	O
62	O
patients	O
received	O
Gemcitabine	O
.	O

Of	O
the	O
54	O
patients	O
diagnosed	B-P
between	O
2011	O
and	O
June	O
2014	O
,	O
28	O
patients	O
received	O
FOLFIRINOX	O
and	O
22	O
Gemcitabine	O
as	O
the	O
first-line	O
chemotherapy	O
.	O

Only	O
34	O
%	O
of	O
the	O
patients	O
in	O
the	O
historical	O
cohort	O
received	O
a	O
second-line	O
chemotherapy	O
in	O
comparison	O
to	O
69	O
%	O
in	O
the	O
2011+	O
cohort	O
.	O

Median	O
overall	O
survival	O
(	O
OS	O
)	O
showed	O
a	O
survival	O
of	O
13.1	O
months	O
(	O
95	O
%	O
CI	O
;	O
11.6	O
-	O
14.5	O
)	O
for	O
the	O
2011+	O
cohort	O
compared	O
to	O
9.6	O
months	O
(	O
95	O
%	O
CI	O
;	O
6.1	O
-	O
13.1	O
)	O
in	O
the	O
historical	O
group	O
.	O

Conclusion	O
:	O
This	O
study	O
shows	O
a	O
marked	O
improvement	O
in	O
survival	O
of	O
patients	O
diagnosed	B-P
with	O
locally	O
advanced	O
or	O
metastatic	O
PDAC	O
in	O
a	O
community-based	O
hospital	O
during	O
the	O
past	O
4	O
years	O
.	O

The	O
most	O
likely	O
reasons	O
are	O
the	O
use	O
of	O
new	O
polychemotherapies	O
like	O
FOLFIRINOX	O
and	O
the	O
use	O
of	O
second-line	O
chemotherapy	O
.	O

Nucleic	B-P
acid	I-P
detection	I-P
with	O
CRISPR	O
-	O
Cas13a	O
/	O
C2c2	O
.	O

Rapid	O
,	O
inexpensive	O
,	O
and	O
sensitive	O
nucleic	B-P
acid	I-P
detection	I-P
may	O
aid	O
point-of-care	O
pathogen	O
detection	O
,	O
genotyping	B-P
,	O
and	O
disease	O
monitoring	O
.	O

The	O
RNA	O
-guided	O
,	O
RNA	O
-	O
targeting	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
(	O
CRISPR	O
)	O
effector	O
Cas13a	O
(	O
previously	O
known	O
as	O
C2c2	O
)	O
exhibits	O
a	O
``	O
collateral	O
effect	O
``	O
of	O
promiscuous	O
ribonuclease	O
activity	O
upon	O
target	O
recognition	O
.	O

We	O
combine	O
the	O
collateral	O
effect	O
of	O
Cas13a	O
with	O
isothermal	B-P
amplification	I-P
to	O
establish	O
a	O
CRISPR	O
-based	O
diagnostic	O
(	O
CRISPR	O
-	O
Dx	O
)	O
,	O
providing	O
rapid	O
DNA	O
or	O
RNA	O
detection	O
with	O
attomolar	O
sensitivity	O
and	O
single-base	O
mismatch	O
specificity	O
.	O

We	O
use	O
this	O
Cas13a	O
-based	O
molecular	O
detection	O
platform	O
,	O
termed	O
Specific	O
High-Sensitivity	O
Enzymatic	O
Reporter	O
UnLOCKing	O
(	O
SHERLOCK	O
)	O
,	O
to	O
detect	O
specific	O
strains	O
of	O
Zika	O
and	O
Dengue	O
virus	O
,	O
distinguish	O
pathogenic	O
bacteria	O
,	O
genotype	O
human	O
DNA	O
,	O
and	O
identify	O
mutations	O
in	O
cell-free	O
tumor	O
DNA	O
.	O

Furthermore	O
,	O
SHERLOCK	O
reaction	O
reagents	O
can	O
be	O
lyophilized	B-P
for	O
cold-chain	O
independence	O
and	O
long-term	O
storage	O
and	O
be	O
readily	O
reconstituted	O
on	O
paper	O
for	O
field	O
applications	O
.	O

Long-range	O
interactions	O
between	O
protein	O
-	O
coated	O
particles	O
and	O
POEGMA	O
brush	O
layers	O
in	O
a	O
serum	O
environment	O
.	O

Hydrophilic	O
poly	O
[	O
oligo	O
(	O
ethylene	O
glycol	O
)	O
methyl	O
methacrylate	O
]	O
(	O
POEGMA	O
)	O
brush	O
layers	O
with	O
different	O
thickness	O
and	O
graft	O
densities	O
were	O
prepared	O
by	O
surface-initiated	O
atom	O
transfer	O
radical	O
polymerization	O
(	O
SI-ATRP	O
)	O
to	O
construct	O
a	O
model	O
surface	O
to	O
examine	O
protein	O
-	O
surface	O
interactions	O
in	O
a	O
serum	O
environment	O
.	O

The	O
thickness	O
of	O
the	O
POEGMA	O
brush	O
layers	O
could	O
be	O
well	O
controlled	O
by	O
the	O
polymerization	O
time	O
and	O
density	O
of	O
the	O
immobilized	O
initiators	O
.	O

The	O
interactions	O
between	O
these	O
brush	O
-	O
modified	O
surfaces	O
and	O
the	O
protein	O
-	O
coated	O
polystyrene	O
(	O
PS	O
)	O
particles	O
in	O
newborn	O
calf	O
serum	O
(	O
NBCS	O
)	O
environment	O
were	O
then	O
measured	O
by	O
total	B-P
internal	I-P
reflection	I-P
microscopy	I-P
(	O
TIRM	B-P
)	O
.	O

In	O
addition	O
,	O
protein	O
adsorption	O
properties	O
onto	O
the	O
polymer	O
brush	O
surface	O
layers	O
were	O
examined	O
by	O
atomic	B-P
force	I-P
microscopy	I-P
(	O
AFM	B-P
)	O
.	O

Relatively	O
large	O
amounts	O
of	O
protein	O
adsorbed	O
to	O
short	O
(	O
4nm	O
and	O
9nm-thick	O
)	O
POEGMA	O
-	O
coated	O
surfaces	O
or	O
surfaces	O
grafted	O
with	O
a	O
low	O
density	O
of	O
polymer	O
chains	O
.	O

It	O
was	O
considered	O
that	O
shorter	O
polymer	O
chains	O
or	O
chains	O
with	O
low	O
grafted	O
density	O
can	O
not	O
fully	O
cover	O
the	O
surfaces	O
,	O
proteins	O
in	O
serum	O
could	O
directly	O
interact	O
with	O
the	O
material	O
surface	O
and	O
then	O
deposited	O
to	O
form	O
an	O
adsorbed	O
layer	O
.	O

The	O
TIRM	B-P
measurements	O
showed	O
that	O
such	O
adsorbed	O
protein	O
layer	O
could	O
mediate	O
the	O
interactions	O
between	O
the	O
two	O
surfaces	O
by	O
generating	O
steric	O
or	O
bridging	O
forces	O
,	O
resulting	O
in	O
different	O
interaction	O
potentials	O
.	O

Some	O
particles	O
were	O
freely	O
diffusing	O
,	O
some	O
experienced	O
intermittent	O
diffusion	O
and	O
more	O
than	O
50	O
%	O
of	O
particles	O
were	O
irreversibly	O
deposited	O
to	O
the	O
surfaces	O
covered	O
by	O
short	O
polymer	O
brushes	O
.	O

However	O
,	O
for	O
longer	O
(	O
17	O
and	O
30nm-thick	O
)	O
POEGMA	O
brush	O
layer	O
surfaces	O
,	O
material	O
surface	O
would	O
be	O
sufficiently	O
covered	O
by	O
the	O
dense	O
coating	O
and	O
the	O
first	O
step	O
of	O
protein	O
adsorption	B-P
on	O
surface	O
was	O
avoided	O
.	O

TIRM	B-P
measurements	O
showed	O
that	O
around	O
95	O
%	O
of	O
the	O
protein	O
-	O
coated	O
particles	O
could	O
freely	O
move	O
in	O
the	O
serum	O
and	O
no	O
attractive	O
force	O
between	O
two	O
surfaces	O
was	O
detected	O
.	O

The	O
steric	O
repulsion	O
generated	O
from	O
the	O
long	O
POEGMA	O
brush	O
layer	O
in	O
the	O
swollen	O
state	O
was	O
long-range	O
and	O
strong	O
so	O
that	O
the	O
protein	O
adsorption	B-P
is	O
very	O
unlikely	O
.	O

These	O
results	O
concluded	O
that	O
the	O
adsorbed	O
protein	O
layer	O
on	O
POEGMA	O
surfaces	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
interaction	O
between	O
protein	O
-	O
coated	O
particles	O
and	O
POEGMA	O
surfaces	O
which	O
are	O
highly	O
repellent	O
toward	O
protein	O
adsorption	B-P
.	O

Efficacy	O
and	O
safety	O
of	O
``	O
unboosting	O
``	O
atazanavir	O
in	O
a	O
randomized	O
controlled	O
trial	O
among	O
HIV-infected	O
patients	O
receiving	O
tenofovir	O
DF	O
.	O

To	O
assess	O
safety	O
and	O
efficacy	O
of	O
a	O
switch	O
to	O
unboosted	O
atazanavir	O
(	O
ATV	O
)	O
among	O
HIV-infected	O
adults	O
receiving	O
ATV	O
/	O
ritonavir	O
(	O
r	O
)	O
and	O
tenofovir	O
disoproxil	O
fumarate	O
(	O
TDF	O
)	O
.	O

HIV-infected	O
adults	O
with	O
viral	B-P
load	I-P
(	O
VL	B-P
)	O
<	O
40	O
copies/mL	O
at	O
screening	O
and	O
<	O
150	O
copies/mL	O
consistently	O
for	O
≥3	O
months	O
while	O
receiving	O
a	O
regimen	O
including	O
ATV	O
/r	O
and	O
TDF	O
were	O
randomized	O
to	O
continue	O
ATV	O
/	O
r	O
300/100	O
mg	O
daily	O
(	O
control	O
)	O
or	O
change	O
to	O
ATV	O
400	O
mg	O
daily	O
(	O
switch	O
)	O
,	O
while	O
maintaining	O
their	O
TDF	O
backbone	O
.	O

The	O
primary	O
outcome	O
was	O
proportion	O
of	O
subjects	O
without	O
treatment	O
failure	O
(	O
regimen	O
switch	O
or	O
VL	O
>	O
200	O
copies/mL	O
twice	O
consecutively	O
)	O
at	O
48	O
weeks	O
.	O

Fifty	O
participants	O
(	O
46	O
male	O
,	O
median	O
age	O
47	O
years	O
)	O
were	O
randomized	O
,	O
25	O
to	O
each	O
arm	O
.	O

At	O
week	O
48	O
,	O
treatment	O
success	O
occurred	O
in	O
76	O
%	O
in	O
the	O
control	O
arm	O
and	O
92	O
%	O
in	O
the	O
switch	O
arm	O
(	O
ITT	O
,	O
p	O
=	O
0.25	O
)	O
.	O

ATV	O
trough	O
levels	O
at	O
week	O
9	O
were	O
higher	O
in	O
controls	O
(	O
median	O
438	O
ng/mL	O
)	O
than	O
in	O
the	O
switch	O
arm	O
(	O
median	O
124	O
ng/mL	O
)	O
(	O
p	O
=	O
0.003	O
)	O
,	O
as	O
was	O
total	O
bilirubin	O
at	O
week	O
48	O
(	O
median	O
38	O
μmol/L	O
and	O
28	O
μmol/L	O
,	O
respectively	O
;	O
p	O
=	O
0.02	O
)	O
.	O

Estimated	B-P
glomerular	I-P
filtration	I-P
rate	I-P
(	O
eGFR	B-P
)	O
decreased	O
in	O
the	O
control	O
arm	O
(	O
p	O
=	O
0.007	O
)	O
,	O
but	O
did	O
not	O
change	O
in	O
the	O
switch	O
arm	O
.	O

At	O
week	O
48	O
,	O
eGFR	B-P
was	O
higher	O
in	O
the	O
switch	O
arm	O
(	O
median	O
96	O
mL/min	O
)	O
than	O
in	O
the	O
control	O
arm	O
(	O
median	O
85	O
mL/min	O
)	O
(	O
p	O
=	O
0.035	O
)	O
,	O
but	O
the	O
arms	O
were	O
similar	O
with	O
respect	O
to	O
fasting	B-P
glucose	I-P
,	O
C-reactive	O
protein	O
,	O
and	O
lipid	O
parameters	O
.	O

Switching	O
from	O
ATV	O
/	O
r	O
to	O
unboosted	O
ATV	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
in	O
selected	O
virologically	O
suppressed	O
patients	O
receiving	O
TDF	O
-containing	O
regimens	O
,	O
and	O
may	O
have	O
favorable	O
effects	O
on	O
bilirubin	O
and	O
renal	O
function	O
.	O

Is	O
minimally	O
invasive	O
thoracoscopic	O
surgery	O
the	O
new	O
benchmark	O
for	O
treating	O
mitral	O
valve	O
disease	O
?	O
.	O

The	O
treatment	O
of	O
mitral	O
valve	O
disease	O
remains	O
dynamic	O
;	O
surgeons	O
and	O
patients	O
must	O
now	O
choose	O
between	O
many	O
different	O
surgical	O
options	O
when	O
addressing	O
mitral	O
regurgitation	O
and	O
mitral	O
stenosis	O
.	O

Notably	O
,	O
advances	O
in	O
imaging	B-P
and	O
surgical	O
instrumentation	O
allow	O
surgeons	O
to	O
perform	O
less	O
invasive	O
mitral	O
valve	O
surgery	O
that	O
spares	O
the	O
sternum	O
.	O

With	O
favorable	O
long-term	O
data	O
now	O
emerging	O
,	O
we	O
compare	O
the	O
benefits	O
and	O
risks	O
of	O
thoracoscopic	O
mitral	O
valve	O
surgery	O
with	O
that	O
through	O
conventional	O
sternotomy	O
or	O
surgery	O
that	O
is	O
robot-assisted	O
.	O

The	O
influence	O
of	O
liposomal	O
formulation	O
on	O
the	O
incorporation	O
and	O
retention	O
of	O
PNA	O
oligomers	O
.	O

Liposomal	O
formulations	O
composed	O
of	O
phospholipids	O
with	O
different	O
unsaturation	O
degrees	O
,	O
head	O
groups	O
and	O
at	O
different	O
cholesterol	B-P
content	I-P
have	I-P
been	I-P
tested	I-P
for	O
the	O
encapsulation	O
of	O
Peptide	O
Nucleic	O
Acid	O
(	O
PNA	O
)	O
oligomers	O
.	O

The	O
best	O
loading	O
capability	O
(	O
177μg	O
,	O
ER	O
%	O
=87.2	O
)	O
was	O
obtained	O
for	O
pure	O
liposomes	O
of	O
phosphatidylglycerol	O
(	O
DOPG	O
)	O
with	O
negatively	O
charged	O
head	O
group	O
.	O

The	O
insertion	O
of	O
a	O
10-20	O
%	O
of	O
cholesterol	O
in	O
DOPG	O
based	O
liposomes	O
provides	O
a	O
slight	O
decrease	O
(	O
∼160μg	O
)	O
of	O
the	O
PNA	O
loading	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
cholesterol	O
addition	O
(	O
20-30	O
%	O
)	O
slows	O
down	O
the	O
PNA	O
's	O
release	O
(	O
∼27	O
%	O
)	O
in	O
fetal	O
bovine	O
serum	O
from	O
the	O
liposomal	O
formulation	O
.	O

Based	O
on	O
the	O
encapsulation	O
and	O
the	O
release	O
properties	O
,	O
PEGylated	O
DOPG	O
liposomes	O
with	O
a	O
percentage	O
of	O
cholesterol	O
of	O
10-20	O
%	O
are	O
the	O
optimal	O
formulation	O
for	O
the	O
loading	O
of	O
PNA-a210	O
.	O

miR-376c	O
inhibits	O
cervical	O
cancer	O
cell	O
proliferation	O
and	O
invasion	O
by	O
targeting	O
BMI1	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
play	O
crucial	O
roles	O
in	O
cancer	O
development	O
and	O
progression	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
explore	O
the	O
role	O
of	O
miR-376c	O
in	O
cervical	O
cancer	O
and	O
to	O
clarify	O
the	O
regulation	O
of	O
BMI1	O
by	O
miR-376c	O
.	O

Quantitative	O
RT-PCR	O
was	O
used	O
to	O
measure	O
miR-376c	O
expression	O
in	O
cervical	O
cancer	O
tissues	O
and	O
cell	O
lines	O
.	O

The	O
cell	O
proliferation	O
,	O
cell	B-P
cycle	I-P
and	O
Transwell	B-P
invasion	I-P
assays	I-P
were	O
performed	O
.	O

A	O
luciferase	B-P
reporter	I-P
assay	I-P
was	O
conducted	O
to	O
confirm	O
the	O
target	O
gene	O
of	O
miR-376c	O
,	O
and	O
the	O
results	O
were	O
validated	O
in	O
cervical	O
cancer	O
cell	O
lines	O
and	O
tissues	O
.	O

MiR-376c	O
was	O
significantly	O
downregulated	O
in	O
cervical	O
cancer	O
cell	O
lines	O
and	O
clinical	O
tissues	O
.	O

Upregulation	O
of	O
miR-376c	O
impaired	O
cell	O
proliferation	O
,	O
blocked	O
G1/S	O
checkpoint	O
of	O
cell	O
cycle	O
and	O
suppressed	O
cell	O
invasion	O
in	O
vitro	O
.	O

BMI1	O
was	O
verified	O
as	O
a	O
direct	O
target	O
of	O
miR-376c	O
,	O
which	O
was	O
further	O
confirmed	O
by	O
the	O
inverse	O
expression	O
of	O
miR-376c	O
and	O
BMI1	O
in	O
patient	O
specimens	O
.	O

The	O
newly	O
identified	O
miR-376c	O
/	O
BMI1	O
pathway	O
provides	O
an	O
insight	O
into	O
cervical	O
cancer	O
progression	O
and	O
may	O
represent	O
a	O
novel	O
therapeutic	O
target	O
.	O

Feasibility	O
and	O
energetic	O
evaluation	O
of	O
air	O
stripping	O
for	O
bioethanol	O
production	O
.	O

Stripping	O
of	O
mashes	O
with	O
air	O
as	O
stripping	O
gas	O
and	O
low	O
ethanol	O
contents	O
between	O
3	O
and	O
5wt	O
%	O
was	O
investigated	O
in	O
terms	O
of	O
its	O
suitability	O
for	O
continuous	O
bioethanol	O
production	O
.	O

Experiments	O
in	O
a	O
Blenke	O
cascade	O
system	O
were	O
carried	O
out	O
and	O
the	O
results	O
were	O
compared	O
with	O
values	O
obtained	O
from	O
theoretical	O
vapour-liquid-equilibrium	O
calculations	O
.	O

The	O
whole	O
stripping	O
process	O
was	O
energetically	O
evaluated	O
by	O
a	O
simulation	O
in	O
ChemCAD	O
and	O
compared	O
to	O
conventional	B-P
distillation	I-P
.	O

Therefore	O
several	O
parameters	O
such	O
as	O
temperature	O
,	O
air	O
volume	O
flow	O
and	O
initial	O
ethanol	O
load	O
of	O
the	O
mash	O
were	O
varied	O
.	O

Air	O
stripping	O
was	O
found	O
to	O
be	O
a	O
suitable	O
separation	O
method	O
for	O
bioethanol	O
from	O
mashes	O
with	O
low	O
concentrations	O
.	O

However	O
,	O
energetic	O
aspects	O
have	O
to	O
be	O
considered	O
,	O
when	O
developing	O
a	O
new	O
process	O
.	O

Long	O
noncoding	O
RNA	O
XIST	O
acts	O
as	O
an	O
oncogene	O
in	O
non-small	O
cell	O
lung	O
cancer	O
by	O
epigenetically	O
repressing	O
KLF2	O
expression	O
.	O

Recently	O
,	O
long	O
noncoding	O
RNAs	O
(	O
lncRNAs	O
)	O
have	O
been	O
identified	O
as	O
critical	O
regulators	O
in	O
numerous	O
types	O
of	O
cancers	O
,	O
including	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

X	O
inactivate-specific	O
transcript	O
(	O
XIST	O
)	O
has	O
been	O
found	O
to	O
be	O
up-regulated	O
and	O
acts	O
as	O
an	O
oncogene	O
in	O
gastric	O
cancer	O
and	O
hepatocellular	O
carcinoma	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
expression	O
pattern	O
,	O
biological	O
function	O
and	O
underlying	O
mechanism	O
in	O
NSCLC	O
.	O

Here	O
,	O
we	O
identified	O
XIST	O
as	O
an	O
oncogenic	O
lncRNA	O
by	O
driving	O
tumorigenesis	O
in	O
NSCLC	O
.	O

We	O
found	O
that	O
XIST	O
is	O
over-	O
expressed	O
in	O
NSCLC	O
,	O
and	O
its	O
increased	O
level	O
is	O
associated	O
with	O
shorter	O
survival	O
and	O
poorer	O
prognosis	O
.	O

Knockdown	O
of	O
XIST	O
impaired	O
NSCLC	O
cells	O
proliferation	O
,	O
migration	O
and	O
invasion	O
in	O
vitro	O
,	O
and	O
repressed	O
the	O
tumorigenicity	O
of	O
NSCLC	O
cells	O
in	O
vivo	O
.	O

Mechanistically	O
,	O
RNA	O
immune-precipitation	B-P
(	O
RIP	B-P
)	O
and	O
RNA	O
pull-down	O
experiment	O
demonstrated	O
that	O
XIST	O
could	O
simultaneously	O
interact	O
with	O
EZH2	O
to	O
suppress	O
transcription	O
of	O
its	O
potential	O
target	O
KLF2	O
.	O

Additionally	O
,	O
rescue	O
experiments	O
revealed	O
that	O
XIST	O
's	O
oncogenic	O
functions	O
were	O
partly	O
depending	O
on	O
silencing	O
KLF2	O
expression	O
.	O

Collectively	O
,	O
our	O
findings	O
expound	O
how	O
XIST	O
over-	O
expression	O
endows	O
an	O
oncogenic	O
function	O
in	O
NSCLC	O
.	O

Cartilage	O
inflammation	O
and	O
degeneration	O
is	O
enhanced	O
by	O
pro-inflammatory	O
(	O
M1	O
)	O
macrophages	O
in	O
vitro	O
,	O
but	O
not	O
inhibited	O
directly	O
by	O
anti-inflammatory	O
(	O
M2	O
)	O
macrophages	O
.	O

Macrophages	O
play	O
a	O
crucial	O
role	O
in	O
the	O
progression	O
of	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

Their	O
phenotype	O
may	O
range	O
from	O
pro-inflammatory	O
to	O
anti-inflammatory	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
direct	O
effects	O
of	O
macrophage	O
subtypes	O
on	O
cartilage	O
by	O
culturing	B-P
macrophage	O
conditioned	O
medium	O
(	O
MCM	O
)	O
on	O
human	O
articular	O
cartilage	O
.	O

Human	O
OA	O
cartilage	O
explants	O
were	O
cultured	B-P
with	O
MCM	O
of	O
pro-inflammatory	O
M	O
(	O
IFNγ	O
+	O
TNFα	O
)	O
,	O
or	O
anti-inflammatory	O
M	O
(	O
IL-4	O
)	O
or	O
M	O
(	O
IL-10	O
)	O
human	O
monocyte-derived	O
macrophages	O
.	O

To	O
assess	O
effects	O
of	O
anti-inflammatory	O
macrophages	O
,	O
the	O
cartilage	O
was	O
cultured	B-P
with	O
a	O
combination	O
of	O
MCM	O
phenotypes	O
as	O
well	O
as	O
pre-stimulated	O
with	O
IFNγ	O
+	O
TNFα	O
cartilage	O
before	O
culture	B-P
with	O
MCM	O
.	O

The	O
reactions	O
of	O
the	O
explants	O
were	O
assessed	O
by	O
gene	O
expression	O
,	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
and	O
release	O
of	O
glycosaminoglycans	O
(	O
GAGs	O
)	O
.	O

M	O
(	O
IFNγ	O
+	O
TNFα	O
)	O
MCM	O
affected	O
OA	O
cartilage	O
by	O
upregulation	O
of	O
IL1B	O
(	O
Interleukin	O
1β	O
)	O
,	O
IL6	O
,	O
MMP13	O
(	O
Matrix	O
Metalloproteinase-13	O
)	O
and	O
ADAMTS5	O
(	O
A	O
Disintegrin	O
And	O
Metalloproteinase	O
with	O
Thrombospondin	O
Motifs-5	O
)	O
,	O
while	O
inhibiting	O
ACAN	O
(	O
aggrecan	O
)	O
and	O
COL2A1	O
(	O
collagen	O
type	O
II	O
)	O
.	O

M	O
(	O
IL-10	O
)	O
upregulated	O
IL1B	O
and	O
Suppressor	O
of	O
cytokine	O
signaling	O
1	O
(	O
SOCS1	O
)	O
.	O

NO	O
production	O
and	O
GAG	O
release	O
by	O
the	O
cartilage	O
was	O
increased	O
when	O
cultured	B-P
with	O
M	O
(	O
IFNγ	O
+	O
TNFα	O
)	O
MCM	O
.	O

M	O
(	O
IL-4	O
)	O
and	O
M	O
(	O
IL-10	O
)	O
did	O
not	O
inhibit	O
the	O
effects	O
of	O
M	O
(	O
IFNγ	O
+	O
TNFα	O
)	O
MCM	O
of	O
neither	O
phenotype	O
affected	O
IFNγ	O
+	O
TNFα	O
pre-stimulated	O
cartilage	O
,	O
in	O
which	O
an	O
inflammatory	O
gene	O
response	O
was	O
deliberately	O
induced	O
.	O

M	O
(	O
IFNγ	O
+	O
TNFα	O
)	O
macrophages	O
have	O
a	O
prominent	O
direct	O
effect	O
on	O
OA	O
cartilage	O
,	O
while	O
M	O
(	O
IL-4	O
)	O
and	O
M	O
(	O
IL-10	O
)	O
do	O
not	O
inhibit	O
the	O
effects	O
of	O
M	O
(	O
IFNγ	O
+	O
TNFα	O
)	O
,	O
or	O
IFN	O
γ+	O
TNFα	O
induced	O
inflammation	O
of	O
the	O
cartilage	O
.	O

Therapies	O
aiming	O
at	O
inhibiting	O
cartilage	O
degeneration	O
may	O
take	O
this	O
into	O
account	O
by	O
directing	O
suppression	O
of	O
pro-inflammatory	O
macrophages	O
or	O
stimulation	O
of	O
anti-inflammatory	O
macrophages	O
.	O

Stem	O
cell	O
registry	O
programme	O
for	O
patients	O
with	O
ischemic	O
cardiomyopathy	O
undergoing	O
coronary	O
artery	O
bypass	O
grafting	O
:	O
what	O
benefits	O
does	O
it	O
derive	O
?	O
.	O

Standardization	O
of	O
stem	O
cell	O
therapy	O
requires	O
application	O
of	O
appropriate	O
methods	O
to	O
evaluate	O
safety	O
and	O
efficac	O
y	O
,	O
including	O
long-term	O
pharmacovigilance	O
.	O

To	O
accomplish	O
this	O
objective	O
,	O
a	O
long-term	O
registry	O
programme	O
was	O
installed	O
.	O

We	O
analysed	O
150	O
patients	O
with	O
ischemic	O
cardiomyopathy	O
,	O
who	O
received	O
intramyocardial	O
CD133+	O
bone	O
marrow	O
mononuclear	O
stem	O
cell	O
treatment	O
combined	O
with	O
coronary	O
artery	O
bypass	O
grafting	O
(	O
CABG	O
)	O
or	O
CABG	O
alone	O
.	O

The	O
mortality	O
rate	O
,	O
major	O
adverse	O
cerebral	O
and	O
cardiac	O
events	O
,	O
and	O
functional	O
outcome	O
parameters	O
were	O
evaluated	O
for	O
the	O
time	O
period	O
up	O
to	O
14	O
years	O
follow-up	O
.	O

As	O
a	O
result	O
,	O
we	O
have	O
stratified	O
the	O
patient	O
population	O
(	O
96	O
patients	O
)	O
into	O
responders	O
and	O
non-responders	O
.	O

Furthermore	O
,	O
the	O
analysis	O
of	O
relevant	O
predictors	O
of	O
good	O
response	O
to	O
CD133+	O
bone	O
marrow	O
mononuclear	O
stem	O
cell	O
treatment	O
was	O
performed	O
.	O

Several	O
positive	O
tendencies	O
related	O
to	O
stem	O
cells	O
transplantation	O
were	O
demonstrated	O
.	O

First	O
,	O
no	O
significant	O
difference	O
in	O
major	O
adverse	O
cardiovascular	O
and	O
cerebral	O
events	O
was	O
observed	O
between	O
stem	O
cell	O
and	O
control	O
group	O
up	O
to	O
14	O
years	O
follow-up	O
.	O

Second	O
,	O
an	O
improvement	O
of	O
left	O
ventricle	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
in	O
stem	O
cell	O
group	O
retained	O
for	O
5	O
years	O
in	O
contrast	O
with	O
CABG	O
-	O
only	O
group	O
,	O
where	O
no	O
significant	O
changes	O
in	O
LVEF	O
after	O
2	O
years	O
were	O
observed	O
.	O

In	O
addition	O
,	O
LVEF	O
under	O
30	O
%	O
and	O
left	B-P
ventricle	I-P
end	I-P
diastolic	I-P
diameter	I-P
above	O
60	O
mm	O
were	O
independent	O
predictors	O
of	O
functional	O
response	O
to	O
CD133+	O
cell	O
therapy	O
.	O

Participants	O
with	O
overt	O
heart	O
failure	O
benefit	O
most	O
from	O
CABG	O
combined	O
with	O
intramyocardial	O
injection	O
of	O
CD133+	O
bone	O
marrow	O
mononuclear	O
cell	O
within	O
the	O
group	O
.	O

An	O
improvement	O
LVEF	O
in	O
stem	O
cell	O
group	O
remained	O
for	O
5	O
years	O
in	O
contrast	O
with	O
the	O
CABG	O
-	O
only	O
group	O
.	O

The	O
patients	O
,	O
in	O
whom	O
the	O
improvement	O
of	O
both	O
LVEF	O
and	O
LVED	B-P
was	O
observed	O
,	O
have	O
benefited	O
by	O
increased	O
life	O
expectancy	O
.	O

Genomic	B-P
Analyses	I-P
of	O
Cladophialophora	O
bantiana	O
,	O
a	O
Major	O
Cause	O
of	O
Cerebral	O
Phaeohyphomycosis	O
Provides	O
Insight	O
into	O
Its	O
Lifestyle	O
,	O
Virulence	O
and	O
Adaption	O
in	O
Host	O
.	O

Cladophialophora	O
bantiana	O
is	O
a	O
dematiaceous	O
fungus	O
with	O
a	O
predilection	O
for	O
causing	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
infection	O
manifesting	O
as	O
brain	O
abscess	O
in	O
both	O
immunocompetent	O
and	O
immunocompromised	O
patients	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
comprehensive	O
genomic	B-P
analyses	I-P
of	O
C.	O
bantiana	O
isolated	O
from	O
the	O
brain	O
abscess	O
of	O
an	O
immunocompetent	O
man	O
,	O
the	O
first	O
reported	O
case	O
in	O
Malaysia	O
and	O
Southeast	O
Asia	O
.	O

The	O
identity	O
of	O
the	O
fungus	O
was	O
determined	O
using	O
combined	O
morphological	O
analysis	O
and	O
multilocus	O
phylogeny	O
.	O

The	O
draft	O
genome	O
sequence	O
of	O
a	O
neurotrophic	O
fungus	O
,	O
C.	O
bantiana	O
UM	O
956	O
was	O
generated	O
using	O
Illumina	O
sequencing	O
technology	O
to	O
dissect	O
its	O
genetic	O
fundamental	O
and	O
basic	O
biology	O
.	O

The	O
assembled	O
37.1	O
Mb	O
genome	O
encodes	O
12,155	O
putative	O
coding	O
genes	O
,	O
of	O
which	O
,	O
1.01	O
%	O
are	O
predicted	O
transposable	O
elements	O
.	O

Its	O
genomic	B-P
features	I-P
support	O
its	O
saprophytic	O
lifestyle	O
,	O
renowned	O
for	O
its	O
versatility	O
in	O
decomposing	O
hemicellulose	O
and	O
pectin	O
components	O
.	O

The	O
C.	O
bantiana	O
UM	O
956	O
was	O
also	O
found	O
to	O
carry	O
some	O
important	O
putative	O
genes	O
that	O
engaged	O
in	O
pathogenicity	O
,	O
iron	O
uptake	O
and	O
homeostasis	O
as	O
well	O
as	O
adaptation	O
to	O
various	O
stresses	O
to	O
enable	O
the	O
organism	O
to	O
survive	O
in	O
hostile	O
microenvironment	O
.	O

This	O
wealth	O
of	O
resource	O
will	O
further	O
catalyse	O
more	O
downstream	O
functional	O
studies	O
to	O
provide	O
better	O
understanding	O
on	O
how	O
this	O
fungus	O
can	O
be	O
a	O
successful	O
and	O
persistent	O
pathogen	O
in	O
human	O
.	O

Mucosal	O
IgM	O
Antibody	O
with	O
d-Mannose	O
Affinity	O
in	O
Fugu	O
Takifugu	O
rubripes	O
Is	O
Utilized	O
by	O
a	O
Monogenean	O
Parasite	O
Heterobothrium	O
okamotoi	O
for	O
Host	O
Recognition	O
.	O

How	O
parasites	O
recognize	O
their	O
definitive	O
hosts	O
is	O
a	O
mystery	O
;	O
however	O
,	O
parasitism	O
is	O
reportedly	O
initiated	O
by	O
recognition	O
of	O
certain	O
molecules	O
on	O
host	O
surfaces	O
.	O

Fish	O
ectoparasites	O
make	O
initial	O
contact	O
with	O
their	O
hosts	O
at	O
body	O
surfaces	O
,	O
such	O
as	O
skin	O
and	O
gills	O
,	O
which	O
are	O
covered	O
with	O
mucosa	O
that	O
are	O
similar	O
to	O
those	O
of	O
mammalian	O
guts	O
.	O

Fish	O
are	O
among	O
the	O
most	O
primitive	O
vertebrates	O
with	O
immune	O
systems	O
that	O
are	O
equivalent	O
to	O
those	O
in	O
mammals	O
,	O
and	O
they	O
produce	O
and	O
secrete	O
IgM	O
into	O
mucus	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
the	O
monogenean	O
parasite	O
Heterobothrium	O
okamotoi	O
utilizes	O
IgM	O
to	O
recognize	O
its	O
host	O
,	O
fugu	O
Takifugu	O
rubripes	O
Oncomiracidia	O
are	O
infective	O
larvae	O
of	O
H.	O
okamotoi	O
that	O
shed	O
their	O
cilia	O
and	O
metamorphose	O
into	O
juveniles	O
when	O
exposed	O
to	O
purified	O
d-mannose	O
-	O
binding	O
fractions	O
from	O
fugu	O
mucus	O
.	O

Using	O
liquid	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
analysis	I-P
,	O
proteins	O
contained	O
in	O
the	O
fraction	O
were	O
identified	O
as	O
d-mannose	O
-specific	O
IgM	O
with	O
two	O
d-mannose	O
-binding	O
lectins	O
.	O

However	O
,	O
although	O
deciliation	O
was	O
significantly	O
induced	O
by	O
IgM	O
and	O
was	O
inhibited	O
by	O
d-mannose	O
or	O
a	O
specific	O
Ab	O
against	O
fugu	O
IgM	O
,	O
other	O
lectins	O
had	O
no	O
effect	O
,	O
and	O
IgM	O
without	O
d-mannose	O
affinity	O
induced	O
deciliation	O
to	O
a	O
limited	O
degree	O
.	O

Subsequent	O
immunofluorescent	B-P
staining	I-P
experiments	I-P
showed	O
that	O
fugu	O
d-mannose	O
-specific	O
IgM	O
binds	O
ciliated	O
epidermal	O
cells	O
of	O
oncomiracidium	O
.	O

These	O
observations	O
suggest	O
that	O
deciliation	O
is	O
triggered	O
by	O
binding	O
of	O
fugu	O
IgM	O
to	O
cell	O
surface	O
Ags	O
via	O
Ag	O
binding	O
sites	O
.	O

Moreover	O
,	O
concentrations	O
of	O
d-mannose	O
-	O
binding	O
IgM	O
in	O
gill	O
mucus	O
were	O
sufficient	O
to	O
induce	O
deciliation	O
in	O
vitro	O
,	O
indicating	O
that	O
H.	O
okamotoi	O
parasites	O
initially	O
use	O
host	O
Abs	O
to	O
colonize	O
host	O
gills	O
.	O

Mechanics	O
,	O
thermodynamics	O
,	O
and	O
kinetics	O
of	O
ligand	O
binding	O
to	O
biopolymers	O
.	O

Ligands	O
binding	O
to	O
polymers	O
regulate	O
polymer	O
functions	O
by	O
changing	O
their	O
physical	O
and	O
chemical	O
properties	O
.	O

This	O
ligand	O
regulation	O
plays	O
a	O
key	O
role	O
in	O
many	O
biological	O
processes	O
.	O

We	O
propose	O
here	O
a	O
model	O
to	O
explain	O
the	O
mechanical	O
,	O
thermodynamic	O
,	O
and	O
kinetic	O
properties	O
of	O
the	O
process	O
of	O
binding	O
of	O
small	O
ligands	O
to	O
long	O
biopolymers	O
.	O

These	O
properties	O
can	O
now	O
be	O
measured	O
at	O
the	O
single	O
molecule	O
level	O
using	O
force	B-P
spectroscopy	I-P
techniques	I-P
.	O

Our	O
model	O
performs	O
an	O
effective	O
decomposition	O
of	O
the	O
ligand-polymer	O
system	O
on	O
its	O
covered	O
and	O
uncovered	O
regions	O
,	O
showing	O
that	O
the	O
elastic	O
properties	O
of	O
the	O
ligand	O
-	O
polymer	O
depend	O
explicitly	O
on	O
the	O
ligand	O
coverage	O
of	O
the	O
polymer	O
(	O
i.e.	O
,	O
the	O
fraction	O
of	O
the	O
polymer	O
covered	O
by	O
the	O
ligand	O
)	O
.	O

The	O
equilibrium	O
coverage	O
that	O
minimizes	O
the	O
free	O
energy	O
of	O
the	O
ligand-polymer	O
system	O
is	O
computed	O
as	O
a	O
function	O
of	O
the	O
applied	O
force	O
.	O

We	O
show	O
how	O
ligands	O
tune	O
the	O
mechanical	O
properties	O
of	O
a	O
polymer	O
,	O
in	O
particular	O
its	O
length	O
and	O
stiffness	O
,	O
in	O
a	O
force	O
dependent	O
manner	O
.	O

In	O
addition	O
,	O
it	O
is	O
shown	O
how	O
ligand	O
binding	O
can	O
be	O
regulated	O
applying	O
mechanical	O
tension	O
on	O
the	O
polymer	O
.	O

Moreover	O
,	O
the	O
binding	O
kinetics	O
study	O
shows	O
that	O
,	O
in	O
the	O
case	O
where	O
the	O
ligand	O
binds	O
and	O
organizes	O
the	O
polymer	O
in	O
different	O
modes	O
,	O
the	O
binding	O
process	O
can	O
present	O
transient	O
shortening	O
or	O
lengthening	O
of	O
the	O
polymer	O
,	O
caused	O
by	O
changes	O
in	O
the	O
relative	O
coverage	O
by	O
the	O
different	O
ligand	O
modes	O
.	O

Our	O
model	O
will	O
be	O
useful	O
to	O
understand	O
ligand-binding	O
regulation	O
of	O
biological	O
processes	O
,	O
such	O
as	O
the	O
metabolism	O
of	O
nucleic	O
acid	O
.	O

In	O
particular	O
,	O
this	O
model	O
allows	O
estimating	O
the	O
coverage	O
fraction	O
and	O
the	O
ligand	O
mode	O
characteristics	O
from	O
the	O
force	O
extension	O
curves	O
of	O
a	O
ligand-polymer	O
system	O
.	O

Orthogonal	O
Chemical	O
Modification	O
of	O
Template	O
-	O
Synthesized	O
Nanostructures	O
with	O
DNA	O
.	O

Very	O
few	O
chemical	O
strategies	O
for	O
the	O
selective	O
functionalization	O
of	O
nanostructures	O
have	O
been	O
developed	O
despite	O
their	O
potential	O
for	O
controlling	O
high-order	O
assembly	O
processes	O
.	O

We	O
report	O
a	O
novel	O
approach	O
for	O
the	O
selective	O
chemical	O
functionalization	O
and	O
localized	O
assembly	O
of	O
one-dimensional	O
nanostructures	O
(	O
rods	O
)	O
,	O
based	O
upon	O
the	O
systematic	O
activation	O
(	O
DNA	O
functionalization	O
)	O
and	O
passivation	O
(	O
self-assembled	O
monolayers	O
)	O
of	O
specific	O
surface	O
sites	O
through	O
the	O
use	O
of	O
orthogonal	O
chemical	O
reactions	O
on	O
electrochemically	B-P
grown	O
metal	O
nanorod	O
arrays	O
in	O
porous	O
anodic	O
aluminum	O
oxide	O
templates	O
.	O

The	O
ability	O
to	O
orthogonally	O
functionalize	O
the	O
ends	O
or	O
the	O
side	O
of	O
a	O
nanorod	O
,	O
as	O
well	O
as	O
the	O
gaps	O
between	O
two	O
rods	O
,	O
with	O
different	O
DNA	O
strands	O
allows	O
one	O
to	O
synthesize	O
nanostructure	O
assemblies	O
that	O
would	O
be	O
difficult	O
to	O
realize	O
any	O
other	O
way	O
and	O
that	O
could	O
ultimately	O
be	O
utilized	O
for	O
making	O
a	O
wide	O
variety	O
of	O
device	O
architectures	O
.	O

The	O
transcription	O
factors	O
MS188	O
and	O
AMS	O
form	O
a	O
complex	O
to	O
activate	O
the	O
expression	O
of	O
CYP703A2	O
for	O
sporopollenin	O
biosynthesis	O
in	O
Arabidopsis	O
thaliana	O
.	O

The	O
sexine	O
layer	O
of	O
pollen	O
grain	O
is	O
mainly	O
composed	O
of	O
sporopollenins	O
.	O

The	O
sporophytic	O
secretory	O
tapetum	O
is	O
required	O
for	O
the	O
biosynthesis	O
of	O
sporopollenin	O
.	O

Although	O
several	O
enzymes	O
involved	O
in	O
sporopollenin	O
biosynthesis	O
have	O
been	O
reported	O
,	O
the	O
regulatory	O
mechanism	O
of	O
these	O
enzymes	O
in	O
tapetal	O
layer	O
remains	O
elusive	O
.	O

ABORTED	O
MICROSPORES	O
(	O
AMS	O
)	O
and	O
MALE	O
STERILE	O
188	O
/	O
MYB103	O
/	O
MYB80	O
(	O
MS188	O
/	O
MYB103	O
/	O
MYB80	O
)	O
are	O
two	O
tapetal	O
cell	O
-specific	O
transcription	O
factors	O
required	O
for	O
pollen	O
wall	O
formation	O
.	O

AMS	O
functions	O
upstream	O
of	O
MS188	O
.	O

Here	O
we	O
report	O
that	O
AMS	O
and	O
MS188	O
target	O
the	O
CYP703A2	O
gene	O
,	O
which	O
is	O
involved	O
in	O
sporopollenin	O
biosynthesis	O
.	O

We	O
found	O
that	O
AMS	O
and	O
MS188	O
were	O
localized	O
in	O
tapetum	O
while	O
CYP703A2	O
was	O
localized	O
in	O
both	O
tapetum	O
and	O
locule	O
.	O

Chromatin	B-P
immunoprecipitation	I-P
(	O
ChIP	B-P
)	O
showed	O
that	O
MS188	O
directly	O
bound	O
to	O
the	O
promoter	O
of	O
CYP703A2	O
and	O
luciferase-inducible	O
assay	B-P
showed	O
that	O
MS188	O
activated	O
the	O
expression	O
of	O
CYP703A2	O
.	O

Yeast	O
two-hybrid	O
and	O
electrophoretic	B-P
mobility	I-P
shift	I-P
assays	I-P
(	O
EMSAs	B-P
)	O
further	O
demonstrated	O
that	O
MS188	O
complexed	O
with	O
AMS	O
.	O

The	O
expression	O
of	O
CYP703A2	O
could	O
be	O
partially	O
restored	O
by	O
the	O
elevated	O
levels	O
of	O
MS188	O
in	O
the	O
ams	O
mutant	O
.	O

Therefore	O
,	O
our	O
data	O
reveal	O
that	O
MS188	O
coordinates	O
with	O
AMS	O
to	O
activate	O
CYP703A2	O
in	O
sporopollenin	O
biosynthesis	O
of	O
plant	O
tapetum	O
.	O

Computed	B-P
Tomography	I-P
Imaging	I-P
Features	O
and	O
Changes	O
in	O
Hemostatic	O
Agents	O
After	O
Laparoscopic	O
Partial	O
Nephrectomy	O
.	O

Urologists	O
and	O
radiologists	O
should	O
be	O
aware	O
of	O
the	O
CT	B-P
scan	I-P
appearance	O
of	O
laparoscopic	O
partial	O
nephrectomy	O
(	O
LPN	O
)	O
with	O
the	O
various	O
hemostatic	O
agents	O
since	O
they	O
may	O
confound	O
the	O
interpretation	O
of	O
these	O
radiographic	O
findings	O
.	O

We	O
report	O
the	O
various	O
postoperative	O
CT	B-P
scan	I-P
appearance	O
and	O
changes	O
after	O
LPN	O
.	O

We	O
reviewed	O
CT	B-P
scans	I-P
retrospectively	O
(	O
within	O
3	O
months	O
)	O
of	O
86	O
patients	O
who	O
underwent	O
LPN	O
using	O
various	O
hemostatic	O
agents	O
between	O
March	O
2008	O
and	O
July	O
2014	O
.	O

We	O
analyzed	O
the	O
CT	B-P
findings	O
after	O
LPN	O
,	O
including	O
postoperative	O
changes	O
,	O
tumor	O
recurrence	O
,	O
and	O
complications	O
.	O

We	O
also	O
discuss	O
changes	O
in	O
abnormal	O
features	O
,	O
such	O
as	O
mass-like	O
lesions	O
and	O
gas	O
formation	O
,	O
on	O
follow-up	O
CT	B-P
scans	I-P
.	O

To	O
categorize	O
the	O
postoperative	O
changes	O
,	O
we	O
classified	O
them	O
according	O
to	O
their	O
specific	O
CT	B-P
findings	O
:	O
(	O
1	O
)	O
a	O
combination	O
of	O
perinephric	O
stranding	O
and	O
postsurgical	O
fluid	O
collection	O
(	O
n	O
=	O
46	O
)	O
,	O
(	O
2	O
)	O
mass-like	O
lesions	O
(	O
n	O
=	O
35	O
)	O
,	O
(	O
3	O
)	O
a	O
parenchymal	O
defect	O
(	O
n	O
=	O
2	O
)	O
,	O
(	O
4	O
)	O
local	O
recurrence	O
at	O
the	O
surgical	O
site	O
(	O
n	O
=	O
1	O
)	O
,	O
(	O
5	O
)	O
a	O
large	O
hematoma	O
as	O
a	O
complication	O
after	O
LPN	O
(	O
n	O
=	O
2	O
)	O
,	O
(	O
6	O
)	O
gas	O
pockets	O
,	O
which	O
may	O
be	O
a	O
response	O
to	O
postsurgical	O
fluid	O
collection	O
around	O
soft	O
tissue	O
(	O
n	O
=	O
35	O
)	O
,	O
(	O
7	O
)	O
fat	O
at	O
the	O
excision	O
site	O
(	O
n	O
=	O
2	O
;	O
Fig	O
.	O

7	O
)	O
,	O
and	O
(	O
8	O
)	O
contrast	O
extravasation	O
in	O
the	O
delayed	O
phase	O
(	O
n	O
=	O
1	O
)	O
.	O

Mass-like	O
lesions	O
were	O
visible	O
in	O
35	O
cases	O
.	O

The	O
average	O
change	O
in	O
size	O
of	O
bolster	O
masses	O
was	O
-1.19	O
mm/month	O
.	O

However	O
,	O
the	O
overall	O
change	O
in	O
enhancement	O
of	O
mass-like	O
lesions	O
was	O
not	O
significant	O
over	O
time	O
.	O

Foci	O
of	O
gas	O
were	O
noted	O
in	O
16	O
patients	O
at	O
the	O
resection	O
site	O
in	O
the	O
first	O
follow-up	O
period	O
(	O
<	O
3	O
months	O
)	O
,	O
as	O
late	O
as	O
40	O
days	O
after	O
the	O
procedure	O
.	O

Knowledge	O
of	O
CT	B-P
imaging	I-P
features	O
and	O
changes	O
in	O
hemostatic	O
agents	O
following	O
LPN	O
is	O
important	O
in	O
interpreting	O
postoperative	O
CT	B-P
scans	I-P
,	O
as	O
postoperative	O
changes	O
can	O
be	O
confused	O
with	O
tumor	O
recurrence	O
and	O
can	O
mimic	O
abscesses	O
.	O

Long	O
Non-Coding	O
RNA	O
SNHG6	O
as	O
a	O
Potential	O
Biomarker	O
for	O
Hepatocellular	O
Carcinoma	O
.	O

Long	O
Non-coding	O
RNAs	O
(	O
lncRNAs	O
)	O
refer	O
to	O
all	O
non-protein	O
coding	O
transcripts	O
longer	O
than	O
200	O
nucleotides	O
.	O

Their	O
critical	O
roles	O
in	O
different	O
biological	O
pathways	O
have	O
been	O
already	O
well	O
established	O
.	O

Altered	O
expression	O
of	O
lncRNAs	O
can	O
be	O
involved	O
in	O
the	O
cancer	O
initiation	O
and/or	O
progression	O
.	O

Since	O
patients	O
with	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
are	O
usually	O
diagnosed	O
in	O
late	O
stages	O
,	O
developing	O
diagnostic	B-P
methods	I-P
seems	O
to	O
be	O
essential	O
.	O

In	O
this	O
study	O
,	O
the	O
expression	O
levels	O
of	O
different	O
lncRNAs	O
were	O
systematically	O
analysed	O
in	O
different	O
genomic	O
and	O
transcriptome	O
datasets	O
.	O

The	O
analyses	O
showed	O
that	O
SNHG6	O
is	O
among	O
the	O
lncRNAs	O
with	O
distinctive	O
dysregulation	O
of	O
expression	O
and	O
copy	O
number	O
variation	O
in	O
HCC	O
tumors	O
compared	O
with	O
normal	O
tissues	O
.	O

The	O
results	O
also	O
suggest	O
that	O
the	O
dysregulation	O
of	O
SNHG6	O
is	O
highly	O
cancer	O
type	O
specific	O
.	O

Through	O
co-occurrence	O
analyses	O
,	O
we	O
found	O
that	O
SNHG6	O
and	O
its	O
related	O
co-expressed	O
genes	O
on	O
8q	O
are	O
involved	O
in	O
the	O
structural	O
integrity	O
of	O
ribosome	O
and	O
translation	O
.	O

This	O
comprehensive	O
in	O
silico	O
analysis	O
,	O
provides	O
a	O
resource	O
for	O
investigating	O
SNHG6	O
in	O
hepatocellular	O
carcinoma	O
and	O
lays	O
the	O
groundwork	O
for	O
design	O
of	O
next	O
researches	O
.	O

Elevated	O
Serum	O
Uric	O
Acid	O
Level	O
Predicts	O
Rapid	O
Decline	O
in	O
Kidney	O
Function	O
.	O

While	O
elevated	O
serum	O
uric	O
acid	O
level	O
(	O
SUA	O
)	O
is	O
a	O
recognized	O
risk	O
factor	O
for	O
chronic	O
kidney	O
disease	O
,	O
it	O
remains	O
unclear	O
whether	O
change	O
in	O
SUA	O
is	O
independently	O
associated	O
with	O
change	O
in	O
estimated	B-P
glomerular	I-P
filtration	I-P
rate	I-P
(	O
eGFR	B-P
)	O
over	O
time	O
.	O

Accordingly	O
,	O
we	O
examined	O
the	O
longitudinal	O
associations	O
between	O
change	O
in	O
SUA	O
and	O
change	O
in	O
eGFR	B-P
over	O
5	O
years	O
in	O
a	O
general	O
Japanese	O
population	O
.	O

This	O
was	O
a	O
large	O
,	O
single-center	O
,	O
retrospective	O
5-	O
year	O
cohort	O
study	O
at	O
St.	O
Luke	O
's	O
International	O
Hospital	O
,	O
Tokyo	O
,	O
Japan	O
,	O
between	O
2004	O
and	O
2009	O
.	O

We	O
included	O
13,070	O
subjects	O
(	O
30-85	O
years	O
)	O
in	O
our	O
analyses	O
whose	O
data	O
were	O
available	O
between	O
2004	O
and	O
2009	O
.	O

Of	O
those	O
,	O
we	O
excluded	O
492	O
subjects	O
with	O
eGFR	B-P
<	O
60	O
mL/min/1.73	O
m2	O
at	O
baseline	O
.	O

In	O
addition	O
to	O
examining	O
the	O
entire	O
cohort	O
(	O
n	O
=	O
12,578	O
)	O
,	O
we	O
stratified	O
our	O
analyses	O
by	O
baseline	O
eGFR	B-P
groups	O
:	O
60-90	O
,	O
90-120	O
,	O
and	O
≥120	O
mL/min/1.73	O
m2	O
.	O

Linear	O
and	O
logistic	O
regressions	O
models	O
were	O
applied	O
to	O
examine	O
the	O
relationships	O
between	O
baseline	O
and	O
change	O
in	O
SUA	O
,	O
change	O
in	O
eGFR	B-P
,	O
and	O
rapid	O
eGFR	B-P
decline	O
(	O
defined	O
as	O
the	O
highest	O
quartile	O
of	O
change	O
in	O
eGFR	B-P
)	O
,	O
adjusted	O
for	O
age	O
,	O
gender	O
,	O
body	O
mass	O
index	O
,	O
abdominal	O
circumference	O
,	O
hypertension	O
,	O
dyslipidemia	O
,	O
and	O
diabetes	O
mellitus	O
.	O

After	O
multivariable	O
adjustments	O
including	O
baseline	O
eGFR	B-P
,	O
1	O
mg/dL	O
increase	O
in	O
baseline	O
SUA	O
was	O
associated	O
with	O
greater	O
odds	O
of	O
developing	O
rapid	O
eGFR	B-P
decline	O
(	O
OR	O
1.27	O
,	O
95	O
%	O
CI	O
1.17-1.38	O
)	O
,	O
and	O
1	O
mg/dL	O
increase	O
in	O
SUA	O
over	O
5	O
years	O
was	O
associated	O
with	O
3.77-fold	O
greater	O
odds	O
of	O
rapid	O
eGFR	B-P
decline	O
(	O
OR	O
3.77	O
,	O
95	O
%	O
CI	O
3.35-4.26	O
)	O
.	O

Elevated	O
baseline	O
SUA	O
and	O
increasing	O
SUA	O
over	O
time	O
were	O
independent	O
risk	O
factors	O
for	O
rapid	O
eGFR	B-P
decline	O
over	O
5	O
years	O
.	O

Primitive	O
Neuroectodermal	O
Tumors	O
of	O
the	O
Female	O
Genital	O
Tract	O
:	O
A	O
Morphologic	O
,	O
Immunohistochemical	B-P
,	O
and	O
Molecular	O
Study	O
of	O
19	O
Cases	O
.	O

Primary	O
primitive	O
neuroectodermal	O
tumor	O
(	O
PNET	O
)	O
of	O
the	O
female	O
genital	O
tract	O
is	O
rare	O
,	O
and	O
its	O
proper	O
classification	O
remains	O
unclear	O
.	O

The	O
clinical	O
,	O
histologic	O
,	O
and	O
immunophenotypic	B-P
features	O
as	O
well	O
as	O
EWSR1	O
rearrangement	O
status	O
of	O
19	O
gynecologic	O
PNETs	O
,	O
including	O
10	O
ovarian	O
,	O
8	O
uterine	O
,	O
and	O
1	O
vulvar	O
tumors	O
,	O
are	O
herein	O
reported	O
.	O

Patient	O
age	O
ranged	O
from	O
12	O
to	O
68	O
years	O
,	O
with	O
a	O
median	O
age	O
of	O
20	O
and	O
51	O
years	O
among	O
those	O
with	O
ovarian	O
and	O
uterine	O
PNETs	O
,	O
respectively	O
.	O

Morphologic	O
features	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
tumors	O
were	O
seen	O
in	O
15	O
PNETs	O
,	O
including	O
9	O
medulloblastomas	O
,	O
3	O
ependymomas	O
,	O
2	O
medulloepitheliomas	O
,	O
and	O
1	O
glioblastoma	O
,	O
consistent	O
with	O
central	O
PNET	O
.	O

The	O
remaining	O
4	O
PNETs	O
were	O
composed	O
entirely	O
of	O
undifferentiated	O
small	O
round	O
blue	O
cells	O
and	O
were	O
classified	O
as	O
Ewing	O
sarcoma/peripheral	O
PNET	O
.	O

Eight	O
PNETs	O
were	O
associated	O
with	O
another	O
tumor	O
type	O
,	O
including	O
5	O
ovarian	O
mature	O
cystic	O
teratomas	O
,	O
2	O
endometrial	O
low-grade	O
endometrioid	O
carcinomas	O
,	O
and	O
a	O
uterine	O
carcinosarcoma	O
.	O

By	O
immunohistochemistry	B-P
,	O
17	O
PNETs	O
expressed	O
at	O
least	O
1	O
marker	O
of	O
neuronal	O
differentiation	O
,	O
including	O
synaptophysin	O
,	O
NSE	O
,	O
CD56	O
,	O
S100	O
,	O
and	O
chromogranin	O
in	O
10	O
,	O
8	O
,	O
14	O
,	O
8	O
,	O
and	O
1	O
tumors	O
,	O
respectively	O
.	O

GFAP	O
was	O
positive	O
in	O
4	O
PNETs	O
,	O
all	O
of	O
which	O
were	O
of	O
central	O
type	O
.	O

Membranous	O
CD99	O
and	O
nuclear	O
Fli-1	O
staining	B-P
was	O
seen	O
in	O
10	O
and	O
16	O
tumors	O
,	O
respectively	O
,	O
and	O
concurrent	O
expression	O
of	O
both	O
markers	O
was	O
seen	O
in	O
both	O
central	O
and	O
Ewing	O
sarcoma/peripheral	O
PNET	O
s.	O
All	O
tumors	O
expressed	O
vimentin	O
,	O
whereas	O
keratin	O
cocktail	O
(	O
CAM5.2	O
,	O
AE1/AE3	O
)	O
staining	B-P
was	O
only	O
focally	O
present	O
in	O
4	O
PNETs	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
was	O
successful	O
in	O
all	O
cases	O
and	O
confirmed	O
EWSR1	O
rearrangement	O
in	O
2	O
of	O
4	O
tumors	O
demonstrating	O
morphologic	O
features	O
of	O
Ewing	O
sarcoma/peripheral	O
PNET	O
and	O
concurrent	O
CD99	O
and	O
Fli-1	O
expression	O
.	O

In	O
conclusion	O
,	O
central	O
and	O
Ewing	O
sarcoma/peripheral	O
PNETs	O
may	O
be	O
encountered	O
in	O
the	O
female	O
genital	O
tract	O
with	O
central	O
PNETs	O
being	O
more	O
common	O
.	O

Central	O
PNETs	O
show	O
a	O
spectrum	O
of	O
morphologic	O
features	O
that	O
overlaps	O
with	O
CNS	O
tumors	O
but	O
lack	O
EWSR1	O
rearrangement	O
s.	O
GFAP	O
expression	O
supports	O
a	O
morphologic	O
impression	O
of	O
central	O
PNET	O
and	O
is	O
absent	O
in	O
Ewing	O
sarcoma/peripheral	O
PNET	O
.	O

Ewing	O
sarcoma/peripheral	O
PNETs	O
lack	O
morphologic	O
features	O
of	O
CNS	O
tumors	O
.	O

Dynamic	B-P
Contrast-enhanced	I-P
MR	I-P
Imaging	I-P
in	O
Renal	O
Cell	O
Carcinoma	O
:	O
Reproducibility	O
of	O
Histogram	O
Analysis	O
on	O
Pharmacokinetic	O
Parameters	O
.	O

Pharmacokinetic	O
parameters	O
derived	O
from	O
dynamic	B-P
contrast-enhanced	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
DCE-MRI	B-P
)	O
have	O
been	O
increasingly	O
used	O
to	O
evaluate	O
the	O
permeability	O
of	O
tumor	O
vessel	O
.	O

Histogram	O
metrics	O
are	O
a	O
recognized	O
promising	O
method	O
of	O
quantitative	O
MR	B-P
imaging	I-P
that	O
has	O
been	O
recently	O
introduced	O
in	O
analysis	O
of	O
DCE-MRI	B-P
pharmacokinetic	O
parameters	O
in	O
oncology	O
due	O
to	O
tumor	O
heterogeneity	O
.	O

In	O
this	O
study	O
,	O
21	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
underwent	O
paired	O
DCE-MRI	B-P
studies	O
on	O
a	O
3.0	O
T	O
MR	O
system	O
.	O

Extended	O
Tofts	O
model	O
and	O
population-based	O
arterial	O
input	O
function	O
were	O
used	O
to	O
calculate	O
kinetic	O
parameters	O
of	O
RCC	O
tumors	O
.	O

Mean	O
value	O
and	O
histogram	O
metrics	O
(	O
Mode	O
,	O
Skewness	O
and	O
Kurtosis	O
)	O
of	O
each	O
pharmacokinetic	O
parameter	O
were	O
generated	O
automatically	O
using	O
ImageJ	O
software	O
.	O

Intra-	O
and	O
inter-observer	O
reproducibility	O
and	O
scan-rescan	O
reproducibility	O
were	O
evaluated	O
using	O
intra-class	O
correlation	O
coefficients	O
(	O
ICCs	O
)	O
and	O
coefficient	O
of	O
variation	O
(	O
CoV	O
)	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
histogram	O
method	O
(	O
Mode	O
,	O
Skewness	O
and	O
Kurtosis	O
)	O
was	O
not	O
superior	O
to	O
the	O
conventional	O
Mean	O
value	O
method	O
in	O
reproducibility	O
evaluation	O
on	O
DCE-MRI	B-P
pharmacokinetic	O
parameters	O
(	O
K	O
(	O
trans	O
)	O
&	O
Ve	O
)	O
in	O
renal	O
cell	O
carcinoma	O
,	O
especially	O
for	O
Skewness	O
and	O
Kurtosis	O
which	O
showed	O
lower	O
intra-	O
,	O
inter-observer	O
and	O
scan-rescan	O
reproducibility	O
than	O
Mean	O
value	O
.	O

Our	O
findings	O
suggest	O
that	O
additional	O
studies	O
are	O
necessary	O
before	O
wide	O
incorporation	O
of	O
histogram	O
metrics	O
in	O
quantitative	O
analysis	O
of	O
DCE-MRI	B-P
pharmacokinetic	O
parameters	O
.	O

Repetitive	O
transcranial	O
magnetic	O
stimulation	O
improves	O
cognitive	O
function	O
of	O
Alzheimer	O
's	O
disease	O
patients	O
.	O

Repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
acts	O
as	O
a	O
kind	O
of	O
widely-applied	O
and	O
non-invasive	O
method	O
in	O
the	O
intervention	O
of	O
some	O
neurological	O
disorders	O
.	O

This	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
investigates	O
the	O
effect	O
of	O
rTMS	O
on	O
30	O
cases	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
participants	O
,	O
who	O
were	O
classified	O
into	O
mild	O
and	O
moderate	O
groups	O
.	O

Neuropsychological	B-P
tests	I-P
were	O
carried	O
out	O
using	O
the	O
AD	O
Assessment	O
Scale	O
-	O
cognitive	O
subscale	O
(	O
ADAS	O
-	O
cog	O
)	O
,	O
Mini-Mental	B-P
State	I-P
Examination	I-P
(	O
MMSE	B-P
)	O
,	O
Montreal	O
Cognitive	O
Assessment	O
(	O
MoCA	O
)	O
,	O
and	O
World	O
Health	O
Organization	O
University	O
of	O
California-Los	O
Angeles	O
,	O
Auditory	O
Verbal	O
Learning	O
Test	O
(	O
WHO-UCLA	O
AVLT	O
)	O
before	O
,	O
immediately	O
after	O
,	O
and	O
6	O
weeks	O
after	O
the	O
intervention	O
.	O

In	O
this	O
work	O
,	O
data	O
from	O
30	O
AD	O
patients	O
revealed	O
that	O
there	O
was	O
no	O
obvious	O
interaction	O
effect	O
of	O
time-by-group	O
.	O

The	O
ADAS	O
-	O
cog	O
,	O
MMSE	B-P
and	O
WHO-UCLA	O
AVLT	O
score	O
in	O
the	O
rTMS	O
group	O
was	O
significantly	O
improved	O
compared	O
with	O
baselines	O
at	O
6	O
weeks	O
after	O
treatment	O
(	O
all	O
p	O
<	O
0.05	O
)	O
.	O

Meanwhile	O
,	O
MoCA	O
scores	O
were	O
also	O
obviously	O
ameliorated	O
in	O
the	O
mild	O
AD	O
patients	O
with	O
rTMS	O
.	O

Besides	O
,	O
subgroup	O
analysis	O
showed	O
that	O
the	O
effect	O
of	O
rTMS	O
on	O
the	O
memory	O
and	O
language	O
of	O
mild	O
AD	O
patients	O
was	O
superior	O
to	O
those	O
of	O
moderate	O
AD	O
patients	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
suggested	O
that	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
improves	O
cognitive	O
function	O
,	O
memory	O
and	O
language	O
level	O
of	O
AD	O
patients	O
,	O
especially	O
in	O
the	O
mild	O
stage	O
of	O
AD	O
.	O

Thus	O
,	O
rTMS	O
can	O
be	O
recommended	O
as	O
a	O
promising	O
adjuvant	O
therapy	O
combined	O
with	O
cholinesterase	O
inhibitors	O
at	O
the	O
mild	O
stage	O
of	O
AD	O
patients	O
.	O

Characteristics	O
of	O
N-Acylhomoserine	O
Lactones	O
Produced	O
by	O
Hafnia	O
alvei	O
H4	O
Isolated	O
from	O
Spoiled	O
Instant	O
Sea	O
Cucumber	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
N-acylhomoserine	O
lactone	O
(	O
AHL	O
)	O
produced	O
by	O
Hafnia	O
alvei	O
H4	O
,	O
which	O
was	O
isolated	O
from	O
spoiled	O
instant	O
sea	O
cucumber	O
,	O
and	O
to	O
investigate	O
the	O
effect	O
of	O
AHLs	O
on	O
biofilm	O
formation	O
.	O

Two	O
biosensor	O
strains	O
,	O
Chromobacterium	O
violaceum	O
CV026	O
and	O
Agrobacterium	O
tumefaciens	O
KYC55	O
,	O
were	O
used	O
to	O
detect	O
the	O
quorum	O
sensing	O
(	O
QS	O
)	O
activity	O
of	O
H.	O
alvei	O
H4	O
and	O
to	O
confirm	O
the	O
existence	O
of	O
AHL	O
-mediated	O
QS	O
system	O
.	O

Thin	B-P
layer	I-P
chromatography	I-P
(	O
TLC	B-P
)	O
and	O
high	B-P
resolution	I-P
triple	I-P
quadrupole	I-P
liquid	I-P
chromatography/mass	I-P
spectrometry	I-P
(	O
LC/MS	B-P
)	O
analysis	O
of	O
the	O
AHLs	O
extracted	O
from	O
the	O
culture	B-P
supernatant	O
of	O
H.	O
alvei	O
H4	O
revealed	O
the	O
existence	O
of	O
at	O
least	O
three	O
AHL	O
s	O
:	O
N-hexanoyl-l-homoserine	O
lactone	O
(	O
C6-HSL	O
)	O
,	O
N-	O
(	O
3-oxo-octanoyl	O
)	O
-l-homoserine	O
lactone	O
(	O
3-oxo-C8-HSL	O
)	O
,	O
and	O
N-butyryl-l-homoserine	O
lactone	O
(	O
C4-HSL	O
)	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
production	O
of	O
C4-HSL	O
by	O
H.	O
alvei	O
.	O

In	O
order	O
to	O
determine	O
the	O
relationship	O
between	O
the	O
production	O
of	O
AHL	O
by	O
H.	O
alvei	O
H4	O
and	O
bacterial	O
growth	O
,	O
the	O
β-galactosidase	O
assay	B-P
was	O
employed	O
to	O
monitor	O
AHL	O
activity	O
during	O
a	O
48-h	O
growth	O
phase	O
.	O

AHLs	O
production	O
reached	O
a	O
maximum	O
level	O
of	O
134.6	O
Miller	O
unites	O
at	O
late	O
log	O
phase	O
(	O
after	O
18	O
h	O
)	O
and	O
then	O
decreased	O
to	O
a	O
stable	O
level	O
of	O
about	O
100	O
Miller	O
unites	O
.	O

AHL	O
production	O
and	O
bacterial	O
growth	O
displayed	O
a	O
similar	O
trend	O
,	O
suggesting	O
that	O
growth	O
of	O
H.	O
alvei	O
H4	O
might	O
be	O
regulated	O
by	O
QS	O
.	O

The	O
effect	O
of	O
AHLs	O
on	O
biofilm	O
formation	O
of	O
H.	O
alvei	O
H4	O
was	O
investigated	O
by	O
adding	O
exogenous	O
AHLs	O
(	O
C4-HSL	O
,	O
C6-HSL	O
and	O
3-oxo-C8-HSL	O
)	O
to	O
H.	O
alvei	O
H4	O
culture	O
.	O

Biofilm	O
formation	O
was	O
significantly	O
promoted	O
(	O
p	O
<	O
0.05	O
)	O
by	O
5	O
and	O
10	O
µM	O
C6-HSL	O
,	O
inhibited	O
(	O
p	O
<	O
0.05	O
)	O
by	O
C4-HSL	O
(	O
5	O
and	O
10	O
µM	O
)	O
and	O
5	O
µM	O
3-oxo-C8-HSL	O
,	O
suggesting	O
that	O
QS	O
may	O
have	O
a	O
regulatory	O
role	O
in	O
the	O
biofilm	O
formation	O
of	O
H.	O
alvei	O
H4	O
.	O

Differential	O
expression	O
of	O
TGF-β	O
superfamily	O
members	O
and	O
role	O
of	O
Smad1	O
/	O
5	O
/	O
9	O
-	O
signalling	O
in	O
chondral	O
versus	O
endochondral	O
chondrocyte	O
differentiation	O
.	O

Proteins	O
of	O
the	O
transforming-growth-factor-β	O
(	O
TGF-β	O
)	O
-	O
superfamily	O
have	O
a	O
remarkable	O
ability	O
to	O
induce	O
cartilage	O
and	O
bone	O
and	O
the	O
crosstalk	O
of	O
TGF-β	O
-	O
and	O
BMP-signalling	O
pathways	O
appears	O
crucial	O
during	O
chondrocyte	O
development	O
.	O

Aim	O
was	O
to	O
assess	O
the	O
regulation	O
of	O
TGF-β	O
-	O
superfamily	O
members	O
and	O
of	O
Smad2	O
/	O
3	O
-	O
and	O
Smad1	O
/	O
5	O
/	O
9	O
-	O
signalling	O
during	O
endochondral	O
in	O
vitro	O
chondrogenesis	O
of	O
mesenchymal	O
stromal	O
cells	O
(	O
MSC	O
)	O
relative	O
to	O
chondral	O
redifferentiation	O
of	O
articular	O
chondrocytes	O
(	O
AC	O
)	O
to	O
adjust	O
chondrocyte	O
development	O
of	O
MSC	O
towards	O
a	O
less	O
hypertrophic	O
phenotype	O
.	O

While	O
MSC	O
increased	O
BMP4	O
and	O
BMP7	O
and	O
reduced	O
TGFBR2	O
and	O
TGFBR3	O
-	O
expression	O
during	O
chondrogenesis	O
,	O
an	O
opposite	O
regulation	O
was	O
observed	O
during	O
AC	O
-	O
redifferentiation	O
.	O

Antagonists	O
CHRD	O
and	O
CHL2	O
rose	O
significantly	O
only	O
in	O
AC	O
-	O
cultures	B-P
.	O

AC	O
showed	O
higher	O
initial	O
BMP4	O
,	O
pSmad1	O
/	O
5	O
/	O
9	O
and	O
SOX9	O
protein	O
levels	O
,	O
a	O
faster	O
(	O
re-	O
)	O
differentiation	O
but	O
a	O
similar	O
decline	O
of	O
pSmad2	O
/	O
3	O
-	O
and	O
pSmad1	O
/	O
5	O
/	O
9	O
-	O
signalling	O
versus	O
MSC	O
-	O
cultures	B-P
.	O

BMP-4	O
/	O
7	O
-	O
stimulation	O
of	O
MSC	O
-pellets	O
enhanced	O
SOX9	O
and	O
accelerated	O
ALP	O
-	O
induction	O
but	O
did	O
not	O
shift	O
differentiation	O
towards	O
osteogenesis	O
.	O

Inhibition	O
of	O
BMP-signalling	O
by	O
dorsomorphin	O
significantly	O
reduced	O
SOX9	O
,	O
raised	O
RUNX2	O
,	O
maintained	O
collagen-type-II	O
and	O
collagen-type-X	O
lower	O
and	O
kept	O
ALP-activity	O
at	O
levels	O
reached	O
at	O
initiation	O
of	O
treatment	O
.	O

Conclusively	O
,	O
ALK1	O
,2,3,6-	O
signalling	O
was	O
essential	O
for	O
MSC	O
-	O
chondrogenesis	O
and	O
its	O
prochondrogenic	O
rather	O
than	O
prohypertrophic	O
role	O
may	O
explain	O
why	O
inhibition	O
of	O
canonical	O
BMP-signalling	O
could	O
not	O
uncouple	O
cartilage	O
matrix	O
production	O
from	O
hypertrophy	O
as	O
this	O
was	O
achieved	O
with	O
pulsed	O
PTHrP	O
-application	O
.	O

Dual-core	O
steered	O
non-rigid	O
registration	O
for	O
multi-modal	O
images	O
via	O
bi-directional	O
image	O
synthesis	O
.	O

In	O
prostate	O
cancer	O
radiotherapy	O
,	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
is	O
widely	O
used	O
for	O
dose	O
planning	O
purposes	O
.	O

However	O
,	O
because	O
CT	B-P
has	O
low	O
soft	O
tissue	O
contrast	O
,	O
it	O
makes	O
manual	O
contouring	O
difficult	O
for	O
major	O
pelvic	O
organs	O
.	O

In	O
contrast	O
,	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
provides	O
high	O
soft	O
tissue	O
contrast	O
,	O
which	O
makes	O
it	O
ideal	O
for	O
accurate	O
manual	O
contouring	O
.	O

Therefore	O
,	O
the	O
contouring	O
accuracy	O
on	O
CT	B-P
can	O
be	O
significantly	O
improved	O
if	O
the	O
contours	O
in	O
MRI	B-P
can	O
be	O
mapped	O
to	O
CT	B-P
domain	O
by	O
registering	O
MRI	B-P
with	O
CT	B-P
of	O
the	O
same	O
subject	O
,	O
which	O
would	O
eventually	O
lead	O
to	O
high	O
treatment	O
efficacy	O
.	O

In	O
this	O
paper	O
,	O
we	O
propose	O
a	O
bi-directional	O
image	O
synthesis	O
based	O
approach	O
for	O
MRI	B-P
-to-	O
CT	B-P
pelvic	O
image	O
registration	O
.	O

First	O
,	O
we	O
use	O
patch-wise	O
random	O
forest	O
with	O
auto-context	O
model	O
to	O
learn	O
the	O
appearance	O
mapping	O
from	O
CT	B-P
to	O
MRI	B-P
domain	O
,	O
and	O
then	O
vice	O
versa	O
.	O

Consequently	O
,	O
we	O
can	O
synthesize	O
a	O
pseudo-MRI	B-P
whose	O
anatomical	O
structures	O
are	O
exactly	O
same	O
with	O
CT	B-P
but	O
with	O
MRI	B-P
-like	O
appearance	O
,	O
and	O
a	O
pseudo-CT	B-P
as	O
well	O
.	O

Then	O
,	O
our	O
MRI	B-P
-to-	O
CT	B-P
registration	O
can	O
be	O
steered	O
in	O
a	O
dual	O
manner	O
,	O
by	O
simultaneously	O
estimating	O
two	O
deformation	O
pathways	O
:	O
1	O
)	O
one	O
from	O
the	O
pseudo-CT	B-P
to	O
the	O
actual	O
CT	B-P
and	O
2	O
)	O
another	O
from	O
actual	O
MRI	B-P
to	O
the	O
pseudo-MRI	B-P
.	O

Next	O
,	O
a	O
dual-core	O
deformation	O
fusion	O
framework	O
is	O
developed	O
to	O
iteratively	O
and	O
effectively	O
combine	O
these	O
two	O
registration	O
pathways	O
by	O
using	O
complementary	O
information	O
from	O
both	O
modalities	O
.	O

Experiments	O
on	O
a	O
dataset	O
with	O
real	O
pelvic	O
CT	B-P
and	O
MRI	B-P
have	O
shown	O
improved	O
registration	O
performance	O
of	O
the	O
proposed	O
method	O
by	O
comparing	O
it	O
to	O
the	O
conventional	O
registration	O
methods	O
,	O
thus	O
indicating	O
its	O
high	O
potential	O
of	O
translation	O
to	O
the	O
routine	O
radiation	O
therapy	O
.	O

Development	O
of	O
an	O
Evaluation	O
Device	O
for	O
Phagocytic	O
Activity	O
of	O
New	O
Phagocytes	O
Using	O
Simple	O
and	O
pH-sensitive	O
Particles	O
that	O
Do	O
Not	O
Require	O
Pre-treatment	O
.	O

Phagocytic	O
activity	O
is	O
affected	O
by	O
a	O
number	O
of	O
different	O
stress	O
and	O
age	O
-dependent	O
factors	O
.	O

An	O
easy	O
measurement	O
of	O
phagocytic	O
activity	O
is	O
thought	O
to	O
allow	O
an	O
indicator	O
of	O
an	O
individual	O
's	O
health	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
conditions	O
of	O
measurement	O
to	O
easily	O
evaluate	O
the	O
activity	O
of	O
phagocytosis	O
of	O
phagocytic	O
cells	O
(	O
macrophages	O
and	O
neutrophils	O
)	O
using	O
an	O
easy-to-use	O
prototype	O
,	O
which	O
was	O
improved	O
from	O
the	O
device	O
by	O
Hamamatsu	O
Photonics	O
K.K.	O
,	O
to	O
detect	O
neutrophil	O
activity	O
using	O
subtle	O
fluorescence	O
.	O

pH-sensitive	O
fluorescent	O
particles	O
(	O
pHrodo-Green	O
E.	O
coli	O
Bio	O
particles	O
,	O
GE	O
particles	O
)	O
were	O
added	O
to	O
mouse	O
-derived	O
macrophage	O
cell	O
lines	O
(	O
J774.1	O
)	O
and	O
then	O
incubated	B-P
for	O
2	O
h	O
at	O
37°C	O
.	O

For	O
negative	O
control	O
,	O
the	O
phagocytosis	O
inhibitor	O
cytochalasin	O
D	O
(	O
CyD	O
)	O
,	O
was	O
added	O
prior	O
to	O
culture	B-P
.	O

Next	O
,	O
fluorescence	O
intensity	O
was	O
measured	O
by	O
the	O
Prototype	O
to	O
evaluate	O
the	O
phagocytic	O
activity	O
of	O
macrophages	O
and	O
neutrophils	O
.	O

Phagocytosis	O
was	O
also	O
confirmed	O
by	O
flow	B-P
cytometry	I-P
.	O

The	O
Prototype	O
detected	O
a	O
steady	O
fluorescence	O
increase	O
in	O
5	O
sec	O
in	O
J774.1	O
after	O
phagocytosis	O
,	O
using	O
GE	O
particles	O
as	O
a	O
negative	O
control	O
in	O
the	O
presence	O
of	O
CyD	O
.	O

Furthermore	O
,	O
detection	O
was	O
possible	O
at	O
10	O
(	O
4	O
)	O
cells/test	O
,	O
a	O
concentration	O
where	O
the	O
flow	O
cytometer	O
had	O
difficulty	O
for	O
detection	O
.	O

The	O
Prototype	O
enables	O
measurement	O
of	O
the	O
phagocytic	O
activity	O
within	O
a	O
short	O
period	O
of	O
time	O
,	O
even	O
with	O
a	O
small	O
sample	O
amount	O
,	O
thus	O
establishing	O
the	O
basic	O
conditions	O
of	O
measurements	O
of	O
phagocytosis	O
.	O

Effects	O
of	O
etomidate	O
and	O
propofol	O
on	O
immune	O
function	O
in	O
patients	O
with	O
lung	O
adenocarcinoma	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
etomidate	O
and	O
propofol	O
on	O
immune	O
function	O
in	O
patients	O
with	O
lung	O
adenocarcinoma	O
.	O

Sixty	O
patients	O
who	O
were	O
scheduled	O
for	O
lung	O
cancer	O
surgery	O
under	O
general	O
anesthesia	O
were	O
studied	O
.	O

The	O
patients	O
were	O
randomly	O
divided	O
into	O
an	O
etomidate	O
total	O
intravenous	O
anesthesia	O
group	O
(	O
group	O
E	O
)	O
and	O
a	O
propofol	O
total	O
intravenous	O
anesthesia	O
group	O
(	O
group	O
P	O
)	O
,	O
with	O
30	O
cases	O
in	O
each	O
group	O
.	O

Within	O
group	O
comparison	O
:	O
The	O
percentage	B-P
of	I-P
CD4+	I-P
in	O
the	O
two	O
groups	O
was	O
significantly	O
reduced	O
at	O
24	O
hours	O
post-operation	O
(	O
T2	O
)	O
compared	O
with	O
the	O
percentage	B-P
before	O
surgery	O
,	O
whereas	O
the	O
percentage	O
of	O
CD8+	O
was	O
higher	O
at	O
T2	O
.	O

Between	O
group	O
comparison	O
:	O
The	O
CD4+	B-P
percentage	I-P
of	O
group	O
E	O
was	O
higher	O
than	O
that	O
of	O
group	O
P	O
(	O
P	O
<	O
0.05	O
)	O
at	O
T2	O
,	O
whereas	O
the	O
CD8+	O
percentage	O
was	O
lower	O
than	O
that	O
of	O
group	O
P	O
(	O
P	O
<	O
0.05	O
)	O
at	O
T1	O
.	O

Using	O
etomidate	O
for	O
anesthesia	O
has	O
less	O
of	O
an	O
effect	O
on	O
immune	O
function	O
in	O
patients	O
with	O
lung	O
adenocarcinoma	O
.	O

Impact	O
of	O
seniority	O
on	O
operative	O
time	O
and	O
short-term	O
outcome	O
in	O
laparoscopic	O
cholecystectomy	O
:	O
Experience	O
of	O
an	O
academic	O
Surgical	O
Department	O
in	O
a	O
developing	O
country	O
.	O

Resident	O
participation	O
in	O
laparoscopic	O
cholecystectomy	O
(	O
LC	O
)	O
is	O
one	O
of	O
the	O
first	O
steps	O
of	O
laparoscopic	O
training	O
.	O

The	O
impact	O
of	O
this	O
training	O
is	O
not	O
well-defined	O
,	O
especially	O
in	O
developing	O
countries	O
.	O

However	O
,	O
this	O
training	O
is	O
of	O
critical	O
importance	O
to	O
monitor	O
surgical	O
teaching	O
programmes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
impact	O
of	O
seniority	O
on	O
operative	O
time	O
and	O
short-term	O
outcome	O
of	O
LC	O
.	O

We	O
performed	O
a	O
retrospective	O
study	O
of	O
all	O
consecutive	O
laparoscopic	O
cholecystectomies	O
for	O
gallbladder	O
lithiasis	O
performed	O
over	O
2	O
academic	O
years	O
in	O
an	O
academic	O
Surgical	O
Department	O
in	O
Morocco	O
.	O

These	O
operations	O
were	O
performed	O
by	O
junior	O
residents	O
(	O
post-graduate	O
year	O
[	O
PGY	O
]	O
4-5	O
)	O
or	O
senior	O
residents	O
(	O
PGY	O
6	O
)	O
,	O
or	O
attending	O
surgeons	O
assisted	O
by	O
junior	O
residents	O
,	O
none	O
of	O
whom	O
had	O
any	O
advanced	O
training	O
in	O
laparoscopy	B-P
.	O

All	O
data	O
concerning	O
demographics	O
(	O
American	O
Society	O
of	O
Anesthesiologists	O
,	O
body	O
mass	O
index	O
and	O
indications	O
)	O
,	O
surgeons	O
,	O
operative	O
time	O
(	O
from	O
skin	O
incision	O
to	O
closure	O
)	O
,	O
conversion	O
rate	O
and	O
operative	O
complications	O
(	O
Clavien-Dindo	O
classification	O
)	O
were	O
recorded	O
and	O
analysed	O
.	O

One-way	O
analysis	O
of	O
variance	O
,	O
Student	O
's	O
t-test	O
and	O
Chi-square	O
tests	O
were	O
used	O
as	O
appropriate	O
with	O
statistical	O
significance	O
attributed	O
to	O
P	O
<	O
0.05	O
.	O

One	O
hundred	O
thirty-eight	O
LC	O
were	O
performed	O
.	O

No	O
differences	O
were	O
found	O
on	O
univariate	O
analysis	O
between	O
groups	O
in	O
demographics	O
or	O
diagnosis	O
category	O
.	O

The	O
overall	O
rate	O
of	O
operative	O
complications	O
or	O
conversions	O
and	O
hospital	O
stay	O
were	O
not	O
significantly	O
different	O
between	O
the	O
three	O
groups	O
.	O

However	O
,	O
mean	O
operative	O
time	O
was	O
significantly	O
longer	O
for	O
junior	O
residents	O
(	O
n	O
=	O
27	O
;	O
115	O
±	O
24	O
min	O
)	O
compared	O
to	O
senior	O
residents	O
(	O
n	O
=	O
37	O
;	O
77	O
±	O
35	O
min	O
)	O
and	O
attending	O
surgeons	O
(	O
n	O
=	O
66	O
;	O
55	O
±	O
17	O
min	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O

LC	O
performed	O
by	O
residents	O
appears	O
to	O
be	O
safe	O
without	O
a	O
significant	O
difference	O
in	O
complication	O
rate	O
;	O
however	O
,	O
seniority	O
influences	O
operative	O
time	O
.	O

This	O
information	O
supports	O
early	O
resident	O
involvement	O
in	O
laparoscopic	O
procedures	O
and	O
also	O
the	O
need	O
to	O
develop	O
cost-effective	O
laboratory	O
training	O
programmes	O
.	O

Microbiology	B-P
of	O
the	O
Upper	O
and	O
Lower	O
Airways	O
in	O
Pediatric	O
Cystic	O
Fibrosis	O
Patients	O
.	O

Objective	O
To	O
evaluate	O
the	O
microbiology	O
of	O
the	O
upper	O
and	O
lower	O
airways	O
in	O
pediatric	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
who	O
underwent	O
sinus	O
surgery	O
.	O

Study	O
Design	O
Retrospective	O
case	O
series	O
with	O
chart	O
review	O
.	O

Setting	O
Tertiary	O
care	O
children	O
's	O
hospital	O
.	O

Subjects	O
and	O
Methods	O
A	O
total	O
of	O
201	O
paired	O
sinus	B-P
and	O
pulmonary	B-P
cultures	I-P
from	O
105	O
CF	O
patients	O
were	O
identified	O
between	O
1996	O
and	O
2014	O
.	O

Demographics	O
and	O
culture	B-P
results	O
were	O
analyzed	O
.	O

Results	O
The	O
mean	O
age	O
of	O
patients	O
was	O
11.2	O
±	O
5.4	O
years	O
(	O
range	O
,	O
1-27	O
years	O
)	O
,	O
and	O
approximately	O
one-half	O
were	O
female	O
.	O

Methicillin	O
-	O
sensitive	O
Staphylococcus	O
aureus	O
was	O
the	O
most	O
common	O
pathogen	O
overall	O
.	O

A	O
significantly	O
higher	O
prevalence	O
of	O
Pseudomonas	O
aeruginosa	O
(	O
32	O
%	O
for	O
pulmonary	B-P
and	O
37	O
%	O
for	O
sinus	B-P
cultures	I-P
)	O
was	O
observed	O
in	O
older	O
patients	O
versus	O
younger	O
patients	O
(	O
P	O
<	O
.001	O
)	O
.	O

There	O
was	O
low	O
to	O
moderate	O
agreement	O
between	O
sinus	B-P
and	O
pulmonary	B-P
cultures	I-P
(	O
Kappa	O
statistic	O
range	O
,	O
0.03-0.56	O
)	O
.	O

The	O
prevalence	O
of	O
methicillin-resistant	O
S	O
aureus	O
(	O
MRSA	O
)	O
increased	O
significantly	O
for	O
lower	B-P
respiratory	I-P
tract	I-P
culture	I-P
(	O
from	O
5	O
%	O
to	O
16	O
%	O
)	O
and	O
sinus	B-P
culture	I-P
(	O
from	O
5	O
%	O
to	O
27	O
%	O
)	O
between	O
1996-2004	O
and	O
2010-2014	O
(	O
P	O
=	O
.016	O
and	O
P	O
<	O
.001	O
,	O
respectively	O
)	O
.	O

The	O
prevalence	O
of	O
positive	O
sinus	B-P
cultures	I-P
increased	O
from	O
40	O
%	O
to	O
85	O
%	O
between	O
1996-2004	O
and	O
2010-2014	O
(	O
P	O
=	O
.018	O
)	O
.	O

Patients	O
with	O
pulmonary	O
MRSA	O
were	O
more	O
likely	O
to	O
be	O
coinfected	O
with	O
pulmonary	O
P	O
aeruginosa	O
(	O
risk	O
ratio	O
,	O
2.4	O
;	O
95	O
%	O
CI	O
,	O
1.2-4.8	O
;	O
P	O
=	O
.015	O
)	O
or	O
Aspergillus	O
fumigatus	O
(	O
risk	O
ratio	O
,	O
2.2	O
;	O
95	O
%	O
CI	O
,	O
1.2-4.8	O
;	O
P	O
=	O
.035	O
)	O
.	O

Conclusions	O
There	O
is	O
low	O
to	O
moderate	O
correlation	O
between	O
pulmonary	O
and	O
sinus	O
pathogens	O
in	O
CF	O
patients	O
.	O

This	O
is	O
important	O
to	O
consider	O
when	O
treating	O
infections	O
.	O

The	O
prevalence	O
of	O
MRSA	O
in	O
sinus	B-P
cultures	I-P
has	O
increased	O
over	O
time	O
and	O
warrants	O
further	O
investigation	O
.	O

Clinical	O
and	O
radiographic	O
outcomes	O
of	O
bilateral	O
decompression	O
via	O
a	O
unilateral	O
approach	O
with	O
transforaminal	O
lumbar	O
interbody	O
fusion	O
for	O
degenerative	O
lumbar	O
spondylolisthesis	O
with	O
stenosis	O
.	O

Laminectomy	O
with	O
posterior	O
lumbar	O
interbody	O
fusion	O
(	O
PLIF	O
)	O
has	O
been	O
shown	O
to	O
achieve	O
satisfactory	O
clinical	O
outcomes	O
,	O
but	O
it	O
leads	O
to	O
potential	O
adverse	O
consequences	O
associated	O
with	O
extensive	O
disruption	O
of	O
posterior	O
bony	O
and	O
soft	O
tissue	O
structures	O
.	O

This	O
study	O
aimed	O
to	O
compare	O
the	O
clinical	O
and	O
radiographic	O
outcomes	O
of	O
bilateral	O
decompression	O
via	O
a	O
unilateral	O
approach	O
(	O
BDUA	O
)	O
with	O
transforaminal	O
lumbar	O
interbody	O
fusion	O
(	O
TLIF	O
)	O
and	O
laminectomy	O
with	O
PLIF	O
in	O
the	O
treatment	O
of	O
degenerative	O
lumbar	O
spondylolisthesis	O
(	O
DLS	O
)	O
with	O
stenosis	O
.	O

This	O
is	O
a	O
prospective	O
cohort	O
study	O
.	O

This	O
study	O
compared	O
43	O
patients	O
undergoing	O
BDUA	O
+	O
TLIF	O
and	O
40	O
patients	O
undergoing	O
laminectomy	O
+	O
PLIF	O
.	O

Visual	B-P
analog	I-P
scale	I-P
(	O
VAS	B-P
)	O
for	O
low	O
back	O
pain	O
and	O
leg	O
pain	O
,	O
Oswestry	O
Disability	O
Index	O
(	O
ODI	O
)	O
,	O
and	O
Zurich	O
Claudication	O
Questionnaire	O
(	O
ZCQ	O
)	O
score	O
.	O

The	O
clinical	O
outcomes	O
were	O
assessed	O
,	O
and	O
intraoperative	O
data	O
and	O
complications	O
were	O
collected	O
.	O

Radiographic	O
outcomes	O
included	O
slippage	O
of	O
the	O
vertebra	O
,	O
disc	O
space	O
height	O
,	O
segmental	O
lordosis	O
,	O
and	O
final	O
fusion	O
rate	O
.	O

This	O
study	O
was	O
supported	O
by	O
a	O
grant	O
from	O
The	O
National	O
Natural	O
Science	O
Foundation	O
of	O
China	O
(	O
81572168	O
)	O
.	O

There	O
were	O
significant	O
improvements	O
in	O
clinical	O
and	O
radiographic	O
outcomes	O
from	O
before	O
surgery	O
to	O
3	O
months	O
and	O
2	O
years	O
after	O
surgery	O
within	O
each	O
group	O
.	O

Analysis	O
of	O
leg	O
pain	O
VAS	O
and	O
ZCQ	O
scores	O
showed	O
no	O
significant	O
differences	O
in	O
improvement	O
between	O
groups	O
at	O
either	O
follow-up	O
.	O

The	O
mean	O
improvements	O
in	O
low	O
back	O
pain	O
VAS	B-P
and	O
ODI	O
scores	O
were	O
significantly	O
greater	O
in	O
the	O
BDUA	O
+	O
TLIF	O
group	O
than	O
in	O
the	O
laminectomy	O
+	O
PLIF	O
group	O
.	O

No	O
significant	O
difference	O
was	O
found	O
in	O
the	O
final	O
fusion	O
rate	O
at	O
2-year	O
follow-up	O
.	O

The	O
BDUA	O
+	O
TLIF	O
group	O
had	O
significantly	O
less	O
blood	O
loss	O
,	O
shorter	O
length	O
of	O
postoperative	O
hospital	O
stay	O
,	O
and	O
lower	O
complication	O
rate	O
compared	O
with	O
the	O
laminectomy	O
+	O
PLIF	O
group	O
.	O

When	O
compared	O
with	O
the	O
conventional	O
laminectomy	O
+	O
PLIF	O
procedure	O
,	O
the	O
BDUA	O
+	O
TLIF	O
procedure	O
achieves	O
similar	O
and	O
satisfactory	O
effects	O
of	O
decompression	O
and	O
fusion	O
for	O
DLS	O
with	O
stenosis	O
.	O

The	O
BDUA	O
+	O
TLIF	O
procedure	O
appears	O
to	O
be	O
associated	O
with	O
less	O
postoperative	O
low	O
back	O
discomfort	O
and	O
quicker	O
recovery	O
.	O

Bioresolution	O
of	O
racemic	O
phenyl	O
glycidyl	O
ether	O
by	O
a	O
putative	O
recombinant	O
epoxide	O
hydrolase	O
from	O
Streptomyces	O
griseus	O
NBRC	O
13350	O
.	O

In	O
order	O
to	O
produce	O
enantiomerically	O
pure	O
epoxides	O
for	O
the	O
synthesis	O
of	O
value-added	O
chemicals	O
,	O
a	O
novel	O
putative	O
epoxide	O
hydrolase	O
(	O
EH	O
)	O
sgeh	O
was	O
cloned	O
and	O
overexpressed	O
in	O
pET28a	O
/	O
Escherichia	O
coli	O
BL21	O
(	O
DE3	O
)	O
.	O

The	O
1047	O
bp	O
sgeh	O
gene	O
was	O
mined	O
from	O
Streptomyces	O
griseus	O
NBRC	O
13350	O
genome	O
sequence	O
.	O

The	O
recombinant	O
hexahistidyl	O
-tagged	O
SGEH	O
was	O
purified	O
(	O
16.6-fold	O
)	O
by	O
immobilized	B-P
metal-affinity	I-P
chromatography	I-P
,	O
with	O
90	O
%	O
yield	O
as	O
a	O
homodimer	O
of	O
100	O
kDa	O
.	O

The	O
recombinant	O
E.	O
coli	O
whole	O
cells	O
overexpressing	O
SGEH	O
could	O
kinetically	O
resolve	O
racemic	O
phenyl	O
glycidyl	O
ether	O
(	O
PGE	O
)	O
into	O
(	O
R	O
)	O
-PGE	O
with	O
98	O
%	O
ee	O
,	O
40	O
%	O
yield	O
,	O
and	O
enantiomeric	O
ratio	O
(	O
E	O
)	O
of	O
20	O
.	O

This	O
was	O
achieved	O
under	O
the	O
optimized	O
reaction	O
conditions	O
i.e	O
.	O

cell	O
/	O
substrate	O
ratio	O
of	O
20:1	O
(	O
w/w	O
)	O
at	O
pH	O
7.5	O
and	O
20	O
°C	O
in	O
10	O
%	O
(	O
v/v	O
)	O
dimethylformamide	O
(	O
DMF	O
)	O
in	O
a	O
10	O
h	O
reaction	O
.	O

99	O
%	O
enantiopure	O
(	O
R	O
)	O
-PGE	O
was	O
obtained	O
when	O
the	O
reaction	O
time	O
was	O
prolonged	O
to	O
12	O
h	O
with	O
a	O
yield	O
of	O
34	O
%	O
.	O

In	O
conclusion	O
,	O
an	O
economically	O
viable	O
and	O
environment	O
friendly	O
green	O
process	O
for	O
the	O
production	O
of	O
enantiopure	O
(	O
R	O
)	O
-PGE	O
was	O
developed	O
by	O
using	O
wet	O
cells	O
of	O
E.	O
coli	O
expressing	O
recombinant	O
SGEH	O
.	O

Residual	O
contamination	O
and	O
bioburden	O
after	O
reprocessing	O
of	O
single-use	O
endoscopic	O
ultrasound	O
needles	O
:	O
An	O
ex	O
vivo	O
study	O
.	O

Endoscopic	O
ultrasound	O
(	O
EUS	O
)	O
aspiration	O
needles	O
are	O
single-use	O
devices	O
.	O

However	O
,	O
in	O
many	O
centers	O
,	O
because	O
of	O
cost	O
-	O
constraints	O
,	O
these	O
devices	O
are	O
reused	O
multiple	O
times	O
.	O

We	O
studied	O
microbiological	O
contamination	O
and	O
bioburden	O
on	O
reprocessed	O
needles	O
to	O
evaluate	O
whether	O
these	O
devices	O
can	O
be	O
successfully	O
sterilized	O
.	O

We	O
studied	O
10	O
EUS	O
needles	O
each	O
of	O
19	O
G	O
,	O
22	O
G	O
,	O
and	O
25	O
G	O
in	O
size	O
,	O
and	O
five	O
22-G	O
ProCore	O
needles	O
.	O

After	O
initial	O
use	O
,	O
each	O
needle	O
was	O
reprocessed	O
by	O
a	O
standardized	O
protocol	O
.	O

We	O
used	O
standard	O
microbiological	B-P
cultures	I-P
,	O
as	O
well	O
as	O
ATP	O
bioluminescence	B-P
technique	I-P
to	O
quantify	O
bioburden	O
as	O
relative	O
light	O
units	O
(	O
RLU	O
)	O
.	O

We	O
defined	O
significant	O
soil	O
contamination	O
by	O
RLU	O
values	O
>	O
200	O
.	O

We	O
also	O
used	O
extractant	O
fluid	O
to	O
disrupt	O
cell	O
membranes	O
in	O
an	O
attempt	O
to	O
enhance	O
ATP	O
detection	O
.	O

We	O
found	O
culture	O
positivity	O
in	O
3/34	O
(	O
8.8	O
%	O
)	O
,	O
and	O
detectable	O
bioburden	O
on	O
the	O
exposed	O
surface	O
of	O
33/35	O
(	O
94.3	O
%	O
)	O
,	O
and	O
inside	O
lumen	O
of	O
29	O
(	O
82.9	O
%	O
)	O
reprocessed	O
FNA	O
needles	O
.	O

Significant	O
bioburden	O
was	O
found	O
in	O
three	O
(	O
8.6	O
%	O
)	O
and	O
two	O
(	O
5.7	O
%	O
)	O
needles	O
on	O
the	O
surface	O
and	O
lumen	O
,	O
respectively	O
.	O

We	O
found	O
that	O
use	O
of	O
extractant	O
fluid	O
enhanced	O
detection	O
of	O
bioburden	O
.	O

Larger	O
(	O
19	O
G	O
)	O
needles	O
had	O
higher	O
surface	O
contamination	O
(	O
P	O
=	O
0.016	O
)	O
,	O
but	O
there	O
was	O
no	O
relation	O
of	O
luminal	O
contamination	O
with	O
needle	O
diameter	O
(	O
P	O
=	O
0.138	O
)	O
.	O

Sheath	O
design	O
and	O
presence	O
of	O
side	O
bevel	O
did	O
not	O
influence	O
extent	O
of	O
contamination	O
.	O

There	O
was	O
significant	O
correlation	O
between	O
the	O
surface	O
and	O
intraluminal	O
bioburden	O
(	O
P	O
<	O
0.001	O
)	O
.	O

There	O
is	O
significant	O
bioburden	O
in	O
reprocessed	O
EUS	O
needles	O
;	O
standard	O
microbiological	B-P
cultures	I-P
have	O
low	O
sensitivity	B-P
for	O
detection	O
of	O
needle	O
contamination	O
.	O

We	O
have	O
provided	O
objective	O
evidence	O
for	O
the	O
futility	O
of	O
reprocessing	O
attempts	O
,	O
and	O
practice	O
of	O
EUS	O
needle	O
reuse	O
should	O
be	O
discontinued	O
.	O

Ultrasound-guided	B-P
pericardiocentesis	B-P
:	O
a	O
novel	O
parasternal	O
approach	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
a	O
novel	O
pericardiocentesis	B-P
technique	O
using	O
an	O
in-plane	O
parasternal	O
medial	O
-to-	O
lateral	O
approach	O
with	O
the	O
use	O
of	O
a	O
high-frequency	O
probe	O
in	O
patients	O
with	O
cardiac	O
tamponade	O
.	O

Echocardiography	B-P
is	O
pivotal	O
in	O
the	O
diagnosis	O
of	O
pericardial	O
effusion	O
and	O
tamponade	O
physiology	O
.	O

Ultrasound	B-P
guidance	I-P
for	O
pericardiocentesis	B-P
is	O
currently	O
considered	O
the	O
standard	O
of	O
care	O
.	O

Several	O
approaches	O
have	O
been	O
described	O
recently	O
,	O
which	O
differ	O
mainly	O
on	O
the	O
site	O
of	O
puncture	O
(	O
subxiphoid	O
,	O
apical	O
,	O
or	O
parasternal	O
)	O
.	O

Although	O
they	O
share	O
the	O
use	O
of	O
low-frequency	O
probes	O
,	O
there	O
is	O
absence	O
of	O
complete	O
control	O
of	O
needle	O
trajectory	O
and	O
real-time	O
needle	O
visualization	B-P
.	O

An	O
in-plane	O
and	O
real-time	O
technique	O
has	O
only	O
been	O
described	O
anecdotally	O
.	O

A	O
retrospective	O
analysis	O
of	O
11	O
patients	O
(	O
63	O
%	O
men	O
,	O
mean	O
age	O
:	O
37.7±21.2	O
years	O
)	O
presenting	O
with	O
cardiac	O
tamponade	O
admitted	O
to	O
the	O
tertiary-care	O
emergency	O
department	O
and	O
treated	O
with	O
parasternal	O
medial-to-lateral	O
in-plane	O
pericardiocentesis	B-P
was	O
carried	O
out	O
.	O

The	O
underlying	O
causes	O
of	O
cardiac	O
tamponade	O
were	O
different	O
among	O
the	O
population	O
.	O

All	O
the	O
pericardiocentesis	B-P
were	O
successfully	O
performed	O
in	O
the	O
emergency	O
department	O
,	O
without	O
complications	O
,	O
relieving	O
the	O
hemodynamic	O
instability	O
.	O

The	O
mean	O
time	O
taken	O
to	O
perform	O
the	O
eight-	O
step	O
procedure	O
was	O
309±76.4	O
s	O
,	O
with	O
no	O
procedure-related	O
complications	O
.	O

The	O
parasternal	O
medial-to-lateral	O
in-plane	O
pericardiocentesis	B-P
is	O
a	O
new	O
technique	O
theoretically	O
free	O
of	O
complications	O
and	O
it	O
enables	O
real-time	O
monitoring	O
of	O
needle	O
trajectory	O
.	O

For	O
the	O
first	O
time	O
,	O
a	O
pericardiocentesis	B-P
approach	O
with	O
a	O
medial-to-lateral	O
needle	O
trajectory	O
and	O
real-time	O
,	O
in-plane	O
,	O
needle	O
visualization	B-P
was	O
performed	O
in	O
a	O
tamponade	O
patient	O
population	O
.This	O
is	O
an	O
open-access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Attribution-Non	O
Commercial-No	O
Derivatives	O
License	O
4.0	O
(	O
CCBY-NC-ND	O
)	O
,	O
where	O
it	O
is	O
permissible	O
to	O
download	O
and	O
share	O
the	O
work	O
provided	O
it	O
is	O
properly	O
cited	O
.	O

The	O
work	O
can	O
not	O
be	O
changed	O
in	O
any	O
way	O
or	O
used	O
commercially	O
without	O
permission	O
from	O
the	O
journal	O
.	O

http	O
:	O
//creativecommons.org/licenses/by-nc-nd/4.0/	O
.	O

Synthesis	O
of	O
Some	O
Unique	O
Carbamate	O
Derivatives	O
bearing	O
2-Furoyl-1-piperazine	O
as	O
a	O
Valuable	O
Therapeutic	O
Agents	O
.	O

The	O
aim	O
of	O
the	O
research	O
work	O
was	O
to	O
synthesize	O
different	O
biologically	O
active	O
carbamate	O
derivatives	O
bearing	O
2-furoyl-1-piperazine	O
and	O
having	O
modest	O
toxicity	O
.	O

The	O
synthesis	O
was	O
completed	O
as	O
a	O
multiple	O
sequence	O
.	O

The	O
structural	O
confirmation	O
of	O
all	O
the	O
synthesized	O
compounds	O
was	O
obtained	O
by	O
EI-MS	B-P
,	O
IR	B-P
and	O
1H-NMR	B-P
spectral	O
data	O
.	O

The	O
enzyme	O
inhibition	O
and	O
antibacterial	O
potential	O
of	O
the	O
synthesized	O
compounds	O
was	O
evaluated	O
.	O

To	O
find	O
the	O
utility	O
of	O
the	O
prepared	O
compounds	O
as	O
possible	O
therapeutic	O
agents	O
their	O
cytotoxicity	O
was	O
also	O
checked	O
.	O

All	O
the	O
compounds	O
were	O
active	O
against	O
acetylcholinesterase	O
enzyme	O
,	O
especially	O
12	O
and	O
14	O
showed	O
very	O
good	O
inhibitory	O
potential	O
relative	O
to	O
Eserine	O
,	O
a	O
reference	O
standard	O
.	O

Almost	O
all	O
the	O
compounds	O
showed	O
good	O
activities	O
against	O
both	O
Gram-positive	O
and	O
Gram-negative	O
bacterial	O
strains	O
.	O

N-Terminal	O
Pro-B-Type	O
Natriuretic	O
Peptide	O
as	O
a	O
Biomarker	O
for	O
Loss	O
of	O
Muscle	O
Mass	O
in	O
Prevalent	O
Hemodialysis	O
Patients	O
.	O

Protein-energy	O
wasting	O
(	O
PEW	O
)	O
is	O
common	O
in	O
hemodialysis	O
(	O
HD	O
)	O
patients	O
.	O

A	O
recent	O
study	O
demonstrated	O
that	O
a	O
high	O
level	O
of	O
N-terminal	O
pro-B-type	O
natriuretic	O
peptide	O
(	O
NT-proBNP	O
)	O
may	O
be	O
associated	O
with	O
PEW	O
in	O
those	O
patients	O
.	O

This	O
prospective	O
study	O
aimed	O
to	O
assess	O
the	O
association	O
of	O
NT-proBNP	O
with	O
body	O
composition	O
and	O
muscle	O
loss	O
.	O

A	O
cohort	O
of	O
prevalent	O
HD	O
patients	O
(	O
n	O
=	O
238	O
)	O
was	O
examined	O
.	O

Blood	O
samples	O
were	O
obtained	O
at	O
baseline	O
to	O
measure	O
high-sensitive	O
C-reactive	O
protein	O
(	O
hsCRP	O
)	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
adiponectin	O
and	O
NT-proBNP	O
.	O

Nutritional	O
status	O
and	O
changes	O
in	O
muscle	O
mass	O
were	O
assessed	O
by	O
subjective	O
global	O
assessment	O
,	O
percentage	O
creatinine	O
generation	O
rate	O
(	O
%	O
CGR	O
)	O
,	O
creatinine	O
index	O
(	O
CI	O
)	O
and	O
lean	O
body	O
mass	O
(	O
LBM	O
)	O
estimated	O
by	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
(	O
DXA	B-P
)	O
.	O

The	O
%	O
CGR	O
and	O
CI	O
were	O
calculated	O
five	O
times	O
for	O
one	O
year	O
,	O
and	O
DXA	B-P
was	O
performed	O
at	O
baseline	O
and	O
one	O
year	O
later	O
.	O

Cardiac	O
function	O
was	O
estimated	O
by	O
ultrasonography	B-P
at	O
baseline	O
.	O

NT-proBNP	O
was	O
significantly	O
higher	O
in	O
HD	O
patients	O
with	O
PEW	O
.	O

High	O
NT-proBNP	O
was	O
associated	O
with	O
cardiac	O
dysfunction	O
,	O
increased	O
levels	O
of	O
hsCRP	O
and	O
IL-6	O
,	O
and	O
serially	O
decreased	O
levels	O
of	O
the	O
indexes	O
for	O
muscle	O
mass	O
.	O

Multiple	O
regression	O
analysis	O
adjusted	O
with	O
confounders	O
showed	O
that	O
NT-proBNP	O
was	O
an	O
independent	O
predictor	O
for	O
decrease	O
in	O
LBM	O
and	O
serial	O
lower	O
levels	O
of	O
%	O
CGR	O
and	O
CI	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrated	O
a	O
novel	O
association	O
between	O
NT-proBNP	O
and	O
muscle	O
loss	O
.	O

NT-proBNP	O
may	O
be	O
an	O
independent	O
biomarker	O
for	O
malnutrition	O
in	O
HD	O
patients	O
,	O
especially	O
in	O
patients	O
with	O
muscles	O
loss	O
,	O
regardless	O
of	O
chronic	O
inflammation	O
,	O
cardiac	O
dysfunction	O
,	O
or	O
overhydration	O
.	O

The	O
association	O
between	O
HIV	O
,	O
antiretroviral	O
therapy	O
,	O
and	O
gestational	O
diabetes	O
mellitus	O
.	O

The	O
widespread	O
,	O
chronic	O
use	O
of	O
antiretroviral	O
therapy	O
raises	O
questions	O
concerning	O
the	O
metabolic	O
consequences	O
of	O
HIV	O
infection	O
and	O
treatment	O
.	O

Antiretroviral	O
therapy	O
,	O
and	O
specifically	O
protease	O
inhibitors	O
,	O
has	O
been	O
associated	O
with	O
hyperglycemia	O
.	O

As	O
pregnant	O
women	O
are	O
vulnerable	O
to	O
development	O
of	O
hyperglycemia	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
explore	O
existing	O
literature	O
on	O
the	O
relationship	O
between	O
HIV	O
infection	O
,	O
HIV	O
treatment	O
,	O
and	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
.	O

A	O
systematic	O
search	O
was	O
conducted	O
in	O
six	O
databases	O
for	O
articles	O
providing	O
data	O
on	O
HIV-positivity	O
,	O
protease	O
inhibitor	O
exposure	O
,	O
and	O
GDM	O
or	O
glucose	O
intolerance	O
development	O
in	O
pregnancy	O
.	O

The	O
quality	O
of	O
articles	O
was	O
evaluated	O
using	O
an	O
adapted	O
Cochrane	O
Collaboration	O
bias	O
assessment	O
tool	O
.	O

Risk	O
ratios	O
were	O
generated	O
from	O
pooled	O
data	O
using	O
meta-analysis	O
by	O
the	O
Mantel-Haenszel	O
method	O
.	O

Of	O
891	O
references	O
screened	O
,	O
six	O
studies	O
on	O
the	O
role	O
of	O
HIV-positivity	O
,	O
10	O
on	O
protease	O
inhibitor	O
use	O
,	O
and	O
two	O
on	O
both	O
were	O
included	O
.	O

Meta-analysis	O
showed	O
no	O
significant	O
relationship	O
between	O
HIV	O
infection	O
and	O
the	O
development	O
of	O
GDM	O
[	O
risk	O
ratio	O
0.80	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.47-1.37	O
,	O
I	O
=	O
0	O
%	O
]	O
.	O

Meta-analysis	O
of	O
protease	O
inhibitor	O
exposure	O
showed	O
increased	O
GDM	O
in	O
studies	O
using	O
first-generation	O
protease	O
inhibitors	O
(	O
risk	O
ratio	O
2.29	O
,	O
95	O
%	O
CI	O
:	O
1.46-3.58	O
)	O
and	O
studies	O
using	O
the	O
strictest	O
diagnosis	O
criteria	O
,	O
the	O
National	O
Diabetes	O
Data	O
Group	O
criteria	O
for	O
3-h	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
(	O
risk	O
ratio	O
3.81	O
,	O
95	O
%	O
CI	O
:	O
2.18-6.67	O
)	O
.	O

Meta-analysis	O
showed	O
no	O
significant	O
association	O
between	O
HIV-positivity	O
and	O
GDM	O
.	O

Significance	O
of	O
protease	O
inhibitor	O
use	O
was	O
limited	O
to	O
studies	O
using	O
the	O
strictest	O
diagnostic	O
criteria	O
for	O
GDM	O
.	O

Results	O
are	O
limited	O
by	O
high	O
risk	O
of	O
bias	O
.	O

Well	O
designed	O
prospective	O
studies	O
are	O
needed	O
to	O
further	O
clarify	O
this	O
relationship	O
and	O
its	O
consequences	O
for	O
clinical	O
practice	O
.	O

Exercise	O
increases	O
lactoferrin	O
,	O
but	O
decreases	O
lysozyme	O
in	O
salivary	O
granulocytes	O
.	O

Intracellular	O
lactoferrin	O
(	O
Lac	O
)	O
and	O
lysozyme	O
(	O
Lys	O
)	O
content	O
play	O
an	O
important	O
role	O
in	O
regulating	O
inflammation	O
and	O
promoting	O
host	O
protection	O
.	O

While	O
exercise	O
has	O
demonstrated	O
an	O
increase	O
in	O
Lac	O
and	O
Lys	O
concentration	O
in	O
exocrine	O
solutions	O
,	O
little	O
is	O
known	O
regarding	O
intracellular	O
concentration	O
changes	O
in	O
response	O
to	O
exercise	O
.	O

To	O
quantify	O
intracellular	O
Lac	O
and	O
Lys	O
concentration	O
before	O
and	O
after	O
exercise	O
in	O
salivary	O
CD45	O
(	O
+	O
)	O
CD15	O
(	O
+	O
)	O
cells	O
.	O

11	O
males	O
(	O
20.3	O
±	O
0.8	O
years	O
,	O
57.2	O
±	O
7.6	O
mL/kg/min	O
V̇O2pk	O
,	O
11.1	O
±	O
3.9	O
%	O
body	O
fat	O
)	O
ran	O
for	O
45	O
min	O
at	O
75	O
%	O
of	O
VO2pk	O
.	O

12	O
mL	O
of	O
stimulated	O
saliva	O
were	O
collected	O
pre	O
and	O
immediately	O
post	O
exercise	O
.	O

Saliva	O
was	O
filtered	O
through	O
a	O
30-µm	O
filter	O
before	O
analysis	O
of	O
leukocytes	O
(	O
CD45	O
(	O
+	O
)	O
)	O
and	O
granulocytes	O
(	O
CD45	O
(	O
+	O
)	O
CD15	O
(	O
+	O
)	O
)	O
using	O
flow	B-P
cytometry	I-P
.	O

Median	O
fluorescent	O
intensity	O
(	O
MFI	O
)	O
of	O
Lac	O
increased	O
from	O
pre	O
(	O
64,268	O
±	O
46,036	O
MFI	O
)	O
to	O
post	O
(	O
117,134	O
±	O
88,115	O
MFI	O
)	O
exercise	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Lys	O
MFI	O
decreased	O
with	O
exercise	O
(	O
pre	O
:	O
16,933	O
±	O
8249	O
;	O
post	O
:	O
11,616	O
±	O
6875	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Acute	O
running	O
resulted	O
in	O
an	O
increased	O
Lac	O
concentration	O
which	O
could	O
lead	O
to	O
a	O
decrease	O
in	O
inflammation	O
,	O
adding	O
further	O
evidence	O
of	O
the	O
anti-inflammatory	O
effects	O
of	O
exercise	O
.	O

Conversely	O
,	O
the	O
exercise	O
-associated	O
decrease	O
of	O
intracellular	O
Lys	O
content	O
could	O
be	O
the	O
cause	O
of	O
increased	O
Lys	O
in	O
exocrine	O
solutions	O
.	O

Interferon-γ	O
assay	B-P
,	O
a	O
high-sensitivity	B-P
,	O
specific	O
and	O
appropriate	O
method	B-P
for	O
detection	O
of	O
bovine	O
tuberculosis	O
in	O
cattle	O
.	O

Bovine	O
tuberculosis	O
(	O
TB	O
)	O
is	O
an	O
important	O
zoonotic	O
disease	O
that	O
is	O
caused	O
by	O
Mycobacterium	O
bovis	O
.	O

Eradication	O
efforts	O
in	O
developed	O
countries	O
have	O
reduced	O
the	O
prevalence	O
of	O
this	O
disease	O
significantly	O
.	O

TB	O
can	O
be	O
difficult	O
to	O
diagnose	O
based	O
only	O
on	O
the	O
clinical	O
signs	O
;	O
therefore	O
,	O
it	O
is	O
usually	O
diagnosed	O
in	O
the	O
field	O
with	O
the	O
tuberculin	B-P
skin	I-P
test	I-P
and	O
diagnostic	B-P
blood	I-P
tests	I-P
,	O
including	O
the	O
lymphocyte	B-P
proliferation	I-P
assay	I-P
,	O
the	O
interferon	O
(	O
IFN	O
)	O
-γ	O
assay	B-P
,	O
and	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
tuberculin	O
and	O
IFN-γ	O
tests	B-P
.	O

A	O
total	O
of	O
110	O
animals	O
were	O
evaluated	O
by	O
tuberculin	B-P
skin	I-P
test	I-P
(	O
TST	B-P
)	O
and	O
IFN-γ	O
assay	B-P
;	O
the	O
culture	B-P
was	O
selected	O
as	O
a	O
gold	O
standard	O
.	O

The	O
animals	O
were	O
selected	O
randomly	O
from	O
700	O
cattle	O
on	O
dairy	O
farms	O
,	O
aged	O
3-5	O
years	O
and	O
suspected	O
of	O
having	O
TB	O
.	O

Ten	O
cattle	O
were	O
positive	O
using	O
the	O
TST	B-P
and	O
nine	O
were	O
positive	O
by	O
IFN-γ	O
assay	B-P
.	O

All	O
nine	O
positive	O
samples	O
in	O
the	O
IFN-γ	O
assay	B-P
were	O
positive	O
in	O
culture	B-P
too	O
.	O

The	O
observed	O
errors	O
in	O
IFN-γ	O
assay	B-P
were	O
less	O
due	O
to	O
laboratorial	B-P
tools	I-P
.	O

It	O
is	O
suggested	O
that	O
all	O
positive	O
samples	O
in	O
TST	B-P
are	O
also	O
positive	O
by	O
IFN-γ	O
too	O
.	O

Unusual	O
Salt	O
and	O
pH	O
Induced	O
Changes	O
in	O
Polyethylenimine	O
Solutions	O
.	O

Linear	O
PEI	O
is	O
a	O
cationic	O
polymer	O
commonly	O
used	O
for	O
complexing	O
DNA	O
into	O
nanoparticles	O
for	O
cell-transfection	O
and	O
gene-therapy	O
applications	O
.	O

The	O
polymer	O
has	O
closely-spaced	O
amines	O
with	O
weak-base	O
protonation	O
capacity	O
,	O
and	O
a	O
hydrophobic	O
backbone	O
that	O
is	O
kept	O
unaggregated	O
by	O
intra-chain	O
repulsion	O
.	O

As	O
a	O
result	O
,	O
in	O
solution	O
PEI	O
exhibits	O
multiple	O
buffering	O
mechanisms	O
,	O
and	O
polyelectrolyte	O
states	O
that	O
shift	O
between	O
aggregated	O
and	O
free	O
forms	O
.	O

We	O
studied	O
the	O
interplay	O
between	O
the	O
aggregation	O
and	O
protonation	O
behavior	O
of	O
2.5	O
kDa	O
linear	O
PEI	O
by	O
pH	O
probing	O
,	O
vapor	O
pressure	O
osmometry	O
,	O
dynamic	B-P
light	I-P
scattering	I-P
,	O
and	O
ninhydrin	O
assay	B-P
.	O

Our	O
results	O
indicate	O
that	O
:	O
At	O
neutral	O
pH	O
,	O
the	O
PEI	O
chains	O
are	O
associated	O
and	O
the	O
addition	O
of	O
NaCl	O
initially	O
reduces	O
and	O
then	O
increases	O
the	O
extent	O
of	O
association	O
.The	O
aggregate	O
form	O
is	O
uncollapsed	O
and	O
co-exists	O
with	O
the	O
free	O
chains	O
.	O

PEI	O
buffering	O
occurs	O
due	O
to	O
continuous	O
or	O
discontinuous	O
charging	O
between	O
stalled	O
states	O
.	O

Ninhydrin	O
assay	B-P
tracks	O
the	O
number	O
of	O
unprotonated	O
amines	O
in	O
PEI	O
.The	O
size	O
of	O
PEI	O
-	O
DNA	O
complexes	O
is	O
not	O
significantly	O
affected	O
by	O
the	O
free	O
vs.	O
aggregated	O
state	O
of	O
the	O
PEI	O
polymer	O
.	O

Despite	O
its	O
simple	O
chemical	O
structure	O
,	O
linear	O
PEI	O
displays	O
intricate	O
solution	O
dynamics	O
,	O
which	O
can	O
be	O
harnessed	O
for	O
environment	O
-	O
sensitive	O
biomaterials	O
and	O
for	O
overcoming	O
current	O
challenges	O
with	O
DNA	O
delivery	O
.	O

Screening	O
of	O
Conditionally	O
Reprogrammed	O
Patient	O
-Derived	O
Carcinoma	O
Cells	O
Identifies	O
ERCC3	O
-	O
MYC	O
Interactions	O
as	O
a	O
Target	O
in	O
Pancreatic	O
Cancer	O
.	O

Even	O
when	O
diagnosed	O
prior	O
to	O
metastasis	O
,	O
pancreatic	O
ductal	O
adenocarcinoma	O
(	O
PDAC	O
)	O
is	O
a	O
devastating	O
malignancy	O
with	O
almost	O
90	O
%	O
lethality	O
,	O
emphasizing	O
the	O
need	O
for	O
new	O
therapies	O
optimally	O
targeting	O
the	O
tumors	O
of	O
individual	O
patients	O
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	O
of	O
PDAC	O
,	O
expanding	O
surgical	O
PDAC	O
tumor	O
samples	O
in	O
culture	B-P
using	O
short-term	O
culture	B-P
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	O
kinase	O
inhibitor	O
Y-27632	O
,	O
and	O
creating	O
matched	O
patient-derived	O
xenografts	O
(	O
PDX	O
)	O
.	O

These	O
were	O
evaluated	O
for	O
sensitivity	O
to	O
a	O
large	O
panel	O
of	O
clinical	O
agents	O
,	O
and	O
promising	O
leads	O
further	O
evaluated	O
mechanistically	O
.	O

Only	O
a	O
small	O
minority	O
of	O
tested	O
agents	O
was	O
cytotoxic	O
in	O
minimally	O
passaged	O
PDAC	O
cultures	B-P
in	O
vitro	O
Drugs	O
interfering	O
with	O
protein	O
turnover	O
and	O
transcription	O
were	O
among	O
most	O
cytotoxic	O
.	O

Among	O
transcriptional	O
repressors	O
,	O
triptolide	O
,	O
a	O
covalent	O
inhibitor	O
of	O
ERCC3	O
,	O
was	O
most	O
consistently	O
effective	O
in	O
vitro	O
and	O
in	O
vivo	O
causing	O
prolonged	O
complete	O
regression	O
in	O
multiple	O
PDX	O
models	O
resistant	O
to	O
standard	O
PDAC	O
therapies	O
.	O

Importantly	O
,	O
triptolide	O
showed	O
superior	O
activity	O
in	O
MYC-amplified	O
PDX	O
models	O
and	O
elicited	O
rapid	O
and	O
profound	O
depletion	O
of	O
the	O
oncoprotein	O
MYC	O
,	O
a	O
transcriptional	O
regulator	O
.	O

Expression	O
of	O
ERCC3	O
and	O
MYC	O
was	O
interdependent	O
in	O
PDACs	O
,	O
and	O
acquired	O
resistance	O
to	O
triptolide	O
depended	O
on	O
elevated	O
ERCC3	O
and	O
MYC	O
expression	O
.	O

The	O
Cancer	O
Genome	O
Atlas	O
analysis	O
indicates	O
ERCC3	O
expression	O
predicts	O
poor	O
prognosis	O
,	O
particularly	O
in	O
CDKN2A-null	O
,	O
highly	O
proliferative	O
tumors	O
.	O

This	O
provides	O
initial	O
preclinical	O
evidence	O
for	O
an	O
essential	O
role	O
of	O
MYC	O
-	O
ERCC3	O
interactions	O
in	O
PDAC	O
,	O
and	O
suggests	O
a	O
new	O
mechanistic	O
approach	O
for	O
disruption	O
of	O
critical	O
survival	O
signaling	O
in	O
MYC	O
-dependent	O
cancers	O
.	O

Clin	O
Cancer	O
Res	O
;	O
22	O
(	O
24	O
)	O
;	O
6153-63	O
.	O

©2016	O
AACR	O
.	O

Chronic	O
exposure	O
to	O
haloperidol	O
and	O
olanzapine	O
leads	O
to	O
common	O
and	O
divergent	O
shape	O
changes	O
in	O
the	O
rat	O
hippocampus	O
in	O
the	O
absence	O
of	O
grey-matter	O
volume	O
loss	O
.	O

One	O
of	O
the	O
most	O
consistently	O
reported	O
brain	O
abnormalities	O
in	O
schizophrenia	O
(	O
SCZ	O
)	O
is	O
decreased	O
volume	O
and	O
shape	O
deformation	O
of	O
the	O
hippocampus	O
.	O

However	O
,	O
the	O
potential	O
contribution	O
of	O
chronic	O
antipsychotic	O
medication	O
exposure	O
to	O
these	O
phenomena	O
remains	O
unclear	O
.	O

We	O
examined	O
the	O
effect	O
of	O
chronic	O
exposure	O
(	O
8	O
weeks	O
)	O
to	O
clinically	O
relevant	O
doses	O
of	O
either	O
haloperidol	O
(	O
HAL	O
)	O
or	O
olanzapine	O
(	O
OLZ	O
)	O
on	O
adult	O
rat	O
hippocampal	O
volume	O
and	O
shape	O
using	O
ex	O
vivo	O
structural	B-P
MRI	I-P
with	O
the	O
brain	O
retained	O
inside	O
the	O
cranium	O
to	O
prevent	O
distortions	O
due	O
to	O
dissection	O
,	O
followed	O
by	O
tensor-based	B-P
morphometry	I-P
(	O
TBM	B-P
)	O
and	O
elastic	O
surface-based	O
shape	O
deformation	O
analysis	O
.	O

The	O
volume	O
of	O
the	O
hippocampus	O
was	O
also	O
measured	O
post-mortem	B-P
from	O
brain	O
tissue	O
sections	O
in	O
each	O
group	O
.	O

Chronic	O
exposure	O
to	O
either	O
HAL	O
or	O
OLZ	O
had	O
no	O
effect	O
on	O
the	O
volume	O
of	O
the	O
hippocampus	O
,	O
even	O
at	O
exploratory	B-P
thresholds	I-P
,	O
which	O
was	O
confirmed	O
post-mortem	B-P
.	O

In	O
contrast	O
,	O
shape	O
deformation	O
analysis	O
revealed	O
that	O
chronic	O
HAL	O
and	O
OLZ	O
exposure	O
lead	O
to	O
both	O
common	O
and	O
divergent	O
shape	O
deformations	O
(	O
q	O
=	O
0.05	O
,	O
FDR-corrected	O
)	O
in	O
the	O
rat	O
hippocampus	O
.	O

In	O
particular	O
,	O
in	O
the	O
dorsal	O
hippocampus	O
,	O
HAL	O
exposure	O
led	O
to	O
inward	O
shape	O
deformation	O
,	O
whereas	O
OLZ	O
exposure	O
led	O
to	O
outward	O
shape	O
deformation	O
.	O

Interestingly	O
,	O
outward	O
shape	O
deformations	O
that	O
were	O
common	O
to	O
both	O
drugs	O
occurred	O
in	O
the	O
ventral	O
hippocampus	O
.	O

These	O
effects	O
remained	O
significant	O
after	O
controlling	O
for	O
hippocampal	O
volume	O
suggesting	O
true	O
shape	O
changes	O
.	O

Chronic	O
exposure	O
to	O
either	O
HAL	O
or	O
OLZ	O
leads	O
to	O
both	O
common	O
and	O
divergent	O
effects	O
on	O
rat	O
hippocampal	O
shape	O
in	O
the	O
absence	O
of	O
volume	O
change	O
.	O

The	O
implications	O
of	O
these	O
findings	O
for	O
the	O
clinic	O
are	O
discussed	O
.	O

Blockade	O
of	O
Rho-associated	O
protein	O
kinase	O
(	O
ROCK	O
)	O
inhibits	O
the	O
contractility	O
and	O
invasion	O
potential	O
of	O
cancer	O
stem	O
like	O
cells	O
.	O

Recent	O
studies	O
have	O
implicated	O
the	O
roles	O
of	O
cancer	O
stem	O
like	O
cells	O
(	O
CSCs	O
)	O
in	O
cancer	O
metastasis	O
.	O

However	O
,	O
very	O
limited	O
knowledge	O
exists	O
at	O
the	O
molecular	O
and	O
cellular	O
level	O
to	O
target	O
CSCs	O
for	O
prevention	O
of	O
cancer	O
metastasis	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
contractile	O
dynamics	O
of	O
CSCs	O
in	O
cell	O
invasion	O
and	O
delineated	O
the	O
underlying	O
molecular	O
mechanisms	O
of	O
their	O
distinct	O
cell	O
invasion	O
potential	O
.	O

Using	O
de-adhesion	B-P
assay	I-P
and	O
atomic	B-P
force	I-P
microscopy	I-P
,	O
we	O
show	O
that	O
CSCs	O
derived	O
from	O
melanoma	O
and	O
breast	O
cancer	O
cell	O
lines	O
exhibit	O
increased	O
contractility	O
compared	O
to	O
non-CSCs	O
across	O
all	O
tumor	O
types	O
.	O

In	O
addition	O
,	O
CSCs	O
possess	O
increased	O
ECM	O
remodeling	O
capacity	O
as	O
quantified	O
by	O
collagen	O
degradation	B-P
assay	I-P
.	O

More	O
importantly	O
,	O
pharmacological	O
blockade	O
of	O
Rho-associated	O
protein	O
kinase	O
completely	O
abolished	O
the	O
contractility	O
and	O
collagen	O
degradation	O
capacity	O
of	O
both	O
CSCs	O
and	O
non-CSCs	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
demonstrates	O
the	O
importance	O
of	O
cell	O
contractility	O
in	O
regulating	O
invasiveness	O
of	O
CSCs	O
and	O
suggests	O
that	O
pharmacological	O
targeting	O
of	O
ROCK	O
pathway	O
represents	O
a	O
novel	O
strategy	O
for	O
targeting	O
both	O
CSCs	O
and	O
bulk	O
population	O
for	O
the	O
treatment	O
of	O
cancer	O
metastasis	O
.	O

Physical	O
Exercise	O
for	O
Late-Life	O
Depression	O
:	O
Effects	O
on	O
Heart	O
Rate	O
Variability	O
.	O

Late-life	O
major	O
depression	O
is	O
associated	O
with	O
increased	O
cardiovascular	O
risk	O
and	O
impaired	O
autonomic	O
control	O
of	O
the	O
heart	O
,	O
as	O
evident	O
from	O
reduced	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
.	O

Moreover	O
,	O
antidepressant	O
drug	O
therapy	O
also	O
might	O
be	O
associated	O
with	O
further	O
reductions	O
of	O
HRV	O
.	O

In	O
the	O
SEEDS	O
study	O
,	O
we	O
investigated	O
whether	O
sertraline	O
associated	O
with	O
physical	O
exercise	O
protocols	O
led	O
to	O
improvements	O
of	O
HRV	O
,	O
compared	O
with	O
antidepressant	O
drug	O
therapy	O
alone	O
.	O

Single-blind	O
randomized	O
controlled	O
trial	O
.	O

Psychiatric	O
consultation	O
-liaison	O
program	O
for	O
primary	O
care	O
.	O

Patients	O
aged	O
65-85	O
years	O
with	O
major	O
depression	O
,	O
recruited	O
from	O
primary	O
care	O
.	O

Sertraline	O
plus	O
structured	O
,	O
tailored	O
group	O
physical	O
exercise	O
(	O
S	O
+	O
EX	O
)	O
versus	O
sertraline	O
alone	O
(	O
S	O
)	O
for	O
24	O
weeks	O
.	O

HRV	O
indices	O
(	O
RR	O
,	O
percentage	O
of	O
NN	O
intervals	O
greater	O
than	O
50	O
msec	O
[	O
pNN50	O
]	O
,	O
square	O
root	O
of	O
the	O
mean	O
squared	O
differences	O
of	O
successive	O
NN	O
intervals	O
[	O
RMSSD	O
]	O
,	O
standard	O
deviation	O
of	O
heart	O
rate	O
[	O
SDHR	O
]	O
,	O
standard	O
deviation	O
of	O
the	O
NN	O
interval	O
[	O
SDNN	O
]	O
,	O
high-frequency	O
band	O
[	O
HF	O
]	O
,	O
low-frequency	O
band	O
[	O
LF	O
]	O
,	O
and	O
their	O
ratio	O
[	O
LF/HF	O
]	O
)	O
were	O
measured	O
at	O
baseline	O
,	O
week	O
12	O
,	O
and	O
week	O
24	O
.	O

Psychiatric	B-P
and	O
medical	O
assessments	O
.	O

Participants	O
displayed	O
significant	O
improvements	O
of	O
most	O
HRV	O
indices	O
over	O
time	O
,	O
irrespective	O
of	O
the	O
group	O
assignment	O
(	O
pNN50	O
,	O
RMSSD	O
,	O
SDHR	O
,	O
SDNN	O
,	O
HF	O
,	O
LF	O
,	O
and	O
LF/HF	O
)	O
.	O

Moreover	O
,	O
patients	O
in	O
the	O
S	O
+	O
EX	O
group	O
displayed	O
greater	O
increases	O
of	O
different	O
HRV	O
indices	O
(	O
RR	O
,	O
pNN50	O
,	O
RMSSD	O
,	O
SDHR	O
,	O
SDNN	O
,	O
HF	O
,	O
and	O
LF	O
)	O
compared	O
with	O
those	O
in	O
the	O
S	O
group	O
.	O

The	O
combination	O
of	O
structured	O
physical	O
exercise	O
and	O
sertraline	O
might	O
exert	O
positive	O
effects	O
on	O
the	O
autonomic	O
control	O
of	O
the	O
heart	O
among	O
older	O
patients	O
with	O
major	O
depression	O
.	O

An	O
Improved	O
Method	O
for	O
Identifying	O
Specific	O
DNA-Protein-Binding	O
Sites	O
In	O
Vitro	O
.	O

Binding	O
of	O
proteins	O
to	O
specific	O
DNA	O
sequences	O
is	O
essential	O
for	O
a	O
variety	O
of	O
cellular	O
processes	O
such	O
as	O
DNA	O
replication	O
,	O
transcription	O
and	O
responses	O
to	O
external	O
stimuli	O
.	O

Chromatin	B-P
immunoprecipitation	I-P
is	O
widely	O
used	O
for	O
determining	O
intracellular	O
DNA	O
fragments	O
bound	O
by	O
a	O
specific	O
protein	O
.	O

However	O
,	O
the	O
subsequent	O
specific	O
or	O
accurate	O
DNA-protein-binding	O
sequence	O
is	O
usually	O
determined	O
by	O
DNA	O
footprinting	O
.	O

Here	O
,	O
we	O
report	O
an	O
alternative	O
method	O
for	O
identifying	O
specific	O
sites	O
of	O
DNA-protein-binding	O
(	O
designated	O
SSDP	O
)	O
in	O
vitro	O
.	O

This	O
technique	O
is	O
mainly	O
dependent	O
on	O
antibody-antigen	O
immunity	O
,	O
simple	O
and	O
convenient	O
,	O
while	O
radioactive	O
isotope	O
labeling	O
and	O
optimization	O
of	O
partial	O
degradation	O
by	O
deoxyribonuclease	O
(	O
DNase	O
)	O
are	O
avoided	O
.	O

As	O
an	O
example	O
,	O
the	O
specific	O
binding	O
sequence	O
of	O
a	O
target	O
promoter	O
by	O
DdrO	O
(	O
a	O
DNA	O
damage	O
response	O
protein	O
from	O
Deinococcus	O
radiodurans	O
)	O
in	O
vitro	O
was	O
determined	O
by	O
the	O
developed	O
method	O
.	O

The	O
central	O
sequence	O
of	O
the	O
binding	O
site	O
could	O
be	O
easily	O
located	O
using	O
this	O
technique	O
.	O

The	O
presence	O
of	O
two	O
rare	O
genomic	O
syndromes	O
,	O
1q21	O
deletion	O
and	O
Xq28	O
duplication	O
,	O
segregating	O
independently	O
in	O
a	O
family	O
with	O
intellectual	O
disability	O
.	O

1q21	O
microdeletion	O
syndrome	O
is	O
a	O
rare	O
contiguous	O
gene	O
deletion	O
disorder	O
with	O
de	O
novo	O
or	O
autosomal	O
dominant	O
inheritance	O
patterns	O
and	O
its	O
phenotypic	O
features	O
include	O
intellectual	O
disability	O
,	O
distinctive	O
facial	O
dysmorphism	O
,	O
microcephaly	O
,	O
cardiac	O
abnormalities	O
,	O
and	O
cataracts	O
.	O

MECP2	O
duplication	O
syndrome	O
is	O
an	O
X-linked	O
recessive	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
intellectual	O
disability	O
,	O
global	O
developmental	O
delay	O
,	O
and	O
other	O
neurological	O
complications	O
including	O
late-onset	O
seizures	O
.	O

Previously	O
,	O
these	O
two	O
different	O
genetic	O
syndromes	O
have	O
not	O
been	O
reported	O
segregating	O
independently	O
in	O
a	O
same	O
family	O
.	O

Here	O
we	O
describe	O
two	O
siblings	O
carrying	O
either	O
a	O
chromosome	O
1q21	O
microdeletion	O
or	O
a	O
chromosome	O
Xq28	O
duplication	O
.	O

Using	O
a	O
comparative	O
genomic	O
hybridization	O
(	O
CGH	O
)	O
array	O
,	O
we	O
identified	O
a	O
1.24	O
Mb	O
heterozygous	O
deletion	O
at	O
1q21	O
resulting	O
in	O
the	O
loss	O
of	O
9	O
genes	O
in	O
a	O
girl	O
with	O
learning	O
disability	O
,	O
hypothyroidism	O
,	O
short	O
stature	O
,	O
sensory	O
integration	O
disorder	O
,	O
and	O
soft	O
dysmorphic	O
features	O
including	O
cupped	O
ears	O
and	O
a	O
unilateral	O
ear	O
pit	O
.	O

We	O
also	O
characterized	O
a	O
508	O
kb	O
Xq28	O
duplication	O
encompassing	O
MECP2	O
in	O
her	O
younger	O
brother	O
with	O
hypotonia	O
,	O
poor	O
speech	O
,	O
cognitive	O
and	O
motor	O
impairment	O
.	O

The	O
parental	O
CGH	O
and	O
quantitative	B-P
PCR	I-P
(	O
qPCR	B-P
)	O
analyses	O
revealed	O
that	O
the	O
1q21	O
deletion	O
in	O
the	O
elder	O
sister	O
is	O
de	O
novo	O
,	O
but	O
the	O
Xq28	O
duplication	O
in	O
the	O
younger	O
brother	O
was	O
originally	O
inherited	O
from	O
the	O
maternal	O
grandmother	O
through	O
the	O
mother	O
,	O
both	O
of	O
whom	O
are	O
asymptomatic	O
carriers	O
.	O

RT-qPCR	O
assays	O
revealed	O
that	O
the	O
affected	O
brother	O
has	O
almost	O
double	O
the	O
amount	O
of	O
MECP2	O
mRNA	O
expression	O
compared	O
to	O
other	O
family	O
members	O
of	O
both	O
genders	O
including	O
maternal	O
grandmother	O
and	O
mother	O
who	O
have	O
the	O
same	O
Xq28	O
duplication	O
with	O
no	O
phenotype	O
.	O

This	O
suggests	O
the	O
X	O
chromosome	O
with	O
an	O
Xq28	O
duplication	O
in	O
the	O
carrier	O
females	O
is	O
preferentially	O
silenced	O
.	O

From	O
our	O
understanding	O
,	O
this	O
would	O
be	O
the	O
first	O
report	O
showing	O
the	O
independent	O
segregation	O
of	O
two	O
genetically	O
unrelated	O
syndromes	O
,	O
1q21	O
microdeletion	O
and	O
Xq28	O
duplication	O
,	O
in	O
a	O
same	O
family	O
,	O
especially	O
in	O
siblings	O
.	O

Although	O
these	O
two	O
chromosomal	O
abnormalities	O
share	O
some	O
similar	O
phenotypes	O
such	O
as	O
intellectual	O
disability	O
,	O
mild	O
dysmorphic	O
features	O
,	O
and	O
cardiac	O
abnormalities	O
,	O
the	O
presence	O
of	O
two	O
unrelated	O
and	O
rare	O
syndromes	O
in	O
siblings	O
is	O
very	O
unusual	O
.	O

Therefore	O
,	O
further	O
comprehensive	O
investigations	O
in	O
similar	O
cases	O
are	O
required	O
for	O
future	O
studies	O
.	O

Do	O
polymorphisms	O
in	O
MDR1	O
and	O
CYP3A5	O
genes	O
influence	O
the	O
risk	O
of	O
cytogenetic	O
relapse	O
in	O
patients	O
with	O
chronic	O
myeloid	O
leukemia	O
on	O
imatinib	O
therapy	O
?	O
.	O

Influence	O
of	O
polymorphisms	O
in	O
the	O
genes	O
coding	O
for	O
imatinib	O
transporters	O
and	O
metabolizing	O
enzymes	O
on	O
cytogenetic	O
relapse	O
in	O
patients	O
with	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
is	O
not	O
known	O
.	O

One	O
hundred	O
and	O
four	O
patients	O
(	O
52	O
cases	O
with	O
cytogenetic	O
relapse	O
and	O
52	O
controls	O
without	O
relapse	O
)	O
with	O
chronic-phase	O
CML	O
on	O
imatinib	O
therapy	O
and	O
have	O
completed	O
5	O
years	O
of	O
follow-up	O
were	O
enrolled	O
.	O

The	O
following	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
genotyped	B-P
;	O
C1236T	O
,	O
C3435T	O
,	O
G2677T	O
/	O
A	O
in	O
MDR1	O
gene	O
and	O
A6986G	O
in	O
CYP3A5	O
gene	O
,	O
using	O
PCR-RFLP	B-P
method	I-P
and	O
validated	O
by	O
direct	O
gene	B-P
sequencing	I-P
.	O

Imatinib	O
trough	O
levels	O
were	O
measured	O
using	O
LC-MS	B-P
/	O
MS	B-P
.	O

Patients	O
with	O
CC	O
genotype	O
for	O
MDR1	O
-	O
C1236T	O
polymorphism	O
were	O
at	O
significantly	O
higher	O
risk	O
for	O
cytogenetic	O
relapse	O
[	O
OR	O
=4.382	O
,	O
95	O
%	O
CI	O
(	O
1.145	O
,	O
16.774	O
)	O
,	O
p	O
=	O
.022	O
]	O
,	O
while	O
those	O
with	O
TT	O
genotype	O
for	O
MDR1	O
-	O
C3435T	O
polymorphism	O
had	O
significantly	O
lower	O
risk	O
of	O
relapse	O
[	O
OR	O
=0.309	O
,	O
95	O
%	O
CI	O
(	O
0.134	O
,	O
0.708	O
)	O
,	O
p	O
=	O
.005	O
]	O
.	O

Imatinib	O
trough	O
levels	O
were	O
lower	O
in	O
patients	O
with	O
relapse	O
compared	O
to	O
those	O
without	O
relapse	O
(	O
1551.4	O
±	O
1324.1	O
vs.	O
2154.2	O
±	O
1358.3	O
ng/mL	O
;	O
p	O
=	O
.041	O
)	O
.	O

MDR1	O
-	O
C3435T	O
genotype	O
[	O
adjusted-OR	O
:	O
0.266	O
;	O
95	O
%	O
CI	O
(	O
0.111	O
,	O
0.636	O
)	O
;	O
p	O
=	O
.003	O
]	O
and	O
trough	O
levels	O
(	O
p	O
=	O
.014	O
)	O
were	O
independent	O
predictors	O
of	O
relapse	O
in	O
multivariate	O
analysis	O
.	O

To	O
conclude	O
,	O
C1236T	O
and	O
C3435T	O
polymorphisms	O
in	O
MDR1	O
gene	O
and	O
trough	O
levels	O
significantly	O
influence	O
the	O
risk	O
of	O
cytogenetic	O
relapse	O
.	O

MDR1	O
-	O
C3435T	O
genotype	O
might	O
emerge	O
as	O
a	O
potential	O
biomarker	O
to	O
predict	O
the	O
risk	O
of	O
cytogenetic	O
relapse	O
in	O
patients	O
with	O
CML	O
.	O

Discordance	O
in	O
pathology	O
report	O
after	O
central	B-P
pathology	I-P
review	I-P
:	O
Implications	O
for	O
breast	O
cancer	O
adjuvant	O
treatment	O
.	O

Pathological	O
predictive	O
factors	O
are	O
the	O
most	O
important	O
markers	O
when	O
selecting	O
early	O
breast	O
cancer	O
adjuvant	O
therapy	O
.	O

In	O
randomized	O
clinical	O
trials	O
the	O
variability	O
in	O
pathology	O
report	O
after	O
central	B-P
pathology	I-P
review	I-P
is	O
noteworthy	O
.	O

We	O
evaluated	O
the	O
discordance	O
rate	O
(	O
DR	O
)	O
and	O
inter-rater	O
agreement	O
between	O
local	O
and	O
central	O
histopathological	O
report	O
and	O
the	O
clinical	O
implication	O
on	O
treatment	O
decision	O
.	O

A	O
retrospective	O
analysis	O
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	O
cancer	O
tumors	O
diagnosed	O
by	O
local	O
pathologists	O
and	O
subsequently	O
reviewed	O
at	O
the	O
Pathology	O
Division	O
of	O
European	O
Institute	O
of	O
Oncology	O
.	O

The	O
inter-rater	O
agreement	O
(	O
k	O
)	O
between	O
local	O
and	O
central	O
pathology	O
was	O
calculated	O
for	O
Ki-67	O
,	O
grading	O
,	O
hormone	O
receptors	O
(	O
ER	O
/	O
PgR	O
)	O
and	O
HER2/neu	O
.	O

The	O
Bland-Altman	O
plots	O
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	O
,	O
ER	O
and	O
PgR	O
.	O

DR	O
was	O
calculated	O
for	O
ER	O
/	O
PgR	O
and	O
HER2	O
.	O

From	O
2007	O
to	O
2013	O
,	O
187	O
pathology	O
specimens	O
from	O
10	O
Cancer	O
Centers	O
were	O
reviewed	O
.	O

Substantial	O
agreement	O
was	O
observed	O
for	O
ER	O
(	O
k0.612	O
;	O
95	O
%	O
CI	O
,	O
0538-0.686	O
)	O
,	O
PgR	O
(	O
k0.659	O
;	O
95	O
%	O
CI	O
,	O
0580-0.737	O
)	O
,	O
Ki-67	O
(	O
k0.609	O
;	O
95	O
%	O
CI	O
,	O
0.534-0.684	O
)	O
and	O
grading	O
(	O
k0.669	O
;	O
95	O
%	O
CI	O
,	O
0.569-0.769	O
)	O
.	O

Moderate	O
agreement	O
was	O
found	O
for	O
HER2	O
(	O
k0.546	O
;	O
95	O
%	O
CI	O
,	O
0444-0.649	O
)	O
.	O

DR	O
was	O
9.5	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
31.7	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
HER2	O
and	O
26.2	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
12.5	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
ER	O
/	O
PgR	O
.	O

According	O
to	O
changes	O
in	O
Her2	O
and	O
ER	O
/	O
PgR	O
status	O
,	O
23	O
(	O
12.2	O
%	O
)	O
and	O
33	O
(	O
17.6	O
%	O
)	O
systemic	O
prescription	O
were	O
respectively	O
modified	O
.	O

In	O
our	O
retrospective	O
analysis	O
,	O
central	B-P
pathological	I-P
review	I-P
has	O
a	O
significant	O
impact	O
in	O
the	O
decision-making	O
process	O
in	O
early	O
breast	O
cancer	O
,	O
as	O
shown	O
in	O
clinical	O
trials	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
confirm	O
these	O
provocative	O
results	O
.	O

Gastrocnemius	O
muscle-tendon	O
interaction	O
during	O
walking	O
in	O
typically-developing	O
adults	O
and	O
children	O
,	O
and	O
in	O
children	O
with	O
spastic	O
cerebral	O
palsy	O
.	O

Our	O
understanding	O
of	O
the	O
interaction	O
of	O
muscle	O
bellies	O
and	O
their	O
tendons	O
in	O
individuals	O
with	O
muscle	O
pathology	O
is	O
limited	O
.	O

Knowledge	O
of	O
these	O
interactions	O
may	O
inform	O
us	O
of	O
the	O
effects	O
of	O
musculoskeletal	O
pathologies	O
on	O
muscle-tendon	O
dynamics	O
and	O
the	O
subsequent	O
neurological	O
control	O
strategies	O
used	O
in	O
gait	O
.	O

Here	O
,	O
we	O
investigate	O
gastrocnemius	O
muscle-tendon	O
interaction	O
in	O
typically-developing	O
(	O
TD	O
)	O
adults	O
and	O
children	O
,	O
and	O
in	O
children	O
with	O
spastic	O
cerebral	O
palsy	O
(	O
SCP	O
)	O
.	O

We	O
recruited	O
six	O
TD	O
adults	O
(	O
4	O
female	O
;	O
mean	O
age	O
:	O
34	O
yrs	O
.	O

(	O
24-54	O
)	O
)	O
,	O
eight	O
TD	O
children	O
(	O
5	O
female	O
;	O
mean	O
age	O
:	O
10	O
yrs	O
.	O

(	O
6-12	O
)	O
)	O
and	O
eight	O
independently	O
ambulant	O
children	O
with	O
SCP	O
(	O
5	O
female	O
;	O
mean	O
age	O
9	O
yrs	O
.	O

(	O
6-12	O
)	O
;	O
3	O
unilaterally-affected	O
)	O
.	O

A	O
combination	O
of	O
3D	B-P
motion	I-P
capture	I-P
and	O
2D	B-P
real-time	I-P
ultrasound	I-P
imaging	I-P
were	O
used	O
to	O
compute	O
the	O
gastrocnemius	O
musculo-tendinous	O
unit	O
(	O
MTU	O
)	O
length	O
and	O
estimate	O
muscle	O
belly	O
and	O
tendon	O
length	O
s	O
during	O
walking	O
.	O

For	O
the	O
TD	O
subjects	O
,	O
the	O
measurements	O
were	O
made	O
for	O
heel-toe	O
walking	O
and	O
voluntary	O
toe-walking	O
.	O

The	O
gastrocnemius	O
muscle	O
bellies	O
of	O
children	O
with	O
SCP	O
lengthened	O
during	O
single	O
support	O
(	O
p	O
=	O
0.003	O
)	O
.	O

In	O
contrast	O
,	O
the	O
muscle	O
bellies	O
of	O
TD	O
subjects	O
did	O
not	O
demonstrate	O
an	O
increase	O
in	O
length	O
over	O
the	O
period	O
of	O
single	O
support	O
under	O
heel-toe	O
or	O
toe-walking	O
conditions	O
.	O

We	O
observed	O
lengthening	O
of	O
the	O
gastrocnemius	O
muscle	O
bellies	O
in	O
children	O
with	O
SCP	O
during	O
single	O
support	O
,	O
a	O
phase	O
of	O
the	O
gait	O
cycle	O
in	O
which	O
the	O
muscle	O
is	O
reported	O
consistently	O
to	O
be	O
active	O
.	O

Repeated	O
lengthening	O
of	O
muscle	O
bellies	O
while	O
they	O
are	O
active	O
may	O
lead	O
to	O
muscle	O
damage	O
and	O
have	O
implications	O
for	O
the	O
natural	O
history	O
of	O
gait	O
in	O
this	O
group	O
.	O

Psychometric	B-P
analysis	I-P
of	O
the	O
Patient	O
Health	O
Questionnaire	O
in	O
Danish	O
patients	O
with	O
an	O
implantable	O
cardioverter	O
defibrillator	O
(	O
The	O
DEFIB-WOMEN	O
study	O
)	O
.	O

To	O
assess	O
the	O
psychometric	B-P
properties	I-P
of	O
the	O
Patient	O
Health	O
Questionnaire	O
(	O
PHQ-9	O
)	O
,	O
a	O
measure	O
of	O
depressive	O
symptoms	O
,	O
in	O
a	O
large	O
Danish	O
national	O
cohort	O
of	O
patients	O
with	O
heart	O
disease	O
,	O
implanted	O
with	O
an	O
implantable	O
cardioverter	O
defibrillator	O
(	O
ICD	O
)	O
,	O
using	O
item	O
response	O
theory	O
.	O

A	O
prospective	O
cohort	O
of	O
patients	O
implanted	O
with	O
an	O
ICD	O
(	O
n=1531	O
;	O
80.4	O
%	O
men	O
)	O
completed	O
the	O
PHQ-9	O
at	O
the	O
time	O
of	O
implant	O
.	O

Data	O
were	O
analyzed	O
using	O
two	O
item	O
response	O
theory	O
models	O
,	O
the	O
partial	O
credit	O
model	O
and	O
the	O
generalized	O
partial	O
credit	O
model	O
.	O

The	O
analysis	O
showed	O
disordered	O
response	O
thresholds	O
in	O
eight	O
of	O
nine	O
items	O
for	O
the	O
partial	O
credit	O
model	O
and	O
five	O
of	O
nine	O
items	O
for	O
the	O
generalized	O
partial	O
credit	O
model	O
,	O
indicating	O
that	O
respondents	O
have	O
difficulty	O
discriminating	O
between	O
response	O
options	O
.	O

When	O
collapsing	O
response	O
options	O
2	O
and	O
3	O
,	O
the	O
rescored	O
PHQ-9	O
had	O
a	O
better	O
fit	O
to	O
both	O
models	O
.	O

The	O
unidimensionality	O
and	O
the	O
precision	O
of	O
the	O
rescored	O
PHQ-9	O
were	O
confirmed	O
.	O

Items	O
did	O
not	O
have	O
any	O
differential	O
functioning	O
(	O
DIF	O
)	O
across	O
educational	O
level	O
,	O
age	O
,	O
indication	O
for	O
ICD	O
implantation	O
,	O
and	O
severity	O
of	O
heart	O
failure	O
that	O
influence	O
depression	O
outcomes	O
in	O
patients	O
with	O
an	O
ICD	O
.	O

One	O
item	O
exhibited	O
DIF	O
by	O
gender	O
.	O

Three	O
items	O
did	O
not	O
fit	O
the	O
partial	O
credit	O
model	O
,	O
but	O
the	O
generalized	O
partial	O
credit	O
model	O
could	O
be	O
fitted	O
to	O
the	O
full	O
item	O
set	O
.	O

The	O
unidimensionality	O
and	O
reliability	O
of	O
the	O
Danish	O
version	O
of	O
the	O
PHQ-9	O
were	O
confirmed	O
.	O

However	O
,	O
the	O
associated	O
consequences	O
of	O
the	O
number	O
of	O
response	O
options	O
(	O
3-point	O
versus	O
4-point	O
Likert	O
scale	O
)	O
need	O
to	O
be	O
further	O
examined	O
for	O
the	O
PHQ-9	O
both	O
as	O
a	O
screening	O
tool	O
and	O
outcome	O
measure	O
.	O

Semianalytical	O
Solution	O
for	O
the	O
Deformation	O
of	O
an	O
Elastic	O
Layer	O
under	O
an	O
Axisymmetrically	O
Distributed	O
Power-Form	O
Load	O
:	O
Application	O
to	O
Fluid-Jet-Induced	B-P
Indentation	I-P
of	O
Biological	O
Soft	O
Tissues	O
.	O

Fluid-jet-based	B-P
indentation	I-P
is	O
used	O
as	O
a	O
noncontact	O
excitation	O
technique	O
by	O
systems	O
measuring	O
the	O
mechanical	O
properties	O
of	O
soft	O
tissues	O
.	O

However	O
,	O
the	O
application	O
of	O
these	O
devices	O
has	O
been	O
hindered	O
by	O
the	O
lack	O
of	O
theoretical	O
solutions	O
.	O

This	O
study	O
developed	O
a	O
mathematical	O
model	O
for	O
testing	O
the	O
indentation	B-P
induced	O
by	O
a	O
fluid	O
jet	O
and	O
determined	O
a	O
semianalytical	O
solution	O
.	O

The	O
soft	O
tissue	O
was	O
modeled	O
as	O
an	O
elastic	O
layer	O
bonded	O
to	O
a	O
rigid	O
base	O
.	O

The	O
pressure	O
of	O
the	O
fluid	O
jet	O
impinging	O
on	O
the	O
soft	O
tissue	O
was	O
assumed	O
to	O
have	O
a	O
power-form	O
function	O
.	O

The	O
semianalytical	O
solution	O
was	O
verified	O
in	O
detail	O
using	O
finite-element	O
modeling	O
,	O
with	O
excellent	O
agreement	O
being	O
achieved	O
.	O

The	O
effects	O
of	O
several	O
parameters	O
on	O
the	O
solution	O
behaviors	O
are	O
reported	O
,	O
and	O
a	O
method	O
for	O
applying	O
the	O
solution	O
to	O
determine	O
the	O
mechanical	O
properties	O
of	O
soft	O
tissues	O
is	O
suggested	O
.	O

Intra-articular	O
implantation	O
of	O
collagen	O
scaffold	O
carriers	O
is	O
safe	O
in	O
both	O
native	O
and	O
arthrofibrotic	O
rabbit	O
knee	O
joints	O
.	O

Sustained	O
intra-articular	O
delivery	O
of	O
pharmacological	O
agents	O
is	O
an	O
attractive	O
modality	O
but	O
requires	O
use	O
of	O
a	O
safe	O
carrier	O
that	O
would	O
not	O
induce	O
cartilage	O
damage	O
or	O
fibrosis	O
.	O

Collagen	O
scaffolds	O
are	O
widely	O
available	O
and	O
could	O
be	O
used	O
intra-articularly	O
,	O
but	O
no	O
investigation	O
has	O
looked	O
at	O
the	O
safety	O
of	O
collagen	O
scaffolds	O
within	O
synovial	O
joints	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
of	O
collagen	O
scaffold	O
implantation	O
in	O
a	O
validated	O
in	O
vivo	O
animal	O
model	O
of	O
knee	O
arthrofibrosis	O
.	O

A	O
total	O
of	O
96	O
rabbits	O
were	O
randomly	O
and	O
equally	O
assigned	O
to	O
four	O
different	O
groups	O
:	O
arthrotomy	O
alone	O
;	O
arthrotomy	O
and	O
collagen	O
scaffold	O
placement	O
;	O
contracture	O
surgery	O
;	O
and	O
contracture	O
surgery	O
and	O
collagen	O
scaffold	O
placement	O
.	O

Animals	O
were	O
killed	O
in	O
equal	O
numbers	O
at	O
72	O
hours	O
,	O
two	O
weeks	O
,	O
eight	O
weeks	O
,	O
and	O
24	O
weeks	O
.	O

Joint	O
contracture	O
was	O
measured	O
,	O
and	O
cartilage	O
and	O
synovial	O
samples	O
underwent	O
histological	B-P
analysis	I-P
.	O

Animals	O
that	O
underwent	O
arthrotomy	O
had	O
equivalent	O
joint	O
contractures	O
regardless	O
of	O
scaffold	O
implantation	O
(	O
-13.9°	O
versus	O
-10.9°	O
,	O
equivalence	O
limit	O
15°	O
)	O
.	O

Animals	O
that	O
underwent	O
surgery	O
to	O
induce	O
contracture	O
did	O
not	O
demonstrate	O
equivalent	O
joint	O
contracture	O
s	O
with	O
(	O
41.8°	O
)	O
or	O
without	O
(	O
53.9°	O
)	O
collagen	O
scaffold	O
implantation	O
.	O

Chondral	O
damage	O
occurred	O
in	O
similar	O
rates	O
with	O
(	O
11	O
of	O
48	O
)	O
and	O
without	O
(	O
nine	O
of	O
48	O
)	O
scaffold	O
implantation	O
.	O

No	O
significant	O
difference	O
in	O
synovitis	O
was	O
noted	O
between	O
groups	O
.	O

Absorption	O
of	O
the	O
collagen	O
scaffold	O
occurred	O
within	O
eight	O
weeks	O
in	O
all	O
animals	O
CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
intra-articular	O
implantation	O
of	O
a	O
collagen	O
sponge	O
does	O
not	O
induce	O
synovitis	O
or	O
cartilage	O
damage	O
.	O

Implantation	O
in	O
a	O
native	O
joint	O
does	O
not	O
seem	O
to	O
induce	O
contracture	O
.	O

Implantation	O
of	O
the	O
collagen	O
sponge	O
in	O
a	O
rabbit	O
knee	O
model	O
of	O
contracture	O
may	O
decrease	O
the	O
severity	O
of	O
the	O
contracture	O
.Cite	O
this	O
article	O
:	O
J	O
.	O

A.	O
Walker	O
,	O
T.	O
J.	O
Ewald	O
,	O
E.	O
Lewallen	O
,	O
A	O
.	O

Van	O
Wijnen	O
,	O
A.	O
D.	O
Hanssen	O
,	O
B.	O
F.	O
Morrey	O
,	O
M.	O
E.	O
Morrey	O
,	O
M.	O
P.	O
Abdel	O
,	O
J.	O
Sanchez-Sotelo	O
.	O

Intra-articular	O
implantation	O
of	O
collagen	O
scaffold	O
carriers	O
is	O
safe	O
in	O
both	O
native	O
and	O
arthrofibrotic	O
rabbit	O
knee	O
joints	O
.	O

Bone	O
Joint	O
Res	O
2016	O
;	O
6:162-171	O
.	O

DOI	O
:	O
10.1302/2046-3758.63.BJR-2016-0193	O
.	O

Molecular	O
structure	O
of	O
clonidine	O
:	O
gas-phase	B-P
electron	I-P
diffraction	I-P
,	O
single-crystal	B-P
X-ray	I-P
diffraction	I-P
and	O
quantum	O
chemical	O
studies	O
.	O

This	O
study	O
presents	O
the	O
first	O
determination	O
of	O
the	O
molecular	O
structure	O
of	O
the	O
antihypertensive	O
drug	O
clonidine	O
in	O
the	O
gas	O
phase	O
using	O
gas	B-P
electron	I-P
diffraction	I-P
(	O
GED	B-P
)	O
.	O

The	O
refinement	O
was	O
supported	O
by	O
quantum	O
chemical	O
calculations	O
(	O
QCs	O
)	O
.	O

The	O
tautomeric	O
and	O
conformational	O
distribution	O
was	O
investigated	O
theoretically	O
,	O
providing	O
an	O
explanation	O
for	O
the	O
presence	O
of	O
the	O
single	O
conformer	O
in	O
the	O
gas	O
phase	O
.	O

The	O
molecular	O
conformation	O
of	O
clonidine	O
has	O
been	O
shown	O
to	O
have	O
a	O
nearly	O
perpendicular	O
arrangement	O
of	O
the	O
phenyl	O
and	O
imidazolidine	O
rings	O
as	O
described	O
by	O
the	O
torsion	O
angle	O
C2-N6-C7-C8	O
=	O
-72	O
(	O
6	O
)	O
°	O
.	O

The	O
following	O
structural	O
parameters	O
were	O
obtained	O
(	O
bond	O
lengths	O
in	O
Angstroms	O
and	O
bond	O
angles	O
in	O
degrees	O
with	O
3σ	O
in	O
parentheses	O
)	O
:	O
r	O
(	O
CHH-CHH	O
)	O
=	O
1.549	O
(	O
7	O
)	O
,	O
r	O
(	O
CHH-NH	O
)	O
av	O
=	O
1.470	O
(	O
7	O
)	O
,	O
r	O
(	O
NH-C	O
)	O
av	O
=	O
1.388	O
(	O
2	O
)	O
,	O
r	O
(	O
C	O
[	O
double	O
bond	O
,	O
length	O
as	O
m-dash	O
]	O
N	O
)	O
=	O
1.286	O
(	O
7	O
)	O
,	O
r	O
(	O
C-N	O
)	O
=	O
1.388	O
(	O
2	O
)	O
,	O
r	O
(	O
C	O
[	O
partial	O
double	O
bond	O
,	O
bottom	O
dashed	O
]	O
C	O
)	O
av	O
=	O
1.403	O
(	O
2	O
)	O
,	O
r	O
(	O
C-Cl	O
)	O
av	O
=	O
1.737	O
(	O
2	O
)	O
;	O
∠	O
(	O
NH-C-NH	O
)	O
=	O
108.1	O
(	O
11	O
)	O
,	O
∠	O
(	O
CHH-NH-C	O
)	O
av	O
=	O
109.7	O
(	O
12	O
)	O
,	O
∠	O
(	O
CHH-CHH-NH	O
)	O
av	O
=	O
100.9	O
(	O
12	O
)	O
,	O
∠	O
(	O
C-N	O
[	O
double	O
bond	O
,	O
length	O
as	O
m-dash	O
]	O
C	O
)	O
=	O
122.5	O
(	O
12	O
)	O
,	O
∠	O
(	O
CCl	O
[	O
partial	O
double	O
bond	O
,	O
bottom	O
dashed	O
]	O
C	O
[	O
partial	O
double	O
bond	O
,	O
bottom	O
dashed	O
]	O
CCl	O
)	O
=	O
114.9	O
(	O
2	O
)	O
,	O
and	O
∠	O
(	O
CH	O
[	O
partial	O
double	O
bond	O
,	O
bottom	O
dashed	O
]	O
CCl	O
[	O
partial	O
double	O
bond	O
,	O
bottom	O
dashed	O
]	O
C	O
)	O
av	O
=	O
123.1	O
(	O
2	O
)	O
.	O

The	O
standard	O
enthalpy	O
of	O
formation	O
of	O
clonidine	O
in	O
the	O
gas	O
phase	O
was	O
calculated	O
using	O
G4	O
theory	O
with	O
both	O
atomisation	O
and	O
isodesmic	O
reaction	O
approaches	O
,	O
yielding	O
the	O
corresponding	O
value	O
of	O
.	O

The	O
molecular	O
structure	O
of	O
clonidine	O
in	O
the	O
solid	O
phase	O
was	O
determined	O
using	O
X-ray	B-P
diffraction	I-P
(	O
XRD	B-P
)	O
.	O

Clonidine	O
crystallizes	O
in	O
the	O
monoclinic	O
space	O
group	O
P21/c	O
as	O
a	O
twinned	O
crystal	O
.	O

The	O
imino-tautomer	O
,	O
as	O
an	O
equimolar	O
mixture	O
of	O
the	O
two	O
conformers	O
with	O
geometries	O
close	O
to	O
the	O
enantiomeric	O
pair	O
,	O
is	O
present	O
in	O
the	O
solid	O
phase	O
.	O

The	O
identical	O
conformers	O
are	O
linked	O
into	O
centrosymmetric	O
dimers	O
by	O
paired	O
N-HN	O
hydrogen	O
bonds	O
.	O

The	O
geometries	O
of	O
gaseous	O
and	O
solid	O
clonidine	O
differ	O
especially	O
in	O
the	O
immediate	O
vicinity	O
of	O
the	O
intermolecular	O
hydrogen	O
bonds	O
formed	O
in	O
the	O
crystal	O
.	O

Engineering	O
monolayer	O
poration	O
for	O
rapid	O
exfoliation	O
of	O
microbial	O
membranes	O
.	O

The	O
spread	O
of	O
bacterial	O
resistance	O
to	O
traditional	O
antibiotics	O
continues	O
to	O
stimulate	O
the	O
search	O
for	O
alternative	O
antimicrobial	O
strategies	O
.	O

All	O
forms	O
of	O
life	O
,	O
from	O
bacteria	O
to	O
humans	O
,	O
are	O
postulated	O
to	O
rely	O
on	O
a	O
fundamental	O
host	O
defense	O
mechanism	O
,	O
which	O
exploits	O
the	O
formation	O
of	O
open	O
pores	O
in	O
microbial	O
phospholipid	O
bilayers	O
.	O

Here	O
we	O
predict	O
that	O
transmembrane	O
poration	O
is	O
not	O
necessary	O
for	O
antimicrobial	O
activity	O
and	O
reveal	O
a	O
distinct	O
poration	O
mechanism	O
that	O
targets	O
the	O
outer	O
leaflet	O
of	O
phospholipid	O
bilayers	O
.	O

Using	O
a	O
combination	O
of	O
molecular	O
-	O
scale	O
and	O
real-time	B-P
imaging	I-P
,	O
spectroscopy	B-P
and	O
spectrometry	B-P
approaches	O
,	O
we	O
introduce	O
a	O
structural	O
motif	O
with	O
a	O
universal	O
insertion	O
mode	O
in	O
reconstituted	O
membranes	O
and	O
live	O
bacteria	O
.	O

We	O
demonstrate	O
that	O
this	O
motif	O
rapidly	O
assembles	O
into	O
monolayer	O
pits	O
that	O
coalesce	O
during	O
progressive	O
membrane	O
exfoliation	O
,	O
leading	O
to	O
bacterial	O
cell	O
death	O
within	O
minutes	O
.	O

The	O
findings	O
offer	O
a	O
new	O
physical	O
basis	O
for	O
designing	O
effective	O
antibiotics	O
.	O

Mycotoxin	O
detoxifiers	O
attenuate	O
deoxynivalenol	O
-	O
induced	O
pro-inflammatory	O
barrier	O
insult	O
in	O
porcine	O
enterocytes	O
as	O
an	O
in	O
vitro	O
evaluation	O
model	O
of	O
feed	O
mycotoxin	O
reduction	O
.	O

Deoxynivalenol	O
(	O
DON	O
)	O
,	O
the	O
most	O
prevalent	O
mycotoxin	O
worldwide	O
,	O
leads	O
to	O
economic	O
losses	O
for	O
animal	O
food	O
production	O
.	O

Swine	O
is	O
a	O
most	O
sensitive	O
domestic	O
animal	O
to	O
DON	O
due	O
to	O
rapid	O
absorption	O
and	O
low	O
detoxification	O
by	O
gut	O
microbiota	O
.	O

Specifically	O
,	O
DON	O
can	O
severely	O
damage	O
pig	O
intestinal	O
tissue	O
by	O
disrupting	O
the	O
intestinal	O
barrier	O
and	O
inducing	O
inflammatory	O
responses	O
.	O

We	O
evaluated	O
the	O
effects	O
of	O
several	O
mycotoxin	O
detoxifiers	O
including	O
bentonites	O
,	O
yeast	O
cell	O
wall	O
components	O
,	O
and	O
mixture-typed	O
detoxifier	O
composed	O
of	O
mineral	O
,	O
microorganisms	O
,	O
and	O
phytogenic	O
substances	O
on	O
DON	O
-	O
insulted	O
intestinal	O
barrier	O
and	O
pro-inflammatory	O
responses	O
using	O
in	O
vitro	O
porcine	O
enterocyte	O
culture	O
model	O
.	O

DON	O
-	O
induced	O
disruption	O
of	O
the	O
in	O
vitro	O
gut	O
barrier	O
was	O
attenuated	O
by	O
all	O
three	O
mycotoxin	O
detoxifiers	O
in	O
dose-dependent	O
manners	O
.	O

These	O
mycotoxin	O
detoxifiers	O
also	O
suppressed	O
DON	O
-	O
induced	O
pro-inflammatory	O
chemokine	O
expression	O
to	O
different	O
degrees	O
,	O
which	O
was	O
mediated	O
by	O
downregulation	O
of	O
mitogen-activated	O
kinases	O
and	O
early	O
growth	O
response-1	O
.	O

Of	O
note	O
,	O
the	O
mixture-typed	O
detoxifier	O
was	O
the	O
most	O
prominent	O
mitigating	O
agent	O
at	O
the	O
cellular	O
levels	O
whereas	O
the	O
high	O
dose	O
of	O
bentonite	O
clay	O
also	O
had	O
suppressive	O
action	O
against	O
DON	O
-	O
induced	O
pro-inflammatory	O
insult	O
.	O

The	O
in	O
vitro	O
porcine	O
enterocyte-based	O
assessment	O
of	O
intestinal	O
barrier	O
integrity	O
and	O
inflammatory	O
signals	O
provides	O
sensitive	O
and	O
simplified	O
alternative	O
bioassay	B-P
of	O
feed	O
additives	O
such	O
as	O
detoxifiers	O
against	O
enteropathogenic	O
mycotoxins	O
with	O
comprehensive	O
mechanistic	O
confirmation	O
.	O

Assessment	O
of	O
the	O
interaction	O
of	O
Portland	O
cement-based	O
materials	O
with	O
blood	O
and	O
tissue	O
fluids	O
using	O
an	O
animal	O
model	O
.	O

Portland	O
cement	O
used	O
in	O
the	O
construction	O
industry	O
improves	O
its	O
properties	O
when	O
wet	O
.	O

Since	O
most	O
dental	O
materials	O
are	O
used	O
in	O
a	O
moist	O
environment	O
,	O
Portland	O
cement	O
has	O
been	O
developed	O
for	O
use	O
in	O
dentistry	O
.	O

The	O
first	O
generation	O
material	O
is	O
mineral	O
trioxide	O
aggregate	O
(	O
MTA	O
)	O
,	O
used	O
in	O
surgical	O
procedures	O
,	O
thus	O
in	O
contact	O
with	O
blood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
setting	O
of	O
MTA	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
contact	O
with	O
blood	O
by	O
subcutaneous	O
implantation	O
in	O
rats	O
.	O

The	O
tissue	O
reaction	O
to	O
the	O
material	O
was	O
also	O
investigated	O
.	O

ProRoot	O
MTA	O
(	O
Dentsply	O
)	O
was	O
implanted	O
in	O
the	O
subcutaneous	O
tissues	O
of	O
Sprague-Dawley	O
rats	O
in	O
opposite	O
flanks	O
and	O
left	O
in	O
situ	O
for	O
3	O
months	O
.	O

Furthermore	O
the	O
material	O
was	O
also	O
stored	O
in	O
physiological	O
solution	O
in	O
vitro	O
.	O

At	O
the	O
end	O
of	O
the	O
incubation	O
time	O
,	O
tissue	O
histology	B-P
and	O
material	O
characterization	O
were	O
performed	O
.	O

Surface	O
assessment	O
showed	O
the	O
formation	O
of	O
calcium	O
carbonate	O
for	O
both	O
environments	O
.	O

The	O
bismuth	O
was	O
evident	O
in	O
the	O
tissues	O
thus	O
showing	O
heavy	O
element	O
contamination	O
of	O
the	O
animal	O
specimen	O
.	O

The	O
tissue	O
histology	B-P
showed	O
a	O
chronic	O
inflammatory	O
cell	O
infiltrate	O
associated	O
with	O
the	O
MTA	O
.	O

MTA	O
interacts	O
with	O
the	O
host	O
tissues	O
and	O
causes	O
a	O
chronic	O
inflammatory	O
reaction	O
when	O
implanted	O
subcutaneously	O
.	O

Hydration	O
in	O
vivo	O
proceeds	O
similarly	O
to	O
the	O
in	O
vitro	O
model	O
with	O
some	O
differences	O
particularly	O
in	O
the	O
bismuth	O
oxide	O
leaching	O
patterns	O
.	O

Palmitoyl	O
Glycol	O
Chitosan	O
Micelles	O
for	O
Corneal	O
Delivery	O
of	O
Cyclosporine	O
.	O

Different	O
substitution	O
degrees	O
of	O
palmitoyl	O
glycol	O
chitosan	O
(	O
PGC	O
)	O
,	O
prepared	O
according	O
to	O
the	O
literature	O
,	O
were	O
used	O
to	O
obtain	O
polymeric	O
micelles	O
that	O
have	O
been	O
assessed	O
in	O
comparison	O
with	O
Pluronic	O
F127	O
micelles	O
as	O
possible	O
carriers	O
for	O
poorly	O
soluble	O
drugs	O
,	O
such	O
as	O
cyclosporine	O
A	O
.	O

Both	O
PGC	O
and	O
Pluronic	O
micelles	O
were	O
studied	O
for	O
their	O
interactions	O
with	O
cell	B-P
culture	I-P
substrates	O
.	O

The	O
least	O
substituted	O
and	O
most	O
hydrophilic	O
derivative	O
,	O
PGC21	O
(	O
approximately	O
5	O
%	O
substitution	O
)	O
,	O
showed	O
a	O
strong	O
association	O
with	O
cyclosporine	O
,	O
more	O
than	O
tripling	O
the	O
colloidal	O
concentration	O
with	O
respect	O
to	O
the	O
saturated	O
solution	O
.	O

It	O
showed	O
a	O
greater	O
ability	O
to	O
open	O
Caco-2	O
tight	O
junctions	O
and	O
to	O
enhance	O
the	O
permeability	O
of	O
Caco-2	O
substrates	O
with	O
respect	O
to	O
micelles	O
based	O
on	O
higher	O
palmitoyl	O
substitution	O
,	O
conceivably	O
due	O
to	O
the	O
lower	O
modification	O
of	O
the	O
chitosan	O
chains	O
.	O

Permeation	O
and	O
penetration	O
experiments	O
were	O
performed	O
with	O
PGC21	O
and	O
Pluronic	O
micelles	O
on	O
a	O
rabbit	O
corneal	O
epithelial	O
cell	O
line	O
(	O
RCE	O
)	O
and	O
on	O
excised	O
pig	O
corneas	O
.	O

It	O
was	O
found	O
that	O
both	O
PGC	O
and	O
Pluronic	O
micelles	O
could	O
increase	O
the	O
permeation	O
of	O
the	O
fluorescent	O
probe	O
rhodamine	O
B	O
through	O
RCE	O
cells	O
by	O
more	O
than	O
ten-fold	O
.	O

In	O
RCE	O
and	O
in	O
pig	O
cornea	O
,	O
the	O
micelles	O
improved	O
the	O
penetration	O
of	O
both	O
rhodamine	O
andr	O
cyclosporine	O
.	O

For	O
cyclosporine	O
,	O
the	O
PGC21	O
micelles	O
allowed	O
penetration	O
of	O
approximately	O
1	O
μg/mg	O
cyclosporine	O
A	O
in	O
corneal	O
tissue	O
,	O
demonstrating	O
a	O
potential	O
for	O
use	O
in	O
immunosuppression	O
therapies	O
.	O

Recombinant	O
MHC	O
Tetramers	O
for	O
Isolation	O
of	O
Virus	O
-	O
Specific	O
CD8	O
(	O
+	O
)	O
Cells	O
from	O
Healthy	O
Donors	O
:	O
Potential	O
Approach	O
for	O
Cell	O
Therapy	O
of	O
Posttransplant	O
Cytomegalovirus	O
Infection	O
.	O

Patients	O
undergoing	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
have	O
a	O
high	O
risk	O
of	O
cytomegalovirus	O
reactivation	O
,	O
which	O
in	O
the	O
absence	O
of	O
T-cell	O
immunity	O
can	O
result	O
in	O
the	O
development	O
of	O
an	O
acute	O
inflammatory	O
reaction	O
and	O
damage	O
of	O
internal	O
organs	O
.	O

Transfusion	O
of	O
the	O
virus-specific	O
donor	O
T-lymphocytes	O
represents	O
an	O
alternative	O
to	O
a	O
highly	O
toxic	O
and	O
often	O
ineffective	O
antiviral	O
therapy	O
.	O

Potentially	O
promising	O
cell	O
therapy	O
approach	O
comprises	O
transfusion	O
of	O
cytotoxic	O
T-lymphocytes	O
,	O
specific	O
to	O
the	O
viral	O
antigens	O
,	O
immediately	O
after	O
their	O
isolation	O
from	O
the	O
donor	O
's	O
blood	O
circulation	O
without	O
any	O
in	O
vitro	O
expansion	O
.	O

Specific	O
T-cells	O
could	O
be	O
separated	O
from	O
potentially	O
alloreactive	O
lymphocytes	O
using	O
recombinant	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
multimers	O
,	O
carrying	O
synthetic	O
viral	O
peptides	O
.	O

Rapid	O
transfusion	O
of	O
virus	O
-	O
specific	O
T-cells	O
to	O
patients	O
has	O
several	O
crucial	O
advantages	O
in	O
comparison	O
with	O
methods	O
based	O
on	O
the	O
in	O
vitro	O
expansion	O
of	O
the	O
cells	O
.	O

About	O
30	O
%	O
of	O
hematopoietic	O
stem	O
cell	O
donors	O
and	O
46	O
%	O
of	O
transplant	O
recipients	O
at	O
the	O
National	O
Research	O
Center	O
for	O
Hematology	O
were	O
carriers	O
of	O
the	O
HLA-A*02	O
allele	O
.	O

Moreover	O
,	O
94	O
%	O
of	O
Russian	O
donors	O
have	O
an	O
immune	O
response	O
against	O
the	O
cytomegalovirus	O
(	O
CMV	O
)	O
.	O

Using	O
recombinant	O
HLA-A*02	O
multimers	O
carrying	O
an	O
immunodominant	O
cytomegalovirus	O
peptide	O
(	O
NLV	O
)	O
,	O
we	O
have	O
shown	O
that	O
the	O
majority	O
of	O
healthy	O
donors	O
have	O
pronounced	O
T-cell	O
immunity	O
against	O
this	O
antigen	O
,	O
whereas	O
shortly	O
after	O
the	O
transplantation	O
the	O
patients	O
do	O
not	O
have	O
specific	O
T-lymphocytes	O
.	O

The	O
donor	O
cells	O
have	O
the	O
immune	O
phenotype	O
of	O
memory	O
cells	O
and	O
can	O
be	O
activated	O
and	O
proliferate	O
after	O
stimulation	O
with	O
the	O
specific	O
antigen	O
.	O

Donor	O
lymphocytes	O
can	O
be	O
substantially	O
enriched	O
to	O
significant	O
purity	O
by	O
magnetic	B-P
separation	I-P
with	O
recombinant	O
MHC	O
multimers	O
and	O
are	O
not	O
activated	O
upon	O
cocultivation	B-P
with	O
the	O
antigen	O
-presenting	O
cells	O
from	O
HLA	O
-	O
incompatible	O
donors	O
without	O
addition	O
of	O
the	O
specific	O
antigen	O
.	O

This	O
study	O
demonstrated	O
that	O
strong	O
immune	O
response	O
to	O
CMV	O
of	O
healthy	O
donors	O
and	O
prevalence	O
of	O
HLA-A*02	O
allele	O
in	O
the	O
Russian	O
population	O
make	O
it	O
possible	O
to	O
isolate	O
a	O
significant	O
number	O
of	O
virus-specific	O
cells	O
using	O
HLA-A*02-NLV	O
multimers	O
.	O

After	O
the	O
transfusion	O
,	O
these	O
cells	O
should	O
protect	O
patients	O
from	O
CMV	O
without	O
development	O
of	O
allogeneic	O
immune	O
response	O
.	O

The	O
relationship	O
between	O
hemorheological	O
parameters	O
and	O
mortality	O
in	O
critically	O
ill	O
patients	O
with	O
and	O
without	O
sepsis	O
.	O

The	O
prognostic	O
scoring	O
systems	O
for	O
mortality	O
of	O
intensive	O
care	O
patients	O
estimate	O
clinical	O
outcome	O
using	O
several	O
physiological	O
and	O
biochemical	O
parameters	O
.	O

In	O
altered	O
hemodynamic	O
conditions	O
of	O
critically	O
ill	O
patients	O
,	O
hemorheological	O
variables	B-P
may	O
play	O
a	O
significant	O
role	O
in	O
appropriate	O
tissue	O
perfusion	O
.	O

We	O
investigated	O
if	O
hemorheological	O
parameters	O
are	O
altered	O
in	O
critical	O
status	O
and	O
if	O
they	O
could	O
be	O
markers	O
of	O
mortality	O
.	O

112	O
patients	O
(	O
67.8	O
±	O
12	O
years	O
,	O
58	O
males	O
,	O
54	O
females	O
)	O
treated	O
in	O
intensive	O
care	O
unit	O
with	O
different	O
non-surgical	O
diseases	O
were	O
investigated	O
.	O

Routine	O
laboratory	B-P
parameters	I-P
and	O
prognostic	O
scores	O
were	O
determined	O
and	O
hemorheological	O
variables	B-P
(	O
hematocrit	O
,	O
plasma	O
and	O
whole	O
blood	O
viscosity	O
,	O
red	O
blood	O
cell	O
aggregation	O
and	O
deformability	O
)	O
were	O
measured	O
on	O
the	O
1st	O
and	O
the	O
2nd	O
day	O
after	O
admission	O
.	O

ICU	O
scores	O
predicted	O
35.2-41.3	O
%	O
mortality	O
rate	O
,	O
real	O
mortality	O
in	O
intensive	O
care	O
unit	O
was	O
37.5	O
%	O
,	O
while	O
30-day	O
mortality	O
was	O
46.6	O
%	O
.	O

Whole	O
blood	O
viscosity	O
(	O
WBV	O
)	O
and	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
deformability	O
were	O
lower	O
,	O
red	O
blood	O
cell	O
aggregation	O
was	O
higher	O
in	O
septic	O
than	O
in	O
nonseptic	O
patients	O
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
septic	O
patients	O
calcium	O
was	O
increased	O
,	O
osmolality	O
was	O
decreased	O
,	O
while	O
in	O
nonseptic	O
patients	O
WBV	O
and	O
RBC	O
aggregation	O
were	O
higher	O
in	O
nonsurvivors	O
compared	O
to	O
survivors	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Worsening	O
of	O
RBC	O
deformability	O
from	O
day	O
1	O
to	O
day	O
2	O
predicted	O
higher	O
mortality	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Calcium	B-P
and	O
osmolality	O
level	O
were	O
associated	O
with	O
outcome	O
in	O
sepsis	O
.	O

Whole	O
blood	O
viscosity	O
,	O
red	O
blood	O
cell	O
aggregation	O
and	O
change	O
in	O
red	O
blood	O
cell	O
deformability	O
could	O
predict	O
mortality	O
in	O
nonseptic	O
patients	O
and	O
they	O
may	O
add	O
prognostic	O
information	O
over	O
the	O
ICU	O
scores	O
.	O

Further	O
investigations	O
are	O
needed	O
to	O
evaluate	O
the	O
benefit	O
of	O
our	O
findings	O
in	O
clinical	O
practice	O
.	O

Serum	O
vascular	O
endothelial	O
growth	O
factor	O
receptor-3	O
levels	O
in	O
patients	O
with	O
esophageal	O
squamous	O
cell	O
cancer	O
.	O

Esophageal	O
cancer	O
is	O
one	O
of	O
the	O
most	O
aggressive	O
tumors	O
of	O
the	O
gastrointestinal	O
tract	O
.	O

In	O
this	O
study	O
,	O
we	O
quantified	O
the	O
serum	O
vascular	O
endothelial	O
growth	O
factor-3	O
(	O
VEGFR-3	O
)	O
expression	O
in	O
patients	O
with	O
esophageal	O
squamous	O
cell	O
carcinoma	O
(	O
ESCC	O
)	O
to	O
evaluate	O
the	O
role	O
of	O
VEGFR-3	O
in	O
ESCC	O
.	O

Ninety	O
five	O
patients	O
with	O
ESCC	O
were	O
studied	O
.	O

Pre-therapy	O
and	O
preoperative	O
samples	O
were	O
stored	O
and	O
ELISA	B-P
was	O
used	O
to	O
designate	O
the	O
concentrations	O
of	O
VEGFR-3	O
.	O

The	O
serum	O
values	O
of	O
VEGFR-3	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
ESCC	O
than	O
in	O
healthy	O
donors	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

The	O
results	O
imply	O
a	O
very	O
good	O
sensitivity	O
of	O
VEGFR-3	O
in	O
ESCC	O
.	O

VEGFR-3	O
may	O
be	O
a	O
good	O
diagnostic	O
biomarker	O
for	O
ESCC	O
.	O

Biomarker	O
,	O
ESCC	O
,	O
VEGFR-3	O
.	O

Chitinibacter	O
fontanus	O
sp	O
.	O

nov.	O
,	O
isolated	O
from	O
a	O
spring	O
.	O

A	O
bacterial	O
strain	O
,	O
designated	O
STM-7T	O
,	O
was	O
isolated	O
from	O
a	O
spring	O
in	O
Taiwan	O
and	O
characterized	O
using	O
a	O
polyphasic	O
taxonomy	O
approach	O
.	O

Cells	O
of	O
strain	O
STM-7T	O
were	O
Gram-staining-negative	O
,	O
aerobic	O
,	O
poly--hydroxybutyrate	O
-accumulating	O
,	O
motile	O
by	O
a	O
single	O
polar	O
flagellum	O
,	O
rod-shaped	O
that	O
were	O
surrounded	O
by	O
a	O
thick	O
capsule	O
and	O
forming	O
milky	O
white	O
colored	O
colonies	O
.	O

Growth	O
occurred	O
at	O
15-37	O
oC	O
(	O
optimum	O
,	O
25-30	O
°C	O
)	O
,	O
at	O
pH	O
6-8	O
(	O
optimum	O
,	O
pH	O
6-7	O
)	O
and	O
with	O
0-2	O
%	O
NaCl	O
(	O
optimum	O
,	O
0-1	O
%	O
)	O
.	O

Phylogenetic	O
analyses	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequences	O
showed	O
that	O
strain	O
STM-7T	O
belonged	O
to	O
the	O
genus	O
Chitinibacter	O
and	O
was	O
most	O
closely	O
related	O
to	O
Chitinibacter	O
tainanensis	O
S1T	O
with	O
sequence	O
similarity	O
of	O
97.3	O
%	O
.	O

Strain	O
STM-7T	O
contained	O
summed	O
feature	O
3	O
(	O
comprising	O
C16:17c	O
and/or	O
C16:16c	O
)	O
and	O
C	O
16:0	O
as	O
the	O
predominant	O
f	O
atty	O
acids	O
.	O

The	O
major	O
h	O
ydroxyl	O
fatty	O
acids	O
were	O
C12:0	O
3-OH	O
and	O
C16:0	O
3-OH	O
.	O

The	O
polar	B-P
lipid	I-P
profile	I-P
consisted	O
of	O
phosphatidylethanolamine	O
,	O
phosphatidylglycerol	O
,	O
diphosphatidylglycerol	O
,	O
an	O
uncharacterized	O
aminophospholipid	O
,	O
an	O
uncharacterized	O
glycolipid	O
and	O
an	O
uncharacterized	O
phospholipid	O
.	O

The	O
major	O
isoprenoid	O
quinone	O
was	O
Q-8	O
.	O

The	O
DNA	O
G+C	O
content	O
of	O
the	O
genomic	O
DNA	O
was	O
52.4	O
mol	O
%	O
.	O

The	O
DNA-DNA	O
hybridization	O
value	O
for	O
strain	O
STM-7T	O
with	O
Chitinibacter	O
tainanensis	O
S1T	O
was	O
less	O
than	O
47	O
%	O
.	O

On	O
the	O
basis	O
of	O
the	O
phylogenetic	O
inference	O
and	O
phenotypic	O
data	O
,	O
strain	O
STM-7T	O
should	O
be	O
classified	O
as	O
a	O
novel	O
species	O
,	O
for	O
which	O
the	O
name	O
Chitinibacter	O
fontanus	O
sp	O
.	O

nov.	O
is	O
proposed	O
.	O

The	O
type	O
strain	O
is	O
STM-7T	O
(	O
=BCRC	O
80923T	O
=LMG	O
29289T	O
=KCTC	O
42982T	O
)	O
.	O

Copolymer	O
Brush	O
-Based	O
Ultralow-Fouling	O
Biorecognition	O
Surface	O
Platform	O
for	O
Food	O
Safety	O
.	O

Functional	O
polymer	O
coatings	O
that	O
combine	O
the	O
ability	O
to	O
resist	O
nonspecific	O
fouling	O
from	O
complex	O
media	O
with	O
high	O
biorecognition	O
element	O
(	O
BRE	O
)	O
immobilization	O
capacity	O
represent	O
an	O
emerging	O
class	O
of	O
new	O
functional	O
materials	O
for	O
a	O
number	O
of	O
bioanalytical	O
and	O
biosensor	O
technologies	O
for	O
medical	B-P
diagnostics	I-P
,	O
security	O
,	O
and	O
food	O
safety	O
.	O

Here	O
,	O
we	O
report	O
on	O
a	O
random	O
copolymer	O
brush	O
surface	O
-	O
poly	O
(	O
CBMAA-ran-HPMAA	O
)	O
-	O
providing	O
high	O
BRE	O
immobilization	O
capacity	O
while	O
simultaneously	O
exhibiting	O
ultralow-fouling	O
behavior	O
in	O
complex	O
food	O
media	O
.	O

We	O
demonstrate	O
that	O
both	O
the	O
functionalization	O
and	O
fouling	O
resistance	O
capabilities	O
of	O
such	O
copolymer	O
brushes	O
can	O
be	O
tuned	O
by	O
changing	O
the	O
surface	O
contents	O
of	O
the	O
two	O
monomer	O
units	O
:	O
nonionic	O
N-	O
(	O
2-hydroxypropyl	O
)	O
methacrylamide	O
(	O
HPMAA	O
)	O
and	O
carboxy-functional	O
zwitterionic	O
carboxybetaine	O
methacrylamide	O
(	O
CBMAA	O
)	O
.	O

It	O
is	O
demonstrated	O
that	O
the	O
resistance	O
to	O
fouling	O
decreases	O
with	O
the	O
surface	O
content	O
of	O
CBMAA	O
;	O
poly	O
(	O
CBMAA-ran-HPMAA	O
)	O
brushes	O
with	O
CBMAA	O
molar	O
content	O
up	O
to	O
15	O
mol	O
%	O
maintain	O
excellent	O
resistance	O
to	O
fouling	O
from	O
a	O
variety	O
of	O
homogenized	O
foods	O
(	O
hamburger	O
,	O
cucumber	O
,	O
milk	O
,	O
and	O
lettuce	O
)	O
even	O
after	O
covalent	O
attachment	O
of	O
BREs	O
to	O
carboxy	O
groups	O
of	O
CBMAA	O
.	O

The	O
poly	O
(	O
CBMAA	O
15	O
mol	O
%	O
-ran-HPMAA	O
)	O
brushes	O
functionalized	O
with	O
antibodies	O
are	O
demonstrated	O
to	O
exhibit	O
fouling	O
resistance	O
from	O
food	O
samples	O
by	O
up	O
to	O
3	O
orders	O
of	O
magnitude	O
better	O
when	O
compared	O
with	O
the	O
widely	O
used	O
low-fouling	O
carboxy-functional	O
oligo	O
(	O
ethylene	O
glycol	O
)	O
(	O
OEG	O
)	O
-based	O
alkanethiolate	O
self-assembled	O
monolayers	O
(	O
AT	O
SAMs	O
)	O
and	O
,	O
furthermore	O
,	O
by	O
up	O
to	O
2	O
orders	O
of	O
magnitude	O
better	O
when	O
compared	O
with	O
the	O
most	O
successful	O
ultralow-fouling	O
biorecognition	O
coatings	O
-	O
poly	O
(	O
carboxybetaine	O
acrylamide	O
)	O
,	O
poly	O
(	O
CBAA	O
)	O
.	O

When	O
model	O
SPR	O
detections	O
of	O
food-borne	O
bacterial	O
pathogens	O
in	O
homogenized	O
foods	O
are	O
used	O
,	O
it	O
is	O
also	O
demonstrated	O
that	O
the	O
antibody	O
-	O
functionalized	O
poly	O
(	O
CBMAA	O
15	O
mol	O
%	O
-ran-HPMAA	O
)	O
brush	O
exhibits	O
superior	O
biorecognition	O
properties	O
over	O
the	O
poly	O
(	O
CBAA	O
)	O
.	O

Structural	O
and	O
tribometric	O
characterization	O
of	O
biomimetically	O
inspired	O
synthetic	O
``	O
insect	O
adhesives	O
``	O
.	O

Background	O
:	O
Based	O
on	O
previous	O
chemical	B-P
analyses	I-P
of	O
insect	O
tarsal	O
adhesives	O
,	O
we	O
prepared	O
12	O
heterogeneous	O
synthetic	O
emulsions	O
mimicking	O
the	O
polar/non-polar	O
principle	O
,	O
analysed	O
their	O
microscopical	O
structure	O
and	O
tested	O
their	O
adhesive	O
,	O
frictional	O
,	O
and	O
rheological	O
properties	O
.	O

Results	O
:	O
The	O
prepared	O
emulsions	O
varied	O
in	O
their	O
consistency	O
from	O
solid	O
rubber-like	O
,	O
over	O
soft	O
elastic	O
,	O
to	O
fluid	O
(	O
watery	O
or	O
oily	O
)	O
.	O

With	O
droplet	O
sizes	O
>	O
100	O
nm	O
,	O
all	O
the	O
emulsions	O
belonged	O
to	O
the	O
common	O
type	O
of	O
macroemulsions	O
.	O

The	O
emulsions	O
of	O
the	O
first	O
generation	O
generally	O
showed	O
broader	O
droplet-size	O
ranges	O
compared	O
with	O
the	O
second	O
generation	O
,	O
especially	O
when	O
less	O
defined	O
components	O
such	O
as	O
petrolatum	O
or	O
waxes	O
were	O
present	O
in	O
the	O
lipophilic	O
fraction	O
of	O
the	O
first	O
generation	O
of	O
emulsions	O
.	O

Some	O
of	O
the	O
prepared	O
emulsions	O
showed	O
a	O
yield	O
point	O
and	O
were	O
Bingham	O
fluids	O
.	O

Tribometric	B-P
adhesion	I-P
was	O
tested	O
via	O
probe	B-P
tack	I-P
tests	I-P
.	O

Compared	O
with	O
the	O
``	O
second	O
generation	O
``	O
(	O
containing	O
less	O
viscous	O
components	O
)	O
,	O
the	O
``	O
first	O
generation	O
``	O
emulsions	O
were	O
much	O
more	O
adhesive	O
(	O
31-93	O
mN	O
)	O
,	O
a	O
finding	O
attributable	O
to	O
their	O
highly	O
viscous	O
components	O
,	O
i.e.	O
,	O
wax	O
,	O
petrolatum	O
,	O
gelatin	O
and	O
poly	O
(	O
vinyl	O
alcohol	O
)	O
.	O

In	O
the	O
second	O
generation	O
emulsions	O
,	O
we	O
attained	O
much	O
lower	O
adhesivenesses	O
,	O
ranging	O
between	O
1-18	O
mN	O
.	O

The	O
adhesive	O
performance	O
was	O
drastically	O
reduced	O
in	O
the	O
emulsions	O
that	O
contained	O
albumin	O
as	O
the	O
protein	O
component	O
or	O
that	O
lacked	O
protein	O
.	O

Tribometric	B-P
shear	I-P
tests	I-P
were	O
performed	O
at	O
moderate	O
normal	O
loads	O
.	O

Our	O
measured	O
friction	O
forces	O
(	O
4-93	O
mN	O
in	O
the	O
first	O
and	O
0.1-5.8	O
mN	O
in	O
the	O
second	O
generation	O
emulsions	O
)	O
were	O
comparatively	O
low	O
.	O

Differences	O
in	O
shear	O
performance	O
were	O
related	O
to	O
the	O
chemical	O
composition	O
and	O
emulsion	O
structure	O
.	O

Conclusion	O
:	O
By	O
varying	O
their	O
chemical	O
composition	O
,	O
synthetic	O
heterogeneous	O
adhesive	O
emulsions	O
can	O
be	O
adjusted	O
to	O
have	O
diverse	O
consistencies	O
and	O
are	O
able	O
to	O
mimic	O
certain	O
rheological	O
and	O
tribological	O
properties	O
of	O
natural	O
tarsal	O
insect	O
adhesives	O
.	O

NAPS	O
-	O
MS	O
:	O
Natalizumab	O
Effects	O
on	O
Parameters	O
of	O
Sleep	O
in	O
Patients	O
with	O
Multiple	O
Sclerosis	O
.	O

Patients	O
with	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
have	O
higher	O
rates	O
of	O
fatigue	O
,	O
mood	O
disturbance	O
,	O
and	O
cognitive	O
impairments	O
than	O
healthy	O
populations	O
.	O

Disease	O
-modifying	O
agents	O
may	O
affect	O
sleep	O
.	O

Although	O
patients	O
taking	O
natalizumab	O
often	O
show	O
improvement	O
in	O
fatigue	O
during	O
the	O
first	O
year	O
of	O
therapy	O
,	O
the	O
mechanism	O
behind	O
this	O
effect	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
the	O
NAPS	O
-	O
MS	O
study	O
was	O
to	O
investigate	O
whether	O
natalizumab	O
affected	O
objective	O
measures	O
of	O
sleep	O
as	O
determined	O
by	O
polysomnography	B-P
(	O
PSG	B-P
)	O
and	O
multiple	B-P
sleep	I-P
latency	I-P
testing	I-P
(	O
MSLT	B-P
)	O
in	O
patients	O
with	O
MS	O
with	O
fatigue	O
or	O
sleepiness	O
initiating	O
therapy	O
.	O

Additional	O
goals	O
were	O
to	O
evaluate	O
changes	O
in	O
measures	O
of	O
fatigue	O
,	O
mood	O
,	O
and	O
cognition	O
and	O
to	O
correlate	O
these	O
measures	O
with	O
objective	O
sleep	O
measures	O
.	O

Patients	O
underwent	O
PSG	B-P
and	O
MSLT	B-P
before	O
their	O
first	O
natalizumab	O
infusion	O
and	O
after	O
their	O
seventh	O
.	O

Patients	O
completed	O
the	O
Modified	O
Fatigue	O
Impact	O
Scale	O
,	O
Fatigue	O
Severity	O
Scale	O
(	O
FSS	O
)	O
,	O
Epworth	O
Sleepiness	O
Scale	O
(	O
ESS	O
)	O
,	O
and	O
visual	O
analogue	O
scale	O
for	O
fatigue	O
(	O
VAS-F	O
)	O
at	O
their	O
first	O
,	O
fourth	O
,	O
and	O
seventh	O
natalizumab	O
infusions	O
.	O

NeuroTrax	B-P
cognitive	I-P
tests	I-P
and	O
the	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
(	O
HADS	O
)	O
were	O
performed	O
at	O
the	O
first	O
and	O
seventh	O
natalizumab	O
infusions	O
.	O

Changes	O
in	O
sleep	O
efficiency	O
,	O
wakefulness	O
after	O
sleep	O
onset	O
,	O
and	O
multiple	B-P
sleep	I-P
latency	I-P
from	O
baseline	O
to	O
6	O
months	O
of	O
therapy	O
did	O
not	O
reach	O
significance	O
.	O

The	O
FSS	O
,	O
VAS-F	O
,	O
ESS	O
,	O
and	O
HADS	O
scores	O
were	O
significantly	O
improved	O
after	O
6	O
months	O
of	O
therapy	O
;	O
cognitive	O
scores	O
were	O
not	O
significantly	O
improved	O
.	O

Although	O
treatment	O
with	O
natalizumab	O
was	O
associated	O
with	O
improvements	O
in	O
fatigue	O
,	O
sleepiness	O
,	O
and	O
mood	O
,	O
changes	O
in	O
objective	O
measures	O
of	O
sleep	O
were	O
not	O
significant	O
.	O

Proteome	O
Profiling	B-P
of	O
Paulownia	O
Seedlings	O
Infected	O
with	O
Phytoplasma	O
.	O

Phytoplasma	O
is	O
an	O
insect	O
-	O
transmitted	O
pathogen	O
that	O
causes	O
witches	O
'	O
broom	O
disease	O
in	O
many	O
plants	O
.	O

Paulownia	O
witches	O
'	O
broom	O
is	O
one	O
of	O
the	O
most	O
destructive	O
diseases	O
threatening	O
Paulownia	O
production	O
.	O

The	O
molecular	O
mechanisms	O
associated	O
with	O
this	O
disease	O
have	O
been	O
investigated	O
by	O
transcriptome	B-P
sequencing	I-P
,	O
but	O
changes	O
in	O
protein	O
abundance	O
have	O
not	O
been	O
investigated	O
with	O
isobaric	B-P
tags	I-P
for	I-P
relative	I-P
and	I-P
absolute	I-P
quantitation	I-P
.	O

Previous	O
results	O
have	O
shown	O
that	O
methyl	O
methane	O
sulfonate	O
(	O
MMS	O
)	O
can	O
help	O
Paulownia	O
seedlings	O
recover	O
from	O
the	O
symptoms	O
of	O
witches	O
'	O
broom	O
and	O
reinstate	O
a	O
healthy	O
morphology	O
.	O

In	O
this	O
study	O
,	O
a	O
transcriptomic-assisted	B-P
proteomic	I-P
technique	I-P
was	O
used	O
to	O
analyze	O
the	O
protein	O
changes	O
in	O
phytoplasma	O
-	O
infected	O
Paulownia	O
tomentosa	O
seedlings	O
,	O
phytoplasma	O
-	O
infected	O
seedlings	O
treated	O
with	O
20	O
and	O
60	O
mg·L	O
(	O
-1	O
)	O
MMS	O
,	O
and	O
healthy	O
seedlings	O
.	O

A	O
total	O
of	O
2,051	O
proteins	O
were	O
obtained	O
,	O
879	O
of	O
which	O
were	O
found	O
to	O
be	O
differentially	O
abundant	O
in	O
pairwise	O
comparisons	O
between	O
the	O
sample	O
groups	O
.	O

Among	O
the	O
differentially	O
abundant	O
proteins	O
,	O
43	O
were	O
related	O
to	O
Paulownia	O
witches	O
'	O
broom	O
disease	O
and	O
many	O
of	O
them	O
were	O
annotated	O
to	O
be	O
involved	O
in	O
photosynthesis	O
,	O
expression	O
of	O
dwarf	O
symptom	O
,	O
energy	O
production	O
,	O
and	O
cell	O
signal	O
pathways	O
.	O

A	O
Caucasian	O
JK*A/JK*B	O
woman	O
with	O
Jk	O
(	O
a+b-	O
)	O
red	O
blood	O
cells	O
,	O
anti-Jkb	O
,	O
and	O
a	O
novel	O
JK*B	O
allele	O
c.1038delG	O
.	O

The	O
Kidd	O
blood	O
group	O
on	O
the	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
glycoprotein	O
urea	O
transporter-B	O
has	O
a	O
growing	O
number	O
of	O
weak	O
and	O
null	O
alleles	O
in	O
its	O
gene	O
SLC14A1	O
that	O
are	O
emerging	O
from	O
more	O
widespread	O
genotyping	B-P
of	O
blood	O
donors	O
and	O
patients	O
.	O

We	O
investigated	O
a	O
64-year-old	O
Caucasian	O
woman	O
of	O
Polish-Czech	O
descent	O
who	O
developed	O
anti-Jkb	O
detected	O
in	O
solid-phase	B-P
RBC	O
adherence	O
testing	O
within	O
12	O
days	O
after	O
7	O
units	O
of	O
RBCs	O
were	O
transfused	O
.	O

Her	O
RBCs	O
subsequently	O
typed	B-P
Jk	O
(	O
a+b–	O
)	O
by	O
licensed	O
reagents	O
and	O
human	O
antisera	O
.	O

Nevertheless	O
,	O
in	O
RBC	O
genotyping	B-P
(	O
BioArray	O
HEA	O
BeadChip	O
,	O
Immucor	O
,	O
Warren	O
,	O
NJ	O
)	O
performed	O
in	O
our	O
transfusion	O
service	O
on	O
all	O
patients	O
with	O
alloantibodies	O
,	O
her	O
Kidd	B-P
typing	I-P
was	O
JK*A/JK*B	O
based	O
on	O
the	O
Jka/Jkb	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
9	O
(	O
c.838G	O
>	O
A	O
,	O
p.Asp280Asn	O
)	O
.	O

Genomic	O
analysis	O
and	O
cDNA	O
sequencing	B-P
of	O
her	O
JK*B	O
allele	O
revealed	O
a	O
novel	O
single-nucleotide	O
deletion	O
of	O
c.1038G	O
in	O
exon	O
11	O
,	O
predicting	O
a	O
frameshift	O
and	O
premature	O
stop	O
(	O
p.Thr346Thrfs*5	O
)	O
after	O
translation	O
of	O
nearly	O
90	O
percent	O
of	O
the	O
expressed	O
exons	O
4–11	O
.	O

This	O
allele	O
has	O
been	O
provisionally	O
named	O
JK*02N.14	O
,	O
subject	O
to	O
approval	O
by	O
the	O
International	O
Society	O
of	O
Blood	O
Transfusion	O
Working	O
Party	O
.	O

The	O
site	O
of	O
this	O
variant	O
is	O
closer	O
to	O
the	O
C-terminus	O
than	O
that	O
of	O
any	O
allele	O
associated	O
with	O
the	O
Jk	O
(	O
a–b–	O
)	O
phenotype	O
reported	O
to	O
date	O
.	O

Routine	O
genotyping	B-P
of	O
patients	O
with	O
RBC	O
alloantibodies	O
can	O
reveal	O
variants	O
posing	O
potential	O
risk	O
of	O
alloimmunization	O
.	O

Continuing	O
investigation	O
of	O
Kidd	O
variants	O
may	O
shed	O
light	O
on	O
the	O
structure	O
of	O
Kidd	O
antigens	O
and	O
the	O
function	O
of	O
urea	O
transporter-B	O
.	O

Low	O
serum	O
vitamin	O
D	O
is	O
associated	O
with	O
higher	O
cortical	O
porosity	O
in	O
elderly	O
men	O
.	O

Bone	O
loss	O
at	O
peripheral	O
sites	O
in	O
the	O
elderly	O
is	O
mainly	O
cortical	O
and	O
involves	O
increased	O
cortical	O
porosity	O
.	O

However	O
,	O
an	O
association	O
between	O
bone	O
loss	O
at	O
these	O
sites	O
and	O
25-hydroxyvitamin	O
D	O
has	O
not	O
been	O
reported	O
.	O

To	O
investigate	O
the	O
association	O
between	O
serum	O
levels	B-P
of	I-P
25-hydroxyvitamin	I-P
D	I-P
,	O
bone	O
microstructure	O
and	O
areal	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
in	O
elderly	O
men	O
.	O

A	O
population	O
-based	O
cohort	O
of	O
444	O
elderly	O
men	O
(	O
mean	O
±	O
SD	O
age	O
80.2	O
±	O
3.5	O
years	O
)	O
was	O
investigated	O
.	O

Bone	O
microstructure	O
was	O
measured	O
by	O
high-resolution	B-P
peripheral	I-P
quantitative	I-P
computed	I-P
tomography	I-P
,	O
areal	O
BMD	O
by	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
and	O
serum	O
25-hydroxyvitamin	B-P
D	I-P
and	O
parathyroid	B-P
hormone	I-P
levels	I-P
by	O
immunoassay	B-P
.	O

Mean	O
cortical	O
porosity	O
at	O
the	O
distal	O
tibia	O
was	O
14.7	O
%	O
higher	O
(	O
12.5	O
±	O
4.3	O
%	O
vs.	O
10.9	O
±	O
4.1	O
%	O
,	O
P	O
<	O
0.05	O
)	O
whilst	O
cortical	O
volumetric	O
BMD	O
,	O
area	O
,	O
trabecular	O
bone	O
volume	O
fraction	O
and	O
femoral	O
neck	O
areal	O
BMD	O
were	O
lower	O
in	O
men	O
in	O
the	O
lowest	O
quartile	O
of	O
vitamin	B-P
D	I-P
levels	I-P
compared	O
to	O
the	O
highest	O
.	O

In	O
men	O
with	O
vitamin	O
D	O
deficiency	O
(	O
<	O
25	O
nmol	O
L	O
(	O
-1	O
)	O
)	O
or	O
insufficiency	O
[	O
25-49	O
nmol	O
L	O
(	O
-1	O
)	O
,	O
in	O
combination	O
with	O
an	O
elevated	O
serum	O
level	B-P
of	I-P
parathyroid	I-P
hormone	I-P
(	O
>	O
6.8	O
pmol	O
L	O
(	O
-1	O
)	O
)	O
]	O
,	O
cortical	O
porosity	O
was	O
17.2	O
%	O
higher	O
than	O
in	O
vitamin	O
D	O
-	O
sufficient	O
men	O
(	O
P	O
<	O
0.01	O
)	O
.	O

A	O
linear	O
regression	O
model	O
including	O
age	O
,	O
weight	O
,	O
height	O
,	O
daily	O
calcium	O
intake	O
,	O
physical	O
activity	O
,	O
smoking	O
vitamin	O
D	O
supplementation	O
and	O
parathyroid	O
hormone	O
showed	O
that	O
25-hydroxyvitamin	O
D	O
independently	O
predicted	O
cortical	O
porosity	O
(	O
standardized	O
β	O
=	O
-0.110	O
,	O
R	O
(	O
2	O
)	O
=	O
1.1	O
%	O
,	O
P	O
=	O
0.024	O
)	O
,	O
area	O
(	O
β	O
=	O
0.123	O
,	O
R	O
(	O
2	O
)	O
=	O
1.4	O
%	O
,	O
P	O
=	O
0.007	O
)	O
and	O
cortical	O
volumetric	O
BMD	O
(	O
β	O
=	O
0.125	O
,	O
R	O
(	O
2	O
)	O
=	O
1.4	O
%	O
,	O
P	O
=	O
0.007	O
)	O
of	O
the	O
tibia	O
as	O
well	O
as	O
areal	O
BMD	O
of	O
the	O
femoral	O
neck	O
(	O
β	O
=	O
0.102	O
,	O
R	O
(	O
2	O
)	O
=	O
0.9	O
%	O
,	O
P	O
=	O
0.04	O
)	O
.	O

Serum	O
vitamin	O
D	O
is	O
associated	O
with	O
cortical	O
porosity	O
,	O
area	O
and	O
density	O
,	O
indicating	O
that	O
bone	O
fragility	O
as	O
a	O
result	O
of	O
low	O
vitamin	O
D	O
could	O
be	O
due	O
to	O
changes	O
in	O
cortical	O
bone	O
microstructure	O
and	O
geometry	O
.	O

Signs	O
of	O
dysarthria	O
in	O
adults	O
with	O
22q11.2	O
deletion	O
syndrome	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
how	O
adults	O
with	O
22q11.2	O
deletion	O
syndrome	O
(	O
22q11DS	O
)	O
performed	O
on	O
dysarthria	O
and	O
intelligibility	O
tests	B-P
compared	O
with	O
a	O
control	O
group	O
.	O

Ten	O
participants	O
with	O
confirmed	O
22q11.2	O
deletion	O
,	O
five	O
males	O
and	O
five	O
females	O
with	O
a	O
mean	O
age	O
of	O
31	O
years	O
(	O
range	O
:	O
19-49	O
)	O
,	O
were	O
compared	O
with	O
a	O
control	O
group	O
matched	O
for	O
gender	O
and	O
age	O
(	O
five	O
males	O
and	O
five	O
females	O
,	O
mean	O
age	O
:	O
32	O
years	O
,	O
range	O
:	O
19-49	O
)	O
.	O

Assessment	O
of	O
non-verbal	B-P
and	I-P
verbal	I-P
tasks	I-P
reflecting	O
respiration	O
,	O
phonation	O
,	O
oral	O
motor	O
function	O
,	O
velopharyngeal	B-P
function	I-P
,	O
articulation	O
,	O
and	O
prosody	O
was	O
performed	O
as	O
well	O
as	O
the	O
Swedish	O
Test	O
of	O
Intelligibility	O
(	O
STI	O
)	O
.	O

All	O
assessments	O
were	O
made	O
by	O
two	O
raters	O
;	O
inter-rater	O
and	O
intra-rater	O
reliability	O
was	O
acceptable	O
.	O

The	O
participants	O
with	O
22q11DS	O
had	O
significantly	O
more	O
problems	O
than	O
the	O
control	O
group	O
on	O
all	O
investigated	O
dimensions	O
except	O
the	O
STI	O
.	O

Overall	O
,	O
the	O
severity	O
of	O
their	O
speech	O
deviation	O
was	O
rated	O
as	O
mild	O
to	O
moderate	O
.	O

The	O
largest	O
difficulties	O
were	O
found	O
regarding	O
speech	O
respiration	O
,	O
phonation	O
,	O
oral	O
motor	O
function	O
,	O
and	O
velopharyngeal	B-P
function	I-P
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
a	O
neurological	O
etiology	O
could	O
be	O
added	O
to	O
the	O
previously	O
described	O
structural	O
etiology	O
explaining	O
the	O
speech	O
difficulties	O
found	O
in	O
22q11DS	O
.	O

Signs	O
of	O
difficulties	O
in	O
both	O
speech	O
motor	O
planning	O
and	O
speech	O
motor	O
programming	O
were	O
found	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
confirm	O
the	O
results	O
,	O
as	O
are	O
studies	O
of	O
the	O
association	O
between	O
structural	O
brain	O
abnormalities	O
and	O
neurological	O
speech	O
symptoms	O
.	O

For	O
clinical	O
purposes	O
,	O
it	O
is	O
important	O
that	O
clinicians	O
have	O
knowledge	O
about	O
the	O
variable	O
speech	O
symptoms	O
that	O
may	O
occur	O
in	O
individuals	O
with	O
22q11DS	O
and	O
that	O
they	O
be	O
aware	O
of	O
the	O
complexity	O
of	O
the	O
etiology	O
of	O
such	O
speech	O
symptoms	O
.	O

©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Complete	O
Genome	O
Sequences	O
of	O
Chikungunya	O
Viruses	O
Isolated	O
from	O
Plasma	O
Specimens	B-P
Collected	I-P
from	O
Haitians	O
in	O
2014	O
.	O

Ten	O
chikungunya	O
virus	O
isolates	O
from	O
human	O
plasma	O
collected	B-P
in	O
Haiti	O
from	O
May	O
to	O
August	O
2014	O
,	O
in	O
the	O
midst	O
of	O
a	O
chikungunya	O
fever	O
outbreak	O
,	O
were	O
fully	O
sequenced	B-P
.	O

The	O
resulting	O
genomic	O
sequences	O
are	O
nearly	O
identical	O
,	O
and	O
phylogenetic	O
analyses	O
indicate	O
they	O
belong	O
to	O
the	O
Asian	O
lineage	O
of	O
the	O
virus	O
.	O

Influence	O
of	O
Plasma	O
Cell	O
Niche	O
Factors	O
on	O
the	O
Recruitment	O
and	O
Maintenance	O
of	O
IRF4hi	O
Plasma	O
Cells	O
and	O
Plasmablasts	O
in	O
Vaccinated	O
,	O
Simian	O
Immunodeficiency	O
Virus	O
-	O
Infected	O
Rhesus	O
Macaques	O
with	O
Low	O
and	O
High	O
Viremia	O
.	O

In	O
a	O
recent	O
study	O
,	O
we	O
found	O
that	O
protection	O
following	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
exposure	O
correlated	O
with	O
rectal	O
plasma	O
cell	O
frequency	O
in	O
vaccinated	O
female	O
rhesus	O
macaques	O
.	O

We	O
sought	O
to	O
determine	O
if	O
the	O
same	O
macaques	O
maintained	O
high	O
mucosal	O
plasma	O
cell	O
frequencies	O
postinfection	O
and	O
if	O
this	O
translated	O
to	O
reduced	O
viremia	O
.	O

Although	O
delayed	O
SIV	O
acquisition	O
did	O
not	O
predict	O
subsequent	O
viral	O
control	O
,	O
alterations	O
existed	O
in	O
the	O
distribution	O
of	O
plasma	O
cells	O
and	O
plasmablasts	O
between	O
macaques	O
that	O
exhibited	O
high	O
or	O
low	O
viremia	O
.	O

Flow	B-P
cytometric	I-P
analysis	I-P
of	O
cells	O
from	O
rectal	O
biopsy	O
specimens	O
,	O
bone	O
marrow	O
,	O
and	O
mesenteric	O
lymph	O
nodes	O
of	O
vaccinated	O
infected	O
,	O
unvaccinated	O
infected	O
,	O
and	O
uninfected	O
macaques	O
identified	O
two	O
main	O
IRF4	O
(	O
hi	O
)	O
subsets	O
of	O
interest	O
:	O
CD138	O
(	O
+	O
)	O
plasma	O
cells	O
,	O
and	O
CD138	O
(	O
-	O
)	O
plasmablasts	O
.	O

In	O
rectal	O
tissue	O
,	O
plasma	O
cell	O
frequency	O
positively	O
correlated	O
with	O
plasma	O
viremia	O
and	O
unvaccinated	O
macaques	O
had	O
increased	O
plasma	O
cells	O
and	O
plasmablasts	O
compared	O
to	O
vaccinated	O
animals	O
.	O

Likewise	O
,	O
plasmablast	O
frequency	O
in	O
the	O
mesenteric	O
lymph	O
node	O
correlated	O
with	O
viremia	O
.	O

However	O
,	O
in	O
bone	O
marrow	O
,	O
plasmablast	O
frequency	O
negatively	O
correlated	O
with	O
viremia	O
.	O

Accordingly	O
,	O
low-viremic	O
macaques	O
had	O
a	O
higher	O
frequency	O
of	O
both	O
bone	O
marrow	O
IRF4	O
(	O
hi	O
)	O
subsets	O
than	O
did	O
animals	O
with	O
high	O
viremia	O
.	O

Significant	O
reciprocal	O
relationships	O
between	O
rectal	O
and	O
bone	O
marrow	O
plasmablasts	O
suggested	O
that	O
efficient	O
trafficking	O
to	O
the	O
bone	O
marrow	O
as	O
opposed	O
to	O
the	O
rectal	O
mucosa	O
was	O
linked	O
to	O
viral	O
control	O
.	O

mRNA	O
expression	O
analysis	O
of	O
proteins	O
involved	O
in	O
establishment	O
of	O
plasma	O
cell	O
niches	O
in	O
sorted	O
bone	O
marrow	O
and	O
rectal	O
cell	O
populations	O
further	O
supported	O
this	O
model	O
and	O
revealed	O
differential	O
mRNA	O
expression	O
patterns	O
in	O
these	O
tissues	O
.	O

As	O
key	O
antibody	O
producers	O
,	O
plasma	O
cells	O
and	O
plasmablasts	O
are	O
critical	O
components	O
of	O
vaccine	O
-induced	O
immunity	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
in	O
humans	O
and	O
SIV	O
in	O
the	O
macaque	O
model	O
;	O
however	O
,	O
few	O
have	O
attempted	O
to	O
examine	O
the	O
role	O
of	O
these	O
cells	O
in	O
viral	O
suppression	O
postinfection	O
.	O

Our	O
results	O
suggest	O
that	O
plasmablast	O
trafficking	O
to	O
and	O
retention	O
in	O
the	O
bone	O
marrow	O
play	O
a	O
previously	O
unappreciated	O
role	O
in	O
viral	O
control	O
and	O
contrast	O
the	O
potential	O
contribution	O
of	O
mucosal	O
plasma	O
cells	O
to	O
mediate	O
protection	O
at	O
sites	O
of	O
infection	O
with	O
that	O
of	O
bone	O
marrow	O
plasmablasts	O
and	O
plasma	O
cells	O
to	O
control	O
viremia	O
during	O
chronic	O
infection	O
.	O

Manipulation	O
of	O
niche	O
factors	O
influencing	O
the	O
distribution	O
and	O
maintenance	O
of	O
these	O
critical	O
antibody-secreting	O
cells	O
may	O
serve	O
as	O
potential	O
therapeutic	O
targets	O
to	O
enhance	O
antiviral	O
responses	O
postvaccination	O
and	O
postinfection	O
.	O

Biochemical	O
evidence	O
for	O
a	O
mitochondrial	O
genetic	O
modifier	O
in	O
the	O
phenotypic	O
manifestation	O
of	O
Leber	O
's	O
hereditary	O
optic	O
neuropathy	O
-associated	O
mitochondrial	O
DNA	O
mutation	O
.	O

Leber	O
's	O
hereditary	O
optic	O
neuropathy	O
(	O
LHON	O
)	O
is	O
the	O
most	O
common	O
mitochondrial	O
disease	O
.	O

Mitochondrial	O
modifiers	O
are	O
proposed	O
to	O
modify	O
the	O
phenotypic	O
expression	O
of	O
primary	O
LHON	O
-associated	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
mutations	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
LHON	O
susceptibility	O
allele	O
(	O
m.14502T	O
>	O
C	O
,	O
p.	O
58I	O
>	O
V	O
)	O
in	O
the	O
ND6	O
gene	O
modulated	O
the	O
phenotypic	O
expression	O
of	O
primary	O
LHON	O
-associated	O
m.11778G	O
>	O
A	O
mutation	O
.	O

Twenty-two	O
Han	O
Chinese	O
pedigrees	O
carrying	O
m.14502T	O
>	O
C	O
and	O
m.11778G	O
>	O
A	O
mutations	O
exhibited	O
significantly	O
higher	O
penetrance	O
of	O
optic	O
neuropathy	O
than	O
those	O
carrying	O
only	O
m.11778G	O
>	O
A	O
mutation	O
.	O

We	O
performed	O
functional	O
assays	B-P
using	O
the	O
cybrid	O
cell	O
models	O
,	O
generated	O
by	O
fusing	O
mtDNA-less	O
ρ	O
(	O
o	O
)	O
cells	O
with	O
enucleated	O
cells	O
from	O
LHON	O
patients	O
carrying	O
both	O
m.11778G	O
>	O
A	O
and	O
m.14502T	O
>	O
C	O
mutations	O
,	O
only	O
m.14502T	O
>	O
C	O
or	O
m.11778G	O
>	O
A	O
mutation	O
and	O
a	O
control	O
belonging	O
to	O
the	O
same	O
mtDNA	O
haplogroup	O
.	O

These	O
cybrids	O
cell	O
lines	O
bearing	O
m.14502T	O
>	O
C	O
mutation	O
exhibited	O
mild	O
effects	O
on	O
mitochondrial	O
functions	O
compared	O
with	O
those	O
carrying	O
only	O
m.11778G	O
>	O
A	O
mutation	O
.	O

However	O
,	O
more	O
severe	O
mitochondrial	O
dysfunctions	O
were	O
observed	O
in	O
cell	O
lines	O
bearing	O
both	O
m.14502T	O
>	O
C	O
and	O
m.11778G	O
>	O
A	O
mutations	O
than	O
those	O
carrying	O
only	O
m.11778G	O
>	O
A	O
or	O
m.14502T	O
>	O
C	O
mutation	O
.	O

In	O
particular	O
,	O
the	O
m.14502T	O
>	O
C	O
mutation	O
altered	O
assemble	O
of	O
complex	O
I	O
,	O
thereby	O
aggravating	O
the	O
respiratory	O
phenotypes	O
associated	O
with	O
m.11778G	O
>	O
A	O
mutation	O
,	O
resulted	O
in	O
a	O
more	O
defective	O
complex	O
I	O
.	O

Furthermore	O
,	O
more	O
reductions	O
in	O
the	O
levels	O
of	O
mitochondrial	O
ATP	O
and	O
increasing	O
production	O
of	O
reactive	O
oxygen	O
species	O
were	O
also	O
observed	O
in	O
mutant	O
cells	O
bearing	O
both	O
m.14502T	O
>	O
C	O
and	O
m.11778G	O
>	O
A	O
mutation	O
than	O
those	O
carrying	O
only	O
11778G	O
>	O
A	O
mutation	O
.	O

Our	O
findings	O
provided	O
new	O
insights	O
into	O
the	O
pathophysiology	O
of	O
LHON	O
that	O
were	O
manifested	O
by	O
interaction	O
between	O
primary	O
and	O
secondary	O
mtDNA	O
mutations	O
.	O

Attenuation	O
of	O
High	O
Glucose	O
-	O
Induced	O
Rat	O
Cardiomyocyte	O
Apoptosis	O
by	O
Exendin-4	O
via	O
Intervention	O
of	O
HO-1	O
/	O
Nrf-2	O
and	O
the	O
PI3K/AKT	O
Signaling	O
Pathway	O
.	O

Exendin-4	O
,	O
a	O
glucagon-like	O
peptide-1	O
receptor	O
agonist	O
,	O
demonstrated	O
cytoprotective	O
actions	O
beyond	O
glycemic	O
control	O
in	O
recent	O
studies	O
.	O

The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
investigate	O
the	O
effects	O
of	O
exendin-4	O
on	O
high	O
glucose	O
(	O
HG	O
)	O
-	O
induced	O
cardiomyocyte	O
apoptosis	O
and	O
the	O
possible	O
mechanisms	O
.	O

Rat	O
cardiomyocytes	O
were	O
divided	O
into	O
3	O
groups	O
:	O
normal	O
glucose	O
group	O
(	O
NG	O
group	O
)	O
,	O
HG	O
group	O
and	O
HG	O
+	O
exendin-4	O
group	O
(	O
HG	O
+	O
Ex	O
Group	O
)	O
.	O

Cardiomyocyte	O
apoptosis	O
was	O
evaluated	O
by	O
double-staining	B-P
with	O
annexin	O
V-fluorescein	O
isothiocyanate	O
(	O
FITC	O
)	O
/	O
propidium	O
iodide	O
(	O
PI	O
)	O
and	O
flow	B-P
cytometry	I-P
.	O

Intracellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
was	O
detected	O
by	O
2	O
’	O
,7	O
’	O
-dichlorodihydrofluorescein	O
diacetate	O
(	O
DCHF-DA	O
)	O
incubation	B-P
and	O
fluorescence	B-P
microscopy	I-P
.	O

LY294002	O
(	O
LY	O
)	O
,	O
a	O
phosphoinositide	O
3-kinase	O
(	O
PI3K	O
)	O
pathway	O
inhibitor	O
,	O
was	O
added	O
to	O
the	O
medium	O
of	O
the	O
HG	O
+	O
Ex	O
+	O
LY	O
Group	O
for	O
further	O
western	B-P
blot	I-P
analysis	I-P
.	O

The	O
proteins	O
analyzed	O
involved	O
oxidative	O
stress	O
-	O
associated	O
proteins	O
,	O
heme	O
oxygenase-1	O
(	O
HO-1	O
)	O
and	O
nuclear	O
factor	O
E2-related	O
factor	O
2	O
(	O
Nrf-2	O
)	O
,	O
and	O
apoptosis	O
-	O
associated	O
proteins	O
,	O
caspase-3	O
,	O
Bax/B-cell	O
lymphoma	O
2	O
(	O
Bcl-2	O
)	O
and	O
p-AKT	O
/	O
AKT	O
.	O

HG	O
treatment	O
induced	O
cardiomyocyte	O
apoptosis	O
(	O
P	O
=	O
0.00	O
)	O
and	O
clearly	O
upregulated	O
ROS	O
production	O
(	O
P	O
=	O
0.00	O
)	O
;	O
exendin-4	O
co-incubation	B-P
also	O
ameliorated	O
cardiomyocyte	O
apoptosis	O
(	O
P	O
=	O
0.004	O
)	O
and	O
decreased	O
ROS	O
(	O
P	O
=	O
0.00	O
)	O
level	O
significantly	O
.	O

HO-1	O
and	O
Nrf-2	O
protein	O
expression	O
levels	O
decreased	O
significantly	O
in	O
the	O
HG	O
group	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
the	O
levels	O
were	O
elevated	O
by	O
exendin-4	O
intervention	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Furthermore	O
,	O
exendin-4	O
attenuated	O
HG	O
-	O
induced	O
higher	O
protein	O
expression	O
,	O
including	O
cleaved	O
caspase-3	O
and	O
Bax	O
,	O
increased	O
the	O
expression	O
of	O
Bcl-2	O
protein	O
(	O
P	O
<	O
0.05	O
)	O
.	O

However	O
,	O
these	O
impacts	O
of	O
exendin-4	O
were	O
counteracted	O
significantly	O
by	O
co-incubation	B-P
with	O
LY294002	O
.	O

In	O
addition	O
,	O
exendin-4	O
ameliorated	O
HG	O
-	O
induced	O
p-AKT	O
/	O
AKT	O
lower	O
expression	O
,	O
and	O
this	O
impact	O
was	O
also	O
suppressed	O
by	O
LY294002	O
.	O

Exendin-4	O
ameliorates	O
HG	O
-	O
induced	O
cardiomyocyte	O
apoptosis	O
,	O
and	O
the	O
mechanisms	O
may	O
involve	O
anti-oxidative	O
stress	O
via	O
the	O
HO-1	O
/	O
Nrf-2	O
system	O
,	O
as	O
well	O
as	O
intervention	O
of	O
the	O
PI3K/AKT	O
signaling	O
pathway	O
.	O

Role	O
of	O
endoscopy	B-P
in	O
primary	O
sclerosing	O
cholangitis	O
:	O
European	O
Society	O
of	O
Gastrointestinal	O
Endoscopy	O
(	O
ESGE	O
)	O
and	O
European	O
Association	O
for	O
the	O
Study	O
of	O
the	O
Liver	O
(	O
EASL	O
)	O
Clinical	O
Guideline	O
.	O

1	O
ESGE	O
/	O
EASL	O
recommend	O
that	O
,	O
as	O
the	O
primary	O
diagnostic	B-P
modality	O
for	O
PSC	O
,	O
magnetic	B-P
resonance	I-P
cholangiography	I-P
(	O
MRC	B-P
)	O
should	O
be	O
preferred	O
over	O
endoscopic	B-P
retrograde	I-P
cholangiopancreatography	I-P
(	O
ERCP	B-P
)	O
.	O

Moderate	O
quality	O
evidence	O
,	O
strong	O
recommendation	O
.	O

2	O
ESGE	O
/	O
EASL	O
suggest	O
that	O
ERCP	B-P
can	O
be	O
considered	O
if	O
MRC	B-P
plus	O
liver	B-P
biopsy	I-P
is	O
equivocal	O
or	O
contraindicated	O
in	O
patients	O
with	O
persisting	O
clinical	O
suspicion	O
of	O
PSC	O
.	O

The	O
risks	O
of	O
ERCP	B-P
have	O
to	O
be	O
weighed	O
against	O
the	O
potential	O
benefit	O
with	O
regard	O
to	O
surveillance	O
and	O
treatment	O
recommendations	O
.	O

Low	O
quality	O
evidence	O
,	O
weak	O
recommendation	O
.	O

6	O
ESGE	O
/	O
EASL	O
suggest	O
that	O
,	O
in	O
patients	O
with	O
an	O
established	O
diagnosis	O
of	O
PSC	O
,	O
MRC	B-P
should	O
be	O
considered	O
before	O
therapeutic	O
ERCP	B-P
.	O

Weak	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

7	O
ESGE	O
/	O
EASL	O
suggest	O
performing	O
endoscopic	B-P
treatment	O
with	O
concomitant	O
ductal	O
sampling	O
(	O
brush	O
cytology	O
,	O
endobiliary	O
biopsies	O
)	O
of	O
suspected	O
significant	O
strictures	O
identified	O
at	O
MRC	B-P
in	O
PSC	O
patients	O
who	O
present	O
with	O
symptoms	O
likely	O
to	O
improve	O
following	O
endoscopic	B-P
treatment	O
.	O

Strong	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

9	O
ESGE	O
/	O
EASL	O
recommend	O
weighing	O
the	O
anticipated	O
benefits	O
of	O
biliary	O
papillotomy	O
/	O
sphincterotomy	O
against	O
its	O
risks	O
on	O
a	O
case-by-case	O
basis	O
.	O

Strong	O
recommendation	O
,	O
moderate	O
quality	O
evidence	O
.	O

Biliary	O
papillotomy	O
/	O
sphincterotomy	O
should	O
be	O
considered	O
especially	O
after	O
difficult	O
cannulation	O
.	O

Strong	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

16	O
ESGE	O
/	O
EASL	O
suggest	O
routine	O
administration	O
of	O
prophylactic	O
antibiotics	O
before	O
ERCP	B-P
in	O
patients	O
with	O
PSC	O
.	O

Strong	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

17	O
EASL	O
/	O
ESGE	O
recommend	O
that	O
cholangiocarcinoma	O
(	O
CCA	O
)	O
should	O
be	O
suspected	O
in	O
any	O
patient	O
with	O
worsening	O
cholestasis	O
,	O
weight	O
loss	O
,	O
raised	O
serum	O
CA19-9	B-P
,	O
and/or	O
new	O
or	O
progressive	O
dominant	O
stricture	O
,	O
particularly	O
with	O
an	O
associated	O
enhancing	O
mass	O
lesion	O
.	O

Strong	O
recommendation	O
,	O
moderate	O
quality	O
evidence	O
.	O

19	O
ESGE	O
/	O
EASL	O
recommend	O
ductal	O
sampling	O
(	O
brush	O
cytology	O
,	O
endobiliary	O
biopsies	O
)	O
as	O
part	O
of	O
the	O
initial	O
investigation	O
for	O
the	O
diagnosis	O
and	O
staging	B-P
of	O
suspected	O
CCA	O
in	O
patients	O
with	O
PSC	O
.	O

Strong	O
recommendation	O
,	O
high	O
quality	O
evidence	O
.	O

Folate	O
-based	O
single	B-P
cell	I-P
screening	I-P
using	O
surface	B-P
enhanced	I-P
Raman	I-P
microimaging	I-P
.	O

Recent	O
progress	O
in	O
nanotechnology	O
and	O
its	O
application	O
to	O
biomedical	O
settings	O
have	O
generated	O
great	O
advantages	O
in	O
dealing	O
with	O
early	B-P
cancer	I-P
diagnosis	I-P
.	O

The	O
identification	O
of	O
the	O
specific	O
properties	O
of	O
cancer	O
cells	O
,	O
such	O
as	O
the	O
expression	O
of	O
particular	O
plasma	O
membrane	O
molecular	O
receptors	O
,	O
has	O
become	O
crucial	O
in	O
revealing	O
the	O
presence	O
and	O
in	O
assessing	O
the	O
stage	O
of	O
development	O
of	O
the	O
disease	O
.	O

Here	O
we	O
report	O
a	O
single	B-P
cell	I-P
screening	I-P
approach	O
based	O
on	O
Surface	B-P
Enhanced	I-P
Raman	I-P
Scattering	I-P
(	I-P
SERS	B-P
)	I-P
microimaging	I-P
.	O

We	O
fabricated	O
a	O
SERS-labelled	B-P
nanovector	O
based	O
on	O
the	O
biofunctionalization	O
of	O
gold	O
nanoparticles	O
with	O
folic	O
acid	O
.	O

After	O
treating	O
the	O
cells	O
with	O
the	O
nanovector	O
,	O
we	O
were	O
able	O
to	O
distinguish	O
three	O
different	O
cell	O
populations	O
from	O
different	O
cell	O
lines	O
(	O
cancer	O
HeLa	O
and	O
PC-3	O
,	O
and	O
normal	O
HaCaT	O
lines	O
)	O
,	O
suitably	O
chosen	O
for	O
their	O
different	O
expressions	O
of	O
folate	O
binding	O
proteins	O
.	O

The	O
nanovector	O
,	O
indeed	O
,	O
binds	O
much	O
more	O
efficiently	O
on	O
cancer	O
cell	O
lines	O
than	O
on	O
normal	O
ones	O
,	O
resulting	O
in	O
a	O
higher	O
SERS	B-P
signal	O
measured	O
on	O
cancer	O
cells	O
.	O

These	O
results	O
pave	O
the	O
way	O
for	O
applications	O
in	O
single	B-P
cell	I-P
diagnostics	I-P
and	O
,	O
potentially	O
,	O
in	O
theranostics	O
.	O

Improved	O
adipose	O
tissue	O
function	O
with	O
initiation	O
of	O
protease	O
inhibitor	O
-	O
only	O
ART	O
.	O

Use	O
of	O
ART	O
containing	O
HIV	O
PIs	O
has	O
previously	O
been	O
associated	O
with	O
toxicity	O
in	O
subcutaneous	O
adipose	O
tissue	O
(	O
SAT	O
)	O
,	O
potentially	O
contributing	O
to	O
the	O
development	O
of	O
lipodystrophy	O
and	O
insulin	O
resistance	O
.	O

However	O
,	O
the	O
effect	O
of	O
PIs	O
on	O
SAT	O
function	O
in	O
ART	O
-	O
naive	O
patients	O
independent	O
of	O
other	O
ART	O
classes	O
is	O
unknown	O
.	O

This	O
study	O
aimed	O
to	O
elucidate	O
the	O
effect	O
of	O
initiating	O
PI	O
-	O
only	O
ART	O
on	O
SAT	O
function	O
in	O
ART	O
-	O
naive	O
subjects	O
.	O

In	O
the	O
HIVNAT-019	O
study	O
,	O
48	O
HIV-infected	O
,	O
ART	O
-	O
naive	O
Thai	O
adults	O
commencing	O
PI	O
-	O
only	O
ART	O
comprising	O
lopinavir	O
/	O
ritonavir	O
/	O
saquinavir	O
for	O
24	O
weeks	O
underwent	O
assessments	O
of	O
fasting	O
metabolic	O
parameters	O
and	O
body	O
composition	O
.	O

In	O
a	O
molecular	O
substudy	O
,	O
20	O
subjects	O
underwent	O
SAT	O
biopsies	B-P
at	O
weeks	O
0	O
,	O
2	O
and	O
24	O
for	O
transcriptional	O
,	O
protein	O
,	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
and	O
histological	B-P
analyses	I-P
.	O

ClinicalTrials.gov	O
registration	O
number	O
:	O
NCT00400738	O
.	O

Over	O
24	O
weeks	O
,	O
limb	O
fat	O
increased	O
(	O
+416.4	O
g	O
,	O
P	O
=	O
0.023	O
)	O
,	O
coinciding	O
with	O
larger	O
adipocytes	O
as	O
indicated	O
by	O
decreased	O
adipocyte	O
density	O
in	O
biopsies	B-P
(	O
-32.3	O
cells	O
/mm	O
(	O
2	O
)	O
,	O
P	O
=	O
0.047	O
)	O
and	O
increased	O
mRNA	O
expression	O
of	O
adipogenesis	O
regulator	O
PPARG	O
at	O
week	O
2	O
(	O
+58.1	O
%	O
,	O
P	O
=	O
0.003	O
)	O
.	O

Increases	O
in	O
mtDNA	O
over	O
24	O
weeks	O
(	O
+600	O
copies/cell	O
,	O
P	O
=	O
0.041	O
)	O
,	O
decreased	O
NRF1	O
mRNA	O
expression	O
at	O
week	O
2	O
(	O
-33.7	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
increased	O
COX2	O
/	O
COX4	O
protein	O
ratio	O
at	O
week	O
24	O
(	O
+288	O
%	O
,	O
P	O
=	O
0.038	O
)	O
indicated	O
improved	O
mitochondrial	O
function	O
.	O

Despite	O
decreased	O
AKT2	O
mRNA	O
at	O
week	O
2	O
(	O
-28.6	O
%	O
,	O
P	O
=	O
0.002	O
)	O
and	O
increased	O
PTPN1	O
mRNA	O
at	O
week	O
24	O
(	O
+50.3	O
%	O
,	O
P	O
=	O
0.016	O
)	O
suggesting	O
insulin	O
resistance	O
,	O
clinical	O
insulin	O
sensitivity	O
[	O
by	O
homeostasis	O
model	O
assessment	O
(	O
HOMA-IR	O
)	O
]	O
was	O
unchanged	O
.	O

Initiation	O
of	O
PI	O
-	O
only	O
ART	O
showed	O
little	O
evidence	O
of	O
SAT	O
toxicity	O
,	O
the	O
changes	O
observed	O
being	O
consistent	O
with	O
a	O
return	O
to	O
health	O
rather	O
than	O
contributing	O
to	O
lipodystrophy	O
.	O

icle	O

Spatial	O
Mnemonic	O
Encoding	O
:	O
Theta	O
Power	O
Decreases	O
and	O
Medial	O
Temporal	O
Lobe	O
BOLD	B-P
Increases	O
Co-Occur	O
during	O
the	O
Usage	O
of	O
the	O
Method	O
of	O
Loci	O
.	O

The	O
method	O
of	O
loci	O
is	O
one	O
,	O
if	O
not	O
the	O
most	O
,	O
efficient	O
mnemonic	O
encoding	O
strategy	O
.	O

This	O
spatial	O
mnemonic	O
combines	O
the	O
core	O
cognitive	O
processes	O
commonly	O
linked	O
to	O
medial	O
temporal	O
lobe	O
(	O
MTL	O
)	O
activity	O
:	O
spatial	O
and	O
associative	O
memory	O
processes	O
.	O

During	O
such	O
processes	O
,	O
fMRI	B-P
studies	O
consistently	O
demonstrate	O
MTL	O
activity	O
,	O
while	O
electrophysiological	B-P
studies	I-P
have	O
emphasized	O
the	O
important	O
role	O
of	O
theta	O
oscillations	O
(	O
3-8	O
Hz	O
)	O
in	O
the	O
MTL	O
.	O

However	O
,	O
it	O
is	O
still	O
unknown	O
whether	O
increases	O
or	O
decreases	O
in	O
theta	O
power	O
co-occur	O
with	O
increased	O
BOLD	B-P
signal	O
in	O
the	O
MTL	O
during	O
memory	O
encoding	O
.	O

To	O
investigate	O
this	O
question	O
,	O
we	O
recorded	O
EEG	B-P
and	O
fMRI	B-P
separately	O
,	O
while	O
human	O
participants	O
used	O
the	O
spatial	O
method	O
of	O
loci	O
or	O
the	O
pegword	O
method	O
,	O
a	O
similarly	O
associative	O
but	O
nonspatial	O
mnemonic	O
.	O

The	O
more	O
effective	O
spatial	O
mnemonic	O
induced	O
a	O
pronounced	O
theta	O
power	O
decrease	O
source	O
localized	O
to	O
the	O
left	O
MTL	O
compared	O
with	O
the	O
nonspatial	O
associative	O
mnemonic	O
strategy	O
.	O

This	O
effect	O
was	O
mirrored	O
by	O
BOLD	B-P
signal	O
increases	O
in	O
the	O
MTL	O
.	O

Successful	O
encoding	O
,	O
irrespective	O
of	O
the	O
strategy	O
used	O
,	O
elicited	O
decreases	O
in	O
left	O
temporal	O
theta	O
power	O
and	O
increases	O
in	O
MTL	O
BOLD	B-P
activity	O
.	O

This	O
pattern	O
of	O
results	O
suggests	O
a	O
negative	O
relationship	O
between	O
theta	O
power	O
and	O
BOLD	B-P
signal	O
changes	O
in	O
the	O
MTL	O
during	O
memory	O
encoding	O
and	O
spatial	O
processing	O
.	O

The	O
findings	O
extend	O
the	O
well	O
known	O
negative	O
relation	O
of	O
alpha	O
/	O
beta	O
oscillations	O
and	O
BOLD	B-P
signals	O
in	O
the	O
cortex	O
to	O
theta	O
oscillations	O
in	O
the	O
MTL	O
.	O

Clinical	O
value	O
of	O
pathologic	B-P
examination	I-P
of	O
non-neoplastic	O
kidney	O
in	O
patients	O
with	O
upper	O
urinary	O
tract	O
malignancies	O
.	O

While	O
surgical	O
resection	O
remains	O
the	O
standard	O
of	O
care	O
in	O
the	O
treatment	O
of	O
upper	O
urinary	O
tract	O
malignancies	O
,	O
nephrectomy	O
is	O
a	O
risk	O
factor	O
for	O
the	O
development	O
of	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
histologic	O
evaluation	O
of	O
non-neoplastic	O
kidney	O
could	O
enable	O
early	O
identification	O
of	O
unrecognized	O
kidney	O
disease	O
and	O
could	O
be	O
of	O
prognostic	O
value	O
in	O
predicting	O
postoperative	O
renal	O
outcomes	O
.	O

We	O
retrospectively	O
analyzed	O
51	O
patients	O
with	O
upper	O
urinary	O
tract	O
malignancies	O
who	O
received	O
uninephrectomy	O
or	O
uninephroureterectomy	O
.	O

A	O
thorough	O
pathologic	O
evaluation	O
of	O
non-neoplastic	O
kidney	O
including	O
special	O
stains	O
,	O
immunofluorescence	B-P
,	O
and	O
electron	B-P
microscopic	I-P
studies	I-P
was	O
performed	O
.	O

The	O
degree	O
of	O
parenchymal	O
changes	O
was	O
graded	O
from	O
0	O
to	O
15	O
.	O

Of	O
51	O
patients	O
,	O
only	O
13	O
showed	O
normal	O
kidney	O
pathology	O
.	O

Fifteen	O
patients	O
showed	O
glomerular	O
abnormalities	O
,	O
14	O
showed	O
diabetic	O
nephropathy	O
,	O
and	O
11	O
showed	O
vascular	O
nephropathy	O
.	O

There	O
was	O
one	O
case	O
each	O
of	O
reflux	O
nephropathy	O
and	O
chronic	O
pyelonephritis	O
.	O

The	O
median	O
histologic	O
score	O
was	O
5	O
points	O
.	O

Only	O
25.4	O
%	O
of	O
patients	O
had	O
≤	O
3	O
points	O
.	O

Score	O
more	O
than	O
5	O
was	O
observed	O
in	O
47.1	O
%	O
of	O
patients	O
.	O

Postoperative	O
estimated	B-P
glomerular	I-P
filtration	I-P
rate	I-P
(	O
eGFR	B-P
)	O
at	O
3	O
to	O
36	O
months	O
were	O
obtained	O
from	O
90.2	O
%	O
of	O
patients	O
,	O
and	O
of	O
those	O
,	O
34.8	O
%	O
had	O
de	O
novo	O
CKD	O
.	O

Since	O
no	O
one	O
had	O
CKD	O
in	O
partial	O
nephrectomized	O
patients	O
,	O
we	O
determined	O
risk	O
factors	O
for	O
CKD	O
in	O
radical	O
nephrectomized	O
patients	O
.	O

Cox	O
regression	O
analysis	O
revealed	O
that	O
postoperative	O
AKI	O
,	O
preoperative	O
eGFR	B-P
,	O
and	O
histologic	O
score	O
of	O
non-neoplastic	O
kidney	O
were	O
the	O
independent	O
predictors	O
for	O
CKD	O
.	O

We	O
conclude	O
that	O
routine	O
pathologic	O
evaluation	O
of	O
non-neoplastic	O
kidney	O
provides	O
valuable	O
diagnostic	O
and	O
prognostic	O
information	O
.	O

Comparison	O
of	O
sonoelastography	B-P
with	O
sonourethrography	B-P
and	O
retrograde	B-P
urethrography	I-P
in	O
the	O
evaluation	O
of	O
male	O
anterior	O
urethral	O
strictures	O
.	O

Retrograde	B-P
urethrography	I-P
(	O
RUG	B-P
)	O
is	O
the	O
most	O
common	O
and	O
preferred	O
imaging	O
modality	O
for	O
imaging	B-P
of	O
the	O
anterior	O
urethral	O
strictures	O
despite	O
its	O
well-known	O
limitations	O
and	O
disadvantages	O
.	O

Sonourethrography	B-P
(	O
SUG	B-P
)	O
was	O
introduced	O
in	O
1988	O
to	O
overcome	O
the	O
limitations	O
of	O
RUG	B-P
and	O
to	O
provide	O
more	O
accurate	O
results	O
.	O

As	O
proper	O
selection	O
of	O
imaging	O
modality	O
is	O
very	O
important	O
for	O
planning	O
the	O
treatment	O
,	O
various	O
advances	O
in	O
this	O
area	O
are	O
required	O
.	O

One	O
of	O
the	O
major	O
factors	O
for	O
recurrence	O
of	O
stricture	O
disease	O
is	O
spongiofibrosis	O
.	O

Sonoelastography	B-P
(	O
SE	B-P
)	O
is	O
a	O
newer	O
technique	O
,	O
tried	O
in	O
various	O
other	O
pathologies	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
this	O
technique	O
for	O
the	O
first	O
time	O
to	O
assess	O
its	O
efficacy	O
in	O
the	O
evaluation	O
of	O
anterior	O
urethral	O
stricture	O
disease	O
by	O
comparison	O
with	O
RUG	B-P
and	O
SUG	B-P
.	O

Between	O
August	O
2014	O
and	O
May	O
2015	O
,	O
77	O
patients	O
with	O
clinical	O
features	O
of	O
anterior	O
urethral	O
stricture	O
disease	O
were	O
included	O
in	O
the	O
study	O
and	O
evaluated	O
by	O
RUG	B-P
followed	O
by	O
SUG	B-P
and	O
SE	B-P
for	O
stricture	O
location	O
,	O
length	O
,	O
depth	O
of	O
spongiofibrosis	O
and	O
periurethral	O
pathologies	O
.	O

The	O
results	O
were	O
then	O
correlated	O
with	O
operative	O
and	O
histopathological	O
findings	O
.	O

Overall	O
diagnostic	O
accuracy	O
of	O
SE	B-P
,	O
SUG	B-P
,	O
and	O
RGU	B-P
for	O
the	O
estimation	O
of	O
stricture	O
location	O
,	O
and	O
length	O
were	O
estimated	O
92.68	O
%	O
vs.	O
91.54	O
%	O
,	O
79	O
%	O
vs.	O
78.87	O
%	O
and	O
80.48	O
%	O
vs.	O
43.66	O
%	O
,	O
respectively	O
,	O
while	O
for	O
depth	O
of	O
spongiofibrosis	O
SE	B-P
,	O
and	O
SUG	B-P
had	O
accuracy	O
rates	O
of	O
87.3	O
%	O
,	O
48	O
%	O
,	O
respectively	O
.	O

The	O
mean	O
length	O
measured	O
on	O
SE	B-P
was	O
nearest	O
to	O
the	O
mean	O
intra-operative	O
stricture	O
length	O
(	O
21.34+11.8	O
mm	O
)	O
.	O

SE	B-P
findings	O
significantly	O
correlated	O
with	O
the	O
colour	O
of	O
bladder	O
mucosa	O
on	O
cystoscopic	B-P
examination	I-P
(	O
p=0.003	O
)	O
whereas	O
the	O
association	O
was	O
non-significant	O
(	O
p=0.127	O
)	O
for	O
difficulty	O
in	O
incision	O
.	O

While	O
a	O
nonsignificant	O
correlation	O
existed	O
between	O
SUG	B-P
findings	O
related	O
both	O
to	O
the	O
colour	O
of	O
the	O
bladder	O
mucosa	O
and	O
difficulty	O
in	O
incision	O
on	O
cystoscopy	B-P
,	O
SE	B-P
findings	O
had	O
a	O
significant	O
association	O
(	O
p	O
<	O
0.001	O
)	O
with	O
histopathology	O
findings	O
for	O
severe	O
degree	B-P
of	I-P
fibrosis	I-P
.	O

Sonoelastography	B-P
estimates	O
stricture	O
site	O
and	O
length	O
better	O
in	O
comparison	O
with	O
RUG	B-P
and	O
SUG	B-P
.	O

It	O
estimates	O
degree	O
of	O
spongiofibrosis	O
which	O
serves	O
as	O
an	O
important	O
prognostic	O
factor	O
for	O
stricture	O
recurrence	O
more	O
accurately	O
than	O
SUG	B-P
.	O

Immature	O
stages	O
and	O
larval	O
chaetotaxy	O
of	O
Notofairchildia	O
stenygros	O
(	O
Quate	O
&	O
Alexander	O
)	O
(	O
Diptera	O
:	O
Psychodidae	O
:	O
Bruchomyiinae	O
)	O
.	O

Some	O
authors	O
have	O
hypothesized	O
that	O
Bruchomyiinae	O
is	O
``	O
the	O
most	O
plesiomorphic	O
subfamily	O
of	O
Psychodidae	O
``	O
and	O
its	O
members	O
``	O
are	O
among	O
the	O
most	O
primitive	O
living	O
Diptera	O
``	O
.	O

Although	O
Bruchomyiinae	O
is	O
of	O
no	O
medical	O
importance	O
,	O
it	O
is	O
of	O
great	O
evolutionary	O
significance	O
,	O
having	O
long	O
been	O
placed	O
as	O
the	O
sister	O
group	O
of	O
Phlebotominae	O
.	O

In	O
general	O
,	O
species	O
of	O
this	O
subfamily	O
are	O
rarely	O
collected	O
in	O
their	O
natural	O
environment	O
;	O
therefore	O
,	O
adults	O
and	O
,	O
even	O
more	O
so	O
,	O
the	O
immature	O
stages	O
of	O
these	O
flies	O
are	O
poorly	O
known	O
.	O

We	O
describe	O
the	O
egg	O
,	O
larvae	O
and	O
pupae	O
of	O
Notofairchildia	O
stenygros	O
and	O
provide	O
nomenclatural	O
notes	O
on	O
larval	O
chaetotaxy	O
based	O
on	O
analyses	O
using	O
scanning	B-P
electron	I-P
microscopy	I-P
(	O
SEM	B-P
)	O
and	O
optic	B-P
microscopy	I-P
.	O

The	O
morphology	O
of	O
immature	O
Nt	O
.	O

stenygros	O
is	O
compared	O
with	O
other	O
Bruchomyiinae	O
and	O
Psychodidae	O
species	O
,	O
especially	O
with	O
species	O
of	O
Phlebotominae	O
that	O
are	O
superficially	O
similar	O
to	O
Bruchomyiinae	O
.	O

Results	O
of	O
this	O
study	O
revealed	O
striking	O
morphological	O
differences	O
between	O
the	O
immature	O
stages	O
of	O
Bruchomyiinae	O
and	O
Phlebotominae	O
;	O
the	O
former	O
are	O
lacking	O
abdominal	O
pseudopods	O
and	O
microtrichia	O
on	O
the	O
cephalic	O
integument	O
,	O
both	O
of	O
which	O
are	O
present	O
in	O
the	O
larvae	O
of	O
Phlebotominae	O
.	O

These	O
morphological	O
differences	O
observed	O
in	O
the	O
immature	O
stages	O
between	O
members	O
of	O
the	O
two	O
subfamilies	O
support	O
the	O
findings	O
of	O
recent	O
molecular	B-P
studies	I-P
indicating	O
that	O
Bruchomyiinae	O
and	O
Phlebtominae	O
are	O
evolutionarily	O
not	O
closely	O
related	O
.	O

Notofairchildia	O
stenygros	O
is	O
now	O
the	O
fourth	O
species	O
of	O
Bruchomyiinae	O
for	O
which	O
the	O
immature	O
stages	O
are	O
described	O
.	O

Association	O
between	O
OCT	B-P
-based	O
microangiography	B-P
perfusion	O
indices	O
and	O
diabetic	O
retinopathy	O
severity	O
.	O

To	O
evaluate	O
the	O
association	O
between	O
retinal	O
capillary	O
non-perfusion	O
and	O
diabetic	O
retinopathy	O
(	O
DR	O
)	O
severity	O
using	O
optical	B-P
coherence	I-P
tomography-based	I-P
microangiography	I-P
(	O
OMAG	B-P
)	O
.	O

33	O
patients	O
(	O
51	O
eyes	O
)	O
with	O
a	O
history	O
of	O
diabetes	O
underwent	O
imaging	B-P
with	O
a	O
68	O
kHz	O
Cirrus-5000	O
spectral	O
domain	O
OMAG	O
prototype	O
.	O

Demographic	O
and	O
clinical	O
characteristics	O
were	O
collected	O
.	O

The	O
perfusion	O
index	O
(	O
PI	O
)	O
was	O
defined	O
as	O
per	O
cent	O
coverage	O
of	O
area	O
by	O
retinal	O
vessels	O
with	O
flow	O
,	O
measured	O
within	O
a	O
minimum	O
of	O
6.8×6.8	O
mm	O
(	O
2	O
)	O
OMAG	B-P
scan	I-P
.	O

The	O
PI	O
in	O
each	O
ETDRS	O
zone	O
was	O
analysed	O
using	O
an	O
automated	O
algorithm	O
.	O

Univariate	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
determine	O
the	O
degree	O
of	O
association	O
between	O
PI	O
and	O
DR	O
severity	O
.	O

51	O
eyes	O
with	O
different	O
DR	O
severities	O
were	O
imaged	B-P
.	O

More	O
severe	O
DR	O
was	O
significantly	O
associated	O
with	O
lower	O
PI	O
after	O
adjusting	O
for	O
logarithm	O
of	O
the	O
minimum	O
angle	O
of	O
resolution	O
best-corrected	O
visual	O
acuity	O
,	O
hyperlipidaemia	O
,	O
diabetes	O
type	O
and	O
ETDRS	O
ring	O
in	O
a	O
multivariate	O
mixed	O
linear	O
model	O
.	O

Compared	O
with	O
the	O
none-	O
mild	O
non-proliferative	O
diabetic	O
retinopathy	O
(	O
NPDR	O
)	O
group	O
,	O
the	O
moderate-severe	O
NPDR	O
group	O
had	O
2.7	O
lower	O
PI	O
(	O
p=0.03	O
)	O
and	O
proliferative	O
DR	O
group	O
had	O
4.3	O
lower	O
PI	O
(	O
p=0.003	O
)	O
.	O

All	O
ETDRS	O
zones	O
except	O
for	O
the	O
foveal	O
centre	O
showed	O
inverse	O
associations	O
between	O
PI	O
and	O
DR	O
severity	O
(	O
p	O
values	O
<	O
0.001	O
to	O
0.862	O
)	O
.	O

A	O
statistically	O
significant	O
inverse	O
association	O
exists	O
between	O
PI	O
and	O
DR	O
severity	O
.	O

Our	O
study	O
suggests	O
that	O
PI	O
may	O
become	O
a	O
useful	O
biomarker	O
in	O
evaluating	O
and	O
following	O
the	O
progression	O
of	O
DR	O
.	O

Protocol	O
for	O
intraoperative	O
assessment	O
of	O
the	O
human	O
cerebrovascular	O
glycocalyx	O
.	O

Adequate	O
functioning	O
of	O
the	O
blood-brain	O
barrier	O
(	O
BBB	O
)	O
is	O
important	O
for	O
brain	O
homoeostasis	O
and	O
normal	O
neuronal	O
function	O
.	O

Disruption	O
of	O
the	O
BBB	O
has	O
been	O
described	O
in	O
several	O
neurological	O
diseases	O
.	O

Recent	O
reports	O
suggest	O
that	O
an	O
increased	O
permeability	O
of	O
the	O
BBB	O
also	O
contributes	O
to	O
increased	O
seizure	O
susceptibility	O
in	O
patients	O
with	O
epilepsy	O
.	O

The	O
endothelial	O
glycocalyx	O
is	O
coating	O
the	O
luminal	O
side	O
of	O
the	O
endothelium	O
and	O
can	O
be	O
considered	O
as	O
the	O
first	O
barrier	O
of	O
the	O
BBB	O
.	O

We	O
hypothesise	O
that	O
an	O
altered	O
glycocalyx	O
thickness	O
plays	O
a	O
role	O
in	O
the	O
aetiology	O
of	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
,	O
the	O
most	O
common	O
type	O
of	O
epilepsy	O
.	O

Here	O
,	O
we	O
propose	O
a	O
protocol	O
that	O
allows	O
intraoperative	O
assessment	O
of	O
the	O
cerebrovascular	O
glycocalyx	O
thickness	O
in	O
patients	O
with	O
TLE	O
and	O
assess	O
whether	O
its	O
thickness	O
is	O
decreased	O
in	O
patients	O
with	O
TLE	O
when	O
compared	O
with	O
controls	O
.	O

This	O
protocol	O
is	O
designed	O
as	O
a	O
prospective	O
observational	O
case-control	O
study	O
in	O
patients	O
who	O
undergo	O
resective	O
brain	O
surgery	O
as	O
treatment	O
for	O
TLE	O
.	O

Control	O
subjects	O
are	O
patients	O
without	O
a	O
history	O
of	O
epileptic	O
seizures	O
,	O
who	O
undergo	O
a	O
craniotomy	O
or	O
burr	O
hole	O
surgery	O
for	O
other	O
indications	O
.	O

Intraoperative	O
glycocalyx	O
thickness	O
measurements	O
of	O
sublingual	O
,	O
cortical	O
and	O
hippocampal	O
microcirculation	O
are	O
performed	O
by	O
video	B-P
microscopy	I-P
using	O
sidestream	B-P
dark-field	I-P
imaging	I-P
.	O

Demographic	O
details	O
,	O
seizure	O
characteristics	O
,	O
epilepsy	O
risk	O
factors	O
,	O
intraoperative	O
haemodynamic	O
parameters	O
and	O
histopathological	O
evaluation	O
are	O
additionally	O
recorded	O
.	O

This	O
protocol	O
has	O
been	O
ethically	O
approved	O
by	O
the	O
local	O
medical	O
ethical	O
committee	O
(	O
ID	O
:	O
NL51594.068.14	O
)	O
and	O
complies	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
principles	O
of	O
Good	O
Clinical	O
Practice	O
.	O

Informed	O
consent	O
is	O
obtained	O
before	O
study	O
enrolment	O
and	O
only	O
coded	O
data	O
will	O
be	O
stored	O
in	O
a	O
secured	O
database	O
,	O
enabling	O
an	O
audit	O
trail	O
.	O

Results	O
will	O
be	O
submitted	O
to	O
international	O
peer-reviewed	O
journals	O
and	O
presented	O
at	O
international	O
conferences	O
.	O

NTR5568	O
.	O

Role	O
of	O
Intestinal	O
LXRα	O
in	O
Regulating	O
Post-prandial	O
Lipid	O
Excursion	O
and	O
Diet	O
-	O
Induced	O
Hypercholesterolemia	O
and	O
Hepatic	O
Lipid	O
Accumulation	O
.	O

Post-prandial	O
hyperlipidemia	O
has	O
emerged	O
as	O
a	O
cardiovascular	O
risk	O
factor	O
with	O
limited	O
therapeutic	O
options	O
.	O

The	O
Liver	O
X	O
receptors	O
(	O
Lxrs	O
)	O
are	O
nuclear	O
hormone	O
receptors	O
that	O
regulate	O
cholesterol	O
elimination	O
.	O

Knowledge	O
of	O
their	O
role	O
in	O
regulating	O
the	O
absorption	O
and	O
handling	O
of	O
dietary	O
fats	O
is	O
incomplete	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
intestinal	O
Lxrα	O
in	O
post-prandial	O
intestinal	O
lipid	O
transport	O
.	O

Using	O
Lxrα	O
knockout	O
(	O
nr1h3	O
(	O
-/-	O
)	O
)	O
and	O
intestine	O
-	O
limited	O
Lxrα	O
over-expressing	O
[	O
Tg	O
(	O
fabp2a	O
:	O
EGFP	O
-	O
nr1h3	O
)	O
]	O
zebrafish	O
strains	O
,	O
we	O
measured	O
post-prandial	O
lipid	O
excursion	O
with	O
live	B-P
imaging	I-P
in	O
larvae	O
and	O
physiological	O
methods	O
in	O
adults	O
.	O

We	O
also	O
conducted	O
a	O
long-term	O
high	O
-	O
cholesterol	O
dietary	O
challenge	O
in	O
adults	O
to	O
examine	O
the	O
chronic	O
effect	O
of	O
modulating	O
nr1h3	O
gene	O
dose	O
on	O
the	O
development	O
of	O
hypercholesterolemia	O
and	O
hepatic	O
lipid	O
accumulation	O
.	O

Over-expression	O
of	O
Lxrα	O
in	O
the	O
intestine	O
delays	O
the	O
transport	O
of	O
ingested	O
lipids	O
in	O
larvae	O
,	O
while	O
deletion	O
of	O
Lxrα	O
increases	O
the	O
rate	O
of	O
lipid	O
transport	O
.	O

Pre-treating	O
wildtype	O
larvae	O
with	O
the	O
liver-sparing	O
Lxr	O
agonist	O
hyodeoxycholic	O
acid	O
also	O
delayed	O
the	O
rate	O
of	O
intestinal	O
lipid	O
transport	O
in	O
larvae	O
.	O

In	O
adult	O
males	O
,	O
deletion	O
of	O
Lxrα	O
accelerates	O
intestinal	O
transport	O
of	O
ingested	O
lipids	O
.	O

Adult	O
females	O
showed	O
higher	O
plasma	O
Lipoprotein	O
lipase	O
(	O
Lpl	O
)	O
activity	O
compared	O
to	O
males	O
,	O
and	O
lower	O
post-gavage	O
blood	O
triacylglycerol	O
(	O
TAG	O
)	O
excursion	O
.	O

Despite	O
the	O
sexually	O
dimorphic	O
effect	O
on	O
acute	O
intestinal	O
lipid	O
handling	O
,	O
Tg	O
(	O
fabp2a	O
:	O
EGFP	O
-	O
nr1h3	O
)	O
adults	O
of	O
both	O
sexes	O
are	O
protected	O
from	O
high	O
cholesterol	O
diet	O
(	O
HCD	O
)	O
-	O
induced	O
hepatic	O
lipid	O
accumulation	O
,	O
while	O
nr1h3	O
(	O
-/-	O
)	O
mutants	O
are	O
sensitive	O
to	O
the	O
effects	O
of	O
HCD	O
challenge	O
.	O

These	O
data	O
indicate	O
that	O
intestinal	O
Lxr	O
activity	O
dampens	O
the	O
pace	O
of	O
intestinal	O
lipid	O
transport	O
cell-autonomously	O
.	O

Selective	O
activation	O
of	O
intestinal	O
Lxrα	O
holds	O
therapeutic	O
promise	O
.	O

Experimental	O
study	O
of	O
GeneXpert	O
(	O
®	O
)	O
system	O
in	O
the	O
diagnosis	O
of	O
extra-pulmonary	O
tuberculosis	O
.	O

To	O
explore	O
the	O
application	O
value	O
of	O
GeneXpert	B-P
MTB/RIF	I-P
for	O
detection	O
of	O
extra-pulmonary	O
tuberculosis	O
and	O
resistance	O
to	O
rifampin	O
.	O

A	O
total	O
of	O
150	O
samples	O
were	O
collected	O
,	O
including	O
33	O
needle	O
aspirates	O
from	O
lymphoid	O
tuberculosis	O
,	O
23	O
needle	O
aspirates	O
from	O
spinal	O
tuberculosis	O
,	O
49	O
from	O
tuberculous	O
pleural	O
effusions	O
,	O
24	O
from	O
cerebrospinal	O
fluid	O
of	O
tuberculous	O
cephalomeningitis	O
,	O
and	O
21	O
urinary	O
sediment	O
samples	O
from	O
renal	O
tuberculosis	O
.	O

Smear	B-P
microscopy	I-P
,	O
mycobacterium	B-P
tuberculosis	I-P
culture	I-P
and	O
the	O
MTB/RIF	B-P
method	I-P
were	O
used	O
to	O
examine	O
these	O
samples	O
and	O
their	O
positive	O
rates	O
were	O
compared	O
.	O

Rifampin	B-P
susceptibility	I-P
tests	I-P
was	O
performed	O
for	O
culture-positive	O
strains	O
using	O
proportion	O
method	O
,	O
which	O
was	O
compared	O
with	O
the	O
result	O
from	O
GeneXpert	B-P
MTB/RIF	I-P
method	I-P
.	O

Of	O
the	O
150	O
cases	O
of	O
extra-pulmonary	O
tuberculosis	O
,	O
17	O
samples	O
were	O
smear-positive	O
,	O
with	O
a	O
sensitivity	O
of	O
11.3	O
%	O
(	O
17/150	O
)	O
;	O
30	O
were	O
culture-positive	O
with	O
a	O
sensitivity	O
of	O
20.0	O
%	O
(	O
30/150	O
)	O
;	O
and	O
96	O
were	O
positive	O
by	O
MTB/RIF	B-P
method	I-P
with	O
a	O
sensitivity	O
of	O
64.0	O
%	O
(	O
96/150	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
MTB/RIF	B-P
method	I-P
and	O
the	O
culture	B-P
method	I-P
(	O
χ	O
(	O
2	O
)	O
=59.61	O
,	O
P	O
<	O
0.01	O
)	O
.	O

The	O
differences	O
were	O
also	O
significant	O
when	O
the	O
MTB/RIF	B-P
method	I-P
was	O
compared	O
with	O
the	O
smear	B-P
method	I-P
(	O
χ	O
(	O
2	O
)	O
=88.60	O
,	O
P	O
<	O
0.01	O
)	O
or	O
compared	O
with	O
culture	B-P
plus	I-P
smear	I-P
methods	I-P
(	O
χ	O
(	O
2	O
)	O
=4.26	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Separately	O
,	O
the	O
differences	O
were	O
statistically	O
significant	O
between	O
GeneXpert	B-P
MTB/RIF	I-P
method	I-P
and	O
other	O
2	O
methods	B-P
for	O
diagnosis	O
of	O
lymphoid	O
tuberculosis	O
(	O
n=33	O
,	O
χ	O
(	O
2	O
)	O
=20.56	O
,	O
P	O
<	O
0.01	O
vs.	O
culture	B-P
method	I-P
;	O
χ	O
(	O
2	O
)	O
=27.13	O
,	O
P	O
<	O
0.01	O
vs.	O
smear	O
results	O
)	O
while	O
no	O
difference	O
was	O
found	O
between	O
culture	B-P
and	O
smear	B-P
method	I-P
(	O
χ	O
(	O
2	O
)	O
=0.67	O
,	O
P	O
>	O
0.05	O
)	O
,	O
spinal	O
tuberculosis	O
(	O
n=23	O
,	O
χ	O
(	O
2	O
)	O
=12.74	O
,	O
P	O
<	O
0.01	O
vs.	O
culture	B-P
method	I-P
;	O
χ	O
(	O
2	O
)	O
=14.81	O
,	O
P	O
<	O
0.01	O
vs.	O
smear	B-P
method	I-P
)	O
,	O
tuberculous	O
pleurisy	O
(	O
n=49	O
,	O
χ	O
(	O
2	O
)	O
=32.34	O
,	O
P	O
<	O
0.01	O
vs.	O
culture	B-P
method	I-P
;	O
χ	O
(	O
2	O
)	O
=49.69	O
,	O
P	O
<	O
0.01	O
vs.	O
smear	B-P
method	I-P
)	O
and	O
renal	O
tuberculosis	O
(	O
n=21	O
,	O
χ	O
(	O
2	O
)	O
=4.20	O
,	O
P	O
<	O
0.05	O
vs.	O
culture	B-P
method	I-P
;	O
χ	O
(	O
2	O
)	O
=8.40	O
,	O
P	O
<	O
0.01	O
vs.	O
smear	O
results	O
)	O
.	O

The	O
sensitivity	O
for	O
tuberculous	O
meningitis	O
had	O
no	O
difference	O
among	O
these	O
3	O
methods	B-P
(	O
n=24	O
,	O
P	O
>	O
0.05	O
)	O
.	O

Rifampicin-resistance	O
of	O
the	O
strains	O
from	O
the	O
30	O
culture-positive	O
cases	O
of	O
extra-pulmonary	O
tuberculosis	O
(	O
20.0	O
%	O
,	O
6/30	O
)	O
exhibited	O
agreement	O
with	O
GeneXpert	B-P
MTB/RIF	I-P
test	I-P
.	O

The	O
simplicity	O
and	O
high	O
sensitivity	O
of	O
GeneXpert	B-P
MTB/RIF	I-P
technology	I-P
make	O
it	O
a	O
good	O
diagnostic	B-P
test	I-P
for	O
rapid	O
detection	O
of	O
extra-pulmonary	O
tuberculosis	O
and	O
resistance	O
to	O
rifampin	O
.	O

Strategies	O
for	O
Assaying	B-P
Lysosomal	O
Membrane	O
Permeabilization	O
.	O

Late	O
endosomal	O
organelles	O
have	O
an	O
acidic	O
pH	O
and	O
contain	O
hydrolytic	O
enzymes	O
to	O
degrade	O
cargo	O
delivered	O
either	O
from	O
the	O
extracellular	O
environment	O
by	O
endocytosis	O
or	O
from	O
within	O
the	O
cell	O
itself	O
by	O
autophagy	O
.	O

In	O
the	O
event	O
of	O
lysosomal	O
membrane	O
permeabilization	O
(	O
LMP	O
)	O
,	O
the	O
contents	O
of	O
late	O
endosomes	O
and	O
lysosomes	O
can	O
be	O
released	O
into	O
the	O
cytosol	O
and	O
then	O
initiate	O
apoptosis	O
.	O

Compounds	O
that	O
can	O
trigger	O
LMP	O
are	O
therefore	O
candidates	O
for	O
the	O
induction	O
of	O
apoptosis	O
,	O
in	O
particular	O
in	O
anticancer	O
therapy	O
.	O

Alternatively	O
,	O
drug-delivery	O
systems	O
,	O
such	O
as	O
nanoparticles	O
,	O
can	O
have	O
side	O
effects	O
that	O
can	O
include	O
LMP	O
,	O
which	O
has	O
toxic	O
consequences	O
for	O
the	O
cells	O
.	O

To	O
determine	O
when	O
,	O
to	O
what	O
extent	O
,	O
and	O
with	O
what	O
consequences	O
LMP	O
occurs	O
is	O
therefore	O
of	O
paramount	O
importance	O
for	O
the	O
evaluation	O
of	O
new	O
potentially	O
LMP	O
-	O
inducing	O
compounds	O
.	O

In	O
this	O
introduction	O
,	O
we	O
provide	O
an	O
overview	O
of	O
some	O
basic	B-P
assays	I-P
for	O
assessing	O
LMP	O
,	O
such	O
as	O
staining	O
with	O
lysosomotropic	O
dyes	O
and	O
measurement	O
of	O
cysteine	O
cathepsin	O
activity	O
,	O
and	O
discuss	O
additional	O
strategies	O
for	O
the	O
detection	O
of	O
the	O
release	O
of	O
endogenous	O
lysosomal	O
molecules	O
or	O
preloaded	O
exogenous	O
tracers	O
into	O
the	O
cytosol	O
.	O

Psychological	O
Distress	O
Is	O
More	O
Prevalent	O
in	O
Fertile	O
Age	O
and	O
Premenopausal	O
Women	O
with	O
PCOS	O
Symptoms	O
-15-yr	O
Follow-up	O
.	O

Polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
is	O
associated	O
with	O
increased	O
psychological	O
distress	O
;	O
obesity	O
and	O
hyperandrogenism	O
being	O
suggested	O
as	O
key	O
promoters	O
.	O

To	O
investigate	O
the	O
prevalence	O
of	O
anxiety	O
/	O
depression	O
and	O
their	O
coexistence	O
in	O
women	O
with	O
PCOS	O
/	O
PCOS	O
symptoms	O
at	O
age	O
s	O
31	O
and	O
46	O
.	O

The	O
roles	O
of	O
obesity	O
,	O
hyperandrogenism	O
and	O
awareness	O
of	O
PCOS	O
on	O
psychological	O
distress	O
were	O
also	O
assessed	O
.	O

Population	O
based	O
follow-up	O
.	O

Northern	O
Finland	O
Birth	O
Cohort	O
1966	O
with	O
15-	O
year	O
follow-up	O
.	O

At	O
age	O
31	O
a	O
questionnaire-based	O
screening	O
for	O
oligoamenorrhea	O
(	O
OA	O
)	O
and	O
hirsutism	O
(	O
H	O
)	O
:	O
2188	O
asymptomatic	O
(	O
controls	O
)	O
,	O
331	O
OA	O
,	O
323	O
H	O
,	O
125	O
OA	O
+	O
H	O
(	O
PCOS	O
)	O
.	O

46	O
year	O
old	O
follow-up	O
:	O
1576	O
controls	O
,	O
239	O
OA	O
,	O
231	O
H	O
and	O
85	O
PCOS	O
.	O

Questionnaire-based	O
screening	O
for	O
anxiety	O
and	O
depression	O
symptoms	O
(	O
Hopkins	O
Symptom	O
Checklist-25	O
)	O
and	O
previously	O
diagnosed	O
/	O
treated	O
depression	O
at	O
age	O
31	O
and	O
46	O
.	O

BMI	O
,	O
serum	B-P
testosterone	I-P
/	O
free	B-P
androgen	I-P
index	I-P
(	O
FAI	B-P
)	O
and	O
awareness	O
of	O
polycystic	O
ovaries	O
/	O
PCOS	O
on	O
psychological	O
distress	O
were	O
also	O
assessed	O
.	O

Population-based	O
prevalence	O
of	O
anxiety	O
and/or	O
depression	O
in	O
women	O
with	O
PCOS	O
/	O
PCOS	O
symptoms	O
at	O
age	O
s	O
31	O
and	O
46	O
.	O

Anxiety	O
and/or	O
depression	O
symptoms	O
,	O
their	O
coexistence	O
and	O
rate	O
of	O
depression	O
were	O
increased	O
at	O
age	O
31	O
and	O
46	O
in	O
women	O
with	O
PCOS	O
or	O
isolated	O
H	O
compared	O
with	O
controls	O
.	O

High	O
BMI	O
or	O
hyperandrogenism	O
did	O
not	O
associate	O
with	O
increased	O
anxiety	O
or	O
depression	O
symptoms	O
.	O

The	O
awareness	O
of	O
PCOS	O
was	O
associated	O
with	O
increased	O
anxiety	O
.	O

Women	O
with	O
PCOS	O
or	O
isolated	O
H	O
present	O
more	O
often	O
with	O
anxiety	O
and/or	O
depression	O
symptoms	O
and	O
their	O
coexistence	O
compared	O
with	O
controls	O
.	O

High	O
BMI	O
or	O
hyperandrogenism	O
did	O
not	O
provoke	O
psychological	O
distress	O
in	O
PCOS	O
.	O

The	O
awareness	O
of	O
PCOS	O
increased	O
anxiety	O
but	O
did	O
not	O
associate	O
with	O
severe	O
anxiety	O
or	O
depression	O
.	O

Targeting	O
brain	O
and	O
peripheral	O
plasticity	O
of	O
the	O
lipidome	O
in	O
acute	O
kainic	O
acid	O
-	O
induced	O
epileptic	O
seizures	O
in	O
mice	O
via	O
quantitative	B-P
mass	I-P
spectrometry	I-P
.	O

Epilepsy	O
is	O
a	O
highly	O
common	O
chronic	O
neurological	O
disorder	O
,	O
manifested	O
in	O
many	O
different	O
types	O
,	O
affecting	O
~1	O
%	O
of	O
the	O
worldwide	O
human	O
population	O
.	O

The	O
molecular	O
mechanisms	O
of	O
epileptogenesis	O
have	O
not	O
yet	O
been	O
clarified	O
,	O
and	O
pharmacoresistance	O
exhibited	O
by	O
30-40	O
%	O
of	O
epilepsy	O
patients	O
remains	O
a	O
major	O
obstacle	O
in	O
medical	O
care	O
.	O

Growing	O
evidence	O
indicates	O
a	O
role	O
of	O
lipid	O
signalling	O
pathways	O
in	O
epileptogenesis	O
,	O
thus	O
lipid	O
signals	O
emerge	O
as	O
potential	O
biomarkers	O
for	O
the	O
onset	O
and	O
evolving	O
course	O
of	O
the	O
epileptic	O
disorder	O
,	O
as	O
well	O
as	O
potential	O
therapeutic	O
agents	O
and	O
targets	O
.	O

For	O
this	O
purpose	O
,	O
we	O
applied	O
a	O
lipidomic	O
strategy	O
to	O
unravel	O
lipid	O
alterations	O
in	O
brain	O
regions	O
,	O
periphery	O
tissues	O
and	O
plasma	O
that	O
are	O
specific	O
for	O
acute	O
epileptic	O
seizures	O
in	O
mice	O
at	O
1h	O
after	O
seizure	O
induction	O
by	O
systemic	O
kainic	O
acid	O
injection	O
as	O
compared	O
to	O
vehicle	O
controls	O
.	O

Specifically	O
,	O
levels	O
of	O
(	O
i	O
)	O
selected	O
phospholipids	O
and	O
sphingomyelins	O
,	O
(	O
ii	O
)	O
the	O
endocannabinoids	O
anandamide	O
(	O
AEA	O
)	O
and	O
2-arachidonoyl	O
glycerol	O
(	O
2-AG	O
)	O
,	O
and	O
the	O
endocannabinoid	O
-related	O
compounds	O
oleoylethanolamide	O
(	O
OEA	O
)	O
and	O
palmitoylethanolamide	O
(	O
PEA	O
)	O
,	O
(	O
iii	O
)	O
arachidonic	O
acid	O
(	O
AA	O
)	O
,	O
(	O
iv	O
)	O
selected	O
eicosanoids	O
,	O
and	O
(	O
v	O
)	O
fatty	O
acyl	O
content	O
of	O
lipidome	O
were	O
determined	O
in	O
pulverized	O
tissues	O
from	O
six	O
brain	O
regions	O
of	O
kainic	O
acid	O
induced	O
epileptic	O
seizure	O
models	O
and	O
vehicle	O
controls	O
:	O
hypothalamus	O
,	O
hippocampus	O
,	O
thalamus	O
,	O
striatum	O
,	O
cerebellum	O
and	O
cerebral	O
cortex	O
,	O
and	O
from	O
peripheral	O
organs	O
,	O
such	O
as	O
heart	O
and	O
lungs	O
,	O
and	O
in	O
plasma	O
.	O

Alterations	O
in	O
lipid	O
levels	O
after	O
acute	O
epileptic	O
seizures	O
as	O
compared	O
to	O
non-seizure	O
controls	O
were	O
found	O
to	O
be	O
brain	O
region	O
-	O
and	O
periphery	O
tissue	O
-	O
specific	O
,	O
including	O
specific	O
plasma	O
lipid	O
correlates	O
,	O
highlighting	O
their	O
value	O
as	O
marker	O
candidates	O
in	O
translational	O
research	O
studies	O
,	O
and/or	O
drug	O
discovery	O
and	O
response	O
monitoring	O
.	O

Distinct	O
Abnormalities	O
of	O
Small	O
Bowel	O
and	O
Regional	O
Colonic	O
Volumes	O
in	O
Subtypes	O
of	O
Irritable	O
Bowel	O
Syndrome	O
Revealed	O
by	O
MRI	B-P
.	O

Non-invasive	O
biomarkers	O
which	O
identify	O
different	O
mechanisms	O
of	O
disease	O
in	O
subgroups	O
of	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
could	O
be	O
valuable	O
.	O

Our	O
aim	O
was	O
to	O
seek	O
useful	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
parameters	O
that	O
could	O
distinguish	O
each	O
IBS	O
subtypes	O
.	O

34	O
healthy	O
volunteers	O
(	O
HV	O
)	O
,	O
30	O
IBS	O
with	O
diarrhea	O
(	O
IBS-D	O
)	O
,	O
16	O
IBS	O
with	O
constipation	O
(	O
IBS-C	O
)	O
,	O
and	O
11	O
IBS	O
with	O
mixed	O
bowel	O
habit	O
(	O
IBS-M	O
)	O
underwent	O
whole-gut	O
transit	O
and	O
small	O
and	O
large	O
bowel	O
volumes	O
assessment	O
with	O
MRI	B-P
scans	B-P
from	O
t=0	O
to	O
t=360	O
min	O
.	O

Since	O
the	O
bowel	O
frequency	O
for	O
IBS-M	O
were	O
similar	O
to	O
IBS-D	O
,	O
IBS-M	O
and	O
IBS-D	O
were	O
grouped	O
together	O
and	O
labeled	O
as	O
IBS	O
non-constipation	O
group	O
(	O
IBS-nonC	O
)	O
.	O

Median	O
(	O
interquartile	O
range	O
)	O
:	O
fasting	O
small	O
bowel	O
water	O
content	O
in	O
IBS-nonC	O
was	O
21	O
(	O
10-42	O
)	O
,	O
significantly	O
less	O
than	O
HV	O
at	O
44	O
ml	O
(	O
15-70	O
)	O
,	O
P	O
<	O
0.01	O
as	O
was	O
the	O
postprandial	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
P	O
<	O
0.01	O
.	O

The	O
fasting	O
transverse	O
colon	O
volumes	O
in	O
IBS-C	O
were	O
significantly	O
larger	O
at	O
253	O
(	O
200-329	O
)	O
compared	O
with	O
HV	O
,	O
IBS-nonC	O
whose	O
values	O
were	O
165	O
(	O
117-255	O
)	O
and	O
198	O
(	O
106-270	O
)	O
ml	O
,	O
respectively	O
,	O
P=0.02	O
.	O

Whole-gut	O
transit	O
time	O
for	O
IBS-C	O
was	O
prolonged	O
at	O
69	O
(	O
51-111	O
)	O
,	O
compared	O
with	O
HV	O
at	O
34	O
(	O
4-63	O
)	O
and	O
IBS-D	O
at	O
34	O
(	O
17-78	O
)	O
h	O
,	O
P=0.03	O
.	O

Bloating	O
score	O
(	O
VAS	O
0-10	O
cm	O
)	O
correlated	O
with	O
transverse	O
colon	O
volume	O
at	O
t=405	O
min	O
,	O
Spearman	O
r=0.21	O
,	O
P=0.04	O
.	O

The	O
constricted	O
small	O
bowel	O
in	O
IBS-nonC	O
and	O
the	O
dilated	O
transverse	O
colon	O
in	O
IBS-C	O
point	O
to	O
significant	O
differences	O
in	O
underlying	O
mechanisms	O
of	O
disease	O
.	O

Morphology	O
,	O
Ultrastructure	O
and	O
Possible	O
Functions	O
of	O
Antennal	O
Sensilla	O
of	O
Sitodiplosis	O
mosellana	O
Géhin	O
(	O
Diptera	O
:	O
Cecidomyiidae	O
)	O
.	O

To	O
better	O
understand	O
the	O
olfactory	O
receptive	O
mechanisms	O
involved	O
in	O
host	O
selection	O
and	O
courtship	O
behavior	O
of	O
Sitodiplosis	O
mosellana	O
(	O
Diptera	O
:	O
Cecidomyiidae	O
)	O
,	O
one	O
of	O
the	O
most	O
important	O
pests	O
of	O
wheat	O
,	O
scanning	B-P
and	O
transmission	B-P
electron	I-P
microscopy	I-P
were	O
used	O
to	O
examine	O
the	O
external	O
morphology	O
and	O
ultrastructure	O
of	O
the	O
antennal	O
sensilla	O
.	O

The	O
moniliform	O
antennae	O
exhibit	O
obvious	O
sexual	O
dimorphism	O
:	O
antennae	O
of	O
the	O
males	O
are	O
markedly	O
longer	O
than	O
those	O
of	O
the	O
females	O
.	O

Furthermore	O
,	O
each	O
male	O
flagellomere	O
consists	O
of	O
two	O
globular	O
nodes	O
,	O
whereas	O
each	O
female	O
flagellomere	O
is	O
cylindrical	O
.	O

Seven	O
types	O
of	O
sensilla	O
were	O
identified	O
in	O
both	O
sexes	O
.	O

Two	O
types	O
of	O
s.	O
chaetica	O
have	O
a	O
lumen	O
without	O
dendrites	O
and	O
thick	O
walls	O
,	O
suggesting	O
that	O
they	O
are	O
mechanoreceptors	O
.	O

S.	O
trichodea	O
and	O
s.	O
circumfila	O
are	O
typical	O
chemoreceptors	O
,	O
possessing	O
thin	O
multiporous	O
walls	O
encircling	O
a	O
lumen	O
with	O
multiple	O
dendrites	O
.	O

There	O
are	O
significantly	O
more	O
s.	O
trichodea	O
in	O
female	O
than	O
in	O
male	O
,	O
which	O
may	O
be	O
related	O
to	O
host	O
plant	O
localization	O
.	O

In	O
contrast	O
,	O
male	O
s.	O
circumfila	O
are	O
highly	O
elongated	O
compared	O
to	O
those	O
of	O
females	O
,	O
perhaps	O
for	O
pheromone	O
detection	O
.	O

Peg-shaped	O
s.	O
coeloconica	O
are	O
innervated	O
with	O
unbranched	O
dendrites	O
extending	O
from	O
the	O
base	O
to	O
the	O
distal	O
tip	O
.	O

Type	O
1	O
s.	O
coeloconica	O
,	O
which	O
have	O
deep	O
longitudinal	O
grooves	O
and	O
finger	O
-like	O
projections	O
on	O
the	O
surface	O
,	O
may	O
serve	O
as	O
olfactory	O
or	O
humidity	O
receptors	O
,	O
whereas	O
type	O
2	O
s.	O
coeloconica	O
,	O
smooth	O
with	O
a	O
terminal	O
pore	O
,	O
may	O
be	O
contact	O
chemoreceptors	O
.	O

Also	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
Böhm	O
'	O
bristles	O
at	O
proximal	O
scape	O
on	O
antennae	O
of	O
Cecidomyiid	O
species	O
potentially	O
functioning	O
as	O
mechanoreceptors	O
.	O

Psychological	O
Stress	O
in	O
Pathogenesis	O
of	O
Essential	O
Hypertension	O
.	O

The	O
article	O
represents	O
literature	O
review	O
and	O
provides	O
evidence	O
for	O
psychological	O
stress	O
to	O
play	O
essential	O
role	O
in	O
the	O
development	O
of	O
arterial	O
hypertension	O
.	O

The	O
pathogenesis	O
of	O
hypertension	O
is	O
complex	O
with	O
a	O
significant	O
diversity	O
and	O
variability	O
of	O
the	O
mechanisms	O
involved	O
in	O
individual	O
patient	O
.	O

In	O
this	O
regard	O
,	O
the	O
determination	B-P
of	O
specific	O
pathogenic	O
pathways	O
underlying	O
sustained	O
blood	O
pressure	O
elevation	O
in	O
each	O
patient	O
would	O
substantially	O
individualize	O
therapeutic	O
approaches	O
,	O
and	O
hence	O
increase	O
the	O
effectiveness	O
of	O
treatment	O
.	O

Psychological	O
stress	O
is	O
proposed	O
as	O
a	O
significant	O
factor	O
contributing	O
to	O
the	O
development	O
of	O
hypertension	O
.	O

Global	O
urbanization	O
,	O
sedentary	O
lifestyle	O
,	O
daily	O
stress	O
at	O
workplace	O
,	O
lack	O
of	O
physical	O
activity	O
and	O
social	O
support	O
lead	O
to	O
increased	O
anxiety	O
,	O
uncertainty	O
,	O
and	O
finally	O
to	O
chronic	O
mental	O
and	O
emotional	O
stress	O
.	O

This	O
review	O
provides	O
information	O
about	O
alterations	O
in	O
neuroendocrine	O
and	O
immune	O
systems	O
as	O
the	O
main	O
pathogenic	O
pathways	O
linking	O
psychological	O
stress	O
and	O
hypertension	O
.	O

Endothelial	O
dysfunction	O
is	O
considered	O
not	O
only	O
as	O
a	O
consequence	O
but	O
also	O
a	O
primary	O
factor	O
causing	O
prohypertensive	O
state	O
.	O

Moreover	O
,	O
physical	O
inactivity	O
is	O
discussed	O
as	O
one	O
of	O
the	O
plausible	O
mechanisms	O
playing	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
hypertension	O
in	O
modern	O
lifestyle	O
conditions	O
.	O

Particularly	O
the	O
loss	O
of	O
connection	O
between	O
psychosocial	O
strain	O
and	O
physical	O
activity	O
may	O
underlie	O
the	O
deleterious	O
effect	O
of	O
stress	O
on	O
cardiovascular	O
and	O
metabolic	O
health	O
.	O

The	O
Prevalence	O
and	O
Clinical	O
Relevance	O
of	O
ASA	O
Nonresponse	O
After	O
Cardiac	O
Surgery	O
.	O

We	O
aimed	O
to	O
identify	O
the	O
prevalence	O
of	O
acetylsalicylic	O
acid	O
(	O
ASA	O
)	O
nonresponse	O
in	O
patients	O
after	O
coronary	O
artery	O
bypass	O
graft	O
(	O
CABG	O
)	O
surgery	O
and	O
the	O
possible	O
consequences	O
for	O
the	O
rate	O
of	O
major	O
cardiovascular	O
events	O
.	O

This	O
prospective	O
,	O
observational	O
,	O
bicentric	O
cohort	O
study	O
was	O
conducted	O
in	O
two	O
German	O
University	O
hospitals	O
.	O

A	O
total	O
of	O
400	O
patients	O
(	O
200	O
in	O
each	O
study	O
center	O
)	O
undergoing	O
elective	O
CABG	O
surgery	O
were	O
enrolled	O
after	O
written	O
informed	O
consent	O
.	O

Platelet	O
function	O
was	O
analyzed	O
on	O
day	O
3	O
(	O
d3	O
)	O
and	O
day	O
5	O
(	O
d5	O
)	O
postoperatively	O
following	O
stimulation	O
with	O
arachidonic	O
acid	O
(	O
ASPItest	B-P
)	O
and	O
with	O
thrombin	O
receptor-activating	O
peptide	O
6	O
(	O
TRAPtest	B-P
)	O
using	O
multiple	B-P
electrode	I-P
aggregometry	I-P
(	O
Multiplate	B-P
)	O
.	O

Individuals	O
with	O
an	O
ASPItest	B-P
≥40	O
AU·min	O
were	O
categorized	O
as	O
ASA	O
nonresponders	O
.	O

A	O
1-year	O
follow-up	O
recorded	O
the	O
combined	O
end	O
point	O
of	O
cardiovascular	O
events	O
,	O
hospital	O
admissions	O
,	O
or	O
deaths	O
related	O
to	O
cardiovascular	O
disease	O
.	O

The	O
prevalence	O
of	O
ASA	O
nonresponse	O
was	O
51.5	O
%	O
on	O
d3	O
,	O
and	O
it	O
significantly	O
increased	O
to	O
71.3	O
%	O
on	O
d5	O
(	O
P	O
=	O
.0049	O
)	O
.	O

The	O
area	O
under	O
the	O
aggregation	B-P
curve	I-P
in	O
the	O
TRAPtest	B-P
(	O
P	O
<	O
.0001	O
)	O
,	O
the	O
platelet	B-P
count	I-P
on	O
d5	O
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
the	O
cardiopulmonary	O
bypass	O
time	O
(	O
P	O
=	O
.01	O
)	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
ASA	O
nonresponse	O
.	O

A	O
1-year	O
follow-up	O
recorded	O
54	O
events	O
fulfilling	O
criteria	O
for	O
the	O
combined	O
end	O
point	O
with	O
no	O
difference	O
between	O
ASA	O
responders	O
and	O
nonresponders	O
.	O

This	O
study	O
indicates	O
a	O
high	O
incidence	O
of	O
perioperative	O
ASA	O
nonresponse	O
in	O
patients	O
following	O
CABG	O
.	O

No	O
effect	O
on	O
the	O
incidence	O
of	O
cardiovascular	O
events	O
was	O
recorded	O
in	O
the	O
1-year	O
follow-up	O
.	O

Therefore	O
,	O
a	O
randomized	O
dosage	O
adjustment	O
trial	O
should	O
elucidate	O
whether	O
a	O
tailored	O
ASA	O
treatment	O
after	O
CABG	O
surgery	O
represents	O
a	O
useful	O
concept	O
.	O

Utility	O
of	O
dual-energy	B-P
spectral	I-P
CT	I-P
and	O
low-	O
iodine	O
contrast	O
medium	O
in	O
DIEP	O
angiography	B-P
.	O

To	O
evaluate	O
the	O
utility	O
of	O
dual-energy	B-P
spectral	I-P
computed	I-P
tomography	I-P
(	O
CT	B-P
)	O
and	O
low-iodine	O
intake	O
in	O
CT	B-P
angiography	I-P
(	O
CTA	B-P
)	O
of	O
deep	O
inferior	O
epigastric	O
perforator	O
(	O
DIEP	O
)	O
flaps	O
.	O

In	O
this	O
prospective	O
study	O
,	O
40	O
patients	O
with	O
a	O
BMI	O
<	O
28.0	O
kg/m	O
(	O
2	O
)	O
underwent	O
CTA	B-P
examination	O
for	O
breast	O
reconstruction	O
and	O
were	O
randomly	O
assigned	O
into	O
two	O
groups	O
(	O
n=20	O
for	O
each	O
group	O
)	O
as	O
follows	O
:	O
Group	O
A	O
was	O
submitted	O
to	O
dual-energy	B-P
spectral	I-P
CT	I-P
and	O
iodixanol	O
(	O
270	O
mg	O
I/mL	O
)	O
and	O
Group	O
B	O
was	O
submitted	O
to	O
conventional	O
high	O
iodine	O
contrast	O
agent	O
iohexol	O
(	O
350	O
mg	O
I/mL	O
)	O
.	O

The	O
volume	O
CT	O
dose	O
index	O
(	O
CTDIvol	O
)	O
and	O
dose	O
length	O
product	O
were	O
recorded	O
and	O
the	O
effective	O
dose	O
(	O
ED	O
)	O
was	O
calculated	O
.	O

The	O
best	O
mono-spectrum	O
images	O
of	O
Group	O
A	O
were	O
selected	O
according	O
to	O
the	O
optimal	O
contrast	O
to	O
noise	O
ratio	O
(	O
CNR	O
)	O
.	O

Both	O
mono-spectrum	O
images	O
of	O
Group	O
A	O
and	O
polychromatic	O
images	O
of	O
Group	O
B	O
were	O
used	O
to	O
reconstruct	O
maximum	O
intensity	O
projection	O
(	O
MIP	O
)	O
and	O
volume	O
rendering	O
(	O
VR	O
)	O
images	O
of	O
the	O
perforating	O
artery	O
,	O
respectively	O
.	O

Two	O
radiologists	O
evaluated	O
subjective	O
image	O
quality	O
using	O
a	O
4-point	O
score	O
.	O

The	O
diameter	O
of	O
the	O
perforating	O
artery	O
,	O
CT	B-P
value	O
and	O
SD	O
value	O
for	O
the	O
common	O
femoral	O
artery	O
were	O
measured	O
and	O
the	O
CNR	O
was	O
calculated	O
.	O

The	O
total	O
iodine	O
intake	O
and	O
radiation	O
doses	O
of	O
the	O
two	O
groups	O
were	O
calculated	O
and	O
compared	O
.	O

The	O
best	O
mono-spectrum	O
energy	O
with	O
the	O
optimal	O
CNR	O
of	O
the	O
perforating	O
artery	O
was	O
63	O
keV	O
.	O

The	O
CT	B-P
value	O
of	O
common	O
femoral	O
artery	O
in	O
Group	O
A	O
(	O
380.96±42.75HU	O
)	O
was	O
7.40	O
%	O
higher	O
than	O
in	O
Group	O
B	O
(	O
354.71±42.01	O
HU	O
)	O
but	O
with	O
no	O
statistical	O
significance	O
(	O
P	O
>	O
.05	O
)	O
.	O

The	O
CNR	O
of	O
the	O
common	O
femoral	O
artery	O
in	O
Group	O
A	O
(	O
23.84±6.73	O
)	O
was	O
6.88	O
%	O
lower	O
than	O
in	O
Group	O
B	O
(	O
25.60±6.20	O
)	O
,	O
with	O
no	O
significant	O
difference	O
(	O
P	O
>	O
.05	O
)	O
.	O

The	O
diameters	O
of	O
the	O
perforator	O
vessels	O
were	O
2.44±0.15	O
and	O
2.49±0.14	O
mm	O
,	O
respectively	O
,	O
with	O
no	O
significant	O
difference	O
(	O
P	O
>	O
.05	O
)	O
.	O

Subjective	O
image	O
qualities	O
for	O
the	O
two	O
groups	O
were	O
both	O
good	O
for	O
diagnostics	B-P
,	O
and	O
the	O
scores	O
for	O
Group	O
A	O
and	O
Group	O
B	O
were	O
(	O
3.88±0.28	O
)	O
and	O
(	O
3.93±0.18	O
)	O
,	O
respectively	O
.	O

The	O
scores	O
of	O
the	O
two	O
radiologists	O
were	O
consistent	O
(	O
kappa=0.634	O
)	O
.	O

The	O
effective	O
radiation	O
dose	O
in	O
Group	O
A	O
(	O
9.09±0	O
mSv	O
)	O
was	O
10.62	O
%	O
lower	O
than	O
in	O
Group	O
B	O
(	O
10.17±1.91	O
mSv	O
)	O
.	O

The	O
total	O
iodine	O
intake	O
in	O
Group	O
A	O
(	O
27	O
000	O
mg	O
)	O
was	O
22.86	O
%	O
lower	O
than	O
in	O
Group	O
B	O
(	O
35	O
000	O
mg	O
)	O
.	O

The	O
combination	O
of	O
dual-energy	B-P
spectral	I-P
CT	I-P
and	O
low-iodine	O
intake	O
in	O
CTA	B-P
of	O
DIEP	O
flap	O
examination	O
with	O
the	O
optimal	O
CNR	O
technology	O
can	O
meet	O
the	O
requirements	O
of	O
clinical	O
diagnostics	O
,	O
with	O
a	O
22.86	O
%	O
reduction	O
in	O
total	O
iodine	O
intake	O
and	O
an	O
11.01	O
%	O
reduction	O
in	O
radiation	O
dose	O
.	O

Variation	O
in	O
the	O
Intensity	O
of	O
Selection	O
on	O
Codon	O
Bias	O
over	O
Time	O
Causes	O
Contrasting	O
Patterns	O
of	O
Base	O
Composition	O
Evolution	O
in	O
Drosophila	O
.	O

Four-fold	O
degenerate	O
coding	O
sites	O
form	O
a	O
major	O
component	O
of	O
the	O
genome	O
,	O
and	O
are	O
often	O
used	O
to	O
make	O
inferences	O
about	O
selection	O
and	O
demography	O
,	O
so	O
that	O
understanding	O
their	O
evolution	O
is	O
important	O
.	O

Despite	O
previous	O
efforts	O
,	O
many	O
questions	O
regarding	O
the	O
causes	O
of	O
base	O
composition	O
changes	O
at	O
these	O
sites	O
in	O
Drosophila	O
remain	O
unanswered	O
.	O

To	O
shed	O
further	O
light	O
on	O
this	O
issue	O
,	O
we	O
obtained	O
a	O
new	O
whole-genome	O
polymorphism	O
data	O
set	O
from	O
D.	O
simulans	O
.	O

We	O
analyzed	O
samples	O
from	O
the	O
putatively	O
ancestral	O
range	O
of	O
D.	O
simulans	O
,	O
as	O
well	O
as	O
an	O
existing	O
polymorphism	O
data	O
set	O
from	O
an	O
African	O
population	O
of	O
D.	O
melanogaster	O
.	O

By	O
using	O
D.	O
yakuba	O
as	O
an	O
outgroup	O
,	O
we	O
found	O
clear	O
evidence	O
for	O
selection	O
on	O
4-fold	O
sites	O
along	O
both	O
lineages	O
over	O
a	O
substantial	O
period	O
,	O
with	O
the	O
intensity	O
of	O
selection	O
increasing	O
with	O
GC	O
content	O
.	O

Based	O
on	O
an	O
explicit	O
model	O
of	O
base	O
composition	O
evolution	O
,	O
we	O
suggest	O
that	O
the	O
observed	O
AT-	O
biased	O
substitution	O
pattern	O
in	O
both	O
lineages	O
is	O
probably	O
due	O
to	O
an	O
ancestral	O
reduction	O
in	O
selection	O
intensity	O
,	O
and	O
is	O
unlikely	O
to	O
be	O
the	O
result	O
of	O
an	O
increase	O
in	O
mutational	O
bias	O
towards	O
AT	O
alone	O
.	O

By	O
using	O
two	O
polymorphism-based	B-P
methods	I-P
for	O
estimating	O
selection	O
coefficients	O
over	O
different	O
timescales	O
,	O
we	O
show	O
that	O
the	O
selection	O
intensity	O
on	O
codon	O
usage	O
has	O
been	O
rather	O
stable	O
in	O
D.	O
simulans	O
in	O
the	O
recent	O
past	O
,	O
but	O
the	O
long-term	O
estimates	O
in	O
D.	O
melanogaster	O
are	O
much	O
higher	O
than	O
the	O
short-term	O
ones	O
,	O
indicating	O
a	O
continuing	O
decline	O
in	O
selection	O
intensity	O
,	O
to	O
such	O
an	O
extent	O
that	O
the	O
short-term	O
estimates	O
suggest	O
that	O
selection	O
is	O
only	O
active	O
in	O
the	O
most	O
GC	O
-rich	O
parts	O
of	O
the	O
genome	O
.	O

Finally	O
,	O
we	O
provide	O
evidence	O
for	O
complex	O
evolutionary	O
patterns	O
in	O
the	O
putatively	O
neutral	O
short	O
introns	O
,	O
which	O
can	O
not	O
be	O
explained	O
by	O
the	O
standard	O
GC	O
-	O
biased	O
gene	O
conversion	O
model	O
.	O

These	O
results	O
reveal	O
a	O
dynamic	O
picture	O
of	O
base	O
composition	O
evolution	O
.	O

Characterization	O
of	O
the	O
Effect	O
of	O
Drug-Drug	O
Interaction	O
on	O
Protein	O
Binding	O
in	O
Concurrent	O
Administration	O
of	O
Sulfamethoxazol	O
and	O
Diclofenac	O
Sodium	O
Using	O
Bovine	O
Serum	O
Albumin	O
.	O

Purpose	O
:	O
This	O
project	O
was	O
aimed	O
to	O
determine	O
the	O
effect	O
of	O
concurrent	O
administration	O
of	O
sulfamethoxazole	O
and	O
diclofenac	O
sodium	O
.	O

Methods	O
:	O
Equilibrium	B-P
dialysis	I-P
method	I-P
was	O
adopted	O
to	O
study	O
different	O
protein	O
binding	O
aspects	O
of	O
sulfamethoxazole	O
and	O
diclofenac	O
sodium	O
.	O

Results	O
:	O
Sulfamethoxazole	O
showed	O
two	O
types	O
of	O
association	O
constants	O
;	O
high	O
affinity	O
constant	O
29.0±0.20×10	O
(	O
6	O
)	O
M	O
(	O
-1	O
)	O
with	O
lower	O
number	O
of	O
binding	O
sites	O
of	O
0.7±1	O
and	O
low	O
affinity	O
constant	O
1.13±0.20×10	O
(	O
6	O
)	O
M	O
(	O
-1	O
)	O
with	O
higher	O
number	O
of	O
binding	O
sites	O
of	O
3.45±1	O
at	O
pH	O
7.4	O
and	O
40	O
°C	O
temperature	O
.	O

Diclofenac	O
sodium	O
showed	O
high	O
affinity	O
constant	O
33.66±0.20×10	O
(	O
6	O
)	O
M	O
(	O
-1	O
)	O
with	O
lower	O
number	O
of	O
binding	O
sites	O
of	O
1.01±1	O
and	O
low	O
affinity	O
constant	O
1.72±0.20×10	O
(	O
6	O
)	O
M	O
(	O
-1	O
)	O
with	O
higher	O
number	O
of	O
binding	O
sites	O
of	O
6.40±1	O
at	O
the	O
same	O
condition	O
.	O

Site	O
specific	O
probe	O
displacement	O
data	O
implied	O
that	O
site-I	O
,	O
warfarin	O
sodium	O
site	O
,	O
was	O
the	O
high	O
affinity	O
site	O
,	O
while	O
site-II	O
,	O
diazepam	O
site	O
,	O
was	O
the	O
low	O
affinity	O
site	O
for	O
these	O
drugs	O
.	O

During	O
concurrent	O
administration	O
,	O
sulfamethoxazole	O
increased	O
the	O
free	O
concentration	O
of	O
diclofenac	O
sodium	O
from	O
17.5±0.14	O
%	O
to	O
70.0±0.014	O
%	O
in	O
absence	O
and	O
from	O
22.5±0.07	O
%	O
to	O
83.0±0.014	O
%	O
in	O
presence	O
of	O
site-I	O
specific	O
probe	O
.	O

Diclofenac	O
sodium	O
also	O
increased	O
the	O
free	O
concentration	O
of	O
sulfamethoxazole	O
from	O
2.8±0.07	O
%	O
to	O
52.0±0.14	O
%	O
and	O
from	O
8.5±0.014	O
%	O
to	O
64.4±0.07	O
%	O
in	O
absence	O
and	O
presence	O
of	O
site-I	O
specific	O
probe	O
respectively	O
.	O

Conclusion	O
:	O
The	O
study	O
revealed	O
that	O
the	O
concurrent	O
administration	O
of	O
sulfamethoxazole	O
and	O
diclofenac	O
sodium	O
may	O
result	O
drug	O
concentration	O
alteration	O
in	O
blood	O
.	O

Effects	O
of	O
obesity	O
on	O
IL-33	O
/	O
ST2	O
system	O
in	O
heart	O
,	O
adipose	O
tissue	O
and	O
liver	O
:	O
study	O
in	O
the	O
experimental	O
model	O
of	O
Zucker	O
rats	O
.	O

Suppression	O
of	O
tumorigenicity	O
2	O
(	O
ST2	O
)	O
mediates	O
the	O
effect	O
of	O
Interleukin-33	O
(	O
IL-33	O
)	O
.	O

Few	O
data	O
are	O
reported	O
on	O
the	O
relationship	O
between	O
IL-33	O
/	O
ST2	O
and	O
obesity	O
.	O

We	O
aimed	O
to	O
investigate	O
effects	O
of	O
obesity	O
on	O
IL-33	O
/	O
ST2	O
system	O
in	O
heart	O
,	O
adipose	O
tissue	O
and	O
liver	O
in	O
a	O
rodent	O
model	O
of	O
obesity	O
.	O

The	O
relationship	O
of	O
cardiac	O
expression	O
of	O
IL-33	O
/	O
ST2	O
system	O
with	O
natriuretic	O
peptides	O
(	O
NPs	O
)	O
system	O
and	O
inflammatory	O
mediators	O
was	O
also	O
studied	O
.	O

mRNA	O
expression	O
of	O
IL-33	O
/	O
ST2	O
system	O
was	O
evaluated	O
in	O
cardiac	B-P
,	O
adipose	O
and	O
hepatic	B-P
biopsies	I-P
from	O
obese	O
Zucker	O
rats	O
(	O
O	O
)	O
and	O
controls	O
(	O
CO	O
)	O
.	O

Expression	O
levels	O
of	O
sST2	O
was	O
significantly	O
lower	O
in	O
O	O
rats	O
compared	O
with	O
CO	O
(	O
p	O
<	O
0.05	O
)	O
in	O
all	O
tissues	O
.	O

Besides	O
,	O
the	O
mRNA	O
levels	O
of	O
IL-33	O
decreased	O
significant	O
in	O
fat	O
of	O
O	O
respect	O
to	O
CO	O
,	O
while	O
,	O
expression	O
levels	O
of	O
ST2L	O
was	O
significantly	O
higher	O
in	O
liver	O
of	O
CO	O
than	O
in	O
O	O
.	O

A	O
strong	O
relationship	O
of	O
IL-33	O
/	O
ST2	O
with	O
NPs	O
and	O
classical	O
inflammatory	O
mediators	O
was	O
observed	O
in	O
cardiac	O
tissue	O
.	O

Expression	O
of	O
sST2	O
in	O
cardiac	O
,	O
adipose	O
and	O
liver	O
tissue	O
decreased	O
in	O
O	O
compared	O
with	O
controls	O
,	O
suggesting	O
an	O
involvement	O
for	O
IL-33	O
/	O
ST2	O
system	O
in	O
molecular	O
mechanisms	O
of	O
obesity	O
.	O

The	O
strong	O
relationships	O
with	O
NP	O
systems	O
and	O
inflammatory	O
mediators	O
could	O
suggest	O
an	O
involvement	O
for	O
IL-33	O
/	O
ST2	O
in	O
molecular	O
pathways	O
leading	O
to	O
cardiac	O
dysfunction	O
and	O
inflammation	O
associated	O
with	O
obesity	O
.	O

Effects	O
of	O
Elevated	O
CO2	O
on	O
the	O
Swainsonine	O
Chemotypes	O
of	O
Astragalus	O
lentiginosus	O
and	O
Astragalus	O
mollissimus	O
.	O

Rapid	O
changes	O
in	O
the	O
Earth	O
's	O
atmosphere	O
and	O
climate	O
associated	O
with	O
human	O
activity	O
can	O
have	O
significant	O
impacts	O
on	O
agriculture	O
including	O
livestock	O
production	O
.	O

CO2	O
concentration	O
has	O
risen	O
from	O
the	O
industrial	O
revolution	O
to	O
the	O
current	O
time	O
,	O
and	O
is	O
expected	O
to	O
continue	O
to	O
rise	O
.	O

Climatic	O
changes	O
alter	O
physiological	O
processes	O
,	O
growth	O
,	O
and	O
development	O
in	O
numerous	O
plant	O
species	O
,	O
potentially	O
changing	O
concentrations	O
of	O
plant	O
secondary	O
compounds	O
.	O

These	O
physiological	O
changes	O
may	O
influence	O
plant	O
population	O
density	O
,	O
growth	O
,	O
fitness	O
,	O
and	O
toxin	O
concentrations	O
and	O
thus	O
influence	O
the	O
risk	O
of	O
toxic	O
plants	O
to	O
grazing	O
livestock	O
.	O

Locoweeds	O
,	O
swainsonine	O
-	O
containing	O
Astragalus	O
species	O
,	O
are	O
one	O
group	O
of	O
plants	O
that	O
may	O
be	O
influenced	O
by	O
climate	O
change	O
.	O

We	O
evaluated	O
how	O
two	O
different	O
swainsonine	O
-	O
containing	O
Astragalus	O
species	O
responded	O
to	O
elevated	O
CO2	O
concentrations	O
.	O

Measurements	O
of	O
biomass	O
,	O
crude	B-P
protein	I-P
,	O
water	O
soluble	O
carbohydrates	B-P
and	O
swainsonine	B-P
concentrations	I-P
were	O
measured	O
in	O
two	O
chemotypes	O
(	O
positive	O
and	O
negative	O
for	O
swainsonine	O
)	O
of	O
each	O
species	O
after	O
growth	O
at	O
CO2	B-P
levels	I-P
near	O
present	O
day	O
and	O
at	O
projected	O
future	O
concentrations	O
.	O

Biomass	O
and	O
water	O
soluble	O
carbohydrate	O
concentrations	O
responded	O
positively	O
while	O
crude	B-P
protein	I-P
concentrations	I-P
responded	O
negatively	O
to	O
elevated	O
CO2	O
in	O
the	O
two	O
species	O
.	O

Swainsonine	O
concentrations	O
were	O
not	O
strongly	O
affected	O
by	O
elevated	O
CO2	O
in	O
the	O
two	O
species	O
.	O

In	O
the	O
different	O
chemotypes	O
,	O
biomass	O
responded	O
negatively	O
and	O
crude	B-P
protein	I-P
concentrations	I-P
responded	O
positively	O
in	O
the	O
swainsonine	O
-	O
positive	O
plants	O
compared	O
to	O
the	O
swainsonine	O
-	O
negative	O
plants	O
.	O

Ultimately	O
,	O
changes	O
in	O
CO2	O
and	O
endophyte	O
status	O
will	O
likely	O
alter	O
multiple	O
physiological	O
responses	O
in	O
toxic	O
plants	O
such	O
as	O
locoweed	O
,	O
but	O
it	O
is	O
difficult	O
to	O
predict	O
how	O
these	O
changes	O
will	O
impact	O
plant	O
herbivore	O
interactions	O
.	O

Anti-inflammatory	O
and	O
antimicrobial	O
coumarins	O
from	O
the	O
stems	O
of	O
Eurya	O
chinensis	O
.	O

Two	O
new	O
coumarins	O
,	O
named	O
(	O
±	O
)	O
-euryacoumarin	O
A	O
(	O
1	O
)	O
and	O
6-demethylobtusinin	O
(	O
2	O
)	O
,	O
and	O
one	O
new	O
natural	O
coumarin	O
,	O
named	O
euryacoumarin	O
B	O
(	O
3	O
)	O
,	O
along	O
with	O
two	O
known	O
compounds	O
,	O
scopoletin	O
(	O
4	O
)	O
and	O
obtusinol	O
(	O
5	O
)	O
,	O
were	O
isolated	O
from	O
the	O
stems	O
of	O
Eurya	O
chinensis	O
.	O

Their	O
structures	O
were	O
elucidated	O
by	O
means	O
of	O
extensive	O
spectroscopic	B-P
methods	I-P
and	O
comparison	O
with	O
data	O
reported	O
in	O
the	O
literatures	O
.	O

Compound	O
1	O
exhibited	O
significant	O
inhibition	O
of	O
LPS-induced	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
in	O
RAW264.7	O
cells	O
with	O
IC50	O
value	O
of	O
35.64	O
±	O
1.73	O
μM	O
,	O
and	O
showed	O
marginal	O
antibacterial	O
activities	O
against	O
Bacillus	O
subtilis	O
and	O
B.	O
cereus	O
with	O
MIC	O
values	O
of	O
50.59	O
±	O
2.12	O
and	O
35.42	O
±	O
0.96	O
μM	O
,	O
respectively	O
.	O

An	O
example	O
of	O
host	O
plant	O
expansion	O
of	O
host	O
-	O
specialized	O
Aphis	O
gossypii	O
Glover	O
in	O
the	O
field	O
.	O

The	O
host	O
plant	O
expansion	O
of	O
host	O
-	O
specialized	O
Aphis	O
gossypii	O
(	O
Glover	O
)	O
has	O
been	O
well	O
studied	O
in	O
the	O
laboratory	O
;	O
however	O
,	O
this	O
phenomenon	O
is	O
poorly	O
understood	O
in	O
the	O
field	O
.	O

Here	O
,	O
we	O
provide	O
a	O
series	O
of	O
laboratory	O
and	O
field	O
experiments	O
to	O
assess	O
the	O
role	O
of	O
zucchini	O
in	O
the	O
host	O
plant	O
expansion	O
of	O
cotton	O
-	O
specialized	O
aphids	O
.	O

We	O
observed	O
that	O
cotton	O
-	O
specialized	O
aphids	O
possessed	O
the	O
ability	O
to	O
expand	O
on	O
a	O
new	O
host	O
plant	O
(	O
cucumber	O
)	O
,	O
with	O
individuals	O
first	O
recorded	O
on	O
June	O
12	O
and	O
consequently	O
increasing	O
exponentially	O
in	O
number	O
in	O
a	O
field	O
cage	O
.	O

A	O
bioassay	B-P
experiment	O
showed	O
that	O
aphids	O
from	O
both	O
cotton	O
and	O
cucumber	O
preferred	O
their	O
natal	O
host	O
,	O
but	O
clones	O
from	O
zucchini	O
have	O
a	O
stronger	O
preference	O
for	O
cucumber	O
than	O
cotton	O
or	O
zucchini	O
.	O

A	O
total	O
of	O
1512	O
individuals	O
were	O
collected	O
from	O
a	O
cotton	O
field	O
(	O
mixed	O
cotton	O
and	O
cucurbit	O
plot	O
)	O
,	O
cotton	O
farmland	O
(	O
cotton	O
alone	O
)	O
and	O
a	O
field	O
cage	O
and	O
sequenced	B-P
to	O
identify	O
their	O
biotypes	O
.	O

The	O
results	O
for	O
apterous	O
individuals	O
from	O
the	O
cotton	O
field	O
showed	O
that	O
more	O
cucurbit	O
-	O
specialized	O
biotypes	O
occurred	O
on	O
cucumber	O
and	O
more	O
cotton	O
-	O
specialized	O
biotypes	O
occurred	O
on	O
cotton	O
and	O
zucchini	O
.	O

A	O
majority	O
(	O
>	O
97.0	O
%	O
)	O
of	O
aphids	O
from	O
both	O
the	O
field	O
cage	O
and	O
cotton	O
farmland	O
were	O
cotton	O
-	O
specialized	O
individuals	O
.	O

Consequently	O
,	O
eliminating	O
intermediate	O
host	O
plants	O
may	O
be	O
an	O
effective	O
measure	O
to	O
suppress	O
A.	O
gossypii	O
outbreaks	O
,	O
because	O
cotton	O
and	O
cucumber	O
are	O
often	O
grown	O
together	O
in	O
fields	O
and	O
greenhouses	O
.	O

Fatty	O
Acids	O
Have	O
Different	O
Adipogenic	O
Differentiation	O
Potentials	O
in	O
Stromal	O
Vascular	O
Cells	O
Isolated	O
from	O
Abdominal	O
Fat	O
in	O
Laying	O
Hens	O
.	O

This	O
study	O
was	O
conducted	O
to	O
examine	O
the	O
effects	O
of	O
fatty	O
acids	O
(	O
FA	O
)	O
with/without	O
chicken	O
serum	O
(	O
CS	O
)	O
on	O
the	O
expression	O
of	O
adipogenic	O
transcripts	O
and	O
adipogenesis	O
in	O
chicken	O
stromal	O
vascular	O
cells	O
(	O
SVC	O
)	O
.	O

In	O
experiment	O
1	O
,	O
SVC	O
were	O
grown	O
in	O
DMEM	O
containing	O
10	O
%	O
FBS	O
(	O
Control	O
)	O
and	O
treated	O
with	O
300	O
µM	O
oleic	O
acid	O
(	O
OLA	O
)	O
+	O
FBS	O
,	O
linoleic	O
acid	O
(	O
LNA	O
)	O
+	O
FBS	O
,	O
palmitic	O
acid	O
(	O
PAM	O
)	O
+	O
FBS	O
,	O
or	O
stearic	O
acid	O
(	O
STA	O
)	O
+	O
FBS	O
for	O
48	O
h.	O
In	O
experiment	O
2	O
,	O
cells	O
were	O
grown	O
in	O
DMEM	O
containing	O
5	O
%	O
CS	O
and	O
treated	O
with	O
300	O
µM	O
OLA	O
(	O
CS	O
+	O
OLA	O
)	O
,	O
PAM	O
(	O
CS	O
+	O
PAM	O
)	O
,	O
STA	O
(	O
CS	O
+	O
STA	O
)	O
or	O
200	O
µM	O
LNA	O
(	O
CS	O
+	O
LNA	O
)	O
for	O
48	O
h.	O
Adipogenesis	O
was	O
determined	O
using	O
Oil	B-P
Red	I-P
O	I-P
staining	I-P
and	O
glycerol-3-phosphate	O
dehydrogenase	O
(	O
GPDH	O
)	O
activity	O
.	O

The	O
proportion	O
of	O
OLA	O
,	O
PAM	O
,	O
or	O
STA	O
was	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
SVC	O
grown	O
in	O
either	O
FBS	O
or	O
CS	O
with	O
OLA	O
,	O
PAM	O
or	O
STA	O
.	O

Adipogenesis	O
was	O
induced	O
in	O
FBS	O
+	O
OLA	O
,	O
FBS	O
+	O
LNA	O
,	O
FBS	O
+	O
PAM	O
,	O
FBS	O
+	O
STA	O
,	O
CS	O
+	O
OLA	O
,	O
CS	O
+	O
LNA	O
,	O
CS	O
+	O
PAM	O
,	O
or	O
CS	O
+	O
STA	O
compared	O
to	O
FBS	O
.	O

GPDH	O
activity	O
was	O
significantly	O
higher	O
in	O
FBS	O
+	O
OLA	O
and	O
FBS	O
+	O
LNA	O
than	O
one	O
in	O
FBS	O
.	O

Compared	O
to	O
FBS	O
,	O
the	O
expression	O
of	O
FABP4	O
mRNA	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
FBS	O
+	O
OLA	O
,	O
FBS	O
+	O
LNA	O
,	O
or	O
FBS	O
+	O
PAM	O
,	O
whereas	O
that	O
of	O
C/EBPα	O
,	O
C/EBPβ	O
,	O
and	O
ATGL	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
FBS	O
+	O
OLA	O
or	O
FBS	O
+	O
LNA	O
cells	O
.	O

Expression	O
of	O
FABP4	O
and	O
C/EBPβ	O
mRNA	O
was	O
higher	O
in	O
CS	O
,	O
CS	O
+	O
OLA	O
,	O
CS	O
+	O
LNA	O
,	O
CS	O
+	O
PAM	O
,	O
or	O
CS	O
+	O
STA	O
compared	O
with	O
(	O
FBS	O
,	O
whereas	O
the	O
expression	O
of	O
ATGL	O
and	O
C/EBPα	O
was	O
higher	O
in	O
CS	O
,	O
CS	O
+	O
OLA	O
,	O
or	O
CS	O
+	O
LNA	O
than	O
FBS	O
cells	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
showed	O
that	O
FA	O
have	O
different	O
potentials	O
to	O
induce	O
adipogenesis	O
,	O
LNA	O
is	O
the	O
most	O
potent	O
among	O
the	O
tested	O
FA	O
,	O
and	O
these	O
potentials	O
can	O
be	O
improved	O
in	O
the	O
presence	O
of	O
CS	O
.	O

Metabolomic	O
analysis	O
of	O
glycerophospholipid	O
signatures	O
of	O
inflammation	O
treated	O
with	O
non-steroidal	O
anti-inflammatory	O
drugs	O
-induced-	O
RAW264.7	O
cells	O
using	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
and	O
U-HPLC	B-P
/	O
Q-TOF-MS.	B-P
Non-destructive	O
proton	O
nuclear	O
magnetic	O
resonance	O
(	O
(	O
1	O
)	O
H	O
NMR	O
)	O
spectroscopy	O
and	O
highly	O
sensitive	O
ultra-performance	O
liquid	O
chromatography	O
quadrupole	O
time-of-flight	O
mass	O
spectrometry	O
(	B-P
U-HPLC	I-P
/	O
Q-TOF-MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	O
changes	O
of	O
glycerophospholipids	O
(	O
GPLs	O
)	O
in	O
RAW264.7	O
cells	O
from	O
inflammation	O
to	O
prognosis	O
.	O

Analysis	O
of	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
was	O
shown	O
that	O
the	O
models	O
were	O
grouped	O
successfully	O
,	O
illustrating	O
that	O
all	O
of	O
them	O
had	O
significant	O
differences	O
.	O

Based	O
on	O
the	O
highly	O
simple	O
,	O
accurate	O
,	O
non-targeted	O
and	O
non-destructively	O
advantages	O
of	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti-inflammatory	O
drugs	O
in	O
the	O
metabolic	O
profiling	O
of	O
GPLs	O
.	O

58	O
GPLs	O
were	O
identified	O
by	O
U-HPLC	B-P
/	O
Q-TOF-MS	B-P
,	O
and	O
19	O
components	O
were	O
firstly	O
identified	O
in	O
this	O
study	O
compared	O
with	O
our	O
previous	O
results	O
.	O

In	O
addition	O
,	O
ten	O
potential	O
biomarkers	O
were	O
proved	O
,	O
of	O
which	O
phosphatidylcholine	O
(	O
PC	O
)	O
(	O
16:0/18:1	O
)	O
and	O
(	O
18:0/18:1	O
)	O
changed	O
consistently	O
in	O
three	O
drug-induced	O
groups	O
and	O
might	O
be	O
the	O
important	O
biomarkers	O
.	O

Compared	O
with	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
,	O
U-HPLC	B-P
/	O
Q-TOF-MS	B-P
showed	O
higher	O
sensitivity	O
and	O
specificity	O
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	B-P
of	O
biomarkers	O
apart	O
from	O
the	O
deficiency	O
of	O
time-consuming	O
sample	B-P
preparation	I-P
steps	I-P
and	O
unambiguous	O
metabolite	O
identification	O
.	O

Therefore	O
,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	O
of	O
GPLs	O
during	O
inflammation	O
by	O
combining	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
spectroscopy	I-P
with	O
U-HPLC	B-P
/	O
Q-TOF-MS	B-P
.	O

The	O
metabolic	O
profiling	O
of	O
GPLs	O
provides	O
valuable	O
evidence	O
for	O
inflammation	O
diagnosis	O
and	O
prognosis	O
,	O
and	O
might	O
unravel	O
the	O
mechanisms	O
involved	O
in	O
inflammation	O
progression	O
.	O

Assessing	O
time-of-flight	O
signal-to-noise	O
ratio	O
gains	O
within	O
the	O
myocardium	O
and	O
subsequent	O
reductions	O
in	O
administered	O
activity	O
in	O
cardiac	O
PET	B-P
studies	O
.	O

Time-of-flight	O
(	O
TOF	O
)	O
is	O
known	O
to	O
increase	O
signal-to-noise	O
ratio	O
(	O
SNR	O
)	O
and	O
facilitate	O
reductions	O
in	O
administered	O
activity	O
.	O

Established	O
measures	O
of	O
SNR	O
gain	O
are	O
derived	O
from	O
areas	O
of	O
uniform	O
uptake	O
,	O
which	O
is	O
not	O
applicable	O
to	O
the	O
heterogeneous	O
uptake	O
in	O
cardiac	O
PET	B-P
images	O
using	O
fluoro-deoxyglucose	O
(	O
FDG	O
)	O
.	O

This	O
study	O
aimed	O
to	O
develop	O
a	O
technique	O
to	O
quantify	O
SNR	O
gains	O
within	O
the	O
myocardium	O
due	O
to	O
TOF	O
.	O

Reference	O
TOF	O
SNR	O
gains	O
were	O
measured	O
in	O
88	O
FDG	O
oncology	O
patients	O
.	O

Phantom	O
data	O
were	O
used	O
to	O
translate	O
reference	O
SNR	O
gains	O
and	O
validate	O
a	O
method	O
of	O
quantifying	O
SNR	O
gains	O
within	O
the	O
myocardium	O
from	O
parametric	B-P
images	I-P
produced	O
from	O
multiple	O
replicate	O
images	O
.	O

This	O
technique	O
was	O
applied	O
to	O
13	O
FDG	O
cardiac	O
viability	O
patients	O
.	O

Reference	O
TOF	O
SNR	O
gains	O
of	O
+23	O
%	O
±	O
8.5	O
%	O
were	O
measured	O
in	O
oncology	O
patients	O
.	O

Measurements	O
of	O
SNR	O
gain	O
from	O
the	O
phantom	O
data	O
were	O
in	O
agreement	O
and	O
showed	O
the	O
parametric	B-P
image	I-P
technique	O
to	O
be	O
sufficiently	O
robust	O
.	O

SNR	O
gains	O
within	O
the	O
myocardium	O
in	O
the	O
viability	O
patients	O
were	O
+21	O
%	O
±	O
2.8	O
%	O
.	O

A	O
method	O
to	O
quantify	O
SNR	O
gains	O
from	O
TOF	O
within	O
the	O
myocardium	O
has	O
been	O
developed	O
and	O
evaluated	O
.	O

SNR	O
gains	O
within	O
the	O
myocardium	O
are	O
comparable	O
to	O
those	O
observed	O
by	O
established	O
methods	O
.	O

This	O
allows	O
guidance	O
for	O
protocol	O
optimization	O
for	O
TOF	O
systems	O
in	O
cardiac	O
PET	B-P
.	O

Surgical	O
Guidance	O
via	O
Multiplexed	B-P
Molecular	I-P
Imaging	I-P
of	O
Fresh	O
Tissues	O
Labeled	O
with	O
SERS	O
-Coded	O
Nanoparticles	O
.	O

The	O
imaging	B-P
of	O
dysregulated	O
cell-surface	O
receptors	O
(	O
or	O
biomarkers	O
)	O
is	O
a	O
potential	O
means	O
of	O
identifying	O
the	O
presence	O
of	O
cancer	O
with	O
high	O
sensitivity	O
and	O
specificity	O
.	O

However	O
,	O
due	O
to	O
heterogeneities	O
in	O
the	O
expression	O
of	O
protein	O
biomarkers	O
in	O
tumors	O
,	O
molecular	B-P
imaging	I-P
technologies	O
should	O
ideally	O
be	O
capable	O
of	O
visualizing	O
a	O
multiplexed	O
panel	O
of	O
cancer	O
biomarkers	O
.	O

Recently	O
,	O
surface-enhanced	O
Raman-scattering	O
(	O
SERS	O
)	O
nanoparticles	O
(	O
NPs	O
)	O
have	O
attracted	O
wide	O
interest	O
due	O
to	O
their	O
potential	O
for	O
sensitive	O
and	O
multiplexed	O
biomarker	O
detection	O
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
the	O
most	O
recent	O
advances	O
in	O
tumor	O
imaging	B-P
using	O
SERS	O
-coded	O
NPs	O
.	O

A	O
brief	O
introduction	O
of	O
the	O
structure	O
and	O
optical	O
properties	O
of	O
SERS	O
NPs	O
is	O
provided	O
,	O
followed	O
by	O
a	O
detailed	O
discussion	O
of	O
key	O
imaging	B-P
issues	O
such	O
as	O
the	O
administration	O
of	O
NPs	O
in	O
tissue	O
(	O
topical	O
versus	O
systemic	O
)	O
,	O
the	O
optical	O
configuration	O
and	O
imaging	B-P
approach	O
of	O
Raman	B-P
imaging	I-P
systems	I-P
,	O
spectral	B-P
demultiplexing	I-P
methods	I-P
for	O
quantifying	O
NP	O
concentrations	O
,	O
and	O
the	O
disambiguation	O
of	O
specific	O
vs.	O
nonspecific	O
sources	O
of	O
contrast	O
through	O
ratiometric	B-P
imaging	I-P
of	O
targeted	O
and	O
untargeted	O
(	O
control	O
)	O
NP	O
pairs	O
.	O

Finally	O
,	O
future	O
challenges	O
and	O
directions	O
are	O
briefly	O
outlined	O
.	O

Associations	O
of	O
gender	O
and	O
a	O
proxy	O
of	O
female	O
menopausal	O
status	O
with	O
histological	O
features	O
of	O
drug-induced	O
liver	O
injury	O
.	O

Gender	O
and	O
menopause	O
may	O
contribute	O
to	O
type	O
and	O
severity	O
of	O
drug-induced	O
liver	O
injury	O
(	O
DILI	O
)	O
by	O
influencing	O
host	O
responses	O
to	O
injury	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
associations	O
of	O
gender	O
and	O
female	O
age	O
50	O
[	O
a	O
proxy	O
of	O
menopause	O
]	O
with	O
histological	O
features	O
of	O
liver	O
injury	O
in	O
212	O
adults	O
enrolled	O
in	O
the	O
Drug-Induced	O
Liver	O
Injury	O
Network	O
(	O
DILIN	O
)	O
registry	O
.	O

All	O
participants	O
had	O
a	O
causality	O
score	O
of	O
at	O
least	O
'	O
probable	O
'	O
,	O
a	O
liver	B-P
biopsy	I-P
within	O
30	O
days	O
of	O
DILI	O
onset	O
,	O
and	O
no	O
prior	O
chronic	O
liver	O
disease	O
.	O

Biochemical	O
and	O
histological	O
injury	O
types	O
were	O
classified	O
as	O
hepatocellular	O
or	O
cholestatic/mixed	O
injury	O
.	O

The	O
cohort	O
was	O
divided	O
into	O
three	O
gender	O
/	O
age	O
categories	O
:	O
men	O
(	O
41.0	O
%	O
)	O
,	O
women	O
<	O
50	O
years	O
(	O
27.4	O
%	O
)	O
and	O
women	O
≥50	O
years	O
of	O
age	O
(	O
31.6	O
%	O
)	O
.	O

Interaction	O
of	O
gender	O
and	O
age	O
category	O
(	O
≥50	O
or	O
not	O
)	O
was	O
assessed	O
.	O

Hepatocellular	O
injury	O
was	O
more	O
prevalent	O
in	O
women	O
<	O
50	O
years	O
vs.	O
others	O
(	O
P=.002	O
)	O
.	O

After	O
adjusting	O
for	O
biochemical	O
injury	O
types	O
,	O
black	O
race	O
and	O
possible	O
ageing	O
effects	O
,	O
more	O
severe	O
interface	O
hepatitis	O
was	O
noted	O
in	O
biopsies	B-P
of	O
women	O
<	O
50	O
years	O
compared	O
to	O
those	O
of	O
men	O
and	O
women	O
≥50	O
years	O
(	O
P=.009	O
and	O
P=.055	O
respectively	O
)	O
.	O

Compared	O
to	O
those	O
of	O
men	O
,	O
biopsies	B-P
of	O
women	O
showed	O
greater	O
plasma	O
cell	O
infiltration	O
,	O
hepatocyte	O
apoptosis	O
,	O
hepatocyte	O
rosettes	O
and	O
lobular	O
disarray	O
but	O
less	O
iron	O
-	O
positive	O
hepatocytes	O
and	O
histological	O
cholestasis	O
(	O
P	O
<	O
.05	O
)	O
.	O

These	O
associations	O
persisted	O
after	O
excluding	O
cases	O
of	O
amoxicillin/clavulanic	O
acid	O
,	O
anabolic	O
steroids	O
or	O
nitrofurantoin	O
DILI	O
which	O
showed	O
gender	O
-specific	O
distributions	O
.	O

Gender	O
and	O
a	O
proxy	O
of	O
menopause	O
were	O
associated	O
with	O
various	O
features	O
of	O
inflammation	O
and	O
injury	O
in	O
DILI	O
.	O

When	O
Is	O
a	O
Test	O
Score	O
Fair	O
for	O
the	O
Individual	O
Who	O
Is	O
Being	O
Tested	O
?	O

Effects	O
of	O
Different	O
Scoring	O
Procedures	O
across	O
Multiple	O
Attempts	O
When	O
Testing	O
a	O
Motor	O
Skill	O
Task	O
.	O

Tests	O
or	O
test	O
batteries	O
used	O
for	O
assessing	O
motor	O
skills	O
,	O
either	O
in	O
research	O
studies	O
or	O
in	O
clinical	O
settings	O
,	O
apply	O
a	O
variety	O
of	O
procedures	O
for	O
scoring	O
performances	O
,	O
including	O
everything	O
from	O
one	O
to	O
ten	O
attempts	O
,	O
of	O
which	O
the	O
best	O
is	O
scored	O
or	O
an	O
average	O
is	O
computed	B-P
.	O

The	O
rationale	O
behind	O
scoring	O
procedures	O
is	O
rarely	O
stated	O
,	O
and	O
it	O
seems	O
that	O
the	O
number	O
of	O
attempts	O
allowed	O
is	O
decided	O
without	O
much	O
qualification	O
from	O
research	O
.	O

It	O
is	O
uncertain	O
whether	O
procedures	O
fairly	O
capture	O
an	O
individual	O
's	O
skill	O
level	O
.	O

Thus	O
,	O
the	O
validity	O
of	O
the	O
tests	O
may	O
be	O
compromised	O
.	O

The	O
present	O
study	O
tested	O
24	O
young	O
female	O
soccer	O
players	O
on	O
the	O
juggling	O
of	O
a	O
soccer	O
ball	O
.	O

They	O
were	O
given	O
10	O
attempts	O
,	O
and	O
trials	O
were	O
scored	O
according	O
to	O
nine	O
different	O
procedures	O
including	O
the	O
'	O
best	O
of	O
'	O
or	O
'	O
mean	O
of	O
'	O
either	O
one	O
,	O
two	O
,	O
three	O
,	O
five	O
,	O
or	O
ten	O
attempts	O
.	O

Individual	O
raw	O
scores	O
differed	O
widely	O
across	O
trials	O
,	O
but	O
no	O
general	O
effect	O
of	O
trials	O
was	O
found	O
.	O

The	O
mean	O
(	O
SD	O
)	O
percentage	O
difference	O
between	O
the	O
lowest	O
and	O
highest	O
scores	O
was	O
27.7	O
(	O
9.9	O
)	O
%	O
,	O
with	O
17	O
players	O
(	O
71	O
%	O
)	O
demonstrating	O
a	O
significant	O
change	O
from	O
lowest	O
to	O
highest	O
score	O
.	O

Correlations	O
between	O
raw	O
scores	O
were	O
low	O
across	O
trials	O
,	O
while	O
they	O
were	O
generally	O
higher	O
across	O
scoring	O
procedures	O
.	O

The	O
first	O
trial	O
was	O
significantly	O
different	O
from	O
the	O
remaining	O
both	O
as	O
a	O
raw	O
score	O
and	O
as	O
scoring	O
procedure	O
.	O

The	O
mean	O
percentage	O
difference	O
between	O
best-of-two	O
and	O
best-of-ten	O
scores	O
was	O
95	O
%	O
,	O
with	O
50	O
%	O
of	O
the	O
players	O
demonstrating	O
a	O
significant	O
difference	O
between	O
the	O
two	O
scoring	O
procedures	O
.	O

No	O
significant	O
differences	O
were	O
found	O
across	O
mean-of-rule	O
scorings	O
.	O

Best-of-rule	O
and	O
mean-of-rule	O
scorings	O
were	O
significantly	O
different	O
except	O
for	O
the	O
best-of-two	O
vs.	O
mean-of-two	O
.	O

The	O
mean	O
difference	O
between	O
highest	O
and	O
lowest	O
rank	O
across	O
players	O
was	O
6.7	O
(	O
3.6	O
)	O
,	O
with	O
individual	O
rankings	O
within	O
the	O
group	O
varying	O
33	O
%	O
on	O
average	O
across	O
procedures	O
.	O

One	O
player	O
moved	O
from	O
3rd	O
to	O
23rd	O
place	O
because	O
of	O
procedural	O
differences	O
.	O

Therefore	O
,	O
it	O
is	O
concluded	O
that	O
scoring	O
procedures	O
affect	O
results	O
and	O
may	O
have	O
an	O
impact	O
on	O
test	O
outcomes	O
.	O

This	O
may	O
present	O
consequences	O
for	O
decision-making	O
from	O
test	O
results	O
,	O
such	O
as	O
diagnosing	O
and	O
selection	O
of	O
intervention	O
groups	O
.	O

We	O
hope	O
that	O
our	O
results	O
would	O
inspire	O
further	O
research	O
into	O
the	O
scoring	O
procedures	O
of	O
the	O
vast	O
amount	O
of	O
tests	O
and	O
tasks	O
in	O
common	O
use	O
.	O

Acoustic	O
Analysis	O
Before	O
and	O
After	O
Voice	O
Therapy	O
for	O
Laryngeal	O
Pathology	O
.	O

Background	O
Voice	O
problems	O
caused	O
by	O
pathologies	O
in	O
vocal	O
folds	O
are	O
well	O
known	O
.	O

Some	O
types	O
of	O
laryngeal	O
pathologies	O
have	O
certain	O
acoustic	O
characteristics	O
.	O

Objective	O
evaluation	O
helps	O
characterize	O
the	O
voice	O
and	O
voice	O
problems	O
providing	O
supporting	O
evidences	O
,	O
severity	O
of	O
disorders	O
.	O

It	O
helps	O
assess	O
the	O
response	O
to	O
the	O
treatment	O
and	O
measures	O
the	O
outcomes	O
.	O

Objective	O
The	O
objective	O
of	O
the	O
study	O
is	O
to	O
determine	O
the	O
effectiveness	O
of	O
the	O
voice	O
therapy	O
and	O
quantify	O
the	O
results	O
objectively	O
by	O
voice	O
parameters	O
.	O

Method	O
Study	O
includes	O
61	O
patients	O
who	O
presented	O
with	O
different	O
types	O
of	O
laryngeal	O
pathologies	O
.	O

Acoustic	O
analyses	O
and	O
voice	B-P
assessment	I-P
was	O
done	O
with	O
Dr	O
.	O

Speech	O
ver	O
4	O
(	O
Tiger	O
DRS	O
Inc.	O
)	O
.	O

Acoustic	O
parameters	O
including	O
fundamental	O
frequency	O
,	O
jitters	O
,	O
shimmers	O
,	O
Harmonic	O
to	O
noise	O
ratio	O
(	O
HNR	O
)	O
,	O
Normalized	O
noise	O
energy	O
(	O
NNE	O
)	O
were	O
analyzed	O
before	O
and	O
after	O
voice	O
therapy	O
.	O

Result	O
Bilateral	O
vocal	O
nodules	O
were	O
the	O
most	O
common	O
pathologies	O
comprising	O
44.26	O
%	O
.	O

All	O
acoustic	O
parameters	O
showed	O
a	O
significant	O
difference	O
after	O
the	O
therapy	O
(	O
p	O
<	O
0.05	O
)	O
except	O
for	O
NNE	O
.	O

Dysphonia	O
due	O
to	O
vocal	O
fold	O
polyp	O
showed	O
no	O
improvement	O
even	O
after	O
voice	O
therapy	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Conclusion	O
Acoustic	O
analysis	O
provides	O
an	O
objective	O
,	O
recordable	O
data	O
regarding	O
the	O
voice	O
parameters	O
and	O
its	O
pathologies	O
.	O

Though	O
,	O
few	O
pathology	O
require	O
alternative	O
therapy	O
rather	O
than	O
voice	O
therapy	O
,	O
overall	O
it	O
has	O
a	O
good	O
effect	O
on	O
glottic	O
closure	O
.	O

As	O
the	O
voice	O
therapy	O
can	O
improve	O
the	O
different	O
indices	O
of	O
voice	O
,	O
it	O
can	O
be	O
viewed	O
as	O
imperative	O
part	O
of	O
treatment	O
and	O
to	O
monitor	O
progression	O
.	O

Diagnostic	O
utility	O
of	O
additional	O
conventional	O
techniques	B-P
after	O
endobronchial	B-P
ultrasonography	I-P
guidance	O
during	O
transbronchial	B-P
biopsy	I-P
.	O

Endobronchial	B-P
ultrasonography	I-P
with	O
a	O
guide	O
sheath	O
transbronchial	B-P
biopsy	I-P
(	O
EBUS	B-P
-	O
GS	O
TBB	B-P
)	O
has	O
been	O
used	O
to	O
diagnose	O
peripheral	O
pulmonary	O
lesions	O
(	O
PPLs	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
diagnostic	O
utility	O
of	O
conventional	O
TBB	B-P
after	O
EBUS	B-P
-	O
GS	O
TBB	B-P
.	O

A	O
retrospective	O
analysis	O
of	O
patients	O
who	O
underwent	O
conventional	O
TBB	B-P
after	O
EBUS	B-P
-	O
GS	O
TBB	B-P
for	O
PPL	O
between	O
August	O
1	O
,	O
2012	O
and	O
December	O
31	O
,	O
2014	O
.	O

We	O
performed	O
multivariate	O
analysis	O
to	O
examine	O
the	O
association	O
of	O
various	O
clinical	O
factors	O
,	O
including	O
EBUS	B-P
probe	O
distance	O
and	O
sample	O
size	O
area	O
,	O
with	O
diagnostic	O
yield	O
.	O

Of	O
88	O
eligible	O
patients	O
,	O
57	O
(	O
65	O
%	O
)	O
were	O
successfully	O
diagnosed	O
by	O
EBUS	B-P
-	O
GS	O
TBB	B-P
.	O

In	O
31	O
patients	O
not	O
diagnosed	O
by	O
EBUS	B-P
-	O
GS	O
TBB	B-P
,	O
15	O
(	O
48	O
%	O
)	O
were	O
successfully	O
diagnosed	O
by	O
additional	O
conventional	O
TBB	B-P
.	O

Ground	O
glass	O
opacity	O
(	O
GGO	O
)	O
was	O
a	O
significant	O
factor	O
associated	O
with	O
the	O
diagnostic	O
yield	O
of	O
additional	O
conventional	O
TBB	B-P
following	O
EBUS	B-P
-	O
GS	O
TBB	B-P
.	O

Multivariate	O
analysis	O
and	O
receiver	O
operator	O
curves	O
revealed	O
that	O
distance	O
between	O
the	O
PPL	O
and	O
the	O
EBUS	B-P
probe	O
of	O
less	O
than	O
2.55	O
mm	O
favored	O
the	O
utility	O
of	O
conventional	O
TBB	B-P
.	O

Additional	O
conventional	O
TBB	B-P
after	O
EBUS	B-P
-	O
GS	O
TBB	B-P
could	O
be	O
a	O
useful	O
procedure	B-P
for	O
the	O
diagnosis	O
of	O
ground	O
glass	O
opacity	O
PPLs	O
and	O
in	O
cases	O
of	O
a	O
distance	O
of	O
less	O
than	O
2.55	O
mm	O
between	O
the	O
EBUS	B-P
probe	O
and	O
the	O
lesion	O
.	O

Generalized	O
Weakness	O
in	O
a	O
Transplant	O
Patient	O
:	O
A	O
Case	O
Presentation	O
.	O

Generalized	O
weakness	O
in	O
transplant	O
patients	O
is	O
a	O
major	O
complaint	O
in	O
tertiary	O
rehabilitation	O
hospitals	O
.	O

The	O
diagnosis	O
and	O
management	O
of	O
generalized	O
weakness	O
in	O
this	O
population	O
pose	O
challenges	O
for	O
physicians	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
transplant	O
patient	O
with	O
generalized	O
weakness	O
who	O
was	O
eventually	O
diagnosed	O
with	O
calciphylaxis	O
using	O
a	O
multidisciplinary	B-P
diagnostic	I-P
approach	I-P
of	O
electrodiagnostics	B-P
,	O
vascular	O
study	B-P
,	O
and	O
skin	B-P
biopsy	I-P
.	O

Calciphylaxis	O
is	O
a	O
rare	O
cutaneous	O
disorder	O
that	O
mimics	O
other	O
collagen	O
vascular	O
diseases	O
in	O
its	O
presentation	O
and	O
fulminant	O
course	O
.	O

Physiatrists	O
should	O
be	O
cognizant	O
of	O
calciphylaxis	O
,	O
as	O
it	O
signals	O
a	O
poor	O
prognosis	O
if	O
not	O
correctly	O
diagnosed	O
and	O
treated	O
in	O
a	O
timely	O
manner	O
,	O
with	O
high	O
incidence	O
of	O
sepsis	O
,	O
wound	O
pain	O
,	O
and	O
disability	O
.	O

V	O
.	O

A	O
Patient	O
Registry	O
to	O
Improve	O
Patient	O
Safety	O
:	O
Recording	O
General	O
Neurosurgery	O
Complications	O
.	O

To	O
improve	O
the	O
transparency	O
of	O
the	O
local	O
health	O
care	O
system	O
,	O
treatment	O
cost	O
was	O
recently	O
referenced	O
to	O
disease	O
related	O
groups	O
.	O

Treatment	O
quality	O
must	O
be	O
legally	O
documented	O
in	O
a	O
patient	O
registry	O
,	O
in	O
particular	O
for	O
the	O
highly	O
specialized	O
treatments	O
provided	O
by	O
neurosurgery	O
departments	O
.	O

In	O
2013	O
we	O
have	O
installed	O
a	O
patient	O
registry	O
focused	O
on	O
cranial	O
neurosurgery	O
.	O

Surgeries	O
are	O
characterized	O
by	O
indication	O
,	O
treatment	O
,	O
location	O
and	O
other	O
specific	O
neurosurgical	O
parameters	O
.	O

Preoperative	O
state	O
and	O
postoperative	O
outcome	O
are	O
recorded	O
prospectively	O
using	O
neurological	O
and	O
sociological	O
scales	O
.	O

Complications	O
are	O
graded	O
by	O
their	O
severity	O
in	O
a	O
therapy-oriented	O
complication	O
score	O
system	O
(	O
Clavien-Dindo-Grading	O
system	O
,	O
CDG	O
)	O
.	O

Results	O
are	O
presented	O
at	O
the	O
monthly	O
clinical	O
staff	O
meeting	O
.	O

Data	O
acquisition	O
compatible	O
with	O
the	O
clinic	O
workflow	O
permitted	O
to	O
include	O
all	O
eligible	O
patients	O
into	O
the	O
registry	O
.	O

Until	O
December	O
2015	O
,	O
we	O
have	O
registered	O
2880	O
patients	O
that	O
were	O
treated	O
in	O
3959	O
surgeries	O
and	O
8528	O
consultations	O
.	O

Since	O
the	O
registry	O
is	O
fully	O
operational	O
(	O
August	O
2014	O
)	O
,	O
we	O
have	O
registered	O
325	O
complications	O
on	O
1341	O
patient	O
discharge	O
forms	O
(	O
24	O
%	O
)	O
.	O

In	O
64	O
%	O
of	O
these	O
complications	O
,	O
no	O
or	O
only	O
pharmacological	O
treatment	O
was	O
required	O
.	O

At	O
discharge	O
,	O
there	O
was	O
a	O
clear	O
correlation	O
of	O
the	O
severity	O
of	O
the	O
complication	O
and	O
the	O
Karnofsky	B-P
Performance	I-P
Status	I-P
(	O
KPS	B-P
,	O
ρ	O
=	O
-0.3	O
,	O
slope	O
-6	O
KPS	B-P
percentage	O
points	O
per	O
increment	O
of	O
CDG	O
)	O
and	O
the	O
length	O
of	O
stay	O
(	O
ρ	O
=	O
0.4	O
,	O
slope	O
1.5	O
days	O
per	O
increment	O
of	O
CDG	O
)	O
.	O

While	O
the	O
therapy-oriented	O
complication	O
scores	O
correlate	O
reasonably	O
well	O
with	O
outcome	O
and	O
length	O
of	O
stay	O
,	O
they	O
do	O
not	O
account	O
for	O
new	O
deficits	O
that	O
can	O
not	O
be	O
treated	O
.	O

Outcome	O
grading	O
and	O
complication	O
severity	O
grading	O
thus	O
serve	O
a	O
complimentary	O
purpose	O
.	O

Overall	O
,	O
the	O
registry	O
serves	O
to	O
streamline	O
and	O
to	O
complete	O
information	O
flow	O
in	O
the	O
clinic	O
,	O
to	O
identify	O
complication	O
rates	O
and	O
trends	O
early	O
for	O
the	O
internal	O
quality	O
monitoring	O
and	O
communication	O
with	O
patients	O
.	O

Conversely	O
,	O
the	O
registry	O
influences	O
clinical	O
practice	O
in	O
that	O
it	O
demands	O
rigorous	O
documentation	O
and	O
standard	O
operating	O
procedures	O
.	O

Quantification	O
of	O
intact	O
plasma	O
AGT	O
consisting	O
of	O
oxidized	O
and	O
reduced	O
conformations	O
using	O
a	O
modified	O
ELISA	B-P
.	O

The	O
pleiotropic	O
actions	O
of	O
the	O
renin-angiotensin	O
system	O
(	O
RAS	O
)	O
depend	O
on	O
the	O
availability	O
of	O
angiotensinogen	O
(	O
AGT	O
)	O
which	O
generates	O
angiotensin	O
I	O
(	O
ANG	O
I	O
)	O
when	O
cleaved	O
by	O
renin	O
.	O

Thus	O
,	O
quantification	O
of	O
the	O
intact	O
AGT	O
(	O
iAGT	O
)	O
concentrations	O
is	O
important	O
to	O
evaluate	O
the	O
actual	O
renin	O
substrate	O
available	O
.	O

The	O
iAGT	O
conformation	O
exists	O
as	O
oxidized	O
AGT	O
(	O
oxi-AGT	O
)	O
and	O
reduced	O
AGT	O
(	O
red-AGT	O
)	O
in	O
a	O
disulfide	O
bond	O
,	O
and	O
oxi-AGT	O
has	O
a	O
higher	O
affinity	O
for	O
renin	O
,	O
which	O
may	O
exacerbate	O
RAS	O
-	O
associated	O
diseases	O
.	O

Accordingly	O
,	O
we	O
determined	O
iAGT	O
,	O
oxi-AGT	O
,	O
and	O
red-AGT	O
levels	O
in	O
plasma	O
from	O
rats	O
and	O
mice	O
.	O

Blood	O
samples	O
were	O
obtained	O
by	O
cardiac	B-P
puncture	I-P
and	O
then	O
immediately	O
mixed	O
with	O
an	O
inhibitor	O
solution	O
containing	O
a	O
renin	O
inhibitor	O
.	O

Total	O
AGT	O
(	O
tAGT	O
)	O
levels	O
were	O
measured	O
by	O
tAGT	O
ELISA	B-P
which	O
detects	O
both	O
cleaved	O
and	O
iAGT	O
.	O

iAGT	O
levels	O
were	O
determined	O
by	O
iAGT	O
ELISA	B-P
which	O
was	O
found	O
to	O
only	O
detect	O
red-AGT	O
.	O

Thus	O
,	O
it	O
was	O
necessary	O
to	O
treat	O
samples	O
with	O
dithiothreitol	O
,	O
a	O
reducing	O
agent	O
,	O
to	O
quantify	O
total	O
iAGT	O
concentration	O
.	O

tAGT	O
levels	O
in	O
rat	O
and	O
mouse	O
plasma	O
were	O
1,839	O
±	O
139	O
and	O
1,082	O
±	O
77	O
ng/ml	O
,	O
respectively	O
.	O

iAGT	O
levels	O
were	O
53	O
%	O
of	O
tAGT	O
in	O
rat	O
plasma	O
but	O
only	O
22	O
%	O
in	O
mouse	O
plasma	O
,	O
probably	O
reflecting	O
the	O
greater	O
plasma	O
renin	O
activity	O
in	O
mice	O
.	O

The	O
ratios	O
of	O
oxi-AGT	O
and	O
red-AGT	O
were	O
∼4:1	O
(	O
rat	O
)	O
and	O
16:1	O
(	O
mouse	O
)	O
.	O

Plasma	O
iAGT	O
consists	O
of	O
oxi-AGT	O
and	O
red-AGT	O
,	O
suggesting	O
that	O
oxidative	O
stress	O
can	O
influence	O
ANG	O
I	O
generation	O
by	O
the	O
AGT	O
conformation	O
switch	O
.	O

Furthermore	O
,	O
the	O
lower	O
availability	O
of	O
plasma	O
iAGT	O
in	O
mice	O
suggests	O
that	O
it	O
may	O
serve	O
as	O
a	O
limiting	O
factor	O
in	O
ANG	O
I	O
formation	O
in	O
this	O
species	O
.	O

Correlation	O
between	O
preoperative	O
physical	O
signs	O
and	O
functional	O
outcomes	O
after	O
laminoplasty	O
for	O
ossification	O
of	O
the	O
posterior	O
longitudinal	O
ligament	O
.	O

Ossification	O
of	O
the	O
posterior	O
longitudinal	O
ligament	O
(	O
OPLL	O
)	O
can	O
cause	O
myelopathy	O
that	O
is	O
often	O
managed	O
surgically	O
.	O

Knowledge	O
of	O
predictors	O
of	O
surgical	O
outcomes	O
can	O
provide	O
decision	O
support	O
to	O
surgeons	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
investigate	O
the	O
relationships	O
between	O
preoperative	O
physical	O
signs	O
and	O
postoperative	O
functional	O
outcomes	O
in	O
patients	O
with	O
OPLL	O
and	O
to	O
clarify	O
whether	O
physical	O
signs	O
could	O
predict	O
functional	O
outcomes	O
.	O

Fifty-five	O
patients	O
with	O
OPLL	O
who	O
had	O
undergone	O
cervical	O
laminoplasty	O
were	O
included	O
in	O
this	O
study	O
.	O

Six	O
physical	O
signs	O
including	O
hyperreflexia	O
,	O
Babinski	O
sign	O
,	O
sensory	O
disturbance	O
,	O
grip	O
strength	O
,	O
10-s	B-P
grip	I-P
and	I-P
release	I-P
test	I-P
,	O
and	O
bladder	O
dysfunction	O
,	O
and	O
four	O
other	O
factors	O
including	O
age	O
,	O
duration	O
of	O
symptoms	O
,	O
history	O
of	O
minor	O
trauma	O
and	O
preoperative	O
Japanese	O
Orthopaedic	O
Association	O
(	O
JOA	O
)	O
score	O
were	O
investigated	O
as	O
potential	O
predictive	O
prognostic	O
factors	O
using	O
both	O
univariate	O
and	O
multivariate	O
analyses	O
.	O

The	O
mean	O
recovery	O
rate	O
of	O
JOA	O
score	O
was	O
62.5	O
±	O
32.5	O
%	O
.	O

The	O
neurological	O
recovery	O
rate	O
was	O
negatively	O
associated	O
with	O
age	O
(	O
P	O
=	O
0.002	O
)	O
,	O
the	O
duration	O
of	O
symptoms	O
(	O
P	O
=	O
0.002	O
)	O
and	O
Babinski	O
sign	O
(	O
P	O
=	O
0.007	O
)	O
,	O
whereas	O
it	O
was	O
positively	O
correlated	O
with	O
grip	O
strength	O
(	O
P	O
=	O
0.011	O
)	O
.	O

Multiple	O
logistic	O
regression	O
analyses	O
revealed	O
that	O
age	O
(	O
Odds	O
ratio	O
:	O
0.89	O
,	O
95	O
%	O
CI	O
:	O
0.81-0.99	O
)	O
and	O
Babinski	O
sign	O
(	O
Odds	O
ratio	O
:	O
0.18	O
,	O
95	O
%	O
CI	O
:	O
0.04-0.89	O
)	O
were	O
factors	O
associated	O
with	O
functional	O
outcomes	O
.	O

Satisfactory	O
functional	O
outcomes	O
could	O
be	O
expected	O
for	O
patients	O
who	O
are	O
young	O
and	O
do	O
not	O
exhibit	O
the	O
Babinski	O
sign	O
,	O
showing	O
that	O
the	O
Babinski	O
sign	O
could	O
be	O
useful	O
as	O
an	O
indicator	O
of	O
the	O
window	O
of	O
opportunity	O
for	O
achieving	O
satisfactory	O
functional	O
outcomes	O
.	O

Covalent	O
Modulators	O
of	O
the	O
Vacuolar	O
ATPase	O
.	O

The	O
vacuolar	O
H	O
(	O
+	O
)	O
ATPase	O
(	O
V-ATPase	O
)	O
is	O
a	O
complex	O
multisubunit	O
machine	O
that	O
regulates	O
important	O
cellular	O
processes	O
through	O
controlling	O
acidity	O
of	O
intracellular	O
compartments	O
in	O
eukaryotes	O
.	O

Existing	O
small-molecule	O
modulators	O
of	O
V-ATPase	O
either	O
are	O
restricted	O
to	O
targeting	O
one	O
membranous	O
subunit	O
of	O
V-ATPase	O
or	O
have	O
poorly	O
understood	O
mechanisms	O
of	O
action	O
.	O

Small	O
molecules	O
with	O
novel	O
and	O
defined	O
mechanisms	O
of	O
inhibition	O
are	O
thus	O
needed	O
to	O
functionally	O
characterize	O
V-ATPase	O
and	O
to	O
fully	O
evaluate	O
the	O
therapeutic	O
relevance	O
of	O
V-ATPase	O
in	O
human	O
diseases	O
.	O

We	O
have	O
discovered	O
electrophilic	O
quinazolines	O
that	O
covalently	O
modify	O
a	O
soluble	O
catalytic	O
subunit	O
of	O
V-ATPase	O
with	O
high	O
potency	O
and	O
exquisite	O
proteomic	O
selectivity	O
as	O
revealed	O
by	O
fluorescence	B-P
imaging	I-P
and	O
chemical	B-P
proteomic	I-P
activity-based	I-P
profiling	I-P
.	O

The	O
site	O
of	O
covalent	O
modification	O
was	O
mapped	O
to	O
a	O
cysteine	O
residue	O
located	O
in	O
a	O
region	O
of	O
V-ATPase	O
subunit	O
A	O
that	O
is	O
thought	O
to	O
regulate	O
the	O
dissociation	O
of	O
V-ATPase	O
.	O

We	O
further	O
demonstrate	O
that	O
a	O
previously	O
reported	O
V-ATPase	O
inhibitor	O
,	O
3-bromopyruvate	O
,	O
also	O
targets	O
the	O
same	O
cysteine	O
residue	O
and	O
that	O
our	O
electrophilic	O
quinazolines	O
modulate	O
the	O
function	O
of	O
V-ATPase	O
in	O
cells	O
.	O

With	O
their	O
well-defined	O
mechanism	O
of	O
action	O
and	O
high	O
proteomic	O
specificity	O
,	O
the	O
described	O
quinazolines	O
offer	O
a	O
powerful	O
set	O
of	O
chemical	O
probes	O
to	O
investigate	O
the	O
physiological	O
and	O
pathological	O
roles	O
of	O
V-ATPase	O
.	O

Identification	O
of	O
a	O
novel	O
PSEN1	O
mutation	O
(	O
Leu232Pro	O
)	O
in	O
a	O
Korean	O
patient	O
with	O
early-onset	O
Alzheimer	O
's	O
disease	O
and	O
a	O
family	O
history	O
of	O
dementia	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
novel	O
mutation	O
in	O
exon	O
7	O
of	O
presenilin	O
1	O
(	O
Leu232Pro	O
)	O
was	O
discovered	O
in	O
a	O
Korean	O
patient	O
with	O
early-onset	O
Alzheimer	O
's	O
disease	O
,	O
who	O
represented	O
memory	O
decline	O
at	O
37	O
years	O
of	O
age	O
,	O
followed	O
by	O
impairment	O
in	O
spatial	O
activity	O
and	O
concentrations	O
and	O
personality	O
changes	O
.	O

Imaging	B-P
analyses	I-P
with	O
magnetic	B-P
resonance	I-P
scan	I-P
showed	O
diffuse	O
atrophy	O
in	O
the	O
frontoparietal	O
regions	O
.	O

Targeted	O
next	O
generation	O
sequencing	O
and	O
Sanger	O
sequencing	O
identified	O
a	O
heterozygous	O
T	O
to	O
C	O
transition	O
at	O
position	O
695	O
(	O
c.695T	O
>	O
C	O
)	O
of	O
in	O
presenilin	O
1	O
gene	O
(	O
PSEN1	O
)	O
,	O
resulting	O
in	O
a	O
novel	O
missense	O
mutation	O
at	O
codon	O
232	O
from	O
leucine	O
to	O
proline	O
(	O
L232P	O
)	O
.	O

Several	O
family	O
members	O
of	O
the	O
patient	O
developed	O
dementia	O
,	O
suggesting	O
an	O
autosomal	O
dominant	O
inheritance	O
;	O
however	O
,	O
we	O
were	O
unable	O
to	O
perform	O
a	O
segregation	O
analysis	O
to	O
confirm	O
this	O
.	O

Since	O
the	O
proline	O
may	O
play	O
a	O
role	O
as	O
a	O
helix	O
breaker	O
,	O
this	O
mutation	O
could	O
significantly	O
disturb	O
the	O
transmembrane	O
helix	O
domain-V	O
of	O
PSEN1	O
and	O
perturb	O
its	O
protein	O
functions	O
.	O

This	O
hypothesis	O
was	O
supported	O
by	O
the	O
results	O
from	O
the	O
in	O
silico	O
analyses	O
,	O
predicted	O
a	O
major	O
kink	O
on	O
this	O
helix	O
.	O

Several	O
leucine	O
>	O
proline	O
substitutions	O
in	O
other	O
PSEN1	O
transmembrane	O
helices	O
revealed	O
aggressive	O
AD	O
phenotypes	O
.	O

Future	O
functional	O
studies	O
would	O
be	O
needed	O
to	O
evaluate	O
the	O
pathogenicity	O
of	O
this	O
mutation	O
in	O
AD	O
.	O

Significant	O
glial	O
alterations	O
in	O
response	O
to	O
iron	O
loading	O
in	O
a	O
novel	O
organotypic	B-P
hippocampal	I-P
slice	I-P
culture	I-P
model	B-P
.	O

Aberrant	O
iron	O
deposition	O
in	O
the	O
brain	O
is	O
associated	O
with	O
neurodegenerative	O
disorders	O
including	O
Multiple	O
Sclerosis	O
,	O
Alzheimer	O
's	O
disease	O
and	O
Parkinson	O
's	O
disease	O
.	O

To	O
study	O
the	O
collective	O
response	O
to	O
iron	O
loading	O
,	O
we	O
have	O
used	O
hippocampal	O
organotypic	O
slices	O
as	O
a	O
platform	O
to	O
develop	O
a	O
novel	O
ex	O
vivo	O
model	O
of	O
iron	O
accumulation	O
.	O

We	O
demonstrated	O
differential	O
uptake	O
and	O
toxicity	O
of	O
iron	O
after	O
12	O
h	O
exposure	O
to	O
10	O
μM	O
ferrous	O
ammonium	O
sulphate	O
,	O
ferric	O
citrate	O
or	O
ferrocene	O
.	O

Having	O
established	O
the	O
supremacy	O
of	O
ferrocene	O
in	O
this	O
model	O
,	O
the	O
cultures	B-P
were	O
then	O
loaded	O
with	O
0.1-100	O
μM	O
ferrocene	O
for	O
12	O
h.	O
One	O
μM	O
ferrocene	O
exposure	O
produced	O
the	O
maximal	O
1.6-fold	O
increase	O
in	O
iron	O
compared	O
with	O
vehicle	O
.	O

This	O
was	O
accompanied	O
by	O
a	O
1.4-fold	O
increase	O
in	O
ferritin	O
transcripts	O
and	O
mild	O
toxicity	O
.	O

Using	O
dual-immunohistochemistry	B-P
,	O
we	O
detected	O
ferritin	O
in	O
oligodendrocytes	O
,	O
microglia	O
,	O
but	O
rarely	O
in	O
astrocytes	O
and	O
never	O
in	O
neurons	O
in	O
iron	O
-loaded	O
slice	B-P
cultures	I-P
.	O

Moreover	O
,	O
iron	O
loading	O
led	O
to	O
a	O
15	O
%	O
loss	O
of	O
olig2	O
-	O
positive	O
cells	O
and	O
a	O
16	O
%	O
increase	O
in	O
number	O
and	O
greater	O
activation	O
of	O
microglia	O
compared	O
with	O
vehicle	O
.	O

However	O
,	O
there	O
was	O
no	O
appreciable	O
effect	O
of	O
iron	O
loading	O
on	O
astrocytes	O
.	O

In	O
what	O
we	O
believe	O
is	O
a	O
significant	O
advance	O
on	O
traditional	O
mono-	B-P
or	I-P
dual-cultures	I-P
,	O
our	O
novel	O
ex	O
vivo	O
slice-culture	B-P
model	B-P
allows	O
characterization	O
of	O
the	O
collective	O
response	O
of	O
brain	O
cells	O
to	O
iron	O
-	O
loading	O
.	O

Experimental	O
demonstration	O
of	O
the	O
possible	O
role	O
of	O
Acanthamoeba	O
polyphaga	O
in	O
the	O
infection	O
and	O
disease	O
progression	O
in	O
Buruli	O
Ulcer	O
(	O
BU	O
)	O
using	O
ICR	O
mice	O
.	O

The	O
transmission	O
of	O
Buruli	O
ulcer	O
(	O
BU	O
)	O
,	O
caused	O
by	O
Mycobacterium	O
ulcerans	O
(	O
MU	O
)	O
,	O
remains	O
puzzling	O
although	O
a	O
number	O
of	O
hypothesis	O
including	O
through	O
bites	O
of	O
infected	O
aquatic	O
insects	O
have	O
been	O
proposed	O
.	O

We	O
report	O
the	O
results	O
of	O
experiments	O
using	O
ICR	O
mice	O
that	O
give	O
credence	O
to	O
our	O
hypothesis	O
that	O
Acanthamoeba	O
species	O
may	O
play	O
a	O
role	O
in	O
BU	O
transmission	O
.	O

We	O
cocultured	B-P
MU	O
N2	O
and	O
MU	O
1615	O
which	O
expresses	O
red	O
fluorescent	O
protein	O
(	O
RFP	O
)	O
and	O
Acanthamoeba	O
polyphaga	O
(	O
AP	O
)	O
,	O
and	O
confirmed	O
infected	O
AP	O
by	O
Ziehl-Neelsen	B-P
(	I-P
ZN	I-P
)	I-P
staining	I-P
.	O

We	O
tested	O
for	O
viability	O
of	O
MU	O
inside	O
AP	O
and	O
observed	O
strong	O
RFP	O
signals	O
inside	O
both	O
trophozoites	O
and	O
cysts	O
after	O
3	O
and	O
42	O
days	O
of	O
coculturing	B-P
respectively	O
.	O

ICR	O
mice	O
were	O
topically	O
treated	O
,	O
either	O
on	O
shaved	O
intact	O
or	O
shaved	O
pinpricked	O
rumps	O
,	O
with	O
one	O
of	O
the	O
following	O
;	O
MU	O
N2	O
only	O
(	O
2.25	O
x	O
106	O
colony	O
forming	O
units	O
[	O
CFU	O
]	O
/	O
ml	O
)	O
,	O
MU	O
N2	O
:	O
AP	O
coculture	B-P
(	O
2.96	O
x	O
104	O
CFU	O
:	O
1.6	O
x	O
106	O
cells/ml	O
)	O
,	O
AP	O
only	O
(	O
1.6	O
x	O
106	O
cells/ml	O
)	O
,	O
PYG	O
medium	O
and	O
sterile	O
distilled	O
water	O
.	O

Both	O
MU	O
N2	O
only	O
and	O
MU	O
N2	O
:	O
AP	O
elicited	O
reddening	O
on	O
day	O
(	O
D	O
)	O
31	O
;	O
edema	O
on	O
D	O
45	O
and	O
D	O
44	O
respectively	O
,	O
and	O
ulcers	O
on	O
D	O
49	O
at	O
pinpricked	O
sites	O
only	O
.	O

To	O
ascertain	O
infectivity	O
and	O
pathogenicity	O
of	O
MU	O
N2	O
only	O
and	O
MU	O
N2	O
:	O
AP	O
,	O
and	O
compare	O
their	O
virulence	O
,	O
the	O
standard	B-P
mouse	I-P
footpad	I-P
inoculation	I-P
method	I-P
was	O
used	O
.	O

MU	O
N2	O
:	O
AP	O
elicited	O
reddening	O
in	O
footpads	O
by	O
D	O
3	O
compared	O
to	O
D	O
14	O
with	O
MU	O
N2	O
only	O
of	O
the	O
same	O
dose	O
of	O
MU	O
N2	O
(	O
2.96	O
x	O
104	O
CFU	O
)	O
.	O

ZN-stained	B-P
MU	O
were	O
observed	O
in	O
both	O
thin	O
sectioned	O
and	O
homogenized	O
lesions	O
,	O
and	O
aspirates	O
from	O
infected	O
sites	O
.	O

Viable	O
MU	O
N2	O
were	O
recovered	O
from	O
cultures	B-P
of	O
the	O
homogenates	O
and	O
aspirates	O
.	O

This	O
study	O
demonstrates	O
in	O
ICR	O
mice	O
MU	O
transmission	O
via	O
passive	O
infection	O
,	O
and	O
shows	O
that	O
punctures	O
in	O
the	O
skin	O
are	O
prerequisite	O
for	O
infection	O
,	O
and	O
that	O
coculturing	B-P
of	O
MU	O
with	O
AP	O
enhances	O
pathogenesis	O
.	O

Anemia	O
complicating	O
type	O
2	O
diabetes	O
:	O
Prevalence	O
,	O
risk	O
factors	O
and	O
prognosis	O
.	O

To	O
determine	O
the	O
prevalence	O
,	O
risk	O
factors	O
and	O
prognosis	O
of	O
anemia	O
in	O
representative	O
community-based	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

Data	O
from	O
the	O
Fremantle	O
Diabetes	O
Study	O
Phase	O
II	O
(	O
FDS2	O
;	O
n=1551	O
,	O
mean	O
age	O
65.7years	O
,	O
51.9	O
%	O
males	O
)	O
and	O
Busselton	O
Diabetes	O
Study	O
(	O
BDS	O
;	O
n=186	O
,	O
mean	O
age	O
70.2years	O
,	O
50.0	O
%	O
males	O
)	O
cohorts	O
,	O
and	O
from	O
186	O
matched	O
BDS	O
participants	O
without	O
diabetes	O
,	O
were	O
analyzed	O
.	O

The	O
prevalence	O
of	O
anemia	O
(	O
hemoglobin	O
≤130g/L	O
males	O
,	O
≤120g/L	O
females	O
)	O
was	O
determined	O
in	O
each	O
sample	O
.	O

In	O
FDS2	O
,	O
associates	O
of	O
anemia	O
were	O
assessed	O
using	O
multiple	O
logistic	O
regression	O
and	O
Cox	O
proportional	O
hazards	O
modeling	O
identified	O
predictors	O
of	O
death	O
during	O
4.3±1.2years	O
post-recruitment	O
.	O

The	O
prevalence	O
of	O
anemia	O
at	O
baseline	O
was	O
11.5	O
%	O
in	O
FDS2	O
participants	O
,	O
17.8	O
%	O
in	O
BDS	O
type	O
2	O
patients	O
and	O
5.4	O
%	O
in	O
BDS	O
participants	O
without	O
diabetes	O
.	O

In	O
FDS2	O
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	O
(	O
91.6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	O
factor	O
(	O
serum	B-P
vitamin	I-P
B12	I-P
<	O
140pmol/L	O
,	O
serum	O
ferritin	O
<	O
30μg/L	O
and/or	O
transferrin	B-P
saturation	I-P
<	O
20	O
%	O
,	O
serum	B-P
testosterone	I-P
<	O
10nmol/L	O
(	O
males	O
)	O
,	O
glitazone	O
therapy	O
,	O
estimated	B-P
glomerular	I-P
filtration	I-P
rate	I-P
(	O
eGFR	B-P
)	O
<	O
60mL/min	O
1.73m	O
(	O
2	O
)	O
,	O
malignancy	O
,	O
hemoglobinopathy	O
)	O
.	O

More	O
anemic	O
than	O
non-anemic	O
FDS2	O
patients	O
died	O
(	O
28.7	O
%	O
versus	O
8.0	O
%	O
;	O
P	O
<	O
0.001	O
)	O
.	O

After	O
adjustment	O
for	O
other	O
independent	O
predictors	O
(	O
age	O
as	O
time-scale	O
,	O
male	O
sex	O
,	O
Aboriginality	O
,	O
marital	O
status	O
,	O
smoking	O
,	O
eGFR	B-P
)	O
,	O
anemia	O
was	O
associated	O
with	O
a	O
57	O
%	O
increase	O
in	O
mortality	O
(	O
P=0.015	O
)	O
.	O

Type	O
2	O
diabetes	O
at	O
least	O
doubles	O
the	O
risk	O
of	O
anemia	O
but	O
other	O
mostly	O
modifiable	O
risk	O
factors	O
are	O
usually	O
present	O
.	O

Anemia	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	O
after	O
adjustment	O
for	O
other	O
predictors	O
.	O

Sensitive	B-P
determination	I-P
of	O
THC	O
and	O
main	O
metabolites	O
in	O
human	O
plasma	O
by	O
means	O
of	O
microextraction	B-P
in	I-P
packed	I-P
sorbent	I-P
and	O
gas	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
.	O

Cannabis	O
is	O
one	O
of	O
the	O
most	O
available	O
and	O
consumed	O
illicit	O
drug	O
in	O
the	O
world	O
and	O
its	O
identification	O
and	O
quantification	O
in	O
biological	O
specimens	O
can	O
be	O
a	O
challenge	O
given	O
its	O
low	O
concentrations	O
in	O
body	O
fluids	O
.	O

The	O
present	O
work	O
describes	O
a	O
fast	O
and	O
fully	O
validated	O
procedure	O
for	O
the	O
simultaneous	O
detection	O
and	O
quantification	O
of	O
▵	O
(	O
9	O
)	O
-tetrahydrocannabinol	O
(	O
▵	O
(	O
9_	O
)	O
THC	O
)	O
and	O
its	O
two	O
main	O
metabolites	O
11-hydroxy	O
▵	O
(	O
9_	O
)	O
tetrahydrocannabinol	O
(	O
11-OH-THC	O
)	O
and	O
11-nor-9-carboxy-▵	O
(	O
9	O
)	O
-	O
tetrahydrocannbinol	O
(	O
THC-COOH	O
)	O
in	O
plasma	O
samples	O
using	O
microextraction	B-P
by	I-P
packed	I-P
sorbent	I-P
(	O
MEPS	B-P
)	O
and	O
gas	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
(	O
GC-MS/MS	B-P
)	O
.	O

A	O
small	O
plasma	O
volume	O
(	O
0.25mL	O
)	O
pre-diluted	O
(	O
1:20	O
)	O
,	O
was	O
extracted	O
with	O
MEPS	B-P
M1	O
sorbent	O
as	O
follows	O
:	O
conditioning	O
(	O
4	O
cycles	O
of	O
250μL	O
methanol	O
and	O
4	O
cycles	O
of	O
250μL	O
0.1	O
%	O
formic	O
acid	O
in	O
water	O
)	O
;	O
sample	O
load	O
(	O
26	O
cycles	O
of	O
250μL	O
)	O
;	O
wash	O
(	O
100μL	O
of	O
3	O
%	O
acetic	O
acid	O
in	O
water	O
followed	O
by	O
100μL	O
5	O
%	O
methanol	O
in	O
water	O
)	O
;	O
and	O
elution	B-P
(	O
6	O
cycles	O
of	O
100μL	O
of	O
10	O
%	O
ammonium	O
hydroxide	O
in	O
methanol	O
)	O
.	O

The	O
procedure	O
allowed	O
the	O
quantification	O
of	O
all	O
analytes	O
in	O
the	O
range	O
of	O
0.1-30ng/mL	O
.	O

Recoveries	O
ranged	O
from	O
53	O
to	O
78	O
%	O
(	O
THC	O
)	O
,	O
57	O
to	O
66	O
%	O
(	O
11-OH-THC	O
)	O
and	O
62	O
to	O
65	O
%	O
(	O
THC-COOH	O
)	O
,	O
allowing	O
the	O
limits	O
of	O
detection	O
and	O
quantification	O
to	O
be	O
set	O
at	O
0.1ng/mL	O
for	O
all	O
compounds	O
.	O

Intra-day	O
precision	O
and	O
accuracy	O
revealed	O
coefficients	O
of	O
variation	O
(	O
CVs	O
)	O
lower	O
than	O
10	O
%	O
at	O
the	O
studied	O
concentrations	O
,	O
with	O
a	O
mean	O
relative	O
error	O
within±9	O
%	O
,	O
while	O
inter-day	O
precision	O
and	O
accuracy	O
showed	O
CVs	O
lower	O
than	O
15	O
%	O
for	O
all	O
analytes	O
at	O
the	O
tested	O
concentrations	O
,	O
with	O
an	O
inaccuracy	O
within±8	O
%	O
.	O

Percutaneous	O
Bullectomy	O
in	O
Conjunction	O
with	O
Endobronchial	O
Valve	O
Placement	O
as	O
an	O
Alternative	O
to	O
Surgical	O
Management	O
of	O
Giant	O
Bullae	O
.	O

We	O
present	O
the	O
first	O
reported	O
case	O
of	O
the	O
treatment	O
and	O
management	O
of	O
a	O
giant	O
bulla	O
using	O
percutaneous	O
bullectomy	O
and	O
endobronchial	O
valve	O
placement	O
.	O

A	O
74-	O
year	O
-old	O
woman	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
a	O
known	O
large	O
bulla	O
in	O
the	O
left	O
chest	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
acute-onset	O
confusion	O
after	O
a	O
traumatic	O
fall	O
.	O

She	O
was	O
subsequently	O
diagnosed	O
with	O
an	O
intracranial	O
hemorrhage	O
in	O
the	O
distribution	O
of	O
the	O
right	O
basal	O
ganglia	O
.	O

Chest	B-P
imaging	I-P
revealed	O
a	O
giant	O
apical	O
bulla	O
occupying	O
80	O
%	O
of	O
the	O
left	O
hemithorax	O
.	O

In	O
addition	O
,	O
there	O
was	O
midline	O
shift	O
away	O
from	O
the	O
affected	O
side	O
associated	O
with	O
volume	O
loss	O
in	O
the	O
right	O
hemithorax	O
and	O
no	O
radiographic	O
evidence	O
of	O
aeration	O
in	O
the	O
remainder	O
of	O
the	O
left	O
lung	O
.	O

Arterial	B-P
blood	I-P
gas	I-P
analysis	I-P
revealed	O
significant	O
hypercapnia	O
.	O

Surgical	O
bullectomy	O
was	O
not	O
an	O
option	O
,	O
and	O
thus	O
,	O
a	O
novel	O
approach	O
was	O
utilized	O
to	O
treat	O
this	O
patient	O
.	O

Neo-yoke	O
repair	O
for	O
severe	O
hypospadias	O
:	O
A	O
simple	O
modification	O
for	O
better	O
outcome	O
.	O

Although	O
staged	O
repair	O
for	O
reconstructing	O
severe	O
hypospadias	O
is	O
more	O
popular	O
,	O
various	O
one-stage	O
repairs	O
have	O
been	O
attempted	O
.	O

Koyanagi	O
repair	O
(	O
parameatal-based	O
and	O
fully	O
extended	O
circumferential	O
foreskin	O
flap	O
urethroplasty	O
)	O
has	O
enabled	O
correction	O
of	O
severe	O
hypospadias	O
in	O
one	O
stage	O
.	O

However	O
,	O
its	O
un-acceptably	O
high	O
incidence	O
of	O
complications	O
has	O
initiated	O
a	O
series	O
of	O
technical	O
modifications	O
,	O
including	O
the	O
``	O
yoke	O
''	O
repair	O
.	O

To	O
retrospectively	O
analyze	O
the	O
outcome	O
of	O
a	O
proposed	O
modification	O
of	O
the	O
originally	O
described	O
yoke	O
repair	O
,	O
for	O
patients	O
with	O
severe	O
hypospadias	O
.	O

This	O
modification	O
was	O
developed	O
to	O
reduce	O
complications	O
.	O

Over	O
4	O
years	O
(	O
between	O
Jan	O
2011	O
and	O
Jan	O
2015	O
)	O
,	O
all	O
cases	O
of	O
severe	O
hypospadias	O
were	O
included	O
in	O
this	O
study	O
;	O
except	O
those	O
with	O
prior	O
attempts	O
at	O
repair	O
,	O
circumcised	O
cases	O
,	O
and	O
cases	O
with	O
severe	O
hypogonadism	O
-	O
because	O
of	O
partial	O
androgen	O
insensitivity	O
-	O
not	O
responding	O
to	O
hormonal	O
manipulations	O
.	O

The	O
make-up	O
of	O
the	O
neo-urethra	O
in	O
this	O
modification	O
is	O
the	O
urethral	O
plate	O
with	O
its	O
spongiosal	O
tissue	O
proximally	O
,	O
a	O
circum-coronal	O
preputial	O
pedicled	O
flap	O
in	O
the	O
middle	O
,	O
and	O
an	O
incorporated	O
part	O
of	O
the	O
augmented	O
preputial	O
flap	O
and	O
the	O
preserved	B-P
V-shaped	O
glanular	O
urethra	O
,	O
distally	O
.	O

Close	O
postoperative	O
follow-up	O
was	O
conducted	O
to	O
investigate	O
the	O
outcome	O
.	O

Thirty-one	O
children	O
with	O
a	O
median	O
age	O
of	O
32.48	O
months	O
had	O
repair	O
of	O
severe	O
hypospadias	O
using	O
the	O
neo-yoke	O
technique	O
.	O

After	O
a	O
median	O
follow-up	O
of	O
26.7	O
months	O
,	O
the	O
overall	O
complication	O
rate	O
was	O
16.1	O
%	O
.	O

Four	O
children	O
developed	O
urethrocutaneous	O
fistula	O
(	O
12.9	O
%	O
)	O
.	O

Meatal	O
drop-back	O
occurred	O
in	O
one	O
case	O
(	O
3.2	O
%	O
)	O
.	O

No	O
meatal	O
stenosis	O
or	O
urethral	O
sacculation	O
was	O
detected	O
during	O
follow-up	O
of	O
the	O
studied	O
group	O
.	O

Almost	O
all	O
cases	O
had	O
cosmetically	O
appealing	O
outlook	O
.	O

Single-staged	O
repair	O
of	O
severe	O
hypospadias	O
using	O
parameatal	O
foreskin	O
-	O
based	O
urethroplasty	O
has	O
passed	O
through	O
different	O
modifications	O
,	O
all	O
aimed	O
at	O
optimizing	O
the	O
outcome	O
(	O
Table	O
)	O
.	O

Neo-yoke	O
repair	O
for	O
severe	O
hypospadias	O
is	O
a	O
natural	O
development	O
of	O
established	O
one-stage	O
techniques	O
,	O
which	O
resulted	O
in	O
better	O
mid-term	O
outcomes	O
.	O

However	O
,	O
an	O
extended	O
study	O
is	O
needed	O
to	O
declare	O
the	O
long-term	O
results	O
.	O

Differences	O
in	O
depression	O
,	O
treatment	O
satisfaction	O
and	O
injection	O
behavior	O
in	O
adults	O
with	O
type	O
1	O
diabetes	O
and	O
different	O
degrees	O
of	O
lipohypertrophy	O
.	O

To	O
assess	O
the	O
prevalence	O
of	O
lipohypertrophy	O
,	O
and	O
to	O
compare	O
differences	O
in	O
external	O
,	O
personal	O
,	O
and	O
regimen	O
factors	O
in	O
adults	O
with	O
type	O
1	O
diabetes	O
and	O
different	O
degrees	O
of	O
lipohypertrophy	O
.	O

Suboptimal	O
insulin	O
injection	O
behavior	O
is	O
associated	O
with	O
lipohypertrophy	O
,	O
which	O
may	O
affect	O
insulin	O
absorption	O
and	O
lead	O
to	O
blood	O
glucose	O
fluctuations	O
.	O

Few	O
,	O
if	O
any	O
studies	O
have	O
investigated	O
how	O
external	O
,	O
personal	O
,	O
and	O
regimen	O
factors	O
differ	O
in	O
people	O
with	O
type	O
1	O
diabetes	O
and	O
different	O
degrees	O
of	O
lipohypertrophy	O
.	O

A	O
cross-sectional	O
study	O
including	O
adults	O
with	O
type	O
1	O
diabetes	O
at	O
a	O
diabetes	O
outpatient	O
clinic	O
in	O
a	O
Norwegian	O
university	O
hospital	O
.	O

Participants	O
(	O
n=215	O
)	O
were	O
included	O
consecutively	O
at	O
scheduled	O
appointments	O
.	O

Sociodemographic	O
-	O
,	O
diabetes	O
-	O
and	O
insulin	O
treatment	O
data	O
,	O
and	O
self-report	O
questionnaires	O
concerning	O
patient	O
activation	O
(	O
PAM	O
)	O
,	O
depression	O
(	O
PHQ-2	O
)	O
,	O
diabetes	O
distress	O
(	O
DDS	O
)	O
,	O
type	O
D	O
personality	O
(	O
DS14	O
)	O
,	O
treatment	O
satisfaction	O
(	O
ITSQ	O
)	O
,	O
and	O
motivation	O
(	O
TSRQ	O
)	O
,	O
were	O
collected	O
.	O

Lipohypertrophic	O
injection	O
sites	O
were	O
identified	O
by	O
palpation	B-P
by	O
diabetes	O
specialist	O
nurses	O
.	O

Lipohypertrophy	O
was	O
present	O
in	O
53	O
%	O
and	O
was	O
more	O
frequent	O
in	O
insulin	O
pen	O
users	O
(	O
63	O
%	O
)	O
compared	O
to	O
insulin	O
pump	O
users	O
(	O
34	O
%	O
)	O
.	O

Participants	O
with	O
two	O
or	O
more	O
lipohypertrophic	O
areas	O
had	O
higher	O
depression	O
scores	O
,	O
lower	O
treatment	O
satisfaction	O
with	O
glycemic	O
control	O
,	O
higher	O
bolus	O
doses	O
,	O
and	O
reported	O
suboptimal	O
injection	O
behavior	O
compared	O
to	O
those	O
with	O
no	O
lipohypertrophic	O
areas	O
.	O

There	O
were	O
no	O
differences	O
in	O
patient	O
activation	O
,	O
diabetes	O
distress	O
,	O
type	O
D	O
personality	O
,	O
or	O
motivation	O
between	O
the	O
groups	O
.	O

Compared	O
to	O
pump	O
treatment	O
,	O
pen	O
treatment	O
requires	O
greater	O
awareness	O
of	O
injection	O
technique	O
.	O

Depressive	O
symptoms	O
and	O
lower	O
treatment	O
satisfaction	O
might	O
affect	O
diabetes	O
self-management	O
and	O
glycemic	O
control	O
,	O
but	O
the	O
association	O
with	O
lipohypertrophy	O
needs	O
further	O
exploration	O
.	O

Lipohypertrophy	O
is	O
more	O
frequent	O
in	O
insulin	O
pen	O
users	O
compared	O
to	O
pump	O
users	O
.	O

Nurses	O
should	O
focus	O
on	O
injection	O
technique	O
education	O
,	O
and	O
should	O
also	O
screen	O
for	O
depressive	O
symptoms	O
and	O
treatment	O
satisfaction	O
as	O
those	O
factors	O
could	O
be	O
associated	O
with	O
development	O
of	O
lipohypertrophy	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Core	O
Privileging	O
and	O
Credentialing	O
:	O
Hospitals	O
'	O
Approach	O
to	O
Gynecologic	O
Surgery	O
.	O

Privileging	O
and	O
credentialing	O
requirements	O
are	O
determined	O
by	O
medical	O
staff	O
leadership	O
at	O
the	O
hospital	O
level	O
to	O
ensure	O
clinicians	O
provide	O
safe	O
healthcare	O
services	O
.	O

No	O
standardized	O
guidelines	O
exist	O
for	O
gynecologic	O
surgery	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
variability	O
of	O
the	O
criteria	O
used	O
to	O
grant	O
surgical	O
privileges	O
and	O
credentials	O
for	O
gynecologic	O
procedures	O
at	O
5	O
high-volume	O
academic	O
and	O
community-based	O
US	O
hospitals	O
.	O

We	O
conducted	O
a	O
cross-sectional	O
study	O
(	O
Canadian	O
Task	O
Force	O
classification	O
III	O
)	O
.	O

Data	O
was	O
obtained	O
from	O
obtained	O
from	O
5	O
geographically	O
diverse	O
hospital	O
systems	O
.	O

We	O
examined	O
criteria	O
for	O
designating	O
core	O
gynecologic	O
privileges	O
,	O
credentialing	O
,	O
and	O
other	O
training	O
requirements	O
as	O
well	O
as	O
minimum	O
and	O
annual	O
case	O
numbers	O
for	O
initial	O
granting	O
and	O
maintenance	O
of	O
surgical	O
privileges	O
.	O

Major	O
inconsistencies	O
in	O
privileging	O
were	O
found	O
alacross	O
the	O
5	O
institutions	O
.	O

Hospitals	O
varied	O
widely	O
in	O
procedures	O
designated	O
as	O
core	O
versus	O
those	O
requiring	O
advanced	O
training	O
.	O

Institutions	O
greatly	O
contrasted	O
in	O
the	O
case	O
numbers	O
and	O
temporal	O
factors	O
used	O
to	O
define	O
experience	O
.	O

Of	O
particular	O
concern	O
was	O
absent	O
privileging	O
criteria	O
for	O
38.4	O
%	O
to	O
76.9	O
%	O
of	O
minor	O
procedures	O
,	O
26.7	O
%	O
to	O
46.7	O
%	O
of	O
endoscopic	B-P
procedures	I-P
,	O
and	O
6.67	O
%	O
to	O
56.7	O
%	O
of	O
major	O
procedures	O
.	O

Initial	O
and	O
maintenance	O
privileging	O
requirements	O
for	O
special	O
procedures	O
(	O
i.e.	O
,	O
robotic-assisted	O
surgery	O
)	O
were	O
likewise	O
discrepant	O
,	O
with	O
minimum	O
annual	O
case	O
numbers	O
ranging	O
from	O
3	O
to	O
48	O
across	O
hospitals	O
.	O

Considerable	O
variability	O
exists	O
in	O
the	O
criteria	O
used	O
by	O
hospitals	O
for	O
granting	O
and	O
maintaining	O
surgical	O
privileges	O
for	O
gynecologic	O
procedures	O
.	O

Standardization	O
will	O
likely	O
require	O
efforts	O
at	O
a	O
national	O
leadership	O
level	O
.	O

Heterogeneous	O
Mechanisms	O
of	O
Primary	O
and	O
Acquired	O
Resistance	O
to	O
Third-Generation	O
EGFR	O
Inhibitors	O
.	O

To	O
identify	O
novel	O
mechanisms	O
of	O
resistance	O
to	O
third-generation	O
EGFR	O
inhibitors	O
in	O
patients	O
with	O
lung	O
adenocarcinoma	O
that	O
progressed	O
under	O
therapy	O
with	O
either	O
AZD9291	O
or	O
rociletinib	O
(	O
CO-1686	O
)	O
.	O

We	O
analyzed	O
tumor	B-P
biopsies	I-P
from	O
seven	O
patients	O
obtained	O
before	O
,	O
during	O
,	O
and/or	O
after	O
treatment	O
with	O
AZD9291	O
or	O
rociletinib	O
(	O
CO-1686	O
)	O
.	O

Targeted	B-P
sequencing	I-P
and	O
FISH	O
analyses	O
were	O
performed	O
,	O
and	O
the	O
relevance	O
of	O
candidate	O
genes	O
was	O
functionally	O
assessed	O
in	O
in	O
vitro	O
models	O
.	O

We	O
found	O
recurrent	O
amplification	O
of	O
either	O
MET	O
or	O
ERBB2	O
in	O
tumors	O
that	O
were	O
resistant	O
or	O
developed	O
resistance	O
to	O
third-generation	O
EGFR	O
inhibitors	O
and	O
show	O
that	O
ERBB2	O
and	O
MET	O
activation	O
can	O
confer	O
resistance	O
to	O
these	O
compounds	O
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
KRAS	O
(	O
G12S	O
)	O
mutation	O
in	O
a	O
patient	O
with	O
acquired	O
resistance	O
to	O
AZD9291	O
as	O
a	O
potential	O
driver	O
of	O
acquired	O
resistance	O
.	O

Finally	O
,	O
we	O
show	O
that	O
dual	O
inhibition	O
of	O
EGFR	O
/MEK	O
might	O
be	O
a	O
viable	O
strategy	O
to	O
overcome	O
resistance	O
in	O
EGFR-mutant	O
cells	O
expressing	O
mutant	O
KRAS	O
CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
heterogeneous	O
mechanisms	O
of	O
resistance	O
can	O
drive	O
primary	O
and	O
acquired	O
resistance	O
to	O
third-generation	O
EGFR	O
inhibitors	O
and	O
provide	O
a	O
rationale	O
for	O
potential	O
combination	O
strategies	O
.	O

Clin	O
Cancer	O
Res	O
;	O
1-11	O
.	O

©2016	O
AACR	O
.	O

Budd-Chiari	O
syndrome	O
secondary	O
to	O
catheter	O
-associated	O
inferior	O
vena	O
cava	O
thrombosis	O
.	O

Patients	O
with	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
are	O
at	O
increased	O
risk	O
for	O
thrombotic	O
complications	O
.	O

The	O
use	O
of	O
central	O
venous	O
catheters	O
as	O
dialysis	O
vascular	O
access	O
additionally	O
increases	O
this	O
risk	O
.	O

We	O
describe	O
the	O
first	O
case	O
of	O
Budd-Chiari	O
syndrome	O
(	O
BCS	O
)	O
secondary	O
to	O
central	O
venous	O
catheter	O
misplacement	O
in	O
a	O
patient	O
with	O
CKD	O
.	O

A	O
30-year-old	O
female	O
patient	O
with	O
HIV/AIDS	O
and	O
CKD	O
on	O
hemodialysis	O
was	O
admitted	O
to	O
the	O
emergency	O
room	O
for	O
complaints	O
of	O
fever	O
,	O
prostration	O
,	O
and	O
headache	O
in	O
the	O
last	O
six	O
days	O
.	O

She	O
had	O
a	O
tunneled	O
dialysis	O
catheter	O
placed	O
at	O
the	O
left	O
jugular	O
vein	O
.	O

The	O
diagnosis	O
of	O
BCS	O
was	O
established	O
by	O
abdominal	B-P
computed	I-P
tomography	I-P
that	O
showed	O
a	O
partial	O
thrombus	O
within	O
the	O
inferior	O
vena	O
cava	O
which	O
extended	O
from	O
the	O
right	O
atrium	O
to	O
medium	O
hepatic	O
vein	O
,	O
and	O
continuing	O
along	O
the	O
left	O
hepatic	O
vein	O
.	O

Patient	O
was	O
treated	O
with	O
anticoagulants	O
and	O
discharged	O
asymptomatic	O
.	O

Budd-Chiari	O
syndrome	O
is	O
a	O
rare	O
medical	O
condition	O
caused	O
by	O
hepatic	O
veins	O
thrombosis	O
.	O

It	O
can	O
involve	O
one	O
,	O
two	O
,	O
or	O
all	O
three	O
of	O
the	O
major	O
hepatic	O
veins	O
.	O

It	O
is	O
usually	O
related	O
to	O
myeloproliferative	O
disorders	O
,	O
malignancy	O
and	O
hypercoagulable	O
states	O
.	O

This	O
case	O
calls	O
attention	O
for	O
inadvertent	O
catheter	O
tip	O
placement	O
into	O
hepatic	O
vein	O
leading	O
to	O
this	O
rare	O
complication	O
.	O

Assessment	O
of	O
catheter	O
dialysis	O
tip	O
location	O
with	O
radiological	O
image	O
seems	O
to	O
be	O
a	O
prudent	O
measure	O
after	O
each	O
procedure	B-P
even	O
if	O
the	O
tunneled	O
dialysis	O
catheter	O
has	O
been	O
introduced	O
with	O
fluoroscopy	O
image	O
.	O

Botulinum	O
Toxin	O
Use	O
in	O
Refractory	O
Pain	O
and	O
Other	O
Symptoms	O
in	O
Parkinsonism	O
.	O

Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
and	O
other	O
parkinsonian	O
syndromes	O
are	O
chronic	O
,	O
progressive	O
neurodegenerative	O
diseases	O
.	O

With	O
advancing	O
disease	O
,	O
both	O
motor	O
and	O
non-motor	O
symptoms	O
represent	O
a	O
considerable	O
burden	O
and	O
symptom	O
relief	O
and	O
quality	O
of	O
life	O
improvement	O
become	O
the	O
main	O
goal	O
of	O
treatment	O
.	O

Botulinum	O
toxins	O
(	O
BTX	O
)	O
are	O
an	O
effective	O
treatment	O
modality	O
for	O
many	O
neurological	O
conditions	O
.	O

To	O
understand	O
the	O
potential	O
usefulness	O
of	O
BTX	O
in	O
this	O
population	O
,	O
we	O
performed	O
a	O
retrospective	O
chart	O
review	O
of	O
all	O
patients	O
with	O
a	O
clinical	B-P
diagnosis	I-P
of	O
idiopathic	O
PD	O
and	O
atypical	O
parkinsonism	O
who	O
received	O
treatment	O
with	O
BTX	O
injections	O
in	O
our	O
center	O
from	O
1995	O
to	O
2014	O
for	O
a	O
variety	O
of	O
symptoms	O
.	O

Response	O
to	O
BTX	O
was	O
assessed	O
using	O
a	O
subjective	O
Clinical	O
Global	O
Impression	O
.	O

Records	O
of	O
160	O
patients	O
were	O
reviewed	O
.	O

Probable	O
idiopathic	O
PD	O
was	O
the	O
diagnosis	O
in	O
117	O
patients	O
(	O
73.1	O
%	O
)	O
.	O

The	O
main	O
indication	O
for	O
BTX	O
treatment	O
was	O
pain	O
(	O
50.6	O
%	O
of	O
cases	O
)	O
.	O

Other	O
indications	O
were	O
the	O
treatment	O
of	O
functional	O
impairment	O
resulting	O
from	O
dystonia	O
(	O
26.25	O
%	O
)	O
,	O
sialorrhea	O
(	O
18.75	O
%	O
)	O
,	O
freezing	O
of	O
gait	O
,	O
and	O
camptocormia	O
.	O

Considering	O
pain	O
as	O
indication	O
,	O
81	O
%	O
of	O
all	O
patients	O
with	O
PD	O
reported	O
benefits	O
after	O
the	O
first	O
BTX	O
injections	O
.	O

This	O
benefit	O
was	O
maintained	O
after	O
the	O
last	O
recorded	O
visit	O
without	O
significant	O
difference	O
in	O
outcome	O
compared	O
with	O
the	O
first	O
injection	O
(	O
p=0.067	O
)	O
.	O

Similar	O
results	O
were	O
observed	O
in	O
patients	O
with	O
atypical	O
parkinsonism	O
.	O

Our	O
results	O
confirm	O
the	O
safety	O
and	O
efficacy	O
of	O
different	O
uses	O
of	O
BTX	O
in	O
the	O
symptomatic	O
treatment	O
of	O
patients	O
with	O
parkinsonism	O
even	O
in	O
advanced	O
stages	O
of	O
the	O
disease	O
,	O
and	O
suggest	O
BTX	O
treatment	O
could	O
have	O
a	O
safe	O
and	O
useful	O
role	O
in	O
the	O
treatment	O
of	O
pain	O
in	O
this	O
population	O
.	O

Short-Term	O
Influence	O
of	O
Radiofrequency	O
Ablation	O
on	O
NT-proBNP	O
,	O
MR-proANP	O
,	O
Copeptin	O
,	O
and	O
MR-proADM	O
in	O
Patients	O
With	O
Atrial	O
Fibrillation	O
:	O
Data	O
From	O
the	O
Observational	O
SMURF	O
Study	O
.	O

There	O
is	O
limited	O
knowledge	O
on	O
the	O
short-term	O
influence	O
of	O
radiofrequency	O
ablation	O
(	O
RFA	O
)	O
of	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
on	O
2	O
cardiac	O
biomarkers	O
;	O
the	O
N-terminal	O
pro-B-type	O
natriuretic	O
peptide	O
(	O
NT-proBNP	O
)	O
and	O
the	O
midregional	O
fragment	O
of	O
the	O
N-terminal	O
of	O
pro-ANP	O
(	O
MR-proANP	O
)	O
and	O
2	O
extracardiac	O
biomarkers	O
;	O
the	O
c-terminal	O
provasopressin	O
(	O
copeptin	O
)	O
and	O
the	O
midregional	O
portion	O
of	O
proadrenomedullin	O
(	O
MR-proADM	O
)	O
.	O

There	O
are	O
also	O
limited	O
data	O
concerning	O
cardiac	O
production	O
of	O
the	O
latter	O
two	O
.	O

We	O
studied	O
192	O
consecutive	O
patients	O
eligible	O
for	O
RFA	O
of	O
AF	O
referred	O
to	O
the	O
University	O
Hospital	O
,	O
Linköping	O
,	O
Sweden	O
.	O

NT-proBNP	O
,	O
MR-proANP	O
,	O
copeptin	O
,	O
and	O
MR-proADM	O
levels	O
were	O
measured	O
in	O
peripheral	O
blood	O
,	O
the	O
coronary	O
sinus	O
(	O
CS	O
)	O
,	O
and	O
the	O
left	O
atrium	O
before	O
ablation	O
,	O
and	O
in	O
peripheral	O
blood	O
immediately	O
and	O
the	O
day	O
after	O
RFA	O
.	O

The	O
level	O
of	O
NT-proBNP	O
decreased	O
the	O
day	O
after	O
RFA	O
in	O
participants	O
in	O
AF	O
at	O
the	O
time	O
of	O
RFA	O
,	O
compared	O
to	O
the	O
participants	O
in	O
sinus	O
rhythm	O
who	O
showed	O
a	O
slight	O
increase	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Furthermore	O
,	O
regardless	O
of	O
the	O
actual	O
rhythm	O
,	O
the	O
level	O
of	O
MR-proANP	O
showed	O
an	O
increase	O
immediately	O
after	O
RFA	O
(	O
P	O
<	O
0.001	O
)	O
,	O
followed	O
by	O
a	O
decrease	O
the	O
day	O
after	O
ablation	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Copeptin	B-P
level	I-P
showed	O
a	O
6-fold	O
increase	O
immediately	O
after	O
RFA	O
compared	O
to	O
baseline	O
(	O
P	O
<	O
0.001	O
)	O
,	O
whereas	O
MR-proADM	O
level	O
increased	O
the	O
day	O
after	O
RFA	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Levels	O
of	O
copeptin	O
and	O
MR-proADM	O
were	O
not	O
higher	O
in	O
the	O
CS	O
compared	O
to	O
peripheral	O
blood	O
.	O

RFA	O
of	O
AF	O
is	O
a	O
strong	O
stimulus	O
with	O
a	O
significant	O
and	O
direct	O
impact	O
on	O
different	O
neurohormonal	O
systems	O
.	O

We	O
found	O
no	O
sign	O
of	O
a	O
cardiac	O
release	O
of	O
MR-proADM	O
or	O
copeptin	O
.	O

URL	O
:	O
http	O
:	O
//www.clinicaltrials.gov	O
.	O

Unique	O
Identifier	O
:	O
NCT01553045	O
.	O

Incidental	O
EBV	O
-	O
positivity	O
in	O
paediatric	O
post-transplant	O
specimens	O
demonstrates	O
the	O
need	O
for	O
stringent	O
criteria	O
for	O
diagnosing	O
post-transplant	O
lymphoproliferative	O
disorders	O
.	O

To	O
examine	O
the	O
need	O
for	O
minimal	O
diagnostic	O
criteria	O
for	O
post-transplant	O
lymphoproliferative	O
disorders	O
(	O
PTLD	O
)	O
in	O
children	O
,	O
we	O
sought	O
to	O
determine	O
the	O
rate	O
of	O
incidental	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-	O
positivity	O
in	O
tissues	O
from	O
organ	O
transplant	O
recipients	O
(	O
OTR	O
)	O
.	O

EBV	O
in	B-P
situ	I-P
hybridisation	I-P
(	O
ISH	B-P
)	O
was	O
done	O
retrospectively	O
on	O
tissue	O
from	O
34	O
paediatric	B-P
autopsies	I-P
of	O
OTR	O
and	O
paediatric	O
tonsillectomy	O
specimens	O
from	O
non-OTR	O
(	O
96	O
)	O
and	O
OTR	O
(	O
6	O
)	O
.	O

Patients	O
with	O
a	O
history	O
of	O
PTLD	O
were	O
excluded	O
from	O
both	O
data	O
sets	O
.	O

EBV	O
-	O
positivity	O
was	O
found	O
incidental	O
ly	O
in	O
2/34	O
autopsy	B-P
cases	O
(	O
5.9	O
%	O
)	O
.	O

Median	O
time	O
from	O
transplant	O
to	O
death	O
for	O
all	O
patients	O
was	O
12.8	O
months	O
(	O
range	O
0.1-153	O
months	O
)	O
.	O

Median	O
time	O
between	O
transplant	O
and	O
death	O
in	O
EBV	O
-	O
positive	O
cases	O
was	O
34	O
months	O
.	O

EBV	O
was	O
positive	O
in	O
26/102	O
tonsils	O
(	O
25	O
%	O
)	O
.	O

Among	O
tonsils	O
from	O
OTR	O
,	O
4/6	O
(	O
67	O
%	O
)	O
were	O
EBV	O
-	O
positive	O
.	O

These	O
findings	O
reinforce	O
the	O
need	O
for	O
strict	O
morphological	O
and	O
clinical	O
criteria	O
,	O
other	O
than	O
EBV	O
-	O
positivity	O
,	O
when	O
diagnosing	O
PTLD	O
in	O
the	O
paediatric	O
population	O
.	O

Personalizing	O
lung	O
cancer	O
risk	O
prediction	O
and	O
imaging	B-P
follow-up	O
recommendations	O
using	O
the	O
National	O
Lung	O
Screening	O
Trial	O
dataset	O
.	O

To	O
demonstrate	O
a	O
data-driven	O
method	O
for	O
personalizing	O
lung	O
cancer	O
risk	O
prediction	O
using	O
a	O
large	O
clinical	O
dataset	O
.	O

An	O
algorithm	O
was	O
used	O
to	O
categorize	O
nodules	O
found	O
in	O
the	O
first	O
screening	B-P
year	O
of	O
the	O
National	O
Lung	O
Screening	O
Trial	O
as	O
malignant	O
or	O
nonmalignant	O
.	O

Risk	O
of	O
malignancy	O
for	O
nodules	O
was	O
calculated	O
based	O
on	O
size	O
criteria	O
according	O
to	O
the	O
Fleischner	O
Society	O
recommendations	O
from	O
2005	O
,	O
along	O
with	O
the	O
additional	O
discriminators	O
of	O
pack-years	O
smoking	O
history	O
,	O
sex	O
,	O
and	O
nodule	O
location	O
.	O

Imaging	B-P
follow-up	O
recommendations	O
were	O
assigned	O
according	O
to	O
Fleischner	O
size	O
category	O
malignancy	O
risk	O
.	O

Nodule	O
size	O
correlated	O
with	O
malignancy	O
risk	O
as	O
predicted	O
by	O
the	O
Fleischner	O
Society	O
recommendations	O
.	O

With	O
the	O
additional	O
discriminators	O
of	O
smoking	O
history	O
,	O
sex	O
,	O
and	O
nodule	O
location	O
,	O
significant	O
risk	O
stratification	O
was	O
observed	O
.	O

For	O
example	O
,	O
men	O
with	O
≥60	O
pack-years	O
smoking	O
history	O
and	O
upper	O
lobe	O
nodules	O
measuring	O
>	O
4	O
and	O
≤6	O
mm	O
demonstrated	O
significantly	O
increased	O
risk	O
of	O
malignancy	O
at	O
12.4	O
%	O
compared	O
to	O
the	O
mean	O
of	O
3.81	O
%	O
for	O
similarly	O
sized	O
nodules	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Based	O
on	O
personalized	O
malignancy	O
risk	O
,	O
54	O
%	O
of	O
nodules	O
>	O
4	O
and	O
≤6	O
mm	O
were	O
reclassified	O
to	O
longer-term	O
follow-up	O
than	O
recommended	O
by	O
Fleischner	O
.	O

Twenty-seven	O
percent	O
of	O
nodules	O
≤4	O
mm	O
were	O
reclassified	O
to	O
shorter-term	O
follow-up	O
.	O

Using	O
available	O
clinical	O
datasets	O
such	O
as	O
the	O
National	O
Lung	O
Screening	O
Trial	O
in	O
conjunction	O
with	O
locally	O
collected	O
datasets	O
can	O
help	O
clinicians	O
provide	O
more	O
personalized	O
malignancy	O
risk	O
prediction	O
s	O
and	O
follow-up	O
recommendations	O
.	O

By	O
incorporating	O
3	O
demographic	O
data	O
points	O
,	O
the	O
risk	O
of	O
lung	O
nodule	O
malignancy	O
within	O
the	O
Fleischner	O
categories	O
can	O
be	O
considerably	O
stratified	O
and	O
more	O
personalized	O
follow-up	O
recommendations	O
can	O
be	O
made	O
.	O

Spinal	O
load	O
in	O
nurses	O
during	O
emergency	O
lifting	O
of	O
obese	O
patients	O
:	O
preliminary	O
results	O
.	O

Nurses	O
are	O
exposed	O
to	O
the	O
risk	O
of	O
injury	O
while	O
handling	O
patients	O
.	O

This	O
is	O
particularly	O
true	O
for	O
obese	O
patients	O
.	O

The	O
goal	O
of	O
this	O
paper	O
is	O
to	O
estimate	O
the	O
spinal	O
loads	O
and	O
the	O
related	O
risk	O
of	O
injury	O
to	O
nurses	O
while	O
lifting	O
obese	O
patients	O
from	O
the	O
floor	O
with	O
a	O
bariatric	O
sheet	O
during	O
a	O
hospital	O
emergency	O
.	O

Six	O
male	O
nurses	O
participated	O
in	O
this	O
study	O
.	O

The	O
biomechanical	B-P
analysis	I-P
focused	O
on	O
the	O
lifting	O
strategy	O
.	O

Thirty	O
obese	O
in-patients	O
were	O
enrolled	O
to	O
take	O
part	O
in	O
the	O
experimental	O
study	O
and	O
divided	O
into	O
three	O
groups	O
according	O
to	O
their	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
.	O

Three-dimensional	B-P
motion	I-P
analysis	I-P
was	O
conducted	O
using	O
an	O
optoelectronic	O
system	O
.	O

The	O
trunk	O
kinematics	O
and	O
the	O
loading	O
on	O
the	O
spines	O
of	O
the	O
operating	O
nurses	O
were	O
computed	B-P
.	O

Our	O
data	O
showed	O
that	O
when	O
the	O
nurse	O
was	O
operating	O
from	O
the	O
central	O
handle	O
,	O
his	O
trunk	O
was	O
more	O
flexed	O
at	O
the	O
end	O
of	O
the	O
lift	O
with	O
a	O
reduced	O
range	O
of	O
motion	O
.	O

The	O
values	O
were	O
higher	O
when	O
the	O
nurse	O
lifted	O
patients	O
with	O
higher	O
BMIs	O
.	O

All	O
kinetic	O
parameters	O
and	O
tension	O
in	O
the	O
lumbar	O
muscles	O
at	O
the	O
end	O
of	O
the	O
movement	O
were	O
characterised	O
by	O
lower	O
values	O
for	O
the	O
nurse	O
placed	O
beside	O
the	O
patient	O
's	O
head	O
or	O
feet	O
if	O
compared	O
to	O
the	O
operator	O
positioned	O
beside	O
the	O
central	O
handle	O
in	O
all	O
patient	O
groups	O
.	O

Our	O
preliminary	O
data	O
suggest	O
that	O
only	O
the	O
reaction	O
load	O
on	O
the	O
spine	O
of	O
the	O
nurse	O
holding	O
the	O
central	O
handle	O
,	O
closest	O
to	O
the	O
patient	O
's	O
centre	O
of	O
mass	O
,	O
seems	O
to	O
exceed	O
the	O
recommended	O
safety	O
limits	O
.	O

A	O
standardized	O
approach	O
for	O
the	O
assessment	O
and	O
treatment	O
of	O
internationally	O
adopted	O
children	O
with	O
a	O
previously	O
repaired	O
anorectal	O
malformation	O
(	O
ARM	O
)	O
.	O

A	O
significant	O
number	O
of	O
internationally	O
adopted	O
children	O
have	O
congenital	O
birth	O
defects	O
.	O

As	O
a	O
specialist	O
center	O
for	O
colorectal	O
diagnoses	B-P
,	O
we	O
evaluate	O
such	O
children	O
with	O
an	O
anorectal	O
malformation	O
(	O
ARM	O
)	O
and	O
have	O
found	O
that	O
a	O
significant	O
number	O
need	O
a	O
reoperation	O
.	O

Knowledge	O
of	O
the	O
common	O
complications	O
following	O
ARM	O
surgery	O
has	O
led	O
us	O
to	O
develop	O
treatment	O
algorithms	O
for	O
patients	O
with	O
unknown	O
past	O
medical	O
and	O
surgical	O
history	O
,	O
a	O
situation	O
typically	O
encountered	O
in	O
the	O
adopted	O
population	O
.	O

The	O
results	O
of	O
investigations	O
,	O
indications	O
,	O
and	O
rate	O
of	O
reoperation	O
were	O
assessed	O
for	O
adopted	O
children	O
with	O
an	O
ARM	O
evaluated	O
between	O
2014	O
and	O
2016	O
.	O

56	O
patients	O
(	O
28	O
males	O
)	O
were	O
identified	O
.	O

76.8	O
%	O
required	O
reoperative	O
surgery	O
.	O

Mislocation	O
of	O
the	O
anus	O
outside	O
the	O
sphincter	O
complex	O
was	O
seen	O
in	O
50	O
%	O
of	O
males	O
and	O
39.3	O
%	O
of	O
females	O
.	O

Anal	O
stricture	O
,	O
rectal	O
prolapse	O
,	O
retained	O
vaginal	O
septum	O
,	O
and	O
a	O
strictured	O
vaginal	O
introitus	O
were	O
also	O
common	O
.	O

The	O
reoperative	O
surgery	O
rate	O
in	O
the	O
internationally	O
adopted	O
child	O
with	O
an	O
ARM	O
is	O
high	O
.	O

Complete	O
,	O
systematic	O
evaluation	O
of	O
these	O
children	O
is	O
required	O
to	O
identify	O
complications	O
following	O
initial	O
repair	O
.	O

Development	O
of	O
mechanisms	O
to	O
improve	O
the	O
primary	O
surgical	O
care	O
these	O
children	O
receive	O
is	O
needed	O
.	O

Lipidomic	B-P
Signatures	I-P
and	O
Associated	O
Transcriptomic	O
Profiles	O
of	O
Clear	O
Cell	O
Renal	O
Cell	O
Carcinoma	O
.	O

Renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
is	O
the	O
most	O
common	O
histological	O
type	O
of	O
adult	O
kidney	O
cancer	O
.	O

In	O
this	O
study	O
,	O
we	O
obtained	O
lipidomic	B-P
profiles	I-P
of	O
clear	O
cell	O
RCC	O
(	O
ccRCC	O
)	O
,	O
a	O
major	O
RCC	O
subtype	O
,	O
by	O
performing	O
a	O
lipidomic	B-P
analysis	I-P
of	O
specimens	O
of	O
cancerous	O
tissue	O
and	O
the	O
surrounding	O
normal	O
renal	O
cortex	O
obtained	O
from	O
the	O
same	O
patients	O
(	O
N	O
=	O
49	O
)	O
.	O

We	O
also	O
compared	O
the	O
lipidomic	B-P
profiles	I-P
with	O
the	O
lipogenic	O
transcriptome	O
of	O
specimens	O
of	O
cancerous	O
tissue	O
and	O
the	O
surrounding	O
normal	O
renal	O
cortex	O
for	O
an	O
additional	O
set	O
of	O
patient	O
samples	O
(	O
N	O
=	O
95	O
)	O
.	O

Overall	O
,	O
we	O
detected	O
326	O
lipids	O
,	O
including	O
phospholipids	O
,	O
sphingolipids	O
,	O
neutral	O
lipids	O
,	O
and	O
eicosanoids	O
.	O

The	O
levels	O
of	O
more	O
than	O
70	O
%	O
of	O
the	O
detected	O
lipids	O
were	O
significantly	O
different	O
(	O
P	O
<	O
0.01	O
,	O
corrected	O
by	O
the	O
false	O
discovery	O
rate	O
)	O
.	O

The	O
cancerous	O
tissue	O
was	O
distinguished	O
by	O
higher	O
levels	O
of	O
ether-type	O
phospholipids	O
,	O
cholesterol	O
esters	O
,	O
and	O
triacylglycerols	O
,	O
as	O
well	O
as	O
by	O
lower	O
levels	O
of	O
phospholipids	O
(	O
except	O
for	O
phosphatidylcholines	O
)	O
and	O
polyunsaturated	O
fatty	O
acids	O
.	O

Characteristic	O
changes	O
in	O
the	O
levels	O
of	O
mRNAs	O
and	O
metabolites	O
suggested	O
that	O
the	O
phosphatidylethanolamine	O
(	O
PE	O
)	O
synthesis	O
pathway	O
is	O
suppressed	O
in	O
ccRCC	O
and	O
associated	O
with	O
cell	O
proliferation	O
.	O

The	O
present	O
study	O
represents	O
the	O
lipidomic	B-P
profiles	I-P
of	O
ccRCC	O
,	O
which	O
provides	O
novel	O
information	O
about	O
the	O
metabolic	O
changes	O
in	O
renal	O
cancerous	O
tissue	O
and	O
RCC	O
pathophysiology	O
.	O

Novel	O
biomarkers	O
for	O
patients	O
with	O
idiopathic	O
acute	O
anterior	O
uveitis	O
:	O
neutrophil	O
to	O
lymphocyte	O
ratio	O
and	O
platelet	O
to	O
lymphocyte	O
ratio	O
.	O

To	O
assess	O
the	O
levels	O
of	O
the	O
neutrophil	O
to	O
lymphocyte	O
ratio	O
(	O
N	O
/	O
L	O
)	O
and	O
the	O
platelet	O
to	O
lymphocyte	O
ratio	O
(	O
P	O
/	O
L	O
)	O
in	O
patients	O
with	O
idiopathic	O
acute	O
anterior	O
uveitis	O
(	O
AAU	O
)	O
and	O
to	O
compare	O
with	O
healthy	O
controls	O
.	O

Thirty-six	O
male	O
patients	O
with	O
idiopathic	O
AAU	O
and	O
36	O
male	O
healthy	O
subjects	O
were	O
enrolled	O
in	O
this	O
retrospective	O
study	O
.	O

Complete	O
ophthalmological	O
examination	O
and	O
complete	O
blood	B-P
count	I-P
measurements	I-P
results	O
of	O
all	O
subjects	O
were	O
evaluated	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
N	O
/	O
L	O
and	O
P	O
/	O
L	O
between	O
idiopathic	O
AAU	O
and	O
control	O
groups	O
(	O
P=0.006	O
,	O
P=0.022	O
)	O
.	O

Also	O
,	O
correlation	O
analysis	O
revealed	O
a	O
significant	O
correlation	O
between	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
and	O
N	O
/	O
L	O
(	O
P=0.002	O
;	O
r=0.461	O
)	O
.	O

Our	O
study	O
for	O
the	O
first	O
time	O
provides	O
evidence	O
of	O
N	O
/	O
L	O
and	O
P	O
/	O
L	O
may	O
be	O
useful	O
biomarkers	O
in	O
patients	O
with	O
idiopathic	O
AAU	O
.	O

N	O
/	O
L	O
is	O
correlated	O
with	O
CRP	O
,	O
so	O
it	O
can	O
be	O
a	O
useful	O
biomarker	O
to	O
predict	O
the	O
prognosis	O
in	O
idiopathic	O
AAU	O
.	O

Correlation	O
between	O
Decreased	O
Parasympathetic	O
Activity	O
and	O
Reduced	O
Cerebrovascular	O
Reactivity	O
in	O
Patients	O
with	O
Lacunar	O
Infarct	O
.	O

Reduced	O
cerebrovascular	O
reactivity	O
(	O
CVR	O
)	O
was	O
found	O
in	O
patients	O
with	O
recent	O
lacunar	O
infarct	O
.	O

However	O
,	O
its	O
mechanisms	O
were	O
controversial	O
.	O

The	O
breath	O
holding	O
maneuver	O
as	O
a	O
vasodilatory	O
stimulus	O
is	O
clinically	O
useful	O
for	O
an	O
estimation	O
of	O
cerebrovasomotor	O
reactivity	O
in	O
well	O
co-operative	O
patients	O
.	O

Patients	O
with	O
lacunar	O
infarct	O
have	O
no	O
higher	O
cortical	O
dysfunction	O
and	O
remain	O
well	O
co-operation	O
.	O

The	O
breath	O
holding	O
maneuver	O
is	O
feasible	O
and	O
safe	O
to	O
perform	O
in	O
patients	O
with	O
lacunar	O
infarct	O
.	O

Autonomic	O
nervous	O
system	O
regulates	O
systemic	O
vascular	O
activity	O
.	O

Regulation	O
of	O
autonomic	O
function	O
to	O
cerebrovascular	O
reactivity	O
has	O
been	O
reported	O
in	O
the	O
literature	O
.	O

We	O
examined	O
the	O
correlation	O
between	O
autonomic	O
functions	O
with	O
frequency	O
and	O
nonlinear	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
and	O
cerebrovascular	O
reactivity	O
in	O
patients	O
with	O
lacunar	O
infarct	O
by	O
application	O
of	O
breath	O
holding	O
maneuver	O
.	O

Fifteen	O
patients	O
with	O
lacunar	O
infarct	O
(	O
8	O
women	O
,	O
age	O
65.6	O
±	O
13.61	O
)	O
and	O
16	O
healthy	O
controls	O
(	O
11	O
women	O
,	O
age	O
27.33	O
±	O
3.85	O
)	O
were	O
continuously	O
monitored	B-P
at	O
baseline	O
before	O
maneuver	O
(	O
basal	O
phase	O
)	O
,	O
during	O
CVR	O
induction	O
(	O
experimental	O
phase	O
)	O
with	O
breath	O
holding	O
maneuver	O
and	O
after	O
maneuver	O
(	O
recovery	O
phase	O
)	O
,	O
for	O
arterial	O
blood	O
pressure	O
(	O
ABP	O
)	O
,	O
electrocardiography	B-P
(	O
EKG	B-P
)	O
,	O
mean	O
cerebral	O
blood	O
flow	O
velocity	O
(	O
mCBFV	O
)	O
of	O
middle	O
cerebral	O
arteries	O
(	O
MCA	O
)	O
by	O
transcranial	B-P
doppler	I-P
(	O
TCD	B-P
)	O
.	O

The	O
short	O
term-one	O
minute	O
HRV	O
was	O
analyzed	O
from	O
EKG	B-P
signals	O
for	O
low	O
frequency	O
(	O
LF	O
)	O
/	O
high	O
frequency	O
(	O
HF	O
)	O
ratio	O
,	O
nonlinear	O
of	O
standard	O
deviation	O
1	O
(	O
SD1	O
)	O
,	O
standard	O
deviation	O
2	O
(	O
SD2	O
)	O
,	O
cardiac	O
Sample	O
Entropy	O
(	O
SampEn	O
)	O
and	O
Shannon	O
Entropy	O
.	O

Significant	O
increasing	O
in	O
mCBFV	O
,	O
LF	O
/	O
HF	O
ratio	O
,	O
SD2	O
/	O
SD1	O
,	O
Shannon	O
Entropy	O
and	O
inversely	O
decreasing	O
SampEn	O
during	O
breath	O
holding	O
maneuver	O
compared	O
with	O
baseline	O
were	O
found	O
in	O
both	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
trend	O
of	O
cerebrovascular	O
reactivity	O
is	O
similar	O
in	O
both	O
groups	O
.	O

However	O
,	O
there	O
were	O
differences	O
of	O
mCBFV	O
,	O
systolic	O
blood	O
pressure	O
(	O
SysBP	O
)	O
in	O
the	O
whole	O
phases	O
(	O
basal	O
,	O
experiment	O
and	O
recovery	O
)	O
between	O
patients	O
and	O
controls	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Less	O
scattered	O
signals	O
of	O
SD1	O
with	O
low	O
value	O
in	O
patient	O
group	O
were	O
illustrated	O
from	O
Poincaré	O
(	O
p	O
<	O
0.05	O
)	O
.	O

This	O
indicated	O
less	O
degree	O
of	O
parasympathetic	O
drive	O
in	O
the	O
patients	O
compared	O
to	O
the	O
controls	O
.	O

Moreover	O
,	O
significant	O
positive	O
correlation	O
between	O
systolic	O
bloods	O
pressure	O
and	O
mCBFV	O
in	O
patients	O
suggests	O
impact	O
of	O
autonomic	O
control	O
and	O
cerebral	O
blood	O
flow	O
on	O
the	O
patho-physiological	O
mechanism	O
of	O
vasodilatation	O
,	O
triggered	O
by	O
hypercapnia	O
from	O
breath	O
holding	O
maneuver	O
in	O
patients	O
with	O
lacunar	O
infarct	O
.	O

Reduction	O
of	O
cerebrovascular	O
reactivity	O
in	O
patients	O
with	O
lacunar	O
infarct	O
may	O
relate	O
with	O
decreased	O
parasympathetic	O
activity	O
.	O

Further	O
study	O
is	O
required	O
to	O
demonstrate	O
whether	O
these	O
findings	O
mean	O
mechanisms	O
of	O
lacunar	O
infarct	O
or	O
the	O
effect	O
of	O
hypertensive	O
response	O
.	O

Integration	O
of	O
Serum	O
Protein	O
Biomarker	O
and	O
Tumor	O
Associated	O
Autoantibody	O
Expression	O
Data	O
Increases	O
the	O
Ability	O
of	O
a	O
Blood-Based	B-P
Proteomic	I-P
Assay	I-P
to	O
Identify	O
Breast	O
Cancer	O
.	O

Despite	O
significant	O
advances	O
in	O
breast	B-P
imaging	I-P
,	O
the	O
ability	O
to	O
accurately	O
detect	O
Breast	O
Cancer	O
(	O
BC	O
)	O
remains	O
a	O
challenge	O
.	O

With	O
the	O
discovery	O
of	O
key	O
biomarkers	O
and	O
protein	O
signatures	O
for	O
BC	O
,	O
proteomic	B-P
technologies	O
are	O
currently	O
poised	O
to	O
serve	O
as	O
an	O
ideal	O
diagnostic	O
adjunct	O
to	O
imaging	B-P
.	O

Research	O
studies	O
have	O
shown	O
that	O
breast	O
tumors	O
are	O
associated	O
with	O
systemic	O
changes	O
in	O
levels	O
of	O
both	O
serum	O
protein	O
biomarkers	O
(	O
SPB	O
)	O
and	O
tumor	O
associated	O
autoantibodies	O
(	O
TAAb	O
)	O
.	O

However	O
,	O
the	O
independent	O
contribution	O
of	O
SPB	O
and	O
TAAb	O
expression	O
data	O
for	O
identifying	O
BC	O
relative	O
to	O
a	O
combinatorial	O
SPB	O
and	O
TAAb	O
approach	O
has	O
not	O
been	O
fully	O
investigated	O
.	O

This	O
study	O
evaluates	O
these	O
contributions	O
using	O
a	O
retrospective	O
cohort	O
of	O
pre	O
-	O
biopsy	B-P
serum	O
samples	O
with	O
known	O
clinical	O
outcomes	O
collected	O
from	O
a	O
single	O
site	O
,	O
thus	O
minimizing	O
potential	O
site-to-site	O
variation	O
and	O
enabling	O
direct	O
assessment	O
of	O
SPB	O
and	O
TAAb	O
contributions	O
to	O
identify	O
BC	O
.	O

All	O
serum	O
samples	O
(	O
n	O
=	O
210	O
)	O
were	O
collected	O
prior	O
to	O
biopsy	B-P
.	O

These	O
specimens	O
were	O
obtained	O
from	O
18	O
participants	O
with	O
no	O
evidence	O
of	O
breast	O
disease	O
(	O
ND	O
)	O
,	O
92	O
participants	O
diagnosed	O
with	O
Benign	O
Breast	O
Disease	O
(	O
BBD	O
)	O
and	O
100	O
participants	O
diagnosed	O
with	O
BC	O
,	O
including	O
DCIS	O
.	O

All	O
BBD	O
and	O
BC	O
diagnoses	O
were	O
based	O
on	O
pathology	O
results	O
from	O
biopsy	B-P
.	O

Statistical	O
models	O
were	O
developed	O
to	O
differentiate	O
BC	O
from	O
non-BC	O
(	O
i.e.	O
,	O
BBD	O
and	O
ND	O
)	O
using	O
expression	O
data	O
from	O
SPB	O
alone	O
,	O
TAAb	O
alone	O
,	O
and	O
a	O
combination	O
of	O
SPB	O
and	O
TAAb	O
.	O

When	O
SPB	O
data	O
was	O
independently	O
used	O
for	O
modeling	O
,	O
clinical	O
sensitivity	O
and	O
specificity	O
for	O
detection	O
of	O
BC	O
were	O
74.7	O
%	O
and	O
77.0	O
%	O
,	O
respectively	O
.	O

When	O
TAAb	O
data	O
was	O
independently	O
used	O
,	O
clinical	O
sensitivity	O
and	O
specificity	O
for	O
detection	O
of	O
BC	O
were	O
72.2	O
%	O
and	O
70.8	O
%	O
,	O
respectively	O
.	O

When	O
modeling	O
integrated	O
data	O
from	O
both	O
SPB	O
and	O
TAAb	O
,	O
the	O
clinical	O
sensitivity	O
and	O
specificity	O
for	O
detection	O
of	O
BC	O
improved	O
to	O
81.0	O
%	O
and	O
78.8	O
%	O
,	O
respectively	O
.	O

These	O
data	O
demonstrate	O
the	O
benefit	O
of	O
the	O
integration	O
of	O
SPB	O
and	O
TAAb	O
data	O
and	O
strongly	O
support	O
the	O
further	O
development	O
of	O
combinatorial	O
proteomic	O
approaches	O
for	O
detecting	O
BC	O
.	O

Quantitative	O
analysis	O
of	O
cell	O
proliferation	O
by	O
a	O
dye	B-P
dilution	I-P
assay	I-P
:	O
Application	O
to	O
cell	O
lines	O
and	O
cocultures	B-P
.	O

Cell	O
proliferation	O
represents	O
one	O
of	O
the	O
most	O
fundamental	O
processes	O
in	O
biological	O
systems	O
,	O
thus	O
the	O
quantitative	O
analysis	O
of	O
cell	O
proliferation	O
is	O
important	O
in	O
many	O
biological	O
applications	O
such	O
as	O
drug	B-P
screening	I-P
,	O
production	O
of	O
biologics	O
,	O
and	O
assessment	O
of	O
cytotoxicity	O
.	O

Conventional	O
proliferation	O
assays	O
mainly	O
quantify	O
cell	B-P
number	I-P
based	O
on	O
a	O
calibration	O
curve	O
of	O
a	O
homogeneous	O
cell	O
population	O
,	O
and	O
therefore	O
are	O
not	O
applicable	O
for	O
the	O
analysis	O
of	O
cocultured	O
cells	O
.	O

Moreover	O
,	O
these	O
assays	B-P
measure	O
cell	O
proliferation	O
indirectly	O
,	O
based	O
on	O
cellular	O
metabolic	O
activity	O
or	O
DNA	O
content	O
.	O

To	O
overcome	O
these	O
shortcomings	O
,	O
a	O
dye	B-P
dilution	I-P
assay	I-P
employing	O
fluorescent	O
cell	O
tracking	O
dyes	O
that	O
are	O
retained	O
within	O
cells	O
was	O
applied	O
and	O
was	O
diluted	O
proportionally	O
by	O
subsequent	O
cell	O
divisions	O
.	O

Here	O
,	O
it	O
was	O
demonstrated	O
that	O
this	O
assay	B-P
could	O
be	O
implemented	O
to	O
quantitatively	O
analyze	O
the	O
cell	O
proliferation	O
of	O
different	O
types	O
of	O
cell	O
lines	O
,	O
and	O
to	O
concurrently	O
analyze	O
the	O
proliferation	O
of	O
two	O
types	O
of	O
cell	O
lines	O
in	O
coculture	B-P
by	O
utilizing	O
cell	O
tracking	O
dyes	O
with	O
different	O
spectral	O
characteristics	O
.	O

The	O
mean	O
division	O
time	O
estimated	O
by	O
the	O
dye	B-P
dilution	I-P
assay	I-P
is	O
compared	O
with	O
the	O
population	O
doubling	O
time	O
obtained	O
from	O
conventional	O
methods	O
and	O
values	O
from	O
literature	O
.	O

Additionally	O
,	O
dye	O
transfer	O
between	O
cocultured	O
cells	O
was	O
investigated	O
and	O
it	O
was	O
found	O
that	O
it	O
is	O
a	O
characteristic	O
of	O
the	O
cells	O
rather	O
than	O
a	O
characteristic	O
of	O
the	O
dye	O
.	O

It	O
was	O
suggested	O
that	O
this	O
method	O
can	O
be	O
easily	O
combined	O
with	O
other	O
flow	B-P
cytometric	I-P
analyses	I-P
of	O
cellular	O
properties	O
,	O
providing	O
valuable	O
information	O
on	O
cell	O
status	O
under	O
diverse	O
conditions	O
.	O

©	O
2017	O
International	O
Society	O
for	O
Advancement	O
of	O
Cytometry	O
.	O

Pattern	O
recognition	O
of	O
enrichment	O
levels	O
of	O
SELEX	O
-based	O
candidate	O
aptamers	O
for	O
human	O
C-reactive	O
protein	O
.	O

Selecting	O
aptamers	O
for	O
human	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
would	O
be	O
of	O
critical	O
importance	O
in	O
predicting	O
the	O
risk	O
for	O
cardiovascular	O
disease	O
.	O

The	O
enrichment	O
level	O
of	O
DNA	O
aptamers	O
is	O
an	O
important	O
parameter	O
for	O
selecting	O
candidate	O
aptamers	O
for	O
further	O
affinity	O
and	O
specificity	O
determination	B-P
.	O

This	O
paper	O
is	O
the	O
first	O
report	O
on	O
pattern	O
recognition	O
used	O
for	O
CRP	O
aptamer	O
enrichment	O
levels	O
in	O
the	O
systematic	O
evolution	O
of	O
ligands	O
by	O
exponential	O
enrichment	O
(	O
SELEX	O
)	O
process	O
,	O
by	O
applying	O
structure-activity	O
relationship	O
models	O
.	O

After	O
generating	O
10	O
rounds	O
of	O
graphene	O
oxide	O
(	O
GO	O
)	O
-	O
SELEX	O
and	O
1670	O
molecular	O
descriptors	O
,	O
eight	O
molecular	O
descriptors	O
were	O
selected	O
and	O
five	O
latent	O
variables	O
were	O
then	O
obtained	O
with	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
,	O
to	O
develop	O
a	O
support	O
vector	O
classification	O
(	O
SVC	O
)	O
model	O
.	O

The	O
SVC	O
model	O
(	O
C=8.1728	O
and	O
γ=0.2333	O
)	O
optimized	O
by	O
the	O
particle	O
swarm	O
optimization	O
(	O
PSO	O
)	O
algorithm	O
possesses	O
an	O
accuracy	O
of	O
88.15	O
%	O
for	O
the	O
training	O
set	O
.	O

Prediction	O
results	O
of	O
enrichment	O
levels	O
for	O
the	O
sequences	O
with	O
the	O
frequencies	O
of	O
6	O
and	O
5	O
are	O
reasonable	O
and	O
acceptable	O
,	O
with	O
accuracies	O
of	O
70.59	O
%	O
and	O
76.37	O
%	O
,	O
respectively	O
.	O

Anti-helminthic	O
activity	O
of	O
Momordica	O
charantia	O
L.	O
against	O
Fasciola	O
hepatica	O
eggs	O
after	O
twelve	O
days	O
of	O
incubation	B-P
in	O
vitro	O
.	O

Fasciolosis	O
,	O
a	O
parasitic	O
disease	O
caused	O
by	O
the	O
trematode	O
Fasciola	O
hepatica	O
underreported	O
is	O
expanding	O
both	O
in	O
human	O
and	O
animal	O
population	O
,	O
throughout	O
the	O
world	O
.	O

The	O
constant	O
use	O
of	O
synthetic	O
drugs	O
to	O
treat	O
this	O
condition	O
has	O
led	O
to	O
the	O
natural	O
selection	O
of	O
resistant	O
strains	O
of	O
the	O
parasite	O
.	O

Hence	O
,	O
there	O
is	O
a	O
growing	O
focus	O
on	O
the	O
potential	O
anti-helminthic	O
properties	O
of	O
medicinal	O
plants	O
and	O
phytopharmaceuticals	O
.	O

The	O
current	O
study	O
assessed	O
the	O
potential	O
anti-fasciolicide	O
action	O
of	O
Momordica	O
charantia	O
leaf	O
extracts	O
and	O
fractions	O
on	O
the	O
eggs	O
of	O
F.	O
hepatica	O
parasites	O
.	O

The	O
lyophilized	O
crude	O
extract	O
(	O
CE	O
)	O
of	O
M.	O
charantia	O
leaves	O
and	O
its	O
sub-fractions	O
,	O
obtained	O
from	O
liquid-liquid	B-P
partitioning	I-P
with	O
organic	O
solvents	O
,	O
were	O
analysed	O
by	O
High	B-P
Performance	I-P
Liquid	I-P
Chromatography	I-P
(	O
HPLC	B-P
)	O
,	O
suspended	O
in	O
1	O
%	O
DMSO	O
and	O
used	O
in	O
in	O
vitro	O
tests	B-P
.	O

Quadruplicates	O
of	O
50	O
F.	O
hepatica	O
eggs	O
were	O
incubated	B-P
at	O
23°C	O
with	O
M.	O
charantia	O
leaf	O
CE	O
in	O
different	O
concentrations	O
.	O

After	O
12	O
days	O
no	O
larvae	O
were	O
formed	O
in	O
eggs	O
incubated	B-P
with	O
CE	O
concentrations	O
above	O
12.5mg/mL	O
.	O

Eggs	O
incubated	B-P
with	O
CE	O
sub-fractions	O
at	O
concentrations	O
of	O
1000	O
,	O
100	O
,	O
10	O
,	O
1	O
,	O
0.1	O
,	O
0.01μg/mL	O
affected	O
embryonic	O
development	O
,	O
with	O
n-butanol	O
presenting	O
the	O
strongest	O
inhibition	O
of	O
miracidia	O
formation	O
.	O

In	O
contrast	O
,	O
on	O
the	O
12th	O
day	O
,	O
90	O
%	O
of	O
the	O
miracidia	O
hatched	O
in	O
the	O
control	O
experiments	O
using	O
0.03	O
%	O
DMSO	O
whereas	O
embryogenesis	O
was	O
completely	O
abolished	O
with	O
any	O
concentration	O
of	O
albendazole	O
sulphoxide	O
ABZ	O
(	O
SO	O
)	O
.	O

Chemical	B-P
analysis	I-P
of	O
the	O
CE	O
and	O
sub-fractions	O
revealed	O
a	O
prominent	O
presence	O
of	O
flavonoids	O
.	O

HPLC-MS	B-P
confirmed	O
Quercetin	O
to	O
be	O
one	O
of	O
the	O
main	O
flavonoids	O
present	O
in	O
the	O
CE	O
and	O
the	O
n-butanol	O
subfraction	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
analyse	O
the	O
potential	O
anti-fasciolicide	O
action	O
of	O
M.	O
charantia	O
leaf	O
CE	O
and	O
subfractions	O
.	O

Multitarget	O
sensing	B-P
of	I-P
glucose	I-P
and	O
cholesterol	B-P
based	O
on	O
Janus	O
hydrogel	O
microparticles	O
.	O

A	O
visualized	O
sensing	B-P
method	I-P
for	I-P
glucose	I-P
and	O
cholesterol	B-P
was	O
developed	O
based	O
on	O
the	O
hemispheres	O
of	O
the	O
same	O
Janus	O
hydrogel	O
microparticles	O
.	O

Single-phase	O
and	O
Janus	O
hydrogel	O
microparticles	O
were	O
both	O
generated	O
using	O
a	O
centrifugal	O
microfluidic	O
chip	O
.	O

For	O
glucose	B-P
sensing	I-P
,	O
concanavalin	O
A	O
and	O
fluorescein	O
labeled	O
dextran	O
used	O
for	O
competitive	B-P
binding	I-P
assay	I-P
were	O
encapsulated	O
in	O
alginate	O
microparticles	O
,	O
and	O
the	O
fluorescence	O
of	O
the	O
microparticles	O
was	O
positively	O
correlated	O
with	O
glucose	O
concentration	O
.	O

For	O
cholesterol	B-P
sensing	I-P
,	O
the	O
microparticles	O
embedded	O
with	O
γ-Fe2O3	O
nanoparticles	O
were	O
used	O
as	O
catalyst	O
for	O
the	O
oxidation	O
of	O
3,3',5,5'-Tetramethylbenzidine	O
by	O
H2O2	O
,	O
an	O
enzymatic	O
hydrolysis	O
product	O
of	O
cholesterol	O
.	O

And	O
the	O
color	O
transition	O
was	O
more	O
sensitive	O
in	O
the	O
microparticles	O
than	O
in	O
solutions	O
,	O
indicating	O
the	O
microparticles	O
are	O
more	O
applicable	O
for	O
visualized	O
determination	B-P
.	O

Furthermore	O
,	O
Janus	O
microparticles	O
were	O
employed	O
for	O
multitarget	O
sensing	O
in	O
the	O
two	O
hemespheres	O
,	O
and	O
glucose	O
and	O
cholesterol	O
were	O
detected	O
within	O
the	O
same	O
microparticles	O
without	O
obvious	O
interference	O
.	O

Besides	O
,	O
the	O
particles	O
could	O
be	O
manipulated	O
by	O
an	O
external	O
magnetic	O
field	O
.	O

The	O
glucose	O
and	O
cholesterol	O
levels	O
were	O
measured	O
in	O
human	O
serum	O
utilizing	O
the	O
microparticles	O
,	O
which	O
confirmed	O
the	O
potential	O
application	O
of	O
the	O
microparticles	O
in	O
real	O
sample	O
detection	O
.	O

Metacarpophalangeal	O
Joint	O
Arthrodesis	O
of	O
the	O
Thumb	O
-	O
Minimum	O
of	O
Eight	O
Months	O
Follow-up	O
.	O

Disorders	O
of	O
the	O
thumb	O
metacarpophalangeal	O
(	O
MCP	O
)	O
joint	O
can	O
lead	O
to	O
significant	O
loss	O
of	O
function	O
and	O
pain	O
.	O

Thumb	O
MCP	O
arthrodesis	O
following	O
traumatic	O
injuries	O
is	O
inadequately	O
described	O
and	O
recent	O
studies	O
have	O
questioned	O
the	O
outcome	O
of	O
this	O
treatment	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
report	O
outcome	O
and	O
disability	O
following	O
thumb	O
MCP	O
joint	O
arthrodesis	O
in	O
the	O
treatment	O
of	O
chronic	O
instability	O
after	O
traumatic	O
injuries	O
.	O

A	O
retrospective	O
review	O
of	O
26	O
patients	O
operated	O
on	O
with	O
MCP	O
joint	O
arthrodesis	O
,	O
median	O
follow-up	O
42	O
months	O
(	O
8-104	O
months	O
)	O
.	O

Subjective	O
outcome	O
was	O
assessed	O
using	O
the	O
disabilities	O
of	O
the	O
Arm	O
,	O
Shoulder	O
,	O
and	O
Hand-questionnaire	O
(	O
DASH	O
)	O
.	O

In	O
addition	O
,	O
patient	O
satisfaction	O
,	O
pain	O
,	O
stiffness	O
,	O
and	O
impairment	O
of	O
activities	O
of	O
daily	O
living	O
were	O
assessed	O
on	O
a	O
Visual	B-P
Analogue	I-P
Scale	I-P
(	O
VAS	B-P
)	O
followed	O
by	O
a	O
question	O
stating	O
whether	O
they	O
would	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O

Two	O
patients	O
(	O
7.7	O
%	O
)	O
needed	O
re-operation	O
due	O
to	O
nonunion	O
.	O

Four	O
patients	O
(	O
15.4	O
%	O
)	O
needed	O
hardware	O
removal	O
.	O

Median	O
DASH	O
-	O
score	O
was	O
18	O
(	O
25-75	O
%	O
range	O
6-47	O
)	O
,	O
with	O
lower	O
DASH	O
score	O
s	O
being	O
better	O
.	O

Score	O
s	O
were	O
significantly	O
worse	O
in	O
gender	O
and	O
age	O
matched	O
individuals	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Median	O
VAS	B-P
for	O
pain	O
was	O
3.7	O
(	O
range	O
0-8	O
)	O
.	O

More	O
than	O
50	O
%	O
of	O
patients	O
reported	O
mild	O
,	O
moderate	O
or	O
severe	O
pain	O
,	O
but	O
all	O
patients	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O

Our	O
data	O
suggest	O
,	O
that	O
patients	O
with	O
post-traumatic	O
thumb	O
injuries	O
managed	O
with	O
thumb	O
MCP	O
joint	O
arthrodesis	O
perform	O
worse	O
than	O
gender	O
and	O
age	O
matched	O
individuals	O
.	O

Many	O
lived	O
with	O
pain	O
,	O
but	O
all	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O

We	O
suggest	O
that	O
the	O
disability	O
scale	O
by	O
the	O
National	O
Board	O
of	O
Industrial	O
Injuries	O
should	O
be	O
reconsidered	O
for	O
patients	O
operated	O
on	O
with	O
thumb	O
MCP	O
arthrodesis	O
.	O

CXCR4	O
(	O
CD184	O
)	O
expression	O
on	O
stem	O
cell	O
harvest	O
and	O
CD34	O
(	O
+	O
)	O
cells	O
post-transplant	O
.	O

CXCR4	O
is	O
a	O
receptor	O
for	O
stromal-derived	O
factor-1	O
(	O
SDF-1	O
)	O
,	O
a	O
molecule	O
that	O
has	O
a	O
chemotactic	O
activity	O
for	O
lymphocytes	O
and	O
is	O
important	O
in	O
homing	O
of	O
hematopoietic	O
stem	O
cells	O
to	O
their	O
adult	O
marrow	O
.	O

We	O
evaluated	O
the	O
CXCR4	O
(	O
CD184	O
)	O
expression	O
in	O
the	O
harvest	O
cells	O
and	O
in	O
the	O
post-transplant	O
bone	O
marrow	O
(	O
BM	O
)	O
and	O
its	O
relation	O
to	O
engraftment	O
,	O
as	O
determined	O
by	O
the	O
consensus	O
criteria	O
and	O
chimerism	O
.	O

This	O
is	O
a	O
prospective	O
study	O
which	O
included	O
30	O
patients	O
undergoing	O
hematopoietic	O
stem	O
cell	O
transplantation	O
;	O
15	O
patients	O
received	O
autograft	O
and	O
15	O
patients	O
received	O
allograft	O
on	O
dates	O
between	O
January	O
2012	O
and	O
May	O
2014	O
.	O

We	O
assessed	O
CD184	O
(	O
CXCR4	O
)	O
using	O
flow	B-P
cytometry	I-P
in	O
the	O
harvest	O
cells	O
together	O
with	O
post-transplant	O
BM	O
assessment	O
on	O
Day	O
28	O
and	O
Day	O
90	O
for	O
complete	O
morphologic	O
,	O
molecular	B-P
studies	I-P
,	O
and	O
detection	O
of	O
CD184	O
expression	O
on	O
CD34	O
(	O
+	O
)	O
cells	O
with	O
chimerism	O
studies	O
on	O
total	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Diagnoses	O
of	O
the	O
enrolled	O
patients	O
were	O
as	O
follows	O
:	O
seven	O
(	O
24.1	O
%	O
)	O
with	O
acute	O
myeloid	O
leukemia	O
,	O
eight	O
(	O
27.6	O
%	O
)	O
with	O
multiple	O
myeloma	O
,	O
four	O
(	O
13.8	O
%	O
)	O
with	O
acute	O
lymphoblastic	O
leukemia	O
,	O
three	O
(	O
10.3	O
%	O
)	O
with	O
non-Hodgkin	O
lymphoma	O
,	O
two	O
(	O
6.9	O
%	O
)	O
with	O
myelodysplastic	O
syndromes	O
,	O
two	O
(	O
6.9	O
%	O
)	O
with	O
aplastic	O
anemia	O
,	O
two	O
(	O
6.9	O
%	O
)	O
with	O
chronic	O
myeloid	O
leukemia	O
,	O
one	O
(	O
3.4	O
%	O
)	O
with	O
Hodgkin	O
lymphoma	O
,	O
and	O
one	O
(	O
3.4	O
%	O
)	O
with	O
plasmacytomas	O
.	O

One	O
patient	O
died	O
and	O
was	O
excluded	O
from	O
the	O
study	O
because	O
there	O
were	O
not	O
enough	O
data	O
about	O
engraftment	O
.	O

There	O
was	O
no	O
statistical	O
significance	O
between	O
the	O
level	O
of	O
CD184	O
in	O
stem	O
cell	O
harvest	O
and	O
the	O
prediction	O
of	O
successful	O
engraftment	O
(	O
p	O
>	O
0.05	O
)	O
as	O
well	O
as	O
in	O
Day	O
28	O
BM	O
sample	O
(	O
p	O
>	O
0.05	O
)	O
,	O
whereas	O
there	O
was	O
a	O
statistical	O
significance	O
between	O
the	O
level	O
of	O
CD184	O
in	O
Day	O
90	O
BM	O
sample	O
and	O
the	O
occurrence	O
of	O
successful	O
engraftment	O
(	O
p=0.002	O
)	O
.	O

SDF-1	O
/	O
CXCR4	O
axis	O
plays	O
a	O
crucial	O
role	O
in	O
engraftment	O
;	O
however	O
,	O
more	O
studies	O
are	O
warranted	O
to	O
assess	O
their	O
expression	O
post-transplant	O
.	O

Evaluating	O
the	O
ligand	O
(	O
chemokine	O
,	O
SDF-1	O
)	O
or	O
its	O
receptor	O
(	O
CXCR4	O
)	O
may	O
serve	O
as	O
potential	O
surrogate	O
markers	O
for	O
assessment	O
of	O
engraftment	O
.	O

HoLEP	O
learning	O
curve	O
:	O
Toward	O
a	O
standardised	O
formation	O
and	O
a	O
team	O
strategy	O
.	O

Holmium	O
laser	O
enucleation	O
of	O
prostate	O
(	O
HoLEP	O
)	O
is	O
renowned	O
for	O
the	O
difficulty	O
of	O
its	O
learning	O
curve	O
.	O

Our	O
aim	O
was	O
to	O
evaluate	O
the	O
interest	O
of	O
a	O
three-step	O
tutorial	O
in	O
the	O
HoLEP	O
learning	O
curve	O
,	O
in	O
a	O
university	O
center	O
.	O

It	O
is	O
a	O
retrospective	O
,	O
monocentric	O
study	O
of	O
the	O
82	O
first	O
procedures	O
done	O
consecutively	O
by	O
the	O
same	O
operator	O
with	O
a	O
proctoring	O
in	O
early	O
experience	O
and	O
after	O
40	O
procedures	O
.	O

For	O
all	O
patients	O
were	O
noted	O
:	O
enucleation	O
efficiency	O
(	O
g/min	O
)	O
,	O
morcellation	O
efficiency	O
(	O
g/min	O
)	O
,	O
percentage	O
of	O
enucleated	O
tissue	O
(	O
enucleated	O
tissue	O
/	O
adenome	O
weigth	O
evaluated	O
by	O
ultrasonography	B-P
.	O

g/g	O
)	O
,	O
perioperative	O
morbidity	O
(	O
Clavien	O
)	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
length	O
of	O
urinary	O
drainage	O
,	O
functional	O
outcomes	O
at	O
short	O
and	O
middle	O
term	O
(	O
Qmax	O
,	O
post-void	O
residual	O
volume	O
[	O
PVR	O
]	O
,	O
QOL	O
scores	O
and	O
IPSS	O
at	O
3	O
and	O
6	O
months	O
)	O
.	O

Enucleation	O
and	O
morcellation	O
efficiency	O
were	O
significantly	O
higher	O
after	O
the	O
second	O
proctoring	O
(	O
0.87	O
vs	O
0.44g/min	O
;	O
P	O
<	O
0.0001	O
and	O
4.2	O
vs	O
3.37g/min	O
,	O
P=0.038	O
,	O
respectively	O
)	O
so	O
as	O
the	O
prostatic	O
volume	O
(	O
43.5	O
vs	O
68.1mL	O
,	O
P=0.0001	O
)	O
.	O

Percentage	O
of	O
enucleated	O
tissue	O
was	O
higher	O
in	O
the	O
second	O
group	O
,	O
however	O
,	O
the	O
difference	O
was	O
not	O
significant	O
(	O
69.5	O
%	O
vs	O
80.4	O
%	O
,	O
P=0.03	O
)	O
.	O

Per-	O
and	O
postoperative	O
complications	O
,	O
hospital	O
length	O
of	O
stay	O
,	O
urinary	O
drainage	O
length	O
and	O
functional	O
results	O
at	O
3	O
and	O
6	O
months	O
were	O
not	O
significantly	O
different	O
.	O

The	O
learning	O
curve	O
did	O
not	O
interfere	O
with	O
functional	O
results	O
.	O

The	O
second	O
proctoring	O
was	O
essential	O
to	O
us	O
in	O
order	O
to	O
grasp	O
the	O
technique	O
.	O

These	O
data	O
underlined	O
the	O
necessity	O
of	O
a	O
pedagogic	O
reflexion	O
in	O
order	O
to	O
built	O
a	O
standardized	O
formation	O
technique	O
to	O
the	O
HoLEP	O
.	O

4	O
.	O

The	O
four-component	O
aureocin	O
A70	O
as	O
a	O
promising	O
agent	O
for	O
food	O
biopreservation	O
.	O

Aureocin	O
A70	O
is	O
the	O
only	O
four-component	O
bacteriocin	O
described	O
to	O
date	O
.	O

As	O
it	O
inhibits	O
the	O
growth	O
of	O
a	O
wide	O
range	O
of	O
Gram-positive	O
bacteria	O
,	O
including	O
Listeria	O
monocytogenes	O
strains	O
isolated	O
from	O
food	O
,	O
its	O
potential	O
for	O
improving	O
food	O
safety	O
was	O
investigated	O
in	O
this	O
study	O
.	O

Aureocin	O
A70	O
(	O
10,240AU/mL	O
)	O
proved	O
to	O
be	O
bactericidal	O
,	O
but	O
not	O
extensively	O
lytic	O
,	O
against	O
listerial	O
strains	O
.	O

The	O
antibacterial	O
activity	O
of	O
aureocin	O
A70	O
(	O
16AU/mL	O
)	O
was	O
then	O
tested	O
in	O
UHT-treated	O
skimmed	O
milk	O
inoculated	B-P
with	O
the	O
food	O
-associated	O
L.	O
monocytogenes	O
L12	O
strain	O
(	O
4-log	O
CFU/mL	O
)	O
during	O
storage	O
at	O
4°C	O
for	O
one	O
week	O
.	O

Aureocin	O
A70	O
caused	O
a	O
time-dependent	O
reduction	O
in	O
the	O
listerial	O
viable	B-P
cell	I-P
counts	I-P
(	O
5.51-log	O
units	O
)	O
up	O
to	O
7days	O
of	O
incubation	B-P
.	O

Aureocin	O
A70	O
was	O
neither	O
toxic	O
to	O
the	O
Vero	O
and	O
the	O
L-929	O
cell	O
lines	O
nor	O
exhibited	O
a	O
hemolytic	O
activity	O
against	O
sheep	O
red	O
blood	O
cells	O
.	O

Aureocin	O
A70	O
proved	O
to	O
be	O
completely	O
stable	O
for	O
one	O
month	O
at	O
25°C	O
,	O
16weeks	O
at	O
4°C	O
and	O
20weeks	O
at	O
-20°C	O
.	O

Aureocin	O
A70	O
exhibited	O
a	O
time-dependent	O
susceptibility	O
to	O
simulated	O
gastric	O
juice	O
and	O
bile	O
salts	O
mimicking	O
gastrointestinal	O
conditions	O
.	O

The	O
entrapment	O
of	O
aureocin	O
A70	O
in	O
an	O
alginate	O
/	O
gelatin	O
matrix	O
revealed	O
that	O
this	O
bacteriocin	O
can	O
be	O
released	O
from	O
this	O
matrix	O
.	O

Moreover	O
,	O
it	O
remained	O
adsorbed	O
to	O
and	O
active	O
on	O
a	O
low-density	O
polyethylene	O
plastic	O
surface	O
suggesting	O
that	O
aureocin	O
A70	O
may	O
be	O
employed	O
in	O
bioactive	O
packaging	O
to	O
control	O
the	O
growth	O
of	O
undesirable	O
bacteria	O
.	O

Taken	O
together	O
these	O
results	O
suggest	O
that	O
aureocin	O
A70	O
is	O
a	O
promising	O
alternative	O
to	O
be	O
used	O
in	O
food	O
applications	O
.	O

Fine	O
structure	O
of	O
the	O
anterior	O
median	O
eyes	O
of	O
the	O
funnel	O
-	O
web	O
spider	O
Agelena	O
labyrinthica	O
(	O
Araneae	O
:	O
Agelenidae	O
)	O
.	O

Only	O
few	O
electron	B-P
microscopic	I-P
studies	I-P
exist	O
on	O
the	O
structure	O
of	O
the	O
main	O
eyes	O
(	O
anterior	O
median	O
eyes	O
,	O
AME	O
)	O
of	O
web	O
spiders	O
.	O

The	O
present	O
paper	O
provides	O
details	O
on	O
the	O
anatomy	O
of	O
the	O
AME	O
in	O
the	O
funnel-web	O
spider	O
Agelena	O
labyrinthica	O
.	O

The	O
retina	O
consists	O
of	O
two	O
separate	O
regions	O
with	O
differently	O
arranged	O
photoreceptor	O
cells	O
.	O

Its	O
central	O
part	O
has	O
sensory	O
cells	O
with	O
rhabdomeres	O
on	O
2	O
,	O
3	O
,	O
or	O
4	O
sides	O
,	O
whereas	O
those	O
of	O
the	O
ventral	O
retina	O
have	O
only	O
two	O
rhabdomeres	O
on	O
opposite	O
sides	O
.	O

In	O
addition	O
,	O
the	O
rhabdomeres	O
of	O
the	O
ventral	O
retina	O
are	O
arranged	O
in	O
a	O
specific	O
way	O
:	O
Whereas	O
in	O
the	O
most	O
ventral	O
part	O
they	O
form	O
long	O
tangential	O
rows	O
,	O
those	O
towards	O
the	O
center	O
are	O
detached	O
and	O
are	O
arranged	O
radially	O
.	O

All	O
sensory	O
cells	O
are	O
wrapped	O
by	O
unpigmented	O
pigment	O
cell	O
processes	O
.	O

In	O
agelenid	O
spiders	O
the	O
axons	O
of	O
the	O
sensory	O
cells	O
exit	O
from	O
the	O
middle	O
of	O
the	O
cell	O
body	O
;	O
their	O
fine	O
structure	O
and	O
course	O
through	O
the	O
eye	O
cup	O
is	O
described	O
in	O
detail	O
.	O

In	O
the	O
central	O
part	O
of	O
the	O
retina	O
efferent	O
nerve	O
fibres	O
were	O
found	O
forming	O
synapses	O
along	O
the	O
distal	O
region	O
of	O
the	O
receptor	O
cells	O
.	O

A	O
muscle	O
is	O
attached	O
laterally	O
to	O
each	O
eye	O
cup	O
that	O
allows	O
mainly	O
rotational	O
movements	O
of	O
the	O
eyes	O
.	O

The	O
optical	O
performance	O
(	O
image	O
resolution	O
)	O
of	O
these	O
main	O
eyes	O
with	O
relatively	O
few	O
visual	O
cells	O
is	O
discussed	O
.	O

Systematic	O
and	O
detailed	O
analysis	O
of	O
behavioural	B-P
tests	I-P
in	O
the	O
rat	O
middle	O
cerebral	O
artery	O
occlusion	O
model	O
of	O
stroke	O
:	O
Tests	O
for	O
long-term	O
assessment	O
.	O

In	O
order	O
to	O
test	O
therapeutics	O
,	O
functional	B-P
assessments	I-P
are	O
required	O
.	O

In	O
pre-clinical	O
stroke	O
research	O
,	O
there	O
is	O
little	O
consensus	O
regarding	O
the	O
most	O
appropriate	O
behavioural	B-P
tasks	I-P
to	O
assess	O
deficits	O
,	O
especially	O
when	O
testing	O
over	O
extended	O
times	O
in	O
milder	O
models	O
with	O
short	O
occlusion	O
times	O
and	O
small	O
lesion	O
volumes	O
.	O

In	O
this	O
study	O
,	O
we	O
comprehensively	O
assessed	O
16	O
different	O
behavioural	B-P
tests	I-P
,	O
with	O
the	O
aim	O
of	O
identifying	O
those	O
that	O
show	O
robust	O
,	O
reliable	O
and	O
stable	O
deficits	O
for	O
up	O
to	O
two	O
months	O
.	O

These	O
tasks	O
are	O
regularly	O
used	O
in	O
stroke	O
research	O
,	O
as	O
well	O
as	O
being	O
useful	O
for	O
examining	O
striatal	O
dysfunction	O
in	O
models	O
of	O
Huntington	O
's	O
and	O
Parkinson	O
's	O
disease	O
.	O

Two	O
cohorts	O
of	O
male	O
Wistar	O
rats	O
underwent	O
the	O
intraluminal	O
filament	O
model	O
of	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
30	O
min	O
)	O
and	O
were	O
imaged	B-P
24	O
h	O
later	O
.	O

This	O
resulted	O
in	O
primarily	O
subcortical	O
infarcts	O
,	O
with	O
a	O
small	O
amount	O
of	O
cortical	O
damage	O
.	O

Animals	O
were	O
tested	O
,	O
along	O
with	O
sham	O
and	O
naïve	O
groups	O
at	O
24	O
h	O
,	O
seven	O
days	O
,	O
and	O
one	O
and	O
two	O
months	O
.	O

Following	O
behavioural	B-P
testing	I-P
,	O
brains	O
were	O
processed	O
and	O
striatal	O
neuronal	O
counts	O
were	O
performed	O
alongside	O
measurements	O
of	O
total	O
brain	O
and	O
white	O
matter	O
atrophy	O
.	O

The	O
staircase	B-P
,	O
adjusting	B-P
steps	I-P
,	O
rotarod	B-P
and	O
apomorphine	B-P
-induced	I-P
rotations	I-P
were	O
the	O
most	O
reliable	O
for	O
assessing	O
long-term	O
deficits	O
in	O
the	O
30	O
min	O
transient	O
middle	O
cerebral	O
artery	O
occlusion	O
model	O
of	O
stroke	O
.	O

Can	O
mean	B-P
platelet	I-P
volume	I-P
be	O
used	O
as	O
a	O
biomarker	O
for	O
asthma	O
?	O
.	O

Platelets	O
play	O
important	O
roles	O
in	O
airway	O
inflammation	O
and	O
are	O
activated	O
in	O
inflammatory	O
lung	O
diseases	O
,	O
including	O
asthma	O
.	O

We	O
evaluated	O
the	O
mean	B-P
platelet	I-P
volume	I-P
(	O
MPV	B-P
)	O
,	O
used	O
as	O
a	O
marker	O
of	O
platelet	O
activation	O
,	O
in	O
asthmatic	O
patients	O
during	O
asymptomatic	O
periods	O
and	O
exacerbations	O
compared	O
to	O
healthy	O
controls	O
to	O
determine	O
whether	O
MPV	B-P
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
inflammation	O
.	O

Our	O
patient	O
group	O
consisted	O
of	O
95	O
children	O
with	O
exacerbation	O
of	O
asthma	O
who	O
were	O
admitted	O
to	O
our	O
allergy	O
clinic	O
.	O

The	O
control	O
group	O
consisted	O
of	O
100	O
healthy	O
children	O
matched	O
for	O
age	O
,	O
gender	O
,	O
and	O
ethnicity	O
.	O

Mean	B-P
platelet	I-P
volume	I-P
values	O
of	O
the	O
patient	O
group	O
obtained	O
during	O
exacerbation	O
of	O
asthma	O
were	O
compared	O
to	O
those	O
of	O
the	O
same	O
group	O
during	O
the	O
asymptomatic	O
period	O
and	O
with	O
the	O
control	O
group	O
.	O

We	O
investigated	O
factors	O
that	O
can	O
affect	O
the	O
MPV	B-P
values	O
of	O
asthma	O
patients	O
,	O
including	O
infection	O
,	O
atopy	O
,	O
immunotherapy	O
treatment	O
,	O
and	O
severity	O
of	O
asthma	O
exacerbation	O
.	O

The	O
patient	O
group	O
consisted	O
of	O
50	O
(	O
52.6	O
%	O
)	O
boys	O
and	O
45	O
(	O
47.4	O
%	O
)	O
girls	O
with	O
a	O
mean	O
age	O
of	O
125	O
±38	O
months	O
old	O
.	O

Mean	O
MPV	B-P
values	O
in	O
the	O
exacerbation	O
period	O
,	O
the	O
healthy	O
period	O
,	O
and	O
in	O
the	O
control	O
group	O
were	O
8.1	O
±0.8	O
fl	O
,	O
8.1	O
±1.06	O
fl	O
,	O
and	O
8.2	O
±0.9	O
fl	O
,	O
respectively	O
;	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
severity	O
of	O
asthma	O
,	O
severity	O
of	O
asthma	O
exacerbation	O
,	O
immunotherapy	O
,	O
coinfection	O
,	O
eosinophil	O
count	O
,	O
and	O
IgE	O
level	O
also	O
had	O
no	O
effect	O
on	O
MPV	B-P
(	O
p	O
>	O
0.05	O
)	O
.	O

Although	O
platelets	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
asthma	O
,	O
MPV	B-P
measurement	I-P
is	O
insufficient	O
to	O
detect	O
inflammation	O
through	O
platelets	O
.	O

Stressful	O
life	O
events	O
and	O
leucocyte	O
telomere	O
length	O
:	O
Do	O
lifestyle	O
factors	O
,	O
somatic	O
and	O
mental	O
health	O
,	O
or	O
low	O
grade	O
inflammation	O
mediate	O
this	O
relationship	O
?	O

Results	O
from	O
a	O
cohort	O
of	O
Danish	O
men	O
born	O
in	O
1953	O
.	O

Exposure	O
to	O
psychosocial	O
stress	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
a	O
number	O
of	O
somatic	O
and	O
mental	O
disorders	O
with	O
relation	O
to	O
immune	O
system	O
functioning	O
.	O

We	O
aimed	O
to	O
explore	O
whether	O
stressful	O
events	O
in	O
early	O
and	O
recent	O
life	O
was	O
associated	O
with	O
leucocyte	O
telomere	O
length	O
(	O
TL	O
)	O
,	O
which	O
is	O
assumed	O
to	O
reflect	O
the	O
accumulated	O
burden	O
of	O
inflammation	O
and	O
oxidative	O
stress	O
occurring	O
during	O
the	O
life	O
course	O
.	O

We	O
specifically	O
aimed	O
to	O
address	O
whether	O
childhood	O
constitutes	O
a	O
sensitive	O
period	O
and	O
how	O
much	O
of	O
the	O
relation	O
between	O
stressful	O
life	O
events	O
and	O
TL	O
is	O
mediated	O
through	O
somatic	O
and	O
mental	O
health	O
,	O
lifestyle	O
,	O
and	O
markers	O
of	O
low-grade	O
inflammation	O
.	O

A	O
cohort	O
of	O
Danish	O
men	O
born	O
in	O
1953	O
has	O
been	O
followed	O
since	O
birth	O
in	O
the	O
Metropolit	O
Cohort	O
.	O

These	O
men	O
underwent	O
a	O
health	O
examination	O
including	O
blood	B-P
sampling	I-P
in	O
2010	O
and	O
a	O
subset	O
of	O
324	O
also	O
had	O
a	O
quantitative	B-P
PCR-based	I-P
measurement	I-P
of	O
TL	O
.	O

The	O
relation	O
between	O
stressful	O
life	O
events	O
and	O
TL	O
was	O
analysed	O
using	O
structural	O
equation	O
modelling	O
,	O
which	O
also	O
provided	O
an	O
estimate	O
of	O
the	O
proportion	O
of	O
the	O
total	O
effect	O
mediated	O
by	O
somatic	O
and	O
mental	O
health	O
(	O
cardiovascular	O
disease	O
,	O
body	O
mass	O
and	O
depressive	O
mood	O
)	O
,	O
lifestyle	O
factors	O
,	O
and	O
low	O
grade	O
inflammation	O
(	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
,	O
interleukin	O
(	O
IL	O
)	O
-6	O
and	O
IL-10	O
)	O
.	O

Total	O
number	O
of	O
stressful	O
events	O
experienced	O
during	O
the	O
life	O
course	O
was	O
not	O
associated	O
with	O
TL	O
.	O

In	O
terms	O
of	O
sensitive	O
periods	O
,	O
we	O
found	O
that	O
number	O
of	O
stressful	O
events	O
in	O
childhood	O
was	O
associated	O
with	O
shorter	O
TL	O
(	O
βper	O
number	O
stressful	O
events	O
in	O
childhood	O
=-0.02	O
(	O
SE=-0.02	O
)	O
;	O
P=0.05	O
)	O
.	O

This	O
relation	O
was	O
particularly	O
strong	O
for	O
being	O
placed	O
away	O
from	O
home	O
(	O
β=-0.16	O
;	O
P	O
<	O
0.000	O
)	O
.	O

Thirty	O
percent	O
of	O
the	O
total	O
effect	O
of	O
stressful	O
events	O
in	O
childhood	O
on	O
TL	O
was	O
mediated	O
by	O
the	O
included	O
variables	O
,	O
with	O
the	O
largest	O
proportion	O
being	O
mediated	O
through	O
depressive	O
mood	O
(	O
16	O
%	O
)	O
and	O
CRP	O
(	O
9	O
%	O
)	O
.	O

This	O
study	O
suggests	O
that	O
stressful	O
events	O
in	O
childhood	O
are	O
associated	O
with	O
shorter	O
TL	O
in	O
middle-aged	O
men	O
and	O
that	O
part	O
of	O
this	O
relation	O
is	O
explained	O
by	O
depressive	O
mood	O
and	O
low	O
grade	O
inflammation	O
.	O

Primary	O
neuroendocrine	O
carcinoma	O
of	O
the	O
breast	O
A	O
single	O
Center	O
experience	O
and	O
review	O
of	O
the	O
literature	O
.	O

Neuroendocrine	O
carcinoma	O
of	O
the	O
breast	O
is	O
an	O
extremely	O
rare	O
tumor	O
.	O

A	O
standard	O
treatment	O
has	O
yet	O
to	O
be	O
established	O
because	O
only	O
a	O
few	O
cases	O
have	O
been	O
reported	O
in	O
literature	O
.	O

The	O
authors	O
report	O
five	O
cases	O
observed	O
from	O
January	O
2007	O
to	O
December	O
2014	O
and	O
a	O
review	O
of	O
literature	O
.	O

Four	O
patients	O
underwent	O
quadrantectomy	O
and	O
in	O
two	O
cases	O
axillary	O
nodal	O
dissection	O
and	O
only	O
one	O
to	O
mastectomy	O
with	O
axillary	O
nodal	O
dissection	O
.	O

Tumor	O
size	O
was	O
from	O
T1	O
to	O
T2	O
with	O
N0	O
to	O
N1	O
,	O
according	O
TNM	O
classification	O
.	O

Pathological	O
specimens	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
an	O
immunohistochemical	B-P
panel	O
of	O
antibodies	O
(	O
Neuron-specific	O
enolase	O
,	O
Chromogranin	O
,	O
Synaptophysin	O
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c-erb	O
and	O
Ki-67	O
)	O
.	O

All	O
cases	O
showed	O
markers	O
positivity	O
to	O
Neuron-specific	O
enolase	O
,	O
Chromogranin	O
,	O
Synaptophysin	O
and	O
Estrogen	O
and	O
Progesterone	O
receptors	O
were	O
found	O
.	O

Ki-67	O
was	O
higher	O
than	O
40	O
%	O
in	O
four	O
patients	O
.	O

Adjuvant	O
chemotherapy	O
was	O
administrated	O
in	O
patients	O
with	O
Ki-67	O
>	O
10	O
%	O
;	O
every	O
patients	O
were	O
treated	O
with	O
radiotherapy	O
and	O
with	O
hormonal	O
therapy	O
too	O
.	O

Although	O
Neuroendocrine	O
breast	O
tumor	O
is	O
considered	O
a	O
distinct	O
entity	O
,	O
the	O
best	O
treatment	O
seems	O
to	O
be	O
correlate	O
to	O
the	O
size	O
of	O
tumor	O
and	O
to	O
the	O
lymph	O
node	O
status	O
and	O
to	O
Ki-67	O
index	O
like	O
the	O
common	O
breast	O
cancer	O
.	O

Diagnosis	O
,	O
Neuroendocrine	O
breast	O
carcinoma	O
.	O

Glucose	O
metabolism	O
-	O
weighted	B-P
imaging	I-P
with	O
chemical	B-P
exchange-sensitive	I-P
MRI	I-P
of	O
2-deoxyglucose	O
(	O
2DG	O
)	O
in	O
brain	O
:	O
Sensitivity	O
and	O
biological	O
sources	O
.	O

Recent	O
proof-of-principle	O
studies	O
have	O
demonstrated	O
the	O
feasibility	O
of	O
measuring	O
the	O
uptake	O
and	O
metabolism	O
of	O
non-labeled	O
2-deoxy-D-glucose	O
(	O
2DG	O
)	O
by	O
a	O
chemical	B-P
exchange-sensitive	I-P
spin-lock	I-P
(	I-P
CESL	I-P
)	I-P
MRI	I-P
approach	I-P
.	O

In	O
order	O
to	O
gain	O
better	O
understanding	O
of	O
this	O
new	O
approach	O
,	O
we	O
performed	O
dynamic	O
in	O
vivo	O
CESL	B-P
MRI	I-P
on	O
healthy	O
rat	O
brains	O
with	O
an	O
intravenous	O
injection	O
of	O
2DG	O
under	O
various	O
conditions	O
at	O
9.4T	O
.	O

For	O
three	O
2DG	O
doses	O
of	O
0.25	O
,	O
0.5	O
and	O
1g/kg	O
,	O
we	O
found	O
that	O
2DG	O
-	O
CESL	B-P
signals	O
increased	O
linearly	O
with	O
injection	O
dose	O
at	O
the	O
initial	O
(	O
<	O
20min	O
)	O
but	O
not	O
the	O
later	O
period	O
(	O
>	O
40min	O
)	O
suggesting	O
time-dependent	O
differential	O
weightings	O
of	O
2DG	O
transport	O
and	O
metabolism	O
.	O

Remaining	O
2DG	O
-	O
CESL	B-P
studies	O
were	O
performed	O
with	O
0.25g/kg	O
2DG	O
.	O

Since	O
a	O
higher	O
isoflurane	O
level	O
reduces	O
glucose	O
metabolism	O
and	O
increases	O
blood	O
flow	O
,	O
2DG	O
-	O
CESL	B-P
was	O
measured	O
under	O
0.5	O
%	O
,	O
1.5	O
%	O
and	O
2.2	O
%	O
isoflurane	O
.	O

The	O
2DG	O
-	O
CESL	B-P
signal	O
was	O
reduced	O
at	O
higher	O
isoflurane	O
levels	O
correlating	O
well	O
with	O
the	O
2DG	O
phosphorylation	O
in	O
the	O
intracellular	O
space	O
.	O

To	O
detect	O
regional	O
heterogeneities	O
of	O
glucose	O
metabolism	O
,	O
2DG	O
-	O
CESL	B-P
with	O
0.33×0.33×1.50mm	O
(	O
3	O
)	O
resolution	O
was	O
obtained	O
,	O
which	O
indeed	O
showed	O
a	O
higher	O
response	O
in	O
the	O
cortex	O
compared	O
to	O
the	O
corpus	O
callosum	O
.	O

Lastly	O
,	O
unlike	O
CESL	B-P
MRI	I-P
with	O
the	O
injection	O
of	O
non-transportable	O
mannitol	O
,	O
the	O
2DG	O
-	O
CESL	B-P
response	O
decreased	O
with	O
an	O
increased	O
spin-lock	O
pulse	O
power	O
confirming	O
that	O
2DG	O
-	O
CESL	B-P
is	O
dominated	O
by	O
chemical	O
exchange	O
processes	O
in	O
the	O
extravascular	O
space	O
.	O

Taken	O
together	O
,	O
our	O
results	O
showed	O
that	O
2DG	O
-	O
CESL	B-P
MRI	I-P
signals	O
mainly	O
indicate	O
glucose	O
transport	O
and	O
metabolism	O
and	O
may	O
be	O
a	O
useful	O
biomarker	O
for	O
metabolic	O
studies	O
of	O
normal	O
and	O
diseased	O
brains	O
.	O

Effect	O
of	O
acute	O
heat	O
stress	O
and	O
slaughter	O
processing	O
on	O
poultry	O
meat	O
quality	O
and	O
postmortem	O
carbohydrate	O
metabolism	O
.	O

This	O
study	B-P
investigated	O
the	O
effects	O
of	O
acute	O
heat	O
stress	O
and	O
slaughter	O
processing	O
on	O
poultry	O
meat	O
quality	O
and	O
carbohydrate	O
metabolism	O
.	O

Broilers	O
(	O
200	O
)	O
were	O
randomly	O
divided	O
into	O
2	O
groups	O
receiving	O
heat	O
stress	O
(	O
HS	O
;	O
36°C	O
for	O
one	O
h	O
)	O
,	O
compared	O
to	O
a	O
non-stressed	O
control	O
(	O
C	O
)	O
.	O

At	O
slaughter	O
,	O
each	O
group	O
was	O
further	O
divided	O
into	O
2	O
groups	O
for	O
slaughter	O
processing	O
(	O
L	O
=	O
laboratory	O
;	O
F	O
=	O
commercial	O
factory	O
)	O
.	O

L	O
group	O
breasts	O
were	O
removed	O
immediately	O
after	O
bleeding	O
without	O
carcass	O
scalding	O
or	O
defeathering	O
,	O
and	O
stored	O
at	O
4°C	O
.	O

F	O
group	O
broilers	O
were	O
scalded	O
(	O
60°C	O
,	O
45	O
s	O
)	O
after	O
bleeding	O
and	O
defeathering	O
.	O

Then	O
the	O
breasts	O
were	O
removed	O
and	O
cooled	O
in	O
ice	O
water	O
until	O
the	O
core	O
temperature	O
was	O
≤4°C	O
.	O

Rates	O
of	O
Pectoralis	O
core	O
temperature	O
and	O
pH	O
decline	O
were	O
changed	O
by	O
slaughter	O
processing	O
,	O
but	O
only	O
HS	O
affected	O
ultimate	O
pH	O
in	O
group	O
L.	O
HS	O
muscles	O
had	O
higher	O
L	O
*	O
values	O
(	O
P	O
<	O
0.05	O
)	O
than	O
controls	O
at	O
24	O
h	O
postmortem	O
.	O

Laboratory	O
processing	O
``	O
hot-deboning	O
``	O
increased	O
drip	O
loss	O
,	O
which	O
resulted	O
in	O
a	O
lower	O
cooked	O
loss	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Postmortem	O
glycolysis	O
was	O
affected	O
only	O
by	O
HS	O
.	O

The	O
speed	O
of	O
lactic	O
acid	O
accumulation	O
and	O
glycogen	O
degradation	O
was	O
faster	O
in	O
the	O
HS	O
group	O
than	O
controls	O
at	O
5	O
min	O
postmortem	O
.	O

During	O
storage	O
the	O
glycolysis	O
rates	O
were	O
not	O
different	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Sarcoplasmic	O
protein	O
solubility	O
was	O
higher	O
in	O
F	O
processed	O
birds	O
(	O
P	O
<	O
0.05	O
)	O
.	O

HS	O
decreased	O
the	O
solubility	O
of	O
myofibrillar	O
and	O
total	O
protein	O
in	O
the	O
L	O
-	O
slaughtered	O
birds	O
.	O

Thus	O
,	O
HS	O
caused	O
a	O
higher	O
frequency	O
of	O
accelerated	O
muscle	O
glycolysis	O
than	O
controls	O
.	O

Factory	O
processing	O
(	O
chilling	O
)	O
could	O
not	O
completely	O
eliminate	O
the	O
effects	O
of	O
accelerated	O
glycolysis	O
caused	O
by	O
pre-	O
slaughter	O
HS	O
.	O

A	O
Head-to-Head	O
Comparison	O
of	O
UK	O
SF-6D	O
and	O
Thai	O
and	O
UK	O
EQ-5D-5L	O
Value	O
Sets	O
in	O
Thai	O
Patients	O
with	O
Chronic	O
Diseases	O
.	O

Little	O
was	O
known	O
about	O
the	O
head-to-head	O
comparison	O
of	O
psychometric	B-P
properties	I-P
between	O
SF-6D	O
and	O
EQ-5D-5L	O
or	O
the	O
different	O
value	O
sets	O
of	O
EQ-5D-5L	O
.	O

Therefore	O
,	O
this	O
study	O
set	O
out	O
to	O
compare	O
the	O
psychometric	B-P
properties	I-P
including	O
agreement	O
,	O
convergent	O
,	O
and	O
known-group	O
validity	O
between	O
the	O
SF-6D	O
and	O
the	O
EQ-5D-5L	O
using	O
the	O
real	O
value	O
sets	O
from	O
Thailand	O
and	O
the	O
UK	O
in	O
patients	O
with	O
chronic	O
diseases	O
.	O

356	O
adults	O
taking	O
a	O
medication	O
for	O
at	O
least	O
3	O
months	O
were	O
identified	O
from	O
a	O
university	O
hospital	O
in	O
Bangkok	O
,	O
Thailand	O
,	O
between	O
July	O
2014	O
and	O
March	O
2015	O
.	O

Agreement	O
was	O
assessed	O
by	O
intraclass	O
correlation	O
coefficients	O
(	O
ICCs	O
)	O
and	O
Bland-Altman	O
plots	O
.	O

Convergent	O
validity	O
was	O
evaluated	O
using	O
Spearman	O
's	O
rank	O
correlation	O
coefficients	O
between	O
SF-6D	O
and	O
EQ-5D-5L	O
and	O
EQ-VAS	O
and	O
SF-12v2	O
.	O

For	O
known-groups	O
validity	O
,	O
the	O
Mann-Whitney	O
U	O
test	O
and	O
Kruskal-Wallis	O
test	O
were	O
used	O
to	O
examine	O
the	O
associations	O
between	O
SF-6D	O
and	O
EQ-5D-5L	O
and	O
patient	O
characteristics	O
.	O

Agreement	O
s	O
between	O
the	O
SF-6D	O
and	O
the	O
EQ-5D-5L	O
using	O
Thai	O
and	O
UK	O
value	O
sets	O
were	O
fair	O
,	O
with	O
ICCs	O
of	O
0.45	O
and	O
0.49	O
,	O
respectively	O
.	O

Bland-Altman	O
plots	O
showed	O
that	O
the	O
majority	O
of	O
the	O
SF-6D	O
index	O
scores	O
were	O
lower	O
than	O
the	O
EQ-5D-5L	O
index	O
scores	O
.	O

Both	O
the	O
EQ-5D-5L	O
value	O
sets	O
were	O
more	O
related	O
to	O
the	O
EQ-VAS	O
and	O
physical	O
health	O
,	O
while	O
the	O
SF-6D	O
was	O
more	O
associated	O
with	O
mental	O
health	O
.	O

Both	O
EQ-5D-5L	O
value	O
sets	O
were	O
more	O
sensitive	O
than	O
the	O
SF-6D	O
in	O
discriminating	O
patients	O
with	O
different	O
levels	O
of	O
more	O
known	O
groups	O
except	O
for	O
adverse	O
drug	O
reactions	O
.	O

The	O
SF-6D	O
and	O
both	O
EQ-5D-5L	O
value	O
sets	O
appeared	O
to	O
be	O
valid	O
but	O
sensitive	O
to	O
different	O
outcomes	O
in	O
Thai	O
patients	O
with	O
chronic	O
diseases	O
.	O

A	O
pilot	O
study	O
of	O
intraocular	O
lens	O
explantation	O
in	O
69	O
eyes	O
in	O
Chinese	O
patients	O
.	O

To	O
study	O
the	O
effects	O
of	O
intraocular	O
lens	O
(	O
IOL	O
)	O
explantation	O
and	O
demographic	O
characteristics	O
.	O

Retrospective	O
non-comparative	O
case	O
series	O
.	O

Clinical	O
data	O
recorded	O
from	O
patient	O
charts	O
included	O
the	O
following	O
:	O
demographic	O
,	O
preoperative	O
and	O
postoperative	O
characteristics	O
;	O
complications	O
;	O
surgical	O
methods	O
,	O
and	O
changes	O
in	O
visual	B-P
acuity	I-P
.	O

A	O
total	O
of	O
69	O
eyes	O
in	O
67	O
Chinese	O
patients	O
who	O
received	O
IOL	O
explants	O
were	O
studied	O
.	O

The	O
patients	O
'	O
mean	O
age	O
at	O
the	O
time	O
of	O
explantation	O
was	O
46.1	O
years	O
old	O
[	O
SD	O
22.5	O
(	O
6-85	O
)	O
]	O
,	O
and	O
37	O
patients	O
were	O
female	O
(	O
55.2	O
%	O
)	O
.	O

Regarding	O
employment	O
,	O
47.8	O
%	O
were	O
farmers	O
,	O
23.9	O
%	O
were	O
retired	O
,	O
16.4	O
%	O
were	O
students	O
,	O
4.5	O
%	O
were	O
unemployed	O
,	O
3	O
%	O
were	O
workers	O
,	O
and	O
4.5	O
%	O
were	O
other	O
(	O
including	O
staff	O
members	O
,	O
teachers	O
and	O
officers	O
)	O
.	O

The	O
main	O
reasons	O
for	O
explantation	O
were	O
dislocation	O
/	O
decentration	O
in	O
41	O
cases	O
(	O
59.4	O
%	O
)	O
and	O
retinal	O
detachment	O
in	O
10	O
cases	O
(	O
14.5	O
%	O
)	O
.	O

The	O
third	O
most	O
prevalent	O
cause	O
was	O
incorrect	O
lens	O
power	O
in	O
7	O
eyes	O
(	O
10.1	O
%	O
)	O
.	O

The	O
remaining	O
reasons	O
were	O
endophthalmitis	O
in	O
6	O
cases	O
(	O
8.7	O
%	O
)	O
,	O
posterior	O
capsular	O
opacity	O
in	O
3	O
eyes	O
(	O
4.3	O
%	O
)	O
,	O
and	O
impacting	O
retinal	O
surgery	O
operation	O
in	O
2	O
cases	O
(	O
2.9	O
%	O
)	O
.	O

The	O
main	O
comorbidities	O
were	O
high	O
myopia	O
in	O
18	O
eyes	O
(	O
26.1	O
%	O
)	O
,	O
trauma	O
in	O
8	O
eyes	O
(	O
11.6	O
%	O
)	O
,	O
retinal	O
detachment	O
in	O
6	O
eyes	O
(	O
8.7	O
%	O
)	O
,	O
congenital	O
cataracts	O
in	O
8	O
eyes	O
(	O
11.6	O
%	O
)	O
,	O
and	O
Marfan	O
's	O
syndrome	O
in	O
2	O
eyes	O
(	O
2.9	O
%	O
)	O
.	O

The	O
mean	O
time	O
from	O
implantation	O
to	O
explantation	O
was	O
4.0y	O
[	O
SD	O
4.2	O
(	O
0.005-15	O
)	O
]	O
.	O

Treatment	O
after	O
explantation	O
included	O
posterior	O
chamber	O
IOL	O
implantation	O
in	O
44	O
eyes	O
(	O
63.8	O
%	O
)	O
and	O
aphakia	O
in	O
25	O
eyes	O
(	O
36.2	O
%	O
)	O
.	O

After	O
surgery	O
,	O
the	O
best	O
corrected	O
visual	O
ability	O
(	O
BCVA	O
)	O
was	O
improved	O
in	O
50	O
cases	O
(	O
72.5	O
%	O
)	O
,	O
including	O
28	O
patients	O
(	O
40.6	O
%	O
)	O
in	O
whom	O
visual	O
ability	O
was	O
improved	O
by	O
more	O
than	O
two	O
lines	O
.	O

Dislocation	O
/	O
decentration	O
is	O
the	O
main	O
cause	O
for	O
explantation	O
,	O
and	O
high	O
myopia	O
is	O
a	O
main	O
risk	O
factor	O
.	O

Posterior	O
chamber	O
IOL	O
implantation	O
remains	O
the	O
most	O
elected	O
treatment	O
after	O
explantation	O
.	O

Who	O
contributes	O
more	O
to	O
N2O	O
emission	O
during	O
sludge	O
bio-drying	O
with	O
two	O
different	O
aeration	O
strategies	O
,	O
nitrifiers	O
or	O
denitrifiers	O
?	O
.	O

Global	O
warming	O
effects	O
have	O
drawn	O
more	O
and	O
more	O
attention	O
to	O
studying	O
all	O
sources	O
and	O
sinks	O
of	O
nitrous	O
oxide	O
(	O
N2O	O
)	O
.	O

Sludge	O
bio-drying	O
,	O
as	O
an	O
effective	O
sludge	O
treatment	O
technology	O
,	O
is	O
being	O
adopted	O
worldwide	O
.	O

In	O
this	O
study	O
,	O
two	O
aeration	O
strategies	O
(	O
piles	O
I	O
and	O
II	O
)	O
were	O
compared	O
to	O
investigate	O
the	O
primary	O
contributors	O
to	O
N2O	O
emission	O
during	O
sludge	O
bio-drying	O
through	O
studying	O
the	O
evolution	O
of	O
functional	O
genes	O
involved	O
in	O
nitrification	O
(	O
amoA	O
,	O
hao	O
,	O
and	O
nxrA	O
)	O
and	O
denitrification	O
(	O
narG	O
,	O
nirS	O
,	O
nirK	O
,	O
norB	O
,	O
and	O
nosZ	O
)	O
by	O
quantitative	B-P
PCR	I-P
(	O
qPCR	B-P
)	O
.	O

Results	O
showed	O
that	O
the	O
profile	O
of	O
N2O	O
emission	O
can	O
be	O
divided	O
into	O
three	O
stages	O
,	O
traditional	O
denitrification	O
contributed	O
largely	O
to	O
N2O	O
emission	O
at	O
stage	O
I	O
(	O
days	O
1-5	O
)	O
,	O
but	O
N2O	O
emission	O
mainly	O
happened	O
at	O
stage	O
II	O
(	O
days	O
5-14	O
)	O
due	O
to	O
nitrifier	O
denitrification	O
and	O
NH2OH	O
accumulation	O
by	O
ammonia-oxidizing	O
bacteria	O
(	O
AOB	O
)	O
,	O
accounting	O
for	O
51.4	O
%	O
and	O
58.2	O
%	O
of	O
total	O
N2O	O
emission	O
for	O
piles	O
I	O
and	O
II	O
,	O
respectively	O
.	O

At	O
stage	O
III	O
(	O
days	O
14-21	O
)	O
,	O
nitrifier	O
denitrification	O
was	O
inhibited	O
because	O
sludge	O
bio-drying	O
proceeded	O
mainly	O
by	O
the	O
physical	O
aeration	O
,	O
thus	O
N2O	O
emission	O
decreased	O
and	O
changed	O
little	O
.	O

The	O
improved	O
aeration	O
strategy	O
availed	O
pile	O
I	O
to	O
reduce	O
N2O	O
emission	O
much	O
especially	O
at	O
stages	O
II	O
and	O
III	O
,	O
respectively	O
.	O

These	O
results	O
indicated	O
that	O
nitrifier	O
denitrification	O
by	O
AOB	O
and	O
biological	O
NH2OH	O
oxidation	O
due	O
to	O
AOB	O
made	O
more	O
contribution	O
to	O
N2O	O
emission	O
,	O
and	O
aeration	O
strategy	O
was	O
crucial	O
to	O
mitigate	O
N2O	O
emission	O
during	O
sludge	O
bio-drying	O
.	O

Barriers	O
and	O
facilitators	O
to	O
smoking	O
cessation	O
in	O
a	O
cancer	O
context	O
:	O
A	O
qualitative	O
study	O
of	O
patient	O
,	O
family	O
and	O
professional	O
views	O
.	O

Continued	O
smoking	O
after	O
cancer	O
adversely	O
affects	O
quality	O
of	O
life	O
and	O
survival	O
,	O
but	O
one	O
fifth	O
of	O
cancer	O
survivors	O
still	O
smoke	O
.	O

Despite	O
its	O
demands	O
,	O
cancer	O
presents	O
an	O
opportunity	O
for	O
positive	O
behaviour	O
change	O
.	O

Smoking	O
often	O
occurs	O
in	O
social	O
groups	O
,	O
therefore	O
interventions	O
which	O
target	O
families	O
and	O
individuals	O
may	O
be	O
more	O
successful	O
.	O

This	O
qualitative	O
study	O
explored	O
patients	O
,	O
family	O
members	O
and	O
health	O
professionals	O
'	O
views	O
and	O
experiences	O
of	O
smoking	O
and	O
smoking	O
cessation	O
after	O
cancer	O
,	O
in	O
order	O
to	O
inform	O
future	O
interventions	O
.	O

In-depth	O
qualitative	O
interviews	O
(	O
n	O
=	O
67	O
)	O
with	O
29	O
patients	O
,	O
14	O
family	O
members	O
and	O
24	O
health	O
professionals	O
.	O

Data	O
were	O
analysed	O
using	O
the	O
'Framework	O
'	O
method	O
.	O

Few	O
patient	O
s	O
and	O
family	O
members	O
had	O
used	O
National	O
Health	O
Service	O
(	O
NHS	O
)	O
smoking	O
cessation	O
services	O
and	O
more	O
than	O
half	O
still	O
smoked	O
.	O

Most	O
recalled	O
little	O
'	O
smoking	O
-related	O
'	O
discussion	O
with	O
clinicians	O
but	O
were	O
receptive	O
to	O
talking	O
openly	O
.	O

Clinicians	O
revealed	O
several	O
barriers	O
to	O
discussion	O
.	O

Participants	O
'	O
continued	O
smoking	O
was	O
explained	O
by	O
the	O
stress	O
of	O
diagnosis	B-P
;	O
desire	O
to	O
maintain	O
personal	O
control	O
;	O
and	O
lack	O
of	O
connection	O
between	O
smoking	O
,	O
cancer	O
and	O
health	O
.	O

A	O
range	O
of	O
barriers	O
to	O
smoking	O
cessation	O
exist	O
for	O
patients	O
and	O
family	O
members	O
.	O

These	O
are	O
insufficiently	O
assessed	O
and	O
considered	O
by	O
clinicians	O
.	O

Interventions	O
must	O
be	O
more	O
effectively	O
integrated	O
into	O
routine	O
practice	O
.	O

Evaluation	O
of	O
the	O
in	O
vitro	O
growth	O
of	O
urinary	O
tract	O
infection	O
-causing	O
gram-negative	O
and	O
gram-positive	O
bacteria	O
in	O
a	O
proposed	O
synthetic	O
human	O
urine	O
(	O
SHU	O
)	O
medium	O
.	O

Bacteriuria	O
is	O
a	O
hallmark	O
of	O
urinary	O
tract	O
infection	O
(	O
UTI	O
)	O
and	O
asymptomatic	O
bacteriuria	O
(	O
ABU	O
)	O
,	O
which	O
are	O
among	O
the	O
most	O
frequent	O
infections	O
in	O
humans	O
.	O

A	O
variety	O
of	O
gram-negative	O
and	O
gram-positive	O
bacteria	O
are	O
associated	O
with	O
these	O
infections	O
but	O
Escherichia	O
coli	O
contributes	O
up	O
to	O
80	O
%	O
of	O
cases	O
.	O

Multiple	O
bacterial	O
species	O
including	O
E.	O
coli	O
can	O
grow	O
in	O
human	O
urine	O
as	O
a	O
means	O
to	O
maintain	O
colonization	O
during	O
infections	O
.	O

In	O
vitro	O
bacteriuria	O
studies	O
aimed	O
at	O
modeling	O
microbial	O
growth	O
in	O
urine	O
have	O
utilized	O
various	O
compositions	O
of	O
synthetic	O
human	O
urine	O
(	O
SHU	O
)	O
and	O
a	O
Composite	O
SHU	O
formulation	O
was	O
recently	O
proposed	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
validate	O
the	O
recently	O
proposed	O
Composite	O
SHU	O
as	O
a	O
medium	O
that	O
supports	O
the	O
growth	O
of	O
several	O
bacterial	O
species	O
that	O
are	O
known	O
to	O
grow	O
in	O
normal	O
human	O
urine	O
and/or	O
artificial	O
urine	O
.	O

Comparative	O
growth	O
assays	O
of	O
gram-negative	O
and	O
gram-positive	O
bacteria	O
E.	O
coli	O
,	O
Pseudomonas	O
aeruginosa	O
,	O
Proteus	O
mirabilis	O
,	O
Streptococcus	O
agalactiae	O
,	O
Staphylococcus	O
saprophyticus	O
and	O
Enterococcus	O
faecalis	O
were	O
undertaken	O
using	O
viable	O
bacterial	B-P
count	I-P
and	O
optical	B-P
density	I-P
measurements	I-P
over	O
a	O
48h	O
culture	B-P
period	O
.	O

Three	O
different	O
SHU	O
formulations	O
were	O
tested	O
in	O
various	O
culture	O
vessels	O
,	O
shaking	O
conditions	O
and	O
volumes	O
and	O
showed	O
that	O
Composite	O
SHU	O
can	O
support	O
the	O
robust	O
growth	O
of	O
gram-negative	O
bacteria	O
but	O
requires	O
supplementation	O
with	O
0.2	O
%	O
yeast	O
extract	O
to	O
support	O
the	O
growth	O
of	O
gram-positive	O
bacteria	O
.	O

Experiments	O
are	O
also	O
presented	O
that	O
show	O
an	O
unexpected	O
but	O
major	O
influence	O
of	O
P.	O
mirabilis	O
towards	O
the	O
ability	O
to	O
measure	O
bacterial	O
growth	O
in	O
generally	O
accepted	O
multiwell	B-P
assays	I-P
using	O
absorbance	O
readings	O
,	O
predicted	O
to	O
have	O
a	O
basis	O
in	O
the	O
release	O
of	O
volatile	O
organic	O
compound	O
(	O
s	O
)	O
from	O
P.	O
mirabilis	O
during	O
growth	O
in	O
Composite	O
SHU	O
medium	O
.	O

This	O
study	O
represents	O
an	O
essential	O
methodological	O
validation	O
of	O
a	O
more	O
chemically	O
defined	O
type	O
of	O
synthetic	O
urine	O
that	O
can	O
be	O
applied	O
to	O
study	O
mechanisms	O
of	O
bacteriuria	O
and	O
we	O
conclude	O
will	O
offer	O
a	O
useful	O
in	O
vitro	O
model	O
to	O
investigate	O
the	O
basis	O
of	O
some	O
of	O
the	O
most	O
common	O
infections	O
of	O
humans	O
.	O

MESOTHELIAL	O
CELL	O
ADHERENCE	O
TO	O
VASCULAR	O
PROSTHESES	O
AND	O
THEIR	O
SUBSEQUENT	O
GROWTH	O
IN	O
VITRO	O
.	O

Cell	O
seeding	B-P
may	O
decrease	O
the	O
thrombogenicity	O
of	O
implanted	O
vascular	O
grafts	O
,	O
but	O
its	O
application	O
is	O
hampered	O
by	O
the	O
limited	O
availability	O
of	O
autologous	O
endothelial	O
cells	O
.	O

Human	O
peritoneal	O
mesothelial	O
cells	O
have	O
blood	O
flow	O
supporting	O
qualities	O
and	O
are	O
readily	O
available	O
.	O

This	O
study	O
investigated	O
the	O
adherence	O
of	O
mesothelial	O
cells	O
to	O
vascular	O
prostheses	O
and	O
their	O
subsequent	O
growth	O
in	O
vitro	O
.	O

Circular	O
pieces	O
of	O
various	O
vascular	O
prosthetic	O
materials	O
were	O
seeded	B-P
with	O
51Chromium-labeled	O
mesothelial	O
and	O
endothelial	O
cells	O
and	O
left	O
for	O
either	O
5	O
,	O
15	O
,	O
30	O
,	O
60	O
,	O
and	O
120	O
minutes	O
.	O

The	O
unattached	O
cells	O
were	O
removed	O
and	O
the	O
degree	O
of	O
cell	O
attachment	O
was	O
measured	O
.	O

The	O
number	O
of	O
mesothelial	O
cells	O
to	O
Dacron	O
increased	O
during	O
the	O
first	O
60	O
min	O
up	O
to	O
35.2	O
%	O
of	O
the	O
seeded	B-P
inoculum	O
where	O
after	O
a	O
plateau	O
was	O
reached	O
.	O

Scanning	B-P
electron	I-P
microscopy	I-P
showed	O
spreaded	O
mesothelial	O
cells	O
adherent	O
to	O
the	O
Dacron	O
fibers	O
.	O

A	O
significant	O
increase	O
in	O
adherence	O
was	O
observed	O
after	O
preincubation	B-P
of	O
Dacron	O
with	O
10	O
μg/mL	O
fibronectin	O
,	O
but	O
no	O
improvement	O
was	O
found	O
after	O
preincubation	B-P
with	O
human	O
serum	O
albumin	O
or	O
gelatin	O
.	O

Mesothelial	O
cells	O
adhered	O
better	O
to	O
Gelcoated	O
than	O
to	O
Gelsealed	O
or	O
plain	O
Dacron	O
.	O

The	O
adherence	O
of	O
mesothelial	O
cells	O
to	O
ePTFE	O
(	O
Teflon	O
)	O
was	O
significantly	O
poorer	O
.	O

No	O
significant	O
differences	O
in	O
adherence	O
were	O
found	O
between	O
mesothelial	O
and	O
endothelial	O
cells	O
.	O

Mesothelial	O
cell	O
growth	O
on	O
Dacron	O
resulted	O
in	O
a	O
modest	O
increase	O
in	O
the	O
number	O
of	O
viable	O
cells	O
during	O
27	O
days	O
,	O
which	O
implies	O
biocompatibility	O
of	O
Dacron	O
and	O
mesothelial	O
cells	O
in	O
vitro	O
.	O

Recovery	O
of	O
orthographic	O
processing	O
after	O
stroke	O
:	O
A	O
longitudinal	O
fMRI	B-P
study	O
.	O

An	O
intact	O
orthographic	O
processing	O
system	O
is	O
critical	O
for	O
normal	O
reading	O
and	O
spelling	O
.	O

Here	O
we	O
investigate	O
the	O
neural	O
changes	O
associated	O
with	O
impairment	O
and	O
subsequent	O
recovery	O
of	O
the	O
orthographic	O
lexical	O
processing	O
system	O
in	O
an	O
individual	O
with	O
an	O
ischemic	O
left	O
posterior	O
cerebral	O
artery	O
(	O
PCA	O
)	O
stroke	O
.	O

This	O
work	O
describes	O
a	O
longitudinal	O
case	O
study	O
of	O
a	O
patient	O
,	O
whose	O
initials	O
are	O
MMY	O
,	O
with	O
impairments	O
in	O
orthographic	O
lexical	O
processing	O
for	O
reading	O
and	O
spelling	O
at	O
stroke	O
onset	O
,	O
and	O
who	O
recovered	O
these	O
skills	O
within	O
1	O
year	O
post	O
stroke	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
this	O
acute	O
impairment	O
to	O
reading	O
and	O
spelling	O
would	O
be	O
associated	O
with	O
a	O
selective	O
loss	O
of	O
neural	O
activation	O
in	O
the	O
left	O
fusiform	O
gyrus	O
(	O
FG	O
)	O
,	O
and	O
that	O
subsequent	O
recovery	O
would	O
be	O
associated	O
with	O
a	O
gain	O
of	O
neural	O
activation	O
in	O
this	O
region	O
.	O

MMY	O
's	O
case	O
provided	O
a	O
unique	O
opportunity	O
to	O
assess	O
the	O
selectivity	O
of	O
neural	O
changes	O
because	O
she	O
demonstrated	O
a	O
behavioral	O
recovery	O
of	O
naming	O
as	O
well	O
;	O
i.e.	O
,	O
if	O
there	O
is	O
neural	O
recovery	O
for	O
reading	O
and	O
spelling	O
,	O
but	O
not	O
naming	O
,	O
then	O
these	O
neural	O
changes	O
are	O
selective	O
to	O
the	O
recovery	O
of	O
orthographic	O
processing	O
.	O

To	O
test	O
our	O
hypothesis	O
,	O
we	O
examined	O
longitudinal	O
behavioral	O
and	O
functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
fMRI	B-P
)	O
data	O
of	O
reading	O
,	O
spelling	O
,	O
and	O
visual	O
object	O
naming	O
acquired	O
acutely	O
,	O
3	O
weeks	O
,	O
5	O
months	O
,	O
and	O
one	O
year	O
post	O
stroke	O
.	O

In	O
confirmation	O
of	O
our	O
hypothesis	O
,	O
the	O
loss	O
and	O
subsequent	O
gain	O
of	O
orthographic	O
lexical	O
processing	O
was	O
associated	O
with	O
up-regulation	O
of	O
neural	O
activation	O
in	O
areas	O
previously	O
associated	O
with	O
orthographic	O
lexical	O
processing	O
:	O
i.e.	O
,	O
the	O
left	O
mid-FG	O
and	O
inferior	O
frontal	O
junction	O
(	O
IFJ	O
)	O
.	O

Furthermore	O
,	O
these	O
neural	O
changes	O
were	O
found	O
to	O
be	O
selective	O
to	O
orthographic	O
processing	O
,	O
as	O
they	O
were	O
observed	O
for	O
reading	O
and	O
spelling	O
,	O
but	O
not	O
for	O
visual	O
object	O
naming	O
within	O
the	O
left	O
mid-FG	O
.	O

This	O
work	O
shows	O
that	O
left	O
PCA	O
stroke	O
can	O
temporarily	O
and	O
selectively	O
disrupt	O
the	O
orthographic	O
lexical	O
processing	O
system	O
,	O
not	O
only	O
in	O
the	O
posterior	O
region	O
adjacent	O
to	O
the	O
stroke	O
,	O
but	O
also	O
in	O
relatively	O
distant	O
frontal	O
orthographic	O
processing	O
regions	O
.	O

Serum	B-P
mass	I-P
profile	I-P
signature	O
as	O
a	O
biomarker	O
of	O
early	O
lung	O
cancer	O
.	O

Circulating	O
molecular	O
biomarkers	O
of	O
lung	O
cancer	O
may	O
allow	O
the	O
pre-selection	O
of	O
candidates	O
for	O
computed	B-P
tomography	I-P
screening	O
or	O
increase	O
its	O
efficacy	O
.	O

We	O
aimed	O
to	O
identify	O
features	O
of	O
serum	B-P
mass	I-P
profile	I-P
distinguishing	O
individuals	O
with	O
early	O
lung	O
cancer	O
from	O
healthy	O
participants	O
of	O
the	O
lung	O
cancer	O
screening	O
program	O
.	O

Blood	O
samples	O
were	O
collected	O
during	O
a	O
low-dose	O
computed	B-P
tomography	I-P
(	O
LD-CT	B-P
)	O
screening	O
program	O
performed	O
by	O
one	O
institution	O
(	O
Medical	O
University	O
of	O
Gdansk	O
,	O
Poland	O
)	O
.	O

MALDI-ToF	O
mass	O
spectrometry	O
was	O
used	O
to	O
characterize	O
the	O
low-	O
molecular-weight	O
(	O
1000-14,000Da	O
)	O
serum	O
fraction	O
.	O

The	O
analysis	O
comprised	O
95	O
patients	O
with	O
early	O
stage	O
lung	O
cancer	O
(	O
including	O
30	O
screen-detected	O
cases	O
)	O
and	O
a	O
matched	O
group	O
of	O
285	O
healthy	O
controls	O
.	O

The	O
cases	O
were	O
split	O
into	O
two	O
independent	O
cohorts	O
(	O
discovery	O
and	O
validation	O
)	O
,	O
analyzed	O
separately	O
6	O
months	O
apart	O
.	O

Several	O
molecular	O
components	O
of	O
serum	O
(	O
putatively	O
components	O
of	O
endogenous	O
peptidome	O
)	O
discriminating	O
patients	O
with	O
early	O
lung	O
cancer	O
from	O
controls	O
were	O
identified	O
in	O
a	O
discovery	O
cohort	O
.	O

This	O
allowed	O
building	O
an	O
effective	O
cancer	O
classifier	O
as	O
a	O
model	O
tuned	O
to	O
maximize	O
negative	O
predictive	O
value	O
,	O
with	O
an	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
of	O
0.88	O
,	O
a	O
negative	O
predictive	O
value	O
of	O
100	O
%	O
,	O
and	O
a	O
positive	O
predictive	O
value	O
of	O
48	O
%	O
.	O

However	O
,	O
the	O
classifier	O
performed	O
worse	O
in	O
a	O
validation	O
cohort	O
including	O
independent	O
sample	O
sets	O
(	O
AUC	O
0.73	O
,	O
NPV	O
88	O
%	O
and	O
PPV	O
30	O
%	O
)	O
.	O

We	O
developed	O
a	O
serum	B-P
mass	I-P
profile	I-P
-based	O
signature	O
identifying	O
patients	O
with	O
early	O
lung	O
cancer	O
.	O

Although	O
this	O
marker	O
has	O
insufficient	O
value	O
as	O
a	O
stand-alone	O
preselecting	O
tool	O
for	O
LD-CT	B-P
screening	O
,	O
its	O
potential	O
clinical	O
usefulness	O
in	O
evaluation	O
of	O
indeterminate	O
pulmonary	O
nodules	O
deserves	O
further	O
investigation	O
.	O

The	O
Effect	O
of	O
Omega-3	O
Supplement	O
on	O
Serum	B-P
Lipid	I-P
Profile	I-P
in	O
Patients	O
Undergoing	O
Hemodialysis	O
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

Some	O
recent	O
suggestions	O
could	O
show	O
omega-3	O
condition	O
deficiency	O
following	O
prolonged	O
hemodialysis	O
;	O
however	O
,	O
these	O
claims	O
and	O
speculations	O
have	O
not	O
been	O
well	O
demonstrated	O
with	O
sufficient	O
evidences	O
.	O

Hence	O
,	O
we	O
attempted	O
to	O
assess	O
the	O
beneficial	O
effects	O
of	O
omega-3	O
on	O
lipid	B-P
profile	I-P
in	O
patients	O
with	O
end-stage	O
renal	O
disease	O
(	O
ESRD	O
)	O
undergoing	O
hemodialysis	O
.	O

One	O
hundred	O
and	O
seventeen	O
ESRD	O
patients	O
who	O
were	O
on	O
maintenance	O
dialysis	O
in	O
Rasoul-e-Akram	O
and	O
Madaen	O
Hospitals	O
were	O
enrolled	O
in	O
this	O
randomized	O
clinical	O
trial	O
.	O

These	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
randomly	O
using	O
block	O
randomization	O
method	O
(	O
57	O
patients	O
as	O
the	O
case	O
group	O
receiving	O
omega-3	O
for	O
12	O
weeks	O
and	O
60	O
as	O
the	O
control	O
group	O
)	O
.	O

Blood	O
sample	O
was	O
taken	O
from	O
all	O
patients	O
for	O
measurement	B-P
of	I-P
lipid	I-P
profile	I-P
,	O
serum	B-P
hemoglobin	I-P
,	O
and	O
C-reactive	B-P
protein	I-P
at	O
baseline	O
as	O
well	O
as	O
after	O
the	O
completion	O
of	O
interventions	O
(	O
after	O
12	O
weeks	O
)	O
.	O

The	O
average	O
change	O
in	O
the	O
value	O
of	O
HDL-C	O
was	O
significantly	O
more	O
in	O
the	O
patients	O
who	O
received	O
omega-3	O
than	O
in	O
the	O
control	O
group	O
(	O
MD	O
,	O
-7	O
mg/dL	O
;	O
95	O
%	O
CI	O
,	O
-11	O
to	O
0	O
p	O
=	O
0.000	O
)	O
.	O

Also	O
,	O
the	O
reduction	O
in	O
serum	O
creatinine	O
level	O
was	O
more	O
in	O
the	O
omega-3	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
MD	O
,	O
0.7	O
mg/dL	O
;	O
95	O
%	O
CI	O
,	O
-0.4	O
to	O
2.1	O
p	O
=	O
0.023	O
)	O
.	O

The	O
change	O
in	O
other	O
indices	O
including	O
serum	O
triglyceride	O
,	O
total	O
cholesterol	O
,	O
and	O
serum	O
hemoglobin	O
levels	O
was	O
not	O
different	O
between	O
the	O
two	O
groups	O
.	O

The	O
multivariable	O
linear	O
regression	O
analysis	O
showed	O
no	O
difference	O
in	O
serum	B-P
HDL	I-P
level	I-P
between	O
the	O
two	O
groups	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
and	O
time	O
of	O
dialysis	O
,	O
while	O
the	O
level	B-P
of	I-P
serum	I-P
HDL-C	I-P
could	O
be	O
adversely	O
predicted	O
by	O
duration	O
time	O
.	O

Similar	O
regression	O
model	O
showed	O
a	O
between-	O
group	O
difference	O
in	O
serum	O
creatinine	O
in	O
the	O
presence	O
of	O
potential	O
confounders	O
.	O

The	O
change	O
in	O
serum	B-P
HDL	I-P
level	I-P
following	O
use	O
of	O
omega-3	O
supplement	O
is	O
influenced	O
by	O
time	O
of	O
dialysis	O
,	O
not	O
by	O
drug	O
effect	O
.	O

However	O
,	O
consumption	O
of	O
omega-3	O
can	O
significantly	O
reduce	O
serum	O
creatinine	O
.	O

Fenretinide	O
targets	O
the	O
side	O
population	O
in	O
myeloma	O
cell	O
line	O
NCI-H929	O
and	O
potentiates	O
the	O
efficacy	O
of	O
antimyeloma	O
with	O
bortezomib	O
and	O
dexamethasone	O
regimen	O
.	O

Side	O
population	O
(	O
SP	O
)	O
cells	O
,	O
a	O
subset	O
of	O
enriched	O
tumor	O
initiating	O
cells	O
,	O
have	O
been	O
demonstrated	O
to	O
have	O
stem	O
cell	O
-like	O
properties	O
in	O
multiple	O
myeloma	O
(	O
MM	O
)	O
by	O
us	O
as	O
well	O
as	O
other	O
previous	O
studies	O
.	O

A	O
lack	O
of	O
agents	O
targeting	O
tumor	O
initiating	O
cells	O
,	O
however	O
,	O
represents	O
a	O
challenge	O
in	O
the	O
treatment	O
of	O
MM	O
.	O

Previously	O
,	O
fenretinide	O
,	O
a	O
well-tolerated	O
vitamin	O
A	O
derivative	O
,	O
has	O
been	O
shown	O
to	O
exert	O
effect	O
on	O
leukemic	O
stem	O
cells	O
,	O
but	O
its	O
actions	O
against	O
myeloma	O
stem-like	O
cells	O
are	O
still	O
unknown	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
fenretinide	O
on	O
myeloma	O
stem-like	O
cells	O
characteristic	O
was	O
comprehensively	O
examined	O
in	O
SP	O
and	O
non-SP	O
(	O
MP	O
)	O
cells	O
of	O
NCI-H929	O
cell	O
sorted	O
by	O
flow	B-P
cytometry	I-P
-based	O
on	O
Hoechst	O
33342	O
stain	O
.	O

We	O
find	O
that	O
fenretinide	O
is	O
capable	O
of	O
eradicating	O
MM	O
SP	O
and	O
MP	O
cells	O
,	O
but	O
not	O
normal	O
bone	O
marrow	O
mononuclear	O
cells	O
(	O
BMMCs	O
)	O
at	O
physiologically	O
achievable	O
concentrations	O
.	O

Fenretinide	O
alone	O
exerted	O
a	O
selective	O
cytotoxic	O
effect	O
on	O
MM	O
SP	O
cells	O
,	O
as	O
well	O
as	O
in	O
combination	O
with	O
bortezomib	O
and	O
dexamethasone	O
.	O

In	O
particular	O
,	O
SP	O
cells	O
were	O
highly	O
sensitive	O
to	O
fenretinide	O
,	O
and	O
in	O
combination	O
with	O
bortezomib	O
and	O
dexamethasone	O
in	O
colony	O
formation	O
and	O
apoptosis	O
assays	B-P
.	O

Accordingly	O
,	O
the	O
apparent	O
fenretinide	O
-induced-	O
apoptosis	O
was	O
linked	O
to	O
the	O
rapid	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
fenretinide	O
is	O
a	O
potent	O
agent	O
that	O
targets	O
tumor	O
initiating	O
cells	O
and	O
may	O
be	O
a	O
promising	O
therapeutic	O
agent	O
in	O
MM	O
treatment	O
.	O

Elucidating	O
a	O
chemical	O
defense	O
mechanism	O
of	O
Antarctic	O
sponges	O
:	O
A	O
computational	B-P
study	I-P
.	O

In	O
2000	O
,	O
a	O
novel	O
secondary	O
metabolite	O
(	O
erebusinone	O
,	O
Ereb	O
)	O
was	O
isolated	O
from	O
the	O
Antarctic	O
sea	O
sponge	O
,	O
Isodictya	O
erinacea	O
.	O

The	O
bioactivity	O
of	O
Ereb	O
was	O
investigated	O
,	O
and	O
it	O
was	O
found	O
to	O
inhibit	O
molting	O
when	O
fed	O
to	O
the	O
arthropod	O
species	O
Orchomene	O
plebs	O
.	O

Xanthurenic	O
acid	O
(	O
XA	O
)	O
is	O
a	O
known	O
endogenous	O
molt	O
regulator	O
present	O
in	O
arthropods	O
.	O

Experimental	O
studies	O
have	O
confirmed	O
that	O
XA	O
inhibits	O
molting	O
by	O
binding	O
to	O
either	O
(	O
or	O
both	O
)	O
of	O
two	O
P450	O
enzymes	O
(	O
CYP315a1	O
or	O
CYP314a1	O
)	O
that	O
are	O
responsible	O
for	O
the	O
final	O
two	O
hydroxylations	O
in	O
the	O
production	O
of	O
the	O
molt-inducing	O
hormone	O
,	O
20-hydroxyecdysone	O
(	O
20E	O
)	O
.	O

The	O
lack	O
of	O
crystal	O
structures	O
and	O
biochemical	B-P
assays	I-P
for	O
CYP315a1	O
or	O
CYP314a1	O
,	O
has	O
prevented	O
further	O
experimental	O
exploration	O
of	O
XA	O
and	O
Ereb	O
's	O
molt	O
inhibition	O
mechanisms	O
.	O

Herein	O
,	O
a	O
wide	O
array	O
of	O
computational	O
techniques	O
-	O
homology	O
modeling	O
,	O
molecular	O
dynamics	O
simulations	O
,	O
binding	O
site	O
bioinformatics	O
,	O
flexible	O
receptor-flexible	O
ligand	O
docking	O
,	O
and	O
molecular	O
mechanics-generalized	O
Born	O
surface	O
area	O
calculations	O
-	O
have	O
been	O
employed	O
to	O
elucidate	O
the	O
structure-function	O
relationships	O
between	O
the	O
aforementioned	O
P450s	O
and	O
the	O
two	O
described	O
small	O
molecule	O
inhibitors	O
(	O
Ereb	O
and	O
XA	O
)	O
.	O

Results	O
indicate	O
that	O
Ereb	O
likely	O
targets	O
CYP315a1	O
by	O
interacting	O
with	O
a	O
network	O
of	O
aromatic	O
residues	O
in	O
the	O
binding	O
site	O
,	O
while	O
XA	O
may	O
inhibit	O
both	O
CYP315a1	O
and	O
CYP314a1	O
because	O
of	O
its	O
aromatic	O
,	O
as	O
well	O
as	O
charged	O
nature	O
.	O

Medication	O
Overuse	O
Headache	O
:	O
Pathophysiological	O
Insights	O
from	O
Structural	O
and	O
Functional	O
Brain	O
MRI	B-P
Research	O
.	O

Research	O
imaging	B-P
of	O
brain	O
structure	O
and	O
function	O
has	O
helped	O
to	O
elucidate	O
the	O
pathophysiology	O
of	O
medication	O
overuse	O
headache	O
(	O
MOH	O
)	O
.	O

This	O
is	O
a	O
narrative	O
review	O
of	O
imaging	B-P
research	O
studies	O
that	O
have	O
investigated	O
brain	O
structural	O
and	O
functional	O
alterations	O
associated	O
with	O
MOH	O
.	O

Studies	O
included	O
in	O
this	O
review	O
have	O
investigated	O
abnormal	O
structure	O
and	O
function	O
of	O
pain	O
processing	O
regions	O
in	O
people	O
with	O
MOH	O
,	O
functional	O
patterns	O
that	O
might	O
predispose	O
individuals	O
to	O
development	O
of	O
MOH	O
,	O
similarity	O
of	O
brain	O
functional	O
patterns	O
in	O
patients	O
with	O
MOH	O
to	O
those	O
found	O
in	O
people	O
with	O
addiction	O
,	O
brain	O
structure	O
that	O
could	O
predict	O
headache	O
improvement	O
following	O
discontinuation	O
of	O
the	O
overused	O
medication	O
,	O
and	O
changes	O
in	O
brain	O
structure	O
and	O
function	O
after	O
discontinuation	O
of	O
medication	O
overuse	O
.	O

MOH	O
is	O
associated	O
with	O
atypical	O
structure	O
and	O
function	O
of	O
brain	O
regions	O
responsible	O
for	O
pain	O
processing	O
as	O
well	O
as	O
brain	O
regions	O
that	O
are	O
commonly	O
implicated	O
in	O
addiction	O
.	O

Several	O
studies	O
have	O
shown	O
``	O
normalization	O
''	O
of	O
structure	O
and	O
function	O
in	O
pain	O
processing	O
regions	O
following	O
discontinuation	O
of	O
the	O
overused	O
medication	O
and	O
resolution	O
of	O
MOH	O
.	O

However	O
,	O
some	O
of	O
the	O
abnormalities	O
in	O
regions	O
also	O
implicated	O
in	O
addiction	O
tend	O
to	O
persist	O
following	O
discontinuation	O
of	O
the	O
overused	O
medication	O
,	O
suggesting	O
that	O
they	O
are	O
a	O
brain	O
trait	O
that	O
predisposes	O
certain	O
individuals	O
to	O
medication	O
overuse	O
and	O
MOH	O
.	O

Halogenated	O
phenolic	O
compounds	O
in	O
wild	O
fish	O
from	O
Canadian	O
Areas	O
of	O
Concern	O
.	O

Concentrations	O
of	O
halogenated	O
phenolic	O
compounds	O
were	O
measured	O
in	O
the	O
plasma	O
of	O
brown	O
bullhead	O
(	O
Ameiurus	O
nebulosus	O
)	O
from	O
4	O
Canadian	O
Areas	O
of	O
Concern	O
(	O
AOCs	O
)	O
,	O
to	O
assess	O
exposure	O
to	O
suspected	O
thyroid	O
-	O
disrupting	O
chemicals	O
.	O

Hydroxylated	O
polychlorinated	O
biphenyls	O
(	O
OH-PCBs	O
)	O
were	O
detected	O
in	O
every	O
sample	O
collected	O
in	O
3	O
of	O
the	O
AOCs	O
;	O
the	O
detection	O
frequency	O
was	O
lower	O
in	O
samples	O
from	O
the	O
Detroit	O
River	O
AOC	O
.	O

The	O
OH-PCBs	O
most	O
frequently	O
detected	O
were	O
pentachloro	O
,	O
hexachloro	O
,	O
and	O
heptachloro	O
congeners	O
,	O
which	O
are	O
structurally	O
similar	O
to	O
thyroid	O
hormones	O
.	O

Pentachlorophenol	O
(	O
PCP	O
)	O
was	O
detected	O
at	O
highest	O
concentrations	O
(	O
1.8	O
ng/g	O
)	O
in	O
fish	O
from	O
Prince	O
Edward	O
Bay	O
,	O
the	O
Bay	O
of	O
Quinte	O
Lake	O
reference	O
site	O
,	O
and	O
Hillman	O
Marsh	O
(	O
the	O
Wheatley	O
Harbour	O
reference	O
site	O
)	O
,	O
suggesting	O
local	O
sources	O
of	O
contamination	O
.	O

Elevated	B-P
PCP	I-P
concentrations	I-P
were	O
also	O
detected	O
in	O
the	O
plasma	O
of	O
brown	O
bullhead	O
from	O
exposed	O
sites	O
in	O
the	O
Toronto	O
and	O
Region	O
AOC	O
(	O
0.4-0.6	O
ng/g	O
)	O
.	O

Triclosan	O
was	O
consistently	O
detected	O
in	O
the	O
Toronto	O
and	O
Region	O
AOC	O
(	O
0.05-0.9	O
ng/g	O
)	O
,	O
consistent	O
with	O
wastewater	O
emission	O
.	O

Greater	O
concentrations	O
were	O
occasionally	O
detected	O
in	O
the	O
plasma	O
of	O
brown	O
bullhead	O
from	O
the	O
Bay	O
of	O
Quinte	O
AOC	O
.	O

Concentrations	O
of	O
polybrominated	O
diphenyl	O
ethers	O
were	O
highest	O
in	O
the	O
Toronto	O
and	O
Region	O
AOC	O
,	O
and	O
at	O
2	O
of	O
the	O
Bay	O
of	O
Quinte	O
AOC	O
exposed	O
sites	O
near	O
Trenton	O
and	O
Belleville	O
.	O

Distribution	O
patterns	O
reflected	O
the	O
properties	O
and	O
usage	O
of	O
the	O
compounds	O
under	O
investigation	O
and	O
the	O
characteristics	O
of	O
each	O
AOC	O
.	O

Environ	O
Toxicol	O
Chem	O
2017	O
;	O
9999:1-8	O
.	O

©	O
2017	O
SETAC	O
.	O

The	O
NCAM1	O
gene	O
set	O
is	O
linked	O
to	O
depressive	O
symptoms	O
and	O
their	O
brain	O
structural	O
correlates	O
in	O
healthy	O
individuals	O
.	O

Depressive	O
symptoms	O
exist	O
on	O
a	O
continuum	O
,	O
the	O
far	O
end	O
of	O
which	O
is	O
found	O
in	O
depressive	O
disorders	O
.	O

Utilizing	O
the	O
continuous	B-P
spectrum	I-P
of	O
depressive	O
symptoms	O
may	O
therefore	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
biological	O
underpinnings	O
of	O
depression	O
.	O

Gene	B-P
set	I-P
enrichment	I-P
analysis	I-P
(	O
GSEA	B-P
)	O
is	O
an	O
important	O
tool	O
for	O
the	O
identification	O
of	O
gene	O
groups	O
linked	O
to	O
complex	O
traits	O
,	O
and	O
was	O
applied	O
in	O
the	O
present	O
study	O
on	O
genome-wide	O
association	O
study	O
(	O
GWAS	O
)	O
data	O
of	O
depression	O
scores	O
and	O
their	O
brain-level	O
structural	O
correlates	O
in	O
healthy	O
young	O
individuals	O
.	O

On	O
symptom	O
level	O
(	O
i.e	O
.	O

depression	O
scores	O
)	O
,	O
robust	O
enrichment	O
was	O
identified	O
for	O
two	O
gene	O
sets	O
:	O
NCAM1	O
Interactions	O
and	O
Collagen	O
Formation	O
.	O

Depression	O
scores	O
were	O
also	O
associated	O
with	O
decreased	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
-	O
a	O
brain	O
white	O
matter	O
property	O
-	O
within	O
the	O
forceps	O
minor	O
and	O
the	O
left	O
superior	O
temporal	O
longitudinal	O
fasciculus	O
.	O

Within	O
each	O
of	O
these	O
tracts	O
,	O
mean	O
FA	O
value	O
of	O
depression	O
score	O
-	O
associated	O
voxels	O
was	O
used	O
as	O
a	O
phenotype	O
in	O
a	O
subsequent	O
GSEA	B-P
.	O

The	O
NCAM1	O
Interactions	O
gene	O
set	O
was	O
significantly	O
enriched	O
in	O
these	O
tracts	O
.	O

By	O
linking	O
the	O
NCAM1	O
Interactions	O
gene	O
set	O
to	O
depression	O
scores	O
and	O
their	O
structural	O
brain	O
correlates	O
in	O
healthy	O
participants	O
,	O
the	O
current	O
study	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
molecular	O
underpinnings	O
of	O
depressive	O
symptomatology	O
.	O

Targeting	O
accuracy	O
of	O
single-isocenter	O
intensity-modulated	O
radiosurgery	O
for	O
multiple	O
lesions	O
.	O

To	O
investigate	O
the	O
targeting	O
accuracy	O
of	O
intensity-modulated	O
SRS	O
(	O
IMRS	O
)	O
plans	O
designed	O
to	O
simultaneously	O
treat	O
multiple	O
brain	O
metastases	O
with	O
a	O
single	O
isocenter	O
.	O

A	O
home-made	O
acrylic	O
phantom	O
able	O
to	O
support	O
a	O
film	O
(	O
EBT3	O
)	O
in	O
its	O
coronal	O
plane	O
was	O
used	O
.	O

The	O
phantom	O
was	O
CT	B-P
scanned	I-P
and	O
three	O
coplanar	O
small	O
targets	O
(	O
a	O
central	O
and	O
two	O
peripheral	O
)	O
were	O
outlined	O
in	O
the	O
Eclipse	O
system	O
.	O

Peripheral	O
targets	O
were	O
6	O
cm	O
apart	O
from	O
the	O
central	O
one	O
.	O

A	O
reference	O
IMRS	O
plan	O
was	O
designed	O
to	O
simultaneously	O
treat	O
the	O
three	O
targets	O
,	O
but	O
only	O
a	O
single	O
isocenter	O
located	O
at	O
the	O
center	O
of	O
the	O
central	O
target	O
was	O
used	O
.	O

After	O
positioning	O
the	O
phantom	O
on	O
the	O
linac	O
using	O
the	O
room	O
lasers	O
,	O
a	O
CBCT	B-P
scan	I-P
was	O
acquired	O
and	O
the	O
reference	O
plan	O
were	O
mapped	O
on	O
it	O
,	O
by	O
placing	O
the	O
planned	O
isocenter	O
at	O
the	O
intersection	O
of	O
the	O
landmarks	O
used	O
in	O
the	O
film	O
showing	O
the	O
linac	O
isocenter	O
.	O

The	O
mapped	O
plan	O
was	O
then	O
recalculated	O
and	O
delivered	O
.	O

The	O
film	O
dose	O
distribution	O
was	O
derived	O
using	O
a	O
cloud	O
computing	O
application	O
(	O
www.radiochromic.com	O
)	O
that	O
uses	O
a	O
triple-channel	O
dosimetry	B-P
algorithm	O
.	O

Comparison	O
of	O
dose	O
distributions	O
using	O
the	O
gamma	O
index	O
(	O
5	O
%	O
/1	O
mm	O
)	O
were	O
performed	O
over	O
a	O
5	O
×	O
5	O
cm	O
(	O
2	O
)	O
region	O
centered	O
over	O
each	O
target	O
.	O

2D	O
shifts	O
required	O
to	O
get	O
the	O
best	O
gamma	O
passing	O
rates	O
on	O
the	O
peripheral	O
target	O
regions	O
were	O
compared	O
with	O
the	O
reported	O
ones	O
for	O
the	O
central	O
target	O
.	O

The	O
experiment	O
was	O
repeated	O
ten	O
times	O
in	O
different	O
sessions	O
.	O

Average	O
2D	O
shifts	O
required	O
to	O
achieve	O
optimal	O
gamma	O
passing	O
rates	O
(	O
99	O
%	O
,	O
97	O
%	O
,	O
99	O
%	O
)	O
were	O
0.7	O
mm	O
(	O
SD	O
:	O
0.3	O
mm	O
)	O
,	O
0.8	O
mm	O
(	O
SD	O
:	O
0.4	O
mm	O
)	O
and	O
0.8	O
mm	O
(	O
SD	O
:	O
0.3	O
mm	O
)	O
,	O
for	O
the	O
central	O
and	O
the	O
two	O
peripheral	O
targets	O
,	O
respectively	O
.	O

No	O
statistical	O
differences	O
(	O
p	O
>	O
0.05	O
)	O
were	O
found	O
for	O
targeting	O
accuracy	O
between	O
the	O
central	O
and	O
the	O
two	O
peripheral	O
targets	O
.	O

The	O
study	O
revealed	O
a	O
targeting	O
accuracy	O
within	O
1	O
mm	O
for	O
off-	O
isocenter	O
targets	O
within	O
6	O
cm	O
of	O
the	O
linac	O
isocenter	O
,	O
when	O
a	O
single-isocenter	O
IMRS	O
plan	O
is	O
designed	O
.	O

Terahertz	B-P
identification	I-P
and	O
quantification	O
of	O
neurotransmitter	O
and	O
neurotrophy	O
mixture	O
.	O

Terahertz	B-P
spectroscopy	I-P
has	O
been	O
widely	O
used	O
for	O
investigating	O
the	O
fingerprint	B-P
spectrum	I-P
of	O
different	O
substances	O
.	O

For	O
cancerous	O
tissues	O
,	O
the	O
greatest	O
difficulty	O
is	O
the	O
absorption	O
peaks	O
of	O
various	O
substances	O
contained	O
in	O
tissues	O
overlap	O
with	O
each	O
other	O
,	O
which	O
are	O
hard	O
to	O
identify	O
and	O
quantitative	O
analyze	O
.	O

As	O
a	O
result	O
,	O
it	O
is	O
very	O
hard	O
to	O
measure	O
the	O
presence	O
of	O
cancer	O
cell	O
and	O
then	O
to	O
diagnose	O
accurately	O
.	O

In	O
this	O
paper	O
,	O
we	O
select	O
three	O
typical	O
neurotransmitters	O
(	O
γ-aminobutyric	O
acid	O
,	O
L-glutamic	O
acid	O
,	O
dopamine	O
hydrochloride	O
)	O
and	O
two	O
typical	O
metabolites	O
(	O
inositol	O
and	O
creatine	O
)	O
in	O
neurons	O
to	O
measure	O
their	O
terahertz	B-P
spectra	I-P
with	O
different	O
mixture	O
ratios	O
.	O

By	O
choosing	O
characteristic	O
absorption	O
peaks	O
,	O
removing	O
baseline	O
and	O
using	O
the	O
least	O
square	O
method	O
,	O
we	O
can	O
identify	O
the	O
components	O
and	O
proportions	O
of	O
each	O
mixture	O
,	O
where	O
the	O
goodness	O
of	O
fit	O
to	O
practical	O
situation	O
is	O
up	O
to	O
94	O
%	O
.	O

These	O
results	O
provide	O
important	O
evidences	O
for	O
identifying	O
nerve	O
substances	O
and	O
obtaining	O
exact	O
quantitative	O
analysis	O
.	O

The	O
Optical	B-P
Coherence	I-P
Tomographic	I-P
Profile	O
of	O
Leber	O
Hereditary	O
Optic	O
Neuropathy	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
changes	O
in	O
the	O
retinal	O
ganglion	O
cell	O
complex	O
(	O
GCC	O
)	O
relative	O
to	O
the	O
retinal	O
nerve	O
fibre	O
layer	O
(	O
RNFL	O
)	O
over	O
time	O
in	O
Leber	O
hereditary	O
optic	O
neuropathy	O
(	O
LHON	O
)	O
patients	O
.	O

Average	O
RNFL	O
and	O
GCC	O
thickness	O
was	O
measured	O
in	O
seven	O
patients	O
in	O
the	O
early	O
acute	O
(	O
123	O
,	O
68.4	O
μm	O
)	O
,	O
late	O
acute	O
(	O
113.5	O
,	O
57.4	O
μm	O
)	O
,	O
and	O
chronic	O
(	O
72.7	O
,	O
50.8	O
μm	O
)	O
phases	O
.	O

Patients	O
showed	O
thinning	O
of	O
the	O
GCC	O
with	O
RNFL	O
swelling	O
in	O
the	O
early	O
acute	O
phase	O
.	O

GCC	O
thinning	O
became	O
severe	O
within	O
weeks	O
and	O
persisted	O
.	O

RNFL	O
swelling	O
normalised	O
during	O
the	O
late	O
acute	O
phase	O
with	O
eventual	O
thinning	O
in	O
the	O
chronic	O
phase	O
.	O

GCC	O
changes	O
appear	O
at	O
the	O
commencement	O
of	O
visual	O
loss	O
and	O
in	O
some	O
cases	O
prior	O
to	O
vision	O
loss	O
.	O

These	O
findings	O
define	O
an	O
optical	B-P
coherence	I-P
tomography	I-P
(	O
OCT	B-P
)	O
profile	O
in	O
LHON	O
.	O

TANGO	O
-	O
a	O
screening	O
tool	O
to	O
identify	O
comorbidities	O
on	O
the	O
causal	O
pathway	O
of	O
nocturia	O
.	O

To	O
develop	O
a	O
robust	O
screening	O
metric	O
for	O
use	O
in	O
identifying	O
non-lower	O
urinary	O
tract	O
comorbidities	O
pertinent	O
to	O
the	O
multidisciplinary	B-P
assessment	I-P
of	O
patients	O
with	O
nocturia	O
.	O

Variables	O
having	O
a	O
significant	O
risk	O
association	O
with	O
nocturia	O
of	O
greater	O
than	O
once	O
per	O
night	O
were	O
identified	O
.	O

Discriminating	O
items	O
from	O
validated	O
and	O
reliable	O
tools	O
measuring	O
these	O
comorbidities	O
were	O
identified	O
.	O

A	O
self-completed	O
57-item	O
questionnaire	O
was	O
developed	O
and	O
a	O
medical	O
checklist	O
and	O
pertinent	O
clinical	O
measures	O
added	O
.	O

Pre-determined	O
criteria	O
were	O
applied	O
to	O
retain	O
or	O
remove	O
items	O
in	O
the	O
development	O
of	O
the	O
Short-Form	O
(	O
SF	O
)	O
screening	O
tool	O
.	O

The	O
tool	O
was	O
administered	O
to	O
252	O
individuals	O
with	O
nocturia	O
who	O
were	O
attending	O
either	O
a	O
tertiary	O
level	O
Sleep	O
,	O
Continence	O
,	O
Falls	O
or	O
Rehabilitation	O
service	O
for	O
routine	O
care	O
.	O

Data	O
collected	O
were	O
subjected	O
to	O
descriptive	O
analysis	O
;	O
criteria	O
were	O
applied	O
to	O
reduce	O
the	O
number	O
of	O
items	O
.	O

Using	O
pre-determined	O
domains	O
,	O
a	O
nocturia	O
screening	O
metric	O
,	O
entitled	O
TANGO	O
,	O
was	O
generated	O
.	O

The	O
acronym	O
TANGO	O
stands	O
for	O
Targeting	O
the	O
individual	O
's	O
Aetiology	O
of	O
Nocturia	O
to	O
Guide	O
Outcomes	O
.	O

The	O
demographic	O
characteristics	O
of	O
the	O
sample	O
are	O
described	O
,	O
along	O
with	O
item	O
endorsement	O
levels	O
.	O

The	O
statistical	O
and	O
structural	O
framework	O
to	O
justify	O
deleting	O
or	O
retaining	O
of	O
items	O
from	O
the	O
TANGO	O
Long-Form	O
to	O
the	O
SF	O
is	O
presented	O
.	O

The	O
resultant	O
TANGO	O
-	O
SF	O
patient	O
-completed	O
nocturia	O
screening	O
tool	O
is	O
reported	O
.	O

A	O
novel	O
all-cause	O
diagnostic	O
metric	O
for	O
identifying	O
co-existing	O
morbidities	O
of	O
clinical	O
relevance	O
to	O
nocturia	O
in	O
patients	O
who	O
present	O
across	O
disciplines	O
and	O
medical	O
specialties	O
has	O
been	O
developed	O
.	O

TANGO	O
has	O
the	O
potential	O
to	O
improve	O
practice	O
and	O
smooth	O
inequalities	O
associated	O
with	O
a	O
siloed	O
approach	O
to	O
assessment	O
and	O
subsequent	O
care	O
of	O
patients	O
with	O
nocturia	O
.	O

Use	O
of	O
bacterial	O
whole-genome	O
sequencing	O
to	O
understand	O
and	O
improve	O
the	O
management	O
of	O
invasive	O
Staphylococcus	O
aureus	O
infections	O
.	O

Management	O
of	O
invasive	O
Staphylococcus	O
aureus	O
infections	O
is	O
complex	O
.	O

Dramatic	O
improvements	O
in	O
bacterial	O
whole	O
genome	O
sequencing	O
(	O
WGS	O
)	O
offer	O
new	O
opportunities	O
for	O
personalising	O
the	O
treatment	O
of	O
S.	O
aureus	O
infections	O
.	O

Areas	O
covered	O
:	O
We	O
address	O
recent	O
achievements	O
in	O
S.	O
aureus	O
genomics	O
,	O
describe	O
genetic	O
determinants	O
of	O
antibiotic	O
resistance	O
and	O
summarise	O
studies	O
that	O
have	O
defined	O
molecular	O
characteristics	O
associated	O
with	O
risk	O
and	O
outcome	O
of	O
S.	O
aureus	O
invasive	O
infections	O
.	O

Potential	O
clinical	O
use	O
of	O
WGS	O
for	O
resistance	O
prediction	O
,	O
infection	O
outcome	O
stratification	O
and	O
management	O
of	O
persisten	O
t	O
/	O
relapsing	O
infections	O
is	O
critically	O
discussed	O
.	O

Expert	O
commentary	O
:	O
WGS	O
is	O
not	O
only	O
providing	O
invaluable	O
information	O
to	O
track	O
the	O
emergence	O
and	O
spread	O
of	O
important	O
S.	O
aureus	O
clones	O
,	O
but	O
also	O
allows	O
rapid	O
determination	B-P
of	O
resistance	O
genotypes	O
in	O
the	O
clinical	O
environment	O
.	O

An	O
evolving	O
opportunity	O
is	O
to	O
infer	O
clinically	O
important	O
outcomes	O
and	O
optimal	O
therapeutic	O
approaches	O
from	O
widely	O
available	O
S.	O
aureus	O
genome	O
data	O
,	O
with	O
the	O
goal	O
of	O
individualizing	O
management	O
of	O
invasive	O
S.	O
aureus	O
infections	O
.	O

Secondary	O
Ossification	O
Center	O
Appearance	O
and	O
Closure	O
in	O
the	O
Pelvis	O
and	O
Proximal	O
Femur	O
.	O

Variable	O
ossification	O
patterns	O
of	O
the	O
pelvis	O
in	O
skeletally	O
immature	O
patients	O
can	O
make	O
the	O
interpretation	O
of	O
pelvic	O
radiographs	B-P
challenging	O
.	O

Inconsistencies	O
among	O
prior	O
studies	O
and	O
lack	O
of	O
sex	O
comparisons	O
underscore	O
the	O
need	O
for	O
a	O
more	O
comprehensive	O
characterization	O
of	O
the	O
secondary	O
ossification	O
centers	O
.	O

This	O
study	O
evaluates	O
the	O
chronology	O
and	O
sex	O
differences	O
for	O
appearance	O
and	O
closure	O
of	O
pelvic	O
and	O
proximal	O
femoral	O
secondary	O
ossification	O
centers	O
using	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
.	O

Patients	O
who	O
underwent	O
abdominal	B-P
and	O
pelvic	B-P
CT	I-P
scans	I-P
between	O
January	O
2009	O
and	O
December	O
2014	O
at	O
2	O
tertiary	O
level	O
1	O
trauma	O
centers	O
were	O
retrospectively	O
reviewed	O
.	O

Patients	O
between	O
the	O
ages	O
of	O
2	O
and	O
32	O
years	O
with	O
adequate	O
imaging	B-P
of	O
the	O
pelvis	O
and	O
proximal	O
femurs	O
were	O
included	O
.	O

Patients	O
with	O
a	O
history	O
of	O
orthopaedic	O
trauma	O
or	O
pathology	O
affecting	O
ossification	O
were	O
excluded	O
.	O

CT	B-P
scans	I-P
were	O
assessed	O
for	O
the	O
appearance	O
and	O
closure	O
of	O
the	O
following	O
secondary	O
ossification	O
centers	O
:	O
anterior	O
inferior	O
iliac	O
spine	O
(	O
AIIS	O
)	O
,	O
anterior	O
superior	O
iliac	O
spine	O
(	O
ASIS	O
)	O
,	O
femoral	O
head	O
(	O
FH	O
)	O
,	O
greater	O
trochanter	O
(	O
GT	O
)	O
,	O
iliac	O
crest	O
(	O
IC	O
)	O
,	O
ischial	O
tuberosity	O
(	O
IT	O
)	O
,	O
lesser	O
trochanter	O
(	O
LT	O
)	O
,	O
posterior	O
superior	O
iliac	O
spine	O
(	O
PSIS	O
)	O
,	O
symphysis	O
pubis	O
(	O
SP	O
)	O
,	O
and	O
triradiate	O
cartilage	O
(	O
TRC	O
)	O
.	O

Basic	O
descriptive	O
statistics	O
are	O
reported	O
.	O

A	O
total	O
of	O
496	O
CT	B-P
scans	I-P
met	O
inclusion	O
criteria	O
(	O
240	O
males	O
and	O
256	O
females	O
)	O
.	O

The	O
order	O
of	O
appearance	O
of	O
the	O
secondary	O
ossification	O
centers	O
was	O
:	O
(	O
male	O
)	O
GT	O
,	O
LT	O
,	O
AIIS	O
,	O
IT	O
,	O
ASIS	O
,	O
PSIS	O
,	O
IC	O
,	O
and	O
SP	O
;	O
(	O
female	O
)	O
GT	O
,	O
LT	O
,	O
IT	O
,	O
AIIS	O
,	O
PSIS	O
,	O
IC	O
,	O
ASIS	O
,	O
and	O
SP	O
.	O

The	O
order	O
of	O
closure	O
was	O
similar	O
:	O
(	O
male	O
)	O
TRC	O
,	O
LT	O
,	O
FH	O
,	O
AIIS	O
,	O
GT	O
,	O
ASIS	O
,	O
PSIS	O
,	O
IT	O
,	O
IC	O
,	O
and	O
SP	O
;	O
(	O
female	O
)	O
LT	O
,	O
TRC	O
,	O
AIIS	O
,	O
FH	O
,	O
GT	O
,	O
ASIS	O
,	O
PSIS	O
,	O
IT	O
,	O
IC	O
,	O
and	O
SP	O
.	O

Female	O
ossification	O
centers	O
appeared	O
~1	O
to	O
2	O
years	O
before	O
males	O
in	O
all	O
locations	O
.	O

Female	O
ossification	O
centers	O
closed	O
~1	O
to	O
2	O
years	O
before	O
males	O
in	O
all	O
locations	O
except	O
TRC	O
,	O
IC	O
,	O
and	O
SP	O
.	O

The	O
appearance	O
and	O
closure	O
of	O
the	O
pelvis	O
and	O
proximal	O
femur	O
secondary	O
ossification	O
centers	O
follow	O
a	O
predictable	O
pattern	O
of	O
development	O
,	O
occurring	O
slightly	O
earlier	O
in	O
females	O
than	O
males	O
.	O

Knowledge	O
of	O
more	O
precise	O
ages	O
of	O
developmen	O
t	O
and	O
sex	O
differences	O
better	O
characterize	O
this	O
complex	O
skeletal	O
development	O
.	O

Future	O
studies	O
may	O
use	O
secondary	O
ossification	O
centers	O
to	O
further	O
evaluate	O
skeletal	B-P
maturity	I-P
,	O
assess	O
pediatric	O
pathology	O
,	O
and	O
aid	O
surgical	O
management	O
.	O

Level	O
III	O
.	O

An	O
indirect	O
method	O
for	O
in	O
vivo	O
T2	B-P
mapping	I-P
of	O
[	O
1-	O
(	O
13	O
)	O
C	O
]	O
pyruvate	O
using	O
hyperpolarized	B-P
(	I-P
13	I-P
)	I-P
C	I-P
CSI	I-P
.	O

An	O
indirect	O
method	O
for	O
in	O
vivo	O
T2	B-P
mapping	I-P
of	O
(	O
13	O
)	O
C-labeled	O
metabolites	O
using	O
T2	O
and	O
T2	O
*	O
information	O
of	O
water	O
protons	O
obtained	O
a	O
priori	O
is	O
proposed	O
.	O

The	O
T2	O
values	O
of	O
(	O
13	O
)	O
C	O
metabolites	O
are	O
inferred	O
using	O
the	O
relationship	O
to	O
T2	O
'	O
of	O
coexisting	O
(	O
1	O
)	O
H	O
and	O
the	O
T2	O
*	O
of	O
(	O
13	O
)	O
C	O
metabolites	O
,	O
which	O
is	O
measured	O
using	O
routine	O
hyperpolarized	B-P
(	I-P
13	I-P
)	I-P
C	I-P
CSI	I-P
data	O
.	O

The	O
concept	O
is	O
verified	O
with	O
phantom	O
studies	O
.	O

Simulations	O
were	O
performed	O
to	O
evaluate	O
the	O
extent	O
of	O
T2	O
estimation	B-P
accuracy	O
due	O
to	O
errors	O
in	O
the	O
other	O
measurements	O
.	O

Also	O
,	O
bias	O
in	O
the	O
(	B-P
13	I-P
)	I-P
C	I-P
T2	I-P
*	I-P
estimation	I-P
from	O
the	O
(	B-P
13	I-P
)	I-P
C	I-P
CSI	I-P
data	O
was	O
studied	O
.	O

In	O
vivo	O
experiments	O
were	O
performed	O
from	O
the	O
brains	O
of	O
normal	O
rats	O
and	O
a	O
rat	O
with	O
C6	O
glioma	O
.	O

Simulation	O
results	O
indicate	O
that	O
the	O
proposed	O
method	O
provides	O
accurate	O
and	O
unbiased	O
(	O
13	O
)	O
C	O
T2	O
values	O
within	O
typical	O
experimental	O
settings	O
.	O

The	O
in	O
vivo	O
studies	O
found	O
that	O
the	O
estimated	O
T2	O
of	O
[	O
1-	O
(	O
13	O
)	O
C	O
]	O
pyruvate	O
using	O
the	O
indirect	O
method	O
was	O
longer	O
in	O
tumor	O
than	O
in	O
normal	O
tissues	O
and	O
gave	O
values	O
similar	O
to	O
previous	O
reports	O
.	O

This	O
method	O
can	O
estimate	O
localized	O
T2	O
relaxation	O
times	O
from	O
multiple	O
voxels	O
using	O
conventional	O
hyperpolarized	B-P
(	I-P
13	I-P
)	I-P
C	I-P
CSI	I-P
and	O
can	O
potentially	O
be	O
used	O
with	O
time	B-P
resolved	I-P
fast	I-P
CSI	I-P
.	O

Entecavir	O
to	O
Telbivudine	O
Switch	O
Therapy	O
in	O
Entecavir	O
-	O
Treated	O
Patients	O
with	O
Undetectable	O
Hepatitis	B-P
B	I-P
Viral	I-P
DNA	I-P
.	O

This	O
study	O
examined	O
2-year	O
outcome	O
of	O
consecutive	O
therapy	O
using	O
entecavir	O
(	O
ETV	O
)	O
followed	O
by	O
telbivudine	O
(	O
LdT	O
)	O
in	O
subjects	O
with	O
undetectable	O
hepatitis	B-P
B	I-P
virus	I-P
(	I-P
HBV	I-P
)	I-P
DNA	I-P
level	I-P
and	O
normal	O
alanine	B-P
aminotransferase	I-P
level	I-P
after	O
the	O
initial	O
6	O
months	O
of	O
ETV	O
treatment	O
.	O

Sixty	O
subjects	O
were	O
randomized	O
to	O
continue	O
with	O
ETV	O
or	O
switch	O
to	O
LdT	O
.	O

Significant	O
difference	O
in	O
baseline	O
characteristics	O
was	O
not	O
found	O
between	O
the	O
two	O
groups	O
.	O

Persistent	O
HBV	B-P
DNA	I-P
level	I-P
of	O
20-60	O
IU/mL	O
in	O
three	O
consecutive	O
samples	O
collected	O
three	O
months	O
apart	O
or	O
singly	O
measured	O
HBV	B-P
DNA	I-P
level	I-P
of	O
>	O
60	O
IU/mL	O
was	O
defined	O
as	O
virological	O
rebound	O
.	O

During	O
96	O
weeks	O
of	O
follow-up	O
,	O
all	O
subjects	O
of	O
the	O
ETV	O
-only	O
group	O
(	O
n=30	O
)	O
resulted	O
in	O
undetectable	O
HBV	B-P
DNA	I-P
level	I-P
.	O

On	O
the	O
other	O
hand	O
,	O
83.3	O
%	O
(	O
n=25	O
)	O
of	O
the	O
LdT	O
-	O
switched	O
group	O
showed	O
treatment	O
success	O
.	O

Virological	O
rebound	O
time	O
varied	O
from	O
week	O
24	O
to	O
84	O
after	O
switching	O
to	O
LdT	O
.	O

HBV	B-P
DNA	I-P
level	I-P
was	O
180	O
to	O
2940	O
IU/mL	O
at	O
rebound	O
time	O
.	O

All	O
subjects	O
with	O
virological	O
rebound	O
(	O
n=5	O
)	O
showed	O
drug-resistant	O
mutation	O
:	O
three	O
had	O
mutation	O
rtM204I	O
,	O
and	O
two	O
had	O
mutation	O
rtM204V	O
.	O

Consecutive	O
treatment	O
using	O
ETV	O
followed	O
by	O
LdT	O
showed	O
virological	O
rebound	O
in	O
16.7	O
%	O
of	O
subjects	O
during	O
96	O
weeks	O
of	O
follow-up	O
.	O

HBV	B-P
DNA	I-P
negativity	O
during	O
initial	O
ETV	O
therapy	O
could	O
not	O
be	O
achieved	O
in	O
patients	O
who	O
switched	O
to	O
LdT	O
.	O

Consecutive	O
treatment	O
using	O
ETV	O
followed	O
by	O
lamivudine	O
was	O
ineffective	O
for	O
treating	O
chronic	O
hepatitis	O
B.	O
LdT	O
was	O
found	O
as	O
a	O
more	O
potent	O
antiviral	O
agent	O
than	O
lamivudine	O
.	O

However	O
,	O
this	O
conclusion	O
requires	O
larger-scale	O
,	O
long-term	O
prospective	O
reviews	O
of	O
the	O
treatment	O
effects	O
of	O
ETV	O
-	O
LdT	O
switch	O
therapy	O
.	O

Predicting	O
MEK	O
Inhibitor	O
Response	O
in	O
Lung	O
Cancer	O
:	O
A	O
Proper	O
Signature	O
Is	O
Required	O
.	O

The	O
ERK	O
signaling	O
pathway	O
is	O
one	O
of	O
the	O
most	O
commonly	O
deregulated	O
pathways	O
in	O
cancer	O
.	O

Assays	B-P
that	O
accurately	O
measure	O
ERK	O
signaling	O
output	O
in	O
clinical	O
specimens	O
would	O
be	O
extremely	O
helpfu	O
l	O
not	O
only	O
in	O
determining	O
the	O
pharmacodynamic	O
effects	O
of	O
drug	O
treatment	O
but	O
also	O
in	O
selecting	O
those	O
patients	O
most	O
likely	O
to	O
respond	O
to	O
therapy	O
.	O

Clin	O
Cancer	O
Res	O
;	O
23	O
(	O
6	O
)	O
;	O
1365-7	O
.	O

©2016	O
AACRSee	O
related	O
article	O
by	O
Brant	O
et	O
al.	O
,	O
p.	O
1471	O
.	O

Breaking	O
sitting	O
with	O
light	O
activities	O
vs	O
structured	O
exercise	O
:	O
a	O
randomised	O
crossover	O
study	O
demonstrating	O
benefits	O
for	O
glycaemic	O
control	O
and	O
insulin	O
sensitivity	O
in	O
type	O
2	O
diabetes	O
.	O

We	O
aimed	O
to	O
examine	O
the	O
effects	O
of	O
breaking	O
sitting	O
with	O
standing	O
and	O
light-intensity	O
walking	O
vs	O
an	O
energy	O
-matched	O
bout	O
of	O
structured	O
exercise	O
on	O
24	O
h	O
glucose	O
levels	O
and	O
insulin	O
resistance	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

In	O
a	O
randomised	O
crossover	O
study	O
,	O
19	O
patients	O
with	O
type	O
2	O
diabetes	O
(	O
13	O
men	O
/6	O
women	O
,	O
63	O
±	O
9	O
years	O
old	O
)	O
who	O
were	O
not	O
using	O
insulin	O
each	O
followed	O
three	O
regimens	O
under	O
free-living	O
condition	O
s	O
,	O
each	O
lasting	O
4	O
days	O
:	O
(	O
1	O
)	O
Sitting	O
:	O
4415	O
steps	O
/	O
day	O
with	O
14	O
h	O
sitting	O
/	O
day	O
;	O
(	O
2	O
)	O
Exercise	O
:	O
4823	O
steps	O
/	O
day	O
with	O
1.1	O
h/	O
day	O
of	O
sitting	O
replaced	O
by	O
moderate	O
-	O
to	O
vigorous-intensity	O
cycling	O
(	O
at	O
an	O
intensity	O
of	O
5.9	O
metabolic	O
equivalents	O
[	O
METs	O
]	O
)	O
;	O
and	O
(	O
3	O
)	O
Sit	O
Less	O
:	O
17,502	O
steps	O
/	O
day	O
with	O
4.7	O
h/	O
day	O
of	O
sitting	O
replaced	O
by	O
standing	O
and	O
light-intensity	O
walking	O
(	O
an	O
additional	O
2.5	O
h	O
and	O
2.2	O
h	O
,	O
respectively	O
,	O
compared	O
with	O
the	O
hours	O
spent	O
doing	O
these	O
activities	O
in	O
the	O
Sitting	O
regimen	O
)	O
.	O

Blocked	O
randomisation	O
was	O
performed	O
using	O
a	O
block	O
size	O
of	O
six	O
regimen	O
orders	O
using	O
sealed	O
,	O
non-translucent	O
envelopes	O
.	O

Individuals	O
who	O
assessed	O
the	O
outcomes	O
were	O
blinded	O
to	O
group	O
assignment	O
.	O

Meals	O
were	O
standardised	O
during	O
each	O
intervention	O
.	O

Physical	O
activity	O
and	O
glucose	O
levels	O
were	O
assessed	O
for	O
24	O
h/	O
day	O
by	O
accelerometry	B-P
(	O
activPAL	B-P
)	O
and	O
a	O
glucose	O
monitor	O
(	O
iPro2	O
)	O
,	O
respectively	O
.	O

The	O
incremental	O
AUC	O
(	O
iAUC	O
)	O
for	O
24	O
h	O
glucose	O
(	O
primary	O
outcome	O
)	O
and	O
insulin	O
resistance	O
(	O
HOMA2-IR	O
)	O
were	O
assessed	O
on	O
days	O
4	O
and	O
5	O
,	O
respectively	O
.	O

The	O
iAUC	O
for	O
24	O
h	O
glucose	O
(	O
mean	O
±	O
SEM	O
)	O
was	O
significantly	O
lower	O
during	O
the	O
Sit	O
Less	O
intervention	O
than	O
in	O
Sitting	O
(	O
1263	O
±	O
189	O
min	O
×	O
mmol/l	O
vs	O
1974	O
±	O
324	O
min	O
×	O
mmol/l	O
;	O
p	O
=	O
0.002	O
)	O
,	O
and	O
was	O
similar	O
between	O
Sit	O
Less	O
and	O
Exercise	O
(	O
Exercise	O
:	O
1383	O
±	O
194	O
min	O
×	O
mmol/l	O
;	O
p	O
=	O
0.499	O
)	O
.	O

Exercise	O
failed	O
to	O
improve	O
HOMA2-IR	O
compared	O
with	O
Sitting	O
(	O
2.06	O
±	O
0.28	O
vs	O
2.16	O
±	O
0.26	O
;	O
p	O
=	O
0.177	O
)	O
.	O

In	O
contrast	O
,	O
Sit	O
Less	O
(	O
1.89	O
±	O
0.26	O
)	O
significantly	O
reduced	O
HOMA2-IR	O
compared	O
with	O
Exercise	O
(	O
p	O
=	O
0.015	O
)	O
as	O
well	O
as	O
Sitting	O
(	O
p	O
=	O
0.001	O
)	O
.	O

Breaking	O
sitting	O
with	O
standing	O
and	O
light-intensity	O
walking	O
effectively	O
improved	O
24	O
h	O
glucose	O
levels	O
and	O
improved	O
insulin	O
sensitivity	O
in	O
individuals	O
with	O
type	O
2	O
diabetes	O
to	O
a	O
greater	O
extent	O
than	O
structured	O
exercise	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
breaking	O
sitting	O
with	O
standing	O
and	O
light-intensity	O
walking	O
may	O
be	O
an	O
alternative	O
to	O
structured	O
exercise	O
to	O
promote	O
glycaemic	O
control	O
in	O
patients	O
type	O
2	O
diabetes	O
.	O

Clinicaltrials.gov	O
NCT02371239	O
FUNDING	O
:	O
:	O
The	O
study	O
was	O
supported	O
by	O
a	O
Kootstra	O
grant	O
from	O
Maastricht	O
University	O
Medical	O
Centre	O
(	O
+	O
)	O
,	O
and	O
the	O
Dutch	O
Heart	O
Foundation	O
.	O

Financial	O
support	O
was	O
also	O
provided	O
by	O
Novo	O
Nordisk	O
BV	O
,	O
and	O
Medtronic	O
and	O
Roche	O
made	O
the	O
equipment	O
available	O
for	O
continuous	O
glucose	O
monitoring	O
.	O

Synthesis	O
,	O
characterization	O
and	O
drug	O
loading	O
property	O
of	O
Monomethoxy-Poly	O
(	O
ethylene	O
glycol	O
)	O
-Poly	O
(	O
ε-caprolactone	O
)	O
-Poly	O
(	O
D	O
,	O
L-lactide	O
)	O
(	O
MPEG-PCLA	O
)	O
copolymers	O
.	O

Amphiphilic	O
block	O
copolymers	O
have	O
attracted	O
a	O
great	O
deal	O
of	O
attention	O
in	O
drug	O
delivery	O
systems	O
.	O

In	O
this	O
work	O
,	O
a	O
series	O
of	O
monomethoxy-poly	O
(	O
ethylene	O
glycol	O
)	O
-poly	O
(	O
ε-caprolactone-co-D	O
,	O
L-lactide	O
)	O
(	O
MPEG-PCLA	O
)	O
copolymers	O
with	O
variable	O
composition	O
of	O
poly	O
(	O
ε-caprolactone	O
)	O
(	O
PCL	O
)	O
and	O
poly	O
(	O
D	O
,	O
L-lactide	O
)	O
(	O
PDLLA	O
)	O
were	O
prepared	O
via	O
ring-opening	O
copolymerization	O
of	O
ε-CL	O
and	O
D	O
,	O
L-LA	O
in	O
the	O
presence	O
of	O
MPEG	O
and	O
stannous	O
octoate	O
.	O

The	O
structure	O
and	O
molecular	O
weight	O
were	O
characterized	O
by	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
and	O
gel	B-P
permeation	I-P
chromatography	I-P
(	O
GPC	B-P
)	O
.	O

The	O
crystallinity	O
,	O
hydrophilicity	O
,	O
thermal	O
stability	O
and	O
hydrolytic	O
degradation	O
behavior	O
were	O
investigated	O
in	O
detail	O
,	O
respectively	O
.	O

The	O
results	O
showed	O
that	O
the	O
prepared	O
amphiphilic	O
MPEG-PCLA	O
copolymers	O
have	O
adjustable	O
properties	O
by	O
altering	O
the	O
composition	O
of	O
PCLA	O
,	O
which	O
make	O
it	O
convenient	O
for	O
clinical	O
applications	O
.	O

Besides	O
,	O
the	O
drug	O
loading	O
properties	O
were	O
also	O
studied	O
.	O

Docetaxel	O
(	O
DTX	O
)	O
could	O
be	O
entrapped	O
in	O
MPEG-PCLA	O
micelles	O
with	O
high	O
loading	O
capacity	O
and	O
encapsulation	O
efficiency	O
.	O

And	O
all	O
lyophilized	O
DTX	O
-loaded	O
MPEG-PCLA	O
micelles	O
except	O
MPEG-PCL	O
micelles	O
were	O
readily	O
re-dissolved	O
in	O
normal	O
saline	O
at	O
25	O
°C	O
.	O

In	O
addition	O
,	O
DTX	O
-loaded	O
MPEG-PCLA	O
micelles	O
showed	O
a	O
slightly	O
enhanced	O
antitumor	O
activity	O
compared	O
with	O
free	O
DTX	O
.	O

Furthermore	O
,	O
DTX	O
micelles	O
exhibited	O
a	O
slower	O
and	O
sustained	O
release	O
behavior	O
in	O
vitro	O
,	O
and	O
higher	O
DTX	O
concentration	O
and	O
longer	O
retention	O
time	O
in	O
vivo	O
.	O

The	O
results	O
suggested	O
that	O
the	O
MPEG-PCLA	O
copolymer	O
with	O
the	O
adjustable	O
ratio	O
of	O
PCL	O
to	O
PDLLA	O
may	O
be	O
a	O
promising	O
drug	O
delivery	O
carrier	O
for	O
DTX	O
.	O

Association	O
of	O
COL4A3	O
(	O
rs55703767	O
)	O
,	O
MMP-9	O
(	O
rs17576	O
)	O
and	O
TIMP-1	O
(	O
rs6609533	O
)	O
gene	O
polymorphisms	O
with	O
susceptibility	O
to	O
type	O
2	O
diabetes	O
.	O

Type	O
2	O
diabetes	O
(	O
T2D	O
)	O
is	O
defined	O
by	O
high	O
levels	O
of	O
glucose	O
in	O
the	O
blood	O
.	O

The	O
collagen	O
IV	O
level	O
is	O
associated	O
with	O
conditions	O
of	O
hyperglycemia	O
and	O
insulin	O
resistance	O
.	O

Collagen	O
type	O
IV	O
α3	O
chain	O
(	O
COL4A3	O
)	O
is	O
a	O
structural	O
protein	O
of	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
.	O

Matrix	O
metallopeptidase	O
9	O
(	O
MMP-9	O
)	O
is	O
an	O
enzyme	O
that	O
degrades	O
the	O
extracellular	O
matrix	O
and	O
its	O
activity	O
is	O
moderated	O
by	O
TIMP	O
metallopeptidase	O
inhibitor	O
1	O
(	O
TIMP-1	O
)	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
examine	O
the	O
association	O
between	O
genetic	O
polymorphisms	O
of	O
COL4A3	O
(	O
rs55703767	O
)	O
,	O
MMP-9	O
(	O
rs17576	O
)	O
and	O
TIMP-1	O
(	O
rs6609533	O
)	O
in	O
patients	O
with	O
T2D	O
.	O

This	O
case-control	O
study	O
was	O
performed	O
on	O
120	O
Iranian	O
patients	O
with	O
T2D	O
and	O
120	O
healthy	O
individuals	O
.	O

Genotypes	O
were	O
analyzed	B-P
using	I-P
the	I-P
amplification	I-P
refractory	I-P
mutation	I-P
system-polymerase	I-P
chain	I-P
reaction	I-P
technique	I-P
.	O

The	O
findings	O
demonstrated	O
significant	O
differences	O
between	O
genotypic	O
and	O
allelic	O
distributions	O
of	O
COL4A3	O
(	O
G	O
/	O
T	O
)	O
and	O
MMP-9	O
(	O
A	O
/	O
G	O
)	O
polymorphisms	O
as	O
follows	O
:	O
COL4A3	O
(	O
G	O
/	O
T	O
)	O
;	O
TT	O
vs.	O
GG	O
,	O
odds	O
ratio	O
(	O
OR	O
)	O
=0.235	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=0.063-0.0802	O
(	O
P=0.013	O
)	O
and	O
T	O
vs.	O
G	O
,	O
OR	O
=0.592	O
,	O
95	O
%	O
CI	O
=0.371-0.943	O
(	O
P=0.026	O
)	O
;	O
MMP-9	O
(	O
A	O
/	O
G	O
)	O
;	O
A	O
G	O
vs.	O
GG	O
,	O
OR	O
=2.429	O
,	O
95	O
%	O
CI	O
=1.232-4.820	O
(	O
P=0.008	O
)	O
and	O
A	O
vs.	O
G	O
,	O
OR	O
=2.176	O
,	O
95	O
%	O
CI	O
=1.155-4.130	O
(	O
P=0.013	O
)	O
.	O

No	O
significant	O
association	O
was	O
identified	O
between	O
TIMP-1	O
(	O
A	O
/	O
G	O
)	O
polymorphism	O
and	O
T2D	O
in	O
females	O
and	O
males	O
.	O

Thus	O
,	O
the	O
genotypic	O
and	O
allelic	O
distributions	O
of	O
COL4A3	O
(	O
G	O
/	O
T	O
)	O
and	O
MMP-9	O
(	O
A	O
/	O
G	O
)	O
polymorphisms	O
were	O
associated	O
with	O
T2D	O
.	O

In	O
addition	O
,	O
no	O
significant	O
association	O
was	O
identified	O
in	O
the	O
genotypic	O
distribution	O
of	O
the	O
TIMP-1	O
(	O
A	O
/	O
G	O
)	O
gene	O
in	O
females	O
and	O
in	O
males	O
.	O

Further	O
studies	O
in	O
other	O
ethnic	O
groups	O
are	O
required	O
to	O
confirm	O
these	O
findings	O
.	O

Development	O
of	O
a	O
Robotic	O
Colonoscopic	O
Manipulation	O
System	O
,	O
Using	O
Haptic	O
Feedback	O
Algorithm	O
.	O

Colonoscopy	B-P
is	O
one	O
of	O
the	O
most	O
effective	O
diagnostic	O
and	O
therapeutic	O
tools	O
for	O
colorectal	O
diseases	O
.	O

We	O
aim	O
to	O
propose	O
a	O
master-slave	O
robotic	O
colonoscopy	B-P
that	O
is	O
controllable	O
in	O
remote	O
site	O
using	O
conventional	O
colonoscopy	B-P
.	O

The	O
master	O
and	O
slave	O
robot	O
were	O
developed	O
to	O
use	O
conventional	O
flexible	O
colonoscopy	B-P
.	O

The	O
robotic	O
colonoscopic	O
procedure	O
was	O
performed	O
using	O
a	O
colonoscope	O
training	O
model	O
by	O
one	O
expert	O
endoscopist	O
and	O
two	O
unexperienced	O
engineers	O
.	O

To	O
provide	O
the	O
haptic	O
sensation	O
,	O
the	O
insertion	O
force	O
and	O
the	O
rotating	O
torque	O
were	O
measured	O
and	O
sent	O
to	O
the	O
master	O
robot	O
.	O

A	O
slave	O
robot	O
was	O
developed	O
to	O
hold	O
the	O
colonoscopy	B-P
and	O
its	O
knob	O
,	O
and	O
perform	O
insertion	O
,	O
rotation	O
,	O
and	O
two	O
tilting	O
motions	O
of	O
colonoscope	O
.	O

A	O
master	O
robot	O
was	O
designed	O
to	O
teach	O
motions	O
of	O
the	O
slave	O
robot	O
.	O

These	O
measured	O
force	O
and	O
torque	O
were	O
scaled	O
down	O
by	O
one	O
tenth	O
to	O
provide	O
the	O
operator	O
with	O
some	O
reflection	O
force	O
and	O
torque	O
at	O
the	O
haptic	O
device	O
.	O

The	O
haptic	O
sensation	O
and	O
feedback	O
system	O
was	O
successful	O
and	O
helpful	O
to	O
feel	O
the	O
constrained	O
force	O
or	O
torque	O
in	O
colon	O
.	O

The	O
insertion	O
time	O
using	O
robotic	O
system	O
decreased	O
with	O
repeated	O
procedures	O
.	O

This	O
work	O
proposed	O
a	O
robotic	O
approach	O
for	O
colonoscopy	B-P
using	O
haptic	O
feedback	O
algorithm	O
,	O
and	O
this	O
robotic	O
device	O
would	O
effectively	O
perform	O
colonoscopy	B-P
with	O
reduced	O
burden	O
and	O
comparable	O
safety	O
for	O
patients	O
in	O
remote	O
site	O
.	O

Prevalence	O
and	O
Hospital	O
Management	O
of	O
Amphotericin	O
B	O
Deoxycholate	O
-Related	O
Toxicities	O
during	O
Treatment	O
of	O
HIV	O
-	O
Associated	O
Cryptococcal	O
Meningitis	O
in	O
South	O
Africa	O
.	O

We	O
aimed	O
to	O
establish	O
the	O
prevalence	O
of	O
amphotericin	O
B	O
deoxycholate	O
(	O
AmBd	O
)	O
-related	O
toxicities	O
among	O
South	O
African	O
patients	O
with	O
cryptococcosis	O
and	O
determine	O
adherence	O
to	O
international	O
recommendations	O
to	O
prevent	O
,	O
monitor	O
and	O
manage	O
AmBd	O
-related	O
toxicities	O
.	O

Clinical	O
data	O
were	O
collected	O
from	O
cases	O
of	O
laboratory-confirmed	O
cryptococcosis	O
at	O
25	O
hospitals	O
,	O
October	O
2012	O
-February	O
2013	O
.	O

Anemia	O
was	O
defined	O
as	O
hemoglobin	O
(	O
Hb	O
)	O
concentration	O
<	O
10	O
g/dl	O
,	O
hypokalemia	O
as	O
serum	B-P
potassium	I-P
(	O
K	B-P
)	O
<	O
3.4	O
mEq/L	O
and	O
nephrotoxicity	O
as	O
an	O
increase	O
in	O
serum	B-P
creatinine	I-P
(	O
Cr	B-P
)	O
to	O
>	O
1.1	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O

To	O
determine	O
adherence	O
to	O
toxicity	O
prevention	O
recommendations	O
,	O
we	O
documented	O
whether	O
baseline	O
Hb	B-P
,	O
K	B-P
and	O
Cr	B-P
tests	I-P
were	O
performed	O
,	O
whether	O
pre-emptive	O
hydration	O
and	O
IV	O
potassium	O
chloride	O
(	O
KCl	O
)	O
was	O
administered	O
prior	O
to	O
80	O
%	O
and	O
60	O
%	O
of	O
AmBd	O
doses	O
and	O
whether	O
daily	O
oral	O
KCl	O
supplementation	O
was	O
given	O
≥60	O
%	O
of	O
the	O
time	O
.	O

To	O
determine	O
adherence	O
to	O
monitoring	O
recommendations	O
,	O
we	O
ascertained	O
whether	O
a	O
daily	O
fluid	O
chart	O
was	O
completed	O
,	O
Hb	O
was	O
monitored	O
weekly	O
and	O
K	B-P
or	O
Cr	B-P
were	O
monitored	O
bi-weekly	O
.	O

Of	O
846	O
patients	O
,	O
clinical	O
data	O
were	O
available	O
for	O
76	O
%	O
(	O
642/846	O
)	O
,	O
82	O
%	O
(	O
524/642	O
)	O
of	O
whom	O
received	O
AmBd	O
.	O

Sixty-four	O
per	O
cent	O
(	O
n	O
=	O
333	O
)	O
had	O
documented	O
baseline	O
laboratory	B-P
tests	I-P
,	O
40	O
%	O
(	O
n	O
=	O
211	O
)	O
were	O
given	O
pre-emptive	O
hydration	O
and	O
14	O
%	O
(	O
n	O
=	O
72	O
)	O
and	O
19	O
%	O
(	O
n	O
=	O
101	O
)	O
received	O
intravenous	O
and	O
oral	O
KCl	O
.	O

While	O
on	O
AmBd	O
,	O
88	O
%	O
(	O
n	O
=	O
452	O
)	O
had	O
fluid	O
monitoring	O
;	O
27	O
%	O
(	O
n	O
=	O
142	O
)	O
,	O
45	O
%	O
(	O
n	O
=	O
235	O
)	O
and	O
44	O
%	O
(	O
n	O
=	O
232	O
)	O
had	O
Hb	O
,	O
K	O
and	O
Cr	O
levels	O
monitored	O
.	O

Toxicities	O
developed	O
frequently	O
during	O
treatment	O
:	O
anemia	O
,	O
16	O
%	O
(	O
86/524	O
)	O
;	O
hypokalemia	O
,	O
43	O
%	O
(	O
226/524	O
)	O
and	O
nephrotoxicity	O
,	O
32	O
%	O
(	O
169/524	O
)	O
.	O

AmBd	O
-related	O
toxicities	O
occurred	O
frequently	O
but	O
were	O
potentially	O
preventable	O
with	O
adequate	O
monitoring	O
,	O
supplemental	O
fluid	O
and	O
electrolyte	O
therapies	O
.	O

Computer-aided	B-P
Dereplication	O
and	O
Structure	O
Elucidation	O
of	O
Natural	O
Products	O
at	O
the	O
University	O
of	O
Reims	O
.	O

Natural	O
product	O
chemistry	O
began	O
in	O
Reims	O
,	O
France	O
,	O
in	O
a	O
pharmacognosy	O
research	O
laboratory	O
whose	O
main	O
emphasis	O
was	O
the	O
isolation	B-P
and	O
identification	B-P
of	O
bioactive	O
molecules	O
,	O
following	O
the	O
guidelines	O
of	O
chemotaxonomy	O
.	O

The	O
structure	O
elucidation	O
of	O
new	O
compounds	O
of	O
steadily	O
increasing	O
complexity	O
favored	O
the	O
emergence	O
of	O
methodological	O
work	O
in	O
nuclear	O
magnetic	O
resonance	O
.	O

As	O
a	O
result	O
,	O
our	O
group	O
was	O
the	O
first	O
to	O
report	O
the	O
use	O
of	O
proton-detected	B-P
heteronuclear	I-P
chemical	I-P
shift	I-P
correlation	I-P
spectra	I-P
for	O
the	O
computer-assisted	B-P
structure	O
elucidation	O
of	O
small	O
organic	O
molecules	O
driven	O
by	O
atom	O
proximity	O
relationships	O
and	O
without	O
relying	O
on	O
databases	O
.	O

The	O
early	O
detection	B-P
of	I-P
known	I-P
compounds	I-P
appeared	O
as	O
a	O
necessity	O
in	O
order	O
to	O
deal	O
more	O
efficiently	O
with	O
complex	O
plant	O
extracts	O
.	O

This	O
goal	O
was	O
reached	O
by	O
an	O
original	O
combination	O
of	O
mixture	B-P
fractionation	I-P
by	O
centrifugal	B-P
partition	I-P
chromatography	I-P
,	O
analysis	B-P
by	I-P
(	I-P
13	I-P
)	I-P
C	I-P
NMR	I-P
,	O
digital	O
data	O
reduction	O
and	O
alignment	O
,	O
hierarchical	O
data	O
clustering	O
,	O
and	O
computer	O
database	O
search	O
.	O

The	O
clinico-	O
radiological	O
paradox	O
of	O
cognitive	O
function	O
and	O
MRI	B-P
burden	O
of	O
white	O
matter	O
lesions	O
in	O
people	O
with	O
multiple	O
sclerosis	O
:	O
A	O
systematic	O
review	O
and	O
meta-analysis	O
.	O

Moderate	O
correlation	O
exists	O
between	O
the	O
imaging	O
quantification	O
of	O
brain	O
white	O
matter	O
lesions	O
and	O
cognitive	O
performance	O
in	O
people	O
with	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

This	O
may	O
reflect	O
the	O
greater	O
importance	O
of	O
other	O
features	O
,	O
including	O
subvisible	O
pathology	O
,	O
or	O
methodological	O
limitations	O
of	O
the	O
primary	O
literature	O
.	O

To	O
summarise	O
the	O
cognitive	O
clinico-	O
radiological	O
paradox	O
and	O
explore	O
the	O
potential	O
methodological	O
factors	O
that	O
could	O
influence	O
the	O
assessment	O
of	O
this	O
relationship	O
.	O

Systematic	O
review	O
and	O
meta-analysis	O
of	O
primary	O
research	O
relating	O
cognitive	O
function	O
to	O
white	O
matter	O
lesion	O
burden	O
.	O

Fifty	O
papers	O
met	O
eligibility	O
criteria	O
for	O
review	O
,	O
and	O
meta-analysis	O
of	O
overall	O
results	O
was	O
possible	O
in	O
thirty-two	O
(	O
2050	O
participants	O
)	O
.	O

Aggregate	O
correlation	O
between	O
cognition	O
and	O
T2	O
lesion	O
burden	O
was	O
r	O
=	O
-0.30	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
-0.34	O
,	O
-0.26	O
)	O
.	O

Wide	O
methodological	O
variability	O
was	O
seen	O
,	O
particularly	O
related	O
to	O
key	O
factors	O
in	O
the	O
cognitive	O
data	O
capture	O
and	O
image	B-P
analysis	I-P
techniques	I-P
.	O

Resolving	O
the	O
persistent	O
clinico-	O
radiological	O
paradox	O
will	O
likely	O
require	O
simultaneous	O
evaluation	O
of	O
multiple	O
components	O
of	O
the	O
complex	O
pathology	O
using	O
optimum	O
measurement	O
techniques	O
for	O
both	O
cognitive	O
and	O
MRI	B-P
feature	O
quantification	O
.	O

We	O
recommend	O
a	O
consensus	O
initiative	O
to	O
support	O
common	O
standards	O
for	O
image	B-P
analysis	I-P
in	O
MS	O
,	O
enabling	O
benchmarking	O
while	O
also	O
supporting	O
ongoing	O
innovation	O
.	O

Acute	O
sensitivity	O
of	O
the	O
vernal	O
pool	O
fairy	O
shrimp	O
,	O
Branchinecta	O
lynchi	O
(	O
Anostraca	O
;	O
Branchinectidae	O
)	O
,	O
and	O
surrogate	O
species	O
to	O
10	O
chemicals	O
.	O

Vernal	O
pool	O
fairy	O
shrimp	O
,	O
Branchinecta	O
lynchi	O
,	O
(	O
Branchiopoda	O
;	O
Anostraca	O
)	O
and	O
other	O
fairy	O
shrimp	O
species	O
have	O
been	O
listed	O
as	O
threatened	O
or	O
endangered	O
under	O
the	O
US	O
Endangered	O
Species	O
Act	O
.	O

Because	O
few	O
data	O
exist	O
about	O
the	O
sensitivity	O
of	O
Branchinecta	O
spp	O
.	O

to	O
toxic	O
effects	O
of	O
contaminants	O
,	O
it	O
is	O
difficult	O
to	O
determine	O
whether	O
they	O
are	O
adequately	O
protected	O
by	O
water	O
quality	O
criteria	O
.	O

A	O
series	O
of	O
acute	B-P
(	I-P
24-h	I-P
)	I-P
lethality/immobilization	I-P
tests	I-P
was	O
conducted	O
with	O
3	O
species	O
of	O
fairy	O
shrimp	O
(	O
B.	O
lynchi	O
,	O
Branchinecta	O
lindahli	O
,	O
and	O
Thamnocephalus	O
platyurus	O
)	O
and	O
10	O
chemicals	O
with	O
varying	O
modes	O
of	O
toxic	O
action	O
:	O
ammonia	O
,	O
potassium	O
,	O
chloride	O
,	O
sulfate	O
,	O
chromium	O
(	O
VI	O
)	O
,	O
copper	O
,	O
nickel	O
,	O
zinc	O
,	O
alachlor	O
,	O
and	O
metolachlor	O
.	O

The	O
same	O
chemicals	O
were	O
tested	O
in	O
48-	O
h	O
tests	B-P
with	O
other	O
branchiopods	O
(	O
the	O
cladocerans	O
Daphnia	O
magna	O
and	O
Ceriodaphnia	O
dubia	O
)	O
and	O
an	O
amphipod	O
(	O
Hyalella	O
azteca	O
)	O
,	O
and	O
in	O
96-	O
h	O
tests	B-P
with	O
snails	O
(	O
Physa	O
gyrina	O
and	O
Lymnaea	O
stagnalis	O
)	O
.	O

Median	O
effect	O
concentrations	O
(	O
EC50s	O
)	O
for	O
B.	O
lynchi	O
were	O
strongly	O
correlated	O
(	O
r	O
(	O
2	O
)	O
=	O
0.975	O
)	O
with	O
EC50s	O
for	O
the	O
commercially	O
available	O
fairy	O
shrimp	O
species	O
T.	O
platyurus	O
for	O
most	O
chemicals	O
tested	O
.	O

Comparison	O
of	O
EC50s	O
for	O
fairy	O
shrimp	O
and	O
EC50s	O
for	O
invertebrate	O
taxa	O
tested	O
concurrently	O
and	O
with	O
other	O
published	O
toxicity	O
data	O
indicated	O
that	O
fairy	O
shrimp	O
were	O
relatively	O
sensitive	O
to	O
potassium	O
and	O
several	O
trace	O
metals	O
compared	O
with	O
other	O
invertebrate	O
taxa	O
,	O
although	O
cladocerans	O
,	O
amphipods	O
,	O
and	O
mussels	O
had	O
similar	O
broad	O
toxicant	O
sensitivity	O
.	O

Interspecies	O
correlation	O
estimation	O
models	O
for	O
predicting	O
toxicity	O
to	O
fairy	O
shrimp	O
from	O
surrogate	O
species	O
indicated	O
that	O
models	O
with	O
cladocerans	O
and	O
freshwater	O
mussels	O
as	O
surrogates	O
produced	O
the	O
best	O
predictions	O
of	O
the	O
sensitivity	O
of	O
fairy	O
shrimp	O
to	O
contaminants	O
.	O

The	O
results	O
of	O
these	O
studies	O
indicate	O
that	O
fairy	O
shrimp	O
are	O
relatively	O
sensitive	O
to	O
a	O
range	O
of	O
toxicants	O
,	O
but	O
Endangered	O
Species	O
Act	O
-listed	O
fairy	O
shrimp	O
of	O
the	O
genus	O
Branchinecta	O
were	O
not	O
consistently	O
more	O
sensitive	O
than	O
other	O
fairy	O
shrimp	O
taxa	O
.	O

Environ	O
Toxicol	O
Chem	O
2016	O
;	O
9999:1-10	O
.	O

Published	O
2016	O
Wiley	O
Periodicals	O
Inc.	O
on	O
behalf	O
of	O
SETAC	O
.	O

This	O
article	O
is	O
a	O
US	O
government	O
work	O
and	O
,	O
as	O
such	O
,	O
is	O
in	O
the	O
public	O
domain	O
in	O
the	O
United	O
States	O
of	O
America	O
.	O

Epigenetic	O
Editing	O
of	O
Ascl1	O
Gene	O
in	O
Neural	O
Stem	O
Cells	O
by	O
Optogenetics	O
.	O

Enzymes	O
involved	O
in	O
epigenetic	O
processes	O
such	O
as	O
methyltransferases	O
or	O
demethylases	O
are	O
becoming	O
highly	O
utilized	O
for	O
their	O
persistent	O
DNA	O
or	O
histone	O
modifying	O
efficacy	O
.	O

Herein	O
,	O
we	O
have	O
developed	O
an	O
optogenetic	O
toolbox	O
fused	O
to	O
the	O
catalytic	O
domain	O
(	O
CD	O
)	O
of	O
DNA-methyltransferase3A	O
(	O
DNMT3A	O
-	O
CD	O
)	O
or	O
Ten-Eleven	O
Dioxygenase-1	O
(	O
TET1	O
-	O
CD	O
)	O
for	O
loci	O
-	O
specific	O
alteration	O
of	O
the	O
methylation	O
state	O
at	O
the	O
promoter	O
of	O
Ascl1	O
(	O
Mash1	O
)	O
,	O
a	O
candidate	O
proneuron	O
gene	O
.	O

Optogenetical	O
protein	O
pairs	O
,	O
CRY2	O
linked	O
to	O
DNMT3A	O
-	O
CD	O
or	O
TET1	O
-	O
CD	O
and	O
CIB1	O
fused	O
to	O
a	O
Transcription	O
Activator-Like	O
Element	O
(	O
TALE	O
)	O
locating	O
an	O
Ascl1	O
promoter	O
region	O
,	O
were	O
designed	O
for	O
site	O
specific	O
epigenetic	O
editing	O
.	O

A	O
differentially	O
methylated	O
region	O
at	O
the	O
Ascl1	O
promoter	O
,	O
isolated	O
from	O
murine	O
dorsal	O
root	O
ganglion	O
(	O
hypermethylated	O
)	O
and	O
striated	O
cells	O
(	O
hypomethylated	O
)	O
,	O
was	O
targeted	O
with	O
these	O
optogenetic-epigenetic	O
constructs	O
.	O

Optimized	O
blue-light	O
illumination	B-P
triggered	O
the	O
co-localization	O
of	O
TALE	O
constructs	O
with	O
DNMT3A	O
-	O
CD	O
or	O
TET1	O
-	O
CD	O
fusion	O
proteins	O
at	O
the	O
targeted	O
site	O
of	O
the	O
Ascl1	O
promoter	O
.	O

We	O
found	O
that	O
this	O
spatiotemporal	O
association	O
of	O
the	O
fusion	O
proteins	O
selectively	O
alters	O
the	O
methylation	O
state	O
and	O
also	O
regulates	O
gene	O
activity	O
.	O

This	O
proof	O
of	O
concept	O
developed	O
herein	O
holds	O
immense	O
promise	O
for	O
the	O
ability	O
to	O
regulate	O
gene	O
activity	O
via	O
epigenetic	O
modulation	O
with	O
spatiotemporal	O
precision	O
.	O

Electrospray	O
deposition	O
device	O
used	O
to	O
precisely	O
control	O
the	O
matrix	O
crystal	O
to	O
improve	O
the	O
performance	O
of	O
MALDI	B-P
MSI	I-P
.	O

MALDI	B-P
MSI	I-P
has	O
been	O
recently	O
applied	O
as	O
an	O
innovative	O
tool	O
for	O
detection	O
of	O
molecular	O
distribution	O
within	O
a	O
specific	O
tissue	O
.	O

MALDI	B-P
MSI	I-P
requires	O
deposition	O
of	O
an	O
organic	O
compound	O
,	O
known	O
as	O
matrix	O
,	O
on	O
the	O
tissue	O
of	O
interest	O
to	O
assist	O
analyte	O
desorption	O
and	O
ionization	O
,	O
in	O
which	O
the	O
matrix	O
crystal	O
homogeneity	O
and	O
size	O
greatly	O
influence	O
the	O
imaging	B-P
reproducibility	O
and	O
spatial	O
resolution	O
in	O
MALDI	B-P
MSI	I-P
.	O

In	O
this	O
work	O
,	O
a	O
homemade	O
electrospray	O
deposition	O
device	O
was	O
developed	O
for	O
deposition	O
of	O
matrix	O
in	O
MALDI	B-P
MSI	I-P
.	O

The	O
device	O
could	O
be	O
used	O
to	O
achieve	O
1	O
μm	O
homogeneous	O
matrix	O
crystals	O
in	O
MALDI	B-P
MSI	I-P
analysis	B-P
.	O

Moreover	O
,	O
it	O
was	O
found	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
the	O
electrospray	O
deposition	O
device	O
could	O
be	O
used	O
to	O
precisely	O
control	O
the	O
matrix	O
crystal	O
size	O
,	O
and	O
the	O
imaging	B-P
spatial	O
resolution	O
was	O
increased	O
greatly	O
as	O
the	O
matrix	O
crystals	O
size	O
becoming	O
smaller	O
.	O

In	O
addition	O
,	O
the	O
easily-built	O
electrospray	O
deposition	O
device	O
was	O
durable	O
for	O
acid	O
,	O
base	O
or	O
organic	O
solvent	O
,	O
and	O
even	O
could	O
be	O
used	O
for	O
deposition	O
of	O
nanoparticles	O
matrix	O
,	O
which	O
made	O
it	O
unparalleled	O
for	O
MALDI	B-P
MSI	I-P
analysis	B-P
.	O

The	O
feasibility	O
of	O
the	O
electrospray	O
deposition	O
device	O
was	O
investigated	O
by	O
combination	O
with	O
MALDI	B-P
FTICR	I-P
MSI	I-P
to	O
analyze	O
the	O
distributions	O
of	O
lipids	O
in	O
mouse	O
brain	O
and	O
liver	O
cancer	O
tissue	O
section	O
.	O

Human	O
cathelicidin	O
LL-37	O
enhance	O
the	O
antibiofilm	O
effect	O
of	O
EGCG	O
on	O
Streptococcus	O
mutans	O
.	O

Streptococcus	O
mutans	O
forms	O
biofilms	O
as	O
a	O
resistance	O
mechanism	O
against	O
antimicrobial	O
agents	O
in	O
the	O
human	O
oral	O
cavity	O
.	O

We	O
recently	O
showed	O
that	O
human	O
cathelicidin	O
LL-37	O
exhibits	O
inhibitory	O
effects	O
on	O
biofilm	O
formation	O
of	O
S.	O
mutans	O
through	O
interaction	O
with	O
lipoteichoic	O
acid	O
(	O
LTA	O
)	O
,	O
but	O
without	O
antibacterial	O
or	O
biofilm	O
dispersal	O
abilities	O
.	O

(	O
-	O
)	O
-Epigallocatechin	O
gallate	O
(	O
EGCG	O
)	O
is	O
the	O
most	O
abundant	O
constituent	O
of	O
tea	O
catechins	O
that	O
has	O
the	O
greatest	O
anti-infective	O
potential	O
to	O
inhibit	O
the	O
growth	O
of	O
various	O
microorganisms	O
and	O
biofilm	O
formation	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
evaluated	O
whether	O
LL-37	O
interacts	O
with	O
EGCG	O
to	O
enhance	O
the	O
antibiofilm	O
effect	O
of	O
EGCG	O
on	O
S.	O
mutans	O
biofilm	O
formation	O
.	O

Clinical	O
S.	O
mutans	O
strains	O
(	O
n	O
=	O
10	O
)	O
isolated	O
from	O
children	O
's	O
saliva	O
were	O
tested	O
in	O
a	O
biofilm	O
formation	O
assay	B-P
.	O

The	O
antibiofilm	O
effect	O
of	O
EGCG	O
with	O
and	O
without	O
LL-37	O
was	O
analyzed	O
by	O
the	O
minimum	O
biofilm	O
eradication	O
concentration	O
assay	B-P
and	O
confirmed	O
using	O
field	O
emission-scanning	B-P
electron	I-P
microscopy	I-P
.	O

In	O
addition	O
,	O
the	O
interaction	O
among	O
EGCG	O
,	O
LL-37	O
,	O
and	O
LTA	O
of	O
S.	O
mutans	O
was	O
determined	O
using	O
quartz	O
crystal	O
microbalance	O
analysis	O
.	O

EGCG	O
killed	O
100	O
%	O
of	O
planktonic	O
S.	O
mutans	O
within	O
5	O
h	O
,	O
inhibited	O
biofilm	O
formation	O
within	O
24	O
h	O
,	O
and	O
reduced	O
bacteria	O
cells	O
in	O
preformed	O
biofilms	O
within	O
3	O
h	O
at	O
a	O
concentration	O
of	O
0.2	O
mg/mL	O
.	O

However	O
,	O
EGCG	O
did	O
not	O
appear	O
to	O
interact	O
with	O
LTA	O
.	O

LL-37	O
effectively	O
enhanced	O
the	O
bactericidal	O
activity	O
of	O
EGCG	O
against	O
biofilm	O
formation	O
and	O
preformed	O
biofilms	O
as	O
determined	O
by	O
quantitative	O
crystal	O
violet	O
staining	B-P
and	O
field	O
emission-scanning	B-P
electron	I-P
microscopy	I-P
.	O

In	O
addition	O
,	O
quartz	O
crystal	O
microbalance	O
analysis	O
revealed	O
that	O
LL-37	O
interacted	O
with	O
EGCG	O
and	O
promoted	O
binding	O
between	O
EGCG	O
and	O
LTA	O
of	O
S.	O
mutans	O
.	O

We	O
show	O
that	O
LL-37	O
enhances	O
the	O
antibiofilm	O
effect	O
of	O
EGCG	O
on	O
S.	O
mutans	O
.	O

This	O
finding	O
provides	O
new	O
knowledge	O
for	O
dental	O
treatment	O
by	O
using	O
LL-37	O
as	O
a	O
potential	O
antibiofilm	O
compound	O
.	O

Usefulness	O
of	O
Embolization	O
for	O
Iatrogenic	O
Dural	O
Arteriovenous	O
Fistula	O
Associated	O
with	O
Recurrent	O
Chronic	O
Subdural	O
Hematoma	O
:	O
A	O
Case	O
Report	O
and	O
Literature	O
Review	O
.	O

Refractory	O
chronic	O
subdural	O
hematomas	O
due	O
to	O
iatrogenic	O
dural	O
arteriovenous	O
fistulas	O
(	O
dAVFs	O
)	O
are	O
difficult	O
to	O
treat	O
.	O

We	O
report	O
our	O
experience	O
and	O
propose	O
a	O
guideline	O
on	O
basis	O
of	O
a	O
literature	O
review	O
for	O
the	O
usefulness	O
of	O
embolization	O
of	O
middle	O
meningeal	O
artery	O
(	O
MMA	O
)	O
for	O
the	O
treatment	O
of	O
the	O
same	O
.	O

We	O
report	O
a	O
case	O
with	O
right	O
hemiparesis	O
and	O
aphasia	O
1	O
month	O
after	O
a	O
fall	O
from	O
a	O
bicycle	O
.	O

Computed	B-P
tomography	I-P
scan	I-P
of	O
the	O
head	O
showed	O
left	O
chronic	O
subdural	O
hematoma	O
,	O
which	O
was	O
evacuated	O
by	O
burr-hole	O
drainage	O
.	O

The	O
postoperative	O
course	O
was	O
complicated	O
by	O
reaccumulation	O
within	O
short	O
period	O
of	O
time	O
.	O

On	O
superselective	B-P
digital	I-P
subtraction	I-P
angiography	I-P
of	O
MMA	O
,	O
iatrogenic	O
dAVF	O
was	O
found	O
on	O
left	O
side	O
.	O

We	O
embolized	O
successfully	O
it	O
using	O
n-butyl	O
cyanoacrylate	O
after	O
a	O
third	O
irrigation	O
.	O

No	O
reaccumulation	O
found	O
in	O
the	O
postoperative	O
period	O
or	O
at	O
last	O
follow-up	O
.	O

We	O
propose	O
treatment	O
protocol	O
based	O
on	O
our	O
experience	O
and	O
literature	O
review	O
.	O

Refractory	O
chronic	O
subdural	O
hematoma	O
with	O
reaccumulation	O
within	O
a	O
short	O
interval	O
should	O
be	O
subjected	O
to	O
digital	B-P
subtraction	I-P
angiography	I-P
of	O
the	O
MMA	O
.	O

Embolization	O
of	O
ipsilateral	O
MMA	O
is	O
safe	O
,	O
effective	O
,	O
and	O
a	O
useful	O
option	O
for	O
the	O
treatment	O
of	O
iatrogenic	O
dAVF	O
and	O
resolution	O
of	O
hematoma	O
.	O

Detachment	O
of	O
the	O
fucoxanthin	O
chlorophyll	O
a/c	O
binding	O
protein	O
(	O
FCP	O
)	O
antenna	O
is	O
not	O
involved	O
in	O
the	O
acclimative	O
regulation	O
of	O
photoprotection	O
in	O
the	O
pennate	O
diatom	O
Phaeodactylum	O
tricornutum	O
.	O

When	O
grown	O
under	O
intermittent	O
light	O
(	O
IL	O
)	O
,	O
the	O
pennate	O
diatom	O
Phaeodactylum	O
tricornutum	O
forms	O
'super	O
'	O
non-photochemical	O
fluorescence	O
quenching	O
(	O
NPQ	O
)	O
in	O
response	O
to	O
excess	O
light	O
.	O

The	O
current	O
model	O
of	O
diatom	O
NPQ	O
mechanism	O
involves	O
two	O
quenching	O
sites	O
,	O
one	O
of	O
which	O
detaches	O
from	O
photosystem	O
II	O
reaction	O
centres	O
(	O
RCIIs	O
)	O
and	O
aggregates	O
into	O
oligomeric	O
complexes	O
.	O

Here	O
we	O
addressed	O
how	O
antenna	O
reorganisation	O
controls	O
NPQ	O
kinetics	O
in	O
P.	O
tricornutum	O
cells	O
grown	O
under	O
continuous	O
light	O
(	O
CL	O
)	O
and	O
IL	O
.	O

Overall	O
,	O
IL	O
acclimation	O
induced	O
:	O
(	O
i	O
)	O
reorganisation	O
of	O
chloroplasts	O
,	O
containing	O
greater	O
pigment	O
pools	O
without	O
a	O
strongly	O
enhanced	O
operation	O
of	O
the	O
xanthophyll	O
cycle	O
,	O
and	O
(	O
ii	O
)	O
'	O
super	O
NPQ	O
'	O
causing	O
a	O
remarkable	O
reduction	O
of	O
the	O
chlorophyll	O
excited	O
state	O
lifetime	O
at	O
Fm	O
'	O
.	O

Regardless	O
of	O
different	O
levels	O
of	O
NPQ	O
formed	O
in	O
both	O
culture	B-P
conditions	O
,	O
its	O
dark	O
recovery	O
was	O
rapid	O
and	O
similar	O
fractions	O
of	O
their	O
antenna	O
uncoupled	O
(	O
~50	O
%	O
)	O
.	O

Although	O
antenna	O
detachment	O
relieved	O
excitation	O
pressure	O
,	O
it	O
provided	O
a	O
minor	O
protective	O
contribution	O
equivalent	O
to	O
NPQ	O
~1	O
,	O
while	O
the	O
largest	O
NPQ	O
was	O
4.4±0.2	O
(	O
CL	O
)	O
and	O
13±0.8	O
(	O
IL	O
)	O
.	O

The	O
PSII	O
cross-section	O
decrease	O
took	O
place	O
only	O
at	O
relatively	O
low	O
NPQ	O
values	O
,	O
beyond	O
which	O
the	O
cross-section	O
remained	O
constant	O
whilst	O
NPQ	O
continued	O
to	O
rise	O
.	O

This	O
finding	O
suggests	O
that	O
the	O
energy	O
trapping	O
efficiency	O
of	O
diatom	O
antenna	O
quenchers	O
can	O
not	O
over-compete	O
that	O
of	O
RCIIs	O
,	O
similarly	O
to	O
what	O
has	O
been	O
observed	O
on	O
higher	O
plants	O
.	O

We	O
conclude	O
that	O
such	O
'	O
economic	O
photoprotection	O
'	O
operates	O
to	O
flexibly	O
adjust	O
the	O
overall	O
efficiency	O
of	O
diatom	O
light	O
harvesting	O
.	O

Aspirin	O
Suppresses	O
Growth	O
in	O
PI3K	O
-	O
Mutant	O
Breast	O
Cancer	O
by	O
Activating	O
AMPK	O
and	O
Inhibiting	O
mTORC1	O
Signaling	O
.	O

Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	O
mutations	O
in	O
PIK3CA	O
,	O
the	O
gene	O
encoding	O
the	O
catalytic	O
subunit	O
of	O
PI3K	O
,	O
PI3K	O
inhibitors	O
have	O
yielded	O
little	O
clinical	O
benefit	O
for	O
breast	O
cancer	O
patients	O
.	O

Recent	O
epidemiologic	O
studies	O
have	O
suggested	O
a	O
therapeutic	O
benefit	O
from	O
aspirin	O
intake	O
in	O
cancers	O
harboring	O
oncogenic	O
PIK3CA	O
Here	O
,	O
we	O
show	O
that	O
mutant	O
PIK3CA	O
-	O
expressing	O
breast	O
cancer	O
cells	O
have	O
greater	O
sensitivity	O
to	O
aspirin	O
-mediated	O
growth	O
suppression	O
than	O
their	O
wild-type	O
counterparts	O
.	O

Aspirin	O
decreased	O
viability	O
and	O
anchorage-independent	B-P
growth	I-P
of	O
mutant	O
PIK3CA	O
breast	O
cancer	O
cells	O
independently	O
of	O
its	O
effects	O
on	O
COX-2	O
and	O
NF-κB	O
.	O

We	O
ascribed	O
the	O
effects	O
of	O
aspirin	O
to	O
AMP-activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
activation	O
,	O
mTORC1	O
inhibition	O
,	O
and	O
autophagy	O
induction	O
.	O

In	O
vivo	O
,	O
oncogenic	O
PIK3CA	O
-driven	O
mouse	O
mammary	O
tumors	O
treated	O
daily	O
with	O
aspirin	O
resulted	O
in	O
decreased	O
tumor	O
growth	O
kinetics	O
,	O
whereas	O
combination	O
therapy	O
of	O
aspirin	O
and	O
a	O
PI3K	O
inhibitor	O
further	O
attenuated	O
tumor	O
growth	O
.	O

Our	O
study	O
supports	O
the	O
evaluation	O
of	O
aspirin	O
and	O
PI3K	O
pathway	O
inhibitors	O
as	O
a	O
combination	O
therapy	O
for	O
targeting	O
breast	O
cancer	O
.	O

Cancer	O
Res	O
;	O
77	O
(	O
3	O
)	O
;	O
790-801	O
.	O

©2016	O
AACR	O
.	O

High	O
Performance	O
Reduction	O
of	O
H2O2	O
with	O
an	O
Electron	O
Transport	O
Decaheme	O
Cytochrome	O
on	O
a	O
Porous	O
ITO	O
Electrode	O
.	O

The	O
decaheme	O
cytochrome	O
MtrC	O
from	O
Shewanella	O
oneidensis	O
MR-1	O
immobilized	O
on	O
an	O
ITO	O
electrode	O
displays	O
unprecedented	O
H2O2	O
reduction	O
activity	O
.	O

Although	O
MtrC	O
showed	O
lower	O
peroxidase	O
activity	O
in	O
solution	O
compared	O
to	O
horseradish	O
peroxidase	O
,	O
the	O
ten	O
heme	O
cofactors	O
enable	O
excellent	O
electronic	O
communication	O
and	O
a	O
superior	O
activity	O
on	O
the	O
electrode	O
surface	O
.	O

A	O
hierarchical	O
ITO	O
electrode	O
enabled	O
optimal	O
immobilization	O
of	O
MtrC	O
and	O
a	O
high	O
current	O
density	O
of	O
1	O
mA	O
cm	O
(	O
-2	O
)	O
at	O
0.4	O
V	O
vs	O
SHE	O
could	O
be	O
obtained	O
at	O
pH	O
6.5	O
(	O
Eonset	O
=	O
0.72	O
V	O
)	O
.	O

UV-visible	O
and	O
Resonance	B-P
Raman	I-P
spectroelectrochemical	I-P
studies	I-P
suggest	O
the	O
formation	O
of	O
a	O
high	O
valent	O
iron-oxo	O
species	O
as	O
the	O
catalytic	O
intermediate	O
.	O

Our	O
findings	O
demonstrate	O
the	O
potential	O
of	O
multiheme	O
cytochromes	O
to	O
catalyze	O
technologically	O
relevant	O
reactions	O
and	O
establish	O
MtrC	O
as	O
a	O
new	O
benchmark	O
in	O
biotechnological	O
H2O2	O
reduction	O
with	O
scope	O
for	O
applications	O
in	O
fuel	O
cells	O
and	O
biosensors	O
.	O

Anemia	O
tolerance	O
during	O
normo	O
-	O
,	O
hypo	O
-	O
,	O
and	O
hypervolemia	O
.	O

Restrictive	O
intraoperative	O
fluid	O
management	O
has	O
been	O
demonstrated	O
to	O
improve	O
outcome	O
of	O
visceral	O
and	O
lung	O
surgery	O
in	O
several	O
studies	O
.	O

However	O
,	O
subsequent	O
hypovolemia	O
(	O
HOV	O
)	O
may	O
be	O
accompanied	O
by	O
a	O
decrease	O
of	O
anemia	O
tolerance	O
,	O
resulting	O
in	O
increased	O
transfusion	O
needs	O
.	O

We	O
therefore	O
investigated	O
the	O
effect	O
of	O
volume	O
status	O
on	O
anemia	O
tolerance	O
.	O

Eighteen	O
domestic	O
pigs	O
of	O
either	O
sex	O
(	O
mean	O
weight	O
,	O
23.5	O
±	O
4.8	O
kg	O
)	O
were	O
anesthetized	O
,	O
ventilated	O
,	O
and	O
randomized	O
into	O
three	O
experimental	O
groups	O
:	O
normovolemia	O
(	O
no	O
intervention	O
)	O
,	O
HOV	O
(	O
blood	O
loss	O
of	O
40	O
%	O
of	O
blood	O
volume	O
)	O
,	O
and	O
hypervolemia	O
(	O
HEV	O
;	O
volume	O
infusion	O
of	O
40	O
%	O
of	O
blood	O
volume	O
)	O
.	O

The	O
animals	O
were	O
then	O
hemodiluted	O
until	O
their	O
individual	O
critical	O
hemoglobin	O
concentrations	O
(	O
Hbcrit	O
)	O
were	O
reached	O
by	O
the	O
exchange	O
of	O
whole	O
blood	O
for	O
hydroxyethyl	O
starch	O
(	O
HES	O
;	O
130:0.4	O
)	O
.	O

Subsequently	O
,	O
organ-specific	O
hypoxia	O
was	O
assessed	O
using	O
pimonidazole	O
tissue	B-P
staining	I-P
in	O
relevant	O
organs	O
.	O

Hemodynamic	O
and	O
metabolic	O
variables	O
were	O
also	O
investigated	O
.	O

Despite	O
significant	O
differences	O
in	O
exchangeable	O
blood	O
volume	O
,	O
Hbcrit	O
was	O
the	O
same	O
in	O
all	O
groups	O
(	O
2.3	O
g/dL	O
,	O
NS	O
)	O
.	O

During	O
HOV	O
,	O
tissue	O
hypoxia	O
was	O
aggravated	O
in	O
the	O
myocardium	O
,	O
brain	O
,	O
and	O
kidneys	O
,	O
whereas	O
tissue	O
oxygenation	O
of	O
the	O
liver	O
and	O
intestine	O
was	O
not	O
influenced	O
by	O
volume	O
status	O
.	O

HEV	O
increased	O
tissue	O
hypoxia	O
in	O
the	O
lungs	O
,	O
but	O
did	O
not	O
impact	O
tissue	O
oxygenation	O
of	O
other	O
organs	O
.	O

The	O
combination	O
of	O
hemorrhagic	O
HOV	O
with	O
subsequent	O
anemia	O
leads	O
to	O
accentuated	O
tissue	O
hypoxia	O
,	O
revealed	O
by	O
a	O
significant	O
increase	O
in	O
pimonidazole	O
binding	O
at	O
Hbcrit	O
,	O
in	O
heart	O
,	O
lungs	O
,	O
brain	O
,	O
and	O
kidney	O
.	O

The	O
lungs	O
were	O
the	O
only	O
organ	O
that	O
showed	O
increased	O
tissue	O
hypoxia	O
after	O
pretreatment	O
of	O
HES	O
infusion	O
and	O
subsequent	O
anemia	O
by	O
normovolemic	O
hemodilution	O
.	O

Comparison	O
of	O
multiple	O
single-nucleotide	O
variant	O
association	B-P
tests	I-P
in	O
a	O
meta-analysis	O
of	O
Genetic	B-P
Analysis	I-P
Workshop	O
19	O
family	O
and	O
unrelated	O
data	O
.	O

Meta-analysis	O
has	O
been	O
widely	O
used	O
in	O
genetic	O
association	O
studies	O
to	O
increase	O
sample	O
size	O
and	O
to	O
improve	O
power	O
,	O
both	O
in	O
the	O
context	O
of	O
single-variant	B-P
analysis	I-P
,	O
as	O
well	O
as	O
for	O
gene	O
-based	O
tests	B-P
.	O

Meta-analysis	O
approaches	O
for	O
haplotype	O
analysis	O
have	O
not	O
been	O
extensively	O
developed	O
and	O
used	O
,	O
and	O
have	O
not	O
been	O
compared	O
with	O
other	O
ways	O
of	O
jointly	O
analysing	B-P
multiple	I-P
genetic	I-P
variants	I-P
.	O

We	O
propose	O
a	O
novel	O
meta-analysis	O
approach	O
for	O
a	O
gene	O
-based	O
haplotype	O
association	B-P
test	I-P
,	O
and	O
compare	O
it	O
with	O
an	O
existing	O
meta-analysis	O
approach	O
of	O
the	O
sequence	B-P
kernel	I-P
association	I-P
test	I-P
(	O
SKAT	B-P
)	O
,	O
using	O
the	O
unrelated	O
samples	O
and	O
family	O
samples	O
of	O
the	O
Genetic	B-P
Analysis	I-P
Workshop	O
19	O
data	O
sets	O
.	O

We	O
performed	O
association	B-P
tests	I-P
with	O
diastolic	O
blood	O
pressure	O
and	O
restricted	O
our	O
analyses	O
to	O
all	O
variants	O
in	O
exonic	O
regions	O
on	O
all	O
odd	O
chromosomes	O
.	O

Meta-analysis	O
of	O
haplotype	O
results	O
and	O
SKAT	B-P
identified	O
different	O
genes	O
.	O

The	O
most	O
significantly	O
associated	O
gene	O
identified	O
by	O
SKAT	B-P
was	O
the	O
ALCAM	O
gene	O
on	O
chromosome	O
3	O
with	O
a	O
p	O
value	O
of	O
7.0	O
×	O
10	O
(	O
-	O
5	O
)	O
.	O

Two	O
of	O
the	O
most	O
associated	O
genes	O
identified	O
by	O
the	O
haplotype	O
method	O
were	O
FPGT	O
(	O
p	O
=	O
6.7	O
×	O
10	O
(	O
-	O
8	O
)	O
)	O
on	O
chromosome	O
1	O
and	O
SPARC	O
(	O
p	O
=	O
3.3	O
×	O
10	O
(	O
-	O
7	O
)	O
)	O
on	O
chromosome	O
5	O
.	O

Both	O
genes	O
were	O
previously	O
implicated	O
in	O
blood	O
pressure	O
regulation	O
and	O
hypertension	O
.	O

We	O
compared	O
two	O
meta-analysis	O
approaches	O
to	O
jointly	O
analyze	O
multiple	O
variants	O
:	O
SKAT	B-P
and	O
haplotype	O
tests	B-P
.	O

The	O
difference	O
in	O
observed	O
results	O
may	O
be	O
because	O
the	O
haplotype	O
method	O
considered	O
all	O
observed	O
haplotypes	O
,	O
whereas	O
SKAT	B-P
weighted	O
variants	O
inversely	O
to	O
their	O
minor	O
allele	O
frequency	O
,	O
masking	O
the	O
effects	O
of	O
common	O
variants	O
.	O

The	O
two	O
approaches	O
identified	O
different	O
top	O
genes	O
,	O
and	O
appear	O
to	O
be	O
complementary	O
.	O

Anxiolytic	O
effects	O
of	O
fluoxetine	O
and	O
nicotine	O
exposure	O
on	O
exploratory	O
behavior	O
in	O
zebrafish	O
.	O

Zebrafish	O
(	O
Danio	O
rerio	O
)	O
have	O
emerged	O
as	O
a	O
popular	O
model	O
for	O
studying	O
the	O
pharmacology	O
and	O
behavior	O
of	O
anxiety	O
.	O

While	O
there	O
have	O
been	O
numerous	O
studies	O
documenting	O
the	O
anxiolytic	O
and	O
anxiogenic	O
effects	O
of	O
common	O
drugs	O
in	O
zebrafish	O
,	O
many	O
do	O
not	O
report	O
or	O
test	O
for	O
behavioral	O
differences	O
between	O
the	O
sexes	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
males	O
and	O
females	O
differ	O
in	O
their	O
baseline	O
level	O
of	O
anxiety	O
.	O

In	O
this	O
study	O
,	O
we	O
test	O
for	O
a	O
sex	O
interaction	O
with	O
fluoxetine	O
and	O
nicotine	O
.	O

We	O
exposed	O
fish	O
to	O
system	O
water	O
(	O
control	O
)	O
,	O
10	O
mg/L	O
fluoxetine	O
,	O
or	O
1	O
mg/L	O
nicotine	O
for	O
three	O
minutes	O
prior	O
to	O
being	O
subjected	O
to	O
four	O
minutes	O
in	O
an	O
open-field	B-P
drop	I-P
test	I-P
.	O

Video	O
recordings	O
were	O
tracked	O
using	O
ProAnalyst	O
.	O

Fish	O
from	O
both	O
drug	O
treatments	O
reduced	O
swimming	O
speed	O
,	O
increased	O
vertical	O
position	O
,	O
and	O
increased	O
use	O
of	O
the	O
top	O
half	O
of	O
the	O
open	O
field	O
when	O
compared	O
with	O
the	O
control	O
,	O
though	O
fluoxetine	O
had	O
a	O
larger	O
effect	O
on	O
depth	O
related	O
behaviors	O
while	O
nicotine	O
mostly	O
affected	O
swimming	O
speed	O
.	O

A	O
significant	O
sex	O
effect	O
was	O
observed	O
where	O
females	O
swam	O
at	O
a	O
slower	O
and	O
more	O
constant	O
speed	O
than	O
males	O
,	O
however	O
neither	O
drug	O
produced	O
a	O
sex	O
-	O
dependent	O
response	O
.	O

Breast	O
cancer	O
cells	O
and	O
bone	O
marrow	O
mesenchymal	O
stromal	O
cells	O
:	O
a	O
regulated	O
modulation	O
of	O
the	O
breast	O
tumor	O
in	O
the	O
context	O
of	O
immune	O
response	O
.	O

The	O
role	O
of	O
direct	O
cell-cell	O
interactions	O
mediating	O
selective	O
bone	O
metastasis	O
by	O
breast	O
cancer	O
cells	O
(	O
BCCs	O
)	O
niche	O
is	O
still	O
mostly	O
unknown	O
.	O

Conditioned	O
medium	O
and	O
direct	O
cell-cell	O
contacts	O
experiments	O
were	O
used	O
to	O
investigate	O
the	O
effect	O
of	O
bone	O
marrow	O
-derived	O
mesenchymal	O
stromal	O
cells	O
(	O
MSCs	O
)	O
,	O
osteoprogenitor-like	O
cells	O
(	O
MG-63	O
)	O
and	O
osteosarcoma	O
cells	O
(	O
SaOS-2	O
)	O
on	O
luminal-like	O
(	O
MCF-7	O
)	O
and	O
basal-like	O
(	O
MDA-MB-231	O
)	O
BCCs	O
flow	B-P
cytometry	I-P
was	O
used	O
to	O
assess	O
the	O
purity	O
of	O
isolated	O
BCCs	O
and	O
osteoblasts	O
.	O

Expression	O
of	O
osteoblastic	O
markers	O
was	O
investigated	O
by	O
semi-quantitative	O
RT-PCR	O
.	O

RANKL	O
and	O
OPG	O
levels	O
were	O
measured	O
by	O
ELISA	B-P
.	O

Conditioned	O
medium	O
from	O
MSCs	O
and	O
osteoblasts	O
induced	O
the	O
expression	O
of	O
osteoblastic	O
markers	O
in	O
BCCs	O
.	O

While	O
co-culture	B-P
assays	B-P
with	O
SaOS-2	O
increased	O
the	O
expression	O
of	O
osteoblastic	O
markers	O
in	O
MCF-7	O
cells	O
,	O
SaOS-2	O
cell	O
conditioned	O
medium	O
increased	O
the	O
expression	O
of	O
RANKL	O
,	O
PTHrP	O
,	O
VEGF	O
and	O
NOGGIN	O
in	O
MCF-7	O
cells	O
.	O

Co-cultures	B-P
with	O
either	O
MG-63	O
cells	O
or	O
MSCs	O
induced	O
OPG	O
and	O
MMP-2	O
in	O
both	O
tumor	O
cell	O
lines	O
.	O

Interestingly	O
,	O
conditioned	O
medium	O
from	O
co-cultures	B-P
of	O
MSCs	O
and	O
MDA-MB-231	O
cells	O
significantly	O
decreased	O
the	O
proliferation	O
of	O
activated	O
T	O
lymphocytes	O
which	O
was	O
reversed	O
by	O
addition	O
of	O
anti-OPG	O
antibodies	O
to	O
the	O
co-cultures	B-P
.	O

Our	O
data	O
suggest	O
that	O
MSCs	O
strongly	O
contribute	O
to	O
the	O
adaptation	O
and	O
invasiveness	O
of	O
breast	O
cancer	O
cells	O
in	O
skeletal	O
tissues	O
.	O

Morphological	O
characteristics	O
regulating	O
phallic	O
glans	O
engorgement	O
in	O
the	O
American	O
alligator	O
.	O

The	O
distal	O
part	O
of	O
the	O
crocodilian	O
phallus	O
consists	O
of	O
a	O
bulbous	O
glans	O
containing	O
well-developed	O
vascular	O
tissues	O
that	O
can	O
inflate	O
before	O
or	O
during	O
sexual	O
activity	O
,	O
enlarging	O
and	O
elaborating	O
the	O
glans	O
into	O
a	O
complex	O
,	O
though	O
still	O
functionally	O
undefined	O
,	O
copulatory	O
structure	O
.	O

An	O
enlarged	O
glans	O
putatively	O
interacts	O
with	O
the	O
female	O
cloaca	O
and	O
may	O
change	O
the	O
shape	O
of	O
her	O
reproductive	O
tract	O
to	O
facilitate	O
insemination	O
and	O
increase	O
the	O
probability	O
of	O
fertilization	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
cellular-level	O
properties	O
of	O
the	O
glans	O
and	O
other	O
inflatable	O
phallic	O
tissues	O
associated	O
with	O
the	O
sperm	O
-conducting	O
sulcus	O
spermaticus	O
in	O
the	O
American	O
alligator	O
(	O
Alligator	O
mississippiensis	O
)	O
.	O

Using	O
histochemical	B-P
staining	I-P
,	O
we	O
visualized	O
and	O
defined	O
collagen	O
and	O
elastin	O
fiber	O
densities	O
and	O
orientations	O
in	O
these	O
tissues	O
.	O

Extracellular	O
matrix	O
architectures	O
provided	O
insights	O
about	O
phallic	O
glans	O
material	O
properties	O
and	O
how	O
they	O
may	O
affect	O
tissue	O
strength	O
and	O
flexibility	O
during	O
inflation	O
and	O
in	O
response	O
to	O
copulatory	O
forces	O
.	O

We	O
also	O
investigated	O
the	O
potential	O
sources	O
of	O
fluids	O
that	O
induce	O
inflation	O
in	O
alligator	O
phalli	O
.	O

Combining	O
serial	B-P
sectioning	I-P
and	O
three-dimensional	B-P
reconstruction	I-P
,	O
we	O
identified	O
a	O
pair	O
of	O
supracrucal	O
plexus	O
vascular	O
bodies	O
at	O
the	O
proximal	O
end	O
of	O
the	O
alligator	O
phallus	O
that	O
extend	O
distally	O
adjacent	O
to	O
ventro-medial	O
sulcus	O
tissues	O
.	O

Together	O
,	O
our	O
gross	O
and	O
histological	O
examination	O
of	O
the	O
American	O
alligator	O
phallic	O
glans	O
suggests	O
that	O
its	O
tissues	O
are	O
arranged	O
in	O
a	O
manner	O
that	O
would	O
allow	O
vascular	O
inflation	O
to	O
expand	O
the	O
glans	O
to	O
a	O
specific	O
and	O
repeatable	O
shape	O
,	O
and	O
potentially	O
release	O
secretory	O
products	O
into	O
the	O
female	O
reproductive	O
tract	O
.	O

Both	O
elements	O
could	O
play	O
roles	O
in	O
postcopulatory	O
sexual	O
selection	O
,	O
by	O
mechanically	O
and/or	O
chemically	O
affecting	O
female	O
reproductive	O
physiology	O
.	O

Comparison	O
of	O
plasma	B-P
ammonia	I-P
results	I-P
from	O
seven	O
different	O
automated	O
platforms	O
in	O
use	O
throughout	O
Central	O
Australia	O
.	O

The	O
clinical	O
catchment	O
area	O
for	O
the	O
Metabolic	O
service	O
at	O
the	O
Women	O
's	O
and	O
Children	O
's	O
Hospital	O
in	O
Adelaide	O
,	O
South	O
Australia	O
,	O
covers	O
nearly	O
2.5millionkm	O
(	O
2	O
)	O
.	O

Care	O
of	O
children	O
with	O
metabolic	O
disorders	O
in	O
these	O
remote	O
areas	O
is	O
assisted	O
from	O
Adelaide	O
,	O
and	O
at	O
times	O
,	O
using	O
plasma	B-P
ammonia	I-P
results	I-P
from	O
laboratories	O
up	O
to	O
3000km	O
away	O
.	O

There	O
are	O
seven	O
different	O
platforms	O
measuring	B-P
plasma	I-P
ammonia	I-P
within	O
this	O
vast	O
clinical	O
catchment	O
area	O
.	O

Hence	O
,	O
a	O
correlation	O
study	O
was	O
conducted	O
to	O
examine	O
the	O
relationship	O
between	O
plasma	B-P
ammonia	I-P
results	I-P
from	O
the	O
seven	O
different	O
platforms	O
in	O
use	O
throughout	O
central	O
Australia	O
.	O

Multiple	O
aliquots	O
of	O
plasma	O
from	O
remainder	O
EDTA	O
samples	O
for	O
haematological	B-P
investigations	I-P
were	O
frozen	O
.	O

Samples	O
were	O
then	O
dispatched	O
on	O
dry	O
ice	O
to	O
the	O
laboratories	O
being	O
correlated	O
.	O

At	O
an	O
agreed	O
date	O
and	O
time	O
correlation	O
samples	O
were	O
thawed	O
and	O
plasma	B-P
ammonia	I-P
measured	I-P
.	O

Passing-Bablok	O
regression	O
analysis	O
showed	O
slopes	O
ranging	O
from	O
1.00	O
to	O
1.10	O
and	O
y-intercepts	O
ranging	O
from	O
-10μmol/L	O
to	O
1μmol/L	O
.	O

Despite	O
the	O
absence	O
of	O
a	O
reference	B-P
method	I-P
or	O
reference	O
material	O
and	O
troublesome	O
pre-analytical	O
effects	O
in	O
ammonia	B-P
measurement	I-P
,	O
plasma	B-P
ammonia	I-P
results	I-P
from	O
the	O
different	O
platforms	O
in	O
general	O
compare	O
well	O
.	O

The	O
study	O
also	O
demonstrates	O
that	O
samples	O
for	O
ammonia	B-P
measurement	I-P
can	O
be	O
transported	O
over	O
great	O
distances	O
and	O
still	O
correlate	O
well	O
.	O

Furthermore	O
,	O
a	O
common	O
reference	O
interval	O
for	O
plasma	O
ammonia	O
may	O
be	O
a	O
possibility	O
.	O

Risk	O
and	O
Predictors	O
of	O
Variceal	O
Bleeding	O
in	O
Cirrhosis	O
Patients	O
Receiving	O
Primary	O
Prophylaxis	O
With	O
Non-Selective	O
Beta-Blockers	O
.	O

Prior	O
studies	O
have	O
demonstrated	O
the	O
efficacy	O
of	O
non-selective	O
beta-blockers	O
(	O
NSBB	O
)	O
in	O
preventing	O
first	O
variceal	O
bleeding	O
in	O
patients	O
with	O
cirrhosis	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
overall	O
effectiveness	O
of	O
NSBB	O
in	O
routine	O
clinical	O
care	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
of	O
cirrhotic	O
patients	O
without	O
prior	O
bleeding	O
who	O
initiated	O
a	O
NSBB	O
(	O
propranolol	O
,	O
nadolol	O
)	O
at	O
any	O
Veterans	O
Administration	O
facility	O
between	O
2008	O
and	O
2013	O
.	O

The	O
primary	O
outcome	O
was	O
variceal	O
bleeding	O
within	O
12	O
months	O
.	O

We	O
conducted	O
Cox-proportional	O
hazards	O
analyses	O
to	O
identify	O
demographic	O
,	O
clinical	O
,	O
and	O
NSBB	O
-related	O
(	O
type	O
of	O
NSBB	O
,	O
mean	O
dose	O
,	O
dose	O
change	O
,	O
and	O
heart	O
rate	O
response	O
)	O
factors	O
associated	O
with	O
variceal	O
bleeding	O
.	O

Of	O
5,775	O
patients	O
,	O
678	O
(	O
11.7	O
%	O
)	O
developed	O
variceal	O
bleeding	O
.	O

Mean	O
daily	O
dose	O
of	O
NSBB	O
was	O
<	O
40	O
mg	O
in	O
58.8	O
%	O
,	O
18.1	O
%	O
had	O
either	O
upward	O
or	O
downward	O
titration	B-P
in	O
NSBB	O
dose	O
,	O
and	O
9.8	O
%	O
had	O
hemodynamic	O
response	O
.	O

Patients	O
who	O
were	O
younger	O
,	O
with	O
ascites	O
,	O
greater	O
medical	O
comorbidity	O
,	O
and	O
higher	O
MELD	O
(	O
Model	O
for	O
end-stage	O
liver	O
disease	O
)	O
scores	O
had	O
a	O
higher	O
risk	O
of	O
variceal	O
bleeding	O
.	O

Patients	O
on	O
a	O
higher	O
daily	O
dose	O
(	O
>	O
60	O
vs.	O
<	O
40	O
mg	O
,	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
0.64	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.51-0.81	O
)	O
,	O
who	O
had	O
either	O
upward	O
or	O
downward	O
dose	O
titration	B-P
(	O
adjusted	O
HR	O
0.69	O
;	O
95	O
%	O
CI	O
:	O
0.52-0.90	O
and	O
0.64	O
;	O
95	O
%	O
CI	O
0.45-0.90	O
,	O
respectively	O
)	O
,	O
and	O
those	O
who	O
achieved	O
hemodynamic	O
response	O
(	O
adjusted	O
HR	O
0.75	O
;	O
95	O
%	O
CI	O
=0.57-1.0	O
)	O
had	O
lower	O
risk	O
.	O

Approximately	O
12	O
%	O
of	O
patients	O
bled	O
while	O
being	O
on	O
NSBB	O
for	O
primary	O
prophylaxis	O
.	O

A	O
higher	O
NSBB	O
dose	O
and	O
dose	O
titration	B-P
were	O
protective	O
;	O
yet	O
most	O
patients	O
did	O
not	O
have	O
the	O
NSBB	O
dose	O
titrated	B-P
to	O
the	O
recommended	O
levels	O
.	O

Our	O
data	O
highlight	O
the	O
need	O
for	O
careful	O
monitoring	O
of	O
cirrhotic	O
patients	O
on	O
NSBB	O
.	O

Keratin	O
13	O
Is	O
Enriched	O
in	O
Prostate	O
Tubule-Initiating	O
Cells	O
and	O
May	O
Identify	O
Primary	O
Prostate	O
Tumors	O
that	O
Metastasize	O
to	O
the	O
Bone	O
.	O

Benign	O
human	O
prostate	O
tubule-initiating	O
cells	O
(	O
TIC	O
)	O
and	O
aggressive	O
prostate	O
cancer	O
display	O
common	O
traits	O
,	O
including	O
tolerance	O
of	O
low	O
androgen	O
levels	O
,	O
resistance	O
to	O
apoptosis	O
,	O
and	O
microenvironment	O
interactions	O
that	O
drive	O
epithelial	O
budding	O
and	O
outgrowth	O
.	O

TIC	O
can	O
be	O
distinguished	O
from	O
epithelial	O
and	O
stromal	O
cells	O
that	O
comprise	O
prostate	O
tissue	O
via	O
cell	B-P
sorting	I-P
based	O
upon	O
Epcam	O
,	O
CD44	O
,	O
and	O
CD49f	O
antigenic	O
profiles	O
.	O

Fetal	O
prostate	O
epithelial	O
cells	O
(	O
FC	O
)	O
possess	O
a	O
similar	O
antigenic	O
profile	O
to	O
adult	O
TIC	O
and	O
are	O
capable	O
of	O
inducing	O
tubule	O
formation	O
.	O

To	O
identify	O
the	O
TIC	O
niche	O
in	O
human	O
prostate	O
tissue	O
,	O
differential	O
keratin	O
(	O
KRT	O
)	O
expression	O
was	O
evaluated	O
.	O

Gene	O
expression	O
data	O
generated	O
from	O
Affymetrix	O
Gene	O
Chip	O
human	O
U133	O
Plus	O
2.0	O
array	O
of	O
sorted	O
adult	O
and	O
fetal	O
epithelial	O
cells	O
revealed	O
KRT13	O
to	O
be	O
significantly	O
enriched	O
in	O
FC	O
and	O
TIC	O
compared	O
to	O
basal	O
cells	O
(	O
BC	O
)	O
and	O
luminal	O
cells	O
(	O
LC	O
)	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Enriched	O
KRT13	O
expression	O
was	O
confirmed	O
by	O
RT-PCR	O
and	O
cytospin	B-P
immunostaining	I-P
.	O

Immunohistochemical	B-P
analysis	I-P
of	O
KRT13	O
expression	O
revealed	O
rare	O
KRT13+	O
epithelia	O
throughout	O
prostatic	O
ducts	O
/	O
acini	O
in	O
adult	O
tissue	O
specimens	O
and	O
differentiated	O
tubules	O
in	O
24-	O
week	O
recombinant	O
grafts	O
,	O
In	O
contrast	O
,	O
abundant	O
KRT13	O
expression	O
was	O
observed	O
in	O
developing	O
ducts	O
/	O
acini	O
in	O
fetal	O
prostate	O
and	O
cord-like	O
structures	O
composing	O
8-	O
week	O
recombinant	O
grafts	O
.	O

Immunostaining	B-P
of	O
a	O
prostate	O
tissue	O
microarray	O
revealed	O
KRT13+	O
tumor	O
foci	O
in	O
approximately	O
9	O
%	O
of	O
cases	O
,	O
and	O
this	O
subset	O
displayed	O
significantly	O
shorter	O
time	O
to	O
recurrence	O
(	O
p	O
=	O
0.031	O
)	O
,	O
metastases	O
(	O
p	O
=	O
0.032	O
)	O
,	O
and	O
decreased	O
overall	O
survival	O
(	O
p	O
=	O
0.004	O
)	O
.	O

Diagnostic	B-P
prostate	I-P
needle	I-P
biopsies	I-P
(	O
PNBX	B-P
)	O
from	O
untreated	O
patients	O
with	O
concurrent	O
bone	O
metastases	O
(	O
clinical	O
stage	O
M1	O
)	O
displayed	O
KRT13+	O
tumor	O
foci	O
,	O
as	O
did	O
bone	O
metastatic	O
foci	O
.	O

The	O
expression	O
profile	O
of	O
KRT13	O
in	O
benign	O
fetal	O
and	O
adult	O
prostate	O
tissue	O
and	O
in	O
recombinant	O
grafts	O
,	O
as	O
well	O
as	O
the	O
frequency	O
of	O
KRT13	O
expression	O
in	O
primary	O
and	O
metastatic	O
prostate	O
cancer	O
indicates	O
that	O
it	O
may	O
be	O
a	O
marker	O
of	O
a	O
stem/progenitor-like	O
cell	O
state	O
that	O
is	O
co-opted	O
in	O
aggressive	O
tumor	O
cells	O
.	O

KRT13	O
is	O
enriched	O
in	O
benign	O
stem-like	O
cells	O
that	O
display	O
androgen	O
-	O
resistance	O
,	O
apoptosis	O
-	O
resistance	O
,	O
and	O
branching	O
morphogenesis	O
properties	O
.	O

Collectively	O
our	O
data	O
demonstrate	O
that	O
KRT13	O
expression	O
is	O
associated	O
with	O
poor	O
prognosis	O
at	O
multiple	O
stages	O
of	O
disease	O
progression	O
and	O
may	O
represent	O
an	O
important	O
biomarker	O
of	O
adverse	O
outcome	O
in	O
patients	O
with	O
prostate	O
cancer	O
.	O

Accurate	O
Quantification	O
of	O
Laminarin	O
in	O
Marine	O
Organic	O
Matter	O
with	O
Enzymes	O
from	O
Marine	O
Microbes	O
.	O

Marine	O
algae	O
produce	O
a	O
variety	O
of	O
glycans	O
,	O
which	O
fulfill	O
diverse	O
biological	O
functions	O
and	O
fuel	O
the	O
carbon	O
and	O
energy	O
demands	O
of	O
heterotrophic	O
microbes	O
.	O

A	O
common	O
approach	O
to	O
analysis	O
of	O
marine	O
organic	O
matter	O
uses	O
acid	O
to	O
hydrolyze	O
the	O
glycans	O
into	O
measurable	O
monosaccharides	O
.	O

The	O
monosaccharides	O
may	O
be	O
derived	O
from	O
different	O
glycans	O
that	O
are	O
built	O
with	O
the	O
same	O
monosaccharides	O
,	O
however	O
,	O
and	O
this	O
approach	O
does	O
not	O
distinguish	O
between	O
glycans	O
in	O
natural	O
samples	O
.	O

Here	O
we	O
use	O
enzymes	O
to	O
digest	O
selectively	O
and	O
thereby	O
quantify	O
laminarin	O
in	O
particulate	O
organic	O
matter	O
.	O

Environmental	O
metaproteome	O
data	O
revealed	O
carbohydrate	O
-active	O
enzymes	O
from	O
marine	O
flavobacteria	O
as	O
tools	O
for	O
selective	O
hydrolysis	O
of	O
the	O
algal	O
β-glucan	O
laminarin	O
.	O

The	O
enzymes	O
digested	O
laminarin	O
into	O
glucose	O
and	O
oligosaccharides	O
,	O
which	O
we	O
measured	O
with	O
standard	O
methods	O
to	O
establish	O
the	O
amounts	O
of	O
laminarin	O
in	O
the	O
samples	O
.	O

We	O
cloned	O
,	O
expressed	O
,	O
purified	O
,	O
and	O
characterized	O
three	O
new	O
glycoside	O
hydrolases	O
(	O
GHs	O
)	O
of	O
Formosa	O
bacteria	O
:	O
two	O
are	O
endo-β-1,3-glucanases	O
,	O
of	O
the	O
GH16	O
and	O
GH17	O
families	O
,	O
and	O
the	O
other	O
is	O
a	O
GH30	O
exo-β-1,6-glucanase	O
.	O

Formosa	O
sp	O
.	O

nov	O
strain	O
Hel1_33_131	O
GH30	O
(	O
FbGH30	O
)	O
removed	O
the	O
β-1,6-glucose	O
side	O
chains	O
,	O
and	O
Formosa	O
agariphila	O
GH17A	O
(	O
FaGH17A	O
)	O
and	O
FaGH16A	O
hydrolyzed	O
the	O
β-1,3-glucose	O
backbone	O
of	O
laminarin	O
.	O

Specificity	O
profiling	O
with	O
a	O
library	O
of	O
glucan	O
oligosaccharides	O
and	O
polysaccharides	O
revealed	O
that	O
FaGH17A	O
and	O
FbGH30	O
were	O
highly	O
specific	O
enzymes	O
,	O
while	O
FaGH16A	O
also	O
hydrolyzed	O
mixed-linked	O
glucans	O
with	O
β-1,4-glucose	O
.	O

Therefore	O
,	O
we	O
chose	O
the	O
more	O
specific	O
FaGH17A	O
and	O
FbGH30	O
to	O
quantify	O
laminarin	O
in	O
two	O
cultured	O
diatoms	O
,	O
namely	O
,	O
Thalassiosira	O
weissflogii	O
and	O
Thalassiosira	O
pseudonana	O
,	O
and	O
in	O
seawater	O
samples	O
from	O
the	O
North	O
Sea	O
and	O
the	O
Arctic	O
Ocean	O
.	O

Combined	O
,	O
these	O
results	O
demonstrate	O
the	O
potential	O
of	O
enzymes	O
for	O
faster	O
,	O
stereospecific	O
,	O
and	O
sequence	O
-	O
specific	O
analysis	O
of	O
select	O
glycans	O
in	O
marine	O
organic	O
matter	O
.IMPORTANCE	O
Marine	O
algae	O
synthesize	O
substantial	O
amounts	O
of	O
the	O
glucose	O
polymer	O
laminarin	O
for	O
energy	O
and	O
carbon	O
storage	O
.	O

Its	O
concentrations	O
,	O
rates	O
of	O
production	O
by	O
autotrophic	O
organisms	O
,	O
and	O
rates	O
of	O
digestion	O
by	O
heterotrophic	O
organisms	O
remain	O
unknown	O
.	O

Here	O
we	O
present	O
a	O
method	O
based	O
on	O
enzymes	O
that	O
hydrolyze	O
laminarin	O
and	O
enable	O
its	O
quantification	O
even	O
in	O
crude	O
substrate	O
mixtures	O
,	O
without	O
purification	O
.	O

Compared	O
to	O
the	O
commonly	O
used	O
acid	O
hydrolysis	O
,	O
the	O
enzymatic	O
method	O
presented	O
here	O
is	O
faster	O
and	O
stereospecific	O
and	O
selectively	O
cleaves	O
laminarin	O
in	O
mixtures	O
of	O
glycans	O
,	O
releasing	O
only	O
glucose	O
and	O
oligosaccharides	O
,	O
which	O
can	O
be	O
easily	O
quantified	O
with	O
reducing	O
sugar	O
assays	B-P
.	O

Soymilk	O
residue	O
(	O
okara	O
)	O
as	O
a	O
natural	O
immobilization	O
carrier	O
for	O
Lactobacillus	O
plantarum	O
cells	O
enhances	O
soymilk	O
fermentation	O
,	O
glucosidic	O
isoflavone	O
bioconversion	O
,	O
and	O
cell	O
survival	O
under	O
simulated	O
gastric	O
and	O
intestinal	O
conditions	O
.	O

Cell	O
immobilization	O
is	O
an	O
alternative	O
to	O
microencapsulation	O
for	O
the	O
maintenance	O
of	O
cells	O
in	O
a	O
liquid	O
medium	O
.	O

However	O
,	O
artificial	O
immobilization	O
carriers	O
are	O
expensive	O
and	O
pose	O
a	O
high	O
safety	O
risk	O
.	O

Okara	O
,	O
a	O
food-grade	O
byproduct	O
from	O
soymilk	O
production	O
,	O
is	O
rich	O
in	O
prebiotics	O
.	O

Lactobacilli	O
could	O
provide	O
health	O
enhancing	O
effects	O
to	O
the	O
host	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
potential	O
of	O
okara	O
as	O
a	O
natural	O
immobilizer	O
for	O
L.	O
plantarum	O
70810	O
cells	O
.	O

The	O
study	O
also	O
aimed	O
to	O
evaluate	O
the	O
effects	O
of	O
okara-immobilized	O
L.	O
plantarum	O
70810	O
cells	O
(	O
IL	O
)	O
on	O
soymilk	O
fermentation	O
,	O
glucosidic	O
isoflavone	O
bioconversion	O
,	O
and	O
cell	O
resistance	O
to	O
simulated	O
gastric	O
and	O
intestinal	O
stresses	O
.	O

Scanning	B-P
electron	I-P
microscopy	I-P
(	O
SEM	B-P
)	O
was	O
used	O
to	O
show	O
cells	O
adherence	O
to	O
the	O
surface	O
of	O
okara	O
.	O

Lactic	O
acid	O
,	O
acetic	O
acid	O
and	O
isoflavone	O
analyses	O
in	O
unfermented	O
and	O
fermented	O
soymilk	O
were	O
performed	O
by	O
HPLC	B-P
with	I-P
UV	I-P
detection	I-P
.	O

Viability	O
and	O
growth	O
kinetics	O
of	O
immobilized	O
and	O
free	O
L.	O
plantarum	O
70810	O
cells	O
(	O
FL	O
)	O
were	O
followed	O
during	O
soymilk	O
fermentation	O
.	O

Moreover	O
,	O
changes	O
in	O
pH	O
,	O
titrable	O
acidity	O
and	O
viscosity	O
were	O
measured	O
by	O
conventional	O
methods	O
.	O

For	O
in	O
vitro	O
testing	O
of	O
simulated	O
gastrointestinal	O
resistance	O
,	O
fermented	O
soymilk	O
was	O
inoculated	O
with	O
FL	O
or	O
IL	O
and	O
an	O
aliquot	O
incubated	B-P
into	O
acidic	O
MRS	O
broth	O
which	O
was	O
conveniently	O
prepared	O
to	O
simulate	O
gastric	O
,	O
pancreatic	O
juices	O
and	O
bile	O
salts	O
.	O

Survival	O
to	O
simulated	O
gastric	O
and	O
intestinal	O
stresses	O
was	O
evaluated	O
by	O
plate	B-P
count	I-P
of	I-P
colony	I-P
forming	I-P
units	I-P
on	O
MRS	O
agar	O
.	O

SEM	B-P
revealed	O
that	O
the	O
lactobacilli	O
cells	O
attached	O
and	O
bound	O
to	O
the	O
surface	O
of	O
okara	O
.	O

Compared	O
with	O
FL	O
,	O
IL	O
exhibited	O
a	O
significantly	O
higher	O
specific	O
growth	O
rate	O
,	O
shorter	O
lag	O
phase	O
of	O
growth	O
,	O
higher	O
productions	O
of	O
lactic	O
and	O
acetic	O
acids	O
,	O
a	O
faster	O
decrease	O
in	O
pH	O
and	O
increase	O
in	O
titrable	O
acidity	O
,	O
and	O
a	O
higher	O
soymilk	O
viscosity	O
.	O

Similarly	O
,	O
IL	O
in	O
soymilk	O
showed	O
higher	O
productions	O
of	O
daizein	O
and	O
genistein	O
compared	O
with	O
the	O
control	O
.	O

Compared	O
with	O
FL	O
,	O
IL	O
showed	O
reinforced	O
resistance	O
to	O
simulatedgastric	O
and	O
intestinal	O
stresses	O
in	O
vitro	O
that	O
included	O
low	O
pH	O
,	O
low	O
pH	O
plus	O
pepsin	O
,	O
pancreatin	O
,	O
and	O
bile	O
salt	O
.	O

Our	O
results	O
indicate	O
that	O
okara	O
is	O
a	O
new	O
potential	O
immobilization	O
carrier	O
to	O
enhance	O
the	O
growth	O
and	O
glucosidic	O
isoflavone	O
bioconversion	O
activities	O
of	O
L.	O
plantarum	O
in	O
soymilk	O
and	O
improve	O
cell	O
survivability	O
following	O
simulated	O
gastric	O
and	O
intestinal	O
conditions	O
.	O

The	O
CLASP2	O
Protein	O
Interaction	O
Network	O
in	O
Adipocytes	O
Links	O
CLIP2	O
to	O
AGAP3	O
,	O
CLASP2	O
to	O
G2L1	O
,	O
MARK2	O
,	O
and	O
SOGA1	O
,	O
and	O
Identifies	O
SOGA1	O
as	O
a	O
Microtubule-Associated	O
Protein	O
.	O

CLASP2	O
is	O
a	O
microtubule-associated	O
protein	O
that	O
undergoes	O
insulin	O
-	O
stimulated	O
phosphorylation	O
and	O
co-localization	O
with	O
reorganized	O
actin	O
and	O
GLUT4	O
at	O
the	O
plasma	O
membrane	O
.	O

To	O
gain	O
insight	O
to	O
the	O
role	O
of	O
CLASP2	O
in	O
this	O
system	O
,	O
we	O
developed	O
and	O
successfully	O
executed	O
a	O
streamlined	O
interactome	O
approach	O
and	O
built	O
a	O
CLASP2	O
protein	O
network	O
in	O
3T3-L1	O
adipocytes	O
.	O

Using	O
two	O
different	O
commercially	O
available	O
antibodies	O
for	O
CLASP2	O
and	O
an	O
antibody	O
for	O
epitope	O
-tagged	O
,	O
overexpressed	O
CLASP2	O
,	O
we	O
performed	O
multiple	O
affinity	B-P
purification	I-P
coupled	O
with	O
mass	B-P
spectrometry	I-P
(	O
AP	B-P
-	O
MS	B-P
)	O
experiments	O
in	O
combination	O
with	O
label-free	O
quantitative	O
proteomics	O
and	O
analyzed	O
the	O
data	O
with	O
the	O
bioinformatics	O
tool	O
Significance	O
Analysis	O
of	O
Interactome	O
(	O
SAINT	O
)	O
.	O

We	O
discovered	O
that	O
CLASP2	O
co-immunoprecipitates	O
(	O
co-IPs	O
)	O
the	O
novel	O
protein	O
SOGA1	O
,	O
the	O
microtubule-associated	O
protein	O
kinase	O
MARK2	O
,	O
and	O
the	O
microtubule	O
/	O
actin	O
-	O
regulating	O
protein	O
G2L1	O
.	O

The	O
GTPase-activating	O
proteins	O
AGAP1	O
and	O
AGAP3	O
were	O
also	O
enriched	O
in	O
the	O
CLASP2	O
interactome	O
,	O
although	O
subsequent	O
AGAP3	O
and	O
CLIP2	O
interactome	O
analysis	O
suggests	O
a	O
preference	O
of	O
AGAP3	O
for	O
CLIP2	O
.	O

Follow-up	O
MARK2	O
interactome	O
analysis	O
confirmed	O
reciprocal	O
co-IP	O
of	O
CLASP2	O
and	O
also	O
revealed	O
MARK2	O
can	O
co-IP	O
SOGA1	O
,	O
glycogen	O
synthase	O
,	O
and	O
glycogenin	O
.	O

Investigating	O
the	O
SOGA1	O
interactome	O
confirmed	O
SOGA1	O
can	O
reciprocal	O
co-IP	O
both	O
CLASP2	O
and	O
MARK2	O
as	O
well	O
as	O
glycogen	O
synthase	O
and	O
glycogenin	O
.	O

SOGA1	O
was	O
confirmed	O
to	O
colocalize	O
with	O
CLASP2	O
and	O
also	O
with	O
tubulin	O
,	O
which	O
identifies	O
SOGA1	O
as	O
a	O
new	O
microtubule-associated	O
protein	O
.	O

These	O
results	O
introduce	O
the	O
metabolic	O
function	O
of	O
these	O
proposed	O
novel	O
protein	O
networks	O
and	O
their	O
relationship	O
with	O
microtubules	O
as	O
new	O
fields	O
of	O
cytoskeleton	O
-	O
associated	O
protein	O
biology	O
.	O

Data	O
-Driven	O
Implementation	O
of	O
Alarm	O
Reduction	O
Interventions	O
in	O
a	O
Cardiovascular	O
Surgical	O
ICU	O
.	O

Alarm	O
fatigue	O
in	O
the	O
ICU	O
setting	O
has	O
been	O
well	O
documented	O
in	O
the	O
literature	O
.	O

The	O
ICU	O
's	O
high-intensity	O
environment	O
requires	O
staff	O
's	O
vigilant	O
attention	O
,	O
and	O
distraction	O
from	O
false	O
and	O
non-actionable	O
alarms	O
pulls	O
staff	O
away	O
from	O
important	O
tasks	O
,	O
creates	O
dissatisfaction	O
,	O
and	O
is	O
a	O
potential	O
patient	O
safety	O
risk	O
if	O
alarms	O
are	O
missed	O
or	O
ignored	O
.	O

This	O
project	O
was	O
intended	O
to	O
improve	O
patient	O
safety	O
by	O
optimizing	O
alarm	O
systems	O
in	O
a	O
cardiovascular	O
surgical	O
intensive	O
care	O
unit	O
(	O
CVSICU	O
)	O
.	O

Specific	O
aims	O
were	O
to	O
examine	O
nurses	O
'	O
attitudes	O
toward	O
clinical	O
alarm	O
signals	O
,	O
assess	O
nurses	O
'	O
ability	O
to	O
discriminate	O
audible	O
alarm	O
signals	O
,	O
and	O
implement	O
a	O
bundled	O
set	O
of	O
best	O
practices	O
for	O
monitor	O
alarm	O
reduction	O
without	O
undermining	O
patient	O
safety	O
.	O

CVSICU	O
nurses	O
completed	O
an	O
alarm	O
perception	O
survey	O
and	O
participated	O
in	O
alarm	O
discriminability	O
testing	O
.	O

Nurse	O
survey	O
data	O
and	O
baseline	O
monitor	O
alarm	O
data	O
were	O
used	O
to	O
select	O
targeted	O
alarm	O
reduction	O
interventions	O
,	O
which	O
were	O
progressively	O
phased	O
in	O
.	O

Monitor	O
alarm	O
data	O
and	O
cardiorespiratory	O
event	O
data	O
were	O
trended	O
over	O
one	O
year	O
.	O

Five	O
of	O
the	O
most	O
frequent	O
CVSICU	O
monitor	O
alarm	O
types-	O
pulse	B-P
oximetry	I-P
,	O
heart	O
rate	O
,	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
,	O
pulse	B-P
oximetry	I-P
sensor	O
,	O
and	O
ventricular	O
tachycardia	O
>	O
2-were	O
targeted	O
.	O

After	O
implementation	O
,	O
there	O
was	O
a	O
61	O
%	O
reduction	O
in	O
average	O
alarms	O
per	O
monitored	O
bed	O
and	O
a	O
downward	O
trend	O
in	O
cardiorespiratory	O
events	O
.	O

To	O
reduce	O
alarm	O
fatigue	O
it	O
is	O
important	O
to	O
decrease	O
alarm	O
burden	O
through	O
targeted	O
interventions	O
.	O

Methods	O
to	O
reduce	O
non-actionable	O
alarms	O
include	O
adding	O
short	O
delays	O
to	O
allow	O
alarm	O
self-correction	O
,	O
adjusting	O
default	O
alarm	O
threshold	O
limits	O
,	O
providing	O
alarm	O
notification	O
through	O
a	O
secondary	O
device	O
,	O
and	O
teaching	O
staff	O
to	O
optimize	O
alarm	O
settings	O
for	O
individual	O
patients	O
.	O

Cardiovascular	O
Toxicity	O
of	O
Illicit	O
Anabolic-Androgenic	O
Steroid	O
Use	O
.	O

Millions	O
of	O
individuals	O
have	O
used	O
illicit	O
anabolic-androgenic	O
steroids	O
(	O
AAS	O
)	O
,	O
but	O
the	O
long-term	O
cardiovascular	O
associations	O
of	O
these	O
drugs	O
remain	O
incompletely	O
understood	O
.	O

Using	O
a	O
cross-sectional	O
cohort	O
design	O
,	O
we	O
recruited	O
140	O
experienced	O
male	O
weightlifters	O
34	O
to	O
54	O
years	O
of	O
age	O
,	O
comprising	O
86	O
men	O
reporting	O
≥2	O
years	O
of	O
cumulative	O
lifetime	O
AAS	O
use	O
and	O
54	O
nonusing	O
men	O
.	O

Using	O
transthoracic	B-P
echocardiography	I-P
and	O
coronary	B-P
computed	I-P
tomography	I-P
angiography	I-P
,	O
we	O
assessed	O
3	O
primary	O
outcome	O
measures	O
:	O
left	O
ventricular	O
(	O
LV	O
)	O
systolic	O
function	O
(	O
left	O
ventricular	O
ejection	O
fraction	O
)	O
,	O
LV	O
diastolic	O
function	O
(	O
early	O
relaxation	O
velocity	O
)	O
,	O
and	O
coronary	O
atherosclerosis	O
(	O
coronary	O
artery	O
plaque	O
volume	O
)	O
.	O

Compared	O
with	O
nonusers	O
,	O
AAS	O
users	O
demonstrated	O
relatively	O
reduced	O
LV	O
systolic	O
function	O
(	O
mean	O
±	O
SD	O
left	O
ventricular	O
ejection	O
fraction	O
=	O
52±11	O
%	O
versus	O
63±8	O
%	O
;	O
P	O
<	O
0.001	O
)	O
and	O
diastolic	O
function	O
(	O
early	O
relaxation	O
velocity	O
=	O
9.3±2.4	O
cm/second	O
versus	O
11.1±2.0	O
cm/second	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Users	O
currently	O
taking	O
AAS	O
at	O
the	O
time	O
of	O
evaluation	O
(	O
N=58	O
)	O
showed	O
significantly	O
reduced	O
LV	O
systolic	O
(	O
left	O
ventricular	O
ejection	O
fraction	O
=	O
49±10	O
%	O
versus	O
58±10	O
%	O
;	O
P	O
<	O
0.001	O
)	O
and	O
diastolic	O
function	O
(	O
early	O
relaxation	O
velocity	O
=	O
8.9±2.4	O
cm/second	O
versus	O
10.1±2.4	O
cm/second	O
;	O
P=0.035	O
)	O
compared	O
with	O
users	O
currently	O
off	O
-	O
drug	O
(	O
N=28	O
)	O
.	O

In	O
addition	O
,	O
AAS	O
users	O
demonstrated	O
higher	O
coronary	O
artery	O
plaque	O
volume	O
than	O
nonusers	O
(	O
median	O
[	O
interquartile	O
range	O
]	O
3	O
[	O
0	O
,	O
174	O
]	O
mL	O
(	O
3	O
)	O
versus	O
0	O
[	O
0	O
,	O
69	O
]	O
mL	O
(	O
3	O
)	O
;	O
P=0.012	O
)	O
.	O

Lifetime	O
AAS	O
dose	O
was	O
strongly	O
associated	O
with	O
coronary	O
atherosclerotic	O
burden	O
(	O
increase	O
[	O
95	O
%	O
confidence	O
interval	O
]	O
in	O
rank	O
of	O
plaque	O
volume	O
for	O
each	O
10-	O
year	O
increase	O
in	O
cumulative	O
duration	O
of	O
AAS	O
use	O
:	O
0.60	O
SD	O
units	O
[	O
0.16-1.03	O
SD	O
units	O
]	O
;	O
P=0.008	O
)	O
.	O

Long-term	O
AAS	O
use	O
appears	O
to	O
be	O
associated	O
with	O
myocardial	O
dysfunction	O
and	O
accelerated	O
coronary	O
atherosclerosis	O
.	O

These	O
forms	O
of	O
AAS	O
-	O
associated	O
adverse	O
cardiovascular	O
phenotypes	O
may	O
represent	O
a	O
previously	O
underrecognized	O
public-health	O
problem	O
.	O

Semimembranosus	O
tenosynovitis	O
:	O
Diagnosis	O
and	O
management	O
of	O
a	O
commonly	O
missed	O
cause	O
of	O
posteromedial	O
knee	O
pain	O
.	O

In	O
orthopedic	O
and	O
sports	O
medicine	O
literature	O
there	O
is	O
minimal	O
information	O
regarding	O
accurate	O
diagnosis	O
and	O
the	O
treatment	O
options	O
for	O
tenosynovitis	O
of	O
the	O
distal	O
semimembranosus	O
tendon	O
.	O

After	O
reviewing	O
the	O
literature	O
,	O
the	O
authors	O
question	O
both	O
the	O
etiology	O
and	O
treatment	O
of	O
this	O
condition	O
.	O

Previous	O
descriptions	O
have	O
associated	O
the	O
condition	O
primarily	O
with	O
the	O
endurance	O
athlete	O
but	O
we	O
have	O
noted	O
multiple	O
cases	O
in	O
which	O
this	O
is	O
a	O
condition	O
common	O
to	O
the	O
'sprinter	O
'	O
as	O
well	O
.	O

There	O
has	O
been	O
very	O
little	O
mention	O
of	O
this	O
condition	O
in	O
recent	O
literature	O
but	O
the	O
most	O
recent	O
complete	O
description	O
of	O
operative	O
treatment	O
for	O
this	O
condition	O
recommends	O
both	O
tendon	O
transfer	O
and	O
concomitant	O
arthroscopy	B-P
.	O

We	O
propose	O
this	O
condition	O
is	O
akin	O
to	O
De	O
Quervain	O
's	O
tenosynovitis	O
of	O
the	O
knee	O
,	O
with	O
sensitive	O
and	O
specific	O
signs	O
on	O
physical	O
examination	O
.	O

We	O
describe	O
a	O
case	O
series	O
of	O
six	O
cases	O
(	O
five	O
patients	O
)	O
,	O
that	O
underwent	O
open	O
surgical	O
release	O
for	O
semimembranosus	O
tenosynovitis	O
.	O

The	O
anatomy	O
and	O
the	O
treatment	O
options	O
for	O
the	O
condition	O
are	O
also	O
discussed	O
.	O

At	O
a	O
follow-up	O
period	O
of	O
18-64months	O
,	O
all	O
cases	O
showed	O
improvement	O
in	O
the	O
Tegner	O
activity	O
score	O
following	O
surgical	O
release	O
.	O

Diagnostic	O
confusion	O
can	O
be	O
decreased	O
with	O
more	O
modern	O
diagnostic	O
imaging	O
modalities	O
than	O
those	O
described	O
in	O
the	O
literature	O
.	O

The	O
authors	O
outline	O
an	O
alternative	O
operative	O
approach	O
significantly	O
decreasing	O
surgical	O
complexity	O
and	O
therefore	O
post-operative	O
morbidity	O
.	O

What	O
is	O
known	O
about	O
this	O
subject	O
:	O
This	O
is	O
a	O
rare	O
condition	O
and	O
the	O
surgical	O
treatment	O
is	O
seldom	O
performed	O
.	O

What	O
this	O
study	O
adds	O
to	O
existing	O
knowledge	O
:	O
We	O
describe	O
the	O
technique	O
for	O
surgical	O
decompression	O
and	O
reveal	O
positive	O
results	O
at	O
medium	O
term	O
follow-up	O
.	O

Functional	O
Neuroimaging	O
Pilot	O
Study	O
of	O
Borderline	O
Personality	O
Disorder	O
in	O
Adolescents	O
.	O

Borderline	O
personality	O
disorder	O
(	O
BPD	O
)	O
is	O
being	O
increasingly	O
recognized	O
by	O
clinicians	O
working	O
with	O
adolescents	O
,	O
and	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
diagnosis	O
have	O
been	O
established	O
in	O
the	O
adolescent	O
population	O
.	O

Adolescence	O
is	O
known	O
to	O
be	O
a	O
period	O
of	O
high	O
risk	O
for	O
BPD	O
development	O
as	O
most	O
patients	O
identify	O
the	O
onset	O
of	O
their	O
symptoms	O
to	O
be	O
in	O
the	O
adolescent	O
period	O
.	O

As	O
with	O
other	O
mental	O
health	O
disorders	O
,	O
personality	O
disorder	O
,	O
are	O
thought	O
to	O
result	O
from	O
the	O
interaction	O
between	O
biological	O
and	O
environmental	O
factors	O
.	O

Functional	O
neuroimaging	O
studies	O
are	O
reporting	O
an	O
increasing	O
amount	O
of	O
data	O
on	O
abnormal	O
neuronal	O
functions	O
in	O
BPD	O
adult	O
patients	O
.	O

However	O
,	O
no	O
functional	O
neuroimaging	O
studies	O
have	O
been	O
conducted	O
in	O
adolescents	O
with	O
BPD	O
.Objectives	O
This	O
pilot	O
project	O
aims	O
to	O
evaluate	O
the	O
feasibility	O
of	O
a	O
functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
fMRI	B-P
)	O
study	O
coupled	O
with	O
clinical	O
and	O
psychological	O
measures	O
in	O
adolescent	O
girls	O
with	O
a	O
diagnosis	O
of	O
BPD	O
.	O

It	O
also	O
aims	O
to	O
identify	O
neuronal	O
regions	O
of	O
interest	O
(	O
ROI	O
)	O
for	O
the	O
study	O
of	O
BPD	O
in	O
adolescent	O
girls	O
.Method	O
Six	O
female	O
adolescents	O
meeting	O
DSM-IV	O
criteria	O
for	O
BPD	O
and	O
6	O
female	O
adolescents	O
without	O
psychiatric	O
disorder	O
were	O
recruited	O
.	O

Both	O
groups	O
were	O
evaluated	O
for	O
BPD	O
symptoms	O
,	O
depressive	O
symptoms	O
,	O
impulsivity	O
,	O
affective	O
lability	O
,	O
and	O
other	O
potential	O
psychiatric	O
comorbidities	O
.	O

We	O
used	O
fMRI	B-P
to	O
compare	O
patterns	O
of	O
regional	O
brain	O
activation	O
between	O
these	O
two	O
groups	O
as	O
they	O
viewed	O
20	O
positive	O
,	O
20	O
negative	O
and	O
20	O
neutral	O
emotion-inducing	O
pictures	O
,	O
which	O
were	O
presented	O
in	O
random	O
order	O
.Results	O
Participants	O
were	O
recruited	O
over	O
a	O
period	O
of	O
22	O
months	O
.	O

The	O
protocol	O
was	O
well	O
tolerated	O
by	O
participants	O
.	O

Mean	O
age	O
of	O
the	O
BPD	O
group	O
and	O
control	O
group	O
was	O
15.8	O
±	O
0.9	O
years-old	O
and	O
15.5	O
±	O
1.2	O
years-old	O
respectively	O
.	O

Psychiatric	O
comorbidity	O
and	O
use	O
of	O
medication	O
was	O
common	O
among	O
participants	O
in	O
the	O
BPD	O
group	O
.	O

This	O
group	O
showed	O
higher	O
impulsivity	O
and	O
affective	O
lability	O
scores	O
.	O

For	O
the	O
fMRI	B-P
task	O
,	O
BPD	O
patients	O
demonstrated	O
greater	O
differences	O
in	O
activation	O
than	O
controls	O
,	O
when	O
viewing	O
negative	O
pictures	O
compared	O
with	O
neutral	O
pictures	O
,	O
in	O
limbic	O
regions	O
(	O
amygdala	O
and	O
right	O
hippocampus	O
and	O
parahippocampal	O
areas	O
)	O
as	O
well	O
as	O
in	O
the	O
superior	O
frontal	O
gyrus	O
,	O
right	O
precentral	O
gyrus	O
and	O
cerebellum	O
,	O
while	O
control	O
group	O
showed	O
greater	O
activation	O
in	O
left	O
precentral	O
gyrus	O
and	O
right	O
orbitofrontal	O
area	O
.	O

Viewing	O
positive	O
pictures	O
compared	O
with	O
neutral	O
pictures	O
led	O
to	O
increased	O
activation	O
of	O
the	O
left	O
hippocampus	O
and	O
both	O
parahippocampal	O
regions	O
,	O
as	O
well	O
as	O
middle	O
cingulate	O
cortex	O
,	O
superior	O
temporal	O
gyrus	O
and	O
cerebellum	O
in	O
the	O
BPD	O
group	O
.	O

In	O
the	O
control	O
group	O
,	O
positive-scene	O
viewing	O
led	O
to	O
increased	O
activity	O
in	O
the	O
left	O
superior	O
parietal	O
gyrus	O
and	O
right	O
middle	O
/	O
superior	O
temporal	O
gyrus	O
.Conclusion	O
Limbic	O
regions	O
and	O
areas	O
from	O
the	O
prefrontal	O
and	O
orbitofrontal	O
cortex	O
are	O
potential	O
ROI	O
for	O
the	O
study	O
of	O
the	O
neurophysiology	O
of	O
BPD	O
in	O
female	O
adolescents	O
.	O

The	O
larger	O
studies	O
are	O
needed	O
to	O
better	O
understand	O
the	O
neural	O
features	O
found	O
in	O
these	O
young	O
patients	O
.	O

Increasing	O
skeletal	O
muscle	O
carnitine	O
availability	O
does	O
not	O
alter	O
the	O
adaptations	O
to	O
high-intensity	O
interval	O
training	O
.	O

Increasing	O
skeletal	O
muscle	O
carnitine	O
availability	O
alters	O
muscle	O
metabolism	O
during	O
steady-state	O
exercise	O
in	O
healthy	O
humans	O
.	O

We	O
investigated	O
whether	O
elevating	O
muscle	O
carnitine	O
,	O
and	O
thereby	O
the	O
acetyl-group	O
buffering	O
capacity	O
,	O
altered	O
the	O
metabolic	O
and	O
physiological	O
adaptations	O
to	O
24	O
weeks	O
of	O
high-intensity	O
interval	O
training	O
(	O
HIIT	O
)	O
at	O
100	O
%	O
maximal	O
exercise	O
capacity	O
(	O
Wattmax	O
)	O
.	O

Twenty-one	O
healthy	O
male	O
volunteers	O
(	O
age	O
23±2	O
years	O
;	O
BMI	O
24.2±1.1	O
kg/m	O
(	O
2	O
)	O
)	O
performed	O
2x3	O
minute	O
bouts	O
of	O
cycling	O
exercise	O
at	O
100	O
%	O
Wattmax	O
,	O
separated	O
by	O
five	O
minutes	O
rest	O
.	O

Fourteen	O
volunteers	O
repeated	O
this	O
protocol	O
following	O
24	O
weeks	O
of	O
HIIT	O
and	O
twice-daily	O
consumption	O
of	O
80g	O
carbohydrate	O
(	O
CON	O
)	O
or	O
3g	O
L-carnitine	O
+	O
carbohydrate	O
(	O
CARN	O
)	O
.	O

Before	O
HIIT	O
,	O
muscle	O
phosphocreatine	O
(	O
PCr	O
)	O
degradation	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
glycogenolysis	O
(	O
P	O
<	O
0.0005	O
)	O
,	O
PDC	O
activation	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
acetylcarnitine	O
(	O
P	O
<	O
0.005	O
)	O
were	O
2.3	O
,	O
2.1	O
,	O
1.5	O
and	O
1.5-fold	O
greater	O
,	O
respectively	O
,	O
in	O
exercise	O
bout	O
two	O
compared	O
to	O
bout	O
one	O
,	O
whilst	O
lactate	O
accumulation	O
tended	O
(	O
P	O
<	O
0.07	O
)	O
to	O
be	O
1.5-fold	O
greater	O
.	O

Following	O
HIIT	O
,	O
muscle	O
free	O
carnitine	O
was	O
30	O
%	O
greater	O
in	O
CARN	O
vs	O
CON	O
at	O
rest	O
and	O
remained	O
40	O
%	O
elevated	O
prior	O
to	O
the	O
start	O
of	O
bout	O
two	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Following	O
bout	O
two	O
,	O
free	B-P
carnitine	I-P
content	I-P
,	O
PCr	O
degradation	O
,	O
glycogenolysis	O
,	O
lactate	O
accumulation	O
,	O
and	O
PDC	O
activation	O
were	O
all	O
similar	O
between	O
CON	O
and	O
CARN	O
,	O
albeit	O
markedly	O
lower	O
than	O
before	O
HIIT	O
.	O

VO2max	O
,	O
Wattmax	O
and	O
work-output	O
were	O
similarly	O
increased	O
in	O
CON	O
and	O
CARN	O
,	O
by	O
9	O
,	O
15	O
and	O
23	O
%	O
(	O
P	O
<	O
0.001	O
)	O
.	O

In	O
summary	O
,	O
increased	O
reliance	O
on	O
non-mitochondrial	O
ATP	O
resynthesis	O
during	O
a	O
second	O
bout	O
of	O
intense	O
exercise	O
is	O
accompanied	O
by	O
increased	O
carnitine	O
acetylation	O
.	O

Augmenting	O
muscle	O
carnitine	O
during	O
24	O
weeks	O
of	O
HIIT	O
did	O
not	O
alter	O
this	O
,	O
nor	O
enhance	O
muscle	O
metabolic	O
adaptations	O
or	O
performance	O
gains	O
beyond	O
those	O
with	O
HIIT	O
alone	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Association	O
of	O
RBP4	O
levels	O
with	O
increased	O
arterial	O
stiffness	O
in	O
adolescents	O
with	O
family	O
history	O
of	O
type	O
2	O
diabetes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
impact	O
of	O
family	O
history	O
of	O
type	O
2	O
diabetes	O
(	O
FH2D	O
)	O
on	O
arterial	O
stiffness	O
in	O
young	O
people	O
and	O
its	O
relationship	O
to	O
adipocytokines	O
.	O

This	O
case-control	O
study	O
included	O
52	O
adolescents	O
(	O
male	O
/	O
female	O
28/24	O
)	O
with	O
FH2D	O
(	O
FH2D+	O
)	O
and	O
40	O
adolescents	O
(	O
male	O
/	O
female	O
21/19	O
)	O
without	O
FH2D	O
(	O
FH2D-	O
)	O
.	O

Anthropometric	O
measurements	O
,	O
including	O
height	O
,	O
weight	O
,	O
waist	O
circumference	O
(	O
WC	O
)	O
,	O
and	O
blood	O
pressure	O
,	O
were	O
obtained	O
.	O

Blood	O
samples	O
were	O
collected	O
,	O
fasting	B-P
plasma	I-P
glucose	I-P
(	O
FPG	B-P
)	O
,	O
serum	B-P
lipids	I-P
,	O
Retinol	O
Binding	O
Protein	O
4	O
(	O
RBP4	O
)	O
,	O
C	B-P
reactive	I-P
protein	I-P
(	O
CRP	B-P
)	O
,	O
adiponectin	B-P
and	O
visfatin	O
were	O
examined	O
.	O

Brachial-ankle	O
pulse	O
wave	O
velocity	O
(	O
baPWV	O
)	O
was	O
used	O
to	O
evaluate	O
arterial	O
stiffness	O
.	O

Visceral	O
fat	O
area	O
(	O
VFA	O
)	O
was	O
measured	O
by	O
computerized	B-P
tomography	I-P
.	O

Compared	O
with	O
FH2D-	O
group	O
,	O
FH2D+	O
group	O
had	O
a	O
significantly	O
higher	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
(	I-P
OGTT	I-P
)	I-P
2-hour	I-P
insulin	I-P
,	O
RBP4	O
and	O
baPWV	O
levels	O
,	O
a	O
lower	O
adiponectin	B-P
and	O
glucose	O
infusing	O
rate	O
(	O
GIR	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

BaPWV	O
was	O
positively	O
correlated	O
with	O
age	O
,	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
,	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
,	O
2-hour	B-P
(	I-P
OGTT	I-P
)	I-P
insulin	I-P
,	O
RBP4	O
,	O
and	O
VFA	O
,	O
and	O
negatively	O
correlated	O
with	O
GIR	O
in	O
FH2D+	O
group	O
.	O

After	O
multivariate	O
analysis	O
,	O
age	O
,	O
SBP	O
,	O
RBP4	O
and	O
VFA	O
maintained	O
an	O
independent	O
association	O
with	O
baPWV	O
in	O
FH2D+	O
group	O
(	O
P	O
<	O
0.05	O
)	O
,	O
while	O
only	O
age	O
,	O
SBP	O
,	O
and	O
VFA	O
were	O
independent	O
predictors	O
of	O
baPWV	O
in	O
FH2D-	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

These	O
findings	O
led	O
to	O
the	O
conclusion	O
that	O
RBP4	O
level	O
was	O
associated	O
with	O
increased	O
arterial	O
stiffness	O
in	O
young	O
subjects	O
with	O
family	O
history	O
of	O
type	O
2	O
diabetes	O
.	O

Meta-Analysis	O
of	O
29	O
Experiments	O
Evaluating	O
the	O
Effects	O
of	O
Rapamycin	O
on	O
Life	O
Span	O
in	O
the	O
Laboratory	O
Mouse	O
.	O

Rapamycin	O
has	O
favorable	O
effects	O
on	O
aging	O
in	O
mice	O
and	O
may	O
eventually	O
be	O
applied	O
to	O
encourage	O
``	O
healthy	O
aging	O
``	O
in	O
humans	O
.	O

This	O
study	O
analyzed	O
raw	O
data	O
from	O
29	O
survival	O
studies	O
of	O
rapamycin	O
-	O
and	O
control	O
-	O
treated	O
mice	O
,	O
with	O
the	O
goals	O
of	O
estimating	O
summary	O
statistics	O
and	O
identifying	O
factors	O
associated	O
with	O
effect	O
size	O
heterogeneity	O
.	O

Meta-analysis	O
demonstrated	O
significant	O
heterogeneity	O
across	O
studies	B-P
,	O
with	O
hazard	O
ratio	O
(	O
HR	O
)	O
estimates	O
ranging	O
from	O
0.22	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
0.06-0.82	O
)	O
to	O
0.92	O
(	O
95	O
%	O
CI	O
:	O
0.65-1.28	O
)	O
.	O

Sex	O
was	O
the	O
major	O
factor	O
accounting	O
for	O
effect	O
size	O
variation	O
,	O
and	O
mortality	O
was	O
decreased	O
more	O
in	O
females	O
(	O
HR	O
=	O
0.41	O
;	O
95	O
%	O
CI	O
:	O
0.35-0.48	O
)	O
as	O
compared	O
with	O
males	O
(	O
HR	O
=	O
0.63	O
;	O
95	O
%	O
CI	O
:	O
0.55-0.71	O
)	O
.	O

Rapamycin	O
effects	O
were	O
also	O
genotype	O
dependent	O
,	O
however	O
,	O
with	O
stronger	O
survivorship	O
increases	O
in	O
hybrid	O
mice	O
(	O
14.4	O
%	O
;	O
95	O
%	O
CI	O
:	O
12.5-16.3	O
%	O
)	O
relative	O
to	O
pure	O
inbred	O
strains	O
(	O
8.8	O
%	O
;	O
95	O
%	O
CI	O
:	O
6.2-11.6	O
%	O
)	O
.	O

Number	O
needed	O
to	O
treat	O
was	O
applied	O
as	O
an	O
effect	O
size	O
metric	O
,	O
which	O
consistently	O
identified	O
early	O
senescence	O
as	O
the	O
age	O
of	O
peak	O
treatment	O
benefit	O
.	O

These	O
results	O
provide	O
synthesis	O
of	O
existing	O
data	O
to	O
support	O
the	O
potential	O
translation	O
of	O
findings	O
from	O
mouse	O
to	O
primate	O
species	O
.	O

Because	O
rapamycin	O
's	O
effect	O
on	O
survival	O
depends	O
on	O
sex	O
and	O
genotype	O
,	O
further	O
work	O
is	O
justified	O
to	O
understand	O
how	O
these	O
factors	O
shape	O
treatment	O
response	O
.	O

Homocysteine	O
as	O
a	O
peripheral	O
biomarker	O
in	O
bipolar	O
disorder	O
:	O
A	O
meta-analysis	O
.	O

Bipolar	O
disorder	O
(	O
BD	O
)	O
is	O
a	O
psychiatric	O
disorder	O
with	O
an	O
uncertain	O
aetiology	O
.	O

Recently	O
,	O
special	O
attention	O
has	O
been	O
given	O
to	O
homocysteine	O
(	O
Hcy	O
)	O
,	O
as	O
it	O
has	O
been	O
suggested	O
that	O
alterations	O
in	O
1-carbon	O
metabolism	O
might	O
be	O
implicated	O
in	O
diverse	O
psychiatric	O
disorders	O
.	O

However	O
,	O
there	O
is	O
uncertainty	O
regarding	O
possible	O
alterations	O
in	O
peripheral	O
Hcy	O
levels	O
in	O
BD	O
.	O

This	O
study	O
comprises	O
a	O
meta-analysis	O
comparing	O
serum	B-P
and	O
plasma	B-P
Hcy	I-P
levels	I-P
in	O
persons	O
with	O
BD	O
and	O
healthy	O
controls	O
.	O

We	O
conducted	O
a	O
systematic	O
search	O
for	O
all	O
eligible	O
English	O
and	O
non-English	O
peer-reviewed	O
articles	O
.	O

Nine	O
cross-sectional	O
studies	O
were	O
included	O
in	O
the	O
meta-analyses	O
,	O
providing	O
data	O
on	O
1547	O
participants	O
.	O

Random-effects	O
meta-analysis	O
showed	O
that	O
serum	B-P
and	O
plasma	B-P
levels	I-P
of	I-P
Hcy	I-P
were	O
increased	O
in	O
subjects	O
with	O
BD	O
in	O
either	O
mania	O
or	O
euthymia	O
when	O
compared	O
to	O
healthy	O
controls	O
,	O
with	O
a	O
large	O
effect	O
size	O
in	O
the	O
mania	O
group	O
(	O
g=0.98	O
,	O
95	O
%	O
CI	O
:	O
0.8-1.17	O
,	O
P	O
<	O
0.001	O
,	O
n=495	O
)	O
and	O
a	O
small	O
effect	O
in	O
the	O
euthymia	O
group	O
(	O
g=0.3	O
,	O
95	O
%	O
CI	O
:	O
0.11-0.48	O
,	O
P=0.002	O
,	O
n=1052	O
)	O
.	O

Our	O
meta-analysis	O
provides	O
evidence	O
that	O
Hcy	O
levels	O
are	O
elevated	O
in	O
persons	O
with	O
BD	O
during	O
mania	O
and	O
euthymia	O
.	O

Peripheral	O
Hcy	O
could	O
be	O
considered	O
as	O
a	O
potential	O
biomarker	O
in	O
BD	O
,	O
both	O
of	O
trait	O
(	O
since	O
it	O
is	O
increased	O
in	O
euthymia	O
)	O
,	O
and	O
also	O
of	O
state	O
(	O
since	O
its	O
increase	O
is	O
more	O
accentuated	O
in	O
mania	O
)	O
.	O

Longitudinal	O
studies	O
are	O
needed	O
to	O
clarify	O
the	O
relationship	O
between	O
bipolar	O
disorder	O
and	O
Hcy	O
,	O
as	O
well	O
as	O
the	O
usefulness	O
of	O
peripheral	O
Hcy	O
as	O
both	O
a	O
trait	O
and	O
state	O
biomarker	O
in	O
BD	O
.	O

Atopy	B-P
patch	I-P
test	I-P
in	O
children	O
with	O
atopic	O
dermatitis	O
.	O

Atopic	O
dermatitis	O
is	O
frequently	O
associated	O
with	O
food	O
and/or	O
aeroallergen	O
allergy	O
.	O

To	O
evaluate	O
atopy	B-P
patch	I-P
tests	I-P
(	O
APTs	B-P
)	O
and	O
skin	B-P
prick	I-P
tests	I-P
(	O
SPTs	B-P
)	O
in	O
children	O
with	O
atopic	O
dermatitis	O
,	O
using	O
allergen	O
extracts	O
from	O
locally	O
lyophilized	B-P
foods	O
(	O
cow	O
's	O
milk	O
,	O
egg	O
white	O
,	O
egg	O
yolk	O
,	O
wheat	O
,	O
soy	O
,	O
and	O
shrimp	O
)	O
,	O
Dermatophagoides	O
pteronyssinus	O
,	O
Dermatophagoides	O
farinae	O
,	O
and	O
American	O
cockroach	O
.	O

This	O
study	O
was	O
a	O
prospective	O
,	O
self-controlled	O
study	O
in	O
children	O
with	O
atopic	O
dermatitis	O
.	O

APTs	B-P
,	O
SPTs	B-P
,	O
and	O
oral	B-P
food	I-P
challenge	I-P
tests	I-P
were	O
performed	O
in	O
the	O
cases	O
with	O
written	O
informed	O
consent	O
.	O

Fifty-six	O
children	O
with	O
atopic	O
dermatitis	O
were	O
enrolled	O
.	O

According	O
to	O
the	O
Severity	O
Scoring	O
of	O
Atopic	O
Dermatitis	O
Index	O
,	O
moderate	O
atopic	O
dermatitis	O
was	O
the	O
most	O
common	O
severity	O
(	O
49.1	O
%	O
)	O
followed	O
by	O
mild	O
(	O
20	O
%	O
)	O
and	O
severe	O
atopic	O
dermatitis	O
(	O
13.2	O
%	O
)	O
.	O

APT	B-P
results	O
were	O
positive	O
for	O
food	O
allergens	O
in	O
49	O
%	O
of	O
participants	O
;	O
SPT	B-P
results	O
were	O
positive	O
in	O
54.7	O
%	O
.	O

The	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
predictive	O
value	O
,	O
and	O
negative	O
predictive	O
value	O
of	O
APTs	B-P
for	O
foods	O
were	O
40	O
%	O
,	O
90.2	O
%	O
,	O
65.2	O
%	O
,	O
and	O
76.6	O
%	O
,	O
respectively	O
.	O

For	O
SPTs	B-P
,	O
those	O
values	O
were	O
40	O
%	O
,	O
93.9	O
%	O
,	O
75	O
%	O
,	O
and	O
77.3	O
%	O
,	O
respectively	O
.	O

APT	B-P
results	O
for	O
D	O
farinae	O
,	O
D	O
pteronyssinus	O
,	O
and	O
American	O
cockroach	O
were	O
positive	O
in	O
33.9	O
%	O
,	O
35.8	O
%	O
,	O
and	O
21.8	O
%	O
of	O
participants	O
,	O
respectively	O
.	O

SPT	B-P
results	O
for	O
these	O
allergens	O
were	O
positive	O
in	O
28.3	O
%	O
,	O
24.5	O
%	O
,	O
and	O
9.4	O
%	O
of	O
participants	O
,	O
respectively	O
.	O

No	O
serious	O
complications	O
occurred	O
.	O

APTs	B-P
with	O
locally	O
prepared	O
lyophilized	B-P
allergen	O
extracts	O
were	O
safe	O
and	O
had	O
high	O
specificity	O
,	O
median	O
positive	O
predictive	O
value	O
,	O
and	O
low	O
sensitivity	O
for	O
evaluation	O
of	O
suspected	O
food	O
allergy	O
in	O
children	O
with	O
atopic	O
dermatitis	O
.	O

clinicaltrials.gov	O
Identifier	O
:	O
NCT01164293	O
.	O

Anatomical	O
subgroup	O
analysis	O
of	O
the	O
MERIDIAN	O
cohort	O
:	O
Posterior	O
fossa	O
abnormalities	O
.	O

To	O
assess	O
the	O
diagnostic	O
and	O
clinical	O
contribution	O
of	O
in	B-P
utero	I-P
magnetic	I-P
resonance	I-P
(	I-P
iuMR	I-P
)	I-P
imaging	I-P
in	O
fetuses	O
diagnosed	O
with	O
abnormalities	O
of	O
the	O
posterior	O
fossa	O
as	O
the	O
only	O
intracranial	O
abnormality	O
recognised	O
on	O
antenatal	B-P
ultrasonography	I-P
(	O
USS	B-P
)	O
.	O

We	O
report	O
a	O
sub-group	O
analysis	O
of	O
fetuses	O
with	O
abnormalities	O
of	O
the	O
posterior	O
fossa	O
diagnosed	O
on	O
antenatal	B-P
USS	I-P
(	O
with	O
or	O
without	O
ventriculomegaly	O
)	O
from	O
the	O
MERIDIAN	O
cohort	O
who	O
had	O
iuMR	B-P
imaging	I-P
within	O
2	O
weeks	O
of	O
USS	B-P
and	O
outcome	O
reference	O
data	O
were	O
available	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
USS	B-P
and	O
iuMR	B-P
are	O
reported	O
as	O
well	O
as	O
indicators	O
of	O
diagnostic	O
confidence	O
and	O
effects	O
on	O
prognosis	O
and	O
clinical	O
management	O
.	O

Abnormalities	O
confined	O
to	O
the	O
posterior	O
fossa	O
according	O
to	O
USS	B-P
were	O
found	O
in	O
81	O
fetuses	O
(	O
67	O
with	O
parenchymal	O
and	O
14	O
with	O
CSF	O
-containing	O
lesions	O
)	O
.	O

The	O
overall	O
diagnostic	O
accuracy	O
for	O
detecting	O
an	O
isolated	O
posterior	O
fossa	O
abnormality	O
was	O
65	O
%	O
for	O
USS	B-P
and	O
88	O
%	O
for	O
iuMR	B-P
(	O
difference	O
=	O
22	O
%	O
,	O
95	O
%	O
CI	O
:	O
14.0	O
to	O
30.5	O
%	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

There	O
was	O
an	O
improvement	O
in	O
'	O
appropriate	O
'	O
diagnostic	O
confidence	O
as	O
assessed	O
by	O
a	O
score	O
-	O
based	O
weighted	O
average	O
'	O
method	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
a	O
three-fold	O
reduction	O
in	O
'high	O
confidence	O
but	O
incorrect	O
diagnoses	O
'	O
was	O
achieved	O
by	O
using	O
iuMR	B-P
imaging	I-P
.	O

The	O
prognostic	O
information	O
given	O
to	O
the	O
women	O
after	O
iuMR	B-P
imaging	I-P
changed	O
in	O
44	O
%	O
of	O
cases	O
and	O
the	O
overall	O
effect	O
of	O
iuMR	B-P
on	O
clinical	O
management	O
was	O
considered	O
to	O
be	O
'	O
significant	O
'	O
,	O
'	O
major	O
'	O
or	O
'	O
decisive	O
'	O
in	O
35	O
%	O
of	O
cases	O
.	O

Our	O
data	O
suggests	O
that	O
any	O
woman	O
whose	O
fetus	O
has	O
a	O
posterior	O
fossa	O
abnormality	O
as	O
the	O
only	O
intracranial	O
finding	O
on	O
USS	B-P
should	O
have	O
iuMR	B-P
imaging	I-P
for	O
further	O
evaluation	O
.	O

This	O
is	O
on	O
the	O
basis	O
of	O
improved	O
diagnostic	O
accuracy	O
and	O
confidence	O
which	O
has	O
substantial	O
effects	O
on	O
the	O
prognostic	O
information	O
given	O
to	O
women	O
and	O
changes	O
in	O
clinical	O
management	O
.	O

In	O
Vivo	O
Expansion	O
of	O
Melanoma	O
-Specific	O
T	O
Cells	O
Using	O
Microneedle	O
Arrays	O
Coated	O
with	O
Immune-Polyelectrolyte	O
Multilayers	O
.	O

Microneedles	O
(	O
MNs	O
)	O
are	O
micron-scale	O
polymeric	O
or	O
metallic	O
structures	O
that	O
offer	O
distinct	O
advantages	O
for	O
vaccines	O
by	O
efficiently	O
targeting	O
skin	O
-resident	O
immune	O
cells	O
,	O
eliminating	O
injection-associated	O
pain	O
,	O
and	O
improving	O
patient	O
compliance	O
.	O

These	O
advantages	O
,	O
along	O
with	O
recent	O
studies	O
showing	O
therapeutic	O
benefits	O
achieved	O
using	O
traditional	O
intradermal	O
injections	O
in	O
human	O
cancer	O
patients	O
,	O
suggest	O
MN	O
delivery	O
might	O
enhance	O
cancer	O
vaccines	O
and	O
immunotherapies	O
.	O

We	O
recently	O
developed	O
a	O
new	O
class	O
of	O
polyelectrolyte	O
multilayers	O
based	O
on	O
the	O
self-assembly	O
of	O
model	O
peptide	O
antigens	O
and	O
molecular	O
toll-like	O
receptor	O
agonists	O
(	O
TLRa	O
)	O
into	O
ultrathin	O
,	O
conformal	O
coatings	O
.	O

Here	O
,	O
we	O
reasoned	O
that	O
these	O
immune	O
polyelectrolyte	O
multilayers	O
(	O
iPEMs	O
)	O
might	O
be	O
a	O
useful	O
platform	O
for	O
assembling	O
cancer	O
vaccine	O
components	O
on	O
MN	O
arrays	O
for	O
intradermal	O
delivery	O
from	O
these	O
substrates	O
.	O

Using	O
conserved	O
human	O
melanoma	O
antigens	O
and	O
a	O
potent	O
TLRa	O
vaccine	O
adjuvant	O
,	O
CpG	O
,	O
we	O
show	O
that	O
iPEMs	O
can	O
be	O
assembled	O
on	O
MNs	O
in	O
an	O
automated	O
fashion	O
.	O

These	O
films	O
,	O
prepared	O
with	O
up	O
to	O
128	O
layers	O
,	O
are	O
approximately	O
200	O
nm	O
thick	O
but	O
provide	O
cancer	O
vaccine	O
cargo	O
loading	O
>	O
225	O
μg/cm	O
(	O
2	O
)	O
.	O

In	O
cell	B-P
culture	I-P
,	O
iPEM	O
cargo	O
released	O
from	O
MNs	O
is	O
internalized	O
by	O
primary	O
dendritic	O
cells	O
,	O
promotes	O
activation	O
of	O
these	O
cells	O
,	O
and	O
expands	O
T	O
cells	O
during	O
coculture	B-P
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-coated	O
MNs	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-specific	O
T	O
cells	O
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	O
responses	O
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

This	O
study	O
support	O
MNs	O
coated	O
with	O
PEMs	O
built	O
from	O
tumor	O
vaccine	O
components	O
as	O
a	O
well-defined	O
,	O
modular	O
system	O
for	O
generating	O
tumor	O
-specific	O
immune	O
responses	O
,	O
enabling	O
new	O
approaches	O
that	O
can	O
be	O
explored	O
in	O
combination	O
with	O
checkpoint	O
blockade	O
or	O
other	O
combination	O
cancer	O
therapies	O
.	O

Assessment	O
of	O
the	O
wish	O
to	O
hasten	O
death	O
in	O
patients	O
with	O
advanced	O
disease	O
:	O
A	O
systematic	O
review	O
of	O
measurement	O
instruments	O
.	O

Patients	O
with	O
advanced	O
conditions	O
may	O
present	O
a	O
wish	O
to	O
hasten	O
death	O
.	O

Assessing	O
this	O
wish	O
is	O
complex	O
due	O
to	O
the	O
nature	O
of	O
the	O
phenomenon	O
and	O
the	O
difficulty	O
of	O
conceptualising	O
it	O
.	O

To	O
identify	O
and	O
analyse	O
existing	O
instruments	O
for	O
assessing	O
the	O
wish	O
to	O
hasten	O
death	O
and	O
to	O
rate	O
their	O
reported	O
psychometric	B-P
properties	O
.	O

Systematic	O
review	O
based	O
on	O
PRISMA	O
guidelines	O
.	O

The	O
COnsensus-based	O
Standards	O
for	O
the	O
selection	O
of	O
health	O
Measurement	O
INstruments	O
checklist	O
was	O
used	O
to	O
evaluate	O
the	O
methodological	O
quality	O
of	O
validation	O
studies	O
and	O
the	O
measurement	O
properties	O
of	O
the	O
instrument	O
described	O
.	O

The	O
CINAHL	O
,	O
PsycINFO	O
,	O
Pubmed	O
and	O
Web	O
of	O
Science	O
databases	O
were	O
searched	O
from	O
inception	O
to	O
November	O
2015	O
.	O

A	O
total	O
of	O
50	O
articles	O
involving	O
assessment	O
of	O
the	O
wish	O
to	O
hasten	O
death	O
were	O
included	O
.	O

Eight	O
concerned	O
instrument	O
validation	O
and	O
were	O
evaluated	O
using	O
COnsensus-based	O
Standards	O
for	O
the	O
selection	O
of	O
health	O
Measurement	O
INstruments	O
criteria	O
.	O

They	O
reported	O
data	O
for	O
between	O
two	O
and	O
seven	O
measurement	O
properties	O
,	O
with	O
ratings	O
between	O
fair	O
and	O
excellent	O
.	O

Of	O
the	O
seven	O
instruments	O
identified	O
,	O
the	O
Desire	O
for	O
Death	O
Rating	O
Scale	O
or	O
the	O
Schedule	O
of	O
Attitudes	O
toward	O
Hastened	O
Death	O
feature	O
in	O
48	O
of	O
the	O
50	O
articles	O
.	O

The	O
Schedule	O
of	O
Attitudes	O
toward	O
Hastened	O
Death	O
is	O
the	O
most	O
widely	O
used	O
and	O
is	O
the	O
instrument	O
whose	O
psychometric	B-P
properties	O
have	O
been	O
most	O
often	O
analysed	O
.	O

Versions	O
of	O
the	O
Schedule	O
of	O
Attitudes	O
toward	O
Hastened	O
Death	O
are	O
available	O
in	O
five	O
languages	O
other	O
than	O
the	O
original	O
English	O
.	O

This	O
systematic	O
review	O
has	O
analysed	O
existing	O
instruments	O
for	O
assessing	O
the	O
wish	O
to	O
hasten	O
death	O
.	O

It	O
has	O
also	O
explored	O
the	O
methodological	O
quality	O
of	O
studies	O
that	O
have	O
examined	O
the	O
measurement	O
properties	O
of	O
these	O
instruments	O
and	O
offers	O
ratings	O
of	O
the	O
reported	O
properties	O
.	O

These	O
results	O
will	O
be	O
useful	O
to	O
clinicians	O
and	O
researchers	O
with	O
an	O
interest	O
in	O
a	O
phenomenon	O
of	O
considerable	O
relevance	O
to	O
advanced	O
patients	O
.	O

Smooth	O
versus	O
Textured	O
Surfaces	O
:	O
Feature	O
-Based	O
Category	O
Selectivity	O
in	O
Human	O
Visual	O
Cortex	O
.	O

In	O
fMRI	B-P
studies	I-P
,	O
human	O
lateral	O
occipital	O
(	O
LO	O
)	O
cortex	O
is	O
thought	O
to	O
respond	O
selectively	O
to	O
images	O
of	O
objects	O
,	O
compared	O
with	O
nonobjects	O
.	O

However	O
,	O
it	O
remains	O
unresolved	O
whether	O
all	O
objects	O
evoke	O
equivalent	O
levels	O
of	O
activity	O
in	O
LO	O
,	O
and	O
,	O
if	O
not	O
,	O
which	O
image	O
features	O
produce	O
stronger	O
activation	O
.	O

Here	O
,	O
we	O
used	O
an	O
unbiased	O
parametric	O
texture	O
model	O
to	O
predict	O
preferred	O
versus	O
nonpreferred	O
stimuli	O
in	O
LO	O
.	O

Observation	O
and	O
psychophysical	O
results	O
showed	O
that	O
predicted	O
preferred	O
stimuli	O
(	O
both	O
objects	O
and	O
nonobjects	O
)	O
had	O
smooth	O
(	O
rather	O
than	O
textured	O
)	O
surfaces	O
.	O

These	O
predictions	O
were	O
confirmed	O
using	O
fMRI	B-P
,	O
for	O
objects	O
and	O
nonobjects	O
.	O

Similar	O
preferences	O
were	O
also	O
found	O
in	O
the	O
fusiform	O
face	O
area	O
(	O
FFA	O
)	O
.	O

Consistent	O
with	O
this	O
:	O
(	O
1	O
)	O
FFA	O
and	O
LO	O
responded	O
more	O
strongly	O
to	O
nonfreckled	O
(	O
smooth	O
)	O
faces	O
,	O
compared	O
with	O
otherwise	O
identical	O
freckled	O
(	O
textured	O
)	O
faces	O
;	O
and	O
(	O
2	O
)	O
strong	O
functional	O
connections	O
were	O
found	O
between	O
LO	O
and	O
FFA	O
.	O

Thus	O
,	O
LO	O
and	O
FFA	O
may	O
be	O
part	O
of	O
an	O
information	O
-	O
processing	O
stream	O
distinguished	O
by	O
feature	O
-based	O
category	O
selectivity	O
(	O
smooth	O
>	O
textured	O
)	O
.	O

Sevoflurane	O
postconditioning	O
improves	O
myocardial	O
mitochondrial	O
respiratory	O
function	O
and	O
reduces	O
myocardial	O
ischemia	O
-	O
reperfusion	O
injury	O
by	O
up-regulating	O
HIF-1	O
.	O

Sevoflurane	O
postconditioning	O
(	O
SPostC	O
)	O
can	O
exert	O
myocardial	O
protective	O
effects	O
similar	O
to	O
ischemic	O
preconditioning	O
.	O

However	O
,	O
the	O
exact	O
myocardial	O
protection	O
mechanism	O
by	O
SPostC	O
is	O
unclear	O
.	O

Studies	O
indicate	O
that	O
hypoxia-inducible	O
factor-1	O
(	O
HIF-1	O
)	O
maintains	O
cellular	O
respiration	O
homeostasis	O
by	O
regulating	O
mitochondrial	O
respiratory	O
chain	O
enzyme	O
activity	O
under	O
hypoxic	O
conditions	O
.	O

This	O
study	O
investigated	O
whether	O
SPostC	O
could	O
regulate	O
the	O
expression	O
of	O
myocardial	O
HIF-1α	O
and	O
to	O
improve	O
mitochondrial	O
respiratory	O
function	O
,	O
thereby	O
relieving	O
myocardial	O
ischemia	O
-	O
reperfusion	O
injury	O
in	O
rats	O
.	O

The	O
myocardial	O
ischemia	O
-	O
reperfusion	O
rat	O
model	O
was	O
established	O
using	O
the	O
Langendorff	B-P
isolated	I-P
heart	I-P
perfusion	I-P
apparatus	I-P
.	O

Additionally	O
,	O
postconditioning	O
was	O
performed	O
using	O
sevoflurane	O
alone	O
or	O
in	O
combination	O
with	O
the	O
HIF-1α	O
inhibitor	O
2-methoxyestradiol	O
(	O
2ME2	O
)	O
.	O

The	O
changes	O
in	O
hemodynamic	O
parameters	O
,	O
HIF-1α	O
protein	O
expression	O
levels	O
,	O
mitochondrial	O
respiratory	O
function	O
and	O
enzyme	O
activity	O
,	O
mitochondrial	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
rates	O
,	O
and	O
mitochondrial	O
ultrastructure	O
were	O
measured	O
or	O
observed	O
.	O

Compared	O
to	O
the	O
ischemia	O
-	O
reperfusion	O
(	O
I	O
/	O
R	O
)	O
group	O
,	O
HIF-1α	O
expression	O
in	O
the	O
SPostC	O
group	O
was	O
significantly	O
up-regulated	O
.	O

Additionally	O
,	O
cardiac	O
function	O
indicators	O
,	O
mitochondrial	O
state	O
3	O
respiratory	O
rate	O
,	O
respiratory	O
control	O
ratio	O
(	O
RCR	O
)	O
,	O
cytochrome	O
C	O
oxidase	O
(	O
CcO	O
)	O
,	O
NADH	O
oxidase	O
(	O
NADHO	O
)	O
,	O
and	O
succinate	O
oxidase	O
(	O
SUCO	O
)	O
activities	O
,	O
mitochondrial	O
ROS	O
production	O
rate	O
,	O
and	O
mitochondrial	O
ultrastructure	O
were	O
significantly	O
better	O
than	O
those	O
in	O
the	O
I	O
/	O
R	O
group	O
.	O

However	O
,	O
these	O
advantages	O
were	O
completely	O
reversed	O
by	O
the	O
HIF-1α	O
specific	O
inhibitor	O
2ME2	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
myocardial	O
protective	O
function	O
of	O
SPostC	O
might	O
be	O
associated	O
with	O
the	O
improvement	O
of	O
mitochondrial	O
respiratory	O
function	O
after	O
up-regulation	O
of	O
HIF-1α	O
expression	O
.	O

Autoantibodies	O
to	O
MOG	O
in	O
a	O
distinct	O
subgroup	O
of	O
adult	O
multiple	O
sclerosis	O
.	O

To	O
evaluate	O
the	O
presence	O
of	O
antibodies	O
to	O
conformation	O
-intact	O
myelin	O
oligodendrocyte	O
glycoprotein	O
(	O
MOG	O
)	O
in	O
a	O
subgroup	O
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	O
cord	O
,	O
optic	O
nerve	O
,	O
and	O
brainstem	O
involvement	O
.	O

Antibodies	O
to	O
MOG	O
were	O
investigated	O
using	O
a	O
cell-based	B-P
assay	I-P
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
MS	O
(	O
group	O
1	O
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
MS	O
(	O
group	O
2	O
)	O
,	O
and	O
in	O
22	O
brain-biopsied	B-P
patients	O
with	O
demyelinating	O
diseases	O
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
MS	O
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	O
II	O
(	O
group	O
3	O
)	O
.	O

Recognized	O
epitopes	O
were	O
identified	O
with	O
mutated	O
variants	O
of	O
MOG	O
.	O

Antibodies	O
to	O
MOG	O
were	O
found	O
in	O
about	O
5	O
%	O
(	O
5/104	O
)	O
of	O
preselected	O
adult	O
patients	O
with	O
MS	O
.	O

In	O
contrast	O
,	O
in	O
groups	O
2	O
and	O
3	O
,	O
none	O
of	O
the	O
patients	O
tested	O
positive	O
for	O
MOG	O
antibodies	O
.	O

Patients	O
with	O
MS	O
with	O
antibodies	O
to	O
MOG	O
predominantly	O
manifested	O
with	O
concomitant	O
severe	O
brainstem	O
and	O
spinal	O
cord	O
involvement	O
and	O
had	O
a	O
severe	O
disease	O
course	O
with	O
high	O
relapse	O
rates	O
and	O
failure	O
to	O
several	O
disease-modifying	O
therapies	O
.	O

Three	O
of	O
them	O
had	O
been	O
treated	O
with	O
plasma	O
exchange	O
with	O
a	O
favorable	O
response	O
.	O

All	O
anti-MOG	O
-positive	O
patients	O
with	O
MS	O
showed	O
typical	O
MS	O
lesions	O
on	O
brain	B-P
MRI	I-P
.	O

Longitudinal	O
analysis	O
up	O
to	O
9	O
years	O
revealed	O
fluctuations	O
and	O
reappearance	O
of	O
anti-MOG	O
reactivity	O
.	O

Epitope	O
mapping	O
indicated	O
interindividual	O
heterogeneity	O
,	O
yet	O
intraindividual	O
stability	O
of	O
the	O
antibody	O
response	O
.	O

Antibodies	O
to	O
MOG	O
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	O
of	O
adult	O
MS	O
with	O
a	O
specific	O
clinical	O
phenotype	O
and	O
may	O
indicate	O
disease	O
heterogeneity	O
.	O

Physicochemical	O
characterization	O
of	O
chitosan	O
-	O
hyaluronan	O
-coated	O
solid	O
lipid	O
nanoparticles	O
for	O
the	O
targeted	O
delivery	O
of	O
paclitaxel	O
:	O
a	O
proof-of-concept	O
study	O
in	O
breast	O
cancer	O
cells	O
.	O

To	O
investigate	O
the	O
potential	O
of	O
modified	O
solid	O
lipid	O
nanoparticles	O
(	O
SLN	O
)	O
for	O
the	O
delivery	O
of	O
paclitaxel	O
(	O
PAX	O
)	O
.	O

SLN	O
loaded	O
with	O
PAX	O
were	O
prepared	O
via	O
modified	O
high-pressure	B-P
hot	I-P
homogenization	I-P
.	O

Formulation	O
parameters	O
were	O
optimized	O
to	O
obtain	O
a	O
high-quality	O
delivery	O
system	O
.	O

SLN	O
cores	O
were	O
coated	O
,	O
layer-by-layer	O
,	O
with	O
a	O
chitosan	O
and	O
hyaluronan	O
(	O
HA	O
)	O
shell	O
.	O

Selectivity	O
toward	O
HA	O
receptors	O
was	O
tested	O
in	O
a	O
breast	O
cancer	O
cell	O
line	O
,	O
MCF-7	O
.	O

Stable	O
and	O
reproducible	O
nano-sized	O
and	O
negatively	O
charged	O
nanoparticles	O
resulted	O
.	O

Findings	O
reveal	O
that	O
chitosan	O
-	O
HA	O
-coated	O
SLN	O
facilitated	O
the	O
targeting	O
,	O
cellular	O
uptake	O
and	O
the	O
time-/dose-controlled	O
delivery	O
and	O
release	O
of	O
PAX	O
,	O
enhancing	O
intrinsic	O
chemotherapeutic	O
activities	O
.	O

SLN	O
are	O
suitable	O
carrier	O
candidates	O
for	O
nano-oncology	O
given	O
their	O
localized	O
,	O
and	O
potent	O
cytotoxic	O
potential	O
overcoming	O
multidrug-resistant	O
cancer	O
cells	O
.	O

Subcutaneous	O
cardioverter	O
defibrillator	O
has	O
longer	O
time	O
to	O
therapy	O
but	O
is	O
less	O
cardiotoxic	O
than	O
transvenous	O
cardioverter	O
defibrillator	O
.	O

Study	O
carried	O
out	O
in	O
a	O
preclinical	O
porcine	O
model	O
.	O

Totally	O
subcutaneous	O
implantable	O
cardioverter	O
defibrillator	O
(	O
S-ICD	O
)	O
delivers	O
higher	O
shock	O
energy	O
and	O
can	O
have	O
longer	O
time	O
to	O
therapy	O
compared	O
to	O
transvenous	O
implantable	O
cardioverter	O
defibrillator	O
(	O
T-ICD	O
)	O
.	O

Aim	O
of	O
the	O
study	O
was	O
to	O
compare	O
time	O
to	O
therapy	O
and	O
to	O
investigate	O
cardiac	O
,	O
cerebral	O
and	O
systemic	O
injuries	O
of	O
S-ICD	O
and	O
T-ICD	O
shocks	O
delivered	O
after	O
ventricular	O
fibrillation	O
(	O
VF	O
)	O
induction	O
.	O

Fourteen	O
pigs	O
were	O
randomly	O
implanted	O
with	O
a	O
S-ICD	O
(	O
n	O
=	O
7	O
)	O
or	O
a	O
T-ICD	O
(	O
n	O
=	O
7	O
)	O
.	O

Five	O
VF	O
episodes	O
were	O
induced	O
in	O
each	O
pig	O
.	O

For	O
each	O
VF	O
episode	O
,	O
up	O
to	O
two	O
shocks	O
could	O
be	O
delivered	O
by	O
the	O
T-ICD	O
or	O
the	O
S-ICD	O
to	O
terminate	O
the	O
arrhythmia	O
.	O

Cardiac	O
,	O
systemic	O
,	O
and	O
cerebral	O
toxicity	O
were	O
monitored	O
.	O

Mean	O
time	O
to	O
therapy	O
was	O
longer	O
in	O
the	O
S-ICD	O
group	O
compared	O
to	O
the	O
T-ICD	O
group	O
(	O
19	O
[	O
18	O
;	O
23	O
]	O
s	O
vs.	O
9	O
[	O
7	O
;	O
10	O
]	O
s	O
;	O
P	O
=	O
0.001	O
,	O
respectively	O
)	O
.	O

High-sensitivity	B-P
troponin	I-P
T	I-P
levels	O
were	O
significantly	O
higher	O
in	O
the	O
T-ICD	O
group	O
from	O
1	O
to	O
24	O
h	O
after	O
the	O
procedure	O
(	O
P	O
≤	O
0.02	O
)	O
.	O

Creatine	O
phosphokinase	O
activity	O
levels	O
were	O
significantly	O
higher	O
in	O
the	O
S-ICD	O
group	O
,	O
at	O
3	O
,	O
6	O
,	O
and	O
24	O
h	O
after	O
the	O
procedure	O
(	O
P	O
≤	O
0.05	O
)	O
.	O

Lactate	O
levels	O
were	O
not	O
significantly	O
different	O
between	O
groups	O
.	O

S100	O
protein	O
level	O
was	O
similar	O
in	O
both	O
groups	O
at	O
1	O
h	O
after	O
the	O
procedure	O
and	O
then	O
decreased	O
in	O
the	O
T-ICD	O
group	O
compared	O
to	O
the	O
S-ICD	O
group	O
(	O
P	O
=	O
0.04	O
)	O
.	O

Time	O
to	O
therapy	O
in	O
S-ICD	O
was	O
twice	O
as	O
long	O
as	O
for	O
T-ICD	O
,	O
but	O
did	O
n't	O
induce	O
relevant	O
brain	O
injury	O
.	O

Conversely	O
,	O
S-ICD	O
shocks	O
were	O
less	O
cardiotoxic	O
than	O
T-ICD	O
shocks	O
.	O

Ventricular	O
pacing	O
site	O
separation	O
by	O
cardiac	O
computed	B-P
tomography	I-P
:	O
validation	O
for	O
the	O
prediction	O
of	O
clinical	O
response	O
to	O
cardiac	O
resynchronization	O
therapy	O
.	O

Cardiac	O
Resynchronization	O
Therapy	O
(	O
CRT	O
)	O
fails	O
to	O
provide	O
benefit	O
in	O
up	O
to	O
one-third	O
of	O
patients	O
.	O

Maximizing	O
the	O
geographic	O
separation	O
of	O
right	O
and	O
left	O
ventricular	O
pacing	O
lead	O
sites	O
has	O
been	O
suggested	O
as	O
one	O
way	O
to	O
improve	O
response	O
.	O

Cardiac	B-P
CT	I-P
provides	O
an	O
opportunity	O
to	O
explore	O
3-dimensional	O
inter-lead	O
distance	O
(	O
ILD	O
)	O
measures	O
for	O
the	O
prediction	O
of	O
CRT	O
response	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
associations	O
between	O
standardized	O
measures	O
of	O
ILD	O
by	O
cardiac	B-P
CT	I-P
and	O
echocardiographic	B-P
response	O
to	O
CRT	O
.	O

Forty-two	O
consecutive	O
patients	O
undergoing	O
CRT	O
had	O
serial	O
clinical	O
and	O
echocardiographic	B-P
evaluations	O
performed	O
in	O
addition	O
to	O
a	O
post-procedural	O
cardiac	O
-gated	O
CT	B-P
with	O
blinded	O
measurement	O
of	O
direct	O
and	O
circumferential	O
(	O
via	O
the	O
myocardium	O
)	O
ILD	O
measures	O
.	O

Clinical	O
response	O
to	O
CRT	O
,	O
the	O
primary	O
clinical	O
outcome	O
,	O
was	O
defined	O
as	O
a	O
≥15	O
%	O
reduction	O
in	O
LVESV	O
using	O
echocardiography	B-P
at	O
6-months	O
.	O

The	O
mean	O
age	O
and	O
ejection	O
fraction	O
was	O
63.6	O
±	O
8.9	O
years	O
and	O
25.2	O
±	O
7.8	O
%	O
,	O
respectively	O
.	O

The	O
primary	O
outcome	O
occurred	O
in	O
35	O
of	O
42	O
patients	O
(	O
83	O
%	O
)	O
.	O

Both	O
direct	O
and	O
circumferential	O
CT	B-P
-based	O
ILD	O
measures	O
were	O
associated	O
with	O
the	O
primary	O
outcome	O
by	O
univariate	O
analysis	O
.	O

Receiver	O
Operator	O
Characteristic	O
analysis	O
identified	O
Circumferential	O
ILD	O
to	O
have	O
the	O
strongest	O
predictive	O
accuracy	O
(	O
AUC	O
0.78	O
)	O
.	O

Inter-	O
and	O
intra-observer	O
reproducibility	O
of	O
CT	B-P
-derived	O
ILD	O
measures	O
was	O
excellent	O
.	O

Circumferential	O
ILD	O
measures	O
on	O
cardiac	B-P
CT	I-P
are	O
predictive	O
of	O
clinical	O
response	O
to	O
CRT	O
.	O

Incorporation	O
of	O
these	O
measures	O
into	O
the	O
selection	O
of	O
optimal	O
pacing	O
targets	O
,	O
particularly	O
from	O
pre-procedural	O
CT	B-P
coronary	O
vein	O
imaging	B-P
may	O
be	O
of	O
therapeutic	O
benefit	O
and	O
warrants	O
further	O
investigation	O
.	O

Radiosensitization	O
of	O
non-small-cell	O
lung	O
cancer	O
cells	O
and	O
xenografts	O
by	O
the	O
interactive	O
effects	O
of	O
pemetrexed	O
and	O
methoxyamine	O
.	O

The	O
anti-folate	O
pemetrexed	O
is	O
a	O
radiosensitizer	O
.	O

In	O
pre-clinical	O
models	O
,	O
pemetrexed	O
is	O
more	O
effective	O
along	O
with	O
the	O
base-excision-repair	O
inhibitor	O
methoxyamine	O
.	O

We	O
tested	O
whether	O
methoxyamine	O
enhances	O
pemetrexed	O
-mediated	O
radiosensitization	O
of	O
lung	O
adenocarcinoma	O
cells	O
and	O
xenografts	O
.	O

A549	O
and	O
H1299	O
cells	O
were	O
evaluated	O
for	O
cell	O
cycle	O
distribution	O
by	O
flow	B-P
cytometry	I-P
,	O
radiosensitization	O
by	O
clonogenic	B-P
assay	I-P
,	O
and	O
DNA	O
repair	O
by	O
neutral	O
comet	O
assay	O
and	O
repair	O
protein	O
activation	O
.	O

H460	O
cells	O
were	O
included	O
in	O
some	O
studies	O
.	O

Xenografts	O
in	O
nude	O
mice	O
received	O
drug	O
(	O
s	O
)	O
and/or	O
radiation	O
,	O
and	O
tumor	O
growth	O
was	O
monitored	O
by	O
caliper	O
and	O
in	O
vivo	O
toxicity	O
by	O
animal	O
weight	O
.	O

Exposure	O
to	O
pemetrexed	O
/	O
methoxyamine	O
for	O
24	O
(	O
H1299	O
,	O
H460	O
)	O
or	O
48	O
(	O
A549	O
)	O
hours	O
before	O
irradiation	O
resulted	O
in	O
accumulation	O
of	O
cells	O
near	O
the	O
radiosensitive	O
G1/S	O
border	O
;	O
dose	O
-	O
enhancement	O
factors	O
of	O
1.62±0.19	O
,	O
1.97±0.25	O
,	O
and	O
1.67±0.30	O
,	O
respectively	O
;	O
reduction	O
of	O
mean	O
inactivation	O
dose	O
by	O
32	O
%	O
,	O
30	O
%	O
,	O
and	O
46	O
%	O
,	O
respectively	O
;	O
and	O
significant	O
reductions	O
of	O
SF2	O
and	O
SF4	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Radiosensitization	O
was	O
associated	O
with	O
rapid	O
DNA	O
double-strand-break	O
rejoining	O
and	O
increased	O
levels	O
of	O
DNA-PKcs	O
.	O

Both	O
tumor-growth	O
rate	O
and	O
tumor-growth	O
delay	O
were	O
significantly	O
improved	O
by	O
adding	O
methoxyamine	O
to	O
pemetrexed	O
pre-irradiation	O
(	O
p	O
<	O
0.0001	O
)	O
;	O
no	O
mice	O
lost	O
weight	O
during	O
treatment	O
.	O

Addition	O
of	O
methoxyamine	O
to	O
pemetrexed	O
and	O
fractionated	O
radiotherapy	O
may	O
improve	O
outcome	O
for	O
patients	O
with	O
locally	O
advanced	O
non-squamous	O
non-small-cell	O
lung	O
cancer	O
.	O

High	O
concordance	O
of	O
findings	O
obtained	O
from	O
transgluteal	O
magnetic	B-P
resonance	I-P
imaging	I-P
-	O
and	O
transrectal	B-P
ultrasonography	I-P
-	O
guided	B-P
biopsy	I-P
as	O
compared	O
with	O
prostatectomy	O
specimens	O
.	O

To	O
determine	O
the	O
utility	O
of	O
our	O
transgluteal	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
-	O
guided	B-P
prostate	I-P
biopsy	I-P
approach	O
.	O

A	O
total	O
of	O
960	O
biopsy	B-P
series	O
,	O
taken	O
within	O
the	O
period	O
of	O
1	O
year	O
,	O
were	O
evaluated	O
,	O
including	O
301	O
MRI-guided	B-P
and	O
659	O
transrectal	B-P
ultrasonography	I-P
(	O
TRUS	B-P
)	O
-	O
guided	B-P
biopsies	I-P
.	O

The	O
positivity	O
rate	O
and	O
proportion	O
of	O
high	O
grade	O
cancers	O
were	O
significantly	O
higher	O
in	O
MRI-guided	B-P
than	O
in	O
TRUS	B-P
-	O
guided	B-P
biopsies	I-P
.	O

Of	O
301	O
MRI-guided	B-P
biopsies	I-P
,	O
65.4	O
%	O
contained	O
cancer	O
while	O
57.2	O
%	O
of	O
659	O
TRUS	B-P
biopsies	B-P
contained	O
cancer	O
(	O
P	O
=	O
0.016	O
)	O
.	O

Gleason	O
grade	O
3	O
+	O
3	O
=	O
6	O
disease	O
was	O
observed	O
in	O
16.8	O
%	O
of	O
197	O
MRI-guided	B-P
and	O
in	O
36.1	O
%	O
of	O
377	O
TRUS	B-P
-	O
guided	B-P
biopsies	I-P
(	O
P	O
<	O
0.001	O
)	O
.	O

There	O
was	O
also	O
a	O
markedly	O
higher	O
quantity	O
of	O
cancer	O
tissue	O
in	O
MRI-guided	B-P
biopsies	I-P
.	O

In	O
all	O
cancers	O
,	O
the	O
mean	O
cancer	O
surface	O
area	O
was	O
64.8	O
±	O
51.6	O
mm	O
(	O
2	O
)	O
in	O
MRI-guided	B-P
biopsies	I-P
as	O
compared	O
with	O
23.0	O
±	O
31.4	O
mm	O
(	O
2	O
)	O
in	O
non-MRI-guided	O
biopsies	O
(	O
P	O
<	O
0.001	O
)	O
.	O

With	O
respect	O
to	O
the	O
tissue	O
quantity	O
,	O
superiority	O
of	O
MRI-guided	B-P
biopsy	I-P
was	O
highest	O
in	O
Gleason	O
grade	O
3	O
+	O
3	O
=	O
6	O
cancers	O
(	O
20.9	O
±	O
27.9	O
vs	O
5.1	O
±	O
10.2	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
and	O
in	O
Gleason	O
grade	O
3	O
+	O
4	O
=	O
7	O
cancers	O
(	O
59.7	O
±	O
38.0	O
vs	O
17.7	O
±	O
18.4	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Comparison	O
of	O
biopsy	B-P
Gleason	O
grades	O
with	O
findings	O
in	O
prostatectomy	O
specimens	O
was	O
possible	O
in	O
80	O
patients	O
with	O
MRI-guided	B-P
and	O
in	O
170	O
patients	O
with	O
non-MRI-guided	O
biopsies	O
.	O

This	O
comparison	O
showed	O
a	O
very	O
high	O
but	O
almost	O
identical	O
concordance	O
of	O
TRUS	B-P
-	O
and	O
MRI-guided	B-P
biopsies	I-P
with	O
the	O
prostatectomy	O
specimen	O
findings	O
.	O

With	O
both	O
approaches	O
,	O
undetected	O
high-risk	O
cancers	O
were	O
present	O
in	O
~10	O
%	O
of	O
patients	O
with	O
low-risk	O
biopsy	B-P
results	O
.	O

A	O
significant	O
difference	O
was	O
observed	O
,	O
however	O
,	O
in	O
the	O
proportion	O
of	O
patients	O
who	O
had	O
clinically	O
insignificant	O
cancers	O
and	O
who	O
underwent	O
surgery	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
Gleason	O
grade	O
3	O
+	O
3	O
=	O
6	O
carcinoma	O
in	O
their	O
prostatectomy	O
specimen	O
was	O
11.2	O
%	O
in	O
the	O
post	O
-	O
TRUS	B-P
biopsy	B-P
cohort	O
,	O
but	O
only	O
2.5	O
%	O
in	O
the	O
post	O
-	O
MRI	B-P
biopsy	I-P
cohort	O
(	O
P	O
=	O
0.021	O
)	O
.	O

MRI-guided	B-P
transgluteal	O
prostate	B-P
biopsy	I-P
has	O
a	O
high	O
detection	O
rate	O
for	O
high-risk	O
carcinomas	O
,	O
while	O
the	O
risk	O
of	O
detecting	O
clinically	O
insignificant	O
carcinomas	O
appears	O
to	O
be	O
reduced	O
.	O

This	O
may	O
by	O
itself	O
lead	O
to	O
a	O
reduction	O
of	O
unnecessary	O
prostatectomies	O
.	O

Overtreatment	O
may	O
be	O
further	O
avoided	O
by	O
better	O
applicability	O
of	O
molecular	B-P
testing	I-P
to	O
MRI-guided	B-P
biopsies	I-P
because	O
of	O
the	O
excessive	O
amount	O
of	O
tissue	O
available	O
for	O
analysis	O
,	O
especially	O
in	O
patients	O
with	O
potential	O
low-risk	O
carcinomas	O
.	O

Molecular	O
serum	O
signature	O
of	O
treatment	O
resistant	O
depression	O
.	O

A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
do	O
not	O
respond	O
to	O
multiple	O
trials	O
of	O
anti-depressants	O
,	O
develop	O
a	O
chronic	O
course	O
of	O
disease	O
and	O
become	O
treatment	O
resistant	O
.	O

Most	O
of	O
the	O
studies	O
investigating	O
molecular	O
changes	O
in	O
treatment-resistant	O
depression	O
(	O
TRD	O
)	O
have	O
only	O
examined	O
a	O
limited	O
number	O
of	O
molecules	O
and	O
genes	O
.	O

Consequently	O
,	O
biomarkers	O
associated	O
with	O
TRD	O
are	O
still	O
lacking	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high-throughput	O
proteomic	O
platforms	O
to	O
identify	O
peripheral	O
biomarkers	O
of	O
TRD	O
defined	O
by	O
two	O
staging	O
models	O
,	O
the	O
Thase	O
and	O
Rush	O
staging	O
model	O
(	O
TRM	O
)	O
and	O
the	O
Maudsley	O
Staging	O
Model	O
(	O
MSM	O
)	O
.	O

Serum	O
collected	O
from	O
an	O
inpatient	O
cohort	O
of	O
65	O
individuals	O
suffering	O
from	O
MDD	O
was	O
analysed	O
using	O
two	O
different	O
mass	B-P
spectrometric-based	I-P
platforms	I-P
,	O
label-free	B-P
liquid	I-P
chromatography	I-P
mass	I-P
spectrometry	I-P
(	O
LC-MS	B-P
(	I-P
E	I-P
)	I-P
)	O
and	O
selective	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	B-P
bead	I-P
based	I-P
assay	I-P
.	O

In	O
the	O
LC-MS	B-P
(	I-P
E	I-P
)	I-P
analysis	I-P
,	O
proteins	O
involved	O
in	O
the	O
acute	O
phase	O
response	O
and	O
complement	O
activation	O
and	O
coagulation	O
were	O
significantly	O
different	O
between	O
the	O
staging	O
groups	O
in	O
both	O
models	O
.	O

In	O
the	O
multiplex	B-P
bead-based	I-P
assay	I-P
analysis	O
TNF-α	B-P
levels	I-P
(	O
log	O
(	O
odds	O
)	O
=	O
-4.95	O
,	O
p	O
=	O
0.045	O
)	O
were	O
significantly	O
different	O
in	O
the	O
TRM	O
comparison	O
.	O

Using	O
SRM	O
,	O
significant	O
changes	O
of	O
three	O
apolipoproteins	O
A-I	O
(	O
β	O
=	O
0.029	O
,	O
p	O
=	O
0.035	O
)	O
,	O
M	O
(	O
β	O
=	O
-0.017	O
,	O
p	O
=	O
0.009	O
)	O
and	O
F	O
(	O
β	O
=	O
-0.031	O
,	O
p	O
=	O
0.024	O
)	O
were	O
associated	O
with	O
the	O
TRM	O
but	O
not	O
the	O
MSM	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
proteins	O
,	O
which	O
are	O
involved	O
in	O
immune	O
and	O
complement	O
activation	O
,	O
may	O
represent	O
potential	O
biomarkers	O
that	O
could	O
be	O
used	O
by	O
clinicians	O
to	O
identify	O
high-risk	O
patients	O
.	O

Nevertheless	O
,	O
given	O
that	O
the	O
molecular	O
changes	O
between	O
the	O
staging	O
groups	O
were	O
subtle	O
,	O
the	O
results	O
need	O
to	O
be	O
interpreted	O
cautiously	O
.	O

Novel	O
biomarkers	O
in	O
primary	O
breast	B-P
core	I-P
biopsies	I-P
to	O
predict	O
poor	O
response	O
to	O
neoadjuvant	O
chemotherapy	O
and	O
appearance	O
of	O
metastases	O
.	O

Drug	O
resistance	O
has	O
been	O
one	O
of	O
the	O
major	O
obstacles	O
limiting	O
the	O
success	O
of	O
cancer	O
chemotherapy	O
.	O

In	O
two	O
thirds	O
of	O
breast	O
cancer	O
patients	O
,	O
large	O
(	O
>	O
1cm	O
)	O
residual	O
tumors	O
are	O
present	O
after	O
neoadjuvant	O
chemotherapy	O
(	O
NCT	O
)	O
.	O

The	O
residual	O
tumor	O
and	O
involved	O
nodes	O
have	O
been	O
indicators	O
of	O
relapse	O
and	O
survival	O
very	O
important	O
in	O
breast	O
cancer	O
.	O

The	O
goal	O
of	O
this	O
preliminary	O
study	O
was	O
to	O
assess	O
the	O
predictive	O
significance	O
of	O
a	O
panel	O
of	O
molecular	O
biomarkers	O
,	O
related	O
with	O
the	O
response	O
to	O
treatment	O
or	O
drug	O
resistance	O
to	O
NCT	O
,	O
as	O
determined	O
on	O
the	O
diagnostic	O
tumor	O
.	O

The	O
expression	O
of	O
22	O
proteins	O
was	O
examined	O
using	O
immunohistochemistry	B-P
in	O
tissue	O
microarrays	O
(	O
TMA	O
)	O
from	O
115	O
patients	O
of	O
stage	O
II	O
-	O
III	O
breast	O
cancer	O
,	O
treated	O
with	O
NCT	O
.	O

Among	O
studied	O
proteins	O
,	O
there	O
are	O
some	O
that	O
are	O
anti-apoptotic	O
,	O
pro-proliferative	O
,	O
cancer	O
stem	O
cell	O
markers	O
and	O
the	O
Vitamin	O
D	O
Receptor	O
.	O

Other	O
proteins	O
are	O
involved	O
in	O
the	O
identification	O
of	O
molecular	O
subtype	O
,	O
cell	O
cycle	O
regulation	O
or	O
DNA	O
repair	O
.	O

Next	O
,	O
a	O
predictive	O
signature	O
of	O
poor	O
response	O
was	O
generated	O
from	O
independent	O
markers	O
of	O
predictive	O
value	O
.	O

Tumors	O
that	O
expressed	O
four	O
or	O
five	O
conditions	O
(	O
biomarkers	O
of	O
chemoresistance	O
with	O
a	O
determinated	O
cutoff	O
)	O
were	O
associated	O
with	O
a	O
9-fold	O
increase	O
in	O
the	O
chances	O
of	O
these	O
patients	O
of	O
having	O
a	O
poor	O
response	O
to	O
NCT	O
.	O

Additionally	O
,	O
we	O
also	O
found	O
a	O
worse	O
prognostic	O
signature	O
,	O
generated	O
from	O
independent	O
markers	O
of	O
prognostic	O
value	O
.	O

Tumors	O
which	O
expressed	O
two	O
or	O
three	O
conditions	O
of	O
worst	O
prognostic	O
,	O
were	O
associated	O
with	O
a	O
6-fold	O
reduction	O
in	O
Distant	O
Disease	O
Free	O
Survival	O
.	O

In	O
conclusion	O
,	O
finding	O
biomarkers	O
of	O
chemoresitance	O
(	O
ypTNM	O
II-III	O
)	O
and	O
metastases	O
can	O
become	O
a	O
stepping	O
stone	O
for	O
future	O
studies	O
that	O
will	O
need	O
to	O
be	O
assessed	O
in	O
a	O
bigger	O
scale	O
.	O

Intrinsic	O
rifamycin	O
resistance	O
of	O
Mycobacterium	O
abscessus	O
is	O
mediated	O
by	O
ADP-ribosyltransferase	O
MAB_0591	O
.	O

Rifampicin	O
,	O
a	O
potent	O
first-line	O
TB	O
drug	O
of	O
the	O
rifamycin	O
group	O
,	O
shows	O
only	O
little	O
activity	O
against	O
the	O
emerging	O
pathogen	O
Mycobacterium	O
abscessus	O
.	O

Reportedly	O
,	O
bacterial	O
resistance	O
to	O
rifampicin	O
is	O
associated	O
with	O
polymorphisms	O
in	O
the	O
target	O
gene	O
rpoB	O
or	O
the	O
presence	O
of	O
enzymes	O
that	O
modify	O
and	O
thereby	O
inactivate	O
rifampicin	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
MAB_0591	O
(	O
arrMab	O
)	O
-encoded	O
rifampicin	O
ADP-ribosyltransferase	O
(	O
Arr_Mab	O
)	O
in	O
innate	O
high-level	O
rifampicin	O
resistance	O
in	O
M.	O
abscessus	O
.	O

Recombinant	O
Escherichia	O
coli	O
and	O
Mycobacterium	O
tuberculosis	O
strains	O
expressing	O
MAB_0591	O
were	O
generated	O
,	O
as	O
was	O
an	O
M.	O
abscessus	O
deletion	O
mutant	O
deficient	O
for	O
MAB_0591	O
.	O

MIC	B-P
assays	I-P
were	O
used	O
to	O
study	O
susceptibility	O
to	O
rifampicin	O
and	O
C25	O
carbamate	O
-modified	O
rifamycin	O
derivatives	O
.	O

Heterologous	O
expression	O
of	O
MAB_0591	O
conferred	O
rifampicin	O
resistance	O
to	O
E.	O
coli	O
and	O
M.	O
tuberculosis	O
Rifamycin	O
MIC	O
values	O
were	O
consistently	O
lower	O
for	O
the	O
M.	O
abscessus	O
ΔarrMab	O
mutant	O
as	O
compared	O
with	O
the	O
M.	O
abscessus	O
ATCC	O
19977	O
parental	O
type	O
strain	O
.	O

The	O
rifamycin	O
WT	O
phenotype	O
was	O
restored	O
after	O
complementation	O
of	O
the	O
M.	O
abscessus	O
ΔarrMab	O
mutant	O
with	O
arrMab	O
Further	O
MIC	O
data	O
demonstrated	O
that	O
a	O
C25	O
modification	O
increases	O
rifamycin	O
activity	O
in	O
WT	O
M.	O
abscessus	O
However	O
,	O
MIC	O
studies	O
in	O
the	O
M.	O
abscessus	O
ΔarrMab	O
mutant	O
suggest	O
that	O
C25	O
modified	O
rifamycins	O
are	O
still	O
subject	O
to	O
modification	O
by	O
Arr_Mab	O
CONCLUSIONS	O
:	O
Our	O
findings	O
identify	O
Arr_Mab	O
as	O
the	O
major	O
innate	O
rifamycin	O
resistance	O
determinant	O
of	O
M.	O
abscessus	O
.	O

Our	O
data	O
also	O
indicate	O
that	O
Arr_Mab	O
-mediated	O
rifamycin	O
resistance	O
in	O
M.	O
abscessus	O
can	O
only	O
in	O
part	O
be	O
overcome	O
by	O
C25	O
carbamate	O
modification	O
.	O

Prospective	O
study	O
of	O
dietary	O
Non	B-P
Enzymatic	I-P
Antioxidant	I-P
Capacity	I-P
on	O
the	O
risk	O
of	O
hip	O
fracture	O
in	O
the	O
elderly	O
.	O

Dietary	O
antioxidants	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
prevention	O
of	O
bone	O
loss	O
and	O
associated	O
fractures	O
by	O
reducing	O
levels	O
of	O
oxidative	O
stress	O
.	O

We	O
prospectively	O
investigated	O
the	O
association	O
between	O
dietary	O
Non	B-P
Enzymatic	I-P
Antioxidant	I-P
Capacity	I-P
(	O
NEAC	B-P
)	O
and	O
the	O
risk	O
of	O
hip	O
fracture	O
and	O
whether	O
this	O
effect	O
was	O
modified	O
by	O
smoking	O
.	O

In	O
the	O
Swedish	O
National	O
March	O
Cohort	O
13,409	O
men	O
and	O
women	O
over	O
the	O
age	O
of	O
55	O
who	O
had	O
not	O
experienced	O
cancer	O
,	O
cardiovascular	O
disease	O
or	O
hip	O
fracture	O
,	O
were	O
followed	O
through	O
record-linkages	O
from	O
1997	O
through	O
2010	O
.	O

NEAC	B-P
was	O
assessed	O
by	O
a	O
validated	O
food	O
frequency	O
questionnaire	O
collected	O
at	O
baseline	O
.	O

We	O
categorized	O
the	O
distribution	O
of	O
NEAC	B-P
into	O
sex	O
-	O
specific	O
quartiles	O
and	O
used	O
multivariable	O
adjusted	O
Cox	O
proportional	O
hazards	O
regression	O
models	O
to	O
estimate	O
hazard	O
ratios	O
(	O
HRs	O
)	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
.	O

During	O
a	O
mean	O
follow-up	O
time	O
of	O
12.4years	O
,	O
we	O
identified	O
491	O
incident	O
cases	O
of	O
first	O
hip	O
fracture	O
.	O

Subjects	O
in	O
the	O
highest	O
quartile	O
of	O
dietary	O
NEAC	B-P
had	O
a	O
39	O
%	O
lower	O
risk	O
of	O
incident	O
hip	O
fracture	O
compared	O
to	O
those	O
in	O
the	O
lowest	O
quartile	O
(	O
HR	O
:	O
0.61	O
;	O
95	O
%	O
CI	O
:	O
0.44-0.85	O
)	O
.	O

The	O
association	O
was	O
non-linear	O
(	O
p	O
for	O
non-linearity	O
:	O
0.004	O
)	O
with	O
a	O
potential	O
threshold	O
between	O
the	O
first	O
and	O
the	O
second	O
quartile	O
and	O
no	O
further	O
risk	O
reduction	O
at	O
higher	O
levels	O
of	O
dietary	O
NEAC	B-P
.	O

Due	O
to	O
a	O
low	O
smoking	O
prevalence	O
in	O
our	O
study	O
population	O
,	O
we	O
had	O
limited	O
power	O
to	O
detect	O
effect	O
modification	O
between	O
dietary	O
NEAC	B-P
and	O
smoking	O
on	O
a	O
multiplicative	O
or	O
additive	O
scale	O
.	O

Higher	O
dietary	O
NEAC	B-P
intake	O
is	O
associated	O
with	O
lower	O
risk	O
of	O
hip	O
fracture	O
in	O
the	O
elderly	O
.	O

Prevalence	O
of	O
Coronary	O
Artery	O
to	O
Pulmonary	O
Artery	O
Collaterals	O
in	O
Patients	O
with	O
Chronic	O
Thromboembolic	O
Pulmonary	O
Hypertension	O
:	O
Retrospective	O
Analysis	O
from	O
a	O
Single	O
Center	O
.	O

Background	O
Our	O
aim	O
was	O
to	O
determine	O
the	O
prevalence	O
of	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
in	O
patients	O
with	O
chronic	O
thromboembolic	O
pulmonary	O
hypertension	O
(	O
CTEPH	O
)	O
by	O
retrospectively	O
evaluating	O
coronary	B-P
angiograms	I-P
of	O
eligible	O
consecutive	O
patients	O
who	O
had	O
undergone	O
pulmonary	O
endarterectomy	O
(	O
PEA	O
)	O
.	O

We	O
also	O
aimed	O
to	O
evaluate	O
predictors	O
and	O
potential	O
clinical	O
associates	O
of	O
these	O
collaterals	O
.	O

Methods	O
Coronary	B-P
angiograms	I-P
of	O
83	O
consecutive	O
CTEPH	O
patients	O
who	O
had	O
undergone	O
coronary	B-P
angiography	I-P
before	O
PEA	O
operation	O
between	O
January	O
1	O
,	O
2012	O
and	O
June	O
1	O
,	O
2015	O
were	O
retrospectively	O
evaluated	O
for	O
presence	O
of	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
.	O

Medical	O
records	O
of	O
all	O
patients	O
were	O
also	O
retrospectively	O
reviewed	O
for	O
demographic	O
information	O
,	O
cardiovascular	O
risk	O
factors	O
,	O
preoperative	O
right	O
heart	O
catheterization	O
reports	O
,	O
operation	O
reports	O
,	O
and	O
follow-up	O
data	O
.	O

Data	O
of	O
CTEPH	O
patients	O
with	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
were	O
compared	O
with	O
data	O
of	O
CTEPH	O
patients	O
without	O
such	O
collaterals	O
.	O

Results	O
There	O
were	O
15	O
patients	O
(	O
18.1	O
%	O
)	O
with	O
definite	O
and	O
4	O
patients	O
(	O
4.8	O
%	O
)	O
with	O
probable	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
among	O
the	O
study	O
population	O
.	O

CTEPH	O
patients	O
with	O
collaterals	O
had	O
higher	O
preoperative	O
pulmonary	O
artery	O
pressures	O
,	O
higher	O
pulmonary	O
vascular	O
resistance	O
(	O
PVR	O
)	O
and	O
lower	O
cardiac	O
index	O
values	O
compared	O
with	O
CTEPH	O
patients	O
without	O
collaterals	O
.	O

However	O
,	O
CTEPH	O
patients	O
with	O
collaterals	O
displayed	O
higher	O
amount	O
of	O
reduction	O
in	O
PVR	O
after	O
PEA	O
compared	O
with	O
patients	O
without	O
collaterals	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
regarding	O
incidence	O
of	O
reperfusion	O
injury	O
or	O
mortality	O
.	O

Conclusion	O
Prevalence	O
of	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
seems	O
to	O
be	O
increased	O
in	O
our	O
CTEPH	O
patients	O
compared	O
with	O
the	O
general	O
population	O
.	O

The	O
presence	O
of	O
coronary	O
artery	O
-	O
pulmonary	O
artery	O
collaterals	O
is	O
often	O
combined	O
with	O
proximal	O
disease	O
with	O
the	O
possibility	O
of	O
increased	O
reduction	O
of	O
PVR	O
after	O
PEA	O
operation	O
.	O

Prognostic	O
implications	O
of	O
the	O
intrinsic	O
molecular	O
subtypes	O
in	O
male	O
breast	O
cancer	O
.	O

Intrinsic	B-P
molecular	I-P
subtyping	I-P
has	O
been	O
widely	O
used	O
in	O
female	O
breast	O
cancer	O
,	O
and	O
it	O
has	O
proven	O
its	O
significance	O
.	O

In	O
this	O
article	O
,	O
we	O
aimed	O
to	O
study	O
the	O
intrinsic	O
subtypes	O
of	O
male	O
breast	O
cancer	O
(	O
MBC	O
)	O
in	O
correlation	O
with	O
clinicopathological	O
features	O
.	O

We	O
retrospectively	O
identified	O
130	O
MBC	O
cases	O
from	O
2004	O
to	O
2013	O
.	O

Intrinsic	O
molecular	O
subtypes	O
were	O
determined	O
by	O
immunohistochemistry	B-P
(	O
IHC	B-P
)	O
.	O

From	O
a	O
total	O
of	O
130	O
MBC	O
cases	O
,	O
45.4	O
%	O
of	O
tumors	O
were	O
luminal	O
A	O
subtype	O
,	O
44.6	O
%	O
were	O
luminal	O
B	O
,	O
5	O
%	O
were	O
HER2	O
positive	O
and	O
5	O
%	O
were	O
triple	O
negative	O
tumors	O
.	O

There	O
were	O
statistically	O
significant	O
differences	O
between	O
different	O
IHC	B-P
intrinsic	O
subtypes	O
regarding	O
tumor	O
size	O
(	O
p=0.001	O
)	O
,	O
estrogen	O
receptor	O
(	O
ER	O
)	O
status	O
(	O
p=0.001	O
)	O
,	O
progesterone	O
receptor	O
(	O
PR	O
)	O
status	O
(	O
p=0.001	O
)	O
,	O
HER2	O
status	O
(	O
p=0.001	O
)	O
and	O
Ki67	O
proliferation	O
index	O
(	O
p=0.001	O
)	O
.	O

The	O
distribution	O
of	O
breast	O
cancer	O
intrinsic	O
subtypes	O
in	O
males	O
is	O
different	O
compared	O
to	O
its	O
female	O
counterpart	O
;	O
however	O
,	O
they	O
do	O
n't	O
seem	O
to	O
give	O
the	O
same	O
prognostic	O
value	O
.	O

Biomagnetic	B-P
monitoring	I-P
of	O
atmospheric	O
pollution	O
:	O
a	O
review	O
of	O
magnetic	O
signatures	O
from	O
biological	O
sensors	O
.	O

Biomagnetic	B-P
monitoring	I-P
of	O
atmospheric	O
pollution	O
is	O
a	O
growing	O
application	O
in	O
the	O
field	O
of	O
environmental	O
magnetism	O
.	O

Particulate	O
matter	O
(	O
PM	O
)	O
in	O
atmospheric	O
pollution	O
contains	O
readily-	O
measurable	O
concentrations	O
of	O
magnetic	O
minerals	O
.	O

Biological	O
surfaces	O
,	O
exposed	O
to	O
atmospheric	O
pollution	O
,	O
accumulate	O
magnetic	O
particles	O
over	O
time	O
,	O
providing	O
a	O
record	O
of	O
location	O
-	O
specific	O
,	O
time-integrated	O
air	O
quality	O
information	O
.	O

This	O
review	O
summarizes	O
current	O
knowledge	O
of	O
biological	O
material	O
(	O
'	O
sensors	O
'	O
)	O
used	O
for	O
biomagnetic	B-P
monitoring	I-P
purposes	O
.	O

Our	O
work	O
addresses	O
:	O
the	O
range	O
of	O
magnetic	O
properties	O
reported	O
for	O
lichens	O
,	O
mosses	O
,	O
leaves	O
,	O
bark	O
,	O
trunk	O
wood	O
,	O
insects	O
,	O
crustaceans	O
,	O
mammal	O
and	O
human	O
tissues	O
;	O
their	O
associations	O
with	O
atmospheric	O
pollutant	O
species	O
(	O
PM	O
,	O
NOx	O
,	O
trace	O
elements	O
,	O
PAHs	O
)	O
;	O
the	O
pros	O
and	O
cons	O
of	O
biomagnetic	B-P
monitoring	I-P
of	O
atmospheric	O
pollution	O
;	O
current	O
challenges	O
for	O
large-scale	O
implementation	O
of	O
biomagnetic	B-P
monitoring	I-P
;	O
and	O
future	O
perspectives	O
.	O

A	O
summary	O
table	O
is	O
presented	O
,	O
with	O
the	O
aim	O
of	O
aiding	O
researchers	O
and	O
policy	O
makers	O
in	O
selecting	O
the	O
most	O
suitable	O
biological	O
sensor	O
for	O
their	O
intended	O
biomagnetic	B-P
monitoring	I-P
purpose	O
.	O

Abnormal	O
metabolic	O
brain	O
network	O
associated	O
with	O
Parkinson	O
's	O
disease	O
:	O
replication	O
on	O
a	O
new	O
European	O
sample	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
specific	O
metabolic	O
brain	O
pattern	O
characteristic	O
for	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
:	O
Parkinson	O
's	O
disease-related	O
pattern	O
(	O
PDRP	O
)	O
,	O
using	O
network	O
analysis	O
of	O
[	B-P
18F	I-P
]	I-P
-fluorodeoxyglucose	I-P
positron	I-P
emission	I-P
tomography	I-P
(	O
FDG-PET	B-P
)	O
brain	O
images	O
in	O
a	O
cohort	O
of	O
Slovenian	O
PD	O
patients	O
.	O

Twenty	O
PD	O
patients	O
(	O
age	O
70.1	O
±	O
7.8	O
years	O
,	O
Movement	O
Disorder	O
Society	O
Unified	O
Parkinson	O
's	O
Disease	O
Motor	O
Rating	O
Scale	O
(	O
MDS-UPDRS-III	O
)	O
38.3	O
±	O
12.2	O
;	O
disease	O
duration	O
4.3	O
±	O
4.1	O
years	O
)	O
and	O
20	O
age	O
-	O
matched	O
normal	O
controls	O
(	O
NCs	O
)	O
underwent	O
FDG-PET	B-P
brain	B-P
imaging	I-P
.	O

An	O
automatic	O
voxel-based	O
scaled	O
subprofile	O
model	O
/	O
principal	O
component	O
analysis	O
(	O
SSM	O
/	O
PCA	O
)	O
was	O
applied	O
to	O
these	O
scans	B-P
for	O
PDRP	O
-	O
Slovenia	O
identification	O
.	O

The	O
pattern	O
was	O
characterized	O
by	O
relative	O
hypermetabolism	O
in	O
pallidum	O
,	O
putamen	O
,	O
thalamus	O
,	O
brain	O
stem	O
,	O
and	O
cerebellum	O
associated	O
with	O
hypometabolism	O
in	O
sensorimotor	O
cortex	O
,	O
posterior	O
parietal	O
,	O
occipital	O
,	O
and	O
frontal	O
cortices	O
.	O

The	O
expression	O
of	O
PDRP	O
-	O
Slovenia	O
discriminated	O
PD	O
patients	O
from	O
NCs	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
correlated	O
positively	O
with	O
patients	O
'	O
clinical	O
score	O
(	O
MDS-UPDRS-III	O
,	O
p	O
=	O
0.03	O
)	O
.	O

Additionally	O
,	O
its	O
topography	O
agrees	O
well	O
with	O
the	O
original	O
PDRP	O
(	O
p	O
<	O
0.001	O
)	O
identified	O
in	O
American	O
cohort	O
of	O
PD	O
patients	O
.	O

We	O
validated	O
the	O
PDRP	O
-	O
Slovenia	O
expression	O
on	O
additional	O
FDG-PET	B-P
scans	B-P
of	O
20	O
PD	O
patients	O
,	O
20	O
NCs	O
,	O
and	O
25	O
patients	O
with	O
atypical	O
parkinsonism	O
(	O
AP	O
)	O
.	O

We	O
confirmed	O
that	O
the	O
expression	O
of	O
PDRP	O
-	O
Slovenia	O
manifests	O
good	O
diagnostic	O
accuracy	O
with	O
specificity	O
and	O
sensitivity	O
of	O
85-90	O
%	O
at	O
optimal	O
pattern	O
expression	O
cutoff	O
for	O
discrimination	O
of	O
PD	O
patients	O
and	O
NCs	O
and	O
is	O
not	O
expressed	O
in	O
AP	O
.	O

PDRP	O
-	O
Slovenia	O
proves	O
to	O
be	O
a	O
robust	O
and	O
reproducible	O
functional	B-P
imaging	I-P
biomarker	O
independent	O
of	O
patient	O
population	O
.	O

It	O
accurately	O
differentiates	O
PD	O
patients	O
from	O
NCs	O
and	O
AP	O
and	O
correlates	O
well	O
with	O
the	O
clinical	O
measure	O
of	O
PD	O
progression	O
.	O

Skin	O
Conductance	O
Responses	O
and	O
Neural	O
Activations	O
During	O
Fear	O
Conditioning	O
and	O
Extinction	O
Recall	O
Across	O
Anxiety	O
Disorders	O
.	O

The	O
fear	O
conditioning	O
and	O
extinction	O
neurocircuitry	O
has	O
been	O
extensively	O
studied	O
in	O
healthy	O
and	O
clinical	O
populations	O
,	O
with	O
a	O
particular	O
focus	O
on	O
posttraumatic	O
stress	O
disorder	O
.	O

Despite	O
significant	O
overlap	O
of	O
symptoms	O
between	O
posttraumatic	O
stress	O
disorder	O
and	O
anxiety	O
disorders	O
,	O
the	O
latter	O
has	O
received	O
less	O
attention	O
.	O

Given	O
that	O
dysregulated	O
fear	O
levels	O
characterize	O
anxiety	O
disorders	O
,	O
examining	O
the	O
neural	O
correlates	O
of	O
fear	O
and	O
extinction	O
learning	O
may	O
shed	O
light	O
on	O
the	O
pathogenesis	O
of	O
underlying	O
anxiety	O
disorders	O
.	O

To	O
investigate	O
the	O
psychophysiological	O
and	O
neural	O
correlates	O
of	O
fear	O
conditioning	O
and	O
extinction	O
recall	O
in	O
anxiety	O
disorders	O
and	O
to	O
document	O
how	O
these	O
features	O
differ	O
as	O
a	O
function	O
of	O
multiple	O
diagnoses	O
or	O
anxiety	O
severity	O
.	O

This	O
investigation	O
was	O
a	O
cross-sectional	O
,	O
case-control	O
,	O
functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
study	O
at	O
an	O
academic	O
medical	O
center	O
.	O

Participants	O
were	O
healthy	O
controls	O
and	O
individuals	O
with	O
at	O
least	O
1	O
of	O
the	O
following	O
anxiety	O
disorders	O
:	O
generalized	O
anxiety	O
disorder	O
,	O
social	O
anxiety	O
disorder	O
,	O
specific	O
phobia	O
,	O
and	O
panic	O
disorder	O
.	O

The	O
study	O
dates	O
were	O
between	O
March	O
2013	O
and	O
May	O
2015	O
.	O

Two-day	O
fear	O
conditioning	O
and	O
extinction	O
paradigm	O
.	O

Skin	O
conductance	O
responses	O
,	O
blood	O
oxygenation	O
level-dependent	O
responses	O
,	O
trait	O
anxiety	O
scores	O
from	O
the	O
State	O
Trait	O
Anxiety	O
Inventory	O
-	O
Trait	O
Form	O
,	O
and	O
functiona	O
l	O
connectivity	O
.	O

This	O
study	O
included	O
21	O
healthy	O
controls	O
(	O
10	O
women	O
)	O
and	O
61	O
individuals	O
with	O
anxiety	O
disorders	O
(	O
36	O
women	O
)	O
.	O

P	O
values	O
reported	O
for	O
the	O
neuroimaging	B-P
results	O
are	O
all	O
familywise	O
error	O
corrected	O
.	O

Skin	O
conductance	O
responses	O
during	O
extinction	O
recall	O
did	O
not	O
differ	O
between	O
individuals	O
with	O
anxiety	O
disorders	O
and	O
healthy	O
controls	O
(	O
ηp2	O
=	O
0.001	O
,	O
P	O
=	O
.79	O
)	O
,	O
where	O
ηp2	O
is	O
partial	O
eta	O
squared	O
.	O

The	O
anxiety	O
group	O
had	O
lower	O
activation	O
of	O
the	O
ventromedial	O
prefrontal	O
cortex	O
(	O
vmPFC	O
)	O
during	O
extinction	O
recall	O
(	O
ηp2	O
=	O
0.178	O
,	O
P	O
=	O
.02	O
)	O
.	O

A	O
similar	O
hypoactive	O
pattern	O
was	O
found	O
during	O
early	O
conditioning	O
(	O
ηp2	O
=	O
0.106	O
,	O
P	O
=	O
.009	O
)	O
.	O

The	O
vmPFC	O
hypoactivation	O
was	O
associated	O
with	O
anxiety	O
symptom	O
severity	O
(	O
r	O
=	O
-0.420	O
,	O
P	O
=	O
.01	O
for	O
conditioning	O
and	O
r	O
=	O
-0.464	O
,	O
P	O
=	O
.004	O
for	O
extinction	O
recall	O
)	O
and	O
the	O
number	O
of	O
co-occuring	O
anxiety	O
disorders	O
diagnosed	O
(	O
ηp2	O
=	O
0.137	O
,	O
P	O
=	O
.009	O
for	O
conditioning	O
and	O
ηp2	O
=	O
0.227	O
,	O
P	O
=	O
.004	O
for	O
extinction	O
recall	O
)	O
.	O

Psychophysiological	O
interaction	O
analyses	O
revealed	O
that	O
the	O
fear	O
network	O
connectivity	O
differed	O
between	O
healthy	O
controls	O
and	O
the	O
anxiety	O
group	O
during	O
fear	O
learning	O
(	O
ηp2	O
range	O
between	O
0.088	O
and	O
0.176	O
and	O
P	O
range	O
between	O
0.02	O
and	O
0.003	O
)	O
and	O
extinction	O
recall	O
(	O
ηp2	O
range	O
between	O
0.111	O
and	O
0.235	O
and	O
P	O
range	O
between	O
0.02	O
and	O
0.002	O
)	O
.	O

Despite	O
no	O
skin	O
conductance	O
response	O
group	O
differences	O
during	O
extinction	O
recall	O
,	O
brain	O
activation	O
patterns	O
between	O
anxious	O
and	O
healthy	O
individuals	O
differed	O
.	O

These	O
findings	O
encourage	O
future	O
studies	O
to	O
examine	O
the	O
conditions	O
longitudinally	O
and	O
in	O
the	O
context	O
of	O
treatment	O
trials	O
to	O
improve	O
and	O
guide	O
therapeutics	O
via	O
advanced	O
neurobiological	O
understanding	O
of	O
each	O
disorder	O
.	O

Data	O
set	O
of	O
interactomes	O
and	O
metabolic	O
pathways	O
of	O
proteins	O
differentially	O
expressed	O
in	O
brains	O
with	O
Alzheimer׳s	O
disease	O
.	O

Alzheimer׳s	O
disease	O
is	O
one	O
of	O
the	O
main	O
causes	O
of	O
dementia	O
in	O
the	O
elderly	O
and	O
its	O
frequency	O
is	O
on	O
the	O
rise	O
worldwide	O
.	O

It	O
is	O
considered	O
the	O
result	O
of	O
complex	O
interactions	O
between	O
genetic	O
and	O
environmental	O
factors	O
,	O
being	O
many	O
of	O
them	O
unknown	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
dire	O
necessity	O
for	O
the	O
identification	O
of	O
novel	O
molecular	O
players	O
for	O
the	O
understanding	O
of	O
this	O
disease	O
.	O

In	O
this	O
data	O
article	O
we	O
determined	O
the	O
protein	O
expression	O
profiles	O
of	O
whole	O
protein	O
extracts	O
from	O
cortex	O
regions	O
of	O
brains	O
from	O
patients	O
with	O
Alzheimer׳s	O
disease	O
in	O
comparison	O
to	O
a	O
normal	O
brain	O
.	O

We	O
identified	O
721	O
iTRAQ-labeled	O
polypeptides	O
with	O
more	O
than	O
95	O
%	O
in	O
confidence	O
.	O

We	O
analyzed	O
all	O
proteins	O
that	O
changed	O
in	O
their	O
expression	O
level	O
and	O
located	O
them	O
in	O
the	O
KEGG	O
metabolic	O
pathways	O
,	O
as	O
well	O
as	O
in	O
the	O
mitochondrial	O
complexes	O
of	O
the	O
electron	O
transport	O
chain	O
and	O
ATP	O
synthase	O
.	O

In	O
addition	O
,	O
we	O
analyzed	O
the	O
over-	O
and	O
sub-expressed	O
polypeptides	O
through	O
IPA	O
software	O
,	O
specifically	O
Core	O
I	O
and	O
Biomarkers	O
I	O
modules	O
.	O

Data	O
in	O
this	O
article	O
is	O
related	O
to	O
the	O
research	O
article	O
``	O
Identification	O
of	O
proteins	O
that	O
are	O
differentially	O
expressed	O
in	O
brains	O
with	O
Alzheimer	O
's	O
disease	O
using	O
iTRAQ	B-P
labeling	I-P
and	O
tandem	O
mass	O
spectrometry	O
``	O
(	O
Minjarez	O
et	O
al.	O
,	O
2016	O
)	O
[	O
1	O
]	O
.	O

Preclinical	O
fibrinolysis	O
in	O
patients	O
with	O
ST-segment	O
elevation	O
myocardial	O
infarction	O
in	O
a	O
rural	O
region	O
.	O

In	O
the	O
current	O
guidelines	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
ST-segment	O
elevation	O
myocardial	O
infarction	O
(	O
STEMI	O
)	O
,	O
the	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
recommends	O
preclinical	O
fibrinolysis	O
as	O
a	O
reperfusion	O
therapy	O
if	O
,	O
due	O
to	O
long	O
transportation	O
times	O
,	O
no	O
cardiac	O
catheterisation	O
is	O
available	O
within	O
90-120	O
min	O
.	O

However	O
,	O
there	O
is	O
little	O
remaining	O
in-depth	O
expertise	O
in	O
this	O
method	O
because	O
fibrinolysis	O
is	O
presently	O
only	O
rarely	O
indicated	O
.	O

In	O
a	O
rural	O
area	O
in	O
southwestern	O
Germany	O
,	O
where	O
an	O
emergency	O
primary	O
percutaneous	O
coronary	O
intervention	O
was	O
not	O
routinely	O
available	O
within	O
90-120	O
min	O
,	O
156	O
STEMI	O
patients	O
underwent	O
fibrinolysis	O
with	O
the	O
plasminogen	O
activator	O
reteplase	O
,	O
performed	O
by	O
trained	O
emergency	O
physicians	O
.	O

The	O
practicality	O
of	O
the	O
treatment	O
,	O
as	O
well	O
as	O
complications	O
and	O
the	O
mortality	O
of	O
the	O
patients	O
in	O
the	O
preclinical	O
phase	O
until	O
arrival	O
at	O
the	O
hospital	O
,	O
were	O
retrospectively	O
studied	O
.	O

The	O
mean	O
time	O
from	O
onset	O
of	O
the	O
symptoms	O
to	O
first	O
medical	O
contact	O
was	O
114	O
±	O
116	O
min	O
.	O

The	O
mean	O
interval	O
to	O
the	O
start	O
of	O
fibrinolysis	O
of	O
13.5	O
±	O
6.4	O
min	O
was	O
within	O
the	O
30	O
min	O
mandated	O
by	O
the	O
ESC	O
.	O

Patients	O
with	O
inferior	O
STEMI	O
represented	O
the	O
largest	O
subgroup	O
.	O

Occurring	O
in	O
39	O
cases	O
(	O
25	O
%	O
)	O
,	O
complications	O
due	O
to	O
infarction	O
were	O
relatively	O
common	O
during	O
the	O
prehospital	O
phase	O
,	O
including	O
15	O
cases	O
(	O
9.6	O
%	O
)	O
of	O
cardiogenic	O
shock	O
,	O
but	O
in	O
all	O
cases	O
the	O
complications	O
were	O
manageable	O
.	O

No	O
patient	O
died	O
before	O
arrival	O
at	O
the	O
hospital	O
.	O

As	O
lysis	O
-	O
associated	O
adverse	O
effects	O
,	O
merely	O
two	O
uncomplicated	O
mucosal	O
haemorrhages	O
and	O
one	O
case	O
of	O
mild	O
allergic	O
skin	O
reactions	O
were	O
seen	O
.	O

In	O
emergency	O
situations	O
with	O
long	O
transportation	O
times	O
to	O
the	O
nearest	O
suitable	O
cardiac	O
catheterisation	O
laboratory	O
,	O
preclinical	O
fibrinolysis	O
in	O
STEMI	O
still	O
represents	O
a	O
workable	O
method	O
.	O

Success	O
of	O
this	O
strategy	O
requires	O
particularly	O
strong	O
training	O
of	O
the	O
emergency	O
physicians	O
in	O
ECG	B-P
and	O
lysis	O
therapy	O
,	O
and	O
co-operation	O
with	O
nearby	O
cardiac	O
centres	O
.	O

Sorting	O
nexin-4	O
regulates	O
β-amyloid	O
production	O
by	O
modulating	O
β-site-activating	O
cleavage	O
enzyme-1	O
.	O

Amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
is	O
cleaved	O
by	O
β-site	O
amyloid	O
precursor	O
protein-cleaving	O
enzyme	O
1	O
(	O
BACE1	O
)	O
to	O
produce	O
β-amyloid	O
(	O
Aβ	O
)	O
,	O
a	O
critical	O
pathogenic	O
peptide	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Aβ	O
generation	O
can	O
be	O
affected	O
by	O
the	O
intracellular	O
trafficking	O
of	O
APP	O
or	O
its	O
related	O
secretases	O
,	O
which	O
is	O
thus	O
important	O
to	O
understanding	O
its	O
pathological	O
alterations	O
.	O

Although	O
sorting	O
nexin	O
(	O
SNX	O
)	O
family	O
proteins	O
regulate	O
this	O
trafficking	O
,	O
the	O
relevance	O
and	O
role	O
of	O
sorting	O
nexin-4	O
(	O
SNX4	O
)	O
regarding	O
AD	O
has	O
not	O
been	O
studied	O
yet	O
.	O

In	O
this	O
study	O
,	O
human	O
brain	O
tissue	O
and	O
APP	O
/	O
PS1	O
mouse	O
brain	O
tissue	O
were	O
used	O
to	O
check	O
the	O
disease	O
relevance	O
of	O
SNX4	O
.	O

To	O
investigate	O
the	O
role	O
of	O
SNX4	O
in	O
AD	O
pathogenesis	O
,	O
several	O
experiments	O
were	O
done	O
,	O
such	O
as	O
coimmunoprecipitation	B-P
,	O
Western	O
blotting	O
,	O
immunohistochemistry	B-P
,	O
and	O
gradient	B-P
fractionation	I-P
.	O

We	O
found	O
that	O
SNX4	O
protein	O
levels	O
changed	O
in	O
the	O
brains	O
of	O
patients	O
with	O
AD	O
and	O
of	O
AD	O
model	O
mice	O
.	O

Overexpression	O
of	O
SNX4	O
significantly	O
increased	O
the	O
levels	O
of	O
BACE1	O
and	O
Aβ	O
.	O

Downregulation	O
of	O
SNX4	O
had	O
the	O
opposite	O
effect	O
.	O

SNX4	O
interacts	O
with	O
BACE1	O
and	O
prevents	O
BACE1	O
trafficking	O
to	O
the	O
lysosomal	O
degradation	O
system	O
,	O
resulting	O
in	O
an	O
increased	O
half-life	O
of	O
BACE1	O
and	O
increased	O
production	O
of	O
Aβ	O
.	O

We	O
show	O
that	O
SNX4	O
regulates	O
BACE1	O
trafficking	O
.	O

Our	O
findings	O
suggest	O
novel	O
therapeutic	O
implications	O
of	O
modulating	O
SNX4	O
to	O
regulate	O
BACE1	O
-mediated	O
β-processing	O
of	O
APP	O
and	O
subsequent	O
Aβ	O
generation	O
.	O

In	O
silico	O
data	O
analyses	O
of	O
recombinases	O
GdDMC1A	O
and	O
GdDMC1B	O
from	O
Giardia	O
duodenalis	O
.	O

Giardia	O
duodenalis	O
is	O
a	O
worldwide	O
protozoa	O
known	O
causing	O
diarrhea	O
in	O
all	O
vertebrates	O
,	O
humans	O
among	O
these	O
.	O

Homologous	O
recombination	O
is	O
a	O
mechanism	O
that	O
provides	O
genomic	O
stability	O
.	O

Two	O
putative	O
recombinases	O
were	O
identified	O
in	O
G.	O
duodenalis	O
genome	O
:	O
GdDMC1A	O
and	O
GdDMC1B	O
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
the	O
identification	O
of	O
conserved	O
domains	O
in	O
GdDMC1A	O
and	O
GdDMC1B	O
,	O
such	O
as	O
:	O
DNA	O
binding	O
domains	O
(	O
Helix-turn-helix	O
motif	O
,	O
loops	O
1	O
and	O
2	O
)	O
and	O
an	O
ATPcap	O
and	O
Walker	O
A	O
and	O
B	O
motifs	O
associated	O
with	O
ATP	O
binding	O
and	O
hydrolysis	O
,	O
phylogenetic	O
analyses	O
among	O
assemblages	O
and	O
three-dimensional	O
structure	O
modeling	O
of	O
these	O
recombinases	O
using	O
bioinformatics	O
tools	O
.	O

Also	O
,	O
experimental	O
data	O
is	O
described	O
about	O
LD50	O
determination	B-P
for	O
ionizing	O
radiation	O
in	O
trophozoites	O
of	O
G.	O
duodenalis	O
.	O

Additionally	O
,	O
as	O
recombinases	O
,	O
GdDMC1A	O
and	O
GdDMC1B	O
were	O
used	O
to	O
rescue	O
a	O
defective	O
Saccharomyces	O
cerevisiae	O
Δ	O
rad51	O
strain	O
under	O
genotoxic	O
conditions	O
and	O
data	O
is	O
described	O
.	O

The	O
data	O
described	O
here	O
are	O
related	O
to	O
the	O
research	O
article	O
entitled	O
``	O
Characterization	O
of	O
recombinase	O
DMC1B	O
and	O
its	O
functional	O
role	O
as	O
Rad51	O
in	O
DNA	O
damage	O
repair	O
in	O
Giardia	O
duodenalis	O
trophozoites	O
``	O
(	O
Torres-Huerta	O
et	O
al.	O
,	O
)	O
[	O
1	O
]	O
.	O

Adequacy	O
criteria	O
for	O
thyroid	B-P
FNA	I-P
evaluated	O
by	O
ThinPrep	B-P
slides	I-P
only	O
.	O

Adequacy	O
criteria	O
for	O
thyroid	B-P
fine-needle	I-P
aspiration	I-P
(	O
FNA	B-P
)	O
recommended	O
by	O
The	O
Bethesda	B-P
System	I-P
for	I-P
Reporting	I-P
Thyroid	I-P
Cytopathology	I-P
(	O
TBS	B-P
)	O
were	O
developed	O
with	O
smears	B-P
,	O
but	O
they	O
are	O
commonly	O
applied	O
to	O
ThinPreps	B-P
(	O
TPs	B-P
)	O
.	O

This	O
study	O
evaluated	O
adequacy	O
in	O
TPs	B-P
at	O
different	O
diagnostic	O
thresholds	O
.	O

All	O
FNA	B-P
procedures	I-P
performed	O
between	O
2010	O
and	O
2015	O
with	O
matched	O
surgical	O
specimens	O
were	O
analyzed	O
.	O

Cell	B-P
counts	I-P
and	O
cytological	O
features	O
were	O
evaluated	O
in	O
all	O
initially	O
nondiagnostic	O
(	O
ND	O
)	O
cases	O
.	O

ND	O
cases	O
were	O
reclassified	O
into	O
TBS	B-P
categories	O
by	O
2	O
pathologists	O
,	O
and	O
the	O
results	O
were	O
compared	O
with	O
surgical	O
outcomes	O
.	O

One	O
hundred	O
forty-six	O
of	O
the	O
151	O
cases	O
initially	O
classified	O
as	O
ND	O
were	O
available	O
for	O
review	O
,	O
and	O
they	O
had	O
a	O
mean	O
cell	B-P
count	I-P
of	O
60.5	O
(	O
standard	O
deviation	O
,	O
71.4	O
)	O
.	O

Interobserver	O
agreement	O
on	O
the	O
reclassification	O
of	O
ND	O
cases	O
was	O
moderate	O
(	O
k	O
=	O
0.57	O
)	O
,	O
and	O
consensus	O
yielded	O
48	O
ND	O
cases	O
(	O
33	O
%	O
)	O
,	O
72	O
benign	O
cases	O
(	O
49	O
%	O
)	O
,	O
24	O
cases	O
of	O
atypia	O
of	O
undetermined	O
significance	O
(	O
16	O
%	O
)	O
,	O
and	O
2	O
cases	O
suspicious	O
for	O
malignancy	O
(	O
1	O
%	O
)	O
.	O

Lowering	O
the	O
diagnostic	O
threshold	O
to	O
any	O
follicular	O
cells	O
yielded	O
a	O
sensitivity	O
of	O
92	O
%	O
,	O
a	O
specificity	O
of	O
60	O
%	O
,	O
a	O
positive	O
predictive	O
value	O
of	O
59	O
%	O
,	O
a	O
negative	O
predictive	O
value	O
of	O
92	O
%	O
,	O
and	O
a	O
false-negative	O
rate	O
of	O
7.7	O
%	O
,	O
whereas	O
the	O
values	O
for	O
the	O
initially	O
diagnostic	O
cases	O
were	O
93	O
%	O
,	O
58	O
%	O
,	O
59	O
%	O
,	O
93	O
%	O
,	O
and	O
7.7	O
%	O
,	O
respectively	O
.	O

Including	O
cases	O
with	O
>	O
60	O
cells	O
but	O
lacking	O
6	O
groups	O
containing	O
at	O
least	O
10	O
cells	O
did	O
not	O
affect	O
test	B-P
performance	I-P
.	O

Nuclear	O
enlargement	O
,	O
pallor	O
,	O
grooves	O
,	O
and	O
the	O
presence	O
of	O
histiocytoid	O
cells	O
in	O
initially	O
ND	O
FNA	B-P
correlated	O
with	O
malignancy	O
.	O

In	O
thyroid	B-P
FNA	I-P
examined	O
with	O
TP	B-P
only	O
,	O
lowering	O
the	O
adequacy	O
threshold	O
and	O
eliminating	O
the	O
requirement	O
of	O
6	O
groups	O
of	O
at	O
least	O
10	O
cells	O
did	O
not	O
significantly	O
affect	O
test	B-P
performance	I-P
if	O
cytological	O
features	O
associated	O
with	O
malignancy	O
were	O
absent	O
.	O

Cancer	O
Cytopathol	O
2017	O
.	O

©	O
2017	O
American	O
Cancer	O
Society	O
.	O

Advanced	O
interlocking	O
systems	O
to	O
improve	O
heavy	O
-	O
load-bearing	O
characteristics	O
of	O
flexible	O
intramedullary	O
nailing	O
.	O

Flexible	O
intramedullary	O
nailing	O
(	O
FIN	O
)	O
is	O
a	O
minimally	O
invasive	O
and	O
widespread	O
standard	O
method	O
for	O
osteosynthesis	O
of	O
pediatric	O
long	O
bone	O
fractures	O
.	O

In	O
the	O
case	O
of	O
unstable	O
fractures	O
of	O
the	O
lower	O
extremity	O
,	O
interlocking	O
systems	O
need	O
to	O
be	O
used	O
to	O
prevent	O
axial	O
shortening	O
and	O
subsequent	O
perforation	O
of	O
the	O
nail	O
at	O
its	O
insertion	O
site	O
.	O

In	O
the	O
present	O
study	O
,	O
four	O
different	O
screw	O
-fixed	O
interlocking	O
systems	O
for	O
FINs	O
(	O
Hofer	O
TwinPlug	O
with	O
two	O
3-mm	O
titanium	O
interlocking	O
screws	O
,	O
Hofer	O
FixPlug	O
with	O
3-mm	O
titanium	O
interlocking	O
screw	O
,	O
Hofer	O
Plug	O
with	O
3.5-mm	O
titanium	O
interlocking	O
screw	O
,	O
and	O
Hofer	O
Plug	O
with	O
3-mm	O
titanium	O
interlocking	O
screw	O
)	O
in	O
comparison	O
with	O
the	O
commonly	O
used	O
Ender	O
stainless	O
steel	O
nails	O
(	O
locked	O
with	O
3.5-mm	O
screw	O
)	O
were	O
experimentally	O
investigated	O
in	O
cadaveric	O
lamb	O
tibiae	O
,	O
regarding	O
their	O
load	O
characteristics	O
and	O
failure	O
modes	O
in	O
the	O
case	O
of	O
heavy	O
loading	O
.	O

The	O
specimens	O
were	O
subjected	O
to	O
sequential	O
axial	O
cyclic	O
loading	O
of	O
5000	O
cycles	O
with	O
stepwise	O
increase	O
of	O
the	O
load	O
amplitude	O
until	O
failure	O
.	O

Migration	O
of	O
locking	O
screws	O
and	O
internal	O
damage	O
of	O
bone	O
tissue	O
was	O
quantified	O
by	O
micro-computed	B-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
imaging	I-P
.	O

Ender	O
nails	O
failed	O
on	O
average	O
at	O
a	O
peak	O
load	O
of	O
800	O
N	O
,	O
TwinPlugs	O
at	O
1367	O
N	O
,	O
FixPlugs	O
at	O
1222	O
N	O
,	O
Plugs	O
3.5mm	O
at	O
1225	O
N	O
and	O
Plugs	O
3.0mm	O
at	O
971	O
N.	O
TwinPlugs	O
,	O
FixPlugs	O
,	O
and	O
Plugs	O
3.5mm	O
failed	O
in	O
a	O
slow	O
manner	O
over	O
several	O
hundred	O
loading	O
cycles	O
,	O
whereas	O
Ender	O
nails	O
and	O
Plugs	O
3.0mm	O
exhibited	O
abrupt	O
failure	O
without	O
any	O
prior	O
indication	O
.	O

Our	O
results	O
confirm	O
that	O
axial	O
stability	O
of	O
FIN	O
can	O
be	O
further	O
improved	O
by	O
screw	O
-fixed	O
plugs	O
by	O
simultaneously	O
avoiding	O
shortcomings	O
of	O
an	O
eye-locked	O
system	O
,	O
which	O
the	O
Ender	O
nails	O
are	O
.	O

Considering	O
biomechanical	O
results	O
,	O
plug	O
interlocking	O
systems	O
with	O
3.5-mm	O
screws	O
should	O
be	O
favored	O
over	O
conventional	O
Ender	O
nails	O
and	O
plugs	O
with	O
3-mm	O
screws	O
.	O

Effects	O
of	O
Transplanted	O
Human	O
Cord	O
Blood	O
-	O
Mononuclear	O
Cells	O
on	O
Pulmonary	O
Hypertension	O
in	O
Immunodeficient	O
Mice	O
and	O
Their	O
Distribution	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
human	O
umbilical	O
cord	O
blood	O
-derived	O
mononuclear	O
cell	O
(	O
hUCB	O
-	O
MNC	O
)	O
transplantation	O
on	O
pulmonary	O
hypertension	O
(	O
PH	O
)	O
induced	O
by	O
monocrotaline	O
(	O
MCT	O
)	O
in	O
immunodeficient	O
mice	O
and	O
their	O
distribution	O
.	O

MCT	O
was	O
administered	O
to	O
BALB/c	O
Slc-nu/nu	O
mice	O
,	O
and	O
PH	O
was	O
induced	O
in	O
mice	O
4	O
weeks	O
later	O
.	O

Fresh	O
hUCB	O
-	O
MNCs	O
harvested	O
from	O
a	O
human	O
donor	O
after	O
her	O
delivery	O
were	O
injected	O
intravenously	O
into	O
those	O
PH	O
mice	O
.	O

The	O
medial	O
thickness	O
of	O
pulmonary	O
arterioles	O
,	O
ratio	O
of	O
right	O
ventricular	O
to	O
septum	O
plus	O
left	O
ventricular	O
weight	O
(	O
RV	O
/	O
S	O
+	O
LV	O
)	O
,	O
and	O
ratio	O
of	O
acceleration	O
time	O
to	O
ejection	O
time	O
of	O
pulmonary	O
blood	O
flow	O
waveform	O
(	O
AT	O
/	O
ET	O
)	O
were	O
determined	O
4	O
weeks	O
after	O
hUCB	O
-	O
MNC	O
transplantation	O
.	O

To	O
reveal	O
the	O
incorporation	O
into	O
the	O
lung	O
,	O
CMTMR	O
-	O
labeled	O
hUCB	O
-	O
MNCs	O
were	O
observed	O
in	O
the	O
lung	O
by	O
fluorescent	B-P
microscopy	I-P
.	O

DiR-labeled	O
hUCB	O
-	O
MNCs	O
were	O
detected	O
in	O
the	O
lung	O
and	O
other	O
organs	O
by	O
bioluminescence	O
images	O
.	O

Medial	O
thickness	O
,	O
RV	O
/	O
S	O
+	O
LV	O
and	O
AT	O
/	O
ET	O
were	O
significantly	O
improved	O
4	O
weeks	O
after	O
hUCB	O
-	O
MNC	O
transplantation	O
compared	O
with	O
those	O
in	O
mice	O
without	O
hUCB	O
-	O
MNC	O
transplantation	O
.	O

CMTMR	O
-	O
positive	O
hUCB	O
-	O
MNCs	O
were	O
observed	O
in	O
the	O
lung	O
3	O
hours	O
after	O
transplantation	O
.	O

Bioluminescence	O
signals	O
were	O
detected	O
more	O
strongly	O
in	O
the	O
lung	O
than	O
in	O
other	O
organs	O
for	O
24	O
hours	O
after	O
transplantation	O
.	O

The	O
results	O
indicate	O
that	O
hUCB	O
-	O
MNCs	O
are	O
incorporated	O
into	O
the	O
lung	O
early	O
after	O
hUCB	O
-	O
MNC	O
transplantation	O
and	O
improve	O
MCT	O
-	O
induced	O
PH	O
.	O

J.	O
Med	O
.	O

Invest	O
.	O

64	O
:	O
43-49	O
,	O
February	O
,	O
2017	O
.	O

Association	O
of	O
Radiomics	O
and	O
Metabolic	O
Tumor	O
Volumes	O
in	O
Radiation	O
Treatment	O
of	O
Glioblastoma	O
Multiforme	O
.	O

To	O
build	O
a	O
framework	O
for	O
investigation	O
of	O
the	O
associations	O
between	O
imaging	B-P
,	O
clinical	O
target	O
volumes	O
(	O
CTVs	O
)	O
,	O
and	O
metabolic	O
tumor	O
volumes	O
(	O
MTVs	O
)	O
features	O
for	O
better	O
understanding	O
of	O
the	O
underlying	O
information	O
in	O
the	O
CTVs	O
and	O
dependencies	O
between	O
these	O
volumes	O
.	O

High-throughput	O
extraction	O
of	O
imaging	B-P
and	O
metabolomic	O
quantitative	O
features	O
from	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
and	O
magnetic	B-P
resonance	I-P
spectroscopic	I-P
imaging	I-P
of	O
glioblastoma	O
multiforme	O
(	O
GBM	O
)	O
results	O
in	O
tens	O
of	O
variables	O
per	O
patient	O
.	O

In	O
radiation	O
therapy	O
of	O
GBM	O
the	O
relevant	O
metabolic	O
tumor	O
volumes	O
(	O
MTVs	O
)	O
are	O
related	O
to	O
aberrant	O
levels	O
of	O
N-acetyl	O
aspartate	O
(	O
NAA	O
)	O
and	O
choline	O
(	O
Cho	O
)	O
.	O

The	O
corresponding	O
clinical	O
target	O
volumes	O
(	O
CTVs	O
)	O
for	O
radiation	O
therapy	O
are	O
based	O
on	O
contrast-enhanced	B-P
T1-weighted	I-P
(	O
CE-T1w	B-P
)	O
and	O
T2-weighted	B-P
(	I-P
T2w	I-P
)	I-P
/fluid-attenuated	I-P
inversion	I-P
recovery	I-P
MRI	I-P
.	O

Necrotic	O
portions	O
,	O
enhancing	O
lesion	O
,	O
and	O
edema	O
were	O
manually	O
contoured	O
on	O
CE-T1w	O
/	O
T2w	O
images	O
for	O
17	O
GBM	O
patients	O
.	O

Clinical	O
target	O
volumes	O
and	O
MTVs	O
for	O
NAA	O
(	O
MTVNAA	O
)	O
and	O
Cho	O
(	O
MTVCho	O
)	O
were	O
constructed	O
.	O

Imaging	B-P
and	O
metabolic	O
features	O
related	O
to	O
size	O
,	O
shape	O
,	O
and	O
signal	O
intensities	O
of	O
the	O
volumes	O
were	O
extracted	O
.	O

Tumors	O
were	O
also	O
scored	O
categorically	O
for	O
10	O
semantic	O
imaging	O
traits	O
by	O
a	O
neuroradiologist	O
.	O

All	O
features	O
were	O
investigated	O
for	O
redundancy	O
.	O

Two-way	O
correlations	O
between	O
imaging	O
and	O
CTVs	O
/	O
MTVs	O
features	O
were	O
visualized	O
as	O
heatmaps	O
.	O

Associations	O
between	O
MTVNAA	O
and	O
MTVCho	O
and	O
imaging	O
features	O
were	O
studied	O
using	O
Spearman	O
correlation	O
.	O

Forty-eight	O
imaging	O
features	O
were	O
extracted	O
per	O
patient	O
.	O

Half	O
of	O
the	O
imaging	O
traits	O
were	O
replaced	O
with	O
automatically	O
extracted	O
continuous	O
variables	O
.	O

Twenty	O
features	O
were	O
extracted	O
from	O
CTVs	O
and	O
MTVs	O
.	O

A	O
series	O
of	O
semantic	O
imaging	O
traits	O
were	O
replaced	O
with	O
automatically	O
extracted	O
continuous	O
variables	O
.	O

There	O
were	O
multiple	O
(	O
22	O
)	O
significant	O
correlations	O
of	O
imaging	O
measures	O
with	O
CTVs	O
/	O
MTVNAA	O
,	O
whereas	O
there	O
were	O
only	O
6	O
with	O
CTVs	O
/	O
MTVCho	O
.	O

A	O
framework	O
for	O
investigation	O
of	O
codependencies	O
between	O
MRI	B-P
and	O
magnetic	B-P
resonance	I-P
spectroscopic	I-P
imaging	I-P
radiomic	O
features	O
and	O
CTVs	O
/	O
MTVs	O
has	O
been	O
established	O
.	O

The	O
MTV	O
for	O
NAA	O
was	O
found	O
to	O
be	O
closely	O
associated	O
with	O
MRI	B-P
volumes	O
,	O
whereas	O
very	O
few	O
imaging	O
features	O
were	O
related	O
to	O
MTVCho	O
,	O
indicating	O
that	O
Cho	O
provides	O
additional	O
information	O
to	O
imaging	B-P
.	O

Toxicity	O
assessment	O
of	O
water-accommodated	O
fractions	O
from	O
two	O
different	O
oils	O
using	O
a	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
embryo	O
-	O
larval	O
bioassay	B-P
with	O
a	O
multilevel	O
approach	O
.	O

Petroleum	O
compounds	O
from	O
chronic	O
discharges	O
and	O
oil	O
spills	O
represent	O
an	O
important	O
source	O
of	O
environmental	O
pollution	O
.	O

To	O
better	O
understand	O
the	O
deleterious	O
effects	O
of	O
these	O
compounds	O
,	O
the	O
toxicity	O
of	O
water-accommodated	O
fractions	O
(	O
WAF	O
)	O
from	O
two	O
different	O
oils	O
(	O
brut	O
Arabian	O
Light	O
and	O
Erika	O
heavy	O
fuel	O
oils	O
)	O
were	O
used	O
in	O
this	O
study	O
.	O

Zebrafish	O
embryos	O
(	O
Danio	O
rerio	O
)	O
were	O
exposed	O
during	O
96	O
h	O
at	O
three	O
WAF	O
concentrations	O
(	O
1	O
,	O
10	O
and	O
100	O
%	O
for	O
Arabian	O
Light	O
and	O
10	O
,	O
50	O
and	O
100	O
%	O
for	O
Erika	O
)	O
in	O
order	O
to	O
cover	O
a	O
wide	O
range	O
of	O
polycyclic	O
aromatic	O
hydrocarbon	O
(	O
PAH	O
)	O
concentrations	O
,	O
representative	O
of	O
the	O
levels	O
found	O
after	O
environmental	O
oil	O
spills	O
.	O

Several	O
endpoints	O
were	O
recorded	O
at	O
different	O
levels	O
of	O
biological	O
organization	O
,	O
including	O
lethal	O
endpoints	O
,	O
morphological	O
abnormalities	O
,	O
photomotor	O
behavioral	O
responses	O
,	O
cardiac	O
activity	O
,	O
DNA	O
damage	O
and	O
exposure	O
level	O
measurements	O
(	O
EROD	O
activity	O
,	O
cyp1a	O
and	O
PAH	O
metabolites	O
)	O
.	O

Neither	O
morphological	O
nor	O
behavioral	O
or	O
physiological	O
alterations	O
were	O
observed	O
after	O
exposure	O
to	O
Arabian	O
Light	O
fractions	O
.	O

In	O
contrast	O
,	O
the	O
Erika	O
fractions	O
led	O
a	O
high	O
degree	O
of	O
toxicity	O
in	O
early	O
life	O
stages	O
of	O
zebrafish	O
.	O

Despite	O
of	O
defense	O
mechanisms	O
induced	O
by	O
oil	O
,	O
acute	O
toxic	O
effects	O
have	O
been	O
recorded	O
including	O
mortality	O
,	O
delayed	O
hatching	O
,	O
high	O
rates	O
of	O
developmental	O
abnormalities	O
,	O
disrupted	O
locomotor	O
activity	O
and	O
cardiac	O
failures	O
at	O
the	O
highest	O
PAH	O
concentrations	O
(	O
∑TPAHs=257,029±47,231ng·L	O
(	O
-1	O
)	O
)	O
.	O

Such	O
differences	O
in	O
toxicity	O
are	O
likely	O
related	O
to	O
the	O
oil	O
composition	O
.	O

The	O
use	O
of	O
developing	O
zebrafish	O
is	O
a	O
good	O
tool	O
to	O
identify	O
wide	O
range	O
of	O
detrimental	O
effects	O
and	O
elucidate	O
their	O
underlying	O
foundations	O
.	O

Our	O
work	O
highlights	O
once	O
more	O
,	O
the	O
cardiotoxic	O
action	O
(	O
and	O
potentially	O
neurotoxic	O
)	O
of	O
petroleum	O
-related	O
PAHs	O
.	O

Modeling	O
adsorption	B-P
of	O
brominated	O
,	O
chlorinated	O
and	O
mixed	O
bromo	O
/	O
chloro-dibenzo-p-dioxins	O
on	O
C60	O
fullerene	O
using	O
Nano-QSPR	O
.	O

Many	O
technological	O
implementations	O
in	O
the	O
field	O
of	O
nanotechnology	O
have	O
involved	O
carbon	O
nanomaterials	O
,	O
including	O
fullerenes	O
such	O
as	O
the	O
buckminsterfullerene	O
,	O
C60	O
.	O

The	O
unprecedented	O
properties	O
of	O
such	O
organic	O
nanomaterials	O
(	O
in	O
particular	O
their	O
large	O
surface	O
area	O
)	O
gained	O
extensive	O
attention	O
for	O
their	O
potential	O
use	O
as	O
organic	O
pollutant	O
sorbents	O
.	O

Sorption	O
interactions	O
can	O
be	O
very	O
hazardous	O
and	O
useful	O
at	O
the	O
same	O
time	O
.	O

This	O
work	O
investigates	O
the	O
influence	O
of	O
halogenation	O
by	O
bromine	O
and/or	O
chlorine	O
in	O
dibenzo-p-dioxins	O
on	O
their	O
sorption	O
ability	O
on	O
the	O
C60	O
fullerene	O
surface	O
.	O

Halogenated	O
dibenzo-p-dioxins	O
(	O
PXDDs	O
,	O
where	O
X	O
=	O
Br	O
or	O
Cl	O
)	O
are	O
ever-present	O
in	O
the	O
environment	O
and	O
accidently	O
produced	O
in	O
many	O
technological	O
processes	O
in	O
only	O
approximately	O
known	O
quantities	O
.	O

If	O
all	O
combinatorial	O
Br	O
and/or	O
Cl	O
dioxin	O
substitution	O
possibilities	O
are	O
present	O
in	O
the	O
environment	O
,	O
the	O
experimental	O
characterization	O
and	O
investigation	O
of	O
sorbent	O
effectiveness	O
is	O
more	O
than	O
difficult	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
developed	O
a	O
quantitative	O
structure-property	O
relationship	O
(	O
QSPR	O
)	O
model	O
(	O
R	O
(	O
2	O
)	O
=	O
0.998	O
)	O
,	O
predicting	O
the	O
adsorption	B-P
energy	O
[	O
kcal/mol	O
]	O
for	O
1,701	O
PXDDs	O
adsorbed	O
on	O
C60	O
(	O
PXDD	O
@	O
C60	O
)	O
.	O

Based	O
on	O
the	O
QSPR	O
model	O
reported	O
herein	O
,	O
we	O
concluded	O
that	O
the	O
lowest	O
energy	O
PXDD	O
@	O
C60	O
complexes	O
are	O
those	O
that	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
considers	O
to	O
be	O
less	O
dangerous	O
with	O
respect	O
to	O
the	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
toxicity	O
mechanism	O
.	O

Therefore	O
,	O
the	O
effectiveness	O
of	O
fullerenes	O
as	O
sorbent	O
agents	O
may	O
be	O
underestimated	O
as	O
sorption	O
could	O
be	O
less	O
effective	O
for	O
toxic	O
congeners	O
than	O
previously	O
believed	O
.	O

Systems	O
Immunology	O
of	O
Diabetes	O
-	O
Tuberculosis	O
Comorbidity	O
Reveals	O
Signatures	O
of	O
Disease	O
Complications	O
.	O

Comorbid	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
increases	O
tuberculosis	O
(	O
TB	O
)	O
risk	O
and	O
adverse	O
outcomes	O
but	O
the	O
pathological	O
interactions	O
between	O
DM	O
and	O
TB	O
remain	O
incompletely	O
understood	O
.	O

We	O
performed	O
an	O
integrative	O
analysis	O
of	O
whole	O
blood	O
gene	O
expression	O
and	O
plasma	O
analytes	O
,	O
comparing	O
South	O
Indian	O
TB	O
patients	O
with	O
and	O
without	O
DM	O
to	O
diabetic	O
and	O
non-diabetic	O
controls	O
without	O
TB	O
.	O

Luminex	B-P
assay	I-P
of	O
plasma	O
cytokines	O
and	O
growth	O
factors	O
delineated	O
a	O
distinct	O
biosignature	O
in	O
comorbid	O
TBDM	O
in	O
this	O
cohort	O
.	O

Transcriptional	O
profiling	O
revealed	O
elements	O
in	O
common	O
with	O
published	O
TB	O
signatures	O
from	O
cohorts	O
that	O
excluded	O
DM	O
.	O

Neutrophil	B-P
count	I-P
correlated	O
with	O
the	O
molecular	O
degree	O
of	O
perturbation	O
,	O
especially	O
in	O
TBDM	O
patients	O
.	O

Body	O
mass	O
index	O
and	O
HDL	O
cholesterol	O
were	O
negatively	O
correlated	O
with	O
molecular	O
degree	O
of	O
perturbation	O
.	O

Diabetic	O
complication	O
pathways	O
including	O
several	O
pathways	O
linked	O
to	O
epigenetic	O
reprogramming	O
were	O
activated	O
in	O
TBDM	O
above	O
levels	O
observed	O
with	O
DM	O
alone	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
trials	O
of	O
host-directed	O
therapies	O
in	O
TBDM	O
,	O
targeting	O
neutrophilic	O
inflammation	O
and	O
diabetic	O
complication	O
pathways	O
to	O
address	O
the	O
greater	O
morbidity	O
and	O
mortality	O
associated	O
with	O
this	O
increasingly	O
prevalent	O
dual	O
burden	O
of	O
communicable	O
and	O
non-communicable	O
diseases	O
.	O

Muscle	O
synergies	O
after	O
stroke	O
are	O
correlated	O
with	O
perilesional	O
high	O
gamma	O
.	O

Movements	O
can	O
be	O
factored	O
into	O
modules	O
termed	O
``	O
muscle	O
synergies	O
``	O
.	O

After	O
stroke	O
,	O
abnormal	O
synergies	O
are	O
linked	O
to	O
impaired	O
movements	O
;	O
however	O
,	O
their	O
neural	O
basis	O
is	O
not	O
understood	O
.	O

In	O
a	O
single	O
subject	O
,	O
we	O
examined	O
how	O
electrocorticography	B-P
signals	I-P
from	O
the	O
perilesional	O
cortex	O
were	O
associated	O
with	O
synergies	O
.	O

The	O
measured	O
synergies	O
contained	O
a	O
mix	O
of	O
both	O
normal	O
and	O
abnormal	O
patterns	O
and	O
were	O
remarkably	O
similar	O
to	O
those	O
described	O
in	O
past	O
work	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
both	O
normal	O
and	O
abnormal	O
synergies	O
were	O
correlated	O
with	O
perilesional	O
high	O
gamma	O
.	O

Given	O
the	O
link	O
between	O
high	O
gamma	O
and	O
cortical	O
spiking	O
,	O
our	O
results	O
suggest	O
that	O
perilesional	O
spiking	O
may	O
organize	O
synergies	O
after	O
stroke	O
.	O

High-throughput	B-P
analysis	I-P
of	O
sub-visible	O
mAb	O
aggregate	O
particles	O
using	O
automated	B-P
fluorescence	I-P
microscopy	I-P
imaging	I-P
.	O

Aggregation	O
of	O
therapeutic	O
proteins	O
is	O
a	O
major	O
concern	O
as	O
aggregates	O
lower	O
the	O
yield	O
and	O
can	O
impact	O
the	O
efficacy	O
of	O
the	O
drug	O
as	O
well	O
as	O
the	O
patient	O
's	O
safety	O
.	O

It	O
can	O
occur	O
in	O
all	O
production	O
stages	O
;	O
thus	O
,	O
it	O
is	O
essential	O
to	O
perform	O
a	O
detailed	O
analysis	O
for	O
protein	O
aggregates	O
.	O

Several	O
methods	O
such	O
as	O
size	B-P
exclusion	I-P
high-performance	I-P
liquid	I-P
chromatography	I-P
(	O
SE-HPLC	B-P
)	O
,	O
light	O
scattering	O
,	O
turbidity	O
,	O
light	B-P
obscuration	I-P
,	O
and	O
microscopy-based	B-P
approaches	O
are	O
used	O
to	O
analyze	O
aggregates	O
.	O

None	O
of	O
these	O
methods	O
allows	O
determination	B-P
of	O
all	O
types	O
of	O
higher	O
molecular	O
weight	O
(	O
HMW	O
)	O
species	O
due	O
to	O
a	O
limited	O
size	O
range	O
.	O

Furthermore	O
,	O
quantification	O
and	O
specification	O
of	O
different	O
HMW	O
species	O
are	O
often	O
not	O
possible	O
.	O

Moreover	O
,	O
automation	O
is	O
a	O
perspective	O
challenge	O
coming	O
up	O
with	O
automated	O
robotic	O
laboratory	O
systems	O
.	O

Hence	O
,	O
there	O
is	O
a	O
need	O
for	O
a	O
fast	O
,	O
high-throughput-compatible	O
method	O
,	O
which	O
can	O
detect	O
a	O
broad	O
size	O
range	O
and	O
enable	O
quantification	O
and	O
classification	O
.	O

We	O
describe	O
a	O
novel	O
approach	O
for	O
the	O
detection	O
of	O
aggregates	O
in	O
the	O
size	O
range	O
1	O
to	O
1000	O
μm	O
combining	O
fluorescent	O
dyes	O
for	O
protein	O
aggregate	O
labelling	O
and	O
automated	B-P
fluorescence	I-P
microscope	I-P
imaging	I-P
(	O
aFMI	B-P
)	O
.	O

After	O
appropriate	O
selection	O
of	O
the	O
dye	O
and	O
method	O
optimization	O
,	O
our	O
method	O
enabled	O
us	O
to	O
detect	O
various	O
types	O
of	O
HMW	O
species	O
of	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
.	O

Using	O
10	O
μmol	O
L	O
(	O
-1	O
)	O
4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonate	O
(	O
Bis-ANS	O
)	O
in	O
combination	O
with	O
aFMI	B-P
allowed	O
the	O
analysis	O
of	O
mAb	O
aggregates	O
induced	O
by	O
different	O
stresses	O
occurring	O
during	O
downstream	O
processing	O
,	O
storage	O
,	O
and	O
administration	O
.	O

Validation	O
of	O
our	O
results	O
was	O
performed	O
by	O
SE-HPLC	B-P
,	O
UV-Vis	B-P
spectroscopy	I-P
,	O
and	O
dynamic	B-P
light	I-P
scattering	I-P
.	O

With	O
this	O
new	O
approach	O
,	O
we	O
could	O
not	O
only	O
reliably	O
detect	O
different	O
HMW	O
species	O
but	O
also	O
quantify	O
and	O
classify	O
them	O
in	O
an	O
automated	O
approach	O
.	O

Our	O
method	O
achieves	O
high-throughput	B-P
requirements	O
and	O
the	O
selection	O
of	O
various	O
fluorescent	O
dyes	O
enables	O
a	O
broad	O
range	O
of	O
applications	O
.	O

Outcomes	O
With	O
Cerclage	O
Alone	O
Compared	O
With	O
Cerclage	O
Plus	O
17α-Hydroxyprogesterone	O
Caproate	O
.	O

To	O
examine	O
the	O
differences	O
in	O
perinatal	O
outcomes	O
among	O
women	O
with	O
a	O
prior	O
preterm	O
birth	O
who	O
received	O
cerclage	O
compared	O
with	O
cerclage	O
plus	O
17α-hydroxyprogesterone	O
caproate	O
.	O

Women	O
with	O
transvaginal	O
cerclage	O
placement	O
and	O
a	O
prior	O
delivery	O
between	O
16	O
and	O
36	O
weeks	O
of	O
gestation	O
were	O
identified	O
over	O
a	O
10-	O
year	O
period	O
(	O
July	O
2002	O
to	O
May	O
2012	O
)	O
in	O
this	O
retrospective	O
cohort	O
study	O
.	O

Exclusion	O
criteria	O
were	O
delivery	O
at	O
another	O
institution	O
,	O
abdominal	O
cerclage	O
,	O
multiple	O
gestations	O
,	O
and	O
major	O
fetal	O
anomalies	O
.	O

Maternal	O
demographics	O
,	O
gestational	O
age	O
at	O
cerclage	O
,	O
gestational	O
age	O
at	O
delivery	O
,	O
preterm	O
prelabor	O
rupture	O
of	O
membranes	O
(	O
PROM	O
)	O
,	O
and	O
birth	O
weight	O
were	O
compared	O
between	O
women	O
with	O
a	O
cerclage	O
and	O
cerclage	O
plus	O
17α-hydroxyprogesterone	O
caproate	O
.	O

The	O
primary	O
outcome	O
was	O
delivery	O
at	O
less	O
than	O
24	O
weeks	O
of	O
gestation	O
.	O

Of	O
the	O
411	O
women	O
who	O
had	O
a	O
cerclage	O
,	O
260	O
met	O
inclusion	O
criteria	O
.	O

Of	O
these	O
,	O
171	O
received	O
a	O
cerclage	O
alone	O
and	O
89	O
received	O
cerclage	O
plus	O
17α-hydroxyprogesterone	O
caproate	O
.	O

The	O
two	O
groups	O
were	O
not	O
different	O
with	O
respect	O
to	O
maternal	O
demographics	O
and	O
gestational	O
age	O
at	O
cerclage	O
.	O

There	O
was	O
a	O
significant	O
difference	O
among	O
those	O
who	O
received	O
indomethacin	O
at	O
the	O
time	O
of	O
cerclage	O
,	O
betamethasone	O
administration	O
,	O
and	O
history	O
of	O
a	O
loop	O
electrosurgical	O
excision	O
procedure	O
-	O
cold	B-P
knife	I-P
cone	I-P
and	O
cerclage	O
.	O

Delivery	O
at	O
less	O
than	O
24	O
weeks	O
of	O
gestation	O
occurred	O
in	O
6	O
%	O
of	O
women	O
receiving	O
both	O
17α-hydroxyprogesterone	O
caproate	O
and	O
cerclage	O
compared	O
with	O
16	O
%	O
in	O
the	O
cerclage	O
only	O
group	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
0.31	O
,	O
95	O
%	O
confidence	O
interval	O
0.10-0.78	O
,	O
P=.01	O
)	O
.	O

In	O
the	O
multivariate	O
analysis	O
controlling	O
for	O
indomethacin	O
use	O
,	O
prior	O
cerclage	O
,	O
and	O
loop	O
electrosurgical	O
excision	O
procedure	O
-	O
cold	B-P
knife	I-P
cone	I-P
there	O
was	O
a	O
73	O
%	O
reduction	O
in	O
delivery	O
in	O
the	O
combined	O
treatment	O
group	O
compared	O
with	O
cerclage	O
alone	O
(	O
adjusted	O
OR	O
0.26	O
,	O
P=.02	O
)	O
.	O

A	O
multivariant	O
analysis	O
was	O
conducted	O
with	O
correction	O
for	O
indomethacin	O
at	O
the	O
time	O
of	O
cerclage	O
,	O
prior	O
cerclage	O
,	O
and	O
loop	O
electrosurgical	O
excision	O
procedure	O
-	O
cold	B-P
knife	I-P
cone	I-P
and	O
cerclage	O
surgery	O
.	O

Even	O
after	O
controlling	O
for	O
significant	O
variables	O
,	O
there	O
remained	O
a	O
73	O
%	O
reduction	O
in	O
delivery	O
at	O
less	O
than	O
24	O
weeks	O
of	O
gestation	O
in	O
the	O
cerclage	O
plus	O
17α-hydroxyprogesterone	O
caproate	O
cohort	O
(	O
adjusted	O
OR	O
0.26	O
,	O
P=.02	O
)	O
.	O

Women	O
receiving	O
transvaginal	O
cerclage	O
plus	O
17α-hydroxyprogesterone	O
caproate	O
had	O
a	O
69	O
%	O
relative	O
reduction	O
in	O
delivery	O
at	O
less	O
than	O
24	O
weeks	O
of	O
gestation	O
when	O
compared	O
with	O
women	O
receiving	O
cerclage	O
alone	O
.	O

We	O
found	O
no	O
difference	O
in	O
overall	O
preterm	O
delivery	O
or	O
preterm	O
PROM	O
.	O

In	O
this	O
cohort	O
,	O
compared	O
with	O
cerclage	O
alone	O
,	O
the	O
likelihood	O
of	O
a	O
viable	O
neonate	O
improves	O
with	O
both	O
treatments	O
.	O

Natural	O
product	O
derivative	O
BIO	O
promotes	O
recovery	O
after	O
myocardial	O
infarction	O
via	O
unique	O
modulation	O
of	O
the	O
cardiac	O
microenvironment	O
.	O

The	O
cardiac	O
microenvironment	O
includes	O
cardiomyocytes	O
,	O
fibroblasts	O
and	O
macrophages	O
,	O
which	O
regulate	O
remodeling	O
after	O
myocardial	O
infarction	O
(	O
MI	O
)	O
.	O

Targeting	O
this	O
microenvironment	O
is	O
a	O
novel	O
therapeutic	O
approach	O
for	O
MI	O
.	O

We	O
found	O
that	O
the	O
natural	O
compound	O
derivative	O
,	O
BIO	O
(	O
(	O
2	O
'	O
Z,3	O
'	O
E	O
)	O
-6-Bromoindirubin-3'-oxime	O
)	O
modulated	O
the	O
cardiac	O
microenvironment	O
to	O
exert	O
a	O
therapeutic	O
effect	O
on	O
MI	O
.	O

Using	O
a	O
series	O
of	O
co-culture	B-P
studies	I-P
,	O
BIO	O
induced	O
proliferation	O
in	O
cardiomyocytes	O
and	O
inhibited	O
proliferation	O
in	O
cardiac	O
fibroblasts	O
.	O

BIO	O
produced	O
multiple	O
anti-fibrotic	O
effects	O
in	O
cardiac	O
fibroblasts	O
.	O

In	O
macrophages	O
,	O
BIO	O
inhibited	O
the	O
expression	O
of	O
pro-inflammatory	O
factors	O
.	O

Significantly	O
,	O
BIO	O
modulated	O
the	O
molecular	O
crosstalk	O
between	O
cardiac	O
fibroblasts	O
and	O
differentiating	O
macrophages	O
to	O
induce	O
polarization	O
to	O
the	O
anti-inflammatory	O
M2	O
phenotype	O
.	O

In	O
the	O
optically	O
transparent	O
zebrafish-based	O
heart	O
failure	O
model	O
,	O
BIO	O
induced	O
cardiomyocyte	O
proliferation	O
and	O
completely	O
recovered	O
survival	O
rate	O
.	O

BIO	O
is	O
a	O
known	O
glycogen	O
synthase	O
kinase-3β	O
inhibitor	O
,	O
but	O
these	O
effects	O
could	O
not	O
be	O
recapitulated	O
using	O
the	O
classical	O
inhibitor	O
,	O
lithium	O
chloride	O
;	O
indicating	O
novel	O
therapeutic	O
effects	O
of	O
BIO	O
.	O

We	O
identified	O
the	O
mechanism	O
of	O
BIO	O
as	O
differential	O
modulation	O
of	O
p27	O
protein	O
expression	O
and	O
potent	O
induction	O
of	O
anti-inflammatory	O
interleukin-10	O
.	O

In	O
a	O
rat	O
MI	O
model	O
,	O
BIO	O
reduced	O
fibrosis	O
and	O
improved	O
cardiac	O
performance	O
.	O

Histological	O
analysis	O
revealed	O
modulation	O
of	O
the	O
cardiac	O
microenvironment	O
by	O
BIO	O
,	O
with	O
increased	O
presence	O
of	O
anti-inflammatory	O
M2	O
macrophages	O
.	O

Our	O
results	O
demonstrate	O
that	O
BIO	O
produces	O
unique	O
effects	O
in	O
the	O
cardiac	O
microenvironment	O
to	O
promote	O
recovery	O
post-MI	O
.	O

RATIONAL	O
DESIGN	O
OF	O
NANOBODY80	O
LOOP	O
PEPTIDOMIMETICS	O
:	O
TOWARDS	O
BIASED	O
β2	O
ADRENERGIC	O
RECEPTOR	O
LIGANDS	O
.	O

G	O
protein-coupled	O
receptors	O
(	O
GPCRs	O
)	O
play	O
an	O
important	O
role	O
for	O
many	O
cellular	O
responses	O
,	O
and	O
as	O
such	O
their	O
mechanism	O
of	O
action	O
is	O
of	O
utmost	O
interest	O
.	O

To	O
gain	O
insight	O
into	O
the	O
active	O
conformation	O
of	O
GPCRs	O
,	O
the	O
X-ray	O
crystal	O
structures	O
of	O
Nanobody	O
(	O
Nb	O
)	O
-stabilized	O
β2-adrenergic	O
receptor	O
(	O
β2AR	O
)	O
have	O
been	O
reported	O
.	O

Nb80	O
in	O
particular	O
is	O
able	O
to	O
bind	O
the	O
intracellular	O
G	O
protein	O
binding	O
site	O
of	O
β2AR	O
and	O
stabilize	O
the	O
receptors	O
in	O
an	O
active	O
conformation	O
.	O

Within	O
Nb80	O
,	O
the	O
complementarity-determining	O
region	O
3	O
(	O
CDR3	O
)	O
is	O
responsible	O
for	O
most	O
of	O
the	O
binding	O
interactions	O
.	O

Hence	O
we	O
hypothesized	O
that	O
peptidomimetics	O
of	O
the	O
CDR3	O
loop	O
might	O
be	O
sufficient	O
for	O
binding	O
to	O
the	O
receptor	O
,	O
inhibiting	O
the	O
interaction	O
of	O
β2AR	O
with	O
intracellular	O
GPCR	O
interacting	O
proteins	O
(	O
e.g	O
.	O

G	O
proteins	O
)	O
.	O

Based	O
on	O
previous	O
crystallographic	B-P
data	I-P
,	O
a	O
set	O
of	O
peptidomimetics	O
were	O
synthesized	O
which	O
,	O
similarly	O
to	O
the	O
Nb80	O
CDR3	O
loop	O
,	O
adopt	O
a	O
	O
-hairpin	O
conformation	O
.	O

Syntheses	O
,	O
conformationa	O
l	O
analysis	O
,	O
binding	O
and	O
functional	O
in	O
vitro	O
assays	O
,	O
as	O
well	O
as	O
internalization	O
experiments	O
were	O
performed	O
.	O

We	O
demonstrate	O
that	O
peptidomimetics	O
can	O
structurally	O
mimic	O
the	O
CDR3	O
loop	O
of	O
a	O
Nanobody	O
and	O
its	O
function	O
by	O
inhibiting	O
G	O
protein	O
coupling	O
as	O
measured	O
by	O
partial	O
inhibition	O
of	O
cAMP	O
production	O
.	O

Activation	O
of	O
the	O
Na	O
(	O
+	O
)	O
/H	O
(	O
+	O
)	O
exchanger	O
in	O
isolated	O
cardiomyocytes	O
through	O
β-Raf	O
dependent	O
pathways	O
.	O

Role	O
of	O
Thr	O
(	O
653	O
)	O
of	O
the	O
cytosolic	O
tail	O
.	O

The	O
mammalian	O
Na	O
(	O
+	O
)	O
/H	O
(	O
+	O
)	O
exchanger	O
isoform	O
1	O
(	O
NHE1	O
)	O
is	O
a	O
ubiquitous	O
plasma	O
membrane	O
protein	O
that	O
is	O
a	O
key	O
regulator	O
of	O
intracellular	O
pH	O
in	O
isolated	O
cardiomyocytes	O
.	O

A	O
500	O
amino	O
acid	O
membrane	O
domain	O
removes	O
protons	O
and	O
is	O
regulated	O
by	O
a	O
315	O
amino	O
acid	O
cytosolic	O
domain	O
.	O

In	O
the	O
myocardium	O
,	O
aberrant	O
regulation	O
of	O
NHE1	O
contributes	O
to	O
ischemia	O
reperfusion	O
damage	O
and	O
to	O
heart	O
hypertrophy	O
.	O

We	O
examined	O
mechanisms	O
of	O
regulation	O
of	O
NHE1	O
in	O
the	O
myocardium	O
by	O
endothelin	O
and	O
β-Raf	O
.	O

Endothelin	O
stimulated	O
NHE1	O
activity	O
and	O
activated	O
Erk-dependent	O
pathways	O
.	O

Inhibition	O
of	O
β-Raf	O
reduced	O
NHE1	O
activity	O
and	O
Erk-pathway	O
activation	O
.	O

We	O
demonstrated	O
that	O
myocardial	O
β-Raf	O
binds	O
to	O
the	O
C-terminal	O
182	O
amino	O
acids	O
of	O
the	O
NHE1	O
protein	O
and	O
that	O
β-Raf	O
is	O
associated	O
with	O
NHE1	O
in	O
intact	O
cardiomyocytes	O
.	O

NHE1	O
was	O
phosphorylated	O
in	O
vivo	O
and	O
the	O
protein	O
kinase	O
inhibitor	O
sorafenib	O
reduced	O
NHE1	O
phosphorylation	O
levels	O
.	O

Immunoprecipitates	O
of	O
β-Raf	O
from	O
cardiomyocytes	O
phosphorylated	O
the	O
C-terminal	O
182	O
amino	O
acids	O
of	O
NHE1	O
and	O
mass	B-P
spectrometry	I-P
analysis	I-P
showed	O
that	O
amino	O
acid	O
Thr	O
(	O
653	O
)	O
was	O
phosphorylated	O
.	O

Mutation	O
of	O
this	O
amino	O
acid	O
to	O
Ala	O
resulted	O
in	O
defective	O
activity	O
while	O
mutation	O
to	O
Asp	O
restored	O
the	O
activity	O
.	O

The	O
results	O
demonstrate	O
that	O
Thr	O
(	O
653	O
)	O
is	O
an	O
important	O
regulator	O
y	O
amino	O
acid	O
of	O
NHE1	O
that	O
is	O
activated	O
through	O
β-Raf	O
dependent	O
pathways	O
by	O
phosphorylation	O
either	O
directly	O
or	O
indirectly	O
by	O
β-Raf	O
,	O
and	O
this	O
affects	O
NHE1	O
activity	O
.	O

Sperm	O
dimorphism	O
in	O
the	O
Triatoma	O
brasiliensis	O
species	O
complex	O
and	O
its	O
applications	O
.	O

Morphological	O
and	O
structural	O
features	O
of	O
the	O
sperm	O
of	O
the	O
Triatoma	O
brasiliensis	O
Neiva	O
,	O
1911	O
(	O
Hemiptera	O
:	O
Reduviidae	O
)	O
species	O
complex	O
were	O
examined	O
in	O
this	O
first	O
study	O
investigating	O
the	O
sperm	O
of	O
Heteroptera	O
and	O
the	O
genus	O
Triatoma	O
.	O

Males	O
were	O
dissected	O
and	O
their	O
seminal	O
vesicles	O
removed	O
.	O

For	O
measurement	O
,	O
seminal	O
vesicles	O
were	O
squashed	O
on	O
glass	O
slides	O
,	O
spread	O
,	O
fixed	O
and	O
observed	O
under	O
a	O
photomicroscope	O
.	O

The	O
images	O
were	O
analysed	O
and	O
measures	O
of	O
sperm	O
were	O
made	O
.	O

Data	O
were	O
analysed	O
using	O
one-way	O
analysis	O
of	O
variance	O
and	O
Tukey	B-P
's	I-P
test	I-P
to	O
detect	O
differentiation	O
among	O
taxa	O
.	O

Furthermore	O
,	O
seminal	O
vesicles	O
were	O
prepared	O
for	O
studies	O
of	O
transmission	B-P
electron	I-P
microscopy	I-P
.	O

All	O
taxa	O
studied	O
showed	O
polymorphic	O
(	O
short	O
and	O
long	O
)	O
sperm	O
.	O

The	O
sperm	O
of	O
Triatoma	O
brasiliensis	O
macromelasoma	O
was	O
significantly	O
longer	O
(	O
in	O
total	O
length	O
)	O
than	O
that	O
of	O
the	O
other	O
four	O
members	O
of	O
the	O
complex	O
,	O
which	O
supports	O
the	O
hypothesis	O
of	O
hybrid	O
speciation	O
of	O
this	O
member	O
of	O
the	O
complex	O
as	O
an	O
increase	O
in	O
the	O
size	O
of	O
typical	O
hybrids	O
under	O
heterosis	O
was	O
previously	O
shown	O
.	O

The	O
sperm	O
cells	O
of	O
the	O
five	O
taxa	O
have	O
similar	O
ultrastructural	O
morphology	O
.	O

The	O
ultrastructural	O
features	O
observed	O
confirm	O
the	O
hypothesis	O
,	O
raised	O
by	O
previous	O
studies	O
,	O
that	O
they	O
are	O
synapomorphic	O
to	O
the	O
suborder	O
Heteroptera	O
.	O

Translating	O
Neurocognitive	O
Models	O
of	O
Auditory-Verbal	O
Hallucinations	O
into	O
Therapy	O
:	O
Using	O
Real-time	O
fMRI	B-P
-	O
Neurofeedback	O
to	O
Treat	O
Voices	O
.	O

Auditory-verbal	O
hallucinations	O
(	O
AVHs	O
)	O
are	O
frequent	O
and	O
disabling	O
symptoms	O
,	O
which	O
can	O
be	O
refractory	O
to	O
conventional	O
psychopharmacological	O
treatment	O
in	O
more	O
than	O
25	O
%	O
of	O
the	O
cases	O
.	O

Recent	O
advances	O
in	O
brain	B-P
imaging	I-P
allow	O
for	O
a	O
better	O
understanding	O
of	O
the	O
neural	O
underpinnings	O
of	O
AVHs	O
.	O

These	O
findings	O
strengthened	O
transdiagnostic	O
neurocognitive	O
models	O
that	O
characterize	O
these	O
frequent	O
and	O
disabling	O
experiences	O
.	O

At	O
the	O
same	O
time	O
,	O
technical	O
improvements	O
in	O
real-time	O
functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
fMRI	B-P
)	O
enabled	O
the	O
development	O
of	O
innovative	O
and	O
non-invasive	O
methods	O
with	O
the	O
potential	O
to	O
relieve	O
psychiatric	O
symptoms	O
,	O
such	O
as	O
fMRI	B-P
-based	O
neurofeedback	O
(	O
fMRI	B-P
-	O
NF	O
)	O
.	O

During	O
fMRI	B-P
-	O
NF	O
,	O
brain	O
activity	O
is	O
measured	O
and	O
fed	O
back	O
in	O
real	O
time	O
to	O
the	O
participant	O
in	O
order	O
to	O
help	O
subjects	O
to	O
progressively	O
achieve	O
voluntary	O
control	O
over	O
their	O
own	O
neural	O
activity	O
.	O

Precisely	O
defining	O
the	O
target	O
brain	O
area	O
/	O
network	O
(	O
s	O
)	O
appears	O
critical	O
in	O
fMRI	B-P
-	O
NF	O
protocols	O
.	O

After	O
reviewing	O
the	O
available	O
neurocognitive	O
models	O
for	O
AVHs	O
,	O
we	O
elaborate	O
on	O
how	O
recent	O
findings	O
in	O
the	O
field	O
may	O
help	O
to	O
develop	O
strong	O
a	O
priori	O
strategies	O
for	O
fMRI	B-P
-	O
NF	O
target	O
localization	O
.	O

The	O
first	O
approach	O
relies	O
on	O
imaging	B-P
-based	O
``	O
trait	O
markers	O
``	O
(	O
i.e.	O
,	O
persistent	O
traits	O
or	O
vulnerability	O
markers	O
that	O
can	O
also	O
be	O
detected	O
in	O
the	O
presymptomatic	O
and	O
remitted	O
phases	O
of	O
AVHs	O
)	O
.	O

The	O
goal	O
of	O
such	O
strategies	O
is	O
to	O
target	O
areas	O
that	O
show	O
aberrant	O
activations	O
during	O
AVHs	O
or	O
are	O
known	O
to	O
be	O
involved	O
in	O
compensatory	O
activation	O
(	O
or	O
resilience	O
processes	O
)	O
.	O

Brain	O
regions	O
,	O
from	O
which	O
the	O
NF	O
signal	O
is	O
derived	O
,	O
can	O
be	O
based	O
on	O
structural	B-P
MRI	I-P
and	O
neurocognitive	O
knowledge	O
,	O
or	O
functional	B-P
MRI	I-P
information	O
collected	O
during	O
specific	O
cognitive	O
tasks	O
.	O

Because	O
hallucinations	O
are	O
acute	O
and	O
intrusive	O
symptoms	O
,	O
a	O
second	O
strategy	O
focuses	O
more	O
on	O
``	O
state	O
markers	O
.	O
''	O

In	O
this	O
case	O
,	O
the	O
signal	O
of	O
interest	O
relies	O
on	O
fMRI	B-P
capture	O
of	O
the	O
neural	O
networks	O
exhibiting	O
increased	O
activity	O
during	O
AVHs	O
occurrences	O
,	O
by	O
means	O
of	O
multivariate	O
pattern	O
recognition	O
methods	O
.	O

The	O
fine-grained	O
activity	O
patterns	O
concomitant	O
to	O
hallucinations	O
can	O
then	O
be	O
fed	O
back	O
to	O
the	O
patients	O
for	O
therapeutic	O
purpose	O
.	O

Considering	O
the	O
potential	O
cost	O
necessary	O
to	O
implement	O
fMRI	B-P
-	O
NF	O
,	O
proof-of-concept	O
studies	O
are	O
urgently	O
required	O
to	O
define	O
the	O
optimal	O
strategy	O
for	O
application	O
in	O
patients	O
with	O
AVHs	O
.	O

This	O
technique	O
has	O
the	O
potential	O
to	O
establish	O
a	O
new	O
brain	B-P
imaging	I-P
-guided	O
psychotherapy	O
for	O
patients	O
that	O
do	O
not	O
respond	O
to	O
conventional	O
treatments	O
and	O
take	O
functional	O
neuroimaging	O
to	O
therapeutic	O
applications	O
.	O

Interleukin-21	O
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
and	O
severity	O
of	O
type	O
I	O
autoimmune	O
hepatitis	O
.	O

Recently	O
,	O
the	O
number	O
of	O
follicular	O
helper	O
T	O
(	O
Tfh	O
)	O
cells	O
expressing	O
interleukin	O
(	O
IL	O
)	O
-21	O
was	O
found	O
to	O
increase	O
in	O
peripheral	O
blood	O
of	O
human	O
and	O
murine	O
models	O
of	O
autoimmune	O
hepatitis	O
(	O
AIH	O
)	O
.	O

IL-21	O
,	O
the	O
most	O
recently	O
discovered	O
member	O
of	O
the	O
type-I	O
cytokine	O
family	O
,	O
exerts	O
various	O
effects	O
on	O
the	O
immune	O
system	O
,	O
including	O
B	O
cell	O
activation	O
,	O
plasma	O
cell	O
differentiation	O
,	O
and	O
immunoglobulin	O
production	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
relationship	O
of	O
serum	O
IL-21	O
levels	O
in	O
patients	O
with	O
type	O
I	O
AIH	O
with	O
clinical	O
and	O
laboratory	O
parameters	O
and	O
histology	O
.	O

Ninety-two	O
Japanese	O
patients	O
with	O
liver	O
disease	O
(	O
22	O
AIH	O
,	O
20	O
primary	O
biliary	O
cholangitis	O
,	O
19	O
drug-induced	O
liver	O
injury	O
,	O
8	O
acute	O
hepatitis	O
B	O
,	O
8	O
chronic	O
hepatitis	O
C	O
,	O
10	O
non-alcoholic	O
steatohepatitis	O
,	O
5	O
viral	O
hepatitis	O
)	O
and	O
10	O
healthy	O
volunteers	O
were	O
recruited	O
.	O

Serum	O
IL-21	O
levels	O
were	O
detected	O
by	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
.	O

Real-time	O
polymerase	O
chain	O
reaction	O
measured	O
mRNA	O
levels	O
of	O
Bcl-6	O
,	O
IL-21	O
,	O
and	O
CXCR5	O
(	O
Tfh-related	O
factors	O
)	O
in	O
peripheral	O
mononuclear	O
cells	O
.	O

Mean	O
age	O
at	O
diagnosis	O
of	O
AIH	O
was	O
58.6	O
years	O
,	O
male-to-female	O
ratio	O
was	O
4:18	O
,	O
18.2	O
%	O
of	O
participants	O
had	O
cirrhosis	O
,	O
and	O
22.7	O
%	O
had	O
severe	O
disease	O
.	O

IL-21	O
levels	O
were	O
significantly	O
increased	O
in	O
the	O
serum	O
of	O
patients	O
with	O
AIH	O
compared	O
to	O
those	O
with	O
other	O
liver	O
diseases	O
and	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Particularly	O
,	O
serum	O
IL-21	O
levels	O
were	O
significantly	O
increased	O
in	O
severe	O
AIH	O
cases	O
compared	O
to	O
non-severe	O
cases	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Serum	O
IL-21	O
levels	O
correlated	O
positively	O
with	O
total	O
serum	O
bilirubin	B-P
levels	I-P
(	O
r	O
=	O
0.46	O
,	O
p	O
<	O
0.05	O
)	O
,	O
grading	O
of	O
necroinflammatory	O
activity	O
(	O
r	O
=	O
0.68	O
,	O
p	O
<	O
0.005	O
)	O
and	O
negatively	O
with	O
serum	O
albumin	O
levels	O
in	O
patients	O
with	O
AIH	O
(	O
r	O
=	O
-0.49	O
,	O
p	O
<	O
0.05	O
)	O
.	O

In	O
patients	O
with	O
biochemical	O
remission	O
of	O
AIH	O
,	O
serum	O
IL-21	O
levels	O
remained	O
elevated	O
and	O
correlated	O
positively	O
with	O
serum	B-P
IgG	I-P
levels	I-P
(	O
r	O
=	O
0.84	O
,	O
p	O
<	O
0.01	O
)	O
.	O

Expression	O
of	O
Tfh-related	O
factors	O
,	O
such	O
as	O
Bcl-6	O
and	O
IL-21	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
patients	O
with	O
AIH	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
healthy	O
volunteers	O
.	O

IL-21	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
and	O
severity	O
of	O
AIH	O
,	O
and	O
may	O
present	O
a	O
promising	O
target	O
for	O
AIH	O
therapy	O
.	O

Simultaneous	O
Bilateral	O
Femur	O
Neck	O
Fracture	O
in	O
A	O
Young	O
Adult	O
with	O
Chronic	O
Renal	O
Failure	O
-	O
A	O
Case	O
Report	O
and	O
Review	O
of	O
Literature	O
.	O

Pathological	O
bilateral	O
femoral	O
neck	O
fracture	O
due	O
to	O
renal	O
osteodystrophy	O
is	O
rare	O
.	O

This	O
is	O
a	O
report	O
of	O
a	O
chronic	O
renal	O
failure	O
patient	O
who	O
had	O
sustained	O
bilateral	O
intra-capsular	O
displaced	O
fracture	O
neck	O
of	O
femur	O
following	O
an	O
episode	O
of	O
convulsion	O
and	O
the	O
difficulties	O
encountered	O
in	O
early	B-P
diagnosis	I-P
and	O
treatment	O
.	O

The	O
pathophysiology	O
of	O
renal	O
osteodystrophy	O
and	O
the	O
treatment	O
of	O
hip	O
fractures	O
in	O
patients	O
with	O
renal	O
failure	O
are	O
also	O
discussed	O
.	O

A	O
23	O
years	O
old	O
male	O
patient	O
admitted	O
with	O
h/o	O
dysuria	O
,	O
pyuria	O
and	O
loss	O
of	O
appetite	O
since	O
3	O
months	O
.	O

He	O
was	O
a	O
known	O
case	O
of	O
chronic	O
renal	O
failure	O
and	O
reflux	O
nephropathy	O
.	O

On	O
investigating	O
,	O
patient	O
's	O
renal	O
parameters	O
were	O
high	O
and	O
he	O
was	O
started	O
with	O
haemodialysis	O
.	O

The	O
next	O
day	O
patient	O
had	O
c/o	O
bilateral	O
hip	O
pain	O
and	O
inability	O
to	O
move	O
bilateral	O
lower	O
limbs	O
following	O
an	O
episode	O
of	O
seizure	O
.	O

Radiograph	B-P
of	I-P
pelvis	I-P
showed	O
vertical	O
sub	O
capital	O
fractures	O
of	O
bilateral	O
neck	O
of	O
femur	O
.	O

In	O
this	O
patient	O
,	O
considering	O
his	O
age	O
,	O
general	O
condition	O
&	O
prognosis	O
,	O
an	O
elective	O
surgery	O
in	O
the	O
form	O
of	O
bilateral	O
uncemented	O
modular	O
bipolar	O
hemiarthroplasty	O
was	O
done	O
.	O

Overall	O
risk	O
of	O
hip	O
fracture	O
among	O
patients	O
with	O
chronic	O
renal	O
failure	O
is	O
considerably	O
higher	O
than	O
in	O
the	O
general	O
population	O
,	O
independent	O
of	O
age	O
and	O
gender	O
.	O

Simultaneous	O
spontaneous	O
bilateral	O
fractures	O
of	O
the	O
femoral	O
neck	O
are	O
rare	O
and	O
a	O
delayed	O
diagnosis	O
is	O
usual	O
.	O

The	O
study	O
of	O
etiological	O
factors	O
of	O
these	O
fractures	O
is	O
essential	O
to	O
guide	O
us	O
in	O
choosing	O
the	O
treatment	O
of	O
choice	O
.	O

Obviously	O
patient	O
's	O
age	O
,	O
life	O
expectancy	O
as	O
well	O
as	O
renal	O
co	O
morbidity	O
has	O
an	O
influence	O
over	O
deciding	O
treatment	O
and	O
outcome	O
.	O

Fluorescence	B-P
hyperspectral	I-P
imaging	I-P
(	O
fHSI	B-P
)	O
using	O
a	O
spectrally	O
resolved	O
detector	O
array	O
.	O

The	O
ability	O
to	O
resolve	O
multiple	O
fluorescent	O
emissions	O
from	O
different	O
biological	O
targets	O
in	O
video	O
rate	O
applications	O
,	O
such	O
as	O
endoscopy	B-P
and	O
intraoperative	B-P
imaging	I-P
,	O
has	O
traditionally	O
been	O
limited	O
by	O
the	O
use	O
of	O
filter-based	O
imaging	O
systems	O
.	O

Hyperspectral	B-P
imaging	I-P
(	O
HSI	B-P
)	O
facilitates	O
the	O
detection	O
of	O
both	O
spatial	O
and	O
spectral	O
information	O
in	O
a	O
single	O
data	O
acquisition	O
,	O
however	O
,	O
instrumentation	O
for	O
HSI	B-P
is	O
typically	O
complex	O
,	O
bulky	O
and	O
expensive	O
.	O

We	O
sought	O
to	O
overcome	O
these	O
limitations	O
using	O
a	O
novel	O
robust	O
and	O
low	O
cost	O
HSI	B-P
camera	O
based	O
on	O
a	O
spectrally	O
resolved	O
detector	O
array	O
(	O
SRDA	O
)	O
.	O

We	O
integrated	O
this	O
HSI	B-P
camera	O
into	O
a	O
wide-field	O
reflectance-based	B-P
imaging	O
system	O
operating	O
in	O
the	O
near-infrared	O
range	O
to	O
assess	O
the	O
suitability	O
for	O
in	B-P
vivo	I-P
imaging	I-P
of	O
exogenous	O
fluorescent	O
contrast	O
agents	O
.	O

Using	O
this	O
fluorescence	B-P
HSI	I-P
(	O
fHSI	B-P
)	O
system	O
,	O
we	O
were	O
able	O
to	O
accurately	O
resolve	O
the	O
presence	O
and	O
concentration	O
of	O
at	O
least	O
7	O
fluorescent	O
dyes	O
in	O
solution	O
.	O

We	O
also	O
demonstrate	O
high	O
spectral	O
unmixing	O
precision	O
,	O
signal	O
linearity	O
with	O
dye	O
concentration	O
and	O
at	O
depth	O
in	O
tissue	O
mimicking	O
phantoms	O
,	O
and	O
delineate	O
4	O
fluorescent	O
dyes	O
in	O
vivo	O
.	O

Our	O
approach	O
,	O
including	O
statistical	O
background	O
removal	O
,	O
could	O
be	O
directly	O
generalised	O
to	O
broader	O
spectral	O
ranges	O
,	O
for	O
example	O
,	O
to	O
resolve	O
tissue	O
reflectance	B-P
or	O
autofluorescence	B-P
and	O
in	O
future	O
be	O
tailored	O
to	O
video	O
rate	O
applications	O
requiring	O
snapshot	O
HSI	B-P
data	O
acquisition	O
.	O

Global	O
DNA	O
methylation	O
levels	O
are	O
altered	O
by	O
modifiable	O
clinical	O
manipulations	O
in	O
assisted	O
reproductive	O
technologies	O
.	O

We	O
analyzed	O
placental	O
DNA	O
methylation	O
levels	O
at	O
repeated	O
sequences	O
(	O
LINE1	O
elements	O
)	O
and	O
all	O
CCGG	O
sites	O
(	O
the	O
LUMA	B-P
assay	I-P
)	O
to	O
study	O
the	O
effect	O
of	O
modifiable	O
clinical	O
or	O
laboratory	B-P
procedures	I-P
involved	O
in	O
in	O
vitro	O
fertilization	O
.	O

We	O
included	O
four	O
potential	O
modifiable	O
factors	O
:	O
oxygen	O
tension	O
during	O
embryo	B-P
culture	I-P
,	O
fresh	O
embryo	O
transfer	O
vs	O
frozen	O
embryo	O
transfer	O
,	O
intracytoplasmic	O
sperm	O
injection	O
(	O
ICSI	O
)	O
vs	O
conventional	O
insemination	O
or	O
day	O
3	O
embryo	O
transfer	O
vs	O
day	O
5	O
embryo	O
transfer	O
.	O

Global	O
methylation	O
levels	O
differed	O
between	O
placentas	O
from	O
natural	O
conceptions	O
compared	O
to	O
placentas	O
conceived	O
by	O
IVF	O
.	O

Placentas	O
from	O
embryos	O
cultured	O
at	O
20	O
%	O
oxygen	O
showed	O
significant	O
differences	O
in	O
LINE1	O
methylation	O
compared	O
to	O
in	O
vivo	O
conceptions	O
,	O
while	O
those	O
from	O
embryos	O
cultured	O
at	O
5	O
%	O
oxygen	O
,	O
did	O
not	O
have	O
significant	O
differences	O
.	O

In	O
addition	O
,	O
placentas	O
from	O
fresh	O
embryo	O
transfer	O
had	O
significant	O
ly	O
different	O
LINE1	O
methylation	O
compared	O
to	O
placentas	O
from	O
in	O
vivo	O
conceptions	O
,	O
while	O
embryos	O
resulting	O
from	O
frozen	O
embryos	O
were	O
not	O
significant	O
ly	O
different	O
from	O
controls	O
.	O

On	O
sex	O
-	O
stratified	O
analysis	O
,	O
only	O
males	O
had	O
significant	O
methylation	O
differences	O
at	O
LINE1	O
elements	O
stratified	O
for	O
the	O
modifiable	O
factors	O
.	O

As	O
expected	O
,	O
LINE1	O
methylation	O
was	O
significantly	O
different	O
between	O
males	O
and	O
females	O
in	O
the	O
control	O
population	O
.	O

However	O
,	O
we	O
did	O
not	O
observe	O
sex	O
-	O
specific	O
differences	O
in	O
the	O
IVF	O
group	O
.	O

We	O
validated	O
this	O
sex	O
-	O
specific	O
observation	O
in	O
an	O
additional	O
cohort	O
and	O
in	O
opposite	O
sex	O
IVF	O
twins	O
.	O

We	O
show	O
that	O
two	O
clinically	O
modifiable	O
factors	O
(	O
embryo	B-P
culture	I-P
in	O
5	O
vs	O
20	O
%	O
oxygen	O
tension	O
and	O
fresh	O
vs	O
frozen	O
embryo	O
transfer	O
)	O
are	O
associated	O
with	O
global	O
placental	O
methylation	O
differences	O
.	O

Interestingly	O
,	O
males	O
appear	O
more	O
vulnerable	O
to	O
such	O
treatment	O
-related	O
global	O
changes	O
in	O
DNA	O
methylation	O
than	O
do	O
females	O
.	O

Comparison	O
of	O
the	O
analgesic	O
efficacy	O
of	O
oral	O
ketorolac	O
versus	O
intramuscular	O
tramadol	O
after	O
third	O
molar	O
surgery	O
:	O
A	O
parallel	O
,	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
clinical	O
trial	O
.	O

Preemptive	O
analgesia	O
is	O
considered	O
an	O
alternative	O
for	O
treating	O
the	O
postsurgical	O
pain	O
of	O
third	O
molar	O
removal	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
preemptive	O
analgesic	O
efficacy	O
of	O
oral	O
ketorolac	O
versus	O
intramuscular	O
tramadol	O
after	O
a	O
mandibular	O
third	O
molar	O
surgery	O
.	O

A	O
parallel	O
,	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
clinical	O
trial	O
was	O
carried	O
out	O
.	O

Thirty	O
patients	O
were	O
randomized	O
into	O
two	O
treatment	O
groups	O
using	O
a	O
series	O
of	O
random	O
numbers	O
:	O
Group	O
A	O
,	O
oral	O
ketorolac	O
10	O
mg	O
plus	O
intramuscular	O
placebo	O
(	O
1	O
mL	O
saline	O
solution	O
)	O
;	O
or	O
Group	O
B	O
,	O
oral	O
placebo	O
(	O
similar	O
tablet	O
to	O
oral	O
ketorolac	O
)	O
plus	O
intramuscular	O
tramadol	O
50	O
mg	O
diluted	O
in	O
1	O
mL	O
saline	O
solution	O
.	O

These	O
treatments	O
were	O
given	O
30	O
min	O
before	O
the	O
surgery	O
.	O

We	O
evaluated	O
the	O
time	O
of	O
first	O
analgesic	O
rescue	O
medication	O
,	O
pain	O
intensity	O
,	O
total	O
analgesic	O
consumption	O
and	O
adverse	O
effects	O
.	O

Patients	O
taking	O
oral	O
ketorolac	O
had	O
longer	O
time	O
of	O
analgesic	O
covering	O
and	O
less	O
postoperative	O
pain	O
when	O
compared	O
with	O
patients	O
receiving	O
intramuscular	O
tramadol	O
.	O

According	O
to	O
the	O
VAS	B-P
and	O
UAC	O
results	O
,	O
this	O
study	O
suggests	O
that	O
10	O
mg	O
of	O
oral	O
ketorolac	O
had	O
superior	O
analgesic	O
effect	O
than	O
50	O
mg	O
of	O
tramadol	O
when	O
administered	O
before	O
a	O
mandibular	O
third	O
molar	O
surgery	O
.	O

Helicobacter	O
pylori	O
infection	O
and	O
its	O
related	O
factors	O
in	O
junior	O
high	O
school	O
students	O
in	O
Nagano	O
Prefecture	O
,	O
Japan	O
.	O

There	O
have	O
been	O
few	O
reports	O
on	O
Helicobacter	O
pylori	O
(	O
H.	O
pylori	O
)	O
infection	O
in	O
asymptomatic	O
Japanese	O
children	O
and	O
adolescents	O
.	O

We	O
hypothesized	O
that	O
the	O
prevalence	O
of	O
H.	O
pylori	O
infection	O
is	O
very	O
low	O
among	O
Japanese	O
children	O
and	O
that	O
clinical	O
variables	O
such	O
as	O
serum	O
pepsinogen	O
and	O
iron	B-P
levels	I-P
are	O
associated	O
with	O
H.	O
pylori	O
infection	O
.	O

We	O
conducted	O
a	O
cross-sectional	O
analysis	O
of	O
a	O
sample	O
of	O
454	O
junior	O
high	O
school	O
students	O
aged	O
12-15	O
years	O
in	O
four	O
areas	O
in	O
Nagano	O
Prefecture	O
.	O

A	O
commercial	O
ELISA	B-P
kit	O
(	O
E-plate	O
Eiken	O
H.	O
pylori	O
antibody	O
)	O
was	O
used	O
to	O
measure	B-P
IgG	I-P
antibody	I-P
against	O
H.	O
pylori	O
.	O

Serum	O
pepsinogen	O
and	O
iron	B-P
levels	I-P
were	O
also	O
measured	O
using	O
standard	O
methods	O
.	O

A	O
urea	B-P
breath	I-P
test	I-P
was	O
performed	O
for	O
seropositive	O
students	O
.	O

The	O
overall	O
prevalence	O
of	O
H.	O
pylori	O
was	O
3.1	O
%	O
(	O
14/454	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
H.	O
pylori	O
prevalence	O
among	O
mountain	O
,	O
rural	O
,	O
and	O
urban	O
areas	O
.	O

The	O
mean	O
level	O
of	O
both	O
serum	O
pepsinogen	O
(	O
PG	O
I	O
)	O
and	O
PG	O
II	O
was	O
significantly	O
increased	O
in	O
the	O
seropositive	O
subjects	O
compared	O
with	O
the	O
seronegative	O
subjects	O
.	O

When	O
the	O
cutoff	O
values	O
for	O
adults	O
(	O
PG	O
I	O
:	O
70	O
ng/mL	O
and	O
PG	O
I	O
/	O
II	O
ratio	O
:	O
3	O
)	O
were	O
used	O
,	O
4	O
of	O
14	O
subjects	O
had	O
PG	O
I	O
≤70	O
ng/mL	O
and	O
PG	O
I	O
/	O
II	O
ratio	O
≤3	O
.	O

The	O
results	O
of	O
a	O
logistic	O
regression	O
analysis	O
showed	O
that	O
low	O
serum	B-P
iron	I-P
levels	I-P
were	O
significantly	O
associated	O
with	O
H.	O
pylori	O
infection	O
(	O
P=.02	O
)	O
.	O

The	O
prevalence	O
of	O
H.	O
pylori	O
infection	O
is	O
as	O
low	O
as	O
3	O
%	O
among	O
junior	O
high	O
school	O
students	O
aged	O
12-	O
15	O
years	O
in	O
Japan	O
.	O

The	O
disappearance	O
of	O
H.	O
pylori	O
is	O
accelerating	O
in	O
Japanese	O
children	O
.	O

Chitosan	O
grafted	O
monomethyl	O
fumaric	O
acid	O
as	O
a	O
potential	O
food	O
preservative	O
.	O

The	O
present	O
study	O
aims	O
at	O
in	O
vitro	O
antibacterial	O
and	O
antioxidant	O
activity	O
evaluation	O
of	O
chitosan	O
modified	O
with	O
monomethyl	O
fumaric	O
acid	O
(	O
MFA	O
)	O
using	O
1-ethyl-3-	O
(	O
3-dimethylaminopropyl	O
)	O
carbodiimide	O
(	O
EDC	O
)	O
as	O
mediator	O
.	O

Three	O
different	O
kinds	O
of	O
chitosan	O
derivatives	O
Ch-Ds-1	O
,	O
Ch-Ds-2	O
and	O
Ch-Ds-3	O
were	O
synthesized	O
by	O
feeding	O
different	O
concentration	O
of	O
MFA	O
.	O

The	O
chemical	O
structures	O
of	O
resulting	O
materials	O
were	O
characterized	O
by	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
,	O
(	B-P
13	I-P
)	I-P
C	I-P
NMR	I-P
,	O
HR-XRD	B-P
,	O
FT-IR	O
and	O
TNBS	B-P
assay	I-P
.	O

The	O
results	O
showed	O
that	O
Ch-Ds-1	O
,	O
Ch-Ds-2	O
and	O
Ch-Ds-3	O
were	O
successfully	O
synthesized	O
.	O

The	O
%	O
amino	O
groups	O
of	O
chitosan	O
modified	O
by	O
MFA	O
were	O
evaluated	O
by	O
TNBS	B-P
assay	I-P
and	O
ranging	O
from	O
1.82±0.05	O
%	O
to	O
7.88±0.04	O
%	O
.	O

All	O
the	O
chitosan	O
derivatives	O
are	O
readily	O
soluble	O
in	O
water	O
and	O
swelled	O
by	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
,	O
toluene	O
and	O
dimethyl	O
formamide	O
(	O
DMF	O
)	O
.	O

The	O
antioxidant	O
activity	O
for	O
all	O
the	O
chitosan	O
derivatives	O
have	O
been	O
significantly	O
improved	O
(	O
P	O
<	O
0.05	O
)	O
compared	O
to	O
the	O
chitosan	O
.	O

Upon	O
antibacterial	O
activity	O
at	O
pH	O
4.0	O
,	O
all	O
the	O
chitosan	O
derivatives	O
showed	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
antibacterial	O
activity	O
against	O
Gram	O
positive	O
Staphylococcus	O
aureus	O
,	O
Listeria	O
monocytogenes	O
strains	O
and	O
Gram	O
negative	O
Escherichia	O
coli	O
and	O
Salmonella	O
enteritidis	O
strains	O
compared	O
to	O
chitosan	O
.	O

In	O
conclusion	O
,	O
MFA	O
modified	O
chitosan	O
has	O
shown	O
enhanced	O
activities	O
along	O
with	O
solubility	O
,	O
and	O
could	O
be	O
used	O
as	O
a	O
novel	O
food	O
preservative	O
and	O
packaging	O
material	O
for	O
long	O
time	O
food	O
safety	O
and	O
security	O
.	O

Energy	O
Expenditure	O
and	O
Intensity	O
of	O
Classroom	O
Physical	O
Activity	O
in	O
Elementary	O
School	O
Children	O
.	O

There	O
is	O
limited	O
data	O
regarding	O
objectively	O
measured	O
energy	O
cost	O
and	O
intensity	O
of	O
classroom	O
instruction	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
current	O
study	O
was	O
to	O
objectively	O
measure	O
energy	O
cost	O
and	O
subsequently	O
calculate	O
MET	B-P
values	I-P
using	O
a	O
portable	O
indirect	O
calorimeter	O
(	O
IC	O
)	O
for	O
both	O
normal	O
classroom	O
instruction	O
(	O
NCI	O
)	O
and	O
active	O
classroom	O
instruction	O
(	O
ACI	O
)	O
.	O

We	O
assessed	O
energy	O
expenditure	O
(	O
EE	O
)	O
and	O
intensity	O
levels	O
(	O
METs	B-P
)	O
in	O
elementary	O
school	O
children	O
(	O
17	O
boys	O
and	O
15	O
girls	O
)	O
using	O
an	O
IC	O
(	O
COSMED	O
K4b2	O
)	O
.	O

Independent	O
t-tests	O
were	O
used	O
to	O
evaluate	O
potential	O
sex	O
and	O
grade	O
level	O
differences	O
for	O
age	O
,	O
BMI	O
,	O
VO2	B-P
,	O
EE	O
,	O
and	O
METs	B-P
.	O

The	O
average	O
EE	O
for	O
NCI	O
and	O
ACI	O
were	O
1.8	O
±	O
0.4	O
and	O
3.9	O
±	O
1.0	O
,	O
respectively	O
.	O

The	O
average	O
intensity	O
level	O
for	O
NCI	O
and	O
ACI	O
were	O
1.9	O
±	O
0.4	O
and	O
4.2	O
±	O
0.9	O
METs	B-P
,	O
respectively	O
.	O

PA	O
delivered	O
through	O
ACI	O
can	O
elicit	O
EE	O
at	O
a	O
moderate	O
intensity	O
level	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
ACI	O
as	O
a	O
convenient/feasible	O
avenue	O
for	O
increasing	O
PA	O
in	O
youth	O
without	O
decreasing	O
instruction	O
time	O
.	O

Suppressive	O
effect	O
of	O
Spirulina	O
fusiformis	O
on	O
diclofenac	O
-	O
induced	O
hepato-renal	O
injury	O
and	O
gastrointestinal	O
ulcer	O
in	O
Wistar	O
albino	O
rats	O
:	O
A	O
biochemical	O
and	O
histological	B-P
approach	I-P
.	O

The	O
non-steroidal	O
anti-inflammatory	O
drug	O
(	O
NSAID	O
)	O
,	O
diclofenac	O
causes	O
hepato-renal	O
toxicity	O
and	O
gastric	O
ulcer	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
Spirulina	O
fusiformis	O
on	O
Diclofenac	O
-	O
induced	O
toxicity	O
in	O
Wistar	O
albino	O
rats	O
.	O

Rats	O
were	O
treated	O
as	O
follows	O
:	O
normal	O
control	O
(	O
group	O
I	O
)	O
;	O
diclofenac	O
(	O
50mg/kgb.w.	O
,	O
i.p	O
.	O
)	O

treated	O
rats	O
(	O
group	O
II	O
)	O
;	O
diclofenac	O
-	O
induced	O
(	O
50mg/kgb.w.	O
,	O
i.p	O
.	O
)	O

rats	O
treated	O
with	O
Spirulina	O
fusiformis	O
(	O
400mg/kgb.w.	O
,	O
p.o	O
.	O
)	O

(	O
group	O
III	O
)	O
;	O
diclofenac	O
-	O
induced	O
(	O
50mg/kgb.w.	O
,	O
i.p	O
.	O
)	O

rats	O
treated	O
with	O
silymarin	O
(	O
25mg/kgb.w.	O
,	O
p.o	O
.	O
)	O

(	O
group	O
IV	O
)	O
;	O
Spirulina	O
fusiformis	O
(	O
400mg/kgb.w.	O
,	O
p.o	O
.	O
)	O

alone	O
treated	O
rats	O
(	O
group	O
V	O
)	O
.	O

Biochemical	O
(	O
liver	O
and	O
kidney	O
functional	O
markers	O
)	O
and	O
antioxidant	O
parameters	O
(	O
enzymic	O
and	O
non-enzymic	O
antioxidants	O
)	O
were	O
measured	O
in	O
the	O
blood	O
and	O
tissue	O
homogenates	O
of	O
the	O
rats	O
.	O

Evaluation	O
of	O
intestinal	O
ulcer	O
score	O
and	O
assessment	O
of	O
liver	O
and	O
kidney	O
histology	O
were	O
also	O
done	O
.	O

Alterations	O
in	O
the	O
levels	O
of	O
biochemical	O
and	O
antioxidant	O
assays	B-P
and	O
histopathological	O
changes	O
in	O
liver	O
and	O
kidney	O
proved	O
the	O
toxic	O
effect	O
of	O
diclofenac	O
.	O

The	O
ulcer	O
score	O
was	O
significantly	O
increased	O
in	O
the	O
diclofenac	O
treated	O
rats	O
.	O

Spirulina	O
fusiformis	O
showed	O
to	O
reduce	O
such	O
changes	O
and	O
was	O
able	O
to	O
restore	O
normal	O
antioxidant	O
status	O
in	O
the	O
rats	O
.	O

Our	O
study	O
proves	O
the	O
hepato-renal	O
and	O
gastroprotective	O
activity	O
of	O
Spirulina	O
fusiformis	O
in	O
diclofenac	O
-	O
treated	O
rats	O
.	O

Overall	O
Quality	O
Properties	O
of	O
Kiwifruit	O
Treated	O
by	O
Cinnamaldehyde	O
and	O
Citral	O
:	O
Microbial	O
,	O
Antioxidant	O
Capacity	O
during	O
Cold	B-P
Storage	I-P
.	O

This	O
work	O
was	O
undertaken	O
to	O
evaluate	O
the	O
microbiological	O
characteristics	O
and	O
antioxidant	O
and	O
physiological	O
activities	O
in	O
kiwifruits	O
(	O
Actinida	O
deliciosa	O
var	O
.	O

Qinmei	O
)	O
with/without	O
cinnamaldehyde	O
(	O
C1	O
)	O
and	O
citral	O
(	O
C2	O
)	O
fumigation	O
treatments	O
(	O
5	O
μL/L	O
)	O
during	O
0	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
d	O
of	O
storage	O
at	O
4	O
°C	O
.	O

Essential	O
oils	O
(	O
EOs	O
)	O
treatment	O
lowered	O
the	O
total	O
viable	O
counts	O
,	O
yeast	O
,	O
and	O
mold	O
to	O
1.54	O
,	O
2.36	O
,	O
and	O
2.05	O
log	O
CFU/g	O
,	O
respectively	O
.	O

Moreover	O
,	O
EOs	O
improved	O
the	O
antioxidant	O
activities	O
of	O
kiwifruit	O
.	O

They	O
enhanced	O
phenolics	O
and	O
flavonoids	O
content	O
in	O
fruit	O
tissue	O
by	O
49.48	O
%	O
at	O
day	O
3	O
and	O
56.93	O
%	O
at	O
day	O
6	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
ascorbic	O
acid	O
in	O
treated	O
groups	O
had	O
the	O
lower	O
losing	O
rate	O
.	O

Similarly	O
,	O
MDA	O
(	O
malondialdehyde	O
)	O
,	O
H2	O
O2	O
(	O
hydrogen	O
peroxide	O
)	O
,	O
and	O
(	O
•	O
)	O
O2	O
(	O
-	O
)	O
(	O
superoxide	O
anion	O
)	O
production	O
were	O
effectively	O
decreased	O
in	O
the	O
range	O
of	O
27.27	O
%	O
to	O
54.38	O
%	O
.	O

Physicochemical	O
characteristics	O
showed	O
that	O
kiwifruits	O
from	O
treated	O
group	O
maintained	O
higher	O
levels	O
of	O
flesh	O
luminosity	O
and	O
firmness	O
.	O

EOs	O
also	O
decreased	O
the	O
levels	O
of	O
reducing	O
sugar	O
by	O
45.97	O
%	O
at	O
day	O
3	O
,	O
and	O
increased	O
the	O
content	O
of	O
soluble	O
protein	O
and	O
hydrolyzed	O
amino	O
acid	O
.	O

Therefore	O
,	O
postharvest	O
EOs	O
treatment	O
has	O
positive	O
effects	O
on	O
delaying	O
senescence	O
and	O
enhancing	O
antioxidant	O
capacities	O
in	O
kiwifruit	O
.	O

Panitumumab	O
-Associated	O
Encephalopathy	O
after	O
Accidental	O
Intra-arterial	O
Application	O
through	O
Dislocated	O
Central	O
Venous	O
Access	O
Device	O
.	O

Acute	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
toxicity	O
and	O
immune	O
-related	O
side	O
effects	O
are	O
increasingly	O
recognized	O
with	O
the	O
use	O
of	O
monoclonal	O
antibodies	O
for	O
cancer	O
therapy	O
.	O

Here	O
,	O
we	O
report	O
a	O
patient	O
who	O
developed	O
of	O
acute-onset	O
encephalopathy	O
and	O
coma	O
,	O
which	O
began	O
shortly	O
after	O
administration	O
of	O
panitumumab	O
for	O
the	O
treatment	O
of	O
metastatic	O
colorectal	O
cancer	O
.	O

Echocardiography	B-P
revealed	O
that	O
the	O
drug	O
had	O
been	O
infused	O
into	O
the	O
left	O
cardiac	O
ventricle	O
via	O
a	O
dislocated	O
central	O
venous	O
line	O
.	O

Diffusion-weighted	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
disclosed	O
multiple	O
cortical	O
hyperintensities	O
,	O
which	O
were	O
preferentially	O
located	O
in	O
the	O
frontal	O
lobes	O
.	O

While	O
the	O
neurological	O
condition	O
improved	O
within	O
a	O
few	O
days	O
,	O
the	O
patient	O
died	O
4	O
weeks	O
later	O
.	O

It	O
seems	O
likely	O
that	O
the	O
administration	O
of	O
the	O
antibody	O
via	O
the	O
intra-arterial	O
route	O
contributed	O
to	O
the	O
development	O
of	O
this	O
condition	O
.	O

Toxic	O
encephalopathy	O
may	O
be	O
a	O
hitherto	O
unrecognized	O
complication	O
of	O
panitumumab	O
treatment	O
and	O
should	O
be	O
taken	O
into	O
consideration	O
in	O
patients	O
developing	O
CNS	O
symptoms	O
undergoing	O
this	O
therapy	O
.	O

Understanding	O
Supportive	O
Care	O
Factors	O
Among	O
African	O
American	O
Breast	O
Cancer	O
Survivors	O
.	O

Comprehensive	O
breast	O
cancer	O
care	O
includes	O
not	O
only	O
diagnosis	O
,	O
staging	B-P
,	O
and	O
treatment	O
of	O
cancer	O
but	O
also	O
assessment	O
and	O
management	O
of	O
the	O
physical	O
,	O
psychological	O
,	O
social	O
,	O
and	O
informational	O
needs	O
,	O
collectively	O
known	O
as	O
supportive	O
care	O
.	O

Several	O
studies	O
have	O
documented	O
the	O
importance	O
of	O
addressing	O
supportive	O
care	O
factors	O
among	O
breast	O
cancer	O
survivors	O
.	O

However	O
,	O
there	O
appears	O
to	O
be	O
a	O
paucity	O
of	O
research	O
concerning	O
African	O
American	O
breast	O
cancer	O
survivors	O
(	O
AABCS	O
)	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
and	O
understand	O
the	O
patient-centered	O
supportive	O
care	O
factors	O
among	O
self-identified	O
AABCS	O
.	O

Using	O
a	O
qualitative	O
descriptive	O
approach	O
,	O
an	O
open-ended	O
question	O
explored	O
supportive	O
care	O
factors	O
that	O
were	O
used	O
by	O
N	O
=	O
155	O
AABCS	O
.	O

Four	O
supportive	O
care	O
factors	O
were	O
identified	O
:	O
faith	O
,	O
supportive	O
structures	O
,	O
optimism	O
,	O
and	O
access	O
to	O
information	O
.	O

An	O
understanding	O
of	O
these	O
factors	O
might	O
facilitate	O
discussion	O
between	O
survivors	O
and	O
the	O
health	O
care	O
team	O
.	O

The	O
resultant	O
effect	O
could	O
also	O
inform	O
and	O
promote	O
the	O
delivery	O
of	O
culturally	O
specific	O
health	O
care	O
to	O
address	O
the	O
supportive	O
care	O
needs	O
among	O
these	O
women	O
.	O

The	O
Bindex	O
(	O
®	O
)	O
ultrasound	O
device	O
:	O
reliability	O
of	O
cortical	O
bone	O
thickness	O
measures	O
and	O
their	O
relationship	O
to	O
regional	O
bone	O
mineral	O
density	O
.	O

The	O
Bindex	O
(	O
®	O
)	O
quantitative	O
ultrasound	O
(	O
QUS	O
)	O
device	O
is	O
currently	O
available	O
and	O
this	O
study	O
analyzed	O
(	O
I	O
)	O
its	O
relative	O
and	O
absolute	O
intra-	O
and	O
inter-session	O
reliability	O
and	O
(	O
II	O
)	O
the	O
relationship	O
between	O
the	O
data	O
provided	O
by	O
Bindex	O
(	O
®	O
)	O
-QUS	O
and	O
the	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
measured	O
by	O
dual-energy	B-P
x-ray	I-P
absorptiometry	I-P
at	O
corresponding	O
skeletal	O
sites	O
in	O
young	O
and	O
healthy	O
subjects	O
(	O
age	O
:	O
25.0	O
±	O
3.6	O
years	O
)	O
.	O

Bindex	O
(	O
®	O
)	O
-QUS	O
calculates	O
a	O
density	O
index	O
on	O
the	O
basis	O
of	O
the	O
thickness	O
of	O
cortical	O
bone	O
measured	O
at	O
the	O
distal	O
radius	O
and	O
the	O
distal	O
plus	O
proximal	O
tibia	O
.	O

The	O
data	O
show	O
a	O
very	O
good	O
relative	O
and	O
absolute	O
intra-	O
(	O
ICC	O
=	O
0.977	O
,	O
CV	O
=	O
1.5	O
%	O
)	O
and	O
inter-session	O
reliability	O
(	O
ICC	O
=	O
0.978	O
,	O
CV	O
=	O
1.4	O
%	O
)	O
for	O
the	O
density	O
index	O
.	O

The	O
highest	O
positive	O
correlations	O
were	O
found	O
between	O
cortical	O
thickness	O
and	O
BMD	O
for	O
the	O
distal	O
radius	O
and	O
distal	O
tibia	O
(	O
r	O
⩾	O
0.71	O
,	O
p	O
<	O
0.001	O
)	O
.	O

The	O
data	O
indicate	O
that	O
the	O
Bindex	O
(	O
®	O
)	O
-QUS	O
parameters	O
are	O
repeatable	O
within	O
and	O
between	O
measurement	O
sessions	O
.	O

Furthermore	O
,	O
the	O
measurements	O
reflect	O
the	O
BMD	O
at	O
specific	O
skeletal	O
sites	O
.	O

Bindex	O
(	O
®	O
)	O
-QUS	O
might	O
be	O
a	O
useful	O
tool	O
for	O
the	O
measurement	O
of	O
skeletal	O
adaptations	O
.	O

Changes	O
in	O
the	O
Dermal	O
Structure	O
during	O
Cultured	O
Epidermal	O
Autograft	O
Engraftment	O
Process	O
.	O

The	O
use	O
of	O
cultured	O
epithelial	O
autografts	O
for	O
the	O
treatment	O
of	O
extensive	O
burn	O
wounds	O
has	O
become	O
popular	O
in	O
recent	O
years	O
.	O

We	O
examined	O
extensive	O
burn	O
wounds	O
in	O
14	O
patients	O
by	O
using	O
a	O
combination	O
of	O
autograft	O
and	O
cultured	O
epithelial	O
autografts	O
developed	O
in	O
Japan	O
(	O
JACE	O
)	O
.	O

We	O
undertook	O
a	O
skin	B-P
biopsy	I-P
at	O
2	O
,	O
4	O
,	O
and	O
6	O
weeks	O
after	O
transplantation	O
with	O
JACE	O
.	O

By	O
using	O
electron	B-P
microscopy	I-P
we	O
observed	O
the	O
engraftment	O
process	O
.	O

In	O
transmission	O
electron	O
microscope	O
findings	O
,	O
we	O
recognized	O
the	O
engraftment	O
process	O
of	O
JACE	O
.	O

Keratinocytes	O
matured	O
gradually	O
.	O

Collagen	O
fibers	O
formed	O
thick	O
bundles	O
in	O
the	O
dermis	O
layer	O
.	O

In	O
scanning	O
electron	O
microscope	O
findings	O
,	O
we	O
observed	O
papillary	O
dermis	O
development	O
on	O
the	O
artificial	O
dermis	O
.	O

After	O
managing	O
wound	O
bed	O
preparation	O
by	O
using	O
artificial	O
dermis	O
,	O
we	O
were	O
able	O
to	O
recognize	O
the	O
good	O
result	O
of	O
grafting	O
JACE	O
on	O
meshed	O
6:1	O
split	O
thickness	O
autografts	O
.	O

This	O
is	O
because	O
the	O
auto	O
dermis	O
from	O
autograft	O
extended	O
under	O
the	O
JACE	O
,	O
binding	O
between	O
JACE	O
,	O
and	O
the	O
dermis	O
became	O
strong	O
.	O

The	O
Netherlands	O
Chlamydia	O
cohort	O
study	O
(	O
NECCST	O
)	O
protocol	O
to	O
assess	O
the	O
risk	O
of	O
late	O
complications	O
following	O
Chlamydia	O
trachomatis	O
infection	O
in	O
women	O
.	O

Chlamydia	O
trachomatis	O
(	O
CT	O
)	O
,	O
the	O
most	O
common	O
bacterial	O
sexually	O
transmitted	O
infection	O
(	O
STI	O
)	O
among	O
young	O
women	O
,	O
can	O
result	O
in	O
serious	O
sequelae	O
.	O

Although	O
the	O
course	O
of	O
infection	O
is	O
often	O
asymptomatic	O
,	O
CT	O
may	O
cause	O
pelvic	O
inflammatory	O
disease	O
(	O
PID	O
)	O
,	O
leading	O
to	O
severe	O
complications	O
,	O
such	O
as	O
prolonged	O
time	O
to	O
pregnancy	O
,	O
ectopic	O
pregnancy	O
,	O
and	O
tubal	O
factor	O
subfertility	O
.	O

The	O
risk	O
of	O
and	O
risk	O
factors	O
for	O
complications	O
following	O
CT-infection	O
have	O
not	O
been	O
assessed	O
in	O
a	O
long-term	O
prospective	O
cohort	O
study	O
,	O
the	O
preferred	O
design	O
to	O
define	O
infections	O
and	O
complications	O
adequately	O
.	O

In	O
the	O
Netherlands	O
Chlamydia	O
Cohort	O
Study	O
(	O
NECCST	O
)	O
,	O
a	O
cohort	O
of	O
women	O
of	O
reproductive	O
age	O
with	O
and	O
without	O
a	O
history	O
of	O
CT-infection	O
is	O
followed	O
over	O
a	O
minimum	O
of	O
ten	O
years	O
to	O
investigate	O
(	O
CT	O
-related	O
)	O
reproductive	O
tract	O
complications	O
.	O

This	O
study	O
is	O
a	O
follow-up	O
of	O
the	O
Chlamydia	B-P
Screening	I-P
Implementation	I-P
(	I-P
CSI	I-P
)	I-P
study	I-P
,	O
executed	O
between	O
2008	O
and	O
2011	O
in	O
the	O
Netherlands	O
.	O

For	O
NECCST	O
,	O
female	O
CSI	B-P
participants	O
who	O
consented	O
to	O
be	O
approached	O
for	O
follow-up	O
studies	O
(	O
n	O
=	O
14,685	O
)	O
are	O
invited	O
,	O
and	O
prospectively	O
followed	O
until	O
2022	O
.	O

Four	O
data	O
collection	O
moments	O
are	O
foreseen	O
every	O
two	O
consecutive	O
years	O
.	O

Questionnaire	O
data	O
and	O
blood	O
samples	O
for	O
CT	O
-	O
Immunoglobulin	B-P
G	I-P
(	I-P
IgG	I-P
)	I-P
measurement	I-P
are	O
obtained	O
as	O
well	O
as	O
host	O
DNA	O
to	O
determine	O
specific	O
genetic	O
biomarkers	O
related	O
to	O
susceptibility	O
and	O
severity	O
of	O
infection	O
.	O

CT	O
-	O
history	O
will	O
be	O
based	O
on	O
CSI	B-P
test	I-P
outcomes	O
,	O
self-reported	O
infections	O
and	O
CT	O
-	O
IgG	O
presence	O
.	O

Information	O
on	O
(	O
time	O
to	O
)	O
pregnancies	O
and	O
the	O
potential	O
long-term	O
complications	O
(	O
i.e	O
.	O

PID	O
,	O
ectopic	O
pregnancy	O
and	O
(	O
tubal	O
factor	O
)	O
subfertility	O
)	O
,	O
will	O
be	O
acquired	O
by	O
questionnaires	O
.	O

Reported	O
subfertility	O
will	O
be	O
verified	O
in	O
medical	O
registers	O
.	O

Occurrence	O
of	O
these	O
late	O
complications	O
and	O
prolonged	O
time	O
to	O
pregnancy	O
,	O
as	O
a	O
proxy	O
for	O
reduced	O
fertility	O
due	O
to	O
a	O
previous	O
CT-infection	O
,	O
or	O
other	O
risk	O
factors	O
,	O
will	O
be	O
investigated	O
using	O
longitudinal	O
statistical	O
procedures	O
.	O

In	O
the	O
proposed	O
study	O
,	O
the	O
occurrence	O
of	O
late	O
complications	O
following	O
CT-infection	O
and	O
its	O
risk	O
factors	O
will	O
be	O
assessed	O
.	O

Ultimately	O
,	O
provided	O
reliable	O
risk	O
factors	O
and/or	O
markers	O
can	O
be	O
identified	O
for	O
such	O
late	O
complications	O
.	O

This	O
will	O
contribute	O
to	O
the	O
development	O
of	O
a	O
prognostic	O
tool	O
to	O
estimate	O
the	O
risk	O
of	O
CT	O
-related	O
complications	O
at	O
an	O
early	O
time	O
point	O
,	O
enabling	O
targeted	O
prevention	O
and	O
care	O
towards	O
women	O
at	O
risk	O
for	O
late	O
complications	O
.	O

Dutch	O
Trial	O
Register	O
NTR-5597	O
.	O

Retrospectively	O
registered	O
14	O
February	O
2016	O
.	O

Mildly	O
raised	O
tricuspid	O
regurgitant	O
velocity	O
2.5-3.0	O
m/s	O
in	O
pregnant	O
women	O
with	O
sickle	O
cell	O
disease	O
is	O
not	O
associated	O
with	O
poor	O
obstetric	O
outcome	O
-	O
An	O
observational	O
cross-sectional	O
study	O
.	O

Pulmonary	O
hypertension	O
is	O
associated	O
with	O
36	O
%	O
mortality	O
in	O
pregnancy	O
,	O
and	O
6-10	O
%	O
of	O
patients	O
with	O
sickle	O
cell	O
disease	O
have	O
pulmonary	O
hypertension	O
.	O

Tricuspid	O
regurgitant	O
velocity	O
≥2.5	O
m/s	O
on	O
echocardiography	B-P
is	O
a	O
well	O
validated	O
means	O
of	O
screening	O
for	O
pulmonary	O
hypertension	O
in	O
the	O
non-pregnant	O
population	O
.	O

This	O
is	O
a	O
pilot	O
study	O
to	O
determine	O
if	O
this	O
is	O
a	O
useful	O
non-invasive	O
screening	O
test	O
for	O
pulmonary	O
hypertension	O
in	O
pregnancy	O
,	O
and	O
whether	O
raised	O
tricuspid	O
regurgitant	O
velocity	O
≥2.5	O
m/s	O
was	O
associated	O
with	O
poor	O
outcomes	O
.	O

This	O
is	O
a	O
cross-sectional	O
study	O
over	O
a	O
five-year	O
period	O
in	O
a	O
tertiary	O
referral	O
centre	O
with	O
a	O
specialised	O
multidisciplinary	O
clinic	O
for	O
pregnant	O
women	O
with	O
sickle	O
cell	O
disease	O
.	O

Women	O
with	O
sickle	O
cell	O
disease	O
,	O
no	O
prior	O
pulmonary	O
hypertension	O
and	O
singleton	O
pregnancies	O
who	O
had	O
echocardiography	B-P
with	O
a	O
measurable	O
tricuspid	O
regurgitant	O
velocity	O
in	O
pregnancy	O
were	O
included	O
.	O

There	O
were	O
34	O
pregnancies	O
,	O
of	O
which	O
eight	O
had	O
tricuspid	O
regurgitant	O
velocity	O
≥2.5	O
m/s	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
their	O
characteristics	O
,	O
sickle	O
cell	O
-related	O
complications	O
or	O
medical	O
co-morbidities	O
.	O

The	O
women	O
with	O
tricuspid	O
regurgitant	O
velocity	O
≥2.5	O
m/s	O
had	O
similar	O
obstetric	O
and	O
perinatal	O
outcomes	O
as	O
those	O
with	O
a	O
tricuspid	O
regurgitant	O
velocity	O
<	O
2.5	O
m/s	O
.	O

Involvement	O
of	O
the	O
endocannabinoid	O
system	O
in	O
the	O
physiological	O
response	O
to	O
transient	O
common	O
carotid	O
artery	O
occlusion	O
and	O
reperfusion	O
.	O

The	O
transient	O
global	O
cerebral	O
hypoperfusion	O
/	O
reperfusion	O
achieved	O
by	O
induction	O
of	O
Bilateral	O
Common	O
Carotid	O
Artery	O
Occlusion	O
followed	O
by	O
Reperfusion	O
(	O
BCCAO	O
/	O
R	O
)	O
may	O
trigger	O
a	O
physiological	O
response	O
in	O
an	O
attempt	O
to	O
preserve	O
tissue	O
and	O
function	O
integrity	O
.	O

There	O
are	O
several	O
candidate	O
molecules	O
among	O
which	O
the	O
endocannabinoid	O
system	O
(	O
ECS	O
)	O
and/or	O
peroxisome-proliferator	O
activated	O
receptor-alpha	O
(	O
PPAR-alpha	O
)	O
may	O
play	O
a	O
role	O
in	O
modulating	O
oxidative	O
stress	O
and	O
inflammation	O
.	O

The	O
aims	O
of	O
the	O
present	O
study	O
are	O
to	O
evaluate	O
whether	O
the	O
ECS	O
,	O
the	O
enzyme	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
and	O
PPAR-alpha	O
are	O
involved	O
during	O
BCCAO	O
/	O
R	O
in	O
rat	O
brain	O
,	O
and	O
to	O
identify	O
possible	O
markers	O
of	O
the	O
ongoing	O
BCCAO	O
/	O
R	O
-	O
induced	O
challenge	O
in	O
plasma	O
.	O

Adult	O
Wistar	O
rats	O
underwent	O
BCCAO	O
/	O
R	O
with	O
30	O
min	O
hypoperfusion	O
followed	O
by	O
60	O
min	O
reperfusion	O
.	O

The	O
frontal	O
and	O
temporal	O
-	O
occipital	O
cortices	O
and	O
plasma	O
were	O
analyzed	O
by	O
high	B-P
performance	I-P
liquid	I-P
chromatography-mass	I-P
spectrometry	I-P
(	O
HPLC-MS	B-P
)	O
to	O
determine	O
concentrations	O
of	O
endocannabinoids	O
(	O
eCBs	O
)	O
and	O
related	O
molecules	O
behaving	O
as	O
ligands	O
of	O
PPAR-alpha	O
,	O
and	O
of	O
oxidative-stress	O
markers	O
such	O
as	O
lipoperoxides	O
,	O
while	O
Western	B-P
Blot	I-P
and	O
immunohistochemistry	B-P
were	O
used	O
to	O
study	O
protein	O
expression	O
of	O
cannabinoid	O
receptors	O
,	O
COX-2	O
and	O
PPAR-alpha	O
.	O

Unpaired	O
Student	O
's	O
t-test	O
was	O
used	O
to	O
evaluate	O
statistical	O
differences	O
between	O
groups	O
.	O

The	O
acute	O
BCCAO	O
/	O
R	O
procedure	O
is	O
followed	O
by	O
increased	O
brain	O
tissue	O
levels	O
of	O
the	O
eCBs	O
2-arachidonoylglycerol	O
and	O
anandamide	O
,	O
palmitoylethanolamide	O
,	O
an	O
avid	O
ligand	O
of	O
PPAR-alpha	O
,	O
lipoperoxides	O
,	O
type	O
1	O
(	O
CB1	O
)	O
and	O
type	O
2	O
(	O
CB2	O
)	O
cannabinoid	O
receptors	O
,	O
and	O
COX-2	O
,	O
and	O
decreased	O
brain	O
tissue	O
concentrations	O
of	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
,	O
one	O
of	O
the	O
major	O
targets	O
of	O
lipid	O
peroxidation	O
.	O

In	O
plasma	O
,	O
increased	O
levels	O
of	O
anandamide	O
and	O
lipoperoxides	O
were	O
observed	O
.	O

The	O
BCCAO	O
/	O
R	O
stimulated	O
early	O
molecular	O
changes	O
that	O
can	O
be	O
easily	O
traced	O
in	O
brain	O
tissue	O
and	O
plasma	O
,	O
and	O
that	O
are	O
indicative	O
of	O
the	O
tissue	O
physiological	O
response	O
to	O
the	O
reperfusion	O
-	O
induced	O
oxidative	O
stress	O
and	O
inflammation	O
.	O

The	O
observed	O
variations	O
suggest	O
that	O
the	O
positive	O
modulation	O
of	O
the	O
ECS	O
and	O
the	O
increase	O
of	O
proinflammatory	O
substances	O
are	O
directly	O
correlated	O
events	O
.	O

Increase	O
of	O
plasmatic	O
levels	O
of	O
anandamide	O
and	O
lipoperoxides	O
further	O
suggests	O
that	O
dysregulation	O
of	O
these	O
molecules	O
may	O
be	O
taken	O
as	O
an	O
indicator	O
of	O
an	O
ongoing	O
hypoperfusion	O
/	O
reperfusion	O
challenge	O
.	O

Novel	O
protein	O
-	O
inhibitor	O
interactions	O
in	O
site	O
3	O
of	O
Ca	O
(	O
2+	O
)	O
-bound	O
S100B	O
as	O
discovered	O
by	O
X-ray	B-P
crystallography	I-P
.	O

Structure-based	O
drug	O
discovery	O
is	O
under	O
way	O
to	O
identify	O
and	O
develop	O
small-molecule	O
S100B	O
inhibitors	O
(	O
SBiXs	O
)	O
.	O

Such	O
inhibitors	O
have	O
therapeutic	O
potential	O
for	O
treating	O
malignant	O
melanoma	O
,	O
since	O
high	O
levels	O
of	O
S100B	O
downregulate	O
wild-type	O
p53	O
tumor	O
suppressor	O
function	O
in	O
this	O
cancer	O
.	O

Computational	B-P
and	O
X-ray	B-P
crystallographic	I-P
studies	I-P
of	O
two	O
S100B	O
-	O
SBiX	O
complexes	O
are	O
described	O
,	O
and	O
both	O
compounds	O
(	O
apomorphine	O
hydrochloride	O
and	O
ethidium	O
bromide	O
)	O
occupy	O
an	O
area	O
of	O
the	O
S100B	O
hydrophobic	O
cleft	O
which	O
is	O
termed	O
site	O
3	O
.	O

These	O
data	O
also	O
reveal	O
novel	O
protein	O
-	O
inhibitor	O
interactions	O
which	O
can	O
be	O
used	O
in	O
future	O
drug-design	O
studies	O
to	O
improve	O
SBiX	O
affinity	O
and	O
specificity	O
.	O

Of	O
particular	O
interest	O
,	O
apomorphine	O
hydrochloride	O
showed	O
S100B	O
-dependent	O
killing	O
in	O
melanoma	O
cell	O
assays	B-P
,	O
although	O
the	O
efficacy	O
exceeds	O
its	O
affinity	O
for	O
S100B	O
and	O
implicates	O
possible	O
off-target	O
contributions	O
.	O

Because	O
there	O
are	O
no	O
structural	O
data	O
available	O
for	O
compounds	O
occupying	O
site	O
3	O
alone	O
,	O
these	O
studies	O
contribute	O
towards	O
the	O
structure-based	O
approach	O
to	O
targeting	O
S100B	O
by	O
including	O
interactions	O
with	O
residues	O
in	O
site	O
3	O
of	O
S100B	O
.	O

Cytotoxic	O
and	O
antimigratory	O
effects	O
of	O
Cratoxy	O
formosum	O
extract	O
against	O
HepG2	O
liver	O
cancer	O
cells	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
underlying	O
Cratoxylum	O
formosum	O
(	O
CF	O
)	O
Dyer-induced	O
cancer	O
cell	O
death	O
and	O
antimigratory	O
effects	O
in	O
HepG2	O
liver	O
cancer	O
cells	O
.	O

The	O
cytotoxic	O
,	O
antiproliferative	O
and	O
antimigratory	O
effects	O
of	O
CF	O
leaf	O
extract	O
on	O
human	O
liver	O
cancer	O
HepG2	O
cell	O
lines	O
were	O
evaluated	O
using	O
sulforhodamine	O
B	O
,	O
colony	B-P
formation	I-P
,	O
and	O
wound	B-P
healing	I-P
assays	I-P
.	O

In	O
addition	O
,	O
apoptosis	O
induction	O
mechanisms	O
were	O
investigated	O
via	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
formation	O
,	O
caspase	O
3	O
activities	O
,	O
and	O
mitochondrial	O
membrane	O
potential	O
(	O
ΔΨm	O
)	O
disruption	O
.	O

Gene	O
expression	O
and	O
apoptosis	O
-associated	O
protein	O
levels	O
were	O
measured	O
by	O
reverse	O
transcription-quantitative	O
polymerase	O
chain	O
reaction	O
and	O
western	O
blotting	O
.	O

CF	O
induced	O
HepG2	O
cell	O
death	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
with	O
half	O
maximal	O
inhibitory	O
concentration	O
values	O
of	O
219.03±9.96	O
and	O
124.90±6.86	O
µg/ml	O
at	O
24	O
and	O
48	O
h	O
,	O
respectively	O
.	O

Treatment	O
with	O
CF	O
caused	O
a	O
significant	O
and	O
dose-dependent	O
decrease	O
in	O
colony	O
forming	O
ability	O
and	O
cell	O
migration	O
.	O

Furthermore	O
,	O
the	O
present	O
study	O
demonstrated	O
that	O
CF	O
induced	O
ROS	O
formation	O
,	O
increased	O
caspase	O
3	O
activities	O
,	O
decreased	O
the	O
ΔΨm	O
,	O
and	O
caused	O
HepG2	O
apoptosis	O
.	O

CF	O
marginally	O
decreased	O
the	O
expression	O
level	O
of	O
the	O
cell	O
cycle	O
regulatory	O
protein	O
,	O
ras-related	O
C3	O
botulinum	O
toxin	O
substrate	O
1	O
(	O
rho	O
family	O
,	O
small	O
GTP	O
binding	O
protein	O
Rac1	O
)	O
and	O
the	O
downstream	O
protein	O
,	O
cyclin	O
dependent	O
kinase	O
6	O
.	O

Additionally	O
,	O
CF	O
significantly	O
enhanced	O
p21	O
levels	O
,	O
reduced	O
cyclin	O
D1	O
protein	O
levels	O
and	O
triggered	O
cancer	O
cell	O
death	O
.	O

CF	O
leaf	O
extracts	O
induced	O
cell	O
death	O
,	O
stimulated	O
apoptosis	O
and	O
inhibited	O
migration	O
in	O
HepG2	O
cells	O
.	O

Thus	O
,	O
CF	O
may	O
be	O
useful	O
for	O
developing	O
an	O
anticancer	O
drug	O
candidate	O
for	O
the	O
treatment	O
of	O
liver	O
cancer	O
.	O

Evolution	O
of	O
imidacloprid	O
resistance	O
in	O
Myzus	O
persicae	O
in	O
Greece	O
and	O
susceptibility	O
data	O
for	O
spirotetramat	O
.	O

Myzus	O
persicae	O
s.l	O
.	O

is	O
a	O
major	O
crop	O
pest	O
globally	O
and	O
has	O
evolved	O
resistance	O
to	O
a	O
range	O
of	O
insecticide	O
classes	O
making	O
it	O
increasingly	O
difficult	O
to	O
control	O
in	O
some	O
areas	O
.	O

Here	O
we	O
compare	O
bioassay	B-P
monitoring	O
data	O
for	O
two	O
important	O
compounds	O
,	O
imidacloprid	O
and	O
spirotetramat	O
,	O
on	O
field	O
samples	O
/	O
clones	O
collected	O
in	O
Greece	O
.	O

A	O
total	O
of	O
122	O
aphid	O
samples	O
/	O
clones	O
from	O
central	O
and	O
northern	O
Greece	O
were	O
examined	O
in	O
dose-response	O
bioassays	B-P
with	O
imidacloprid	O
.	O

There	O
was	O
an	O
overall	O
increase	O
in	O
the	O
level	O
of	O
resistance	O
(	O
resistance	O
factor	O
=	O
15-40	O
)	O
within	O
tobacco	O
-	O
collected	O
samples	O
from	O
78.7	O
%	O
in	O
2007	O
to	O
86.7	O
%	O
in	O
2015	O
.	O

The	O
corresponding	O
frequencies	O
for	O
peach	O
samples	O
were	O
13.3	O
%	O
and	O
6.7	O
%	O
.	O

These	O
results	O
were	O
confounded	O
however	O
by	O
the	O
first	O
identification	O
of	O
the	O
R81T	O
target	O
mutation	O
in	O
Greece	O
during	O
2015	O
(	O
4.3	O
%	O
as	O
heterozygotes	O
in	O
peach	O
)	O
and	O
2016	O
(	O
21.3	O
%	O
as	O
heterozygotes	O
in	O
peach	O
)	O
.	O

No	O
resistance	O
to	O
spirotetramat	O
was	O
found	O
at	O
the	O
60	O
clones	O
collected	O
in	O
2015	O
.	O

Resistance	O
to	O
imidacloprid	O
is	O
continuing	O
to	O
increase	O
within	O
Greek	O
M.	O
persicae	O
s.l	O
.	O

populations	O
and	O
the	O
situation	O
is	O
likely	O
to	O
deteriorate	O
further	O
with	O
the	O
recent	O
identification	O
of	O
the	O
R81T	O
resistance	O
mutation	O
.	O

Resistance	O
to	O
spirotetramat	O
has	O
not	O
been	O
found	O
and	O
is	O
therefore	O
a	O
good	O
alternative	O
to	O
neonicotinoids	O
for	O
resistance	O
management	O
.	O

©	O
2017	O
Society	O
of	O
Chemical	O
Industry	O
.	O

Novel	O
Acinetobacter	O
parvus	O
HANDI	O
309	O
microbial	O
biomass	O
for	O
the	O
production	O
of	O
N-acetyl-β-d-glucosamine	O
(	O
GlcNAc	O
)	O
using	O
swollen	O
chitin	O
substrate	O
in	O
submerged	O
fermentation	O
.	O

N-acetyl-β-d-glucosamine	O
(	O
GlcNAc	O
)	O
6	O
is	O
extensively	O
used	O
as	O
an	O
important	O
bio-agent	O
and	O
a	O
functional	O
food	O
additive	O
.	O

The	O
traditional	O
chemical	O
process	O
for	O
GlcNAc	O
production	O
has	O
some	O
problems	O
such	O
as	O
high	O
production	O
cost	O
,	O
low	O
yield	O
,	O
and	O
acidic	O
pollution	O
.Therefore	O
,	O
to	O
discover	O
a	O
novel	O
chitinase	O
that	O
is	O
suitable	O
for	O
bioconversion	O
of	O
chitin	O
to	O
GlcNAc	O
would	O
be	O
of	O
great	O
value	O
.	O

Here	O
,	O
we	O
describe	O
the	O
complete	O
isolation	O
and	O
functional	O
characterization	O
of	O
a	O
novel	O
exo-chitinase	O
from	O
Acinetobacter	O
parvus	O
HANDI	O
309	O
for	O
the	O
conversion	O
of	O
chitin	O
.	O

The	O
identified	O
exo-chitinase	O
mainly	O
produced	O
N-acetyl-d-glucosamine	O
,	O
using	O
chitin	O
as	O
a	O
substrate	O
by	O
submerged	O
fermentation	O
.	O

The	O
A.	O
parvus	O
HANDI	O
309	O
biofuels	O
producing	O
exo-chitinase	O
were	O
characterized	O
by	O
TLC	B-P
,	O
and	O
was	O
further	O
validated	O
and	O
quantified	O
by	O
HPLC	B-P
.	O

Furthermore	O
,	O
the	O
optimal	O
temperature	O
and	O
pH	O
for	O
the	O
exo-chitinase	O
activity	O
was	O
obtained	O
in	O
the	O
culture	O
conditions	O
of	O
30	O
°C	O
and	O
7.0	O
,	O
respectively	O
.	O

The	O
maximum	O
growth	O
of	O
the	O
stationary	O
phase	O
was	O
reached	O
in	O
24	O
h	O
after	O
incubation	O
.	O

These	O
results	O
suggest	O
that	O
A.	O
parvus	O
HANDI	O
309	O
biofuels	O
producing	O
exo-chitinases	O
may	O
have	O
great	O
potential	O
in	O
chitin	O
to	O
N-acetyl-d-glucosamine	O
conversion	O
.	O

The	O
excellent	O
thermostability	O
and	O
hydrolytic	O
properties	O
may	O
give	O
the	O
exo-chitinase	O
great	O
potential	O
in	O
chitin	O
to	O
GlcNAc	O
conversion	O
in	O
industry	O
.	O

This	O
is	O
the	O
first	O
report	O
that	O
A.	O
parvus	O
HANDI	O
309	O
is	O
a	O
novel	O
bacterial	O
strain	O
that	O
has	O
the	O
ability	O
to	O
produce	O
an	O
enormous	O
amount	O
of	O
exo-chitinase	O
-	O
producing	O
bio-agents	O
in	O
a	O
short	O
time	O
on	O
an	O
industrial	O
scale	O
without	O
any	O
pretreatment	O
,	O
as	O
well	O
as	O
being	O
potentially	O
valuable	O
in	O
the	O
food	O
and	O
pharmaceutical	O
industries	O
.	O

ANTI	O
ANGIOGENIC	O
EFFECT	O
OF	O
CHEBULAGIC	O
ACID	O
INVOLVES	O
INHIBITION	O
OF	O
VEGFR2	O
AND	O
GSK3β	O
DEPENDENT	O
SIGNALING	O
PATHWAYS	O
.	O

Inhibition	O
of	O
angiogenesis	O
is	O
a	O
useful	O
strategy	O
to	O
prevent	O
cancer	O
growth	O
,	O
which	O
targets	O
new	O
vessels	O
that	O
grow	O
to	O
nourish	O
actively	O
proliferating	O
tumor	O
cells	O
.	O

Endothelial	O
cells	O
can	O
use	O
a	O
number	O
of	O
different	O
pathways	O
to	O
cause	O
angiogenesis	O
and	O
each	O
step	O
in	O
these	O
pathways	O
can	O
be	O
targeted	O
.	O

The	O
use	O
of	O
multi	O
targeted	O
drugs	O
is	O
gaining	O
much	O
importance	O
in	O
this	O
scenario	O
.	O

Our	O
previous	O
results	O
have	O
shown	O
the	O
anti	O
angiogenic	O
effect	O
of	O
Chebulagic	O
acid	O
-	O
a	O
benzopyran	O
tannin	O
present	O
in	O
the	O
fruits	O
of	O
Terminalia	O
chebula	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
molecular	O
mechanism	O
of	O
the	O
anti	O
angiogenic	O
effect	O
of	O
chebulagic	O
acid	O
.	O

Results	O
of	O
our	O
investigations	O
using	O
molecular	O
docking	O
studies	O
and	O
HUVECs	O
in	O
culture	B-P
suggested	O
that	O
Chebulagic	O
acid	O
inhibited	O
GSK-3β	O
dependent	O
β-catenin	O
phosphorylation	O
,	O
an	O
important	O
mediator	O
of	O
VE-cadherin	O
/	O
β-catenin	O
signaling	O
and	O
VEGFR2	O
phosphorylation	O
which	O
is	O
an	O
important	O
step	O
involved	O
in	O
VEGF	O
signaling	O
.	O

Chebulagic	O
acid	O
inhibits	O
angiogenesis	O
by	O
blocking	O
both	O
VEGF	O
/	O
VEGFR2	O
and	O
cell-cell	O
contact	O
dependent	O
downstream	O
signaling	O
pathway	O
.	O

Posterior	O
dislocation	O
of	O
the	O
sternoclavicular	O
joint	O
:	O
report	O
of	O
two	O
cases	O
.	O

The	O
authors	O
report	O
the	O
cases	O
of	O
two	O
young	O
patients	O
who	O
had	O
suffered	O
a	O
sporting	O
accident	O
with	O
posterior	O
traumatic	O
dislocation	O
of	O
sternoclavicular	O
joint	O
.	O

In	O
one	O
of	O
the	O
patients	O
closed	O
reduction	O
was	O
accomplished	O
by	O
keeping	O
the	O
limb	O
in	O
a	O
sling	O
.	O

The	O
second	O
patient	O
,	O
after	O
reduction	O
was	O
done	O
,	O
presented	O
recurrence	O
of	O
the	O
dislocation	O
,	O
thus	O
requiring	O
surgical	O
treatment	O
.	O

It	O
is	O
important	O
to	O
observe	O
the	O
relevance	O
of	O
computed	B-P
tomography	I-P
to	O
help	O
diagnosing	O
,	O
as	O
well	O
as	O
monitoring	O
the	O
reduction	O
procedure	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
demonstrate	O
two	O
different	O
types	O
of	O
treatment	O
in	O
a	O
rare	O
injury	O
such	O
as	O
the	O
posterior	O
dislocation	O
of	O
sternoclavicular	O
joint	O
.	O

Sudden	O
sensorineural	O
hearing	O
loss	O
:	O
is	O
there	O
a	O
relationship	O
between	O
routine	O
haematological	O
parameters	O
and	O
audiogram	B-P
shapes	O
?	O
.	O

To	O
investigate	O
the	O
relationship	O
between	O
haematological	O
routine	O
parameters	O
and	O
audiogram	B-P
shapes	O
in	O
patients	O
affected	O
by	O
sudden	O
sensorineural	O
hearing	O
loss	O
(	O
SSNHL	O
)	O
.	O

A	O
retrospective	O
study	O
.	O

All	O
patients	O
were	O
divided	O
into	O
four	O
groups	O
according	O
to	O
the	O
audiometric	B-P
curve	O
and	O
mean	O
values	O
of	O
haematological	O
parameters	O
(	O
haemoglobin	B-P
,	O
white	O
blood	O
cell	O
,	O
neutrophils	B-P
and	O
lymphocytes	B-P
relative	I-P
count	I-P
,	O
platelet	O
count	O
,	O
haematocrit	B-P
,	O
prothrombin	B-P
time	I-P
,	O
activated	B-P
partial	I-P
thromboplastin	I-P
time	I-P
,	O
fibrinogen	O
and	O
neutrophil-to-lymphocite	B-P
ratio	I-P
)	O
of	O
each	O
group	O
were	O
statistically	O
compared	O
.	O

The	O
prognostic	O
role	O
of	O
blood	B-P
profile	I-P
and	O
coagulation	B-P
test	I-P
was	O
also	O
examined	O
.	O

A	O
cohort	O
of	O
183	O
SSNHL	O
patients	O
without	O
comorbidities	O
.	O

With	O
a	O
48.78	O
%	O
of	O
complete	O
hearing	O
recovery	O
,	O
individuals	O
affected	O
by	O
upsloping	O
hearing	O
loss	O
presented	O
a	O
better	O
prognosis	O
instead	O
of	O
flat	O
(	O
18.36	O
%	O
)	O
,	O
downsloping	O
(	O
19.23	O
%	O
)	O
and	O
anacusis	O
(	O
2.45	O
%	O
)	O
groups	O
(	O
p	O
=	O
0.0001	O
)	O
.	O

The	O
multivariate	O
analysis	O
of	O
complete	B-P
blood	I-P
count	I-P
values	I-P
revealed	O
lower	O
mean	O
percentage	O
of	O
lymphocytes	O
(	O
p	O
=	O
0.041	O
)	O
and	O
higher	O
platelet	O
levels	O
(	O
p	O
=	O
0.015	O
)	O
in	O
case	O
of	O
downsloping	O
hearing	O
loss	O
;	O
with	O
the	O
exception	O
of	O
fibrinogen	O
(	O
p	O
=	O
0.041	O
)	O
,	O
none	O
of	O
the	O
main	O
haematological	O
parameters	O
studied	O
resulted	O
associated	O
with	O
poorer	O
prognosis	O
.	O

Our	O
work	O
suggested	O
a	O
lack	O
of	O
association	O
between	O
haematological	O
parameters	O
and	O
a	O
defined	O
audiometric	B-P
picture	O
in	O
SSNHL	O
patients	O
;	O
furthermore	O
,	O
only	O
fibrinogen	O
seems	O
to	O
influence	O
the	O
prognosis	O
of	O
this	O
disease	O
.	O

Posterior	O
corrective	O
surgery	O
with	O
a	O
multilevel	O
transforaminal	O
lumbar	O
interbody	O
fusion	O
and	O
a	O
rod	O
rotation	O
maneuver	O
for	O
patients	O
with	O
degenerative	O
lumbar	O
kyphoscoliosis	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
results	O
of	O
posterior	O
corrective	O
surgery	O
using	O
a	O
multilevel	O
transforaminal	O
lumbar	O
interbody	O
fusion	O
(	O
TLIF	O
)	O
with	O
a	O
rod	O
rotation	O
(	O
RR	O
)	O
and	O
to	O
evaluate	O
the	O
segmental	O
corrective	O
effect	O
of	O
a	O
TLIF	O
using	O
CT	O
imaging	O
.	O

The	O
medical	O
records	O
of	O
15	O
consecutive	O
patients	O
with	O
degenerative	O
lumbar	O
kyphoscoliosis	O
(	O
DLKS	O
)	O
who	O
had	O
undergone	O
posterior	O
spinal	O
corrective	O
surgery	O
using	O
a	O
multileve	O
l	O
TLIF	O
with	O
an	O
RR	O
technique	O
and	O
who	O
had	O
a	O
minimum	O
follow-up	O
of	O
2	O
years	O
were	O
retrospectively	O
reviewed	O
.	O

Radiographic	B-P
parameters	O
were	O
evaluated	O
using	O
plain	B-P
radiographs	I-P
,	O
and	O
segmental	O
correction	O
was	O
evaluated	O
using	O
CT	O
imaging	O
.	O

Clinical	O
outcomes	O
were	O
evaluated	O
with	O
the	O
Scoliosis	O
Research	O
Society	O
Patient	O
Questionnaire-22	O
(	O
SRS-22	O
)	O
and	O
the	O
SF-36	O
.	O

The	O
mean	O
follow-up	O
period	O
was	O
46.7	O
months	O
,	O
and	O
the	O
mean	O
age	O
at	O
the	O
time	O
of	O
surgery	O
was	O
60.7	O
years	O
.	O

The	O
mean	O
total	O
SRS-22	O
score	O
was	O
2.9	O
before	O
surgery	O
and	O
significantly	O
improved	O
to	O
4.0	O
at	O
the	O
latest	O
follow-up	O
.	O

The	O
physical	O
functioning	O
,	O
role	O
functioning	O
(	O
physical	O
)	O
,	O
and	O
social	O
functioning	O
subcategories	O
of	O
the	O
SF-36	O
were	O
generally	O
improved	O
at	O
the	O
latest	O
follow-up	O
,	O
although	O
the	O
changes	O
in	O
these	O
scores	O
were	O
not	O
statistically	O
significant	O
.	O

The	O
bodily	O
pain	O
,	O
vitality	O
,	O
and	O
mental	O
health	O
subcategories	O
were	O
significantly	O
improved	O
at	O
the	O
latest	O
follow-up	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Three	O
complications	O
occurred	O
in	O
3	O
patients	O
(	O
20	O
%	O
)	O
.	O

The	O
Cobb	O
angle	O
of	O
the	O
lumbar	O
curve	O
was	O
reduced	O
to	O
20.3°	O
after	O
surgery	O
.	O

The	O
overall	O
correction	O
rate	O
was	O
66.4	O
%	O
.	O

The	O
pelvic	O
incidence	O
-	O
lumbar	O
lordosis	O
(	O
preoperative	O
/	O
postoperative	O
=	O
31.5°/4.3°	O
)	O
,	O
pelvic	O
tilt	O
(	O
29.2°/18.9°	O
)	O
,	O
and	O
sagittal	O
vertical	O
axis	O
(	O
78.3/27.6	O
mm	O
)	O
were	O
improved	O
after	O
surgery	O
and	O
remained	O
so	O
throughout	O
the	O
follow-up	O
.	O

Computed	O
tomography	O
image	O
analysis	O
suggested	O
that	O
a	O
1-level	O
TLIF	O
can	O
result	O
in	O
10.9°	O
of	O
scoliosis	O
correction	O
and	O
6.8°	O
of	O
lordosis	O
.	O

Posterior	O
corrective	O
surgery	O
using	O
a	O
multilevel	O
TLIF	O
with	O
an	O
RR	O
on	O
patients	O
with	O
DLKS	O
can	O
provide	O
effective	O
correction	O
in	O
the	O
coronal	O
plane	O
but	O
allows	O
only	O
limited	O
sagittal	O
correction	O
.	O

Identification	O
of	O
Chlamydia	O
trachomatis	O
Antigens	O
Recognized	O
by	O
T	O
Cells	O
From	O
Highly	O
Exposed	O
Women	O
Who	O
Limit	O
or	O
Resist	O
Genital	O
Tract	O
Infection	O
.	O

Natural	O
infection	O
induces	O
partial	O
immunity	O
to	O
Chlamydia	O
trachomatis	O
Identification	O
of	O
chlamydial	O
antigens	O
that	O
induce	O
interferon	O
γ	O
(	O
IFN-	O
)	O
secretion	O
by	O
T	O
cells	O
from	O
immune	O
women	O
could	O
advance	O
vaccine	O
development	O
.	O

IFN-γ	O
production	O
by	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
peripheral	O
blood	O
T	O
cells	O
from	O
58	O
high-risk	O
women	O
was	O
measured	O
after	O
coculture	B-P
with	O
antigen-presenting	O
cells	O
preincubated	O
with	O
recombinant	O
Escherichia	O
coli	O
expressing	O
a	O
panel	O
of	O
275	O
chlamydial	O
antigens	O
.	O

Quantile	O
median	O
regression	O
analysis	O
was	O
used	O
to	O
compare	O
frequencies	O
of	O
IFN-γ	O
responses	O
in	O
women	O
with	O
only	O
cervical	O
infection	O
to	O
those	O
in	O
women	O
with	O
endometrial	O
infection	O
and	O
frequencies	O
in	O
women	O
who	O
remained	O
uninfected	O
for	O
over	O
1	O
year	O
to	O
those	O
in	O
women	O
who	O
developed	O
incident	O
infection	O
.	O

Statistical	O
methods	O
were	O
then	O
used	O
to	O
identify	O
proteins	O
associated	O
with	O
protection	O
.	O

A	O
higher	O
median	O
frequency	O
of	O
CD8	O
(	O
+	O
)	O
T-cell	O
responses	O
was	O
detected	O
in	O
women	O
with	O
lower	O
genital	O
tract	O
chlamydial	O
infection	O
,	O
compared	O
with	O
those	O
with	O
upper	O
genital	O
tract	O
chlamydial	O
infection	O
(	O
13.8	O
%	O
vs	O
9.5	O
%	O
;	O
P	O
=04	O
)	O
,	O
but	O
the	O
CD4	O
(	O
+	O
)	O
T-cell	O
response	O
frequencies	O
were	O
not	O
different	O
.	O

Women	O
who	O
remained	O
uninfected	O
displayed	O
a	O
greater	O
frequency	O
of	O
positive	O
CD4	O
(	O
+	O
)	O
T-cell	O
responses	O
(	O
29	O
%	O
vs	O
18	O
%	O
;	O
P	O
<	O
.0001	O
)	O
,	O
compared	O
with	O
women	O
who	O
had	O
incident	O
infection	O
,	O
while	O
the	O
frequencies	O
of	O
CD8	O
(	O
+	O
)	O
T-cell	O
responses	O
did	O
not	O
differ	O
.	O

A	O
subset	O
of	O
proteins	O
involved	O
in	O
central	O
metabolism	O
,	O
type	O
III	O
secretion	O
,	O
and	O
protein	O
synthesis	O
were	O
associated	O
with	O
protection	O
.	O

Investigations	O
in	O
naturally	O
exposed	O
women	O
reveal	O
protective	O
responses	O
and	O
identify	O
chlamydial	O
vaccine	O
candidate	O
antigens	O
.	O

Inhibition	O
of	O
N-glycan	O
processing	O
modulates	O
the	O
network	O
of	O
EDEM3	O
interactors	O
.	O

We	O
present	O
here	O
data	O
on	O
EDEM3	O
network	O
of	O
ER	O
resident	O
interactors	O
and	O
the	O
changes	O
induced	O
upon	O
this	O
network	O
by	O
perturbing	O
the	O
early	O
ER	O
N-glycan	O
processing	O
with	O
mannosidase	O
and	O
glucosidase	O
inhibitors	O
.	O

By	O
coupling	O
immunoprecipitation	B-P
with	O
mass	B-P
spectrometry	I-P
we	O
identified	O
EDEM3	O
interactors	O
and	O
assigned	O
statistical	O
significance	O
to	O
those	O
most	O
abundant	O
ER	O
-	O
residents	O
that	O
might	O
form	O
functional	O
complexes	O
with	O
EDEM3	O
.	O

We	O
further	O
show	O
that	O
this	O
ER	O
interaction	O
network	O
changes	O
in	O
both	O
content	O
and	O
abundance	O
upon	O
treatment	O
with	O
kifunensine	O
(	O
kif	O
)	O
and	O
N-butyldeoxynojirimycin	O
(	O
NB-DNJ	O
)	O
which	O
suggests	O
that	O
when	O
interfering	O
with	O
the	O
N-glycan	O
processing	O
pathway	O
,	O
the	O
functional	O
complexes	O
involving	O
EDEM3	O
adapt	O
to	O
maintain	O
the	O
cellular	O
homeostasis	O
.	O

In	O
order	O
to	O
increase	O
the	O
scope	O
of	O
EDEM3	O
network	O
contenders	O
,	O
the	O
set	O
of	O
MS	B-P
identified	O
species	O
was	O
further	O
supplemented	O
with	O
putative	O
interactors	O
derived	O
from	O
in	O
silico	O
simulations	O
performed	O
with	O
STRING	O
.	O

Finally	O
,	O
the	O
most	O
interesting	O
candidates	O
to	O
this	O
network	O
were	O
further	O
validated	O
by	O
immunoprecipitation	B-P
coupled	O
with	O
Western	O
Blotting	O
,	O
which	O
strengthened	O
the	O
confidence	O
in	O
the	O
inferred	O
interactions	O
.	O

The	O
data	O
corroborated	O
herein	O
suggest	O
that	O
besides	O
ER	O
residents	O
,	O
EDEM3	O
interacts	O
also	O
with	O
proteins	O
involved	O
in	O
the	O
ERAD	O
cargo	O
recognition	O
and	O
targeting	O
to	O
degradation	O
translocation	O
into	O
the	O
cytosol	O
,	O
including	O
UBA1	O
and	O
UBA2	O
ubiquitinating	O
enzymes	O
.	O

In	O
addition	O
,	O
the	O
results	O
indicate	O
that	O
this	O
network	O
of	O
EDEM3	O
interactors	O
is	O
highly	O
sensitive	O
to	O
interfering	O
with	O
early	O
ER	O
N-glycan	O
processing	O
.	O

Meningitis	O
due	O
to	O
Moraxella	O
nonliquefaciens	O
in	O
a	O
paediatric	O
patient	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

Introduction	O
.	O

Moraxella	O
nonliquefaciens	O
is	O
an	O
unusual	O
organism	O
to	O
be	O
isolated	O
from	O
cerebral	O
spinal	O
fluid	O
(	O
CSF	O
)	O
and	O
there	O
exists	O
only	O
one	O
case	O
report	O
of	O
M.	O
nonliquefaciens	O
meningitis	O
from	O
a	O
neonate	O
.	O

Moraxella	O
species	O
normally	O
exist	O
as	O
part	O
of	O
the	O
human	O
upper	O
respiratory	O
tract	O
flora	O
and	O
rarely	O
cause	O
invasive	O
human	O
disease	O
.	O

There	O
are	O
only	O
a	O
handful	O
of	O
case	O
reports	O
implicating	O
the	O
organism	O
as	O
a	O
cause	O
of	O
endocarditis	O
,	O
bacteraemia	O
,	O
septic	O
arthritis	O
and	O
endophthalmitis	O
.	O

Identification	O
to	O
the	O
species	O
level	O
based	O
on	O
routine	O
laboratory	O
techniques	O
has	O
been	O
challenging	O
,	O
with	O
final	O
identification	O
often	O
made	O
through	O
16S	B-P
rRNA	I-P
sequencing	I-P
.	O

With	O
the	O
use	O
of	O
a	O
newer	O
diagnostic	O
tool	O
,	O
matrix-assisted	O
laser	O
desorption	O
ionization-time	O
of	O
flight	O
(	O
MALDI-TOF	O
)	O
MS	O
,	O
we	O
were	O
able	O
to	O
rapidly	O
identify	O
the	O
organism	O
and	O
initiate	O
appropriate	O
treatment	O
.	O

Case	O
presentation	O
.	O

We	O
present	O
a	O
rare	O
care	O
of	O
M.	O
nonliquefaciens	O
meningitis	O
in	O
a	O
paediatric	O
patient	O
with	O
an	O
underlying	O
cranial	O
anatomical	O
defect	O
due	O
to	O
Crouzon	O
syndrome	O
.	O

She	O
had	O
been	O
admitted	O
to	O
hospital	O
3	O
months	O
previously	O
with	O
Streptococcus	O
pneumoniae	O
meningitis	O
and	O
mastoiditis	O
,	O
and	O
returned	O
to	O
the	O
emergency	O
department	O
with	O
meningismus	O
.	O

CSF	B-P
culture	I-P
grew	O
M.	O
nonliquefaciens	O
.	O

She	O
was	O
treated	O
with	O
ceftriaxone	O
with	O
rapid	O
improvement	O
and	O
eventually	O
was	O
taken	O
for	O
endoscopic	B-P
surgical	I-P
repair	O
of	O
a	O
right	O
encephalocele	O
defect	O
.	O

Conclusion	O
.	O

The	O
use	O
of	O
MALDI-TOF	O
MS	O
allowed	O
for	O
the	O
rapid	O
identification	O
of	O
the	O
organism	O
.	O

The	O
patient	O
recovered	O
with	O
appropriate	O
antimicrobial	O
therapy	O
and	O
eventual	O
surgical	O
correction	O
.	O

An	O
underlying	O
anatomical	O
defect	O
should	O
be	O
considered	O
in	O
all	O
patients	O
who	O
present	O
with	O
meningitis	O
due	O
to	O
this	O
unusual	O
organism	O
.	O

Increase	O
in	O
average	O
foveal	O
thickness	O
after	O
internal	O
limiting	O
membrane	O
peeling	O
.	O

To	O
report	O
the	O
findings	O
in	O
three	O
cases	O
in	O
which	O
the	O
average	O
foveal	O
thickness	O
was	O
increased	O
after	O
a	O
thin	O
epiretinal	O
membrane	O
(	O
ERM	O
)	O
was	O
removed	O
by	O
vitrectomy	O
with	O
internal	O
limiting	O
membrane	O
(	O
ILM	O
)	O
peeling	O
.	O

The	O
foveal	O
contour	O
was	O
normal	O
preoperatively	O
in	O
all	O
eyes	O
.	O

All	O
cases	O
underwent	O
successful	O
phacovitrectomy	O
with	O
ILM	O
peeling	O
for	O
a	O
thin	O
ERM	O
.	O

The	O
optical	B-P
coherence	I-P
tomography	I-P
(	O
OCT	B-P
)	O
images	O
were	O
examined	O
before	O
and	O
after	O
the	O
surgery	O
.	O

The	O
changes	O
in	O
the	O
average	O
foveal	O
(	O
1	O
mm	O
)	O
thickness	O
and	O
the	O
foveal	O
areas	O
within	O
500	O
μm	O
from	O
the	O
foveal	O
center	O
were	O
measured	O
.	O

The	O
postoperative	O
changes	O
in	O
the	O
inner	O
and	O
outer	O
retinal	O
areas	O
determined	O
from	O
the	O
cross-sectional	O
OCT	B-P
images	O
were	O
analyzed	O
.	O

The	O
average	O
foveal	O
thickness	O
and	O
the	O
inner	O
and	O
outer	O
foveal	O
areas	O
increased	O
significantly	O
after	O
the	O
surgery	O
in	O
each	O
of	O
the	O
three	O
cases	O
.	O

The	O
percentage	O
increase	O
in	O
the	O
average	O
foveal	O
thickness	O
relative	O
to	O
the	O
baseline	O
thickness	O
was	O
26	O
%	O
in	O
Case	O
1	O
,	O
29	O
%	O
in	O
Case	O
2	O
,	O
and	O
31	O
%	O
in	O
Case	O
3	O
.	O

The	O
percentage	O
increase	O
in	O
the	O
foveal	O
inner	O
retinal	O
area	O
was	O
71	O
%	O
in	O
Case	O
1	O
,	O
113	O
%	O
in	O
Case	O
2	O
,	O
and	O
110	O
%	O
in	O
Case	O
3	O
,	O
and	O
the	O
percentage	O
increase	O
in	O
foveal	O
outer	O
retinal	O
area	O
was	O
8	O
%	O
in	O
Case	O
1	O
,	O
13	O
%	O
in	O
Case	O
2	O
,	O
and	O
18	O
%	O
in	O
Case	O
3	O
.	O

The	O
increase	O
in	O
the	O
average	O
foveal	O
thickness	O
and	O
the	O
inner	O
and	O
outer	O
foveal	O
areas	O
suggests	O
that	O
a	O
centripetal	O
movement	O
of	O
the	O
inner	O
and	O
outer	O
retinal	O
layers	O
toward	O
the	O
foveal	O
center	O
probably	O
occurred	O
due	O
to	O
the	O
ILM	O
peeling	O
.	O

Identification	O
of	O
low	O
micromolar	O
dual	O
inhibitors	O
for	O
aldose	O
reductase	O
(	O
ALR2	O
)	O
and	O
poly	O
(	O
ADP-ribose	O
)	O
polymerase	O
(	O
PARP-1	O
)	O
using	O
structure	O
based	O
design	O
approach	O
.	O

Clinical	O
studies	O
have	O
revealed	O
that	O
diabetic	O
retinopathy	O
is	O
a	O
multifactorial	O
disorder	O
.	O

Moreover	O
,	O
studies	O
also	O
suggest	O
that	O
ALR2	O
and	O
PARP-1	O
co-occur	O
in	O
retinal	O
cells	O
,	O
making	O
them	O
appropriate	O
targets	O
for	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	O
.	O

To	O
find	O
the	O
dual	O
inhibitors	O
of	O
ALR2	O
and	O
PARP-1	O
,	O
the	O
structure	O
based	O
design	O
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	O
proteins	O
.	O

A	O
series	O
of	O
novel	O
thiazolidine-2,4-dione	O
(	O
TZD	O
)	O
derivatives	O
were	O
therefore	O
rationally	O
designed	O
,	O
synthesized	O
and	O
their	O
in	O
vitro	O
inhibitory	O
activities	O
against	O
ALR2	O
and	O
PARP-1	O
were	O
evaluated	O
.	O

The	O
experimental	O
results	O
showed	O
that	O
compounds	O
5b	O
and	O
5f	O
,	O
with	O
2-chloro	O
and	O
4-fluoro	O
substitutions	O
,	O
showed	O
biochemical	O
activities	O
in	O
micromolar	O
and	O
submicromolar	O
range	O
(	O
IC50	O
1.34-5.03μM	O
)	O
against	O
both	O
the	O
targeted	O
enzymes	O
.	O

The	O
structure-activity	O
relationship	O
elucidated	O
for	O
these	O
novel	O
inhibitors	O
against	O
both	O
the	O
enzymes	O
provide	O
new	O
insight	O
into	O
the	O
binding	O
mode	O
of	O
the	O
inhibitors	O
to	O
the	O
active	O
sites	O
of	O
enzymes	O
.	O

The	O
positive	O
results	O
of	O
the	O
biochemical	O
assay	B-P
suggest	O
that	O
these	O
compounds	O
may	O
be	O
further	O
optimized	O
and	O
utilized	O
for	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	O
.	O

Clinicopathological	O
relevance	O
of	O
kinesin	O
family	O
member	O
18A	O
expression	O
in	O
invasive	O
breast	O
cancer	O
.	O

Recently	O
,	O
kinesin	O
motor	O
proteins	O
have	O
been	O
focused	O
on	O
as	O
targets	O
for	O
cancer	O
therapy	O
.	O

Kinesins	O
are	O
microtubule	O
-based	O
motor	O
proteins	O
that	O
mediate	O
diverse	O
functions	O
within	O
the	O
cell	O
,	O
including	O
the	O
transport	O
of	O
vesicles	O
,	O
organelles	O
,	O
chromosomes	O
and	O
protein	O
complexes	O
,	O
as	O
well	O
as	O
the	O
movement	O
of	O
microtubules	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
expression	O
of	O
kinesin	O
family	O
member	O
18A	O
(	O
KIF18A	O
)	O
,	O
a	O
member	O
of	O
kinesin	O
superfamily	O
,	O
was	O
investigated	O
in	O
breast	O
cancer	O
using	O
immunohistochemistry	B-P
,	O
and	O
its	O
effect	O
on	O
breast	O
cancer	O
prognosis	O
was	O
examined	O
.	O

KIF18A	O
expression	O
level	O
was	O
significantly	O
associated	O
with	O
lymph	O
node	O
metastasis	O
(	O
P=0.047	O
)	O
.	O

In	O
patients	O
with	O
high	O
levels	O
of	O
KIF18A	O
expression	O
,	O
survival	O
was	O
significantly	O
poorer	O
compared	O
to	O
patients	O
with	O
low	O
levels	O
of	O
KIF18A	O
expression	O
(	O
disease-free	O
survival	O
,	O
P=0.030	O
)	O
.	O

Multivariate	O
analysis	O
revealed	O
that	O
venous	O
invasion	O
(	O
hazard	O
ratio	O
,	O
9.22	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
3.90-23.66	O
;	O
P	O
<	O
0.001	O
)	O
and	O
KIF18A	O
expression	O
(	O
hazard	O
ratio	O
,	O
3.20	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.34-6.09	O
;	O
P=0.010	O
)	O
were	O
independent	O
predictive	O
factors	O
for	O
lymph	O
node	O
metastasis	O
.	O

KIF18A	O
may	O
be	O
a	O
useful	O
predictive	O
marker	O
for	O
lymph	O
node	O
metastasis	O
in	O
breast	O
cancer	O
,	O
which	O
could	O
facilitate	O
curative	O
adjuvant	O
treatment	O
.	O

Cost-effectiveness	O
of	O
diabetes	B-P
screening	I-P
initiated	O
through	O
a	O
dental	O
visit	O
.	O

To	O
analyse	O
the	O
cost-effectiveness	O
of	O
a	O
screening	B-P
programme	O
and	O
follow-up	O
interventions	O
for	O
persons	O
with	O
dysglycemia	O
who	O
are	O
identified	O
during	O
a	O
dental	O
visit	O
.	O

This	O
study	O
is	O
a	O
secondary	O
analysis	O
utilizing	O
data	O
from	O
two	O
relevant	O
publications	O
.	O

Those	O
studies	O
identified	O
persons	O
with	O
dysglycemia	O
who	O
were	O
seen	O
in	O
a	O
dental	O
school	O
clinic	O
for	O
routine	O
dental	O
care	O
and	O
determined	O
compliance	O
with	O
a	O
recommendation	O
to	O
seek	O
medical	O
care	O
.	O

The	O
response	O
site	O
was	O
59.4	O
%	O
.	O

The	O
Archimedes	O
disease	O
simulation	O
model	O
was	O
utilized	O
to	O
simulate	O
the	O
effect	O
of	O
a	O
weight	O
loss	O
programme	O
for	O
identified	O
subjects	O
on	O
several	O
outcomes	O
.	O

Two	O
scenarios	O
for	O
weight	O
loss	O
programmes	O
were	O
considered	O
:	O
a	O
10	O
%	O
permanent	O
loss	O
in	O
body	O
weight	O
and	O
a	O
10	O
%	O
loss	O
that	O
decays	O
over	O
time	O
.	O

Both	O
diabetes	O
and	O
prediabetes	O
were	O
analysed	O
.	O

The	O
decay	O
path	O
costs	O
$	O
21	O
243	O
per	O
quality	O
adjusted	O
life	O
year	O
(	O
QALY	O
)	O
with	O
3	O
years	O
required	O
to	O
achieve	O
the	O
weight	O
reduction	O
.	O

This	O
cost	O
decreases	O
to	O
$	O
6655	O
if	O
only	O
1	O
year	O
is	O
needed	O
to	O
achieve	O
the	O
weight	O
goal	O
.	O

Without	O
decay	O
,	O
the	O
cost	O
per	O
QALY	O
is	O
$	O
15	O
873	O
with	O
20	O
years	O
of	O
intervention	O
,	O
vs	O
$	O
647	O
per	O
QALY	O
with	O
10	O
years	O
of	O
intervention	O
.	O

For	O
individuals	O
with	O
type	O
2	O
diabetes	O
mellitus	O
,	O
the	O
cost	O
per	O
QALY	O
is	O
$	O
48	O
604	O
to	O
$	O
56	O
207	O
depending	O
on	O
adherence	O
.	O

With	O
the	O
addition	O
of	O
oral	O
medication	O
(	O
a	O
sulfonylurea	O
)	O
,	O
the	O
cost	O
is	O
three	O
times	O
higher	O
.	O

Under	O
the	O
conditions	O
described	O
here	O
,	O
identification	O
of	O
persons	O
with	O
dysglycemia	O
in	O
the	O
dental	O
office	O
for	O
initiating	O
prediabetic	O
care	O
is	O
a	O
cost-effective	O
means	O
of	O
identifying	O
and	O
treating	O
affected	O
individuals	O
.	O

Metalloproteinase	O
meprin	O
α	O
regulates	O
migration	O
and	O
invasion	O
of	O
human	O
hepatocarcinoma	O
cells	O
and	O
is	O
a	O
mediator	O
of	O
the	O
oncoprotein	O
Reptin	O
.	O

Hepatocellular	O
carcinoma	O
is	O
associated	O
with	O
a	O
high	O
rate	O
of	O
intra-hepatic	O
invasion	O
that	O
carries	O
a	O
poor	O
prognosis	O
.	O

Meprin	O
alpha	O
(	O
Mep1A	O
)	O
is	O
a	O
secreted	O
metalloproteinase	O
with	O
many	O
substrates	O
relevant	O
to	O
cancer	O
invasion	O
.	O

We	O
found	O
that	O
Mep1A	O
was	O
a	O
target	O
of	O
Reptin	O
,	O
a	O
protein	O
that	O
is	O
oncogenic	O
in	O
HCC	O
.	O

We	O
studied	O
Mep1A	O
regulation	O
by	O
Reptin	O
,	O
its	O
role	O
in	O
HCC	O
,	O
and	O
whether	O
it	O
mediates	O
Reptin	O
oncogenic	O
effects	O
.	O

MepA	O
and	O
Reptin	O
expression	O
was	O
measured	O
in	O
human	O
HCC	O
by	O
qRT-PCR	O
and	O
in	O
cultured	O
cells	O
by	O
PCR	O
,	O
western	B-P
blot	I-P
and	O
enzymatic	O
activity	O
measurements	O
.	O

Cell	O
growth	O
was	O
assessed	O
by	O
counting	B-P
and	O
MTS	O
assay	O
.	O

Cell	O
migration	O
was	O
measured	O
in	O
Boyden	O
chambers	O
and	O
wound	O
healing	O
assays	B-P
,	O
and	O
cell	O
invasion	O
in	O
Boyden	O
chambers	O
.	O

Silencing	O
Reptin	O
decreased	O
Mep1A	O
expression	O
and	O
activity	O
,	O
without	O
affecting	O
meprin	O
β.	O
Mep1A	O
,	O
but	O
not	O
meprin	O
β	O
,	O
was	O
overexpressed	O
in	O
a	O
series	O
of	O
242	O
human	O
HCC	O
(	O
2.04	O
fold	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
and	O
a	O
high	O
expression	O
correlated	O
with	O
a	O
poor	O
prognosis	O
.	O

Mep1A	O
and	O
Reptin	O
expressions	O
were	O
positively	O
correlated	O
(	O
r	O
=	O
0.39	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Silencing	O
Mep1A	O
had	O
little	O
effect	O
on	O
cell	O
proliferation	O
,	O
but	O
decreased	O
cell	O
migration	O
and	O
invasion	O
of	O
HuH7	O
and	O
Hep3B	O
cells	O
.	O

Conversely	O
,	O
overexpression	O
of	O
Mep1A	O
or	O
addition	O
of	O
recombinant	O
Mep1A	O
increased	O
migration	O
and	O
invasion	O
.	O

Finally	O
,	O
overexpression	O
of	O
Mep1A	O
restored	O
a	O
normal	O
cell	O
migration	O
in	O
cells	O
where	O
Reptin	O
was	O
depleted	O
.	O

Mep1A	O
is	O
overexpressed	O
in	O
most	O
HCC	O
and	O
induces	O
HCC	O
cell	O
migration	O
and	O
invasion	O
.	O

Mep1A	O
expression	O
is	O
regulated	O
by	O
Reptin	O
,	O
and	O
Mep1A	O
mediates	O
Reptin	O
-	O
induced	O
migration	O
.	O

Overall	O
,	O
we	O
suggest	O
that	O
Mep1A	O
may	O
be	O
a	O
useful	O
target	O
in	O
HCC	O
.	O

Bioactive	O
Constituents	O
from	O
an	O
Endophytic	O
Fungus	O
,	O
Penicillium	O
polonicum	O
NFW9	O
,	O
associated	O
with	O
Taxus	O
fauna	O
.	O

Endophytic	O
fungi	O
are	O
being	O
recognized	O
as	O
vital	O
and	O
untapped	O
sources	O
of	O
a	O
variety	O
of	O
structurally	O
novel	O
and	O
unique	O
bioactive	O
secondary	O
metabolites	O
in	O
the	O
field	O
of	O
natural	O
products	O
drug	O
discovery	O
.	O

Herein	O
,	O
this	O
study	O
reports	O
the	O
isolation	O
and	O
characterization	O
of	O
secondary	O
metabolites	O
from	O
an	O
endophytic	O
fungus	O
Penicillium	O
polonicum	O
(	O
NFW9	O
)	O
associated	O
with	O
Taxus	O
fuana	O
.	O

Extracts	O
of	O
the	O
endophytic	O
fungus	O
cultured	O
on	O
potato	O
dextrose	O
agar	O
were	O
purified	O
using	O
several	O
chromatographic	B-P
techniques	I-P
.	O

Biological	O
evaluation	O
was	O
performed	O
based	O
on	O
their	O
abilities	O
to	O
inhibit	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-α	O
)	O
-	O
induced	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-κB	O
)	O
and	O
cytotoxicity	B-P
assays	I-P
.	O

Bioactivity	O
-	O
directed	O
fractionation	O
of	O
the	O
ethyl	O
acetate	O
extract	O
of	O
a	O
fermentation	O
culture	B-P
of	O
an	O
endophytic	O
fungus	O
,	O
Penicillium	O
polonicum	O
led	O
to	O
the	O
isolation	O
of	O
a	O
dimeric	O
anthraquinone	O
,	O
(	O
R	O
)	O
-1,1',3,3',5,5'-hexahydroxy-7,7'-dimethyl	O
[	O
2,2'-bianthracene	O
]	O
-9,9',10,10'-tetraone	O
(	O
1	O
)	O
,	O
a	O
steroidal	O
furanoid	O
(	O
-	O
)	O
-wortmannolone	O
(	O
2	O
)	O
,	O
along	O
with	O
three	O
other	O
compounds	O
(	O
3	O
	O
4	O
)	O
.	O

Moreover	O
,	O
this	O
is	O
the	O
first	O
report	O
on	O
the	O
isolation	O
of	O
compound	O
1	O
from	O
an	O
endophytic	O
fungus	O
.	O

All	O
purified	O
metabolites	O
were	O
characterized	O
by	O
NMR	B-P
and	O
MS	B-P
data	O
analyses	O
.	O

The	O
stereo	O
structure	O
of	O
compound	O
1	O
was	O
determined	O
by	O
the	O
measurement	O
of	O
specific	O
optical	O
rotation	O
and	O
CD	O
spectrum	O
.	O

The	O
relative	O
stereochemistry	O
of	O
2	O
was	O
confirmed	O
by	O
single-crystal	B-P
X-ray	I-P
diffraction	I-P
.	O

Compounds	O
2	O
	O
3	O
showed	O
inhibitory	O
activities	O
in	O
TNF-α	O
-	O
induced	O
NF-κB	O
assay	B-P
with	O
IC50	O
values	O
in	O
the	O
range	O
of	O
0.472.11	O
µM	O
.	O

Compounds	O
1	O
,	O
4	O
and	O
5	O
showed	O
moderate	O
inhibition	O
against	O
NF-κB	O
and	O
cancer	O
cell	O
lines	O
.	O

The	O
endophytic	O
fungus	O
Penicillium	O
polonicum	O
of	O
Taxus	O
fuana	O
is	O
capable	O
of	O
producing	O
biologically	O
active	O
natural	O
compounds	O
.	O

Our	O
results	O
provide	O
a	O
scientific	O
rationale	O
for	O
further	O
chemical	O
investigations	O
into	O
endophyte	O
-producing	O
natural	O
products	O
,	O
drug	O
discovery	O
and	O
development	O
.	O

Severity	O
of	O
Gastric	O
Mucosal	O
Atrophy	O
Is	O
the	O
Major	O
Determinant	O
of	O
Plasma	O
Ghrelin	O
Level	O
in	O
Hemodialysis	O
Patients	O
.	O

Ghrelin	O
,	O
an	O
orexigenic	O
hormone	O
,	O
has	O
multiple	O
favorable	O
functions	O
including	O
protein	O
anabolism	O
enhancement	O
,	O
anti-inflammatory	O
actions	O
,	O
and	O
cardiovascular	O
protection	O
.	O

A	O
low	O
plasma	O
ghrelin	O
level	O
is	O
associated	O
with	O
increased	O
mortality	O
in	O
patients	O
treated	O
with	O
hemodialysis	O
(	O
HD	O
)	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
plasma	O
ghrelin	O
level	O
in	O
HD	O
patients	O
correlates	O
with	O
the	O
severity	O
of	O
gastric	O
mucosal	O
atrophy	O
and	O
Helicobacter	O
pylori	O
status	O
.	O

Seventy-eight	O
maintenance	O
HD	O
patients	O
and	O
51	O
non-dialysis	O
patients	O
with	O
chronic	O
kidney	O
disease	O
were	O
evaluated	O
for	O
severity	O
of	O
gastric	O
mucosal	O
atrophy	O
by	O
gastroduodenoscopy	O
and	O
for	O
H.	O
pylori	O
status	O
using	O
an	O
anti-H.	B-P
pylori-antibody	I-P
and	O
rapid	O
urease	B-P
test	I-P
.	O

Plasma	O
acyl	O
and	O
des-acyl	O
ghrelin	O
levels	O
were	O
measured	O
and	O
their	O
associations	O
with	O
relevant	O
clinical	O
parameters	O
were	O
investigated	O
.	O

Des-acyl	O
ghrelin	O
level	O
in	O
HD	O
patients	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
patients	O
with	O
kidney	O
function	O
preserved	O
.	O

Although	O
acyl	O
and	O
des-acyl	O
ghrelin	O
levels	O
were	O
similar	O
between	O
current	O
H.	O
pylori	O
positive	O
and	O
negative	O
HD	O
patients	O
,	O
both	O
levels	O
decreased	O
significantly	O
with	O
the	O
progress	O
of	O
endoscopic	O
gastric	O
mucosal	O
atrophy	O
in	O
HD	O
patients	O
.	O

Serum	O
pepsinogen	O
(	O
PG	O
)	O
I	O
level	O
and	O
PG	O
I	O
/	O
II	O
ratio	O
decreased	O
significantly	O
according	O
to	O
the	O
severity	O
of	O
atrophy	O
in	O
HD	O
patients	O
and	O
positively	O
significantly	O
correlated	O
with	O
both	O
ghrelin	O
levels	O
.	O

Multiple	O
regression	O
analysis	O
showed	O
significant	O
positive	O
correlations	O
between	O
acyl	O
ghrelin	O
and	O
PG	O
I	O
levels	O
(	O
β	O
=	O
0.738	O
,	O
p	O
<	O
0.001	O
)	O
and	O
significant	O
negative	O
correlations	O
between	O
ghrelin	O
and	O
age	O
,	O
albumin	O
,	O
and	O
creatinine	O
levels	O
.	O

Gastric	O
atrophy	O
is	O
the	O
major	O
determinant	O
of	O
ghrelin	O
level	O
in	O
HD	O
patients	O
.	O

Management	O
practices	O
,	O
such	O
as	O
H.	O
pylori	O
eradication	O
,	O
before	O
advanced	O
atrophy	O
may	O
be	O
required	O
to	O
prevent	O
the	O
decrease	O
of	O
ghrelin	O
levels	O
and	O
improve	O
the	O
prognosis	O
of	O
HD	O
patients	O
.	O

The	O
efficacy	O
of	O
human	O
placenta	O
-derived	O
mesenchymal	O
stem	O
cells	O
on	O
radiation	O
enteropathy	O
along	O
with	O
proteomic	O
biomarkers	O
predicting	O
a	O
favorable	O
response	O
.	O

Radiation	O
enteropathy	O
is	O
a	O
common	O
complication	O
in	O
patients	O
with	O
abdominopelvic	O
cancer	O
,	O
but	O
no	O
treatment	O
has	O
yet	O
been	O
established	O
.	O

Stem	O
cell	O
therapy	O
may	O
be	O
a	O
viable	O
therapeutic	O
option	O
because	O
intestinal	O
stem	O
cells	O
are	O
highly	O
vulnerable	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
and	O
stem	O
cell	O
loss	O
explains	O
its	O
intractability	O
to	O
general	O
treatment	O
.	O

Here	O
,	O
we	O
investigated	O
either	O
prophylactic	O
or	O
therapeutic	O
efficacy	O
of	O
human	O
placenta	O
-derived	O
mesenchymal	O
stem	O
cells	O
(	O
hPDSCs	O
)	O
against	O
radiation	O
enteropathy	O
and	O
could	O
identify	O
biomarkers	O
predicting	O
a	O
favorable	O
response	O
to	O
stem	O
cell	O
therapy	O
.	O

We	O
challenged	O
a	O
radiation-induced	O
enteropathy	O
model	O
with	O
hPDSCs	O
.	O

After	O
sacrifice	O
,	O
we	O
checked	O
the	O
gross	O
anatomy	O
of	O
small	O
intestine	O
,	O
histology	O
gross	O
,	O
and	O
analyzed	O
that	O
,	O
accompanied	O
with	O
molecular	O
changes	O
implicated	O
in	O
this	O
model	O
.	O

hPDSCs	O
significantly	O
improved	O
the	O
outcome	O
of	O
mice	O
induced	O
with	O
either	O
radiation	O
enteropathy	O
or	O
lethal	O
radiation	O
syndrome	O
(	O
P	O
<	O
0.01	O
)	O
.	O

hPDSCs	O
exerted	O
inhibitory	O
actions	O
on	O
inflammatory	O
cytokines	O
,	O
the	O
re-establishment	O
of	O
epithelium	O
homeostasis	O
was	O
completed	O
with	O
increasing	O
endogenous	O
restorative	O
processes	O
as	O
assessed	O
with	O
increased	O
levels	O
of	O
proliferative	O
markers	O
in	O
the	O
hPDSCs	O
group	O
,	O
and	O
a	O
significant	O
inhibition	O
of	O
IR	O
-	O
induced	O
apoptosis	O
.	O

The	O
preservation	B-P
of	O
cells	O
expressing	O
lysozyme	O
,	O
and	O
Musashi-1	O
were	O
significantly	O
increased	O
in	O
the	O
hPDSC	O
treatment	O
group	O
.	O

Both	O
preventive	O
and	O
therapeutic	O
efficacies	O
of	O
hPDSCs	O
were	O
noted	O
against	O
IR-induced	O
enteropathy	O
.	O

Label-free	O
quantification	O
was	O
used	O
to	O
identify	O
biomarkers	O
which	O
predict	O
favorable	O
responses	O
after	O
hPDSC	O
treatment	O
,	O
and	O
finally	O
glutathione	O
S-transferase-mu	O
type	O
,	O
interleukin-10	O
,	O
and	O
peroxiredoxin-2	O
were	O
validated	O
as	O
proteomic	O
biomarkers	O
predicting	O
a	O
favorable	O
response	O
to	O
hPDSCs	O
in	O
radiation	O
enteropathy	O
.	O

hPDSCs	O
may	O
be	O
a	O
useful	O
prophylactic	O
and	O
therapeutic	O
cell	O
therapy	O
for	O
radiation	O
enteropathy	O
.	O

Subepidermal	O
Calcified	O
Nodules	O
of	O
the	O
Eyelid	O
Differ	O
in	O
Children	O
and	O
Adults	O
.	O

Subepidermal	O
calcified	O
nodule	O
of	O
the	O
eyelid	O
is	O
considered	O
as	O
one	O
of	O
the	O
types	O
of	O
calcinosis	O
cutis	O
.	O

It	O
generally	O
occurs	O
in	O
children	O
,	O
and	O
is	O
not	O
known	O
to	O
be	O
associated	O
with	O
systemic	O
disease	O
.	O

The	O
authors	O
report	O
histopathological	O
and	O
clinical	O
findings	O
in	O
14	O
cases	O
of	O
subepidermal	O
calcified	O
nodule	O
of	O
the	O
eyelid	O
,	O
including	O
3	O
older	O
patients	O
with	O
unique	O
microscopic	O
features	O
.	O

Clinical	O
records	O
and	O
pathological	O
materials	O
were	O
critically	O
reviewed	O
in	O
each	O
case	O
,	O
including	O
von	B-P
kossa	I-P
,	O
CD3	O
,	O
CD20	O
,	O
and	O
CD68	O
stains	O
.	O

The	O
14	O
cases	O
presented	O
clinically	O
as	O
nodular	O
eyelid	O
lesions	O
.	O

All	O
were	O
treated	O
with	O
surgical	O
excision	O
.	O

The	O
authors	O
found	O
2	O
distinct	O
histopathological	O
patterns	O
which	O
correlated	O
with	O
the	O
patients	O
'	O
age	O
.	O

In	O
young	O
patients	O
,	O
the	O
authors	O
observed	O
multiple	O
,	O
small	O
calcified	O
bodies	O
within	O
the	O
dermis	O
surrounded	O
by	O
chronic	O
inflammation	O
and	O
granulomatous	O
foreign	O
body	O
reaction	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
elderly	O
patients	O
,	O
lesions	O
were	O
characterized	O
by	O
a	O
single	O
,	O
large	O
,	O
well-demarcated	O
amorphous	O
calcified	O
deposit	O
surrounded	O
by	O
fibrous	O
tissue	O
,	O
without	O
chronic	O
inflammation	O
or	O
foreign	O
body	O
reaction	O
.	O

One	O
of	O
these	O
patients	O
,	O
a	O
70-	O
year-old	O
man	O
,	O
also	O
suffered	O
from	O
gout	O
.	O

The	O
presence	O
of	O
subepidermal	O
calcified	O
nodule	O
was	O
not	O
documented	O
as	O
a	O
preoperative	O
diagnostic	O
possibility	O
in	O
any	O
of	O
the	O
cases	O
.	O

Subepidermal	O
calcified	O
nodule	O
of	O
the	O
eyelid	O
is	O
a	O
rare	O
condition	O
,	O
but	O
should	O
be	O
considered	O
in	O
any	O
patient	O
presenting	O
with	O
a	O
painless	O
white	O
to	O
yellowish	O
colored	O
nodule	O
of	O
the	O
ocular	O
adnexa	O
,	O
particularly	O
during	O
the	O
teenage	O
years	O
.	O

Clinicians	O
and	O
pathologists	O
should	O
be	O
aware	O
that	O
this	O
entity	O
has	O
a	O
distinct	O
appearance	O
and	O
could	O
be	O
associated	O
with	O
systemic	O
conditions	O
in	O
elderly	O
patients	O
.	O

The	O
Effectiveness	O
of	O
a	O
Systematic	O
Algorithm	O
for	O
the	O
Management	O
of	O
Vascular	O
Injuries	O
during	O
the	O
Laparoscopic	O
Surgery	O
.	O

Currently	O
,	O
there	O
is	O
no	O
standardized	O
training	O
protocol	O
to	O
teach	O
surgeons	O
how	O
to	O
deal	O
with	O
vascular	O
injuries	O
during	O
laparoscopic	O
procedures	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
develop	O
and	O
evaluate	O
the	O
effectiveness	O
of	O
a	O
standardized	O
algorithm	O
for	O
managing	O
vascular	O
injury	O
during	O
laparoscopic	O
nephrectomies	O
.	O

The	O
performance	O
of	O
6	O
surgeons	O
was	O
assessed	O
during	O
10	O
laparoscopic	O
nephrectomies	O
in	O
a	O
porcine	O
model	O
.	O

During	O
the	O
first	O
and	O
tenth	O
operations	O
,	O
an	O
injury	O
was	O
made	O
in	O
the	O
renal	O
vein	O
without	O
warning	O
the	O
surgeon	O
.	O

After	O
the	O
first	O
procedure	O
,	O
the	O
surgeons	O
were	O
instructed	O
on	O
how	O
to	O
proceed	O
in	O
dealing	O
with	O
the	O
vascular	O
injury	O
,	O
according	O
to	O
an	O
algorithm	O
developed	O
by	O
the	O
designers	O
of	O
this	O
study	O
.	O

The	O
performance	O
of	O
each	O
surgeon	O
before	O
and	O
after	O
learning	O
the	O
algorithm	O
was	O
assessed	O
.	O

After	O
learning	O
the	O
algorithm	O
there	O
was	O
a	O
decreased	O
blood	O
loss	O
from	O
327	O
±	O
403.11	O
ml	O
to	O
37	O
±	O
18.92	O
ml	O
(	O
p	O
=	O
0.031	O
)	O
and	O
decreased	O
operative	O
time	O
from	O
43	O
±	O
14.53	O
min	O
to	O
27	O
±	O
8.27	O
min	O
(	O
p	O
=	O
0.015	O
)	O
.	O

There	O
was	O
also	O
improvement	O
in	O
the	O
time	O
to	O
start	O
lesion	O
repair	O
from	O
147	O
±	O
117.65	O
sec	O
to	O
51	O
±	O
39.09	O
sec	O
(	O
p	O
=	O
0.025	O
)	O
.	O

There	O
was	O
a	O
trend	O
toward	O
improvement	O
in	O
the	O
reaction	O
time	O
to	O
the	O
injury	O
(	O
22	O
±	O
21.55	O
sec	O
vs.	O
14	O
±	O
6.39	O
,	O
p	O
=	O
0.188	O
)	O
,	O
the	O
time	O
required	O
to	O
control	O
the	O
bleeding	O
(	O
50	O
±	O
94.2	O
sec	O
vs.	O
14	O
±	O
6.95	O
sec	O
,	O
p	O
=	O
0.141	O
)	O
,	O
and	O
the	O
total	O
time	O
required	O
to	O
completely	O
repair	O
of	O
the	O
vascular	O
injury	O
(	O
178	O
±	O
170.4	O
sec	O
vs.	O
119	O
±	O
183.87	O
sec	O
,	O
p	O
=	O
0.302	O
)	O
.	O

A	O
standardized	O
algorithm	O
may	O
help	O
to	O
reduce	O
the	O
potential	O
risks	O
associated	O
with	O
laparoscopic	O
surgery	O
.	O

Further	O
studies	O
will	O
help	O
to	O
refine	O
and	O
determine	O
the	O
benefits	O
of	O
standardized	O
protocols	O
such	O
as	O
that	O
developed	O
in	O
this	O
study	O
for	O
the	O
management	O
of	O
life-threatening	O
laparoscopic	B-P
complications	O
.	O

Methylation	O
dynamics	O
during	O
folliculogenesis	O
and	O
early	O
embryo	O
development	O
in	O
sheep	O
.	O

Genome	O
-wide	O
DNA	O
methylation	O
reprogramming	O
occurs	O
during	O
mammalian	O
gametogenesis	O
and	O
early	O
embryogenesis	O
.	O

Post	O
-	O
fertilization	O
demethylation	O
of	O
paternal	O
and	O
maternal	O
genomes	O
is	O
considered	O
to	O
occur	O
by	O
an	O
active	O
and	O
passive	O
mechanism	O
respectively	O
,	O
in	O
most	O
mammals	O
but	O
sheep	O
;	O
in	O
this	O
species	O
no	O
loss	O
of	O
methylation	O
was	O
observed	O
in	O
either	O
pronucleus	O
.	O

Post	O
-	O
fertilization	O
reprogramming	O
relies	O
on	O
methylating	O
and	O
demethylating	O
enzymes	O
and	O
co-factors	O
that	O
are	O
stored	O
during	O
oocyte	O
growth	O
,	O
concurrently	O
with	O
the	O
re-methylation	O
of	O
the	O
oocyte	O
itself	O
.	O

The	O
crucial	O
remodelling	O
of	O
the	O
oocyte	O
epigenetic	O
baggage	O
often	O
overlaps	O
with	O
potential	O
interfering	O
events	O
such	O
as	O
exposure	O
to	O
assisted	O
reproduction	O
technologies	O
or	O
environmental	O
changes	O
.	O

Here	O
,	O
we	O
report	O
a	O
temporal	O
analysis	O
of	O
methylation	O
dynamics	O
during	O
folliculogenesis	O
and	O
early	O
embryo	O
development	O
in	O
sheep	O
.	O

We	O
characterized	O
global	O
DNA	O
methylation	O
and	O
hydroxymethylation	O
by	O
immunofluorescence	B-P
and	O
relatively	O
quantified	O
the	O
expression	O
of	O
the	O
enzymes	O
and	O
co-factors	O
mainly	O
responsible	O
for	O
their	O
remodelling	O
(	O
DNA	O
methyltransferases	O
(	O
DNMTs	O
)	O
,	O
ten-eleven	O
translocation	O
(	O
TET	O
)	O
proteins	O
and	O
methyl-CpG-binding	O
domain	O
(	O
MBD	O
)	O
proteins	O
)	O
.	O

Our	O
results	O
illustrate	O
for	O
the	O
first	O
time	O
the	O
patterns	O
of	O
hydroxymethylation	O
during	O
oocyte	O
growth	O
.	O

We	O
observed	O
different	O
patterns	O
of	O
methylation	O
and	O
hydroxymethylation	O
between	O
the	O
two	O
parental	O
pronuclei	O
,	O
suggesting	O
that	O
male	O
pronucleus	O
undergoes	O
active	O
demethylation	O
also	O
in	O
sheep	O
.	O

Finally	O
,	O
we	O
describe	O
gene	O
-specific	O
accumulation	O
dynamics	O
for	O
methylating	O
and	O
demethylating	O
enzymes	O
during	O
oocyte	O
growth	O
and	O
observe	O
patterns	O
of	O
expression	O
associated	O
with	O
developmental	O
competence	O
in	O
a	O
differential	O
model	O
of	O
oocyte	O
potential	O
.	O

Our	O
work	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
methylation	O
dynamics	O
during	O
folliculogenesis	O
and	O
early	O
embryo	O
development	O
and	O
improves	O
the	O
overall	O
picture	O
of	O
early	O
rearrangements	O
that	O
will	O
originate	O
the	O
embryo	O
epigenome	O
.	O

The	O
health	O
care	O
experience	O
of	O
patients	O
with	O
cancer	O
during	O
the	O
last	O
year	O
of	O
life	O
:	O
Analysis	O
of	O
the	O
SEER	O
-	O
CAHPS	O
data	O
set	O
.	O

Providing	O
high-quality	O
medical	O
care	O
for	O
individuals	O
with	O
cancer	O
during	O
their	O
last	O
year	O
of	O
life	O
involves	O
a	O
range	O
of	O
challenges	O
.	O

An	O
important	O
component	O
of	O
high-quality	O
care	O
during	O
this	O
critical	O
period	O
is	O
ensuring	O
optimal	O
patient	O
satisfaction	O
.	O

The	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
factors	O
influencing	O
health	O
care	O
ratings	O
among	O
individuals	O
with	O
cancer	O
within	O
1	O
year	O
before	O
death	O
.	O

The	O
current	O
study	O
used	O
the	O
Surveillance	O
,	O
Epidemiology	O
,	O
and	O
End	O
Results	O
(	O
SEER	O
)	O
-	O
Consumer	O
Assessment	O
of	O
Healthcare	O
Providers	O
and	O
Systems	O
(	O
CAHPS	O
)	O
data	O
set	O
,	O
a	O
new	O
data	O
resource	O
linking	O
patient-reported	O
information	O
from	O
the	O
CAHPS	O
Medicare	O
Survey	O
with	O
clinical	O
information	O
from	O
the	O
National	O
Cancer	O
Institute	O
's	O
SEER	O
program	O
.	O

The	O
study	O
included	O
5102	O
Medicare	O
beneficiaries	O
diagnosed	B-P
with	I-P
cancer	I-P
who	O
completed	O
CAHPS	O
between	O
1998	O
and	O
2011	O
within	O
1	O
year	O
before	O
their	O
death	O
.	O

Multivariable	O
logistic	O
regression	O
analyses	O
examined	O
associations	O
between	O
patient	O
demographic	O
and	O
insurance	O
characteristics	O
with	O
9	O
measures	O
of	O
health	O
care	O
experience	O
.	O

Patients	O
with	O
higher	O
general	O
or	O
mental	O
health	O
status	O
were	O
significantly	O
more	O
likely	O
to	O
indicate	O
excellent	O
experience	O
with	O
nearly	O
all	O
measures	O
examined	O
.	O

Sex	O
,	O
race/ethnicity	O
,	O
and	O
education	O
also	O
were	O
found	O
to	O
be	O
significant	O
predictors	O
for	O
certain	O
ratings	O
.	O

Greater	O
time	O
before	O
death	O
predicted	O
an	O
increased	O
likelihood	O
of	O
higher	O
ratings	O
for	O
health	O
plan	O
and	O
specialist	O
physician	O
.	O

Clinical	O
characteristics	O
were	O
found	O
to	O
have	O
few	O
significant	O
associations	O
with	O
experience	O
of	O
care	O
.	O

Individuals	O
in	O
fee-for-service	O
Medicare	O
plans	O
(	O
vs	O
Medicare	O
Advantage	O
)	O
had	O
a	O
greater	O
likelihood	O
of	O
excellent	O
experience	O
with	O
health	O
plans	O
,	O
getting	O
care	O
quickly	O
,	O
and	O
getting	O
needed	O
care	O
.	O

Among	O
patients	O
with	O
cancer	O
within	O
1	O
year	O
before	O
death	O
,	O
experience	O
with	O
health	O
plans	O
,	O
physicians	O
,	O
and	O
medical	O
care	O
were	O
found	O
to	O
be	O
associated	O
with	O
sociodemographic	O
,	O
insurance	O
,	O
and	O
clinical	O
characteristics	O
.	O

These	O
findings	O
provide	O
guidance	O
for	O
the	O
development	O
of	O
programs	O
to	O
improve	O
the	O
experience	O
of	O
care	O
among	O
individuals	O
with	O
cancer	O
.	O

Cancer	O
2017	O
;	O
123:336-344	O
.	O

©	O
2016	O
American	O
Cancer	O
Society	O
.	O

Optimization	O
of	O
Image	O
Reconstruction	O
for	O
(	O
90	O
)	O
Y	O
Selective	O
Internal	O
Radiotherapy	O
on	O
a	O
Lutetium	O
Yttrium	O
Orthosilicate	O
PET/CT	O
System	O
Using	O
a	O
Bayesian	O
Penalized	O
Likelihood	O
Reconstruction	O
Algorithm	O
.	O

Imaging	B-P
on	O
a	O
γ-camera	O
with	O
(	O
90	O
)	O
Y	O
after	O
selective	O
internal	O
radiotherapy	O
(	O
SIRT	O
)	O
may	O
allow	O
for	O
verification	O
of	O
treatment	O
delivery	O
but	O
suffers	O
relatively	O
poor	O
spatial	O
resolution	O
and	O
imprecise	O
dosimetry	O
calculation	O
.	O

(	O
90	O
)	O
Y	O
PET/CT	O
imaging	B-P
is	O
possible	O
on	O
3-dimensional	O
,	O
time-of-flight	O
machines	O
;	O
however	O
,	O
images	O
are	O
usually	O
poor	O
because	O
of	O
low	O
count	O
statistics	O
and	O
noise	O
.	O

A	O
new	O
PET	B-P
reconstruction	O
software	O
using	O
a	O
Bayesian	O
penalized	O
likelihood	O
(	O
BPL	O
)	O
reconstruction	O
algorithm	O
(	O
termed	O
Q.Clear	O
)	O
was	O
investigated	O
using	O
phantom	O
and	O
patient	O
scans	B-P
to	O
optimize	O
the	O
reconstruction	O
for	O
post-SIRT	O
imaging	B-P
and	O
clarify	O
whether	O
BPL	O
leads	O
to	O
an	O
improvement	O
in	O
clinical	O
image	O
quality	O
using	O
(	O
90	O
)	O
Y	O
.	O

Methods	O
:	O
Phantom	O
studies	O
over	O
an	O
activity	O
range	O
of	O
0.5-4.2	O
GBq	O
were	O
performed	O
to	O
assess	O
the	O
contrast	O
recovery	O
,	O
background	O
variability	O
,	O
and	O
contrast-to-noise	O
ratio	O
for	O
a	O
range	O
of	O
BPL	O
and	O
ordered-subset	O
expectation	O
maximization	O
(	O
OSEM	O
)	O
reconstructions	O
on	O
a	O
PET/CT	O
scanner	O
.	O

Patient	O
images	O
after	O
SIRT	O
were	O
reconstructed	O
using	O
the	O
same	O
parameters	O
and	O
were	O
scored	O
and	O
ranked	O
on	O
the	O
basis	O
of	O
image	O
quality	O
,	O
as	O
assessed	O
by	O
visual	O
evaluation	O
,	O
with	O
the	O
corresponding	O
SPECT/CT	B-P
Bremsstrahlung	O
images	O
by	O
2	O
experienced	O
radiologists	O
.	O

Results	O
:	O
Contrast-to-noise	O
ratio	O
was	O
significantly	O
better	O
in	O
BPL	O
reconstructions	O
when	O
compared	O
with	O
OSEM	O
in	O
phantom	O
studies	O
.	O

The	O
patient	O
-derived	O
BPL	O
and	O
matching	O
Bremsstrahlung	O
images	O
scored	O
higher	O
than	O
OSEM	O
reconstructions	O
when	O
scored	O
by	O
radiologists	O
.	O

BPL	O
with	O
a	O
β	O
value	O
of	O
4,000	O
was	O
ranked	O
the	O
highest	O
of	O
all	O
images	O
.	O

Deadtime	O
was	O
apparent	O
in	O
the	O
system	O
above	O
a	O
total	O
phantom	O
activity	O
of	O
3.3	O
GBq	O
.	O

Conclusion	O
:	O
BPL	O
with	O
a	O
β	O
value	O
of	O
4,000	O
is	O
the	O
optimal	O
image	O
reconstruction	O
in	O
PET/CT	O
for	O
confident	O
radiologic	O
reading	O
when	O
compared	O
with	O
other	O
reconstruction	O
parameters	O
for	O
(	O
90	O
)	O
Y	O
imaging	B-P
after	O
SIRT	O
imaging	B-P
.	O

Activity	O
in	O
the	O
field	O
of	O
view	O
should	O
be	O
below	O
3.3	O
GBq	O
at	O
the	O
time	O
of	O
PET	B-P
imaging	I-P
to	O
avoid	O
deadtime	O
losses	O
for	O
this	O
scanner	O
.	O

Quantitative	O
assessment	O
of	O
fluorescent	O
proteins	O
.	O

The	O
advent	O
of	O
fluorescent	O
proteins	O
(	O
FPs	O
)	O
for	O
genetic	O
labeling	O
of	O
molecules	O
and	O
cells	O
has	O
revolutionized	O
fluorescence	B-P
microscopy	I-P
.	O

Genetic	O
manipulations	O
have	O
created	O
a	O
vast	O
array	O
of	O
bright	O
and	O
stable	O
FPs	O
spanning	O
blue	O
to	O
red	O
spectral	O
regions	O
.	O

Common	O
to	O
autofluorescent	B-P
FPs	O
is	O
their	O
tight	O
β-barrel	O
structure	O
,	O
which	O
provides	O
the	O
rigidity	O
and	O
chemical	O
environment	O
needed	O
for	O
effectual	O
fluorescence	O
.	O

Despite	O
the	O
common	O
structure	O
,	O
each	O
FP	O
has	O
unique	O
properties	O
.	O

Thus	O
,	O
there	O
is	O
no	O
single	O
'best	O
'	O
FP	O
for	O
every	O
circumstance	O
,	O
and	O
each	O
FP	O
has	O
advantages	O
and	O
disadvantages	O
.	O

To	O
guide	O
decisions	O
about	O
which	O
FP	O
is	O
right	O
for	O
a	O
given	O
application	O
,	O
we	O
have	O
quantitatively	O
characterized	O
the	O
brightness	O
,	O
photostability	O
,	O
pH	O
stability	O
and	O
monomeric	O
properties	O
of	O
more	O
than	O
40	O
FPs	O
to	O
enable	O
straightforward	O
and	O
direct	O
comparison	O
between	O
them	O
.	O

We	O
focus	O
on	O
popular	O
and/or	O
top-performing	O
FPs	O
in	O
each	O
spectral	O
region	O
.	O

An	O
Accessible	O
and	O
Pragmatic	O
Experimental	O
Model	O
of	O
Nonalcoholic	O
Fatty	O
Liver	O
Disease	O
.	O

BACKGROUND	O
There	O
is	O
no	O
convenient	O
cheap	O
pragmatic	O
experimental	O
model	O
for	O
Nonalcoholic	O
Fatty	O
Liver	O
Disease	O
(	O
NAFLD	O
)	O
/	O
Nonalcoholic	O
Steatohepatitis	O
(	O
NASH	O
)	O
.	O

Our	O
objective	O
was	O
to	O
create	O
a	O
pragmatic	O
model	O
of	O
NAFLD	O
/	O
NASH	O
.	O

METHODS	O
Sprague-Dawley	O
rats	O
were	O
fed	O
a	O
high-fat	O
,	O
high	O
sugar	O
homemade	O
diet	O
ad	O
libitum	O
for	O
seven	O
weeks	O
.	O

The	O
high-fat	O
,	O
high	O
sugar	O
diet	O
included	O
59	O
%	O
of	O
energy	O
derived	O
from	O
fat	O
,	O
30	O
%	O
from	O
carbohydrates	O
,	O
and	O
11	O
%	O
from	O
protein	O
.	O

Serum	B-P
levels	I-P
of	I-P
fasting	I-P
glucose	I-P
,	O
triglyceride	B-P
,	O
cholesterol	B-P
,	O
liver	B-P
enzymes	I-P
,	O
insulin	B-P
,	O
and	O
hepatic	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-α	O
)	O
gene	O
expression	O
were	O
determined	O
.	O

Hepatic	O
histology	B-P
was	O
examined	O
by	O
H	B-P
&	I-P
E	I-P
stain	I-P
.	O

RESULTS	O
Rats	O
fed	O
the	O
high-fat	O
,	O
high	O
sugar	O
diet	O
developed	O
hepatic	O
steatosis	O
,	O
and	O
a	O
moderate	O
inflammation	O
,	O
which	O
was	O
associated	O
with	O
increased	O
serum	O
levels	O
of	O
liver	O
enzymes	O
,	O
glucose	O
,	O
insulin	O
,	O
triglyceride	O
,	O
cholesterol	O
,	O
and	O
hepatic	O
TNF-α	O
gene	O
expression	O
.	O

CONCLUSION	O
This	O
rat	O
model	O
resembles	O
the	O
key	O
features	O
of	O
human	O
NAFLD	O
/	O
NASH	O
and	O
provides	O
a	O
simple	O
pragmatic	O
experimental	O
model	O
for	O
elucidating	O
the	O
disease	O
prevention	O
and	O
treatment	O
.	O

Isolation	O
and	O
characterization	O
of	O
Burkholderia	O
sp	O
.	O

strain	O
CCA53	O
exhibiting	O
ligninolytic	O
potential	O
.	O

Microbial	O
degradation	O
of	O
lignin	O
releases	O
fermentable	O
sugars	O
,	O
effective	O
utilization	O
of	O
which	O
could	O
support	O
biofuel	O
production	O
from	O
lignocellulosic	O
biomass	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
lignin-degrading	O
bacterium	O
was	O
isolated	O
from	O
leaf	O
soil	O
and	O
identified	O
as	O
Burkholderia	O
sp	O
.	O

based	O
on	O
16S	O
rRNA	O
gene	B-P
sequencing	I-P
.	O

This	O
strain	O
was	O
named	O
CCA53	O
,	O
and	O
its	O
lignin-degrading	O
capability	O
was	O
assessed	O
by	O
observing	O
its	O
growth	O
on	O
medium	O
containing	O
alkali	O
lignin	O
or	O
lignin	O
-associated	O
aromatic	O
monomers	O
as	O
the	O
sole	O
carbon	O
source	O
.	O

Alkali	O
lignin	O
and	O
at	O
least	O
eight	O
lignin	O
-associated	O
aromatic	O
monomers	O
supported	O
growth	O
of	O
this	O
strain	O
,	O
and	O
the	O
most	O
effective	O
utilization	O
was	O
observed	O
for	O
p-hydroxybenzene	O
monomers	O
.	O

These	O
findings	O
indicate	O
that	O
Burkholderia	O
sp	O
.	O

strain	O
CCA53	O
has	O
fragmentary	O
activity	O
for	O
lignin	O
degradation	O
.	O

Dobutamine	B-P
Stress	I-P
Echocardiography	I-P
:	O
Impact	O
of	O
Abnormal	O
Blood	O
Potassium	O
Levels	O
on	O
Cardiac	O
Arrhythmias	O
.	O

Guidelines	O
suggest	O
that	O
an	O
abnormal	O
blood	O
potassium	O
level	O
is	O
a	O
relative	O
contraindication	O
to	O
performing	O
dobutamine	B-P
stress	I-P
echocardiography	I-P
(	O
DSE	B-P
)	O
.	O

However	O
,	O
this	O
has	O
not	O
been	O
previously	O
studied	O
.	O

We	O
reviewed	O
a	O
consecutive	O
series	O
of	O
patients	O
who	O
had	O
potassium	O
testing	O
within	O
48	O
hours	O
of	O
undergoing	O
DSE	B-P
for	O
the	O
evaluation	O
of	O
myocardial	O
ischemia	O
over	O
a	O
10-	O
year	O
period	O
(	O
N	O
=	O
13,198	O
)	O
.	O

Normal	O
potassium	O
range	O
in	O
our	O
laboratory	O
is	O
3.6-5.2	O
mmol/L	O
.	O

Hemolyzed	O
samples	O
were	O
not	O
included	O
.	O

The	O
association	O
of	O
potassium	O
levels	O
with	O
the	O
development	O
of	O
supraventricular	O
and	O
ventricular	O
arrhythmias	O
was	O
assessed	O
.	O

The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	O
was	O
very	O
low	O
(	O
supraventricular	O
tachycardia	O
/	O
atrial	O
fibrillation	O
,	O
4.9	O
%	O
;	O
nonsustained	O
ventricular	O
tachycardia	O
,	O
2.9	O
%	O
;	O
sustained	O
ventricular	O
tachycardia	O
or	O
ventricular	O
fibrillation	O
,	O
0.1	O
%	O
)	O
,	O
confirming	O
the	O
overall	O
safety	O
of	O
DSE	B-P
.	O

Most	O
arrhythmias	O
(	O
88	O
%	O
)	O
occurred	O
in	O
patients	O
with	O
normal	O
potassium	O
levels	O
,	O
and	O
arrhythmia	O
rates	O
remained	O
low	O
in	O
patients	O
with	O
potassium	O
abnormalities	O
.	O

Patients	O
with	O
hyperkalemia	O
had	O
a	O
lower	O
risk	O
of	O
developing	O
mild	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
0.39	O
;	O
95	O
%	O
CI	O
,	O
0.22-0.71	O
)	O
and	O
severe	O
(	O
OR	O
,	O
0.13	O
;	O
95	O
%	O
CI	O
,	O
0.01-0.68	O
)	O
supraventricular	O
arrhythmias	O
as	O
well	O
as	O
mild	O
ventricular	O
arrhythmias	O
(	O
OR	O
,	O
0.58	O
;	O
95	O
%	O
CI	O
,	O
0.40-0.83	O
)	O
.	O

Even	O
though	O
events	O
were	O
rare	O
,	O
patients	O
with	O
severe	O
hypokalemia	O
(	O
potassium	O
levels	O
≤	O
3.1	O
mmol/L	O
)	O
had	O
an	O
increased	O
risk	O
of	O
supraventricular	O
arrhythmia	O
and	O
ventricular	O
ectopy	O
.	O

DSE	B-P
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	O
in	O
blood	O
potassium	O
concentrations	O
,	O
and	O
hence	O
cancellation	O
of	O
DSE	B-P
in	O
patients	O
with	O
potassium	O
abnormalities	O
does	O
not	O
appear	O
warranted	O
.	O

Elevated	O
potassium	O
levels	O
are	O
associated	O
with	O
lower	O
rates	O
of	O
clinically	O
significant	O
supraventricular	O
and	O
ventricular	O
arrhythmias	O
.	O

While	O
remaining	O
at	O
relatively	O
low	O
risk	O
,	O
patients	O
with	O
very	O
low	O
potassium	O
levels	O
(	O
≤3.1	O
mmol/L	O
)	O
at	O
the	O
time	O
of	O
DSE	B-P
have	O
a	O
modestly	O
increased	O
risk	O
of	O
arrhythmia	O
.	O

Consideration	O
could	O
be	O
given	O
to	O
correcting	O
severe	O
hypokalemia	O
prior	O
to	O
DSE	B-P
.	O

Thermo-reversible	O
capture	O
and	O
release	O
of	O
DNA	O
by	O
zwitterionic	O
surfactants	O
.	O

The	O
thermo-reversible	O
capture	O
and	O
release	O
of	O
DNA	O
were	O
studied	O
by	O
the	O
protonation	O
and	O
deprotonation	O
of	O
alkyldimethylamine	O
oxide	O
(	O
CnDMAO	O
,	O
n	O
=	O
10	O
,	O
12	O
and	O
14	O
)	O
in	O
Tris-HCl	O
buffer	O
solution	O
.	O

DNA	O
/	O
C14DMAO	O
in	O
Tris-HCl	O
buffer	O
solution	O
with	O
pH	O
=	O
7.2	O
is	O
transparent	O
at	O
25	O
°C	O
,	O
indicating	O
that	O
DNA	O
molecules	O
exist	O
mainly	O
in	O
individuals	O
and	O
the	O
binding	O
of	O
C14DMAO	O
is	O
weak	O
.	O

With	O
the	O
increase	O
of	O
temperature	O
,	O
the	O
pH	O
of	O
the	O
buffer	O
solution	O
continuously	O
decreases	O
,	O
which	O
leads	O
to	O
protonation	O
of	O
C14DMAO	O
(	O
C14DMAO	O
+	O
H	O
(	O
+	O
)	O
→	O
C14DMAOH	O
(	O
+	O
)	O
)	O
and	O
an	O
obvious	O
increase	O
of	O
the	O
turbidity	O
of	O
the	O
samples	O
.	O

This	O
indicates	O
a	O
stronger	O
binding	O
of	O
the	O
protonated	O
C14DMAOH	O
(	O
+	O
)	O
to	O
DNA	O
.	O

Further	O
investigations	O
demonstrated	O
the	O
formation	O
of	O
DNA	O
/	O
C14DMAOH	O
(	O
+	O
)	O
complexes	O
,	O
in	O
which	O
the	O
stretched	O
DNA	O
molecules	O
are	O
effectively	O
compacted	O
as	O
evidenced	O
from	O
UV-vis	B-P
absorptions	I-P
,	O
circular	B-P
dichroism	I-P
(	O
CD	B-P
)	O
measurements	O
,	O
atomic	B-P
force	I-P
microscopy	I-P
(	O
AFM	B-P
)	O
observations	O
,	O
dynamic	B-P
light	I-P
scattering	I-P
(	O
DLS	B-P
)	O
measurements	O
and	O
agarose	B-P
gel	I-P
electrophoresis	I-P
(	O
AGE	B-P
)	O
.	O

Interestingly	O
,	O
when	O
the	O
temperature	O
is	O
turned	O
back	O
to	O
25	O
°C	O
,	O
the	O
compacted	O
DNA	O
molecules	O
can	O
fully	O
recover	O
to	O
the	O
stretched	O
conformation	O
.	O

This	O
cycle	O
can	O
be	O
repeated	O
several	O
times	O
without	O
obvious	O
loss	O
of	O
efficiency	O
.	O

The	O
effect	O
of	O
the	O
chain	O
length	O
of	O
CnDMAO	O
has	O
also	O
been	O
investigated	O
.	O

When	O
C14DMAO	O
was	O
replaced	O
by	O
C12DMAO	O
,	O
similar	O
phenomena	O
can	O
be	O
observed	O
with	O
a	O
slightly	O
higher	O
critical	O
surfactant	O
concentration	O
for	O
DNA	O
compaction	O
and	O
a	O
slightly	O
lower	O
pH	O
of	O
Tris-HCl	O
buffer	O
solution	O
with	O
pH	O
=	O
6.8	O
.	O

For	O
the	O
DNA	O
/	O
C10DMAO	O
system	O
,	O
however	O
,	O
no	O
DNA	O
compaction	O
was	O
observed	O
even	O
in	O
Tris-HCl	O
buffer	O
solution	O
with	O
a	O
much	O
lower	O
pH	O
and	O
a	O
much	O
higher	O
C10DMAO	O
concentration	O
.	O

The	O
negative	O
charges	O
of	O
DNA	O
molecules	O
can	O
easily	O
be	O
neutralized	O
by	O
positive	O
charges	O
of	O
cationic	O
CnDMAOH	O
(	O
+	O
)	O
(	O
n	O
=	O
12	O
and	O
14	O
)	O
micelles	O
.	O

DNA	O
was	O
compacted	O
and	O
then	O
insoluble	O
DNA	O
/	O
CnDMAOH	O
(	O
+	O
)	O
complexes	O
were	O
formed	O
.	O

Because	O
of	O
the	O
much	O
higher	O
critical	O
micelle	O
concentration	O
(	O
cmc	O
)	O
of	O
the	O
shorter	O
chain	O
length	O
C10DMAOH	O
(	O
+	O
)	O
,	O
cationic	O
C10DMAOH	O
(	O
+	O
)	O
micelles	O
can	O
not	O
form	O
under	O
the	O
studied	O
condition	O
to	O
compact	O
DNA	O
.	O

The	O
strategy	O
may	O
provide	O
an	O
efficient	O
and	O
alternative	O
approach	O
for	O
stimuli-responsive	O
gene	O
therapy	O
and	O
drug	O
release	O
.	O

DEVELOPMENT	O
OF	O
A	O
TECHNIQUE	O
FOR	O
DETERMINATION	B-P
OF	O
PULMONARY	O
ARTERY	O
PULSE	O
WAVE	O
VELOCITY	O
IN	O
HORSES	O
.	O

Calcification	O
of	O
the	O
tunica	O
media	O
of	O
the	O
axial	O
pulmonary	O
arteries	O
(	O
PA	O
)	O
has	O
been	O
reported	O
in	O
a	O
large	O
proportion	O
of	O
racehorses	O
.	O

In	O
humans	O
,	O
medial	O
calcification	O
is	O
a	O
significant	O
cause	O
of	O
arterial	O
stiffening	O
and	O
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
cardiac	O
,	O
cerebral	O
and	O
renal	O
microvascular	O
diseases	O
.	O

Pulse	O
wave	O
velocity	O
(	O
PWV	O
)	O
provides	O
a	O
measure	O
of	O
arterial	O
stiffness	O
.	O

This	O
study	O
aimed	O
to	O
develop	O
a	O
technique	O
to	O
determine	O
PA	O
-	O
PWV	O
in	O
horses	O
,	O
and	O
secondarily	O
to	O
investigate	O
a	O
potential	O
association	O
between	O
PA	O
-	O
PWV	O
and	O
arterial	O
fibro-calcification	O
.	O

A	O
dual	O
pressure	O
sensor	O
catheter	O
(	O
PSC	O
)	O
was	O
placed	O
in	O
the	O
main	O
PA	O
of	O
10	O
sedated	O
horses	O
.	O

The	O
pressure	O
waves	O
were	O
used	O
to	O
determine	O
PWV	O
along	O
the	O
PA	O
,	O
using	O
the	O
statistical	O
phase	O
offset	O
method	O
.	O

Histological	O
analysis	O
of	O
the	O
PA	O
was	O
performed	O
to	O
investigate	O
the	O
presence	O
of	O
fibro-calcified	O
lesions	O
.	O

The	O
mean	O
(	O
±SD	O
)	O
PWV	O
was	O
2.3±0.7m/s	O
in	O
the	O
proximal	O
PA	O
trunk	O
and	O
1.1±0.1m/s	O
further	O
distal	O
(	O
15cm	O
)	O
in	O
a	O
main	O
PA	O
branch	O
.	O

The	O
mean	O
(	O
±SD	O
)	O
of	O
mean	O
arterial	O
pressures	O
in	O
the	O
proximal	O
PA	O
trunk	O
was	O
30.1±5.2mmHg	O
,	O
and	O
22.0±6.0mmHg	O
further	O
distal	O
(	O
15cm	O
)	O
within	O
the	O
main	O
PA	O
branch	O
.	O

The	O
mean	O
(	O
±SD	O
)	O
pulse	O
pressure	O
in	O
the	O
proximal	O
PA	O
trunk	O
was	O
15.0±4.7mmHg	O
,	O
and	O
13.5±3.3mmHg	O
further	O
distal	O
(	O
15cm	O
)	O
within	O
the	O
main	O
PA	O
branch	O
.	O

Moderate	O
to	O
severe	O
lesions	O
of	O
the	O
tunica	O
media	O
of	O
the	O
PAs	O
were	O
observed	O
in	O
7	O
horses	O
,	O
but	O
a	O
correlation	O
with	O
PWV	O
could	O
not	O
be	O
established	O
yet	O
.	O

Pulmonary	O
artery	O
PWV	O
may	O
be	O
determined	O
in	O
standing	O
horses	O
.	O

The	O
technique	O
described	O
may	O
allow	O
further	O
investigation	O
of	O
the	O
effect	O
of	O
calcification	O
of	O
large	O
PAs	O
in	O
the	O
pathogenesis	O
of	O
equine	O
pulmonary	O
circulatory	O
disorders	O
.	O

Numerical	O
simulation	O
of	O
motion	O
and	O
deformation	O
of	O
healthy	O
and	O
sick	O
red	O
blood	O
cell	O
through	O
a	O
constricted	O
vessel	O
using	O
hybrid	O
lattice	O
Boltzmann-immersed	O
boundary	O
method	O
.	O

In	O
the	O
present	O
article	O
,	O
hybrid	O
lattice	O
Boltzmann-immersed	O
boundary	O
method	O
is	O
utilized	O
to	O
simulate	O
two-dimensional	O
incompressible	O
viscous	O
flow	O
involving	O
flexible	O
immersed	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
in	O
a	O
microchannel	O
.	O

The	O
main	O
focus	O
of	O
the	O
present	O
research	O
is	O
to	O
study	O
motion	O
and	O
deformation	O
of	O
both	O
healthy	O
and	O
sick	O
RBCs	O
in	O
a	O
vessel	O
with	O
different	O
sizes	O
of	O
stenosis	O
.	O

The	O
presented	O
computational	B-P
results	O
consent	O
reasonably	O
well	O
with	O
the	O
available	O
data	O
in	O
the	O
literature	O
.	O

Two	O
different	O
channels	O
i.e	O
.	O

a	O
simple	O
and	O
a	O
constricted	O
channel	O
are	O
investigated	O
in	O
the	O
present	O
manuscript	O
.	O

The	O
results	O
show	O
that	O
the	O
RBC	O
transfer	O
and	O
deform	O
without	O
any	O
lift	O
force	O
and	O
rotation	O
induced	O
when	O
it	O
is	O
located	O
on	O
the	O
symmetry	O
axis	O
of	O
the	O
microchannel	O
.	O

However	O
,	O
when	O
the	O
RBC	O
is	O
located	O
off	O
the	O
symmetry	O
axis	O
,	O
the	O
pressure	O
difference	O
produced	O
in	O
the	O
flow	O
around	O
the	O
RBC	O
would	O
apply	O
lift	O
forces	O
on	O
them	O
and	O
expel	O
them	O
towards	O
the	O
center	O
of	O
the	O
channel	O
.	O

The	O
healthy	O
RBC	O
always	O
shows	O
more	O
deformation	O
related	O
to	O
the	O
sick	O
one	O
along	O
the	O
channel	O
.	O

Another	O
important	O
result	O
of	O
the	O
present	O
research	O
is	O
that	O
for	O
the	O
ratio	O
of	O
[	O
Formula	O
:	O
see	O
text	O
]	O
a	O
sick	O
RBC	O
can	O
not	O
pass	O
the	O
stenosis	O
,	O
and	O
it	O
reasons	O
serious	O
difficulties	O
for	O
body	O
.	O

The	O
present	O
result	O
s	O
have	O
been	O
compared	O
with	O
the	O
available	O
experimental	O
and	O
numerical	O
results	O
which	O
show	O
good	O
agreements	O
.	O

The	O
Origin	O
of	O
Selectivity	O
in	O
the	O
Complexation	O
of	O
N-Methyl	O
Amino	O
Acids	O
by	O
Tetraphosphonate	O
Cavitands	O
.	O

We	O
report	O
on	O
the	O
eligibility	O
of	O
tetraphosphonate	O
resorcinarene	O
cavitands	O
for	O
the	O
molecular	O
recognition	O
of	O
amino	O
acids	O
.	O

We	O
determined	O
the	O
crystal	O
structure	O
of	O
13	O
complexes	O
of	O
the	O
tetraphosphonate	O
cavitand	O
Tiiii	O
[	O
H	O
,	O
CH3	O
,	O
CH3	O
]	O
with	O
amino	O
acids	O
.	O

(	O
1	O
)	O
H	O
NMR	O
and	O
(	O
31	O
)	O
P	O
NMR	O
experiments	O
and	O
ITC	O
analysis	O
were	O
performed	O
to	O
probe	B-P
the	O
binding	O
between	O
cavitand	O
Tiiii	O
[	O
C3H7	O
,	O
CH3	O
,	O
C2H5	O
]	O
or	O
the	O
water	O
-	O
soluble	O
counterpart	O
Tiiii	O
[	O
C3H6Py	O
(	O
+	O
)	O
Cl	O
(	O
-	O
)	O
,	O
CH3	O
,	O
C2H5	O
]	O
and	O
a	O
selection	O
of	O
representative	O
amino	O
acids	O
.	O

The	O
reported	O
studies	O
and	O
results	O
allowed	O
us	O
(	O
i	O
)	O
to	O
highlight	O
the	O
noncovalent	O
interactions	O
involved	O
in	O
the	O
binding	O
event	O
in	O
each	O
case	O
;	O
(	O
ii	O
)	O
to	O
investigate	O
the	O
ability	O
of	O
tetraphosphonate	O
cavitand	O
receptors	O
to	O
discriminate	O
between	O
the	O
different	O
amino	O
acids	O
;	O
(	O
iii	O
)	O
to	O
calculate	O
the	O
Ka	O
values	O
of	O
the	O
different	O
complexes	O
formed	O
and	O
evaluate	O
the	O
thermodynamic	O
parameters	O
of	O
the	O
complexation	O
process	O
,	O
dissecting	O
the	O
entropic	O
and	O
enthalpic	O
contributions	O
;	O
and	O
(	O
iv	O
)	O
to	O
determine	B-P
the	O
solvent	O
influence	O
on	O
the	O
complexation	O
selectivity	O
.	O

By	O
moving	O
from	O
methanol	O
to	O
water	O
,	O
the	O
complexation	O
changed	O
from	O
entropy	O
driven	O
to	O
entropy	O
opposed	O
,	O
leading	O
to	O
a	O
drop	O
of	O
almost	O
three	O
orders	O
in	O
the	O
magnitude	O
of	O
the	O
Ka	O
.	O

However	O
,	O
this	O
reduction	O
in	O
binding	O
affinity	O
is	O
associated	O
with	O
a	O
dramatic	O
increase	O
in	O
selectivity	O
,	O
since	O
in	O
aqueous	O
solutions	O
only	O
N-methylated	O
amino	O
acids	O
are	O
effectively	O
recognized	O
.	O

The	O
thermodynamic	O
profile	B-P
of	O
the	O
binding	O
does	O
not	O
change	O
in	O
PBS	O
solution	O
.	O

The	O
pivotal	O
role	O
played	O
by	O
cation-π	O
interactions	O
is	O
demonstrated	O
by	O
the	O
linear	O
correlation	O
found	O
between	O
the	O
log	O
Ka	O
in	O
methanol	O
solution	O
and	O
the	O
depth	O
of	O
(	O
+	O
)	O
N-CH3	O
cavity	O
inclusion	O
in	O
the	O
molecular	O
structures	O
.	O

These	O
findings	O
are	O
relevant	O
for	O
the	O
potential	O
use	O
of	O
phosphonate	O
cavitands	O
as	O
synthetic	O
receptors	O
for	O
the	O
detection	O
of	O
epigenetic	O
modifications	O
of	O
histones	O
in	O
physiological	O
media	O
.	O

Sella	O
turcica	O
bridging	O
and	O
dental	O
anomalies	O
:	O
is	O
there	O
an	O
association	O
?	O
.	O

Sella	O
turcica	O
bridging	O
(	O
STB	O
)	O
,	O
or	O
calcification	O
of	O
the	O
interclinoid	O
ligament	O
of	O
sella	O
turcica	O
,	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
some	O
dental	O
anomalies	O
(	O
palatal	O
canine	O
impaction	O
and	O
transposition	O
)	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
find	O
any	O
association	O
between	O
canine	O
impaction	O
,	O
hyperdontia	O
or	O
hypodontia	O
and	O
sellar	O
dimensions	O
or	O
bridging	O
.	O

Lateral	O
cephalometric	B-P
radiographs	B-P
from	O
78	O
patients	O
with	O
impacted	O
canines	O
,	O
68	O
with	O
dental	O
agenesis	O
and	O
17	O
with	O
hyperdontia	O
were	O
collected	O
.	O

Linear	O
dimensions	O
of	O
sella	O
turcica	O
were	O
calculated	O
and	O
compared	O
to	O
those	O
of	O
a	O
control	O
group	O
(	O
47	O
individuals	O
)	O
.	O

A	O
standardize	O
scoring	O
scale	O
was	O
used	O
to	O
quantify	O
the	O
extent	O
of	O
STB	O
from	O
each	O
radiographs	B-P
.	O

The	O
frequency	O
of	O
partial	O
and	O
complete	O
calcifications	O
of	O
sella	O
in	O
patients	O
with	O
dental	O
anomalies	O
is	O
increased	O
when	O
compared	O
to	O
controls	O
.	O

STB	O
can	O
influence	O
the	O
interclinoid	O
distance	O
but	O
does	O
not	O
affect	O
other	O
linear	O
dimensions	O
of	O
sella	O
.	O

No	O
statistically	O
significant	O
difference	O
has	O
been	O
found	O
in	O
sellar	O
dimensions	O
and	O
STB	O
expression	O
when	O
evaluating	O
radiographs	B-P
at	O
different	O
ages	O
.	O

STB	O
is	O
frequently	O
found	O
in	O
patients	O
with	O
dental	O
abnormalities	O
.	O

Sinus	O
augmentation	O
using	O
a	O
histone	O
deacetylase	O
inhibitor	O
in	O
a	O
calcium	O
sulfate	O
carrier	O
in	O
rabbit	O
:	O
A	O
pilot	O
study	O
.	O

Histone	O
deacetylase	O
inhibitors	O
such	O
as	O
sodium	O
butyrate	O
(	O
SB	O
)	O
have	O
been	O
suggested	O
to	O
be	O
promising	O
candidate	O
small	O
molecules	O
for	O
bone	O
regeneration	O
.	O

In	O
this	O
study	O
,	O
the	O
capacity	O
of	O
SB	O
loaded	O
onto	O
calcium	O
sulfate	O
(	O
CaS	O
)	O
to	O
enhance	O
bone	O
formation	O
was	O
investigated	O
in	O
a	O
rabbit	O
sinus	O
model	O
.	O

Following	O
preparation	O
of	O
the	O
sinus	O
access	O
window	O
on	O
a	O
randomly	O
selected	O
side	O
,	O
SB	O
loaded	O
onto	O
CaS	O
(	O
CaS	O
/	O
SB	O
)	O
was	O
grafted	O
in	O
five	O
rabbits	O
,	O
and	O
CaS	O
alone	O
(	O
control	O
)	O
was	O
grafted	O
in	O
another	O
five	O
rabbits	O
.	O

The	O
animals	O
were	O
euthanized	O
after	O
4	O
weeks	O
for	O
radiographic	B-P
,	O
histometric	B-P
,	O
and	O
immunohistochemical	B-P
analyses	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
difference	O
in	O
the	O
total	O
augmented	O
volume	O
between	O
the	O
groups	O
in	O
the	O
radiographic	B-P
analysis	I-P
(	O
158.22	O
±	O
39.31	O
mm	O
(	O
3	O
)	O
and	O
107.09	O
±	O
39.69	O
mm	O
(	O
3	O
)	O
,	O
respectively	O
,	O
p	O
=	O
0.040	O
)	O
.	O

The	O
CaS	O
/	O
SB	O
group	O
showed	O
a	O
larger	O
portion	O
of	O
mature	O
lamellar	O
bone	O
and	O
a	O
higher	O
level	O
of	O
mineralization	O
of	O
bone	O
trabeculae	O
,	O
characterized	O
by	O
more	O
intense	O
labeling	B-P
with	O
osteocalcin	O
compared	O
with	O
the	O
control	O
group	O
in	O
the	O
immunohistochemical	B-P
analysis	O
.	O

The	O
number	O
of	O
osteocalcin-positive	O
cells	O
within	O
the	O
central	O
area	O
of	O
the	O
augmented	O
sinus	O
was	O
significantly	O
higher	O
in	O
the	O
CaS	O
/	O
SB	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
179	O
±	O
26.0	O
mm	O
(	O
2	O
)	O
and	O
123	O
±	O
33.2	O
mm	O
(	O
2	O
)	O
,	O
respectively	O
,	O
p	O
=	O
0.027	O
)	O
.	O

In	O
conclusion	O
,	O
CaS	O
/	O
SB	O
exhibited	O
superior	O
osteogenic	O
potential	O
,	O
especially	O
in	O
the	O
central	O
portion	O
of	O
the	O
augmented	O
sinus	O
as	O
well	O
as	O
improvement	O
of	O
the	O
volume	O
maintenance	O
for	O
sinus	O
augmentation	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
J	O
Biomed	O
Mater	O
Res	O
Part	O
B	O
:	O
Appl	O
Biomater	O
,	O
2016	O
.	O

A	O
Single	O
Nanoprobe	O
for	O
Ratiometric	B-P
Imaging	I-P
and	O
Biosensing	B-P
of	O
Hypochlorite	O
and	O
Glutathione	O
in	O
Live	O
Cells	O
Using	O
Surface-Enhanced	B-P
Raman	I-P
Scattering	I-P
.	O

Hypochlorite	O
(	O
ClO	O
(	O
-	O
)	O
)	O
and	O
glutathione	O
(	O
GSH	O
)	O
have	O
been	O
reported	O
to	O
closely	O
correlate	O
with	O
oxidative	O
stress	O
and	O
related	O
diseases	O
;	O
however	O
,	O
a	O
clear	O
mechanism	O
is	O
still	O
unknown	O
,	O
mainly	O
owing	O
to	O
a	O
lack	O
of	O
accurate	O
analytical	O
methods	O
for	O
live	O
cells	O
.	O

Herein	O
we	O
create	O
a	O
novel	O
surface-enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
nanoprobe	O
,	O
4-mercaptophenol	O
(	O
4-MP	O
)	O
-functionalized	O
gold	O
flowers	O
(	O
AuF	O
/	O
MP	O
)	O
,	O
for	O
imaging	B-P
and	O
biosensing	B-P
of	O
ClO	O
(	O
-	O
)	O
and	O
GSH	O
in	O
RAW	O
264.7	O
macrophage	O
cells	O
upon	O
oxidative	O
stress	O
.	O

The	O
SERS	B-P
spectra	O
of	O
AuF	O
/	O
MP	O
change	O
with	O
the	O
reaction	O
between	O
ClO	O
(	O
-	O
)	O
and	O
4-MP	O
on	O
AuFs	O
within	O
1	O
min	O
and	O
then	O
recover	O
after	O
reaction	O
with	O
GSH	O
,	O
resulting	O
in	O
the	O
ratiometric	O
detection	O
of	O
ClO	O
(	O
-	O
)	O
and	O
GSH	O
with	O
high	O
accuracy	O
.	O

The	O
single	O
SERS	O
probe	O
also	O
shows	O
high	O
selectivity	O
for	O
ClO	O
(	O
-	O
)	O
and	O
GSH	O
detection	O
against	O
other	O
reactive	O
oxygen	O
species	O
and	O
amino	O
acids	O
which	O
may	O
exist	O
in	O
biological	O
systems	O
,	O
as	O
well	O
as	O
remarkable	O
sensitivity	O
ascribed	O
to	O
a	O
larger	O
amount	O
of	O
hot	O
spots	O
on	O
AuFs	O
.	O

The	O
significant	O
analytical	O
performance	O
of	O
the	O
developed	O
nanoprobe	O
,	O
together	O
with	O
good	O
biocompatibility	O
and	O
high	O
cell-permeability	O
,	O
enables	O
the	O
present	O
SERS	B-P
probe	I-P
imaging	I-P
and	O
real-time	O
detection	O
of	O
ClO	O
(	O
-	O
)	O
and	O
GSH	O
in	O
live	O
cells	O
upon	O
oxidative	O
stress	O
.	O

pH	O
-Dependent	O
Transmembrane	O
Activity	O
of	O
Peptide	O
-Functionalized	O
Gold	O
Nanostars	O
for	O
Computed	B-P
Tomography	I-P
/	O
Photoacoustic	B-P
Imaging	I-P
and	O
Photothermal	O
Therapy	O
.	O

Progress	O
in	O
multifunctional	O
nanomaterials	O
for	O
tumor	O
therapy	O
mostly	O
depends	O
on	O
the	O
development	O
of	O
tumor	O
-	O
targeting	O
delivery	O
strategies	O
.	O

One	O
approach	O
is	O
to	O
explore	O
a	O
pH	O
-responsive	O
strategy	O
to	O
target	O
the	O
slightly	O
acidic	O
solid	O
tumor	O
microenvironment	O
.	O

A	O
novel	O
class	O
of	O
pH	O
(	O
low	O
)	O
insertion	O
peptides	O
(	O
pHLIPs	O
)	O
with	O
pH	O
-dependent	O
transmembrane	O
activity	O
can	O
fold	O
and	O
rapidly	O
insert	O
into	O
the	O
lipid	O
bilayer	O
of	O
tumor	O
cells	O
triggered	O
by	O
acidity	O
,	O
facilitating	O
the	O
cellular	O
internalization	O
of	O
nanomaterials	O
synchronously	O
.	O

Here	O
,	O
we	O
innovatively	O
decorated	O
gold	O
nanostars	O
(	O
GNSs	O
)	O
with	O
pHLIPs	O
(	O
GNS	O
-	O
pHLIP	O
)	O
to	O
improve	O
their	O
targeting	O
ability	O
and	O
photothermal	O
therapeutic	O
(	O
PTT	O
)	O
efficiency	O
.	O

The	O
obtained	O
GNS	O
-	O
pHLIP	O
exhibited	O
the	O
excellent	O
characteristics	O
of	O
uniform	O
size	O
and	O
good	O
biocompatibility	O
.	O

As	O
compared	O
to	O
GNS	O
-	O
mPEG	O
,	O
the	O
cellular	O
internalization	O
of	O
GNS	O
-	O
pHLIP	O
was	O
1-fold	O
higher	O
after	O
a	O
2	O
h	O
incubation	O
with	O
cells	O
in	O
media	O
at	O
pH	O
6.4	O
than	O
at	O
pH	O
7.4	O
.	O

Moreover	O
,	O
the	O
tumor	O
accumulation	O
of	O
the	O
GNS	O
-	O
pHLIP	O
was	O
3-fold	O
higher	O
than	O
that	O
of	O
GNS	O
-	O
mPEG	O
after	O
intravenous	O
injection	O
into	O
MCF-7	O
breast	O
tumor	O
animal	O
models	O
for	O
24	O
h.	O
Furthermore	O
,	O
GNS	O
-	O
pHLIP	O
exhibited	O
stronger	O
signals	O
than	O
the	O
GNS	O
-	O
mPEG	O
through	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
and	O
photoacoustic	B-P
(	I-P
PA	I-P
)	I-P
imaging	I-P
.	O

Simultaneously	O
,	O
the	O
desirable	O
targeting	O
efficiency	O
significantly	O
improved	O
the	O
PTT	O
efficacy	O
to	O
tumors	O
,	O
with	O
low	O
side	O
effects	O
on	O
normal	O
tissues	O
.	O

The	O
results	O
clearly	O
demonstrate	O
that	O
the	O
GNS	O
-	O
pHLIP	O
successfully	O
took	O
advantage	O
of	O
the	O
tumor	O
-	O
targeting	O
ability	O
of	O
pHLIPs	O
and	O
the	O
good	O
characteristics	O
of	O
GNS	O
s	O
,	O
which	O
may	O
contribute	O
to	O
the	O
study	O
of	O
tumor	O
imaging	B-P
and	O
therapy	O
.	O

The	O
C	O
Isoform	O
of	O
Dictyostelium	O
Tetraspanins	O
Localizes	O
to	O
the	O
Contractile	O
Vacuole	O
and	O
Contributes	O
to	O
Resistance	O
against	O
Osmotic	O
Stress	O
.	O

Tetraspanins	O
(	O
Tsps	O
)	O
are	O
membrane	O
proteins	O
that	O
are	O
widely	O
expressed	O
in	O
eukaryotic	O
organisms	O
.	O

Only	O
recently	O
,	O
Tsps	O
have	O
started	O
to	O
acquire	O
relevance	O
as	O
potential	O
new	O
drug	O
targets	O
as	O
they	O
contribute	O
,	O
via	O
protein-protein	O
interactions	O
,	O
to	O
numerous	O
pathophysiological	O
processes	O
including	O
infectious	O
diseases	O
and	O
cancer	O
.	O

However	O
,	O
due	O
to	O
a	O
high	O
number	O
of	O
isoforms	O
and	O
functional	O
redundancy	O
,	O
knowledge	O
on	O
specific	O
functions	O
of	O
most	O
Tsps	O
is	O
still	O
scarce	O
.	O

We	O
set	O
out	O
to	O
characterize	O
five	O
previously	O
annotated	O
Tsps	O
,	O
TspA-E	O
,	O
from	O
Dictyostelium	O
discoideum	O
,	O
a	O
model	O
for	O
studying	O
proteins	O
that	O
have	O
human	O
orthologues	O
.	O

Using	O
reverse	O
transcriptase	O
PCRs	O
,	O
we	O
found	O
mRNAs	O
for	O
TspA-E	O
in	O
the	O
multicellular	O
slug	O
stage	O
,	O
whereas	O
vegetative	O
cells	O
expressed	O
only	O
TspA	O
,	O
TspC	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
TspD	O
.	O

We	O
raised	O
antibodies	O
against	O
TspA	O
,	O
TspC	O
and	O
TspD	O
and	O
detected	O
endogenous	O
TspA	O
,	O
as	O
well	O
as	O
heterologously	O
expressed	O
TspA	O
and	O
TspC	O
by	O
Western	B-P
blot	I-P
.	O

N-deglycosylation	O
assays	B-P
and	O
mutational	O
analyses	O
showed	O
glycosylation	O
of	O
TspA	O
and	O
TspC	O
in	O
vivo	O
.	O

GFP	O
-tagged	O
Tsps	O
co-localized	O
with	O
the	O
proton	O
pump	O
on	O
the	O
contractile	O
vacuole	O
network	O
.	O

Deletion	O
strains	O
of	O
TspC	O
and	O
TspD	O
exibited	O
unaltered	O
growth	O
,	O
adhesion	O
,	O
random	O
motility	O
and	O
development	O
.	O

Yet	O
,	O
tspC-	O
cells	O
showed	O
a	O
defect	O
in	O
coping	O
with	O
hypo-osmotic	O
stress	O
,	O
due	O
to	O
accumulation	O
of	O
contractile	O
vacuoles	O
,	O
but	O
heterologous	O
expression	O
of	O
TspC	O
rescued	O
their	O
phenotype	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
fill	O
a	O
gap	O
in	O
Dictyostelium	O
research	O
and	O
open	O
up	O
the	O
possibility	O
that	O
Tsps	O
in	O
contractile	O
vacuoles	O
of	O
e.g	O
.	O

Trypanosoma	O
may	O
one	O
day	O
constitute	O
a	O
valuable	O
drug	O
target	O
for	O
treating	O
sleeping	O
sickness	O
,	O
one	O
of	O
the	O
most	O
threatening	O
tropical	O
diseases	O
.	O

The	O
effects	O
of	O
a	O
data	O
driven	O
maximum	O
surgical	O
blood	O
ordering	O
schedule	O
on	O
preoperative	O
blood	O
ordering	O
practices	O
.	O

The	O
maximum	O
surgical	O
blood	O
ordering	O
schedule	O
(	O
MSBOS	O
)	O
provides	O
guidelines	O
for	O
pre-operative	O
pre-transfusion	O
testing	B-P
for	O
elective	O
surgical	O
procedures	O
.	O

This	O
study	O
compared	O
blood	O
ordering	O
and	O
utilization	O
during	O
the	O
period	O
when	O
the	O
MSBOS	O
was	O
created	O
by	O
achieving	O
consensus	O
between	O
the	O
blood	O
bank	O
and	O
the	O
various	O
surgical	O
specialties	O
,	O
and	O
after	O
the	O
introduction	O
of	O
an	O
MSBOS	O
created	O
by	O
using	O
department-specific	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
transfusion	O
data	O
(	O
data	O
driven	O
MSBOS	O
,	O
dMSBOS	O
)	O
.	O

The	O
dMSBOS	O
was	O
created	O
by	O
analyzing	O
12	O
months	O
of	O
RBC	O
transfusion	O
data	O
for	O
each	O
procedure	O
across	O
a	O
regional	O
health	O
system	O
.	O

Pre-transfusion	O
testing	B-P
and	O
the	O
RBC	O
crossmatch	B-P
:	O
transfusion	O
(	O
C	O
:	O
T	O
)	O
ratios	O
at	O
8	O
of	O
the	O
hospitals	O
were	O
compared	O
between	O
the	O
12	O
month	O
period	O
before	O
the	O
dMSBOS	O
was	O
introduced	O
,	O
and	O
the	O
15	O
months	O
after	O
its	O
introduction	O
.	O

There	O
were	O
significant	O
reductions	O
in	O
the	O
median	O
monthly	O
number	O
of	O
type	O
and	O
screens	O
not	O
associated	O
with	O
RBC	O
crossmatches	B-P
(	O
10	O
714-10	O
061	O
;	O
p	O
<	O
0.0001	O
)	O
and	O
the	O
median	O
number	O
of	O
type	O
and	O
screens	O
associated	O
with	O
RBC	O
crossmatches	B-P
(	O
10	O
127-9	O
349	O
;	O
p	O
=	O
0.0014	O
)	O
on	O
surgical	O
patients	O
after	O
dMSBOS	O
implementation	O
.	O

There	O
were	O
significant	O
decreases	O
in	O
the	O
median	O
number	O
of	O
monthly	O
RBC	O
units	O
crossmatched	B-P
(	O
2	O
981-2	O
444	O
;	O
p	O
<	O
0.0001	O
)	O
and	O
transfused	O
(	O
890-791	O
;	O
p	O
<	O
0.0001	O
)	O
to	O
surgical	O
patients	O
after	O
implementing	O
the	O
dMSBOS	O
.	O

The	O
overall	O
system-wide	O
C	O
:	O
T	O
ratio	O
trended	O
down	O
after	O
dMSBOS	O
implementation	O
(	O
from	O
3.34	O
to	O
3.17	O
,	O
p	O
=	O
0.067	O
)	O
.	O

Crossmatching	B-P
fewer	O
RBC	O
units	O
facilitates	O
more	O
efficient	O
management	O
of	O
the	O
blood	B-P
bank	I-P
's	I-P
inventory	I-P
.	O

The	O
dMSBOS	O
was	O
effective	O
in	O
reducing	O
the	O
extent	O
of	O
unnecessary	O
pre-transfusion	O
testing	B-P
before	O
surgery	O
and	O
reduced	O
the	O
number	O
of	O
RBCs	O
that	O
were	O
crossmatched	B-P
for	O
specific	O
patients	O
.	O

Effect	O
of	O
Genotype	O
and	O
Previous	O
GH	O
Treatment	O
on	O
Adiposity	O
in	O
Adults	O
With	O
Prader-Willi	O
Syndrome	O
.	O

Adults	O
with	O
Prader-Willi	O
syndrome	O
(	O
PWS	O
)	O
have	O
an	O
increased	O
proportion	O
of	O
sc	O
fat	O
mass	O
compared	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
-matched	O
controls	O
,	O
but	O
whether	O
the	O
genotype	O
influences	O
body	O
composition	O
and	O
metabolic	O
profile	O
remains	O
controversial	O
.	O

To	O
assess	O
body	O
composition	O
and	O
metabolic	O
features	O
in	O
adults	O
with	O
PWS	O
,	O
according	O
to	O
genetic	O
subtype	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
previous	O
GH	O
treatment	O
was	O
assessed	O
.	O

Main	O
Outcomes	O
and	O
Measures	O
:	O
Body	O
composition	O
(	O
Dual	B-P
Energy	I-P
X-ray	I-P
Absorptiometry	I-P
)	O
and	O
metabolic	O
parameters	O
were	O
compared	O
in	O
PWS	O
adults	O
(	O
mean	O
age	O
,	O
25.5	O
±	O
8.9	O
y	O
)	O
with	O
deletion	O
(	O
n	O
=	O
47	O
)	O
or	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
(	O
n	O
=	O
26	O
)	O
,	O
taking	O
into	O
account	O
GH	O
treatment	O
in	O
childhood	O
and/or	O
adolescence	O
.	O

In	O
subgroups	O
,	O
adipocyte	O
size	O
,	O
fasting	O
total	B-P
ghrelin	I-P
levels	I-P
,	O
and	O
resting	O
energy	O
expenditure	O
were	O
measured	O
,	O
and	O
hyperphagia	O
was	O
assessed	O
by	O
the	O
Dykens	O
Hyperphagia	O
Questionnaire	O
.	O

In	O
the	O
whole	O
sample	O
,	O
the	O
deletion	O
group	O
had	O
a	O
higher	O
BMI	O
compared	O
with	O
UPD	O
(	O
40.9	O
±	O
11.5	O
vs	O
34.6	O
±	O
9.6	O
kg/m	O
(	O
2	O
)	O
,	O
P	O
=	O
.02	O
)	O
,	O
but	O
there	O
was	O
no	O
difference	O
between	O
groups	O
in	O
percent	O
body	O
fat	O
,	O
metabolic	O
profile	O
,	O
adipocyte	O
size	O
,	O
resting	O
energy	O
expenditure	O
,	O
hyperphagia	O
score	O
,	O
or	O
ghrelin	B-P
levels	I-P
.	O

In	O
subjects	O
previously	O
treated	O
with	O
GH	O
,	O
BMI	O
was	O
not	O
different	O
between	O
UPD	O
and	O
deletion	O
groups	O
(	O
33.0	O
±	O
9.7	O
vs	O
33.5	O
±	O
11.1	O
kg/m	O
(	O
2	O
)	O
)	O
.	O

In	O
addition	O
,	O
previous	O
GH	O
treatment	O
was	O
associated	O
with	O
decreased	O
percent	O
body	O
fat	O
and	O
adipocyte	O
volume	O
only	O
in	O
the	O
deletion	O
group	O
.	O

A	O
deletion	O
genotype	O
in	O
adults	O
with	O
PWS	O
is	O
associated	O
with	O
increased	O
BMI	O
.	O

GH	O
treatment	O
in	O
childhood	O
and/or	O
adolescence	O
limits	O
this	O
deleterious	O
phenotypic	O
effect	O
with	O
improved	O
adiposity	O
markers	O
.	O

This	O
study	O
suggests	O
relationships	O
between	O
the	O
molecular	O
phenotype	O
of	O
PWS	O
and	O
adipose	O
tissue	O
development	O
as	O
well	O
as	O
sensitivity	O
to	O
GH	O
.	O

NLRP3	O
protects	O
alveolar	O
barrier	O
integrity	O
by	O
an	O
inflammasome	O
-	O
independent	O
increase	O
of	O
epithelial	O
cell	O
adherence	O
.	O

Bacterial	O
pneumonia	O
is	O
a	O
major	O
cause	O
of	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
characterized	O
by	O
alveolar	O
barrier	O
disruption	O
.	O

NLRP3	O
is	O
best	O
known	O
for	O
its	O
ability	O
to	O
form	O
inflammasomes	O
and	O
to	O
regulate	O
IL-1β	O
and	O
IL-18	O
production	O
in	O
myeloid	O
cells	O
.	O

Here	O
we	O
show	O
that	O
NLRP3	O
protects	O
the	O
integrity	O
of	O
the	O
alveolar	O
barrier	O
in	O
a	O
mouse	O
model	O
of	O
Streptococcus	O
pneumoniae	O
-	O
induced	O
pneumonia	O
,	O
and	O
ex	O
vivo	O
upon	O
treatment	O
of	O
isolated	O
perfused	O
and	O
ventilated	O
lungs	O
with	O
the	O
purified	O
bacterial	O
toxin	O
,	O
pneumolysin	O
.	O

We	O
reveal	O
that	O
the	O
preserving	O
effect	O
of	O
NLRP3	O
on	O
the	O
lung	O
barrier	O
is	O
independent	O
of	O
inflammasomes	O
,	O
IL-1β	O
and	O
IL-18	O
.	O

NLRP3	O
improves	O
the	O
integrity	O
of	O
alveolar	O
epithelial	O
cell	O
monolayers	O
by	O
enhancing	O
cellular	B-P
adherence	O
.	O

Collectively	O
,	O
our	O
study	B-P
uncovers	O
a	O
novel	O
function	O
of	O
NLRP3	O
by	O
demonstrating	O
that	O
it	O
protects	O
epithelial	O
barrier	O
function	O
independently	O
of	O
inflammasomes	O
.	O

Correlation	O
of	O
the	O
Lipid	O
Profile	B-P
,	O
BMI	O
and	O
Bone	O
Mineral	O
Density	O
in	O
Postmenopausal	O
Women	O
.	O

To	O
the	O
reduction	O
of	O
bone	O
density	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
contribute	O
elevated	O
lipid	O
parameters	O
and	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
.	O

The	O
goal	O
of	O
our	O
study	O
was	O
to	O
determine	O
the	O
correlation	O
between	O
lipid	O
parameters	O
,	O
BMI	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
.	O

The	O
study	O
was	O
carried	O
out	O
by	O
matched	O
type	O
between	O
experimental	O
group	O
and	O
controls	O
.	O

The	O
experimental	O
group	O
consisted	O
of	O
100	O
females	O
at	O
postmenopausal	O
age	O
,	O
in	O
which	O
by	O
the	O
DEXA	B-P
method	I-P
was	O
diagnosed	O
osteoporosis	O
at	O
the	O
Department	O
of	O
Endocrinology	O
,	O
Diabetes	O
and	O
Metabolic	O
Diseases	O
,	O
University	O
Medical	O
Center	O
of	O
RS	O
during	O
2015-2016	O
,	O
while	O
the	O
control	O
group	O
consisted	O
of	O
100	O
females	O
in	O
a	O
postmenopausal	O
age	O
but	O
without	O
diagnosed	O
osteoporosis	O
.	O

The	O
groups	O
were	O
matched	O
by	O
age	O
(	O
±	O
2	O
years	O
)	O
.	O

To	O
all	O
participants	O
of	O
the	O
study	O
were	O
carried	O
out	O
biochemical	B-P
analysis	I-P
of	I-P
blood	I-P
,	O
or	O
the	O
analysis	O
of	O
the	O
lipid	O
profile	B-P
that	O
included	O
total	O
cholesterol	O
,	O
LDL	O
cholesterol	O
,	O
triglycerides	O
(	O
TG	O
)	O
and	O
HDL	O
cholesterol	O
,	O
and	O
was	O
determined	O
the	O
values	O
of	O
BMI	O
and	O
waist	O
circumference	O
(	O
WC	O
)	O
.	O

Analysis	O
of	O
the	O
data	O
of	O
our	O
research	O
shows	O
that	O
by	O
the	O
univariate	O
logistic	O
regression	O
the	O
values	O
of	O
lipid	O
parameters	O
total	O
cholesterol	O
(	O
p=0.000	O
)	O
,	O
LDL	O
(	O
p=0.005	O
)	O
and	O
TG	O
(	O
p=0.033	O
)	O
were	O
significantly	O
associated	O
with	O
osteoporosis	O
,	O
while	O
in	O
multivariate	O
logistic	O
model	O
only	O
total	O
cholesterol	O
(	O
p=	O
0.018	O
)	O
was	O
found	O
as	O
an	O
independent	O
risk	O
factor	O
for	O
osteoporosis	O
in	O
postmenopausal	O
women	O
.	O

BMI	O
values	O
were	O
not	O
statistically	O
significantly	O
associated	O
with	O
osteoporosis	O
(	O
p=0.727	O
)	O
.	O

On	O
the	O
decrease	O
in	O
bone	O
mineral	O
density	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
influence	O
many	O
risk	O
factors	O
whose	O
identification	O
has	O
the	O
aim	O
to	O
develop	O
more	O
effective	O
prevention	O
of	O
this	O
disease	O
in	O
the	O
elderly	O
.	O

Cortical	O
Reorganization	O
following	O
Injury	O
Early	O
in	O
Life	O
.	O

The	O
brain	O
has	O
a	O
remarkable	O
capacity	O
for	O
reorganization	O
following	O
injury	O
,	O
especially	O
during	O
the	O
first	O
years	O
of	O
life	O
.	O

Knowledge	O
of	O
structural	O
reorganization	O
and	O
its	O
consequences	O
following	O
perinatal	O
injury	O
is	O
sparse	O
.	O

Here	O
we	O
studied	O
changes	O
in	O
brain	O
tissue	O
volume	O
,	O
morphology	O
,	O
perfusion	O
,	O
and	O
integrity	O
in	O
children	O
with	O
hemiplegia	O
compared	O
to	O
typically	O
developing	O
children	O
,	O
using	O
MRI	B-P
.	O

Children	O
with	O
hemiplegia	O
demonstrated	O
reduced	O
total	O
cerebral	O
volume	O
,	O
with	O
increased	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
and	O
reduced	O
total	O
white	O
matter	O
volumes	O
,	O
with	O
no	O
differences	O
in	O
total	O
gray	O
matter	O
volume	O
,	O
compared	O
to	O
typically	O
developing	O
children	O
.	O

An	O
increase	O
in	O
cortical	O
thickness	O
at	O
the	O
hemisphere	O
contralateral	O
to	O
the	O
lesion	O
(	O
CLH	O
)	O
was	O
detected	O
in	O
motor	O
and	O
language	O
areas	O
,	O
which	O
may	O
reflect	O
compensation	O
for	O
the	O
gray	O
matter	O
loss	O
in	O
the	O
lesion	O
area	O
or	O
retention	O
of	O
ipsilateral	O
pathways	O
.	O

In	O
addition	O
,	O
reduced	O
cortical	O
thickness	O
,	O
perfusion	O
,	O
and	O
surface	O
area	O
were	O
detected	O
in	O
limbic	O
areas	O
.	O

Increased	O
CSF	O
volume	O
and	O
precentral	O
cortical	O
thickness	O
and	O
reduced	O
white	O
matter	O
volume	O
were	O
correlated	O
with	O
worse	O
motor	O
performance	O
.	O

Brain	O
reorganization	O
of	O
the	O
gray	O
matter	O
within	O
the	O
CLH	O
,	O
while	O
not	O
necessarily	O
indicating	O
better	O
outcome	O
,	O
is	O
suggested	O
as	O
a	O
response	O
to	O
neuronal	O
deficits	O
following	O
injury	O
early	O
in	O
life	O
.	O

Physical	O
and	O
virtual	O
modelling	O
of	O
the	O
head	O
and	O
neck	O
for	O
surgical	O
simulation	O
and	O
training	O
.	O

Investigation	O
and	O
surgical	O
manipulation	O
of	O
the	O
larynx	O
,	O
pharynx	O
,	O
and	O
oesophagus	O
suffer	O
from	O
inherent	O
challenges	O
with	O
access	O
to	O
the	O
sites	O
of	O
interest	O
.	O

To	O
reduce	O
trauma	O
and	O
external	O
scarring	O
,	O
visualization	O
and	O
minimally	O
invasive	O
interventions	O
by	O
the	O
transnasal	O
or	O
transoral	O
routes	O
have	O
become	O
more	O
prevalent	O
.	O

This	O
article	O
discusses	O
engineering	O
methods	O
used	O
to	O
understand	O
and	O
overcome	O
the	O
mechanical	O
constraints	O
inside	O
the	O
airway	O
and	O
upper	O
gastrointestinal	O
tract	O
,	O
and	O
examines	O
the	O
role	O
that	O
robotics	O
and	O
engineering	O
are	O
beginning	O
to	O
play	O
in	O
modelling	O
of	O
surgical	O
interventions	O
in	O
this	O
region	O
.	O

Although	O
robotic	O
solutions	O
to	O
minimally	O
invasive	O
surgery	O
of	O
the	O
airway	O
and	O
upper	O
gastrointestinal	O
tract	O
already	O
exist	O
,	O
there	O
is	O
still	O
scope	O
for	O
increasing	O
the	O
breadth	O
of	O
their	O
use	O
.	O

Physical	O
and	O
virtual	O
models	O
of	O
these	O
organs	O
are	O
used	O
to	O
investigate	O
the	O
capability	O
and	O
limitations	O
of	O
manual	O
and	O
robotic	O
surgical	O
interventions	O
in	O
this	O
region	O
.	O

Understanding	O
the	O
tissue	O
mechanics	O
and	O
tool	O
capabilities	O
is	O
central	O
to	O
improving	O
outcomes	O
in	O
the	O
clinical	O
setting	O
.	O

Both	O
physical	O
and	O
virtual	O
modelling	O
modalities	O
are	O
used	O
in	O
training	O
surgeons	O
for	O
both	O
manual	O
-	O
assisted	O
and	O
robot-assisted	O
surgeries	O
.	O

Minimally	O
invasive	O
surgical	O
interventions	O
via	O
the	O
transnasal	O
and	O
the	O
transoral	O
route	O
are	O
strong	O
candidates	O
for	O
overcoming	O
access	O
issues	O
to	O
the	O
airway	O
.	O

They	O
are	O
likely	O
to	O
become	O
more	O
robotically	O
driven	O
as	O
the	O
demand	O
for	O
higher	O
dexterity	O
and	O
accuracy	O
increases	O
for	O
fine	O
manipulation	O
.	O

Physical	O
and	O
virtual	B-P
organ	O
models	O
are	O
required	O
to	O
enable	O
surgical	O
training	O
for	O
these	O
procedures	O
.	O

Binding	O
of	O
Pollutants	O
to	O
Biomolecules	O
:	O
A	O
Simulation	O
Study	O
.	O

A	O
number	O
of	O
cases	O
around	O
the	O
world	O
have	O
been	O
reported	O
where	O
animals	O
were	O
found	O
dead	O
or	O
dying	O
with	O
symptoms	O
resembling	O
a	O
thiamine	O
(	O
vitamin	O
B	O
)	O
deficiency	O
,	O
and	O
for	O
some	O
of	O
these	O
,	O
a	O
link	O
to	O
pollutants	O
has	O
been	O
suggested	O
.	O

Here	O
,	O
we	O
investigate	O
whether	O
biomolecules	O
involved	O
in	O
thiamin	O
binding	O
and	O
transport	O
could	O
be	O
blocked	O
by	O
a	O
range	O
of	O
different	O
pollutants	O
.	O

We	O
used	O
in	O
silico	O
docking	O
of	O
five	O
compound	O
classes	O
(	O
25	O
compounds	O
in	O
total	O
)	O
to	O
each	O
of	O
five	O
targets	O
(	O
prion	O
protein	O
,	O
ECF-type	O
ABC	O
transporter	O
,	O
thi-box	O
riboswitch	O
receptor	O
,	O
thiamin	O
pyrophosphokinase	O
,	O
and	O
YKoF	O
protein	O
)	O
and	O
subsequently	O
performed	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
to	O
assess	O
the	O
stability	O
of	O
the	O
complexes	O
.	O

The	O
compound	O
classes	O
were	O
thiamin	O
analogues	O
(	O
control	O
)	O
,	O
pesticides	O
,	O
veterinary	O
medicines	O
,	O
polychlorinated	O
biphenyls	O
,	O
and	O
dioxins	O
,	O
all	O
of	O
which	O
are	O
prevalent	O
in	O
the	O
environment	O
to	O
some	O
extent	O
.	O

A	O
few	O
anthropogenic	O
compounds	O
were	O
found	O
to	O
bind	O
the	O
ECF-type	O
ABC	O
transporter	O
,	O
but	O
none	O
binds	O
stably	O
to	O
prion	O
protein	O
.	O

For	O
the	O
riboswitch	O
,	O
most	O
compounds	O
remained	O
in	O
their	O
binding	O
pockets	O
during	O
50	O
ns	O
of	O
MD	O
simulation	O
,	O
indicating	O
that	O
RNA	O
provides	O
a	O
promiscuous	O
binding	O
site	O
.	O

In	O
both	O
YKoF	O
and	O
thiamin	O
pyrophosphokinase	O
(	O
TPK	O
)	O
,	O
most	O
compounds	O
remain	O
tightly	O
bound	O
.	O

However	O
,	O
TPK	O
biomolecules	O
undergo	O
pollutant	O
-	O
induced	O
conformational	O
changes	O
.	O

Although	O
most	O
compounds	O
are	O
found	O
to	O
bind	O
to	O
some	O
of	O
these	O
targets	O
,	O
a	O
larger	O
data	O
set	O
is	O
needed	O
along	O
with	O
more	O
quantitative	O
methods	O
like	O
free	O
energy	O
perturbation	O
calculations	O
before	O
firm	O
conclusions	O
can	O
be	O
drawn	O
.	O

This	O
study	O
is	O
in	O
part	O
a	O
test	O
bed	O
for	O
large-scale	O
quantitative	O
computational	B-P
screening	I-P
of	O
interactions	O
between	O
biological	O
entities	O
and	O
pollutant	O
molecules	O
.	O

Diagnosis	O
of	O
retinal	O
health	O
in	O
digital	B-P
fundus	I-P
images	I-P
using	O
continuous	O
wavelet	O
transform	O
(	O
CWT	O
)	O
and	O
entropies	O
.	O

Vision	O
is	O
paramount	O
to	O
humans	O
to	O
lead	O
an	O
active	O
personal	O
and	O
professional	O
life	O
.	O

The	O
prevalence	O
of	O
ocular	O
diseases	O
is	O
rising	O
,	O
and	O
diseases	O
such	O
as	O
glaucoma	O
,	O
Diabetic	O
Retinopathy	O
(	O
DR	O
)	O
and	O
Age-related	O
Macular	O
Degeneration	O
(	O
AMD	O
)	O
are	O
the	O
leading	O
causes	O
of	O
blindness	O
in	O
developed	O
countries	O
.	O

Identifying	O
these	O
diseases	O
in	O
mass	O
screening	O
programmes	O
is	O
time-consuming	O
,	O
labor	O
-intensive	O
and	O
the	O
diagnosis	O
can	O
be	O
subjective	O
.	O

The	O
use	O
of	O
an	O
automated	B-P
computer	I-P
aided	I-P
diagnosis	I-P
system	I-P
will	O
reduce	O
the	O
time	O
taken	O
for	O
analysis	O
and	O
will	O
also	O
reduce	O
the	O
inter-observer	O
subjective	O
variabilities	O
in	O
image	O
interpretation	O
.	O

In	O
this	O
work	O
,	O
we	O
propose	O
one	O
such	O
system	O
for	O
the	O
automatic	O
classification	O
of	O
normal	O
from	O
abnormal	O
(	O
DR	O
,	O
AMD	O
,	O
glaucoma	O
)	O
images	O
.	O

We	O
had	O
a	O
total	O
of	O
404	O
normal	O
and	O
1082	O
abnormal	O
fundus	B-P
images	I-P
in	O
our	O
database	O
.	O

As	O
the	O
first	O
step	O
,	O
2D-Continuous	O
Wavelet	O
Transform	O
(	O
CWT	O
)	O
decomposition	O
on	O
the	O
fundus	B-P
images	I-P
of	O
two	O
classes	O
was	O
performed	O
.	O

Subsequently	O
,	O
energy	O
features	O
and	O
various	O
entropies	O
namely	O
Yager	O
,	O
Renyi	O
,	O
Kapoor	O
,	O
Shannon	O
,	O
and	O
Fuzzy	O
were	O
extracted	O
from	O
the	O
decomposed	O
images	O
.	O

Then	O
,	O
adaptive	O
synthetic	O
sampling	O
approach	O
was	O
applied	O
to	O
balance	O
the	O
normal	O
and	O
abnormal	O
datasets	O
.	O

Next	O
,	O
the	O
extracted	O
features	O
were	O
ranked	O
according	O
to	O
the	O
significances	O
using	O
Particle	O
Swarm	O
Optimization	O
(	O
PSO	O
)	O
.	O

Thereupon	O
,	O
the	O
ranked	O
and	O
selected	O
features	O
were	O
used	O
to	O
train	O
the	O
random	O
forest	O
classifier	O
using	O
stratified	O
10-fold	O
cross	O
validation	O
.	O

Overall	O
,	O
the	O
proposed	O
system	O
presented	O
a	O
performance	O
rate	O
of	O
92.48	O
%	O
,	O
and	O
a	O
sensitivity	O
and	O
specificity	O
of	O
89.37	O
%	O
and	O
95.58	O
%	O
respectively	O
using	O
15	O
features	O
.	O

This	O
novel	O
system	O
shows	O
promise	O
in	O
detecting	O
abnormal	O
fundus	B-P
images	I-P
,	O
and	O
hence	O
,	O
could	O
be	O
a	O
valuable	O
adjunct	O
eye	O
health	O
screening	O
tool	O
that	O
could	O
be	O
employed	O
in	O
polyclinics	O
,	O
and	O
thereby	O
reduce	O
the	O
workload	O
of	O
specialists	O
at	O
hospitals	O
.	O

A	O
case	O
of	O
retrograde	O
intussusception	O
at	O
Roux-en-Y	O
anastomosis	O
10	O
years	O
after	O
total	O
gastrectomy	O
:	O
review	O
of	O
the	O
literature	O
.	O

A	O
63-year-	O
old	O
man	O
,	O
who	O
had	O
undergone	O
total	O
gastrectomy	O
and	O
Roux-en-Y	O
reconstruction	O
for	O
gastric	O
cancer	O
10	O
years	O
previously	O
,	O
was	O
admitted	O
to	O
our	O
hospital	O
with	O
complaints	O
of	O
abdominal	O
pain	O
,	O
palpable	O
abdominal	O
tumor	O
,	O
and	O
hematemesis	O
.	O

On	O
admission	O
,	O
the	O
abdominal	O
tenderness	O
was	O
improving	O
and	O
no	O
abdominal	O
tumor	O
was	O
palpable	O
.	O

Mild	O
inflammatory	O
changes	O
and	O
anemia	O
were	O
noted	O
on	O
blood	B-P
examination	I-P
.	O

Abdominal	O
computed	B-P
tomography	I-P
revealed	O
a	O
tumor	O
with	O
a	O
layered	O
structure	O
in	O
the	O
left	O
abdomen	O
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
intestinal	O
obstruction	O
secondary	O
to	O
intussusception	O
,	O
and	O
surgery	O
was	O
performed	O
.	O

Retrograde	O
intussusception	O
was	O
found	O
at	O
the	O
site	O
of	O
the	O
Y	O
anastomosis	O
.	O

We	O
conducted	O
manual	O
reduction	O
using	O
the	O
Hutchinson	O
procedure	O
.	O

The	O
intestinal	O
color	O
after	O
the	O
reduction	O
was	O
good	O
,	O
and	O
no	O
intestinal	O
resection	O
was	O
required	O
.	O

Postoperative	O
recovery	O
was	O
uneventful	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
12	O
days	O
after	O
surgery	O
.	O

Reports	O
of	O
jejunal	O
intussusception	O
after	O
total	O
gastrectomy	O
with	O
Roux-en-Y	O
reconstruction	O
are	O
relatively	O
rare	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
jejunal	O
intussusception	O
after	O
total	O
gastrectomy	O
with	O
Roux-en-Y	O
reconstruction	O
.	O

Enhanced	O
gastric	O
stability	O
of	O
esomeprazole	O
by	O
molecular	O
interaction	O
and	O
modulation	O
of	O
microenvironmental	O
pH	O
with	O
alkalizers	O
in	O
solid	O
dispersion	O
.	O

Due	O
to	O
the	O
instability	O
of	O
esomeprazole	O
magnesium	O
dihydrate	O
(	O
EPM	O
)	O
,	O
a	O
proton	O
pump	O
inhibitor	O
,	O
in	O
gastric	O
fluid	O
,	O
enteric-coated	O
dosage	O
form	O
is	O
commonly	O
used	O
for	O
therapeutic	O
application	O
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
new	O
gastric	O
fluid	O
resistant	O
solid	O
dispersions	O
(	O
SDs	O
)	O
containing	O
alkalizers	O
.	O

Then	O
,	O
new	O
mechanistic	O
evidence	O
regarding	O
the	O
effects	O
of	O
pharmaceutical	O
alkalizers	O
on	O
the	O
aqueous	O
stability	O
of	O
EPM	O
in	O
simulated	O
gastric	O
fluid	O
was	O
investigated	O
.	O

The	O
alkalizer	O
-loaded	O
SD	O
were	O
prepared	O
by	O
dissolving	O
or	O
dispersing	O
EPM	O
,	O
hydroxypropyl	O
methylcellulose	O
(	O
HPMC	O
)	O
6	O
cps	O
,	O
and	O
an	O
alkalizer	O
,	O
in	O
ethanol	O
50	O
%	O
(	O
v/v	O
)	O
followed	O
by	O
spray	B-P
drying	I-P
.	O

Nine	O
different	O
alkalizer	O
s	O
were	O
assessed	O
for	O
in	O
vitro	O
stability	O
in	O
two	O
media	O
,	O
simulated	O
gastric	O
fluid	O
(	O
pH	O
1.2	O
buffer	O
)	O
and	O
simulated	O
intestinal	O
fluid	O
(	O
pH	O
6.8	O
buffer	O
)	O
.	O

The	O
microenvironmental	O
pH	O
(	O
pHM	O
)	O
was	O
measured	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
alkalizer	O
on	O
the	O
pHM	O
of	O
SDs	O
.	O

Drug	O
crystallinity	O
and	O
morphology	O
of	O
the	O
SDs	O
were	O
also	O
examined	O
by	O
differential	B-P
scanning	I-P
calorimetry	I-P
(	O
DSC	B-P
)	O
,	O
powder	B-P
X-ray	I-P
diffraction	I-P
(	O
PXRD	B-P
)	O
,	O
and	O
scanning	B-P
electron	I-P
microscopy	I-P
(	O
SEM	B-P
)	O
.	O

The	O
interactions	O
among	O
EPM	O
,	O
the	O
polymer	O
,	O
and	O
the	O
alkalizer	O
were	O
elucidated	O
by	O
Fourier	O
transform	O
infrared	O
(	O
FTIR	O
)	O
spectroscopy	O
.	O

The	O
in	O
vivo	O
absorption	O
studies	O
of	O
the	O
optimized	O
alkalizer	O
-containing	O
SD	O
and	O
the	O
enteric-coated	O
reference	O
tablet	O
Nexium	O
(	O
®	O
)	O
were	O
then	O
conducted	O
in	O
beagle	O
dogs	O
.	O

Among	O
alkalizer	O
s	O
,	O
MgO	O
loaded	O
in	O
SDs	O
proved	O
to	O
be	O
the	O
best	O
alkalizer	O
to	O
stabilize	O
EPM	O
in	O
simulated	O
gastric	O
fluid	O
.	O

pHM	O
values	O
of	O
the	O
alkalizer	O
-containing	O
SDs	O
were	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
SD	O
without	O
alkalizer	O
.	O

The	O
pHM	O
values	O
decreased	O
in	O
the	O
following	O
order	O
:	O
MgO	O
,	O
Na2CO3	O
,	O
Ca	O
(	O
OH	O
)	O
2	O
,	O
and	O
no	O
alkalizer	O
.	O

DSC	B-P
and	O
PXRD	B-P
data	O
exhibited	O
a	O
change	O
in	O
the	O
drug	O
crystallinity	O
of	O
the	O
SDs	O
from	O
crystalline	O
to	O
amorphous	O
form	O
.	O

SEM	B-P
data	O
showed	O
a	O
relatively	O
spherical	O
shape	O
of	O
the	O
MgO	O
-loaded	O
SD	O
compared	O
to	O
the	O
less-defined	O
shape	O
of	O
pure	O
drug	O
.	O

FTIR	O
indicated	O
a	O
strong	O
molecular	O
interaction	O
among	O
EPM	O
,	O
alkalizer	O
and	O
polymer	O
;	O
in	O
particular	O
,	O
MgO	O
showed	O
the	O
strongest	O
interaction	O
with	O
EPM	O
.	O

It	O
was	O
evident	O
that	O
alkalizer	O
interacts	O
with	O
benzimidazole	O
ring	O
and/or	O
sulfonyl	O
group	O
of	O
EPM	O
for	O
enhancing	O
EPM	O
stability	O
in	O
gastric	O
fluid	O
.	O

Regarding	O
the	O
in	O
vivo	O
absorption	O
studies	O
in	O
beagle	O
dogs	O
,	O
the	O
optimized	O
SD	O
(	O
C16	O
)	O
was	O
bioequivalent	O
to	O
the	O
reference	O
Nexium	O
(	O
®	O
)	O
and	O
had	O
a	O
considerable	O
greater	O
absorption	O
at	O
the	O
early	O
stages	O
.	O

The	O
current	O
alkalizer	O
-containing	O
SD	O
could	O
provide	O
a	O
promising	O
approach	O
for	O
aqueous	O
stabilization	O
of	O
acid	O
-	O
labile	O
drugs	O
without	O
using	O
enteric	O
coating	O
method	O
.	O

Kinematic	O
and	O
EMG	B-P
Responses	O
to	O
Pelvis	O
and	O
Leg	O
Assistance	O
Force	O
during	O
Treadmill	O
Walking	O
in	O
Children	O
with	O
Cerebral	O
Palsy	O
.	O

Treadmill	O
training	O
has	O
been	O
used	O
for	O
improving	O
locomotor	O
function	O
in	O
children	O
with	O
cerebral	O
palsy	O
(	O
CP	O
)	O
,	O
but	O
the	O
functional	O
gains	O
are	O
relatively	O
small	O
,	O
suggesting	O
a	O
need	O
to	O
improve	O
current	O
paradigms	O
.	O

The	O
understanding	O
of	O
the	O
kinematic	O
and	O
EMG	B-P
responses	O
to	O
force	O
s	O
applied	O
to	O
the	O
body	O
of	O
subjects	O
during	O
treadmill	O
walking	O
is	O
crucial	O
for	O
improving	O
current	O
paradigms	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
kinematic	O
s	O
and	O
EMG	B-P
responses	O
to	O
the	O
pelvis	O
and/or	O
leg	O
assistance	O
force	O
.	O

Ten	O
children	O
with	O
spastic	O
CP	O
were	O
recruited	O
to	O
participate	O
in	O
this	O
study	O
.	O

A	O
controlled	O
assistance	O
force	O
was	O
applied	O
to	O
the	O
pelvis	O
and/or	O
legs	O
during	O
stance	O
and	O
swing	O
phase	O
of	O
gait	O
through	O
a	O
custom	O
designed	O
robotic	O
system	O
during	O
walking	O
.	O

Muscle	O
activities	O
and	O
spatial	O
-	O
temporal	O
gait	O
parameters	O
were	O
measured	O
at	O
different	O
loading	O
conditions	O
during	O
walking	O
.	O

In	O
addition	O
,	O
the	O
spatial-temporal	O
gait	O
parameters	O
during	O
overground	O
walking	O
before	O
and	O
after	O
treadmill	O
training	O
were	O
also	O
collected	O
.	O

Applying	O
pelvis	O
assistance	O
improved	O
step	O
height	O
and	O
applying	O
leg	O
assistance	O
improved	O
step	O
length	O
during	O
walking	O
,	O
but	O
applying	O
leg	O
assistance	O
also	O
reduced	O
muscle	O
activation	O
of	O
ankle	O
flexor	O
during	O
the	O
swing	O
phase	O
of	O
gait	O
.	O

In	O
addition	O
,	O
step	O
length	O
and	O
self-selected	O
walking	O
speed	O
significantly	O
improved	O
after	O
one	O
session	O
of	O
treadmill	O
training	O
with	O
combined	O
pelvis	O
and	O
leg	O
assistance	O
.	O

Design	O
of	O
a	O
candidate	O
vibrational	O
signal	O
for	O
mating	O
disruption	O
against	O
the	O
glassy-winged	O
sharpshooter	O
,	O
Homalodisca	O
vitripennis	O
.	O

The	O
glassy-winged	O
sharpshooter	O
(	O
GWSS	O
)	O
,	O
Homalodisca	O
vitripennis	O
,	O
is	O
an	O
important	O
pest	O
of	O
grapevines	O
due	O
to	O
its	O
ability	O
to	O
transmit	O
Xylella	O
fastidiosa	O
,	O
the	O
causal	O
agent	O
of	O
Pierce	O
's	O
disease	O
.	O

GWSS	O
mating	O
communication	O
is	O
based	O
on	O
vibrational	O
signals	O
;	O
therefore	O
,	O
vibrational	O
mating	O
disruption	O
could	O
be	O
an	O
alternative	O
to	O
insecticides	O
for	O
suppression	O
of	O
GWSS	O
population	O
.	O

Our	O
objectives	O
were	O
to	O
identify	O
spectral	O
features	O
of	O
female	O
signal	O
that	O
elicit	O
male	O
signaling	O
,	O
design	O
disruptive	O
signals	O
able	O
to	O
alter	O
male	O
perception	O
and	O
acceptance	O
of	O
a	O
female	O
,	O
and	O
determine	O
the	O
signal	O
intensity	O
required	O
for	O
future	O
field	O
applications	O
.	O

Results	O
showed	O
that	O
male	O
responses	O
to	O
playback	O
of	O
modified	O
female	O
signals	O
were	O
significantly	O
reduced	O
by	O
60-75	O
%	O
when	O
part	O
of	O
the	O
female	O
signal	O
spectral	O
components	O
above	O
or	O
below	O
400	O
Hz	O
were	O
deleted	O
.	O

Playback	O
bioassays	B-P
showed	O
that	O
transmission	O
of	O
an	O
80	O
Hz	O
pure	O
frequency	O
tone	O
to	O
plants	O
completely	O
suppressed	O
male	O
signaling	O
to	O
female	O
signal	O
playback	O
,	O
even	O
if	O
the	O
disruptive	O
signal	O
amplitude	O
was	O
10	O
dB	O
lower	O
than	O
the	O
female	O
signal	O
playback	O
.	O

Although	O
the	O
mechanism	O
underlying	O
cessation	O
of	O
male	O
signaling	O
activity	O
in	O
the	O
presence	O
of	O
disruption	O
is	O
not	O
yet	O
understood	O
,	O
results	O
suggest	O
that	O
an	O
80	O
Hz	O
vibrational	O
signal	O
should	O
be	O
tested	O
in	O
laboratory	O
and	O
field	O
experiments	O
to	O
assess	O
its	O
efficacy	O
in	O
disrupting	O
mating	O
of	O
GWSS	O
.	O

Neutrophil	O
and	O
Monocyte	O
Function	O
in	O
Patients	O
with	O
Chronic	O
Hepatitis	O
C	O
Undergoing	O
Antiviral	O
Therapy	O
with	O
Regimens	O
Containing	O
Protease	O
Inhibitors	O
with	O
and	O
without	O
Interferon	O
.	O

Real-life	O
data	O
showed	O
an	O
increased	O
incidence	O
of	O
bacterial	O
infections	O
in	O
patients	O
with	O
advanced	O
liver	O
disease	O
receiving	O
a	O
protease	O
inhibitor	O
(	O
PI	O
)	O
-containing	O
antiviral	O
regimen	O
against	O
hepatitis	O
C	O
(	O
HCV	O
)	O
.	O

However	O
,	O
the	O
causes	O
of	O
this	O
event	O
are	O
unknown	O
.	O

We	O
hypothesized	O
that	O
PIs	O
might	O
impair	O
innate	O
immune	O
responses	O
through	O
the	O
inhibition	O
of	O
proteases	O
participating	O
in	O
the	O
anti-bacterial	O
functions	O
of	O
neutrophils	O
and	O
monocytes	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	O
phagocytic	O
and	O
oxidative	O
burst	O
capacity	O
in	O
neutrophils	O
and	O
monocytes	O
obtained	O
from	O
patients	O
receiving	O
a	O
PI	O
containing-	O
antiviral	O
regimen	O
,	O
and	O
to	O
determine	O
cytokine	O
secretion	O
after	O
neutrophil	O
stimulation	O
with	O
flagellin	O
.	O

Forty	O
patients	O
with	O
chronic	O
HCV	O
(	O
80	O
%	O
with	O
cirrhosis	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	O
therapy	O
(	O
Group	O
A	O
)	O
with	O
pegylated-interferon	O
and	O
ribavirin	O
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
PI	O
(	O
telaprevir	O
,	O
boceprevir	O
or	O
simeprevir	O
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	O
-free	O
regimen	O
(	O
Group	O
B	O
)	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O

Phagocytosis	O
and	O
oxidative	O
burst	O
capacity	O
were	O
analyzed	O
by	O
flow	B-P
cytometry	I-P
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
of	O
therapy	O
.	O

In	O
neutrophils	O
from	O
Group	O
A	O
patients	O
,	O
oxidative	O
burst	O
rate	O
and	O
oxidative	O
enzymatic	O
activity	O
per	O
cell	O
significantly	O
decreased	O
throughout	O
the	O
study	O
period	O
(	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.010	O
,	O
respectively	O
)	O
.	O

Pairwise	O
comparisons	O
showed	O
a	O
decrease	O
between	O
baseline	O
and	O
week	O
4	O
and	O
8	O
of	O
therapy	O
.	O

No	O
differences	O
were	O
observed	O
after	O
the	O
introduction	O
of	O
the	O
PI	O
.	O

The	O
oxidative	O
enzymatic	O
activity	O
per	O
cell	O
in	O
monocytes	O
significantly	O
decrease	O
during	O
the	O
study	O
period	O
(	O
p	O
=	O
0.042	O
)	O
due	O
to	O
a	O
decrease	O
from	O
baseline	O
to	O
week	O
8	O
of	O
therapy	O
(	O
p	O
=	O
0.037	O
)	O
in	O
patients	O
from	O
Group	O
A	O
.	O

None	O
of	O
these	O
findings	O
were	O
observed	O
in	O
Group	O
B	O
patients	O
.	O

Cytokine	O
secretion	O
did	O
not	O
significantly	O
change	O
during	O
the	O
study	O
in	O
both	O
groups	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	O
(	O
rather	O
than	O
the	O
PI	O
)	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	O
and	O
monocyte	O
phagocytic	O
and	O
oxidative	O
burst	O
capacity	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
HCV	O
-related	O
advanced	O
liver	O
fibrosis	O
.	O

Outcomes	O
of	O
Subaortic	O
Obstruction	O
Resection	O
in	O
Children	O
.	O

Studies	O
of	O
long-term	O
outcomes	O
of	O
discrete	O
subaortic	O
stenosis	O
are	O
rare	O
.	O

Therefore	O
,	O
we	O
reviewed	O
the	O
long-term	O
outcomes	O
of	O
fibromuscular	O
resection	O
in	O
children	O
with	O
subaortic	O
stenosis	O
over	O
26	O
years	O
from	O
a	O
single	O
institution	O
.	O

We	O
conducted	O
a	O
retrospective	O
review	O
of	O
all	O
children	O
(	O
n=72	O
)	O
who	O
underwent	O
resection	O
of	O
subaortic	O
obstruction	O
for	O
discrete	O
subaortic	O
stenosis	O
between	O
1989	O
and	O
2015	O
.	O

Median	O
age	O
at	O
surgery	O
was	O
5.0	O
years	O
(	O
2.7-7.6	O
years	O
)	O
.	O

There	O
were	O
no	O
operative	O
deaths	O
but	O
three	O
late	O
deaths	O
(	O
4.2	O
%	O
,	O
3/72	O
)	O
.	O

Overall	O
Kaplan-Meier	O
survival	O
at	O
10	O
years	O
was	O
93.0	O
±	O
3.9	O
%	O
(	O
95	O
%	O
CI	O
:	O
79.6	O
,	O
97.7	O
)	O
.	O

Peak	O
instantaneous	O
left	O
ventricular	O
outflow	O
tract	O
Doppler	B-P
gradient	O
decreased	O
from	O
74.2±36.7mmHg	O
(	O
16.0-242.0mmHg	O
)	O
preoperatively	O
to	O
12.8±7.4mmHg	O
(	O
2.6-36.0mmHg	O
)	O
postoperatively	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Mean	O
left	O
ventricular	O
outflow	O
tract	O
Doppler	B-P
gradient	O
decreased	O
from	O
42.4±17.2mmHg	O
(	O
12.0-98.0	O
)	O
preoperatively	O
to	O
7.5±2.7mmHg	O
(	O
1.4-19.3mmHg	O
)	O
postoperatively	O
(	O
p	O
<	O
0.001	O
)	O
.	O

However	O
,	O
over	O
the	O
mean	O
follow-up	O
period	O
of	O
7.8±6.1	O
years	O
(	O
0.1-25.2	O
years	O
)	O
,	O
29.0	O
%	O
(	O
20/69	O
)	O
of	O
patients	O
had	O
recurrence	O
and	O
18.8	O
%	O
(	O
13/69	O
)	O
required	O
reoperation	O
at	O
median	O
time	O
of	O
4.8	O
years	O
(	O
3.1-9.1	O
years	O
)	O
after	O
the	O
initial	O
repair	O
.	O

Freedom	O
from	O
reoperation	O
at	O
10	O
years	O
was	O
71.1±7.1	O
%	O
(	O
95	O
%	O
CI	O
:	O
54.6	O
,	O
82.3	O
)	O
.	O

Risk	O
factors	O
for	O
reoperation	O
were	O
age	O
less	O
than	O
five	O
years	O
at	O
initial	O
repair	O
(	O
p=0.036	O
)	O
and	O
extension	O
of	O
the	O
membrane	O
to	O
the	O
aortic	O
valve	O
(	O
p=0.001	O
)	O
.	O

Aortic	O
insufficiency	O
was	O
present	O
in	O
54.2	O
%	O
(	O
39/72	O
)	O
of	O
patients	O
preoperatively	O
.	O

Progression	O
of	O
aortic	O
insufficiency	O
occurred	O
in	O
38.9	O
%	O
(	O
28/72	O
)	O
.	O

Involvement	O
of	O
the	O
aortic	O
valve	O
at	O
initial	O
repair	O
was	O
associated	O
with	O
need	O
for	O
subsequent	O
aortic	O
valve	O
repair	O
or	O
replacement	O
(	O
p=0.01	O
)	O
.	O

Resection	O
of	O
subaortic	O
obstruction	O
is	O
associated	O
with	O
low	O
mortality	O
and	O
morbidity	O
.	O

Recurrence	O
and	O
reoperation	O
rates	O
are	O
high	O
and	O
progression	O
of	O
aortic	O
insufficiency	O
following	O
subaortic	O
resection	O
is	O
common	O
.	O

Therefore	O
,	O
these	O
patients	O
warrant	O
close	O
follow-up	O
into	O
adult	O
life	O
.	O

Espindolol	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
cachexia	O
in	O
patients	O
with	O
stage	O
III/IV	O
non-small	O
cell	O
lung	O
cancer	O
or	O
colorectal	O
cancer	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
international	O
multicentre	O
phase	O
II	O
study	O
(	O
the	O
ACT-ONE	O
trial	O
)	O
.	O

Cancer	O
cachexia	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
with	O
no	O
widely	O
approved	O
treatment	O
.	O

The	O
ACT-ONE	O
trial	O
is	O
a	O
randomized	O
,	O
double-blind	O
,	O
parallel	O
group	O
,	O
placebo-controlled	O
,	O
phase	O
II	O
multicentre	O
trial	O
in	O
patients	O
(	O
25-80	O
years	O
)	O
with	O
stages	O
III	O
or	O
IV	O
colorectal	O
cancer	O
or	O
non-small	O
cell	O
lung	O
cancer	O
-related	O
cachexia	O
that	O
tested	O
two	O
doses	O
of	O
espindolol	O
(	O
a	O
novel	O
non-selective	O
β	O
blocker	O
with	O
central	O
5-HT1a	O
and	O
partial	O
β2	O
receptor	O
agonist	O
effects	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
difference	O
in	O
the	O
rate	O
of	O
weight	O
change	O
over	O
16	O
weeks	O
(	O
linear	O
mixed-effect	O
model	O
for	O
repeated	O
measures	O
)	O
between	O
high-dose	O
espindolol	O
and	O
placebo	O
.	O

Eighty-seven	O
patients	O
were	O
randomized	O
centrally	O
in	O
blocks	O
in	O
a	O
ratio	O
3:2:1	O
[	O
42	O
high	O
dose	O
,	O
10	O
mg	O
twice	O
daily	O
(	O
bd	O
)	O
:31	O
placebo	O
:14	O
low	O
dose	O
,	O
2.5	O
mg	O
bd	O
]	O
.	O

High-dose	O
espindolol	O
produced	O
a	O
statistically	O
and	O
clinically	O
significant	O
weight	O
gain	O
(	O
+0.54	O
kg/4	O
weeks	O
,	O
95	O
%	O
CI	O
0.38-0.70	O
)	O
compared	O
with	O
a	O
weight	O
loss	O
on	O
placebo	O
(	O
-0.21	O
kg/4	O
weeks	O
,	O
95	O
%	O
CI	O
-0.37-0.05	O
)	O
;	O
P	O
<	O
0.0001	O
.	O

High-dose	O
espindolol	O
produced	O
a	O
statistically	O
significant	O
increase	O
in	O
lean	O
body	O
mass	O
,	O
whilst	O
changes	O
in	O
fat	O
mass	O
were	O
neutral	O
.	O

Hand	O
grip	O
strength	O
significantly	O
(	O
high	O
dose	O
-1.15	O
±	O
0.7	O
kg	O
,	O
placebo	O
-3.51	O
±	O
0.8	O
kg	O
change	O
per	O
4	O
weeks	O
;	O
P	O
=	O
0.0134	O
)	O
,	O
stair	O
climbing	O
power	O
,	O
and	O
6-min	B-P
walk	I-P
test	I-P
non-significantly	O
were	O
all	O
directionally	O
in	O
favour	O
of	O
high-dose	O
espindolol	O
.	O

There	O
were	O
no	O
clinically	O
significant	O
differences	O
in	O
safety	O
signals	O
or	O
survival	O
between	O
treatment	O
groups	O
,	O
although	O
a	O
numerical	O
excess	O
of	O
dyspnoea	O
was	O
seen	O
with	O
high-dose	O
espindolol	O
(	O
19.1	O
%	O
)	O
compared	O
with	O
placebo	O
(	O
3.2	O
%	O
)	O
.	O

This	O
positive	O
trial	O
showed	O
that	O
espindolol	O
10	O
mg	O
bd	O
significantly	O
reversed	O
weight	O
loss	O
,	O
improved	O
fat	O
free	O
mass	O
,	O
and	O
maintained	O
fat	O
mass	O
in	O
advanced	O
colorectal	O
cancer	O
and	O
non-small	O
cell	O
lung	O
cancer	O
-related	O
cachexia	O
.	O

This	O
was	O
associated	O
with	O
a	O
significant	O
improvement	O
in	O
handgrip	O
strength	O
,	O
supporting	O
the	O
further	O
investigation	O
of	O
10	O
mg	O
bd	O
espindolol	O
for	O
the	O
treatment	O
of	O
cancer	O
cachexia	O
.	O

Although	O
not	O
powered	O
to	O
look	O
at	O
dose	O
response	O
,	O
most	O
treatment	O
effects	O
for	O
low	O
dose	O
lay	O
between	O
high	O
dose	O
and	O
placebo	O
,	O
suggesting	O
that	O
there	O
may	O
be	O
a	O
dose	O
response	O
in	O
the	O
effects	O
of	O
espindolol	O
.	O

Slow-Growing	O
Large	O
Irritation	O
Fibroma	O
of	O
the	O
Anterior	O
Hard	O
Palate	O
:	O
A	O
Case	O
Report	O
Using	O
Immunohistochemical	B-P
Analysis	I-P
.	O

Irritation	O
fibromas	O
are	O
recognized	O
as	O
fibrous	O
lesions	O
,	O
usually	O
reactive	O
hyperplasias	O
;	O
however	O
,	O
the	O
mechanism	O
of	O
enlargement	O
is	O
unclear	O
.	O

This	O
paper	O
reports	O
on	O
an	O
abnormally	O
large	O
irritation	O
fibroma	O
of	O
extremely	O
gradual	O
growth	O
.	O

The	O
immunohistochemical	B-P
features	O
(	O
CD34	O
,	O
α-SMA	O
,	O
vimentin	O
,	O
Ki-67	O
,	O
and	O
TGF-α	O
)	O
of	O
this	O
irritation	O
fibroma	O
are	O
presented	O
to	O
distinguish	O
reactive	O
hyperplasia	O
from	O
other	O
true	O
fibrous	O
neoplasm	O
diseases	O
.	O

In	O
the	O
only	O
previous	O
study	O
,	O
it	O
was	O
reported	O
that	O
the	O
expression	O
of	O
TGF-α	O
might	O
be	O
associated	O
with	O
the	O
development	O
of	O
oral	O
fibromas	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
this	O
exceptionally-large	O
fibrous	O
lesion	O
of	O
extremely	O
slow	O
growth	O
and	O
the	O
immunohistochemical	O
reactivity	O
of	O
TGF-α	O
,	O
finding	O
that	O
,	O
in	O
contrast	O
to	O
the	O
previous	O
study	O
,	O
TGF-α	O
was	O
not	O
expressed	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
evaluate	O
the	O
enlargement	O
mechanism	O
of	O
such	O
a	O
large	O
irritation	O
fibroma	O
using	O
the	O
approach	O
of	O
immunohistochemical	B-P
analysis	I-P
,	O
and	O
it	O
indicates	O
that	O
such	O
analysis	B-P
can	O
help	O
elucidate	O
the	O
diverse	O
causes	O
and	O
enlargement	O
mechanisms	O
of	O
irritation	O
fibromas	O
.	O

Moberg	B-P
Picking-Up	I-P
Test	I-P
in	O
patients	O
with	O
hand	O
osteoarthritis	O
.	O

Clinical	O
measurement	O
.	O

The	O
Moberg	B-P
Pick-up	I-P
Test	I-P
(	O
MPUT	B-P
)	O
was	O
previously	O
used	O
to	O
evaluate	O
functional	O
performance	O
in	O
patients	O
with	O
hand	O
inflammatory	O
disease	O
.	O

This	O
is	O
the	O
first	O
study	O
using	O
the	O
MPUT	B-P
in	O
hand	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

Compare	O
the	O
functional	O
performance	O
(	O
MPUT	B-P
)	O
in	O
hand	O
OA	O
patients	O
and	O
healthy	O
controls	O
.	O

Fifty	O
hand	O
OA	O
patients	O
and	O
50	O
controls	O
were	O
assessed	O
using	O
the	O
MPUT	B-P
,	O
AUSCAN	O
and	O
Cochin	O
questionnaires	O
,	O
grip	O
and	O
pinch	B-P
strength	I-P
,	O
pain	O
using	O
a	O
visual	B-P
analog	I-P
scale	I-P
and	O
a	O
Likert	O
scale	O
regarding	O
difficulty	O
to	O
perform	O
MPUT	B-P
.	O

In	O
the	O
MPUT	B-P
evaluation	O
,	O
the	O
OA	O
group	O
presented	O
a	O
statistically	O
significant	O
difference	O
from	O
the	O
control	O
group	O
.	O

The	O
OA	O
group	O
spent	O
more	O
time	O
executing	O
test	O
.	O

The	O
grip	O
and	O
pinch	B-P
strength	I-P
measurements	I-P
showed	O
higher	O
values	O
for	O
the	O
control	O
group	O
.	O

The	O
OA	O
group	O
reported	O
a	O
greater	O
difficulty	O
than	O
the	O
control	O
group	O
in	O
performing	O
the	O
test	O
.	O

The	O
MPUT	B-P
is	O
a	O
short	O
and	O
easy	O
to	O
apply	O
test	O
,	O
which	O
can	O
be	O
safely	O
used	O
to	O
assess	O
the	O
functional	O
performance	O
of	O
the	O
hand	O
OA	O
.	O

II	O
.	O

PRESENCE	O
OF	O
CITRININ	O
IN	O
GRAINS	O
AND	O
ITS	O
POSSIBLE	O
HEALTH	O
EFFECTS	O
.	O

Citrinin	O
is	O
a	O
mycotoxin	O
produced	O
by	O
several	O
species	O
of	O
the	O
genera	O
Aspergillus	O
,	O
Penicillium	O
and	O
Monascus	O
and	O
it	O
occurs	O
mainly	O
in	O
stored	O
grain	O
.	O

Citrinin	O
is	O
generally	O
formed	O
after	O
harvest	O
and	O
occurs	O
mainly	O
in	O
stored	O
grains	O
,	O
it	O
also	O
occurs	O
in	O
other	O
plant	O
products	O
.	O

Often	O
,	O
the	O
co-occurrence	O
with	O
other	O
mycotoxins	O
is	O
observed	O
,	O
especially	O
ochratoxin	O
A	O
,	O
which	O
is	O
usually	O
associated	O
with	O
endemic	O
nephropathy	O
.	O

At	O
the	O
European	O
Union	O
level	O
,	O
systematic	O
monitoring	O
of	O
Citrinin	O
in	O
grains	O
began	O
with	O
the	O
aim	O
of	O
determining	O
its	O
highest	O
permissible	O
amount	O
in	O
food	O
.	O

Thus	O
,	O
far	O
the	O
systematic	O
monitoring	O
of	O
the	O
above	O
mentioned	O
mycotoxin	O
in	O
Croatia	O
is	O
yet	O
to	O
begin	O
.	O

The	O
main	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
presence	O
of	O
Citrinin	O
in	O
grains	O
sampled	O
in	O
the	O
area	O
of	O
Međimurje	O
,	O
Osijek-Baranja	O
,	O
Vukovar-Srijem	O
and	O
Brod-Posavina	O
County	O
.	O

For	O
the	O
purpose	O
of	O
identification	O
and	O
quantification	O
of	O
citrinin	O
,	O
high	B-P
performance	I-P
liquid	I-P
chromatograph	I-P
(	I-P
HPLC	I-P
)	I-P
with	I-P
fluorescence	I-P
was	O
used	O
(	O
Calibration	O
curve	O
k	O
>	O
0.999	O
;	O
Intra	O
assay	O
CV	O
=	O
2.1	O
%	O
;	O
Inter	O
assay	O
CV	O
=	O
4.3	O
%	O
;	O
LOQ	O
<	O
1	O
μg/kg	O
)	O
.	O

From	O
the	O
area	O
of	O
Međimurje	O
County	O
,	O
10	O
samples	O
of	O
corn	O
and	O
10	O
samples	O
of	O
wheat	O
were	O
analyzed	O
.	O

None	O
of	O
the	O
samples	O
contained	O
Citrinin	O
(	O
<	O
1	O
μg/kg	O
)	O
.	O

From	O
the	O
area	O
of	O
Osijek-Baranja	O
and	O
Vukovar-Srijem	O
County	O
,	O
15	O
samples	O
from	O
each	O
County	O
were	O
analyzed	O
.	O

The	O
mean	O
value	O
for	O
the	O
samples	O
of	O
Osijek-Baranja	O
County	O
was	O
19.63	O
μg/kg	O
(	O
median	O
=15.8	O
μg/kg	O
)	O
,	O
while	O
for	O
Vukovar-Srijem	O
County	O
the	O
mean	O
value	O
of	O
citrinin	O
was	O
14,6	O
μg/kg	O
(	O
median	O
=1.23	O
μg/kg	O
)	O
.	O

From	O
5	O
analyzed	O
samples	O
from	O
Brod-Posavina	O
County	O
,	O
one	O
of	O
the	O
samples	O
contained	O
citrinin	O
in	O
the	O
amount	O
of	O
23.8	O
μg/kg	O
,	O
while	O
the	O
registered	O
amount	O
s	O
in	O
the	O
other	O
samples	O
were	O
<	O
1	O
μg/kg	O
.	O

The	O
results	O
show	O
that	O
grains	O
from	O
several	O
Counties	O
contain	O
certain	O
amounts	O
of	O
Citrinin	O
possibly	O
indicating	O
a	O
significant	O
intake	O
of	O
citrinin	O
in	O
humans	O
.	O

It	O
must	O
be	O
stated	O
that	O
grains	O
and	O
grain-based	O
products	O
are	O
the	O
basis	O
of	O
everyday	O
diet	O
of	O
all	O
age	O
groups	O
,	O
especially	O
small	O
children	O
,	O
where	O
higher	O
intake	O
of	O
citrinin	O
can	O
occur	O
.	O

Consequently	O
,	O
we	O
emphasize	O
the	O
need	O
for	O
systematic	O
analysis	O
of	O
larger	O
amount	O
of	O
samples	O
,	O
from	O
both	O
large	O
grains	O
and	O
small	O
grains	O
,	O
especially	O
in	O
the	O
area	O
of	O
Brod-Posavina	O
County	O
,	O
in	O
order	O
to	O
obtain	O
more	O
realistic	O
notion	O
of	O
citrinin	O
contamination	O
of	O
grains	O
and	O
to	O
asses	O
the	O
health	O
risk	O
in	O
humans	O
.	O

TNF-α	O
promotes	O
survival	O
and	O
migration	O
of	O
MSCs	O
under	O
oxidative	O
stress	O
via	O
NF-κB	O
pathway	O
to	O
attenuate	O
intimal	O
hyperplasia	O
in	O
vein	O
grafts	O
.	O

The	O
oxidative	O
stress	O
caused	O
by	O
endothelial	O
injury	O
is	O
involved	O
in	O
intimal	O
hyperplasia	O
(	O
IH	O
)	O
in	O
vein	O
grafts	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
can	O
home	O
to	O
injured	O
intima	O
and	O
promote	O
endothelial	O
repair	O
.	O

However	O
,	O
MSC	O
apoptosis	O
is	O
increased	O
accompanied	O
by	O
decreased	O
functional	O
activity	O
under	O
oxidative	O
stress	O
.	O

Thus	O
,	O
we	O
investigate	O
whether	O
tumour	O
necrosis	O
factor-α	O
(	O
TNF-α	O
)	O
can	O
promote	O
the	O
survival	O
and	O
activity	O
of	O
MSCs	O
under	O
oxidative	O
stress	O
to	O
reduce	O
IH	O
more	O
effectively	O
,	O
and	O
establish	O
what	O
role	O
the	O
NF-κB	O
pathway	O
plays	O
in	O
this	O
.	O

In	O
this	O
study	O
,	O
we	O
preconditioned	O
MSCs	O
with	O
TNF-α	O
(	O
(	O
TNF	O
)	O
(	O
-α-PC	O
)	O
MSCs	O
)	O
for	O
24	O
hrs	O
and	O
measured	O
the	O
activation	O
of	O
the	O
IKK	O
/	O
NF-κB	O
pathway	O
.	O

EdU	O
and	O
transwell	B-P
assays	I-P
were	O
performed	O
to	O
assess	O
proliferation	O
and	O
migration	O
of	O
(	O
TNF	O
)	O
(	O
-α-PC	O
)	O
MSCs	O
.	O

Apoptosis	O
and	O
migration	O
of	O
(	O
TNF	O
)	O
(	O
-α-	O
)	O
(	O
PC	O
)	O
MSCs	O
were	O
evaluated	O
in	O
conditions	O
of	O
oxidative	O
stress	O
by	O
analysis	O
of	O
the	O
expression	O
of	O
Bcl-2	O
and	O
CXCR4	O
proteins	O
.	O

(	O
TNF	O
)	O
(	O
-α-	O
)	O
(	O
PC	O
)	O
MSCs	O
were	O
transplanted	O
into	O
a	O
vein	O
graft	O
model	O
,	O
so	O
that	O
cell	O
homing	O
could	O
be	O
tracked	O
,	O
and	O
endothelial	O
apoptosis	O
and	O
IH	O
of	O
vein	O
grafts	O
were	O
measured	O
.	O

The	O
results	O
demonstrated	O
that	O
TNF-α	O
promotes	O
proliferation	O
and	O
migration	O
of	O
MSCs	O
.	O

Furthermore	O
,	O
survival	O
and	O
migration	O
of	O
(	O
TNF	O
)	O
(	O
-α-	O
)	O
(	O
PC	O
)	O
MSCs	O
under	O
oxidative	O
stress	O
were	O
both	O
enhanced	O
.	O

A	O
greater	O
number	O
of	O
MSCs	O
migrated	O
to	O
the	O
intima	O
of	O
vein	O
grafts	O
after	O
preconditioning	O
with	O
TNF-α	O
,	O
and	O
the	O
formation	O
of	O
neointima	O
was	O
significantly	O
reduced	O
.	O

These	O
effects	O
could	O
be	O
partially	O
abolished	O
by	O
IKK	O
XII	O
(	O
NF-κB	O
inhibitor	O
)	O
.	O

All	O
these	O
results	O
indicate	O
that	O
preconditioning	O
with	O
TNF-α	O
can	O
promote	O
survival	O
and	O
migration	O
of	O
MSCs	O
under	O
oxidative	O
stress	O
via	O
the	O
NF-κB	O
pathway	O
and	O
thus	O
attenuate	O
IH	O
of	O
vein	O
grafts	O
.	O

High-fructose	O
diet	O
is	O
as	O
detrimental	O
as	O
high-fat	O
diet	O
in	O
the	O
induction	O
of	O
insulin	O
resistance	O
and	O
diabetes	O
mediated	O
by	O
hepatic	O
/	O
pancreatic	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
.	O

In	O
the	O
context	O
of	O
high	O
human	O
consumption	O
of	O
fructose	O
diets	O
,	O
there	O
is	O
an	O
imperative	O
need	O
to	O
understand	O
how	O
dietary	O
fructose	O
intake	O
influence	O
cellular	O
and	O
molecular	O
mechanisms	O
and	O
thereby	O
affect	O
β-cell	O
dysfunction	O
and	O
insulin	O
resistance	O
.	O

While	O
evidence	O
exists	O
for	O
a	O
relationship	O
between	O
high	O
-	O
fat	O
-	O
induced	O
insulin	O
resistance	O
and	O
metabolic	O
disorders	O
,	O
there	O
is	O
lack	O
of	O
studies	O
in	O
relation	O
to	O
high-fructose	O
diet	O
.	O

Therefore	O
,	O
we	O
attempted	O
to	O
study	O
the	O
effect	O
of	O
different	O
diets	O
viz.	O
,	O
high-fat	O
diet	O
(	O
HFD	O
)	O
,	O
high-fructose	O
diet	O
(	O
HFS	O
)	O
,	O
and	O
a	O
combination	O
(	O
HFS	O
+	O
HFD	O
)	O
diet	O
on	O
glucose	O
homeostasis	O
and	O
insulin	O
sensitivity	O
in	O
male	O
Wistar	O
rats	O
compared	O
to	O
control	O
animals	O
fed	O
with	O
normal	O
pellet	O
diet	O
.	O

Investigations	O
include	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
,	O
insulin	B-P
tolerance	I-P
test	I-P
,	O
histopathology	B-P
by	O
H	B-P
&	I-P
E	I-P
and	O
Masson	B-P
's	I-P
trichrome	I-P
staining	I-P
,	O
mRNA	O
expression	O
by	O
real-time	O
PCR	O
,	O
protein	B-P
expression	I-P
by	O
Western	B-P
blot	I-P
,	O
and	O
caspase-3	O
activity	O
by	O
colorimetry	B-P
.	O

Rats	O
subjected	O
to	O
high-fat	O
/	O
fructose	O
diets	O
became	O
glucose	O
intolerant	O
,	O
insulin-resistant	O
,	O
and	O
dyslipidemic	O
.	O

Compared	O
to	O
control	O
animals	O
,	O
rats	O
subjected	O
to	O
different	O
combination	O
of	O
fat	O
/	O
fructose	O
diets	O
showed	O
increased	O
mRNA	O
and	O
protein	O
expression	O
of	O
a	O
battery	O
of	O
ER	O
stress	O
markers	O
both	O
in	O
pancreas	O
and	O
liver	O
.	O

Transcription	O
factors	O
of	O
β-cell	O
function	O
(	O
INSIG1	O
,	O
SREBP1c	O
and	O
PDX1	O
)	O
as	O
well	O
as	O
hepatic	O
gluconeogenesis	O
(	O
FOXO1	O
and	O
PEPCK	O
)	O
were	O
adversely	O
affected	O
in	O
diet	O
-	O
induced	O
insulin-resistant	O
rats	O
.	O

The	O
convergence	O
of	O
chronic	O
ER	O
stress	O
towards	O
apoptosis	O
in	O
pancreas	O
/	O
liver	O
was	O
also	O
indicated	O
by	O
increased	O
levels	O
of	O
CHOP	O
mRNA	O
&	O
increased	O
activity	O
of	O
both	O
JNK	O
and	O
Caspase-3	O
in	O
rats	O
subjected	O
to	O
high-fat	O
/	O
fructose	O
diets	O
.	O

Our	O
study	O
exposes	O
the	O
experimental	O
support	O
in	O
that	O
high-fructose	O
diet	O
is	O
equally	O
detrimental	O
in	O
causing	O
metabolic	O
disorders	O
.	O

Fluoranthene	O
degradation	O
and	O
binding	O
mechanism	O
study	O
based	O
on	O
the	O
active-site	O
structure	O
of	O
ring-hydroxylating	O
dioxygenase	O
in	O
Microbacterium	O
paraoxydans	O
JPM1	O
.	O

In	O
this	O
study	O
,	O
a	O
gram-positive	O
fluoranthene-degrading	O
bacterial	O
strain	O
was	O
isolated	O
from	O
crude	O
oil	O
in	O
Dagang	O
Oilfield	O
and	O
identified	O
as	O
Microbacterium	O
paraoxydans	O
JPM1	O
by	O
the	O
analysis	O
of	O
16S	O
rDNA	O
sequence	O
.	O

After	O
25	O
days	O
of	O
incubation	B-P
,	O
the	O
strain	O
JPM1	O
could	O
degrade	O
91.78	O
%	O
of	O
the	O
initial	O
amount	O
of	O
fluoranthene	O
.	O

Moreover	O
,	O
four	O
metabolites	O
9-fluorenone-1-carboxylic	O
acid	O
,	O
9-fluorenone	O
,	O
phthalic	O
acid	O
,	O
and	O
benzoic	O
acid	O
were	O
detected	O
in	O
the	O
culture	O
solution	O
.	O

The	O
gene	O
sequence	O
encoding	O
the	O
aromatic-ring-hydroxylating	O
dioxygenase	O
was	O
amplified	O
in	O
the	O
strain	O
JPM1	O
by	O
PCR	O
.	O

Based	O
on	O
the	O
translated	O
protein	O
sequence	O
,	O
a	O
homology	O
modeling	O
method	O
was	O
applied	O
to	O
build	O
the	O
crystal	O
structure	O
of	O
dioxygenase	O
.	O

Subsequently	O
,	O
the	O
interaction	O
mechanism	O
between	O
fluoranthene	O
and	O
the	O
active	O
site	O
of	O
dioxygenase	O
was	O
simulated	O
and	O
analyzed	O
by	O
molecular	O
docking	O
.	O

Consequently	O
,	O
a	O
feasible	O
degrading	O
pathway	O
of	O
fluoranthene	O
in	O
the	O
strain	O
JPM1	O
was	O
proposed	O
based	O
on	O
the	O
metabolites	O
and	O
the	O
interaction	O
analyses	O
.	O

Additionally	O
,	O
the	O
thermodynamic	O
analysis	O
showed	O
that	O
the	O
strain	O
JPM1	O
had	O
high	O
tolerance	O
for	O
fluoranthene	O
,	O
and	O
the	O
influence	O
of	O
fluoranthene	O
for	O
the	O
bacterial	O
growth	O
activity	O
was	O
negligible	O
under	O
100	O
to	O
400	O
mg	O
L	O
(	O
-1	O
)	O
concentrations	O
.	O

Taken	O
together	O
,	O
this	O
study	O
indicates	O
that	O
the	O
strain	O
JPM1	O
has	O
high	O
potential	O
for	O
further	O
study	O
in	O
bioremediation	O
of	O
polycyclic	O
aromatic	O
hydrocarbon	O
(	O
PAH	O
)	O
-	O
contaminated	O
sites	O
.	O

Development	O
of	O
a	O
liquid	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
method	O
for	O
quantitative	O
analysis	O
of	O
trace	O
d-amino	O
acids	O
.	O

d-Amino	O
acids	O
have	O
recently	O
attracted	O
much	O
attention	O
in	O
various	O
research	O
fields	O
including	O
medical	O
,	O
clinical	O
and	O
food	O
industry	O
due	O
to	O
their	O
important	O
biological	O
functions	O
that	O
differ	O
from	O
l-amino	O
acid	O
.	O

Most	O
chiral	O
amino	O
acid	O
separation	B-P
techniques	O
require	O
complicated	O
derivatization	O
procedures	O
in	O
order	O
to	O
achieve	O
the	O
desirable	O
chromatographic	O
behavior	O
and	O
detectability	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
this	O
research	O
is	O
to	O
develop	O
a	O
highly	O
sensitive	O
analytical	O
method	O
for	O
the	O
enantioseparation	B-P
of	O
chiral	O
amino	O
acids	O
without	O
any	O
derivatization	O
process	O
using	O
liquid	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
(	O
LC-MS/MS	B-P
)	O
.	O

By	O
optimizing	O
MS/MS	B-P
parameters	O
,	O
we	O
established	O
a	O
quantification	O
method	O
that	O
allowed	O
the	O
simultaneous	O
analysis	O
of	O
18	O
d-amino	O
acids	O
with	O
high	O
sensitivity	O
and	O
reproducibility	O
.	O

Additionally	O
,	O
we	O
applied	O
the	O
method	O
to	O
food	O
sample	O
(	O
vinegar	O
)	O
for	O
the	O
validation	O
,	O
and	O
successfully	O
quantified	O
trace	O
levels	O
of	O
d-amino	O
acids	O
in	O
samples	O
.	O

These	O
results	O
demonstrated	O
the	O
applicability	O
and	O
feasibility	O
of	O
the	O
LC-MS/MS	B-P
method	O
as	O
a	O
novel	O
,	O
effective	O
tool	O
for	O
d-amino	O
acid	O
measurement	O
in	O
various	O
biological	O
samples	O
.	O

Narcolepsy	O
Following	O
Yellow	O
Fever	O
Vaccination	O
:	O
A	O
Case	O
Report	O
.	O

Narcolepsy	O
with	O
cataplexy	O
is	O
a	O
rare	O
,	O
but	O
important	O
differential	B-P
diagnosis	I-P
for	O
daytime	O
sleepiness	O
and	O
atonic	O
paroxysms	O
in	O
an	O
adolescent	O
.	O

A	O
recent	O
increase	O
in	O
incidence	O
in	O
the	O
pediatric	O
age	O
group	O
probably	O
linked	O
to	O
the	O
use	O
of	O
the	O
Pandemrix	O
influenza	O
vaccine	O
in	O
2009	O
,	O
has	O
increased	O
awareness	O
that	O
different	O
environmental	O
factors	O
can	O
``	O
trigger	O
''	O
narcolepsy	O
with	O
cataplexy	O
in	O
a	O
genetically	O
susceptible	O
population	O
.	O

Here	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
13-year-old	O
boy	O
with	O
narcolepsy	O
following	O
yellow	O
fever	O
vaccination	O
.	O

He	O
carries	O
the	O
HLA	O
DQB1*0602	O
haplotype	O
strongly	O
associated	O
with	O
narcolepsy	O
and	O
cataplexy	O
.	O

Polysomnography	B-P
showed	O
rapid	O
sleep	O
onset	O
with	O
rapid	O
eye	O
movement	O
(	O
REM	O
)	O
latency	O
of	O
47	O
min	O
,	O
significant	O
sleep	O
fragmentation	O
and	O
a	O
mean	O
sleep	O
latency	O
of	O
1.6	O
min	O
with	O
sleep	O
onset	O
REM	O
in	O
four	O
out	O
of	O
four	O
nap	O
periods	O
.	O

Together	O
with	O
the	O
clinical	O
history	O
,	O
these	O
findings	O
are	O
diagnostic	O
of	O
narcolepsy	O
type	O
1	O
.	O

The	O
envelope	O
protein	O
E	O
of	O
the	O
yellow	O
fever	O
vaccine	O
strain	O
17D	O
has	O
significant	O
amino	O
acid	O
sequence	O
overlap	O
with	O
both	O
hypocretin	O
and	O
the	O
hypocretin	O
receptor	O
2	O
receptors	O
in	O
protein	O
regions	O
that	O
are	O
predicted	O
to	O
act	O
as	O
epitopes	O
for	O
antibody	O
production	O
.	O

These	O
findings	O
raise	O
the	O
question	O
whether	O
the	O
yellow	O
fever	O
vaccine	O
strain	O
may	O
,	O
through	O
a	O
potential	O
molecular	O
mimicry	O
mechanism	O
,	O
be	O
another	O
infectious	O
trigger	O
for	O
this	O
neuro-immunological	O
disorder	O
.	O

N-	O
(	O
1H-Pyrazol-3-yl	O
)	O
quinazolin-4-amines	O
as	O
a	O
novel	O
class	O
of	O
casein	O
kinase	O
1δ	O
/	O
ε	O
inhibitors	O
:	O
Synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	O
modeling	O
studies	O
.	O

Described	O
herein	O
is	O
the	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
N-	O
(	O
1H-pyrazol-3-yl	O
)	O
quinazolin-4-amines	O
against	O
a	O
panel	O
of	O
eight	O
disease	O
relevant	O
protein	O
kinases	O
.	O

The	O
kinase	O
inhibition	O
results	O
indicated	O
that	O
two	O
compounds	O
inhibited	O
casein	O
kinase	O
1δ	O
/	O
ε	O
(	O
CK1δ	O
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5/p25	O
,	O
GSK-3α	O
/	O
β	O
,	O
and	O
DYRK1A	O
.	O

Docking	O
studies	B-P
with	O
3c	O
and	O
3d	O
revealed	O
the	O
key	O
interactions	O
with	O
desired	O
amino	O
acids	O
in	O
the	O
ATP	O
binding	O
site	O
of	O
CK1δ	O
.	O

Furthermore	O
,	O
compound	O
3c	O
also	O
elicited	O
selective	O
cytotoxic	O
activity	O
against	O
the	O
pancreas	O
ductal	O
adenocarcinoma	O
(	O
PANC-1	O
)	O
cell	O
line	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
establish	O
N-	O
(	O
1H-pyrazol-3-yl	O
)	O
quinazolin-4-amines	O
especially	O
3c	O
and	O
3d	O
as	O
valuable	O
lead	O
molecules	O
with	O
great	O
potential	O
for	O
CK1δ	O
/	O
ε	O
inhibitor	O
development	O
targeting	O
neurodegenerative	O
disorders	O
and	O
cancer	O
.	O

Absorption	O
Characteristics	O
of	O
Vertebrate	O
Non	O
-	O
Visual	O
Opsin	O
,	O
Opn3	O
.	O

Most	O
animals	O
possess	O
multiple	O
opsins	O
which	O
sense	O
light	O
for	O
visual	O
and	O
non	O
-	O
visual	O
functions	O
.	O

Here	O
,	O
we	O
show	O
spectral	O
characteristics	O
of	O
non	O
-	O
visual	O
opsins	O
,	O
vertebrate	O
Opn3s	O
,	O
which	O
are	O
widely	O
distributed	O
among	O
vertebrates	O
.	O

We	O
successfully	O
expressed	O
zebrafish	O
Opn3	O
in	O
mammalian	O
cultured	O
cells	O
and	O
measured	O
its	O
absorption	B-P
spectrum	I-P
spectroscopically	I-P
.	O

When	O
incubated	B-P
with	O
11-cis	O
retinal	O
,	O
zebrafish	O
Opn3	O
formed	O
a	O
blue-sensitive	O
photopigment	O
with	O
an	O
absorption	O
maximum	O
around	O
465	O
nm	O
.	O

The	O
Opn3	O
converts	O
to	O
an	O
all-trans	O
retinal-bearing	O
photoproduct	O
with	O
an	O
absorption	B-P
spectrum	I-P
similar	O
to	O
the	O
dark	O
state	O
following	O
brief	O
blue-light	O
irradiation	O
.	O

The	O
photoproduct	O
experienced	O
a	O
remarkable	O
blue-shift	O
,	O
with	O
changes	O
in	O
position	O
of	O
the	O
isosbestic	O
point	O
,	O
during	O
further	O
irradiation	O
.	O

We	O
then	O
used	O
a	O
cAMP	O
-	O
dependent	O
luciferase	O
reporter	O
assay	B-P
to	O
investigate	O
light	O
-	O
dependent	O
cAMP	O
responses	O
in	O
cultured	O
cells	O
expressing	O
zebrafish	O
,	O
pufferfish	O
,	O
anole	O
and	O
chicken	O
Opn3	O
.	O

The	O
wild	O
type	O
opsins	O
did	O
not	O
produce	O
responses	O
,	O
but	O
cells	O
expressing	O
chimera	O
mutants	O
(	O
WT	O
Opn3s	O
in	O
which	O
the	O
third	O
intracellular	O
loops	O
were	O
replaced	O
with	O
the	O
third	O
intracellular	O
loop	O
of	O
a	O
Gs-coupled	O
jellyfish	O
opsin	O
)	O
displayed	O
light	O
-	O
dependent	O
changes	O
in	O
cAMP	O
.	O

The	O
results	O
suggest	O
that	O
Opn3	O
is	O
capable	O
of	O
activating	O
G	O
protein	O
(	O
s	O
)	O
in	O
a	O
light	O
-	O
dependent	O
manner	O
.	O

Finally	O
,	O
we	O
used	O
this	O
assay	B-P
to	O
measure	O
the	O
relative	O
wavelength	O
-	O
dependent	O
response	O
of	O
cells	O
expressing	O
Opn3	O
chimeras	O
to	O
multiple	O
quantally	O
-	O
matched	O
stimuli	O
.	O

The	O
inferred	O
spectral	O
sensitivity	O
curve	O
of	O
zebrafish	O
Opn3	O
accurately	O
matched	O
the	O
measured	O
absorption	B-P
spectrum	I-P
.	O

We	O
were	O
unable	O
to	O
estimate	O
the	O
spectral	O
sensitivity	O
curve	O
of	O
mouse	O
or	O
anole	O
Opn3	O
,	O
but	O
,	O
like	O
zebrafish	O
Opn3	O
,	O
the	O
chicken	O
and	O
pufferfish	O
Opn3-JiL3	O
chimeras	O
also	O
formed	O
blue-sensitive	O
pigments	O
.	O

These	O
findings	O
suggest	O
that	O
vertebrate	O
Opn3s	O
may	O
form	O
blue-sensitive	O
G	O
protein-coupled	O
pigments	O
.	O

Further	O
,	O
we	O
suggest	O
that	O
the	O
method	O
described	O
here	O
,	O
combining	O
a	O
cAMP	O
-	O
dependent	O
luciferase	O
reporter	O
assay	B-P
with	O
chimeric	O
opsins	O
possessing	O
the	O
third	O
intracellular	O
loop	O
of	O
jellyfish	O
opsin	O
,	O
is	O
a	O
versatile	O
approach	O
for	O
estimating	O
absorption	B-P
spectra	I-P
of	O
opsins	O
with	O
unknown	O
signaling	O
cascades	O
or	O
for	O
which	O
absorption	B-P
spectra	I-P
are	O
difficult	O
to	O
obtain	O
.	O

Vessel-sparing	O
Radiotherapy	O
for	O
Localized	O
Prostate	O
Cancer	O
to	O
Preserve	O
Erectile	O
Function	O
:	O
A	O
Single-arm	O
Phase	O
2	O
Trial	O
.	O

Erectile	O
dysfunction	O
remains	O
the	O
most	O
common	O
side	O
effect	O
from	O
radical	O
treatment	O
of	O
localized	O
prostate	O
cancer	O
.	O

We	O
hypothesized	O
that	O
the	O
use	O
of	O
vessel-sparing	O
radiotherapy	O
,	O
analogous	O
to	O
the	O
functional	O
anatomy	O
approach	O
of	O
nerve-sparing	O
radical	O
prostatectomy	O
(	O
RP	O
)	O
,	O
would	O
improve	O
erectile	O
function	O
preservation	O
while	O
maintaining	O
tumor	O
control	O
for	O
men	O
with	O
localized	O
prostate	O
cancer	O
.	O

To	O
determine	O
erectile	O
function	O
rates	O
after	O
vessel-sparing	O
radiotherapy	O
.	O

Men	O
with	O
localized	O
prostate	O
cancer	O
were	O
enrolled	O
in	O
a	O
phase	O
2	O
single-arm	O
trial	O
(	O
NCT02958787	O
)	O
at	O
a	O
single	O
academic	O
center	O
.	O

Patients	O
received	O
vessel-sparing	O
radiotherapy	O
utilizing	O
a	O
planning	O
MRI	B-P
and	O
MRI	B-P
-	O
angiogram	B-P
to	O
delineate	O
and	O
avoid	O
the	O
erectile	O
vasculature	O
.	O

Both	O
physician	O
-	O
and	O
patient	O
-reported	O
inventories	O
were	O
used	O
to	O
capture	O
erectile	O
function	O
at	O
baseline	O
and	O
at	O
2	O
and	O
5	O
yr	O
after	O
treatment	O
.	O

Validated	O
model	O
-based	O
comparisons	O
were	O
performed	O
to	O
compare	O
vessel-sparing	O
results	O
to	O
nerve-sparing	O
RP	O
and	O
conventional	O
radiotherapy	O
.	O

From	O
2001	O
to	O
2009	O
,	O
135	O
men	O
underwent	O
vessel-sparing	O
radiotherapy	O
.	O

After	O
a	O
planned	O
interim	O
analysis	O
,	O
the	O
trial	O
was	O
stopped	O
after	O
meeting	O
the	O
primary	O
endpoint	O
.	O

The	O
median	O
follow-up	O
was	O
8.7	O
yr	O
,	O
with	O
a	O
≥94	O
%	O
response	O
rate	O
to	O
all	O
inventories	O
at	O
each	O
time	O
point	O
.	O

At	O
5	O
yr	O
,	O
88	O
%	O
of	O
patients	O
were	O
sexually	O
active	O
with	O
or	O
without	O
the	O
use	O
of	O
sexual	O
aids	O
.	O

The	O
2-yr	O
erectile	O
function	O
rates	O
were	O
significantly	O
improved	O
with	O
vessel-sparing	O
radiotherapy	O
(	O
78	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
71-85	O
%	O
)	O
compared	O
to	O
modeled	O
rates	O
for	O
convention	O
radiotherapy	O
(	O
42	O
%	O
,	O
95	O
%	O
CI	O
38-45	O
%	O
;	O
p	O
<	O
0.001	O
)	O
or	O
nerve-sparing	O
prostatectomy	O
(	O
24	O
%	O
,	O
95	O
%	O
CI	O
22-27	O
%	O
;	O
p	O
<	O
0.001	O
)	O
.	O

At	O
2	O
yr	O
after	O
treatment	O
,	O
87	O
%	O
of	O
baseline-potent	O
men	O
retained	O
erections	O
suitable	O
for	O
intercourse	O
.	O

The	O
5-	O
and	O
10-yr	O
rates	O
of	O
biochemical	O
relapse-free	O
survival	O
were	O
99.3	O
%	O
and	O
89.9	O
%	O
,	O
and	O
at	O
5	O
yr	O
the	O
biochemical	O
failures	O
were	O
limited	O
to	O
the	O
National	O
Comprehensive	O
Cancer	O
Network	O
high-risk	O
group	O
.	O

The	O
single-arm	O
design	O
is	O
a	O
limitation	O
.	O

Vessel-sparing	O
radiotherapy	O
appears	O
to	O
more	O
effectively	O
preserve	O
erectile	O
function	O
when	O
compared	O
to	O
historical	O
series	O
and	O
model	O
-predicted	O
outcomes	O
following	O
nerve-sparing	O
RP	O
or	O
conventional	O
radiotherapy	O
,	O
with	O
maintenance	O
of	O
tumor	O
control	O
.	O

This	O
approach	O
warrants	O
independent	O
validation	O
.	O

In	O
this	O
interim	O
analysis	O
we	O
looked	O
at	O
using	O
a	O
novel	O
approach	O
to	O
spare	O
critical	O
erectile	O
structures	O
to	O
preserve	O
erectile	O
function	O
after	O
prostate	O
cancer	O
radiotherapy	O
.	O

We	O
found	O
that	O
almost	O
90	O
%	O
of	O
patients	O
at	O
5	O
yr	O
after	O
treatment	O
remained	O
sexually	O
active	O
,	O
significantly	O
higher	O
than	O
previous	O
studies	O
with	O
surgery	O
or	O
radiotherapy	O
.	O

Perioperative	O
Transfusion	O
of	O
Leukocyte	O
-	O
depleted	O
Blood	O
Products	O
in	O
Contemporary	O
Radical	O
Cystectomy	O
Cohort	O
Does	O
Not	O
Adversely	O
Impact	O
Short-term	O
Survival	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
leukoreduced	O
-only	O
perioperative	O
blood	O
transfusion	O
(	O
PBT	O
)	O
and	O
corresponding	O
survival	O
outcomes	O
in	O
a	O
radical	O
cystectomy	O
cohort	O
of	O
patients	O
.	O

We	O
analyzed	O
data	O
from	O
1026	O
patients	O
who	O
underwent	O
radical	O
cystectomy	O
at	O
our	O
institution	O
.	O

PBT	O
was	O
defined	O
as	O
transfusion	O
in	O
the	O
intraoperative	O
or	O
within	O
the	O
postoperative	O
hospitalization	O
period	O
.	O

Multivariable	O
analyses	O
using	O
Cox	O
proportional	O
hazards	O
were	O
performed	O
to	O
measure	O
the	O
association	O
between	O
PBT	O
,	O
patient	O
variables	O
,	O
and	O
3	O
primary	O
end	O
points	O
:	O
recurrence-free	O
survival	O
,	O
disease-specific	O
survival	O
,	O
and	O
overall	O
survival	O
.	O

Kaplan-Meier	O
curves	O
estimated	O
survival	O
times	O
and	O
were	O
compared	O
with	O
log-rank	B-P
test	I-P
.	O

Overall	O
,	O
of	O
a	O
total	O
of	O
1026	O
patients	O
,	O
341	O
(	O
33.2	O
%	O
)	O
received	O
leukoreduced	O
PBT	O
.	O

The	O
median	O
follow-up	O
was	O
27.5	O
months	O
.	O

Transfused	O
patients	O
were	O
more	O
likely	O
to	O
be	O
female	O
,	O
had	O
higher	O
estimated	O
blood	O
loss	O
,	O
lower	O
preoperative	O
hemoglobin	O
,	O
were	O
more	O
likely	O
to	O
have	O
received	O
neoadjuvant	O
chemotherapy	O
,	O
or	O
had	O
undergone	O
a	O
continent	O
urinary	O
diversion	O
.	O

Higher	O
pathologic	O
tumor	O
and	O
nodal	O
stage	O
were	O
observed	O
more	O
frequently	O
in	O
patients	O
who	O
received	O
PBT	O
.	O

On	O
multivariable	O
analysis	O
,	O
PBT	O
was	O
not	O
associated	O
with	O
worse	O
recurrence-free	O
survival	O
,	O
disease-specific	O
survival	O
,	O
and	O
overall	O
survival	O
(	O
all	O
P	O
>	O
.05	O
)	O
.	O

Kaplan-Meier	O
curves	O
did	O
not	O
show	O
any	O
significant	O
differences	O
(	O
all	O
P	O
>	O
.05	O
)	O
between	O
the	O
transfused	O
and	O
nontransfused	O
groups	O
.	O

In	O
addition	O
,	O
no	O
differences	O
were	O
found	O
in	O
regard	O
to	O
timing	O
of	O
transfusion	O
,	O
that	O
is	O
,	O
intraoperative	O
vs	O
postoperative	O
,	O
in	O
distinct	O
analysis	O
.	O

No	O
significant	O
association	O
was	O
found	O
between	O
leukoreduced	O
PBT	O
and	O
worse	O
survival	O
outcomes	O
at	O
short-term	O
follow-up	O
in	O
a	O
contemporary	O
cohort	O
of	O
cystectomy	O
patients	O
.	O

Prospective	O
long-term	O
follow-up	O
is	O
warranted	O
.	O

Genotyping	B-P
of	O
German	O
and	O
Austrian	O
Taylorella	O
equigenitalis	O
isolates	O
using	O
repetitive	O
extragenic	O
palindromic	O
(	O
REP	O
)	O
PCR	O
and	O
pulsed-field	B-P
gel	I-P
electrophoresis	I-P
(	O
PFGE	B-P
)	O
.	O

A	O
total	O
of	O
124	O
Taylorella	O
(	O
T.	O
)	O
equigenitalis	O
and	O
five	O
T.	O
asinigenitalis	O
field	O
isolates	O
collected	O
between	O
2002	O
and	O
2014	O
were	O
available	O
for	O
genotyping	B-P
using	O
REP-	O
(	O
repetitive	O
extragenic	O
palindromic	O
)	O
PCR	O
and	O
PFGE	B-P
(	O
pulsed-field	B-P
gel	I-P
electrophoresis	I-P
)	O
.	O

The	O
study	O
comprised	O
79	O
T.	O
equigenitalis	O
field	O
isolates	O
originating	O
from	O
ten	O
defined	O
breeds	O
of	O
German	O
horses	O
and	O
revealed	O
a	O
spectrum	O
of	O
five	O
REP	O
(	O
rep-E1-E4	O
,	O
rep-E3a	O
)	O
and	O
15	O
PFGE	B-P
(	O
TE-A1-A9	O
,	O
TE-B1-B3	O
,	O
TE-C	O
,	O
TE-E1	O
,	O
and	O
TE-E2	O
)	O
genotypes	O
.	O

T.	O
equigenitalis	O
field	O
isolates	O
(	O
n=40	O
)	O
obtained	O
from	O
Austrian	O
Lipizzaner	O
horses	O
were	O
differentiated	O
into	O
three	O
REP	O
(	O
rep-E1	O
,	O
rep-E3a	O
,	O
and	O
rep-E4	O
)	O
and	O
three	O
PFGE	B-P
genotypes	O
(	O
TE-A2	O
,	O
TE-A5	O
,	O
and	O
TE-D	O
)	O
;	O
those	O
isolated	O
from	O
four	O
Austrian	O
Trotters	O
belonged	O
to	O
the	O
REP	O
/	O
PFGE	B-P
genotype	O
rep-E2/TE-A1	O
.	O

Interestingly	O
,	O
a	O
T.	O
equigenitalis	O
isolate	O
recovered	O
from	O
a	O
Holsteiner	O
stallion	O
living	O
in	O
South	O
Africa	O
revealed	O
the	O
REP	O
/	O
PFGE	B-P
genotype	O
rep-E1/TE-A5	O
which	O
was	O
otherwise	O
exclusively	O
present	O
in	O
the	O
majority	O
of	O
Austrian	O
Lipizzaner	O
horses	O
in	O
our	O
study	O
.	O

The	O
type	O
strain	O
included	O
in	O
this	O
study	O
revealed	O
the	O
genotype	O
REP	O
/	O
PFGE	B-P
rep-E1/TE-F.	O
Six	O
strains	O
of	O
T.	O
asinigenitalis	O
including	O
the	O
type	O
strain	O
were	O
separated	O
into	O
three	O
REP	O
(	O
rep-A1-A3	O
)	O
and	O
six	O
PFGE	B-P
genotypes	O
(	O
TA-A1	O
,	O
TA-A2	O
,	O
TA-A3	O
,	O
TA-B	O
,	O
TA-C	O
,	O
TA-D	O
)	O
.	O

Overall	O
,	O
the	O
generated	O
REP	O
and	O
PFGE	B-P
genotypes	O
showed	O
a	O
good	O
correlation	O
,	O
whereas	O
REP-PCR	O
proved	O
to	O
be	O
a	O
suitable	B-P
method	I-P
for	O
molecular	B-P
epidemiological	I-P
screening	I-P
of	O
T.	O
equigenitalis	O
and	O
T.	O
asinigenitalis	O
isolates	O
that	O
should	O
be	O
differentiated	O
in	O
detail	O
by	O
genotyping	B-P
using	O
PFGE	B-P
.	O

Automated	O
basal	O
cell	O
carcinoma	O
detection	O
in	O
high-definition	B-P
optical	I-P
coherence	I-P
tomography	I-P
.	O

Basal	O
cell	O
carcinoma	O
(	O
BCC	O
)	O
is	O
the	O
most	O
common	O
non-melanoma	O
skin	O
cancer	O
.	O

Conventional	O
diagnosis	O
of	O
BCC	O
requires	O
invasive	O
biopsies	B-P
.	O

Recently	O
,	O
a	O
high-definition	B-P
optical	I-P
coherence	I-P
tomography	I-P
(	O
HD-OCT	B-P
)	O
technique	O
has	O
been	O
developed	O
,	O
which	O
provides	O
a	O
non-invasive	O
in	B-P
vivo	I-P
imaging	I-P
method	I-P
of	O
skin	O
.	O

Good	O
agreements	O
of	O
BCC	O
features	O
between	O
HD-OCT	B-P
images	O
and	O
histopathological	O
architecture	O
have	O
been	O
found	O
.	O

Therefore	O
it	O
is	O
possible	O
to	O
automatically	O
detect	O
BCC	O
using	O
HD-OCT	B-P
.	O

This	O
paper	O
presents	O
a	O
novel	O
BCC	O
detection	B-P
method	I-P
that	O
consists	O
of	O
four	O
steps	O
:	O
graph	O
based	O
skin	O
surface	O
segmentation	O
,	O
surface	O
flattening	O
,	O
deep	O
feature	O
extraction	O
and	O
the	O
BCC	O
classification	O
.	O

The	O
effectiveness	O
of	O
the	O
proposed	O
method	O
is	O
well	O
demonstrated	O
on	O
a	O
dataset	O
of	O
5,040	O
images	O
.	O

It	O
can	O
therefore	O
serve	O
as	O
an	O
automatic	O
tool	O
for	O
screening	O
BCC	O
.	O

Developmental	O
Profile	B-P
and	O
Diagnoses	O
in	O
Children	O
Presenting	O
with	O
Motor	O
Stereotypies	O
.	O

Motor	O
stereotypies	O
represent	O
a	O
typical	O
example	O
of	O
the	O
difficulty	O
in	O
distinguishing	O
non-clinical	O
behaviors	O
(	O
physiological	O
and	O
transient	O
)	O
from	O
symptoms	O
or	O
among	O
different	O
disorders	O
[	O
``	O
primary	O
stereotypies	O
,	O
''	O
associated	O
with	O
autistic	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
,	O
intellectual	O
disabilities	O
,	O
genetic	O
syndromes	O
,	O
and	O
sensory	O
impairment	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
obtain	O
an	O
accurate	O
assessment	O
on	O
the	O
relationship	O
between	O
stereotypies	O
and	O
neurodevelopmental	O
disorders	O
.	O

We	O
studied	O
23	O
children	O
(	O
3	O
girls	O
)	O
,	O
aged	O
36-95	O
months	O
,	O
who	O
requested	O
a	O
consultation	O
due	O
to	O
the	O
persistence	O
or	O
increased	O
severity	O
of	O
motor	O
stereotypies	O
.	O

None	O
of	O
the	O
patients	O
had	O
a	O
previous	O
diagnosis	O
of	O
ASD	O
.	O

The	O
assessment	O
included	O
the	O
Motor	O
Severity	O
Stereotypy	O
Scale	O
(	O
MSSS	O
)	O
,	O
the	O
Repetitive	O
Behavior	O
Scale-Revised	O
(	O
RBS-R	O
)	O
,	O
the	O
Raven	O
's	O
Colored	O
Progressive	O
Matrices	O
,	O
the	O
Child	O
Behavior	O
CheckList	O
for	O
ages	O
1½-5	O
or	O
4-18	O
(	O
CBCL	O
)	O
,	O
the	O
Social	O
Responsiveness	O
Scale	O
(	O
SRS	O
)	O
,	O
and	O
the	O
Autism	O
Diagnostic	O
Observation	O
Schedule-second	O
edition	O
(	O
ADOS	O
2	O
)	O
.	O

All	O
patients	O
were	O
showing	O
motor	O
stereotypies	O
for	O
periods	O
of	O
time	O
varying	O
from	O
6	O
to	O
77	O
months	O
.	O

The	O
MSSS	O
showed	O
that	O
each	O
child	O
had	O
a	O
limited	O
number	O
of	O
stereotypies	O
;	O
their	O
frequency	O
and	O
intensity	O
were	O
mild	O
.	O

The	O
interference	O
of	O
stereotypies	O
was	O
variable	O
;	O
the	O
impairment	O
in	O
daily	O
life	O
was	O
mild	O
.	O

The	O
RBS-R	O
scores	O
were	O
positive	O
for	O
the	O
subscale	O
of	O
``	O
stereotypic	O
behaviors	O
``	O
in	O
all	O
children	O
.	O

Moreover	O
,	O
several	O
children	O
presented	O
other	O
repetitive	O
behaviors	O
,	O
mainly	O
``	O
ritualistic	O
behavior	O
``	O
and	O
``	O
sameness	O
behavior	O
.	O
''	O

All	O
patients	O
showed	O
a	O
normal	O
cognitive	O
level	O
.	O

The	O
CBCL	O
evidenced	O
behavioral	O
problems	O
in	O
22	O
%	O
of	O
the	O
children	O
:	O
internalizing	O
problems	O
,	O
attention	O
,	O
and	O
withdrawn	O
were	O
the	O
main	O
complaints	O
.	O

On	O
the	O
SRS	O
,	O
all	O
but	O
one	O
of	O
the	O
tested	O
patients	O
obtained	O
clinical	O
scores	O
in	O
the	O
clinical	O
range	O
for	O
at	O
least	O
one	O
area	O
.	O

On	O
the	O
ADOS	O
2	O
,	O
4	O
patients	O
obtained	O
scores	O
indicating	O
a	O
moderate	O
level	O
of	O
ASD	O
symptoms	O
,	O
4	O
had	O
a	O
mild	O
level	O
,	O
and	O
15	O
showed	O
no	O
or	O
minimal	O
signs	O
of	O
ASD	O
.	O

Motor	O
stereotypies	O
in	O
children	O
with	O
normal	O
cognitive	O
level	O
represent	O
a	O
challenging	O
diagnostic	O
issue	O
for	O
which	O
a	O
finely	O
tailored	O
assessment	O
is	O
mandatory	O
in	O
order	O
to	O
define	O
a	O
precise	O
developmental	O
profile	O
.	O

Thus	O
,	O
careful	O
and	O
cautious	O
use	O
of	O
standardized	O
tests	O
is	O
warranted	O
to	O
avoid	O
misdiagnosis	O
.	O

Furthermore	O
,	O
it	O
is	O
hard	O
to	O
consider	O
motor	O
stereotypies	O
,	O
even	O
the	O
primary	O
ones	O
,	O
exclusively	O
as	O
a	O
movement	O
disorder	O
.	O

Dynamic	B-P
CT	I-P
myocardial	I-P
perfusion	I-P
imaging	I-P
identifies	O
early	O
perfusion	O
abnormalities	O
in	O
diabetes	O
and	O
hypertension	O
:	O
Insights	O
from	O
a	O
multicenter	O
registry	O
.	O

To	O
identify	O
patients	O
with	O
early	O
signs	O
of	O
myocardial	O
perfusion	O
reduction	O
,	O
a	O
reference	O
base	O
for	O
perfusion	O
measures	O
is	O
needed	O
.	O

To	O
analyze	O
perfusion	O
parameters	O
derived	O
from	O
dynamic	B-P
computed	I-P
tomography	I-P
perfusion	I-P
imaging	I-P
(	O
CTPI	B-P
)	O
in	O
patients	O
with	O
suspected	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
,	O
and	O
relationship	O
with	O
risk	O
factors	O
.	O

In	O
this	O
multicenter	O
study	O
,	O
coronary	B-P
CT	I-P
angiography	I-P
(	O
cCTA	B-P
)	O
and	O
dynamic	B-P
CTPI	I-P
were	O
performed	O
by	O
second-generation	B-P
dual-source	I-P
CT	I-P
in	O
patients	O
suspected	O
of	O
CAD	O
.	O

Risk	O
factors	O
were	O
collected	O
from	O
hospital	O
records	O
.	O

Patients	O
with	O
visual	O
perfusion	O
defects	O
on	O
CTPI	B-P
,	O
previous	O
coronary	O
intervention	O
,	O
or	O
missing	O
risk	O
factor	O
details	O
were	O
excluded	O
.	O

This	O
analysis	O
included	O
98	O
patients	O
(	O
mean	O
age	O
±	O
standard	O
deviation	O
[	O
SD	O
]	O
,	O
59.0	O
±	O
8.6yrs	O
;	O
73	O
male	O
)	O
.	O

Global	O
measures	O
of	O
left	O
ventricular	O
myocardial	O
blood	O
flow	O
(	O
MBF	O
)	O
,	O
myocardial	O
blood	O
volume	O
(	O
MBV	O
)	O
and	O
volume	O
transfer	O
constant	O
(	O
K	O
(	O
trans	O
)	O
)	O
were	O
calculated	O
.	O

Mean	O
MBF	O
was	O
139.3	O
±	O
31.4	O
mL/100	O
mL/min	O
,	O
MBV	O
19.1	O
±	O
2.7	O
mL/100	O
mL	O
,	O
and	O
Ktrans	O
85.0	O
±	O
17.5	O
mL/100	O
mL/min	O
.	O

No	O
significant	O
differences	O
in	O
perfusion	O
parameters	O
were	O
found	O
by	O
gender	O
or	O
age	O
category	O
.	O

Hypertension	O
and	O
diabetes	O
mellitus	O
resulted	O
in	O
lower	O
perfusion	O
parameters	O
(	O
hypertension	O
vs	O
normotension	O
:	O
MBV	O
18.5	O
±	O
3.0	O
vs	O
19.7	O
±	O
2.3	O
mL/100	O
mL	O
and	O
K	O
(	O
trans	O
)	O
82.0	O
±	O
18.0	O
vs	O
89.0	O
±	O
16.0	O
,	O
p	O
<	O
0.05	O
;	O
diabetes	O
vs	O
no	O
diabetes	O
:	O
MBF	O
128.5	O
±	O
31.5	O
vs	O
144.0	O
±	O
30.5	O
mL/100	O
mL/min	O
and	O
MBV	O
17.9	O
±	O
2.4	O
vs	O
19.4	O
±	O
2.8	O
mL/100	O
mL	O
,	O
p	O
<	O
0.05	O
)	O
.	O

In	O
patients	O
with	O
hyperlipidemia	O
,	O
MBF	O
was	O
higher	O
(	O
146.8	O
±	O
34.4	O
vs	O
130.7	O
±	O
24.3	O
mL/100	O
mL/min	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Smoking	O
and	O
family	O
history	O
did	O
not	O
show	O
perfusion	O
parameter	O
differences	O
.	O

Dynamic	B-P
CTPI	I-P
identifies	O
early	O
perfusion	O
disturbances	O
in	O
conditions	O
like	O
diabetes	O
and	O
hypertension	O
.	O

With	O
further	O
standardization	O
,	O
absolute	O
perfusion	O
measures	O
may	O
improve	O
CAD	O
risk	O
stratification	O
in	O
patients	O
without	O
visual	O
perfusion	O
defects	O
.	O

A	O
novel	O
rapid	O
analysis	O
using	O
mass	B-P
spectrometry	I-P
to	O
evaluate	O
downstream	O
refolding	O
of	O
recombinant	O
human	O
insulin-like	O
growth	O
factor-1	O
(	O
mecasermin	O
)	O
.	O

Mecasermin	O
is	O
used	O
to	O
treat	O
elevated	O
blood	O
sugar	O
as	O
well	O
as	O
growth	O
hormone	O
-	O
resistant	O
Laron-type	O
dwarfism	O
.	O

Mecasermin	O
isolated	O
from	O
inclusion	O
bodies	O
in	O
extracts	O
of	O
E.coli	O
must	O
be	O
refolded	O
to	O
acquire	O
sufficient	O
activity	O
.	O

However	O
,	O
there	O
is	O
no	O
rapid	O
analytical	O
method	O
for	O
monitoring	O
refolding	O
during	O
the	O
purification	B-P
process	O
.	O

We	O
prepared	O
mecasermin	O
drug	O
product	O
,	O
in-process	O
samples	O
during	O
the	O
oxidation	O
of	O
mecasermin	O
,	O
forced-reduced	O
mecasermin	O
,	O
and	O
aerially	O
oxidized	O
mecasermin	O
after	O
forced	O
reduction	O
.	O

Desalted	O
mecasermin	O
samples	O
were	O
analyzed	O
using	O
MALDI-ISD	B-P
.	O

The	O
peak	O
intensity	O
ratio	O
of	O
product	O
to	O
precursor	O
ion	O
was	O
determined	O
.	O

The	O
charge	O
state	O
distribution	O
(	O
CSD	O
)	O
of	O
mecasermin	O
ions	O
was	O
evaluated	O
using	O
ESI-MS	B-P
coupled	O
with	O
SEC-mode	O
HPLC	B-P
.	O

The	O
drift	O
time	O
and	O
collision	O
cross-sectional	O
areas	O
(	O
CCS	O
)	O
of	O
mecasermin	O
ions	O
were	O
evaluated	O
using	O
ESI-IMS-MS	B-P
coupled	O
with	O
SEC-mode	O
HPLC	B-P
.	O

MALDI-ISD	B-P
data	O
,	O
CSD	O
values	O
determined	O
using	O
ESI-MS	B-P
,	O
and	O
the	O
CCS	O
acquired	O
using	O
ESI-IMS-MS	B-P
revealed	O
the	O
relationship	O
between	O
the	O
folded	O
and	O
unfolded	O
proteoforms	O
of	O
forced-reduced	O
mecasermin	O
and	O
aerially	O
oxidized	O
mecasermin	O
with	O
the	O
free-SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
drug	O
product	O
.	O

The	O
collision	O
cross-sectional	O
area	O
,	O
which	O
is	O
determined	O
using	O
ESI-IMS-MS	B-P
,	O
provided	O
proteoform	O
information	O
through	O
rapid	O
monitoring	O
(	O
<	O
2	O
min	O
)	O
of	O
in-process	O
samples	O
during	O
the	O
manufacture	O
of	O
mecasermin	O
.	O

ESI-IMS-MS	B-P
coupled	O
with	O
SEC-mode	O
HPLC	B-P
is	O
a	O
rapid	O
and	O
robust	O
method	O
for	O
analyzing	O
the	O
free-SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	O
changes	O
during	O
the	O
oxidation	O
of	O
mecasermin	O
.	O

ESI-IMS-MS	B-P
is	O
applicable	O
as	O
a	O
process	O
analytical	O
technology	O
tool	O
for	O
identifying	O
the	O
``	O
critical	O
quality	O
attributes	O
``	O
and	O
implementing	O
``	O
quality	O
by	O
design	O
``	O
for	O
manufacturing	O
mecasermin	O
.	O

Prognostic	O
significance	O
of	O
blood	O
pressure	O
response	O
during	O
vasodilator	B-P
stress	I-P
Rb-82	I-P
positron	I-P
emission	I-P
tomography	I-P
myocardial	I-P
perfusion	I-P
imaging	I-P
.	O

A	O
drop	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
or	O
blunted	O
BP	O
response	O
is	O
an	O
established	O
high-risk	O
marker	O
during	O
exercise	O
myocardial	B-P
perfusion	I-P
imaging	I-P
(	O
MPI	B-P
)	O
;	O
however	O
,	O
data	O
are	O
sparse	O
regarding	O
the	O
prognostic	O
value	O
of	O
BP	O
response	O
in	O
patients	O
undergoing	O
vasodilator	B-P
stress	I-P
rubidium-82	I-P
(	I-P
Rb-82	I-P
)	I-P
Positron	I-P
Emission	I-P
Tomography	I-P
(	I-P
PET	B-P
)	I-P
MPI	I-P
.	O

From	O
the	O
PET	B-P
Prognosis	O
Multicenter	O
Registry	O
,	O
a	O
cohort	O
of	O
3413	O
patients	O
underwent	O
vasodilator	B-P
stress	I-P
Rb-82	I-P
PET	I-P
MPI	I-P
with	O
dipyridamole	O
or	O
adenosine	O
.	O

We	O
used	O
multivariable	O
Cox	O
proportional	O
hazard	O
regression	O
to	O
analyze	O
the	O
association	O
with	O
mortality	O
of	O
four	O
BP	O
variables	O
:	O
stress	O
minus	O
rest	O
systolic	O
BP	O
(	O
∆SBP	B-P
)	O
,	O
stress	O
minus	O
rest	O
diastolic	O
BP	O
(	O
∆DBP	B-P
)	O
,	O
resting	O
systolic	O
BP	O
(	O
rSBP	O
)	O
,	O
and	O
resting	O
diastolic	O
BP	O
(	O
rDBP	O
)	O
.	O

Covariates	O
that	O
had	O
univariate	O
P	O
values	O
<	O
.10	O
were	O
entered	O
into	O
the	O
multivariable	O
model	O
.	O

After	O
median	O
1.7	O
years	O
follow-up	O
,	O
270	O
patients	O
died	O
.	O

In	O
univariate	O
analyses	O
,	O
∆SBP	B-P
(	O
P	O
=	O
.082	O
)	O
,	O
rSBP	O
(	O
P	O
=	O
.008	O
)	O
,	O
and	O
rDBP	O
(	O
P	O
<	O
.001	O
)	O
were	O
of	O
potential	O
prognostic	O
value	O
(	O
P	O
<	O
.10	O
)	O
,	O
but	O
∆DBP	B-P
was	O
not	O
(	O
P	O
=	O
.96	O
)	O
.	O

After	O
adjustment	O
for	O
other	O
clinical	O
and	O
MPI	B-P
variables	O
,	O
∆SBP	B-P
no	O
longer	O
independently	O
predicted	O
mortality	O
(	O
P	O
=	O
.082	O
)	O
;	O
only	O
lower	O
rSBP	O
(	O
P	O
=	O
.026	O
)	O
and	O
lower	O
rDBP	O
(	O
P	O
=	O
.045	O
)	O
remained	O
independently	O
prognostic	O
.	O

In	O
patients	O
undergoing	O
vasodilator	B-P
stress	I-P
MPI	I-P
,	O
only	O
lower	O
resting	O
BP	O
is	O
an	O
independent	O
predictor	O
of	O
mortality	O
along	O
with	O
other	O
clinical	O
and	O
MPI	B-P
variables	O
;	O
BP	O
response	O
does	O
not	O
appear	O
to	O
add	O
to	O
risk	O
stratification	O
in	O
these	O
patients	O
.	O

Hepatitis	O
E	O
virus	O
in	O
donor	O
plasma	O
collected	O
in	O
Japan	O
.	O

Human	O
hepatitis	O
E	O
virus	O
(	O
HEV	O
)	O
is	O
prevalent	O
worldwide	O
.	O

Iatrogenic	O
HEV	O
has	O
recently	O
been	O
identified	O
based	O
on	O
the	O
reports	O
of	O
transfusion-transmitted	O
cases	O
.	O

The	O
detection	O
rate	O
of	O
HEV-RNA	O
and	O
seroprevalence	O
of	O
HEV-IgG	O
/	O
IgM	O
have	O
been	O
regionally	O
evaluated	O
in	O
Japan	O
,	O
and	O
donor	O
plasma	O
collected	O
in	O
Hokkaido	O
is	O
currently	O
screened	O
by	O
nucleic	B-P
acid	I-P
amplification	I-P
testing	I-P
.	O

However	O
,	O
the	O
detection	O
rate	O
of	O
HEV-RNA	O
in	O
blood	O
donors	O
in	O
Japan	O
outside	O
of	O
Hokkaido	O
has	O
not	O
been	O
reported	O
.	O

A	O
total	O
of	O
620	O
140	O
qualified	O
donor	O
plasma	O
samples	O
from	O
Japanese	O
regions	O
excluding	O
Hokkaido	O
were	O
tested	O
for	O
HEV-RNA	O
(	O
pools	O
of	O
50	O
or	O
500	O
)	O
between	O
2004	O
and	O
2014	O
.	O

HEV-RNA-positive	O
plasma	O
bags	O
were	O
identified	O
,	O
and	O
the	O
HEV	O
viral	B-P
load	I-P
,	O
genotype	O
and	O
anti-HEV	O
immunoglobulin	O
(	O
Ig	O
)	O
G/IgM	O
were	O
evaluated	O
.	O

The	O
detection	O
rate	O
of	O
HEV-RNA	O
(	O
pools	O
of	O
50	O
)	O
was	O
1/15	O
075	O
and	O
higher	O
in	O
eastern	O
than	O
in	O
western	O
Japan	O
.	O

All	O
36	O
HEV-RNA-positive	O
samples	O
were	O
genotype	O
3	O
with	O
viral	O
load	O
ranging	O
from	O
<	O
1·69	O
to	O
7·22	O
log10	O
copies/ml	O
.	O

Our	O
detection	O
rate	O
of	O
HEV-RNA	O
in	O
donor	O
populations	O
in	O
Japan	O
outside	O
Hokkaido	O
(	O
1/15	O
075	O
donations	O
)	O
is	O
generally	O
lower	O
than	O
reported	O
in	O
Europe	O
and	O
lower	O
than	O
previously	O
reported	O
for	O
Hokkaido	O
(	O
1/8173	O
donations	O
)	O
.	O

As	O
methods	O
varied	O
,	O
we	O
can	O
not	O
exclude	O
that	O
these	O
differences	O
are	O
reflective	O
of	O
differing	O
RNA	O
detection	O
limits	O
.	O

In	O
contrast	O
to	O
Hokkaido	O
where	O
genotype	O
4	O
has	O
been	O
reported	O
among	O
blood	O
donations	O
,	O
all	O
our	O
positive	O
donations	O
were	O
genotype	O
3	O
,	O
which	O
is	O
less	O
pathogenic	O
.	O

Propranolol	O
Effects	O
on	O
Decompression	O
Sickness	O
in	O
a	O
Simulated	O
DISSUB	O
Rescue	O
in	O
Swine	O
.	O

Disabled	O
submarine	O
(	O
DISSUB	O
)	O
survivors	O
may	O
face	O
elevated	O
CO2	O
levels	O
and	O
inert	O
gas	O
saturation	O
,	O
putting	O
them	O
at	O
risk	O
for	O
CO2	O
toxicity	O
and	O
decompression	O
sickness	O
(	O
DCS	O
)	O
.	O

Propranolol	O
was	O
shown	O
to	O
reduce	B-P
CO2	I-P
production	I-P
in	O
an	O
experimental	O
DISSUB	O
model	O
in	O
humans	O
but	O
its	O
effects	O
on	O
DCS	O
in	O
a	O
DISSUB	O
rescue	O
scenario	O
are	O
unknown	O
.	O

A	O
100	O
%	O
oxygen	O
prebreathe	O
(	O
OPB	O
)	O
reduces	O
DCS	O
incidence	O
and	O
severity	O
and	O
is	O
incorporated	O
into	O
some	O
DISSUB	O
rescue	O
protocols	O
.	O

We	O
used	O
a	O
swine	O
model	O
of	O
DISSUB	O
rescue	O
to	O
study	O
the	O
effect	O
of	O
propranolol	O
on	O
DCS	O
incidence	O
and	O
mortality	O
with	O
and	O
without	O
an	O
OPB	O
.	O

In	O
Experiment	O
1	O
,	O
male	O
Yorkshire	O
Swine	O
(	O
70	O
kg	O
)	O
were	O
pressurized	O
to	O
2.8	O
ATA	O
for	O
22	O
h.	O
Propranolol	O
1.0	O
mg	O
·	O
kg-1	O
(	O
IV	O
)	O
was	O
administered	O
at	O
21.25	O
h.	O
At	O
22	O
h	O
,	O
the	O
animal	O
was	O
rapidly	O
decompressed	O
and	O
observed	O
for	O
DCS	O
type	O
,	O
onset	O
time	O
,	O
and	O
mortality	O
.	O

Experimental	O
animals	O
(	O
N	O
=	O
21	O
;	O
69	O
±	O
4.1	O
kg	O
)	O
,	O
PROP1.0	O
,	O
were	O
compared	O
to	O
PROP1.0	O
-	O
OPB45	O
(	O
N	O
=	O
8	O
;	O
69	O
±	O
2.8	O
kg	O
)	O
with	O
the	O
same	O
dive	O
profile	O
,	O
except	O
for	O
a	O
45	O
min	O
OPB	O
prior	O
to	O
decompression	O
.	O

In	O
Experiment	O
2	O
,	O
the	O
same	O
methodology	O
was	O
used	O
with	O
the	O
following	O
changes	O
:	O
swine	O
pressurized	O
to	O
2.8	O
ATA	O
for	O
28	O
h	O
;	O
experimental	O
group	O
(	O
N	O
=	O
25	O
;	O
67	O
±	O
3.3	O
kg	O
)	O
,	O
PROP0.5	O
bis	O
,	O
propranolol	O
0.5	O
mg	O
·	O
kg-1	O
bis	O
(	O
twice	O
)	O
(	O
IV	O
)	O
was	O
administered	O
at	O
22	O
h	O
and	O
26	O
h.	O
Control	O
animals	O
(	O
N	O
=	O
25	O
;	O
67	O
±	O
3.9	O
kg	O
)	O
received	O
normal	O
saline	O
.	O

OPB	O
reduced	O
mortality	O
in	O
PROP1.0	O
-	O
OBP45	O
compared	O
to	O
PROP1.0	O
(	O
0	O
%	O
vs.	O
71	O
%	O
)	O
.	O

PROP0.5	O
bis	O
had	O
increased	O
mortality	O
compared	O
to	O
CONTROL	O
(	O
60-	O
%	O
vs.	O
4	O
%	O
)	O
.	O

Administration	O
of	O
beta	O
blockers	O
prior	O
to	O
saturation	O
decompression	O
appears	O
to	O
increase	O
DCS	O
and	O
worsen	O
mortality	O
in	O
a	O
swine	O
model	O
;	O
however	O
,	O
their	O
effects	O
in	O
bounce	O
diving	O
remain	O
unknown.Forbes	O
AS	O
,	O
Regis	O
DP	O
,	O
HallAA	O
,	O
Mahon	O
RT	O
,	O
Cronin	O
WA	O
.	O

Propranolol	O
effects	O
on	O
decompression	O
sickness	O
in	O
a	O
simulated	O
DISSUB	O
rescue	O
in	O
swine	O
.	O

Aerosp	O
Med	O
Hum	O
Perform	O
.	O

2017	O
;	O
88	O
(	O
4	O
)	O
:385-391	O
.	O

Burden	O
of	O
cervical	O
cancer	O
and	O
role	O
of	O
screening	O
in	O
India	O
.	O

Cervical	O
cancer	O
is	O
a	O
major	O
cause	O
of	O
cancer	O
mortality	O
in	O
women	O
and	O
more	O
than	O
a	O
quarter	O
of	O
its	O
global	O
burden	O
is	O
contributed	O
by	O
developing	O
countries	O
.	O

In	O
India	O
,	O
in	O
spite	O
of	O
alarmingly	O
high	O
figures	O
,	O
there	O
is	O
no	O
nationwide	O
government-sponsored	O
screening	O
program	O
.	O

This	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
burden	O
of	O
cervical	O
cancer	O
in	O
India	O
and	O
review	O
the	O
performance	O
characteristics	O
of	O
available	O
cervical	O
cancer	O
screening	O
tools	O
,	O
so	O
as	O
to	O
provide	O
evidence	O
-based	O
recommendations	O
for	O
application	O
of	O
most	O
practically	O
suited	O
screening	B-P
test	I-P
to	O
be	O
used	O
in	O
resource	O
-poor	O
field	O
settings	O
.	O

MEDLINE	O
and	O
Web	O
of	O
Science	O
electronic	O
database	O
were	O
searched	O
from	O
January	O
1990	O
to	O
December	O
2015	O
,	O
using	O
the	O
keywords	O
such	O
as	O
``	O
cervical	O
cancer	O
``	O
,	O
``	O
screening	B-P
``	O
,	O
``	O
early	B-P
detection	I-P
``	O
,	O
``	O
cervical	B-P
cytology	I-P
``	O
and	O
``	O
visual	O
inspection	O
``	O
,	O
and	O
their	O
corresponding	O
MeSH	O
terms	O
in	O
combination	O
with	O
Boolean	O
operators	O
``	O
OR	O
,	O
AND	O
.	O
''	O

Two	O
authors	O
independently	O
selected	O
studies	O
that	O
are	O
published	O
in	O
English	O
and	O
conducted	O
in	O
India	O
.	O

A	O
total	O
of	O
11	O
studies	O
were	O
found	O
to	O
be	O
relevant	O
and	O
eligible	O
to	O
be	O
included	O
in	O
the	O
present	O
study	O
.	O

In	O
India	O
,	O
cervical	O
cancer	O
contributes	O
to	O
approximately	O
6-29	O
%	O
of	O
all	O
cancers	O
in	O
women	O
.	O

The	O
age-adjusted	O
incidence	O
rate	O
of	O
cervical	O
cancer	O
varies	O
widely	O
among	O
registries	O
;	O
highest	O
is	O
23.07/100,000	O
in	O
Mizoram	O
state	O
and	O
the	O
lowest	O
is	O
4.91/100,000	O
in	O
Dibrugarh	O
district	O
.	O

The	O
pooled	O
estimates	O
of	O
sensitivity	O
and	O
specificity	O
of	O
visual	B-P
inspection	I-P
with	I-P
acetic	I-P
acid	I-P
(	O
VIA	B-P
)	O
,	O
magnified	B-P
VIA	I-P
,	O
visual	B-P
inspection	I-P
with	I-P
Lugol	I-P
's	I-P
iodine	I-P
(	O
VILI	B-P
)	O
,	O
cytology	B-P
(	O
Pap	B-P
smear	I-P
)	O
,	O
and	O
human	B-P
papillomavirus	I-P
DNA	I-P
were	O
found	O
to	O
be	O
67.65	O
%	O
and	O
84.32	O
%	O
,	O
65.36	O
%	O
and	O
85.76	O
%	O
,	O
78.27	O
%	O
and	O
87.10	O
%	O
,	O
62.11	O
%	O
and	O
93.51	O
%	O
,	O
and	O
77.81	O
%	O
and	O
91.54	O
%	O
,	O
respectively	O
.	O

In	O
developing	O
countries	O
because	O
of	O
lack	O
of	O
necessary	O
infrastructure	O
and	O
quality	O
control	O
,	O
high-quality	O
cytology	B-P
screening	I-P
may	O
not	O
be	O
feasible	O
for	O
wide-scale	O
implementation	O
.	O

Hence	O
,	O
cervical	O
cancer	O
screening	O
program	O
based	O
on	O
visual	B-P
screening	I-P
test	I-P
such	O
as	O
VIA	B-P
/	O
VILI	B-P
should	O
be	O
adopted	O
as	O
an	O
integral	O
part	O
of	O
primary	O
health-care	O
setup	O
in	O
resource	O
-	O
poor	O
countries	O
like	O
India	O
.	O

Ultrasonography	B-P
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
evaluation	O
of	O
pediatric	O
spinal	O
anomalies	O
.	O

Spinal	O
dysraphisms	O
are	O
congenital	O
abnormalities	O
of	O
the	O
spine	O
due	O
to	O
imperfect	O
fusion	O
of	O
midline	O
mesenchymal	O
,	O
bony	O
and	O
neural	O
structures	O
.	O

Imaging	B-P
plays	O
a	O
vital	O
role	O
in	O
their	O
evaluation	O
as	O
significant	O
portion	O
of	O
patients	O
may	O
present	O
with	O
concurrent	O
anomalies	O
that	O
need	O
to	O
be	O
corrected	O
simultaneously	O
to	O
avoid	O
repeat	O
surgeries	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
evaluate	O
Spinal	O
dysraphisms	O
using	O
USG	B-P
and	O
MRI	B-P
and	O
to	O
correlate	O
imaging	B-P
findings	O
with	O
operative	O
findings	O
in	O
patients	O
undergoing	O
surgery	O
.	O

Hospital	O
based	O
observational	O
study	O
conducted	O
over	O
a	O
period	O
of	O
year	O
.	O

38	O
cases	O
of	O
both	O
sexes	O
and	O
below	O
12	O
years	O
of	O
age	O
with	O
spinal	O
dysraphism	O
were	O
studied	O
.	O

USG	B-P
was	O
performed	O
in	O
29	O
cases	O
where	O
acoustic	O
window	O
was	O
available	O
for	O
proper	O
evaluation	O
.	O

MRI	B-P
was	O
performed	O
in	O
all	O
cases	O
.	O

USG	B-P
findings	O
were	O
compared	O
with	O
MRI	B-P
findings	O
and	O
operative	O
follow	O
up	O
was	O
taken	O
in	O
23	O
cases	O
who	O
underwent	O
operative	O
management	O
.	O

Results	O
were	O
analysed	O
using	O
percentage	O
and	O
arithmetic	O
mean	O
.	O

39.47	O
%	O
cases	O
were	O
male	O
and	O
60.53	O
%	O
cases	O
were	O
female	O
.	O

Neonatal	O
period	O
was	O
the	O
most	O
common	O
presenting	O
age	O
group	O
.	O

Closed	O
spinal	O
dysraphism	O
(	O
63.16	O
%	O
)	O
was	O
more	O
common	O
than	O
open	O
(	O
36.84	O
%	O
)	O
.	O

79.31	O
%	O
cases	O
showed	O
full	O
agreement	O
between	O
spinal	O
USG	B-P
and	O
MRI	B-P
examinations	O
and	O
6	O
out	O
of	O
20.69	O
%	O
showed	O
partial	O
agreement	O
.	O

On	O
operative	O
correlation	O
,	O
USG	B-P
findings	O
were	O
confirmatory	O
in	O
91.30	O
%	O
cases	O
and	O
MRI	B-P
findings	O
were	O
confirmatory	O
in	O
100	O
%	O
cases	O
.	O

USG	B-P
can	O
be	O
used	O
as	O
the	O
initial	O
modality	O
for	O
evaluation	O
of	O
spinal	O
dysraphism	O
as	O
well	O
as	O
for	O
screening	O
of	O
suspected	O
cases	O
.	O

MRI	B-P
is	O
indicated	O
to	O
confirm	O
abnormal	O
USG	B-P
findings	O
,	O
which	O
shows	O
all	O
concurrent	O
abnormalities	O
and	O
also	O
provides	O
additional	O
anatomical	O
details	O
relevant	O
to	O
surgical	O
planning	O
.	O

Undisclosed	O
HIV	O
infection	O
and	O
art	O
use	O
in	O
the	O
kenya	O
AIDS	O
indicator	O
survey	O
2012	O
:	O
relevance	O
to	O
targets	O
for	O
HIV	B-P
diagnosis	I-P
and	O
treatment	O
in	O
kenya	O
.	O

To	O
assess	O
the	O
impact	O
of	O
undisclosed	O
HIV	O
infection	O
and	O
antiretroviral	O
(	O
ARV	O
)	O
therapy	O
(	O
ART	O
)	O
on	O
national	O
estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	O
coverage	O
in	O
Kenya	O
.	O

HIV-positive	O
dried	O
blood	O
spot	O
samples	O
from	O
Kenya	O
's	O
second	O
AIDS	O
Indicator	O
Survey	O
were	O
tested	O
for	O
an	O
ARV	O
biomarker	O
by	O
liquid	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
.	O

Estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	O
use	O
based	O
on	O
self-report	O
were	O
compared	O
with	O
those	O
corrected	O
for	O
undisclosed	O
HIV	O
infection	O
and	O
ART	O
use	O
based	O
on	O
ARV	O
testing	O
.	O

Multivariate	O
analysis	O
determined	O
factors	O
associated	O
with	O
undisclosed	O
HIV	O
infection	O
and	O
ART	O
use	O
among	O
persons	O
on	O
ART	O
.	O

Among	O
559	O
HIV-positive	O
samples	O
,	O
the	O
ARV	O
biomarker	O
was	O
detected	O
in	O
42.5	O
%	O
(	O
CI	O
37.4-47.7	O
)	O
.	O

ARV	O
drugs	O
were	O
present	O
in	O
90.7	O
%	O
(	O
CI	O
86.1-95.2	O
)	O
reporting	O
HIV-positive	O
status	O
and	O
receiving	O
ART	O
,	O
66.7	O
%	O
(	O
CI	O
59.9-73.4	O
)	O
reporting	O
HIV-positive	O
status	O
irrespective	O
of	O
ART	O
use	O
,	O
21.0	O
%	O
(	O
CI	O
13.4-28.6	O
)	O
reporting	O
HIV-negative	O
status	O
,	O
and	O
19.3	O
%	O
(	O
CI	O
9.0-29.5	O
)	O
reporting	O
no	O
previous	O
HIV	B-P
test	I-P
.	O

After	O
correcting	O
for	O
undisclosed	O
HIV	O
infection	O
and	O
ART	O
use	O
,	O
diagnosed	O
HIV	O
increased	O
from	O
46.9	O
%	O
to	O
57.2	O
%	O
and	O
ART	O
coverage	O
increased	O
from	O
31.8	O
%	O
to	O
42.8	O
%	O
.	O

Undisclosed	O
HIV	O
infection	O
on	O
ART	O
was	O
associated	O
with	O
being	O
aged	O
25-39	O
years	O
and	O
not	O
visiting	O
a	O
health	O
provider	O
in	O
the	O
past	O
year	O
,	O
while	O
younger	O
age	O
and	O
higher	O
wealth	O
was	O
associated	O
with	O
undisclosed	O
ART	O
use	O
.	O

Substantial	O
levels	O
of	O
undisclosed	O
HIV	O
infection	O
and	O
ART	O
use	O
while	O
on	O
ART	O
were	O
observed	O
,	O
resulting	O
in	O
diagnosed	O
HIV	O
underestimated	O
by	O
112,000	O
persons	O
and	O
ART	O
coverage	O
by	O
131,000	O
persons	O
.	O

Supplementing	O
self-reported	O
ART	O
status	O
with	O
objective	O
measures	O
of	O
ART	O
use	O
in	O
national	O
population	O
-based	O
sero-surveys	O
can	O
improve	O
monitoring	O
of	O
treatment	O
targets	O
in	O
countries	O
.	O

Impact	O
of	O
Soil	O
Salinity	O
on	O
the	O
Structure	O
of	O
the	O
Bacterial	O
Endophytic	O
Community	O
Identified	O
from	O
the	O
Roots	O
of	O
Caliph	O
Medic	O
(	O
Medicago	O
truncatula	O
)	O
.	O

In	O
addition	O
to	O
being	O
a	O
forage	O
crop	O
,	O
Caliph	O
medic	O
(	O
Medicago	O
truncatula	O
)	O
is	O
also	O
a	O
model	O
legume	O
plant	O
and	O
is	O
used	O
for	O
research	O
focusing	O
on	O
the	O
molecular	O
characterization	O
of	O
the	O
interaction	O
between	O
rhizobia	O
and	O
plants	O
.	O

However	O
,	O
the	O
endophytic	O
microbiome	O
in	O
this	O
plant	O
is	O
poorly	O
defined	O
.	O

Endophytic	O
bacteria	O
play	O
a	O
role	O
in	O
supplying	O
plants	O
with	O
the	O
basic	O
requirements	O
necessary	O
for	O
growth	O
and	O
development	O
.	O

Moreover	O
,	O
these	O
bacteria	O
also	O
play	O
a	O
role	O
in	O
the	O
mechanism	O
of	O
salinity	O
stress	O
adaptation	O
in	O
plants	O
.	O

As	O
a	O
prelude	O
to	O
the	O
isolation	B-P
and	O
utilization	O
of	O
these	O
bacteria	O
in	O
Caliph	O
medic	O
farming	O
,	O
41	O
bacterial	O
OTUs	O
were	O
identified	O
in	O
this	O
project	O
from	O
within	O
the	O
interior	O
of	O
the	O
roots	O
of	O
this	O
plant	O
by	O
pyrosequencing	B-P
of	O
the	O
small	O
ribosomal	O
subunit	O
gene	O
(	O
16S	O
rDNA	O
)	O
using	O
a	O
cultivation-independent	B-P
approach	I-P
.	O

In	O
addition	O
,	O
the	O
differential	O
abundance	O
of	O
these	O
bacteria	O
was	O
studied	O
following	O
exposure	O
of	O
the	O
plants	O
to	O
salinity	O
stress	O
.	O

About	O
29,064	O
high-quality	O
reads	O
were	O
obtained	O
from	O
the	O
sequencing	B-P
of	O
six	O
libraries	O
prepared	O
from	O
control	O
and	O
salinity-treated	O
tissues	O
.	O

Statistical	O
analysis	O
revealed	O
that	O
the	O
abundance	O
of	O
~70	O
%	O
of	O
the	O
OTUs	O
was	O
significantly	O
(	O
p	O
≤	O
0.05	O
)	O
altered	O
in	O
roots	O
that	O
were	O
exposed	O
to	O
salinity	O
stress	O
.	O

Sequence	O
analysis	O
showed	O
a	O
similarity	O
between	O
some	O
of	O
the	O
identified	O
species	O
and	O
other	O
,	O
known	O
,	O
growth-promoting	O
bacteria	O
,	O
marine	O
and	O
salt-stressed	O
soil-borne	O
bacteria	O
,	O
and	O
nitrogen-fixing	O
bacterial	O
isolates	O
.	O

Determination	O
of	O
the	O
amendments	O
to	O
the	O
bacteria	O
l	O
community	O
due	O
to	O
salinity	O
stress	O
in	O
Caliph	O
medic	O
provides	O
a	O
crucial	O
step	O
toward	O
developing	O
an	O
understanding	O
of	O
the	O
association	O
of	O
these	O
endophytes	O
,	O
under	O
salt	O
stress	O
conditions	O
,	O
in	O
this	O
model	O
plant	O
.	O

To	O
provide	O
direct	O
evidence	O
regarding	O
their	O
growth	O
promoting	O
activity	O
,	O
a	O
group	O
of	O
endophytic	O
bacteria	O
were	O
isolated	O
from	O
inside	O
of	O
plant	O
roots	O
using	O
a	O
cultivation-dependent	B-P
approach	I-P
.	O

Several	O
of	O
these	O
isolates	O
were	O
able	O
to	O
produce	O
ACC-deaminase	O
,	O
ammonia	O
and	O
IAA	O
;	O
and	O
to	O
solubilize	O
Zn+2	O
and	O
PO4-3	O
.	O

This	O
data	O
is	O
consistent	O
with	O
the	O
predicted	O
occurrence	O
(	O
based	O
on	O
cultivation-independent	B-P
techniques	I-P
)	O
of	O
these	O
bacteria	O
and	O
provides	O
some	O
insight	O
into	O
the	O
importance	O
of	O
the	O
endophytic	O
bacteria	O
in	O
Caliph	O
medic	O
when	O
grown	O
under	O
normal	O
and	O
saline	O
conditions	O
.	O

Regulation	O
of	O
bone	O
homeostasis	O
by	O
glucose	O
.	O

Synthesis	O
of	O
type	O
Ⅰ	O
collagen	O
,	O
a	O
m	O
ajor	O
c	O
omponent	O
of	O
the	O
b	O
one	O
matrix	O
,	O
p	O
recedes	O
t	O
he	O
expression	O
of	O
R	O
unt-related	O
transcription	O
factor	O
2	O
(	O
R	O
unx2	O
)	O
,	O
a	O
master	O
regulator	O
in	O
osteoblast	O
differentiation	O
.	O

Thus	O
,	O
a	O
direct	O
link	O
between	O
osteoblast	O
differentiation	O
and	O
bone	O
formation	O
is	O
seemingly	O
absent	O
,	O
and	O
how	O
these	O
are	O
maintained	O
in	O
a	O
coordinated	O
matter	O
remains	O
unclear	O
.	O

It	O
was	O
recently	O
demonstrated	O
that	O
osteoblasts	O
depend	O
on	O
glucose	O
,	O
which	O
glucose	O
transporter	O
type	O
1	O
(	O
GLUT1	O
)	O
takes	O
up	O
as	O
an	O
energy	O
source	O
,	O
and	O
it	O
was	O
found	O
that	O
glucose	O
uptake	O
promotes	O
osteoblast	O
differentiation	O
and	O
bone	O
formation	O
via	O
AMP-activated	O
protein	O
kinase	O
.	O

It	O
was	O
also	O
shown	O
that	O
Runx2	O
upregulates	O
GLUT1	O
expression	O
,	O
and	O
this	O
Runx2	O
-	O
GLUT1	O
feedforward	O
regulation	O
integrates	O
and	O
coordinates	O
osteoblast	O
differentiation	O
and	O
bone	O
formation	O
throughout	O
life	O
.	O

These	O
previous	O
findings	O
revealed	O
that	O
the	O
energy	O
metabolism	O
balance	O
in	O
osteoblasts	O
integrates	O
the	O
differentiation	O
and	O
function	O
of	O
osteoblasts	O
,	O
and	O
re-emphasized	O
the	O
importance	O
of	O
crosstalk	O
between	O
bone	O
and	O
sugar	B-P
metabolism	I-P
.	O

Hypoxia	O
/	O
reoxygenation	O
-induced	O
HMGB1	O
translocation	O
and	O
release	O
promotes	O
islet	O
proinflammatory	O
cytokine	O
production	O
and	O
early	O
islet	O
graft	O
failure	O
through	O
TLRs	O
signaling	O
.	O

High-mobility	O
group	O
box	O
1	O
(	O
HMGB1	O
)	O
translocation	O
and	O
release	O
,	O
which	O
is	O
involved	O
in	O
several	O
tissue	O
types	O
of	O
ischemia-reperfusion	O
injuries	O
,	O
activate	O
innate	O
immunity	O
by	O
inducing	O
proinflammatory	O
cytokine	O
production	O
through	O
its	O
interaction	O
with	O
toll-like	O
receptors	O
(	O
TLRs	O
)	O
.	O

Our	O
objective	O
was	O
to	O
determine	O
the	O
role	O
of	O
HMGB1	O
and	O
the	O
degree	O
of	O
activation	O
of	O
TLR	O
-related	O
signal	O
transduction	O
pathways	O
in	O
hypoxia	O
/	O
reoxygenation	O
(	O
H	O
/	O
R	O
)	O
-induced	O
proinflammatory	O
cytokine	O
production	O
and	O
intra-islet	O
graft	O
inflammation	O
.	O

After	O
islets	O
are	O
exposed	O
to	O
hypoxia	O
-	O
reoxygenation	O
for	O
24h	O
,	O
TLR2	O
/	O
4	O
expression	O
and	O
TLR	O
-mediated	O
signaling	O
was	O
up-regulated	O
in	O
islets	O
,	O
and	O
HMGB1	O
was	O
translocated	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
and	O
released	O
to	O
the	O
extracellular	O
space	O
.	O

With	O
H	O
/	O
R	O
exposure	O
,	O
proinflammatory	O
cytokine	O
production	O
(	O
IL-1β	O
and	O
TNF-α	O
)	O
and	O
islet	O
injury	O
were	O
significantly	O
increased	O
,	O
and	O
these	O
effects	O
depend	O
on	O
TLR2	O
/	O
4	O
signaling	O
pathways	O
.	O

Exogenous	O
HMGB1	O
also	O
induces	O
islet	O
inflammation	O
and	O
increases	O
the	O
phosphorylation	O
of	O
STAT3	O
,	O
p38	O
and	O
IκBα	O
in	O
wild-type	O
islets	O
.	O

TLR2	O
deficiency	O
in	O
TLR2	O
-	O
KO	O
islets	O
resulted	O
in	O
the	O
inhibition	O
of	O
IL-1β	O
production	O
and	O
STAT3	O
/	O
p38	O
phosphorylation	O
after	O
HMGB1	O
exposure	O
.	O

TLR4	O
deficiency	O
in	O
TLR4	O
-	O
KO	O
islets	O
resulted	O
in	O
the	O
inhibition	O
of	O
TNF-α	O
production	O
and	O
IκBα	O
phosphorylation	O
after	O
HMGB1	O
exposure	O
.	O

Pre-incubation	B-P
of	O
the	O
STAT3	O
,	O
p38	O
,	O
or	O
NF-κB	O
inhibitors	O
significantly	O
inhibited	O
HMGB1	O
-induced	O
IL-1β	O
or	O
TNF-α	O
production	O
in	O
islets	O
,	O
but	O
the	O
effect	O
of	O
HMGB1	O
or	O
H	O
/	O
R	O
-induced	O
islet	O
injury	O
was	O
not	O
counteracted	O
by	O
a	O
separate	O
treatment	O
of	O
the	O
STAT3	O
inhibitor	O
,	O
p38	O
inhibitor	O
,	O
or	O
NF-κB	O
inhibitors	O
.	O

HMGB1	O
inhibition	O
by	O
ethyl	O
pyruvate	O
or	O
blockade	O
by	O
neutralizing	O
antibodies	O
significantly	O
decreased	O
the	O
phosphorylation	O
of	O
STAT3	O
,	O
p38	O
and	O
IκBα	O
,	O
the	O
production	O
of	O
IL-1β	O
and	O
TNF-α	O
,	O
and	O
the	O
islet	O
injury	O
in	O
wild-type	O
islets	O
after	O
exposure	O
to	O
H	O
/	O
R	O
and	O
significantly	O
improved	O
early	O
islet	O
graft	O
failure	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
HMGB1	O
released	O
from	O
H	O
/	O
R	O
induced	O
islets	O
works	O
in	O
an	O
autocrine	O
manner	O
to	O
up-regulate	O
STAT	O
or	O
p38	O
and	O
augment	O
IL-1β	O
production	O
via	O
TLR2	O
,	O
and	O
up-regulate	O
NF-κB	O
and	O
augment	O
TNF-α	O
production	O
via	O
TLR4	O
in	O
intra-islet	O
,	O
which	O
are	O
associated	O
with	O
H	O
/	O
R	O
-induced	O
islet	O
injury	O
and	O
early	O
graft	O
failure	O
.	O

Effect	O
of	O
alpha	O
lipoic	O
acid	O
on	O
in	O
vitro	O
development	O
of	O
bovine	O
secondary	O
preantral	O
follicles	O
.	O

The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
in	O
vitro	O
effect	O
of	O
alpha	O
lipoic	O
acid	O
(	O
ALA	O
)	O
addition	O
to	O
the	O
culture	O
medium	O
on	O
the	O
development	O
of	O
the	O
bovine	O
secondary	O
preantral	O
follicles	O
.	O

Bovine	O
secondary	O
preantral	O
follicles	O
were	O
collected	O
and	O
divided	O
into	O
two	O
groups	O
depending	O
on	O
their	O
size	O
(	O
80-100	O
μm	O
and	O
100-110	O
μm	O
)	O
.	O

They	O
were	O
cultured	O
in	O
vitro	O
for	O
15	O
days	O
(	O
D	O
)	O
using	O
different	O
media	O
including	O
at	O
three	O
different	O
doses	O
of	O
ALA	O
.	O

The	O
genes	O
expression	O
levels	O
of	O
follicle-stimulating	O
hormone	O
beta-subunit	O
(	O
FSHR	O
)	O
,	O
insulin-like	O
growth	O
factor	O
(	O
IGF-1	O
)	O
,	O
Activin	O
,	O
luteinizing	O
hormone/choriogonadotropin	O
receptor	O
,	O
bone	O
morphogenetic	O
protein	O
receptor	O
type	O
IA	O
,	O
transforming	O
growth	O
factor	O
beta	O
receptor	O
1	O
,	O
growth	O
differentiation	O
factor	O
9	O
,	O
BCL2-associated	O
X	O
protein	O
(	O
BAX	O
)	O
,	O
and	O
C-Myc	O
were	O
studied	O
using	O
real-time	O
polymerase	O
chain	O
reaction	O
.	O

The	O
protein	O
expression	O
levels	O
of	O
FSHR	O
,	O
IGF-1	O
,	O
and	O
BAX	O
were	O
measured	O
using	O
Western	B-P
blot	I-P
analysis	I-P
.	O

The	O
results	O
of	O
the	O
present	O
work	O
revealed	O
that	O
in	O
vitro	O
addition	O
of	O
ALA	O
-	O
induced	O
significant	O
increase	O
in	O
the	O
growth	O
and	O
development	O
of	O
secondary	O
preantral	O
follicles	O
throughout	O
the	O
culture	B-P
period	O
as	O
compared	O
to	O
control	O
.	O

The	O
FSHR	O
,	O
IGF-1	O
,	O
luteinizing	O
hormone/choriogonadotropin	O
receptor	O
,	O
bone	O
morphogenetic	O
protein	O
receptor	O
type	O
IA	O
,	O
transforming	O
growth	O
factor	O
beta	O
receptor	O
1	O
,	O
growth	O
differentiation	O
factor	O
9	O
,	O
and	O
Activin	O
A	O
genes	O
were	O
upregulated	O
in	O
ALA	O
-	O
treated	O
follicles	O
as	O
compared	O
to	O
the	O
control	O
.	O

On	O
contrary	O
,	O
preapoptotic	O
genes	O
BAX	O
and	O
C-Myc	O
were	O
downregulated	O
in	O
treated	O
follicles	O
compared	O
to	O
control	O
ones	O
.	O

The	O
protein	O
levels	O
of	O
FSHR	O
and	O
IGF-1	O
were	O
highly	O
expressed	O
in	O
treated	O
follicles	O
compared	O
to	O
control	O
;	O
however	O
,	O
BAX	O
protein	O
was	O
downregulated	O
in	O
the	O
treated	O
follicles	O
groups	O
.	O

The	O
addition	O
of	O
ALA	O
to	O
the	O
culture	O
medium	O
enhances	O
secondary	O
preantral	O
follicles	O
development	O
and	O
growth	O
.	O

A	O
Novel	O
Selective	O
Inhibitor	O
of	O
Delta-5	O
Desaturase	O
Lowers	O
Insulin	O
Resistance	O
and	O
Reduces	O
Body	O
Weight	O
in	O
Diet	O
-Induced	O
Obese	O
C57BL/6J	O
Mice	O
.	O

Obesity	O
is	O
now	O
recognized	O
as	O
a	O
state	O
of	O
chronic	O
low-grade	O
inflammation	O
and	O
is	O
called	O
as	O
metabolic	O
inflammation	O
.	O

Delta-5	O
desaturase	O
(	O
D5D	O
)	O
is	O
an	O
enzyme	O
that	O
metabolizes	O
dihomo-γ-linolenic	O
acid	O
(	O
DGLA	O
)	O
to	O
arachidonic	O
acid	O
(	O
AA	O
)	O
.	O

Thus	O
,	O
D5D	O
inhibition	O
increases	O
DGLA	O
(	O
precursor	O
to	O
anti-inflammatory	O
eicosanoids	O
)	O
while	O
decreasing	O
AA	O
(	O
precursor	O
to	O
pro-inflammatory	O
eicosanoids	O
)	O
,	O
and	O
could	O
result	O
in	O
synergistic	O
improvement	O
in	O
the	O
low-grade	O
inflammatory	O
state	O
.	O

Here	O
,	O
we	O
demonstrate	O
reduced	O
insulin	O
resistance	O
and	O
the	O
anti-obesity	O
effect	O
of	O
a	O
D5D	O
selective	O
inhibitor	O
(	O
compound-326	O
)	O
,	O
an	O
orally	O
active	O
small-molecule	O
,	O
in	O
a	O
high-fat	O
diet	O
-induced	O
obese	O
(	O
DIO	O
)	O
mouse	O
model	O
.	O

In	O
vivo	O
D5D	O
inhibition	O
was	O
confirmed	O
by	O
determining	O
changes	O
in	O
blood	O
AA	O
/	O
DGLA	O
profiles	B-P
.	O

In	O
DIO	O
mice	O
,	O
chronic	O
treatment	O
with	O
compound-326	O
lowered	O
insulin	O
resistance	O
and	O
caused	O
body	O
weight	O
loss	O
without	O
significant	O
impact	O
on	O
cumulative	O
calorie	O
intake	O
.	O

Decreased	O
macrophage	O
infiltration	O
into	O
adipose	O
tissue	O
was	O
expected	O
from	O
mRNA	O
analysis	O
.	O

Increased	O
daily	O
energy	O
expenditure	O
was	O
also	O
observed	O
following	O
administration	O
of	O
compound-326	O
,	O
in	O
line	O
with	O
sustained	O
body	O
weight	O
loss	O
.	O

These	O
data	O
indicate	O
that	O
the	O
novel	O
D5D	O
selective	O
inhibitor	O
,	O
compound-326	O
,	O
will	O
be	O
a	O
new	O
class	O
of	O
drug	O
for	O
the	O
treatment	O
of	O
obese	O
and	O
diabetic	O
patients	O
.	O

Peptide	O
-Mediated	O
Interference	O
of	O
PB2	O
-	O
eIF4G1	O
Interaction	O
Inhibits	O
Influenza	O
A	O
Viruses	O
'	O
Replication	O
in	O
Vitro	O
and	O
in	O
Vivo	O
.	O

Influenza	O
viruses	O
are	O
obligate	O
parasites	O
that	O
hijack	O
the	O
host	O
cellular	O
system	O
.	O

Previous	O
results	O
have	O
shown	O
that	O
the	O
influenza	O
virus	O
PB2	O
subunit	O
confers	O
a	O
dependence	O
of	O
host	O
eukaryotic	O
translation	O
initiation	O
factor	O
4-γ	O
1	O
(	O
eIF4G1	O
)	O
for	O
viral	O
mRNA	O
translation	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
peptide	O
-mediated	O
interference	O
of	O
the	O
PB2	O
-	O
eIF4G1	O
interaction	O
inhibited	O
virus	O
replication	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Remarkably	O
,	O
intranasal	O
administration	O
of	O
the	O
peptide	O
provided	O
100	O
%	O
protection	O
against	O
lethal	O
challenges	O
of	O
influenza	O
A	O
viruses	O
in	O
BALB/c	O
mice	O
,	O
including	O
H1N1	O
,	O
H5N1	O
,	O
and	O
H7N9	O
influenza	O
virus	O
subtypes	O
.	O

Mapping	O
of	O
the	O
PB2	O
protein	O
indicated	O
that	O
the	O
eIF4G1	O
binding	O
sites	O
resided	O
within	O
the	O
PB2	O
cap	O
-	O
binding	O
domain	O
.	O

Virtual	O
docking	O
analysis	O
suggested	O
that	O
the	O
inhibitory	O
peptide	O
associated	O
with	O
the	O
conserved	O
amino	O
acid	O
residues	O
that	O
were	O
essential	O
to	O
PB2	O
cap-binding	B-P
activity	I-P
.	O

Overall	O
,	O
our	O
results	O
identified	O
the	O
PB2	O
-	O
eIF4G1	O
interactive	O
site	O
as	O
a	O
druggable	O
target	O
for	O
influenza	O
therapeutics	O
.	O

A	O
randomized	O
trial	O
of	O
Plasma-Lyte	O
A	O
and	O
0.9	O
%	O
sodium	O
chloride	O
in	O
acute	O
pediatric	O
gastroenteritis	O
.	O

Compare	O
the	O
efficacy	O
and	O
safety	O
of	O
Plasma-Lyte	O
A	O
(	O
PLA	O
)	O
versus	O
0.9	O
%	O
sodium	O
chloride	O
(	O
NaCl	O
)	O
intravenous	O
(	O
IV	O
)	O
fluid	O
replacement	O
in	O
children	O
with	O
moderate	O
to	O
severe	O
dehydration	O
secondary	O
to	O
acute	O
gastroenteritis	O
(	O
AGE	O
)	O
.	O

Prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
conducted	O
at	O
eight	O
pediatric	O
emergency	O
departments	O
(	O
EDs	O
)	O
in	O
the	O
US	O
and	O
Canada	O
(	O
NCT	O
#	O
01234883	O
)	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
serum	O
bicarbonate	O
level	O
at	O
4	O
h.	O
Secondary	O
outcomes	O
included	O
safety	O
and	O
tolerability	O
.	O

The	O
hypothesis	O
was	O
that	O
PLA	O
would	O
be	O
superior	O
to	O
0.9	O
%	O
NaCl	O
in	O
improvement	B-P
of	I-P
4-h	I-P
bicarbonate	I-P
.	O

Patients	O
(	O
n	O
=	O
100	O
)	O
aged	O
≥6	O
months	O
to	O
<	O
11	O
years	O
with	O
AGE	O
-induced	O
moderate-to-	O
severe	O
dehydration	O
were	O
enrolled	O
.	O

Patients	O
with	O
a	O
baseline	O
bicarbonate	O
level	O
≤22	O
mEq/L	O
formed	O
the	O
modified	O
intent	O
to	O
treat	O
(	O
mITT	O
)	O
group	O
.	O

At	O
baseline	O
,	O
the	O
treatment	O
groups	O
were	O
comparable	O
except	O
that	O
the	O
PLA	O
group	O
was	O
older	O
.	O

At	O
hour	O
4	O
,	O
the	O
PLA	O
group	O
had	O
greater	O
increases	O
in	O
serum	O
bicarbonate	O
from	O
baseline	O
than	O
did	O
the	O
0.9	O
%	O
NaCl	O
group	O
(	O
mean	O
±	O
SD	O
at	O
4	O
h	O
:	O
18	O
±	O
3.74	O
vs	O
18.0	O
±	O
3.67	O
;	O
change	O
from	O
baseline	O
of	O
1.6	O
and	O
0.0	O
,	O
respectively	O
;	O
P	O
=	O
.004	O
)	O
.	O

Both	O
treatment	O
groups	O
received	O
similar	O
fluid	O
volumes	O
.	O

The	O
PLA	O
group	O
had	O
less	O
abdominal	O
pain	O
and	O
better	O
dehydration	O
scores	O
at	O
hour	O
2	O
(	O
both	O
P	O
=	O
.03	O
)	O
but	O
not	O
at	O
hour	O
4	O
(	O
P	O
=	O
0.15	O
and	O
0.08	O
,	O
respectively	O
)	O
.	O

No	O
patient	O
experienced	O
clinically	O
relevant	O
worsening	O
of	O
laboratory	O
findings	O
or	O
physical	O
examination	O
,	O
and	O
hospital	O
admission	O
rates	O
were	O
similar	O
.	O

One	O
patient	O
in	O
each	O
treatment	O
group	O
developed	O
hyponatremia	O
.	O

Four	O
patients	O
developed	O
hyperkalemia	O
(	O
PLA	O
:1	O
,	O
0.9	O
%	O
NaCl	O
:3	O
)	O
.	O

In	O
comparison	O
with	O
0.9	O
%	O
NaCl	O
,	O
PLA	O
for	O
rehydration	O
in	O
children	O
with	O
AGE	O
was	O
well	O
tolerated	O
and	O
led	O
to	O
more	O
rapid	O
improvement	B-P
in	I-P
serum	I-P
bicarbonate	I-P
and	O
dehydration	O
score	O
.	O

NCT	O
#	O
01234883	O
(	O
Registration	O
Date	O
:	O
November	O
3	O
,	O
2010	O
)	O
.	O

Evaluation	O
of	O
the	O
economic	O
and	O
clinical	O
feasibility	O
of	O
introducing	O
rigid	B-P
endoscopy	I-P
and	O
laparoscopy	B-P
to	O
a	O
small	O
animal	O
general	O
practice	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
economic	O
and	O
clinical	O
feasibility	O
of	O
introducing	O
rigid	B-P
endoscopy	I-P
and	O
laparoscopy	B-P
to	O
a	O
small	O
animal	O
general	O
practice	O
.	O

DESIGN	O
Prospective	O
study	O
.	O

SAMPLE	O
A	O
single	O
2-	O
veterinarian	O
small	O
animal	O
practice	O
in	O
southern	O
California	O
.	O

PROCEDURES	O
In	O
early	O
2012	O
,	O
endoscopic	B-P
equipment	O
was	O
purchased	O
,	O
and	O
both	O
veterinarians	O
in	O
the	O
practice	O
undertook	O
training	O
in	O
rigid	B-P
endoscopic	I-P
and	O
laparoscopic	B-P
procedures	I-P
.	O

Subsequently	O
,	O
information	O
for	O
client	O
-owned	O
animals	O
that	O
underwent	O
endoscopic	B-P
and	O
laparoscopic	B-P
procedures	I-P
during	O
a	O
12-	O
month	O
period	O
(	O
2012	O
to	O
2013	O
)	O
was	O
collected	O
.	O

Cost	O
of	O
equipment	O
and	O
training	O
,	O
revenue	O
generated	O
,	O
specific	O
procedures	O
performed	O
,	O
surgery	O
time	O
,	O
complications	O
,	O
and	O
client	O
satisfaction	O
were	O
evaluated	O
.	O

RESULTS	O
78	O
endoscopic	B-P
procedures	I-P
were	O
performed	O
in	O
73	O
patients	O
,	O
including	O
71	O
dogs	O
,	O
1	O
cat	O
,	O
and	O
1	O
rabbit	O
.	O

Cost	O
of	O
endoscopic	B-P
and	O
laparoscopic	B-P
equipment	O
and	O
training	O
in	O
the	O
first	O
year	O
was	O
$	O
14,809.71	O
;	O
most	O
equipment	O
was	O
financed	O
through	O
a	O
5-	O
year	O
lease	O
at	O
a	O
total	O
cost	O
of	O
$	O
57,507.70	O
(	O
$	O
10,675.20/y	O
)	O
.	O

Total	O
revenue	O
generated	O
in	O
the	O
first	O
year	O
was	O
$	O
50,423.63	O
.	O

The	O
most	O
common	O
procedures	O
performed	O
were	O
ovariectomy	O
(	O
OVE	O
;	O
n	O
=	O
49	O
)	O
,	O
prophylactic	O
gastropexy	O
(	O
6	O
)	O
,	O
and	O
video	B-P
otoscopy	I-P
(	O
12	O
)	O
.	O

Mean	O
±	O
SD	O
surgery	O
times	O
for	O
OVE	O
(	O
n	O
=	O
44	O
)	O
and	O
for	O
OVE	O
with	O
gastropexy	O
(	O
5	O
)	O
were	O
63.7	O
±	O
19.7	O
minutes	O
and	O
73.0	O
±	O
33.5	O
minutes	O
;	O
respectively	O
.	O

Twelve	O
of	O
54	O
patients	O
undergoing	O
laparoscopic	B-P
procedures	I-P
experienced	O
minor	O
intraoperative	O
complications	O
.	O

Conversion	O
to	O
laparotomy	O
was	O
not	O
required	O
in	O
any	O
patient	O
.	O

There	O
were	O
no	O
major	O
complications	O
.	O

All	O
49	O
clients	O
available	O
for	O
follow-up	O
were	O
satisfied	O
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
With	O
appropriate	O
training	O
and	O
equipment	O
,	O
incorporation	O
of	O
basic	O
rigid	B-P
endoscopy	I-P
and	O
laparoscopy	B-P
may	O
be	O
feasible	O
in	O
small	O
animal	O
general	O
practice	O
.	O

However	O
,	O
results	O
of	O
the	O
present	O
study	O
are	O
not	O
applicable	O
to	O
all	O
veterinarians	O
and	O
practice	O
settings	O
,	O
and	O
patient	O
safety	O
considerations	O
should	O
always	O
be	O
paramount	O
.	O

A	O
lab-on-a-chip	O
for	O
monolith	O
-based	O
preconcentration	O
and	O
electrophoresis	O
separation	O
of	O
phosphopeptides	O
.	O

A	O
microdevice	O
combining	O
online	O
preconcentration	O
and	O
separation	O
of	O
phosphopeptides	O
was	O
developed	O
in	O
a	O
glass	O
microchip	O
.	O

An	O
ethylene	O
glycol	O
methacrylate	O
phosphate	O
(	O
EGMP	O
)	O
,	O
acrylamide	O
(	O
AM	O
)	O
and	O
bisacrylamide	O
(	O
BAA	O
)	O
based	O
monolith	O
was	O
synthesized	O
within	O
microchannels	O
through	O
a	O
photo-driven	O
process	O
.	O

Morphological	O
investigations	B-P
revealed	O
a	O
homogeneous	O
monolithic	O
structure	O
composed	O
of	O
uniform	O
nodules	O
(	O
∼0.8	O
μm	O
)	O
,	O
with	O
a	O
large	O
pore	O
volume	O
(	O
0.62	O
cm	O
(	O
3	O
)	O
g	O
(	O
-1	O
)	O
)	O
and	O
sufficiently	O
high	O
specific	O
surface	O
area	O
(	O
34.1	O
m	O
(	O
2	O
)	O
g	O
(	O
-1	O
)	O
)	O
.	O

These	O
features	O
make	O
the	O
monolith	O
particularly	O
interesting	O
for	O
preconcentration	O
purposes	O
.	O

Immobilization	O
of	O
Zr	O
(	O
4+	O
)	O
ions	O
on	O
the	O
phosphate	O
groups	O
present	O
at	O
the	O
poly	O
(	O
EGMP-co-AM-co-BAA	O
)	O
monolith	O
surface	O
leads	O
to	O
immobilized	O
metal	O
affinity	B-P
chromatography	I-P
support	O
.	O

This	O
monolith	O
-	O
Zr	O
(	O
4+	O
)	O
showed	O
a	O
great	O
capacity	O
to	O
capture	O
phosphopeptides	O
.	O

Successful	O
preconcentration	O
and	O
separation	O
of	O
a	O
mixture	O
of	O
ERK2	O
derived	O
peptides	O
differing	O
only	O
by	O
their	O
phosphorylation	O
degree	O
and	O
sites	O
could	O
be	O
achieved	O
with	O
signal	O
enhancement	O
factors	O
between	O
340	O
and	O
910	O
after	O
only	O
7	O
min	O
of	O
preconcentration	O
.	O

This	O
integrated	O
microdevice	O
represents	O
a	O
novel	O
approach	O
for	O
phosphoproteomic	O
applications	O
.	O

The	O
binding	O
orientations	O
of	O
structurally	O
-related	O
ligands	O
can	O
differ	O
;	O
A	O
cautionary	O
note	O
.	O

Crystal	O
structures	O
can	O
identify	O
ligand-receptor	O
interactions	O
and	O
assist	O
the	O
development	O
of	O
novel	O
therapeutics	O
,	O
but	O
experimental	O
challenges	O
sometimes	O
necessitate	O
the	O
use	O
of	O
homologous	O
proteins	O
.	O

Tropisetron	O
is	O
an	O
orthosteric	O
ligand	O
at	O
both	O
5-HT3	O
and	O
α7	O
nACh	O
receptors	O
and	O
its	O
binding	O
orientation	O
has	O
been	O
determined	O
in	O
the	O
structural	O
homologue	O
AChBP	O
(	O
pdbid	O
:	O
2WNC	O
)	O
.	O

Co-crystallisation	O
with	O
a	O
structurally	O
-related	O
ligand	O
,	O
granisetron	O
,	O
reveals	O
an	O
almost	O
identical	O
orientation	O
(	O
pdbid	O
;	O
2YME	O
)	O
.	O

However	O
,	O
there	O
is	O
a	O
>	O
1000-fold	O
difference	O
in	O
the	O
affinity	O
of	O
tropisetron	O
at	O
5-HT3	O
versus	O
α7	O
nACh	O
receptors	O
,	O
and	O
α7	O
nACh	O
receptors	O
do	O
not	O
bind	O
granisetron	O
.	O

These	O
striking	O
pharmacological	O
differences	O
prompt	O
questions	O
about	O
which	O
receptor	O
the	O
crystal	O
structures	O
most	O
closely	O
represent	O
and	O
whether	O
the	O
ligand	O
orientations	O
are	O
correct	O
.	O

Here	O
we	O
probe	O
the	O
binding	O
orientation	O
of	O
tropisetron	O
and	O
granisetron	O
at	O
5-HT3	O
receptors	O
by	O
in	O
silico	O
modelling	O
and	O
docking	O
,	O
radioligand	O
binding	O
on	O
cysteine	O
-	O
substituted	O
5-HT3	O
receptor	O
mutants	O
transiently	O
expressed	O
in	O
HEK	O
293	O
cells	O
,	O
and	O
synthetic	O
modification	O
of	O
the	O
ligands	O
.	O

For	O
15	O
of	O
the	O
23	O
cysteine	O
substitutions	O
,	O
the	O
effects	O
on	O
tropisetron	O
and	O
granisetron	O
were	O
different	O
.	O

Structure-activity	O
relationships	O
on	O
synthesised	O
derivatives	O
of	O
both	O
ligands	O
were	O
also	O
consistent	O
with	O
different	O
orientations	O
,	O
revealing	O
that	O
contrary	O
to	O
the	O
crystallographic	B-P
evidence	O
from	O
AChBP	O
,	O
the	O
two	O
ligands	O
adopt	O
different	O
orientations	O
in	O
the	O
5-HT3	O
receptor	O
binding	O
site	O
.	O

Our	O
results	O
show	O
that	O
even	O
quite	O
structurally	O
similar	O
molecules	O
can	O
adopt	O
different	O
orientations	O
in	O
the	O
same	O
binding	O
site	O
,	O
and	O
that	O
caution	O
may	O
be	O
needed	O
when	O
using	O
homologous	O
proteins	O
to	O
predict	O
ligand	O
binding	O
.	O

Asystole	O
From	O
Direct	B-P
Laryngoscopy	I-P
:	O
A	O
Case	O
Report	O
and	O
Literature	O
Review	O
.	O

The	O
rare	O
and	O
potentially	O
fatal	O
complication	O
of	O
asystole	O
during	O
direct	B-P
laryngoscopy	I-P
is	O
linked	O
to	O
direct	O
vagal	B-P
stimulation	I-P
.	O

This	O
case	O
describes	O
asystole	O
in	O
an	O
85-year-old	O
female	O
who	O
underwent	O
suspension	B-P
microlaryngoscopy	I-P
with	O
tracheal	O
dilation	O
for	O
subglottic	O
stenosis	O
.	O

Quick	O
recognition	O
of	O
this	O
rare	O
event	O
with	O
immediate	O
cessation	O
of	O
laryngoscopy	B-P
resulted	O
in	O
the	O
return	O
of	O
normal	O
sinus	O
rhythm	O
.	O

This	O
incident	O
emphasizes	O
the	O
implications	O
of	O
continued	O
vigilance	O
during	O
laryngoscopy	B-P
and	O
the	O
importance	O
of	O
communication	O
between	O
the	O
anesthesia	O
and	O
surgical	O
staff	O
to	O
identify	O
and	O
treat	O
this	O
rare	O
complication	O
.	O

The	O
case	O
was	O
successfully	O
concluded	O
by	O
premedication	O
with	O
an	O
anticholinergic	O
and	O
by	O
increasing	O
the	O
depth	O
of	O
anesthesia	O
.	O

Can	O
Sergentomyia	O
(	O
Diptera	O
,	O
Psychodidae	O
)	O
play	O
a	O
role	O
in	O
the	O
transmission	O
of	O
mammal	O
-	O
infecting	O
Leishmania	O
?	O
.	O

Leishmaniases	O
are	O
parasitic	O
diseases	O
caused	O
by	O
protozoa	O
of	O
the	O
genus	O
Leishmania	O
.	O

The	O
parasites	O
,	O
which	O
infect	O
various	O
wild	O
and	O
domestic	O
mammals	O
,	O
including	O
humans	O
,	O
are	O
transmitted	O
by	O
the	O
bite	O
of	O
phlebotomine	O
sand	O
flies	O
belonging	O
to	O
the	O
Phlebotomus	O
genus	O
in	O
the	O
Old	O
World	O
and	O
to	O
several	O
genera	O
(	O
including	O
Lutzomyia	O
,	O
Psychodopygus	O
and	O
Nyssomyia	O
)	O
in	O
the	O
New	O
World	O
.	O

In	O
this	O
paper	O
,	O
we	O
consider	O
the	O
genus	O
Sergentomyia	O
as	O
divided	O
into	O
seven	O
subgenera	O
,	O
mainly	O
based	O
on	O
spermathecal	O
morphology	O
:	O
Sergentomyia	O
,	O
Sintonius	O
,	O
Parrotomyia	O
,	O
Rondanomyia	O
,	O
Capensomyia	O
,	O
Vattieromyia	O
and	O
Trouilletomyia	O
.	O

We	O
also	O
include	O
the	O
groups	O
Grassomyia	O
and	O
Demeillonius	O
but	O
exclude	O
the	O
genera	O
Spelaeomyia	O
and	O
Parvidens	O
.	O

The	O
possible	O
role	O
of	O
Sergentomyia	O
in	O
the	O
circulation	O
of	O
mammalian	O
leishmaniases	O
in	O
the	O
Old	O
World	O
has	O
been	O
considered	O
as	O
Leishmania	O
DNA	O
and/or	O
parasites	O
have	O
been	O
identified	O
in	O
several	O
species	O
.	O

However	O
,	O
several	O
criteria	O
must	O
be	O
fulfilled	O
to	O
incriminate	O
an	O
arthropod	O
as	O
a	O
biological	O
vector	O
of	O
leishmaniasis	O
,	O
namely	O
:	O
it	O
must	O
be	O
attracted	O
to	O
and	O
willing	O
to	O
feed	O
on	O
humans	O
and	O
any	O
reservoir	O
host	O
,	O
and	O
be	O
present	O
in	O
the	O
same	O
environment	O
;	O
several	O
unambiguously	O
identified	O
wild	O
female	O
flies	O
not	O
containing	O
blood	O
meals	O
have	O
to	O
be	O
found	O
infected	O
(	O
through	O
isolation	B-P
and/or	O
typing	B-P
of	O
parasites	O
)	O
with	O
the	O
same	O
strain	O
of	O
Leishmania	O
as	O
occurs	O
in	O
humans	O
or	O
any	O
reservoir	O
host	O
;	O
the	O
presence	O
of	O
infective	O
forms	O
of	O
Leishmania	O
on	O
naturally	O
infected	O
females	O
and/or	O
on	O
colonized	O
sand	O
flies	O
infected	O
experimentally	O
should	O
be	O
observed	O
;	O
and	O
finally	O
,	O
the	O
vector	O
has	O
to	O
be	O
able	O
to	O
transmit	O
parasites	O
as	O
a	O
result	O
of	O
blood	O
-	O
feeding	O
on	O
a	O
susceptible	O
mammal	O
.	O

The	O
feasibility	O
of	O
Forward-projected	B-P
model-based	I-P
Iterative	I-P
Reconstruction	I-P
SoluTion	I-P
(	O
FIRST	B-P
)	O
for	O
coronary	O
320-row	B-P
computed	I-P
tomography	I-P
angiography	I-P
:	O
A	O
pilot	O
study	O
.	O

We	O
aimed	O
to	O
assess	O
and	O
compare	O
the	O
influence	O
of	O
Forward	B-P
projected	I-P
model-based	I-P
Iterative	I-P
Reconstruction	I-P
SoluTion	I-P
(	O
FIRST	B-P
)	O
,	O
a	O
recently	O
introduced	O
full	O
iterative	B-P
reconstruction	I-P
method	I-P
,	O
on	O
radiation	O
doses	O
and	O
image	O
quality	O
with	O
that	O
of	O
Adaptive	O
Iterative	O
Dose	O
Reduction	O
(	O
AIDR	O
)	O
3D	O
for	O
320-row	B-P
cardiac	I-P
computed	I-P
tomography	I-P
(	O
CT	B-P
)	O
.	O

A	O
total	O
of	O
184	O
patients	O
subjected	O
to	O
single-beat	B-P
reconstruction	I-P
cardiac	I-P
CT	I-P
were	O
retrospectively	O
included	O
.	O

The	O
first	O
89	O
patients	O
received	O
standard	O
radiation	O
doses	O
;	O
their	O
data	O
were	O
reconstructed	O
using	O
AIDR	O
3D	O
,	O
whereas	O
the	O
last	O
95	O
patients	O
received	O
in	O
average	O
20	O
%	O
reduction	O
in	O
tube	O
current	O
;	O
their	O
data	O
were	O
reconstructed	O
using	O
FIRST	B-P
.	O

Subjective	O
image	O
quality	O
(	O
blooming	O
,	O
image	O
sharpness	O
,	O
image	O
noise	O
,	O
and	O
overall	O
subjective	O
image	O
quality	O
)	O
were	O
graded	O
using	O
3-	O
,	O
5-	O
,	O
4-	O
,	O
and	O
4-point	O
scales	O
(	O
0-2	O
,	O
1-5	O
,	O
1-4	O
,	O
and	O
1-4	O
)	O
,	O
respectively	O
;	O
for	O
all	O
items	O
,	O
the	O
highest	O
score	O
indicated	O
excellent	O
image	O
quality	O
.	O

Image	O
noise	O
and	O
signal-to-noise	O
ratios	O
at	O
proximal	O
segments	O
were	O
analyzed	O
as	O
objective	O
measures	O
of	O
image	O
quality	O
.	O

FIRST	B-P
reconstruction	I-P
allowed	O
28	O
%	O
dose	O
reduction	O
compared	O
with	O
AIDR	O
3D	O
(	O
1.88	O
vs.	O
2.61	O
mSv	O
,	O
p	O
=	O
0.012	O
)	O
and	O
yielded	O
better	O
subjective	O
image	O
quality	O
in	O
terms	O
of	O
blooming	O
,	O
image	O
sharpness	O
,	O
image	O
noise	O
,	O
and	O
overall	O
image	O
quality	O
(	O
1.10	O
vs.	O
1.01	O
,	O
p	O
=	O
0.0007	O
;	O
3.02	O
vs.	O
2.74	O
,	O
p	O
<	O
0.0001	O
;	O
3.61	O
vs.	O
3.17	O
,	O
p	O
<	O
0.0001	O
;	O
and	O
3.30	O
vs.	O
2.98	O
,	O
p	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O

Although	O
no	O
significant	O
difference	O
was	O
observed	O
in	O
image	O
noise	O
,	O
the	O
signal-to-noise	O
ratio	O
was	O
significantly	O
higher	O
with	O
FIRST	B-P
(	O
18.4	O
vs.	O
16.6	O
,	O
p	O
=	O
0.0066	O
)	O
.	O

FIRST	B-P
allowed	O
28	O
%	O
dose	O
reduction	O
while	O
improving	O
image	O
quality	O
.	O

Dynamic	O
and	O
steady-state	O
oxygen	O
-	O
dependent	O
lung	B-P
relaxometry	I-P
using	O
inversion	B-P
recovery	I-P
ultra-fast	I-P
steady-state	I-P
free	I-P
precession	I-P
imaging	I-P
at	O
1.5	O
T.	O
To	O
demonstrate	O
the	O
feasibility	O
of	O
oxygen	O
-	O
dependent	O
relaxometry	O
in	O
human	O
lung	O
using	O
an	O
inversion	O
recovery	O
ultra-fast	O
steady-state	O
free	O
precession	O
(	O
IR-ufSSFP	O
)	O
technique	O
.	O

Electrocardiogram-triggered	B-P
pulmonary	I-P
relaxometry	I-P
with	O
IR-ufSSFP	B-P
was	O
performed	O
in	O
7	O
healthy	O
human	O
subjects	O
at	O
1.5	O
T.	O
The	O
data	O
were	O
acquired	O
under	O
both	O
normoxic	O
and	O
hyperoxic	O
conditions	O
.	O

In	O
a	O
single	O
breath	O
-	O
hold	O
of	O
less	O
than	O
9	O
seconds	O
,	O
30	O
transient	O
state	O
IR-ufSSFP	O
images	O
were	O
acquired	O
,	O
yielding	O
longitudinal	B-P
(	I-P
T1	I-P
)	I-P
and	O
transversal	B-P
(	I-P
T2	I-P
)	I-P
relaxometry	I-P
parameter	O
maps	O
using	O
voxel	O
-wise	O
nonlinear	O
fitting	O
.	O

Possible	O
spatial	O
misalignments	O
between	O
consecutive	O
IR-ufSSFP	B-P
parameter	O
maps	O
were	O
corrected	O
using	O
elastic	O
image	O
registration	O
.	O

Furthermore	O
,	O
dynamic	O
relaxometry	B-P
oxygen	O
wash-in	B-P
and	O
wash-out	B-P
scans	I-P
were	O
performed	O
in	O
one	O
volunteer	O
.	O

From	O
this	O
,	O
T1	O
-related	O
wash-in	O
and	O
wash-out	O
time	O
constants	O
(	O
τwi	O
,	O
τwo	O
)	O
were	O
calculated	O
voxel	O
-wise	O
on	O
registered	O
maps	O
using	O
an	O
exponential	O
fitting	O
model	O
.	O

For	O
healthy	O
lung	O
,	O
observed	O
T1	O
values	O
were	O
1399	O
±	O
77	O
and	O
1290	O
±	O
76	O
ms	O
under	O
normoxic	O
and	O
hyperoxic	O
conditions	O
,	O
respectively	O
.	O

Oxygen	O
-related	O
reduction	O
of	O
T1	O
was	O
statistically	O
significant	O
in	O
every	O
volunteer	O
.	O

No	O
statistically	O
significant	O
change	O
,	O
however	O
,	O
was	O
observed	O
in	O
T2	O
,	O
with	O
normoxic	O
and	O
hyperoxic	O
T2	O
values	O
of	O
55	O
±	O
16	O
and	O
56	O
±	O
17	O
ms	O
,	O
respectively	O
.	O

The	O
observed	O
average	O
τwi	O
was	O
87.0	O
±	O
28.7	O
seconds	O
,	O
whereas	O
the	O
average	O
τwo	O
was	O
73.5	O
±	O
21.6	O
seconds	O
.	O

IR-ufSSFP	B-P
allows	O
fast	O
,	O
steady-state	O
,	O
and	O
dynamic	O
oxygen	O
-	O
dependent	O
relaxometry	B-P
of	O
the	O
human	O
lung	O
.	O

Magn	O
Reson	O
Med	O
,	O
2017	O
.	O

©	O
2017	O
International	O
Society	O
for	O
Magnetic	O
Resonance	O
in	O
Medicine	O
.	O

An	O
amperometric	O
H2O2	O
biosensor	O
based	O
on	O
hemoglobin	O
nanoparticles	O
immobilized	O
onto	O
a	O
gold	O
electrode	O
.	O

The	O
nanoparticles	O
(	O
NPs	O
)	O
of	O
hemoglobin	O
(	O
Hb	O
)	O
were	O
prepared	O
by	O
desolvation	O
method	O
and	O
characterized	O
by	O
transmission	B-P
electron	I-P
microscopy	I-P
(	O
TEM	B-P
)	O
,	O
ultraviolet	B-P
(	I-P
UV	I-P
)	I-P
spectroscopy	I-P
and	O
Fourier-transform	O
infrared	O
spectroscopy	O
(	O
FTIR	O
)	O
.	O

An	O
amperometric	O
H2O2	O
biosensor	O
was	O
constructed	O
by	O
immobilizing	O
Hb	O
NPs	O
covalently	O
onto	O
a	O
polycrystalline	O
Au	O
electrode	O
(	O
Au	O
E	O
)	O
.	O

Hb	O
NPs	O
/	O
Au	O
E	O
was	O
characterized	O
by	O
scanning	B-P
electron	I-P
microscopy	I-P
(	O
SEM	B-P
)	O
,	O
cyclic	O
voltammetry	O
(	O
CV	O
)	O
and	O
electrochemical	B-P
impedance	I-P
spectra	I-P
(	O
EIS	B-P
)	O
before	O
and	O
after	O
immobilization	O
of	O
Hb	O
NPs	O
.	O

The	O
Hb	O
NPs	O
/	O
Au	O
electrode	O
showed	O
optimum	O
response	O
within	O
2.5s	O
at	O
pH	O
6.5	O
in	O
0.1M	O
sodium	O
phosphate	O
buffer	O
containing	O
100μM	O
H2O2	O
and	O
30⁰C	O
,	O
when	O
operated	O
at	O
-0.2V	O
against	O
Ag/AgCl	O
.	O

The	O
H	O
bN	O
Ps/	O
A	O
uE	O
exhibited	O
Vmax	O
of	O
5.161±0.1	O
μA	O
cm	O
(	O
-2	O
)	O
with	O
Michaelis-Menten	O
constant	O
(	O
Km	O
)	O
of	O
0.1±0.01mM	O
.	O

The	O
biosensor	O
showed	O
lower	O
detection	O
limit	O
(	O
1.0μM	O
)	O
,	O
high	B-P
sensitivity	I-P
(	O
129±0.25μA	O
cm	O
(	O
-2	O
)	O
mM	O
(	O
-1	O
)	O
)	O
and	O
wider	O
linear	O
range	O
(	O
1.0-1200μM	O
)	O
for	O
H2O2	O
as	O
compared	O
to	O
earlier	O
biosensors	O
.	O

The	O
analytical	O
recoveries	O
of	O
added	O
H2O2	O
in	O
serum	O
(	O
0.5μM	O
and1.0μM	O
)	O
were	O
97.77	O
%	O
and	O
98.01	O
%	O
respectively	O
and	O
within	O
and	O
between	O
batch	O
coefficients	O
of	O
variation	O
(	O
CV	O
)	O
were	O
3.16	O
%	O
and	O
3.36	O
%	O
respectively	O
.	O

There	O
was	O
a	O
good	O
correlation	O
between	O
sera	O
H2O2	O
values	O
obtained	O
by	O
standard	O
enzymic	O
colourimetric	B-P
method	I-P
and	O
the	O
present	O
biosensor	O
(	O
R	O
(	O
2	O
)	O
=0.99	O
)	O
.	O

The	O
biosensor	O
measured	O
H2O2	O
level	O
in	O
sera	O
of	O
apparently	O
healthy	O
subjects	O
and	O
persons	O
suffering	O
from	O
diabetes	O
type	O
II	O
.	O

The	O
Hb	O
NPs	O
/	O
Au	O
electrode	O
lost	O
10	O
%	O
of	O
its	O
initial	O
activity	O
after	O
90	O
days	O
of	O
its	O
regular	O
uses	O
,	O
when	O
stored	O
dry	O
at	O
4	O
(	O
o	O
)	O
C	O
.	O

Bispectral	O
pairwise	O
interacting	O
source	O
analysis	O
for	O
identifying	O
systems	O
of	O
cross-frequency	O
interacting	O
brain	O
sources	O
from	O
electroencephalographic	B-P
or	O
magnetoencephalographic	B-P
signals	O
.	O

Brain	O
cognitive	O
functions	O
arise	O
through	O
the	O
coordinated	O
activity	O
of	O
several	O
brain	O
regions	O
,	O
which	O
actually	O
form	O
complex	O
dynamical	O
systems	O
operating	O
at	O
multiple	O
frequencies	O
.	O

These	O
systems	O
often	O
consist	O
of	O
interacting	O
subsystems	O
,	O
whose	O
characterization	O
is	O
of	O
importance	O
for	O
a	O
complete	O
understanding	O
of	O
the	O
brain	O
interaction	O
processes	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
present	O
a	O
technique	O
,	O
namely	O
the	O
bispectral	O
pairwise	O
interacting	O
source	O
analysis	O
(	O
biPISA	O
)	O
,	O
for	O
analyzing	O
systems	O
of	O
cross-frequency	O
interacting	O
brain	O
sources	O
when	O
multichannel	B-P
electroencephalographic	I-P
(	O
EEG	B-P
)	O
or	O
magnetoencephalographic	B-P
(	O
MEG	B-P
)	O
data	O
are	O
available	O
.	O

Specifically	O
,	O
the	O
biPISA	O
makes	O
it	O
possible	O
to	O
identify	O
one	O
or	O
many	O
subsystems	O
of	O
cross-frequency	O
interacting	O
sources	O
by	O
decomposing	O
the	O
antisymmetric	O
components	O
of	O
the	O
cross-bispectra	O
between	O
EEG	B-P
or	O
MEG	B-P
signals	O
,	O
based	O
on	O
the	O
assumption	O
that	O
interactions	O
are	O
pairwise	O
.	O

Thanks	O
to	O
the	O
properties	O
of	O
the	O
antisymmetric	O
components	O
of	O
the	O
cross-bispectra	O
,	O
biPISA	O
is	O
also	O
robust	O
to	O
spurious	O
interactions	O
arising	O
from	O
mixing	O
artifacts	O
,	O
i.e.	O
,	O
volume	O
conduction	O
or	O
field	O
spread	O
,	O
which	O
always	O
affect	O
EEG	B-P
or	O
MEG	B-P
functional	O
connectivity	O
estimates	O
.	O

This	O
method	O
is	O
an	O
extension	O
of	O
the	O
pairwise	O
interacting	O
source	O
analysis	O
(	O
PISA	O
)	O
,	O
which	O
was	O
originally	O
introduced	O
for	O
investigating	O
interactions	O
at	O
the	O
same	O
frequency	O
,	O
to	O
the	O
study	O
of	O
cross-frequency	O
interactions	O
.	O

The	O
effectiveness	O
of	O
this	O
approach	O
is	O
demonstrated	O
in	O
simulations	O
for	O
up	O
to	O
three	O
interacting	O
source	O
pairs	O
and	O
for	O
real	O
MEG	B-P
recordings	O
of	O
spontaneous	O
brain	O
activity	O
.	O

Simulations	O
show	O
that	O
the	O
performances	O
of	O
biPISA	O
in	O
estimating	O
the	O
phase	O
difference	O
between	O
the	O
interacting	O
sources	O
are	O
affected	O
by	O
the	O
increasing	O
level	O
of	O
noise	O
rather	O
than	O
by	O
the	O
number	O
of	O
the	O
interacting	O
subsystems	O
.	O

The	O
analysis	O
of	O
real	O
MEG	B-P
data	O
reveals	O
an	O
interaction	O
between	O
two	O
pairs	O
of	O
sources	O
of	O
central	O
mu	O
and	O
beta	O
rhythms	O
,	O
localizing	O
in	O
the	O
proximity	O
of	O
the	O
left	O
and	O
right	O
central	O
sulci	O
.	O

Atypical	O
microglial	O
response	O
to	O
biodiesel	O
exhaust	O
in	O
healthy	O
and	O
hypertensive	O
rats	O
.	O

Accumulating	O
evidence	O
suggests	O
a	O
deleterious	O
role	O
for	O
urban	O
air	O
pollution	O
in	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
diseases	O
and	O
neurodevelopmental	O
disorders	O
.	O

Microglia	O
,	O
the	O
resident	O
innate	O
immune	O
cells	O
and	O
sentinels	O
in	O
the	O
brain	O
,	O
are	O
a	O
common	O
source	O
of	O
neuroinflammation	O
and	O
are	O
implicated	O
in	O
air	O
pollution	O
-	O
induced	O
CNS	O
effects	O
.	O

While	O
renewable	O
energy	O
,	O
such	O
as	O
soy-based	O
biofuel	O
,	O
is	O
of	O
increasing	O
public	O
interest	O
,	O
there	O
is	O
little	O
information	O
on	O
how	O
soy	O
biofuel	O
may	O
affect	O
the	O
brain	O
,	O
especially	O
in	O
people	O
with	O
preexisting	O
disease	O
conditions	O
.	O

To	O
address	O
this	O
,	O
male	O
spontaneously	O
hypertensive	O
rats	O
(	O
SHR	O
)	O
and	O
normotensive	O
Wistar	O
Kyoto	O
(	O
WKY	O
)	O
rats	O
were	O
exposed	O
to	O
100	O
%	O
Soy-based	O
Biodiesel	O
Exhaust	O
(	O
100SBDE	O
;	O
0	O
,	O
50	O
,	O
150	O
and	O
500μg/m	O
(	O
3	O
)	O
)	O
by	O
inhalation	O
,	O
4h/	O
day	O
for	O
4	O
weeks	O
(	O
5	O
days	O
/	O
week	O
)	O
.	O

Ionized	O
calcium-binding	O
adapter	O
molecule-1	O
(	O
IBA-1	O
)	O
staining	B-P
of	O
microglia	O
in	O
the	O
substantia	O
nigra	O
revealed	O
significant	O
changes	O
in	O
morphology	O
with	O
100SBDE	O
exposure	O
in	O
rats	O
from	O
both	O
genotypes	O
,	O
where	O
SHR	O
were	O
less	O
sensitive	O
.	O

Aconitase	O
activity	O
was	O
inhibited	O
in	O
the	O
frontal	O
cortex	O
and	O
cerebellum	O
of	O
WKY	O
rats	O
exposed	O
to	O
100SBDE	O
.	O

No	O
consistent	O
changes	O
occurred	O
in	O
pro-inflammatory	O
cytokine	O
expression	O
,	O
nitrated	O
protein	O
,	O
or	O
arginase1	O
expression	O
in	O
brain	O
regions	O
from	O
either	O
rat	O
strain	O
exposed	O
to	O
100SBDE	O
.	O

However	O
,	O
while	O
IBA-1	O
mRNA	O
expression	O
was	O
not	O
modified	O
,	O
CX3CR1	O
mRNA	O
expression	O
was	O
lower	O
in	O
the	O
striatum	O
of	O
100SBDE	O
exposed	O
rats	O
regardless	O
of	O
genotype	O
,	O
suggesting	O
a	O
downregulation	O
of	O
the	O
fractalkine	O
receptor	O
on	O
microglia	O
in	O
this	O
brain	O
region	O
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
while	O
microglia	O
are	O
detecting	O
and	O
responding	O
to	O
100SBDE	O
exposure	O
with	O
changes	O
in	O
morphology	O
,	O
there	O
is	O
reduced	O
expression	O
of	O
CX3CR1	O
regardless	O
of	O
genetic	O
background	O
and	O
the	O
activation	O
response	O
is	O
atypical	O
without	O
traditional	O
inflammatory	O
markers	O
of	O
M1	O
or	O
M2	O
activation	O
in	O
the	O
brain	O
.	O

Photocatalytic	O
and	O
antibacterial	O
response	O
of	O
biosynthesized	O
gold	O
nanoparticles	O
.	O

Increase	O
in	O
the	O
bacterial	O
resistance	O
to	O
available	O
antibiotics	O
and	O
water	O
contamination	O
by	O
different	O
toxic	O
organic	O
dyes	O
are	O
both	O
severe	O
problems	O
throughout	O
the	O
world	O
.	O

To	O
overcome	O
these	O
concerns	O
,	O
new	O
methodologies	O
including	O
synthesis	O
of	O
nontoxic	O
,	O
human	O
friendly	O
and	O
efficient	O
nanoparticles	O
is	O
required	O
.	O

These	O
nanoparticles	O
not	O
even	O
inhibit	O
the	O
growth	O
of	O
microorganisms	O
but	O
are	O
also	O
effective	O
in	O
the	O
degradation	O
of	O
toxic	O
organics	O
in	O
waste	O
water	O
thus	O
providing	O
a	O
clean	O
and	O
human	O
friendly	O
environment	O
.	O

The	O
use	O
of	O
plants	O
extracts	O
to	O
synthesize	O
and	O
stabilize	O
noble	O
metal	O
nanoparticles	O
have	O
been	O
considered	O
as	O
safe	O
,	O
cost-effective	O
,	O
eco-benign	O
and	O
green	O
approach	O
nowadays	O
.	O

In	O
the	O
present	O
study	O
,	O
Longan	O
fruit	O
juice	O
proficiently	O
reduced	O
ionic	O
gold	O
(	O
Au	O
(	O
+3	O
)	O
)	O
to	O
gold	O
nanoparticles	O
(	O
AuNPs	O
)	O
as	O
well	O
as	O
mediated	O
the	O
stabilization	O
of	O
AuNPs	O
.	O

The	O
antibacterial	O
activity	O
of	O
AuNPs	O
was	O
carried	O
out	O
against	O
both	O
gram	O
positive	O
and	O
gram	O
negative	O
bacteria	O
using	O
agar	B-P
well	I-P
diffusion	I-P
method	I-P
,	O
followed	O
by	O
the	O
determination	O
of	O
Minimum	B-P
inhibitory	I-P
concentration	I-P
(	O
MIC	B-P
)	O
values	O
.	O

AuNPs	O
were	O
found	O
to	O
have	O
significant	O
antibacterial	O
activity	O
against	O
Escherichia	O
coli	O
with	O
MIC	B-P
values	O
of	O
75μg/ml	O
while	O
outstanding	O
MIC	B-P
values	O
of	O
50μg/ml	O
against	O
Staphylococcus	O
areous	O
and	O
Basilus	O
subtilus	O
.	O

AuNPs	O
revealed	O
significant	O
photocatalytic	O
degradation	O
(	O
76	O
%	O
)	O
of	O
methylene	O
blue	O
in	O
time	O
period	O
of	O
55	O
min	O
,	O
indicating	O
the	O
effective	O
photocatalytic	O
property	O
of	O
biosynthesized	O
AuNPs	O
(	O
K=0.29/min	O
,	O
r	O
(	O
2	O
)	O
=0.95	O
)	O
.	O

The	O
considerable	O
antibacterial	O
and	O
photocatalytic	O
activities	O
of	O
the	O
photosynthesized	O
AuNPs	O
can	O
be	O
attributed	O
towards	O
their	O
small	O
size	O
,	O
spherical	O
morphology	O
and	O
uniform	O
dispersion	O
.	O

Our	O
finding	O
suggests	O
the	O
possible	O
therapeutic	O
potential	O
of	O
biogenic	O
AuNPs	O
in	O
the	O
development	O
of	O
new	O
antibacterial	O
agents	O
as	O
well	O
as	O
in	O
the	O
development	O
of	O
effective	O
photocatalysts	O
.	O

Encountering	O
``	O
Dropped	O
''	O
Gallstones	O
During	O
Robotic-assisted	O
Laparoscopic	O
Radical	O
Prostatectomy	O
.	O

We	O
describe	O
a	O
case	O
of	O
an	O
unusual	O
finding	O
during	O
robotic-assisted	O
laparoscopic	O
radical	O
prostatectomy	O
and	O
bilateral	O
pelvic	O
lymphadenectomy	O
in	O
a	O
66-year-old	O
man	O
with	O
stage	O
IIb	O
(	O
T2c	O
,	O
N0	O
,	O
M0	O
)	O
prostate	O
adenocarcinoma	O
.	O

During	O
the	O
operation	O
,	O
intraperitoneal	O
examination	O
of	O
the	O
rectovesical	O
pouch	O
revealed	O
calcifications	O
and	O
stones	O
,	O
which	O
were	O
subsequently	O
identified	O
as	O
gallstones	O
.	O

Although	O
these	O
stones	O
were	O
not	O
noted	O
initially	O
on	O
this	O
patient	O
's	O
preoperative	O
multiparametric	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
,	O
a	O
retrospective	O
review	O
demonstrated	O
hypointense	O
foci	O
in	O
the	O
rectovesical	O
pouch	O
.	O

Here	O
,	O
we	O
describe	O
the	O
first	O
reported	O
case	O
of	O
visualization	O
of	O
dropped	O
gallstones	O
on	O
a	O
prostate	B-P
multiparametric	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
and	O
retrieval	O
during	O
robotic	O
prostatectomy	O
.	O

Functional	O
Impairment	O
in	O
Children	O
With	O
Externalizing	O
Behavior	O
Disorders	O
:	O
Psychometric	B-P
Properties	O
of	O
the	O
Weiss	O
Functional	O
Impairment	O
Rating	O
Scale-Parent	O
Report	O
in	O
a	O
German	O
Clinical	O
Sample	O
.	O

To	O
examine	O
the	O
psychometric	B-P
properties	O
of	O
a	O
German	O
adaptation	O
of	O
the	O
Weiss	O
Functional	O
Impairment	O
Rating	O
Scale-Parent	O
Report	O
(	O
WFIRS-P	O
)	O
in	O
a	O
clinical	O
sample	O
of	O
children	O
(	O
4-12	O
years	O
)	O
with	O
externalizing	O
behavior	O
disorders	O
.	O

Data	O
were	O
collected	O
within	O
two	O
clinical	O
trials	O
(	O
N	O
=	O
264	O
)	O
.	O

Factorial	O
validity	O
,	O
reliability	O
,	O
and	O
divergent	O
validity	O
from	O
symptoms	O
of	O
ADHD	O
and	O
oppositional	O
defiant	O
disorder	O
(	O
ODD	O
)	O
were	O
assessed	O
.	O

Confirmatory	O
factor	O
analyses	O
revealed	O
that	O
a	O
bifactor	O
model	O
consistent	O
with	O
the	O
theoretical	O
assumption	O
of	O
a	O
general	O
construct	O
of	O
impairment	O
(	O
total	O
scale	O
)	O
and	O
additional	O
specific	O
factors	O
(	O
subscales	O
)	O
provided	O
satisfactory	O
data	O
fit	O
.	O

Model	O
-based	O
reliability	O
estimates	O
showed	O
that	O
both	O
the	O
general	O
construct	O
and	O
specific	O
factors	O
accounted	O
for	O
item	O
variance	O
.	O

Internal	O
consistencies	O
were	O
>	O
.70	O
,	O
part-whole	O
corrected	O
item-scale	O
correlations	O
mostly	O
>	O
.30	O
.	O

Correlations	O
between	O
the	O
WFIRS-P	O
Scales	O
and	O
ADHD	O
and	O
ODD	O
symptoms	O
were	O
low	O
to	O
moderate	O
.	O

The	O
results	O
support	O
the	O
factorial	O
validity	O
,	O
reliability	O
,	O
and	O
divergent	O
validity	O
of	O
the	O
WFIRS-P	O
.	O

The	O
effects	O
of	O
probiotic	O
and	O
synbiotic	O
supplementation	O
on	O
metabolic	O
syndrome	O
indices	O
in	O
adults	O
at	O
risk	O
of	O
type	O
2	O
diabetes	O
:	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O

The	O
incidence	O
of	O
type	O
2	O
diabetes	O
,	O
cardiovascular	O
diseases	O
,	O
and	O
obesity	O
has	O
been	O
rising	O
dramatically	O
;	O
however	O
,	O
their	O
pathogenesis	O
is	O
particularly	O
intriguing	O
.	O

Recently	O
,	O
dysbiosis	O
of	O
the	O
intestinal	O
microbiota	O
has	O
emerged	O
as	O
a	O
new	O
candidate	O
that	O
may	O
be	O
linked	O
to	O
metabolic	O
diseases	O
.	O

We	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal	O
microbiota	O
by	O
probiotic	O
or	O
synbiotic	O
supplementation	O
may	O
improve	O
metabolic	O
dysfunction	O
and	O
prevent	O
diabetes	O
in	O
prediabetics	O
.	O

In	O
this	O
study	O
,	O
a	O
synthesis	O
and	O
study	O
of	O
synbiotics	O
will	O
be	O
carried	O
out	O
for	O
the	O
first	O
time	O
in	O
Iran	O
.	O

In	O
a	O
randomized	O
triple-blind	O
controlled	O
clinical	O
trial	O
,	O
120	O
adults	O
with	O
impaired	O
glucose	O
tolerance	O
based	O
on	O
the	O
inclusion	O
criteria	O
will	O
be	O
selected	O
by	O
a	O
simple	O
random	O
sampling	O
method	O
and	O
will	O
be	O
randomly	O
allocated	O
to	O
6	O
months	O
of	O
6	O
g/d	O
probiotic	O
,	O
synbiotic	O
or	O
placebo	O
.	O

The	O
fecal	O
abundance	O
of	O
bacteria	O
,	O
blood	O
pressure	O
,	O
height	O
,	O
weight	O
,	O
and	O
waist	O
and	O
hip	O
circumferences	O
will	O
be	O
measured	O
at	O
baseline	O
and	O
following	O
treatment	O
.	O

Also	O
,	O
plasma	B-P
lipid	I-P
profiles	I-P
,	O
HbA1C	O
,	O
fasting	B-P
plasma	I-P
glucose	I-P
,	O
and	O
insulin	O
levels	O
,	O
will	O
be	O
measured	O
and	O
insulin	B-P
resistance	I-P
(	O
HOMA-IR	B-P
)	O
and	O
beta-cell	B-P
function	I-P
(	O
HOMA-B	B-P
)	O
will	O
be	O
calculated	O
at	O
baseline	O
and	O
will	O
be	O
repeated	O
at	O
months	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O

The	O
data	O
will	O
be	O
compared	O
within	O
and	O
between	O
groups	O
using	O
statistical	O
methods	O
.	O

The	O
results	O
of	O
this	O
trial	O
could	O
contribute	O
to	O
the	O
evidence-based	O
clinical	O
guidelines	O
that	O
address	O
gut	O
microbiota	O
manipulation	O
to	O
maximize	O
health	O
benefits	O
in	O
prevention	O
and	O
management	O
of	O
metabolic	O
syndrome	O
in	O
prediabetes	O
.	O

Iranian	O
Registry	O
of	O
Clinical	O
Trials	O
:	O
IRCT201511032321N2	O
.	O

Registered	O
on	O
27	O
February	O
2016	O
.	O

Pupillary	O
response	O
abnormalities	O
in	O
depressive	O
disorders	O
.	O

Depressive	O
disorders	O
lack	O
objective	O
physiological	O
measurements	O
to	O
characterize	O
the	O
affected	O
population	O
and	O
facilitate	O
study	O
of	O
relevant	O
mechanisms	O
.	O

The	O
melanopsin	O
-	O
mediated	O
light	O
signaling	O
pathway	O
may	O
contribute	O
to	O
seasonal	O
variation	O
and	O
can	O
be	O
measured	O
non-invasively	O
by	O
pupillometry	B-P
.	O

We	O
prospectively	O
studied	O
changes	O
in	O
melanopsin	O
-	O
mediated	O
pupillary	O
constriction	O
in	O
19	O
participants	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
and	O
10	O
control	O
across	O
the	O
summer	O
and	O
winter	O
solstices	O
.	O

The	O
melanopsin	O
-	O
mediated	O
response	O
,	O
as	O
measured	O
by	O
the	O
pupil	O
's	O
sustained	O
constriction	O
six	O
s	O
after	O
a	O
high	O
intensity	O
blue	O
light	O
stimulus	O
,	O
was	O
marginally	O
attenuated	O
in	O
those	O
with	O
MDD	O
relative	O
to	O
controls	O
(	O
p	O
=0.071	O
)	O
.	O

The	O
participants	O
with	O
MDD	O
unexpectedly	O
showed	O
a	O
significantly	O
reduced	O
transient	O
pupillary	O
response	O
to	O
low	O
intensity	O
red	O
(	O
p	O
=0.011	O
)	O
and	O
blue	O
light	O
(	O
p	O
=0.013	O
)	O
,	O
but	O
not	O
high	O
intensity	O
red	O
and	O
blue	O
light	O
.	O

Sustained	O
pupillary	O
constriction	O
in	O
response	O
to	O
high	O
intensity	O
blue	O
light	O
was	O
more	O
pronounced	O
with	O
increasing	O
daylight	O
hours	O
(	O
p	O
=0.037	O
)	O
and	O
was	O
more	O
strongly	O
related	O
to	O
objectively	O
measured	O
versus	O
estimated	O
light	O
exposure	O
.	O

Melanopsin	O
-	O
mediated	O
impairments	O
in	O
pupil	O
response	O
may	O
serve	O
as	O
a	O
biological	O
marker	O
for	O
vulnerability	O
to	O
depression	O
in	O
low	O
light	O
conditions	O
.	O

Assessment	O
of	O
these	O
and	O
other	O
responses	O
to	O
light	O
stimuli	O
,	O
such	O
as	O
response	O
to	O
low	O
intensity	O
light	O
,	O
may	O
be	O
useful	O
for	O
the	O
study	O
of	O
the	O
neurobiology	O
of	O
MDD	O
and	O
related	O
mood	O
disorders	O
.	O

Trivalent	O
f-elements	O
in	O
human	O
saliva	O
:	O
a	O
comprehensive	O
speciation	O
study	O
by	O
time-resolved	B-P
laser-induced	I-P
fluorescence	I-P
spectroscopy	I-P
and	O
thermodynamic	B-P
calculations	I-P
.	O

In	O
the	O
case	O
of	O
oral	O
ingestion	O
of	O
radioactive	O
contaminants	O
,	O
the	O
first	O
contact	O
medium	O
is	O
saliva	O
in	O
the	O
mouth	O
.	O

To	O
gain	O
a	O
first	O
insight	O
into	O
the	O
interaction	O
of	O
radioactive	O
contaminants	O
in	O
human	O
saliva	O
,	O
the	O
speciation	O
of	O
curium	O
(	O
Cm	O
(	O
iii	O
)	O
)	O
and	O
europium	O
(	O
Eu	O
(	O
iii	O
)	O
)	O
,	O
i.e.	O
,	O
trivalent	O
f-elements	O
,	O
was	O
investigated	O
in	O
different	O
salivary	O
media	O
with	O
time-resolved	B-P
laser-induced	I-P
fluorescence	I-P
spectroscopy	I-P
(	O
TRLFS	B-P
)	O
.	O

The	O
results	O
indicate	O
that	O
these	O
metal	O
cations	O
are	O
primarily	O
complexed	O
with	O
carbonates	O
and	O
phosphates	O
,	O
forming	O
ternary	O
complexes	O
with	O
a	O
possible	O
stoichiometry	O
of	O
1	O
:	O
1	O
:	O
2	O
(	O
M	O
(	O
iii	O
)	O
:	O
carbonate	O
:	O
phosphate	O
)	O
.	O

For	O
charge	O
compensation	O
,	O
calcium	O
is	O
also	O
involved	O
in	O
these	O
ternary	O
complexes	O
.	O

In	O
addition	O
to	O
these	O
inorganic	O
components	O
,	O
organic	O
substances	O
,	O
namely	O
α-amylase	O
,	O
show	O
a	O
significant	O
contribution	O
to	O
the	O
speciation	O
of	O
the	O
trivalent	O
f-elements	O
in	O
saliva	O
.	O

This	O
protein	O
is	O
the	O
major	O
enzyme	O
in	O
saliva	O
and	O
catalyzes	O
the	O
hydrolysis	O
of	O
polysaccharides	O
.	O

In	O
this	O
context	O
,	O
the	O
effect	O
of	O
Eu	O
(	O
iii	O
)	O
on	O
the	O
activity	O
of	O
α-amylase	O
was	O
investigated	O
to	O
reveal	O
the	O
potential	O
implication	O
of	O
these	O
metal	O
cations	O
for	O
the	O
in	O
vivo	O
functions	O
of	O
saliva	O
.	O

The	O
results	O
indicate	O
that	O
the	O
enzyme	O
activity	O
is	O
strongly	O
inhibited	O
by	O
the	O
presence	O
of	O
Eu	O
(	O
iii	O
)	O
,	O
which	O
is	O
suppressed	O
by	O
an	O
excess	O
of	O
calcium	O
.	O

Synthesis	O
and	O
Photophysical	O
Properties	O
of	O
Fluorescence	O
Molecular	O
Probe	O
for	O
Turn-ON-Type	B-P
Detection	I-P
of	O
Cytosine	O
Bulge	O
DNA	O
.	O

A	O
fluorescent	O
molecule	O
DANP	O
that	O
binds	O
to	O
cytosine	O
bulge	O
DNA	O
and	O
emits	O
characteristic	O
fluorescence	O
was	O
conjugated	O
to	O
pyrene	O
to	O
give	O
a	O
new	O
fluorescence	O
probe	O
PyDANP	O
.	O

Temperature	O
-	O
and	O
solvent	O
-dependent	O
absorption	O
changes	O
showed	O
that	O
DANP	O
and	O
pyrene	O
chromophores	O
stacked	O
at	O
room	O
temperature	O
in	O
an	O
aqueous	O
buffer	O
solution	O
and	O
quenched	B-P
fluorescence	I-P
.	O

Upon	O
binding	O
of	O
DANP	O
moiety	O
in	O
PyDANP	O
to	O
cytosine	O
bulge	O
DNA	O
,	O
the	O
fluorescence	O
from	O
DANP	O
bound	O
to	O
C-bulge	O
increased	O
by	O
∼12-fold	O
,	O
showing	O
that	O
PyDANP	O
is	O
a	O
turn-ON	B-P
probe	I-P
for	I-P
the	I-P
detection	I-P
of	O
C-bulge	O
DNA	O
.	O

Osthole	O
Protects	O
Bone	O
Marrow-Derived	O
Neural	O
Stem	O
Cells	O
from	O
Oxidative	O
Damage	O
through	O
PI3K/Akt-1	O
Pathway	O
.	O

In	O
recent	O
years	O
,	O
neural	O
stem	O
cell	O
(	O
NSC	O
)	O
transplantation	O
has	O
been	O
widely	O
explored	O
as	O
a	O
treatment	O
for	O
neurodegenerative	O
diseases	O
.	O

NSCs	O
are	O
special	O
cells	O
that	O
have	O
some	O
capacity	O
for	O
self-renewal	O
and	O
the	O
potential	O
to	O
differentiate	O
into	O
multiple	O
cell	O
types	O
.	O

However	O
,	O
the	O
inflammatory	O
environment	O
of	O
diseased	O
tissue	O
is	O
not	O
conducive	O
to	O
the	O
survival	O
of	O
transplanted	O
cells	O
.	O

Osthole	O
(	O
Ost	O
)	O
is	O
a	O
principal	O
bioactive	O
component	O
of	O
Fructus	O
Cnidii	O
,	O
Radix	O
Angelicae	O
Pubescentis	O
and	O
other	O
traditional	O
Chinese	O
medicines	O
.	O

Ost	O
has	O
a	O
wide	O
range	O
of	O
pharmacological	O
activities	O
,	O
such	O
as	O
anti-inflammation	O
,	O
immunomodulation	O
,	O
and	O
neuroprotection	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
assessed	O
the	O
protective	O
effects	O
of	O
Ost	O
on	O
bone	O
marrow-derived	O
-	O
NSCs	O
(	O
BM	O
-	O
NSCs	O
)	O
against	O
injury	O
induced	O
by	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

BM	O
-	O
NSCs	O
were	O
pre	O
-	O
treated	O
with	O
different	O
doses	O
of	O
Ost	O
and	O
treated	O
with	O
H2O2	O
.	O

The	O
cell	O
counting	O
kit-8	O
(	O
CCK-8	O
)	O
method	O
and	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
leakage	B-P
assay	I-P
were	O
used	O
to	O
determine	O
cell	O
viability	O
.	O

Using	O
the	O
TUNEL	O
assay	O
and	O
RT-PCR	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
Ost	O
on	O
cell	O
apoptosis	O
.	O

The	O
results	O
showed	O
that	O
Ost	O
had	O
protective	O
effects	O
against	O
H2O2	O
-	O
induced	O
cell	O
damage	O
,	O
and	O
the	O
number	B-P
of	I-P
apoptotic	O
cells	O
was	O
significantly	O
decreased	O
in	O
the	O
Ost	O
pre	O
-	O
treated	O
groups	O
compared	O
to	O
the	O
H2O2	O
group	O
.	O

The	O
expression	O
ratio	O
of	O
Bax/Bcl-2	O
mRNA	O
was	O
also	O
decreased	O
.	O

Furthermore	O
,	O
western	O
blotting	O
was	O
used	O
to	O
analyze	B-P
levels	O
of	O
proteins	O
related	O
to	O
PI3K/Akt-1	O
signaling	O
pathway	O
,	O
and	O
results	O
indicated	O
that	O
ost	O
can	O
increase	O
p-Akt	O
and	O
PI3K	O
.	O

Our	O
findings	O
suggested	O
that	O
Ost	O
protects	O
BM	O
-	O
NSCs	O
against	O
oxidative	O
stress	O
injury	O
,	O
and	O
it	O
can	O
be	O
used	O
to	O
improve	O
the	O
inflammatory	O
environment	O
of	O
neurodegenerative	O
diseases	O
so	O
and	O
promote	O
the	O
survival	O
rate	O
of	O
transplanted	O
NSCs	O
.	O

Co-ChIP	B-P
enables	O
genome-wide	O
mapping	O
of	O
histone	O
mark	O
co-occurrence	O
at	O
single-molecule	O
resolution	O
.	O

Histone	O
modifications	O
play	O
an	O
important	O
role	O
in	O
chromatin	O
organization	O
and	O
transcriptional	O
regulation	O
,	O
but	O
despite	O
the	O
large	O
amount	O
of	O
genome-wide	O
histone	O
modification	O
data	O
collected	O
in	O
different	O
cells	O
and	O
tissues	O
,	O
little	O
is	O
known	O
about	O
co-occurrence	O
of	O
modifications	O
on	O
the	O
same	O
nucleosome	O
.	O

Here	O
we	O
present	O
a	O
genome-wide	O
quantitative	O
method	O
for	O
combinatorial	O
indexed	O
chromatin	B-P
immunoprecipitation	I-P
(	O
co-ChIP	B-P
)	O
to	O
characterize	O
co-occurrence	O
of	O
histone	O
modifications	O
on	O
nucleosomes	O
.	O

Using	O
co-ChIP	B-P
,	O
we	O
study	O
the	O
genome-wide	O
co-occurrence	O
of	O
14	O
chromatin	O
marks	O
(	O
70	O
pairwise	O
combinations	O
)	O
,	O
and	O
find	O
previously	O
undescribed	O
co-occurrence	O
patterns	O
,	O
including	O
the	O
co-occurrence	O
of	O
H3K9me1	O
and	O
H3K27ac	O
in	O
super-enhancers	O
.	O

Finally	O
,	O
we	O
apply	O
co-ChIP	B-P
to	O
measure	O
the	O
distribution	O
of	O
the	O
bivalent	O
H3K4me3	O
-	O
H3K27me3	O
domains	O
in	O
two	O
distinct	O
mouse	O
embryonic	O
stem	O
cell	O
(	O
mESC	O
)	O
states	O
and	O
in	O
four	O
adult	O
tissues	O
.	O

We	O
observe	O
dynamic	O
changes	O
in	O
5,786	O
regions	O
and	O
discover	O
both	O
loss	O
and	O
de	O
novo	O
gain	O
of	O
bivalency	O
in	O
key	O
tissue-specific	O
regulatory	O
genes	O
,	O
suggesting	O
a	O
functional	O
role	O
for	O
bivalent	O
domains	O
during	O
different	O
stages	O
of	O
development	O
.	O

These	O
results	O
show	O
that	O
co-ChIP	B-P
can	O
reveal	O
the	O
complex	O
interactions	O
between	O
histone	O
modifications	O
.	O

Association	O
of	O
leukemia	O
inhibitory	O
factor	O
gene	O
polymorphism	O
and	O
in	O
vitro	O
fertilization	O
outcome	O
in	O
a	O
population	O
in	O
northern	O
Iran	O
.	O

Several	O
studies	O
have	O
been	O
demonstrated	O
that	O
endometrial	O
leukemia	O
inhibitory	O
factor	O
(	O
LIF	O
)	O
is	O
important	O
in	O
embryo	O
implantation	O
.	O

LIF	O
is	O
a	O
secreted	O
glycoprotein	O
with	O
a	O
variety	O
of	O
biological	O
functions	O
including	O
stimulation	O
of	O
cell	O
proliferation	O
,	O
differentiation	O
and	O
survival	O
that	O
are	O
all	O
essential	O
for	O
blastocyete	O
development	O
and	O
implantation	O
.	O

The	O
LIF	O
receptor	O
activates	O
several	O
signaling	O
pathways	O
in	O
diverse	O
cell	O
types	O
,	O
including	O
Jak/STAT	O
,	O
MAPK	O
and	O
PI3-kinase	O
pathways	O
in	O
the	O
endometrium	O
of	O
fertile	O
woman	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
initial	O
lower	O
expression	O
of	O
LIF	O
in	O
proliferative	O
phase	O
may	O
be	O
one	O
of	O
the	O
causes	O
for	O
multiple	O
failure	O
of	O
implantation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
association	O
between	O
maternal	O
genotype	O
of	O
SNP	O
3951C/T	O
LIF	O
and	O
in	O
vitro	O
fertilization	O
and	O
embryo	O
transfer	O
(	O
IVF	O
-	O
ET	O
)	O
outcome	O
in	O
infertile	O
women	O
.	O

This	O
case-control	O
study	O
was	O
comprised	O
of	O
infertile	O
patients	O
(	O
n=70	O
)	O
and	O
women	O
having	O
one	O
healthy	O
child	O
as	O
controls	O
(	O
n=73	O
)	O
.	O

Genotyping	B-P
for	O
SNP-3951C/T	O
was	O
performed	O
by	O
PCR/RFLP	B-P
.	O

Allele	O
and	O
genotype	O
distribution	O
did	O
not	O
differ	O
significantly	O
between	O
patients	O
and	O
controls	O
(	O
P	O
>	O
0.05	O
)	O
.	O

The	O
LIF	O
genotype	O
frequencies	O
amongst	O
the	O
70	O
cases	O
were	O
C/C	O
=40	O
%	O
,	O
C/T	O
=52.8	O
%	O
and	O
T/T	O
=7.2	O
%	O
;	O
the	O
C	O
and	O
T	O
allele	O
frequencies	O
were	O
66	O
%	O
and	O
34	O
%	O
,	O
respectively	O
.	O

The	O
LIF	O
genotype	O
frequencies	O
amongst	O
the	O
73	O
controls	O
were	O
C/C	O
=45.20	O
%	O
,	O
C/T	O
=50.70	O
%	O
and	O
T/T	O
=4.1	O
%	O
;	O
the	O
C	O
and	O
T	O
allele	O
frequencies	O
were	O
70	O
%	O
and	O
30	O
%	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
this	O
study	O
indicate	O
that	O
SNP	O
3951C/T	O
of	O
LIF	O
may	O
not	O
be	O
associated	O
with	O
IVF	O
-	O
ET	O
outcome	O
in	O
this	O
population	O
.	O

Although	O
more	O
studies	O
should	O
be	O
considered	O
with	O
larger	O
number	O
of	O
patients	O
and	O
control	O
subjects	O
to	O
confirm	O
our	O
results	O
.	O

Accuracy	O
of	O
FDG-PET/CT	B-P
for	O
Detection	O
of	O
Incidental	O
Pre-Malignant	O
and	O
Malignant	O
Colonic	O
Lesions	O
-	O
Correlation	O
with	O
Colonoscopic	B-P
and	O
Histopathologic	O
Findings	O
.	O

We	O
evaluated	O
all	O
PET/CTs	B-P
acquired	O
for	O
patients	O
without	O
a	O
primary	O
diagnosis	O
of	O
colorectal	O
cancer	O
,	O
and	O
compared	O
results	O
for	O
those	O
who	O
had	O
subsequent	O
colonoscopy	B-P
within	O
6	O
months	O
,	O
to	O
assess	O
the	O
accuracy	O
of	O
FDG	B-P
PET/CT	I-P
for	O
detection	O
of	O
incidental	O
pre-malignant	O
polyps	O
and	O
malignant	O
colon	O
cancers	O
.	O

Medical	O
records	O
of	O
9,545	O
patients	O
who	O
underwent	O
F-18	O
FDG	O
PET/CT	O
studies	O
over	O
3.5	O
years	O
were	O
retrospectively	O
reviewed	O
.	O

Due	O
to	O
pre-existing	O
diagnosis	O
of	O
colorectal	O
cancer	O
,	O
818	O
patients	O
were	O
excluded	O
.	O

Of	O
the	O
remainder	O
,	O
157	O
patients	O
had	O
colonoscopy	B-P
within	O
6	O
months	O
(	O
79	O
males	O
;	O
mean	O
age	O
61	O
)	O
.	O

We	O
divided	O
the	O
colon	O
into	O
4	O
regions	O
and	O
compared	O
PET/CT	B-P
results	O
for	O
each	O
region	O
with	O
colonoscopy	B-P
and	O
histopathologic	O
findings	O
.	O

True	O
positive	O
lesions	O
included	O
colorectal	O
cancer	O
,	O
villous	O
adenoma	O
,	O
tubulovillous	O
adenoma	O
,	O
tubular	O
adenoma	O
and	O
serrated	O
hyperplastic	O
polyp	O
/	O
hyperplastic	O
polyposis	O
.	O

Of	O
157	O
patients	O
,	O
44	O
had	O
incidental	O
colonic	O
uptake	O
on	O
PET/CT	B-P
(	O
28	O
%	O
)	O
.	O

Of	O
those	O
,	O
25	O
had	O
true	O
positive	O
(	O
TP	O
)	O
uptake	O
,	O
yielding	O
a	O
48	O
%	O
positive	O
predictive	O
value	O
(	O
PPV	O
)	O
;	O
9	O
%	O
(	O
4/44	O
)	O
were	O
adenocarcinoma	O
.	O

There	O
were	O
23	O
false	O
positive	O
(	O
FP	O
)	O
lesions	O
of	O
which	O
4	O
were	O
hyperplastic	O
polyps	O
,	O
one	O
was	O
a	O
juvenile	O
polyp	O
and	O
7	O
were	O
explained	O
by	O
diverticulitis	O
.	O

Fifty	O
eight	O
patients	O
had	O
false	O
negative	O
PET	B-P
scans	I-P
but	O
colonoscopy	B-P
revealed	O
true	O
pre-malignant	O
and	O
malignant	O
pathology	O
,	O
yielding	O
23	O
%	O
sensitivity	O
.	O

The	O
specificity	O
,	O
negative	O
predictive	O
value	O
(	O
NPV	O
)	O
and	O
accuracy	O
were	O
96	O
%	O
,	O
90	O
%	O
and	O
87	O
%	O
,	O
respectively	O
.	O

The	O
average	O
SUVmax	O
values	O
of	O
TP	O
,	O
FP	O
and	O
FN	O
lesions	O
were	O
7.25	O
,	O
6.11	O
and	O
2.76	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
difference	O
between	O
SUVmax	O
of	O
TP	O
lesions	O
and	O
FP	O
lesions	O
(	O
p	O
>	O
0.95	O
)	O
but	O
significantly	O
higher	O
than	O
in	O
FN	O
lesions	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
average	O
size	O
(	O
by	O
histopathology	O
and	O
colonoscopy	B-P
)	O
of	O
TP	O
lesion	O
s	O
was	O
18.1	O
mm	O
,	O
statistically	O
different	O
from	O
that	O
of	O
FN	O
lesions	O
which	O
was	O
5.9	O
mm	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Fifty-one	O
percent	O
of	O
FN	O
lesion	O
s	O
were	O
smaller	O
than	O
5	O
mm	O
(	O
29/57	O
)	O
and	O
88	O
%	O
smaller	O
than	O
10	O
mm	O
(	O
50/57	O
)	O
.	O

The	O
high	O
positive	O
predictive	O
value	O
of	O
incidental	O
focal	O
colonic	O
FDG	O
uptake	O
of	O
48	O
%	O
for	O
colonic	O
neoplasia	O
suggests	O
that	O
colonoscopy	B-P
follow-up	O
is	O
warranted	O
with	O
this	O
finding	O
.	O

We	O
observed	O
a	O
low	O
sensitivity	O
of	O
standardly	O
acquired	O
FDG-PET/CT	B-P
for	O
detecting	O
small	O
polyps	O
,	O
especially	O
those	O
less	O
than	O
5	O
mm	O
.	O

Clinicians	O
and	O
radiologists	O
should	O
be	O
aware	O
of	O
the	O
high	O
PPV	O
of	O
focal	O
colonic	O
uptake	O
reflecting	O
pre-malignant	O
and	O
malignant	O
lesion	O
s	O
,	O
and	O
the	O
need	O
for	O
appropriate	O
follow	O
up	O
.	O

Single-Nucleotide	O
Polymorphism	O
rs17611	O
of	O
Complement	O
Component	O
5	O
Shows	O
Association	O
with	O
Ischemic	O
Stroke	O
in	O
Northeast	O
Chinese	O
Population	O
.	O

Complement	O
component	O
5	O
(	O
C5	O
)	O
has	O
been	O
described	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
atherosclerosis	O
and	O
cardiovascular	O
disease	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
whether	O
genetic	O
variation	O
of	O
C5	O
was	O
associated	O
with	O
ischemic	O
stroke	O
(	O
IS	O
)	O
in	O
northeast	O
Chinese	O
population	O
.	O

We	O
used	O
a	O
case-control	O
study	O
involving	O
386	O
IS	O
patients	O
and	O
386	O
non-IS	O
controls	O
from	O
a	O
rural	O
population	O
and	O
determined	O
the	O
genotypes	O
of	O
five	O
polymorphisms	O
(	O
rs12237774	O
,	O
rs17611	O
,	O
rs4837805	O
,	O
rs7026551	O
,	O
and	O
rs1017119	O
)	O
of	O
C5	O
gene	O
by	O
Snapshot	O
single-nucleotide	B-P
polymorphism	I-P
genotyping	I-P
assays	I-P
to	O
assess	O
any	O
links	O
with	O
IS	O
.	O

In	O
univariate	O
analysis	O
,	O
rs17611	O
was	O
significantly	O
associated	O
with	O
IS	O
in	O
the	O
additive	O
model	O
,	O
the	O
dominant	O
model	O
,	O
and	O
recessive	O
model	O
(	O
additive	O
p	O
0.031	O
,	O
dominant	O
p	O
0.034	O
,	O
and	O
recessive	O
p	O
0.027	O
)	O
.	O

After	O
adjustment	O
for	O
Binary	O
Logistic	O
Regression	O
,	O
rs17611	O
polymorphism	O
was	O
still	O
significant	O
in	O
three	O
models	O
(	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.306	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.069-1.595	O
,	O
p-value	O
=	O
0.009	O
in	O
an	O
additive	O
model	O
;	O
OR	O
=	O
1.378	O
,	O
95	O
%	O
CI	O
=	O
1.024-1.856	O
,	O
p-value	O
=	O
0.035	O
in	O
a	O
dominant	O
model	O
;	O
and	O
OR	O
=	O
1.511	O
,	O
95	O
%	O
CI	O
=	O
1.048-2.18	O
,	O
p-value	O
=	O
0.027	O
in	O
a	O
recessive	O
model	O
)	O
.	O

In	O
this	O
sample	O
of	O
patients	O
,	O
genetic	O
variation	O
of	O
rs17611	O
in	O
C5	O
is	O
associated	O
with	O
higher	O
prevalence	O
of	O
IS	O
.	O

Polymer	O
brush	O
-	O
functionalized	O
chitosan	O
hydrogels	O
as	O
antifouling	O
implant	O
coatings	O
.	O

Implantable	O
sensor	O
devices	O
require	O
coatings	O
that	O
efficiently	O
interface	O
with	O
the	O
tissue	O
environment	O
to	O
mediate	O
biochemical	B-P
analysis	I-P
.	O

In	O
this	O
regard	O
,	O
bioinspired	O
polymer	O
hydrogels	O
offer	O
an	O
attractive	O
and	O
abundant	O
source	O
of	O
coating	O
materials	O
.	O

However	O
,	O
upon	O
implantation	O
these	O
materials	O
generally	O
elicit	O
inflammation	O
and	O
the	O
foreign	O
body	O
reaction	O
as	O
a	O
consequence	O
of	O
protein	O
fouling	O
on	O
their	O
surface	O
and	O
concomitant	O
poor	O
hemocompatibility	O
.	O

In	O
this	O
report	O
we	O
investigate	O
a	O
strategy	O
to	O
endow	O
chitosan	O
hydrogel	O
coatings	O
with	O
antifouling	O
properties	O
by	O
the	O
grafting	O
of	O
polymer	O
brushes	O
in	O
a	O
``	O
grafting-from	O
``	O
approach	O
.	O

Chitosan	O
coatings	O
were	O
functionalized	O
with	O
polymer	O
brushes	O
of	O
oligo	O
(	O
ethylene	O
glycol	O
)	O
methyl	O
ether	O
methacrylate	O
and	O
2-hydroxyethyl	O
methacrylate	O
using	O
photoinduced	O
single	O
electron	O
transfer	O
living	O
radical	O
polymerization	O
and	O
the	O
surfaces	O
were	O
thoroughly	O
characterized	O
by	O
XPS	B-P
,	O
AFM	B-P
,	O
water	B-P
contact	I-P
angle	I-P
goniometry	I-P
,	O
and	O
in	O
situ	O
ellipsometry	B-P
.	O

The	O
antifouling	O
properties	O
of	O
these	O
new	O
bioinspired	O
hydrogel-brush	O
coatings	O
were	O
investigated	O
by	O
surface	O
plasmon	O
resonance	O
.	O

The	O
influence	O
of	O
the	O
modifications	O
to	O
the	O
chitosan	O
on	O
hemocompatibility	O
was	O
assessed	O
by	O
contacting	O
the	O
surfaces	O
with	O
platelets	O
and	O
leukocytes	O
.	O

The	O
coatings	O
were	O
hydrophilic	O
and	O
reached	O
a	O
thickness	O
of	O
up	O
to	O
180	O
nm	O
within	O
30	O
min	O
of	O
polymerization	O
.	O

The	O
functionalization	O
of	O
the	O
surface	O
with	O
polymer	O
brushes	O
significantly	O
reduced	O
the	O
protein	O
fouling	O
and	O
eliminated	O
platelet	O
activation	O
and	O
leukocyte	O
adhesion	O
.	O

This	O
methodology	O
offers	O
a	O
facile	O
route	O
to	O
functionalizing	O
implantable	O
sensor	O
systems	O
with	O
antifouling	O
coatings	O
that	O
improve	O
hemocompatibility	O
and	O
pave	O
the	O
way	O
for	O
enhanced	O
device	O
integration	O
in	O
tissue	O
.	O

C-5a-substituted	O
validamine	O
type	O
glycosidase	O
inhibitors	O
.	O

A	O
series	O
of	O
N-alkyl	O
derivatives	O
of	O
the	O
D-galactosidase	O
inhibitor	O
1,4-di-epi-validamine	O
featuring	O
lipophilic	O
substituents	O
at	O
position	O
C-5a	O
was	O
prepared	O
and	O
screened	B-P
for	O
their	O
glycosidase	O
inhibitory	O
properties	O
.	O

Products	O
turned	O
out	O
selective	O
for	O
β-galactosidases	O
as	O
well	O
as	O
β-glucosidases	O
.	O

Laparoscopic	B-P
radical	O
lymph	O
node	O
dissection	O
for	O
advanced	O
colon	O
cancer	O
close	O
to	O
the	O
hepatic	O
flexure	O
.	O

Complete	O
mesocolic	O
excision	O
is	O
currently	O
recognized	O
as	O
a	O
standard	O
procedure	O
for	O
colon	O
cancer	O
.	O

Gastroepiploic	O
,	O
infrapyloric	O
,	O
and	O
superficial	O
pancreatic	O
head	O
lymph	O
node	O
metastases	O
in	O
the	O
gastrocolic	O
ligament	O
have	O
been	O
reported	O
for	O
colon	O
cancer	O
close	O
to	O
the	O
hepatic	O
flexure	O
.	O

We	O
sought	O
to	O
investigate	O
metastases	O
in	O
the	O
gastrocolic	O
ligament	O
in	O
colon	O
cancer	O
close	O
to	O
the	O
hepatic	O
flexure	O
.	O

This	O
was	O
a	O
single-center	O
retrospective	O
study	O
.	O

All	O
patients	O
with	O
T2	O
or	O
deeper	O
invasive	O
colon	O
cancer	O
in	O
the	O
relevant	O
tumor	O
location	O
who	O
underwent	O
laparoscopic	O
right	O
hemicolectomy	O
or	O
extended	O
right	O
hemicolectomy	O
at	O
our	O
institution	O
between	O
1	O
April	O
2011	O
and	O
31	O
March	O
2015	O
were	O
included	O
.	O

Lymph	O
node	O
dissection	O
in	O
the	O
gastrocolic	O
ligament	O
was	O
performed	O
in	O
35	O
cases	O
.	O

Complications	O
occurred	O
in	O
11	O
patients	O
(	O
31	O
%	O
)	O
and	O
were	O
grades	O
I	O
and	O
II	O
according	O
to	O
the	O
Clavien-Dindo	O
classification	O
.	O

Lymph	O
node	O
metastases	O
in	O
the	O
gastrocolic	O
ligament	O
were	O
found	O
in	O
only	O
three	O
patients	O
(	O
9	O
%	O
)	O
.	O

Each	O
metastasis	O
was	O
larger	O
than	O
9	O
mm	O
.	O

Metastases	O
in	O
the	O
gastrocolic	O
ligament	O
occurred	O
in	O
9	O
%	O
of	O
patients	O
with	O
T2	O
or	O
deeper	O
invasive	O
colon	O
cancer	O
close	O
to	O
the	O
hepatic	O
flexure	O
.	O

Laparoscopy	O
was	O
feasible	O
and	O
useful	O
during	O
gastrocolic	O
ligament	O
resection	O
.	O

This	O
study	O
included	O
a	O
small	O
sample	O
and	O
lacked	O
an	O
extended	O
follow-up	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
clinical	O
relevance	O
of	O
this	O
finding	O
,	O
particularly	O
in	O
terms	O
of	O
recurrence	O
and	O
long-term	O
survival	O
.	O

Cardiac	O
protective	O
effects	O
of	O
remote	O
ischaemic	O
preconditioning	O
in	O
children	O
undergoing	O
tetralogy	O
of	O
fallot	O
repair	O
surgery	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

Remote	O
ischaemic	O
preconditioning	O
(	O
RIPC	O
)	O
by	O
inducing	O
brief	O
ischaemia	O
in	O
distant	O
tissues	O
protects	O
the	O
heart	O
against	O
myocardial	O
ischaemia-reperfusion	O
injury	O
(	O
IRI	O
)	O
in	O
children	O
undergoing	O
open-heart	O
surgery	O
,	O
although	O
its	O
effectiveness	O
in	O
adults	O
with	O
comorbidities	O
is	O
controversial	O
.	O

The	O
effectiveness	O
and	O
mechanism	O
of	O
RIPC	O
with	O
respect	O
to	O
myocardial	O
IRI	O
in	O
children	O
with	O
tetralogy	O
of	O
Fallot	O
(	O
ToF	O
)	O
,	O
a	O
severe	O
cyanotic	O
congenital	O
cardiac	O
disease	O
,	O
undergoing	O
open	O
heart	O
surgery	O
are	O
unclear	O
.	O

We	O
hypothesized	O
that	O
RIPC	O
can	O
confer	O
cardioprotection	O
in	O
children	O
undergoing	O
ToF	O
repair	O
surgery	O
.	O

Overall	O
,	O
112	O
ToF	O
children	O
undergoing	O
radical	O
open	O
cardiac	O
surgery	O
using	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
were	O
randomized	O
to	O
either	O
a	O
RIPC	O
group	O
(	O
n	O
=	O
55	O
)	O
or	O
a	O
control	O
group	O
(	O
n	O
=	O
57	O
)	O
.	O

The	O
RIPC	O
protocol	O
consisted	O
of	O
three	O
cycles	O
of	O
5-min	O
lower	O
limb	O
occlusion	O
and	O
5-min	O
reperfusion	O
using	O
a	O
cuff-inflator	O
.	O

Serum	O
inflammatory	O
cytokines	O
and	O
cardiac	O
injury	O
markers	O
were	O
measured	O
before	O
surgery	O
and	O
after	O
CPB	O
.	O

Right	O
ventricle	O
outflow	O
tract	O
(	O
RVOT	O
)	O
tissues	O
were	O
collected	O
during	O
the	O
surgery	O
to	O
assess	O
hypoxia-inducible	O
factor	O
(	O
Hif	O
)	O
-1α	O
and	O
other	O
signalling	O
proteins	O
.	O

Cardiac	O
mitochondrial	O
injury	O
was	O
assessed	O
by	O
electron	B-P
microscopy	I-P
.	O

The	O
primary	O
results	O
showed	O
that	O
the	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
was	O
longer	O
in	O
the	O
control	O
group	O
than	O
in	O
the	O
RIPC	O
group	O
(	O
52.30	O
±	O
13.43	O
h	O
vs.	O
47.55	O
±	O
10.34	O
h	O
,	O
respectively	O
,	O
P	O
=	O
0.039	O
)	O
.	O

Patients	O
in	O
the	O
control	O
group	O
needed	O
longer	O
post-operative	O
ventilation	O
time	O
compared	O
to	O
the	O
RIPC	O
group	O
(	O
35.02	O
±	O
6.56	O
h	O
vs.	O
31.96	O
±	O
6.60	O
h	O
,	O
respectively	O
,	O
P	O
=	O
0.016	O
)	O
.	O

The	O
levels	O
of	O
post-operative	O
serum	O
troponin-T	O
at	O
12	O
and	O
18	O
h	O
,	O
CK-MB	B-P
at	O
24	O
h	O
,	O
as	O
well	O
as	O
the	O
serum	O
h-FABP	O
levels	O
at	O
6	O
h	O
,	O
after	O
CPB	O
were	O
significantly	O
lower	O
,	O
which	O
was	O
coincident	O
with	O
significantly	O
higher	O
protein	O
expression	O
of	O
cardiac	O
Hif-1α	O
,	O
p-Akt	O
,	O
p-STAT3	O
,	O
p-STAT5	O
,	O
and	O
p-eNOS	O
and	O
less	O
vacuolization	O
of	O
mitochondria	O
in	O
the	O
RIPC	O
group	O
compared	O
to	O
the	O
control	O
group	O
.	O

In	O
ToF	O
children	O
undergoing	O
open	O
heart	O
surgery	O
,	O
RIPC	O
attenuates	O
myocardial	O
IRI	O
and	O
improves	O
the	O
short-term	O
prognosis	O
.	O

Electrochemically	O
triggered	O
release	O
of	O
acetylcholine	O
from	O
scCO2	O
impregnated	O
conductive	O
polymer	O
films	O
evokes	O
intracellular	O
Ca	O
(	O
2+	O
)	O
signaling	O
in	O
neurotypic	O
SH-SY5Y	O
cells	O
.	O

Implantable	O
devices	O
for	O
electronically	O
triggered	O
drug	O
release	O
are	O
attractive	O
to	O
achieve	O
spatial	O
and	O
temporal	O
control	O
over	O
drug	O
concentrations	O
in	O
patients	O
.	O

Realization	O
of	O
such	O
devices	O
is	O
,	O
however	O
,	O
associated	O
with	O
technical	O
and	O
biological	O
challenges	O
.	O

Among	O
these	O
are	O
containment	O
of	O
drug	O
reservoirs	O
,	O
lack	O
of	O
precise	O
control	O
cues	O
,	O
as	O
well	O
as	O
the	O
charge	O
and	O
size	O
of	O
the	O
drug	O
.	O

Here	O
,	O
we	O
present	O
a	O
method	O
for	O
electronically	O
triggered	O
release	O
of	O
the	O
quaternary	O
ammonium	O
cation	O
acetylcholine	O
(	O
ACh	O
)	O
from	O
an	O
impregnated	O
conductive	O
polymer	O
film	O
.	O

Using	O
supercritical	O
carbon	O
dioxide	O
(	O
scCO2	O
)	O
,	O
a	O
film	O
of	O
PEDOT/PSS	O
(	O
poly	O
(	O
3,4	O
)	O
-ethylenedioxythiophene	O
doped	O
with	O
poly	O
(	O
styrenesulfonate	O
)	O
)	O
is	O
impregnated	O
with	O
the	O
neurotransmitter	O
acetylcholine	O
.	O

The	O
gentle	O
scCO2	O
process	O
generated	O
a	O
dry	O
,	O
drug	O
-	O
impregnated	O
surface	O
,	O
well	O
suited	O
for	O
interaction	O
with	O
biological	O
material	O
,	O
while	O
maintaining	O
normal	O
electrochemical	O
properties	O
of	O
the	O
polymer	O
.	O

Electrochemical	O
switching	O
of	O
impregnated	O
PEDOT/PSS	O
films	O
stimulated	O
release	O
of	O
ACh	O
from	O
the	O
polymer	O
matrix	O
,	O
likely	O
due	O
to	O
swelling	O
mediated	O
by	O
the	O
influx	O
and	O
efflux	O
of	O
charged	O
and	O
solvated	O
ions	O
.	O

Triggered	O
release	O
of	O
ACh	O
did	O
not	O
affect	O
the	O
biological	O
activity	O
of	O
the	O
drug	O
.	O

This	O
was	O
shown	O
by	O
real-time	O
monitoring	O
of	O
intracellular	O
Ca	O
(	O
2+	O
)	O
signaling	O
in	O
neurotypic	O
cells	O
growing	O
on	O
the	O
impregnated	O
polymer	O
surface	O
.	O

Collectively	O
,	O
scCO2	O
impregnation	O
of	O
conducting	O
polymers	O
offers	O
the	O
first	O
one-step	O
,	O
dopant-independent	O
drug	O
impregnation	O
process	O
,	O
potentially	O
facilitating	O
loading	O
of	O
both	O
anionic	O
and	O
cationic	O
drugs	O
that	O
can	O
be	O
dissolved	B-P
in	O
scCO2	O
on	O
its	O
own	O
or	O
by	O
using	O
a	O
co-solvent	O
.	O

We	O
foresee	O
that	O
scCO2	O
-loaded	O
devices	O
for	O
electronically	O
triggered	O
drug	O
release	O
will	O
create	O
novel	O
opportunities	O
when	O
generating	O
active	O
bio-coatings	O
,	O
tunable	O
for	O
specific	O
needs	O
,	O
in	O
a	O
variety	O
of	O
medical	O
settings	O
.	O

Cultivation	B-P
of	O
four	O
microalgae	O
species	O
in	O
the	O
effluent	O
of	O
anaerobic	O
digester	O
for	O
biodiesel	O
production	O
.	O

This	O
study	O
investigated	O
if	O
an	O
effluent	O
from	O
anaerobic	O
digestion	O
(	O
AD	O
)	O
system	O
can	O
be	O
used	O
as	O
a	O
nutrients	O
source	O
for	O
the	O
microalgae	O
cultivation	B-P
,	O
and	O
in	O
so	O
doing	O
,	O
if	O
the	O
effluent	O
can	O
be	O
properly	O
treated	O
.	O

Nitrogen	O
and	O
phosphorus	O
in	O
the	O
AD	O
effluent	O
well	O
supported	O
microalgal	O
growth	O
,	O
and	O
their	O
removal	O
efficiency	O
reached	O
>	O
97.9	O
%	O
and	O
99.2	O
%	O
,	O
respectively	O
.	O

Among	O
four	O
different	O
algal	O
species	O
tested	O
,	O
Micractinium	O
inermum	O
particularly	O
stood	O
out	O
,	O
showing	O
the	O
highest	O
biomass	O
and	O
FAME	O
productivity	O
:	O
0.16gL	O
(	O
-1	O
)	O
d	O
(	O
-1	O
)	O
with	O
3.23gL	O
(	O
-1	O
)	O
of	O
dry	O
cell	O
weight	O
,	O
and	O
0.04gL	O
(	O
-1	O
)	O
d	O
(	O
-1	O
)	O
with	O
27.54	O
%	O
(	O
w/w	O
)	O
of	O
FAME	O
contents	O
,	O
respectively	O
.	O

As	O
the	O
concentrations	O
of	O
the	O
nutrients	O
decreased	O
over	O
time	O
,	O
the	O
FAME	O
contents	O
were	O
increased	O
and	O
its	O
quality	O
as	O
well	O
,	O
satisfying	O
several	O
biodiesel	O
quality	O
standards	O
.	O

This	O
study	O
supports	O
that	O
the	O
AD	O
effluent	O
can	O
indeed	O
serve	O
as	O
a	O
cheap	O
and	O
nutrient	O
-	O
rich	O
medium	O
for	O
microalgae	O
cultivation	B-P
,	O
and	O
equally	O
importantly	O
,	O
microalgae	O
can	O
be	O
a	O
workable	O
treatment	O
option	O
for	O
it	O
.	O

Brief	O
Potentially	O
Ictal	O
Rhythmic	O
Discharges	O
[	O
B	O
(	O
I	O
)	O
RDs	O
]	O
in	O
Noncritically	O
Ill	O
Adults	O
.	O

Brief	O
potentially	O
ictal	O
rhythmic	O
discharges	O
(	O
B	O
(	O
I	O
)	O
RDs	O
)	O
have	O
been	O
described	O
in	O
neonates	O
and	O
critically	O
ill	O
adults	O
,	O
and	O
their	O
association	O
with	O
seizures	O
has	O
been	O
demonstrated	O
.	O

Their	O
significance	O
in	O
noncritically	O
ill	O
adults	O
remains	O
unclear	O
.	O

We	O
aimed	O
to	O
investigate	O
their	O
prevalence	O
,	O
electrographic	O
characteristics	O
,	O
and	O
clinical	O
significance	O
.	O

We	O
identified	O
adult	O
patients	O
with	O
B	O
(	O
I	O
)	O
RDs	O
who	O
received	O
long-term	O
EEG	B-P
recordings	O
either	O
in	O
the	O
epilepsy	O
monitoring	O
unit	O
or	O
in	O
the	O
ambulatory	O
setting	O
.	O

Patients	O
with	O
acute	O
findings	O
on	O
imaging	B-P
or	O
status	O
epilepticus	O
were	O
excluded	O
.	O

B	O
(	O
I	O
)	O
RDs	O
were	O
defined	O
as	O
very	O
brief	O
(	O
<	O
10	O
seconds	O
)	O
runs	O
of	O
focal	O
or	O
generalized	O
sharply	O
contoured	O
rhythmic	O
activity	O
greater	O
than	O
4	O
Hz	O
,	O
with	O
or	O
without	O
evolution	O
,	O
that	O
were	O
not	O
consistent	O
with	O
any	O
known	O
normal	O
or	O
benign	O
pattern	O
.	O

The	O
clinical	O
history	O
,	O
EEG	B-P
,	O
and	O
imaging	B-P
results	O
were	O
retrieved	O
.	O

Each	O
patient	O
with	O
B	O
(	O
I	O
)	O
RDs	O
was	O
matched	O
by	O
age	O
and	O
etiology	O
to	O
a	O
control	O
group	O
with	O
epileptiform	O
discharges	O
but	O
without	O
B	O
(	O
I	O
)	O
RDs	O
in	O
a	O
1:2	O
ratio	O
.	O

We	O
identified	O
B	O
(	O
I	O
)	O
RDs	O
in	O
15	O
patients	O
of	O
1,230	O
EEGs	B-P
(	O
1.2	O
%	O
)	O
.	O

The	O
pattern	O
typically	O
consisted	O
of	O
0.5	O
to	O
4	O
second	O
runs	O
of	O
sharply	O
contoured	O
alpha	O
activity	O
without	O
evolution	O
.	O

All	O
patients	O
with	O
B	O
(	O
I	O
)	O
RDs	O
had	O
epilepsy	O
,	O
and	O
,	O
when	O
compared	O
with	O
controls	O
with	O
epilepsy	O
but	O
without	O
BIRDs	O
,	O
were	O
more	O
likely	O
to	O
be	O
medically	O
refractory	O
(	O
10	O
of	O
15	O
[	O
67	O
%	O
]	O
vs.	O
5	O
of	O
30	O
[	O
17	O
%	O
]	O
;	O
P	O
<	O
0.01	O
)	O
.	O

All	O
seizure	O
onsets	O
colocalized	O
to	O
the	O
B	O
(	O
I	O
)	O
RDs	O
,	O
and	O
most	O
were	O
morphologically	O
similar	O
.	O

In	O
noncritically	O
ill	O
patients	O
,	O
B	O
(	O
I	O
)	O
RDs	O
are	O
associated	O
with	O
refractory	O
epilepsy	O
and	O
their	O
location	O
is	O
correlated	O
with	O
the	O
seizure	O
onset	O
area	O
.	O

Differential	O
effects	O
of	O
crude	O
oil	O
on	O
denitrification	O
and	O
anammox	O
,	O
and	O
the	O
impact	O
on	O
N2O	O
production	O
.	O

Denitrification	O
and	O
anammox	O
are	O
key	O
processes	O
for	O
reducing	O
the	O
external	O
nitrogen	O
loads	O
delivered	O
to	O
coastal	O
ecosystems	O
,	O
and	O
these	O
processes	O
can	O
be	O
affected	O
by	O
pollutants	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
crude	O
oil	O
on	O
denitrification	O
and	O
anammox	O
.	O

Controlled	O
laboratory	O
experiments	O
were	O
performed	O
using	O
sediment	O
slurries	O
from	O
the	O
Lima	O
Estuary	O
(	O
NW	O
Portugal	O
)	O
.	O

Anammox	O
and	O
denitrification	O
rates	O
were	O
measured	O
using	O
(	O
15	O
)	O
N-labeled	O
NO3	O
(	O
-	O
)	O
,	O
and	O
the	O
production	O
of	O
(	O
29	O
)	O
N2	O
and	O
(	O
30	O
)	O
N2	O
quantified	O
by	O
membrane	B-P
inlet	I-P
mass	I-P
spectrometry	I-P
.	O

Results	O
revealed	O
that	O
while	O
denitrification	O
rates	O
were	O
stimulated	O
between	O
10	O
and	O
25	O
000	O
times	O
after	O
crude	O
oil	O
amendment	O
,	O
anammox	O
activity	O
was	O
partially	O
(	O
between	O
2	O
and	O
5	O
times	O
)	O
or	O
completely	O
inhibited	O
by	O
the	O
addition	O
of	O
crude	O
oil	O
when	O
comparing	O
to	O
rates	O
in	O
unamended	O
controls	O
.	O

Similar	O
results	O
were	O
observed	O
across	O
four	O
estuarine	O
sediment	O
types	O
,	O
despite	O
their	O
different	O
physical-chemical	O
characteristics	O
.	O

Moreover	O
,	O
N2O	O
production	O
was	O
reduced	O
by	O
2-36	O
times	O
following	O
crude	O
oil	O
addition	O
.	O

Further	O
work	O
is	O
required	O
to	O
fully	O
understand	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
the	O
observed	O
reduction	O
in	O
N2O	O
production	O
.	O

This	O
study	O
represents	O
one	O
of	O
the	O
first	O
contributions	O
to	O
the	O
understanding	O
of	O
the	O
impact	O
of	O
crude	O
oil	O
pollution	O
on	O
denitrification	O
and	O
anammox	O
,	O
with	O
profound	O
implications	O
for	O
the	O
management	O
of	O
aquatic	O
ecosystems	O
regarding	O
eutrophication	O
(	O
N-removal	O
)	O
.	O

A	O
Comparison	O
of	O
Thermal	O
Plasma	O
Energy	O
Versus	O
Argon	O
Beam	O
Coagulator	O
-	O
Induced	O
Intestinal	O
Injury	O
After	O
Vaporization	O
in	O
a	O
Porcine	O
Model	O
.	O

Complete	O
cytoreduction	O
of	O
ovarian	O
cancer	O
often	O
requires	O
excision	O
or	O
ablation	O
of	O
bowel	O
serosa	O
implants	O
.	O

Both	O
argon	O
beam	O
coagulator	O
(	O
ABC	O
)	O
and	O
thermal	O
plasma	O
energy	O
(	O
TPE	O
)	O
(	O
PlasmaJet	O
;	O
PlasmaSurgical	O
,	O
Roswell	O
,	O
Ga	O
)	O
have	O
been	O
used	O
to	O
ablate	O
bowel	O
serosa	O
implants	O
.	O

Our	O
objective	O
was	O
to	O
identify	O
comparable	O
power	O
settings	O
as	O
well	O
as	O
determine	O
the	O
rate	O
of	O
bowel	O
perforation	O
,	O
depth	O
of	O
thermal	O
injury	O
,	O
and	O
extent	O
of	O
inflammatory	O
response	O
with	O
ABC	O
versus	O
TPE	O
in	O
a	O
porcine	O
model	O
.	O

Nine	O
pigs	O
underwent	O
vaporization	O
of	O
small	O
bowel	O
and	O
colon	O
serosa	O
according	O
to	O
assigned	O
treatment	O
group	O
(	O
TPE	O
vs	O
ABC	O
)	O
and	O
settings	O
(	O
ABC	O
:	O
30	O
,	O
50	O
,	O
and	O
70	O
W	O
;	O
TPE	O
:	O
Cut	O
10U	O
,	O
20U	O
,	O
and	O
30U	O
and	O
Coagulation	O
10U	O
,	O
20U	O
,	O
and	O
30U	O
)	O
.	O

Animals	O
underwent	O
necropsy	B-P
with	O
blinded	O
histomorphologic	B-P
evaluation	I-P
on	O
days	O
0	O
,	O
3	O
,	O
and	O
10	O
postprocedure	O
to	O
assess	O
for	O
presence	O
of	O
bowel	O
perforation	O
,	O
depth	O
of	O
thermal	O
injury	O
,	O
and	O
extent	O
of	O
inflammatory	O
response	O
.	O

At	O
necropsy	B-P
,	O
bowel	O
perforation	O
was	O
not	O
identified	O
in	O
any	O
animals	O
.	O

Depth	O
of	O
treatment	O
with	O
ABC	O
in	O
the	O
porcine	O
colon	O
was	O
variable	O
and	O
unrelated	O
to	O
power	O
settings	O
whereas	O
TPE	O
was	O
associated	O
with	O
a	O
consistent	O
treatment	O
depth	O
of	O
1.0	O
mm	O
regardless	O
of	O
location	O
or	O
power	O
.	O

Treatment	O
with	O
ABC	O
resulted	O
in	O
greater	O
tissue	O
coagulation	O
and	O
desiccation	O
as	O
well	O
as	O
increased	O
rates	O
of	O
mucosal	O
necrosis	O
,	O
especially	O
at	O
higher	O
settings	O
(	O
>	O
50	O
W	O
)	O
.	O

Treatment	O
with	O
TPE	O
primarily	O
resulted	O
in	O
tissue	O
ablation	O
and	O
minimal	O
mucosal	O
necrosis	O
at	O
low	O
settings	O
(	O
Coag	O
10U-20U	O
)	O
.	O

The	O
inflammatory	O
response	O
associated	O
with	O
TPE	O
treatments	O
was	O
interpreted	O
as	O
biologically	O
benign	O
,	O
and	O
less	O
than	O
that	O
observed	O
with	O
the	O
ABC	O
regardless	O
of	O
treatment	O
settings	O
.	O

Both	O
ABC	O
and	O
TPE	O
effectively	O
ablate	O
bowel	O
serosa	O
in	O
a	O
porcine	O
model	O
.	O

The	O
TPE	O
seems	O
to	O
result	O
in	O
a	O
more	O
predictable	O
tissue	O
effect	O
with	O
less	O
inflammatory	O
response	O
,	O
especially	O
when	O
used	O
at	O
low	O
power	O
settings	O
such	O
as	O
Coag	O
10U	O
or	O
20U	O
.	O

These	O
characteristics	O
are	O
appealing	O
for	O
ablation	O
of	O
bowel	O
serosa	O
implants	O
during	O
ovarian	O
cancer	O
surgery	O
and	O
warrant	O
further	O
investigation	O
.	O

Comparative	O
Epidemiologic	O
Characteristics	O
of	O
Pertussis	O
in	O
10	O
Central	O
and	O
Eastern	O
European	O
Countries	O
,	O
2000-2013	O
.	O

We	O
undertook	O
an	O
epidemiological	O
survey	O
of	O
the	O
annual	O
incidence	O
of	O
pertussis	O
reported	O
from	O
2000	O
to	O
2013	O
in	O
ten	O
Central	O
and	O
Eastern	O
European	O
countries	O
to	O
ascertain	O
whether	O
increased	O
pertussis	O
reports	O
in	O
some	O
countries	O
share	O
common	O
underlying	O
drivers	O
or	O
whether	O
there	O
are	O
specific	O
features	O
in	O
each	O
country	O
.	O

The	O
annual	O
incidence	O
of	O
pertussis	O
in	O
the	O
participating	O
countries	O
was	O
obtained	O
from	O
relevant	O
government	O
institutions	O
and/or	O
national	O
surveillance	O
systems	O
.	O

We	O
reviewed	O
the	O
changes	O
in	O
the	O
pertussis	O
incidence	O
rates	O
in	O
each	O
country	O
to	O
explore	O
differences	O
and/or	O
similarities	O
between	O
countries	O
in	O
relation	O
to	O
pertussis	O
surveillance	O
;	O
case	O
definitions	O
for	O
detection	O
and	O
confirmation	O
of	O
pertussis	O
;	O
incidence	O
and	O
number	O
of	O
cases	O
of	O
pertussis	O
by	O
year	O
,	O
overall	O
and	O
by	O
age	O
group	O
;	O
population	O
by	O
year	O
,	O
overall	O
and	O
by	O
age	O
group	O
;	O
pertussis	O
immunization	O
schedule	O
and	O
coverage	O
,	O
and	O
switch	O
from	O
whole-cell	O
pertussis	O
vaccines	O
(	O
wP	O
)	O
to	O
acellular	O
pertussis	O
vaccines	O
(	O
aP	O
)	O
.	O

There	O
was	O
heterogeneity	O
in	O
the	O
reported	O
annual	O
incidence	O
rates	O
and	O
trends	O
observed	O
across	O
countries	O
.	O

Reported	O
pertussis	O
incidence	O
rates	O
varied	O
considerably	O
,	O
ranging	O
from	O
0.01	O
to	O
96	O
per	O
100,000	O
population	O
,	O
with	O
the	O
highest	O
rates	O
generally	O
reported	O
in	O
Estonia	O
and	O
the	O
lowest	O
in	O
Hungary	O
and	O
Serbia	O
.	O

The	O
greatest	O
burden	O
appears	O
for	O
the	O
most	O
part	O
in	O
infants	O
(	O
<	O
1	O
year	O
)	O
in	O
Bulgaria	O
,	O
Hungary	O
,	O
Latvia	O
,	O
Romania	O
,	O
and	O
Serbia	O
,	O
but	O
not	O
in	O
the	O
other	O
participating	O
countries	O
where	O
the	O
burden	O
may	O
have	O
shifted	O
to	O
older	O
children	O
,	O
though	O
surveillance	O
of	O
adults	O
may	O
be	O
inappropriate	O
.	O

There	O
was	O
no	O
consistent	O
pattern	O
associated	O
with	O
the	O
switch	O
from	O
wP	O
to	O
aP	O
vaccines	O
on	O
reported	O
pertussis	O
incidence	O
rates	O
.	O

The	O
heterogeneity	O
in	O
reported	O
data	O
may	O
be	O
related	O
to	O
a	O
number	O
of	O
factors	O
including	O
surveillance	O
system	O
characteristics	O
or	O
capabilities	O
,	O
different	O
case	O
definitions	O
,	O
type	O
of	O
pertussis	O
confirmation	B-P
tests	I-P
used	O
,	O
public	O
awareness	O
of	O
the	O
disease	O
,	O
as	O
well	O
as	O
real	O
differences	O
in	O
the	O
magnitude	O
of	O
the	O
disease	O
,	O
or	O
a	O
combination	O
of	O
these	O
factors	O
.	O

Our	O
study	O
highlights	O
the	O
need	O
to	O
standardize	O
pertussis	O
detection	O
and	O
confirmation	O
in	O
surveillance	O
programs	O
across	O
Europe	O
,	O
complemented	O
with	O
carefully-designed	O
seroprevalence	O
studies	O
using	O
the	O
same	O
protocols	O
and	O
methodologies	O
.	O

Pharmacogenomic	B-P
identification	I-P
of	O
small	O
molecules	O
for	O
lineage	O
specific	O
manipulation	O
of	O
subventricular	O
zone	O
germinal	O
activity	O
.	O

Strategies	O
for	O
promoting	O
neural	O
regeneration	O
are	O
hindered	O
by	O
the	O
difficulty	O
of	O
manipulating	O
desired	O
neural	O
fates	O
in	O
the	O
brain	O
without	O
complex	O
genetic	B-P
methods	I-P
.	O

The	O
subventricular	O
zone	O
(	O
SVZ	O
)	O
is	O
the	O
largest	O
germinal	O
zone	O
of	O
the	O
forebrain	O
and	O
is	O
responsible	O
for	O
the	O
lifelong	O
generation	O
of	O
interneuron	O
subtypes	O
and	O
oligodendrocytes	O
.	O

Here	O
,	O
we	O
have	O
performed	O
a	O
bioinformatics	O
analysis	O
of	O
the	O
transcriptome	O
of	O
dorsal	O
and	O
lateral	O
SVZ	O
in	O
early	O
postnatal	O
mice	O
,	O
including	O
neural	O
stem	O
cells	O
(	O
NSCs	O
)	O
and	O
their	O
immediate	O
progenies	O
,	O
which	O
generate	O
distinct	O
neural	O
lineages	O
.	O

We	O
identified	O
multiple	O
signaling	O
pathways	O
that	O
trigger	O
distinct	O
downstream	O
transcriptional	O
networks	O
to	O
regulate	O
the	O
diversity	O
of	O
neural	O
cells	O
originating	O
from	O
the	O
SVZ	O
.	O

Next	O
,	O
we	O
used	O
a	O
novel	O
in	O
silico	O
genomic	O
analysis	O
,	O
searchable	O
platform-independent	O
expression	O
database	O
/	O
connectivity	O
map	O
(	O
SPIED	O
/	O
CMAP	O
)	O
,	O
to	O
generate	O
a	O
catalogue	O
of	O
small	O
molecules	O
that	O
can	O
be	O
used	O
to	O
manipulate	O
SVZ	O
microdomain-specific	O
lineages	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
compounds	O
identified	O
in	O
this	O
analysis	O
promote	O
the	O
generation	O
of	O
specific	O
cell	O
lineages	O
from	O
NSCs	O
in	O
vivo	O
,	O
during	O
postnatal	O
life	O
and	O
adulthood	O
,	O
as	O
well	O
as	O
in	O
regenerative	O
contexts	O
.	O

This	O
study	O
unravels	O
new	O
strategies	O
for	O
using	O
small	O
bioactive	O
molecules	O
to	O
direct	O
germinal	O
activity	O
in	O
the	O
SVZ	O
,	O
which	O
has	O
therapeutic	O
potential	O
in	O
neurodegenerative	O
diseases	O
.	O

Th1	O
and	O
Innate	O
Lymphoid	O
Cells	O
accumulate	O
in	O
Primary	O
Sclerosing	O
Cholangitis	O
-	O
associated	O
Inflammatory	O
Bowel	O
Disease	O
.	O

Primary	O
sclerosing	O
cholangitis	O
(	O
PSC	O
)	O
is	O
an	O
idiopathic	O
chronic	O
disorder	O
of	O
the	O
hepatobiliary	O
system	O
associated	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
,	O
mainly	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
.	O

Colitis	O
in	O
patients	O
with	O
PSC	O
and	O
UC	O
(	O
PSC	O
-	O
UC	O
)	O
exhibits	O
characteristic	O
features	O
and	O
is	O
linked	O
to	O
increased	O
colon	O
cancer	O
risk	O
.	O

Genetic	O
studies	O
have	O
identified	O
immune	O
-	O
related	O
susceptibility	O
genes	O
that	O
only	O
partially	O
overlap	O
with	O
those	O
involved	O
in	O
IBD	O
.	O

These	O
observations	O
suggest	O
that	O
PSC	O
-	O
UC	O
may	O
represent	O
a	O
distinct	O
form	O
of	O
IBD	O
.	O

It	O
remains	O
to	O
be	O
elucidated	O
whether	O
different	O
immune-mechanisms	O
are	O
involved	O
in	O
colitis	O
in	O
these	O
patients	O
.	O

We	O
aimed	O
to	O
evaluate	O
systemic	O
and	O
intestinal	O
T-cell	O
and	O
innate	O
lymphoid	O
cell	O
(	O
ILC	O
)	O
responses	O
,	O
previously	O
associated	O
to	O
IBD	O
,	O
in	O
patients	O
with	O
PSC	O
-	O
UC	O
compared	O
to	O
patients	O
with	O
UC	O
and	O
healthy	O
controls	O
.	O

Blood	O
samples	O
and	O
colorectal	O
biopsies	B-P
were	O
collected	O
from	O
patients	O
with	O
PSC	O
-	O
UC	O
,	O
patients	O
with	O
UC	O
and	O
healthy	O
controls	O
.	O

T-cell	O
and	O
ILC	O
phenotype	O
was	O
analysed	O
by	O
multicolour	B-P
flow	I-P
cytometry	I-P
.	O

Chemokine	O
receptor	O
(	O
CCR	O
)	O
profiling	B-P
of	O
circulating	O
T-cell	O
s	O
showed	O
decreased	O
CCR6-CXCR3+	O
Th1	O
cells	O
in	O
PSC	O
-	O
UC	O
,	O
but	O
increased	O
CCR6-CCR4+	O
Th2	O
cells	O
only	O
in	O
UC	O
,	O
while	O
increased	O
CCR6+CCR4+	O
Th17	O
cells	O
were	O
found	O
in	O
both	O
patient	O
groups	O
compared	O
to	O
healthy	O
controls	O
.	O

Increased	O
frequencies	O
of	O
IFN-γ	O
secreting	O
T-cells	O
were	O
found	O
in	O
the	O
colon	O
of	O
patients	O
with	O
PSC	O
-	O
UC	O
compared	O
to	O
UC	O
.	O

Interestingly	O
,	O
we	O
observed	O
accumulation	O
of	O
ILC	O
in	O
the	O
colon	O
in	O
PSC	O
-	O
UC	O
.	O

Our	O
study	O
suggests	O
that	O
PSC	O
-	O
UC	O
represent	O
a	O
different	O
immunological	O
disorder	O
from	O
UC	O
,	O
characterised	O
by	O
increased	O
intestinal	O
Th1	O
and	O
ILC	O
responses	O
.	O

These	O
results	O
provide	O
further	O
evidence	O
that	O
PSC	O
-	O
UC	O
may	O
represent	O
a	O
distinct	O
form	O
of	O
IBD	O
.	O

Reference	O
data	O
for	O
jumping	B-P
mechanography	I-P
in	O
Canadian	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
.	O

To	O
provide	O
age	O
-	O
and	O
sex	O
-	O
specific	O
reference	O
data	O
for	O
mechanography	B-P
-derived	O
parameters	O
of	O
muscle	O
function	O
in	O
Canadian	O
children	O
and	O
youth	O
using	O
the	O
single	O
two-legged	O
jump	O
(	O
S2LJ	O
)	O
with	O
hands-on-waist	O
.	O

Our	O
sample	O
included	O
2017	O
observations	O
from	O
715	O
participants	O
(	O
9-21	O
years	O
;	O
338	O
girls	O
)	O
.	O

Participants	O
performed	O
three	O
S2LJ	O
with	O
hands-on-waist	O
on	O
a	O
force	O
platform	O
(	O
Leonardo	O
Mechanograph	O
,	O
Novotec	O
)	O
.	O

Outcomes	O
were	O
maximum	O
peak	O
power	O
(	O
Pmax	O
)	O
,	O
Pmax	O
/	O
mass	O
,	O
peak	O
force	O
/	O
body	O
weight	O
(	O
Fmax	O
/	O
BW	O
)	O
,	O
force	O
efficiency	O
,	O
maximum	O
jump	O
height	O
(	O
Hmax	O
)	O
,	O
and	O
velocity	O
(	O
Vmax	O
)	O
.	O

We	O
used	O
the	O
LMS	O
method	O
to	O
construct	O
age	O
-	O
and	O
sex	O
-	O
specific	O
percentile	O
curves	O
and	O
mixed	O
effects	O
models	O
to	O
examine	O
sex	O
and	O
ethnic	O
differences	O
.	O

With	O
the	O
exception	O
of	O
Efficiency	O
,	O
mechanography	B-P
outcomes	O
were	O
greater	O
in	O
girls	O
(	O
4-40	O
%	O
,	O
p	O
<	O
0.05	O
)	O
than	O
boys	O
at	O
age	O
9	O
.	O

Boys	O
'	O
advantage	O
in	O
mechanography	B-P
parameters	O
emerged	O
in	O
adolescence	O
(	O
age	O
11-13	O
years	O
;	O
3-65	O
%	O
,	O
p	O
<	O
0.05	O
)	O
and	O
persisted	O
into	O
young	O
adulthood	O
,	O
except	O
for	O
Fmax	O
/	O
BW	O
which	O
was	O
not	O
greater	O
in	O
boys	O
until	O
age	O
17	O
(	O
4-10	O
%	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Mechanography	B-P
outcomes	O
were	O
3-9	O
%	O
(	O
p	O
<	O
0.05	O
)	O
greater	O
in	O
Asian	O
compared	O
with	O
white	O
participants	O
.	O

We	O
provide	O
the	O
first	O
reference	O
data	O
for	O
the	O
S2LJ	O
using	O
the	O
hands-on-waist	O
protocol	O
in	O
children	O
,	O
youth	O
and	O
young	O
adults	O
.	O

These	O
data	O
support	O
previous	O
findings	O
using	O
freely	O
moving	O
arms	O
and	O
can	O
be	O
used	O
when	O
evaluating	O
muscle	O
function	O
in	O
pediatric	O
studies	O
.	O

Transcranial	O
magnetic	O
stimulation	O
modifies	O
astrocytosis	O
,	O
cell	O
density	O
and	O
lipopolysaccharide	O
levels	O
in	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
is	O
considered	O
a	O
valid	O
experimental	O
model	O
for	O
multiple	O
sclerosis	O
,	O
a	O
chronic	O
neuroinflammatory	O
condition	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Additionally	O
,	O
some	O
evidence	O
has	O
shown	O
that	O
some	O
microbial	O
products	O
such	O
as	O
the	O
bacterial	O
lipopolysaccharide	O
could	O
lead	O
to	O
the	O
activation	O
of	O
reactive	O
immune	O
cells	O
,	O
triggering	O
neuroinflammation	O
.	O

Several	O
studies	O
have	O
found	O
that	O
transcranial	O
magnetic	O
stimulation	O
(	O
TMS	O
)	O
may	O
exert	O
a	O
neuroprotective	O
effect	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
TMS	O
on	O
the	O
neuroinflammation	O
occurring	O
in	O
EAE	O
.	O

A	O
total	O
of	O
44	O
male	O
Dark	O
Agouti	O
rats	O
were	O
used	O
.	O

EAE	O
induction	O
was	O
performed	O
administering	O
subcutaneously	O
at	O
the	O
dorsal	O
base	O
of	O
the	O
tail	O
a	O
single	O
dose	O
of	O
myelin	O
oligodendrocyte	O
glycoprotein	O
.	O

Clinical	O
evaluation	O
of	O
motor	O
symptoms	O
was	O
performed	O
.	O

Brain	O
and	O
spinal	O
cord	O
were	O
collected	O
and	O
analyzed	O
for	O
nitric	O
oxide	O
,	O
bacterial	O
lipopolysaccharide	O
and	O
lipopolysaccharide-binding	O
protein	O
.	O

We	O
also	O
carried	O
out	O
a	O
histologic	B-P
exam	I-P
,	O
which	O
included	O
an	O
astrocyte	O
immunostaining	B-P
and	O
Nissl	B-P
staining	I-P
for	O
the	O
assessment	O
of	O
brain	O
cell	O
density	O
and	O
pyknotic	O
nuclei	O
.	O

TMS	O
effectively	O
ameliorated	O
motor	O
impairment	O
secondary	O
to	O
EAE	O
.	O

This	O
form	O
of	O
magnetic	O
field	O
was	O
capable	O
of	O
decreasing	O
the	O
proliferation	O
of	O
astrocytes	O
as	O
a	O
response	O
to	O
the	O
autoimmune	O
attack	O
,	O
reducing	O
the	O
content	O
of	O
nitric	O
oxide	O
,	O
bacterial	O
lipopolysaccharide	O
and	O
lipopolysaccharide-binding	O
protein	O
in	O
central	O
nervous	O
system	O
.	O

Moreover	O
,	O
in	O
treated	O
animals	O
,	O
brain	O
cell	O
density	O
was	O
improved	O
and	O
the	O
number	O
of	O
pyknotic	O
nuclei	O
was	O
decreased	O
.	O

Transcranial	O
magnetic	O
stimulation	O
modifies	O
astrocytosis	O
,	O
cell	O
density	O
and	O
lipopolysaccharide	O
levels	O
in	O
EAE	O
.	O

These	O
results	O
suggest	O
that	O
TMS	O
could	O
be	O
a	O
promising	O
treatment	O
for	O
neuroinflammatory	O
conditions	O
such	O
as	O
multiple	O
sclerosis	O
.	O

In	O
Vivo	O
Visualization	B-P
of	O
Cardiomyocyte	O
Apicobasal	O
Polarity	O
Reveals	O
Epithelial	O
to	O
Mesenchymal-like	O
Transition	O
during	O
Cardiac	O
Trabeculation	O
.	O

Despite	O
great	O
strides	O
in	O
understanding	O
cardiac	O
trabeculation	O
,	O
many	O
mechanistic	O
aspects	O
remain	O
unclear	O
.	O

To	O
elucidate	O
how	O
cardiomyocyte	O
shape	O
changes	O
are	O
regulated	O
during	O
this	O
process	O
,	O
we	O
engineered	O
transgenes	O
to	O
label	O
their	O
apical	O
and	O
basolateral	O
membranes	O
.	O

Using	O
these	O
tools	O
,	O
we	O
observed	O
that	O
compact-layer	O
cardiomyocytes	O
are	O
clearly	O
polarized	O
while	O
delaminating	O
cardiomyocytes	O
have	O
lost	O
their	O
polarity	O
.	O

The	O
apical	O
transgene	O
also	O
enabled	O
the	O
imaging	B-P
of	O
cardiomyocyte	O
apical	O
constriction	O
in	O
real	O
time	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
Neuregulin	O
signaling	O
and	O
blood	O
flow	O
/	O
cardiac	O
contractility	O
are	O
required	O
for	O
cardiomyocyte	O
apical	O
constriction	O
and	O
depolarization	O
.	O

Notably	O
,	O
we	O
observed	O
the	O
activation	O
of	O
Notch	O
signaling	O
in	O
cardiomyocytes	O
adjacent	O
to	O
those	O
undergoing	O
apical	O
constriction	O
,	O
and	O
we	O
showed	O
that	O
this	O
activation	O
is	O
positively	O
regulated	O
by	O
Neuregulin	O
signaling	O
.	O

Inhibition	O
of	O
Notch	O
signaling	O
did	O
not	O
increase	O
the	O
percentage	O
of	O
cardiomyocytes	O
undergoing	O
apical	O
constriction	O
or	O
of	O
trabecular	O
cardiomyocytes	O
.	O

These	O
studies	O
provide	O
information	O
about	O
cardiomyocyte	O
polarization	O
and	O
enhance	O
our	O
understanding	O
of	O
the	O
complex	O
mechanisms	O
underlying	O
ventricular	O
morphogenesis	O
and	O
maturation	O
.	O

Observation	O
of	O
Network	O
Dynamics	O
of	O
Ryanodine	O
Receptors	O
on	O
Skeletal	O
Muscle	O
Sarcoplasmic	O
Reticulum	O
Membranes	O
.	O

Rabbit	O
muscle	O
vesicles	O
derived	O
from	O
sarcoplasmic	O
reticulum	O
were	O
used	O
as	O
a	O
material	O
in	O
studying	O
networks	O
of	O
ryanodine	O
receptors	O
by	O
cryo	O
electron	B-P
tomography	I-P
.	O

Three-dimensional	O
analysis	O
reveals	O
the	O
dynamical	O
features	O
of	O
these	O
networks	O
.	O

It	O
was	O
found	O
that	O
the	O
connection	O
angles	O
were	O
rotated	O
along	O
the	O
transmembrane	O
axis	O
of	O
ryanodine	O
receptors	O
.	O

Majority	O
of	O
the	O
connections	O
was	O
observed	O
at	O
domains	O
6/6	O
of	O
ryanodine	O
receptors	O
while	O
a	O
small	O
group	O
of	O
connections	O
were	O
showed	O
at	O
domains	O
9/10	O
.	O

The	O
flexible	O
rotation	O
and	O
connection	O
shift	O
seem	O
to	O
facilitate	O
the	O
extension	O
of	O
an	O
annular	O
network	O
on	O
the	O
wall	O
of	O
the	O
sarcoplasmic	O
reticulum	O
in	O
a	O
triad	O
.	O

Crocetin	O
improves	O
the	O
quality	O
of	O
in	O
vitro	O
-	O
produced	O
bovine	O
embryos	O
:	O
Implications	O
for	O
blastocyst	O
development	O
,	O
cryotolerance	O
,	O
and	O
apoptosis	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
assess	O
the	O
effect	O
of	O
supplementation	O
of	O
bovine	O
culture	O
medium	O
with	O
the	O
natural	O
antioxidant	O
crocetin	O
on	O
in	O
vitro	O
blastocyst	O
development	O
and	O
quality	O
.	O

This	O
was	O
evaluated	O
as	O
cryotolerance	O
,	O
apoptosis	O
index	O
,	O
and	O
total	B-P
cells	I-P
number	I-P
and	O
allocation	O
.	O

Abattoir	O
-derived	O
oocytes	O
were	O
matured	O
and	O
fertilized	O
in	O
vitro	O
according	O
to	O
standard	O
procedure	O
.	O

Twenty	O
hours	O
after	O
IVF	O
,	O
presumptive	O
zygotes	O
were	O
cultured	B-P
in	O
synthetic	O
oviduct	O
fluid	O
medium	O
,	O
supplemented	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μM	O
crocetin	O
(	O
experiment	O
1	O
)	O
at	O
39	O
°C	O
under	O
humidified	O
air	O
with	O
5	O
%	O
CO2	O
,	O
7	O
%	O
O2	O
,	O
and	O
88	O
%	O
N2	O
.	O

On	O
Day	O
7	O
,	O
embryo	O
yields	O
were	O
assessed	O
and	O
the	O
blastocysts	O
were	O
vitrified	O
by	O
Cryotop	O
method	O
in	O
16.5	O
%	O
ethylene	O
glycol	O
,	O
16.5	O
%	O
DMSO	O
,	O
and	O
0.5	O
M	O
sucrose	O
.	O

Finally	O
,	O
blastocysts	O
produced	O
on	O
Day	O
8	O
in	O
the	O
absence	O
(	O
control	O
)	O
and	O
presence	O
of	O
1	O
μM	O
crocetin	O
were	O
used	O
for	O
terminal	O
deoxynucleotidyl	O
transferase-mediated	O
dUTP	O
nick	O
end	O
labelling	O
and	O
differential	B-P
staining	I-P
to	O
evaluate	O
,	O
respectively	O
,	O
the	O
apoptotic	O
rate	O
and	O
the	O
allocation	O
of	O
cells	O
into	O
inner	O
cell	O
mass	O
(	O
ICM	O
)	O
and	O
trophectoderm	O
(	O
TE	O
)	O
lineages	O
(	O
experiment	O
2	O
)	O
.	O

Embryo	O
development	O
was	O
higher	O
in	O
the	O
1	O
μM	O
crocetin	O
group	O
compared	O
to	O
the	O
control	O
,	O
both	O
in	O
terms	O
of	O
total	O
embryo	O
output	O
(	O
37.7	O
±	O
4.2	O
%	O
,	O
52.9	O
±	O
6.3	O
%	O
,	O
40.9	O
±	O
7.6	O
%	O
,	O
and	O
42.4	O
±	O
8.7	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0.01	O
)	O
and	O
grade	O
1	O
and	O
2	O
blastocysts	O
(	O
33.6	O
±	O
4.9	O
%	O
,	O
46.1	O
±	O
7.3	O
%	O
,	O
37.8	O
±	O
7.9	O
%	O
,	O
and	O
39.4	O
±	O
7.9	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0.05	O
)	O
.	O

Moreover	O
,	O
the	O
percentage	O
of	O
fast-developing	O
embryos	O
increased	O
in	O
1	O
μM	O
crocetin	O
group	O
compared	O
to	O
the	O
control	O
(	O
23.4	O
±	O
4.7	O
%	O
,	O
32.7	O
±	O
6.6	O
%	O
,	O
27.2	O
±	O
6.6	O
%	O
,	O
and	O
30.1	O
±	O
7.2	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
the	O
enrichment	O
of	O
culture	O
medium	O
with	O
1	O
μM	O
crocetin	O
improved	O
embryo	O
cryotolerance	O
compared	O
to	O
the	O
control	O
,	O
as	O
indicated	O
by	O
higher	O
hatching	O
rates	O
recorded	O
after	O
48	O
hours	O
postwarming	O
culture	O
(	O
46.5	O
%	O
vs.	O
60.4	O
%	O
;	O
P	O
<	O
0.05	O
)	O
.	O

Furthermore	O
,	O
1	O
μM	O
crocetin	O
decreased	O
both	O
the	O
average	O
number	O
(	O
9.9	O
±	O
0.4	O
vs.	O
7.1	O
±	O
0.3	O
)	O
and	O
the	O
percentage	O
of	O
apoptotic	O
cells	O
(	O
7.1	O
±	O
0.4	O
vs.	O
4.2	O
±	O
0.2	O
)	O
in	O
blastocysts	O
compared	O
to	O
the	O
control	O
(	O
P	O
<	O
0.01	O
)	O
.	O

However	O
,	O
no	O
differences	O
were	O
recorded	O
in	O
the	O
average	O
number	O
of	O
ICM	O
,	O
TE	O
,	O
and	O
total	O
cells	O
between	O
1	O
μM	O
crocetin	O
and	O
control	O
groups	O
.	O

In	O
conclusion	O
,	O
the	O
enrichment	O
of	O
bovine	O
culture	O
medium	O
with	O
1	O
μM	O
crocetin	O
increased	O
both	O
blastocyst	O
yield	O
and	O
quality	O
,	O
as	O
indicated	O
by	O
the	O
improved	O
chronology	O
of	O
embryo	O
development	O
,	O
increased	O
resistance	O
to	O
cryopreservation	B-P
,	O
and	O
reduced	O
incidence	O
of	O
apoptosis	O
.	O

A	O
Support	O
Vector	O
Machine	O
Classification	O
of	O
Thyroid	O
Bioptic	O
Specimens	O
Using	O
MALDI-MSI	B-P
Data	O
.	O

Biomarkers	O
able	O
to	O
characterise	O
and	O
predict	O
multifactorial	O
diseases	O
are	O
still	O
one	O
of	O
the	O
most	O
important	O
targets	O
for	O
all	O
the	O
``	O
omics	O
``	O
investigations	O
.	O

In	O
this	O
context	O
,	O
Matrix-Assisted	B-P
Laser	I-P
Desorption/Ionisation-Mass	I-P
Spectrometry	I-P
Imaging	I-P
(	O
MALDI-MSI	B-P
)	O
has	O
gained	O
considerable	O
attention	O
in	O
recent	O
years	O
,	O
but	O
it	O
also	O
led	O
to	O
a	O
huge	O
amount	O
of	O
complex	O
data	O
to	O
be	O
elaborated	O
and	O
interpreted	O
.	O

For	O
this	O
reason	O
,	O
computational	O
and	O
machine	O
learning	O
procedures	O
for	O
biomarker	O
discovery	O
are	O
important	O
tools	O
to	O
consider	O
,	O
both	O
to	O
reduce	O
data	O
dimension	O
and	O
to	O
provide	O
predictive	O
markers	O
for	O
specific	O
diseases	O
.	O

For	O
instance	O
,	O
the	O
availability	O
of	O
protein	O
and	O
genetic	O
markers	O
to	O
support	O
thyroid	O
lesion	O
diagnoses	O
would	O
impact	O
deeply	O
on	O
society	O
due	O
to	O
the	O
high	O
presence	O
of	O
undetermined	O
reports	O
(	O
THY3	O
)	O
that	O
are	O
generally	O
treated	O
as	O
malignant	O
patients	O
.	O

In	O
this	O
paper	O
we	O
show	O
how	O
an	O
accurate	O
classification	O
of	O
thyroid	O
bioptic	O
specimens	O
can	O
be	O
obtained	O
through	O
the	O
application	O
of	O
a	O
state-of-the-art	O
machine	O
learning	O
approach	O
(	O
i.e.	O
,	O
Support	O
Vector	O
Machines	O
)	O
on	O
MALDI-MSI	B-P
data	O
,	O
together	O
with	O
a	O
particular	O
wrapper	O
feature	O
selection	O
algorithm	O
(	O
i.e.	O
,	O
recursive	O
feature	O
elimination	O
)	O
.	O

The	O
model	O
is	O
able	O
to	O
provide	O
an	O
accurate	O
discriminatory	O
capability	O
using	O
only	O
20	O
out	O
of	O
144	O
features	O
,	O
resulting	O
in	O
an	O
increase	O
of	O
the	O
model	O
performances	O
,	O
reliability	O
,	O
and	O
computational	O
efficiency	O
.	O

Finally	O
,	O
tissue	O
areas	O
rather	O
than	O
average	O
proteomic	O
profiles	O
are	O
classified	O
,	O
highlighting	O
potential	O
discriminating	O
areas	O
of	O
clinical	O
interest	O
.	O

Haemoglobinopathies	O
and	O
β-Thalassaemia	O
among	O
the	O
Tribals	O
Working	O
in	O
the	O
Tea	O
Gardens	O
of	O
Assam	O
,	O
India	O
.	O

Prevalence	O
of	O
haemoglobinopathies	O
and	O
β-thalassaemia	O
are	O
very	O
high	O
in	O
India	O
but	O
information	O
about	O
its	O
status	O
among	O
the	O
tribals	O
working	O
in	O
the	O
tea	O
gardens	O
of	O
Assam	O
is	O
very	O
less	O
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
prevalence	O
of	O
haemoglobinopathies	O
and	O
β-thalassaemia	O
among	O
the	O
tribals	O
working	O
in	O
the	O
tea	O
gardens	O
of	O
Assam	O
.	O

A	O
total	O
1204	O
samples	O
from	O
the	O
tribals	O
working	O
in	O
tea	O
gardens	O
of	O
Assam	O
were	O
analysed	O
for	O
both	O
Complete	B-P
Blood	I-P
Count	I-P
(	O
CBC	B-P
)	O
and	O
High	B-P
Pressure	I-P
Liquid	I-P
Chromatography	I-P
(	O
HPLC	B-P
)	O
for	O
detection	O
of	O
haemoglobinopathies	O
and	O
β-thalassaemia	O
.	O

This	O
study	O
showed	O
that	O
the	O
prevalence	O
of	O
sickle	O
cell	O
anaemia	O
and	O
β-thalassaemia	O
were	O
very	O
high	O
among	O
this	O
population	O
.	O

Our	O
results	O
indicated	O
a	O
higher	O
prevalence	O
of	O
β-thalassaemia	O
(	O
3.07	O
%	O
)	O
among	O
the	O
Munda	O
ethnic	O
group	O
and	O
higher	O
prevalence	O
of	O
sickle	O
cell	O
anaemia	O
(	O
4.73	O
%	O
)	O
among	O
the	O
Lohar	O
ethnic	O
group	O
.	O

This	O
was	O
the	O
first	O
study	O
to	O
report	O
the	O
presence	O
of	O
HbE	O
among	O
the	O
tribals	O
working	O
in	O
the	O
tea	O
gardens	O
of	O
Assam	O
.	O

Based	O
on	O
the	O
present	O
findings	O
,	O
sickle	O
cell	O
anaemia	O
and	O
β-thalassaemia	O
were	O
major	O
health	O
problem	O
for	O
the	O
tribals	O
working	O
in	O
the	O
tea	O
gardens	O
of	O
Assam	O
.	O

Proper	O
diagnostic	O
facilities	O
for	O
haemoglobinopathy	O
and	O
thalassaemia	O
should	O
be	O
established	O
in	O
these	O
areas	O
,	O
including	O
establishment	O
of	O
haemoglobinopathy	O
and	O
thalassaemia	O
database	O
collection	O
,	O
haematological	O
analysis	O
laboratories	O
,	O
genetic	O
counselling	O
clinics	O
,	O
prenatal	O
diagnosis	O
centres	O
and	O
neonatal	O
screening	O
centres	O
.	O

Approximate	O
Bayesian	O
computation	O
for	O
estimating	O
number	O
concentrations	O
of	O
monodisperse	O
nanoparticles	O
in	O
suspension	O
by	O
optical	B-P
microscopy	I-P
.	O

We	O
present	O
an	O
approximate	O
Bayesian	O
computation	O
scheme	O
for	O
estimating	O
number	O
concentrations	O
of	O
monodisperse	O
diffusing	O
nanoparticles	O
in	O
suspension	O
by	O
optical	B-P
particle	I-P
tracking	I-P
microscopy	I-P
.	O

The	O
method	O
is	O
based	O
on	O
the	O
probability	O
distribution	O
of	O
the	O
time	O
spent	O
by	O
a	O
particle	O
inside	O
a	O
detection	O
region	O
.	O

We	O
validate	O
the	O
method	O
on	O
suspensions	O
of	O
well-controlled	O
reference	O
particles	O
.	O

We	O
illustrate	O
its	O
usefulness	O
with	O
an	O
application	O
in	O
gene	O
therapy	O
,	O
applying	O
the	O
method	O
to	O
estimate	O
number	O
concentrations	O
of	O
plasmid	O
DNA	O
molecules	O
and	O
the	O
average	O
number	O
of	O
DNA	O
molecules	O
complexed	O
with	O
liposomal	O
drug	O
delivery	O
particles	O
.	O

A	O
novel	O
method	O
for	O
interactive	O
multi-objective	O
dose-guided	O
patient	O
positioning	O
.	O

In	O
intensity-modulated	O
radiation	O
therapy	O
(	O
IMRT	O
)	O
,	O
3D	O
in-room	O
imaging	B-P
data	O
is	O
typically	O
utilized	O
for	O
accurate	O
patient	O
alignment	O
on	O
the	O
basis	O
of	O
anatomical	O
landmarks	O
.	O

In	O
the	O
presence	O
of	O
non-rigid	O
anatomical	O
changes	O
,	O
it	O
is	O
often	O
not	O
obvious	O
which	O
patient	O
position	O
is	O
most	O
suitable	O
.	O

Thus	O
,	O
dose	O
-guided	O
patient	O
alignment	O
is	O
an	O
interesting	O
approach	O
to	O
use	O
available	O
in-room	O
imaging	B-P
data	O
for	O
up-to-date	O
dose	O
calculation	O
,	O
aimed	O
at	O
finding	O
the	O
position	O
that	O
yields	O
the	O
optimal	O
dose	O
distribution	O
.	O

This	O
contribution	O
presents	O
the	O
first	O
implementation	O
of	O
dose	O
-guided	O
patient	O
alignment	O
as	O
multi-criteria	O
optimization	O
problem	O
.	O

User-defined	O
clinical	O
objectives	O
are	O
employed	O
for	O
setting	O
up	O
a	O
multi-objective	O
problem	O
.	O

Using	O
pre-calculated	O
dose	O
distributions	O
at	O
a	O
limited	O
number	O
of	O
patient	O
shifts	O
and	O
dose	O
interpolation	O
,	O
a	O
continuous	O
space	O
of	O
Pareto-efficient	O
patient	O
shifts	O
becomes	O
accessible	O
.	O

Pareto	O
sliders	O
facilitate	O
interactive	O
browsing	O
of	O
the	O
possible	O
shifts	O
with	O
real-time	O
dose	O
display	O
to	O
the	O
user	O
.	O

Dose	O
interpolation	O
accuracy	O
is	O
validated	O
and	O
the	O
potential	O
of	O
multi-objective	O
dose-guided	O
positioning	O
demonstrated	O
for	O
three	O
head	O
and	O
neck	O
(	O
H	O
&	O
N	O
)	O
and	O
three	O
prostate	O
cancer	O
patients	O
.	O

Dose-guided	O
positioning	O
is	O
compared	O
to	O
replanning	O
for	O
all	O
cases	O
.	O

A	O
delineated	O
replanning	O
CT	B-P
served	O
as	O
surrogate	O
for	O
in-room	O
imaging	B-P
data	O
.	O

Dose	O
interpolation	O
accuracy	O
was	O
high	O
.	O

Using	O
a	O
[	O
Formula	O
:	O
see	O
text	O
]	O
dose	O
difference	O
criterion	O
,	O
a	O
median	O
pass-rate	O
of	O
95.7	O
%	O
for	O
H	O
&	O
N	O
and	O
99.6	O
%	O
for	O
prostate	O
cases	O
was	O
determined	O
in	O
a	O
comparison	O
to	O
exact	O
dose	O
calculations	O
.	O

For	O
all	O
patients	O
,	O
dose-guided	O
positioning	O
allowed	O
to	O
find	O
a	O
clinically	O
preferable	O
dose	O
distribution	O
compared	O
to	O
bony	O
anatomy	O
based	O
alignment	O
.	O

For	O
all	O
H	O
&	O
N	O
cases	O
,	O
mean	O
dose	O
to	O
the	O
spared	O
parotid	O
glands	O
was	O
below	O
[	O
Formula	O
:	O
see	O
text	O
]	O
(	O
up	O
to	O
[	O
Formula	O
:	O
see	O
text	O
]	O
with	O
bony	O
alignment	O
)	O
and	O
clinical	O
target	O
volume	O
(	O
CTV	O
)	O
[	O
Formula	O
:	O
see	O
text	O
]	O
above	O
99.1	O
%	O
(	O
compared	O
to	O
95.1	O
%	O
)	O
.	O

For	O
all	O
prostate	O
patients	O
,	O
CTV	O
[	O
Formula	O
:	O
see	O
text	O
]	O
was	O
above	O
98.9	O
%	O
(	O
compared	O
to	O
88.5	O
%	O
)	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
to	O
the	O
rectum	O
below	O
[	O
Formula	O
:	O
see	O
text	O
]	O
(	O
compared	O
to	O
56.1	O
%	O
)	O
.	O

Replanning	O
yielded	O
improved	O
results	O
for	O
the	O
H	O
&	O
N	O
cases	O
.	O

For	O
the	O
prostate	O
cases	O
,	O
differences	O
to	O
dose-guided	O
positioning	O
were	O
minor	O
.	O

Insensitivity	O
of	O
astrocytes	O
to	O
interleukin	O
10	O
signaling	O
following	O
peripheral	O
immune	O
challenge	O
results	O
in	O
prolonged	O
microglial	O
activation	O
in	O
the	O
aged	O
brain	O
.	O

Immune-activated	O
microglia	O
from	O
aged	O
mice	O
produce	O
exaggerated	O
levels	O
of	O
cytokines	O
.	O

Despite	O
high	O
levels	O
of	O
microglia	O
l	O
interleukin	O
(	O
IL	O
)	O
-10	O
in	O
the	O
aged	O
brain	O
,	O
neuroinflammation	O
was	O
prolonged	O
and	O
associated	O
with	O
depressive-like	O
deficits	O
.	O

Because	O
astrocytes	O
respond	O
to	O
IL-10	O
and	O
,	O
in	O
turn	O
,	O
attenuate	O
microglial	O
activation	O
,	O
we	O
investigated	O
if	O
astrocyte-mediated	O
resolution	O
of	O
microglial	O
activation	O
was	O
impaired	O
with	O
age	O
.	O

Here	O
,	O
aged	O
astrocytes	O
had	O
a	O
dysfunctional	O
profile	O
with	O
higher	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
lower	O
glutamate	O
transporter	O
expression	O
,	O
and	O
significant	O
cytoskeletal	O
re-arrangement	O
.	O

Moreover	O
,	O
aged	O
astrocytes	O
had	O
reduced	O
expression	O
of	O
growth	O
factors	O
and	O
IL-10	O
receptor-1	O
(	O
IL-10R1	O
)	O
.	O

After	O
in	O
vivo	O
lipopolysaccharide	O
immune	O
challenge	O
,	O
aged	O
astrocytes	O
had	O
a	O
molecular	O
signature	O
associated	O
with	O
reduced	O
responsiveness	O
to	O
IL-10	O
.	O

This	O
IL-10	O
insensitivity	O
of	O
aged	O
astrocytes	O
resulted	O
in	O
a	O
failure	O
to	O
induce	O
IL-10R1	O
and	O
transforming	O
growth	O
factor	O
β	O
and	O
resolve	O
microglial	O
activation	O
.	O

In	O
addition	O
,	O
adult	O
astrocytes	O
reduced	O
microglial	O
activation	O
when	O
co-cultured	B-P
ex	O
vivo	O
,	O
whereas	O
aged	O
astrocytes	O
did	O
not	O
.	O

Consistent	O
with	O
the	O
aging	O
studies	O
,	O
IL-10R	O
(	O
KO	O
)	O
astrocytes	O
did	O
not	O
augment	O
transforming	O
growth	O
factor	O
β	O
after	O
immune	O
challenge	O
and	O
failed	O
to	O
resolve	O
microglial	O
activation	O
.	O

Collectively	O
,	O
a	O
major	O
cytokine	O
-	O
regulatory	O
loop	O
between	O
activated	O
microglia	O
and	O
astrocytes	O
is	O
impaired	O
in	O
the	O
aged	O
brain	O
.	O

Effects	O
of	O
a	O
novel	O
phosphodiesterase	O
10A	O
inhibitor	O
in	O
non-human	O
primates	O
:	O
A	O
therapeutic	O
approach	O
for	O
schizophrenia	O
with	O
improved	O
side	O
effect	O
profile	O
.	O

Schizophrenia	O
symptoms	O
are	O
associated	O
with	O
alterations	O
in	O
basal	O
ganglia-cortical	O
networks	O
that	O
include	O
the	O
cyclic	O
nucleotides	O
(	O
cAMP	O
/	O
cGMP	O
)	O
signaling	O
pathways	O
.	O

Phosphodiesterase	O
10A	O
(	O
PDE10A	O
)	O
inhibitors	O
have	O
been	O
considered	O
as	O
therapeutic	O
agents	O
for	O
schizophrenia	O
because	O
the	O
regulation	O
of	O
cAMP	O
and	O
cGMP	O
in	O
the	O
striatum	O
by	O
PDE10A	O
plays	O
an	O
important	O
role	O
in	O
the	O
signaling	O
mechanisms	O
of	O
the	O
striatal-cortical	O
network	O
,	O
and	O
thereby	O
in	O
cognitive	O
function	O
.	O

In	O
the	O
present	O
study	O
we	O
assessed	O
in	O
non-human	O
primates	O
(	O
NHPs	O
)	O
the	O
effects	O
of	O
a	O
novel	O
PDE10A	O
inhibitor	O
(	O
FRM-6308	O
)	O
that	O
has	O
demonstrated	O
high	O
potency	O
and	O
selectivity	O
for	O
human	O
recombinant	O
PDE10A	O
in	O
vitro	O
.	O

The	O
behavioral	O
effects	O
of	O
FRM-6308	O
in	O
a	O
dose	O
range	O
were	O
determined	O
in	O
rhesus	O
monkeys	O
using	O
a	O
standardized	O
motor	O
disability	O
scale	O
for	O
primates	O
,	O
motor	O
tasks	O
,	O
and	O
the	O
``	O
drug	O
effects	O
on	O
the	O
nervous	O
system	O
''	O
(	O
DENS	O
)	O
scale	O
.	O

The	O
neuronal	O
metabolic	O
effects	O
of	O
FRM-6308	O
were	O
determined	O
with	O
[	B-P
(	I-P
18	I-P
)	I-P
F	I-P
]	I-P
-fluorodeoxyglucose	I-P
PET	I-P
imaging	I-P
.	O

Results	O
showed	O
that	O
FRM-6308	O
did	O
not	O
have	O
any	O
specific	O
effects	O
on	O
the	O
motor	O
system	O
at	O
s.c.	O
doses	O
up	O
to	O
0.32	O
mg/kg	O
in	O
NHPs	O
,	O
which	O
induced	O
a	O
significant	O
increase	O
in	O
the	O
FDG	O
-	O
SUV	O
in	O
striatum	O
(	O
F	O
16.069	O
,	O
p	O
<	O
0.05	O
)	O
and	O
cortical	O
(	O
F	O
15.181	O
,	O
p	O
<	O
0.05	O
)	O
regions	O
.	O

Higher	O
doses	O
induced	O
sedation	O
and	O
occasional	O
involuntary	O
movements	O
with	O
clear	O
development	O
of	O
tolerance	O
after	O
repeated	O
exposures	O
.	O

These	O
findings	O
suggest	O
that	O
FRM-6308	O
has	O
the	O
adequate	O
pharmacological	O
profile	O
to	O
advance	O
testing	O
in	O
clinical	O
trials	O
and	O
demonstrate	O
antipsychotic	O
efficacy	O
of	O
PDE10A	O
inhibition	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
patients	O
.	O

Primary	O
pituitary	O
diffuse	O
large	O
B-cell	O
lymphoma	O
with	O
somatotroph	O
hyperplasia	O
and	O
acromegaly	O
:	O
case	O
report	O
.	O

Diffuse	O
large	O
B-cell	O
lymphoma	O
(	O
DLBCL	O
)	O
is	O
the	O
most	O
common	O
type	O
of	O
non-Hodgkin	O
lymphoma	O
and	O
comprises	O
approximately	O
30	O
%	O
of	O
all	O
lymphomas	O
.	O

Patients	O
typically	O
present	O
with	O
a	O
nonpainful	O
mass	O
in	O
the	O
neck	O
,	O
groin	O
,	O
or	O
abdomen	O
associated	O
with	O
constitutional	O
symptoms	O
.	O

In	O
this	O
report	O
,	O
however	O
,	O
the	O
authors	O
describe	O
a	O
rare	O
case	O
of	O
a	O
61-	O
year	O
-old	O
woman	O
with	O
hyperprolactinemia	O
,	O
hypothyroidism	O
,	O
and	O
acromegaly	O
(	O
elevation	O
of	O
insulin-like	O
growth	O
factor-1	O
[	O
IGF-1	O
]	O
)	O
with	O
elevated	O
growth	O
hormone-releasing	O
hormone	O
(	O
GHRH	O
)	O
in	O
whom	O
an	O
MRI	B-P
demonstrated	O
diffuse	O
enlargement	O
of	O
the	O
pituitary	O
gland	O
.	O

Despite	O
medical	O
treatment	O
,	O
the	O
patient	O
had	O
persistent	O
elevation	O
of	O
IGF-1	O
.	O

She	O
underwent	O
a	O
transsphenoidal	B-P
biopsy	I-P
,	O
which	O
yielded	O
a	O
diagnosis	O
of	O
DLBCL	O
with	O
an	O
activated	O
B-cell	O
immunophenotype	B-P
with	O
somatotroph	O
hyperplasia	O
.	O

After	O
stereo-tactic	O
radiation	O
therapy	O
in	O
combination	O
with	O
chemotherapy	O
,	O
she	O
is	O
currently	O
in	O
remission	O
from	O
her	O
lymphoma	O
and	O
has	O
normalized	O
IGF-1	O
levels	O
without	O
medical	O
therapy	O
,	O
8	O
months	O
after	O
her	O
histopathological	O
diagnosis	O
.	O

This	O
is	O
the	O
only	O
reported	O
case	O
of	O
its	O
kind	O
and	O
displays	O
the	O
importance	O
of	O
a	O
broad	O
differential	B-P
diagnosis	I-P
,	O
multidisciplinary	B-P
evaluation	I-P
,	O
and	O
critical	O
intraoperative	O
decision-making	O
when	O
treating	O
atypical	O
sellar	O
lesions	O
.	O

Causes	O
of	O
Death	O
among	O
Children	O
Aged	O
5	O
to	O
14	O
Years	O
Old	O
from	O
2008	O
to	O
2013	O
in	O
Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
Kersa	O
HDSS	O
)	O
,	O
Ethiopia	O
.	O

The	O
global	O
burden	O
of	O
mortality	O
among	O
children	O
is	O
still	O
very	O
huge	O
though	O
its	O
trend	O
has	O
started	O
declining	O
following	O
the	O
improvements	O
in	O
the	O
living	O
standard	O
.	O

It	O
presents	O
serious	O
challenges	O
to	O
the	O
well-being	O
of	O
children	O
in	O
many	O
African	O
countries	O
.	O

Today	O
,	O
Sub-Saharan	O
Africa	O
alone	O
accounts	O
for	O
about	O
50	O
%	O
of	O
global	O
child	O
mortality	O
.	O

The	O
overall	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
magnitude	O
and	O
distribution	O
of	O
causes	O
of	O
death	O
among	O
children	O
aged	O
5	O
to	O
14	O
year	O
olds	O
in	O
the	O
population	O
of	O
Kersa	O
HDSS	O
using	O
verbal	O
autopsy	B-P
method	O
for	O
the	O
period	O
2008	O
to	O
2013	O
.	O

Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
Kersa	O
HDSS	O
)	O
was	O
established	O
in	O
September	O
2007	O
.	O

The	O
center	O
consists	O
of	O
10	O
rural	O
and	O
2	O
urban	O
kebeles	O
which	O
were	O
selected	O
randomly	O
from	O
38	O
kebeles	O
in	O
the	O
district	O
.	O

Thus	O
this	O
study	O
was	O
conducted	O
in	O
Kersa	O
HDSS	O
and	O
data	O
was	O
taken	O
from	O
Kersa	O
HDSS	O
database	O
.	O

The	O
study	O
population	O
included	O
all	O
children	O
aged	O
5	O
to	O
14	O
years	O
registered	O
during	O
the	O
period	O
of	O
2008	O
to	O
2013	O
in	O
Kersa	O
HDSS	O
using	O
age	O
specific	O
VA	O
questionnaires	O
.	O

Data	O
were	O
extracted	O
from	O
SPSS	O
database	O
and	O
analyzed	O
using	O
STATA	O
.	O

A	O
total	O
of	O
229	O
deaths	O
were	O
recorded	O
over	O
the	O
period	O
of	O
six	O
years	O
with	O
a	O
crude	O
death	O
rate	O
of	O
219.6	O
per	O
100,000	O
population	O
of	O
this	O
age	O
group	O
over	O
the	O
study	O
period	O
.	O

This	O
death	O
rate	O
was	O
217.5	O
and	O
221.5	O
per	O
100,000	O
populations	O
for	O
females	O
and	O
males	O
,	O
respectively	O
.	O

75	O
%	O
of	O
deaths	O
took	O
place	O
at	O
home	O
.	O

The	O
study	O
identified	O
severe	O
malnutrition	O
(	O
33.9	O
%	O
)	O
,	O
intestinal	O
infectious	O
diseases	O
(	O
13.8	O
%	O
)	O
and	O
acute	O
lower	O
respiratory	O
infections	O
(	O
9.2	O
%	O
)	O
to	O
be	O
the	O
three	O
most	O
leading	O
causes	O
of	O
death	O
.	O

In	O
broad	O
causes	O
of	O
death	O
classification	O
,	O
injuries	O
have	O
been	O
found	O
to	O
be	O
the	O
second	O
most	O
cause	O
of	O
death	O
next	O
to	O
communicable	O
diseases	O
(	O
56.3	O
%	O
)	O
attributing	O
to	O
13.1	O
%	O
of	O
the	O
total	O
deaths	O
.	O

In	O
specific	O
causes	O
of	O
death	O
classification	O
severe	O
malnutrition	O
,	O
intestinal	O
infectious	O
diseases	O
and	O
acute	O
lower	O
respiratory	O
infections	O
were	O
the	O
three	O
leading	O
causes	O
of	O
death	O
where	O
,	O
in	O
broad	O
causes	O
of	O
death	O
communicable	O
diseases	O
and	O
injuries	O
were	O
among	O
the	O
leading	O
causes	O
of	O
death	O
.	O

Hence	O
,	O
concerned	O
bodies	O
should	O
take	O
measures	O
to	O
avert	O
the	O
situation	O
of	O
mortality	O
from	O
these	O
causes	O
of	O
death	O
and	O
further	O
inferential	O
analysis	O
into	O
the	O
prevention	O
and	O
management	O
of	O
infectious	O
diseases	O
should	O
also	O
be	O
taken	O
.	O

Volumetric	B-P
absorptive	I-P
microsampling	I-P
at	O
home	O
as	O
an	O
alternative	O
tool	O
for	O
the	O
monitoring	O
of	O
HbA1c	O
in	O
diabetes	O
patients	O
.	O

Microsampling	O
techniques	O
have	O
several	O
advantages	O
over	O
traditional	O
blood	B-P
collection	I-P
.	O

Dried	B-P
blood	I-P
spot	I-P
(	I-P
DBS	I-P
)	I-P
sampling	I-P
and	O
blood	B-P
collection	I-P
with	O
heparinized	O
capillaries	O
are	O
the	O
standard	O
techniques	B-P
.	O

Volumetric	B-P
absorptive	I-P
microsampling	I-P
(	O
VAMS	B-P
)	O
is	O
a	O
novel	O
technique	B-P
that	O
collects	O
a	O
fixed	O
volume	O
of	O
blood	O
by	O
applying	O
an	O
absorbent	O
tip	O
to	O
a	O
blood	O
drop	O
.	O

In	O
the	O
present	O
study	O
we	O
explored	O
the	O
feasibility	O
of	O
HbA1c	O
monitoring	O
with	O
VAMS	B-P
sampling	I-P
at	O
home	O
and	O
analysis	O
in	O
the	O
laboratory	O
.	O

Diabetic	O
patients	O
were	O
enrolled	O
in	O
this	O
study	O
during	O
consultation	O
with	O
the	O
endocrinologist	O
.	O

A	O
venous	O
(	O
adults	O
)	O
or	O
capillary	O
(	O
children	O
)	O
sample	O
was	O
taken	O
for	O
immediate	O
HbA1c	O
analysis	O
.	O

DBS	B-P
(	O
n=1	O
)	O
and	O
dried	B-P
VAMS	I-P
(	O
n=2	O
)	O
were	O
collected	O
at	O
home	O
and	O
sent	O
to	O
the	O
laboratory	O
.	O

For	O
25	O
pediatric	O
patients	O
one	O
VAMS	B-P
was	O
collected	O
during	O
consultation	O
for	O
immediate	O
analysis	O
(	O
without	O
drying	O
)	O
,	O
referred	O
to	O
as	O
``	O
wet	B-P
VAMS	I-P
``	O
.	O

HbA1c	O
analyses	O
were	O
performed	O
on	O
a	O
Tosoh	O
HLC-723	O
G8	O
high-performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
analyzer	O
.	O

The	O
median	O
time	O
between	O
sampling	B-P
at	O
home	O
and	O
analysis	O
was	O
3	O
days	O
.	O

Results	O
of	O
HbA1c	O
in	O
dried	O
VAMS	B-P
showed	O
a	O
poor	O
agreement	O
with	O
venous	O
/	O
capillary	O
blood	O
collected	O
in	O
hospital	O
(	O
concordance	O
correlation	O
coefficient	O
CCC	O
=0.72	O
)	O
.	O

Similar	O
observations	O
were	O
found	O
with	O
standard	O
DBS	B-P
.	O

An	O
excellent	O
agreement	O
was	O
obtained	O
between	O
HbA1c	O
results	O
on	O
wet	B-P
VAMS	I-P
(	O
CCC	O
=0.996	O
)	O
and	O
standard	O
blood	O
samples	O
.	O

Patients	O
experienced	O
VAMS	B-P
and	O
DBS	B-P
as	O
easy	O
and	O
convenient	O
to	O
use	O
.	O

Utilizing	O
equipment	O
standard	O
available	O
in	O
the	O
clinical	O
laboratory	O
,	O
the	O
use	O
of	O
home	O
-sampled	O
dried	B-P
VAMS	I-P
and	O
DBS	B-P
is	O
not	O
a	O
reliable	O
tool	O
for	O
the	O
monitoring	O
of	O
HbA1c	O
.	O

However	O
,	O
perfect	O
agreement	O
between	O
HbA1c	O
measured	O
on	O
wet	B-P
VAMS	I-P
and	O
capillary	O
microsamples	O
was	O
obtained	O
.	O

Unbiased	O
estimates	O
of	O
cerebrospinal	O
fluid	O
β-amyloid	O
1-42	O
cutoffs	O
in	O
a	O
large	O
memory	O
clinic	O
population	O
.	O

We	O
sought	O
to	O
define	O
a	O
cutoff	O
for	O
β-amyloid	O
1-42	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
,	O
a	O
key	O
marker	O
for	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
with	O
data-driven	O
Gaussian	O
mixture	O
modeling	O
in	O
a	O
memory	O
clinic	O
population	O
.	O

We	O
performed	O
a	O
combined	O
cross-sectional	O
and	O
prospective	O
cohort	O
study	O
.	O

We	O
selected	O
2462	O
subjects	O
with	O
subjective	O
cognitive	O
decline	O
,	O
mild	O
cognitive	O
impairment	O
,	O
AD	O
-type	O
dementia	O
,	O
and	O
dementia	O
other	O
than	O
AD	O
from	O
the	O
Amsterdam	O
Dementia	O
Cohort	O
.	O

We	O
defined	O
CSF	O
β-amyloid	O
1-42	O
cutoffs	O
by	O
data-driven	O
Gaussian	O
mixture	O
modeling	O
in	O
the	O
total	O
population	O
and	O
in	O
subgroups	O
based	O
on	O
clinical	B-P
diagnosis	I-P
,	O
age	O
,	O
and	O
apolipoprotein	B-P
E	I-P
(	I-P
APOE	I-P
)	I-P
genotype	I-P
.	O

We	O
investigated	O
whether	O
abnormal	O
β-amyloid	O
1-42	O
as	O
defined	O
by	O
the	O
data-driven	O
cutoff	O
could	O
better	O
predict	O
progression	O
to	O
AD	O
-type	O
dementia	O
than	O
abnormal	O
β-amyloid	O
1-42	O
defined	O
by	O
a	O
clinical	B-P
diagnosis	I-P
-based	O
cutoff	O
using	O
Cox	O
proportional	O
hazards	O
regression	O
.	O

In	O
the	O
total	O
group	O
of	O
patients	O
,	O
we	O
found	O
a	O
cutoff	O
for	O
abnormal	O
CSF	O
β-amyloid	O
1-42	O
of	O
680	O
pg/ml	O
(	O
95	O
%	O
CI	O
660-705	O
pg/ml	O
)	O
.	O

Similar	O
cutoffs	O
were	O
found	O
within	O
diagnostic	O
and	O
APOE	B-P
genotype	I-P
subgroups	O
.	O

The	O
cutoff	O
was	O
higher	O
in	O
elderly	O
subjects	O
than	O
in	O
younger	O
subjects	O
.	O

The	O
data-driven	O
cutoff	O
was	O
higher	O
than	O
our	O
clinical	B-P
diagnosis	I-P
-based	O
cutoff	O
and	O
had	O
a	O
better	O
predictive	O
accuracy	O
for	O
progression	O
to	O
AD	O
-type	O
dementia	O
in	O
nondemented	O
subjects	O
(	O
HR	O
7.6	O
versus	O
5.2	O
,	O
p	O
<	O
0.01	O
)	O
.	O

Mixture	O
modeling	O
is	O
a	O
robust	O
method	O
to	O
determine	O
cutoffs	O
for	O
CSF	O
β-amyloid	O
1-42	O
.	O

It	O
might	O
better	O
capture	O
biological	O
changes	O
that	O
are	O
related	O
to	O
AD	O
than	O
cutoffs	O
based	O
on	O
clinical	B-P
diagnosis	I-P
.	O

Identification	O
of	O
novel	O
macrolides	O
with	O
antibacterial	O
,	O
anti-inflammatory	O
and	O
type	O
I	O
and	O
III	O
IFN	O
-	O
augmenting	O
activity	O
in	O
airway	O
epithelium	O
.	O

Exacerbations	O
of	O
asthma	O
and	O
COPD	O
are	O
triggered	O
by	O
rhinoviruses	O
.	O

Uncontrolled	O
inflammatory	O
pathways	O
,	O
pathogenic	O
bacterial	O
burden	O
and	O
impaired	O
antiviral	O
immunity	O
are	O
thought	O
to	O
be	O
important	O
factors	O
in	O
disease	O
severity	O
and	O
duration	O
.	O

Macrolides	O
including	O
azithromycin	O
are	O
often	O
used	O
to	O
treat	O
the	O
above	O
diseases	O
,	O
but	O
exhibit	O
variable	O
levels	O
of	O
efficacy	O
.	O

Inhaled	O
corticosteroids	O
are	O
also	O
readily	O
used	O
in	O
treatment	O
,	O
but	O
may	O
lack	O
specificity	O
.	O

Ideally	O
,	O
new	O
treatment	O
alternatives	O
should	O
suppress	O
unwanted	O
inflammation	O
,	O
but	O
spare	O
beneficial	O
antiviral	O
immunity	O
.	O

In	O
the	O
present	O
study	B-P
,	O
we	O
screened	O
225	O
novel	O
macrolides	O
and	O
tested	O
them	O
for	O
enhanced	O
antiviral	O
activity	O
against	O
rhinovirus	O
,	O
as	O
well	O
as	O
anti-inflammatory	O
activity	O
and	O
activity	O
against	O
Gram-positive	O
and	O
Gram-negative	O
bacteria	O
.	O

Primary	O
bronchial	O
epithelial	O
cells	O
were	O
grown	O
from	O
10	O
asthmatic	O
individuals	O
and	O
the	O
effects	O
of	O
macrolides	O
on	O
rhinovirus	O
replication	O
were	O
also	O
examined	O
.	O

Another	O
30	O
structurally	O
similar	O
macrolides	O
were	O
also	O
examined	O
.	O

The	O
oleandomycin	O
derivative	O
Mac5	O
,	O
compared	O
with	O
azithromycin	O
,	O
showed	O
superior	O
induction	O
(	O
up	O
to	O
5-fold	O
,	O
EC	O
50	O
=	O
5-11	O
μM	O
)	O
of	O
rhinovirus	O
-	O
induced	O
type	O
I	O
IFNβ	O
,	O
type	O
III	O
IFNλ1	O
and	O
type	O
III	O
IFNλ2/3	O
mRNA	O
and	O
the	O
IFN	O
-	O
stimulated	O
genes	O
viperin	O
and	O
MxA	O
,	O
yet	O
had	O
no	O
effect	O
on	O
IL-6	O
and	O
IL-8	O
mRNA	O
.	O

Mac5	O
also	O
suppressed	O
rhinovirus	O
replication	O
at	O
48	O
h	O
,	O
proving	O
antiviral	O
activity	O
.	O

Mac5	O
showed	O
antibacterial	O
activity	O
against	O
Gram-positive	O
Streptococcus	O
pneumoniae	O
;	O
however	O
,	O
it	O
did	O
not	O
have	O
any	O
antibacterial	O
properties	O
compared	O
with	O
azithromycin	O
when	O
used	O
against	O
Gram-negative	O
Escherichia	O
coli	O
(	O
as	O
a	O
model	O
organism	O
)	O
and	O
also	O
the	O
respiratory	O
pathogens	O
Pseudomonas	O
aeruginosa	O
and	O
non-typeable	O
Haemophilus	O
influenzae	O
.	O

Further	O
non-toxic	O
Mac5	O
derivatives	O
were	O
identified	O
with	O
various	O
anti-inflammatory	O
,	O
antiviral	O
and	O
antibacterial	O
activities	O
.	O

The	O
data	O
support	O
the	O
idea	O
that	O
macrolides	O
have	O
antiviral	O
properties	O
through	O
a	O
mechanism	O
that	O
is	O
yet	O
to	O
be	O
ascertained	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
macrolides	O
can	O
be	O
developed	O
with	O
anti-inflammatory	O
,	O
antibacterial	O
and	O
antiviral	O
activity	O
and	O
show	O
surprising	O
versatility	O
depending	O
on	O
the	O
clinical	O
need	O
.	O

Metabolomics	O
of	O
Therapy	O
Response	O
in	O
Preclinical	O
Glioblastoma	O
:	O
A	O
Multi-Slice	B-P
MRSI	I-P
-Based	O
Volumetric	B-P
Analysis	I-P
for	O
Noninvasive	B-P
Assessmen	I-P
t	O
of	O
Temozolomide	O
Treatment	O
.	O

Glioblastoma	O
(	O
GBM	O
)	O
is	O
the	O
most	O
common	O
aggressive	O
primary	O
brain	O
tumor	O
in	O
adults	O
,	O
with	O
a	O
short	O
survival	O
time	O
even	O
after	O
aggressive	O
therapy	O
.	O

Non-invasive	O
surrogate	O
biomarkers	O
of	O
therapy	O
response	O
may	O
be	O
relevant	O
for	O
improving	O
patient	O
survival	O
.	O

Previous	O
work	O
produced	O
such	O
biomarkers	O
in	O
preclinical	O
GBM	O
using	O
semi-supervised	B-P
source	I-P
extraction	I-P
and	O
single-slice	B-P
Magnetic	I-P
Resonance	I-P
Spectroscopic	I-P
Imaging	I-P
(	O
MRSI	B-P
)	O
.	O

Nevertheless	O
,	O
GBMs	O
are	O
heterogeneous	O
and	O
single-slice	O
studies	O
could	O
prevent	O
obtaining	O
relevant	O
information	O
.	O

The	O
purpose	O
of	O
this	O
work	O
was	O
to	O
evaluate	O
whether	O
a	O
multi-slice	B-P
MRSI	I-P
approach	O
,	O
acquiring	O
consecutive	O
grids	O
across	O
the	O
tumor	O
,	O
is	O
feasible	O
for	O
preclinical	O
models	O
and	O
may	O
produce	O
additional	O
insight	O
into	O
therapy	O
response	O
.	O

Nosological	O
images	O
were	O
analyzed	O
pixel-by-pixel	O
and	O
a	O
relative	O
responding	O
volume	O
,	O
the	O
Tumor	O
Responding	O
Index	O
(	O
TRI	O
)	O
,	O
was	O
defined	O
to	O
quantify	O
response	O
.	O

Heterogeneous	O
response	O
levels	O
were	O
observed	O
and	O
treated	O
animals	O
were	O
ascribed	O
to	O
three	O
arbitrary	O
predefined	O
groups	O
:	O
high	O
response	O
(	O
HR	O
,	O
n	O
=	O
2	O
)	O
,	O
TRI	O
=	O
68.2	O
±	O
2.8	O
%	O
,	O
intermediate	O
response	O
(	O
IR	O
,	O
n	O
=	O
6	O
)	O
,	O
TRI	O
=	O
41.1	O
±	O
4.2	O
%	O
and	O
low	O
response	O
(	O
LR	O
,	O
n	O
=	O
2	O
)	O
,	O
TRI	O
=	O
13.4	O
±	O
14.3	O
%	O
,	O
producing	O
therapy	O
response	O
categorization	O
which	O
had	O
not	O
been	O
fully	O
registered	O
in	O
single-slice	O
studies	O
.	O

Results	O
agreed	O
with	O
the	O
multi-slice	B-P
approach	I-P
being	O
feasible	O
and	O
producing	O
an	O
inverse	O
correlation	O
between	O
TRI	O
and	O
Ki67	B-P
immunostaining	I-P
.	O

Additionally	O
,	O
ca	O
.	O

7-day	O
oscillations	O
of	O
TRI	O
were	O
observed	O
,	O
suggesting	O
that	O
host	O
immune	O
system	O
activation	O
in	O
response	O
to	O
treatment	O
could	O
contribute	O
to	O
the	O
responding	O
patterns	O
detected	O
.	O

Multifocal	O
bone	O
and	O
bone	O
marrow	O
lesions	O
in	O
children	O
-	O
MRI	O
findings	O
.	O

Polyostotic	O
bone	O
and	O
bone	O
marrow	O
lesions	O
in	O
children	O
may	O
be	O
due	O
to	O
various	O
disorders	O
.	O

Radiographically	O
,	O
lytic	O
lesions	O
may	O
become	O
apparent	O
after	O
loss	O
of	O
more	O
than	O
50	O
%	O
of	O
the	O
bone	O
mineral	O
content	O
.	O

Scintigraphy	B-P
requires	O
osteoblastic	O
activity	O
and	O
is	O
not	O
specific	O
.	O

MRI	B-P
may	O
significantly	O
contribute	O
to	O
the	O
correct	O
diagnosis	O
and	O
management	O
.	O

Accurate	O
interpretation	O
of	O
MRI	B-P
examinations	I-P
requires	O
understanding	O
of	O
the	O
normal	O
conversion	O
pattern	O
of	O
bone	O
marrow	O
in	O
childhood	O
and	O
of	O
the	O
appearances	O
of	O
red	O
marrow	O
rests	O
and	O
hyperplasia	O
.	O

Differential	B-P
diagnosis	I-P
is	O
wide	O
:	O
Malignancies	O
include	O
metastases	O
,	O
multifocal	O
primary	O
sarcomas	O
and	O
hematological	O
diseases	O
.	O

Benign	O
entities	O
include	O
benign	O
tumors	O
and	O
tumor-like	O
lesions	O
,	O
histiocytosis	O
,	O
infectious	O
and	O
inflammatory	O
diseases	O
,	O
multiple	O
stress	O
fractures	O
/	O
reactions	O
and	O
bone	O
infarcts	O
/	O
ischemia	O
.	O

A	O
new	O
angle	O
and	O
its	O
relationship	O
with	O
early	O
fixation	O
failure	O
of	O
femoral	O
neck	O
fractures	O
treated	O
with	O
three	O
cannulated	O
compression	O
screws	O
.	O

The	O
Pauwels	O
angle	O
has	O
been	O
used	O
widely	O
,	O
however	O
an	O
accurate	O
evaluation	O
of	O
this	O
angle	O
is	O
difficult	O
because	O
of	O
deformity	O
of	O
the	O
affected	O
lower	O
extremity	O
.	O

Therefore	O
we	O
designed	O
a	O
new	O
measurement	O
of	O
the	O
orientation	O
of	O
femoral	O
neck	O
fracture	O
and	O
applied	O
this	O
in	O
a	O
retrospective	O
study	O
to	O
assess	O
:	O
(	O
1	O
)	O
its	O
reproducibility	O
,	O
(	O
2	O
)	O
its	O
advantages	O
compared	O
with	O
the	O
Pauwels	O
angle	O
,	O
(	O
3	O
)	O
its	O
relationship	O
with	O
the	O
short-term	O
prognosis	O
treated	O
with	O
three	O
cannulated	O
compression	O
screws	O
.	O

This	O
new	O
measurement	O
is	O
reproducible	O
and	O
has	O
some	O
reference	O
meaning	O
for	O
the	O
treatment	O
of	O
femoral	O
neck	O
fractures	O
.	O

Two	O
hundred	O
and	O
twenty-eight	O
patients	O
with	O
femoral	O
neck	O
fractures	O
treated	O
with	O
three	O
cannulated	O
compression	O
screws	O
were	O
retrospectively	O
analyzed	O
.	O

The	O
VN	O
angle	O
,	O
which	O
was	O
the	O
angle	O
between	O
the	O
fracture	O
line	O
and	O
the	O
vertical	O
of	O
the	O
neck	O
axis	O
,	O
and	O
the	O
Pauwels	O
angle	O
were	O
measured	O
respectively	O
.	O

The	O
method	O
of	O
ICC	O
was	O
performed	O
to	O
assess	O
the	O
reproducibility	O
of	O
the	O
two	O
angles	O
,	O
and	O
the	O
absolute	O
value	O
of	O
difference	O
in	O
pre-operative	O
and	O
post-operative	O
radiographs	B-P
was	O
used	O
to	O
evaluate	O
the	O
uniformity	O
of	O
the	O
two	O
angles	O
.	O

These	O
fractures	O
were	O
divided	O
into	O
four	O
groups	O
according	O
to	O
VN	O
angle	O
(	O
VN	O
<	O
0°	O
(	O
n=92	O
)	O
,	O
0°≤VN	O
<	O
10°	O
(	O
n=82	O
)	O
,	O
10°≤VN	O
<	O
15°	O
(	O
n=26	O
)	O
,	O
VN≥15°	O
(	O
n=28	O
)	O
)	O
,	O
and	O
the	O
short-term	O
(	O
within	O
6	O
months	O
)	O
fixation	O
results	O
of	O
radiographs	B-P
in	O
these	O
fractures	O
were	O
evaluated	O
.	O

The	O
ICC	O
of	O
the	O
VN	O
angle	O
and	O
the	O
Pauwels	O
angle	O
in	O
pre-operative	O
radiographs	B-P
were	O
0.937	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.922-0.950	O
)	O
and	O
0.942	O
respectively	O
(	O
95	O
%	O
CI	O
:	O
0.914-0.970	O
)	O
,	O
indicating	O
both	O
angles	O
had	O
a	O
good	O
inter-rater	O
reproducibility	O
.	O

However	O
,	O
there	O
was	O
a	O
great	O
difference	O
between	O
the	O
Pauwels	O
angle	O
in	O
pre-operative	O
and	O
post-operative	O
radiographs	B-P
(	O
P=0.037	O
)	O
,	O
the	O
absolute	O
difference	O
was	O
10.66±6.47	O
(	O
range	O
:	O
1.72-38.48	O
)	O
,	O
while	O
no	O
statistical	O
difference	O
for	O
the	O
VN	O
angle	O
(	O
P=0.084	O
)	O
and	O
the	O
absolute	O
difference	O
was	O
2.20±1.63	O
(	O
range	O
:	O
0.05-7.56	O
)	O
.	O

The	O
overall	O
fixation	O
failure	O
rate	O
which	O
was	O
defined	O
as	O
screw	O
loosening	O
,	O
varus	O
collapse	O
,	O
obvious	O
fracture	O
displacement	O
or	O
femoral	O
neck	O
shortening	O
was	O
11.84	O
%	O
,	O
and	O
the	O
mean	O
failure	O
rates	O
according	O
to	O
VN	O
angles	O
were	O
respectively	O
0	O
%	O
,	O
3.24	O
%	O
(	O
95	O
%	O
CI	O
:	O
1.64-4.84	O
)	O
,	O
22.69	O
%	O
(	O
95	O
%	O
CI	O
:	O
16.43-28.96	O
)	O
,	O
65.45	O
%	O
(	O
95	O
%	O
CI	O
:	O
59.36-71.53	O
)	O
.	O

The	O
mean	O
failure	O
rates	O
of	O
fractures	O
according	O
to	O
post-operative	O
Pauwels	O
angle	O
(	O
<	O
30°	O
,	O
30-50°	O
,	O
>	O
50°	O
)	O
were	O
respectively	O
0	O
%	O
,	O
1.46	O
%	O
(	O
95	O
%	O
CI	O
:	O
1.42-1.50	O
)	O
and	O
36.24	O
%	O
(	O
95	O
%	O
CI	O
:	O
34.93-37.54	O
)	O
.	O

The	O
VN	O
angle	O
has	O
a	O
good	O
inter-rater	O
reproducibility	O
,	O
a	O
higher	O
reliability	O
than	O
the	O
Pauwels	O
angle	O
and	O
is	O
closely	O
related	O
to	O
the	O
short-term	O
prognosis	O
of	O
femoral	O
neck	O
fractures	O
treated	O
with	O
cannulated	O
compression	O
screws	O
.	O

Level	O
IV	O
,	O
retrospective	O
diagnostic	O
study	O
.	O

Scutellarin	O
attenuates	O
vasospasm	O
through	O
the	O
Erk5	O
-	O
KLF2	O
-	O
eNOS	O
pathway	O
after	O
subarachnoid	O
hemorrhage	O
in	O
rats	O
.	O

Angiographic	B-P
vasospasm	O
,	O
especially	O
in	O
the	O
early	O
phases	O
(	O
<	O
72h	O
)	O
of	O
subarachnoid	O
hemorrhage	O
(	O
SAH	O
)	O
,	O
is	O
one	O
of	O
the	O
major	O
complications	O
after	O
an	O
aneurysm	O
rupture	O
and	O
is	O
often	O
the	O
cause	O
of	O
delayed	O
neurological	O
deterioration	O
.	O

Scutellarin	O
(	O
SCU	O
)	O
,	O
a	O
flavonoid	O
extracted	O
from	O
the	O
traditional	O
Chinese	O
herb	O
Erigeron	O
breviscapus	O
,	O
has	O
been	O
widely	O
accepted	O
as	O
an	O
antioxidant	O
,	O
but	O
the	O
effect	O
of	O
SCU	O
on	O
vasospasm	O
after	O
SAH	O
remains	O
elusive	O
.	O

Endovascular	O
perforation	O
was	O
conducted	O
to	O
induce	O
SAH	O
in	O
Sprague-Dawley	O
rats	O
.	O

Then	O
,	O
the	O
underlying	O
mechanism	O
of	O
the	O
anti-vasospasm	O
effect	O
of	O
SCU	O
was	O
investigated	O
using	O
a	O
modified	O
Garcia	O
scale	O
,	O
India	B-P
ink	I-P
angiography	I-P
,	O
cross-sectional	O
area	O
analysis	O
,	O
immunohistochemistry	B-P
staining	I-P
and	O
western	B-P
blot	I-P
.	O

SCU	O
(	O
50μM	O
,	O
100mg/kg	O
)	O
alleviated	O
angiographic	B-P
vasospasm	O
and	O
improved	O
neurological	O
function	O
48h	O
after	O
SAH	O
and	O
enhanced	O
the	O
expression	O
of	O
endothelial	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
)	O
at	O
the	O
intima	O
of	O
cerebral	O
arteries	O
.	O

In	O
addition	O
,	O
SCU	O
upregulated	O
the	O
expression	O
of	O
phosphorylated	O
extracellular-regulated	O
kinase	O
5	O
(	O
p-Erk5	O
)	O
and	O
Kruppel-like	O
factor	O
2	O
(	O
KLF2	O
)	O
at	O
48h	O
after	O
SAH	O
.	O

However	O
,	O
the	O
effects	O
of	O
SCU	O
were	O
reversed	O
by	O
the	O
Erk5	O
inhibitor	O
XMD8-92	O
.	O

Our	O
results	O
indicate	O
that	O
SCU	O
could	O
attenuate	O
vasospasm	O
and	O
neurological	O
deficits	O
via	O
modulating	O
the	O
Erk5	O
-	O
KLF2	O
-	O
eNOS	O
pathway	O
after	O
SAH	O
,	O
which	O
may	O
provide	O
an	O
experimental	O
basis	O
for	O
the	O
clinical	O
use	O
of	O
SCU	O
treatment	O
in	O
SAH	O
patients	O
.	O

Relation	O
of	O
Plasma	O
Lipoprotein	O
(	O
a	O
)	O
to	O
Subclinical	O
Coronary	O
Plaque	O
Volumes	O
,	O
Three-Vessel	O
and	O
Left	O
Main	O
Coronary	O
Disease	O
,	O
and	O
Severe	O
Coronary	O
Stenoses	O
in	O
Apparently	O
Healthy	O
African-Americans	O
With	O
a	O
Family	O
History	O
of	O
Early-Onset	O
Coronary	O
Artery	O
Disease	O
.	O

Serum	O
lipoprotein	O
(	O
a	O
)	O
[	O
Lp	O
(	O
a	O
)	O
]	O
is	O
a	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
risk	O
factor	O
in	O
persons	O
of	O
European	O
ancestry	O
.	O

Levels	O
are	O
twofold	O
to	O
threefold	O
higher	O
in	O
African-Americans	O
(	O
AAs	O
)	O
,	O
but	O
reported	O
associations	O
with	O
CAD	O
have	O
been	O
inconsistent	O
.	O

The	O
relation	O
of	O
Lp	O
(	O
a	O
)	O
with	O
the	O
extent	O
and	O
severity	O
of	O
subclinical	O
coronary	O
plaque	O
has	O
not	O
been	O
described	O
in	O
AAs	O
.	O

We	O
screened	O
269	O
apparently	O
healthy	O
AAs	O
for	O
risk	O
factors	O
and	O
coronary	O
plaque	O
using	O
advanced	O
coronary	B-P
computed	I-P
tomographic	I-P
angiography	I-P
.	O

Total	O
coronary	O
plaque	O
(	O
TCP	O
)	O
,	O
noncalcified	O
coronary	O
plaque	O
,	O
and	O
calcified	O
coronary	O
plaque	O
volumes	O
(	O
mm	O
(	O
3	O
)	O
)	O
were	O
quantified	O
using	O
a	O
validated	O
automated	B-P
method	I-P
.	O

Lp	O
(	O
a	O
)	O
was	O
measured	O
by	O
ELISA	B-P
.	O

Multivariable	O
modeling	O
was	O
performed	O
with	O
adjustment	O
for	O
traditional	O
CAD	O
risk	O
factors	O
and	O
intrafamilial	O
correlations	O
.	O

Mean	O
age	O
was	O
51	O
±	O
11	O
years	O
and	O
64	O
%	O
were	O
female	O
.	O

Plaque	O
was	O
present	O
in	O
41	O
%	O
.	O

Lp	O
(	O
a	O
)	O
was	O
independently	O
associated	O
with	O
TCP	O
volume	O
[	O
log	O
(	O
TCP	O
+	O
1	O
)	O
]	O
(	O
p	O
=	O
0.04	O
)	O
,	O
3-vessel	O
and/or	O
left	O
main	O
involvement	O
(	O
p	O
=	O
0.04	O
)	O
,	O
and	O
at	O
least	O
1	O
stenosis	O
>	O
50	O
%	O
(	O
p	O
=	O
0.006	O
)	O
.	O

Best-fit	O
regression	O
analyses	O
showed	O
that	O
subjects	O
with	O
Lp	O
(	O
a	O
)	O
>	O
40	O
mg/dl	O
were	O
threefold	O
more	O
likely	O
to	O
have	O
3-vessel	O
and/or	O
left	O
main	O
disease	O
(	O
95	O
%	O
confidence	O
interval	O
1.4	O
to	O
6.8	O
,	O
p	O
=	O
0.005	O
)	O
and	O
fourfold	O
more	O
likely	O
to	O
have	O
stenosis	O
>	O
50	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
1.3	O
to	O
15.0	O
,	O
p	O
=	O
0.02	O
)	O
.	O

In	O
subjects	O
with	O
plaque	O
(	O
n	O
=	O
110	O
)	O
,	O
multivariable	O
models	O
showed	O
the	O
Lp	O
(	O
a	O
)	O
level	O
was	O
significantly	O
and	O
independently	O
associated	O
with	O
TCP	O
(	O
p	O
=	O
0.009	O
)	O
,	O
noncalcified	O
coronary	O
plaque	O
(	O
p	O
=	O
0.01	O
)	O
,	O
and	O
calcified	O
coronary	O
plaque	O
(	O
p	O
=	O
0.003	O
)	O
and	O
affected	O
vessel	O
length	O
(	O
p	O
=	O
0.01	O
)	O
.	O

In	O
conclusion	O
,	O
high	O
Lp	O
(	O
a	O
)	O
is	O
strongly	O
associated	O
with	O
coronary	O
plaque	O
volumes	O
,	O
extent	O
,	O
and	O
severity	O
in	O
apparently	O
healthy	O
AAs	O
.	O

High	O
levels	O
of	O
Lp	O
(	O
a	O
)	O
may	O
be	O
particularly	O
important	O
in	O
the	O
pathogenesis	O
of	O
CAD	O
in	O
AAs	O
.	O

Multicentric	O
studies	O
of	O
the	O
fetal	O
neurobehavior	O
by	O
KANET	B-P
test	I-P
.	O

Assessment	B-P
of	O
fetal	O
neurobehavior	O
and	O
detection	O
of	O
neurological	O
impairment	O
prenatally	O
has	O
been	O
a	O
great	O
challenge	O
in	O
perinatal	O
medicine	O
.	O

The	O
evolution	B-P
of	O
four-dimensional	B-P
(	I-P
4D	I-P
)	I-P
ultrasound	I-P
not	O
only	O
enabled	O
a	O
better	O
visualization	O
of	O
fetal	B-P
anatomy	I-P
but	O
also	O
allowed	O
the	O
study	O
of	O
fetal	O
behavior	O
in	O
real	O
time	O
.	O

Kurjak	B-P
Antenatal	I-P
Neurodevelopmental	I-P
Test	I-P
(	O
KANET	B-P
)	O
was	O
developed	O
for	O
the	O
assessment	B-P
of	O
fetal	O
neurobehavior	O
and	O
the	O
detection	O
of	O
neurological	O
disorders	O
,	O
based	O
on	O
the	O
assessment	B-P
of	O
the	O
fetus	O
by	O
application	O
of	O
4D	B-P
ultrasound	I-P
in	O
the	O
same	O
way	O
that	O
a	O
neonate	O
is	O
assessed	O
postnatally	O
.	O

KANET	B-P
is	O
a	O
method	B-P
that	O
has	O
been	O
applied	O
for	O
the	O
past	O
10	O
years	O
and	O
studies	O
show	O
that	O
it	O
is	O
a	O
strong	O
diagnostic	B-P
tool	I-P
and	O
can	O
be	O
introduced	O
into	O
everyday	O
clinical	O
practice	O
.	O

We	O
present	O
all	O
data	O
from	O
studies	O
performed	O
up	O
to	O
now	O
on	O
KANET	B-P
.	O

Mechanisms	O
of	O
Improved	O
Exercise	O
Performance	O
under	O
Hyperoxia	O
.	O

The	O
impact	O
of	O
hyperoxia	O
on	O
exercise	O
limitation	O
is	O
still	O
incompletely	O
understood	O
.	O

We	O
investigated	O
to	O
which	O
extent	O
breathing	O
hyperoxia	O
enhances	O
the	O
exercise	O
performance	O
of	O
healthy	O
subjects	O
and	O
which	O
physiologic	O
mechanisms	O
are	O
involved	O
.	O

A	O
total	O
of	O
32	O
healthy	O
volunteers	O
(	O
43	O
±	O
15	O
years	O
,	O
12	O
women	O
)	O
performed	O
4	O
bicycle	O
exercise	O
tests	O
to	O
exhaustion	O
with	O
ramp	O
and	O
constant-load	O
protocols	O
(	O
at	O
75	O
%	O
of	O
the	O
maximal	O
workload	O
[	O
Wmax	O
]	O
on	O
FiO2	O
0.21	O
)	O
on	O
separate	O
occasions	O
while	O
breathing	O
ambient	O
(	O
FiO2	O
0.21	O
)	O
or	O
oxygen-enriched	O
air	O
(	O
FiO2	O
0.50	O
)	O
in	O
a	O
random	O
,	O
blinded	O
order	O
.	O

Workload	O
,	O
endurance	O
,	O
gas	O
exchange	O
,	O
pulse	B-P
oximetry	I-P
(	O
SpO2	B-P
)	O
,	O
and	O
cerebral	O
(	O
CTO	O
)	O
and	O
quadriceps	O
muscle	O
tissue	O
oxygenation	O
(	O
QMTO	O
)	O
were	O
measured	O
.	O

During	O
the	O
final	O
15	O
s	O
of	O
ramp	O
exercising	O
with	O
FiO2	O
0.50	O
,	O
Wmax	O
(	O
mean	O
±	O
SD	O
270	O
±	O
80	O
W	O
)	O
,	O
SpO2	B-P
(	O
99	O
±	O
1	O
%	O
)	O
,	O
and	O
CTO	O
(	O
67	O
±	O
9	O
%	O
)	O
were	O
higher	O
and	O
the	O
Borg	O
CR10	O
Scale	O
dyspnea	O
score	O
was	O
lower	O
(	O
4.8	O
±	O
2.2	O
)	O
than	O
the	O
corresponding	O
values	O
with	O
FiO2	O
0.21	O
(	O
Wmax	O
257	O
±	O
76	O
W	O
,	O
SpO2	B-P
96	O
±	O
3	O
%	O
,	O
CTO	O
61	O
±	O
9	O
%	O
,	O
and	O
Borg	O
CR10	O
Scale	O
dyspnea	O
score	O
5.7	O
±	O
2.6	O
,	O
p	O
<	O
0.05	O
,	O
all	O
comparisons	O
)	O
.	O

In	O
constant-load	O
exercising	O
with	O
FiO2	O
0.50	O
,	O
endurance	O
was	O
longer	O
than	O
with	O
FiO2	O
0.21	O
(	O
16	O
min	O
22	O
s	O
±	O
7	O
min	O
39	O
s	O
vs.	O
10	O
min	O
47	O
s	O
±	O
5	O
min	O
58	O
s	O
)	O
.	O

With	O
FiO2	O
0.50	O
,	O
SpO2	B-P
(	O
99	O
±	O
0	O
%	O
)	O
and	O
QMTO	O
(	O
69	O
±	O
8	O
%	O
)	O
were	O
higher	O
than	O
the	O
corresponding	O
isotime	O
values	O
to	O
end-exercise	O
with	O
FiO2	O
0.21	O
(	O
SpO2	B-P
96	O
±	O
4	O
%	O
,	O
QMTO	O
66	O
±	O
9	O
%	O
)	O
,	O
while	O
minute	O
ventilation	O
was	O
lower	O
in	O
hyperoxia	O
(	O
82	O
±	O
18	O
vs.	O
93	O
±	O
23	O
L/min	O
,	O
p	O
<	O
0.05	O
,	O
all	O
comparisons	O
)	O
.	O

In	O
healthy	O
subjects	O
,	O
hyperoxia	O
increased	O
maximal	O
power	O
output	O
and	O
endurance	O
.	O

It	O
improved	O
arterial	O
,	O
cerebral	O
,	O
and	O
muscle	O
tissue	O
oxygenation	O
,	O
while	O
minute	O
ventilation	O
and	O
dyspnea	O
perception	O
were	O
reduced	O
.	O

The	O
findings	O
suggest	O
that	O
hyperoxia	O
enhanced	O
cycling	O
performance	O
through	O
a	O
more	O
efficient	O
pulmonary	O
gas	O
exchange	O
and	O
a	O
greater	O
availability	O
of	O
oxygen	O
to	O
muscles	O
and	O
the	O
brain	O
(	O
cerebral	O
motor	O
and	O
sensory	O
neurons	O
)	O
.	O

Preliminary	O
investigation	O
of	O
energy	O
comparation	O
between	O
gyroscope	O
,	O
electromyography	B-P
and	O
VO2	O
wearable	O
sensors	O
.	O

Building	O
on	O
previous	O
experiments	O
in	O
the	O
domain	O
of	O
energy	O
expenditure	O
estimation	O
using	O
wearable	O
sensors	O
,	O
the	O
measurements	O
of	O
energy	O
ratios	O
of	O
a	O
runner	O
on	O
a	O
treadmill	O
were	O
analyzed	O
to	O
observe	O
any	O
commonalities	O
between	O
an	O
inertia	O
measurement	O
unit	O
and	O
an	O
electromyograph	B-P
sensor	O
.	O

The	O
subjects	O
were	O
equipped	O
with	O
a	O
VO2	O
gas	O
measurement	O
device	O
,	O
an	O
Inertial	O
Measurement	O
Unit	O
(	O
IMU	O
)	O
measuring	O
gyroscopic	B-P
activity	I-P
and	O
an	O
electromyography	B-P
(	O
EMG	B-P
)	O
sensor	O
network	O
whilst	O
running	O
at	O
5	O
different	O
speeds	O
on	O
a	O
calibrated	O
treadmill	O
.	O

The	O
observed	O
results	O
established	O
a	O
co-linear	O
relationship	O
with	O
the	O
gyroscope	O
based	O
measurements	O
,	O
EMG	B-P
based	O
measurements	O
with	O
the	O
VO2	B-P
measurements	I-P
.	O

Transformation	O
of	O
Lettuce	O
with	O
rol	O
ABC	O
Genes	O
:	O
Extracts	O
Show	O
Enhanced	O
Antioxidant	O
,	O
Analgesic	O
,	O
Anti-Inflammatory	O
,	O
Antidepressant	O
,	O
and	O
Anticoagulant	O
Activities	O
in	O
Rats	O
.	O

Lettuce	O
is	O
an	O
edible	O
crop	O
that	O
is	O
well	O
known	O
for	O
dietary	O
and	O
antioxidant	O
benefits	O
.	O

The	O
present	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
effects	O
of	O
rol	O
ABC	O
genes	O
on	O
antioxidant	O
and	O
medicinal	O
potential	O
of	O
lettuce	O
by	O
Agrobacterium	O
-mediated	O
transformation	O
.	O

Transgene	O
integration	O
and	O
expression	O
was	O
confirmed	O
through	O
PCR	O
and	O
real-time	O
RT-PCR	O
,	O
respectively	O
.	O

The	O
transformed	O
plants	O
showed	O
91-102	O
%	O
increase	O
in	O
total	O
phenolic	O
contents	O
and	O
53-65	O
%	O
increase	O
in	O
total	O
flavonoid	O
contents	O
compared	O
to	O
untransformed	O
plants	O
.	O

Total	O
antioxidant	O
capacity	O
and	O
total	O
reducing	O
power	O
increased	O
up	O
to	O
112	O
and	O
133	O
%	O
in	O
transformed	O
plants	O
,	O
respectively	O
.	O

Results	O
of	O
DPPH	O
assay	B-P
showed	O
maximum	O
51	O
%	O
increase	O
,	O
and	O
lipid	O
peroxidation	O
assay	B-P
exhibited	O
20	O
%	O
increase	O
in	O
antioxidant	O
activity	O
of	O
transformed	O
plants	O
compared	O
to	O
controls	O
.	O

Different	O
in	O
vivo	O
assays	O
were	O
carried	O
out	O
in	O
rats	O
.	O

The	O
transgenic	O
plants	O
showed	O
up	O
to	O
80	O
%	O
inhibition	O
in	O
both	O
hot	B-P
plate	I-P
analgesic	I-P
assay	I-P
and	O
carrageenan	O
-	O
induced	O
hind	B-P
paw	I-P
edema	I-P
test	I-P
,	O
while	O
untransformed	O
plants	O
showed	O
only	O
45	O
%	O
inhibition	O
.	O

Antidepressant	O
and	O
anticoagulant	O
potential	O
of	O
transformed	O
plants	O
was	O
also	O
significantly	O
enhanced	O
compared	O
to	O
untransformed	O
plants	O
.	O

Taken	O
together	O
,	O
the	O
present	O
work	O
highlights	O
the	O
use	O
of	O
rol	O
genes	O
to	O
enhance	O
the	O
secondary	O
metabolite	O
production	O
in	O
lettuce	O
and	O
improve	O
its	O
analgesic	O
,	O
anti-inflammatory	O
,	O
antidepressant	O
,	O
and	O
anticoagulatory	O
properties	O
.	O

miR-181	O
interacts	O
with	O
signaling	O
adaptor	O
molecule	O
DENN/MADD	O
and	O
enhances	O
TNF	O
-	O
induced	O
cell	O
death	O
.	O

MicroRNAs	O
are	O
small	O
noncoding	O
RNAs	O
,	O
which	O
regulate	O
the	O
expression	O
of	O
protein	O
coding	O
transcripts	O
through	O
mRNA	O
degradation	O
or	O
translational	O
inhibition	O
.	O

Numerous	O
reports	O
have	O
highlighted	O
the	O
role	O
of	O
miRNAs	O
in	O
regulating	O
cell	O
death	O
pathways	O
including	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
the	O
induction	O
of	O
apoptosis	O
.	O

Tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-α	O
)	O
is	O
a	O
proinflammatory	O
cytokine	O
which	O
can	O
send	O
pro-death	O
signals	O
through	O
its	O
receptor	O
TNFR1	O
.	O

Diverse	O
adaptor	O
molecules	O
including	O
DENN/MADD	O
adaptor	O
protein	O
have	O
been	O
shown	O
to	O
modulate	O
TNF-α	O
pro-death	O
signaling	O
via	O
recruitment	O
of	O
MAP	O
kinases	O
to	O
TNFR1	O
and	O
activation	O
of	O
pro-survival	O
NFκB	O
signaling	O
.	O

Herein	O
,	O
we	O
investigated	O
the	O
role	O
of	O
microRNA-181	O
(	O
miR-181	O
)	O
in	O
regulating	O
DENN/MADD	O
expression	O
levels	O
and	O
its	O
subsequent	O
effects	O
on	O
TNF-α	O
-	O
induced	O
cell	O
death	O
.	O

Using	O
bioinformatics	O
analyses	O
followed	O
by	O
luciferase	O
reporter	B-P
assays	I-P
we	O
showed	O
that	O
miR-181	O
interacts	O
with	O
the	O
3	O
'	O
UTR	O
of	O
DENN/MADD	O
transcripts	O
.	O

miR-181	O
overexpression	O
also	O
led	O
to	O
decreased	O
endogenous	O
DENN/MADD	O
mRNA	O
levels	O
in	O
L929	O
murine	O
fibroblasts	O
.	O

Flow	B-P
cytometric	I-P
analysis	I-P
of	O
miR-181	O
transfected	O
cells	O
showed	O
this	O
miRNA	O
accentuates	O
mitochondrial	O
membrane	O
potential	O
loss	O
caused	O
by	O
TNF-α	O
.	O

These	O
findings	O
were	O
associated	O
with	O
enhanced	O
apoptosis	O
of	O
L929	O
cells	O
following	O
TNF-α	O
treatment	O
.	O

Overall	O
,	O
these	O
data	O
point	O
to	O
the	O
potential	O
role	O
of	O
miR-181	O
in	O
regulating	O
TNF-α	O
pro-death	O
signaling	O
,	O
which	O
could	O
be	O
of	O
importance	O
from	O
pathogenesis	O
and	O
therapeutic	O
perspectives	O
in	O
inflammatory	O
disorders	O
associated	O
with	O
tissue	O
degeneration	O
and	O
cell	O
death	O
.	O

Blood	O
Pressure	O
and	O
All-Cause	O
Mortality	O
by	O
Level	O
of	O
Cognitive	O
Function	O
in	O
the	O
Elderly	O
:	O
Results	O
From	O
a	O
Population-Based	O
Study	O
in	O
Rural	O
Greece	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
whether	O
the	O
effect	O
of	O
blood	O
pressure	O
(	O
BP	O
)	O
on	O
mortality	O
differs	O
by	O
levels	O
of	O
cognitive	O
function	O
.	O

The	O
associations	O
of	O
brachial	O
systolic	O
BP	O
,	O
diastolic	O
BP	O
,	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
,	O
and	O
pulse	O
pressure	O
with	O
all-cause	O
mortality	O
were	O
prospectively	O
explored	O
(	O
follow-up	O
7.0±2.2	O
years	O
)	O
in	O
660	O
community-dwelling	O
individuals	O
(	O
≥60	O
years	O
)	O
using	O
adjusted	O
Cox	O
models	O
,	O
stratified	O
by	O
cognitive	O
impairment	O
(	O
Mini-Mental	B-P
State	I-P
Examination	I-P
[	O
MMSE	B-P
]	O
<	O
24	O
)	O
.	O

No	O
association	O
between	O
brachial	O
BP	O
variables	O
and	O
mortality	O
was	O
shown	O
for	O
the	O
total	O
sample	O
in	O
quartiles	O
analysis	O
;	O
however	O
,	O
MAP	O
in	O
the	O
highest	O
quartile	O
,	O
compared	O
with	O
the	O
second	O
,	O
was	O
associated	O
with	O
mortality	O
(	O
hazard	O
ratio	O
,	O
1.85	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
1.09-3.12	O
)	O
among	O
cognitively	O
impaired	O
individuals	O
.	O

The	O
fractional-polynomials	O
approach	O
for	O
BP	O
confirmed	O
this	O
finding	O
and	O
further	O
showed	O
,	O
solely	O
in	O
the	O
MMSE	B-P
<	O
24	O
subcohort	O
,	O
U-shaped	O
trends	O
of	O
MAP	O
and	O
systolic	O
BP	O
,	O
with	O
increased	O
mortality	O
risk	O
in	O
extremely	O
low	O
or	O
high	O
values	O
;	O
no	O
such	O
pattern	O
was	O
evident	O
for	O
patients	O
with	O
MMSE	B-P
≥24	O
.	O

Elderly	O
individuals	O
with	O
cognitive	O
impairment	O
might	O
be	O
more	O
susceptible	O
to	O
the	O
detrimental	O
effects	O
of	O
low	O
and	O
elevated	O
MAP	O
and	O
systolic	O
BP	O
.	O

The	O
cost-effectiveness	O
of	O
family	O
/	O
family-based	O
therapy	O
for	O
treatment	O
of	O
externalizing	O
disorders	O
,	O
substance	O
use	O
disorders	O
and	O
delinquency	O
:	O
a	O
systematic	O
review	O
.	O

Family	O
therapy	O
and	O
family-based	O
treatment	O
has	O
been	O
commonly	O
applied	O
in	O
children	O
and	O
adolescents	O
in	O
mental	O
health	O
care	O
and	O
has	O
been	O
proven	O
to	O
be	O
effective	O
.	O

There	O
is	O
an	O
increased	O
interest	O
in	O
economic	O
evaluations	O
of	O
these	O
,	O
often	O
expensive	O
,	O
interventions	O
.	O

The	O
aim	O
of	O
this	O
systematic	O
review	O
is	O
to	O
summarize	O
and	O
evaluate	O
the	O
evidence	O
on	O
cost-effectiveness	O
of	O
family	O
/	O
family-based	O
therapy	O
for	O
externalizing	O
disorders	O
,	O
substance	O
use	O
disorders	O
and	O
delinquency	O
.	O

A	O
systematic	O
literature	O
search	O
was	O
performed	O
in	O
PubMed	O
,	O
Education	O
Resource	O
information	O
Centre	O
(	O
ERIC	O
)	O
,	O
Psycinfo	O
and	O
Cochrane	O
reviews	O
including	O
studies	B-P
conducted	O
after	O
1990	O
and	O
before	O
the	O
first	O
of	O
August	O
of	O
2013	O
.	O

Full	O
economic	O
evaluations	O
investigating	O
family	O
/	O
family-based	O
interventions	O
for	O
adolescents	O
between	O
10	O
and	O
20	O
years	O
treated	O
for	O
substance	O
use	O
disorders	O
,	O
delinquency	O
or	O
externalizing	O
disorders	O
were	O
included	O
.	O

Seven	O
hundred	O
thirty-one	O
articles	O
met	O
the	O
search	O
criteria	O
and	O
51	O
studies	B-P
were	O
initially	O
selected	O
.	O

The	O
final	O
selection	O
resulted	O
in	O
the	O
inclusion	O
of	O
11	O
studies	B-P
.	O

The	O
quality	O
of	O
these	O
studies	B-P
was	O
assessed	O
.	O

Within	O
the	O
identified	O
studies	B-P
,	O
there	O
was	O
great	O
variation	O
in	O
the	O
specific	O
type	O
of	O
family	O
/	O
family-based	O
interventions	O
and	O
disorders	O
.	O

According	O
to	O
the	O
outcomes	O
of	O
the	O
checklists	O
,	O
the	O
overall	O
quality	O
of	O
the	O
economic	O
evaluations	O
was	O
low	O
.	O

Results	O
varied	O
by	O
study	B-P
.	O

Due	O
to	O
the	O
variations	O
in	O
setting	O
,	O
design	O
and	O
outcome	O
it	O
was	O
not	O
feasible	O
to	O
pool	O
results	O
using	O
a	O
meta-analysis	O
.	O

The	O
quality	O
of	O
the	O
identified	O
economic	O
evaluations	O
of	O
family	O
/	O
family-based	O
therapy	O
for	O
treatment	O
of	O
externalizing	O
disorders	O
,	O
adolescent	O
substance	O
use	O
disorders	O
and	O
delinquency	O
was	O
insufficient	O
to	O
determine	O
the	O
cost-effectiveness	O
.	O

Although	O
commonly	O
applied	O
,	O
family	O
/	O
family-based	O
therapy	O
is	O
costly	O
and	O
more	O
research	O
of	O
higher	O
quality	O
is	O
needed	O
.	O

A	O
16	O
Yin	O
Yang	O
gene	O
expression	O
ratio	O
signature	O
for	O
ER+	O
/	O
node-	O
breast	O
cancer	O
.	O

Breast	O
cancer	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
cancer	O
death	O
in	O
women	O
.	O

It	O
is	O
a	O
complex	O
and	O
heterogeneous	O
disease	O
with	O
different	O
clinical	O
outcomes	O
.	O

Stratifying	O
patients	O
into	O
subgroups	O
with	O
different	O
outcomes	O
could	O
help	O
guide	O
clinical	B-P
decision	I-P
making	I-P
.	O

In	O
this	O
study	O
,	O
we	O
used	O
two	O
opposing	O
groups	O
of	O
genes	O
,	O
Yin	O
and	O
Yang	O
,	O
to	O
develop	O
a	O
prognostic	O
expression	O
ratio	O
signature	O
.	O

Using	O
the	O
METABRIC	O
cohort	O
we	O
identified	O
a16-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	O
cancer	O
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low-risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	O
therapy	O
,	O
intermediate	O
-	O
low-risk	O
patients	O
will	O
be	O
treated	O
with	O
hormonal	O
therapy	O
only	O
,	O
and	O
intermediate	O
-high-	O
and	O
high-risk	O
groups	O
will	O
be	O
treated	O
by	O
chemotherapy	O
in	O
addition	O
to	O
the	O
hormonal	O
therapy	O
.	O

The	O
16-	O
gene	O
signature	O
for	O
four	O
risk	O
level	O
stratifications	O
of	O
breast	O
cancer	O
patients	O
has	O
been	O
validated	O
using	O
14	O
independent	O
datasets	O
.	O

Notably	O
,	O
the	O
low-risk	O
group	O
(	O
n	O
=	O
51	O
)	O
of	O
205	O
estrogen	O
receptor-positive	O
and	O
node	O
negative	O
(	O
ER+	O
/	O
node-	O
)	O
patients	O
from	O
three	O
different	O
datasets	O
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	O
therapy	O
had	O
100	O
%	O
15-	O
year	O
disease-specific	O
survival	O
rate	O
.	O

The	O
Concordance	O
Index	O
of	O
YMR	B-P
for	O
ER+	O
/	O
node	O
negative	O
patients	O
is	O
close	O
to	O
the	O
commercially	O
available	O
signatures	O
.	O

However	O
,	O
YMR	B-P
showed	O
more	O
significance	O
(	O
HR	O
=	O
3.7	O
,	O
p	O
=	O
8.7e-12	O
)	O
in	O
stratifying	O
ER+	O
/	O
node-	O
subgroup	O
than	O
OncotypeDx	B-P
(	O
HR	O
=	O
2.7	O
,	O
p	O
=	O
1.3e-7	O
)	O
,	O
MammaPrint	B-P
(	O
HR	O
=	O
2.5	O
,	O
p	O
=	O
5.8e-7	O
)	O
,	O
rorS	B-P
(	O
HR	O
=	O
2.4	O
,	O
p	O
=	O
1.4e-6	O
)	O
,	O
and	O
NPI	B-P
(	O
HR	O
=	O
2.6	O
,	O
p	O
=	O
1.2e-6	O
)	O
.	O

YMR	B-P
signature	O
may	O
be	O
developed	O
as	O
a	O
clinical	O
tool	O
to	O
select	O
a	O
subgroup	O
of	O
low-risk	O
ER+	O
/	O
node-	O
patients	O
who	O
do	O
not	O
require	O
any	O
adjuvant	O
hormonal	O
therapy	O
(	O
AHT	O
)	O
.	O

Correlations	O
between	O
physical	O
activity	O
and	O
neurocognitive	O
domain	O
functions	O
in	O
patients	O
with	O
schizophrenia	O
:	O
a	O
cross-sectional	O
study	O
.	O

Neurocognitive	O
dysfunction	O
is	O
a	O
critical	O
target	O
symptom	O
of	O
schizophrenia	O
treatment	O
.	O

A	O
positive	O
correlation	O
between	O
physical	O
activity	O
level	O
and	O
neurocognitive	O
function	O
has	O
been	O
reported	O
in	O
healthy	O
individuals	O
,	O
but	O
it	O
is	O
unclear	O
whether	O
such	O
a	O
correlation	O
exists	O
in	O
patients	O
with	O
schizophrenia	O
and	O
whether	O
the	O
relationship	O
is	O
different	O
according	O
to	O
inpatients	O
or	O
outpatients	O
.	O

This	O
study	O
aimed	O
to	O
examine	O
the	O
differences	O
in	O
the	O
correlations	O
between	O
physical	O
activity	O
and	O
multiple	O
neurocognitive	O
domains	O
in	O
inpatients	O
and	O
outpatients	O
with	O
schizophrenia	O
and	O
obtain	O
suggestions	O
for	O
further	O
study	O
to	O
facilitate	O
this	O
field	O
.	O

Twenty-nine	O
patients	O
with	O
schizophrenia	O
were	O
examined	O
(	O
16	O
inpatients	O
and	O
13	O
outpatients	O
,	O
56.0	O
±	O
11.4	O
years	O
of	O
age	O
)	O
.	O

Current	O
symptoms	O
were	O
assessed	O
using	O
the	O
Positive	O
and	O
Negative	O
Symptom	O
Scale	O
and	O
neurocognitive	O
functions	O
using	O
Cognitrax	O
,	O
which	O
yields	O
a	O
composite	O
neurocognitive	B-P
index	I-P
(	O
NCI	B-P
)	O
and	O
11	O
domain	O
scores	O
.	O

After	O
testing	O
,	O
participants	O
wore	O
an	O
HJA-750C	O
accelerometer	O
for	O
one	O
week	O
to	O
measure	O
physical	O
activity	O
levels	O
and	O
durations	O
.	O

Partial	O
correlation	O
analyses	O
were	O
performed	O
between	O
exercise	O
and	O
cognitive	O
parameters	O
.	O

In	O
the	O
outpatient	O
group	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
faster	O
Motor	O
and	O
Psychomotor	O
Speeds	O
in	O
outpatients	O
.	O

However	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
lower	O
overall	O
NCI	B-P
,	O
Attention	O
score	O
,	O
and	O
Memory	O
scores	O
in	O
inpatients	O
.	O

Although	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
better	O
neurocognitive	O
functions	O
of	O
outpatients	O
,	O
in	O
inpatients	O
with	O
non-remitted	O
schizophrenia	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
worsening	O
of	O
several	O
cognitive	O
domains	O
.	O

In	O
a	O
future	O
study	O
examining	O
the	O
relationship	O
between	O
physical	O
activity	O
and	O
neurocognitive	O
function	O
for	O
facilitating	O
this	O
research	O
field	O
,	O
separation	O
between	O
inpatients	O
and	O
outpatients	O
are	O
needed	O
because	O
the	O
relationship	O
is	O
different	O
between	O
inpatients	O
and	O
outpatients	O
.	O

Inwardly	O
rectifying	O
K	O
(	O
+	O
)	O
channels	O
are	O
major	O
contributors	O
to	O
flow	O
-	O
induced	O
vasodilatation	O
in	O
resistance	O
arteries	O
.	O

Endothelial	O
inwardly	O
rectifying	O
K	O
(	O
+	O
)	O
(	O
Kir2.1	O
)	O
channels	O
regulate	O
flow	O
-	O
induced	O
vasodilatation	O
via	O
nitric	O
oxide	O
(	O
NO	O
)	O
in	O
mouse	O
mesenteric	O
resistance	O
arteries	O
.	O

Deficiency	O
of	O
Kir2.1	O
channels	O
results	O
in	O
elevated	O
blood	O
pressure	O
and	O
increased	O
vascular	O
resistance	O
.	O

Flow	O
-	O
induced	O
vasodilatation	O
in	O
human	O
resistance	O
arteries	O
is	O
also	O
regulated	O
by	O
inwardly	O
rectifying	O
K	O
(	O
+	O
)	O
channels	O
.	O

This	O
study	O
presents	O
the	O
first	O
direct	O
evidence	O
that	O
Kir	O
channels	O
play	O
a	O
critical	O
role	O
in	O
physiological	O
endothelial	O
responses	O
to	O
flow	O
.	O

Inwardly	O
rectifying	O
K	O
(	O
+	O
)	O
(	O
Kir	O
)	O
channels	O
are	O
known	O
to	O
be	O
sensitive	O
to	O
flow	O
,	O
but	O
their	O
role	O
in	O
flow	O
-	O
induced	O
endothelial	O
responses	O
is	O
not	O
known	O
.	O

The	O
goal	O
of	O
this	O
study	O
is	O
to	O
establish	O
the	O
role	O
of	O
Kir	O
channels	O
in	O
flow	O
-	O
induced	O
vasodilatation	O
and	O
to	O
provide	O
first	O
insights	O
into	O
the	O
mechanisms	O
responsible	O
for	O
Kir	O
signalling	O
in	O
this	O
process	O
.	O

First	O
,	O
we	O
establish	O
that	O
primary	O
endothelial	O
cells	O
isolated	O
from	O
murine	O
mesenteric	O
arteries	O
express	O
functional	O
Kir2.1	O
channels	O
sensitive	O
to	O
shear	O
stress	O
.	O

Then	O
,	O
using	O
the	O
Kir2.1	O
(	O
+/-	O
)	O
heterozygous	O
mouse	O
model	O
,	O
we	O
establish	O
that	O
downregulation	O
of	O
Kir2.1	O
results	O
in	O
significant	O
decrease	O
in	O
shear	O
-	O
activated	O
Kir	O
currents	O
and	O
inhibition	O
of	O
endothelium	O
-dependent	O
flow	O
-	O
induced	O
vasodilatation	O
(	O
FIV	O
)	O
assayed	O
in	O
pressurized	O
mesenteric	O
arteries	O
pre-constricted	O
with	O
endothelin-1	O
.	O

Deficiency	O
in	O
Kir2.1	O
also	O
results	O
in	O
the	O
loss	O
of	O
flow	O
-	O
induced	O
phosphorylation	O
of	O
eNOS	O
and	O
Akt	O
,	O
as	O
well	O
as	O
inhibition	O
of	O
NO	O
generation	O
.	O

All	O
the	O
effects	O
are	O
fully	O
rescued	O
by	O
endothelial	O
cell	O
(	O
EC	O
)	O
-specific	O
overexpression	O
of	O
Kir2.1	O
.	O

A	O
component	O
of	O
FIV	O
that	O
is	O
Kir	O
independent	O
is	O
abrogated	O
by	O
blocking	O
Ca	O
(	O
2+	O
)	O
-sensitive	O
K	O
(	O
+	O
)	O
channels	O
.	O

Kir2.1	O
has	O
no	O
effect	O
on	O
endothelium	O
-independent	O
and	O
K	O
(	O
+	O
)	O
-	O
induced	O
vasodilatation	O
in	O
denuded	O
arteries	O
.	O

Kir2.1	O
(	O
+/-	O
)	O
mice	O
also	O
show	O
increased	O
mean	O
blood	O
pressure	O
measured	O
by	O
carotid	O
artery	O
cannulation	O
and	O
increased	O
microvascular	O
resistance	O
measured	O
using	O
a	O
tail-cuff	B-P
.	O

Importantly	O
,	O
blocking	O
Kir	O
channels	O
also	O
inhibits	O
flow	O
-	O
induced	O
vasodilatation	O
in	O
human	O
subcutaneous	O
adipose	O
microvessels	O
.	O

Endothelial	O
Kir	O
channels	O
contribute	O
to	O
FIV	O
of	O
mouse	O
mesenteric	O
arteries	O
via	O
an	O
NO	O
-dependent	O
mechanism	O
,	O
whereas	O
Ca	O
(	O
2+	O
)	O
-sensitive	O
K	O
(	O
+	O
)	O
channels	O
mediate	O
FIV	O
via	O
an	O
NO	O
-independent	O
pathway	O
.	O

Kir2	O
channels	O
also	O
regulate	O
vascular	O
resistance	O
and	O
blood	O
pressure	O
.	O

Finally	O
,	O
Kir	O
channels	O
also	O
contribute	O
to	O
FIV	O
in	O
human	O
subcutaneous	O
microvessels	O
.	O

Intraoperative	O
ketamine	O
reduces	O
immediate	O
postoperative	O
opioid	O
consumption	O
after	O
spinal	O
fusion	O
surgery	O
in	O
chronic	O
pain	O
patients	O
with	O
opioid	O
dependency	O
:	O
a	O
randomized	O
,	O
blinded	O
trial	O
.	O

Perioperative	O
handling	O
of	O
surgical	O
patients	O
with	O
opioid	O
dependency	O
represents	O
an	O
important	O
clinical	O
problem	O
.	O

Animal	O
studies	O
suggest	O
that	O
ketamine	O
attenuates	O
central	O
sensitization	O
and	O
hyperalgesia	O
and	O
thereby	O
reduces	O
postoperative	O
opioid	O
tolerance	O
.	O

We	O
hypothesized	O
that	O
intraoperative	O
ketamine	O
would	O
reduce	O
immediate	O
postoperative	O
opioid	O
consumption	O
compared	O
with	O
placebo	O
in	O
chronic	O
pain	O
patients	O
with	O
opioid	O
dependency	O
undergoing	O
lumbar	O
spinal	O
fusion	O
surgery	O
.	O

Primary	O
outcome	O
was	O
morphine	O
consumption	O
0	O
to	O
24	O
hours	O
postoperatively	O
.	O

Secondary	O
outcomes	O
were	O
acute	O
pain	O
at	O
rest	O
and	O
during	O
mobilization	O
2	O
to	O
24	O
hours	O
postoperatively	O
(	O
visual	B-P
analogue	I-P
scale	I-P
)	O
,	O
adverse	O
events	O
,	O
and	O
persistent	O
pain	O
6	O
months	O
postoperatively	O
.	O

One	O
hundred	O
fifty	O
patients	O
were	O
randomly	O
assigned	O
to	O
intraoperative	O
S-ketamine	O
bolus	O
0.5	O
mg/kg	O
and	O
infusion	O
0.25	O
mg·kg·h	O
or	O
placebo	O
.	O

Postoperatively	O
,	O
patients	O
received	O
their	O
usual	O
opioids	O
,	O
paracetamol	O
and	O
IV	O
patient-controlled	O
analgesia	O
with	O
morphine	O
.	O

In	O
the	O
final	O
analyses	O
,	O
147	O
patients	O
were	O
included	O
.	O

Patient-controlled	O
analgesia	O
IV	O
morphine	O
consumption	O
0	O
to	O
24	O
hours	O
postoperatively	O
was	O
significantly	O
reduced	O
in	O
the	O
ketamine	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
:	O
79	O
(	O
47	O
)	O
vs	O
121	O
(	O
53	O
)	O
mg	O
IV	O
,	O
mean	O
difference	O
42	O
mg	O
(	O
95	O
%	O
confidence	O
interval	O
-59	O
to	O
-25	O
)	O
,	O
P	O
<	O
0.001	O
.	O

Sedation	O
was	O
significantly	O
reduced	O
in	O
the	O
ketamine	O
group	O
6	O
and	O
24	O
hours	O
postoperatively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
regarding	O
acute	O
pain	O
,	O
nausea	O
,	O
vomiting	O
,	O
hallucinations	O
,	O
or	O
nightmares	O
.	O

Back	O
pain	O
at	O
6	O
months	O
postoperatively	O
compared	O
with	O
preoperative	O
pain	O
was	O
significantly	O
more	O
improved	O
in	O
the	O
ketamine	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
,	O
P	O
=	O
0.005	O
.	O

In	O
conclusion	O
,	O
intraoperative	O
ketamine	O
significantly	O
reduced	O
morphine	O
consumption	O
0	O
to	O
24	O
hours	O
after	O
lumbar	O
fusion	O
surgery	O
in	O
opioid	O
-	O
dependent	O
patients	O
.	O

The	O
trend	O
regarding	O
less	O
persistent	O
pain	O
6	O
months	O
postoperatively	O
needs	O
further	O
investigation	O
.	O

Neospora	O
caninum	O
in	O
Axis	O
Deer	O
(	O
Axis	O
axis	O
)	O
and	O
Fallow	O
Deer	O
(	O
Dama	O
dama	O
)	O
in	O
Northern	O
Mexico	O
.	O

Serum	O
samples	O
from	O
18	O
axis	O
deer	O
(	O
Axis	O
axis	O
)	O
and	O
19	O
fallow	O
deer	O
(	O
Dama	O
dama	O
)	O
were	O
analyzed	O
with	O
an	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
for	O
Neospora	O
caninum	O
antibodies	O
.	O

Two	O
axis	O
(	O
11	O
%	O
)	O
and	O
two	O
fallow	O
deer	O
(	O
11	O
%	O
)	O
were	O
positive	O
for	O
N.	O
caninum	O
antibodies	O
.	O

Isolation	B-P
and	O
characterization	O
of	O
lignocellulose	O
nanofibers	O
from	O
different	O
wheat	O
straw	O
pulps	O
.	O

Wheat	O
straw	O
was	O
cooked	O
under	O
different	O
pulping	O
processes	O
:	O
Soda	O
(	O
100°C	O
,	O
7	O
%	O
NaOH	O
,	O
150min	O
)	O
,	O
Kraft	O
(	O
170°C	O
,	O
16	O
%	O
alkalinity	O
,	O
25	O
%	O
sulfidity	O
,	O
40min	O
)	O
and	O
Organosolv	O
(	O
210°C	O
,	O
60	O
%	O
ethanol	O
,	O
60min	O
)	O
.	O

Once	O
the	O
pulps	O
were	O
obtained	O
,	O
lignocellulose	O
nanofibers	O
(	O
LCNF	O
)	O
were	O
isolated	O
by	O
mechanical	O
process	O
and	O
TEMPO	O
-mediated	O
oxidation	O
followed	O
by	O
a	O
high	O
pressure	O
homogenization	O
.	O

After	O
pulping	O
process	O
,	O
the	O
different	O
pulps	O
were	O
characterized	O
and	O
its	O
chemical	O
composition	O
was	O
determined	O
.	O

The	O
pulps	O
characterization	O
indicates	O
that	O
the	O
Soda	O
process	O
is	O
the	O
process	O
that	O
,	O
despite	O
producing	O
less	O
delignification	O
,	O
retains	O
much	O
of	O
the	O
hemicelluloses	O
in	O
the	O
pulp	O
,	O
being	O
this	O
content	O
a	O
key	O
factor	O
in	O
the	O
nanofibrillation	O
process	O
.	O

Regarding	O
the	O
LCNF	O
obtained	O
by	O
mechanical	O
process	O
,	O
those	O
nanofibers	O
isolated	O
from	O
Organosolv	O
wheat	O
pulp	O
(	O
OWP	O
)	O
and	O
Kraft	O
wheat	O
pulp	O
(	O
KWP	O
)	O
show	O
low	O
values	O
for	O
nanofibrillation	O
yield	O
,	O
specific	O
surface	O
area	O
and	O
greater	O
diameter	O
.	O

However	O
,	O
those	O
nanofibers	O
isolated	O
from	O
Soda	O
wheat	O
pulp	O
(	O
SWP	O
)	O
reach	O
much	O
higher	O
values	O
for	O
these	O
parameters	O
and	O
presents	O
a	O
diameter	O
of	O
14nm	O
,	O
smaller	O
than	O
those	O
obtained	O
by	O
TEMPO	O
-mediated	O
oxidation	O
from	O
OWP	O
.	O

Smaller	O
diameters	O
are	O
generally	O
obtained	O
in	O
TEMPO	O
-	O
oxidized	O
LCNF	O
.	O

This	O
work	O
concludes	O
that	O
the	O
lignin	O
content	O
does	O
not	O
affect	O
greatly	O
to	O
obtain	O
LCNF	O
as	O
does	O
the	O
hemicellulose	O
content	O
,	O
so	O
it	O
is	O
accurate	O
to	O
use	O
a	O
soft	O
pulping	O
process	O
.	O

Galectin-3	O
is	O
a	O
target	O
for	O
proteases	O
involved	O
in	O
the	O
virulence	O
of	O
Staphylococcus	O
aureus	O
.	O

Staphylococcus	O
aureus	O
is	O
a	O
major	O
cause	O
of	O
skin	O
and	O
soft-tissue	O
infection	O
.	O

The	O
bacterium	O
expresses	O
four	O
major	O
proteases	O
emerging	O
as	O
virulence	O
factors	O
;	O
aureolysin	O
(	O
Aur	O
)	O
,	O
V8	O
protease	O
(	O
SspA	O
)	O
,	O
staphopain	O
A	O
(	O
ScpA	O
)	O
,	O
and	O
staphopain	O
B	O
(	O
SspB	O
)	O
.	O

We	O
hypothesized	O
that	O
human	O
galectin-3	O
,	O
a	O
β-galactoside-binding	O
lectin	O
involved	O
in	O
immune	O
regulation	O
and	O
antimicrobial	O
defense	O
,	O
is	O
a	O
target	O
for	O
these	O
proteases	O
,	O
and	O
that	O
proteolysis	O
of	O
galectin-3	O
is	O
a	O
novel	O
immune	O
evasion	O
mechanism	O
.	O

Indeed	O
,	O
supernatants	O
from	O
laboratory	B-P
strains	I-P
and	O
clinical	O
isolates	O
of	O
S.	O
aureus	O
caused	O
galectin-3	O
degradation	O
.	O

Similar	O
proteolytic	O
capacity	O
was	O
found	O
in	O
Staphylococcus	O
epidermidis	O
isolates	O
,	O
but	O
not	O
Staphylococcus	O
saprophyticus	O
Galectin-3	O
-induced	O
activation	O
of	O
the	O
neutrophil	O
NADPH-oxidase	O
was	O
abrogated	O
by	O
bacteria	O
-derived	O
proteolysis	O
of	O
galectin-3	O
,	O
and	O
SspB	O
was	O
identified	O
as	O
the	O
major	O
protease	O
responsible	O
.	O

The	O
impact	O
of	O
galectin-3	O
and	O
protease	O
expression	O
on	O
S.	O
aureus	O
virulence	O
was	O
studied	O
in	O
a	O
murine	O
skin	O
infection	O
model	O
.	O

In	O
galectin-3	O
(	O
+/+	O
)	O
mice	O
,	O
SspB	O
-	O
expressing	O
S.	O
aureus	O
caused	O
larger	O
lesions	O
and	O
higher	O
bacterial	O
load	O
than	O
protease-lacking	O
bacteria	O
.	O

No	O
such	O
difference	O
was	O
detected	O
in	O
galectin-3	O
(	O
-/-	O
)	O
mice	O
,	O
which	O
also	O
showed	O
smaller	O
lesion	O
size	O
as	O
compared	O
to	O
the	O
galectin-3	O
(	O
+/+	O
)	O
animals	O
.	O

In	O
conclusion	O
,	O
the	O
staphylococcal	O
protease	O
SspB	O
inactivates	O
galectin-3	O
,	O
abrogating	O
its	O
stimulation	O
of	O
oxygen	O
radical	O
production	O
in	O
human	O
neutrophils	O
and	O
increasing	O
tissue	O
damage	O
during	O
skin	O
infection	O
.	O

Construction	O
of	O
an	O
Acetylcholinesterase	O
Sensor	O
Based	O
on	O
Synthesized	O
Paramagnetic	O
Nanoparticles	O
,	O
a	O
Simple	O
Tool	O
for	O
Neurotoxic	O
Compounds	O
Assay	B-P
.	O

Magnetic	O
particles	O
(	O
MPs	O
)	O
have	O
been	O
widely	O
used	O
in	O
biological	O
applications	O
in	O
recent	O
years	O
as	O
a	O
carrier	O
for	O
various	O
molecules	O
.	O

Their	O
big	O
advantage	O
is	O
in	O
repeated	O
use	O
of	O
immobilized	O
molecules	O
including	O
enzymes	O
.	O

Acetylcholinesterase	O
(	O
AChE	O
)	O
is	O
an	O
enzyme	O
playing	O
crucial	O
role	O
in	O
neurotransmission	O
and	O
the	O
enzyme	O
is	O
targeted	O
by	O
various	O
molecules	O
like	O
Alzheimer	O
's	O
drugs	O
,	O
pesticides	O
and	O
warfare	O
agents	O
.	O

In	O
this	O
work	O
,	O
an	O
electrochemical	O
biosensor	O
having	O
AChE	O
immobilized	O
onto	O
MPs	O
and	O
stabilized	O
through	O
glutaraldehyde	O
(	O
GA	O
)	O
molecule	O
was	O
proposed	O
for	O
assay	B-P
of	O
the	O
neurotoxic	O
compounds	O
.	O

The	O
prepared	O
nanoparticles	O
were	O
modified	O
by	O
pure	O
AChE	O
and	O
they	O
were	O
used	O
for	O
the	O
measurement	O
anti-Alzheimer	O
's	O
drug	O
galantamine	O
and	O
carbamate	O
pesticide	O
carbofuran	O
with	O
limit	O
of	O
detection	O
1.5	O
µM	O
and	O
20	O
nM	O
,	O
respectively	O
.	O

All	O
measurements	O
were	O
carried	O
out	O
using	O
screen-printed	O
sensor	O
with	O
carbon	O
working	O
,	O
silver	O
reference	O
,	O
and	O
carbon	O
auxiliary	O
electrode	O
.	O

Standard	B-P
Ellman	I-P
's	I-P
assay	I-P
was	O
used	O
for	O
validation	O
measurement	O
of	O
both	O
inhibitors	O
.	O

Part	O
of	O
this	O
work	O
was	O
the	O
elimination	O
of	O
reversible	O
inhibitors	O
represented	O
by	O
galantamine	O
from	O
the	O
active	O
site	O
of	O
AChE	O
.	O

For	O
this	O
purpose	O
,	O
we	O
used	O
a	O
lower	O
pH	O
to	O
get	O
the	O
original	O
activity	O
of	O
AChE	O
after	O
inhibition	O
by	O
galantamine	O
.	O

We	O
also	O
observed	O
decarbamylation	O
of	O
the	O
AChE	O
-	O
carbofuran	O
adduct	O
.	O

Influence	O
of	O
organic	O
solvents	O
to	O
AChE	O
as	O
well	O
as	O
repeatability	O
of	O
measurement	O
with	O
MPs	O
with	O
AChE	O
was	O
also	O
established	O
.	O

Kinematics	O
and	O
kinetics	O
during	O
stair	O
ascent	O
in	O
individuals	O
with	O
Gluteal	O
Tendinopathy	O
.	O

Individuals	O
with	O
gluteal	O
tendinopathy	O
commonly	O
report	O
lateral	O
hip	O
pain	O
and	O
disability	O
during	O
stair	O
ascent	O
.	O

This	O
study	O
aimed	O
to	O
compare	O
kinematics	O
and	O
kinetics	O
between	O
individuals	O
with	O
and	O
without	O
gluteal	O
tendinopathy	O
during	O
a	O
step	O
up	O
task	O
.	O

35	O
individuals	O
with	O
unilateral	O
gluteal	O
tendinopathy	O
and	O
35	O
pain-free	O
controls	O
underwent	O
three-dimensional	O
motion	B-P
analysis	I-P
of	O
stance	O
phase	O
during	O
stair	O
ascent	O
.	O

An	O
analysis	O
of	O
covariance	O
was	O
performed	O
to	O
compare	O
hip	O
,	O
pelvis	O
and	O
trunk	O
kinematic	O
and	O
kinetic	O
variables	O
between	O
groups	O
.	O

A	O
K-means	O
cluster	O
analysis	O
was	O
performed	O
to	O
identify	O
subgroups	O
from	O
the	O
entire	O
group	O
(	O
n=70	O
)	O
based	O
on	O
the	O
characteristics	O
of	O
the	O
external	O
hip	O
adduction	O
moment	O
.	O

Finally	O
,	O
a	O
Newcombe-Wilson	O
test	O
was	O
performed	O
to	O
evaluate	O
the	O
relationship	O
between	O
group	O
and	O
cluster	O
codes	O
and	O
a	O
3×2	O
ANOVA	O
to	O
investigate	O
the	O
differences	O
in	O
kinematics	O
between	O
groups	O
and	O
cluster	O
codes	O
.	O

Individuals	O
with	O
gluteal	O
tendinopathy	O
exhibited	O
a	O
greater	O
hip	O
adduction	O
moment	O
impulse	O
during	O
stair	O
ascent	O
(	O
ES=0.83	O
)	O
,	O
greater	O
internal	O
rotation	O
impulse	O
during	O
the	O
first	O
50	O
%	O
stance	O
phase	O
(	O
ES=0.63	O
)	O
and	O
greater	O
contralateral	O
trunk	O
lean	O
throughout	O
stance	O
than	O
controls	O
(	O
ranging	O
from	O
ES=0.67-0.93	O
)	O
.	O

Three	O
subgroups	O
based	O
on	O
hip	O
adduction	O
moment	O
characteristics	O
were	O
identified	O
.	O

Individuals	O
with	O
GT	O
were	O
4.5	O
times	O
more	O
likely	O
to	O
have	O
a	O
hip	O
adduction	O
moment	O
characteristic	O
of	O
a	O
large	O
impulse	O
and	O
greater	O
lateral	O
pelvic	O
translation	O
at	O
heel	O
strike	O
than	O
the	O
subgroup	O
most	O
likely	O
to	O
contain	O
controls	O
.	O

Individuals	O
with	O
GT	O
exhibit	O
greater	O
hip	O
adduction	O
moment	O
impulse	O
and	O
alterations	O
in	O
trunk	O
and	O
pelvic	O
kinematics	O
during	O
stair	O
ascent	O
.	O

Findings	O
provide	O
a	O
basis	O
to	O
consider	O
frontal	O
plane	O
trunk	O
and	O
pelvic	O
control	O
in	O
the	O
management	O
of	O
gluteal	O
tendinopathy	O
.	O

Biological	O
basis	O
of	O
radiation	O
protection	O
needs	O
rejuvenation	O
.	O

Human	O
beings	O
encounter	O
radiation	O
in	O
many	O
different	O
situations	O
-	O
from	O
proximity	O
to	O
radioactive	O
waste	O
sites	O
to	O
participation	O
in	O
medical	O
procedures	O
using	O
X-rays	O
etc	O
.	O

Limits	O
for	O
radiation	O
exposures	O
are	O
legally	O
regulated	O
;	O
however	O
,	O
current	O
radiation	O
protection	O
policy	O
does	O
not	O
explicitly	O
acknowledge	O
that	O
biological	O
,	O
cellular	B-P
and	O
molecular	O
effects	O
of	O
low	O
doses	O
and	O
low	O
dose	O
rates	O
of	O
radiation	O
differ	O
from	O
effects	O
induced	O
by	O
medium	O
and	O
high	O
dose	O
radiation	O
exposures	O
.	O

Recent	O
technical	O
developments	O
in	O
biology	O
and	O
medicine	O
,	O
from	O
single	B-P
cell	I-P
techniques	I-P
to	O
big	B-P
data	I-P
computational	I-P
research	I-P
,	O
have	O
enabled	O
new	O
approaches	O
for	O
study	O
of	O
biology	O
of	O
low	O
doses	O
of	O
radiation	O
.	O

Results	O
of	O
the	O
work	O
done	O
so	O
far	O
support	O
the	O
idea	O
that	O
low	O
doses	O
of	O
radiation	O
have	O
effects	O
that	O
differ	O
from	O
those	O
associated	O
with	O
high	O
dose	O
exposures	O
;	O
this	O
work	O
,	O
however	O
,	O
is	O
far	O
from	O
sufficient	O
for	O
the	O
development	O
of	O
a	O
new	O
theoretical	O
framework	O
needed	O
for	O
the	O
understanding	O
of	O
low	O
dose	O
radiation	O
exposures	O
.	O

Mechanistic	O
understanding	O
of	O
radiation	O
effects	O
at	O
low	O
doses	O
is	O
necessary	O
in	O
order	O
to	O
develop	O
better	O
radiation	O
protection	O
policy	O
.	O

Learning	O
in	O
Complex	O
Environments	O
:	O
The	O
Effects	O
of	O
Background	O
Speech	O
on	O
Early	O
Word	O
Learning	O
.	O

Although	O
most	O
studies	O
of	O
language	O
learning	O
take	O
place	O
in	O
quiet	O
laboratory	O
settings	O
,	O
everyday	O
language	O
learning	O
occurs	O
under	O
noisy	O
conditions	O
.	O

The	O
current	O
research	O
investigated	O
the	O
effects	O
of	O
background	O
speech	O
on	O
word	O
learning	O
.	O

Both	O
younger	O
(	O
22-	O
to	O
24-month-olds	O
;	O
n	O
=	O
40	O
)	O
and	O
older	O
(	O
28-	O
to	O
30-month-olds	O
;	O
n	O
=	O
40	O
)	O
toddlers	O
successfully	O
learned	O
novel	O
label	O
-	O
object	O
pairings	O
when	O
target	O
speech	O
was	O
10	O
dB	O
louder	O
than	O
background	O
speech	O
but	O
not	O
when	O
the	O
signal-to-noise	O
ratio	O
(	O
SNR	O
)	O
was	O
5	O
dB	O
.	O

Toddlers	O
(	O
28-	O
to	O
30-month-olds	O
;	O
n	O
=	O
26	O
)	O
successfully	O
learned	O
novel	O
words	O
with	O
a	O
5-dB	O
SNR	O
when	O
they	O
initially	O
heard	O
the	O
labels	O
embedded	B-P
in	O
fluent	O
speech	O
without	O
background	O
noise	O
,	O
before	O
they	O
were	O
mapped	O
to	O
objects	O
.	O

The	O
results	O
point	O
to	O
both	O
challenges	O
and	O
protective	O
factors	O
that	O
may	O
impact	O
language	O
learning	O
in	O
complex	O
auditory	O
environments	O
.	O

Distinct	O
cortical	O
and	O
sub-cortical	O
neurogenic	O
domains	O
for	O
GABAergic	O
interneuron	O
precursor	O
transcription	O
factors	O
NKX2.1	O
,	O
OLIG2	O
and	O
COUP-TFII	O
in	O
early	O
fetal	O
human	O
telencephalon	O
.	O

The	O
extent	O
of	O
similarities	O
and	O
differences	O
between	O
cortical	O
GABAergic	O
interneuron	O
generation	O
in	O
rodent	O
and	O
primate	O
telencephalon	O
remains	O
contentious	O
.	O

We	O
examined	O
expression	O
of	O
three	O
interneuron	O
precursor	O
transcription	O
factors	O
,	O
alongside	O
other	O
markers	O
,	O
using	O
immunohistochemistry	B-P
on	O
8-12	O
post-conceptional	O
weeks	O
(	O
PCW	O
)	O
human	O
telencephalon	O
sections	O
.	O

NKX2.1	O
,	O
OLIG2	O
,	O
and	O
COUP-TFII	O
expression	O
occupied	O
distinct	O
(	O
although	O
overlapping	O
)	O
neurogenic	O
domains	O
which	O
extended	O
into	O
the	O
cortex	O
and	O
revealed	O
three	O
CGE	O
compartments	O
:	O
lateral	O
,	O
medial	O
,	O
and	O
ventral	O
.	O

NKX2.1	O
expression	O
was	O
very	O
largely	O
confined	O
to	O
the	O
MGE	O
,	O
medial	O
CGE	O
,	O
and	O
ventral	O
septum	O
confirming	O
that	O
,	O
at	O
this	O
developmental	O
stage	O
,	O
interneuron	O
generation	O
from	O
NKX2.1	O
+	O
precursor	O
s	O
closely	O
resembles	O
the	O
process	O
observed	O
in	O
rodents	O
.	O

OLIG2	O
immunoreactivity	O
was	O
observed	O
in	O
GABAergic	O
cells	O
of	O
the	O
proliferative	O
zones	O
of	O
the	O
MGE	O
and	O
septum	O
,	O
but	O
not	O
necessarily	O
co-expressed	O
with	O
NKX2.1	O
,	O
and	O
OLIG2	O
expression	O
was	O
also	O
extensively	O
seen	O
in	O
the	O
LGE	O
,	O
CGE	O
,	O
and	O
cortex	O
.	O

At	O
8	O
PCW	O
,	O
OLIG2	O
+	O
cells	O
were	O
only	O
present	O
in	O
the	O
medial	O
and	O
anterior	O
cortical	O
wall	O
suggesting	O
a	O
migratory	O
pathway	O
for	O
interneuron	O
precursor	O
s	O
via	O
the	O
septum	O
into	O
the	O
medial	O
cortex	O
.	O

By	O
12	O
PCW	O
,	O
OLIG2	O
+	O
cells	O
were	O
present	O
throughout	O
the	O
cortex	O
and	O
many	O
were	O
actively	O
dividing	O
but	O
without	O
co-expressing	O
cortical	O
progenitor	O
markers	O
.	O

Dividing	O
COUP-TFII	O
+	O
progenitor	O
cells	O
were	O
localized	O
to	O
ventral	O
CGE	O
as	O
previously	O
described	O
but	O
were	O
also	O
numerous	O
in	O
adjacent	O
ventral	O
cortex	O
;	O
in	O
both	O
the	O
cases	O
,	O
COUP-TFII	O
was	O
co-expressed	O
with	O
PAX6	O
in	O
proliferative	O
zones	O
and	O
TBR1	O
or	O
calretinin	O
in	O
post-	O
mitotic	O
cortical	O
neurons	O
.	O

Thus	O
COUP-TFII	O
+	O
progenitors	O
gave	O
rise	O
to	O
pyramidal	O
cells	O
,	O
but	O
also	O
interneurons	O
which	O
not	O
only	O
migrated	O
posteriorly	O
into	O
the	O
cortex	O
from	O
ventral	O
CGE	O
but	O
also	O
anteriorly	O
via	O
the	O
LGE	O
.	O

Thixotropic	O
injectable	O
hydrogel	O
using	O
a	O
polyampholyte	O
and	O
nanosilicate	O
prepared	O
directly	O
after	O
cryopreservation	B-P
.	O

Success	O
of	O
tissue	O
engineering	O
applications	O
in	O
regenerative	O
medicine	O
requires	O
the	O
preservation	O
of	O
tissue-engineered	O
products	O
at	O
a	O
low	O
temperature	O
.	O

This	O
can	O
be	O
successfully	O
achieved	O
by	O
the	O
use	O
of	O
cryoprotective	O
agent	O
(	O
CPA	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
formulated	O
a	O
unique	O
injectable	O
hydrogel	O
for	O
the	O
purpose	O
of	O
cell	O
delivery	O
after	O
cryopreservation	B-P
by	O
using	O
polyampholyte	O
CPA	O
.	O

The	O
polyampholyte	O
showed	O
excellent	O
post-thaw	O
cell	O
survival	O
,	O
and	O
after	O
thawing	B-P
,	O
the	O
polymeric	O
CPA	O
did	O
not	O
have	O
to	O
be	O
removed	O
because	O
of	O
its	O
low	O
cytotoxicity	O
.	O

The	O
polyampholyte	O
could	O
be	O
transformed	O
into	O
a	O
hydrogel	O
by	O
mixing	O
with	O
nanosilicates	O
.	O

Previously	O
,	O
nanosilicates	O
were	O
used	O
to	O
improve	O
mechanical	O
properties	O
,	O
but	O
this	O
is	O
the	O
first	O
report	O
of	O
the	O
use	O
of	O
a	O
nanosilicate	O
together	O
with	O
CPA	O
to	O
formulate	O
hydrogels	O
.	O

Inclusion	O
of	O
the	O
nanosilicate	O
led	O
to	O
the	O
formation	O
of	O
thixotropic	O
hydrogels	O
,	O
which	O
can	O
be	O
injected	O
using	O
fine	O
needles	O
.	O

These	O
gels	O
with	O
tunable	O
mechanical	O
properties	O
can	O
be	O
injected	O
into	O
defect	O
sites	O
to	O
form	O
scaffolds	O
for	O
cell	O
growth	O
and	O
tissue	O
repair	O
,	O
and	O
they	O
do	O
not	O
require	O
any	O
separate	O
seeding	O
of	O
cells	O
before	O
injection	O
,	O
thus	O
eliminating	O
the	O
need	O
for	O
cell	O
harvesting	O
and	O
cell	O
maintenance	O
.	O

This	O
is	O
a	O
distinct	O
system	O
in	O
which	O
cells	O
can	O
be	O
cryopreserved	O
until	O
before	O
usage	O
;	O
when	O
required	O
,	O
the	O
cells	O
in	O
the	O
polyampholyte	O
can	O
be	O
revived	O
to	O
their	O
original	O
state	O
and	O
the	O
thixotropic	O
hydrogel	O
can	O
be	O
formed	O
.	O

The	O
combination	O
of	O
thixotropy	O
and	O
cytocompatibility	O
of	O
the	O
gels	O
could	O
enable	O
a	O
wide	O
range	O
of	O
biomedical	O
applications	O
such	O
as	O
cell	O
delivery	O
and	O
orthopedic	O
repair	O
.	O

Bioelectrochemical	B-P
anaerobic	O
sewage	O
treatment	O
technology	O
for	O
Arctic	O
communities	O
.	O

This	O
study	O
describes	O
a	O
novel	O
wastewater	O
treatment	O
technology	O
suitable	O
for	O
small	O
remote	O
northern	O
communities	O
.	O

The	O
technology	O
is	O
based	O
on	O
an	O
enhanced	O
biodegradation	O
of	O
organic	O
carbon	O
through	O
a	O
combination	O
of	O
anaerobic	O
methanogenic	O
and	O
microbial	O
electrochemical	B-P
(	O
bioelectrochemical	B-P
)	O
degradation	O
processes	O
leading	O
to	O
biomethane	O
production	O
.	O

The	O
microbial	O
electrochemical	B-P
degradation	O
is	O
achieved	O
in	O
a	O
membraneless	O
flow	O
-through	O
bioanode	O
-	O
biocathode	O
setup	O
operating	O
at	O
an	O
applied	O
voltage	O
below	O
the	O
water	O
electrolysis	O
threshold	O
.	O

Laboratory	O
wastewater	O
treatment	O
tests	O
conducted	O
through	O
a	O
broad	O
range	O
of	O
mesophilic	O
and	O
psychrophilic	O
temperatures	O
(	O
5-23	O
°C	O
)	O
using	O
synthetic	O
wastewater	O
showed	O
a	O
biochemical	B-P
oxygen	I-P
demand	I-P
(	O
BOD5	B-P
)	O
removal	O
efficiency	O
of	O
90-97	O
%	O
and	O
an	O
effluent	O
BOD5	B-P
concentration	O
as	O
low	O
as	O
7	O
mg	O
L	O
(	O
-1	O
)	O
.	O

An	O
electricity	O
consumption	O
of	O
0.6	O
kWh	O
kg	O
(	O
-1	O
)	O
of	O
chemical	O
oxygen	O
demand	O
(	O
COD	O
)	O
removed	O
was	O
observed	O
.	O

Low	O
energy	O
consumption	O
coupled	O
with	O
enhanced	O
methane	O
production	O
led	O
to	O
a	O
net	O
positive	O
energy	O
balance	O
in	O
the	O
bioelectrochemical	B-P
treatment	O
system	O
.	O

The	O
role	O
of	O
IGF-1	O
and	O
the	O
distribution	O
of	O
body	O
fat	O
in	O
decreasing	O
the	O
number	O
of	O
prostate	B-P
rebiopsies	I-P
.	O

To	O
assess	O
the	O
usefulness	O
of	O
IGF-1	O
and	O
internal	O
organ	O
fat	O
measured	O
by	O
bioelectrical	O
impedance	O
audiometry	B-P
to	O
avoid	O
rebiopsies	B-P
in	O
patients	O
with	O
persistently	O
high	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
levels	O
.	O

A	O
prospective	O
study	O
was	O
conducted	O
with	O
92	O
patients	O
who	O
underwent	O
prostate	B-P
rebiopsy	I-P
due	O
to	O
high	O
PSA	O
levels	O
with	O
negative	O
results	O
in	O
the	O
rectal	B-P
examination	I-P
and	O
a	O
lack	O
of	O
preneoplastic	O
lesions	O
.	O

The	O
patients	O
previously	O
had	O
their	O
IGF-1	O
levels	O
measured	O
and	O
had	O
undergone	O
an	O
impedance	B-P
audiometry	I-P
test	I-P
using	O
the	O
abdominal	O
Fat	O
Analyser	O
AB-140	O
TANITA	O
system	O
.	O

We	O
calculated	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
for	O
the	O
PSA	O
levels	O
,	O
%	O
PSA	O
,	O
internal	O
organ	O
fat	O
and	O
IGF-1	O
and	O
PSA	O
density	O
.	O

Twenty-five	O
patients	O
were	O
diagnosed	O
with	O
prostate	O
cancer	O
.	O

These	O
patients	O
had	O
significantly	O
higher	O
PSA	O
,	O
PSAd	O
and	O
IGF-1	O
values	O
and	O
a	O
tendency	O
towards	O
higher	O
internal	O
organ	O
fat	O
levels	O
and	O
lower	O
%	O
PSA	O
readings	O
(	O
p=.001	O
,	O
p=.003	O
,	O
p=.001	O
,	O
p=.24	O
and	O
P=0.28	O
,	O
respectively	O
)	O
.	O

The	O
ROC	O
curve	O
showed	O
an	O
area	O
under	O
the	O
curve	O
for	O
IGF-1	O
and	O
PSA	O
of	O
.82	O
and	O
.81	O
,	O
respectively	O
.	O

Using	O
the	O
cutoff	O
points	O
for	O
95	O
%	O
sensitivity	O
and	O
using	O
the	O
3	O
criteria	O
as	O
an	O
indication	O
of	O
rebiopsy	B-P
,	O
74	O
%	O
of	O
the	O
biopsies	B-P
would	O
have	O
been	O
spared	O
,	O
leaving	O
undiagnosed	O
only	O
1	O
patient	O
with	O
clinically	O
significant	O
cancer	O
-	O
Gleason	O
score	O
>	O
7	O
(	O
4+3	O
)	O
-	O
.	O

The	O
positive	O
and	O
negative	O
predictive	O
values	O
for	O
the	O
set	O
of	O
variables	O
were	O
higher	O
than	O
for	O
each	O
one	O
separately	O
(	O
PPV	O
:	O
66/NPV	O
:	O
63	O
)	O
.	O

The	O
cost	O
of	O
both	O
determinations	B-P
was	O
82	O
euros	O
.	O

Our	O
results	O
suggest	O
that	O
measuring	O
IGF-1	O
could	O
significantly	O
decrease	O
the	O
number	O
of	O
unnecessary	O
rebiopsies	B-P
in	O
an	O
inexpensive	O
and	O
safe	O
manner	O
.	O

Suicidal	O
thoughts	O
and	O
behaviors	O
in	O
psychiatrically	O
referred	O
young	O
children	O
.	O

Despite	O
increased	O
awareness	O
of	O
the	O
prevalence	O
and	O
seriousness	O
of	O
mental	O
health	O
problems	O
in	O
early	O
childhood	O
,	O
there	O
have	O
been	O
few	O
empirical	O
studies	O
of	O
suicidal	O
thoughts	O
and	O
behaviors	O
in	O
this	O
age	O
group	O
.	O

This	O
study	O
examined	O
suicidal	O
thoughts	O
and	O
behaviors	O
in	O
360	O
preschool-aged	O
children	O
(	O
ages	O
3	O
to	O
7	O
years	O
)	O
presenting	O
to	O
a	O
psychiatric	O
day	O
treatment	O
program	O
.	O

A	O
semi-structured	B-P
diagnostic	I-P
interview	I-P
(	O
conducted	O
with	O
primary	O
caregivers	O
)	O
was	O
used	O
to	O
assess	O
for	O
child	O
suicidal	O
thoughts	O
and	O
behaviors	O
and	O
psychiatric	O
disorders	O
.	O

Participating	O
mothers	O
also	O
reported	O
on	O
their	O
own	O
psychological	O
distress	O
and	O
family	O
psychiatric	O
history	O
.	O

Forty-eight	O
children	O
(	O
13	O
%	O
)	O
were	O
reported	O
to	O
have	O
suicidal	O
thoughts	O
and	O
behaviors	O
,	O
with	O
suicidal	O
plans	O
or	O
attempts	O
endorsed	O
for	O
2-3	O
%	O
of	O
the	O
sample	O
.	O

Suicidal	O
thinking	O
and	O
behavior	O
was	O
associated	O
with	O
older	O
child	O
age	O
and	O
with	O
higher	O
rates	O
of	O
concurrent	O
depression	O
,	O
oppositional	O
defiant	O
disorder	O
,	O
and	O
posttraumatic	O
stress	O
disorder	O
in	O
univariate	O
analyses	O
,	O
with	O
age	O
and	O
depression	O
remaining	O
as	O
significant	O
predictors	O
in	O
a	O
multivariate	O
logistic	O
regression	O
model	O
.	O

Findings	O
suggest	O
that	O
suicidal	O
thoughts	O
and	O
behaviors	O
are	O
a	O
significant	O
clinical	O
concern	O
for	O
young	O
children	O
presenting	O
with	O
early	O
psychopathology	O
,	O
particularly	O
depression	O
,	O
with	O
implications	O
for	O
early	O
childhood	O
psychiatric	B-P
assessment	I-P
and	O
treatment	O
.	O

Developmental	O
Regression	O
,	O
Depression	O
,	O
and	O
Psychosocial	O
Stress	O
in	O
an	O
Adolescent	O
with	O
Down	O
Syndrome	O
.	O

Kristen	O
is	O
a	O
13-	O
year	O
-old	O
girl	O
with	O
Down	O
syndrome	O
(	O
DS	O
)	O
who	O
was	O
seen	O
urgently	O
with	O
concerns	O
of	O
cognitive	O
and	O
developmental	O
regression	O
including	O
loss	O
of	O
language	O
,	O
social	O
,	O
and	O
toileting	O
skills	O
.	O

The	O
evaluation	O
in	O
the	O
DS	O
clinic	O
focused	O
on	O
potential	O
medical	B-P
diagnoses	I-P
including	O
atlantoaxial	O
joint	O
instability	O
,	O
vitamin	O
deficiency	O
,	O
obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
,	O
and	O
seizures	O
.	O

A	O
comprehensive	O
medical	O
evaluation	O
yielded	O
only	O
a	O
finding	O
of	O
moderate	O
OSA	O
.	O

A	O
reactive	O
depression	O
was	O
considered	O
in	O
association	O
with	O
several	O
psychosocial	O
factors	O
including	O
moving	O
homes	O
,	O
entering	O
puberty	O
/	O
onset	O
of	O
menses	O
,	O
and	O
classroom	O
change	O
from	O
an	O
integrated	O
setting	O
to	O
a	O
self-	O
contained	O
classroom	O
comprising	O
unfamiliar	O
peers	O
with	O
behavior	O
challenges	O
.	O

Urgent	O
referrals	O
for	O
psychological	O
and	O
psychiatric	B-P
evaluations	I-P
were	O
initiated	O
.	O

Neuropsychological	B-P
testing	I-P
did	O
not	O
suggest	O
true	O
regression	O
in	O
cognitive	O
,	O
language	O
,	O
and	O
academic	O
skills	O
,	O
although	O
decreases	O
in	O
motivation	O
and	O
performance	O
were	O
noted	O
with	O
a	O
reaction	O
to	O
stress	O
and	O
multiple	O
environmental	O
changes	O
as	O
a	O
potential	O
causative	O
factor	O
.	O

Psychiatry	O
consultation	O
supported	O
this	O
finding	O
in	O
that	O
psychosocial	O
stress	O
temporally	O
correlated	O
with	O
Kristen	O
's	O
regression	O
in	O
skills	O
.Working	O
collaboratively	O
,	O
the	O
team	O
determined	O
that	O
Kristen	O
's	O
presentation	O
was	O
consistent	O
with	O
a	O
reactive	O
form	O
of	O
depression	O
(	O
DSM-IV-TR	O
:	O
depressive	O
disorder	O
,	O
not	O
otherwise	O
specified	O
)	O
.	O

Kristen	O
's	O
presentation	O
was	O
exacerbated	O
by	O
salient	O
environmental	O
stress	O
and	O
sleep	O
apnea	O
,	O
rather	O
than	O
a	O
cognitive	O
regression	O
associated	O
with	O
a	O
medical	O
cause	O
.	O

Treatment	O
consisted	O
of	O
an	O
antidepressant	O
medication	O
,	O
continuous	O
positive	O
airway	O
pressure	O
for	O
OSA	O
,	O
and	O
increased	O
psychosocial	O
supports	O
.	O

Her	O
school	O
initiated	O
a	O
change	O
in	O
classroom	O
placement	O
.	O

With	O
this	O
multimodal	O
approach	O
to	O
evaluation	O
and	O
intervention	O
,	O
Kristen	O
steadily	O
improved	O
and	O
she	O
returned	O
to	O
her	O
baseline	O
function	O
.	O

Neuroprotective	O
Role	O
of	O
MicroRNA-22	O
in	O
a	O
6-Hydroxydopamine	O
-	O
Induced	O
Cell	O
Model	O
of	O
Parkinson	O
's	O
Disease	O
via	O
Regulation	O
of	O
Its	O
Target	O
Gene	O
TRPM7	O
.	O

Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
,	O
the	O
second	O
most	O
prevalent	O
neurodegenerative	O
disorder	O
with	O
only	O
symptomatic	O
treatment	O
available	O
,	O
is	O
characterized	O
by	O
a	O
progressive	O
loss	O
of	O
dopaminergic	O
neurons	O
in	O
the	O
midbrain	O
.	O

Ample	O
evidence	O
indicated	O
that	O
microRNAs	O
(	O
miRs	O
)	O
could	O
regulate	O
post-transcriptional	O
gene	O
expression	O
and	O
neuronal	O
disease	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
evaluated	O
the	O
effects	O
and	O
mechanism	O
of	O
miR-22	O
in	O
PC12	O
pheochromocytoma	O
cells	O
treated	O
with	O
6-hydroxydopamine	O
(	O
6-OHDA	O
)	O
to	O
mimic	O
PD	O
.	O

RT-PCR	O
results	O
showed	O
that	O
the	O
expression	O
of	O
miR-22	O
is	O
downregulated	O
in	O
6-OHDA	O
-	O
treated	O
PC12	O
cells	O
,	O
and	O
the	O
overexpression	O
of	O
miR-22	O
significantly	O
promoted	O
the	O
survival	O
and	O
proliferation	O
of	O
6-OHDA	O
-	O
induced	O
PC12	O
cells	O
,	O
whereas	O
miR-22	O
inhibitor	O
reversed	O
these	O
effects	O
.	O

In	O
addition	O
,	O
PC12	O
cells	O
were	O
treated	O
with	O
miR-22	O
mimics	O
or	O
inhibitor	O
following	O
6-OHDA	O
administration	O
,	O
which	O
medicated	O
ROS	O
production	O
and	O
upregulation	O
or	O
downregulation	O
of	O
caspase-3	O
activity	O
,	O
respectively	O
.	O

A	O
luciferase	O
reporter	O
assay	B-P
revealed	O
that	O
transient	O
receptor	O
potential	O
melastatin	O
7	O
(	O
TRPM7	O
)	O
is	O
a	O
direct	O
target	O
gene	O
of	O
miR-22	O
,	O
and	O
miR-22	O
overexpression	O
markedly	O
downregulated	O
the	O
level	O
of	O
TRPM7	O
.	O

Strikingly	O
,	O
further	O
analysis	O
showed	O
that	O
miR-22	O
mediated	O
6-OHDA	O
-	O
induced	O
PC12	O
cell	O
survival	O
and	O
proliferation	O
by	O
targeting	O
TRPM7	O
.	O

Taken	O
together	O
,	O
the	O
present	O
study	O
showed	O
that	O
miR-22	O
overexpression	O
exhibited	O
neuroprotective	O
and	O
reversal	O
effects	O
on	O
the	O
6-OHDA	O
-	O
induced	O
PC12	O
cell	O
growth	O
and	O
apoptosis	O
by	O
targeting	O
TRPM7	O
.	O

Systematic	O
Identification	O
of	O
Pharmacological	O
Targets	O
from	O
Small-Molecule	O
Phenotypic	B-P
Screens	I-P
.	O

Phenotypic	O
drug	O
discovery	O
offers	O
some	O
advantages	O
over	O
target	O
-	O
based	O
methods	O
,	O
mainly	O
because	O
it	O
allows	O
drug	O
leads	O
to	O
be	O
tested	O
in	O
systems	O
that	O
more	O
closely	O
model	O
distinct	O
disease	O
states	O
.	O

However	O
,	O
a	O
potential	O
disadvantage	O
is	O
the	O
difficulty	O
of	O
linking	O
the	O
observed	O
phenotype	O
to	O
a	O
specific	O
cellular	O
target	O
.	O

To	O
address	O
this	O
problem	O
,	O
we	O
developed	O
DePick	O
,	O
a	O
computational	O
target	O
de-convolution	O
tool	O
to	O
determine	B-P
targets	O
specifically	O
linked	O
to	O
small-molecule	O
phenotypic	B-P
screens	I-P
.	O

We	O
applied	O
DePick	O
to	O
eight	O
publicly	O
available	O
screens	O
and	O
predicted	O
59	O
drug	O
target	O
-	O
phenotype	O
associations	O
.	O

In	O
addition	O
to	O
literature	O
-	O
based	O
evidence	O
for	O
our	O
predictions	O
,	O
we	O
provide	O
experimental	O
support	O
for	O
seven	O
predicted	O
associations	O
.	O

Interestingly	O
,	O
our	O
analysis	O
led	O
to	O
the	O
discovery	O
of	O
a	O
previously	O
unrecognized	O
connection	O
between	O
the	O
Wnt	O
signaling	O
pathway	O
and	O
an	O
aromatase	O
,	O
CYP19A1	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
DePick	O
approach	O
can	O
not	O
only	O
accelerate	O
target	O
de-convolution	O
but	O
also	O
aid	O
in	O
discovery	O
of	O
new	O
functionally	O
relevant	O
biological	O
relationships	O
.	O

Ultrasound	B-P
assessment	O
of	O
lung	O
consolidation	O
and	O
reaeration	O
after	O
pleural	O
effusion	O
drainage	O
in	O
patients	O
with	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
:	O
a	O
pilot	O
study	O
.	O

The	O
aim	O
of	O
the	O
pilot	O
study	O
was	O
to	O
assess	O
by	O
ultrasound	B-P
changes	O
in	O
dimensions	O
of	O
lung	O
consolidation	O
and	O
reaeration	O
after	O
drainage	O
of	O
large	O
pleural	O
effusion	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
.	O

Lung	B-P
ultrasound	I-P
and	O
blood	B-P
gas	I-P
were	O
performed	O
before	O
,	O
2	O
hours	O
(	O
H2	O
)	O
and	O
24	O
hours	O
(	O
H24	O
)	O
after	O
drainage	O
of	O
pleural	O
effusion	O
.	O

Lung	O
ultrasound	O
aeration	O
score	O
was	O
calculated	O
.	O

Cephalocaudal	O
dimension	O
and	O
diaphragmatic	O
transversal	O
area	O
of	O
lung	O
consolidation	O
were	O
measured	O
.	O

Ten	O
patients	O
were	O
studied	O
.	O

Median	O
volume	O
of	O
drained	O
effusion	O
was	O
675	O
ml	O
at	O
H2	O
and	O
895	O
at	O
H24	O
.	O

Two	O
hours	O
after	O
drainage	O
,	O
dimension	O
of	O
cephalocaudal	O
consolidation	O
and	O
diaphragmatic	O
transversal	O
area	O
decreased	O
significantly	O
.	O

Lung	O
reaeration	O
after	O
drainage	O
occurred	O
mainly	O
in	O
latero-inferior	O
and	O
postero-superior	O
regions	O
.	O

PaO2/FiO2	B-P
increased	O
significantly	O
at	O
H24	O
.	O

Ultrasound	B-P
is	O
a	O
useful	O
method	O
to	O
assess	O
lung	O
consolidation	O
after	O
pleural	O
effusion	O
drainage	O
.	O

Drainage	O
of	O
pleural	O
effusion	O
may	O
lead	O
to	O
a	O
decrease	O
of	O
lung	O
consolidation	O
and	O
improvement	O
of	O
lung	O
reaeration	O
.	O

Chaetomium	O
thermophilum	O
formate	O
dehydrogenase	O
has	O
high	O
activity	O
in	O
the	O
reduction	O
of	O
hydrogen	O
carbonate	O
(	O
HCO3	O
-	O
)	O
to	O
formate	O
.	O

While	O
formate	O
dehydrogenases	O
(	O
FDHs	O
)	O
have	O
been	O
used	O
for	O
cofactor	O
recycling	O
in	O
chemoenzymatic	O
synthesis	O
,	O
the	O
ability	O
of	O
FDH	O
to	O
reduce	O
CO2	O
could	O
also	O
be	O
utilized	O
in	O
the	O
conversion	O
of	O
CO2	O
to	O
useful	O
products	O
via	O
formate	O
(	O
HCOO	O
(	O
-	O
)	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
reduction	O
of	O
CO2	O
in	O
the	O
form	O
of	O
hydrogen	O
carbonate	O
(	O
HCO3	O
(	O
-	O
)	O
)	O
to	O
formate	O
by	O
FDHs	O
from	O
Candida	O
methylica	O
(	O
CmFDH	O
)	O
and	O
Chaetomium	O
thermophilum	O
(	O
CtFDH	O
)	O
in	O
a	O
NADH	O
-dependent	O
reaction	O
.	O

The	O
catalytic	O
performance	O
with	O
HCO3	O
(	O
-	O
)	O
as	O
a	O
substrate	O
was	O
evaluated	O
by	O
measuring	O
the	O
kinetic	O
rates	O
and	O
conducting	O
productivity	B-P
assays	I-P
.	O

CtFDH	O
showed	O
a	O
higher	O
efficiency	O
in	O
converting	O
HCO3	O
(	O
-	O
)	O
to	O
formate	O
than	O
CmFDH	O
,	O
whereas	O
CmFDH	O
was	O
better	O
in	O
the	O
oxidation	O
of	O
formate	O
.	O

The	O
pH	O
optimum	O
of	O
the	O
reduction	O
was	O
at	O
pH	O
7-8	O
.	O

However	O
,	O
the	O
high	O
concentrations	O
of	O
HCO3	O
(	O
-	O
)	O
reduced	O
the	O
reaction	O
rate	O
.	O

CtFDH	O
was	O
modeled	O
in	O
the	O
presence	O
of	O
HCO3	O
(	O
-	O
)	O
showing	O
that	O
it	O
fits	O
to	O
the	O
active	O
site	O
.	O

The	O
active	O
site	O
setting	O
for	O
hydride	O
transfer	O
in	O
CO2	O
reduction	O
was	O
modeled	O
.	O

The	O
hydride	O
donated	O
by	O
NADH	O
would	O
form	O
a	O
favorable	O
contact	O
to	O
the	O
carbon	O
atom	O
of	O
HCO3	O
(	O
-	O
)	O
,	O
resulting	O
in	O
a	O
surplus	O
of	O
electrons	O
within	O
the	O
molecule	O
.	O

This	O
would	O
cause	O
the	O
complex	O
formed	O
by	O
hydrogen	O
carbonate	O
and	O
the	O
hydride	O
to	O
break	O
into	O
formate	O
and	O
hydroxide	O
ions	O
.	O

A	O
Comparative	O
Study	O
of	O
Enamel	O
Surface	O
Roughness	O
After	O
Bleaching	O
With	O
Diode	O
Laser	O
and	O
Nd	O
:	O
YAG	O
Laser	O
.	O

Introduction	O
:	O
Bleaching	O
process	O
can	O
affect	O
surface	O
roughness	O
of	O
enamel	O
,	O
which	O
is	O
a	O
vital	O
factor	O
in	O
esthetic	O
and	O
resistance	O
of	O
tooth	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
surface	O
roughness	O
of	O
enamel	O
in	O
teeth	O
bleached	O
using	O
Diode	O
and	O
Neodymium-Doped	O
Yttrium	O
Aluminium	O
Garnet	O
(	O
Nd	O
:	O
YAG	O
)	O
lasers	O
with	O
those	O
bleached	O
using	O
conventional	O
method	O
.	O

Methods	O
:	O
In	O
this	O
study	O
,	O
75	O
anterior	O
human	O
teeth	O
from	O
upper	O
and	O
lower	O
jaws	O
(	O
These	O
teeth	O
extracted	O
because	O
of	O
periodontal	O
disease	O
)	O
were	O
randomly	O
divided	O
into	O
5	O
groups	O
.	O

Group	O
1	O
:	O
Laser	O
white	O
gel	O
(	O
Biolase	O
,	O
USA	O
)	O
with	O
45	O
%	O
hydrogen	O
peroxide	O
concentration	O
and	O
GaAlAs	O
Diode	O
laser	O
(	O
CHEESE	O
(	O
TM	O
)	O
,	O
GIGAA	O
,	O
China	O
)	O
,	O
group	O
2	O
:	O
Heydent	O
gel	O
(	O
JW	O
,	O
Germany	O
)	O
with	O
30	O
%	O
Hydrogen	O
peroxide	O
concentration	O
and	O
Diode	O
laser	O
,	O
group	O
3	O
:	O
Laser	O
white	O
gel	O
and	O
Nd	O
:	O
YAG	O
laser	O
(	O
FIDELIS	O
(	O
TM	O
)	O
,	O
Fotona	O
,	O
Slovenia	O
)	O
,	O
group	O
4	O
:	O
Heydent	O
gel	O
and	O
Nd	O
:	O
YAG	O
laser	O
and	O
group	O
5	O
:	O
The	O
Iranian	O
gel	O
Kimia	O
(	O
Iran	O
)	O
with	O
35	O
%	O
hydrogen	O
peroxide	O
concentration	O
were	O
used	O
.	O

Surface	O
roughness	O
of	O
the	O
samples	O
was	O
measured	O
using	O
the	O
Surface	O
Roughness	O
Tester	O
system	O
(	O
TR	O
200	O
Time	O
Group	O
,	O
Germany	O
)	O
before	O
and	O
after	O
bleaching	O
.	O

In	O
each	O
group	O
,	O
one	O
sample	O
was	O
randomly	O
selected	O
for	O
SEM	B-P
analysis	I-P
.	O

Results	O
:	O
The	O
results	O
showed	O
that	O
the	O
mean	O
surface	O
roughness	O
of	O
the	O
teeth	O
before	O
and	O
after	O
bleaching	O
had	O
a	O
significant	O
difference	O
in	O
all	O
the	O
study	O
groups	O
.	O

It	O
was	O
indicated	O
that	O
after	O
bleaching	O
,	O
the	O
mean	O
surface	O
roughness	O
had	O
increased	O
in	O
all	O
the	O
study	O
groups	O
.	O

The	O
highest	O
surface	O
roughness	O
was	O
seen	O
in	O
the	O
conventional	O
bleaching	O
group	O
and	O
the	O
lowest	O
surface	O
roughness	O
was	O
reported	O
in	O
group	O
3	O
(	O
laser	O
white	O
gel	O
+	O
diode	O
laser	O
)	O
,	O
in	O
which	O
the	O
average	O
surface	O
roughness	O
increased	O
by	O
only	O
0.1	O
μm	O
.	O

Conclusion	O
:	O
It	O
was	O
concluded	O
that	O
using	O
the	O
Laser	O
white	O
gel	O
and	O
the	O
diode	O
laser	O
for	O
bleaching	O
resulted	O
in	O
the	O
least	O
surface	O
roughness	O
compared	O
to	O
conventional	O
method	O
.	O

Major	O
amyloid-β-degrading	O
enzymes	O
,	O
endothelin-converting	O
enzyme-2	O
and	O
neprilysin	O
,	O
are	O
expressed	O
by	O
distinct	O
populations	O
of	O
GABAergic	O
interneurons	O
in	O
hippocampus	O
and	O
neocortex	O
.	O

Impaired	O
clearance	O
of	O
amyloid-β	O
peptide	O
(	O
Aβ	O
)	O
has	O
been	O
postulated	O
to	O
significantly	O
contribute	O
to	O
the	O
amyloid	O
accumulation	O
typical	O
of	O
Alzheimer	O
's	O
disease	O
.	O

Among	O
the	O
enzymes	O
known	O
to	O
degrade	O
Aβ	O
in	O
vivo	O
are	O
endothelin-converting	O
enzyme	O
(	O
ECE	O
)	O
-1	O
,	O
ECE-2	O
,	O
and	O
neprilysin	O
(	O
NEP	O
)	O
,	O
and	O
evidence	O
suggests	O
that	O
they	O
regulate	O
independent	O
pools	O
of	O
Aβ	O
that	O
may	O
be	O
functionally	O
significant	O
.	O

To	O
better	O
understand	O
the	O
differential	O
regulation	O
of	O
Aβ	O
concentration	O
by	O
its	O
physiological	O
degrading	O
enzymes	O
,	O
we	O
characterized	O
the	O
cell	O
and	O
region-specific	O
expression	O
pattern	O
of	O
ECE-1	O
,	O
ECE-2	O
,	O
and	O
NEP	O
by	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	B-P
in	O
brain	O
areas	O
relevant	O
to	O
Alzheimer	O
's	O
disease	O
.	O

In	O
contrast	O
to	O
the	O
broader	O
distribution	O
of	O
ECE-1	O
,	O
ECE-2	O
and	O
NEP	O
were	O
found	O
enriched	O
in	O
GABAergic	O
neurons	O
.	O

ECE-2	O
was	O
majorly	O
expressed	O
by	O
somatostatin	O
-	O
expressing	O
interneurons	O
and	O
was	O
active	O
in	O
isolated	O
synaptosomes	O
.	O

NEP	O
messenger	O
RNA	O
was	O
found	O
mainly	O
in	O
parvalbumin	O
-	O
expressing	O
interneurons	O
,	O
with	O
NEP	O
protein	O
localized	O
to	O
perisomatic	O
parvalbuminergic	O
synapses	O
.	O

The	O
identification	O
of	O
somatostatinergic	O
and	O
parvalbuminergic	O
synapses	O
as	O
hubs	O
for	O
Aβ	O
degradation	O
is	O
consistent	O
with	O
the	O
possibility	O
that	O
Aβ	O
may	O
have	O
a	O
physiological	O
function	O
related	O
to	O
the	O
regulation	O
of	O
inhibitory	O
signaling	O
.	O

Loss	O
of	O
Snf5	O
Induces	O
Formation	O
of	O
an	O
Aberrant	O
SWI/SNF	O
Complex	O
.	O

The	O
SWI/SNF	O
chromatin	O
remodeling	O
complex	O
is	O
highly	O
conserved	O
from	O
yeast	O
to	O
human	O
,	O
and	O
aberrant	O
SWI/SNF	O
complexes	O
contribute	O
to	O
human	O
disease	O
.	O

The	O
Snf5/SMARCB1/INI1	O
subunit	O
of	O
SWI/SNF	O
is	O
a	O
tumor	O
suppressor	O
frequently	O
lost	O
in	O
pediatric	O
rhabdoid	O
cancers	O
.	O

We	O
examined	O
the	O
effects	O
of	O
Snf5	O
loss	O
on	O
the	O
composition	O
,	O
nucleosome	O
binding	O
,	O
recruitment	O
,	O
and	O
remodeling	O
activities	O
of	O
yeast	O
SWI/SNF	O
.	O

The	O
Snf5	O
subunit	O
is	O
shown	O
by	O
crosslinking-mass	B-P
spectrometry	I-P
(	O
CX-MS	B-P
)	O
and	O
subunit	O
deletion	B-P
analysis	I-P
to	O
interact	O
with	O
the	O
ATPase	O
domain	O
of	O
Snf2	O
and	O
to	O
form	O
a	O
submodule	O
consisting	O
of	O
Snf5	O
,	O
Swp82	O
,	O
and	O
Taf14	O
.	O

Snf5	O
promotes	O
binding	O
of	O
the	O
Snf2	O
ATPase	O
domain	O
to	O
nucleosomal	O
DNA	O
and	O
enhances	O
the	O
catalytic	O
and	O
nucleosome	O
remodeling	O
activities	O
of	O
SWI/SNF	O
.	O

Snf5	O
is	O
also	O
required	O
for	O
SWI/SNF	O
recruitment	O
by	O
acidic	O
transcription	O
factors	O
.	O

RNA-seq	O
analysis	O
suggests	O
that	O
both	O
the	O
recruitment	O
and	O
remodeling	O
functions	O
of	O
Snf5	O
are	O
required	O
in	O
vivo	O
for	O
SWI/SNF	O
regulation	O
of	O
gene	O
expression	O
.	O

Thus	O
,	O
loss	O
of	O
SNF5	O
alters	O
the	O
structure	O
and	O
function	O
of	O
SWI/SNF	O
.	O

Comparison	O
of	O
non-invasive	B-P
blood	I-P
pressure	I-P
monitoring	I-P
using	O
modified	O
arterial	O
applanation	B-P
tonometry	I-P
with	O
intra-arterial	B-P
measurement	I-P
.	O

Intermittent	O
non-invasive	O
blood	O
pressure	O
measurement	O
with	O
tourniquets	O
is	O
slow	O
,	O
can	O
cause	O
nerve	O
and	O
skin	O
damage	O
,	O
and	O
interferes	O
with	O
other	O
measurements	O
.	O

Invasive	B-P
measurement	I-P
can	O
not	O
be	O
safely	O
used	O
in	O
all	O
conditions	O
.	O

Modified	O
arterial	O
tonometry	B-P
may	O
be	O
an	O
alternative	O
for	O
fast	O
and	O
continuous	O
measurement	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
arterial	O
tonometry	O
sensor	O
(	O
BPro	O
(	O
®	O
)	O
)	O
with	O
invasive	B-P
blood	I-P
pressure	I-P
measurement	O
to	O
clarify	O
whether	O
it	O
could	O
be	O
utilized	O
in	O
the	O
postoperative	O
setting	O
.	O

28	O
patients	O
who	O
underwent	O
elective	O
surgery	O
requiring	O
arterial	O
cannulation	O
were	O
analyzed	O
.	O

Patients	O
were	O
monitored	O
post-operatively	O
for	O
2	O
h	O
with	O
standard	O
invasive	B-P
monitoring	I-P
and	O
with	O
a	O
study	O
device	O
comprising	O
an	O
arterial	O
tonometry	O
sensor	O
(	O
BPro	O
(	O
®	O
)	O
)	O
added	O
with	O
a	O
three-dimensional	O
accelerometer	O
to	O
investigate	O
the	O
potential	O
impact	O
of	O
movement	O
.	O

Recordings	O
were	O
collected	O
electronically	O
.	O

The	O
results	O
revealed	O
inaccurate	O
readings	O
in	O
method	O
comparison	O
between	O
the	O
devices	O
based	O
on	O
recommendations	O
by	O
Association	O
for	O
the	O
Advancement	O
of	O
Medical	O
Instrumentation	O
(	O
AAMI	O
)	O
.	O

On	O
a	O
Bland-Altman	O
plot	O
,	O
the	O
bias	O
and	O
precision	O
between	O
these	O
two	O
methods	O
was	O
19.8	O
±	O
16.7	O
(	O
Limits	O
of	O
agreement	O
-	O
20.1	O
to	O
59.6	O
)	O
mmHg	O
,	O
Spearman	O
correlation	O
coefficient	O
r	O
=	O
0.61	O
.	O

For	O
diastolic	O
pressure	O
,	O
the	O
difference	O
was	O
4.8	O
±	O
7.7	O
(	O
LoA	O
-	O
14.1	O
to	O
23.6	O
)	O
mmHg	O
(	O
r	O
=	O
0.72	O
)	O
,	O
and	O
for	O
mean	O
arterial	O
pressure	O
it	O
was	O
11.18	O
±	O
11.1	O
(	O
LoA	O
-	O
12.1	O
to	O
34.2	O
)	O
mmHg	O
(	O
r	O
=	O
0.642	O
)	O
.	O

Our	O
study	O
revealed	O
inaccurate	O
agreement	O
(	O
AAMI	O
)	O
between	O
the	O
two	O
methods	O
when	O
measuring	O
systolic	O
and	O
mean	O
blood	O
pressures	O
during	O
post-operative	O
care	O
.	O

The	O
readings	O
for	O
diastolic	O
pressures	O
were	O
inside	O
the	O
limits	O
recommended	O
by	O
AAMI	O
.	O

Movement	O
increased	O
the	O
failure	O
rate	O
significantly	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Thus	O
,	O
arterial	O
tonometry	B-P
is	O
not	O
an	O
appropriate	O
replacement	O
for	O
invasive	B-P
blood	I-P
pressure	I-P
measurement	I-P
in	O
these	O
patients	O
.	O

Case	O
report	O
:	O
imaging	O
the	O
clinical	O
course	O
of	O
FOPE	O
-a	O
cause	O
of	O
adolescent	O
knee	O
pain	O
.	O

Focal	O
periphyseal	O
oedema	O
(	O
FOPE	O
)	O
is	O
a	O
rare	O
MRI	B-P
finding	O
associated	O
with	O
pain	O
in	O
adolescent	O
patients	O
with	O
very	O
few	O
reported	O
cases	O
.	O

We	O
present	O
a	O
case	O
of	O
FOPE	O
in	O
a	O
13-year-old	O
girl	O
and	O
the	O
only	O
follow-up	O
imaging	B-P
available	O
for	O
an	O
isolated	O
presentation	O
of	O
this	O
condition	O
.This	O
article	O
describes	O
a	O
clinical	O
course	O
that	O
correlates	O
well	O
with	O
the	O
imaging	B-P
obtained	O
.	O

This	O
article	O
describes	O
a	O
clinical	O
course	O
that	O
correlates	O
well	O
with	O
the	O
imaging	B-P
obtained	O
.	O

Toll-like	O
receptors	O
genes	O
polymorphisms	O
and	O
the	O
occurrence	O
of	O
HCMV	O
infection	O
among	O
pregnant	O
women	O
.	O

Human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
the	O
most	O
common	O
cause	O
of	O
intrauterine	O
infections	O
worldwide	O
.	O

The	O
toll-like	O
receptors	O
(	O
TLRs	O
)	O
have	O
been	O
reported	O
as	O
important	O
factors	O
in	O
immune	O
response	O
against	O
HCMV	O
.	O

Particularly	O
,	O
TLR2	O
,	O
TLR4	O
and	O
TLR9	O
have	O
been	O
shown	O
to	O
be	O
involved	O
in	O
antiviral	O
immunity	O
.	O

Evaluation	O
of	O
the	O
role	O
of	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
,	O
located	O
within	O
TLR2	O
,	O
TLR4	O
and	O
TLR9	O
genes	O
,	O
in	O
the	O
development	O
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
infection	O
in	O
pregnant	O
women	O
and	O
their	O
fetuses	O
and	O
neonates	O
,	O
was	O
performed	O
.	O

The	O
study	O
was	O
performed	O
for	O
131	O
pregnant	O
women	O
,	O
including	O
66	O
patients	O
infected	O
with	O
HCMV	O
during	O
pregnancy	O
,	O
and	O
65	O
age	O
-	O
matched	O
control	O
pregnant	O
individuals	O
.	O

The	O
patients	O
were	O
selected	O
to	O
the	O
study	O
,	O
based	O
on	O
serological	O
status	O
of	O
anti-HCMV	O
IgG	O
and	O
IgM	O
antibodies	O
and	O
on	O
the	O
presence	O
of	O
viral	O
DNA	O
in	O
their	O
body	O
fluids	O
.	O

Genotypes	O
in	O
TLR2	O
2258	O
A	O
>	O
G	O
,	O
TLR4	O
896	O
G	O
>	O
A	O
and	O
1196	O
C	O
>	O
T	O
and	O
TLR9	O
2848	O
G	O
>	O
A	O
SNPs	O
were	O
determined	O
by	O
self-designed	O
nested	O
PCR	O
-	O
RFLP	B-P
assays	I-P
.	O

Randomly	O
selected	O
PCR	O
products	O
,	O
representative	O
for	O
distinct	O
genotypes	O
in	O
TLR	O
SNPs	O
,	O
were	O
confirmed	O
by	O
sequencing	B-P
.	O

A	O
relationship	O
between	O
the	O
genotypes	O
,	O
alleles	O
,	O
haplotypes	O
and	O
multiple	O
variants	O
in	O
the	O
studied	O
polymorphisms	O
,	O
and	O
the	O
occurrence	O
of	O
HCMV	O
infection	O
in	O
pregnant	O
women	O
and	O
their	O
offsprings	O
,	O
was	O
determined	O
,	O
using	O
a	O
logistic	O
regression	O
model	O
.	O

Genotypes	O
in	O
all	O
the	O
analyzed	O
polymorphisms	O
preserved	O
the	O
Hardy-Weinberg	O
equilibrium	O
in	O
pregnant	O
women	O
,	O
both	O
infected	O
and	O
uninfected	O
with	O
HCMV	O
(	O
P	O
>	O
0.050	O
)	O
.	O

G	O
G	O
homozygotic	O
and	O
G	O
A	O
heterozygotic	O
status	O
in	O
TLR9	O
2848	O
G	O
>	O
A	O
SNP	O
decreased	O
significantly	O
the	O
occurrence	O
of	O
HCMV	O
infection	O
(	O
OR	O
0.44	O
95	O
%	O
CI	O
0.21-0.94	O
in	O
the	O
dominant	O
model	O
,	O
P	O
≤	O
0.050	O
)	O
.	O

The	O
G	O
allele	O
in	O
TLR9	O
SNP	O
was	O
significantly	O
more	O
frequent	O
among	O
the	O
uninfected	O
pregnant	O
women	O
than	O
among	O
the	O
infected	O
ones	O
(	O
χ	O
(	O
2	O
)	O
=	O
4.14	O
,	O
P	O
≤	O
0.050	O
)	O
.	O

Considering	O
other	O
polymorphisms	O
,	O
similar	O
frequencies	O
of	O
distinct	O
genotypes	O
,	O
haplotypes	O
and	O
multiple-SNP	O
variants	O
were	O
observed	O
between	O
the	O
studied	O
groups	O
of	O
patients	O
.	O

TLR9	O
2848	O
G	O
>	O
A	O
SNP	O
may	O
be	O
associated	O
with	O
HCMV	O
infection	O
in	O
pregnant	O
women	O
.	O

Self-assembled	O
polymeric	O
vectors	O
mixtures	O
:	O
characterization	O
of	O
the	O
polymorphism	O
and	O
existence	O
of	O
synergistic	O
effects	O
in	O
photodynamic	O
therapy	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
assess	O
the	O
relation	O
between	O
the	O
purity	O
of	O
polymeric	O
self-assemblies	O
vectors	O
solution	O
and	O
their	O
photodynamic	O
therapeutic	O
efficiency	O
.	O

For	O
this	O
,	O
several	O
amphiphilic	O
block	O
copolymers	O
of	O
poly	O
(	O
ethyleneoxide-b-ε-caprolactone	O
)	O
have	O
been	O
used	O
to	O
form	O
self-assemblies	O
with	O
different	O
morphologies	O
(	O
micelles	O
,	O
worm-like	O
micelles	O
or	O
vesicles	O
)	O
.	O

In	O
a	O
first	O
step	O
,	O
controlled	O
mixtures	O
of	O
preformed	O
micelles	O
and	O
vesicles	O
have	O
been	O
characterized	O
both	O
by	O
dynamic	B-P
light	I-P
scattering	I-P
and	O
asymmetrical	B-P
flow	I-P
field	I-P
flow	I-P
fractionation	I-P
(	O
AsFlFFF	B-P
)	O
.	O

For	O
this	O
,	O
a	O
custom-made	O
program	O
,	O
STORMS	O
,	O
was	O
developed	O
to	O
analyze	O
DLS	B-P
data	O
in	O
a	O
thorough	O
manner	O
by	O
providing	O
a	O
large	O
set	O
of	O
fitting	O
parameters	O
.	O

This	O
showed	O
that	O
DLS	B-P
only	O
sensed	O
the	O
larger	O
vesicles	O
when	O
the	O
micelles	O
/	O
vesicles	O
ratio	O
was	O
80/20	O
w/w	O
.	O

On	O
the	O
other	O
hand	O
,	O
AsFlFFF	B-P
allowed	O
clear	O
detection	O
of	O
the	O
presence	O
of	O
micelles	O
when	O
this	O
same	O
ratio	O
was	O
as	O
low	O
as	O
10/90	O
.	O

Subsequently	O
,	O
the	O
photodynamic	O
therapy	O
efficiency	O
of	O
various	O
controlled	O
mixtures	O
was	O
assessed	O
using	O
multicellular	O
spheroids	O
when	O
a	O
photosensitizer	O
,	O
pheophorbide	O
a	O
,	O
was	O
encapsulated	O
in	O
the	O
polymer	O
self-assemblies	O
.	O

Some	O
mixtures	O
were	O
shown	O
to	O
be	O
as	O
efficient	O
as	O
monomorphous	O
systems	O
.	O

In	O
some	O
cases	O
,	O
mixtures	O
were	O
found	O
to	O
exhibit	O
a	O
higher	O
PDT	O
efficiency	O
compared	O
to	O
the	O
individual	O
nano	O
-	O
objects	O
,	O
revealing	O
a	O
synergistic	O
effect	O
for	O
the	O
efficient	O
delivery	O
of	O
the	O
photosensitizer	O
.	O

Polymorphous	O
vectors	O
can	O
therefore	O
be	O
superior	O
in	O
therapeutic	O
applications	O
.	O

Role	O
of	O
breast	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
in	O
predicting	O
residual	O
lobular	O
carcinoma	O
in	O
situ	O
after	O
initial	O
excision	O
.	O

Breast	B-P
magnetic	I-P
resonance	I-P
(	I-P
MR	I-P
)	I-P
imaging	I-P
is	O
a	O
useful	O
screening	B-P
modality	O
in	O
detecting	O
suspicious	O
lesions	O
in	O
patients	O
with	O
a	O
history	O
of	O
lobular	O
carcinoma	O
in	O
situ	O
(	O
LCIS	O
)	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
breast	B-P
MR	I-P
imaging	I-P
in	O
detecting	O
remnant	O
LCIS	O
lesions	O
after	O
initial	O
excision	O
.	O

Between	O
2011	O
and	O
2015	O
,	O
29	O
patients	O
with	O
LCIS	O
who	O
underwent	O
initial	O
excision	O
were	O
enrolled	O
.	O

Breast	B-P
ultrasonography	I-P
and	O
breast	B-P
MR	I-P
imaging	I-P
was	O
conducted	O
after	O
initial	O
excision	O
.	O

Imaging	O
findings	O
were	O
compared	O
with	O
pathologic	O
results	O
.	O

There	O
were	O
nine	O
(	O
31.0	O
%	O
)	O
cases	O
with	O
positive	O
margins	O
after	O
initial	O
excision	O
;	O
they	O
were	O
LCIS	O
(	O
n=8	O
)	O
and	O
atypical	O
lobular	O
hyperplasia	O
(	O
n=1	O
)	O
.	O

Residual	O
lesions	O
were	O
identified	O
in	O
12	O
cases	O
;	O
they	O
were	O
invasive	O
lobular	O
carcinoma	O
(	O
n=1	O
;	O
3.4	O
%	O
)	O
,	O
LCIS	O
(	O
n=9	O
;	O
31.0	O
%	O
)	O
,	O
atypical	O
lobular	O
hyperplasia	O
(	O
n=1	O
;	O
3.4	O
%	O
)	O
,	O
and	O
papillary	O
carcinoma	O
in	O
situ	O
(	O
n=1	O
;	O
3.4	O
%	O
)	O
.	O

Prior	O
to	O
the	O
second	O
operation	O
,	O
these	O
lesions	O
could	O
be	O
detected	O
in	O
seven	O
cases	O
using	O
ultrasonography	B-P
(	O
sensitivity	O
,	O
53.3	O
%	O
;	O
specificity	O
,	O
100	O
%	O
)	O
and	O
in	O
10	O
cases	O
using	O
breast	B-P
MR	I-P
imaging	I-P
(	O
sensitivity	O
,	O
83.3	O
%	O
;	O
specificity	O
,	O
100	O
%	O
)	O
.	O

Breast	B-P
MR	I-P
imaging	I-P
showed	O
higher	O
sensitivity	O
than	O
breast	B-P
ultrasonography	I-P
in	O
detecting	O
remnant	O
LCIS	O
lesions	O
.	O

If	O
a	O
suspicious	O
lesion	O
was	O
found	O
using	O
breast	B-P
MR	I-P
imaging	I-P
,	O
a	O
second	O
operation	O
should	O
be	O
considered	O
because	O
of	O
the	O
possibility	O
of	O
multifocality	O
,	O
even	O
if	O
LCIS	O
was	O
confirmed	O
at	O
the	O
initial	O
operation	O
.	O

Differential	O
miRNA	O
expression	O
analysis	O
during	O
late	O
stage	O
terminal	O
hindgut	O
development	O
in	O
fetal	O
rats	O
.	O

Terminal	O
hindgut	O
deformity	O
is	O
the	O
leading	O
digestive	O
tract	O
malformation	O
,	O
however	O
,	O
the	O
etiology	O
and	O
pathogenesis	O
remained	O
unknown	O
.	O

To	O
date	O
,	O
gene	O
expression	O
abnormalities	O
were	O
considered	O
the	O
primary	O
cause	O
of	O
these	O
diseases	O
.	O

miRNAs	O
have	O
been	O
found	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
genes	O
.	O

A	O
total	O
of	O
24	O
pregnant	O
rats	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O

The	O
experimental	O
group	O
(	O
n=12	O
)	O
received	O
1	O
%	O
ethylenethiourea	O
(	O
125mg/kg	O
)	O
by	O
gavage	O
on	O
gestational	O
day	O
11	O
,	O
while	O
the	O
control	O
group	O
(	O
n=12	O
)	O
received	O
the	O
same	O
volume	O
of	O
distilled	O
water	O
.	O

From	O
each	O
group	O
,	O
fetal	O
rats	O
were	O
obtained	O
by	O
cesarean	O
section	O
on	O
gestational	O
day	O
16	O
.	O

For	O
the	O
extraction	O
of	O
total	O
RNA	O
,	O
1	O
cm	O
rectum	O
samples	O
were	O
obtained	O
from	O
four	O
fetal	O
rats	O
that	O
had	O
similar	O
weights	O
.	O

Chip	O
hybridization	O
was	O
conducted	O
after	O
poly	O
(	O
A	O
)	O
and	O
biotin	O
were	O
added	O
to	O
the	O
RNA	O
samples	O
,	O
and	O
this	O
was	O
followed	O
by	O
washing	O
,	O
dyeing	O
,	O
and	O
scanning	B-P
of	O
the	O
chip	O
.	O

Differences	O
identified	O
in	O
the	O
miRNA	O
expression	O
profiles	O
and	O
the	O
target	O
gene	O
analysis	O
results	O
were	O
further	O
analyzed	O
to	O
identify	O
potential	O
regulators	O
of	O
terminal	O
hindgut	O
development	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
111	O
miRNAs	O
expressed	O
in	O
the	O
terminal	O
hindgut	O
of	O
the	O
experimental	O
group	O
were	O
up-regulated	O
on	O
gestational	O
day	O
16	O
,	O
while	O
117	O
miRNAs	O
were	O
down-regulated	O
.	O

The	O
ten	O
miRNAs	O
with	O
the	O
greatest	O
differential	O
expression	O
profiles	O
between	O
the	O
experimental	O
and	O
control	O
samples	O
were	O
selected	O
for	O
target	O
gene	O
prediction	O
,	O
pathway	O
analysis	O
,	O
and	O
gene	O
ontology	O
analysis	O
.	O

A	O
subset	O
of	O
these	O
miRNAs	O
was	O
found	O
to	O
be	O
closely	O
related	O
to	O
rat	O
fetus	O
terminal	O
hindgut	O
growth	O
and	O
development	O
.	O

In	O
addition	O
,	O
target	O
gene	O
analysis	O
showed	O
that	O
miR-193	O
may	O
have	O
an	O
important	O
role	O
in	O
regulating	O
a	O
key	O
gene	O
in	O
anorectal	O
development	O
,	O
Hoxd13	O
.	O

This	O
role	O
was	O
confirmed	O
in	O
a	O
dual	B-P
luciferase	I-P
reporter	I-P
assay	I-P
when	O
miR-193	O
was	O
able	O
to	O
inhibit	O
expression	O
of	O
a	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
Hoxd13	O
gene	O
in	O
the	O
human	O
embryonic	O
kidney	O
cell	O
line	O
,	O
293T	O
.	O

Real-time	O
PCR	O
and	O
Western	O
blotting	O
experiments	O
further	O
showed	O
that	O
the	O
expression	O
of	O
Hoxd13	O
was	O
significantly	O
lower	O
when	O
miR-193	O
was	O
highly	O
expressed	O
in	O
rat	O
intestinal	O
epithelial	O
cells	O
.	O

The	O
differences	O
in	O
both	O
sets	O
of	O
experiments	O
were	O
statistically	O
significant	O
compared	O
with	O
the	O
negative	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

These	O
data	O
support	O
an	O
important	O
regulatory	O
role	O
for	O
miRNAs	O
in	O
the	O
expression	O
of	O
target	O
genes	O
during	O
terminal	O
hindgut	O
development	O
in	O
fetal	O
rats	O
.	O

In	O
particular	O
,	O
miR-193	O
-mediated	O
inhibition	O
of	O
Hoxd13	O
was	O
found	O
to	O
be	O
significant	O
in	O
rat	O
intestinal	O
epithelial	O
cells	O
.	O

Microarray-Based	B-P
Analysis	I-P
of	O
Methylation	O
of	O
1st	O
Trimester	O
Trisomic	O
Placentas	O
from	O
Down	O
Syndrome	O
,	O
Edwards	O
Syndrome	O
and	O
Patau	O
Syndrome	O
.	O

Methylation	O
-based	O
non-invasive	O
prenatal	O
testing	O
of	O
fetal	O
aneuploidies	O
is	O
an	O
alternative	O
method	B-P
that	O
could	O
possibly	O
improve	O
fetal	B-P
aneuploidy	I-P
diagnosis	I-P
,	I-P
especially	I-P
for	I-P
trisomy	I-P
13	I-P
(	I-P
T13	I-P
)	I-P
and	I-P
trisomy	I-P
18	I-P
(	I-P
T18	I-P
)	I-P
.	O

Our	O
aim	O
was	O
to	O
study	O
the	O
methylation	O
landscape	O
in	O
placenta	O
DNA	O
from	O
trisomy	O
13	O
,	O
18	O
and	O
21	O
pregnancies	O
in	O
an	O
attempt	O
to	O
find	O
trisomy	O
-specific	O
methylation	O
differences	O
better	O
suited	O
for	O
non-invasive	O
prenatal	O
diagnosis	O
.	O

We	O
have	O
conducted	O
high-resolution	B-P
methylation	O
specific	O
bead	B-P
chip	I-P
microarray	I-P
analyses	I-P
assessing	O
more	O
than	O
450,000	O
CpGs	O
analyzing	O
placentas	O
from	O
12	O
T21	O
pregnancies	O
,	O
12	O
T18	O
pregnancies	O
and	O
6	O
T13	O
pregnancies	O
.	O

We	O
have	O
compared	O
the	O
methylation	O
landscape	O
of	O
the	O
trisomic	O
placentas	O
to	O
the	O
methylation	O
landscape	O
from	O
normal	O
placental	O
DNA	O
and	O
to	O
maternal	O
blood	O
cell	O
DNA	O
.	O

Comparing	O
trisomic	O
placentas	O
to	O
normal	O
placentas	O
we	O
identified	O
217	O
and	O
219	O
differentially	O
methylated	O
CpGs	O
for	O
CVS	B-P
T18	O
and	O
CVS	B-P
T13	O
,	O
respectively	O
(	O
delta	O
β	O
>	O
0.2	O
,	O
FDR	O
<	O
0.05	O
)	O
,	O
but	O
only	O
three	O
differentially	O
methylated	O
CpGs	O
for	O
T21	O
.	O

However	O
,	O
the	O
methylation	O
differences	O
was	O
only	O
modest	O
(	O
delta	O
β	O
<	O
0.4	O
)	O
,	O
making	O
them	O
less	O
suitable	O
as	O
diagnostic	O
markers	O
.	O

Gene	O
ontology	O
enrichment	O
analysis	O
revealed	O
that	O
the	O
gene	O
set	O
connected	O
to	O
the	O
T18	O
differentially	O
methylated	O
CpGs	O
was	O
highly	O
enriched	O
for	O
GO	O
terms	O
related	O
to	O
''	O
DNA	O
binding	O
``	O
and	O
``	O
transcription	O
factor	O
binding	O
``	O
coupled	O
to	O
the	O
RNA	O
polymerase	O
II	O
transcription	O
.	O

In	O
the	O
gene	O
set	O
connected	O
to	O
the	O
T13	O
differentially	O
methylated	O
CpGs	O
we	O
found	O
no	O
significant	O
enrichments	O
.	O

Immunogenicity	O
of	O
a	O
DNA	O
Vaccine	O
Encoding	O
Ag85a	O
-	O
Tb10.4	O
Antigens	O
from	O
Mycobacterium	O
Tuberculosis	O
.	O

Tuberculosis	O
is	O
a	O
life	O
threatening	O
disease	O
that	O
is	O
partially	O
prevented	O
by	O
BCG	O
vaccine	O
.	O

Development	O
of	O
more	O
effective	O
vaccines	O
is	O
an	O
urgent	O
priority	O
in	O
TB	O
control	O
.	O

Ag85a	O
and	O
Tb10.4	O
are	O
the	O
members	O
of	O
culture	O
filter	O
protein	O
(	O
CFP	O
)	O
of	O
M.	O
tuberculosis	O
that	O
have	O
high	O
immunogenicity	O
.	O

To	O
analyze	O
the	O
immunogenicity	O
of	O
Ag85a	O
-	O
Tb10.4	O
DNA	O
vaccine	O
by	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
(	O
ELISA	B-P
)	O
.	O

In	O
this	O
study	O
a	O
previously	O
described	O
plasmid	O
DNA	O
vaccine	O
encoding	O
Ag85a	O
-	O
Tb10.4	O
was	O
used	O
to	O
examine	O
its	O
capability	O
in	O
the	O
stimulation	O
of	O
immune	O
responses	O
in	O
an	O
animal	O
model	O
.	O

Female	O
BALB/c	O
mice	O
were	O
vaccinated	O
with	O
100	O
μg	O
of	O
purified	O
recombinant	O
vector	O
intramuscularly	O
3	O
times	O
at	O
two-	O
week	O
intervals	O
and	O
the	O
levels	O
of	O
five	O
cytokines	O
including	O
IFN-γ	O
,	O
IL-12	O
,	O
IL-4	O
,	O
IL-10	O
and	O
TGF-β	O
were	O
measured	O
.	O

The	O
levels	O
of	O
IFN-γ	O
and	O
IL-12	O
for	O
the	O
mice	O
following	O
immunization	O
with	O
Ag85A	O
-	O
Tb10.4	O
was	O
significantly	O
greater	O
than	O
that	O
of	O
the	O
BCG	O
and	O
control	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
levels	O
of	O
IL-4	O
,	O
IL-10	O
and	O
TGF-β	O
between	O
groups	O
.	O

IFN-γ	O
and	O
IL-12	O
Th1	O
cytokines	O
increased	O
significantly	O
in	O
mice	O
vaccinated	O
with	O
Ag85a	O
-	O
TB10.4	O
DNA	O
vaccine	O
in	O
comparison	O
to	O
the	O
control	O
and	O
BCG	O
groups	O
.	O

Our	O
results	O
may	O
serve	O
as	O
a	O
groundwork	O
for	O
further	O
research	O
into	O
the	O
prevention	O
and	O
treatment	O
of	O
tuberculosis	O
.	O

S-Nitrosylation	O
Induces	O
Structural	O
and	O
Dynamical	O
Changes	O
in	O
a	O
Rhodanese	O
Family	O
Protein	O
.	O

S-Nitrosylation	O
is	O
well	O
established	O
as	O
an	O
important	O
post-translational	O
regulator	O
in	O
protein	O
function	O
and	O
signaling	O
.	O

However	O
,	O
relatively	O
little	O
is	O
known	O
about	O
its	O
structural	O
and	O
dynamical	O
consequences	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
S-nitrosylation	O
on	O
the	O
rhodanese	O
domain	O
of	O
the	O
Escherichia	O
coli	O
integral	O
membrane	O
protein	O
YgaP	O
by	O
NMR	O
,	O
X-ray	B-P
crystallography	I-P
,	O
and	O
mass	B-P
spectrometry	I-P
.	O

The	O
results	O
show	O
that	O
the	O
active	O
cysteine	O
in	O
the	O
rhodanese	O
domain	O
of	O
YgaP	O
is	O
subjected	O
to	O
two	O
competing	O
modifications	O
:	O
S-nitrosylation	O
and	O
S-sulfhydration	O
,	O
which	O
are	O
naturally	O
occurring	O
in	O
vivo	O
.	O

It	O
has	O
been	O
observed	O
that	O
in	O
addition	O
to	O
inhibition	O
of	O
the	O
sulfur	O
transfer	O
activity	O
,	O
S-nitrosylation	O
of	O
the	O
active	O
site	O
residue	O
Cys63	O
causes	O
an	O
increase	O
in	O
slow	O
motion	O
and	O
a	O
displacement	O
of	O
helix	O
5	O
due	O
to	O
a	O
weakening	O
of	O
the	O
interaction	O
between	O
the	O
active	O
site	O
and	O
the	O
helix	O
dipole	O
.	O

These	O
findings	O
provide	O
an	O
example	O
of	O
how	O
nitrosative	O
stress	O
can	O
exert	O
action	O
at	O
the	O
atomic	O
level	O
.	O

Barriers	O
to	O
access	O
and	O
uptake	O
of	O
antiretroviral	O
therapy	O
among	O
HIV-positive	O
men	O
who	O
have	O
sex	O
with	O
men	O
in	O
Hanoi	O
,	O
Vietnam	O
:	O
from	O
HIV	B-P
testing	I-P
to	O
treatment	O
.	O

Little	O
is	O
known	O
about	O
the	O
experiences	O
of	O
Vietnamese	O
men	O
who	O
have	O
sex	O
with	O
men	O
in	O
accessing	O
HIV	B-P
testing	I-P
and	O
treatment	O
.	O

We	O
aimed	O
to	O
explore	O
barriers	O
to	O
access	O
and	O
uptake	O
of	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
among	O
HIV-positive	O
men	O
who	O
have	O
sex	O
with	O
men	O
in	O
Hanoi	O
.	O

During	O
2015	O
,	O
we	O
conducted	O
qualitative	O
interviews	O
with	O
35	O
participants	O
recruited	O
using	O
snowball	O
sampling	O
based	O
on	O
previous	O
research	O
and	O
social	O
networks	O
.	O

Key	O
individual	O
impediments	O
to	O
ART	O
uptake	O
included	O
inadequate	O
preparation	O
for	O
a	O
positive	O
diagnosis	O
and	O
the	O
dual	O
stigmatisation	O
of	O
homosexuality	O
and	O
HIV	O
and	O
its	O
consequences	O
,	O
leading	O
to	O
fear	O
of	O
disclosure	O
of	O
HIV	O
status	O
.	O

Health	O
system	O
barriers	O
included	O
lack	O
of	O
clarity	O
and	O
consistency	O
about	O
how	O
to	O
register	O
for	O
and	O
access	O
ART	O
,	O
failure	O
to	O
protect	O
patient	O
confidentiality	O
and	O
a	O
reticence	O
by	O
providers	O
to	O
discuss	O
sexual	O
identity	O
and	O
same-sex	O
issues	O
.	O

Results	O
suggest	O
fundamental	O
problems	O
in	O
the	O
way	O
HIV	B-P
testing	I-P
is	O
currently	O
delivered	O
in	O
Hanoi	O
,	O
including	O
a	O
lack	O
of	O
client-centred	O
counselling	O
,	O
peer	O
support	O
and	O
clear	O
referral	O
pathways	O
.	O

Overcoming	O
these	O
barriers	O
will	O
require	O
educating	O
men	O
who	O
have	O
sex	O
with	O
men	O
about	O
the	O
benefits	O
of	O
routine	B-P
testing	I-P
,	O
improving	O
access	O
to	O
quality	O
diagnostic	O
services	O
and	O
building	O
a	O
safe	O
,	O
confidential	O
treatment	O
environment	O
for	O
HIV-positive	O
men	O
to	O
access	O
,	O
receive	O
and	O
remain	O
in	O
care	O
.	O

First	O
complete	O
genome	O
sequence	O
of	O
parainfluenza	O
virus	O
5	O
isolated	O
from	O
lesser	O
panda	O
.	O

Parainfluenza	O
virus	O
5	O
(	O
PIV5	O
)	O
is	O
widespread	O
in	O
mammals	O
and	O
humans	O
.	O

Up	O
to	O
now	O
,	O
there	O
is	O
little	O
information	O
about	O
PIV5	O
infection	O
in	O
lesser	O
pandas	O
.	O

In	O
this	O
study	O
,	O
a	O
PIV5	O
variant	O
(	O
named	O
ZJQ-221	O
)	O
was	O
isolated	O
from	O
a	O
lesser	O
panda	O
with	O
respiratory	O
disease	O
in	O
Guangzhou	O
zoo	O
in	O
Guangdong	O
province	O
,	O
southern	O
China	O
.	O

The	O
full-length	O
genome	O
of	O
ZJQ-221	O
was	O
found	O
to	O
be	O
15,246	O
nucleotides	O
and	O
consisted	O
of	O
seven	O
non-overlapping	O
genes	O
encoding	O
eight	O
proteins	O
(	O
i.e.	O
,	O
NP	O
,	O
V	O
,	O
P	O
,	O
M	O
,	O
F	O
,	O
SH	O
,	O
HN	O
and	O
L	O
)	O
.	O

Sequence	O
alignment	O
and	O
genetic	B-P
analysis	I-P
revealed	O
that	O
ZJQ-221	O
shared	O
a	O
close	O
relationship	O
with	O
a	O
PIV5	O
strain	O
of	O
canine	O
-origin	O
(	O
1168-1	O
)	O
from	O
South	O
Korea	O
.	O

The	O
findings	O
of	O
this	O
study	O
confirm	O
the	O
presence	O
of	O
PIV5	O
in	O
lesser	O
panda	O
and	O
indicate	O
this	O
mammal	O
as	O
a	O
possible	O
natural	O
reservoir	O
.	O

Furthermore	O
they	O
highlight	O
the	O
urgent	O
need	O
to	O
strengthen	O
viral	O
surveillance	O
and	O
control	O
of	O
PIV5	O
in	O
zoo	O
animals	O
.	O

Tissue-engineered	O
cardiac	O
patch	O
seeded	B-P
with	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
derived	O
cardiomyocytes	O
promoted	O
the	O
regeneration	O
of	O
host	O
cardiomyocytes	O
in	O
a	O
rat	O
model	O
.	O

Thousands	O
of	O
babies	O
are	O
born	O
with	O
congenital	O
heart	O
defects	O
that	O
require	O
surgical	O
repair	O
involving	O
a	O
prosthetic	O
implant	O
.	O

Lack	O
of	O
growth	O
in	O
prosthetic	O
grafts	O
is	O
especially	O
detrimental	O
in	O
pediatric	O
surgery	O
.	O

Cell	O
seeded	B-P
biodegradable	O
tissue	O
engineered	O
grafts	O
are	O
a	O
novel	O
solution	O
to	O
this	O
problem	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
the	O
feasibility	O
of	O
seeding	B-P
human	O
induced	O
pluripotent	O
stem	O
cell	O
derived	O
cardiomyocytes	O
(	O
hiPS-CMs	O
)	O
onto	O
a	O
biodegradable	O
cardiac	O
patch	O
.	O

The	O
hiPS-CMs	O
were	O
cultured	B-P
on	O
a	O
biodegradable	O
patch	O
composed	O
of	O
a	O
polyglycolic	O
acid	O
(	O
PGA	O
)	O
and	O
a	O
50:50	O
poly	O
(	O
l-lactic-co-ε-caprolactone	O
)	O
copolymer	O
(	O
PLCL	O
)	O
for	O
1	O
week	O
.	O

Male	O
athymic	O
rats	O
were	O
randomly	O
divided	O
into	O
2	O
groups	O
of	O
10	O
animals	O
each	O
:	O
1.	O
hiPS-CM	O
seeded	B-P
group	O
,	O
and	O
2	O
.	O

Unseeded	O
group	O
.	O

After	O
culture	B-P
,	O
the	O
cardiac	O
patch	O
was	O
implanted	O
to	O
repair	O
a	O
defect	O
with	O
a	O
diameter	O
of	O
2	O
mm	O
created	O
in	O
the	O
right	O
ventricular	O
outflow	O
tract	O
(	O
RVOT	O
)	O
wall	O
.	O

Hearts	O
were	O
explanted	O
at	O
4	O
(	O
n	O
=	O
2	O
)	O
,	O
8	O
(	O
n	O
=	O
2	O
)	O
,	O
and	O
16	O
(	O
n	O
=	O
6	O
)	O
weeks	O
after	O
patch	O
implantation	O
.	O

Explanted	O
patches	O
were	O
assessed	O
immunohistochemically	B-P
.	O

Seeded	B-P
patch	O
explants	O
did	O
not	O
stain	O
positive	O
for	O
α-actinin	O
(	O
marker	O
of	O
cardiomyocytes	O
)	O
at	O
the	O
4	O
week	O
time	O
point	O
,	O
suggesting	O
that	O
the	O
cultured	B-P
hiPS-CMs	O
evacuated	O
the	O
patch	O
in	O
the	O
early	O
phase	O
of	O
tissue	O
remodeling	O
.	O

However	O
,	O
after	O
16	O
weeks	O
implantation	O
,	O
the	O
area	O
fraction	O
of	O
positively	O
stained	O
α-actinin	O
cells	O
was	O
significantly	O
higher	O
in	O
the	O
seeded	B-P
group	O
than	O
in	O
the	O
unseeded	O
group	O
(	O
Seeded	B-P
group	O
:	O
6.1	O
±	O
2.8	O
%	O
vs.	O
Unseeded	O
group	O
:	O
0.95	O
±	O
0.50	O
%	O
,	O
p	O
=	O
0.004	O
)	O
,	O
suggesting	O
cell	O
seeding	B-P
promoted	O
regenerative	O
proliferation	O
of	O
host	O
cardiomyocytes	O
.	O

Seeded	B-P
hiPS-CMs	O
were	O
not	O
present	O
in	O
the	O
patch	O
after	O
4	O
weeks	O
.	O

However	O
,	O
we	O
surmise	O
that	O
they	O
influenced	O
the	O
regeneration	O
of	O
host	O
cardiomyocytes	O
via	O
a	O
paracrine	O
mechanism	O
.	O

Tissue-engineered	O
hiPS-CMs	O
seeded	B-P
cardiac	O
patches	O
warrant	O
further	O
investigation	O
for	O
use	O
in	O
the	O
repair	O
of	O
congenital	O
heart	O
diseases	O
.	O

An	O
ultrasensitive	O
electrochemiluminescence	B-P
sensor	O
based	O
on	O
reduced	O
graphene	O
oxide	O
-	O
copper	O
sulfide	O
composite	O
coupled	O
with	O
capillary	B-P
electrophoresis	I-P
for	O
determination	B-P
of	O
amlodipine	O
besylate	O
in	O
mice	O
plasma	O
.	O

A	O
new	O
electrochemiluminescence	B-P
(	O
ECL	B-P
)	O
sensor	O
based	O
on	O
reduced	O
graphene	O
oxide	O
-	O
copper	O
sulfide	O
(	O
rGO	O
-	O
CuS	O
)	O
composite	O
coupled	O
with	O
capillary	B-P
electrophoresis	I-P
(	O
CE	B-P
)	O
was	O
constructed	O
for	O
the	O
ultrasensitive	O
detection	O
of	O
amlodipine	O
besylate	O
(	O
AML	O
)	O
for	O
the	O
first	O
time	O
.	O

In	O
this	O
work	O
,	O
rGO	O
-	O
CuS	O
composite	O
was	O
synthesized	O
by	O
one-pot	O
hydrothermal	O
method	O
and	O
used	O
for	O
electrode	O
modification	O
.	O

The	O
electrochemical	B-P
and	O
ECL	B-P
behaviors	O
of	O
the	O
sensor	O
were	O
investigated	O
.	O

More	O
than	O
5-fold	O
enhance	O
in	O
ECL	B-P
intensity	O
was	O
observed	O
after	O
modified	O
with	O
rGO	O
-	O
CuS	O
composite	O
.	O

The	O
results	O
can	O
be	O
ascribed	O
to	O
the	O
presence	O
of	O
rGO	O
-	O
CuS	O
composite	O
on	O
the	O
electrode	O
surface	O
that	O
facilitates	O
the	O
electron	O
transfer	O
rate	O
between	O
the	O
electroactive	O
center	O
of	O
Ru	O
(	O
bpy	O
)	O
3	O
(	O
2+	O
)	O
and	O
the	O
electrode	O
.	O

The	O
ECL	B-P
sensor	O
was	O
coupled	O
with	O
CE	B-P
to	O
improve	O
the	O
selectivity	O
and	O
the	O
CE	B-P
-	O
ECL	B-P
parameters	O
that	O
affect	O
separation	O
and	O
detection	O
were	O
optimized	O
.	O

Under	O
the	O
optimum	O
conditions	O
,	O
the	O
linear	O
ranges	O
for	O
AML	O
was	O
0.008-5.0μg/mL	O
with	O
a	O
detection	O
limit	O
of	O
2.8ng/mL	O
(	O
S/N=3	O
)	O
.	O

The	O
method	B-P
displayed	O
the	O
advantages	O
of	O
high	O
sensitivity	O
,	O
good	O
selectivity	O
,	O
wide	O
linear	O
range	O
,	O
low	O
detection	O
limit	O
and	O
fine	O
reproducibility	O
,	O
and	O
was	O
used	O
to	O
analyze	O
AML	O
in	O
mice	O
plasma	O
with	O
a	O
satisfactory	O
result	O
,	O
which	O
holds	O
a	O
great	O
potential	O
in	O
the	O
field	O
of	O
pharmaceutical	O
analysis	O
.	O

Elevated	O
Plasma	O
Level	O
of	O
Interferon-λ1	O
in	O
Chronic	O
Spontaneous	O
Urticaria	O
:	O
Upregulated	O
Expression	O
in	O
CD8	O
(	O
+	O
)	O
and	O
Epithelial	O
Cells	O
and	O
Induction	O
of	O
Inflammatory	O
Cell	O
Accumulation	O
.	O

Interferon-	O
(	O
IFN-	O
)	O
λ1	O
is	O
regarded	O
as	O
a	O
potent	O
bio-active	O
molecule	O
in	O
innate	O
immunity	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
its	O
role	O
in	O
chronic	O
spontaneous	O
urticaria	O
(	O
CSU	O
)	O
.	O

We	O
therefore	O
investigated	O
expression	O
of	O
IFN-λ1	O
in	O
CSU	O
,	O
its	O
cellular	O
location	O
,	O
and	O
its	O
influence	O
on	O
inflammatory	O
cell	O
accumulation	O
by	O
using	O
flow	B-P
cytometry	I-P
analysis	I-P
,	O
skin	O
tissue	O
dispersion	O
,	O
immunohistochemical	B-P
stain	I-P
,	O
and	O
a	O
mouse	O
peritoneal	O
inflammation	O
model	O
.	O

The	O
results	O
showed	O
that	O
level	O
of	O
IFN-λ1	O
was	O
2.0-fold	O
higher	O
in	O
plasma	O
of	O
the	O
patients	O
with	O
CSU	O
than	O
the	O
level	O
in	O
healthy	O
control	O
(	O
HC	O
)	O
subjects	O
.	O

Among	O
leukocytes	O
examined	O
,	O
only	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
expressed	O
more	O
IFN-λ1	O
in	O
CSU	O
blood	O
.	O

Double	B-P
labeling	I-P
immunohistochemical	I-P
staining	I-P
revealed	O
that	O
IFN-λ1	O
(	O
+	O
)	O
inflammatory	O
cells	O
such	O
as	O
mast	O
cells	O
,	O
eosinophils	O
,	O
B	O
cells	O
,	O
neutrophils	O
,	O
and	O
macrophages	O
were	O
mainly	O
located	O
in	O
dermis	O
,	O
whereas	O
epidermis	O
tissue	O
highly	O
expressed	O
IFN-λ1	O
.	O

IFN-λ1	O
induced	O
a	O
dose-dependent	O
increase	O
in	O
number	O
of	O
eosinophils	O
,	O
lymphocytes	O
,	O
mast	O
cells	O
,	O
macrophages	O
,	O
and	O
neutrophils	O
in	O
the	O
peritoneum	O
of	O
mice	O
at	O
6	O
h	O
following	O
injection	O
,	O
which	O
was	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
animals	O
with	O
anti-intercellular	O
adhesion	O
molecule-	O
(	O
ICAM-	O
)	O
1	O
and/or	O
anti-L-selectin	O
antibodies	O
.	O

In	O
conclusion	O
,	O
IFN-λ1	O
is	O
likely	O
to	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
CSU	O
.	O

Blocking	O
IFN-λ1	O
production	O
may	O
help	O
to	O
reduce	O
the	O
accumulation	O
of	O
inflammatory	O
cells	O
in	O
the	O
involved	O
CSU	O
skin	O
.	O

CD44	O
positive	O
/	O
CD24	O
negative	O
(	O
stem	O
cell	O
like	O
property	O
)	O
breast	O
carcinoma	O
cells	O
as	O
marker	O
of	O
tumor	O
aggression	O
.	O

Cells	O
with	O
stem	O
cell	O
like	O
properties	O
in	O
solid	O
organ	O
malignancies	O
like	O
breast	O
and	O
pancreas	O
have	O
been	O
studied	O
over	O
the	O
last	O
decade	O
and	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
poor	O
prognosis	O
.	O

Presence	O
of	O
CD44	O
positive	O
and	O
CD24	O
negative	O
tumor	O
cells	O
in	O
breast	O
carcinoma	O
(	O
cells	O
with	O
'	O
stem	O
cell	O
'	O
like	O
property	O
)	O
as	O
marker	O
of	O
aggressiveness	O
and	O
poor	O
prognosis	O
was	O
checked	O
for	O
association	O
with	O
various	O
markers	O
of	O
disease	O
aggression	O
like	O
age	O
at	O
presentation	O
,	O
size	O
of	O
tumor	O
,	O
histological	O
grade	O
of	O
tumor	O
,	O
triple	O
negative	O
status	O
,	O
level	O
of	O
micro-vessel	O
density	O
,	O
and	O
nodal	O
status	O
.	O

Single	B-P
and	I-P
double	I-P
staining	I-P
immunohistochemistry	I-P
protocol	I-P
was	O
used	O
for	O
CD24	O
and	O
CD44	O
staining	B-P
.	O

The	O
staining	B-P
protocol	I-P
was	O
repeated	O
with	O
more	O
contemporary	O
techniques	O
using	O
fluorescent	O
chromogen	O
also	O
.	O

52	O
cases	O
,	O
all	O
females	O
who	O
underwent	O
modified	O
radical	O
mastectomy	O
at	O
a	O
tertiary	O
care	O
hospital	O
over	O
a	O
period	O
of	O
3	O
years	O
,	O
were	O
evaluated	O
.	O

No	O
association	O
was	O
found	O
between	O
presence	O
of	O
stem	O
cells	O
and	O
size	O
of	O
lesion	O
,	O
histological	O
grade	O
,	O
triple	O
negative	O
status	O
or	O
micro-vessel	O
density	O
.	O

However	O
,	O
significant	O
association	O
was	O
found	O
with	O
respect	O
to	O
younger	O
age	O
of	O
presentation	O
(	O
p	O
value	O
=	O
0.044	O
)	O
.	O

20	O
out	O
of	O
25	O
cases	O
with	O
nodal	O
metastasis	O
were	O
positive	O
for	O
presence	O
of	O
stem	O
cells	O
(	O
p	O
value	O
is	O
0.0003	O
)	O
.	O

Further	O
,	O
18	O
of	O
these	O
20	O
cases	O
also	O
had	O
stem	O
cells	O
in	O
the	O
metastatic	O
nodule	O
.	O

Fluorescent	O
chromogens	O
(	O
FITC	O
and	O
Cyanine	O
Red	O
)	O
revealed	O
similar	O
results	O
.	O

Cases	O
positive	O
for	O
stem	O
cells	O
showed	O
earlier	O
onset	O
of	O
disease	O
and	O
proneness	O
to	O
nodal	O
metastasis	O
.	O

Fluid-Attenuated	B-P
Inversion	I-P
Recovery	I-P
Hyperintensity	O
Is	O
Associated	O
with	O
Hemorrhagic	O
Transformation	O
following	O
Reperfusion	O
Therapy	O
.	O

It	O
is	O
still	O
controversial	O
whether	O
early	O
fluid-attenuated	B-P
inversion	I-P
recovery	I-P
(	O
FLAIR	B-P
)	O
hyperintensity	O
within	O
acute	O
ischemic	O
lesions	O
carries	O
the	O
risk	O
of	O
hemorrhagic	O
transformation	O
(	O
HT	O
)	O
after	O
reperfusion	O
therapy	O
.	O

Furthermore	O
,	O
the	O
association	O
between	O
the	O
location	O
of	O
FLAIR	B-P
hyperintensity	O
and	O
HT	O
has	O
not	O
been	O
investigated	O
.	O

We	O
retrospectively	O
reviewed	O
patients	O
who	O
underwent	O
reperfusion	O
therapy	O
within	O
6	O
hours	O
of	O
stroke	O
onset	O
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
including	O
a	O
FLAIR	B-P
sequence	O
before	O
completing	O
reperfusion	O
therapy	O
.	O

FLAIR	B-P
hyperintensity	O
within	O
the	O
diffusion-weighted	B-P
imaging	I-P
(	O
DWI	B-P
)	O
lesion	O
was	O
rated	O
qualitatively	O
,	O
and	O
HT	O
was	O
assessed	O
on	O
follow-up	O
gradient	O
echo	B-P
imaging	I-P
.	O

The	O
location	O
of	O
the	O
FLAIR	B-P
change	O
and	O
HT	O
was	O
classified	O
as	O
subcortical	O
,	O
cortical	O
,	O
or	O
cortico-subcortical	O
.	O

Of	O
134	O
patients	O
with	O
acute	O
ischemic	O
stroke	O
included	O
in	O
this	O
study	O
,	O
early	O
FLAIR	B-P
changes	O
within	O
DWI	B-P
lesions	O
were	O
identified	O
in	O
56	O
(	O
41.8	O
%	O
)	O
patients	O
,	O
and	O
HT	O
was	O
noted	O
in	O
51	O
(	O
38.1	O
%	O
)	O
patients	O
.	O

FLAIR	B-P
change	O
was	O
independently	O
associated	O
with	O
HT	O
(	O
odds	O
ratio	O
:	O
4.37	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
1.72-11.12	O
)	O
.	O

Geographically	O
,	O
48.2	O
%	O
of	O
the	O
patients	O
with	O
a	O
FLAIR	B-P
change	O
developed	O
a	O
matched	O
HT	O
(	O
restricted	O
to	O
the	O
region	O
with	O
the	O
FLAIR	B-P
change	O
)	O
,	O
and	O
the	O
risk	O
of	O
HT	O
was	O
further	O
increased	O
in	O
patients	O
with	O
a	O
FLAIR	B-P
change	O
in	O
the	O
cortico-subcortical	O
region	O
(	O
68.8	O
%	O
)	O
.	O

In	O
patients	O
in	O
the	O
acute	O
stage	O
of	O
stroke	O
,	O
an	O
early	O
FLAIR	B-P
change	O
is	O
associated	O
with	O
the	O
risk	O
of	O
HT	O
following	O
reperfusion	O
therapy	O
with	O
a	O
highly	O
matched	O
geographic	O
relationship	O
and	O
common	O
risk	O
factors	O
.	O

Thus	O
,	O
identification	O
of	O
FLAIR	B-P
change	O
may	O
be	O
a	O
useful	O
surrogate	O
marker	O
to	O
assess	O
the	O
likelihood	O
of	O
subsequent	O
HT	O
in	O
patients	O
treated	O
with	O
reperfusion	O
therapy	O
.	O

Development	O
of	O
a	O
platelet	O
adhesion	O
transport	O
equation	O
for	O
a	O
computational	O
thrombosis	O
model	O
.	O

Thrombosis	O
is	O
a	O
significant	O
issue	O
for	O
cardiovascular	O
device	O
development	O
and	O
use	O
.	O

While	O
thrombosis	O
models	O
are	O
available	O
,	O
very	O
few	O
are	O
device	O
-	O
related	O
and	O
none	O
have	O
been	O
thoroughly	O
validated	O
experimentally	O
.	O

Here	O
,	O
we	O
introduce	O
a	O
surface	O
adherent	O
platelet	O
transport	O
equation	O
into	O
a	O
continuum	O
model	O
to	O
account	O
for	O
the	O
biomaterial	O
interface/blood	O
interaction	O
.	O

Using	O
a	O
rotating	O
disc	O
system	O
and	O
polyurethane-urea	O
material	O
,	O
we	O
characterize	O
steady	O
and	O
pulsatile	O
flow	O
fields	O
using	O
laser	B-P
Doppler	I-P
velocimetry	I-P
.	O

In	O
vitro	O
measurements	O
of	O
platelet	O
adhesion	O
are	O
used	O
in	O
combination	O
with	O
the	O
LDV	B-P
data	O
to	O
provide	O
further	O
experimental	O
validation	O
.	O

The	O
rotating	O
disc	O
system	O
is	O
computationally	O
studied	O
using	O
the	O
device	O
-	O
induced	O
thrombosis	O
model	O
with	O
the	O
surface	O
platelet	O
adherent	O
transport	O
equation	O
.	O

The	O
results	O
indicate	O
that	O
the	O
flow	O
field	O
is	O
in	O
excellent	O
agreement	O
to	O
the	O
experimental	O
LDV	B-P
data	O
and	O
that	O
the	O
platelet	O
adhesion	O
simulations	O
are	O
in	O
good	O
agreement	O
with	O
the	O
in	O
vitro	O
platelet	O
data	O
.	O

These	O
results	O
provide	O
good	O
evidence	O
that	O
this	O
transport	O
equation	O
can	O
be	O
used	O
to	O
express	O
the	O
relationship	O
between	O
blood	O
and	O
a	O
biomaterial	O
if	O
the	O
correct	O
platelet	O
adhesion	O
characteristics	O
are	O
known	O
for	O
the	O
biomaterial	O
.	O

Further	O
validation	O
is	O
necessary	O
with	O
other	O
materials	O
.	O

The	O
metastasis	O
suppressor	O
CD82/KAI1	O
inhibits	O
fibronectin	O
adhesion	O
-	O
induced	O
epithelial-to-mesenchymal	O
transition	O
in	O
prostate	O
cancer	O
cells	O
by	O
repressing	O
the	O
associated	O
integrin	O
signaling	O
.	O

The	O
transmembrane	O
protein	O
CD82/KAI1	O
suppresses	O
the	O
metastatic	O
potential	O
of	O
various	O
cancer	O
cell	O
types	O
.	O

Moreover	O
,	O
decrease	O
or	O
loss	O
of	O
CD82	O
expression	O
is	O
closely	O
associated	O
with	O
malignancy	O
and	O
poor	O
prognosis	O
in	O
many	O
human	O
cancers	O
including	O
prostate	O
cancer	O
.	O

Despite	O
intense	O
scrutiny	O
,	O
the	O
mechanisms	O
underlying	O
the	O
metastasis	O
-	O
suppressing	O
role	O
of	O
CD82	O
are	O
still	O
not	O
fully	O
understood	O
.	O

Here	O
,	O
we	O
found	O
that	O
a	O
fibronectin	O
matrix	O
induced	O
mesenchymal	O
phenotypes	O
in	O
human	O
prostate	O
cancer	O
cells	O
with	O
no	O
or	O
low	O
CD82	O
expression	O
levels	O
.	O

However	O
,	O
high	O
CD82	O
expression	O
rendered	O
prostate	O
cancer	O
cells	O
to	O
have	O
intensified	O
epithelial	O
characteristics	O
upon	O
fibronectin	O
engagement	O
,	O
along	O
with	O
decreased	O
cell	O
motility	O
and	O
invasiveness	O
.	O

The	O
CD82	O
function	O
of	O
inhibiting	O
fibronectin	O
-	O
induced	O
epithelial-to-mesenchymal	O
transition	O
(	O
EMT	O
)	O
was	O
dependent	O
not	O
only	O
on	O
CD82	O
interactions	O
with	O
fibronectin	O
-	O
binding	O
α3β1	O
/	O
α5β1	O
integrins	O
but	O
also	O
on	O
the	O
integrin-mediated	O
intracellular	O
signaling	O
events	O
.	O

Notably	O
,	O
CD82	O
attenuated	O
the	O
FAK-Src	O
and	O
ILK	O
pathways	O
downstream	O
of	O
the	O
fibronectin	O
-	O
receptor	O
integrins	O
.	O

Immunofluorescence	B-P
staining	B-P
of	O
human	O
prostate	O
cancer	O
tissue	O
specimens	O
illustrated	O
a	O
negative	O
association	O
of	O
CD82	O
with	O
EMT	O
-related	O
gene	O
expression	O
as	O
well	O
as	O
prostate	O
malignancy	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
CD82	O
suppresses	O
EMT	O
in	O
prostate	O
cancer	O
cells	O
adhered	O
to	O
the	O
fibronectin	O
matrix	O
by	O
repressing	O
adhesion	O
signaling	O
through	O
lateral	O
interactions	O
with	O
the	O
associated	O
α3β1	O
and	O
α5β1	O
integrins	O
,	O
leading	O
to	O
reduced	O
cell	O
migration	O
and	O
invasive	O
capacities	O
.	O

Entropy-driven	O
reactions	O
in	O
living	O
cells	O
for	O
assay	B-P
let-7a	O
microRNA	O
.	O

Imaging	B-P
of	O
microRNA	O
(	O
miRNA	O
)	O
in	O
living	O
cells	O
could	O
facilitate	O
the	O
monitoring	O
of	O
the	O
expression	O
and	O
distribution	O
of	O
miRNA	O
and	O
research	O
on	O
miRNA	O
-related	O
diseases	O
.	O

Given	O
the	O
low	O
expression	O
levels	O
and	O
even	O
down-regulation	O
of	O
cellular	O
miRNA	O
that	O
is	O
associated	O
with	O
some	O
diseases	O
,	O
enzyme	O
-	O
free	O
amplification	O
strategies	O
are	O
imperative	O
for	O
intracellular	O
miRNA	O
assay	B-P
.	O

In	O
this	O
work	O
,	O
we	O
report	O
an	O
entropy-driven	O
reaction	O
for	O
amplification	O
assay	B-P
miRNA	O
with	O
a	O
detection	O
limit	O
of	O
0.27	O
pM	O
.	O

The	O
resulting	O
signal	O
amplification	O
provides	O
excellent	O
recognition	O
and	O
signal	O
enhancement	O
of	O
specific	O
miRNA	O
s	O
in	O
living	O
cells	O
.	O

This	O
method	O
supplies	O
accurate	O
information	O
regarding	O
cellular	O
miRNA	O
-related	O
biological	O
events	O
and	O
provides	O
a	O
new	O
tool	O
for	O
highly	O
sensitive	O
and	O
simultaneous	O
imaging	B-P
of	O
multiple	O
low-level	O
biomarkers	O
,	O
thereby	O
improving	O
the	O
accuracy	O
of	O
early	B-P
disease	I-P
diagnosis	I-P
.	O

Bioactivity	O
and	O
electrochemical	O
behavior	O
of	O
hydroxyapatite	O
-	O
silicon	O
-	O
multi	O
walled	O
carbon	O
nano-tubes	O
composite	O
coatings	O
synthesized	O
by	O
EPD	B-P
on	O
NiTi	O
alloys	O
in	O
simulated	O
body	O
fluid	O
.	O

In	O
order	O
to	O
improve	O
the	O
surface	O
bioactivity	O
of	O
NiTi	O
bone	O
implant	O
and	O
corrosion	O
resistance	O
,	O
hydroxyapatite	O
coating	O
with	O
addition	O
of	O
20wt	O
%	O
silicon	O
,	O
1wt	O
%	O
multi	O
walled	O
carbon	O
nano-tubes	O
and	O
both	O
of	O
them	O
were	O
deposited	O
on	O
a	O
NiTi	O
substrate	O
using	O
a	O
cathodic	B-P
electrophoretic	I-P
method	I-P
.	O

The	O
apatite	O
formation	O
ability	O
was	O
estimated	O
using	O
immersion	B-P
test	I-P
in	O
the	O
simulated	O
body	O
fluid	O
for	O
10	O
days	O
.	O

The	O
SEM	B-P
images	O
of	O
the	O
surface	O
of	O
coatings	O
after	O
immersion	B-P
in	O
simulated	O
body	O
fluid	O
show	O
that	O
the	O
presence	O
of	O
silicon	O
in	O
the	O
hydroxyapatite	O
coatings	O
accelerates	O
in	O
vitro	O
growth	O
of	O
apatite	O
layer	O
on	O
the	O
coatings	O
.	O

The	O
Open-circuit	O
potential	O
and	O
electrochemical	B-P
impedance	I-P
spectroscopy	I-P
were	O
measured	O
to	O
evaluate	O
the	O
electrochemical	O
behavior	O
of	O
the	O
coatings	O
in	O
the	O
simulated	O
body	O
fluid	O
at	O
37°C	O
.	O

The	O
results	O
indicate	O
that	O
the	O
compact	O
structure	O
of	O
hydroxyapatite	O
-20wt	O
%	O
silicon	O
and	O
hydroxyapatite	O
-20wt	O
%	O
silicon	O
-1wt	O
%	O
multi	O
walled	O
carbon	O
nano-tubes	O
coatings	O
could	O
efficiently	O
increase	O
the	O
corrosion	O
resistance	O
of	O
NiTi	O
substrate	O
.	O

Neural	O
Correlates	O
of	O
Belief	O
and	O
Emotion	O
Attribution	O
in	O
Schizophrenia	O
.	O

Impaired	O
mental	O
state	O
attribution	O
is	O
a	O
core	O
social	O
cognitive	O
deficit	O
in	O
schizophrenia	O
.	O

With	O
functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
fMRI	B-P
)	O
,	O
this	O
study	O
examined	O
the	O
extent	O
to	O
which	O
the	O
core	O
neural	O
system	O
of	O
mental	O
state	O
attribution	O
is	O
involved	O
in	O
mental	O
state	O
attribution	O
,	O
focusing	O
on	O
belief	O
attribution	O
and	O
emotion	O
attribution	O
.	O

Fifteen	O
schizophrenia	O
outpatients	O
and	O
14	O
healthy	O
controls	O
performed	O
two	O
mental	O
state	O
attribution	O
tasks	O
in	O
the	O
scanner	O
.	O

In	O
a	O
Belief	O
Attribution	O
Task	O
,	O
after	O
reading	O
a	O
short	O
vignette	O
,	O
participants	O
were	O
asked	O
infer	O
either	O
the	O
belief	O
of	O
a	O
character	O
(	O
a	O
false	O
belief	O
condition	O
)	O
or	O
a	O
physical	O
state	O
of	O
an	O
affair	O
(	O
a	O
false	O
photograph	O
condition	O
)	O
.	O

In	O
an	O
Emotion	O
Attribution	O
Task	O
,	O
participants	O
were	O
asked	O
either	O
to	O
judge	O
whether	O
character	O
(	O
s	O
)	O
in	O
pictures	O
felt	O
unpleasant	O
,	O
pleasant	O
,	O
or	O
neutral	O
emotion	O
(	O
other	O
condition	O
)	O
or	O
to	O
look	O
at	O
pictures	O
that	O
did	O
not	O
have	O
any	O
human	O
characters	O
(	O
view	O
condition	O
)	O
.	O

fMRI	B-P
data	O
were	O
analyzing	O
focusing	O
on	O
a	O
priori	O
regions	O
of	O
interest	O
(	O
ROIs	O
)	O
of	O
the	O
core	O
neural	O
systems	O
of	O
mental	O
state	O
attribution	O
:	O
the	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
,	O
temporoparietal	O
junction	O
(	O
TPJ	O
)	O
and	O
precuneus	O
.	O

An	O
exploratory	O
whole	O
brain	O
analysis	O
was	O
also	O
performed	O
.	O

Both	O
patients	O
and	O
controls	O
showed	O
greater	O
activation	O
in	O
all	O
four	O
ROIs	O
during	O
the	O
Belief	O
Attribution	O
Task	O
than	O
the	O
Emotion	O
Attribution	O
Task	O
.	O

Patients	O
also	O
showed	O
less	O
activation	O
in	O
the	O
precuneus	O
and	O
left	O
TPJ	O
compared	O
to	O
controls	O
during	O
the	O
Belief	O
Attribution	O
Task	O
.	O

No	O
significant	O
group	O
difference	O
was	O
found	O
during	O
the	O
Emotion	O
Attribution	O
Task	O
in	O
any	O
of	O
ROIs	O
.	O

An	O
exploratory	O
whole	O
brain	O
analysis	O
showed	O
a	O
similar	O
pattern	O
of	O
neural	O
activation	O
s.	O
These	O
findings	O
suggest	O
that	O
while	O
schizophrenia	O
patients	O
rely	O
on	O
the	O
same	O
neural	O
network	O
as	O
controls	O
do	O
when	O
attributing	O
beliefs	O
of	O
others	O
,	O
patients	O
did	O
not	O
show	O
reduced	O
activation	O
in	O
the	O
key	O
regions	O
such	O
as	O
the	O
TPJ	O
.	O

Further	O
,	O
this	O
study	O
did	O
not	O
find	O
evidence	O
for	O
aberrant	O
neural	O
activation	O
during	O
emotion	O
attribution	O
or	O
recruitment	O
of	O
compensatory	O
brain	O
regions	O
in	O
schizophrenia	O
.	O

Evaluation	O
of	O
Three	O
Protein-Extraction	B-P
Methods	I-P
for	O
Proteome	O
Analysis	B-P
of	O
Maize	O
Leaf	O
Midrib	O
,	O
a	O
Compound	O
Tissue	O
Rich	O
in	O
Sclerenchyma	O
Cells	O
.	O

Leaf	O
morphology	O
is	O
closely	O
related	O
to	O
the	O
growth	O
and	O
development	O
of	O
maize	O
(	O
Zea	O
mays	O
L.	O
)	O
plants	O
and	O
final	O
kernel	O
production	O
.	O

As	O
an	O
important	O
part	O
of	O
the	O
maize	O
leaf	O
,	O
the	O
midrib	O
holds	O
leaf	O
blades	O
in	O
the	O
aerial	O
position	O
for	O
maximum	O
sunlight	O
capture	O
.	O

Leaf	O
midrib	O
s	O
of	O
adult	O
plants	O
contain	O
substantial	O
sclerenchyma	O
cells	O
with	O
heavily	O
thickened	O
and	O
lignified	O
secondary	O
walls	O
and	O
have	O
a	O
high	O
amount	O
of	O
phenolics	O
,	O
making	O
protein	B-P
extraction	I-P
and	O
proteome	O
analysis	B-P
difficult	O
in	O
leaf	O
midrib	O
tissue	O
.	O

In	O
the	O
present	O
study	O
,	O
three	O
protein-extraction	B-P
methods	I-P
that	O
are	O
commonly	O
used	O
in	O
plant	O
proteomics	O
,	O
i.e.	O
,	O
phenol	O
extraction	B-P
,	O
TCA	O
/	O
acetone	O
extraction	B-P
,	O
and	O
TCA	O
/	O
acetone	O
/	O
phenol	O
extraction	B-P
,	O
were	O
qualitatively	O
and	O
quantitatively	O
evaluated	O
based	O
on	O
2DE	O
maps	O
and	O
MS/MS	B-P
analysis	I-P
using	O
the	O
midribs	O
of	O
the	O
10th	O
newly	O
expanded	O
leaves	O
of	O
maize	O
plants	O
.	O

Microscopy	B-P
revealed	O
the	O
existence	O
of	O
substantial	O
amounts	O
of	O
sclerenchyma	O
underneath	O
maize	O
midrib	O
epidermises	O
(	O
particularly	O
abaxial	O
epidermises	O
)	O
.	O

The	O
spot-number	O
order	O
obtained	O
via	O
2DE	B-P
mapping	I-P
was	O
as	O
follows	O
:	O
phenol	O
extraction	B-P
(	O
655	O
)	O
>	O
TCA	O
/	O
acetone	O
extraction	B-P
(	O
589	O
)	O
>	O
TCA	O
/	O
acetone	O
/	O
phenol	O
extraction	B-P
(	O
545	O
)	O
.	O

MS/MS	B-P
analysis	I-P
identified	O
a	O
total	O
of	O
17	O
spots	O
that	O
exhibited	O
2-fold	O
changes	O
in	O
abundance	O
among	O
the	O
three	O
methods	O
(	O
using	O
phenol	O
extraction	B-P
as	O
a	O
control	O
)	O
.	O

Sixteen	O
of	O
the	O
proteins	O
identified	O
were	O
hydrophilic	O
,	O
with	O
GRAVY	O
values	O
ranging	O
from	O
-0.026	O
to	O
-0.487	O
.	O

For	O
all	O
three	O
methods	O
,	O
we	O
were	O
able	O
to	O
obtain	O
high-quality	O
protein	O
samples	O
and	O
good	O
2DE	B-P
maps	I-P
for	O
the	O
maize	O
leaf	O
midrib	O
.	O

However	O
,	O
phenol	O
extraction	B-P
produced	O
a	O
better	O
2DE	B-P
map	I-P
with	O
greater	O
resolution	O
between	O
spots	O
,	O
and	O
TCA	O
/	O
acetone	O
extraction	B-P
produced	O
higher	O
protein	O
yields	O
.	O

Thus	O
,	O
this	O
paper	O
includes	O
a	O
discussion	O
regarding	O
the	O
possible	O
reasons	O
for	O
differential	O
protein	B-P
extraction	I-P
among	O
the	O
three	O
methods	O
.	O

This	O
study	O
provides	O
useful	O
information	O
that	O
can	O
be	O
used	O
to	O
select	O
suitable	O
protein	B-P
extraction	I-P
methods	O
for	O
the	O
proteome	O
analysis	B-P
of	O
recalcitrant	O
plant	O
tissues	O
that	O
are	O
rich	O
in	O
sclerenchyma	O
cells	O
.	O

Leptin	O
receptor	O
antagonism	O
of	O
iNKT	O
cell	O
function	O
:	O
a	O
novel	O
strategy	O
to	O
combat	O
multiple	O
myeloma	O
.	O

A	O
hallmark	O
of	O
bone	O
marrow	O
changes	O
with	O
aging	O
is	O
the	O
increase	O
in	O
adipocyte	O
composition	O
,	O
but	O
how	O
this	O
impacts	O
development	O
of	O
multiple	O
myeloma	O
(	O
MM	O
)	O
is	O
unknown	O
.	O

Here	O
,	O
we	O
report	O
the	O
role	O
of	O
the	O
adipokine	O
leptin	O
as	O
master	O
regulator	O
of	O
anti-	O
myeloma	O
tumor	O
immunity	O
by	O
modulating	O
the	O
invariant	O
natural	O
killer	O
T	O
(	O
iNKT	O
)	O
cell	O
function	O
.	O

A	O
marked	O
increase	O
in	O
serum	O
leptin	O
levels	O
and	O
leptin	O
receptor	O
(	O
LR	O
)	O
expression	O
on	O
iNKT	O
cells	O
in	O
MM	O
patients	O
and	O
the	O
5T33	O
murine	O
MM	O
model	O
was	O
observed	O
.	O

MM	O
cells	O
and	O
leptin	O
synergistically	O
counteracted	O
anti-tumor	O
functionality	O
of	O
both	O
murine	O
and	O
human	O
iNKT	O
cells	O
.	O

In	O
vivo	O
blockade	O
of	O
LR	O
signalling	O
combined	O
with	O
iNKT	O
stimulation	O
resulted	O
in	O
superior	O
anti-tumor	O
protection	O
.	O

This	O
was	O
linked	O
to	O
persistent	O
IFN-γ	O
secretion	O
upon	O
repeated	O
iNKT	O
cell	O
stimulation	O
and	O
a	O
restoration	O
of	O
the	O
dynamic	O
antigen	O
-	O
induced	O
motility	O
arrest	O
as	O
observed	O
by	O
intravital	B-P
microscopy	I-P
,	O
thereby	O
showing	O
alleviation	O
of	O
iNKT	O
cell	O
anergy	O
.	O

Overall	O
our	O
data	O
reveal	O
the	O
LR	O
axis	O
as	O
novel	O
therapeutic	O
target	O
for	O
checkpoint	O
inhibition	O
to	O
treat	O
MM	O
.Leukemia	O
accepted	O
article	O
preview	O
online	O
,	O
11	O
May	O
2017.	O
doi:10.1038/leu.2017.146	O
.	O

Role	O
of	O
infrared	B-P
spectroscopy	I-P
and	O
imaging	B-P
in	O
cancer	O
diagnosis	O
.	O

FTIR	O
imaging	B-P
has	O
been	O
used	O
to	O
diagnose	O
and	O
differentiate	O
the	O
molecular	O
differences	O
between	O
normal	O
and	O
diseased	O
tissues	O
.	O

The	O
differences	O
correspond	O
to	O
the	O
distribution	O
and	O
structure	O
of	O
lipids	O
,	O
proteins	O
,	O
nucleic	O
acids	O
as	O
well	O
as	O
other	O
metabolites	O
.	O

These	O
differences	O
depended	O
on	O
the	O
type	O
and	O
the	O
grade	O
of	O
cancer	O
.	O

The	O
sensitivity	O
of	O
chemotherapy	O
drugs	O
on	O
individual	O
specific	O
was	O
also	O
discussed	O
.	O

Here	O
,	O
we	O
emphasize	O
that	O
FTIR	O
spectroscopy	O
and	O
imaging	B-P
can	O
be	O
considered	O
as	O
a	O
promising	O
technique	O
and	O
will	O
find	O
its	O
place	O
on	O
the	O
detection	O
of	O
this	O
dreadful	O
disease	O
because	O
of	O
high	B-P
sensitivity	I-P
,	O
accuracy	O
and	O
inexpensive	O
technique	O
.	O

Now	O
the	O
medical	O
community	O
started	O
using	O
and	O
accepting	O
this	O
technique	O
for	O
early	O
stage	O
cancer	O
detection	O
.	O

But	O
,	O
this	O
technique	O
endures	O
several	O
challenges	O
on	O
its	O
application	O
into	O
the	O
diagnosis	O
of	O
cancer	O
in	O
regards	O
of	O
sample	B-P
preparations	I-P
,	O
data	O
interpretation	O
,	O
and	O
data	O
analysis	O
.	O

In	O
general	O
,	O
more	O
research	O
is	O
needed	O
in	O
this	O
field	O
and	O
it	O
is	O
necessary	O
to	O
understand	O
the	O
morphology	O
and	O
biology	O
of	O
the	O
sample	O
before	O
using	O
the	O
spectroscopy	O
and	O
imaging	B-P
because	O
invaluable	O
information	O
to	O
be	O
figured	O
out	O
.	O

Identification	O
of	O
mineral	O
-	O
binding	O
peptides	O
that	O
discriminate	O
between	O
chalcopyrite	O
and	O
enargite	O
.	O

Innovative	O
approaches	O
to	O
the	O
separation	O
of	O
minerals	O
and	O
subsequent	O
extraction	B-P
of	O
metals	O
are	O
imperative	O
owing	O
to	O
the	O
increasing	O
mineralogical	O
complexity	O
of	O
ore	O
deposits	O
that	O
are	O
difficult	O
or	O
even	O
impossible	O
to	O
separate	O
into	O
slurries	O
or	O
solutions	O
containing	O
only	O
the	O
minerals	O
or	O
metals	O
of	O
interest	O
.	O

Low	O
recovery	O
of	O
metal	O
is	O
typical	O
for	O
these	O
complex	O
deposits	O
leading	O
to	O
significant	O
losses	O
to	O
tailings	O
.	O

In	O
addition	O
,	O
the	O
minerals	O
often	O
contain	O
impurities	O
,	O
some	O
toxic	O
,	O
which	O
are	O
difficult	O
and	O
costly	O
to	O
control	O
or	O
manage	O
during	O
the	O
processing	O
of	O
a	O
concentrate	O
or	O
other	O
mineral	O
product	O
.	O

One	O
example	O
of	O
this	O
complex	O
situation	O
is	O
the	O
significant	O
economic	O
and	O
environmental	O
costs	O
associated	O
with	O
diluting	O
and	O
processing	O
copper	O
concentrates	O
containing	O
arsenic	O
(	O
in	O
the	O
form	O
of	O
the	O
mineral	O
enargite	O
,	O
Cu3	O
AsS4	O
)	O
in	O
the	O
production	O
of	O
pure	O
copper	O
.	O

To	O
overcome	O
these	O
separation	O
problems	O
,	O
we	O
have	O
utilized	O
phage	O
display	O
to	O
identify	O
peptides	O
that	O
demonstrate	O
selective	O
recognition	O
of	O
enargite	O
and	O
the	O
arsenic	O
-	O
free	O
copper	O
sulfide	O
,	O
chalcopyrite	O
.	O

Screening	O
of	O
two	O
random	O
peptide	O
phage	O
display	O
libraries	O
resulted	O
in	O
the	O
identification	O
of	O
an	O
enargite	O
-	O
selective	O
peptide	O
with	O
the	O
sequence	O
MHKPTVHIKGPT	O
and	O
a	O
chalcopyrite	O
-	O
selective	O
peptide	O
with	O
the	O
sequence	O
RKKKCKGNCCYTPQ	O
.	O

Mineral	O
-	O
binding	O
selectivity	O
was	O
demonstrated	O
by	O
binding	O
studies	O
,	O
zeta	O
potential	O
determination	B-P
and	O
immunochemistry	O
.	O

Peptides	O
that	O
have	O
the	O
ability	O
to	O
discriminate	O
between	O
enargite	O
and	O
chalcopyrite	O
provide	O
a	O
greener	O
option	O
for	O
the	O
separation	O
of	O
arsenic	O
containing	O
contaminants	O
from	O
copper	O
concentrates	O
.	O

This	O
represents	O
the	O
first	O
step	O
towards	O
a	O
major	O
advance	O
in	O
the	O
replacement	O
or	O
reduction	O
of	O
toxic	O
collectors	O
as	O
well	O
as	O
reducing	O
the	O
level	O
of	O
arsenic	O
-	O
bearing	O
minerals	O
in	O
the	O
early	O
stages	O
of	O
mineral	O
processing	O
.	O

Biotechnol	O
.	O

Bioeng	O
.	O

2016	O
;	O
9999	O
:	O
1-8	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Next-Generation	O
Sequencing	O
Approaches	O
to	O
Define	O
the	O
Role	O
of	O
the	O
Autophagy	O
Lysosomal	O
Pathway	O
in	O
Human	O
Disease	O
:	O
The	O
Example	O
of	O
LysoPlex	O
.	O

Next-Generation	O
Sequencing	O
(	O
NGS	O
)	O
technologies	O
have	O
deeply	O
changed	O
the	O
throughput	O
of	O
genetic	B-P
testing	I-P
allowing	O
analyzing	O
millions	O
of	O
DNA	O
fragments	O
in	O
parallel	O
.	O

One	O
key	O
application	O
is	O
the	O
understanding	O
of	O
genetically	O
heterogeneous	O
and	O
complex	O
diseases	O
where	O
50-100	O
different	O
genes	O
may	O
converge	O
to	O
control	O
the	O
same	O
pathways	O
.	O

These	O
disorders	O
can	O
not	O
be	O
studied	O
using	O
traditional	O
approaches	O
,	O
based	O
on	O
gene-by-gene	O
Sanger	O
sequencing	O
.	O

We	O
have	O
set	O
up	O
an	O
NGS	O
protocol	O
based	O
on	O
a	O
specific	O
selection	O
of	O
DNA	O
regions	O
belonging	O
to	O
about	O
900	O
genes	O
of	O
the	O
autophagy-lysosomal	O
(	O
ALP	O
)	O
pathway	O
.	O

We	O
here	O
specify	O
all	O
the	O
technical	O
steps	O
and	O
challenges	O
of	O
our	O
protocol	O
,	O
named	O
LysoPlex	O
.	O

This	O
is	O
based	O
on	O
the	O
Haloplex	O
technology	O
and	O
together	O
with	O
high-coverage	O
sequencing	O
empowers	O
a	O
high	O
and	O
uniform	O
coverage	O
of	O
ALP	O
genes	O
.	O

LysoPlex	O
outplays	O
other	O
NGS	O
applications	O
in	O
sensitivity	O
and	O
specificity	O
,	O
providing	O
an	O
accurate	O
picture	O
of	O
all	O
variations	O
in	O
ALP	O
genes	O
.	O

Identification	O
of	O
In-Chain-Functionalized	O
Compounds	O
and	O
Methyl-Branched	O
Alkanes	O
in	O
Cuticular	O
Waxes	O
of	O
Triticum	O
aestivum	O
cv	O
.	O

Bethlehem	O
.	O

In	O
this	O
work	O
,	O
cuticular	O
waxes	O
from	O
flag	O
leaf	O
blades	O
and	O
peduncles	O
of	O
Triticum	O
aestivum	O
cv	O
.	O

Bethlehem	O
were	O
investigated	O
in	O
search	O
for	O
novel	O
wax	O
compounds	O
.	O

Seven	O
wax	O
compound	O
classes	O
were	O
detected	O
that	O
had	O
previously	O
not	O
been	O
reported	O
,	O
and	O
their	O
structures	O
were	O
elucidated	O
using	O
gas	B-P
chromatography-mass	I-P
spectrometry	I-P
of	O
various	O
derivatives	O
.	O

Six	O
of	O
the	O
classes	O
were	O
identified	O
as	O
series	O
of	O
homologs	O
differing	O
by	O
two	O
methylene	O
units	O
,	O
while	O
the	O
seventh	O
was	O
a	O
homologous	O
series	O
with	O
homologs	O
with	O
single	O
methylene	O
unit	O
differences	O
.	O

In	O
the	O
waxes	O
of	O
flag	O
leaf	O
blades	O
,	O
secondary	O
alcohols	O
(	O
predominantly	O
C27	O
and	O
C33	O
)	O
,	O
primary	O
/	O
secondary	O
diols	O
(	O
predominantly	O
C28	O
)	O
and	O
esters	O
of	O
primary	O
/	O
secondary	O
diols	O
(	O
predominantly	O
C50	O
,	O
combining	O
C28	O
diol	O
with	O
C22	O
acid	O
)	O
were	O
found	O
,	O
all	O
sharing	O
similar	O
secondary	O
hydroxyl	O
group	O
positions	O
at	O
and	O
around	O
C-12	O
or	O
ω-12	O
.	O

7-	O
and	O
8-hydroxy-2-alkanol	O
esters	O
(	O
predominantly	O
C35	O
)	O
,	O
7-	O
and	O
8-oxo-2-alkanol	O
esters	O
(	O
predominantly	O
C35	O
)	O
,	O
and	O
4-alkylbutan-4-olides	O
(	O
predominantly	O
C28	O
)	O
were	O
found	O
both	O
in	O
flag	O
leaf	O
and	O
peduncle	O
wax	O
mixtures	O
.	O

Finally	O
,	O
a	O
series	O
of	O
even	O
-	O
and	O
odd-numbered	O
alkane	O
homologs	O
was	O
identified	O
in	O
both	O
leaf	O
and	O
peduncle	O
waxes	O
,	O
with	O
an	O
internal	O
methyl	O
branch	O
preferentially	O
on	O
C-11	O
and	O
C-13	O
of	O
homologs	O
with	O
even	O
total	O
carbon	O
number	O
and	O
on	O
C-12	O
of	O
odd-numbered	O
homologs	O
.	O

Biosynthetic	O
pathways	O
are	O
suggested	O
for	O
all	O
compounds	O
,	O
based	O
on	O
common	O
structural	O
features	O
and	O
matching	O
chain	O
length	O
profiles	O
with	O
other	O
wheat	O
wax	O
compound	O
classes	O
.	O

Effect	O
of	O
Successive	O
Administration	O
of	O
Vancomycin	O
and	O
Amikacin	O
on	O
Auditory	O
Function	O
of	O
Immature	O
Animals	O
.	O

Effect	O
of	O
successive	O
administration	O
vancomycin	O
and	O
amikacin	O
in	O
therapeutic	O
doses	O
on	O
immature	O
auditory	O
organ	O
was	O
compared	O
to	O
single	O
administration	O
of	O
the	O
same	O
drugs	O
in	O
chronic	O
experiments	O
on	O
immature	O
rabbits	O
by	O
recording	O
of	O
short-latency	O
auditory	O
brainstem	O
response	O
(	O
ABR	O
)	O
and	O
distortion	B-P
product	I-P
otoacoustic	I-P
emission	I-P
(	O
DPOAE	B-P
)	O
.	O

Drug	O
administration	O
always	O
increased	O
significantly	O
the	O
ABR	O
peak	O
I	O
threshold	O
.	O

Ototoxic	O
antibiotics	O
did	O
not	O
change	O
DPOAE	B-P
,	O
but	O
selectively	O
affected	O
activity	O
of	O
outer	O
hair	O
cells	O
.	O

No	O
enhancement	O
of	O
the	O
ototoxic	O
effects	O
was	O
observed	O
after	O
successive	O
administration	O
of	O
the	O
two	O
antibiotics	O
.	O

Meibomian	O
gland	O
dysfunction	O
and	O
its	O
determinants	O
in	O
Iranian	O
adults	O
:	O
A	O
population-based	O
study	O
.	O

To	O
estimate	O
the	O
prevalence	O
of	O
Meibomian	O
gland	O
dysfunction	O
(	O
MGD	O
)	O
and	O
determine	O
the	O
associated	O
factors	O
in	O
the	O
general	O
population	O
in	O
Iran	O
.	O

This	O
cross-sectional	O
study	O
is	O
based	O
on	O
the	O
data	O
from	O
the	O
second	O
phase	O
of	O
the	O
Shahroud	O
Eye	O
Cohort	O
Study	O
conducted	O
in	O
2014	O
.	O

Of	O
the	O
4737	O
participants	O
of	O
the	O
second	O
phase	O
,	O
data	O
was	O
available	O
for	O
4700	O
people	O
;	O
their	O
mean	O
age	O
was	O
55.9±6.2	O
years	O
and	O
2768	O
(	O
58.9	O
%	O
)	O
were	O
women	O
.	O

Diagnosis	O
of	O
MGD	O
was	O
made	O
based	O
on	O
the	O
classification	O
of	O
the	O
International	O
Workshop	O
on	O
MGD	O
as	O
judged	O
by	O
the	O
examining	O
ophthalmologist	O
.	O

The	O
prevalence	O
of	O
MGD	O
was	O
summarized	O
as	O
percentage	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
,	O
and	O
related	O
factors	O
were	O
studied	O
through	O
simple	O
and	O
multiple	O
logistic	O
regressions	O
.	O

The	O
diagnosis	O
of	O
MGD	O
in	O
at	O
least	O
one	O
eye	O
was	O
recorded	O
for	O
1235	O
(	O
26.3	O
%	O
)	O
participants	O
;	O
the	O
prevalence	O
of	O
unilateral	O
and	O
bilateral	O
MGD	O
was	O
26.3	O
%	O
(	O
95	O
%	O
CI	O
:	O
24.5-28.1	O
)	O
and	O
26.1	O
%	O
(	O
95	O
%	O
CI	O
:	O
24.3-27.9	O
)	O
,	O
respectively	O
.	O

In	O
the	O
multiple	O
logistic	O
regression	O
analyses	O
,	O
MGD	O
significantly	O
correlated	O
with	O
pinguecula	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=1.3	O
,	O
95	O
%	O
CI	O
:	O
1.12-1.50	O
]	O
,	O
hypertension	O
(	O
OR	O
=1.34	O
,	O
95	O
%	O
CI	O
:	O
1.11-1.61	O
)	O
,	O
high-density	B-P
lipoprotein	I-P
(	I-P
HDL	I-P
)	I-P
level	I-P
(	O
OR	O
=0.0992	O
,	O
95	O
%	O
CI	O
:	O
0.986-0.999	O
)	O
,	O
diabetes	O
mellitus	O
(	O
OR	O
=0.83	O
,	O
95	O
%	O
CI	O
:	O
0.71-0.97	O
)	O
,	O
and	O
years	O
of	O
education	O
(	O
OR	O
=0.98	O
,	O
95	O
%	O
CI	O
:	O
0.96-0.99	O
)	O
.	O

MGD	O
prevalence	O
in	O
this	O
study	O
was	O
lower	O
than	O
the	O
rates	O
reported	O
in	O
other	O
studies	O
on	O
Asian	O
populations	O
.	O

Besides	O
HDL	B-P
level	I-P
,	O
MGD	O
is	O
associated	O
with	O
another	O
ocular	O
surface	O
disorder	O
,	O
namely	O
pinguecula	O
,	O
as	O
well	O
as	O
certain	O
systemic	O
diseases	O
such	O
as	O
hypertension	O
and	O
diabetes	O
mellitus	O
.	O

These	O
associations	O
should	O
be	O
taken	O
into	O
consideration	O
when	O
diagnosing	O
MGD	O
.	O

Quadrilateral	O
Space	O
Syndrome	O
:	O
A	O
Case	O
Report	O
.	O

We	O
present	O
a	O
case	O
of	O
quadrilateral	O
space	O
syndrome	O
(	O
QSS	O
)	O
in	O
a	O
patient	O
with	O
left	O
arm	O
pain	O
.	O

The	O
patient	O
sustained	O
a	O
trauma	O
to	O
his	O
left	O
arm	O
,	O
and	O
QSS	O
was	O
successfully	O
diagnosed	O
by	O
physical	O
examination	O
,	O
magnetic	B-P
resonance	I-P
image	I-P
,	O
electromyographic	B-P
evaluation	I-P
,	O
and	O
nerve	B-P
conduction	I-P
studies	I-P
.	O

Surgery	O
was	O
performed	O
to	O
decompress	O
the	O
axillary	O
nerve	O
and	O
the	O
patient	O
recovered	O
fully	O
with	O
minimal	O
residual	O
symptoms	O
.	O

Rapid	O
Fabrication	O
of	O
a	O
Cell	O
-	O
Seeded	B-P
Collagen	O
Gel	O
-Based	O
Tubular	O
Construct	O
that	O
Withstands	O
Arterial	O
Pressure	O
:	O
Rapid	O
Fabrication	O
of	O
a	O
Gel	O
-Based	O
Media	O
Equivalent	O
.	O

Based	O
on	O
plastically	O
compressed	O
cell	O
-	O
seeded	B-P
collagen	O
gels	O
,	O
we	O
fabricated	O
a	O
small-diameter	O
tubular	O
construct	O
that	O
withstands	O
arterial	O
pressure	O
without	O
prolonged	O
culture	B-P
in	O
vitro	O
.	O

Specifically	O
,	O
to	O
mimic	O
the	O
microstructure	O
of	O
vascular	O
media	O
,	O
the	O
cell	O
-	O
seeded	B-P
collagen	O
gel	O
was	O
uniaxially	O
stretched	O
prior	O
to	O
plastic	O
compression	O
to	O
align	O
collagen	O
fibers	O
and	O
hence	O
cells	O
in	O
the	O
gel	O
.	O

The	O
resulting	O
gel	O
sheet	O
was	O
then	O
wrapped	O
around	O
a	O
custom-made	O
multi-layered	O
braided	O
tube	O
to	O
form	O
aligned	O
tubular	O
constructs	O
whereas	O
the	O
gel	O
sheet	O
prepared	O
similarly	O
but	O
without	O
uniaxial	O
stretching	O
formed	O
control	O
constructs	O
.	O

With	O
the	O
braided	O
tube	O
,	O
fluid	O
in	O
the	O
gel	O
construct	O
was	O
further	O
removed	O
by	O
vacuum	O
suction	O
aiming	O
to	O
consolidate	O
the	O
concentric	O
layers	O
of	O
the	O
construct	O
.	O

The	O
construct	O
was	O
finally	O
treated	O
with	O
transglutaminase	O
.	O

Both	O
SEM	B-P
and	O
histology	B-P
confirmed	O
the	O
absence	O
of	O
gaps	O
in	O
the	O
wall	O
of	O
the	O
construct	O
.	O

Particularly	O
,	O
cells	O
in	O
the	O
wall	O
of	O
the	O
aligned	O
tubular	O
construct	O
were	O
circumferentially	O
aligned	O
.	O

The	O
enzyme	O
-mediated	O
crosslinking	O
increased	O
burst	O
pressure	O
of	O
both	O
the	O
constructs	O
significantly	O
;	O
the	O
extent	O
of	O
the	O
increase	O
of	O
burst	O
pressure	O
for	O
the	O
aligned	O
tubular	O
construct	O
was	O
greater	O
than	O
that	O
for	O
the	O
control	O
counterpart	O
.	O

Increasing	O
crosslinking	O
left	O
the	O
compliance	O
of	O
the	O
aligned	O
tubular	O
construct	O
unchanged	O
but	O
reduced	O
that	O
of	O
the	O
control	O
construct	O
.	O

Cells	O
remained	O
viable	O
in	O
transglutaminase	O
-treated	O
plastically	O
compressed	O
gels	O
after	O
6	O
days	O
in	O
culture	O
.	O

This	O
study	O
demonstrated	O
that	O
by	O
combining	O
stretch-induced	O
fiber	O
alignment	O
,	O
plastic	O
compression	O
,	O
and	O
enzyme	O
-mediated	O
crosslinking	O
,	O
a	O
cell	O
-	O
seeded	B-P
collagen	O
gel	O
-based	O
tubular	O
construct	O
with	O
potential	O
to	O
be	O
used	O
as	O
vascular	O
media	O
can	O
be	O
made	O
within	O
3	O
days	O
.	O

Green	O
and	O
rapid	O
synthesis	O
of	O
silver	O
nanoparticles	O
using	O
Borago	O
officinalis	O
leaf	O
extract	O
:	O
anticancer	O
and	O
antibacterial	O
activities	O
.	O

This	O
study	O
highlights	O
the	O
facile	O
,	O
reliable	O
,	O
cost	O
effective	O
,	O
and	O
ecofriendly	O
synthesis	O
of	O
silver	O
nanoparticles	O
(	O
AgNPs	O
)	O
using	O
Borago	O
officinalis	O
leaves	O
extract	O
efficiently	O
.	O

The	O
biosynthesis	O
of	O
AgNPs	O
was	O
verified	O
by	O
UV-Vis	O
spectrum	O
which	O
showed	O
the	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
band	O
at	O
422	O
nm	O
.	O

Transmission	B-P
electron	I-P
microscope	I-P
(	I-P
TEM	I-P
)	I-P
analysis	I-P
revealed	O
that	O
the	O
particles	O
were	O
spherical	O
,	O
hexagonal	O
,	O
and	O
irregular	O
in	O
shape	O
and	O
had	O
size	O
ranging	O
from	O
30	O
to	O
80	O
nm	O
.	O

The	O
energy	B-P
dispersive	I-P
X-ray	I-P
spectroscopy	I-P
(	O
EDX	B-P
)	O
and	O
elemental	B-P
mapping	I-P
have	O
displayed	O
the	O
purity	O
and	O
maximum	O
distribution	O
of	O
silver	O
in	O
the	O
AgNPs	O
.	O

The	O
crystalline	O
nature	O
of	O
AgNPs	O
had	O
been	O
identified	O
using	O
X-ray	B-P
diffraction	I-P
(	O
XRD	B-P
)	O
and	O
selected	B-P
area	I-P
diffraction	I-P
pattern	I-P
(	O
SAED	O
)	O
.	O

The	O
particle	O
size	O
analysis	O
revealed	O
that	O
the	O
Z-average	O
diameter	O
of	O
the	O
AgNPs	O
was	O
50.86	O
nm	O
with	O
polydispersity	O
index	O
(	O
PDI	O
)	O
0.136	O
.	O

Zeta	O
potential	O
analysis	O
displayed	O
the	O
colloidal	O
stability	O
of	O
AgNPs	O
.	O

This	O
work	O
also	O
showed	O
the	O
efficacy	O
of	O
AgNPs	O
against	O
lung	O
cancer	O
cell	O
lines	O
(	O
A549	O
)	O
and	O
cervical	O
cancer	O
cell	O
line	O
(	O
HeLa	O
)	O
,	O
in	O
vitro	O
.	O

The	O
AgNPs	O
showed	O
cytotoxicity	O
to	O
the	O
A549	O
and	O
HeLa	O
cancer	O
cell	O
line	O
at	O
the	O
concentrations	O
5	O
and	O
2	O
μg/ml	O
.	O

The	O
AgNPs	O
were	O
also	O
explored	O
for	O
the	O
antibacterial	O
activity	O
including	O
biofilm	O
inhibition	O
against	O
pathogenic	O
bacteria	O
.	O

The	O
B.	O
officinalis	O
leaves	O
extract	O
can	O
be	O
used	O
efficiently	O
for	O
green	O
synthesis	O
AgNPs	O
.	O

The	O
biosynthesized	O
AgNPs	O
demonstrated	O
potentials	O
as	O
anticancer	O
and	O
antibacterial	O
agents	O
.	O

This	O
work	O
provides	O
helpful	O
insight	O
into	O
the	O
development	O
of	O
new	O
anticancer	O
and	O
antimicrobial	O
agents	O
.	O

Mercury	O
Mining	O
in	O
Mexico	O
:	O
I	O
.	O

Community	O
Engagement	O
to	O
Improve	O
Health	O
Outcomes	O
from	O
Artisanal	O
Mining	O
.	O

Mercury	O
is	O
an	O
element	O
that	O
can	O
not	O
be	O
destroyed	O
and	O
is	O
a	O
global	O
threat	O
to	O
human	O
and	O
environmental	O
health	O
.	O

In	O
Latin	O
America	O
and	O
the	O
Caribbean	O
,	O
artisanal	O
and	O
small-scale	O
gold	O
mining	O
represents	O
the	O
main	O
source	O
of	O
mercury	O
emissions	O
,	O
releases	O
,	O
and	O
consumption	O
.	O

However	O
,	O
another	O
source	O
of	O
concern	O
is	O
the	O
primary	O
production	O
of	O
mercury	O
.	O

In	O
the	O
case	O
of	O
Mexico	O
,	O
in	O
the	O
past	O
2	O
years	O
the	O
informal	O
production	O
of	O
mercury	O
mining	O
has	O
increased	O
10-fold	O
.	O

Considering	O
this	O
scenario	O
,	O
an	O
intervention	O
program	O
was	O
initiated	O
to	O
reduce	O
health	O
risks	O
in	O
the	O
mining	O
communities	O
.	O

The	O
program	O
's	O
final	O
goal	O
is	O
to	O
introduce	O
different	O
alternatives	O
in	O
line	O
to	O
stop	O
the	O
mining	O
of	O
mercury	O
,	O
but	O
introducing	O
at	O
the	O
same	O
time	O
,	O
a	O
community	O
-based	O
development	O
program	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
present	O
results	O
from	O
a	O
preliminary	O
study	O
in	O
the	O
community	O
of	O
Plazuela	O
,	O
located	O
in	O
the	O
municipality	O
of	O
Peñamiller	O
in	O
the	O
State	O
of	O
Queretaro	O
,	O
Mexico	O
.	O

Total	O
mercury	O
was	O
measured	O
in	O
urine	O
and	O
environmental	O
samples	O
using	O
atomic	B-P
absorption	I-P
spectrometry	I-P
by	I-P
cold	I-P
vapor	I-P
technique	I-P
.	O

Urine	O
samples	O
were	O
collected	O
from	O
children	O
aged	O
6-14	O
years	O
and	O
who	O
had	O
lived	O
in	O
the	O
selected	O
area	O
from	O
birth	O
.	O

Urine	O
samples	O
were	O
also	O
collected	O
from	O
miners	O
who	O
were	O
currently	O
working	O
in	O
the	O
mine	O
.	O

To	O
confirm	O
the	O
presence	O
of	O
mercury	O
in	O
the	O
community	O
,	O
mining	O
waste	O
,	O
water	O
,	O
soil	O
,	O
and	O
sediment	O
samples	O
were	O
collected	O
from	O
those	O
high-risk	O
areas	O
identified	O
by	O
members	O
of	O
the	O
community	O
.	O

Children	O
,	O
women	O
,	O
and	O
miners	O
were	O
heavily	O
exposed	O
to	O
mercury	O
(	O
urine	O
samples	O
)	O
;	O
and	O
in	O
agreement	O
,	O
we	O
registered	O
high	O
concentrations	O
of	O
mercury	O
in	O
soils	O
and	O
sediments	O
.	O

Considering	O
these	O
results	O
and	O
taking	O
into	O
account	O
that	O
the	O
risk	O
perception	O
toward	O
mercury	O
toxicity	O
is	O
very	O
low	O
in	O
the	O
community	O
(	O
mining	O
is	O
the	O
only	O
economic	O
activity	O
)	O
,	O
an	O
integral	O
intervention	O
program	O
has	O
started	O
.	O

MiR-4638-5p	O
inhibits	O
castration	O
resistance	O
of	O
prostate	O
cancer	O
through	O
repressing	O
Kidins220	O
expression	O
and	O
PI3K/AKT	O
pathway	O
activity	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
short	O
,	O
conserved	O
segments	O
of	O
non-coding	O
RNA	O
which	O
play	O
a	O
significant	O
role	O
in	O
prostate	O
cancer	O
development	O
and	O
progression	O
.	O

To	O
identify	O
miRNAs	O
associated	O
with	O
castration	O
resistance	O
,	O
we	O
performed	O
miRNA	B-P
microarray	I-P
analysis	I-P
comparing	O
castration	O
resistant	O
prostate	O
cancer	O
(	O
CRPC	O
)	O
with	O
androgen	O
dependent	O
prostate	O
cancer	O
(	O
ADPC	O
)	O
.	O

We	O
identified	O
common	O
underexpression	O
of	O
miR-4638-5p	O
in	O
CRPC	O
compared	O
to	O
ADPC	O
samples	O
,	O
which	O
were	O
further	O
confirmed	O
by	O
quantitative	B-P
PCR	I-P
analysis	I-P
.	O

The	O
role	O
of	O
miR-4638-5p	O
in	O
prostate	O
cancer	O
androgen-independent	O
growth	O
has	O
been	O
demonstrated	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
also	O
identified	O
Kidins220	O
as	O
a	O
target	O
gene	O
directly	O
regulated	O
by	O
miR-4638-5p	O
and	O
shRNA	O
-mediated	O
knockdown	O
of	O
Kidins220	O
phenocopied	O
miR-4638-5p	O
restoration	O
.	O

Subsequently	O
,	O
we	O
revealed	O
that	O
Kidins220	O
activates	O
PI3K/AKT	O
pathway	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
CRPC	O
.	O

Loss	O
of	O
miR-	O
4638-5p	O
may	O
lead	O
to	O
CRPC	O
through	O
the	O
activity	O
of	O
Kidins220	O
and	O
PI3K/AKT	O
pathway	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
miR-4638-5p	O
,	O
through	O
regulating	O
Kidins220	O
and	O
the	O
downstream	O
activity	O
of	O
VEGF	O
and	O
PI3K/AKT	O
pathway	O
,	O
influences	O
prostate	O
cancer	O
progression	O
via	O
angiogenesis	O
.	O

The	O
identification	O
of	O
miR-4638-5p	O
down-regulation	O
in	O
CRPC	O
and	O
the	O
understanding	O
of	O
the	O
functional	O
role	O
of	O
miR-4638-5p	O
and	O
its	O
downstream	O
genes	O
/	O
pathways	O
have	O
the	O
potential	O
to	O
develop	O
biomarkers	O
for	O
CRPC	O
onset	O
and	O
to	O
identify	O
novel	O
targets	O
for	O
novel	O
forms	O
of	O
treatments	O
of	O
this	O
lethal	O
form	O
of	O
PCa	O
.	O

Update	O
on	O
the	O
Role	O
of	O
Cardiac	B-P
Magnetic	I-P
Resonance	I-P
in	O
Acquired	O
Nonischemic	O
Cardiomyopathies	O
.	O

Cardiomyopathies	O
refer	O
to	O
a	O
variety	O
of	O
myocardial	O
disorders	O
without	O
underlying	O
coronary	O
artery	O
disease	O
,	O
valvular	O
heart	O
disease	O
,	O
hypertension	O
,	O
or	O
congenital	O
heart	O
disease	O
.	O

Several	O
imaging	O
modalities	O
are	O
available	O
,	O
but	O
cardiac	B-P
magnetic	I-P
resonance	I-P
(	O
CMR	B-P
)	O
has	O
now	O
established	O
itself	O
as	O
a	O
crucial	O
imaging	B-P
technique	I-P
in	O
the	O
evaluation	O
of	O
several	O
cardiomyopathies	O
.	O

It	O
not	O
only	O
provides	O
comprehensive	O
information	O
on	O
structure	O
and	O
function	O
,	O
but	O
also	O
can	O
perform	O
tissue	O
characterization	O
,	O
which	O
helps	O
in	O
establishing	O
the	O
etiology	O
of	O
cardiomyopathy	O
.	O

CMR	B-P
is	O
also	O
useful	O
in	O
establishing	O
the	O
diagnosis	O
,	O
providing	O
guidance	O
for	O
endomyocardial	B-P
biopsy	I-P
,	O
accurate	O
quantification	O
of	O
function	O
,	O
volumes	O
,	O
and	O
fibrosis	O
,	O
prognostic	O
determination	O
,	O
risk	O
stratification	O
,	O
and	O
monitoring	O
response	O
to	O
therapy	O
.	O

In	O
this	O
article	O
,	O
we	O
review	O
the	O
current	O
role	O
of	O
CMR	B-P
in	O
the	O
evaluation	O
of	O
several	O
acquired	O
nonischemic	O
cardiomyopathies	O
,	O
particularly	O
focusing	O
on	O
recent	O
advances	O
in	O
knowledge	O
.	O

We	O
also	O
discuss	O
in	O
detail	O
a	O
select	O
group	O
of	O
common	O
acquired	O
nonischemic	O
cardiomyopathies	O
.	O

Implementation	O
of	O
infrared	B-P
and	O
Raman	B-P
modalities	O
for	O
glycosaminoglycan	O
characterization	O
in	O
complex	O
systems	O
.	O

Glycosaminoglycans	O
(	O
GAGs	O
)	O
are	O
natural	O
,	O
linear	O
and	O
negatively	O
charged	O
heteropolysaccharides	O
which	O
are	O
incident	O
in	O
every	O
mammalian	O
tissue	O
.	O

They	O
consist	O
of	O
repeating	O
disaccharide	O
units	O
,	O
which	O
are	O
composed	O
of	O
either	O
sulfated	O
or	O
non-sulfated	O
monosaccharides	O
.	O

Depending	O
on	O
tissue	O
types	O
,	O
GAGs	O
exhibit	O
structural	O
heterogeneity	O
such	O
as	O
the	O
position	O
and	O
degree	O
of	O
sulfation	O
or	O
within	O
their	O
disaccharide	O
units	O
composition	O
being	O
heparin	O
,	O
heparan	O
sulfate	O
,	O
chondroitine	O
sulfate	O
,	O
dermatan	O
sulfate	O
,	O
keratan	O
sulfate	O
,	O
and	O
hyaluronic	O
acid	O
.	O

They	O
are	O
covalently	O
linked	O
to	O
a	O
core	O
protein	O
(	O
proteoglycans	O
)	O
or	O
as	O
free	O
chains	O
(	O
hyaluronan	O
)	O
.	O

GAGs	O
affect	O
cell	O
properties	O
and	O
functions	O
either	O
by	O
direct	O
interaction	O
with	O
cell	O
receptors	O
or	O
by	O
sequestration	O
of	O
growth	O
factors	O
.	O

These	O
evidences	O
of	O
divert	O
biological	O
roles	O
of	O
GAGs	O
make	O
their	O
characterization	O
at	O
cell	O
and	O
tissue	O
levels	O
of	O
importance	O
.	O

Thus	O
,	O
non-invasive	O
techniques	O
are	O
interesting	O
to	O
investigate	O
,	O
to	O
qualitatively	O
and	O
quantitatively	O
characterize	O
GAGs	O
in	O
vitro	O
in	O
order	O
to	O
use	O
them	O
as	O
diagnostic	O
biomarkers	O
and/or	O
as	O
therapeutic	O
targets	O
in	O
several	O
human	O
diseases	O
including	O
cancer	O
.	O

Infrared	B-P
and	O
Raman	B-P
microspectroscopies	I-P
and	O
imaging	B-P
are	O
sensitive	O
enough	O
to	O
differentiate	O
and	O
classify	O
GAG	O
types	O
and	O
subtypes	O
in	O
spite	O
of	O
their	O
close	O
molecular	O
structures	O
.	O

Spectroscopic	B-P
markers	O
characteristic	O
of	O
reference	O
GAG	O
molecules	O
were	O
identified	O
.	O

Beyond	O
these	O
investigations	O
of	O
the	O
standard	O
GAG	O
spectral	O
signature	O
,	O
infrared	B-P
and	O
Raman	B-P
spectral	O
signatures	O
of	O
GAG	O
were	O
searched	O
in	O
complex	O
biological	O
systems	O
like	O
cells	O
.	O

The	O
aim	O
of	O
the	O
present	O
review	O
is	O
to	O
describe	O
the	O
implementation	O
of	O
these	O
complementary	O
vibrational	B-P
spectroscopy	I-P
techniques	I-P
,	O
and	O
to	O
discuss	O
their	O
potentials	O
,	O
advantages	O
and	O
disadvantages	O
for	O
GAG	O
analysis	B-P
.	O

In	O
addition	O
,	O
this	O
review	O
presents	O
new	O
data	O
as	O
we	O
show	O
for	O
the	O
first	O
time	O
GAG	O
infrared	B-P
and	O
Raman	B-P
spectral	O
signatures	O
from	O
conditioned	O
media	O
and	O
live	O
cells	O
,	O
respectively	O
.	O

Aquaporin-2	O
excretion	O
in	O
hospitalized	O
patients	O
with	O
cirrhosis	O
:	O
Relation	O
to	O
development	O
of	O
renal	O
insufficiency	O
and	O
mortality	O
.	O

Urinary	O
aquaporin-2	O
(	O
AQP2	O
)	O
is	O
a	O
parameter	O
of	O
water	O
transport	O
in	O
the	O
principal	O
cells	O
in	O
the	O
distal	O
part	O
of	O
the	O
nephron	O
and	O
involved	O
in	O
water	O
retention	O
in	O
cirrhosis	O
and	O
may	O
be	O
a	O
marker	O
of	O
renal	O
function	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
AQP2	O
as	O
a	O
predictor	O
of	O
renal	O
insufficiency	O
and	O
death	O
in	O
patients	O
with	O
cirrhosis	O
.	O

Urine	O
samples	O
from	O
199	O
patients	O
(	O
90	O
patients	O
without	O
organ	O
failure	O
[	O
Group	O
1	O
]	O
,	O
58	O
patients	O
with	O
organ	O
failure	O
excluding	O
renal	O
failure	O
[	O
Group	O
2	O
]	O
,	O
and	O
51	O
patients	O
with	O
organ	O
failure	O
including	O
renal	O
failure	O
[	O
Group	O
3	O
]	O
)	O
from	O
the	O
CANONIC	O
study	O
were	O
analyzed	O
for	O
urine	O
AQP2	O
and	O
urine	O
osmolality	O
.	O

There	O
was	O
no	O
difference	O
in	O
AQP2	O
between	O
the	O
three	O
groups	O
.	O

Urine	O
osmolality	O
was	O
significantly	O
lower	O
in	O
patients	O
in	O
Group	O
3	O
versus	O
Group	O
1	O
and	O
Group	O
2	O
(	O
P	O
=	O
0.0004	O
)	O
.	O

No	O
relation	O
was	O
found	O
between	O
AQP2	O
and	O
glomerular	B-P
filtration	I-P
rate	I-P
or	O
creatinine	O
;	O
however	O
,	O
AQP2	O
was	O
a	O
significant	O
predictor	O
of	O
the	O
development	O
of	O
renal	O
insufficiency	O
(	O
P	O
=	O
0.0485	O
)	O
.	O

In	O
a	O
univariate	O
analysis	O
,	O
AQP2	O
was	O
a	O
significant	O
predictor	O
of	O
14	O
and	O
28-day	O
survival	O
,	O
but	O
this	O
was	O
not	O
confirmed	O
in	O
multivariate	O
analysis	O
.	O

Aquaporin-2	O
was	O
not	O
associated	O
with	O
disease	O
severity	O
or	O
markers	O
of	O
renal	O
function	O
but	O
was	O
a	O
predictor	O
for	O
the	O
development	O
of	O
renal	O
insufficiency	O
and	O
death	O
.	O

Therefore	O
,	O
its	O
future	O
use	O
as	O
marker	O
of	O
renal	O
insufficiency	O
could	O
be	O
promising	O
,	O
but	O
further	O
research	O
is	O
needed	O
before	O
it	O
can	O
be	O
considered	O
a	O
clinical	O
useful	O
tool	O
.	O

Mild	O
encephalitis/encephalopathy	O
with	O
reversible	O
splenial	O
lesion	O
(	O
MERS	O
)	O
associated	O
with	O
Streptococcus	O
pneumoniae	O
Bacteraemia	O
.	O

Mild	O
encephalopathy	O
with	O
a	O
reversible	O
splenial	O
lesion	O
(	O
MERS	O
)	O
is	O
a	O
clinico-radiological	O
syndrome	O
that	O
can	O
be	O
related	O
to	O
infectious	O
and	O
non-infectious	O
conditions	O
.	O

Patients	O
present	O
with	O
mild	O
neurological	O
symptoms	O
,	O
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
typically	O
demonstrate	O
a	O
reversible	O
lesion	O
with	O
transiently	O
reduced	O
diffusion	O
in	O
the	O
splenium	O
of	O
the	O
corpus	O
callosum	O
.	O

Here	O
,	O
we	O
describe	O
MERS	O
in	O
a	O
10-year-old	O
boy	O
who	O
presented	O
with	O
fever	O
and	O
consciousness	O
and	O
who	O
completely	O
recovered	O
within	O
a	O
few	O
days	O
.	O

Streptococcus	O
pneumoniae	O
was	O
the	O
causative	O
agent	O
.	O

Although	O
viruses	O
(	O
especially	O
influenza	O
A	O
and	O
B	O
)	O
are	O
the	O
most	O
common	O
pathogen	O
of	O
MERS	O
,	O
for	O
proper	O
management	O
,	O
bacteria	O
should	O
be	O
considered	O
,	O
as	O
they	O
may	O
also	O
lead	O
to	O
this	O
condition	O
.	O

Limited	O
effectiveness	O
of	O
patent	O
blue	O
dye	O
in	O
addition	O
to	O
isotope	B-P
scanning	I-P
for	O
identification	B-P
of	O
sentinel	O
lymph	O
nodes	O
:	O
Cross-sectional	O
real-life	O
study	O
in	O
1024	O
breast	O
cancer	O
patients	O
.	O

Although	O
morbidity	O
is	O
reduced	O
when	O
sentinel	B-P
lymph	I-P
node	I-P
(	I-P
SLN	I-P
)	I-P
biopsy	I-P
is	O
performed	O
with	O
dual	B-P
isotopic	I-P
and	O
blue	O
dye	O
identification	B-P
,	O
the	O
effectiveness	O
of	O
adding	O
blue	O
dye	O
to	O
radioisotope	O
remains	O
debated	O
because	O
side	O
effects	O
including	O
anaphylactic	O
reactions	O
.	O

Using	O
data	O
from	O
a	O
prospectively	O
maintained	O
database	O
,	O
1884	O
lymph	O
node-negative	O
breast	O
cancer	O
patients	O
who	O
underwent	O
partial	O
mastectomy	O
with	O
SLN	B-P
mapping	I-P
by	O
a	O
dual-tracer	O
using	O
patent	O
blue	O
dye	O
(	O
PBD	O
)	O
and	O
radioisotope	O
were	O
retrospectively	O
studied	O
between	O
January	O
2000	O
and	O
July	O
2013	O
.	O

Patients	O
with	O
tumors	O
<	O
3	O
cm	O
and	O
with	O
>	O
1	O
node	O
detected	O
by	O
one	O
of	O
the	O
two	O
techniques	O
(	O
N	O
=	O
1024	O
)	O
were	O
included	O
in	O
this	O
real-life	O
cross-sectional	O
study	O
.	O

Among	O
the	O
1024	O
patients	O
,	O
274	O
had	O
positive	O
SLN	O
detected	O
by	O
isotopic	O
and/or	O
PBD	O
staining	B-P
.	O

Only	O
4	O
patients	O
having	O
no	O
detectable	O
radioactivity	O
in	O
the	O
axilla	O
had	O
SLN	O
identified	O
only	O
by	O
PBD	O
staining	B-P
(	O
blue-only	O
)	O
while	O
26	O
patients	O
had	O
SLN	O
only	O
identified	O
by	O
isotopic	O
detection	O
(	O
hot-only	O
)	O
illustrating	O
failure	O
rates	O
of	O
9.5	O
%	O
(	O
26/274	O
)	O
and	O
1.5	O
%	O
(	O
4/274	O
)	O
,	O
respectively	O
.	O

Among	O
these	O
four	O
patients	O
,	O
two	O
had	O
negative	O
lymphoscintigraphy	B-P
.	O

Therefore	O
,	O
the	O
contribution	O
of	O
PBD	O
to	O
metastatic	O
nodes	O
identification	B-P
was	O
relevant	O
for	O
only	O
2/274	O
patients	O
(	O
0.8	O
%	O
)	O
.	O

Three	O
patients	O
(	O
0.3	O
%	O
)	O
had	O
an	O
allergic	O
reaction	O
with	O
PBD	O
,	O
and	O
anaphylactic	O
shock	O
occurred	O
in	O
two	O
cases	O
(	O
0.2	O
%	O
)	O
.	O

The	O
added-value	O
of	O
PBD	O
to	O
reduce	O
the	O
false-negative	O
rate	O
of	O
SLN	B-P
mapping	I-P
is	O
only	O
limited	O
to	O
the	O
rare	O
cases	O
in	O
which	O
no	O
radioactivity	O
is	O
detectable	O
in	O
the	O
axilla	O
(	O
<	O
1	O
%	O
)	O
.	O

When	O
a	O
radioisotope	O
mapping	O
agent	O
is	O
available	O
,	O
the	O
use	O
of	O
PBD	O
should	O
be	O
avoided	O
,	O
because	O
it	O
can	O
induce	O
anaphylaxis	O
.	O

The	O
Antibacterial	O
Effect	O
of	O
Additional	O
Photodynamic	O
Therapy	O
in	O
Failed	O
Endodontically	O
Treated	O
Teeth	O
:	O
A	O
Pilot	O
Study	O
.	O

Introduction	O
:	O
Root	O
canal	O
therapy	O
as	O
a	O
routine	O
dental	O
procedure	O
has	O
resulted	O
in	O
retention	O
of	O
millions	O
of	O
teeth	O
that	O
would	O
otherwise	O
be	O
lost	O
.	O

Unfortunately	O
,	O
successful	O
outcomes	O
are	O
not	O
always	O
achievable	O
within	O
initial	O
endodontic	O
treatments	O
,	O
and	O
that	O
necessitates	O
further	O
treatment	O
.	O

Nonsurgical	O
retreatment	O
is	O
the	O
first	O
choice	O
in	O
most	O
clinical	O
situations	O
.	O

The	O
aim	O
of	O
this	O
clinical	O
pilot	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
additional	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
on	O
intraradicular	O
bacterial	O
load	O
following	O
retreatment	O
of	O
failed	O
previously	O
root	O
treated	O
teeth	O
.	O

Methods	O
:	O
Thirty	O
single-rooted	O
/	O
canalled	O
endodontically	O
treated	O
matured	O
teeth	O
(	O
in	O
27	O
healthy	O
patients	O
)	O
accompanied	O
by	O
apical	O
periodontitis	O
(	O
AP	O
)	O
were	O
selected	O
for	O
this	O
study	O
.	O

Standard	O
protocol	O
was	O
followed	O
for	O
nonsurgical	O
retreatment	O
of	O
each	O
tooth	O
.	O

Microbiological	B-P
samples	I-P
were	O
taken	O
after	O
establishment	O
of	O
apical	O
patency	O
,	O
finished	O
cleaning/shaping	O
procedure	O
,	O
and	O
PDT	O
(	O
665	O
nm	O
,	O
1	O
W	O
,	O
240	O
seconds	O
)	O
.	O

All	O
samples	O
were	O
cultured	B-P
for	O
72	O
hours	O
and	O
colony-forming	O
unit	O
(	O
CFU	O
)	O
was	O
counted	O
.	O

McNemar	O
test	O
was	O
used	O
for	O
statistical	O
analysis	O
of	O
the	O
data	O
.	O

The	O
level	O
of	O
significance	O
was	O
set	O
at	O
0.001	O
.	O

Results	O
:	O
Routine	O
cleaning	O
and	O
shaping	O
resulted	O
in	O
twenty	O
four	O
negative	O
(	O
80	O
%	O
)	O
out	O
of	O
30	O
cultures	B-P
.	O

Four	O
additional	O
negative	O
results	O
were	O
obtained	O
after	O
additional	O
PDT	O
(	O
93.3	O
%	O
)	O
.	O

The	O
addition	O
of	O
PDT	O
to	O
routine	O
procedures	O
significantly	O
enhanced	O
the	O
number	O
of	O
bacteria	O
-free	O
samples	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Conclusion	O
:	O
Regarding	O
elimination	O
of	O
intraradicular	O
microbiota	O
,	O
additional	O
PDT	O
may	O
increase	O
the	O
effectiveness	O
of	O
conventional	O
chemomechanical	O
preparation	O
in	O
previously	O
root	O
filled	O
teeth	O
accompanied	O
by	O
AP	O
.	O

Well	O
controlled	O
randomized	O
clinical	O
trials	O
should	O
be	O
planned	O
for	O
future	O
.	O

Visualization	B-P
of	O
the	O
Intimal	O
Flap	O
in	O
Intracranial	O
Arterial	O
Dissection	O
Using	O
High-Resolution	B-P
3T	B-P
MRI	I-P
.	O

Presence	O
of	O
an	O
intimal	O
flap	O
is	O
a	O
critical	O
imaging	O
finding	O
in	O
diagnosing	O
intracranial	O
artery	O
dissection	O
(	O
ICAD	O
)	O
.	O

Recent	O
reports	O
showed	O
that	O
high-resolution	B-P
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
was	O
better	O
at	O
identifying	O
intimal	O
flaps	O
as	O
compared	O
with	O
routine	O
MRI	B-P
techniques	I-P
used	O
in	O
clinical	O
settings	O
.	O

However	O
,	O
no	O
current	O
standardized	O
sequence	O
for	O
high-resolution	B-P
MRI	B-P
without	O
gadolinium	O
enhancement	O
produces	O
images	O
of	O
satisfactory	O
quality	O
with	O
clinically	O
tolerable	O
scanning	B-P
times	O
.	O

This	O
study	O
evaluated	O
a	O
nonenhanced	B-P
high-resolution	I-P
fast	I-P
spin	I-P
echo	I-P
(	I-P
HR-FSE	I-P
)	I-P
MRI	I-P
sequence	O
for	O
visualizing	O
intimal	O
flaps	O
in	O
patients	O
with	O
ICAD	O
.	O

Three	O
patients	O
with	O
ICAD	O
underwent	O
plain	O
MRI	B-P
examination	O
using	O
a	O
2-dimensional	O
T2-weighted	B-P
FSE	I-P
imaging	I-P
sequence	O
optimized	O
for	O
our	O
3T	O
system	O
(	O
in-plane	O
pixel	O
size	O
,	O
.23	O
mm	O
×	O
.23	O
mm	O
;	O
slice	O
thickness	O
3	O
mm	O
with	O
no	O
interslice	O
gap	O
)	O
,	O
as	O
well	O
as	O
scanning	B-P
with	O
conventional	O
modalities	O
,	O
including	O
CT	B-P
angiography	I-P
,	O
magnetic	B-P
resonance	I-P
angiography	I-P
,	O
and	O
digital	B-P
subtraction	I-P
angiography	I-P
.	O

We	O
assessed	O
whether	O
these	O
imaging	O
methods	O
could	O
visualize	O
an	O
intimal	O
flap	O
and/or	O
double	O
lumen	O
sign	O
in	O
the	O
participants	O
and	O
compared	O
the	O
results	O
between	O
HR-FSE	B-P
and	O
the	O
other	O
modalities	O
.	O

HR-FSE	B-P
images	O
clearly	O
showed	O
intimal	O
flaps	O
and	O
double	O
lumen	O
signs	O
in	O
all	O
3	O
patients	O
,	O
whereas	O
the	O
conventional	O
modalities	O
identified	O
a	O
double	O
lumen	O
sign	O
in	O
only	O
2	O
of	O
the	O
3	O
patients	O
.	O

The	O
present	O
method	O
of	O
optimized	O
HR-FSE	B-P
imaging	I-P
with	O
a	O
3T	O
system	O
improved	O
visualization	B-P
of	O
intimal	O
flaps	O
and	O
should	O
thus	O
be	O
considered	O
for	O
assessing	O
patients	O
with	O
suspected	O
ICAD	O
that	O
can	O
not	O
be	O
definitively	O
diagnosed	O
by	O
conventional	O
imaging	O
modalities	O
.	O

Draft	O
Genome	O
Sequence	O
of	O
Bacillus	O
cereus	O
LA2007	O
,	O
a	O
Human-Pathogenic	O
Isolate	O
Harboring	O
Anthrax	O
-Like	O
Plasmids	O
.	O

We	O
present	O
the	O
genome	O
sequence	O
of	O
Bacillus	O
cereus	O
LA2007	O
,	O
a	O
strain	O
isolated	O
in	O
2007	O
from	O
a	O
fatal	O
pneumonia	O
case	O
in	O
Louisiana	O
.	O

Sequence-based	B-P
genome	I-P
analysis	I-P
revealed	O
that	O
LA2007	O
carries	O
a	O
plasmid	O
highly	O
similar	O
to	O
Bacillus	O
anthracis	O
pXO1	O
,	O
including	O
the	O
genes	O
responsible	O
for	O
the	O
production	O
and	O
regulation	O
of	O
anthrax	O
toxin	O
.	O

Unplanned	O
readmissions	O
within	O
30	O
days	O
after	O
discharge	O
:	O
improving	O
quality	O
through	O
easy	O
prediction	O
.	O

To	O
propose	O
an	O
easy	O
predictive	O
model	O
for	O
the	O
risk	O
of	O
rehospitalization	O
,	O
built	O
from	O
hospital	O
administrative	O
data	O
,	O
in	O
order	O
to	O
prevent	O
repeated	O
admissions	O
and	O
to	O
improve	O
transitional	O
care	O
.	O

Retrospective	O
cohort	O
study	O
.	O

Azienda	O
Ospedaliero	O
Universitaria	O
Pisana	O
(	O
Pisa	O
University	O
Hospital	O
)	O
.	O

Patients	O
residing	O
in	O
the	O
territory	O
of	O
the	O
province	O
of	O
Pisa	O
(	O
Tuscany	O
Region	O
)	O
with	O
at	O
least	O
one	O
unplanned	O
hospital	O
admission	O
leading	O
to	O
a	O
medical	O
Diagnosis-Related	O
Group	O
(	O
DRG	O
)	O
in	O
the	O
calendar	O
year	O
2012	O
.	O

We	O
compared	O
two	O
groups	O
of	O
patients	O
:	O
patients	O
coded	O
as	O
'RA30	O
'	O
(	O
readmitted	O
within	O
30	O
days	O
after	O
the	O
previous	O
discharge	O
)	O
and	O
patients	O
coded	O
as	O
'NRA30	O
'	O
(	O
either	O
admitted	O
only	O
once	O
or	O
readmitted	O
after	O
30	O
days	O
since	O
the	O
latest	O
discharge	O
)	O
.	O

The	O
effect	O
of	O
age	O
,	O
sex	O
,	O
length	O
of	O
stay	O
,	O
number	O
of	O
diagnoses	O
,	O
normalized	O
number	O
of	O
admissions	O
and	O
presence	O
of	O
diseases	O
on	O
the	O
probability	O
of	O
rehospitalization	O
within	O
30	O
days	O
after	O
discharge	O
was	O
evaluated	O
.	O

The	O
significant	O
variables	O
included	O
in	O
the	O
predictive	O
model	O
were	O
:	O
age	O
,	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.018	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.011-1.026	O
;	O
normalized	O
number	O
of	O
admissions	O
,	O
OR	O
=	O
1.257	O
,	O
CI	O
=	O
1.225-1.290	O
;	O
number	O
of	O
diagnoses	O
,	O
OR	O
=	O
1.306	O
,	O
CI	O
=	O
1.174-1.452	O
and	O
presence	O
of	O
cancer	B-P
diagnosis	I-P
,	O
OR	O
=	O
1.479	O
,	O
CI	O
=	O
1.088-2.011	O
.	O

The	O
model	O
can	O
be	O
easily	O
applied	O
when	O
discharging	O
patients	O
who	O
have	O
been	O
hospitalized	O
after	O
an	O
access	O
to	O
the	O
Emergency	O
Department	O
to	O
predict	O
the	O
risk	O
of	O
rehospitalization	O
within	O
30	O
days	O
.	O

The	O
prediction	O
can	O
be	O
used	O
to	O
activate	O
focused	O
hospital-primary	O
care	O
transitional	O
interventions	O
.	O

The	O
model	O
has	O
to	O
be	O
validated	O
first	O
in	O
order	O
to	O
be	O
implemented	O
in	O
clinical	O
practice	O
.	O

Altered	O
pH	O
gradient	O
at	O
the	O
plasma	O
membrane	O
of	O
osteosarcoma	O
cells	O
is	O
a	O
key	O
mechanism	O
of	O
drug	O
resistance	O
.	O

Current	O
therapy	O
of	O
osteosarcoma	O
(	O
OS	O
)	O
,	O
the	O
most	O
common	O
primary	O
bone	O
malignancy	O
,	O
is	O
based	O
on	O
a	O
combination	O
of	O
surgery	O
and	O
chemotherapy	O
.	O

Multidrug	O
resistance	O
mediated	O
by	O
P-glycoprotein	O
(	O
P-gp	O
)	O
overexpression	O
has	O
been	O
previously	O
associated	O
with	O
treatment	O
failure	O
and	O
progression	O
of	O
OS	O
,	O
although	O
other	O
mechanisms	O
may	O
also	O
play	O
a	O
role	O
.	O

We	O
considered	O
the	O
typical	O
acidic	O
extracellular	O
pH	O
(	O
pHe	O
)	O
of	O
sarcomas	O
,	O
and	O
found	O
that	O
doxorubicin	O
(	O
DXR	O
)	O
cytotoxicity	O
is	O
reduced	O
in	O
P-gp	O
negative	O
OS	O
cells	O
cultured	O
at	O
pHe	O
6.5	O
compared	O
to	O
standard	O
7.4	O
.	O

Short-time	O
(	O
24-48	O
hours	O
)	O
exposure	O
to	O
low	O
pHe	O
significantly	O
increased	O
the	O
number	O
and	O
acidity	O
of	O
lysosomes	O
,	O
and	O
the	O
combination	O
of	O
DXR	O
with	O
omeprazole	O
,	O
a	O
proton	O
pump	O
inhibitor	O
targeting	O
lysosomal	O
acidity	O
,	O
significantly	O
enhanced	O
DXR	O
cytotoxicity	O
.	O

In	O
OS	O
xenografts	O
,	O
the	O
combination	O
treatment	O
of	O
DXR	O
and	O
omeprazole	O
significantly	O
reduced	O
tumor	O
volume	O
and	O
body	O
weight	O
loss	O
.	O

The	O
impaired	O
toxicity	O
of	O
DXR	O
at	O
low	O
pHe	O
was	O
not	O
associated	O
with	O
increased	O
autophagy	O
or	O
lysosomal	O
acidification	O
,	O
but	O
rather	O
,	O
as	O
shown	O
by	O
SNARF	O
staining	B-P
,	O
with	O
a	O
reversal	O
of	O
the	O
pH	O
gradient	O
at	O
the	O
plasma	O
membrane	O
(	O
ΔpHcm	O
)	O
,	O
eventually	O
leading	O
to	O
a	O
reduced	O
DXR	O
intracellular	O
accumulation	O
.	O

Finally	O
,	O
the	O
reversal	O
of	O
ΔpHcm	O
in	O
OS	O
cells	O
promoted	O
resistance	O
not	O
only	O
to	O
DXR	O
,	O
but	O
also	O
to	O
cisplatin	O
and	O
methotrexate	O
,	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
to	O
vincristine	O
.	O

Altogether	O
,	O
our	O
findings	O
show	O
that	O
,	O
in	O
OS	O
cells	O
,	O
short-term	O
acidosis	O
induces	O
resistance	O
to	O
different	O
chemotherapeutic	O
drugs	O
by	O
a	O
reversal	O
of	O
ΔpHcm	O
,	O
suggesting	O
that	O
buffer	O
therapies	O
or	O
regimens	O
including	O
proton	O
pump	O
inhibitors	O
in	O
combination	O
to	O
low	O
concentrations	O
of	O
conventional	O
anticancer	O
agents	O
may	O
offer	O
novel	O
solutions	O
to	O
overcome	O
drug	O
resistance	O
.	O

Seated	O
maximum	O
flexion	O
:	O
An	O
alternative	O
to	O
standing	O
maximum	O
flexion	O
for	O
determining	O
presence	O
of	O
flexion	O
-	O
relaxation	O
?	O
.	O

The	O
flexion	O
-	O
relaxation	O
phenomenon	O
(	O
FRP	O
)	O
in	O
standing	O
is	O
a	O
specific	O
and	O
sensitive	O
diagnostic	B-P
tool	I-P
for	O
low	O
back	O
pain	O
.	O

Seated	O
flexion	O
as	O
an	O
alternative	O
could	O
be	O
beneficial	O
for	O
certain	O
populations	O
,	O
yet	O
the	O
behavior	O
of	O
the	O
trunk	O
extensors	O
during	O
seated	O
maximum	O
flexion	O
compared	O
to	O
standing	O
flexion	O
remains	O
unclear	O
.	O

Compare	O
FRP	O
occurrences	O
and	O
spine	O
angles	O
between	O
seated	O
and	O
standing	O
flexion	O
postures	O
in	O
three	O
levels	O
of	O
the	O
erector	O
spinae	O
muscles	O
.	O

Thirty-one	O
participants	O
free	O
of	O
back	O
pain	O
performed	O
seated	O
and	O
standing	O
maximum	O
trunk	O
flexion	O
.	O

Electromyographical	O
signals	O
were	O
recorded	O
from	O
the	O
bilateral	O
lumbar	O
(	O
L3	O
)	O
,	O
lower-thoracic	O
(	O
T9	O
)	O
,	O
and	O
upper-thoracic	O
(	O
T4	O
)	O
erector	O
spinae	O
and	O
assessed	O
for	O
the	O
occurrence	O
of	O
FRP	O
.	O

Spine	O
angles	O
corresponding	O
to	O
FRP	O
onset	O
and	O
cessation	O
were	O
determined	O
,	O
and	O
FRP	O
occurrences	O
and	O
angles	O
were	O
compared	O
between	O
posture	O
and	O
muscle	O
.	O

FRP	O
occurrence	O
was	O
similar	O
in	O
standing	O
and	O
seated	O
maximum	O
flexion	O
across	O
all	O
muscles	O
,	O
with	O
the	O
lumbar	O
muscles	O
showing	O
the	O
greatest	O
consistency	O
.	O

Standing	O
FRP	O
onset	O
and	O
cessation	O
angles	O
were	O
consistently	O
greater	O
than	O
the	O
corresponding	O
seated	O
FRP	O
angles	O
.	O

Considering	O
the	O
similar	O
number	O
of	O
FRP	O
occurrences	O
,	O
seated	O
maximum	O
flexion	O
may	O
constitute	O
an	O
objective	O
criterion	O
for	O
low	O
back	O
pain	O
diagnosis	O
.	O

Future	O
work	O
should	O
seek	O
to	O
confirm	O
the	O
utility	O
of	O
this	O
test	O
in	O
individuals	O
with	O
low	O
back	O
pain	O
.	O

Relation	O
of	O
Left	O
Ventricular	O
Mass	O
and	O
Infarct	O
Size	O
in	O
Anterior	O
Wall	O
ST-Segment	O
Elevation	O
Acute	O
Myocardial	O
Infarction	O
(	O
from	O
the	O
EMBRACE	O
STEMI	O
Clinical	O
Trial	O
)	O
.	O

Biomarker	O
measures	O
of	O
infarct	O
size	O
and	O
myocardial	O
salvage	O
index	O
(	O
MSI	O
)	O
are	O
important	O
surrogate	O
measures	O
of	O
clinical	O
outcomes	O
after	O
a	O
myocardial	O
infarction	O
.	O

However	O
,	O
there	O
is	O
variability	O
in	O
infarct	O
size	O
unaccounted	O
for	O
by	O
conventional	O
adjustment	O
factors	O
.	O

This	O
post	O
hoc	O
analysis	O
of	O
Evaluation	O
of	O
Myocardial	O
Effects	O
of	O
Bendavia	O
for	O
Reducing	O
Reperfusion	O
Injury	O
in	O
Patients	O
With	O
Acute	O
Coronary	O
Events	O
(	O
EMBRACE	O
)	O
ST-Segment	O
Elevation	O
Myocardial	O
Infarction	O
(	O
STEMI	O
)	O
trial	O
evaluates	O
the	O
association	O
between	O
left	O
ventricular	O
(	O
LV	O
)	O
mass	O
and	O
infarct	O
size	O
as	O
assessed	O
by	O
areas	O
under	O
the	O
curve	O
for	O
creatine	B-P
kinase-MB	I-P
(	O
CK-MB	B-P
)	O
and	O
troponin	B-P
I	I-P
release	I-P
over	O
the	O
first	O
72	O
hours	O
(	O
CK-MB	B-P
area	O
under	O
the	O
curve	O
[	O
AUC	O
]	O
and	O
troponin	O
I	O
[	O
TnI	O
]	O
AUC	O
)	O
and	O
the	O
MSI	O
.	O

Patients	O
with	O
first	O
anterior	O
STEMI	O
,	O
occluded	O
left	O
anterior	O
descending	O
artery	O
,	O
and	O
available	O
LV	O
mass	O
measurement	O
in	O
EMBRACE	O
STEMI	O
trial	O
were	O
included	O
(	O
n	O
=	O
100	O
)	O
(	O
ClinicalTrials.govNCT01572909	O
)	O
.	O

MSI	O
,	O
end-diastolic	O
LV	O
mass	O
on	O
day	O
4	O
cardiac	B-P
magnetic	I-P
resonance	I-P
,	O
and	O
CK-MB	B-P
and	O
troponin	O
I	O
concentrations	O
were	O
evaluated	O
by	O
a	O
core	O
laboratory	O
.	O

After	O
saturated	O
multivariate	O
analysis	O
,	O
dominance	O
analysis	O
was	O
performed	O
to	O
estimate	O
the	O
contribution	O
of	O
each	O
independent	O
variable	O
to	O
the	O
predicted	O
variance	O
of	O
each	O
outcome	O
.	O

In	O
multivariate	O
models	O
that	O
included	O
age	O
,	O
gender	O
,	O
body	O
surface	O
area	O
,	O
lesion	O
location	O
,	O
smoking	O
,	O
and	O
ischemia	O
time	O
,	O
LV	O
mass	O
remained	O
independently	O
associated	O
with	O
biomarker	O
measures	O
of	O
infarct	O
size	O
(	O
CK-MB	B-P
AUC	O
p	O
=	O
0.02	O
,	O
TnI	O
AUC	O
p	O
=	O
0.03	O
)	O
and	O
MSI	O
(	O
p	O
=	O
0.003	O
)	O
.	O

Dominance	O
analysis	O
demonstrated	O
that	O
LV	O
mass	O
accounted	O
for	O
58	O
%	O
,	O
47	O
%	O
,	O
and	O
60	O
%	O
of	O
the	O
predicted	O
variances	O
for	O
CK-MB	B-P
AUC	O
,	O
TnI	O
AUC	O
,	O
and	O
MSI	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
LV	O
mass	O
accounts	O
for	O
approximately	O
half	O
of	O
the	O
predicted	O
variance	O
in	O
biomarker	O
measures	O
of	O
infarct	O
size	O
.	O

It	O
should	O
be	O
considered	O
as	O
an	O
adjustment	O
variable	O
in	O
studies	O
evaluating	O
infarct	O
size	O
.	O

Effects	O
of	O
Static	B-P
Cold	I-P
Storage	I-P
and	O
Hypothermic	O
Machine	O
Perfusion	O
on	O
Oxidative	B-P
Stress	I-P
Factors	I-P
,	O
Adhesion	O
Molecules	O
,	O
and	O
Zinc	O
Finger	O
Transcription	O
Factor	O
Proteins	O
Before	O
and	O
After	O
Liver	O
Transplantation	O
.	O

BACKGROUND	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
static	B-P
cold	I-P
storage	I-P
(	O
SCS	B-P
)	O
and	O
hypothermic	O
machine	O
perfusion	O
(	O
HMP	O
)	O
on	O
the	O
oxidative	B-P
stress	I-P
factors	I-P
(	O
OSF	B-P
)	O
,	O
adhesion	O
molecules	O
(	O
AM	O
)	O
,	O
and	O
zinc	O
finger	O
transcription	O
factor	O
(	O
Snail	O
)	O
before	O
and	O
after	O
liver	O
transplantation	O
.	O

MATERIAL	O
AND	O
METHODS	O
Experimental	O
dogs	O
were	O
randomly	O
divided	O
into	O
donor	O
(	O
group	O
A	O
)	O
,	O
SCS	B-P
(	O
group	O
B	O
)	O
,	O
and	O
HMP	O
(	O
group	O
C	O
)	O
(	O
n=30	O
)	O
groups	O
.	O

Livers	O
retrieved	O
from	O
group	O
A	O
were	O
transplanted	O
into	O
group	O
B	O
after	O
SCS	B-P
,	O
and	O
the	O
livers	O
sampled	O
from	O
group	O
B	O
were	O
transplanted	O
into	O
group	O
C	O
after	O
HMP	O
.	O

The	O
dogs	O
in	O
group	O
A	O
were	O
euthanized	O
and	O
discarded	O
,	O
and	O
the	O
livers	O
sampled	O
from	O
group	O
C	O
were	O
used	O
for	O
other	O
experiments	O
.	O

Twenty	O
dogs	O
with	O
successful	O
liver	O
transplants	O
were	O
randomly	O
selected	O
from	O
groups	O
B	O
and	O
C	O
for	O
analysis	O
.	O

RESULTS	O
During	O
the	O
liver	O
sampling	O
process	O
,	O
the	O
levels	O
of	O
OSF	B-P
,	O
AM	O
,	O
and	O
Snail	O
between	O
the	O
2	O
groups	O
showed	O
no	O
significant	O
differences	O
(	O
P	O
>	O
0.05	O
)	O
;	O
before	O
the	O
transplantation	O
,	O
the	O
levels	O
of	O
chemokine	O
CXCL14	O
and	O
Snail	O
between	O
the	O
2	O
groups	O
showed	O
no	O
significant	O
differences	O
(	O
P	O
>	O
0.05	O
)	O
,	O
and	O
compared	O
with	O
group	O
B	O
,	O
HIF-1α	O
and	O
P-selectin	O
in	O
group	O
C	O
were	O
lower	O
(	O
P	O
<	O
0.01	O
)	O
;	O
60	O
min	O
after	O
the	O
transplantation	O
,	O
HIF-1α	O
,	O
chemokine	O
CXCL14	O
,	O
P-selectin	O
,	O
and	O
Snail	O
in	O
group	O
C	O
were	O
lower	O
than	O
that	O
in	O
group	O
B	O
(	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
HMP	O
can	O
significantly	O
reduce	O
the	O
levels	O
of	O
OSF	B-P
and	O
inflammatory	O
factors	O
,	O
which	O
is	O
conducive	O
for	O
liver	O
transplantation	O
.	O

Inter-observer	O
agreement	O
for	O
clinical	O
examinations	O
of	O
foot	O
lesions	O
of	O
sheep	O
.	O

In	O
sheep	O
,	O
the	O
diagnosis	O
of	O
foot	O
lesions	O
is	O
routinely	O
based	O
on	O
physical	O
examination	O
of	O
the	O
hoof	O
.	O

Correct	O
diagnosis	O
is	O
important	O
for	O
the	O
effective	O
treatment	O
,	O
prevention	O
and	O
control	O
of	O
both	O
infectious	O
and	O
non-infectious	O
causes	O
of	O
lameness	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
level	O
of	O
inter-observer	O
agreement	O
for	O
clinical	O
examination	O
of	O
ovine	O
foot	O
lesions	O
.	O

Eight	O
observers	O
of	O
varying	O
experience	O
,	O
training	O
and	O
occupation	O
performed	O
foot	B-P
examinations	I-P
on	O
a	O
total	O
of	O
1158	O
sheep	O
from	O
38	O
farms	O
across	O
North	O
England	O
and	O
Wales	O
.	O

On	O
each	O
farm	O
,	O
a	O
group	O
of	O
two	O
to	O
four	O
observers	O
independently	O
examined	O
a	O
sample	O
of	O
24	O
to	O
30	O
sheep	O
to	O
diagnose	O
the	O
presence	O
or	O
absence	O
of	O
specific	O
foot	O
lesions	O
including	O
white	O
line	O
lesions	O
(	O
WL	O
)	O
,	O
contagious	O
ovine	O
digital	O
dermatitis	O
(	O
CODD	O
)	O
,	O
footrot	O
(	O
FR	O
)	O
,	O
inter-digital	O
dermatitis	O
(	O
ID	O
)	O
and	O
toe	O
granuloma	O
(	O
TG	O
)	O
.	O

The	O
inter-observer	O
agreement	O
of	O
foot	O
lesion	O
assessments	O
was	O
examined	O
using	O
Fleiss	O
kappa	O
(	O
κ	O
)	O
,	O
and	O
Cohen	O
's	O
κ	O
examined	O
the	O
paired	O
agreement	O
between	O
the	O
test	O
standard	O
observer	O
(	O
TSO	O
)	O
and	O
each	O
observer	O
.	O

Scoring	O
differences	O
with	O
the	O
TSO	O
were	O
examined	O
as	O
the	O
percentage	O
of	O
scoring	O
errors	O
and	O
assessed	O
for	O
evidence	O
of	O
systematic	O
scoring	O
bias	O
.	O

With	O
the	O
exception	O
of	O
WL	O
(	O
maximum	O
error	O
rate	O
33.3	O
%	O
)	O
,	O
few	O
scoring	O
differences	O
with	O
the	O
TSO	O
occurred	O
(	O
maximum	O
error	O
rate	O
3.3	O
%	O
)	O
.	O

This	O
suggests	O
that	O
observers	O
can	O
achieve	O
good	O
levels	O
of	O
reliability	O
when	O
diagnosing	O
most	O
of	O
the	O
commonly	O
observed	O
foot	O
conditions	O
associated	O
with	O
lameness	O
in	O
sheep	O
.	O

Ocular	O
Argyrosis	O
Mimicking	O
Conjunctival	O
Melanoma	O
.	O

To	O
present	O
a	O
novel	O
case	O
of	O
ocular	O
argyrosis	O
mimicking	O
conjunctival	O
melanoma	O
.	O

A	O
48-year-old	O
man	O
who	O
is	O
a	O
jewelry	O
manufacturer	O
presented	O
with	O
raised	O
pigmented	O
lesions	O
in	O
the	O
inferior	O
fornices	O
of	O
both	O
eyes	O
.	O

Brown	O
-	O
black	O
colored	O
,	O
follicle-like	O
,	O
masses	O
were	O
observed	O
in	O
both	O
fornices	O
.	O

An	O
incisional	B-P
biopsy	I-P
confirmed	O
the	O
presence	O
of	O
silver	O
and	O
the	O
diagnosis	O
of	O
ocular	O
argyrosis	O
.	O

Despite	O
its	O
limited	O
negative	O
health	O
effects	O
,	O
ocular	O
argyrosis	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
conjunctival	O
pigmented	O
lesions	O
because	O
of	O
the	O
potential	O
for	O
misidentification	O
of	O
neoplastic	O
growth	O
.	O

Assessment	O
of	O
cerebral	O
blood	O
perfusion	O
reserve	O
with	O
acetazolamide	O
using	O
3D	B-P
spiral	I-P
ASL	I-P
MRI	I-P
:	O
Preliminary	O
experience	O
in	O
pediatric	O
patients	O
.	O

To	O
demonstrate	O
the	O
clinical	O
feasibility	O
of	O
a	O
new	O
non-Cartesian	B-P
cylindrically-distributed	I-P
spiral	I-P
3D	I-P
pseudo-continuous	I-P
arterial	I-P
spin	I-P
labeling	I-P
(	I-P
pCASL	I-P
)	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	I-P
MRI	I-P
)	I-P
pulse	O
sequence	O
in	O
pediatric	O
patients	O
in	O
quantifying	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
response	O
to	O
an	O
acetazolamide	O
(	O
ACZ	O
)	O
vasodilator	O
challenge	O
.	O

MRI	B-P
exams	I-P
were	O
performed	O
on	O
two	O
3	O
Tesla	O
Philips	O
Ingenia	O
systems	O
using	O
32	O
channel	O
head	O
coil	O
arrays	O
.	O

After	O
local	O
institutional	O
review	O
board	O
approval	O
,	O
the	O
3D	B-P
spiral-based	I-P
pCASL	I-P
technique	I-P
was	O
added	O
to	O
a	O
standard	O
brain	B-P
MRI	I-P
exam	I-P
and	O
evaluated	O
in	O
13	O
pediatric	O
patients	O
(	O
average	O
age	O
:	O
11.7±6.4years	O
,	O
range	O
:	O
1.4-22.2years	O
)	O
.	O

All	O
patients	O
were	O
administered	O
ACZ	O
for	O
clinically	O
indicated	O
reasons	O
.	O

Quantitative	O
whole-brain	B-P
CBF	I-P
measurements	I-P
were	O
computed	O
pre	O
-	O
and	O
post	O
-	O
ACZ	O
to	O
assess	O
cerebrovascular	O
reserve	O
.	O

3D	B-P
spiral	I-P
pCASL	I-P
data	O
were	O
successfully	O
reconstructed	O
in	O
all	O
13	O
cases	O
.	O

In	O
11	O
patients	O
,	O
CBF	O
increased	O
2.8	O
%	O
to	O
93.2	O
%	O
after	O
administration	O
of	O
ACZ	O
.	O

In	O
the	O
two	O
remaining	O
patients	O
,	O
CBF	O
decreased	O
by	O
2.4	O
to	O
6.0	O
%	O
after	O
ACZ	O
.	O

The	O
group	O
average	O
change	O
in	O
CBF	O
due	O
to	O
ACZ	O
was	O
approximately	O
25.0	O
%	O
and	O
individual	O
changes	O
were	O
statistically	O
significant	O
(	O
p	O
<	O
0.01	O
)	O
in	O
all	O
patients	O
using	O
a	O
paired	O
t-test	O
analysis	O
.	O

CBF	O
perfusion	O
data	O
were	O
diagnostically	O
useful	O
in	O
supporting	O
conventional	O
MR	B-P
angiography	I-P
and	O
clinical	O
findings	O
.	O

3D	B-P
cylindrically-distributed	I-P
spiral	I-P
pCASL	I-P
MRI	I-P
provides	O
a	O
robust	O
approach	O
to	O
assess	O
cerebral	O
blood	O
flow	O
and	O
reserve	O
in	O
pediatric	O
patients	O
.	O

Risk	O
Factors	O
Associated	O
With	O
Repeated	O
HIV	B-P
Testing	I-P
Among	O
Internet	O
-Using	O
Men	O
Who	O
Have	O
Sex	O
With	O
Men	O
.	O

Men	O
who	O
have	O
sex	O
with	O
men	O
(	O
MSM	O
)	O
represent	O
a	O
disproportionately	O
impacted	O
risk	O
group	O
for	O
HIV	O
incidence	O
among	O
at-risk	O
U.S.	O
Few	O
studies	O
have	O
identified	O
risk	O
factors	O
associated	O
with	O
HIV	B-P
testing	I-P
frequency	O
both	O
within	O
and	O
outside	O
of	O
traditional	O
health	O
care	O
settings	O
.	O

MSM	O
enrolled	O
in	O
a	O
prospective	O
cohort	O
were	O
mailed	O
at-home	O
specimen	O
collection	O
kits	O
and	O
followed	O
for	O
a	O
year	O
.	O

Incidence	O
density	O
rate	O
ratios	O
(	O
IDRR	O
)	O
of	O
testing	O
were	O
calculated	O
,	O
and	O
generalized	O
estimating	O
equations	O
were	O
used	O
to	O
analyze	O
the	O
association	O
between	O
HIV	B-P
testing	I-P
and	O
behavioral	O
factors	O
.	O

The	O
incidence	O
rate	O
of	O
testing	O
was	O
higher	O
among	O
Black	O
MSM	O
than	O
White	O
MSM	O
(	O
IDRR	O
:	O
1.3	O
,	O
95	O
%	O
confidence	O
interval	O
CI	O
[	O
1.1	O
,	O
1.5	O
]	O
)	O
and	O
higher	O
among	O
MSM	O
who	O
reported	O
3+	O
condomless	O
anal	O
intercourse	O
partners	O
(	O
CAI	O
)	O
than	O
MSM	O
who	O
reported	O
no	O
CAI	O
(	O
IDRR	O
:	O
1.6	O
,	O
95	O
%	O
CI	O
[	O
1.3	O
,	O
2.0	O
]	O
)	O
.	O

Increasing	O
availability	O
of	O
HIV	B-P
testing	I-P
outside	O
traditional	O
health	O
care	O
settings	O
,	O
including	O
at-home	O
testing	O
kits	O
,	O
in	O
conjunction	O
with	O
targeted	O
behavioral	O
interventions	O
and	O
biomedical	O
treatment	O
preventions	O
is	O
needed	O
.	O

Individual	O
Leg	O
Muscle	O
Contributions	O
to	O
the	O
Cost	O
of	O
Walking	O
:	O
Effects	O
of	O
Age	O
and	O
Walking	O
Speed	O
.	O

This	O
study	O
examined	O
the	O
contributions	O
of	O
individual	O
muscles	O
to	O
changes	O
in	O
energetic	O
cost	O
of	O
transport	O
(	O
COT	O
)	O
over	O
seven	O
walking	O
speeds	O
,	O
and	O
compared	O
results	O
between	O
healthy	O
young	O
and	O
elderly	O
subjects	O
.	O

Twenty	O
six	O
participants	O
(	O
13	O
young	O
aged	O
18-30	O
;	O
13	O
old	O
aged	O
70-80	O
)	O
were	O
recruited	O
.	O

COT	O
(	O
O2/kg	O
body	O
mass/km	O
)	O
was	O
calculated	O
by	O
standardizing	O
the	O
mean	O
oxygen	O
consumption	O
recorded	O
during	O
steady	O
state	O
walking	O
.	O

Electromyography	B-P
signals	O
from	O
10	O
leg	O
muscles	O
were	O
used	O
to	O
calculate	O
the	O
cumulative	O
activity	O
required	O
to	O
traverse	O
a	O
unit	O
of	O
distance	O
(	O
CMAPD	O
)	O
for	O
each	O
muscle	O
at	O
each	O
speed	O
.	O

In	O
the	O
old	O
group	O
CMAPD	O
was	O
correlated	O
with	O
COT	O
,	O
presented	O
higher	O
and	O
more	O
variable	O
values	O
,	O
and	O
showed	O
greater	O
increases	O
around	O
optimal	O
speed	O
for	O
all	O
studied	O
muscles	O
.	O

Soleus	O
CMAPD	O
was	O
independent	O
of	O
speed	O
in	O
the	O
young	O
group	O
,	O
but	O
this	O
was	O
not	O
evident	O
with	O
aging	O
.	O

Greater	O
energy	O
cost	O
of	O
walking	O
in	O
older	O
individuals	O
seems	O
to	O
be	O
attributable	O
to	O
increased	O
energy	O
cost	O
of	O
all	O
lower	O
limb	O
muscles	O
.	O

Redistribution	O
of	O
Cav2.1	O
channels	O
and	O
calcium	O
ions	O
in	O
nerve	O
terminals	O
following	O
end-to-side	O
neurorrhaphy	O
:	O
ionic	B-P
imaging	I-P
analysis	I-P
by	O
TOF-SIMS	B-P
.	O

The	O
P/Q-type	O
voltage-dependent	O
calcium	O
channel	O
(	O
Cav2.1	O
)	O
in	O
the	O
presynaptic	O
membranes	O
of	O
motor	O
nerve	O
terminals	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
Ca	O
(	O
2+	O
)	O
transport	O
,	O
resulting	O
in	O
transmitter	O
release	O
within	O
the	O
nervous	O
system	O
.	O

The	O
recovery	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal	O
transduction	O
on	O
motor	O
end	O
plates	O
(	O
MEPs	O
)	O
and	O
innervated	O
muscle	O
may	O
directly	O
reflect	O
nerve	O
regeneration	O
following	O
peripheral	O
nerve	O
injury	O
.	O

Although	O
the	O
functional	O
significance	O
of	O
calcium	O
channels	O
and	O
the	O
levels	O
of	O
Ca	O
(	O
2+	O
)	O
signalling	O
in	O
nerve	O
regeneration	O
are	O
well	O
documented	O
,	O
little	O
is	O
known	O
about	O
calcium	O
channel	O
expression	O
and	O
its	O
relation	O
with	O
the	O
dynamic	O
Ca	O
(	O
2+	O
)	O
ion	O
distribution	O
at	O
regenerating	O
MEPs	O
.	O

In	O
the	O
present	O
study	O
,	O
end-to-side	O
neurorrhaphy	O
(	O
ESN	O
)	O
was	O
performed	O
as	O
an	O
in	O
vivo	O
model	O
of	O
peripheral	O
nerve	O
injury	O
.	O

The	O
distribution	O
of	O
Ca	O
(	O
2+	O
)	O
at	O
regenerating	O
MEPs	O
following	O
ESN	O
was	O
first	O
detected	O
by	O
time-of-flight	B-P
secondary	I-P
ion	I-P
mass	I-P
spectrometry	I-P
,	O
and	O
the	O
specific	O
localization	O
and	O
expression	O
of	O
Cav2.1	O
channels	O
were	O
examined	O
by	O
confocal	B-P
microscopy	I-P
and	O
western	O
blotting	O
.	O

Compared	O
with	O
other	O
fundamental	O
ions	O
,	O
such	O
as	O
Na	O
(	O
+	O
)	O
and	O
K	O
(	O
+	O
)	O
,	O
dramatic	O
changes	O
in	O
the	O
Ca	O
(	O
2+	O
)	O
distribution	O
were	O
detected	O
along	O
with	O
the	O
progression	O
of	O
MEP	O
regeneration	O
.	O

The	O
re-establishment	O
of	O
Ca	O
(	O
2+	O
)	O
distribution	O
and	O
intensity	O
were	O
correlated	O
with	O
the	O
functional	O
recovery	O
of	O
muscle	O
in	O
ESN	O
rats	O
.	O

Furthermore	O
,	O
the	O
re-clustering	O
of	O
Cav2.1	O
channels	O
after	O
ESN	O
at	O
the	O
nerve	O
terminals	O
corresponded	O
with	O
changes	O
in	O
the	O
Ca	O
(	O
2+	O
)	O
distribution	O
.	O

These	O
results	O
indicated	O
that	O
renewal	O
of	O
the	O
Cav2.1	O
distribution	O
within	O
the	O
presynaptic	O
nerve	O
terminals	O
may	O
be	O
necessary	O
for	O
initiating	O
a	O
proper	O
Ca	O
(	O
2+	O
)	O
influx	O
and	O
shortening	O
the	O
latency	O
of	O
muscle	O
contraction	O
during	O
nerve	O
regeneration	O
.	O

Prevalence	O
of	O
depression	O
in	O
patients	O
of	O
type	O
2	O
diabetes	O
mellitus	O
:	O
A	O
cross	O
sectional	O
study	O
in	O
a	O
tertiary	O
care	O
centre	O
.	O

The	O
present	O
study	O
aims	O
to	O
study	O
the	O
prevalence	O
of	O
depression	O
in	O
patients	O
with	O
uncomplicated	O
type	O
II	O
diabetes	O
mellitus	O
and	O
to	O
find	O
its	O
association	O
with	O
various	O
socio-demographic	O
factors	O
in	O
the	O
same	O
.	O

A	O
cross-sectional	O
,	O
single	O
interview	O
study	O
was	O
performed	O
in	O
an	O
outpatient	O
department	O
of	O
an	O
endocrinology	O
institute	O
.	O

Total	O
80	O
type	O
II	O
DM	O
patients	O
without	O
any	O
associated	O
complications	O
of	O
diabetes	O
were	O
included	O
in	O
this	O
study	O
.	O

To	O
diagnose	O
Depressive	O
Episode	O
,	O
structured	B-P
clinical	I-P
interview	I-P
for	O
DSM	O
V	O
was	O
applied	O
.	O

Severity	O
of	O
depression	O
was	O
assessed	O
by	O
Hamilton	O
Rating	O
Scale	O
for	O
Depression	O
(	O
HAM-D	O
)	O
.	O

To	O
assess	O
socio-demographic	O
characteristics	O
of	O
the	O
patients	O
,	O
all	O
of	O
them	O
were	O
evaluated	O
with	O
a	O
semi-structured	O
socio-demographic	O
performa	O
.	O

38.75	O
%	O
patients	O
(	O
N=31	O
)	O
were	O
found	O
to	O
be	O
suffering	O
from	O
depression	O
.	O

Among	O
them	O
48.38	O
%	O
were	O
moderately	O
depressed	O
and	O
none	O
were	O
suffering	O
from	O
very	O
severe	O
depression	O
.	O

Significant	O
association	O
was	O
not	O
found	O
between	O
depression	O
and	O
socio-demographic	O
factors	O
of	O
age	O
(	O
p=0.920	O
)	O
,	O
gender	O
(	O
p=0.251	O
)	O
,	O
economic	O
profile	O
(	O
p=0.583	O
)	O
,	O
local	O
background	O
of	O
the	O
patient	O
(	O
p=0.646	O
)	O
,	O
educational	O
qualification	O
(	O
p=0.935	O
)	O
and	O
marital	O
status	O
(	O
p=0.644	O
)	O
.	O

Similarly	O
no	O
association	O
was	O
found	O
with	O
duration	O
of	O
diabetes	O
,	O
HbA1c	O
and	O
BMI	O
.	O

Exclusion	O
of	O
complicated	O
cases	O
did	O
n't	O
seem	O
to	O
influence	O
overall	O
prevalence	O
of	O
depression	O
,	O
although	O
reduction	O
in	O
severity	O
was	O
apparent	O
.	O

Thus	O
even	O
in	O
those	O
diabetic	O
patients	O
who	O
are	O
leading	O
a	O
complication	O
free	O
life	O
,	O
a	O
detailed	O
psychiatric	O
analysis	O
to	O
rule	O
out	O
depression	O
is	O
mandatory	O
.	O

Diffuse	O
traumatic	O
brain	O
injury	O
affects	O
chronic	O
corticosterone	O
function	O
in	O
the	O
rat	O
.	O

As	O
many	O
as	O
20-55	O
%	O
of	O
patients	O
with	O
a	O
history	O
of	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
experience	O
chronic	O
endocrine	O
dysfunction	O
,	O
leading	O
to	O
impaired	O
quality	O
of	O
life	O
,	O
impaired	O
rehabilitation	O
efforts	O
and	O
lowered	O
life	O
expectancy	O
.	O

Endocrine	O
dysfunction	O
after	O
TBI	O
is	O
thought	O
to	O
result	O
from	O
acceleration	O
-	O
deceleration	O
forces	O
to	O
the	O
brain	O
within	O
the	O
skull	O
,	O
creating	O
enduring	O
hypothalamic	O
and	O
pituitary	O
neuropathology	O
,	O
and	O
subsequent	O
hypothalamic	O
-pituitary	O
endocrine	O
(	O
HPE	O
)	O
dysfunction	O
.	O

These	O
experiments	O
were	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
single	O
diffuse	O
TBI	O
results	O
in	O
chronic	O
dysfunction	O
of	O
corticosterone	O
(	O
CORT	O
)	O
,	O
a	O
glucocorticoid	O
released	O
in	O
response	O
to	O
stress	O
and	O
testosterone	O
.	O

We	O
used	O
a	O
rodent	O
model	O
of	O
diffuse	O
TBI	O
induced	O
by	O
midline	O
fluid	O
percussion	O
injury	O
(	O
mFPI	O
)	O
.	O

At	O
2	O
months	O
postinjury	O
compared	O
with	O
uninjured	O
control	O
animals	O
,	O
circulating	O
levels	O
of	O
CORT	O
were	O
evaluated	O
at	O
rest	O
,	O
under	O
restraint	O
stress	O
and	O
in	O
response	O
to	O
dexamethasone	O
,	O
a	O
synthetic	O
glucocorticoid	O
commonly	O
used	O
to	O
test	O
HPE	O
axis	O
regulation	O
.	O

Testosterone	O
was	O
evaluated	O
at	O
rest	O
.	O

Further	O
,	O
we	O
assessed	O
changes	O
in	O
injury	O
-	O
induced	O
neuron	O
morphology	O
(	O
Golgi	B-P
stain	I-P
)	O
,	O
neuropathology	O
(	O
silver	B-P
stain	I-P
)	O
and	O
activated	O
astrocytes	O
(	O
GFAP	B-P
)	O
in	O
the	O
paraventricular	O
nucleus	O
(	O
PVN	O
)	O
of	O
the	O
hypothalamus	O
.	O

Resting	O
plasma	O
CORT	O
levels	O
were	O
decreased	O
at	O
2	O
months	O
postinjury	O
and	O
there	O
was	O
a	O
blunted	O
CORT	O
increase	O
in	O
response	O
to	O
restraint	O
induced	O
stress	O
.	O

No	O
changes	O
in	O
testosterone	O
were	O
measured	O
.	O

These	O
changes	O
in	O
CORT	O
were	O
observed	O
concomitantly	O
with	O
altered	O
complexity	O
of	O
neuron	O
processes	O
in	O
the	O
PVN	O
over	O
time	O
,	O
devoid	O
of	O
neuropathology	O
or	O
astrocytosis	O
.	O

Results	O
provide	O
evidence	O
that	O
a	O
single	O
moderate	O
diffuse	O
TBI	O
leads	O
to	O
changes	O
in	O
CORT	O
function	O
,	O
which	O
can	O
contribute	O
to	O
the	O
persistence	O
of	O
symptoms	O
related	O
to	O
endocrine	O
dysfunction	O
.	O

Future	O
experiments	O
aim	O
to	O
evaluate	O
additional	O
HP-related	O
hormones	O
and	O
endocrine	O
circuit	O
pathology	O
following	O
diffuse	O
TBI	O
.	O

White	O
matter	O
deficits	O
in	O
schizophrenia	O
are	O
global	O
and	O
do	O
n't	O
progress	O
with	O
age	O
.	O

Diffusion	B-P
tensor	I-P
imaging	I-P
has	O
revealed	O
differences	O
in	O
all	O
examined	O
white	O
matter	O
tracts	O
in	O
schizophrenia	O
,	O
with	O
a	O
range	O
of	O
explanations	O
for	O
why	O
this	O
may	O
be	O
.	O

The	O
distribution	O
and	O
timing	O
of	O
differences	O
may	O
help	O
explain	O
their	O
origin	O
;	O
however	O
,	O
results	O
are	O
usually	O
dependent	O
on	O
the	O
analytical	O
method	O
.	O

We	O
therefore	O
sought	O
to	O
examine	O
the	O
extent	O
of	O
differences	O
and	O
their	O
relationship	O
with	O
age	O
using	O
two	O
different	O
methods	O
.	O

A	O
combined	O
voxel	O
-based	O
whole-brain	O
study	O
and	O
a	O
tract	O
-based	O
spatial-statistics	O
study	O
of	O
104	O
patients	O
with	O
schizophrenia	O
and	O
200	O
matched	O
healthy	O
controls	O
,	O
aged	O
between	O
17	O
and	O
63	O
years	O
.	O

Fractional	O
anisotropy	O
was	O
reduced	O
throughout	O
the	O
brain	O
in	O
both	O
analyses	O
.	O

The	O
relationship	O
of	O
fractional	O
anisotropy	O
with	O
age	O
differed	O
between	O
patients	O
and	O
controls	O
,	O
with	O
controls	O
showing	O
the	O
gentle	O
fractional	O
anisotropy	O
decline	O
widely	O
noted	O
but	O
patients	O
showing	O
an	O
essentially	O
flat	O
relationship	O
:	O
younger	O
patients	O
had	O
lower	O
fractional	O
anisotropy	O
than	O
controls	O
,	O
but	O
the	O
difference	O
disappeared	O
with	O
age	O
.	O

Mean	O
diffusivity	O
was	O
widely	O
increased	O
in	O
patients	O
.	O

Reduction	O
in	O
fractional	O
anisotropy	O
and	O
increase	O
in	O
mean	O
diffusivity	O
would	O
be	O
consistent	O
with	O
global	O
disruption	O
in	O
myelination	O
;	O
the	O
relationship	O
with	O
age	O
would	O
suggest	O
this	O
is	O
present	O
already	O
at	O
the	O
onset	O
of	O
their	O
illness	O
,	O
but	O
does	O
not	O
progress	O
.	O

The	O
Shear	O
Bond	O
Strength	O
of	O
Porcelain	O
Laminate	O
to	O
Prepared	O
and	O
Unprepared	O
Anterior	O
Teeth	O
.	O

Porcelain	O
laminate	O
veneer	O
is	O
an	O
esthetic	O
restoration	O
used	O
as	O
an	O
alternative	O
to	O
full	O
veneer	O
crowns	O
and	O
requires	O
minimal	O
tooth	O
preparation	O
.	O

In	O
restoration	O
with	O
porcelain	O
laminate	O
veneers	O
,	O
both	O
the	O
longevity	O
of	O
the	O
laminate	O
and	O
conservation	O
of	O
the	O
sound	O
tooth	O
structure	O
are	O
imperative	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
shear	O
bond	O
strength	O
of	O
porcelain	O
laminates	O
to	O
prepared	O
-	O
and	O
unprepared	O
-	O
anterior	O
teeth	O
in	O
order	O
to	O
compare	O
their	O
longevity	O
and	O
success	O
rate	O
.	O

Thirty	O
extracted	O
maxillary	O
central	O
incisors	O
were	O
randomly	O
divided	O
into	O
3	O
groups	O
regarding	O
their	O
preparation	O
methods	O
.	O

The	O
preparation	O
methods	O
were	O
full-preparation	O
in	O
group	O
A	O
,	O
full-preparation	O
and	O
finishing	O
with	O
fine	O
diamond	O
bur	O
in	O
group	O
B	O
,	O
and	O
no-preparation	O
,	O
only	O
grinding	O
with	O
diamond	O
bur	O
in	O
group	O
C.	O
After	O
conditioning	O
the	O
teeth	O
,	O
ceramic	O
veneers	O
(	O
IP	O
S	O
e.max	O
)	O
were	O
silanated	O
and	O
then	O
cemented	O
with	O
DuoLink	O
luting	O
cement	O
.	O

The	O
shear	O
bond	O
strength	O
was	O
measured	O
for	O
each	O
group	O
and	O
failure	O
mode	O
was	O
determined	O
by	O
stereomicroscopic	B-P
examination	I-P
.	O

Group	O
C	O
exhibited	O
the	O
highest	O
shear	O
bond	O
strength	O
.	O

The	O
shear	O
bond	O
strength	O
was	O
significantly	O
different	O
between	O
groups	O
C	O
and	O
B	O
(	O
p	O
<	O
0.05	O
)	O
.	O

However	O
,	O
the	O
difference	O
between	O
group	O
A	O
and	O
C	O
was	O
insignificant	O
,	O
as	O
was	O
the	O
difference	O
between	O
group	O
A	O
and	O
B	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Adhesion	O
failure	O
mode	O
was	O
found	O
to	O
be	O
more	O
common	O
than	O
the	O
cohesive	O
mode	O
.	O

Regarding	O
the	O
shear	O
bond	O
strength	O
of	O
unprepared	O
anterior	O
teeth	O
to	O
porcelain	O
laminate	O
veneers	O
yielded	O
by	O
this	O
study	O
,	O
no-preparation	O
veneers	O
might	O
be	O
used	O
when	O
the	O
enamel	O
is	O
affected	O
by	O
wearing	O
,	O
trauma	O
,	O
or	O
abrasion	O
.	O

It	O
can	O
also	O
be	O
used	O
in	O
patients	O
who	O
refuse	O
the	O
treatments	O
which	O
involve	O
tooth	O
reduction	O
and	O
preparation	O
.	O

Transcriptome	O
and	O
Metabolome	O
Analyses	O
of	O
Glucosinolates	O
in	O
Two	O
Broccoli	O
Cultivars	O
Following	O
Jasmonate	O
Treatment	O
for	O
the	O
Induction	O
of	O
Glucosinolate	O
Defense	O
to	O
Trichoplusia	O
ni	O
(	O
Hübner	O
)	O
.	O

Lepidopteran	O
larvae	O
growth	O
is	O
influenced	O
by	O
host	O
plant	O
glucosinolate	O
(	O
GS	O
)	O
concentrations	O
,	O
which	O
are	O
,	O
in	O
turn	O
,	O
influenced	O
by	O
the	O
phytohormone	O
jasmonate	O
(	O
JA	O
)	O
.	O

In	O
order	O
to	O
elucidate	O
insect	O
resistance	O
biomarkers	O
to	O
lepidopteran	O
pests	O
,	O
transcriptome	O
and	O
metabolome	O
analyses	O
following	O
JA	O
treatments	O
were	O
conducted	O
with	O
two	O
broccoli	O
cultivars	O
,	O
Green	O
Magic	O
and	O
VI-158	O
,	O
which	O
have	O
differentially	O
induced	O
indole	O
GSs	O
,	O
neoglucobrassicin	O
and	O
glucobrassicin	O
,	O
respectively	O
.	O

To	O
test	O
these	O
two	O
inducible	O
GSs	O
on	O
growth	O
of	O
cabbage	O
looper	O
(	O
Trichoplusia	O
ni	O
)	O
,	O
eight	O
neonate	O
cabbage	O
looper	O
larvae	O
were	O
placed	O
onto	O
each	O
of	O
three	O
plants	O
per	O
JA	O
treatments	O
(	O
0	O
,	O
100	O
,	O
200	O
,	O
400	O
µM	O
)	O
three	O
days	O
after	O
treatment	O
.	O

After	O
five	O
days	O
of	O
feeding	O
,	O
weight	O
of	O
larvae	O
and	O
their	O
survival	O
rate	O
was	O
found	O
to	O
decrease	O
with	O
increasing	O
JA	O
concentrations	O
in	O
both	O
broccoli	O
cultivars	O
.	O

JA	O
-	O
inducible	O
GSs	O
were	O
measured	O
by	O
high	B-P
performance	I-P
liquid	I-P
chromatography	I-P
.	O

Neoglucobrassicin	O
in	O
Green	O
Magic	O
and	O
glucobrassicin	O
in	O
VI-158	O
leaves	O
were	O
increased	O
in	O
a	O
dose-dependent	O
manner	O
.	O

One	O
or	O
both	O
of	O
these	O
glucosinolates	O
and/or	O
their	O
hydrolysis	O
products	O
showed	O
significant	O
inverse	O
correlations	O
with	O
larval	O
weight	O
and	O
survival	O
(	O
five	O
days	O
after	O
treatment	O
)	O
while	O
being	O
positively	O
correlated	O
with	O
the	O
number	O
of	O
days	O
to	O
pupation	O
.	O

This	O
implies	O
that	O
these	O
two	O
JA	O
-	O
inducible	O
glucosinolates	O
can	O
influence	O
the	O
growth	O
and	O
survival	O
of	O
cabbage	O
looper	O
larvae	O
.	O

Transcriptome	O
profiling	O
supported	O
the	O
observed	O
changes	O
in	O
glucosinolate	O
and	O
their	O
hydrolysis	O
product	O
concentrations	O
following	O
JA	O
treatments	O
.	O

Several	O
genes	O
related	O
to	O
GS	O
metabolism	O
differentiate	O
the	O
two	O
broccoli	O
cultivars	O
in	O
their	O
pattern	O
of	O
transcriptional	O
response	O
to	O
JA	O
treatments	O
.	O

Indicative	O
of	O
the	O
corresponding	O
change	O
in	O
indole	O
GS	O
concentrations	O
,	O
transcripts	O
of	O
the	O
transcription	O
factor	O
MYB122	O
,	O
core	O
structure	O
biosynthesis	O
genes	O
(	O
CYP79B2	O
,	O
UGT74B1	O
,	O
SUR1	O
,	O
SOT16	O
,	O
SOT17	O
,	O
and	O
SOT18	O
)	O
,	O
an	O
indole	O
glucosinolate	O
side	O
chain	O
modification	O
gene	O
(	O
IGMT1	O
)	O
,	O
and	O
several	O
glucosinolate	O
hydrolysis	O
genes	O
(	O
TGG1	O
,	O
TGG2	O
,	O
and	O
ESM1	O
)	O
were	O
significantly	O
increased	O
in	O
Green	O
Magic	O
(	O
statistically	O
significant	O
in	O
most	O
cases	O
at	O
400	O
µM	O
)	O
while	O
UGT74B1	O
and	O
MYB122	O
were	O
significantly	O
increased	O
in	O
VI-158	O
.	O

Therefore	O
,	O
these	O
metabolite	O
and	O
transcript	O
biomarker	O
results	O
indicate	O
that	O
transcriptome	O
profiling	O
can	O
identify	O
genes	O
associated	O
with	O
the	O
formation	O
of	O
two	O
different	O
indole	O
GS	O
and	O
their	O
hydrolysis	O
products	O
.	O

Therefore	O
,	O
these	O
metabolite	O
and	O
transcript	O
biomarkers	O
could	O
be	O
useful	O
in	O
an	O
effective	O
marker	O
-	O
assisted	O
breeding	O
strategy	O
for	O
resistance	O
to	O
generalist	O
lepidopteran	O
pests	O
in	O
broccoli	O
and	O
potentially	O
other	O
Brassica	O
vegetables	O
.	O

Phenotypic	O
and	O
genetic	O
heterogeneity	O
of	O
tumor	O
tissue	O
and	O
circulating	O
tumor	O
cells	O
in	O
patients	O
with	O
metastatic	O
castration-resistant	O
prostate	O
cancer	O
:	O
A	O
report	O
from	O
the	O
PETRUS	O
prospective	O
study	O
.	O

Molecular	O
characterization	O
of	O
cancer	O
samples	O
is	O
hampered	O
by	O
tumor	O
tissue	O
availability	O
in	O
metastatic	O
castration-resistant	O
prostate	O
cancer	O
(	O
mCRPC	O
)	O
patients	O
.	O

We	O
reported	O
the	O
results	O
of	O
prospective	O
PETRUS	O
study	O
of	O
biomarker	O
assessment	O
in	O
paired	O
primary	O
prostatic	O
tumors	O
,	O
metastatic	O
biopsies	B-P
and	O
circulating	O
tumor	O
cells	O
(	O
CTCs	O
)	O
.	O

Among	O
54	O
mCRPC	O
patients	O
enrolled	O
,	O
38	O
(	O
70	O
%	O
)	O
had	O
biopsies	B-P
containing	O
more	O
than	O
50	O
%	O
tumour	O
cells	O
.	O

28	O
(	O
52	O
%	O
)	O
patients	O
were	O
analyzed	O
for	O
both	O
tissue	O
samples	O
and	O
CTCs	O
.	O

FISH	O
for	O
AR	O
-	O
amplification	O
and	O
TMPRSS2	O
-	O
ERG	O
translocation	O
were	O
successful	O
in	O
54	O
%	O
and	O
32	O
%	O
in	O
metastatic	O
biopsies	B-P
and	O
primary	O
tumors	O
,	O
respectively	O
.	O

By	O
comparing	O
CellSearch	B-P
and	O
filtration	B-P
(	I-P
ISET	I-P
)	O
-enrichment	O
combined	O
to	O
four	O
color	O
immunofluorescent	B-P
staining	I-P
,	O
we	O
showed	O
that	O
CellSearch	B-P
and	O
ISET	B-P
isolated	O
distinct	O
subpopulations	O
of	O
CTCs	O
:	O
CTCs	O
undergoing	O
epithelial-to-mesenchymal	O
transition	O
,	O
CTC	O
clusters	O
and	O
large	O
CTCs	O
with	O
cytomorphological	O
characteristics	O
but	O
no	O
detectable	O
markers	O
were	O
isolated	O
using	O
ISET	B-P
.	O

Epithelial	O
CTCs	O
detected	O
by	O
the	O
CellSearch	B-P
were	O
mostly	O
lost	O
during	O
the	O
ISET-filtration	B-P
.	O

AR	O
-	O
amplification	O
was	O
detected	O
in	O
CellSearch	B-P
-captured	O
CTCs	O
,	O
but	O
not	O
in	O
ISET	B-P
-enriched	O
CTCs	O
which	O
harbor	O
exclusively	O
AR	O
gain	O
of	O
copies	O
.	O

Eighty-eight	O
percent	O
concordance	O
for	O
ERG-rearrangement	O
was	O
observed	O
between	O
metastatic	O
biopsies	B-P
and	O
CTCs	O
even	O
if	O
additional	O
ERG-alteration	O
patterns	O
were	O
detected	O
in	O
ISET	B-P
-enriched	O
CTCs	O
indicating	O
a	O
higher	O
heterogeneity	O
in	O
CTCs	O
.	O

Molecular	O
screening	O
of	O
metastatic	O
biopsies	B-P
is	O
achievable	O
in	O
a	O
multicenter	O
context	O
.	O

Our	O
data	O
indicate	O
that	O
CTCs	O
detected	O
by	O
the	O
CellSearch	B-P
and	O
the	O
ISET-filtration	B-P
systems	I-P
are	O
not	O
only	O
phenotypically	O
but	O
also	O
genetically	O
different	O
.	O

Close	O
attention	O
must	O
be	O
paid	O
to	O
CTC	O
characterization	O
since	O
neither	O
approach	O
tested	O
here	O
fully	O
reflects	O
the	O
tremendous	O
phenotypic	O
and	O
genetic	O
heterogeneity	O
present	O
in	O
CTCs	O
from	O
mCRPC	O
patients	O
.	O

Correction	O
of	O
dilutional	O
anemia	O
induces	O
renal	O
dysfunction	O
in	O
diabetic	O
patients	O
undergoing	O
coronary	O
artery	O
bypass	O
grafting	O
:	O
a	O
consequence	O
of	O
microcirculatory	O
alterations	O
?	O
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	O
the	O
effects	O
of	O
dilutional	O
anemia	O
resulting	O
from	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
and	O
its	O
correction	O
with	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
transfusion	O
on	O
tissue	O
oxygenation	O
and	O
renal	O
function	O
in	O
diabetic	O
patients	O
undergoing	O
coronary	O
artery	O
bypass	O
grafting	O
(	O
CABG	O
)	O
.	O

70	O
diabetic	O
patients	O
who	O
underwent	O
elective	O
CABG	O
and	O
whose	O
hematocrit	O
values	O
had	O
been	O
between	O
24-28	O
%	O
at	O
any	O
time	O
during	O
CBP	O
were	O
prospectively	O
randomized	O
and	O
equally	O
allocated	O
to	O
two	O
groups	O
:	O
patients	O
who	O
received	O
RBC	O
during	O
CPB	O
(	O
group	O
I	O
,	O
n	O
=	O
35	O
)	O
vs.	O
did	O
not	O
receive	O
RBC	O
during	O
CPB	O
(	O
group	O
II	O
,	O
n	O
=	O
35	O
)	O
.	O

Besides	O
routine	O
hemodynamic	O
and	O
biochemical	O
parameters	O
,	O
biomarkers	O
of	O
ischemia	O
and	O
renal	O
injury	O
such	O
as	O
ischemia	O
modified	O
albumin	O
(	O
IMA	O
)	O
,	O
protein	O
oxidation	O
parameters	O
[	O
advanced	O
oxidative	O
protein	O
products	O
(	O
AOPP	O
)	O
,	O
total	O
thiol	O
(	O
T-SH	O
)	O
]	O
,	O
neutrophil	O
gelatinase-associated	O
lipocalin	O
(	O
NGAL	O
)	O
and	O
estimated	B-P
glomerular	I-P
filtration	I-P
rate	I-P
(	O
eGFR	B-P
)	O
were	O
measured	O
in	O
both	O
groups	O
.	O

In	O
group	O
I	O
,	O
T-SH	O
,	O
NGAL	O
and	O
urea	O
levels	O
were	O
found	O
to	O
be	O
significantly	O
increased	O
postoperatively	O
compared	O
to	O
preoperative	O
measurements	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Also	O
,	O
postoperatively	O
,	O
NGAL	O
,	O
creatinine	O
,	O
aspartate	O
aminotransferase	O
and	O
AOPP	O
levels	O
were	O
higher	O
in	O
group	O
I	O
than	O
group	O
II	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
correction	O
of	O
anemia	O
with	O
RBC	O
transfusion	O
in	O
diabetic	O
patients	O
undergoing	O
CABG	O
could	O
increase	O
the	O
risk	O
of	O
renal	O
injury	O
.	O

Further	O
studies	O
verifying	O
the	O
effects	O
of	O
blood	O
transfusions	O
at	O
the	O
microcirculatory	O
level	O
are	O
needed	O
to	O
optimize	O
the	O
efficacy	O
of	O
transfusions	O
.	O

Laparoscopic	B-P
Approach	I-P
for	O
Thermoablation	O
Microwave	O
in	O
the	O
Treatment	O
of	O
Hepatocellular	O
Carcinoma	O
:	O
A	O
Single	O
Center	O
Experience	O
.	O

The	O
surgical	O
therapy	O
of	O
choice	O
for	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
is	O
liver	O
transplantation	O
(	O
LT	O
)	O
or	O
hepatic	O
resection	O
,	O
although	O
only	O
a	O
small	O
percentage	O
of	O
patients	O
can	O
undergo	O
these	O
procedures	O
.	O

Microwave	O
thermal	O
ablation	O
(	O
MWTA	O
)	O
can	O
be	O
an	O
effective	O
alternative	O
treatment	O
for	O
HCC	O
that	O
complicates	O
a	O
cirrhotic	O
liver	O
disease	O
,	O
either	O
as	O
a	O
final	O
procedure	O
or	O
for	O
downstaging	B-P
patients	O
on	O
the	O
waiting	O
list	O
for	O
LT	O
,	O
or	O
in	O
combination	O
with	O
resective	O
surgery	O
to	O
achieve	O
oncological	O
radicality	O
.	O

The	O
purpose	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
evaluate	O
experience	O
with	O
the	O
laparoscopic	B-P
approach	I-P
of	O
MWTA	O
at	O
our	O
center	O
.	O

In	O
a	O
cohort	O
of	O
35	O
consecutive	O
patients	O
undergoing	O
MWTA	O
with	O
laparoscopic	B-P
approach	I-P
between	O
January	O
,	O
2013	O
and	O
May	O
,	O
2016	O
,	O
we	O
reviewed	O
the	O
demographic	O
data	O
,	O
the	O
Barcelona	O
clinic	O
liver	O
cancer	O
stage	O
,	O
the	O
severity	O
of	O
cirrhotic	O
liver	O
disease	O
,	O
the	O
size	O
of	O
the	O
ablated	O
lesion	O
,	O
the	O
duration	O
of	O
the	O
procedure	O
,	O
and	O
complications	O
occurring	O
within	O
90	O
days	O
of	O
surgery	O
.	O

MWTA	O
was	O
performed	O
by	O
applying	O
one	O
to	O
three	O
hepatic	O
parenchymal	O
insertions	O
(	O
mean	O
1.8	O
)	O
per	O
patient	O
.	O

The	O
mean	O
duration	O
of	O
surgery	O
was	O
163	O
±	O
18	O
minutes	O
.	O

There	O
was	O
no	O
blood	O
loss	O
in	O
any	O
of	O
the	O
procedures	O
.	O

Complete	O
necrosis	O
on	O
CT	B-P
scan	I-P
was	O
achieved	O
in	O
26/35	O
patients	O
(	O
75	O
%	O
)	O
.	O

The	O
mean	O
hospital	O
stay	O
was	O
4.6	O
(	O
range	O
2-7	O
)	O
days	O
;	O
major	O
complications	O
were	O
postablation	O
syndrome	O
in	O
2/35	O
(	O
5.7	O
%	O
)	O
,	O
peritoneal	O
fluid	O
in	O
4/35	O
(	O
11.4	O
%	O
)	O
,	O
and	O
transient	O
jaundice	O
in	O
1/35	O
(	O
2.8	O
%	O
)	O
patients	O
.	O

There	O
was	O
no	O
mortality	O
.	O

Laparoscopic	B-P
MWTA	O
is	O
a	O
safe	O
and	O
effective	O
treatment	O
for	O
unresectable	O
HCC	O
and	O
when	O
a	O
percutaneous	O
procedure	O
is	O
not	O
feasible	O
.	O

Does	O
Video	O
Laryngoscopy	O
Offer	O
Advantages	O
over	O
Direct	B-P
Laryngoscopy	I-P
during	O
Cardiopulmonary	O
Resuscitation	O
?	O
.	O

Interruption	O
of	O
chest	O
compressions	O
should	O
be	O
minimized	O
because	O
of	O
its	O
negative	O
effects	O
on	O
survival	O
.	O

This	O
randomized	O
,	O
controlled	O
,	O
cross-over	O
study	O
aimed	O
to	O
analyze	O
the	O
effectiveness	O
of	O
Macintosh	O
,	O
Miller	O
,	O
McCoy	O
and	O
McGrath	O
laryngoscopes	O
during	O
with	O
or	O
without	O
chest	O
compressions	O
in	O
the	O
scope	O
of	O
a	O
simulated	O
cardiopulmonary	O
resuscitation	O
scenario	O
.	O

The	O
time	O
required	O
for	O
successful	O
tracheal	O
intubation	O
,	O
number	O
of	O
attempts	O
,	O
dental	O
trauma	O
severity	O
and	O
the	O
need	O
for	O
optimization	O
manoeuvres	O
were	O
recorded	O
during	O
cardiopulmonary	O
resuscitation	O
with	O
and	O
without	O
chest	O
compressions	O
.	O

The	O
experience	O
with	O
computer	O
games	O
during	O
the	O
last	O
10	O
years	O
were	O
asked	O
to	O
the	O
participants	O
and	O
recorded	O
.	O

McCoy	O
laryngoscope	O
yielded	O
the	O
shortest	O
time	O
for	O
successful	O
tracheal	O
intubation	O
both	O
in	O
the	O
presence	O
of	O
and	O
without	O
chest	O
compressions	O
.	O

During	O
the	O
use	O
of	O
McCoy	O
laryngoscopes	O
,	O
fewer	O
tracheal	O
intubation	O
attempts	O
,	O
lower	O
incidence	O
of	O
dental	O
trauma	O
and	O
lower	O
visual	O
analogue	O
scale	O
scores	O
on	O
the	O
ease	O
of	O
intubation	O
were	O
recorded	O
.	O

Participants	O
who	O
are	O
experienced	O
computer	O
game	O
players	O
using	O
Macintosh	O
,	O
McCoy	O
and	O
McGrath	O
achieved	O
successful	O
tracheal	O
intubation	O
in	O
a	O
significantly	O
shorter	O
time	O
during	O
resuscitation	O
without	O
chest	O
compressions	O
.	O

Dental	O
trauma	O
incidence	O
and	O
number	O
of	O
tracheal	O
intubation	O
attempts	O
did	O
not	O
show	O
any	O
significant	O
difference	O
between	O
the	O
four	O
laryngoscopes	O
being	O
related	O
to	O
the	O
rate	O
of	O
playing	O
computer	O
games	O
.	O

McGrath	O
video	O
laryngoscopes	O
do	O
not	O
appear	O
to	O
have	O
advantages	O
over	O
direct	B-P
laryngoscopes	I-P
for	O
securing	O
a	O
smooth	O
and	O
successful	O
tracheal	O
intubation	O
during	O
rhythmic	O
chest	O
compressions	O
.	O

We	O
believe	O
that	O
as	O
McCoy	O
laryngoscope	O
provided	O
tracheal	O
intubation	O
in	O
a	O
shorter	O
time	O
and	O
with	O
fewer	O
attempts	O
,	O
this	O
laryngoscope	O
may	O
increase	O
the	O
success	O
rate	O
of	O
resuscitation	O
.	O

Chemosensitivity	O
,	O
Cardiovascular	O
Risk	O
,	O
and	O
the	O
Ventilatory	O
Response	O
to	O
Exercise	O
in	O
COPD	O
.	O

COPD	O
is	O
associated	O
with	O
elevated	O
cardiovascular	O
risk	O
and	O
a	O
potentiated	O
ventilatory	O
response	O
to	O
exercise	O
.	O

Enhanced	O
carotid	O
chemoreceptor	O
(	O
CC	O
)	O
activity	O
/	O
sensitivity	O
is	O
present	O
in	O
other	O
clinical	O
conditions	O
,	O
has	O
been	O
shown	O
to	O
contribute	O
to	O
sympathetic	O
vasoconstrictor	O
outflow	O
,	O
and	O
is	O
predictive	O
of	O
mortality	O
.	O

CC	O
activity	O
/	O
sensitivity	O
,	O
and	O
the	O
resulting	O
functional	O
significance	O
,	O
has	O
not	O
been	O
well	O
examined	O
in	O
COPD	O
.	O

We	O
hypothesized	O
that	O
CC	O
activity	O
/	O
sensitivity	O
would	O
be	O
elevated	O
in	O
COPD	O
,	O
and	O
related	O
to	O
increased	O
pulse	O
wave	O
velocity	O
(	O
a	O
marker	O
of	O
CV	O
risk	O
)	O
and	O
the	O
ventilatory	O
response	O
to	O
exercise	O
.	O

30	O
COPD	O
patients	O
and	O
10	O
healthy	O
age-matched	O
controls	O
were	O
examined	O
.	O

Participants	O
performed	O
baseline	O
cardiopulmonary	B-P
exercise	I-P
and	O
pulmonary	B-P
function	I-P
testing	I-P
.	O

CC	O
activity	O
was	O
later	O
evaluated	O
by	O
the	O
drop	O
in	O
ventilation	O
with	O
breathing	O
100	O
%	O
O2	O
,	O
and	O
CC	O
sensitivity	O
was	O
then	O
assessed	O
by	O
the	O
ventilatory	B-P
response	I-P
to	I-P
hypoxia	I-P
(	O
ΔVE/ΔS	O
pO2	B-P
)	O
.	O

Peripheral	O
arterial	O
stiffness	O
was	O
subsequently	O
evaluated	O
by	O
measurement	O
of	O
pulse	O
wave	O
velocity	O
(	O
PWV	O
)	O
using	O
applanation	B-P
tonometry	I-P
while	O
the	O
subjects	O
were	O
breathing	O
room	O
air	O
,	O
and	O
then	O
following	O
chemoreceptor	O
inhibition	O
by	O
breathing	O
100	O
%	O
O2	O
for	O
2	O
minutes	O
.	O

CC	O
activity	O
,	O
CC	O
sensitivity	O
,	O
PWV	O
and	O
the	O
ventilatory	O
response	O
to	O
exercise	O
were	O
all	O
increased	O
in	O
COPD	O
relative	O
to	O
controls	O
.	O

CC	O
sensitivity	O
was	O
related	O
to	O
PWV	O
;	O
however	O
,	O
neither	O
CC	O
activity	O
nor	O
CC	O
sensitivity	O
was	O
related	O
to	O
the	O
ventilatory	O
response	O
to	O
exercise	O
in	O
COPD	O
.	O

CC	O
inhibition	O
by	O
breathing	O
100	O
%	O
O2	O
normalized	O
PWV	O
in	O
COPD	O
,	O
while	O
no	O
effect	O
was	O
observed	O
in	O
controls	O
.	O

CC	O
activity	O
and	O
sensitivity	O
are	O
elevated	O
in	O
COPD	O
,	O
and	O
appear	O
related	O
to	O
cardiovascular	O
risk	O
;	O
however	O
,	O
CC	O
activity	O
/	O
sensitivity	O
does	O
not	O
contribute	O
to	O
the	O
potentiated	O
ventilatory	O
response	O
to	O
exercise	O
.	O

Nitrogen	O
utilization	O
efficiency	O
and	O
prediction	O
of	O
nitrogen	O
excretion	O
in	O
sheep	O
offered	O
fresh	O
perennial	O
ryegrass	O
(	O
)	O
.	O

Nitrogen	O
excretion	O
from	O
sheep	O
production	O
systems	O
is	O
an	O
important	O
source	O
of	O
nitrate	O
,	O
ammonia	O
,	O
and	O
nitrous	O
oxide	O
responsible	O
for	O
groundwater	O
pollution	O
and	O
global	O
warming	O
.	O

The	O
present	O
study	O
aimed	O
to	O
identify	O
key	O
parameters	O
influencing	O
N	O
utilization	O
efficiency	O
and	O
develop	O
prediction	O
equations	O
for	O
manure	O
N	O
,	O
feces	O
N	O
,	O
and	O
urine	O
N	O
outputs	O
in	O
sheep	O
.	O

Data	O
used	O
were	O
collected	O
from	O
82	O
sheep	O
offered	O
fresh	O
perennial	O
ryegrass	O
(	O
)	O
as	O
the	O
sole	O
diet	O
in	O
6	O
metabolism	O
experiments	O
(	O
data	O
from	O
non-grass-only	O
diets	O
were	O
not	O
used	O
)	O
.	O

Sheep	O
were	O
from	O
breeds	O
of	O
Highlander	O
,	O
Texel	O
,	O
Scottish	O
Blackface	O
,	O
and	O
Swaledale	O
at	O
the	O
age	O
of	O
5	O
to	O
18	O
mo	O
and	O
weighing	O
from	O
24.5	O
to	O
62.7	O
kg	O
.	O

Herbage	O
was	O
harvested	O
daily	O
from	O
6	O
swards	O
of	O
contrasting	O
harvest	O
dates	O
(	O
May	O
to	O
December	O
)	O
,	O
offering	O
wide	O
variation	O
in	O
feed	O
value	O
to	O
cover	O
the	O
range	O
that	O
would	O
be	O
offered	O
in	O
most	O
practical	O
farm	O
situations	O
.	O

Before	O
the	O
commencement	O
of	O
each	O
study	O
,	O
the	O
experimental	O
sward	O
was	O
harvested	O
at	O
a	O
residual	O
height	O
of	O
4	O
cm	O
and	O
allowed	O
to	O
grow	O
for	O
2	O
to	O
4	O
wk	O
to	O
target	O
an	O
average	O
pregrazing	O
sward	O
height	O
in	O
a	O
range	O
of	O
8	O
to	O
15	O
cm	O
depending	O
on	O
the	O
time	O
of	O
year	O
.	O

Sheep	O
were	O
housed	O
in	O
individual	O
pens	O
for	O
14	O
d	O
and	O
then	O
transferred	O
to	O
individual	O
metabolism	O
crates	O
for	O
4	O
d	O
with	O
feed	O
intake	O
and	O
feces	O
and	O
urine	O
outputs	O
measured	O
.	O

Data	O
were	O
analyzed	O
using	O
the	O
linear	O
mixed	O
model	O
procedure	O
to	O
develop	O
prediction	O
equations	O
for	O
feces	O
N	O
,	O
urine	O
N	O
,	O
and	O
manure	O
N	O
outputs	O
using	O
N	O
intake	O
,	O
herbage	O
chemical	O
composition	O
,	O
and	O
digestibility	O
with	O
effects	O
of	O
sex	O
,	O
breed	O
,	O
and	O
experimental	O
periods	O
removed	O
.	O

Nitrogen	O
intake	O
was	O
the	O
best	O
single	O
predictor	O
for	O
N	O
output	O
in	O
feces	O
,	O
urine	O
,	O
and	O
manure	O
,	O
and	O
the	O
value	O
for	O
prediction	O
of	O
manure	O
N	O
output	O
was	O
greater	O
than	O
those	O
for	O
feces	O
N	O
and	O
urine	O
N	O
(	O
0.86	O
vs.	O
0.70	O
and	O
0.77	O
,	O
respectively	O
;	O
<	O
0.001	O
)	O
.	O

Animal	O
BW	O
and	O
herbage	O
DM	O
,	O
ether	O
extract	O
,	O
NDF	O
,	O
ADF	O
,	O
water	B-P
soluble	I-P
carbohydrate	I-P
,	O
and	O
DE	O
concentrations	O
and	O
N	O
digestibility	O
were	O
also	O
used	O
to	O
predict	O
N	O
outputs	O
because	O
N	O
intake	O
may	O
not	O
be	O
available	O
in	O
commercial	O
practice	O
.	O

The	O
prediction	O
equations	O
for	O
N	O
utilizatio	O
n	O
efficiency	O
indicated	O
that	O
increasing	O
feeding	O
level	O
and	O
ME	O
concentration	O
and	O
reducing	O
N	O
concentration	O
could	O
improve	O
N	O
utilization	O
efficiency	O
and	O
shift	O
N	O
excretion	O
into	O
feces	O
rather	O
than	O
urine	O
(	O
<	O
0.001	O
)	O
.	O

The	O
equations	O
developed	O
in	O
the	O
current	O
study	O
provide	O
an	O
approach	O
for	O
sheep	O
producers	O
to	O
quantify	O
N	O
excretion	O
against	O
production	O
and	O
,	O
consequently	O
,	O
to	O
develop	O
their	O
own	O
mitigation	O
strategies	O
to	O
reduce	O
the	O
environmental	O
impact	O
of	O
sheep	O
production	O
systems	O
.	O

Tracing	O
cytotoxic	O
effects	O
of	O
small	O
organic	O
Se	O
species	O
in	O
human	O
liver	O
cells	O
back	O
to	O
total	O
cellular	O
Se	O
and	O
Se	O
metabolites	O
.	O

Small	O
selenium	O
(	O
Se	O
)	O
species	O
play	O
a	O
major	O
role	O
in	O
the	O
metabolism	O
,	O
excretion	O
and	O
dietary	O
supply	O
of	O
the	O
essential	O
trace	O
element	O
selenium	O
.	O

Human	O
cells	O
provide	O
a	O
valuable	O
tool	O
for	O
investigating	O
currently	O
unresolved	O
issues	O
on	O
the	O
cellular	O
mechanisms	O
of	O
Se	O
toxicity	O
and	O
metabolism	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
two	O
isotope	B-P
dilution	I-P
inductively	B-P
coupled	I-P
plasma	I-P
tandem-mass	I-P
spectrometry	I-P
based	O
methods	O
and	O
applied	O
them	O
to	O
human	O
hepatoma	O
cells	O
(	O
HepG2	O
)	O
in	O
order	O
to	O
quantitatively	O
elucidate	O
total	O
cellular	O
Se	O
concentrations	O
and	O
cellular	O
Se	O
species	O
transformations	O
in	O
relation	O
to	O
the	O
cytotoxic	O
effects	O
of	O
four	O
small	O
organic	O
Se	O
species	O
.	O

Species	O
-	O
and	O
incubation	O
time	O
-	O
dependent	O
results	O
were	O
obtained	O
:	O
the	O
two	O
major	O
urinary	O
excretion	O
metabolites	O
trimethylselenonium	O
(	O
TMSe	O
)	O
and	O
methyl-2-acetamido-2-deoxy-1-seleno-β-d-galactopyranoside	O
(	O
SeSugar	O
1	O
)	O
were	O
taken	O
up	O
by	O
the	O
HepG2	O
cells	O
in	O
an	O
unmodified	O
manner	O
and	O
did	O
not	O
considerably	O
contribute	O
to	O
the	O
Se	O
pool	O
.	O

In	O
contrast	O
,	O
Se-methylselenocysteine	O
(	O
MeSeCys	O
)	O
and	O
selenomethionine	O
(	O
SeMet	O
)	O
were	O
taken	O
up	O
in	O
higher	O
amounts	O
,	O
they	O
were	O
largely	O
incorporated	O
by	O
the	O
cells	O
(	O
most	O
likely	O
into	O
proteins	O
)	O
and	O
metabolized	O
to	O
other	O
small	O
Se	O
species	O
.	O

Two	O
new	O
metabolites	O
of	O
MeSeCys	O
,	O
namely	O
γ-glutamyl-Se-methylselenocysteine	O
and	O
Se-methylselenoglutathione	O
,	O
were	O
identified	O
by	O
means	O
of	O
HPLC-electrospray-ionization-Orbitrap-MS	B-P
.	O

They	O
are	O
certainly	O
involved	O
in	O
the	O
(	O
de-	O
)	O
toxification	O
modes	O
of	O
Se	O
metabolism	O
and	O
require	O
further	O
investigation	O
.	O

Coupling	O
of	O
TRPV6	O
and	O
TMEM16A	O
in	O
epithelial	O
principal	O
cells	O
of	O
the	O
rat	O
epididymis	O
.	O

The	O
epididymis	O
establishes	O
a	O
congenial	O
environment	O
for	O
sperm	O
maturation	O
and	O
protection	O
.	O

Its	O
fluid	O
is	O
acidic	O
,	O
and	O
the	O
calcium	O
concentration	O
is	O
low	O
and	O
declines	O
along	O
the	O
length	O
of	O
the	O
epididymal	O
tubule	O
.	O

However	O
,	O
our	O
knowledge	O
of	O
ionic	O
currents	O
and	O
mechanisms	O
of	O
calcium	O
homeostasis	O
in	O
rat	O
epididymal	O
epithelial	O
cells	O
remains	O
enigmatic	O
.	O

In	O
this	O
study	O
,	O
to	O
better	O
understand	O
calcium	O
regulation	O
in	O
the	O
epididymis	O
,	O
we	O
use	O
the	O
patch-clamp	O
method	O
to	O
record	O
from	O
single	O
rat	O
cauda	O
epididymal	O
principal	O
cells	O
.	O

We	O
detect	O
a	O
constitutively	O
active	O
Ca	O
(	O
2+	O
)	O
current	O
with	O
characteristics	O
that	O
match	O
the	O
epithelial	O
calcium	O
channel	O
TRPV6	O
.	O

Electrophysiological	B-P
and	O
pharmacological	B-P
data	I-P
also	O
reveal	O
a	O
constitutively	O
active	O
calcium-activated	O
chloride	O
conductance	O
(	O
CaCC	O
)	O
.	O

Removal	O
of	O
extracellular	O
calcium	O
attenuates	O
not	O
only	O
the	O
TRPV6	O
-like	O
conductance	O
,	O
but	O
also	O
the	O
CaCC	O
.	O

Lanthanide	O
block	O
is	O
time	O
dependent	O
such	O
that	O
the	O
TRPV6	O
-like	O
component	O
is	O
inhibited	O
first	O
,	O
followed	O
by	O
the	O
CaCC	O
.	O

The	O
putative	O
CaCC	O
blocker	O
niflumic	O
acid	O
partially	O
inhibits	O
whole-cell	O
currents	O
,	O
whereas	O
La	O
(	O
3+	O
)	O
almost	O
abolishes	O
whole-cell	O
currents	O
in	O
principal	O
cells	O
.	O

Membrane	O
potential	O
measurements	O
reveal	O
an	O
interplay	O
between	O
La	O
(	O
3+	O
)	O
-	O
sensitive	O
ion	O
channels	O
and	O
those	O
that	O
are	O
sensitive	O
to	O
the	O
specific	O
TMEM16A	O
inhibitor	O
tannic	O
acid	O
.	O

In	O
vivo	O
perfusion	O
of	O
the	O
cauda	O
epididymal	O
tubule	O
shows	O
a	O
substantial	O
rate	O
of	O
Ca	O
(	O
2+	O
)	O
reabsorption	O
from	O
the	O
luminal	O
side	O
,	O
which	O
is	O
dose-dependently	O
suppressed	O
by	O
ruthenium	O
red	O
,	O
a	O
putative	O
blocker	O
of	O
epithelial	O
Ca	O
(	O
2+	O
)	O
channels	O
and	O
CaCC	O
.	O

Finally	O
,	O
we	O
discover	O
messenger	O
RNA	O
for	O
both	O
TRPV6	O
and	O
TMEM16A	O
in	O
the	O
rat	O
epididymis	O
and	O
show	O
that	O
their	O
proteins	O
colocalize	O
in	O
the	O
apical	O
membrane	O
of	O
principal	O
cells	O
.	O

Collectively	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
a	O
coupling	O
mechanism	O
between	O
TRPV6	O
and	O
TMEM16A	O
in	O
principal	O
cells	O
that	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
calcium	O
homeostasis	O
in	O
the	O
epididymis	O
.	O

ISX-9	O
can	O
potentiate	O
cell	O
proliferation	O
and	O
neuronal	O
commitment	O
in	O
the	O
rat	O
dentate	O
gyrus	O
.	O

Adult	O
hippocampal	O
neurogenesis	O
can	O
be	O
modulated	O
by	O
various	O
physiological	O
and	O
pathological	O
conditions	O
,	O
including	O
stress	O
,	O
affective	O
disorders	O
,	O
and	O
several	O
neurological	O
conditions	O
.	O

Given	O
the	O
proposed	O
role	O
of	O
this	O
form	O
of	O
structural	O
plasticity	O
in	O
the	O
functioning	O
of	O
the	O
hippocampus	O
(	O
namely	O
learning	O
and	O
memory	O
and	O
affective	O
behaviors	O
)	O
,	O
it	O
is	O
believed	O
that	O
alterations	O
in	O
hippocampal	O
neurogenesis	O
might	O
underlie	O
some	O
of	O
the	O
behavioral	O
deficits	O
associated	O
with	O
these	O
psychiatric	O
and	O
neurological	O
conditions	O
.	O

Thus	O
,	O
the	O
search	O
for	O
compounds	O
that	O
can	O
reverse	O
these	O
deficits	O
with	O
minimal	O
side	O
effects	O
has	O
become	O
a	O
recognized	O
priority	O
.	O

In	O
the	O
present	O
study	O
we	O
tested	O
the	O
pro-neurogenic	O
effects	O
of	O
isoxazole	O
9	O
(	O
Isx-9	O
)	O
,	O
a	O
small	O
synthetic	O
molecule	O
that	O
has	O
been	O
recently	O
identified	O
through	O
the	O
screening	B-P
of	I-P
chemical	I-P
libraries	I-P
in	O
stem	B-P
cell-based	I-P
assays	I-P
.	O

We	O
found	O
that	O
administration	O
of	O
Isx-9	O
for	O
14days	O
was	O
able	O
to	O
potentiate	O
cell	O
proliferation	O
and	O
increase	O
the	O
number	O
of	O
immature	O
neurons	O
in	O
the	O
hippocampal	O
DG	O
of	O
adult	O
rats	O
.	O

In	O
addition	O
,	O
Isx-9	O
treatment	O
was	O
able	O
to	O
completely	O
reverse	O
the	O
marked	O
reduction	O
in	O
these	O
initial	O
stages	O
of	O
the	O
neurogenic	O
process	O
observed	O
in	O
vehicle	O
-	O
treated	O
animals	O
(	O
which	O
were	O
submitted	O
to	O
repeated	O
handling	B-P
and	O
exposure	O
to	O
daily	O
intraperitoneal	O
injections	O
)	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
recommend	O
that	O
future	O
neurogenesis	O
studies	O
that	O
require	O
repeated	O
handling	B-P
and	O
manipulation	O
of	O
animals	O
should	O
include	O
a	O
naïve	O
(	O
non-manipulated	O
)	O
control	O
to	O
determine	O
the	O
baseline	O
levels	O
of	O
hippocampal	O
cell	O
proliferation	O
and	O
neuronal	O
differentiation	O
.	O

Overall	O
,	O
these	O
findings	O
demonstrate	O
that	O
Isx-9	O
is	O
a	O
promising	O
synthetic	O
compound	O
for	O
the	O
mitigation	O
of	O
stress	O
-	O
induced	O
deficits	O
in	O
adult	O
hippocampal	O
neurogenesis	O
.	O

Future	O
studies	O
are	O
thus	O
warranted	O
to	O
evaluate	O
the	O
pro-neurogenic	O
properties	O
of	O
Isx-9	O
in	O
animal	O
models	O
of	O
affective	O
and	O
neurological	O
disorders	O
associated	O
with	O
impaired	O
hippocampal	O
structural	O
plasticity	O
.	O

Thrombosis	O
of	O
the	O
Saphenous	O
Vein	O
Stump	O
after	O
Varicose	O
Vein	O
Surgery	O
.	O

We	O
evaluated	O
thrombus	O
extension	O
in	O
the	O
proximal	O
stump	O
of	O
the	O
saphenous	O
vein	O
at	O
6	O
days	O
,	O
4	O
weeks	O
,	O
and	O
16	O
weeks	O
after	O
saphenous	O
vein	O
surgery	O
performed	O
between	O
July	O
2013	O
and	O
March	O
2014	O
(	O
18	O
patients	O
,	O
29	O
limbs	O
,	O
and	O
31	O
stumps	O
)	O
using	O
duplex	B-P
ultrasonography	I-P
.	O

All	O
thrombotic	O
events	O
were	O
classified	O
as	O
endovenous	O
heat-induced	O
thrombosis	O
(	O
EHIT	O
)	O
.	O

Thrombus	O
was	O
observed	O
in	O
27	O
stumps	O
(	O
87.1	O
%	O
)	O
,	O
with	O
only	O
four	O
(	O
12.9	O
%	O
)	O
stumps	O
remaining	O
without	O
thrombus	O
on	O
postoperative	O
day	O
6	O
.	O

Thrombus	O
as	O
EHIT	O
class	O
2	O
was	O
observed	O
in	O
one	O
stump	O
and	O
as	O
EHIT	O
class	O
3	O
in	O
another	O
;	O
in	O
the	O
remaining	O
25	O
stumps	O
,	O
it	O
was	O
observed	O
as	O
EHIT	O
class	O
1	O
postoperatively	O
.	O

No	O
further	O
extension	O
of	O
thrombus	O
was	O
found	O
at	O
4	O
and	O
16	O
weeks	O
after	O
surgery	O
.	O

The	O
rate	O
of	O
thrombus	O
formation	O
in	O
the	O
proximal	O
stump	O
of	O
the	O
saphenous	O
vein	O
after	O
conventional	O
surgery	O
is	O
comparatively	O
higher	O
than	O
that	O
after	O
thermoablation	O
techniques	O
.	O

Further	O
studies	O
are	O
required	O
to	O
determine	O
adequate	O
evaluation	O
methods	O
and	O
appropriate	O
therapies	O
for	O
stump	O
thrombosis	O
after	O
varicose	O
vein	O
surgery	O
.	O

(	O
This	O
article	O
is	O
a	O
translation	O
of	O
J	O
Jpn	O
Coll	O
Angiol	O
2015	O
;	O
55	O
:	O
105-110	O
)	O
.	O

CT	B-P
angiography	I-P
for	O
planning	O
transcatheter	O
aortic	O
valve	O
replacement	O
using	O
automated	O
tube	O
voltage	O
selection	O
:	O
Image	O
quality	O
and	O
radiation	O
exposure	O
.	O

To	O
assess	O
image	O
quality	O
and	O
accuracy	O
of	O
CT	B-P
angiography	I-P
(	O
CTA	B-P
)	O
for	O
transcatheter	O
aortic	O
valve	O
replacement	O
(	O
TAVR	O
)	O
planning	O
performed	O
with	O
3rd	B-P
generation	I-P
dual-source	I-P
CT	I-P
(	O
DSCT	B-P
)	O
.	O

We	O
evaluated	O
125	O
patients	O
who	O
underwent	O
TAVR	O
-	O
planning	O
CTA	B-P
on	O
3rd	B-P
generation	I-P
DSCT	I-P
.	O

A	O
two-part	O
protocol	O
was	O
performed	O
including	O
retrospectively	O
ECG-gated	B-P
coronary	I-P
CTA	I-P
(	O
CCTA	B-P
)	O
and	O
prospectively	O
ECG-triggered	B-P
aortoiliac	I-P
CTA	I-P
using	O
60mL	O
of	O
contrast	O
medium	O
.	O

Automated	O
tube	O
voltage	O
selection	O
and	O
advanced	B-P
iterative	I-P
reconstruction	I-P
were	O
applied	O
.	O

Effective	O
dose	O
(	O
ED	O
)	O
,	O
signal-to-noise	O
(	O
SNR	O
)	O
and	O
contrast-to-noise	O
ratios	O
(	O
CNR	O
)	O
were	O
calculated	O
.	O

Five-point	O
scales	O
were	O
used	O
for	O
subjective	O
image	B-P
quality	I-P
analysis	I-P
.	O

In	O
patients	O
who	O
underwent	O
TAVR	O
,	O
sizing	O
parameters	O
were	O
obtained	O
.	O

Image	O
quality	O
was	O
rated	O
good	O
to	O
excellent	O
in	O
97.6	O
%	O
of	O
CCTA	B-P
and	O
100	O
%	O
of	O
aortoiliac	B-P
CTAs	I-P
.	O

CTA	B-P
studies	O
at	O
>	O
100kV	O
showed	O
decreased	O
objective	O
image	O
quality	O
compared	O
to	O
70-100kV	O
(	O
SNR	O
,	O
all	O
p≤0.0459	O
;	O
CNR	O
,	O
all	O
p≤0.0462	O
)	O
.	O

Mean	O
ED	O
increased	O
continuously	O
from	O
70	O
to	O
>	O
100kV	O
(	O
CCTA	B-P
:	O
4.5±1.7mSv-13.6±2.9mSv	O
,	O
all	O
p≤0.0233	O
;	O
aortoiliac	B-P
CTA	I-P
:	O
2.4±0.9mSv-6.8±2.7mSv	O
,	O
all	O
p≤0.0414	O
)	O
.	O

In	O
39	O
patients	O
TAVR	O
was	O
performed	O
and	O
annulus	O
diameter	O
was	O
within	O
the	O
recommended	O
range	O
in	O
all	O
patients	O
.	O

No	O
severe	O
cardiac	O
or	O
vascular	O
complications	O
were	O
noted	O
.	O

3rd	B-P
generation	I-P
DSCT	I-P
provides	O
diagnostic	O
image	O
quality	O
in	O
TAVR	O
-	O
planning	O
CTA	B-P
and	O
facilitates	O
reliable	O
assessment	O
of	O
TAVR	O
device	O
and	O
delivery	O
option	O
while	O
reducing	O
radiation	O
dose	O
.	O

Comparison	O
of	O
270	O
Versus	O
320	O
mg	O
I/mL	O
of	O
Iodixanol	O
in	O
1	O
Image	O
Assessment	O
of	O
Both	O
Renal	O
Arteries	O
and	O
Veins	O
With	O
Dual-Energy	B-P
Spectral	I-P
CT	I-P
Imaging	I-P
in	O
Late	O
Arterial	O
Phase	O
and	O
Their	O
Influence	O
on	O
Renal	O
Function	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
image	O
quality	O
of	O
renal	O
arteries	O
and	O
veins	O
with	O
dual-energy	B-P
spectral	I-P
computed	I-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
imaging	I-P
in	O
late	O
arterial	O
phase	O
using	O
270	O
and	O
320	O
mg	O
I/mL	O
of	O
iodixanol	O
and	O
their	O
influence	O
on	O
renal	O
function	O
.	O

A	O
total	O
of	O
1062	O
patients	O
underwent	O
renal	B-P
CT	I-P
angiography	I-P
with	O
270	O
or	O
320	O
mg	O
I/mL	O
of	O
iodixanol	O
with	O
dual-energy	B-P
spectral	I-P
CT	I-P
imaging	I-P
in	O
late	O
arterial	O
phase	O
.	O

Image	O
quality	O
and	O
their	O
influence	O
on	O
renal	O
function	O
were	O
compared	O
.	O

There	O
were	O
no	O
significant	O
differences	O
of	O
CT	O
value	O
,	O
signal-to-noise	O
ratio	O
,	O
contrast-to-noise	O
ratio	O
,	O
and	O
subjective	O
score	O
of	O
renal	O
vessels	O
between	O
2	O
groups	O
(	O
all	O
P	O
>	O
0.05	O
)	O
.	O

The	O
incidence	O
of	O
contrast-induced	O
nephropathy	O
in	O
patients	O
with	O
abnormal	O
renal	O
function	O
using	O
320	O
mg	O
I/mL	O
of	O
iodixanol	O
was	O
significantly	O
higher	O
than	O
using	O
270	O
mg	O
I/mL	O
of	O
iodixanol	O
(	O
P	O
=	O
0.043	O
)	O
.	O

The	O
renal	O
arteries	O
and	O
veins	O
can	O
be	O
fully	O
assessed	O
in	O
late	O
arterial	O
phase	O
with	O
270	O
mg	O
I/mL	O
of	O
iodixanol	O
using	O
dual-energy	B-P
spectral	I-P
CT	I-P
scan	I-P
with	O
better	O
preserved	O
renal	O
function	O
.	O

Development	O
of	O
(	O
111	O
)	O
In	O
-labeled	O
exendin	O
(	O
9-39	O
)	O
derivatives	O
for	O
single-photon	B-P
emission	I-P
computed	I-P
tomography	I-P
imaging	I-P
of	O
insulinoma	O
.	O

Insulinoma	O
is	O
a	O
tumor	O
derived	O
from	O
pancreatic	O
β-cells	O
,	O
and	O
the	O
resulting	O
hyperinsulinemia	O
leads	O
to	O
characteristic	O
hypoglycemia	O
.	O

Recent	O
studies	O
have	O
reported	O
the	O
frequent	O
overexpression	O
of	O
glucagon-like	O
peptide-1	O
receptor	O
(	O
GLP-1R	O
)	O
in	O
human	O
insulinomas	O
,	O
suggesting	O
that	O
the	O
binding	O
of	O
a	O
radiolabeled	O
compound	O
to	O
GLP-1R	O
is	O
useful	O
for	O
the	O
imaging	B-P
of	O
such	O
tumors	O
.	O

Exendin	O
(	O
9-39	O
)	O
,	O
a	O
fragment	O
peptide	O
of	O
exendin-3	O
and	O
-4	O
,	O
binds	O
GLP-1R	O
with	O
high	O
affinity	O
and	O
acts	O
as	O
an	O
antagonist	O
.	O

Accordingly	O
,	O
radiolabeled	O
exendin	O
(	O
9-39	O
)	O
derivatives	O
have	O
also	O
been	O
investigated	O
as	O
insulinoma	O
imaging	O
probes	O
that	O
might	O
be	O
less	O
likely	O
to	O
induce	O
hypoglycemia	O
.	O

In	O
this	O
study	O
,	O
we	O
synthesized	O
a	O
novel	O
indium-111	O
(	O
(	O
111	O
)	O
In	O
)	O
-benzyl-diethylenetriaminepentaacetic	O
acid	O
(	O
(	O
111	O
)	O
In-BnDTPA	O
)	O
-conjugated	O
exendin	O
(	O
9-39	O
)	O
,	O
(	O
111	O
)	O
In-BnDTPA-exendin	O
(	O
9-39	O
)	O
,	O
and	O
evaluated	O
its	O
utility	O
as	O
a	O
probe	O
for	O
the	O
SPECT	B-P
imaging	I-P
of	O
insulinoma	O
.	O

natIn-BnDTPA-exendin	O
(	O
9-39	O
)	O
exhibited	O
a	O
high	O
affinity	O
for	O
GLP-1R	O
(	O
IC50=2.5nM	O
)	O
,	O
stability	O
in	O
plasma	O
,	O
and	O
a	O
specific	O
activity	O
that	O
improved	O
following	O
reactions	O
with	O
a	O
solvent	O
and	O
solubilizer	O
.	O

Regarding	O
the	O
in	O
vivo	O
biodistribution	O
of	O
(	O
111	O
)	O
In-BnDTPA-exendin	O
(	O
9-39	O
)	O
in	O
INS-1	O
tumor	O
-bearing	O
mice	O
,	O
high	O
uptake	O
levels	O
were	O
observed	O
in	O
tumors	O
(	O
14.6	O
%	O
ID/g	O
at	O
15min	O
)	O
,	O
with	O
corresponding	O
high	O
tumor	O
-to-	O
blood	O
(	O
T/B	O
)	O
,	O
tumor	O
-to-	O
muscle	O
(	O
T/M	O
)	O
,	O
and	O
tumor	O
-to-	O
pancreas	O
(	O
T/P	O
)	O
ratios	O
(	O
T/B	O
=2.55	O
,	O
T/M	O
=22.7	O
,	O
T/P	O
=2.7	O
at	O
1h	O
)	O
.	O

The	O
pre-administration	O
of	O
excess	O
nonradioactive	O
exendin	O
(	O
9-39	O
)	O
significantly	O
reduced	O
accumulation	O
in	O
both	O
the	O
tumor	O
and	O
pancreas	O
(	O
76	O
%	O
and	O
68	O
%	O
inhibition	O
,	O
respectively	O
)	O
at	O
1h	O
after	O
(	O
111	O
)	O
In-BnDTPA-exendin	O
(	O
9-39	O
)	O
injection	O
,	O
indicating	O
that	O
the	O
GLP-1R	O
mediated	O
a	O
majority	O
of	O
(	O
111	O
)	O
In-BnDTPA-exendin	O
(	O
9-39	O
)	O
uptake	O
in	O
the	O
tumor	O
and	O
pancreas	O
.	O

Finally	O
,	O
(	O
111	O
)	O
In-BnDTPA-exendin	O
(	O
9-39	O
)	O
SPECT/CT	B-P
studies	I-P
in	O
mice	O
yielded	O
clear	O
images	O
of	O
tumors	O
at	O
30min	O
post-injection	O
.	O

These	O
results	O
suggest	O
that	O
(	O
111	O
)	O
In-BnDTPA-exendin	O
(	O
9-39	O
)	O
could	O
be	O
a	O
useful	O
SPECT	B-P
molecular	O
imaging	O
probe	O
for	O
the	O
detection	O
and	O
exact	O
localization	O
of	O
insulinomas	O
.	O

Family	O
Psychosocial	O
Risk	O
Screening	O
in	O
Infants	O
and	O
Older	O
Children	O
in	O
the	O
Acute	O
Pediatric	O
Hospital	O
Setting	O
Using	O
the	O
Psychosocial	O
Assessment	O
Tool	O
.	O

To	O
examine	O
the	O
validity	O
of	O
the	O
Psychosocial	O
Assessment	O
Tool	O
(	O
PAT	O
)	O
with	O
families	O
of	O
infants	O
(	O
<	O
2	O
years	O
)	O
and	O
children	O
admitted	O
to	O
hospital	O
with	O
acute	O
life-threatening	O
illnesses	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
235	O
parents	O
of	O
177	O
children	O
admitted	O
to	O
oncology	O
,	O
cardiology	O
,	O
or	O
pediatric	O
intensive	O
care	O
completed	O
the	O
PAT	O
and	O
measures	O
of	O
acute	O
stress	O
,	O
trait	O
anxiety	O
,	O
family	O
functioning	O
,	O
and	O
quality	O
of	O
life	O
,	O
a	O
mean	O
3.7	O
weeks	O
following	O
diagnosis	O
.	O

A	O
modified	O
PAT	O
was	O
used	O
for	O
families	O
of	O
infants	O
,	O
rendering	O
two	O
forms	O
,	O
PAT	O
(	O
<	O
2	O
)	O
and	O
PAT	O
(	O
2+	O
)	O
.	O

RESULTS	O
:	O
Psychometrics	B-P
for	O
PAT	O
(	O
<	O
2	O
)	O
and	O
PAT	O
(	O
2+	O
)	O
were	O
acceptable	O
.	O

PAT	O
Total	O
and	O
Subscale	O
scores	O
for	O
each	O
version	O
were	O
significantly	O
correlated	O
with	O
validation	O
measures	O
.	O

Internal	O
consistency	O
for	O
PAT	O
subscales	O
was	O
variable	O
.	O

Receiver	O
Operating	O
Characteristics	O
provided	O
some	O
support	O
for	O
PAT	O
cutoffs	O
.	O

PAT	O
scores	O
across	O
illness	O
groups	O
were	O
comparable	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provides	O
promising	O
support	O
for	O
the	O
PAT	O
as	O
a	O
psychosocial	O
screener	O
for	O
families	O
of	O
infants	O
and	O
older	O
children	O
across	O
illness	O
conditions	O
.	O

Paradoxical	O
physiological	O
responses	O
to	O
propranolol	O
in	O
a	O
Rett	O
syndrome	O
patient	O
:	O
a	O
case	O
report	O
.	O

Rett	O
Syndrome	O
(	O
RTT	O
)	O
,	O
caused	O
by	O
a	O
loss-of-function	O
in	O
the	O
epigenetic	O
modulator	O
:	O
X-linked	O
methyl-CpG	O
binding	O
protein	O
2	O
(	O
MeCP2	O
)	O
,	O
is	O
a	O
pervasive	O
neurological	O
disorder	O
characterized	O
by	O
compromised	O
brain	O
functions	O
,	O
anxiety	O
,	O
severe	O
mental	O
retardation	O
,	O
language	O
and	O
learning	O
disabilities	O
,	O
repetitive	O
stereotyped	O
hand	O
movements	O
and	O
developmental	O
regression	O
.	O

An	O
imbalance	O
in	O
the	O
sympathetic	O
and	O
the	O
parasympathetic	O
nervous	O
system	O
(	O
dysautonomia	O
)	O
and	O
the	O
resulting	O
autonomic	O
storms	O
is	O
a	O
frequent	O
occurrence	O
in	O
patients	O
with	O
RTT	O
.	O

The	O
prototypical	O
beta	O
blocker	O
propranolol	O
has	O
been	O
used	O
to	O
manage	O
sympathetic	O
hyperactivity	O
in	O
patients	O
with	O
RTT	O
.	O

A	O
13	O
year	O
old	O
girl	O
with	O
RTT	O
was	O
referred	O
to	O
the	O
Centre	O
for	O
Interventional	O
Paediatric	O
Psychopharmacology	O
and	O
Rare	O
Diseases	O
(	O
CIPPRD	O
)	O
,	O
South	O
London	O
and	O
Maudsley	O
NHS	O
Foundation	O
Trust	O
.	O

Her	O
clinical	O
picture	O
included	O
disordered	O
breathing	O
with	O
concomitant	O
hyperventilation	O
and	O
apnoea	O
,	O
epilepsy	O
,	O
scoliosis	O
,	O
no	O
QT	O
prolongation	O
(	O
QT/QTc	O
[	O
372/467	O
ms	O
on	O
automated	O
electrocardiogram	B-P
[	O
ECG	B-P
]	O
,	O
but	O
manually	O
calculated	O
to	O
be	O
440	O
ms	O
]	O
)	O
,	O
no	O
cardiac	O
abnormalities	O
(	O
PR	O
interval	O
:	O
104	O
ms	O
,	O
QRS	O
duration	O
:	O
78	O
ms	O
)	O
,	O
and	O
generalised	O
anxiety	O
disorder	O
(	O
ICD-10-CM	O
Diagnosis	O
Code	O
F41.1	O
)	O
.	O

She	O
was	O
also	O
constipated	O
and	O
was	O
fed	O
via	O
percutaneous	O
endoscopic	O
gastrostomy	O
(	O
PEG	O
)	O
.	O

To	O
manage	O
the	O
dysautonomia	O
,	O
propranolol	O
was	O
given	O
(	O
5	O
mg	O
and	O
10	O
mg	O
)	O
and	O
in	O
parallel	O
her	O
physiological	O
parameters	O
,	O
including	O
heart	O
rate	O
,	O
skin	O
temperature	O
and	O
skin	O
transpiration	O
,	O
were	O
monitored	O
continuously	O
for	O
24	O
h	O
as	O
she	O
went	O
about	O
her	O
activities	O
of	O
daily	O
living	O
.	O

Whilst	O
her	O
skin	O
temperature	O
increased	O
and	O
skin	O
transpiration	O
decreased	O
,	O
unexpectedly	O
there	O
was	O
a	O
significant	O
paradoxical	O
increase	O
in	O
the	O
patient	O
's	O
average	O
heart	O
rate	O
following	O
propranolol	O
treatment	O
.	O

Here	O
,	O
we	O
present	O
a	O
unique	O
case	O
of	O
a	O
paradoxical	O
increase	O
in	O
heart	O
rate	O
response	O
following	O
propranolol	O
treatment	O
for	O
managing	O
dysautonomia	O
in	O
a	O
child	O
with	O
RTT	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
better	O
understand	O
the	O
underlying	O
dysautonomia	O
in	O
patients	O
with	O
RTT	O
and	O
the	O
impact	O
this	O
might	O
have	O
on	O
treatment	O
strategies	O
in	O
rare	O
disorders	O
such	O
as	O
RTT	O
.	O

Long-term	O
biological	O
hydrogen	O
production	O
by	O
agar	O
immobilized	O
Rhodobacter	O
capsulatus	O
in	O
a	O
sequential	O
batch	O
photobioreactor	O
.	O

In	O
this	O
study	O
,	O
agar	O
immobilization	O
technique	O
was	O
employed	O
for	O
biological	O
hydrogen	O
production	O
using	O
Rhodobacter	O
capsulatus	O
DSM	O
1710	O
(	O
wild	O
type	O
)	O
and	O
YO3	O
(	O
hup-mutant	O
)	O
strains	O
in	O
sequential	O
batch	O
process	O
.	O

Different	O
agar	O
and	O
glutamate	O
concentrations	O
were	O
tested	O
with	O
defined	O
nutrient	O
medium	O
.	O

Agar	O
concentration	O
4	O
%	O
(	O
w/v	O
)	O
and	O
4	O
mM	O
glutamate	O
were	O
selected	O
for	O
bacterial	O
immobilization	O
in	O
terms	O
of	O
rate	O
and	O
longevity	O
of	O
hydrogen	O
production	O
.	O

Acetate	O
concentration	O
was	O
increased	O
from	O
40	O
to	O
60-100	O
and	O
60	O
mM	O
gave	O
best	O
results	O
with	O
both	O
bacterial	O
strains	O
immobilized	O
in	O
4	O
%	O
(	O
w/v	O
)	O
agar	O
.	O

Cell	O
concentration	O
was	O
increased	O
from	O
2.5	O
to	O
5	O
mg	O
dcw	O
mL	O
(	O
-1	O
)	O
agar	O
and	O
it	O
was	O
found	O
that	O
increasing	O
cell	O
concentration	O
of	O
wild-type	O
strain	O
caused	O
decrease	O
in	O
yield	O
and	O
productivity	O
while	O
these	O
parameters	O
improved	O
by	O
increasing	O
cell	O
concentration	O
of	O
mutant	O
strain	O
.	O

Also	O
,	O
the	O
hydrogen	O
production	O
time	O
has	O
extended	O
from	O
17	O
days	O
up	O
to	O
60	O
days	O
according	O
to	O
the	O
process	O
conditions	O
and	O
parameters	O
.	O

Hydrogen	O
production	O
by	O
immobilized	O
photosynthetic	O
bacteria	O
is	O
a	O
convenient	O
technology	O
for	O
hydrogen	O
production	O
as	O
it	O
enables	O
to	O
produce	O
hydrogen	O
with	O
high	O
organic	O
acid	O
concentrations	O
comparing	O
to	O
suspended	B-P
cultures	I-P
.	O

Besides	O
,	O
immobilization	O
increases	O
the	O
stability	O
of	O
the	O
system	O
and	O
allowed	O
sequential	O
batch	O
operation	O
for	O
long-term	O
application	O
.	O

Cerebellar	O
ataxia	O
and	O
sensory	O
ganglionopathy	O
associated	O
with	O
light-chain	O
myeloma	O
.	O

Cerebellar	O
ataxia	O
with	O
sensory	O
ganglionopathy	O
is	O
a	O
rare	O
neurological	O
combination	O
that	O
can	O
occur	O
in	O
some	O
hereditary	O
ataxias	O
including	O
mitochondrial	O
diseases	O
and	O
in	O
gluten	O
sensitivity	O
.	O

Individually	O
each	O
condition	O
can	O
be	O
a	O
classic	O
paraneoplastic	O
neurological	O
syndrome	O
.	O

We	O
report	O
a	O
patient	O
with	O
this	O
combination	O
who	O
was	O
diagnosed	O
with	O
light-chain	O
myeloma	O
ten	O
years	O
after	O
initial	O
presentation	O
.	O

A	O
65-year-old	O
Caucasian	O
lady	O
was	O
referred	O
to	O
our	O
Ataxia	O
Clinic	O
because	O
of	O
a	O
6-year	O
history	O
of	O
progressive	O
unsteadiness	O
and	O
a	O
2-year	O
history	O
of	O
slurred	O
speech	O
.	O

Past	O
medical	O
history	O
included	O
arterial	O
hypertension	O
.	O

The	O
patient	O
was	O
a	O
non-smoker	O
was	O
not	O
consuming	O
alcohol	O
excessively	O
.	O

There	O
was	O
no	O
family	O
history	O
of	O
ataxia	O
.	O

Neurological	B-P
examination	I-P
revealed	O
prominent	O
gaze-evoked	O
nystagmus	O
,	O
heel	O
to	O
shin	O
ataxia	O
,	O
gait	O
ataxia	O
,	O
reduced	O
reflexes	O
and	O
loss	O
of	O
vibration	O
sensation	O
in	O
the	O
legs	O
.	O

Cerebellar	O
ataxia	O
was	O
confirmed	O
using	O
magnetic	B-P
resonance	I-P
spectroscopy	I-P
of	O
the	O
cerebellum	O
and	O
sensory	O
ganglionopathy	O
using	O
neurophysiological	B-P
assessments	I-P
including	O
blink	B-P
reflex	I-P
study	I-P
.	O

A	O
muscle	B-P
biopsy	I-P
that	O
was	O
arranged	O
to	O
explore	O
the	O
possibility	O
of	O
mitochondrial	O
disease	O
revealed	O
amyloidosis	O
.	O

Urinalysis	B-P
confirmed	O
the	O
presence	O
of	O
light	O
chains	O
.	O

A	O
bone	B-P
marrow	I-P
biopsy	I-P
confirmed	O
the	O
diagnosis	O
of	O
light	O
chain	O
multiple	O
myeloma	O
.	O

Whilst	O
it	O
could	O
be	O
argued	O
that	O
this	O
could	O
simply	O
be	O
a	O
coincidence	O
,	O
the	O
rarity	O
of	O
these	O
conditions	O
and	O
the	O
absence	O
of	O
an	O
alternative	O
aetiology	O
for	O
the	O
neurological	O
dysfunction	O
argue	O
in	O
favour	O
of	O
a	O
paraneoplastic	O
phenomenon	O
.	O

Disease	O
Activity	O
and	O
Increased	O
Risk	O
of	O
Cardiovascular	O
Death	O
among	O
Patients	O
with	O
Psoriatic	O
Arthritis	O
.	O

Recent	O
studies	O
indicate	O
increased	O
cardiovascular	O
(	O
CV	O
)	O
morbidity	O
and	O
mortality	O
in	O
patients	O
with	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
,	O
but	O
results	O
are	O
inconsistent	O
.	O

This	O
prompted	O
our	O
investigation	O
of	O
the	O
mortality	O
rate	O
,	O
cause	O
of	O
death	O
,	O
and	O
incidence	O
of	O
acute	O
CV	O
events	O
in	O
patients	O
from	O
northern	O
Sweden	O
with	O
PsA	O
.	O

Patients	O
with	O
established	O
PsA	O
(	O
464	O
)	O
were	O
included	O
.	O

To	O
calculate	O
standardized	O
mortality	O
ratio	O
(	O
SMR	O
)	O
and	O
standardized	O
incidence	O
ratio	O
(	O
SIR	O
)	O
for	O
CV	O
events	O
,	O
data	O
were	O
extracted	O
from	O
the	O
National	O
Causes	O
of	O
Death	O
Register	O
and	O
the	O
National	O
Inpatient	O
Care	O
Register	O
in	O
Sweden	O
,	O
and	O
compared	O
with	O
the	O
general	O
population	O
.	O

The	O
study	O
period	O
was	O
1995-2011	O
.	O

To	O
study	O
the	O
effect	O
of	O
inflammatory	O
activity	O
,	O
a	O
composite	O
disease	B-P
activity	I-P
index	I-P
(	O
DAI	B-P
)	O
was	O
used	O
.	O

The	O
SMR	O
(	O
95	O
%	O
CI	O
)	O
for	O
overall	O
mortality	O
and	O
diseases	O
of	O
the	O
circulatory	O
system	O
(	O
International	O
Classification	O
of	O
Diseases	O
,	O
10th	O
edition	O
;	O
I00-I99	O
)	O
was	O
1.22	O
(	O
0.89-1.63	O
)	O
and	O
1.64	O
(	O
1.02-2.52	O
)	O
,	O
respectively	O
.	O

In	O
regression	O
analysis	O
,	O
DAI	B-P
was	O
significantly	O
associated	O
with	O
death	O
(	O
OR	O
1.99	O
,	O
95	O
%	O
CI	O
1.41-2.80	O
)	O
when	O
adjusted	O
for	O
age	O
and	O
sex	O
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
remained	O
significant	O
after	O
stratifying	O
patients	O
into	O
the	O
2	O
major	O
causes	O
of	O
death	O
:	O
diseases	O
of	O
the	O
circulatory	O
system	O
and	O
malignant	O
neoplasms	O
.	O

Peripheral	O
and	O
axial	O
disease	O
was	O
associated	O
with	O
death	O
(	O
OR	O
4.02	O
,	O
95	O
%	O
CI	O
1.84-8.84	O
,	O
p	O
<	O
0.001	O
)	O
compared	O
with	O
peripheral	O
disease	O
only	O
.	O

The	O
SIR	O
(	O
95	O
%	O
CI	O
)	O
for	O
a	O
CV	O
event	O
(	O
myocardial	O
infarction	O
or	O
stroke	O
)	O
was	O
0.597	O
(	O
0.40-0.86	O
)	O
;	O
this	O
association	O
was	O
only	O
significant	O
in	O
men	O
.	O

Patients	O
with	O
PsA	O
had	O
a	O
small	O
but	O
significant	O
increase	O
in	O
SMR	O
for	O
death	O
due	O
to	O
diseases	O
of	O
the	O
circulatory	O
system	O
compared	O
with	O
the	O
general	O
population	O
.	O

Among	O
patients	O
,	O
death	O
was	O
associated	O
with	O
DAI	B-P
,	O
as	O
well	O
as	O
axial	O
involvement	O
in	O
combination	O
with	O
peripheral	O
disease	O
,	O
indicating	O
more	O
aggressive	O
disease	O
phenotypes	O
.	O

Flexible	O
information	O
routing	O
by	O
transient	O
synchrony	B-P
.	O

Perception	O
,	O
cognition	O
and	O
behavior	O
rely	O
on	O
flexible	O
communication	O
between	O
microcircuits	O
in	O
distinct	O
cortical	O
regions	O
.	O

The	O
mechanisms	O
underlying	O
rapid	O
information	O
rerouting	O
between	O
such	O
microcircuits	O
are	O
still	O
unknown	O
.	O

It	O
has	O
been	O
proposed	O
that	O
changing	O
patterns	O
of	O
coherence	O
between	O
local	O
gamma	O
rhythms	O
support	O
flexible	O
information	O
rerouting	O
.	O

The	O
stochastic	O
and	O
transient	O
nature	O
of	O
gamma	O
oscillations	O
in	O
vivo	O
,	O
however	O
,	O
is	O
hard	O
to	O
reconcile	O
with	O
such	O
a	O
function	O
.	O

Here	O
we	O
show	O
that	O
models	O
of	O
cortical	O
circuits	O
near	O
the	O
onset	O
of	O
oscillatory	O
synchrony	B-P
selectively	O
route	O
input	O
signals	O
despite	O
the	O
short	O
duration	O
of	O
gamma	O
bursts	O
and	O
the	O
irregularity	O
of	O
neuronal	O
firing	O
.	O

In	O
canonical	O
multiarea	O
circuits	O
,	O
we	O
find	O
that	O
gamma	O
bursts	O
spontaneously	O
arise	O
with	O
matched	O
timing	O
and	O
frequency	O
and	O
that	O
they	O
organize	O
information	O
flow	O
by	O
large-scale	O
routing	O
states	O
.	O

Specific	O
self-organized	O
routing	O
states	O
can	O
be	O
induced	O
by	O
minor	O
modulations	O
of	O
background	O
activity	O
.	O

The	O
Effect	O
of	O
Oxygen	O
Inhalation	O
Plus	O
Oxytocin	O
Compared	O
with	O
Oxytocin	O
Only	O
on	O
Postpartum	O
Haemorrhage	O
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

Post	O
Partum	O
Haemorrhage	O
(	O
PPH	O
)	O
is	O
the	O
leading	O
cause	O
of	O
maternal	O
mortality	O
across	O
the	O
world	O
,	O
mainly	O
in	O
the	O
developing	O
countries	O
.	O

The	O
present	O
study	O
was	O
conducted	O
with	O
the	O
aim	O
to	O
investigate	O
effect	O
of	O
oxygen	O
inhalation	O
plus	O
oxytocin	O
compared	O
with	O
oxytocin	O
only	O
on	O
PPH	O
.	O

This	O
study	O
was	O
a	O
clinical	O
trial	O
which	O
was	O
performed	O
in	O
Shahid	O
Mustafa	O
Khomieni	O
Teaching	O
Hospital	O
of	O
Ilam	O
(	O
western	O
Iran	O
)	O
from	O
April	O
2012	O
to	O
Nov	O
2013	O
.	O

One	O
hundred	O
and	O
twenty	O
pregnant	O
women	O
who	O
were	O
referred	O
to	O
delivery	O
ward	O
for	O
normal	O
vaginal	O
delivery	O
were	O
selected	O
with	O
convenience	O
sampling	O
method	O
and	O
they	O
were	O
randomly	O
assigned	O
into	O
two	O
groups	O
.	O

For	O
both	O
groups	O
management	O
of	O
the	O
third	O
stage	O
of	O
labour	O
was	O
done	O
using	O
1000CC	O
Ringer	O
and	O
20	O
units	O
of	O
Oxytocin	O
.	O

In	O
the	O
intervention	O
group	O
,	O
in	O
addition	O
to	O
the	O
routine	O
administration	O
,	O
8	O
liters	O
of	O
oxygen	O
via	O
face	O
mask	O
was	O
used	O
continuously	O
until	O
2	O
hours	O
after	O
delivery	O
.	O

Blood	O
loss	O
was	O
determined	O
by	O
regular	O
weighing	O
of	O
the	O
buttocks	O
that	O
were	O
previously	O
weighted	O
.	O

The	O
difference	O
was	O
calculated	B-P
before	O
and	O
after	O
weighing	O
(	O
1	O
gram	O
increasing	O
of	O
weight	O
was	O
considered	O
to	O
be	O
equivalent	O
to	O
1CC	O
blood	O
loss	O
)	O
.	O

Data	O
were	O
analysed	O
by	O
SPSS	O
16	O
version	O
using	O
Student-	O
t	O
and	O
Chi-square	O
tests	O
.	O

The	O
two	O
groups	O
were	O
homogenous	O
in	O
regard	O
to	O
all	O
the	O
base	O
line	O
variables	O
.	O

The	O
study	O
results	O
indicated	O
that	O
the	O
mean	O
of	O
blood	O
loss	O
were	O
(	O
256.16±97	O
)	O
ml	O
at	O
two	O
hours	O
after	O
delivery	O
in	O
the	O
control	O
group	O
and	O
(	O
149.5±46.49	O
)	O
ml	O
in	O
the	O
intervention	O
group	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
PPH	O
of	O
the	O
two	O
groups	O
(	O
p	O
<	O
0.006	O
)	O
.	O

Research	O
findings	O
showed	O
that	O
the	O
use	O
of	O
inspired	O
oxygen	O
during	O
the	O
third	O
stage	O
of	O
labour	O
and	O
oxytocin	O
infusion	O
during	O
2hours	O
later	O
resulted	O
in	O
a	O
significant	O
decreasing	O
in	O
the	O
amount	O
of	O
bleeding	O
after	O
normal	O
vaginal	O
delivery	O
.	O

Highly	B-P
sensitive	I-P
detection	I-P
of	I-P
influenza	I-P
virus	I-P
by	O
boron-doped	O
diamond	O
electrode	O
terminated	O
with	O
sialic	O
acid-mimic	O
peptide	O
.	O

The	O
progression	O
of	O
influenza	O
varies	O
according	O
to	O
age	O
and	O
the	O
presence	O
of	O
an	O
underlying	O
disease	O
;	O
appropriate	O
treatment	O
is	O
therefore	O
required	O
to	O
prevent	O
severe	O
disease	O
.	O

Anti-influenza	O
therapy	O
,	O
such	O
as	O
with	O
neuraminidase	O
inhibitors	O
,	O
is	O
effective	O
,	O
but	O
diagnosis	O
at	O
an	O
early	O
phase	O
of	O
infection	O
before	O
viral	O
propagation	O
is	O
critical	O
.	O

Here	O
,	O
we	O
show	O
that	O
several	O
dozen	O
plaque-forming	O
units	O
(	O
pfu	O
)	O
of	O
influenza	O
virus	O
(	O
IFV	O
)	O
can	O
be	O
detected	O
using	O
a	O
boron-doped	O
diamond	O
(	O
BDD	O
)	O
electrode	O
terminated	O
with	O
a	O
sialic	O
acid-mimic	O
peptide	O
.	O

The	O
peptide	O
was	O
used	O
instead	O
of	O
the	O
sialyloligosaccharide	O
receptor	O
,	O
which	O
is	O
the	O
common	O
receptor	O
of	O
influenza	O
A	O
and	O
B	O
viruses	O
required	O
during	O
the	O
early	O
phase	O
of	O
infection	O
,	O
to	O
capture	O
IFV	O
particles	O
.	O

The	O
peptide	O
,	O
which	O
was	O
previously	O
identified	O
by	O
phage-display	O
technology	O
,	O
was	O
immobilized	O
by	O
click	O
chemistry	O
on	O
the	O
BDD	O
electrode	O
,	O
which	O
has	O
excellent	O
electrochemical	O
characteristics	O
such	O
as	O
low	O
background	O
current	O
and	O
weak	O
adsorption	B-P
of	I-P
biomolecules	I-P
.	O

Electrochemical	B-P
impedance	I-P
spectroscopy	I-P
revealed	O
that	O
H1N1	O
and	O
H3N2	O
IFVs	O
were	O
detectable	O
in	O
the	O
range	O
of	O
20-500	O
pfu	O
by	O
using	O
the	O
peptide-terminated	O
BDD	O
electrode	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
BDD	O
device	O
integrated	O
with	O
the	O
receptor-mimic	O
peptide	O
has	O
high	O
sensitivity	O
for	O
detection	O
of	O
a	O
low	O
number	O
of	O
virus	O
particles	O
in	O
the	O
early	O
phase	O
of	O
infection	O
.	O

Amphetamine	O
Withdrawal	O
Differentially	O
Increases	O
the	O
Expression	O
of	O
Organic	O
Cation	O
Transporter	O
3	O
and	O
Serotonin	O
Transporter	O
in	O
Limbic	O
Brain	O
Regions	O
.	O

Amphetamine	O
withdrawal	O
increases	O
anxiety	O
and	O
stress	O
sensitivity	O
related	O
to	O
blunted	O
ventral	O
hippocampus	O
(	O
vHipp	O
)	O
and	O
enhances	O
the	O
central	O
nucleus	O
of	O
the	O
amygdala	O
(	O
CeA	O
)	O
serotonin	O
responses	O
.	O

Extracellular	O
serotonin	O
levels	O
are	O
regulated	O
by	O
the	O
serotonin	O
transporter	O
(	O
SERT	O
)	O
and	O
organic	O
cation	O
transporter	O
3	O
(	O
OCT3	O
)	O
,	O
and	O
vHipp	O
OCT3	O
expression	O
is	O
enhanced	O
during	O
24	O
hours	O
of	O
amphetamine	O
withdrawal	O
,	O
while	O
SERT	O
expression	O
is	O
unaltered	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
OCT3	O
and	O
SERT	O
expression	O
in	O
the	O
CeA	O
is	O
also	O
affected	O
during	O
acute	O
withdrawal	O
to	O
explain	O
opposing	O
regional	O
alterations	O
in	O
limbic	O
serotonergic	O
neurotransmission	O
and	O
if	O
respective	O
changes	O
continued	O
with	O
two	O
weeks	O
of	O
withdrawal	O
.	O

We	O
also	O
determined	O
whether	O
changes	O
in	O
transporter	O
expression	O
were	O
confined	O
to	O
these	O
regions	O
.	O

Male	O
rats	O
received	O
amphetamine	O
or	O
saline	O
for	O
two	O
weeks	O
followed	O
by	O
24	O
hours	O
or	O
two	O
weeks	O
of	O
withdrawal	O
,	O
with	O
transporter	O
expression	O
measured	O
using	O
Western	B-P
immunoblot	I-P
.	O

OCT3	O
and	O
SERT	O
expression	O
increased	O
in	O
the	O
CeA	O
at	O
both	O
withdrawal	O
timepoints	O
.	O

In	O
the	O
vHipp	O
,	O
OCT3	O
expression	O
increased	O
only	O
at	O
24	O
hours	O
of	O
withdrawal	O
,	O
with	O
an	O
equivalent	O
pattern	O
seen	O
in	O
the	O
dorsomedial	O
hypothalamus	O
.	O

No	O
changes	O
were	O
evident	O
in	O
any	O
other	O
regions	O
sampled	O
.	O

These	O
regionally	O
specific	O
changes	O
in	O
limbic	O
OCT3	O
and	O
SERT	O
expression	O
may	O
partially	O
contribute	O
to	O
the	O
serotonergic	O
imbalance	O
and	O
negative	O
affect	O
during	O
amphetamine	O
withdrawal	O
.	O

Modulation	O
of	O
IL-6	O
induced	O
RANKL	O
expression	O
in	O
arthritic	O
synovium	O
by	O
a	O
transcription	O
factor	O
SOX5	O
.	O

Receptor	O
activator	O
of	O
nuclear	O
factor	O
κB	O
ligand	O
(	O
RANKL	O
)	O
is	O
critically	O
involved	O
in	O
bone	O
erosion	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

We	O
previously	O
reported	O
association	O
between	O
younger	O
age	O
at	O
onset	O
of	O
RA	O
and	O
a	O
RANKL	O
promoter	O
SNP	O
that	O
conferred	O
an	O
elevated	O
promoter	O
activity	O
via	O
binding	O
to	O
a	O
transcription	O
factor	O
SOX5	O
.	O

Here	O
we	O
study	O
the	O
regulation	O
of	O
SOX5	O
levels	O
in	O
relation	O
to	O
RANKL	O
expression	O
in	O
RA	O
synovial	O
fibroblasts	O
(	O
SF	O
)	O
and	O
the	O
development	O
of	O
bone	O
erosion	O
in	O
the	O
collagen-induced	O
arthritis	O
(	O
CIA	O
)	O
mouse	O
.	O

Our	O
data	O
indicated	O
SOX5	O
levels	O
were	O
higher	O
in	O
synovium	O
and	O
synovial	O
fluid	O
from	O
RA	O
compared	O
to	O
osteoarthritis	O
patients	O
.	O

Pro-inflammatory	O
cytokines	O
upregulated	O
SOX5	O
and	O
RANKL	O
expression	O
in	O
both	O
primary	O
RA	O
SF	O
and	O
the	O
rheumatoid	O
synovial	O
fibroblast	O
cell	O
line	O
,	O
MH7A	O
.	O

Overexpression	O
of	O
SOX5	O
resulted	O
in	O
significantly	O
increased	O
RANKL	O
levels	O
,	O
while	O
knockdown	O
of	O
SOX5	O
resulted	O
in	O
diminished	O
IL-6	O
mediated	O
RANKL	O
upregulation	O
in	O
MH7A	O
cells	O
.	O

Chromatin	B-P
immunoprecipitation	I-P
(	O
ChIP	B-P
)	O
showed	O
approximately	O
3-fold	O
enrichment	O
of	O
RANKL-specific	O
DNA	O
in	O
anti-SOX5	O
immunoprecipitate	O
in	O
IL-6	O
treated	O
MH7A	O
cells	O
as	O
compared	O
to	O
untreated	O
cells	O
.	O

Locally	O
silencing	O
SOX5	O
gene	O
significantly	O
diminished	O
RANKL	O
positive	O
cells	O
and	O
bone	O
erosion	O
in	O
CIA	O
mice	O
.	O

These	O
findings	O
suggest	O
SOX5	O
is	O
an	O
important	O
regulator	O
of	O
IL-6	O
-	O
induced	O
RANKL	O
expression	O
in	O
RA	O
SF	O
.	O

Blood	O
Collection	O
Tubes	O
and	O
Storage	O
Temperature	O
Should	O
Be	O
Evaluated	O
when	O
Using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
for	O
Measuring	B-P
25-Hydroxyvitamin	I-P
D.	I-P
A	O
significant	O
bias	O
was	O
found	O
when	O
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
for	O
measurement	O
of	O
25-hydroxyvitamin	O
D	O
(	O
25OHD	O
)	O
with	O
VACUETTE®	O
tubes	O
with	O
Serum	O
Clot	O
Activator	O
and	O
Gel	O
.	O

Here	O
,	O
we	O
examined	O
whether	O
other	O
commonly	O
used	O
tubes	O
or	O
temperatures	O
affected	O
25OHD	B-P
results	I-P
obtained	O
with	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
.	O

Serum	O
was	O
collected	O
into	O
five	O
types	O
of	O
vacuum	O
blood	O
collection	O
tubes	O
from	O
three	O
manufacturers	O
,	O
and	O
25OHD	B-P
was	I-P
analyzed	I-P
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
and	O
liquid	B-P
chromatography	I-P
tandem	I-P
mass	I-P
spectrometry	I-P
(	O
LC-MS/MS	B-P
)	O
immediately	O
or	O
after	O
storage	O
at	O
4°C	O
or	O
-80°C	O
for	O
48	O
h.	O
Significantly	O
higher	O
25OHD	B-P
values	I-P
were	O
found	O
when	O
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
with	O
VACUETTE®	O
tubes	O
with	O
serum	O
clot	O
activator	O
and	O
gel	O
and	O
VACUETTE®	O
tubes	O
with	O
clot	O
activator	O
but	O
no	O
gel	O
compared	O
with	O
VACUETTE®	O
tubes	O
with	O
no	O
additives	O
.	O

The	O
25OHD	B-P
values	I-P
in	O
all	O
of	O
these	O
tubes	O
were	O
not	O
significantly	O
different	O
from	O
those	O
obtained	O
by	O
LC-MS/MS	B-P
.	O

Moreover	O
,	O
after	O
storage	O
at	O
-80°C	O
for	O
48	O
h	O
,	O
the	O
values	O
obtained	O
in	O
IMPROVEVACUTER®	O
tubes	O
with	O
serum	O
clot	O
activator	O
and	O
ge	O
l	O
significantly	O
increased	O
,	O
with	O
a	O
mean	O
bias	O
of	O
74.6	O
%	O
compared	O
with	O
the	O
values	O
before	O
storage	O
,	O
on	O
analysis	O
with	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
.	O

VACUETTE®	O
tubes	O
containing	O
additives	O
significantly	O
affect	O
the	O
accuracy	O
of	O
25OHD	B-P
results	I-P
obtained	O
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
.	O

Additionally	O
,	O
the	O
composition	O
of	O
serum	O
collected	O
in	O
IMPROVEVACUTER®	O
tubes	O
was	O
affected	O
by	O
freezing	O
,	O
resulting	O
in	O
different	O
measurements	O
when	O
using	O
the	O
Siemens	O
25OHD	O
assay	O
platform	O
.	O

Succinic	O
acid	O
production	O
by	O
immobilized	O
cultures	B-P
using	O
spent	O
sulphite	O
liquor	O
as	O
fermentation	O
medium	O
.	O

Spent	O
sulphite	O
liquor	O
(	O
SSL	O
)	O
was	O
used	O
as	O
carbon	O
source	O
for	O
the	O
production	O
of	O
succinic	O
acid	O
using	O
immobilized	O
cultures	B-P
of	O
Actinobacillus	O
succinogenes	O
and	O
Basfia	O
succiniciproducens	O
on	O
two	O
different	O
supports	O
,	O
delignified	O
cellulosic	O
material	O
(	O
DCM	O
)	O
and	O
alginate	O
beads	O
.	O

Fed-batch	B-P
immobilized	I-P
cultures	I-P
with	O
A.	O
succinogenes	O
in	O
alginates	O
resulted	O
in	O
higher	O
sugar	O
to	O
succinic	O
acid	O
conversion	O
yield	O
(	O
0.81g/g	O
)	O
than	O
the	O
respective	O
yield	O
achieved	O
(	O
0.65g/g	O
)	O
when	O
DCM	O
immobilized	O
cultures	B-P
were	O
used	O
.	O

The	O
final	O
succinic	O
acid	O
concentration	O
and	O
yield	O
achieved	O
in	O
fed-batch	B-P
with	O
immobilized	O
cultures	B-P
of	O
B.	O
succiniciproducens	O
in	O
alginates	O
(	O
45g/L	O
and	O
0.66g/g	O
)	O
were	O
higher	O
than	O
A.	O
succinogenes	O
immobilized	O
cultures	B-P
(	O
35.4g/L	O
and	O
0.61g/g	O
)	O
using	O
nano	O
-	O
filtrated	O
SSL	O
as	O
fermentation	O
medium	O
.	O

Immobilized	O
cultures	B-P
of	O
B.	O
succiniciproducens	O
in	O
alginate	O
beads	O
were	O
reused	O
in	O
four	O
sequential	B-P
fed-batch	I-P
fermentations	O
of	O
nano	O
-	O
filtrated	O
SSL	O
leading	O
to	O
the	O
production	O
of	O
64.7g	O
of	O
succinic	O
acid	O
with	O
a	O
yield	O
range	O
of	O
0.42-0.67g/g	O
and	O
productivity	O
range	O
of	O
0.29-0.65g/L/h	O
.	O

The	O
immobilized	O
cultures	B-P
improved	O
the	O
efficiency	O
of	O
succinic	O
acid	O
production	O
as	O
compared	O
to	O
free	B-P
cell	I-P
cultures	I-P
.	O

Adult	O
Survivors	O
of	O
Childhood	O
Cancer	O
Have	O
Poor	O
Adherence	O
to	O
Dietary	O
Guidelines	O
.	O

Poor	O
nutritional	O
intake	O
can	O
exacerbate	O
the	O
chronic	O
disease	O
burden	O
in	O
childhood	O
cancer	O
survivors	O
,	O
whereas	O
a	O
healthful	O
diet	O
serves	O
a	O
protective	O
function	O
.	O

Few	O
studies	O
have	O
provided	O
detailed	O
evaluations	O
of	O
the	O
diet	O
of	O
childhood	O
cancer	O
survivors	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
diet	O
quality	O
and	O
dietary	O
intakes	O
of	O
key	O
food	O
groups	O
and	O
nutrients	O
in	O
a	O
large	O
cohort	O
of	O
childhood	O
cancer	O
survivors	O
and	O
whether	O
cancer	O
and	O
treatment	O
characteristics	O
have	O
an	O
impact	O
on	O
survivors	O
'	O
long-term	O
intake	O
.	O

Diet	O
was	O
assessed	O
in	O
2570	O
adult	O
survivors	O
of	O
childhood	O
cancer	O
enrolled	O
in	O
the	O
St.	O
Jude	O
Lifetime	O
cohort	O
(	O
mean	O
age	O
=	O
32.3	O
y	O
)	O
by	O
using	O
the	O
Block	O
food-frequency	O
questionnaire	O
.	O

The	O
Healthy	O
Eating	O
Index-2010	O
(	O
HEI-2010	O
)	O
was	O
calculated	O
to	O
quantify	O
diet	O
quality	O
.	O

Cancer	B-P
diagnosis	I-P
and	O
treatment	O
exposure	O
were	O
abstracted	O
from	O
medical	O
records	O
.	O

Differences	O
in	O
HEI-2010	O
by	O
patient	O
characteristics	O
and	O
treatment	O
exposure	O
were	O
examined	O
by	O
using	O
ANCOVA	O
.	O

The	O
mean	O
±	O
SD	O
HEI-2010	O
in	O
childhood	O
cancer	O
survivors	O
was	O
57.9	O
±	O
12.4	O
of	O
a	O
maximum	O
score	O
of	O
100	O
.	O

Referenced	O
to	O
Dietary	O
Reference	O
Intakes	O
,	O
survivors	O
consumed	O
inadequate	O
amounts	O
of	O
vitamin	O
D	O
,	O
vitamin	O
E	O
,	O
potassium	O
,	O
fiber	O
,	O
magnesium	O
,	O
and	O
calcium	O
(	O
27	O
%	O
,	O
54	O
%	O
,	O
58	O
%	O
,	O
59	O
%	O
,	O
84	O
%	O
,	O
and	O
90	O
%	O
of	O
the	O
recommended	O
intakes	O
)	O
but	O
excessive	O
amounts	O
of	O
sodium	O
and	O
saturated	O
fat	O
(	O
155	O
%	O
and	O
115	O
%	O
of	O
the	O
recommended	O
intakes	O
)	O
from	O
foods	O
.	O

Survivors	O
diagnosed	O
when	O
<	O
5	O
y	O
of	O
age	O
had	O
a	O
lower	O
diet	O
quality	O
than	O
did	O
those	O
diagnosed	O
when	O
≥5	O
y	O
of	O
age	O
(	O
mean	O
HEI-2010	O
score	O
:	O
56.9	O
compared	O
with	O
58.2	O
;	O
P	O
=	O
0.046	O
)	O
.	O

Survivors	O
who	O
received	O
higher	O
radiation	O
doses	O
to	O
the	O
abdomen	O
had	O
a	O
lower	O
diet	O
quality	O
than	O
those	O
who	O
received	O
lower	O
doses	O
(	O
mean	O
HEI-2010	O
scores	O
=	O
58.9	O
,	O
57.2	O
,	O
56.7	O
,	O
and	O
56.1	O
for	O
doses	O
of	O
0	O
,	O
1-19.9	O
,	O
20-29.9	O
,	O
and	O
≥30	O
Gy	O
,	O
respectively	O
;	O
P	O
=	O
0.02	O
)	O
.	O

Long-term	O
childhood	O
cancer	O
survivors	O
have	O
poor	O
adherence	O
to	O
the	O
2010	O
Dietary	O
Guidelines	O
for	O
Americans	O
.	O

Findings	O
reinforce	O
the	O
need	O
to	O
incorporate	O
nutrition	O
into	O
cancer	O
care	O
to	O
improve	O
diet	O
quality	O
and	O
to	O
reduce	O
morbidities	O
.	O

Initial	O
experience	O
with	O
laparoscopic	O
radical	O
antegrade	O
modular	O
pancreatosplenectomy	O
for	O
left-sided	O
pancreatic	O
cancer	O
in	O
a	O
single	O
institution	O
:	O
technical	O
aspects	O
and	O
oncological	O
outcomes	O
.	O

Laparoscopic	O
surgery	O
has	O
been	O
performed	O
less	O
frequently	O
in	O
the	O
era	O
of	O
pancreatic	O
cancer	O
due	O
to	O
technical	O
difficulties	O
and	O
concerns	O
about	O
oncological	O
safety	O
.	O

Radical	O
antegrade	O
modular	O
pancreatosplenectomy	O
(	O
RAMPS	O
)	O
is	O
expected	O
to	O
be	O
helpful	O
to	O
obtain	O
a	O
negative	O
margin	O
during	O
radical	O
lymph	O
node	O
dissection	O
.	O

We	O
hypothesized	O
that	O
it	O
would	O
also	O
be	O
favorable	O
as	O
a	O
laparoscopic	O
application	O
due	O
to	O
unique	O
features	O
.	O

Fifteen	O
laparoscopic	B-P
RAMPS	O
for	O
well-selected	O
patients	O
with	O
left-sided	O
pancreatic	O
cancer	O
were	O
performed	O
from	O
July	O
2011	O
to	O
April	O
2016	O
.	O

Five	O
trocars	O
were	O
usually	O
used	O
,	O
and	O
the	O
operative	O
procedures	O
and	O
range	O
of	O
dissection	O
were	O
similar	O
to	O
or	O
the	O
same	O
as	O
those	O
of	O
open	O
RAMPS	O
described	O
by	O
Strasberg	O
.	O

All	O
medical	O
records	O
and	O
follow-up	O
data	O
were	O
reviewed	O
and	O
analyzed	O
.	O

All	O
patients	O
had	O
pancreatic	O
ductal	O
adenocarcinoma	O
.	O

Mean	O
operative	O
time	O
was	O
219.3	O
±	O
53.8	O
min	O
,	O
and	O
estimated	O
blood	O
loss	O
was	O
250	O
±	O
70	O
ml	O
.	O

The	O
length	O
of	O
postoperative	O
hospital	O
stay	O
was	O
6.1	O
±	O
1.2	O
days	O
,	O
and	O
postoperative	O
morbidities	O
developed	O
in	O
two	O
patients	O
(	O
13.3	O
%	O
)	O
with	O
urinary	O
retention	O
.	O

The	O
median	O
number	O
of	O
retrieved	O
lymph	O
nodes	O
was	O
18.1	O
±	O
6.2	O
and	O
all	O
had	O
negative	O
margins	O
.	O

Median	O
follow-up	O
time	O
was	O
46.0	O
months	O
,	O
and	O
the	O
3-year	O
disease	O
free	O
survival	O
and	O
overall	O
survival	O
rates	O
were	O
56.3	O
%	O
and	O
74.1	O
%	O
,	O
respectively	O
.	O

Our	O
early	O
experience	O
with	O
laparoscopic	B-P
RAMPS	O
achieved	O
feasible	O
perioperative	O
results	O
accompanied	O
by	O
acceptable	O
survival	O
outcomes	O
.	O

Laparoscopic	B-P
RAMPS	O
could	O
be	O
a	O
safe	O
and	O
oncologically	O
feasible	O
procedure	O
in	O
well-selected	O
patients	O
with	O
left-sided	O
pancreatic	O
cancer	O
.	O

Inhibition	O
of	O
STEP61	O
ameliorates	O
deficits	O
in	O
mouse	O
and	O
hiPSC	O
-based	O
schizophrenia	O
models	O
.	O

The	O
brain	O
-	O
specific	O
tyrosine	O
phosphatase	O
,	O
STEP	O
(	O
STriatal-Enriched	O
protein	O
tyrosine	O
Phosphatase	O
)	O
is	O
an	O
important	O
regulator	O
of	O
synaptic	O
function	O
.	O

STEP	O
normally	O
opposes	O
synaptic	O
strengthening	O
by	O
increasing	O
N-methyl	O
D-aspartate	O
glutamate	O
receptor	O
(	O
NMDAR	O
)	O
internalization	O
through	O
dephosphorylation	O
of	O
GluN2B	O
and	O
inactivation	O
of	O
the	O
kinases	O
extracellular	O
signal-regulated	O
kinase	O
1	O
/	O
2	O
and	O
Fyn	O
.	O

Here	O
we	O
show	O
that	O
STEP61	O
is	O
elevated	O
in	O
the	O
cortex	O
in	O
the	O
Nrg1	O
(	O
+/-	O
)	O
knockout	O
mouse	O
model	O
of	O
schizophrenia	O
(	O
SZ	O
)	O
.	O

Genetic	O
reduction	O
or	O
pharmacological	O
inhibition	O
of	O
STEP	O
prevents	O
the	O
loss	O
of	O
NMDARs	O
from	O
synaptic	O
membranes	O
and	O
reverses	O
behavioral	O
deficits	O
in	O
Nrg1	O
(	O
+/-	O
)	O
mice	O
.	O

STEP61	O
protein	O
is	O
also	O
increased	O
in	O
cortical	O
lysates	O
from	O
the	O
central	O
nervous	O
system	O
-	O
specific	O
ErbB2	O
/	O
4	O
mouse	O
model	O
of	O
SZ	O
,	O
as	O
well	O
as	O
in	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
(	O
hiPSC	O
)	O
-derived	O
forebrain	O
neurons	O
and	O
Ngn2	O
-	O
induced	O
excitatory	O
neurons	O
,	O
from	O
two	O
independent	O
SZ	O
patient	O
cohorts	O
.	O

In	O
these	O
selected	O
SZ	O
models	O
,	O
increased	O
STEP61	O
protein	B-P
levels	I-P
likely	O
reflect	O
reduced	O
ubiquitination	O
and	O
degradation	O
.	O

These	O
convergent	O
findings	O
from	O
mouse	O
and	O
hiPSC	O
SZ	O
models	O
provide	O
evidence	O
for	O
STEP61	O
dysfunction	O
in	O
SZ	O
.Molecular	O
Psychiatry	O
advance	O
online	O
publication	O
,	O
18	O
October	O
2016	O
;	O
doi:10.1038/mp.2016.163	O
.	O

Measuring	O
nonlinear	O
signal	O
combination	O
using	O
EEG	B-P
.	O

Relatively	O
little	O
is	O
known	O
about	O
the	O
processes	O
,	O
both	O
linear	O
and	O
nonlinear	O
,	O
by	O
which	O
signals	O
are	O
combined	O
beyond	O
V1	O
.	O

By	O
presenting	O
two	O
stimulus	O
components	O
simultaneously	O
,	O
flickering	O
at	O
different	O
temporal	O
frequencies	O
(	O
frequency	O
tagging	O
)	O
while	O
measuring	O
steady-state	O
visual	O
evoked	O
potentials	O
,	O
we	O
can	O
assess	O
responses	O
to	O
the	O
individual	O
components	O
,	O
including	O
direct	O
measurements	O
of	O
suppression	O
on	O
each	O
other	O
,	O
and	O
various	O
nonlinear	O
responses	O
to	O
their	O
combination	O
found	O
at	O
intermodulation	O
frequencies	O
.	O

The	O
result	O
is	O
a	O
rather	O
rich	O
dataset	O
of	O
frequencies	O
at	O
which	O
responses	O
can	O
be	O
found	O
.	O

We	O
presented	O
pairs	O
of	O
sinusoidal	O
gratings	O
at	O
different	O
temporal	O
frequencies	O
,	O
forming	O
plaid	O
patterns	O
that	O
were	O
``	O
coherent	O
``	O
(	O
looking	O
like	O
a	O
checkerboar	O
d	O
)	O
and	O
``	O
noncoherent	O
``	O
(	O
looking	O
like	O
a	O
pair	O
of	O
transparently	O
overlaid	O
gratings	O
)	O
,	O
and	O
found	O
clear	O
intermodulation	O
responses	O
to	O
compound	O
stimuli	O
,	O
indicating	O
nonlinear	O
summation	O
.	O

This	O
might	O
have	O
been	O
attributed	O
to	O
cross-orientation	O
suppression	O
except	O
that	O
the	O
pattern	O
of	O
intermodulation	O
responses	O
differed	O
for	O
coherent	O
and	O
noncoherent	O
patterns	O
,	O
whereas	O
the	O
effects	O
of	O
suppression	O
(	O
measured	O
at	O
the	O
component	O
frequencies	O
)	O
did	O
not	O
.	O

A	O
two-stage	O
model	O
of	O
nonlinear	O
summation	O
involving	O
conjunction	O
detection	O
with	O
a	O
logical	O
AND	O
gate	O
described	O
the	O
data	O
well	O
,	O
capturing	O
the	O
difference	O
between	O
coherent	O
and	O
noncoherent	O
plaids	O
over	O
a	O
wide	O
array	O
of	O
possible	O
response	O
frequencies	O
.	O

Multistimulus	O
frequency	O
-tagged	O
EEG	B-P
in	O
combination	O
with	O
computational	O
modeling	O
may	O
be	O
a	O
very	O
valuable	O
tool	O
in	O
studying	O
the	O
conjunction	O
of	O
these	O
signals	O
.	O

In	O
the	O
current	O
study	O
the	O
results	O
suggest	O
a	O
second-order	O
mechanism	O
responding	O
selectively	O
to	O
coherent	O
plaid	O
patterns	O
.	O

Coffee	O
-	O
Antihypertensive	O
Drug	O
Interaction	O
:	O
A	O
Hemodynamic	O
and	O
Pharmacokinetic	O
Study	O
With	O
Felodipine	O
.	O

A	O
period	O
of	O
abstinence	O
from	O
coffee	O
to	O
permit	O
caffeine	O
elimination	O
appears	O
to	O
enable	O
increased	O
blood	O
pressure	O
on	O
subsequent	O
exposure	O
.	O

We	O
hypothesized	O
that	O
this	O
would	O
offset	O
the	O
antihypertensive	O
effect	O
of	O
the	O
dihydropyridine	O
calcium	O
channel	O
blocker	O
felodipine	O
.	O

A	O
randomized	O
,	O
single-dose	O
,	O
crossover	O
study	O
assessed	O
hemodynamic	O
and	O
pharmacokinetic	O
effects	O
following	O
2	O
days	O
without	O
coffee	O
and	O
caffeine	O
-	O
containing	O
foods	O
.	O

Consistently	O
brewed	O
black	O
coffee	O
(	O
2×300ml	O
)	O
,	O
felodipine	O
maximum	O
recommended	O
dose	O
(	O
10mg	O
)	O
,	O
and	O
coffee	O
plus	O
felodipine	O
were	O
tested	O
in	O
middle-aged	O
normotensive	O
subjects	O
.	O

Pretreatment	O
plasma	O
caffeine	B-P
concentrations	I-P
were	O
unquantifiable	O
.	O

After	O
coffee	O
,	O
blood	O
pressure	O
changes	O
(	O
mm	O
Hg	O
)	O
averaged	O
over	O
study	O
hours	O
1-4	O
were	O
increased	O
for	O
brachial	O
systolic	O
(	O
7.6	O
,	O
P	O
<	O
0.001	O
)	O
and	O
diastolic	O
(	O
4.9	O
,	O
P	O
<	O
0.001	O
)	O
and	O
aortic	O
systolic	O
(	O
7.4	O
,	O
P	O
<	O
0.001	O
)	O
,	O
pulse	O
(	O
3.0	O
,	O
P	O
<	O
0.05	O
)	O
and	O
augmentation	O
(	O
1.4	O
,	O
P	O
<	O
0.05	O
)	O
relative	O
to	O
baseline	O
.	O

After	O
coffee	O
plus	O
felodipine	O
,	O
they	O
were	O
higher	O
for	O
brachial	O
systolic	O
(	O
4.0	O
,	O
P	O
<	O
0.05	O
)	O
and	O
diastolic	O
(	O
3.9	O
,	O
P	O
<	O
0.001	O
)	O
and	O
aortic	O
systolic	O
(	O
4.6	O
,	O
P	O
<	O
0.05	O
)	O
compared	O
to	O
felodipine	O
alone	O
.	O

The	O
pressor	O
effects	O
of	O
coffee	O
and	O
its	O
modulation	O
by	O
felodipine	O
were	O
variable	O
among	O
individuals	O
.	O

Coffee	O
containing	O
caffeine	O
(	O
127mg	O
)	O
caused	O
maximum	O
pressor	O
effect	O
.	O

Caffeine	O
and	O
felodipine	O
pharmacokinetics	O
were	O
similar	O
for	O
coffee	O
and	O
felodipine	O
given	O
alone	O
or	O
in	O
combination	O
indicating	O
an	O
interaction	O
having	O
a	O
pharmacodynamic	O
basis	O
.	O

Plasma	O
felodipine	O
concentration	O
-	O
diastolic	O
blood	O
pressure	O
reduction	O
relationship	O
shifted	O
with	O
coffee	O
such	O
that	O
doubling	O
the	O
felodipine	O
concentration	O
would	O
eliminate	O
the	O
pressor	O
effect	O
.	O

However	O
,	O
this	O
may	O
increase	O
the	O
risk	O
of	O
adverse	O
drug	O
events	O
particularly	O
during	O
the	O
timeframe	O
without	O
coffee	O
.	O

Intermittent	O
coffee	O
ingestion	O
might	O
complicate	O
hypertension	O
diagnosis	O
and	O
management	O
for	O
many	O
individuals	O
.	O

All-arthroscopic	O
AMIC	O
(	O
®	O
)	O
(	O
AT-AMIC	O
(	O
®	O
)	O
)	O
technique	O
with	O
autologous	O
bone	O
graft	O
for	O
talar	O
osteochondral	O
defects	O
:	O
clinical	O
and	O
radiological	O
results	O
.	O

Autologous	O
Matrix-Induced	O
Chondrogenesis	O
(	O
AMIC	O
(	O
®	O
)	O
)	O
is	O
known	O
to	O
provide	O
satisfactory	O
clinical	O
results	O
for	O
the	O
treatment	O
of	O
knee	O
,	O
hip	O
,	O
and	O
ankle	O
cartilage	O
lesions	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
clinical	O
and	O
radiological	O
outcomes	O
of	O
patients	O
treated	O
with	O
a	O
new	O
all-arthroscopic	O
AMIC	O
(	O
®	O
)	O
(	O
AT-AMIC	O
(	O
®	O
)	O
)	O
technique	O
with	O
autologous	O
bone	O
graft	O
for	O
talar	O
osteochondral	O
defects	O
at	O
a	O
follow-up	O
of	O
24	O
months	O
.	O

Twenty	O
patients	O
underwent	O
the	O
AT-AMIC	O
(	O
®	O
)	O
procedure	O
and	O
autologous	O
bone	O
graft	O
for	O
type	O
III	O
and	O
IV	O
talar	O
osteochondral	O
lesions	O
.	O

Patients	O
were	O
evaluated	O
pre-operatively	O
and	O
at	O
6	O
,	O
12	O
,	O
and	O
24	O
months	O
post-operatively	O
using	O
the	O
American	B-P
Orthopedic	I-P
Foot	I-P
and	I-P
Ankle	I-P
Society	I-P
(	I-P
AOFAS	I-P
)	I-P
score	I-P
,	O
the	O
visual	B-P
analog	I-P
scale	I-P
,	O
and	O
the	O
SF-12	O
(	O
Short	O
Form-12	O
)	O
.	O

Radiological	B-P
assessment	I-P
included	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
,	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
,	O
and	O
magnetic	B-P
resonance	I-P
observation	I-P
of	I-P
cartilage	I-P
repair	I-P
tissue	I-P
(	O
MOCART	B-P
)	O
.	O

All	O
scores	O
significantly	O
improved	O
(	O
p	O
<	O
0.05	O
)	O
with	O
respect	O
to	O
pre-operative	O
values	O
after	O
6	O
months	O
.	O

Further	O
improvements	O
were	O
detected	O
at	O
24	O
months	O
(	O
AOFAS	O
,	O
from	O
57.1	O
±	O
14.9	O
before	O
surgery	O
to	O
86.6	O
±	O
10.9	O
after	O
24	O
months	O
;	O
VAS	B-P
,	O
from	O
8.1	O
±	O
1.4	O
to	O
2.5	O
±	O
2.2	O
;	O
SF-12	O
,	O
from	O
29.9	O
±	O
4.1	O
to	O
48.5	O
±	O
6.9	O
and	O
from	O
43.8	O
±	O
2.9	O
to	O
53.1	O
±	O
3.9	O
,	O
respectively	O
,	O
for	O
Physical	O
and	O
Mental	O
component	O
score	O
)	O
.	O

Lesion	O
area	O
significantly	O
reduced	O
from	O
111.1	O
±	O
43.2	O
mm	O
(	O
2	O
)	O
pre-operatively	O
to	O
76.9	O
±	O
38.1	O
mm	O
(	O
2	O
)	O
(	O
p	O
<	O
0.05	O
)	O
at	O
final	O
follow-up	O
as	O
assessed	O
by	O
CT	B-P
,	O
and	O
from	O
154.1	O
±	O
93.6	O
to	O
94.3	O
±	O
61.3	O
mm	O
(	O
2	O
)	O
(	O
p	O
<	O
0.05	O
)	O
as	O
assessed	O
by	O
MRI	B-P
.	O

The	O
mean	B-P
MOCART	I-P
score	I-P
was	O
42.8	O
±	O
23.5	O
points	O
and	O
50.9	O
±	O
24.9	O
points	O
,	O
respectively	O
,	O
at	O
12	O
and	O
24	O
months	O
after	O
surgery	O
(	O
p	O
<	O
0.05	O
)	O
.	O

AT-AMIC	O
(	O
®	O
)	O
with	O
autologous	O
bone	O
grafting	O
has	O
proven	O
to	O
be	O
a	O
safe	O
and	O
effective	O
minimal	O
invasive	O
technique	O
,	O
able	O
to	O
rapidly	O
and	O
significantly	O
improve	O
pain	O
,	O
function	O
,	O
and	O
radiological	O
healing	O
of	O
osteochondral	O
talar	O
lesions	O
,	O
with	O
progressive	O
further	O
improvements	O
up	O
to	O
24	O
months	O
.	O

Orthopedic	O
surgeons	O
specialized	O
in	O
foot	O
and	O
ankle	O
surgery	O
should	O
adopt	O
the	O
AT-AMIC	O
(	O
®	O
)	O
technique	O
for	O
the	O
treatment	O
of	O
osteochondral	O
talar	O
lesions	O
,	O
which	O
proved	O
to	O
be	O
effective	O
and	O
minimally	O
invasive	O
,	O
avoiding	O
malleolar	O
osteotomy	O
with	O
a	O
low	O
risk	O
of	O
complications	O
.	O

IV	O
.	O

Neural	O
activity	O
promotes	O
long-distance	O
,	O
target	O
-	O
specific	O
regeneration	O
of	O
adult	O
retinal	O
axons	O
.	O

Axons	O
in	O
the	O
mammalian	O
CNS	O
fail	O
to	O
regenerate	O
after	O
injury	O
.	O

Here	O
we	O
show	O
that	O
if	O
the	O
activity	O
of	O
mouse	O
retinal	O
ganglion	O
cells	O
(	O
RGCs	O
)	O
is	O
increased	O
by	O
visual	B-P
stimulation	I-P
or	O
using	O
chemogenetics	O
,	O
their	O
axons	O
regenerate	O
.	O

We	O
also	O
show	O
that	O
if	O
enhancement	O
of	O
neural	O
activity	O
is	O
combined	O
with	O
elevation	O
of	O
the	O
cell-growth	O
-promoting	O
pathway	O
involving	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
,	O
RGC	O
axons	O
regenerate	O
long	O
distances	O
and	O
re-innervate	O
the	O
brain	O
.	O

Analysis	O
of	O
genetically	O
labeled	O
RGCs	O
revealed	O
that	O
this	O
regrowth	O
can	O
be	O
target	O
specific	O
:	O
RGC	O
axons	O
navigated	O
back	O
to	O
their	O
correct	O
visual	O
targets	O
and	O
avoided	O
targets	O
incorrect	O
for	O
their	O
function	O
.	O

Moreover	O
,	O
these	O
regenerated	O
connections	O
were	O
successful	O
in	O
partially	O
rescuing	O
a	O
subset	O
of	O
visual	O
behaviors	O
.	O

Our	O
findings	O
indicate	O
that	O
combining	O
neural	O
activity	O
with	O
activation	O
of	O
mTOR	O
can	O
serve	O
as	O
powerful	O
tool	O
for	O
enhancing	O
axon	O
regeneration	O
,	O
and	O
they	O
highlight	O
the	O
remarkable	O
capacity	O
of	O
CNS	O
neurons	O
to	O
re-establish	O
accurate	O
circuit	O
connections	O
in	O
adulthood	O
.	O

Enhanced	O
Sensitivity	O
to	O
Hyperpolarizing	O
Inhibition	O
in	O
Mesoaccumbal	O
Relative	O
to	O
Nigrostriatal	O
Dopamine	O
Neuron	O
Subpopulations	O
.	O

Midbrain	O
dopamine	O
neurons	O
recorded	O
in	O
vivo	O
pause	O
their	O
firing	O
in	O
response	O
to	O
reward	O
omission	O
and	O
aversive	O
stimuli	O
.	O

While	O
the	O
initiation	O
of	O
pauses	O
typically	O
involves	O
synaptic	O
or	O
modulatory	O
input	O
,	O
intrinsic	O
membrane	O
properties	O
may	O
also	O
enhance	O
or	O
limit	O
hyperpolarization	O
,	O
raising	O
the	O
question	O
of	O
how	O
intrinsic	O
conductances	O
shape	O
pause	O
s	O
in	O
dopamine	O
neurons	O
.	O

Using	O
retrograde	O
labeling	B-P
and	O
electrophysiological	B-P
techniques	I-P
combined	O
with	O
computational	O
modeling	O
,	O
we	O
examined	O
the	O
intrinsic	O
conductances	O
that	O
shape	O
pauses	O
evoked	O
by	O
current	O
injections	O
and	O
synaptic	O
stimulation	O
in	O
subpopulations	O
of	O
dopamine	O
neurons	O
grouped	O
according	O
to	O
their	O
axonal	O
projections	O
to	O
the	O
nucleus	O
accumbens	O
or	O
dorsal	O
striatum	O
in	O
mice	O
.	O

Testing	O
across	O
a	O
range	O
of	O
conditions	O
and	O
pulse	O
durations	O
,	O
we	O
found	O
that	O
mesoaccumbal	O
and	O
nigrostriatal	O
neurons	O
differ	O
substantially	O
in	O
rebound	O
properties	O
with	O
mesoaccumbal	O
neurons	O
displaying	O
significantly	O
longer	O
delays	O
to	O
spiking	O
following	O
hyperpolarization	O
.	O

The	O
underlying	O
mechanism	O
involves	O
an	O
inactivating	O
potassium	O
(	O
IA	O
)	O
current	O
with	O
decay	O
time	O
constants	O
of	O
up	O
to	O
225	O
ms	O
,	O
and	O
small-amplitude	O
hyperpolarization	O
-	O
activated	O
currents	O
(	O
IH	O
)	O
,	O
characteristics	O
that	O
were	O
most	O
often	O
observed	O
in	O
mesoaccumbal	O
neurons	O
.	O

Pharmacological	O
block	O
of	O
IA	O
completely	O
abolished	O
rebound	O
delays	O
and	O
,	O
importantly	O
,	O
shortened	O
synaptically	O
evoked	O
inhibitory	O
pauses	O
,	O
thereby	O
demonstrating	O
the	O
involvement	O
of	O
A-type	O
potassium	O
channels	O
in	O
prolonging	O
pauses	O
evoked	O
by	O
GABAergic	O
inhibition	O
.	O

Therefore	O
,	O
these	O
results	O
show	O
that	O
mesoaccumbal	O
and	O
nigrostriatal	O
neurons	O
display	O
differential	O
responses	O
to	O
hyperpolarizing	O
inhibitory	O
stimuli	O
that	O
favors	O
a	O
higher	O
sensitivity	O
to	O
inhibition	O
in	O
mesoaccumbal	O
neurons	O
.	O

These	O
findings	O
may	O
explain	O
,	O
in	O
part	O
,	O
observations	O
from	O
in	O
vivo	O
experiments	O
that	O
ventral	O
tegmental	O
area	O
neurons	O
tend	O
to	O
exhibit	O
longer	O
aversive	O
pauses	O
relative	O
to	O
SNc	O
neurons	O
.	O

SIGNIFICANCE	O
STATEMENT	O
Our	O
study	O
examines	O
rebound	O
,	O
postburst	O
,	O
and	O
synaptically	O
evoked	O
inhibitory	O
pauses	O
in	O
subpopulations	O
of	O
midbrain	O
dopamine	O
neurons	O
.	O

We	O
show	O
that	O
pauses	O
in	O
dopamine	O
neuron	O
firing	O
,	O
evoked	O
by	O
either	O
stimulation	O
of	O
GABAergic	O
input	O
s	O
or	O
hyperpolarizing	O
current	O
injections	O
,	O
are	O
enhanced	O
by	O
a	O
subclass	O
of	O
potassium	O
conductances	O
that	O
are	O
recruited	O
at	O
voltages	O
below	O
spike	O
threshold	O
.	O

Importantly	O
,	O
A-type	O
potassium	O
currents	O
recorded	O
in	O
mesoaccumbal	O
neurons	O
displayed	O
substantially	O
slower	O
inactivation	O
kinetics	O
,	O
which	O
,	O
combined	O
with	O
weaker	O
expression	O
of	O
hyperpolarization	O
-	O
activated	O
currents	O
,	O
lengthened	O
hyperpolarization	O
-induced	O
delays	O
in	O
spiking	O
relative	O
to	O
nigrostriatal	O
neurons	O
.	O

These	O
results	O
suggest	O
that	O
input	O
integration	O
differs	O
among	O
dopamine	O
neurons	O
favoring	O
higher	O
sensitivity	O
to	O
inhibition	O
in	O
mesoaccumbal	O
neurons	O
and	O
may	O
partially	O
explain	O
in	O
vivo	O
observations	O
that	O
ventral	O
tegmental	O
area	O
neurons	O
exhibit	O
longer	O
aversive	O
pauses	O
relative	O
to	O
SNc	O
neurons	O
.	O

Automated	O
characterization	O
and	O
counting	O
of	O
Ki-67	O
protein	O
for	O
breast	O
cancer	O
prognosis	O
:	O
A	O
quantitative	O
immunohistochemistry	B-P
approach	O
.	O

Ki-67	O
protein	O
expression	O
plays	O
an	O
important	O
role	O
in	O
predicting	O
the	O
proliferative	O
status	O
of	O
tumour	O
cell	O
s	O
and	O
deciding	O
the	O
future	O
course	O
of	O
therapy	O
in	O
breast	O
cancer	O
.	O

Immunohistochemical	B-P
(	I-P
IHC	I-P
)	I-P
determination	I-P
of	O
Ki-67	B-P
score	I-P
or	O
labelling	B-P
index	I-P
,	O
by	O
estimating	O
the	O
fraction	O
of	O
Ki67	O
positively	O
stained	O
tumour	O
cells	O
,	O
is	O
the	O
most	O
widely	O
practiced	O
method	B-P
to	O
assess	O
tumour	O
proliferation	O
(	O
Dowsett	O
et	O
al	O
.	O

2011	O
)	O
.	O

Accurate	O
manual	B-P
counting	I-P
of	O
these	O
cells	O
(	O
specifically	O
nuclei	O
)	O
due	O
to	O
complex	O
and	O
dense	O
distribution	O
of	O
cells	O
,	O
therefore	O
,	O
becomes	O
critical	O
and	O
presents	O
a	O
major	O
challenge	O
to	O
pathologists	O
.	O

In	O
this	O
paper	O
,	O
we	O
suggest	O
a	O
hybrid	O
clustering	O
algorithm	O
to	O
quantify	O
the	O
proliferative	O
index	O
of	O
breast	O
cancer	O
cells	O
based	O
on	O
automated	B-P
counting	I-P
of	O
Ki-67	O
nuclei	O
.	O

The	O
proposed	O
methodology	B-P
initially	O
pre-processes	O
the	O
IHC	B-P
images	O
of	O
Ki-67	O
stained	O
slides	O
of	O
breast	O
cancer	O
.	O

The	O
RGB	O
images	O
are	O
converted	O
to	O
grey	O
,	O
L*a*b*	O
,	O
HSI	O
,	O
YCbCr	O
,	O
YIQ	O
and	O
XYZ	O
colour	O
space	O
.	O

All	O
the	O
stained	O
cells	O
are	O
then	O
characterized	O
by	O
two	B-P
stage	I-P
segmentation	I-P
process	I-P
.	O

Fuzzy	O
C-means	O
quantifies	O
all	O
the	O
stained	O
cells	O
as	O
one	O
cluster	O
.	O

The	O
blue	O
channel	O
of	O
the	O
first	O
stage	O
output	O
is	O
given	O
as	O
input	O
to	O
k-means	O
algorithm	O
,	O
which	O
provides	O
separate	O
cluster	O
for	O
Ki-67	O
positive	O
and	O
negative	O
cells	O
.	O

The	O
count	O
of	O
positive	O
and	O
negative	O
nuclei	O
is	O
used	O
to	O
calculate	B-P
the	O
F-measure	O
for	O
each	O
colour	O
space	O
.	O

A	O
comparative	O
study	O
of	O
our	O
work	O
with	O
the	O
expert	O
opinion	O
is	O
studied	O
to	O
evaluate	O
the	O
error	O
rate	O
.	O

The	O
positive	O
and	O
negative	O
nuclei	O
detection	O
results	O
for	O
all	O
colour	O
space	O
s	O
are	O
compared	O
with	O
the	O
ground	O
truth	O
for	O
validation	O
and	O
F-measure	O
is	O
calculated	B-P
.	O

The	O
F-measure	O
for	O
L*a*b*	O
colour	O
space	O
(	O
0.8847	O
)	O
provides	O
the	O
best	O
statistical	O
result	O
as	O
compared	O
to	O
grey	O
,	O
HSI	O
,	O
YCbCr	O
,	O
YIQ	O
and	O
XYZ	O
colour	O
space	O
.	O

Further	O
,	O
a	O
study	O
is	O
carried	O
out	O
to	O
count	O
nuclei	O
manually	B-P
and	O
automatically	B-P
from	O
the	O
proposed	O
algorithm	O
with	O
an	O
average	O
error	O
rate	O
of	O
6.84	O
%	O
which	O
is	O
significant	O
.	O

The	O
study	O
provides	O
an	O
automated	O
count	O
of	O
positive	O
and	O
negative	O
nuclei	O
using	O
L*a*b*	O
colour	O
space	O
and	O
hybrid	O
segmentation	O
technique	O
.	O

Computerized	B-P
evaluation	I-P
of	O
proliferation	O
index	O
can	O
aid	O
pathologist	O
in	O
assessing	O
breast	O
cancer	O
severity	O
.	O

The	O
proposed	O
methodology	B-P
,	O
further	O
,	O
has	O
the	O
potential	O
advantage	O
of	O
saving	O
time	O
and	O
assisting	O
in	O
decision	O
making	O
over	O
the	O
present	O
manual	B-P
procedure	I-P
and	O
could	O
evolve	O
as	O
an	O
assistive	O
pathological	O
decision	O
support	O
system	O
.	O

New	O
metabolites	O
from	O
the	O
sponge	O
-derived	O
fungus	O
Aspergillus	O
sydowii	O
J05B-7F-4	O
.	O

Two	O
new	O
metabolites	O
,	O
diorcinolic	O
acid	O
(	O
1	O
)	O
and	O
β-d-glucopyranosyl	O
aspergillusene	O
A	O
(	O
8	O
)	O
,	O
together	O
with	O
six	O
diphenylethers	O
(	O
2-7	O
)	O
,	O
a	O
diketopiperazine	O
(	O
9	O
)	O
,	O
a	O
chromone	O
(	O
10	O
)	O
and	O
a	O
xanthone	O
(	O
11	O
)	O
were	O
isolated	O
from	O
the	O
fungus	O
Aspergillus	O
sydowii	O
derived	O
from	O
the	O
marine	O
sponge	O
Stelletta	O
sp	O
.	O

The	O
planar	O
structures	O
and	O
their	O
relative	O
configurations	O
were	O
elucidated	O
by	O
analysing	O
1D	O
,	O
2D	O
NMR	O
and	O
HRESIMS	B-P
data	O
.	O

Compound	O
8	O
is	O
the	O
first	O
glycoside	O
of	O
phenolic	O
bisabolane	O
sesquiterpenes	O
.	O

Compounds	O
1	O
and	O
8	O
exhibited	O
mild	O
cytotoxicity	O
against	O
KB	O
(	O
human	O
nasopharyngeal	O
carcinoma	O
cells	O
)	O
,	O
HepG2	O
(	O
human	O
liver	O
cancer	O
cells	O
)	O
and	O
HCT	O
116	O
(	O
human	O
colon	O
cancer	O
cells	O
)	O
.	O

All	O
compounds	O
were	O
evaluated	O
for	O
antibacterial	O
activity	O
and	O
their	O
abilities	O
to	O
suppress	O
LPS	O
-induced	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
.	O

Compounds	O
2	O
and	O
4-7	O
showed	O
mild	O
antibacterial	O
activity	O
against	O
human	O
pathogen	O
Staphylococcus	O
aureus	O
and	O
fish	O
pathogens	O
Streptococcus	O
iniae	O
and	O
Vibrio	O
ichthyoenteri	O
,	O
and	O
compounds	O
4	O
and	O
7	O
weakly	O
suppressed	O
NO	O
production	O
.	O

Blastocystis	O
subtyping	O
and	O
its	O
association	O
with	O
intestinal	O
parasites	O
in	O
children	O
from	O
different	O
geographical	O
regions	O
of	O
Colombia	O
.	O

Blastocystis	O
is	O
a	O
common	O
enteric	O
protist	O
colonizing	O
probably	O
more	O
than	O
1	O
billion	O
people	O
with	O
a	O
large	O
variety	O
of	O
non-human	O
hosts	O
.	O

Remarkable	O
genetic	O
diversity	O
has	O
been	O
observed	O
,	O
leading	O
to	O
the	O
subdivision	O
of	O
the	O
genus	O
into	O
multiple	O
subtypes	O
(	O
ST	O
)	O
,	O
some	O
of	O
which	O
are	O
exclusively	O
found	O
in	O
non-human	O
hosts	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
distribution	O
of	O
Blastocystis	O
STs	O
/	O
18S	O
alleles	O
in	O
symptomatic	O
(	O
abdominal	O
pain	O
,	O
anal	O
pruritus	O
,	O
diarrhea	O
,	O
headache	O
,	O
nauseas	O
and/or	O
vomit	O
)	O
and	O
asymptomatic	O
children	O
from	O
nine	O
geographical	O
regions	O
of	O
Colombia	O
.	O

A	O
total	O
of	O
2026	O
fecal	O
samples	O
were	O
collected	O
as	O
part	O
of	O
a	O
national	O
survey	O
to	O
estimate	O
the	O
frequency	O
of	O
intestinal	O
parasites	O
in	O
children	O
.	O

A	O
set	O
of	O
256	O
samples	O
that	O
were	O
Blastocystis	O
positive	O
was	O
finally	O
selected	O
.	O

The	O
samples	O
were	O
submitted	O
to	O
DNA	O
extraction	O
,	O
Real	O
Time	O
PCR	O
and	O
sequencing	B-P
using	O
Blastocystis	O
-specific	O
primers	O
targeting	O
the	O
small	O
subunit	O
rRNA	O
gene	O
for	O
ST	B-P
identification	I-P
.	O

DNA	O
of	O
Ascaris	O
lumbricoides	O
(	O
16.4	O
%	O
)	O
,	O
Trichuris	O
trichiura	O
(	O
8.2	O
%	O
)	O
,	O
hookworms	O
(	O
Necator	O
americanus	O
/	O
Ancylostoma	O
duodenale	O
)	O
(	O
7.3	O
%	O
)	O
,	O
Giardia	O
duodenalis	O
(	O
23.1	O
%	O
)	O
,	O
Entamoeba	O
complex	O
(	O
82	O
%	O
)	O
,	O
Entamoeba	O
coli	O
(	O
55	O
%	O
)	O
,	O
Hymenolepis	O
nana	O
(	O
0.8	O
%	O
)	O
,	O
Endolimax	O
nana	O
(	O
33.2	O
%	O
)	O
and	O
Neobalantidium	O
coli	O
(	O
2.7	O
%	O
)	O
was	O
detected	O
in	O
the	O
Blastocystis	O
-	O
positive	O
samples	O
.	O

We	O
detected	O
ST1	O
(	O
21.4	O
%	O
)	O
,	O
ST2	O
(	O
19.5	O
%	O
)	O
,	O
ST3	O
(	O
55.5	O
%	O
)	O
,	O
ST4	O
(	O
0.8	O
%	O
)	O
,	O
ST6	O
(	O
2	O
%	O
)	O
and	O
ST7	O
(	O
0.8	O
%	O
)	O
;	O
alleles	O
1	O
,	O
2	O
,	O
4	O
,	O
81	O
,	O
82	O
and	O
83	O
for	O
ST1	O
;	O
alleles	O
9	O
,	O
11	O
,	O
12	O
,	O
15	O
,	O
67	O
,	O
71	O
and	O
73	O
for	O
ST2	O
;	O
alleles	O
34	O
,	O
36	O
,	O
38	O
,	O
45	O
,	O
49	O
,	O
55	O
,	O
134	O
and	O
128	O
for	O
ST3	O
;	O
allele	O
42	O
for	O
ST4	O
;	O
allele	O
122	O
for	O
ST6	O
,	O
and	O
allele	O
142	O
for	O
ST7	O
.	O

Further	O
studies	O
implementing	O
high-resolution	B-P
molecular	O
markers	O
are	O
necessary	O
to	O
understand	O
the	O
dynamics	O
of	O
Blastocystis	O
transmission	O
and	O
the	O
role	O
of	O
this	O
Stramenopila	O
in	O
health	O
and	O
disease	O
.	O

Fabrication	O
and	O
modelling	O
of	O
fractal	O
,	O
biomimetic	O
,	O
micro	O
and	O
nano-topographical	O
surfaces	O
.	O

Natural	O
surface	O
topographies	O
are	O
often	O
self-similar	O
with	O
hierarchical	O
features	O
at	O
the	O
micro	O
and	O
nanoscale	O
,	O
which	O
may	O
be	O
mimicked	O
to	O
overcome	O
modern	O
tissue	O
engineering	O
and	O
biomaterial	O
design	O
limitations	O
.	O

Specifically	O
,	O
a	O
cell	O
's	O
microenvironment	O
within	O
the	O
human	O
body	O
contains	O
highly	O
optimised	O
,	O
fractal	O
topographical	O
cues	O
,	O
which	O
directs	O
precise	O
cell	O
behaviour	O
.	O

However	O
,	O
recreating	O
biomimetic	O
,	O
fractal	O
topographies	O
in	O
vitro	O
is	O
not	O
a	O
trivial	O
process	O
and	O
a	O
number	O
of	O
fabrication	O
methods	O
have	O
been	O
proposed	O
but	O
often	O
fail	O
to	O
precisely	O
control	O
the	O
spatial	O
resolution	O
of	O
features	O
at	O
different	O
lengths	O
scales	O
and	O
hence	O
,	O
to	O
provide	O
true	O
biomimetic	O
properties	O
.	O

Here	O
,	O
we	O
propose	O
a	O
method	O
of	O
accurately	O
reproducing	O
the	O
self-similar	O
,	O
micro	O
and	O
nanoscale	O
topography	O
of	O
a	O
human	O
biological	O
tissue	O
into	O
a	O
synthetic	O
polymer	O
through	O
an	O
innovative	O
fabrication	O
process	O
.	O

The	O
biological	O
tissue	O
surface	O
was	O
characterised	O
using	O
atomic	B-P
force	I-P
microscopy	I-P
(	O
AFM	B-P
)	O
to	O
obtain	O
spatial	O
data	O
in	O
X	O
,	O
Y	O
and	O
Z	O
,	O
which	O
was	O
converted	O
into	O
a	O
grayscale	O
'digital	O
photomask	O
'	O
.	O

As	O
a	O
result	O
of	O
maskless	O
grayscale	O
optical	O
lithography	O
followed	O
by	O
modified	O
deep	O
reactive	O
ion	O
etching	O
and	O
replica	O
molding	O
,	O
we	O
were	O
able	O
to	O
accurately	O
reproduce	O
the	O
fractal	O
topography	O
of	O
acellular	O
dermal	O
matrix	O
(	O
ADM	O
)	O
into	O
polydimethylsiloxane	O
(	O
PDMS	O
)	O
.	O

Characterisation	O
using	O
AFM	B-P
at	O
three	O
different	O
length	O
scales	O
revealed	O
that	O
the	O
nano	O
and	O
micro-topographical	O
features	O
,	O
in	O
addition	O
to	O
the	O
fractal	O
dimension	O
,	O
of	O
native	O
ADM	O
were	O
reproduced	O
in	O
PDMS	O
.	O

In	O
conclusion	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
fractal	O
topography	O
of	O
biological	O
surfaces	O
can	O
be	O
mimicked	O
in	O
synthetic	O
materials	O
using	O
the	O
novel	O
fabrication	O
process	O
outlined	O
,	O
which	O
may	O
be	O
applied	O
to	O
significantly	O
enhance	O
medical	O
device	O
biocompatibility	O
and	O
performance	O
.	O

Influence	O
of	O
drug	O
load	O
on	O
dissolution	O
behavior	O
of	O
tablets	O
containing	O
a	O
poorly	O
water	O
-	O
soluble	O
drug	O
:	O
estimation	O
of	O
the	O
percolation	O
threshold	O
.	O

Drug	O
load	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
solid	O
dosage	O
forms	O
,	O
since	O
it	O
can	O
significantly	O
influence	O
both	O
processability	O
and	O
final	O
product	O
properties	O
.	O

The	O
percolation	O
threshold	O
of	O
the	O
active	O
pharmaceutical	O
ingredient	O
(	O
API	O
)	O
corresponds	O
to	O
a	O
critical	O
concentration	O
,	O
above	O
which	O
an	O
abrupt	O
change	O
in	O
drug	O
product	O
characteristics	O
can	O
occur	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
percolation	O
threshold	O
of	O
a	O
poorly	O
water	O
-	O
soluble	O
drug	O
with	O
regard	O
to	O
the	O
dissolution	O
behavior	O
from	O
immediate	O
release	O
tablets	O
.	O

The	O
influence	O
of	O
the	O
API	O
particle	O
size	O
on	O
the	O
percolation	O
threshold	O
was	O
also	O
studied	O
.	O

Formulations	O
with	O
increasing	O
drug	O
loads	O
were	O
manufactured	O
via	O
roll	B-P
compaction	I-P
using	O
constant	O
process	O
parameters	O
and	O
subsequent	O
tableting	O
.	O

Drug	O
dissolution	O
was	O
investigated	O
in	O
biorelevant	O
medium	O
.	O

The	O
percolation	O
threshold	O
was	O
estimated	O
via	O
a	O
model	O
dependent	O
and	O
a	O
model	O
independent	O
method	B-P
based	O
on	O
the	O
dissolution	O
data	O
.	O

The	O
intragranular	O
concentration	O
of	O
mefenamic	O
acid	O
had	O
a	O
significant	O
effect	O
on	O
granules	O
and	O
tablet	O
characteristics	O
,	O
such	O
as	O
particle	O
size	O
distribution	O
,	O
compactibility	O
and	O
tablet	O
disintegration	O
.	O

Increasing	O
the	O
intragranular	O
drug	O
concentration	O
of	O
the	O
tablets	O
resulted	O
in	O
lower	O
dissolution	O
rates	O
.	O

A	O
percolation	O
threshold	O
of	O
approximately	O
20	O
%	O
v/v	O
could	O
be	O
determined	O
for	O
both	O
particle	O
sizes	O
of	O
the	O
API	O
above	O
which	O
an	O
abrupt	O
decrease	O
of	O
the	O
dissolution	O
rate	O
occurred	O
.	O

However	O
,	O
the	O
increasing	O
drug	O
load	O
had	O
a	O
more	O
pronounced	O
effect	O
on	O
dissolution	O
rate	O
of	O
tablets	O
containing	O
the	O
micronized	B-P
API	O
,	O
which	O
can	O
be	O
attributed	O
to	O
the	O
high	O
agglomeration	O
tendency	O
of	O
micronized	B-P
substances	O
during	O
manufacturing	O
steps	O
,	O
such	O
as	O
roll	B-P
compaction	I-P
and	O
tableting	O
.	O

Both	O
methods	B-P
that	O
were	O
applied	O
for	O
the	O
estimation	O
of	O
percolation	O
threshold	O
provided	O
comparable	O
values	O
.	O

Prevalence	O
of	O
Self-Reported	O
Prescription	O
Drug	O
Use	O
in	O
a	O
National	O
Sample	O
of	O
U.S	O
.	O

Drivers	O
.	O

Drug	O
-involved	O
driving	O
has	O
become	O
an	O
increasing	O
concern	O
.	O

Although	O
the	O
focus	O
has	O
been	O
on	O
illegal	O
drugs	O
,	O
there	O
is	O
evidence	O
that	O
prescribed	O
medications	O
can	O
impair	O
driving	O
ability	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	B-P
the	O
self-reported	O
prevalence	O
of	O
prescription	O
drug	O
use	O
,	O
including	O
medical	O
and	O
nonmedical	O
use	O
,	O
among	O
a	O
nationally	O
representative	O
sample	O
of	O
drivers	O
and	O
to	O
report	O
related	O
driver	O
characteristics	O
.	O

As	O
part	O
of	O
the	O
2013-2014	O
National	O
Roadside	O
Survey	O
,	O
drivers	O
from	O
60	O
sites	O
were	O
randomly	O
recruited	O
and	O
asked	O
to	O
complete	O
a	O
survey	O
on	O
prescription	O
drug	O
use	O
.	O

Almost	O
20	O
%	O
of	O
drivers	O
reported	O
using	O
a	O
prescription	O
drug	O
within	O
the	O
past	O
2	O
days	O
,	O
with	O
the	O
most	O
common	O
drug	O
class	O
being	O
sedatives	O
(	O
8.0	O
%	O
)	O
,	O
followed	O
by	O
antidepressants	O
(	O
7.7	O
%	O
)	O
,	O
narcotics	O
(	O
7.5	O
%	O
)	O
,	O
and	O
stimulants	O
(	O
3.9	O
%	O
)	O
.	O

Drivers	O
who	O
reported	O
prescription	O
drug	O
use	O
were	O
significantly	O
more	O
likely	O
to	O
be	O
female	O
,	O
older	O
,	O
non-Hispanic	O
White	O
,	O
and	O
report	O
disability	O
.	O

Three	O
of	O
four	O
drivers	O
who	O
reported	O
medication	O
use	O
(	O
78.2	O
%	O
)	O
said	O
the	O
drug	O
was	O
prescribed	O
for	O
their	O
use	O
;	O
the	O
odds	O
of	O
using	O
without	O
a	O
prescription	O
were	O
significantly	O
higher	O
for	O
males	O
,	O
Black/African	O
American	O
,	O
and	O
Hispanic	O
drivers	O
,	O
and	O
lower	O
for	O
older	O
drivers	O
.	O

Among	O
those	O
with	O
a	O
prescription	O
,	O
taking	O
more	O
than	O
prescribed	O
was	O
most	O
common	O
for	O
narcotics	O
(	O
6.8	O
%	O
)	O
,	O
followed	O
by	O
sedatives	O
(	O
4.8	O
%	O
)	O
,	O
stimulants	O
(	O
3.8	O
%	O
)	O
,	O
and	O
antidepressants	O
(	O
1.5	O
%	O
)	O
.	O

These	O
findings	O
help	O
to	O
identify	O
drivers	O
using	O
potentially	O
impairing	O
prescription	O
drugs	O
,	O
both	O
medically	O
and	O
nonmedically	O
,	O
and	O
may	O
inform	O
the	O
targeting	O
of	O
interventions	O
to	O
reduce	O
impaired	O
driving	O
related	O
to	O
medications	O
.	O

